drug,adverse_event,comp_term,is_overlapping
XEOMIN,Dysphagia,Contraindications and Warnings and Dysphagia,1
XEOMIN,Dysphagia,Contraindications,0
XEOMIN,Dysphagia,Dysphagia,1
XEOMIN,Dysphagia,cervical,0
XEOMIN,Dysphagia,Warnings and,0
XEOMIN,Dysphagia,Dysphagia,1
XEOMIN,Dysphagia,,0
XEOMIN,Breathing Difficulties,Breathing Difficulties,1
XEOMIN,Breathing Difficulties,of cervical dystonia see,0
XEOMIN,Breathing Difficulties,Breathing Difficulties,1
XEOMIN,dysphagia,Dystonia The most commonly observed adverse reactions of patients and placebo,0
XEOMIN,neck pain,patients and placebo are neck pain,1
XEOMIN,neck pain,and placebo are neck pain,1
XEOMIN,neck pain,neck,1
XEOMIN,neck pain,pain,1
XEOMIN,muscle weakness,muscle weakness,1
XEOMIN,muscle weakness,neck pain,0
XEOMIN,muscle weakness,are dysphagia,0
XEOMIN,muscle weakness,of patients,0
XEOMIN,muscle weakness,,0
XEOMIN,muscle weakness,muscle weakness,1
XEOMIN,muscle weakness,dysphagia neck muscle weakness,1
XEOMIN,injection site pain,dysphagia neck pain muscle injection site,1
XEOMIN,musculoskeletal pain,injection site pain musculoskeletal pain,1
XEOMIN,musculoskeletal pain,are dysphagia neck pain muscle weakness,0
XEOMIN,musculoskeletal pain,pain musculoskeletal pain,1
XEOMIN,dry eye,dry mouth diarrhea headache visual impairment dyspnea nasopharyngitis and,0
XEOMIN,dry eye,visual impairment dyspnea nasopharyngitis and respiratory,0
XEOMIN,dry eye,dry eye,1
XEOMIN,dry eye,dry,1
XEOMIN,dry eye,dry mouth diarrhea,0
XEOMIN,dry eye,dry,1
XEOMIN,dry mouth,,0
XEOMIN,dry mouth,ptosis dry dry mouth,1
XEOMIN,dry mouth,dry mouth,1
XEOMIN,dry mouth,mouth,1
XEOMIN,dry mouth,mouth,1
XEOMIN,diarrhea,diarrhea,1
XEOMIN,diarrhea,diarrhea,1
XEOMIN,diarrhea,diarrhea,1
XEOMIN,diarrhea,headache visual impairment dyspnea,0
XEOMIN,diarrhea,and respiratory,0
XEOMIN,diarrhea,diarrhea,1
XEOMIN,diarrhea,diarrhea,1
XEOMIN,diarrhea,diarrhea,1
XEOMIN,diarrhea,respiratory,0
XEOMIN,diarrhea,diarrhea,1
XEOMIN,headache,headache,1
XEOMIN,headache,,0
XEOMIN,headache,diarrhea,0
XEOMIN,headache,dry mouth headache,1
XEOMIN,headache,reactions,0
XEOMIN,headache,dyspnea nasopharyngitis and,0
XEOMIN,headache,mouth headache,1
XEOMIN,dyspnea,nasopharyngitis and respiratory tract infection Glabellar Lines,0
XEOMIN,dyspnea,dyspnea,1
XEOMIN,nasopharyngitis,,0
XEOMIN,nasopharyngitis,,0
XEOMIN,nasopharyngitis,,0
XEOMIN,respiratory tract infection,visual impairment dyspnea nasopharyngitis respiratory tract,1
XEOMIN,respiratory tract infection,infection,1
XEOMIN,respiratory tract infection,Glabellar Lines The most commonly observed adverse reaction of patients and,0
XEOMIN,respiratory tract infection,Lines The most commonly observed,0
XEOMIN,respiratory tract infection,dry eye dry mouth diarrhea,0
XEOMIN,respiratory tract infection,infection,1
XEOMIN,headache,is,0
XEOMIN,headache,most commonly observed,0
XEOMIN,headache,headache,1
XEOMIN,headache,of patients and placebo headache,1
XEOMIN,headache,The most commonly observed adverse,0
XEOMIN,headache,headache,1
XEOMIN,dysphagia,weakness injection site pain and musculoskeletal pain,0
XEOMIN,dysphagia,in patients who received XEOMIN Units or Units,0
XEOMIN,muscle weakness,muscle weakness,1
XEOMIN,muscle weakness,muscle weakness,1
XEOMIN,muscle weakness,,0
XEOMIN,muscle weakness,muscle,1
XEOMIN,muscle weakness,patients who received XEOMIN Units or Units included dysphagia neck,0
XEOMIN,injection site pain,dysphagia neck pain muscle injection,1
XEOMIN,injection site pain,,0
XEOMIN,musculoskeletal pain,weakness injection site pain musculoskeletal pain,1
XEOMIN,musculoskeletal pain,weakness injection site pain musculoskeletal pain,1
XEOMIN,musculoskeletal pain,injection site,0
XEOMIN,musculoskeletal pain,Clinical Tri,0
XEOMIN,Neck pain,,0
XEOMIN,Neck pain,tive tissue Neck pain,1
XEOMIN,Neck pain,,0
XEOMIN,Neck pain,tissue disorders,0
XEOMIN,Neck pain,tive tissue Neck,1
XEOMIN,Neck pain,,0
XEOMIN,Neck pain,tissue,0
XEOMIN,Neck pain,tissue Neck,1
XEOMIN,Neck pain,pain,1
XEOMIN,Neck pain,tive tissue Neck pain,1
XEOMIN,Muscular weakness,Muscular weakness Muscul,1
XEOMIN,Muscular weakness,Muscular weakness Muscul,1
XEOMIN,Muscular weakness,,0
XEOMIN,Musculoskeletal pain,akness Musculoskeletal pain Gastrointes,1
XEOMIN,Musculoskeletal pain,akness Musculoskeletal pain Gastrointes,1
XEOMIN,Musculoskeletal pain,akness Musculoskeletal,1
XEOMIN,Musculoskeletal pain,,0
XEOMIN,Musculoskeletal pain,pain Gastrointes,1
XEOMIN,Dysphagia,Dysphagia,1
XEOMIN,Dysphagia,Dysphagia,1
XEOMIN,Dysphagia,disorders,0
XEOMIN,Dysphagia,Dysphagia,1
XEOMIN,Dysphagia,Dysphagia,1
XEOMIN,Injection site pain,ation site Injection site pain Infections,1
XEOMIN,Injection site pain,pain Infections,1
XEOMIN,Injection site pain,site Injection site,1
XEOMIN,Injection site pain,Injection site,1
XEOMIN,Injection site pain,,0
XEOMIN,Injection site pain,site pain Infections,1
XEOMIN,blepharospasm,,0
XEOMIN,blepharospasm,with,0
XEOMIN,blepharospasm,,0
XEOMIN,blepharospasm,in patients with,0
XEOMIN,blepharospasm,blepharospasm previously,1
XEOMIN,blepharospasm,patients blepharospasm previously,1
XEOMIN,blepharospasm,blepharospasm previously,1
XEOMIN,eyelid ptosis,and respirato,0
XEOMIN,dry eye,dry,1
XEOMIN,dry eye,dyspnea nasopharyngitis,0
XEOMIN,dry eye,dry,1
XEOMIN,dry eye,of XEOMINtreated patients and,0
XEOMIN,diarrhea,nasopharyngitis and respiratory tract infection No,0
XEOMIN,diarrhea,diarrhea headache,1
XEOMIN,diarrhea,placebo in the Phase study were eyelid ptosis dry eye,0
XEOMIN,diarrhea,diarrhea headache,1
XEOMIN,diarrhea,dry eye dry diarrhea headache,1
XEOMIN,diarrhea,eye dry diarrhea headache,1
XEOMIN,diarrhea,eye dry diarrhea headache,1
XEOMIN,diarrhea,ptosis dry eye dry diarrhea headache,1
XEOMIN,diarrhea,dry eye,0
XEOMIN,headache,eye dry mouth headache visual,1
XEOMIN,headache,mouth diarrhea,0
XEOMIN,headache,headache visual,1
XEOMIN,dyspnea,dyspnea nasopharyngitis,1
XEOMIN,dyspnea,ptosis dry,0
XEOMIN,dyspnea,ptosis,0
XEOMIN,dyspnea,dyspnea nasopharyngitis,1
XEOMIN,dyspnea,mouth diarrhea headache visual dyspnea nasopharyngitis,1
XEOMIN,nasopharyngitis,nasopharyngitis and,1
XEOMIN,nasopharyngitis,headache visual impairment nasopharyngitis and,1
XEOMIN,nasopharyngitis,who received XEOMI,0
XEOMIN,nasopharyngitis,visual impairment nasopharyngitis and,1
XEOMIN,nasopharyngitis,,0
XEOMIN,nasopharyngitis,nasopharyngitis and,1
XEOMIN,nasopharyngitis,,0
XEOMIN,nasopharyngitis,impairment nasopharyngitis and,1
XEOMIN,respiratory tract infection,impairment dyspnea nasopharyngitis respiratory tract,1
XEOMIN,respiratory tract infection,tract infection No,1
XEOMIN,respiratory tract infection,No serious adverse,0
XEOMIN,respiratory tract infection,,0
XEOMIN,respiratory tract infection,tract infection No,1
XEOMIN,respiratory tract infection,received XEOMIN one placebotreated,0
XEOMIN,respiratory tract infection,infection No,1
XEOMIN,respiratory tract infection,respiratory,1
XEOMIN,dyspnea,dyspnea Table,1
XEOMIN,dyspnea,dyspnea Table,1
XEOMIN,dyspnea,dyspnea Table,1
XEOMIN,Eyelid ptosis,rs,0
XEOMIN,Eyelid ptosis,,0
XEOMIN,Eyelid ptosis,rs Eyelid ptosis Dry,1
XEOMIN,Eyelid ptosis,rs Eyelid ptosis Dry,1
XEOMIN,Eyelid ptosis,rs,0
XEOMIN,Eyelid ptosis,Eyelid ptosis Dry,1
XEOMIN,Eyelid ptosis,ptosis Dry,1
XEOMIN,Dry eye,eye,1
XEOMIN,Dry eye,Dry eye,1
XEOMIN,Dry eye,eye,1
XEOMIN,Dry eye,Dry eye,1
XEOMIN,Dry eye,osis Dry eye,1
XEOMIN,Dry eye,Dry eye,1
XEOMIN,Dry eye,osis,0
XEOMIN,Dry eye,,0
XEOMIN,Dry eye,,0
XEOMIN,Dry eye,,0
XEOMIN,Visual impairment,Visual impairment Gastrointe,1
XEOMIN,Visual impairment,Gastrointe,0
XEOMIN,Visual impairment,,0
XEOMIN,Visual impairment,Visual,1
XEOMIN,Visual impairment,Visual,1
XEOMIN,Visual impairment,,0
XEOMIN,Visual impairment,Visual,1
XEOMIN,Visual impairment,,0
XEOMIN,Visual impairment,,0
XEOMIN,Visual impairment,,0
XEOMIN,Dry mouth,,0
XEOMIN,Dry mouth,tinal Dry,1
XEOMIN,Dry mouth,Dry mouth,1
XEOMIN,Dry mouth,Dry mouth,1
XEOMIN,Dry mouth,Dry,1
XEOMIN,Dry mouth,,0
XEOMIN,Dry mouth,,0
XEOMIN,Diarrhoea,In,0
XEOMIN,Diarrhoea,,0
XEOMIN,Diarrhoea,Diarrhoea In,1
XEOMIN,Diarrhoea,,0
XEOMIN,Diarrhoea,,0
XEOMIN,Diarrhoea,,0
XEOMIN,Diarrhoea,Diarrhoea In,1
XEOMIN,Diarrhoea,Diarrhoea In,1
XEOMIN,Diarrhoea,Diarrhoea In,1
XEOMIN,Diarrhoea,Diarrhoea In,1
XEOMIN,Nasopharyngitis,Nasopharyngitis Respirat,1
XEOMIN,Nasopharyngitis,,0
XEOMIN,Nasopharyngitis,Nasopharyngitis Respirat,1
XEOMIN,Nasopharyngitis,infestations,0
XEOMIN,Nasopharyngitis,,0
XEOMIN,Nasopharyngitis,and Nasopharyngitis Respirat,1
XEOMIN,Nasopharyngitis,Nasopharyngitis Respirat,1
XEOMIN,Nasopharyngitis,,0
XEOMIN,Nasopharyngitis,Nasopharyngitis Respirat,1
XEOMIN,Respiratory tract infection,ryngitis Respiratory tract,1
XEOMIN,Respiratory tract infection,ryngitis Respiratory tract infection Nervous,1
XEOMIN,Respiratory tract infection,ryngitis Respiratory tract,1
XEOMIN,Respiratory tract infection,ryngitis Respiratory tract infection Nervous system dis,1
XEOMIN,Respiratory tract infection,ryngitis,0
XEOMIN,Respiratory tract infection,Nervous system,0
XEOMIN,Respiratory tract infection,system dis,0
XEOMIN,Respiratory tract infection,ryngitis Respiratory,1
XEOMIN,Headache,,0
XEOMIN,Headache,disorders,0
XEOMIN,Headache,Headache G,1
XEOMIN,Headache,,0
XEOMIN,Headache,disorders,0
XEOMIN,Dyspnoea,,0
XEOMIN,Dyspnoea,,0
XEOMIN,Dyspnoea,Dyspnoea,1
XEOMIN,Dyspnoea,,0
XEOMIN,Dyspnoea,and mediastinal Dyspnoea,1
XEOMIN,Dyspnoea,thoracic and mediastinal Dyspnoea,1
XEOMIN,Dyspnoea,Dyspnoea,1
XEOMIN,Dyspnoea,,0
XEOMIN,headache,injection site hematoma and eyelid edema,0
XEOMIN,headache,subjects headache facial paresis,1
XEOMIN,headache,injection site hematoma and,0
XEOMIN,headache,and eyelid,0
XEOMIN,headache,adverse reactions in XEOMIN treated subjects,0
XEOMIN,headache,site hematoma and eyelid edema,0
XEOMIN,headache,paresis injection site hematoma and eyelid,0
XEOMIN,headache,treated,0
XEOMIN,headache,in XEOMIN treated subjects headache facial paresis,1
XEOMIN,headache,treated subjects headache facial paresis,1
XEOMIN,facial paresis,adverse events,0
XEOMIN,facial paresis,treated subjects were facial paresis injection site,1
XEOMIN,facial paresis,subjects were facial paresis injection site,1
XEOMIN,facial paresis,facial paresis injection site,1
XEOMIN,facial paresis,facial,1
XEOMIN,injection site hematoma,subjects were headache facial injection site hematoma and eyelid,1
XEOMIN,injection site hematoma,,0
XEOMIN,injection site hematoma,occurred in two,0
XEOMIN,injection site hematoma,subjects were headache facial injection site hematoma and eyelid,1
XEOMIN,injection site hematoma,sub,0
XEOMIN,Headache,Headache Facial,1
XEOMIN,Headache,disorders Headache Facial,1
XEOMIN,Headache,,0
XEOMIN,Headache,Headache Facial,1
XEOMIN,Headache,,0
XEOMIN,Headache,Headache Facial,1
XEOMIN,Headache,disorders Headache Facial,1
XEOMIN,Headache,Headache Facial,1
XEOMIN,Headache,disorders,0
XEOMIN,Facial paresis,adache,0
XEOMIN,Facial paresis,adache,0
XEOMIN,Facial paresis,General,0
XEOMIN,Facial paresis,adache Facial paresis brow ptosis,1
XEOMIN,Facial paresis,adache,0
XEOMIN,Facial paresis,ptosis General,0
XEOMIN,Facial paresis,adache,0
XEOMIN,Facial paresis,,0
XEOMIN,Facial paresis,ptosis General,0
XEOMIN,brow ptosis,,0
XEOMIN,brow ptosis,and,0
XEOMIN,brow ptosis,ptosis General,1
XEOMIN,brow ptosis,disorders and,0
XEOMIN,Injection site hematoma,,0
XEOMIN,Injection site hematoma,tion site Injection site hematoma Injection,1
XEOMIN,Injection site hematoma,site Injection site hematoma Injection,1
XEOMIN,Injection site hematoma,Injection si,0
XEOMIN,Injection site hematoma,site conditions,0
XEOMIN,Injection site hematoma,tion site Injection site,1
XEOMIN,Injection site hematoma,si,0
XEOMIN,Injection site hematoma,Injection site hematoma Injection,1
XEOMIN,Injection site hematoma,Injection site hematoma Injection,1
XEOMIN,Injection site hematoma,si,0
XEOMIN,Injection site pain,pain Facial,1
XEOMIN,Injection site pain,pain Facial,1
XEOMIN,Injection site pain,,0
XEOMIN,Facial pain,Facial,1
XEOMIN,Facial pain,,0
XEOMIN,Facial pain,,0
XEOMIN,Facial pain,Facial pain Injectio,1
XEOMIN,Facial pain,e Facial pain Injectio,1
XEOMIN,Facial pain,Facial pain Injectio,1
XEOMIN,Sensation of pressure,swelling,0
XEOMIN,Sensation of pressure,,0
XEOMIN,Sensation of pressure,,0
XEOMIN,Sensation of pressure,Sensation of pressure Eye,1
XEOMIN,Sensation of pressure,Eye diso,0
XEOMIN,Sensation of pressure,site Sensation,1
XEOMIN,Sensation of pressure,diso,0
XEOMIN,Sensation of pressure,swelling,0
XEOMIN,Eyelid edema,ers Eyelid,1
XEOMIN,Eyelid edema,Blep,0
XEOMIN,Eyelid edema,edema Blep,1
XEOMIN,Eyelid edema,ers Eyelid,1
XEOMIN,Eyelid edema,ers Eyelid edema Blep,1
XEOMIN,Eyelid edema,edema Blep,1
XEOMIN,Eyelid edema,edema Blep,1
XEOMIN,Eyelid edema,Blep,0
XEOMIN,Eyelid edema,ers,0
XEOMIN,Blepharospasm,dema Blepharospasm Eye,1
XEOMIN,Blepharospasm,,0
XEOMIN,Blepharospasm,,0
XEOMIN,Blepharospasm,Blepharospasm Eye,1
XEOMIN,Blepharospasm,dema,0
XEOMIN,Blepharospasm,,0
XEOMIN,Blepharospasm,,0
XEOMIN,Blepharospasm,Blepharospasm Eye,1
XEOMIN,Blepharospasm,Blepharospasm Eye,1
XEOMIN,Blepharospasm,dema Blepharospasm Eye,1
XEOMIN,Eye disorder,,0
XEOMIN,Eye disorder,disorder Eyel,1
XEOMIN,Eye disorder,asm,0
XEOMIN,Eye disorder,asm,0
XEOMIN,Eye disorder,Eye disorder Eyel,1
XEOMIN,Eye disorder,asm Eye disorder Eyel,1
XEOMIN,Eyelid ptosis,rder Eyelid,1
XEOMIN,Eyelid ptosis,rder Eyelid ptosis In open,1
XEOMIN,Eyelid ptosis,rder Eyelid,1
XEOMIN,Eyelid ptosis,rder,0
XEOMIN,Eyelid ptosis,In open,0
XEOMIN,Eyelid ptosis,ptosis In open,1
XEOMIN,Eyelid ptosis,open,0
XEOMIN,Eyelid ptosis,Eyelid ptosis In open,1
XEOMIN,Eyelid ptosis,rder Eyelid ptosis In,1
XEOMIN,Eyelid ptosis,,0
XEOMIN,Headache,reported for of the,0
XEOMIN,Headache,Headache was,1
XEOMIN,Headache,reaction reported for subjects followed by injection site,0
XEOMIN,Headache,adverse reactions were,0
XEOMIN,Headache,Headache was,1
XEOMIN,Headache,multiple dose trials adverse,0
XEOMIN,Headache,Headache was,1
XEOMIN,Headache,was the most common adverse,0
XEOMIN,injection site hematoma,reported in less than of subjects were,0
XEOMIN,injection site hematoma,injection site hematoma in,1
XEOMIN,injection site hematoma,in subjects Adverse reactions reported in less than of subjects,0
XEOMIN,injection site hematoma,injection,1
XEOMIN,injection site hematoma,in less than of subjects were facial,0
XEOMIN,injection site hematoma,followed by,0
XEOMIN,facial paresis,facial paresis brow,1
XEOMIN,facial paresis,hematoma in subjects Adverse reactions reported in less than of subjects,0
XEOMIN,facial paresis,in less than,0
XEOMIN,facial paresis,,0
XEOMIN,facial paresis,,0
XEOMIN,facial paresis,less than of subjects facial paresis brow,1
XEOMIN,facial paresis,subjects Adverse reactions reported in less than,0
XEOMIN,brow ptosis,in less than of subjects,0
XEOMIN,brow ptosis,brow ptosis muscle,1
XEOMIN,brow ptosis,muscle,0
XEOMIN,brow ptosis,were facial brow ptosis muscle,1
XEOMIN,brow ptosis,,0
XEOMIN,brow ptosis,reported in,0
XEOMIN,brow ptosis,ptosis muscle,1
XEOMIN,brow ptosis,and eyelid edema Immunoge,0
XEOMIN,brow ptosis,brow ptosis muscle,1
XEOMIN,brow ptosis,edema Immunoge,0
XEOMIN,muscle disorder,,0
XEOMIN,muscle disorder,brow muscle,1
XEOMIN,muscle disorder,brow muscle disorder elevation,1
XEOMIN,muscle disorder,brow muscle,1
XEOMIN,muscle disorder,muscle,1
XEOMIN,muscle disorder,muscle disorder elevation,1
XEOMIN,elevation of eyebrow,injection site pain and eyelid edema Immunogenicity As with all therapeutic,0
XEOMIN,elevation of eyebrow,,0
XEOMIN,elevation of eyebrow,muscle elevation of eyebrow injection,1
XEOMIN,elevation of eyebrow,elevation,1
XEOMIN,injection site pain,site pain and,1
XEOMIN,injection site pain,site pain and,1
XEOMIN,injection site pain,eyebrow,0
XEOMIN,injection site pain,site pain and,1
XEOMIN,injection site pain,injection site pain and,1
XEOMIN,injection site pain,of injection,1
XEOMIN,injection site pain,site pain and,1
XEOMIN,injection site pain,therapeutic proteins,0
XEOMIN,eyelid edema,site pain eyelid,1
XEOMIN,eyelid edema,ptosis muscle disorder elevation of eyebrow injection site pain,0
XEOMIN,eyelid edema,pain eyelid,1
XEOMIN,eyelid edema,proteins there is a potential,0
XEOMIN,eyelid edema,disorder elevation of eyebrow injection site pain and,0
XEOMIN,eyelid edema,pain eyelid,1
XEOMIN,eyelid edema,edema Immunogenicity,1
XEOMIN,eye swelling,eye,1
XEOMIN,eye swelling,site,0
XEOMIN,eye swelling,causal relationship to drug eye swelling eyelid,1
XEOMIN,dysphagia,dysphagia nausea,1
XEOMIN,dysphagia,eye swelling eyelid dysphagia nausea,1
XEOMIN,dysphagia,dysphagia nausea,1
XEOMIN,dysphagia,,0
XEOMIN,nausea,,0
XEOMIN,flu-like symptoms,flu-like symptoms injection,1
XEOMIN,flu-like symptoms,eye swelling eyelid edema,0
XEOMIN,flu-like symptoms,flu-like symptoms injection,1
XEOMIN,flu-like symptoms,edema dysphagia flu-like,1
XEOMIN,flu-like symptoms,eyelid edema dysphagia flu-like symptoms injection,1
XEOMIN,flu-like symptoms,,0
XEOMIN,flu-like symptoms,to drug exposure eye swelling eyelid edema dysphagia nausea,0
XEOMIN,flu-like symptoms,causal,0
XEOMIN,injection site pain,nausea flulike injection,1
XEOMIN,injection site pain,pain injection,1
XEOMIN,injection site reaction,symptoms injection site injection site reaction allergic,1
XEOMIN,injection site reaction,,0
XEOMIN,injection site reaction,reaction allergic,1
XEOMIN,allergic dermatitis,allergic,1
XEOMIN,allergic dermatitis,injection site allergic,1
XEOMIN,allergic dermatitis,site pain,0
XEOMIN,allergic dermatitis,dermatitis localized,1
XEOMIN,allergic dermatitis,dermatitis localized,1
XEOMIN,allergic dermatitis,site pain injection site allergic,1
XEOMIN,allergic dermatitis,allergic dermatitis localized,1
XEOMIN,allergic dermatitis,site allergic,1
XEOMIN,localized allergic reactions,localized allergic,1
XEOMIN,localized allergic reactions,reaction allergic localized allergic reactions like,1
XEOMIN,localized allergic reactions,flulike symptoms injection site pain,0
XEOMIN,localized allergic reactions,,0
XEOMIN,localized allergic reactions,site reaction allergic localized,1
XEOMIN,herpes zoster,pruritus or herpes zoster muscular,1
XEOMIN,herpes zoster,,0
XEOMIN,muscular weakness,herpes muscular weakness muscle,1
XEOMIN,muscle spasm,muscle spasm dysarthria,1
XEOMIN,muscle spasm,muscular,0
XEOMIN,muscle spasm,,0
XEOMIN,muscle spasm,muscle spasm dysarthria,1
XEOMIN,muscle spasm,herpes zoster muscular muscle spasm dysarthria,1
XEOMIN,muscle spasm,and hypersensitivity,0
XEOMIN,muscle spasm,,0
XEOMIN,muscle spasm,hypersensitivity,0
XEOMIN,muscle spasm,muscle spasm dysarthria,1
XEOMIN,dysarthria,,0
XEOMIN,dysarthria,swelling edema erythema pruritus or rash herpes,0
XEOMIN,dysarthria,,0
XEOMIN,dysarthria,myalgia and hypersensitivity,0
XEOMIN,myalgia,myalgia and,1
XEOMIN,myalgia,muscular weakness muscle spasm,0
XEOMIN,myalgia,edema erythema pruritus or rash herpes zoster muscular,0
XEOMIN,myalgia,spasm myalgia and,1
XEOMIN,myalgia,myalgia and,1
XEOMIN,hypersensitivity,,0
XEOMIN,hypersensitivity,hypersensitivity,1
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,following adverse,1
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,following adverse,1
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT, following adverse reactions t o XEOMIN are discussed,1
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,,0
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,following adverse reactions,1
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,following adverse reactions t o XEOMIN,1
XEOMIN,spread from the area of injection,Precautions (5.3) ] * Dyspha gia and,1
XEOMIN,spread from the area of injection,in Treatment of cervical dystonia see,0
XEOMIN,spread from the area of injection,Treatment of cervical,0
XEOMIN,spread from the area of injection,gia and Breathing Difficulties in Treatment of cervical dystonia see Warnings,0
XEOMIN,toxin effects,onia see Warnings and Precautions,0
XEOMIN,toxin effects,dyst onia see,1
XEOMIN,toxin effects,of,0
XEOMIN,toxin effects,and Breathing Difficulties in Treatment,0
XEOMIN,toxin effects,in Treatment cervical,1
XEOMIN,toxin effects,cervical dyst onia see,1
XEOMIN,toxin effects,Breathing Difficulties in Treatment cervical dyst onia see,1
XEOMIN,toxin effects,Treatment cervical dyst onia see,1
XEOMIN,toxin effects,Difficulties in Treatment cervical,1
XEOMIN,toxin effects,and Precautions Dysphagia and Breathing Difficulties in Treatment,0
XEOMIN,asthenia,and,1
XEOMIN,asthenia,,0
XEOMIN,asthenia,Toxin see Warnings and,0
XEOMIN,asthenia,and Breathing Difficulties in Treatment of cervical dystonia see,0
XEOMIN,generalized muscle weakness,(5.4) ] * Sprea d of,1
XEOMIN,generalized muscle weakness,"Warnings and utions (5.4)   ] 
 *  Sprea d of",1
XEOMIN,generalized muscle weakness,Precautions EXCERPT Cervical,0
XEOMIN,generalized muscle weakness,and,0
XEOMIN,generalized muscle weakness,and utions (5.4) ] *,1
XEOMIN,generalized muscle weakness,utions (5.4) ] * Sprea d of,1
XEOMIN,generalized muscle weakness,Treatment,0
XEOMIN,generalized muscle weakness,"and utions (5.4)   ] 
 *  Sprea d of",1
XEOMIN,diplopia,Spread,0
XEOMIN,blurred vision,,0
XEOMIN,blurred vision,Spread of from,1
XEOMIN,blurred vision,Warnings and Precautions EXCERPT Cervical Dystonia The most commonly,0
XEOMIN,blurred vision,[s ee Warnings,1
XEOMIN,blurred vision,Warnings and Precautions Spread,0
XEOMIN,blurred vision,from Toxin,1
XEOMIN,blurred vision,Toxin [s ee Warnings,1
XEOMIN,blurred vision,Spread of  from Toxin [s ee Warnings,1
XEOMIN,blurred vision,Spread of  from Toxin [s ee Warnings,1
XEOMIN,ptosis,Dystonia,0
XEOMIN,ptosis,  Warn ings and,1
XEOMIN,ptosis,  Warn ings and,1
XEOMIN,ptosis,  Warn ings and,1
XEOMIN,ptosis,  Warn ings and,1
XEOMIN,ptosis,and Precautions EXCERPT,0
XEOMIN,ptosis,  Warn ings and,1
XEOMIN,ptosis,and Precautions Spread of Effects from Toxin,0
XEOMIN,dysphagia,Pr ecautions EXCERPT,1
XEOMIN,dysphagia,Cervical,0
XEOMIN,dysphagia,gs and Pr ecautions EXCERPT,1
XEOMIN,dysphagia,Effects from Toxin see gs,1
XEOMIN,dysarthria,Toxin see Warnings and 1),1
XEOMIN,dysarthria,see Warnings and 1),1
XEOMIN,dysarthria,"Toxin see Warnings and 1)  ]  
   EXCERPT Cervical",1
XEOMIN,dysarthria,"and 1)  ]  
   EXCERPT Cervical",1
XEOMIN,breathing difficulties,of Effects from Toxin see Warnings and Precautions EXCERPT,0
XEOMIN,breathing difficulties,Precautions EXCERPT Cervical ystonia: The most,1
XEOMIN,breathing difficulties,of Effects from Toxin see Warnings,0
XEOMIN,breathing difficulties,and,0
XEOMIN,breathing difficulties,Precautions,0
XEOMIN,breathing difficulties,EXCERPT Cervical ystonia:  The most com monly observed,1
XEOMIN,breathing difficulties,ystonia:,1
XEOMIN,breathing difficulties,and musculoskeletal pain Blepharospasm The most,0
XEOMIN,breathing difficulties,"are dysphagia ck pain, muscle weakne ss injection",1
XEOMIN,breathing difficulties,muscle weakne ss injection,1
XEOMIN,breathing difficulties,"pain, muscle weakne ss injection",1
XEOMIN,breathing difficulties,of patients and,0
XEOMIN,death,"  ).
 Blepharospasm The",1
XEOMIN,death,pain and,0
XEOMIN,death,muscle weakness injection site pain and,0
XEOMIN,death,dysphagia neck pain muscle weakness injection site,0
XEOMIN,death,"  ).
 Blepharospasm The",1
XEOMIN,death,observed adverse reactions of patients and placebo,0
XEOMIN,spread of effect,placebo is    To report SUS PECTED ADVERSE,1
XEOMIN,spread of effect,is,0
XEOMIN,spread of effect,is To report,1
XEOMIN,spread of effect,,0
XEOMIN,spread of effect,patients and placebo is To,1
XEOMIN,spread of effect,patients and placebo is To,1
XEOMIN,spread of effect,and placebo is To report,1
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,wwwfdagovmedwatch Clinical Trials Experience  clinical trials are conducted under widely,1
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,clinical trials are,1
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,clinical trials,1
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,varying conditions adverse reaction,0
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,wwwfdagovmedwatch Clinical Trials Experience  clinical trials are conducted under widely,1
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,Clinical Trials Experience  clinical trials are conducted under widely,1
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,Clinical Trials Experience clinical,1
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,a,0
XEOMIN,spread from the area of injection,observed in the clinical trials of a drug cannot be,0
XEOMIN,spread from the area of injection,drug and,0
XEOMIN,spread from the area of injection,rates observed in practice,0
XEOMIN,spread from the area of injection,compared to in,1
XEOMIN,spread from the area of injection,in the clinical trials,1
XEOMIN,spread from the area of injection, in the clinical trials of anothe r drug,1
XEOMIN,spread from the area of injection,in the clinical trials of anothe r drug,1
XEOMIN,spread from the area of injection,be directly compared to  in the clinical trials of anothe r drug,1
XEOMIN,spread from the area of injection,directly compared to  in the clinical trials of anothe r drug,1
XEOMIN,spread from the area of injection, in the clinical trials of anothe r drug,1
XEOMIN,toxin effects,"the rates in practice.
 Cervical Dystonia",1
XEOMIN,toxin effects,,0
XEOMIN,toxin effects,in practice. Cervical Dystonia,1
XEOMIN,toxin effects,below reflect exposure to,0
XEOMIN,toxin effects,"rates in practice.
 Cervical Dystonia",1
XEOMIN,toxin effects,in practice. Cervical Dystonia,1
XEOMIN,toxin effects,"not reflect the rates in practice.
 Cervical Dystonia",1
XEOMIN,toxin effects,The data described below reflect exposure to,0
XEOMIN,breathing difficulties,a,0
XEOMIN,death,exposure,0
XEOMIN,dysphagia,respiratory tract infection Glabellar Lines The most commonly observed adverse,0
XEOMIN,Corneal exposure,"is e (  6.1  ).



 To report",1
XEOMIN,reduced blinking,,0
XEOMIN,reduced blinking,LLC 6646 or,1
XEOMIN,reduced blinking,,0
XEOMIN,corneal exposure,fdagovmedwatch Clinical Trials Experience Because,0
XEOMIN,corneal exposure,or www fdagovmedwatch Clinical,1
XEOMIN,corneal exposure,at or FDA FDA-1088 or  www fdagovmedwatch Clinical,1
XEOMIN,corneal exposure,Merz Pharmaceuticals LLC at or FDA at,0
XEOMIN,ptosis,in the clinical trials of another drug,0
XEOMIN,ptosis,widely varying conditions adverse reaction rates observed in the clinical trials,0
XEOMIN,ptosis,be directly compared,1
XEOMIN,ptosis,and may not reflect the,0
XEOMIN,ptosis,a drug not be directly compared,1
XEOMIN,ptosis,the clinical trials,0
XEOMIN,ptosis,drug not be directly compared,1
XEOMIN,ptosis,a drug not be directly compared,1
XEOMIN,ptosis,not be directly compared,1
XEOMIN,asthenia,Clinical tudies ( In this,1
XEOMIN,asthenia,dystonia see Clinical tudies,1
XEOMIN,asthenia,XEOMIN were randomized to receive a total dose,0
XEOMIN,asthenia,XEOMIN were randomized,0
XEOMIN,asthenia,randomized,0
XEOMIN,asthenia,total dose,0
XEOMIN,asthenia,see,0
XEOMIN,generalized muscle weakness,see,0
XEOMIN,generalized muscle weakness,"cervical dystonia see Clinical .1)    ]. In this study, 15 patients received",1
XEOMIN,generalized muscle weakness,were ran,0
XEOMIN,generalized muscle weakness,a total dose of Units and were,0
XEOMIN,generalized muscle weakness,"In this study, 15 patients received",1
XEOMIN,generalized muscle weakness,ran,0
XEOMIN,generalized muscle weakness,"In this study, 15 patients received",1
XEOMIN,generalized muscle weakness,"study, 15 patients received",1
XEOMIN,generalized muscle weakness,cervical dystonia,0
XEOMIN,diplopia,patients received XEOMIN,1
XEOMIN,diplopia,patients received XEOMIN,1
XEOMIN,blurred vision,In this study patients,0
XEOMIN,blurred vision,,0
XEOMIN,blurred vision,,0
XEOMIN,blurred vision,this study patients eceived,1
XEOMIN,blurred vision,with cervical dystonia see Clinical Studies In this,0
XEOMIN,blurred vision,,0
XEOMIN,blurred vision,XEOMIN were randomized,1
XEOMIN,blurred vision,eceived XEOMIN were randomized,1
XEOMIN,blurred vision,Clinical,0
XEOMIN,ptosis,total dose,0
XEOMIN,ptosis,this study patients received 78,1
XEOMIN,ptosis,study patients received 78,1
XEOMIN,ptosis,dystonia see Clinical Studies,0
XEOMIN,ptosis,78 wer e randomized,1
XEOMIN,ptosis,study patients received 78,1
XEOMIN,ptosis,78 wer e randomized,1
XEOMIN,ptosis,this study,0
XEOMIN,dysphagia,dose of Units,0
XEOMIN,dysphagia,,0
XEOMIN,dysphagia,randomized to receive a total dose of,0
XEOMIN,dysphagia,randomize d to,1
XEOMIN,dysphonia,to receiv e a,1
XEOMIN,dysphonia,receiv e a,1
XEOMIN,dysphonia,and were randomized to receive a,0
XEOMIN,dysphonia,patients received XEOMIN were to,1
XEOMIN,dysphonia,total dose of Units,0
XEOMIN,dysphonia,In this study patients received XEOMIN were randomized,0
XEOMIN,dysphonia,,0
XEOMIN,dysphonia,XEOMIN were to receiv e a,1
XEOMIN,dysphonia,XEOMIN were to receiv e a,1
XEOMIN,dysphonia,,0
XEOMIN,dysarthria,XEOMIN were randomized to a total do se of,1
XEOMIN,dysarthria,XEOMINtreated,0
XEOMIN,dysarthria,received XEOMIN were,0
XEOMIN,dysarthria,received XEOMIN were randomized to receive,0
XEOMIN,dysarthria,XEOMIN were randomized to a,1
XEOMIN,urinary incontinence,"total  of 120 Units, and 8 were randomized",1
XEOMIN,urinary incontinence,total,0
XEOMIN,urinary incontinence,to years,0
XEOMIN,urinary incontinence,"receive a total  of 120 Units, and 8 were randomized",1
XEOMIN,breathing difficulties,receive a total,1
XEOMIN,breathing difficulties,XEOMIN were,0
XEOMIN,breathing difficulties,"to years old 53 years),",1
XEOMIN,breathing difficulties,"53 years), and were",1
XEOMIN,breathing difficulties,,0
XEOMIN,breathing difficulties,patients were to years old mean,0
XEOMIN,breathing difficulties,"were to years old 53 years), and were pr edominantly female",1
XEOMIN,breathing difficulties,"53 years), and",1
XEOMIN,breathing difficulties,"53 years), and",1
XEOMIN,breathing difficulties,"old 53 years), and were pr edominantly female",1
XEOMIN,death,aseli ne approximately,1
XEOMIN,death,and were predominantly,0
XEOMIN,death,b,0
XEOMIN,death,years old mean years and were predominantly female and Caucasian,0
XEOMIN,death,Caucasian At study aseli ne approximately,1
XEOMIN,spread of toxin effects,study baseline y,1
XEOMIN,spread of toxin effects,"At study baseline y 25% had mild, 50% had moderate and",1
XEOMIN,spread of toxin effects,Caucasian At study baseline y,1
XEOMIN,spread of toxin effect,,0
XEOMIN,spread of toxin effect,musculoskeletal pain 2: Most Common TEAEs,1
XEOMIN,Hypersensitivity reactions,         7%                Gastrointestinal disorders,1
XEOMIN,Hypersensitivity reactions,,0
XEOMIN,Hypersensitivity reactions,,0
XEOMIN,Hypersensitivity reactions,Musculoskeletal          7%                Gastrointestinal disorders,1
XEOMIN,anaphylaxis,,0
XEOMIN,anaphylaxis,"     
 Gast rointestinal disorders",1
XEOMIN,anaphylaxis,,0
XEOMIN,serum sickness,pain intestinal,1
XEOMIN,serum sickness,pain intestinal,1
XEOMIN,serum sickness,Dysphag,0
XEOMIN,serum sickness,dis orders Dysphag,1
XEOMIN,serum sickness,,0
XEOMIN,serum sickness,Gastro,0
XEOMIN,serum sickness,intestinal dis orders Dysphag,1
XEOMIN,soft tissue edema,   18%            Dysphagia,1
XEOMIN,soft tissue edema,Dysphagia,0
XEOMIN,soft tissue edema,,0
XEOMIN,soft tissue edema,   18%            Dysphagia,1
XEOMIN,soft tissue edema,Dysphagia,0
XEOMIN,soft tissue edema,,0
XEOMIN,soft tissue edema,,0
XEOMIN,soft tissue edema,Gastrointestinal    18%            Dysphagia,1
XEOMIN,soft tissue edema,,0
XEOMIN,dyspnea,Gastrointestinal     24% Dysphagia,1
XEOMIN,dyspnea,,0
XEOMIN,dyspnea,,0
XEOMIN,dyspnea,,0
XEOMIN,dyspnea,,0
XEOMIN,breathing difficulties,disorders and administration site conditions,0
XEOMIN,breathing difficulties,,0
XEOMIN,breathing difficulties,     11%               Injection site,1
XEOMIN,breathing difficulties,     11%               Injection site,1
XEOMIN,breathing difficulties,conditions,0
XEOMIN,Deaths,thoracic and mediastinal        Blepharospasm In,1
XEOMIN,Deaths,trial in patients,0
XEOMIN,Deaths,In the placebocontrolled Phase,0
XEOMIN,dysphagia,Blepharosp,0
XEOMIN,dysphagia,trial,0
XEOMIN,Dysphagia,,0
XEOMIN,Aspiration,,0
XEOMIN,Aspiration,,0
XEOMIN,Aspiration,at a mean dose,1
XEOMIN,Aspiration,patients  XEOMIN at a mean dose,1
XEOMIN,Aspiration,see,0
XEOMIN,Aspiration,see Clinical Studies patients received,0
XEOMIN,Aspiration,XEOMIN at a mean dose,1
XEOMIN,Aspiration,see Clinical Studies patients XEOMIN,1
XEOMIN,Aspiration,with onabotulinumtoxinA Botox see,0
XEOMIN,Aspiration,Clinical Studies patients  XEOMIN at a mean dose,1
XEOMIN,dysphagia,dose,0
XEOMIN,dysphagia,ately,1
XEOMIN,dysphagia,ately 33 Units per eye,1
XEOMIN,weaken neck muscles,an time,1
XEOMIN,weaken neck muscles,a an,1
XEOMIN,weaken neck muscles,occurring in of XEOMINtreated patients a,0
XEOMIN,weaken neck muscles,occurring in of XEOMINtreated,0
XEOMIN,weaken neck muscles,,0
XEOMIN,weaken neck muscles,since diagn osis of approximately,1
XEOMIN,weaken neck muscles,an time since diagn osis of approximately,1
XEOMIN,weaken neck muscles,an,1
XEOMIN,loss of breathing capacity,in of OMIN-treated patients and  greater than placebo,1
XEOMIN,breathing difficulties,respiratory tract inf ection No serious,1
XEOMIN,breathing difficulties,respiratory tract inf ection No serious,1
XEOMIN,respiratory failure,XEOMIN one placebotreated patient experienced a serious adver,0
XEOMIN,respiratory failure,No erious adverse even ts occurred in,1
XEOMIN,respiratory failure,respiratory tract infection No erious,1
XEOMIN,respiratory failure,who received XEOMIN one placebotreated patient experienced,0
XEOMIN,respiratory failure,adverse even ts occurred in,1
XEOMIN,respiratory failure,adverse even ts occurred in,1
XEOMIN,respiratory failure,,0
XEOMIN,dysphagia,Phase of Clinical           DoubleBlind Phase System,1
XEOMIN,dysphagia,          DoubleBlind Phase System,1
XEOMIN,dysphagia,%         Diarrhoea,1
XEOMIN,dysphagia,,0
XEOMIN,dysphagia,%         Diarrhoea,1
XEOMIN,dysphagia,mouth,0
XEOMIN,dysphagia,Dry %         Diarrhoea,1
XEOMIN,dysphagia,%         Diarrhoea,1
XEOMIN,dysphagia,,0
XEOMIN,dysphagia,mouth,0
XEOMIN,dysphagia,%         Diarrhoea,1
XEOMIN,dysphagia,%         Diarrhoea,1
XEOMIN,respiratory compromise,Dry            3%          Diarrhoea,1
XEOMIN,respiratory compromise,Dry            3%          Diarrhoea,1
XEOMIN,respiratory compromise,           3%          Diarrhoea,1
XEOMIN,respiratory compromise,           3%          Diarrhoea,1
XEOMIN,respiratory compromise,Dry            3%          Diarrhoea,1
XEOMIN,Reduced blinking,and,0
XEOMIN,Reduced blinking,,0
XEOMIN,Reduced blinking,                 Nasopharyngitis,1
XEOMIN,Reduced blinking,                 Nasopharyngitis,1
XEOMIN,Reduced blinking,and                  Nasopharyngitis,1
XEOMIN,Reduced blinking,,0
XEOMIN,Reduced blinking,                 Nasopharyngitis,1
XEOMIN,Reduced blinking,and,0
XEOMIN,Reduced blinking,                 Nasopharyngitis,1
XEOMIN,Reduced blinking,,0
XEOMIN,corneal exposure,       5%        Respiratory tract,1
XEOMIN,corneal exposure,Nasopharyngitis        5%        Respiratory tract,1
XEOMIN,corneal exposure,Nasopharyngitis,0
XEOMIN,corneal exposure,Nasopharyngitis        5%        Respiratory tract,1
XEOMIN,corneal exposure,Nasopharyngitis,0
XEOMIN,corneal exposure,Nasopharyngitis        5%        Respiratory tract,1
XEOMIN,corneal exposure,Nasopharyngitis,0
XEOMIN,corneal ulceration,,0
XEOMIN,corneal ulceration,trac,1
XEOMIN,corneal ulceration,haryngitis Respiratory,1
XEOMIN,corneal ulceration,Respiratory trac t infection Nervous,1
XEOMIN,corneal ulceration,haryngitis,0
XEOMIN,corneal ulceration,"haryngitis 
 Respiratory trac t",1
XEOMIN,transmission of viral diseases,in there is some basis to believe there,1
XEOMIN,transmission of viral diseases,,0
XEOMIN,transmission of viral diseases,basis to believe there,1
XEOMIN,transmission of viral diseases,to believe there,1
XEOMIN,transmission of viral diseases,a causal relationship between the drug and the occurrence of the,0
XEOMIN,Creutzfeldt-Jakob disease,of the adverse event Because clinical,0
XEOMIN,Creutzfeldt-Jakob disease,and the occurrenc e,1
XEOMIN,Creutzfeldt-Jakob disease,a causal relationship between he drug and the occurrenc e,1
XEOMIN,Creutzfeldt-Jakob disease,a causal relationship between he drug and,1
XEOMIN,Creutzfeldt-Jakob disease,occurrenc e,1
XEOMIN,Creutzfeldt-Jakob disease,t,0
XEOMIN,Creutzfeldt-Jakob disease,drug and the occurrenc e,1
XEOMIN,Creutzfeldt-Jakob disease,t,0
XEOMIN,Creutzfeldt-Jakob disease,,0
XEOMIN,Creutzfeldt-Jakob disease,he drug and the occurrenc e,1
XEOMIN,CJD,there is some basis to believe there is,0
XEOMIN,CJD,of  the,1
XEOMIN,CJD,event,0
QUTENZA,Increase in Blood Pressure,Precautions EXCERPT The most common,0
QUTENZA,Increase in Blood Pressure,in Blood Pressure see,1
QUTENZA,Increase in Blood Pressure,see Warnings and Increase,1
QUTENZA,Increase in Blood Pressure,Precautions,0
QUTENZA,Increase in Blood Pressure,adverse reactions,0
QUTENZA,Increase in Blood Pressure,Pressure see,1
QUTENZA,Increase in Blood Pressure,,0
QUTENZA,Increase in Blood Pressure,see Warnings and Increase in Blood Pressure see,1
QUTENZA,application site erythema,and,0
QUTENZA,application site erythema,and greater than control application site erythema application,1
QUTENZA,application site erythema,erythema application,1
QUTENZA,application site erythema,To,0
QUTENZA,application site erythema,greater than control application site erythema application,1
QUTENZA,application site erythema,application site erythema application,1
QUTENZA,application site erythema,reactions and greater,0
QUTENZA,application site erythema,adverse,0
QUTENZA,application site pain,site application,1
QUTENZA,application site pain,site pruritus and application site papules To report SUSPECTED,0
QUTENZA,application site pain,,0
QUTENZA,application site pain,site,0
QUTENZA,application site pain,and application site,0
QUTENZA,application site pain,application site pain application,1
QUTENZA,application site pain,are application site application site,1
QUTENZA,application site pain,site application,1
QUTENZA,application site pain,site application site,1
QUTENZA,application site pain,application site application,1
QUTENZA,application site papules,pruritus application site papules To,1
QUTENZA,application site papules,application site papules To,1
QUTENZA,application site papules,control are application site erythema application site pain application site pruritus,0
QUTENZA,application site papules,site pruritus application site papules To,1
QUTENZA,application site papules,site papules To,1
QUTENZA,application site papules,application site papules To,1
QUTENZA,application site papules,,0
QUTENZA,application site papules,site pruritus and,0
QUTENZA,application site papules,pain application site pruritus application site,1
QUTENZA,application site erythema,application site,0
QUTENZA,application site erythema,control group application site,1
QUTENZA,application site erythema,control group application site,1
QUTENZA,application site erythema,,0
QUTENZA,application site erythema,group application site erythema application,1
QUTENZA,application site erythema,application site pruritus and application site papules Table summari,0
QUTENZA,application site erythema,Table,0
QUTENZA,application site pruritus,group,0
QUTENZA,application site pruritus,application,1
QUTENZA,application site pruritus,site pruritus and,1
QUTENZA,application site pruritus,,0
QUTENZA,application site pruritus,application site pruritus and,1
QUTENZA,application site papules,application site papules Table,1
QUTENZA,application site papules,pruritus application,1
QUTENZA,application site papules,Table summarizes,0
QUTENZA,application site papules,pain application site pruritus application site papules Table,1
QUTENZA,application site papules,site pruritus application site,1
QUTENZA,application site papules,patie,0
QUTENZA,application site papules,site pain application site,0
QUTENZA,application site papules,occurring in,0
QUTENZA,application site papules,application site erythema application site pain application site pruritus,0
QUTENZA,application site papules,,0
QUTENZA,application site reactions,,0
QUTENZA,application site reactions,of t,0
QUTENZA,application site reactions,for which the incidence was greater than in the control group,0
QUTENZA,application site reactions,the Qutenza group for which the incidence was greater than in the control group The,0
QUTENZA,application site reactions,,0
QUTENZA,application site reactions,majority application site,1
QUTENZA,application site reactions,group The majority application site,1
QUTENZA,application site reactions,application site,1
QUTENZA,increases in pain,increases,1
QUTENZA,increases in pain,reactions were transient and,0
QUTENZA,increases in pain,transient and selflimited increases in pain were,1
QUTENZA,increases in pain,increases in pain were,1
QUTENZA,increases in pain,and selflimited increases in pain were,1
QUTENZA,increases in pain,,0
QUTENZA,increases in pain,pain were,1
QUTENZA,Pain increases,Pain increases occurring,1
QUTENZA,Pain increases,increases occurring,1
QUTENZA,Pain increases,Pain,1
QUTENZA,Pain increases,,0
QUTENZA,Pain increases,treated with Qutenza,0
QUTENZA,Pain increases,pain were commonly observed on the,0
QUTENZA,Application Site Erythema,Erythema Application,1
QUTENZA,Application Site Erythema,Application,1
QUTENZA,Application Site Erythema,Application,0
QUTENZA,Application Site Erythema,Erythema Application,1
QUTENZA,Application Site Erythema,Administration Site Application Site Erythema Application,1
QUTENZA,Application Site Erythema,Administration Site Application Site Erythema Application,1
QUTENZA,Application Site Erythema,,0
QUTENZA,Application Site Erythema,Site,0
QUTENZA,Application Site Pain,on Site Application Site Pain Application,1
QUTENZA,Application Site Pain,Application Site,1
QUTENZA,Application Site Pruritus,on Site Application,1
QUTENZA,Application Site Pruritus,Application Site Pruritus Application,1
QUTENZA,Application Site Pruritus,,0
QUTENZA,Application Site Pruritus,Application Site,0
QUTENZA,Application Site Papules,Site Application Site Papules Application,1
QUTENZA,Application Site Papules,Site Application,1
QUTENZA,Application Site Papules,Site Pruritus,0
QUTENZA,Application Site Edema,Site Application,1
QUTENZA,Application Site Edema,Site Papules,0
QUTENZA,Application Site Edema,Application Site,1
QUTENZA,Application Site Edema,Site Application Site,1
QUTENZA,Application Site Edema,Site,0
QUTENZA,Application Site Edema,on Site Application,1
QUTENZA,Application Site Edema,,0
QUTENZA,Application Site Edema,Site Edema Application,1
QUTENZA,Application Site Edema,Application Site,1
QUTENZA,Application Site Swelling,Application,0
QUTENZA,Application Site Swelling,Site,0
QUTENZA,Application Site Swelling,Site Application,1
QUTENZA,Application Site Swelling,Site,0
QUTENZA,Application Site Swelling,Application Site Swelling Application,1
QUTENZA,Application Site Dryness,Swelling,0
QUTENZA,Bronchitis,ngitis Bronchitis S,1
QUTENZA,Sinusitis,Sinusitis,1
QUTENZA,Sinusitis,,0
QUTENZA,Sinusitis,Sinusitis,1
QUTENZA,Sinusitis,Sinusitis,1
QUTENZA,Sinusitis,Sinusitis,1
QUTENZA,Sinusitis,Sinusitis,1
QUTENZA,Sinusitis,s Sinusitis,1
QUTENZA,Sinusitis,s Sinusitis,1
QUTENZA,Nausea,Nausea,1
QUTENZA,Nausea,ntestinal Nausea,1
QUTENZA,Nausea,Nausea,1
QUTENZA,Nausea,,0
QUTENZA,Nausea,Nausea,1
QUTENZA,Nausea,Disorders,0
QUTENZA,Nausea,Nausea,1
QUTENZA,Nausea,Disorders,0
QUTENZA,Pruritus,Pruritus,1
QUTENZA,Pruritus,Subcutaneous Tissue Pruritus,1
QUTENZA,Application site paresthesia,Application site paresthesia,1
QUTENZA,Application site paresthesia,Application,1
QUTENZA,Application site paresthesia,site urticaria,0
QUTENZA,Application site paresthesia,site paresthesia,1
QUTENZA,Application site paresthesia,Application,0
QUTENZA,Application site paresthesia,site Application,1
QUTENZA,Application site paresthesia,Conditions Application site Application site paresthesia,1
QUTENZA,Application site paresthesia,Site Conditions Application site Application site paresthesia,1
QUTENZA,Application site paresthesia,Conditions Application site Application site paresthesia,1
QUTENZA,Application site paresthesia,Application site Application,1
QUTENZA,Application site dermatitis,Application site Application site dermatitis,1
QUTENZA,Application site dermatitis,Application site dermatitis,1
QUTENZA,Application site dermatitis,urticaria Application site paresthesia,0
QUTENZA,Application site dermatitis,Application,0
QUTENZA,Application site dermatitis,,0
QUTENZA,Application site hyperesthesia,site dermatitis,0
QUTENZA,Application site hyperesthesia,dermatitis,0
QUTENZA,Application site hyperesthesia,Application site hyperesthesia,1
QUTENZA,Application site hyperesthesia,,0
QUTENZA,Application site hyperesthesia,Application site,0
QUTENZA,Application site hyperesthesia,site,0
QUTENZA,Application site hyperesthesia,site excoriation Application site,0
QUTENZA,Application site hyperesthesia,,0
QUTENZA,Application site excoriation,site Application site excoriation,1
QUTENZA,Application site excoriation,site dermatitis Application site Application site,1
QUTENZA,Application site warmth,site Application site warmth,1
QUTENZA,Application site warmth,anesthesia Application site bruising,0
QUTENZA,Application site warmth,site warmth,1
QUTENZA,Application site warmth,Application,0
QUTENZA,Application site warmth,excoriation,0
QUTENZA,Application site warmth,,0
QUTENZA,Application site warmth,site Application,1
QUTENZA,Application site warmth,Application site hyperesthesia Application site,0
QUTENZA,Application site anesthesia,excoriation Application site Application site anesthesia,1
QUTENZA,Application site anesthesia,,0
QUTENZA,Application site anesthesia,bruising Application site inflammation,0
QUTENZA,Application site anesthesia,bruising Application site,0
QUTENZA,Application site anesthesia,Application site warmth,0
QUTENZA,Application site anesthesia,site exfoliation Peripheral,0
QUTENZA,Application site anesthesia,Application site anesthesia,1
QUTENZA,Application site bruising,Application site Application site bruising,1
QUTENZA,Application site bruising,Application site inflammation Application site,0
QUTENZA,Application site bruising,System,0
QUTENZA,Application site bruising,,0
QUTENZA,Application site exfoliation,bruising Application site Application site exfoliation,1
QUTENZA,Application site exfoliation,Application site bruising Application site,0
QUTENZA,Application site exfoliation,exfoliation,1
QUTENZA,Peripheral edema,sensory,0
QUTENZA,Peripheral edema,site inflammation Application site Peripheral edema,1
QUTENZA,Peripheral edema,Peripheral,1
QUTENZA,Peripheral edema,,0
QUTENZA,Peripheral edema,Nervous System Disorders Headache Burning,0
QUTENZA,Peripheral edema,Headache Burning,0
QUTENZA,Peripheral edema,,0
QUTENZA,Peripheral edema,Peripheral,1
QUTENZA,Peripheral edema,inflammation Application site Peripheral edema,1
QUTENZA,Peripheral edema,site inflammation Application site Peripheral edema,1
QUTENZA,Headache,Dizziness,0
QUTENZA,Headache,Headache,1
QUTENZA,Headache,site inflammation Application site exfoliation Peripheral edema Nervous,0
QUTENZA,Headache,,0
QUTENZA,Headache,Peripheral edema Nervous,0
QUTENZA,Headache,,0
QUTENZA,Headache,edema Nervous,0
QUTENZA,Burning sensation,exfoliation Peripheral edema Nervous System Disorders Headache,0
QUTENZA,Burning sensation,Disorders,0
QUTENZA,Burning sensation,System Disorders Headache,0
QUTENZA,Burning sensation,Dizziness Dysgeusia,0
QUTENZA,Burning sensation,,0
QUTENZA,Burning sensation,System Disorders,0
QUTENZA,Burning sensation,Burning,1
QUTENZA,Burning sensation,Nervous System Disorders Burning,1
QUTENZA,Burning sensation,edema Nervous System Disorders Burning,1
QUTENZA,Burning sensation,,0
QUTENZA,Peripheral sensory neuropathy,,0
QUTENZA,Dizziness,Disorders,0
QUTENZA,Dizziness,Dizziness,1
QUTENZA,Dizziness,Dizziness,1
QUTENZA,Dizziness,Dizziness,1
QUTENZA,Dysgeusia,Dysgeusia,1
QUTENZA,Dysgeusia,,0
QUTENZA,Dysgeusia,Dysgeusia,1
QUTENZA,Dysgeusia,Disorders Headache Burning,0
QUTENZA,Dysgeusia,System Disorders Headache Burning sensation Peripheral sensory,0
QUTENZA,Dysgeusia,Burning sensation Peripheral sensory,0
QUTENZA,Dysgeusia,,0
QUTENZA,Hyperesthesia,Dizziness Hyperesthesia,1
QUTENZA,Hyperesthesia,Thoracic and Mediastinal Disorders Cough Throat,0
QUTENZA,Hyperesthesia,Disorders Headache Burning sensation Peripheral,0
QUTENZA,Hyperesthesia,,0
QUTENZA,Hyperesthesia,Burning sensation,0
QUTENZA,Hypoesthesia,Thoracic and Mediastinal Disorders Cough Throat,0
QUTENZA,Hypoesthesia,Dizziness Dysgeusia Hypoesthesia,1
QUTENZA,Hypoesthesia,sensory,0
QUTENZA,Hypoesthesia,Mediastinal Disorders Cough Throat irritation Skin,0
QUTENZA,Hypoesthesia,Respiratory Thoracic and Mediastinal,0
QUTENZA,Hypoesthesia,sensation Peripheral sensory,0
QUTENZA,Hypoesthesia,Subcutan,0
QUTENZA,Hypoesthesia,Subcutan,0
QUTENZA,Hypoesthesia,Dysgeusia Hypoesthesia,1
QUTENZA,Cough,Cough,1
QUTENZA,Cough,Tissue Disorders Abnormal skin odor,0
QUTENZA,Cough,Respiratory Thoracic and Mediastinal Cough,1
QUTENZA,Cough,and Subcutaneous Tissue Disorders Abnormal skin odor,0
QUTENZA,Cough,Hypoesthesia Respiratory Thoracic,0
QUTENZA,Cough,,0
QUTENZA,Throat irritation,Throat irritation,1
QUTENZA,Throat irritation,Disorders Throat irritation,1
QUTENZA,Throat irritation,and Subcutaneous,0
QUTENZA,Abnormal skin odor,odor,1
QUTENZA,Abnormal skin odor,odor,1
QUTENZA,Abnormal skin odor,,0
QUTENZA,Abnormal skin odor,Skin and Subcutaneous Tissue Abnormal skin,1
QUTENZA,Abnormal skin odor,,0
QUTENZA,Abnormal skin odor,Skin and Subcutaneous Tissue Abnormal skin odor,1
QUTENZA,Abnormal skin odor,Skin and Subcutaneous Tissue Disorders,0
QUTENZA,Abnormal skin odor,,0
QUTENZA,Abnormal skin odor,Mediastinal Disorders Cough Throat irritation Skin and Subcutaneous Tissue Disorders,0
QUTENZA,Abnormal skin odor,Skin and Subcutaneous Tissue Abnormal,1
QUTENZA,coughing,Pre,1
QUTENZA,coughing,and Pre,1
QUTENZA,coughing,Pre,1
QUTENZA,coughing,and Pre,1
QUTENZA,coughing,labeling ApplicationAssociated Pain see  and Pre,1
QUTENZA,coughing,Pressure see,0
QUTENZA,coughing,see and,1
QUTENZA,coughing,in Blood Pressure see Warnings and Precautions,0
QUTENZA,coughing,the labeling ApplicationAssociated Pain see Warnings,0
QUTENZA,sneezing,Warnings and ions (5.,1
QUTENZA,sneezing,ions (5.,1
QUTENZA,sneezing,Warnings and Precaut,0
QUTENZA,sneezing,Blood,0
QUTENZA,sneezing,Increase in Blood Pressure see Warnings and Precautions,0
QUTENZA,sneezing,see Warnings and ions (5.,1
QUTENZA,sneezing,and Precaut,0
QUTENZA,increases in blood pressure,"To report SUSPECTED ADVERSE ACTIONS,",1
QUTENZA,coughing,and at an e greate,1
QUTENZA,coughing,an incidenc,0
QUTENZA,coughing,an e greate,1
QUTENZA,coughing,group and at an e,1
QUTENZA,sneezing,in th,1
QUTENZA,sneezing,were application site erythema application site pain application,0
QUTENZA,sneezing,of,0
QUTENZA,sneezing,application site erythema application site pain application site,0
QUTENZA,increases in blood pressure,"reactions with a maximum ntensity of ""mild"" or ""mode",1
QUTENZA,increases in blood pressure,"maximum ntensity of ""mild""",1
QUTENZA,Increases in blood pressure,in of Qutenzatreated patients and at least greater in the Qutenza group than,0
QUTENZA,Increases in blood pressure,group) Body S,1
QUTENZA,Increases in blood pressure,Control group) Body S,1
QUTENZA,Increases in blood pressure,the,1
QUTENZA,Increases in blood pressure,,0
QUTENZA,Increases in blood pressure,Control group) Body S,1
QUTENZA,Increases in blood pressure,least greater in the Qutenza group than in,0
QUTENZA,increases in pain,tes(N = 495)%,1
QUTENZA,increases in pain,and,0
QUTENZA,increases in pain,and Administration Site Conditions,0
QUTENZA,increases in pain,= 495)%,1
QUTENZA,increases in pain,,0
QUTENZA,increases in pain,"minutesN Control tes(N = 495)%   
",1
QUTENZA,increases in pain,minu,0
QUTENZA,adverse cardiovascular effects,Pain,0
QUTENZA,adverse cardiovascular effects,Pain,0
QUTENZA,adverse cardiovascular effects,                     42       ,1
QUTENZA,adverse cardiovascular effects,Site                      42       ,1
QUTENZA,adverse cardiovascular effects,,0
QUTENZA,adverse cardiovascular effects,Pain,0
ZYTIGA,Hypertension,Hypertension,1
ZYTIGA,Hypertension,Hypertension,1
ZYTIGA,Hypertension,Hypertension,1
ZYTIGA,Hypertension,Hypertension,1
ZYTIGA,Hypertension,other sections of the Hypertension,1
ZYTIGA,Hypertension,in more detail,0
ZYTIGA,Fluid Retention,detail,0
ZYTIGA,Fluid Retention,and,0
ZYTIGA,Mineralocorticoid Excess,and Fluid Retention,0
ZYTIGA,Mineralocorticoid Excess,sections of the labeling Hypertension Hypokalemia,0
ZYTIGA,Mineralocorticoid Excess,Retention due Mineralocorticoid Excess,1
ZYTIGA,Mineralocorticoid Excess,Excess,1
ZYTIGA,Mineralocorticoid Excess,sections,0
ZYTIGA,Mineralocorticoid Excess,due Mineralocorticoid,1
ZYTIGA,Adrenocortical Insufficiency,seeWarnings and Precautions,0
ZYTIGA,Adrenocortical Insufficiency,Mineralocorticoid Excess seeWarnings and Adrenocortical Insufficiency,1
ZYTIGA,Adrenocortical Insufficiency,seeWarnings and Precautions Hepatotoxicity,0
ZYTIGA,Adrenocortical Insufficiency,Adrenocortical Insufficiency,1
ZYTIGA,Adrenocortical Insufficiency,Excess seeWarnings and Adrenocortical,1
ZYTIGA,Adrenocortical Insufficiency,Precautions,0
ZYTIGA,Hepatotoxicity,Precautions,0
ZYTIGA,Hepatotoxicity,,0
ZYTIGA,Hepatotoxicity,Hepatotoxicity,1
ZYTIGA,fatigue,Precautions EXCERPT The most common adverse reactions are,0
ZYTIGA,fatigue,reactions are,0
ZYTIGA,fatigue,fatigue,1
ZYTIGA,fatigue,most common adverse reactions fatigue,1
ZYTIGA,fatigue,edema hot flush,0
ZYTIGA,fatigue,fatigue,1
ZYTIGA,fatigue,most common adverse reactions,0
ZYTIGA,fatigue,,0
ZYTIGA,fatigue,fatigue,1
ZYTIGA,fatigue,fatigue,1
ZYTIGA,joint swelling,reactions,0
ZYTIGA,joint swelling,swelling,1
ZYTIGA,joint swelling,hot flush diarrhea vomiting cough hypertension dyspnea urinary,0
ZYTIGA,joint swelling,,0
ZYTIGA,joint swelling,common,0
ZYTIGA,edema,most common adverse reactions are,0
ZYTIGA,hot flush,discomfort hot flush,1
ZYTIGA,hot flush,hot flush,1
ZYTIGA,diarrhea,contusion The most,0
ZYTIGA,diarrhea,diarrhea,1
ZYTIGA,diarrhea,diarrhea,1
ZYTIGA,diarrhea,hot diarrhea,1
ZYTIGA,diarrhea,,0
ZYTIGA,diarrhea,,0
ZYTIGA,cough,cough,1
ZYTIGA,cough,cough,1
ZYTIGA,cough,cough,1
ZYTIGA,cough,and contusion The most common laboratory,0
ZYTIGA,cough,laboratory,0
ZYTIGA,cough,cough,1
ZYTIGA,cough,edema hot flush diarrhea cough,1
ZYTIGA,cough,diarrhea,0
ZYTIGA,cough,edema hot flush diarrhea cough,1
ZYTIGA,cough,flush diarrhea,0
ZYTIGA,dyspnea,discomfort edema hot flush diarrhea vomiting,0
ZYTIGA,dyspnea,diarrhea vomiting cough dyspnea,1
ZYTIGA,dyspnea,dyspnea,1
ZYTIGA,dyspnea,,0
ZYTIGA,dyspnea,dyspnea,1
ZYTIGA,dyspnea,,0
ZYTIGA,urinary tract infection,elevated,0
ZYTIGA,urinary tract infection,swelling or,0
ZYTIGA,urinary tract infection,vomiting cough hypertension urinary tract infection,1
ZYTIGA,urinary tract infection,urinary,1
ZYTIGA,contusion,dyspnea urinary tract infection contusion,1
ZYTIGA,anemia,infection and contusion The,0
ZYTIGA,anemia,anemia,1
ZYTIGA,anemia,anemia,1
ZYTIGA,anemia,anemia,1
ZYTIGA,anemia,laboratory abnormalities anemia,1
ZYTIGA,anemia,hypercholesterolemia hyperglyce,0
ZYTIGA,anemia,anemia,1
ZYTIGA,anemia,alkaline phosphatase hypertriglyceridemia lymphopenia,0
ZYTIGA,anemia,tract infection and contusion The most,0
ZYTIGA,elevated alkaline phosphatase,abnormalities are anemia,0
ZYTIGA,hypertriglyceridemia,hypertriglyceridemia,1
ZYTIGA,hypertriglyceridemia,anemia elevated alkaline hypertriglyceridemia,1
ZYTIGA,hypertriglyceridemia,hypertriglyceridemia,1
ZYTIGA,hypertriglyceridemia,most common laboratory abnormalities,0
ZYTIGA,hypertriglyceridemia,are anemia elevated alkaline hypertriglyceridemia,1
ZYTIGA,hypertriglyceridemia,hypercholesterolemia hyperglycemia elevated AST hypophosphatemia elevated ALT and,0
ZYTIGA,hypertriglyceridemia,hypertriglyceridemia,1
ZYTIGA,hypertriglyceridemia,hypertriglyceridemia,1
ZYTIGA,lymphopenia,anemia elevated alkaline phosphatase lymphopenia,1
ZYTIGA,lymphopenia,laboratory abnormalities,0
ZYTIGA,lymphopenia,lymphopenia,1
ZYTIGA,hyperglycemia,hyperglycemia,1
ZYTIGA,hyperglycemia,,0
ZYTIGA,hyperglycemia,elevated AST hypophosphatemia,0
ZYTIGA,hyperglycemia,hyperglycemia,1
ZYTIGA,hyperglycemia,report SUSPECTED,0
ZYTIGA,hyperglycemia,hyperglycemia,1
ZYTIGA,hyperglycemia,SUSPECTED ADVERSE REA,0
ZYTIGA,elevated AST,phosphatase hypertriglyceridemia,0
ZYTIGA,hypophosphatemia,ALT and hypokalemia To report SUSPECTED ADVERSE,0
ZYTIGA,hypophosphatemia,lymphopenia hypercholesterolemia hyperglycemia elevated hypophosphatemia,1
ZYTIGA,hypophosphatemia,hypophosphatemia,1
ZYTIGA,hypophosphatemia,hypertriglyceridemia lymphopenia hypercholesterolemia hyperglycemia elevated,0
ZYTIGA,hypophosphatemia,hypokalemia To report SUSPECTED ADVERSE REACTIONS contact Janssen Biotech,0
ZYTIGA,hypophosphatemia,,0
ZYTIGA,hypophosphatemia,hypophosphatemia,1
ZYTIGA,hypophosphatemia,To report SUSPECTED,0
ZYTIGA,hypophosphatemia,hypophosphatemia,1
ZYTIGA,elevated ALT,,0
ZYTIGA,elevated ALT,hyperglycemia elevated AST elevated ALT,1
ZYTIGA,elevated ALT,AST,0
ZYTIGA,elevated ALT,,0
ZYTIGA,elevated ALT,elevated ALT,1
ZYTIGA,elevated ALT,ALT,1
ZYTIGA,elevated ALT,hypercholesterolemia hyperglycemia elevated AST elevated,1
ZYTIGA,elevated ALT,lymphopenia,0
ZYTIGA,elevated ALT,and hypokalemia To report SUSPECTED ADVERSE REACTIONS contact Janssen Biotech Inc at,0
ZYTIGA,hypokalemia,hypokalemia,1
ZYTIGA,hypokalemia,hypokalemia,1
ZYTIGA,hypokalemia,ADVERSE REACTIONS contact Janssen,0
ZYTIGA,hypokalemia,hypokalemia,1
ZYTIGA,hypokalemia,ALT,0
ZYTIGA,hypokalemia,hypophosphatemia elevated ALT hypokalemia,1
ZYTIGA,hypokalemia,ALT and,0
ZYTIGA,hypokalemia,Biotech,0
ZYTIGA,fatigue,dyspnea,0
ZYTIGA,fatigue,fatigue,1
ZYTIGA,fatigue,,0
ZYTIGA,fatigue,fatigue,1
ZYTIGA,joint swelling,acetate arm were joint swelling,1
ZYTIGA,joint swelling,urinary tract,0
ZYTIGA,joint swelling,swelling,1
ZYTIGA,joint swelling,abiraterone,0
ZYTIGA,joint swelling,hypertension dyspnea,0
ZYTIGA,joint swelling,arm were joint,1
ZYTIGA,joint swelling,were joint swelling,1
ZYTIGA,joint swelling,cough hypertension,0
ZYTIGA,joint swelling,joint swelling,1
ZYTIGA,edema,edema,1
ZYTIGA,edema,edema,1
ZYTIGA,edema,edema,1
ZYTIGA,edema,edema,1
ZYTIGA,edema,,0
ZYTIGA,edema,abiraterone acetate arm were fatigue joint,0
ZYTIGA,edema,edema,1
ZYTIGA,edema,joint swelling or edema,1
ZYTIGA,edema,tract,0
ZYTIGA,edema,fatigue joint swelling or edema,1
ZYTIGA,hot flush,infection and,0
ZYTIGA,hot flush,swelling or discomfort hot flush,1
ZYTIGA,hot flush,joint swelling or discomfort hot flush,1
ZYTIGA,diarrhea,diarrhea,1
ZYTIGA,diarrhea,swelling or discomfort edema hot flush,0
ZYTIGA,diarrhea,diarrhea,1
ZYTIGA,diarrhea,and contusion The most common,0
ZYTIGA,diarrhea,diarrhea,1
ZYTIGA,diarrhea,,0
ZYTIGA,diarrhea,diarrhea,1
ZYTIGA,diarrhea,diarrhea,1
ZYTIGA,diarrhea,swelling or discomfort,0
ZYTIGA,diarrhea,or discomfort edema hot diarrhea,1
ZYTIGA,cough,,0
ZYTIGA,cough,arm were fatigue joint swelling or,0
ZYTIGA,hypertension,flush diarrhea vomiting hypertension,1
ZYTIGA,hypertension,hypertension,1
ZYTIGA,hypertension,hypertension,1
ZYTIGA,hypertension,fatigue joint swelling or discomfort edema hot,0
ZYTIGA,hypertension,hypertension,1
ZYTIGA,hypertension,were fatigue joint swelling or discomfort edema hot flush diarrhea,0
ZYTIGA,hypertension,hypertension,1
ZYTIGA,hypertension,hypertension,1
ZYTIGA,hypertension,vomiting hypertension,1
ZYTIGA,dyspnea,joint swelling or discomfort edema hot,0
ZYTIGA,dyspnea,dyspnea,1
ZYTIGA,dyspnea,dyspnea,1
ZYTIGA,urinary tract infection,urinary tract,1
ZYTIGA,urinary tract infection,hypertension urinary tract infection,1
ZYTIGA,urinary tract infection,contusion The most common laboratory abnormalities reported in the two randomized c,0
ZYTIGA,urinary tract infection,tract infection,1
ZYTIGA,urinary tract infection,,0
ZYTIGA,urinary tract infection,cough hypertension urinary tract infection,1
ZYTIGA,urinary tract infection,tract infection,1
ZYTIGA,urinary tract infection,cough hypertension,0
ZYTIGA,urinary tract infection,,0
ZYTIGA,urinary tract infection,,0
ZYTIGA,contusion,contusion,1
ZYTIGA,contusion,contusion,1
ZYTIGA,contusion,contusion,1
ZYTIGA,anemia,,0
ZYTIGA,anemia,abiraterone acetate,0
ZYTIGA,anemia,anemia,1
ZYTIGA,anemia,occurred,0
ZYTIGA,anemia,elevated alkaline phosphatase hypertriglyceridemia,0
ZYTIGA,anemia,the abiraterone acetate arm anemia,1
ZYTIGA,anemia,anemia,1
ZYTIGA,anemia,,0
ZYTIGA,anemia,arm anemia,1
ZYTIGA,elevated alkaline phosphatase,,0
ZYTIGA,elevated alkaline phosphatase,elevated alkaline phosphatase,1
ZYTIGA,elevated alkaline phosphatase,hypercholesterolemia,0
ZYTIGA,elevated alkaline phosphatase,arm were elevated alkaline phosphatase,1
ZYTIGA,hypertriglyceridemia,lymphopenia hypercholesterolemia hyperglycemia,0
ZYTIGA,hypertriglyceridemia,ALT,0
ZYTIGA,hypertriglyceridemia,hypertriglyceridemia,1
ZYTIGA,hypertriglyceridemia,in,0
ZYTIGA,hypertriglyceridemia,,0
ZYTIGA,hypertriglyceridemia,hypercholesterolemia hyperglycemia,0
ZYTIGA,hypertriglyceridemia,hyperglycemia elevated AST hypophosphatemia elevated ALT and,0
ZYTIGA,lymphopenia,AST hypophosphatemia elevated ALT,0
ZYTIGA,lymphopenia,,0
ZYTIGA,lymphopenia,lymphopenia,1
ZYTIGA,lymphopenia,lymphopenia,1
ZYTIGA,lymphopenia,lymphopenia,1
ZYTIGA,lymphopenia,,0
ZYTIGA,lymphopenia,hypokalemia,0
ZYTIGA,lymphopenia,lymphopenia,1
ZYTIGA,hypercholesterolemia,hypercholesterolemia,1
ZYTIGA,hypercholesterolemia,hypercholesterolemia,1
ZYTIGA,hypercholesterolemia,hyperglycemia elevated AST hypophosphatemia elevated ALT and,0
ZYTIGA,hypercholesterolemia,anemia elevated alkaline phosphatase hypertriglyceridemia,0
ZYTIGA,hypercholesterolemia,acetate arm were anemia elevated alkaline phosphatase hypertriglyceridemia lymphopenia,0
ZYTIGA,hypercholesterolemia,anemia elevated alkaline,0
ZYTIGA,hypercholesterolemia,anemia elevated,0
ZYTIGA,hypercholesterolemia,hypercholesterolemia,1
ZYTIGA,hypercholesterolemia,hypercholesterolemia,1
ZYTIGA,hyperglycemia,hyperglycemia,1
ZYTIGA,hyperglycemia,phosphatase hypertriglyceridemia lymphopenia hyperglycemia,1
ZYTIGA,hyperglycemia,phosphatase hypertriglyceridemia lymphopenia hyperglycemia,1
ZYTIGA,hyperglycemia,phosphatase hypertriglyceridemia lymphopenia hyperglycemia,1
ZYTIGA,hyperglycemia,hypertriglyceridemia lymphopenia hyperglycemia,1
ZYTIGA,hyperglycemia,Study Metastatic CRPC Fol,0
ZYTIGA,hyperglycemia,alkaline phosphatase hypertriglyceridemia lymphopenia,0
ZYTIGA,hyperglycemia,phosphatase hypertriglyceridemia lymphopenia hyperglycemia,1
ZYTIGA,hyperglycemia,,0
ZYTIGA,elevated AST,AST,1
ZYTIGA,elevated AST,lymphopenia hypercholesterolemia,0
ZYTIGA,elevated AST,elevated,0
ZYTIGA,elevated AST,AST,1
ZYTIGA,elevated AST,,0
ZYTIGA,elevated AST,elevated AST,1
ZYTIGA,elevated AST,lymphopenia hypercholesterolemia hyperglycemia,0
ZYTIGA,elevated AST,elevated,1
ZYTIGA,elevated AST,hypertriglyceridemia lymphopenia,0
ZYTIGA,hypophosphatemia,hypophosphatemia,1
ZYTIGA,hypophosphatemia,,0
ZYTIGA,hypophosphatemia,hypophosphatemia,1
ZYTIGA,hypophosphatemia,hypokalemia Study Metastatic CRPC Following,0
ZYTIGA,hypophosphatemia,hypophosphatemia,1
ZYTIGA,hypophosphatemia,hypophosphatemia,1
ZYTIGA,hypophosphatemia,hypophosphatemia,1
ZYTIGA,hypophosphatemia,hypophosphatemia,1
ZYTIGA,elevated ALT,Chemotherapy Study,0
ZYTIGA,hypokalemia,elevated AST,0
ZYTIGA,hypokalemia,hypokalemia,1
ZYTIGA,hypokalemia,CRPC Following,0
ZYTIGA,hypokalemia,,0
ZYTIGA,hypokalemia,enrolled patients with,0
ZYTIGA,hypokalemia,Study enrolled patients with,0
ZYTIGA,hypokalemia,hyperglycemia elevated AST,0
ZYTIGA,hypokalemia,Metastatic CRPC,0
ZYTIGA,hypokalemia,hypokalemia,1
ZYTIGA,Joint swelling,discomfort M,0
ZYTIGA,Muscle discomfort,gdiscomfort Muscle,1
ZYTIGA,Edema,ders,0
ZYTIGA,Hot flush,,0
ZYTIGA,Hypertension,Hypertension,1
ZYTIGA,Hypertension,Hypertension,1
ZYTIGA,Hypertension,,0
ZYTIGA,Hypertension,,0
ZYTIGA,Hypertension,,0
ZYTIGA,Hypertension,Hypertension,1
ZYTIGA,Hypertension,,0
ZYTIGA,Diarrhea,Diarrhea,1
ZYTIGA,Diarrhea,nal Diarrhea,1
ZYTIGA,Dyspepsia,,0
ZYTIGA,Dyspepsia,,0
ZYTIGA,Dyspepsia,Dyspepsia,1
ZYTIGA,Dyspepsia,,0
ZYTIGA,Urinary tract infection,,0
ZYTIGA,Urinary tract infection,Urinary tract infection,1
ZYTIGA,Urinary tract infection,,0
ZYTIGA,Urinary tract infection,Urinary tract infection,1
ZYTIGA,Urinary tract infection,infestations,0
ZYTIGA,Upper respiratory tract infection,infection Upper,1
ZYTIGA,Upper respiratory tract infection,infection,0
ZYTIGA,Upper respiratory tract infection,infection Upper,1
ZYTIGA,Upper respiratory tract infection,infection,0
ZYTIGA,Upper respiratory tract infection,,0
ZYTIGA,Upper respiratory tract infection,,0
ZYTIGA,Upper respiratory tract infection,,0
ZYTIGA,Cough,,0
ZYTIGA,Cough,Cough,1
ZYTIGA,Cough,,0
ZYTIGA,Cough,Cough,1
ZYTIGA,Cough,Cough,1
ZYTIGA,Cough,Cough,1
ZYTIGA,Cough,mediastinal disorders,0
ZYTIGA,Cough,mediastinal,0
ZYTIGA,Cough,Cough,1
ZYTIGA,Urinary frequency,nary Urinary frequency Noct,1
ZYTIGA,Urinary frequency,nary Urinary,1
ZYTIGA,Urinary frequency,Urinary frequency Noct,1
ZYTIGA,Urinary frequency,disorders,0
ZYTIGA,Urinary frequency,Noct,0
ZYTIGA,Urinary frequency,disorders,0
ZYTIGA,Urinary frequency,Urinary,1
ZYTIGA,Urinary frequency,,0
ZYTIGA,Urinary frequency,disorders,0
ZYTIGA,Urinary frequency,,0
ZYTIGA,Nocturia,,0
ZYTIGA,Nocturia,ency,0
ZYTIGA,Nocturia,ency Nocturia,1
ZYTIGA,Nocturia,Nocturia,1
ZYTIGA,Nocturia,ency Nocturia,1
ZYTIGA,Nocturia,,0
ZYTIGA,Nocturia,ency,0
ZYTIGA,Nocturia,,0
ZYTIGA,Nocturia,,0
ZYTIGA,Nocturia,,0
ZYTIGA,Arrhythmia,Arrhythmia,1
ZYTIGA,Arrhythmia,Arrhythmia,1
ZYTIGA,Arrhythmia,ders,0
ZYTIGA,Arrhythmia,ders,0
ZYTIGA,Arrhythmia,Arrhythmia,1
ZYTIGA,Arrhythmia,,0
ZYTIGA,Arrhythmia,ders Arrhythmia,1
ZYTIGA,Arrhythmia,,0
ZYTIGA,Chest pain,Chest pain or chest,1
ZYTIGA,Chest pain,,0
ZYTIGA,Chest pain,Chest,1
ZYTIGA,Chest pain,,0
ZYTIGA,Chest pain,or chest,0
ZYTIGA,chest discomfort,discomfort Cardiac failure,1
ZYTIGA,chest discomfort,chest discomfort Cardiac failure,1
ZYTIGA,chest discomfort,pain chest,1
ZYTIGA,chest discomfort,discomfort Cardiac failure,1
ZYTIGA,chest discomfort,failure,0
ZYTIGA,chest discomfort,,0
ZYTIGA,chest discomfort,or,0
ZYTIGA,chest discomfort,pain chest,1
ZYTIGA,chest discomfort,,0
ZYTIGA,Cardiac failure,Cardiac failure,1
ZYTIGA,Cardiac failure,Cardiac,1
ZYTIGA,Cardiac failure,Cardiac,1
ZYTIGA,Cardiac failure,,0
ZYTIGA,Cardiac failure,,0
ZYTIGA,Cardiac failure,Cardiac,1
ZYTIGA,Cardiac failure,,0
ZYTIGA,low serum phosphorus,abnormalities of,0
ZYTIGA,low serum phosphorus,the,0
ZYTIGA,low serum phosphorus,of interest from Study Grade,0
ZYTIGA,low serum phosphorus,Study low serum,1
ZYTIGA,low serum phosphorus,Study Grade,0
ZYTIGA,low serum phosphorus,Study Grade,0
ZYTIGA,low serum phosphorus,potassium occurred at a greater than or equal to rate,0
ZYTIGA,low potassium,potassium occurred at,1
ZYTIGA,low potassium,Abno,0
ZYTIGA,low potassium,,0
ZYTIGA,low potassium,Laboratory,0
ZYTIGA,low potassium,Grade low serum phosphorus low,1
ZYTIGA,low potassium,low serum phosphorus low,1
ZYTIGA,low potassium,low potassium occurred at,1
ZYTIGA,low potassium,low potassium occurred at,1
ZYTIGA,Hypertriglyceridemia,Hypertriglyceridemia High AS,1
ZYTIGA,Hypertriglyceridemia,High,0
ZYTIGA,Hypertriglyceridemia,,0
ZYTIGA,Hypertriglyceridemia,,0
ZYTIGA,High AST,ridemia High AST,1
ZYTIGA,High AST,ridemia High AST,1
ZYTIGA,High AST,ridemia High,1
ZYTIGA,High AST,ridemia,0
ZYTIGA,Hypokalemia,Hypokalemia,1
ZYTIGA,Hypokalemia,Hypokalemia,1
ZYTIGA,Hypokalemia,,0
ZYTIGA,Hypokalemia,,0
ZYTIGA,Hypokalemia,Hypokalemia,1
ZYTIGA,Hypokalemia,Hypokalemia,1
ZYTIGA,Hypokalemia,Hypokalemia,1
ZYTIGA,Hypokalemia,Hypokalemia,1
ZYTIGA,Hypokalemia,Hypokalemia,1
ZYTIGA,Hypokalemia,Hypokalemia,1
ZYTIGA,Hypophosphatemia,,0
ZYTIGA,Hypophosphatemia,Hypophosphatemia Hig,1
ZYTIGA,Hypophosphatemia,Hypophosphatemia Hig,1
ZYTIGA,High ALT,,0
ZYTIGA,High ALT,mia High,1
ZYTIGA,High ALT,,0
ZYTIGA,High ALT,,0
ZYTIGA,High ALT,mia,0
ZYTIGA,High ALT,mia High ALT,1
ZYTIGA,High ALT,,0
ZYTIGA,High ALT,mia High ALT,1
ZYTIGA,High ALT,mia High ALT,1
ZYTIGA,High Total Bilirubin,High Total Bilirubin,1
ZYTIGA,High Total Bilirubin,,0
ZYTIGA,High Total Bilirubin,,0
ZYTIGA,High Total Bilirubin,,0
ZYTIGA,High Total Bilirubin,High Total Bilirubin,1
ZYTIGA,High Total Bilirubin,,0
ZYTIGA,High Total Bilirubin,High Total Bilirubin,1
ZYTIGA,High Total Bilirubin,High,1
ZYTIGA,High Total Bilirubin,High Total Bilirubin,1
ZYTIGA,High Total Bilirubin,High Total,1
ZYTIGA,Fatigue,Fatigue,1
ZYTIGA,Fatigue,Fatigue,1
ZYTIGA,Fatigue,ders,0
ZYTIGA,Fatigue,ders,0
ZYTIGA,Fatigue,Fatigue,1
ZYTIGA,Fatigue,,0
ZYTIGA,Edema,Edema,1
ZYTIGA,Edema,,0
ZYTIGA,Edema,Edema,1
ZYTIGA,Edema,,0
ZYTIGA,Pyrexia,,0
ZYTIGA,Pyrexia,,0
ZYTIGA,Pyrexia,,0
ZYTIGA,Pyrexia,Pyrexia,1
ZYTIGA,Pyrexia,,0
ZYTIGA,Joint swelling,ective tissue Joint,1
ZYTIGA,Groin pain,gdiscomfort,0
ZYTIGA,Groin pain,gdiscomfort Groin,1
ZYTIGA,Groin pain,gdiscomfort Groin pain,1
ZYTIGA,Groin pain,gdiscomfort Groin,1
ZYTIGA,Groin pain,gdiscomfort,0
ZYTIGA,Groin pain,,0
ZYTIGA,Groin pain,,0
ZYTIGA,Groin pain,gdiscomfort Groin,1
ZYTIGA,Groin pain,pain,1
ZYTIGA,Constipation,Constipation,1
ZYTIGA,Diarrhea,,0
ZYTIGA,Diarrhea,Diarrhea,1
ZYTIGA,Diarrhea,,0
ZYTIGA,Diarrhea,Diarrhea,1
ZYTIGA,Diarrhea,,0
ZYTIGA,Diarrhea,,0
ZYTIGA,Diarrhea,Diarrhea,1
ZYTIGA,Diarrhea,,0
ZYTIGA,Diarrhea,Diarrhea,1
ZYTIGA,Diarrhea,Diarrhea,1
ZYTIGA,Dyspepsia,,0
ZYTIGA,Dyspepsia,,0
ZYTIGA,Dyspepsia,,0
ZYTIGA,Dyspepsia,,0
ZYTIGA,Dyspepsia,,0
ZYTIGA,Dyspepsia,Dyspepsia,1
ZYTIGA,Dyspepsia,,0
ZYTIGA,Hot flush,,0
ZYTIGA,Hot flush,rders Hot flush,1
ZYTIGA,Hot flush,rders Hot,1
ZYTIGA,Hot flush,rders,0
ZYTIGA,Hot flush,rders Hot,1
ZYTIGA,Hypertension,Hypertension,1
ZYTIGA,Hypertension,,0
ZYTIGA,Insomnia,Insomnia,1
ZYTIGA,Insomnia,,0
ZYTIGA,Contusion,,0
ZYTIGA,Contusion,,0
ZYTIGA,Contusion,Contusion,1
ZYTIGA,Falls,Falls,1
ZYTIGA,Falls,,0
ZYTIGA,Falls,,0
ZYTIGA,Falls,,0
ZYTIGA,Falls,Falls,1
ZYTIGA,Upper respiratory tract infection,infection Nasopharyngitis,1
ZYTIGA,Upper respiratory tract infection,Upper respiratory tract,1
ZYTIGA,Upper respiratory tract infection,Nasopharyngitis,0
ZYTIGA,Nasopharyngitis,Nasopharyngitis Re,1
ZYTIGA,Nasopharyngitis,Re,0
ZYTIGA,Nasopharyngitis,,0
ZYTIGA,Nasopharyngitis,,0
ZYTIGA,Nasopharyngitis,Nasopharyngitis Re,1
ZYTIGA,Nasopharyngitis,infection,0
ZYTIGA,Rash,,0
ZYTIGA,Rash,disorders,0
ZYTIGA,Rash,Rash,1
ZYTIGA,Rash,,0
ZYTIGA,Rash,Rash,1
ZYTIGA,lymphopenia,,0
ZYTIGA,lymphopenia,lymphopenia,1
ZYTIGA,lymphopenia,at a,0
ZYTIGA,lymphopenia,to placebo in Study lymphopenia,1
ZYTIGA,lymphopenia,lymphopenia,1
ZYTIGA,lymphopenia,Study Grade,0
ZYTIGA,lymphopenia,lymphopenia,1
ZYTIGA,lymphopenia,lymphopenia,1
ZYTIGA,lymphopenia,hyperglycemia and,0
ZYTIGA,lymphopenia,frequently in the ZYTIGA arm compared,0
ZYTIGA,hyperglycemia,hyperglycemia,1
ZYTIGA,high alanine aminotransferase,Study Grade lymphopenia hyperglycemia high,1
ZYTIGA,high alanine aminotransferase,placebo in Study Grade lymphopenia,0
ZYTIGA,high alanine aminotransferase,high,1
ZYTIGA,high alanine aminotransferase,a greater than rate,0
ZYTIGA,Lymphopenia,Lymphopenia,1
ZYTIGA,Lymphopenia,Lymphopenia,1
ZYTIGA,Hyperglycemia,,0
ZYTIGA,Hyperglycemia,,0
ZYTIGA,Hyperglycemia,Hyperglycemia,1
ZYTIGA,Hyperglycemia,,0
ZYTIGA,Hyperglycemia,Hyperglycemia,1
ZYTIGA,Hyperglycemia,,0
ZYTIGA,Hyperglycemia,,0
ZYTIGA,Hyperglycemia,Hyperglycemia,1
ZYTIGA,Hyperglycemia,Hyperglycemia,1
ZYTIGA,Hyperglycemia,Hyperglycemia,1
ZYTIGA,High ALT,ALT,1
ZYTIGA,High ALT,,0
ZYTIGA,High ALT,High ALT,1
ZYTIGA,High ALT,High,1
ZYTIGA,High ALT,High ALT,1
ZYTIGA,High AST,High AST,1
ZYTIGA,High AST,High AST,1
ZYTIGA,High AST,AST,1
ZYTIGA,High AST,High,1
ZYTIGA,High AST,,0
ZYTIGA,Hypernatremia,,0
ZYTIGA,Hypernatremia,,0
ZYTIGA,Hypernatremia,,0
ZYTIGA,Hypokalemia,Hypokalemia,1
ZYTIGA,Hypokalemia,Hypokalemia,1
ZYTIGA,cardiac failure,commonly in patients treated,0
ZYTIGA,cardiac failure,cardiac failure,1
ZYTIGA,cardiac failure,the placebo arm,0
ZYTIGA,deaths,occurred in of patients taking placebo There were,0
ZYTIGA,deaths,cardiac failure occurred in of,0
ZYTIGA,deaths,and led to treatment discontinuations,0
ZYTIGA,deaths,deaths,1
ZYTIGA,deaths,deaths,1
ZYTIGA,deaths,deaths,1
ZYTIGA,deaths,Grade cardiac failure occurred in,0
ZYTIGA,cardiac failure,,0
ZYTIGA,cardiac failure,treatment discontinuations and deaths cardiac failure,1
ZYTIGA,cardiac failure,deaths cardiac,1
ZYTIGA,cardiac failure,patients taking ZYTIGA and,0
ZYTIGA,cardiac failure,discontinuations and,0
ZYTIGA,cardiac failure,failure,1
ZYTIGA,cardiac failure,treatment discontinuations and deaths cardiac failure,1
ZYTIGA,cardiac failure,deaths cardiac,1
ZYTIGA,cardiac failure,treatment discontinuations and deaths cardiac,1
ZYTIGA,cardiac failure,failure,1
ZYTIGA,cardiac failure,cardiac failure,1
ZYTIGA,cardiac failure,cardiac failure,1
ZYTIGA,cardiac failure,,0
ZYTIGA,arrhythmias,arrhythmias,1
ZYTIGA,arrhythmias,arrhythmias,1
ZYTIGA,arrhythmias,,0
ZYTIGA,arrhythmias,arrhythmias,1
ZYTIGA,arrhythmias,and the majority arrhythmias,1
ZYTIGA,arrhythmias,,0
ZYTIGA,arrhythmias,death associated with arrhythmia and one,0
ZYTIGA,arrhythmias,arrhythmias,1
ZYTIGA,arrhythmias,majority,0
ZYTIGA,arrhythmias,majority arrhythmias,1
ZYTIGA,arrhythmias,In Study and,0
ZYTIGA,death,group In Study and the majority of arrhythmias,0
ZYTIGA,arrhythmia,,0
ZYTIGA,arrhythmia,There was one death associated,0
ZYTIGA,arrhythmia,arrhythmia,1
ZYTIGA,arrhythmia,one death associated arrhythmia,1
ZYTIGA,sudden death,sudden,1
ZYTIGA,sudden death,patient sudden death,1
ZYTIGA,sudden death,sudden death,1
ZYTIGA,sudden death,were grade or There was one death associated with arrhythmia and one patient with,0
ZYTIGA,sudden death,sudden death,1
ZYTIGA,sudden death,sudden death,1
ZYTIGA,deaths,deaths,1
ZYTIGA,deaths,,0
ZYTIGA,deaths,deaths due to cardiorespiratory arrest in,0
ZYTIGA,deaths,deaths,1
ZYTIGA,deaths,deaths,1
ZYTIGA,deaths,arms and deaths,1
ZYTIGA,deaths,arrest in the,0
ZYTIGA,deaths,placebo arms There deaths,1
ZYTIGA,deaths,deaths in the placebo,0
ZYTIGA,deaths,deaths,1
ZYTIGA,deaths,arms There deaths,1
ZYTIGA,deaths,arms and no deaths in the,0
ZYTIGA,deaths,the ZYTIGA arms and deaths in the placebo arms Myocard,0
ZYTIGA,deaths,There deaths,1
ZYTIGA,deaths,in the placebo arms,0
ZYTIGA,deaths,deaths,1
ZYTIGA,cardiorespiratory arrest,in the ZYTIGA arms and no deaths in the placebo arms There were deaths due to,0
ZYTIGA,deaths,in the ZYTIGA arms deaths,1
ZYTIGA,deaths,arms deaths,1
ZYTIGA,Myocardial ischemia,in the placebo Myocardial ischemia,1
ZYTIGA,Myocardial ischemia,deaths in the placebo Myocardial ischemia,1
ZYTIGA,myocardial infarction,myocardial,1
ZYTIGA,myocardial infarction,myocardial infarction,1
ZYTIGA,myocardial infarction,myocardial infarction,1
ZYTIGA,myocardial infarction,deaths,0
ZYTIGA,myocardial infarction,,0
ZYTIGA,death,death,1
ZYTIGA,death,death,1
ZYTIGA,death,arms and deaths in the ZYTIGA arms,0
ZYTIGA,death,Post,0
ZYTIGA,death,led death,1
ZYTIGA,death,Myocardial,0
ZYTIGA,death,death,1
ZYTIGA,death,the ZYTIGA arms,0
ZYTIGA,death,death,1
ZYTIGA,death,infarction led death,1
ZYTIGA,deaths,The,0
ZYTIGA,deaths,the ZYTIGA arms Post Marketing Experience The following additional adverse,0
ZYTIGA,deaths,deaths,1
ZYTIGA,deaths,deaths,1
ZYTIGA,deaths,deaths,1
ZYTIGA,deaths,additional adverse reactio,0
ZYTIGA,deaths,placebo arms deaths,1
ZYTIGA,deaths,the,0
ZYTIGA,non-infectious pneumonitis,Thoracic and Mediastinal non-infectious pneumonitis,1
ZYTIGA,non-infectious pneumonitis,Respiratory Thoracic and Mediastinal non-infectious,1
ZYTIGA,non-infectious pneumonitis,Respiratory,0
ZYTIGA,non-infectious pneumonitis,Thoracic and Mediastinal Disorders,0
ZYTIGA,non-infectious pneumonitis,,0
ZYTIGA,non-infectious pneumonitis,and Mediastinal non-infectious pneumonitis,1
ZYTIGA,non-infectious pneumonitis,pneumonitis,1
ZYTIGA,non-infectious pneumonitis,non-infectious pneumonitis,1
ZYTIGA,non-infectious pneumonitis,Thoracic and Mediastinal non-infectious pneumonitis,1
ZYTIGA,non-infectious pneumonitis,non-infectious,1
ZYTIGA,myopathy,myopathy,1
ZYTIGA,Mineralocorticoid excess,in more detail in o ther sections,1
ZYTIGA,Mineralocorticoid excess,Hypertension Hypokalemia,0
ZYTIGA,Mineralocorticoid excess,of the labeling Hypertension Hypokalemia,0
ZYTIGA,Mineralocorticoid excess,,0
ZYTIGA,Mineralocorticoid excess,sections of,0
ZYTIGA,Mineralocorticoid excess,sections of the labeling Hypertension Hypokalemia and Fluid Retention,0
ZYTIGA,Mineralocorticoid excess,in o,1
ZYTIGA,Adrenocortical insufficiency,fatigue joint swelling or discomfort edema hot flush diarrhea,0
ZYTIGA,Adrenocortical insufficiency,most common laboratory abnormalities are an,0
ZYTIGA,Adrenocortical insufficiency,,0
ZYTIGA,Adrenocortical insufficiency,contusion The most common laboratory,0
ZYTIGA,Adrenocortical insufficiency,dyspne,1
ZYTIGA,Adrenocortical insufficiency,tract infection and contusion The,0
ZYTIGA,Adrenocortical insufficiency,"diarrhea cough, hypertension,",1
ZYTIGA,Adrenocortical insufficiency,or,0
ZYTIGA,Hepatotoxicity,report,0
ZYTIGA,Hepatotoxicity,a hyperglycemia elevated AST hypophosphatemia elevated ALT and hypokalemia To report,0
ZYTIGA,Hepatotoxicity,a,0
ZYTIGA,Hepatotoxicity,a hyperglycemia elevated AST hypophosphatemia elevated ALT and hypokalemia,0
ZYTIGA,Hepatotoxicity,alkaline phosphatase hypertriglyceridemia lymphopenia cholesterolemi,1
ZYTIGA,Increases in liver enzymes,elevated A,1
ZYTIGA,Increases in liver enzymes,ALT and,0
ZYTIGA,Increases in liver enzymes,"lymphopenia  hyperglycemia, elevated A",1
ZYTIGA,Increases in liver enzymes,,0
ZYTIGA,Increases in liver enzymes,and hypokalemia To,0
ZYTIGA,Increases in liver enzymes,"alkaline phosphatase hypertriglyceridemia lymphopenia hyperglycemia, elevated",1
ZYTIGA,hypertension,trials e,1
ZYTIGA,hypertension,conducted,1
ZYTIGA,hypertension,e,1
ZYTIGA,hypokalemia,Because clinical trials are conducted un,0
ZYTIGA,hypokalemia,clinical trials of a drug cannot be,0
ZYTIGA,hypokalemia,conducted der,1
ZYTIGA,hypokalemia,,0
ZYTIGA,hypokalemia,reaction rates observed in,0
ZYTIGA,hypokalemia,Clinical Trial,0
ZYTIGA,hypokalemia,der widely,1
ZYTIGA,fluid retention,"widely g conditions, a",1
ZYTIGA,increased mineralocorticoid levels,,0
ZYTIGA,increased mineralocorticoid levels,,0
ZYTIGA,increased mineralocorticoid levels,in,0
ZYTIGA,increased mineralocorticoid levels,trials of,0
ZYTIGA,increased mineralocorticoid levels,not,0
ZYTIGA,increased mineralocorticoid levels,,0
ZYTIGA,hypertension,multicenter clinical trials enrolled,0
ZYTIGA,hypertension,in clinical,1
ZYTIGA,hypertension,,0
ZYTIGA,hypertension,drug and may not reflect the rates observed,0
ZYTIGA,hypertension,in clinical,1
ZYTIGA,hypertension,reflect the rates in,1
ZYTIGA,hypertension,in,1
ZYTIGA,hypertension,to rates in the clinical trials of another drug and may not,0
ZYTIGA,hypertension,practice Two randomized placebocontrolled,0
ZYTIGA,hypertension,,0
ZYTIGA,hypokalemia,"rolled, mul",1
ZYTIGA,hypokalemia,"rolled, mul",1
ZYTIGA,hypokalemia,ticenter clinical trials enrolled patients who had metastatic castrationresistant,0
ZYTIGA,hypokalemia,"rolled, mul",1
ZYTIGA,hypokalemia,"randomized rolled, mul",1
ZYTIGA,hypokalemia,placebocont,0
ZYTIGA,hypokalemia,"clinical practice Two randomized rolled,",1
ZYTIGA,hypokalemia,"randomized rolled,",1
ZYTIGA,hypokalemia,"rolled, mul",1
ZYTIGA,edema,,0
ZYTIGA,edema,clinical,0
ZYTIGA,edema,randomized placebocontrolled multicenter clinical,0
ZYTIGA,edema,prostate cancer who were using a gonadotropinreleasing,0
ZYTIGA,edema,enrolled ients,1
ZYTIGA,edema,,0
ZYTIGA,Adrenal insufficiency,chemotherapy Patients were not eligible if,0
ZYTIGA,Adrenal insufficiency,nrolled 1195 patients,1
ZYTIGA,Adrenal insufficiency,if A,0
ZYTIGA,Adrenal insufficiency,nrolled 1195 patients,1
ZYTIGA,Adrenal insufficiency,nrolled,1
ZYTIGA,Adrenocortical insufficiency,andor ALT,0
ZYTIGA,Adrenocortical insufficiency,absence of liver me,1
ZYTIGA,Adrenocortical insufficiency,N in the absence of liver me,1
ZYTIGA,Adrenocortical insufficiency,eligible if AST,0
ZYTIGA,Adrenocortical insufficiency,eligible if AST,0
ZYTIGA,adrenocortical insufficiency,,0
ZYTIGA,adrenocortical insufficiency,                            ,1
ZYTIGA,adrenocortical insufficiency,PrednisoneN Placebo with PrednisoneN SystemOrgan Class,0
ZYTIGA,adrenocortical insufficiency,PrednisoneN,0
ZYTIGA,adrenocortical insufficiency,was months Table Adverse Reactions due,0
ZYTIGA,adrenocortical insufficiency,Adve,0
ZYTIGA,adrenocortical insufficiency,months Table,0
ZYTIGA,adrenocortical insufficiency,to ZYTIGA in                             ,1
ZYTIGA,adrenocortical insufficiency,ZYTIGA was months Table,0
ZYTIGA,mineralocorticoid excess,Adverse reaction All Grades Grade All,0
ZYTIGA,mineralocorticoid excess,Grades,0
ZYTIGA,mineralocorticoid excess,h Prednisone(N=394),1
ZYTIGA,mineralocorticoid excess,h Prednisone(N=394),1
ZYTIGA,mineralocorticoid excess,Study ZYTIGA with PrednisoneN,0
ZYTIGA,mineralocorticoid excess,,0
ZYTIGA,mineralocorticoid excess,Study ZYTIGA with PrednisoneN,0
ZYTIGA,mineralocorticoid excess,h Prednisone(N=394),1
ZYTIGA,mineralocorticoid excess,h Prednisone(N=394),1
ZYTIGA,AST increases,,0
ZYTIGA,AST increases,             ,1
ZYTIGA,AST increases,,0
ZYTIGA,AST increases,             ,1
ZYTIGA,liver test elevation,Edema,0
ZYTIGA,liver test elevation,                     Vascular disorders,1
ZYTIGA,deaths,       Hot flush,1
ZYTIGA,deaths,       Hot flush,1
ZYTIGA,hepatotoxicity,Hot                Hypertension,1
ZYTIGA,hepatotoxicity,Hypertension,0
ZYTIGA,hepatotoxicity,flush,0
ZYTIGA,hepatotoxicity,flush,0
ZYTIGA,hepatotoxicity,               Hypertension,1
ZYTIGA,hepatotoxicity,               Hypertension,1
TOVIAZ,constipation,were dry mouth placebo Toviaz mg,0
TOVIAZ,angina,most commonly,0
TOVIAZ,gastroenteritis,chest gastroenteritis and QT,1
TOVIAZ,gastroenteritis,reported one serious adverse event,0
TOVIAZ,gastroenteritis,,0
TOVIAZ,gastroenteritis,event each angina chest gastroenteritis and QT,1
TOVIAZ,gastroenteritis,one serious adverse event each,0
TOVIAZ,gastroenteritis,chest gastroenteritis and QT,1
TOVIAZ,gastroenteritis,gastroenteritis and QT,1
TOVIAZ,gastroenteritis,most commonly reported,0
TOVIAZ,gastroenteritis,,0
TOVIAZ,dry mouth,treated with Toviaz dry,1
TOVIAZ,dry mouth,patients treated with Toviaz dry,1
TOVIAZ,dry mouth,Toviaz dry mouth The incidence,1
TOVIAZ,dry mouth,The most commonly reported adverse event in,0
TOVIAZ,dry mouth,patients treated,0
TOVIAZ,dry mouth,mouth The incidence,1
TOVIAZ,dry mouth,reported adverse event in patients treated with Toviaz was dry,0
TOVIAZ,Dry mouth,receiving placebo Toviaz mg,0
TOVIAZ,Dry mouth,Dry mouth led to,1
TOVIAZ,Dry mouth,mouth led to,1
TOVIAZ,Dry mouth,,0
TOVIAZ,Dry mouth,to Dry,1
TOVIAZ,Dry mouth,those taking,0
TOVIAZ,Dry mouth,compared to Dry mouth led to,1
TOVIAZ,Dry mouth,to Dry mouth led to,1
TOVIAZ,Dry mouth,,0
TOVIAZ,Dry mouth,mouth led to,1
TOVIAZ,dry mouth,who dry mouth most had,1
TOVIAZ,dry mouth,For those patients who dry,1
TOVIAZ,dry mouth,For those patients who dry,1
TOVIAZ,dry mouth,,0
TOVIAZ,constipation,taking mgday and in,0
TOVIAZ,constipation,,0
TOVIAZ,constipation,The,0
TOVIAZ,constipation,placebo in,0
TOVIAZ,constipation,was constipation,0
TOVIAZ,constipation,constipation was in,1
TOVIAZ,constipation,was constipation The incidence constipation was in,1
TOVIAZ,constipation,placebo in those taking,0
TOVIAZ,constipation,,0
TOVIAZ,Dry mouth,,0
TOVIAZ,Dry mouth,,0
TOVIAZ,Dry mouth,,0
TOVIAZ,Dry mouth,tinal Dry mouth,1
TOVIAZ,Dry mouth,Dry,1
TOVIAZ,Dyspepsia,ion,0
TOVIAZ,Abdominal pain upper,,0
TOVIAZ,Abdominal pain upper,,0
TOVIAZ,Abdominal pain upper,,0
TOVIAZ,Abdominal pain upper,,0
TOVIAZ,Abdominal pain upper,Abdominal pain upper Infections,1
TOVIAZ,Abdominal pain upper,pain upper Infections,1
TOVIAZ,Abdominal pain upper,Abdominal,1
TOVIAZ,Abdominal pain upper,Abdominal pain upper Infections,1
TOVIAZ,Urinary tract infection,Urinary tract,1
TOVIAZ,Urinary tract infection,Urinary tract infection,1
TOVIAZ,Urinary tract infection,Urinary tract,1
TOVIAZ,Urinary tract infection,,0
TOVIAZ,Urinary tract infection,Urinary tract infection Upper respirat,1
TOVIAZ,Upper respiratory tract infection,,0
TOVIAZ,Upper respiratory tract infection,,0
TOVIAZ,Upper respiratory tract infection,ract Upper respiratory tract infection Eye disorders,1
TOVIAZ,Upper respiratory tract infection,infection Eye disorders,1
TOVIAZ,Upper respiratory tract infection,ract Upper respiratory tract infection Eye disorders,1
TOVIAZ,Upper respiratory tract infection,Upper respiratory tract infection Eye disorders,1
TOVIAZ,Dry eyes,rs,0
TOVIAZ,Dry eyes,rs Dry,1
TOVIAZ,Dry eyes,rs Dry,1
TOVIAZ,Dry eyes,rs,0
TOVIAZ,Dry eyes,rs Dry,1
TOVIAZ,Dry eyes,rs Dry eyes R,1
TOVIAZ,Dry eyes,rs Dry,1
TOVIAZ,Dry eyes,rs,0
TOVIAZ,Dry eyes,rs Dry,1
TOVIAZ,Dysuria,Dysuria,1
TOVIAZ,Urinary retention,,0
TOVIAZ,Urinary retention,Urinary,1
TOVIAZ,Cough,Cough,1
TOVIAZ,Cough,,0
TOVIAZ,Cough,,0
TOVIAZ,Cough,Cough,1
TOVIAZ,Cough,disorders,0
TOVIAZ,Cough,disorders,0
TOVIAZ,Cough,Cough,1
TOVIAZ,Cough,disorders Cough,1
TOVIAZ,Cough,disorders,0
TOVIAZ,Cough,disorders Cough,1
TOVIAZ,Dry throat,Dry throat Gen,1
TOVIAZ,Dry throat,Dry,1
TOVIAZ,Edema peripheral,,0
TOVIAZ,Edema peripheral,orders,0
TOVIAZ,Edema peripheral,orders,0
TOVIAZ,Edema peripheral,orders,0
TOVIAZ,Edema peripheral,,0
TOVIAZ,Back pain,pain Ps,1
TOVIAZ,Back pain,disorders,0
TOVIAZ,Back pain,disorders,0
TOVIAZ,Back pain,etal Back pain Ps,1
TOVIAZ,Insomnia,Insomnia I,1
TOVIAZ,Insomnia,Insomnia I,1
TOVIAZ,Insomnia,Insomnia I,1
TOVIAZ,Insomnia,disorders,0
TOVIAZ,Insomnia,,0
TOVIAZ,Insomnia,I,0
TOVIAZ,Insomnia,disorders,0
TOVIAZ,ALT increased,ALT increased GGT,1
TOVIAZ,ALT increased,,0
TOVIAZ,ALT increased,ons ALT increased GGT,1
TOVIAZ,ALT increased,,0
TOVIAZ,ALT increased,ALT increased GGT,1
TOVIAZ,ALT increased,,0
TOVIAZ,ALT increased,ons,0
TOVIAZ,ALT increased,,0
TOVIAZ,GGT increased,,0
TOVIAZ,GGT increased,ased,0
TOVIAZ,GGT increased,,0
TOVIAZ,Rash,Rash,1
TOVIAZ,Rash,ers,0
TOVIAZ,Rash,ers Rash,1
TOVIAZ,Rash,ers,0
TOVIAZ,Rash,ers,0
TOVIAZ,Rash,,0
TOVIAZ,Rash,,0
TOVIAZ,dry mouth,to those observed in the week placebocontrolled studies,0
TOVIAZ,dry mouth,and,0
TOVIAZ,dry mouth,dry,1
TOVIAZ,dry mouth,placebocontrolled studies and dry,1
TOVIAZ,dry mouth,and dry,1
TOVIAZ,dry mouth,and included,0
TOVIAZ,dry mouth,dry mouth,1
TOVIAZ,dry mouth,studies were similar to,0
TOVIAZ,dry mouth,week placebocontrolled studies and dry mouth,1
TOVIAZ,constipation,controlled studies most adverse events,0
TOVIAZ,constipation,Similar to the controlled,0
TOVIAZ,constipation,and included dry constipation,1
TOVIAZ,constipation,,0
TOVIAZ,constipation,included dry,0
TOVIAZ,constipation,in the week placebocontrolled studies and included,0
TOVIAZ,constipation,in the,0
TOVIAZ,constipation,week placebocontrolled studies and,0
TOVIAZ,dry eyes,included dry mouth dry,1
TOVIAZ,dry eyes,,0
TOVIAZ,dry eyes,dry mouth,0
TOVIAZ,dry eyes,mouth dry,1
TOVIAZ,dry eyes,included dry mouth dry eyes,1
TOVIAZ,dry eyes,,0
TOVIAZ,dry eyes,dry,1
TOVIAZ,dyspepsia,dyspepsia,1
TOVIAZ,dyspepsia,dyspepsia,1
TOVIAZ,dyspepsia,dyspepsia,1
TOVIAZ,dyspepsia,dyspepsia,1
TOVIAZ,abdominal pain,controlled studies most adverse events of dry mouth,0
TOVIAZ,abdominal pain,to the controlled studies most adverse events of dry mouth and constipation,0
TOVIAZ,dry mouth,mild to moderate in intensity Serious adverse events judged to be at,0
TOVIAZ,dry mouth,mouth,1
TOVIAZ,dry mouth,and constipation were mild to moderate in intensity Serious adverse events,0
TOVIAZ,dry mouth,controlled studies most adverse,0
TOVIAZ,dry mouth,,0
TOVIAZ,dry mouth,and constipation were mild to moderate in intensity Serious adverse events judged to be,0
TOVIAZ,dry mouth,studies most adverse events dry,1
TOVIAZ,dry mouth,dry,1
TOVIAZ,dry mouth,,0
TOVIAZ,dry mouth,dry mouth,1
TOVIAZ,constipation,constipation,1
TOVIAZ,constipation,dry mouth constipation,1
TOVIAZ,constipation,constipation,1
TOVIAZ,urinary retention,retention,1
TOVIAZ,urinary retention,constipation cases irritable bowel syndrome cases an,0
TOVIAZ,urinary retention,urinary,1
TOVIAZ,urinary retention,urinary retention,1
TOVIAZ,urinary retention,years urinary,1
TOVIAZ,urinary retention,of,0
TOVIAZ,urinary retention,cases an,0
TOVIAZ,diverticulitis,to years included,0
TOVIAZ,irritable bowel syndrome,cases Postmarke,0
TOVIAZ,irritable bowel syndrome,cases diverticulitis cases constipation,0
TOVIAZ,irritable bowel syndrome,constipation irritable bowel syndrome,1
TOVIAZ,irritable bowel syndrome,interval prolongation cases Postmarke,0
TOVIAZ,irritable bowel syndrome,bowel syndrome,1
TOVIAZ,irritable bowel syndrome,included urinary retention cases diverticulitis,0
TOVIAZ,QT corrected interval prolongation,Postmarketing Experience The following events have been reported in,0
TOVIAZ,QT corrected interval prolongation,QT corrected interval,1
TOVIAZ,QT corrected interval prolongation,reported,0
TOVIAZ,QT corrected interval prolongation,syndrome cases and QT corrected,1
TOVIAZ,QT corrected interval prolongation,syndrome cases and QT,1
TOVIAZ,QT corrected interval prolongation,corrected interval prolongation,1
TOVIAZ,QT corrected interval prolongation,cases,0
TOVIAZ,Blurred vision,disorders,0
TOVIAZ,Blurred vision,disorders and administrative site conditions,0
TOVIAZ,Blurred vision,,0
TOVIAZ,Blurred vision,,0
TOVIAZ,Blurred vision,Palpitations General disorders and,0
TOVIAZ,Blurred vision,with fesoterodine use in worldwide,0
TOVIAZ,Blurred vision,worldwide postmarketing,0
TOVIAZ,Blurred vision,and,0
TOVIAZ,Blurred vision,in association with fesoterodine use in worldwide,0
TOVIAZ,Palpitations,Palpitations,1
TOVIAZ,Palpitations,experience Eye disorders Blurred vision,0
TOVIAZ,Palpitations,General disorders and administrative site conditions Hypersensitivity reactions,0
TOVIAZ,Hypersensitivity reactions,conditions,0
TOVIAZ,Hypersensitivity reactions,General,0
TOVIAZ,angioedema,angioedema,1
TOVIAZ,airway obstruction,,0
TOVIAZ,airway obstruction,obstruction,1
TOVIAZ,airway obstruction,and administrative site conditions,0
TOVIAZ,face edema,face edema,1
TOVIAZ,face edema,,0
TOVIAZ,face edema,obstruction,0
TOVIAZ,face edema,including angioedema with airway face,1
TOVIAZ,Dizziness,disorders,0
TOVIAZ,Dizziness,,0
TOVIAZ,Dizziness,system disorders,0
TOVIAZ,headache,obstruction,0
TOVIAZ,headache,system disorders headache,1
TOVIAZ,headache,headache,1
TOVIAZ,headache,system disorders headache,1
TOVIAZ,headache,headache,1
TOVIAZ,somnolence,spontaneously,0
TOVIAZ,somnolence,somnolence,1
TOVIAZ,somnolence,somnolence,1
TOVIAZ,Urticaria,Urticaria,1
TOVIAZ,Urticaria,tissue Urticaria,1
TOVIAZ,pruritus,and subcutaneous tissue disorders,0
TOVIAZ,pruritus,postmarketing experience,0
TOVIAZ,pruritus,Dizziness headache somnolence Skin and subcutaneous tissue disorders Urticaria,0
TOVIAZ,pruritus,pruritus,1
TOVIAZ,pruritus,somnolence Skin and subcutaneous,0
TOVIAZ,Angioedema of the face,tly reported adverse,1
TOVIAZ,Angioedema of the face,tly reported,1
TOVIAZ,Angioedema of the face,Toviaz were dry mouth placebo Toviaz,0
TOVIAZ,Angioedema of the face,,0
TOVIAZ,Central Nervous System Effects,,0
TOVIAZ,Central Nervous System Effects,,0
TOVIAZ,Central Nervous System Effects,3 studies with treatment periods of,1
TOVIAZ,Central Nervous System Effects,2 or 3 studies with treatment  periods of,1
TOVIAZ,Central Nervous System Effects,total received Toviaz mgday and,0
TOVIAZ,Central Nervous System Effects,of these patients had weeks exposure to Toviaz in th,0
TOVIAZ,Somnolence,and received Toviaz mgday in Phase or studies with treatment,0
TOVIAZ,Somnolence,treatment riods of,1
TOVIAZ,Somnolence,studies with treatment riods of,1
TOVIAZ,Somnolence,studies with treatment riods,1
TOVIAZ,Somnolence,and received Toviaz mgday,0
TOVIAZ,Somnolence,with treatment riods,1
TOVIAZ,Angioedema of the face,In Phase 2 and placebocontrolled trials,1
TOVIAZ,Angioedema of the face,Toviaz ay. In Phase,1
TOVIAZ,Angioedema of the face,patients received Toviaz mgday and patients,0
TOVIAZ,Angioedema of the face,patients received Toviaz ay. In Phase,1
TOVIAZ,Angioedema of the face,and patients received Toviaz,0
TOVIAZ,Angioedema of the face,,0
TOVIAZ,Angioedema of the face,,0
TOVIAZ,Angioedema of the face,,0
TOVIAZ,Angioedema of the face,Toviaz ay. In Phase,1
TOVIAZ,Angioedema,adverse events,0
TOVIAZ,Angioedema,receiving placebo Toviaz and,1
TOVIAZ,Angioedema,the incidences of serious adverse events in patients,0
TOVIAZ,Angioedema,placebo Toviaz and,1
TOVIAZ,Angioedema,to be not rel,0
TOVIAZ,Angioedema,the incidences of serious adverse events,0
TOVIAZ,Angioedema,patients receiving placebo Toviaz and,1
TOVIAZ,Angioedema,events were judged to,0
TOVIAZ,Angioedema,Toviaz and,1
TOVIAZ,Angioedema,Tovia z mg,1
TOVIAZ,Angioedema,receiving placebo Toviaz  and Tovia z mg,1
TOVIAZ,Angioedema,,0
TOVIAZ,Angioedema,z mg were and respectively All serious adverse events were judged to be not rel,0
TOVIAZ,Angioedema,Toviaz and,1
TOVIAZ,Angioedema,and Tovia z mg,1
TOVIAZ,Angioedema,patients receiving placebo Toviaz and,1
TOVIAZ,Angioedema,patients receiving placebo Toviaz and,1
TOVIAZ,Angioedema,were judged to be,0
TOVIAZ,upper airway swelling,,0
TOVIAZ,CNS anticholinergic effects,the combined,0
TOVIAZ,CNS anticholinergic effects,"ized, placebo-controlled",1
TOVIAZ,CNS anticholinergic effects,and in or more,0
TOVIAZ,headache,in the combined Phase randomized placebocontrolled trials at an incidence,0
TOVIAZ,headache,th,0
TOVIAZ,dizziness,than,0
TOVIAZ,dizziness,greater than  and in 1 or more,1
TOVIAZ,dizziness,incidence greater than and,1
TOVIAZ,dizziness,greater than and,1
TOVIAZ,somnolence,ore of pat ients treated,1
TOVIAZ,somnolence,in,0
TOVIAZ,somnolence,placebo and in or ore of pat ients treated,1
TOVIAZ,somnolence,ore of pat ients treated,1
TOVIAZ,somnolence,,0
TOVIAZ,somnolence,in or ore of,1
TOVIAZ,somnolence,in or ore of pat ients treated,1
TOVIAZ,somnolence,ore of pat ients treated,1
TOVIAZ,somnolence,placebo,0
STRIBILD,Lactic Acidosis,following adverse drug reactions are discussed in other sections of the,0
STRIBILD,Lactic Acidosis,Acidosis Severe Hepatomegaly,1
STRIBILD,Lactic Acidosis,sections of the Lactic Acidosis Severe Hepatomegaly,1
STRIBILD,Lactic Acidosis,,0
STRIBILD,Lactic Acidosis,Lactic Acidosis Severe Hepatomegaly,1
STRIBILD,Lactic Acidosis,reactions are discussed in other sections of,0
STRIBILD,Lactic Acidosis,Lactic Acidosis Severe Hepatomegaly,1
STRIBILD,Lactic Acidosis,Warnings and Precautions,0
STRIBILD,Hepatomegaly,the labeling,0
STRIBILD,Hepatomegaly,of the labeling Lactic Hepatomegaly with Steatosis,1
STRIBILD,Hepatomegaly,labeling,0
STRIBILD,Hepatomegaly,Steatosis see Boxed Warning Warnings and Precautions Severe Acute,0
STRIBILD,Hepatomegaly,Warnings and Precautions Severe Acute,0
STRIBILD,Hepatomegaly,,0
STRIBILD,Hepatomegaly,Severe Acute,0
STRIBILD,Steatosis,Steatosis see Boxed,1
STRIBILD,Steatosis,,0
STRIBILD,Steatosis,Steatosis see Boxed,1
STRIBILD,Steatosis,discussed in other sections of,0
STRIBILD,Steatosis,Steatosis see Boxed,1
STRIBILD,Steatosis,Severe,0
STRIBILD,Steatosis,AcidosisSevere Hepatomegaly Steatosis see Boxed,1
STRIBILD,Steatosis,labeling Lactic AcidosisSevere Hepatomegaly Steatosis see Boxed,1
STRIBILD,Steatosis,Steatosis see Boxed,1
STRIBILD,Steatosis,and Precautions Severe Acute Exacerbations,0
STRIBILD,Acute Exacerbations of Hepatitis B,Hepatitis B see Boxed,1
STRIBILD,Worsening Renal Impairment,see Boxed Warning Warnings,0
STRIBILD,Worsening Renal Impairment,Onset,0
STRIBILD,Worsening Renal Impairment,B see Boxed Warning Warnings and Precautions,0
STRIBILD,Bone Effects,see Warnings and Bone Effects of Tenofovir,1
STRIBILD,Bone Effects,Onset or Worsening Renal,0
STRIBILD,Bone Effects,or,0
STRIBILD,Bone Effects,Effects of Tenofovir,1
STRIBILD,Bone Effects,Renal,0
STRIBILD,Bone Effects,,0
STRIBILD,Bone Effects,and Bone,1
STRIBILD,Bone Effects,see,0
STRIBILD,Immune Reconstitution Syndrome,Reconstitution Syndrome see Warnings,1
STRIBILD,nausea,nausea and diarrhea,1
STRIBILD,diarrhea,greater than or equal,0
STRIBILD,diarrhea,diarrhea To report,1
STRIBILD,diarrhea,SUSPECTED ADVERSE REACTIONS contact Gilead Sciences Inc at GILE,0
STRIBILD,diarrhea,nausea diarrhea To report,1
STRIBILD,diarrhea,diarrhea To report,1
STRIBILD,diarrhea,ADVERSE REACTIONS contact Gilead Sciences Inc at,0
STRIBILD,diarrhea,nausea diarrhea To report,1
STRIBILD,Ocular icterus,,0
STRIBILD,Ocular icterus,Ocular icterus GASTR,1
STRIBILD,Ocular icterus,Ocular icterus GASTR,1
STRIBILD,Ocular icterus,,0
STRIBILD,Ocular icterus,Ocular icterus GASTR,1
STRIBILD,Ocular icterus,Ocular icterus GASTR,1
STRIBILD,Ocular icterus,GASTR,0
STRIBILD,Diarrhea,NAL Diarrhea,1
STRIBILD,Diarrhea,,0
STRIBILD,Diarrhea,Diarrhea,1
STRIBILD,Diarrhea,,0
STRIBILD,Diarrhea,,0
STRIBILD,Flatulence,Flatulence,1
STRIBILD,Flatulence,,0
STRIBILD,Flatulence,,0
STRIBILD,Flatulence,,0
STRIBILD,Flatulence,Flatulence,1
STRIBILD,Flatulence,,0
STRIBILD,Flatulence,Flatulence,1
STRIBILD,Nausea,Nausea,1
STRIBILD,Nausea,Nausea,1
STRIBILD,Nausea,Nausea,1
STRIBILD,Nausea,,0
STRIBILD,Nausea,Nausea,1
STRIBILD,Fatigue,AND ADMINISTRATION,0
STRIBILD,Fatigue,Fatigue,1
STRIBILD,Fatigue,Fatigue,1
STRIBILD,Fatigue,SITE Fatigue,1
STRIBILD,Fatigue,Fatigue,1
STRIBILD,Fatigue,ADMINISTRATION,0
STRIBILD,Fatigue,Fatigue,1
STRIBILD,Jaundice,DISORDERS,0
STRIBILD,Somnolence,Somnolence,1
STRIBILD,Somnolence,DISORDERS,0
STRIBILD,Somnolence,Somnolence,1
STRIBILD,Somnolence,Somnolence,1
STRIBILD,Somnolence,,0
STRIBILD,Somnolence,,0
STRIBILD,Somnolence,Somnolence,1
STRIBILD,Somnolence,,0
STRIBILD,Somnolence,Somnolence,1
STRIBILD,Somnolence,Somnolence,1
STRIBILD,Dizziness,,0
STRIBILD,Dizziness,Dizziness,1
STRIBILD,Insomnia,ISORDERS Insomnia,1
STRIBILD,Abnormal dreams,Abnormal dreams SKIN,1
STRIBILD,Abnormal dreams,Abnormal dreams,1
STRIBILD,Abnormal dreams,Abnormal,1
STRIBILD,Abnormal dreams,,0
STRIBILD,Rash,,0
STRIBILD,Rash,,0
STRIBILD,Rash,Rash,1
STRIBILD,Rash,TISSUE,0
STRIBILD,Rash,TISSUE,0
STRIBILD,Rash,TISSUE,0
STRIBILD,Rash,Rash,1
STRIBILD,renal adverse reactions,reactions observed with,0
STRIBILD,renal adverse reactions,renal adverse reactions from clinical,1
STRIBILD,renal adverse reactions,clinical,0
STRIBILD,renal adverse reactions,from clinical,0
STRIBILD,renal adverse reactions,,0
STRIBILD,renal adverse reactions,STRIBILD Additional,0
STRIBILD,renal adverse reactions,a discussion renal,1
STRIBILD,renal adverse reactions,discussion renal,1
STRIBILD,renal adverse reactions,drug reactions observed,0
STRIBILD,suicidal ideation,of,0
STRIBILD,suicidal ideation,observed with STRIBILD suicidal ideation and suicide,1
STRIBILD,suicide attempt,of depression,0
STRIBILD,nausea,switching to STRIBILD nausea flatulence and,1
STRIBILD,nausea,of,0
STRIBILD,nausea,switching to STRIBILD nausea flatulence and,1
STRIBILD,nausea,subjects switching to STRIBILD nausea flatulence and,1
STRIBILD,flatulence,flatulence and headache,1
STRIBILD,flatulence,proportion,0
STRIBILD,flatulence,flatulence and headache,1
STRIBILD,flatulence,than,0
STRIBILD,flatulence,flatulence and headache,1
STRIBILD,flatulence,flatulence and headache,1
STRIBILD,flatulence,flatulence and headache,1
STRIBILD,flatulence,that occurred,0
STRIBILD,flatulence,to STRIBILD were flatulence and headache,1
STRIBILD,depression,clinical depression abdominal pain,1
STRIBILD,depression,,0
STRIBILD,depression,other clinical depression abdominal pain,1
STRIBILD,depression,pain dyspepsia vomiting,0
STRIBILD,depression,depression abdominal pain,1
STRIBILD,depression,depression abdominal pain,1
STRIBILD,depression,,0
STRIBILD,depression,or tenofovir DF with,0
STRIBILD,abdominal pain,trials abdominal pain dyspepsia vomiting,1
STRIBILD,abdominal pain,vomiting fever pain nasopharyngitis pneumonia sinusitis upper respiratory tract i,0
STRIBILD,dyspepsia,other clinical trials,0
STRIBILD,dyspepsia,,0
STRIBILD,dyspepsia,nasopharyngitis pneumonia sinusitis upper respiratory tract,0
STRIBILD,dyspepsia,other clinical,0
STRIBILD,dyspepsia,dyspepsia vomiting fever,1
STRIBILD,dyspepsia,DF with other antiretroviral agents in other clinical trials depression abdominal pain,0
STRIBILD,vomiting,abdominal pain vomiting fever pain,1
STRIBILD,vomiting,other antiretroviral agents in other clinical trials depression,0
STRIBILD,vomiting,other,0
STRIBILD,vomiting,,0
STRIBILD,vomiting,vomiting fever pain,1
STRIBILD,vomiting,vomiting fever pain,1
STRIBILD,vomiting,vomiting fever pain,1
STRIBILD,vomiting,clinical trials depression abdominal pain dyspepsia,0
STRIBILD,vomiting,vomiting fever pain,1
STRIBILD,vomiting,vomiting fever pain,1
STRIBILD,fever,dyspepsia fever pain nasopharyngitis,1
STRIBILD,fever,in other,0
STRIBILD,fever,,0
STRIBILD,fever,fever pain nasopharyngitis,1
STRIBILD,fever,fever pain nasopharyngitis,1
STRIBILD,pain,pain,0
STRIBILD,pain,vomiting pain nasopharyngitis pneumonia,1
STRIBILD,pain,,0
STRIBILD,pain,pain nasopharyngitis pneumonia,1
STRIBILD,pain,pain nasopharyngitis pneumonia,1
STRIBILD,pain,pain nasopharyngitis pneumonia,1
STRIBILD,nasopharyngitis,nasopharyngitis pneumonia sinusitis,1
STRIBILD,nasopharyngitis,nasopharyngitis pneumonia sinusitis,1
STRIBILD,nasopharyngitis,nasopharyngitis pneumonia sinusitis,1
STRIBILD,nasopharyngitis,,0
STRIBILD,nasopharyngitis,vomiting fever nasopharyngitis pneumonia sinusitis,1
STRIBILD,nasopharyngitis,,0
STRIBILD,pneumonia,vomiting fever,0
STRIBILD,sinusitis,pain myalgia paresthesia peripheral neuropa,0
STRIBILD,sinusitis,depression abdominal pain dyspepsia vomiting,0
STRIBILD,upper respiratory tract infection,infection arthralgia back,1
STRIBILD,upper respiratory tract infection,myalgia paresthesia peripheral neuropathy including peripheral,0
STRIBILD,upper respiratory tract infection,,0
STRIBILD,upper respiratory tract infection,peripheral,0
STRIBILD,upper respiratory tract infection,fever pain nasopharyngitis,0
STRIBILD,upper respiratory tract infection,neuropathy including peripheral neuritis,0
STRIBILD,upper respiratory tract infection,upper respiratory tract,1
STRIBILD,upper respiratory tract infection,pneumonia upper respiratory tract infection arthralgia back,1
STRIBILD,upper respiratory tract infection,pain myalgia paresthesia peripheral neuropathy including peripheral neuritis,0
STRIBILD,arthralgia,arthralgia back pain,1
STRIBILD,arthralgia,peripheral neuropathy including peripheral,0
STRIBILD,arthralgia,upper respiratory tract infection,0
STRIBILD,arthralgia,arthralgia back pain,1
STRIBILD,back pain,upper respiratory tract infection back,1
STRIBILD,myalgia,back myalgia paresthesia peripheral,1
STRIBILD,myalgia,upper respiratory,0
STRIBILD,anxiety,and neuropathy,0
STRIBILD,anxiety,anxiety increased cough,1
STRIBILD,anxiety,,0
STRIBILD,anxiety,paresthesia peripheral neuropathy including peripheral neuritis and neuropathy,0
STRIBILD,anxiety,peripheral neuropathy including peripheral,0
STRIBILD,anxiety,peripheral neuritis and anxiety increased cough,1
STRIBILD,anxiety,neuritis and anxiety increased cough,1
STRIBILD,anxiety,anxiety increased cough,1
STRIBILD,increased cough,increased,1
STRIBILD,rhinitis,peripheral neuritis and neuropathy anxiety increased cough and,0
STRIBILD,rhinitis,reported with higher frequency among,0
STRIBILD,rhinitis,increased cough rhinitis Skin discoloration,1
STRIBILD,rhinitis,frequency,0
STRIBILD,rhinitis,,0
STRIBILD,rhinitis,rhinitis Skin discoloration,1
STRIBILD,rhinitis,higher frequency among emtricitabinetreated,0
STRIBILD,rhinitis,with higher frequency among emtricitabinetreated,0
STRIBILD,Skin discoloration,anxiety increased cough and Skin discoloration has been,1
STRIBILD,Skin discoloration,Skin discoloration has been,1
STRIBILD,Skin discoloration,anxiety increased cough and Skin,1
STRIBILD,Skin discoloration,,0
STRIBILD,Skin discoloration,increased cough,0
STRIBILD,Skin discoloration,was manifested,0
STRIBILD,Skin discoloration,frequency among emtricitabinetreated subjects it,0
STRIBILD,Skin discoloration,peripheral neuritis and neuropathy anxiety,0
STRIBILD,Skin discoloration,cough and Skin,1
STRIBILD,Urine RBC,,0
STRIBILD,Urine RBC,Urine RBC Hematuria RBCHPF,1
STRIBILD,Urine RBC,Urine RBC Hematuria RBCHPF,1
STRIBILD,Urine RBC,nase Urine RBC Hematuria RBCHPF,1
STRIBILD,Urine RBC,,0
STRIBILD,Urine RBC,Urine RBC Hematuria RBCHPF,1
STRIBILD,Urine RBC,Urine,1
STRIBILD,Urine RBC,,0
STRIBILD,Hematuria,Hematuria RBCHPF,1
STRIBILD,Hematuria,RBCHPF,0
STRIBILD,decreases in BMD,RTV TRUVADA,0
STRIBILD,decreases in BMD,STRIBILD group were,0
STRIBILD,decreases in BMD,N Mean decreases,1
STRIBILD,decreases in BMD,group N Mean decreases,1
STRIBILD,decreases in BMD,group N ATV RTV TRUVADA,0
STRIBILD,decreases in BMD,at,0
STRIBILD,decreases in BMD,from baseline to Week in the STRIBILD group were comparable to the,0
STRIBILD,decreases in BMD,Mean decreases,1
STRIBILD,decreases in BMD,RTV TRUVADA group at,0
STRIBILD,decreases in BMD,TRUVADA group N Mean decreases,1
STRIBILD,bone fractures,subjects in the STRIBILD group subjects in the ATRIPLA,0
STRIBILD,bone fractures,,0
STRIBILD,bone fractures,respectively In Studies bone,1
STRIBILD,bone fractures,the STRIBILD group subjects in,0
STRIBILD,increase serum creatinine,TRUVADA The cobicistat component,0
STRIBILD,decrease estimated creatinine clearance,,0
STRIBILD,decrease estimated creatinine clearance,of creatinine without affecting renal glomerular function,0
STRIBILD,decrease estimated creatinine clearance,to increase serum creatinine decrease estimated creatinine,1
STRIBILD,decrease estimated creatinine clearance,decrease estimated creatinine clearance due to,1
STRIBILD,decrease estimated creatinine clearance,serum creatinine and,0
STRIBILD,decrease estimated creatinine clearance,estimated creatinine clearance due to,1
STRIBILD,decrease estimated creatinine clearance,inhibition of tubular secretion of creatinine without affecting,0
STRIBILD,affecting renal glomerular function,secretion of creatinine affecting renal glomerular function In Studies,1
STRIBILD,affecting renal glomerular function,in estimated creatinine,0
STRIBILD,affecting renal glomerular function,creatinine cleara,0
STRIBILD,affecting renal glomerular function,of creatinine affecting,1
STRIBILD,affecting renal glomerular function,tubular secretion of creatinine affecting renal glomerular function In Studies,1
STRIBILD,increases in serum creatinine,increases in serum creatinine and decreases,1
STRIBILD,increases in serum creatinine,,0
STRIBILD,increases in serum creatinine,Studies and,0
STRIBILD,increases in serum creatinine,,0
STRIBILD,decreases in estimated creatinine clearance,decreases in estimated,1
STRIBILD,decreases in estimated creatinine clearance,creatinine clearance occurred early,1
STRIBILD,elevations in serum creatinine,elevations in serum creatinine All Grades,1
STRIBILD,elevations in serum creatinine,from Baseline in Serum Creatinine and,0
STRIBILD,elevations in serum creatinine,with,0
STRIBILD,elevations in serum creatinine,percentage of subjects,0
STRIBILD,elevations in serum creatinine,Change from Baseline in Serum Creatinine and eGFR and Incidence,0
STRIBILD,elevations in serum creatinine,creatinine All Grades,1
STRIBILD,elevations in serum creatinine,changes,0
STRIBILD,elevations in serum creatinine,percentage of subjects elevations in serum,1
STRIBILD,elevations in serum creatinine,with,0
STRIBILD,elevations in serum creatinine,and Incidence,0
STRIBILD,Elevated Serum Creatinine,Elevated,1
STRIBILD,Elevated Serum Creatinine,Serum Creatinine All Grades,1
STRIBILD,Elevated Serum Creatinine,and Incidence Elevated Serum,1
STRIBILD,Elevated Serum Creatinine,Serum Creatinine and eGFR,0
STRIBILD,Elevated Serum Creatinine,Grades Table,0
STRIBILD,Elevated Serum Creatinine,All Grades Table Change from Baseline in Serum,0
STRIBILD,Elevated Serum Creatinine,at,0
STRIBILD,Elevations in Serum Creatinine,,0
STRIBILD,Elevations in Serum Creatinine,mLminute Subjects Elevations in Serum,1
STRIBILD,Elevations in Serum Creatinine,with,0
STRIBILD,Elevations in Serum Creatinine,with,0
STRIBILD,Elevations in Serum Creatinine,Serum Creatinine All Grades,1
STRIBILD,Elevations in Serum Creatinine,Subjects,0
STRIBILD,Elevations in Serum Creatinine,Subjects,0
STRIBILD,Elevations in Serum Creatinine,in Serum Creatinine All Grades,1
STRIBILD,Elevations in Serum Creatinine,Subjects Elevations in Serum,1
STRIBILD,Elevations in Serum Creatinine,Serum Creatinine All Grades,1
STRIBILD,abnormalities of ALT,of ALT M greater,1
STRIBILD,angioedema,have been identified Immune System,0
STRIBILD,angioedema,angioedema Metabolism and,1
STRIBILD,angioedema,reaction angioedema Metabolism and,1
STRIBILD,angioedema,angioedema Metabolism and,1
STRIBILD,angioedema,angioedema Metabolism and,1
STRIBILD,angioedema,angioedema Metabolism and,1
STRIBILD,angioedema,angioedema Metabolism and,1
STRIBILD,angioedema,angioedema Metabolism and,1
STRIBILD,lactic acidosis,Nutrition lactic,1
STRIBILD,lactic acidosis,hypophosphatemia Respiratory Thoracic and Mediastinal,0
STRIBILD,hypokalemia,and Nutrition Disorders,0
STRIBILD,hypokalemia,Mediastinal Disorders dyspnea Gastro,0
STRIBILD,hypokalemia,hypophosphatemia Respiratory Thoracic and,0
STRIBILD,hypophosphatemia,hypophosphatemia Respiratory Thoracic,1
STRIBILD,hypophosphatemia,lactic acidosis hypokalemia,0
STRIBILD,hypophosphatemia,and Mediastinal Disorders dyspnea Gastrointestinal,0
STRIBILD,hypophosphatemia,Disorders lactic acidosis hypophosphatemia Respiratory Thoracic,1
STRIBILD,hypophosphatemia,hypophosphatemia Respiratory Thoracic,1
STRIBILD,hypophosphatemia,and Mediastinal,0
STRIBILD,hypophosphatemia,hypophosphatemia Respiratory Thoracic,1
STRIBILD,hypophosphatemia,Disorders lactic acidosis hypokalemia,0
STRIBILD,hypophosphatemia,hypophosphatemia Respiratory Thoracic,1
STRIBILD,hypophosphatemia,hypokalemia,0
STRIBILD,dyspnea,abdominal,0
STRIBILD,pancreatitis,Disorders dyspnea Gastrointestinal pancreatitis increased amylase,1
STRIBILD,pancreatitis,Disorders hepatic,0
STRIBILD,pancreatitis,Gastrointestinal pancreatitis increased amylase,1
STRIBILD,pancreatitis,pancreatitis increased amylase,1
STRIBILD,increased amylase,increased amylase abdominal pain,1
STRIBILD,increased amylase,abdominal pain Hepatobiliary Disorders hepatic steatosis hepatitis increased liver,0
STRIBILD,increased amylase,dyspnea Gastrointestinal Disorders increased amylase abdominal pain,1
STRIBILD,increased amylase,,0
STRIBILD,increased amylase,,0
STRIBILD,increased amylase,Disorders increased,1
STRIBILD,increased amylase,increased amylase abdominal pain,1
STRIBILD,increased amylase,dyspnea Gastrointestinal,0
STRIBILD,increased amylase,liver,0
STRIBILD,increased amylase,steatosis,0
STRIBILD,abdominal pain,increased,0
STRIBILD,abdominal pain,increased abdominal pain Hepatobiliary Disorders,1
STRIBILD,abdominal pain,Disorders hepatic steatosis,0
STRIBILD,abdominal pain,Disorders pancreatitis increased abdominal,1
STRIBILD,abdominal pain,hepatic steatosis hepatitis increased,0
STRIBILD,abdominal pain,hepatitis increased liver enzymes,0
STRIBILD,abdominal pain,abdominal pain Hepatobiliary Disorders,1
STRIBILD,hepatic steatosis,Subcutaneous T,0
STRIBILD,hepatic steatosis,abdominal pain Hepatobiliary,0
STRIBILD,hepatic steatosis,pain,0
STRIBILD,hepatic steatosis,ALT gamma GT Skin,0
STRIBILD,hepatic steatosis,hepatic,1
STRIBILD,hepatic steatosis,steatosis hepatitis increased,1
STRIBILD,hepatitis,Tissue,0
STRIBILD,hepatitis,,0
STRIBILD,hepatitis,hepatic hepatitis increased liver,1
STRIBILD,increased liver enzymes,Disorders hepatic steatosis increased liver,1
STRIBILD,increased liver enzymes,,0
STRIBILD,rash,rash Musculoskeletal and,1
STRIBILD,rhabdomyolysis,rhabdomyolysis osteomalacia manifested,1
STRIBILD,rhabdomyolysis,,0
STRIBILD,rhabdomyolysis,Connective Tissue Disorders,0
STRIBILD,rhabdomyolysis,,0
STRIBILD,rhabdomyolysis,rhabdomyolysis osteomalacia manifested,1
STRIBILD,osteomalacia,osteomalacia manifested as,1
STRIBILD,osteomalacia,osteomalacia manifested as,1
STRIBILD,osteomalacia,Connective Tissue Disorders osteomalacia manifested as,1
STRIBILD,osteomalacia,osteomalacia manifested as,1
STRIBILD,osteomalacia,Musculoskeletal and Connective Tissue Disorders,0
STRIBILD,osteomalacia,osteomalacia manifested as,1
STRIBILD,osteomalacia,osteomalacia manifested as,1
STRIBILD,bone pain,,0
STRIBILD,bone pain,pain and which,1
STRIBILD,bone pain,as,0
STRIBILD,bone pain,Connective,0
STRIBILD,bone pain,bone,1
STRIBILD,bone pain,bone,1
STRIBILD,fractures,fractures muscular weakness,1
STRIBILD,fractures,fractures muscular weakness,1
STRIBILD,fractures,bone pain and which may contribute,0
STRIBILD,muscular weakness,manifested as,0
STRIBILD,muscular weakness,bone pain and which may contribute to,0
STRIBILD,muscular weakness,,0
STRIBILD,muscular weakness,may contribute to muscular weakness myopathy Renal,1
STRIBILD,muscular weakness,muscular weakness myopathy Renal,1
STRIBILD,muscular weakness,,0
STRIBILD,muscular weakness,muscular weakness myopathy Renal,1
STRIBILD,muscular weakness,muscular weakness myopathy Renal,1
STRIBILD,myopathy,myopathy Renal and,1
STRIBILD,myopathy,renal failure renal failure acute,0
STRIBILD,myopathy,myopathy Renal and,1
STRIBILD,myopathy,myopathy Renal and,1
STRIBILD,myopathy,weakness,0
STRIBILD,myopathy,acute renal failure renal failure,0
STRIBILD,myopathy,muscular myopathy Renal and,1
STRIBILD,myopathy,,0
STRIBILD,acute renal failure,contribute to fractures muscular weakness myopathy Renal and Urinary,0
STRIBILD,renal failure,renal failure acute tubular,1
STRIBILD,acute tubular necrosis,renal tubulopathy,0
STRIBILD,acute tubular necrosis,acute renal failure renal acute tubular necrosis Fanconi syndrome,1
STRIBILD,acute tubular necrosis,,0
STRIBILD,acute tubular necrosis,acute tubular necrosis Fanconi syndrome,1
STRIBILD,acute tubular necrosis,necrosis Fanconi syndrome,1
STRIBILD,proximal renal tubulopathy,proximal,1
STRIBILD,nephrogenic diabetes insipidus,nephritis,0
STRIBILD,nephrogenic diabetes insipidus,nephritis including,0
STRIBILD,nephrogenic diabetes insipidus,insipidus renal insufficiency,1
STRIBILD,nephrogenic diabetes insipidus,acute,0
STRIBILD,nephrogenic diabetes insipidus,Fanconi syndrome proximal renal tubulopathy interstitial nephritis including acute,0
STRIBILD,renal insufficiency,acute cases nephrogenic diabetes renal insufficiency increased creatinine,1
STRIBILD,renal insufficiency,,0
STRIBILD,renal insufficiency,Disorders and Administration Site Condit,0
STRIBILD,renal insufficiency,diabetes renal insufficiency increased creatinine,1
STRIBILD,renal insufficiency,Administration Site Condit,0
STRIBILD,renal insufficiency,insufficiency increased creatinine,1
STRIBILD,renal insufficiency,nephritis including acute,0
STRIBILD,renal insufficiency,diabetes renal,1
STRIBILD,renal insufficiency,,0
STRIBILD,increased creatinine,insipidus renal increased,1
STRIBILD,increased creatinine,nephrogenic diabetes insipidus renal increased,1
STRIBILD,proteinuria,,0
STRIBILD,proteinuria,renal,0
STRIBILD,proteinuria,acute cases nephrogenic diabetes,0
STRIBILD,proteinuria,,0
STRIBILD,proteinuria,renal insufficiency increased proteinuria polyuria General,1
STRIBILD,proteinuria,proteinuria polyuria General,1
STRIBILD,proteinuria,proteinuria polyuria General,1
STRIBILD,proteinuria,proteinuria polyuria General,1
STRIBILD,proteinuria,proteinuria polyuria General,1
STRIBILD,proteinuria,proteinuria polyuria General,1
STRIBILD,polyuria,polyuria General Disorders,1
STRIBILD,polyuria,polyuria General Disorders,1
STRIBILD,polyuria,insufficiency increased creatinine polyuria General Disorders,1
STRIBILD,asthenia,asthenia The following,1
STRIBILD,proximal renal tubulopathy,tubulopathy rhabdomyolysis osteomalacia,1
STRIBILD,rhabdomyolysis,consequence,0
STRIBILD,osteomalacia,renal,0
STRIBILD,osteomalacia,hypophosphatemia,0
STRIBILD,osteomalacia,osteomalacia hypokalemia muscular,1
STRIBILD,osteomalacia,consequence of proximal,0
STRIBILD,osteomalacia,muscular weakness myopathy hypophosphatemia,0
STRIBILD,osteomalacia,,0
STRIBILD,hypokalemia,hypophosphatemia,0
STRIBILD,hypokalemia,proximal renal tubulopathy rhabdomyolysis hypokalemia muscular weakness,1
STRIBILD,muscular weakness,myopathy hypophosphatemia,0
STRIBILD,muscular weakness,tubulopathy rhabdomyolysis,0
STRIBILD,muscular weakness,osteomalacia muscular,1
STRIBILD,muscular weakness,a consequence of proximal,0
STRIBILD,muscular weakness,of proximal,0
STRIBILD,muscular weakness,renal tubulopathy rhabdomyolysis osteomalacia muscular weakness myopathy hypophosphatemia,1
STRIBILD,myopathy,myopathy hypophosphatemia,1
STRIBILD,myopathy,myopathy hypophosphatemia,1
STRIBILD,myopathy,myopathy hypophosphatemia,1
STRIBILD,myopathy,,0
STRIBILD,myopathy,myopathy hypophosphatemia,1
STRIBILD,myopathy,myopathy hypophosphatemia,1
STRIBILD,hypophosphatemia,,0
STRIBILD,LACTIC ACIDOSIS,following adve rse drug,1
STRIBILD,LACTIC ACIDOSIS,,0
STRIBILD,LACTIC ACIDOSIS, following adve,1
STRIBILD,LACTIC ACIDOSIS,following adve rse,1
STRIBILD,LACTIC ACIDOSIS,in other sections of the labeling Lactic AcidosisSevere,0
STRIBILD,LACTIC ACIDOSIS,,0
STRIBILD,HEPATOMEGALY,,0
STRIBILD,HEPATOMEGALY,reactions,1
STRIBILD,HEPATOMEGALY,discussed in other sections of the labeling Lactic AcidosisSevere,0
STRIBILD,HEPATOMEGALY,,0
STRIBILD,HEPATOMEGALY,reactions,1
STRIBILD,STEATOSIS,cussed in,1
STRIBILD,STEATOSIS,in other sections of the labeling,1
STRIBILD,STEATOSIS,see,0
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,,0
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,Acidos isSevere Hepatomegaly with,1
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,Warning Warnings,0
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,Warnings,0
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,,0
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,,0
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,"he labeling:



 *  Lactic Acidos isSevere Hepatomegaly with",1
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,"of he labeling:



 *  Lactic Acidos isSevere Hepatomegaly with",1
STRIBILD,LACTIC ACIDOSIS,the labeling Lactic AcidosisSevere omegaly,1
STRIBILD,LACTIC ACIDOSIS,Precautions Severe Acute Exacerbations,0
STRIBILD,LACTIC ACIDOSIS,the labeling Lactic AcidosisSevere omegaly with St eatosis see Boxed,1
STRIBILD,LACTIC ACIDOSIS,AcidosisSevere omegaly with St eatosis see Boxed,1
STRIBILD,LACTIC ACIDOSIS,Warnings and Precautions Severe,0
STRIBILD,LACTIC ACIDOSIS,Acute,0
STRIBILD,LACTIC ACIDOSIS,Precautions Severe,0
STRIBILD,LACTIC ACIDOSIS,omegaly with St eatosis see Boxed,1
STRIBILD,LACTIC ACIDOSIS,St eatosis see Boxed,1
STRIBILD,LACTIC ACIDOSIS,AcidosisSevere omegaly with St eatosis see Boxed,1
STRIBILD,HEPATOMEGALY,with [see  Boxed  Warning Warnings and,1
STRIBILD,HEPATOMEGALY,Boxed Warning Warnings and,1
STRIBILD,HEPATOMEGALY,Hepatomegaly with [see  Boxed  Warning Warnings and,1
STRIBILD,HEPATOMEGALY,[see  Boxed  Warning Warnings and,1
STRIBILD,HEPATOMEGALY,Acute Exacerbations of,0
STRIBILD,HEPATOMEGALY,Hepatitis B,0
STRIBILD,HEPATOMEGALY,[see Boxed Warning Warnings and,1
STRIBILD,HEPATOMEGALY,Hepatomegaly,0
STRIBILD,HEPATOMEGALY,Hepatomegaly with [see  Boxed  Warning Warnings and,1
STRIBILD,STEATOSIS,"Steatosis see Boxed g ,",1
STRIBILD,STEATOSIS,"see Boxed g ,",1
STRIBILD,STEATOSIS,"g , War nings and Precautions",1
STRIBILD,STEATOSIS,"Steatosis see Boxed g  ,  War nings and Precautions",1
STRIBILD,STEATOSIS,", War nings and Precautions",1
STRIBILD,STEATOSIS,,0
STRIBILD,STEATOSIS,Steatosis see Boxed g,1
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,with Steatosis see Boxed Warning Warnings,0
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,Warnings,0
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,* Severe Acute Ex acerbations of Hepatitis,1
STRIBILD,Lactic acidosis,ons,1
STRIBILD,Lactic acidosis,Precautions Severe Acute,0
STRIBILD,Lactic acidosis,Acute ons,1
STRIBILD,hepatomegaly,Acute Exacerbations of Hepatitis B,0
STRIBILD,hepatomegaly,of Hepatitis B see Bo,0
STRIBILD,steatosis,see Boxed Warning rnings an d Precautions New,1
STRIBILD,steatosis,Renal Impairment see,0
STRIBILD,steatosis,Onset or Worsening Renal Impairment see Warnings and Precautions,0
STRIBILD,steatosis,Boxed Warning rnings an d Precautions New,1
STRIBILD,steatosis,B see Boxed Warning rnings,1
STRIBILD,steatosis,Severe Acute Exacerbations of Hepatitis B see Boxed,0
STRIBILD,fatal,,0
STRIBILD,fatal,Warnings and s,1
STRIBILD,fatal,Boxed Warning Warnings and s,1
STRIBILD,fatal,Impairment see Warnings and,0
STRIBILD,fatal,Worsening,0
STRIBILD,acute exacerbations of hepatitis B,ciences Inc at,0
STRIBILD,acute exacerbations of hepatitis B,GILEAD or FDA at FDA or,0
STRIBILD,acute exacerbations of hepatitis B,nausea and,0
STRIBILD,acute exacerbations of hepatitis B,,0
STRIBILD,acute exacerbations of hepatitis B,"report SUSPECTED DVERSE REACTIONS, contact Gilead S ciences Inc at",1
STRIBILD,LACTIC ACIDOSIS,Subjects With No Antiretroviral Treatment History The,0
STRIBILD,LACTIC ACIDOSIS,The safety of STRIBILD,1
STRIBILD,LACTIC ACIDOSIS,,0
STRIBILD,LACTIC ACIDOSIS,is based on the,1
STRIBILD,LACTIC ACIDOSIS,Treatment History The safety of STRIBILD,1
STRIBILD,LACTIC ACIDOSIS,is based on the,1
STRIBILD,LACTIC ACIDOSIS,from subjects in two randomized doubleblind activecontrol,0
STRIBILD,LACTIC ACIDOSIS,on the Week pooled data from subjects in two randomized,0
STRIBILD,HEPATOMEGALY,is based the,1
STRIBILD,HEPATOMEGALY, the Week 14 pooled data from,1
STRIBILD,HEPATOMEGALY,14 pooled data from,1
STRIBILD,HEPATOMEGALY,of STRIBILD is based on,0
STRIBILD,HEPATOMEGALY,based the,1
STRIBILD,HEPATOMEGALY,is based  the Week 14 pooled data from,1
STRIBILD,HEPATOMEGALY,in,0
STRIBILD,STEATOSIS,trials Study,0
STRIBILD,STEATOSIS,Treatment History The safety assessment of,0
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,of STRIBILD is based on the Week pooled,0
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,assessment of STRIBILD is based on the Week pooled data from subjects in,0
STRIBILD,Lactic acidosis,in antiretroviral reatment-naive  HIV infected adult,1
STRIBILD,Lactic acidosis,reatment-naive  HIV infected adult,1
STRIBILD,hepatomegaly,daily in,0
STRIBILD,hepatomegaly,in antiretroviral treatmentnaive HIV ed adult,1
STRIBILD,hepatomegaly,sub jects see Clinical,1
STRIBILD,hepatomegaly,see Clinical Studies A total of subjects,0
STRIBILD,hepatomegaly,adult sub jects see Clinical,1
STRIBILD,hepatomegaly,trials Study and Study in antiretroviral treatmentnaive HIV infect,0
STRIBILD,hepatomegaly,antiretroviral treatmentnaive,0
STRIBILD,hepatomegaly,,0
STRIBILD,hepatomegaly,Study in antiretroviral treatmentnaive,0
STRIBILD,hepatomegaly,subjects received STRIBILD,0
STRIBILD,steatosis,[see Cl inical Studies A,1
STRIBILD,steatosis,Cl inical Studies A,1
STRIBILD,steatosis,two,0
STRIBILD,steatosis,in antiretroviral,0
STRIBILD,fatal,adult subjects see Clinical es (1 A total of,1
STRIBILD,fatal,see Clinical es (1 A total of,1
STRIBILD,fatal,subjects see Clinical es (1 A total of,1
STRIBILD,acute exacerbations of hepatitis B,DF mg PLA (efavirenz 600 mg/emtricitabin e mgtenofovir DF,1
STRIBILD,worsening renal impairment,re discussed in other sect,1
STRIBILD,worsening renal impairment,,0
STRIBILD,worsening renal impairment,,0
STRIBILD,worsening renal impairment,,0
STRIBILD,worsening renal impairment,re discussed in other sect ions of the,1
STRIBILD,worsening renal impairment,other sect ions,1
STRIBILD,acute renal failure,beling: * Lact ic,1
STRIBILD,acute renal failure,of the la,0
STRIBILD,acute renal failure,Lact ic,1
STRIBILD,acute renal failure,drug reactions are discussed in,0
STRIBILD,acute renal failure,"sections of the beling:



 *  Lact ic",1
STRIBILD,acute renal failure,other sections of the beling: *,1
STRIBILD,acute renal failure,"sections of the beling:



 *  Lact ic",1
STRIBILD,acute renal failure,,0
STRIBILD,acute renal failure,AcidosisSevere Hepatomegaly,0
STRIBILD,acute renal failure,drug reactions,0
STRIBILD,Fanconi syndrome,labeling Lactic Ac,0
STRIBILD,Fanconi syndrome,adverse drug reactions are discussed in other sections of the labeling Lactic Ac,0
STRIBILD,Fanconi syndrome,Lactic idosis/Severe He patomegaly,1
STRIBILD,Fanconi syndrome,idosis/Severe He patomegaly,1
STRIBILD,Fanconi syndrome,Severe Ac,0
STRIBILD,Fanconi syndrome,drug reactions are discussed in other sections of the labeling Lactic Ac,0
STRIBILD,Fanconi syndrome,He patomegaly,1
STRIBILD,Fanconi syndrome,the labeling Lactic idosis/Severe,1
STRIBILD,Decreases in bone mineral density,STRIBILD is sed on the Week 144 pooled data f rom,1
STRIBILD,Decreases in bone mineral density,,0
STRIBILD,Decreases in bone mineral density,,0
STRIBILD,accumulation of body fat,HIV,0
STRIBILD,accumulation of body fat,Clinic al,1
STRIBILD,Immune reconstitution syndrome,"STRIBILD once y in these two studies.



 Th e",1
STRIBILD,Immune reconstitution syndrome,y in these two,1
STRIBILD,Immune reconstitution syndrome,of subjects who discontinued treatment with,0
STRIBILD,Immune reconstitution syndrome,two studies. Th e,1
STRIBILD,Immune reconstitution syndrome,subjects received STRIBILD once y in these two,1
STRIBILD,Immune reconstitution syndrome,y in these two studies. Th e,1
STRIBILD,Lactic acidosis,,0
STRIBILD,Lactic acidosis,elvitegravir mgcobicistat mgemtricitabine,0
STRIBILD,Lactic acidosis,DF 300 mg); A TRIPLA,1
STRIBILD,Lactic acidosis,elvitegravir mgcobicistat mgemtricitabine r DF 300 mg); A TRIPLA,1
STRIBILD,Lactic acidosis,elvitegravir mgcobicistat mgemtricitabine r,1
STRIBILD,hepatomegaly,ATRIPLA irenz,1
STRIBILD,hepatomegaly,irenz 600 mg emtricitabine,1
STRIBILD,steatosis,citabine  mgtenofovir,1
STRIBILD,steatosis,citabine  mgtenofovir,1
STRIBILD,steatosis,,0
STRIBILD,steatosis,efavirenz mgemtri,0
STRIBILD,fatal,efavirenz mgemtricitabine ovir  DF,1
STRIBILD,fatal,ovir  DF,1
STRIBILD,fatal,DF mg ATRIPLA efavirenz mgemtricitabine,0
STRIBILD,fatal,efavirenz mgemtricitabine ovir  DF,1
STRIBILD,fatal,or atazanavir ATV,0
STRIBILD,fatal,mgtenofovir DF,0
STRIBILD,fatal,,0
STRIBILD,fatal,,0
STRIBILD,exacerbations of hepatitis B,ADMINISTRATION SI,0
STRIBILD,exacerbations of hepatitis B,TE CONDITIONS Fatigue,1
STRIBILD,exacerbations of hepatitis B,TE CONDITIONS Fatigue,1
STRIBILD,exacerbations of hepatitis B,AND ADMINISTRATION,0
STRIBILD,exacerbations of hepatitis B,DISORDERS AND ADMINISTRATION TE CONDITIONS                Fatigue,1
STRIBILD,exacerbations of hepatitis B,AND ADMINISTRATION,0
STRIBILD,exacerbations of hepatitis B,GENERAL DISORDERS AND ADMINISTRATION TE CONDITIONS                Fatigue,1
STRIBILD,liver decompensation,                     Fatigue,1
STRIBILD,liver decompensation,                     Fatigue,1
STRIBILD,liver decompensation,                     Fatigue,1
STRIBILD,liver decompensation,                     Fatigue,1
STRIBILD,liver decompensation,,0
STRIBILD,liver decompensation,                     Fatigue,1
STRIBILD,liver decompensation,                     Fatigue,1
STRIBILD,liver decompensation,ADMINISTRATION,0
STRIBILD,liver decompensation,Fatigue,0
STRIBILD,Renal impairment,e NERVOUS,1
STRIBILD,Renal impairment,"e 
 NERVOUS SYSTEM DISORDERS S",1
STRIBILD,Renal impairment,,0
STRIBILD,Renal impairment,DISORDERS,0
STRIBILD,Renal impairment,e NERVOUS,1
STRIBILD,Renal impairment,e,0
STRIBILD,Renal impairment,"e 
 NERVOUS SYSTEM DISORDERS S",1
STRIBILD,acute renal failure,SYSTEM,0
STRIBILD,acute renal failure,                    Somnolence,1
STRIBILD,renal tubular injury,NERVOUS SYSTEM                      Somnolence,1
STRIBILD,renal tubular injury,,0
STRIBILD,renal tubular injury,Somnolence,0
STRIBILD,renal tubular injury,                     Somnolence,1
STRIBILD,renal tubular injury,Somnolence,0
STRIBILD,renal tubular injury,                     Somnolence,1
STRIBILD,renal tubular injury,                     Somnolence,1
STRIBILD,renal tubular injury,                     Somnolence,1
STRIBILD,hypophosphatemia,   Somnolence    He,1
STRIBILD,hypophosphatemia,   Somnolence    He,1
STRIBILD,renal adverse reaction,,0
STRIBILD,renal adverse reaction,,0
STRIBILD,renal adverse reaction,                       Insomnia,1
STRIBILD,renal adverse reaction,,0
STRIBILD,proximal renal tubular dysfunction,,0
STRIBILD,proximal renal tubular dysfunction,"Abnormal            4%           
 SKIN AND SUBCUTANEOUS TISSUE",1
STRIBILD,proximal renal tubular dysfunction,,0
STRIBILD,proximal renal tubular dysfunction,psychiatric illness In VirologicallySuppressed HIVInfected Subjects No new adver,0
STRIBILD,proximal renal tubular dysfunction,in subjects with a -existing history of depression or psychiatric illness,1
STRIBILD,increases in serum creatinine,vomiting fever,0
STRIBILD,increases in serum creatinine,trials depression abdominal pain dyspepsia vomiting fever,0
STRIBILD,increases in serum creatinine,"vomiting fever pain asopharyngitis,",1
STRIBILD,increases in serum creatinine,"pain asopharyngitis,",1
STRIBILD,increases in serum creatinine,"pain asopharyngitis, pneumonia,",1
STRIBILD,increases in serum creatinine,dyspepsia vomiting fever pain,0
STRIBILD,increases in serum creatinine,abdominal pain dyspepsia vomiting fever pain,0
STRIBILD,declines in estimated creatinine clearance,sinusitis er respiratory tract,1
STRIBILD,declines in estimated creatinine clearance,"er respiratory tract infection, arthralgia back pain",1
STRIBILD,declines in estimated creatinine clearance,pain dyspepsia vomiting,0
STRIBILD,declines in estimated creatinine clearance,"respiratory tract infection, arthralgia back pain",1
STRIBILD,declines in estimated creatinine clearance,arthralgia back pain,1
STRIBILD,declines in estimated creatinine clearance,"er respiratory tract infection, arthralgia back pain",1
STRIBILD,declines in estimated creatinine clearance,pneumonia sinusitis,0
STRIBILD,declines in estimated creatinine clearance,"sinusitis er respiratory tract infection,",1
STRIBILD,declines in estimated creatinine clearance,pain nasopharyngitis pneumonia sinusitis er,1
STRIBILD,decreases in bone mineral density,ATV RTV,0
STRIBILD,decreases in bone mineral density,grades occurred in subjects receiving,1
STRIBILD,decreases in bone mineral density,"in subjects receiving STRIBILD, 41%  of subjects",1
STRIBILD,decreases in bone mineral density,"subjects receiving STRIBILD, 41%  of subjects",1
STRIBILD,decreases in bone mineral density,"in subjects receiving STRIBILD, 41%  of subjects",1
STRIBILD,decreases in bone mineral density,receiving tenofovir DF lamivudine efavirenz Proteinuria all grades occurred in of,0
STRIBILD,increases in biochemical markers of bone metabolism,"of  receiving ATRIPLA, and 42% of subjects receiving A TV RTV",1
STRIBILD,increases in biochemical markers of bone metabolism,creati,0
STRIBILD,increases in biochemical markers of bone metabolism,"subjects receiving STRIBILD of receiving ATRIPLA, and 42% of",1
STRIBILD,increases in biochemical markers of bone metabolism,"receiving ATRIPLA, and",1
STRIBILD,increases in biochemical markers of bone metabolism,serum creati,0
STRIBILD,increases in biochemical markers of bone metabolism,TRUVADA,0
STRIBILD,increases in biochemical markers of bone metabolism," receiving ATRIPLA, and 42% of subjects receiving A TV RTV",1
STRIBILD,increases in biochemical markers of bone metabolism,"receiving STRIBILD of  receiving ATRIPLA, and 42% of subjects receiving A TV RTV",1
STRIBILD,increases in biochemical markers of bone metabolism,"subjects receiving STRIBILD of  receiving ATRIPLA, and 42% of subjects receiving A TV RTV",1
STRIBILD,increases in biochemical markers of bone metabolism,in of subjects receiving STRIBILD of subjects,0
STRIBILD,increased bone turnover,STRIBILD of subjects receiving ATRIPLA and of subjects receiving ATV,0
STRIBILD,increased bone turnover,The cobicist at component,1
STRIBILD,increased bone turnover,receiving ATV RTV UVADA. The,1
STRIBILD,increased bone turnover,,0
STRIBILD,osteomalacia,,0
STRIBILD,osteomalacia,Creatinine mgdL eGFR,1
STRIBILD,osteomalacia,ATRIPLAN,0
STRIBILD,osteomalacia,ATRIPLAN,0
STRIBILD,osteomalacia,m Creatinine mgdL eGFR,1
STRIBILD,osteomalacia,Creatinine mgdL eGFR,1
STRIBILD,osteomalacia,TRUVADAN m Creatinine mgdL eGFR,1
STRIBILD,osteomalacia,m Creatinine mgdL eGFR,1
STRIBILD,proximal renal tubulopathy,CockcroftGault mLminute,0
STRIBILD,proximal renal tubulopathy,,0
STRIBILD,proximal renal tubulopathy,,0
STRIBILD,proximal renal tubulopathy,,0
STRIBILD,proximal renal tubulopathy,Serum Creatinine,0
STRIBILD,proximal renal tubulopathy,ATV RTV TRUVADAN Serum,0
STRIBILD,proximal renal tubulopathy,0.14 (+/-0.1 eGFR by,1
STRIBILD,proximal renal tubulopathy,RTV TRUVADAN Serum,0
STRIBILD,proximal renal tubulopathy,Serum Creatinine 0.14,1
STRIBILD,proximal renal tubulopathy,ATV RTV,0
STRIBILD,bone pain,-0.12)    eGFR by,1
STRIBILD,bone pain,-0.12)    eGFR by,1
STRIBILD,bone pain,-0.12)    eGFR by,1
STRIBILD,bone pain,-0.12)    eGFR by,1
STRIBILD,bone pain,-0.12)    eGFR by,1
STRIBILD,bone pain,mgdL,0
STRIBILD,bone pain,,0
STRIBILD,bone pain,-0.12)    eGFR by,1
STRIBILD,pain in extremities,mgdL,0
STRIBILD,pain in extremities,,0
STRIBILD,pain in extremities,mgdL,0
STRIBILD,pain in extremities,eGFR by,0
STRIBILD,pain in extremities,mLminute,0
STRIBILD,pain in extremities,,0
STRIBILD,pain in extremities,Serum Creatinine 0.09 (+/-0.15)      eGFR by,1
STRIBILD,pain in extremities,0.09 (+/-0.15) eGFR by,1
STRIBILD,fractures,mL/minute Subjects with,1
STRIBILD,fractures,,0
STRIBILD,fractures,,0
STRIBILD,fractures,with Elevation,0
STRIBILD,Arthralgias,with,0
STRIBILD,Arthralgias,with Elevations,0
STRIBILD,Arthralgias,Elevations,0
STRIBILD,Arthralgias,in,1
STRIBILD,Arthralgias,Subjects with  in Serum C reatinine All,1
STRIBILD,Arthralgias,,0
STRIBILD,Arthralgias,in,1
STRIBILD,Arthralgias,with Elevations,0
STRIBILD,proximal renal tubulopathy,with Elevations in Serum,0
STRIBILD,proximal renal tubulopathy,in Serum Creatinine,0
STRIBILD,proximal renal tubulopathy,,0
STRIBILD,proximal renal tubulopathy,All Grades,0
STRIBILD,proximal renal tubulopathy,            6              Emtricitabine or,1
STRIBILD,proximal renal tubulopathy,,0
STRIBILD,central obesity,than 170 U per L,1
STRIBILD,central obesity,U per L,1
STRIBILD,central obesity,or laboratory abnormalities of ALT M greater than,0
STRIBILD,central obesity,than 170 U per L,1
STRIBILD,central obesity,trials Grade or laboratory,0
STRIBILD,central obesity,per L bilirubin greater than ULN,0
STRIBILD,central obesity,U per L F ter than 170,1
STRIBILD,dorsocervical fat enlargement,U,0
STRIBILD,dorsocervical fat enlargement,(g reater than,1
STRIBILD,dorsocervical fat enlargement,L bilirubin greater than ULN serum,0
STRIBILD,buffalo hump,per L,0
STRIBILD,buffalo hump,ALT M,0
STRIBILD,buffalo hump,L alkaline phosphatase ater than 55 U per,1
STRIBILD,buffalo hump,phosphatase ater than 55 U per,1
STRIBILD,buffalo hump,ater than 55 U per,1
STRIBILD,buffalo hump,55 U per,1
STRIBILD,buffalo hump,alkaline phosphatase ater than 55 U per,1
STRIBILD,buffalo hump,ULN serum glucose less than or greater than mg,0
STRIBILD,facial wasting,L F greater than U per L alkaline,0
STRIBILD,breast enlargement,"ULN), serum glu cose less",1
STRIBILD,breast enlargement,L bilirubin greater *,1
STRIBILD,cushingoid appearance,serum glucose ess than 40 or greate r than,1
STRIBILD,cushingoid appearance,greater than or equal to,0
STRIBILD,cushingoid appearance,glucose ess than,1
STRIBILD,Immune reconstitution syndrome,In clinical trials,1
STRIBILD,Immune reconstitution syndrome,RTV,0
STRIBILD,Immune reconstitution syndrome,"dL Serum Lipids In clinical trials of STRIBILD, a similar percentage",1
STRIBILD,Immune reconstitution syndrome,"clinical trials of STRIBILD, a similar percentage",1
STRIBILD,Immune reconstitution syndrome,on,0
STRIBILD,Immune reconstitution syndrome,,0
STRIBILD,Immune reconstitution syndrome,"Lipids In clinical trials of STRIBILD,",1
STRIBILD,Immune reconstitution syndrome,In clinical,1
STRIBILD,Immune reconstitution syndrome,dL and fasting triglycerides,0
STRIBILD,Immune reconstitution syndrome,"Lipids In clinical trials of STRIBILD,",1
STRIBILD,residual opportunistic infections,ared to of ATRIPLA and of ATV RTV TRUVADA subjects Changes from baseline in total,0
STRIBILD,residual opportunistic infections,from baseline in total c,0
STRIBILD,residual opportunistic infections,"lipid lowering agents, comp ared to",1
STRIBILD,residual opportunistic infections,were start,0
STRIBILD,residual opportunistic infections,STRIBILD subjects were ed on lipid lowering,1
STRIBILD,residual opportunistic infections,of STRIBILD subjects,0
STRIBILD,residual opportunistic infections,"subjects were ed on lipid lowering agents, comp ared to",1
STRIBILD,residual opportunistic infections,"were ed on lipid lowering agents, comp ared to",1
STRIBILD,residual opportunistic infections,STRIBILD subjects were ed on,1
STRIBILD,cytomegalovirus,,0
STRIBILD,cytomegalovirus,V + TRUVADA sub jects Changes,1
STRIBILD,cytomegalovirus,lowering agents compared to of ATRIPLA,0
STRIBILD,cytomegalovirus,V + TRUVADA sub jects Changes,1
STRIBILD,cytomegalovirus,ATRIPLA and of ATV V + TRUVADA sub jects Changes,1
STRIBILD,Pneumocystis jirovecii pneumonia,cts. Changes from baseline,1
STRIBILD,Pneumocystis jirovecii pneumonia,agents compared to of ATRIPLA and of ATV,0
STRIBILD,Pneumocystis jirovecii pneumonia,from baseline in total cholesterol,1
STRIBILD,PCP,ota l cholesterol,1
STRIBILD,PCP,ota l cholesterol,1
STRIBILD,PCP,ota l cholesterol,1
STRIBILD,PCP,LDLcholesterol and triglycerides are presented in Table Tab,0
STRIBILD,PCP,triglycerides are,0
STRIBILD,PCP,ATRIPLA and,0
STRIBILD,PCP,ota l cholesterol,1
STRIBILD,Autoimmune disorders,,0
STRIBILD,Autoimmune disorders,Comparator,0
STRIBILD,Autoimmune disorders,from Baseline,0
STRIBILD,Autoimmune disorders,Table 5. Tabl e Lipid,1
STRIBILD,Autoimmune disorders,,0
STRIBILD,Autoimmune disorders,Tabl e Lipid,1
STRIBILD,Autoimmune disorders,triglycerides,0
STRIBILD,Graves' disease,"Values, Mean",1
STRIBILD,Graves' disease,,0
STRIBILD,polymyositis,ge from Base line at,1
STRIBILD,Guillain-Barre syndrome,t Week 144 in Subjects  Receiving STRIBILD,1
STRIBILD,Guillain-Barre syndrome,Mean Change from Baseline t Week 144 in,1
STRIBILD,Guillain-Barre syndrome,from Baseline t Week 144,1
STRIBILD,Guillain-Barre syndrome,from,0
FARXIGA,Hypotension,reactions are described below and elsewhere in the,0
FARXIGA,Hypotension,the,0
FARXIGA,Hypotension,are described below and elsewhere in,0
FARXIGA,Hypotension,in the Hypotension see Warnings,1
FARXIGA,Hypotension,and elsewhere in the Hypotension see Warnings,1
FARXIGA,Hypotension,below and elsewhere in,0
FARXIGA,Impairment in Renal Function,Precautions Hypoglycemia with Concomitant,0
FARXIGA,Impairment in Renal Function,elsewhere in the labeling Hypotension see Warnings,0
FARXIGA,Impairment in Renal Function,Hypotension see Warnings and Impairment in Renal Function see Warnings,1
FARXIGA,Impairment in Renal Function,and Impairment in,1
FARXIGA,Impairment in Renal Function,Precautions Hypoglycemia with,0
FARXIGA,Impairment in Renal Function,with Insulin,0
FARXIGA,Impairment in Renal Function,Warnings and Precautions,0
FARXIGA,Hypoglycemia,,0
FARXIGA,Hypoglycemia,Insulin Secretagogues see Warnings and Precautions,0
FARXIGA,Hypoglycemia,Hypoglycemia with Concomitant,1
FARXIGA,Hypoglycemia,,0
FARXIGA,Genital Mycotic Infections,and Insulin Secretagogues see,0
FARXIGA,Genital Mycotic Infections,Mycotic Infections see Warnings,1
FARXIGA,Genital Mycotic Infections,and Genital Mycotic Infections see Warnings,1
FARXIGA,Genital Mycotic Infections,see Warnings and Genital,1
FARXIGA,Genital Mycotic Infections,see Warnings and Genital,1
FARXIGA,Genital Mycotic Infections,and Genital Mycotic Infections see Warnings,1
FARXIGA,Genital Mycotic Infections,Secretagogues see Warnings and Genital Mycotic Infections see Warnings,1
FARXIGA,Increases in Low-Density Lipoprotein Cholesterol,Precautions,0
FARXIGA,Increases in Low-Density Lipoprotein Cholesterol,,0
FARXIGA,Increases in Low-Density Lipoprotein Cholesterol,Bladder Cancer,0
FARXIGA,Increases in Low-Density Lipoprotein Cholesterol,Warnings and Precautions Bladder Cancer see Warnings and,0
FARXIGA,Bladder Cancer,Bladder Cancer see Warnings,1
FARXIGA,Bladder Cancer,Warnings and Bladder,1
FARXIGA,female genital mycotic infections,report SUSPECTED,0
FARXIGA,female genital mycotic infections,mycotic infections nasopharyngitis and,1
FARXIGA,female genital mycotic infections,greater incidence female genital mycotic infections nasopharyngitis and,1
FARXIGA,female genital mycotic infections,incidence female genital,1
FARXIGA,female genital mycotic infections,FARXIGA or greater incidence female genital,1
FARXIGA,female genital mycotic infections,,0
FARXIGA,female genital mycotic infections,female genital mycotic infections nasopharyngitis and,1
FARXIGA,female genital mycotic infections,To,0
FARXIGA,female genital mycotic infections,greater incidence female,1
FARXIGA,urinary tract infections,genital mycotic infections nasopharyngitis urinary tract infections EXCERPT To,1
FARXIGA,urinary tract infections,urinary tract infections EXCERPT To,1
FARXIGA,urinary tract infections,,0
FARXIGA,urinary tract infections,,0
FARXIGA,urinary tract infections,nasopharyngitis urinary tract infections EXCERPT To,1
FARXIGA,urinary tract infections,nasopharyngitis,0
FARXIGA,urinary tract infections,nasopharyngitis urinary,1
FARXIGA,urinary tract infections,tract infections EXCERPT To,1
FARXIGA,urinary tract infections,tract infections EXCERPT To,1
FARXIGA,vulvovaginal mycotic infection,reported for vulvovaginal mycotic infection vaginal infection,1
FARXIGA,vulvovaginal mycotic infection,candidiasi,0
FARXIGA,vulvovaginal mycotic infection,adverse reactions listed in order of frequency reported for,0
FARXIGA,vulvovaginal mycotic infection,vaginal infection vulvovaginal candidiasis vulvovaginitis genital infection genital candidiasi,0
FARXIGA,vulvovaginal mycotic infection,candidiasi,0
FARXIGA,vulvovaginal mycotic infection,reported for vulvovaginal mycotic infection vaginal infection,1
FARXIGA,vulvovaginal mycotic infection,listed in,0
FARXIGA,vaginal infection,vulvovaginal candidiasis vulvovaginitis genital,0
FARXIGA,vaginal infection,candidiasis vulvovaginitis genital infection genital candidiasis,0
FARXIGA,vaginal infection,,0
FARXIGA,vaginal infection,infection vulvovaginal candidiasis,1
FARXIGA,vulvovaginal candidiasis,vulvovaginitis genital,0
FARXIGA,vulvovaginitis,vulvovaginitis genital infection,1
FARXIGA,genital infection,infection genital candidiasis,1
FARXIGA,genital infection,vulvovaginal candidiasis vulvovaginitis,0
FARXIGA,genital infection,genital infection vulvitis genitourinary tract,0
FARXIGA,genital infection,genital infection genital candidiasis,1
FARXIGA,genital infection,vaginal infection,0
FARXIGA,genital infection,,0
FARXIGA,genital infection,fungal genital infection vulvitis genitourinary tract,0
FARXIGA,genital infection,vulvovaginal,0
FARXIGA,genital infection,candidiasis genital,1
FARXIGA,genital candidiasis,candidiasis vulvovaginitis,0
FARXIGA,genital candidiasis,candidiasis fungal genital,1
FARXIGA,genital candidiasis,candidiasis fungal genital,1
FARXIGA,genital candidiasis,candidiasis fungal genital,1
FARXIGA,genital candidiasis,genital genital candidiasis fungal genital,1
FARXIGA,genital candidiasis,genital candidiasis fungal genital,1
FARXIGA,genital candidiasis,,0
FARXIGA,genital candidiasis,genital candidiasis fungal genital,1
FARXIGA,genital candidiasis,vulvovaginitis genital genital,1
FARXIGA,fungal genital infection,candidiasis,0
FARXIGA,fungal genital infection,infection genital candidiasis,0
FARXIGA,fungal genital infection,infection vulval abscess and,0
FARXIGA,fungal genital infection,infection vulvitis genitourinary,1
FARXIGA,vulvitis,fungal genital vulvitis genitourinary tract,1
FARXIGA,genitourinary tract infection,genital infection genital candidiasis fungal genital,0
FARXIGA,genitourinary tract infection,females Placebo FARXIGA mg FARXIGA,0
FARXIGA,genitourinary tract infection,,0
FARXIGA,genitourinary tract infection,infection genitourinary tract infection vulval abscess,1
FARXIGA,genitourinary tract infection,,0
FARXIGA,genitourinary tract infection,genitourinary tract infection vulval abscess,1
FARXIGA,genitourinary tract infection,bacterial N for,0
FARXIGA,genitourinary tract infection,,0
FARXIGA,genitourinary tract infection,fungal genital infection genitourinary tract,1
FARXIGA,vulval abscess,candidiasis fungal genital infection,0
FARXIGA,vaginitis bacterial,fungal,0
FARXIGA,vaginitis bacterial,vulval abscess vaginitis bacterial N for,1
FARXIGA,vaginitis bacterial,genital infection vulvitis genitourinary,0
FARXIGA,vaginitis bacterial,abscess,0
FARXIGA,vaginitis bacterial,vulval abscess vaginitis bacterial N for,1
FARXIGA,cystitis,in order of,0
FARXIGA,cystitis,urinary tract cystitis Escherichia urinary,1
FARXIGA,cystitis,cystitis Escherichia urinary,1
FARXIGA,cystitis,cystitis Escherichia urinary,1
FARXIGA,cystitis,infection pyelonephritis,0
FARXIGA,cystitis,cystitis Escherichia urinary,1
FARXIGA,cystitis,cystitis Escherichia urinary,1
FARXIGA,Escherichia urinary tract infection,,0
FARXIGA,Escherichia urinary tract infection,reported urinary tract infection Escherichia urinary tract infection genitourinary tract,1
FARXIGA,Escherichia urinary tract infection,,0
FARXIGA,Escherichia urinary tract infection,Escherichia urinary tract,1
FARXIGA,genitourinary tract infection,and,0
FARXIGA,genitourinary tract infection,kidney,0
FARXIGA,pyelonephritis,,0
FARXIGA,pyelonephritis,prostatitis,0
FARXIGA,pyelonephritis,trigonitis urethritis,0
FARXIGA,pyelonephritis,pyelonephritis trigonitis urethritis,1
FARXIGA,pyelonephritis,pyelonephritis trigonitis urethritis,1
FARXIGA,pyelonephritis,,0
FARXIGA,pyelonephritis,tract pyelonephritis trigonitis urethritis,1
FARXIGA,pyelonephritis,and prostatitis,0
FARXIGA,pyelonephritis,pyelonephritis trigonitis urethritis,1
FARXIGA,pyelonephritis,,0
FARXIGA,trigonitis,,0
FARXIGA,trigonitis,,0
FARXIGA,trigonitis,kidney infection,0
FARXIGA,trigonitis,infection and prostatitis,0
FARXIGA,trigonitis,genitourinary tract,0
FARXIGA,urethritis,urethritis kidney infection,1
FARXIGA,urethritis,kidney infection and prostatitis,0
FARXIGA,urethritis,tract infection pyelonephritis,0
FARXIGA,urethritis,urethritis kidney infection,1
FARXIGA,urethritis,urethritis kidney infection,1
FARXIGA,urethritis,,0
FARXIGA,urethritis,,0
FARXIGA,urethritis,urethritis kidney infection,1
FARXIGA,kidney infection,,0
FARXIGA,kidney infection,and prostatitis,0
FARXIGA,kidney infection,tract infection pyelonephritis trigonitis kidney infection and prostatitis,1
FARXIGA,kidney infection,tract infection genitourinary tract infection pyelonephritis,0
FARXIGA,kidney infection,kidney infection and prostatitis,1
FARXIGA,kidney infection,,0
FARXIGA,kidney infection,prostatitis,0
FARXIGA,prostatitis,,0
FARXIGA,Back pain,,0
FARXIGA,Back pain,Back pain,1
FARXIGA,Back pain,and,0
FARXIGA,Back pain,y infection and Back,1
FARXIGA,Back pain,and prostatitis,0
FARXIGA,Back pain,infection and,0
FARXIGA,Back pain,,0
FARXIGA,Back pain,y infection and Back pain,1
FARXIGA,Back pain,infection and prostatitis,0
FARXIGA,Increased urination,,0
FARXIGA,pollakiuria,listed in order of frequency,0
FARXIGA,polyuria,polyuria and urine,1
FARXIGA,polyuria,adverse reactions,0
FARXIGA,polyuria,listed in order of frequency reported,0
FARXIGA,polyuria,in order of frequency reported,0
FARXIGA,polyuria,polyuria and urine,1
FARXIGA,polyuria,,0
FARXIGA,urine output increased,urine output increased Male genital,1
FARXIGA,urine output increased,,0
FARXIGA,urine output increased,,0
FARXIGA,urine output increased,,0
FARXIGA,urine output increased,polyuria urine output increased Male genital,1
FARXIGA,balanitis,,0
FARXIGA,balanitis,following adverse,0
FARXIGA,balanitis,male,0
FARXIGA,balanitis,balanitis fungal genital,1
FARXIGA,balanitis,balanitis fungal genital,1
FARXIGA,balanitis,balanitis fungal genital,1
FARXIGA,balanitis,of frequency reported for balanitis fungal genital,1
FARXIGA,balanitis,fungal genital infection,0
FARXIGA,fungal genital infection,infection balanitis candida,1
FARXIGA,fungal genital infection,for males balanitis,0
FARXIGA,fungal genital infection,candida genital,0
FARXIGA,fungal genital infection,frequency reported for,0
FARXIGA,fungal genital infection,males fungal genital,1
FARXIGA,fungal genital infection,adverse reactions listed in order of frequency reported for males,0
FARXIGA,fungal genital infection,,0
FARXIGA,fungal genital infection,following adverse reactions listed in order,0
FARXIGA,balanitis candida,fungal genital,0
FARXIGA,balanitis candida,penile infection balanoposthitis balanoposthitis in,0
FARXIGA,balanitis candida,balanitis candida genital candidiasis,1
FARXIGA,genital candidiasis,males balanitis,0
FARXIGA,genital candidiasis,order of frequency reported,0
FARXIGA,genital candidiasis,candidiasis genital infection,1
FARXIGA,genital candidiasis,in,0
FARXIGA,genital candidiasis,genital infection balanitis genital candidiasis genital infection,1
FARXIGA,genital candidiasis,infection balanitis genital,1
FARXIGA,genital candidiasis,infection male penile infection balanoposthitis balanoposthitis infective,0
FARXIGA,genital candidiasis,balanitis genital,1
FARXIGA,genital candidiasis,candida,0
FARXIGA,genital infection male,infection male penile infection,1
FARXIGA,genital infection male,for,0
FARXIGA,genital infection male,candidiasis,0
FARXIGA,genital infection male,balanitis candida genital genital infection male penile infection,1
FARXIGA,genital infection male,,0
FARXIGA,genital infection male,,0
FARXIGA,genital infection male,,0
FARXIGA,genital infection male,infection balanoposthitis,0
FARXIGA,penile infection,genital infection,0
FARXIGA,penile infection,balanoposthitis balanoposthitis infective genital,0
FARXIGA,penile infection,genital infection balanitis candida genital candidiasis genital,0
FARXIGA,penile infection,candidiasis genital,0
FARXIGA,penile infection,,0
FARXIGA,penile infection,Placebo,0
FARXIGA,penile infection,fungal genital infection balanitis candida genital candidiasis genital infection male,0
FARXIGA,penile infection,candidiasis genital infection penile infection balanoposthitis balanoposthitis,1
FARXIGA,penile infection,Placebo,0
FARXIGA,penile infection,infection penile,1
FARXIGA,balanoposthitis,penile balanoposthitis balanoposthitis infective,1
FARXIGA,balanoposthitis,genital infection,0
FARXIGA,balanoposthitis,,0
FARXIGA,balanoposthitis,penile balanoposthitis balanoposthitis infective,1
FARXIGA,balanoposthitis,balanoposthitis balanoposthitis infective,1
FARXIGA,balanoposthitis,genital infection male penile,0
FARXIGA,balanoposthitis,balanoposthitis balanoposthitis infective,1
FARXIGA,balanoposthitis infective,Placebo FARXIGA,0
FARXIGA,balanoposthitis infective,infection balanoposthitis,1
FARXIGA,balanoposthitis infective,male,0
FARXIGA,balanoposthitis infective,infective genital infection,1
FARXIGA,balanoposthitis infective,posthitis N for males Placebo FARXIGA mg FARXIGA,0
FARXIGA,balanoposthitis infective,genital infection male penile infection,0
FARXIGA,balanoposthitis infective,infective genital infection,1
FARXIGA,balanoposthitis infective,infection male penile infection balanoposthitis infective genital infection,1
FARXIGA,balanoposthitis infective,infection male,0
FARXIGA,genital infection,,0
FARXIGA,genital infection,Placebo FARXIGA mg FARXIGA mg,0
FARXIGA,genital infection,genital,1
FARXIGA,genital infection,Placebo FARXIGA mg FARXIGA mg,0
FARXIGA,genital infection,,0
FARXIGA,genital infection,infection male penile infection balanoposthitis,0
FARXIGA,genital infection,balanoposthitis balanoposthitis genital,1
FARXIGA,genital infection,penile infection balanoposthitis balanoposthitis genital infection posthitis N,1
FARXIGA,genital infection,infection,0
FARXIGA,posthitis,FARXIGA mg FARXIGA,0
FARXIGA,posthitis,posthitis N for,1
FARXIGA,posthitis,penile infection balanoposthitis,0
FARXIGA,posthitis,mg,0
FARXIGA,posthitis,Placebo FARXIGA,0
FARXIGA,posthitis,FARXIGA mg FARXIGA mg,0
FARXIGA,posthitis,infection,0
FARXIGA,posthitis,posthitis N for,1
FARXIGA,posthitis,posthitis N for,1
FARXIGA,posthitis,genital,0
FARXIGA,Nausea,,0
FARXIGA,Nausea,,0
FARXIGA,Influenza,,0
FARXIGA,Influenza,,0
FARXIGA,Influenza,Influenza,1
FARXIGA,Influenza,Influenza,1
FARXIGA,Influenza,Influenza,1
FARXIGA,Influenza,,0
FARXIGA,Dyslipidemia,,0
FARXIGA,Dyslipidemia,Dyslipidemia C,1
FARXIGA,Dyslipidemia,,0
FARXIGA,Dyslipidemia,Dyslipidemia C,1
FARXIGA,Dyslipidemia,Dyslipidemia C,1
FARXIGA,Constipation,a Constipation D,1
FARXIGA,Constipation,Constipation D,1
FARXIGA,Constipation,Constipation D,1
FARXIGA,Constipation,,0
FARXIGA,Constipation,a,0
FARXIGA,Discomfort with urination,n,0
FARXIGA,Pain in extremity,,0
FARXIGA,Pain in extremity,,0
FARXIGA,Pain in extremity,,0
FARXIGA,osmotic diuresis,mLmin m Volume Depletion FARXIGA causes an,0
FARXIGA,osmotic diuresis,diuresis,1
FARXIGA,osmotic diuresis,causes an,0
FARXIGA,osmotic diuresis,FARXIGA causes osmotic,1
FARXIGA,osmotic diuresis,an,0
FARXIGA,osmotic diuresis,which may lead to reductions,0
FARXIGA,reductions in intravascular volume,reductions in intravascular volume,1
FARXIGA,reductions in intravascular volume,volume depletion including reports of dehydration hypovolemia,0
FARXIGA,reductions in intravascular volume,which may,0
FARXIGA,reductions in intravascular volume,may lead reductions in,1
FARXIGA,reductions in intravascular volume,,0
FARXIGA,reductions in intravascular volume,,0
FARXIGA,reductions in intravascular volume,may lead reductions in,1
FARXIGA,reductions in intravascular volume,intravascular volume,1
FARXIGA,reductions in intravascular volume,which may lead,0
FARXIGA,reductions in intravascular volume,depletion including reports of,0
FARXIGA,volume depletion,related volume,1
FARXIGA,volume depletion,volume,1
FARXIGA,volume depletion,volume,1
FARXIGA,volume depletion,hypotension,0
FARXIGA,volume depletion,volume Adverse reactions related volume,1
FARXIGA,dehydration,,0
FARXIGA,hypovolemia,hypotension are shown in Table for the study and study,0
FARXIGA,hypovolemia,hypovolemia,1
FARXIGA,hypovolemia,of hypovolemia,1
FARXIGA,hypovolemia,reports of hypovolemia,1
FARXIGA,hypovolemia,hypotension are shown in Table for the study and study,0
FARXIGA,hypovolemia,depletion including reports,0
FARXIGA,hypovolemia,depletion including,0
FARXIGA,hypovolemia,hypovolemia,1
FARXIGA,hypovolemia,of dehydration,0
FARXIGA,hypovolemia,reports of hypovolemia,1
FARXIGA,Volume depletion,depletion,1
FARXIGA,Volume depletion,see Warnings and Precautions,0
FARXIGA,Volume depletion,Volume Volume,1
FARXIGA,Volume depletion,Adverse Reactions of Volume Volume depletion,1
FARXIGA,Volume depletion,Reactions of Volume,0
FARXIGA,Volume depletion,depletion,1
FARXIGA,Volume depletion,Table Adverse Reactions of Volume,0
FARXIGA,dehydration,,0
FARXIGA,dehydration,depletion includes reports dehydration,1
FARXIGA,dehydration,Volume DepletionVolume depletion includes reports,0
FARXIGA,dehydration,Studies with,0
FARXIGA,dehydration,dehydration,1
FARXIGA,dehydration,dehydration,1
FARXIGA,dehydration,,0
FARXIGA,dehydration,dehydration,1
FARXIGA,dehydration,hypotension,0
FARXIGA,hypovolemia,hypotension in Clinical Studies with,0
FARXIGA,hypovolemia,of hypovolemia,1
FARXIGA,hypovolemia,hypovolemia,1
FARXIGA,hypovolemia,hypotension in Clinical Studies,0
FARXIGA,hypovolemia,hypovolemia,1
FARXIGA,hypovolemia,Reactions of Volume,0
FARXIGA,hypovolemia,Studies with,0
FARXIGA,hypovolemia,of hypovolemia,1
FARXIGA,orthostatic hypotension,includes reports of,0
FARXIGA,orthostatic hypotension,Volume DepletionVolume depletion includes reports,0
FARXIGA,orthostatic hypotension,includes reports of dehydration orthostatic,1
FARXIGA,hypotension,depletion includes reports of dehydration hypovolemia orthostatic hypotension,0
FARXIGA,hypotension,hypotension,1
FARXIGA,hypotension,hypotension,0
FARXIGA,hypotension,orthostatic hypotension hypotension,1
FARXIGA,hypotension,Studies,0
FARXIGA,increases in serum creatinine,FARXIGA was associated increases in serum creatinine,1
FARXIGA,increases in serum creatinine,was associated increases in serum creatinine,1
FARXIGA,decreases in eGFR,in serum creatinine decreases in eGFR,1
FARXIGA,decreases in eGFR,in serum creatinine decreases in,1
FARXIGA,decreases in eGFR,see Table In patients with normal or mildly impaired renal function at baseline,0
FARXIGA,decreases in eGFR,,0
FARXIGA,decreases in eGFR,increases in serum creatinine decreases in eGFR,1
FARXIGA,decreases in eGFR,patients with normal or,0
FARXIGA,decreases in eGFR,renal function at baseline serum creatin,0
FARXIGA,decreases in eGFR,,0
FARXIGA,Renal-related adverse reactions,Renal-related adverse reactions,1
FARXIGA,Renal-related adverse reactions,eGFR returned to,0
FARXIGA,Renal-related adverse reactions,frequent in,0
FARXIGA,Renal-related adverse reactions,including renal failure and blood creatinine increase were more frequent in,0
FARXIGA,Renal-related adverse reactions,Renal-related,1
FARXIGA,Renal-related adverse reactions,values at Renal-related adverse,1
FARXIGA,Renal-related adverse reactions,,0
FARXIGA,Renal-related adverse reactions,blood creatinine increase were more frequent in patients treated,0
FARXIGA,renal failure,with FARXIGA see Table,0
FARXIGA,renal failure,failure,1
FARXIGA,renal failure,frequent in patients treated with FARXIGA see,0
FARXIGA,blood creatinine increase,failure blood creatinine increase,1
FARXIGA,blood creatinine increase,including renal failure blood creatinine increase,1
FARXIGA,blood creatinine increase,reactions including renal failure and,0
FARXIGA,blood creatinine increase,patients w,0
FARXIGA,blood creatinine increase,including renal failure blood creatinine increase,1
FARXIGA,blood creatinine increase,including renal failure blood creatinine increase,1
FARXIGA,blood creatinine increase,patients treated with FARXIGA see,0
FARXIGA,blood creatinine increase,Elderly patients and,0
FARXIGA,blood creatinine increase,values at Week Renalrelated adverse,0
FARXIGA,blood creatinine increase,including renal failure blood creatinine increase,1
FARXIGA,Renal Impairment-Related Adverse Reaction,Reaction,1
FARXIGA,Renal Impairment-Related Adverse Reaction,Patients with at Least Renal Impairment-Related Adverse Reaction,1
FARXIGA,fractures,was no apparent pattern with respect to the,0
FARXIGA,fractures,,0
FARXIGA,fractures,fractures,1
FARXIGA,fractures,the first,0
FARXIGA,fractures,There was no,0
FARXIGA,fractures,who had a baseline eGFR of to mLmin m,0
FARXIGA,fractures,weeks There was no apparent pattern with respect,0
FARXIGA,fractures,to the,0
FARXIGA,fracture,of,0
FARXIGA,fracture,fracture,1
FARXIGA,fracture,respect,0
FARXIGA,fracture,fracture,1
FARXIGA,fracture,anatomic,0
FARXIGA,fracture,to the anatomic site fracture,1
FARXIGA,fracture,study see Clinical,0
FARXIGA,fracture,site of,0
FARXIGA,fracture,fracture,1
FARXIGA,fracture,the anatomic site,0
FARXIGA,hypoglycemia,hypoglycemia,1
FARXIGA,hypoglycemia,Table Hypoglycemia was more frequent,0
FARXIGA,hypoglycemia,in Table Hypoglycemia was more,0
FARXIGA,Hypoglycemia,Studies is shown in Hypoglycemia,1
FARXIGA,Hypoglycemia,Hypoglycemia,1
FARXIGA,Hypoglycemia,Hypoglycemia,1
FARXIGA,Hypoglycemia,Hypoglycemia,1
FARXIGA,hypoglycemia,MajorMajor episodes,0
FARXIGA,hypoglycemia,hypoglycemia,1
FARXIGA,hypoglycemia,party assistance due to severe impa,0
FARXIGA,hypoglycemia,third party assistance due to severe,0
FARXIGA,impairment in consciousness,party assistance due to severe,0
FARXIGA,impairment in consciousness,consciousness,1
FARXIGA,impairment in consciousness,or behavior with a capillary or plasma glucose value,0
FARXIGA,impairment in consciousness,,0
FARXIGA,impairment in consciousness,third,0
FARXIGA,impairment in consciousness,party assistance due to impairment in consciousness,1
FARXIGA,impairment in consciousness,external third party assistance due to severe,0
FARXIGA,impairment in consciousness,defined as symptomatic episodes requiring external third,0
FARXIGA,impairment in consciousness,,0
FARXIGA,impairment in consciousness,glucose value mgdL and prompt recovery after glucose,0
FARXIGA,plasma glucose value <54 mg/dL,or,0
FARXIGA,plasma glucose value <54 mg/dL,severe impairment in consciousness or,0
FARXIGA,plasma glucose value <54 mg/dL,glucose or glucagon administration,0
FARXIGA,plasma glucose value <54 mg/dL,and MinorMinor episodes of,0
FARXIGA,plasma glucose value <54 mg/dL,recovery after glucose or glucagon administration and,0
FARXIGA,hypoglycemia,hypoglycemia,1
FARXIGA,plasma glucose measurement <63 mg/dL,either a symptomatic episode with,0
FARXIGA,plasma glucose measurement <63 mg/dL,plasma,0
FARXIGA,plasma glucose measurement <63 mg/dL,in Controlled,0
FARXIGA,plasma glucose measurement <63 mg/dL,Controlled Clinical,0
FARXIGA,plasma glucose measurement <63 mg/dL,plasma glucose,1
FARXIGA,plasma glucose measurement <63 mg/dL,an asymptomatic capillary plasma glucose measurement <63 mg/dL,1
FARXIGA,Hypoglycemia,PlaceboActiv,0
FARXIGA,Hypoglycemia,,0
FARXIGA,Hypoglycemia,a major Hypoglycemia,1
FARXIGA,Hypoglycemia,a major Hypoglycemia,1
FARXIGA,Hypoglycemia,Hypoglycemia,1
FARXIGA,Hypoglycemia,a major,0
FARXIGA,Hypoglycemia,Hypoglycemia,1
FARXIGA,Genital mycotic infections,Mycotic,0
FARXIGA,Genital mycotic infections,,0
FARXIGA,Genital mycotic infections,Genital mycotic infections,1
FARXIGA,Genital mycotic infections,pati,0
FARXIGA,Genital mycotic infections,,0
FARXIGA,Genital mycotic infections,Mycotic Infections,0
FARXIGA,Genital mycotic infections,reported in of patients on placebo,0
FARXIGA,Genital mycotic infections,FARXIGA Genital mycotic infections,1
FARXIGA,Genital mycotic infections,frequent with FARXIGA Genital,1
FARXIGA,Genital mycotic infections,mg,0
FARXIGA,Genital mycotic infections,on placebo on FARXIGA,0
FARXIGA,Genital mycotic infections,infections,1
FARXIGA,Genital mycotic infections,Genital mycotic infections were more frequent with FARXIGA,0
FARXIGA,genital infection,study due,0
FARXIGA,genital infection,due genital,1
FARXIGA,genital infection,study due genital infection,1
FARXIGA,genital infection,infection,1
FARXIGA,genital infection,infection,1
FARXIGA,genital infection,from study due genital infection,1
FARXIGA,Infections,patients treated with FARXIGA mg,0
FARXIGA,Infections,Infections,1
FARXIGA,Infections,Infections,1
FARXIGA,Infections,Infections,1
FARXIGA,Infections,patients,0
FARXIGA,Infections,Infections,1
FARXIGA,Infections,Infections,1
FARXIGA,Infections,Infections,1
FARXIGA,Infections,Infections,1
FARXIGA,genital mycotic infections,in,0
FARXIGA,genital mycotic infections,The most frequently genital mycotic,1
FARXIGA,genital mycotic infections,males see Table The,0
FARXIGA,genital mycotic infections,frequently genital,1
FARXIGA,genital mycotic infections,The most frequently genital mycotic infections,1
FARXIGA,genital mycotic infections,frequently reported in females,0
FARXIGA,genital mycotic infections,genital mycotic infections,1
FARXIGA,genital mycotic infections,most frequently genital,1
FARXIGA,vulvovaginal mycotic infections,infections vulvovaginal mycotic infections,1
FARXIGA,vulvovaginal mycotic infections,mycotic infections,1
FARXIGA,vulvovaginal mycotic infections,genital mycotic infections vulvovaginal,1
FARXIGA,vulvovaginal mycotic infections,mycotic infections vulvovaginal mycotic infections,1
FARXIGA,vulvovaginal mycotic infections,reported genital mycotic infections vulvovaginal mycotic,1
FARXIGA,vulvovaginal mycotic infections,genital mycotic infections vulvovaginal,1
FARXIGA,balanitis,balanitis,1
FARXIGA,balanitis,balanitis,1
FARXIGA,balanitis,,0
FARXIGA,balanitis,more likely to,0
FARXIGA,balanitis,infections were vulvovaginal mycotic infections in females and,0
FARXIGA,balanitis,balanitis,1
FARXIGA,genital mycotic infection,prior,0
FARXIGA,genital mycotic infection,in males Patients with a history of genital mycotic infections were more,0
FARXIGA,genital mycotic infection,likely to have genital mycotic infection,1
FARXIGA,genital mycotic infection,mycotic infection,1
FARXIGA,genital mycotic infection,more likely to have a,0
FARXIGA,genital mycotic infection,more likely to have genital mycotic infection,1
FARXIGA,genital mycotic infection,genital mycotic infection,1
FARXIGA,genital mycotic infection,have genital mycotic infection,1
FARXIGA,genital mycotic infection,a history of genital mycotic,0
FARXIGA,Hypersensitivity reactions,,0
FARXIGA,angioedema,angioedema,1
FARXIGA,urticaria,hypersensitivity were reported with FARXIGA treatment Across the clinical program serious,0
FARXIGA,urticaria,urticaria,1
FARXIGA,urticaria,reported with FARXIGA treatment Across the clinical program,0
FARXIGA,urticaria,urticaria,1
FARXIGA,urticaria,Hypersensitivity,0
FARXIGA,urticaria,Hypersensitivity reactions eg urticaria,1
FARXIGA,urticaria,,0
FARXIGA,hypersensitivity,hypersensitivity,1
FARXIGA,hypersensitivity,Hypersensitivity reactions,0
FARXIGA,hypersensitivity,hypersensitivity,1
FARXIGA,hypersensitivity,Hypersensitivity reactions,0
FARXIGA,hypersensitivity,hypersensitivity,1
FARXIGA,hypersensitivity,hypersensitivity,1
FARXIGA,anaphylactic reactions,comparatortreated,0
FARXIGA,anaphylactic reactions,,0
FARXIGA,anaphylactic reactions,anaphylactic,1
FARXIGA,anaphylactic reactions,anaphylactic reactions,1
FARXIGA,cutaneous adverse reactions,,0
FARXIGA,cutaneous adverse reactions,,0
FARXIGA,hematocrit values >55%,group By hematocrit values >55%,1
FARXIGA,hematocrit values >55%,hematocrit values >55%,1
FARXIGA,hyperphosphatemia,of patients with marked laboratory abnormalities,0
FARXIGA,hyperphosphatemia,with marked laboratory abnormalities hyperphosphatemia,1
FARXIGA,hyperphosphatemia,years or mgdL for age,0
FARXIGA,hyperphosphatemia,mgdL for age years or mgdL,0
FARXIGA,Hypotension,rse,1
FARXIGA,Hypotension,rse reactio ns are,1
FARXIGA,Hypotension,,0
FARXIGA,Hypotension,are described below and elsewhere,0
FARXIGA,Hypotension,rse,1
FARXIGA,Hypotension,,0
FARXIGA,Hypotension,,0
FARXIGA,Hypotension,,0
FARXIGA,Hypotension,rse,1
FARXIGA,Hypotension,reactio ns are described below,1
FARXIGA,Impairment in renal function,with Concomitant Use with Insulin and Insulin,0
FARXIGA,Impairment in renal function,,0
FARXIGA,Hypoglycemia,Genital Mycotic ons [see,1
FARXIGA,Hypoglycemia,and Precautions Genital Mycotic ons,1
FARXIGA,Hypoglycemia,Mycotic ons [see  Wa rnings and Precautions Increases,1
FARXIGA,Hypoglycemia,,0
FARXIGA,Hypoglycemia,Genital Mycotic ons [see  Wa rnings and Precautions Increases,1
FARXIGA,Hypoglycemia,and Precautions Genital Mycotic ons,1
FARXIGA,Hypoglycemia,Insulin Secretagogues see Warnings and Precautions Genital,0
FARXIGA,Hypoglycemia,Warnings and Precautions Genital Mycotic,0
FARXIGA,Hypoglycemia,Genital Mycotic ons [see  Wa rnings and Precautions Increases,1
FARXIGA,Hypoglycemia,Mycotic ons,1
FARXIGA,Genital mycotic infections,The most,0
FARXIGA,Genital mycotic infections,Warnings and Precautions Bladder Cancer see Warnings and,0
FARXIGA,Genital mycotic infections,"Warnings and utions (5.6)  ]  
   *     The most common adverse",1
FARXIGA,Genital mycotic infections,most,0
FARXIGA,Genital mycotic infections,FARXIGA or greater incidence were female geni,0
FARXIGA,Genital mycotic infections,"Warnings and utions (5.6)  ]  
   *     The most common adverse",1
FARXIGA,Genital mycotic infections,Precautions,0
FARXIGA,Increased LDL-C,adverse reactions associated with ARXIGA (5%,1
FARXIGA,Increased LDL-C,reactions associated with,0
FARXIGA,Increased LDL-C,mycotic infections nasopharyngitis and urinary,0
FARXIGA,Increased LDL-C,associated with ARXIGA (5% or g reater incidence were female,1
FARXIGA,Increased LDL-C,and,0
FARXIGA,Increased LDL-C,(5% or g reater incidence were female,1
FARXIGA,Increased LDL-C,ARXIGA (5% or g reater incidence were female,1
FARXIGA,Increased LDL-C,,0
FARXIGA,Increased LDL-C,incidence were female genital mycotic infections nasopharyngitis and urinary tract infecti,0
FARXIGA,Bladder Cancer,mycotic,0
FARXIGA,Bladder Cancer,genital mycotic infections asopharyngitis and urinary tract infections,1
FARXIGA,Bladder Cancer,genital mycotic infections asopharyngitis and urinary tract infections,1
FARXIGA,Bladder Cancer,genital mycotic infections asopharyngitis and urinary tract infections,1
FARXIGA,Bladder Cancer,asopharyngitis and urinary tract infections,1
FARXIGA,Bladder Cancer,with FARXIGA,0
FARXIGA,bladder cancers,nasopharyngitis and,0
FARXIGA,bladder cancers,trac,0
FARXIGA,bladder cancers,and urinary t,1
FARXIGA,bladder cancers,genital mycotic infections,0
FARXIGA,bladder cancers,greater incidence were female genital mycotic infections nasopharyngitis and urinary,0
FARXIGA,bladder cancers,SUSPECTED ADVERSE REACTIONS,0
FARXIGA,bladder cancers,report SUSPECTED ADVERSE REACTIONS,0
FARXIGA,intravascular volume contraction,,0
FARXIGA,intravascular volume contraction,eflect the rates observed in cli nical practice Pool of,1
FARXIGA,intravascular volume contraction,nical practice Pool of PlaceboControlled Studies for FARXIGA and mg The,0
FARXIGA,Symptomatic hypotension,practice. P ool of PlaceboControlled Studies,1
FARXIGA,Symptomatic hypotension,,0
FARXIGA,Symptomatic hypotension,PlaceboControlled Studies for FARXIGA and mg The,0
FARXIGA,increases serum creatinine,daily The mean age of the,0
FARXIGA,increases serum creatinine,age,0
FARXIGA,increases serum creatinine,of weeks tients received placebo (N FARXIGA mg N or,1
FARXIGA,increases serum creatinine,mean,0
FARXIGA,increases serum creatinine,daily The,0
FARXIGA,increases serum creatinine,patients to FARXIGA with a mean exposure duration,0
FARXIGA,increases serum creatinine,duration of weeks tients received placebo,1
FARXIGA,decreases eGFR,,0
FARXIGA,decreases eGFR,of,0
FARXIGA,decreases eGFR,"placebo ), FARXIGA 5 m g N or FARXIGA",1
FARXIGA,decreases eGFR,m g N or FARXIGA,1
FARXIGA,decreases eGFR,,0
FARXIGA,decreases eGFR,exposure duration of weeks Patients received placebo N,0
FARXIGA,decreases eGFR,"), FARXIGA 5 m g N or FARXIGA",1
FARXIGA,decreases eGFR,mean age of the,0
FARXIGA,decreases eGFR,FARXIGA 5 m g N or FARXIGA,1
FARXIGA,hypoglycemia,in of,0
FARXIGA,hypoglycemia,and ately impair ed in of patients,1
FARXIGA,hypoglycemia,normal or mildly impaired in of patients and,0
FARXIGA,hypoglycemia,in of patients and ately,1
FARXIGA,hypoglycemia,and ately,1
FARXIGA,hypoglycemia,ately,1
FARXIGA,hypoglycemia,patients and ately impair ed in of patients,1
FARXIGA,genital mycotic infections,Table,1
FARXIGA,genital mycotic infections,or FARXIGA Table 1: Adverse,1
FARXIGA,genital mycotic infections,"mg or FARXIGA 

 Table 1: Adverse Reacti ons in PlaceboControlled Studies",1
FARXIGA,genital mycotic infections,Reaction of Patients Pool of,1
FARXIGA,genital mycotic infections,P,0
FARXIGA,genital mycotic infections,"of Patients Treated with 
   Adverse Reaction       of Patients Pool of",1
FARXIGA,genital mycotic infections,Patients Treated with Adverse,1
FARXIGA,genital mycotic infections,,0
FARXIGA,genital mycotic infections,Treated with FARXIGA,0
FARXIGA,genital mycotic infections,Reported,0
FARXIGA,genital mycotic infections,in PlaceboControlled,0
FARXIGA,genital mycotic infections,,0
FARXIGA,Increases in LDL-C,Pool of PlaceboControlled                    Placebo N FARXIGA mg,1
FARXIGA,Increases in LDL-C,of PlaceboControlled,0
FARXIGA,Increases in LDL-C,of PlaceboControlled Studies,0
FARXIGA,Increases in LDL-C,                   Placebo N FARXIGA mg,1
FARXIGA,Increases in LDL-C,Placebo N FARXIGA,0
FARXIGA,Increases in LDL-C,                   Placebo N FARXIGA mg,1
FARXIGA,Increases in LDL-C,,0
FARXIGA,Increases in LDL-C,                   Placebo N FARXIGA mg,1
FARXIGA,Increases in LDL-C,                   Placebo N FARXIGA mg,1
FARXIGA,bladder cancer,following adverse reactions,0
FARXIGA,bladder cancer,,0
FARXIGA,bladder cancer,reported for females vulvovaginal mycotic infection vaginal infection vulvovaginal candidi,0
FARXIGA,bladder cancer,include the following adverse reactions listed,0
FARXIGA,bladder cancer,females vulvovaginal mycotic infection vaginal infection vulvovaginal candidi,0
FARXIGA,bladder cancer,following,0
FARXIGA,bladder cancer,reactions listed n order of fre quency reported for females,1
FARXIGA,bladder cancer,infection,0
FARXIGA,bladder cancer,following adverse reactions listed n order of fre quency reported for females,1
FARXIGA,bladder cancer,n order of fre quency reported for females,1
FARXIGA,bladder cancer,infection vu,0
FARXIGA,bladder cancer,"lval abscess, and vaginitis bacterial N",1
FARXIGA,bladder cancer,"lval abscess,  and vaginitis bacterial N",1
FARXIGA,bladder cancer,and vaginitis bacterial N for females Placebo FARXIGA,0
FARXIGA,bladder cancer,vulvitis genitourinary tract infection,0
FARXIGA,bladder cancer,"genitourinary tract infection lval abscess,  and vaginitis bacterial N",1
FARXIGA,bladder cancer,genitourinary tract infection vu,0
FARXIGA,bladder cancer,"lval abscess, and vaginitis bacterial N",1
VICTRELIS,fatigue,con,0
VICTRELIS,anemia,dysgeusia To report SUSPECTED ADVERSE REACTIONS,0
VICTRELIS,anemia,anemia nausea headache and dysgeusia,1
VICTRELIS,anemia,dysgeusia To report SUSPECTED ADVERSE REACTIONS contact Mer,0
VICTRELIS,headache,headache and dysgeusia To report,1
VICTRELIS,headache,the combination of VICTRELIS with PegIntron and,0
VICTRELIS,headache,were fatigue anemia headache and dysgeusia To report,1
VICTRELIS,headache,report SUSPECTED ADVERSE REACTIONS contact,0
VICTRELIS,headache,the combination of VICTRELIS with PegIntron and REBETOL were,0
VICTRELIS,dysgeusia,dysgeusia To report SUSPECTED ADVERSE,1
VICTRELIS,dysgeusia,and,0
VICTRELIS,dysgeusia,Corp,0
VICTRELIS,dysgeusia,dysgeusia To report SUSPECTED ADVERSE,1
VICTRELIS,dysgeusia,,0
VICTRELIS,dysgeusia,anemia nausea,0
VICTRELIS,dysgeusia,REACTIONS contact Merck Sharp Dohme,0
VICTRELIS,dysgeusia,ADVERSE REACTIONS contact Merck Sharp Dohme Corp a subsid,0
VICTRELIS,Anemia,Anemia see Warnings and Precautions,1
VICTRELIS,Anemia,and,0
VICTRELIS,Anemia,Anemia see Warnings and Precautions,1
VICTRELIS,Anemia,reactions ADRs,0
VICTRELIS,Anemia,Anemia see Warnings and Precautions,1
VICTRELIS,Neutropenia,Neutropenia see Warnings and Precautions,1
VICTRELIS,Neutropenia,and Precautions Pancytopenia see Warnings and Precautions,0
VICTRELIS,Neutropenia,Precautions Pancytopenia see Warnings and,0
VICTRELIS,Neutropenia,Neutropenia see Warnings and Precautions,1
VICTRELIS,Neutropenia,Neutropenia see Warnings and Precautions,1
VICTRELIS,Neutropenia,Precautions,0
VICTRELIS,Pancytopenia,Hypersensitivity,0
VICTRELIS,Pancytopenia,and Pancytopenia see Warnings and Precautions,1
VICTRELIS,Hypersensitivity,and Hypersensitivity see Contraindications and Warnings,1
VICTRELIS,Hypersensitivity,,0
VICTRELIS,Hypersensitivity,Contraindications and Warnings and Precautions The most commonly,0
VICTRELIS,Hypersensitivity,Pancytopenia see Warnings and Hypersensitivity see Contraindications and Warnings,1
VICTRELIS,Hypersensitivity,and Precautions,0
VICTRELIS,Hypersensitivity,and Hypersensitivity see Contraindications and Warnings,1
VICTRELIS,Hypersensitivity,and Hypersensitivity see Contraindications and Warnings,1
VICTRELIS,Hypersensitivity,The most,0
VICTRELIS,Hypersensitivity,Hypersensitivity see Contraindications and Warnings,1
VICTRELIS,Hypersensitivity,and Precautions Pancytopenia see,0
VICTRELIS,fatigue,fatigue anemia nausea headache and,1
VICTRELIS,fatigue,VICTRELIS was used in combination with PegIntron,0
VICTRELIS,fatigue,assessment in adult subjects fatigue anemia nausea headache and,1
VICTRELIS,fatigue,in adult subjects fatigue anemia nausea headache and,1
VICTRELIS,anemia,anemia nausea headache and dysgeusia,1
VICTRELIS,anemia,anemia nausea headache and dysgeusia,1
VICTRELIS,anemia,regardless of,0
VICTRELIS,anemia,used in combination with PegIntron and REBETOL,0
VICTRELIS,anemia,investigators,0
VICTRELIS,anemia,adult subjects were anemia nausea headache and dysgeusia,1
VICTRELIS,anemia,causality assessment,0
VICTRELIS,anemia,anemia nausea headache and dysgeusia,1
VICTRELIS,nausea,adult subjects were fatigue,0
VICTRELIS,nausea,nausea headache and dysgeusia when,1
VICTRELIS,nausea,nausea headache and dysgeusia when,1
VICTRELIS,nausea,nausea headache and dysgeusia when,1
VICTRELIS,nausea,,0
VICTRELIS,nausea,,0
VICTRELIS,nausea,was used in combination,0
VICTRELIS,nausea,,0
VICTRELIS,nausea,nausea headache and dysgeusia when,1
VICTRELIS,nausea,,0
VICTRELIS,headache,with PegIntron and REBETOL The safety of,0
VICTRELIS,headache,headache and dysgeusia when VICTRELIS,1
VICTRELIS,headache,investigators causality assessment,0
VICTRELIS,headache,in combination with PegIntron and REBETOL The,0
VICTRELIS,headache,headache and dysgeusia when VICTRELIS,1
VICTRELIS,headache,anemia,0
VICTRELIS,headache,headache and dysgeusia when VICTRELIS,1
VICTRELIS,headache,were fatigue anemia,0
VICTRELIS,headache,headache and dysgeusia when VICTRELIS,1
VICTRELIS,anemia,anemia and fatigue were reported,1
VICTRELIS,anemia,were reported as events that led to discontinuation in more than of subjects,0
VICTRELIS,anemia,that led to discontinuation in more than of subjects,0
VICTRELIS,anemia,to discontinuation,0
VICTRELIS,anemia,with PegIntronREBETOL anemia and fatigue were reported,1
VICTRELIS,anemia,anemia and fatigue were reported,1
VICTRELIS,anemia,anemia and fatigue were reported,1
VICTRELIS,anemia,anemia and fatigue were reported,1
VICTRELIS,anemia,anemia and fatigue were reported,1
VICTRELIS,anemia,anemia and fatigue were reported,1
VICTRELIS,fatigue,Only anemia fatigue were reported as events,1
VICTRELIS,fatigue,,0
VICTRELIS,fatigue,fatigue were reported as events,1
VICTRELIS,fatigue,PegIntronREBETOL Only anemia and,0
VICTRELIS,fatigue,fatigue were reported as events,1
VICTRELIS,anemia,anemia which occurred more frequently,1
VICTRELIS,anemia,receiving the combination of,0
VICTRELIS,anemia,combination of VICTRELIS with,0
VICTRELIS,anemia,anemia which occurred more frequently,1
VICTRELIS,Anemia,,0
VICTRELIS,Anemia,,0
VICTRELIS,Anemia,Anemia,1
VICTRELIS,Anemia,,0
VICTRELIS,Anemia,Anemia,1
VICTRELIS,Anemia,Anemia,1
VICTRELIS,Anemia,,0
VICTRELIS,Neutropenia,Neutropenia,1
VICTRELIS,Neutropenia,Neutropenia,1
VICTRELIS,Nausea,,0
VICTRELIS,Nausea,Nausea,1
VICTRELIS,Nausea,Gastrointestinal Nausea,1
VICTRELIS,Dysgeusia,Dysgeusia,1
VICTRELIS,Dysgeusia,,0
VICTRELIS,Dysgeusia,Dysgeusia,1
VICTRELIS,Dysgeusia,Dysgeusia,1
VICTRELIS,Dysgeusia,Dysgeusia,1
VICTRELIS,Dysgeusia,,0
VICTRELIS,Dysgeusia,Dysgeusia,1
VICTRELIS,Dysgeusia,Dysgeusia,1
VICTRELIS,Dysgeusia,Dysgeusia,1
VICTRELIS,Dysgeusia,,0
VICTRELIS,Diarrhea,Diarrhea,1
VICTRELIS,Diarrhea,,0
VICTRELIS,Diarrhea,,0
VICTRELIS,Vomiting,Vomiting,1
VICTRELIS,Dry Mouth,,0
VICTRELIS,Dry Mouth,,0
VICTRELIS,Dry Mouth,,0
VICTRELIS,Dry Mouth,,0
VICTRELIS,Fatigue,Fatigue,1
VICTRELIS,Chills,,0
VICTRELIS,Chills,,0
VICTRELIS,Chills,Chills,1
VICTRELIS,Chills,,0
VICTRELIS,Asthenia,Asthenia,1
VICTRELIS,Asthenia,Asthenia,1
VICTRELIS,Asthenia,,0
VICTRELIS,Asthenia,Asthenia,1
VICTRELIS,Asthenia,,0
VICTRELIS,Asthenia,Asthenia,1
VICTRELIS,Asthenia,Asthenia,1
VICTRELIS,Asthenia,Asthenia,1
VICTRELIS,Arthralgia,,0
VICTRELIS,Arthralgia,Tissue Arthralgia,1
VICTRELIS,Arthralgia,Arthralgia,1
VICTRELIS,Arthralgia,Connective Tissue Arthralgia,1
VICTRELIS,Arthralgia,Arthralgia,1
VICTRELIS,Arthralgia,Arthralgia,1
VICTRELIS,Dizziness,Dizziness,1
VICTRELIS,Dizziness,,0
VICTRELIS,Dizziness,Dizziness,1
VICTRELIS,Dizziness,,0
VICTRELIS,Dizziness,Dizziness,1
VICTRELIS,Insomnia,Insomnia,1
VICTRELIS,Irritability,,0
VICTRELIS,Irritability,,0
VICTRELIS,Dyspnea Exertional,,0
VICTRELIS,Dyspnea Exertional,Respiratory Thoracic and Mediastinal Dyspnea,1
VICTRELIS,Alopecia,Alopecia,1
VICTRELIS,Alopecia,,0
VICTRELIS,Alopecia,,0
VICTRELIS,Alopecia,Tissue,0
VICTRELIS,Alopecia,Tissue,0
VICTRELIS,Alopecia,and Subcutaneous Tissue Alopecia,1
VICTRELIS,Alopecia,Alopecia,1
VICTRELIS,Dry Skin,,0
VICTRELIS,Dry Skin,Dry,1
VICTRELIS,Dry Skin,,0
VICTRELIS,Dry Skin,Dry Skin,1
VICTRELIS,Dry Skin,,0
VICTRELIS,Dry Skin,Dry,1
VICTRELIS,Rash,Rash,1
VICTRELIS,Rash,Rash,1
VICTRELIS,Rash,Rash,1
VICTRELIS,Dysgeusia,Gastrointestinal,0
VICTRELIS,Dysgeusia,Dysgeusia,1
VICTRELIS,Dysgeusia,in,0
VICTRELIS,alteration of taste,only peginterferon,0
VICTRELIS,alteration of taste,taste,1
VICTRELIS,alteration of taste,alteration of taste,1
VICTRELIS,alteration of taste,receiving VICTRELIS in combina,0
VICTRELIS,alteration of taste,alfa,0
VICTRELIS,alteration of taste,ribavirin Gastrointestinal Disorders alteration of,1
VICTRELIS,alteration of taste,ribavirin Gastrointestinal,0
VICTRELIS,nausea,Adverse events such,0
VICTRELIS,nausea,nausea,1
VICTRELIS,vomiting,vomiting,1
VICTRELIS,vomiting,,0
VICTRELIS,vomiting,receiving,0
VICTRELIS,vomiting,vomiting,1
VICTRELIS,vomiting,as dry mouth vomiting,1
VICTRELIS,vomiting,in subjects receiving VICTRELIS in combin,0
VICTRELIS,vomiting,dry mouth vomiting,1
VICTRELIS,diarrhea,,0
VICTRELIS,diarrhea,with pe,0
VICTRELIS,diarrhea,frequency in subjects receiving VICTRELIS in combination with pe,0
VICTRELIS,diarrhea,ribavirin alone Table Adverse events such as dry mouth nausea vomiting,0
VICTRELIS,diarrhea,Table Adverse events such,0
VICTRELIS,diarrhea,dry mouth nausea vomiting,0
VICTRELIS,platelet counts of less than 50 * 10 9 per L,VICTRELIS with PegIntronREBETOL platelet counts of less than 50 * 10 9,1
VICTRELIS,platelet counts of less than 50 * 10 9 per L,,0
VICTRELIS,platelet counts of less than 50 * 10 9 per L,with PegIntronREBETOL platelet counts of less than 50 *,1
VICTRELIS,platelet counts of less than 50 * 10 9 per L,receiving the combination of,0
VICTRELIS,platelet counts of less than 50 * 10 9 per L,platelet counts of less than 50 * 10,1
VICTRELIS,platelet counts of less than 50 * 10 9 per L,with PegIntronREBETOL platelet counts of less than 50 * 10  9  per L,1
VICTRELIS,platelet counts of less than 50 * 10 9 per L,PegIntronREBETOL platelet counts of less than 50 * 10  9  per L,1
VICTRELIS,platelet counts of less than 50 * 10 9 per L,,0
VICTRELIS,platelet counts of less than 50 * 10 9 per L,subjects receiving the combination of VICTRELIS with PegIntronREBETOL,0
VICTRELIS,platelet counts of less than 50 * 10 9 per L,with PegIntronREBETOL platelet counts of less than 50 * 10  9  per L,1
VICTRELIS,Hemoglobin (g/dL) <10,,0
VICTRELIS,Neutrophils (* 10 9 /L) <0.75,Neutrophils (* 10,1
VICTRELIS,Neutrophils (* 10 9 /L) <0.75,,0
VICTRELIS,Platelets (* 10 9 /L) <50,,0
VICTRELIS,Platelets (* 10 9 /L) <50,,0
VICTRELIS,Platelets (* 10 9 /L) <50,,0
VICTRELIS,Platelets (* 10 9 /L) <50,9 /L) <50,1
VICTRELIS,Platelets (* 10 9 /L) <50,"Platelets (* 10  9  /L)     
 <50",1
VICTRELIS,Platelets (* 10 9 /L) <50,,0
VICTRELIS,Platelets (* 10 9 /L) <50,,0
VICTRELIS,Platelets (* 10 9 /L) <50,"Platelets (* 10  9  /L)     
 <50",1
VICTRELIS,Platelets (* 10 9 /L) <50,,0
VICTRELIS,Platelets (* 10 9 /L) <50,9 /L) <50,1
VICTRELIS,agranulocytosis,,0
VICTRELIS,agranulocytosis,see,0
VICTRELIS,agranulocytosis,agranulocytosis,1
VICTRELIS,agranulocytosis,agranulocytosis,1
VICTRELIS,agranulocytosis,agranulocytosis,1
VICTRELIS,agranulocytosis,Warnings,0
VICTRELIS,agranulocytosis,System agranulocytosis,1
VICTRELIS,agranulocytosis,or establish a causal relationship to,0
VICTRELIS,pancytopenia,,0
VICTRELIS,pancytopenia,relationship to drug exposure Blood,0
VICTRELIS,pancytopenia,,0
VICTRELIS,pancytopenia,pancytopenia,1
VICTRELIS,pancytopenia,Lymphatic System Disorders pancytopenia,1
VICTRELIS,pancytopenia,Blood and Lymphatic System Disorders,0
VICTRELIS,pancytopenia,thrombocytopenia see,0
VICTRELIS,pancytopenia,pancytopenia,1
VICTRELIS,thrombocytopenia,thrombocytopenia,1
VICTRELIS,thrombocytopenia,,0
VICTRELIS,thrombocytopenia,thrombocytopenia,1
VICTRELIS,thrombocytopenia,mouth ulceration,0
VICTRELIS,thrombocytopenia,thrombocytopenia,1
VICTRELIS,mouth ulceration,Gastrointestinal mouth ulceration,1
VICTRELIS,stomatitis,stomatitis,1
VICTRELIS,stomatitis,sepsis Skin,0
VICTRELIS,stomatitis,pneumonia sepsis Skin and Subcutaneous,0
VICTRELIS,stomatitis,Subcutaneous Tissue Disorders,0
VICTRELIS,stomatitis,,0
VICTRELIS,stomatitis,Disorders,0
VICTRELIS,pneumonia,,0
VICTRELIS,sepsis,sepsis,1
VICTRELIS,sepsis,sepsis,1
VICTRELIS,sepsis,,0
VICTRELIS,sepsis,stomatitis Infections and Infestations pneumonia,0
VICTRELIS,sepsis,Skin,0
VICTRELIS,sepsis,mouth,0
VICTRELIS,sepsis,sepsis,1
VICTRELIS,angioedema,,0
VICTRELIS,angioedema,sepsis Skin and Subcutaneous,0
VICTRELIS,angioedema,angioedema,1
VICTRELIS,angioedema,and Subcutaneous Tissue angioedema,1
VICTRELIS,urticaria,Warnings and,0
VICTRELIS,urticaria,urticaria,1
VICTRELIS,urticaria,sepsis,0
VICTRELIS,urticaria,urticaria,1
VICTRELIS,exfoliative rash,eosinophilia and systemic symptoms DRESS syndrome,0
VICTRELIS,exfoliative rash,symptoms DRESS,0
VICTRELIS,exfoliative rash,,0
VICTRELIS,exfoliative rash,drug rash with,0
VICTRELIS,exfoliative rash,DRESS exfoliative rash,1
VICTRELIS,exfoliative rash,systemic symptoms DRESS exfoliative,1
VICTRELIS,exfoliative rash,symptoms DRESS exfoliative rash,1
VICTRELIS,exfoliative rash,rash with eosinophilia and systemic,0
VICTRELIS,exfoliative rash,exfoliative rash,1
VICTRELIS,Stevens-Johnson syndrome,,0
VICTRELIS,Stevens-Johnson syndrome,,0
VICTRELIS,Stevens-Johnson syndrome,,0
VICTRELIS,Stevens-Johnson syndrome,syndrome,1
VICTRELIS,Stevens-Johnson syndrome,syndrome,1
VICTRELIS,Stevens-Johnson syndrome,toxicoderma,0
VICTRELIS,Stevens-Johnson syndrome,eosinophilia and,0
VICTRELIS,Stevens-Johnson syndrome,dermatitis,0
VICTRELIS,Stevens-Johnson syndrome,skin eruption,0
VICTRELIS,Stevens-Johnson syndrome,rash exfoliative Stevens-Johnson,1
VICTRELIS,toxic skin eruption,,0
VICTRELIS,toxic skin eruption,rash exfoliative dermatitis StevensJohnson toxic skin eruption toxicoderma,1
VICTRELIS,toxic skin eruption,toxic skin eruption toxicoderma,1
VICTRELIS,toxic skin eruption,rash exfoliative dermatitis StevensJohnson toxic,1
VICTRELIS,toxic skin eruption,exfoliative rash,0
VICTRELIS,toxic skin eruption,syndrome,0
VICTRELIS,toxic skin eruption,StevensJohnson toxic skin eruption toxicoderma,1
VICTRELIS,Embryofetal Toxicity,information for,0
VICTRELIS,Embryofetal Toxicity,reactions assoc,1
VICTRELIS,Embryofetal Toxicity,information for description of erse reactions assoc,1
VICTRELIS,Embryofetal Toxicity,erse reactions assoc,1
VICTRELIS,Embryofetal Toxicity,information for description of erse reactions assoc,1
VICTRELIS,Embryofetal Toxicity,erse reactions assoc,1
VICTRELIS,Embryofetal Toxicity,,0
VICTRELIS,birth defects,their use EXCERPT The,0
VICTRELIS,birth defects,The most commonly adverse react,1
VICTRELIS,birth defects,react,1
VICTRELIS,birth defects,EXCERPT The most,0
VICTRELIS,birth defects,adverse react,1
VICTRELIS,birth defects,,0
VICTRELIS,fetal death,reported adverse (greater,1
VICTRELIS,fetal death,their use EXCERPT The most commonly reported adverse,0
VICTRELIS,fetal death,adverse (greater th,1
VICTRELIS,fetal death,clinical trials,0
VICTRELIS,fetal death,clinical trials in adult subjects receiving the,0
VICTRELIS,fetal death,receiving the combination,0
VICTRELIS,fetal death,,0
VICTRELIS,fetal death,,0
VICTRELIS,fetal death,of subjects in,0
VICTRELIS,fetal death,use EXCERPT The,0
VICTRELIS,Anemia,"ONS,",1
VICTRELIS,Anemia,"To report SUSPECTED ADVERSE ONS,",1
VICTRELIS,Anemia,"ONS, c",1
VICTRELIS,Anemia,Sharp Dohme Corp a subsidiary of Merck Co Inc at or,0
VICTRELIS,Anemia,headache,0
VICTRELIS,Anemia,Co Inc at,0
VICTRELIS,Anemia,"ONS, c",1
VICTRELIS,Anemia,"ADVERSE ONS, c",1
VICTRELIS,decrease in hemoglobin concentrations,Inc at or FDA -800-FDA-1088,1
VICTRELIS,Neutropenia,Trials Experience Because trials,1
VICTRELIS,Neutropenia,,0
VICTRELIS,Neutropenia,Trials Experience Because trials,1
VICTRELIS,Hypersensitivity,another and may not refl,1
VICTRELIS,Hypersensitivity,,0
VICTRELIS,acute hypersensitivity reactions,and otherwise,0
VICTRELIS,acute hypersensitivity reactions,to rates in the clinical,0
VICTRELIS,acute hypersensitivity reactions,"may not reflect the es observed in practice.



 The",1
VICTRELIS,acute hypersensitivity reactions,in practice. The,1
VICTRELIS,acute hypersensitivity reactions,The,1
VICTRELIS,acute hypersensitivity reactions,"may not reflect the es observed in practice.



 The",1
VICTRELIS,urticaria,in detail,0
VICTRELIS,urticaria,practice The ng seriou,1
VICTRELIS,urticaria,practice The ng,1
VICTRELIS,urticaria,ng seriou,1
VICTRELIS,urticaria,ng seriou,1
VICTRELIS,urticaria,ng seriou,1
VICTRELIS,urticaria,The ng,1
VICTRELIS,urticaria,practice The ng seriou,1
VICTRELIS,angioedema,in practice The following and otherw,1
VICTRELIS,angioedema,otherw,1
VICTRELIS,angioedema,following and,1
VICTRELIS,birth defects,,0
VICTRELIS,birth defects,,0
VICTRELIS,birth defects,"see Warnings and ]  
 *  Pancy",1
VICTRELIS,birth defects,and Precautions,0
VICTRELIS,birth defects,topenia see Warnings and,0
VICTRELIS,birth defects,and Precautions Hypersensitivity,0
VICTRELIS,birth defects,,0
VICTRELIS,birth defects,Warnings and Precautions Neutropenia,0
VICTRELIS,birth defects,"]  
 *  Pancy",1
VICTRELIS,death of the exposed fetus,Warnings and Precautions [see  Warnings and Precaut,1
VICTRELIS,death of the exposed fetus,Precaut,1
VICTRELIS,death of the exposed fetus,Precautions [see Warnings,1
VICTRELIS,Anemia,previous therapy evaluated he use,1
VICTRELIS,Anemia,previous therapy evaluated he,1
VICTRELIS,Anemia,,0
VICTRELIS,Anemia,subjects who had failed previous therapy,0
VICTRELIS,Anemia,of VICTRELIS mg three times daily in combination,0
VICTRELIS,Anemia,previously untreated and RESPOND subjects who had failed previous therapy evaluated t,0
VICTRELIS,Anemia,,0
VICTRELIS,additional decrease in hemoglobin concentrations,alone [see Clinical Studies (14),1
VICTRELIS,additional decrease in hemoglobin concentrations,,0
VICTRELIS,additional decrease in hemoglobin concentrations,PegIntronREBETOL compared to,0
VICTRELIS,additional decrease in hemoglobin concentrations,compared to ron/REBETOL alone  [see  Clinical Studies (14)  ,1
VICTRELIS,additional decrease in hemoglobin concentrations,PegIntronREBETOL compared,0
VICTRELIS,additional decrease in hemoglobin concentrations,population studied had a mean age of years of subjects were older,0
VICTRELIS,additional decrease in hemoglobin concentrations,than,0
VICTRELIS,additional decrease in hemoglobin concentrations,fourweek leadin period with PegIntronREBETOL compared to,0
VICTRELIS,additional decrease in hemoglobin concentrations,(14),1
VICTRELIS,hemoglobin values less than 10 g per dL,jects in any arm. Adverse reactions,1
VICTRELIS,hemoglobin values less than 10 g per dL,jects in any,1
VICTRELIS,hemoglobin values less than 10 g per dL,"in more than of jects in any arm.



 Adverse reactions",1
VICTRELIS,hemoglobin values less than 10 g per dL,"in more than of jects in any arm.



 Adverse reactions",1
VICTRELIS,hemoglobin values less than 10 g per dL,of jects in any arm. Adverse,1
VICTRELIS,hemoglobin less than 10 g per dL,with PegIntronREBETOL than in bjects receiving,1
VICTRELIS,hemoglobin less than 10 g per dL,Serious adverse events were reported in of subjects,0
VICTRELIS,hemoglobin less than 10 g per dL,bjects receiving PegIntron/REBET,1
VICTRELIS,hemoglobin less than 10 g per dL,PegIntronREBETOL than in bjects,1
VICTRELIS,hemoglobin less than 10 g per dL,with,0
VICTRELIS,anemia,equal to of cts,1
VICTRELIS,anemia,of cts re,1
VICTRELIS,anemia,a,0
VICTRELIS,dyspnea,e combi,1
VICTRELIS,exertional dyspnea,rate of,0
VICTRELIS,exertional dyspnea,,0
VICTRELIS,exertional dyspnea,receiving the tion of VICTRELIS ,1
VICTRELIS,dizziness,the combination of VICTRELIS th,1
VICTRELIS,syncope,EBETOL ,1
VICTRELIS,syncope,,0
VICTRELIS,syncope,EBETOL ,1
VICTRELIS,syncope,VICTRELIS with EBETOL ,1
VICTRELIS,syncope,with,0
VICTRELIS,syncope,to than PegIntronREBETOL alone,0
VICTRELIS,syncope,of VICTRELIS with EBETOL ,1
VICTRELIS,anemia, >=5% ,1
VICTRELIS,anemia, >=5% ,1
VICTRELIS,anemia, >=5% ,1
VICTRELIS,anemia, >=5% ,1
VICTRELIS,anemia,,0
VICTRELIS,anemia,Rate  >=5% ,1
VICTRELIS,anemia,,0
VICTRELIS,anemia,,0
VICTRELIS,anemia, >=5% ,1
VICTRELIS,anemia,of Subjects Reporting Adverse Events Body System Organ Class VICTRELIS Peg,0
VICTRELIS,anemia,Percentage of Subjects Reporting Adverse Events Body System Organ Class,0
VICTRELIS,anemia,Percentage of Subjects Reporting erse,1
VICTRELIS,anemia,Treatment FailuresRESPOND Percentage of Subjects Reporting Adv,0
VICTRELIS,Thromboembolic events,,0
VICTRELIS,Thromboembolic events,         24           Vomiting,1
VICTRELIS,Thromboembolic events,         24           Vomiting,1
VICTRELIS,infections,,0
VICTRELIS,infections,,0
VICTRELIS,infections,Adverse Reactions,0
VICTRELIS,infections,    19     Other Important Adverse,1
VICTRELIS,infections,Rash,0
VICTRELIS,infections,Rash     19     Other,1
VICTRELIS,neutropenia,            Other,1
VICTRELIS,neutropenia,,0
VICTRELIS,neutropenia,rtant Adver se Reactions Reported in,1
VICTRELIS,pancytopenia,Adverse events such as dry,0
VICTRELIS,pancytopenia,ribavirin Table 3,1
VICTRELIS,pancytopenia,alone,0
VICTRELIS,pancytopenia,ribavirin Table,1
VICTRELIS,pancytopenia,,0
VICTRELIS,pancytopenia,alfa and ribavirin Table 3,1
VICTRELIS,pancytopenia,ribavirin compared with subjects receiving peginterferon alfa and ribavirin,0
VICTRELIS,pancytopenia,alfa and ribavirin Table,1
VICTRELIS,pancytopenia, Table 3  ). Adverse events such as,1
VICTRELIS,acute hypersensitivity reactions,and Clinical Studies (14) see prescribing information for,1
VICTRELIS,acute hypersensitivity reactions,5.2) and Clinical Studies (14) see prescribing information for,1
VICTRELIS,urticaria,and Clinical Studies  prescrib ing information for ribavirin,1
VICTRELIS,urticaria, prescrib ing information for ribavirin,1
VICTRELIS,urticaria,ribavirin,0
VICTRELIS,urticaria,Studies  prescrib ing information for ribavirin,1
VICTRELIS,urticaria,see,0
VICTRELIS,urticaria, prescrib ing information for ribavirin,1
VICTRELIS,angioedema,informat ion for ribavirin If,1
VICTRELIS,angioedema,ribavirin,0
VICTRELIS,angioedema,informat ion for ribavirin If,1
VIMIZIM,Anaphylaxis,Anaphylaxis and hypersensitivity reactions see,1
VIMIZIM,hypersensitivity reactions,reactions see Warnings and Precautions,1
VIMIZIM,hypersensitivity reactions,Anaphylaxis hypersensitivity,1
VIMIZIM,hypersensitivity reactions,reactions,0
VIMIZIM,hypersensitivity reactions,in the labeling Anaphylaxis hypersensitivity,1
VIMIZIM,hypersensitivity reactions,hypersensitivity reactions see Warnings and Precautions,1
VIMIZIM,hypersensitivity reactions,in the labeling Anaphylaxis hypersensitivity,1
VIMIZIM,hypersensitivity reactions,adverse reactions obse,0
VIMIZIM,hypersensitivity reactions,reactions obse,0
VIMIZIM,pyrexia,,0
VIMIZIM,pyrexia,than,0
VIMIZIM,vomiting,,0
VIMIZIM,vomiting,placebotreated patients were vomiting headache nausea abdominal pain,1
VIMIZIM,vomiting,vomiting headache nausea abdominal pain,1
VIMIZIM,vomiting,SUSPECTED ADVERSE,0
VIMIZIM,vomiting,patients were vomiting headache nausea abdominal pain,1
VIMIZIM,vomiting,vomiting headache nausea abdominal pain,1
VIMIZIM,vomiting,fatigue To report SUSPECTED ADVERSE,0
VIMIZIM,vomiting,vomiting headache nausea abdominal pain,1
VIMIZIM,vomiting,a higher,0
VIMIZIM,headache,headache nausea abdominal pain chills,1
VIMIZIM,headache,,0
VIMIZIM,nausea,fatigue To report SUSPECTED ADVERSE,0
VIMIZIM,nausea,nausea abdominal pain chills and,1
VIMIZIM,nausea,were pyrexia vomiting nausea abdominal pain chills and,1
VIMIZIM,nausea,nausea abdominal pain chills and,1
VIMIZIM,abdominal pain,SUSPECTED ADVERSE,0
VIMIZIM,abdominal pain,,0
VIMIZIM,abdominal pain,abdominal pain chills and fatigue To,1
VIMIZIM,chills,chills and fatigue To report,1
VIMIZIM,chills,headache nausea abdominal chills and fatigue To report,1
VIMIZIM,chills,To report SUSPECTED ADVERSE REACTIONS contact,0
VIMIZIM,chills,abdominal,0
VIMIZIM,chills,chills and fatigue To report,1
VIMIZIM,chills,chills and fatigue To report,1
VIMIZIM,chills,were,0
VIMIZIM,chills,To report SUSPECTED ADVERSE,0
VIMIZIM,chills,chills and fatigue To report,1
VIMIZIM,chills,chills and fatigue To report,1
VIMIZIM,fatigue,fatigue To report SUSPECTED ADVERSE,1
VIMIZIM,fatigue,abdominal pain chills fatigue To report SUSPECTED ADVERSE,1
VIMIZIM,fatigue,fatigue To report SUSPECTED ADVERSE,1
VIMIZIM,fatigue,pain chills fatigue To report SUSPECTED ADVERSE,1
VIMIZIM,fatigue,headache nausea abdominal pain,0
VIMIZIM,fatigue,fatigue To report SUSPECTED ADVERSE,1
VIMIZIM,fatigue,fatigue To report SUSPECTED ADVERSE,1
VIMIZIM,fatigue,fatigue To report SUSPECTED ADVERSE,1
VIMIZIM,fatigue,fatigue To report SUSPECTED ADVERSE,1
VIMIZIM,Pyrexia,Pyrexia Vomiting,1
VIMIZIM,Pyrexia,,0
VIMIZIM,Pyrexia,Pyrexia Vomiting,1
VIMIZIM,Pyrexia,n N Pyrexia Vomiting,1
VIMIZIM,Pyrexia,Placebo N n N Pyrexia Vomiting,1
VIMIZIM,Pyrexia,N Pyrexia Vomiting,1
VIMIZIM,Headache,Headache Nausea,1
VIMIZIM,Headache,,0
VIMIZIM,Headache,Vomiting,0
VIMIZIM,Headache,Vomiting Headache Nausea,1
VIMIZIM,Headache,,0
VIMIZIM,Headache,Vomiting,0
VIMIZIM,Headache,Vomiting,0
VIMIZIM,Headache,Headache Nausea,1
VIMIZIM,Nausea,Headache Nausea Abdominal,1
VIMIZIM,Abdominal pain,Nausea Abdominal,1
VIMIZIM,Abdominal pain,pain,1
VIMIZIM,Abdominal pain,,0
VIMIZIM,Abdominal pain,Nausea,0
VIMIZIM,Abdominal pain,Nausea Abdominal pain Chills Fatig,1
VIMIZIM,Chills,Abdominal Chills Fatigue,1
VIMIZIM,Chills,Chills Fatigue,1
VIMIZIM,Fatigue,Chills,0
VIMIZIM,Fatigue,,0
VIMIZIM,Fatigue,Chills,0
VIMIZIM,ANAPHYLAXIS,trial,1
VIMIZIM,ANAPHYLAXIS,nical,1
VIMIZIM,ANAPHYLAXIS,nical trial s are,1
VIMIZIM,ANAPHYLAXIS,idely varyi ng conditions,1
VIMIZIM,ANAPHYLAXIS,idely varyi ng conditions adverse reaction rates,1
VIMIZIM,ANAPHYLAXIS,idely varyi,1
VIMIZIM,ANAPHYLAXIS,idely varyi ng conditions adverse reaction rates,1
VIMIZIM,ANAPHYLAXIS,idely,1
VIMIZIM,ANAPHYLAXIS,idely varyi ng conditions adverse reaction,1
VIMIZIM,ANAPHYLAXIS,a drug cannot,0
VIMIZIM,anaphylactic reactions,,0
VIMIZIM,anaphylactic reactions,conducted under widely varying conditions adverse re,0
VIMIZIM,anaphylactic reactions,observed in the clinical,1
VIMIZIM,anaphylactic reactions,in the clinical,0
VIMIZIM,anaphylactic reactions,widely varying conditions adverse action rates observed  in the clinical,1
VIMIZIM,anaphylactic reactions,action rates observed in the clinical,1
VIMIZIM,Anaphylaxis,in the clinical trials of another drug and may,0
VIMIZIM,Anaphylaxis,practice,0
VIMIZIM,Anaphylaxis,reflect the rates observed in practice,0
VIMIZIM,Anaphylaxis,in the clinical trials of another drug and may,0
VIMIZIM,Anaphylaxis,reaction rates observed in the clinical,0
VIMIZIM,Anaphylaxis,cannot,0
VIMIZIM,Anaphylaxis,ed,1
VIMIZIM,Anaphylaxis,,0
VIMIZIM,Anaphylaxis,a drug cannot be,0
VIMIZIM,erythema,be directly compared to rates,0
VIMIZIM,erythema,rates in the clinical of,1
VIMIZIM,erythema,anot her drug and,1
VIMIZIM,erythema,rates in the clinical  of anot her drug and,1
VIMIZIM,erythema,following,0
VIMIZIM,throat tightness,trials of r drug and may n ot reflect the,1
VIMIZIM,throat tightness,reactions are described,0
VIMIZIM,throat tightness,observed in practice The,0
VIMIZIM,throat tightness,anothe,0
VIMIZIM,throat tightness,described,0
VIMIZIM,throat tightness,clinical trials of r drug and may,1
VIMIZIM,throat tightness,r,1
VIMIZIM,throat tightness,clinical trials of r drug and may n ot reflect the,1
VIMIZIM,throat tightness,directly compared to rates,0
VIMIZIM,throat tightness,directly compared,0
VIMIZIM,urticaria,cannot be,0
VIMIZIM,urticaria,described,0
VIMIZIM,urticaria,may  reflect  the rates observed,1
VIMIZIM,urticaria,adverse reactions are described below,0
VIMIZIM,urticaria, reflect  the rates observed,1
VIMIZIM,flushing,and may not reflect e rates  observed in practice,1
VIMIZIM,cyanosis,the rates served i n practice The,1
VIMIZIM,cyanosis,and may not reflect,0
VIMIZIM,cyanosis,of,0
VIMIZIM,cyanosis,rates served,1
VIMIZIM,cyanosis,compared to rates in the clinical trials of another drug and may,0
VIMIZIM,cyanosis,served i n practice The,1
VIMIZIM,hypotension,"practice.

 The following serious",1
VIMIZIM,hypotension,"rates observed practice.

 The following serious",1
VIMIZIM,hypotension,and may not,0
VIMIZIM,hypotension,"practice.

 The following serious",1
VIMIZIM,hypotension,and may not reflect,0
VIMIZIM,rash, The following serious adverse,1
VIMIZIM,rash, The following serious adverse,1
VIMIZIM,rash, The following serious adverse,1
VIMIZIM,rash,not reflect,0
VIMIZIM,rash,elsewhere in the labeling Anaphy,0
VIMIZIM,rash,serious adverse reactions are described below,0
VIMIZIM,dyspnea,,0
VIMIZIM,dyspnea,of another drug,0
VIMIZIM,chest discomfort,drug and may not reflect the rates,0
VIMIZIM,chest discomfort,described below and elsewhere in the labeling,0
VIMIZIM,chest discomfort,another drug and may not reflect the rates observed in,0
VIMIZIM,gastrointestinal symptoms,serious adverse ons are described,1
VIMIZIM,gastrointestinal symptoms,The following serious adverse ons,1
VIMIZIM,gastrointestinal symptoms,and,0
VIMIZIM,gastrointestinal symptoms,the,0
VIMIZIM,gastrointestinal symptoms,serious adverse ons are,1
VIMIZIM,nausea,and here,1
VIMIZIM,nausea,,0
VIMIZIM,nausea,serious adverse,0
VIMIZIM,nausea,here i n the labeling,1
VIMIZIM,nausea,,0
VIMIZIM,nausea,Warnings and,0
VIMIZIM,nausea,here i n the labeling,1
VIMIZIM,nausea,i n the labeling,1
VIMIZIM,nausea,here,1
VIMIZIM,nausea,are described below and here,1
VIMIZIM,abdominal pain,"the labeling:
 Anaphylaxis and hypersensitivity",1
VIMIZIM,abdominal pain,,0
VIMIZIM,abdominal pain,reactions see Warnings,0
VIMIZIM,abdominal pain,described below and elsewhere the,1
VIMIZIM,abdominal pain,"the labeling:
 Anaphylaxis and hypersensitivity",1
VIMIZIM,abdominal pain,,0
VIMIZIM,abdominal pain,,0
VIMIZIM,abdominal pain,are described,0
VIMIZIM,retching,.,1
VIMIZIM,retching,"
 . Anap hylaxis and hypersensitivity",1
VIMIZIM,retching,"elsewhere in the 
 . Anap hylaxis and hypersensitivity",1
VIMIZIM,retching,elsewhere in the .,1
VIMIZIM,retching,in the .,1
VIMIZIM,retching,,0
VIMIZIM,retching,,0
VIMIZIM,retching,in the,0
VIMIZIM,retching,in the .,1
VIMIZIM,retching,,0
VIMIZIM,vomiting,s and hy persensitivity reactions see,1
VIMIZIM,vomiting,s and hy persensitivity reactions see,1
VIMIZIM,vomiting,,0
VIMIZIM,vomiting,s and hy persensitivity reactions see,1
VIMIZIM,vomiting,,0
VIMIZIM,vomiting,labeling s and hy persensitivity reactions see,1
VIMIZIM,urticaria,,0
VIMIZIM,urticaria,labeling Anaphylaxis and hypersensitivity ns  [     see Warnings and,1
VIMIZIM,urticaria,Anaphylaxis and hypersensitivity ns,1
VIMIZIM,urticaria,are described below and elsewhere in the labeling Anaphylaxis and hypersensitivity reactio,0
VIMIZIM,urticaria,most common adverse,0
VIMIZIM,urticaria,Warnings and Precautions The most common adverse reactions observed,0
VIMIZIM,urticaria,[ see Warnings and,1
VIMIZIM,urticaria,and hypersensitivity ns  [     see Warnings and,1
VIMIZIM,ANAPHYLAXIS,nausea abdominal pain chills d fatigue ( To report SUSPECTED,1
VIMIZIM,ANAPHYLAXIS,,0
VIMIZIM,ANAPHYLAXIS,chills d fatigue,1
VIMIZIM,ANAPHYLAXIS,nausea abdominal pain chills d,1
VIMIZIM,ANAPHYLAXIS,nausea abdominal pain chills d fatigue,1
VIMIZIM,ANAPHYLAXIS,fatigue ( To report SUSPECTED,1
VIMIZIM,anaphylactic reactions,at,0
VIMIZIM,Anaphylaxis,placebocontrolled clinical trial of Vimizim,0
VIMIZIM,Anaphylaxis,wwwfdagovmedwatch Clinical Trials e A,1
VIMIZIM,cough, doub leblind placebocontrolled clinical,1
VIMIZIM,cough,,0
VIMIZIM,cough,Vimizim was conducted in patients with MPS IVA a,0
VIMIZIM,cough, doub leblind placebocontrolled clinical,1
VIMIZIM,cough, doub leblind placebocontrolled clinical,1
VIMIZIM,cough,of Vimizim was conducted in patients with,0
VIMIZIM,cough, doub leblind placebocontrolled clinical,1
VIMIZIM,erythema,"-blind,  placebocontrolled clinical trial",1
VIMIZIM,erythema,,0
VIMIZIM,throat tightness,A week randomized doubleblind acebo-controlled clinical trial of,1
VIMIZIM,throat tightness,clinical trial of Vimizim was,0
VIMIZIM,throat tightness,A week randomized doubleblind acebo-controlled clinical trial of,1
VIMIZIM,throat tightness,clinical trial of Vimizim was conducted,0
VIMIZIM,throat tightness,,0
VIMIZIM,throat tightness,doubleblind,0
VIMIZIM,throat tightness,acebo-controlled clinical trial of,1
VIMIZIM,throat tightness,acebo-controlled clinical trial of,1
VIMIZIM,urticaria,,0
VIMIZIM,urticaria,linical,1
VIMIZIM,urticaria,,0
VIMIZIM,urticaria,randomized doubleblind placebocontrolled linical t rial of Vimizim,1
VIMIZIM,urticaria,t rial of Vimizim,1
VIMIZIM,urticaria,week randomized doubleblind placebocontrolled linical,1
VIMIZIM,urticaria,,0
VIMIZIM,urticaria,placebocontrolled linical t rial of Vimizim,1
VIMIZIM,urticaria,of Vimizim was conducted in patients with MPS IVA ages to,0
VIMIZIM,flushing,half of,0
VIMIZIM,cyanosis,clinical trial of Vimi,0
VIMIZIM,cyanosis,conducted,0
VIMIZIM,cyanosis,clinical trial of zim was  conducted in patients,1
VIMIZIM,hypotension,nducted in patients with MPS,1
VIMIZIM,hypotension,nducted,1
VIMIZIM,hypotension,of Vimizim was nducted in  patients with MPS,1
VIMIZIM,hypotension,ages to years old Approximately half of,0
VIMIZIM,hypotension,trial of Vimizim was nducted in  patients with MPS,1
VIMIZIM,hypotension,,0
VIMIZIM,rash,was conducted 6 pa tients with MPS,1
VIMIZIM,dyspnea,was conducted in,0
VIMIZIM,dyspnea,was conducted in ents wi th MPS IVA,1
VIMIZIM,dyspnea,Vimizim,0
VIMIZIM,gastrointestinal symptoms,patients were,0
VIMIZIM,gastrointestinal symptoms,MPS IVA ages  years old.  Approximatel y half of,1
VIMIZIM,gastrointestinal symptoms,IVA,0
VIMIZIM,gastrointestinal symptoms,ages  years old.  Approximatel y half of,1
VIMIZIM,urticaria,w ere male Of,1
VIMIZIM,urticaria,The majori,0
VIMIZIM,urticaria,Other race The,0
VIMIZIM,urticaria,s (49%) w ere male Of,1
VIMIZIM,Anaphylaxis,s are condu cted,1
VIMIZIM,Anaphylaxis,,0
VIMIZIM,Anaphylaxis,s are condu cted,1
VIMIZIM,Anaphylaxis,,0
VIMIZIM,Anaphylaxis,,0
VIMIZIM,Anaphylaxis,under,0
VIMIZIM,Anaphylaxis,s are condu cted under widely varying conditions,1
VIMIZIM,Anaphylaxis,s are condu cted under,1
VIMIZIM,Hypersensitivity Reactions,varying condi tions adverse,1
VIMIZIM,Hypersensitivity Reactions,under widely varying condi tions adverse reaction rates observed,1
VIMIZIM,Hypersensitivity Reactions,,0
VIMIZIM,Hypersensitivity Reactions,condi tions adverse reaction,1
VIMIZIM,Hypersensitivity Reactions,the clinical trials of,0
VIMIZIM,Hypersensitivity Reactions,,0
VIMIZIM,Hypersensitivity Reactions,under widely varying,1
VIMIZIM,Hypersensitivity Reactions,under widely varying condi tions adverse,1
VIMIZIM,Hypersensitivity Reactions,widely varying condi tions adverse,1
VIMIZIM,anaphylaxis,tion rates observed in,1
VIMIZIM,anaphylaxis,clinical trials are conducted,0
VIMIZIM,anaphylaxis,trials of a drug cannot be,0
VIMIZIM,anaphylaxis,tion,1
VIMIZIM,anaphylaxis,rates in the clinical trial,0
VIMIZIM,anaphylaxis,,0
VIMIZIM,anaphylaxis,tion rates observed in,1
VIMIZIM,anaphylaxis,tion rates  observed in,1
VIMIZIM,anaphylaxis,varying conditions adverse tion rates  observed in,1
VIMIZIM,hypersensitivity,adverse reaction rates ved,1
VIMIZIM,hypersensitivity,rates ved in the,1
VIMIZIM,hypersensitivity,trials of another drug and,0
VIMIZIM,hypersensitivity,in the clinical trials of,0
VIMIZIM,hypersensitivity,,0
VIMIZIM,hypersensitivity,,0
VIMIZIM,hypersensitivity,clinical,0
VIMIZIM,Acute Respiratory Complications,The most common adverse reactio ns observed,1
VIMIZIM,Acute Respiratory Complications,Warnings and The most common adverse reactio ns observed,1
VIMIZIM,Acute Respiratory Complications,,0
VIMIZIM,Acute Respiratory Complications,Warnings and The most common adverse reactio ns observed,1
VIMIZIM,Acute Respiratory Complications,hypersensitivity,0
VIMIZIM,Acute Respiratory Complications,,0
VIMIZIM,hypersensitivity reactions,,0
VIMIZIM,hypersensitivity reactions,placebo-controlled tria l see,1
VIMIZIM,Anaphylaxis,antipyretics or corticosteroids : The,1
VIMIZIM,Anaphylaxis,The mos t common,1
VIMIZIM,Anaphylaxis,antipyretics or corticosteroids :,1
VIMIZIM,Anaphylaxis,: The mos t common,1
VIMIZIM,hypersensitivity,mon adverse reac tions in,1
VIMIZIM,hypersensitivity,,0
VIMIZIM,hypersensitivity,corticosteroids EXCERPT The most mon adverse reac tions in,1
VIMIZIM,anaphylaxis,abdominal pain chills and To,1
VIMIZIM,anaphylaxis,pain chills and To,1
VIMIZIM,anaphylactic reactions,report SUSPECTED ADVERSE REACTIONS tact BioMarin at,1
VIMIZIM,cough,edwat ch Clinical,1
VIMIZIM,cough,,0
VIMIZIM,cough,edwat ch Clinical,1
VIMIZIM,cough,or edwat ch Clinical,1
VIMIZIM,cough,doubleblind,0
VIMIZIM,cough,,0
VIMIZIM,cough,at or FDA at FDA,0
VIMIZIM,cough,edwat ch Clinical,1
VIMIZIM,cough,Experience A,0
VIMIZIM,cough,or FDA at FDA or,0
VIMIZIM,erythema,contact BioMarin at or FDA,0
VIMIZIM,erythema,at FDA,0
VIMIZIM,erythema,".  



  Clinical Trials",1
VIMIZIM,erythema,".  



  Clinical Trials",1
VIMIZIM,erythema,"or .  



  Clinical Trials",1
VIMIZIM,erythema,,0
VIMIZIM,erythema,or,0
VIMIZIM,erythema,".  



  Clinical Trials",1
VIMIZIM,throat tightness,placebocontrolled clinical trial of,0
VIMIZIM,throat tightness,at FDA or   6.1 Clinical T rials Experience,1
VIMIZIM,throat tightness,6.1 Clinical T rials Experience,1
VIMIZIM,throat tightness,rials,0
VIMIZIM,urticaria,als Exper ience A,1
VIMIZIM,urticaria,or FDA at FDA,0
VIMIZIM,flushing,"or wwwfdagovmedwatch Clinical Trials nce

  A week randomized",1
VIMIZIM,flushing,conducted in,0
VIMIZIM,flushing,"nce

  A week randomized",1
VIMIZIM,flushing,or wwwfdagovmedwatch Clinical Trials nce,1
VIMIZIM,flushing,conducted,0
VIMIZIM,flushing,Clinical,0
VIMIZIM,flushing,randomized doubleblind placebocontrolled clinical trial of Vimizim was conducted in,0
VIMIZIM,flushing,Trials,0
VIMIZIM,flushing,,0
VIMIZIM,cyanosis,"4-week,  randomized doubleblind",1
VIMIZIM,cyanosis,wwwfdagovmedwatch Clinical Trials Experience A,0
VIMIZIM,cyanosis,Vimizim was conducted in,0
VIMIZIM,cyanosis,"4-week,  randomized doubleblind",1
VIMIZIM,cyanosis,,0
VIMIZIM,cyanosis,,0
VIMIZIM,cyanosis,"4-week,  randomized doubleblind",1
VIMIZIM,cyanosis,clinical trial of Vimizim was conducted in patients,0
VIMIZIM,cyanosis,"4-week,  randomized doubleblind",1
VIMIZIM,hypotension,"A week ndomized, d oubleblind placebocontrolled",1
VIMIZIM,hypotension,Experience,0
VIMIZIM,hypotension,conducted in patients with,0
VIMIZIM,hypotension,clinical trial of,0
VIMIZIM,hypotension,Trials Experience A week ra,0
VIMIZIM,hypotension,FDA or wwwfdagovmedwatch Clinical Trials,0
VIMIZIM,hypotension,d oubleblind placebocontrolled,1
VIMIZIM,rash,ble- blind placebocontrolled,1
VIMIZIM,rash,ble- blind placebocontrolled,1
VIMIZIM,rash,,0
VIMIZIM,rash,Trials Experience A week,0
VIMIZIM,rash,A week randomized ble- blind placebocontrolled,1
VIMIZIM,dyspnea,"A week randomized ind, pl acebocontrolled clinical",1
VIMIZIM,dyspnea,"ind,",1
VIMIZIM,dyspnea,patients with MPS IVA,0
VIMIZIM,dyspnea,"ind,",1
VIMIZIM,dyspnea,Trials Experience A week randomized doublebl,0
VIMIZIM,chest discomfort,in patients with MPS IVA ages to years old Approx,0
VIMIZIM,chest discomfort,c linical trial,1
VIMIZIM,chest discomfort,Clinical,0
VIMIZIM,chest discomfort,randomized doubleblind plac,0
VIMIZIM,chest discomfort,randomized doubleblind ebo-controlled,1
VIMIZIM,chest discomfort,,0
VIMIZIM,chest discomfort,ebo-controlled c linical trial,1
VIMIZIM,chest discomfort,patients with MPS IVA,0
VIMIZIM,chest discomfort,Clinical Trials Experience,0
VIMIZIM,gastrointestinal symptoms,Trials,0
VIMIZIM,gastrointestinal symptoms,l,1
VIMIZIM,gastrointestinal symptoms,doubleblind,0
VIMIZIM,nausea,of Vimizim,0
VIMIZIM,nausea,was in 176 patients with,1
VIMIZIM,nausea,176 patients with,1
VIMIZIM,nausea,of Vimizim was conducted,0
VIMIZIM,retching,ag es to,1
VIMIZIM,retching,clinical trial of Vimizim was conducted in patients with,0
VIMIZIM,retching,of Vimizim was conducted in patients,0
VIMIZIM,retching,ag es to,1
VIMIZIM,retching,"with  IVA, ag es to",1
VIMIZIM,retching,"IVA, ag es to",1
VIMIZIM,retching,were male Of the,0
VIMIZIM,vomiting,old Approximately half of the patients were male,0
VIMIZIM,urticaria,was conducted in patients with MPS IVA ages,0
VIMIZIM,urticaria,of the patients,1
VIMIZIM,urticaria,ages to,0
VIMIZIM,urticaria,ages to years old half,1
VIMIZIM,urticaria,old half,1
VIMIZIM,urticaria,of the patients,1
VIMIZIM,urticaria,to years old half,1
VIMIZIM,urticaria,old  half of  the patients,1
VIMIZIM,urticaria,half of the patients,1
VIMIZIM,urticaria,the patients were White Asian,0
VIMIZIM,anaphylaxis,to years old Approximately,0
VIMIZIM,anaphylaxis,were White,0
VIMIZIM,anaphylaxis,pa,0
VIMIZIM,anaphylaxis,were male Of the,1
VIMIZIM,anaphylaxis,) were,1
VIMIZIM,anaphylaxis,,0
VIMIZIM,anaphylaxis,patients with,0
VIMIZIM,Anaphylaxis,Patients were randomized to three treatment,0
VIMIZIM,Anaphylaxis,The majority of atients (78 were nonHispanic,1
VIMIZIM,Anaphylaxis,(78 were nonHispanic,1
VIMIZIM,Anaphylaxis,,0
VIMIZIM,Anaphylaxis,were randomized to three treatment groups Vimizim,0
VIMIZIM,Anaphylaxis,of atients (78 were nonHispanic,1
VIMIZIM,hypersensitivity,other week n or,1
VIMIZIM,hypersensitivity,week n Vimizim mgkg every,1
VIMIZIM,hypersensitivity,or placebo n All patients were treated with antihistamines prior to each,0
VIMIZIM,hypersensitivity,patients,0
VIMIZIM,anaphylaxis,placebo =59).  All  patients were,1
VIMIZIM,anaphylaxis,patients were treated with antihistamines prior to each infusion Table summarizes,0
VIMIZIM,anaphylaxis,All patients were,1
VIMIZIM,anaphylactic reactions,2 mg/kg once per w eek and,1
VIMIZIM,anaphylactic reactions,patients treated with zim 2 mg/kg once per w eek and,1
VIMIZIM,anaphylactic reactions,patients treated with zim 2 mg/kg once per w eek and,1
VIMIZIM,anaphylactic reactions,than in the placebotreated patients Table,0
VIMIZIM,urticaria,wit h a,1
VIMIZIM,urticaria,,0
VIMIZIM,urticaria,a higher,0
VIMIZIM,urticaria,Oc,0
VIMIZIM,peripheral edema,with an incidence of in,0
VIMIZIM,peripheral edema,placebotreated patients,0
VIMIZIM,peripheral edema,inciden ce than,1
VIMIZIM,peripheral edema,inciden ce than,1
VIMIZIM,peripheral edema,per week and a higher,1
VIMIZIM,peripheral edema,week and a higher inciden ce than,1
VIMIZIM,peripheral edema,,0
VIMIZIM,peripheral edema,treated with,0
VIMIZIM,peripheral edema,a higher inciden ce than,1
VIMIZIM,cough, than in the,1
VIMIZIM,cough, than in the,1
VIMIZIM,cough,a higher  than in the,1
VIMIZIM,cough,in,0
VIMIZIM,dyspnea,the p lacebotreated patients,1
VIMIZIM,dyspnea,,0
VIMIZIM,dyspnea,higher incidence than n,1
VIMIZIM,dyspnea,than n the p lacebotreated patients,1
VIMIZIM,dyspnea,Adverse Reactions That Occurred in the PlaceboControlled T,0
VIMIZIM,dyspnea,the,0
VIMIZIM,dyspnea,than n the p lacebotreated patients,1
VIMIZIM,dyspnea,higher incidence than n the,1
VIMIZIM,flushing,-treated patients Table,1
VIMIZIM,flushing,PlaceboControlled,0
VIMIZIM,hypersensitivity reactions,patients developed ant idrug antibodies,1
VIMIZIM,hypersensitivity reactions,treatment,0
VIMIZIM,hypersensitivity reactions,between antibody titers and reductions in treatment effect or the oc,0
VIMIZIM,hypersensitivity reactions,or,0
VIMIZIM,hypersensitivity reactions,patients developed ant idrug antibodies,1
VIMIZIM,hypersensitivity reactions,and reductions in treatment effect or the,0
VIMIZIM,hypersensitivity reactions,antibody titers and reductions in treatment,0
BEPREVE,taste following instillation,a taste following instillation Other adverse,1
BEPREVE,taste following instillation,subjects were eye irritation headache,0
BEPREVE,taste following instillation,following instillation Other adverse,1
BEPREVE,taste following instillation,occurred in of subjects were eye irritation,0
BEPREVE,taste following instillation,taste following instillation Other adverse,1
BEPREVE,taste following instillation,most common adverse reaction occurring in approximately of patients,0
BEPREVE,taste following instillation,,0
BEPREVE,eye irritation,To report SUSPECTED,0
BEPREVE,headache,headache and nasopharyngitis,1
BEPREVE,headache,of subjects were eye headache and nasopharyngitis,1
BEPREVE,nasopharyngitis,nasopharyngitis To report,1
BEPREVE,taste following instillation,most,0
BEPREVE,taste following instillation,in approximately of subjects was,0
BEPREVE,taste following instillation,instillation Other adverse,1
BEPREVE,taste following instillation,occurring in approximately,0
BEPREVE,taste following instillation,taste following instillation Other adverse,1
BEPREVE,taste following instillation,following instillation Other adverse,1
BEPREVE,taste following instillation,subjects was a mild,0
BEPREVE,taste following instillation,following instillation Other adverse,1
BEPREVE,taste following instillation,in,0
BEPREVE,taste following instillation,following instillation Other adverse,1
BEPREVE,eye irritation,,0
BEPREVE,eye irritation,of subjects eye irritation headache and,1
BEPREVE,eye irritation,subjects eye,1
BEPREVE,eye irritation,eye,1
BEPREVE,eye irritation,,0
BEPREVE,eye irritation,eye irritation headache and,1
BEPREVE,eye irritation,eye irritation headache and,1
BEPREVE,headache,headache and nasopharyngitis,1
BEPREVE,headache,Experience,0
BEPREVE,headache,subjects were eye headache and nasopharyngitis,1
BEPREVE,headache,Experience Hypersensitivity reactions have been,0
BEPREVE,headache,headache and nasopharyngitis,1
BEPREVE,nasopharyngitis,eye irritation headache and,0
BEPREVE,nasopharyngitis,nasopharyngitis Post Marketing,1
BEPREVE,nasopharyngitis,Other adverse reactions occurring in of subjects were eye,0
BEPREVE,nasopharyngitis,Marketing Experience Hypersensitivity reactions have been reported rarely during,0
BEPREVE,nasopharyngitis,nasopharyngitis Post Marketing,1
BEPREVE,nasopharyngitis,rarely during,0
BEPREVE,Hypersensitivity reactions,headache and nasopharyngitis Post,0
BEPREVE,Hypersensitivity reactions,Post Marketing Hypersensitivity,1
BEPREVE,hypersensitivity reactions,,0
BEPREVE,hypersensitivity reactions,relationship to drug exposure hypersensitivity reactions include itching,1
BEPREVE,hypersensitivity reactions,relationship to drug exposure hypersensitivity reactions include itching,1
BEPREVE,hypersensitivity reactions,,0
BEPREVE,itching,hypersensitivity reactions itching body rash,1
BEPREVE,itching,hypersensitivity,0
BEPREVE,itching,hypersensitivity reactions itching body rash,1
BEPREVE,itching,hypersensitivity reactions itching body rash,1
BEPREVE,itching,relationship to drug exposure The hypersensitivity reactions include,0
BEPREVE,body rash,The hypersensitivity reactions include body rash and swelling,1
BEPREVE,body rash,hypersensitivity reactions include body,1
BEPREVE,body rash,body rash and swelling,1
BEPREVE,body rash,The hypersensitivity reactions include body rash and swelling,1
BEPREVE,body rash,body rash and swelling,1
BEPREVE,body rash,The hypersensitivity reactions,0
BEPREVE,body rash,swelling,0
BEPREVE,body rash,a,0
BEPREVE,body rash,body rash and swelling,1
BEPREVE,body rash,establish a casual relationship to drug exposure The,0
BEPREVE,swelling of lips,lips tongue andor,1
PRISTIQ,Hypersensitivity,Hypersensitivity see Contraindications,1
PRISTIQ,Hypersensitivity,Hypersensitivity see Contraindications,1
PRISTIQ,Hypersensitivity,Hypersensitivity see Contraindications,1
PRISTIQ,Hypersensitivity,in,0
PRISTIQ,Hypersensitivity,Hypersensitivity see Contraindications,1
PRISTIQ,Hypersensitivity,Hypersensitivity see Contraindications,1
PRISTIQ,Suicidal Thoughts,Suicidal Thoughts and Behaviors,1
PRISTIQ,Suicidal Thoughts,label Hypersensitivity see Suicidal,1
PRISTIQ,Suicidal Thoughts,the label Hypersensitivity see Suicidal,1
PRISTIQ,Suicidal Thoughts,Adults see,0
PRISTIQ,Suicidal Thoughts,,0
PRISTIQ,Suicidal Thoughts,in other,0
PRISTIQ,Serotonin Syndrome,Adolescents and Young Adults see,0
PRISTIQ,Serotonin Syndrome,Serotonin Syndrome see Warnings,1
PRISTIQ,Serotonin Syndrome,,0
PRISTIQ,Serotonin Syndrome,Adults see Warnings and Serotonin,1
PRISTIQ,Serotonin Syndrome,Adults see Warnings and Serotonin,1
PRISTIQ,Serotonin Syndrome,Behaviors in Adolescents,0
PRISTIQ,Serotonin Syndrome,Serotonin,1
PRISTIQ,Serotonin Syndrome,Young Adults see Warnings and,0
PRISTIQ,Serotonin Syndrome,Syndrome see Warnings,1
PRISTIQ,Serotonin Syndrome,see Warnings and Serotonin,1
PRISTIQ,Elevated Blood Pressure,Syndrome,0
PRISTIQ,Elevated Blood Pressure,see,0
PRISTIQ,Elevated Blood Pressure,Bleeding,0
PRISTIQ,Elevated Blood Pressure,and Elevated,1
PRISTIQ,Elevated Blood Pressure,,0
PRISTIQ,Elevated Blood Pressure,Bleeding see Warnings and,0
PRISTIQ,Elevated Blood Pressure,Syndrome see Warnings,0
PRISTIQ,Abnormal Bleeding,Precauti,0
PRISTIQ,Abnormal Bleeding,,0
PRISTIQ,Abnormal Bleeding,Pressure see Warnings,0
PRISTIQ,Abnormal Bleeding,Elevated Blood Pressure see Warnings and Precautions,0
PRISTIQ,Angle Closure Glaucoma,see Warnings and Angle Closure Glaucoma see Warnings,1
PRISTIQ,Angle Closure Glaucoma,,0
PRISTIQ,Angle Closure Glaucoma,Warnings and Angle Closure Glaucoma see Warnings,1
PRISTIQ,Angle Closure Glaucoma,Angle Closure,1
PRISTIQ,Mania,Mania Hypomania see,1
PRISTIQ,Mania,Warnings and,0
PRISTIQ,Mania,Mania Hypomania see,1
PRISTIQ,Mania,Mania Hypomania see,1
PRISTIQ,Mania,Mania Hypomania see,1
PRISTIQ,Mania,Warnings and Precautions Activation Mania Hypomania see,1
PRISTIQ,Mania,,0
PRISTIQ,Mania,Mania Hypomania see,1
PRISTIQ,Mania,Mania Hypomania see,1
PRISTIQ,Discontinuation Syndrome,Syndrome see Warnings,1
PRISTIQ,Seizure,,0
PRISTIQ,Seizure,Syndrome see Warnings and Seizure see Warnings,1
PRISTIQ,Seizure,Warnings and,0
PRISTIQ,Seizure,,0
PRISTIQ,Seizure,Syndrome see Warnings and Seizure see Warnings,1
PRISTIQ,Seizure,Seizure see Warnings,1
PRISTIQ,Seizure,and Seizure see Warnings,1
PRISTIQ,Seizure,Precautions,0
PRISTIQ,Seizure,Seizure see Warnings,1
PRISTIQ,Seizure,Seizure see Warnings,1
PRISTIQ,Hyponatremia,Disease and,0
PRISTIQ,Hyponatremia,Warnings and Hyponatremia see Warnings,1
PRISTIQ,Hyponatremia,and Hyponatremia see Warnings,1
PRISTIQ,Hyponatremia,Hyponatremia see Warnings,1
PRISTIQ,Hyponatremia,Hyponatremia see Warnings,1
PRISTIQ,Hyponatremia,Hyponatremia see Warnings,1
PRISTIQ,Hyponatremia,,0
PRISTIQ,Hyponatremia,and,0
PRISTIQ,Hyponatremia,,0
PRISTIQ,Hyponatremia,Hyponatremia see Warnings,1
PRISTIQ,Eosinophilic Pneumonia,Interstitial Lung Disease Eosinophilic Pneumonia see Warnings,1
PRISTIQ,Eosinophilic Pneumonia,Eosinophilic Pneumonia see Warnings,1
PRISTIQ,Eosinophilic Pneumonia,Eosinophilic Pneumonia see Warnings,1
PRISTIQ,Eosinophilic Pneumonia,Eosinophilic Pneumonia see Warnings,1
PRISTIQ,Eosinophilic Pneumonia,,0
PRISTIQ,Eosinophilic Pneumonia,Interstitial Lung Disease Eosinophilic,1
PRISTIQ,Eosinophilic Pneumonia,see Warnings and Precautions Interstitial,0
PRISTIQ,nausea,nausea dizziness insomnia,1
PRISTIQ,nausea,nausea dizziness insomnia,1
PRISTIQ,nausea,nausea dizziness insomnia,1
PRISTIQ,nausea,groups nausea dizziness insomnia,1
PRISTIQ,nausea,dizziness insomnia hyperhidrosis constipation somnolence decreased appetite anxiety and spe,0
PRISTIQ,dizziness,dizziness insomnia hyperhidrosis,1
PRISTIQ,dizziness,dose groups were dizziness insomnia hyperhidrosis,1
PRISTIQ,insomnia,insomnia hyperhidrosis constipation,1
PRISTIQ,insomnia,,0
PRISTIQ,insomnia,insomnia hyperhidrosis constipation,1
PRISTIQ,insomnia,insomnia hyperhidrosis constipation,1
PRISTIQ,insomnia,,0
PRISTIQ,insomnia,the rate of placebo in the or,0
PRISTIQ,insomnia,groups were nausea insomnia hyperhidrosis constipation,1
PRISTIQ,hyperhidrosis,and specific,0
PRISTIQ,hyperhidrosis,specific male sexual function disorders,0
PRISTIQ,hyperhidrosis,or mg dose,0
PRISTIQ,hyperhidrosis,constipation somnolence decreased appetite anxiety and,0
PRISTIQ,hyperhidrosis,groups were nausea dizziness hyperhidrosis constipation somnolence,1
PRISTIQ,hyperhidrosis,hyperhidrosis constipation somnolence,1
PRISTIQ,hyperhidrosis,were nausea dizziness hyperhidrosis constipation somnolence,1
PRISTIQ,constipation,,0
PRISTIQ,constipation,constipation somnolence decreased,1
PRISTIQ,constipation,constipation somnolence decreased,1
PRISTIQ,constipation,function disorders,0
PRISTIQ,constipation,were,0
PRISTIQ,constipation,and specific male sexual,0
PRISTIQ,constipation,nausea dizziness insomnia,0
PRISTIQ,constipation,constipation somnolence decreased,1
PRISTIQ,constipation,constipation somnolence decreased,1
PRISTIQ,somnolence,insomnia hyperhidrosis somnolence decreased appetite,1
PRISTIQ,somnolence,somnolence decreased appetite,1
PRISTIQ,somnolence,nausea dizziness insomnia hyperhidrosis somnolence decreased appetite,1
PRISTIQ,somnolence,somnolence decreased appetite,1
PRISTIQ,somnolence,somnolence decreased appetite,1
PRISTIQ,somnolence,insomnia hyperhidrosis,0
PRISTIQ,somnolence,hyperhidrosis somnolence decreased appetite,1
PRISTIQ,somnolence,somnolence decreased appetite,1
PRISTIQ,decreased appetite,,0
PRISTIQ,decreased appetite,decreased,1
PRISTIQ,anxiety,constipation somnolence decreased anxiety and specific,1
PRISTIQ,anxiety,male sexual function,0
PRISTIQ,anxiety,anxiety and specific,1
PRISTIQ,anxiety,To report,0
PRISTIQ,anxiety,,0
PRISTIQ,anxiety,anxiety and specific,1
PRISTIQ,anxiety,anxiety and specific,1
PRISTIQ,anxiety,were nausea dizziness,0
PRISTIQ,anxiety,constipation somnolence decreased,0
PRISTIQ,male sexual function disorders,decreased appetite anxiety and male sexual function disorders To report,1
PRISTIQ,male sexual function disorders,male sexual function,1
PRISTIQ,male sexual function disorders,hyperhidrosis constipation somnolence decreased appetite,0
PRISTIQ,male sexual function disorders,and male sexual function disorders To report,1
PRISTIQ,male sexual function disorders,report SUSPECTED,0
PRISTIQ,male sexual function disorders,sexual function disorders To report,1
PRISTIQ,male sexual function disorders,specific,0
PRISTIQ,male sexual function disorders,male sexual function,1
PRISTIQ,male sexual function disorders,decreased appetite anxiety and,0
PRISTIQ,male sexual function disorders,To report,0
PRISTIQ,nausea,up to weeks nausea dizziness headache,1
PRISTIQ,nausea,nausea dizziness headache,1
PRISTIQ,nausea,nausea dizziness headache,1
PRISTIQ,nausea,,0
PRISTIQ,nausea,a longerterm study up to months,0
PRISTIQ,nausea,placebo of the PRISTIQ treated patients in the shortterm studies up to weeks were,0
PRISTIQ,nausea,placebo of the PRISTIQ treated patients in the shortterm studies up,0
PRISTIQ,dizziness,longerterm study up to months the most common,0
PRISTIQ,dizziness,dizziness headache and,1
PRISTIQ,dizziness,dizziness headache and,1
PRISTIQ,dizziness,dizziness headache and,1
PRISTIQ,dizziness,each In a longerterm study up to months the most common,0
PRISTIQ,dizziness,dizziness headache and,1
PRISTIQ,headache,headache and vomiting,1
PRISTIQ,headache,the most,0
PRISTIQ,headache,to,0
PRISTIQ,headache,were nausea headache and vomiting,1
PRISTIQ,headache,headache and vomiting,1
PRISTIQ,headache,headache and vomiting,1
PRISTIQ,headache,vomiting each In a longerterm study up to months the most common was vomiting,0
PRISTIQ,headache,was vomiting,0
PRISTIQ,headache,studies,0
PRISTIQ,vomiting,was vomiting Commo,0
PRISTIQ,vomiting,headache vomiting each In,1
PRISTIQ,vomiting,,0
PRISTIQ,vomiting,vomiting each In,1
PRISTIQ,vomiting,dizziness headache vomiting each In,1
PRISTIQ,vomiting,the most common was vomiting Commo,0
PRISTIQ,vomiting,vomiting each In,1
PRISTIQ,vomiting,studies up to weeks were nausea dizziness headache,0
PRISTIQ,vomiting,headache and vomiting each In a longerterm study up to,0
PRISTIQ,vomiting,vomiting Common adverse,1
PRISTIQ,vomiting,common was,0
PRISTIQ,vomiting,vomiting Common adverse,1
PRISTIQ,vomiting,headache and vomiting each In a longerterm,0
PRISTIQ,vomiting,adverse reactions in placebocontrolled MDD studies The,0
PRISTIQ,nausea,were,0
PRISTIQ,nausea,least twice the rate,0
PRISTIQ,nausea,,0
PRISTIQ,dizziness,dizziness insomnia hyperhidrosis,1
PRISTIQ,dizziness,mg dose groups,0
PRISTIQ,dizziness,groups were nausea,0
PRISTIQ,dizziness,dizziness insomnia hyperhidrosis,1
PRISTIQ,dizziness,dizziness insomnia hyperhidrosis,1
PRISTIQ,dizziness,placebo in the or mg,0
PRISTIQ,dizziness,dizziness insomnia hyperhidrosis,1
PRISTIQ,dizziness,,0
PRISTIQ,dizziness,dizziness insomnia hyperhidrosis,1
PRISTIQ,dizziness,,0
PRISTIQ,hyperhidrosis,specific,0
PRISTIQ,hyperhidrosis,or mg dose groups,0
PRISTIQ,hyperhidrosis,function disorders,0
PRISTIQ,hyperhidrosis,disorders,0
PRISTIQ,hyperhidrosis,of placebo,0
PRISTIQ,hyperhidrosis,male,0
PRISTIQ,hyperhidrosis,,0
PRISTIQ,hyperhidrosis,specific male,0
PRISTIQ,hyperhidrosis,groups were nausea dizziness hyperhidrosis constipation somnolence,1
PRISTIQ,constipation,constipation somnolence decreased,1
PRISTIQ,constipation,constipation somnolence decreased,1
PRISTIQ,constipation,constipation somnolence decreased,1
PRISTIQ,constipation,,0
PRISTIQ,constipation,sexual function disorders,0
PRISTIQ,constipation,were nausea dizziness insomnia constipation somnolence decreased,1
PRISTIQ,constipation,constipation somnolence decreased,1
PRISTIQ,constipation,constipation somnolence decreased,1
PRISTIQ,constipation,constipation somnolence decreased,1
PRISTIQ,constipation,the or mg dose groups were,0
PRISTIQ,somnolence,,0
PRISTIQ,decreased appetite,insomnia,0
PRISTIQ,decreased appetite,insomnia hyperhidrosis constipation decreased,1
PRISTIQ,decreased appetite,,0
PRISTIQ,decreased appetite,insomnia hyperhidrosis,0
PRISTIQ,decreased appetite,hyperhidrosis constipation decreased appetite anxiety and,1
PRISTIQ,anxiety,decreased appetite,0
PRISTIQ,anxiety,,0
PRISTIQ,anxiety,nausea dizziness insomnia hyperhidrosis constipation,0
PRISTIQ,anxiety,anxiety and specific,1
PRISTIQ,anxiety,appetite,0
PRISTIQ,anxiety,anxiety and specific,1
PRISTIQ,anxiety,anxiety and specific,1
PRISTIQ,anxiety,Table shows,0
PRISTIQ,anxiety,decreased anxiety and specific,1
PRISTIQ,anxiety,disorders Table shows,0
PRISTIQ,male sexual function disorders,decreased appetite anxiety and male,1
PRISTIQ,male sexual function disorders,that,0
PRISTIQ,male sexual function disorders,and male sexual function,1
PRISTIQ,male sexual function disorders,and male,1
PRISTIQ,male sexual function disorders,,0
PRISTIQ,male sexual function disorders,specific,0
PRISTIQ,male sexual function disorders,anxiety and male sexual function,1
PRISTIQ,Blood pressure increased,,0
PRISTIQ,Blood pressure increased,disorders,0
PRISTIQ,Blood pressure increased,Cardiac disorders,0
PRISTIQ,Blood pressure increased,Cardiac Blood pressure increased Gastroin,1
PRISTIQ,Blood pressure increased,,0
PRISTIQ,Blood pressure increased,pressure increased Gastroin,1
PRISTIQ,Blood pressure increased,n,0
PRISTIQ,Blood pressure increased,,0
PRISTIQ,Blood pressure increased,,0
PRISTIQ,Nausea,disorders,0
PRISTIQ,Nausea,,0
PRISTIQ,Nausea,Nausea,1
PRISTIQ,Nausea,,0
PRISTIQ,Nausea,Nausea,1
PRISTIQ,Nausea,,0
PRISTIQ,Nausea,,0
PRISTIQ,Nausea,Nausea,1
PRISTIQ,Nausea,Nausea,1
PRISTIQ,Dry mouth,Dry mouth,1
PRISTIQ,Dry mouth,Dry,1
PRISTIQ,Dry mouth,mouth,1
PRISTIQ,Dry mouth,mouth,1
PRISTIQ,Dry mouth,mouth,1
PRISTIQ,Dry mouth,mouth,1
PRISTIQ,Dry mouth,,0
PRISTIQ,Dry mouth,mouth,1
PRISTIQ,Dry mouth,Dry mouth,1
PRISTIQ,Constipation,,0
PRISTIQ,Constipation,Constipation,1
PRISTIQ,Constipation,,0
PRISTIQ,Constipation,Constipation,1
PRISTIQ,Constipation,,0
PRISTIQ,Constipation,Constipation,1
PRISTIQ,Constipation,,0
PRISTIQ,Vomiting,,0
PRISTIQ,Vomiting,,0
PRISTIQ,Vomiting,,0
PRISTIQ,Vomiting,,0
PRISTIQ,Fatigue,,0
PRISTIQ,Fatigue,administration site Fatigue,1
PRISTIQ,Fatigue,administration site conditions,0
PRISTIQ,Fatigue,,0
PRISTIQ,Fatigue,,0
PRISTIQ,Fatigue,administration site Fatigue,1
PRISTIQ,Fatigue,,0
PRISTIQ,Chills,,0
PRISTIQ,Chills,Chills,1
PRISTIQ,Chills,Chills,1
PRISTIQ,Chills,,0
PRISTIQ,Chills,Chills,1
PRISTIQ,Chills,Chills,1
PRISTIQ,Chills,,0
PRISTIQ,Chills,,0
PRISTIQ,Chills,,0
PRISTIQ,Feeling jittery,,0
PRISTIQ,Feeling jittery,Feeling,1
PRISTIQ,Feeling jittery,,0
PRISTIQ,Feeling jittery,Feeling,1
PRISTIQ,Decreased appetite,,0
PRISTIQ,Decreased appetite,Decreased appetite Nervo,1
PRISTIQ,Decreased appetite,Decreased appetite Nervo,1
PRISTIQ,Dizziness,,0
PRISTIQ,Dizziness,,0
PRISTIQ,Dizziness,Dizziness,1
PRISTIQ,Dizziness,,0
PRISTIQ,Dizziness,Dizziness,1
PRISTIQ,Dizziness,system disorders,0
PRISTIQ,Dizziness,,0
PRISTIQ,Dizziness,Dizziness,1
PRISTIQ,Somnolence,Somnolence,1
PRISTIQ,Tremor,Tremor,1
PRISTIQ,Tremor,,0
PRISTIQ,Tremor,Tremor,1
PRISTIQ,Tremor,Tremor,1
PRISTIQ,Tremor,,0
PRISTIQ,Tremor,Tremor,1
PRISTIQ,Disturbance in attention,Disturbance,1
PRISTIQ,Disturbance in attention,Disturbance in attention Psychiat,1
PRISTIQ,Disturbance in attention,,0
PRISTIQ,Disturbance in attention,,0
PRISTIQ,Disturbance in attention,in attention Psychiat,1
PRISTIQ,Disturbance in attention,Disturbance,1
PRISTIQ,Disturbance in attention,in attention Psychiat,1
PRISTIQ,Disturbance in attention,,0
PRISTIQ,Disturbance in attention,Disturbance in attention Psychiat,1
PRISTIQ,Insomnia,,0
PRISTIQ,Anxiety,,0
PRISTIQ,Anxiety,Anxiety,1
PRISTIQ,Anxiety,,0
PRISTIQ,Anxiety,Anxiety,1
PRISTIQ,Anxiety,,0
PRISTIQ,Anxiety,Anxiety,1
PRISTIQ,Anxiety,Anxiety,1
PRISTIQ,Anxiety,Anxiety,1
PRISTIQ,Anxiety,Anxiety,1
PRISTIQ,Anxiety,,0
PRISTIQ,Nervousness,Nervousness,1
PRISTIQ,Abnormal dreams,,0
PRISTIQ,Abnormal dreams,Re,0
PRISTIQ,Abnormal dreams,,0
PRISTIQ,Abnormal dreams,Abnormal,1
PRISTIQ,Abnormal dreams,,0
PRISTIQ,Abnormal dreams,Abnormal dreams Re,1
PRISTIQ,Abnormal dreams,,0
PRISTIQ,Abnormal dreams,Re,0
PRISTIQ,Urinary hesitation,Renal and urinary Urinary,1
PRISTIQ,Yawning,Yawning,1
PRISTIQ,Yawning,Yawning,1
PRISTIQ,Yawning,Yawning,1
PRISTIQ,Yawning,Yawning,1
PRISTIQ,Yawning,,0
PRISTIQ,Yawning,thoracic and mediastinal,0
PRISTIQ,Yawning,and mediastinal disorders,0
PRISTIQ,Hyperhidrosis,Hyperhidrosis,1
PRISTIQ,Hyperhidrosis,and subcutaneous tissue Hyperhidrosis,1
PRISTIQ,Hyperhidrosis,Hyperhidrosis,1
PRISTIQ,Hyperhidrosis,Hyperhidrosis,1
PRISTIQ,Hyperhidrosis,,0
PRISTIQ,Hyperhidrosis,tissue,0
PRISTIQ,Hyperhidrosis,Hyperhidrosis,1
PRISTIQ,Hyperhidrosis,,0
PRISTIQ,Hyperhidrosis,and,0
PRISTIQ,Hyperhidrosis,tissue,0
PRISTIQ,Vision blurred,Senses,0
PRISTIQ,Vision blurred,,0
PRISTIQ,Vision blurred,Senses,0
PRISTIQ,Vision blurred,Vision blurred,1
PRISTIQ,Vision blurred,,0
PRISTIQ,Vision blurred,,0
PRISTIQ,Vision blurred,Senses,0
PRISTIQ,Vision blurred,,0
PRISTIQ,Mydriasis,Mydriasis,1
PRISTIQ,Mydriasis,,0
PRISTIQ,Vertigo,,0
PRISTIQ,Vertigo,,0
PRISTIQ,Vertigo,Vertigo,1
PRISTIQ,Vertigo,,0
PRISTIQ,Vertigo,,0
PRISTIQ,Tinnitus,,0
PRISTIQ,Tinnitus,,0
PRISTIQ,Dysgeusia,Dysgeusia,1
PRISTIQ,Hot flush,flush,1
PRISTIQ,Hot flush,Vascular Hot,1
PRISTIQ,Hot flush,,0
PRISTIQ,Hot flush,,0
PRISTIQ,Hot flush,Vascular Hot flush,1
PRISTIQ,Hot flush,Vascular Hot flush,1
PRISTIQ,Hot flush,Hot flush,1
PRISTIQ,Hot flush,,0
PRISTIQ,Hot flush,,0
PRISTIQ,Hot flush,disorders,0
PRISTIQ,sexual function adverse reactions,Table shows the incidence sexual function adverse reactions,1
PRISTIQ,sexual function adverse reactions,of,0
PRISTIQ,sexual function adverse reactions,that occurred in of PRISTIQ treated,0
PRISTIQ,sexual function adverse reactions,shows the incidence sexual function adverse,1
PRISTIQ,sexual function adverse reactions,incidence sexual function,1
PRISTIQ,sexual function adverse reactions,reactions,1
PRISTIQ,sexual function adverse reactions,Table shows the incidence sexual function adverse reactions,1
PRISTIQ,sexual function adverse reactions,Table shows,0
PRISTIQ,sexual function adverse reactions,that occurred in of PRISTIQ treated,0
PRISTIQ,Sexual Function Adverse Reactions,clinical,0
PRISTIQ,Sexual Function Adverse Reactions,placebocontrolled,0
PRISTIQ,Sexual Function Adverse Reactions,,0
PRISTIQ,Sexual Function Adverse Reactions,Women in any,0
PRISTIQ,Sexual Function Adverse Reactions,Sexual Function,1
PRISTIQ,Sexual Function Adverse Reactions,clinical studies Sexual Function Adverse Reactions,1
PRISTIQ,Sexual Function Adverse Reactions,Sexual Function Adverse Reactions,1
PRISTIQ,Sexual Function Adverse Reactions,dose clinical studies Table,0
PRISTIQ,Libido decreased,,0
PRISTIQ,Libido decreased,,0
PRISTIQ,Libido decreased,,0
PRISTIQ,Libido decreased,,0
PRISTIQ,Libido decreased,Libido decreased O,1
PRISTIQ,Libido decreased,O,0
PRISTIQ,Libido decreased,decreased O,1
PRISTIQ,Orgasm abnormal,,0
PRISTIQ,Orgasm abnormal,,0
PRISTIQ,Orgasm abnormal,,0
PRISTIQ,Orgasm abnormal,,0
PRISTIQ,Ejaculation delayed,,0
PRISTIQ,Ejaculation delayed,Ejaculation delayed E,1
PRISTIQ,Ejaculation delayed,,0
PRISTIQ,Ejaculation delayed,,0
PRISTIQ,Ejaculation delayed,E,0
PRISTIQ,Erectile dysfunction,,0
PRISTIQ,Erectile dysfunction,d,0
PRISTIQ,Erectile dysfunction,dysfunction E,1
PRISTIQ,Erectile dysfunction,d,0
PRISTIQ,Erectile dysfunction,d Erectile dysfunction E,1
PRISTIQ,Erectile dysfunction,,0
PRISTIQ,Erectile dysfunction,,0
PRISTIQ,Erectile dysfunction,dysfunction E,1
PRISTIQ,Erectile dysfunction,,0
PRISTIQ,Erectile dysfunction,d Erectile dysfunction E,1
PRISTIQ,Ejaculation disorder,,0
PRISTIQ,Ejaculation disorder,n Ejaculation,1
PRISTIQ,Ejaculation disorder,n Ejaculation disorder E,1
PRISTIQ,Ejaculation disorder,n,0
PRISTIQ,Ejaculation disorder,n Ejaculation,1
PRISTIQ,Ejaculation disorder,disorder E,1
PRISTIQ,Sexual dysfunction,e Sexual,1
PRISTIQ,Sexual dysfunction,e Sexual dysfunction,1
PRISTIQ,Sexual dysfunction,Sexual dysfunction,1
PRISTIQ,Sexual dysfunction,e,0
PRISTIQ,Sexual dysfunction,e,0
PRISTIQ,Sexual dysfunction,,0
PRISTIQ,Sexual dysfunction,e,0
PRISTIQ,Sexual dysfunction,,0
PRISTIQ,Sexual dysfunction,e,0
PRISTIQ,Sexual dysfunction,e Sexual,1
PRISTIQ,Anorgasmia,Anorgasmia,1
PRISTIQ,Anorgasmia,Women only,0
PRISTIQ,Anorgasmia,,0
PRISTIQ,Anorgasmia,Women Anorgasmia,1
PRISTIQ,Anorgasmia,Women Anorgasmia,1
PRISTIQ,Anorgasmia,only,0
PRISTIQ,Anorgasmia,mgn Women Anorgasmia,1
PRISTIQ,Anorgasmia,,0
PRISTIQ,Anorgasmia,Anorgasmia,1
PRISTIQ,Tachycardia,Tachycardia,1
PRISTIQ,Tachycardia,,0
PRISTIQ,Asthenia,Weight,0
PRISTIQ,Asthenia,,0
PRISTIQ,Asthenia,,0
PRISTIQ,Asthenia,Asthenia,1
PRISTIQ,Asthenia,General,0
PRISTIQ,Asthenia,conditions,0
PRISTIQ,Asthenia,Asthenia,1
PRISTIQ,liver function test abnormal,Investigations Weight liver function test,1
PRISTIQ,liver function test abnormal,liver function test abnormal,1
PRISTIQ,liver function test abnormal,and administration site,0
PRISTIQ,liver function test abnormal,and connective tissue,0
PRISTIQ,liver function test abnormal,abnormal,1
PRISTIQ,liver function test abnormal,Weight liver function test abnormal,1
PRISTIQ,liver function test abnormal,site,0
PRISTIQ,blood prolactin increased,increased liver function test blood prolactin,1
PRISTIQ,blood prolactin increased,and connective tissue disorders,0
PRISTIQ,blood prolactin increased,test blood prolactin,1
PRISTIQ,blood prolactin increased,Investigations Weight increased,0
PRISTIQ,blood prolactin increased,and connective tissue,0
PRISTIQ,blood prolactin increased,increased liver function test blood prolactin increased,1
PRISTIQ,blood prolactin increased,,0
PRISTIQ,Musculoskeletal stiffness,,0
PRISTIQ,Musculoskeletal stiffness,Musculoskeletal,1
PRISTIQ,Musculoskeletal stiffness,connective tissue disorders,0
PRISTIQ,Syncope,Syncope,1
PRISTIQ,Syncope,Syncope,1
PRISTIQ,convulsion,,0
PRISTIQ,dystonia,dystonia,1
PRISTIQ,dystonia,Syncope convulsion,0
PRISTIQ,dystonia,Nervous system disorders,0
PRISTIQ,dystonia,Musculoskeletal stiffness,0
PRISTIQ,dystonia,disorders Syncope dystonia,1
PRISTIQ,dystonia,,0
PRISTIQ,Depersonalization,Renal and urinary disorders Urinary retention Skin and subcutaneous,0
PRISTIQ,Depersonalization,Depersonalization,1
PRISTIQ,Depersonalization,Depersonalization,1
PRISTIQ,Depersonalization,Depersonalization,1
PRISTIQ,bruxism,,0
PRISTIQ,bruxism,Syncope convulsion,0
PRISTIQ,bruxism,bruxism,1
PRISTIQ,bruxism,disorders bruxism,1
PRISTIQ,bruxism,Urinary retention Skin and subcutaneous tissue d,0
PRISTIQ,bruxism,disorders,0
PRISTIQ,bruxism,convulsion,0
PRISTIQ,Urinary retention,bruxism Renal and,0
PRISTIQ,Rash,alopecia photosensitivity reaction angioedema In clinical studies there were uncommon repo,0
PRISTIQ,Rash,there were uncommon repo,0
PRISTIQ,Rash,Urinary retention Skin and subcutaneous tissue disorders,0
PRISTIQ,Rash,and subcutaneous tissue Rash,1
PRISTIQ,Rash,Urinary retention,0
PRISTIQ,Rash,and subcutaneous tissue Rash,1
PRISTIQ,alopecia,and,0
PRISTIQ,alopecia,alopecia,1
PRISTIQ,alopecia,and,0
PRISTIQ,alopecia,alopecia,1
PRISTIQ,alopecia,Skin and subcutaneous tissue disorders,0
PRISTIQ,alopecia,reaction angioedema In clinical studies there,0
PRISTIQ,alopecia,alopecia,1
PRISTIQ,alopecia,disorders alopecia,1
PRISTIQ,photosensitivity,disorders Rash photosensitivity,1
PRISTIQ,photosensitivity,photosensitivity,1
PRISTIQ,photosensitivity,photosensitivity,1
PRISTIQ,photosensitivity,Skin and,0
PRISTIQ,photosensitivity,photosensitivity,1
PRISTIQ,photosensitivity,alopecia,0
PRISTIQ,angioedema,Skin and subcutaneous tissue disorders Rash alopecia photosensitivity reaction,0
PRISTIQ,angioedema,disorders Rash alopecia photosensitivity angioedema,1
PRISTIQ,angioedema,subcutaneous tissue disorders,0
PRISTIQ,ischemic cardiac adverse reactions,ischemic cardiac adverse,1
PRISTIQ,ischemic cardiac adverse reactions,,0
PRISTIQ,ischemic cardiac adverse reactions,reactions,1
PRISTIQ,ischemic cardiac adverse reactions,ischemic,1
PRISTIQ,ischemic cardiac adverse reactions,myocardial,0
PRISTIQ,ischemic cardiac adverse reactions,reports ischemic cardiac adverse reactions,1
PRISTIQ,ischemic cardiac adverse reactions,myocardial ischemia myocardial,0
PRISTIQ,ischemic cardiac adverse reactions,cardiac adverse reactions,1
PRISTIQ,ischemic cardiac adverse reactions,myocardial ischemia myocardial infarction and coronary,0
PRISTIQ,myocardial ischemia,revascularization,0
PRISTIQ,myocardial ischemia,reactions myocardial ischemia,1
PRISTIQ,myocardial infarction,reactions including myocardial myocardial infarction,1
PRISTIQ,myocardial infarction,of ischemic cardiac adverse,0
PRISTIQ,myocardial infarction,adverse reactions including,0
PRISTIQ,myocardial infarction,and coronary occlusion requiring revascularization these patients had multiple underlying,0
PRISTIQ,myocardial infarction,ischemic cardiac adverse reactions,0
PRISTIQ,myocardial infarction,infarction,1
PRISTIQ,myocardial infarction,reactions including myocardial myocardial infarction,1
PRISTIQ,myocardial infarction,were uncommon reports of ischemic cardiac,0
PRISTIQ,coronary occlusion,had multiple underlying cardiac risk factors,0
PRISTIQ,coronary occlusion,,0
PRISTIQ,coronary occlusion,coronary occlusion,1
PRISTIQ,coronary occlusion,ischemia myocardial infarction coronary,1
PRISTIQ,coronary occlusion,underlying cardiac risk,0
PRISTIQ,Elevations in fasting serum total cholesterol,with PRISTIQ Elevations in fasting serum total,1
PRISTIQ,Elevations in fasting serum total cholesterol,serum total cholesterol,1
PRISTIQ,Proteinuria,Proteinuria,0
PRISTIQ,Proteinuria,Proteinuria,1
PRISTIQ,Proteinuria,Proteinuria Proteinuria,1
PRISTIQ,Proteinuria,Proteinuria,0
PRISTIQ,Proteinuria,Proteinuria Proteinuria greater,1
PRISTIQ,Proteinuria,Proteinuria,0
PRISTIQ,Proteinuria,Proteinuria greater than or equal to,1
PRISTIQ,proteinuria,proteinuria was not associated with increases,1
PRISTIQ,proteinuria,,0
PRISTIQ,proteinuria,proteinuria was not associated with increases,1
PRISTIQ,proteinuria,and was generally transient Table,0
PRISTIQ,increases in BUN,not associated increases,1
PRISTIQ,increases in BUN,,0
PRISTIQ,increases in BUN,not associated increases,1
PRISTIQ,increases in BUN,not associated increases,1
PRISTIQ,increases in BUN,,0
PRISTIQ,Proteinuria,Proteinuria in the Fixeddose Clinical Studies,1
PRISTIQ,Proteinuria,Patients Proteinuria in the Fixeddose Clinical Studies,1
PRISTIQ,Proteinuria,Patients Proteinuria in the Fixeddose Clinical Studies,1
PRISTIQ,Proteinuria,Proteinuria in the Fixeddose Clinical Studies,1
PRISTIQ,Proteinuria,,0
PRISTIQ,Proteinuria,Proteinuria in the Fixeddose Clinical Studies,1
PRISTIQ,Proteinuria,Proteinuria in the Fixeddose Clinical Studies,1
PRISTIQ,Proteinuria,Proteinuria,1
PRISTIQ,Proteinuria,,0
PRISTIQ,Proteinuria,Proteinuria,1
PRISTIQ,Proteinuria,Placebo mg mg mg Proteinuria,1
PRISTIQ,Proteinuria,Proteinuria,1
PRISTIQ,Proteinuria,,0
PRISTIQ,Proteinuria,Proteinuria,1
PRISTIQ,hypertension,hypertension defined as treatmentemergent supine diastolic,1
PRISTIQ,hypertension,supine diastolic blood pressure SDBP mm Hg and mm Hg abo,0
PRISTIQ,hypertension,,0
PRISTIQ,hypertension,patients,0
PRISTIQ,hypertension,hypertension revealed a consistent increase in,1
PRISTIQ,hypertension,hypertension revealed a consistent increase in,1
PRISTIQ,hypertension,hypertension revealed a consistent increase in,1
PRISTIQ,hypertension,controlled studies who met,0
PRISTIQ,hypertension,hypertension revealed a consistent increase in,1
PRISTIQ,hypertension,hypertension revealed a consistent increase in,1
PRISTIQ,hypertension,sustained hypertension,0
PRISTIQ,hypertension,,0
PRISTIQ,hypertension,PRISTIQ,0
PRISTIQ,hypertension,hypertension This was seen at all,1
PRISTIQ,hypertension,of patients who,0
PRISTIQ,hypertension,,0
PRISTIQ,hypertension,the,0
PRISTIQ,hypertension,hypertension This was seen at all,1
PRISTIQ,hypertension,at all doses with a,0
PRISTIQ,Elevation of Supine Diastolic Blood Pressure,Table,0
PRISTIQ,Elevation of Supine Diastolic Blood Pressure,Treatment Group Proportion of,0
PRISTIQ,systolic orthostatic hypotension,studies,0
PRISTIQ,systolic orthostatic hypotension,systolic orthostatic hypotension decrease mm Hg from supine,1
PRISTIQ,systolic orthostatic hypotension,hypotension decrease mm Hg from supine,1
PRISTIQ,Stevens-Johnson syndrome,,0
PRISTIQ,Stevens-Johnson syndrome,syndrome,1
PRISTIQ,Stevens-Johnson syndrome,subcutaneous tissue Stevens-Johnson syndrome,1
PRISTIQ,Stevens-Johnson syndrome,a causal relationship to drug exposure Skin and subcutaneous,0
PRISTIQ,Stevens-Johnson syndrome,Skin,0
PRISTIQ,Stevens-Johnson syndrome,,0
PRISTIQ,Stevens-Johnson syndrome,,0
PRISTIQ,SUICIDAL THOUGHTS, following advers e reactions are,1
PRISTIQ,SUICIDAL THOUGHTS,following,1
PRISTIQ,SUICIDAL THOUGHTS,advers e reactions are,1
PRISTIQ,SUICIDAL THOUGHTS,following,1
PRISTIQ,SUICIDAL THOUGHTS,,0
PRISTIQ,SUICIDAL THOUGHTS,,0
PRISTIQ,SUICIDAL THOUGHTS, following advers e reactions,1
PRISTIQ,SUICIDAL THOUGHTS,detail in,0
PRISTIQ,SUICIDAL THOUGHTS,detail in other sections of,1
PRISTIQ,SUICIDAL THOUGHTS,,0
PRISTIQ,SUICIDAL THOUGHTS,in other sections of the,1
PRISTIQ,SUICIDAL THOUGHTS,,0
PRISTIQ,SUICIDAL THOUGHTS,label Hypersensitivity,0
PRISTIQ,SUICIDAL THOUGHTS,greater detail,1
PRISTIQ,SUICIDAL THOUGHTS,greater detail in other sections of,1
PRISTIQ,SUICIDAL THOUGHTS,in other sections of the label,1
PRISTIQ,suicidal thoughts,Hypersensitivity see,0
PRISTIQ,suicidal thoughts,,0
PRISTIQ,suicidal thoughts,  Contraindicatio ns Suicidal Thoughts and Behaviors,1
PRISTIQ,suicidal thoughts,  Contraindicatio ns Suicidal Thoughts and Behaviors,1
PRISTIQ,suicidal thoughts,Adults,0
PRISTIQ,suicidal thoughts,and Precautions tonin Syndrome [s ee Warnings and Precautions Elevated,1
PRISTIQ,suicidal thoughts,and Precautions tonin Syndrome [s ee Warnings and Precautions Elevated,1
PRISTIQ,suicidal thoughts,tonin,1
PRISTIQ,suicidal thoughts,tonin Syndrome [s ee Warnings and Precautions Elevated,1
PRISTIQ,suicidal thoughts,,0
PRISTIQ,suicidal thoughts,tonin Syndrome,1
PRISTIQ,suicidal thoughts,Warnings and Precautions tonin Syndrome [s ee Warnings and Precautions Elevated,1
PRISTIQ,suicidal thoughts,in Adolescents and Young Adults see Warnings and Precautions Sero,0
PRISTIQ,suicidal thoughts,tonin Syndrome [s ee Warnings and Precautions Elevated,1
PRISTIQ,SUICIDAL THOUGHTS,and Precautions EXCERPT Most ommon adverse rea ctions incidence and twice the,1
PRISTIQ,SUICIDAL THOUGHTS,Precautions EXCERPT Most ommon adverse rea ctions incidence and twice the,1
PRISTIQ,suicidal thinking,"somnia, hyperhidr osis constipation somnolence decreased appetite",1
PRISTIQ,suicidal thinking,hyperhidr osis constipation somnolence decreased appetite,1
PRISTIQ,suicidal thinking,"nausea dizziness somnia,",1
PRISTIQ,suicidal thinking,"dizziness somnia, hyperhidr osis constipation somnolence decreased appetite",1
PRISTIQ,suicidal thinking,male sexual,0
PRISTIQ,suicidal thinking,osis constipation somnolence decreased appetite anxiety and,0
PRISTIQ,suicidal thinking,and specific,0
PRISTIQ,suicidal thinking,"somnia, hyperhidr osis constipation somnolence decreased appetite",1
PRISTIQ,Clinical Worsening,discussed in greater,1
PRISTIQ,Clinical Worsening,ons are discussed  in greater,1
PRISTIQ,Clinical Worsening,ons are discussed  in greater,1
PRISTIQ,Clinical Worsening,ons are,1
PRISTIQ,Clinical Worsening,are discussed in greater detail in,1
PRISTIQ,Clinical Worsening,ons are discussed ,1
PRISTIQ,Suicide Risk,n greater de tail in,1
PRISTIQ,Serotonin Syndrome,Behaviors in Adolescents and Young Adults see Warnings,0
PRISTIQ,Serotonin Syndrome,are discussed in,0
PRISTIQ,Serotonin syndrome,in Adolescents and Young Adults see,0
PRISTIQ,Serotonin syndrome,) ],1
PRISTIQ,Elevated Blood Pressure,Warnings and Precautions,0
PRISTIQ,Elevated Blood Pressure,and Precautions [see  Warnings and Prec autions Interstitial,1
PRISTIQ,Elevated Blood Pressure,Precautions [see  Warnings and Prec autions Interstitial,1
PRISTIQ,Elevated Blood Pressure,Interstitial Lung Disease and Eosinophilic Pneumonia,0
PRISTIQ,Elevated Blood Pressure,see,0
PRISTIQ,Elevated Blood Pressure,Disease and Eosinophilic Pneumonia see Warnings,0
PRISTIQ,Elevated Blood Pressure,Warnings and Precautions [see Warnings,1
PRISTIQ,Elevated Blood Pressure,[see  Warnings and Prec autions Interstitial,1
PRISTIQ,Abnormal Bleeding,      EXCERPT:    Most common,1
PRISTIQ,Abnormal Bleeding,see,0
PRISTIQ,Abnormal Bleeding,Warnings and,0
PRISTIQ,Abnormal Bleeding,Eosinophilic Pneumonia see,0
PRISTIQ,Abnormal Bleeding,      EXCERPT:    Most common,1
PRISTIQ,Abnormal Bleeding,see Warnings,0
PRISTIQ,Abnormal Bleeding,Eosinophilic Pneumonia see Warnings and,0
PRISTIQ,Angle closure glaucoma,and specific male xual function disorder s To,1
PRISTIQ,Angle closure glaucoma,and specific male xual,1
PRISTIQ,Angle closure glaucoma,report SUSPECTED ADVERSE REACTIONS,0
PRISTIQ,Activation of Mania,"Inc a subsidiary of Inc., at",1
PRISTIQ,Activation of Mania,,0
PRISTIQ,Activation of Mania,at 1-800-438 or FDA,1
PRISTIQ,Activation of Mania,,0
PRISTIQ,Activation of Mania,SUSPECTED ADVERSE REACTIONS contact,0
PRISTIQ,Activation of Mania,1-800-438 or FDA,1
PRISTIQ,Discontinuation Syndrome,clinical trials,0
PRISTIQ,Discontinuation Syndrome,Studies Experience Because clinical trials,0
PRISTIQ,Discontinuation Syndrome,conducted unde,0
PRISTIQ,Discontinuation Syndrome,directly compared,0
PRISTIQ,Discontinuation Syndrome,r widely varying conditi ons adverse,1
PRISTIQ,Discontinuation Syndrome,compared,0
PRISTIQ,Discontinuation Syndrome,are conducted r widely varying,1
PRISTIQ,Seizure,rates observed in the clinical trials of a drug cannot,0
PRISTIQ,Seizure,the clinical trials of a drug cannot be directl,0
PRISTIQ,Seizure,be y,1
PRISTIQ,Seizure,red to rates in the clinical studies of another drug and,0
PRISTIQ,Seizure,y compa red to,1
PRISTIQ,Hyponatremia,the s observed,1
PRISTIQ,Hyponatremia,reflect the s observed,1
PRISTIQ,Hyponatremia,,0
PRISTIQ,Hyponatremia,may not reflect the s observed,1
PRISTIQ,Hyponatremia,,0
PRISTIQ,Hyponatremia,the s,1
PRISTIQ,Interstitial Lung Disease,with major depressive disorder who participated in multipledose pre,0
PRISTIQ,Eosinophilic Pneumonia,safety in,0
PRISTIQ,Eosinophilic Pneumonia,"safety 8,394",1
PRISTIQ,worsening of depression,placebo-treated patient s At,1
PRISTIQ,worsening of depression,patient s At,1
PRISTIQ,worsening of depression,adverse reaction compared with,0
PRISTIQ,worsening of depression,mg,0
PRISTIQ,worsening of depression,reaction compared with of placebo-treated patient s At,1
PRISTIQ,worsening of depression,mg the discontinuation rate due,0
PRISTIQ,worsening of depression,recommended dose of mg the,0
PRISTIQ,suicidality,At the dose of 50  mg the,1
PRISTIQ,suicidal thinking,"s 8.7%.



 The m ost common",1
PRISTIQ,suicidal thinking,,0
PRISTIQ,suicidal thinking,8.7%. The m ost common,1
PRISTIQ,suicidal thinking,m ost common,1
PRISTIQ,suicidality,discontinuation rate due to an adverse reaction,0
PRISTIQ,suicidality,adve,0
PRISTIQ,suicidality,shortterm studies,0
PRISTIQ,suicidality,were nausea dizziness he and vomi ting each,1
PRISTIQ,suicidality,were nausea dizziness he,1
PRISTIQ,suicidality,Common Adverse in,1
PRISTIQ,suicidality,clinical studies Table Common Adverse Reactions,0
PRISTIQ,suicidality,Twice the Rate of Placebo in Premarketing Pooled MDD Week PlaceboControlled S,0
PRISTIQ,suicidality,Common Adverse Reactions,0
PRISTIQ,suicidality,Fix edDose Group,1
PRISTIQ,suicidality,any Fix edDose Group,1
PRISTIQ,suicidality,Table Common Adverse  in any Fix edDose Group,1
PRISTIQ,suicidality,studies Table Common Adverse in any,1
PRISTIQ,suicidality,placebocontrolled fixed dose clinical studies Table Common,0
PRISTIQ,suicidality,Term Placebo,0
PRISTIQ,suicidality,Term Placebo n mg n mg n mg,0
PRISTIQ,suicidality,PRISTIQ Organ Class Preferred Term,1
PRISTIQ,suicidality,Reaction PRISTIQ Organ Class Preferred Term,1
PRISTIQ,Suicidality,mg n mg,0
PRISTIQ,suicides,site conditions Fatigue,1
PRISTIQ,suicides,site conditions Fatigue,1
PRISTIQ,suicides,on,1
PRISTIQ,suicides,on,1
PRISTIQ,suicides,Fatigue,0
PRISTIQ,suicides,,0
PRISTIQ,suicides,on site conditions Fatigue,1
PRISTIQ,suicides,on site conditions Fatigue,1
PRISTIQ,suicidality,,0
PRISTIQ,suicidality,Chills             Fee,1
PRISTIQ,suicidality,            Fee,1
PRISTIQ,suicidality,            Fee,1
PRISTIQ,suicidality,Chills             Fee,1
PRISTIQ,suicidality,            Fee,1
PRISTIQ,suicidality,            Fee,1
PRISTIQ,suicidality,            Fee,1
PRISTIQ,anxiety,Somnolence       1 Tremor,1
PRISTIQ,anxiety,,0
PRISTIQ,anxiety,Somnolence,0
PRISTIQ,agitation,Somnolence           Tremor,1
PRISTIQ,agitation,          Tremor,1
PRISTIQ,agitation,Somnolence,0
PRISTIQ,agitation,Somnolence,0
PRISTIQ,agitation,Somnolence,0
PRISTIQ,panic attacks,"   
    Tremo r",1
PRISTIQ,panic attacks,"   
    Tremo r",1
PRISTIQ,panic attacks,"   
    Tremo r",1
PRISTIQ,panic attacks,,0
PRISTIQ,panic attacks,,0
PRISTIQ,insomnia,        ,1
PRISTIQ,insomnia,        ,1
PRISTIQ,irritability,Tremor         2    Disturbance in,1
PRISTIQ,irritability,Tremor         2    Disturbance,1
PRISTIQ,hostility,Tremor,0
PRISTIQ,hostility,in,0
PRISTIQ,hostility,Tremor,0
PRISTIQ,hostility,Tremor           Disturbance,1
PRISTIQ,hostility,         ,1
PRISTIQ,hostility,,0
PRISTIQ,hostility,Tremor           Disturbance,1
PRISTIQ,hostility,,0
PRISTIQ,hostility,Tremor,0
PRISTIQ,hostility,          Disturbance in attention,1
PRISTIQ,impulsivity,Tremor  3          Disturbance in attention,1
PRISTIQ,impulsivity,Tremor  3          Disturbance,1
PRISTIQ,impulsivity, 3          Disturbance in attention,1
PRISTIQ,impulsivity,Tremor,0
PRISTIQ,akathisia,Tremor,0
PRISTIQ,akathisia,,0
PRISTIQ,akathisia,     9    Disturbance,1
PRISTIQ,akathisia,Tremor,0
PRISTIQ,akathisia,Tremor,0
PRISTIQ,akathisia,Tremor,0
PRISTIQ,akathisia,Tremor,0
PRISTIQ,akathisia,Tremor,0
PRISTIQ,psychomotor restlessness,,0
PRISTIQ,psychomotor restlessness,           9            ,1
PRISTIQ,psychomotor restlessness,,0
PRISTIQ,psychomotor restlessness,           9             Disturbance in attention,1
PRISTIQ,psychomotor restlessness,Tremor            9             Disturbance,1
PRISTIQ,hypomania,turbance,0
PRISTIQ,hypomania,attention,0
PRISTIQ,hypomania,,0
PRISTIQ,hypomania," 
    Dis",1
PRISTIQ,hypomania,,0
PRISTIQ,hypomania,,0
PRISTIQ,hypomania,,0
PRISTIQ,mania,Disturban,0
PRISTIQ,mania,,0
PRISTIQ,mania,Disturban,0
PRISTIQ,mania,Disturban ce,1
PRISTIQ,mania,Disturban,0
PRISTIQ,mania,Disturban,0
PRISTIQ,mania,Disturban ce in attention,1
PRISTIQ,mania,,0
PRISTIQ,worsening of depression,        2               Nervousness,1
PRISTIQ,worsening of depression,        2               Nervousness,1
PRISTIQ,worsening of depression,Anxiety         2               Nervousness,1
PRISTIQ,worsening of depression,Anxiety,0
PRISTIQ,worsening of depression,Nervousness,0
PRISTIQ,worsening of depression,Anxiety,0
PRISTIQ,worsening of depression,,0
PRISTIQ,worsening of depression,Nervousness,0
PRISTIQ,worsening of depression,,0
PRISTIQ,worsening of depression,        2               Nervousness,1
PRISTIQ,suicidal impulses,Anxiety,0
PRISTIQ,suicidal impulses,Anxiety            4      Nervousness,1
PRISTIQ,suicidal impulses,Anxiety,0
PRISTIQ,suicidal impulses,           4      Nervousness,1
PRISTIQ,suicidal impulses,           4      Nervousness,1
PRISTIQ,suicidality,Nervousness,0
PRISTIQ,serotonin syndrome,                7  Erectile,1
PRISTIQ,serotonin syndrome,                7  Erectile,1
PRISTIQ,serotonin syndrome,Erectile dysfunction,0
PRISTIQ,mental status changes,Placebon,0
PRISTIQ,mental status changes,"                
     PRISTIQ",1
PRISTIQ,mental status changes,,0
PRISTIQ,mental status changes,"                
     PRISTIQ",1
PRISTIQ,mental status changes,PRISTIQ Placebon,0
PRISTIQ,agitation,,0
PRISTIQ,agitation,          PRISTIQ,1
PRISTIQ,agitation,         ,1
PRISTIQ,agitation,,0
PRISTIQ,agitation,,0
PRISTIQ,agitation,          PRISTIQ Placebon mgn,1
PRISTIQ,agitation,          PRISTIQ Placebon,1
PRISTIQ,agitation,         ,1
PRISTIQ,agitation,          PRISTIQ Placebon mgn,1
PRISTIQ,agitation,,0
PRISTIQ,hallucinations,PRISTIQ,0
PRISTIQ,hallucinations,,0
PRISTIQ,hallucinations,               PRISTIQ Placebon mgn mgn,1
PRISTIQ,hallucinations,,0
PRISTIQ,hallucinations,               PRISTIQ Placebon mgn,1
PRISTIQ,hallucinations,               PRISTIQ Placebon mgn mgn,1
PRISTIQ,hallucinations,,0
PRISTIQ,hallucinations,              ,1
PRISTIQ,hallucinations,,0
PRISTIQ,delirium,   PRIST,1
PRISTIQ,delirium,,0
PRISTIQ,delirium,   PRIST IQ,1
PRISTIQ,delirium,   PRIST IQ Placebon mgn,1
PRISTIQ,delirium,   PRIST IQ Placebon,1
PRISTIQ,delirium,   PRIST IQ Placebon mgn,1
PRISTIQ,delirium,IQ,0
PRISTIQ,delirium,IQ Placebon mgn,0
PRISTIQ,coma,    ,1
PRISTIQ,coma,    ,1
PRISTIQ,coma,mgn,0
PRISTIQ,coma,PRISTIQ,0
PRISTIQ,coma,    ,1
PRISTIQ,coma,     Placebon mgn mgn mgn,1
PRISTIQ,coma,PRISTIQ     ,1
PRISTIQ,autonomic instability,"
                     Placebon mgn",1
PRISTIQ,autonomic instability,"
                    ",1
PRISTIQ,tachycardia,mgn mgn mgn mgn,0
PRISTIQ,tachycardia,ebo(n=397) ,1
PRISTIQ,tachycardia,mgn,0
PRISTIQ,labile blood pressure,,0
PRISTIQ,labile blood pressure,PRISTIQ  50 mg(n=209)      10,1
PRISTIQ,labile blood pressure,Placebon,0
PRISTIQ,labile blood pressure,50,1
PRISTIQ,labile blood pressure,PRISTIQ  50 mg(n=209)      10,1
PRISTIQ,labile blood pressure,10,1
PRISTIQ,labile blood pressure,mgn mgn Women only Anorgasmia,0
PRISTIQ,labile blood pressure,Women only Anorgasmia,0
PRISTIQ,dizziness,,0
PRISTIQ,dizziness,,0
PRISTIQ,dizziness,mg(n=267),1
PRISTIQ,dizziness,mg(n=267),1
PRISTIQ,dizziness,mg(n=267),1
PRISTIQ,dizziness,,0
PRISTIQ,dizziness,mgn,0
PRISTIQ,diaphoresis,200 mg(n,1
PRISTIQ,diaphoresis,,0
PRISTIQ,diaphoresis,200 mg(n,1
PRISTIQ,diaphoresis,Women,0
PRISTIQ,diaphoresis,Placebon mgn    200 mg(n,1
PRISTIQ,diaphoresis,,0
PRISTIQ,diaphoresis,,0
PRISTIQ,diaphoresis,mgn 200,1
PRISTIQ,flushing,76)     ,1
PRISTIQ,flushing,76)     ,1
PRISTIQ,flushing,only,0
PRISTIQ,flushing,Anorgasmia,0
PRISTIQ,flushing,76)     ,1
PRISTIQ,flushing,76)     ,1
PRISTIQ,flushing,Anorgasmia,0
PRISTIQ,flushing,mgn,0
PRISTIQ,flushing,76)     ,1
PRISTIQ,flushing,76)     ,1
PRISTIQ,hyperthermia,,0
PRISTIQ,hyperthermia,mgn mgn 0,1
PRISTIQ,neuromuscular symptoms,Women only Anorgasmia,1
PRISTIQ,tremor,mgn mgn,0
PRISTIQ,tremor,mgn mgn mgn Women  Anorg asmia,1
PRISTIQ,tremor,,0
PRISTIQ,tremor,,0
PRISTIQ,tremor,,0
PRISTIQ,tremor, Anorg asmia,1
PRISTIQ,tremor,,0
PRISTIQ,tremor, Anorg asmia,1
PRISTIQ,tremor, Anorg asmia,1
PRISTIQ,rigidity,,0
PRISTIQ,rigidity,only Anorgas,0
PRISTIQ,myoclonus,   0     ,1
PRISTIQ,myoclonus,Women only    0     ,1
PRISTIQ,myoclonus,   0     ,1
PRISTIQ,myoclonus,,0
PRISTIQ,myoclonus,   0     ,1
PRISTIQ,myoclonus,only,0
PRISTIQ,myoclonus,,0
PRISTIQ,myoclonus,mgn Women only    0     ,1
PRISTIQ,myoclonus,   0     ,1
PRISTIQ,hyperreflexia,          1  ,1
PRISTIQ,hyperreflexia,Women only Anorgasmia,0
PRISTIQ,hyperreflexia,mgn mgn Women only           1  ,1
PRISTIQ,hyperreflexia,          1  ,1
PRISTIQ,hyperreflexia,,0
PRISTIQ,incoordination,             1,1
PRISTIQ,incoordination,,0
PRISTIQ,incoordination,adverse reactions observ,0
PRISTIQ,incoordination,adverse reactions observ,0
PRISTIQ,incoordination,             1,1
PRISTIQ,incoordination,mgn Women only              1,1
PRISTIQ,incoordination,             1,1
PRISTIQ,incoordination,,0
PRISTIQ,incoordination,reactions,0
PRISTIQ,incoordination,             1,1
PRISTIQ,gastrointestinal symptoms,               3         ,1
PRISTIQ,gastrointestinal symptoms,               3         ,1
PRISTIQ,gastrointestinal symptoms,               3         ,1
PRISTIQ,gastrointestinal symptoms,               3         ,1
PRISTIQ,gastrointestinal symptoms,               3         ,1
PRISTIQ,gastrointestinal symptoms,men only                3         ,1
PRISTIQ,gastrointestinal symptoms,               3         ,1
PRISTIQ,gastrointestinal symptoms,only                3         ,1
PRISTIQ,nausea,"
      Other adverse reactions",1
PRISTIQ,nausea,reactions observed in premarketing and postmarketing,0
PRISTIQ,nausea,"
      Other adverse",1
PRISTIQ,diarrhea,O ther,1
PRISTIQ,diarrhea,ther adv,1
PRISTIQ,diarrhea,ther adv erse reactions observed in premarketing,1
PRISTIQ,diarrhea,O,0
PRISTIQ,diarrhea,O,0
PRISTIQ,increases in blood pressure,who exceeded a predetermined threshold,0
PRISTIQ,increases in blood pressure,considered potentia lly clinically significant The,1
PRISTIQ,increases in blood pressure,studies Some of these es were considered potentia lly clinically significant The,1
PRISTIQ,increases in blood pressure,of,0
PRISTIQ,increases in blood pressure,Some of these es were considered potentia lly clinically significant The,1
PRISTIQ,elevated blood pressure,,0
PRISTIQ,elevated blood pressure,Placebo,0
PRISTIQ,blood pressure increases,mgdl LDL,0
PRISTIQ,blood pressure increases,absolute value of,1
PRISTIQ,blood pressure increases,,0
PRISTIQ,blood pressure increases,and absolute value of >=,1
PRISTIQ,blood pressure increases,261 mgdl LDL Cholesterol,1
PRISTIQ,bleeding,         Proteinuria Proteinuria greater than,1
PRISTIQ,bleeding,         Proteinuria Proteinuria greater than,1
PRISTIQ,bleeding,than,0
PRISTIQ,bleeding,fastingFasting,0
PRISTIQ,bleeding,fastingFasting,0
PRISTIQ,bleeding,fastingFasting          Proteinuria Proteinuria greater than,1
PRISTIQ,bleeding,fastingFasting          Proteinuria Proteinuria greater than,1
PRISTIQ,bleeding,fastingFasting mgdl,0
PRISTIQ,gastrointestinal bleeding,and was generally,0
PRISTIQ,gastrointestinal bleeding,(%) of Patients with Pr oteinuria in the Fixeddose,1
PRISTIQ,Bleeding,einuria  in the Fixeddose Clinical,1
PRISTIQ,Bleeding,,0
PRISTIQ,Bleeding,Patients with einuria  in the Fixeddose Clinical,1
PRISTIQ,ecchymosis,in the Fixeddose,0
PRISTIQ,ecchymosis,           PRISTIQ Placebo mg mg,1
PRISTIQ,ecchymosis,,0
PRISTIQ,ecchymosis,with Proteinuria in the Fixeddose,0
PRISTIQ,ecchymosis,,0
PRISTIQ,ecchymosis,Fixeddose Clinical            PRISTIQ Placebo mg mg,1
PRISTIQ,ecchymosis,           PRISTIQ Placebo mg mg,1
PRISTIQ,hematoma,,0
PRISTIQ,hematoma,,0
PRISTIQ,hematoma,         PRISTIQ Placebo mg mg,1
PRISTIQ,hematoma,         PRISTIQ Placebo mg mg,1
PRISTIQ,hematoma,Patients with Proteinuria in,0
PRISTIQ,hematoma,         PRISTIQ Placebo mg mg,1
PRISTIQ,hematoma,Fixeddose Clinical          PRISTIQ Placebo mg mg,1
PRISTIQ,hematoma,Clinical          PRISTIQ Placebo mg mg,1
PRISTIQ,epistaxis,,0
PRISTIQ,epistaxis,mg mg,0
PRISTIQ,epistaxis,mg,0
PRISTIQ,epistaxis,Clinical    PRISTI Q Placebo mg mg,1
PRISTIQ,epistaxis,   PRISTI Q Placebo mg mg,1
PRISTIQ,epistaxis,Clinical,0
PRISTIQ,epistaxis,Q Placebo,0
PRISTIQ,petechiae,"    
     Placebo mg mg mg",1
PRISTIQ,petechiae,"    
     Placebo mg mg mg",1
PRISTIQ,petechiae,,0
PRISTIQ,petechiae,"    
     Placebo mg mg mg",1
PRISTIQ,petechiae,mg,0
PRISTIQ,petechiae,"    
     Placebo mg mg mg",1
PRISTIQ,hemorrhages,linical Studies PRISTIQ lacebo      mg mg mg mg,1
PRISTIQ,hemorrhages,lacebo      mg mg mg mg,1
PRISTIQ,hemorrhages,lacebo      mg mg mg mg,1
PRISTIQ,hemorrhages,,0
PRISTIQ,hemorrhages,lacebo      mg mg mg mg,1
PRISTIQ,hemorrhages,lacebo      mg mg mg mg,1
PRISTIQ,hemorrhages,PRISTIQ,0
PRISTIQ,angle closure attack,premarketing,0
PRISTIQ,angle closure attack,premarketing studies with,0
PRISTIQ,angle closure attack,Mean Changes in Vital,0
PRISTIQ,angle closure attack,All Shortterm,0
PRISTIQ,angle closure attack,Final,0
PRISTIQ,angle closure attack,oses to mg Table Mean Changes in Vital Signs at Final on,0
PRISTIQ,mania,Controlled,0
PRISTIQ,mania,Fixeddose Controlled Studies TIQ   Placebo mg mg mg,1
PRISTIQ,mania,PRIS,0
PRISTIQ,mania,TIQ   Placebo mg mg mg,1
PRISTIQ,mania,,0
PRISTIQ,mania,TIQ   Placebo mg mg mg,1
PRISTIQ,mania,mg mg,0
PRISTIQ,mania,,0
PRISTIQ,mania,mg,0
PRISTIQ,Activation of mania,mg Blood pressure Supine,0
PRISTIQ,Activation of mania,mg mg Blood pressure Supine,1
PRISTIQ,dizziness,from mg per to,1
PRISTIQ,dizziness, to 400 m g per day in,1
PRISTIQ,dizziness,400 m g per day in,1
PRISTIQ,dizziness,doses from mg per to 400,1
PRISTIQ,dizziness,to,1
PRISTIQ,dizziness,doses from mg per  to 400 m g per day in,1
PRISTIQ,dizziness,per day in controlled studies,0
PRISTIQ,nausea,all doses from,0
PRISTIQ,nausea,mg,0
PRISTIQ,headache,contr olled studies was associated,1
PRISTIQ,headache,in contr olled studies was associated,1
PRISTIQ,headache,per in,1
PRISTIQ,headache,in,1
PRISTIQ,headache,to mg per in contr olled studies was associated,1
PRISTIQ,headache,to mg per in contr olled studies was associated,1
PRISTIQ,headache,with,0
PRISTIQ,headache,defined as treatmentemergent supine,0
PRISTIQ,irritability,,0
PRISTIQ,irritability,PRISTIQ at all doses,0
PRISTIQ,irritability,doses from mg,0
PRISTIQ,irritability,,0
PRISTIQ,irritability,,0
PRISTIQ,irritability,day in led,1
PRISTIQ,irritability,blood,0
PRISTIQ,insomnia,from mg per day to mg per,0
PRISTIQ,insomnia,in controlled studies s associ ated with sustained hypertension,1
PRISTIQ,insomnia,studies s associ ated with sustained hypertension,1
PRISTIQ,insomnia,controlled studies s associ ated with sustained hypertension,1
PRISTIQ,insomnia,studies s associ ated with sustained hypertension,1
PRISTIQ,insomnia,day in controlled studies wa,0
PRISTIQ,diarrhea,in controlled studies was ed with  sustained hypertension defined as,1
PRISTIQ,diarrhea,in controlled studies was ed,1
PRISTIQ,diarrhea,mg,0
PRISTIQ,diarrhea,ed with sustained hypertension defined as,1
PRISTIQ,anxiety,day in controlled studies was associated with su,0
PRISTIQ,anxiety,stained hypertension defined as treatmentemergent,1
PRISTIQ,anxiety,Hg and,0
PRISTIQ,anxiety,from mg per day to mg,0
PRISTIQ,anxiety,treatmentemergent supine diastolic,0
PRISTIQ,anxiety,stained hypertension defined as treatmentemergent,1
PRISTIQ,anxiety,all doses from mg per day to mg per day in controlled studies was associated with su,0
PRISTIQ,anxiety,stained hypertension defined as treatmentemergent,1
PRISTIQ,fatigue,and mm Hg,0
PRISTIQ,fatigue,blood pressure SDBP,0
PRISTIQ,fatigue,as treatmentemergent,0
PRISTIQ,fatigue,with sustained yperten sion defined as treatmentemergent,1
PRISTIQ,fatigue,studies was associated with sustained h,0
PRISTIQ,abnormal dreams,diastolic blood pressure SDBP mm Hg and mm Hg,0
PRISTIQ,abnormal dreams,as treatmentemergent supine diastolic blood,1
PRISTIQ,abnormal dreams,"associated with sustained on, defined",1
PRISTIQ,hyperhidrosis,ent-emergent  supine diastolic blood pressure,1
PRISTIQ,hyperhidrosis,day in controlled studies was associated with sustained hypertension defined as treatm,0
PRISTIQ,seizure,mg lic ort hostatic hypotension decrease mm,1
PRISTIQ,seizure,doses of to mg lic,1
PRISTIQ,seizure,ort hostatic hypotension decrease mm,1
PRISTIQ,Hyponatremia,postapproval use of PRISTIQ Because these reactions are,0
PRISTIQ,Hyponatremia,has,0
PRISTIQ,hyponatremia,are d,1
PRISTIQ,hyponatremia,been identified during postapproval use of PRISTIQ Because,0
PRISTIQ,hyponatremia,reactions are d,1
PRISTIQ,hyponatremia,d voluntaril y from a population,1
PRISTIQ,hyponatremia,,0
PRISTIQ,hyponatremia,identified during postapproval use of PRISTIQ,0
PRISTIQ,hyponatremia,postapproval use of PRISTIQ Because these reactions are,0
PRISTIQ,hyponatremia,voluntaril y from a population,1
PRISTIQ,syndrome of inappropriate antidiuretic hormone secretion,are reported voluntarily from a population,0
PRISTIQ,syndrome of inappropriate antidiuretic hormone secretion,"size, it is not always possible to reliably estimate the ir frequency or establish",1
PRISTIQ,syndrome of inappropriate antidiuretic hormone secretion,"size, it",1
PRISTIQ,SIADH,size it is not always,0
PRISTIQ,SIADH, freq uency or establish a,1
PRISTIQ,SIADH,,0
PRISTIQ,SIADH,possible to reliably estimate  freq uency or establish a,1
PRISTIQ,SIADH, freq uency or establish a,1
PRISTIQ,SIADH, freq uency or establish a,1
PRISTIQ,hyponatremia,,0
PRISTIQ,hyponatremia,drug,0
PRISTIQ,hyponatremia,subcutaneous tissue disorders,0
PRISTIQ,hyponatremia,subcutaneous tissue disorders son,1
PRISTIQ,hyponatremia,,0
PRISTIQ,hyponatremia,,1
PRISTIQ,hyponatremia,,0
PRISTIQ,hyponatremia,,1
PRISTIQ,hyponatremia,,1
PRISTIQ,hyponatremia,,1
PRISTIQ,hyponatremia,,1
PRISTIQ,hyponatremia,,0
PRISTIQ,headache,,0
PRISTIQ,headache,,1
PRISTIQ,headache,,0
PRISTIQ,headache,,0
PRISTIQ,headache,,0
PRISTIQ,headache,,1
PRISTIQ,memory impairment,,0
PRISTIQ,memory impairment,,0
PRISTIQ,memory impairment,,1
PRISTIQ,memory impairment,,1
PRISTIQ,confusion,,1
PRISTIQ,confusion,,0
PRISTIQ,confusion,,0
PRISTIQ,confusion,,1
PRISTIQ,confusion,,1
PRISTIQ,confusion,,0
PRISTIQ,confusion,,1
PRISTIQ,confusion,,1
PRISTIQ,confusion,,1
PRISTIQ,confusion,,0
PRISTIQ,weakness,,0
PRISTIQ,weakness,,1
PRISTIQ,weakness,,1
PRISTIQ,unsteadiness,,0
PRISTIQ,unsteadiness,,0
PRISTIQ,unsteadiness,,0
PRISTIQ,unsteadiness,,0
PRISTIQ,unsteadiness,,1
PRISTIQ,unsteadiness,,0
PRISTIQ,unsteadiness,,1
PRISTIQ,unsteadiness,,0
PRISTIQ,unsteadiness,,0
PRISTIQ,unsteadiness,,0
PRISTIQ,falls,,1
PRISTIQ,falls,,1
PRISTIQ,hallucination,,0
PRISTIQ,hallucination,,1
PRISTIQ,hallucination,,0
PRISTIQ,hallucination,,0
PRISTIQ,hallucination,,0
PRISTIQ,syncope,,1
PRISTIQ,syncope,,1
PRISTIQ,syncope,,0
PRISTIQ,syncope,,0
PRISTIQ,syncope,,0
PRISTIQ,syncope,,0
PRISTIQ,syncope,,1
PRISTIQ,syncope,,0
PRISTIQ,seizure,,1
PRISTIQ,seizure,,0
PRISTIQ,seizure,,0
PRISTIQ,seizure,,0
PRISTIQ,respiratory arrest,,0
PRISTIQ,respiratory arrest,,0
PRISTIQ,respiratory arrest,,1
PRISTIQ,respiratory arrest,,0
PRISTIQ,respiratory arrest,,1
PRISTIQ,respiratory arrest,,0
PRISTIQ,respiratory arrest,,0
PRISTIQ,respiratory arrest,,0
PRISTIQ,respiratory arrest,,0
PRISTIQ,respiratory arrest,,0
PRISTIQ,death,,0
PRISTIQ,death,,1
PRISTIQ,death,,0
PRISTIQ,death,,1
PRISTIQ,death,,1
PRISTIQ,Interstitial lung disease,,1
PRISTIQ,Interstitial lung disease,,1
PRISTIQ,Interstitial lung disease,,0
PRISTIQ,Interstitial lung disease,,0
PRISTIQ,Interstitial lung disease,,1
PRISTIQ,Interstitial lung disease,,1
PRISTIQ,Interstitial lung disease,,1
PRISTIQ,Interstitial lung disease,,0
PRISTIQ,eosinophilic pneumonia,,0
PRISTIQ,eosinophilic pneumonia,,0
TAFINLAR,Primary Malignancies,label,0
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,Melanoma,1
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,see Warnings and Precautions,0
TAFINLAR,Hemorrhage,Precautions Venous,0
TAFINLAR,Hemorrhage,and Hemorrhage,1
TAFINLAR,Hemorrhage,and Precautions,0
TAFINLAR,Hemorrhage,Hemorrhage,1
TAFINLAR,Hemorrhage,Hemorrhage,1
TAFINLAR,Hemorrhage,WildType Melanoma,0
TAFINLAR,Cardiomyopathy,,0
TAFINLAR,Cardiomyopathy,Venous Thromboembolism see Warnings,0
TAFINLAR,Cardiomyopathy,Cardiomyopathy,1
TAFINLAR,Cardiomyopathy,Toxicities see Warnings and Precautions,0
TAFINLAR,Cardiomyopathy,and Cardiomyopathy,1
TAFINLAR,Cardiomyopathy,and Precautions Ocular Toxicities see Warnings,0
TAFINLAR,Ocular Toxicities,and Ocular,1
TAFINLAR,Ocular Toxicities,Toxicities,1
TAFINLAR,Febrile Reactions,Serious,0
TAFINLAR,Febrile Reactions,Reactions,1
TAFINLAR,Febrile Reactions,,0
TAFINLAR,Febrile Reactions,Febrile,1
TAFINLAR,Febrile Reactions,Skin,0
TAFINLAR,Febrile Reactions,see Warnings,0
TAFINLAR,Febrile Reactions,Precautions Ocular Toxicities see Warnings and Precautions,0
TAFINLAR,Febrile Reactions,and Precautions Febrile,1
TAFINLAR,Febrile Reactions,Warnings and Precautions Febrile,1
TAFINLAR,Febrile Reactions,Skin Toxicity see Warnings and Precautions,0
TAFINLAR,Hyperglycemia,Hyperglycemia,1
TAFINLAR,Hyperglycemia,see Warn,0
TAFINLAR,Hyperglycemia,Hyperglycemia,1
TAFINLAR,Glucose-6-Phosphate Dehydrogenase Deficiency,see Warnings and Precautions Most common adverse reactions,0
TAFINLAR,hyperkeratosis,hyperkeratosis,1
TAFINLAR,hyperkeratosis,,0
TAFINLAR,hyperkeratosis,for TAFINLAR as a,0
TAFINLAR,hyperkeratosis,adverse reactions for TAFINLAR as a single,0
TAFINLAR,hyperkeratosis,,0
TAFINLAR,hyperkeratosis,TAFINLAR as a single,0
TAFINLAR,hyperkeratosis,as a single,0
TAFINLAR,pyrexia,single agent are hyperkeratosis pyrexia,1
TAFINLAR,pyrexia,papilloma alopecia and,0
TAFINLAR,pyrexia,,0
TAFINLAR,pyrexia,reactions for TAFINLAR as a single agent are hyperkeratosis,0
TAFINLAR,pyrexia,hyperkeratosis pyrexia,1
TAFINLAR,pyrexia,,0
TAFINLAR,pyrexia,hyperkeratosis pyrexia,1
TAFINLAR,arthralgia,arthralgia,1
TAFINLAR,arthralgia,arthralgia,1
TAFINLAR,arthralgia,reactions for TAFINLAR as a single agent are,0
TAFINLAR,arthralgia,,0
TAFINLAR,arthralgia,arthralgia,1
TAFINLAR,arthralgia,as a,0
TAFINLAR,arthralgia,alopecia and,0
TAFINLAR,arthralgia,palmarplantar erythrodysesthesia syndrome,0
TAFINLAR,arthralgia,papilloma alopecia and,0
TAFINLAR,arthralgia,,0
TAFINLAR,papilloma,papilloma,1
TAFINLAR,papilloma,are,0
TAFINLAR,papilloma,papilloma,1
TAFINLAR,papilloma,,0
TAFINLAR,papilloma,pyrexia papilloma,1
TAFINLAR,papilloma,papilloma,1
TAFINLAR,papilloma,papilloma,1
TAFINLAR,papilloma,papilloma,1
TAFINLAR,alopecia,,0
TAFINLAR,alopecia,,0
TAFINLAR,alopecia,arthralgia papilloma,0
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,,0
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,single agent are hyperkeratosis headache pyrexia,0
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,palmar-plantar erythrodysesthesia,1
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,arthralgia papilloma alopecia palmar-plantar erythrodysesthesia syndrome,1
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,papilloma alopecia palmar-plantar erythrodysesthesia,1
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,palmar-plantar erythrodysesthesia syndrome,1
TAFINLAR,pyrexia,pyrexia,1
TAFINLAR,pyrexia,headac,0
TAFINLAR,pyrexia,pyrexia,1
TAFINLAR,pyrexia,chills fatigue rash nausea vomiting diarrhea abdominal pain peripheral edema,0
TAFINLAR,pyrexia,with trametinib pyrexia,1
TAFINLAR,pyrexia,,0
TAFINLAR,pyrexia,diarrhea abdominal pain peripheral,0
TAFINLAR,pyrexia,diarrhea abdominal pain,0
TAFINLAR,pyrexia,trametinib pyrexia,1
TAFINLAR,pyrexia,pyrexia,1
TAFINLAR,chills,chills,1
TAFINLAR,chills,chills,1
TAFINLAR,chills,pain peripheral,0
TAFINLAR,chills,pyrexia,0
TAFINLAR,chills,chills,1
TAFINLAR,chills,for,0
TAFINLAR,chills,pain peripheral edema cough headache arth,0
TAFINLAR,fatigue,fatigue,1
TAFINLAR,fatigue,fatigue,1
TAFINLAR,fatigue,fatigue,1
TAFINLAR,rash,,0
TAFINLAR,rash,night s,0
TAFINLAR,rash,edema cough headache arthralgia,0
TAFINLAR,rash,rash,1
TAFINLAR,rash,in combination with trametinib are pyrexia chills,0
TAFINLAR,rash,rash,1
TAFINLAR,rash,with trametinib,0
TAFINLAR,rash,trametinib are pyrexia chills rash,1
TAFINLAR,nausea,combination,0
TAFINLAR,nausea,,0
TAFINLAR,nausea,nausea,1
TAFINLAR,nausea,nausea,1
TAFINLAR,nausea,nausea,1
TAFINLAR,nausea,pain peripheral edema cough,0
TAFINLAR,nausea,sweats d,0
TAFINLAR,nausea,nausea,1
TAFINLAR,nausea,nausea,1
TAFINLAR,nausea,nausea,1
TAFINLAR,diarrhea,nausea diarrhea,1
TAFINLAR,abdominal pain,in combination with trametinib are pyrexia chills fatigue rash nausea vomiting,0
TAFINLAR,abdominal pain,rash nausea vomiting abdominal,1
TAFINLAR,abdominal pain,abdominal pain,1
TAFINLAR,abdominal pain,,0
TAFINLAR,abdominal pain,arthralgia night sweats decreased appetite,0
TAFINLAR,abdominal pain,,0
TAFINLAR,cough,cough,1
TAFINLAR,cough,edema,0
TAFINLAR,cough,cough,1
TAFINLAR,cough,cough,1
TAFINLAR,cough,diarrhea abdominal pain peripheral cough,1
TAFINLAR,cough,pain peripheral cough,1
TAFINLAR,cough,cough,1
TAFINLAR,headache,,0
TAFINLAR,headache,decreased,0
TAFINLAR,headache,headache,1
TAFINLAR,arthralgia,,0
TAFINLAR,arthralgia,pain peripheral edema,0
TAFINLAR,arthralgia,arthralgia,1
TAFINLAR,arthralgia,edema cough arthralgia,1
TAFINLAR,arthralgia,edema cough arthralgia,1
TAFINLAR,arthralgia,arthralgia,1
TAFINLAR,night sweats,constipation and myalgia EXCERPT To,0
TAFINLAR,night sweats,sweats,1
TAFINLAR,night sweats,constipation and myalgia,0
TAFINLAR,night sweats,constipation,0
TAFINLAR,night sweats,cough headache night sweats,1
TAFINLAR,night sweats,appetite constipation and myalgia EXCERPT To report SUSPECTED A,0
TAFINLAR,night sweats,night sweats,1
TAFINLAR,decreased appetite,decreased appetite,1
TAFINLAR,constipation,,0
TAFINLAR,constipation,constipation,1
TAFINLAR,constipation,constipation,1
TAFINLAR,constipation,arthralgia night sweats decreased constipation,1
TAFINLAR,constipation,constipation,1
TAFINLAR,constipation,constipation,1
TAFINLAR,constipation,,0
TAFINLAR,constipation,night sweats decreased appetite,0
TAFINLAR,constipation,decreased constipation,1
TAFINLAR,constipation,,0
TAFINLAR,myalgia,myalgia,1
TAFINLAR,myalgia,,0
TAFINLAR,myalgia,To,0
TAFINLAR,myalgia,SUSPECTED ADVERSE REACTIONS contact GlaxoSmithKline at,0
TAFINLAR,myalgia,myalgia,1
TAFINLAR,myalgia,headache arthralgia night sweats decreased appetite constipation and,0
TAFINLAR,myalgia,report SUSPECTED ADVERSE REACTIONS contact GlaxoSmithKline,0
TAFINLAR,hyperkeratosis,order of decreasing hyperkeratosis,1
TAFINLAR,hyperkeratosis,and palmarplantar,0
TAFINLAR,hyperkeratosis,hyperkeratosis,1
TAFINLAR,headache,headache,1
TAFINLAR,headache,headache,1
TAFINLAR,pyrexia,,0
TAFINLAR,pyrexia,pyrexia,1
TAFINLAR,pyrexia,order of decreasing,0
TAFINLAR,pyrexia,alopecia and palmarplantar erythrodysesthesia syndrome PPES The in,0
TAFINLAR,pyrexia,frequency hyperkeratosis pyrexia,1
TAFINLAR,pyrexia,hyperkeratosis pyrexia,1
TAFINLAR,arthralgia,of a,0
TAFINLAR,papilloma,papilloma,1
TAFINLAR,papilloma,syndrome PPES The,0
TAFINLAR,papilloma,papilloma,1
TAFINLAR,alopecia,hyperkeratosis,0
TAFINLAR,alopecia,hyperkeratosis headache pyrexia,0
TAFINLAR,alopecia,alopecia,1
TAFINLAR,alopecia,alopecia,1
TAFINLAR,alopecia,alopecia,1
TAFINLAR,alopecia,alopecia,1
TAFINLAR,alopecia,of decreasing frequency hyperkeratosis headache,0
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,syndrome,1
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,pyrexia arthralgia papilloma alopecia palmar-plantar erythrodysesthesia syndrome,1
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,and,0
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,of adverse events resulting in permanent discontinuation of study medicat,0
TAFINLAR,PPES,PPES,1
TAFINLAR,PPES,PPES,1
TAFINLAR,PPES,,0
TAFINLAR,PPES,palmarplantar erythrodysesthesia syndrome,0
TAFINLAR,PPES,and palmarplantar erythrodysesthesia PPES,1
TAFINLAR,PPES,PPES,1
TAFINLAR,PPES,PPES,1
TAFINLAR,PPES,TAFINLAR were PPES,1
TAFINLAR,PPES,PPES,1
TAFINLAR,PPES,PPES,1
TAFINLAR,PPES,,0
TAFINLAR,PPES,adverse reactions leading to,0
TAFINLAR,PPES,frequent adverse reactions leading to dose reduction of TAFINLAR were,0
TAFINLAR,PPES,,0
TAFINLAR,PPES,reactions leading to dose reduction of TAFINLAR were,0
TAFINLAR,chills,pyrexia chills,1
TAFINLAR,chills,chills,1
TAFINLAR,fatigue,fatigue,1
TAFINLAR,headache,and,0
TAFINLAR,headache,in All Grades or Grade,0
TAFINLAR,headache,pyrexia PPES chills fatigue headache,1
TAFINLAR,Hyperkeratosis,Hyperkeratosis,1
TAFINLAR,Hyperkeratosis,,0
TAFINLAR,Hyperkeratosis,,0
TAFINLAR,Hyperkeratosis,Hyperkeratosis,1
TAFINLAR,Hyperkeratosis,Hyperkeratosis,1
TAFINLAR,Hyperkeratosis,Hyperkeratosis,1
TAFINLAR,Hyperkeratosis,Hyperkeratosis,1
TAFINLAR,Hyperkeratosis,Hyperkeratosis,1
TAFINLAR,Hyperkeratosis,Hyperkeratosis,1
TAFINLAR,Hyperkeratosis,Hyperkeratosis,1
TAFINLAR,Alopecia,,0
TAFINLAR,Alopecia,,0
TAFINLAR,Alopecia,,0
TAFINLAR,Alopecia,,0
TAFINLAR,Alopecia,,0
TAFINLAR,Alopecia,,0
TAFINLAR,Alopecia,Alopecia,1
TAFINLAR,Palmar-plantar erythrodysesthesia syndrome,syndrome,1
TAFINLAR,Palmar-plantar erythrodysesthesia syndrome,,0
TAFINLAR,Palmar-plantar erythrodysesthesia syndrome,NAf,0
TAFINLAR,Palmar-plantar erythrodysesthesia syndrome,Palmar-plantar erythrodysesthesia syndrome,1
TAFINLAR,Palmar-plantar erythrodysesthesia syndrome,NAf,0
TAFINLAR,Palmar-plantar erythrodysesthesia syndrome,NAf Palmar-plantar,1
TAFINLAR,Rash,Rash,1
TAFINLAR,Rash,Rash,1
TAFINLAR,Rash,Rash,1
TAFINLAR,Rash,Rash,1
TAFINLAR,Rash,,0
TAFINLAR,Rash,,0
TAFINLAR,Rash,,0
TAFINLAR,Rash,,0
TAFINLAR,Rash,,0
TAFINLAR,Rash,Rash,1
TAFINLAR,Headache,Headache,1
TAFINLAR,Headache,,0
TAFINLAR,Headache,Headache,1
TAFINLAR,Headache,Headache,1
TAFINLAR,Headache,Headache,1
TAFINLAR,Headache,,0
TAFINLAR,Headache,Headache,1
TAFINLAR,Pyrexia,,0
TAFINLAR,Arthralgia,,0
TAFINLAR,Arthralgia,,0
TAFINLAR,Arthralgia,Arthralgia,1
TAFINLAR,Arthralgia,Arthralgia,1
TAFINLAR,Arthralgia,,0
TAFINLAR,Arthralgia,Arthralgia,1
TAFINLAR,Arthralgia,,0
TAFINLAR,Arthralgia,,0
TAFINLAR,Arthralgia,Arthralgia,1
TAFINLAR,Arthralgia,,0
TAFINLAR,Back pain,Back pain,1
TAFINLAR,Back pain,pain,1
TAFINLAR,Back pain,Back pain,1
TAFINLAR,Back pain,,0
TAFINLAR,Back pain,,0
TAFINLAR,Back pain,,0
TAFINLAR,Back pain,,0
TAFINLAR,Back pain,,0
TAFINLAR,Myalgia,Myalgia,1
TAFINLAR,Papilloma,,0
TAFINLAR,Papilloma,Papilloma c,1
TAFINLAR,Papilloma,,0
TAFINLAR,Papilloma,Papilloma c,1
TAFINLAR,Papilloma,,0
TAFINLAR,Papilloma,,0
TAFINLAR,Papilloma,,0
TAFINLAR,Papilloma,,0
TAFINLAR,cuSCC,cuSCC d e,1
TAFINLAR,cuSCC,,0
TAFINLAR,cuSCC,,0
TAFINLAR,cuSCC,cuSCC d e,1
TAFINLAR,cuSCC,cuSCC d e,1
TAFINLAR,Constipation,Constipation,1
TAFINLAR,Constipation,Constipation,1
TAFINLAR,Nasopharyngitis,Nasopharyngitis,1
TAFINLAR,Nasopharyngitis,,0
TAFINLAR,Nasopharyngitis,,0
TAFINLAR,Nasopharyngitis,,0
TAFINLAR,hyperkeratosis,hyperkeratosis,1
TAFINLAR,hyperkeratosis,hyperkeratosis,1
TAFINLAR,hyperkeratosis,adverse reactions,0
TAFINLAR,constipation,papilloma d Includes squamous cell carcinoma,0
TAFINLAR,constipation,cell,0
TAFINLAR,constipation,of toxicity b Grade adverse reactions limited,0
TAFINLAR,skin papilloma,skin,1
TAFINLAR,skin papilloma,,0
TAFINLAR,skin papilloma,and,0
TAFINLAR,skin papilloma,skin papilloma,1
TAFINLAR,skin papilloma,adverse,0
TAFINLAR,skin papilloma,,0
TAFINLAR,skin papilloma,the skin,0
TAFINLAR,skin papilloma,Includes,0
TAFINLAR,skin papilloma,c,0
TAFINLAR,papilloma,and constipation,0
TAFINLAR,papilloma,skin papilloma papilloma,1
TAFINLAR,squamous cell carcinoma of the skin,papilloma and papilloma d squamous cell carcinoma of the,1
TAFINLAR,squamous cell carcinoma of the skin,of the skin,1
TAFINLAR,squamous cell carcinoma of the skin,keratoacanthoma,0
TAFINLAR,squamous cell carcinoma of the skin,papilloma d squamous cell carcinoma of,1
TAFINLAR,squamous cell carcinoma of the skin,squamous cell carcinoma of the skin,1
TAFINLAR,squamous cell carcinoma of the skin,papilloma and papilloma d squamous cell carcinoma of the skin,1
TAFINLAR,squamous cell carcinoma of the skin,papilloma d squamous cell carcinoma of the skin,1
TAFINLAR,squamous cell carcinoma of the skin,of the skin,1
TAFINLAR,squamous cell carcinoma of the skin,papilloma d squamous cell carcinoma of the,1
TAFINLAR,keratoacanthoma,keratoacanthoma,1
TAFINLAR,keratoacanthoma,e Cases of cutaneous squamous cell carcinoma were required to be,0
TAFINLAR,keratoacanthoma,keratoacanthoma,1
TAFINLAR,cutaneous squamous cell carcinoma,,0
TAFINLAR,cutaneous squamous cell carcinoma,e Cases cutaneous squamous cell carcinoma,1
TAFINLAR,cutaneous squamous cell carcinoma,of,0
TAFINLAR,cutaneous squamous cell carcinoma,squamous cell carcinoma,1
TAFINLAR,cutaneous squamous cell carcinoma,cutaneous squamous,1
TAFINLAR,Hyperglycemia,Hyperglycemia,1
TAFINLAR,Hyperglycemia,and,0
TAFINLAR,Hyperglycemia,Hyperglycemia,1
TAFINLAR,Hyperglycemia,,0
TAFINLAR,Hyperglycemia,Grades,0
TAFINLAR,Hyperglycemia,Hyperglycemia,1
TAFINLAR,Hyperglycemia,Hyperglycemia,1
TAFINLAR,Hyperglycemia,All,0
TAFINLAR,Hyperglycemia,,0
TAFINLAR,Hyperglycemia,Hyperglycemia,1
TAFINLAR,Increased alkaline phosphatase,ia Increased alkaline,1
TAFINLAR,Increased alkaline phosphatase,,0
TAFINLAR,Increased alkaline phosphatase,ia Increased alkaline phosphatase Hyponatremia,1
TAFINLAR,Increased alkaline phosphatase,Increased alkaline phosphatase Hyponatremia,1
TAFINLAR,Increased alkaline phosphatase,Increased alkaline phosphatase Hyponatremia,1
TAFINLAR,Hyponatremia,,0
TAFINLAR,Hyponatremia,,0
TAFINLAR,hypophosphatemia,hypophosphatemia,1
TAFINLAR,hypophosphatemia,Grade laboratory abnormality limited hypophosphatemia,1
TAFINLAR,hypophosphatemia,,0
TAFINLAR,hypophosphatemia,limited to,0
TAFINLAR,hypophosphatemia,abnormality limited,0
TAFINLAR,hypophosphatemia,abnormality,0
TAFINLAR,hypophosphatemia,hypophosphatemia,1
TAFINLAR,hypophosphatemia,Other clinically important adverse reactions observed in of patients N,0
TAFINLAR,hypophosphatemia,to,0
TAFINLAR,hypophosphatemia,limited to,0
TAFINLAR,Hypersensitivity,,0
TAFINLAR,Hypersensitivity,Hypersensitivity,1
TAFINLAR,Hypersensitivity,Hypersensitivity,1
TAFINLAR,Hypersensitivity,Urinary Disorders,0
TAFINLAR,Hypersensitivity,Hypersensitivity,1
TAFINLAR,Hypersensitivity,Renal and Urinary Disorders Interstitial nephritis BRAF,0
TAFINLAR,bullous rash,,0
TAFINLAR,pyrexia,permanent discontinuation pyrexia,1
TAFINLAR,pyrexia,pyrexia,1
TAFINLAR,pyrexia,Adverse reactions led to dose reductions in and dose,0
TAFINLAR,pyrexia,was,0
TAFINLAR,pyrexia,pyrexia,1
TAFINLAR,pyrexia,to dose reductions in and dose interruptions in of,0
TAFINLAR,pyrexia,resulting in permanent discontinuation pyrexia,1
TAFINLAR,Pyrexia,in of patients treated,0
TAFINLAR,Pyrexia,Pyrexia,1
TAFINLAR,Pyrexia,Pyrexia,1
TAFINLAR,Pyrexia,chills and,0
TAFINLAR,Pyrexia,pyrexia chills and,0
TAFINLAR,Pyrexia,combination with Pyrexia,1
TAFINLAR,chills,,0
TAFINLAR,chills,,0
TAFINLAR,chills,chills,1
TAFINLAR,chills,with trametinib chills,1
TAFINLAR,chills,chills,1
TAFINLAR,nausea,cited for dose reductions and pyrexia chills and decreased,0
TAFINLAR,nausea,,0
TAFINLAR,nausea,Pyrexia chills,0
TAFINLAR,nausea,with trametinib Pyrexia chills,0
TAFINLAR,pyrexia,most common,0
TAFINLAR,pyrexia,,0
TAFINLAR,pyrexia,reductions pyrexia,1
TAFINLAR,pyrexia,for dose,0
TAFINLAR,pyrexia,for dose reductions pyrexia,1
TAFINLAR,pyrexia,pyrexia,1
TAFINLAR,pyrexia,for dose reductions pyrexia,1
TAFINLAR,pyrexia,pyrexia,1
TAFINLAR,pyrexia,and,0
TAFINLAR,pyrexia,pyrexia,1
TAFINLAR,chills,chills,1
TAFINLAR,chills,reductions and chills,1
TAFINLAR,chills,and decreased,0
TAFINLAR,chills,chills and nausea were the most common reasons,0
TAFINLAR,chills,and chills,1
TAFINLAR,chills,Pyrexia chills and nausea were the,0
TAFINLAR,chills,chills,1
TAFINLAR,chills,chills,1
TAFINLAR,chills,chills and nausea were,0
TAFINLAR,Chills,,0
TAFINLAR,Chills,Chills,1
TAFINLAR,Chills,Chills,1
TAFINLAR,Chills,,0
TAFINLAR,Chills,,0
TAFINLAR,Chills,Chills,1
TAFINLAR,Chills,,0
TAFINLAR,Fatigue,Fatigue,1
TAFINLAR,Fatigue,,0
TAFINLAR,Fatigue,,0
TAFINLAR,Fatigue,Fatigue,1
TAFINLAR,Fatigue,Fatigue,1
TAFINLAR,Fatigue,,0
TAFINLAR,Fatigue,,0
TAFINLAR,Fatigue,Fatigue,1
TAFINLAR,Fatigue,Fatigue,1
TAFINLAR,Fatigue,Fatigue,1
TAFINLAR,Edema peripheral,,0
TAFINLAR,Edema peripheral,Edema peripheral b,1
TAFINLAR,Edema peripheral,Edema peripheral b,1
TAFINLAR,Edema peripheral,,0
TAFINLAR,Edema peripheral,,0
TAFINLAR,Night Sweats,,0
TAFINLAR,Night Sweats,,0
TAFINLAR,Night Sweats,Night Sweats,1
TAFINLAR,Night Sweats,Night Sweats,1
TAFINLAR,Dry skin,,0
TAFINLAR,Dry skin,Dry,1
TAFINLAR,Dry skin,,0
TAFINLAR,Dry skin,Dry,1
TAFINLAR,Dermatitis acneiform,,0
TAFINLAR,Dermatitis acneiform,Dermatitis,1
TAFINLAR,Dermatitis acneiform,,0
TAFINLAR,Dermatitis acneiform,Dermatitis acneiform,1
TAFINLAR,Dermatitis acneiform,,0
TAFINLAR,Actinic keratosis,,0
TAFINLAR,Actinic keratosis,Actinic keratosis,1
TAFINLAR,Actinic keratosis,,0
TAFINLAR,Actinic keratosis,Actinic keratosis,1
TAFINLAR,Actinic keratosis,,0
TAFINLAR,Actinic keratosis,,0
TAFINLAR,Erythema,Erythema,1
TAFINLAR,Erythema,,0
TAFINLAR,Erythema,,0
TAFINLAR,Erythema,Erythema,1
TAFINLAR,Erythema,Erythema,1
TAFINLAR,Erythema,,0
TAFINLAR,Pruritus,Pruritus,1
TAFINLAR,Nausea,Nausea,1
TAFINLAR,Vomiting,,0
TAFINLAR,Vomiting,,0
TAFINLAR,Vomiting,Vomiting,1
TAFINLAR,Vomiting,Vomiting,1
TAFINLAR,Vomiting,Vomiting,1
TAFINLAR,Diarrhea,Diarrhea,1
TAFINLAR,Diarrhea,,0
TAFINLAR,Diarrhea,Diarrhea,1
TAFINLAR,Abdominal pain,,0
TAFINLAR,Dry mouth,mouth,1
TAFINLAR,Dry mouth,,0
TAFINLAR,Dry mouth,,0
TAFINLAR,Dry mouth,Dry mouth,1
TAFINLAR,Dry mouth,Dry,1
TAFINLAR,Headache,Nervous system Headache,1
TAFINLAR,Cough,Cough,1
TAFINLAR,Cough,,0
TAFINLAR,Cough,mediastinal Cough,1
TAFINLAR,Cough,,0
TAFINLAR,Cough,Cough,1
TAFINLAR,Cough,and mediastinal Cough,1
TAFINLAR,Oropharyngeal pain,,0
TAFINLAR,Oropharyngeal pain,Oropharyngeal,1
TAFINLAR,Oropharyngeal pain,,0
TAFINLAR,Oropharyngeal pain,,0
TAFINLAR,Oropharyngeal pain,,0
TAFINLAR,Oropharyngeal pain,Oropharyngeal,1
TAFINLAR,Oropharyngeal pain,,0
TAFINLAR,Myalgia,Myalgia,1
TAFINLAR,Myalgia,Myalgia,1
TAFINLAR,Myalgia,,0
TAFINLAR,Myalgia,,0
TAFINLAR,Myalgia,Myalgia,1
TAFINLAR,Myalgia,,0
TAFINLAR,Myalgia,Myalgia,1
TAFINLAR,Myalgia,,0
TAFINLAR,Myalgia,,0
TAFINLAR,Back pain,Back pain,1
TAFINLAR,Back pain,Back,1
TAFINLAR,Back pain,,0
TAFINLAR,Back pain,Back pain,1
TAFINLAR,Back pain,,0
TAFINLAR,Back pain,,0
TAFINLAR,Back pain,Back pain,1
TAFINLAR,Back pain,Back pain,1
TAFINLAR,Back pain,,0
TAFINLAR,Back pain,Back pain,1
TAFINLAR,Pain in extremity,,0
TAFINLAR,Pain in extremity,Pain,1
TAFINLAR,Pain in extremity,,0
TAFINLAR,Pain in extremity,Pain in extremity,1
TAFINLAR,Pain in extremity,in extremity,1
TAFINLAR,Pain in extremity,,0
TAFINLAR,Pain in extremity,Pain in extremity,1
TAFINLAR,Dehydration,,0
TAFINLAR,Dehydration,,0
TAFINLAR,Dehydration,,0
TAFINLAR,Dehydration,Dehydration,1
TAFINLAR,Dehydration,,0
TAFINLAR,Dehydration,,0
TAFINLAR,Dehydration,Dehydration,1
TAFINLAR,Dehydration,Dehydration,1
TAFINLAR,Hemorrhage,disorders,0
TAFINLAR,Hemorrhage,e,0
TAFINLAR,Hemorrhage,,0
TAFINLAR,Hemorrhage,Hemorrhage e,1
TAFINLAR,Hemorrhage,,0
TAFINLAR,Hemorrhage,,0
TAFINLAR,Hemorrhage,Hemorrhage e,1
TAFINLAR,Hemorrhage,disorders,0
TAFINLAR,Hemorrhage,,0
TAFINLAR,Hemorrhage,Hemorrhage e,1
TAFINLAR,Urinary tract infection,Urinary tract infection,1
TAFINLAR,Urinary tract infection,and infestations,0
TAFINLAR,Urinary tract infection,,0
TAFINLAR,Urinary tract infection,Urinary tract infection,1
TAFINLAR,Urinary tract infection,and,0
TAFINLAR,Urinary tract infection,Infections and Urinary,1
TAFINLAR,Urinary tract infection,,0
TAFINLAR,Renal failure,urinary,0
TAFINLAR,Renal failure,,0
TAFINLAR,Renal failure,,0
TAFINLAR,Renal failure,f,0
TAFINLAR,Renal failure,urinary disorders,0
TAFINLAR,Renal failure,,0
TAFINLAR,Renal failure,failure f,1
TAFINLAR,peripheral edema,Includes the following terms,0
TAFINLAR,peripheral edema,rash,0
TAFINLAR,peripheral edema,,0
TAFINLAR,peripheral edema,edema,1
TAFINLAR,peripheral edema,following peripheral,1
TAFINLAR,peripheral edema,following peripheral edema,1
TAFINLAR,peripheral edema,b Includes the following peripheral edema,1
TAFINLAR,edema,edema,1
TAFINLAR,edema,edema,1
TAFINLAR,edema,terms rash rash generalized,0
TAFINLAR,edema,rash pruritic rash,0
TAFINLAR,edema,terms peripheral edema,0
TAFINLAR,lymphedema,rash rash generalized rash pruritic rash,0
TAFINLAR,lymphedema,following terms peripheral edema edema,0
TAFINLAR,lymphedema,b Includes the,0
TAFINLAR,lymphedema,edema edema lymphedema,1
TAFINLAR,rash,following terms peripheral edema edema and lymphedema c Includes the following,0
TAFINLAR,rash,rash,1
TAFINLAR,rash,terms,0
TAFINLAR,rash,rash,0
TAFINLAR,rash,macular,0
TAFINLAR,rash,the,0
TAFINLAR,rash,rash,1
TAFINLAR,rash,following rash,1
TAFINLAR,rash pruritic,following terms rash rash generalized,0
TAFINLAR,rash pruritic,macular and rash maculopapular,0
TAFINLAR,rash pruritic,rash rash rash pruritic,1
TAFINLAR,rash pruritic,pruritic,1
TAFINLAR,rash pruritic,rash erythematous rash papular rash vesicular rash macular and rash,0
TAFINLAR,rash pruritic,rash pruritic,1
TAFINLAR,rash pruritic,rash pruritic,1
TAFINLAR,rash pruritic,and rash maculopapular,0
TAFINLAR,rash erythematous,pruritic,0
TAFINLAR,rash erythematous,rash,1
TAFINLAR,rash erythematous,,0
TAFINLAR,rash erythematous,erythematous,1
TAFINLAR,rash erythematous,generalized rash rash,1
TAFINLAR,rash erythematous,,0
TAFINLAR,rash erythematous,rash rash generalized rash rash,1
TAFINLAR,rash erythematous,terms rash,0
TAFINLAR,rash erythematous,following terms rash rash generalized rash,0
TAFINLAR,rash papular,rash pruritic rash,0
TAFINLAR,rash papular,rash vesicular rash macular and rash maculopapular,0
TAFINLAR,rash papular,rash pruritic rash rash,1
TAFINLAR,rash vesicular,maculopapular d,0
TAFINLAR,rash vesicular,vesicular,1
TAFINLAR,rash macular,macular,1
TAFINLAR,rash macular,terms,0
TAFINLAR,rash macular,rash rash macular,1
TAFINLAR,rash macular,,0
TAFINLAR,rash macular,rash,0
TAFINLAR,rash macular,,0
TAFINLAR,rash macular,rash papular rash rash,1
TAFINLAR,rash maculo-papular,rash,0
TAFINLAR,rash maculo-papular,macular rash,1
TAFINLAR,abdominal pain,d Includes the following abdominal,1
TAFINLAR,abdominal pain,macular and rash,0
TAFINLAR,abdominal pain,pain,1
TAFINLAR,abdominal pain,d Includes the following abdominal,1
TAFINLAR,abdominal pain,upper abdominal pain lower and abdominal,0
TAFINLAR,abdominal pain,rash macular and rash maculopapular d Includes the,0
TAFINLAR,abdominal pain,follow,0
TAFINLAR,abdominal pain,abdominal pain,1
TAFINLAR,abdominal pain,pain,1
TAFINLAR,abdominal pain upper,the following terms abdominal abdominal pain upper,1
TAFINLAR,abdominal pain upper,brain,0
TAFINLAR,abdominal pain upper,,0
TAFINLAR,abdominal pain upper,terms abdominal abdominal,1
TAFINLAR,abdominal pain upper,maculopapular d Includes the following terms abdominal,0
TAFINLAR,abdominal pain upper,abdominal pain upper,1
TAFINLAR,abdominal pain upper,abdominal abdominal pain,1
TAFINLAR,abdominal pain upper,Includes the following terms,0
TAFINLAR,abdominal pain upper,abdominal abdominal pain,1
TAFINLAR,abdominal pain lower,pain abdominal pain lower,1
TAFINLAR,abdominal pain lower,abdominal pain,0
TAFINLAR,abdominal pain lower,lower,1
TAFINLAR,abdominal pain lower,lower,1
TAFINLAR,abdominal pain lower,e Includes the following terms brain stem hemorrhage cerebral,0
TAFINLAR,abdominal pain lower,discomfort e Includes the following terms brain,0
TAFINLAR,abdominal pain lower,pain abdominal pain lower,1
TAFINLAR,abdominal pain lower,pain abdominal,1
TAFINLAR,abdominal pain lower,maculopapular d Includes the following terms,0
TAFINLAR,abdominal pain lower,the following terms,0
TAFINLAR,abdominal discomfort,upper abdominal pain lower,0
TAFINLAR,brain stem hemorrhage,e Includes the following,0
TAFINLAR,brain stem hemorrhage,lower and abdominal discomfort e Includes the following,0
TAFINLAR,brain stem hemorrhage,brain stem hemorrhage,1
TAFINLAR,brain stem hemorrhage,abdominal pain lower and abdominal discomfort e,0
TAFINLAR,brain stem hemorrhage,the following,0
TAFINLAR,brain stem hemorrhage,hemorr,0
TAFINLAR,brain stem hemorrhage,the following brain stem,1
TAFINLAR,brain stem hemorrhage,,0
TAFINLAR,brain stem hemorrhage,,0
TAFINLAR,brain stem hemorrhage,Includes the following brain,1
TAFINLAR,epistaxis,epistaxis,1
TAFINLAR,gingival hemorrhage,hemorrhage gingival hemorrhage,1
TAFINLAR,gingival hemorrhage,hemorrhage intracranial eye hemorrhage and,0
TAFINLAR,hematuria,cerebral hemorrhage gastric hemorrhage,0
TAFINLAR,hematuria,gastric hemorrhage epistaxis gingival,0
TAFINLAR,hematuria,gingival hematuria,1
TAFINLAR,hematuria,epistaxis gingival,0
TAFINLAR,hematuria,hematuria,1
TAFINLAR,hematuria,eye hemorrhage and vitreous hemorrhage f Inc,0
TAFINLAR,hematuria,hemorrhage f Inc,0
TAFINLAR,hematuria,,0
TAFINLAR,hematuria,vitreous,0
TAFINLAR,hematuria,hematuria,1
TAFINLAR,vaginal hemorrhage,hemorrhage,0
TAFINLAR,vaginal hemorrhage,cerebral hemorrhage gastric hemorrhage epistaxis gingival,0
TAFINLAR,vaginal hemorrhage,hemorrhage,1
TAFINLAR,vaginal hemorrhage,hemorrhage epistaxis gingival hemorrhage vaginal,1
TAFINLAR,vaginal hemorrhage,hemorrhage vaginal hemorrhage,1
TAFINLAR,vaginal hemorrhage,,0
TAFINLAR,hemorrhage intracranial,,0
TAFINLAR,hemorrhage intracranial,and,0
TAFINLAR,hemorrhage intracranial,epistaxis,0
TAFINLAR,hemorrhage intracranial,hemorrhage gastric hemorrhage epistaxis gingival hemorrhage hematuria vaginal hemorrhage,0
TAFINLAR,eye hemorrhage,hematuria vaginal hemorrhage hemorrhage eye hemorrhage,1
TAFINLAR,eye hemorrhage,hemorrhage hemorrhage eye,1
TAFINLAR,eye hemorrhage,,0
TAFINLAR,eye hemorrhage,hematuria,0
TAFINLAR,eye hemorrhage,vaginal hemorrhage hemorrhage eye hemorrhage,1
TAFINLAR,vitreous hemorrhage,,0
TAFINLAR,vitreous hemorrhage,,0
TAFINLAR,vitreous hemorrhage,hemorrhage vitreous,1
TAFINLAR,vitreous hemorrhage,hemorrhage,1
TAFINLAR,vitreous hemorrhage,hemorrhage vitreous hemorrhage,1
TAFINLAR,renal failure,the following,0
TAFINLAR,renal failure,adverse reactions N,0
TAFINLAR,renal failure,following,0
TAFINLAR,renal failure,renal failure acute Other clinically important adverse,0
TAFINLAR,renal failure,f Includes the following renal,1
TAFINLAR,renal failure,f Includes the following terms,0
TAFINLAR,renal failure,the following renal,1
TAFINLAR,renal failure,and renal,0
TAFINLAR,renal failure,the following renal failure,1
TAFINLAR,renal failure,following,0
TAFINLAR,Vision blurred,patients treated with,0
TAFINLAR,Vision blurred,trametinib were Eye,0
TAFINLAR,Vision blurred,with trametinib were Eye Vision blurred,1
TAFINLAR,Vision blurred,Vision blurred,1
TAFINLAR,transient blindness,blindness,1
TAFINLAR,transient blindness,transient blindness,1
TAFINLAR,transient blindness,with TAFINLAR in combination with trametinib were Eye Disorders Vision blurred,0
TAFINLAR,transient blindness,Eye Disorders Vision blurred,0
TAFINLAR,transient blindness,Disorders Vision transient blindness,1
TAFINLAR,transient blindness,Disorders Stomatitis pancreatitis General Disorders and,0
TAFINLAR,transient blindness,Disorders Vision transient,1
TAFINLAR,transient blindness,Eye Disorders Vision transient,1
TAFINLAR,transient blindness,,0
TAFINLAR,Stomatitis,Stomatitis,1
TAFINLAR,Stomatitis,Stomatitis,1
TAFINLAR,Stomatitis,Vision blurred transient,0
TAFINLAR,Stomatitis,blindness Gastrointestinal Stomatitis,1
TAFINLAR,Stomatitis,Stomatitis,1
TAFINLAR,pancreatitis,pancreatitis,1
TAFINLAR,pancreatitis,transient blindness Gastrointestinal Disorders pancreatitis,1
TAFINLAR,pancreatitis,pancreatitis,1
TAFINLAR,pancreatitis,Site Conditions Asthenia Infections and,0
TAFINLAR,pancreatitis,,0
TAFINLAR,pancreatitis,blindness Gastrointestinal Disorders pancreatitis,1
TAFINLAR,pancreatitis,pancreatitis,1
TAFINLAR,pancreatitis,pancreatitis,1
TAFINLAR,pancreatitis,pancreatitis,1
TAFINLAR,pancreatitis,pancreatitis,1
TAFINLAR,Asthenia,and Administration Site,0
TAFINLAR,Asthenia,General Disorders and Administration Site,0
TAFINLAR,Asthenia,Asthenia,1
TAFINLAR,Cellulitis,Cellulitis,1
TAFINLAR,Cellulitis,Cellulitis,1
TAFINLAR,Cellulitis,Asthenia Infections and Cellulitis,1
TAFINLAR,Cellulitis,Conditions Asthenia Infections and Cellulitis,1
TAFINLAR,Cellulitis,Cellulitis,1
TAFINLAR,Cellulitis,Cellulitis,1
TAFINLAR,Cellulitis,Unspecified inclu,0
TAFINLAR,folliculitis,Asthenia Infections and,0
TAFINLAR,folliculitis,and Infestations folliculitis,1
TAFINLAR,folliculitis,Administration Site Conditions Asthenia Infections and Infestations Cellulitis,0
TAFINLAR,folliculitis,and,0
TAFINLAR,folliculitis,Infections,0
TAFINLAR,folliculitis,folliculitis,1
TAFINLAR,folliculitis,folliculitis,1
TAFINLAR,folliculitis,,0
TAFINLAR,paronychia,paronychia,1
TAFINLAR,paronychia,Conditions Asthenia Infections and,0
TAFINLAR,paronychia,Neoplasms Benign Malignant and Unspecified,0
TAFINLAR,paronychia,,0
TAFINLAR,rash pustular,and Infestations Cellulitis folliculitis rash,1
TAFINLAR,rash pustular,and Unspecified including cysts and polyps Skin papilloma,0
TAFINLAR,rash pustular,,0
TAFINLAR,rash pustular,,0
TAFINLAR,rash pustular,,0
TAFINLAR,rash pustular,Malignant and Unspecified including cysts and polyps,0
TAFINLAR,rash pustular,,0
TAFINLAR,Skin papilloma,papilloma,1
TAFINLAR,Skin papilloma,cysts and Skin papilloma,1
TAFINLAR,Skin papilloma,papilloma,1
TAFINLAR,Skin papilloma,Neoplasms Benign Malignant and Unspecified including cysts and,0
TAFINLAR,Palmar-plantar erythrodysesthesia syndrome,Palmar-plantar erythrodysesthesia syndrome,1
TAFINLAR,Palmar-plantar erythrodysesthesia syndrome,erythrodysesthesia syndrome,1
TAFINLAR,Palmar-plantar erythrodysesthesia syndrome,Vascular,0
TAFINLAR,Palmar-plantar erythrodysesthesia syndrome,erythrodysesthesia syndrome,1
TAFINLAR,Palmar-plantar erythrodysesthesia syndrome,papilloma Skin,0
TAFINLAR,hyperkeratosis,hyperkeratosis,1
TAFINLAR,hyperkeratosis,hyperkeratosis,1
TAFINLAR,hyperkeratosis,,0
TAFINLAR,hyperkeratosis,,0
TAFINLAR,hyperkeratosis,hyperkeratosis,1
TAFINLAR,hyperkeratosis,Tissue Disorders,0
TAFINLAR,hyperkeratosis,hyperkeratosis,1
TAFINLAR,hyperkeratosis,Subcutaneous Tissue Disorders Palmarplantar erythrodysesthesia syndrome,0
TAFINLAR,hyperkeratosis,hyperkeratosis,1
TAFINLAR,hyperhidrosis,Table,0
TAFINLAR,hyperhidrosis,,0
TAFINLAR,hyperhidrosis,Subcutaneous Tissue Disorders,0
TAFINLAR,hyperhidrosis,Disorders,0
TAFINLAR,hyperhidrosis,,0
TAFINLAR,hyperhidrosis,Hypertension,0
TAFINLAR,Hypertension,erythrodysesthesia syndrome,0
TAFINLAR,Hypertension,Hypertension,1
TAFINLAR,Hypertension,erythrodysesthesia,0
TAFINLAR,Hypertension,syndrome hyperkeratosis hyperhidrosis Vascular Hypertension,1
TAFINLAR,Hypertension,hyperkeratosis hyperhidrosis,0
TAFINLAR,Hypertension,Hypertension,1
TAFINLAR,Hypertension,Occurring at All,0
TAFINLAR,Leukopenia,,0
TAFINLAR,Leukopenia,,0
TAFINLAR,Leukopenia,Leukopenia,1
TAFINLAR,Leukopenia,Leukopenia,1
TAFINLAR,Leukopenia,Leukopenia,1
TAFINLAR,Leukopenia,a Leukopenia,1
TAFINLAR,Leukopenia,,0
TAFINLAR,Leukopenia,,0
TAFINLAR,Leukopenia,,0
TAFINLAR,Lymphopenia,Lymphopenia,1
TAFINLAR,Lymphopenia,Lymphopenia,1
TAFINLAR,Lymphopenia,Lymphopenia,1
TAFINLAR,Neutropenia,,0
TAFINLAR,Anemia,Anemia,1
TAFINLAR,Anemia,Anemia,1
TAFINLAR,Anemia,,0
TAFINLAR,Anemia,Anemia,1
TAFINLAR,Thrombocytopenia,,0
TAFINLAR,Thrombocytopenia,,0
TAFINLAR,Thrombocytopenia,,0
TAFINLAR,Thrombocytopenia,,0
TAFINLAR,Thrombocytopenia,,0
TAFINLAR,Thrombocytopenia,,0
TAFINLAR,Thrombocytopenia,Thrombocytopenia,1
TAFINLAR,Thrombocytopenia,Thrombocytopenia,1
TAFINLAR,Thrombocytopenia,,0
TAFINLAR,Thrombocytopenia,,0
TAFINLAR,Increased AST,Function Increased AST,1
TAFINLAR,Increased AST,,0
TAFINLAR,Increased AST,Liver Function Increased,1
TAFINLAR,Increased AST,,0
TAFINLAR,Increased AST,AST,1
TAFINLAR,Increased alkaline phosphatase,Increased alkaline phosphatase,1
TAFINLAR,Increased alkaline phosphatase,Increased alkaline phosphatase,1
TAFINLAR,Increased alkaline phosphatase,,0
TAFINLAR,Increased alkaline phosphatase,,0
TAFINLAR,Increased alkaline phosphatase,Increased alkaline phosphatase,1
TAFINLAR,Increased alkaline phosphatase,,0
TAFINLAR,Increased alkaline phosphatase,Increased,1
TAFINLAR,Increased alkaline phosphatase,,0
TAFINLAR,Increased ALT,,0
TAFINLAR,Increased ALT,Increased ALT,1
TAFINLAR,Hyperbilirubinemia,Hyperbilirubinemia,1
TAFINLAR,Hyperbilirubinemia,Hyperbilirubinemia,1
TAFINLAR,Hyperbilirubinemia,,0
TAFINLAR,Hyperbilirubinemia,Hyperbilirubinemia,1
TAFINLAR,Hyperbilirubinemia,,0
TAFINLAR,Hyperglycemia,Hyperglycemia,1
TAFINLAR,Increased GGT,,0
TAFINLAR,Increased GGT,Increased GGT,1
TAFINLAR,Increased GGT,GGT,1
TAFINLAR,Increased GGT,,0
TAFINLAR,Hyponatremia,Hyponatremia,1
TAFINLAR,Hyponatremia,Hyponatremia,1
TAFINLAR,Hyponatremia,Hyponatremia,1
TAFINLAR,Hyponatremia,Hyponatremia,1
TAFINLAR,Hyponatremia,,0
TAFINLAR,Hypoalbuminemia,,0
TAFINLAR,Hypoalbuminemia,Hypoalbuminemia,1
TAFINLAR,Hypoalbuminemia,Hypoalbuminemia,1
TAFINLAR,Hypoalbuminemia,Hypoalbuminemia,1
TAFINLAR,Hypoalbuminemia,Hypoalbuminemia,1
TAFINLAR,Hypoalbuminemia,,0
TAFINLAR,Hypoalbuminemia,Hypoalbuminemia,1
TAFINLAR,Hypoalbuminemia,,0
TAFINLAR,Hypoalbuminemia,,0
TAFINLAR,Hypophosphatemia,Hypophosphatemia,1
TAFINLAR,Hypophosphatemia,Hypophosphatemia,1
TAFINLAR,Hypophosphatemia,Hypophosphatemia,1
TAFINLAR,Hypophosphatemia,,0
TAFINLAR,Hypophosphatemia,,0
TAFINLAR,Hypophosphatemia,Hypophosphatemia,1
TAFINLAR,Hypophosphatemia,Hypophosphatemia,1
TAFINLAR,Hypophosphatemia,,0
TAFINLAR,Hypophosphatemia,,0
TAFINLAR,Hypophosphatemia,,0
TAFINLAR,Hypokalemia,Hypokalemia,1
TAFINLAR,Hypokalemia,Hypokalemia,1
TAFINLAR,Hypokalemia,,0
TAFINLAR,Hypokalemia,Hypokalemia,1
TAFINLAR,Hypokalemia,,0
TAFINLAR,Hypokalemia,,0
TAFINLAR,Increased creatinine,,0
TAFINLAR,Increased creatinine,,0
TAFINLAR,Increased creatinine,,0
TAFINLAR,Increased creatinine,Increased,1
TAFINLAR,Increased creatinine,,0
TAFINLAR,Increased creatinine,Increased creatinine,1
TAFINLAR,Increased creatinine,creatinine,1
TAFINLAR,Increased creatinine,Increased creatinine,1
TAFINLAR,Hypomagnesemia,Hypomagnesemia,1
TAFINLAR,Hyperkalemia,,0
TAFINLAR,Hyperkalemia,,0
TAFINLAR,Hyperkalemia,,0
TAFINLAR,Hyperkalemia,,0
TAFINLAR,Hyperkalemia,Hyperkalemia,1
TAFINLAR,Hypercalcemia,Hypercalcemia,1
TAFINLAR,Hypercalcemia,Hypercalcemia,1
TAFINLAR,Hypercalcemia,Hypercalcemia,1
TAFINLAR,Hypercalcemia,Hypercalcemia,1
TAFINLAR,Hypercalcemia,,0
TAFINLAR,Hypercalcemia,Hypercalcemia,1
TAFINLAR,Hypercalcemia,,0
TAFINLAR,Hypocalcemia,Hypocalcemia,1
TAFINLAR,Hypocalcemia,,0
TAFINLAR,Hypocalcemia,,0
TAFINLAR,Hypocalcemia,,0
TAFINLAR,Hypocalcemia,Hypocalcemia,1
TAFINLAR,Hypocalcemia,,0
TAFINLAR,Hypocalcemia,,0
TAFINLAR,Hypocalcemia,,0
TAFINLAR,Hypocalcemia,Hypocalcemia,1
TAFINLAR,QTcF prolongation,QTcF prolongation,1
TAFINLAR,QTcF prolongation,glutamyltransferase QT Prolongation In QTcF prolongation,1
TAFINLAR,QTcF prolongation,glutamyltransferase QT Prolongation,0
TAFINLAR,QTcF prolongation,,0
TAFINLAR,QTcF prolongation,occurred in of,0
TAFINLAR,QTcF prolongation,glutamyltransferase QT Prolongation In QTcF prolongation,1
TAFINLAR,QTcF prolongation,glutamyltransferase QT,0
TAFINLAR,QTcF prolongation,QTcF prolongation,1
TAFINLAR,QTcF prolongation,glutamyltransferase QT Prolongation In,0
TAFINLAR,QTcF prolongation,Prolongation In QTcF prolongation,1
TAFINLAR,QTcF was increased,increased,1
TAFINLAR,QTcF was increased,patients,0
TAFINLAR,Retinal vein occlusion,ings and Precautions (,1
TAFINLAR,Retinal vein occlusion,Precautions Venous Thromboembolism see ings and,1
TAFINLAR,Interstitial lung disease,Precautions,0
TAFINLAR,Interstitial lung disease,[see W,1
TAFINLAR,Interstitial lung disease,Thromboembolism see Warnings and Precautions,0
TAFINLAR,Interstitial lung disease,    Cardiomyopathy [see W,1
TAFINLAR,Interstitial lung disease,Cardiomyopathy [see W,1
TAFINLAR,Interstitial lung disease,Precautions Ocular Toxicities,0
TAFINLAR,Interstitial lung disease,see Warnings,0
TAFINLAR,"primary malignancies, cutaneous",* Ocular,1
TAFINLAR,"primary malignancies, cutaneous",Warnings,0
TAFINLAR,"primary malignancies, cutaneous","see Warnings and cautions (5.5)]  
 *    Ocular ",1
TAFINLAR,"primary malignancies, cutaneous",Thromboembolism see Warnings and,0
TAFINLAR,"primary malignancies, cutaneous",see Warnings and,0
TAFINLAR,"primary malignancies, cutaneous","and cautions (5.5)]  
 *    Ocular ",1
TAFINLAR,"primary malignancies, cutaneous",cautions (5.5)] * Ocular,1
TAFINLAR,"primary malignancies, cutaneous",see Warnings,0
TAFINLAR,"primary malignancies, cutaneous","Warnings and cautions (5.5)]  
 *    Ocular ",1
TAFINLAR,"primary malignancies, cutaneous",see,0
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,"Dehydrogenase y [see Warnings and Precautions (5.10)]  
",1
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,y,1
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,,0
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,y [see Warnings and,1
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,hea,0
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,y [see Warnings and Precautions (5.10)],1
TAFINLAR,Increased cell proliferation,* Most,1
TAFINLAR,Increased cell proliferation,Warnings and  *    Most common adverse re,1
TAFINLAR,Increased cell proliferation,Warnings and Precautions,0
TAFINLAR,Hemorrhage, hyperkera,1
TAFINLAR,Hemorrhage,pyrexia arthralgia papilloma alopecia and palmarplantar erythrodysesthesia syn,0
TAFINLAR,Hemorrhage, hyperkera,1
TAFINLAR,Hemorrhage,,0
TAFINLAR,hemorrhagic events,,0
TAFINLAR,hemorrhagic events,arthralgia papilloma alopecia,0
TAFINLAR,hemorrhagic events,"are hyperkeratosis eadache, pyrexia, ",1
TAFINLAR,hemorrhagic events,papilloma alopecia,0
TAFINLAR,hemorrhagic events,,0
TAFINLAR,hemorrhagic events,"eadache, pyrexia,",1
TAFINLAR,hemorrhagic events,a single agent are,0
TAFINLAR,hemorrhagic events,agent are,0
TAFINLAR,Venous Thromboembolism,nausea,0
TAFINLAR,Venous Thromboembolism,common adverse  for TAFINLAR in combi,1
TAFINLAR,Venous Thromboembolism,fatigue rash nausea vomiting diarrhea abdominal,0
TAFINLAR,Venous Thromboembolism,pyrexia chills fatigue rash nausea vomiting diarrhea,0
TAFINLAR,Deep vein thrombosis,tion with trametinib,1
TAFINLAR,Deep vein thrombosis,for TAFINLAR in tion,1
TAFINLAR,Deep vein thrombosis,TAFINLAR in tion with trametinib,1
TAFINLAR,Deep vein thrombosis,tion with trametinib,1
TAFINLAR,Deep vein thrombosis,fatigue,0
TAFINLAR,Deep vein thrombosis,TAFINLAR in tion with,1
TAFINLAR,Deep vein thrombosis,tion with trametinib,1
TAFINLAR,Deep vein thrombosis,syndrome Most common adverse reactions,0
TAFINLAR,pulmonary embolism,,0
TAFINLAR,Cardiomyopathy,,0
TAFINLAR,Cardiomyopathy,"edema cough headache lgia, night sw",1
TAFINLAR,Cardiomyopathy,"headache lgia, night sw",1
TAFINLAR,Cardiomyopathy,"peripheral edema cough headache lgia, night sw",1
TAFINLAR,Cardiomyopathy,"edema cough headache lgia, night",1
TAFINLAR,Cardiomyopathy,,0
TAFINLAR,Cardiomyopathy,cough headache,0
TAFINLAR,Ocular Toxicities,,0
TAFINLAR,Ocular Toxicities,at or A,1
TAFINLAR,Ocular Toxicities,Trials Experience Because clinical,0
TAFINLAR,Ocular Toxicities,To report SUSPECTED ADVERSE REACTIONS contact GlaxoSmithKline at,0
TAFINLAR,Ocular Toxicities,at or A at 1-800-FDA-10,1
TAFINLAR,Ocular Toxicities,report SUSPECTED ADVERSE,0
TAFINLAR,Ocular Toxicities,A at 1-800-FDA-10,1
TAFINLAR,Ocular Toxicities,,0
TAFINLAR,Febrile Reactions,Trials Experience Because clinical are,1
TAFINLAR,pyrexia,"varying s,",1
TAFINLAR,pyrexia,adve,1
TAFINLAR,pyrexia,,0
TAFINLAR,pyrexia,condition,0
TAFINLAR,pyrexia,"s, adve",1
TAFINLAR,pyrexia,"conducted under widely varying s, adve",1
TAFINLAR,pyrexia,"s, adve",1
TAFINLAR,pyrexia,"conducted under widely varying s,",1
TAFINLAR,pyrexia,drug cannot be directly compared to,0
TAFINLAR,Skin Toxicity,the cl,1
TAFINLAR,Skin Toxicity,tes,1
TAFINLAR,Skin Toxicity,the cl,1
TAFINLAR,Skin Toxicity,compared to tes in the cl,1
TAFINLAR,Skin Toxicity,the clinical,0
TAFINLAR,Hyperglycemia,as a single agent in,1
TAFINLAR,Embryofetal Toxicity,"unresectable or ic melanoma,",1
TAFINLAR,Embryofetal Toxicity,"melanoma, previou",1
TAFINLAR,Embryofetal Toxicity,,0
TAFINLAR,Embryofetal Toxicity,"V mutationpositive unresectable or ic melanoma, previou",1
TAFINLAR,Embryofetal Toxicity,"ic melanoma, previou",1
TAFINLAR,Embryofetal Toxicity,or metastat,0
TAFINLAR,fetal harm,or metastatic melanoma,0
TAFINLAR,fetal harm,progression or,0
TAFINLAR,fetal harm,or metastatic melanoma previously or untreat,1
TAFINLAR,fetal harm,metastatic melanoma previously treated,0
TAFINLAR,fetal harm,BRAF V mutationpositive,0
TAFINLAR,fetal harm,BRAF V mutationpositive,0
TAFINLAR,fetal harm,mg orally twice daily until disease progression,0
TAFINLAR,fetal harm,,0
TAFINLAR,fetal harm,treated,0
TAFINLAR,fetal harm,metastatic melanoma previously or,1
TAFINLAR,"primary malignancies, cutaneous",in openlabel singlearm trials d,1
TAFINLAR,"primary malignancies, cutaneous",patients treated for more than months TAFINLAR was studied in,0
TAFINLAR,"primary malignancies, cutaneous","randomized,",1
TAFINLAR,"primary malignancies, cutaneous","an open-label, randomized,",1
TAFINLAR,"primary malignancies, cutaneous",mg range,0
TAFINLAR,cutaneous squamous cell carcinoma,identified from of Trial 1  [see Clinical Studies,1
TAFINLAR,keratoacanthoma,,0
TAFINLAR,keratoacanthoma,14.1)]. Trial,1
TAFINLAR,keratoacanthoma,14.1)]. Trial,1
TAFINLAR,keratoacanthoma,of Trial see Clinical 14.1)].,1
TAFINLAR,keratoacanthoma,see Clinical 14.1)].  Trial ,1
TAFINLAR,keratoacanthoma,Clinical 14.1)].,1
TAFINLAR,keratoacanthoma,see Clinical 14.1)].  Trial ,1
TAFINLAR,keratoacanthoma,Clinical 14.1)].  Trial ,1
TAFINLAR,keratoacanthoma,identified from analyses of Trial see,0
TAFINLAR,melanoma,m,0
TAFINLAR,melanoma,,0
TAFINLAR,melanoma,ulticent,1
TAFINLAR,melanoma,ulticent,1
TAFINLAR,melanoma,,0
TAFINLAR,melanoma,ulticent,1
TAFINLAR,melanoma,analyses of Trial see,0
TAFINLAR,basal cell carcinoma,,0
TAFINLAR,basal cell carcinoma,trial allocated with unresectable or,1
TAFINLAR,basal cell carcinoma,multicenter international,0
TAFINLAR,basal cell carcinoma,randomized controlled trial allocated with unresectable,1
TAFINLAR,basal cell carcinoma,TAFINLAR mg orally twice daily,0
TAFINLAR,basal cell carcinoma,n,0
TAFINLAR,cutaneous squamous cell carcinomas,,0
TAFINLAR,cutaneous squamous cell carcinomas,0E mutation-positive melanoma to r,1
TAFINLAR,cutaneous squamous cell carcinomas,twice daily n or,0
TAFINLAR,cutaneous squamous cell carcinomas,or metastatic BRAF 0E mutation-positive,1
TAFINLAR,cutaneous squamous cell carcinomas,unresectable or metastatic BRAF 0E mutation-positive melanoma,1
TAFINLAR,cutaneous squamous cell carcinomas,twice daily n or dacarbazine,0
TAFINLAR,cutaneous squamous cell carcinomas,mgm intravenously,0
TAFINLAR,keratoacanthomas,m,1
TAFINLAR,keratoacanthomas,to e TAFINLAR,1
TAFINLAR,keratoacanthomas,with unresectable or,0
TAFINLAR,keratoacanthomas,T,0
TAFINLAR,keratoacanthomas,or,0
TAFINLAR,keratoacanthomas,,0
TAFINLAR,keratoacanthomas,unresectable or metastatic BRAF VE mutationpositive melanoma,0
TAFINLAR,keratoacanthomas,to e TAFINLAR 150 m,1
TAFINLAR,keratoacanthomas,BRAF VE mutationpositive melanoma,0
TAFINLAR,cuSCC,orall,1
TAFINLAR,cuSCC,every,0
TAFINLAR,cuSCC,weeks n,0
TAFINLAR,cuSCC,melanoma to receive TAFINLAR orall,1
TAFINLAR,cuSCC,orall,1
TAFINLAR,cuSCC,unresectable or metastatic BRAF VE mutationpositive,0
TAFINLAR,cuSCC,y twice daily n or dacarbazine mgm,0
TAFINLAR,cuSCC,mgm intravenously every,0
TAFINLAR,cuSCC,orall,1
TAFINLAR,cuSCC,alve ,1
TAFINLAR,cuSCC,alve ,1
TAFINLAR,cuSCC,morphology Grade corrected,0
TAFINLAR,cuSCC,,0
TAFINLAR,cuSCC,alve ,1
TAFINLAR,cuSCC,trial excluded patients with abnormal,0
TAFINLAR,cuSCC,alve ,1
TAFINLAR,cuSCC,Grade corrected T,1
TAFINLAR,cuSCC,int,1
TAFINLAR,cuSCC,T int,1
TAFINLAR,cuSCC,valve morphology Grade corrected T int,1
TAFINLAR,cuSCC,int,1
TAFINLAR,cuSCC,ose-6,1
TAFINLAR,cuSCC,phosphate dehydrogenase deficiency The median duration on treatment was months for patients tr,0
TAFINLAR,cuSCC,or a known,0
TAFINLAR,cuSCC,a known history of glucosephosphate dehydrogenase,0
TAFINLAR,cuSCC,of,0
TAFINLAR,cuSCC,edian,1
TAFINLAR,cuSCC,patie,1
TAFINLAR,cuSCC,age of years,0
TAFINLAR,cuSCC,patie,1
TAFINLAR,cuSCC,months for patie,1
TAFINLAR,cuSCC,months for patie,1
TAFINLAR,cuSCC,patie,1
TAFINLAR,cuSCC,dacarbazinetreated,0
TAFINLAR,primary malignant melanomas,"99% white, and had a med",1
TAFINLAR,primary malignant melanomas,"e, 99% white, and had a med",1
TAFINLAR,primary malignant melanomas,,0
TAFINLAR,primary malignant melanomas,"to TAFINLAR was e, 99%",1
TAFINLAR,primary malignant melanomas,,0
TAFINLAR,primary malignant melanomas,commonly occurring adverse reactions in patients,0
TAFINLAR,primary malignant melanomas,The population exposed to,0
TAFINLAR,primary malignant melanomas,"was e, 99% white, and had a med",1
TAFINLAR,primary malignant melanomas,"e, 99% white, and had a med",1
TAFINLAR,primary malignant melanomas,dacarbazinetreated patients The population exposed to,0
TAFINLAR,basal cell carcinoma,"decreasing frequency hyperkeratosis eadache,",1
TAFINLAR,basal cell carcinoma,"decreasing frequency hyperkeratosis eadache,",1
TAFINLAR,basal cell carcinoma,"of decreasing frequency hyperkeratosis eadache, pyrexia, ar",1
TAFINLAR,basal cell carcinoma,"eadache,",1
TAFINLAR,basal cell carcinoma,hyperkeratosis,0
TAFINLAR,basal cell carcinoma,decreasing,0
TAFINLAR,basal cell carcinoma,ted with dacarbazine,1
TAFINLAR,basal cell carcinoma,,0
TAFINLAR,basal cell carcinoma,patients ted,1
TAFINLAR,basal cell carcinoma,dose,0
TAFINLAR,basal cell carcinoma,The most frequent adverse reactions leading to dose reduction of,0
TAFINLAR,basal cell carcinoma,medication in,0
TAFINLAR,Cutaneous squamous cell carcinoma,,0
TAFINLAR,Cutaneous squamous cell carcinoma,Table 3. Selected Common Adver,1
TAFINLAR,SCC,headache Table Selected,0
TAFINLAR,SCC,Occurring in All Grades or Grades or of Patients Treated,0
TAFINLAR,SCC,and headache Table Selected Common Adverse,0
TAFINLAR,SCC, Re,1
TAFINLAR,SCC,,0
TAFINLAR,SCC,Occurring in All Grades or Grades or of,0
TAFINLAR,SCC,Occurring in All Grades or Grades or of Patients Treated,0
TAFINLAR,SCC, Re,1
TAFINLAR,SCC, Re,1
TAFINLAR,SCC,,0
TAFINLAR,keratoacanthoma,ring in >=10% (,1
TAFINLAR,keratoacanthoma,of,0
TAFINLAR,keratoacanthoma,,0
TAFINLAR,cuSCC,and,0
TAFINLAR,cuSCC,Preferred Term All Grades Grades and,0
TAFINLAR,cuSCC,Dacarbazine 59   ,1
TAFINLAR,cuSCC,All Grades,0
TAFINLAR,cuSCC,,0
TAFINLAR,cuSCC,59   ,1
TAFINLAR,cuSCC,,0
TAFINLAR,cuSCC,Dacarbazine,0
TAFINLAR,cuSCC,and,0
TAFINLAR,primary melanoma,    Grades  3 an,1
TAFINLAR,malignancies,             NAf,1
TAFINLAR,malignancies,             NAf,1
TAFINLAR,non-cutaneous malignancies,erythrodysest,0
TAFINLAR,non-cutaneous malignancies,f Palmarplantar hesia,1
TAFINLAR,non-cutaneous malignancies,hesia syndrome            ,1
TAFINLAR,non-cutaneous malignancies,Palmarplantar hesia,1
TAFINLAR,non-cutaneous malignancies,Palmarplantar hesia syndrome            ,1
TAFINLAR,KRAS mutation-positive pancreatic adenocarcinoma,,0
TAFINLAR,KRAS mutation-positive pancreatic adenocarcinoma,,0
TAFINLAR,recurrent NRAS mutation-positive colorectal carcinoma,sia                                                      ,1
TAFINLAR,recurrent NRAS mutation-positive colorectal carcinoma,                                                     ,1
TAFINLAR,recurrent NRAS mutation-positive colorectal carcinoma,syndrome,0
TAFINLAR,recurrent NRAS mutation-positive colorectal carcinoma,,0
TAFINLAR,recurrent NRAS mutation-positive colorectal carcinoma,syndrome,0
TAFINLAR,head and neck carcinoma,2 2 Rash,1
TAFINLAR,head and neck carcinoma,,0
TAFINLAR,head and neck carcinoma,2 2 Rash,1
TAFINLAR,head and neck carcinoma,2,1
TAFINLAR,head and neck carcinoma,2 2 Rash,1
TAFINLAR,head and neck carcinoma,2 Rash,1
TAFINLAR,head and neck carcinoma,,0
TAFINLAR,head and neck carcinoma,,0
TAFINLAR,head and neck carcinoma,,0
TAFINLAR,glioblastoma,,0
TAFINLAR,increased cell proliferation,,0
TAFINLAR,increased cell proliferation,Headache                             ,1
TAFINLAR,increased cell proliferation,Headache                             ,1
TAFINLAR,increased cell proliferation,                            ,1
TAFINLAR,increased cell proliferation,,0
TAFINLAR,increased cell proliferation,                            ,1
TAFINLAR,increased cell proliferation,Headache,0
TAFINLAR,increased cell proliferation,Headache,0
TAFINLAR,Hemorrhages,,0
TAFINLAR,Hemorrhages,"
           Pyrexia",1
TAFINLAR,Hemorrhages,administration site conditions,0
TAFINLAR,Hemorrhages,"
           Pyrexia",1
TAFINLAR,Hemorrhages,"
           Pyrexia",1
TAFINLAR,hemorrhages,,0
TAFINLAR,hemorrhages,            Pyrexia,1
TAFINLAR,hemorrhages,            Pyrexia,1
TAFINLAR,hemorrhagic event,"    
  Musculoske letal and",1
TAFINLAR,hemorrhagic event,,0
TAFINLAR,hemorrhagic event,,0
TAFINLAR,hemorrhagic event,"    
  Musculoske letal and connective tissue disorders",1
TAFINLAR,hemorrhagic event,,0
TAFINLAR,hemorrhagic event,"    
  Musculoske letal and connective tissue disorders",1
TAFINLAR,hemorrhagic event,and,0
TAFINLAR,hemorrhagic event,,0
TAFINLAR,hemorrhagic event,"    
  Musculoske letal",1
TAFINLAR,hemorrhagic events,thralgia          ,1
TAFINLAR,hemorrhagic events,Ar,0
TAFINLAR,hemorrhagic events,Ar,0
TAFINLAR,hemorrhagic events,Ar thralgia          ,1
TAFINLAR,hemorrhagic events,,0
TAFINLAR,hemorrhagic events,Ar thralgia          ,1
TAFINLAR,hemorrhagic events,thralgia          ,1
TAFINLAR,hemorrhagic events,Ar thralgia          ,1
TAFINLAR,hemorrhagic events,Ar thralgia          ,1
TAFINLAR,gastric hemorrhage,                  ,1
TAFINLAR,gastric hemorrhage,,0
TAFINLAR,gastric hemorrhage,Arthralgia                   ,1
TAFINLAR,gastric hemorrhage,,0
TAFINLAR,gastric hemorrhage,,0
TAFINLAR,gastric hemorrhage,,0
TAFINLAR,gastric hemorrhage,,0
TAFINLAR,gastric hemorrhage,Arthralgia,0
TAFINLAR,Intracranial hemorrhage,"0         
             Back",1
TAFINLAR,Intracranial hemorrhage,"0         
            ",1
TAFINLAR,Intracranial hemorrhage,"0         
            ",1
TAFINLAR,Intracranial hemorrhage,,0
TAFINLAR,Intracranial hemorrhage,"0         
             Back",1
TAFINLAR,Intracranial hemorrhage,,0
TAFINLAR,Intracranial hemorrhage,"0         
             Back pain",1
TAFINLAR,Intracranial hemorrhage,"0         
            ",1
TAFINLAR,Intracranial hemorrhage,"0         
             Back pain",1
TAFINLAR,fatal,,0
TAFINLAR,fatal,      Back,1
TAFINLAR,fatal,      Back pain,1
TAFINLAR,fatal,      Back pain,1
TAFINLAR,fatal,Back,0
TAFINLAR,fatal,,0
TAFINLAR,fatal,,0
TAFINLAR,fatal,     ,1
TAFINLAR,Venous thromboembolism,                       Neoplasms,1
TAFINLAR,DVT,"  
 Papilloma",1
TAFINLAR,DVT,and polyps,0
TAFINLAR,DVT,,0
TAFINLAR,DVT,polyps,0
TAFINLAR,DVT,c,0
TAFINLAR,DVT,Papilloma,0
TAFINLAR,DVT,"  
 Papilloma",1
TAFINLAR,DVT,,0
TAFINLAR,DVT,"  
 Papilloma",1
TAFINLAR,pulmonary embolism,cysts and                    Papilloma,1
TAFINLAR,pulmonary embolism,                   Papilloma,1
TAFINLAR,pulmonary embolism,Papilloma c,0
TAFINLAR,pulmonary embolism,c,0
TAFINLAR,pulmonary embolism,,0
TAFINLAR,pulmonary embolism,c,0
TAFINLAR,pulmonary embolism,unspecified including,0
TAFINLAR,PE,,0
TAFINLAR,Pulmonary embolism,,0
TAFINLAR,Pulmonary embolism,                  ,1
TAFINLAR,fatal,     ,1
TAFINLAR,fatal,     ,1
TAFINLAR,fatal,,0
TAFINLAR,Cardiomyopathy,        Cough ,1
TAFINLAR,Cardiomyopathy,        Cough ,1
TAFINLAR,Cardiomyopathy,,0
TAFINLAR,Cardiomyopathy,,0
TAFINLAR,Cardiomyopathy,,0
TAFINLAR,Cardiomyopathy,        Cough ,1
TAFINLAR,cardiomyopathy,disorders,0
TAFINLAR,cardiomyopathy,Gastrointestinal,0
TAFINLAR,cardiomyopathy,,0
TAFINLAR,cardiomyopathy,,0
TAFINLAR,cardiomyopathy,               Constipation,1
TAFINLAR,cardiomyopathy,               Constipation,1
TAFINLAR,cardiomyopathy,,0
TAFINLAR,cardiomyopathy,               Constipation,1
TAFINLAR,cardiomyopathy,               Constipation,1
TAFINLAR,cardiomyopathy,               Constipation,1
TAFINLAR,cardiomyopathy,               Constipation,1
TAFINLAR,cardiomyopathy,               Constipation,1
TAFINLAR,cardiomyopathy,               Constipation,1
TAFINLAR,Cardiomyopathy,,0
TAFINLAR,cardiomyopathy,Infections,1
TAFINLAR,cardiomyopathy,Infections an d,1
TAFINLAR,cardiomyopathy, Infections an,1
TAFINLAR,cardiomyopathy,,0
TAFINLAR,cardiomyopathy,,0
TAFINLAR,cardiomyopathy, Infections an,1
TAFINLAR,cardiomyopathy, Infections an d infestations,1
TAFINLAR,cardiomyopathy,              ,1
TAFINLAR,decrease in LVEF,Nasopharyngitis,0
TAFINLAR,decrease in LVEF,Nasopharyngitis                 ,1
TAFINLAR,decrease in LVEF,Nasopharyngitis,0
TAFINLAR,decrease in LVEF,Nasopharyngitis                 ,1
TAFINLAR,absolute decrease in LVEF,                          a,1
TAFINLAR,absolute decrease in LVEF,                          a Adverse,1
TAFINLAR,absolute decrease in LVEF,,0
TAFINLAR,absolute decrease in LVEF,CTCAE ve,1
TAFINLAR,Retinal pigment epithelial detachments,emia                                   Hypophosphatemia,1
TAFINLAR,Retinal pigment epithelial detachments,emia                                   Hypophosphatemia,1
TAFINLAR,Retinal pigment epithelial detachments,Grades Grades,0
TAFINLAR,Retinal pigment epithelial detachments,,0
TAFINLAR,Retinal pigment epithelial detachments,emia                                   Hypophosphatemia,1
TAFINLAR,Retinal pigment epithelial detachments,emia                                   Hypophosphatemia,1
TAFINLAR,Retinal pigment epithelial detachments,,0
TAFINLAR,Retinal pigment epithelial detachments,All Grades Grades and emia                                   Hypophosphatemia,1
TAFINLAR,RPED,,0
TAFINLAR,RPED,All Grades Grades and      Hypophosphatemia,1
TAFINLAR,RPED,     Hypophosphatemia,1
TAFINLAR,Retinal detachments,"           
  Incre",1
TAFINLAR,Retinal detachments,"           
  Incre",1
TAFINLAR,Retinal detachments,"           
  Incre",1
TAFINLAR,Retinal detachments,,0
TAFINLAR,Retinal detachments,"           
  Incre",1
TAFINLAR,RPED,bnor,1
TAFINLAR,RPED,,0
TAFINLAR,RPED,bnor,1
TAFINLAR,RPED,reactions,0
TAFINLAR,RPED,,0
TAFINLAR,RPED,Other clinically important,0
TAFINLAR,RPED,,0
TAFINLAR,RPED,Other,0
TAFINLAR,RPED,Immune System Disorders Hypersensitivity manifesting as,0
TAFINLAR,RPED,in of patients N treated with TAFINLAR were Gastrointestinal Disorders,0
TAFINLAR,RPED,treated with,0
TAFINLAR,Uveitis,combination,0
TAFINLAR,Uveitis,toxicity Among these patients were exposed to TAFINLAR,0
TAFINLAR,Uveitis,to TAFINLAR and were ex,0
TAFINLAR,Uveitis,once daily until disease or,1
TAFINLAR,Uveitis,or,1
TAFINLAR,Uveitis,daily in combination with trametinib mg orally once daily until disease,0
TAFINLAR,iritis,these patients were exposed to TAFINLAR and were exposed to,0
TAFINLAR,iritis,Among these patients were exposed to,0
TAFINLAR,iritis,t,1
TAFINLAR,iritis,able t,1
TAFINLAR,Uveitis,these,0
TAFINLAR,Uveitis,r great,1
TAFINLAR,Uveitis,great,1
TAFINLAR,Uveitis,were exposed,0
TAFINLAR,Uveitis,to trametinib fo,0
TAFINLAR,Uveitis,exposed to TAFINLAR and,0
TAFINLAR,iritis,,0
TAFINLAR,iritis, 12 mo,1
TAFINLAR,iritis,to TAFINLAR and were exposed to trametinib for greater tha,0
TAFINLAR,iritis,greater than 12,1
TAFINLAR,uveitis,years were,0
TAFINLAR,uveitis,years were,0
TAFINLAR,febrile reactions,of acute coronary syndrome within months,0
TAFINLAR,febrile reactions,current evidence,0
TAFINLAR,febrile reactions,. Pa,1
TAFINLAR,febrile reactions,daily n see Clinical ies (14.2)],1
TAFINLAR,fever,s wit,1
TAFINLAR,fever,Clinical Studies s wit,1
TAFINLAR,fever,,0
TAFINLAR,hypotension,of e coronary ,1
TAFINLAR,hypotension,York,0
TAFINLAR,rigors,of acute coronary ndrome,1
TAFINLAR,rigors,of acute coronary ndrome,1
TAFINLAR,rigors,coronary,0
TAFINLAR,rigors,ndrome,1
TAFINLAR,rigors,of acute coronary ndrome,1
TAFINLAR,rigors,ndrome,1
TAFINLAR,rigors,abnormal LVEF history of acute coronary,0
TAFINLAR,rigors,with abnormal LVEF history of acute,0
TAFINLAR,rigors,ndrome,1
TAFINLAR,chills,hin 6,1
TAFINLAR,chills,of acute coronary syndrome hin 6 ,1
TAFINLAR,chills,Studies Patients with abnormal,0
TAFINLAR,chills,York Heart,0
TAFINLAR,dehydration,with,0
TAFINLAR,dehydration,LVEF history,0
TAFINLAR,dehydration,failure New York Heart Association,0
TAFINLAR,dehydration,Class II,0
TAFINLAR,dehydration,Patients with abnormal LVEF history of acute coronary syndrome,0
TAFINLAR,dehydration,failure,0
TAFINLAR,dehydration,"coronary syndrome within nths, curre",1
TAFINLAR,dehydration,,0
TAFINLAR,renal failure,idence of Cla,1
TAFINLAR,renal failure,idence of,1
TAFINLAR,renal failure,current,0
TAFINLAR,renal failure,current idence of Cla,1
TAFINLAR,renal failure,current idence of,1
TAFINLAR,renal failure,months current idence of Cla,1
TAFINLAR,renal failure,Cla,1
TAFINLAR,renal failure,of Cla,1
TAFINLAR,renal failure,syndrome within months current idence of,1
TAFINLAR,pyrexia,treatment,0
TAFINLAR,pyrexia,lung disease or,0
TAFINLAR,pyrexia,ory,1
TAFINLAR,fever,treatment group,0
TAFINLAR,fever,as 10,1
TAFINLAR,fever,as 10,1
TAFINLAR,fever,treatment w,0
TAFINLAR,fever,median duration of treatment as 10,1
TAFINLAR,fever,disease or a known history of GPD,0
TAFINLAR,fever,as,1
TAFINLAR,fever,of GPD deficiency were excluded The,0
TAFINLAR,fever,duration of treatment as,1
TAFINLAR,fever,10,1
TAFINLAR,fever,oncedaily nt gr,1
TAFINLAR,fever,a single agent,0
TAFINLAR,fever,a single,0
TAFINLAR,febrile reactions,single agent In Trial of,0
TAFINLAR,febrile reactions,R in combination,1
TAFINLAR,febrile reactions,R,1
TAFINLAR,febrile reactions,receiving R,1
TAFINLAR,febrile reactions,in combination,1
TAFINLAR,fever,trame,1
TAFINLAR,fever,adverse reactions resulting,0
TAFINLAR,fever,in combination trame,1
TAFINLAR,fever,of trial medications T,0
TAFINLAR,fever,,0
TAFINLAR,fever,trame,1
TAFINLAR,fever,patients receiving TAFINLAR in,0
TAFINLAR,hypotension,with trametinib experienced adverse,0
TAFINLAR,hypotension,ons resulti,1
TAFINLAR,hypotension,trametinib experienced adverse ons,1
TAFINLAR,hypotension,,0
TAFINLAR,hypotension,resulting,0
TAFINLAR,rigors,TAFINLAR,0
TAFINLAR,rigors,reaction resulting,0
TAFINLAR,rigors,in pe,1
TAFINLAR,rigors,rmanent discontinuation of trial medications The most common adverse reaction resulting in perman,0
TAFINLAR,rigors,pe,1
TAFINLAR,rigors,trametinib experienced adverse reactions,0
TAFINLAR,rigors,pe,1
TAFINLAR,chills,di,1
TAFINLAR,chills,experienced adverse reactions resulting in perman,0
TAFINLAR,chills,reactions,0
TAFINLAR,chills,di,1
TAFINLAR,chills,,0
TAFINLAR,chills,medications The most common adverse reaction resulting in permanent discon,0
TAFINLAR,chills,ent di,1
TAFINLAR,fever,dose ,1
TAFINLAR,fever,led dose ,1
TAFINLAR,fever,dose ,1
TAFINLAR,fever,TAFINLAR in,0
TAFINLAR,fever,,0
TAFINLAR,fever,resulting in permanent discontinuation was pyrexia,0
TAFINLAR,fever,dose ,1
TAFINLAR,fever,reactions,0
TAFINLAR,fever,to,0
TAFINLAR,fever,dose ,1
TAFINLAR,fever,dose interruptions,0
TAFINLAR,fever,in and dose,0
TAFINLAR,fever,,0
TAFINLAR,fever,TAFINLAR in combination wit,0
TAFINLAR,fever,dose ,1
TAFINLAR,febrile reactions,yrexia,0
TAFINLAR,febrile reactions,reasons cited for reductions,1
TAFINLAR,febrile reactions,,0
TAFINLAR,fever,of,0
TAFINLAR,fever,ch,1
TAFINLAR,fever,"and a, ch",1
TAFINLAR,fever,nausea were,0
TAFINLAR,fever,"and a,",1
TAFINLAR,fever,pyrexi,0
TAFINLAR,fever,"dose reductions and a, ch",1
TAFINLAR,fever,"a, ch",1
TAFINLAR,hypotension,the,0
TAFINLAR,hypotension,were,1
TAFINLAR,hypotension,for dose reductions and pyrexia chills and decreased,0
TAFINLAR,hypotension,of TAFINLAR and trametinib when used,0
TAFINLAR,hypotension,ction,1
TAFINLAR,hypotension,,0
TAFINLAR,hypotension,for dose reductions and pyrexia chills and decreased ejection,0
TAFINLAR,hypotension,reasons cited for dose reductions,0
TAFINLAR,hypotension,were,1
TAFINLAR,rigors,pyrexia chills and decreased ejection fraction were th,0
TAFINLAR,rigors,decreased ejection fraction were e most,1
TAFINLAR,rigors,common reasons cited for dose interruptions of TAFINLAR and trametinib when used in combination,0
TAFINLAR,rigors,fraction were e,1
TAFINLAR,rigors,fraction were e most,1
TAFINLAR,rigors,used in,0
TAFINLAR,rigors,for dose interruptions of TAFINLAR and,0
TAFINLAR,rigors,TAFINLAR and trametinib when used in combination,0
TAFINLAR,chills,and trametinib when used in combination,0
TAFINLAR,chills,mon,1
TAFINLAR,chills,mon,1
TAFINLAR,chills,interruptions of TAFINLAR,0
TAFINLAR,chills,fraction were the most mon re,1
TAFINLAR,chills,fraction were,0
TAFINLAR,chills,were the most com,0
TAFINLAR,Fever,Common Adverse Drug Reactions Occurring,0
TAFINLAR,Fever,Combination With Trametinib in Trial,0
TAFINLAR,Fever,Grades or of Patients Treated,0
TAFINLAR,Fever,in at All Grades r >=5,1
TAFINLAR,Fever,in at All,0
TAFINLAR,rigors,TAFINLAR in Combination With Trametinib in Trial Adverse Reactions TAFINLAR,0
TAFINLAR,rigors,or Grades or of  Treat,1
TAFINLAR,dehydration,Combinat,1
TAFINLAR,renal failure,in Combination With inib in Trial,1
TAFINLAR,renal failure,TAFINLAR in Combination With inib in Trial,1
TAFINLAR,renal failure,TAFINLAR in Combination With inib,1
TAFINLAR,renal failure,Patients,0
TAFINLAR,renal failure,plus Trametinib,0
TAFINLAR,renal failure,in Combination,0
TAFINLAR,renal failure,or Grades or of Patients Treated With TAFINLAR in Combination With,0
TAFINLAR,fever,All Gradesa 3,1
TAFINLAR,fever,3,1
TAFINLAR,fever,All Gradesa 3,1
TAFINLAR,fever,N All,0
TAFINLAR,fever,All Gradesa Grades and General disorders,0
TAFINLAR,fever,and,1
TAFINLAR,fever,,0
TAFINLAR,fever,General disorders and ive s,1
TAFINLAR,fever,and administrat,0
TAFINLAR,fever,,0
TAFINLAR,fever,Grades and All Gradesa Grades,0
TAFINLAR,fever,and General disorders and ive,1
TAFINLAR,pyrexia,      0 Chills,1
TAFINLAR,pyrexia,,0
TAFINLAR,pyrexia,      0 Chills,1
TAFINLAR,pyrexia,      0 Chills,1
TAFINLAR,pyrexia,,0
TAFINLAR,pyrexia,      0 Chills,1
TAFINLAR,pyrexia,,0
TAFINLAR,pyrexia,      0 Chills,1
TAFINLAR,skin toxicity,Skin,1
TAFINLAR,skin toxicity," 
  Skin and  subcutaneous tissue disorders",1
TAFINLAR,skin toxicity,,0
TAFINLAR,skin toxicity,,0
TAFINLAR,skin toxicity,,0
TAFINLAR,skin toxicity,Sweats,0
TAFINLAR,skin toxicity,,0
TAFINLAR,skin toxicity,    6        ,1
TAFINLAR,skin toxicity,Dry skin,0
TAFINLAR,skin toxicity,,0
TAFINLAR,skin toxicity,,0
TAFINLAR,skin toxicity,    6         Dry skin,1
TAFINLAR,skin toxicity,    6        ,1
TAFINLAR,skin toxicity,,0
TAFINLAR,skin toxicity,,0
TAFINLAR,skin toxicity,,0
TAFINLAR,skin toxicity,,0
TAFINLAR,skin toxicity,     4        Actinic,1
TAFINLAR,skin toxicity,     4       ,1
TAFINLAR,secondary infections of the skin,keratosis,0
TAFINLAR,secondary infections of the skin,"        
                        Actinic",1
TAFINLAR,secondary infections of the skin,,0
TAFINLAR,Hyperglycemia,Pruritus,0
TAFINLAR,Hyperglycemia,             ,1
TAFINLAR,Hyperglycemia,Pruritus,0
TAFINLAR,Hyperglycemia,Pruritus,0
TAFINLAR,hyperglycemia,             ,1
TAFINLAR,hyperglycemia,Nausea              ,1
TAFINLAR,hyperglycemia,Vomiting              ,1
TAFINLAR,hyperglycemia,,0
TAFINLAR,hyperglycemia,Vomiting,0
TAFINLAR,hyperglycemia,Vomiting,0
TAFINLAR,hyperglycemia,,0
TAFINLAR,hyperglycemia,             ,1
TAFINLAR,hyperglycemia,Vomiting              ,1
TAFINLAR,hyperglycemia,Vomiting,0
TAFINLAR,hyperglycemia,Vomiting              ,1
TAFINLAR,hemolytic anemia,,0
TAFINLAR,hemolytic anemia,,0
TAFINLAR,hemolytic anemia,         0      ,1
TAFINLAR,hemolytic anemia,         0       Dry,1
TAFINLAR,fetal harm,           Headache,1
TAFINLAR,fetal harm,,0
TAFINLAR,fetal harm,,0
TAFINLAR,fetal harm,           Headache,1
TAFINLAR,teratogenic,           ,1
TAFINLAR,teratogenic,           ,1
TAFINLAR,teratogenic,           ,1
TAFINLAR,teratogenic,           ,1
TAFINLAR,teratogenic,system disorders            ,1
TAFINLAR,teratogenic,           ,1
TAFINLAR,teratogenic,,0
TAFINLAR,embryotoxic,,0
TAFINLAR,embryotoxic,           ,1
TAFINLAR,embryotoxic,,0
TAFINLAR,embryotoxic,,0
TAFINLAR,embryotoxic,           ,1
TAFINLAR,embryotoxic,,0
TAFINLAR,embryotoxic,,0
TAFINLAR,embryotoxic,           ,1
TAFINLAR,embryotoxic,,0
MULTAQ,worsening heart failure,New worsening heart failure see,1
MULTAQ,worsening heart failure,heart failure see,1
MULTAQ,Liver Injury,Warnings and Liver Injury see,1
MULTAQ,Hypokalemia,and Hypokalemia and,1
MULTAQ,Hypokalemia,and Hypokalemia and,1
MULTAQ,Hypokalemia,,0
MULTAQ,Hypokalemia,Precautions,0
MULTAQ,Hypokalemia,Hypokalemia and,1
MULTAQ,Hypokalemia,Warnings and Precautions,0
MULTAQ,hypomagnesemia,diuretics see Warnings and Precautions QT prolongation,0
MULTAQ,hypomagnesemia,,0
MULTAQ,hypomagnesemia,hypomagnesemia with,1
MULTAQ,hypomagnesemia,Hypokalemia,0
MULTAQ,hypomagnesemia,and Precautions Hypokalemia hypomagnesemia with,1
MULTAQ,hypomagnesemia,Precautions,0
MULTAQ,hypomagnesemia,toxicity see Warnings and Precautions Hypokalemia and,0
MULTAQ,hypomagnesemia,toxicity,0
MULTAQ,QT prolongation,,0
MULTAQ,QT prolongation,,0
MULTAQ,QT prolongation,,0
MULTAQ,QT prolongation,hypomagnesemia with potassiumdepleting diuretics,0
MULTAQ,QT prolongation,Warnings and QT prolongation see,1
MULTAQ,QT prolongation,,0
MULTAQ,diarrhea,diarrhea nausea,1
MULTAQ,diarrhea,common,0
MULTAQ,diarrhea,diarrhea nausea,1
MULTAQ,diarrhea,abdominal pain vomiting and asthenia To report SUSPECTED,0
MULTAQ,diarrhea,and Precautions EXCERPT Most,0
MULTAQ,diarrhea,diarrhea nausea,1
MULTAQ,diarrhea,adverse reactions diarrhea nausea,1
MULTAQ,diarrhea,adverse reactions diarrhea nausea,1
MULTAQ,diarrhea,diarrhea nausea,1
MULTAQ,nausea,nausea abdominal,1
MULTAQ,abdominal pain,pain vomiting,1
MULTAQ,abdominal pain,Most,0
MULTAQ,abdominal pain,,0
MULTAQ,abdominal pain,ADVERSE REACTIONS,0
MULTAQ,abdominal pain,vomiting and asthenia To,0
MULTAQ,abdominal pain,vomiting,0
MULTAQ,abdominal pain,diarrhea,0
MULTAQ,vomiting,vomiting and,1
MULTAQ,asthenia,ADVERSE REACTIONS contact sanofiaventis US,0
MULTAQ,asthenia,asthenia To,1
MULTAQ,asthenia,pain vomiting asthenia To,1
MULTAQ,asthenia,contact sanofiaventis US LLC at,0
MULTAQ,gastrointestinal disorders,gastrointestinal,1
MULTAQ,gastrointestinal disorders,the placebo group,0
MULTAQ,gastrointestinal disorders,the placebo group and QT prolongation versus,0
MULTAQ,gastrointestinal disorders,with MULTAQ gastrointestinal,1
MULTAQ,gastrointestinal disorders,gastrointestinal disorders versus,1
MULTAQ,gastrointestinal disorders,disorders versus,1
MULTAQ,gastrointestinal disorders,gastrointestinal disorders versus,1
MULTAQ,QT prolongation,QT prolongation versus,1
MULTAQ,QT prolongation,gastrointestinal disorders versus in the placebo group,0
MULTAQ,QT prolongation,,0
MULTAQ,QT prolongation,with MULT,0
MULTAQ,QT prolongation,QT,1
MULTAQ,QT prolongation,The most frequent adverse reactions observed with,0
MULTAQ,QT prolongation,group The,0
MULTAQ,diarrhea,nausea abdominal pain vomiting and asthenia Table displays adverse reactions more common,0
MULTAQ,diarrhea,diarrhea nausea,1
MULTAQ,diarrhea,,0
MULTAQ,diarrhea,mg twice daily in the studies,0
MULTAQ,diarrhea,studies diarrhea nausea,1
MULTAQ,nausea,nausea abdominal,1
MULTAQ,nausea,nausea abdominal,1
MULTAQ,nausea,nausea abdominal,1
MULTAQ,nausea,,0
MULTAQ,nausea,nausea abdominal,1
MULTAQ,abdominal pain,abdominal pain vomiting,1
MULTAQ,abdominal pain,vomiting,0
MULTAQ,abdominal pain,dronedarone mg,0
MULTAQ,asthenia,asthenia Table,1
MULTAQ,asthenia,asthenia Table,1
MULTAQ,Diarrhea,tinal,0
MULTAQ,Diarrhea,Diarrhea,1
MULTAQ,Nausea,,0
MULTAQ,Nausea,,0
MULTAQ,Nausea,,0
MULTAQ,Nausea,Nausea,1
MULTAQ,Nausea,,0
MULTAQ,Nausea,Nausea,1
MULTAQ,Nausea,,0
MULTAQ,Nausea,,0
MULTAQ,Nausea,,0
MULTAQ,Abdominal pain,,0
MULTAQ,Abdominal pain,,0
MULTAQ,Abdominal pain,Abdominal,1
MULTAQ,Abdominal pain,Abdominal pain Vomit,1
MULTAQ,Abdominal pain,,0
MULTAQ,Vomiting,pain Vomiting,1
MULTAQ,Vomiting,,0
MULTAQ,Vomiting,pain,0
MULTAQ,Vomiting,,0
MULTAQ,Dyspeptic signs and symptoms,,0
MULTAQ,Dyspeptic signs and symptoms,,0
MULTAQ,Dyspeptic signs and symptoms,,0
MULTAQ,Dyspeptic signs and symptoms,Dyspeptic signs and,1
MULTAQ,Dyspeptic signs and symptoms,,0
MULTAQ,Dyspeptic signs and symptoms,Dyspeptic signs and,1
MULTAQ,Asthenic conditions,Asthenic conditions Cardiac,1
MULTAQ,Bradycardia,Bradycardia Skin,1
MULTAQ,Bradycardia,,0
MULTAQ,Bradycardia,,0
MULTAQ,Bradycardia,,0
MULTAQ,Bradycardia,,0
MULTAQ,Bradycardia,Skin,0
MULTAQ,Bradycardia,Bradycardia Skin,1
MULTAQ,rashes,Including,0
MULTAQ,rashes,rashes generalized,1
MULTAQ,rashes,eczema dermatitis dermatitis,0
MULTAQ,rashes,dermatitis dermatitis alle,0
MULTAQ,rashes,rashes generalized,1
MULTAQ,rashes,rashes generalized,1
MULTAQ,pruritus,pruritus eczema,1
MULTAQ,pruritus,pruritus eczema,1
MULTAQ,eczema,eczema dermatitis,1
MULTAQ,eczema,,0
MULTAQ,eczema,macular maculopapular erythematous pruritus,0
MULTAQ,eczema,macular maculopapular erythematous eczema dermatitis,1
MULTAQ,dermatitis,dermatitis dermatitis,1
MULTAQ,dermatitis,,0
MULTAQ,dermatitis,maculopapular erythematous pruritus dermatitis dermatitis,1
MULTAQ,dermatitis,allergic P,0
MULTAQ,dermatitis allergic,,0
MULTAQ,dermatitis allergic,allergic Photosensitivity,1
MULTAQ,dermatitis allergic,dermatitis allergic Photosensitivity,1
MULTAQ,dermatitis allergic,maculopapular erythematous pruritus eczema dermatitis allergic Photosensitivity,1
MULTAQ,dermatitis allergic,generalized,0
MULTAQ,dermatitis allergic,dermatitis allergic Photosensitivity,1
MULTAQ,dermatitis allergic,pruritus,0
MULTAQ,dermatitis allergic,Photosensitivity react,0
MULTAQ,dermatitis allergic,,0
MULTAQ,Photosensitivity reaction,have also been reported at an incidence less than in,0
MULTAQ,dysgeusia,dysgeusia have,1
MULTAQ,dysgeusia,Photosensitivity reaction dysgeusia have,1
MULTAQ,dysgeusia,dysgeusia have,1
MULTAQ,dysgeusia,,0
MULTAQ,dysgeusia,dysgeusia have,1
MULTAQ,dysgeusia,dysgeusia have,1
MULTAQ,dysgeusia,reaction dysgeusia have,1
MULTAQ,dysgeusia,,0
MULTAQ,dysgeusia,,0
MULTAQ,increases in creatinine,increases in creatinine,1
MULTAQ,increases in creatinine,,0
MULTAQ,increases in creatinine,creatinine,1
MULTAQ,increases in creatinine,in creatinine,1
MULTAQ,increases in creatinine,N increases,1
MULTAQ,increases in creatinine,creatinine,1
MULTAQ,increases in creatinine,,0
MULTAQ,QTc prolonged,,0
MULTAQ,QTc prolonged,QTc prolonged,1
MULTAQ,heart failure,or heart failure see,1
MULTAQ,heart failure,Atrial flutter with atrioventricular conduction,0
MULTAQ,heart failure,heart,1
MULTAQ,heart failure,failure see,1
MULTAQ,heart failure,or heart failure see,1
MULTAQ,heart failure,establish a causal relationship,0
MULTAQ,heart failure,heart failure see,1
MULTAQ,heart failure,failure see,1
MULTAQ,Atrial flutter,with atrioventricular conduction has been reported very rarely Hepatic,0
MULTAQ,Atrial flutter,and Atrial flutter with,1
MULTAQ,Atrial flutter,with atrioventricular conduction has been reported very,0
MULTAQ,Atrial flutter,atrioventricular conduction has been reported,0
MULTAQ,Atrial flutter,flutter with,1
MULTAQ,Atrial flutter,,0
MULTAQ,Atrial flutter with 1:1 atrioventricular conduction,atrioventricular conduction has,1
MULTAQ,Atrial flutter with 1:1 atrioventricular conduction,Injury see Warnings,0
MULTAQ,Atrial flutter with 1:1 atrioventricular conduction,Atrial flutter with 1:1 atrioventricular conduction has,1
MULTAQ,Atrial flutter with 1:1 atrioventricular conduction,and Precautions,0
MULTAQ,Atrial flutter with 1:1 atrioventricular conduction,Cardiac New or worsening,0
MULTAQ,Atrial flutter with 1:1 atrioventricular conduction,reported very rarely Hepatic Liver Injury see Warnings and Precautions,0
MULTAQ,Atrial flutter with 1:1 atrioventricular conduction,flutter with 1:1 atrioventricular conduction has,1
MULTAQ,Liver Injury,reported very rarely Liver Injury see,1
MULTAQ,Interstitial lung disease,see Warnings and Precautions,0
MULTAQ,Interstitial lung disease,see Warnings and Precautions Interstitial lung,1
MULTAQ,Interstitial lung disease,Interstitial lung disease including,1
MULTAQ,Interstitial lung disease,lung disease including,1
MULTAQ,pneumonitis,pneumonitis and,1
MULTAQ,pneumonitis,Precautions Respiratory Interstitial lung disease,0
MULTAQ,pneumonitis,pneumonitis and,1
MULTAQ,pulmonary fibrosis,pulmonary,1
MULTAQ,pulmonary fibrosis,Interstitial lung disease,0
MULTAQ,pulmonary fibrosis,lung disease including pneumonitis pulmonary,1
MULTAQ,pulmonary fibrosis,pulmonary,1
MULTAQ,pulmonary fibrosis,Respiratory Interstitial,0
MULTAQ,pulmonary fibrosis,lung disease including pneumonitis,0
MULTAQ,angioedema,angioedema Vascular,1
MULTAQ,angioedema,,0
MULTAQ,angioedema,Precautions Immune Anaphylactic reactions angioedema Vascular,1
MULTAQ,leukocytoclastic vasculitis,Vascular,0
MULTAQ,leukocytoclastic vasculitis,,0
MULTAQ,leukocytoclastic vasculitis,vasculitis,1
MULTAQ,leukocytoclastic vasculitis,,0
MULTAQ,leukocytoclastic vasculitis,Vascular,0
MULTAQ,leukocytoclastic vasculitis,,0
MULTAQ,leukocytoclastic vasculitis,,0
MULTAQ,DEATH,conce rns are described elsewhere in,1
MULTAQ,DEATH,conce rns,1
MULTAQ,DEATH,conce rns are described elsewhere,1
MULTAQ,DEATH,conce rns are,1
MULTAQ,STROKE,s are  described elsewhere in the,1
MULTAQ,STROKE,s,1
MULTAQ,STROKE,,0
MULTAQ,STROKE,,0
MULTAQ,STROKE,s are  described elsewhere in the label,1
MULTAQ,HEART FAILURE,,0
MULTAQ,HEART FAILURE,ibed elsewher e,1
MULTAQ,DEATH,Warnings,0
MULTAQ,DEATH,and Precautions Pulmonary toxicity,0
MULTAQ,DEATH,and Precautions Liver njury see,1
MULTAQ,DEATH,Precautions Liver njury see,1
MULTAQ,DEATH,Precautions Liver njury see,1
MULTAQ,STROKE,failure see Warnings,0
MULTAQ,STROKE,see W arnings,1
MULTAQ,STROKE,Precautions Liver Injury,0
MULTAQ,STROKE,Precautions Liver see  W arnings,1
MULTAQ,STROKE,Precautions Liver Injury,0
MULTAQ,STROKE,,0
MULTAQ,STROKE,see W arnings,1
MULTAQ,HEART FAILURE,heart failure see Warnings and Precautions Liver Injury see,0
MULTAQ,HEART FAILURE,,0
MULTAQ,HEART FAILURE,,0
MULTAQ,death,recau tions,1
MULTAQ,death,,0
MULTAQ,death,adverse reactions,0
MULTAQ,death,recau tions,1
MULTAQ,death,and recau tions,1
MULTAQ,death,r www fdagovmedwatch,1
MULTAQ,death,at,0
MULTAQ,death,FDA r www fdagovmedwatch,1
MULTAQ,death,safety,0
MULTAQ,death,or FDA at FDA r www fdagovmedwatch,1
MULTAQ,death,,0
MULTAQ,death,FDA r www fdagovmedwatch,1
MULTAQ,death,,0
MULTAQ,death,evaluation of,0
MULTAQ,stroke,da.gov medwatch,1
MULTAQ,stroke,or da.gov medwatch,1
MULTAQ,stroke,,0
MULTAQ,stroke,LLC at or FDA,0
MULTAQ,stroke,da.gov medwatch,1
MULTAQ,stroke,tw,0
MULTAQ,stroke,da.gov medwatch,1
MULTAQ,stroke,Trials Experience The safety evaluation of dronedarone,0
MULTAQ,heart failure,or wwwfdagovmedwatch linical,1
MULTAQ,heart failure,,0
MULTAQ,heart failure,patients with AF,0
MULTAQ,heart failure,linical Trial s,1
MULTAQ,heart failure,,0
MULTAQ,heart failure,at FDA or wwwfdagovmedwatch linical Trial s,1
MULTAQ,DEATH,randomized and treated patients with MULTAQ,0
MULTAQ,DEATH,,0
MULTAQ,DEATH,In these studies,0
MULTAQ,DEATH,of 62 patients,1
MULTAQ,DEATH,these studies a of,1
MULTAQ,STROKE, patie nts,1
MULTAQ,STROKE, patie nts,1
MULTAQ,STROKE,ATHENA EURIDIS ADONIS ERATO and DAFNE In these studies a,0
MULTAQ,STROKE,ADONIS ERATO and DAFNE In these,0
MULTAQ,STROKE,ATHENA EURIDIS ADONIS ERATO and DAFNE In these studies a total,0
MULTAQ,HEART FAILURE,of patients ere randomize d,1
MULTAQ,HEART FAILURE,d and treated patients,0
MULTAQ,death,adverse reactions occurred 1.8%  of,1
MULTAQ,death,1.8%  of,1
MULTAQ,death,,0
MULTAQ,death,of adverse reactions occurred 1.8%  of,1
MULTAQ,death,trials premature discontinuation because of adverse reactions occurred,0
MULTAQ,death,1.8%  of,1
MULTAQ,death,of adverse,0
MULTAQ,death,1.8%  of,1
MULTAQ,death,and QT prolongation,0
MULTAQ,death,,0
MULTAQ,death,versu s,1
MULTAQ,death,versu s,1
MULTAQ,death,,0
MULTAQ,stroke,i n,1
MULTAQ,heart failure,The most freq uent,1
MULTAQ,Liver injury,toxicity see rnings,1
MULTAQ,Hypokalemia,prolongatio n,1
MULTAQ,Hypokalemia,,0
MULTAQ,Hypokalemia,prolongatio n,1
MULTAQ,Hypokalemia,and Precautions prolongatio n,1
MULTAQ,Hypokalemia,,0
MULTAQ,Hypokalemia,and Precautions EXCERPT Most common adverse,0
MULTAQ,Hypokalemia,,0
MULTAQ,hypomagnesemia,Warnings an d,1
MULTAQ,hypomagnesemia,,0
MULTAQ,hypomagnesemia,and Precautions QT prolongation e  Warnings an d,1
MULTAQ,hypomagnesemia,e,1
MULTAQ,Renal Impairment,Warnings and Precautions EXCERPT Most common,0
MULTAQ,Teratogen,contact sanofiaventis US LLC at or FDA,0
MULTAQ,Teratogen,FDA,0
MULTAQ,Teratogen,"pain vomiting and 


   To  report",1
MULTAQ,Teratogen,"


   To  report",1
MULTAQ,Teratogen,REACTIONS contact sanofiaventis US LLC,0
MULTAQ,death,,0
MULTAQ,death,with,0
MULTAQ,death,628 patients,1
MULTAQ,death,studies a total f 628 patients,1
MULTAQ,death,,0
MULTAQ,death,patients with MULTAQ mg twice,0
MULTAQ,death,and with,0
MULTAQ,death,studies a total f,1
MULTAQ,death,treated patients with MULTAQ,0
MULTAQ,cardiovascular death,and treated patients with MULTAQ mg,0
MULTAQ,cardiovascular death,placebo. The mean ex posure,1
MULTAQ,cardiovascular death,studies was months In ATHENA,0
MULTAQ,cardiovascular death,ex posure,1
MULTAQ,cardiovascular death,In ATHENA,0
MULTAQ,cardiovascular death,placebo. The mean,1
MULTAQ,cardiovascular death,treated patients with,0
MULTAQ,cardiovascular death,In ATHENA the maximum followup was months In clinical,0
MULTAQ,heart failure events,placebo,0
MULTAQ,heart failure events,twice daily,0
MULTAQ,heart failure events,12 months.,1
MULTAQ,heart failure events,studies 12 months. In ATHENA the,1
MULTAQ,heart failure events,The mean exposure across studies was,0
MULTAQ,heart failure events,In ATHENA the,1
MULTAQ,heart failure events,was months In,0
MULTAQ,heart failure events,across studies 12 months.,1
MULTAQ,heart failure events,In ATHENA the,1
MULTAQ,heart failure events,and with,0
MULTAQ,stroke,e dail y,1
MULTAQ,stroke,observed with MULTAQ mg e,1
MULTAQ,stroke,abdominal pain,0
MULTAQ,stroke,dail y,1
MULTAQ,stroke,mg e dail y,1
MULTAQ,stroke,y in the studies were diarrhea nausea,0
MULTAQ,stroke,,0
MULTAQ,worsening of heart failure,Adverse laboratory ECG effects are presented  separately,1
MULTAQ,worsening of heart failure,effects are presented separately,1
MULTAQ,worsening of heart failure,frequency Adverse laboratory ECG effects are presented  separately,1
MULTAQ,worsening of heart failure,frequency Adverse laboratory ECG effects are presented  separately,1
MULTAQ,worsening of heart failure,Patients,0
MULTAQ,worsening of heart failure,order,0
MULTAQ,heart failure,,0
MULTAQ,heart failure,              Placebo,1
MULTAQ,heart failure,in at Least of Patients and Were More Frequent than,0
MULTAQ,heart failure,Frequent than               Placebo,1
MULTAQ,heart failure,              Placebo,1
MULTAQ,heart failure,,0
MULTAQ,heart failure,              Placebo,1
MULTAQ,heart failure,              Placebo,1
MULTAQ,heart failure,              Placebo,1
MULTAQ,Hepatocellular liver injury,"Nausea                     
    Ab",1
MULTAQ,Hepatocellular liver injury,"Nausea                     
    Ab",1
MULTAQ,acute liver failure,,0
MULTAQ,acute liver failure,Vomiting,0
MULTAQ,acute liver failure,pain,0
MULTAQ,interstitial lung disease,reaction and dysgeusia have also been reported at an incidence less than in patients treated wi,0
MULTAQ,interstitial lung disease,"
         Photosensitivit",1
MULTAQ,interstitial lung disease,also been,0
MULTAQ,pneumonitis,,0
MULTAQ,pneumonitis,,0
MULTAQ,pneumonitis,fol,0
MULTAQ,pneumonitis,and,1
MULTAQ,pneumonitis,,0
MULTAQ,pneumonitis,Photosensitivity and dysgeus,1
MULTAQ,pneumonitis,,0
MULTAQ,pneumonitis,with MULTAQ,0
MULTAQ,pneumonitis,dysgeus,1
MULTAQ,pulmonary fibrosis,reaction and dysgeusia ve also been repor,1
MULTAQ,pulmonary fibrosis,less than in patients treated,0
MULTAQ,pulmonary fibrosis,data,0
MULTAQ,pulmonary fibrosis,The following laboratory data,0
MULTAQ,Hypokalemia,mg twice daily,0
MULTAQ,Hypokalemia,Early,0
MULTAQ,Hypokalemia,           ,1
MULTAQ,Hypokalemia,mg twice daily,0
MULTAQ,hypomagnesemia,       (N=2875,1
MULTAQ,hypomagnesemia,       (N=2875,1
MULTAQ,hypomagnesemia,MULTAQ mg twice        (N=2875,1
MULTAQ,increase in serum creatinine,Postmarketing Experience The wing adverse reactions have ,1
MULTAQ,increase in serum creatinine,Experience The wing,1
MULTAQ,increase in serum creatinine,of adverse events in any particular subgroup Postmarketing,0
MULTAQ,increase in serum creatinine,Postmarketing Experience The follo,0
MULTAQ,pre-renal azotemia,reported,0
MULTAQ,pre-renal azotemia,reactions have,0
MULTAQ,pre-renal azotemia,be,0
MULTAQ,pre-renal azotemia,Experience The following adverse reactions have be,0
MULTAQ,pre-renal azotemia,The following adverse reactions,0
MULTAQ,pre-renal azotemia,en identified,1
MULTAQ,pre-renal azotemia,,0
MULTAQ,acute renal failure,st-approval use of,1
MULTAQ,acute renal failure,,0
MULTAQ,acute renal failure,adverse reactions have,0
MULTAQ,acute renal failure,The following adverse,0
MULTAQ,acute renal failure,identified during st-approval use of ,1
MULTAQ,acute renal failure,voluntarily from a population of an unknown size it is,0
MULTAQ,hypovolemia,estimate their frequency or establish a causal,0
MULTAQ,hypovolemia,"e, it is no",1
MULTAQ,hypovolemia,estimate their frequency or establish a causal relationship,0
MULTAQ,hypovolemia,no,1
MULTAQ,hypovolemia,unknown siz,0
MULTAQ,increases in creatinine levels,or worsening heart failure see Warnings,0
MULTAQ,increases in creatinine levels,er with 1:1 atrioventricular c,1
MULTAQ,increases in creatinine levels,Warnings and Precautions Atrial er with,1
MULTAQ,fetal harm,,1
MULTAQ,fetal harm,,1
MULTAQ,fetal harm,,1
MULTAQ,fetal harm,leukocytoclastic vasculitis,0
MULTAQ,fetal harm,,0
MULTAQ,fetal harm,,1
MULTAQ,fetal harm,leukocytoclastic vasculitis,0
MULTAQ,fetal harm,,0
MULTAQ,fetal harm,vasculitis,0
TANZEUM,Thyroid C-cell Tumors,C-cell Tumors,1
TANZEUM,Thyroid C-cell Tumors,are described below or,0
TANZEUM,Thyroid C-cell Tumors,elsewhere in the,0
TANZEUM,Acute Pancreatitis,information Risk of Thyroid Ccell Tumors see,0
TANZEUM,Hypoglycemia,Hypoglycemia,1
TANZEUM,Renal Impairment,Precautions,0
TANZEUM,upper respiratory tract infection,on placebo upper respiratory,1
TANZEUM,upper respiratory tract infection,patients on placebo upper respiratory tract,1
TANZEUM,upper respiratory tract infection,than in patients,0
TANZEUM,diarrhea,than in patients on placebo were upper respiratory tract infection,0
TANZEUM,diarrhea,tract diarrhea,1
TANZEUM,diarrhea,,0
TANZEUM,diarrhea,cough,0
TANZEUM,diarrhea,diarrhea,1
TANZEUM,diarrhea,diarrhea,1
TANZEUM,diarrhea,were upper respiratory tract diarrhea,1
TANZEUM,diarrhea,diarrhea,1
TANZEUM,diarrhea,diarrhea,1
TANZEUM,nausea,frequently than in patients on placebo were upper respiratory tract infection diarrhea,0
TANZEUM,nausea,upper respiratory tract infection nausea,1
TANZEUM,nausea,nausea,1
TANZEUM,injection site reaction,,0
TANZEUM,cough,tract infection diarrhea nausea injection site,0
TANZEUM,back pain,upper respiratory tract infection,0
TANZEUM,back pain,,0
TANZEUM,back pain,report SUSPECTED ADVERSE REACTIONS contact,0
TANZEUM,back pain,pain,1
TANZEUM,back pain,site reaction back pain,1
TANZEUM,back pain,nausea injection site reaction back,1
TANZEUM,back pain,nausea injection site reaction back,1
TANZEUM,back pain,influenza To report SUSPECTED ADVERSE REACTIONS contact G,0
TANZEUM,back pain,injection site,0
TANZEUM,back pain,back pain,1
TANZEUM,sinusitis,influenza To report SUSPECTED ADVERSE,0
TANZEUM,sinusitis,back pain,0
TANZEUM,sinusitis,sinusitis,1
TANZEUM,sinusitis,site reaction cough back pain arthralgia,0
TANZEUM,sinusitis,and influenza To report SUSPECTED ADVERSE REACTIONS contact,0
TANZEUM,sinusitis,sinusitis,1
TANZEUM,influenza,injection site,0
TANZEUM,influenza,influenza,1
TANZEUM,influenza,influenza,1
TANZEUM,influenza,influenza,1
TANZEUM,hypoglycemia,hypoglycemia,1
TANZEUM,hypoglycemia,hypoglycemia,1
TANZEUM,hypoglycemia,of TANZEUM in,0
TANZEUM,hypoglycemia,adverse reactions hypoglycemia,1
TANZEUM,hypoglycemia,hypoglycemia,1
TANZEUM,hypoglycemia,reactions excluding,0
TANZEUM,hypoglycemia,hypoglycemia,1
TANZEUM,hypoglycemia,,0
TANZEUM,Upper respiratory tract infection,Upper respiratory tract infection Diarrhea,1
TANZEUM,Diarrhea,tract Diarrhea,1
TANZEUM,Diarrhea,Diarrhea,1
TANZEUM,Diarrhea,Diarrhea,1
TANZEUM,Diarrhea,piratory tract Diarrhea,1
TANZEUM,Diarrhea,piratory tract Diarrhea,1
TANZEUM,Diarrhea,tract infection,0
TANZEUM,Diarrhea,infection,0
TANZEUM,Diarrhea,Diarrhea,1
TANZEUM,Diarrhea,Diarrhea,1
TANZEUM,Nausea,Nausea,1
TANZEUM,Nausea,Nausea,1
TANZEUM,Nausea,Nausea,1
TANZEUM,Nausea,,0
TANZEUM,Nausea,Nausea,1
TANZEUM,Nausea,Nausea,1
TANZEUM,Injection site reaction,Injection,1
TANZEUM,Injection site reaction,,0
TANZEUM,Injection site reaction,site reaction b,1
TANZEUM,Cough,Cough,1
TANZEUM,Cough,,0
TANZEUM,Cough,Cough,1
TANZEUM,Cough,reactionb,0
TANZEUM,Back pain,,0
TANZEUM,Back pain,,0
TANZEUM,Back pain,Back,1
TANZEUM,Back pain,pain,1
TANZEUM,Back pain,,0
TANZEUM,Back pain,Back,1
TANZEUM,Back pain,Back,1
TANZEUM,Arthralgia,Arthralgia S,1
TANZEUM,Arthralgia,,0
TANZEUM,Arthralgia,Arthralgia S,1
TANZEUM,Arthralgia,Arthralgia S,1
TANZEUM,Arthralgia,S,0
TANZEUM,Arthralgia,Arthralgia S,1
TANZEUM,Arthralgia,,0
TANZEUM,Sinusitis,a,0
TANZEUM,Influenza,,0
TANZEUM,Influenza,,0
TANZEUM,Influenza,,0
TANZEUM,Influenza,,0
TANZEUM,injection site reactions,Gastrointestinal Adverse Reactions In the pool of placebocontrolled trials,0
TANZEUM,injection site reactions,events injection site reactions,1
TANZEUM,injection site reactions,and insulin for placebo and for TANZEUM b See below,0
TANZEUM,injection site reactions,other events injection,1
TANZEUM,injection site reactions,other events of,0
TANZEUM,injection site reactions,,0
TANZEUM,gastrointestinal complaints,pool of placebocontrolled gastrointestinal,1
TANZEUM,gastrointestinal complaints,pool of placebocontrolled trials,0
TANZEUM,gastrointestinal complaints,gastrointestinal,1
TANZEUM,gastrointestinal complaints,receiving TANZEUM than patients,0
TANZEUM,gastrointestinal complaints,of placebocontrolled,0
TANZEUM,diarrhea,,0
TANZEUM,nausea,nausea,1
TANZEUM,nausea,occurred more frequently,0
TANZEUM,nausea,nausea,1
TANZEUM,nausea,,0
TANZEUM,nausea,In addition to diarrhea nausea,1
TANZEUM,nausea,nausea,1
TANZEUM,nausea,the following gastrointestinal adverse reactions,0
TANZEUM,nausea,nausea,1
TANZEUM,nausea,In addition,0
TANZEUM,nausea,adverse,0
TANZEUM,gastrointestinal adverse reactions,see Table the gastrointestinal adverse,1
TANZEUM,gastrointestinal adverse reactions,to diarrhea and nausea see Table,0
TANZEUM,vomiting,more frequently in,0
TANZEUM,vomiting,vomiting,1
TANZEUM,vomiting,receiving,0
TANZEUM,vomiting,vomiting,1
TANZEUM,vomiting,,0
TANZEUM,vomiting,versus,0
TANZEUM,vomiting,for,0
TANZEUM,vomiting,vomiting,1
TANZEUM,vomiting,,0
TANZEUM,gastroesophageal reflux disease,for placebo versus gastroesophageal reflux,1
TANZEUM,gastroesophageal reflux disease,gastroesophageal reflux disease,1
TANZEUM,gastroesophageal reflux disease,for placebo versus TANZEUM and dyspepsia versus,0
TANZEUM,gastroesophageal reflux disease,gastroesophageal reflux disease,1
TANZEUM,gastroesophageal reflux disease,placebo versus gastroesophageal reflux disease,1
TANZEUM,gastroesophageal reflux disease,reflux disease,1
TANZEUM,gastroesophageal reflux disease,versus TANZEUM and,0
TANZEUM,gastroesophageal reflux disease,in patients,0
TANZEUM,gastroesophageal reflux disease,versus,0
TANZEUM,gastroesophageal reflux disease,for placebo versus T,0
TANZEUM,dyspepsia,dyspepsia,1
TANZEUM,dyspepsia,versus TANZEUM dyspepsia,1
TANZEUM,dyspepsia,the frequently repo,0
TANZEUM,Constipation,placebo versus TANZEUM and dyspepsia versus for,0
TANZEUM,Constipation,placebo versus Constipation,1
TANZEUM,Constipation,to,0
TANZEUM,Constipation,Constipation,1
TANZEUM,Constipation,for placebo versus Constipation,1
TANZEUM,Constipation,versus Constipation,1
TANZEUM,Constipation,Constipation,1
TANZEUM,Constipation,Constipation,1
TANZEUM,Constipation,Constipation,1
TANZEUM,Constipation,reactions In the,0
TANZEUM,GI reactions,,0
TANZEUM,GI reactions,moderate in of cases and severe in of cases,0
TANZEUM,GI reactions,GI,1
TANZEUM,GI reactions,investigators graded the severity GI reactions,1
TANZEUM,GI reactions,the severity GI,1
TANZEUM,GI reactions,graded the severity GI,1
TANZEUM,GI reactions,graded,0
TANZEUM,GI adverse reactions,GI adverse reactions,1
TANZEUM,GI adverse reactions,cases Discontinuation due,0
TANZEUM,GI adverse reactions,moderate in of cases and,0
TANZEUM,GI adverse reactions,GI adverse reactions,1
TANZEUM,GI adverse reactions,GI adverse reactions,1
TANZEUM,GI adverse reactions,cases,0
TANZEUM,GI adverse reactions,of cases Discontinuation due GI adverse reactions,1
TANZEUM,injection site reactions,,0
TANZEUM,injection site reactions,placebocontrolled trials,0
TANZEUM,injection site reactions,placebo Injection Site Reactions In the pool,0
TANZEUM,injection site reactions,injection site reactions,1
TANZEUM,injection site reactions,injection site,1
TANZEUM,injection site reactions,injection site,1
TANZEUM,injection site reactions,the pool of placebocontrolled injection site,1
TANZEUM,injection site reaction,other types of injection site reactions also occurred more frequently,0
TANZEUM,injection site reactions,,0
TANZEUM,injection site reactions,other types injection,1
TANZEUM,injection site reactions,site reactions,1
TANZEUM,injection site reactions,following other types injection site reactions,1
TANZEUM,injection site reactions,reactions,1
TANZEUM,injection site reactions,injection site reactions,1
TANZEUM,injection site reactions,more frequently,0
TANZEUM,injection site reactions,the following other types,0
TANZEUM,injection site hematoma,on injection,1
TANZEUM,injection site hematoma,injection site hematoma,1
TANZEUM,injection site hematoma,also occurred more frequently on,0
TANZEUM,injection site hematoma,occurred more frequently on injection site,1
TANZEUM,injection site hematoma,injection site erythema,0
TANZEUM,injection site erythema,injection site erythema,1
TANZEUM,injection site rash,placebo versus TANZEUM injection,0
TANZEUM,injection site rash,versus,0
TANZEUM,injection site rash,versus injection site rash,1
TANZEUM,injection site rash,for placebo versus injection site rash,1
TANZEUM,injection site rash,versus for placebo versus TANZEUM injection site hypersensitivity versus for pl,0
TANZEUM,injection site rash,placebo versus TANZEUM injection site erythema,0
TANZEUM,injection site hypersensitivity,versus TANZEUM,0
TANZEUM,injection site hypersensitivity,versus for placebo versus injection site hypersensitivity,1
TANZEUM,injection site hypersensitivity,versus for placebo versus injection site hypersensitivity,1
TANZEUM,injection site hypersensitivity,placebo versus injection site hypersensitivity,1
TANZEUM,injection site hypersensitivity,versus for placebo versus injection site hypersensitivity,1
TANZEUM,injection site hemorrhage,to the,0
TANZEUM,injection site hemorrhage,for placebo versus TANZEUM injection site,1
TANZEUM,injection site hemorrhage,placebo versus TANZEUM Injection site,0
TANZEUM,injection site hemorrhage,injection site hemorrhage,1
TANZEUM,injection site hemorrhage,hypersensitivity versus for placebo versus,0
TANZEUM,injection site reactions,majority injection site,1
TANZEUM,injection site reactions,site reactions,1
TANZEUM,injection site reactions,judged as mild by,0
TANZEUM,injection site reactions,The majority injection site reactions,1
TANZEUM,injection site reactions,majority injection site reactions,1
TANZEUM,injection site reactions,reported reactions The majority injection,1
TANZEUM,injection site reactions,reported reactions The majority injection,1
TANZEUM,injection site reactions,groups for,0
TANZEUM,injection site reactions,injection site reactions,1
TANZEUM,injection site reactions,majority injection,1
TANZEUM,injection site reactions,TANZEUM,0
TANZEUM,injection site reactions,The majority injection site reactions,1
TANZEUM,hypoglycemia,hypoglycemia,1
TANZEUM,hypoglycemia,hypoglycemia,1
TANZEUM,hypoglycemia,T,0
TANZEUM,hypoglycemia,hypoglycemia,1
TANZEUM,hypoglycemic episode,hypoglycemic,1
TANZEUM,hypoglycemic episode,least one documented hypoglycemic episode,1
TANZEUM,hypoglycemic episode,documented,0
TANZEUM,hypoglycemic episode,hypoglycemic,1
TANZEUM,hypoglycemic episode,,0
TANZEUM,Hypoglycemia,is shown,0
TANZEUM,Hypoglycemia,Hypoglycemia,1
TANZEUM,Hypoglycemia,in Table,0
TANZEUM,Hypoglycemia,Hypoglycemia,1
TANZEUM,Hypoglycemia,Hypoglycemia,1
TANZEUM,Hypoglycemia,Hypoglycemia,1
TANZEUM,Plasma glucose concentration <=70 mg/dL,concentration <=70 mg/dL,1
TANZEUM,Plasma glucose concentration <=70 mg/dL,Plasma glucose concentration <=70 mg/dL,1
TANZEUM,Plasma glucose concentration <=70 mg/dL,d Event requiring,0
TANZEUM,Plasma glucose concentration <=70 mg/dL,the table Plasma glucose concentration,1
TANZEUM,hypoglycemic symptoms,,0
TANZEUM,hypoglycemic symptoms,,0
TANZEUM,hypoglycemic symptoms,and presence hypoglycemic symptoms,1
TANZEUM,hypoglycemia,hypoglycemia,1
TANZEUM,hypoglycemia,,0
TANZEUM,hypoglycemia,,0
TANZEUM,hypoglycemia,the pool of,0
TANZEUM,hypoglycemia,,0
TANZEUM,hypoglycemia,hypoglycemia,1
TANZEUM,hypoglycemia,glimepiride and sitagliptin Pneumonia In the pool,0
TANZEUM,hypoglycemia,the pool of,0
TANZEUM,hypoglycemia,hypoglycemia,1
TANZEUM,hypoglycemia,hypoglycemia,1
TANZEUM,pneumonia,frequently in patients,0
TANZEUM,pneumonia,of placebo and activecontrolled,0
TANZEUM,pneumonia,and activecontrolled,0
TANZEUM,pneumonia,patients receiving TANZEUM than in patients in the,0
TANZEUM,pneumonia,adverse reaction,0
TANZEUM,pneumonia,,0
TANZEUM,pneumonia,pneumonia,1
TANZEUM,pneumonia,reaction pneumonia,1
TANZEUM,pneumonia,,0
TANZEUM,pneumonia,TANZEUM versus for all,0
TANZEUM,pneumonia,for all,0
TANZEUM,pneumonia,receiving,0
TANZEUM,pneumonia,pneumonia,1
TANZEUM,pneumonia,patients in the allcomparators group More cases of,0
TANZEUM,pneumonia,TANZEUM than in patients in the allcomparators group More cases,0
TANZEUM,atrial fibrillation,atrial fibrillation,1
TANZEUM,atrial flutter,atrial fibrillation atrial flutter,1
TANZEUM,atrial flutter,fibrillation atrial,1
TANZEUM,atrial flutter,of atrial fibrillation atrial flutter,1
TANZEUM,atrial flutter,and,0
TANZEUM,atrial flutter,trials,0
TANZEUM,atrial flutter,reported more frequently for,0
TANZEUM,appendicitis,placebo and activecontrolled trials,0
TANZEUM,appendicitis,,0
TANZEUM,ALT increase,the cases,0
TANZEUM,ALT increase,on TANZEUM and one subject,0
TANZEUM,ALT increase,event ALT,1
TANZEUM,ALT increase,,0
TANZEUM,ALT increase,in the allcomparator group experienced,0
TANZEUM,rise in liver enzyme,rise in liver enzyme,1
TANZEUM,rise in liver enzyme,was identified to explain rise in,1
TANZEUM,increase in total bilirubin,elevation in ALT times the upper limit of normal was accompanied,0
TANZEUM,increase in total bilirubin,dose,0
TANZEUM,increase in total bilirubin,increase in total bilirubin,1
TANZEUM,increase in total bilirubin,limit of normal was accompanied by,0
TANZEUM,hepatocellular injury,the presence,0
TANZEUM,hepatocellular injury,the presence of,0
TANZEUM,increase in heart rate,in heart rate,1
TANZEUM,increase in heart rate,,0
TANZEUM,increase in heart rate,clinical effects of increase in,1
TANZEUM,THYROID C-CELL TUMORS,described below or elsewhere,0
TANZEUM,THYROID C-CELL TUMORS,ng serious reactions are described below or,1
TANZEUM,THYROID C-CELL TUMORS,,0
TANZEUM,THYROID C-CELL TUMORS,escribing information Risk of Thyroid,0
TANZEUM,THYROID C-CELL TUMORS,r elsewhere,1
TANZEUM,thyroid C-cell tumors,Warnings and Precauti,0
TANZEUM,thyroid C-cell tumors,see Warnings and,0
TANZEUM,thyroid C-cell tumors,see Warnings and ecautions (5.2)],1
TANZEUM,thyroid C-cell tumors,Precauti,0
TANZEUM,thyroid C-cell tumors,,0
TANZEUM,thyroid C-cell tumors,Reactions see Warnings and * Renal,1
TANZEUM,thyroid C-cell tumors,*,1
TANZEUM,thyroid C-cell tumors,,0
TANZEUM,thyroid C-cell tumors,Warnings,0
TANZEUM,thyroid C-cell tumors,*,1
TANZEUM,medullary thyroid carcinoma,gs and Precautions (5.5)]   EXCERPT Adverse reactions reported in,1
TANZEUM,medullary thyroid carcinoma,Renal Impairment see gs and Precautions (5.5)]   EXCERPT Adverse reactions reported in,1
TANZEUM,medullary thyroid carcinoma,Precautions (5.5)] EXCERPT Adverse reactions reported in,1
TANZEUM,medullary thyroid carcinoma,Reactions see,0
TANZEUM,medullary thyroid carcinoma,Impairment see,0
TANZEUM,MTC,with,0
TANZEUM,MTC,    EXCERPT Adverse reactions reported in,1
TANZEUM,MTC,    EXCERPT Adverse reactions reported in,1
TANZEUM,MTC,    EXCERPT Adverse reactions reported in,1
TANZEUM,MTC,    EXCERPT Adverse reactions reported in,1
TANZEUM,MTC,    EXCERPT Adverse reactions reported in,1
TANZEUM,THYROID C-CELL TUMORS,drug and may not lect the rates,1
TANZEUM,THYROID C-CELL TUMORS,and may not lect the rates observ ed in practice Pool of,1
TANZEUM,THYROID C-CELL TUMORS,rates observ ed in practice Pool of,1
TANZEUM,thyroid C-cell tumors,nical Studies (14)] These data reflect exposure of,1
TANZEUM,thyroid C-cell tumors,TANZEUM was used as monotherapy in,0
TANZEUM,thyroid C-cell tumors,,0
TANZEUM,thyroid C-cell tumors,nical,1
TANZEUM,thyroid C-cell tumors,mean duration,0
TANZEUM,thyroid C-cell tumors,nical Studies (14)]   These data reflect exposure of,1
TANZEUM,thyroid C-cell tumors,TANZEUM was used as monotherapy in trial and as addon therapy in trials,0
TANZEUM,thyroid C-cell tumors,,0
TANZEUM,thyroid C-cell tumors,as monotherapy in trial,0
TANZEUM,thyroid C-cell tumors,,0
TANZEUM,C-cell tumors,older and of,0
TANZEUM,thyroid C-cell tumors,participants years or older and 53 of participants were male The,1
TANZEUM,thyroid C-cell tumors,in these studies was white AfricanAfrican,0
TANZEUM,thyroid C-cell tumors,was years of,0
TANZEUM,thyroid C-cell tumors,age of participants was years of,0
TANZEUM,thyroid C-cell tumors,weeks The mean age of participants,0
TANZEUM,thyroid C-cell tumors,were male The population,0
TANZEUM,thyroid C-cell tumors,53 of participants were male The,1
TANZEUM,medullary thyroid carcinoma,pants were male. The popula tion in these studies was,1
TANZEUM,MTC,years or,0
TANZEUM,MTC,on  in these studies was white,1
TANZEUM,MTC,and of participants,0
TANZEUM,MTC,on  in these studies was white,1
TANZEUM,MTC,on  in these studies was white,1
TANZEUM,MTC,participants were years,0
TANZEUM,MTC,on  in these studies was white,1
TANZEUM,Thyroid C-cell Tumors,,0
TANZEUM,Thyroid C-cell Tumors,b,1
TANZEUM,Thyroid C-cell Tumors,Risk,0
TANZEUM,Thyroid C-cell Tumors,tions,1
TANZEUM,Thyroid C-cell Tumors,tions are described b elow,1
TANZEUM,Pancreatitis,Thyroid,0
TANZEUM,Pancreatitis,elsewhere in the g informatio n,1
TANZEUM,Pancreatitis,g informatio n,1
TANZEUM,Pancreatitis,g informatio n,1
TANZEUM,Pancreatitis,,0
TANZEUM,Pancreatitis,Warnings and Precautions Acute,0
TANZEUM,Hypoglycemia,and Precautions a with Conco mitant,1
TANZEUM,Hypoglycemia,with Conco mitant,1
TANZEUM,Hypoglycemia,Hypoglycemi,0
TANZEUM,Hypersensitivity Reactions,Warnings and Precautions EXCERPT,1
TANZEUM,Hypersensitivity Reactions,Precautions Renal Impairment e Warnings and,1
TANZEUM,Hypersensitivity Reactions,TANZEUM and,0
TANZEUM,Hypersensitivity Reactions,Impairment e Warnings and Precautions EXCERPT,1
TANZEUM,Hypersensitivity Reactions,e Warnings and Precautions EXCERPT,1
TANZEUM,Hypersensitivity Reactions,and Precautions Renal Impairment se,0
TANZEUM,Hypersensitivity Reactions,se,0
TANZEUM,Renal Impairment,,0
TANZEUM,Renal Impairment,in of patients treated with TANZEUM,0
TANZEUM,Renal Impairment,pain,0
TANZEUM,C-cell tumors,These data,0
TANZEUM,C-cell tumors,,0
TANZEUM,C-cell tumors, monotherapy  in,1
TANZEUM,C-cell tumors,TANZEUM was used  monotherapy  in,1
TANZEUM,C-cell tumors,These data,0
TANZEUM,C-cell tumors,,0
TANZEUM,C-cell tumors,was,0
TANZEUM,C-cell tumors,data reflect,0
TANZEUM,C-cell tumors, monotherapy  in,1
TANZEUM,thyroid C-cell tumors,exposure of patients to TANZEUM and a mean duration of exposure,0
TANZEUM,thyroid C-cell tumors,,0
TANZEUM,thyroid C-cell tumors,,0
TANZEUM,thyroid C-cell tumors,as monotherapy,0
TANZEUM,thyroid C-cell tumors,addon therapy in trials see Clinical Studies,0
TANZEUM,thyroid C-cell tumors,. These data reflect exposure,1
TANZEUM,thyroid C-cell tumors,trial and as addon,0
TANZEUM,thyroid C-cell tumors,trial and as addon therapy in,0
TANZEUM,thyroid C-cell tumors,Clinical . These,1
TANZEUM,MTC, 92 patients,1
TANZEUM,MTC,TANZEUM and a mean,0
TANZEUM,MTC, 92 patients,1
TANZEUM,MTC,participants,0
TANZEUM,MTC,baseline the population had,0
TANZEUM,MTC,in these,0
TANZEUM,MTC,c/L atino,1
TANZEUM,MTC,was white AfricanAfrican American Asian and Hispani,0
TANZEUM,MTC,c/L atino,1
TANZEUM,MTC,reported pat hy,1
TANZEUM,MTC,pat hy,1
TANZEUM,MTC,pat hy,1
TANZEUM,MTC,pat hy,1
TANZEUM,MTC,pat hy,1
TANZEUM,MTC,pat hy,1
TANZEUM,MTC,pat hy,1
TANZEUM,acute pancreatitis,Injectio,0
TANZEUM,acute pancreatitis,Injectio,0
TANZEUM,pancreatitis,Back pain,0
TANZEUM,pancreatitis,             Back,1
TANZEUM,pancreatitis,Back,0
TANZEUM,hypoglycemia,of,0
TANZEUM,hypoglycemia,pati,0
TANZEUM,hypoglycemia,In the pool,0
TANZEUM,hypoglycemia,,0
TANZEUM,hypoglycemia,"ed trials, g",1
TANZEUM,hypoglycemia,"trials, g",1
TANZEUM,hypoglycemia,,0
TANZEUM,hypoglycemia,"trials, g",1
TANZEUM,hypoglycemia,e reactions also occurred more frequently in patients receiving TANZEUM vomiting versus,0
TANZEUM,hypoglycemia,,0
TANZEUM,hypoglycemia,tinal advers,1
TANZEUM,hypoglycemia,advers,1
TANZEUM,hypoglycemia,tinal advers,1
TANZEUM,hypoglycemia,the following tinal,1
TANZEUM,hypoglycemia,In addition to diarrhea and nausea see,0
TANZEUM,hypersensitivity reaction,dyspepsia (2.8,1
TANZEUM,hypersensitivity reaction,"versus for placebo versus ZEUM),",1
TANZEUM,hypersensitivity reaction,"ZEUM), and dyspepsia (2.8",1
TANZEUM,hypersensitivity reaction,"for placebo versus ZEUM), and dyspepsia",1
TANZEUM,hypersensitivity reaction,"for placebo versus ZEUM), and",1
TANZEUM,hypersensitivity reaction,Constipation also contributed to the,0
TANZEUM,pruritus,dyspepsia us 3.4% ,1
TANZEUM,pruritus,versus TANZEUM and dyspepsia us 3.4% ,1
TANZEUM,pruritus,3.4%,1
TANZEUM,pruritus,us 3.4% ,1
TANZEUM,pruritus,dyspepsia us,1
TANZEUM,pruritus,dyspepsia us,1
TANZEUM,pruritus,contributed to the,0
TANZEUM,dyspnea,versus ,1
TANZEUM,dyspnea,for versus ,1
TANZEUM,dyspnea,versus ,1
TANZEUM,dyspnea,versus TANZEUM and dyspepsia,0
TANZEUM,dyspnea,,0
TANZEUM,acute renal failure,Site,1
TANZEUM,acute renal failure,Site,1
TANZEUM,acute renal failure,of individuals on TANZEUM or placebo,0
TANZEUM,acute renal failure,Site,1
TANZEUM,acute renal failure,Site,1
TANZEUM,acute renal failure,GI adverse reactions occurred,0
TANZEUM,acute renal failure,,0
TANZEUM,acute renal failure,adverse reactions occurred in,0
TANZEUM,worsening of chronic renal failure,placebo Injection Site ions In the pool,1
TANZEUM,worsening of chronic renal failure,Site React,0
TANZEUM,worsening of chronic renal failure,occurred in of individuals on TANZEUM or placebo,0
TANZEUM,worsening of chronic renal failure,"or placebo Injection Site ions  



 In the pool of placebo-",1
TANZEUM,nausea,on TANZEUM injection site hematoma,0
TANZEUM,nausea,,0
TANZEUM,nausea,following other types of jectio,1
TANZEUM,nausea,jectio,1
TANZEUM,nausea,frequently on TANZEUM injection site hematoma versus,0
TANZEUM,nausea,jectio,1
TANZEUM,nausea,see Table the following other types,0
TANZEUM,vomiting,,0
TANZEUM,vomiting,types of site rea,1
TANZEUM,vomiting,site rea,1
TANZEUM,vomiting,,0
TANZEUM,vomiting,,0
TANZEUM,vomiting,TANZEUM injection site hematoma versus for place,0
TANZEUM,vomiting,of site,1
TANZEUM,vomiting,types of site rea,1
TANZEUM,diarrhea,of injection site react,0
TANZEUM,diarrhea,als,1
TANZEUM,diarrhea,of injection site ions als,1
TANZEUM,diarrhea,o occurred more frequently on,0
TANZEUM,diarrhea,ions als,1
TANZEUM,dehydration,placebo versus TANZEUM injec,0
TANZEUM,gastrointestinal reactions,TANZEUM injection site eryt,0
TANZEUM,gastrointestinal reactions,TANZEUM injection site hema (0.4% versus,1
TANZEUM,gastrointestinal reactions,for placebo versus TANZEUM,0
TANZEUM,gastrointestinal reactions,site rash versus for placebo versus,0
TANZEUM,gastrointestinal reactions,,0
TANZEUM,gastrointestinal reactions,versus TANZEUM,0
TANZEUM,renal function declined,"TANZEUM), injection s",1
BELEODAQ,Hematologic Toxicity,Precautions,0
BELEODAQ,Hematologic Toxicity,Precautions Infection,0
BELEODAQ,Infection,Infection,1
BELEODAQ,Infection,see Warnings and Infection,1
BELEODAQ,Infection,Toxicity see Warnings and Infection,1
BELEODAQ,Infection,Infection,1
BELEODAQ,Infection,Hepatotoxicity see Warnings and Precautions,0
BELEODAQ,Infection,Toxicity see Warnings and,0
BELEODAQ,Infection,see Warnings and Infection,1
BELEODAQ,Infection,see Warnings and Precautions Hepatotoxicity see Warnings and,0
BELEODAQ,Infection,,0
BELEODAQ,Infection,see,0
BELEODAQ,Hepatotoxicity,Hepatotoxicity,1
BELEODAQ,Hepatotoxicity,Hepatotoxicity,1
BELEODAQ,Hepatotoxicity,Hepatotoxicity,1
BELEODAQ,Hepatotoxicity,Precautions Infection see Warnings and Precautions,0
BELEODAQ,Hepatotoxicity,Warnings and Precautions,0
BELEODAQ,Hepatotoxicity,Hepatotoxicity,1
BELEODAQ,Hepatotoxicity,Hepatotoxicity,1
BELEODAQ,Hepatotoxicity,Hepatotoxicity,1
BELEODAQ,Hepatotoxicity,Warnings and Hepatotoxicity,1
BELEODAQ,Gastrointestinal Toxicity,,0
BELEODAQ,Gastrointestinal Toxicity,Syndrome see Warnings and Gastrointestinal Toxicity,1
BELEODAQ,Gastrointestinal Toxicity,Tumor,0
BELEODAQ,Gastrointestinal Toxicity,Gastrointestinal,1
BELEODAQ,Gastrointestinal Toxicity,Warnings and Precautions The,0
BELEODAQ,Gastrointestinal Toxicity,Warnings and Gastrointestinal Toxicity,1
BELEODAQ,Gastrointestinal Toxicity,adverse reactions observed in the,0
BELEODAQ,Gastrointestinal Toxicity,see Warnings and Precautions The,0
BELEODAQ,Gastrointestinal Toxicity,and Gastrointestinal Toxicity,1
BELEODAQ,Gastrointestinal Toxicity,Gastrointestinal,1
BELEODAQ,nausea,nausea,1
BELEODAQ,nausea,nausea,1
BELEODAQ,nausea,nausea,1
BELEODAQ,nausea,Beleodaq were,0
BELEODAQ,fatigue,were fatigue,1
BELEODAQ,fatigue,Clinical Studies,0
BELEODAQ,fatigue,fatigue,1
BELEODAQ,fatigue,Studies EXCERPT The,0
BELEODAQ,fatigue,fatigue,1
BELEODAQ,fatigue,,0
BELEODAQ,fatigue,fatigue,1
BELEODAQ,fatigue,with Beleodaq were,0
BELEODAQ,fatigue,Beleodaq were fatigue,1
BELEODAQ,pyrexia,vomiting see Clinical Studies EXCERPT The,0
BELEODAQ,pyrexia,of patients with relapsed or refractory PTCL treated with Beleodaq were nausea,0
BELEODAQ,pyrexia,,0
BELEODAQ,pyrexia,pyrexia,1
BELEODAQ,pyrexia,fatigue,0
BELEODAQ,anemia,fatigue anemia,1
BELEODAQ,anemia,,0
BELEODAQ,anemia,Beleodaq were nausea fatigue pyrexia,0
BELEODAQ,anemia,PTCL treated with Beleodaq were nausea fatigue pyrexia,0
BELEODAQ,anemia,PTCL,0
BELEODAQ,anemia,treated with Beleodaq were nausea fatigue,0
BELEODAQ,vomiting,with Beleodaq were nausea,0
BELEODAQ,vomiting,vomiting,1
BELEODAQ,vomiting,vomiting,1
BELEODAQ,nausea,nausea,1
BELEODAQ,nausea,most common adverse,0
BELEODAQ,nausea,report SUSPECTED ADVERSE REACTIONS,0
BELEODAQ,nausea,,0
BELEODAQ,nausea,common adverse reactions are,0
BELEODAQ,nausea,adverse reactions nausea,1
BELEODAQ,nausea,EXCERPT The most,0
BELEODAQ,nausea,c,0
BELEODAQ,fatigue,fatigue,1
BELEODAQ,fatigue,,0
BELEODAQ,fatigue,report,0
BELEODAQ,fatigue,fatigue,1
BELEODAQ,pyrexia,ADVERSE,0
BELEODAQ,pyrexia,pyrexia,1
BELEODAQ,anemia,anemia,1
BELEODAQ,anemia,,0
BELEODAQ,anemia,anemia,1
BELEODAQ,anemia,are nausea fatigue anemia,1
BELEODAQ,anemia,report SUSPECTED ADVERSE REACTIONS,0
BELEODAQ,anemia,,0
BELEODAQ,vomiting,,0
BELEODAQ,vomiting,vomiting,1
BELEODAQ,vomiting,vomiting,1
BELEODAQ,vomiting,common adverse reactions are,0
BELEODAQ,vomiting,at,0
BELEODAQ,vomiting,nausea,0
BELEODAQ,vomiting,vomiting,1
BELEODAQ,vomiting,vomiting,1
BELEODAQ,Nausea,Nausea,1
BELEODAQ,Nausea,,0
BELEODAQ,Nausea,Nausea,1
BELEODAQ,Nausea,Nausea,1
BELEODAQ,Nausea,Nausea,1
BELEODAQ,Nausea,,0
BELEODAQ,Nausea,,0
BELEODAQ,Nausea,Nausea,1
BELEODAQ,Nausea,Nausea,1
BELEODAQ,Nausea,,0
BELEODAQ,Fatigue,,0
BELEODAQ,Fatigue,Fatigue,1
BELEODAQ,Fatigue,Fatigue,1
BELEODAQ,Pyrexia,Pyrexia,1
BELEODAQ,Pyrexia,,0
BELEODAQ,Pyrexia,Pyrexia,1
BELEODAQ,Pyrexia,Pyrexia,1
BELEODAQ,Pyrexia,Pyrexia,1
BELEODAQ,Pyrexia,Pyrexia,1
BELEODAQ,Pyrexia,Pyrexia,1
BELEODAQ,Pyrexia,Pyrexia,1
BELEODAQ,Pyrexia,Pyrexia,1
BELEODAQ,Pyrexia,Pyrexia,1
BELEODAQ,Anemia,Anemia,1
BELEODAQ,Anemia,,0
BELEODAQ,Anemia,Anemia,1
BELEODAQ,Anemia,Anemia,1
BELEODAQ,Anemia,Anemia,1
BELEODAQ,Anemia,Anemia,1
BELEODAQ,Anemia,Anemia,1
BELEODAQ,Anemia,,0
BELEODAQ,Anemia,Anemia,1
BELEODAQ,Vomiting,,0
BELEODAQ,Vomiting,Vomiting,1
BELEODAQ,Vomiting,Vomiting,1
BELEODAQ,Vomiting,,0
BELEODAQ,Vomiting,Vomiting,1
BELEODAQ,Vomiting,Vomiting,1
BELEODAQ,Vomiting,Vomiting,1
BELEODAQ,Vomiting,Vomiting,1
BELEODAQ,Constipation,Constipation Dia,1
BELEODAQ,Constipation,Constipation Dia,1
BELEODAQ,Constipation,,0
BELEODAQ,Constipation,Constipation Dia,1
BELEODAQ,Constipation,,0
BELEODAQ,Constipation,,0
BELEODAQ,Constipation,,0
BELEODAQ,Constipation,,0
BELEODAQ,Constipation,Constipation Dia,1
BELEODAQ,Constipation,,0
BELEODAQ,Diarrhea,,0
BELEODAQ,Diarrhea,,0
BELEODAQ,Diarrhea,Diarrhea,1
BELEODAQ,Diarrhea,,0
BELEODAQ,Diarrhea,,0
BELEODAQ,Diarrhea,ion,0
BELEODAQ,Dyspnea,Dyspnea,1
BELEODAQ,Dyspnea,Dyspnea,1
BELEODAQ,Dyspnea,,0
BELEODAQ,Dyspnea,,0
BELEODAQ,Dyspnea,Dyspnea,1
BELEODAQ,Dyspnea,,0
BELEODAQ,Dyspnea,Dyspnea,1
BELEODAQ,Dyspnea,Dyspnea,1
BELEODAQ,Rash,Rash,1
BELEODAQ,Rash,,0
BELEODAQ,Rash,,0
BELEODAQ,Peripheral Edema,Peripheral,1
BELEODAQ,Cough,,0
BELEODAQ,Cough,Edema,0
BELEODAQ,Cough,,0
BELEODAQ,Cough,Edema,0
BELEODAQ,Cough,,0
BELEODAQ,Cough,,0
BELEODAQ,Cough,,0
BELEODAQ,Thrombocytopenia,,0
BELEODAQ,Thrombocytopenia,,0
BELEODAQ,Thrombocytopenia,Thrombocytopenia Pruritu,1
BELEODAQ,Thrombocytopenia,,0
BELEODAQ,Thrombocytopenia,,0
BELEODAQ,Thrombocytopenia,,0
BELEODAQ,Thrombocytopenia,,0
BELEODAQ,Pruritus,Pruritus,1
BELEODAQ,Pruritus,topenia,0
BELEODAQ,Pruritus,topenia Pruritus,1
BELEODAQ,Pruritus,topenia,0
BELEODAQ,Pruritus,topenia,0
BELEODAQ,Pruritus,topenia,0
BELEODAQ,Pruritus,topenia,0
BELEODAQ,Chills,Chills,1
BELEODAQ,Chills,,0
BELEODAQ,Chills,Chills,1
BELEODAQ,Chills,Chills,1
BELEODAQ,Chills,Chills,1
BELEODAQ,Chills,,0
BELEODAQ,Chills,,0
BELEODAQ,Chills,,0
BELEODAQ,Chills,,0
BELEODAQ,Increased Blood Lactate Dehydrogenase,Blood Lactate Dehydrogenase,1
BELEODAQ,Increased Blood Lactate Dehydrogenase,,0
BELEODAQ,Increased Blood Lactate Dehydrogenase,Increased Blood,1
BELEODAQ,Increased Blood Lactate Dehydrogenase,Increased Blood Lactate Dehydrogenase,1
BELEODAQ,Increased Blood Lactate Dehydrogenase,Decreased,0
BELEODAQ,Increased Blood Lactate Dehydrogenase,Lactate Dehydrogenase Decreased,1
BELEODAQ,Increased Blood Lactate Dehydrogenase,Increased Blood Lactate Dehydrogenase Decreased,1
BELEODAQ,Increased Blood Lactate Dehydrogenase,,0
BELEODAQ,Increased Blood Lactate Dehydrogenase,Increased Blood Lactate Dehydrogenase Decreased,1
BELEODAQ,Increased Blood Lactate Dehydrogenase,Dehydrogenase Decreased,1
BELEODAQ,Decreased Appetite,,0
BELEODAQ,Decreased Appetite,,0
BELEODAQ,Decreased Appetite,Decreased Appetite Headache,1
BELEODAQ,Headache,Headache,1
BELEODAQ,Infusion Site Pain,Infusion Site,1
BELEODAQ,Hypokalemia,,0
BELEODAQ,Hypokalemia,Hypokalemia Pr,1
BELEODAQ,Hypokalemia,Hypokalemia Pr,1
BELEODAQ,Hypokalemia,,0
BELEODAQ,Hypokalemia,Hypokalemia Pr,1
BELEODAQ,Hypokalemia,,0
BELEODAQ,Hypokalemia,Hypokalemia Pr,1
BELEODAQ,Prolonged QT,ia Prolonged,1
BELEODAQ,Abdominal pain,QT,0
BELEODAQ,Abdominal pain,Abdominal pain Hypot,1
BELEODAQ,Hypotension,pain Hypotension Ph,1
BELEODAQ,Hypotension,pain,0
BELEODAQ,Hypotension,Hypotension Ph,1
BELEODAQ,Hypotension,pain Hypotension Ph,1
BELEODAQ,Hypotension,pain,0
BELEODAQ,Hypotension,Hypotension Ph,1
BELEODAQ,Hypotension,,0
BELEODAQ,Hypotension,Hypotension Ph,1
BELEODAQ,Hypotension,pain,0
BELEODAQ,Phlebitis,,0
BELEODAQ,Phlebitis,Phlebitis,1
BELEODAQ,Phlebitis,,0
BELEODAQ,Phlebitis,,0
BELEODAQ,Phlebitis,Phlebitis,1
BELEODAQ,Phlebitis,,0
BELEODAQ,Dizziness,Dizziness,1
BELEODAQ,Dizziness,Dizziness,1
BELEODAQ,Dizziness,Dizziness,1
BELEODAQ,pneumonia,pneumonia,1
BELEODAQ,pneumonia,pyrexia infection,0
BELEODAQ,pyrexia,pyrexia,1
BELEODAQ,infection,pneumonia,0
BELEODAQ,infection,adverse reactions were pneumonia infection,1
BELEODAQ,infection,infection,1
BELEODAQ,infection,creatinine thrombocytopenia and multiorgan failure One,0
BELEODAQ,infection,infection,1
BELEODAQ,infection,infection,1
BELEODAQ,infection,infection,1
BELEODAQ,infection,dea,0
BELEODAQ,anemia,,0
BELEODAQ,anemia,anemia,1
BELEODAQ,anemia,anemia,1
BELEODAQ,anemia,serious adverse reactions were pneumonia,0
BELEODAQ,increased creatinine,increased creatinine,1
BELEODAQ,increased creatinine,increased creatinine,1
BELEODAQ,increased creatinine,increased creatinine,1
BELEODAQ,increased creatinine,,0
BELEODAQ,increased creatinine,creatinine,1
BELEODAQ,increased creatinine,death associated with,0
BELEODAQ,increased creatinine,increased creatinine,1
BELEODAQ,thrombocytopenia,thrombocytopenia,1
BELEODAQ,thrombocytopenia,thrombocytopenia,1
BELEODAQ,multi-organ failure,thrombocytopenia multi-organ,1
BELEODAQ,multi-organ failure,thrombocytopenia multi-organ,1
BELEODAQ,multi-organ failure,failure was reported,0
BELEODAQ,multi-organ failure,multi-organ failure,1
BELEODAQ,multi-organ failure,increased creatinine thrombocytopenia multi-organ failure,1
BELEODAQ,multi-organ failure,,0
BELEODAQ,death,,0
BELEODAQ,death,,0
BELEODAQ,death,and multiorgan failure,0
BELEODAQ,death,,0
BELEODAQ,hepatic failure,One treatmentrelated death associated hepatic,1
BELEODAQ,hepatic failure,hepatic failure,1
BELEODAQ,hepatic failure,failure,1
BELEODAQ,hepatic failure,hepatic failure,1
BELEODAQ,hepatic failure,and multiorgan failure,0
BELEODAQ,hepatic failure,failure,1
BELEODAQ,hepatic failure,with,0
BELEODAQ,hepatic failure,death associated hepatic failure,1
BELEODAQ,tumor lysis syndrome,and bulky disease experienced tumor lysis syndrome,1
BELEODAQ,tumor lysis syndrome,due to multiorgan failure A treatmentrelated,0
BELEODAQ,tumor lysis syndrome,and died due to,0
BELEODAQ,tumor lysis syndrome,tumor lysis syndrome,1
BELEODAQ,tumor lysis syndrome,due,0
BELEODAQ,tumor lysis syndrome,,0
BELEODAQ,tumor lysis syndrome,disease experienced tumor lysis syndrome,1
BELEODAQ,tumor lysis syndrome,due to multiorgan failure,0
BELEODAQ,tumor lysis syndrome,bulky disease experienced tumor lysis syndrome,1
BELEODAQ,died,treatment died,1
BELEODAQ,died,ventricular fibrillation,0
BELEODAQ,died,experienced Grade tumor lysis syndrome during the first cycle of treatment and,0
BELEODAQ,died,cycle of treatment died,1
BELEODAQ,died,died,1
BELEODAQ,died,died,1
BELEODAQ,died,,0
BELEODAQ,died,died,1
BELEODAQ,ventricular fibrillation,treatmentrelated death ventricular fibrillation,1
BELEODAQ,ventricular fibrillation,fibrillation,1
BELEODAQ,ventricular fibrillation,not,0
BELEODAQ,QTc prolongation,Discontinuations due to Adverse Reactions Twentyfive patients,0
BELEODAQ,QTc prolongation,did not QTc,1
BELEODAQ,QTc prolongation,Discontinuations due to Adverse Reactions Twentyfive patients discontinued,0
BELEODAQ,QTc prolongation,did not QTc prolongation,1
BELEODAQ,QTc prolongation,analysis did not QTc prolongation,1
BELEODAQ,QTc prolongation,ECG analysis did not QTc,1
BELEODAQ,anemia,anemia,1
BELEODAQ,anemia,fatigue and multiorgan,0
BELEODAQ,anemia,multiorgan,0
BELEODAQ,anemia,Modifications due to Adverse R,0
BELEODAQ,febrile neutropenia,Dosage Modifications,0
BELEODAQ,febrile neutropenia,febrile neutropenia,1
BELEODAQ,febrile neutropenia,discontinuation of treatment included febrile,1
BELEODAQ,febrile neutropenia,multiorgan failure Dosage,0
BELEODAQ,fatigue,treatment included anemia febrile fatigue,1
BELEODAQ,fatigue,the reason for discontinuation of treatment included anemia febrile,0
BELEODAQ,fatigue,failure Dosage Modifications due to Adverse Reactions,0
BELEODAQ,fatigue,fatigue,1
BELEODAQ,fatigue,anemia febrile fatigue,1
BELEODAQ,multi-organ failure,treatment included anemia febrile neutropenia,0
BELEODAQ,multi-organ failure,fatigue multi-organ failure,1
BELEODAQ,multi-organ failure,fatigue and,0
BELEODAQ,multi-organ failure,neutropenia fatigue multi-organ,1
BELEODAQ,multi-organ failure,,0
BELEODAQ,multi-organ failure,,0
BELEODAQ,multi-organ failure,failure,1
BELEODAQ,multi-organ failure,multi-organ failure,1
BELEODAQ,multi-organ failure,,0
BELEODAQ,Thrombocytopenia,se reactions are described,1
BELEODAQ,Thrombocytopenia,se reactions are,1
BELEODAQ,Thrombocytopenia,described in more detail in other sections of the prescribing information,0
BELEODAQ,leukopenia,detail,0
BELEODAQ,leukopenia,,0
BELEODAQ,leukopenia,,0
BELEODAQ,leukopenia,,0
BELEODAQ,leukopenia,escribed i n more detail in,1
BELEODAQ,neutropenia,more detail in,1
BELEODAQ,neutropenia,more detail,1
BELEODAQ,neutropenia,other sections,0
BELEODAQ,neutropenia,more detail in other sections,1
BELEODAQ,neutropenia,,0
BELEODAQ,neutropenia,,0
BELEODAQ,neutropenia,more detail in other sections of,1
BELEODAQ,lymphopenia,in more detail in ther sectio ns of the prescribing,1
BELEODAQ,lymphopenia,more detail in ther,1
BELEODAQ,lymphopenia,ther sectio ns of the prescribing,1
BELEODAQ,anemia,of t,0
BELEODAQ,anemia,he pre scribing information Hematologic Toxicity,1
BELEODAQ,anemia,,0
BELEODAQ,anemia,sections of he pre scribing information Hematologic Toxicity,1
BELEODAQ,anemia,of he,1
BELEODAQ,Infection,,0
BELEODAQ,Infection,and *,1
BELEODAQ,fatal,see arnin gs and Precautions Hepatotoxicity,1
BELEODAQ,fatal,Hepatotoxicity,0
BELEODAQ,fatal,,0
BELEODAQ,fatal,and Precautions Infection see arnin gs and Precautions Hepatotoxicity,1
BELEODAQ,infections,and Precautions Infection see s and,1
BELEODAQ,infections,see Warnings,0
BELEODAQ,infections,Hepatotoxicity,0
BELEODAQ,infections,s and Prec autions Hepatotoxicity see Warnings,1
BELEODAQ,infections,s and,1
BELEODAQ,infections,s and Prec autions Hepatotoxicity see Warnings,1
BELEODAQ,infections,Lys,0
BELEODAQ,infections,Prec autions Hepatotoxicity see Warnings,1
BELEODAQ,infections,Lys,0
BELEODAQ,infections,Infection see s and Prec autions Hepatotoxicity see Warnings,1
BELEODAQ,infections,and Precautions Infection see s and Prec autions Hepatotoxicity see Warnings,1
BELEODAQ,infections,s and Prec autions Hepatotoxicity see Warnings,1
BELEODAQ,infections,Infection see s and Prec autions Hepatotoxicity see Warnings,1
BELEODAQ,infections,Precautions,0
BELEODAQ,infections,Toxicity see Warnings and,0
BELEODAQ,infections,Warnings and Precautions Infection see Warning,0
BELEODAQ,infections,Precautions Infection see s,1
BELEODAQ,infections,Warning,0
BELEODAQ,infections,and Prec autions Hepatotoxicity see Warnings,1
BELEODAQ,pneumonia,and ( 5.2,1
BELEODAQ,pneumonia,( 5.2,1
BELEODAQ,pneumonia,( 5.2 ) Hepatotoxicity see Warnings and,1
BELEODAQ,pneumonia,) Hepatotoxicity see Warnings and,1
BELEODAQ,pneumonia,Warnings,0
BELEODAQ,sepsis,*,1
BELEODAQ,sepsis,see Warnings and *    H epatotoxicity see Warnings and,1
BELEODAQ,sepsis,,0
BELEODAQ,sepsis,Infection see Warnings and *    H epatotoxicity see Warnings and,1
BELEODAQ,sepsis,Infection see Warnings and,0
BELEODAQ,sepsis,and Precautions,0
BELEODAQ,sepsis,Infection see Warnings and *    H epatotoxicity see Warnings and,1
BELEODAQ,sepsis,and Precautions Infection see Warnings and Precautions,0
BELEODAQ,sepsis,and *,1
BELEODAQ,sepsis,* H epatotoxicity see Warnings and,1
BELEODAQ,Hepatotoxicity,Syndrome see,0
BELEODAQ,Hepatotoxicity,see nings and Prec autions Tumor Lysis Syndrome,1
BELEODAQ,Hepatotoxicity,nings and Prec autions Tumor Lysis Syndrome,1
BELEODAQ,hepatic toxicity,and *,1
BELEODAQ,hepatic toxicity,Precautions Hepatotoxicity,0
BELEODAQ,liver function test abnormalities,drome [see,1
BELEODAQ,liver function test abnormalities,The,0
BELEODAQ,liver function test abnormalities,,0
BELEODAQ,Tumor lysis syndrome,the trial of patients with,0
BELEODAQ,Tumor lysis syndrome,on adverse reactions observed in the trial,1
BELEODAQ,Tumor lysis syndrome,Toxicity see Warnings and,0
BELEODAQ,Embryo-fetal toxicity,nausea fatigue,0
BELEODAQ,Embryo-fetal toxicity,vomiting [se e Clinical Studies EXCERPT,1
BELEODAQ,Embryo-fetal toxicity,[se e Clinical Studies EXCERPT,1
BELEODAQ,Embryo-fetal toxicity,adverse reactions are,0
BELEODAQ,fetal harm,    14     EXCERPT The most common,1
BELEODAQ,fetal harm,fatigue pyrexia anem,0
BELEODAQ,fetal harm,    14     EXCERPT The most common,1
BELEODAQ,fetal harm,    14     EXCERPT The most common,1
BELEODAQ,thrombocytopenia,or wwwfdagovmedwatch,0
BELEODAQ,thrombocytopenia,"s, Inc. at 1-888 or FDA at FDA",1
BELEODAQ,thrombocytopenia,"REACTIONS contact Spectrum s, Inc. at 1-888 or FDA at FDA",1
BELEODAQ,thrombocytopenia,Inc. at 1-888 or FDA at FDA,1
BELEODAQ,thrombocytopenia,,0
BELEODAQ,thrombocytopenia,To report SUSPECTED ADVERSE REACTIONS contact Spectrum Pharmaceutical,0
BELEODAQ,thrombocytopenia,or FDA at,0
BELEODAQ,thrombocytopenia,"contact Spectrum s, Inc. at",1
BELEODAQ,thrombocytopenia,,0
BELEODAQ,neutropenia,F,0
BELEODAQ,neutropenia,Inc,0
BELEODAQ,neutropenia,or DA,1
BELEODAQ,neutropenia,report SUSPECTED,0
BELEODAQ,neutropenia,Trials Experience,0
BELEODAQ,neutropenia,at 1-800 FDA or wwwfdagovmedwatch Clinical,1
BELEODAQ,neutropenia,or F,0
BELEODAQ,neutropenia,at or DA at 1-800 FDA or wwwfdagovmedwatch Clinical,1
BELEODAQ,neutropenia,or wwwfdagovmedwatch Clinical,0
BELEODAQ,lymphopenia,or FDA at 1088     or wwwfdagovmedwatch Clinical Trials Experience,1
BELEODAQ,lymphopenia,trials,0
BELEODAQ,anemia,or,0
BELEODAQ,anemia,FDA at FDA or .fda.g ovmedwatch Clinical Trials Experience,1
BELEODAQ,anemia,.fda.g ovmedwatch Clinical Trials Experience,1
BELEODAQ,anemia,.fda.g ovmedwatch Clinical Trials Experience,1
BELEODAQ,anemia,.fda.g ovmedwatch Clinical Trials Experience,1
BELEODAQ,anemia,ovmedwatch Clinical Trials Experience Because clinical trials,0
BELEODAQ,anemia,conducted unde,0
BELEODAQ,anemia,.fda.g ovmedwatch Clinical Trials Experience,1
BELEODAQ,anemia,FDA at FDA or .fda.g ovmedwatch Clinical Trials Experience,1
BELEODAQ,fatal,of Beleodaq may not t the rates observed in practice,1
BELEODAQ,fatal,,0
BELEODAQ,fatal,practice Adverse Reactions in Patients with Peripheral,0
BELEODAQ,fatal,observed,0
BELEODAQ,fatal,not,0
BELEODAQ,fatal,t,1
BELEODAQ,fatal,of Beleodaq may not t the rates observed in practice,1
BELEODAQ,fatal,t the rates observed in practice,1
BELEODAQ,fatal,t the rates observed in practice,1
BELEODAQ,infections,Reactions,0
BELEODAQ,infections,may not reflect rates,1
BELEODAQ,infections,in the clinical trials of Beleodaq may,0
BELEODAQ,pneumonia,"tice.



 Adverse Reactions in Patients",1
BELEODAQ,pneumonia,"tice.



 Adverse Reactions in Patients",1
BELEODAQ,pneumonia,"tice.



 Adverse Reactions in Patients",1
BELEODAQ,pneumonia,"observed in tice.



 Adverse Reactions in Patients",1
BELEODAQ,pneumonia,may not reflect the rates observed in prac,0
BELEODAQ,pneumonia,"tice.



 Adverse Reactions in Patients",1
BELEODAQ,pneumonia,TCell Lymphoma The safety of Beleodaq was,0
BELEODAQ,pneumonia,Peripheral TCell Lymphoma,0
BELEODAQ,pneumonia,Beleodaq may not reflect the rates observed in,0
BELEODAQ,sepsis,verse  Reactions in Patients with,1
BELEODAQ,sepsis,safety of,0
BELEODAQ,fatal,administered Beleodaq at a dosage of mgm,0
BELEODAQ,fatal, dail y on Days of,1
BELEODAQ,fatal,infusion  dail y on Days of,1
BELEODAQ,fatal,on Days of a day cycle see Clinical Studies The,0
BELEODAQ,hepatotoxicity,Beleodaq at a dosage of mgm administered over minutes by IV infusion once daily,0
BELEODAQ,hepatotoxicity,on Days 1-5 o f a day cycle,1
BELEODAQ,hepatotoxicity,by IV infusion once on,1
BELEODAQ,hepatotoxicity,Beleodaq at a dosage of mgm administered over minutes by IV infusion once,0
BELEODAQ,hepatotoxicity,o f a day cycle,1
BELEODAQ,hepatotoxicity,mgm,0
BELEODAQ,liver function test abnormalities,treatment was cycles range cycles Table,0
BELEODAQ,liver function test abnormalities,of treatment,0
BELEODAQ,liver function test abnormalities,[see Clinical Studie s The median duration,1
BELEODAQ,liver function test abnormalities,a dosage of mgm administered over minutes by IV infusion once,0
BELEODAQ,liver function test abnormalities,of 1-day cycle [see Clinical,1
BELEODAQ,liver function test abnormalities,,0
BELEODAQ,Tumor lysis syndrome,,0
BELEODAQ,Tumor lysis syndrome,psed or Refractory P TCL NCICTC Grade MedDRA,1
BELEODAQ,Tumor lysis syndrome,in Patients with psed or Refractory P TCL NCICTC Grade MedDRA,1
BELEODAQ,Tumor lysis syndrome,of Patients by Preferred Term and Severity in Patients,0
BELEODAQ,Tumor lysis syndrome,in Patients with psed or Refractory P TCL NCICTC Grade MedDRA,1
BELEODAQ,Tumor lysis syndrome,,0
BELEODAQ,Tumor lysis syndrome,Term,0
BELEODAQ,Tumor lysis syndrome,in Patients with psed or Refractory,1
BELEODAQ,Tumor lysis syndrome,psed or Refractory P TCL NCICTC Grade MedDRA,1
BELEODAQ,Nausea,ea     F,1
BELEODAQ,Nausea,,0
BELEODAQ,Nausea,F,0
BELEODAQ,Nausea,ea     F,1
BELEODAQ,Nausea,eactions ea     F,1
BELEODAQ,Nausea,ea     F,1
BELEODAQ,vomiting,,0
BELEODAQ,vomiting,         Fatigue,1
BELEODAQ,vomiting,Nausea,0
BELEODAQ,diarrhea,         Fatigue,1
BELEODAQ,diarrhea,,0
BELEODAQ,diarrhea,,0
BELEODAQ,diarrhea,Nausea,0
BELEODAQ,diarrhea,Nausea          Fatigue,1
BELEODAQ,fetal harm,,0
BELEODAQ,fetal harm,  Pyrexia ,1
BELEODAQ,fetal harm,,0
BELEODAQ,fetal harm,,0
BELEODAQ,fetal harm,,0
BELEODAQ,fetal harm,,0
BELEODAQ,fetal harm,  Pyrexia ,1
BELEODAQ,teratogenicity,Pyrexia              2 Anemia,1
BELEODAQ,embryo-fetal lethality,"                 
  An emia",1
BELEODAQ,embryo-fetal lethality,Pyrexia,0
BELEODAQ,embryo-fetal lethality,"                 
  An emia",1
BELEODAQ,genotoxic,Anemia,0
BELEODAQ,genotoxic,Anemia,0
HALAVEN,neutropenia,nausea and,0
HALAVEN,neutropenia,astheniafatigue alopecia peripheral neuropathy nausea and,0
HALAVEN,neutropenia,incidence neutropenia anemia,1
HALAVEN,neutropenia,neutropenia anemia,1
HALAVEN,neutropenia,neutropenia anemia,1
HALAVEN,anemia,anemia astheniafatigue,1
HALAVEN,anemia,,0
HALAVEN,anemia,were anemia astheniafatigue,1
HALAVEN,asthenia,common adverse reactions incidence,0
HALAVEN,fatigue,fatigue alopecia,1
HALAVEN,fatigue,The,0
HALAVEN,fatigue,fatigue alopecia,1
HALAVEN,alopecia,alopecia peripheral,1
HALAVEN,alopecia,alopecia peripheral,1
HALAVEN,alopecia,alopecia peripheral,1
HALAVEN,alopecia,alopecia peripheral,1
HALAVEN,alopecia,,0
HALAVEN,alopecia,ADVERSE,0
HALAVEN,alopecia,alopecia peripheral,1
HALAVEN,alopecia,neutropenia anemia astheniafatigue,0
HALAVEN,peripheral neuropathy,anemia astheniafatigue peripheral neuropathy nausea,1
HALAVEN,peripheral neuropathy,neutropenia anemia astheniafatigue peripheral,1
HALAVEN,peripheral neuropathy,SUSPECTED ADVERSE REACTIONS contact,0
HALAVEN,peripheral neuropathy,reactions incidence were neutropenia anemia astheniafatigue alopecia,0
HALAVEN,peripheral neuropathy,astheniafatigue peripheral,1
HALAVEN,peripheral neuropathy,were neutropenia anemia astheniafatigue peripheral,1
HALAVEN,peripheral neuropathy,To report,0
HALAVEN,nausea,anemia astheniafatigue,0
HALAVEN,nausea,incidence were neutropenia anemia astheniafatigue alopecia,0
HALAVEN,nausea,nausea and,1
HALAVEN,nausea,anemia astheniafatigue alopecia peripheral nausea and,1
HALAVEN,nausea,anemia astheniafatigue alopecia peripheral nausea and,1
HALAVEN,nausea,nausea and,1
HALAVEN,nausea,nausea and,1
HALAVEN,constipation,,0
HALAVEN,constipation,,0
HALAVEN,constipation,anemia astheniafatigue alopecia,0
HALAVEN,constipation,,0
HALAVEN,constipation,anemia,0
HALAVEN,constipation,constipation To,1
HALAVEN,Neutropenia,Warnings and Preca,0
HALAVEN,Neutropenia,sections of the Neutropenia see,1
HALAVEN,Neutropenia,and,0
HALAVEN,Peripheral neuropathy,Neutropenia see Warnings and Peripheral neuropathy see,1
HALAVEN,QT interval prolongation,see Warnings and Precautions,0
HALAVEN,QT interval prolongation,Precautions,0
HALAVEN,QT interval prolongation,,0
HALAVEN,QT interval prolongation,,0
HALAVEN,QT interval prolongation,,0
HALAVEN,QT interval prolongation,,0
HALAVEN,QT interval prolongation,,0
HALAVEN,QT interval prolongation,Warnings and QT,1
HALAVEN,neutropenia,receiving HALAVEN,0
HALAVEN,neutropenia,neutropenia anemia,1
HALAVEN,neutropenia,neutropenia anemia,1
HALAVEN,neutropenia,,0
HALAVEN,neutropenia,neutropenia anemia,1
HALAVEN,anemia,anemia astheniafatigue,1
HALAVEN,anemia,astheniafatigue alopecia peripheral neuropathy nausea and constipation The most common serio,0
HALAVEN,anemia,nausea and constipation The most common,0
HALAVEN,asthenia,receiving HALAVEN were neutropenia asthenia fatigue,1
HALAVEN,asthenia,receiving HALAVEN were neutropenia asthenia fatigue,1
HALAVEN,asthenia,common serious,0
HALAVEN,asthenia,adverse,0
HALAVEN,asthenia,asthenia fatigue,1
HALAVEN,asthenia,receiving HALAVEN were neutropenia asthenia fatigue,1
HALAVEN,asthenia,reported in patients receiving HALAVEN were neutropenia anemia,0
HALAVEN,asthenia,alopecia peripheral neuropathy,0
HALAVEN,asthenia,HALAVEN were neutropenia,0
HALAVEN,fatigue,fatigue alopecia,1
HALAVEN,alopecia,were neutropenia,0
HALAVEN,alopecia,peripheral neuropathy nausea and constipation The most,0
HALAVEN,alopecia,neuropathy nausea and constipation The most common,0
HALAVEN,peripheral neuropathy,patients receiving HALAVEN,0
HALAVEN,peripheral neuropathy,nausea and constipation The most common serious adverse,0
HALAVEN,peripheral neuropathy,constipation The most common serious adverse reactions reported in,0
HALAVEN,peripheral neuropathy,nausea and constipation The most common serious adverse,0
HALAVEN,peripheral neuropathy,HALAVEN,0
HALAVEN,peripheral neuropathy,,0
HALAVEN,peripheral neuropathy,,0
HALAVEN,peripheral neuropathy,reported in,0
HALAVEN,peripheral neuropathy,constipation The most common serious adverse reactions,0
HALAVEN,peripheral neuropathy,neuropathy nausea,1
HALAVEN,nausea,HALAVEN,0
HALAVEN,nausea,,0
HALAVEN,nausea,nausea and,1
HALAVEN,constipation,neuropathy nausea and,0
HALAVEN,constipation,constipation The,1
HALAVEN,constipation,constipation The,1
HALAVEN,constipation,peripheral neuropathy nausea constipation The,1
HALAVEN,constipation,constipation The,1
HALAVEN,constipation,constipation The,1
HALAVEN,constipation,alopecia peripheral neuropathy nausea constipation The,1
HALAVEN,constipation,anemia astheniafatigue alopecia peripheral,0
HALAVEN,constipation,astheniafatigue alopecia peripheral neuropathy nausea,0
HALAVEN,constipation,peripheral neuropathy nausea constipation The,1
HALAVEN,febrile neutropenia,,0
HALAVEN,febrile neutropenia,HALAVEN febrile,1
HALAVEN,febrile neutropenia,patients receiving HALAVEN febrile,1
HALAVEN,neutropenia,neutropenia The,1
HALAVEN,neutropenia,febrile neutropenia neutropenia The,1
HALAVEN,neutropenia,adverse reactions reported in patients receiving HALAVEN were febrile,0
HALAVEN,neutropenia,febrile neutropenia neutropenia The,1
HALAVEN,neutropenia,,0
HALAVEN,neutropenia,of HALAVEN was peripheral,0
HALAVEN,neutropenia,neutropenia The,1
HALAVEN,neutropenia,patients receiving,0
HALAVEN,neutropenia,reactions reported in patients receiving HALAVEN were,0
HALAVEN,peripheral neuropathy,peripheral neuropathy In,1
HALAVEN,Neutropenia,System Disorders Neutropenia Anemia,1
HALAVEN,Neutropenia,Neutropenia Anemia,1
HALAVEN,Neutropenia,Neutropenia Anemia,1
HALAVEN,Neutropenia,Neutropenia Anemia,1
HALAVEN,Neutropenia,,0
HALAVEN,Neutropenia,Disorders,0
HALAVEN,Neutropenia,Disorders Neutropenia Anemia,1
HALAVEN,Neutropenia,,0
HALAVEN,Anemia,Anemia Nervous,1
HALAVEN,Anemia,Anemia Nervous system,1
HALAVEN,Anemia,Anemia Nervous,1
HALAVEN,Anemia,,0
HALAVEN,Peripheral neuropathy,system Peripheral neuropathy,1
HALAVEN,Peripheral neuropathy,rvous system Peripheral,1
HALAVEN,Peripheral neuropathy,,0
HALAVEN,Peripheral neuropathy,Peripheral neuropathy,1
HALAVEN,Peripheral neuropathy,b Headache,0
HALAVEN,Peripheral neuropathy,system Peripheral,1
HALAVEN,Peripheral neuropathy,rvous system Peripheral,1
HALAVEN,Peripheral neuropathy,neuropathy,1
HALAVEN,Peripheral neuropathy,b,0
HALAVEN,Headache,Headache,1
HALAVEN,Headache,,0
HALAVEN,Headache,Headache,1
HALAVEN,Headache,Headache,1
HALAVEN,Asthenia,site,0
HALAVEN,Asthenia,Asthenia,1
HALAVEN,Asthenia,Asthenia,1
HALAVEN,Asthenia,Asthenia,1
HALAVEN,Fatigue,Mucosal,0
HALAVEN,Fatigue,Fatigue,1
HALAVEN,Fatigue,Fatigue,1
HALAVEN,Fatigue,,0
HALAVEN,Fatigue,Fatigue,1
HALAVEN,Mucosal inflammation,AstheniaFatigue Mucosal inflammation Pyrexia,1
HALAVEN,Mucosal inflammation,,0
HALAVEN,Pyrexia,Pyrexia Gastrointestinal,1
HALAVEN,Pyrexia,,0
HALAVEN,Pyrexia,Pyrexia Gastrointestinal,1
HALAVEN,Pyrexia,Pyrexia Gastrointestinal,1
HALAVEN,Pyrexia,Pyrexia Gastrointestinal,1
HALAVEN,Pyrexia,,0
HALAVEN,Constipation,Constipation Diarrhea,1
HALAVEN,Constipation,disorders,0
HALAVEN,Constipation,Constipation Diarrhea,1
HALAVEN,Constipation,disorders,0
HALAVEN,Constipation,disorders,0
HALAVEN,Diarrhea,Constipation Diarrhea Nausea,1
HALAVEN,Diarrhea,Constipation,0
HALAVEN,Diarrhea,Constipation,0
HALAVEN,Diarrhea,Constipation Diarrhea Nausea,1
HALAVEN,Diarrhea,Constipation,0
HALAVEN,Diarrhea,Diarrhea Nausea,1
HALAVEN,Diarrhea,Constipation,0
HALAVEN,Nausea,,0
HALAVEN,Vomiting,Vomiting,1
HALAVEN,Arthralgia,tissue disorders,0
HALAVEN,Arthralgia,,0
HALAVEN,Arthralgia,tissue disorders,0
HALAVEN,Arthralgia,tissue disorders,0
HALAVEN,Arthralgia,tissue,0
HALAVEN,Myalgia,Myalgia,1
HALAVEN,Myalgia,,0
HALAVEN,Myalgia,Myalgia,1
HALAVEN,Myalgia,,0
HALAVEN,Myalgia,,0
HALAVEN,Myalgia,Myalgia,1
HALAVEN,Myalgia,,0
HALAVEN,Back pain,ArthralgiaMyalgia Back,1
HALAVEN,Back pain,ArthralgiaMyalgia,0
HALAVEN,Back pain,ArthralgiaMyalgia,0
HALAVEN,Back pain,Back pain,1
HALAVEN,Back pain,ArthralgiaMyalgia,0
HALAVEN,Back pain,ArthralgiaMyalgia Back,1
HALAVEN,Bone pain,,0
HALAVEN,Bone pain,pain,0
HALAVEN,Bone pain,Bone pain,1
HALAVEN,Pain in extremity,,0
HALAVEN,Pain in extremity,Bone Pain in,1
HALAVEN,Pain in extremity,pain,0
HALAVEN,Pain in extremity,Bone Pain in extremity Investigations,1
HALAVEN,Pain in extremity,,0
HALAVEN,Pain in extremity,pain,0
HALAVEN,Pain in extremity,Investigations,0
HALAVEN,Pain in extremity,Bone Pain in,1
HALAVEN,Pain in extremity,,0
HALAVEN,Weight decreased,Investigations,0
HALAVEN,Weight decreased,,0
HALAVEN,Weight decreased,Investigations Weight decreased Metabolism and nutrition,1
HALAVEN,Weight decreased,Investigations,0
HALAVEN,Weight decreased,Weight decreased Metabolism,1
HALAVEN,Weight decreased,Investigations,0
HALAVEN,Anorexia,Anorexia Respiratory,1
HALAVEN,Anorexia,Anorexia Respiratory,1
HALAVEN,Anorexia,Anorexia Respiratory,1
HALAVEN,Anorexia,,0
HALAVEN,Anorexia,Anorexia Respiratory,1
HALAVEN,Anorexia,,0
HALAVEN,Anorexia,Anorexia Respiratory,1
HALAVEN,Anorexia,Anorexia Respiratory,1
HALAVEN,Anorexia,nutrition Anorexia Respiratory,1
HALAVEN,Anorexia,nutrition,0
HALAVEN,Dyspnea,Cough,0
HALAVEN,Dyspnea,Cough Dyspnea,1
HALAVEN,Alopecia,c NA c Infections,0
HALAVEN,Alopecia,disorders,0
HALAVEN,Alopecia,,0
HALAVEN,Alopecia,,0
HALAVEN,Urinary Tract Infection,,0
HALAVEN,Urinary Tract Infection,Infestations,0
HALAVEN,Urinary Tract Infection,Urinary Tract Infection,1
HALAVEN,Urinary Tract Infection,a,0
HALAVEN,Urinary Tract Infection,Infestations,0
HALAVEN,Urinary Tract Infection,,0
HALAVEN,Urinary Tract Infection,,0
HALAVEN,Urinary Tract Infection,and Infestations,0
HALAVEN,Urinary Tract Infection,a,0
HALAVEN,Urinary Tract Infection,a based,0
HALAVEN,neuropathy peripheral,based upon laboratory data b,0
HALAVEN,neuropathy,b includes,0
HALAVEN,neuropathy,,0
HALAVEN,neuropathy,neuropathy,1
HALAVEN,neuropathy,includes neuropathy peripheral,0
HALAVEN,neuropathy,motor neuropathy polyneuropathy peripheral sensoryneuropathy,0
HALAVEN,neuropathy,b includes,0
HALAVEN,neuropathy,and paraesthesia,0
HALAVEN,neuropathy,peripheral sensoryneuropathy,0
HALAVEN,neuropathy,neuropathy neuropathy,1
HALAVEN,peripheral motor neuropathy,peripheral motor,1
HALAVEN,peripheral motor neuropathy,peripheral motor neuropathy,1
HALAVEN,peripheral motor neuropathy,peripheral peripheral,1
HALAVEN,peripheral motor neuropathy,,0
HALAVEN,polyneuropathy,c not applicable grading system does,0
HALAVEN,polyneuropathy,sensoryneuropathy and paraesthesia c not applicable,0
HALAVEN,polyneuropathy,motor polyneuropathy,1
HALAVEN,polyneuropathy,polyneuropathy,1
HALAVEN,peripheral sensoryneuropathy,system,0
HALAVEN,peripheral sensoryneuropathy,,0
HALAVEN,paraesthesia,neuropathy polyneuropathy peripheral sensoryneuropathy,0
HALAVEN,paraesthesia,paraesthesia,1
HALAVEN,paraesthesia,and,0
HALAVEN,paraesthesia,sensoryneuropathy paraesthesia,1
HALAVEN,paraesthesia,paraesthesia,1
HALAVEN,alopecia,who,0
HALAVEN,alopecia,specify Grade alopecia,1
HALAVEN,alopecia,who receiv,0
HALAVEN,neutropenia,alopecia Cytopenias neutropenia,1
HALAVEN,neutropenia,and of,0
HALAVEN,neutropenia,from,0
HALAVEN,Febrile neutropenia,febrile,0
HALAVEN,Febrile neutropenia,Febrile neutropenia,1
HALAVEN,Febrile neutropenia,received HALAVEN in Study and of patients experienced Grade,0
HALAVEN,Febrile neutropenia,and of patients experienced Grade neutropenia,0
HALAVEN,Febrile neutropenia,of patients two patients died,0
HALAVEN,Febrile neutropenia,of patients experienced Grade Febrile neutropenia,1
HALAVEN,Febrile neutropenia,complications of febrile,0
HALAVEN,Febrile neutropenia,,0
HALAVEN,Febrile neutropenia,occurred in of patients two patients died from complications of febrile neutrop,0
HALAVEN,died,reduction due to,0
HALAVEN,febrile neutropenia,died from complications febrile,1
HALAVEN,febrile neutropenia,patients died from complications febrile,1
HALAVEN,febrile neutropenia,,0
HALAVEN,febrile neutropenia,two patients died,0
HALAVEN,neutropenia,complications of febrile,0
HALAVEN,neutropenia,reduction,0
HALAVEN,neutropenia,neutropenia,1
HALAVEN,neutropenia,neutropenia,1
HALAVEN,neutropenia,,0
HALAVEN,neutropenia,neutropenia,1
HALAVEN,neutropenia,in of,0
HALAVEN,neutropenia,patients,0
HALAVEN,neutropenia,time to nadir was days and the mean time to recovery,0
HALAVEN,neutropenia,thrombocytopenia occurred in of,0
HALAVEN,neutropenia,time to recovery from neutropenia,1
HALAVEN,thrombocytopenia,,0
HALAVEN,thrombocytopenia,was days Grade,0
HALAVEN,thrombocytopenia,mean time to recovery from severe neutropenia mm was days,0
HALAVEN,thrombocytopenia,time to recovery from severe neutropenia,0
HALAVEN,peripheral neuropathy,had peripheral neuropathy,1
HALAVEN,peripheral neuropathy,required,0
HALAVEN,peripheral neuropathy,of patients had peripheral,1
HALAVEN,peripheral neuropathy,had Grade peripheral neuropathy and of patients,0
HALAVEN,peripheral neuropathy,baseline Dose reduction due to,0
HALAVEN,peripheral neuropathy,baseline Dose reduction due peripheral neuropathy,1
HALAVEN,peripheral neuropathy,neuropathy,1
HALAVEN,peripheral neuropathy,baseline Dose reduction due peripheral,1
HALAVEN,peripheral neuropathy,neuropathy,1
HALAVEN,peripheral neuropathy,peripheral neuropathy,1
HALAVEN,peripheral neuropathy,baseline Dose reduction due,0
HALAVEN,peripheral neuropathy,Four percent of patients exp,0
HALAVEN,peripheral neuropathy,,0
HALAVEN,peripheral neuropathy,,0
HALAVEN,peripheral motor neuropathy,Four percent of patients peripheral,1
HALAVEN,peripheral motor neuropathy,and of,0
HALAVEN,peripheral motor neuropathy,experienced,0
HALAVEN,peripheral motor neuropathy,,0
HALAVEN,peripheral motor neuropathy,developed peripheral motor neuropathy,1
HALAVEN,peripheral motor neuropathy,,0
HALAVEN,peripheral motor neuropathy,neuropathy,1
HALAVEN,peripheral motor neuropathy,,0
HALAVEN,peripheral motor neuropathy,motor neuropathy of any grade and of,0
HALAVEN,peripheral motor neuropathy,,0
HALAVEN,peripheral motor neuropathy,any grade and of patients developed,0
HALAVEN,ALT elevation,or ALT levels at baseline,0
HALAVEN,ALT elevation,of HALAVENtreated patients experienced Grade,0
HALAVEN,ALT elevation,had concomitant Grade,0
HALAVEN,ALT elevation,concomitant Grade,0
HALAVEN,elevations in bilirubin,elevations in bilirubin,1
HALAVEN,elevations in bilirubin,HALAVENtreated patient without documented liver metastases had concomitant Grade,0
HALAVEN,elevations in bilirubin,metastases had concomitant elevations,1
HALAVEN,elevations in bilirubin,liver metastases had,0
HALAVEN,elevations in bilirubin,bilirubin,1
HALAVEN,elevations in bilirubin,elevations in bilirubin,1
HALAVEN,elevations in bilirubin,in bilirubin,1
HALAVEN,elevations in bilirubin,elevations in bilirubin,1
HALAVEN,elevations in bilirubin,not recur with reexposure,0
HALAVEN,increased lacrimation,Eye increased lacrimation,1
HALAVEN,increased lacrimation,,0
HALAVEN,increased lacrimation,,0
HALAVEN,increased lacrimation,Disorders dyspepsia,0
HALAVEN,increased lacrimation,,0
HALAVEN,increased lacrimation,Eye increased,1
HALAVEN,increased lacrimation,group Eye increased,1
HALAVEN,dyspepsia,dyspepsia,1
HALAVEN,dyspepsia,dyspepsia,1
HALAVEN,dyspepsia,dyspepsia,1
HALAVEN,dyspepsia,Site Conditions,0
HALAVEN,dyspepsia,Administration,0
HALAVEN,dyspepsia,dyspepsia,1
HALAVEN,abdominal pain,Disorders and Administration Site Conditions peripheral edema,0
HALAVEN,abdominal pain,abdominal pain,1
HALAVEN,abdominal pain,lacrimation Gastrointestinal Disorders dyspepsia,0
HALAVEN,abdominal pain,Disorders and,0
HALAVEN,stomatitis,stomatitis,1
HALAVEN,stomatitis,stomatitis,1
HALAVEN,stomatitis,stomatitis,1
HALAVEN,stomatitis,,0
HALAVEN,stomatitis,lacrimation,0
HALAVEN,stomatitis,dry mouth General Disorders and Administration Site,0
HALAVEN,dry mouth,increased lacrimation Gastrointestinal,0
HALAVEN,dry mouth,dyspepsia abdominal pain,0
HALAVEN,dry mouth,abdominal pain dry mouth,1
HALAVEN,dry mouth,dyspepsia abdominal pain dry mouth,1
HALAVEN,dry mouth,dry,1
HALAVEN,dry mouth,,0
HALAVEN,dry mouth,increased,0
HALAVEN,dry mouth,dry mouth,1
HALAVEN,peripheral edema,Site Conditions,0
HALAVEN,peripheral edema,edema,1
HALAVEN,peripheral edema,Infections and Infestations,0
HALAVEN,upper respiratory tract infection,tract infection,1
HALAVEN,upper respiratory tract infection,edema Infections and Infestations,0
HALAVEN,upper respiratory tract infection,Infections and Infestations,0
HALAVEN,upper respiratory tract infection,upper respiratory tract infection,1
HALAVEN,upper respiratory tract infection,edema Infections and,0
HALAVEN,upper respiratory tract infection,upper respiratory tract infection,1
HALAVEN,upper respiratory tract infection,,0
HALAVEN,upper respiratory tract infection,Disorders hypokalemia Musculoskeletal and Connective,0
HALAVEN,hypokalemia,,0
HALAVEN,hypokalemia,hypokalemia,1
HALAVEN,muscle spasms,muscle spasms,1
HALAVEN,muscle spasms,and Connective Tissue muscle,1
HALAVEN,muscle spasms,weakness Nervous System Disorders dysgeusia dizziness,0
HALAVEN,muscle spasms,muscle spasms,1
HALAVEN,muscular weakness,dizziness Psychiatric Disorders insomnia depress,0
HALAVEN,muscular weakness,weakness,1
HALAVEN,muscular weakness,Tissue Disorders muscle muscular,1
HALAVEN,muscular weakness,,0
HALAVEN,muscular weakness,Musculoskeletal and Connective,0
HALAVEN,muscular weakness,Disorders insomnia depress,0
HALAVEN,muscular weakness,hypokalemia Musculoskeletal and Connective Tissue,0
HALAVEN,dysgeusia,System dysgeusia,1
HALAVEN,dysgeusia,and,0
HALAVEN,dysgeusia,weakness Nervous System dysgeusia,1
HALAVEN,dysgeusia,dysgeusia,1
HALAVEN,dizziness,dizziness,1
HALAVEN,dizziness,and Subcutaneous Tissue Disorders ras,0
HALAVEN,dizziness,insomnia depression Skin and Subcutaneous,0
HALAVEN,dizziness,and,0
HALAVEN,dizziness,Nervous System Disorders dizziness,1
HALAVEN,dizziness,and,0
HALAVEN,dizziness,dizziness,1
HALAVEN,dizziness,,0
HALAVEN,dizziness,dizziness,1
HALAVEN,dizziness,Tissue Disorders muscle spasms muscular weakness Nervous,0
HALAVEN,insomnia,Disorders dysgeusia dizziness Psychiatric insomnia,1
HALAVEN,insomnia,Psychiatric,0
HALAVEN,depression,,0
HALAVEN,depression,depression,1
HALAVEN,depression,depression,1
HALAVEN,rash,have,0
HALAVEN,rash,been,0
HALAVEN,rash,rash,1
HALAVEN,rash,rash,1
HALAVEN,rash,have been,0
HALAVEN,rash,Subcutaneous Tissue Disorders,0
HALAVEN,rash,,0
HALAVEN,lymphopenia,and Lymphatic System lymphopenia,1
HALAVEN,lymphopenia,pancreatitis Hepatobiliary,0
HALAVEN,lymphopenia,relationship to drug exposure Blood and,0
HALAVEN,pancreatitis,pancreatitis,1
HALAVEN,pancreatitis,and Lymphatic System Disorders,0
HALAVEN,pancreatitis,Lymphatic,0
HALAVEN,pancreatitis,Immune System Disorders drug hypersensitivity,0
HALAVEN,pancreatitis,Disorders lymphopenia,0
HALAVEN,pancreatitis,System Disorders drug hypersensitivity,0
HALAVEN,hepatotoxicity,Disorders,0
HALAVEN,hepatotoxicity,hepatotoxicity,1
HALAVEN,hepatotoxicity,System Disorders drug hypersensitivity Infections,0
HALAVEN,hypersensitivity,hypersensitivity,1
HALAVEN,hypersensitivity,,0
HALAVEN,hypersensitivity,hypersensitivity,1
HALAVEN,hypersensitivity,hepatotoxicity,0
HALAVEN,hypersensitivity,hypersensitivity,1
HALAVEN,hypersensitivity,hypersensitivity,1
HALAVEN,hypersensitivity,hypersensitivity,1
HALAVEN,hypersensitivity,hypersensitivity,1
HALAVEN,hypersensitivity,hypersensitivity,1
HALAVEN,hypersensitivity,hypersensitivity,1
HALAVEN,pneumonia,and,0
HALAVEN,pneumonia,,0
HALAVEN,pneumonia,pneumonia,1
HALAVEN,pneumonia,pneumonia,1
HALAVEN,pneumonia,,0
HALAVEN,pneumonia,Disorders drug hypersensitivity Infections,0
HALAVEN,pneumonia,pneumonia,1
HALAVEN,pneumonia,hypersensitivity Infections,0
HALAVEN,sepsis,pneumonia,0
HALAVEN,sepsis,sepsis,1
HALAVEN,sepsis,hypersensitivity Infections and Infestations sepsis,1
HALAVEN,sepsis,drug hypersensitivity Infections,0
HALAVEN,neutropenic sepsis,Infections and Infestations pneumonia neutropenic sepsis,1
HALAVEN,neutropenic sepsis,a,0
HALAVEN,neutropenic sepsis,,0
HALAVEN,dehydration,Metabolism and,0
HALAVEN,dehydration,dehydration,1
HALAVEN,dehydration,dehydration,1
HALAVEN,dehydration,interstitial lung,0
HALAVEN,dehydration,Metabolism and Nutrition Disorders dehydration,1
HALAVEN,dehydration,,0
HALAVEN,dehydration,dehydration,1
HALAVEN,dehydration,dehydration,1
HALAVEN,dehydration,dehydration,1
HALAVEN,dehydration,dehydration,1
HALAVEN,interstitial lung disease,disease,1
HALAVEN,interstitial lung disease,Subcutaneous Tissue Disorders,0
HALAVEN,interstitial lung disease,Respiratory thoracic and mediastinal interstitial lung disease,1
HALAVEN,interstitial lung disease,,0
HALAVEN,interstitial lung disease,interstitial lung disease,1
HALAVEN,pruritus,pruritus,1
HALAVEN,pruritus,Skin and Subcutaneous Tissue pruritus,1
HALAVEN,pruritus,,0
HALAVEN,pruritus,pruritus,1
HALAVEN,pruritus,,0
HALAVEN,pruritus,pruritus,1
HALAVEN,pruritus,,0
HALAVEN,Neutropenia,,0
HALAVEN,Neutropenia,adverse reactions incidence were neutropenia,1
HALAVEN,Neutropenia,,0
HALAVEN,Neutropenia,on adverse  reactions,1
HALAVEN,Peripheral Neuropathy,"hy, nausea, and const ipation",1
HALAVEN,Peripheral Neuropathy,contact Eisai,0
HALAVEN,Peripheral Neuropathy,"hy, nausea,",1
HALAVEN,Peripheral Neuropathy,"alopecia peripheral hy, nausea, and const ipation",1
HALAVEN,Peripheral Neuropathy,"hy, nausea, and const ipation",1
HALAVEN,Peripheral Neuropathy,were neutropenia,0
HALAVEN,Peripheral Neuropathy,neutropenia anemia astheniafatigue alopecia peripheral,0
HALAVEN,Peripheral Neuropathy,incidence were neutropenia anemia astheniafatigue alopecia peripheral,0
HALAVEN,Embryo-Fetal Toxicity,To report SUSPECTED,0
HALAVEN,Embryo-Fetal Toxicity,1-800-F DA,1
HALAVEN,Embryo-Fetal Toxicity,,0
HALAVEN,Embryo-Fetal Toxicity,contact Eisai Inc at or c,0
HALAVEN,Embryo-Fetal Toxicity,Trials Experience Because,0
HALAVEN,Embryo-Fetal Toxicity,,0
HALAVEN,Embryo-Fetal Toxicity,To report SUSPECTED ADVERSE REACTIONS contact Eisai,0
HALAVEN,Embryo-Fetal Toxicity,1-800-F DA,1
HALAVEN,Embryo-Fetal Toxicity,FDA at 1-800-F DA,1
HALAVEN,Embryo-Fetal Toxicity,or ontact FDA at 1-800-F DA,1
HALAVEN,Fetal harm,1088 or ww wfdagovmedwatch,1
HALAVEN,Fetal harm,or contact FDA at 1088 or,1
HALAVEN,Fetal harm,or contact FDA at 1088 or,1
HALAVEN,Fetal harm,ww wfdagovmedwatch,1
HALAVEN,Fetal harm,,0
HALAVEN,Fetal harm,contact FDA at 1088 or ww wfdagovmedwatch,1
HALAVEN,Fetal harm,FDA at 1088 or ww wfdagovmedwatch,1
HALAVEN,Fetal harm,ADVERSE REACTIONS contact Eisai,0
HALAVEN,Fetal harm,contact Eisai Inc at or,0
HALAVEN,neutropenia,common adverse reactions reported patients,1
HALAVEN,neutropenia,re ceiving,1
HALAVEN,neutropenia,most,0
HALAVEN,neutropenia,were neutropenia anemia,0
HALAVEN,neutropenia,patients re ceiving,1
HALAVEN,neutropenia,re ceiving,1
HALAVEN,neutropenia,,0
HALAVEN,neutropenia,,0
HALAVEN,neutropenia,re ceiving,1
HALAVEN,febrile neutropenia,ng HALAVEN were neu tropenia,1
HALAVEN,febrile neutropenia,adverse reactions reported,0
HALAVEN,neutropenia,neuropathy nausea,0
HALAVEN,neutropenia,The most common serious reactions,1
HALAVEN,neutropenia,The most common serious reactions r eported,1
HALAVEN,neutropenia,constipation The,0
HALAVEN,neutropenia,The most common serious,0
HALAVEN,neutropenia,The most common serious,0
HALAVEN,neutropenia,most,0
HALAVEN,neutropenia,r eported,1
HALAVEN,febrile neutropenia,were febrile neutropenia,0
HALAVEN,febrile neutropenia,were febrile neutropenia and neutropenia The most common adverse reaction,0
HALAVEN,febrile neutropenia,ed,1
HALAVEN,febrile neutropenia,febrile neutropenia and neutropenia The most common adverse reaction,0
HALAVEN,febrile neutropenia,serious adverse reactions ed,1
HALAVEN,febrile neutropenia,,0
HALAVEN,febrile neutropenia,and constipation The,0
HALAVEN,febrile neutropenia,common serious adverse reactions report,0
HALAVEN,peripheral neuropathy,treated,0
HALAVEN,peripheral neuropathy,"),",1
HALAVEN,peripheral neuropathy,"Caucasian ), Asian (2%), and ot her",1
HALAVEN,peripheral neuropathy,reactions described in Table were identified in patients treated,0
HALAVEN,peripheral neuropathy,in patients treated,0
HALAVEN,peripheral neuropathy,range to years The racial and ethnic distribution was Caucasian Black,0
HALAVEN,peripheral neuropathy,ot her,1
HALAVEN,peripheral neuropathy,in,0
HALAVEN,peripheral neuropathy,"), Asian",1
HALAVEN,peripheral neuropathy,ethnic distribution was Caucasian Black,0
HALAVEN,peripheral neuropathy,reactions described in Table were identified,0
HALAVEN,peripheral neuropathy,ot her,1
HALAVEN,Peripheral neuropathy,,0
HALAVEN,Neuropathy,randomized to e either H ALAVEN,1
HALAVEN,Neuropathy,agent treatment chosen,0
HALAVEN,Neuropathy,H ALAVEN,1
HALAVEN,Neuropathy,of a day cycle or single agent treatment chosen by,0
HALAVEN,Neuropathy,on Days and of a,0
HALAVEN,Neuropathy,to e either H ALAVEN,1
HALAVEN,Neuropathy,single agent treatment chosen by,0
HALAVEN,neuropathy,total 503,1
HALAVEN,neuropathy,total 503,1
HALAVEN,neuropathy,physician control group A total,0
HALAVEN,neuropathy,503,1
HALAVEN,neuropathy,nts received HALAVEN and patients,0
HALAVEN,fetal harm,Inc idence,1
HALAVEN,fetal harm,Inc idence,1
HALAVEN,fetal harm,Reactions with a atient,1
HALAVEN,fetal harm,at,0
HALAVEN,fetal harm,HALAVEN n,0
HALAVEN,fetal harm,MedDRA ver HALAVEN n Control,0
HALAVEN,fetal harm,,0
HALAVEN,teratogenicity,,0
HALAVEN,teratogenicity,ver     n=503      Control,1
HALAVEN,teratogenicity,in Study MedDRA ver     n=503      Control,1
HALAVEN,teratogenicity,All Grades Grade All Grades,0
HALAVEN,teratogenicity,,0
HALAVEN,QT prolongation,Nervous system dis,0
HALAVEN,QT prolongation,,0
HALAVEN,QT prolongation,ripheral neurop athy,1
HALAVEN,QT prolongation,,0
XIAFLEX,Tendon ruptures,greater detail elsewhere in the labeling,0
XIAFLEX,Tendon ruptures,in the labeling,0
XIAFLEX,Tendon ruptures,detail elsewhere in the Tendon ruptures or,1
XIAFLEX,Tendon ruptures,elsewhere in the Tendon,1
XIAFLEX,Tendon ruptures,Tendon ruptures or,1
XIAFLEX,Tendon ruptures,,0
XIAFLEX,Tendon ruptures,in the Tendon ruptures or,1
XIAFLEX,injury to the injected extremity,Tendon ruptures or other injury to the injected,1
XIAFLEX,Corporal rupture,fracture,0
XIAFLEX,Corporal rupture,detail elsewhere in the Corporal,1
XIAFLEX,Corporal rupture,,0
XIAFLEX,Corporal rupture,fracture and severe penile hematoma see Warnings,0
XIAFLEX,Corporal rupture,,0
XIAFLEX,Corporal rupture,Corporal rupture penile,1
XIAFLEX,Corporal rupture,rupture penile,1
XIAFLEX,Corporal rupture,greater detail,0
XIAFLEX,Corporal rupture,are discussed in greater detail elsewhere,0
XIAFLEX,penile fracture,fracture and,1
XIAFLEX,penile fracture,the labeling Corporal penile,1
XIAFLEX,penile fracture,in the labeling Corporal penile fracture and,1
XIAFLEX,penile fracture,severe penile hematoma,0
XIAFLEX,penile hematoma,penile hematoma see,1
XIAFLEX,penile hematoma,hematoma see,1
XIAFLEX,penile hematoma,patients a combination,0
XIAFLEX,penile hematoma,and,0
XIAFLEX,penile hematoma,penile fracture and severe,0
XIAFLEX,penile hematoma,hematoma see,1
XIAFLEX,penile ecchymoses,sensation was reported,0
XIAFLEX,penile detumescence,other,0
XIAFLEX,penile detumescence,hematoma penile,1
XIAFLEX,penile detumescence,diagnosis,0
XIAFLEX,penile detumescence,XIAFLEXtreated patients a combination,0
XIAFLEX,penile detumescence,patients a,0
XIAFLEX,penile detumescence,penile detumescence andor,1
XIAFLEX,penile detumescence,penile ecchymoses or hematoma penile detumescence andor,1
XIAFLEX,penile detumescence,ecchymoses or hematoma sudden,0
XIAFLEX,penile detumescence,or hematoma penile detumescence andor,1
XIAFLEX,penile detumescence,penile popping sound or sensation was reported and in these cases a diagnosis of corp,0
XIAFLEX,"penile ""popping"" sound","penile detumescence andor penile ""popping""",1
XIAFLEX,"penile ""popping"" sound",be excluded,0
XIAFLEX,"penile ""popping"" sound",of penile ecchymoses or hematoma sudden penile detumescence andor,0
XIAFLEX,"penile ""popping"" sound","andor penile ""popping"" sound or",1
XIAFLEX,corporal rupture,sound or sensation was reported,0
XIAFLEX,corporal rupture,rupture cannot,1
XIAFLEX,corporal rupture,,0
XIAFLEX,corporal rupture,popping,0
XIAFLEX,edema peripheral,greater than placebo edema,1
XIAFLEX,edema peripheral,placebo edema,1
XIAFLEX,edema peripheral,edema peripheral eg,1
XIAFLEX,edema peripheral,of the injected hand contusion,0
XIAFLEX,edema peripheral,placebo edema,1
XIAFLEX,edema peripheral,edema peripheral eg,1
XIAFLEX,edema peripheral,than placebo edema peripheral eg,1
XIAFLEX,edema peripheral,peripheral eg,1
XIAFLEX,edema peripheral,incidence greater than placebo edema,1
XIAFLEX,swelling of the injected hand,injected hand contusion,1
XIAFLEX,swelling of the injected hand,,0
XIAFLEX,swelling of the injected hand,placebo were edema peripheral swelling of the injected hand contusion,1
XIAFLEX,injection site hemorrhage,the injected,0
XIAFLEX,injection site hemorrhage,,0
XIAFLEX,injection site hemorrhage,injection site hemorrhage injection,1
XIAFLEX,injection site hemorrhage,site hemorrhage injection,1
XIAFLEX,injection site hemorrhage,injection site hemorrhage injection,1
XIAFLEX,injection site hemorrhage,hand injection,1
XIAFLEX,injection site hemorrhage,injected extremity,0
XIAFLEX,injection site hemorrhage,the injected hand injection site hemorrhage injection,1
XIAFLEX,injection site reaction,injection,1
XIAFLEX,injection site reaction,contusion injection site hemorrhage,0
XIAFLEX,injection site reaction,injection site reaction and,1
XIAFLEX,injection site reaction,site reaction and,1
XIAFLEX,injection site reaction,site reaction and,1
XIAFLEX,injection site reaction,,0
XIAFLEX,injection site reaction,site reaction and,1
XIAFLEX,injection site reaction,frequently,0
XIAFLEX,injection site reaction,injection site,1
XIAFLEX,pain in the injected extremity,injected hand contusion injection site hemorrhage injection site reaction and,0
XIAFLEX,pain in the injected extremity,the injected hand contusion injection site hemorrhage,0
XIAFLEX,pain in the injected extremity,Peyronies Disease The most frequently reported adverse,0
XIAFLEX,penile swelling,placebo were penile penile swelling and,1
XIAFLEX,penile swelling,placebo were penile penile swelling and,1
XIAFLEX,penile swelling,penile penile swelling and,1
XIAFLEX,penile swelling,placebo were penile penile swelling and,1
XIAFLEX,penile swelling,penile swelling and,1
XIAFLEX,penile swelling,penile,1
XIAFLEX,penile swelling,XIAFLEX and at an incidence greater than placebo were,0
XIAFLEX,penile swelling,ADVERSE REACTIONS contact Auxilium Pharmaceuticals,0
XIAFLEX,penile swelling,penile,1
XIAFLEX,penile pain,XIAFLEX and,0
XIAFLEX,penile pain,penile pain To,1
XIAFLEX,penile pain,penile pain To,1
XIAFLEX,penile pain,,0
XIAFLEX,penile pain,,0
XIAFLEX,penile pain,report SUSPECTED ADVERSE,0
XIAFLEX,penile pain,penile pain To,1
XIAFLEX,penile pain,with XIAFLEX and at an incidence greater than placebo were penile,0
XIAFLEX,penile pain,,0
XIAFLEX,penile pain,penile pain To,1
XIAFLEX,pruritus,pruritus increased,1
XIAFLEX,pruritus,administered However the incidence pruritus increased,1
XIAFLEX,pruritus,pruritus increased,1
XIAFLEX,pruritus,number of injections administered However the,0
XIAFLEX,edema peripheral,Dupuytrens contracture edema peripheral mostly,1
XIAFLEX,edema peripheral,in patients,0
XIAFLEX,swelling of the injected hand,included edema peripheral,0
XIAFLEX,contusion,contusion injection,1
XIAFLEX,contusion,,0
XIAFLEX,contusion,swelling of the injected contusion injection,1
XIAFLEX,contusion,contusion injection,1
XIAFLEX,contusion,contusion injection,1
XIAFLEX,contusion,contusion injection,1
XIAFLEX,contusion,,0
XIAFLEX,injection site hemorrhage,hand injection,1
XIAFLEX,injection site hemorrhage,hemorrhage injection,1
XIAFLEX,injection site hemorrhage,hand injection site hemorrhage injection,1
XIAFLEX,injection site reaction,,0
XIAFLEX,injection site reaction,contusion injection site injection site reaction and,1
XIAFLEX,injection site reaction,the,0
XIAFLEX,injection site reaction,and pain in the treated extremity Table shows the incidence of adverse reactions,0
XIAFLEX,injection site reaction,contusion injection site injection site,1
XIAFLEX,injection site reaction,site injection site reaction and,1
XIAFLEX,injection site reaction,site reaction and,1
XIAFLEX,pain in the treated extremity,incidence of adverse reactions that were reported in,0
XIAFLEX,pain in the treated extremity,the treated extremity Table,1
XIAFLEX,pain in the treated extremity,pain in the treated extremity Table,1
XIAFLEX,pain in the treated extremity,injection site reaction pain in the treated extremity Table,1
XIAFLEX,pain in the treated extremity,were reported in greater,0
XIAFLEX,pain in the treated extremity,treated extremity Table,1
XIAFLEX,pain in the treated extremity,of adverse reactions,0
XIAFLEX,pain in the treated extremity,the injected hand contusion injection site hemorrhage injection site reaction and,0
XIAFLEX,swelling of the injected hand,the terms contusion any body system and ecchymosis c Includes the te,0
XIAFLEX,swelling of the injected hand,these events swelling of the injected hand b,1
XIAFLEX,swelling of the injected hand,,0
XIAFLEX,swelling of the injected hand,Includes the terms contusion,0
XIAFLEX,swelling of the injected hand,of these events swelling of the injected hand b,1
XIAFLEX,contusion,injected hand b Includes the,0
XIAFLEX,ecchymosis,c Includes the terms injection site reaction injection site erythema injection site infl,0
XIAFLEX,ecchymosis,ecchymosis c,1
XIAFLEX,ecchymosis,hand b,0
XIAFLEX,ecchymosis,ecchymosis c,1
XIAFLEX,ecchymosis,,0
XIAFLEX,ecchymosis,body system ecchymosis c,1
XIAFLEX,ecchymosis,ecchymosis c,1
XIAFLEX,ecchymosis,body system and,0
XIAFLEX,ecchymosis,system ecchymosis c,1
XIAFLEX,ecchymosis,injection site erythema injection,0
XIAFLEX,injection site reaction,c Includes the injection,1
XIAFLEX,injection site reaction,Includes the injection site reaction injection,1
XIAFLEX,injection site reaction,injection site inflammation injection site,0
XIAFLEX,injection site reaction,injection site reaction injection,1
XIAFLEX,injection site erythema,injection site injection site,1
XIAFLEX,injection site erythema,injection site injection,1
XIAFLEX,injection site erythema,the terms injection site injection site erythema injection,1
XIAFLEX,injection site inflammation,warmth d,0
XIAFLEX,injection site irritation,the terms injection site reaction injection site erythema injection,0
XIAFLEX,injection site warmth,site pain injection,1
XIAFLEX,injection site warmth,terms injection site,0
XIAFLEX,injection site warmth,swelling and,0
XIAFLEX,injection site warmth,site pain injection site warmth d,1
XIAFLEX,injection site warmth,pain injection site warmth d,1
XIAFLEX,injection site warmth,injection site pain injection site warmth d,1
XIAFLEX,injection site warmth,site warmth d,1
XIAFLEX,injection site warmth,and,0
XIAFLEX,injection site swelling,edema e Includes the terms pruritus,0
XIAFLEX,injection site swelling,injection site swelling and,1
XIAFLEX,injection site swelling,warmth d Includes the injection site swelling and,1
XIAFLEX,injection site swelling,site pruritus,0
XIAFLEX,injection site swelling,swelling and,1
XIAFLEX,injection site swelling,Includes the,0
XIAFLEX,injection site swelling,pain and injection site warmth d Includes the terms,0
XIAFLEX,injection site swelling,d Includes the injection site swelling and,1
XIAFLEX,injection site swelling,site,0
XIAFLEX,injection site edema,swelling injection site,1
XIAFLEX,injection site edema,terms injection site swelling injection site edema e,1
XIAFLEX,injection site edema,and,0
XIAFLEX,injection site edema,swelling injection site,1
XIAFLEX,injection site edema,and,0
XIAFLEX,injection site edema,site swelling injection site edema e,1
XIAFLEX,injection site edema,edema e,1
XIAFLEX,injection site edema,terms,0
XIAFLEX,injection site edema,injection site swelling injection site edema e,1
XIAFLEX,injection site edema,site swelling injection,1
XIAFLEX,pruritus,pruritus and,1
XIAFLEX,pruritus,pruritus and,1
XIAFLEX,pruritus,injection site swelling and injection site edema e Includes,0
XIAFLEX,pruritus,pruritus and,1
XIAFLEX,pruritus,lymphadenopathy and axillary,0
XIAFLEX,pruritus,pruritus and,1
XIAFLEX,pruritus,pruritus and,1
XIAFLEX,pruritus,,0
XIAFLEX,pruritus,e Includes the pruritus and,1
XIAFLEX,injection site pruritus,terms,0
XIAFLEX,injection site pruritus,injection site pruritus f,1
XIAFLEX,injection site pruritus,the terms pruritus and,0
XIAFLEX,injection site pruritus,edema e Includes,0
XIAFLEX,injection site pruritus,terms pruritus injection site pruritus f,1
XIAFLEX,lymphadenopathy,Includes the lymphadenopathy and,1
XIAFLEX,lymphadenopathy,lymphadenopathy and,1
XIAFLEX,lymphadenopathy,Adverse Reaction,0
XIAFLEX,lymphadenopathy,the lymphadenopathy and,1
XIAFLEX,lymphadenopathy,,0
XIAFLEX,lymphadenopathy,the lymphadenopathy and,1
XIAFLEX,lymphadenopathy,lymphadenopathy and,1
XIAFLEX,lymphadenopathy,XIAFLEXN PlaceboN,0
XIAFLEX,lymphadenopathy,XIAFLEXN PlaceboN All,0
XIAFLEX,lymphadenopathy,Includes the lymphadenopathy and,1
XIAFLEX,axillary mass,terms lymphadenopathy axillary mass Adverse,1
XIAFLEX,axillary mass,injection site pruritus,0
XIAFLEX,Edema Peripheral,Site,0
XIAFLEX,Edema Peripheral,Edema Peripheral a,1
XIAFLEX,Edema Peripheral,Edema,1
XIAFLEX,Edema Peripheral,Edema Peripheral a,1
XIAFLEX,Edema Peripheral,All Adverse,0
XIAFLEX,Edema Peripheral,,0
XIAFLEX,Edema Peripheral,All Adverse Edema Peripheral a,1
XIAFLEX,Edema Peripheral,,0
XIAFLEX,Edema Peripheral,XIAFLEXN,0
XIAFLEX,Injection Site Hemorrhage,Peripheral a Contusion Injection,1
XIAFLEX,Injection Site Hemorrhage,,0
XIAFLEX,Injection Site Hemorrhage,Peripheral a Contusion,0
XIAFLEX,Injection Site Hemorrhage,Edema Peripheral a Contusion Injection,1
XIAFLEX,Injection Site Hemorrhage,Reactions Edema Peripheral a,0
XIAFLEX,Injection Site Hemorrhage,Injection Site,1
XIAFLEX,Injection Site Hemorrhage,Contusion,0
XIAFLEX,Injection Site Hemorrhage,,0
XIAFLEX,Injection Site Hemorrhage,,0
XIAFLEX,Injection Site Reaction,Contusion b Injection Site Injection,1
XIAFLEX,Injection Site Reaction,b Injection Site,0
XIAFLEX,Injection Site Reaction,Injection Site Hemorrhage,0
XIAFLEX,Injection Site Reaction,Contusion b Injection Site Injection Site Reaction c,1
XIAFLEX,Injection Site Reaction,Hemorrhage,0
XIAFLEX,Pain in Extremity,Hemorrhage Injection Site Reaction Pain,1
XIAFLEX,Pain in Extremity,Hemorrhage Injection Site Reaction Pain in Extremity Tenderness,1
XIAFLEX,Pain in Extremity,Pruritus,0
XIAFLEX,Pain in Extremity,Extremity Tenderness,1
XIAFLEX,Pain in Extremity,Hemorrhage Injection Site Reaction Pain,1
XIAFLEX,Pain in Extremity,,0
XIAFLEX,Pain in Extremity,Reaction Pain in Extremity Tenderness,1
XIAFLEX,Tenderness,Tenderness Injection,1
XIAFLEX,Tenderness,,0
XIAFLEX,Injection Site Swelling,Injection,1
XIAFLEX,Injection Site Swelling,Site Swelling d,1
XIAFLEX,Injection Site Swelling,in Extremity Injection,1
XIAFLEX,Injection Site Swelling,Reaction c Pain in Extremity,0
XIAFLEX,Injection Site Swelling,Pain in Extremity,0
XIAFLEX,Injection Site Swelling,,0
XIAFLEX,Injection Site Swelling,e Lymphadenopathy,0
XIAFLEX,Injection Site Swelling,Swelling d,1
XIAFLEX,Injection Site Swelling,Site Swelling d,1
XIAFLEX,Injection Site Swelling,d Pruritus,0
XIAFLEX,Pruritus,Node,0
XIAFLEX,Pruritus,,0
XIAFLEX,Pruritus,Pruritus e,1
XIAFLEX,Pruritus,Swelling Pruritus e,1
XIAFLEX,Pruritus,Pruritus e,1
XIAFLEX,Pruritus,Site Swelling Pruritus e,1
XIAFLEX,Pruritus,Swelling Pruritus e,1
XIAFLEX,Pruritus,Extremity Tenderness Injection Site Swelling d,0
XIAFLEX,Pruritus,,0
XIAFLEX,Lymphadenopathy,Swelling d Pruritus,0
XIAFLEX,Skin Laceration,Lymphadenopathy f,0
XIAFLEX,Skin Laceration,Pruritus e Lymphadenopathy,0
XIAFLEX,Skin Laceration,Pruritus e Lymphadenopathy Skin,1
XIAFLEX,Skin Laceration,Laceration Lymph,1
XIAFLEX,Skin Laceration,Swelling,0
XIAFLEX,Skin Laceration,,0
XIAFLEX,Lymph Node Pain,,0
XIAFLEX,Erythema,Erythema Axillary,1
XIAFLEX,Axillary Pain,developed vasovagal,0
XIAFLEX,Axillary Pain,Lymph Node Pain Axillary Pain Some,1
XIAFLEX,Axillary Pain,,0
XIAFLEX,Axillary Pain,patients developed,0
XIAFLEX,Axillary Pain,Pain Some,1
XIAFLEX,Axillary Pain,Node Pain Axillary,1
XIAFLEX,vasovagal syncope,of two concurrent injections of XIAFLEX mg i,0
XIAFLEX,vasovagal syncope,Some patients,0
XIAFLEX,vasovagal syncope,Some patients developed,0
XIAFLEX,vasovagal syncope,Pain Some patients vasovagal syncope after,1
XIAFLEX,vasovagal syncope,syncope after,1
XIAFLEX,vasovagal syncope,Pain Some patients vasovagal,1
XIAFLEX,Edema peripheral,Edema peripheral Contusion,1
XIAFLEX,Edema peripheral,,0
XIAFLEX,Edema peripheral,Contusion,0
XIAFLEX,Edema peripheral,with adverse reaction,0
XIAFLEX,Edema peripheral,adverse Edema peripheral Contusion,1
XIAFLEX,Edema peripheral,adverse Edema,1
XIAFLEX,Edema peripheral,with adverse Edema peripheral Contusion,1
XIAFLEX,Edema peripheral,Edema peripheral Contusion,1
XIAFLEX,Contusion,Pa,0
XIAFLEX,Pain in extremity,on Pain in extremity Laceration,1
XIAFLEX,Pain in extremity,,0
XIAFLEX,Pain in extremity,on Pain in,1
XIAFLEX,Pain in extremity,,0
XIAFLEX,Laceration,,0
XIAFLEX,Laceration,extremity,0
XIAFLEX,Laceration,Pru,0
XIAFLEX,Pruritus,ion Pruritus I,1
XIAFLEX,Pruritus,Pruritus I,1
XIAFLEX,Pruritus,,0
XIAFLEX,Pruritus,,0
XIAFLEX,Lymphadenopathy,Lymphadenopathy Blood,1
XIAFLEX,Lymphadenopathy,Blood bl,0
XIAFLEX,Lymphadenopathy,,0
XIAFLEX,Lymphadenopathy,Lymphadenopathy Blood,1
XIAFLEX,Lymphadenopathy,site,0
XIAFLEX,Blood blister,enopathy Blood blister Inject,1
XIAFLEX,Blood blister,Blood blister Inject,1
XIAFLEX,Blood blister,enopathy,0
XIAFLEX,Blood blister,enopathy,0
XIAFLEX,Blood blister,enopathy Blood,1
XIAFLEX,Blood blister,enopathy Blood,1
XIAFLEX,Blood blister,enopathy Blood blister Inject,1
XIAFLEX,Blood blister,enopathy,0
XIAFLEX,Blood blister,Blood blister Inject,1
XIAFLEX,Injection site hematoma,,0
XIAFLEX,Injection site hematoma,lister Injection site,1
XIAFLEX,Axillary pain,,0
XIAFLEX,Axillary pain,,0
XIAFLEX,Axillary pain,Axillary,1
XIAFLEX,Axillary pain,pain Inject,1
XIAFLEX,Injection site hemorrhage,Injection site,1
XIAFLEX,Injection site hemorrhage,,0
XIAFLEX,Injection site hemorrhage,,0
XIAFLEX,Injection site hemorrhage,,0
XIAFLEX,Injection site swelling,,0
XIAFLEX,Injection site swelling,hemorrhage,0
XIAFLEX,Injection site swelling,,0
XIAFLEX,Injection site swelling,Injection site swelling Ecchymosis,1
XIAFLEX,Ecchymosis,Ecchymosis,1
XIAFLEX,Ecchymosis,Ecchymosis,1
XIAFLEX,Ecchymosis,,0
XIAFLEX,Ecchymosis,,0
XIAFLEX,Ecchymosis,Ecchymosis,1
XIAFLEX,Corporal rupture,Injury,0
XIAFLEX,Corporal rupture,Corporal rupture was reported,1
XIAFLEX,Corporal rupture,,0
XIAFLEX,Corporal rupture,and Other Serious Penile,0
XIAFLEX,Corporal rupture,Rupture and Other Serious Penile,0
XIAFLEX,penile ecchymoses,patients of a combination penile,1
XIAFLEX,penile ecchymoses,detumescence andor a penile popping sound,0
XIAFLEX,penile detumescence,a penile popping sound or sensation was reported and in these,0
XIAFLEX,penile detumescence,or hematoma,0
XIAFLEX,penile detumescence,or hematoma penile,1
XIAFLEX,penile detumescence,ecchymoses or hematoma,0
XIAFLEX,penile detumescence,ecchymoses or hematoma penile detumescence andor a,1
XIAFLEX,penile detumescence,penile ecchymoses or hematoma penile detumescence andor a,1
XIAFLEX,penile detumescence,detumescence andor a,1
XIAFLEX,penile detumescence,penile detumescence andor a,1
XIAFLEX,penile detumescence,penile detumescence andor a,1
XIAFLEX,penile detumescence,penile detumescence andor a,1
XIAFLEX,"penile ""popping"" sound",,0
XIAFLEX,"penile ""popping"" sound","andor penile ""popping"" sound or sensation",1
XIAFLEX,"penile ""popping"" sound",be,0
XIAFLEX,"penile ""popping"" sound","sudden penile detumescence andor penile ""popping"" sound or sensation",1
XIAFLEX,"penile ""popping"" sound","penile detumescence andor penile ""popping"" sound or sensation",1
XIAFLEX,"penile ""popping"" sound",penile,0
XIAFLEX,"penile ""popping"" sound",sound or sensation,1
XIAFLEX,"penile ""popping"" sound",reported and in these cases,0
XIAFLEX,"penile ""popping"" sound","andor penile ""popping""",1
XIAFLEX,"penile ""popping"" sound","andor penile ""popping"" sound or sensation",1
XIAFLEX,corporal rupture,rupture cannot be,1
XIAFLEX,corporal rupture,rupture cannot be,1
XIAFLEX,corporal rupture,a diagnosis corporal rupture cannot be,1
XIAFLEX,corporal rupture,corporal rupture cannot be,1
XIAFLEX,penile hematoma,managed without surgical intervention but the longterm consequences,0
XIAFLEX,penile hematoma,are unknown penile hematoma was also,1
XIAFLEX,penile hematoma,hematoma was also,1
XIAFLEX,penile hematoma,managed without,0
XIAFLEX,penile hematoma,,0
XIAFLEX,penile hematoma,consequences are unknown penile,1
XIAFLEX,penile hematoma,hematoma was also,1
XIAFLEX,penile hematoma,was also reported as an adverse reaction in of patients in the controlled,0
XIAFLEX,penile hematoma,penile hematoma was also,1
XIAFLEX,penile hematoma,longterm consequences are unknown,0
XIAFLEX,penile hematoma,drug reactions in the XIAFLEX clinical trials in,0
XIAFLEX,penile hematoma,hematoma penile swelling,1
XIAFLEX,penile hematoma,hematoma penile swelling,1
XIAFLEX,penile hematoma,penile hematoma penile swelling,1
XIAFLEX,penile hematoma,Peyronies disease penile hematoma penile swelling,1
XIAFLEX,penile hematoma,,0
XIAFLEX,penile pain,penile swelling,0
XIAFLEX,penile pain,pain Table shows,1
XIAFLEX,penile pain,penile pain Table shows,1
XIAFLEX,penile pain,penile,1
XIAFLEX,penile pain,penile pain Table shows,1
XIAFLEX,penile pain,equal,0
XIAFLEX,penile pain,hematoma penile swelling penile,1
XIAFLEX,penile pain,trials in patients with Peyronies disease were penile,0
XIAFLEX,penile pain,penile hematoma penile swelling penile pain Table shows,1
XIAFLEX,penile pain,reported in greater than or,0
XIAFLEX,injection site hematoma,penile hematoma were reported with the verbatim term of penile bruising or injection,0
XIAFLEX,injection site hematoma,hematoma and penile,1
XIAFLEX,injection site hematoma,Studies and Combined a injection site,1
XIAFLEX,injection site hematoma,hematoma and penile,1
XIAFLEX,penile hematoma,,0
XIAFLEX,penile hematoma,injection site bruising in,0
XIAFLEX,penile hematoma,injection,0
XIAFLEX,penile hematoma,,0
XIAFLEX,penile bruising,term penile bruising or injection,1
XIAFLEX,penile bruising,penile bruising or injection,1
XIAFLEX,penile bruising,b Includes injection site,0
XIAFLEX,penile bruising,,0
XIAFLEX,penile bruising,penile bruising or injection,1
XIAFLEX,penile bruising,term penile,1
XIAFLEX,penile bruising,with the verbatim term penile,1
XIAFLEX,penile bruising,with the verbatim term penile bruising or injection,1
XIAFLEX,injection site bruising,of penile bruising injection site bruising in of,1
XIAFLEX,injection site bruising,injection site bruising in of,1
XIAFLEX,injection site bruising,swelling loc,0
XIAFLEX,injection site bruising,or,0
XIAFLEX,injection site bruising,term of penile bruising injection site bruising in of,1
XIAFLEX,injection site bruising,injection site bruising in of,1
XIAFLEX,injection site bruising,,0
XIAFLEX,injection site bruising,injection site bruising in of,1
XIAFLEX,injection site bruising,loc,0
XIAFLEX,injection site bruising,Includes injection,0
XIAFLEX,injection site swelling,bruising,0
XIAFLEX,injection site swelling,of subjects b injection site,1
XIAFLEX,injection site swelling,in of subjects b injection site swelling penile edema,1
XIAFLEX,injection site swelling,scrotal swelling and injection site edema,0
XIAFLEX,injection site swelling,b injection,1
XIAFLEX,injection site swelling,swelling penile edema,1
XIAFLEX,injection site swelling,in of,0
XIAFLEX,penile edema,,0
XIAFLEX,penile swelling,,0
XIAFLEX,penile swelling,penile swelling local swelling,1
XIAFLEX,penile swelling,Includes injection site swelling penile,0
XIAFLEX,penile swelling,swelling local swelling,1
XIAFLEX,penile swelling,penile penile,1
XIAFLEX,penile swelling,bruising in of subjects b Includes injection,0
XIAFLEX,penile swelling,scrotal swelling and,0
XIAFLEX,penile swelling,penile edema,0
XIAFLEX,scrotal swelling,swelling,0
XIAFLEX,scrotal swelling,scrotal swelling and injection,1
XIAFLEX,scrotal swelling,penile swelling local swelling,0
XIAFLEX,scrotal swelling,penile swelling local scrotal,1
XIAFLEX,scrotal swelling,penile swelling local scrotal swelling and injection,1
XIAFLEX,scrotal swelling,scrotal swelling and injection,1
XIAFLEX,injection site edema,,0
XIAFLEX,injection site edema,swelling penile edema penile swelling local,0
XIAFLEX,injection site edema,injection site pain penile pain and,0
XIAFLEX,injection site edema,edema c Includes,1
XIAFLEX,injection site edema,injection site,1
XIAFLEX,injection site edema,edema c Includes,1
XIAFLEX,injection site edema,Includes injection site pain penile pain and injection site discomfort d,0
XIAFLEX,injection site pain,discomfort,0
XIAFLEX,injection site pain,pain penile pain,1
XIAFLEX,injection site pain,and injection site edema,0
XIAFLEX,injection site pain,edema c injection,1
XIAFLEX,injection site pain,penile,0
XIAFLEX,injection site pain,,0
XIAFLEX,injection site pain,injection site pain penile pain,1
XIAFLEX,injection site pain,injection site pain penile pain,1
XIAFLEX,injection site pain,pain penile pain,1
XIAFLEX,injection site pain,c Includes,0
XIAFLEX,penile pain,injection,0
XIAFLEX,penile pain,,0
XIAFLEX,penile pain,penile pain and injection,1
XIAFLEX,penile pain,site penile,1
XIAFLEX,penile pain,Includes,0
XIAFLEX,penile pain,pain,0
XIAFLEX,penile pain,pain and injection,1
XIAFLEX,penile pain,penile pain and injection,1
XIAFLEX,injection site discomfort,hemorrhage,0
XIAFLEX,injection site discomfort,site pain,0
XIAFLEX,injection site discomfort,injection site discomfort d Includes,1
XIAFLEX,injection site discomfort,edema c Includes,0
XIAFLEX,injection site discomfort,site pain penile pain injection,1
XIAFLEX,injection site discomfort,,0
XIAFLEX,injection site discomfort,injection site discomfort d Includes,1
XIAFLEX,injection site discomfort,pain penile pain,0
XIAFLEX,injection site discomfort,site pain penile pain,0
XIAFLEX,contusion,Includes,0
XIAFLEX,contusion,site discomfort d contusion ecchymoses penile,1
XIAFLEX,contusion,injection site discomfort,0
XIAFLEX,contusion,penile hemorrhage and,0
XIAFLEX,contusion,contusion ecchymoses penile,1
XIAFLEX,contusion,d,0
XIAFLEX,ecchymoses,,0
XIAFLEX,ecchymoses,injection site discomfort,0
XIAFLEX,ecchymoses,penile pain,0
XIAFLEX,ecchymoses,,0
XIAFLEX,ecchymoses,hemorrhage and injection site hemorrhage,0
XIAFLEX,ecchymoses,ecchymoses penile hemorrhage,1
XIAFLEX,ecchymoses,and injection site hemorrhage Adverse,0
XIAFLEX,penile hemorrhage,,0
XIAFLEX,penile hemorrhage,,0
XIAFLEX,penile hemorrhage,contusion penile hemorrhage and injection,1
XIAFLEX,penile hemorrhage,discomfort d Includes contusion,0
XIAFLEX,penile hemorrhage,penile hemorrhage and injection,1
XIAFLEX,penile hemorrhage,d Includes contusion penile hemorrhage and injection,1
XIAFLEX,penile hemorrhage,injection site discomfort,0
XIAFLEX,penile hemorrhage,penile,1
XIAFLEX,penile hemorrhage,,0
XIAFLEX,injection site hemorrhage,XIAFLEXN PlaceboN,0
XIAFLEX,injection site hemorrhage,site hemorrhage Adverse Reaction,1
XIAFLEX,injection site hemorrhage,contusion ecchymoses penile hemorrhage injection site hemorrhage Adverse Reaction,1
XIAFLEX,Penile hematoma,Penile hematoma a Penile,1
XIAFLEX,Penile hematoma,hematoma a Penile,1
XIAFLEX,Penile hematoma,,0
XIAFLEX,Penile hematoma,,0
XIAFLEX,Penile hematoma,Penile hematoma a Penile,1
XIAFLEX,Penile hematoma,,0
XIAFLEX,Penile hematoma,,0
XIAFLEX,Penile hematoma,se Penile,1
XIAFLEX,Penile hematoma,,0
XIAFLEX,Penile hematoma,,0
XIAFLEX,Penile swelling,matoma Penile swelling b Penile,1
XIAFLEX,Penile swelling,Penile,0
XIAFLEX,Penile swelling,swelling b Penile,1
XIAFLEX,Penile swelling,,0
XIAFLEX,Penile swelling,,0
XIAFLEX,Penile swelling,swelling b Penile,1
XIAFLEX,Penile swelling,matoma Penile swelling b Penile,1
XIAFLEX,Penile swelling,,0
XIAFLEX,Penile pain,b,0
XIAFLEX,Penile pain,Penile pain c Pe,1
XIAFLEX,Penile pain,,0
XIAFLEX,Penile pain,b,0
XIAFLEX,Penile pain,elling Penile,1
XIAFLEX,Penile pain,elling Penile,1
XIAFLEX,Penile ecchymoses,Penile ecchymoses d Blood,1
XIAFLEX,Blood blister,Peni,0
XIAFLEX,Blood blister,,0
XIAFLEX,Blood blister,Peni,0
XIAFLEX,Blood blister,Blood blister Peni,1
XIAFLEX,Penile blister,ster,0
XIAFLEX,Penile blister,,0
XIAFLEX,Penile blister,ster Penile,1
XIAFLEX,Penile blister,ster Penile,1
XIAFLEX,Penile blister,blister Pruri,1
XIAFLEX,Penile blister,blister Pruri,1
XIAFLEX,Penile blister,ster,0
XIAFLEX,Penile blister,ster,0
XIAFLEX,Penile blister,Pruri,0
XIAFLEX,Penile blister,ster Penile blister Pruri,1
XIAFLEX,Pruritus genital,ister Pruritus,1
XIAFLEX,Pruritus genital,ister,0
XIAFLEX,Pruritus genital,,0
XIAFLEX,Pruritus genital,Pruritus genital Painful,1
XIAFLEX,Pruritus genital,,0
XIAFLEX,Pruritus genital,ister Pruritus genital Painful,1
XIAFLEX,Painful erection,genital,0
XIAFLEX,Painful erection,genital,0
XIAFLEX,Painful erection,genital Painful,1
XIAFLEX,Painful erection,Painful erection Erectil,1
XIAFLEX,Painful erection,genital Painful,1
XIAFLEX,Painful erection,genital,0
XIAFLEX,Painful erection,Painful erection Erectil,1
XIAFLEX,Painful erection,,0
XIAFLEX,Painful erection,genital,0
XIAFLEX,Painful erection,genital,0
XIAFLEX,Erectile dysfunction,Erectile dysfunction Skin,1
XIAFLEX,Erectile dysfunction,rection Erectile,1
XIAFLEX,Erectile dysfunction,rection Erectile dysfunction,1
XIAFLEX,Erectile dysfunction,rection,0
XIAFLEX,Erectile dysfunction,rection Erectile,1
XIAFLEX,Skin discoloration,Skin discoloration Procedura,1
XIAFLEX,Skin discoloration,dysfunction,0
XIAFLEX,Skin discoloration,,0
XIAFLEX,Skin discoloration,dysfunction Skin,1
XIAFLEX,Skin discoloration,dysfunction Skin discoloration Procedura,1
XIAFLEX,Skin discoloration,dysfunction Skin discoloration Procedura,1
XIAFLEX,Skin discoloration,Skin discoloration Procedura,1
XIAFLEX,Skin discoloration,Skin discoloration Procedura,1
XIAFLEX,Skin discoloration,Procedura,0
XIAFLEX,Skin discoloration,dysfunction,0
XIAFLEX,Injection site vesicles,,0
XIAFLEX,Injection site vesicles,site vesicles Localized,1
XIAFLEX,Injection site vesicles,pain,0
XIAFLEX,Injection site vesicles,,0
XIAFLEX,Injection site vesicles,Localized,0
XIAFLEX,Injection site vesicles,,0
XIAFLEX,Injection site vesicles,pain,0
XIAFLEX,Injection site vesicles,Injection site vesicles Localized,1
XIAFLEX,Injection site vesicles,Injection,1
XIAFLEX,Localized edema,,0
XIAFLEX,Localized edema,,0
XIAFLEX,Dyspareunia,Dyspareunia In,1
XIAFLEX,Dyspareunia,,0
XIAFLEX,Dyspareunia,,0
XIAFLEX,Dyspareunia,Dyspareunia In,1
XIAFLEX,Dyspareunia,edema,0
XIAFLEX,Dyspareunia,Dyspareunia In,1
XIAFLEX,Injection site pruritus,Injection site pruritus Nodule,1
XIAFLEX,Injection site pruritus,ia Injection site pruritus Nodule,1
XIAFLEX,Injection site pruritus,ia Injection site pruritus Nodule,1
XIAFLEX,Nodule,,0
XIAFLEX,Nodule,Nodule,1
XIAFLEX,Nodule,,0
XIAFLEX,Suprapubic pain,pain,1
XIAFLEX,Suprapubic pain,,0
XIAFLEX,Suprapubic pain,Suprapubic pain,1
XIAFLEX,Suprapubic pain,Suprapubic,1
XIAFLEX,Suprapubic pain,Suprapubic,1
XIAFLEX,Suprapubic pain,Suprapubic pain,1
XIAFLEX,Suprapubic pain,,0
XIAFLEX,penile hematoma,Severe penile,1
XIAFLEX,penile hematoma,,0
XIAFLEX,penile hematoma,hematoma or,1
XIAFLEX,penile hematoma,,0
XIAFLEX,penile hematoma,Severe,0
XIAFLEX,penile hematoma,,0
XIAFLEX,penile hematoma,site hematoma were,0
XIAFLEX,penile hematoma,Severe penile,1
XIAFLEX,penile hematoma,Severe penile hematoma or severe injection site,1
XIAFLEX,penile hematoma,Severe penile,1
XIAFLEX,injection site hematoma,hematoma,1
XIAFLEX,injection site hematoma,were reported in of XIAFLEXtreated patients and,0
XIAFLEX,injection site hematoma,in of XIAFLEXtreated patients,0
XIAFLEX,injection site hematoma,penile hematoma or,0
XIAFLEX,injection site hematoma,reported in of XIAFLEXtreated patients,0
XIAFLEX,popping sensation in the penis,,0
XIAFLEX,popping sensation in the penis,popping noise popping sensation in the penis,1
XIAFLEX,popping sensation in the penis,,0
XIAFLEX,popping sensation in the penis,,0
XIAFLEX,popping sensation in the penis,popping noise popping sensation in the,1
XIAFLEX,popping sensation in the penis,sensations A popping noise,0
XIAFLEX,popping sensation in the penis,sensation in the penis,1
XIAFLEX,detumescence,and sometimes accompanied by,0
XIAFLEX,detumescence,by,0
XIAFLEX,detumescence,,0
XIAFLEX,hematoma,hematoma,1
XIAFLEX,hematoma,,0
XIAFLEX,hematoma,hematoma,1
XIAFLEX,pain,as snapping or cracking and sometimes accompanied by,0
XIAFLEX,pain,pain,1
XIAFLEX,pain,accompanied by detumescence hematoma pain,1
XIAFLEX,pain,,0
XIAFLEX,pain,pain,1
XIAFLEX,pain,in,0
XIAFLEX,pain,pain,1
XIAFLEX,shortening of penile length,Peyronies disease Immunogenicity During clini,0
XIAFLEX,shortening of penile length,the treatment of Peyronies disease,0
XIAFLEX,shortening of penile length,associated shortening of penile length,1
XIAFLEX,shortening of penile length,associated shortening of penile length,1
XIAFLEX,shortening of penile length,,0
XIAFLEX,CORPORAL RUPTURE,,0
XIAFLEX,CORPORAL RUPTURE,,0
XIAFLEX,CORPORAL RUPTURE,,0
XIAFLEX,CORPORAL RUPTURE,a dverse reactions,1
XIAFLEX,CORPORAL RUPTURE,discussed in greater,0
XIAFLEX,CORPORAL RUPTURE,,0
XIAFLEX,CORPORAL RUPTURE,,0
XIAFLEX,CORPORAL RUPTURE,,0
XIAFLEX,PENILE INJURY,uytren's cont racture are discussed,1
XIAFLEX,PENILE INJURY,,0
XIAFLEX,PENILE INJURY,cont racture are discussed,1
XIAFLEX,PENILE INJURY,,0
XIAFLEX,PENILE INJURY,uytren's cont,1
XIAFLEX,PENILE INJURY,ruptures,0
XIAFLEX,PENILE INJURY,,0
XIAFLEX,PENILE INJURY,,0
XIAFLEX,PENILE INJURY,uytren's cont racture are,1
XIAFLEX,CORPORAL RUPTURE,,0
XIAFLEX,PENILE FRACTURE,Tendon ruptures or other,1
XIAFLEX,PENILE FRACTURE,,0
XIAFLEX,PENILE FRACTURE,in the labeling,0
XIAFLEX,PENILE FRACTURE,the injected extremity,0
XIAFLEX,Corporal rupture,and utions,1
XIAFLEX,Corporal rupture,utions (5.1)]    The following,1
XIAFLEX,Corporal rupture,utions (5.1)] The following,1
XIAFLEX,penile fracture,The followi ng serious,1
XIAFLEX,penile fracture,The followi ng serious,1
XIAFLEX,penile fracture,Warnings and The,1
XIAFLEX,penile fracture,Warnings and     The followi ng serious,1
XIAFLEX,penile fracture,,0
XIAFLEX,penile ecchymoses,re penile,1
XIAFLEX,penile detumescence,penile ecchymoses,0
XIAFLEX,penile detumescence,labeling Corporal rupture,0
XIAFLEX,penile detumescence,In other XIAFLEXtreated patients,0
XIAFLEX,"penile ""popping"" sound",hematoma sudden penile,0
XIAFLEX,"penile ""popping"" sound",Precautions other,1
XIAFLEX,"penile ""popping"" sound",and Precautions other,1
XIAFLEX,"penile ""popping"" sound",Warnings and Precautions In,0
XIAFLEX,"penile ""popping"" sound",penile ecchymoses or hematoma sudden penile detumescence andor a peni,0
XIAFLEX,"penile ""popping"" sound",Precautions  other XIAFLEX-treated patients a,1
XIAFLEX,"penile ""popping"" sound", other XIAFLEX-treated patients a,1
XIAFLEX,"penile ""popping"" sound",,0
XIAFLEX,"penile ""popping"" sound",other XIAFLEX-treated patients a,1
XIAFLEX,"penile ""popping"" sound",and Precautions other,1
XIAFLEX,corporal rupture,detume scence andor,1
XIAFLEX,corporal rupture,detume scence andor,1
XIAFLEX,corporal rupture,penile detume scence andor,1
XIAFLEX,corporal rupture,o,0
XIAFLEX,corporal rupture,penile ecchymoses or hematoma en,1
XIAFLEX,corporal rupture,hematoma en penile detume scence andor,1
XIAFLEX,corporal rupture,en penile detume scence andor,1
XIAFLEX,corporal rupture,detume scence andor,1
XIAFLEX,corporal rupture,a,0
XIAFLEX,penile hematoma,"andor a penile ping"" sound",1
XIAFLEX,penile hematoma,"penile ping"" sound or  sensation was",1
XIAFLEX,penile hematoma,"andor a penile ping"" sound",1
XIAFLEX,penile hematoma,or hematoma sudden penile detumescence andor a penile,0
XIAFLEX,penile hematoma,or sensation was,1
XIAFLEX,penile hematoma,sound or sensation was,1
XIAFLEX,penile hematoma,hematoma sudden penile detumescence andor,0
XIAFLEX,penile hematoma,"penile ping""",1
XIAFLEX,corporal rupture,,0
XIAFLEX,corporal rupture,"ntusion,",1
XIAFLEX,corporal rupture,were,0
XIAFLEX,corporal rupture,"ntusion, injecti on site",1
XIAFLEX,corporal rupture,"of the injected hand ntusion, injecti on site",1
XIAFLEX,corporal rupture,peripheral eg swelling of the injected hand,0
XIAFLEX,penile injury,",",1
XIAFLEX,penile injury,injection s ite reaction,1
XIAFLEX,penile injury,"injection site , injection s ite reaction",1
XIAFLEX,penile injury,pain in the injected extremity Peyronies,0
XIAFLEX,penile injury,pain in the,0
XIAFLEX,CORPORAL RUPTURE,with XIAFLEX and at an incidence,0
XIAFLEX,CORPORAL RUPTURE,To,0
XIAFLEX,CORPORAL RUPTURE,"matoma, penile s welling and",1
XIAFLEX,CORPORAL RUPTURE,penile s welling and,1
XIAFLEX,CORPORAL RUPTURE,placebo were,0
XIAFLEX,CORPORAL RUPTURE,,0
XIAFLEX,CORPORAL RUPTURE,with XIAFLEX and at,0
XIAFLEX,CORPORAL RUPTURE,s welling and,1
XIAFLEX,CORPORAL RUPTURE,"than placebo were penile matoma, penile s welling and",1
XIAFLEX,PENILE FRACTURE,,0
XIAFLEX,PENILE FRACTURE,penile hematoma penile lling and penil e pain,1
XIAFLEX,PENILE FRACTURE,To report SUSPECTED ADVERSE REACTIONS contact Auxilium,0
XIAFLEX,PENILE FRACTURE,an incidence greater than placebo were penile hematoma,0
XIAFLEX,PENILE FRACTURE,at an incidence greater,0
XIAFLEX,PENILE FRACTURE,,0
XIAFLEX,PENILE FRACTURE,at an incidence greater than placebo,0
XIAFLEX,PENILE FRACTURE,hematoma penile lling and,1
XIAFLEX,PENILE FRACTURE,penile hematoma penile lling,1
XIAFLEX,PENILE INJURY,penile pain To port,1
XIAFLEX,PENILE INJURY,penile pain To port,1
XIAFLEX,PENILE INJURY,pain To port,1
XIAFLEX,PENILE INJURY,pain To port SUSPECTE D ADVERSE,1
XIAFLEX,PENILE INJURY,than placebo were penile hematoma penile swelling and penile pain,0
XIAFLEX,PENILE INJURY,,0
XIAFLEX,PENILE INJURY,,0
XIAFLEX,PENILE INJURY,re,0
XIAFLEX,Corporal rupture,"medwatch.    


 Clinical Studies",1
XIAFLEX,Corporal rupture,clinical s,0
XIAFLEX,Corporal rupture,"medwatch.    


 Clinical Studies",1
XIAFLEX,Corporal rupture,Auxilium Pharmaceuticals Inc,0
XIAFLEX,penile fracture,Inc at or FDA at FDA or wwwfdagovmedwatch,0
XIAFLEX,penile fracture,FDA at FDA,0
XIAFLEX,penile fracture,Because clinical,0
XIAFLEX,penile fracture,conduc,0
XIAFLEX,penile hematoma,compared to rates,1
XIAFLEX,Tendon rupture,erse reactions in,1
XIAFLEX,Tendon rupture,,0
XIAFLEX,Tendon rupture,erse reactions in,1
XIAFLEX,Tendon rupture,with Dupuytrens contracture,0
XIAFLEX,Tendon rupture,erse reactions in patients with Dupuytrens,1
XIAFLEX,Tendon rupture,,0
XIAFLEX,Tendon rupture,contracture are discussed in greater detail elsewhere in the,0
XIAFLEX,Tendon rupture,,0
XIAFLEX,injury to the injected finger,with Dupuytren's,1
XIAFLEX,injury to the injected finger,,0
XIAFLEX,injury to the injected finger,with Dupuytren's,1
XIAFLEX,injury to the injected finger, with Dupuytren's contracture are discussed in greater,1
XIAFLEX,injury to the injected finger,,0
XIAFLEX,Corporal rupture,,0
XIAFLEX,Corporal rupture,n,1
XIAFLEX,Corporal rupture,the labeling Corporal rupture penile fracture and severe penile,0
XIAFLEX,Corporal rupture,hematoma,0
XIAFLEX,Corporal rupture,discussed i,0
XIAFLEX,penile fracture,e,0
XIAFLEX,penile fracture,lsewhere in the labeling Corporal rupture penile,1
XIAFLEX,penile fracture,adverse reactions in patients with Peyronies disease are discussed in greater detail,0
XIAFLEX,penile fracture,reactions in patients with Peyronies disease are discussed in greater,0
XIAFLEX,penile fracture,detail lsewhere in,1
XIAFLEX,injury to the penis,orporal rupture (pe nile fracture and severe,1
XIAFLEX,injury to the penis,orporal rupture (pe nile fracture and severe,1
XIAFLEX,injury to the penis,Warnings and,0
XIAFLEX,injury to the penis,Warnings and Precautions In other,0
XIAFLEX,injury to the penis,orporal rupture (pe nile fracture and severe,1
XIAFLEX,injury to the penis,severe penile,0
XIAFLEX,injury to the penis,greater detail,0
XIAFLEX,injury to the penis,(pe nile fracture and severe,1
XIAFLEX,injury to the penis,with Peyronies disease are discussed in greater detail elsewhere in,0
XIAFLEX,permanent injury,an dor a penile popping,1
XIAFLEX,permanent injury,patients a combination of,0
XIAFLEX,permanent injury,in these cases a,0
XIAFLEX,permanent injury,or hematoma sudden,0
XIAFLEX,permanent injury,an dor a penile popping,1
XIAFLEX,permanent injury,penile popping,0
XIAFLEX,permanent injury,"detumescence, an dor a penile popping",1
XIAFLEX,permanent injury,penile,0
XIAFLEX,permanent injury,penile ecchymoses or hematoma sudden,0
XIAFLEX,permanent injury,or,0
XIAFLEX,corporal rupture,and in these cases a diagnosis of corporal rupture cannot,0
XIAFLEX,corporal rupture,"andor a nile ""popping""",1
XIAFLEX,penile fracture,cannot,0
XIAFLEX,penile fracture,andor a penile popping nd,1
XIAFLEX,penile fracture,sensation was reported and in,1
XIAFLEX,penile fracture,cannot be excluded see,0
XIAFLEX,penile fracture,nd,1
XIAFLEX,penile fracture,nd or,1
XIAFLEX,penile fracture,ecchymoses or hematoma sudden penile detumescence andor,0
XIAFLEX,Hypersensitivity reactions,,0
XIAFLEX,anaphylaxis,see Warnings and Precautions EXCERPT,0
XIAFLEX,anaphylaxis,of al,1
XIAFLEX,anaphylaxis,,0
XIAFLEX,anaphylaxis,a diagnosis of al rupture  cannot be excluded see,1
XIAFLEX,anaphylaxis,EXCERPT Dupuytrens Contrac,0
XIAFLEX,anaphylaxis,diagnosis of al rupture  cannot be excluded see,1
XIAFLEX,anaphylaxis,rupture cannot be excluded see,1
XIAFLEX,anaphylaxis,of al rupture  cannot be excluded see,1
XIAFLEX,anaphylaxis,a penile popping sound,0
XIAFLEX,flexor tendon ruptures,adverse drug reactions reported with of patients treated with,0
XIAFLEX,flexor tendon ruptures,incidence greater t han placebo were penile,1
XIAFLEX,permanent injury,or FDA at FDA,0
XIAFLEX,permanent injury,Patients with Dupuytrens,0
XIAFLEX,permanent injury,Cli nical Studies Experience in,1
XIAFLEX,permanent injury,"or 



 

  6.1 Cli nical Studies Experience in",1
XIAFLEX,permanent injury,6.1 Cli nical Studies Experience in,1
XIAFLEX,permanent injury,or 6.1,1
XIAFLEX,permanent injury,,0
XIAFLEX,permanent injury,"FDA at FDA or 



 

  6.1 Cli nical Studies Experience in",1
XIAFLEX,permanent injury,nical Studies Experience in,0
XIAFLEX,permanent injury,,0
XIAFLEX,tendon rupture,FDA or wwwfdagovmedwatch Clinical Stu,0
XIAFLEX,tendon rupture,Stu,0
XIAFLEX,tendon rupture,,0
XIAFLEX,tendon rupture,studies are conducted under widely va,0
XIAFLEX,tendon rupture,or wwwfdagovmedwatch,0
XIAFLEX,tendon rupture,conducted under widely va,0
XIAFLEX,ligament damage,Clinical Studies Experience Patients,1
XIAFLEX,ligament damage,a,0
XIAFLEX,ligament damage,FDA at FDA or wwwfdagovmedwatch,0
XIAFLEX,ligament damage,Patients with Dupuytrens Contracture Because clinical,1
XIAFLEX,ligament damage,,0
XIAFLEX,ligament damage,Experience Patients,1
XIAFLEX,ligament damage,wwwfdagovmedwatch Clinical Studies Experience  Patients with  Dupuytrens Contracture Because clinical,1
XIAFLEX,ligament damage,Experience,0
XIAFLEX,ligament damage,Clinical Studies Experience Patients,1
XIAFLEX,ligament damage,Dupuytrens Contracture Because clinical studies are conducted under,0
XIAFLEX,pulley rupture,placebocontrolled,0
XIAFLEX,ligament injury,two pooled randomized doubleblind placebocontrolled trials through Day in patients with Dup,0
XIAFLEX,ligament injury,of,0
XIAFLEX,ligament injury,n two pooled randomized doubleblind placebocontrolled trials through Day,0
XIAFLEX,ligament injury,o n two pooled randomized,1
XIAFLEX,ligament injury,are based o n two pooled randomized,1
XIAFLEX,ligament injury,days of,0
XIAFLEX,complex regional pain syndrome,are,0
XIAFLEX,complex regional pain syndrome,"two pooled randomized,",1
XIAFLEX,complex regional pain syndrome,days of the injection The data described below,0
XIAFLEX,complex regional pain syndrome,two,1
XIAFLEX,complex regional pain syndrome,through Day in patients,0
XIAFLEX,complex regional pain syndrome,blind placebocontrolled trials through Day in patients with Dupuytrens contracture Studies,0
XIAFLEX,complex regional pain syndrome,,0
XIAFLEX,CRPS,on two pooled,0
XIAFLEX,CRPS,described below are based on two pooled randomized,0
XIAFLEX,sensory abnormality of the hand,trials through Day in patients with,1
XIAFLEX,sensory abnormality of the hand,acebo-controlled,1
XIAFLEX,sensory abnormality of the hand,described below are based,0
XIAFLEX,skin laceration,placebocontrolled trials through 0 in patients w ith Dupuytrens contracture Studies,1
XIAFLEX,skin laceration,doubleblind placebocontrolled trials through 0 in patients w ith Dupuytrens contracture Studies,1
XIAFLEX,skin laceration,trials patients were,0
XIAFLEX,skin laceration,w ith Dupuytrens contracture Studies,1
XIAFLEX,skin laceration,ith Dupuytrens contracture Studies and In these trials patients,0
XIAFLEX,skin laceration,,0
XIAFLEX,skin laceration,between,0
XIAFLEX,skin laceration,with Dupuytrens contracture Studies and In these trials,0
XIAFLEX,skin laceration,treated,1
XIAFLEX,skin laceration,between,0
XIAFLEX,skin laceration,trials were comprised of patients,0
XIAFLEX,skin laceration,day after injection if needed,0
XIAFLEX,skin laceration,facilitate ruption of the  cord see Clinical Studies,1
XIAFLEX,skin laceration,needed to facilitate ruption of the  cord see Clinical Studies,1
XIAFLEX,skin laceration,needed to facilitate ruption of the  cord see Clinical Studies,1
XIAFLEX,skin laceration,of the cord see Clinical Studies,1
XIAFLEX,skin laceration,if needed to facilitate ruption,1
XIAFLEX,skin laceration,facilitate ruption of,1
XIAFLEX,skin laceration,,0
XIAFLEX,Corporal rupture,XIAFLEXtreated,0
XIAFLEX,Corporal rupture,ts had an advers e reaction after up,1
XIAFLEX,Corporal rupture,patien,0
XIAFLEX,Corporal rupture,patien,0
XIAFLEX,penile ecchymoses,Approximately of these local reactions resolved without intervention within,0
XIAFLEX,penile ecchymoses,,0
XIAFLEX,penile ecchymoses,within weeks XIAFLEX,1
XIAFLEX,penile ecchymoses,XIAFLEX injection s The adverse reaction,1
XIAFLEX,penile ecchymoses,of,0
XIAFLEX,penile ecchymoses,,0
XIAFLEX,penile ecchymoses,,0
XIAFLEX,penile ecchymoses,within weeks XIAFLEX,1
XIAFLEX,penile ecchymoses,,0
XIAFLEX,penile ecchymoses,intervention within weeks XIAFLEX,1
XIAFLEX,penile detumescence,of injections administered However the incidence,0
XIAFLEX,penile detumescence,XIAFLEX injections The adverse on,1
XIAFLEX,penile detumescence,The adverse on profile,1
XIAFLEX,penile detumescence,lar for each injection regardless of the number of injections administered However the incidence,0
XIAFLEX,penile detumescence,within weeks of XIAFLEX injections The,0
XIAFLEX,penile detumescence,The adverse on profile,1
XIAFLEX,penile detumescence,resolved without intervention within weeks of XIAFLEX,0
XIAFLEX,penile detumescence,,0
XIAFLEX,penile detumescence,XIAFLEX injections The adverse on profile was simi lar for each injection,1
XIAFLEX,penile detumescence,XIAFLEX injections The adverse on profile was,1
XIAFLEX,corporal rupture,nce,1
XIAFLEX,corporal rupture,,0
XIAFLEX,corporal rupture,administered However the,0
XIAFLEX,corporal rupture,injections administered However the nce of pruritus  increased with more injections,1
XIAFLEX,corporal rupture,and Precautions The,0
XIAFLEX,penile hematoma,,0
XIAFLEX,penile hematoma,reported adverse drug 25%) in,1
XIAFLEX,corporal rupture,Table Adverse Reactions Occurring,0
XIAFLEX,corporal rupture,Placebo in the,0
XIAFLEX,corporal rupture,Occurring of,1
XIAFLEX,corporal rupture,,0
XIAFLEX,corporal rupture,in,0
XIAFLEX,corporal rupture,Reactions Occurring of,1
XIAFLEX,corporal rupture,Occurring of,1
XIAFLEX,corporal rupture,XIAFLEX-Trea ted Patients with Dupuytrens,1
XIAFLEX,corporal rupture,Studies and,0
XIAFLEX,corporal rupture,trials,0
XIAFLEX,penile fracture,Reactions Occurring in of d Patients,1
XIAFLEX,penile fracture,d Patients with Dupuytrens Contracture and at,1
XIAFLEX,penile fracture,,0
XIAFLEX,penile fracture,Reactions Occurring in of d,1
XIAFLEX,penile fracture,Adverse Reactions Occurring,0
XIAFLEX,allergic reactions,"   
         Some  patients developed vasovagal syncope",1
XIAFLEX,allergic reactions,Pain,0
XIAFLEX,allergic reactions,Pain Erythema,0
XIAFLEX,allergic reactions,,0
XIAFLEX,allergic reactions,Axillary,0
XIAFLEX,allergic reactions,Lymph Node,0
XIAFLEX,pruritus,Erythema Axillary Pain Some tients d eveloped vasovagal syncope after,1
XIAFLEX,pruritus,Erythema Axillary Pain Some tients,1
XIAFLEX,pruritus,Some pa,0
XIAFLEX,pruritus,Pain Some pa,0
XIAFLEX,pruritus,d eveloped vasovagal syncope after,1
XIAFLEX,pruritus,Erythema Axillary Pain Some tients,1
XIAFLEX,pruritus,Erythema Axillary Pain Some tients,1
XIAFLEX,pruritus,tients d eveloped vasovagal syncope after,1
XIAFLEX,pruritus,tients d eveloped vasovagal syncope after,1
XIAFLEX,pruritus,Axillary Pain,0
XIAFLEX,localized pruritus,were similar to Studies and Out of patients who,0
XIAFLEX,localized pruritus,hours after injection The patient demographics,1
XIAFLEX,localized pruritus,contracture Study In Study finger extension,0
XIAFLEX,localized pruritus,performed to 72 hours,1
XIAFLEX,pruritus,mg in the same hand,0
XIAFLEX,pruritus,who received two nt,1
XIAFLEX,pruritus,nt injec tions of XIAFLEX mg,1
XIAFLEX,pruritus,similar to Studies and,0
XIAFLEX,pruritus,two nt injec tions of XIAFLEX mg,1
XIAFLEX,pruritus,nt injec tions of XIAFLEX mg,1
XIAFLEX,allergic reactions,inger within 3 day s of the injection,1
XIAFLEX,allergic reactions,inger within 3 day s of the injection,1
XIAFLEX,allergic reactions,treated inger within 3 day s of the injection,1
XIAFLEX,allergic reactions,day s of the injection,1
XIAFLEX,allergic reactions,were reported,0
XIAFLEX,Anaphylaxis,,0
XIAFLEX,Anaphylaxis,Table 4,1
XIAFLEX,Anaphylaxis,the incidence of,0
XIAFLEX,Anaphylaxis, Table 4 sh ows the incidence of,1
XIAFLEX,ecchymosis,   77%     Contusion,1
XIAFLEX,ecchymosis,Contusion,0
XIAFLEX,ecchymosis,Edema    77%     Contusion,1
XIAFLEX,ecchymosis,peripheral,0
XIAFLEX,ecchymosis,   77%     Contusion,1
XIAFLEX,ecchymosis,   77%     Contusion,1
XIAFLEX,ecchymosis,,0
XIAFLEX,ecchymosis,,0
XIAFLEX,ecchymosis,,0
XIAFLEX,injection site hemorrhage,"         
 Contusion      Pain in",1
XIAFLEX,injection site hemorrhage,"         
 Contusion      Pain in",1
XIAFLEX,injection site hemorrhage,"         
 Contusion      Pain in",1
XIAFLEX,injection site hemorrhage,"         
 Contusion      Pain in",1
XIAFLEX,penile hematoma,in extremity,0
XIAFLEX,penile ecchymosis,"in              
 La ceration",1
XIAFLEX,penile ecchymosis,,0
CIMZIA,upper respiratory tract infection,ADVERSE REACTIONS contact UCB I,0
CIMZIA,upper respiratory tract infection,common adverse reactions incidence and higher,0
CIMZIA,upper respiratory tract infection,and higher than placebo,0
CIMZIA,upper respiratory tract infection,and higher than upper respiratory tract infection rash and urinary tract,1
CIMZIA,upper respiratory tract infection,most common adverse reactions incidence and higher than,0
CIMZIA,upper respiratory tract infection,reactions incidence and higher than,0
CIMZIA,upper respiratory tract infection,upper respiratory tract infection rash and urinary tract,1
CIMZIA,upper respiratory tract infection,infection rash and urinary tract,1
CIMZIA,upper respiratory tract infection,,0
CIMZIA,upper respiratory tract infection,than upper respiratory tract infection rash and urinary tract,1
CIMZIA,rash,rash and urinary tract infection,1
CIMZIA,rash,adverse reactions incidence and higher,0
CIMZIA,rash,reactions incidence and higher than,0
CIMZIA,rash,upper respiratory tract rash and urinary tract infection,1
CIMZIA,rash,report SUSPECTED ADVERSE REACTIONS contact UCB Inc at,0
CIMZIA,rash,,0
CIMZIA,rash,and urinary tract infection To report SUSPECTED ADVERSE REACTIONS contact UCB Inc,0
CIMZIA,rash,rash and urinary tract infection,1
CIMZIA,urinary tract infection,contact UCB Inc at or,0
CIMZIA,Infections,Precautions,0
CIMZIA,Infections,reactions were Serious,0
CIMZIA,Infections,Infections see Warnings and Precautions,1
CIMZIA,Infections,adverse reactions were Infections see Warnings and Precautions,1
CIMZIA,Infections,reactions were Infections see Warnings and Precautions,1
CIMZIA,Infections,Serious,0
CIMZIA,Infections,were,0
CIMZIA,Infections,adverse reactions were Serious,0
CIMZIA,Infections,Infections see Warnings and Precautions,1
CIMZIA,Infections,Trials,0
CIMZIA,Malignancies,see Warnings and Malignancies see Warnings and Precautions,1
CIMZIA,Malignancies,and Malignancies see Warnings and Precautions,1
CIMZIA,Malignancies,Infections see Warnings and Malignancies see Warnings and Precautions,1
CIMZIA,upper respiratory infections,upper,1
CIMZIA,upper respiratory infections,Adverse Reactions Most Commonly,0
CIMZIA,rash,,0
CIMZIA,rash,were,0
CIMZIA,rash,,0
CIMZIA,urinary tract infections,infections Adverse Reactions Most Commonly,1
CIMZIA,urinary tract infections,urinary tract infections Adverse Reactions Most Commonly,1
CIMZIA,urinary tract infections,tract infections Adverse Reactions Most Commonly,1
CIMZIA,urinary tract infections,in Premarketi,0
CIMZIA,abdominal pain,abdominal,1
CIMZIA,abdominal pain,intestinal obstruction C,0
CIMZIA,abdominal pain,abdominal pain CIMZIA placebo diarrhea CIMZIA,1
CIMZIA,abdominal pain,,0
CIMZIA,abdominal pain,patients and with a higher incidence than placebo,0
CIMZIA,abdominal pain,,0
CIMZIA,diarrhea,placebo,0
CIMZIA,diarrhea,than placebo were,0
CIMZIA,diarrhea,,0
CIMZIA,diarrhea,higher,0
CIMZIA,diarrhea,,0
CIMZIA,diarrhea,and with a higher incidence than placebo were abdominal pain CIMZIA placebo,0
CIMZIA,diarrhea,diarrhea CIMZIA placebo and intestinal,1
CIMZIA,diarrhea,obstruction CIMZIA placebo The,0
CIMZIA,diarrhea,diarrhea CIMZIA placebo and intestinal,1
CIMZIA,intestinal obstruction,intestinal obstruction CIMZIA placebo The proportion,1
CIMZIA,tuberculosis infections,of CIMZIA were,0
CIMZIA,pyrexia,CIMZIA were tuberculosis infections pyrexia urticaria pneumonia and rash,1
CIMZIA,pyrexia,were tuberculosis infections pyrexia urticaria pneumonia and rash,1
CIMZIA,pyrexia,pyrexia urticaria pneumonia and rash,1
CIMZIA,pyrexia,d,0
CIMZIA,pyrexia,pyrexia urticaria pneumonia and rash,1
CIMZIA,pyrexia,adverse reactions leading to,0
CIMZIA,pyrexia,tuberculosis,0
CIMZIA,pyrexia,pyrexia urticaria pneumonia and rash,1
CIMZIA,pyrexia,were,0
CIMZIA,urticaria,pyrexia,0
CIMZIA,urticaria,,0
CIMZIA,urticaria,urticaria pneumonia and rash Controlled,1
CIMZIA,urticaria,,0
CIMZIA,urticaria,and urticaria pneumonia and rash Controlled,1
CIMZIA,urticaria,and,0
CIMZIA,urticaria,urticaria pneumonia and rash Controlled,1
CIMZIA,pneumonia,pneumonia and rash Controlled Studies,1
CIMZIA,pneumonia,were tuberculosis infections,0
CIMZIA,pneumonia,Controlled Studies with Crohns Disease The data described,0
CIMZIA,pneumonia,pneumonia and rash Controlled Studies,1
CIMZIA,pneumonia,to discontinuation of CIMZIA were tuberculosis,0
CIMZIA,pneumonia,described below re,0
CIMZIA,pneumonia,pneumonia and rash Controlled Studies,1
CIMZIA,rash,pneumonia,0
CIMZIA,rash,below reflect,0
CIMZIA,rash,rash Controlled Studies with Crohns,1
CIMZIA,rash,and pyrexia urticaria pneumonia rash Controlled Studies with Crohns,1
CIMZIA,rash,pneumonia and,0
CIMZIA,upper respiratory infections,viral infection,0
CIMZIA,upper respiratory infections,CIMZIA upper respiratory infections eg nasopharyngitis laryngitis viral,1
CIMZIA,upper respiratory infections,of,0
CIMZIA,upper respiratory infections,upper,1
CIMZIA,upper respiratory infections,infections eg nasopharyngitis laryngitis viral,1
CIMZIA,upper respiratory infections,with CIMZIA upper respiratory infections eg nasopharyngitis laryngitis viral,1
CIMZIA,upper respiratory infections,laryngitis viral infection in of CIMZIAtreated patients and of pl,0
CIMZIA,nasopharyngitis,,0
CIMZIA,laryngitis,,0
CIMZIA,laryngitis,respiratory infections eg laryngitis viral infection in of,1
CIMZIA,laryngitis,were upper,0
CIMZIA,laryngitis,respiratory infections,0
CIMZIA,laryngitis,CIMZIA were upper respiratory infections eg,0
CIMZIA,viral infection,infections eg nasopharyngitis viral infection in of CIMZIAtreated patients,1
CIMZIA,viral infection,respiratory,0
CIMZIA,viral infection,infection in of CIMZIAtreated patients,1
CIMZIA,viral infection,respiratory infections eg nasopharyngitis viral,1
CIMZIA,viral infection,infections eg nasopharyngitis viral infection in of CIMZIAtreated patients,1
CIMZIA,bladder infection,eg,0
CIMZIA,bladder infection,infection bacteriuria cystitis in of,1
CIMZIA,bladder infection,,0
CIMZIA,bladder infection,bladder infection bacteriuria cystitis in of,1
CIMZIA,bladder infection,,0
CIMZIA,bladder infection,patients and of placebotreated patients urinary,0
CIMZIA,bladder infection,,0
CIMZIA,bladder infection,tract infections bladder infection bacteriuria cystitis in of,1
CIMZIA,bladder infection,in of placebotreated patients,0
CIMZIA,bladder infection,infections,0
CIMZIA,bacteriuria,placebotreated patients urinary tract infections eg bladder,0
CIMZIA,bacteriuria,bacteriuria cystitis in of CIMZIAtreated,1
CIMZIA,bacteriuria,,0
CIMZIA,bacteriuria,bacteriuria cystitis in of CIMZIAtreated,1
CIMZIA,cystitis,cystitis in of CIMZIAtreated patients,1
CIMZIA,cystitis,cystitis in of CIMZIAtreated patients,1
CIMZIA,cystitis,urinary tract infections eg bladder infection,0
CIMZIA,cystitis,cystitis in of CIMZIAtreated patients,1
CIMZIA,cystitis,cystitis in of CIMZIAtreated patients,1
CIMZIA,cystitis,placebotreated patients urinary tract infections,0
CIMZIA,cystitis,infection cystitis in of CIMZIAtreated patients,1
CIMZIA,cystitis,,0
CIMZIA,arthralgia,most commonly occurring adve,0
CIMZIA,arthralgia,most commonly occurring adve,0
CIMZIA,arthralgia,occurring adve,0
CIMZIA,Anemia,Anemia leukopenia lymphadenopathy pancytopenia and,1
CIMZIA,Anemia,and lymphatic system Anemia leukopenia lymphadenopathy pancytopenia and,1
CIMZIA,Anemia,Anemia leukopenia lymphadenopathy pancytopenia and,1
CIMZIA,Anemia,and lymphatic system Anemia leukopenia lymphadenopathy pancytopenia and,1
CIMZIA,Anemia,Anemia leukopenia lymphadenopathy pancytopenia and,1
CIMZIA,Anemia,Anemia leukopenia lymphadenopathy pancytopenia and,1
CIMZIA,leukopenia,leukopenia lymphadenopathy pancytopenia and thrombophilia,1
CIMZIA,leukopenia,and thrombophilia Cardiac,0
CIMZIA,leukopenia,leukopenia lymphadenopathy pancytopenia and thrombophilia,1
CIMZIA,leukopenia,lymphatic system disorders leukopenia lymphadenopathy pancytopenia and thrombophilia,1
CIMZIA,leukopenia,leukopenia lymphadenopathy pancytopenia and thrombophilia,1
CIMZIA,leukopenia,leukopenia lymphadenopathy pancytopenia and thrombophilia,1
CIMZIA,leukopenia,leukopenia lymphadenopathy pancytopenia and thrombophilia,1
CIMZIA,leukopenia,leukopenia lymphadenopathy pancytopenia and thrombophilia,1
CIMZIA,leukopenia,and lymphatic,0
CIMZIA,pancytopenia,pancytopenia and thrombophilia Cardiac disorders,1
CIMZIA,pancytopenia,Anemia leukopenia,0
CIMZIA,pancytopenia,pectoris arrhythmias atrial fibrillation,0
CIMZIA,pancytopenia,pancytopenia and thrombophilia Cardiac disorders,1
CIMZIA,pancytopenia,pancytopenia and thrombophilia Cardiac disorders,1
CIMZIA,pancytopenia,Blood and lymphatic system disorders Anemia leukopenia,0
CIMZIA,pancytopenia,pancytopenia and thrombophilia Cardiac disorders,1
CIMZIA,pancytopenia,pancytopenia and thrombophilia Cardiac disorders,1
CIMZIA,thrombophilia,leukopenia lymphadenopathy pancytopenia thrombophilia Cardiac disorders Angina pectoris,1
CIMZIA,thrombophilia,thrombophilia Cardiac disorders Angina pectoris,1
CIMZIA,thrombophilia,thrombophilia Cardiac disorders Angina pectoris,1
CIMZIA,thrombophilia,Anemia leukopenia lymphadenopathy pancytopenia thrombophilia Cardiac disorders Angina pectoris,1
CIMZIA,thrombophilia,thrombophilia Cardiac disorders Angina pectoris,1
CIMZIA,thrombophilia,pectoris arrhythmias atrial fibrillation cardiac failure,0
CIMZIA,thrombophilia,thrombophilia Cardiac disorders Angina pectoris,1
CIMZIA,Angina pectoris,atrial fibrillation cardiac failure hypertensive heart,0
CIMZIA,Angina pectoris,pancytopenia and thrombophilia Cardiac Angina,1
CIMZIA,Angina pectoris,Cardiac Angina,1
CIMZIA,Angina pectoris,thrombophilia Cardiac Angina pectoris arrhythmias atrial fibrillation cardiac,1
CIMZIA,Angina pectoris,and thrombophilia Cardiac Angina,1
CIMZIA,Angina pectoris,cardiac failure hypertensive heart,0
CIMZIA,Angina pectoris,and thrombophilia Cardiac Angina,1
CIMZIA,Angina pectoris,fibrillation,0
CIMZIA,Angina pectoris,fibrillation cardiac failure,0
CIMZIA,Angina pectoris,Cardiac Angina,1
CIMZIA,arrhythmias,arrhythmias atrial fibrillation cardiac failure,1
CIMZIA,arrhythmias,infarction myocardia,0
CIMZIA,arrhythmias,heart disease,0
CIMZIA,arrhythmias,,0
CIMZIA,arrhythmias,Cardiac disorders Angina arrhythmias atrial fibrillation cardiac failure,1
CIMZIA,arrhythmias,lymphadenopathy pancytopenia and thrombophilia Cardiac disorders,0
CIMZIA,arrhythmias,infarction,0
CIMZIA,atrial fibrillation,pericardi,0
CIMZIA,atrial fibrillation,disorders Angina pectoris atrial,1
CIMZIA,atrial fibrillation,disorders Angina pectoris atrial,1
CIMZIA,atrial fibrillation,myocardial infarction myocardial ischemia,0
CIMZIA,atrial fibrillation,Angina pectoris atrial fibrillation cardiac failure hypertensive heart,1
CIMZIA,cardiac failure,pectoris arrhythmias atrial cardiac failure hypertensive heart disease myocardial,1
CIMZIA,cardiac failure,atrial cardiac failure hypertensive heart disease myocardial,1
CIMZIA,cardiac failure,failure hypertensive heart disease myocardial,1
CIMZIA,cardiac failure,atrial cardiac failure hypertensive heart disease myocardial,1
CIMZIA,cardiac failure,,0
CIMZIA,cardiac failure,infarction,0
CIMZIA,hypertensive heart disease,stroke,0
CIMZIA,hypertensive heart disease,ischemia,0
CIMZIA,hypertensive heart disease,cardiac hypertensive heart disease myocardial infarction myocardial ischemia,1
CIMZIA,hypertensive heart disease,transie,0
CIMZIA,hypertensive heart disease,atrial fibrillation cardiac failure,0
CIMZIA,hypertensive heart disease,cardiac,0
CIMZIA,hypertensive heart disease,cardiac hypertensive,1
CIMZIA,myocardial infarction,myocardial ischemia pericardial effusion pericarditis stroke and,0
CIMZIA,myocardial infarction,attack,0
CIMZIA,myocardial infarction,myocardial infarction myocardial ischemia pericardial effusion,1
CIMZIA,myocardial infarction,,0
CIMZIA,myocardial infarction,failure hypertensive heart myocardial infarction myocardial ischemia pericardial effusion,1
CIMZIA,myocardial infarction,effusion pericarditis stroke and transient ischemic attack,0
CIMZIA,myocardial infarction,heart myocardial infarction myocardial ischemia pericardial effusion,1
CIMZIA,myocardial infarction,attack,0
CIMZIA,myocardial ischemia,,0
CIMZIA,myocardial ischemia,heart,0
CIMZIA,myocardial ischemia,hypertensive heart disease myocardial myocardial ischemia pericardial effusion pericarditis stroke,1
CIMZIA,myocardial ischemia,myocardial ischemia pericardial effusion pericarditis stroke,1
CIMZIA,pericardial effusion,stroke and transient ischemic,0
CIMZIA,pericardial effusion,pericardial effusion pericarditis stroke and transient,1
CIMZIA,pericardial effusion,Optic neuritis retinal,0
CIMZIA,pericardial effusion,effusion pericarditis stroke and transient,1
CIMZIA,pericardial effusion,pericardial,1
CIMZIA,pericardial effusion,attack Eye disorders Optic,0
CIMZIA,pericardial effusion,pericardial,1
CIMZIA,pericardial effusion,pericardial,1
CIMZIA,pericardial effusion,myocardial pericardial effusion pericarditis stroke and transient,1
CIMZIA,pericardial effusion,,0
CIMZIA,stroke,ischemia pericardial effusion stroke and transient ischemic attack,1
CIMZIA,stroke,,0
CIMZIA,stroke,myocardial ischemia pericardial effusion stroke and transient ischemic attack,1
CIMZIA,stroke,myocardial,0
CIMZIA,stroke,heart disease myocardial infarction myocardial,0
CIMZIA,stroke,stroke and transient ischemic attack,1
CIMZIA,stroke,transient ischemic attack Eye disorders Optic neuritis retinal hemorrhage and uveiti,0
CIMZIA,stroke,pericardial effusion stroke and transient ischemic attack,1
CIMZIA,stroke,pericardial effusion stroke and transient ischemic attack,1
CIMZIA,transient ischemic attack,transient ischemic attack Eye disorders Optic neuritis,1
CIMZIA,transient ischemic attack,,0
CIMZIA,transient ischemic attack,and,0
CIMZIA,transient ischemic attack,hemorrhage and uveitis General disorders and,0
CIMZIA,transient ischemic attack,myocardial,0
CIMZIA,transient ischemic attack,stroke transient ischemic,1
CIMZIA,Optic neuritis,,0
CIMZIA,Optic neuritis,Blee,0
CIMZIA,Optic neuritis,attack Eye disorders,0
CIMZIA,Optic neuritis,pericarditis stroke,0
CIMZIA,Optic neuritis,hemorrhage and uveitis General disorders,0
CIMZIA,Optic neuritis,Optic neuritis retinal hemorrhage and uveitis,1
CIMZIA,Optic neuritis,transient ischemic attack Eye Optic neuritis retinal hemorrhage and uveitis,1
CIMZIA,Optic neuritis,,0
CIMZIA,Optic neuritis,ischemic,0
CIMZIA,Optic neuritis,and,0
CIMZIA,retinal hemorrhage,Optic retinal hemorrhage and uveitis General disorders,1
CIMZIA,retinal hemorrhage,Optic retinal hemorrhage and uveitis General disorders,1
CIMZIA,retinal hemorrhage,hemorrhage and uveitis General disorders,1
CIMZIA,retinal hemorrhage,hemorrhage and uveitis General disorders,1
CIMZIA,retinal hemorrhage,administration site conditions Bleeding and,0
CIMZIA,uveitis,uveitis General disorders and administration,1
CIMZIA,uveitis,retinal hemorrhage,0
CIMZIA,uveitis,uveitis General disorders and administration,1
CIMZIA,Bleeding,uveitis General disorders and administration site conditions,0
CIMZIA,Bleeding,Bleeding and injection site reactions,1
CIMZIA,injection site reactions,injection site reactions Hepatobiliary disorders Elevated liver,1
CIMZIA,injection site reactions,administration site conditions Bleeding,0
CIMZIA,injection site reactions,Bleeding injection,1
CIMZIA,injection site reactions,hepatitis,0
CIMZIA,injection site reactions,and administration site conditions Bleeding,0
CIMZIA,Elevated liver enzymes,,0
CIMZIA,Elevated liver enzymes,liver enzymes and hepatitis Immune system,1
CIMZIA,Elevated liver enzymes,and hepatitis Immune system disorders Alopecia totalis,0
CIMZIA,Elevated liver enzymes,Hepatobiliary Elevated liver enzymes and hepatitis Immune system,1
CIMZIA,Elevated liver enzymes,liver enzymes and hepatitis Immune system,1
CIMZIA,Elevated liver enzymes,,0
CIMZIA,Elevated liver enzymes,Hepatobiliary Elevated liver,1
CIMZIA,Elevated liver enzymes,site,0
CIMZIA,Elevated liver enzymes,Elevated liver enzymes and hepatitis Immune system,1
CIMZIA,hepatitis,,0
CIMZIA,hepatitis,hepatitis Immune system disorders Alopecia,1
CIMZIA,hepatitis,system disorders Alopecia totalis Psychiatric disorders,0
CIMZIA,hepatitis,hepatitis Immune system disorders Alopecia,1
CIMZIA,hepatitis,totalis Psychiatric,0
CIMZIA,hepatitis,reactions Hepatobiliary disorders Elevated liver enzymes,0
CIMZIA,hepatitis,Immune system disorders Alopecia totalis Psychiatric disorders Anxiety bipolar,0
CIMZIA,hepatitis,hepatitis Immune system disorders Alopecia,1
CIMZIA,Alopecia totalis,enzymes and hepatitis,0
CIMZIA,Anxiety,Anxiety bipolar disorder and suicide,1
CIMZIA,Anxiety,totalis Psychiatric Anxiety bipolar disorder and suicide,1
CIMZIA,bipolar disorder,,0
CIMZIA,bipolar disorder,totalis Psychiatric disorders bipolar disorder and suicide attempt Renal,1
CIMZIA,bipolar disorder,totalis Psychiatric disorders bipolar disorder and suicide attempt Renal,1
CIMZIA,bipolar disorder,Alopecia totalis Psychiatric disorders bipolar,1
CIMZIA,bipolar disorder,Psychiatric disorders bipolar disorder and suicide attempt Renal,1
CIMZIA,bipolar disorder,Renal and urinary disorders Nephrotic syndrome and renal failure,0
CIMZIA,bipolar disorder,disorder and suicide attempt Renal,1
CIMZIA,bipolar disorder,,0
CIMZIA,suicide attempt,and,0
CIMZIA,suicide attempt,and,0
CIMZIA,suicide attempt,totalis Psychiatric disorders Anxiety bipolar,0
CIMZIA,suicide attempt,,0
CIMZIA,suicide attempt,bipolar disorder suicide attempt Renal and urinary disorders,1
CIMZIA,suicide attempt,failure,0
CIMZIA,suicide attempt,suicide,1
CIMZIA,suicide attempt,suicide,1
CIMZIA,suicide attempt,,0
CIMZIA,renal failure,Nephrotic,0
CIMZIA,renal failure,Reproductive system and breast,0
CIMZIA,renal failure,,0
CIMZIA,renal failure,urinary disorders Nephrotic syndrome renal,1
CIMZIA,renal failure,urinary disorders Nephrotic syndrome renal,1
CIMZIA,renal failure,Nephrotic syndrome renal,1
CIMZIA,renal failure,Reproductive system and breast disorders Menstrual disorder Skin and,0
CIMZIA,renal failure,renal failure Reproductive system and breast,1
CIMZIA,Menstrual disorder,system and breast Menstrual disorder Skin and subcutaneous tissue,1
CIMZIA,Menstrual disorder,Menstrual disorder Skin and subcutaneous tissue,1
CIMZIA,Menstrual disorder,Menstrual,1
CIMZIA,Menstrual disorder,tissue disorders Dermatitis erythema nodosum and urticaria,0
CIMZIA,Menstrual disorder,failure Reproductive,0
CIMZIA,Menstrual disorder,and subcutaneous tissue,0
CIMZIA,Menstrual disorder,Menstrual disorder Skin and subcutaneous tissue,1
CIMZIA,Menstrual disorder,and renal,0
CIMZIA,Menstrual disorder,disorder Skin and subcutaneous tissue,1
CIMZIA,Menstrual disorder,Menstrual disorder Skin and subcutaneous tissue,1
CIMZIA,Dermatitis,Dermatitis erythema nodosum and urticaria,1
CIMZIA,Dermatitis,disorders,0
CIMZIA,Dermatitis,,0
CIMZIA,Dermatitis,erythema nodosum and,0
CIMZIA,Dermatitis,,0
CIMZIA,Dermatitis,tissue disorders,0
CIMZIA,Dermatitis,Dermatitis erythema nodosum and urticaria,1
CIMZIA,Dermatitis,disorders,0
CIMZIA,Dermatitis,Dermatitis erythema nodosum and urticaria,1
CIMZIA,Dermatitis,,0
CIMZIA,erythema nodosum,Thrombophlebitis,0
CIMZIA,erythema nodosum,Thrombophlebitis vasculitis Controlled Studies,0
CIMZIA,erythema nodosum,and subcutaneous tissue disorders erythema,1
CIMZIA,urticaria,,0
CIMZIA,urticaria,urticaria Vascular disorders Thrombophlebitis vasculitis,1
CIMZIA,urticaria,with,0
CIMZIA,urticaria,,0
CIMZIA,urticaria,Vascular disorders Thrombophlebitis vasculitis Controlled Studies,0
CIMZIA,urticaria,urticaria Vascular disorders Thrombophlebitis vasculitis,1
CIMZIA,urticaria,Dermatitis,0
CIMZIA,Thrombophlebitis,Thrombophlebitis vasculitis Controlled Studies with,1
CIMZIA,Thrombophlebitis,,0
CIMZIA,Thrombophlebitis,Vascular Thrombophlebitis vasculitis Controlled Studies with,1
CIMZIA,Thrombophlebitis,studied primaril,0
CIMZIA,Thrombophlebitis,Thrombophlebitis vasculitis Controlled Studies with,1
CIMZIA,Thrombophlebitis,disorders Dermatitis erythema,0
CIMZIA,Thrombophlebitis,erythema nodosum,0
CIMZIA,Thrombophlebitis,disorders,0
CIMZIA,vasculitis,vasculitis Controlled Studies with Rheumatoid,1
CIMZIA,vasculitis,Vascular,0
CIMZIA,vasculitis,placebo,0
CIMZIA,vasculitis,vasculitis Controlled Studies with Rheumatoid,1
CIMZIA,vasculitis,,0
CIMZIA,vasculitis,vasculitis Controlled Studies with Rheumatoid,1
CIMZIA,vasculitis,vasculitis Controlled Studies with Rheumatoid,1
CIMZIA,Upper respiratory tract infection,Upper respiratory tract infection Headache,1
CIMZIA,Upper respiratory tract infection,EOW Upper respiratory,1
CIMZIA,Upper respiratory tract infection,Headache,0
CIMZIA,Upper respiratory tract infection,EOW Upper respiratory tract infection Headache,1
CIMZIA,Upper respiratory tract infection,MTXN,0
CIMZIA,Upper respiratory tract infection,respiratory tract infection Headache,1
CIMZIA,Upper respiratory tract infection,mg EOW Upper respiratory,1
CIMZIA,Upper respiratory tract infection,mg,0
CIMZIA,Upper respiratory tract infection,Headache,0
CIMZIA,Upper respiratory tract infection,Headache,0
CIMZIA,Headache,Headache,1
CIMZIA,Back pain,ngitis Back,1
CIMZIA,Back pain,Back pain,1
CIMZIA,Back pain,,0
CIMZIA,Back pain,,0
CIMZIA,Back pain,ngitis Back pain,1
CIMZIA,Back pain,,0
CIMZIA,Pyrexia,,0
CIMZIA,Pyrexia,Pyrexia,1
CIMZIA,Pyrexia,Pyrexia,1
CIMZIA,Pharyngitis,,0
CIMZIA,Pharyngitis,Pharyngitis Ra,1
CIMZIA,Pharyngitis,,0
CIMZIA,Pharyngitis,,0
CIMZIA,Pharyngitis,Pharyngitis Ra,1
CIMZIA,Pharyngitis,Ra,0
CIMZIA,Pharyngitis,Pharyngitis Ra,1
CIMZIA,Pharyngitis,,0
CIMZIA,Pharyngitis,Ra,0
CIMZIA,Pharyngitis,Pharyngitis Ra,1
CIMZIA,Rash,is Rash,1
CIMZIA,Rash,is,0
CIMZIA,Fatigue,Fatigue,1
CIMZIA,Fatigue,,0
CIMZIA,Fatigue,nchitis Fatigue,1
CIMZIA,Hypertensive adverse reactions,Hypertensive adverse reactions were observed,1
CIMZIA,Hypertensive adverse reactions,in controls These adverse,0
CIMZIA,Hypertensive adverse reactions,reactions were,1
CIMZIA,Hypertensive adverse reactions,Hypertensive adverse reactions,1
CIMZIA,Hypertensive adverse reactions,These adverse reaction,0
CIMZIA,Hypertensive adverse reactions,Hypertensive adverse,1
CIMZIA,infections,infections consisted primarily,1
CIMZIA,infections,,0
CIMZIA,infections,incidenc,0
CIMZIA,infections,The,0
CIMZIA,infections,incidenc,0
CIMZIA,infections,The,0
CIMZIA,infections,infections consisted primarily,1
CIMZIA,upper respiratory infections,,0
CIMZIA,infections,The incidence of infections during the,1
CIMZIA,infections,infections during the,1
CIMZIA,infections,placebo,0
CIMZIA,infections,infections during the,1
CIMZIA,infections,and for placebotreated,0
CIMZIA,infections,and viral infections pneumonia,0
CIMZIA,viral infections,patients and for placebotreated patients Serious infections observed included bacterial and,0
CIMZIA,viral infections,for placebotreated patients Serious infections observed,0
CIMZIA,viral infections,infections observed included bacterial viral infections pneumonia and,1
CIMZIA,viral infections,and for,0
CIMZIA,viral infections,observed included bacterial viral infections pneumonia and,1
CIMZIA,viral infections,and pyelonephritis The incidence of new cases of infections in controlled,0
CIMZIA,viral infections,patients and for placebotreated patients,0
CIMZIA,pneumonia,,0
CIMZIA,pneumonia,controlled,0
CIMZIA,pneumonia,controlled clinical studies in,0
CIMZIA,pneumonia,pneumonia and pyelonephritis,1
CIMZIA,pneumonia,bacterial and viral pneumonia and pyelonephritis,1
CIMZIA,pneumonia,pneumonia and pyelonephritis,1
CIMZIA,pneumonia,clinical,0
CIMZIA,infections,cases of,0
CIMZIA,infections,infections in controlled,1
CIMZIA,infections,infections in controlled,1
CIMZIA,infections,infections in controlled,1
CIMZIA,infections,for placebotreated patients infections consisted primarily,1
CIMZIA,infections,infections consisted primarily,1
CIMZIA,infections,tract,0
CIMZIA,infections,primarily of upper respiratory tract infections herpes,0
CIMZIA,upper respiratory tract infections,,0
CIMZIA,upper respiratory tract infections,tract infections herpes infections,1
CIMZIA,upper respiratory tract infections,infections consisted primarily upper respiratory tract infections herpes infections,1
CIMZIA,upper respiratory tract infections,,0
CIMZIA,upper respiratory tract infections,respiratory tract infections herpes infections,1
CIMZIA,herpes infections,herpes infections urinary tract,1
CIMZIA,herpes infections,respiratory tract infections,0
CIMZIA,herpes infections,infections urinary tract,1
CIMZIA,herpes infections,infections urinary tract,1
CIMZIA,urinary tract infections,respiratory tract infections,0
CIMZIA,urinary tract infections,urinary tract infections and lower,1
CIMZIA,urinary tract infections,urinary tract infections and lower,1
CIMZIA,urinary tract infections,,0
CIMZIA,urinary tract infections,rheumatoid arthritis studies,0
CIMZIA,urinary tract infections,were,0
CIMZIA,urinary tract infections,The infections consisted primarily of upper respiratory tract infections,0
CIMZIA,urinary tract infections,urinary tract,1
CIMZIA,urinary tract infections,urinary tract infections and lower,1
CIMZIA,lower respiratory tract infections,tract infections In the,1
CIMZIA,lower respiratory tract infections,tract infections lower,1
CIMZIA,lower respiratory tract infections,infections In the,1
CIMZIA,lower respiratory tract infections,urinary tract infections lower respiratory,1
CIMZIA,infection,infection adverse reactions,1
CIMZIA,infection,of infection adverse reactions,1
CIMZIA,infection,infection adverse reactions,1
CIMZIA,infection,infection adverse reactions,1
CIMZIA,infection,infection adverse reactions,1
CIMZIA,infections,infections in the,1
CIMZIA,infections,infections in the,1
CIMZIA,infections,dose group were per patientyear,0
CIMZIA,infections,all CIMZIA doses vs per patientyear for placebo,0
CIMZIA,infections,week dose group were per patientyear and,0
CIMZIA,infections,vs per patientyear for placebo,0
CIMZIA,infections,infections in the,1
CIMZIA,infections,,0
CIMZIA,infections,placebo Rates of serious,0
CIMZIA,infections,were per,0
CIMZIA,infections,dose group were per patientyear Serious,0
CIMZIA,infections,placebo group,0
CIMZIA,infections,included,0
CIMZIA,infections,In the placebo,0
CIMZIA,infections,infections included tuberculosis,1
CIMZIA,infections,infections included tuberculosis,1
CIMZIA,infections,in the mg every weeks dose,0
CIMZIA,infections,patientyear infections included tuberculosis,1
CIMZIA,infections,were per patientyear infections included tuberculosis,1
CIMZIA,infections,cellulitis and pyelonephritis In the placebo group,0
CIMZIA,tuberculosis,tuberculosis pneumonia cellulitis,1
CIMZIA,pneumonia,dose group were per patientyear,0
CIMZIA,pneumonia,,0
CIMZIA,pneumonia,per patientyear Serious infections,0
CIMZIA,pneumonia,included pneumonia cellulitis and,1
CIMZIA,cellulitis,infections included tuberculosis cellulitis and pyelonephritis,1
CIMZIA,cellulitis,infection occurred in,0
CIMZIA,cellulitis,and pyelonephritis,0
CIMZIA,cellulitis,pyelonephritis In,0
CIMZIA,cellulitis,cellulitis and pyelonephritis,1
CIMZIA,cellulitis,cellulitis and pyelonephritis,1
CIMZIA,cellulitis,cellulitis and pyelonephritis,1
CIMZIA,cellulitis,Serious infections included tuberculosis cellulitis and pyelonephritis,1
CIMZIA,cellulitis,,0
CIMZIA,cellulitis,patientyear Serious infections,0
CIMZIA,pyelonephritis,pyelonephritis In the,1
CIMZIA,pyelonephritis,pyelonephritis In the,1
CIMZIA,pyelonephritis,pyelonephritis In the,1
CIMZIA,pyelonephritis,pneumonia cellulitis pyelonephritis In the,1
CIMZIA,infection,in more than one subject There is no evidence of increased risk of infections with,0
CIMZIA,infection,infection occurred in,1
CIMZIA,infection,infection occurred in,1
CIMZIA,infection,infection occurred in,1
CIMZIA,infection,infection occurred in,1
CIMZIA,infection,infection occurred in,1
CIMZIA,infection,group no infection occurred in,1
CIMZIA,infection,the placebo group,0
CIMZIA,infection,infection occurred in,1
CIMZIA,tuberculosis,tuberculosis is approximately,1
CIMZIA,tuberculosis,patients the overall rate tuberculosis is approximately,1
CIMZIA,tuberculosis,tuberculosis is approximately,1
CIMZIA,tuberculosis,,0
CIMZIA,tuberculosis,tuberculosis is approximately,1
CIMZIA,tuberculosis,including,0
CIMZIA,TB,in,0
CIMZIA,TB,with high endemic rates TB Reports include,1
CIMZIA,TB,TB Reports include,1
CIMZIA,TB,lymphatic peritoneal as well as,0
CIMZIA,TB,,0
CIMZIA,TB,The,0
CIMZIA,pulmonary TB,well pulmonary TB The median,1
CIMZIA,pulmonary TB,pulmonary TB The median,1
CIMZIA,pulmonary TB,pulmonary TB The median,1
CIMZIA,pulmonary TB,exposed to,0
CIMZIA,pulmonary TB,high endemic,0
CIMZIA,pulmonary TB,pulmonary TB The median,1
CIMZIA,TB,TB for all,1
CIMZIA,TB,TB for all,1
CIMZIA,TB,across all indications was days In the studies with CIMZIA in RA there were cases,0
CIMZIA,TB,cases,0
CIMZIA,TB,TB among exposed,1
CIMZIA,opportunistic infections,were cases of TB among,0
CIMZIA,opportunistic infections,some fatal,0
CIMZIA,opportunistic infections,cases opportunistic infections have also,1
CIMZIA,malignancies,control patients For some TNF blockers more cases,0
CIMZIA,malignancies,of,0
CIMZIA,malignancies,malignancies was similar,1
CIMZIA,malignancies,was similar for CIMZIAtreated and control patients For,0
CIMZIA,malignancies,malignancies have been,1
CIMZIA,malignancies,receiving those TNF,0
CIMZIA,malignancies,malignancies have been,1
CIMZIA,lupus-like syndrome,CIMZIA developed symptoms of lupus-like syndrome In clinical,1
CIMZIA,lupus-like syndrome,blockers including CIMZIA in patients with RA some,0
CIMZIA,lupus-like syndrome,syndrome In clinical,1
CIMZIA,lupus-like syndrome,developed symptoms of,0
CIMZIA,lupus-like syndrome,symptoms of lupus-like,1
CIMZIA,lupus-like syndrome,studies One,0
CIMZIA,lupus-like syndrome,,0
CIMZIA,ANA,ANA Four patients,1
CIMZIA,ANA,ANA Four patients,1
CIMZIA,lupus-like syndrome,syndrome The impact,1
CIMZIA,lupus-like syndrome,CIMZIA,0
CIMZIA,lupus-like syndrome,lupus-like syndrome The impact,1
CIMZIA,lupus-like syndrome,clinical studies developed clinical signs,0
CIMZIA,lupus-like syndrome,clinical signs suggestive of lupus-like syndrome The impact,1
CIMZIA,lupus-like syndrome,RA clinical studies developed,0
CIMZIA,lupus-like syndrome,of lupus-like,1
CIMZIA,lupus-like syndrome,a,0
CIMZIA,lupus-like syndrome,clinical signs suggestive of lupus-like syndrome The impact,1
CIMZIA,lupus-like syndrome,of lupus-like,1
CIMZIA,erythema nodosum,edema erythema,1
CIMZIA,erythema nodosum,,0
CIMZIA,injection site erythema,site erythema injection site,1
CIMZIA,injection site erythema,injection site erythema injection site,1
CIMZIA,injection site erythema,erythema injection site erythema injection site,1
CIMZIA,injection site erythema,edema peripheral erythema injection site erythema injection site,1
CIMZIA,injection site erythema,arthralgia edema peripheral erythema injection site,1
CIMZIA,injection site erythema,infection,0
CIMZIA,injection site pain,nodosum injection site,0
CIMZIA,injection site pain,pain pain in,1
CIMZIA,injection site pain,site injection site pain pain in,1
CIMZIA,injection site pain,peripheral erythema nodosum injection,0
CIMZIA,injection site pain,percentage of,0
CIMZIA,injection site pain,edema peripheral erythema nodosum injection site erythema,0
CIMZIA,injection site pain,edema,0
CIMZIA,pain in extremity,infection The overall percentage of patients with antibodies to c,0
CIMZIA,pain in extremity,injection site pain in,1
CIMZIA,pain in extremity,injection site pain in,1
CIMZIA,pain in extremity,injection site pain in,1
CIMZIA,pain in extremity,percentage of patients,0
CIMZIA,pain in extremity,injection site pain in,1
CIMZIA,pain in extremity,site erythema injection site pain,1
CIMZIA,pain in extremity,injection site pain,1
CIMZIA,upper respiratory tract infection,upper,1
CIMZIA,hypersensitivity reactions,administration to patients angioedema,0
CIMZIA,hypersensitivity reactions,administration to patients,0
CIMZIA,hypersensitivity reactions,following symptoms that,0
CIMZIA,hypersensitivity reactions,compatible,0
CIMZIA,hypersensitivity reactions,,0
CIMZIA,hypersensitivity reactions,hypersensitivity reactions have been,1
CIMZIA,hypersensitivity reactions,could be compatible hypersensitivity reactions have been,1
CIMZIA,angioedema,reactions have been reported rarely following CIMZIA administration to,0
CIMZIA,angioedema,angioedema dermatitis allergic,1
CIMZIA,dermatitis allergic,allergic dizziness postural,1
CIMZIA,dermatitis allergic,,0
CIMZIA,dermatitis allergic,reactions malaise pyrexia,0
CIMZIA,dermatitis allergic,allergic dizziness postural,1
CIMZIA,dermatitis allergic,site,0
CIMZIA,dermatitis allergic,,0
CIMZIA,dermatitis allergic,reactions,0
CIMZIA,dyspnea,allergic dizziness,0
CIMZIA,dyspnea,dyspnea hot flush,1
CIMZIA,dyspnea,CIMZIA administration to patients angioedema dermatitis allergic dizziness,0
CIMZIA,dyspnea,dyspnea hot flush,1
CIMZIA,dyspnea,sickness and,0
CIMZIA,dyspnea,dermatitis allergic dizziness dyspnea hot flush,1
CIMZIA,dyspnea,dyspnea hot flush,1
CIMZIA,dyspnea,dyspnea hot flush,1
CIMZIA,hot flush,allergic dizziness postural hot flush hypotension injection,1
CIMZIA,hot flush,allergic dizziness postural hot,1
CIMZIA,hot flush,,0
CIMZIA,hot flush,dizziness postural dyspnea,0
CIMZIA,hypotension,malaise pyrexia rash serum sickness and vasovagal syncope see,0
CIMZIA,hypotension,to patients angioedema dermatitis,0
CIMZIA,hypotension,hypotension injection site,1
CIMZIA,injection site reactions,flush injection site reactions malaise pyrexia,1
CIMZIA,injection site reactions,flush injection,1
CIMZIA,injection site reactions,dyspnea hot flush injection site reactions malaise pyrexia,1
CIMZIA,injection site reactions,,0
CIMZIA,injection site reactions,site reactions malaise pyrexia,1
CIMZIA,malaise,malaise pyrexia rash,1
CIMZIA,malaise,hot flush hypotension injection site reactions,0
CIMZIA,malaise,Precautions,0
CIMZIA,malaise,and,0
CIMZIA,malaise,malaise pyrexia rash,1
CIMZIA,malaise,and vasovagal,0
CIMZIA,malaise,malaise pyrexia rash,1
CIMZIA,pyrexia,pyrexia rash serum,1
CIMZIA,pyrexia,pyrexia rash serum,1
CIMZIA,pyrexia,pyrexia rash serum,1
CIMZIA,pyrexia,dizziness postural dyspnea hot flush hypotension,0
CIMZIA,pyrexia,serum sickness and vasovagal syncope,0
CIMZIA,pyrexia,pyrexia rash serum,1
CIMZIA,pyrexia,pyrexia rash serum,1
CIMZIA,pyrexia,,0
CIMZIA,rash,,0
CIMZIA,rash,rash serum sickness,1
CIMZIA,rash,rash serum sickness,1
CIMZIA,rash,sickness and vasovagal syncope see,0
CIMZIA,rash,and,0
CIMZIA,rash,see,0
CIMZIA,rash,reactions malaise rash serum sickness,1
CIMZIA,rash,,0
CIMZIA,serum sickness,serum sickness and vasovagal,1
CIMZIA,serum sickness,reactions malaise pyrexia serum,1
CIMZIA,serum sickness,malaise,0
CIMZIA,serum sickness,serum sickness and vasovagal,1
CIMZIA,serum sickness,sickness and vasovagal,1
CIMZIA,serum sickness,malaise pyrexia serum sickness and vasovagal,1
CIMZIA,serum sickness,site reactions malaise,0
CIMZIA,systemic vasculitis,case of severe skin reactio,0
CIMZIA,systemic vasculitis,drug exposure Vascular systemic vasculitis has been,1
CIMZIA,systemic vasculitis,case,0
CIMZIA,systemic vasculitis,exposure Vascular systemic,1
CIMZIA,systemic vasculitis,disorder,0
CIMZIA,systemic vasculitis,drug exposure Vascular disorder,0
CIMZIA,systemic vasculitis,to drug exposure Vascular systemic,1
CIMZIA,systemic vasculitis,vasculitis has been,1
CIMZIA,systemic vasculitis,drug exposure Vascular,0
CIMZIA,skin reactions,blockers Skin,0
CIMZIA,skin reactions,reactions including StevensJohnson,1
CIMZIA,skin reactions,case of skin,1
CIMZIA,skin reactions,skin reactions including StevensJohnson,1
CIMZIA,skin reactions,during postapproval use of TNF,0
CIMZIA,skin reactions,severe,0
CIMZIA,skin reactions,toxic epidermal necrolysis erythema multiforme and new,0
CIMZIA,skin reactions,skin reactions including StevensJohnson,1
CIMZIA,skin reactions,of,0
CIMZIA,Stevens-Johnson syndrome,blockers Skin case of severe skin,0
CIMZIA,Stevens-Johnson syndrome,toxic epidermal necrolysis erythema multiforme and new or worsening,0
CIMZIA,Stevens-Johnson syndrome,,0
CIMZIA,Stevens-Johnson syndrome,reactions Stevens-Johnson syndrome toxic epidermal,1
CIMZIA,toxic epidermal necrolysis,worsening psoriasis all,0
CIMZIA,toxic epidermal necrolysis,including StevensJohnson toxic,1
CIMZIA,toxic epidermal necrolysis,new,0
CIMZIA,toxic epidermal necrolysis,necrolysis erythema multiforme,1
CIMZIA,toxic epidermal necrolysis,severe skin reactions including StevensJohnson,0
CIMZIA,toxic epidermal necrolysis,toxic epidermal necrolysis erythema multiforme,1
CIMZIA,toxic epidermal necrolysis,toxic epidermal necrolysis erythema multiforme,1
CIMZIA,erythema multiforme,syndrome toxic epidermal erythema multiforme and new,1
CIMZIA,erythema multiforme,or worsening,0
CIMZIA,erythema multiforme,StevensJohnson syndrome toxic epidermal erythema multiforme and new,1
CIMZIA,erythema multiforme,and palmoplantar have been,0
CIMZIA,erythema multiforme,multiforme and new,1
CIMZIA,erythema multiforme,reactions,0
CIMZIA,erythema multiforme,subtypes including pustular,0
CIMZIA,erythema multiforme,or worsening psoriasis all subtypes including pustular,0
CIMZIA,psoriasis,multiforme and new or psoriasis all subtypes,1
CIMZIA,psoriasis,and new,0
CIMZIA,psoriasis,psoriasis all subtypes,1
CIMZIA,psoriasis,StevensJohnson syndrome toxic epidermal,0
CIMZIA,psoriasis,psoriasis all subtypes,1
CIMZIA,psoriasis,psoriasis all subtypes,1
CIMZIA,sarcoidosis,System,0
CIMZIA,sarcoidosis,,0
CIMZIA,sarcoidosis,identified,0
CIMZIA,sarcoidosis,,0
CIMZIA,INFECTIONS,The,1
CIMZIA,INFECTIONS,The most,1
CIMZIA,INFECTIONS,,0
CIMZIA,MALIGNANCY,adverse,1
CIMZIA,MALIGNANCY,r eactions incidence and,1
CIMZIA,MALIGNANCY,eactions incidence and higher than placebo upper respiratory tract,0
CIMZIA,MALIGNANCY,,0
CIMZIA,MALIGNANCY,adverse r,1
CIMZIA,MALIGNANCY, adverse r,1
CIMZIA,MALIGNANCY,adverse r eactions incidence and,1
CIMZIA,MALIGNANCY,adverse r eactions incidence and,1
CIMZIA,MALIGNANCY,adverse,1
CIMZIA,INFECTIONS,,0
CIMZIA,INFECTIONS,% and high er,1
CIMZIA,INFECTIONS,,0
CIMZIA,INFECTIONS,% and high,1
CIMZIA,INFECTIONS,,0
CIMZIA,INFECTIONS,% and,1
CIMZIA,INFECTIONS,%,1
CIMZIA,MALIGNANCY,an placebo upper respiratory tract infection,1
CIMZIA,infections,infection To report SUSPECTED E REACTION S contact UCB Inc,1
CIMZIA,infections,report,0
CIMZIA,infections,SUSPECTED E,1
CIMZIA,infections,REACTION S contact UCB Inc,1
CIMZIA,infections,S,0
CIMZIA,infections,To report SUSPECTED E REACTION S contact UCB Inc,1
CIMZIA,infections,E REACTION S contact UCB Inc,1
CIMZIA,infections,,0
CIMZIA,infections,SUSPECTED E,1
CIMZIA,death,or wwwfdagovmedwatch,0
CIMZIA,death,REACTIONS contact UCB Inc 8,1
CIMZIA,death,most,0
CIMZIA,death,contact UCB Inc 8,1
CIMZIA,death,8,1
CIMZIA,death,wwwfdagovmedwatch,0
CIMZIA,death,UCB Inc 8 or  FDA at FDA or,1
CIMZIA,death,,0
CIMZIA,infections,se reactio ns were Serious Infections,1
CIMZIA,infections,se reactio ns were Serious Infections,1
CIMZIA,Active tuberculosis,der widely varying and controlled,0
CIMZIA,Active tuberculosis,,0
CIMZIA,Active tuberculosis,,0
CIMZIA,Active tuberculosis,,0
CIMZIA,Active tuberculosis,es are conducted un der widely varying and,1
CIMZIA,Active tuberculosis,see Warnings and Precautions,0
CIMZIA,Active tuberculosis,studi,0
CIMZIA,Active tuberculosis,and Precautions Because clinical es are conducted un der widely varying and,1
CIMZIA,Active tuberculosis,Precautions Because clinical es are conducted,1
CIMZIA,Active tuberculosis,are conducted un der widely varying and,1
CIMZIA,reactivation of latent tuberculosis,"controlled conditions, a dverse reaction rates observed",1
CIMZIA,reactivation of latent tuberculosis,,0
CIMZIA,reactivation of latent tuberculosis,"conducted under widely arying and controlled conditions, a dverse reaction rates observed",1
CIMZIA,reactivation of latent tuberculosis,"are conducted under widely arying and controlled conditions, a dverse reaction rates observed",1
CIMZIA,Invasive fungal infections,reactions were,0
CIMZIA,Invasive fungal infections,were upper,0
CIMZIA,histoplasmosis,rash and,0
CIMZIA,coccidioidomycosis,reactio ns were upper respiratory,1
CIMZIA,coccidioidomycosis,reactio ns were upper respiratory,1
CIMZIA,coccidioidomycosis,reactio ns were upper respiratory,1
CIMZIA,coccidioidomycosis,reactio ns were upper respiratory,1
CIMZIA,candidiasis,respiratory infections rash,0
CIMZIA,candidiasis,the most common adverse (>=,1
CIMZIA,candidiasis,combined the most,0
CIMZIA,candidiasis,rash and,0
CIMZIA,candidiasis,respiratory infections rash and urinary tract infections,0
CIMZIA,candidiasis,combined the most common adverse reactions,0
CIMZIA,candidiasis,we re upper respiratory infections,1
CIMZIA,candidiasis,adverse (>= 8%),1
CIMZIA,aspergillosis,reactions upper,1
CIMZIA,aspergillosis,infections Adverse Reactions,0
CIMZIA,blastomycosis,,0
CIMZIA,blastomycosis,infection s rash and urinary,1
CIMZIA,blastomycosis,ory infection s rash and urinary,1
CIMZIA,histoplasmosis,to Discontinuation of Treatment in,0
CIMZIA,histoplasmosis,rash and urinary  infections (8 Adverse Reactions Most Commonly,1
CIMZIA,histoplasmosis,,0
CIMZIA,invasive fungal infections,Discontinuation,0
CIMZIA,invasive fungal infections,tract Adverse,1
CIMZIA,Lymphoma,disease In,0
CIMZIA,Lymphoma,sa,0
CIMZIA,Lymphoma,,0
CIMZIA,Lymphoma,of patients with Crohns disease In,0
CIMZIA,Lymphoma,,0
CIMZIA,Lymphoma,Studies with,0
CIMZIA,malignancies,to MZIA at 400  mg subcutaneous dosing in,1
CIMZIA,malignancies,population,0
CIMZIA,malignancies,,0
CIMZIA,malignancies,data described,0
CIMZIA,malignancies,below reflect exposure to MZIA at,1
CIMZIA,malignancies,at 400 mg subcutaneous dosing in,1
CIMZIA,malignancies,exposure to MZIA,1
CIMZIA,malignancies,The data described below,0
CIMZIA,fatal,described,0
CIMZIA,fatal,utane ous dosing in studies,1
CIMZIA,fatal,utane ous dosing in studies,1
CIMZIA,fatal,utane ous dosing in studies,1
CIMZIA,INFECTIONS,to placebo in Study CD following,1
CIMZIA,INFECTIONS,,0
CIMZIA,INFECTIONS,placebo in Study CD following,1
CIMZIA,MALIGNANCY,randomized to placebo in tudy,1
CIMZIA,MALIGNANCY,of mg and subjects received placebo including subjects randomized to,0
CIMZIA,MALIGNANCY,to placebo in tudy CD2,1
CIMZIA,MALIGNANCY,randomized to placebo in tudy CD2 f ollowing open label dosing,1
CIMZIA,MALIGNANCY,placebo in tudy CD2 f ollowing open label dosing,1
CIMZIA,MALIGNANCY,to placebo in tudy CD2,1
CIMZIA,MALIGNANCY,tudy CD2 f ollowing open label dosing,1
CIMZIA,MALIGNANCY,and uncontrolled,0
CIMZIA,MALIGNANCY,in tudy CD2,1
CIMZIA,infections,,0
CIMZIA,infections,patients received mg CIMZIA,0
CIMZIA,infections,rece ived CIMZIA at some,1
CIMZIA,infections,rece ived CIMZIA at some,1
CIMZIA,infections,Weeks In controlled,0
CIMZIA,infections,rece ived CIMZIA at some,1
CIMZIA,death,,0
CIMZIA,death,w hom patients received mg,1
CIMZIA,death,,0
CIMZIA,death,w hom patients received mg,1
CIMZIA,death,,0
CIMZIA,death,dose of,1
CIMZIA,tuberculosis,rece ived mg CIMZIA Approximately,1
CIMZIA,tuberculosis,and uncontrolled studies patients,0
CIMZIA,tuberculosis,of whom p,0
CIMZIA,tuberculosis,whom atients,1
CIMZIA,tuberculosis,dose level of whom atients,1
CIMZIA,tuberculosis,level of whom atients,1
CIMZIA,tuberculosis,at some,0
CIMZIA,TB,patients ed mg CIMZIA Approximately of,1
CIMZIA,TB,ed mg CIMZIA Approximately of,1
CIMZIA,TB,male and were Caucasian Th,0
CIMZIA,TB,ed mg CIMZIA Approximately of,1
CIMZIA,TB,,0
CIMZIA,TB,ed mg CIMZIA Approximately of,1
CIMZIA,TB,CIMZIA at some dose level of whom,0
CIMZIA,TB,ed mg CIMZIA Approximately of,1
CIMZIA,TB,and,0
CIMZIA,bacterial sepsis,some,0
CIMZIA,bacterial sepsis,of whom patients received,0
CIMZIA,bacterial sepsis,level of whom patients 0 mg,1
CIMZIA,bacterial sepsis,0 mg,1
CIMZIA,bacterial sepsis,,0
CIMZIA,invasive fungal infections,patients received mg CIMZIA ximately 55%,1
CIMZIA,invasive fungal infections,mg CIMZIA ximately 55% of,1
CIMZIA,invasive fungal infections,patients received mg CIMZIA ximately 55% of subjects,1
CIMZIA,histoplasmosis,"of subjects were , 45%",1
CIMZIA,histoplasmosis,"of subjects were , 45% were",1
CIMZIA,histoplasmosis,45% were mal e and were Caucasian,1
CIMZIA,histoplasmosis,the ages of,0
CIMZIA,histoplasmosis,"Approximately of subjects were , 45%",1
CIMZIA,histoplasmosis,The majority,0
CIMZIA,histoplasmosis,,0
CIMZIA,histoplasmosis,mal e and were Caucasian,1
CIMZIA,histoplasmosis,"Approximately of subjects were , 45% were mal e and were Caucasian",1
CIMZIA,histoplasmosis,"Approximately of subjects were , 45% were mal e and were Caucasian",1
CIMZIA,infections due to other opportunistic pathogens,in the active group were,1
CIMZIA,Lymphoma,compared to,0
CIMZIA,Lymphoma,occurring in of CIMZIAtreated patients and with,0
CIMZIA,Lymphoma,with,0
CIMZIA,Lymphoma,to acebo) i n controlled clinical studies,1
CIMZIA,Lymphoma,to acebo) i n controlled clinical studies,1
CIMZIA,Lymphoma,occurring in of CIMZIAtreated patients and with,0
CIMZIA,Lymphoma,higher incidence compared,0
CIMZIA,Lymphoma,acebo) i n controlled clinical studies,1
CIMZIA,Lymphoma,to acebo) i n controlled clinical studies,1
CIMZIA,malignancies,s tudies with CIMZIA were,1
CIMZIA,malignancies,compared to placebo in d clinical,1
CIMZIA,malignancies,eg nasopharyngitis,0
CIMZIA,malignancies,CIMZIA were upper respiratory,0
CIMZIA,malignancies,clinical s tudies with CIMZIA were,1
CIMZIA,malignancies,compared to placebo in d clinical,1
CIMZIA,malignancies,compared to placebo in d clinical s tudies with CIMZIA were,1
CIMZIA,malignancies,to placebo in d clinical s tudies with CIMZIA were,1
CIMZIA,malignancies,d clinical s tudies with CIMZIA were,1
CIMZIA,fatal,with  CIMZIA were upper respiratory,1
CIMZIA,fatal,with  CIMZIA were upper respiratory,1
CIMZIA,fatal,,0
CIMZIA,fatal,controlled clinical with  CIMZIA were upper respiratory,1
CIMZIA,fatal,with  CIMZIA were upper respiratory,1
CIMZIA,fatal,incidence compared to placebo in controlled,0
CIMZIA,fatal,laryngitis viral,0
CIMZIA,infections,reaction s incidence and higher,1
CIMZIA,infections,,0
CIMZIA,infections,,0
CIMZIA,infections,,0
CIMZIA,infections,,0
CIMZIA,Invasive fungal infections,,0
CIMZIA,Invasive fungal infections,"SUSPECTED ADVERSE TIONS,",1
CIMZIA,Invasive fungal infections,,0
CIMZIA,Invasive fungal infections,"To report SUSPECTED ADVERSE TIONS, contact UCB, Inc. a t or FDA at FDA",1
CIMZIA,Invasive fungal infections,"UCB, Inc. a t or FDA at FDA",1
CIMZIA,Invasive fungal infections,"SUSPECTED ADVERSE TIONS, contact",1
CIMZIA,lymphoma,Serious Infections see rnings a nd Precautions Malignancies see Warnings,1
CIMZIA,lymphoma,,0
CIMZIA,lymphoma,Serious Infections see rnings a nd Precautions Malignancies see Warnings,1
CIMZIA,malignancies,Warnings and ons (5.1)  ] Malignancies see Warnings and Precautions,1
CIMZIA,malignancies,see Warnings and ons (5.1),1
CIMZIA,malignancies,and,0
CIMZIA,malignancies,,0
CIMZIA,malignancies,see,0
CIMZIA,malignancies,] Malignancies see Warnings and Precautions,1
CIMZIA,"Heart failure, worsening",Precautions Heart ailure [see  Warnings an d Precautions Because clinical studies,1
CIMZIA,"Heart failure, worsening",Heart ailure [see  Warnings an d Precautions Because clinical studies,1
CIMZIA,"Heart failure, worsening",studies,0
CIMZIA,"Heart failure, worsening",ailure [see Warnings an d Precautions Because clinical studies,1
CIMZIA,"Heart failure, worsening",ailure [see Warnings an d Precautions Because clinical studies,1
CIMZIA,Anaphylaxis,inical,1
CIMZIA,Anaphylaxis,inical,1
CIMZIA,Anaphylaxis,Warnings,0
CIMZIA,Anaphylaxis,under widely varying and controlled,0
CIMZIA,Anaphylaxis,inical stud ies are conducted under widely,1
CIMZIA,allergic reactions,clinical studies are ucted under widely varying and controlled conditions adverse,1
CIMZIA,allergic reactions,reaction rates observed in,0
CIMZIA,allergic reactions,Precautions Because clinical,0
CIMZIA,allergic reactions,Because clinical studies are ucted under widely varying and controlled conditions adverse,1
CIMZIA,allergic reactions,studies are ucted under,1
CIMZIA,allergic reactions,and Precautions Because clinical,0
CIMZIA,allergic reactions,see Warnings,0
CIMZIA,allergic reactions,conditions adverse reaction rates observed in clinical studies of a drug,0
CIMZIA,Hepatitis B virus reactivation,co,0
CIMZIA,Hepatitis B virus reactivation,clinical studies of a drug cannot,0
CIMZIA,Hepatitis B virus reactivation,rat es observed in clinical studies,1
CIMZIA,Hepatitis B virus reactivation,"widely varying and controlled nditions, adverse",1
CIMZIA,Hepatitis B virus reactivation,"varying and controlled nditions, adverse reaction rat es observed in clinical studies",1
CIMZIA,Hepatitis B virus reactivation,conducted under widely,0
CIMZIA,Hepatitis B virus reactivation,"controlled nditions, adverse reaction rat es observed in clinical studies",1
CIMZIA,Hepatitis B virus reactivation,Because clinical studies are conducted under widely varying and controlled co,0
CIMZIA,Hepatitis B virus reactivation,"and controlled nditions, adverse reaction",1
CIMZIA,Cytopenias,reactions were upper respiratory infections,0
CIMZIA,Cytopenias,opulations combined the most common adverse,1
CIMZIA,Cytopenias,reactions were upper respiratory infections,0
CIMZIA,Cytopenias,opulations combined the most common adverse,1
CIMZIA,Cytopenias,,0
CIMZIA,Cytopenias,premarketing controlled trials of all patient,0
CIMZIA,pancytopenia,c,0
CIMZIA,pancytopenia,,0
CIMZIA,pancytopenia,premarketing controlled trials of all,0
CIMZIA,pancytopenia,all patient populations ombined the  most common adverse reactions were,1
CIMZIA,pancytopenia,ombined the  most common adverse reactions were,1
CIMZIA,pancytopenia,ombined the most common adverse reactions were,1
CIMZIA,pancytopenia,populations ombined,1
CIMZIA,Lupus-like syndrome,%). Adverse Reactions Most Commonly Leading to,1
CIMZIA,Lupus-like syndrome,to Discontinuation of Treatment in Premarketing,0
CIMZIA,Lupus-like syndrome,"and urinary tract %).



     Adverse Reactions Most Commonly Leading to",1
CIMZIA,infections,disease who discontinued treatment due to,0
CIMZIA,infections,ons,1
CIMZIA,infections,the controlled clinical studies was for,1
CIMZIA,infections,treatment due to adverse ons in the controlled clinical studies was for,1
CIMZIA,infections,ons,1
CIMZIA,death,at,0
CIMZIA,death,the controlled clinical studies,0
CIMZIA,death,a dverse reactions leading to the,1
CIMZIA,death,higher,0
CIMZIA,death,,0
CIMZIA,death,to,0
CIMZIA,death,CIMZIA and,0
CIMZIA,death,controlled clinical studies was,0
CIMZIA,death,a dverse reactions leading to the,1
CIMZIA,aspergillosis,in,1
CIMZIA,aspergillosis,patients and,0
CIMZIA,aspergillosis,in,1
CIMZIA,aspergillosis,than placebo were abdominal,0
CIMZIA,blastomycosis,0.2% placeb o diarrhea CIMZIA placebo and,1
CIMZIA,candidiasis,CIMZIA placebo The proportion,0
CIMZIA,candidiasis,"pain CIMZIA ,",1
CIMZIA,candidiasis,a higher incidence than placebo were,0
CIMZIA,candidiasis,",",1
CIMZIA,candidiasis,,0
CIMZIA,coccidioidomycosis,,0
CIMZIA,coccidioidomycosis,,0
CIMZIA,coccidioidomycosis,placebo diarrhea,0
CIMZIA,coccidioidomycosis,and intestinal obstruction,0
CIMZIA,coccidioidomycosis,and intestinal obstruction CIMZIA placebo The proportion of patients,0
CIMZIA,coccidioidomycosis,incidence than placebo were abdominal,0
CIMZIA,coccidioidomycosis,patients with,0
CIMZIA,coccidioidomycosis,pain CIMZIA placebo .4%,1
CIMZIA,coccidioidomycosis,pain CIMZIA placebo,0
CIMZIA,histoplasmosis,,0
CIMZIA,histoplasmosis,"CIMZIA bo), and intes tinal obstruction CIMZIA placebo The",1
CIMZIA,histoplasmosis,,0
CIMZIA,histoplasmosis,"bo),",1
CIMZIA,histoplasmosis,"CIMZIA placebo diarrhea CIMZIA bo), and intes tinal obstruction CIMZIA placebo The",1
CIMZIA,legionellosis,CIMZIA placebo and,0
CIMZIA,legionellosis,obstructi on CIMZIA placebo The proportion,1
CIMZIA,legionellosis,The proportion of patients with rheumatoid arthritis who,0
CIMZIA,listeriosis,,0
CIMZIA,listeriosis,placebo and intestinal  (0.4% CIMZ IA placebo The proportion of,1
CIMZIA,listeriosis,and intestinal (0.4%,1
CIMZIA,listeriosis,,0
CIMZIA,listeriosis,(0.4% CIMZ IA placebo The proportion of,1
CIMZIA,listeriosis,CIMZ IA placebo The proportion of,1
CIMZIA,listeriosis,and intestinal  (0.4% CIMZ IA placebo The proportion of,1
CIMZIA,listeriosis,pain CIMZIA placebo diarrhea CIMZIA placebo and intestinal,0
CIMZIA,listeriosis, (0.4% CIMZ IA placebo The proportion of,1
CIMZIA,listeriosis,patients with rheumatoid arthritis who,0
CIMZIA,pneumocystosis,placebo). The proportion of patients with,1
CIMZIA,pneumocystosis,"and intestinal obstruction ,",1
CIMZIA,pneumocystosis,,0
CIMZIA,pneumocystosis,", 0% placebo). The proportion of patients with",1
CIMZIA,pneumocystosis,placebo diarrhea CIMZIA placebo and,0
CIMZIA,pneumocystosis,0% placebo). The proportion of patients with,1
CIMZIA,pneumocystosis,placebo,0
CIMZIA,pneumocystosis,0% placebo). The proportion of patients with,1
CIMZIA,tuberculosis,who discontinued treatment due to adverse,0
CIMZIA,reactivation of tuberculosis,,0
CIMZIA,reactivation of tuberculosis,The majority of patients in the active group were between the ages of,0
CIMZIA,reactivation of tuberculosis,of patients in the active,0
CIMZIA,reactivation of tuberculosis,"were emale, 45% were male, and 94 were Caucasian The majority of",1
CIMZIA,tuberculosis infections,majority of patients in the active,1
CIMZIA,tuberculosis infections,female were male and were C,0
CIMZIA,tuberculosis infections,were female were male and,0
CIMZIA,tuberculosis infections,C,0
CIMZIA,tuberculosis infections,CIMZIA Approximately of subjects were female were male,0
CIMZIA,tuberculosis infections,female were,0
CIMZIA,tuberculosis infections,Approximately of subjects were female were,0
CIMZIA,malignancies,Placebo-Cont rolled Period of Rheumatoid Arthritis,1
CIMZIA,malignancies,Placebo-Cont rolled Period of Rheumatoid Arthritis,1
CIMZIA,malignancies,Period of Rheumatoid Arthritis Studies with Concomitant Methotrexate,0
CIMZIA,malignancies,with CIMZIA Dosed Every,0
CIMZIA,malignancies,Other Week,0
CIMZIA,malignancies,Adverse,0
CIMZIA,malignancies,,0
CIMZIA,malignancies,Placebo MTXN CIMZIA mg EOW MTXN,0
CIMZIA,malignancies,MTXN,0
CIMZIA,malignancies,EOW Upper,1
CIMZIA,malignancies,"EOW  
 Upper res piratory tract infection",1
CIMZIA,malignancies,EOW Upper,1
CIMZIA,non-melanoma skin cancer,,0
CIMZIA,non-melanoma skin cancer,infection Headache,1
CIMZIA,non-melanoma skin cancer,,0
CIMZIA,non-melanoma skin cancer,,0
CIMZIA,Malignancies,   5        ,1
CIMZIA,Malignancies,Nasopharyngitis,0
CIMZIA,Malignancies,,0
CIMZIA,Malignancies,Nasopharyngitis,0
CIMZIA,lymphomas,Ras,0
CIMZIA,non-Hodgkin's lymphoma,               1       Rash,1
CIMZIA,non-Hodgkin's lymphoma,Pharyngitis,0
CIMZIA,malignancies,,0
CIMZIA,malignancies,             Acute,1
CIMZIA,malignancies,Rash              Acute,1
CIMZIA,malignancies,,0
CIMZIA,malignancies,Rash,0
CIMZIA,malignancies,,0
CIMZIA,malignancies,,0
CIMZIA,malignancies,Acute,0
CIMZIA,malignancies,             Acute b,1
CIMZIA,rare malignancies,Rash                   Acute,1
CIMZIA,rare malignancies,Rash,0
CIMZIA,rare malignancies,                  Acute bronchitis,1
CIMZIA,rare malignancies,                 ,1
CIMZIA,rare malignancies,                  Acute bronchitis,1
CIMZIA,rare malignancies,                  Acute bronchitis,1
CIMZIA,rare malignancies,Acute,0
CIMZIA,malignancies,Rash              Acute,1
CIMZIA,malignancies,Rash,0
CIMZIA,malignancies,             Acute bronchitis,1
CIMZIA,malignancies,Rash             ,1
CIMZIA,malignancies,bronchitis,0
CIMZIA,malignancies,,0
CIMZIA,malignancies,Rash              Acute bronchitis,1
CIMZIA,malignancies,,0
CIMZIA,malignancies,             Acute,1
CIMZIA,malignancies,             Fatigue,1
CIMZIA,malignancies,             Fatigue,1
CIMZIA,malignancies,,0
CIMZIA,malignancies,Fatigue,0
CIMZIA,malignancies,             Fatigue,1
CIMZIA,lymphoma,eiving C IMZIA,1
CIMZIA,lymphoma,eiving,1
CIMZIA,lymphoma,had similar adverse,0
CIMZIA,lymphoma,had similar adverse,0
CIMZIA,lymphoma,other week Other Adverse Reactions Other infrequent,0
CIMZIA,lymphoma,controlled clinical trials,0
CIMZIA,lymphoma,,0
CIMZIA,lymphoma,,0
CIMZIA,lymphoma,every other week Other,0
CIMZIA,Hodgkin's lymphoma,,0
CIMZIA,Hodgkin's lymphoma,reactions to those patients receiving CIMZIA mg every other,0
CIMZIA,Hodgkin's lymphoma,to thos,0
CIMZIA,Hodgkin's lymphoma,,0
CIMZIA,Hodgkin's lymphoma,e,1
CIMZIA,lymphoma,,0
CIMZIA,lymphoma,seen in Crohns disease,0
CIMZIA,lymphoma,been studied in patients,0
CIMZIA,lymphoma,"
     Ps oriatic",1
CIMZIA,lymphoma,similar to the ty,1
CIMZIA,lymphoma,similar to the ty profi le,1
CIMZIA,lymphoma,ty profi le,1
CIMZIA,lymphoma,seen in patients with RA Infections,0
CIMZIA,hepatosplenic T-cell lymphoma,infec,0
CIMZIA,hepatosplenic T-cell lymphoma,,0
CIMZIA,hepatosplenic T-cell lymphoma,infections for CIMZIA for placebo The incidence of serious infections,0
CIMZIA,hepatosplenic T-cell lymphoma,patients The tions,1
CIMZIA,fatal,incidence of serious s,1
CIMZIA,fatal,the controlled clinical studies was per patientyear,0
CIMZIA,fatal,studies was per patientyear for CIMZIAtreated patients and for,0
CIMZIA,fatal,clinical studies was per patientyear for,0
CIMZIA,fatal,serious infection,0
CIMZIA,chronic leukemia,,0
CIMZIA,chronic leukemia,new cases of serious fection adverse  reactions,1
CIMZIA,chronic leukemia,new cases of serious fection,1
CIMZIA,chronic leukemia,cases of serious fection,1
CIMZIA,chronic leukemia,rheumatoid arthritis studies there were more,0
CIMZIA,worsening congestive heart failure,more than one subject,0
CIMZIA,worsening congestive heart failure,", no serious infection occurred in more",1
CIMZIA,worsening congestive heart failure,"In the placebo , no serious infection",1
CIMZIA,worsening congestive heart failure,"the placebo , no serious",1
CIMZIA,worsening congestive heart failure,"the placebo , no serious",1
CIMZIA,worsening congestive heart failure,no serious infection occurred in more,1
CIMZIA,worsening congestive heart failure,Tuberculosis and Opportunistic Infections n completed,1
CIMZIA,worsening congestive heart failure,Tuberculosis and Opportunistic Infections I,0
CIMZIA,worsening congestive heart failure,Opportunistic Infections n completed and ongoing global cli nical,1
CIMZIA,worsening congestive heart failure,ongoing global cli nical,1
CIMZIA,increased mortality,,0
CIMZIA,increased mortality,and ongoing global clinical es in all indicatio ns,1
CIMZIA,increased mortality,,0
CIMZIA,increased mortality,global clinical es in all indicatio ns,1
CIMZIA,increased mortality,and Opportunistic,0
CIMZIA,increased mortality,es in all indicatio ns,1
CIMZIA,increased mortality,CIMZIAtreated patients the overall rate of,0
CIMZIA,CHF,,0
CIMZIA,CHF,completed and ongoing global clinical studies in all indications,0
CIMZIA,CHF,patients the overall rate of tuberculosis is approximately per pati,0
CIMZIA,CHF,,0
CIMZIA,CHF,tuberculosis is,0
CIMZIA,CHF,all indications,0
CIMZIA,CHF,per,0
CIMZIA,hypersensitivity reactions,"ude cases of miliary, lymp hatic",1
CIMZIA,hypersensitivity reactions,ude cases,1
CIMZIA,angioedema,median time to onset TB for all patients,1
CIMZIA,angioedema,peritoneal,0
CIMZIA,angioedema,TB for all patients,1
CIMZIA,angioedema,for all patients,1
CIMZIA,angioedema,onset TB for all patients,1
CIMZIA,angioedema,to onset TB for all patients,1
CIMZIA,angioedema,TB,0
CIMZIA,angioedema,,0
CIMZIA,dyspnea,time to,0
CIMZIA,dyspnea,the studies with CIMZIA in RA there,0
CIMZIA,dyspnea,all atients exposed,1
CIMZIA,dyspnea,time to onset,0
CIMZIA,dyspnea,TB,0
CIMZIA,dyspnea,were,0
CIMZIA,dyspnea,atients exposed,1
CIMZIA,dyspnea,studies with CIMZIA in RA there were,0
CIMZIA,hypotension,RA there were cases of,0
CIMZIA,hypotension,TB for all patients xposed to C IMZIA,1
CIMZIA,hypotension,,0
CIMZIA,hypotension,to C IMZIA,1
CIMZIA,hypotension,for all patients xposed to,1
CIMZIA,hypotension,xposed to C IMZIA,1
CIMZIA,hypotension,The median time to onset of TB for,0
CIMZIA,hypotension,,0
CIMZIA,hypotension,were cases,0
CIMZIA,hypotension,,0
CIMZIA,rash,ZIA  across,1
CIMZIA,rash,all patients exposed to ZIA  across,1
CIMZIA,serum sickness,,0
CIMZIA,serum sickness,well as pulmonary TB The median,0
CIMZIA,serum sickness,,0
CIMZIA,serum sickness,ross all indic ations,1
CIMZIA,serum sickness,patients exposed to CIMZIA ross all,1
CIMZIA,serum sickness,indic ations,1
CIMZIA,serum sickness,with CIMZIA in RA there were cases of TB among exposed,0
CIMZIA,serum sickness,there were cases of,0
CIMZIA,urticaria,345 days,1
CIMZIA,urticaria,all was,1
CIMZIA,urticaria,345 days,1
CIMZIA,reactivation of hepatitis B virus,observed among patients receiving ose TNF blockers compared to cont rol,1
CIMZIA,reactivation of hepatitis B virus,of malignancies have been observed among,0
CIMZIA,reactivation of hepatitis B virus,among patients receiving ose TNF blockers compared to cont rol,1
CIMZIA,reactivation of hepatitis B virus,,0
CIMZIA,HBV reactivation,Heart ailure,1
CIMZIA,fatal,"dies, cases",1
CIMZIA,fatal,The majorit,0
CIMZIA,fatal,In placebocontrolled and openlabel rheumatoid arthritis,0
CIMZIA,HBV reactivation,moderate and occurred ng the first yea r,1
CIMZIA,HBV reactivation,were mild to moderate and,0
CIMZIA,HBV reactivation,to moderate and occurred duri,0
CIMZIA,HBV reactivation,ng the first yea r,1
CIMZIA,HBV reactivation,,0
CIMZIA,HBV reactivation,yea r,1
CIMZIA,HBV reactivation,ng the first yea r,1
CIMZIA,central nervous system demyelinating disease,treated with t immunosuppressants had a lower,1
CIMZIA,central nervous system demyelinating disease,efficacy was observed Patients treated with concomitan,0
CIMZIA,central nervous system demyelinating disease,immunosuppressants at baseline and,0
CIMZIA,central nervous system demyelinating disease,,0
CIMZIA,multiple sclerosis,rate of antibody pment than patient s,1
CIMZIA,multiple sclerosis,antibody pment,1
CIMZIA,multiple sclerosis,lower rate of antibody pment than patient s,1
CIMZIA,multiple sclerosis,had a,0
CIMZIA,peripheral demyelinating disease,g immunosuppressants,1
CIMZIA,peripheral demyelinating disease,g immunosuppressants at,1
CIMZIA,peripheral demyelinating disease,than patients not g immunosuppressants at baseline and,1
CIMZIA,Guillain-Barre syndrome,"at baseline , respectively). The fo llowing",1
CIMZIA,Guillain-Barre syndrome,"at baseline ,",1
CIMZIA,Guillain-Barre syndrome,were,0
CIMZIA,Guillain-Barre syndrome,"at baseline , respectively).",1
CIMZIA,Guillain-Barre syndrome,llowing adverse events were reported in Crohns disease patients who were,0
CIMZIA,Guillain-Barre syndrome,of antibody development than patients not taking immunosuppressants at,0
CIMZIA,Guillain-Barre syndrome,The fo llowing,1
CIMZIA,neurological disorders,"= 1,242): abdomina l",1
CIMZIA,neurological disorders," (N = 1,242): abdomina l",1
CIMZIA,neurological disorders,"1,242): abdomina l",1
CIMZIA,neurological disorders,an incidence at,0
CIMZIA,neurological disorders,(N =,1
CIMZIA,neurological disorders,"1,242): abdomina l",1
CIMZIA,neurological disorders,at an incidence at least,0
CIMZIA,neurological disorders,compared to antibodynegative (N,1
CIMZIA,optic neuritis,edema peri,0
CIMZIA,optic neuritis,"abdominal pain arthralgia edema pheral,",1
CIMZIA,optic neuritis,,0
CIMZIA,optic neuritis,site pain pain in extremity and upper respiratory t,0
CIMZIA,optic neuritis,patients N abdominal,0
CIMZIA,optic neuritis,"pheral,",1
CIMZIA,optic neuritis,"pain arthralgia edema pheral,",1
CIMZIA,optic neuritis,erythe ma,1
CIMZIA,optic neuritis,in extremity and upper respiratory t,0
CIMZIA,peripheral neuropathy,site pain pain in extremity and upper respiratory,0
CIMZIA,peripheral neuropathy,"osum, injection site erythema",1
CIMZIA,peripheral neuropathy,,0
CIMZIA,peripheral neuropathy,"arthralgia edema peripheral erythema osum, injection site  erythema",1
CIMZIA,peripheral neuropathy,pain,0
CIMZIA,peripheral neuropathy,patients N abdominal pain arthralgia edema peripheral erythema,0
CIMZIA,peripheral neuropathy,antibodynegative patients N abdominal pain arthralgia edema,0
CIMZIA,peripheral neuropathy,N abdominal pain arthralgia edema peripheral,0
CIMZIA,pancytopenia,The overall percentage,0
CIMZIA,pancytopenia,certolizu mab,1
CIMZIA,pancytopenia,with to certolizu mab,1
CIMZIA,pancytopenia,rheumatoid arthritis plac,0
CIMZIA,pancytopenia,detectable on at least one occasion was of in the rheumatoid,0
CIMZIA,pancytopenia,tract infection The overall percentage of patients with,0
CIMZIA,pancytopenia,upper respiratory tract infection,0
CIMZIA,pancytopenia,least one occasion was of,0
CIMZIA,pancytopenia,patients with to certolizu mab,1
CIMZIA,Adverse reactions of the hematologic system,one occasion was in,1
CIMZIA,Adverse reactions of the hematologic system,to certolizumab pegol detectable on at least one,0
CIMZIA,Adverse reactions of the hematologic system,occasion was in,1
CIMZIA,Adverse reactions of the hematologic system,least one occasion was in the rheumatoid arthritis,1
CIMZIA,Adverse reactions of the hematologic system,rheumatoid arthritis placebo-contro lled,1
CIMZIA,Adverse reactions of the hematologic system,was of,0
CIMZIA,Adverse reactions of the hematologic system,at,0
CIMZIA,Adverse reactions of the hematologic system,was of,0
CIMZIA,Adverse reactions of the hematologic system,these patients,0
CIMZIA,Adverse reactions of the hematologic system,one,0
CIMZIA,cytopenia,"trials Approximately one rd (3%,",1
CIMZIA,cytopenia,in the rheumatoid,0
CIMZIA,leukopenia,trials Approximately one third 09) of the se,1
CIMZIA,leukopenia,Approximately one third 09) of the se,1
CIMZIA,pancytopenia,rheumatoid arthritis placebocontrolled,0
CIMZIA,pancytopenia,of of  patients ha d,1
CIMZIA,pancytopenia,of of  patients ha d,1
CIMZIA,pancytopenia,Approximately one third of of these,0
CIMZIA,pancytopenia,ha d,1
CIMZIA,pancytopenia,of patients,1
CIMZIA,pancytopenia,placebocontrolled trials Approximately,0
CIMZIA,pancytopenia,of of patients,1
CIMZIA,pancytopenia,patients,1
CIMZIA,thrombocytopenia,patients antibodies,1
CIMZIA,thrombocytopenia,of of these patients antibodies,1
CIMZIA,thrombocytopenia,concomitant immunosuppressants,0
CIMZIA,thrombocytopenia,one,0
CIMZIA,infections,patients,0
CIMZIA,infections,allow for meaningful analysis of ACR response by,0
CIMZIA,infections,In Study RAIII too few patients,0
CIMZIA,infections,,0
CIMZIA,infections,few patients d,1
CIMZIA,infections,Study RAIV,0
CIMZIA,infections,few patients d,1
CIMZIA,infections,,0
CIMZIA,infections,too few patients d antibodi es,1
CIMZIA,infections,too few patients d antibodi es,1
CIMZIA,formation of autoantibodies,ibodies to,1
CIMZIA,formation of autoantibodies,positive for ibodies,1
CIMZIA,formation of autoantibodies,were considered positive for ibodies to,1
CIMZIA,lupus-like syndrome,highly ent on the sensitiv ity,1
CIMZIA,lupus-like syndrome,ELISA and are highly ent on the sensitiv ity,1
CIMZIA,lupus-like syndrome,highly ent,1
CIMZIA,lupus-like syndrome,highly ent on,1
CIMZIA,lupus-like syndrome,are highly ent on the sensitiv ity,1
CIMZIA,lupus-like syndrome,an ELISA and are,0
CIMZIA,lupus-like syndrome,incidence of antibody,0
CIMZIA,lupus-like syndrome,and are highly ent on the sensitiv ity,1
CIMZIA,lupus-like syndrome,are highly,0
CIMZIA,lupus-like syndrome,and are highly ent on the sensitiv ity,1
GRANIX,Splenic Rupture,Rupture see,1
GRANIX,Splenic Rupture,adverse,0
GRANIX,Splenic Rupture,Syndrome see,0
GRANIX,Splenic Rupture,,0
GRANIX,Acute Respiratory Distress Syndrome,Acute Respiratory Distress Syndrome see,1
GRANIX,Acute Respiratory Distress Syndrome,Warnings,0
GRANIX,Acute Respiratory Distress Syndrome,Splenic,0
GRANIX,Acute Respiratory Distress Syndrome,,0
GRANIX,Acute Respiratory Distress Syndrome,Rupture see Warnings and,0
GRANIX,Allergic Reactions,Precautions Serious,0
GRANIX,Allergic Reactions,and Precautions Use in Patients with,0
GRANIX,Capillary Leak Syndrome,Syndrome see,1
GRANIX,Capillary Leak Syndrome,see Warnings and Precautions Potential,0
GRANIX,Capillary Leak Syndrome,and Precautions,0
GRANIX,Capillary Leak Syndrome,Capillary Leak Syndrome see,1
GRANIX,Capillary Leak Syndrome,Disease see Warnings and Precautions,0
GRANIX,Capillary Leak Syndrome,,0
GRANIX,Capillary Leak Syndrome,see Warnings and Capillary Leak,1
GRANIX,Capillary Leak Syndrome,and Capillary Leak,1
GRANIX,Capillary Leak Syndrome,see Warnings and Capillary Leak Syndrome see,1
GRANIX,Capillary Leak Syndrome,see Warnings and Precautions,0
GRANIX,Tumor Growth Stimulatory Effects on Malignant Cells,for,0
GRANIX,Tumor Growth Stimulatory Effects on Malignant Cells,,0
GRANIX,Tumor Growth Stimulatory Effects on Malignant Cells,,0
GRANIX,Tumor Growth Stimulatory Effects on Malignant Cells,see Warnings and Precautions The most,0
GRANIX,Tumor Growth Stimulatory Effects on Malignant Cells,Potential Tumor Growth Stimulatory Effects on Malignant,1
GRANIX,Tumor Growth Stimulatory Effects on Malignant Cells,,0
GRANIX,bone pain,frequent than in the placebo group was,0
GRANIX,bone pain,bone,1
GRANIX,bone pain,report,0
GRANIX,bone pain,group bone pain EXCERPT,1
GRANIX,bone pain,group,0
GRANIX,bone pain,frequent than in the placebo group was,0
GRANIX,bone pain,bone pain To,0
GRANIX,bone pain,at the recommended,0
GRANIX,bone pain,pain EXCERPT,1
GRANIX,bone pain,pain To,1
GRANIX,bone pain,,0
GRANIX,bone pain,To report,0
GRANIX,bone pain,bone pain,0
GRANIX,bone pain,adverse reaction to GRANIX bone pain To,1
GRANIX,Bone pain,L after nadir was Bone pain was,1
GRANIX,Bone pain,pain was,1
GRANIX,Bone pain,that,0
GRANIX,Bone pain,nadir was Bone pain was,1
GRANIX,Bone pain,treatmentemergent adverse reaction that occurred in at,0
GRANIX,Bone pain,most frequent treatmentemergent adverse reaction that occurred in at,0
GRANIX,Bone pain,was Bone,1
GRANIX,Bone pain,Bone pain was,1
GRANIX,bone pain,bone pain in,1
GRANIX,bone pain,treatment was,0
GRANIX,bone pain,of treatment was GRANIX placebo nonUSapproved filgrastim,0
GRANIX,bone pain,placebo nonUSapproved filgrastim,0
GRANIX,leukocytosis,leukocytosis WBC,1
GRANIX,leukocytosis,In clinical leukocytosis WBC,1
GRANIX,"WBC counts > 100,000 x 10 6 /L",complicat,0
GRANIX,"WBC counts > 100,000 x 10 6 /L",10 6 /L was,1
GRANIX,"WBC counts > 100,000 x 10 6 /L",,0
GRANIX,"WBC counts > 100,000 x 10 6 /L",product Leukocytosis,0
GRANIX,"WBC counts > 100,000 x 10 6 /L","WBC counts > 100,000 x 10  6  /L was",1
GRANIX,leukocytosis,,0
GRANIX,leukocytosis,leukocytosis were,1
GRANIX,leukocytosis,studies Additional Adverse Reactions Other adverse,0
GRANIX,leukocytosis,No complications attributable,0
GRANIX,leukocytosis,leukocytosis were,1
GRANIX,leukocytosis,leukocytosis were,1
GRANIX,leukocytosis,studies Additional Adverse,0
GRANIX,leukocytosis,attributable to,0
GRANIX,leukocytosis,patients with nonmyeloid malignancies,0
GRANIX,leukocytosis,leukocytosis were,1
GRANIX,headache,include headache vomiting,1
GRANIX,headache,headache vomiting,1
GRANIX,headache,Sweets syndrome,0
GRANIX,headache,headache vomiting,1
GRANIX,headache,headache vomiting,1
GRANIX,headache,headache vomiting,1
GRANIX,headache,headache vomiting,1
GRANIX,headache,cutaneous vasculitis and throm,0
GRANIX,vomiting,Sweets syndrome acute febrile neutrophilic dermatosis cutaneous vasculitis and thrombocytopeni,0
GRANIX,vomiting,factors include myalgia vomiting Sweets,1
GRANIX,vomiting,vomiting Sweets,1
GRANIX,vomiting,include myalgia vomiting Sweets,1
GRANIX,vomiting,vomiting Sweets,1
GRANIX,vomiting,vomiting Sweets,1
GRANIX,vomiting,vomiting Sweets,1
GRANIX,vomiting,vomiting Sweets,1
GRANIX,vomiting,vomiting Sweets,1
GRANIX,vomiting,vomiting Sweets,1
GRANIX,Sweet's syndrome,include myalgia headache Sweet's syndrome acute,1
GRANIX,Sweet's syndrome,human granulocyte colonystimulating factors,0
GRANIX,acute febrile neutrophilic dermatosis,syndrome,0
GRANIX,acute febrile neutrophilic dermatosis,febrile neutrophilic dermatosis cutaneous,1
GRANIX,acute febrile neutrophilic dermatosis,,0
GRANIX,acute febrile neutrophilic dermatosis,with all,0
GRANIX,acute febrile neutrophilic dermatosis,syndrome,0
GRANIX,acute febrile neutrophilic dermatosis,include,0
GRANIX,acute febrile neutrophilic dermatosis,acute febrile neutrophilic,1
GRANIX,acute febrile neutrophilic dermatosis,granulocyte colonystimulating factors include myalgia headache vomiting,0
GRANIX,acute febrile neutrophilic dermatosis,acute febrile neutrophilic dermatosis cutaneous,1
GRANIX,acute febrile neutrophilic dermatosis,acute febrile neutrophilic dermatosis cutaneous,1
GRANIX,cutaneous vasculitis,cutaneous,1
GRANIX,cutaneous vasculitis,febrile,0
GRANIX,cutaneous vasculitis,syndrome acute febrile,0
GRANIX,cutaneous vasculitis,and,0
GRANIX,cutaneous vasculitis,therapeutic proteins there,0
GRANIX,cutaneous vasculitis,syndrome acute febrile neutrophilic cutaneous,1
GRANIX,cutaneous vasculitis,syndrome,0
GRANIX,cutaneous vasculitis,vasculitis and,1
GRANIX,thrombocytopenia,neutrophilic dermatosis,0
GRANIX,Splenic Rupture,ious adverse re actions are discussed in greater,1
GRANIX,Splenic Rupture,adverse re,1
GRANIX,Splenic Rupture,ious adverse,1
GRANIX,Splenic Rupture,adverse re,1
GRANIX,Splenic Rupture,,0
GRANIX,Splenic Rupture,Rupture s,0
GRANIX,Splenic Rupture,,0
GRANIX,Acute Respiratory Distress Syndrome,"detail in other ctions of the labeling:



  Spleni",1
GRANIX,Acute Respiratory Distress Syndrome,,0
GRANIX,Acute Respiratory Distress Syndrome,Warnings and Precautions Acute,0
GRANIX,Acute Respiratory Distress Syndrome,greater detail in other ctions of the labeling:,1
GRANIX,Acute Respiratory Distress Syndrome,,0
GRANIX,Acute Respiratory Distress Syndrome,labeling: Spleni,1
GRANIX,Acute Respiratory Distress Syndrome,se,0
GRANIX,Acute Respiratory Distress Syndrome,discussed in greater detail in other,0
GRANIX,Acute Respiratory Distress Syndrome,detail in other se,0
GRANIX,Acute Respiratory Distress Syndrome,in,0
GRANIX,ARDS,labeling Rupt,1
GRANIX,ARDS,labeling Rupt,1
GRANIX,ARDS,Warnings and Precautions Acute,0
GRANIX,ARDS,,0
GRANIX,ARDS,Rupt,1
GRANIX,Allergic reactions,Warnings,1
GRANIX,Allergic reactions,,0
GRANIX,Allergic reactions,Distress  [  see  Warnings ,1
GRANIX,Allergic reactions,,0
GRANIX,Allergic reactions,Rupture see Warnings and,0
GRANIX,angioneurotic edema,an,0
GRANIX,angioneurotic edema,d Precautions (5.2),1
GRANIX,dermatitis allergic,Syndrome see Warnings and ],1
GRANIX,dermatitis allergic,see Warnings and Precautions,0
GRANIX,dermatitis allergic,Al,1
GRANIX,dermatitis allergic,Distress Syndrome see Warnings and Precautions,0
GRANIX,dermatitis allergic,"  ]



  Serious Al",1
GRANIX,dermatitis allergic,Syndrome see Warnings and ],1
GRANIX,drug hypersensitivity,Warnings and Precautions Serious rgic Reactions [  see,1
GRANIX,drug hypersensitivity,,0
GRANIX,drug hypersensitivity,Precautions Use in Patients with Sickle Cell,0
GRANIX,drug hypersensitivity,,0
GRANIX,drug hypersensitivity,rgic Reactions,1
GRANIX,drug hypersensitivity,see,0
GRANIX,drug hypersensitivity,see,1
GRANIX,drug hypersensitivity,see,1
GRANIX,drug hypersensitivity,Cell Disease see,0
GRANIX,drug hypersensitivity,rgic Reactions [  see,1
GRANIX,hypersensitivity,in Patients with Sickle Cell Disease see,0
GRANIX,hypersensitivity,Reactions,0
GRANIX,hypersensitivity,Reactions see,0
GRANIX,hypersensitivity,Warnings,1
GRANIX,hypersensitivity,Reactions Warnings and Pre,1
GRANIX,hypersensitivity,Reactions Warnings and,1
GRANIX,hypersensitivity,Pre,1
GRANIX,hypersensitivity,,0
GRANIX,hypersensitivity,,0
GRANIX,rash,utio,1
GRANIX,rash,ns Use in Patients with Sickle Cell,0
GRANIX,pruritic rash,],1
GRANIX,Sickle cell crisis,in Patients with Sickle ell Disease [,1
GRANIX,Sickle cell crisis,with Sickle ell Disease [  see,1
GRANIX,fatal,see Warnings and ons (,1
GRANIX,fatal,ons (,1
GRANIX,fatal,Use in Patients with Sickle Cell,0
GRANIX,fatal,Warnings and ons (,1
GRANIX,fatal,see Warnings and ons,1
GRANIX,fatal,ons (,1
GRANIX,fatal,Disease see Warnings,0
GRANIX,fatal,Use in Patients with Sickle Cell Disease see,0
GRANIX,fatal,Warnings and,0
GRANIX,Capillary Leak Syndrome,,0
GRANIX,Capillary Leak Syndrome,"see Warnings and autions (5.5)    ]



 ",1
GRANIX,Capillary Leak Syndrome,on Malignant Cells see,0
GRANIX,Acute respiratory distress syndrome,bone pain To eport,1
GRANIX,Acute respiratory distress syndrome,"REACTIONS,",1
GRANIX,ARDS,ntac,1
GRANIX,ARDS,adverse reaction to GRANIX,0
GRANIX,allergic reactions,be directly,0
GRANIX,allergic reactions,directly red to,1
GRANIX,allergic reactions,red to rates in th,1
GRANIX,allergic reactions,another drug and,0
GRANIX,allergic reactions,trials of another drug and may not reflect the rates observed,0
GRANIX,allergic reactions,clinical trials of another drug and may not reflect the,0
GRANIX,anaphylaxis,trials of a,1
GRANIX,anaphylaxis,of a,1
GRANIX,anaphylaxis,trials of,1
GRANIX,anaphylaxis,rates in the trials,1
GRANIX,anaphylaxis,rates in the clinical,0
GRANIX,anaphylaxis,not reflect the rates,0
GRANIX,anaphylaxis,the clinical trials of a drug cannot be directly compared to rates in,0
GRANIX,anaphylaxis,the trials of a,1
GRANIX,sickle cell crises,,0
GRANIX,sickle cell crises,and patients,1
GRANIX,sickle cell crises,patients,1
GRANIX,sickle cell crises,the nonHodgkins lymphoma study of patients were male the median age,0
GRANIX,sickle cell crises,cancer study of patients were male the median age was years and,0
GRANIX,sickle cell crises,patients were male the median,0
GRANIX,sickle cell crises,,0
GRANIX,sickle cell crises,and  patients were Cau,1
GRANIX,sickle cell crises,In the lung cancer study of patients were male the median age was,0
GRANIX,Capillary leak syndrome,aneously once,1
GRANIX,CLS,and continued to,0
GRANIX,CLS,nin,1
GRANIX,CLS,nin,1
GRANIX,CLS,subcutaneously once daily nin,1
GRANIX,CLS,nin,1
GRANIX,hypotension,"an NC of >=10,",1
GRANIX,hypotension,of days or until,0
GRANIX,hypotension,"or until an NC of >=10,",1
GRANIX,hypotension,"NC of >=10,",1
GRANIX,hypotension,or until an NC,1
GRANIX,hypotension,after nadir was,0
GRANIX,hypotension,until an NC,1
GRANIX,hypotension,"until an NC of >=10,",1
GRANIX,hypotension,"of >=10,",1
GRANIX,hypotension,until an NC,1
GRANIX,hypoalbuminemia,or until an ANC 0 x,1
GRANIX,hypoalbuminemia,6 /L a,1
GRANIX,hypoalbuminemia,10 6 /L a,1
GRANIX,edema,ANC of x L er na,1
GRANIX,edema,of x L er,1
GRANIX,edema,continued to a maximum of,0
GRANIX,edema,dir was reached Bone pain was the most frequent treatmentemergent adverse,0
GRANIX,edema,of x L er,1
GRANIX,edema,x L er,1
GRANIX,edema,x L er na,1
GRANIX,hemoconcentration,most frequent treatmentemergent adverse,0
GRANIX,hemoconcentration,"x L after nadir as reached.



 B",1
GRANIX,hemoconcentration,"L after nadir as reached.



 B",1
GRANIX,myeloid malignancies,with nonmyeloid,0
GRANIX,myeloid malignancies,receiving IX. No complications,1
GRANIX,myeloid malignancies,Adverse Reactions,0
GRANIX,myeloid malignancies,,0
GRANIX,myeloid malignancies,No complications,1
GRANIX,myeloid malignancies,in less,0
GRANIX,myeloid malignancies,with nonmyeloid malignancies receiving IX. No complications,1
GRANIX,myelodysplasia,complications ibutable to le,1
GRANIX,myelodysplasia,complications ibutable,1
GRANIX,myelodysplasia,ukocytosis were reported in clinical studies Additional Adverse Reactions Other adverse,0
GRANIX,myelodysplasia,le,1
GRANIX,myelodysplasia,were reported in clinical studies Additional Adverse Reactions Other adverse rea,0
GRANIX,myelodysplasia,to le,1
GRANIX,myelodysplasia,complications ibutable to le,1
GRANIX,myelodysplasia,GRANIX No complications ibutable,1
GRANIX,myelodysplasia,receiving GRANIX No complications ibutable to le,1
TUDORZA,Paradoxical bronchospasm,Paradoxical bronchospasm,1
TUDORZA,Paradoxical bronchospasm,in other,0
TUDORZA,Paradoxical bronchospasm,in other,0
TUDORZA,Paradoxical bronchospasm,,0
TUDORZA,Paradoxical bronchospasm,bronchospasm,1
TUDORZA,Paradoxical bronchospasm,other Paradoxical,1
TUDORZA,Worsening of narrow-angle glaucoma,Worsening of,0
TUDORZA,Worsening of narrow-angle glaucoma,urinary retention,0
TUDORZA,Worsening of narrow-angle glaucoma,Worsening of narrow-angle glaucoma,1
TUDORZA,Immediate Hypersensitivity Reactions,Immediate Hypersensitivity Reactions,1
TUDORZA,Immediate Hypersensitivity Reactions,see Warnings and Immediate Hypersensitivity Reactions,1
TUDORZA,Immediate Hypersensitivity Reactions,,0
TUDORZA,cough,cough,1
TUDORZA,cough,cough,1
TUDORZA,cough,cough,1
TUDORZA,cough,cough,1
TUDORZA,cough,and,0
TUDORZA,cough,adverse reactions incidence and greater,0
TUDORZA,cough,at or,0
TUDORZA,cough,cough,1
TUDORZA,cough,Contact AstraZeneca,0
TUDORZA,Headache,Headache,1
TUDORZA,Headache,Headache,1
TUDORZA,Headache,,0
TUDORZA,Headache,Headache,1
TUDORZA,Headache,n Headache,1
TUDORZA,Headache,n,0
TUDORZA,Nasopharyngitis,,0
TUDORZA,Nasopharyngitis,Nasopharyngitis Cough,1
TUDORZA,Nasopharyngitis,Nasopharyngitis Cough,1
TUDORZA,Nasopharyngitis,Nasopharyngitis Cough,1
TUDORZA,Nasopharyngitis,,0
TUDORZA,Nasopharyngitis,Nasopharyngitis Cough,1
TUDORZA,Nasopharyngitis,,0
TUDORZA,Nasopharyngitis,,0
TUDORZA,Nasopharyngitis,Nasopharyngitis Cough,1
TUDORZA,Nasopharyngitis,,0
TUDORZA,Cough,,0
TUDORZA,Cough,Cough,1
TUDORZA,Cough,ngitis Cough,1
TUDORZA,Cough,,0
TUDORZA,Cough,ngitis Cough,1
TUDORZA,Cough,ngitis Cough,1
TUDORZA,Diarrhea,,0
TUDORZA,Diarrhea,,0
TUDORZA,Diarrhea,,0
TUDORZA,Diarrhea,Diarrhea,1
TUDORZA,Sinusitis,,0
TUDORZA,Sinusitis,,0
TUDORZA,Sinusitis,,0
TUDORZA,Sinusitis,,0
TUDORZA,Sinusitis,,0
TUDORZA,Sinusitis,Sinusitis,1
TUDORZA,Sinusitis,,0
TUDORZA,Sinusitis,,0
TUDORZA,Sinusitis,,0
TUDORZA,Sinusitis,,0
TUDORZA,Rhinitis,,0
TUDORZA,Rhinitis,Rhinitis,1
TUDORZA,Rhinitis,,0
TUDORZA,Rhinitis,Rhinitis,1
TUDORZA,Rhinitis,Rhinitis,1
TUDORZA,Rhinitis,,0
TUDORZA,Rhinitis,Rhinitis,1
TUDORZA,Rhinitis,Rhinitis,1
TUDORZA,Rhinitis,Rhinitis,1
TUDORZA,Rhinitis,,0
TUDORZA,Toothache,Toothache,1
TUDORZA,Toothache,,0
TUDORZA,Toothache,,0
TUDORZA,Toothache,Toothache,1
TUDORZA,Toothache,,0
TUDORZA,Toothache,,0
TUDORZA,Vomiting,Vomiting,1
TUDORZA,Vomiting,,0
TUDORZA,Vomiting,Vomiting,1
TUDORZA,Vomiting,Vomiting,1
TUDORZA,Vomiting,Vomiting,1
TUDORZA,Vomiting,,0
TUDORZA,diabetes mellitus,mellitus,1
TUDORZA,diabetes mellitus,diabetes mellitus,1
TUDORZA,diabetes mellitus,osteoarthritis cardiac failure and cardiorespiratory arrest,0
TUDORZA,diabetes mellitus,dry mouth st,0
TUDORZA,diabetes mellitus,st degree AV block osteoarthritis cardiac failure and,0
TUDORZA,diabetes mellitus,and,0
TUDORZA,diabetes mellitus,incidence of less than diabetes,1
TUDORZA,diabetes mellitus,mellitus,1
TUDORZA,dry mouth,clinical trials with an,0
TUDORZA,dry mouth,mouth,1
TUDORZA,dry mouth,osteoarthritis cardiac failure and cardiorespiratory arrest Lon,0
TUDORZA,dry mouth,arrest Lon,0
TUDORZA,dry mouth,dry mouth,1
TUDORZA,AV block,than were diabetes mellitus dry mouth,0
TUDORZA,AV block,AV block,1
TUDORZA,AV block,Trials,0
TUDORZA,AV block,,0
TUDORZA,AV block,trials with an incidence of less than were diabetes mellitus dry mouth st,0
TUDORZA,AV block,failure and cardiorespiratory,0
TUDORZA,osteoarthritis,degree AV osteoarthritis,1
TUDORZA,osteoarthritis,cardiorespiratory arrest,0
TUDORZA,osteoarthritis,trials,0
TUDORZA,cardiac failure,less than were,0
TUDORZA,cardio-respiratory arrest,block osteoarthritis cardiac failure cardio-respiratory arrest,1
TUDORZA,cardio-respiratory arrest,safety,0
TUDORZA,cardio-respiratory arrest,block osteoarthritis cardiac failure cardio-respiratory,1
TUDORZA,cardio-respiratory arrest,failure cardio-respiratory arrest,1
TUDORZA,cardio-respiratory arrest,cardiac failure cardio-respiratory arrest,1
TUDORZA,cardio-respiratory arrest,arrest,1
TUDORZA,cardio-respiratory arrest,degree AV block,0
TUDORZA,cardio-respiratory arrest,Trials TUDORZA PRESSAIR was studied,0
TUDORZA,cardio-respiratory arrest,block osteoarthritis cardiac failure cardio-respiratory arrest,1
TUDORZA,immediate hypersensitivity reactions,experience with TUDORZA immediate hypersensitivity reactions,1
TUDORZA,anaphylaxis,,0
TUDORZA,anaphylaxis,PRESSAIR immediate hypersensitivity reactions anaphylaxis,1
TUDORZA,anaphylaxis,rash bronchospasm or,0
TUDORZA,anaphylaxis,anaphylaxis,1
TUDORZA,anaphylaxis,,0
TUDORZA,anaphylaxis,anaphylaxis,1
TUDORZA,anaphylaxis,anaphylaxis,1
TUDORZA,anaphylaxis,anaphylaxis,1
TUDORZA,anaphylaxis,anaphylaxis,1
TUDORZA,anaphylaxis,,0
TUDORZA,angioedema,have,0
TUDORZA,angioedema,the lips tongue or throat,0
TUDORZA,angioedema,angioedema,1
TUDORZA,angioedema,including angioedema,1
TUDORZA,angioedema,PRESSAIR,0
TUDORZA,angioedema,urticaria rash bronchospasm,0
TUDORZA,angioedema,angioedema,1
TUDORZA,swelling of the lips,reactions including anaphylaxis angioedema swelling,1
TUDORZA,swelling of the lips,reported,0
TUDORZA,swelling of the lips,including anaphylaxis angioedema including,0
TUDORZA,swelling of the lips,,0
TUDORZA,swelling of the lips,anaphylaxis angioedema swelling of the lips,1
TUDORZA,swelling of the lips,,0
TUDORZA,swelling of the lips,lips,1
TUDORZA,swelling of the lips,itching have been,0
TUDORZA,swelling of the lips,the lips,1
TUDORZA,urticaria,urticaria,1
TUDORZA,urticaria,urticaria,1
TUDORZA,urticaria,lips tongue or urticaria,1
TUDORZA,urticaria,,0
TUDORZA,urticaria,,0
TUDORZA,urticaria,,0
TUDORZA,urticaria,rash bronchospasm,0
TUDORZA,urticaria,,0
TUDORZA,urticaria,urticaria,1
TUDORZA,rash,rash,1
TUDORZA,rash,rash,1
TUDORZA,rash,,0
TUDORZA,rash,or throat urticaria,0
TUDORZA,rash,rash,1
TUDORZA,bronchospasm,bronchospasm,1
TUDORZA,bronchospasm,anaphylaxis angioedema,0
TUDORZA,bronchospasm,been,0
TUDORZA,bronchospasm,bronchospasm,1
TUDORZA,bronchospasm,have,0
TUDORZA,bronchospasm,tongue,0
TUDORZA,itching,itching,1
TUDORZA,itching,reported,0
TUDORZA,itching,including swelling,0
TUDORZA,itching,itching,1
TUDORZA,itching,have been reported,0
TUDORZA,Paradoxical bronchospasm,described in greater detail in,0
TUDORZA,Paradoxical bronchospasm,detail in other sections aradoxical bronchospasm ,1
TUDORZA,Paradoxical bronchospasm,detail in other sections aradoxical bronchospasm ,1
TUDORZA,Paradoxical bronchospasm,bronchospasm,1
TUDORZA,Paradoxical bronchospasm,aradoxical bronchospasm,1
TUDORZA,Paradoxical bronchospasm,other,0
TUDORZA,Paradoxical bronchospasm,bronchospasm,1
TUDORZA,Paradoxical bronchospasm,Warnings and Precautions Worsening of narrowangle,0
TUDORZA,Worsening of narrow-angle glaucoma,"glaucoma see Warnings and (5.3)]  
 *    Worsening of urinar",1
TUDORZA,Worsening of narrow-angle glaucoma,retention,0
TUDORZA,Worsening of narrow-angle glaucoma,Worsening of urinar,1
TUDORZA,Worsening of narrow-angle glaucoma,"and (5.3)]  
 *    Worsening of urinar",1
TUDORZA,Worsening of narrow-angle glaucoma,"see Warnings and (5.3)]  
 *    Worsening of urinar",1
TUDORZA,Worsening of narrow-angle glaucoma,see Warnings and Precautions Immediate Hypersensitivity Reactions,0
TUDORZA,Worsening of narrow-angle glaucoma,see Warnings and (5.3)] * Worsening of,1
TUDORZA,Worsening of narrow-angle glaucoma,Immediate Hypersensitivity Reactions see,0
TUDORZA,Worsening of urinary retention,and,0
TUDORZA,Worsening of urinary retention,Precautions EXCERPT t common adverse reactions,1
TUDORZA,Worsening of urinary retention,and greater than placebo are headache nasopharyngitis and cough To repor,0
TUDORZA,Worsening of urinary retention,To,0
TUDORZA,Worsening of urinary retention,Reactions see Warnings,0
TUDORZA,Worsening of urinary retention,Warnings,0
TUDORZA,Worsening of urinary retention,(>=,1
TUDORZA,Worsening of urinary retention,Precautions EXCERPT t common adverse reactions (>=,1
TUDORZA,Worsening of urinary retention,(>=,1
TUDORZA,hypersensitivity reactions,clinical trials are,0
TUDORZA,hypersensitivity reactions,FDA,0
TUDORZA,hypersensitivity reactions,,0
TUDORZA,hypersensitivity reactions,,0
TUDORZA,hypersensitivity reactions,REACTIONS Contact AstraZeneca at or,0
TUDORZA,paradoxical bronchospasm,PRESSAIR at recommended dose of 400 ,1
TUDORZA,paradoxical bronchospasm,a mean,0
TUDORZA,paradoxical bronchospasm,PRESSAIR at recommended dose of,1
TUDORZA,Immediate hypersensitivity reactions,"N=640)             
                ",1
TUDORZA,Immediate hypersensitivity reactions,n n,0
TUDORZA,anaphylaxis,           ,1
TUDORZA,anaphylaxis,n,0
TUDORZA,anaphylaxis,,0
TUDORZA,anaphylaxis,           ,1
TUDORZA,anaphylaxis,           ,1
TUDORZA,anaphylaxis,           ,1
TUDORZA,anaphylaxis,           ,1
TUDORZA,anaphylaxis,           ,1
TUDORZA,anaphylaxis,N            ,1
TUDORZA,anaphylaxis,           ,1
TUDORZA,angioedema,n,0
TUDORZA,swelling of the lips,,0
TUDORZA,urticaria,,0
TUDORZA,urticaria,,0
TUDORZA,urticaria,n,0
TUDORZA,urticaria,,0
TUDORZA,rash,,0
TUDORZA,rash,,0
TUDORZA,rash,che ,1
TUDORZA,rash,che ,1
TUDORZA,rash,che ,1
TUDORZA,bronchospasm,n,0
TUDORZA,bronchospasm,             Nasopharyngiti,1
TUDORZA,bronchospasm,             Nasopharyngiti,1
TUDORZA,bronchospasm,Nasopharyngiti,0
TUDORZA,itching,,0
TUDORZA,itching,        Nasopharyngitis,1
TUDORZA,itching,,0
TUDORZA,itching,        Nasopharyngitis,1
TUDORZA,itching,,0
TUDORZA,itching,,0
JEVTANA,Bone Marrow Suppression,Bone Marrow,1
JEVTANA,Bone Marrow Suppression,another section of the Bone Marrow,1
JEVTANA,Bone Marrow Suppression,Warnings,0
JEVTANA,Bone Marrow Suppression,of the Bone Marrow Suppression,1
JEVTANA,Hypersensitivity Reactions,Reactions,1
JEVTANA,Hypersensitivity Reactions,Adverse Reactions see Warnings,0
JEVTANA,Gastrointestinal Adverse Reactions,Warnings and Gastrointestinal Adverse Reactions,1
JEVTANA,Gastrointestinal Adverse Reactions,and Gastrointestinal Adverse Reactions,1
JEVTANA,Gastrointestinal Adverse Reactions,Hypersensitivity Reactions see Warnings and Precautions,0
JEVTANA,Gastrointestinal Adverse Reactions,see Warnings,0
JEVTANA,Gastrointestinal Adverse Reactions,Warnings and,0
JEVTANA,Gastrointestinal Adverse Reactions,Renal,0
JEVTANA,Renal Failure,in Elderly Patients,0
JEVTANA,Renal Failure,see,0
JEVTANA,Renal Failure,Failure,1
JEVTANA,Renal Failure,and Renal Failure,1
JEVTANA,Renal Failure,see Warnings and Renal Failure,1
JEVTANA,Renal Failure,Precautions,0
JEVTANA,Renal Failure,see Warnings and,0
JEVTANA,Renal Failure,and Renal Failure,1
JEVTANA,neutropenia,adverse reactions,0
JEVTANA,neutropenia,constipation asthenia,0
JEVTANA,neutropenia,neutropenia,1
JEVTANA,neutropenia,diarrhea fatigue nausea vomiting,0
JEVTANA,anemia,,0
JEVTANA,anemia,,0
JEVTANA,anemia,grades adverse reactions are anemia,1
JEVTANA,anemia,are anemia,1
JEVTANA,anemia,anemia,1
JEVTANA,anemia,are neutropenia,0
JEVTANA,anemia,reactions are anemia,1
JEVTANA,anemia,are anemia,1
JEVTANA,leukopenia,reactions are neutropenia leukopenia,1
JEVTANA,leukopenia,neutropenia leukopenia,1
JEVTANA,leukopenia,Most common all grades adverse reactions,0
JEVTANA,thrombocytopenia,thrombocytopenia,1
JEVTANA,thrombocytopenia,thrombocytopenia,1
JEVTANA,thrombocytopenia,thrombocytopenia,1
JEVTANA,thrombocytopenia,thrombocytopenia,1
JEVTANA,thrombocytopenia,,0
JEVTANA,thrombocytopenia,neutropenia anemia thrombocytopenia,1
JEVTANA,thrombocytopenia,thrombocytopenia,1
JEVTANA,thrombocytopenia,anemia leukopenia,0
JEVTANA,thrombocytopenia,fatigue nausea vomiting constipation asthenia abdominal pain hematuria,0
JEVTANA,thrombocytopenia,vomiting constipation asthenia abdominal,0
JEVTANA,diarrhea,,0
JEVTANA,diarrhea,,0
JEVTANA,diarrhea,neutropenia anemia leukopenia diarrhea,1
JEVTANA,diarrhea,,0
JEVTANA,diarrhea,are neutropenia anemia leukopenia thrombocytopenia,0
JEVTANA,diarrhea,neutropenia,0
JEVTANA,diarrhea,nausea vomiting constipation asthenia abdominal pain hematuria back pain anorexia,0
JEVTANA,fatigue,fatigue,1
JEVTANA,fatigue,fatigue,1
JEVTANA,fatigue,,0
JEVTANA,fatigue,fatigue,1
JEVTANA,fatigue,fatigue,1
JEVTANA,nausea,nausea,1
JEVTANA,nausea,nausea,1
JEVTANA,nausea,back pain anorexia peripheral,0
JEVTANA,constipation,constipation,1
JEVTANA,abdominal pain,pain,1
JEVTANA,abdominal pain,vomiting constipation asthenia,0
JEVTANA,abdominal pain,constipation abdominal pain,1
JEVTANA,abdominal pain,nausea vomiting constipation abdominal,1
JEVTANA,abdominal pain,pain,1
JEVTANA,abdominal pain,pain,1
JEVTANA,abdominal pain,,0
JEVTANA,abdominal pain,diarrhea fatigue nausea vomiting constipation,0
JEVTANA,abdominal pain,,0
JEVTANA,abdominal pain,constipation abdominal pain,1
JEVTANA,hematuria,hematuria,1
JEVTANA,hematuria,hematuria,1
JEVTANA,hematuria,constipation asthenia abdominal hematuria,1
JEVTANA,hematuria,arthralgia,0
JEVTANA,hematuria,constipation asthenia abdominal hematuria,1
JEVTANA,hematuria,thrombocytopenia diarrhea,0
JEVTANA,back pain,asthenia abdominal pain back,1
JEVTANA,back pain,nausea vomiting constipation asthenia abdominal pain,0
JEVTANA,anorexia,anorexia,1
JEVTANA,anorexia,anorexia,1
JEVTANA,anorexia,constipation asthenia,0
JEVTANA,anorexia,anorexia,1
JEVTANA,anorexia,anorexia,1
JEVTANA,anorexia,asthenia abdominal pain hematuria back pain,0
JEVTANA,anorexia,anorexia,1
JEVTANA,anorexia,anorexia,1
JEVTANA,anorexia,,0
JEVTANA,anorexia,anorexia,1
JEVTANA,peripheral neuropathy,abdominal pain hematuria back pain,0
JEVTANA,peripheral neuropathy,pain hematuria back pain peripheral,1
JEVTANA,peripheral neuropathy,arthralgia and alopecia,0
JEVTANA,peripheral neuropathy,arthralgia and,0
JEVTANA,peripheral neuropathy,hematuria back pain peripheral neuropathy,1
JEVTANA,pyrexia,,0
JEVTANA,pyrexia,pyrexia,1
JEVTANA,pyrexia,pyrexia,1
JEVTANA,pyrexia,pyrexia,1
JEVTANA,pyrexia,pain anorexia peripheral pyrexia,1
JEVTANA,pyrexia,pyrexia,1
JEVTANA,pyrexia,pain hematuria back pain anorexia peripheral neuropathy,0
JEVTANA,pyrexia,SUSPECTED,0
JEVTANA,dyspnea,SUSPECTED,0
JEVTANA,dyspnea,dyspnea,1
JEVTANA,dyspnea,,0
JEVTANA,dyspnea,neuropathy pyrexia,0
JEVTANA,dyspnea,dysgeusia cough arthralgia and alopecia To report SUSPECTED ADVERSE REACTIONS,0
JEVTANA,dysgeusia,dysgeusia,1
JEVTANA,dysgeusia,anorexia peripheral neuropathy pyrexia dysgeusia,1
JEVTANA,dysgeusia,alopecia To report SUSPECTED ADVERSE,0
JEVTANA,dysgeusia,,0
JEVTANA,cough,ADVERSE REACTIONS,0
JEVTANA,arthralgia,arthralgia,1
JEVTANA,arthralgia,pyrexia dyspnea dysgeusia cough,0
JEVTANA,arthralgia,peripheral neuropathy pyrexia dyspnea,0
JEVTANA,arthralgia,arthralgia,1
JEVTANA,arthralgia,neuropathy pyrexia dyspnea dysgeusia arthralgia,1
JEVTANA,arthralgia,arthralgia,1
JEVTANA,arthralgia,alopecia To,0
JEVTANA,alopecia,alopecia,1
JEVTANA,alopecia,cough arthralgia and,0
JEVTANA,alopecia,alopecia,1
JEVTANA,alopecia,alopecia,1
JEVTANA,alopecia,US,0
JEVTANA,Deaths,plus Deaths,1
JEVTANA,Deaths,days of last study,0
JEVTANA,Deaths,Deaths,1
JEVTANA,Deaths,,0
JEVTANA,Deaths,reported,0
JEVTANA,Deaths,to mitoxantrone plus Deaths,1
JEVTANA,Deaths,Deaths,1
JEVTANA,Deaths,other than,0
JEVTANA,Deaths,causes other than disease progression within days of last study drug,0
JEVTANA,Deaths,Deaths,1
JEVTANA,fatal,n,0
JEVTANA,infections,adverse re,0
JEVTANA,infections,common fatal adverse reactions in,0
JEVTANA,infections,,0
JEVTANA,infections,infections,1
JEVTANA,infections,infections,1
JEVTANA,renal failure,n renal failure,1
JEVTANA,renal failure,renal failure,1
JEVTANA,renal failure,renal,1
JEVTANA,renal failure,n The majority of patients of fatal infectionrelated adverse reactions occurred,0
JEVTANA,renal failure,of fatal infectionrelated adverse reactions occurred after,0
JEVTANA,renal failure,,0
JEVTANA,renal failure,infections n renal failure,1
JEVTANA,renal failure,failure,1
JEVTANA,renal failure,of,0
JEVTANA,renal failure,n renal failure,1
JEVTANA,fatal,fatal,1
JEVTANA,fatal,majority of patients fatal,1
JEVTANA,fatal,dose of JEVTANA Other fatal,0
JEVTANA,fatal,fatal,1
JEVTANA,fatal,of patients fatal,1
JEVTANA,fatal,patients were infections n,0
JEVTANA,fatal,fatal,1
JEVTANA,fatal,fatal,1
JEVTANA,infection-related adverse reactions,patients of fatal,0
JEVTANA,infection-related adverse reactions,infection-related adverse reactions,1
JEVTANA,fatal,dose of JEVTANA fatal,1
JEVTANA,fatal,fatal infectionrelated adverse reactions occurred after a,0
JEVTANA,fatal,in JEVTANAtreated patients,0
JEVTANA,fatal,fatal,1
JEVTANA,fatal,Other,0
JEVTANA,fatal,of JEVTANA fatal,1
JEVTANA,fatal,adverse reactions in,0
JEVTANA,fatal,in JEVTANAtreated patients included ventricular fibrillation cerebral hemorrhag,0
JEVTANA,ventricular fibrillation,ventricular fibrillation,1
JEVTANA,ventricular fibrillation,Other,0
JEVTANA,ventricular fibrillation,adverse,0
JEVTANA,ventricular fibrillation,reactions in JEVTANAtreated patients ventricular fibrillation,1
JEVTANA,ventricular fibrillation,dose of JEVTANA Other fatal adverse reactions in,0
JEVTANA,ventricular fibrillation,fibrillation,1
JEVTANA,ventricular fibrillation,dyspnea The most,0
JEVTANA,cerebral hemorrhage,fibrillation,0
JEVTANA,cerebral hemorrhage,ventricular cerebral hemorrhage,1
JEVTANA,cerebral hemorrhage,Other fatal adverse reactions in JEVTANAtreated,0
JEVTANA,cerebral hemorrhage,,0
JEVTANA,cerebral hemorrhage,patients included ventricular cerebral,1
JEVTANA,cerebral hemorrhage,were,0
JEVTANA,cerebral hemorrhage,dyspnea The most common grade adverse,0
JEVTANA,cerebral hemorrhage,hemorrhage,1
JEVTANA,cerebral hemorrhage,included ventricular cerebral hemorrhage,1
JEVTANA,cerebral hemorrhage,ventricular cerebral,1
JEVTANA,dyspnea,hemorrhage and,0
JEVTANA,dyspnea,,0
JEVTANA,dyspnea,ventricular fibrillation cerebral,0
JEVTANA,dyspnea,dyspnea,1
JEVTANA,dyspnea,dyspnea,1
JEVTANA,dyspnea,dyspnea,1
JEVTANA,dyspnea,dyspnea,1
JEVTANA,dyspnea,anemia leukopenia neutropenia thr,0
JEVTANA,dyspnea,reactions in JEVTANAtreated patients included ventricular fibrillation,0
JEVTANA,anemia,nausea vomiting constipation,0
JEVTANA,leukopenia,leukopenia,1
JEVTANA,leukopenia,leukopenia,1
JEVTANA,leukopenia,leukopenia,1
JEVTANA,leukopenia,leukopenia,1
JEVTANA,leukopenia,leukopenia,1
JEVTANA,leukopenia,leukopenia,1
JEVTANA,neutropenia,neutropenia,1
JEVTANA,neutropenia,vomiting constipation asthenia abdominal pain hem,0
JEVTANA,neutropenia,neutropenia,1
JEVTANA,neutropenia,and dyspnea The most common,0
JEVTANA,neutropenia,dyspnea The most common grade adverse reactions were anemia,0
JEVTANA,neutropenia,diarrhea fatigue nausea vomiting constipation asthenia abdominal pain,0
JEVTANA,neutropenia,neutropenia,1
JEVTANA,neutropenia,neutropenia,1
JEVTANA,neutropenia,neutropenia,1
JEVTANA,thrombocytopenia,nausea vomiting constipation asthenia,0
JEVTANA,thrombocytopenia,thrombocytopenia,1
JEVTANA,thrombocytopenia,reactions were anemia,0
JEVTANA,thrombocytopenia,were anemia leukopenia thrombocytopenia,1
JEVTANA,thrombocytopenia,,0
JEVTANA,thrombocytopenia,The most common grade adverse,0
JEVTANA,diarrhea,diarrhea,1
JEVTANA,diarrhea,adverse reactions were anemia,0
JEVTANA,diarrhea,nausea vomiting constipation asthenia abdominal pain hematuria back pain,0
JEVTANA,diarrhea,,0
JEVTANA,diarrhea,diarrhea,1
JEVTANA,diarrhea,grade adverse reactions were anemia leukopenia neutropenia thrombocytopenia,0
JEVTANA,diarrhea,,0
JEVTANA,fatigue,fatigue,1
JEVTANA,fatigue,constipation asthenia abdominal,0
JEVTANA,fatigue,abdominal,0
JEVTANA,fatigue,pain hematuria back pain anorexia,0
JEVTANA,fatigue,asthenia abdominal,0
JEVTANA,fatigue,hematuria back pain anorexia,0
JEVTANA,fatigue,diarrhea,0
JEVTANA,fatigue,,0
JEVTANA,fatigue,,0
JEVTANA,fatigue,fatigue,1
JEVTANA,nausea,,0
JEVTANA,nausea,neuro,0
JEVTANA,nausea,nausea,1
JEVTANA,nausea,nausea,1
JEVTANA,nausea,neutropenia,0
JEVTANA,nausea,pain,0
JEVTANA,vomiting,anemia leukopenia neutropenia thrombocytopenia,0
JEVTANA,vomiting,,0
JEVTANA,vomiting,,0
JEVTANA,vomiting,vomiting,1
JEVTANA,vomiting,vomiting,1
JEVTANA,constipation,diarrhea fatigue nausea vomiting,0
JEVTANA,constipation,,0
JEVTANA,constipation,nausea constipation,1
JEVTANA,constipation,constipation,1
JEVTANA,constipation,constipation,1
JEVTANA,asthenia,asthenia,1
JEVTANA,asthenia,back pain anorexia peripheral neuropathy pyrexia dyspnea dysguesia,0
JEVTANA,asthenia,diarrhea fatigue nausea vomiting asthenia,1
JEVTANA,asthenia,fatigue nausea vomiting,0
JEVTANA,abdominal pain,nausea vomiting constipation,0
JEVTANA,abdominal pain,nausea vomiting constipation abdominal pain,1
JEVTANA,abdominal pain,constipation abdominal pain,1
JEVTANA,abdominal pain,abdominal pain,1
JEVTANA,abdominal pain,,0
JEVTANA,abdominal pain,nausea vomiting constipation abdominal pain,1
JEVTANA,abdominal pain,nausea vomiting constipation abdominal,1
JEVTANA,abdominal pain,constipation,0
JEVTANA,abdominal pain,hematuria back pain anorexia peripheral,0
JEVTANA,abdominal pain,,0
JEVTANA,hematuria,,0
JEVTANA,hematuria,diarrhea fatigue nausea vomiting constipation asthenia abdominal pain,0
JEVTANA,hematuria,,0
JEVTANA,hematuria,constipation,0
JEVTANA,hematuria,pyrexia dyspnea dysguesia cough,0
JEVTANA,hematuria,dyspnea dysguesia cough arthralgia,0
JEVTANA,hematuria,hematuria,1
JEVTANA,hematuria,,0
JEVTANA,back pain,back pain,1
JEVTANA,back pain,pain,1
JEVTANA,back pain,pyrexia,0
JEVTANA,back pain,fatigue nausea,0
JEVTANA,anorexia,pyrexia,0
JEVTANA,anorexia,anorexia,1
JEVTANA,peripheral neuropathy,pain peripheral neuropathy,1
JEVTANA,pyrexia,pyrexia,1
JEVTANA,pyrexia,dyspnea dysguesia cough arthralgia and alopecia The most common,0
JEVTANA,pyrexia,anorexia peripheral pyrexia,1
JEVTANA,pyrexia,peripheral pyrexia,1
JEVTANA,pyrexia,pyrexia,1
JEVTANA,pyrexia,most common,0
JEVTANA,dyspnea,back pain,0
JEVTANA,dyspnea,anorexia,0
JEVTANA,dyspnea,dysguesia cough arthralgia and alopecia The most common grade,0
JEVTANA,dyspnea,common grade adverse reaction,0
JEVTANA,dyspnea,dyspnea,1
JEVTANA,dyspnea,pain anorexia peripheral neuropathy dyspnea,1
JEVTANA,dyspnea,The most common grade,0
JEVTANA,dysguesia,dysguesia,1
JEVTANA,dysguesia,pyrexia,0
JEVTANA,dysguesia,dysguesia,1
JEVTANA,dysguesia,cough arthralgia and alopecia The,0
JEVTANA,dysguesia,pain hematuria back pain anorexia,0
JEVTANA,dysguesia,pain,0
JEVTANA,dysguesia,,0
JEVTANA,dysguesia,dysguesia,1
JEVTANA,cough,cough,1
JEVTANA,cough,cough,1
JEVTANA,cough,peripheral neuropathy pyrexia dyspnea cough,1
JEVTANA,cough,,0
JEVTANA,cough,,0
JEVTANA,cough,The most common grade adverse reactions in,0
JEVTANA,cough,pain hematuria back,0
JEVTANA,cough,peripheral neuropathy pyrexia dyspnea cough,1
JEVTANA,arthralgia,arthralgia,1
JEVTANA,arthralgia,adverse reactions in patients who,0
JEVTANA,arthralgia,arthralgia,1
JEVTANA,arthralgia,arthralgia,1
JEVTANA,arthralgia,dyspnea dysguesia arthralgia,1
JEVTANA,alopecia,and,0
JEVTANA,neutropenia,neutropenia,1
JEVTANA,neutropenia,were,0
JEVTANA,neutropenia,grade adverse reactions in patients,0
JEVTANA,neutropenia,JEVTANA neutropenia,1
JEVTANA,neutropenia,patients who received JEVTANA neutropenia,1
JEVTANA,neutropenia,neutropenia,1
JEVTANA,neutropenia,and,0
JEVTANA,neutropenia,,0
JEVTANA,leukopenia,leukopenia,1
JEVTANA,leukopenia,,0
JEVTANA,anemia,anemia,1
JEVTANA,anemia,neutropenia,0
JEVTANA,anemia,in patients who received JEVTANA were neutropenia,0
JEVTANA,anemia,neutropenia,0
JEVTANA,febrile neutropenia,reactions in patients,0
JEVTANA,febrile neutropenia,who received JEVTANA were,0
JEVTANA,febrile neutropenia,neutropenia,1
JEVTANA,diarrhea,neutropenia leukopenia anemia febrile diarrhea,1
JEVTANA,diarrhea,occurred,0
JEVTANA,diarrhea,anemia febrile diarrhea,1
JEVTANA,diarrhea,neutropenia leukopenia anemia febrile diarrhea,1
JEVTANA,fatigue,occurred in,0
JEVTANA,fatigue,febrile neutropenia fatigue,1
JEVTANA,fatigue,neutropenia diarrhea,0
JEVTANA,fatigue,fatigue,1
JEVTANA,fatigue,Treatment discontinuations due to adverse drug reactions occurred in of,0
JEVTANA,fatigue,discontinuations due to adverse,0
JEVTANA,fatigue,discontinuations due to adverse drug reactions,0
JEVTANA,fatigue,were neutropenia,0
JEVTANA,fatigue,fatigue,1
JEVTANA,fatigue,fatigue,1
JEVTANA,asthenia,neutropenia leukopenia anemia febrile,0
JEVTANA,asthenia,neutropenia leukopenia anemia febrile neutropenia diarrhea fatigue and,0
JEVTANA,asthenia,in of patients who,0
JEVTANA,asthenia,asthenia,1
JEVTANA,asthenia,discontinuations due to adverse drug reactions occurred in of patients who recei,0
JEVTANA,asthenia,to adverse drug reactions occurred in of patients who recei,0
JEVTANA,neutropenia,the JEVTANA group were,0
JEVTANA,neutropenia,neutropenia,1
JEVTANA,neutropenia,mitox,0
JEVTANA,neutropenia,neutropenia,1
JEVTANA,neutropenia,reported in of JEVTANAtreated patients,0
JEVTANA,renal failure,reported in of,0
JEVTANA,renal failure,to treatment discontinuation in the JEVTANA,0
JEVTANA,renal failure,JEVTANA group were neutropenia renal,1
JEVTANA,renal failure,neutropenia,0
JEVTANA,renal failure,in the JEVTANA group were neutropenia,0
JEVTANA,renal failure,treatment discontinuation in the JEVTANA group were neutropenia and,0
JEVTANA,renal failure,failure,1
JEVTANA,renal failure,treatment discontinuation in the JEVTANA group,0
JEVTANA,renal failure,JEVTANA group were neutropenia renal,1
JEVTANA,Hematologic Abnormalities,,0
JEVTANA,Hematologic Abnormalities,Hematologic Abnormalities,1
JEVTANA,Hematologic Abnormalities,NCI CTCAE version Hematologic Abnormalities,1
JEVTANA,Hematologic Abnormalities,version Hematologic,1
JEVTANA,Neutropenia,Disorders,0
JEVTANA,Neutropenia,Neutropenia,1
JEVTANA,Neutropenia,Neutropenia,1
JEVTANA,Febrile Neutropenia,Febrile,1
JEVTANA,Febrile Neutropenia,,0
JEVTANA,Febrile Neutropenia,Neutropenia Anemia,1
JEVTANA,Anemia,openia,0
JEVTANA,Anemia,,0
JEVTANA,Anemia,Anemia,1
JEVTANA,Anemia,Anemia,1
JEVTANA,Anemia,Anemia,1
JEVTANA,Leukopenia,,0
JEVTANA,Leukopenia,,0
JEVTANA,Leukopenia,,0
JEVTANA,Leukopenia,,0
JEVTANA,Leukopenia,,0
JEVTANA,Leukopenia,Leukopenia,1
JEVTANA,Leukopenia,Leukopenia,1
JEVTANA,Leukopenia,Leukopenia,1
JEVTANA,Leukopenia,Leukopenia,1
JEVTANA,Leukopenia,Leukopenia,1
JEVTANA,Thrombocytopenia,Thrombocytopenia Car,1
JEVTANA,Thrombocytopenia,,0
JEVTANA,Thrombocytopenia,,0
JEVTANA,Thrombocytopenia,Thrombocytopenia Car,1
JEVTANA,Thrombocytopenia,,0
JEVTANA,Thrombocytopenia,,0
JEVTANA,Thrombocytopenia,Car,0
JEVTANA,Thrombocytopenia,,0
JEVTANA,Thrombocytopenia,Thrombocytopenia Car,1
JEVTANA,Diarrhea,Diarrhea,1
JEVTANA,Diarrhea,,0
JEVTANA,Diarrhea,Diarrhea,1
JEVTANA,Diarrhea,Diarrhea,1
JEVTANA,Diarrhea,nal Diarrhea,1
JEVTANA,Diarrhea,,0
JEVTANA,Diarrhea,Diarrhea,1
JEVTANA,Diarrhea,Diarrhea,1
JEVTANA,Diarrhea,Diarrhea,1
JEVTANA,Diarrhea,,0
JEVTANA,Nausea,Nausea,1
JEVTANA,Nausea,Nausea,1
JEVTANA,Nausea,Nausea,1
JEVTANA,Nausea,,0
JEVTANA,Nausea,,0
JEVTANA,Nausea,,0
JEVTANA,Vomiting,,0
JEVTANA,Vomiting,,0
JEVTANA,Vomiting,,0
JEVTANA,Vomiting,,0
JEVTANA,Vomiting,Vomiting,1
JEVTANA,Vomiting,Vomiting,1
JEVTANA,Vomiting,,0
JEVTANA,Vomiting,Vomiting,1
JEVTANA,Vomiting,,0
JEVTANA,Vomiting,Vomiting,1
JEVTANA,Constipation,,0
JEVTANA,Constipation,,0
JEVTANA,Constipation,,0
JEVTANA,Constipation,,0
JEVTANA,Constipation,,0
JEVTANA,Constipation,,0
JEVTANA,Constipation,Constipation,1
JEVTANA,Constipation,Constipation,1
JEVTANA,Abdominal Pain,Abdominal,1
JEVTANA,Dyspepsia,Dyspepsia,1
JEVTANA,Dyspepsia,Dyspepsia,1
JEVTANA,Dyspepsia,n,0
JEVTANA,Dyspepsia,,0
JEVTANA,Dyspepsia,n Dyspepsia,1
JEVTANA,Dyspepsia,Dyspepsia,1
JEVTANA,Dyspepsia,,0
JEVTANA,Dyspepsia,,0
JEVTANA,Fatigue,Fatigue,1
JEVTANA,Fatigue,Conditions,0
JEVTANA,Fatigue,Disorders and Administration Site Fatigue,1
JEVTANA,Fatigue,and Administration Site Conditions,0
JEVTANA,Fatigue,Conditions,0
JEVTANA,Asthenia,Asthenia,1
JEVTANA,Asthenia,,0
JEVTANA,Asthenia,,0
JEVTANA,Asthenia,,0
JEVTANA,Asthenia,,0
JEVTANA,Asthenia,,0
JEVTANA,Pyrexia,,0
JEVTANA,Pyrexia,Pyrexia,1
JEVTANA,Pyrexia,,0
JEVTANA,Pyrexia,,0
JEVTANA,Pyrexia,Pyrexia,1
JEVTANA,Peripheral Edema,Peripheral Edema Muc,1
JEVTANA,Peripheral Edema,Peripheral Edema Muc,1
JEVTANA,Peripheral Edema,Peripheral Edema Muc,1
JEVTANA,Peripheral Edema,Peripheral Edema Muc,1
JEVTANA,Peripheral Edema,Edema Muc,1
JEVTANA,Peripheral Edema,,0
JEVTANA,Peripheral Edema,,0
JEVTANA,Peripheral Edema,,0
JEVTANA,Peripheral Edema,Peripheral Edema Muc,1
JEVTANA,Mucosal Inflammation,ema,0
JEVTANA,Mucosal Inflammation,ema Mucosal,1
JEVTANA,Mucosal Inflammation,Mucosal Inflammation Pain,1
JEVTANA,Mucosal Inflammation,ema Mucosal,1
JEVTANA,Pain,,0
JEVTANA,Pain,Pain,1
JEVTANA,Pain,,0
JEVTANA,Pain,,0
JEVTANA,Pain,mmation,0
JEVTANA,Pain,,0
JEVTANA,Pain,,0
JEVTANA,Pain,,0
JEVTANA,Pain,mmation,0
JEVTANA,Urinary Tract Infection,d Urinary Tract,1
JEVTANA,Urinary Tract Infection,Infection Investigat,1
JEVTANA,Urinary Tract Infection,Investigat,0
JEVTANA,Weight Decreased,s Weight,1
JEVTANA,Weight Decreased,s Weight Decreased Met,1
JEVTANA,Weight Decreased,s Weight Decreased Met,1
JEVTANA,Weight Decreased,s Weight,1
JEVTANA,Weight Decreased,,0
JEVTANA,Weight Decreased,s,0
JEVTANA,Anorexia,,0
JEVTANA,Anorexia,Anorexia,1
JEVTANA,Anorexia,,0
JEVTANA,Anorexia,Nutrition Disorders,0
JEVTANA,Dehydration,Dehydration,1
JEVTANA,Dehydration,Dehydration,1
JEVTANA,Dehydration,,0
JEVTANA,Dehydration,Dehydration,1
JEVTANA,Dehydration,Dehydration,1
JEVTANA,Dehydration,Dehydration,1
JEVTANA,Back Pain,and Connective Tissue,0
JEVTANA,Back Pain,Connective Tissue,0
JEVTANA,Back Pain,and Connective Tissue,0
JEVTANA,Back Pain,Back,1
JEVTANA,Back Pain,Back Pain,1
JEVTANA,Arthralgia,Arthralgia,1
JEVTANA,Arthralgia,,0
JEVTANA,Arthralgia,Arthralgia,1
JEVTANA,Muscle Spasms,Muscle,1
JEVTANA,Peripheral Neuropathy,,0
JEVTANA,Dizziness,Dizziness,1
JEVTANA,Dizziness,,0
JEVTANA,Dizziness,,0
JEVTANA,Dizziness,Dizziness,1
JEVTANA,Dizziness,,0
JEVTANA,Dizziness,,0
JEVTANA,Dizziness,,0
JEVTANA,Dizziness,Dizziness,1
JEVTANA,Dizziness,,0
JEVTANA,Headache,Headache,1
JEVTANA,Headache,Headache,1
JEVTANA,Headache,,0
JEVTANA,Headache,,0
JEVTANA,Headache,Headache,1
JEVTANA,Headache,,0
JEVTANA,Headache,,0
JEVTANA,Headache,,0
JEVTANA,Headache,Headache,1
JEVTANA,Hematuria,,0
JEVTANA,Hematuria,Hematuria,1
JEVTANA,Hematuria,Tract Hematuria,1
JEVTANA,Hematuria,,0
JEVTANA,Hematuria,Hematuria,1
JEVTANA,Hematuria,Urinary Tract Hematuria,1
JEVTANA,Hematuria,Hematuria,1
JEVTANA,Dysuria,Dysuria,1
JEVTANA,Dysuria,,0
JEVTANA,Dysuria,Dysuria,1
JEVTANA,Dysuria,Dysuria,1
JEVTANA,Dysuria,Dysuria,1
JEVTANA,Dyspnea,Dyspnea,1
JEVTANA,Dyspnea,Mediastinal,0
JEVTANA,Dyspnea,,0
JEVTANA,Dyspnea,,0
JEVTANA,Alopecia,,0
JEVTANA,Alopecia,Alopecia,1
JEVTANA,Alopecia,Alopecia,1
JEVTANA,Alopecia,and Subcutaneous,0
JEVTANA,Alopecia,,0
JEVTANA,Alopecia,,0
JEVTANA,Alopecia,Subcutaneous Tissue Alopecia,1
JEVTANA,Alopecia,Alopecia,1
JEVTANA,Alopecia,Alopecia,1
JEVTANA,Alopecia,Subcutaneous Tissue Disorders,0
JEVTANA,Hypotension,Hypotension,1
JEVTANA,fatal,fatal,1
JEVTANA,fatal,fatal,1
JEVTANA,fatal,fatal,1
JEVTANA,fatal,fatal,1
JEVTANA,fatal,infectious adverse events sepsis or septic shock All had grade neutropenia,0
JEVTANA,fatal,experienced,0
JEVTANA,sepsis,sepsis,1
JEVTANA,sepsis,,0
JEVTANA,sepsis,sepsis,1
JEVTANA,sepsis,,0
JEVTANA,sepsis,fatal infectious adverse sepsis,1
JEVTANA,sepsis,Clinical Events,0
JEVTANA,sepsis,sepsis,1
JEVTANA,sepsis,,0
JEVTANA,septic shock,death,0
JEVTANA,septic shock,infectious adverse events sepsis septic shock,1
JEVTANA,death,death,1
JEVTANA,death,death,1
JEVTANA,death,to neutropenia without a,0
JEVTANA,death,one had febrile neutropenia One,0
JEVTANA,death,One additional death,1
JEVTANA,death,death,1
JEVTANA,death,,0
JEVTANA,death,,0
JEVTANA,death,death,1
JEVTANA,neutropenia,patients death was attributed,0
JEVTANA,neutropenia,,0
JEVTANA,neutropenia,had febrile neutropenia One additional,0
JEVTANA,neutropenia,patients discontinued JEVTANA treatment due to neut,0
JEVTANA,neutropenia,patients death was,0
JEVTANA,neutropenia,to,0
JEVTANA,infection,infection,1
JEVTANA,infection,,0
JEVTANA,infection,One additional patients death was attributed to neutropenia,0
JEVTANA,neutropenia,neutropenia,1
JEVTANA,neutropenia,patients discontinued,0
JEVTANA,neutropenia,patients discontinued,0
JEVTANA,neutropenia,neutropenia,1
JEVTANA,neutropenia,neutropenia,1
JEVTANA,neutropenia,treatment due neutropenia,1
JEVTANA,neutropenia,treatment due neutropenia,1
JEVTANA,neutropenia,adverse,0
JEVTANA,febrile neutropenia,febrile neutropenia,1
JEVTANA,febrile neutropenia,to febrile neutropenia,1
JEVTANA,febrile neutropenia,,0
JEVTANA,febrile neutropenia,febrile,1
JEVTANA,febrile neutropenia,discontinued,0
JEVTANA,febrile neutropenia,neutropenia,1
JEVTANA,febrile neutropenia,patients discontinued,0
JEVTANA,febrile neutropenia,JEVTANA treatment due to febrile neutropenia,1
JEVTANA,febrile neutropenia,infection Twentytwo patients discontinued JEVTANA,0
JEVTANA,febrile neutropenia,,0
JEVTANA,infection,,0
JEVTANA,infection,infection,1
JEVTANA,infection,JEVTANA,0
JEVTANA,infection,infection,1
JEVTANA,sepsis,discontinued JEVTANA treatment due to neutropenia febrile neutropenia infection or,0
JEVTANA,sepsis,was neu,0
JEVTANA,sepsis,,0
JEVTANA,sepsis,to,0
JEVTANA,sepsis,in the JEVTANA group was neu,0
JEVTANA,sepsis,sepsis,1
JEVTANA,neutropenia,neutropenia,1
JEVTANA,neutropenia,intervent,0
JEVTANA,neutropenia,The most common adverse reaction leading to treatment discontinuation in the JEVTANA group was,0
JEVTANA,neutropenia,,0
JEVTANA,neutropenia,in the JEVTANA group neutropenia,1
JEVTANA,neutropenia,Adverse events of hematuria including those,0
JEVTANA,neutropenia,group neutropenia,1
JEVTANA,neutropenia,the JEVTANA group neutropenia,1
JEVTANA,neutropenia,most common adverse reaction leading to treatment discontinuation,0
JEVTANA,hematuria,group was,0
JEVTANA,hematuria,Adverse events hematuria,1
JEVTANA,hematuria,hematuria,1
JEVTANA,hematuria,hematuria,1
JEVTANA,hematuria,hematuria,1
JEVTANA,hematuria,and in mitoxantronetreated,0
JEVTANA,hematuria,hematuria,1
JEVTANA,hematuria,were wellbalanced between arms and do not account for the increased rate,0
JEVTANA,hematuria,Other factors,0
JEVTANA,hematuria,hematuria,1
JEVTANA,hematuria,,0
JEVTANA,hematuria,increased rate hematuria,1
JEVTANA,hematuria,on the JEVTANA arm Hepatic Laboratory Abnormalities The incidences of grade increas,0
JEVTANA,hematuria,increased rate hematuria,1
JEVTANA,increased AST,AST,1
JEVTANA,increased AST,The followin,0
JEVTANA,increased ALT,increased ALT,1
JEVTANA,increased ALT,Hepatic Laboratory Abnormalities The incidences of grade increased AST,0
JEVTANA,increased ALT,increased ALT,1
JEVTANA,increased ALT,incidences of grade increased AST,0
JEVTANA,increased ALT,grade increased increased ALT,1
JEVTANA,increased ALT,,0
JEVTANA,increased ALT,The following,0
JEVTANA,increased bilirubin,increased AST increased ALT increased,1
JEVTANA,neutropenia,vs dizziness vs urinary,0
JEVTANA,neutropenia,,0
JEVTANA,neutropenia,age or greater compared to younger patients fatigue vs,0
JEVTANA,asthenia,asthenia,1
JEVTANA,asthenia,asthenia,1
JEVTANA,asthenia,vs neutropenia vs,0
JEVTANA,asthenia,neutropenia asthenia,1
JEVTANA,asthenia,asthenia,1
JEVTANA,asthenia,asthenia,1
JEVTANA,asthenia,,0
JEVTANA,asthenia,pyrexia,0
JEVTANA,asthenia,asthenia,1
JEVTANA,dizziness,dizziness,1
JEVTANA,dizziness,vs asthenia vs pyrexia dizziness,1
JEVTANA,dizziness,dizziness,1
JEVTANA,dizziness,neutropenia vs asthenia,0
JEVTANA,dizziness,infection vs and dehydration vs,0
JEVTANA,dizziness,vs,0
JEVTANA,dizziness,vs,0
JEVTANA,dizziness,pyrexia dizziness,1
JEVTANA,dizziness,dizziness,1
JEVTANA,urinary tract infection,,0
JEVTANA,urinary tract infection,urinary tract infection,1
JEVTANA,urinary tract infection,pyrexia vs dizziness urinary tract infection,1
JEVTANA,urinary tract infection,pyrexia vs,0
JEVTANA,urinary tract infection,infection,1
JEVTANA,dehydration,dehydration,1
JEVTANA,dehydration,,0
JEVTANA,dehydration,dehydration,1
JEVTANA,dehydration,tract,0
JEVTANA,neutropenia,younger neutropenia,1
JEVTANA,neutropenia,years of age compared,0
JEVTANA,neutropenia,neutropenia,1
JEVTANA,neutropenia,vs see Use in Specific,0
JEVTANA,neutropenia,neutropenia,1
JEVTANA,neutropenia,,0
JEVTANA,neutropenia,Populations,0
JEVTANA,neutropenia,age compared to younger neutropenia,1
JEVTANA,neutropenia,higher,0
JEVTANA,febrile neutropenia,neutropenia vs febrile,1
JEVTANA,febrile neutropenia,febrile,1
JEVTANA,febrile neutropenia,Postmarketing Experience Th,0
JEVTANA,febrile neutropenia,neutropenia,0
JEVTANA,febrile neutropenia,vs see Use in Specific Populations Postmarketing,0
JEVTANA,febrile neutropenia,,0
JEVTANA,febrile neutropenia,vs febrile neutropenia,1
JEVTANA,febrile neutropenia,patients neutropenia vs febrile,1
JEVTANA,febrile neutropenia,Th,0
JEVTANA,febrile neutropenia,younger patients neutropenia vs febrile neutropenia,1
JEVTANA,Gastritis,Gastritis,1
JEVTANA,Gastritis,,0
JEVTANA,Gastritis,be made Gastrointestinal,0
JEVTANA,NEUTROPENIA,,0
JEVTANA,NEUTROPENIA, following  serious adverse reactions are discussed,1
JEVTANA,NEUTROPENIA, following ,1
JEVTANA,NEUTROPENIA, following  serious adverse reactions are,1
JEVTANA,NEUTROPENIA,another section of,0
JEVTANA,NEUTROPENIA, following  serious adverse reactions are,1
JEVTANA,HYPERSENSITIVITY,us,1
JEVTANA,HYPERSENSITIVITY,ions are discussed in,0
JEVTANA,HYPERSENSITIVITY,adverse react ions are,1
JEVTANA,HYPERSENSITIVITY,us adverse react ions are discussed,1
JEVTANA,HYPERSENSITIVITY,us adverse react ions are,1
JEVTANA,NEUTROPENIA,,0
JEVTANA,NEUTROPENIA,,0
JEVTANA,NEUTROPENIA,,0
JEVTANA,NEUTROPENIA,,0
JEVTANA,NEUTROPENIA,grea,1
JEVTANA,NEUTROPENIA,sed in grea ter detail,1
JEVTANA,NEUTROPENIA,another section of the label Bone Marrow Suppression see Warnings and,0
JEVTANA,HYPERSENSITIVITY,Suppression see,0
JEVTANA,NEUTROPENIA,reactions are discussed in,0
JEVTANA,NEUTROPENIA,,0
JEVTANA,NEUTROPENIA,Bone,1
JEVTANA,NEUTROPENIA,Bone Marr,1
JEVTANA,NEUTROPENIA,section of the Bone,1
JEVTANA,NEUTROPENIA,of the   Bone Marr,1
JEVTANA,NEUTROPENIA,the Bone,1
JEVTANA,NEUTROPENIA,section,0
JEVTANA,NEUTROPENIA,greater detail in another section of the label,0
JEVTANA,NEUTROPENIA,and Precautions Hypersensitivity,0
JEVTANA,HYPERSENSITIVITY,Warnings,0
JEVTANA,HYPERSENSITIVITY,[see,1
JEVTANA,HYPERSENSITIVITY,label Bone Marrow,0
JEVTANA,HYPERSENSITIVITY,Bone Marrow ppression [see  ,1
JEVTANA,HYPERSENSITIVITY,Precautions,0
JEVTANA,Neutropenic,see Warnings,0
JEVTANA,Neutropenic,Hypersensitivity Reactions see and Precaut,1
JEVTANA,Neutropenic,and Precautions,0
JEVTANA,Neutropenic,,0
JEVTANA,deaths,and,0
JEVTANA,deaths,see Warnings and ons,1
JEVTANA,hypersensitivity,see,0
JEVTANA,erythema,Elderly Patients see Warnings,0
JEVTANA,erythema,Tox,0
JEVTANA,erythema,,0
JEVTANA,erythema,,0
JEVTANA,erythema,Warnings and *,1
JEVTANA,erythema,Hepatic,0
JEVTANA,erythema,,0
JEVTANA,erythema,Use,1
JEVTANA,hypotension,Patients,1
JEVTANA,hypotension,Impairment see Warnings and Precautions EmbryoFetal Toxicity see,0
JEVTANA,hypotension,Precautions Use n,1
JEVTANA,hypotension,Toxicity,0
JEVTANA,bronchospasm,Warnings,0
JEVTANA,bronchospasm,Hepatic Impa,1
JEVTANA,bronchospasm,Elderly Patients see Warnings and Precautions Use in,0
JEVTANA,bronchospasm,see Warnings,0
JEVTANA,bronchospasm,Hepatic Impa,1
JEVTANA,bronchospasm,,0
JEVTANA,bronchospasm,Hepatic,1
JEVTANA,bronchospasm,Use in Patients Hepatic Impa,1
JEVTANA,bronchospasm,Patients Hepatic,1
JEVTANA,Neutropenic,pain hematuria back pain anorexia peripheral,0
JEVTANA,Neutropenic,"fatigue , vomiting,",1
JEVTANA,Neutropenic,nausea,0
JEVTANA,Neutropenic,",",1
JEVTANA,Neutropenic,nausea,0
JEVTANA,Neutropenic,"thrombocytopenia diarrhea fatigue ,",1
JEVTANA,Neutropenic,reactions are neutropenia,0
JEVTANA,Neutropenic,", vomiting,",1
JEVTANA,deaths,consti,1
JEVTANA,deaths,pain anorexia peripheral,0
JEVTANA,deaths,pain anorexia peripheral neuropathy pyrexia dy,0
JEVTANA,deaths,,0
JEVTANA,hypersensitivity reactions,Trial,0
JEVTANA,hypersensitivity reactions,trials are conducted under,1
JEVTANA,hypersensitivity reactions,or wwwfdagovmedwatch Clinical Trial Experience Because clinical,0
JEVTANA,hypersensitivity reactions,,0
JEVTANA,generalized rash,under widely varying the,1
JEVTANA,generalized rash,under widely varying the adverse,1
JEVTANA,generalized rash,rates observed,0
JEVTANA,generalized rash,,0
JEVTANA,generalized rash,trials and may,0
JEVTANA,erythema,the adverse tion rat,1
JEVTANA,erythema,the adverse,0
JEVTANA,erythema,tion rat,1
JEVTANA,erythema,conditions the adverse tion,1
JEVTANA,erythema,under widely varying conditions the adverse,0
JEVTANA,erythema,under widely varying conditions the adverse,0
JEVTANA,erythema,conducted under widely varying conditions the adverse,0
JEVTANA,erythema,the rates obser,0
JEVTANA,erythema,clinical trials are conducted under widely varying conditions the adverse reac,0
JEVTANA,erythema,Because clinical trials are conducted,0
JEVTANA,hypotension,rates,0
JEVTANA,hypotension,conditions the adverse reaction  observed c,1
JEVTANA,hypotension,,0
JEVTANA,hypotension,observed c,1
JEVTANA,bronchospasm,be,1
JEVTANA,bronchospasm,trials are conducted under widely varying conditions the adverse,0
JEVTANA,bronchospasm,adverse reaction rates observed  be directly,1
JEVTANA,hypersensitivity reactions,cannot be directly to rates in,1
JEVTANA,hypersensitivity reactions,trials,1
JEVTANA,hypersensitivity reactions,observed cannot be directly to,1
JEVTANA,hypersensitivity reactions,rates in other trials,1
JEVTANA,hypersensitivity reactions,cannot be directly compared,0
JEVTANA,hypersensitivity reactions,,0
JEVTANA,Bone marrow suppression,Marrow Suppression,0
JEVTANA,Bone marrow suppression,erse reactions are disc ussed in greater,1
JEVTANA,neutropenia,r detail,1
JEVTANA,neutropenia,r detail,1
JEVTANA,neutropenia,r,1
JEVTANA,neutropenia,r,1
JEVTANA,neutropenia,r detail,1
JEVTANA,febrile neutropenia,in greater detail in another,0
JEVTANA,febrile neutropenia,Hypersensitivity,0
JEVTANA,neutropenic infections,reactions are,0
JEVTANA,neutropenic infections,[see Warnings and,1
JEVTANA,neutropenic infections,Bone Marrow ression [see  Warnings and,1
JEVTANA,neutropenic infections,ression [see Warnings and,1
JEVTANA,neutropenic infections,Warnings and,1
JEVTANA,neutropenic infections,label Bone Marrow Supp,0
JEVTANA,neutropenic infections,Warnings and,1
JEVTANA,neutropenic infections,the label Bone Marrow ression [see,1
JEVTANA,neutropenic infections,discussed in greater detail in another section of the label Bone,0
JEVTANA,Hypersensitivity,Precautions,0
JEVTANA,Hypersensitivity,see ngs and Precauti ons,1
JEVTANA,Hypersensitivity,ngs and Precauti ons,1
JEVTANA,Hypersensitivity,in Elderly Patients see ngs and Precauti ons,1
JEVTANA,Hypersensitivity,Warnings and Precautions Use in Elderly Patients see Warni,0
JEVTANA,Hypersensitivity,Use in Elderly Patients see,0
JEVTANA,Hypersensitivity,Use in Patients with Hepatic Impairment see Warnings and Precautions,0
JEVTANA,Hypersensitivity,,0
JEVTANA,hypersensitivity reactions,Toxicity,0
JEVTANA,hypersensitivity reactions,] . *,1
JEVTANA,hypersensitivity reactions,Impairment see Warnings and Precautions,0
JEVTANA,hypersensitivity reactions,* Use in Patients with,1
JEVTANA,hypersensitivity reactions,] .,1
JEVTANA,Gastrointestinal disorders,adverse reactions (>=10%) are,1
JEVTANA,Gastrointestinal disorders,leukopenia thrombocytopenia diarrhea fatigue nausea vomiting constip,0
JEVTANA,Gastrointestinal disorders,Most common all adverse reactions,1
JEVTANA,Nausea,adverse,0
JEVTANA,Nausea,,0
JEVTANA,vomiting,"openia,  anemia",1
JEVTANA,diarrhea,constipation,0
JEVTANA,diarrhea,fatigue nausea vomiting constipation,0
JEVTANA,diarrhea,",",1
JEVTANA,diarrhea,"are neutropenia ,",1
JEVTANA,diarrhea,", leukop enia",1
JEVTANA,diarrhea,fatigue nausea vomiting constipation,0
JEVTANA,diarrhea,leukop enia,1
JEVTANA,diarrhea,", leukop enia",1
JEVTANA,Mortality,ocytopeni a,1
JEVTANA,Mortality,leukopenia ocytopeni a,1
JEVTANA,Mortality,anemia leukopenia ocytopeni a,1
JEVTANA,Mortality,ocytopeni a,1
JEVTANA,Mortality,,0
JEVTANA,Mortality,ocytopeni a,1
JEVTANA,diarrhea, fatigue nausea,1
JEVTANA,diarrhea,reactions are neutropenia anemia leukopenia thrombocytopenia,0
JEVTANA,diarrhea,neutropenia anemia leukopenia thrombocytopenia  fatigue nausea,1
JEVTANA,Deaths,pain anorexia peripheral neuropathy pyrexia,0
JEVTANA,Deaths,and al opecia,1
JEVTANA,Deaths,dyspnea dysgeusia,0
JEVTANA,Deaths,REACTIONS contact sanofiaventis,0
JEVTANA,Deaths,anorexia peripheral,0
JEVTANA,Deaths,sanofiaventis US,0
JEVTANA,Deaths,anorexia peripheral neuropathy,0
JEVTANA,Deaths,and al opecia,1
JEVTANA,Deaths,anorexia peripheral neuropathy pyrexia dyspnea dysgeusia cough,0
JEVTANA,Deaths,pain anorexia peripheral neuropathy pyrexia dyspnea dysgeusia,0
JEVTANA,Renal failure,trials,0
JEVTANA,Renal failure,,0
JEVTANA,Renal failure,are,0
JEVTANA,Renal failure,conducted,0
JEVTANA,Renal failure,LLC at,0
JEVTANA,Renal failure, www.fda.gov/ medwatch,1
JEVTANA,Renal failure,,0
JEVTANA,Renal failure,at,0
JEVTANA,Renal failure,Experience,0
JEVTANA,fatal,FDA at FDA or .1 Cl inical,1
JEVTANA,fatal,,0
JEVTANA,fatal,FDA at FDA or .1,1
JEVTANA,fatal,under widely varying conditions,0
JEVTANA,fatal,directly to ra tes,1
JEVTANA,fatal,under,0
JEVTANA,fatal,observed cannot be directly to ra tes,1
JEVTANA,fatal,in other trials and may not reflect the rates observed in clinical practice The safety of,0
JEVTANA,fatal,observed,0
JEVTANA,neutropenia,observed in clinical practice he safety o f,1
JEVTANA,neutropenia,trials and may not reflect the rates observed in clinical practice,0
JEVTANA,neutropenia,he safety o f,1
JEVTANA,neutropenia,he safety,1
JEVTANA,neutropenia,in clinical practice he safety,1
JEVTANA,neutropenia,in combination with prednisone was,0
JEVTANA,neutropenia,safety o f,1
JEVTANA,febrile neutropenia,and may not reflect the rates observed in,0
JEVTANA,febrile neutropenia,in,0
JEVTANA,Hepatic impairment,in a,0
JEVTANA,Hepatic impairment,hormone-refracto ry,1
JEVTANA,fetal harm,progression within  of last s tudy,1
JEVTANA,fetal harm,,0
JEVTANA,fetal harm,of,1
JEVTANA,fetal harm,last s tudy,1
JEVTANA,fetal harm,reported in JEVTANAtreated patients and,0
JEVTANA,fetal harm,progression within  of last s tudy,1
JEVTANA,fetal harm,of last s tudy,1
JEVTANA,fetal harm,s tudy,1
JEVTANA,fetal harm,JEVTANAtreated patients and,0
JEVTANA,fetal harm,than disease progression within  of last s tudy,1
JEVTANA,Bone marrow suppression,dose,0
JEVTANA,Bone marrow suppression,patients and mitoxantronetreated ts. The most common fat al,1
JEVTANA,Bone marrow suppression,in JEVTANAtreated patients,0
JEVTANA,Bone marrow suppression,common fat al,1
JEVTANA,Bone marrow suppression,mitoxantronetreated ts. The most common fat al,1
JEVTANA,Bone marrow suppression,The most common fat al,1
JEVTANA,Bone marrow suppression,patients and mitoxantronetreated ts. The most common fat al,1
JEVTANA,Bone marrow suppression,,0
JEVTANA,Bone marrow suppression,The most common fat al,1
JEVTANA,neutropenia,The most,0
JEVTANA,neutropenia,failure n The majority,0
JEVTANA,neutropenia,common fatal adverse,0
JEVTANA,neutropenia,tions in JE VTANAtreated,1
JEVTANA,neutropenia,patients,0
JEVTANA,anemia,majority,0
JEVTANA,anemia,fatal,0
JEVTANA,anemia,ANA-tr eated,1
JEVTANA,anemia,common,0
JEVTANA,pancytopenia,n The majority of patients of,0
JEVTANA,pancytopenia,fatal,0
JEVTANA,pancytopenia,JEVTANAtreated patients were ions (n=5) a nd,1
JEVTANA,pancytopenia,failure n The majority,0
JEVTANA,pancytopenia,,0
JEVTANA,pancytopenia,patients The,0
JEVTANA,pancytopenia,patients were ions (n=5) a nd,1
JEVTANA,pancytopenia,patients were ions (n=5),1
JEVTANA,pancytopenia,ions (n=5) a nd,1
JEVTANA,Neutropenic,infections n and renal lure,1
JEVTANA,Neutropenic,,0
JEVTANA,Neutropenic,of patients of fatal infectionrelated adverse reactions occurred after a,0
JEVTANA,Neutropenic,were infections,0
JEVTANA,Neutropenic,,0
JEVTANA,deaths,renal failure n,0
JEVTANA,deaths,The ma jority,1
JEVTANA,deaths,,0
JEVTANA,deaths,n and renal failure The ma jority,1
JEVTANA,deaths,n and renal failure The ma jority,1
JEVTANA,deaths,,0
JEVTANA,deaths,The ma jority,1
JEVTANA,deaths,in JEVTANAtreated patients were infections n and,0
JEVTANA,fatal,,0
JEVTANA,fatal,after a,1
JEVTANA,fatal,adverse reactions occurred,0
JEVTANA,fatal,of JEVTANA Other fatal adverse reactions in,0
JEVTANA,fatal,fatal adverse reactions in,0
JEVTANA,fatal,adverse reactions after a,1
JEVTANA,fatal,,0
JEVTANA,infectious adverse events,a single dose of,1
JEVTANA,infectious adverse events,infectionrelated adverse reactions occurred a single dose of JEVTANA. Other,1
JEVTANA,infectious adverse events,,0
JEVTANA,sepsis,JEVTANA ther f atal,1
JEVTANA,sepsis,ther f atal,1
JEVTANA,sepsis,ther f atal,1
JEVTANA,sepsis,of JEVTANA,0
JEVTANA,sepsis,infectionrelated adverse reactions occurred,0
JEVTANA,sepsis,dose of JEVTANA ther f atal,1
JEVTANA,septic shock,a single dose of JEVTANA Other fatal,0
JEVTANA,septic shock, adverse rea ctions,1
JEVTANA,septic shock,JEVTANA Other  adverse rea ctions,1
JEVTANA,septic shock,JEVTANA Other  adverse rea ctions,1
JEVTANA,septic shock,Other  adverse rea ctions,1
JEVTANA,septic shock,cerebral hemorrhage and,0
JEVTANA,septic shock,and,0
JEVTANA,septic shock,infectionrelated adverse reactions occurred after a single dose of JEVTANA,0
JEVTANA,neutropenia,adverse reactions in reated pati ents,1
JEVTANA,neutropenia,included ventricular fibrillation,0
JEVTANA,neutropenia,fibrillation cerebral hemorrhage,0
JEVTANA,neutropenia,fatal adverse reactions in JEVTANAt,0
JEVTANA,neutropenia,ventricular fibrillation,0
JEVTANA,neutropenia,most common,0
JEVTANA,neutropenia,in reated,1
JEVTANA,neutropenia,cerebral hemorrhage and dyspnea The most common,0
JEVTANA,febrile neutropenia,lation cerebral hemorrhage and,0
JEVTANA,febrile neutropenia,in JEVTANAtreated patients ventricular,1
JEVTANA,febrile neutropenia,ventricular fibril lation,1
JEVTANA,febrile neutropenia,and dyspnea,0
JEVTANA,death,"cerebral , and dyspnea",1
JEVTANA,death,", and dyspnea",1
JEVTANA,death,grade,0
JEVTANA,death,"cerebral , and dyspnea",1
JEVTANA,death,", and dyspnea",1
JEVTANA,death,"ventricular fibrillation cerebral ,",1
JEVTANA,death,,0
JEVTANA,death,"ventricular fibrillation cerebral ,",1
JEVTANA,death,adverse,0
JEVTANA,death,,0
JEVTANA,infection,,0
JEVTANA,infection,erse reac tions,1
JEVTANA,infection,grade erse,1
JEVTANA,neutropenia,,0
JEVTANA,neutropenia,leuk openia,1
JEVTANA,neutropenia,cerebral hemorrhage and dyspnea The,0
JEVTANA,neutropenia,leuk openia,1
JEVTANA,neutropenia,"nemia, leuk openia",1
JEVTANA,neutropenia,openia neutropenia thrombocytopenia diarrhea,0
JEVTANA,neutropenia,,0
JEVTANA,neutropenia,,0
JEVTANA,neutropenia,,0
JEVTANA,Hypersensitivity reactions,"sone 
                     JEVTANA",1
JEVTANA,Hypersensitivity reactions,Mitoxantr,0
JEVTANA,Hypersensitivity reactions,Prednisone or Mitoxantrone in Combination,0
JEVTANA,Hypersensitivity reactions,in Combination with,0
JEVTANA,Hypersensitivity reactions,JEVTANA mgm,0
JEVTANA,Hypersensitivity reactions,"Combination with sone 
                     JEVTANA",1
JEVTANA,Hypersensitivity reactions,Combination,0
JEVTANA,Hypersensitivity reactions,,0
JEVTANA,Hypersensitivity reactions,with Prednisone or Mitoxantrone in Combination,0
JEVTANA,Hypersensitivity reactions,"sone 
                     JEVTANA",1
JEVTANA,hypersensitivity reactions,Grade 1-4n Grade,1
JEVTANA,hypersensitivity reactions,n,0
JEVTANA,hypersensitivity reactions,Grade n Grade n Grade n Any Adverse,0
JEVTANA,hypersensitivity reactions,with prednisone mg Grade,1
JEVTANA,hypersensitivity reactions,,0
JEVTANA,hypersensitivity reactions,Grade 1-4n Grade,1
JEVTANA,hypersensitivity reactions,1-4n Grade,1
JEVTANA,hypersensitivity reactions,with prednisone mg dailyn,0
JEVTANA,generalized rash,Grade n de 1-4n (%),1
JEVTANA,generalized rash,1-4n (%) Gr ade,1
JEVTANA,generalized rash,1-4n (%) Gr ade,1
JEVTANA,generalized rash,n de 1-4n (%)   Gr ade,1
JEVTANA,generalized rash,,0
JEVTANA,generalized rash,n Grade n de 1-4n,1
JEVTANA,generalized rash,1-4n (%) Gr ade,1
JEVTANA,generalized rash,Adverse Reaction,0
JEVTANA,erythema,n Grade n de 3-4n  Any,1
JEVTANA,erythema,,0
JEVTANA,hypotension,,0
JEVTANA,hypotension,,0
JEVTANA,hypotension,Any Adverse,0
JEVTANA,bronchospasm,Grade,0
JEVTANA,bronchospasm,n Grade n Adverse Reac tion,1
JEVTANA,bronchospasm,Reac tion,1
JEVTANA,bronchospasm,,0
JEVTANA,bronchospasm,Adverse,1
JEVTANA,bronchospasm,Adverse Reac tion,1
JEVTANA,bronchospasm,Adverse Reac tion,1
JEVTANA,bronchospasm,Grade n Grade n Adverse Reac tion,1
JEVTANA,bronchospasm,,0
JEVTANA,bronchospasm,tion Blo,0
JEVTANA,hypersensitivity reactions,,0
JEVTANA,hypersensitivity reactions,Neutropenia (94%) 303,1
JEVTANA,hypersensitivity reactions,Neutropenia,0
JEVTANA,hypersensitivity reactions,Neutropenia (94%) 303,1
JEVTANA,hypersensitivity reactions,Neutropenia (94%)        303 (82%)     Febrile,1
JEVTANA,hypersensitivity reactions,Neutropenia (94%),1
JEVTANA,hypersensitivity reactions,Neutropenia (94%),1
JEVTANA,hypersensitivity reactions,Neutropenia,0
JEVTANA,hypersensitivity reactions,Neutropenia,0
JEVTANA,Nausea,,0
JEVTANA,Nausea,Leukopenia   253  Thrombocytopenia,1
JEVTANA,Nausea,Leukopenia,0
JEVTANA,Nausea,Leukopenia   253  Thrombocytopenia,1
JEVTANA,Nausea,Leukopenia   253  Thrombocytopenia,1
JEVTANA,Nausea,Leukopenia   253  Thrombocytopenia,1
JEVTANA,Nausea,  253  Thrombocytopenia,1
JEVTANA,Nausea,  253  Thrombocytopenia,1
JEVTANA,Nausea,  253  Thrombocytopenia,1
JEVTANA,Nausea,Leukopenia   253  Thrombocytopenia,1
JEVTANA,diarrhea,         Thrombocytopenia,1
JEVTANA,diarrhea,,0
JEVTANA,diarrhea,Leukopenia,0
JEVTANA,diarrhea,Leukopenia          Thrombocytopenia,1
JEVTANA,diarrhea,Leukopenia,0
JEVTANA,diarrhea,Leukopenia,0
JEVTANA,diarrhea,Leukopenia,0
JEVTANA,diarrhea,,0
JEVTANA,Death,Thro mbocy topenia,1
JEVTANA,Death,mbocy topenia,1
JEVTANA,Death,Thro,0
JEVTANA,Death,,0
JEVTANA,diarrhea,Thrombocytopenia,0
JEVTANA,diarrhea,         Cardiac Disorder,1
JEVTANA,diarrhea,,0
JEVTANA,diarrhea,Thrombocytopenia,0
JEVTANA,diarrhea,        ,1
JEVTANA,electrolyte imbalance,Thrombocytopenia          176 (48%)    Cardiac,1
JEVTANA,ileus,Diarrhea,0
JEVTANA,ileus,Diarrhea 47%)  Nausea,1
JEVTANA,ileus,,0
JEVTANA,enterocolitis,,0
JEVTANA,enterocolitis,23 (6%) Nausea,1
JEVTANA,enterocolitis,,0
JEVTANA,enterocolitis,Diarrhea 23,1
JEVTANA,enterocolitis,Nausea,0
JEVTANA,enterocolitis,,0
JEVTANA,enterocolitis,Diarrhea,0
JEVTANA,enterocolitis,Diarrhea,0
JEVTANA,enterocolitis,Diarrhea       23 (6%) Nausea,1
JEVTANA,enterocolitis,Diarrhea 23,1
JEVTANA,neutropenic enterocolitis,1 Nausea,1
JEVTANA,neutropenic enterocolitis,Diarrhea,0
JEVTANA,neutropenic enterocolitis,(11%) 1 Nausea,1
JEVTANA,neutropenic enterocolitis,1 Nausea,1
JEVTANA,neutropenic enterocolitis,Diarrhea 39,1
JEVTANA,fatal,"  
   Nausea",1
JEVTANA,fatal,"a   
   Nausea",1
JEVTANA,fatal,"a   
   Nausea",1
JEVTANA,renal failure,,0
JEVTANA,renal failure,Conditions 136,1
JEVTANA,renal failure,Disorders and Administration Site Conditions Fatigue,0
JEVTANA,renal failure,136,1
JEVTANA,fatal,,0
JEVTANA,fatal,,0
JEVTANA,fatal,      Pyrexia,1
JEVTANA,fatal,Asthenia       Pyrexia,1
JEVTANA,fatal,,0
JEVTANA,fatal,Asthenia,0
JEVTANA,fatal,      Pyrexia,1
JEVTANA,fatal,,0
JEVTANA,sepsis,Asthenia     9  Pyrexia,1
JEVTANA,sepsis,Pyrexia,0
JEVTANA,sepsis,,0
JEVTANA,sepsis,Asthenia,0
JEVTANA,sepsis,    9  Pyrexia,1
JEVTANA,sepsis,Asthenia,0
JEVTANA,dehydration,"%)        
 Pyrexia",1
JEVTANA,dehydration,Pyrexia,0
JEVTANA,dehydration,"Asthenia %)        
 Pyrexia",1
JEVTANA,dehydration,,0
JEVTANA,dehydration,"%)        
 Pyrexia",1
JEVTANA,obstructive uropathy,,0
JEVTANA,deaths,Pyrexia 1%)    Peripheral,1
JEVTANA,renal failure,,0
JEVTANA,renal failure,Pyrexia,0
JEVTANA,renal failure,(6%) Peripheral,1
JEVTANA,renal failure,Pyrexia 23 (6%)       Peripheral Edema,1
JEVTANA,renal failure,Edema,0
JEVTANA,renal failure,Pyrexia 23,1
JEVTANA,neutropenia,"  
   Urina ry Tract",1
JEVTANA,neutropenia,"  
   Urina ry Tract",1
JEVTANA,neutropenia,"ons and   
   Urina ry Tract",1
JEVTANA,neutropenia,,0
JEVTANA,neutropenia,"  
   Urina ry Tract",1
JEVTANA,neutropenia,,0
JEVTANA,neutropenia,"  
   Urina ry Tract",1
JEVTANA,neutropenia,and Infestations,0
JEVTANA,febrile neutropenia,Infection Investigations,1
JEVTANA,febrile neutropenia,,0
JEVTANA,febrile neutropenia,act Infection       Investigations,1
JEVTANA,fetal harm,Spasms,0
JEVTANA,fetal harm, (7%)      Nervous System,1
JEVTANA,embryotoxic,,0
JEVTANA,embryotoxic,System,0
JEVTANA,fetotoxic,          Peripheral Neuropathy,1
JEVTANA,fetotoxic,,0
JEVTANA,fetotoxic,,0
JEVTANA,fetotoxic,          Peripheral Neuropathy,1
ILARIS,infections,reported adverse drug reactions infections predominantly of,1
ILARIS,infections,reported adverse drug reactions,0
ILARIS,infections,infections predominantly of,1
ILARIS,infections,reported adverse drug reactions,0
ILARIS,infections,infections predominantly of,1
ILARIS,infections,majority,0
ILARIS,infections,,0
ILARIS,infections,infections predominantly of,1
ILARIS,infections,infections predominantly of,1
ILARIS,infections,moderate although infections were observed,1
ILARIS,infections,,0
ILARIS,infections,mild to moderate although infections were observed,1
ILARIS,infections,drug reactions,0
ILARIS,infections,moderate although infections were observed,1
ILARIS,infections,upper respiratory tract The majority of the events were mild to moderate although serious,0
ILARIS,infections,to moderate although infections were observed,1
ILARIS,infections,to,0
ILARIS,Opportunistic infections,ILARIS see Warnings,0
ILARIS,Opportunistic infections,Opportunistic,1
ILARIS,Opportunistic infections,time,0
ILARIS,Opportunistic infections,be consistent over,0
ILARIS,Opportunistic infections,Opportunistic,1
ILARIS,Opportunistic infections,consistent over Opportunistic,1
ILARIS,Opportunistic infections,with ILARIS,0
ILARIS,Opportunistic infections,Opportunistic infections have also,1
ILARIS,Opportunistic infections,infections have also,1
ILARIS,Opportunistic infections,treated with,0
ILARIS,diarrhea,than reported by patients with CAPS treated with ILARIS,0
ILARIS,diarrhea,diarrhea influenza headache,1
ILARIS,influenza,influenza headache and,1
ILARIS,influenza,common adverse,0
ILARIS,influenza,with ILARIS are nasopharyngitis diarrhea,0
ILARIS,influenza,influenza headache and,1
ILARIS,influenza,with ILARIS,0
ILARIS,influenza,treated with ILARIS are nasopharyngitis,0
ILARIS,influenza,headache and nausea SJIA The most common adverse drug reactions,0
ILARIS,influenza,CAPS treated with ILARIS are nasopharyngitis diarrhea,0
ILARIS,influenza,greater than,0
ILARIS,headache,headache and nausea,1
ILARIS,headache,headache and nausea,1
ILARIS,headache,ILARIS are,0
ILARIS,nausea,The most common,0
ILARIS,nausea,,0
ILARIS,nausea,CAPS treated with ILARIS are nasopharyngitis,0
ILARIS,infections,upper respiratory tract infections,0
ILARIS,infections,infections nasopharyngitis and,1
ILARIS,infections,and injection site reactio,0
ILARIS,infections,infections nasopharyngitis and,1
ILARIS,infections,infections nasopharyngitis and,1
ILARIS,infections,treated with ILARIS infections nasopharyngitis and,1
ILARIS,infections,SJIA treated with ILARIS are,0
ILARIS,infections,greater than reported by,0
ILARIS,nasopharyngitis,nasopharyngitis and upper,1
ILARIS,nasopharyngitis,with ILARIS are infections,0
ILARIS,nasopharyngitis,nasopharyngitis and upper,1
ILARIS,nasopharyngitis,nasopharyngitis and upper,1
ILARIS,nasopharyngitis,infections,0
ILARIS,upper respiratory tract infections,infections nasopharyngitis upper respiratory tract infections abdominal pain,1
ILARIS,upper respiratory tract infections,upper respiratory tract infections abdominal pain,1
ILARIS,upper respiratory tract infections,infections abdominal pain,1
ILARIS,upper respiratory tract infections,infections nasopharyngitis upper respiratory tract infections abdominal pain,1
ILARIS,upper respiratory tract infections,tract infections abdominal pain,1
ILARIS,upper respiratory tract infections,tract infections abdominal pain,1
ILARIS,upper respiratory tract infections,are infections nasopharyngitis upper respiratory tract,1
ILARIS,upper respiratory tract infections,,0
ILARIS,upper respiratory tract infections,patients with SJIA,0
ILARIS,injection site reactions,abdominal pain injection,1
ILARIS,injection site reactions,infections abdominal pain injection,1
ILARIS,injection site reactions,tract infections abdominal pain injection site reactions To report,1
ILARIS,injection site reactions,reactions To report,1
ILARIS,vertigo,adverse reactions were,0
ILARIS,vertigo,vertigo patients infections,1
ILARIS,vertigo,A total of serious adverse reactions were reported for CAPS patients,0
ILARIS,vertigo,total of serious adverse reactions were reported for CAPS patients Among these were,0
ILARIS,vertigo,vertigo patients infections,1
ILARIS,vertigo,Among these,0
ILARIS,vertigo,vertigo patients infections,1
ILARIS,vertigo,years A total of serious adverse reactions were reported for CAPS patients Among,0
ILARIS,intra-abdominal abscess,intra-abdominal,1
ILARIS,nasopharyngitis,nasopharyngitis diarrhea influenza,1
ILARIS,nasopharyngitis,due to,0
ILARIS,nasopharyngitis,the CAPS patients nasopharyngitis diarrhea influenza,1
ILARIS,nasopharyngitis,reactions associated with ILARIS,0
ILARIS,nasopharyngitis,CAPS patients nasopharyngitis diarrhea influenza,1
ILARIS,influenza,patients were,0
ILARIS,influenza,the,0
ILARIS,influenza,in the CAPS patients,0
ILARIS,influenza,with ILARIS treatment in the,0
ILARIS,influenza,patient discontinued treatment,0
ILARIS,influenza,influenza headache and,1
ILARIS,influenza,influenza headache and,1
ILARIS,influenza,,0
ILARIS,headache,headache and nausea,1
ILARIS,headache,headache and nausea,1
ILARIS,headache,headache and nausea,1
ILARIS,headache,associated with ILARIS treatment in the CAPS patients,0
ILARIS,headache,,0
ILARIS,headache,headache and nausea,1
ILARIS,headache,associated with ILARIS treatment in the CAPS,0
ILARIS,headache,patients were,0
ILARIS,headache,to potential,0
ILARIS,headache,,0
ILARIS,nausea,treatment due to,0
ILARIS,nausea,,0
ILARIS,nausea,ILARIS treatment in the CAPS patients,0
ILARIS,nausea,nausea One patient,1
ILARIS,nausea,nausea One patient,1
ILARIS,nausea,headache nausea One patient,1
ILARIS,nausea,nausea One patient,1
ILARIS,nausea,patient discontinued treatment due to potential infection CAPS Study investigated,0
ILARIS,nausea,investigated the,0
ILARIS,nausea,nasopharyngitis,0
ILARIS,infection,and nausea,0
ILARIS,infection,,0
ILARIS,infection,influenza headache and nausea One patient discontinued treatment due,0
ILARIS,infection,infection CAPS Study,1
ILARIS,infection,due to infection CAPS Study,1
ILARIS,Nasopharyngitis,with Adverse Nasopharyngitis Diarrhea Influenza,1
ILARIS,Nasopharyngitis,Influenza,0
ILARIS,Diarrhea,,0
ILARIS,Diarrhea,Diarrhea Influenza Rhinitis,1
ILARIS,Diarrhea,Diarrhea Influenza Rhinitis,1
ILARIS,Diarrhea,,0
ILARIS,Diarrhea,Diarrhea Influenza Rhinitis,1
ILARIS,Diarrhea,Patients with,0
ILARIS,Diarrhea,Diarrhea Influenza Rhinitis,1
ILARIS,Influenza,Influenza Rhinitis Nausea,1
ILARIS,Influenza,Rhinitis,0
ILARIS,Influenza,,0
ILARIS,Influenza,Influenza Rhinitis Nausea,1
ILARIS,Influenza,Influenza Rhinitis Nausea,1
ILARIS,Influenza,Influenza Rhinitis Nausea,1
ILARIS,Influenza,,0
ILARIS,Influenza,,0
ILARIS,Influenza,Rhinitis,0
ILARIS,Rhinitis,,0
ILARIS,Rhinitis,,0
ILARIS,Rhinitis,Influenza,0
ILARIS,Rhinitis,Rhinitis Nausea Headache,1
ILARIS,Rhinitis,,0
ILARIS,Rhinitis,,0
ILARIS,Rhinitis,Rhinitis Nausea Headache,1
ILARIS,Nausea,Bronchitis,0
ILARIS,Nausea,Nausea Headache Bronchitis,1
ILARIS,Nausea,Nausea Headache Bronchitis,1
ILARIS,Nausea,Nausea Headache Bronchitis,1
ILARIS,Nausea,Nausea Headache Bronchitis,1
ILARIS,Nausea,Influenza Nausea Headache Bronchitis,1
ILARIS,Nausea,Headache,0
ILARIS,Nausea,Nausea Headache Bronchitis,1
ILARIS,Headache,,0
ILARIS,Headache,,0
ILARIS,Headache,Headache Bronchitis Gastroenteritis,1
ILARIS,Headache,Headache Bronchitis Gastroenteritis,1
ILARIS,Headache,Headache Bronchitis Gastroenteritis,1
ILARIS,Headache,Gastroenteritis,0
ILARIS,Headache,Headache Bronchitis Gastroenteritis,1
ILARIS,Headache,Nausea,0
ILARIS,Gastroenteritis,,0
ILARIS,Gastroenteritis,,0
ILARIS,Gastroenteritis,Bronchitis,0
ILARIS,Gastroenteritis,Gastroenteritis Pharyngitis Weight,1
ILARIS,Pharyngitis,Musculoskeletal,0
ILARIS,Pharyngitis,Pharyngitis Weight increased,1
ILARIS,Pharyngitis,pain,0
ILARIS,Weight increased,Musculoskeletal pain,0
ILARIS,Weight increased,Weight,1
ILARIS,Weight increased,pain Vertigo,0
ILARIS,Weight increased,Gastroenteritis Weight increased Musculoskeletal pain,1
ILARIS,Weight increased,Weight increased Musculoskeletal pain,1
ILARIS,Weight increased,increased Musculoskeletal pain,1
ILARIS,Weight increased,Vertigo,0
ILARIS,Weight increased,Weight increased Musculoskeletal pain,1
ILARIS,Weight increased,Weight increased Musculoskeletal pain,1
ILARIS,Weight increased,Gastroenteritis Weight,1
ILARIS,Musculoskeletal pain,Musculoskeletal pain Vertigo Vertigo,1
ILARIS,Musculoskeletal pain,Pharyngitis Weight Musculoskeletal,1
ILARIS,Musculoskeletal pain,,0
ILARIS,Musculoskeletal pain,Weight Musculoskeletal,1
ILARIS,Musculoskeletal pain,Weight,0
ILARIS,Vertigo,increased Musculoskeletal pain,0
ILARIS,Vertigo,,0
ILARIS,Vertigo,pain,0
ILARIS,Vertigo,,0
ILARIS,Vertigo,,0
ILARIS,Vertigo,Musculoskeletal Vertigo Vertigo Vertigo,1
ILARIS,Vertigo,Vertigo Vertigo Vertigo,1
ILARIS,Vertigo,,0
ILARIS,Vertigo,Vertigo Vertigo Vertigo,1
ILARIS,Vertigo,Vertigo has been,1
ILARIS,Vertigo,Vertigo has been,1
ILARIS,Vertigo,,0
ILARIS,Vertigo,Vertigo has been,1
ILARIS,Vertigo,sculoskeletal pain Vertigo Vertigo has been,1
ILARIS,Vertigo,Vertigo,0
ILARIS,Vertigo,pain,0
ILARIS,Vertigo,Vertigo,0
ILARIS,Vertigo,Vertigo has been,1
ILARIS,Vertigo,pain Vertigo Vertigo,0
ILARIS,Vertigo,sculoskeletal pain Vertigo Vertigo has been,1
ILARIS,Vertigo,Vertigo has been,1
ILARIS,subcutaneous injection site reactions,injection site reactions were observed,1
ILARIS,local tolerability reaction,,0
ILARIS,local tolerability reaction,,0
ILARIS,local tolerability reaction,a local tolerability reaction No severe,1
ILARIS,local tolerability reaction,patient had a local tolerability reaction No severe,1
ILARIS,local tolerability reaction,were reported,0
ILARIS,local tolerability reaction,treatment,0
ILARIS,local tolerability reaction,had a local,1
ILARIS,local tolerability reaction,local tolerability,1
ILARIS,injection-site reactions,reported and none led to discontinuation,0
ILARIS,injection-site reactions,No injection-site reactions were reported,1
ILARIS,injection-site reactions,tolerability reaction No injection-site,1
ILARIS,injection-site reactions,reported and none led to,0
ILARIS,injection-site reactions,reaction No,0
ILARIS,injection-site reactions,and in Part one patient,0
ILARIS,injection-site reactions,No injection-site,1
ILARIS,injection-site reactions,reaction No injection-site,1
ILARIS,injection-site reactions,reported and,0
ILARIS,infections,trials The adverse drug reactions associated with ILARIS,0
ILARIS,infections,infections abdominal pain,1
ILARIS,infections,infections abdominal pain,1
ILARIS,infections,infections abdominal pain,1
ILARIS,infections,,0
ILARIS,infections,,0
ILARIS,infections,infections abdominal pain,1
ILARIS,infections,infections abdominal pain,1
ILARIS,abdominal pain,abdominal pain and injection,1
ILARIS,abdominal pain,adverse drug reactions associated with ILARIS treatment in,0
ILARIS,abdominal pain,abdominal pain and injection,1
ILARIS,abdominal pain,pain and injection,1
ILARIS,abdominal pain,site reactions,0
ILARIS,abdominal pain,pain and injection,1
ILARIS,injection site reactions,injection site reactions Serious infections,1
ILARIS,injection site reactions,,0
ILARIS,injection site reactions,pain injection site,1
ILARIS,injection site reactions,pneumonia varicella,0
ILARIS,infections,infections eg pneumonia,1
ILARIS,infections,infections eg pneumonia,1
ILARIS,infections,site reactions Serious,0
ILARIS,infections,infections eg pneumonia,1
ILARIS,infections,infections eg pneumonia,1
ILARIS,infections,varicella gastroenteritis measles sepsis otitis,0
ILARIS,infections,sepsis otitis,0
ILARIS,infections,site reactions infections eg pneumonia,1
ILARIS,infections,infections eg pneumonia,1
ILARIS,infections,infections eg pneumonia,1
ILARIS,pneumonia,reactions Serious infections pneumonia varicella gastroenteritis,1
ILARIS,pneumonia,patients were infections,0
ILARIS,pneumonia,varicella gastroenteritis measles sepsis otitis media sinusitis,0
ILARIS,pneumonia,infections,0
ILARIS,varicella,sinusitis,0
ILARIS,varicella,Serious infections eg varicella gastroenteritis measles,1
ILARIS,gastroenteritis,infections eg,0
ILARIS,gastroenteritis,Serious infections eg pneumonia gastroenteritis measles sepsis,1
ILARIS,gastroenteritis,gastroenteritis measles sepsis,1
ILARIS,gastroenteritis,reactions Serious infections eg pneumonia,0
ILARIS,gastroenteritis,gastroenteritis measles sepsis,1
ILARIS,gastroenteritis,gastroenteritis measles sepsis,1
ILARIS,gastroenteritis,were observ,0
ILARIS,gastroenteritis,and,0
ILARIS,gastroenteritis,node abscess pharyngitis,0
ILARIS,measles,sepsis otitis media sinusitis adenovirus lymph,0
ILARIS,sepsis,lymph,0
ILARIS,sepsis,lymph node abscess pharyngitis were,0
ILARIS,sepsis,sepsis otitis media,1
ILARIS,sepsis,infections eg pneumonia varicella gastroenteritis,0
ILARIS,sepsis,sinusitis adenovirus lymph node abscess,0
ILARIS,sepsis,sepsis otitis media,1
ILARIS,sepsis,,0
ILARIS,sepsis,sepsis otitis media,1
ILARIS,sepsis,site reactions Serious infections eg pneumonia,0
ILARIS,sepsis,site reactions Serious infections eg pneumonia varicella,0
ILARIS,otitis media,Serious infections eg pneumonia varicella gastroenteritis measles sepsis,0
ILARIS,otitis media,observed in approximately,0
ILARIS,sinusitis,gastroenteritis measles,0
ILARIS,sinusitis,adenovirus lymph,0
ILARIS,sinusitis,sinusitis adenovirus lymph,1
ILARIS,sinusitis,measles sepsis otitis sinusitis adenovirus lymph,1
ILARIS,sinusitis,sinusitis adenovirus lymph,1
ILARIS,sinusitis,sinusitis adenovirus lymph,1
ILARIS,sinusitis,sinusitis adenovirus lymph,1
ILARIS,sinusitis,sinusitis adenovirus lymph,1
ILARIS,sinusitis,adenovirus lymph node abscess pharyngitis were,0
ILARIS,sinusitis,gastroenteritis measles sepsis otitis sinusitis adenovirus lymph,1
ILARIS,adenovirus,adenovirus lymph node,1
ILARIS,adenovirus,,0
ILARIS,adenovirus,adenovirus lymph node,1
ILARIS,adenovirus,adenovirus lymph node,1
ILARIS,adenovirus,,0
ILARIS,adenovirus,,0
ILARIS,adenovirus,adenovirus lymph node,1
ILARIS,adenovirus,eg pneumonia,0
ILARIS,adenovirus,otitis media adenovirus lymph node,1
ILARIS,lymph node abscess,lymph node abscess pharyngitis were,1
ILARIS,lymph node abscess,media sinusitis lymph,1
ILARIS,pharyngitis,patients,0
ILARIS,pharyngitis,pharyngitis were observed,1
ILARIS,pharyngitis,pharyngitis were observed,1
ILARIS,pharyngitis,in,0
ILARIS,pharyngitis,in approximately to to per,0
ILARIS,pharyngitis,pharyngitis were observed,1
ILARIS,Infections,Infections eg nasopharyngitis,1
ILARIS,Infections,IR Infections and infestations Infections eg nasopharyngitis,1
ILARIS,Infections,infection,0
ILARIS,Infections,Infections eg nasopharyngitis,1
ILARIS,Infections,ILARISNn IR PlaceboNn IR Infections and infestations,0
ILARIS,Infections,eg nasopharyngitis viral upper,0
ILARIS,nasopharyngitis,nasopharyngitis viral upper,1
ILARIS,nasopharyngitis,nasopharyngitis viral upper,1
ILARIS,nasopharyngitis,rhinitis pharyngitis tonsillitis sinusiti,0
ILARIS,pneumonia,pneumonia rhinitis pharyngitis,1
ILARIS,pneumonia,tonsillitis sinusitis,0
ILARIS,pneumonia,viral upper respiratory tract pneumonia rhinitis pharyngitis,1
ILARIS,pneumonia,pneumonia rhinitis pharyngitis,1
ILARIS,rhinitis,rhinitis pharyngitis tonsillitis,1
ILARIS,rhinitis,,0
ILARIS,rhinitis,rhinitis pharyngitis tonsillitis,1
ILARIS,rhinitis,tract infection gastroenteritis viral infection,0
ILARIS,rhinitis,rhinitis pharyngitis tonsillitis,1
ILARIS,rhinitis,,0
ILARIS,rhinitis,infection rhinitis pharyngitis tonsillitis,1
ILARIS,pharyngitis,pharyngitis tonsillitis sinusitis,1
ILARIS,pharyngitis,pharyngitis tonsillitis sinusitis,1
ILARIS,pharyngitis,,0
ILARIS,pharyngitis,respiratory,0
ILARIS,pharyngitis,upper respiratory,0
ILARIS,pharyngitis,pharyngitis tonsillitis sinusitis,1
ILARIS,pharyngitis,pharyngitis tonsillitis sinusitis,1
ILARIS,pharyngitis,pharyngitis tonsillitis sinusitis,1
ILARIS,pharyngitis,infection,0
ILARIS,tonsillitis,tonsillitis sinusitis urinary,1
ILARIS,tonsillitis,nasopharyngitis viral upper respiratory tract,0
ILARIS,tonsillitis,tonsillitis sinusitis urinary,1
ILARIS,tonsillitis,tonsillitis sinusitis urinary,1
ILARIS,tonsillitis,tonsillitis sinusitis urinary,1
ILARIS,tonsillitis,tonsillitis sinusitis urinary,1
ILARIS,sinusitis,tract infection gastroenteritis,0
ILARIS,sinusitis,rhinitis pharyngitis,0
ILARIS,sinusitis,infection,0
ILARIS,sinusitis,sinusitis urinary tract,1
ILARIS,urinary tract infection,,0
ILARIS,urinary tract infection,tract infection pneumonia rhinitis pharyngitis tonsillitis sinusitis,0
ILARIS,urinary tract infection,,0
ILARIS,gastroenteritis,,0
ILARIS,gastroenteritis,tract gastroenteritis viral infection,1
ILARIS,gastroenteritis,,0
ILARIS,gastroenteritis,,0
ILARIS,gastroenteritis,gastroenteritis viral infection,1
ILARIS,gastroenteritis,,0
ILARIS,viral infection,viral infection Gastr,1
ILARIS,viral infection,sinusitis urinary tract infection viral,1
ILARIS,viral infection,rhinitis,0
ILARIS,viral infection,urinary tract infection viral infection Gastr,1
ILARIS,viral infection,infection gastroenteritis,0
ILARIS,viral infection,,0
ILARIS,viral infection,infection viral infection Gastr,1
ILARIS,viral infection,urinary tract infection viral,1
ILARIS,viral infection,viral infection Gastr,1
ILARIS,Injection site reaction,reaction mild,1
ILARIS,Injection site reaction,mild,0
ILARIS,Injection site reaction,Skin and subcutaneous tissue Injection site reaction mild,1
ILARIS,Injection site reaction,tissue,0
ILARIS,Injection site reaction,,0
ILARIS,Injection site reaction,and subcutaneous tissue,0
ILARIS,Injection site reaction,reaction mild,1
ILARIS,Injection site reaction,mild,0
ILARIS,Injection site reaction,,0
ILARIS,anaphylactic reactions,During clinical trials,0
ILARIS,anaphylactic reactions,trials no,0
ILARIS,anaphylactic reactions,SJIA trials no patients,0
ILARIS,anaphylactic reactions,anaphylactic reactions have been,1
ILARIS,anaphylactic reactions,,0
ILARIS,anaphylactic reactions,reactions have been,1
ILARIS,anaphylactic reactions,During clinical trials anaphylactic,1
ILARIS,anaphylactic reactions,CAPS trials one patient discontinued and in,0
ILARIS,hypersensitivity reactions,trials no patients discontinued due to,0
ILARIS,decreased white blood cell counts,In the randomized placebocontrolled portion of SJIA Study,0
ILARIS,decreased white blood cell counts,,0
ILARIS,decreased white blood cell counts,portion of SJIA decreased white,1
ILARIS,decreased white blood cell counts,SJIA,0
ILARIS,decreases in absolute neutrophil count,in the placebo group decreases in absolute neutrophil count ANC to,1
ILARIS,decreases in absolute neutrophil count,less than x L were reported in patients in the ILARIS group compared,0
ILARIS,decreases in absolute neutrophil count,the ILARIS group,0
ILARIS,decreases in absolute neutrophil count,in absolute neutrophil count ANC to,1
ILARIS,ANC less than 0.5x10 9 /L,ANC less than 0.5x10 9 /L was observed,1
ILARIS,ANC less than 0.5x10 9 /L,placebo group One case ANC less than 0.5x10  9  /L was observed,1
ILARIS,ANC less than 0.5x10 9 /L,9 /L was observed,1
ILARIS,ANC less than 0.5x10 9 /L,compared to patient in the placebo group One,0
ILARIS,ANC less than 0.5x10 9 /L,the ILARIS group compared to patient,0
ILARIS,ANC less than 0.5x10 9 /L,case ANC less than 0.5x10  9  /L was observed,1
ILARIS,ANC less than 0.5x10 9 /L,group and none in the placebo group Mild less,0
ILARIS,decreases in platelet counts,decreases in platelet counts were observed,1
ILARIS,decreases in platelet counts,platelet counts were observed,1
ILARIS,decreases in platelet counts,and decreases,1
ILARIS,decreases in platelet counts,none in the placebo group Mild less than LLN and greater than x L,0
ILARIS,decreases in platelet counts,than LLN and greater than x L and,0
ILARIS,decreases in platelet counts,patient He,0
ILARIS,decreases in platelet counts,in platelet counts were observed,1
ILARIS,Elevations of transaminases,treated patients versus placebotreated patient Hepatic,0
ILARIS,Elevations of transaminases,with ILARIS In the randomized placebocontrolled,0
ILARIS,Elevations of transaminases,Elevations,1
ILARIS,Elevations of transaminases,Elevations of transaminases have been,1
ILARIS,Elevations of transaminases,Hepatic Elevations of transaminases have been,1
ILARIS,high ALT,randomized placebocontrolled portion of,0
ILARIS,high ALT,ILARIS In the,0
ILARIS,high ALT,AST,0
ILARIS,high ALT,patients treated with ILARIS,0
ILARIS,high ALT,equal to times upper limit,0
ILARIS,high ALT,portion of SJIA high ALT andor AST,1
ILARIS,high ALT,were reported in I,0
ILARIS,elevations of serum bilirubin,elevations of serum bilirubin have been,1
ILARIS,elevations of serum bilirubin,serum bilirubin have been,1
ILARIS,elevations of serum bilirubin,and elevations of serum bilirubin have been,1
ILARIS,elevations of serum bilirubin,Asymptomatic and elevations,1
ILARIS,elevations of serum bilirubin,visit Bilirubin Asymptomatic and elevations of,1
ILARIS,elevations of serum bilirubin,,0
ILARIS,elevations of serum bilirubin,,0
ILARIS,elevations of serum bilirubin,elevations of serum bilirubin have been,1
ILARIS,infections,fections predominantly of the,0
ILARIS,infections,ns were in fections predominantly,1
ILARIS,infections,drug ns,1
ILARIS,infections,reported adverse drug reactio,0
ILARIS,infections,ns were,1
ILARIS,infections,were in fections predominantly,1
ILARIS,infections,,0
ILARIS,infections,in interventional trials in CAPS or,0
ILARIS,infections,fections predominantly of the upper respiratory tract,0
ILARIS,infections,fections predominantly of the upper respiratory tract The majority,0
ILARIS,infections,the eve nts were,1
ILARIS,infections,,0
ILARIS,infections,site reactions To report,0
ILARIS,Infections,a dr ug cannot,1
ILARIS,Infections,ls of a dr ug cannot,1
ILARIS,Infections,in the clinical ls of a dr ug cannot,1
ILARIS,Infections,ls of a dr ug cannot,1
ILARIS,Infections,in the clinical ls,1
ILARIS,infections,"


   Trea tment of",1
ILARIS,infections,"


   Trea tment of",1
ILARIS,infections,"


   Trea tment of",1
ILARIS,infections,"rates observed in 


   Trea tment of",1
ILARIS,infections,"rates observed in 


   Trea tment of",1
ILARIS,infections,,0
ILARIS,infections,"


   Trea tment of",1
ILARIS,infections,"


   Trea tment of",1
ILARIS,opportunistic infections,to ILARIS in 104 adult and pediatric,1
ILARIS,opportunistic infections,described herein reflect e to ILARIS in 104 adult and pediatric,1
ILARIS,opportunistic infections,described herein reflect e to,1
ILARIS,opportunistic infections,,0
ILARIS,opportunistic infections,in 104 adult and pediatric,1
ILARIS,aspergillosis,,0
ILARIS,aspergillosis,ILARIS in adult and iatric CAPS p atients including,1
ILARIS,aspergillosis,ped,0
ILARIS,aspergillosis,iatric CAPS p atients including,1
ILARIS,aspergillosis,ILARIS,0
ILARIS,aspergillosis,Neonatal,0
ILARIS,aspergillosis,and iatric CAPS p atients including,1
ILARIS,atypical mycobacterial infections,,0
ILARIS,herpes zoster,,0
ILARIS,herpes zoster,ILARIS,0
ILARIS,herpes zoster,including FCAS,0
ILARIS,infections,were vertigo,0
ILARIS,infections,A total of serious,1
ILARIS,infections,s. A,1
ILARIS,infections,at least s. A total of serious,1
ILARIS,infections,least months for at least year and for at,0
ILARIS,infections,at least months for at least year and for,0
ILARIS,infections,for CAPS patients Among these,0
ILARIS,infections,total of serious,1
ILARIS,reactivation of tuberculosis,"1), followed by a week randomized",1
ILARIS,opportunistic infections,withdrawal period Part,1
ILARIS,malignancies,usculoskelet al pain,1
ILARIS,malignancies,M,0
ILARIS,malignancies,usculoskelet al pain,1
ILARIS,Hypersensitivity reactions,pain,0
ILARIS,Hypersensitivity reactions,(11) Vertigo Vertigo,1
ILARIS,Hypersensitivity reactions,Musculoskeletal pain Vertigo,0
ILARIS,Hypersensitivity reactions,"Musculoskeletal pain        4 (11)            
 Vertigo Vertigo",1
ILARIS,Hypersensitivity reactions,Vertigo,0
ILARIS,Hypersensitivity reactions,increased Musculoskeletal,0
ILARIS,Hypersensitivity reactions,,0
ILARIS,Hypersensitivity reactions,"pain        4 (11)            
 Vertigo Vertigo",1
ILARIS,Hypersensitivity reactions,increased Musculoskeletal pain 4,1
ILARIS,Hypersensitivity reactions,pain Vertigo,0
ILARIS,anaphylactic reactions,,0
ILARIS,anaphylactic reactions,Vertigo Vertigo has been reported,0
ILARIS,anaphylactic reactions,in,0
ILARIS,anaphylactic reactions,in to of tients in,1
ILARIS,interfere with normal immune response,,0
ILARIS,interfere with normal immune response,received ILARIS in trials.,1
ILARIS,MAS,"is, adenovirus lymph",1
ILARIS,MAS,,0
ILARIS,MAS,"is, adenovirus lymph",1
ILARIS,MAS,are listed according to MedDRA version system organ class,0
ILARIS,MAS,to MedDRA version system organ class Table Tabulated,0
ILARIS,MAS,both studies A,0
ILARIS,MAS,ILARIS in both studies dve rse reactions,1
ILARIS,MAS,are listed according to MedDRA version system organ class Table Tabulated,0
ILARIS,MAS,organ,0
ILARIS,MAS,in both studies dve rse reactions,1
ILARIS,MAS,ILARIS,0
ILARIS,MAS,MedDRA version system,0
AMPYRA,Seizures,Precautions section of the Seizures Anaphylaxis and,1
AMPYRA,Seizures,Urinary,0
AMPYRA,Seizures,Anaphylaxis and Urinary Tract,0
AMPYRA,Seizures,Precautions section of the Seizures Anaphylaxis and,1
AMPYRA,Seizures,The,0
AMPYRA,Seizures,in,0
AMPYRA,Seizures,Seizures Anaphylaxis and,1
AMPYRA,Seizures,Seizures Anaphylaxis and,1
AMPYRA,Anaphylaxis,the,0
AMPYRA,Anaphylaxis,Anaphylaxis and Urinary,1
AMPYRA,Anaphylaxis,are described in more,0
AMPYRA,Anaphylaxis,,0
AMPYRA,Anaphylaxis,Anaphylaxis and Urinary,1
AMPYRA,Anaphylaxis,Anaphylaxis and Urinary,1
AMPYRA,Anaphylaxis,Anaphylaxis and Urinary,1
AMPYRA,Anaphylaxis,in the Warnings and,0
AMPYRA,Anaphylaxis,Precautions section of the label,0
AMPYRA,Urinary Tract Infections,pla,0
AMPYRA,urinary tract infection,placebo rate for AMPYRA urinary tract,1
AMPYRA,urinary tract infection,urinary tract infection insomnia dizziness,1
AMPYRA,urinary tract infection,sclerosis,0
AMPYRA,urinary tract infection,tract infection insomnia dizziness,1
AMPYRA,urinary tract infection,nausea,0
AMPYRA,urinary tract infection,urinary tract infection insomnia dizziness,1
AMPYRA,urinary tract infection,placebo rate for AMPYRA urinary,1
AMPYRA,urinary tract infection,insomnia dizziness headache nausea asthenia back,0
AMPYRA,urinary tract infection,asthenia back pain balance disorder multiple,0
AMPYRA,insomnia,AMPYRA were urinary tract infection,0
AMPYRA,insomnia,insomnia dizziness headache,1
AMPYRA,insomnia,tract insomnia dizziness headache,1
AMPYRA,insomnia,insomnia dizziness headache,1
AMPYRA,insomnia,tract insomnia dizziness headache,1
AMPYRA,dizziness,dizziness headache nausea,1
AMPYRA,dizziness,dizziness headache nausea,1
AMPYRA,dizziness,greater than,0
AMPYRA,dizziness,were urinary tract infection dizziness headache nausea,1
AMPYRA,dizziness,dizziness headache nausea,1
AMPYRA,dizziness,dizziness headache nausea,1
AMPYRA,dizziness,dizziness headache nausea,1
AMPYRA,nausea,disorder,0
AMPYRA,nausea,multiple sclerosis relapse paresthesia nasopharyngitis,0
AMPYRA,nausea,nausea asthenia back,1
AMPYRA,nausea,dizziness nausea asthenia back,1
AMPYRA,nausea,nausea asthenia back,1
AMPYRA,nausea,nausea asthenia back,1
AMPYRA,nausea,nausea asthenia back,1
AMPYRA,asthenia,for AMPYRA were urinary tract infection insomnia,0
AMPYRA,back pain,disorder multiple sclerosis relapse paresthesia nasopharyngitis constipation,0
AMPYRA,back pain,headache nausea,0
AMPYRA,back pain,relapse,0
AMPYRA,back pain,nausea back,1
AMPYRA,back pain,nausea back,1
AMPYRA,back pain,nausea back pain balance disorder,1
AMPYRA,back pain,insomnia dizziness headache nausea back pain balance disorder,1
AMPYRA,back pain,paresthesia nasopharyngitis constipation,0
AMPYRA,back pain,dizziness headache nausea back pain balance disorder,1
AMPYRA,back pain,for AMPYRA were urinary tract infection insomnia dizziness headache nausea,0
AMPYRA,balance disorder,nausea asthenia back balance,1
AMPYRA,balance disorder,back,0
AMPYRA,balance disorder,balance,1
AMPYRA,multiple sclerosis relapse,,0
AMPYRA,nasopharyngitis,nasopharyngitis constipation dyspepsia,1
AMPYRA,nasopharyngitis,nasopharyngitis constipation dyspepsia,1
AMPYRA,nasopharyngitis,multiple sclerosis relapse paresthesia,0
AMPYRA,nasopharyngitis,ADVERSE REACTI,0
AMPYRA,nasopharyngitis,nasopharyngitis constipation dyspepsia,1
AMPYRA,nasopharyngitis,nasopharyngitis constipation dyspepsia,1
AMPYRA,nasopharyngitis,nasopharyngitis constipation dyspepsia,1
AMPYRA,nasopharyngitis,nasopharyngitis constipation dyspepsia,1
AMPYRA,constipation,multiple sclerosis relapse paresthesia constipation dyspepsia and,1
AMPYRA,constipation,constipation dyspepsia and,1
AMPYRA,constipation,constipation dyspepsia and,1
AMPYRA,constipation,nasopharyngitis,0
AMPYRA,constipation,sclerosis relapse paresthesia constipation dyspepsia and,1
AMPYRA,constipation,pain balance disorder multiple sclerosis,0
AMPYRA,constipation,relapse paresthesia constipation dyspepsia and,1
AMPYRA,constipation,relapse paresthesia constipation dyspepsia and,1
AMPYRA,constipation,constipation dyspepsia and,1
AMPYRA,dyspepsia,disorder multiple sclerosis relapse paresthesia nasopharyngitis,0
AMPYRA,dyspepsia,pain To report SUSPECTED ADVERSE REACTIONS contact Acorda,0
AMPYRA,dyspepsia,dyspepsia and pharyngolaryngeal,1
AMPYRA,dyspepsia,dyspepsia and pharyngolaryngeal,1
AMPYRA,dyspepsia,dyspepsia and pharyngolaryngeal,1
AMPYRA,dyspepsia,dyspepsia and pharyngolaryngeal,1
AMPYRA,pharyngolaryngeal pain,,0
AMPYRA,headache,led,0
AMPYRA,headache,headache AMPYRA placebo,1
AMPYRA,headache,disorder AMPYRA,0
AMPYRA,headache,and,0
AMPYRA,headache,headache AMPYRA placebo,1
AMPYRA,balance disorder,balance disorder AMPYRA placebo,1
AMPYRA,balance disorder,placebo were headache AMPYRA placebo,0
AMPYRA,balance disorder,,0
AMPYRA,dizziness,,0
AMPYRA,dizziness,dizziness AMPYRA placebo,1
AMPYRA,dizziness,placebo were headache AMPYRA placebo,0
AMPYRA,dizziness,dizziness AMPYRA placebo,1
AMPYRA,dizziness,AMPYRA dizziness AMPYRA placebo,1
AMPYRA,dizziness,placebo Table lists adver,0
AMPYRA,dizziness,lists,0
AMPYRA,dizziness,placebo Table,0
AMPYRA,confusional state,state AMPYRA placebo,1
AMPYRA,confusional state,placebo dizziness AMPYRA placebo confusional state AMPYRA placebo,1
AMPYRA,Urinary tract infection,mg twice dailyN,0
AMPYRA,Urinary tract infection,Urinary tract infection Insomnia,1
AMPYRA,Urinary tract infection,twice,0
AMPYRA,Urinary tract infection,mg twice dailyN,0
AMPYRA,Urinary tract infection,twice,0
AMPYRA,Urinary tract infection,mg twice dailyN,0
AMPYRA,Urinary tract infection,,0
AMPYRA,Urinary tract infection,Urinary,1
AMPYRA,Urinary tract infection,AMPYRA mg twice Urinary tract infection Insomnia,1
AMPYRA,Urinary tract infection,AMPYRA mg twice Urinary tract infection Insomnia,1
AMPYRA,Insomnia,Insomnia,1
AMPYRA,Insomnia,,0
AMPYRA,Insomnia,ract Insomnia,1
AMPYRA,Insomnia,Insomnia,1
AMPYRA,Insomnia,Insomnia,1
AMPYRA,Dizziness,Dizziness,1
AMPYRA,Headache,Headache,1
AMPYRA,Headache,,0
AMPYRA,Headache,,0
AMPYRA,Headache,Headache,1
AMPYRA,Headache,,0
AMPYRA,Headache,,0
AMPYRA,Headache,Headache,1
AMPYRA,Headache,,0
AMPYRA,Nausea,,0
AMPYRA,Nausea,,0
AMPYRA,Nausea,Nausea,1
AMPYRA,Nausea,,0
AMPYRA,Nausea,Nausea,1
AMPYRA,Nausea,Nausea,1
AMPYRA,Nausea,,0
AMPYRA,Nausea,Nausea,1
AMPYRA,Nausea,Nausea,1
AMPYRA,Asthenia,,0
AMPYRA,Asthenia,Asthenia,1
AMPYRA,Asthenia,Asthenia,1
AMPYRA,Back pain,Back pain,1
AMPYRA,Back pain,Back,1
AMPYRA,Back pain,Back pain,1
AMPYRA,Back pain,Back,1
AMPYRA,Balance disorder,Balance disorder Multipl,1
AMPYRA,Balance disorder,,0
AMPYRA,Balance disorder,,0
AMPYRA,Balance disorder,,0
AMPYRA,Balance disorder,,0
AMPYRA,Balance disorder,,0
AMPYRA,Balance disorder,disorder Multipl,1
AMPYRA,Multiple sclerosis relapse,relapse Paresthesia,1
AMPYRA,Multiple sclerosis relapse,isorder Multiple sclerosis,1
AMPYRA,Multiple sclerosis relapse,isorder Multiple,1
AMPYRA,Multiple sclerosis relapse,isorder Multiple,1
AMPYRA,Multiple sclerosis relapse,isorder,0
AMPYRA,Multiple sclerosis relapse,,0
AMPYRA,Multiple sclerosis relapse,isorder Multiple sclerosis relapse Paresthesia,1
AMPYRA,Multiple sclerosis relapse,isorder Multiple sclerosis relapse Paresthesia,1
AMPYRA,Multiple sclerosis relapse,isorder Multiple,1
AMPYRA,Paresthesia,Na,0
AMPYRA,Paresthesia,Paresthesia Na,1
AMPYRA,Nasopharyngitis,Nasopharyngitis Consti,1
AMPYRA,Nasopharyngitis,ia Nasopharyngitis Consti,1
AMPYRA,Nasopharyngitis,ia,0
AMPYRA,Nasopharyngitis,Nasopharyngitis Consti,1
AMPYRA,Nasopharyngitis,ia,0
AMPYRA,Nasopharyngitis,ia Nasopharyngitis Consti,1
AMPYRA,Nasopharyngitis,Nasopharyngitis Consti,1
AMPYRA,Nasopharyngitis,ia,0
AMPYRA,Constipation,ngitis Constipation Dys,1
AMPYRA,Constipation,Constipation Dys,1
AMPYRA,Constipation,Constipation Dys,1
AMPYRA,Constipation,ngitis,0
AMPYRA,Constipation,Constipation Dys,1
AMPYRA,Constipation,ngitis,0
AMPYRA,Constipation,ngitis,0
AMPYRA,Constipation,,0
AMPYRA,Dyspepsia,,0
AMPYRA,Dyspepsia,,0
AMPYRA,Dyspepsia,ion,0
AMPYRA,Dyspepsia,ion Dyspepsia,1
AMPYRA,Dyspepsia,Dyspepsia,1
AMPYRA,Dyspepsia,,0
AMPYRA,Dyspepsia,ion Dyspepsia,1
AMPYRA,Dyspepsia,Dyspepsia,1
AMPYRA,Pharyngolaryngeal pain,,0
AMPYRA,Pharyngolaryngeal pain,Pharyngolaryngeal,1
AMPYRA,Pharyngolaryngeal pain,Pharyngolaryngeal pain,1
AMPYRA,Pharyngolaryngeal pain,,0
AMPYRA,Pharyngolaryngeal pain,,0
AMPYRA,seizures,,0
AMPYRA,seizures,seizures,1
AMPYRA,seizures,,0
AMPYRA,seizures,increase in the,0
AMPYRA,seizures,seizures,1
AMPYRA,seizures,increase in the incidence seizures,1
AMPYRA,seizures,seizures,1
AMPYRA,seizures,been observed in openlabel,0
AMPYRA,seizures,er widel y varying conditions,1
AMPYRA,seizures,widel,1
AMPYRA,seizures,drug cannot be di,0
AMPYRA,seizures,er,1
AMPYRA,seizures,y varying conditions adverse reaction rates observed in the clinical studies of a drug,0
AMPYRA,seizures,widel y varying conditions adverse,1
AMPYRA,seizures,er widel y varying conditions,1
AMPYRA,seizures,er widel y varying conditions adverse,1
AMPYRA,seizures,er widel,1
AMPYRA,seizures,"itions,  adverse reaction rates observed in",1
AMPYRA,seizures,,0
AMPYRA,seizures,"itions,  adverse reaction",1
AMPYRA,seizures, common  adverse events,1
AMPYRA,seizures, common  adverse events,1
AMPYRA,seizures, common  adverse events,1
AMPYRA,seizures,urinary,0
AMPYRA,seizures, common  adverse events,1
AMPYRA,seizures,an d at,1
AMPYRA,seizures,>=2% an d at,1
AMPYRA,seizures,>=2%,1
AMPYRA,seizures, >=2% an d at,1
AMPYRA,seizures,>=2%,1
AMPYRA,seizures,"sia,",1
AMPYRA,seizures,"sia, nas opharyngitis constipation",1
AMPYRA,seizures,"relapse sia,",1
AMPYRA,seizures,opharyngitis constipation dyspepsia and pharyngolaryngeal pain To report,0
AMPYRA,seizures,ww.fda.g ovmedwatch Controlled,1
AMPYRA,seizures,ww.fda.g ovmedwatch Controlled,1
AMPYRA,seizures,         Dizziness,1
AMPYRA,respiratory compromise,                 5%   ,1
AMPYRA,respiratory compromise,pain,0
AMPYRA,respiratory compromise,                 5%   ,1
AMPYRA,respiratory compromise,                 5%   ,1
AMPYRA,respiratory compromise,Balance disorder,0
AMPYRA,respiratory compromise,,0
AMPYRA,urticaria,         ,1
AMPYRA,urticaria,         ,1
AMPYRA,urticaria,,0
AMPYRA,urticaria,         ,1
AMPYRA,urticaria,,0
AMPYRA,urticaria,,0
AMPYRA,urticaria,         ,1
AMPYRA,angioedema of the throat,pain,0
AMPYRA,angioedema of the throat,,0
AMPYRA,angioedema of the throat,,0
AMPYRA,angioedema of the throat,"pain   
 Balance disorder     Multiple",1
AMPYRA,angioedema of the throat,pain Balance,1
AMPYRA,angioedema of the throat,pain,0
AMPYRA,angioedema of the throat,,0
AMPYRA,angioedema of the throat,"pain   
 Balance disorder     Multiple sc",1
AMPYRA,angioedema of the throat,,0
AMPYRA,Urinary tract infections,    3%                   Nasopharyngitis,1
AMPYRA,Urinary tract infections,Paresthesia     3%                   Nasopharyngitis,1
AMPYRA,Urinary tract infections,Paresthesia     3%                   Nasopharyngitis,1
AMPYRA,Urinary tract infections,Paresthesia,0
AMPYRA,Urinary tract infections,    3%                   Nasopharyngitis,1
AMPYRA,Urinary tract infections,Paresthesia     3%                   Nasopharyngitis,1
AMPYRA,Urinary tract infections,Paresthesia     3%                   Nasopharyngitis,1
AMPYRA,Urinary tract infections,,0
AMPYRA,Urinary tract infections,Paresthesia     3%                   Nasopharyngitis,1
AMPYRA,UTIs,,0
SIRTURO,Increased mortality,the Increased,1
SIRTURO,Increased mortality,mortality,1
SIRTURO,Increased mortality,Increased mortality,1
SIRTURO,Increased mortality,Warnings and Precautions,0
SIRTURO,Increased mortality,elsewhere in the Increased,1
SIRTURO,QT Prolongation,Prolongation,1
SIRTURO,QT Prolongation,Prolongation,1
SIRTURO,QT Prolongation,Prolongation,1
SIRTURO,Hepatotoxicity,Hepatotoxicity,1
SIRTURO,Hepatotoxicity,Hepatotoxicity,1
SIRTURO,Hepatotoxicity,Hepatotoxicity,1
SIRTURO,Hepatotoxicity,see Warnings and Precautions and,0
SIRTURO,nausea,nausea,1
SIRTURO,nausea,nausea,1
SIRTURO,nausea,EXCERPT To report,0
SIRTURO,nausea,,0
SIRTURO,arthralgia,headache hemoptysis and chest pain EXCERPT To report SUSPECTED,0
SIRTURO,arthralgia,arthralgia,1
SIRTURO,arthralgia,report SUSPECTED ADVERSE REA,0
SIRTURO,arthralgia,common adverse reactions,0
SIRTURO,arthralgia,,0
SIRTURO,arthralgia,arthralgia,1
SIRTURO,arthralgia,arthralgia,1
SIRTURO,headache,with SIRTURO were nausea headache,1
SIRTURO,headache,,0
SIRTURO,hemoptysis,To report,0
SIRTURO,hemoptysis,,0
SIRTURO,hemoptysis,were nausea arthralgia,0
SIRTURO,hemoptysis,hemoptysis,1
SIRTURO,hemoptysis,hemoptysis,1
SIRTURO,hemoptysis,or more of patients,0
SIRTURO,chest pain,nausea arthralgia,0
SIRTURO,chest pain,chest pain,1
SIRTURO,chest pain,Therapeutics,0
SIRTURO,chest pain,contact,0
SIRTURO,chest pain,,0
SIRTURO,chest pain,in or more of patients treated with SIRTURO were nausea arthralgia,0
SIRTURO,chest pain,hemoptysis chest,1
SIRTURO,chest pain,headache hemoptysis chest pain,1
SIRTURO,chest pain,treated with SIRTURO,0
SIRTURO,chest pain,,0
SIRTURO,Nausea,Treatment GroupNn Placebo Treatment Nausea,1
SIRTURO,Nausea,Treatment GroupNn Placebo Treatment Nausea,1
SIRTURO,Nausea,Treatment,0
SIRTURO,Nausea,Treatment Nausea,1
SIRTURO,Nausea,Treatment GroupNn Placebo Treatment Nausea,1
SIRTURO,Nausea,Placebo Treatment Nausea,1
SIRTURO,Nausea,Nausea,1
SIRTURO,Arthralgia,H,0
SIRTURO,Arthralgia,Arthralgia H,1
SIRTURO,Arthralgia,,0
SIRTURO,Arthralgia,,0
SIRTURO,Arthralgia,,0
SIRTURO,Arthralgia,,0
SIRTURO,Arthralgia,Arthralgia H,1
SIRTURO,Arthralgia,,0
SIRTURO,Arthralgia,Arthralgia H,1
SIRTURO,Arthralgia,Arthralgia H,1
SIRTURO,Headache,Headache,1
SIRTURO,Hemoptysis,Hemoptysis C,1
SIRTURO,Hemoptysis,,0
SIRTURO,Hemoptysis,,0
SIRTURO,Hemoptysis,,0
SIRTURO,Chest Pain,s Chest Pain A,1
SIRTURO,Chest Pain,,0
SIRTURO,Anorexia,n Anorexia,1
SIRTURO,Anorexia,n,0
SIRTURO,Anorexia,Anorexia,1
SIRTURO,Anorexia,,0
SIRTURO,Anorexia,n Anorexia,1
SIRTURO,Anorexia,,0
SIRTURO,Anorexia,,0
SIRTURO,Anorexia,Anorexia,1
SIRTURO,Anorexia,Anorexia,1
SIRTURO,Transaminases Increased,Transaminases Increased Rash,1
SIRTURO,Transaminases Increased,,0
SIRTURO,Transaminases Increased,,0
SIRTURO,Rash,Rash,1
SIRTURO,Blood Amylase Increased,No,0
SIRTURO,Blood Amylase Increased,Blood,1
SIRTURO,Blood Amylase Increased,,0
SIRTURO,Blood Amylase Increased,Blood Amylase,1
SIRTURO,Blood Amylase Increased,,0
SIRTURO,aminotransferase elevations,both Studies aminotransferase,1
SIRTURO,aminotransferase elevations,times the upper limit of normal developed more,0
SIRTURO,aminotransferase elevations,normal developed more frequently in the SIRTURO treatment,0
SIRTURO,increased mortality,mortality risk by,1
SIRTURO,increased mortality,mortality risk by,1
SIRTURO,increased mortality,group compared to the placebo,0
SIRTURO,deaths,deaths were tuberculosisrelated One death occurred during the,0
SIRTURO,deaths,,0
SIRTURO,deaths,difference Five of,0
SIRTURO,deaths,,0
SIRTURO,deaths,,0
SIRTURO,deaths,deaths were tuberculosisrelated,1
SIRTURO,deaths,deaths were tuberculosisrelated,1
SIRTURO,deaths,SIRTURO deaths and the deaths were tuberculosisrelated,1
SIRTURO,deaths,The medi,0
SIRTURO,deaths,deaths were tuberculosisrelated,1
SIRTURO,deaths,the deaths were tuberculosisrelated,1
SIRTURO,deaths,,0
SIRTURO,deaths,deaths were tuberculosisrelated,1
SIRTURO,deaths,,0
SIRTURO,deaths,week SIRTURO,0
SIRTURO,death,the placebo deaths were,0
SIRTURO,death,death occurred during,1
SIRTURO,death,death for the,1
SIRTURO,death,,0
SIRTURO,death,death for the,1
SIRTURO,death,time death for the,1
SIRTURO,death,SIRTURO treatment group was days after,0
SIRTURO,death,death for the,1
SIRTURO,death,death for the,1
SIRTURO,death,the SIRTURO treatment group was,0
SIRTURO,deaths,pattern between death and,0
SIRTURO,deaths,,0
SIRTURO,deaths,treatment group was days after last,0
SIRTURO,deaths,no discernible pattern between death,0
SIRTURO,deaths,deaths is unexplained,1
SIRTURO,deaths,deaths is unexplained,1
SIRTURO,deaths,conversion relapse,0
SIRTURO,deaths,death and sputum conversion relapse sensitivity to,0
SIRTURO,death,death and sputum,1
SIRTURO,death,death and sputum,1
SIRTURO,death,to,0
SIRTURO,death,,0
SIRTURO,death,death and sputum,1
SIRTURO,died,died The most,1
SIRTURO,died,Study died The most,1
SIRTURO,died,,0
SIRTURO,died,openlabel Study,0
SIRTURO,died,severity of disease was observed In,0
SIRTURO,death,was TB subjects All but one subject,0
SIRTURO,death,,0
SIRTURO,death,was TB subjects All but one,0
SIRTURO,death,not con,0
SIRTURO,death,death as reported,1
SIRTURO,death,died The most common,0
SIRTURO,death,death as reported,1
SIRTURO,death,died,0
SIRTURO,death,common cause death as reported,1
SIRTURO,death,subjects All but one subject who died,0
SIRTURO,died,died of TB,1
SIRTURO,died,subject who,0
SIRTURO,died,died of TB,1
SIRTURO,died,died of TB,1
SIRTURO,died,died of TB,1
SIRTURO,died,had,0
SIRTURO,died,died of TB,1
SIRTURO,died,converted or had relapsed The causes of death in the remaining subjects,0
SIRTURO,death,death in the,1
SIRTURO,death,relapsed The causes death in the,1
SIRTURO,death,The causes death in the,1
SIRTURO,death,had not converted or had relapsed,0
SIRTURO,death,,0
SIRTURO,death,death in the,1
SIRTURO,death,death in the,1
SIRTURO,death,death in the,1
SIRTURO,QT PROLONGATION,erse,1
SIRTURO,QT PROLONGATION,erse reactions are discussed elsewhere in,1
SIRTURO,QT PROLONGATION,erse,1
SIRTURO,QT PROLONGATION,reactions are discussed elsewhere in,1
SIRTURO,QT PROLONGATION,Increased mortality see,0
SIRTURO,QT PROLONGATION,erse reactions are,1
SIRTURO,QT PROLONGATION,Warnings and Precautions,0
SIRTURO,QT PROLONGATION,erse,1
SIRTURO,QT PROLONGATION,Warnings and Precautions,0
SIRTURO,INCREASED MORTALITY,elsewhere in the la beling Increased mortality see Warnings,1
SIRTURO,INCREASED MORTALITY,elsewhere in the la beling,1
SIRTURO,INCREASED MORTALITY,beling Increased mortality see Warnings and,0
SIRTURO,INCREASED MORTALITY,the la beling Increased mortality see,1
SIRTURO,QT PROLONGATION,In creased mortality see Warnings,1
SIRTURO,QT PROLONGATION,in the,0
SIRTURO,QT PROLONGATION,labe,0
SIRTURO,QT PROLONGATION,,0
SIRTURO,QT PROLONGATION,,0
SIRTURO,INCREASED MORTALITY,see arnings,1
SIRTURO,INCREASED MORTALITY,labeling Increased mortality see arnings and Precaut ions QT Prolongation see,1
SIRTURO,INCREASED MORTALITY,labeling Increased mortality see arnings and Precaut ions QT Prolongation see,1
SIRTURO,QT PROLONGATION,ns (5.1) ] QT Prolongation see Warnings,1
SIRTURO,QT PROLONGATION,Prolongation,0
SIRTURO,QT PROLONGATION,"mortality see Warnings and ns (5.1)  ]  
  QT Prolongation see Warnings",1
SIRTURO,QT PROLONGATION,ns (5.1) ] QT Prolongation see Warnings,1
SIRTURO,QT PROLONGATION,"Warnings and ns (5.1)  ]  
  QT Prolongation see Warnings",1
SIRTURO,QT PROLONGATION,,0
SIRTURO,QT PROLONGATION,"mortality see Warnings and ns (5.1)  ]  
  QT Prolongation see Warnings",1
SIRTURO,death,Drug Interactions,0
SIRTURO,death,nings and Precautions Drug Interactions,1
SIRTURO,death,War,0
SIRTURO,QT prolongation,arthralgia headache hemoptysis,0
SIRTURO,QT prolongation,ADVERSE REACTIONS contact Janssen Therapeutics Division of,0
SIRTURO,QT prolongation,and chest       EXCERPT:  To report SUSPECTED ADVERSE,1
SIRTURO,QT prolongation,hemoptysis and chest       EXCERPT:  To report SUSPECTED ADVERSE,1
SIRTURO,QT prolongation,hemoptysis and chest       EXCERPT:  To report SUSPECTED ADVERSE,1
SIRTURO,QT prolongation,headache,0
SIRTURO,QT prolongation,Therapeutics Division of ssen,1
SIRTURO,QT prolongation,"of ssen Products,  LP at JANSSEN or",1
SIRTURO,QT prolongation,"Division of ssen Products,  LP at JANSSEN or",1
SIRTURO,QT prolongation,"ssen Products, LP at JANSSEN or",1
SIRTURO,QT prolongation,Division of Jan,0
SIRTURO,QT prolongation,identified from the pooled safety data,0
SIRTURO,QT prolongation,,0
SIRTURO,QT prolongation,335 SIRTU ROexposed patients who received,1
SIRTURO,QT prolongation,practice Adverse,0
SIRTURO,QT prolongation,SIRTU ROexposed patients who received,1
SIRTURO,QT prolongation,and,0
SIRTURO,QT prolongation,the pooled safety from,1
SIRTURO,additive QT prolongation,weeks Studies 3) at the proposed dose. Studies and were randomized,1
SIRTURO,additive QT prolongation,3) at the proposed,1
SIRTURO,additive QT prolongation,Studies,0
SIRTURO,additive QT prolongation,Studies,0
SIRTURO,additive QT prolongation,and weeks Studies 3) at the proposed dose. Studies and were randomized,1
SIRTURO,additive QT prolongation,Studies 3) at the proposed dose. Studies and were randomized,1
SIRTURO,QT prolongation,erse reactions are discussed elsewhere in the,1
SIRTURO,QT prolongation,,0
SIRTURO,QT prolongation,erse,1
SIRTURO,QT prolongation,erse,1
SIRTURO,QT prolongation,,0
SIRTURO,QT prolongation,erse reactions are,1
SIRTURO,QT prolongation,,0
SIRTURO,QT prolongation,,0
SIRTURO,QT prolongation,,0
SIRTURO,QT prolongation,Warnings and,0
SIRTURO,Hepatotoxicity,ecautions (5.2 and Clinical Pharmacology,1
SIRTURO,death,most ommon adverse reactions reported,1
SIRTURO,death,ommon adverse reactions reported,1
SIRTURO,death,most ommon adverse reactions reported,1
SIRTURO,death,ommon adverse reactions reported,1
SIRTURO,death,ommon adverse reactions reported,1
SIRTURO,death,ommon adverse reactions reported,1
SIRTURO,death,more of patients treated with SIRTURO were,0
SIRTURO,death,ECTED ADVERSE REACTIONS contact,1
SIRTURO,death,ECTED ADVERSE REACTIONS contact,1
SIRTURO,deaths,"of Janssen s,",1
SIRTURO,deaths,JANSSEN or FDA at,0
SIRTURO,deaths,"Division of Janssen s,",1
SIRTURO,deaths,Therapeutics Division of Janssen Product,0
SIRTURO,deaths,,0
SIRTURO,deaths,"s, LP at JANSSEN or",1
SIRTURO,death,JANSSEN or at,1
SIRTURO,death,,0
SIRTURO,death,,0
SIRTURO,death,at 1- FDA or wwwfdagovmedwatch,1
SIRTURO,death,Therapeutics Division of Janssen Products LP at,0
SIRTURO,death,of Janssen Products,0
SIRTURO,death,at JANSSEN or at,1
SIRTURO,death,cl,0
SIRTURO,prolongs the QT interval,not reflect t he rates observed,1
SIRTURO,prolongs the QT interval,drug reactions,0
SIRTURO,prolongs the QT interval,clinical studies of another ug and may not reflect,1
SIRTURO,prolongs the QT interval,ug and may not reflect t he rates observed,1
SIRTURO,QT prolongation,an openlabel noncomparative study with SIRTURO,0
ADREVIEW,hypersensitivity reactions,reactions have been reported following AdreView,1
ADREVIEW,hypersensitivity reactions,hypersensitivity,1
ADREVIEW,hypersensitivity reactions,hypersensitivity reactions have been,1
ADREVIEW,hypersensitivity reactions,hypersensitivity,1
ADREVIEW,dizziness,dizziness rash pruritis,1
ADREVIEW,dizziness,dizziness rash pruritis,1
ADREVIEW,dizziness,occurred in of patients,0
ADREVIEW,rash,rash pruritis flushing,1
ADREVIEW,rash,rash pruritis flushing,1
ADREVIEW,rash,reactions rash pruritis flushing,1
ADREVIEW,rash,AdreView administration The most,0
ADREVIEW,rash,rash pruritis flushing,1
ADREVIEW,rash,rash pruritis flushing,1
ADREVIEW,rash,rash pruritis flushing,1
ADREVIEW,rash,hemorrhage occurred in of,0
ADREVIEW,rash,rash pruritis flushing,1
ADREVIEW,rash,rash pruritis flushing,1
ADREVIEW,pruritis,common adverse reactions dizziness rash,0
ADREVIEW,pruritis,adverse reactions dizziness pruritis flushing headache,1
ADREVIEW,pruritis,in,0
ADREVIEW,pruritis,adverse reactions dizziness pruritis flushing headache,1
ADREVIEW,pruritis,pruritis flushing headache,1
ADREVIEW,pruritis,pruritis flushing headache,1
ADREVIEW,pruritis,reactions dizziness pruritis flushing headache,1
ADREVIEW,flushing,,0
ADREVIEW,flushing,following AdreView administration The most common adverse,0
ADREVIEW,flushing,,0
ADREVIEW,flushing,flushing headache and,1
ADREVIEW,headache,headache and injection,1
ADREVIEW,headache,AdreView administration The most,0
ADREVIEW,headache,rash pruritis headache and injection,1
ADREVIEW,headache,rash pruritis headache and injection,1
ADREVIEW,headache,headache and injection,1
ADREVIEW,headache,headache and injection,1
ADREVIEW,injection site hemorrhage,injection site hemorrhage occurred in,1
ADREVIEW,injection site hemorrhage,rash pruritis flushing headache,0
ADREVIEW,injection site hemorrhage,in of patients To report SUSPECTED ADVERSE REACTIONS,0
ADREVIEW,injection site hemorrhage,dizziness rash pruritis flushing headache,0
ADREVIEW,injection site hemorrhage,injection site hemorrhage occurred in,1
ADREVIEW,injection site hemorrhage,injection site,1
ADREVIEW,injection site hemorrhage,pruritis flushing headache and,0
ADREVIEW,injection site hemorrhage,flushing headache injection,1
ADREVIEW,dizziness,,0
ADREVIEW,dizziness,,0
ADREVIEW,dizziness,the following dizziness rash pruritus,1
ADREVIEW,dizziness,,0
ADREVIEW,dizziness,pruritus,0
ADREVIEW,dizziness,dizziness rash pruritus,1
ADREVIEW,dizziness,hemorrhage Congestive Heart Failure No,0
ADREVIEW,rash,rash pruritus flushing,1
ADREVIEW,rash,patients of one of the following reactions dizziness,0
ADREVIEW,rash,the following reactions rash pruritus flushing,1
ADREVIEW,rash,pruritus flushing or injection site hemorrhage,0
ADREVIEW,rash,rash pruritus flushing,1
ADREVIEW,rash,rash pruritus flushing,1
ADREVIEW,rash,of one,0
ADREVIEW,rash,reactions rash pruritus flushing,1
ADREVIEW,rash,rash pruritus flushing,1
ADREVIEW,pruritus,following reactions dizziness pruritus flushing or,1
ADREVIEW,pruritus,following reactions dizziness pruritus flushing or,1
ADREVIEW,flushing,patients of one of the following reactions,0
ADREVIEW,flushing,flushing or injection,1
ADREVIEW,injection site hemorrhage,site hemorrhage Congestive Heart,1
ADREVIEW,flushing,,0
ADREVIEW,flushing,reactions were predominantly of mild to,0
ADREVIEW,headache,headache The adverse,1
ADREVIEW,Hypersensitivity reactions,to drug Hypersensitivity,1
ADREVIEW,Hypersensitivity reactions,known or,0
ADREVIEW,Hypersensitivity reactions,and 110 control patie nts All,1
ADREVIEW,Hypersensitivity reactions,"ure, and 110 control patie nts All",1
ADREVIEW,Hypersensitivity reactions,hour period following AdreView admi,0
ADREVIEW,fatal,,0
ADREVIEW,fatal,,1
ADREVIEW,fatal,,0
ADREVIEW,fatal,,0
ADREVIEW,fatal,,0
ADREVIEW,fatal,,1
ADREVIEW,fatal,,1
ADREVIEW,fatal,,0
ADREVIEW,fatal,,0
ADREVIEW,fatal,,0
ADREVIEW,Gasping Syndrome,,1
ADREVIEW,Gasping Syndrome,,0
ADREVIEW,Gasping Syndrome,,0
ADREVIEW,Gasping Syndrome,,0
ADREVIEW,Gasping Syndrome,,0
ADREVIEW,Gasping Syndrome,,0
ADREVIEW,Gasping Syndrome,,1
ADREVIEW,transient episode of hypertension,,0
ADREVIEW,transient episode of hypertension,,0
ARCAPTA,asthma,the risk asthma,1
ARCAPTA,asthma,asthma,1
ARCAPTA,asthma,asthma,1
ARCAPTA,asthma,NEOHALER,0
ARCAPTA,asthma,asthma See B,0
ARCAPTA,asthma,increase the risk asthma,1
ARCAPTA,asthma,beta adrenergic,0
ARCAPTA,asthma,A RCAPTA NEOHALER increase the,0
ARCAPTA,asthma,,0
ARCAPTA,death,B oxed,0
ARCAPTA,oropharyngeal pain,are,0
ARCAPTA,oropharyngeal pain,than placebo are oropharyngeal,1
ARCAPTA,oropharyngeal pain,oropharyngeal pain,1
ARCAPTA,oropharyngeal pain,pain,1
ARCAPTA,oropharyngeal pain,common than placebo are oropharyngeal pain,1
ARCAPTA,oropharyngeal pain,,0
ARCAPTA,oropharyngeal pain,oropharyngeal pain,1
ARCAPTA,nasopharyngitis,nasopharyngitis,1
ARCAPTA,nasopharyngitis,are cough,0
ARCAPTA,nasopharyngitis,than placebo are cough,0
ARCAPTA,nasopharyngitis,common adverse reactions and more common,0
ARCAPTA,nasopharyngitis,headache and nausea To report SUSPECTED ADVERSE REACTIONS,0
ARCAPTA,nasopharyngitis,nasopharyngitis,1
ARCAPTA,nasopharyngitis,nasopharyngitis,1
ARCAPTA,nasopharyngitis,oropharyngeal pain,0
ARCAPTA,nasopharyngitis,To report SUSPECTED ADVERSE REACTIONS contact Novartis Pharma,0
ARCAPTA,headache,To report SUSPECTED ADVERSE REACTIONS contact Novartis,0
ARCAPTA,headache,headache,1
ARCAPTA,headache,pain nasopharyngitis,0
ARCAPTA,headache,and nausea To report SUSPECTED ADVERSE,0
ARCAPTA,headache,headache,1
ARCAPTA,headache,headache,1
ARCAPTA,nausea,,0
ARCAPTA,nausea,pain nasopharyngitis headache and,0
ARCAPTA,nausea,and,0
ARCAPTA,nausea,than placebo are cough oropharyngeal pain nasopharyngitis headache and,0
ARCAPTA,nausea,nasopharyngitis headache nausea,1
ARCAPTA,COPD,COPD,1
ARCAPTA,COPD,dyspnea The most common,0
ARCAPTA,COPD,adverse reactions,0
ARCAPTA,COPD,COPD,1
ARCAPTA,COPD,and dyspnea The most common serious adverse reactions were COPD exacerbation pneumonia,0
ARCAPTA,COPD,common adverse reactions that lead,0
ARCAPTA,COPD,and dyspnea The most,0
ARCAPTA,COPD,pneumonia,0
ARCAPTA,COPD,,0
ARCAPTA,COPD,pneumonia angin,0
ARCAPTA,dyspnea,that lead to discontinuation of ARCAPTA NEOHALER were COPD,0
ARCAPTA,dyspnea,COPD dyspnea,1
ARCAPTA,dyspnea,dyspnea,1
ARCAPTA,dyspnea,dyspnea,1
ARCAPTA,dyspnea,of ARCAPTA,0
ARCAPTA,dyspnea,dyspnea,1
ARCAPTA,dyspnea,dyspnea,1
ARCAPTA,dyspnea,NEOHALER were COPD dyspnea,1
ARCAPTA,dyspnea,The most common serious adverse reactions were COPD exacerbation pneumonia angina pectoris,0
ARCAPTA,dyspnea,dyspnea,1
ARCAPTA,COPD exacerbation,across,0
ARCAPTA,COPD exacerbation,adverse reactions COPD exacerbation,1
ARCAPTA,pneumonia,pneumonia,1
ARCAPTA,pneumonia,,0
ARCAPTA,angina pectoris,dyspnea The most common serious,0
ARCAPTA,angina pectoris,,0
ARCAPTA,angina pectoris,exacerbation angina pectoris,1
ARCAPTA,angina pectoris,angina pectoris,1
ARCAPTA,angina pectoris,,0
ARCAPTA,angina pectoris,which occurred at similar rates across treatment groups,0
ARCAPTA,angina pectoris,reactions were COPD exacerbation angina pectoris,1
ARCAPTA,angina pectoris,pectoris,1
ARCAPTA,angina pectoris,COPD exacerbation angina pectoris,1
ARCAPTA,Cough,Respiratory thoracic and mediastinal Cough,1
ARCAPTA,Cough,Cough,1
ARCAPTA,Cough,Cough,1
ARCAPTA,Oropharyngeal pain,Cough,0
ARCAPTA,Nasopharyngitis,and Nasopharyngitis,1
ARCAPTA,Nasopharyngitis,Nasopharyngitis,1
ARCAPTA,Nasopharyngitis,,0
ARCAPTA,Nasopharyngitis,Nasopharyngitis,1
ARCAPTA,Nasopharyngitis,,0
ARCAPTA,Nasopharyngitis,disorders,0
ARCAPTA,Nasopharyngitis,and,0
ARCAPTA,Nasopharyngitis,Nasopharyngitis,1
ARCAPTA,Nasopharyngitis,,0
ARCAPTA,Nausea,Nausea,1
ARCAPTA,Nausea,Nausea,1
ARCAPTA,Nausea,Nausea,1
ARCAPTA,Nausea,of all,0
ARCAPTA,Nausea,,0
ARCAPTA,Nausea,Headache Gastrointestinal disorders,0
ARCAPTA,muscle spasm,muscle spasm,1
ARCAPTA,muscle spasm,musculoskeletal pain General disorders,0
ARCAPTA,muscle spasm,disorders and administration site conditions edema peripheral,0
ARCAPTA,muscle spasm,Musculoskeletal and connective tissue muscle spasm,1
ARCAPTA,muscle spasm,,0
ARCAPTA,muscle spasm,follows Musculoskeletal and,0
ARCAPTA,muscle spasm,,0
ARCAPTA,muscle spasm,Musculoskeletal and connective tissue disorders,0
ARCAPTA,muscle spasm,tissue muscle spasm,1
ARCAPTA,musculoskeletal pain,muscle musculoskeletal,1
ARCAPTA,musculoskeletal pain,pain,1
ARCAPTA,musculoskeletal pain,musculoskeletal pain,1
ARCAPTA,musculoskeletal pain,musculoskeletal,1
ARCAPTA,musculoskeletal pain,musculoskeletal,1
ARCAPTA,musculoskeletal pain,disorders muscle musculoskeletal,1
ARCAPTA,musculoskeletal pain,musculoskeletal pain,1
ARCAPTA,edema peripheral,site edema,1
ARCAPTA,edema peripheral,edema peripheral,1
ARCAPTA,edema peripheral,spasm musculoskeletal pain General disorders,0
ARCAPTA,edema peripheral,administration site,0
ARCAPTA,edema peripheral,disorders and administration site edema,1
ARCAPTA,edema peripheral,disorders and,0
ARCAPTA,edema peripheral,General disorders and administration site conditions,0
ARCAPTA,diabetes mellitus,sinusitis upper respiratory,0
ARCAPTA,diabetes mellitus,diabetes,1
ARCAPTA,diabetes mellitus,diabetes,1
ARCAPTA,diabetes mellitus,infestations sinusitis upper respiratory tract infection,0
ARCAPTA,diabetes mellitus,and nutrition diabetes mellitus,1
ARCAPTA,diabetes mellitus,nutrition diabetes mellitus,1
ARCAPTA,diabetes mellitus,diabetes,1
ARCAPTA,diabetes mellitus,Metabolism and nutrition diabetes,1
ARCAPTA,diabetes mellitus,nutrition disorder,0
ARCAPTA,hyperglycemia,diabetes hyperglycemia,1
ARCAPTA,hyperglycemia,,0
ARCAPTA,hyperglycemia,disorder diabetes,0
ARCAPTA,hyperglycemia,nutrition disorder diabetes hyperglycemia,1
ARCAPTA,hyperglycemia,hyperglycemia,1
ARCAPTA,hyperglycemia,hyperglycemia,1
ARCAPTA,hyperglycemia,nutrition disorder diabetes hyperglycemia,1
ARCAPTA,sinusitis,p ost inhalation,0
ARCAPTA,sinusitis,nutrition disorder diabetes mellitus hyperglycemia,0
ARCAPTA,sinusitis,sinusitis,1
ARCAPTA,sinusitis,,0
ARCAPTA,sinusitis,Infections and sinusitis,1
ARCAPTA,sinusitis,mellitus,0
ARCAPTA,sinusitis,and nutrition disorder diabetes mellitus hyperglycemia Infections and infestations,0
ARCAPTA,upper respiratory tract infection,experienced p ost,0
ARCAPTA,upper respiratory tract infection,Infections and infestations sinusitis,0
ARCAPTA,upper respiratory tract infection,hyperglycemia Infections and infestations upper respiratory,1
ARCAPTA,upper respiratory tract infection,tract infection,1
ARCAPTA,upper respiratory tract infection,disorder diabetes,0
ARCAPTA,upper respiratory tract infection,Infections and infestations upper respiratory tract infection,1
ARCAPTA,upper respiratory tract infection,upper respiratory tract infection,1
ARCAPTA,upper respiratory tract infection,disorder diabetes mellitus hyperglycemia Infections and infestations sinusitis,0
ARCAPTA,upper respiratory tract infection,,0
ARCAPTA,upper respiratory tract infection,,0
ARCAPTA,cough,providers observed during,0
ARCAPTA,cough,,0
ARCAPTA,cough,experienced cough,1
ARCAPTA,cough,following inhalation of the recommended mcg dose of ARCAPTA NEOHALER c,0
ARCAPTA,cough,of ARCAPTA NEOHALER,0
ARCAPTA,cough,recommended mcg dose of ARCAPTA,0
ARCAPTA,cough,inhalation and lasted,0
ARCAPTA,cough,following inhalation and lasted for no more than seconds Cou,0
ARCAPTA,cough,cough,1
ARCAPTA,cough,of patients receiving placebo cough,1
ARCAPTA,cough,seconds Cou,0
ARCAPTA,cough,cough,1
ARCAPTA,Cough,lasted for,0
ARCAPTA,Cough,clinical trials was not associated with bronchospasm exacerbations deteri,0
ARCAPTA,bronchospasm,bronchospasm,1
ARCAPTA,bronchospasm,bronchospasm,1
ARCAPTA,bronchospasm,bronchospasm,1
ARCAPTA,bronchospasm,deteriorations of disease or,0
ARCAPTA,bronchospasm,was not associated bronchospasm,1
ARCAPTA,loss of efficacy,bronchospasm exacerbations deteriorations,0
ARCAPTA,loss of efficacy,loss of efficacy,1
ARCAPTA,loss of efficacy,loss of efficacy,1
ARCAPTA,loss of efficacy,,0
ARCAPTA,loss of efficacy,disease loss of efficacy,1
ARCAPTA,loss of efficacy,deteriorations of disease,0
ARCAPTA,loss of efficacy,associated with bronchospasm exacerbations,0
ARCAPTA,loss of efficacy,not associated with bronchospasm exacerbations deteriorations of,0
ARCAPTA,loss of efficacy,exacerbations deteriorations of disease loss of,1
ARCAPTA,deaths,deaths,1
ARCAPTA,deaths,the ARCAPTA NEOHALER mcg dose group There were no,0
ARCAPTA,deaths,were deaths,1
ARCAPTA,deaths,deaths in,0
ARCAPTA,deaths,these patients there were deaths,1
ARCAPTA,deaths,deaths,1
ARCAPTA,deaths,group or in the salmeterol active control group Serious adver,0
ARCAPTA,deaths,There,0
ARCAPTA,deaths,were respiratoryrelated deaths in the ARCAPTA NEOHALER mcg dose group There were,0
ARCAPTA,deaths,deaths,1
ARCAPTA,deaths,ARCAPTA NEOHALER mcg,0
ARCAPTA,deaths,group,0
ARCAPTA,deaths,,0
ARCAPTA,deaths,deaths,1
ARCAPTA,asthma exacerbation,,0
ARCAPTA,asthma exacerbation,the salmeterol active,0
ARCAPTA,asthma exacerbation,related asthma exacerbation,1
ARCAPTA,asthma exacerbation,exacerbation,1
ARCAPTA,asthma exacerbation,Serious adverse reactions related asthma,1
ARCAPTA,asthma exacerbation,patients in the indacaterol mcg group patients in the indacaterol mc,0
ARCAPTA,asthma exacerbation,related asthma exacerbation,1
ARCAPTA,asthma exacerbation,,0
ARCAPTA,hypersensitivity reactions,reactions,1
ARCAPTA,hypersensitivity reactions,are,0
ARCAPTA,hypersensitivity reactions,exposure These adverse reactions hypersensitivity reactions,1
ARCAPTA,hypersensitivity reactions,exposure These adverse reactions hypersensitivity,1
ARCAPTA,hypersensitivity reactions,exposure These adverse reactions,0
ARCAPTA,hypersensitivity reactions,hypersensitivity reactions,1
ARCAPTA,paradoxical bronchospasm,relationship,0
ARCAPTA,paradoxical bronchospasm,increasepalpitations pruritusrash and dizziness,0
ARCAPTA,paradoxical bronchospasm,paradoxical bronchospasm,1
ARCAPTA,tachycardia,exposure These adverse reactions are hypersensitivity reactions paradoxical,0
ARCAPTA,tachycardia,are hypersensitivity reactions paradoxical tachycardia,1
ARCAPTA,tachycardia,paradoxical tachycardia,1
ARCAPTA,tachycardia,paradoxical tachycardia,1
ARCAPTA,tachycardia,tachycardia,1
ARCAPTA,tachycardia,tachycardia,1
ARCAPTA,tachycardia,pruritusrash and dizziness,0
ARCAPTA,tachycardia,rate increasepalpitations pruritusrash and dizziness,0
ARCAPTA,tachycardia,reactions paradoxical tachycardia,1
ARCAPTA,heart rate increase,,0
ARCAPTA,heart rate increase,These adverse,0
ARCAPTA,heart rate increase,,0
ARCAPTA,heart rate increase,heart rate increase,1
ARCAPTA,heart rate increase,,0
ARCAPTA,heart rate increase,bronchospasm heart rate,1
ARCAPTA,heart rate increase,,0
ARCAPTA,palpitations,palpitations,1
ARCAPTA,palpitations,palpitations,1
ARCAPTA,palpitations,,0
ARCAPTA,palpitations,palpitations,1
ARCAPTA,pruritus,,0
ARCAPTA,pruritus,pruritus,1
ARCAPTA,pruritus,pruritus,1
ARCAPTA,pruritus,pruritus,1
ARCAPTA,pruritus,pruritus,1
ARCAPTA,pruritus,,0
ARCAPTA,pruritus,rate pruritus,1
ARCAPTA,pruritus,paradoxical bronchospasm tachycardiaheart rate,0
ARCAPTA,rash,,0
ARCAPTA,rash,bronchospasm tachycardiaheart rate increasepalpitations rash,1
ARCAPTA,rash,dizziness,0
ARCAPTA,rash,rate increasepalpitations rash,1
ARCAPTA,rash,rash,1
ARCAPTA,rash,rash,1
ARCAPTA,dizziness,dizziness,1
ARCAPTA,dizziness,and,0
ARCAPTA,dizziness,pruritusrash,0
ARCAPTA,dizziness,dizziness,1
ARCAPTA,dizziness,,0
ARCAPTA,dizziness,dizziness,1
ARCAPTA,dizziness,rate increasepalpitations pruritusrash dizziness,1
ARCAPTA,dizziness,,0
ARCAPTA,DEATH,    - acting beta adrenergic agonists,1
ARCAPTA,DEATH,acting beta adrenergic agonists such as A RCAPTA NEOHALER increase the,0
ARCAPTA,DEATH,    - acting beta adrenergic agonists,1
ARCAPTA,DEATH,    - acting beta adrenergic agonists,1
ARCAPTA,DEATH,,0
ARCAPTA,DEATH,,0
ARCAPTA,DEATH,,0
ARCAPTA,death,indicated,0
ARCAPTA,death,n ot indicated for the treatment,1
ARCAPTA,death,n ot indicated for the treatment,1
ARCAPTA,death,See B oxed Warning and W arning,0
ARCAPTA,death,treatment of asthma See B oxed Warning,0
ARCAPTA,death,asthmarelated death ARCAPTA  is n ot indicated for the treatment,1
ARCAPTA,death,NEOHALER increase the risk of asthmarelated death ARCAPTA NEOHALER,0
ARCAPTA,death,n ot indicated for the treatment,1
ARCAPTA,deaths,yngeal pain nasopharyngitis headache and nausea,1
ARCAPTA,deaths,yngeal pain nasopharyngitis headache and nausea,1
ARCAPTA,deaths,yngeal pain nasopharyngitis headache and nausea,1
ARCAPTA,deaths,ADVERSE,0
ARCAPTA,deaths,placebo are cough yngeal pain nasopharyngitis headache and nausea,1
ARCAPTA,deaths,ADVERSE,0
ARCAPTA,deaths,yngeal pain nasopharyngitis headache and nausea,1
ARCAPTA,deaths,,0
ARCAPTA,DEATH,,0
ARCAPTA,DEATH,,0
ARCAPTA,DEATH,and not,1
ARCAPTA,DEATH,,0
ARCAPTA,DEATH,drug and not r eflect the rates observed in,1
ARCAPTA,DEATH,and not r eflect the rates observed in,1
ARCAPTA,DEATH,be directly compared to rates in the clinical,0
ARCAPTA,DEATH,and not r eflect the rates observed in,1
ARCAPTA,death,eater for at least weeks in,1
ARCAPTA,death,confirmatory randomized doubleblind placebo and activecontrolled c,0
ARCAPTA,death,,0
ARCAPTA,death,in six,0
ARCAPTA,death,eater for at least weeks in,1
ARCAPTA,death,,0
ARCAPTA,death,mcg or eater for at least weeks in,1
ARCAPTA,death,eater for at least weeks in,1
ARCAPTA,death,eater for at least weeks in,1
ARCAPTA,death,eater for at least weeks in,1
ARCAPTA,deaths,,0
ARCAPTA,deaths, trial s patients were exposed to,1
ARCAPTA,deaths,randomized doubleblind placebo and activecontrolled clinical trials see Section,0
ARCAPTA,deaths,trials,0
ARCAPTA,deaths,trials see Section In  trial s patients were exposed to,1
ARCAPTA,deaths, trial s patients were exposed to,1
ARCAPTA,deaths, trial s patients were exposed to,1
ARCAPTA,deaths, trial s patients were exposed to,1
ARCAPTA,death,a dose of or mcg,0
ARCAPTA,death,mcg for up to,0
ARCAPTA,cardiovascular effects,To,0
ARCAPTA,cardiovascular effects,"and more common placebo) are cough,",1
ARCAPTA,fatal,"pain, nasopharyngitis headache and nausea To",1
ARCAPTA,fatal,Most common adverse,0
ARCAPTA,fatal,nasopharyngitis headache and,0
ARCAPTA,fatal,"pain, nasopharyngitis headache and nausea To",1
ARCAPTA,fatal,"pain, nasopharyngitis headache and nausea To",1
ARCAPTA,fatal,"pain, nasopharyngitis headache and nausea To",1
ARCAPTA,fatal,"pain, nasopharyngitis headache and nausea To",1
ARCAPTA,fatal,common than placebo are cough,0
ARCAPTA,fatal,contact,0
ARCAPTA,fatal,"pain, nasopharyngitis headache and nausea To",1
ARCAPTA,hypersensitivity reactions,and,1
ARCAPTA,hypersensitivity reactions,cough oropharyngeal pain nasopharyngitis and nausea. ( 6,1
ARCAPTA,hypersensitivity reactions,and nausea. (,1
ARCAPTA,hypersensitivity reactions,To report SUSPECTED ADVERSE,0
ARCAPTA,paradoxical bronchospasm,To,0
ARCAPTA,death,another drug and may,0
ARCAPTA,death,EOHAL ER safety database reflects exposure,1
ARCAPTA,death,mcg or,0
ARCAPTA,death,EOHAL ER safety database reflects exposure,1
ARCAPTA,death,N,0
ARCAPTA,death,may not reflect the rates observed in,0
ARCAPTA,death,The ARCAPTA EOHAL ER safety database reflects exposure,1
ARCAPTA,death,ARCAPTA EOHAL ER safety database reflects exposure,1
ARCAPTA,death,NEOHALER at doses of mcg or,0
ARCAPTA,deaths,of or mcg for one year respectively Overall patients had a,0
ARCAPTA,deaths,and COPD were e xposed to a dose of,1
ARCAPTA,deaths,to months,0
ARCAPTA,deaths,e xposed to a dose of,1
ARCAPTA,deaths,mean pre,0
ARCAPTA,deaths,xposed to a,0
ARCAPTA,deaths,e xposed to a dose of,1
ARCAPTA,deaths,for one year,0
ARCAPTA,death,dyspnea The most,0
ARCAPTA,death,adverse reactions that lead to discontinuati,0
ARCAPTA,death,lead,0
ARCAPTA,death,,0
ARCAPTA,death,lead to on of ARCAPTA NEOHALER were COPD and,1
ARCAPTA,death,of ARCAPTA NEOHALER were COPD and,1
ARCAPTA,death,ARCAPTA NEOHALER were COPD,0
ARCAPTA,death,exa,0
ARCAPTA,death,of ARCAPTA NEOHALER were COPD and,1
ARCAPTA,paradoxical bronchospasm,salmeterol n all concomitant with inhaled,0
ARCAPTA,paradoxical bronchospasm,Of these pati ents there were respiratoryrelated deaths,1
ARCAPTA,paradoxical bronchospasm,andomized. Of these pati ents there were respiratoryrelated deaths,1
ARCAPTA,paradoxical bronchospasm,Of these pati ents there were respiratoryrelated deaths,1
ARCAPTA,paradoxical bronchospasm,inhaled corticosteroids which,0
ARCAPTA,paradoxical bronchospasm,,0
ARCAPTA,cardiovascular effect,in the indacaterol mcg group patients in the,1
ARCAPTA,cardiovascular effect,in,0
ARCAPTA,cardiovascular effect,for ts in,1
ARCAPTA,cardiovascular effect,Serious adverse reactions related to asthma exacerbation,0
ARCAPTA,cardiovascular effect,exacerbation were reported for ts in the indacaterol mcg group patients in the,1
ARCAPTA,increases in pulse rate, indacaterol 600 mcg gr oup and no patients in,1
ARCAPTA,increases in pulse rate,indacaterol mcg group,0
ARCAPTA,increases in pulse rate,indacaterol 600 mcg gr oup and no patients in,1
ARCAPTA,increases in pulse rate,group patients in indacaterol 600,1
ARCAPTA,increases in pulse rate,group In addition a,0
ARCAPTA,increases in pulse rate,indacaterol mcg,0
ARCAPTA,increases in pulse rate,gr oup and no patients in,1
ARCAPTA,ECG changes,inhaled cor ticosteroids No deaths intubations or,1
ARCAPTA,ECG changes,inhaled cor ticosteroids No deaths intubations or,1
ARCAPTA,ECG changes,was conducted in,0
ARCAPTA,ECG changes,,0
ARCAPTA,ECG changes,,0
ARCAPTA,ECG changes,,0
ARCAPTA,ECG changes,persistent asthma inhaled,1
ARCAPTA,ECG changes,conducted in adult patients with mild,0
ARCAPTA,ECG changes,inhaled cor ticosteroids No deaths intubations or,1
ARCAPTA,ECG changes,inhaled,1
ARCAPTA,flattening of the T wave,conducted in adult patients with mild persistent asthma taking inhaled,0
ARCAPTA,flattening of the T wave,,0
ARCAPTA,flattening of the T wave,"taking inhaled ds. No deaths,",1
ARCAPTA,flattening of the T wave,persistent asthma,0
ARCAPTA,flattening of the T wave,"ds. No deaths, intubatio ns or serious adverse reactions",1
ARCAPTA,flattening of the T wave,corticosteroi,0
ARCAPTA,flattening of the T wave,persistent asthma taking inhaled ds.,1
ARCAPTA,prolongation of the QTc interval,,0
ARCAPTA,ST segment depression,following,0
ARCAPTA,ST segment depression,adverse reactions  to asthma exacerbati on were reported in this,1
ARCAPTA,ST segment depression,or serious adverse reactions  to asthma exacerbati on were reported in this,1
ARCAPTA,aggravate pre-existing diabetes mellitus,and dizziness,0
ARCAPTA,hypokalemia,,1
ARCAPTA,hypokalemia,,1
ARCAPTA,hypokalemia,,1
ARCAPTA,hypokalemia,,0
ARCAPTA,hypokalemia,,0
ARCAPTA,hypokalemia,,1
ARCAPTA,adverse cardiovascular effects,,1
ARCAPTA,adverse cardiovascular effects,,1
ARCAPTA,adverse cardiovascular effects,,0
ARCAPTA,decrease in serum potassium,,1
ARCAPTA,decrease in serum potassium,,1
ARCAPTA,decrease in serum potassium,,0
ARCAPTA,decrease in serum potassium,,1
ARCAPTA,decrease in serum potassium,,0
ARCAPTA,decrease in serum potassium,,1
ARCAPTA,decrease in serum potassium,,1
ARCAPTA,increases in plasma glucose,,1
ARCAPTA,increases in plasma glucose,,1
ARCAPTA,increases in plasma glucose,,0
ARCAPTA,increases in plasma glucose,,1
ARCAPTA,increases in plasma glucose,,1
ARCAPTA,increases in plasma glucose,,0
ARCAPTA,increases in plasma glucose,,1
ARCAPTA,increases in plasma glucose,,0
ARCAPTA,increases in plasma glucose,,0
ARCAPTA,increases in plasma glucose,,0
ARCAPTA,changes in blood glucose,,1
ARCAPTA,changes in blood glucose,,1
ARCAPTA,changes in blood glucose,,1
ARCAPTA,changes in blood glucose,,1
ARCAPTA,changes in blood glucose,,1
ARCAPTA,changes in blood glucose,,0
ARCAPTA,changes in blood glucose,,1
ARCAPTA,changes in blood glucose,,1
ARCAPTA,changes in blood glucose,,0
INTELENCE,hypersensitivity reactions,skin hypersensitivity reactions,1
INTELENCE,hypersensitivity reactions,adverse reactions are described in greater detail,0
INTELENCE,hypersensitivity reactions,other sections Severe skin hypersensitivity reactions,1
INTELENCE,hypersensitivity reactions,sections Severe skin hypersensitivity reactions,1
INTELENCE,hypersensitivity reactions,Severe skin hypersensitivity reactions,1
INTELENCE,hypersensitivity reactions,other sections Severe skin hypersensitivity reactions,1
INTELENCE,rash,rate than,0
INTELENCE,rash,at least,0
INTELENCE,rash,rash,1
INTELENCE,rash,rash,1
INTELENCE,rash,rash,1
INTELENCE,rash,rash,1
INTELENCE,rash,,0
INTELENCE,rash,than placebo in adults rash,1
INTELENCE,diarrhea,at,0
INTELENCE,diarrhea,pediatric patients are rash and,0
INTELENCE,diarrhea,diarrhea,1
INTELENCE,diarrhea,diarrhea,1
INTELENCE,diarrhea,diarrhea,1
INTELENCE,diarrhea,diarrhea,1
INTELENCE,diarrhea,at,0
INTELENCE,diarrhea,REACTIONS contact Janssen,0
INTELENCE,diarrhea,patients are rash diarrhea,1
INTELENCE,diarrhea,REACTIONS contact Janssen Products LP,0
INTELENCE,rash,rash,1
INTELENCE,rash,ADR,0
INTELENCE,rash,at,0
INTELENCE,rash,rash,1
INTELENCE,rash,rash,1
INTELENCE,rash,arm The most frequently reported ADR at,0
INTELENCE,rash,,0
INTELENCE,rash,the placebo arm The most frequently reported ADR at least Grade in severity was,0
INTELENCE,rash,in severity rash,1
INTELENCE,Stevens-Johnson syndrome,Stevens-Johnson syndrome,1
INTELENCE,hypersensitivity,was rash StevensJohnson syndrome hypersensitivity,1
INTELENCE,hypersensitivity,hypersensitivity,1
INTELENCE,hypersensitivity,hypersensitivity,1
INTELENCE,hypersensitivity,erythema multiforme were reported in less,0
INTELENCE,erythema multiforme,syndrome drug hypersensitivity reaction erythema,1
INTELENCE,erythema multiforme,,0
INTELENCE,erythema multiforme,drug hypersensitivity reaction erythema multiforme,1
INTELENCE,erythema multiforme,in less than of subjects during clinical development,0
INTELENCE,erythema multiforme,StevensJohnson syndrome drug hypersensitivity reaction,0
INTELENCE,erythema multiforme,drug hypersensitivity reaction,0
INTELENCE,erythema multiforme,syndrome drug hypersensitivity reaction erythema,1
INTELENCE,rash,rash,1
INTELENCE,rash,Phase trials receiving,0
INTELENCE,rash,primarily in the,0
INTELENCE,rash,rash,1
INTELENCE,rash,INTELENCE r discontinued due to rash In,0
INTELENCE,rash,,0
INTELENCE,rash,after,0
INTELENCE,Rash,Rash,1
INTELENCE,Rash,Rash,1
INTELENCE,Rash,Rash,1
INTELENCE,rash,rash,1
INTELENCE,rash,rash,1
INTELENCE,rash,rash Grade,0
INTELENCE,rash,,0
INTELENCE,rash,Precautions,0
INTELENCE,rash,,0
INTELENCE,rash,in women versus men,0
INTELENCE,rash,rash,1
INTELENCE,rash,rash,1
INTELENCE,rash,see Warnings and Precautions Patients with a history of,0
INTELENCE,rash,rash compare,0
INTELENCE,rash,rash,1
INTELENCE,rash,,0
INTELENCE,rash,rash,1
INTELENCE,rash,development of INTELENCE r related,0
INTELENCE,rash,rash did,0
INTELENCE,rash,INTELENCE r rash,1
INTELENCE,rash,compared to patients without a history of NNRTIrelated rash Common Adverse,0
INTELENCE,rash,rash,1
INTELENCE,rash,development of INTELENCE r rash,1
INTELENCE,rash,rash,1
INTELENCE,rash,rash,1
INTELENCE,rash,history of,0
INTELENCE,rash,NNRTIrelated,0
INTELENCE,rash,,0
INTELENCE,rash,rash,1
INTELENCE,rash,,0
INTELENCE,rash,rash,1
INTELENCE,rash,,0
INTELENCE,rash,rash,1
INTELENCE,Peripheral neuropathy,,0
INTELENCE,Peripheral neuropathy,regimen Nervous,0
INTELENCE,Peripheral neuropathy,ground regimen Nervous System Peripheral,1
INTELENCE,Peripheral neuropathy,neuropathy,1
INTELENCE,Peripheral neuropathy,Peripheral neuropathy,1
INTELENCE,Peripheral neuropathy,,0
INTELENCE,Peripheral neuropathy,neuropathy,1
INTELENCE,Peripheral neuropathy,Nervous System Peripheral,1
INTELENCE,Peripheral neuropathy,Sub,0
INTELENCE,Peripheral neuropathy,regimen Nervous System Peripheral neuropathy,1
INTELENCE,angina pectoris,blurred vi,0
INTELENCE,angina pectoris,by body system,0
INTELENCE,atrial fibrillation,atrial,1
INTELENCE,atrial fibrillation,atrial fibrillation,1
INTELENCE,atrial fibrillation,and Labyrinth,0
INTELENCE,atrial fibrillation,myocardial infarction angina atrial,1
INTELENCE,atrial fibrillation,Cardiac Disorders myocardial infarction angina,0
INTELENCE,atrial fibrillation,pectoris,0
INTELENCE,atrial fibrillation,infarction angina atrial fibrillation,1
INTELENCE,atrial fibrillation,vision Gastrointe,0
INTELENCE,blurred vision,Eye blurred vision,1
INTELENCE,blurred vision,Disorders vertigo Eye blurred,1
INTELENCE,blurred vision,,0
INTELENCE,blurred vision,vertigo,0
INTELENCE,gastroesophageal reflux disease,blurred vision Gastrointestinal gastroesophageal reflux disease,1
INTELENCE,gastroesophageal reflux disease,reflux disease,1
INTELENCE,gastroesophageal reflux disease,gastroesophageal reflux disease,1
INTELENCE,gastroesophageal reflux disease,dry mouth hematemesis,0
INTELENCE,gastroesophageal reflux disease,blurred vision Gastrointestinal gastroesophageal reflux disease,1
INTELENCE,gastroesophageal reflux disease,gastritis abdominal distension pancreatitis constipation dry mouth hematemesis,0
INTELENCE,flatulence,gastroesophageal reflux flatulence,1
INTELENCE,flatulence,pancreatitis constipation dry mouth hematemesis retching,0
INTELENCE,flatulence,pancreatitis constipation dry mouth hematemesis retching,0
INTELENCE,flatulence,Disorders blurred vision Gastrointestinal Disorders,0
INTELENCE,flatulence,Disorders blurred vision Gastrointestinal Disorders gastroesophageal reflux disease,0
INTELENCE,flatulence,gastroesophageal,0
INTELENCE,gastritis,gastroesophageal reflux disease gastritis,1
INTELENCE,gastritis,gastritis,1
INTELENCE,gastritis,disease gastritis,1
INTELENCE,gastritis,gastritis,1
INTELENCE,gastritis,distension pancreatitis constipation dry mouth hematemesis,0
INTELENCE,gastritis,disease flatulence,0
INTELENCE,gastritis,Disorders gastroesophageal reflux disease,0
INTELENCE,abdominal distension,,0
INTELENCE,abdominal distension,distension,1
INTELENCE,abdominal distension,distension,1
INTELENCE,dry mouth,Site Conditions,0
INTELENCE,dry mouth,distension pancreatitis dry mouth,1
INTELENCE,dry mouth,Administration,0
INTELENCE,dry mouth,,0
INTELENCE,dry mouth,abdominal distension pancreatitis dry mouth,1
INTELENCE,dry mouth,dry mouth,1
INTELENCE,dry mouth,abdominal distension pancreatitis dry,1
INTELENCE,hematemesis,hematemesis,1
INTELENCE,hematemesis,distension pancreatitis constipation dry hematemesis,1
INTELENCE,hematemesis,hematemesis,1
INTELENCE,hematemesis,hematemesis,1
INTELENCE,hematemesis,disease flatulence gastritis abdominal distension pancreatitis constipation dry mouth,0
INTELENCE,hematemesis,hematemesis,1
INTELENCE,retching,Administration Site Conditions,0
INTELENCE,retching,pancreatitis constipation,0
INTELENCE,retching,,0
INTELENCE,retching,General Disorders and,0
INTELENCE,retching,,0
INTELENCE,retching,,0
INTELENCE,retching,distension pancreatitis constipation dry,0
INTELENCE,retching,dry mouth retching,1
INTELENCE,stomatitis,,0
INTELENCE,stomatitis,hematemesis,0
INTELENCE,stomatitis,abdominal distension pancreatitis,0
INTELENCE,stomatitis,,0
INTELENCE,sluggishness,and Administration Site sluggishness,1
INTELENCE,sluggishness,Site sluggishness,1
INTELENCE,sluggishness,sluggishness,1
INTELENCE,sluggishness,Disorders hemolytic anemia Hepatobiliary Disorders hepatic,0
INTELENCE,sluggishness,sluggishness,1
INTELENCE,sluggishness,Site sluggishness,1
INTELENCE,sluggishness,sluggishness,1
INTELENCE,sluggishness,,0
INTELENCE,hemolytic anemia,Hematologic,0
INTELENCE,hemolytic anemia,Hepatobiliary,0
INTELENCE,hemolytic anemia,Conditions sluggishness Hematologic hemolytic anemia,1
INTELENCE,hemolytic anemia,Site Conditions sluggishness Hematologic hemolytic,1
INTELENCE,hemolytic anemia,and Administration Site Conditions sluggishness Hematologic Disorders,0
INTELENCE,hemolytic anemia,,0
INTELENCE,hemolytic anemia,hepatic failure hepatomegaly cytolytic hepatitis,0
INTELENCE,hemolytic anemia,Site Conditions sluggishness Hematologic hemolytic anemia,1
INTELENCE,hemolytic anemia,Conditions sluggishness Hematologic hemolytic,1
INTELENCE,hemolytic anemia,sluggishness Hematologic hemolytic anemia,1
INTELENCE,hepatic failure,hepatitis Immune System,0
INTELENCE,hepatic failure,hepatic,1
INTELENCE,hepatic failure,sluggishness Hematologic Disorders hemolytic,0
INTELENCE,hepatic failure,anemia Hepatobiliary hepatic,1
INTELENCE,hepatic failure,hemolytic anemia Hepatobiliary hepatic,1
INTELENCE,cytolytic hepatitis,hepatic failure cytolytic hepatitis,1
INTELENCE,cytolytic hepatitis,hepatitis,1
INTELENCE,hepatic steatosis,Immune System Disorders drug hypersensitivity immune reconstitution,0
INTELENCE,hepatic steatosis,,0
INTELENCE,hepatitis,hepatitis hepatic steatosis,0
INTELENCE,hepatitis,,0
INTELENCE,drug hypersensitivity,,0
INTELENCE,drug hypersensitivity,drug hypersensitivity,1
INTELENCE,drug hypersensitivity,drug hypersensitivity,1
INTELENCE,drug hypersensitivity,drug,1
INTELENCE,drug hypersensitivity,Disorders diabetes,0
INTELENCE,drug hypersensitivity,,0
INTELENCE,drug hypersensitivity,and Nutrition Disorders diabetes mellitus anor,0
INTELENCE,drug hypersensitivity,steatosis hepatitis,0
INTELENCE,drug hypersensitivity,drug hypersensitivity,1
INTELENCE,drug hypersensitivity,System drug hypersensitivity,1
INTELENCE,diabetes mellitus,somnolence convulsion,0
INTELENCE,diabetes mellitus,mellitus,1
INTELENCE,diabetes mellitus,Nervous,0
INTELENCE,diabetes mellitus,and Nutrition diabetes mellitus,1
INTELENCE,anorexia,paraesthesia,0
INTELENCE,anorexia,diabetes anorexia,1
INTELENCE,anorexia,paraesthesia somnolence convulsion,0
INTELENCE,anorexia,,0
INTELENCE,anorexia,paraesthesia somnolence,0
INTELENCE,anorexia,Disorders diabetes anorexia,1
INTELENCE,anorexia,anorexia,1
INTELENCE,anorexia,Nervous System,0
INTELENCE,anorexia,,0
INTELENCE,anorexia,anorexia,1
INTELENCE,somnolence,somnolence,1
INTELENCE,somnolence,somnolence,1
INTELENCE,somnolence,somnolence,1
INTELENCE,somnolence,somnolence,1
INTELENCE,somnolence,dyslipidemia,0
INTELENCE,somnolence,somnolence,1
INTELENCE,somnolence,hypoesthesia,0
INTELENCE,somnolence,hypersomnia tremor,0
INTELENCE,somnolence,System Disorders somnolence,1
INTELENCE,convulsion,Nervous System Disorders paraesthesia convulsion,1
INTELENCE,convulsion,convulsion,1
INTELENCE,convulsion,,0
INTELENCE,convulsion,System Disorders paraesthesia somnolence,0
INTELENCE,convulsion,anorexia dyslipidemia,0
INTELENCE,convulsion,convulsion,1
INTELENCE,convulsion,anorexia,0
INTELENCE,convulsion,convulsion,1
INTELENCE,convulsion,convulsion,1
INTELENCE,hypoesthesia,Disorders,0
INTELENCE,amnesia,Disorders paraesthesia somnolence convulsion amnesia,1
INTELENCE,amnesia,System Disorders paraesthesia,0
INTELENCE,amnesia,tremor Psychiatric Disorders anxiety sle,0
INTELENCE,amnesia,,0
INTELENCE,amnesia,disturbance,0
INTELENCE,amnesia,convulsion,0
INTELENCE,amnesia,somnolence convulsion hypoesthesia,0
INTELENCE,syncope,hypoesthesia syncope,1
INTELENCE,syncope,System Disorders paraesthesia somnolence convulsion hypoesthesia,0
INTELENCE,syncope,syncope,1
INTELENCE,syncope,syncope,1
INTELENCE,syncope,somnolence convulsion hypoesthesia,0
INTELENCE,syncope,syncope,1
INTELENCE,hypersomnia,anxiety sleep disorders abnormal dreams confusional state,0
INTELENCE,hypersomnia,hypersomnia,1
INTELENCE,hypersomnia,hypersomnia,1
INTELENCE,hypersomnia,hypersomnia,1
INTELENCE,hypersomnia,tremor Psychiatric Disorders anxiety sleep disorders abnormal dreams confusional state,0
INTELENCE,hypersomnia,hypersomnia,1
INTELENCE,hypersomnia,hypersomnia,1
INTELENCE,hypersomnia,in hypersomnia,1
INTELENCE,tremor,,0
INTELENCE,tremor,tremor,1
INTELENCE,tremor,Disorders anxiety sleep,0
INTELENCE,tremor,disturbance in attention tremor,1
INTELENCE,tremor,hypersomnia,0
INTELENCE,tremor,tremor,1
INTELENCE,tremor,,0
INTELENCE,tremor,Psychiatric Disorders anxiety sleep disorders abnormal dreams confusional state disori,0
INTELENCE,anxiety,state disorientation nervousness nightmares,0
INTELENCE,anxiety,hypersomnia tremor Psychiatric anxiety,1
INTELENCE,anxiety,anxiety,1
INTELENCE,anxiety,anxiety,1
INTELENCE,anxiety,anxiety,1
INTELENCE,anxiety,anxiety,1
INTELENCE,sleep disorders,dreams confusional state disorientation,0
INTELENCE,sleep disorders,and,0
INTELENCE,sleep disorders,,0
INTELENCE,abnormal dreams,abnormal dreams,1
INTELENCE,abnormal dreams,Renal and Urinary,0
INTELENCE,abnormal dreams,confusional state disorientation nervousness nightmares Renal and Urinary,0
INTELENCE,abnormal dreams,Disorders anxiety sleep abnormal dreams,1
INTELENCE,abnormal dreams,Disorders anxiety sleep abnormal,1
INTELENCE,nervousness,nervousness,1
INTELENCE,nervousness,nervousness,1
INTELENCE,nervousness,nervousness,1
INTELENCE,nervousness,Urinary,0
INTELENCE,nervousness,abnormal dreams confusional state,0
INTELENCE,nightmares,sleep disorders abnormal dreams confusional state disorientation,0
INTELENCE,nightmares,nightmares,1
INTELENCE,nightmares,and Urinary Disorders,0
INTELENCE,acute renal failure,and Urinary acute,1
INTELENCE,acute renal failure,Renal and Urinary acute renal,1
INTELENCE,acute renal failure,Urinary acute renal,1
INTELENCE,gynecomastia,gynecomastia,1
INTELENCE,gynecomastia,Disorders acute renal,0
INTELENCE,gynecomastia,System and Breast gynecomastia,1
INTELENCE,gynecomastia,gynecomastia,1
INTELENCE,gynecomastia,,0
INTELENCE,gynecomastia,failure Reproductive System,0
INTELENCE,gynecomastia,Breast,0
INTELENCE,gynecomastia,System and Breast gynecomastia,1
INTELENCE,gynecomastia,gynecomastia,1
INTELENCE,gynecomastia,gynecomastia,1
INTELENCE,gynecomastia,gynecomastia,1
INTELENCE,gynecomastia,System and Breast gynecomastia,1
INTELENCE,gynecomastia,and Urinary Disorders,0
INTELENCE,gynecomastia,Reproductive System and,0
INTELENCE,gynecomastia,Disorders acute renal,0
INTELENCE,exertional dyspnea,dyspnea,1
INTELENCE,exertional dyspnea,,0
INTELENCE,exertional dyspnea,sweats lipohypertrophy,0
INTELENCE,exertional dyspnea,exertional,1
INTELENCE,exertional dyspnea,RespiratoryThoracic and Mediastinal exertional dyspnea,1
INTELENCE,exertional dyspnea,gynecomastia RespiratoryThoracic and Mediastinal exertional dyspnea,1
INTELENCE,exertional dyspnea,dyspnea,1
INTELENCE,exertional dyspnea,,0
INTELENCE,exertional dyspnea,Mediastinal Disorders,0
INTELENCE,bronchospasm,bronchospasm,1
INTELENCE,bronchospasm,Mediastinal,0
INTELENCE,bronchospasm,,0
INTELENCE,bronchospasm,RespiratoryThoracic,0
INTELENCE,bronchospasm,gynecomastia RespiratoryThoracic and Mediastinal Disorders exertional dyspnea,0
INTELENCE,bronchospasm,,0
INTELENCE,bronchospasm,Mediastinal Disorders exertional bronchospasm,1
INTELENCE,night sweats,Disorders exertional dyspnea bronchospasm Skin and Subcutaneous Tissue,0
INTELENCE,night sweats,Skin and Subcutaneous Tissue night,1
INTELENCE,night sweats,Skin and Subcutaneous Tissue Disorders,0
INTELENCE,night sweats,sweats,1
INTELENCE,night sweats,night sweats,1
INTELENCE,night sweats,night sweats,1
INTELENCE,prurigo,Tissue Disorders night sweats prurigo,1
INTELENCE,prurigo,,0
INTELENCE,prurigo,prurigo,1
INTELENCE,prurigo,prurigo,1
INTELENCE,prurigo,bronchospasm Skin and Subcutaneous Tissue Disorders night,0
INTELENCE,hyperhidrosis,lipohypertrophy hyperhidrosis,1
INTELENCE,hyperhidrosis,Subcutaneous Tissue Disorders,0
INTELENCE,hyperhidrosis,hyperhidrosis,1
INTELENCE,hyperhidrosis,Skin and Subcutaneous Tissue Disorders night sweats,0
INTELENCE,hyperhidrosis,Subcutaneous,0
INTELENCE,hyperhidrosis,,0
INTELENCE,hyperhidrosis,and Subcutaneous Tissue Disorders night sweats,0
INTELENCE,hyperhidrosis,,0
INTELENCE,hyperhidrosis,moderate intensity observed in other,0
INTELENCE,dry skin,night sweats lipohypertrophy prurigo dry skin,1
INTELENCE,dry skin,were acq,0
INTELENCE,dry skin,sweats lipohypertrophy prurigo dry,1
INTELENCE,dry skin,prurigo dry skin,1
INTELENCE,dry skin,dry skin,1
INTELENCE,dry skin,,0
INTELENCE,dry skin,face Additional ADRs of at least moderate intensity observed in other trials were,0
INTELENCE,swelling face,lipohypertrophy prurigo hyperhidrosis dry swelling,1
INTELENCE,swelling face,swelling face,1
INTELENCE,swelling face,prurigo hyperhidrosis dry swelling,1
INTELENCE,swelling face,swelling face,1
INTELENCE,swelling face,swelling face,1
INTELENCE,swelling face,other trials were,0
INTELENCE,swelling face,lipohypertrophy prurigo hyperhidrosis dry swelling face,1
INTELENCE,swelling face,prurigo hyperhidrosis dry skin,0
INTELENCE,swelling face,face,1
INTELENCE,acquired lipodystrophy,face Additional ADRs of at least moderate intensity observed in other trials,0
INTELENCE,acquired lipodystrophy,other trials acquired,1
INTELENCE,acquired lipodystrophy,in no more than,0
INTELENCE,acquired lipodystrophy,acquired lipodystrophy,1
INTELENCE,acquired lipodystrophy,Additional ADRs of at least moderate intensity observed,0
INTELENCE,acquired lipodystrophy,edema erythema multiforme,0
INTELENCE,acquired lipodystrophy,each reported in no more,0
INTELENCE,acquired lipodystrophy,,0
INTELENCE,acquired lipodystrophy,lipodystrophy,1
INTELENCE,angioneurotic edema,stroke each reported in no more than,0
INTELENCE,erythema multiforme,erythema multiforme,1
INTELENCE,erythema multiforme,more than of,0
INTELENCE,erythema multiforme,erythema multiforme,1
INTELENCE,erythema multiforme,no,0
INTELENCE,erythema multiforme,erythema multiforme,1
INTELENCE,erythema multiforme,multiforme,1
INTELENCE,erythema multiforme,erythema multiforme,1
INTELENCE,erythema multiforme,multiforme,1
INTELENCE,haemorrhagic stroke,multiforme haemorrhagic stroke,1
INTELENCE,haemorrhagic stroke,acquired lipodystrophy angioneurotic edema erythema,0
INTELENCE,haemorrhagic stroke,haemorrhagic stroke,1
INTELENCE,haemorrhagic stroke,trials were acquired lipodystrophy angioneurotic,0
INTELENCE,Decreased hemoglobin,,0
INTELENCE,Decreased hemoglobin,hemoglobin Grade,1
INTELENCE,Decreased hemoglobin,Decreased hemoglobin Grade,1
INTELENCE,Decreased hemoglobin,Decreased,1
INTELENCE,Decreased hemoglobin,Decreased,1
INTELENCE,Decreased hemoglobin,Grade,0
INTELENCE,Decreased hemoglobin,,0
INTELENCE,Elevated glucose levels,Grade,0
INTELENCE,Elevated glucose levels,,0
INTELENCE,Elevated glucose levels,mmolL Elevated glucose levels Grade,1
INTELENCE,Elevated glucose levels,Grade,0
INTELENCE,Elevated glucose levels,,0
INTELENCE,Elevated glucose levels,mgdL,0
INTELENCE,Elevated glucose levels,Elevated,1
INTELENCE,ALT abnormalities,ALT abnormalities occurred,1
INTELENCE,ALT abnormalities,C virus coinfection out of subjects were permitted to,0
INTELENCE,ALT abnormalities,hepatitis C virus coinfection out of subjects were permitted,0
INTELENCE,ALT abnormalities,ALT,1
INTELENCE,ALT abnormalities,AST ALT,1
INTELENCE,rash,adult subjects except for,0
INTELENCE,rash,observed in adult,0
INTELENCE,rash,rash which,1
INTELENCE,rash,,0
INTELENCE,rash,rash and,1
INTELENCE,rash,most common adverse drug reactions in at least of pediatric subjects,0
INTELENCE,rash,rash and,1
INTELENCE,rash,rash and,1
INTELENCE,rash,rash and,1
INTELENCE,diarrhea,subjects were rash diarrhea Rash,1
INTELENCE,diarrhea,diarrhea Rash,1
INTELENCE,Rash,Rash was,1
INTELENCE,Rash,Rash was,1
INTELENCE,Rash,were rash and Rash was,1
INTELENCE,Rash,subjects were rash and Rash was,1
INTELENCE,Rash,,0
INTELENCE,Rash,Rash was,1
INTELENCE,Rash,and diarrhea,0
INTELENCE,Rash,versus Rash greater,1
INTELENCE,Rash,occurred in of pediatric,0
INTELENCE,Rash,discontinuations,0
INTELENCE,Rash,subjects In the majority of,0
INTELENCE,Rash,Rash greater,1
INTELENCE,Rash,of pediatric subjects In the majority of cases,0
INTELENCE,rash,rash was,1
INTELENCE,rash,,0
INTELENCE,rash,rash was,1
INTELENCE,Rash,and occurred in the second week of therapy,0
INTELENCE,Rash,Rash was,1
INTELENCE,Rash,the second week of Rash was,1
INTELENCE,Rash,Rash was,1
INTELENCE,Rash,Rash was,1
INTELENCE,Rash,in the second week of,0
INTELENCE,Rash,Rash was,1
INTELENCE,Rash,Rash was,1
INTELENCE,Rash,therapy The safety,0
INTELENCE,hypersensitivity,hypersensitivity reactions,1
INTELENCE,hypersensitivity,Disorders hypersensitivity reactions,1
INTELENCE,hypersensitivity,or establish a causal relationship to drug exposure Immune,0
INTELENCE,hypersensitivity,System Disorders hypersensitivity reactions,1
INTELENCE,hypersensitivity,hypersensitivity reactions,1
INTELENCE,hypersensitivity,hepatic failure have been reported see Warnings and,0
INTELENCE,hypersensitivity,to,0
INTELENCE,hypersensitivity,hypersensitivity reactions,1
INTELENCE,DRESS,been reported,0
INTELENCE,DRESS,Immune System Disorders Severe hypersensitivity reactions,0
INTELENCE,DRESS,to drug exposure Immune,0
INTELENCE,rhabdomyolysis,rhabdomyolysis Skin,1
INTELENCE,rhabdomyolysis,of,0
INTELENCE,rhabdomyolysis,Musculoskeletal and Connective,0
INTELENCE,rhabdomyolysis,,0
INTELENCE,toxic epidermal necrolysis,Skin and,0
INTELENCE,toxic epidermal necrolysis,reported see Warnings and,0
INTELENCE,toxic epidermal necrolysis,,0
INTELENCE,toxic epidermal necrolysis,Precautions,0
INTELENCE,fatal,,0
INTELENCE,fatal,il in other sections Severe,1
INTELENCE,fatal,il in other sections Severe,1
INTELENCE,fatal,Severe,0
INTELENCE,fatal,in,1
INTELENCE,fatal,il in other sections Severe skin,1
INTELENCE,fatal,,0
INTELENCE,fatal,in other sections Severe,1
INTELENCE,skin reactions,other sections Severe skin,1
INTELENCE,skin reactions,,0
INTELENCE,skin reactions,other,1
INTELENCE,skin reactions,,0
INTELENCE,skin reactions,Severe skin and hypersensitivity reactions see Warnings and Precautions,0
INTELENCE,skin reactions,other sections Severe skin,1
INTELENCE,Stevens-Johnson syndrome,hypersensitivity actions [ see  Warnings  and Precautions,1
INTELENCE,Stevens-Johnson syndrome,and Precautions EXCERPT The most,0
INTELENCE,Stevens-Johnson syndrome,reactions of,0
INTELENCE,Stevens-Johnson syndrome,actions [ see Warnings and Precautions,1
INTELENCE,Stevens-Johnson syndrome,and hypersensitivity actions [ see  Warnings  and Precautions,1
INTELENCE,Stevens-Johnson syndrome,Severe skin and hypersensitivity actions [ see  Warnings  and Precautions,1
INTELENCE,Stevens-Johnson syndrome,in greater detail in other sections Severe skin and,0
INTELENCE,Stevens-Johnson syndrome,hypersensitivity actions,1
INTELENCE,hypersensitivity reaction,,0
INTELENCE,hypersensitivity reaction,d Precautions,1
INTELENCE,hypersensitivity reaction,most,0
INTELENCE,erythema multiforme,drug react ions of,1
INTELENCE,erythema multiforme,EXCERPT The most  adverse drug react ions of,1
INTELENCE,erythema multiforme,EXCERPT The most adverse drug,1
INTELENCE,erythema multiforme,adverse drug react ions of,1
INTELENCE,erythema multiforme,ions of moderate,0
INTELENCE,erythema multiforme,adverse,1
INTELENCE,erythema multiforme,Precautions EXCERPT The,0
INTELENCE,erythema multiforme,drug react ions of,1
INTELENCE,fatal,"ADVERSE REACTIONS contact Janssen ts,",1
INTELENCE,fatal,and diarrhea To report SUSPECTED ADVERSE,0
INTELENCE,fatal,SUSPECTED ADVERSE REACTIONS contact,0
INTELENCE,fatal,"REACTIONS contact Janssen ts,",1
INTELENCE,fatal,"REACTIONS contact Janssen ts, L P at",1
INTELENCE,fatal,,0
INTELENCE,fatal,"ts, L P at",1
INTELENCE,skin reactions,Janssen Products at,1
INTELENCE,skin reactions,Products at,1
INTELENCE,skin reactions,REACTIONS contact,0
INTELENCE,Stevens-Johnson syndrome,at,0
INTELENCE,Stevens-Johnson syndrome,LP at JANSSEN or FDA at FDA,0
INTELENCE,Stevens-Johnson syndrome,Trials Experience Adults Because clinical trials,0
INTELENCE,toxic epidermal necrolysis,are conducted,0
INTELENCE,toxic epidermal necrolysis,FDA at FDA or tch . 6.1,1
INTELENCE,toxic epidermal necrolysis,widely varying conditio,0
INTELENCE,toxic epidermal necrolysis,6.1 Clini cal Trials,1
INTELENCE,toxic epidermal necrolysis,at FDA or tch .,1
INTELENCE,toxic epidermal necrolysis,conducted under widely varying,0
INTELENCE,toxic epidermal necrolysis,clinical trials,0
INTELENCE,erythema multiforme,widely varying conditions adverse reaction,0
INTELENCE,erythema multiforme,Clinical rials Experience: A dults Because,1
INTELENCE,erythema multiforme,varying conditions adverse reaction rat,0
INTELENCE,erythema multiforme,wwwfdagovmedwatch,0
INTELENCE,erythema multiforme,or wwwfdagovmedwatch Clinical rials Experience:,1
INTELENCE,Hypersensitivity reactions,Adu,0
INTELENCE,Drug Rash with Eosinophilia and Systemic Symptoms,,0
INTELENCE,Drug Rash with Eosinophilia and Systemic Symptoms,clinical trials are co,0
INTELENCE,Drug Rash with Eosinophilia and Systemic Symptoms,"nducted under widely varying conditions, adverse  reaction rates",1
INTELENCE,Drug Rash with Eosinophilia and Systemic Symptoms,"nducted under widely varying conditions, adverse  reaction rates",1
INTELENCE,Drug Rash with Eosinophilia and Systemic Symptoms,"are nducted under widely varying conditions, adverse  reaction rates",1
INTELENCE,Drug Rash with Eosinophilia and Systemic Symptoms,"varying conditions, adverse reaction rates",1
INTELENCE,DRESS,actio n rates,1
INTELENCE,DRESS,trials are conducted under,0
INTELENCE,DRESS,actio n rates,1
INTELENCE,DRESS,actio n rates,1
INTELENCE,DRESS,Adults Because clinical trials are conducted under widely,0
INTELENCE,DRESS,Adults Because,0
INTELENCE,DRESS,widely varying conditions adverse actio n rates,1
INTELENCE,DRESS,,0
INTELENCE,DRESS,clinical trials are conducted under widely,0
INTELENCE,DRESS,actio n rates,1
INTELENCE,rash,be directly compared to rates in the clinical trials,0
INTELENCE,rash,,0
INTELENCE,rash,nnot be directly,1
INTELENCE,rash,clinical trials of a drug ca,0
INTELENCE,rash,,0
INTELENCE,rash,drug nnot be directly,1
INTELENCE,organ dysfunction,nical trials of a nother drug,1
INTELENCE,organ dysfunction,the nical trials of a nother drug,1
INTELENCE,organ dysfunction,nical,1
INTELENCE,hepatic failure,practice The safety assessment is based on all data from subjec,0
INTELENCE,rashes,in practice  safet y assessment,1
INTELENCE,rash, of  whom received,1
INTELENCE,rash, of  whom received,1
INTELENCE,Rash,,0
INTELENCE,rash,weeks respectively Discontinuations due to,0
INTELENCE,rash,NCE r arm and placebo arm was and weeks respectively Discontinuations due to,0
INTELENCE,accumulation of body fat,in clinical trials,0
INTELENCE,accumulation of body fat,moderate red,1
INTELENCE,accumulation of body fat,to moderate red primarily in the sec ond week,1
INTELENCE,accumulation of body fat,to moderate red primarily in the,1
INTELENCE,accumulation of body fat,the sec ond week,1
INTELENCE,accumulation of body fat,trials rash was mild to,0
INTELENCE,accumulation of body fat,,0
INTELENCE,accumulation of body fat,was infrequent after Week Rash generally resolved within,0
INTELENCE,accumulation of body fat,red primarily,1
INTELENCE,accumulation of body fat,rash In general,0
INTELENCE,central obesity,"therapy,",1
INTELENCE,central obesity,within to weeks on continued,0
INTELENCE,dorsocervical fat enlargement,of therapy and infrequent after Week 4. Rash generally resolved,1
INTELENCE,dorsocervical fat enlargement,,0
INTELENCE,dorsocervical fat enlargement,of therapy and infrequent after Week 4. Rash generally resolved,1
INTELENCE,dorsocervical fat enlargement,of therapy and infrequent after Week 4. Rash generally resolved,1
INTELENCE,buffalo hump,res olved within,1
INTELENCE,buffalo hump,Rash enerally res olved within,1
INTELENCE,buffalo hump,infrequent after Week Rash enerally,1
INTELENCE,buffalo hump,Rash enerally res olved within,1
INTELENCE,facial wasting,ks on continue d therapy,1
INTELENCE,facial wasting,was,0
INTELENCE,facial wasting,,0
INTELENCE,facial wasting,resolved within to ks on,1
INTELENCE,facial wasting,was infrequent after,0
INTELENCE,facial wasting,Week Rash generally resolved,0
INTELENCE,facial wasting,of therapy and was infrequent after Week Rash generally resolved,0
INTELENCE,facial wasting,compared to men in the INTELENCE,0
INTELENCE,breast enlargement,incid ence of,1
INTELENCE,breast enlargement,was higher in women compared to men in the,0
INTELENCE,Immune reconstitution syndrome,in women versus men ee  Warnings and Precautions ( Patients with,1
INTELENCE,inflammatory response,r related rash compared to,0
INTELENCE,inflammatory response,NNRTIrelated rash Common A,0
INTELENCE,opportunistic infections,,0
INTELENCE,opportunistic infections,Clinical ADRs of modera,0
INTELENCE,opportunistic infections,of NNRTIrelated rash Common Adverse Reactions Clinical,0
INTELENCE,Mycobacterium avium infection,treated with INTELENCE r and occurring at a higher,0
INTELENCE,Mycobacterium avium infection,greater han or equal to Grade 2) and r eported in,1
INTELENCE,Mycobacterium avium infection,in at least of subjects treated with INTELENCE r,0
INTELENCE,Mycobacterium avium infection,ADRs of moderate intensity or greater greater,0
INTELENCE,Mycobacterium avium infection,greater han,1
INTELENCE,Mycobacterium avium infection,han or equal to Grade,1
INTELENCE,Mycobacterium avium infection,least of subjects treated with,0
INTELENCE,Mycobacterium avium infection,greater han or equal to Grade 2) and r eported in,1
INTELENCE,Mycobacterium avium infection,han or equal to Grade 2) and r eported in,1
INTELENCE,cytomegalovirus,and occurring,0
INTELENCE,cytomegalovirus,or,0
INTELENCE,cytomegalovirus,orted in at lea st of,1
INTELENCE,cytomegalovirus,in at lea st of,1
INTELENCE,cytomegalovirus,,0
INTELENCE,cytomegalovirus,at lea st of,1
INTELENCE,cytomegalovirus,with INTELENCE r and occurring,0
INTELENCE,cytomegalovirus,Grade,0
INTELENCE,cytomegalovirus,and orted in at lea st of,1
INTELENCE,Pneumocystis jiroveci pneumonia,,0
INTELENCE,Pneumocystis jiroveci pneumonia,reported in at 2% of,1
INTELENCE,Pneumocystis jiroveci pneumonia,,0
INTELENCE,Pneumocystis jiroveci pneumonia,reported in at  2% of subjects treated with INT ELENCE r,1
INTELENCE,PCP,ENC E r,1
INTELENCE,PCP,ENC E r,1
INTELENCE,PCP,equal to,0
INTELENCE,PCP,treated with ENC E r,1
INTELENCE,PCP,ENC E r,1
INTELENCE,PCP,in,0
INTELENCE,PCP,of subjects treated with ENC E r,1
INTELENCE,PCP,ENC E r,1
INTELENCE,tuberculosis,with,0
INTELENCE,tuberculosis,subjects treated with INTELENCE )  and occur ring at,1
INTELENCE,tuberculosis,with INTELENCE ) and,1
INTELENCE,tuberculosis,equal to Grade and reported in at least of subjects treated with,0
INTELENCE,tuberculosis,r,0
INTELENCE,tuberculosis,in,0
INTELENCE,tuberculosis,with INTELENCE ) and,1
INTELENCE,Autoimmune disorders,1. Laboratory abnormalities,1
INTELENCE,Autoimmune disorders,included in,0
INTELENCE,Autoimmune disorders,in Table 1. Laboratory abnormalities,1
INTELENCE,Autoimmune disorders,Table Table,0
INTELENCE,Autoimmune disorders,included in Table,0
INTELENCE,Graves' disease, abnormalities  considered ADRs,1
INTELENCE,Guillain-Barre syndrome,ReactionsIncludes adverse reactions,0
INTELENCE,Guillain-Barre syndrome,of are presented in Table Laboratory abnormalities considered,0
PICATO,Ophthalmic Adverse Reaction,,0
PICATO,Ophthalmic Adverse Reaction,,0
PICATO,Ophthalmic Adverse Reaction,adverse reactions are,0
PICATO,Ophthalmic Adverse Reaction,of the Ophthalmic,1
PICATO,Hypersensitivity Reactions,common adverse,0
PICATO,Hypersensitivity Reactions,see Warnings and Hypersensitivity,1
PICATO,Hypersensitivity Reactions,Adverse Reaction see Warnings,0
PICATO,Hypersensitivity Reactions,Reaction see Warnings and Hypersensitivity,1
PICATO,Hypersensitivity Reactions,,0
PICATO,Hypersensitivity Reactions,Hypersensitivity,1
PICATO,Hypersensitivity Reactions,see Warnings and,0
PICATO,Hypersensitivity Reactions,Precautions EXCERPT,0
PICATO,local skin reactions,most common adverse reactions local skin reactions application site,1
PICATO,local skin reactions,most common,0
PICATO,local skin reactions,most common adverse reactions local skin,1
PICATO,local skin reactions,most common adverse reactions local skin reactions application site,1
PICATO,local skin reactions,site pruritus application site,0
PICATO,local skin reactions,adverse reactions local skin,1
PICATO,local skin reactions,reactions local,1
PICATO,local skin reactions,local,1
PICATO,local skin reactions,common adverse reactions local skin reactions application site,1
PICATO,application site pain,local skin application site,1
PICATO,application site pain,most common adverse reactions are,0
PICATO,application site pain,,0
PICATO,application site pain,local,0
PICATO,application site pain,application site pain application site,1
PICATO,application site pain,common adverse,0
PICATO,application site pain,site irritation application site infection periorbital ed,0
PICATO,application site pain,are local skin application,1
PICATO,application site pain,The most,0
PICATO,application site pruritus,are local skin reactions application site pain,0
PICATO,application site pruritus,adverse reactions are local,0
PICATO,application site pruritus,local skin,0
PICATO,application site pruritus,,0
PICATO,application site pruritus,,0
PICATO,application site pruritus,are local skin,0
PICATO,application site pruritus,application site pruritus application site,1
PICATO,application site pruritus,site pruritus application site,1
PICATO,application site irritation,irritation application site,1
PICATO,application site irritation,are local skin reactions application site pain,0
PICATO,application site irritation,pruritus,0
PICATO,application site irritation,,0
PICATO,application site irritation,,0
PICATO,application site irritation,are local,0
PICATO,application site infection,application,0
PICATO,periorbital edema,site irritation application site periorbital,1
PICATO,periorbital edema,periorbital edema nasopharyngitis and,1
PICATO,periorbital edema,periorbital edema nasopharyngitis and,1
PICATO,periorbital edema,edema nasopharyngitis and,1
PICATO,periorbital edema,site irritation application site periorbital edema nasopharyngitis and,1
PICATO,nasopharyngitis,To report SUSPECTED ADVERSE REACTIONS contact LEO Pharma Inc,0
PICATO,headache,periorbital,0
PICATO,headache,headache To report,1
PICATO,headache,headache To report,1
PICATO,headache,infection periorbital edema nasopharyngitis headache To report,1
PICATO,headache,headache To report,1
PICATO,headache,REACTIONS contact LEO,0
PICATO,headache,,0
PICATO,headache,headache To report,1
PICATO,headache,SUSPECTED ADVERSE REACTIONS contact LEO,0
PICATO,headache,headache To report,1
PICATO,Local skin reactions,consecutive Local skin,1
PICATO,Local skin reactions,once daily for consecutive Local skin reactions including erythema,1
PICATO,Local skin reactions,consecutive Local skin,1
PICATO,Local skin reactions,including erythema flakingscaling crusting swelling vesiculationpustulation,0
PICATO,Local skin reactions,daily for consecutive Local skin reactions including erythema,1
PICATO,Local Skin Reactions,Investigator Assessment of Local Skin,1
PICATO,Local Skin Reactions,Local Skin Reactions in the,1
PICATO,Local Skin Reactions,the Days Post Treatment Period facescalp trials Face,0
PICATO,Local Skin Reactions,Skin Reactions in the,1
PICATO,Local Skin Reactions,Table Investigator Assessment of Local Skin,1
PICATO,Local Skin Reactions,,0
PICATO,Local Skin Reactions,Treatment Period facescalp trials Face and,0
PICATO,Local Skin Reactions,Local Skin Reactions in the,1
PICATO,Local Skin Reactions,Local Skin Reactions in the,1
PICATO,Local Skin Reactions,Local,1
PICATO,Local Skin Reactions,Assessment of Local Skin,1
PICATO,Local Skin Reactions,,0
PICATO,Local Skin Reactions,Local Skin,1
PICATO,Local Skin Reactions,,0
PICATO,Local Skin Reactions,Assessment of Local Skin Reactions in the,1
PICATO,Local skin reactions,,0
PICATO,Local skin reactions,grade or Severe Local skin reactions typically occurred,1
PICATO,Local skin reactions,or Severe Local skin reactions typically occurred,1
PICATO,Local skin reactions,or Severe Local skin,1
PICATO,Application Site Pain,N Vehicle Application Site,1
PICATO,Application Site Pain,N,0
PICATO,Application Site Pain,Application Site,1
PICATO,Application Site Pruritus,Application,1
PICATO,Application Site Infection,Application Site Infection Periorbital Edema,1
PICATO,Periorbital Edema,,0
PICATO,Periorbital Edema,Site Infection,0
PICATO,Periorbital Edema,,0
PICATO,Periorbital Edema,Site Periorbital,1
PICATO,Periorbital Edema,,0
PICATO,Periorbital Edema,Application Site Periorbital,1
PICATO,Periorbital Edema,Periorbital,1
PICATO,Periorbital Edema,Application Site Periorbital,1
PICATO,Periorbital Edema,Site Periorbital Edema Headache,1
PICATO,Periorbital Edema,Periorbital Edema Headache,1
PICATO,Headache,,0
PICATO,Headache,Edema,0
PICATO,Headache,,0
PICATO,Application Site Pruritus,,0
PICATO,Application Site Irritation,,0
PICATO,Application Site Irritation,Site Irritation Nasopharyngitis,1
PICATO,Nasopharyngitis,Nasopharyngitis Application Site,1
PICATO,Nasopharyngitis,Nasopharyngitis Application Site,1
PICATO,Application Site Pain,Nasopharyngitis,0
PICATO,eyelid edema,gel on the fa,0
PICATO,eyelid edema,edema eye pain,1
PICATO,eyelid edema,treated with Picato,0
PICATO,eyelid edema,treated with Picato r eyelid,1
PICATO,eyelid edema,edema eye pain,1
PICATO,eyelid edema,edema eye pain,1
PICATO,eyelid edema,fa,0
PICATO,eyelid edema,with Picato r eyelid,1
PICATO,eyelid edema,with,0
PICATO,eye pain,eyelid,0
PICATO,eye pain,Picato r included eyelid eye,1
PICATO,eye pain,adverse reactions in subjects treated,0
PICATO,eye pain,eye pain conjunctivitis A,1
PICATO,eye pain,eye pain conjunctivitis A,1
PICATO,eye pain,r included eyelid,0
PICATO,conjunctivitis,conjunctivitis A total,1
PICATO,conjunctivitis,conjunctivitis A total,1
PICATO,conjunctivitis,conjunctivitis A total,1
PICATO,conjunctivitis,,0
PICATO,conjunctivitis,,0
PICATO,conjunctivitis,conjunctivitis A total,1
PICATO,conjunctivitis,treated with,0
PICATO,conjunctivitis,conjunctivitis A total,1
PICATO,conjunctivitis,conjunctivitis A total,1
PICATO,conjunctivitis,conjunctivitis A total,1
PICATO,hypersensitivity,hypersensitivity allergic contact,1
PICATO,hypersensitivity,ingenol mebutate gel hypersensitivity allergic contact,1
PICATO,hypersensitivity,mebutate gel hypersensitivity allergic contact,1
PICATO,hypersensitivity,hypersensitivity allergic contact,1
PICATO,hypersensitivity,chemical conjunctivitis,0
PICATO,hypersensitivity,r ingenol mebutate gel hypersensitivity allergic contact,1
PICATO,hypersensitivity,hypersensitivity allergic contact,1
PICATO,hypersensitivity,corneal,0
PICATO,hypersensitivity,of Picato r ingenol,0
PICATO,allergic contact dermatitis,and allergic contact dermatitis herpes zoster,1
PICATO,allergic contact dermatitis,and allergic contact,1
PICATO,herpes zoster,herpes zoster chemical conjunctivitis,1
PICATO,herpes zoster,zoster chemical conjunctivitis,1
PICATO,herpes zoster,reactions,0
PICATO,herpes zoster,allergic contact herpes zoster chemical conjunctivitis,1
PICATO,herpes zoster,and hypersensitivity allergic contact herpes,1
PICATO,chemical conjunctivitis,chemical conjunctivitis and corneal,1
PICATO,chemical conjunctivitis,and,0
PICATO,corneal burn,chemical,0
PICATO,corneal burn,,0
PICATO,corneal burn,burn Because these,1
PICATO,corneal burn,zoster chemical conjunctivitis corneal burn Because these,1
PICATO,corneal burn,corneal burn Because these,1
PICATO,corneal burn,corneal burn Because these,1
PICATO,Eye disorders,of the labeling Ophthalmic Adverse Reaction see Warnings a,0
PICATO,eye pain,of the,1
PICATO,eye pain,Adverse Reaction,0
PICATO,eye pain,are discussed,0
PICATO,eye pain,serious adverse reactions are discussed,0
PICATO,chemical conjunctivitis,see Warnings,0
PICATO,chemical conjunctivitis,e labeling: Ophthalmic,1
PICATO,chemical conjunctivitis,of e,1
PICATO,chemical conjunctivitis,of e,1
PICATO,chemical conjunctivitis,Reaction see Warnings and Precautions Hypersensitivity,0
PICATO,chemical conjunctivitis,of th,0
PICATO,chemical conjunctivitis,"in other sections of e labeling:



     


 Ophthalmic",1
PICATO,eyelid edema,sections of the labeling Adverse,1
PICATO,eyelid edema,,0
PICATO,eyelid edema,in more,0
PICATO,eyelid ptosis,and,0
PICATO,eyelid ptosis,labeling Ophthalmic Adverse on,1
PICATO,eyelid ptosis,labeling Ophthalmic Adverse on [see,1
PICATO,periorbital edema,s and Precautions Hypersensitivity,1
PICATO,periorbital edema,Ophthalmic Adverse Reaction see s,1
PICATO,periorbital edema,,0
PICATO,periorbital edema,see,0
PICATO,periorbital edema,s and Precautions Hypersensitivity,1
PICATO,periorbital edema,of the labeling,0
PICATO,periorbital edema,Precautions Hypersensitivity,1
PICATO,periorbital edema,see s and,1
PICATO,periorbital edema,Reactions,0
PICATO,periorbital edema,Ophthalmic Adverse Reaction see s and,1
PICATO,Local skin reactions,prur itus,1
PICATO,Local skin reactions,pain,0
PICATO,Local skin reactions,site pain pplication site,1
PICATO,Local skin reactions,itus,0
PICATO,Local skin reactions,pain pplication site prur itus,1
PICATO,Local skin reactions,application site pain pplication site prur itus,1
PICATO,Local skin reactions,prur itus,1
PICATO,Local skin reactions,an,0
PICATO,eye pain,a drug cannot,0
PICATO,eye pain,trials are ted,1
PICATO,eye pain,,0
PICATO,eye pain,Because clinical trials are ted,1
PICATO,eye pain,,0
PICATO,eye pain,trials are ted unde r,1
PICATO,eye pain,Because clinical trials are ted,1
PICATO,chemical conjunctivitis,clinical trials,0
PICATO,chemical conjunctivitis,are conducted widely varying conditio ns,1
PICATO,chemical conjunctivitis,compared to,0
PICATO,chemical conjunctivitis,Experience Because,0
PICATO,chemical conjunctivitis,conducted widely varying conditio ns,1
PICATO,chemical conjunctivitis,Clinical Trials Experience Because clinical trials are conducted,0
PICATO,chemical conjunctivitis,are conducted widely varying conditio ns,1
PICATO,chemical conjunctivitis,are conducted widely,1
PICATO,corneal burn,Because,0
PICATO,corneal burn,Trials Experience Because clinical trials are conducted under widely varying,0
PICATO,corneal burn,trials are conducted under,0
PICATO,corneal burn,directly compared to rates,0
PICATO,corneal burn,conditions,0
PICATO,corneal burn,re action,1
PICATO,corneal burn,", adverse re action",1
PICATO,corneal burn,", adverse re action",1
PICATO,eyelid edema,the clinical trials of a drug,0
PICATO,eyelid edema,adverse tion rates,1
PICATO,eyelid edema,varying conditions adverse tion,1
PICATO,eyelid edema,widely varying conditions adverse tion,1
PICATO,eyelid edema,,0
PICATO,eyelid edema,conditions adverse tion rates o bserved,1
PICATO,eyelid edema,are conducted under widely,0
PICATO,eyelid edema,trials of a,0
PICATO,eyelid ptosis,varying conditions,0
PICATO,eyelid ptosis,rates erved in,1
PICATO,periorbital edema,trials of a,1
PICATO,periorbital edema,inical trials of a,1
PICATO,periorbital edema,in the inical,1
PICATO,periorbital edema,the clinical trials of another drug and may not,0
PICATO,periorbital edema,drug and may,0
PICATO,periorbital edema,another drug and may not refle,0
PICATO,periorbital edema,trials of a,1
PICATO,periorbital edema,the inical trials of  a,1
PICATO,periorbital edema,are conducted under widely,0
PICATO,periorbital edema,in the clinical trials of another drug and may,0
PICATO,Hypersensitivity reactions,"3 consecutive days, an d",1
PICATO,Hypersensitivity reactions,treatment skin area of,0
PICATO,Hypersensitivity reactions,"concentration of once for 3 consecutive days,",1
PICATO,Hypersensitivity reactions,trunk or e,0
PICATO,Hypersensitivity reactions,"consecutive days, an d",1
PICATO,Hypersensitivity reactions,,0
PICATO,Hypersensitivity reactions,"concentration of once for 3 consecutive days, an d",1
PICATO,Hypersensitivity reactions,at a concentration of once,0
PICATO,Hypersensitivity reactions,"once for 3 consecutive days, an d",1
PICATO,anaphylaxis,area of,0
PICATO,allergic contact dermatitis,once daily for consecutive days and subjects exposed,0
PICATO,allergic contact dermatitis,regions at a concentration of,0
PICATO,allergic contact dermatitis,cato (r) gel,1
PICATO,allergic contact dermatitis,treatm ent,1
PICATO,allergic contact dermatitis,once da,0
PICATO,allergic contact dermatitis,subjects exposed to cato,1
PICATO,allergic contact dermatitis,a concentration of once daily for,0
PICATO,skin reactions in the treated area,and erosionulceration were within the selected treatment area and,1
PICATO,skin reactions in the treated area,erosionulceration were within the,1
PICATO,skin reactions in the treated area,and,0
PICATO,skin reactions in the treated area,were within the selected treatment area and,1
PICATO,skin reactions in the treated area,vesiculationpustulation and erosionulceration,0
VIZAMYL,flushing,flushing headache increased,1
VIZAMYL,flushing,flushing headache increased,1
VIZAMYL,flushing,repor,0
VIZAMYL,flushing,flushing headache increased,1
VIZAMYL,flushing,,0
VIZAMYL,flushing,,0
VIZAMYL,flushing,blood pressure nausea and dizziness,0
VIZAMYL,flushing,,0
VIZAMYL,headache,,0
VIZAMYL,headache,report SUSPECTED,0
VIZAMYL,headache,headache,1
VIZAMYL,headache,headache increased blood pressure nausea and,1
VIZAMYL,headache,pressure nausea and dizziness To report SUSPECTED,0
VIZAMYL,increased blood pressure,blood pressure nausea and dizziness,1
VIZAMYL,increased blood pressure,flushing increased blood,1
VIZAMYL,increased blood pressure,EXCERPT Most commonly,0
VIZAMYL,nausea,,0
VIZAMYL,nausea,nausea and dizziness To,1
VIZAMYL,nausea,flushing headache increased blood nausea and dizziness To,1
VIZAMYL,nausea,nausea and dizziness To,1
VIZAMYL,nausea,nausea and dizziness To,1
VIZAMYL,nausea,headache increased blood nausea and dizziness To,1
VIZAMYL,dizziness,were flushing headache increased blood,0
VIZAMYL,dizziness,,0
VIZAMYL,dizziness,headache increased blood pressure nausea,0
VIZAMYL,dizziness,dizziness To report SUSPECTED,1
VIZAMYL,dizziness,dizziness To report SUSPECTED,1
VIZAMYL,dizziness,Healthcare at,0
VIZAMYL,dizziness,increased blood pressure nausea,0
VIZAMYL,dizziness,pressure nausea dizziness To report SUSPECTED,1
VIZAMYL,dizziness,dizziness To report SUSPECTED,1
VIZAMYL,hypersensitivity reaction,experienced a hypersensitivity reaction with flushing dyspnea,1
VIZAMYL,hypersensitivity reaction,minutes following Vizamyl administration and recov,0
VIZAMYL,flushing,flushing dyspnea and chest,1
VIZAMYL,flushing,administration and recovered,0
VIZAMYL,flushing,experienced a,0
VIZAMYL,dyspnea,reaction with,0
VIZAMYL,dyspnea,dyspnea and chest pressure,1
VIZAMYL,dyspnea,dyspnea and chest pressure,1
VIZAMYL,dyspnea,administration and recovered,0
VIZAMYL,dyspnea,dyspnea and chest pressure,1
VIZAMYL,dyspnea,flushing,0
VIZAMYL,dyspnea,dyspnea and chest pressure,1
VIZAMYL,dyspnea,dyspnea and chest pressure,1
VIZAMYL,dyspnea,dyspnea and chest pressure,1
VIZAMYL,chest pressure,,0
VIZAMYL,chest pressure,with flushing dyspnea chest,1
VIZAMYL,chest pressure,pressure within minutes following,1
VIZAMYL,chest pressure,chest,1
VIZAMYL,chest pressure,chest,1
VIZAMYL,chest pressure,chest pressure within minutes following,1
VIZAMYL,chest pressure,flushing dyspnea chest,1
VIZAMYL,Flushing,N percent of,0
VIZAMYL,Flushing,Flushing I,1
VIZAMYL,Flushing,,0
VIZAMYL,Flushing,patients,0
VIZAMYL,Flushing,,0
VIZAMYL,Flushing,Flushing I,1
VIZAMYL,Flushing,N percent of patients,0
VIZAMYL,Increased blood pressure,blood pressure Headache,1
VIZAMYL,Increased blood pressure,Headache,0
VIZAMYL,Increased blood pressure,g,0
VIZAMYL,Increased blood pressure,g,0
VIZAMYL,Increased blood pressure,,0
VIZAMYL,Increased blood pressure,Increased blood pressure Headache,1
VIZAMYL,Increased blood pressure,,0
VIZAMYL,Headache,blood,0
VIZAMYL,Headache,blood,0
VIZAMYL,Nausea,,0
VIZAMYL,Nausea,,0
VIZAMYL,Nausea,e Nausea,1
VIZAMYL,Hypersensitivity reactions,reported,1
VIZAMYL,Hypersensitivity reactions,reported adverse reactions were flushing headache increased blood,1
VIZAMYL,Hypersensitivity reactions,,0
VIZAMYL,Hypersensitivity reactions,reported adverse reactions were flushing headache increased,1
VIZAMYL,Hypersensitivity reactions,,0
VIZAMYL,Hypersensitivity reactions,reported adverse reactions were flushing headache,1
VIZAMYL,Hypersensitivity reactions,,0
VIZAMYL,Hypersensitivity reactions,headache increased blood,0
VIZAMYL,Hypersensitivity reactions,,0
VIZAMYL,Hypersensitivity reactions,,0
VIZAMYL,Radiation risk,rates observed,0
VIZAMYL,Radiation risk,widely ying condition,1
VIZAMYL,long-term cumulative radiation exposure,varying conditions and adverse reaction,0
VIZAMYL,long-term cumulative radiation exposure,of another drug and may not reflect the,0
VIZAMYL,long-term cumulative radiation exposure,e clinical trials of another drug and may not reflect the rates observed in clinical practice,0
VIZAMYL,Hypersensitivity reactions,and women Caucasian th a mean age of,1
VIZAMYL,Hypersensitivity reactions,men and women Caucasian wi,0
VIZAMYL,Hypersensitivity reactions,and women Caucasian th a mean age of 62 years ,1
VIZAMYL,Hypersensitivity reactions,th a mean age of 62 years ,1
VIZAMYL,Hypersensitivity reactions,and women Caucasian wi,0
VIZAMYL,flushing,with a mean,0
VIZAMYL,flushing,s received Vizamyl Most subjects received a dose of MBq mCi One subject ou,0
VIZAMYL,flushing,age of years -93,1
VIZAMYL,dyspnea,received a dose of MBq mCi One subject out of,0
VIZAMYL,dyspnea,received a dose,0
VIZAMYL,dyspnea,Most subjects received a dose of MBq mCi One subject out of,0
VIZAMYL,dyspnea,ceived ,1
VIZAMYL,dyspnea,mCi One subject out,0
VIZAMYL,dyspnea,ceived ,1
VIZAMYL,dyspnea,women Caucasian with a mean,0
VIZAMYL,dyspnea,ceived ,1
VIZAMYL,long-term cumulative radiation exposure,,1
VIZAMYL,long-term cumulative radiation exposure,,1
VIZAMYL,long-term cumulative radiation exposure,,0
VIZAMYL,long-term cumulative radiation exposure,,1
VIZAMYL,Long-term cumulative radiation exposure,,1
VIZAMYL,Long-term cumulative radiation exposure,,0
VIZAMYL,Long-term cumulative radiation exposure,,1
VIZAMYL,Long-term cumulative radiation exposure,,0
VIZAMYL,Long-term cumulative radiation exposure,,1
VIZAMYL,Long-term cumulative radiation exposure,,0
VIZAMYL,Long-term cumulative radiation exposure,,0
VIZAMYL,Long-term cumulative radiation exposure,,0
POTIGA,Retinal abnormalities,,0
POTIGA,Retinal abnormalities,retention see,0
POTIGA,Retinal abnormalities,the Retinal abnormalities,1
POTIGA,Retinal abnormalities,Retinal abnormalities,1
POTIGA,Retinal abnormalities,,0
POTIGA,Retinal abnormalities,abnormalities,1
POTIGA,Retinal abnormalities,abnormalities,1
POTIGA,Retinal abnormalities,,0
POTIGA,Retinal abnormalities,see Warnings and Precautions Urinary retention,0
POTIGA,Retinal abnormalities,,0
POTIGA,vision loss,Precautions,0
POTIGA,vision loss,label Retinal abnormalities and vision,1
POTIGA,vision loss,abnormalities and vision loss,1
POTIGA,vision loss,abnormalities and vision loss,1
POTIGA,vision loss,and Precautions Urinary,0
POTIGA,vision loss,vision loss,1
POTIGA,vision loss,vision loss,1
POTIGA,vision loss,label Retinal abnormalities and,0
POTIGA,vision loss,label Retinal abnormalities and vision loss,1
POTIGA,vision loss,abnormalities,0
POTIGA,Urinary retention,and Precautions Skin discoloration see Warnings and,0
POTIGA,Urinary retention,Warnings and Urinary,1
POTIGA,Urinary retention,Skin,0
POTIGA,Urinary retention,retention,1
POTIGA,Urinary retention,retention,1
POTIGA,Urinary retention,Urinary retention,1
POTIGA,Skin discoloration,Skin discoloration,1
POTIGA,Neuropsychiatric symptoms,discoloration see Warnings,0
POTIGA,Neuropsychiatric symptoms,Neuropsychiatric symptoms,1
POTIGA,Neuropsychiatric symptoms,,0
POTIGA,Neuropsychiatric symptoms,,0
POTIGA,Neuropsychiatric symptoms,,0
POTIGA,Neuropsychiatric symptoms,,0
POTIGA,Neuropsychiatric symptoms,Neuropsychiatric,1
POTIGA,Dizziness,see Warnings and Dizziness,1
POTIGA,Dizziness,Precautions Neuropsychiatric symptoms see,0
POTIGA,Dizziness,and Dizziness,1
POTIGA,Dizziness,see Warnings and,0
POTIGA,QT interval effect,interval effect,1
POTIGA,QT interval effect,Precautions Dizziness and somnolence see Warnings and,0
POTIGA,QT interval effect,Warnings and Precautions,0
POTIGA,QT interval effect,Precautions,0
POTIGA,QT interval effect,and ideation see,0
POTIGA,QT interval effect,QT interval effect,1
POTIGA,QT interval effect,somnolence see Warnings and QT interval,1
POTIGA,QT interval effect,see Warnings and QT,1
POTIGA,QT interval effect,Precautions,0
POTIGA,QT interval effect,see,0
POTIGA,Suicidal behavior,see Warnings and Pre,0
POTIGA,Suicidal behavior,Precautions Withdrawal seizures see Warnings,0
POTIGA,Suicidal behavior,Warnings and,0
POTIGA,Suicidal behavior,behavior,1
POTIGA,Withdrawal seizures,and Withdrawal,1
POTIGA,Withdrawal seizures,see Warnings and,0
POTIGA,Withdrawal seizures,seizures,1
POTIGA,dizziness,dizziness,1
POTIGA,dizziness,confusional state vertigo tremor abnormal,0
POTIGA,dizziness,abnormal,0
POTIGA,dizziness,incidence and twice placebo were,0
POTIGA,dizziness,were,0
POTIGA,dizziness,diplopia,0
POTIGA,dizziness,dizziness,1
POTIGA,dizziness,dizziness,1
POTIGA,dizziness,placebo dizziness,1
POTIGA,dizziness,confusional state vertigo,0
POTIGA,somnolence,diplopia disturbance in atten,0
POTIGA,somnolence,disturbance in,0
POTIGA,somnolence,twice placebo,0
POTIGA,fatigue,,0
POTIGA,fatigue,incidence and twice placebo were dizziness,0
POTIGA,fatigue,confusional state vertigo tremor abnormal coordination diplopia disturbance in,0
POTIGA,fatigue,attention mem,0
POTIGA,fatigue,placebo were dizziness fatigue,1
POTIGA,fatigue,were dizziness fatigue,1
POTIGA,fatigue,dizziness fatigue,1
POTIGA,fatigue,,0
POTIGA,vertigo,vertigo,1
POTIGA,tremor,state tremor,1
POTIGA,tremor,confusional state tremor,1
POTIGA,tremor,vi,0
POTIGA,tremor,tremor,1
POTIGA,tremor,,0
POTIGA,tremor,state,0
POTIGA,tremor,in,0
POTIGA,tremor,tremor,1
POTIGA,tremor,tremor,1
POTIGA,abnormal coordination,,0
POTIGA,abnormal coordination,asthenia blurred vision,0
POTIGA,abnormal coordination,vertigo abnormal coordination,1
POTIGA,abnormal coordination,abnormal coordination,1
POTIGA,diplopia,,0
POTIGA,diplopia,gait,0
POTIGA,diplopia,diplopia,1
POTIGA,diplopia,tremor abnormal,0
POTIGA,disturbance in attention,vertigo tremor abnormal coordination,0
POTIGA,disturbance in attention,disturbance in attention,1
POTIGA,disturbance in attention,vision gait disturbance aphasia dysarthria and balance di,0
POTIGA,disturbance in attention,in attention,1
POTIGA,disturbance in attention,somnolence fatigue confusional state vertigo tremor abnormal,0
POTIGA,memory impairment,impairment,1
POTIGA,memory impairment,state,0
POTIGA,memory impairment,,0
POTIGA,memory impairment,impairment,1
POTIGA,memory impairment,disturbance in memory impairment,1
POTIGA,memory impairment,asthenia blurred vision gait disturbance aphasia dysarthria,0
POTIGA,asthenia,blurred vision gait disturbance aphasia,0
POTIGA,asthenia,blurred vision,0
POTIGA,asthenia,asthenia,1
POTIGA,asthenia,disturbance,0
POTIGA,asthenia,asthenia,1
POTIGA,asthenia,aphasia dysarthria and balance disorder,0
POTIGA,blurred vision,,0
POTIGA,gait disturbance,memory impairment asthenia blurred gait,1
POTIGA,aphasia,,0
POTIGA,aphasia,REACTIONS contact,0
POTIGA,dysarthria,dysarthria,1
POTIGA,balance disorder,GlaxoSmithKline,0
POTIGA,balance disorder,balance,1
POTIGA,balance disorder,balance disorder,1
POTIGA,balance disorder,dysarthria balance disorder,1
POTIGA,balance disorder,balance disorder,1
POTIGA,balance disorder,disturbance,0
POTIGA,balance disorder,balance disorder,1
POTIGA,balance disorder,,0
POTIGA,balance disorder,contact GlaxoSmithKline at,0
POTIGA,balance disorder,REACTIONS contact,0
POTIGA,dizziness,dizziness,1
POTIGA,dizziness,dizziness,1
POTIGA,dizziness,Adverse Reactions,0
POTIGA,dizziness,,0
POTIGA,dizziness,dizziness,1
POTIGA,dizziness,dizziness,1
POTIGA,confusional state,receiving POTIGA were confusional state,1
POTIGA,confusional state,state,1
POTIGA,confusional state,,0
POTIGA,fatigue,dizziness confusional fatigue,1
POTIGA,fatigue,POTIGA were dizziness confusional fatigue,1
POTIGA,fatigue,dizziness confusional state,0
POTIGA,fatigue,fatigue,1
POTIGA,fatigue,fatigue,1
POTIGA,somnolence,,0
POTIGA,dizziness,dizziness,1
POTIGA,somnolence,placebo rate were somnolence,1
POTIGA,somnolence,somnolence,1
POTIGA,somnolence,somnolence,1
POTIGA,somnolence,confusional,0
POTIGA,somnolence,,0
POTIGA,somnolence,,0
POTIGA,somnolence,somnolence,1
POTIGA,somnolence,somnolence,1
POTIGA,somnolence,,0
POTIGA,fatigue,rate were dizziness fatigue,1
POTIGA,fatigue,fatigue,1
POTIGA,fatigue,,0
POTIGA,confusional state,disturbance,0
POTIGA,confusional state,vertigo tremor abnormal coordination,0
POTIGA,confusional state,disturbance,0
POTIGA,confusional state,confusional state,1
POTIGA,vertigo,vertigo,1
POTIGA,vertigo,vertigo,1
POTIGA,tremor,diplopia disturbance in attention memory impairment,0
POTIGA,tremor,confusional state tremor,1
POTIGA,tremor,attention,0
POTIGA,abnormal coordination,confusional state vertigo abnormal coordination,1
POTIGA,abnormal coordination,,0
POTIGA,diplopia,diplopia,1
POTIGA,diplopia,diplopia,1
POTIGA,diplopia,diplopia,1
POTIGA,diplopia,diplopia,1
POTIGA,diplopia,diplopia,1
POTIGA,diplopia,blurred vision,0
POTIGA,diplopia,state vertigo tremor abnormal diplopia,1
POTIGA,diplopia,abnormal coordination,0
POTIGA,disturbance in attention,abnormal,0
POTIGA,memory impairment,vision gait,0
POTIGA,memory impairment,memory impairment,1
POTIGA,memory impairment,blurred vision,0
POTIGA,asthenia,gait,0
POTIGA,asthenia,asthenia,1
POTIGA,asthenia,,0
POTIGA,blurred vision,Table,0
POTIGA,blurred vision,see,0
POTIGA,blurred vision,memory impairment blurred vision,1
POTIGA,gait disturbance,blurred gait disturbance,1
POTIGA,gait disturbance,blurred gait,1
POTIGA,gait disturbance,in attention memory impairment asthenia blurred vision,0
POTIGA,gait disturbance,impairment asthenia,0
POTIGA,gait disturbance,disturbance in attention memory impairment asthenia blurred vision,0
POTIGA,gait disturbance,gait disturbance,1
POTIGA,gait disturbance,,0
POTIGA,gait disturbance,see Table In most cases the,0
POTIGA,gait disturbance,blurred gait disturbance,1
POTIGA,aphasia,aphasia,1
POTIGA,aphasia,aphasia,1
POTIGA,aphasia,vision gait aphasia,1
POTIGA,aphasia,aphasia,1
POTIGA,aphasia,gait disturbance,0
POTIGA,aphasia,most cases the reactions were,0
POTIGA,aphasia,asthenia blurred vision,0
POTIGA,aphasia,asthenia blurred vision gait aphasia,1
POTIGA,aphasia,disorder,0
POTIGA,dysarthria,disorder see Table In most cases the reactions were of,0
POTIGA,balance disorder,most cases the reactions were of mild or moderate,0
POTIGA,balance disorder,vision gait disturbance aphasia,0
POTIGA,Diplopia,,0
POTIGA,Diplopia,,0
POTIGA,Diplopia,,0
POTIGA,Blurred vision,Blurred vision,1
POTIGA,Blurred vision,vision,1
POTIGA,Blurred vision,,0
POTIGA,Blurred vision,,0
POTIGA,Blurred vision,Blurred vision,1
POTIGA,Blurred vision,,0
POTIGA,Nausea,Nausea,1
POTIGA,Nausea,,0
POTIGA,Nausea,Nausea,1
POTIGA,Nausea,,0
POTIGA,Nausea,Nausea,1
POTIGA,Nausea,,0
POTIGA,Constipation,Constipation,1
POTIGA,Constipation,Constipation,1
POTIGA,Constipation,,0
POTIGA,Dyspepsia,Dyspepsia,1
POTIGA,Dyspepsia,Dyspepsia,1
POTIGA,Dyspepsia,Dyspepsia,1
POTIGA,Dyspepsia,,0
POTIGA,Dyspepsia,Dyspepsia,1
POTIGA,Dyspepsia,Dyspepsia,1
POTIGA,Dyspepsia,,0
POTIGA,Dyspepsia,Dyspepsia,1
POTIGA,Fatigue,Fatigue,1
POTIGA,Fatigue,,0
POTIGA,Fatigue,,0
POTIGA,Asthenia,Asthenia,1
POTIGA,Asthenia,Asthenia,1
POTIGA,Asthenia,Asthenia,1
POTIGA,Asthenia,Asthenia,1
POTIGA,Asthenia,,0
POTIGA,Asthenia,,0
POTIGA,Asthenia,Asthenia,1
POTIGA,Asthenia,,0
POTIGA,Asthenia,,0
POTIGA,Asthenia,,0
POTIGA,Influenza,,0
POTIGA,Influenza,Influenza,1
POTIGA,Influenza,,0
POTIGA,Influenza,,0
POTIGA,Influenza,,0
POTIGA,Influenza,Influenza,1
POTIGA,Weight increased,,0
POTIGA,Weight increased,,0
POTIGA,Weight increased,,0
POTIGA,Dizziness,,0
POTIGA,Dizziness,,0
POTIGA,Dizziness,Dizziness,1
POTIGA,Dizziness,Dizziness,1
POTIGA,Dizziness,,0
POTIGA,Dizziness,,0
POTIGA,Somnolence,Somnolence,1
POTIGA,Somnolence,,0
POTIGA,Somnolence,,0
POTIGA,Somnolence,Somnolence,1
POTIGA,Somnolence,Somnolence,1
POTIGA,Somnolence,Somnolence,1
POTIGA,Somnolence,Somnolence,1
POTIGA,Somnolence,,0
POTIGA,Somnolence,,0
POTIGA,Vertigo,Vertigo,1
POTIGA,Vertigo,,0
POTIGA,Vertigo,,0
POTIGA,Vertigo,,0
POTIGA,Vertigo,,0
POTIGA,Vertigo,,0
POTIGA,Vertigo,,0
POTIGA,Abnormal coordination,,0
POTIGA,Abnormal coordination,,0
POTIGA,Disturbance in attention,,0
POTIGA,Disturbance in attention,Disturbance,1
POTIGA,Disturbance in attention,attention,1
POTIGA,Disturbance in attention,attention,1
POTIGA,Disturbance in attention,attention,1
POTIGA,Disturbance in attention,,0
POTIGA,Disturbance in attention,Disturbance in attention,1
POTIGA,Disturbance in attention,Disturbance,1
POTIGA,Gait disturbance,,0
POTIGA,Aphasia,Aphasia,1
POTIGA,Aphasia,Aphasia,1
POTIGA,Aphasia,,0
POTIGA,Dysarthria,Dysarthria,1
POTIGA,Dysarthria,,0
POTIGA,Dysarthria,,0
POTIGA,Dysarthria,,0
POTIGA,Dysarthria,,0
POTIGA,Dysarthria,,0
POTIGA,Balance disorder,,0
POTIGA,Balance disorder,Balance,1
POTIGA,Balance disorder,Balance disorder,1
POTIGA,Balance disorder,,0
POTIGA,Balance disorder,,0
POTIGA,Balance disorder,,0
POTIGA,Balance disorder,,0
POTIGA,Balance disorder,,0
POTIGA,Balance disorder,disorder,1
POTIGA,Paresthesia,,0
POTIGA,Paresthesia,,0
POTIGA,Paresthesia,,0
POTIGA,Paresthesia,Paresthesia,1
POTIGA,Amnesia,Amnesia,1
POTIGA,Amnesia,Amnesia,1
POTIGA,Amnesia,,0
POTIGA,Amnesia,Amnesia,1
POTIGA,Amnesia,,0
POTIGA,Amnesia,Amnesia,1
POTIGA,Amnesia,Amnesia,1
POTIGA,Dysphasia,Dysphasia,1
POTIGA,Dysphasia,,0
POTIGA,Dysphasia,Dysphasia,1
POTIGA,Confusional state,Confusional state,1
POTIGA,Confusional state,,0
POTIGA,Confusional state,Confusional state,1
POTIGA,Confusional state,Confusional state,1
POTIGA,Confusional state,,0
POTIGA,Confusional state,Confusional,1
POTIGA,Confusional state,Confusional state,1
POTIGA,Confusional state,Confusional,1
POTIGA,Confusional state,Confusional state,1
POTIGA,Confusional state,,0
POTIGA,Disorientation,Disorientation,1
POTIGA,Disorientation,Disorientation,1
POTIGA,Disorientation,Disorientation,1
POTIGA,Disorientation,,0
POTIGA,Disorientation,Disorientation,1
POTIGA,Psychotic disorder,,0
POTIGA,Psychotic disorder,,0
POTIGA,Psychotic disorder,Psychotic disorder,1
POTIGA,Psychotic disorder,,0
POTIGA,Psychotic disorder,,0
POTIGA,Dysuria,Dysuria,1
POTIGA,Dysuria,Dysuria,1
POTIGA,Urinary hesitation,,0
POTIGA,Hematuria,,0
POTIGA,Chromaturia,,0
POTIGA,Chromaturia,,0
POTIGA,increased appetite,greater than placebo increased appetite,1
POTIGA,increased appetite,uri,0
POTIGA,increased appetite,mouth,0
POTIGA,increased appetite,dysphagia,0
POTIGA,increased appetite,were,0
POTIGA,increased appetite,with POTIGA and numerically greater than,0
POTIGA,increased appetite,edema hypokinesia,0
POTIGA,hallucinations,hallucinations,1
POTIGA,myoclonus,,0
POTIGA,peripheral edema,appetite hallucinations peripheral edema,1
POTIGA,peripheral edema,increased appetite,0
POTIGA,peripheral edema,increased appetite hallucinations peripheral edema,1
POTIGA,peripheral edema,hallucinations,0
POTIGA,peripheral edema,,0
POTIGA,peripheral edema,peripheral edema,1
POTIGA,peripheral edema,retention malaise and,0
POTIGA,peripheral edema,increased appetite hallucinations peripheral edema,1
POTIGA,peripheral edema,,0
POTIGA,peripheral edema,were increased appetite hallucinations peripheral,1
POTIGA,hypokinesia,peripheral,0
POTIGA,hypokinesia,hypokinesia,1
POTIGA,hypokinesia,hypokinesia,1
POTIGA,hypokinesia,hypokinesia,1
POTIGA,hypokinesia,hypokinesia,1
POTIGA,hypokinesia,myoclonus peripheral edema,0
POTIGA,hypokinesia,hypokinesia,1
POTIGA,hypokinesia,appetite hallucinations myoclonus peripheral hypokinesia,1
POTIGA,dry mouth,edema dry,1
POTIGA,dry mouth,,0
POTIGA,hyperhydrosis,edema hypokinesia dry mouth dysphagia,0
POTIGA,hyperhydrosis,hyperhydrosis,1
POTIGA,hyperhydrosis,myoclonus peripheral edema hypokinesia dry,0
POTIGA,hyperhydrosis,peripheral edema hypokinesia dry mouth,0
POTIGA,hyperhydrosis,of the adverse reactions appear,0
POTIGA,hyperhydrosis,hyperhydrosis,1
POTIGA,hyperhydrosis,hyperhydrosis,1
POTIGA,hyperhydrosis,mouth hyperhydrosis,1
POTIGA,hyperhydrosis,hyperhydrosis,1
POTIGA,hyperhydrosis,,0
POTIGA,urinary retention,urinary retention,1
POTIGA,malaise,edema hypokinesia dry mouth dysphagia hyperhydrosis urinary,0
POTIGA,malaise,malaise,1
POTIGA,malaise,related,0
POTIGA,malaise,reactions appear to be dose,0
POTIGA,malaise,,0
POTIGA,increased liver enzymes,,0
POTIGA,dizziness,dizziness,1
POTIGA,dizziness,,0
POTIGA,somnolence,somnolence,1
POTIGA,somnolence,confusional state tremor abnormal coordination memory impairment blurred vision gait,0
POTIGA,somnolence,abnormal,0
POTIGA,somnolence,system symptoms including somnolence,1
POTIGA,somnolence,somnolence,1
POTIGA,somnolence,somnolence,1
POTIGA,confusional state,,0
POTIGA,confusional state,confusional,1
POTIGA,tremor,gait disturbance aphasia balance disor,0
POTIGA,tremor,and nervous system symptoms including,0
POTIGA,tremor,memory impairment blurred vision,0
POTIGA,tremor,psychiatric and nervous system symptoms including dizziness somnolence confusional state,0
POTIGA,tremor,memory impairment blurred vision gait disturbance,0
POTIGA,tremor,,0
POTIGA,abnormal coordination,coordination,1
POTIGA,abnormal coordination,state abnormal coordination,1
POTIGA,abnormal coordination,tremor,0
POTIGA,abnormal coordination,coordination,1
POTIGA,abnormal coordination,somnolence,0
POTIGA,memory impairment,memory impairment,1
POTIGA,memory impairment,aphasia,0
POTIGA,memory impairment,memory impairment,1
POTIGA,memory impairment,abnormal memory impairment,1
POTIGA,memory impairment,memory impairment,1
POTIGA,memory impairment,memory impairment,1
POTIGA,memory impairment,,0
POTIGA,memory impairment,memory impairment,1
POTIGA,blurred vision,aphasia balance disorder constipation dysuria and chromaturia POTIGA wa,0
POTIGA,blurred vision,blurred,1
POTIGA,blurred vision,constipation dysuria and chromaturia POTIGA wa,0
POTIGA,blurred vision,tremor abnormal coordination memory blurred vision,1
POTIGA,blurred vision,aphasia balance disorder constipation dysuria,0
POTIGA,blurred vision,coordination memory impairment,0
POTIGA,blurred vision,somnolence confusional,0
POTIGA,blurred vision,confusional state tremor abnormal coordination memory,0
POTIGA,blurred vision,blurred vision,1
POTIGA,blurred vision,vision,1
POTIGA,gait disturbance,aphasia balance disorder constipation dysuria,0
POTIGA,gait disturbance,memory impairment blurred gait,1
POTIGA,gait disturbance,coordination memory impairment blurred gait disturbance,1
POTIGA,gait disturbance,impairment blurred gait,1
POTIGA,gait disturbance,disturbance,1
POTIGA,gait disturbance,confusional state tremor abnormal coordination memory impairment blurred vision,0
POTIGA,gait disturbance,blurred gait disturbance,1
POTIGA,gait disturbance,impairment blurred gait,1
POTIGA,aphasia,chromaturia POTIGA was associated,0
POTIGA,aphasia,aphasia,1
POTIGA,aphasia,aphasia,1
POTIGA,aphasia,associated with,0
POTIGA,aphasia,tremor abnormal coordination memory impairment blurred vision gait,0
POTIGA,aphasia,memory impairment,0
POTIGA,aphasia,aphasia,1
POTIGA,aphasia,and chromaturia POTIGA was,0
POTIGA,aphasia,aphasia,1
POTIGA,aphasia,gait aphasia,1
POTIGA,balance disorder,aphasia,0
POTIGA,balance disorder,impairment,0
POTIGA,balance disorder,abnormal coordination memory impairment blurred vision gait disturbance aphasia,0
POTIGA,balance disorder,constipation dysuria,0
POTIGA,balance disorder,disorder,1
POTIGA,balance disorder,memory impairment blurred vision gait disturbance,0
POTIGA,balance disorder,dysuria and chromaturia POTIGA was,0
POTIGA,balance disorder,disorder,1
POTIGA,balance disorder,blurred vision gait disturbance balance,1
POTIGA,balance disorder,disorder,1
POTIGA,constipation,constipation,1
POTIGA,constipation,,0
POTIGA,constipation,constipation,1
POTIGA,constipation,constipation,1
POTIGA,constipation,constipation,1
POTIGA,constipation,aphasia balance,0
POTIGA,dysuria,dysuria,1
POTIGA,dysuria,dysuria,1
POTIGA,dysuria,aphasia,0
POTIGA,dysuria,dysuria,1
POTIGA,dysuria,dysuria,1
POTIGA,dysuria,balance disorder dysuria,1
POTIGA,dysuria,vision gait disturbance aphasia balance,0
POTIGA,chromaturia,disturbance aphasia balance disorder,0
POTIGA,chromaturia,chromaturia,1
POTIGA,chromaturia,,0
POTIGA,weight gain,weight gain,1
POTIGA,weight gain,POTIGA was associated with weight gain,1
POTIGA,weight gain,kg kg and,0
POTIGA,weight gain,placebo,0
POTIGA,weight increasing,weight increasing,1
POTIGA,rash,,0
POTIGA,rash,rash,1
POTIGA,rash,syncope neutropenia th,0
POTIGA,leukopenia,rash nystagmus leukopenia,1
POTIGA,muscle spasms,trials rash nystagmus dyspnea muscle spasms,1
POTIGA,muscle spasms,leukopenia,0
POTIGA,muscle spasms,trials rash,0
POTIGA,muscle spasms,POTIGA,0
POTIGA,alopecia,muscle alopecia,1
POTIGA,alopecia,,0
POTIGA,nephrolithiasis,,0
POTIGA,nephrolithiasis,nephrolithiasis,1
POTIGA,nephrolithiasis,,0
POTIGA,nephrolithiasis,leukopenia muscle spasms,0
POTIGA,nephrolithiasis,,0
POTIGA,nephrolithiasis,nephrolithiasis,1
POTIGA,nephrolithiasis,nephrolithiasis,1
POTIGA,nephrolithiasis,muscle spasms alopecia,0
POTIGA,nephrolithiasis,clinical trials rash,0
POTIGA,nephrolithiasis,clinical trials rash nystagmus dyspnea leukopenia muscle spasms alopecia,0
POTIGA,syncope,syncope,1
POTIGA,syncope,syncope,1
POTIGA,syncope,muscle,0
POTIGA,syncope,syncope,1
POTIGA,syncope,syncope,1
POTIGA,syncope,encephalopathy,0
POTIGA,neutropenia,coma encephalopathy Comparison of Gender Ag,0
POTIGA,neutropenia,neutropenia,1
POTIGA,neutropenia,coma encephalopathy,0
POTIGA,thrombocytopenia,thrombocytopenia,1
POTIGA,thrombocytopenia,thrombocytopenia,1
POTIGA,thrombocytopenia,and,0
POTIGA,euphoric mood,mood,1
POTIGA,euphoric mood,colic coma encephalopathy Comparison of Gender Age and Race,0
POTIGA,euphoric mood,nephrolithiasis syncope neutropenia euphoric,1
POTIGA,euphoric mood,and Race The overall,0
POTIGA,renal colic,spasms alopecia nephrolithiasis syncope neutropenia thrombocytopenia,0
POTIGA,renal colic,nephrolithiasis syncope,0
POTIGA,renal colic,neutropenia thrombocytopenia euphoric renal colic,1
POTIGA,renal colic,colic,1
POTIGA,renal colic,renal colic,1
POTIGA,renal colic,colic,1
POTIGA,renal colic,spasms alopecia,0
POTIGA,renal colic,Gender Age and Race The,0
POTIGA,coma,coma,1
POTIGA,coma,coma,1
POTIGA,encephalopathy,encephalopathy,1
POTIGA,encephalopathy,and Race The overall,0
POTIGA,encephalopathy,Age and Race The overall adverse reaction profile of POTIGA,0
POTIGA,RETINAL ABNORMALITIES,,0
POTIGA,RETINAL ABNORMALITIES,,0
POTIGA,VISION LOSS,,0
POTIGA,VISION LOSS,label Retinal abnormalities an,0
POTIGA,VISION LOSS,,0
POTIGA,VISION LOSS,,0
POTIGA,VISION LOSS,section of the,0
POTIGA,VISION LOSS,,0
POTIGA,VISION LOSS,,0
POTIGA,RETINAL ABNORMALITIES,Warnings and Pr ecautions section,1
POTIGA,RETINAL ABNORMALITIES,see Warni,0
POTIGA,RETINAL ABNORMALITIES,,0
POTIGA,RETINAL ABNORMALITIES, the  Warnings and Pr ecautions section of the label,1
POTIGA,RETINAL ABNORMALITIES,,0
POTIGA,VISION LOSS,,0
POTIGA,retinal abnormalities,po tential vision loss see Warnings,1
POTIGA,retinal abnormalities,of the label abnormalities and,1
POTIGA,retinal abnormalities,section of the label abnormalities,1
POTIGA,retinal abnormalities,the label  abnormalities and po tential vision loss see Warnings,1
POTIGA,retinal abnormalities,abnormalities and po tential vision loss see Warnings,1
POTIGA,retinal abnormalities,po tential vision loss see Warnings,1
POTIGA,damage to the photoreceptors,Skin disco loration see Warnings and Precautions,1
POTIGA,damage to the photoreceptors,Precautio,0
POTIGA,damage to the photoreceptors,"and ns (5.2)]  
 *    Skin disco loration see Warnings and Precautions",1
POTIGA,damage to the photoreceptors,"retention see Warnings and ns (5.2)]  
 *    Skin disco loration see Warnings and Precautions",1
POTIGA,damage to the photoreceptors,loss see Warnings and Precautions,0
POTIGA,damage to the photoreceptors,Urinary,0
POTIGA,damage to the photoreceptors,ns,1
POTIGA,damage to the photoreceptors,see Warnings and ns (5.2)],1
POTIGA,damage to the photoreceptors,see Warnings and ns (5.2)] * Skin,1
POTIGA,vision loss,ion [see Wa rnings and Precautions Neuropsychiatric symptoms,1
POTIGA,vision loss,Warnings and Precautions,0
POTIGA,vision loss,and Precautions Skin ion [see Wa rnings and Precautions Neuropsychiatric symptoms,1
POTIGA,vision loss,Warnings and Precautions Skin ion,1
POTIGA,retinal abnormalities,see Warnings and *,1
POTIGA,retinal abnormalities,discoloration see Warnings and *,1
POTIGA,retinal abnormalities,and *,1
POTIGA,retinal abnormalities,"  
 *    Neuropsychia tric symptoms see Warnings and",1
POTIGA,retinal abnormalities,* Neuropsychia tric symptoms see Warnings and,1
POTIGA,retinal abnormalities,*,1
POTIGA,retinal abnormalities,Precautions Dizziness,0
POTIGA,abnormal visual acuity,symptoms see gs and Precautions (5. Dizziness and somnolence see Warnings,1
POTIGA,abnormal visual acuity,and Precautions Neuropsychiatric symptoms see,0
POTIGA,abnormal visual acuity,Warnin,0
POTIGA,decreased visual acuity,Warnings and Precautions Dizziness and somnolence see Warnings and Precau,0
POTIGA,decreased visual acuity,,0
POTIGA,decreased visual acuity,tions (5.5)] * QT interval effect see Warnings and,1
POTIGA,decreased visual acuity,somnolence,0
POTIGA,decreased visual acuity,Precau,0
POTIGA,decreased visual acuity,Dizziness and somnolence,0
POTIGA,decreased visual acuity,see Warnings and Precautions Dizziness,0
POTIGA,decreased visual acuity,and Precautions Suicidal behavior and,0
POTIGA,decreased visual acuity,Precautions Dizziness and somnolence see Warnings and,0
POTIGA,decreased visual acuity,and somnolence,0
POTIGA,retinal pigmentary abnormalities,see Warnings and Precautions RPT:   Most common adverse react ions incidence and twice placebo,1
POTIGA,retinal pigmentary abnormalities,and Precautions RPT: Most common,1
POTIGA,retinal pigmentary abnormalities,,0
POTIGA,retinal pigmentary abnormalities,Most common adverse react ions incidence and twice placebo,1
POTIGA,retinal pigmentary abnormalities,and Precautions RPT: Most common,1
POTIGA,retinal pigmentary abnormalities,Warnings and Precautions RPT:,1
POTIGA,retinal abnormalities,"dizziness ce, fatigue, confusio nal state vertigo tremor abnormal",1
POTIGA,retinal abnormalities,"ce, fatigue, confusio nal state vertigo tremor abnormal",1
POTIGA,retinal abnormalities,"impairment, a sthenia blurred vision gait disturbance",1
POTIGA,retinal abnormalities,sthenia blurred,0
POTIGA,retinal abnormalities,,0
POTIGA,retinal abnormalities,"diplopia disturbance in  memory impairment, a sthenia blurred vision gait disturbance",1
POTIGA,RETINAL ABNORMALITIES,the randomized doubleblind placebocontrolled studies of,1
POTIGA,RETINAL ABNORMALITIES,,0
POTIGA,VISION LOSS,,0
POTIGA,VISION LOSS,double-blin d placebocontrolled studies of patients,1
POTIGA,VISION LOSS,Studies In,0
POTIGA,VISION LOSS,double-blin d placebocontrolled studies of patients,1
POTIGA,VISION LOSS,double-blin d placebocontrolled studies of patients,1
POTIGA,VISION LOSS,,0
POTIGA,VISION LOSS,double-blin d placebocontrolled studies of patients,1
POTIGA,VISION LOSS,double-blin d placebocontrolled studies of patients,1
POTIGA,retinal abnormalities,POTIGA and of ts (11%) receiving pl acebo discontinued treatment because of,1
POTIGA,retinal abnormalities,ts (11%) receiving,1
POTIGA,retinal abnormalities,receiving,0
POTIGA,damage to the photoreceptors,common,0
POTIGA,damage to the photoreceptors,to awal in patients receiving P OTIGA were dizziness confusional state,1
POTIGA,damage to the photoreceptors,P OTIGA were dizziness confusional state,1
POTIGA,damage to the photoreceptors,,0
POTIGA,damage to the photoreceptors,reactions leading to awal in patients,1
POTIGA,damage to the photoreceptors,patients receiving P OTIGA were dizziness confusional state,1
POTIGA,damage to the photoreceptors,in patients receiving P OTIGA were dizziness confusional state,1
POTIGA,damage to the photoreceptors,,0
POTIGA,damage to the photoreceptors,were dizziness confusional state fatigue and,0
POTIGA,damage to the photoreceptors,because of adverse,0
POTIGA,decreased visual acuity,Overall the most requently,1
POTIGA,decreased visual acuity,Overall,0
POTIGA,decreased visual acuity,Overall the most requently,1
POTIGA,decreased visual acuity,rse reactions in patients receiving POTIGA and occurring approximately twice the placebo,0
POTIGA,decreased visual acuity,requently reported,1
POTIGA,decreased visual acuity,Clinical Studies Overall,0
POTIGA,decreased visual acuity,Clinical Studies,0
POTIGA,decreased visual acuity,Studies Overall the most requently,1
POTIGA,Urinary retention,are describe d in more detail in,1
POTIGA,Urinary retention,in the Warnings and,0
POTIGA,Urinary retention,ions are describe d in more detail in,1
POTIGA,Urinary retention,Precautions section of the label Retinal,0
POTIGA,Urinary retention,ions are describe d in,1
POTIGA,Urinary retention,Warnings and,0
POTIGA,Urinary retention,d in more detail in the Warnings and Precautions section of the label Retinal abnormalit,0
POTIGA,Urinary retention,the,0
POTIGA,Urinary retention,,0
POTIGA,skin discoloration,,0
POTIGA,skin discoloration,abnormal,0
POTIGA,skin discoloration,vision loss see,0
POTIGA,skin discoloration,ities and potentia,1
POTIGA,skin discoloration,of the label Retinal ities and,1
POTIGA,skin discoloration,and Preca,0
POTIGA,skin discoloration,label Retinal ities and potentia,1
POTIGA,skin discoloration,vision loss see Warnings and Precautions Urinary retention see Warnings and Preca,0
POTIGA,skin discoloration,label Retinal ities,1
POTIGA,Neuropsychiatric symptoms,Precautions Neuropsychiatric,0
POTIGA,Neuropsychiatric symptoms,iscoloration [see Warning,1
POTIGA,Neuropsychiatric symptoms,[see Warning,1
POTIGA,Neuropsychiatric symptoms,Warnings,0
POTIGA,Neuropsychiatric symptoms,and Precautions,0
POTIGA,Neuropsychiatric symptoms,,0
POTIGA,QT prolongation,d Precautions (,1
POTIGA,QT prolongation,somnolence see Warnings an,0
POTIGA,abnormalities of the retina,confusional,0
POTIGA,abnormalities of the retina,,0
POTIGA,damage to photoreceptors,"asia, dysarthria,",1
POTIGA,damage to photoreceptors,,0
POTIGA,damage to photoreceptors,at,0
POTIGA,damage to photoreceptors,lance disorder To report SUSPECTED ADVERSE REACTIONS contact GlaxoSmithKline at,0
POTIGA,damage to photoreceptors,ADVERSE REACTIONS contact,0
POTIGA,vision loss,vision gait disturbance aphasia dysarthria and balance,0
POTIGA,vision loss, disorder. ,1
POTIGA,vision loss,ADVERSE REACTIONS contact GlaxoSmithKline at or,0
POTIGA,vision loss,To report SUSPECTED ADVERSE REACTIONS contact GlaxoSmithKline at,0
POTIGA,vision loss,disturbance aphasia dysarthria and  disorder. ,1
POTIGA,vision loss,aphasia dysarthria and  disorder. ,1
POTIGA,vision loss,To report SUSPECTED ADVERSE,0
POTIGA,vision loss,To report,0
POTIGA,retinal abnormalities,"dysarthria and balance  

   To report SUSPE",1
POTIGA,retinal abnormalities,vision gait,0
POTIGA,retinal abnormalities,FDA,0
POTIGA,retinal abnormalities,CTED ADVERSE REACTIONS contact GlaxoSmithKline at,0
POTIGA,retinal abnormalities,FDA at,0
POTIGA,retinal pigmentary abnormalities,,0
POTIGA,retinal pigmentary abnormalities,,0
POTIGA,retinal abnormalities,POTIGA was nistered,1
POTIGA,retinal abnormalities,nistered as adjunctiv,1
POTIGA,retinal abnormalities,was nistered,1
POTIGA,retinal abnormalities,observed in practice,0
POTIGA,retinal abnormalities,to patients,0
POTIGA,retinal abnormalities,reflect the rates,0
POTIGA,retinal abnormalities,nistered as adjunctiv,1
POTIGA,retinal abnormalities,practice POTIGA was,0
POTIGA,retinal abnormalities,reflect the rates observed in practice POTIGA,0
POTIGA,retinal abnormalities,uncontrolled clinical,0
POTIGA,mucous membrane discoloration,in all controlled and uncontrolled clinical studies duri,0
POTIGA,mucous membrane discoloration,months,0
POTIGA,mucous membrane discoloration,patients were treated,0
POTIGA,mucous membrane discoloration,studies ng the premarketing developme,1
POTIGA,discoloration,patients,0
POTIGA,discoloration,were treated for year or longer and patients were treated,0
POTIGA,retinal abnormalities,"treated for at least , 585 patients were t",1
POTIGA,retinal abnormalities,during the premarketing development A total of patients were treated,0
POTIGA,retinal abnormalities,"at least , 585",1
POTIGA,retinal abnormalities,patients were t,1
POTIGA,retinal abnormalities,"treated for at least , 585 patients",1
POTIGA,retinal abnormalities,,0
POTIGA,retinal abnormalities,reated for year or longer and patients,0
POTIGA,retinal abnormalities,"treated for at least , 585 patients were t",1
POTIGA,retinal pigmentary abnormalities,Discontinuation in All,0
POTIGA,retinal pigmentary abnormalities,randomized,0
POTIGA,retinal pigmentary abnormalities,Reactions Lea,1
POTIGA,retinal pigmentary abnormalities,,0
POTIGA,retinal pigmentary abnormalities,longer and patients were,0
POTIGA,retinal pigmentary abnormalities,ars. Adverse Reactions Lea,1
POTIGA,retinal pigmentary abnormalities,at least ars.,1
POTIGA,discoloration,Clinical Studies In the randomized,0
POTIGA,discoloration,years Adverse,0
POTIGA,discoloration,Adverse Reactions Leading to ntinuation in,1
POTIGA,discoloration,to ntinuation in,1
POTIGA,discoloration,Reactions Leading to ntinuation,1
POTIGA,discoloration,Reactions,0
POTIGA,discoloration,Leading to ntinuation,1
POTIGA,discoloration,Leading to ntinuation in,1
POTIGA,Funduscopic abnormalities,Discontinuation in All,0
POTIGA,Funduscopic abnormalities,ontrolled Clinical Studie,1
POTIGA,Funduscopic abnormalities,Leading to Discontinuation in All,0
POTIGA,Funduscopic abnormalities,Studie,1
POTIGA,Funduscopic abnormalities,ontrolled Clinical Studie,1
POTIGA,Funduscopic abnormalities,In the randomized,0
POTIGA,Funduscopic abnormalities,Leading to Discontinuation in All,0
POTIGA,Funduscopic abnormalities,at least years Adverse Reactions Leading to Discontinuation in All C,0
POTIGA,Funduscopic abnormalities,Leading,0
POTIGA,focal retinal pigment epithelium clumping,,0
POTIGA,retinal abnormalities,were,0
POTIGA,retinal abnormalities,of adverse ons. The most,1
POTIGA,retinal abnormalities,,0
POTIGA,retinal abnormalities,POTIGA were dizziness confusiona,0
POTIGA,retinal abnormalities,adverse reacti,0
POTIGA,retinal abnormalities,treatment because of adverse reacti,0
POTIGA,retinal abnormalities,because,0
POTIGA,retinal abnormalities,treatment because,0
POTIGA,retinal abnormalities,because of adverse ons. The,1
POTIGA,retinal abnormalities,and of patients receiving placebo discontinued,0
POTIGA,abnormal visual acuity,treatment because,0
POTIGA,retinal abnormalities,Common Adverse,0
POTIGA,retinal abnormalities,"ies Overall,",1
POTIGA,retinal abnormalities,"Controlled Clinical ies Overall,",1
POTIGA,retinal abnormalities,"ies Overall, th",1
POTIGA,retinal abnormalities,most frequently reported adverse reactions,0
POTIGA,retinal dystrophy,,0
POTIGA,retinal dystrophy,approximately the placebo,1
POTIGA,retinal dystrophy,vertigo,0
POTIGA,abnormalities in the electroretinogram,placebo rate were ness,1
POTIGA,abnormalities in the electroretinogram,"rate were ness (23%), somnolence (22%), fatigue ",1
POTIGA,abnormalities in the electroretinogram,"were ness (23%), somnolence (22%),",1
POTIGA,abnormalities in the electroretinogram,approximately twice the placebo,0
POTIGA,abnormalities in the electroretinogram,"somnolence (22%), fatigue",1
POTIGA,abnormalities in the electroretinogram,placebo rate were dizzi,0
POTIGA,abnormalities in the electroretinogram,dizzi,0
POTIGA,abnormalities in the electroretinogram,rate,0
POTIGA,abnormalities in the electroretinogram,confusional state vertigo tremor,0
POTIGA,abnormalities in the electroretinogram,rate,0
POTIGA,abnormal fluorescein angiography,"tremor (8%), abnormal coordinati",1
POTIGA,abnormal fluorescein angiography,attention,0
POTIGA,abnormal fluorescein angiography,coordinati,1
POTIGA,abnormal fluorescein angiography,"confusional state tremor (8%), abnormal coordinati",1
POTIGA,diminished sensitivity on visual field,fatigue confusional state vertigo tremor abnormal,0
POTIGA,diminished sensitivity on visual field,"tremor abnormal %),",1
POTIGA,diminished sensitivity on visual field,atte,1
POTIGA,diminished sensitivity on visual field,tremor abnormal coordination,0
POTIGA,diminished sensitivity on visual field,"%), diplopia (7%), disturbance in atte",1
POTIGA,retinal abnormalities,memory impairment asthenia ed,1
POTIGA,retinal abnormalities,attention,0
POTIGA,retinal abnormalities,"(5%), gait",1
POTIGA,retinal abnormalities,aphasia dysarthria and balance,0
POTIGA,retinal abnormalities,"memory impairment asthenia ed vision (5%), gait ",1
POTIGA,retinal abnormalities,In most ca,0
POTIGA,retinal abnormalities,disturbance in attention memory impairment,0
POTIGA,retinal abnormalities,impairment asthenia ed vision,1
POTIGA,retinal abnormalities,aphasia dysarthria and balance disorder see,0
POTIGA,urinary retention,Gas,0
POTIGA,urinary retention,trointestinal    ,1
POTIGA,urinary retention,trointestinal    ,1
POTIGA,urinary retention,Gas,0
POTIGA,urinary retention,,0
POTIGA,urinary retention,trointestinal    ,1
POTIGA,Urinary retention,                 ,1
POTIGA,Urinary retention,Gastrointestinal                  ,1
POTIGA,Urinary retention,                 ,1
POTIGA,Urinary retention,                 ,1
POTIGA,Urinary retention,Gastrointestinal                  ,1
POTIGA,Urinary retention,Gastrointestinal,0
POTIGA,Urinary retention,                 ,1
POTIGA,Urinary retention,Gastrointestinal,0
POTIGA,Urinary retention,,0
POTIGA,Urinary retention,"             
    Nausea",1
POTIGA,Urinary retention,,0
POTIGA,Hydronephrosis,               General,1
POTIGA,Hydronephrosis,General,0
POTIGA,Hydronephrosis,               General,1
POTIGA,renal function impairment,General,0
POTIGA,renal function impairment,General                          ,1
POTIGA,renal function impairment,General,0
POTIGA,renal function impairment,General,0
POTIGA,Hydronephrosis,,0
POTIGA,Hydronephrosis,,0
POTIGA,Hydronephrosis,               Fatigue,1
POTIGA,Hydronephrosis,,0
POTIGA,Hydronephrosis,               Fatigue,1
POTIGA,Hydronephrosis,Fatigue,0
POTIGA,Hydronephrosis,,0
POTIGA,Hydronephrosis,,0
POTIGA,Hydronephrosis,,0
POTIGA,Hydronephrosis,,0
POTIGA,urinary hesitation,Fatigue                   ,1
POTIGA,urinary hesitation,Fatigue,0
POTIGA,urinary hesitation,Fatigue,0
POTIGA,urinary hesitation,,0
POTIGA,urinary hesitation,,0
POTIGA,urinary hesitation,                  ,1
POTIGA,urinary hesitation,Fatigue,0
POTIGA,urinary hesitation,,0
POTIGA,dysuria,,0
POTIGA,dysuria,,0
POTIGA,dysuria,Fatigue,0
POTIGA,dysuria,,0
POTIGA,dysuria,Fatigue        ,1
POTIGA,dysuria,Fatigue        ,1
POTIGA,dysuria,Fatigue        ,1
POTIGA,dysuria,Fatigue        ,1
POTIGA,dysuria,       ,1
POTIGA,dysuria,       ,1
POTIGA,skin discoloration,,0
POTIGA,skin discoloration,                  ,1
POTIGA,skin discoloration,,0
POTIGA,skin discoloration,Investigations,0
POTIGA,skin discoloration,Investigations,0
POTIGA,skin discoloration,Investigations                   ,1
POTIGA,Discoloration of the palate,"        
                   Nervous system",1
POTIGA,Discoloration of the palate,"        
                  ",1
POTIGA,Discoloration of the palate,"        
                  ",1
POTIGA,Discoloration of the palate,system,0
POTIGA,Discoloration of the palate,"        
                   Nervous",1
POTIGA,Discoloration of the palate,,0
POTIGA,Discoloration of the palate,,0
POTIGA,Discoloration of the palate,,0
POTIGA,Discoloration of the palate,"        
                   Nervous system",1
POTIGA,skin discoloration,                   Dizziness,1
POTIGA,skin discoloration,tem,0
POTIGA,skin discoloration,tem,0
POTIGA,skin discoloration,tem,0
POTIGA,skin discoloration,tem,0
POTIGA,skin discoloration,                   Dizziness,1
POTIGA,skin discoloration,tem                    Dizziness,1
POTIGA,mucous membrane discoloration,Dizziness,0
POTIGA,mucous membrane discoloration,Dizziness,0
POTIGA,mucous membrane discoloration,Dizziness         15              23    Somnolence,1
POTIGA,mucous membrane discoloration,,0
POTIGA,mucous membrane discoloration,15 23 Somnolence,1
POTIGA,mucous membrane discoloration,                             ,1
POTIGA,mucous membrane discoloration,,0
POTIGA,retinal pigmentary abnormalities,Somnolence       12           15            Memory,1
POTIGA,retinal pigmentary abnormalities,Somnolence 12,1
POTIGA,retinal pigmentary abnormalities,Somnolence,0
POTIGA,retinal pigmentary abnormalities,Somnolence,0
POTIGA,retinal pigmentary abnormalities,,0
POTIGA,skin abnormalities,                  ,1
POTIGA,skin abnormalities,,0
POTIGA,skin abnormalities,                  ,1
POTIGA,skin abnormalities,,0
POTIGA,skin abnormalities,                  ,1
POTIGA,skin abnormalities,                  ,1
POTIGA,Confusional state,,0
POTIGA,Confusional state,            8     Vertigo,1
POTIGA,Confusional state,,0
POTIGA,psychotic symptoms,,0
POTIGA,psychotic symptoms,"      
            Vertigo",1
POTIGA,hallucinations,ertigo,0
POTIGA,hallucinations,in,0
POTIGA,hallucinations,              ,1
POTIGA,hallucinations,in,0
POTIGA,hallucinations,              ,1
POTIGA,hallucinations,              ,1
POTIGA,hallucinations,,0
POTIGA,hallucinations,              ,1
POTIGA,hallucinations,,0
POTIGA,psychosis,attention,0
POTIGA,psychosis,,0
POTIGA,psychosis,         ,1
POTIGA,psychosis,         ,1
POTIGA,psychosis,in,0
POTIGA,psychosis,"        
",1
POTIGA,psychosis,,0
POTIGA,psychosis,"        
",1
POTIGA,psychosis,"        
",1
POTIGA,psychosis,"        
 Gait disturbance",1
POTIGA,psychosis,"        
 Gait disturbance",1
POTIGA,psychosis,Gait,0
POTIGA,psychosis,,0
POTIGA,psychiatric symptoms,Gait                     ,1
POTIGA,psychiatric symptoms,                    ,1
POTIGA,psychiatric symptoms,,0
POTIGA,psychiatric symptoms,,0
POTIGA,psychiatric symptoms,                    ,1
POTIGA,psychiatric symptoms,disturbance,0
POTIGA,psychiatric symptoms,,0
POTIGA,psychosis,,0
POTIGA,psychosis,Aphasia          ,1
POTIGA,psychosis,Aphasia,0
POTIGA,psychosis,         ,1
POTIGA,psychosis,,0
POTIGA,psychosis,         ,1
POTIGA,psychosis,,0
POTIGA,hallucinations,     <1        Dys,1
POTIGA,hallucinations,Aphasia,0
POTIGA,hallucinations,Aphasia,0
POTIGA,hallucinations,Dys,0
POTIGA,hallucinations,,0
POTIGA,hallucinations,Aphasia      <1        Dys,1
POTIGA,Neuropsychiatric Symptoms,,0
POTIGA,Confusional state,,0
POTIGA,Confusional state,                 ,1
POTIGA,Confusional state,                  Balance,1
POTIGA,Confusional state,,0
POTIGA,Confusional state,disorder,0
POTIGA,Hallucinations,               Paresthesia,1
POTIGA,Hallucinations,               Paresthesia,1
POTIGA,Hallucinations,,0
POTIGA,Hallucinations,               Paresthesia,1
POTIGA,Hallucinations,               Paresthesia,1
POTIGA,Hallucinations,               Paresthesia,1
POTIGA,Hallucinations,               Paresthesia,1
POTIGA,Hallucinations,,0
POTIGA,Hallucinations,               Paresthesia,1
POTIGA,Hallucinations,               Paresthesia,1
POTIGA,Hallucinations,Paresthesia   3            Amnesia,1
POTIGA,Hallucinations,Paresthesia,0
POTIGA,Hallucinations,,0
POTIGA,Hallucinations,  3            Amnesia,1
POTIGA,mixed hallucinations,,0
POTIGA,mixed hallucinations,"     3            
  Amnesia",1
POTIGA,mixed hallucinations,"     3            
  Amnesia",1
POTIGA,mixed hallucinations,,0
POTIGA,mixed hallucinations,"     3            
  Amnesia",1
POTIGA,mixed hallucinations,,0
POTIGA,dizziness,         ,1
POTIGA,dizziness,Amnesia          ,1
POTIGA,somnolence,,0
POTIGA,somnolence,Amnesia,0
POTIGA,somnolence,Amnesia,0
POTIGA,dizziness,,0
POTIGA,dizziness,Dysphasia,0
POTIGA,dizziness,,0
POTIGA,dizziness,          Dysphasia,1
POTIGA,dizziness,          Dysphasia,1
POTIGA,dizziness,          Dysphasia,1
POTIGA,dizziness,,0
POTIGA,dizziness,,0
POTIGA,dizziness,          Dysphasia,1
POTIGA,Somnolence,,0
POTIGA,Somnolence,          ,1
POTIGA,Somnolence,Dysphasia           ,1
POTIGA,Somnolence,          ,1
POTIGA,Somnolence,,0
POTIGA,dizziness,Psychiatric,0
POTIGA,dizziness,         ,1
POTIGA,somnolence,"  
        Confusional state",1
POTIGA,dizziness,,0
POTIGA,dizziness,,0
POTIGA,dizziness,   16     Anxiety,1
POTIGA,dizziness,   16     Anxiety,1
POTIGA,dizziness,,0
POTIGA,dizziness,,0
POTIGA,dizziness,,0
POTIGA,dizziness,   16     Anxiety,1
POTIGA,dizziness,,0
POTIGA,dizziness,,0
POTIGA,somnolence,,0
POTIGA,somnolence,      9    Anxiety,1
POTIGA,somnolence,      9    Anxiety,1
POTIGA,somnolence,,0
POTIGA,somnolence,Anxiety,0
POTIGA,somnolence,,0
POTIGA,somnolence,,0
POTIGA,QT prolongation,       2        Disorientation,1
POTIGA,QT prolongation,       2        Disorientation,1
POTIGA,QT prolongation,       2        Disorientation,1
POTIGA,QT prolongation,       2        Disorientation,1
POTIGA,QT prolongation,       2        Disorientation,1
POTIGA,QT prolongation,,0
POTIGA,QT prolongation,,0
POTIGA,QT prolongation,       2        Disorientation,1
POTIGA,QT prolongation,       2        Disorientation,1
POTIGA,QT-prolonging,,0
POTIGA,QT-prolonging,        Disor ientation,1
POTIGA,QT-prolonging,,0
POTIGA,QT-prolonging,,0
POTIGA,QT-prolonging,        Disor ientation,1
POTIGA,suicidal thoughts,and                  ,1
POTIGA,suicidal thoughts,Renal and                  ,1
POTIGA,suicidal thinking, Hematuria       ,1
POTIGA,suicidal thinking,,0
POTIGA,suicidal thinking, Hematuria       ,1
POTIGA,suicidal thinking, Hematuria       ,1
POTIGA,suicidal thinking, Hematuria       ,1
POTIGA,suicidal thinking, Hematuria       ,1
POTIGA,suicidal behavior,,0
POTIGA,suicidal behavior,,0
POTIGA,suicidal behavior,                  Chromaturia,1
POTIGA,suicidal behavior,,0
POTIGA,suicidal thinking,"    
            ",1
POTIGA,suicidal thinking,in of patients treated,0
POTIGA,suicidal thinking,"    
             Other adverse reactions",1
POTIGA,suicidal thinking,,0
POTIGA,suicidal thinking,"    
             Other adverse reactions reported in",1
POTIGA,suicidal thinking,"    
             Other",1
POTIGA,suicidal thinking,,0
POTIGA,suicidal thinking,"    
             Other adverse reactions reported",1
POTIGA,suicidal thinking,"    
            ",1
POTIGA,suicidal thinking,,0
POTIGA,suicides,,0
POTIGA,suicides,and numerically greater than,0
POTIGA,suicides,of,1
POTIGA,suicides,these studies in,0
POTIGA,suicides,these studies of,1
POTIGA,suicides,of,1
POTIGA,suicides,in these studies of,1
POTIGA,suicides,placebo,0
POTIGA,suicide,peripheral,0
POTIGA,suicide,,0
POTIGA,suicide,hyperhydrosis urinary retention malaise and increased liver enzymes Most of,0
POTIGA,suicide,"uth, dy sphagia hyperhydrosis urinary",1
POTIGA,suicide,appetite hallucinations myoclonus,0
POTIGA,suicidal thoughts,"aphasia ance disorder, co nstipation dysuria and",1
POTIGA,suicidal thoughts,,0
POTIGA,suicidal thoughts,aphasia ance,1
POTIGA,suicidal thoughts,"aphasia ance disorder, co nstipation dysuria and",1
POTIGA,Suicidal Thoughts,muscle spasms alopecia nephrolithiasis syncope neutropenia throm,0
POTIGA,Suicidal Thoughts,treated with POTIGA during,0
POTIGA,suicidal thoughts,,1
POTIGA,suicidal thoughts,,0
POTIGA,suicidal thoughts,,0
POTIGA,suicidal thoughts,,0
POTIGA,suicidal thoughts,,0
POTIGA,suicidal thoughts,,1
POTIGA,suicidal thoughts,,0
POTIGA,suicidal thoughts,,0
POTIGA,suicidal thoughts,,1
POTIGA,suicidal thoughts,,0
BREO,death,risk of death,1
BREO,death,death,1
BREO,death,death,1
BREO,death,LABA increase the risk,0
BREO,death,death,1
BREO,death,death,1
BREO,death,LABA increase,0
BREO,death,mitigates the increased risk of,0
BREO,death,death,1
BREO,death,control drugs mitigates the increased risk,0
BREO,death,or other longterm asthma control drugs mitigates the increased,0
BREO,death,Available data from controlled clinical trials suggest that LABA increase the risk of,0
BREO,deaths,deaths,1
BREO,deaths,deaths,1
BREO,Candida albicans infection,and local corticosteroid use may result in the,0
BREO,Candida albicans infection,corticosteroid use may result in,0
BREO,Candida albicans infection,Warnings,0
BREO,Candida albicans infection,,0
BREO,Candida albicans infection,and Precautions Increased risk of,0
BREO,Candida albicans infection,the Candida albicans,1
BREO,Candida albicans infection,Candida albicans infection,1
BREO,pneumonia,of,0
BREO,pneumonia,and Precautions Increased risk of,0
BREO,pneumonia,risk,0
BREO,pneumonia,,0
BREO,pneumonia,Precautions Increased risk pneumonia,1
BREO,pneumonia,pneumonia,1
BREO,pneumonia,,0
BREO,Immunosuppression,Immunosuppression,1
BREO,Immunosuppression,Immunosuppression,1
BREO,Immunosuppression,COPD see Warnings and Immunosuppression,1
BREO,Hypercorticism,,0
BREO,Hypercorticism,Warnings and Hypercorticism,1
BREO,Hypercorticism,Hypercorticism,1
BREO,Hypercorticism,Immunosuppression see Warnings and Hypercorticism,1
BREO,Hypercorticism,Hypercorticism,1
BREO,Hypercorticism,Hypercorticism,1
BREO,Hypercorticism,,0
BREO,adrenal suppression,Precautions Hypercorticism adrenal,1
BREO,adrenal suppression,and Precautions Hypercorticism adrenal suppression,1
BREO,adrenal suppression,Precautions Reduction in bone mineral,0
BREO,adrenal suppression,Warnings and Precautions,0
BREO,adrenal suppression,,0
BREO,adrenal suppression,Pr,0
BREO,adrenal suppression,Immunosuppression see Warnings and,0
BREO,adrenal suppression,Hypercorticism adrenal,1
BREO,Reduction in bone mineral density,and,0
BREO,Reduction in bone mineral density,suppression see Warnings,0
BREO,Reduction in bone mineral density,Because clinical,0
BREO,Reduction in bone mineral density,,0
BREO,Reduction in bone mineral density,see Warnings and,0
BREO,Reduction in bone mineral density,suppression see Warnings and Reduction in bone mineral density,1
BREO,nasopharyngitis,Most common adverse reactions,0
BREO,nasopharyngitis,tract infection headache and oral candidiasis,0
BREO,upper respiratory tract infection,oral candidiasis,0
BREO,headache,greater than or equal to are nasopharyngitis upper respiratory tract,0
BREO,headache,headache,1
BREO,headache,nasopharyngitis upper respiratory tract headache,1
BREO,headache,are,0
BREO,oral candidiasis,reactions incidence greater than or,0
BREO,nasopharyngitis,to nasopharyngitis,1
BREO,nasopharyngitis,nasopharyngitis,1
BREO,nasopharyngitis,upper respiratory tract infection bronchitis,0
BREO,nasopharyngitis,nasopharyngitis,1
BREO,nasopharyngitis,headache influenza upper respiratory,0
BREO,nasopharyngitis,common adverse reactions incidence greater than or equal to are,0
BREO,nasopharyngitis,nasopharyngitis,1
BREO,nasopharyngitis,reactions incidence greater than or equal to are,0
BREO,nasopharyngitis,common adverse reactions incidence greater,0
BREO,nasopharyngitis,nasopharyngitis,1
BREO,oral candidiasis,to are oral candidiasis,1
BREO,oral candidiasis,incidence greater than,0
BREO,oral candidiasis,equal to are oral candidiasis,1
BREO,oral candidiasis,oral candidiasis,1
BREO,oral candidiasis,to are oral candidiasis,1
BREO,oral candidiasis,oral candidiasis,1
BREO,oral candidiasis,bronchitis,0
BREO,headache,headache,1
BREO,headache,incidence greater than or equal to are nasopharyngitis oral,0
BREO,influenza,influenza,1
BREO,influenza,influenza,1
BREO,influenza,influenza,1
BREO,influenza,incidence greater than,0
BREO,influenza,to are nasopharyngitis oral candidiasis,0
BREO,influenza,sinusitis oropharyngeal pain,0
BREO,influenza,,0
BREO,influenza,to are nasopharyngitis oral candidiasis,0
BREO,upper respiratory tract infection,tract infection,1
BREO,upper respiratory tract infection,nasopharyngitis oral,0
BREO,upper respiratory tract infection,to are nasopharyngitis,0
BREO,upper respiratory tract infection,sinusitis oropharyngeal pain,0
BREO,upper respiratory tract infection,headache upper respiratory tract,1
BREO,upper respiratory tract infection,oral candidiasis headache upper respiratory tract infection,1
BREO,upper respiratory tract infection,,0
BREO,upper respiratory tract infection,upper respiratory tract infection,1
BREO,bronchitis,bronchitis,1
BREO,bronchitis,bronchitis,1
BREO,bronchitis,,0
BREO,bronchitis,bronchitis,1
BREO,bronchitis,nasopharyngitis oral,0
BREO,sinusitis,upper respiratory tract infection sinusitis,1
BREO,sinusitis,sinusitis,1
BREO,sinusitis,sinusitis,1
BREO,sinusitis,sinusitis,1
BREO,oropharyngeal pain,respiratory tract infection bronchitis oropharyngeal,1
BREO,oropharyngeal pain,report,0
BREO,oropharyngeal pain,pain,1
BREO,oropharyngeal pain,contact,0
BREO,oropharyngeal pain,pain,1
BREO,oropharyngeal pain,respiratory tract infection bronchitis oropharyngeal pain,1
BREO,oropharyngeal pain,REACTIONS contact,0
BREO,dysphonia,,0
BREO,dysphonia,dysphonia,1
BREO,dysphonia,infection bronchitis sinusitis oropharyngeal dysphonia,1
BREO,dysphonia,dysphonia,1
BREO,dysphonia,dysphonia,1
BREO,cough,,0
BREO,cough,cough,1
BREO,cough,oropharyngeal pain dysphonia,0
BREO,cough,and,0
BREO,cough,cough,1
BREO,cough,cough,1
BREO,cough,sinusitis oropharyngeal pain dysphonia cough,1
BREO,Nasopharyngitis,,0
BREO,Nasopharyngitis,,0
BREO,Nasopharyngitis,Nasopharyngitis,1
BREO,Nasopharyngitis,Nasopharyngitis,1
BREO,Nasopharyngitis,,0
BREO,Upper respiratory tract infection,Upper respiratory tract infection,1
BREO,Upper respiratory tract infection,Upper,1
BREO,Upper respiratory tract infection,Upper respiratory tract infection,1
BREO,Upper respiratory tract infection,,0
BREO,Upper respiratory tract infection,Upper,1
BREO,Upper respiratory tract infection,,0
BREO,Upper respiratory tract infection,,0
BREO,Upper respiratory tract infection,,0
BREO,Oropharyngeal candidiasis,,0
BREO,Oropharyngeal candidiasis,,0
BREO,Oropharyngeal candidiasis,Oropharyngeal candidiasis a,1
BREO,Oropharyngeal candidiasis,a,0
BREO,Oropharyngeal candidiasis,Oropharyngeal candidiasis a,1
BREO,Headache,,0
BREO,Headache,,0
BREO,Headache,Headache,1
BREO,Headache,,0
BREO,Headache,,0
BREO,Headache,Headache,1
BREO,Headache,,0
BREO,Headache,,0
BREO,Headache,Headache,1
BREO,oral candidiasis,candidiasis,1
BREO,oral candidiasis,oropharyngeal candidiasis candidiasis and fungal oropharyngitis,0
BREO,oral candidiasis,oropharyngitis,0
BREO,oral candidiasis,,0
BREO,oral candidiasis,a oral,1
BREO,oral candidiasis,oral candidiasis,1
BREO,candidiasis,candidiasis oropharyngeal candidiasis,1
BREO,candidiasis,,0
BREO,candidiasis,mo,0
BREO,candidiasis,,0
BREO,candidiasis,oral candidiasis,0
BREO,candidiasis,candidiasis,1
BREO,candidiasis,candidiasis oropharyngeal candidiasis,0
BREO,candidiasis,,0
BREO,fungal oropharyngitis,,0
BREO,fungal oropharyngitis,candidiasis oropharyngeal candidiasis candidiasis,0
BREO,fungal oropharyngitis,candidiasis candidiasis and,0
BREO,fungal oropharyngitis,candidiasis oropharyngeal candidiasis candidiasis fungal,1
BREO,fungal oropharyngitis,fungal oropharyngitis,1
BREO,fungal oropharyngitis,fungal,1
BREO,fungal oropharyngitis,candidiasis oropharyngeal candidiasis candidiasis and,0
BREO,fungal oropharyngitis,candidiasis fungal oropharyngitis,1
BREO,back pain,pain,1
BREO,back pain,subjects treated with BREO ELLIPTA,0
BREO,back pain,,0
BREO,back pain,pai,0
BREO,back pain,cough oropharyngeal pai,0
BREO,back pain,,0
BREO,back pain,,0
BREO,bronchitis,see Warnings and bronchitis,1
BREO,bronchitis,bronchitis,1
BREO,sinusitis,pharyngitis,0
BREO,sinusitis,pain arthralgia influenza pharyngitis,0
BREO,cough,cough,1
BREO,cough,cough,1
BREO,oropharyngeal pain,Precautions bronchitis sinusitis oropharyngeal,1
BREO,oropharyngeal pain,,0
BREO,oropharyngeal pain,oropharyngeal,1
BREO,oropharyngeal pain,bronchitis sinusitis oropharyngeal,1
BREO,oropharyngeal pain,Warnings and Precautions bronchitis sinusitis cough,0
BREO,oropharyngeal pain,oropharyngeal pain,1
BREO,oropharyngeal pain,pyrexia Clinical Trials Experience in,0
BREO,oropharyngeal pain,oropharyngeal pain,1
BREO,oropharyngeal pain,oropharyngeal pain,1
BREO,arthralgia,cough oropharyngeal arthralgia,1
BREO,arthralgia,arthralgia,1
BREO,arthralgia,arthralgia,1
BREO,arthralgia,,0
BREO,arthralgia,Precautions bronchitis sinusitis cough,0
BREO,arthralgia,Precautions bronchitis sinusitis cough,0
BREO,arthralgia,pharyngitis and pyrexia Clinical Trials Experience in Asthma,0
BREO,arthralgia,in Asthma BREO,0
BREO,arthralgia,Precautions bronchitis sinusitis cough oropharyngeal pain,0
BREO,arthralgia,Warnings and Precautions bronchitis sinusitis,0
BREO,influenza,pharyngitis and pyrexia Clinical Trials Experience in Asthma BREO,0
BREO,influenza,influenza,1
BREO,influenza,pain,0
BREO,influenza,Warnings and,0
BREO,influenza,the t,0
BREO,influenza,influenza,1
BREO,influenza,,0
BREO,pharyngitis,sinusitis cough oropharyngeal,0
BREO,pharyngitis,,0
BREO,pharyngitis,pharyngitis,1
BREO,pharyngitis,oropharyngeal pain arthralgia pharyngitis,1
BREO,pyrexia,sinusitis cough oropharyngeal pain arthralgia influenza pharyngitis and,0
BREO,pyrexia,the treatment of asthma,0
BREO,pyrexia,,0
BREO,pyrexia,and,0
BREO,pyrexia,and,0
BREO,pyrexia,pyrexia,1
BREO,pyrexia,pyrexia,1
BREO,pyrexia,pyrexia,1
BREO,pyrexia,stu,0
BREO,Nasopharyngitis,Nasopharyngitis,1
BREO,Oral candidiasis,candidiasis a,1
BREO,Oral candidiasis,,0
BREO,Oral candidiasis,,0
BREO,Oral candidiasis,Oral candidiasis a,1
BREO,Oral candidiasis,,0
BREO,Oral candidiasis,Oral candidiasis a,1
BREO,Oral candidiasis,,0
BREO,Oral candidiasis,Oral,1
BREO,Oral candidiasis,candidiasis a,1
BREO,Headache,Headache,1
BREO,Headache,Headache,1
BREO,Headache,Headache,1
BREO,Headache,Headache,1
BREO,Headache,Headache,1
BREO,Headache,Headache,1
BREO,Headache,Headache,1
BREO,Headache,Headache,1
BREO,Headache,Headache,1
BREO,Headache,Headache,1
BREO,Oropharyngeal pain,,0
BREO,Oropharyngeal pain,,0
BREO,Oropharyngeal pain,,0
BREO,Dysphonia,,0
BREO,Dysphonia,,0
BREO,Dysphonia,,0
BREO,Dysphonia,,0
BREO,Dysphonia,Dysphonia,1
BREO,oral candidiasis,a oral candidiasis,1
BREO,oral candidiasis,candidiasis,1
BREO,oral candidiasis,of,0
BREO,oral candidiasis,oral,1
BREO,oral candidiasis,oral candidiasis,1
BREO,oral candidiasis,a oral candidiasis,1
BREO,oral candidiasis,oral candidiasis,1
BREO,oral candidiasis,Includes,0
BREO,oral candidiasis,oral candidiasis,1
BREO,oropharyngeal candidiasis,oropharyngeal candidiasis,1
BREO,oropharyngeal candidiasis,a Includes oral candidiasis oropharyngeal,1
BREO,oropharyngeal candidiasis,oral candidiasis oropharyngeal candidiasis,1
BREO,oropharyngeal candidiasis,and,0
BREO,oropharyngeal candidiasis,,0
BREO,oropharyngeal candidiasis,and,0
BREO,oropharyngeal candidiasis,efficacy of BREO ELLIPTA BREO,0
BREO,oropharyngeal candidiasis,Includes oral candidiasis oropharyngeal candidiasis,1
BREO,Headache,Headache,1
BREO,Headache,,0
BREO,Headache,Headache,1
BREO,Headache,Headache,1
BREO,Headache,Headache,1
BREO,Headache,Headache,1
BREO,Nasopharyngitis,,0
BREO,Nasopharyngitis,Nasopharyngitis,1
BREO,Nasopharyngitis,Nasopharyngitis,1
BREO,Nasopharyngitis,Nasopharyngitis,1
BREO,Nasopharyngitis,Nasopharyngitis,1
BREO,Influenza,Influenza,1
BREO,Influenza,Influenza,1
BREO,Influenza,,0
BREO,Influenza,,0
BREO,Influenza,Influenza,1
BREO,Influenza,Influenza,1
BREO,Influenza,Influenza,1
BREO,Influenza,Influenza,1
BREO,Upper respiratory tract infection,,0
BREO,Upper respiratory tract infection,Upper,1
BREO,Upper respiratory tract infection,Upper respiratory,1
BREO,Upper respiratory tract infection,tract infection,1
BREO,Upper respiratory tract infection,Upper respiratory tract infection,1
BREO,Upper respiratory tract infection,Upper respiratory tract infection,1
BREO,Upper respiratory tract infection,respiratory tract infection,1
BREO,Upper respiratory tract infection,,0
BREO,Sinusitis,,0
BREO,Sinusitis,Sinusitis,1
BREO,Sinusitis,Sinusitis,1
BREO,Sinusitis,,0
BREO,Sinusitis,Sinusitis,1
BREO,Sinusitis,Sinusitis,1
BREO,Bronchitis,Bronchitis,1
BREO,Bronchitis,Bronchitis,1
BREO,Bronchitis,Bronchitis,1
BREO,Bronchitis,Bronchitis,1
BREO,Bronchitis,,0
BREO,Bronchitis,Bronchitis,1
BREO,Bronchitis,,0
BREO,Bronchitis,Bronchitis,1
BREO,Bronchitis,Bronchitis,1
BREO,Bronchitis,Bronchitis,1
BREO,Cough,Cough,1
BREO,Cough,Cough,1
BREO,Cough,,0
BREO,Cough,Cough,1
BREO,viral respiratory tract infection,and arthralgia Month Trial Longterm safety data,0
BREO,viral respiratory tract infection,in greater than or,0
BREO,viral respiratory tract infection,BREO ELLIPTA viral respiratory tract infection,1
BREO,viral respiratory tract infection,pyrexia and,0
BREO,pharyngitis,included viral respiratory tract,0
BREO,pharyngitis,respiratory tract pharyngitis,1
BREO,pharyngitis,Longterm,0
BREO,pharyngitis,pharyngitis,1
BREO,pharyngitis,on a month t,0
BREO,pyrexia,that,0
BREO,pyrexia,pyrexia,1
BREO,pyrexia,arthralgia Month,0
BREO,pyrexia,pharyngitis,0
BREO,pyrexia,pyrexia,1
BREO,pyrexia,pyrexia,1
BREO,arthralgia,arthralgia,1
BREO,arthralgia,pyrexia arthralgia,1
BREO,arthralgia,Longterm safety data is,0
BREO,arthralgia,arthralgia,1
BREO,back pain,,0
BREO,back pain,months included back,1
BREO,back pain,upper abdominal pain respiratory tract infection,0
BREO,back pain,back pain,1
BREO,back pain,ELLIPTA for months included back,1
BREO,back pain,months included back pain,1
BREO,back pain,subjects treated with BREO ELLIPTA or BREO ELLIPTA for,0
BREO,back pain,respiratory tract infection allergic,0
BREO,back pain,BREO ELLIPTA for months included,0
BREO,extrasystoles,extrasystoles,1
BREO,extrasystoles,,0
BREO,extrasystoles,ELLIPTA for months,0
BREO,extrasystoles,upper abdominal pain respiratory tract infection allergic,0
BREO,extrasystoles,,0
BREO,extrasystoles,extrasystoles,1
BREO,extrasystoles,extrasystoles,1
BREO,extrasystoles,respiratory tract infection allergic,0
BREO,upper abdominal pain,pharyngitis rhinitis,0
BREO,upper abdominal pain,upper abdominal pain,1
BREO,upper abdominal pain,upper abdominal pain,1
BREO,upper abdominal pain,,0
BREO,upper abdominal pain,included pyrexia back pain upper abdominal pain,1
BREO,upper abdominal pain,back pain upper,1
BREO,upper abdominal pain,abdominal pain,1
BREO,upper abdominal pain,,0
BREO,upper abdominal pain,abdominal pain,1
BREO,respiratory tract infection,respiratory tract infection,1
BREO,respiratory tract infection,allergic rhinitis pharyngitis rhinitis,0
BREO,respiratory tract infection,pain extrasystoles upper abdominal respiratory,1
BREO,respiratory tract infection,pyrexia back pain extrasystoles upper abdominal pain,0
BREO,respiratory tract infection,rhinitis arthralgia supraventricular extrasystoles ventricular,0
BREO,respiratory tract infection,supraventricular extrasystoles ventricular,0
BREO,allergic rhinitis,,0
BREO,allergic rhinitis,ventricular,0
BREO,allergic rhinitis,pain respiratory tract allergic,1
BREO,allergic rhinitis,allergic rhinitis,1
BREO,pharyngitis,pharyngitis,1
BREO,pharyngitis,extrasystoles ventricular extrasystoles acute,0
BREO,pharyngitis,pharyngitis,1
BREO,pharyngitis,,0
BREO,pharyngitis,,0
BREO,pharyngitis,pharyngitis,1
BREO,arthralgia,pain respiratory tract infection allergic rhinitis pharyngitis rhinitis,0
BREO,arthralgia,arthralgia,1
BREO,arthralgia,,0
BREO,arthralgia,abdominal pain,0
BREO,arthralgia,rhinitis,0
BREO,supraventricular extrasystoles,rhinitis pharyngitis rhinitis supraventricular extrasystoles,1
BREO,supraventricular extrasystoles,rhinitis supraventricular extrasystoles,1
BREO,supraventricular extrasystoles,sinusitis and,0
BREO,supraventricular extrasystoles,rhinitis arthralgia,0
BREO,supraventricular extrasystoles,extrasystoles,1
BREO,supraventricular extrasystoles,,0
BREO,supraventricular extrasystoles,acute sinusitis and pneumonia Exacerbation Trial In,0
BREO,supraventricular extrasystoles,,0
BREO,supraventricular extrasystoles,ventricular extrasystoles acute sinusitis,0
BREO,ventricular extrasystoles,,0
BREO,ventricular extrasystoles,pharyngitis rhinitis arthralgia supraventricular ventricular extrasystoles,1
BREO,ventricular extrasystoles,subjects,0
BREO,ventricular extrasystoles,arthralgia supraventricular ventricular extrasystoles,1
BREO,ventricular extrasystoles,ventricular,1
BREO,ventricular extrasystoles,,0
BREO,ventricular extrasystoles,arthralgia supraventricular ventricular,1
BREO,ventricular extrasystoles,arthralgia supraventricular ventricular,1
BREO,ventricular extrasystoles,ventricular extrasystoles,1
BREO,acute sinusitis,received BREO EL,0
BREO,acute sinusitis,week trial subjects received BREO EL,0
BREO,pneumonia,,0
BREO,pneumonia,pneumonia,1
BREO,pneumonia,pneumonia,1
BREO,deaths,deaths,1
BREO,Palpitations,these factors Cardiac Palpitations,1
BREO,Palpitations,Hypersensitivity,0
BREO,Palpitations,BREO ELLIPTA or a combination of these factors Cardiac Disorders,0
BREO,tachycardia,tachycardia,1
BREO,tachycardia,Cardiac Disorders tachycardia,1
BREO,tachycardia,tachycardia,1
BREO,tachycardia,,0
BREO,tachycardia,tachycardia,1
BREO,tachycardia,reactions including anaphylaxis angioedema,0
BREO,tachycardia,tachycardia,1
BREO,tachycardia,,0
BREO,tachycardia,or a combination,0
BREO,tachycardia,Immune,0
BREO,anaphylaxis,angioedema,0
BREO,anaphylaxis,anaphylaxis,1
BREO,anaphylaxis,angioedema rash and,0
BREO,anaphylaxis,,0
BREO,anaphylaxis,anaphylaxis,1
BREO,anaphylaxis,tachycardia Immune System,0
BREO,anaphylaxis,,0
BREO,anaphylaxis,System Disorders Hypersensitivity reactions anaphylaxis,1
BREO,anaphylaxis,anaphylaxis,1
BREO,angioedema,angioedema,1
BREO,angioedema,Disorders Hypersensitivity reactions including angioedema,1
BREO,angioedema,angioedema,1
BREO,angioedema,angioedema,1
BREO,angioedema,angioedema,1
BREO,angioedema,Disorders Hypersensitivity reactions including angioedema,1
BREO,angioedema,Connective Tissue Disorders Muscle,0
BREO,angioedema,Disorders Hypersensitivity reactions including,0
BREO,angioedema,rash and urticaria Musculoskeletal and Connective Tissue Disorders Muscle,0
BREO,angioedema,Disorders,0
BREO,rash,rash,1
BREO,rash,Hypersensitivity,0
BREO,rash,rash,1
BREO,rash,and urticaria Musculoskeletal and Connective,0
BREO,rash,Connective Tissue Disorders Muscle spasms,0
BREO,rash,rash,1
BREO,rash,and urticaria Musculoskeletal and,0
BREO,rash,reactions including anaphylaxis rash,1
BREO,rash,Hypersensitivity reactions including anaphylaxis rash,1
BREO,urticaria,urticaria,1
BREO,urticaria,,0
BREO,urticaria,including anaphylaxis angioedema rash urticaria,1
BREO,Muscle spasms,Disorders,0
BREO,Muscle spasms,,0
BREO,Muscle spasms,urticaria Musculoskeletal and Connective,0
BREO,Muscle spasms,Connective Tissue Muscle,1
BREO,Muscle spasms,Tremor Psychiatric,0
BREO,Muscle spasms,Tissue Muscle,1
BREO,Muscle spasms,Disorders Tremor Psychiatric,0
BREO,Muscle spasms,,0
BREO,Tremor,Tremor,1
BREO,Tremor,spasms Nervous System Tremor,1
BREO,Tremor,Disorders,0
BREO,Tremor,Psychiatric,0
BREO,Tremor,and Connective Tissue Disorders Muscle spasms Nervous,0
BREO,Tremor,Disorders Muscle spasms Nervous System,0
BREO,Tremor,Tremor,1
BREO,Tremor,System Tremor,1
BREO,Tremor,Tremor,1
BREO,Nervousness,Nervousness,1
BREO,Nervousness,System Disorders Tremor Psychiatric,0
BREO,DEATH,,0
BREO,DEATH,of the active ingredients in,0
BREO,DEATH,lante rol,1
BREO,DEATH,,0
BREO,DEATH,lante rol one of the,1
BREO,DEATH,ingredients in BREO ELLIPTA increase the risk of,0
BREO,DEATH,lante rol one of the,1
BREO,DEATH,,0
BREO,DEATH,dient s,1
BREO,DEATH,dient s in BREO,1
BREO,death,oster oids or other,1
BREO,death,oster oids or other,1
BREO,death,oster oids or other,1
BREO,death,oster oids or other,1
BREO,death,data,0
BREO,death,oster oids or other,1
BREO,deaths,,0
BREO,deaths,the r isk of asthmarelated,1
BREO,deaths,r isk of asthmarelated,1
BREO,deaths,clinical trials suggest,0
BREO,deaths,in,0
BREO,deaths,suggest that LABA increase,0
BREO,deaths,trials suggest that LABA the,1
BREO,deaths,r isk of asthmarelated,1
BREO,death,salmeterol ee Wa rnings and Precautions,1
BREO,death,subjects receiving salmeterol ee Wa rnings and Precautions,1
BREO,death,receiving salmeterol ee,1
BREO,death,receiving salmeterol,0
BREO,death,Wa rnings and Precautions,1
BREO,death,ee Wa rnings and Precautions,1
BREO,death,corticosteroid,0
BREO,death,salmeterol ee,1
BREO,death,ee Wa rnings and Precautions,1
BREO,death,,0
BREO,DEATH,eacti ons incidence greater,1
BREO,DEATH,infection headache and oral,0
BREO,DEATH,infection,0
BREO,DEATH,eacti ons incidence greater,1
BREO,DEATH,candidiasis Asthma Most,0
BREO,DEATH,oral candidiasis,0
BREO,deaths,ne at or FDA at,1
BREO,deaths,REACTIONS contact ne at  or FDA at,1
BREO,deaths,,0
BREO,deaths,at or FDA at,1
BREO,deaths,,0
BREO,deaths,REACTIONS contact ne at  or FDA at,1
BREO,deaths,REACTIONS contact ne at  or FDA at,1
BREO,deaths,at FDA or wwwfdagovmedwatch Clinical Trials,0
BREO,deaths,at FDA,0
BREO,deaths,,0
BREO,death,for BREO ELLIPTA included subjects with COPD in two month lung function,0
BREO,death,trials of,0
BREO,death,,0
BREO,death,th ex acerbation trials and,1
BREO,death,in two month lung function trials,0
BREO,death,ex acerbation trials and,1
BREO,death,LIPTA increase the risk of asthmarelated,1
BREO,death,LIPTA increase,1
BREO,death,,0
BREO,death,LIPTA increase,1
BREO,Candida albicans infection of the mouth,suggest that,0
BREO,Candida albicans infection of the mouth,,0
BREO,Candida albicans infection of the mouth,from controlled clinical trials suggest that LABA increase,0
BREO,Candida albicans infection of the mouth,the risk f asthma-related hospitalization in ped iatric,1
BREO,Candida albicans infection of the mouth,LABA,0
BREO,worsening of infections,Warnings and Precautions Systemic and local c,0
BREO,worsening of infections,receiving salmeterol See Warnings and Precautions Systemic and local,0
BREO,worsening of infections,local orticosteroid use may,1
BREO,worsening of infections,in the following,0
BREO,worsening of infections,,0
BREO,fatal," 
 *  Immunosuppression",1
BREO,fatal," 
 *  Immunosuppression",1
BREO,fatal,,0
BREO,fatal,"Warnings and  
 *  Immunosuppression",1
BREO,fatal," 
 *  Immunosuppression",1
BREO,fatal,in COPD see Warnings and Precautions,0
BREO,fatal," 
 *  Immunosuppression",1
BREO,fatal,Immunosuppression see Warnings and,0
BREO,fatal,adrenal,0
BREO,fatal," 
 *  Immunosuppression",1
BREO,chickenpox,ppression  see,1
BREO,chickenpox,and Precautions,0
BREO,chickenpox,ppression  see,1
BREO,measles,see,0
BREO,measles,Immunosuppression  Warnin gs,1
BREO,measles,suppression see,0
BREO,measles,Immunosuppression  Warnin gs,1
BREO,measles,and Precautions Hypercorticism and adrenal,0
BREO,measles, Warnin gs,1
BREO,measles, Warnin gs,1
BREO,impaired adrenal function,and suppression,1
BREO,impaired adrenal function,see Warnings,0
BREO,impaired adrenal function,and Precautions Hypercorticism and suppression [see Warnings and,1
BREO,impaired adrenal function,,0
BREO,impaired adrenal function,Hypercorticism and suppression [see,1
BREO,impaired adrenal function,Warnings and Precautions Hypercorticism,0
BREO,Hypercorticism,see Warnings and Precautions Because,0
BREO,Hypercorticism,,0
BREO,Hypercorticism,are conducted r,1
BREO,Hypercorticism,,0
BREO,Hypercorticism,r widely varyi ng,1
BREO,Hypercorticism,Warnings and Precautions Because,0
BREO,Hypercorticism,varyi ng,1
BREO,adrenal suppression,,0
BREO,adrenal suppression,r eaction,1
BREO,adrenal suppression,r eaction,1
BREO,death,for BREO ELLIPTA nclud ed,1
BREO,death,program,0
BREO,death,subjects with COPD in two month lung function trials two month exacerbation trials a,0
BREO,death,,0
BREO,death,program for BREO ELLIPTA nclud ed,1
BREO,death,subjects with COPD in two month,0
BREO,death,program for BREO ELLIPTA nclud ed,1
BREO,death,ELLIPTA nclud ed,1
BREO,death,nclud ed,1
BREO,death,for BREO ELLIPTA nclud ed,1
BREO,death,1,1
BREO,death,of shorter duration A total of subjects with COPD received at least,0
BREO,death,BREO ELLIPTA and subjects,0
BREO,death,total of subjects with COPD received,0
BREO,death,do se,1
BREO,death,,0
BREO,death,received at  1 do se,1
BREO,death,1 do se,1
BREO,death,do se,1
BREO,deaths,,0
BREO,deaths,fluticasone furoate mcg fluticasone furoate mcg vilanterol mcg,0
BREO,deaths,fluticasone erol 5 mcg,1
BREO,deaths,ELLIPTA BREO ELLIPTA fluticasone furoatevilant,0
BREO,deaths,ELLIPTA fluticasone erol,1
BREO,deaths,BREO ELLIPTA fluticasone erol 5 mcg,1
BREO,death,,0
BREO,death,in S ubjects,1
BREO,death,and More Common than  in S ubjects,1
BREO,death,S ubjects,1
BREO,death, in S ubjects,1
BREO,death,More Common than in,1
BREO,death,More Common than in,1
BREO,death,S ubjects,1
BREO,death,and More Common than in,1
BREO,death,Fluti casone,1
BREO,death,,0
BREO,death,,0
BREO,death,Fluti casone,1
BREO,death,mcg n,0
BREO,death,,0
BREO,death,Furoate mcg,0
BREO,death,Furoate mcg n Placebo n Infections and,0
BREO,death,mcg Fluti casone,1
BREO,death,Fluti casone,1
BREO,death,      Nasopharyngiti,1
BREO,death,      Nasopharyngiti,1
BREO,fatalities,BREO ELLIPTA,1
BREO,fatalities,with thma.,1
BREO,fatalities,thma. BREO ELLIPTA,1
BREO,fatalities,BREO ELLIPTA,1
BREO,fatalities,thma. BREO ELLIPTA,1
BREO,fatalities,of,0
BREO,pneumonia,n Fluticasone,0
BREO,pneumonias,,0
BREO,pneumonias,Fluticasone Furoate,0
BREO,pneumonias,  Placebo  n,1
BREO,pneumonias,  Placebo  n,1
BREO,pneumonias,  Placebo  n,1
BREO,pneumonias,Fluticasone Furoate mcg   Placebo  n,1
BREO,pneumonias,ELLIPTA n Fluticasone,0
BREO,pneumonias,,0
BREO,pneumonias,Fluticasone Furoate,0
BREO,pneumonia,,0
BREO,pneumonia,         ,1
BREO,pneumonia,,0
BREO,pneumonia,         ,1
BREO,pneumonia,         ,1
BREO,pneumonia,and,0
BREO,pneumonia,         ,1
BREO,fatal,,0
BREO,pneumonia,,0
BREO,pneumonia,       Or,1
BREO,fatal,system       Headache,1
BREO,fatal,,0
BREO,fatal,      Headache,1
BREO,fatal,,0
BREO,fatal,Nervous system       Headache,1
BREO,fatal,Headache,0
BREO,fatal,      Headache,1
BREO,fatal,,0
BREO,pneumonia,          Headache,1
BREO,fatal,     ,1
BREO,fatal,,0
BREO,fatal,Headache,0
BREO,fatal,,0
BREO,fatal,,0
BREO,fatal,Headache      ,1
BREO,fatal,,0
BREO,fatal,,0
BREO,pneumonia,Headache,0
BREO,pneumonia,,0
BREO,infections,pain,0
BREO,infections,Respiratory thoracic and mediastinal           ,1
BREO,infections,          ,1
BREO,infections,Respiratory thoracic and mediastinal           ,1
BREO,infections,          ,1
BREO,infections,pain,0
BREO,Chickenpox,          ,1
BREO,Chickenpox,mediastinal,0
BREO,fatal,Oropharyngeal      ,1
BREO,fatal,,0
BREO,fatal,,0
BREO,fatal,     ,1
BREO,fatal,     ,1
BREO,fatal,,0
BREO,fatal,,0
BREO,fatal,Oropharyngeal      ,1
BREO,fatal,,0
BREO,HPA dysfunction,fluti,1
BREO,HPA dysfunction,"202), and fluti",1
BREO,HPA dysfunction,"daily 202), and fluti",1
BREO,HPA dysfunction,"daily 202), and",1
BREO,HPA dysfunction,daily n,0
BREO,HPA dysfunction,,0
BREO,hypercorticism,supraventricular,0
BREO,hypercorticism,,0
BREO,hypercorticism,respiratory tr,1
BREO,adrenal suppression,"nfection, allergic",1
BREO,adrenal suppression,allergic,1
BREO,adrenal suppression,"abdominal pain respiratory tract nfection,",1
BREO,adrenal suppression,,0
BREO,adrenal suppression,pharyngitis rhinitis arthralgia,0
BREO,adrenal crisis,rhi,1
BREO,adrenal crisis,,0
BREO,adrenal crisis,tract,0
BREO,adrenal crisis,rhi,1
BREO,adrenal crisis,,0
BREO,adrenal crisis,,0
BREO,adrenal crisis,infection allergic rhinitis ph,0
BREO,paradoxical bronchospasm,BREO,0
BREO,paradoxical bronchospasm,furoate mcg Among,0
BREO,paradoxical bronchospasm,,0
BREO,paradoxical bronchospasm,in subjects treated with,0
BREO,paradoxical bronchospasm,mcg,0
BREO,paradoxical bronchospasm,jects (0.7%) treated wit,1
BREO,paradoxical bronchospasm,,0
BREO,paradoxical bronchospasm,hospitalizations,0
BREO,paradoxical bronchospasm,compared with sub,0
BREO,paradoxical bronchospasm,with jects (0.7%) treated,1
BREO,paradoxical bronchospasm,,0
BREO,paradoxical bronchospasm,BREO ELLIPTA,0
BREO,Hypersensitivity reactions,the following adverse,0
BREO,Hypersensitivity reactions,asthmarelated,0
BREO,Hypersensitivity reactions,asthmarelated intubations observed in,0
BREO,Hypersensitivity reactions,reported,0
BREO,Hypersensitivity reactions,,0
BREO,Hypersensitivity reactions,asthmarelated intubations,0
BREO,Hypersensitivity reactions,this 6.3 Postmarketing Experien,1
BREO,Hypersensitivity reactions,,0
BREO,Hypersensitivity reactions,the following adverse reaction,0
BREO,Hypersensitivity reactions,Experien,1
BREO,anaphylaxis,this trial Postmarketing Experience addition,1
BREO,anaphylaxis,observed,0
BREO,anaphylaxis,to,1
BREO,anaphylaxis,,0
BREO,anaphylaxis,trial Postmarketing Experience addition to,1
BREO,angioedema,trial,0
BREO,angioedema,In addition to dverse,1
BREO,angioedema,,0
BREO,angioedema,,0
BREO,angioedema,Postmarketing,0
BREO,angioedema,adverse reactions have been identified during,0
BREO,angioedema,,0
BREO,angioedema,rea,1
BREO,rash,react,0
BREO,urticaria,trials the following adverse reactions have been identified,0
BREO,urticaria,trial Postmarketing Experience In addition to adverse reactions repor,0
BREO,urticaria,the following adverse reactions have been identified during,0
BREO,anaphylactic reactions,ELLIPTA Because these eactions,1
BREO,anaphylactic reactions,eactions are,1
BREO,increases in pulse rate,"Palpitations .



   Immune System D",1
BREO,increases in pulse rate,angioedema rash,0
BREO,cardiac arrhythmias,,0
BREO,cardiac arrhythmias,"Hypersensitivity reactions ing anaphylaxis, an",1
BREO,cardiac arrhythmias,an,1
BREO,cardiac arrhythmias,"anaphylaxis, an",1
BREO,cardiac arrhythmias,System Disorders Hypersensitivity,0
BREO,cardiac arrhythmias,"ing anaphylaxis, an",1
BREO,cardiac arrhythmias,Musculoskeletal and Connective Tissue Disorders,0
BREO,cardiac arrhythmias,"Disorders Hypersensitivity reactions ing anaphylaxis,",1
BREO,cardiac arrhythmias,an,1
BREO,supraventricular tachycardia,and urticaria. M,1
BREO,supraventricular tachycardia,anaphylaxis angioedema,0
BREO,supraventricular tachycardia,Hypersensitivity reactions including,0
BREO,supraventricular tachycardia,"including anaphylaxis rash,",1
BREO,extrasystoles,and,1
BREO,extrasystoles,Connective,0
BREO,extrasystoles,urticaria oskeletal and,1
BREO,extrasystoles,rash and urticaria oskeletal and,1
BREO,extrasystoles,Muscle spasms Nervous System Disorders,0
BREO,extrasystoles,rash and urticaria oskeletal and,1
BREO,extrasystoles,oskeletal and,1
BREO,extrasystoles,,0
BREO,extrasystoles,spasms Nervous,0
BREO,extrasystoles,oskeletal and,1
BREO,electrocardiographic changes,,0
BREO,electrocardiographic changes,"Psychiatric 



 Nervousness.
",1
BREO,electrocardiographic changes,"



 Nervousness.
",1
BREO,flattening of the T wave,,1
BREO,flattening of the T wave,Psychiatric Disorders ,1
BREO,flattening of the T wave,,1
BREO,flattening of the T wave,,0
BREO,flattening of the T wave,Tremor Psychiatric Disorders ,1
BREO,flattening of the T wave,,0
BREO,flattening of the T wave,,1
BREO,flattening of the T wave,,0
BREO,flattening of the T wave,Psychiatric Disorders ,1
BREO,prolongation of the QTc interval,,0
BREO,prolongation of the QTc interval,,0
BREO,prolongation of the QTc interval,,1
BREO,prolongation of the QTc interval,,1
BREO,prolongation of the QTc interval,,0
BREO,Fatalities,,1
BREO,Fatalities,,0
BREO,prolongation of the QTc interval,,1
BREO,prolongation of the QTc interval,,1
BREO,prolongation of the QTc interval,,0
BREO,prolongation of the QTc interval,,0
BREO,prolongation of the QTc interval,,0
BREO,prolongation of the QTc interval,,0
BREO,prolongation of the QTc interval,,0
BREO,ventricular arrhythmias,,1
BREO,ventricular arrhythmias,,0
BREO,ventricular arrhythmias,,0
BREO,ventricular arrhythmias,,1
BREO,ventricular arrhythmias,,1
BREO,ventricular arrhythmias,,1
BREO,ventricular arrhythmias,,0
BREO,ventricular arrhythmias,,0
BREO,Decreases in bone mineral density,,1
BREO,Decreases in bone mineral density,,0
BREO,Decreases in bone mineral density,,1
BREO,Decreases in bone mineral density,,0
BREO,Decreases in bone mineral density,,1
BREO,Glaucoma,,1
BREO,Glaucoma,,1
BREO,Glaucoma,,1
BREO,Glaucoma,,1
BREO,Glaucoma,,0
BREO,Glaucoma,,0
BREO,Glaucoma,,0
BREO,Glaucoma,,1
BREO,Glaucoma,,0
BREO,Glaucoma,,1
BREO,increased intraocular pressure,,0
BREO,increased intraocular pressure,,1
BREO,cataracts,,0
BREO,cataracts,,0
BREO,cataracts,,0
BREO,aggravate preexisting diabetes mellitus,,0
BREO,aggravate preexisting diabetes mellitus,,1
BREO,aggravate preexisting diabetes mellitus,,0
BREO,aggravate preexisting diabetes mellitus,,1
BREO,aggravate preexisting diabetes mellitus,,1
BREO,aggravate preexisting diabetes mellitus,,0
BREO,aggravate preexisting diabetes mellitus,,0
BREO,aggravate preexisting diabetes mellitus,,1
BREO,hypokalemia,,1
BREO,hypokalemia,,0
BREO,hypokalemia,,1
BREO,hypokalemia,,0
BREO,hypokalemia,,1
BREO,hypokalemia,,1
BREO,hyperglycemia,,1
BREO,hyperglycemia,,1
BREO,hyperglycemia,,0
BREO,hyperglycemia,,1
BREO,hyperglycemia,,0
BREO,reduction in growth velocity,,1
BREO,reduction in growth velocity,,0
BREO,reduction in growth velocity,,0
BREO,reduction in growth velocity,,0
BREO,reduction in growth velocity,,1
BREO,reduction in growth velocity,,0
BREO,reduction in growth velocity,,0
BREO,reduction in growth velocity,,1
BREO,reduction in growth velocity,,1
BREO,reduction in growth velocity,,1
DOTAREM,NSF,,0
DOTAREM,NSF,,0
DOTAREM,NSF,,0
DOTAREM,NSF,NSF has not been reported in patients,0
DOTAREM,NSF,with a clear his,0
DOTAREM,NSF,his,0
DOTAREM,NSF,NSF,1
DOTAREM,NSF,,0
DOTAREM,Hypersensitivity reactions,of exposure,0
DOTAREM,Hypersensitivity reactions,Warnings,0
DOTAREM,Hypersensitivity reactions,Hypersensitivity reactions,1
DOTAREM,Hypersensitivity reactions,reactions,1
DOTAREM,Hypersensitivity reactions,described in other sections of the labeling see,0
DOTAREM,Hypersensitivity reactions,,0
DOTAREM,Hypersensitivity reactions,clear,0
DOTAREM,Hypersensitivity reactions,DOTAREM Hypersensitivity reactions,1
DOTAREM,acute kidney injury,a clear history of exposure to DOTAREM alone Hypersensitivity,0
DOTAREM,acute kidney injury,are described in other,0
DOTAREM,acute kidney injury,DOTAREM alone Hypersensitivity reactions acute kidney injury,1
DOTAREM,acute kidney injury,acute kidney,1
DOTAREM,acute kidney injury,DOTAREM,0
DOTAREM,acute kidney injury,Hypersensitivity reactions acute kidney,1
DOTAREM,acute kidney injury,alone Hypersensitivity reactions acute kidney,1
DOTAREM,nausea,injection site coldness and burning,0
DOTAREM,nausea,studies,0
DOTAREM,nausea,To report SUS,0
DOTAREM,injection site pain,pain,1
DOTAREM,injection site pain,burning sensation To report SUSPECTED ADVERSE REACTIONS conta,0
DOTAREM,injection site coldness,site injection,1
DOTAREM,injection site coldness,injection site injection site coldness,1
DOTAREM,burning sensation,injection site coldness burning,1
DOTAREM,burning sensation,,0
DOTAREM,burning sensation,site coldness burning,1
DOTAREM,Nausea,Nausea,1
DOTAREM,Nausea,Nausea,1
DOTAREM,Nausea,Nausea,1
DOTAREM,Nausea,Nausea,1
DOTAREM,Nausea,Nausea,1
DOTAREM,Headache,Headache I,1
DOTAREM,Headache,,0
DOTAREM,Headache,,0
DOTAREM,Headache,,0
DOTAREM,Headache,,0
DOTAREM,Headache,,0
DOTAREM,Headache,,0
DOTAREM,Headache,,0
DOTAREM,Headache,Headache I,1
DOTAREM,Headache,,0
DOTAREM,Injection Site Pain,Injection Site Pain Injection,1
DOTAREM,Injection Site Pain,,0
DOTAREM,Injection Site Pain,e Injection Site Pain Injection Si,1
DOTAREM,Injection Site Pain,e Injection Site Pain Injection Si,1
DOTAREM,Injection Site Coldness,Site Coldness Burning Sensatio,1
DOTAREM,Injection Site Coldness,Pain,0
DOTAREM,Injection Site Coldness,Injection Site Coldness Burning Sensatio,1
DOTAREM,Injection Site Coldness,Site Injection Site,1
DOTAREM,Injection Site Coldness,Injection Site,1
DOTAREM,Injection Site Coldness,Injection Site Coldness Burning Sensatio,1
DOTAREM,Injection Site Coldness,Site Injection,1
DOTAREM,Injection Site Coldness,Site Pain,0
DOTAREM,Injection Site Coldness,Site,0
DOTAREM,Burning Sensation,Burning Sensation,1
DOTAREM,Burning Sensation,on Site Burning Sensation,1
DOTAREM,Burning Sensation,Burning Sensation,1
DOTAREM,feeling cold,occurred with a frequency in patients,0
DOTAREM,feeling cold,feeling cold rash somnolence,1
DOTAREM,feeling cold,extremit,0
DOTAREM,feeling cold,cold rash somnolence,1
DOTAREM,rash,in extremity,0
DOTAREM,somnolence,somnolence fatigue dizziness,1
DOTAREM,somnolence,with a frequency in patients who received DOTAREM include,0
DOTAREM,somnolence,cold somnolence fatigue dizziness,1
DOTAREM,somnolence,somnolence fatigue dizziness,1
DOTAREM,somnolence,frequency in patients who received DOTAREM include feeling,0
DOTAREM,somnolence,DOTAREM include feeling cold,0
DOTAREM,somnolence,,0
DOTAREM,somnolence,somnolence fatigue dizziness,1
DOTAREM,fatigue,fatigue dizziness vomiting,1
DOTAREM,fatigue,fatigue dizziness vomiting,1
DOTAREM,fatigue,,0
DOTAREM,fatigue,fatigue dizziness vomiting,1
DOTAREM,fatigue,fatigue dizziness vomiting,1
DOTAREM,fatigue,p,0
DOTAREM,fatigue,rash somnolence,0
DOTAREM,dizziness,dizziness vomiting pruritus,1
DOTAREM,dizziness,dizziness vomiting pruritus,1
DOTAREM,vomiting,vomiting pruritus paresthesia,1
DOTAREM,vomiting,dizziness,0
DOTAREM,vomiting,in,0
DOTAREM,vomiting,received,0
DOTAREM,vomiting,,0
DOTAREM,vomiting,rash,0
DOTAREM,pruritus,pruritus paresthesia dysgeusia,1
DOTAREM,pruritus,vomiting,0
DOTAREM,pruritus,,0
DOTAREM,pruritus,vomiting,0
DOTAREM,paresthesia,pruritus,0
DOTAREM,paresthesia,paresthesia dysgeusia pain,1
DOTAREM,paresthesia,,0
DOTAREM,paresthesia,paresthesia dysgeusia pain,1
DOTAREM,paresthesia,anxiety hypertension palpitations oropharyngeal,0
DOTAREM,paresthesia,paresthesia dysgeusia pain,1
DOTAREM,dysgeusia,pruritus dysgeusia pain in,1
DOTAREM,dysgeusia,anxiety hypertension palpitations oropharyngeal discomfort serum,0
DOTAREM,dysgeusia,paresthesia,0
DOTAREM,dysgeusia,vomiting pruritus dysgeusia pain in,1
DOTAREM,dysgeusia,pruritus dysgeusia pain in,1
DOTAREM,pain in extremity,vomiting pruritus paresthesia pain,1
DOTAREM,pain in extremity,dizziness vomiting pruritus paresthesia pain in,1
DOTAREM,pain in extremity,,0
DOTAREM,pain in extremity,vomiting pruritus paresthesia pain,1
DOTAREM,pain in extremity,pain,1
DOTAREM,pain in extremity,extremity anxiety hypertension,1
DOTAREM,anxiety,pain,0
DOTAREM,anxiety,,0
DOTAREM,hypertension,,0
DOTAREM,hypertension,in extremity,0
DOTAREM,hypertension,hypertension palpitations oropharyngeal,1
DOTAREM,hypertension,hypertension palpitations oropharyngeal,1
DOTAREM,hypertension,vomiting pruritus paresthesia dysgeusia,0
DOTAREM,hypertension,,0
DOTAREM,hypertension,in extremity hypertension palpitations oropharyngeal,1
DOTAREM,hypertension,palpitations oropharyngeal discomfort,0
DOTAREM,hypertension,pain in extremity hypertension palpitations oropharyngeal,1
DOTAREM,palpitations,pain in extremity anxiety palpitations oropharyngeal discomfort,1
DOTAREM,palpitations,palpitations oropharyngeal discomfort,1
DOTAREM,palpitations,palpitations oropharyngeal discomfort,1
DOTAREM,palpitations,palpitations oropharyngeal discomfort,1
DOTAREM,palpitations,paresthesia dysgeusia pain in,0
DOTAREM,palpitations,in extremity,0
DOTAREM,palpitations,oropharyngeal discomfort serum creatinine increased and injection site reactions including site,0
DOTAREM,palpitations,extremity anxiety palpitations oropharyngeal discomfort,1
DOTAREM,palpitations,palpitations oropharyngeal discomfort,1
DOTAREM,palpitations,palpitations oropharyngeal discomfort,1
DOTAREM,oropharyngeal discomfort,discomfort serum creatinine,1
DOTAREM,oropharyngeal discomfort,creatinine increased and injection site,0
DOTAREM,serum creatinine increased,site inflammation,0
DOTAREM,serum creatinine increased,serum creatinine increased and injection,1
DOTAREM,serum creatinine increased,,0
DOTAREM,serum creatinine increased,hypertension palpitations oropharyngeal serum creatinine increased and injection,1
DOTAREM,serum creatinine increased,,0
DOTAREM,headache,reaction headache Most adverse,1
DOTAREM,headache,frequently reported adverse reaction headache Most adverse,1
DOTAREM,headache,adverse reaction was,0
DOTAREM,tachycardia,,0
DOTAREM,tachycardia,tachycardia arrhythmia Immune,1
DOTAREM,tachycardia,tachycardia arrhythmia Immune,1
DOTAREM,tachycardia,tachycardia arrhythmia Immune,1
DOTAREM,tachycardia,tachycardia arrhythmia Immune,1
DOTAREM,tachycardia,,0
DOTAREM,arrhythmia,arrhythmia Immune System,1
DOTAREM,arrhythmia,arrhythmia Immune System,1
DOTAREM,hypersensitivity,reactions,0
DOTAREM,hypersensitivity,tachycardia arrhythmia Immune System hypersensitivity anaphylactoid reactions,1
DOTAREM,hypersensitivity,hypersensitivity anaphylactoid reactions,1
DOTAREM,hypersensitivity,,0
DOTAREM,hypersensitivity,Immune System hypersensitivity anaphylactoid reactions,1
DOTAREM,anaphylactoid reactions,anaphylactoid,1
DOTAREM,anaphylactoid reactions,anaphylactoid reactions including cardiac,1
DOTAREM,anaphylactoid reactions,anaphylactoid reactions including cardiac,1
DOTAREM,cardiac arrest,arrest respiratory arrest,1
DOTAREM,cardiac arrest,,0
DOTAREM,cardiac arrest,cardiac,1
DOTAREM,cardiac arrest,cardiac arrest respiratory arrest,1
DOTAREM,cardiac arrest,,0
DOTAREM,cardiac arrest,hypersensitivity anaphylactoid reactions cardiac arrest respiratory arrest,1
DOTAREM,cardiac arrest,reactions including,0
DOTAREM,respiratory arrest,hypersensitivity anaphylactoid reactions including cardiac arrest,0
DOTAREM,respiratory arrest,,0
DOTAREM,cyanosis,anaphylactoid reactions including cardiac arrest,0
DOTAREM,cyanosis,respiratory cyanosis pharyngeal edema,1
DOTAREM,cyanosis,,0
DOTAREM,cyanosis,laryngospasm,0
DOTAREM,cyanosis,,0
DOTAREM,cyanosis,arrest respiratory cyanosis pharyngeal edema,1
DOTAREM,cyanosis,conjunctivitis ocular hyperemia eyelid,0
DOTAREM,cyanosis,reactions including cardiac arrest respiratory arrest,0
DOTAREM,pharyngeal edema,,0
DOTAREM,pharyngeal edema,edema laryngospasm bronchospasm,1
DOTAREM,pharyngeal edema,arrest respiratory arrest pharyngeal edema laryngospasm bronchospasm,1
DOTAREM,pharyngeal edema,,0
DOTAREM,bronchospasm,pharyngeal edema laryngospasm,0
DOTAREM,bronchospasm,,0
DOTAREM,bronchospasm,,0
DOTAREM,bronchospasm,arrest respiratory arrest,0
DOTAREM,bronchospasm,edema laryngospasm,0
DOTAREM,bronchospasm,,0
DOTAREM,bronchospasm,ocular hyperemia eyelid,0
DOTAREM,bronchospasm,reactions including cardiac,0
DOTAREM,bronchospasm,bronchospasm angioedema conjunctivitis,1
DOTAREM,bronchospasm,reactions including cardiac arrest respiratory arrest cyanosis,0
DOTAREM,angioedema,pharyngeal,0
DOTAREM,angioedema,increased hyperhidrosis urticaria,0
DOTAREM,angioedema,edema laryngospasm angioedema conjunctivitis ocular,1
DOTAREM,angioedema,,0
DOTAREM,angioedema,angioedema conjunctivitis ocular,1
DOTAREM,angioedema,angioedema conjunctivitis ocular,1
DOTAREM,angioedema,respiratory arrest cyanosis pharyngeal edema laryngospasm,0
DOTAREM,angioedema,pharyngeal edema laryngospasm bronchospasm,0
DOTAREM,angioedema,angioedema conjunctivitis ocular,1
DOTAREM,eyelid edema,bronchospasm angioedema conjunctivitis,0
DOTAREM,eyelid edema,lacrimation increased hyperhidrosis,0
DOTAREM,urticaria,increased urticaria Nervous System,1
DOTAREM,coma,urticaria Nervous System coma convulsion syncope,1
DOTAREM,coma,convulsion syncope presyncope parosmia tremor Musculoskeletal,0
DOTAREM,coma,coma convulsion syncope,1
DOTAREM,coma,Nervous System coma convulsion syncope,1
DOTAREM,coma,System coma convulsion syncope,1
DOTAREM,coma,coma convulsion syncope,1
DOTAREM,convulsion,urticaria,0
DOTAREM,convulsion,increased hyperhidrosis urticaria,0
DOTAREM,convulsion,System Disorders,0
DOTAREM,convulsion,syncope presyncope parosmia,0
DOTAREM,convulsion,Disorders convulsion syncope presyncope,1
DOTAREM,convulsion,,0
DOTAREM,convulsion,Connective,0
DOTAREM,convulsion,and Connective Tissue,0
DOTAREM,syncope,,0
DOTAREM,syncope,syncope presyncope parosmia,1
DOTAREM,syncope,and,0
DOTAREM,syncope,Disorders coma,0
DOTAREM,syncope,,0
DOTAREM,syncope,parosmia tremor Musculoskeletal and Connective Tissue Disorders,0
DOTAREM,syncope,parosmia tremor Musculoskeletal and,0
DOTAREM,syncope,syncope presyncope parosmia,1
DOTAREM,presyncope,,0
DOTAREM,presyncope,coma convulsion syncope,0
DOTAREM,presyncope,Musculoskeletal,0
DOTAREM,presyncope,,0
DOTAREM,presyncope,presyncope parosmia tremor,1
DOTAREM,presyncope,presyncope parosmia tremor,1
DOTAREM,presyncope,,0
DOTAREM,presyncope,,0
DOTAREM,parosmia,parosmia tremor Musculoskeletal,1
DOTAREM,parosmia,syncope presyncope,0
DOTAREM,tremor,tremor Musculoskeletal and,1
DOTAREM,tremor,syncope,0
DOTAREM,tremor,presyncope tremor Musculoskeletal and,1
DOTAREM,tremor,Disorders coma convulsion syncope presyncope parosmia,0
DOTAREM,tremor,muscle contracture muscle weakness,0
DOTAREM,muscle weakness,Gastrointestinal Disorders diarrhea salivary hypersecr,0
DOTAREM,muscle weakness,muscle weakness Gastrointestinal Disorders,1
DOTAREM,muscle weakness,and Connective Tissue Disorders muscle,0
DOTAREM,muscle weakness,muscle weakness Gastrointestinal Disorders,1
DOTAREM,muscle weakness,weakness Gastrointestinal Disorders,1
DOTAREM,muscle weakness,muscle,1
DOTAREM,diarrhea,muscle weakness Gastrointestinal diarrhea salivary hypersecretion,1
DOTAREM,diarrhea,diarrhea salivary hypersecretion,1
DOTAREM,malaise,malaise fever Skin,1
DOTAREM,malaise,Conditions,0
DOTAREM,malaise,malaise fever Skin,1
DOTAREM,malaise,,0
DOTAREM,malaise,Administration Site malaise fever Skin,1
DOTAREM,fever,General Disorders and Administration Site Conditions malaise,0
DOTAREM,fever,Administration Site Conditions fever Skin and,1
DOTAREM,fever,,0
DOTAREM,fever,fever Skin and,1
DOTAREM,fever,fever Skin and,1
DOTAREM,fever,Administration Site Conditions,0
DOTAREM,fever,Site Conditions fever Skin and,1
DOTAREM,fever,,0
DOTAREM,NSF,GBCAs could not be,0
DOTAREM,NSF,NSF have been,1
DOTAREM,NSF,NSF have been,1
DOTAREM,NSF,NSF have been,1
DOTAREM,NSF,NSF have been,1
DOTAREM,NSF,NSF have been,1
DOTAREM,NSF,,0
DOTAREM,superficial phlebitis,,0
DOTAREM,superficial phlebitis,NSF,0
DOTAREM,superficial phlebitis,DOTAREM Vascular superficial,1
DOTAREM,NEPHROGENIC SYSTEMIC FIBROSIS,As have been associated with ,1
DOTAREM,NEPHROGENIC SYSTEMIC FIBROSIS,,0
DOTAREM,NSF,ris,1
DOTAREM,NSF,,0
DOTAREM,NSF,ris,1
DOTAREM,NSF,ris k for NSF,1
DOTAREM,NEPHROGENIC SYSTEMIC FIBROSIS,e Warnings and,1
DOTAREM,NEPHROGENIC SYSTEMIC FIBROSIS,e Warnings and Precautions,1
DOTAREM,NEPHROGENIC SYSTEMIC FIBROSIS,Precautions ( NSF,1
DOTAREM,NEPHROGENIC SYSTEMIC FIBROSIS,e Warnings and Precautions,1
DOTAREM,NEPHROGENIC SYSTEMIC FIBROSIS,e Warnings and Precautions (  NSF has not been reported,1
DOTAREM,NEPHROGENIC SYSTEMIC FIBROSIS,e Warnings and Precautions (  NSF has,1
DOTAREM,NSF,.1  NSF has,1
DOTAREM,NSF,.1  NSF has,1
DOTAREM,NSF,see Warnings and .1  NSF has,1
DOTAREM,NSF,associated with a risk,0
DOTAREM,NSF,.1  NSF has,1
DOTAREM,NSF,,0
DOTAREM,NSF,injury are,0
DOTAREM,NSF,,0
DOTAREM,NSF,with a clear history of,0
DOTAREM,NSF,to DOTAREM alone Hypersensitivity reactions and acute kidney injury,0
DOTAREM,NSF,reactions in clinical,0
DOTAREM,NSF,Precautions and EXCERPT he  most frequent,1
DOTAREM,NSF,,0
DOTAREM,NSF,and Precautions and EXCERPT he  most frequent,1
DOTAREM,NSF,reactions in clinical studies,0
DOTAREM,fatal,Precautions and EXCERPT The most,0
DOTAREM,fatal,>= 0. adverse reactions,1
DOTAREM,fatal,pain injection site,0
DOTAREM,fatal,>= 0. adverse reactions,1
DOTAREM,fatal,most >= 0. adverse reactions,1
DOTAREM,fatal,most >= 0. adverse reactions,1
DOTAREM,fatal,The most >= 0. adverse reactions,1
DOTAREM,fatal,most >= 0. adverse reactions,1
DOTAREM,fatal,The most >= 0. adverse reactions,1
DOTAREM,fatal,,0
DOTAREM,fibrosis,EXCERPT The,0
DOTAREM,fibrosis,EXCERPT The,0
DOTAREM,fibrosis,and burning,0
DOTAREM,fibrosis,most frequent adverse react,0
DOTAREM,fibrosis,in clinical studies,1
DOTAREM,fibrosis,Precautions and EXCERPT The most frequent,0
DOTAREM,NEPHROGENIC SYSTEMIC FIBROSIS,were men In clinical  where ethnicity was recorded the ethnic,1
DOTAREM,NSF,,0
DOTAREM,NSF,,0
DOTAREM,NSF,reported at least one adverse reaction,0
DOTAREM,NSF,mild or moderate in severity,0
DOTAREM,NSF,in nature,0
DOTAREM,NSF,Tab le lists,1
DOTAREM,Nephrogenic Systemic Fibrosis,,0
DOTAREM,Nephrogenic Systemic Fibrosis,,0
DOTAREM,Nephrogenic Systemic Fibrosis,not been reported in patients,0
DOTAREM,Nephrogenic Systemic Fibrosis,with a risk,1
DOTAREM,Nephrogenic Systemic Fibrosis,[see War nings and Precautions,1
DOTAREM,Nephrogenic Systemic Fibrosis,with a,1
DOTAREM,anaphylactic reactions,,0
DOTAREM,anaphylactic reactions,injury are scribed in other secti ons of the labeling see,1
DOTAREM,anaphylactic reactions,alone Hypersensitivity reactions and acute kidney injury are de,0
DOTAREM,anaphylactic reactions,to DOTAREM alone Hypersensitivity reactions,0
DOTAREM,anaphylactic reactions,acute kidney injury are scribed in,1
DOTAREM,anaphylactic reactions,scribed in other,1
DOTAREM,anaphylactic reactions,,0
DOTAREM,cutaneous manifestations,d Precautions ( 5.2 ) and EXCERPT The most frequent,1
DOTAREM,death,reactions in clinical studies were nausea headache injection,0
DOTAREM,death,The mo,0
DOTAREM,death,in clinical studies were nausea headache,0
DOTAREM,NSF,at FDA  ww wfdagovmedwatch Clinical Studies Experience Because,1
DOTAREM,NSF, ww wfdagovmedwatch Clinical Studies Experience Because,1
DOTAREM,NSF,at,0
DOTAREM,NSF,,0
DOTAREM,NSF,auc asian Asian Black and others,1
DOTAREM,NSF,auc asian Asian Black and others,1
DOTAREM,NSF,auc asian Asian Black and others,1
DOTAREM,NSF,years range from to years,0
DOTAREM,NSF,and others The average age was years range,0
DOTAREM,NSF,auc asian Asian Black and others,1
DOTAREM,NSF,distribution was auc asian Asian Black and others,1
DOTAREM,NSF,auc asian Asian Black and others,1
DOTAREM,NSF,auc asian Asian Black and others,1
DOTAREM,NSF,where,0
DOTAREM,fatal,distribution was Caucasian Asia,0
DOTAREM,fatal,"Caucasian n, 4% Black and others The average",1
DOTAREM,fatal,was,0
DOTAREM,fatal,"n, 4% Black and others The average",1
DOTAREM,fatal,Black,0
DOTAREM,fatal,"n, 4% Black and others The average",1
DOTAREM,fatal,years range from to years,0
DOTAREM,fibrosis,thers. T he average age was years,1
DOTAREM,fibrosis,thers. T he average age was years,1
DOTAREM,fibrosis,o,0
DOTAREM,anaphylactoid reactions,"aged s, 33 aged 2",1
DOTAREM,anaphylactoid reactions,Overall,0
DOTAREM,anaphylactoid reactions,"s, 33 aged 2 - 5 years, aged years and aged received",1
DOTAREM,anaphylactoid reactions,aged years,0
DOTAREM,anaphylactoid reactions,"33 aged 2 - 5 years, aged years and aged received",1
DOTAREM,circulatory collapse,administration The,0
DOTAREM,circulatory collapse,tion,1
DOTAREM,circulatory collapse,least one adverse tion following,1
DOTAREM,circulatory collapse,one adverse tion following DOTAR EM administration The most frequently,1
DOTAREM,circulatory collapse,tion following DOTAR EM administration The most frequently,1
DOTAREM,circulatory collapse,DOTAR EM administration The most frequently,1
DOTAREM,circulatory collapse,tion following,1
DOTAREM,died,mini stration The most frequently reported,1
DOTAREM,died,mini stration The most frequently reported,1
DOTAREM,died,mini stration The most frequently reported,1
DOTAREM,died,mini stration The most frequently reported,1
DOTAREM,died,,0
DOTAREM,died,,0
DOTAREM,died,stration The most frequently reported adverse reaction was headache Most,0
DOTAREM,died,wer,0
DOTAREM,died,Most adverse events,0
DOTAREM,died,adverse reaction was,0
DOTAREM,hypersensitivity reaction,are ted voluntarily from a po pulation of uncertain size it,1
DOTAREM,hypersensitivity reaction,,0
DOTAREM,hypersensitivity reaction,DOTAREM Because these reactions,0
DOTAREM,acute kidney injury,diac Disorders bradycardia tachycardia Immune,1
DOTAREM,acute kidney injury,"bradycardia tachycardia  
  Immune System D isorders hypersensitivity anaphylactoid reactions including",1
DOTAREM,acute kidney injury,"tachycardia  
  Immune System D isorders hypersensitivity anaphylactoid reactions including",1
DOTAREM,acute kidney injury,reactions including cardiac arrest,0
DOTAREM,acute kidney injury,tachycardia arrhythmia,0
DOTAREM,acute kidney injury,D isorders hypersensitivity anaphylactoid reactions including,1
DOTAREM,acute kidney injury,"bradycardia tachycardia  
  Immune System D isorders hypersensitivity anaphylactoid reactions including",1
DOTAREM,acute kidney injury,"Disorders bradycardia tachycardia  
  Immune System D isorders hypersensitivity anaphylactoid reactions including",1
DOTAREM,acute kidney injury,Immune,1
DOTAREM,acute kidney injury,bradycardia tachycardia arrhythmia,0
NESINA,nasopharyngitis,nasopharyngitis headache and upper respiratory tract,1
NESINA,nasopharyngitis,nasopharyngitis headache and upper respiratory tract,1
NESINA,upper respiratory tract infection,,0
NESINA,upper respiratory tract infection,placebo are nasopharyngitis headache upper respiratory tract infection To report SUSPECTED ADVERSE REACTIONS,1
NESINA,upper respiratory tract infection,headache upper respiratory,1
NESINA,upper respiratory tract infection,received placebo,0
NESINA,upper respiratory tract infection,are nasopharyngitis headache and,0
NESINA,Nasopharyngitis,,0
NESINA,Nasopharyngitis,Nasopharyngitis Heada,1
NESINA,Nasopharyngitis,N N Nasopharyngitis Heada,1
NESINA,Nasopharyngitis,Nasopharyngitis Heada,1
NESINA,Nasopharyngitis,N,0
NESINA,Nasopharyngitis,N N,0
NESINA,Nasopharyngitis,Nasopharyngitis Heada,1
NESINA,Nasopharyngitis,Nasopharyngitis Heada,1
NESINA,Nasopharyngitis,Nasopharyngitis Heada,1
NESINA,Headache,Headache,1
NESINA,Headache,Headache,1
NESINA,Headache,Headache,1
NESINA,Headache,gitis,0
NESINA,Headache,Headache,1
NESINA,Headache,Headache,1
NESINA,Headache,gitis,0
NESINA,Headache,gitis Headache,1
NESINA,Headache,,0
NESINA,Upper Respiratory Tract Infection,Upper Respiratory Tract Infection Pancreatiti,1
NESINA,Upper Respiratory Tract Infection,Upper Respiratory Tract Infection Pancreatiti,1
NESINA,Upper Respiratory Tract Infection,,0
NESINA,Upper Respiratory Tract Infection,Upper,1
NESINA,Upper Respiratory Tract Infection,,0
NESINA,Upper Respiratory Tract Infection,,0
NESINA,Upper Respiratory Tract Infection,Pancreatiti,0
NESINA,Upper Respiratory Tract Infection,Tract Infection Pancreatiti,1
NESINA,Upper Respiratory Tract Infection,,0
NESINA,hypersensitivity reactions,In a pooled analysis the overall,0
NESINA,hypersensitivity reactions,reactions,1
NESINA,hypersensitivity reactions,the overall incidence hypersensitivity,1
NESINA,hypersensitivity reactions,Hypersensitivity Reactions In a,0
NESINA,hypersensitivity reactions,NESINA mg compared to with all comparators A,0
NESINA,hypersensitivity reactions,incidence hypersensitivity reactions,1
NESINA,hypersensitivity reactions,A single event of serum sickness,0
NESINA,serum sickness,Hypoglycemic,0
NESINA,serum sickness,sickness,1
NESINA,serum sickness,serum sickness,1
NESINA,serum sickness,single event serum,1
NESINA,serum sickness,event serum,1
NESINA,serum sickness,reactions was with,0
NESINA,serum sickness,was reported in a patient treated with NESINA mg Hypoglycemia Hypoglycemic,0
NESINA,serum sickness,,0
NESINA,serum sickness,event serum,1
NESINA,Hypoglycemic events,were documented,0
NESINA,Hypoglycemic events,Hypoglycemic events,1
NESINA,Hypoglycemic events,,0
NESINA,Hypoglycemic events,Hypoglycemic events,1
NESINA,hypoglycemia,value andor clinical signs and symptoms of,0
NESINA,hypoglycemia,hypoglycemia,1
NESINA,hypoglycemia,hypoglycemia,1
NESINA,hypoglycemia,incidence hypoglycemia,1
NESINA,hypoglycemia,hypoglycemia,0
NESINA,hypoglycemia,patients treated,0
NESINA,hypoglycemia,,0
NESINA,hypoglycemia,,0
NESINA,hypoglycemia,signs and,0
NESINA,hypoglycemia,not increase the incidence hypoglycemia,1
NESINA,hypoglycemia,the incidence hypoglycemia,1
NESINA,hypoglycemia,compared to with glipizide Table Table Incidence,0
NESINA,hypoglycemia,,0
NESINA,hypoglycemia,hypoglycemia,1
NESINA,hypoglycemia,hypoglycemia,1
NESINA,hypoglycemia,with NESINA compared to with glipizide Table Table Incidence and,0
NESINA,hypoglycemia,hypoglycemia,1
NESINA,hypoglycemia,and Rate,0
NESINA,hypoglycemia,,0
NESINA,hypoglycemia,to a sulfonylurea in,0
NESINA,Hypoglycemia,Hypoglycemia,1
NESINA,hypoglycemia,hypoglycemia,1
NESINA,hypoglycemia,hypoglycemia,1
NESINA,hypoglycemia,asymptomatic hypoglycemia a concurrent glucose,0
NESINA,hypoglycemia,symptomatic,0
NESINA,hypoglycemia,hypoglycemia,1
NESINA,hypoglycemia,hypoglycemia,1
NESINA,hypoglycemia,reactions hypoglycemia,1
NESINA,hypoglycemia,hypoglycemia,1
NESINA,hypoglycemia,hypoglycemia,1
NESINA,hypoglycemia,,0
NESINA,hypoglycemia,hypoglycemia,1
NESINA,hypoglycemia,,0
NESINA,hypoglycemia,population in Placebo and,0
NESINA,hypoglycemia,of hypoglycemia were based on all,0
NESINA,hypoglycemia,Placebo,0
NESINA,hypoglycemia,hypoglycemia,1
NESINA,hypoglycemia,Severe,0
NESINA,hypoglycemia,hypoglycemia,1
NESINA,hypoglycemia,hypoglycemia,1
NESINA,hypoglycemia,Severe events hypoglycemia,1
NESINA,hypoglycemia,,0
NESINA,hypoglycemia,hypoglycemia,1
NESINA,hypoglycemia,Severe Severe events hypoglycemia,1
NESINA,hypoglycemia,of,0
NESINA,hypoglycemia,hypoglycemia,1
NESINA,hypoglycemia,hypoglycemia,1
NESINA,changes in vital signs,clinically changes in vital,1
NESINA,changes in vital signs,patients treated with NESINA Laboratory Tests,0
NESINA,changes in vital signs,vital signs,1
NESINA,Hypersensitivity reactions,,0
NESINA,Hypersensitivity reactions,drug Hypersensitivity reactions,1
NESINA,Hypersensitivity reactions,causal relationship to drug Hypersensitivity reactions,1
NESINA,Hypersensitivity reactions,Hypersensitivity reactions,1
NESINA,Hypersensitivity reactions,including anaphylaxis angioedema rash,0
NESINA,anaphylaxis,,0
NESINA,anaphylaxis,anaphylaxis,1
NESINA,anaphylaxis,urticaria and severe cutaneous adverse,0
NESINA,anaphylaxis,or establish a causal,0
NESINA,anaphylaxis,anaphylaxis,1
NESINA,angioedema,angioedema,1
NESINA,angioedema,angioedema,1
NESINA,angioedema,,0
NESINA,angioedema,reactions including angioedema,1
NESINA,angioedema,angioedema,1
NESINA,rash,severe cutaneous adverse reactions including StevensJohnson syndrome hepatic,0
NESINA,rash,and severe cutaneous,0
NESINA,rash,cutaneous adverse reactions including StevensJohnson syndrome,0
NESINA,rash,,0
NESINA,rash,including anaphylaxis angioedema,0
NESINA,rash,reactions including anaphylaxis rash,1
NESINA,rash,rash,1
NESINA,urticaria,including anaphylaxis angioedema urticaria,1
NESINA,urticaria,urticaria,1
NESINA,urticaria,urticaria,1
NESINA,urticaria,angioedema,0
NESINA,urticaria,urticaria,1
NESINA,urticaria,reactions including anaphylaxis angioedema urticaria,1
NESINA,urticaria,cutaneous adverse reactions including,0
NESINA,urticaria,reactions including StevensJohnson syndrome,0
NESINA,urticaria,urticaria,1
NESINA,cutaneous adverse reactions,urticaria and cutaneous adverse reactions,1
NESINA,cutaneous adverse reactions,reactions,1
NESINA,cutaneous adverse reactions,rash urticaria and cutaneous adverse reactions,1
NESINA,cutaneous adverse reactions,,0
NESINA,cutaneous adverse reactions,and,0
NESINA,cutaneous adverse reactions,hepatic enzyme,0
NESINA,cutaneous adverse reactions,and severe,0
NESINA,Stevens-Johnson syndrome,cutaneous adverse reactions Stevens-Johnson,1
NESINA,Stevens-Johnson syndrome,Stevens-Johnson syndrome,1
NESINA,Stevens-Johnson syndrome,reactions Stevens-Johnson syndrome,1
NESINA,Stevens-Johnson syndrome,,0
NESINA,Stevens-Johnson syndrome,adverse reactions Stevens-Johnson syndrome,1
NESINA,Stevens-Johnson syndrome,urticaria and,0
NESINA,Stevens-Johnson syndrome,Stevens-Johnson syndrome,1
NESINA,Stevens-Johnson syndrome,syndrome,1
NESINA,Stevens-Johnson syndrome,severe cutaneous adverse,0
NESINA,Stevens-Johnson syndrome,reactions,0
NESINA,hepatic enzyme elevations,including StevensJohnson hepatic,1
NESINA,hepatic enzyme elevations,adverse reactions including StevensJohnson hepatic enzyme,1
NESINA,hepatic enzyme elevations,StevensJohnson hepatic,1
NESINA,hepatic enzyme elevations,and disabling arthralgia and,0
NESINA,hepatic enzyme elevations,StevensJohnson syndrome,0
NESINA,hepatic enzyme elevations,hepatic,1
NESINA,hepatic enzyme elevations,enzyme elevations,1
NESINA,fulminant hepatic failure,,0
NESINA,fulminant hepatic failure,StevensJohnson syndrome hepatic enzyme fulminant hepatic failure,1
NESINA,fulminant hepatic failure,failure,1
NESINA,fulminant hepatic failure,pancreatitis see,0
NESINA,arthralgia,disabling,0
NESINA,acute pancreatitis,elevations fulminant,0
NESINA,Acute pancreatitis,,0
NESINA,Acute pancreatitis, reactions (report,1
NESINA,acute pancreatitis,nasopharyngitis,0
NESINA,acute pancreatitis,treated with 25 mg,1
NESINA,acute pancreatitis,placebo are nasopharyngitis headache,0
NESINA,acute pancreatitis,EXCERPT Common adverse reactions reported in of,0
NESINA,acute pancreatitis,with 25 mg,1
NESINA,acute pancreatitis,with NESINA,0
NESINA,acute pancreatitis,with 25 mg and more fre,1
NESINA,acute pancreatitis,treated with 25 mg and,1
NESINA,acute pancreatitis,of patients treated,0
NESINA,Hypersensitivity,ADVERSE REACTIONS contact Takeda,0
NESINA,anaphylaxis,or FDA at FDA or wwwfdagovmedwatch Clini,0
NESINA,anaphylaxis,contact,0
NESINA,anaphylaxis,1-877-TAKED,1
NESINA,anaphylaxis,1-877-TAKED,1
NESINA,anaphylaxis,,0
NESINA,anaphylaxis,To report SUSPECTED ADVERSE REACTIONS,0
NESINA,anaphylaxis,Pharmaceuticals 1-877-TAKED,1
NESINA,anaphylaxis,1-877-TAKED,1
NESINA,angioedema,Clinical,0
NESINA,angioedema,contact Takeda Pharmaceuticals at 7,1
NESINA,angioedema,(1-877-8,1
NESINA,angioedema,,0
NESINA,angioedema,contact Takeda Pharmaceuticals at 7 (1-877-8,1
NESINA,angioedema,REACTIONS contact Takeda Pharmaceuticals at,0
NESINA,angioedema,contact Takeda Pharmaceuticals at TAKEDA,0
NESINA,angioedema,Clinical,0
NESINA,angioedema,Takeda Pharmaceuticals at 7,1
NESINA,Hepatic effects,a,1
NESINA,Hepatic effects,in the cal trials,1
NESINA,Hepatic effects,the cal trials of,1
NESINA,Hepatic effects,conditions adverse reaction rates,0
NESINA,hepatic failure,practice,0
NESINA,hepatic failure,mpared to,1
NESINA,hepatic failure,to rates,1
NESINA,hepatic failure,be directly mpared,1
NESINA,hepatic failure,clinical,0
NESINA,hepatic failure,drug cannot be directly mpared,1
NESINA,hepatic failure,adverse reaction rates observed in the,0
NESINA,fatal,ical ,1
NESINA,Hypoglycemia,to placebo and tely 2200 to,1
NESINA,Hypoglycemia,with approximately subjects,0
NESINA,Hypoglycemia,and approxima,0
NESINA,Arthralgia,history of hypertension had a history of dyslipidemia,0
NESINA,Arthralgia,5% had a h,1
NESINA,Arthralgia,these patients had a history of hypertension had a,0
NESINA,Arthralgia,of,0
NESINA,Arthralgia,5% had a h,1
NESINA,Arthralgia,had a history of 5% had a h,1
NESINA,Arthralgia,a history of 5% had a h,1
NESINA,Arthralgia,had a h,1
NESINA,Arthralgia,a h,1
NESINA,arthralgia,"farction, ",1
NESINA,acute pancreatitis,addon combination therapy,0
NESINA,acute pancreatitis,with NESINA 12.5,1
NESINA,acute pancreatitis,NESINA 12.5,1
NESINA,acute pancreatitis,with NESINA 12.5,1
NESINA,acute pancreatitis,therapy trials,0
NESINA,acute pancreatitis,were conducted in patients  with NESINA 12.5 ,1
NESINA,acute pancreatitis,,0
NESINA,acute pancreatitis,patients with,1
NESINA,acute pancreatitis,were conducted in patients with,1
NESINA,acute pancreatitis,placebocontrolled addon,0
NESINA,hypersensitivity reactions,patients treated with pioglitazone and,0
NESINA,hypersensitivity reactions,active-controlled trial,1
NESINA,hypersensitivity reactions,metformin therapy ee active-controlled,1
NESINA,anaphylaxis,in patients ed with pio,1
NESINA,anaphylaxis,,0
NESINA,anaphylaxis,,0
NESINA,anaphylaxis,were conducted in patients ed with,1
NESINA,anaphylaxis,conducted in patients ed with pio,1
NESINA,anaphylaxis,patients ed with,1
NESINA,anaphylaxis,duration were conducted in patients,0
NESINA,anaphylaxis,of weeks in duration were conducted in,0
NESINA,angioedema,of weeks in duration were conducted in patients treated with,0
NESINA,angioedema,an,1
NESINA,angioedema,in patients treated with itazone,1
NESINA,angioedema,itazone an,1
NESINA,angioedema,itazone an,1
NESINA,angioedema,combination,0
NESINA,cutaneous adverse reactions,in patients treated with,0
NESINA,cutaneous adverse reactions,duration were conducted,0
NESINA,cutaneous adverse reactions,in combination with,1
NESINA,cutaneous adverse reactions,combination with metfor,1
NESINA,cutaneous adverse reactions,of weeks in duration were conducted in patients treated with pioglitazone,0
NESINA,cutaneous adverse reactions, in combination with metfor,1
NESINA,cutaneous adverse reactions,analysis,0
NESINA,cutaneous adverse reactions,and  in combination with metfor,1
NESINA,Stevens-Johnson syndrome,with metformin and as onotherapy compared to g,1
NESINA,Stevens-Johnson syndrome,in combination with metformin and,0
NESINA,Stevens-Johnson syndrome,compared to g,1
NESINA,Stevens-Johnson syndrome,,0
NESINA,Stevens-Johnson syndrome,incidence of,0
NESINA,Stevens-Johnson syndrome,metformin and as onotherapy compared to g,1
NESINA,Stevens-Johnson syndrome,to g,1
NESINA,hepatic failure,Reported in,0
NESINA,hepatic failure,reported in of patients treated,0
NESINA,hepatic failure,in patients w,1
NESINA,hepatic failure,Reactions Reported in,0
NESINA,hepatic failure,Table Table Adverse Reactions Reported in Pat,0
NESINA,arthralgia,In a monotherapy y,1
NESINA,arthralgia,elderly patients,0
EYLEA,Endophthalmitis,intraocular pressure Thromboembolic,0
EYLEA,Endophthalmitis,Endophthalmitis,1
EYLEA,Endophthalmitis,the Endophthalmitis,1
EYLEA,Endophthalmitis,pressure Thromboembolic events,0
EYLEA,Endophthalmitis,in the,0
EYLEA,Endophthalmitis,Endophthalmitis,1
EYLEA,Endophthalmitis,the Warnings and,0
EYLEA,Endophthalmitis,Endophthalmitis,1
EYLEA,Endophthalmitis,Increased intraocular pressure Thromboembolic events EXCER,0
EYLEA,retinal detachments,labeling Endophthalmitis retinal,1
EYLEA,retinal detachments,the labeling Endophthalmitis retinal,1
EYLEA,retinal detachments,retinal detachments,1
EYLEA,retinal detachments,Increased intraocular pressure Thromboembolic events EXCERPT The most common ad,0
EYLEA,retinal detachments,Thromboembolic events,0
EYLEA,retinal detachments,labeling Endophthalmitis retinal detachments,1
EYLEA,retinal detachments,Endophthalmitis retinal,1
EYLEA,retinal detachments,retinal detachments,1
EYLEA,retinal detachments,,0
EYLEA,Increased intraocular pressure,p,0
EYLEA,Increased intraocular pressure,and retinal Increased intraocular pressure,1
EYLEA,Increased intraocular pressure,retinal Increased intraocular pressure,1
EYLEA,Increased intraocular pressure,The most common adverse reactions reported in,0
EYLEA,Increased intraocular pressure,most common adverse reactions,0
EYLEA,Increased intraocular pressure,labeling Endophthalmitis and retinal Increased intraocular pressure,1
EYLEA,Increased intraocular pressure,Increased intraocular pressure,1
EYLEA,Increased intraocular pressure,pressure,1
EYLEA,Increased intraocular pressure,intraocular pressure,1
EYLEA,Thromboembolic events,pressure,0
EYLEA,Thromboembolic events,Thromboembolic events,1
EYLEA,Thromboembolic events,detachments Increased intraocular Thromboembolic events,1
EYLEA,conjunctival hemorrhage,in patients receiving EYLEA conjunctival hemorrhage,1
EYLEA,conjunctival hemorrhage,hemorrhage,1
EYLEA,conjunctival hemorrhage,EYLEA conjunctival hemorrhage,1
EYLEA,conjunctival hemorrhage,receiving EYLEA,0
EYLEA,conjunctival hemorrhage,hemorrhage,1
EYLEA,conjunctival hemorrhage,EYLEA conjunctival,1
EYLEA,eye pain,receiving EYLEA were conjunctival eye pain,1
EYLEA,eye pain,were conjunctival eye,1
EYLEA,eye pain,eye,1
EYLEA,eye pain,conjunctival eye,1
EYLEA,eye pain,eye pain,1
EYLEA,eye pain,eye pain,1
EYLEA,eye pain,vitreous,0
EYLEA,cataract,cataract,1
EYLEA,cataract,report,0
EYLEA,cataract,cataract,1
EYLEA,cataract,cataract,1
EYLEA,cataract,hemorrhage eye cataract,1
EYLEA,cataract,cataract,1
EYLEA,cataract,report,0
EYLEA,cataract,in patients receiving,0
EYLEA,vitreous floaters,conjunctival hemorrhage eye pain vitreous floaters,1
EYLEA,vitreous floaters,,0
EYLEA,vitreous floaters,pain vitreous floaters,1
EYLEA,intraocular pressure increased,eye pain cataract vitreous intraocular pressure increased,1
EYLEA,intraocular pressure increased,REACTIONS contact,0
EYLEA,intraocular pressure increased,intraocular,1
EYLEA,intraocular pressure increased,floaters,0
EYLEA,vitreous detachment,intraocular pressure increased vitreous,1
EYLEA,endophthalmitis,endophthalmitis,1
EYLEA,endophthalmitis,with EYLEA endophthalmitis,1
EYLEA,endophthalmitis,endophthalmitis,1
EYLEA,endophthalmitis,endophthalmitis,1
EYLEA,endophthalmitis,to the injection procedure have occurred in of intravitreal injections with,0
EYLEA,endophthalmitis,endophthalmitis,1
EYLEA,endophthalmitis,endophthalmitis,1
EYLEA,endophthalmitis,have occurred in of intravitreal injections with,0
EYLEA,endophthalmitis,reactions reported in patients receiving,0
EYLEA,endophthalmitis,EYLEA endophthalmitis,1
EYLEA,retinal detachment,were,0
EYLEA,retinal detachment,,0
EYLEA,retinal detachment,common adverse reactions reported in patients,0
EYLEA,retinal detachment,,0
EYLEA,retinal detachment,,0
EYLEA,conjunctival hemorrhage,receiving EYLEA conjunctival,1
EYLEA,conjunctival hemorrhage,,0
EYLEA,conjunctival hemorrhage,,0
EYLEA,conjunctival hemorrhage,conjunctival hemorrhage,1
EYLEA,conjunctival hemorrhage,,0
EYLEA,conjunctival hemorrhage,intraocular pressure increased,0
EYLEA,conjunctival hemorrhage,hemorrhage,1
EYLEA,eye pain,eye pain,1
EYLEA,cataract,cataract,1
EYLEA,cataract,hemorrhage eye cataract,1
EYLEA,cataract,cataract,1
EYLEA,cataract,eye cataract,1
EYLEA,cataract,hemorrhage eye cataract,1
EYLEA,cataract,conjunctival hemorrhage eye cataract,1
EYLEA,cataract,cataract,1
EYLEA,cataract,conjunctival hemorrhage eye cataract,1
EYLEA,cataract,and vitreous detachment Neovascular W,0
EYLEA,vitreous floaters,Neovascular Wet AgeRelated Mac,0
EYLEA,vitreous floaters,EYLEA were conjunctival hemorrhage eye pain,0
EYLEA,vitreous floaters,vitreous detachment,0
EYLEA,vitreous floaters,cataract,0
EYLEA,vitreous floaters,floaters,1
EYLEA,vitreous floaters,vitreous floaters,1
EYLEA,vitreous floaters,pain cataract,0
EYLEA,vitreous floaters,intraocular pressure increased and vitreous detachment Neovascular,0
EYLEA,vitreous floaters,reported,0
EYLEA,intraocular pressure increased,,0
EYLEA,intraocular pressure increased,eye pain cataract vitreous intraocular pressure increased,1
EYLEA,intraocular pressure increased,,0
EYLEA,intraocular pressure increased,Degeneration AMD Th,0
EYLEA,vitreous detachment,eye pain,0
EYLEA,vitreous detachment,,0
EYLEA,vitreous detachment,detachment,1
EYLEA,vitreous detachment,pressure increased vitreous,1
EYLEA,Conjunctival hemorrhage,Conjunctival hemorrhage,1
EYLEA,Conjunctival hemorrhage,Control Conjunctival hemorrhage,1
EYLEA,Conjunctival hemorrhage,Conjunctival,1
EYLEA,Conjunctival hemorrhage,Active,0
EYLEA,Conjunctival hemorrhage,,0
EYLEA,Eye pain,,0
EYLEA,Eye pain,,0
EYLEA,Eye pain,Eye pain,1
EYLEA,Eye pain,pain,1
EYLEA,Eye pain,Eye,1
EYLEA,Vitreous detachment,,0
EYLEA,Vitreous detachment,Vitreous detachment Vitreous,1
EYLEA,Vitreous floaters,detachment Vitreous floaters Intraocu,1
EYLEA,Vitreous floaters,detachment Vitreous floaters Intraocu,1
EYLEA,Vitreous floaters,,0
EYLEA,Vitreous floaters,detachment,0
EYLEA,Intraocular pressure increased,floaters,0
EYLEA,Intraocular pressure increased,,0
EYLEA,Intraocular pressure increased,floaters,0
EYLEA,Intraocular pressure increased,floaters Intraocular pressure increased Ocular hyperemia,1
EYLEA,Intraocular pressure increased,floaters Intraocular,1
EYLEA,Intraocular pressure increased,floaters Intraocular pressure increased Ocular hyperemia,1
EYLEA,Intraocular pressure increased,floaters,0
EYLEA,Intraocular pressure increased,Intraocular pressure increased Ocular,1
EYLEA,Intraocular pressure increased,floaters Intraocular pressure increased,1
EYLEA,Ocular hyperemia,pressure Ocular hyperemia Corneal,1
EYLEA,Ocular hyperemia,Ocular hyperemia Corneal,1
EYLEA,Ocular hyperemia,,0
EYLEA,Ocular hyperemia,,0
EYLEA,Ocular hyperemia,ar pressure Ocular hyperemia Corneal,1
EYLEA,Ocular hyperemia,pressure,0
EYLEA,Corneal epithelium defect,defect Detachment of th,1
EYLEA,Corneal epithelium defect,Detachment of,0
EYLEA,Corneal epithelium defect,peremia Corneal epithelium defect Detachment of,1
EYLEA,Corneal epithelium defect,,0
EYLEA,Corneal epithelium defect,peremia,0
EYLEA,Corneal epithelium defect,peremia,0
EYLEA,Detachment of the retinal pigment epithelium,Detachment of the retinal,1
EYLEA,Detachment of the retinal pigment epithelium,,0
EYLEA,Injection site pain,Injection site pain Foreign bo,1
EYLEA,Injection site pain,pain Foreign bo,1
EYLEA,Injection site pain,,0
EYLEA,Foreign body sensation in eyes,Foreign body,1
EYLEA,Foreign body sensation in eyes,pain,0
EYLEA,Foreign body sensation in eyes,Foreign body sensation in eyes Lacrimation increased,1
EYLEA,Foreign body sensation in eyes,Lacrimation increased,0
EYLEA,Foreign body sensation in eyes,,0
EYLEA,Foreign body sensation in eyes,body sensation in eyes Lacrimation increased,1
EYLEA,Foreign body sensation in eyes,site Foreign body sensation in eyes Lacrimation increased,1
EYLEA,Lacrimation increased,Lacrimation increased Vision blurr,1
EYLEA,Lacrimation increased,eyes,0
EYLEA,Lacrimation increased,sensation in,0
EYLEA,Lacrimation increased,in Lacrimation,1
EYLEA,Lacrimation increased,,0
EYLEA,Lacrimation increased,,0
EYLEA,Lacrimation increased,Vision blurr,0
EYLEA,Vision blurred,,0
EYLEA,Vision blurred,on Vision,1
EYLEA,Vision blurred,on Vision,1
EYLEA,Intraocular inflammation,inflammation,1
EYLEA,Intraocular inflammation,urred Intraocular inflammation,1
EYLEA,Retinal pigment epithelium tear,Retinal,1
EYLEA,Retinal pigment epithelium tear,,0
EYLEA,Injection site hemorrhage,hemorrhage,1
EYLEA,Injection site hemorrhage,Eyelid,0
EYLEA,Injection site hemorrhage,Injection,1
EYLEA,Injection site hemorrhage,Injection site hemorrhage,1
EYLEA,Injection site hemorrhage,epithelium Injection site hemorrhage,1
EYLEA,Injection site hemorrhage,,0
EYLEA,Injection site hemorrhage,igment epithelium Injection site hemorrhage,1
EYLEA,Injection site hemorrhage,,0
EYLEA,Injection site hemorrhage,tear,0
EYLEA,Eyelid edema,,0
EYLEA,Eyelid edema,,0
EYLEA,Eyelid edema,Eyelid edema Cor,1
EYLEA,Eyelid edema,Eyelid edema Cor,1
EYLEA,Eyelid edema,site Eyelid,1
EYLEA,Eyelid edema,site Eyelid,1
EYLEA,Eyelid edema,,0
EYLEA,hypersensitivity,EYLEA hypersensitivity,1
EYLEA,retinal detachment,retinal detachment,1
EYLEA,retinal tear,Occlusion,0
EYLEA,retinal tear,retinal tear,1
EYLEA,retinal tear,were,0
EYLEA,retinal tear,retinal retinal,1
EYLEA,retinal tear,,0
EYLEA,endophthalmitis,endophthalmitis,1
EYLEA,endophthalmitis,described,0
EYLEA,endophthalmitis,endophthalmitis,1
EYLEA,endophthalmitis,with EYLEA were,0
EYLEA,endophthalmitis,endophthalmitis,1
EYLEA,endophthalmitis,Retinal,0
EYLEA,endophthalmitis,retinal tear endophthalmitis,1
EYLEA,endophthalmitis,endophthalmitis,1
EYLEA,endophthalmitis,with EYLEA were hypersensitivity retinal detachment,0
EYLEA,Eye pain,EYLEAN,0
EYLEA,Eye pain,,0
EYLEA,Eye pain,,0
EYLEA,Eye pain,ControlN,0
EYLEA,Eye pain,,0
EYLEA,Eye pain,ControlN EYLEAN ControlN,0
EYLEA,Intraocular pressure increased,hemorrhage,0
EYLEA,Intraocular pressure increased,hemorrhage Intraocular pressure,1
EYLEA,Intraocular pressure increased,Corneal,0
EYLEA,Corneal epithelium defect,Corneal epithelium,1
EYLEA,Vitreous floaters,,0
EYLEA,Vitreous floaters,,0
EYLEA,Vitreous floaters,Vitreous,1
EYLEA,Vitreous floaters,elium Vitreous floaters Ocul,1
EYLEA,Vitreous floaters,elium Vitreous,1
EYLEA,Ocular hyperemia,ters,0
EYLEA,Ocular hyperemia,ters Ocular hyperemia For,1
EYLEA,Ocular hyperemia,,0
EYLEA,Ocular hyperemia,ters Ocular hyperemia For,1
EYLEA,Foreign body sensation in eyes,mia Foreign body sensation,1
EYLEA,Foreign body sensation in eyes,mia Foreign body sensation,1
EYLEA,Foreign body sensation in eyes,sensation in eyes Vitreous detachme,1
EYLEA,Foreign body sensation in eyes,body sensation in eyes,1
EYLEA,Foreign body sensation in eyes,mia Foreign body sensation in eyes,1
EYLEA,Foreign body sensation in eyes,mia,0
EYLEA,Foreign body sensation in eyes,,0
EYLEA,Foreign body sensation in eyes,,0
EYLEA,Vitreous detachment,Vitreous detachment Lacrim,1
EYLEA,Vitreous detachment,,0
EYLEA,Vitreous detachment,Vitreous detachment Lacrim,1
EYLEA,Vitreous detachment,sensation in Vitreous,1
EYLEA,Lacrimation increased,chment Lacrimation increased Injectio,1
EYLEA,Lacrimation increased,chment Lacrimation increased Injectio,1
EYLEA,Lacrimation increased,increased Injectio,1
EYLEA,Lacrimation increased,chment Lacrimation,1
EYLEA,Lacrimation increased,chment,0
EYLEA,Lacrimation increased,chment,0
EYLEA,Lacrimation increased,,0
EYLEA,Lacrimation increased,chment Lacrimation increased Injectio,1
EYLEA,Lacrimation increased,chment Lacrimation increased Injectio,1
EYLEA,Lacrimation increased,chment,0
EYLEA,Injection site pain,,0
EYLEA,Injection site pain,ncreased Injection site pain Vision,1
EYLEA,Injection site pain,ncreased,0
EYLEA,Injection site pain,,0
EYLEA,Injection site pain,Injection site pain Vision,1
EYLEA,Injection site pain,Injection site pain Vision,1
EYLEA,Injection site pain,Vision,0
EYLEA,Injection site pain,ncreased Injection site pain Vision,1
EYLEA,Injection site pain,Vision,0
EYLEA,Injection site pain,ncreased Injection site,1
EYLEA,Vision blurred,,0
EYLEA,Vision blurred,pain,0
EYLEA,Vision blurred,e Vision,1
EYLEA,Cataract,Cataract,1
EYLEA,Cataract,nflammation,0
EYLEA,Cataract,,0
EYLEA,Cataract,nflammation,0
EYLEA,Eyelid edema,Eyelid,1
EYLEA,Eyelid edema,Eyelid,1
EYLEA,Eyelid edema,Eyelid edema,1
EYLEA,Eyelid edema,edema,1
EYLEA,Eyelid edema,Eyelid,1
EYLEA,Eyelid edema,Eyelid edema,1
EYLEA,Eyelid edema,Eyelid edema,1
EYLEA,Eyelid edema,Eyelid,1
EYLEA,Eyelid edema,Eyelid edema,1
EYLEA,Eyelid edema,Eyelid edema,1
EYLEA,corneal edema,Edema DME Th,0
EYLEA,corneal edema,the CRVO studies corneal,1
EYLEA,corneal edema,and,0
EYLEA,corneal edema,adverse reactions reported in of the patients treated with EYLEA in the,0
EYLEA,corneal edema,and endophthalmitis Diabetic Macular,0
EYLEA,corneal edema,studies corneal edema,1
EYLEA,corneal edema,reported in of the patients treated with EYLEA,0
EYLEA,corneal edema,edema,1
EYLEA,retinal tear,tear,1
EYLEA,retinal tear,hypersensitivity and endophthalmitis Diabetic Macular Edema DME,0
EYLEA,retinal tear,The,0
EYLEA,retinal tear,retinal tear,1
EYLEA,retinal tear,retinal,1
EYLEA,retinal tear,tear,1
EYLEA,retinal tear,were corneal retinal tear,1
EYLEA,hypersensitivity,hypersensitivity,1
EYLEA,hypersensitivity,below,0
EYLEA,hypersensitivity,,0
EYLEA,endophthalmitis,tear hypersensitivity endophthalmitis,1
EYLEA,endophthalmitis,and,0
EYLEA,endophthalmitis,,0
EYLEA,endophthalmitis,endophthalmitis,1
EYLEA,endophthalmitis,endophthalmitis,1
EYLEA,endophthalmitis,data described,0
EYLEA,endophthalmitis,CRVO studies were corneal edema retinal,0
EYLEA,Conjunctival hemorrhage,EYLEAN,0
EYLEA,Conjunctival hemorrhage,,0
EYLEA,Conjunctival hemorrhage,Eye pain,0
EYLEA,Conjunctival hemorrhage,EYLEAN ControlN EYLEAN Conjunctival,1
EYLEA,Conjunctival hemorrhage,ControlN EYLEAN Conjunctival,1
EYLEA,Conjunctival hemorrhage,ControlN EYLEAN Conjunctival hemorrhage,1
EYLEA,Eye pain,hemorrhage Eye pain,1
EYLEA,Eye pain,hemorrhage Eye,1
EYLEA,Eye pain,hemorrhage Eye pain,1
EYLEA,Eye pain,hemorrhage Eye pain,1
EYLEA,Eye pain,Eye pain,1
EYLEA,Cataract,Cataract,1
EYLEA,Cataract,,0
EYLEA,Vitreous floaters,,0
EYLEA,Vitreous floaters,,0
EYLEA,Vitreous floaters,floaters Corn,1
EYLEA,Vitreous floaters,,0
EYLEA,Vitreous floaters,,0
EYLEA,Vitreous floaters,Vitreous floaters Corn,1
EYLEA,Vitreous floaters,Vitreous,1
EYLEA,Vitreous floaters,Vitreous,1
EYLEA,Vitreous floaters,,0
EYLEA,Vitreous floaters,Vitreous floaters Corn,1
EYLEA,Corneal epithelium defect,,0
EYLEA,Corneal epithelium defect,ters Corneal epithelium defect Intraocular,1
EYLEA,Corneal epithelium defect,Corneal epithelium defect Intraocular,1
EYLEA,Corneal epithelium defect,ters Corneal epithelium defect Intraocular,1
EYLEA,Corneal epithelium defect,ters Corneal epithelium,1
EYLEA,Corneal epithelium defect,ters,0
EYLEA,Corneal epithelium defect,ters Corneal,1
EYLEA,Corneal epithelium defect,ters Corneal epithelium defect Intraocular,1
EYLEA,Corneal epithelium defect,ters Corneal epithelium,1
EYLEA,Intraocular pressure increased,,0
EYLEA,Intraocular pressure increased,,0
EYLEA,Intraocular pressure increased,Intraocular,1
EYLEA,Intraocular pressure increased,elium Intraocular,1
EYLEA,Intraocular pressure increased,elium Intraocular,1
EYLEA,Intraocular pressure increased,defect,0
EYLEA,Vitreous detachment,Vitreous detachment Foreig,1
EYLEA,Foreign body sensation in eyes,in eyes Lacrimation incre,1
EYLEA,Foreign body sensation in eyes,chment Foreign body sensation in eyes Lacrimation,1
EYLEA,Foreign body sensation in eyes,chment Foreign body sensation in eyes Lacrimation incre,1
EYLEA,Foreign body sensation in eyes,chment,0
EYLEA,Foreign body sensation in eyes,Lacrimation incre,0
EYLEA,Foreign body sensation in eyes,chment Foreign body sensation in,1
EYLEA,Foreign body sensation in eyes,sensation in eyes Lacrimation incre,1
EYLEA,Foreign body sensation in eyes,,0
EYLEA,Foreign body sensation in eyes,chment Foreign,1
EYLEA,Lacrimation increased,,0
EYLEA,Lacrimation increased,sensation in Lacrimation increased Vision b,1
EYLEA,Lacrimation increased,Lacrimation,1
EYLEA,Lacrimation increased,Lacrimation increased Vision b,1
EYLEA,Lacrimation increased,increased Vision b,1
EYLEA,Lacrimation increased,in eyes,0
EYLEA,Lacrimation increased,sensation in Lacrimation increased Vision b,1
EYLEA,Lacrimation increased,,0
EYLEA,Lacrimation increased,Vision b,0
EYLEA,Lacrimation increased,increased Vision b,1
EYLEA,Vision blurred,Vision blurred I,1
EYLEA,Vision blurred,ncreased,0
EYLEA,Intraocular inflammation,,0
EYLEA,Intraocular inflammation,d,0
EYLEA,Intraocular inflammation,,0
EYLEA,Intraocular inflammation,d Intraocular,1
EYLEA,Intraocular inflammation,,0
EYLEA,Intraocular inflammation,d Intraocular,1
EYLEA,Intraocular inflammation,d Intraocular inflammation Injection s,1
EYLEA,Intraocular inflammation,d,0
EYLEA,Injection site pain,site pain Eyelid,1
EYLEA,Injection site pain,nflammation,0
EYLEA,Injection site pain,nflammation,0
EYLEA,Eyelid edema,,0
EYLEA,Eyelid edema,e Eyelid edema,1
EYLEA,Eyelid edema,,0
EYLEA,hypersensitivity,edema and injection,0
EYLEA,hypersensitivity,the patients treated with EYLEA were,0
EYLEA,hypersensitivity,,0
EYLEA,hypersensitivity,detachment retinal,0
EYLEA,hypersensitivity,of the patients treated,0
EYLEA,hypersensitivity,hypersensitivity retinal,1
EYLEA,hypersensitivity,,0
EYLEA,hypersensitivity,with EYLEA hypersensitivity retinal,1
EYLEA,retinal detachment,As,0
EYLEA,retinal detachment,EYLEA were hypersensitivity,0
EYLEA,retinal detachment,were retinal detachment retinal,1
EYLEA,retinal detachment,,0
EYLEA,retinal detachment,EYLEA were retinal,1
EYLEA,retinal detachment,with EYLEA were retinal detachment retinal,1
EYLEA,retinal detachment,EYLEA were retinal,1
EYLEA,retinal tear,hypersensitivity retinal retinal tear corneal,1
EYLEA,retinal tear,injection site hemorrhage Immunogenicity As,0
EYLEA,retinal tear,were hypersensitivity retinal retinal,1
EYLEA,retinal tear,retinal tear corneal,1
EYLEA,retinal tear,and injection site hemorrhage Immunogenicity As,0
EYLEA,corneal edema,retinal detachment retinal corneal edema and,1
EYLEA,corneal edema,therapeutic proteins there,0
EYLEA,corneal edema,hypersensitivity retinal detachment retinal corneal,1
EYLEA,corneal edema,with EYLEA were hypersensitivity retinal,0
EYLEA,injection site hemorrhage,were hypersensitivity retinal detachment,0
EYLEA,injection site hemorrhage,As with,0
EYLEA,injection site hemorrhage,retinal tear corneal edema injection site hemorrhage Immunogenicity,1
EYLEA,injection site hemorrhage,tear corneal edema injection site hemorrhage Immunogenicity,1
EYLEA,injection site hemorrhage,treated with EYLEA,0
EYLEA,Endophthalmitis,eactions,1
EYLEA,Endophthalmitis,eactions,1
EYLEA,Endophthalmitis,di,1
EYLEA,Endophthalmitis,,0
EYLEA,Endophthalmitis,Warnings and Precautions section,0
EYLEA,Endophthalmitis,,0
EYLEA,Endophthalmitis,,0
EYLEA,Endophthalmitis,,0
EYLEA,retinal detachments,,0
EYLEA,retinal detachments,ed in greater detai l in the Warnings and,1
EYLEA,retinal detachments,ed in greater,1
EYLEA,Increases in intraocular pressure,EXCERPT The,0
EYLEA,Increases in intraocular pressure,,0
EYLEA,Increases in intraocular pressure,EXCERPT The most common rse reactions (>=5%) reported in ,1
EYLEA,Increases in intraocular pressure,most common rse reactions (>=5%) reported in ,1
EYLEA,Increases in intraocular pressure,in,1
EYLEA,Increases in intraocular pressure,rse reactions (>=5%) reported in ,1
EYLEA,Increases in intraocular pressure,rse reactions,1
EYLEA,arterial thromboembolic events,"pain cataract vitreous floaters r pressure increased, and vitr",1
EYLEA,arterial thromboembolic events,EYLEA were conjunctival,0
EYLEA,arterial thromboembolic events,"pain cataract vitreous floaters r pressure increased, and vitr",1
EYLEA,arterial thromboembolic events,"r pressure increased, and vitr",1
EYLEA,arterial thromboembolic events,"pressure increased, and vitr",1
EYLEA,retinal detachments,FDA or wwwfdagovmedwatch Clinical,0
EYLEA,retinal detachments,clinical trials are,1
EYLEA,retinal detachments,Experience clinical trials,1
EYLEA,retinal detachments,rates observed in the clinical trials,0
EYLEA,retinal detachments,Clinical Trials Experience clinical,1
EYLEA,retinal detachments,clinical trials,1
EYLEA,retinal detachments,conducted under widely varying conditions adverse reaction rates observed in the clinical trials,0
EYLEA,Acute increases in intraocular pressure,constituted the safety population in seven phase studies Among,0
EYLEA,Acute increases in intraocular pressure,those patients were d with the recommended,1
EYLEA,Acute increases in intraocular pressure,seven phase studies Among those patients,0
EYLEA,Acute increases in intraocular pressure,the recommended dose of 2 mg. Se,1
EYLEA,Acute increases in intraocular pressure,d with the recommended dose of 2 mg. Se,1
EYLEA,Acute increases in intraocular pressure,were d with the recommended dose of 2 mg. Se,1
EYLEA,Acute increases in intraocular pressure,injection procedure have occurred in of,0
EYLEA,Sustained increases in intraocular pressure,including endophthalmitis and retinal d,1
EYLEA,Sustained increases in intraocular pressure,,0
EYLEA,Sustained increases in intraocular pressure,including endophthalmitis and retinal d,1
EYLEA,Sustained increases in intraocular pressure,intravitreal injections,0
EYLEA,Sustained increases in intraocular pressure,most common adverse reactions,0
EYLEA,Sustained increases in intraocular pressure,with LEA including,1
EYLEA,Sustained increases in intraocular pressure,with LEA including endophthalmitis and retinal d,1
EYLEA,Sustained increases in intraocular pressure,,0
EYLEA,arterial thromboembolic events,treated with the mg dose,0
EYLEA,arterial thromboembolic events, in 1824 patients with wet AMD,1
EYLEA,arterial thromboembolic events, in 1824 patients with wet AMD,1
EYLEA,arterial thromboembolic events,below reflect exposure to in 1824 patients with wet,1
EYLEA,ATEs,with wet incl,1
EYLEA,ATEs,incl,1
EYLEA,ATEs,data described below reflect,0
EYLEA,ATEs,incl,1
EYLEA,ATEs,,0
EYLEA,ATEs,incl,1
EYLEA,ATEs,incl,1
EYLEA,ATEs,incl,1
EYLEA,ATEs,incl,1
EYLEA,ATEs,incl,1
EYLEA,thromboembolic events,Most Common,0
EYLEA,thromboembolic events,for months seeClinical Studies Table Most Common Adverse,0
EYLEA,thromboembolic events,Most Common Adverse %) in,1
EYLEA,thromboembolic events,Reactions EYLEAN Active Control,0
EYLEA,thromboembolic events,%) in Wet AMD Studies,1
EYLEA,thromboembolic events,months seeClinical Studies Table,0
EYLEA,thromboembolic events,Most Common,0
EYLEA,thromboembolic events,detachment,0
EYLEA,thromboembolic events,                     ,1
EYLEA,thromboembolic events,                     ,1
EYLEA,thromboembolic events,,0
EYLEA,thromboembolic events,Vitreous                      ,1
EYLEA,thromboembolic events,detachment,0
TECFIDERA,Anaphylaxis,and Angioedema see Warnings and,0
TECFIDERA,Anaphylaxis,,0
TECFIDERA,Anaphylaxis,Anaphylaxis,1
TECFIDERA,Anaphylaxis,following important adverse reactions are described elsewhere,0
TECFIDERA,Anaphylaxis,leukoencephal,0
TECFIDERA,Anaphylaxis,,0
TECFIDERA,Anaphylaxis,,0
TECFIDERA,Anaphylaxis,Anaphylaxis,1
TECFIDERA,Anaphylaxis,are described,0
TECFIDERA,Angioedema,Angioedema,1
TECFIDERA,Angioedema,and,0
TECFIDERA,Progressive multifocal leukoencephalopathy,see Warnings and Progressive multifocal leukoencephalopathy,1
TECFIDERA,Progressive multifocal leukoencephalopathy,in labeling Anaphylaxis and Angioedema see Warnings and Precautions,0
TECFIDERA,Progressive multifocal leukoencephalopathy,,0
TECFIDERA,Progressive multifocal leukoencephalopathy,Angioedema see Warnings and Progressive multifocal leukoencephalopathy,1
TECFIDERA,Progressive multifocal leukoencephalopathy,Lymphopenia see,0
TECFIDERA,Lymphopenia,Lymphopenia,1
TECFIDERA,Lymphopenia,see Warnings and Precautions Flushing see,0
TECFIDERA,Lymphopenia,Precautions,0
TECFIDERA,Lymphopenia,Precautions,0
TECFIDERA,Lymphopenia,,0
TECFIDERA,Lymphopenia,multifocal leukoencephalopathy see Warnings and,0
TECFIDERA,Lymphopenia,Warnings,0
TECFIDERA,Flushing,Flushing,1
TECFIDERA,Flushing,Lymphopenia see Warnings and Flushing,1
TECFIDERA,Flushing,,0
TECFIDERA,Flushing,Flushing,1
TECFIDERA,Flushing,,0
TECFIDERA,Flushing,Flushing,1
TECFIDERA,Flushing,Flushing,1
TECFIDERA,Flushing,Flushing,1
TECFIDERA,flushing,,0
TECFIDERA,flushing,ADVERSE REACTIONS,0
TECFIDERA,flushing,flushing,1
TECFIDERA,flushing,flushing,1
TECFIDERA,flushing,,0
TECFIDERA,abdominal pain,were abdominal,1
TECFIDERA,abdominal pain,incidence and placebo were,0
TECFIDERA,abdominal pain,abdominal pain,1
TECFIDERA,abdominal pain,were abdominal pain,1
TECFIDERA,diarrhea,To report SUSPECTED ADVERSE REACTIONS,0
TECFIDERA,diarrhea,flushing abdominal pain,0
TECFIDERA,diarrhea,diarrhea,1
TECFIDERA,nausea,diarrhea nausea,1
TECFIDERA,flushing,flushing,1
TECFIDERA,flushing,flushing,1
TECFIDERA,flushing,flushing,1
TECFIDERA,flushing,flushing,1
TECFIDERA,flushing,flushing,1
TECFIDERA,flushing,flushing,1
TECFIDERA,abdominal pain,abdominal pain,1
TECFIDERA,abdominal pain,were abdominal,1
TECFIDERA,abdominal pain,placebo,0
TECFIDERA,abdominal pain,TECFIDERA were abdominal pain,1
TECFIDERA,abdominal pain,TECFIDERA were,0
TECFIDERA,abdominal pain,for TECFIDERA were abdominal pain,1
TECFIDERA,abdominal pain,nausea Adverse Reactions in PlaceboControlled Trials In,0
TECFIDERA,nausea,and more than placebo for TECFIDERA were flushing abdominal pain diarrhea,0
TECFIDERA,nausea,the two wellcontrolled studies de,0
TECFIDERA,Flushing,,0
TECFIDERA,Flushing,Flushing A,1
TECFIDERA,Flushing,,0
TECFIDERA,Abdominal pain,Diarrhe,0
TECFIDERA,Abdominal pain,pain Diarrhe,1
TECFIDERA,Abdominal pain,g,0
TECFIDERA,Abdominal pain,,0
TECFIDERA,Abdominal pain,,0
TECFIDERA,Abdominal pain,,0
TECFIDERA,Abdominal pain,Abdominal pain Diarrhe,1
TECFIDERA,Abdominal pain,pain Diarrhe,1
TECFIDERA,Abdominal pain,g,0
TECFIDERA,Diarrhea,Diarrhea N,1
TECFIDERA,Diarrhea,,0
TECFIDERA,Diarrhea,pain,0
TECFIDERA,Diarrhea,N,0
TECFIDERA,Diarrhea,,0
TECFIDERA,Nausea,,0
TECFIDERA,Nausea,a Nausea,1
TECFIDERA,Nausea,Nausea,1
TECFIDERA,Nausea,Nausea,1
TECFIDERA,Nausea,a,0
TECFIDERA,Nausea,,0
TECFIDERA,Nausea,Nausea,1
TECFIDERA,Vomiting,Vomiting P,1
TECFIDERA,Vomiting,,0
TECFIDERA,Vomiting,,0
TECFIDERA,Vomiting,,0
TECFIDERA,Pruritus,g Pruritus R,1
TECFIDERA,Pruritus,,0
TECFIDERA,Pruritus,Pruritus R,1
TECFIDERA,Pruritus,g Pruritus R,1
TECFIDERA,Pruritus,g Pruritus R,1
TECFIDERA,Pruritus,g Pruritus R,1
TECFIDERA,Pruritus,R,0
TECFIDERA,Pruritus,g Pruritus R,1
TECFIDERA,Pruritus,R,0
TECFIDERA,Rash,,0
TECFIDERA,Rash,Rash,1
TECFIDERA,Rash,s,0
TECFIDERA,Rash,s Rash,1
TECFIDERA,Rash,Rash,1
TECFIDERA,Rash,,0
TECFIDERA,Albumin urine present,,0
TECFIDERA,Albumin urine present,Albumin urine present Erythema,1
TECFIDERA,Albumin urine present,urine present Erythema,1
TECFIDERA,Albumin urine present,Erythema,0
TECFIDERA,Albumin urine present,,0
TECFIDERA,Erythema,D,0
TECFIDERA,Erythema,Erythema D,1
TECFIDERA,Erythema,Erythema D,1
TECFIDERA,Dyspepsia,a,0
TECFIDERA,Aspartate aminotransferase increased,Lymphopenia,0
TECFIDERA,Aspartate aminotransferase increased,Aspartate aminotransferase increased Lymphopenia,1
TECFIDERA,Aspartate aminotransferase increased,ia,0
TECFIDERA,Aspartate aminotransferase increased,,0
TECFIDERA,Aspartate aminotransferase increased,ia,0
TECFIDERA,Aspartate aminotransferase increased,increased Lymphopenia,1
TECFIDERA,Aspartate aminotransferase increased,ia Aspartate aminotransferase increased Lymphopenia,1
TECFIDERA,Aspartate aminotransferase increased,ia,0
TECFIDERA,Aspartate aminotransferase increased,ia Aspartate aminotransferase increased Lymphopenia,1
TECFIDERA,Aspartate aminotransferase increased,Lymphopenia,0
TECFIDERA,Lymphopenia,Lymphopenia,1
TECFIDERA,Lymphopenia,Lymphopenia,1
TECFIDERA,Lymphopenia,Lymphopenia,1
TECFIDERA,Lymphopenia,increased,0
TECFIDERA,Lymphopenia,,0
TECFIDERA,Lymphopenia,Lymphopenia,1
TECFIDERA,Lymphopenia,aminotransferase increased,0
TECFIDERA,Lymphopenia,,0
TECFIDERA,Lymphopenia,,0
TECFIDERA,Lymphopenia,,0
TECFIDERA,GI events,dyspepsia The incidence,0
TECFIDERA,GI events,diarrhea,0
TECFIDERA,GI events,Gastrointestinal TECFIDERA GI events,1
TECFIDERA,GI events,,0
TECFIDERA,GI events,GI events,1
TECFIDERA,GI events,events,1
TECFIDERA,GI events,GI events,1
TECFIDERA,nausea,,0
TECFIDERA,nausea,nausea,1
TECFIDERA,nausea,,0
TECFIDERA,nausea,TECFIDERA caused GI events eg,0
TECFIDERA,nausea,eg,0
TECFIDERA,nausea,GI events nausea,1
TECFIDERA,vomiting,vomiting,1
TECFIDERA,vomiting,eg nausea,0
TECFIDERA,vomiting,vomiting,1
TECFIDERA,vomiting,vomiting,1
TECFIDERA,vomiting,vomiting,1
TECFIDERA,vomiting,vomiting,1
TECFIDERA,vomiting,vomiting,1
TECFIDERA,diarrhea,diarrhea,1
TECFIDERA,diarrhea,GI events eg,0
TECFIDERA,diarrhea,GI events eg nausea diarrhea,1
TECFIDERA,abdominal pain,abdominal pain,1
TECFIDERA,dyspepsia,vomiting diarrhea abdominal pain dyspepsia,1
TECFIDERA,GI events,early in the course of treatment primarily in,0
TECFIDERA,GI events,nausea vomiting diarrhea abdominal pain and dyspepsia The,0
TECFIDERA,GI events,dyspepsia The incidence GI,1
TECFIDERA,GI events,events,1
TECFIDERA,GI events,The incidence GI,1
TECFIDERA,gastrointestinal events,discontinued due,0
TECFIDERA,gastrointestinal events,TECFIDERA Hepatic,0
TECFIDERA,gastrointestinal events,in patients,0
TECFIDERA,gastrointestinal events,patients discontinued due gastrointestinal,1
TECFIDERA,gastrointestinal events,TECFIDERA,0
TECFIDERA,gastrointestinal events,serious,0
TECFIDERA,GI events,serious,0
TECFIDERA,GI events,The incidence of GI,1
TECFIDERA,GI events,patients discontinued due,0
TECFIDERA,GI events,events,1
TECFIDERA,GI events,,0
TECFIDERA,GI events,GI events,1
TECFIDERA,GI events,GI,1
TECFIDERA,GI events,of GI,1
TECFIDERA,GI events,due to,0
TECFIDERA,GI events,of placebo patients discontinued due to gastrointestinal events The incidence of serious,0
TECFIDERA,elevations of hepatic transaminases,increased incidence elevations of hepatic transaminases,1
TECFIDERA,elevations of hepatic transaminases,transaminases,1
TECFIDERA,elevations of hepatic transaminases,treatment,0
TECFIDERA,elevations of hepatic transaminases,seen primarily during the first six months of treatment and,0
TECFIDERA,elevations of hepatic transaminases,,0
TECFIDERA,elevations of hepatic transaminases,with TECFIDERA Hepatic,0
TECFIDERA,elevations of hepatic transaminases,in patients treated with TECFIDERA was seen primarily during the first six,0
TECFIDERA,elevations of hepatic transaminases,incidence,0
TECFIDERA,elevations of hepatic transaminases,An increased incidence elevations of hepatic transaminases,1
TECFIDERA,elevations of hepatic transaminases,An increased incidence elevations,1
TECFIDERA,Elevations of alanine aminotransferase,Elevations of alanine aminotransferase,1
TECFIDERA,Elevations of alanine aminotransferase,Elevations of alanine aminotransferase,1
TECFIDERA,Elevations of alanine aminotransferase,alanine aminotransferase,1
TECFIDERA,Elevations of alanine aminotransferase,of normal Elevations of alanine,1
TECFIDERA,Elevations of alanine aminotransferase,of normal,0
TECFIDERA,Elevations of alanine aminotransferase,times the upper limit,0
TECFIDERA,Elevations of alanine aminotransferase,,0
TECFIDERA,Elevations of alanine aminotransferase,normal Elevations of alanine aminotransferase,1
TECFIDERA,elevations in transaminases,in transaminases,1
TECFIDERA,elevations in transaminases,,0
TECFIDERA,elevations in transaminases,in transaminases,1
TECFIDERA,elevations in transaminases,There were elevations in transaminases,1
TECFIDERA,elevations in transaminases,the ULN with concomitant elevations in total bilirubin times the ULN,0
TECFIDERA,elevations in transaminases,bilirubin times the ULN Discontinuatio,0
TECFIDERA,elevations in transaminases,between groups There were elevations in transaminases,1
TECFIDERA,elevations in total bilirubin,the ULN with elevations in total,1
TECFIDERA,elevations in total bilirubin,were simila,0
TECFIDERA,elevations in total bilirubin,ULN with concomitant,0
TECFIDERA,elevations in total bilirubin,in total bilirubin,1
TECFIDERA,elevations in total bilirubin,and,0
TECFIDERA,elevations in total bilirubin,,0
TECFIDERA,elevations in total bilirubin,elevations in total bilirubin,1
TECFIDERA,elevations in total bilirubin,times the ULN with,0
TECFIDERA,elevations in total bilirubin,were and were,0
TECFIDERA,elevations in total bilirubin,elevations in total bilirubin,1
TECFIDERA,elevated hepatic transaminases,,0
TECFIDERA,elevated hepatic transaminases,transaminases,1
TECFIDERA,elevated hepatic transaminases,and were similar in patients,0
TECFIDERA,elevated hepatic transaminases,the ULN Discontinuations due elevated hepatic transaminases,1
TECFIDERA,increase in mean eosinophil counts,or placebo Eosinophilia A increase in mean eosinophil counts,1
TECFIDERA,increase in mean eosinophil counts,,0
TECFIDERA,increase in mean eosinophil counts,placebo Eosinophilia A,0
TECFIDERA,increase in mean eosinophil counts,with TECFIDERA,0
TECFIDERA,increase in mean eosinophil counts,eosinophil counts,1
TECFIDERA,increase in mean eosinophil counts,transient,0
TECFIDERA,increase in mean eosinophil counts,Eosinophilia A increase in mean,1
TECFIDERA,Anaphylaxis,are described elsewhere in labeling,0
TECFIDERA,Anaphylaxis,dverse reac tions are,1
TECFIDERA,angioedema, are descr ibed elsewhere in labeling Anaphylaxis,1
TECFIDERA,angioedema,are,1
TECFIDERA,angioedema,are,1
TECFIDERA,Progressive multifocal leukoencephalopathy,see s and Precautions,1
TECFIDERA,Progressive multifocal leukoencephalopathy,( 5.1 )]. * Progre ssive multifocal leukoencephalopathy see Warnings,1
TECFIDERA,Progressive multifocal leukoencephalopathy,Anaphylaxis and Angioedema see s and Precautions,1
TECFIDERA,Progressive multifocal leukoencephalopathy,"see s and Precautions (  5.1  )].  
 *  Progre ssive multifocal leukoencephalopathy see Warnings",1
TECFIDERA,Progressive multifocal leukoencephalopathy,and Precautions ( 5.1 )]. * Progre ssive multifocal leukoencephalopathy see Warnings,1
TECFIDERA,Progressive multifocal leukoencephalopathy,s and Precautions ( 5.1 )]. * Progre ssive multifocal leukoencephalopathy see Warnings,1
TECFIDERA,Progressive multifocal leukoencephalopathy,multifocal leukoencephalopathy see Warnings and,0
TECFIDERA,Progressive multifocal leukoencephalopathy,leukoencephalopathy see Warnings and Precautions Lymphopenia se,0
TECFIDERA,PML,ive multifocal leukoencephalopathy see Warnings and,1
TECFIDERA,PML,,0
TECFIDERA,PML,see Warnings,0
TECFIDERA,PML,Lymphopenia,0
TECFIDERA,PML,,0
TECFIDERA,PML,and Precautions Lymphopenia see,0
TECFIDERA,PML,Warnings and Precautions ive multifocal leukoencephalopathy see Warnings and,1
TECFIDERA,Lymphopenia,openia,1
TECFIDERA,Lymphopenia,see Warnings,0
TECFIDERA,Lymphopenia,openia,1
TECFIDERA,Lymphopenia,Warnings and Precautions,0
TECFIDERA,Lymphopenia,,0
TECFIDERA,Lymphopenia,and Precautions openia [see Warnings and Precautions Flushing see,1
TECFIDERA,Lymphopenia,[see Warnings and Precautions Flushing see,1
TECFIDERA,anaphylaxis,nausea,0
TECFIDERA,anaphylaxis,FDA at FDA or wwwfdagovmedwatch Clinical,1
TECFIDERA,anaphylaxis,ADVERSE REACTIONS contact Biogen 2255 or FDA at FDA or wwwfdagovmedwatch Clinical,1
TECFIDERA,anaphylaxis,or FDA at FDA or wwwfdagovmedwatch Clinical,1
TECFIDERA,anaphylaxis,or FDA at FDA or wwwfdagovmedwatch Clinical,1
TECFIDERA,anaphylaxis,Experience Because,0
TECFIDERA,angioedema,,0
TECFIDERA,angioedema,FDA,0
TECFIDERA,angioedema,-800-FDA-1 or wwwfdagovmedwatch Clinical Trials Experience,1
TECFIDERA,angioedema,SUSPECTED ADVERSE REACTIONS,0
TECFIDERA,angioedema,at or FDA,0
TECFIDERA,angioedema,Clinical Trials,0
TECFIDERA,angioedema,,0
TECFIDERA,angioedema,Because clinical trials,0
TECFIDERA,angioedema,Because,0
TECFIDERA,difficulty breathing,reaction rates observed in clinical trials of a drug,0
TECFIDERA,difficulty breathing,,0
TECFIDERA,difficulty breathing,conduct ed under widely varying conditions,1
TECFIDERA,difficulty breathing,l trials are conduct ed under widely varying conditions,1
TECFIDERA,urticaria,are under,1
TECFIDERA,urticaria,under,1
TECFIDERA,urticaria,conditions adverse reaction rates observed in clinical trials of a drug cannot be dire,0
TECFIDERA,urticaria,wi dely varying conditions adverse reaction,1
TECFIDERA,swelling of the throat,directly compared to rates in,0
TECFIDERA,swelling of the throat,drug,0
TECFIDERA,swelling of the throat,conducted under widely arying,1
TECFIDERA,swelling of the throat,Because clinical trials are conducted under widely,0
TECFIDERA,swelling of the throat,"arying conditions, adv erse reaction rates observed in",1
TECFIDERA,swelling of the throat,"arying conditions,",1
TECFIDERA,fatal,,0
TECFIDERA,fatal,the,0
TECFIDERA,progressive multifocal leukoencephalopathy,common adverse reactions incidence  >=2% more than placebo) for TECFIDERA wer e flushing abdominal pain diarrhea,1
TECFIDERA,progressive multifocal leukoencephalopathy,Tr,0
TECFIDERA,progressive multifocal leukoencephalopathy, >=2% more than placebo) for TECFIDERA wer e flushing abdominal pain diarrhea,1
TECFIDERA,progressive multifocal leukoencephalopathy,diarrhea and nausea Adverse,0
TECFIDERA,progressive multifocal leukoencephalopathy,Reactions in,0
TECFIDERA,progressive multifocal leukoencephalopathy,clinical practice The most common adverse reactions,0
TECFIDERA,PML,TECFIDERA flu shing abdominal pain diarrhea and,1
TECFIDERA,PML,flu shing abdominal pain diarrhea and,1
TECFIDERA,PML,flu shing abdominal pain diarrhea and,1
TECFIDERA,PML,flu shing abdominal pain diarrhea and,1
TECFIDERA,PML,and,0
TECFIDERA,PML,,0
TECFIDERA,PML,,0
TECFIDERA,PML,abdominal pain,0
TECFIDERA,PML,and nausea Adverse Reactions in PlaceboControlled,0
TECFIDERA,lymphopenia,and ed for,1
TECFIDERA,lymphopenia,in Study and ed,1
TECFIDERA,lymphopenia,and placebotreated,0
TECFIDERA,lymphopenia,report,0
TECFIDERA,lymphopenia,incidence than placebo,0
TECFIDERA,lymphopenia,Adverse Reactions in Study and report,0
TECFIDERA,lymphopenia,TECF IDERA mg BID at higher,1
TECFIDERA,lymphopenia,mg BID at higher incidence,0
TECFIDERA,decrease lymphocyte counts, 5                         Pruritus,1
TECFIDERA,decrease lymphocyte counts, 5                         Pruritus,1
TECFIDERA,decrease lymphocyte counts,Pruritus,0
TECFIDERA,decrease lymphocyte counts,Vomiting,0
TECFIDERA,decrease lymphocyte counts,,0
TECFIDERA,lymphocyte counts decreased,          8                 Rash,1
TECFIDERA,lymphocyte counts decreased,          8                 Rash,1
TECFIDERA,lymphocyte counts decreased,          8                 Rash,1
TECFIDERA,lymphocyte counts decreased,Pruritus,0
TECFIDERA,lymphocyte counts decreased,Pruritus,0
TECFIDERA,lymphocyte counts decreased,          8                 Rash,1
TECFIDERA,lymphocyte counts decreased,          8                 Rash,1
TECFIDERA,lymphocyte counts decreased,          8                 Rash,1
TECFIDERA,infections,Dyspeps ia         Aspartate,1
TECFIDERA,infections,ia         Aspartate,1
TECFIDERA,infections,Dyspeps ia         Aspartate,1
TECFIDERA,infections,Dyspeps ia         Aspartate,1
TECFIDERA,infections,,0
TECFIDERA,infections,Dyspeps,0
TECFIDERA,infections,ia         Aspartate,1
TECFIDERA,infections,ia         Aspartate,1
TECFIDERA,infections,,0
TECFIDERA,infections,ia         Aspartate,1
TECFIDERA,infections,Dyspepsia,0
TECFIDERA,infections,Dyspepsia       5    Aspartate aminotransferase increased,1
TECFIDERA,infections,Aspartate aminotransferase increased,0
TECFIDERA,infections,      5    Aspartate aminotransferase increased,1
TECFIDERA,infections,Dyspepsia       5    Aspartate aminotransferase increased,1
TECFIDERA,infections,Aspartate aminotransferase increased,0
TECFIDERA,infections,      5    Aspartate aminotransferase increased,1
TECFIDERA,infections,Dyspepsia,0
TECFIDERA,infections,,0
TECFIDERA,infections,      5    Aspartate aminotransferase,1
TECFIDERA,PML,tin al TECFIDERA caused GI,1
TECFIDERA,PML,tin,1
TECFIDERA,PML,Gastrointes,0
TECFIDERA,PML,tin al,1
TECFIDERA,PML,tin al,1
TECFIDERA,PML,abdominal,0
TECFIDERA,PML,diarrhea,0
TECFIDERA,PML,tin al TECFIDERA,1
TECFIDERA,PML,Gastrointes tin,1
TECFIDERA,PML,tin al,1
TECFIDERA,prolonged lymphopenia,,0
TECFIDERA,prolonged lymphopenia,and dyspepsia The incidence of GI,0
TECFIDERA,prolonged lymphopenia,higher,0
TECFIDERA,prolonged lymphopenia,nausea vomiting diarrhea abdominal pain and,0
TECFIDERA,prolonged lymphopenia,TECFIDERA,0
TECFIDERA,prolonged lymphopenia,(e.g nausea,1
TECFIDERA,prolonged lymphopenia,caused GI events (e.g nausea,1
TECFIDERA,lymphocyte counts <0.5 x 10 9 /L,in patients treated with TEC FIDERA,1
TECFIDERA,lymphocyte counts <0.5 x 10 9 /L,usually decreased time in patients treated,1
TECFIDERA,lymphocyte counts <0.5 x 10 9 /L,treatment primarily in month and,0
TECFIDERA,lymphocyte counts <0.5 x 10 9 /L,decreased time in patients treated,1
TECFIDERA,lymphocyte counts <0.5 x 10 9 /L,of treatment primarily in month and usually decreased over,0
TECFIDERA,lymphocyte counts <0.5 x 10 9 /L,decreased  time in patients treated with TEC FIDERA,1
TECFIDERA,flushing,ansient  increase,1
TECFIDERA,flushing,the,0
TECFIDERA,flushing,seen during the first months of,0
TECFIDERA,warmth,transient,0
TECFIDERA,warmth,,0
TECFIDERA,warmth,in,1
TECFIDERA,warmth,Eosinophilia A,0
TECFIDERA,warmth,transient in,1
TECFIDERA,redness,or placebo Eosinophilia,0
TECFIDERA,redness,in  eosino phil,1
TECFIDERA,redness, eosino phil,1
TECFIDERA,redness, eosino phil,1
TECFIDERA,redness, eosino phil,1
TECFIDERA,redness,increase in,0
TECFIDERA,redness,or,0
TECFIDERA,redness, eosino phil,1
TECFIDERA,redness,A transient increase in  eosino phil,1
TECFIDERA,itching,,0
TECFIDERA,flushing,of,0
TECFIDERA,Flushing,months of therapy Adverse Reactions,0
TECFIDERA,Flushing,Unc,0
TECFIDERA,Flushing,PlaceboControlled and Unc,0
TECFIDERA,Flushing,ontrolle d,1
TECFIDERA,Flushing,total of,0
TECFIDERA,Flushing,and ontrolle d,1
TECFIDERA,Flushing,ontrolle d,1
TECFIDERA,Flushing,ontrolle d,1
TECFIDERA,Flushing,Reactions in PlaceboControlled and ontrolle d,1
TECFIDERA,Flushing,,0
TECFIDERA,flushing,riods up to,1
TECFIDERA,flushing,followed for riods,1
TECFIDERA,flushing,for riods up to,1
TECFIDERA,flushing,riods up to,1
TECFIDERA,flushing,,0
TECFIDERA,flushing,been followed for riods,1
TECFIDERA,flushing,up to,1
TECFIDERA,flushing,riods up to,1
TECFIDERA,flushing,,0
TECFIDERA,flushing,ved,1
TECFIDERA,flushing,patients have recei,0
TECFIDERA,flushing,,0
TECFIDERA,flushing,of TECFIDERA in the,0
TECFIDERA,flushing,profile of TECFIDERA in the uncontro,0
TECFIDERA,flushing,of tment,1
TECFIDERA,flushing,years of tment,1
TECFIDERA,flushing,tment,1
TECFIDERA,flushing,profile,0
TECFIDERA,flushing,tment wi th,1
TECFIDERA,flushing,tment wi th,1
TECFIDERA,flushing,uncontrolled clinical,0
TECFIDERA,flushing,of tment,1
TECFIDERA,flushing,of tment wi th,1
TECFIDERA,flushing,than years of tment wi th,1
TECFIDERA,flushing,placebo- controlled,1
TECFIDERA,flushing,,0
TECFIDERA,flushing,clinical trials,0
TECFIDERA,flushing,placebo- controlled,1
TECFIDERA,flushing,placebo- controlled,1
TECFIDERA,flushing,,0
TECFIDERA,flushing,controlled,0
TECFIDERA,flushing,placebo- controlled,1
TECFIDERA,flushing,,0
TECFIDERA,flushing,,1
TECFIDERA,flushing,,1
TECFIDERA,flushing,,0
TECFIDERA,flushing,,0
TREANDA,Myelosuppression,Myelosuppression,1
TREANDA,Myelosuppression,Myelosuppression,1
TREANDA,Myelosuppression,and Precautions Infections,0
TREANDA,Myelosuppression,,0
TREANDA,Myelosuppression,Warnings,0
TREANDA,Myelosuppression,,0
TREANDA,Infections,Infections,1
TREANDA,Infections,Infections,1
TREANDA,Infections,Infections,1
TREANDA,Infections,and Infusion Reactions see Warning,0
TREANDA,Anaphylaxis,,0
TREANDA,Anaphylaxis,,0
TREANDA,Anaphylaxis,Anaphylaxis,1
TREANDA,Anaphylaxis,,0
TREANDA,Anaphylaxis,Anaphylaxis,1
TREANDA,Anaphylaxis,Anaphylaxis,1
TREANDA,Anaphylaxis,Anaphylaxis,1
TREANDA,Infusion Reactions,,0
TREANDA,Tumor Lysis Syndrome,see Warnings and Precautions,0
TREANDA,Tumor Lysis Syndrome,Precautions,0
TREANDA,Tumor Lysis Syndrome,Precautions Skin Reactions see Warnings and Precautions,0
TREANDA,Tumor Lysis Syndrome,see Warnings,0
TREANDA,Tumor Lysis Syndrome,Syndrome,1
TREANDA,Tumor Lysis Syndrome,Syndrome,1
TREANDA,Tumor Lysis Syndrome,Reactions see Warnings and Tumor,1
TREANDA,Tumor Lysis Syndrome,Warnings and Tumor Lysis,1
TREANDA,Skin Reactions,Skin Reactions,1
TREANDA,Skin Reactions,see Warnings,0
TREANDA,Skin Reactions,Skin,1
TREANDA,Skin Reactions,and,0
TREANDA,Skin Reactions,and Precautions Other Malignancies see Warnings and Precaution,0
TREANDA,Malignancies,Malignancies,1
TREANDA,Malignancies,,0
TREANDA,Malignancies,Precautions Malignancies,1
TREANDA,Malignancies,Malignancies,1
TREANDA,Extravasation injury,,0
TREANDA,Extravasation injury,Other Malignancies,0
TREANDA,Extravasation injury,Malignancies see Warnings and Extravasation injury,1
TREANDA,Extravasation injury,Malignancies see Warnings and Extravasation,1
TREANDA,Extravasation injury,rea,0
TREANDA,pyrexia,Most,0
TREANDA,pyrexia,frequency pyrexia,1
TREANDA,pyrexia,,0
TREANDA,pyrexia,pyrexia,1
TREANDA,pyrexia,pyrexia,1
TREANDA,pyrexia,adverse,0
TREANDA,nausea,,0
TREANDA,nausea,,0
TREANDA,nausea,nausea,1
TREANDA,nausea,nausea,1
TREANDA,nausea,adverse reactions for CLL,0
TREANDA,nausea,nausea,1
TREANDA,nausea,adverse reactions for CLL frequency are pyrexia,0
TREANDA,nausea,common nonhematologic adverse reactions for,0
TREANDA,fatigue,fatigue,1
TREANDA,fatigue,fatigue,1
TREANDA,fatigue,,0
TREANDA,fatigue,headache weight decreased dyspnea,0
TREANDA,fatigue,reactions for NHL frequency are nausea,0
TREANDA,fatigue,are fatigue,1
TREANDA,fatigue,nonhematologic adverse,0
TREANDA,fatigue,,0
TREANDA,vomiting,NHL frequency are nausea,0
TREANDA,vomiting,frequency are nausea vomiting,1
TREANDA,vomiting,frequency are nausea vomiting,1
TREANDA,vomiting,NHL frequency,0
TREANDA,vomiting,weight decreased dyspnea rash and,0
TREANDA,vomiting,,0
TREANDA,vomiting,nausea vomiting,1
TREANDA,vomiting,are nausea vomiting,1
TREANDA,diarrhea,rash and,0
TREANDA,diarrhea,diarrhea,1
TREANDA,pyrexia,pyrexia,1
TREANDA,pyrexia,diarrhea,0
TREANDA,pyrexia,pyrexia,1
TREANDA,pyrexia,diarrhea,0
TREANDA,pyrexia,stomatitis,0
TREANDA,pyrexia,weight decreased,0
TREANDA,pyrexia,pyrexia,1
TREANDA,constipation,constipation,1
TREANDA,constipation,constipation,1
TREANDA,constipation,and,0
TREANDA,constipation,constipation,1
TREANDA,anorexia,nausea fatigue vomiting diarrhea,0
TREANDA,anorexia,decreased dyspnea rash and stomatitis Most common,0
TREANDA,anorexia,anorexia,1
TREANDA,anorexia,anorexia,1
TREANDA,anorexia,vomiting diarrhea pyrexia,0
TREANDA,anorexia,pyrexia anorexia,1
TREANDA,anorexia,fatigue vomiting diarrhea,0
TREANDA,headache,dyspnea rash and stomatitis Most common hematologic abnor,0
TREANDA,headache,constipation anorexia headache,1
TREANDA,headache,headache,1
TREANDA,headache,headache,1
TREANDA,headache,stomatitis Most common,0
TREANDA,headache,Most common hematologic abnor,0
TREANDA,headache,nausea fatigue,0
TREANDA,headache,hematologic abnor,0
TREANDA,headache,diarrhea pyrexia constipation anorexia cough,0
TREANDA,headache,headache,1
TREANDA,weight decreased,weight,1
TREANDA,weight decreased,constipation anorexia cough weight,1
TREANDA,weight decreased,dyspnea rash,0
TREANDA,weight decreased,decreased,1
TREANDA,weight decreased,for both,0
TREANDA,weight decreased,hematologic abnormalities,0
TREANDA,weight decreased,,0
TREANDA,weight decreased,fatigue vomiting diarrhea pyrexia,0
TREANDA,dyspnea,,0
TREANDA,dyspnea,cough headache weight decreased,0
TREANDA,dyspnea,common hematologic abnormalities,0
TREANDA,dyspnea,constipation anorexia cough headache weight decreased,0
TREANDA,dyspnea,dyspnea,1
TREANDA,rash,for,0
TREANDA,rash,fr,0
TREANDA,rash,cough headache weight decreased rash,1
TREANDA,rash,rash,1
TREANDA,rash,decreased dyspnea,0
TREANDA,rash,rash,1
TREANDA,stomatitis,,0
TREANDA,stomatitis,rash stomatitis,1
TREANDA,stomatitis,stomatitis,1
TREANDA,stomatitis,anorexia cough,0
TREANDA,stomatitis,weight decreased dyspnea rash and,0
TREANDA,stomatitis,stomatitis,1
TREANDA,hematologic abnormalities,and,0
TREANDA,hematologic abnormalities,lymphopenia anemia leukopenia thrombocytopenia,0
TREANDA,hematologic abnormalities,,0
TREANDA,hematologic abnormalities,hematologic,1
TREANDA,lymphopenia,and neutropenia EXCERPT To,0
TREANDA,lymphopenia,common hematologic abnormalities for both indications frequency are,0
TREANDA,lymphopenia,indications frequency lymphopenia,1
TREANDA,lymphopenia,lymphopenia,1
TREANDA,lymphopenia,indications,0
TREANDA,lymphopenia,,0
TREANDA,lymphopenia,,0
TREANDA,anemia,anemia,1
TREANDA,anemia,neutropenia EXCERPT To report SUSPECTED A,0
TREANDA,anemia,anemia,1
TREANDA,anemia,anemia,1
TREANDA,anemia,lymphopenia,0
TREANDA,anemia,,0
TREANDA,anemia,anemia,1
TREANDA,anemia,,0
TREANDA,leukopenia,SUSPECTED ADVERSE,0
TREANDA,leukopenia,,0
TREANDA,leukopenia,leukopenia,1
TREANDA,leukopenia,frequency are lymphopenia leukopenia,1
TREANDA,leukopenia,leukopenia,1
TREANDA,leukopenia,leukopenia,1
TREANDA,leukopenia,report,0
TREANDA,leukopenia,leukopenia,1
TREANDA,thrombocytopenia,thrombocytopenia,1
TREANDA,thrombocytopenia,lymphopenia anemia leukopenia,0
TREANDA,thrombocytopenia,thrombocytopenia,1
TREANDA,thrombocytopenia,REACTIONS,0
TREANDA,thrombocytopenia,are lymphopenia anemia thrombocytopenia,1
TREANDA,neutropenia,neutropenia,1
TREANDA,neutropenia,neutropenia,1
TREANDA,pyrexia,a,0
TREANDA,pyrexia,pyrexia,1
TREANDA,pyrexia,greater than pyrexia,1
TREANDA,nausea,nausea,1
TREANDA,vomiting,,0
TREANDA,vomiting,vomiting,1
TREANDA,vomiting,occurred with a frequency greater than were pyrexia,0
TREANDA,vomiting,vomiting,1
TREANDA,vomiting,a,0
TREANDA,vomiting,group,0
TREANDA,vomiting,than were pyrexia nausea,0
TREANDA,vomiting,with a frequency greater than were pyrexia,0
TREANDA,vomiting,vomiting,1
TREANDA,asthenia,asthenia,1
TREANDA,asthenia,asthenia,1
TREANDA,asthenia,or more studies,0
TREANDA,asthenia,studies asthenia,1
TREANDA,asthenia,asthenia,1
TREANDA,asthenia,asthenia,1
TREANDA,asthenia,asthenia,1
TREANDA,asthenia,and weakness dry mouth somnolence cough constipation headache,0
TREANDA,asthenia,Other adverse reactions seen frequently in one or more,0
TREANDA,asthenia,asthenia,1
TREANDA,fatigue,or,0
TREANDA,fatigue,inflammation,0
TREANDA,fatigue,fatigue,1
TREANDA,malaise,adverse reactions seen frequently in one or more,0
TREANDA,malaise,malaise,1
TREANDA,malaise,fatigue,0
TREANDA,malaise,studies included asthenia malaise,1
TREANDA,malaise,asthenia malaise,1
TREANDA,malaise,malaise,1
TREANDA,malaise,headache,0
TREANDA,weakness,frequently in one or more,0
TREANDA,weakness,Wo,0
TREANDA,somnolence,somnolence,1
TREANDA,somnolence,and stomatitis Worsening,0
TREANDA,somnolence,weakness dry somnolence,1
TREANDA,somnolence,,0
TREANDA,somnolence,mucosal,0
TREANDA,somnolence,somnolence,1
TREANDA,somnolence,somnolence,1
TREANDA,somnolence,malaise and weakness dry somnolence,1
TREANDA,somnolence,mucosal inflammation and stomatitis Worsening hypertension,0
TREANDA,somnolence,somnolence,1
TREANDA,cough,inflammation and stomatitis Worsening hypertension,0
TREANDA,cough,cough,1
TREANDA,cough,,0
TREANDA,cough,cough,1
TREANDA,constipation,constipation,1
TREANDA,constipation,,0
TREANDA,constipation,constipation,1
TREANDA,constipation,weakness dry mouth somnolence constipation,1
TREANDA,constipation,,0
TREANDA,constipation,constipation,1
TREANDA,constipation,constipation,1
TREANDA,constipation,constipation,1
TREANDA,constipation,,0
TREANDA,headache,headache,1
TREANDA,mucosal inflammation,,0
TREANDA,mucosal inflammation,Worsening hypertension was reported in patients treated with TREANDA,0
TREANDA,mucosal inflammation,was reported in patients treated,0
TREANDA,mucosal inflammation,cough constipation mucosal inflammation,1
TREANDA,mucosal inflammation,treated,0
TREANDA,mucosal inflammation,mouth somnolence cough constipation mucosal,1
TREANDA,mucosal inflammation,somnolence cough constipation mucosal,1
TREANDA,stomatitis,constipation,0
TREANDA,stomatitis,mucosal inflammation stomatitis,1
TREANDA,Worsening hypertension,none treated with,0
TREANDA,Worsening hypertension,none treated with,0
TREANDA,Worsening hypertension,and Worsening hypertension,1
TREANDA,Worsening hypertension,trial,0
TREANDA,hypertensive crisis,crisis,1
TREANDA,hypertensive crisis,hypertensive,1
TREANDA,hypertensive crisis,hypertensive,1
TREANDA,hypersensitivity,regardless,0
TREANDA,hypersensitivity,hypersensitivity,1
TREANDA,hypersensitivity,TREANDA hypersensitivity,1
TREANDA,hypersensitivity,hypersensitivity,1
TREANDA,hypersensitivity,treatment emergent,0
TREANDA,hypersensitivity,hypersensitivity,1
TREANDA,hypersensitivity,patients receiving TREANDA were,0
TREANDA,hypersensitivity,of,0
TREANDA,pyrexia,regardless of attribution,0
TREANDA,pyrexia,pyrexia,1
TREANDA,pyrexia,receiving TREANDA were hypersensitivity and,0
TREANDA,pyrexia,pyrexia,1
TREANDA,pyrexia,TREANDA were hypersensitivity pyrexia,1
TREANDA,pyrexia,leading to study,0
TREANDA,pyrexia,were hypersensitivity pyrexia,1
TREANDA,pyrexia,,0
TREANDA,Nausea,,0
TREANDA,Nausea,,0
TREANDA,Nausea,Nausea,1
TREANDA,Nausea,,0
TREANDA,Nausea,,0
TREANDA,Nausea,Nausea,1
TREANDA,Nausea,Nausea,1
TREANDA,Nausea,Nausea,1
TREANDA,Nausea,Nausea,1
TREANDA,Vomiting,,0
TREANDA,Vomiting,Vomiting,1
TREANDA,Vomiting,Vomiting,1
TREANDA,Diarrhea,,0
TREANDA,Diarrhea,,0
TREANDA,Diarrhea,,0
TREANDA,Diarrhea,Diarrhea,1
TREANDA,Diarrhea,Diarrhea,1
TREANDA,Diarrhea,,0
TREANDA,Diarrhea,,0
TREANDA,Diarrhea,,0
TREANDA,Diarrhea,,0
TREANDA,Pyrexia,and administration site,0
TREANDA,Fatigue,,0
TREANDA,Fatigue,Fatigue,1
TREANDA,Asthenia,Asthenia,1
TREANDA,Asthenia,Asthenia,1
TREANDA,Asthenia,,0
TREANDA,Asthenia,,0
TREANDA,Asthenia,Asthenia,1
TREANDA,Chills,,0
TREANDA,Chills,,0
TREANDA,Chills,,0
TREANDA,Chills,Chills,1
TREANDA,Chills,Chills,1
TREANDA,Hypersensitivity,Hypersensitivity Infecti,1
TREANDA,Hypersensitivity,disorders,0
TREANDA,Hypersensitivity,disorders Hypersensitivity Infecti,1
TREANDA,Hypersensitivity,Hypersensitivity Infecti,1
TREANDA,Hypersensitivity,disorders Hypersensitivity Infecti,1
TREANDA,Infection,Infection,1
TREANDA,Infection,Infection,1
TREANDA,Infection,itis Infection,1
TREANDA,Infection,,0
TREANDA,Infection,,0
TREANDA,Infection,Infection,1
TREANDA,Herpes simplex,Herpes simplex Inves,1
TREANDA,Herpes simplex,Inves,0
TREANDA,Herpes simplex,Herpes simplex Inves,1
TREANDA,Herpes simplex,Herpes simplex Inves,1
TREANDA,Herpes simplex,,0
TREANDA,Weight decreased,s Weight,1
TREANDA,Weight decreased,,0
TREANDA,Weight decreased,Weight decreased Metabol,1
TREANDA,Weight decreased,,0
TREANDA,Weight decreased,s Weight decreased Metabol,1
TREANDA,Weight decreased,s Weight decreased Metabol,1
TREANDA,Weight decreased,Weight decreased Metabol,1
TREANDA,Hyperuricemia,nutrition disorders,0
TREANDA,Hyperuricemia,,0
TREANDA,Hyperuricemia,Hyperuricemia Resp,1
TREANDA,Hyperuricemia,Hyperuricemia Resp,1
TREANDA,Hyperuricemia,,0
TREANDA,Hyperuricemia,Hyperuricemia Resp,1
TREANDA,Hyperuricemia,Hyperuricemia Resp,1
TREANDA,Hyperuricemia,Hyperuricemia Resp,1
TREANDA,Hyperuricemia,nutrition Hyperuricemia Resp,1
TREANDA,Hyperuricemia,Resp,0
TREANDA,Cough,disorders,0
TREANDA,Cough,,0
TREANDA,Cough,,0
TREANDA,Cough,,0
TREANDA,Cough,Cough,1
TREANDA,Pruritus,,0
TREANDA,Pruritus,,0
TREANDA,Pruritus,,0
TREANDA,Pruritus,Pruritus,1
TREANDA,Pruritus,,0
TREANDA,myelosuppressive effects,study are described in Table These,0
TREANDA,myelosuppressive effects,myelosuppressive effects,1
TREANDA,myelosuppressive effects,Table These findings confirm myelosuppressive effects,1
TREANDA,myelosuppressive effects,Red blood cell,0
TREANDA,myelosuppressive effects,Table These findings confirm myelosuppressive,1
TREANDA,myelosuppressive effects,findings confirm myelosuppressive,1
TREANDA,myelosuppressive effects,in,0
TREANDA,myelosuppressive effects,cell transfusions were administered to of pati,0
TREANDA,myelosuppressive effects,in Table,0
TREANDA,Hemoglobin Decreased,All Gradesn Grade Hemoglobin,1
TREANDA,Hemoglobin Decreased,Decreased,1
TREANDA,Hemoglobin Decreased,Platelets Decreased,0
TREANDA,Hemoglobin Decreased,All Gradesn Grade Hemoglobin Decreased,1
TREANDA,Hemoglobin Decreased,,0
TREANDA,Hemoglobin Decreased,n All Gradesn Grade Hemoglobin Decreased,1
TREANDA,Hemoglobin Decreased,Grade n All Gradesn Grade n,0
TREANDA,Hemoglobin Decreased,,0
TREANDA,Hemoglobin Decreased,Platelets,0
TREANDA,Hemoglobin Decreased,Abnormality All Gradesn Grade n All Gradesn,0
TREANDA,Platelets Decreased,Hemoglobin Platelets Decreased,1
TREANDA,Platelets Decreased,,0
TREANDA,Platelets Decreased,,0
TREANDA,Platelets Decreased,Platelets Decreased,1
TREANDA,Platelets Decreased,Platelets Decreased,1
TREANDA,Platelets Decreased,,0
TREANDA,Platelets Decreased,,0
TREANDA,Platelets Decreased,Platelets,1
TREANDA,Leukocytes Decreased,Decreased,0
TREANDA,Leukocytes Decreased,Platelets Leukocytes,1
TREANDA,Leukocytes Decreased,Platelets Leukocytes,1
TREANDA,Lymphocytes Decreased,,0
TREANDA,Lymphocytes Decreased,,0
TREANDA,Lymphocytes Decreased,,0
TREANDA,Neutrophils Decreased,,0
TREANDA,Neutrophils Decreased,Lymphocytes Neutrophils,1
TREANDA,Neutrophils Decreased,,0
TREANDA,Neutrophils Decreased,Lymphocytes Neutrophils Decreased,1
TREANDA,Neutrophils Decreased,Neutrophils Decreased,1
TREANDA,bilirubin elevations,trial of patients bilirubin elevations,1
TREANDA,bilirubin elevations,trial of patients bilirubin elevations,1
TREANDA,bilirubin elevations,,0
TREANDA,bilirubin elevations,CLL trial of patients bilirubin elevations,1
TREANDA,bilirubin elevations,elevations,1
TREANDA,bilirubin elevations,had,0
TREANDA,bilirubin elevations,CLL trial of patients bilirubin elevations,1
TREANDA,bilirubin elevations,the CLL trial,0
TREANDA,bilirubin elevations,elevations in AST and ALT Grade or increased,0
TREANDA,elevations in AST,in AST,1
TREANDA,elevations in AST,some without associated elevations,1
TREANDA,elevations in AST,elevations in AST,1
TREANDA,elevations in AST,some without associated,0
TREANDA,elevations in AST,Grade,0
TREANDA,elevations in AST,,0
TREANDA,elevations in AST,Increases in,0
TREANDA,elevations in AST,in AST,1
TREANDA,elevations in AST,ALT,0
TREANDA,elevations in AST,some without associated elevations in AST,1
TREANDA,elevations in AST,,0
TREANDA,elevations in AST,or increased bilirubin occurred in of patients Increases in,0
TREANDA,elevations in AST,bilirubin elevations some without associated,0
TREANDA,increased bilirubin,bilirubin,1
TREANDA,increased bilirubin,and,0
TREANDA,Increases in AST,occurred,0
TREANDA,Increases in AST,bilirubin occurred in of patients,0
TREANDA,Increases in AST,occurred in of Increases in AST,1
TREANDA,Increases in AST,Increases in AST,1
TREANDA,Increases in AST,in AST,1
TREANDA,Increases in AST,occurred in of Increases in,1
TREANDA,nausea,,0
TREANDA,nausea,,0
TREANDA,nausea,nausea,1
TREANDA,nausea,common nonhemato,0
TREANDA,nausea,vomiting diarrhea and pyrexia The most common,0
TREANDA,nausea,The,0
TREANDA,nausea,,0
TREANDA,nausea,diarrhea and,0
TREANDA,fatigue,fatigue,1
TREANDA,fatigue,and pyrexia The most common nonhematologic,0
TREANDA,fatigue,most common nonhematologic adverse reactions were nausea,0
TREANDA,fatigue,fatigue,1
TREANDA,fatigue,fatigue,1
TREANDA,fatigue,,0
TREANDA,fatigue,The most,0
TREANDA,vomiting,vomiting,1
TREANDA,vomiting,vomiting,1
TREANDA,vomiting,nausea vomiting,1
TREANDA,vomiting,vomiting,1
TREANDA,vomiting,vomiting,1
TREANDA,diarrhea,nausea fatigue vomiting,0
TREANDA,diarrhea,,0
TREANDA,pyrexia,pyrexia,1
TREANDA,pyrexia,adverse reactions,0
TREANDA,pyrexia,pyrexia,1
TREANDA,pyrexia,pyrexia,1
TREANDA,pyrexia,pyrexia,1
TREANDA,pyrexia,pyrexia,1
TREANDA,pyrexia,fatigue vomiting diarrhea,0
TREANDA,pyrexia,vomiting diarrhea pyrexia,1
TREANDA,pyrexia,were nausea fatigue vomiting,0
TREANDA,pyrexia,adverse reactions were nausea fatigue vomiting,0
TREANDA,fatigue,Grade,0
TREANDA,fatigue,fatigue,1
TREANDA,febrile neutropenia,and pneumonia,0
TREANDA,febrile neutropenia,febrile neutropenia,1
TREANDA,febrile neutropenia,neutropenia,1
TREANDA,febrile neutropenia,Non,0
TREANDA,febrile neutropenia,febrile neutropenia,1
TREANDA,febrile neutropenia,common nonhematologic Grade,0
TREANDA,febrile neutropenia,adverse reactions were febrile neutropenia,1
TREANDA,febrile neutropenia,patients,0
TREANDA,febrile neutropenia,were febrile neutropenia,1
TREANDA,febrile neutropenia,were febrile,1
TREANDA,pneumonia,febrile,0
TREANDA,pneumonia,hypokalemia and dehydration each,0
TREANDA,pneumonia,reported in,0
TREANDA,dehydration,fatigue febrile neutropenia and,0
TREANDA,dehydration,hypokalemia,0
TREANDA,dehydration,,0
TREANDA,dehydration,hypokalemia dehydration,1
TREANDA,dehydration,patients Table NonHematologic Adverse Reactions Occurring,0
TREANDA,dehydration,dehydration,1
TREANDA,dehydration,pneumonia hypokalemia dehydration,1
TREANDA,dehydration,,0
TREANDA,Tachycardia,Gastroi,0
TREANDA,Tachycardia,disorders,0
TREANDA,Tachycardia,,0
TREANDA,Tachycardia,Gastroi,0
TREANDA,Nausea,,0
TREANDA,Nausea,Nausea,1
TREANDA,Nausea,,0
TREANDA,Nausea,Nausea,1
TREANDA,Nausea,Nausea,1
TREANDA,Nausea,,0
TREANDA,Nausea,Nausea,1
TREANDA,Nausea,disorders,0
TREANDA,Nausea,Nausea,1
TREANDA,Nausea,Nausea,1
TREANDA,Vomiting,Vomiting,1
TREANDA,Vomiting,,0
TREANDA,Vomiting,,0
TREANDA,Vomiting,Vomiting,1
TREANDA,Vomiting,Vomiting,1
TREANDA,Vomiting,Vomiting,1
TREANDA,Vomiting,Vomiting,1
TREANDA,Diarrhea,Diarrhea,1
TREANDA,Diarrhea,Diarrhea,1
TREANDA,Diarrhea,,0
TREANDA,Diarrhea,,0
TREANDA,Constipation,Constipation Stom,1
TREANDA,Constipation,Constipation Stom,1
TREANDA,Constipation,Constipation Stom,1
TREANDA,Constipation,,0
TREANDA,Abdominal pain,,0
TREANDA,Abdominal pain,Abdominal pain Dyspep,1
TREANDA,Abdominal pain,Dyspep,0
TREANDA,Abdominal pain,is Abdominal pain Dyspep,1
TREANDA,Abdominal pain,is,0
TREANDA,Abdominal pain,is Abdominal,1
TREANDA,Dyspepsia,Dyspepsia G,1
TREANDA,Dyspepsia,Dyspepsia G,1
TREANDA,Dyspepsia,Dyspepsia G,1
TREANDA,Dyspepsia,l Dyspepsia G,1
TREANDA,Dyspepsia,Dyspepsia G,1
TREANDA,Dyspepsia,,0
TREANDA,Dyspepsia,pain,0
TREANDA,Dyspepsia,pain,0
TREANDA,Gastroesophageal reflux disease,a Gastroesophageal reflux disease,1
TREANDA,Gastroesophageal reflux disease,,0
TREANDA,Gastroesophageal reflux disease,a,0
TREANDA,Gastroesophageal reflux disease,a Gastroesophageal reflux disease,1
TREANDA,Gastroesophageal reflux disease,a,0
TREANDA,Gastroesophageal reflux disease,mouth,0
TREANDA,Gastroesophageal reflux disease,,0
TREANDA,Dry mouth,reflux disease,0
TREANDA,Dry mouth,,0
TREANDA,Dry mouth,ophageal reflux Dry,1
TREANDA,Dry mouth,A,0
TREANDA,Dry mouth,,0
TREANDA,Dry mouth,,0
TREANDA,Dry mouth,disease,0
TREANDA,Abdominal pain upper,Abdominal,0
TREANDA,Abdominal pain upper,h Abdominal,1
TREANDA,Abdominal pain upper,Abdominal,0
TREANDA,Abdominal pain upper,h,0
TREANDA,Abdominal pain upper,,0
TREANDA,Abdominal pain upper,di,0
TREANDA,Abdominal pain upper,di,0
TREANDA,Abdominal pain upper,upper Abdominal,1
TREANDA,Fatigue,,0
TREANDA,Fatigue,Fatigue,1
TREANDA,Fatigue,and administration site Fatigue,1
TREANDA,Fatigue,administration site Fatigue,1
TREANDA,Fatigue,,0
TREANDA,Pyrexia,Pyrexia,1
TREANDA,Pyrexia,Pyrexia,1
TREANDA,Pyrexia,Pyrexia,1
TREANDA,Pyrexia,Pyrexia,1
TREANDA,Pyrexia,,0
TREANDA,Pyrexia,Pyrexia,1
TREANDA,Pyrexia,Pyrexia,1
TREANDA,Pyrexia,,0
TREANDA,Pyrexia,Pyrexia,1
TREANDA,Chills,,0
TREANDA,Chills,,0
TREANDA,Chills,,0
TREANDA,Chills,,0
TREANDA,Edema peripheral,peripheral Asthenia,1
TREANDA,Edema peripheral,Edema peripheral Asthenia,1
TREANDA,Asthenia,Asthenia,1
TREANDA,Chest pain,,0
TREANDA,Chest pain,pain In,1
TREANDA,Chest pain,,0
TREANDA,Chest pain,Chest pain In,1
TREANDA,Chest pain,,0
TREANDA,Chest pain,pain In,1
TREANDA,Infusion site pain,,0
TREANDA,Infusion site pain,pain Pain,1
TREANDA,Infusion site pain,site pain Pain,1
TREANDA,Infusion site pain,in,0
TREANDA,Infusion site pain,Infusion site pain Pain,1
TREANDA,Infusion site pain,in Infusion,1
TREANDA,Infusion site pain,pain Pain,1
TREANDA,Infusion site pain,site pain Pain,1
TREANDA,Infusion site pain,in Infusion site pain Pain,1
TREANDA,Infusion site pain,in Infusion site pain Pain,1
TREANDA,Pain,Pain,1
TREANDA,Pain,,0
TREANDA,Catheter site pain,site pain Infections and,1
TREANDA,Catheter site pain,Catheter site pain Infections and,1
TREANDA,Catheter site pain,Catheter site pain Infections,1
TREANDA,Catheter site pain,Catheter site,1
TREANDA,Herpes zoster,zoster Upper,1
TREANDA,Herpes zoster,and Herpes zoster Upper,1
TREANDA,Herpes zoster,and Herpes zoster Upper,1
TREANDA,Herpes zoster,Infections and Herpes,1
TREANDA,Herpes zoster,Herpes zoster Upper,1
TREANDA,Herpes zoster,Herpes zoster Upper,1
TREANDA,Herpes zoster,,0
TREANDA,Upper respiratory tract infection,,0
TREANDA,Upper respiratory tract infection,tract infection,1
TREANDA,Upper respiratory tract infection,tract infection,0
TREANDA,Upper respiratory tract infection,oster,0
TREANDA,Upper respiratory tract infection,infection,0
TREANDA,Upper respiratory tract infection,oster,0
TREANDA,Upper respiratory tract infection,oster Upper respiratory tract,1
TREANDA,Upper respiratory tract infection,oster Upper,1
TREANDA,Urinary tract infection,Sinusitis,0
TREANDA,Urinary tract infection,tract,0
TREANDA,Urinary tract infection,infection,0
TREANDA,Sinusitis,Sinusitis P,1
TREANDA,Sinusitis,Sinusitis P,1
TREANDA,Sinusitis,Sinusitis P,1
TREANDA,Sinusitis,Sinusitis P,1
TREANDA,Sinusitis,,0
TREANDA,Sinusitis,Sinusitis P,1
TREANDA,Sinusitis,,0
TREANDA,Sinusitis,Sinusitis P,1
TREANDA,Pneumonia,s,0
TREANDA,Pneumonia,s Pneumonia F,1
TREANDA,Pneumonia,F,0
TREANDA,Pneumonia,Pneumonia F,1
TREANDA,Pneumonia,Pneumonia F,1
TREANDA,Pneumonia,Pneumonia F,1
TREANDA,Pneumonia,s,0
TREANDA,Pneumonia,Pneumonia F,1
TREANDA,Pneumonia,Pneumonia F,1
TREANDA,Pneumonia,s,0
TREANDA,Oral candidiasis,neutropenia,0
TREANDA,Oral candidiasis,,0
TREANDA,Oral candidiasis,neutropenia Oral,1
TREANDA,Nasopharyngitis,,0
TREANDA,Nasopharyngitis,Nasopharyngitis Investigati,1
TREANDA,Nasopharyngitis,Nasopharyngitis Investigati,1
TREANDA,Nasopharyngitis,Nasopharyngitis Investigati,1
TREANDA,Weight decreased,Investigations,0
TREANDA,Weight decreased,Investigations Weight,1
TREANDA,Weight decreased,Investigations Weight,1
TREANDA,Weight decreased,Investigations,0
TREANDA,Weight decreased,decreased Metabolism a,1
TREANDA,Weight decreased,Investigations Weight,1
TREANDA,Weight decreased,Weight decreased Metabolism,1
TREANDA,Weight decreased,,0
TREANDA,Weight decreased,,0
TREANDA,Anorexia,nutrition,0
TREANDA,Anorexia,Anorexia,1
TREANDA,Anorexia,Anorexia,1
TREANDA,Anorexia,,0
TREANDA,Anorexia,Anorexia,1
TREANDA,Anorexia,,0
TREANDA,Anorexia,Anorexia,1
TREANDA,Anorexia,Anorexia,1
TREANDA,Anorexia,,0
TREANDA,Dehydration,,0
TREANDA,Dehydration,Dehydration Dec,1
TREANDA,Dehydration,,0
TREANDA,Dehydration,Dehydration Dec,1
TREANDA,Dehydration,Dehydration Dec,1
TREANDA,Dehydration,,0
TREANDA,Dehydration,Dehydration Dec,1
TREANDA,Dehydration,Dehydration Dec,1
TREANDA,Dehydration,,0
TREANDA,Decreased appetite,ion Decreased,1
TREANDA,Decreased appetite,ion Decreased appetite Hypokalemi,1
TREANDA,Hypokalemia,Hypokalemia Musculo,1
TREANDA,Hypokalemia,Hypokalemia Musculo,1
TREANDA,Hypokalemia,Hypokalemia Musculo,1
TREANDA,Hypokalemia,Hypokalemia Musculo,1
TREANDA,Back pain,A,0
TREANDA,Back pain,,0
TREANDA,Back pain,Back pain A,1
TREANDA,Back pain,connective tissue Back,1
TREANDA,Back pain,pain A,1
TREANDA,Back pain,Musculoskeletal and connective tissue Back pain A,1
TREANDA,Arthralgia,Arthralgia Pa,1
TREANDA,Arthralgia,Pa,0
TREANDA,Arthralgia,Pa,0
TREANDA,Pain in extremity,ia Pain in extremity Bone,1
TREANDA,Pain in extremity,in extremity,1
TREANDA,Pain in extremity,ia Pain in,1
TREANDA,Bone pain,pain Nervo,1
TREANDA,Bone pain,Nervo,0
TREANDA,Bone pain,extremity Bone,1
TREANDA,Bone pain,extremity Bone pain Nervo,1
TREANDA,Bone pain,extremity,0
TREANDA,Bone pain,extremity Bone pain Nervo,1
TREANDA,Bone pain,extremity Bone,1
TREANDA,Headache,system,0
TREANDA,Headache,Nervous system Headache,1
TREANDA,Headache,Headache,1
TREANDA,Headache,Headache,1
TREANDA,Headache,Headache,1
TREANDA,Headache,Headache,1
TREANDA,Headache,,0
TREANDA,Headache,,0
TREANDA,Dizziness,,0
TREANDA,Dysgeusia,s,0
TREANDA,Dysgeusia,,0
TREANDA,Dysgeusia,Psych,0
TREANDA,Dysgeusia,s,0
TREANDA,Dysgeusia,Dysgeusia Psych,1
TREANDA,Dysgeusia,s,0
TREANDA,Dysgeusia,Psych,0
TREANDA,Insomnia,Insomnia,1
TREANDA,Insomnia,disorders,0
TREANDA,Insomnia,Insomnia,1
TREANDA,Insomnia,,0
TREANDA,Insomnia,Psychiatric Insomnia,1
TREANDA,Insomnia,Insomnia,1
TREANDA,Insomnia,,0
TREANDA,Insomnia,disorders,0
TREANDA,Anxiety,Anxiety,1
TREANDA,Anxiety,Anxiety,1
TREANDA,Anxiety,Anxiety,1
TREANDA,Anxiety,,0
TREANDA,Anxiety,Anxiety,1
TREANDA,Anxiety,Anxiety,1
TREANDA,Anxiety,,0
TREANDA,Anxiety,Anxiety,1
TREANDA,Depression,,0
TREANDA,Depression,,0
TREANDA,Depression,Depression Respir,1
TREANDA,Depression,,0
TREANDA,Depression,,0
TREANDA,Depression,,0
TREANDA,Depression,Depression Respir,1
TREANDA,Depression,,0
TREANDA,Depression,,0
TREANDA,Depression,,0
TREANDA,Cough,Cough,1
TREANDA,Cough,Cough,1
TREANDA,Dyspnea,Dyspnea,1
TREANDA,Pharyngolaryngeal pain,Pharyngolaryngeal pain Wheezing,1
TREANDA,Pharyngolaryngeal pain,Pharyngolaryngeal pain Wheezing,1
TREANDA,Pharyngolaryngeal pain,Pharyngolaryngeal pain Wheezing,1
TREANDA,Pharyngolaryngeal pain,Pharyngolaryngeal pain Wheezing,1
TREANDA,Pharyngolaryngeal pain,,0
TREANDA,Wheezing,Wheezing,1
TREANDA,Wheezing,,0
TREANDA,Wheezing,,0
TREANDA,Wheezing,,0
TREANDA,Wheezing,Wheezing,1
TREANDA,Nasal congestion,,0
TREANDA,Rash,subcutaneous tissue,0
TREANDA,Pruritus,,0
TREANDA,Pruritus,Pruritus,1
TREANDA,Pruritus,Pruritus,1
TREANDA,Pruritus,,0
TREANDA,Pruritus,Pruritus,1
TREANDA,Dry skin,Dry skin,1
TREANDA,Dry skin,,0
TREANDA,Dry skin,skin,1
TREANDA,Dry skin,,0
TREANDA,Dry skin,skin,1
TREANDA,Night sweats,Night sweats Hype,1
TREANDA,Night sweats,Night sweats Hype,1
TREANDA,Night sweats,Night,1
TREANDA,Night sweats,Night sweats Hype,1
TREANDA,Night sweats,Night,1
TREANDA,Night sweats,,0
TREANDA,Hyperhidrosis,Hyperhidrosis Vascular,1
TREANDA,Hyperhidrosis,Hyperhidrosis Vascular,1
TREANDA,Hyperhidrosis,,0
TREANDA,Hypotension,disorders,0
TREANDA,Hypotension,,0
TREANDA,Hypotension,Hypotension Patien,1
TREANDA,Hypotension,Hypotension Patien,1
TREANDA,Hypotension,Hypotension Patien,1
TREANDA,Hypotension,,0
TREANDA,Hypotension,Hypotension Patien,1
TREANDA,Hematologic toxicities,treated in both single arm studies combi,0
TREANDA,Hematologic toxicities,combi,0
TREANDA,Hematologic toxicities,Hematologic toxicities,1
TREANDA,Hematologic toxicities,in each preferred term,0
TREANDA,Hematologic toxicities,once in each system organ class,0
TREANDA,Hematologic toxicities,values and CTC grade in NHL patients treated in both,0
TREANDA,Hematologic toxicities,class,0
TREANDA,Hematologic toxicities,class Hematologic toxicities,1
TREANDA,Hematologic toxicities,toxicities,1
TREANDA,hyperglycemia,combined,0
TREANDA,hyperglycemia,Incidence o,0
TREANDA,elevated creatinine,both,0
TREANDA,elevated creatinine,studies combined were elevated creatinine,1
TREANDA,hyponatremia,hyponatremia,1
TREANDA,hyponatremia,combined were hyperglycemia elevated hyponatremia,1
TREANDA,hypocalcemia,hyperglycemia elevated creatinine hyponatremia hypocalcemia,1
TREANDA,hypocalcemia,Hematology Laboratory Abnormalities in,0
TREANDA,hypocalcemia,arm studies,0
TREANDA,hypocalcemia,,0
TREANDA,Lymphocytes Decreased,Decreased,1
TREANDA,Lymphocytes Decreased,,0
TREANDA,Lymphocytes Decreased,Lymphocytes Decreased,1
TREANDA,Lymphocytes Decreased,All Grades Lymphocytes,1
TREANDA,Lymphocytes Decreased,Decreased,1
TREANDA,Leukocytes Decreased,Decreased,0
TREANDA,Hemoglobin Decreased,Neutrophils Decreased Plat,0
TREANDA,Hemoglobin Decreased,Decreased,1
TREANDA,Hemoglobin Decreased,eased Leukocytes Hemoglobin,1
TREANDA,Hemoglobin Decreased,eased Leukocytes Hemoglobin,1
TREANDA,Hemoglobin Decreased,Decreased,0
TREANDA,Hemoglobin Decreased,,0
TREANDA,Hemoglobin Decreased,Leukocytes Decreased,0
TREANDA,Hemoglobin Decreased,Hemoglobin,1
TREANDA,Hemoglobin Decreased,Leukocytes Hemoglobin,1
TREANDA,Hemoglobin Decreased,,0
TREANDA,Neutrophils Decreased,,0
TREANDA,Neutrophils Decreased,Hemoglobin Decreased,0
TREANDA,Neutrophils Decreased,,0
TREANDA,Neutrophils Decreased,Decreased,0
TREANDA,Platelets Decreased,,0
TREANDA,Platelets Decreased,serious,0
TREANDA,Platelets Decreased,regardless,0
TREANDA,febrile neutropenia,of patients were,0
TREANDA,febrile neutropenia,in of patients febrile,1
TREANDA,pneumonia,patients were febrile neutropenia pneumonia,1
TREANDA,pneumonia,reported in clinical trials,0
TREANDA,pneumonia,were febrile neutropenia pneumonia,1
TREANDA,pneumonia,pneumonia,1
TREANDA,pneumonia,febrile neutropenia pneumonia,1
TREANDA,pneumonia,reactions occurring in,0
TREANDA,acute renal failure,reactions reported in clinical trials andor postmarketing,0
TREANDA,acute renal failure,myelodysplastic syndrom,0
TREANDA,acute renal failure,,0
TREANDA,cardiac failure,,0
TREANDA,cardiac failure,dr,0
TREANDA,cardiac failure,postmarketing experience were acute renal,0
TREANDA,hypersensitivity,in clinical trials andor postmarketing experience were acute,0
TREANDA,hypersensitivity,hypersensitivity,1
TREANDA,hypersensitivity,hypersensitivity,1
TREANDA,hypersensitivity,hypersensitivity,1
TREANDA,hypersensitivity,acute renal failure cardiac hypersensitivity,1
TREANDA,hypersensitivity,renal failure cardiac hypersensitivity,1
TREANDA,hypersensitivity,hypersensitivity,1
TREANDA,pulmonary fibrosis,were acute renal failure,0
TREANDA,pulmonary fibrosis,renal,0
TREANDA,pulmonary fibrosis,skin pulmonary,1
TREANDA,pulmonary fibrosis,skin pulmonary,1
TREANDA,myelodysplastic syndrome,syndrome,1
TREANDA,myelodysplastic syndrome,,0
TREANDA,myelosuppression,,0
TREANDA,myelosuppression,trials myelosuppression,1
TREANDA,myelosuppression,,0
TREANDA,myelosuppression,myelosuppression,1
TREANDA,infection,clinical trials included myelosuppression,0
TREANDA,infection,infection,1
TREANDA,infection,reported in clinical trials included myelosuppression,0
TREANDA,infection,and,0
TREANDA,infection,infection,1
TREANDA,infection,infection,1
TREANDA,infection,drugrelated adverse reactions reported in clinical trials,0
TREANDA,infection,clinical trials included infection,1
TREANDA,infection,in clinical trials included infection,1
TREANDA,infection,infection,1
TREANDA,pneumonia,,0
TREANDA,pneumonia,lysis syndrome and infusion reactions see Warnings and Precautions Adverse r,0
TREANDA,pneumonia,pneumonia,1
TREANDA,pneumonia,reactions reported,0
TREANDA,pneumonia,reactions,0
TREANDA,tumor lysis syndrome,myelosuppression infection tumor lysis,1
TREANDA,infusion reactions,clinical trials included myelosuppression infection pneumonia tumor lysis,0
TREANDA,hemolysis,treatment were,0
TREANDA,hemolysis,occurring less frequently but possibly related,0
TREANDA,hemolysis,hemolysis,1
TREANDA,hemolysis,hemolysis,1
TREANDA,hemolysis,hemolysis,1
TREANDA,dysgeusia,dysgeusia,1
TREANDA,dysgeusia,related to TREANDA treatment were,0
TREANDA,dysgeusia,related to,0
TREANDA,taste disorder,hemolysis taste disorder,1
TREANDA,taste disorder,TREANDA treatment,0
TREANDA,taste disorder,,0
TREANDA,taste disorder,disorder,1
TREANDA,taste disorder,were hemolysis taste,1
TREANDA,atypical pneumonia,necrosis Postmarketing Experienc,0
TREANDA,sepsis,sepsis,1
TREANDA,sepsis,sepsis,1
TREANDA,sepsis,,0
TREANDA,sepsis,disorder,0
TREANDA,sepsis,,0
TREANDA,sepsis,,0
TREANDA,sepsis,zoster erythema dermatitis and,0
TREANDA,herpes zoster,TREANDA treatment were,0
TREANDA,herpes zoster,atypical pneumonia herpes zoster,1
TREANDA,herpes zoster,skin necrosis Postmarketing Experience,0
TREANDA,herpes zoster,following,0
TREANDA,erythema,erythema,1
TREANDA,erythema,following adverse,0
TREANDA,erythema,erythema,1
TREANDA,erythema,erythema,1
TREANDA,erythema,Experience The following adverse,0
TREANDA,erythema,erythema,1
TREANDA,erythema,disorder atypical,0
TREANDA,erythema,erythema,1
TREANDA,dermatitis,dermatitis,1
TREANDA,dermatitis,following adverse,0
TREANDA,dermatitis,disorder atypical pneumonia sepsis herpes zoster erythema,0
TREANDA,skin necrosis,dermatitis skin,1
TREANDA,skin necrosis,erythema dermatitis skin necrosis,1
TREANDA,skin necrosis,necrosis,1
TREANDA,skin necrosis,herpes zoster erythema dermatitis skin,1
TREANDA,anaphylaxis,drug anaphylaxis,1
TREANDA,anaphylaxis,,0
TREANDA,anaphylaxis,anaphylaxis,1
TREANDA,anaphylaxis,exposure,0
TREANDA,anaphylaxis,to drug anaphylaxis,1
TREANDA,anaphylaxis,a causal,0
TREANDA,anaphylaxis,relationship to drug anaphylaxis,1
TREANDA,anaphylaxis,anaphylaxis,1
TREANDA,anaphylaxis,causal relationship to drug anaphylaxis,1
TREANDA,anaphylaxis,or,0
TREANDA,infusion site reactions,causal relationship,0
TREANDA,infusion site reactions,and injection or,0
TREANDA,infusion site reactions,swelling pneumocystis jiroveci pneumonia and,0
TREANDA,infusion site reactions,irritation pain and swelling pneumocystis jiroveci pneumonia,0
TREANDA,infusion site reactions,,0
TREANDA,infusion site reactions,injection infusion site reactions,1
TREANDA,pneumocystis jiroveci pneumonia,including SJS and,0
TREANDA,pneumocystis jiroveci pneumonia,when TREANDA was administer,0
TREANDA,pneumocystis jiroveci pneumonia,pneumocystis jiroveci pneumonia,1
TREANDA,pneumocystis jiroveci pneumonia,including,0
TREANDA,pneumonitis,TREANDA,0
TREANDA,Skin reactions,pneumocystis jiroveci pneumonia and Skin reactions,1
TREANDA,Skin reactions,,0
TREANDA,Skin reactions,Skin,1
TREANDA,Skin reactions,and swelling,0
TREANDA,Skin reactions,and Skin reactions,1
TREANDA,Skin reactions,was administered,0
TREANDA,Skin reactions,Skin reactions,1
TREANDA,Skin reactions,pneumocystis,0
TREANDA,Skin reactions,reactions,1
TREANDA,SJS,SJS,1
TREANDA,SJS,,0
TREANDA,SJS,SJS,1
TREANDA,SJS,allopurinol and,0
TREANDA,SJS,SJS,1
TREANDA,TEN,,0
TREANDA,TEN,concomitantly with allopurinol and other medications,0
TREANDA,TEN,TEN,1
TREANDA,TEN,SJS TEN,1
TREANDA,TEN,and pneumonitis Skin reactions including SJS and,0
TREANDA,TEN,allopurinol and other medications,0
TREANDA,TEN,SJS TEN,1
TREANDA,Myelosuppression,se reactions hav,1
TREANDA,Myelosuppression,and are discussed in greater detail in other,0
TREANDA,Myelosuppression,associated with,0
TREANDA,Myelosuppression,se reactions hav e,1
TREANDA,Myelosuppression,greater detail in other secti,0
TREANDA,Myelosuppression,clinical trials and are discussed in greater detail,0
TREANDA,Myelosuppression,,0
TREANDA,Myelosuppression,se,1
TREANDA,myelosuppression,M yelosuppression see Warnings,1
TREANDA,death,detail,0
TREANDA,Infections,sections,0
TREANDA,Infections,ecautions  Infections see Warnings,1
TREANDA,Anaphylaxis,see Warnings and Precautions ylaxis and  Infusion Reactions see,1
TREANDA,Anaphylaxis,Warnings and Precautions Tumor Lysis Syndrome see War,0
TREANDA,Anaphylaxis,Warnings,0
TREANDA,Anaphylaxis,Warnings and Precautions,0
TREANDA,Anaphylaxis,and Precautions ylaxis,1
TREANDA,Anaphylaxis,,0
TREANDA,Infusion Reactions,Warnings and Precautions Anaphylaxis,0
TREANDA,Infusion Reactions,,0
TREANDA,Infusion Reactions,Tumor Lysis Syndrome,0
TREANDA,Infusion Reactions,and Precautions Anaphylaxis and ion Reactions,1
TREANDA,Infusion Reactions,Precautions Anaphylaxis and ion,1
TREANDA,Infusion Reactions,Warnings and Precautions,0
TREANDA,anaphylactic reactions,d Precautions ( 5.3 Tumor Lysis Syndrome,1
TREANDA,anaphylactic reactions,Warnings an,0
TREANDA,anaphylactic reactions,see Warnings,0
TREANDA,anaphylactic reactions,Warnings d,1
TREANDA,anaphylactic reactions,5.3 Tumor Lysis Syndrome,1
TREANDA,Tumor Lysis Syndrome,"Warnings and  5.5  )]  
 *    Oth er Malignancies see",1
TREANDA,Tumor Lysis Syndrome,5.5 )],1
TREANDA,Tumor Lysis Syndrome,Oth er Malignancies see,1
TREANDA,Tumor Lysis Syndrome,,0
TREANDA,Tumor Lysis Syndrome,Reactions see Warnings and 5.5 )] *,1
TREANDA,Acute renal failure,see Warnings and,0
TREANDA,Acute renal failure,see Warnings and Precautions Other,0
TREANDA,Acute renal failure,and,0
TREANDA,Acute renal failure,Malignancies,1
TREANDA,Acute renal failure,Reactions see Warnings,0
TREANDA,Acute renal failure,and Precautions,0
TREANDA,Acute renal failure,[see Warnings and Precautions,1
TREANDA,death,a nd Precautions Extravasation,1
TREANDA,death,and Precautions Other Malignancies,0
TREANDA,death,ngs a nd Precautions Extravasation,1
TREANDA,death,Malignancies see ngs,1
TREANDA,death,see ngs,1
TREANDA,death,see Warni,0
TREANDA,death,and Precautions,0
TREANDA,death,ngs a nd Precautions Extravasation,1
TREANDA,death,injury see Warnings and,0
TREANDA,death,injury see Warnings and Precautions,0
TREANDA,SJS,,0
TREANDA,TEN,Warnings,0
TREANDA,TEN,hem atologic adverse reactions,1
TREANDA,TEN,,0
TREANDA,TEN,hem atologic adverse reactions,1
TREANDA,TEN,hem atologic adverse reactions,1
TREANDA,TEN,common hem atologic adverse reactions,1
TREANDA,fatal,,0
TREANDA,fatal,and Precautions Most,0
TREANDA,fatal,and Precautions Most common c adv erse reactions for,1
TREANDA,fatal,nonhematologi,0
TREANDA,fatal,nausea and,0
TREANDA,fatal,Precautions Most common c,1
TREANDA,fatal,Precautions Most common c adv erse reactions for,1
TREANDA,fatal,c,1
TREANDA,Malignancies,anorexia cough,0
TREANDA,Malignancies,e nausea fatigue vomiting diarrhea,0
TREANDA,malignant diseases,pyrexia constipation anorexia cough headache weight decreased dyspnea rash,0
TREANDA,Extravasation,"anorexia h, headache,  weight decreased dyspnea",1
TREANDA,Extravasation,nausea fatigue vomiting diarrhea pyrexia constipation anorexia coug,0
TREANDA,Extravasation,"diarrhea pyrexia constipation anorexia h, headache,  weight decreased dyspnea",1
TREANDA,Extravasation,"pyrexia constipation anorexia h,",1
TREANDA,Extravasation,hematologic abnorma,0
TREANDA,Extravasation,vomiting diarrhea pyrexia constipation,0
TREANDA,Extravasation,hematologic,0
TREANDA,Fetal harm,(frequency are lymphopenia anemia,1
TREANDA,Fetal harm,lymphopenia anemia leukopenia,0
TREANDA,Fetal harm,(frequency are lymphopenia anemia,1
TREANDA,Fetal harm,neutropenia EX,0
TREANDA,myelosuppression,or at 1-800-FDA-108 or wwwfdagovmedwatch Clinical,1
TREANDA,myelosuppression,at 1-800-FDA-108 or wwwfdagovmedwatch Clinical,1
TREANDA,myelosuppression,,0
TREANDA,myelosuppression,at 1-800-FDA-108 or wwwfdagovmedwatch Clinical,1
TREANDA,died,ical trials are conducted,1
TREANDA,died,ical trials are conducted,1
TREANDA,died,ical trials are conducted,1
TREANDA,died,ical trials are conducted,1
TREANDA,died,are,0
TREANDA,died,adverse reaction rates observed in the,0
TREANDA,died,Because ical trials are conducted,1
TREANDA,died,,0
TREANDA,died,ical trials are conducted,1
TREANDA,died,ical trials are conducted,1
TREANDA,myelosuppression-related adverse reactions,Experience Because,0
TREANDA,myelosuppression-related adverse reactions,a drug cannot be directly compared,0
TREANDA,myelosuppression-related adverse reactions,tions adverse reaction rates observed in,0
TREANDA,thrombocytopenia,drug t be directly co mpared to rates,1
TREANDA,thrombocytopenia,drug t be directly co mpared to rates,1
TREANDA,thrombocytopenia,co mpared to rates,1
TREANDA,thrombocytopenia,rates,0
TREANDA,thrombocytopenia,trials of a drug t,1
TREANDA,pneumonia,cannot,0
TREANDA,pneumonia,rates in the clinical,1
TREANDA,opportunistic infection,anoth er drug and,1
TREANDA,Infection,,0
TREANDA,pneumonia,n one or more studies included,1
TREANDA,pneumonia,seen frequently n one,1
TREANDA,pneumonia,weakness dry mouth somnolence cough,0
TREANDA,pneumonia,vomiting Other adverse,0
TREANDA,sepsis,cough,0
TREANDA,sepsis,or re stu dies included asthenia,1
TREANDA,septic shock,es included asthenia fatigue malaise,1
TREANDA,septic shock,included asthenia fatigue malaise,1
TREANDA,septic shock,more es,1
TREANDA,death,"ia, f atigue malaise and",1
TREANDA,death,atigue malaise and weakness dry mouth somnolence cough constipation headache mucosal inflamm,0
TREANDA,death,atigue malaise and weakness dry,0
TREANDA,death,constipation headache mucosal inflamm,0
TREANDA,death,Other adverse,0
TREANDA,death,"more studies included ia,",1
TREANDA,myelosuppression,"mucosal inflammation stomatitis. 



 Worsening hypertension was",1
TREANDA,myelosuppression,"stomatitis. 



 Worsening hypertension was",1
TREANDA,myelosuppression,"stomatitis. 



 Worsening hypertension was",1
TREANDA,myelosuppression,TREANDA in the CLL trial and,0
TREANDA,myelosuppression,"stomatitis. 



 Worsening hypertension was",1
TREANDA,Infusion reactions,crisis,0
TREANDA,Infusion reactions,The,1
TREANDA,Infusion reactions,"and 



 The most freq uent adverse reactions",1
TREANDA,Infusion reactions,"



 The most freq uent adverse reactions",1
TREANDA,Infusion reactions,with oral medications and The most,1
TREANDA,Infusion reactions,most freq uent adverse reactions,1
TREANDA,Infusion reactions,with oral medications and The,1
TREANDA,fever,g TRE ANDA were hypersensitivity,1
TREANDA,fever,patients g,1
TREANDA,fever,,0
TREANDA,fever,contains the treatment emergent,0
TREANDA,fever,leading to,0
TREANDA,fever,were hypersensitivity and pyrexia Table contains,0
TREANDA,chills,contains the treatment emergent,0
TREANDA,chills,reacti,0
TREANDA,chills,DA wer e hypersensitivity and,1
TREANDA,chills,for patients receiving DA wer e hypersensitivity and,1
TREANDA,chills,wer e hypersensitivity and,1
TREANDA,chills,pyrexia Table contains the treatment,0
TREANDA,chills,patients receiving DA,1
TREANDA,chills,withdrawal for patients receiving DA wer e hypersensitivity and,1
TREANDA,chills,DA wer e hypersensitivity and,1
TREANDA,chills,for patients receiving DA wer e hypersensitivity and,1
TREANDA,pruritus,most frequent adverse reactions leading to study withdrawal,0
TREANDA,pruritus,adverse reactions leading to study,0
TREANDA,pruritus,for patients receiving TREANDA were,0
TREANDA,pruritus,hypersen sitivity and pyrexia,1
TREANDA,pruritus,and pyrexia Table contains the treatment emergent,0
TREANDA,pruritus,and pyrexia Table contains the treatment emergent adverse reactions regar,0
TREANDA,pruritus,hypersen sitivity and pyrexia,1
TREANDA,anaphylactoid reactions,,0
TREANDA,anaphylactoid reactions,receiving TREANDA,0
TREANDA,anaphylactoid reactions,emergent adverse reactions regardless,1
TREANDA,Tumor lysis syndrome,                     Nausea,1
TREANDA,Tumor lysis syndrome,Nausea,0
TREANDA,acute renal failure,"           
    Dia rrhea",1
TREANDA,acute renal failure,"           
    Dia rrhea",1
TREANDA,death,Diarrhea,0
TREANDA,death,      Gene,1
TREANDA,death,Diarrhea,0
TREANDA,death,      Gene,1
TREANDA,death,Diarrhea,0
TREANDA,death,Diarrhea,0
TREANDA,death,Gene,0
TREANDA,death,Diarrhea       Gene,1
TREANDA,death,Diarrhea,0
TREANDA,death,      Gene,1
TREANDA,skin toxicity,Pyrexia       36 (24) Fatigue,1
TREANDA,skin toxicity,,0
TREANDA,skin toxicity,Pyrexia 36,1
TREANDA,Skin reactions,Fatigue       0        Asthenia,1
TREANDA,Skin reactions,      0        Asthenia,1
TREANDA,Skin reactions,      0        Asthenia,1
TREANDA,Skin reactions,Fatigue,0
TREANDA,Skin reactions,,0
TREANDA,rash,     Chills,1
TREANDA,rash,     Chills,1
TREANDA,rash,,0
TREANDA,rash,     Chills,1
TREANDA,rash,Asthenia,0
TREANDA,rash,     Chills,1
TREANDA,rash,     Chills,1
TREANDA,rash,,0
TREANDA,rash,Asthenia,0
TREANDA,toxic skin reactions,"    
    Chills      Im",1
TREANDA,toxic skin reactions,"    
    Chills      Im",1
TREANDA,toxic skin reactions,"    
    Chills      Im",1
TREANDA,toxic skin reactions,"    
    Chills      Im",1
TREANDA,bullous exanthema,system disorders,0
TREANDA,bullous exanthema,                  Immune system disorders,1
TREANDA,bullous exanthema,                 ,1
TREANDA,bullous exanthema,Chills,0
TREANDA,TEN,ty  Infectio,1
TREANDA,TEN,Hypersensitivi ty  Infectio,1
TREANDA,TEN,,0
TREANDA,TEN,Hypersensitivi ty  Infectio,1
TREANDA,TEN,,0
TREANDA,TEN,,0
TREANDA,TEN,ty  Infectio,1
TREANDA,TEN,,0
TREANDA,TEN,ty  Infectio,1
TREANDA,TEN,Hypersensitivi,0
TREANDA,Stevens-Johnson syndrome,,0
TREANDA,Stevens-Johnson syndrome,ensitivity Infections,1
TREANDA,Stevens-Johnson syndrome,and infest ations,1
TREANDA,SJS,and,0
TREANDA,SJS,and ion s,1
TREANDA,SJS,ion s,1
TREANDA,SJS,ion s,1
TREANDA,TEN,,0
TREANDA,TEN,,0
TREANDA,TEN,Infections and     Nasopharyngitis,1
TREANDA,TEN,    Nasopharyngitis,1
TREANDA,TEN,    Nasopharyngitis,1
TREANDA,TEN,,0
TREANDA,TEN,,0
TREANDA,TEN,    Nasopharyngitis,1
TREANDA,fatal,,0
TREANDA,fatal,      Nasopharyngitis,1
TREANDA,fatal,      Nasopharyngitis,1
TREANDA,fatal,Infections and       Nasopharyngitis,1
TREANDA,fatal,      Nasopharyngitis,1
TREANDA,fatal,Infections and       Nasopharyngitis,1
TREANDA,fatal,and,0
TREANDA,fatal,,0
TREANDA,skin reactions,simplex,0
TREANDA,skin reactions,Infection,0
TREANDA,skin reactions,Infection               ,1
TREANDA,skin reactions,Infection,0
TREANDA,malignant diseases,"               
   Weight decreased",1
TREANDA,malignant diseases,,0
TREANDA,malignant diseases,Investigations,0
TREANDA,malignant diseases,"               
   Weight",1
TREANDA,malignant diseases,Weight decreased,0
TREANDA,malignant diseases,Investigations,0
TREANDA,myelodysplastic syndrome,5 (3),1
TREANDA,myelodysplastic syndrome,,0
TREANDA,myelodysplastic syndrome,  5 (3)         0        Metabolism,1
TREANDA,myelodysplastic syndrome,0 Metabolism,1
TREANDA,myelodysplastic syndrome,Weight 5,1
TREANDA,myelodysplastic syndrome,5 (3),1
TREANDA,myelodysplastic syndrome,Weight   5 (3)         0        Metabolism,1
TREANDA,myeloproliferative disorders,"ght    
  Metabolism and nutriti on",1
TREANDA,myeloproliferative disorders,,0
TREANDA,myeloproliferative disorders,disorders Hyperuric,0
TREANDA,myeloproliferative disorders,on,0
TREANDA,myeloproliferative disorders,decreased,0
TREANDA,acute myeloid leukemia,and,0
TREANDA,acute myeloid leukemia,and,0
TREANDA,acute myeloid leukemia,Metabolism and  disorders             Hyperuricemia,1
TREANDA,acute myeloid leukemia, disorders             Hyperuricemia,1
TREANDA,acute myeloid leukemia,,0
TREANDA,acute myeloid leukemia,Metabolism and  disorders             Hyperuricemia,1
TREANDA,acute myeloid leukemia, disorders             Hyperuricemia,1
TREANDA,bronchial carcinoma,,0
TREANDA,bronchial carcinoma,nutrition                     Hyperuricemia,1
TREANDA,bronchial carcinoma,and nutrition,0
TREANDA,bronchial carcinoma,,0
TREANDA,bronchial carcinoma,and nutrition disorders,0
TREANDA,bronchial carcinoma,                    Hyperuricemia,1
TREANDA,bronchial carcinoma,and nutrition                     Hyperuricemia,1
TREANDA,bronchial carcinoma,disorders,0
TREANDA,bronchial carcinoma,                    Hyperuricemia,1
TREANDA,extravasations,(2) 2 (,1
TREANDA,extravasations,,0
TREANDA,extravasations,Hyperuricemia (2)        2 ( Respiratory,1
TREANDA,extravasations,,0
TREANDA,extravasations,Hyperuricemia,0
TREANDA,extravasations,thoracic and,0
TREANDA,extravasations,,0
TREANDA,extravasations,(2) 2 ( Respiratory thoracic,1
TREANDA,extravasations,2 ( Respiratory thoracic and mediastinal disorders,1
TREANDA,erythema,thoracic and mediastinal s        Cough,1
TREANDA,erythema,s        Cough,1
TREANDA,erythema,s        Cough,1
TREANDA,erythema,and mediastinal disorder,0
TREANDA,erythema,disorder,0
TREANDA,erythema,Cough,0
TREANDA,erythema,,0
TREANDA,swelling,         Cough,1
TREANDA,swelling,         Cough,1
TREANDA,pain,     Cough,1
TREANDA,pain,,0
TREANDA,pain,     Cough,1
TREANDA,pain,,0
TREANDA,pain,     Cough,1
TREANDA,pain,     Cough,1
TREANDA,pain,     Cough,1
TREANDA,fetal harm,tissue disorders            Prur,1
TREANDA,fetal harm,           Prur,1
TREANDA,fetal harm,,0
TREANDA,fetal harm,disorders Rash,0
TREANDA,fetal harm,tissue disorders            Prur,1
TREANDA,fetal harm,           Prur,1
TREANDA,fetal harm,tissue disorders Rash,0
TREANDA,fetal harm,,0
TREANDA,fetal harm,disorders Rash,0
TREANDA,fetal harm,           Prur,1
TREANDA,visceral malformations,"    0            
    ",1
TREANDA,visceral malformations,Pruritus,0
TREANDA,visceral malformations,Pruritus,0
TREANDA,visceral malformations,"    0            
     The Grade and hematology",1
TREANDA,visceral malformations,Pruritus,0
TREANDA,visceral malformations,Pruritus,0
TREANDA,visceral malformations,"    0            
     The Grade and hematology laboratory",1
TREANDA,visceral malformations,"    0            
     The Grade and hematology",1
TREANDA,decreased fetal body weights,The Grade 3,1
TREANDA,decreased fetal body weights,The Grade 3 and 4,1
TREANDA,decreased fetal body weights,,0
TREANDA,decreased fetal body weights,4 hematolog y,1
TREANDA,decreased fetal body weights,,0
TREANDA,decreased fetal body weights,The Grade,1
ELIQUIS,thrombotic events,,0
ELIQUIS,thrombotic events,greater detail in other sections of the prescribing information Increased risk of,0
ELIQUIS,thrombotic events,prescribing information Increased risk thrombotic events after premature,1
ELIQUIS,thrombotic events,Increased,0
ELIQUIS,Bleeding,Bleeding seeWarnings and,1
ELIQUIS,Bleeding,or puncture seeWarnings an,0
ELIQUIS,bleeding,and Precautions EXCERPT,0
ELIQUIS,bleeding-related adverse reactions,reactions in ARISTOTLE,1
ELIQUIS,bleeding-related adverse reactions,common reason for treatment discontinuation in both studies was for,0
ELIQUIS,bleeding,one,0
ELIQUIS,bleeding,of patients experiencing bleeding during the,1
ELIQUIS,bleeding,bleeding during the,1
ELIQUIS,bleeding,bleeding during the,1
ELIQUIS,bleeding,bleeding during the,1
ELIQUIS,bleeding,bleeding during the,1
ELIQUIS,bleeding,one,0
ELIQUIS,bleeding,bleeding rate percentage,1
ELIQUIS,bleeding,treatment period and bleeding rate percentage,1
ELIQUIS,bleeding,,0
ELIQUIS,bleeding,bleeding event per,1
ELIQUIS,bleeding,bleeding event per,1
ELIQUIS,bleeding,bleeding event per,1
ELIQUIS,bleeding,bleeding event per,1
ELIQUIS,bleeding,least bleeding event per,1
ELIQUIS,bleeding,rate percentage of subjects with at,0
ELIQUIS,Bleeding,,0
ELIQUIS,Bleeding,Patients,0
ELIQUIS,Bleeding,at least one bleeding event per patientyears in,0
ELIQUIS,Bleeding,Bleeding Events in,1
ELIQUIS,Bleeding,in ARISTOTLE and AVERROES Bleeding Events in,1
ELIQUIS,Bleeding,,0
ELIQUIS,Bleeding,Bleeding events within,1
ELIQUIS,Bleeding,events within each subcategory were,0
ELIQUIS,Bleeding,,0
ELIQUIS,Bleeding,Bleeding events were,1
ELIQUIS,Bleeding,during,0
ELIQUIS,Bleeding,once per subject,0
ELIQUIS,Bleeding,Bleeding events were,1
ELIQUIS,Bleeding,stopping study,0
ELIQUIS,bleeding,bleeding accompanied by,1
ELIQUIS,decrease in hemoglobin,cells bleeding at,0
ELIQUIS,decrease in hemoglobin,in hemoglobin of gdL,1
ELIQUIS,decrease in hemoglobin,a transfusion of or more units,0
ELIQUIS,decrease in hemoglobin,of the following decrease in,1
ELIQUIS,decrease in hemoglobin,the following decrease in hemoglobin of gdL,1
ELIQUIS,decrease in hemoglobin,cells bleeding at a,0
ELIQUIS,decrease in hemoglobin,in hemoglobin of gdL,1
ELIQUIS,decrease in hemoglobin,,0
ELIQUIS,bleeding at a critical site,intracranial intraspinal intraocular pericardial intraarticular intramuscular with compartme,0
ELIQUIS,bleeding at a critical site,blood,0
ELIQUIS,bleeding at a critical site,site intracranial intraspinal,1
ELIQUIS,bleeding at a critical site,packed red blood bleeding at a critical site intracranial intraspinal,1
ELIQUIS,bleeding at a critical site,decrease in hemoglobin of gdL a transfusion of or more units of,0
ELIQUIS,bleeding at a critical site,critical site intracranial intraspinal,1
ELIQUIS,bleeding at a critical site,of packed red,0
ELIQUIS,bleeding at a critical site,intraarticular,0
ELIQUIS,compartment syndrome,fatal outcome Intracranial bleed includes,0
ELIQUIS,Intracranial bleed,intramuscular with compartment syndrome retroperitoneal or with,0
ELIQUIS,Intracranial bleed,outcome,0
ELIQUIS,Intracranial bleed,with compartment syndrome retroperitoneal or with,0
ELIQUIS,Intracranial bleed,outcome,0
ELIQUIS,Intracranial bleed,bleed includes intracerebral,1
ELIQUIS,Intracranial bleed,bleed includes intracerebral,1
ELIQUIS,Intracranial bleed,Any type,0
ELIQUIS,Intracranial bleed,Intracranial bleed includes intracerebral,1
ELIQUIS,Intracranial bleed,Intracranial bleed includes intracerebral,1
ELIQUIS,Intracranial bleed,,0
ELIQUIS,subarachnoid bleeding,includes intracerebral intraventricular subdural subarachnoid,1
ELIQUIS,subarachnoid bleeding,subarachnoid,1
ELIQUIS,subarachnoid bleeding,subdural subarachnoid bleeding Any type,1
ELIQUIS,subarachnoid bleeding,outcome,0
ELIQUIS,subarachnoid bleeding,intraventricular subdural subarachnoid bleeding Any type,1
ELIQUIS,subarachnoid bleeding,includes intracerebral intraventricular subdural subarachnoid bleeding Any type,1
ELIQUIS,hemorrhagic stroke,subarachnoid bleeding Any type hemorrhagic,1
ELIQUIS,hemorrhagic stroke,hemorrhagic stroke was adjudicated,1
ELIQUIS,GI bleed,,0
ELIQUIS,GI bleed,,0
ELIQUIS,GI bleed,ITT analysis presented in GI bleed includes upper,1
ELIQUIS,rectal bleeding,analysis presented in Section GI bleed includes upper GI lower GI and,0
ELIQUIS,rectal bleeding,bleeding Fatal bleeding,1
ELIQUIS,Fatal,Fatal bleeding is,1
ELIQUIS,Fatal,Fatal bleeding is,1
ELIQUIS,death,bleed includes,0
ELIQUIS,death,an death with the,1
ELIQUIS,death,primary cause of death as intracranial,0
ELIQUIS,death,death with the,1
ELIQUIS,death,death,0
ELIQUIS,death,with the primary cause,0
ELIQUIS,death,bleeding is an death with the,1
ELIQUIS,death,cause of death as intracranial bleeding or nonintracranial bleeding during the on,0
ELIQUIS,death,GI and rectal,0
ELIQUIS,death,the primary cause death as intracranial,1
ELIQUIS,death,period,0
ELIQUIS,death,death as intracranial,1
ELIQUIS,death,death as intracranial,1
ELIQUIS,death,death as intracranial,1
ELIQUIS,death,intracranial bleeding or nonintracranial bleeding during the ontreatment period Major,0
ELIQUIS,death,,0
ELIQUIS,death,cause death as intracranial,1
ELIQUIS,intracranial bleeding,intracranial bleeding or nonintracranial,1
ELIQUIS,intracranial bleeding,cause of death intracranial,1
ELIQUIS,intracranial bleeding,,0
ELIQUIS,intracranial bleeding,of death as,0
ELIQUIS,intracranial bleeding,death with the primary cause,0
ELIQUIS,intracranial bleeding,of death intracranial,1
ELIQUIS,intracranial bleeding,,0
ELIQUIS,non-intracranial bleeding,non-intracranial bleeding during the,1
ELIQUIS,non-intracranial bleeding,death as intracranial bleeding non-intracranial bleeding during the,1
ELIQUIS,non-intracranial bleeding,,0
ELIQUIS,non-intracranial bleeding,,0
ELIQUIS,ICH,Intracranial,0
ELIQUIS,ICH,ICH He,1
ELIQUIS,ICH,ICH He,1
ELIQUIS,ICH,,0
ELIQUIS,ICH,Intracranial,0
ELIQUIS,ICH,ICH He,1
ELIQUIS,ICH,Intracranial ICH He,1
ELIQUIS,ICH,ICH He,1
ELIQUIS,Hemorrhagic stroke,CH,0
ELIQUIS,Hemorrhagic stroke,S Other,0
ELIQUIS,Hemorrhagic stroke,,0
ELIQUIS,Hemorrhagic stroke,CH,0
ELIQUIS,Hemorrhagic stroke,CH Hemorrhagic stroke S,1
ELIQUIS,Hemorrhagic stroke,Hemorrhagic stroke S,1
ELIQUIS,Hemorrhagic stroke,CH Hemorrhagic,1
ELIQUIS,Hemorrhagic stroke,,0
ELIQUIS,ICH,Other,0
ELIQUIS,ICH,Other ICH,1
ELIQUIS,ICH,,0
ELIQUIS,Fatal,Fatal,1
ELIQUIS,Fatal,al Fatal,1
ELIQUIS,Fatal,GI,0
ELIQUIS,Fatal,GI,0
ELIQUIS,Fatal,GI,0
ELIQUIS,bled,region and aspirin use at,0
ELIQUIS,bled,Major Bl,0
ELIQUIS,bled,use at randomization Figure Subjects treated with,0
ELIQUIS,bled,diabetes,0
ELIQUIS,bled,bled,1
ELIQUIS,bled,more per year than did subjects without diabetes per year Figure Major,0
ELIQUIS,bled,Figure Major Bl,0
ELIQUIS,bled,aspirin,0
ELIQUIS,bled,did subjects,0
ELIQUIS,Bleeding,without diabetes per,0
ELIQUIS,Bleeding,per year Figure Bleeding,1
ELIQUIS,Bleeding,diabetes per year Figure Bleeding,1
ELIQUIS,Bleeding,per,0
ELIQUIS,Bleeding,per year than did subjects without diabetes per year Figure Major,0
ELIQUIS,Bleeding,more per year than,0
ELIQUIS,Bleeding,Bleeding,1
ELIQUIS,Bleeding,overinterpreted,0
ELIQUIS,Bleeding,Bleeding,1
ELIQUIS,Fatal,,0
ELIQUIS,Fatal,Fatal,1
ELIQUIS,Fatal,,0
ELIQUIS,Fatal,,0
ELIQUIS,Fatal,Fatal,1
ELIQUIS,Fatal,,0
ELIQUIS,Bleeding,,0
ELIQUIS,Bleeding,ARISTOTLE Bleeding,1
ELIQUIS,Bleeding,Bleeding,1
ELIQUIS,Bleeding,Major,0
ELIQUIS,Bleeding,reactions including drug hypersensitivit,0
ELIQUIS,Bleeding,Reactions Hypersensitivity reactions including,0
ELIQUIS,Bleeding,,0
ELIQUIS,Hypersensitivity reactions,Plot Other Adverse Hypersensitivity reactions,1
ELIQUIS,drug hypersensitivity,,0
ELIQUIS,drug hypersensitivity,Adverse Reactions Hypersensitivity reactions drug,1
ELIQUIS,drug hypersensitivity,Adverse Reactions Hypersensitivity reactions drug,1
ELIQUIS,drug hypersensitivity,,0
ELIQUIS,drug hypersensitivity,as skin rash and anaphylactic reactions such as,0
ELIQUIS,drug hypersensitivity,,0
ELIQUIS,drug hypersensitivity,drug hypersensitivity,1
ELIQUIS,drug hypersensitivity,reactions including,0
ELIQUIS,drug hypersensitivity,drug hypersensitivity,1
ELIQUIS,drug hypersensitivity,rash and anaphylactic,0
ELIQUIS,skin rash,Adverse Reactions Hypersensitivity,0
ELIQUIS,skin rash,,0
ELIQUIS,anaphylactic reactions,Prop,0
ELIQUIS,anaphylactic reactions,were,0
ELIQUIS,anaphylactic reactions,skin rash and,0
ELIQUIS,anaphylactic reactions,anaphylactic reactions,1
ELIQUIS,anaphylactic reactions,such as skin rash anaphylactic,1
ELIQUIS,anaphylactic reactions,Reactions Hypersensitivity reactions including drug hypersensitivity such as skin,0
ELIQUIS,anaphylactic reactions,skin rash,0
ELIQUIS,allergic edema,were reported in of patients receiving ELIQUIS Prophylaxis of Deep Vein,0
ELIQUIS,Bleeding,Bleeding,1
ELIQUIS,Bleeding,studies are,0
ELIQUIS,Bleeding,,0
ELIQUIS,Bleeding,period,0
ELIQUIS,Bleeding,during the treatment period in the Phase III studies are shown,0
ELIQUIS,Bleeding,with,0
ELIQUIS,Bleeding,study,0
ELIQUIS,Bleeding,Bleeding,1
ELIQUIS,Bleeding,,0
ELIQUIS,Bleeding,Bleeding,1
ELIQUIS,bleeding,,0
ELIQUIS,bleeding,bleeding,1
ELIQUIS,surgical site bleeding,surgical site bleeding,1
ELIQUIS,surgical site bleeding,Surgery All bleeding criteria surgical site,1
ELIQUIS,surgical site bleeding,Includes subjects with major bleeding events that occurred,0
ELIQUIS,surgical site bleeding,bleeding,1
ELIQUIS,bleeding,surgery,0
ELIQUIS,bleeding,bleeding,1
ELIQUIS,bleeding,bleeding,1
ELIQUIS,bleeding,bleeding,1
ELIQUIS,bleeding,bleeding,1
ELIQUIS,bleeding,,0
ELIQUIS,bleeding,the first,0
ELIQUIS,bleeding,included surgical site bleeding,0
ELIQUIS,Bleeding into an operated joint,in all,0
ELIQUIS,Bleeding into an operated joint,into an operated joint,1
ELIQUIS,Bleeding into an operated joint,was present in,0
ELIQUIS,bleeding,requiring,0
ELIQUIS,bleeding,this,0
ELIQUIS,intracranial hemorrhage,clinically relevant nonmajor ELIQUIS mg po,0
ELIQUIS,intracranial hemorrhage,ADVANCE who also intracranial,1
ELIQUIS,intracranial hemorrhage,event rates include one enoxaparintreated patient in,0
ELIQUIS,intracranial hemorrhage,ADVANCE,0
ELIQUIS,intracranial hemorrhage,hemorrhage,1
ELIQUIS,intracranial hemorrhage,who also intracranial,1
ELIQUIS,intracranial hemorrhage,who also intracranial,1
ELIQUIS,intracranial hemorrhage,ADVANCE who also intracranial hemorrhage,1
ELIQUIS,Fatal,Fatal,1
ELIQUIS,Fatal,,0
ELIQUIS,Fatal,,0
ELIQUIS,Fatal,,0
ELIQUIS,Fatal,,0
ELIQUIS,Hgb decrease,,0
ELIQUIS,Hgb decrease,,0
ELIQUIS,Bleed at critical site,,0
ELIQUIS,Bleed at critical site,Bleed at,1
ELIQUIS,Bleed at critical site,site S,1
ELIQUIS,Bleed at critical site,S,0
ELIQUIS,Nausea,Nausea,1
ELIQUIS,Nausea,Enoxaparin n mg sc,0
ELIQUIS,Nausea,bidN Enoxaparin n mg sc qd or mg sc qhN,0
ELIQUIS,Nausea,bidN Enoxaparin n mg sc qd or mg,0
ELIQUIS,Nausea,mg sc Nausea,1
ELIQUIS,Nausea,n,0
ELIQUIS,Nausea,Nausea,1
ELIQUIS,Nausea,Nausea,1
ELIQUIS,Nausea,Nausea,1
ELIQUIS,Anemia,Anemia including postoperative and hemorrhagic,1
ELIQUIS,Anemia,,0
ELIQUIS,hemorrhagic anemia,hemorrhagic anemia and respective laboratory parameters Contu,1
ELIQUIS,hemorrhagic anemia,including,0
ELIQUIS,hemorrhagic anemia,respective laboratory parameters Contu,0
ELIQUIS,hemorrhagic anemia,hemorrhagic anemia and respective laboratory parameters Contu,1
ELIQUIS,hemorrhagic anemia,anemia and respective laboratory parameters Contu,1
ELIQUIS,Contusion,and respective laboratory parameters,0
ELIQUIS,Contusion,Contusion,1
ELIQUIS,Hemorrhage,Hemorrhage including hematoma and vaginal,1
ELIQUIS,Hemorrhage,vaginal and urethral hemorrhage,0
ELIQUIS,Hemorrhage,Hemorrhage,1
ELIQUIS,Hemorrhage,,0
ELIQUIS,hematoma,,0
ELIQUIS,hematoma,,0
ELIQUIS,hematoma,hematoma and vaginal,1
ELIQUIS,urethral hemorrhage,urethral hemorrhage Postprocedural hemorrhage,1
ELIQUIS,urethral hemorrhage,vaginal urethral hemorrhage Postprocedural hemorrhage,1
ELIQUIS,urethral hemorrhage,hemorrhage Postprocedural hemorrhage,1
ELIQUIS,Postprocedural hemorrhage,Postprocedural hemorrhage including postprocedural,1
ELIQUIS,Postprocedural hemorrhage,and urethral hemorrhage,0
ELIQUIS,Postprocedural hemorrhage,Postprocedural hemorrhage including postprocedural,1
ELIQUIS,Postprocedural hemorrhage,hemorrhage,0
ELIQUIS,Postprocedural hemorrhage,urethral Postprocedural hemorrhage including postprocedural,1
ELIQUIS,postprocedural hematoma,rrhage Postprocedural hemorrhage postprocedural hematoma wound hemorrhage,1
ELIQUIS,postprocedural hematoma,,0
ELIQUIS,postprocedural hematoma,hematoma wound hemorrhage,1
ELIQUIS,postprocedural hematoma,postprocedural hematoma wound hemorrhage,1
ELIQUIS,postprocedural hematoma,hemorrhage postprocedural,1
ELIQUIS,postprocedural hematoma,hemorrhage,0
ELIQUIS,postprocedural hematoma,catheter site,0
ELIQUIS,postprocedural hematoma,,0
ELIQUIS,postprocedural hematoma,vessel puncture site,0
ELIQUIS,wound hemorrhage,hematoma and catheter site,0
ELIQUIS,wound hemorrhage,hemorrhage including postprocedural,0
ELIQUIS,wound hemorrhage,,0
ELIQUIS,catheter site hemorrhage,and,0
ELIQUIS,catheter site hemorrhage,alanine,0
ELIQUIS,catheter site hemorrhage,hematoma catheter site hemorrhage Transaminases increased,1
ELIQUIS,catheter site hemorrhage,Transaminases increased including alanine,0
ELIQUIS,catheter site hemorrhage,hemorrhage vessel puncture,0
ELIQUIS,Transaminases increased,increased and alanine aminotransferase abnormal,0
ELIQUIS,Transaminases increased,,0
ELIQUIS,Transaminases increased,hematoma and catheter site Transaminases increased including alanine,1
ELIQUIS,alanine aminotransferase increased,alanine aminotransferase increased and alanine,1
ELIQUIS,alanine aminotransferase increased,,0
ELIQUIS,alanine aminotransferase increased,alanine aminotransferase,0
ELIQUIS,alanine aminotransferase increased,including,0
ELIQUIS,alanine aminotransferase increased,increased and alanine,1
ELIQUIS,alanine aminotransferase increased,increased alanine,1
ELIQUIS,alanine aminotransferase increased,,0
ELIQUIS,alanine aminotransferase increased,alanine aminotransferase increased and alanine,1
ELIQUIS,alanine aminotransferase increased,alanine aminotransferase increased and alanine,1
ELIQUIS,alanine aminotransferase increased,alanine aminotransferase increased and alanine,1
ELIQUIS,alanine aminotransferase abnormal,abnormal Aspartate aminotransferase,1
ELIQUIS,alanine aminotransferase abnormal,aminotransferase,0
ELIQUIS,alanine aminotransferase abnormal,aminotransferase,0
ELIQUIS,alanine aminotransferase abnormal,,0
ELIQUIS,alanine aminotransferase abnormal,including alanine aminotransferase increased alanine aminotransferase,1
ELIQUIS,alanine aminotransferase abnormal,,0
ELIQUIS,alanine aminotransferase abnormal,aminotransferase increased alanine aminotransferase abnormal Aspartate aminotransferase,1
ELIQUIS,Aspartate aminotransferase increased,Gammaglutamyltransferase,0
ELIQUIS,Aspartate aminotransferase increased,aminotransferase increased Gammaglutamyltransferase i,1
ELIQUIS,Aspartate aminotransferase increased,and,0
ELIQUIS,Aspartate aminotransferase increased,aminotransferase Aspartate aminotransferase,1
ELIQUIS,Aspartate aminotransferase increased,and alanine,0
ELIQUIS,Aspartate aminotransferase increased,,0
ELIQUIS,Aspartate aminotransferase increased,aminotransferase Aspartate,1
ELIQUIS,Aspartate aminotransferase increased,abnormal,0
ELIQUIS,Gamma-glutamyltransferase increased,aminotransferase Gamma-glutamyltransferase,1
ELIQUIS,Gamma-glutamyltransferase increased,increased,0
ELIQUIS,Gamma-glutamyltransferase increased,Gamma-glutamyltransferase increased Less common,1
ELIQUIS,Gamma-glutamyltransferase increased,increased,0
ELIQUIS,Gamma-glutamyltransferase increased,,0
ELIQUIS,Gamma-glutamyltransferase increased,Gamma-glutamyltransferase,1
ELIQUIS,Gamma-glutamyltransferase increased,Gamma-glutamyltransferase increased Less common,1
ELIQUIS,Gamma-glutamyltransferase increased,,0
ELIQUIS,Gamma-glutamyltransferase increased,Gamma-glutamyltransferase,1
ELIQUIS,Gamma-glutamyltransferase increased,Gamma-glutamyltransferase increased Less common,1
ELIQUIS,platelet count decreases,system disorders thrombocytopenia platelet count,1
ELIQUIS,platelet count decreases,procedural hypotension,0
ELIQUIS,platelet count decreases,including,0
ELIQUIS,platelet count decreases,procedural hypotension Respiratory thora,0
ELIQUIS,platelet count decreases,disorders hypotension,0
ELIQUIS,platelet count decreases,to Blood,0
ELIQUIS,platelet count decreases,to Blood,0
ELIQUIS,platelet count decreases,thrombocytopenia including,0
ELIQUIS,hypotension,hypotension including procedural,1
ELIQUIS,hypotension,hypotension including procedural,1
ELIQUIS,hypotension,procedural hypotension Respiratory,0
ELIQUIS,hypotension,hypotension including procedural,1
ELIQUIS,hypotension,hypotension including procedural,1
ELIQUIS,hypotension,including procedural hypotension Respiratory thoracic,0
ELIQUIS,procedural hypotension,Vascular disorders hypotension procedural,1
ELIQUIS,procedural hypotension,,0
ELIQUIS,epistaxis,gastrointestinal hemorrhage including hematemesis,0
ELIQUIS,epistaxis,epistaxis Gastrointestinal disorders,1
ELIQUIS,gastrointestinal hemorrhage,,0
ELIQUIS,gastrointestinal hemorrhage,,0
ELIQUIS,gastrointestinal hemorrhage,gastrointestinal hemorrhage including hematemesis,1
ELIQUIS,gastrointestinal hemorrhage,liver function,0
ELIQUIS,gastrointestinal hemorrhage,mediastinal disorders epistaxis Gastrointestinal gastrointestinal,1
ELIQUIS,hematemesis,gastrointestinal hemorrhage,0
ELIQUIS,hematemesis,hemorrhage including,0
ELIQUIS,hematemesis,disorders gastrointestinal hemorrhage hematemesis and melena,1
ELIQUIS,hematemesis,,0
ELIQUIS,melena,,0
ELIQUIS,melena,melena hematochezia Hepatobiliary,1
ELIQUIS,melena,hemorrhage including hematemesis melena hematochezia Hepatobiliary,1
ELIQUIS,melena,test abnormal,0
ELIQUIS,hematochezia,hematochezia Hepatobiliary disorders,1
ELIQUIS,hematochezia,,0
ELIQUIS,liver function test abnormal,increased blood bilirubin,0
ELIQUIS,liver function test abnormal,liver function test abnormal blood alkaline,1
ELIQUIS,liver function test abnormal,,0
ELIQUIS,liver function test abnormal,hematochezia Hepatobiliary liver function,1
ELIQUIS,liver function test abnormal,hemorrhage including hematemesis,0
ELIQUIS,liver function test abnormal,alkaline phosphatase increased blood bilirubin,0
ELIQUIS,liver function test abnormal,,0
ELIQUIS,liver function test abnormal,hematemesis,0
ELIQUIS,liver function test abnormal,hematochezia Hepatobiliary disorders,0
ELIQUIS,blood alkaline phosphatase increased,blood alkaline phosphatase increased blood bilirubin,1
ELIQUIS,blood alkaline phosphatase increased,,0
ELIQUIS,blood bilirubin increased,blood alkaline phosphatase blood bilirubin increased Renal and,1
ELIQUIS,wound secretion,wound secretion incisionsite hemorrhage,1
ELIQUIS,wound secretion,complications,0
ELIQUIS,wound secretion,poisoning,0
ELIQUIS,wound secretion,incisionsite hemorrhage including incisionsite hematoma operative hemorrhage Less,0
ELIQUIS,wound secretion,,0
ELIQUIS,wound secretion,procedural wound secretion incisionsite hemorrhage,1
ELIQUIS,wound secretion,hemorrhage Less common,0
ELIQUIS,wound secretion,and procedural complications,0
ELIQUIS,wound secretion,Injury poisoning and procedural wound secretion incisionsite hemorrhage,1
ELIQUIS,wound secretion,incisionsite,0
ELIQUIS,incision-site hemorrhage,and procedural complications wound incision-site hemorrhage including incisionsite,1
ELIQUIS,incision-site hemorrhage,incision-site hemorrhage including incisionsite,1
ELIQUIS,incision-site hemorrhage,,0
ELIQUIS,incision-site hemorrhage,Injury poisoning,0
ELIQUIS,incision-site hemorrhage,incision-site hemorrhage including incisionsite,1
ELIQUIS,incision-site hemorrhage,incisionsite hematoma operative hemorrhage Less common adverse reactions in,0
ELIQUIS,incision-site hemorrhage,complications wound secretion,0
ELIQUIS,incision-site hematoma,hematoma operative hemorrhage,1
ELIQUIS,incision-site hematoma,hemorrhage,0
ELIQUIS,incision-site hematoma,,0
ELIQUIS,incision-site hematoma,incision-site hematoma operative hemorrhage,1
ELIQUIS,incision-site hematoma,incision-site,1
ELIQUIS,operative hemorrhage,complications wound secretion,0
ELIQUIS,operative hemorrhage,including incisionsite operative,1
ELIQUIS,Gingival bleeding,Gingival,1
ELIQUIS,Gingival bleeding,undergoing hip or knee,0
ELIQUIS,Gingival bleeding,frequency Gingival bleeding hemoptysis hypersensitivity,1
ELIQUIS,Gingival bleeding,a frequency,0
ELIQUIS,Gingival bleeding,hemoptysis hypersensitivity muscle,0
ELIQUIS,Gingival bleeding,knee replacement surgery occurring at a,0
ELIQUIS,Gingival bleeding,Gingival bleeding hemoptysis hypersensitivity,1
ELIQUIS,hemoptysis,,0
ELIQUIS,hypersensitivity,hypersensitivity muscle hemorrhage,1
ELIQUIS,hypersensitivity,hypersensitivity muscle hemorrhage,1
ELIQUIS,hypersensitivity,hypersensitivity muscle hemorrhage,1
ELIQUIS,hypersensitivity,hypersensitivity muscle hemorrhage,1
ELIQUIS,hypersensitivity,hypersensitivity muscle hemorrhage,1
ELIQUIS,hypersensitivity,hypersensitivity muscle hemorrhage,1
ELIQUIS,hypersensitivity,hypersensitivity muscle hemorrhage,1
ELIQUIS,hypersensitivity,of Gingival bleeding hypersensitivity muscle hemorrhage,1
ELIQUIS,hypersensitivity,hypersensitivity muscle hemorrhage,1
ELIQUIS,hypersensitivity,hypersensitivity muscle hemorrhage,1
ELIQUIS,muscle hemorrhage,,0
ELIQUIS,muscle hemorrhage,muscle hemorrhage ocular hemorrhage,1
ELIQUIS,muscle hemorrhage,hemoptysis hypersensitivity,0
ELIQUIS,muscle hemorrhage,hemoptysis hypersensitivity,0
ELIQUIS,muscle hemorrhage,bleeding hemoptysis muscle hemorrhage ocular hemorrhage,1
ELIQUIS,muscle hemorrhage,muscle hemorrhage ocular hemorrhage,1
ELIQUIS,muscle hemorrhage,DVT an,0
ELIQUIS,muscle hemorrhage,Gingival bleeding hemoptysis muscle,1
ELIQUIS,ocular hemorrhage,frequency of,0
ELIQUIS,ocular hemorrhage,hypersensitivity muscle ocular,1
ELIQUIS,ocular hemorrhage,,0
ELIQUIS,ocular hemorrhage,muscle ocular hemorrhage including conjunctival,1
ELIQUIS,ocular hemorrhage,frequency of Gingival bleeding hemoptysis hypersensitivity,0
ELIQUIS,ocular hemorrhage,ocular,1
ELIQUIS,conjunctival hemorrhage,and Reduction,0
ELIQUIS,conjunctival hemorrhage,hemorrhage ocular,0
ELIQUIS,conjunctival hemorrhage,the Risk,0
ELIQUIS,conjunctival hemorrhage,conjunctival hemorrhage rectal hemorrhage,1
ELIQUIS,conjunctival hemorrhage,hemoptysis hypersensitivity muscle,0
ELIQUIS,conjunctival hemorrhage,and PE and,0
ELIQUIS,conjunctival hemorrhage,conjunctival hemorrhage rectal hemorrhage,1
ELIQUIS,conjunctival hemorrhage,hemorrhage rectal hemorrhage,1
ELIQUIS,conjunctival hemorrhage,hemorrhage ocular hemorrhage conjunctival hemorrhage rectal hemorrhage,1
ELIQUIS,conjunctival hemorrhage,hemorrhage conjunctival hemorrhage rectal hemorrhage,1
ELIQUIS,rectal hemorrhage,ocular hemorrhage including conjunctival hemorrhage,0
ELIQUIS,rectal hemorrhage,rectal,1
ELIQUIS,gingival bleeding,exposed to ELIQUIS mg twice daily Common,0
ELIQUIS,gingival bleeding,,0
ELIQUIS,gingival bleeding,daily Common adverse reactions were,0
ELIQUIS,gingival bleeding,Common adverse reactions gingival,1
ELIQUIS,gingival bleeding,mg twice daily Common adverse reactions were,0
ELIQUIS,gingival bleeding,reactions gingival,1
ELIQUIS,epistaxis,hemorrhage hematoma menorrhagia and,0
ELIQUIS,contusion,gingival bleeding contusion hematuria rectal,1
ELIQUIS,contusion,contusion hematuria rectal,1
ELIQUIS,contusion,bleeding contusion hematuria rectal,1
ELIQUIS,contusion,,0
ELIQUIS,contusion,hemorrhage hematoma menorrhagia,0
ELIQUIS,contusion,were gingival,0
ELIQUIS,hematuria,Study,0
ELIQUIS,rectal hemorrhage,reactions were gingival bleeding epistaxis contusion hematuria,0
ELIQUIS,rectal hemorrhage,,0
ELIQUIS,rectal hemorrhage,rectal hemorrhage hematoma menorrhagia,1
ELIQUIS,rectal hemorrhage,mean duration of exposure to ELI,0
ELIQUIS,rectal hemorrhage,bleeding epistaxis,0
ELIQUIS,rectal hemorrhage,duration of exposure to ELI,0
ELIQUIS,rectal hemorrhage,rectal hemorrhage hematoma menorrhagia,1
ELIQUIS,rectal hemorrhage,gingival bleeding epistaxis contusion rectal,1
ELIQUIS,rectal hemorrhage,rectal,1
ELIQUIS,rectal hemorrhage,,0
ELIQUIS,hematoma,of exposure to,0
ELIQUIS,hematoma,,0
ELIQUIS,hematoma,hemorrhage,0
ELIQUIS,hematoma,duration of exposure to,0
ELIQUIS,hematoma,,0
ELIQUIS,hematoma,hemoptysis AMPLIFY Study The mean duration,0
ELIQUIS,hematoma,hematuria rectal hematoma menorrhagia and,1
ELIQUIS,menorrhagia,menorrhagia and hemoptysis,1
ELIQUIS,menorrhagia,menorrhagia and hemoptysis,1
ELIQUIS,menorrhagia,menorrhagia and hemoptysis,1
ELIQUIS,menorrhagia,The,0
ELIQUIS,menorrhagia,mean duration of,0
ELIQUIS,menorrhagia,menorrhagia and hemoptysis,1
ELIQUIS,menorrhagia,bleeding epistaxis contusion hematuria rectal hemorrhage hematoma,0
ELIQUIS,menorrhagia,menorrhagia and hemoptysis,1
ELIQUIS,menorrhagia,,0
ELIQUIS,menorrhagia,menorrhagia and hemoptysis,1
ELIQUIS,hemoptysis,hemoptysis AMPLIFY Study,1
ELIQUIS,hemoptysis,and to enoxaparinwar,0
ELIQUIS,bleeding,enoxaparinwarfarintreate,0
ELIQUIS,bleeding,,0
ELIQUIS,bleeding,enoxaparinwarfarintreated,0
ELIQUIS,bleeding,,0
ELIQUIS,bleeding,,0
ELIQUIS,bleeding,bleeding events was,1
ELIQUIS,bleeding,compared to in enoxaparinwarfarintreated,0
ELIQUIS,bleeding,relative,0
ELIQUIS,bleeding,bleeding relative risk,1
ELIQUIS,bleeding,Pvalue,0
ELIQUIS,Bleeding,Bleeding results from,1
ELIQUIS,Bleeding,CI,0
ELIQUIS,Bleeding,endpoint of major bleeding relative risk CI Pvalue,0
ELIQUIS,Bleeding,bleeding relative risk CI Bleeding results from,1
ELIQUIS,Bleeding,are summarized in Table Bleeding Results in,1
ELIQUIS,Bleeding,study are summarized in Table,0
ELIQUIS,Bleeding,from the AMPLIFY study are summarized in Table,0
ELIQUIS,Bleeding,Bleeding Results in,1
ELIQUIS,Bleeding,Bleeding Results in,1
ELIQUIS,Bleeding,Bleeding Results in,1
ELIQUIS,Bleeding,Results in the AMPLIFY Study ELIQUISNn Enoxaparin,0
ELIQUIS,Bleeding,,0
ELIQUIS,Bleeding,the AMPLIFY study are,0
ELIQUIS,CRNM,bleedingEvents associated with each endpoint were counted once,0
ELIQUIS,CRNM,,0
ELIQUIS,CRNM,CRNM clinically relevant,1
ELIQUIS,CRNM,clinically relevant nonmajor,0
ELIQUIS,CRNM,CRNM clinically relevant,1
ELIQUIS,CRNM,nonmajor bleedingEvents associated with,0
ELIQUIS,CRNM,CRNM clinically relevant,1
ELIQUIS,clinically relevant nonmajor bleeding,Relative Risk CI clinically relevant nonmajor,1
ELIQUIS,clinically relevant nonmajor bleeding,each endpoint were counted once per subject but subjects may have contribut,0
ELIQUIS,clinically relevant nonmajor bleeding,,0
ELIQUIS,CRNM,Major CRNM,1
ELIQUIS,CRNM,,0
ELIQUIS,CRNM,,0
ELIQUIS,CRNM,Major CRNM,1
ELIQUIS,CRNM,CRNM,1
ELIQUIS,CRNM,CRNM,1
ELIQUIS,CRNM,CRNM,1
ELIQUIS,CRNM,Major CRNM,1
ELIQUIS,CRNM,Major CRNM,1
ELIQUIS,CRNM,,0
ELIQUIS,Epistaxis,Epistaxis C,1
ELIQUIS,Contusion,Contusion H,1
ELIQUIS,Contusion,Contusion H,1
ELIQUIS,Contusion,Contusion H,1
ELIQUIS,Contusion,s Contusion H,1
ELIQUIS,Contusion,,0
ELIQUIS,Contusion,s,0
ELIQUIS,Contusion,Contusion H,1
ELIQUIS,Contusion,H,0
ELIQUIS,Contusion,s,0
ELIQUIS,Hematuria,Hematuria M,1
ELIQUIS,Hematuria,Hematuria M,1
ELIQUIS,Hematuria,Hematuria M,1
ELIQUIS,Menorrhagia,Hem,0
ELIQUIS,Menorrhagia,,0
ELIQUIS,Menorrhagia,a,0
ELIQUIS,Hematoma,Hematoma,1
ELIQUIS,Hematoma,Hematoma,1
ELIQUIS,Hematoma,gia,0
ELIQUIS,Hematoma,,0
ELIQUIS,Hemoptysis,,0
ELIQUIS,Hemoptysis,,0
ELIQUIS,Hemoptysis,Hemoptysis Re,1
ELIQUIS,Rectal hemorrhage,is,0
ELIQUIS,Gingival bleeding,emorrhage Gingival bleeding,1
ELIQUIS,Gingival bleeding,emorrhage Gingival,1
ELIQUIS,Gingival bleeding,emorrhage,0
ELIQUIS,Gingival bleeding,Gingival bleeding,1
ELIQUIS,Gingival bleeding,emorrhage Gingival,1
ELIQUIS,Gingival bleeding,,0
ELIQUIS,bleeding,bleeding,1
ELIQUIS,bleeding,,0
ELIQUIS,bleeding,bleeding,1
ELIQUIS,bleeding,bleeding,1
ELIQUIS,bleeding,reactions,0
ELIQUIS,Bleeding,AMPLIFYEXT study are summarized in Table Table,0
ELIQUIS,Bleeding,the AMPLIFYEXT study are summarized in Table,0
ELIQUIS,Bleeding,Bleeding,1
ELIQUIS,Bleeding,Bleeding,1
ELIQUIS,Bleeding,,0
ELIQUIS,Bleeding,,0
ELIQUIS,Bleeding,study are summarized in,0
ELIQUIS,Bleeding,Table Bleeding,1
ELIQUIS,Bleeding,Bleeding,1
ELIQUIS,Bleeding,in the AMPLIFYEXT,0
ELIQUIS,Bleeding,Bleeding,1
ELIQUIS,Bleeding,bidNn ELIQ,0
ELIQUIS,Bleeding,the AMPLIFYEXT study are summarized in Table,0
ELIQUIS,CRNM,CRNM,1
ELIQUIS,CRNM,bidNn PlaceboNn,0
ELIQUIS,CRNM,nonmajor bleedingEvents associated with each,0
ELIQUIS,clinically relevant nonmajor bleeding,relevant nonmajor bleeding,1
ELIQUIS,clinically relevant nonmajor bleeding,mg,0
ELIQUIS,clinically relevant nonmajor bleeding,bidNn PlaceboNn clinically relevant nonmajor,1
ELIQUIS,clinically relevant nonmajor bleeding,ELIQUIS mg bidNn PlaceboNn clinically relevant,1
ELIQUIS,CRNM,,0
ELIQUIS,CRNM,CRNM,1
ELIQUIS,CRNM,CRNM,1
ELIQUIS,CRNM,,0
ELIQUIS,CRNM,CRNM,1
ELIQUIS,CRNM,CRNM,1
ELIQUIS,CRNM,,0
ELIQUIS,CRNM,Major,0
ELIQUIS,CRNM,,0
ELIQUIS,CRNM,Major,0
ELIQUIS,CRNM,Major,0
ELIQUIS,CRNM,CRNM,1
ELIQUIS,CRNM,Major CRNM,1
ELIQUIS,CRNM,CRNM,1
ELIQUIS,CRNM,Major,0
ELIQUIS,CRNM,Major,0
ELIQUIS,Epistaxis,bidNn,0
ELIQUIS,Hematuria,Hematuria,1
ELIQUIS,Hematuria,Hematuria,1
ELIQUIS,Hematuria,Hematuria,1
ELIQUIS,Hematuria,Hematuria,1
ELIQUIS,Hematoma,Hematoma,1
ELIQUIS,Hematoma,,0
ELIQUIS,Hematoma,,0
ELIQUIS,Hematoma,,0
ELIQUIS,Hematoma,,0
ELIQUIS,Hematoma,,0
ELIQUIS,Contusion,Contusion,1
ELIQUIS,Gingival bleeding,,0
ELIQUIS,Gingival bleeding,,0
ELIQUIS,Gingival bleeding,,0
ELIQUIS,Gingival bleeding,,0
ELIQUIS,Gingival bleeding,Gingival bleeding,1
ELIQUIS,Gingival bleeding,,0
ELIQUIS,Gingival bleeding,,0
ELIQUIS,hemorrhagic anemia,,0
ELIQUIS,hemorrhagic anemia,of to Blood and lymphatic,0
ELIQUIS,hemorrhagic anemia,,0
ELIQUIS,hematochezia,gastrointestinal,0
ELIQUIS,hematochezia,hematochezia,1
ELIQUIS,hematochezia,hemorrhage I,0
ELIQUIS,hematochezia,disorders hemorrhagic anemia Gastrointestinal hematochezia,1
ELIQUIS,hematochezia,hematochezia,1
ELIQUIS,hematochezia,hematochezia,1
ELIQUIS,hematochezia,anemia Gastrointestinal hematochezia,1
ELIQUIS,hemorrhoidal hemorrhage,Gastrointestinal disorders hemorrhoidal hemorrhage,1
ELIQUIS,hemorrhoidal hemorrhage,disorders hemorrhoidal hemorrhage,1
ELIQUIS,hemorrhoidal hemorrhage,lymphatic,0
ELIQUIS,hemorrhoidal hemorrhage,Gastrointestinal disorders hemorrhoidal hemorrhage,1
ELIQUIS,hemorrhoidal hemorrhage,disorders hematochezia,0
ELIQUIS,hemorrhoidal hemorrhage,Gastrointestinal disorders,0
ELIQUIS,hemorrhoidal hemorrhage,anemia Gastrointestinal disorders hemorrhoidal,1
ELIQUIS,hemorrhoidal hemorrhage,disorders hemorrhoidal hemorrhage,1
ELIQUIS,hemorrhoidal hemorrhage,hemorrhoidal hemorrhage,1
ELIQUIS,hematemesis,hematemesis,1
ELIQUIS,hematemesis,wound hemorrhage,0
ELIQUIS,hematemesis,disorders hematochezia hemorrhoidal hemorrhage gastrointestinal,0
ELIQUIS,hematemesis,complications,0
ELIQUIS,melena,melena,1
ELIQUIS,melena,,0
ELIQUIS,melena,melena,1
ELIQUIS,anal hemorrhage,hemorrhage hematemesis anal,1
ELIQUIS,anal hemorrhage,anal hemorrhage,1
ELIQUIS,anal hemorrhage,hemorrhage,1
ELIQUIS,anal hemorrhage,hemorrhage hematemesis anal,1
ELIQUIS,anal hemorrhage,hemorrhage,1
ELIQUIS,anal hemorrhage,hemorrhage hematemesis anal,1
ELIQUIS,anal hemorrhage,,0
ELIQUIS,anal hemorrhage,anal hemorrhage,1
ELIQUIS,anal hemorrhage,and procedural complications wound hemorrhage,0
ELIQUIS,wound hemorrhage,wound hemorrhage,1
ELIQUIS,postprocedural hemorrhage,postprocedural hemorrhage,1
ELIQUIS,postprocedural hemorrhage,hemorrhage,1
ELIQUIS,traumatic hematoma,hemorrhage postprocedural hemorrhage,0
ELIQUIS,traumatic hematoma,,0
ELIQUIS,traumatic hematoma,traumatic hematoma,1
ELIQUIS,traumatic hematoma,disorders muscle hemorrhage,0
ELIQUIS,traumatic hematoma,Musculoskeletal and connective tissue,0
ELIQUIS,traumatic hematoma,complications wound hemorrhage postprocedural traumatic,1
ELIQUIS,traumatic hematoma,wound hemorrhage postprocedural hemorrhage,0
ELIQUIS,periorbital hematoma,periorbital hematoma,1
ELIQUIS,periorbital hematoma,periorbital hematoma,1
ELIQUIS,muscle hemorrhage,system and breast disorders vaginal hemorrhage metrorrhagia,0
ELIQUIS,muscle hemorrhage,tissue muscle hemorrhage,1
ELIQUIS,muscle hemorrhage,hemorrhage,1
ELIQUIS,vaginal hemorrhage,vaginal hemorrhage,1
ELIQUIS,metrorrhagia,hemorrhage Reproductive system and breast disorders vaginal,0
ELIQUIS,metrorrhagia,,0
ELIQUIS,metrorrhagia,metrorrhagia,1
ELIQUIS,metrorrhagia,disorders vaginal metrorrhagia,1
ELIQUIS,metrorrhagia,metrorrhagia,1
ELIQUIS,metrorrhagia,breast disorders vaginal,0
ELIQUIS,menometrorrhagia,disorders vaginal,0
ELIQUIS,menometrorrhagia,genital hemorrhage Vascular disorders hemorrhage Skin and subcutaneous tissue,0
ELIQUIS,menometrorrhagia,menometrorrhagia,1
ELIQUIS,menometrorrhagia,hemorrhage,0
ELIQUIS,menometrorrhagia,,0
ELIQUIS,menometrorrhagia,,0
ELIQUIS,menometrorrhagia,menometrorrhagia,1
ELIQUIS,menometrorrhagia,menometrorrhagia,1
ELIQUIS,menometrorrhagia,menometrorrhagia,1
ELIQUIS,menometrorrhagia,disorders hemorrhage Skin and subcutaneous tissue disor,0
ELIQUIS,genital hemorrhage,and breast disorders vaginal hemorrhage metrorrhagia menometrorrhagia,0
ELIQUIS,genital hemorrhage,disorders vaginal hemorrhage metrorrhagia genital,1
ELIQUIS,hemorrhage,skin,0
ELIQUIS,hemorrhage,,0
ELIQUIS,hemorrhage,hemorrhage,1
ELIQUIS,hemorrhage,hemorrhage,1
ELIQUIS,hemorrhage,hemorrhage,1
ELIQUIS,hemorrhage,Eye dis,0
ELIQUIS,hemorrhage,skin hemorrhage petechiae,0
ELIQUIS,hemorrhage,hemorrhage,1
ELIQUIS,hemorrhage,menometrorrhagia genital,0
ELIQUIS,ecchymosis,ecchymosis,1
ELIQUIS,skin hemorrhage,conjunctival hemorrhage retinal,0
ELIQUIS,skin hemorrhage,hemorrhage,1
ELIQUIS,skin hemorrhage,hemorrhage,1
ELIQUIS,skin hemorrhage,hemorrhage,1
ELIQUIS,skin hemorrhage,skin hemorrhage,1
ELIQUIS,petechiae,tissue disorders ecchymosis skin,0
ELIQUIS,conjunctival hemorrhage,hemorrhage,1
ELIQUIS,retinal hemorrhage,disorders conjunctival retinal hemorrhage,1
ELIQUIS,eye hemorrhage,,0
ELIQUIS,eye hemorrhage,,0
ELIQUIS,eye hemorrhage,hemorrhage,1
ELIQUIS,blood urine present,eye hemorrhage blood urine,1
ELIQUIS,blood urine present,,0
ELIQUIS,occult blood positive,Investigations blood urine present,0
ELIQUIS,occult blood positive,retinal hemorrhage eye hemorrhage Investigations blood urine,0
ELIQUIS,occult blood positive,administrationsite condi,0
ELIQUIS,occult blood positive,hemorrhage eye hemorrhage Investigations,0
ELIQUIS,occult blood positive,blood,0
ELIQUIS,occult blood,urine present occult blood occult blood,1
ELIQUIS,occult blood,blood,1
ELIQUIS,occult blood,blood occult blood,1
ELIQUIS,occult blood,occult blood,0
ELIQUIS,red blood cells urine positive,occult blood positive occult red blood cells urine positive,1
ELIQUIS,red blood cells urine positive,blood positive occult red blood cells urine positive,1
ELIQUIS,red blood cells urine positive,,0
ELIQUIS,red blood cells urine positive,occult red,1
ELIQUIS,red blood cells urine positive,present occult blood positive occult,0
ELIQUIS,red blood cells urine positive,occult blood positive occult red blood cells,1
ELIQUIS,red blood cells urine positive,hematoma,0
ELIQUIS,red blood cells urine positive,hemorrhage Investigations blood urine present occult blood positive,0
ELIQUIS,injection-site hematoma,administrationsite injection-site,1
ELIQUIS,injection-site hematoma,injection-site hematoma,1
ELIQUIS,injection-site hematoma,injection-site hematoma,1
ELIQUIS,injection-site hematoma,and administrationsite,0
ELIQUIS,injection-site hematoma,red blood cells urine positive General disorders and,0
ELIQUIS,injection-site hematoma,disorders and administrationsite injection-site,1
ELIQUIS,injection-site hematoma,hematoma,1
ELIQUIS,injection-site hematoma,,0
ELIQUIS,injection-site hematoma,disorders and administrationsite,0
ELIQUIS,injection-site hematoma,injection-site hematoma,1
ELIQUIS,vessel puncture-site hematoma,,0
ELIQUIS,vessel puncture-site hematoma,vessel puncture-site hematoma,1
ELIQUIS,vessel puncture-site hematoma,injectionsite hematoma,0
ELIQUIS,THROMBOTIC EVENTS,se ctions of,1
ELIQUIS,THROMBOTIC EVENTS,etail in other se ctions of,1
ELIQUIS,THROMBOTIC EVENTS,,0
ELIQUIS,THROMBOTIC EVENTS,etail in other se ctions of the prescribing,1
ELIQUIS,THROMBOTIC EVENTS,the prescribing information Increased risk of thrombotic,0
ELIQUIS,THROMBOTIC EVENTS,thrombotic events,0
ELIQUIS,THROMBOTIC EVENTS,,0
ELIQUIS,THROMBOTIC EVENTS,premature continuation [see Warnings and,1
ELIQUIS,THROMBOTIC EVENTS,premature continuation,1
ELIQUIS,THROMBOTIC EVENTS,thrombotic events after premature continuation [see Warnings and,1
ELIQUIS,THROMBOTIC EVENTS,after premature continuation [see Warnings and,1
ELIQUIS,THROMBOTIC EVENTS,prescribing information,0
ELIQUIS,THROMBOTIC EVENTS,[see Warnings and,1
ELIQUIS,THROMBOTIC EVENTS,after premature continuation [see Warnings and,1
ELIQUIS,THROMBOTIC EVENTS,continuation [see Warnings and,1
ELIQUIS,THROMBOTIC EVENTS,Bleeding seeWarnings and Precautions inal/epidural ane sthesia or,1
ELIQUIS,THROMBOTIC EVENTS,inal/epidural ane sthesia or,1
ELIQUIS,THROMBOTIC EVENTS,Precautions inal/epidural ane sthesia or,1
ELIQUIS,THROMBOTIC EVENTS,adverse react,0
ELIQUIS,THROMBOTIC EVENTS,,0
ELIQUIS,THROMBOTIC EVENTS,react,0
ELIQUIS,THROMBOTIC EVENTS,Precautions,0
ELIQUIS,THROMBOTIC EVENTS,or puncture seeWarnings and Precautions EXCERPT Most common,0
ELIQUIS,THROMBOTIC EVENTS,Precautions inal/epidural,1
ELIQUIS,THROMBOTIC EVENTS,and Precautions inal/epidural ane sthesia or,1
ELIQUIS,thrombotic events,contact BristolMyers Squibb at,0
ELIQUIS,thrombotic events,BristolMyers Squibb,0
ELIQUIS,thrombotic events,,0
ELIQUIS,thrombotic events,REACTIONS,0
ELIQUIS,thrombotic events,common adverse s (>1%) are relat ed to,1
ELIQUIS,thrombotic events,relat ed to,1
ELIQUIS,thrombotic events,s (>1%) are,1
ELIQUIS,thrombotic events,Precautions EXCERPT,0
ELIQUIS,spinal hematomas,g cannot be,1
ELIQUIS,spinal hematomas,clinical trials of a g cannot,1
ELIQUIS,spinal hematomas,of a g cannot be,1
ELIQUIS,spinal hematomas,dru,0
ELIQUIS,spinal hematomas,trials of a g cannot be dire ctly compared,1
ELIQUIS,spinal hematomas,a g,1
ELIQUIS,spinal hematomas,varying conditions adverse reaction rates observed in the clinical,0
ELIQUIS,spinal hematomas,g cannot be dire ctly compared,1
ELIQUIS,spinal hematomas,clinical trials of a g cannot be dire ctly compared,1
ELIQUIS,spinal hematomas,clinical trials of a g cannot be dire ctly compared,1
ELIQUIS,hematomas,,0
ELIQUIS,hematomas,,0
ELIQUIS,hematomas,,0
ELIQUIS,hematomas,"

   Redu ction of",1
ELIQUIS,hematomas,rates observed,0
ELIQUIS,hematomas,"

   Redu ction of",1
ELIQUIS,hematomas,"

   Redu ction of",1
ELIQUIS,spinal hematomas,ELIQUIS was evaluated in the ARISTOTLE and AVERROES studies,0
ELIQUIS,spinal hematomas,AVERROES studies inical Studies ( including patients,1
ELIQUIS,spinal hematomas,and AVERROES studies inical Studies,1
ELIQUIS,spinal hematomas,to,0
ELIQUIS,spinal hematomas,daily and patients exposed,0
ELIQUIS,spinal hematomas,inical Studies ( including patients,1
ELIQUIS,THROMBOTIC EVENTS,subjects with at least,1
ELIQUIS,THROMBOTIC EVENTS,and the bleeding rate,0
ELIQUIS,THROMBOTIC EVENTS,bleeding event per patientyears in ARISTOTLE and AVERROES,0
ELIQUIS,THROMBOTIC EVENTS,bleeding rate  of subjects with at least,1
ELIQUIS,EPIDURAL HEMATOMA,ne bleeding event per patientyears,1
ELIQUIS,EPIDURAL HEMATOMA,the bleeding rate percentage,0
ELIQUIS,EPIDURAL HEMATOMA,bleeding during the treatment period and the bleeding rate percentage of subjects with at least o,0
ELIQUIS,EPIDURAL HEMATOMA,bleeding event per patientyears,1
ELIQUIS,THROMBOTIC EVENTS,ELIQUISNn per ptyear,0
ELIQUIS,THROMBOTIC EVENTS,,0
ELIQUIS,THROMBOTIC EVENTS,"STOTLE* 
         ELIQUISNn per",1
ELIQUIS,THROMBOTIC EVENTS,,0
ELIQUIS,THROMBOTIC EVENTS,"Atrial Fibrillation in STOTLE* 
         ELIQUISNn per",1
ELIQUIS,THROMBOTIC EVENTS,"in STOTLE* 
         ELIQUISNn per",1
ELIQUIS,THROMBOTIC EVENTS,"Nonvalvular Atrial Fibrillation in STOTLE* 
         ELIQUISNn per",1
ELIQUIS,THROMBOTIC EVENTS,Patients with Nonvalvular Atrial Fibrillation in,0
ELIQUIS,THROMBOTIC EVENTS,"STOTLE* 
         ELIQUISNn per",1
ELIQUIS,thrombotic events,subject but,0
ELIQUIS,thrombotic events,,0
ELIQUIS,thrombotic events,Ratio(95% CI) P- value Bleeding,1
ELIQUIS,thrombotic events,Ratio(95% CI)  P- value Bleeding,1
ELIQUIS,thrombotic events,ptyear WarfarinNn per ptyear Hazard,0
ELIQUIS,thrombotic events,WarfarinNn per ptyear,0
ELIQUIS,thrombotic events,within each subcategory,0
ELIQUIS,spinal hematomas,tment period). Defined as,1
ELIQUIS,spinal hematomas,of the following,0
ELIQUIS,spinal hematomas,,0
ELIQUIS,spinal hematomas,a decrease,0
ELIQUIS,spinal hematomas,of stopping study treatment tment period).   Defined as,1
ELIQUIS,hematomas,cells bleeding at a,0
ELIQUIS,hematomas,overt bleeding accompanied by one or more of the following,0
ELIQUIS,hematomas,of or more units of packed red blood cells bleeding at,0
ELIQUIS,hematomas,"/dL, a tr ansfusion of",1
ELIQUIS,permanent paralysis,transfusion of or more  of packed red bloo d cells,1
ELIQUIS,permanent paralysis,more  of packed red bloo d cells,1
ELIQUIS,permanent paralysis,more of,1
ELIQUIS,fatal,,0
ELIQUIS,fatal,prescribing information Increased,0
ELIQUIS,fatal,detai l in other sections,1
ELIQUIS,fatal,detai l,1
ELIQUIS,fatal,detai l in other sections of,1
ELIQUIS,fatal,detai l,1
ELIQUIS,fatal,the prescribing information Increased risk,0
ELIQUIS,fatal,,0
ELIQUIS,bleeding,in,1
ELIQUIS,bleeding,in,1
ELIQUIS,bleeding,,0
ELIQUIS,bleeding,after prema,0
ELIQUIS,bleeding,of the prescribing information Increased risk of thrombotic events,0
ELIQUIS,bleeding,,0
ELIQUIS,bleeding, in othe r,1
ELIQUIS,thrombotic events,,0
ELIQUIS,thrombotic events,ed to bleeding.(6 To,1
ELIQUIS,thrombotic events,contact BristolMyers Squibb at or,0
ELIQUIS,thrombotic events,F,0
ELIQUIS,stroke,PECTED ADVERSE,1
ELIQUIS,stroke,PECTED ADVERSE,1
ELIQUIS,stroke,,0
ELIQUIS,stroke,related,0
ELIQUIS,stroke,to bleeding To report PECTED ADVERSE,1
ELIQUIS,bleeding,not ect,1
ELIQUIS,bleeding,of Stroke and Systemic Embolism,0
ELIQUIS,bleeding,,0
ELIQUIS,bleeding,drug cannot be directly compared to rates in the,0
ELIQUIS,bleeding,and may not ect the  rates,1
ELIQUIS,fatal,in    Re duction,1
ELIQUIS,fatal,observed in practice,0
ELIQUIS,bleeding,another drug and may not reflect,0
ELIQUIS,bleeding,and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation The,0
ELIQUIS,bleeding,observed in,0
ELIQUIS,bleeding,ction of Risk,1
ELIQUIS,bleeding,exposed to,0
ELIQUIS,bleeding,in the ARISTOTLE and VERROES  studies,1
ELIQUIS,bleeding,including patients exposed to ELIQUIS mg twice,0
ELIQUIS,bleeding,Studies including patients exposed,0
ELIQUIS,bleeding,patients exposed to ELIQUIS,0
ELIQUIS,bleeding,VERROES  studies,1
ELIQUIS,bleeding,and VERROES  studies,1
ELIQUIS,bleeding,,0
ELIQUIS,bleeding,to ELIQUIS,0
ELIQUIS,bleeding,the ARISTOTLE and VERROES  studies,1
ELIQUIS,spinal hematoma,red blood,0
ELIQUIS,spinal hematoma,intra-arti cular,1
ELIQUIS,spinal hematoma,intra-arti cular,1
ELIQUIS,spinal hematoma,intra-arti cular,1
BOSULIF,Gastrointestinal toxicity,Gastrointestinal toxicity see,1
BOSULIF,Gastrointestinal toxicity,,0
BOSULIF,Gastrointestinal toxicity,other sections of the Gastrointestinal toxicity see,1
BOSULIF,Gastrointestinal toxicity,toxicity see,1
BOSULIF,Gastrointestinal toxicity,Administration and Warnings and,0
BOSULIF,Gastrointestinal toxicity,adverse reactions are discussed in greater detail in other sections of the labeling,0
BOSULIF,Gastrointestinal toxicity,the Gastrointestinal toxicity see,1
BOSULIF,Gastrointestinal toxicity,,0
BOSULIF,Gastrointestinal toxicity,the,0
BOSULIF,Gastrointestinal toxicity,Gastrointestinal toxicity see,1
BOSULIF,Myelosuppression,,0
BOSULIF,Myelosuppression,toxicity see,0
BOSULIF,Myelosuppression,and Warnings and Myelosuppression see,1
BOSULIF,Myelosuppression,and Warnings and Precautions,0
BOSULIF,Myelosuppression,Myelosuppression see,1
BOSULIF,Hepatic toxicity,Hepatic,1
BOSULIF,Hepatic toxicity,,0
BOSULIF,Hepatic toxicity,Precautions,0
BOSULIF,Fluid retention,Precautions,0
BOSULIF,Fluid retention,and Precautions,0
BOSULIF,Fluid retention,and Warnings and Fluid retention see,1
BOSULIF,Fluid retention,,0
BOSULIF,Fluid retention,Warnings,0
BOSULIF,Fluid retention,and Fluid retention see,1
BOSULIF,Renal toxicity,Warnings and Precautions EXCERPT Most common,0
BOSULIF,diarrhea,common adverse,0
BOSULIF,diarrhea,incidence greater than diarrhea nausea,1
BOSULIF,diarrhea,diarrhea nausea,1
BOSULIF,diarrhea,,0
BOSULIF,diarrhea,adverse reactions,0
BOSULIF,diarrhea,,0
BOSULIF,diarrhea,vomiting,0
BOSULIF,diarrhea,than are,0
BOSULIF,nausea,Most common adverse reactions incidence greater than are,0
BOSULIF,thrombocytopenia,thrombocytopenia vomiting,1
BOSULIF,thrombocytopenia,pyrexia and fatigue To report SUSPECTED,0
BOSULIF,thrombocytopenia,diarrhea thrombocytopenia vomiting,1
BOSULIF,thrombocytopenia,are diarrhea,0
BOSULIF,vomiting,nausea,0
BOSULIF,vomiting,anemia pyrexia and fatigue To report,0
BOSULIF,vomiting,,0
BOSULIF,vomiting,diarrhea nausea vomiting abdominal,1
BOSULIF,vomiting,are diarrhea nausea vomiting abdominal,1
BOSULIF,vomiting,vomiting abdominal,1
BOSULIF,vomiting,vomiting abdominal,1
BOSULIF,vomiting,abdominal pain rash,0
BOSULIF,vomiting,vomiting abdominal,1
BOSULIF,abdominal pain,nausea thrombocytopenia abdominal pain rash,1
BOSULIF,rash,,0
BOSULIF,rash,rash anemia,1
BOSULIF,rash,pain,0
BOSULIF,rash,diarrhea nausea thrombocytopenia vomiting,0
BOSULIF,rash,REACTIONS contact,0
BOSULIF,rash,vomiting abdominal rash anemia,1
BOSULIF,rash,than are diarrhea nausea thrombocytopenia vomiting abdominal pain,0
BOSULIF,anemia,anemia pyrexia,1
BOSULIF,anemia,,0
BOSULIF,anemia,SUSPECTED,0
BOSULIF,anemia,vomiting abdominal pain anemia pyrexia,1
BOSULIF,anemia,anemia pyrexia,1
BOSULIF,anemia,report SUSPECTED ADVERSE REACTIONS contact Pfizer Inc,0
BOSULIF,anemia,thrombocytopenia vomiting abdominal pain anemia pyrexia,1
BOSULIF,anemia,To report SUSPECTED ADVERSE REACTIONS,0
BOSULIF,pyrexia,fatigue To report SUSPECTED,0
BOSULIF,anaphylactic shock,gastrointestinal toxicity,0
BOSULIF,anaphylactic shock,reflect,0
BOSULIF,anaphylactic shock,anaphylactic,1
BOSULIF,anaphylactic shock,observed in practice Serious adverse reactions reported include,0
BOSULIF,anaphylactic shock,Serious adverse reactions reported anaphylactic shock see,1
BOSULIF,myelosuppression,myelosuppression gastrointestinal,1
BOSULIF,diarrhea,any toxicity grade,0
BOSULIF,fluid retention,toxicity fluid,1
BOSULIF,fluid retention,myelosuppression gastrointestinal toxicity diarrhea,0
BOSULIF,fluid retention,shock,0
BOSULIF,fluid retention,retention hepatotoxicity,1
BOSULIF,hepatotoxicity,hepatotoxicity and,1
BOSULIF,hepatotoxicity,hepatotoxicity and,1
BOSULIF,hepatotoxicity,,0
BOSULIF,rash,fluid retention hepatotoxicity rash Adverse,1
BOSULIF,rash,diarrhea fluid retention hepatotoxicity rash Adverse,1
BOSULIF,diarrhea,diarrhea nausea,1
BOSULIF,diarrhea,,0
BOSULIF,diarrhea,diarrhea nausea,1
BOSULIF,nausea,in the Phase,0
BOSULIF,nausea,n were nausea thrombocytopenia,1
BOSULIF,nausea,than of patients in the Phase safety population,0
BOSULIF,nausea,Phase safety population n were,0
BOSULIF,nausea,abdominal pain rash,0
BOSULIF,thrombocytopenia,thrombocytopenia vomiting,1
BOSULIF,vomiting,vomiting abdominal,1
BOSULIF,vomiting,n were diarrhea nausea vomiting abdominal,1
BOSULIF,vomiting,Phase safety population n were diarrhea nausea,0
BOSULIF,vomiting,vomiting abdominal,1
BOSULIF,vomiting,vomiting abdominal,1
BOSULIF,vomiting,fatigue see Clin,0
BOSULIF,abdominal pain,were diarrhea nausea thrombocytopenia abdominal pain rash,1
BOSULIF,rash,diarrhea nausea,0
BOSULIF,rash,rash anemia,1
BOSULIF,rash,rash anemia,1
BOSULIF,rash,rash anemia,1
BOSULIF,rash,rash anemia,1
BOSULIF,rash,diarrhea nausea thrombocytopenia vomiting,0
BOSULIF,rash,rash anemia,1
BOSULIF,rash,see Clinical Studies,0
BOSULIF,rash,rash anemia,1
BOSULIF,anemia,anemia pyrexia,1
BOSULIF,anemia,abdominal pain,0
BOSULIF,anemia,pain anemia pyrexia,1
BOSULIF,anemia,thrombocytopenia vomiting abdominal pain anemia pyrexia,1
BOSULIF,anemia,abdominal pain rash,0
BOSULIF,anemia,thrombocytopenia vomiting abdominal pain anemia pyrexia,1
BOSULIF,anemia,Adverse Reaction,0
BOSULIF,anemia,fatigue see Clinical Studies Adverse Reaction,0
BOSULIF,anemia,,0
BOSULIF,pyrexia,vomiting abdominal,0
BOSULIF,pyrexia,pain rash pyrexia and,1
BOSULIF,pyrexia,vomiting abdominal pain,0
BOSULIF,pyrexia,pyrexia and,1
BOSULIF,fatigue,rash,0
BOSULIF,fatigue,fatigue see,1
BOSULIF,fatigue,rash anemia pyrexia fatigue see,1
BOSULIF,fatigue,pyrexia fatigue see,1
BOSULIF,fatigue,fatigue see,1
BOSULIF,fatigue,rash anemia pyrexia fatigue see,1
BOSULIF,Diarrhea,Diarrhea,1
BOSULIF,Diarrhea,,0
BOSULIF,Nausea,Nausea,1
BOSULIF,Nausea,,0
BOSULIF,Abdominal Pain,Pain T,1
BOSULIF,Abdominal Pain,,0
BOSULIF,Abdominal Pain,,0
BOSULIF,Abdominal Pain,Abdominal Pain T,1
BOSULIF,Abdominal Pain,,0
BOSULIF,Thrombocytopenia,Thrombocytopenia Vom,1
BOSULIF,Thrombocytopenia,n,0
BOSULIF,Thrombocytopenia,,0
BOSULIF,Vomiting,Vomiting,1
BOSULIF,Vomiting,nia Vomiting,1
BOSULIF,Vomiting,,0
BOSULIF,Vomiting,Vomiting,1
BOSULIF,Rash,Rash,1
BOSULIF,Rash,Rash,1
BOSULIF,Rash,,0
BOSULIF,Rash,,0
BOSULIF,Rash,,0
BOSULIF,Rash,Rash,1
BOSULIF,Fatigue,,0
BOSULIF,Fatigue,Fatigue,1
BOSULIF,Fatigue,Fatigue,1
BOSULIF,Fatigue,,0
BOSULIF,Anemia,Anemia,1
BOSULIF,Anemia,,0
BOSULIF,Anemia,Anemia,1
BOSULIF,Anemia,Anemia,1
BOSULIF,Anemia,,0
BOSULIF,Anemia,Anemia,1
BOSULIF,Anemia,Anemia,1
BOSULIF,Anemia,Anemia,1
BOSULIF,Anemia,,0
BOSULIF,Pyrexia,Pyrexia,1
BOSULIF,Headache,sferase Headache,1
BOSULIF,Headache,sferase Headache,1
BOSULIF,Headache,Headache,1
BOSULIF,Cough,Cough,1
BOSULIF,Cough,,0
BOSULIF,Cough,Cough,1
BOSULIF,Cough,,0
BOSULIF,Cough,Cough,1
BOSULIF,Increased aspartate aminotransferase,Increased,1
BOSULIF,Increased aspartate aminotransferase,,0
BOSULIF,Neutropenia,,0
BOSULIF,Neutropenia,sferase Neutropenia,1
BOSULIF,Neutropenia,,0
BOSULIF,Neutropenia,,0
BOSULIF,Neutropenia,,0
BOSULIF,Edema,,0
BOSULIF,Edema,,0
BOSULIF,Edema,Edema,1
BOSULIF,Edema,Edema,1
BOSULIF,Edema,,0
BOSULIF,Edema,,0
BOSULIF,Edema,,0
BOSULIF,Arthralgia,,0
BOSULIF,Decreased appetite,,0
BOSULIF,Respiratory tract infection,etite Respiratory tract infection Nasopha,1
BOSULIF,Respiratory tract infection,etite,0
BOSULIF,Respiratory tract infection,etite,0
BOSULIF,Respiratory tract infection,etite,0
BOSULIF,Respiratory tract infection,infection Nasopha,1
BOSULIF,Respiratory tract infection,,0
BOSULIF,Respiratory tract infection,etite Respiratory tract,1
BOSULIF,Nasopharyngitis,Nasopharyngitis Ba,1
BOSULIF,Nasopharyngitis,fection Nasopharyngitis Ba,1
BOSULIF,Nasopharyngitis,Nasopharyngitis Ba,1
BOSULIF,Nasopharyngitis,,0
BOSULIF,Nasopharyngitis,Ba,0
BOSULIF,Nasopharyngitis,Nasopharyngitis Ba,1
BOSULIF,Nasopharyngitis,Nasopharyngitis Ba,1
BOSULIF,Nasopharyngitis,,0
BOSULIF,Back pain,,0
BOSULIF,Back pain,is,0
BOSULIF,Back pain,is,0
BOSULIF,Back pain,is Back pain,1
BOSULIF,Back pain,,0
BOSULIF,Back pain,is,0
BOSULIF,Back pain,,0
BOSULIF,Back pain,,0
BOSULIF,Back pain,is,0
BOSULIF,Back pain,,0
BOSULIF,Asthenia,Asthenia,1
BOSULIF,Asthenia,Asthenia,1
BOSULIF,Asthenia,Asthenia,1
BOSULIF,Asthenia,,0
BOSULIF,Asthenia,,0
BOSULIF,Asthenia,,0
BOSULIF,Asthenia,,0
BOSULIF,Asthenia,Asthenia,1
BOSULIF,Asthenia,,0
BOSULIF,Asthenia,Asthenia,1
BOSULIF,Pruritus,,0
BOSULIF,Dizziness,Dizziness,1
BOSULIF,Dizziness,,0
BOSULIF,Dyspnea,,0
BOSULIF,Dyspnea,,0
BOSULIF,Dyspnea,,0
BOSULIF,Dyspnea,Dyspnea,1
BOSULIF,Dyspnea,Dyspnea,1
BOSULIF,Dyspnea,Dyspnea,1
BOSULIF,Dyspnea,,0
BOSULIF,Dyspnea,Dyspnea,1
BOSULIF,Dyspnea,,0
BOSULIF,QTcF interval of greater than 500 milliseconds,,0
BOSULIF,Absolute Neutrophil Count less than 1*10 9 /L,than Absolute Neutrophil Count less than,1
BOSULIF,Absolute Neutrophil Count less than 1*10 9 /L,than Absolute,1
BOSULIF,Absolute Neutrophil Count less than 1*10 9 /L,less,0
BOSULIF,Absolute Neutrophil Count less than 1*10 9 /L,Hemoglobin Low less than,0
BOSULIF,Absolute Neutrophil Count less than 1*10 9 /L,than Absolute Neutrophil Count less than 1*10  9  /L,1
BOSULIF,Absolute Neutrophil Count less than 1*10 9 /L,,0
BOSULIF,Absolute Neutrophil Count less than 1*10 9 /L,Absolute Neutrophil Count less than 1*10 9 /L,1
BOSULIF,ALT greater than 5.0*ULN,,0
BOSULIF,ALT greater than 5.0*ULN,Biochemistry Parameters ALT,1
BOSULIF,AST greater than 5.0*ULN,than 5.0*ULN,1
BOSULIF,AST greater than 5.0*ULN,greater tha,0
BOSULIF,AST greater than 5.0*ULN,,0
BOSULIF,Lipase greater than 2*ULN,than Lipase,1
BOSULIF,Total Bilirubin greater than 3.0*ULN,mmolL,0
BOSULIF,Total Bilirubin greater than 3.0*ULN,,0
BOSULIF,Total Bilirubin greater than 3.0*ULN,less than Total Bilirubin,1
BOSULIF,febrile neutropenia,System Disorders and less febrile neutropenia,1
BOSULIF,febrile neutropenia,Disorders and less febrile neutropenia,1
BOSULIF,febrile neutropenia,less febrile,1
BOSULIF,febrile neutropenia,less than,0
BOSULIF,febrile neutropenia,and less than,0
BOSULIF,febrile neutropenia,neutropenia,1
BOSULIF,febrile neutropenia,febrile neutropenia,1
BOSULIF,febrile neutropenia,Cardiac Disorders and less than pericardial,0
BOSULIF,febrile neutropenia,neutropenia,1
BOSULIF,febrile neutropenia,each category Blood and,0
BOSULIF,pericardial effusion,pericardial effusion,1
BOSULIF,pericardial effusion,Disorders and less than,0
BOSULIF,pericardial effusion,and less than,0
BOSULIF,pericardial effusion,Cardiac Disorders and less pericardial effusion,1
BOSULIF,pericardial effusion,,0
BOSULIF,pericardial effusion,effusion,1
BOSULIF,pericardial effusion,Cardiac Disorders and less pericardial,1
BOSULIF,pericardial effusion,and less than pericarditis Ear and Labyrinth Disorders,0
BOSULIF,tinnitus,gastritis,0
BOSULIF,tinnitus,pericarditis,0
BOSULIF,tinnitus,tinnitus,1
BOSULIF,tinnitus,Labyrinth Disorders and less tinnitus,1
BOSULIF,tinnitus,Ear and Labyrinth,0
BOSULIF,tinnitus,,0
BOSULIF,tinnitus,tinnitus,1
BOSULIF,tinnitus,tinnitus,1
BOSULIF,tinnitus,and less than a,0
BOSULIF,tinnitus,Disorders,0
BOSULIF,gastritis,,0
BOSULIF,gastritis,,0
BOSULIF,gastritis,tinnitus Gastrointestinal Disorders and less than,0
BOSULIF,gastritis,and less than,0
BOSULIF,acute pancreatitis,gastrointestinal hemorrhage gastric hemorrhage upper gastr,0
BOSULIF,acute pancreatitis,upper gastr,0
BOSULIF,acute pancreatitis,and less acute pancreatitis,1
BOSULIF,acute pancreatitis,acute pancreatitis,1
BOSULIF,acute pancreatitis,acute,1
BOSULIF,acute pancreatitis,,0
BOSULIF,acute pancreatitis,and less than gastritis,0
BOSULIF,acute pancreatitis,than gastritis and less acute pancreatitis,1
BOSULIF,gastrointestinal hemorrhage,hemorrhage,1
BOSULIF,gastrointestinal hemorrhage,than acute gastrointestinal,1
BOSULIF,gastrointestinal hemorrhage,hemorrhage,1
BOSULIF,gastrointestinal hemorrhage,hemorrhage gastric hemorrhage upper gastrointestinal,0
BOSULIF,gastrointestinal hemorrhage,gastrointestinal,1
BOSULIF,gastrointestinal hemorrhage,,0
BOSULIF,gastrointestinal hemorrhage,hemorrhage gastrointestinal,1
BOSULIF,gastrointestinal hemorrhage,pancreatitis gastrointestinal hemorrhage gastrointestinal,1
BOSULIF,gastrointestinal hemorrhage,gastrointestinal,1
BOSULIF,gastric hemorrhage,General Disorders and Administrative,0
BOSULIF,gastric hemorrhage,,0
BOSULIF,gastric hemorrhage,gastrointestinal hemorrhage,0
BOSULIF,gastric hemorrhage,,0
BOSULIF,gastric hemorrhage,gastric hemorrhage,1
BOSULIF,gastric hemorrhage,hemorrhage includes gastrointestinal gastric,1
BOSULIF,gastric hemorrhage,gastric,1
BOSULIF,upper gastrointestinal hemorrhage,gastrointestinal hemorrhage,1
BOSULIF,upper gastrointestinal hemorrhage,gastrointestinal hemorrhage includes gastrointestinal,0
BOSULIF,upper gastrointestinal hemorrhage,gastric upper gastrointestinal hemorrhage,1
BOSULIF,upper gastrointestinal hemorrhage,,0
BOSULIF,upper gastrointestinal hemorrhage,Administrative Site Conditions and,0
BOSULIF,upper gastrointestinal hemorrhage,includes gastrointestinal hemorrhage gastric upper gastrointestinal hemorrhage,1
BOSULIF,upper gastrointestinal hemorrhage,upper gastrointestinal hemorrhage,1
BOSULIF,chest pain,Site Conditions and less chest,1
BOSULIF,chest pain,less chest,1
BOSULIF,chest pain,less chest pain,1
BOSULIF,chest pain,pain,1
BOSULIF,chest pain,and less than,0
BOSULIF,chest pain,and less,0
BOSULIF,chest pain,and less chest,1
BOSULIF,chest pain,chest pain,1
BOSULIF,chest pain,than chest pain chest pain,1
BOSULIF,chest pain,chest pain,1
BOSULIF,chest pain,pain chest,1
BOSULIF,chest pain,pain,1
BOSULIF,chest discomfort,includes hepatotox,0
BOSULIF,pain,pain,1
BOSULIF,pain,pain,1
BOSULIF,hepatotoxicity,hepatotoxicity,1
BOSULIF,toxic hepatitis,toxic hepatitis,1
BOSULIF,toxic hepatitis,than hepatotoxicity includes toxic,1
BOSULIF,toxic hepatitis,hepatotoxicity includes toxic hepatitis,1
BOSULIF,toxic hepatitis,hepatitis abnormal hepatic function includes abnormal,0
BOSULIF,toxic hepatitis,hepatic function includes abnormal hepatic,0
BOSULIF,toxic hepatitis,abnormal hepatic function,0
BOSULIF,toxic hepatitis,hepatotoxicity,0
BOSULIF,toxic hepatitis,toxic hepatitis,1
BOSULIF,toxic hepatitis,,0
BOSULIF,cytolytic hepatitis,includes hepatotoxicity toxic hepatitis cytolytic,1
BOSULIF,cytolytic hepatitis,cytolytic hepatitis,1
BOSULIF,cytolytic hepatitis,hepatotoxicity toxic,0
BOSULIF,cytolytic hepatitis,toxic hepatitis cytolytic hepatitis,1
BOSULIF,cytolytic hepatitis,hepatic function includes abnormal hepatic function liver disorder and less th,0
BOSULIF,abnormal hepatic function,function,1
BOSULIF,abnormal hepatic function,hepatic function,1
BOSULIF,abnormal hepatic function,toxic hepatitis and cytolytic abnormal,1
BOSULIF,abnormal hepatic function,liver disorder,0
BOSULIF,abnormal hepatic function,function liver disorder and less,0
BOSULIF,abnormal hepatic function,than liver injury Immune System Disorders and,0
BOSULIF,abnormal hepatic function,cytolytic,0
BOSULIF,abnormal hepatic function,function,1
BOSULIF,abnormal hepatic function,function abnormal,1
BOSULIF,abnormal hepatic function,and less,0
BOSULIF,liver disorder,less than liver injury Immune System Disorders and less,0
BOSULIF,liver disorder,System Disorders and,0
BOSULIF,liver disorder,disorder,1
BOSULIF,liver disorder,disorder,1
BOSULIF,liver injury,injury,1
BOSULIF,liver injury,liver disorder and less liver,1
BOSULIF,liver injury,injury,1
BOSULIF,liver injury,includes,0
BOSULIF,liver injury,liver injury,1
BOSULIF,liver injury,less liver injury,1
BOSULIF,liver injury,function,0
BOSULIF,drug hypersensitivity,than,0
BOSULIF,anaphylactic shock,,0
BOSULIF,anaphylactic shock,,0
BOSULIF,anaphylactic shock,,0
BOSULIF,anaphylactic shock,,0
BOSULIF,anaphylactic shock,anaphylactic shock,1
BOSULIF,anaphylactic shock,,0
BOSULIF,anaphylactic shock,Infestations and,0
BOSULIF,pneumonia,includes pneumonia bronchopneumonia lobar pneumonia,0
BOSULIF,pneumonia,pneumonia,1
BOSULIF,pneumonia,pneumonia,1
BOSULIF,pneumonia,anaphylactic,0
BOSULIF,pneumonia,includes pneumonia bronchopneumonia lobar pneumonia primary atypical pneumonia,0
BOSULIF,pneumonia,and,0
BOSULIF,pneumonia,pneumonia,1
BOSULIF,pneumonia,pneumonia,1
BOSULIF,pneumonia,pneumonia,0
BOSULIF,pneumonia,bronchitis Invest,0
BOSULIF,pneumonia,atypical,0
BOSULIF,pneumonia,,0
BOSULIF,pneumonia,pneumonia,1
BOSULIF,bronchopneumonia,,0
BOSULIF,bronchopneumonia,bronchopneumonia,1
BOSULIF,bronchopneumonia,than pneumonia includes bronchopneumonia,1
BOSULIF,bronchopneumonia,bronchopneumonia,1
BOSULIF,lobar pneumonia,pneumonia,1
BOSULIF,lobar pneumonia,includes pneumonia lobar,1
BOSULIF,lobar pneumonia,,0
BOSULIF,lobar pneumonia,lobar pneumonia,1
BOSULIF,lobar pneumonia,lobar,1
BOSULIF,lobar pneumonia,pneumonia,1
BOSULIF,lobar pneumonia,than,0
BOSULIF,primary atypical pneumonia,pneumonia bronchopneumonia lobar primary atypical,1
BOSULIF,primary atypical pneumonia,QT,0
BOSULIF,influenza,influenza,1
BOSULIF,electrocardiogram QT prolonged,QT prolonged,1
BOSULIF,electrocardiogram QT prolonged,atypical pneumonia influenza bronchitis Investigations and,0
BOSULIF,electrocardiogram QT prolonged,less electrocardiogram QT prolonged,1
BOSULIF,electrocardiogram QT prolonged,creatinine,0
BOSULIF,electrocardiogram QT prolonged,electrocardiogram QT prolonged,1
BOSULIF,electrocardiogram QT prolonged,less than,0
BOSULIF,electrocardiogram QT prolonged,less electrocardiogram QT,1
BOSULIF,electrocardiogram QT prolonged,than,0
BOSULIF,electrocardiogram QT prolonged,QT prolonged,1
BOSULIF,increased blood creatine phosphokinase,blood creatine phosphokinase,1
BOSULIF,increased blood creatine phosphokinase,electrocardiogram QT increased blood,1
BOSULIF,increased blood creatine phosphokinase,than electrocardiogram QT increased blood creatine phosphokinase,1
BOSULIF,increased blood creatinine,increased blood creatine increased,1
BOSULIF,increased blood creatinine,blood creatine,0
BOSULIF,increased blood creatinine,Metabolism and Nutrition Disorder and less than hyperkalemia,0
BOSULIF,increased blood creatinine,increased blood creatinine,1
BOSULIF,increased blood creatinine,dehydration,0
BOSULIF,increased blood creatinine,blood creatine increased blood creatinine,1
BOSULIF,increased blood creatinine,blood creatine increased,1
BOSULIF,increased blood creatinine,electrocardiogram QT prolonged increased blood,0
BOSULIF,increased blood creatinine,blood creatinine,1
BOSULIF,increased blood creatinine,blood creatine increased blood,1
BOSULIF,hyperkalemia,hyperkalemia,1
BOSULIF,hyperkalemia,myalg,0
BOSULIF,hyperkalemia,and Nutrition Disorder and less than,0
BOSULIF,hyperkalemia,hyperkalemia,1
BOSULIF,hyperkalemia,hyperkalemia,1
BOSULIF,dehydration,Metabolism and Nutrition Disorder and less than hyperkalemia,0
BOSULIF,dehydration,dehydration,1
BOSULIF,dehydration,and less than,0
BOSULIF,dehydration,,0
BOSULIF,dehydration,dehydration,1
BOSULIF,dehydration,less than dehydration,1
BOSULIF,myalgia,Tissue Disorder and less,0
BOSULIF,myalgia,Connective Tissue Disorder,0
BOSULIF,myalgia,Disorder and less myalgia,1
BOSULIF,myalgia,and Connective Tissue,0
BOSULIF,myalgia,myalgia,1
BOSULIF,myalgia,Disorder and less myalgia,1
BOSULIF,myalgia,myalgia,1
BOSULIF,myalgia,than dysgeusia,0
BOSULIF,myalgia,myalgia,1
BOSULIF,myalgia,less myalgia,1
BOSULIF,dysgeusia,and less than,0
BOSULIF,dysgeusia,System Disorders and less dysgeusia,1
BOSULIF,dysgeusia,than,0
BOSULIF,dysgeusia,dysgeusia,1
BOSULIF,dysgeusia,System Disorders and less than,0
BOSULIF,acute renal failure,failure Respiratory Thoracic and Mediastinal Disorders,0
BOSULIF,acute renal failure,,0
BOSULIF,acute renal failure,,0
BOSULIF,acute renal failure,Disorders and less acute renal failure,1
BOSULIF,acute renal failure,,0
BOSULIF,acute renal failure,less than,0
BOSULIF,acute renal failure,dysgeusia Renal and Urinary Disorders,0
BOSULIF,acute renal failure,,0
BOSULIF,renal failure,pleural effusion,0
BOSULIF,renal failure,Disorders and less than acute,0
BOSULIF,renal failure,Urinary Disorders and less,0
BOSULIF,renal failure,acute renal renal failure,1
BOSULIF,renal failure,failure,0
BOSULIF,renal failure,acute renal renal failure,1
BOSULIF,renal failure,than acute renal renal failure,1
BOSULIF,pleural effusion,Respiratory Thoracic and Mediastinal Disorders and less,0
BOSULIF,pleural effusion,,0
BOSULIF,respiratory failure,than pleural effusion and less than acute pulmonary,0
BOSULIF,respiratory failure,than acute pulmonary respiratory,1
BOSULIF,respiratory failure,and less than pleural effusion and,0
BOSULIF,respiratory failure,edema,0
BOSULIF,respiratory failure,less than urticaria,0
BOSULIF,respiratory failure,less than acute pulmonary respiratory failure,1
BOSULIF,respiratory failure,and less,0
BOSULIF,respiratory failure,,0
BOSULIF,respiratory failure,respiratory failure,1
BOSULIF,respiratory failure,,0
BOSULIF,pulmonary hypertension,respiratory pulmonary,1
BOSULIF,pulmonary hypertension,and less than urticaria,0
BOSULIF,pulmonary hypertension,urticaria pruritus acne,0
BOSULIF,pulmonary hypertension,respiratory pulmonary hypertension,1
BOSULIF,pulmonary hypertension,,0
BOSULIF,pulmonary hypertension,pulmonary edema respiratory pulmonary hypertension,1
BOSULIF,pulmonary hypertension,pulmonary edema respiratory pulmonary hypertension,1
BOSULIF,pulmonary hypertension,pleural,0
BOSULIF,urticaria,urticaria,1
BOSULIF,urticaria,failure pulmonary hypertension Skin and Subcutaneous Disorders and less,0
BOSULIF,urticaria,urticaria,1
BOSULIF,urticaria,pulmonary hypertension Skin and Subcutaneous,0
BOSULIF,urticaria,Disorders and less urticaria,1
BOSULIF,urticaria,and Subcutaneous Disorders and,0
BOSULIF,urticaria,erythema multiforme exfoliative rash drug eruption,0
BOSULIF,urticaria,urticaria,1
BOSULIF,urticaria,urticaria,1
BOSULIF,pruritus,pruritus,1
BOSULIF,pruritus,Subcutaneous Disorders,0
BOSULIF,pruritus,and less than pruritus,1
BOSULIF,pruritus,than erythema multiforme exfoliative,0
BOSULIF,pruritus,than,0
BOSULIF,pruritus,pruritus,1
BOSULIF,pruritus,less than erythema,0
BOSULIF,pruritus,drug,0
BOSULIF,pruritus,than pruritus,1
BOSULIF,acne,acne,1
BOSULIF,acne,and Subcutaneous Disorders,0
BOSULIF,acne,,0
BOSULIF,acne,acne,1
BOSULIF,acne,and,0
BOSULIF,acne,acne,1
BOSULIF,acne,and less than urticaria acne,1
BOSULIF,erythema multiforme,multiforme,1
BOSULIF,erythema multiforme,,0
BOSULIF,erythema multiforme,erythema multiforme,1
BOSULIF,erythema multiforme,pruritus acne and,0
BOSULIF,erythema multiforme,pruritus acne and less erythema,1
BOSULIF,erythema multiforme,acne and less erythema multiforme,1
BOSULIF,erythema multiforme,less than,0
BOSULIF,erythema multiforme,less erythema multiforme,1
BOSULIF,erythema multiforme,and less,0
BOSULIF,erythema multiforme,,0
BOSULIF,exfoliative rash,,0
BOSULIF,exfoliative rash,drug,0
BOSULIF,exfoliative rash,drug,0
BOSULIF,exfoliative rash,than erythema exfoliative rash,1
BOSULIF,exfoliative rash,less than,0
BOSULIF,drug eruption,pruritus acne and less than erythema multiforme exfoliative,0
BOSULIF,drug eruption,than erythema multiforme exfoliative drug,1
BOSULIF,drug eruption,drug eruption,1
BOSULIF,drug eruption,,0
BOSULIF,drug eruption,exfoliative drug eruption,1
BOSULIF,drug eruption,,0
BOSULIF,drug eruption,,0
BOSULIF,drug eruption,drug eruption,1
BOSULIF,drug eruption,than erythema multiforme exfoliative drug,1
BOSULIF,Gastrointestinal Toxicity,,0
BOSULIF,Gastrointestinal Toxicity,ctions are,1
BOSULIF,Gastrointestinal Toxicity,ctions are,1
BOSULIF,Gastrointestinal Toxicity,discussed in g reater detail in other,1
BOSULIF,Gastrointestinal Toxicity,,0
BOSULIF,Gastrointestinal Toxicity,ctions are discussed in g reater detail,1
BOSULIF,Gastrointestinal Toxicity,,0
BOSULIF,Gastrointestinal Toxicity,Gastrointestinal toxicity see,0
BOSULIF,Gastrointestinal Toxicity,other sections of the labeling Gastrointestinal toxicity see Dosage and,0
BOSULIF,Gastrointestinal Toxicity,ctions are discussed in,1
BOSULIF,Myelosuppression,,0
BOSULIF,Myelosuppression,Gastrointestinal toxicity see Dosage,0
BOSULIF,Myelosuppression,stration (2.3) and Warnings,1
BOSULIF,Myelosuppression,Dosage and,0
BOSULIF,Myelosuppression,Precautions Myelosuppression see Dosage and Administration,0
BOSULIF,Myelosuppression,,0
BOSULIF,Myelosuppression,,0
BOSULIF,Myelosuppression,,0
BOSULIF,Myelosuppression,Dosage,0
BOSULIF,Hepatic Toxicity,,0
BOSULIF,Hepatic Toxicity,and Precautions Hepatic,0
BOSULIF,Fluid Retention,and Precautions,0
BOSULIF,Fluid Retention,] . * Fluid retention see,1
BOSULIF,Fluid Retention,"Administration and Warnings and  ] . 
 *  Fluid retention see",1
BOSULIF,Fluid Retention,] . * Fluid retention see,1
BOSULIF,Fluid Retention,* Fluid retention see,1
BOSULIF,Fluid Retention,retention see Warnings and Precautions Renal toxicity see Warnings and,0
BOSULIF,Renal Toxicity,Precautions EXCERPT ost common adv erse reactions,1
BOSULIF,fetal harm,f atigue To,1
BOSULIF,fetal harm,and f atigue To,1
BOSULIF,fetal harm,and f atigue To,1
BOSULIF,fetal harm,"xia, and",1
BOSULIF,fetal harm,"xia, and f atigue To",1
BOSULIF,fetal harm,nausea thrombocytopenia vomiting abdominal pain rash anemia pyre,0
BOSULIF,fetal harm,rash,0
BOSULIF,fetal harm,"rash anemia xia, and f atigue To",1
BOSULIF,fetal harm,"pain rash anemia xia, and f atigue To",1
BOSULIF,Diarrhea,"

  6.1  Clinical Trials",1
BOSULIF,Diarrhea,"

  6.1  Clinical Trials",1
BOSULIF,Diarrhea,at or FDA at FDA,0
BOSULIF,nausea,,0
BOSULIF,nausea,or wwwfdagovmedwatch inical Trials Experience,1
BOSULIF,nausea,,0
BOSULIF,nausea,wwwfdagovmedwatch inical Trials Experience,1
BOSULIF,nausea,wwwfdagovmedwatch inical Trials Experience,1
BOSULIF,nausea,inical Trials Experience,1
BOSULIF,nausea,at FDA,0
BOSULIF,nausea,inical Trials Experience,1
BOSULIF,nausea,Because clinical trials,0
BOSULIF,vomiting,rials Ex perience Because,1
BOSULIF,vomiting,rials,1
BOSULIF,abdominal pain,conducted under widely varying conditions adverse reaction rates observed in,0
BOSULIF,abdominal pain,or wwwfdagovmedwatch Clinical Trials ce,1
BOSULIF,abdominal pain,in th,0
BOSULIF,abdominal pain,Clinical Trials ce,1
BOSULIF,Thrombocytopenia,and fatigue see Clinical Studies,0
BOSULIF,Thrombocytopenia,were diarrhea nausea thrombocytopenia ing,1
BOSULIF,Thrombocytopenia,nausea thrombocytopenia ing,1
BOSULIF,Thrombocytopenia,,0
BOSULIF,Thrombocytopenia,"ing (39%), abdom inal pain",1
BOSULIF,Thrombocytopenia,see,0
BOSULIF,anemia,pai n rash,1
BOSULIF,neutropenia,"thrombocytopenia vomiting abdominal %),",1
BOSULIF,neutropenia,"vomiting abdominal %), rash (3 anemia pyrexia",1
BOSULIF,neutropenia,vomiting,0
BOSULIF,neutropenia,"%), rash (3 anemia pyrexia",1
BOSULIF,neutropenia,"vomiting abdominal %), rash",1
BOSULIF,neutropenia,Adver,0
BOSULIF,neutropenia,vomiting abdominal,0
BOSULIF,neutropenia,"vomiting abdominal %),",1
BOSULIF,neutropenia,,0
BOSULIF,drug induced liver injury,ous leukemia,1
BOSULIF,drug induced liver injury,and wi th resistance,1
BOSULIF,drug induced liver injury,or blast phase chronic,0
BOSULIF,drug induced liver injury,,0
BOSULIF,total bilirubin greater than 2*ULN,safety population (received at lea st dose,1
BOSULIF,total bilirubin greater than 2*ULN,see Clinical Studies safety population (received at lea st dose,1
BOSULIF,total bilirubin greater than 2*ULN,Studies safety population (received,1
BOSULIF,total bilirubin greater than 2*ULN,resistance or intolerance to prior therapy see Clinical,0
BOSULIF,total bilirubin greater than 2*ULN,Clinical Studies safety population (received at,1
BOSULIF,total bilirubin greater than 2*ULN,or intolerance to prior therapy see Clinical,0
BOSULIF,total bilirubin greater than 2*ULN,therapy see Clinical Studies safety population (received,1
BOSULIF,alkaline phosphatase less than 2*ULN,dose of BOSULIF) included 546 CML pa tients patients,1
BOSULIF,ALT elevation,nal TKI,1
BOSULIF,ALT elevation,,0
BOSULIF,ALT elevation,imatinib and at least nal TKI who,1
BOSULIF,ALT elevation,of BOSULIF treatment of months and a median dose intensity of mgday,0
BOSULIF,ALT elevation,dose intensity of,0
BOSULIF,ALT elevation,patients,0
BOSULIF,ALT elevation,least nal TKI who h ad a,1
BOSULIF,ALT elevation,h ad a,1
BOSULIF,AST elevation,of BO SULIF treatment,1
BOSULIF,AST elevation,of BO SULIF treatment,1
BOSULIF,AST elevation,uration of,1
BOSULIF,AST elevation,uration,1
BOSULIF,AST elevation,BO SULIF treatment,1
BOSULIF,AST elevation,a median uration,1
BOSULIF,transaminase elevations,with AP CML and BP,0
BOSULIF,transaminase elevations,CML In,0
BOSULIF,transaminase elevations,patients with d phase CML including 7 patients with,1
BOSULIF,transaminase elevations,CML In  patients with AP CML a nd BP,1
BOSULIF,transaminase elevations,with BP CML In patients with AP,1
BOSULIF,transaminase elevations,The,0
BOSULIF,transaminase elevations,was months and,0
BOSULIF,transaminase elevations,with AP CML a nd BP,1
BOSULIF,transaminase elevations,including patients,0
BOSULIF,Fluid retention,Grade All es(%)           Grade Advanced,1
BOSULIF,Fluid retention,Grades Grade All es(%)           Grade Advanced,1
BOSULIF,Fluid retention,All es(%)           Grade Advanced,1
BOSULIF,Fluid retention,Phase CML includes patients,0
BOSULIF,Fluid retention,Grade Advanced Phase CML includes patients with Accelerated Phase and Blast,0
BOSULIF,Fluid retention,es(%)           Grade Advanced,1
BOSULIF,Fluid retention,Grade All,0
BOSULIF,Fluid retention,Grades Grade All es(%)           Grade Advanced,1
BOSULIF,Fluid retention,Phase and,0
BOSULIF,pericardial effusion,Grade All Grades Grade Advanced Phase CM,0
BOSULIF,pericardial effusion,L includes patients with Accelerated,1
BOSULIF,pericardial effusion,Blast Phase CML Diarrhea,0
BOSULIF,pericardial effusion,Grade Advanced Phase,0
BOSULIF,pericardial effusion,CM,0
BOSULIF,pericardial effusion,Grade Advanced Phase L,1
BOSULIF,pericardial effusion,Advanced Phase L includes patients  with Accelerated,1
BOSULIF,pericardial effusion,with Accelerated Phase and Blast,0
BOSULIF,pericardial effusion,Grade Advanced Phase L includes patients  with Accelerated,1
BOSULIF,pericardial effusion,Grades Grade Advanced Phase L includes,1
BOSULIF,pleural effusion,Phase CML includes patients th Accelerated P hase and,1
BOSULIF,pleural effusion,and Blast Phase,0
BOSULIF,pulmonary edema,,0
BOSULIF,pulmonary edema,Accelerated Pha,0
BOSULIF,pulmonary edema,includes patients with Accelerated se and Blast Ph ase CML,1
BOSULIF,pulmonary edema,ase,0
BOSULIF,pulmonary edema,,0
BOSULIF,pulmonary edema,,0
BOSULIF,peripheral edema," 
  
 Diarrhea  ",1
BOSULIF,peripheral edema,,0
BOSULIF,peripheral edema," 
  
 Diarrhea  ",1
BOSULIF,peripheral edema," 
  
 Diarrhea  ",1
BOSULIF,peripheral edema," 
  
 Diarrhea  ",1
BOSULIF,peripheral edema," 
  
 Diarrhea  ",1
BOSULIF,peripheral edema,"and Blast Phase  
  
 Diarrhea  ",1
BOSULIF,peripheral edema,with Accelerated,0
BOSULIF,peripheral edema," 
  
 Diarrhea  ",1
BOSULIF,fluid retention,Nausea,0
BOSULIF,fluid retention,Nausea,0
BOSULIF,fluid retention,Abdomina,0
BOSULIF,fluid retention,                Abdomina,1
BOSULIF,fluid retention,Nausea,0
BOSULIF,fluid retention,Nausea,0
BOSULIF,fluid retention,Nausea                 Abdomina,1
BOSULIF,fluid retention,                Abdomina,1
BOSULIF,fluid retention,,0
BOSULIF,fluid retention,Nausea                 Abdomina,1
BOSULIF,pleural effusion,"Nausea            
 Abd",1
BOSULIF,pleural effusion,,0
BOSULIF,pleural effusion,"Nausea            
 Abd ominal Pain",1
BOSULIF,pleural effusion,"Nausea            
 Abd ominal",1
BOSULIF,pericardial effusions,Pain,0
BOSULIF,pericardial effusions,Abdominal            29         Thrombocytopenia,1
BOSULIF,pericardial effusions,Pain,0
BOSULIF,pericardial effusions,           29         Thrombocytopenia,1
BOSULIF,pericardial effusions,           29         Thrombocytopenia,1
BOSULIF,pericardial effusions,,0
BOSULIF,pericardial effusions,Abdominal            29         Thrombocytopenia,1
BOSULIF,pericardial effusions,,0
BOSULIF,pericardial effusions,,0
BOSULIF,pericardial effusions,           29         Thrombocytopenia,1
BOSULIF,edema,Vomiting,0
BOSULIF,edema,Vomiting,0
BOSULIF,edema,,0
BOSULIF,edema,      Vomiting,1
BOSULIF,decline in estimated glomerular filtration rate,"Rash                 4             
 Fatigue         An",1
BOSULIF,decline in estimated glomerular filtration rate,Rash,0
BOSULIF,decline in estimated glomerular filtration rate,Rash 4,1
BOSULIF,decline in estimated glomerular filtration rate,Rash,0
BOSULIF,Kidney Failure,,0
BOSULIF,Kidney Failure,aspartate aminotransferase,0
BOSULIF,Kidney Failure,Neutropenia,0
BOSULIF,Kidney Failure,,0
BOSULIF,Kidney Failure,aminotransferase,0
BOSULIF,Kidney Failure,,0
BOSULIF,Kidney Failure,,0
BOSULIF,fetal harm,by protocol Table fies,1
BOSULIF,fetal harm,disease including QT interval prolongation were excluded by protocol Table identi,0
BOSULIF,fetal harm,excluded by protocol Table fies the,1
BOSULIF,embryofetal toxicities,population,0
BOSULIF,embryofetal toxicities,Ph ase,1
BOSULIF,embryofetal toxicities,ase,0
BOSULIF,embryofetal toxicities,Clinically Relevant or,0
BOSULIF,embryofetal toxicities,test normalities for the Ph ase,1
BOSULIF,embryofetal toxicities,Grade laboratory test normalities,1
BOSULIF,embryofetal toxicities,,0
GILENYA,Bradyarrhythmia,,0
GILENYA,Bradyarrhythmia,Bradyarrhythmia and,1
GILENYA,Bradyarrhythmia,Warnings and,0
GILENYA,Bradyarrhythmia,Bradyarrhythmia and,1
GILENYA,Bradyarrhythmia,Bradyarrhythmia and,1
GILENYA,Bradyarrhythmia,Bradyarrhythmia and,1
GILENYA,Bradyarrhythmia,described,0
GILENYA,Bradyarrhythmia,Bradyarrhythmia and,1
GILENYA,Bradyarrhythmia,described elsewhere in Bradyarrhythmia and,1
GILENYA,Bradyarrhythmia,elsewhere in labeling,0
GILENYA,Atrioventricular Blocks,described elsewhere in labeling,0
GILENYA,Infections,Infections see,1
GILENYA,Infections,Infections see,1
GILENYA,Infections,and Atrioventricular Blocks see,0
GILENYA,Infections,leukoencephalopathy,0
GILENYA,Infections,Infections see,1
GILENYA,Progressive multifocal leukoencephalopathy,Edema,0
GILENYA,Progressive multifocal leukoencephalopathy,Infections,0
GILENYA,Progressive multifocal leukoencephalopathy,Warnings and Precautions,0
GILENYA,Progressive multifocal leukoencephalopathy,,0
GILENYA,Macular Edema,Edema see,1
GILENYA,Macular Edema,Macular,1
GILENYA,Posterior Reversible Encephalopathy Syndrome,Posterior Reversible Encephalopathy,1
GILENYA,Posterior Reversible Encephalopathy Syndrome,and Posterior Reversible Encephalopathy Syndrome see,1
GILENYA,Posterior Reversible Encephalopathy Syndrome,Edema see Warnings and Posterior Reversible Encephalopathy Syndrome see,1
GILENYA,Posterior Reversible Encephalopathy Syndrome,Warnings and Precautions,0
GILENYA,Posterior Reversible Encephalopathy Syndrome,Precautions Macular Edema,0
GILENYA,Posterior Reversible Encephalopathy Syndrome,and Posterior Reversible Encephalopathy Syndrome see,1
GILENYA,Posterior Reversible Encephalopathy Syndrome,Warnings and,0
GILENYA,Posterior Reversible Encephalopathy Syndrome,Precautions Macular Edema see,0
GILENYA,Respiratory Effects,,0
GILENYA,Liver Injury,see Warnings and Liver Injury see,1
GILENYA,Liver Injury,and Liver,1
GILENYA,Liver Injury,Precautions EXCERPT Most common adverse reactions incidence,0
GILENYA,Headache,and,0
GILENYA,liver transaminase elevation,,0
GILENYA,liver transaminase elevation,reactions incidence and placebo liver transaminase elevation diarrhea,1
GILENYA,liver transaminase elevation,and,0
GILENYA,liver transaminase elevation,pain abdominal pain and pain,0
GILENYA,diarrhea,diarrhea cough,1
GILENYA,diarrhea,diarrhea cough,1
GILENYA,cough,cough influenza,1
GILENYA,cough,transaminase elevation cough influenza,1
GILENYA,cough,placebo Headache liver transaminase elevation diarrhea,0
GILENYA,cough,cough influenza,1
GILENYA,cough,cough influenza,1
GILENYA,cough,elevation cough influenza,1
GILENYA,cough,Headache liver transaminase,0
GILENYA,cough,cough influenza,1
GILENYA,influenza,elevation diarrhea influenza sinusitis,1
GILENYA,influenza,influenza sinusitis,1
GILENYA,influenza,liver transaminase elevation diarrhea influenza sinusitis,1
GILENYA,sinusitis,sinusitis back,1
GILENYA,sinusitis,To report,0
GILENYA,sinusitis,sinusitis back,1
GILENYA,sinusitis,transaminase elevation diarrhea cough sinusitis back,1
GILENYA,back pain,pain abdominal,1
GILENYA,back pain,elevation diarrhea cough influenza back,1
GILENYA,abdominal pain,elevation diarrhea cough influenza,0
GILENYA,abdominal pain,abdominal pain and,1
GILENYA,abdominal pain,back,0
GILENYA,abdominal pain,pain and,1
GILENYA,abdominal pain,influenza sinusitis back abdominal,1
GILENYA,abdominal pain,extremity,0
GILENYA,abdominal pain,,0
GILENYA,pain in extremity,pain in extremity To,1
GILENYA,pain in extremity,in extremity To,1
GILENYA,pain in extremity,influenza sinusitis back pain abdominal pain and,0
GILENYA,pain in extremity,abdominal,0
GILENYA,headache,headache liver,1
GILENYA,headache,pain,0
GILENYA,headache,most frequent adverse reactions incidence and placebo for,0
GILENYA,headache,mg headache liver,1
GILENYA,headache,transaminase elevation diarrhea cough influenza sinusitis,0
GILENYA,liver transaminase elevation,liver transaminase elevation diarrhea,1
GILENYA,liver transaminase elevation,incidence and placebo for GILENYA,0
GILENYA,liver transaminase elevation,cough influenza sinusitis back pain abdominal pain,0
GILENYA,liver transaminase elevation,,0
GILENYA,liver transaminase elevation,liver transaminase elevation diarrhea,1
GILENYA,liver transaminase elevation,transaminase elevation diarrhea,1
GILENYA,liver transaminase elevation,liver transaminase elevation diarrhea,1
GILENYA,liver transaminase elevation,liver transaminase elevation diarrhea,1
GILENYA,liver transaminase elevation,back pain abdominal pain and pain in extremity,0
GILENYA,diarrhea,,0
GILENYA,diarrhea,mg,0
GILENYA,diarrhea,liver transaminase diarrhea cough,1
GILENYA,diarrhea,liver transaminase diarrhea cough,1
GILENYA,diarrhea,diarrhea cough,1
GILENYA,cough,cough influenza,1
GILENYA,cough,transaminase elevation cough influenza,1
GILENYA,cough,cough influenza,1
GILENYA,cough,cough influenza,1
GILENYA,cough,,0
GILENYA,cough,cough influenza,1
GILENYA,cough,were headache liver transaminase elevation diarrhea,0
GILENYA,cough,diarrhea,0
GILENYA,cough,cough influenza,1
GILENYA,influenza,Adverse,0
GILENYA,influenza,influenza sinusitis,1
GILENYA,influenza,influenza sinusitis,1
GILENYA,influenza,liver transaminase elevation diarrhea influenza sinusitis,1
GILENYA,influenza,influenza sinusitis,1
GILENYA,influenza,influenza sinusitis,1
GILENYA,influenza,influenza sinusitis,1
GILENYA,influenza,liver transaminase elevation diarrhea influenza sinusitis,1
GILENYA,influenza,influenza sinusitis,1
GILENYA,influenza,that led to treatment,0
GILENYA,sinusitis,sinusitis back,1
GILENYA,back pain,headache,0
GILENYA,back pain,,0
GILENYA,back pain,,0
GILENYA,back pain,pain abdominal,1
GILENYA,back pain,in extremity Adverse events that led to treatment discontinuation,0
GILENYA,back pain,diarrhea cough influenza back pain abdominal,1
GILENYA,back pain,to treatment discontinuation and,0
GILENYA,back pain,treatment discontinuation,0
GILENYA,back pain,in extremity Adverse events that led to,0
GILENYA,abdominal pain,Adverse,0
GILENYA,abdominal pain,back,0
GILENYA,abdominal pain,,0
GILENYA,abdominal pain,and occurred in more,0
GILENYA,abdominal pain,abdominal pain and,1
GILENYA,abdominal pain,diarrhea cough,0
GILENYA,abdominal pain,occurred,0
GILENYA,pain in extremity,led to treatment discontinuation and occurred in more than of,0
GILENYA,pain in extremity,back pain abdominal pain pain in extremity Adverse,1
GILENYA,pain in extremity,pain in,1
GILENYA,serum transaminase elevations,compared to on placebo and basal cell carcinoma,0
GILENYA,serum transaminase elevations,GILENYA mg serum transaminase elevations compared,1
GILENYA,serum transaminase elevations,transaminase elevations compared,1
GILENYA,serum transaminase elevations,on placebo and basal cell,0
GILENYA,basal cell carcinoma,compared to on placebo basal cell carcinoma compared,1
GILENYA,basal cell carcinoma,on placebo basal,1
GILENYA,basal cell carcinoma,basal cell,1
GILENYA,basal cell carcinoma,cell carcinoma compared,1
GILENYA,basal cell carcinoma,placebo and,0
GILENYA,basal cell carcinoma,compared to on placebo basal cell carcinoma compared,1
GILENYA,basal cell carcinoma,to on placebo Table lists adverse,0
GILENYA,basal cell carcinoma,,0
GILENYA,basal cell carcinoma,on placebo,0
GILENYA,Influenza,Sinusitis,0
GILENYA,Influenza,Influenza Sinusitis,1
GILENYA,Influenza,N,0
GILENYA,Influenza,Influenza Sinusitis,1
GILENYA,Influenza,,0
GILENYA,Influenza,Influenza Sinusitis,1
GILENYA,Influenza,,0
GILENYA,Influenza,Influenza Sinusitis,1
GILENYA,Influenza,Influenza Sinusitis,1
GILENYA,Sinusitis,Sinusitis Bronchitis,1
GILENYA,Sinusitis,Sinusitis Bronchitis,1
GILENYA,Sinusitis,Sinusitis Bronchitis,1
GILENYA,Sinusitis,Sinusitis Bronchitis,1
GILENYA,Sinusitis,,0
GILENYA,Sinusitis,Sinusitis Bronchitis,1
GILENYA,Sinusitis,Influenza,0
GILENYA,Sinusitis,Sinusitis Bronchitis,1
GILENYA,Sinusitis,,0
GILENYA,Bronchitis,,0
GILENYA,Bronchitis,,0
GILENYA,Bronchitis,Bronchitis,1
GILENYA,Bronchitis,,0
GILENYA,Bronchitis,Sinusitis,0
GILENYA,Herpes zoster,Bronchitis Herpes,1
GILENYA,Herpes zoster,Bronchitis,0
GILENYA,Herpes zoster,Bronchitis Herpes zoster Tinea,1
GILENYA,Herpes zoster,Bronchitis Herpes,1
GILENYA,Herpes zoster,Bronchitis Herpes zoster Tinea,1
GILENYA,Herpes zoster,zoster Tinea versicolor,1
GILENYA,Tinea versicolor,zoster,0
GILENYA,Tinea versicolor,Tinea versicolor Cardiac Disorders,1
GILENYA,Headache,Headache Migraine Gast,1
GILENYA,Headache,,0
GILENYA,Headache,Headache Migraine Gast,1
GILENYA,Headache,Headache Migraine Gast,1
GILENYA,Headache,Headache Migraine Gast,1
GILENYA,Headache,,0
GILENYA,Headache,system Headache Migraine Gast,1
GILENYA,Migraine,,0
GILENYA,Nausea,disorders,0
GILENYA,Nausea,Gastrointestinal Nausea Diarrhea,1
GILENYA,Nausea,Nausea Diarrhea,1
GILENYA,Nausea,Nausea Diarrhea,1
GILENYA,Nausea,,0
GILENYA,Nausea,Diarrhea,0
GILENYA,Diarrhea,Diarrhea Abdominal,1
GILENYA,Diarrhea,Nausea,0
GILENYA,Diarrhea,Abdominal pain,0
GILENYA,Diarrhea,Diarrhea Abdominal pain,1
GILENYA,Diarrhea,Diarrhea Abdominal pain,1
GILENYA,Diarrhea,Abdominal,0
GILENYA,Diarrhea,Diarrhea Abdominal,1
GILENYA,Diarrhea,Diarrhea Abdominal,1
GILENYA,Diarrhea,,0
GILENYA,Abdominal pain,Abdominal pain General disorders and,1
GILENYA,Abdominal pain,conditions,0
GILENYA,Back pain,Pain,0
GILENYA,Back pain,,0
GILENYA,Pain in extremity,extremity Skin and subcutaneous tissue disorders,1
GILENYA,Pain in extremity,pain,0
GILENYA,Pain in extremity,Back Pain in extremity Skin and subcutaneous tissue disorders,1
GILENYA,Pain in extremity,Pain in extremity Skin and subcutaneous tissue disorders,1
GILENYA,Pain in extremity,Pain,1
GILENYA,Pain in extremity,pain,0
GILENYA,Pain in extremity,Pain in extremity Skin and subcutaneous tissue disorders,1
GILENYA,Pain in extremity,,0
GILENYA,Alopecia,Alopecia Actinic keratosis,1
GILENYA,Alopecia,Actinic,0
GILENYA,Alopecia,,0
GILENYA,Alopecia,and subcutaneous tissue,0
GILENYA,Alopecia,Alopecia Actinic keratosis,1
GILENYA,Alopecia,and subcutaneous tissue disorders,0
GILENYA,Alopecia,keratosis,0
GILENYA,Actinic keratosis,,0
GILENYA,Actinic keratosis,,0
GILENYA,Actinic keratosis,Actinic keratosis Investigations,1
GILENYA,Actinic keratosis,Alopecia,0
GILENYA,Liver transaminase elevations,,0
GILENYA,Liver transaminase elevations,,0
GILENYA,Liver transaminase elevations,ALTGGTAST,0
GILENYA,Liver transaminase elevations,elevations ALTGGTAST Blood triglycerides increased,1
GILENYA,Blood triglycerides increased,ALTGGTAST,0
GILENYA,Blood triglycerides increased,Blood triglycerides increased Respiratory thoracic and mediastinal,1
GILENYA,Blood triglycerides increased,Liver transaminase elevations Blood triglycerides increased Respiratory thoracic and mediastinal,1
GILENYA,Blood triglycerides increased,transaminase,0
GILENYA,Blood triglycerides increased,Blood triglycerides increased Respiratory thoracic and mediastinal,1
GILENYA,Blood triglycerides increased,Blood,1
GILENYA,Blood triglycerides increased,mediastinal,0
GILENYA,Blood triglycerides increased,elevations Blood triglycerides,1
GILENYA,Blood triglycerides increased,and,0
GILENYA,Cough,mediastinal,0
GILENYA,Cough,,0
GILENYA,Cough,mediastinal disorders,0
GILENYA,Cough,Cough Dyspnea E,1
GILENYA,Cough,Cough Dyspnea E,1
GILENYA,Dyspnea,Dyspnea,1
GILENYA,Dyspnea,Cough,0
GILENYA,Dyspnea,Dyspnea Eye,1
GILENYA,Dyspnea,Cough,0
GILENYA,Dyspnea,Dyspnea Eye,1
GILENYA,Dyspnea,,0
GILENYA,Dyspnea,Dyspnea,1
GILENYA,Dyspnea,Cough Dyspnea,1
GILENYA,Dyspnea,Cough Dyspnea,1
GILENYA,Dyspnea,Cough,0
GILENYA,Vision blurred,Vision blurred Vascular disorders,1
GILENYA,Vision blurred,Vision blurred Vascular disorders,1
GILENYA,Vision blurred,Eye Vision blurred Vascular disorders,1
GILENYA,Vision blurred,Vision,1
GILENYA,Vision blurred,disorders,0
GILENYA,Vision blurred,,0
GILENYA,Vision blurred,Vascular,0
GILENYA,Vision blurred,Eye Vision,1
GILENYA,Hypertension,Hypertension Blood and,1
GILENYA,Hypertension,Hypertension Blood and,1
GILENYA,Hypertension,,0
GILENYA,Hypertension,disorders,0
GILENYA,Hypertension,Hypertension Blood and,1
GILENYA,Hypertension,Hypertension Blood and,1
GILENYA,Hypertension,disorders,0
GILENYA,Hypertension,,0
GILENYA,Hypertension,disorders,0
GILENYA,Hypertension,,0
GILENYA,Lymphopenia,lymphatic system Lymphopenia Leukopenia Neop,1
GILENYA,Lymphopenia,lymphatic,0
GILENYA,Lymphopenia,system Lymphopenia Leukopenia Neop,1
GILENYA,Lymphopenia,,0
GILENYA,Lymphopenia,Lymphopenia Leukopenia Neop,1
GILENYA,Lymphopenia,Lymphopenia Leukopenia Neop,1
GILENYA,Lymphopenia,Lymphopenia Leukopenia Neop,1
GILENYA,Lymphopenia,,0
GILENYA,Lymphopenia,Blood and lymphatic system Lymphopenia Leukopenia Neop,1
GILENYA,Leukopenia,,0
GILENYA,Leukopenia,Leukopenia,1
GILENYA,Leukopenia,benign malignant and unspecifiedincluding,0
GILENYA,Leukopenia,Lymphopenia Leukopenia Neoplasms,1
GILENYA,Leukopenia,Lymphopenia,0
GILENYA,Leukopenia,Lymphopenia,0
GILENYA,Leukopenia,Lymphopenia,0
GILENYA,Basal cell carcinoma,carcinoma Adverse,1
GILENYA,Basal cell carcinoma,Basal,1
GILENYA,Basal cell carcinoma,of dizziness,0
GILENYA,Basal cell carcinoma,Basal cell carcinoma Adverse,1
GILENYA,Basal cell carcinoma,Basal cell carcinoma Adverse,1
GILENYA,Basal cell carcinoma,of dizziness pneumonia eczema and,0
GILENYA,Basal cell carcinoma,,0
GILENYA,dizziness,dizziness pneumonia,1
GILENYA,dizziness,dizziness pneumonia,1
GILENYA,dizziness,carcinoma Adverse reactions dizziness pneumonia,1
GILENYA,dizziness,reactions dizziness pneumonia,1
GILENYA,dizziness,dizziness pneumonia,1
GILENYA,dizziness,pneumonia eczema and pruritus were also reported in Studies and but did not meet,0
GILENYA,dizziness,cell carcinoma Adverse reactions,0
GILENYA,dizziness,Adverse reactions dizziness pneumonia,1
GILENYA,eczema,reactions of dizziness pneumonia,0
GILENYA,eczema,eczema and,1
GILENYA,eczema,eczema and,1
GILENYA,eczema,reactions of,0
GILENYA,eczema,eczema and,1
GILENYA,eczema,dizziness pneumonia,0
GILENYA,eczema,eczema and,1
GILENYA,pruritus,,0
GILENYA,pruritus,but,0
GILENYA,Vascular events,Vascular Vascular,1
GILENYA,Vascular events,Vascular events including,1
GILENYA,Vascular events,Vascular events including,1
GILENYA,Vascular events,Studies and Vascular Vascular,1
GILENYA,Vascular events,in Studies and Vascular Vascular events including,1
GILENYA,Vascular events,Vascular,1
GILENYA,Vascular events,Vascular events including,1
GILENYA,hemorrhagic strokes,in Studies and Vascular Events,0
GILENYA,hemorrhagic strokes,patient,0
GILENYA,hemorrhagic strokes,premarketing clinical trials in patient,0
GILENYA,hemorrhagic strokes,arterial occlusive disease were reported in,0
GILENYA,hemorrhagic strokes,ischemic hemorrhagic strokes and,1
GILENYA,peripheral arterial occlusive disease,hemorrhagic strokes peripheral,1
GILENYA,peripheral arterial occlusive disease,strokes peripheral arterial occlusive,1
GILENYA,peripheral arterial occlusive disease,strokes peripheral,1
GILENYA,peripheral arterial occlusive disease,hemorrhagic strokes peripheral arterial occlusive disease were,1
GILENYA,peripheral arterial occlusive disease,,0
GILENYA,lymphoma,lymphoma have,1
GILENYA,lymphoma,Lymphomas Cases lymphoma have,1
GILENYA,lymphoma,,0
GILENYA,lymphoma,and in the postmarketing setting The relationship to,0
GILENYA,lymphoma,Cases lymphoma have,1
GILENYA,lymphoma,in the,0
GILENYA,Bradycardia,see War,0
GILENYA,Bradycardia,erse,1
GILENYA,Bradycardia,erse reacti ons are described,1
GILENYA,atrioventricular conduction,described elsewhere in,1
GILENYA,atrioventricular conduction,,0
GILENYA,atrioventricular conduction,described elsewhere in labe ling Bradyarrhythmia and Atrioventricular,1
GILENYA,atrioventricular conduction,described elsewhere in,1
GILENYA,atrioventricular conduction,described elsewhere in,1
GILENYA,atrioventricular conduction,and,0
GILENYA,Infections,Warnings and,0
GILENYA,Infections,Atrioventricular see Warnin,1
GILENYA,Infections,labeling Bradyarrhythmia,0
GILENYA,Infections,labeling Bradyarrhythmia and Atrioventricular see,1
GILENYA,Infections,see Warnings and,0
GILENYA,Infections,and Atrioventricular see Warnin,1
GILENYA,Infections,see,1
GILENYA,infections,Atrioventricular Blocks see Warnings and,0
GILENYA,infections,[s,1
GILENYA,infections,[s,1
GILENYA,infections,,0
GILENYA,Progressive multifocal leukoencephalopathy,Syndrome [see Warnings and Pr,1
GILENYA,Progressive multifocal leukoencephalopathy,Reversible,0
GILENYA,Progressive multifocal leukoencephalopathy,Warnings and Pr,1
GILENYA,PML,Precautions Liver Injury,0
GILENYA,PML,Syndrome see Warnings and Prec,0
GILENYA,PML,,0
GILENYA,PML,Warnings and aut,1
GILENYA,PML,,0
GILENYA,PML,Syndrome see Warnings and aut,1
GILENYA,Macular edema,adverse reactions,0
GILENYA,Macular edema,and Precautions Respiratory Effects see,0
GILENYA,Macular edema,Warnings and Precautions ver Injury [s,1
GILENYA,Macular edema,and,0
GILENYA,Macular edema,Warnings and Precautions,0
GILENYA,Macular edema,,0
GILENYA,Macular edema,ver Injury,1
GILENYA,Macular edema,ver Injury [s,1
GILENYA,Macular edema,and,0
GILENYA,Posterior reversible encephalopathy syndrome,report SUSPECTED,0
GILENYA,Posterior reversible encephalopathy syndrome,"pain, and pain in extremity (",1
GILENYA,Posterior reversible encephalopathy syndrome,cough influenza sinusitis,0
GILENYA,Posterior reversible encephalopathy syndrome,liver transaminase elevation diarrhea cough influenza sinusitis back pai,0
GILENYA,Posterior reversible encephalopathy syndrome,extremity (,1
GILENYA,Posterior reversible encephalopathy syndrome,and pain in extremity (,1
GILENYA,Posterior reversible encephalopathy syndrome,and pain in extremity (,1
GILENYA,PRES,Novartis Pharmaceuticals Corporation at,0
GILENYA,PRES,pain and pain in 1,1
GILENYA,PRES,and pain in 1  ),1
GILENYA,PRES,in 1  ),1
GILENYA,PRES,back pain abdominal,0
GILENYA,PRES,cough influenza sinusitis back pain abdominal pain and pain in,0
GILENYA,PRES,pain and pain in 1  ),1
GILENYA,PRES,),1
GILENYA,PRES,ADVERSE REACTIONS contact,0
GILENYA,PRES,and pain in 1  ),1
GILENYA,Decrease in pulmonary function tests, Novartis Pharmaceuticals Corporatio,1
GILENYA,Decrease in pulmonary function tests,wwwfdagovmedwatch Clinical,0
GILENYA,Decrease in pulmonary function tests,,0
GILENYA,Decrease in pulmonary function tests,Novartis Pharmaceuticals Corporatio,1
GILENYA,Decrease in pulmonary function tests,Clinical,0
GILENYA,Decrease in pulmonary function tests,,0
GILENYA,Decrease in pulmonary function tests,or,0
GILENYA,Decrease in pulmonary function tests,SUSPECTED ADVERSE REACTIONS Novartis Pharmaceuticals,1
GILENYA,Decrease in pulmonary function tests,,0
GILENYA,Liver injury,.,1
GILENYA,Liver injury,.,1
GILENYA,Liver injury,medwatch,1
GILENYA,Liver injury,FDA or medwatch,1
GILENYA,Liver injury,medwatch .,1
GILENYA,Liver injury,Corporation at or FDA at FDA or,0
GILENYA,Liver injury,FDA,0
GILENYA,Liver injury,Experience Because,0
GILENYA,Liver injury,,0
GILENYA,Liver injury,FDA or medwatch  . ,1
GILENYA,heart rate decrease,who received GILENYA mg in,0
GILENYA,decline in heart rate,with,0
GILENYA,decline in heart rate,ls was equivalent to,1
GILENYA,decline in heart rate,ls was equivalent to ,1
GILENYA,decline in heart rate,was equivalent to,1
GILENYA,decline in heart rate,,0
GILENYA,decline in heart rate,controlled ls was equivalent to ,1
GILENYA,decline in heart rate,ls was equivalent,1
GILENYA,decline in heart rate,in the controlled ls was equivalent to ,1
GILENYA,decline in heart rate,treatment with,0
GILENYA,decline in heart rate,controlled ls was equivalent,1
GILENYA,heart rate decrease,xposure to GILENYA ,1
GILENYA,heart rate decrease,clinical studies,0
GILENYA,heart rate decrease,xposure to GILENYA ,1
GILENYA,heart rate decrease,GILENYA,1
GILENYA,heart rate decrease,most,0
GILENYA,heart rate decrease,GILENYA mg were headach,0
GILENYA,heart rate decrease,studies the exposure to GILENYA mg was approximately personyears,0
GILENYA,heart rate decrease,o-controlled trials,1
GILENYA,symptomatic bradycardia,influenza sinusitis back pain abdominal pain,0
GILENYA,symptomatic bradycardia,discontinuation and,0
GILENYA,symptomatic bradycardia,pain abdominal pain and n in extremity. Adverse,1
GILENYA,bradycardia,serum transaminase .7% compare,1
GILENYA,bradycardia,compare,1
GILENYA,hypotension,patients,0
GILENYA,hypotension,cell carcinoma compared 0.5%,1
GILENYA,hypotension, 0.5% on pl,1
GILENYA,hypotension,basal,0
GILENYA,hypotension,acebo,0
GILENYA,hypotension,cell carcinoma compared  0.5% on pl,1
GILENYA,hypotension,0.5% on pl,1
GILENYA,hypotension,basal cell carcinoma compared  0.5% on pl,1
GILENYA,hypotension,0.5% on,1
GILENYA,dizziness,compared to on,0
GILENYA,dizziness,adverse reactions that occurred in of GILENYAtreated patients and higher,0
GILENYA,dizziness,,0
GILENYA,dizziness,"ebo).



",1
GILENYA,fatigue,able 1,1
GILENYA,fatigue,that occurred,0
GILENYA,fatigue,1,1
GILENYA,fatigue,carcinoma compared to,0
GILENYA,fatigue,to on placebo able,1
GILENYA,fatigue,to on placebo able 1 ,1
GILENYA,palpitations,Table sts,1
GILENYA,palpitations,to on placebo Table li,0
GILENYA,palpitations,li,0
GILENYA,palpitations,Table sts adverse ,1
GILENYA,palpitations,on placebo Table sts adverse ,1
GILENYA,palpitations,Table sts,1
GILENYA,palpitations,patients and higher rate than for,0
GILENYA,palpitations,li,0
GILENYA,palpitations,placebo and basal cell carcinoma,0
GILENYA,chest pain,patients and higher rate than for placebo,0
GILENYA,chest pain,that occu,1
GILENYA,chest pain,placebo,0
GILENYA,chest pain,rred in of GILENYAtreated patients and higher,0
GILENYA,chest pain,basal cell carcinoma compared to on placebo Table,0
GILENYA,chest pain,Table lists adverse,0
GILENYA,chest pain,rred in of GILENYAtreated,0
GILENYA,decrease in heart rate,placebo Table Adverse tions Reported in,1
GILENYA,decrease in heart rate,than for placebo Table,0
GILENYA,decrease in heart rate,tions Reported in Stud,1
GILENYA,decrease in heart rate,for placebo Table Adverse tions,1
GILENYA,decrease in heart rate,for placebo Table Adverse tions Reported in Stud,1
GILENYA,decrease in heart rate,of GILENYAtreated patients and higher rate than for placebo Table Adverse Reac,0
GILENYA,decrease in heart rate,tions Reported,1
GILENYA,decrease in heart rate,tions Reported in Stud,1
GILENYA,AV conduction delays,,0
GILENYA,AV conduction delays,Sinus,0
GILENYA,AV conduction delays,Influenza itis,1
GILENYA,AV conduction delays,Influenza itis  11            ,1
GILENYA,AV conduction delays,,0
GILENYA,AV conduction delays,Bronchitis Herpes,0
GILENYA,first-degree AV block,Sinusitis chitis,1
GILENYA,first-degree AV block,Sinusitis chitis  8            ,1
GILENYA,first-degree AV block,,0
GILENYA,second-degree AV blocks,"           
   Nervous ",1
GILENYA,second-degree AV blocks,Disorders,0
GILENYA,2:1 AV blocks,system              ,1
GILENYA,2:1 AV blocks,Headache Migraine,0
GILENYA,2:1 AV blocks,Bradycardia Nervous system              ,1
GILENYA,2:1 AV blocks,             ,1
GILENYA,2:1 AV blocks,             ,1
GILENYA,2:1 AV block,,0
GILENYA,2:1 AV block,ers         ,1
GILENYA,2:1 AV block,Nausea,0
GILENYA,2:1 AV block,,0
GILENYA,2:1 AV block,,0
GILENYA,2:1 AV block,Nausea Diarrhea,0
GILENYA,2:1 AV block,Gastrointestinal ers         ,1
GILENYA,2:1 AV block,Migraine Gastrointestinal ers         ,1
GILENYA,conduction abnormalities,"hea Abdominal 
   General disorders an",1
GILENYA,conduction abnormalities,,0
GILENYA,conduction abnormalities,"
   General disorders an",1
GILENYA,conduction abnormalities,,0
GILENYA,conduction abnormalities,disorders an,1
GILENYA,conduction abnormalities,hea Abdominal General disorders,1
GILENYA,conduction abnormalities,pain,0
GILENYA,conduction abnormalities,administration site,0
GILENYA,junctional escape,Back  Pain in extremit,1
GILENYA,junctional escape,,0
GILENYA,junctional escape,,0
GILENYA,junctional escape,y Skin and subcutaneous tissue,0
GILENYA,junctional escape,Back  Pain in extremit,1
GILENYA,junctional escape,Skin and subcutaneous tissue disorders,0
GILENYA,asystole,Alopec,0
GILENYA,asystole,ia,1
GILENYA,asystole,tissue disorders Alopec,0
GILENYA,asystole,ia,1
GILENYA,asystole,disorders Alopec,0
GILENYA,asystole,subcutaneous tissue disorders ia,1
GILENYA,asystole,subcutaneous tissue disorders ia,1
GILENYA,asystole,and,0
GILENYA,asystole,keratosis,0
GILENYA,death,neous tissue disorders      ,1
GILENYA,death,tissue disorders      ,1
GILENYA,death,     ,1
GILENYA,death,     ,1
GILENYA,syncope,       ,1
GILENYA,reduction in peripheral lymphocyte count,and disorders                               ,1
GILENYA,reduction in peripheral lymphocyte count,increased Respiratory thoracic and mediastinal,0
GILENYA,reduction in peripheral lymphocyte count,,0
GILENYA,reduction in peripheral lymphocyte count,Dyspnea,0
GILENYA,reduction in peripheral lymphocyte count,disorders                               ,1
GILENYA,reduction in peripheral lymphocyte count,,0
GILENYA,sequestration of lymphocytes in lymphoid tissues,Dyspnea 9,1
GILENYA,sequestration of lymphocytes in lymphoid tissues,"         
       Dyspnea    9                7  ",1
GILENYA,sequestration of lymphocytes in lymphoid tissues,Dyspnea,1
GILENYA,sequestration of lymphocytes in lymphoid tissues,stinal disorders Dyspnea,1
GILENYA,sequestration of lymphocytes in lymphoid tissues,,0
GILENYA,sequestration of lymphocytes in lymphoid tissues,,0
GILENYA,sequestration of lymphocytes in lymphoid tissues,7,1
GILENYA,sequestration of lymphocytes in lymphoid tissues,9 7,1
GILENYA,sequestration of lymphocytes in lymphoid tissues,Dyspnea,1
GILENYA,sequestration of lymphocytes in lymphoid tissues,disorders Vision blurred,0
GILENYA,infections,,0
GILENYA,infections,disorders,0
GILENYA,infections,Eye           ,1
GILENYA,infections,Eye disorders,0
GILENYA,infections,          ,1
GILENYA,infections,          ,1
GILENYA,infections,Eye disorders,0
GILENYA,infections,Eye,0
GILENYA,infections,          ,1
GILENYA,infections,,0
GILENYA,infections,          ,1
GILENYA,infections,Eye,0
GILENYA,infections,,0
GILENYA,infections,disorders,0
GILENYA,infections,          ,1
GILENYA,infections,Eye,0
GILENYA,infections,blurred,0
GILENYA,infections,          ,1
GILENYA,infections,,0
GILENYA,infections,Studies,0
GILENYA,herpes zoster,,0
GILENYA,herpes zoster,,0
GILENYA,herpes zoster,mg in Study the,0
GILENYA,herpes zoster,se,1
GILENYA,herpes zoster,were,0
GILENYA,herpes zoster,,0
GILENYA,influenza,th GILENY,1
GILENYA,influenza,,0
GILENYA,influenza,mg in Study the year activecontrolled versus interferon betaa study were,0
GILENYA,influenza,activecontrolled versus interferon betaa study,0
GILENYA,influenza,th GILENY,1
GILENYA,influenza,th,1
GILENYA,sinusitis,the year,0
GILENYA,sinusitis,with 0.5,1
GILENYA,sinusitis,0.5 mg in,1
GILENYA,sinusitis,reactions with 0.5 mg in,1
GILENYA,sinusitis,mg in,1
GILENYA,sinusitis,were generally similar to t,0
GILENYA,sinusitis,,0
GILENYA,infections,,0
GILENYA,infections,betaa dy were,1
GILENYA,infections,ge,1
GILENYA,infections,Studies and,0
GILENYA,died,patients who received GILENYA mg) ,1
GILENYA,died,been reported with GILENYA mg in,0
GILENYA,died,mg) ,1
GILENYA,died,patients who received GILENYA mg) ,1
GILENYA,died,in,0
GILENYA,died,events have been,0
GILENYA,died,patients who received GILENYA mg) ,1
GILENYA,herpetic infections,in MS Similar events have been reported,0
GILENYA,herpetic infections,GILENYA doses,0
GILENYA,herpetic infections,er than recommended,1
GILENYA,death,,0
GILENYA,death,received GILENYA doses mg higher than recommended for use in MS Similar,0
GILENYA,disseminated primary herpes zoster,postm,1
GILENYA,disseminated primary herpes zoster,Similar events have been d with,1
GILENYA,disseminated primary herpes zoster,events have been,0
GILENYA,disseminated primary herpes zoster,have been d with GILENYA 0.5 mg in,1
GILENYA,disseminated primary herpes zoster,has not been established,0
GILENYA,disseminated primary herpes zoster,higher than recommended for use in MS Similar,0
GILENYA,herpes simplex encephalitis,lthough a causal,1
GILENYA,herpes simplex encephalitis,lymphoma have occurred,0
GILENYA,herpes simplex encephalitis,in the postmarketing setting lthough a causal relationsh,1
GILENYA,herpes simplex encephalitis,with GILENYA mg in the postmarketing,0
GILENYA,herpes simplex encephalitis,setting lthough a causal relationsh,1
GILENYA,herpes simplex encephalitis,causal relationsh,1
GILENYA,herpes simplex encephalitis,mg,0
GILENYA,herpes simplex infections,,1
GILENYA,herpes simplex infections,remains,0
GILENYA,herpes simplex infections,,1
GILENYA,herpes simplex infections,,1
GILENYA,herpes simplex infections,uncertain,0
GILENYA,herpes simplex infections,remains ,1
GILENYA,herpes simplex infections,,0
GILENYA,herpes simplex infections,remains,0
GILENYA,herpes simplex infections,,1
GILENYA,herpes simplex infections,,0
GILENYA,encephalitis,,1
GILENYA,encephalitis,,1
GILENYA,multiorgan failure,,1
GILENYA,multiorgan failure,,1
GILENYA,multiorgan failure,,1
GILENYA,multiorgan failure,,1
GILENYA,Cryptococcal infections,,0
GILENYA,Cryptococcal infections,,0
GILENYA,Cryptococcal infections,,1
GILENYA,Cryptococcal infections,,1
GILENYA,Cryptococcal infections,,0
GILENYA,Cryptococcal infections,,1
GILENYA,Cryptococcal infections,,1
GILENYA,Cryptococcal infections,,0
GILENYA,Cryptococcal infections,,1
GILENYA,cryptococcal meningitis,,0
GILENYA,cryptococcal meningitis,,0
GILENYA,cryptococcal meningitis,,1
GILENYA,cryptococcal meningitis,,1
GILENYA,cryptococcal meningitis,,0
GILENYA,cryptococcal meningitis,,1
GILENYA,cryptococcal meningitis,,0
GILENYA,cryptococcal meningitis,,0
GILENYA,immunosuppression,,0
GILENYA,immunosuppression,,0
GILENYA,immunosuppression,,0
GILENYA,immunosuppression,,0
GILENYA,immunosuppression,,0
GILENYA,immunosuppression,,0
GILENYA,immunosuppression,,1
GILENYA,immunosuppression,,1
GILENYA,immunosuppression,,0
GILENYA,immunosuppression,,1
GILENYA,progressive multifocal leukoencephalopathy,,0
GILENYA,progressive multifocal leukoencephalopathy,,1
GILENYA,progressive multifocal leukoencephalopathy,,0
GILENYA,progressive multifocal leukoencephalopathy,,0
GILENYA,progressive multifocal leukoencephalopathy,,1
GILENYA,progressive multifocal leukoencephalopathy,,0
GILENYA,progressive multifocal leukoencephalopathy,,1
GILENYA,progressive multifocal leukoencephalopathy,,1
GILENYA,progressive multifocal leukoencephalopathy,,1
GILENYA,progressive multifocal leukoencephalopathy,,0
GILENYA,PML,,1
GILENYA,PML,,1
GILENYA,PML,,0
GILENYA,PML,,1
GILENYA,PML,,0
GILENYA,PML,,0
GILENYA,PML,,0
GILENYA,PML,,0
GILENYA,PML,,0
GILENYA,PML,,0
GILENYA,PML,,1
GILENYA,PML,,1
GILENYA,PML,,1
GILENYA,PML,,0
GILENYA,PML,,0
GILENYA,opportunistic viral infection of the brain,,1
GILENYA,opportunistic viral infection of the brain,,1
GILENYA,opportunistic viral infection of the brain,,0
GILENYA,opportunistic viral infection of the brain,,1
GILENYA,opportunistic viral infection of the brain,,0
GILENYA,opportunistic viral infection of the brain,,1
GILENYA,opportunistic viral infection of the brain,,0
GILENYA,opportunistic viral infection of the brain,,0
GILENYA,JC virus,,0
GILENYA,JC virus,,1
GILENYA,JC virus,,0
GILENYA,JC virus,,1
GILENYA,JC virus,,0
GILENYA,JC virus,,1
GILENYA,JC virus,,0
GILENYA,JC virus,,0
GILENYA,JCV,,0
GILENYA,JCV,,0
GILENYA,JCV,,0
GILENYA,JCV,,0
GILENYA,JCV,,0
GILENYA,JCV,,0
GILENYA,JCV,,0
GILENYA,JCV,,1
GILENYA,JCV,,0
GILENYA,death,,1
GILENYA,death,,1
GILENYA,death,,0
GILENYA,death,,0
GILENYA,death,,1
GILENYA,death,,1
GILENYA,death,,1
GILENYA,disability,,1
GILENYA,disability,,0
GILENYA,disability,,0
GILENYA,disability,,1
GILENYA,PML,,1
GILENYA,PML,,0
GILENYA,PML,,1
GILENYA,PML,,1
GILENYA,PML,,0
GILENYA,PML,,1
GILENYA,PML,,0
GILENYA,PML,,0
GILENYA,PML,,1
GILENYA,PML,,0
GILENYA,PML,,0
GILENYA,PML,,1
GILENYA,PML,,1
GILENYA,PML,,0
GILENYA,PML,,1
GILENYA,PML,,0
GILENYA,PML,,0
GILENYA,PML,,0
GILENYA,PML,,0
GILENYA,PML,,0
GILENYA,PML,,1
GILENYA,PML,,0
GILENYA,PML,,1
GILENYA,PML,,0
GILENYA,PML,,0
GILENYA,PML,,1
GILENYA,PML,,0
GILENYA,PML,,0
GILENYA,PML,,0
GILENYA,PML,,0
GILENYA,compromised immune system,,0
GILENYA,compromised immune system,,1
GILENYA,PML,,0
GILENYA,PML,,1
GILENYA,PML,,0
GILENYA,PML,,1
GILENYA,PML,,1
GILENYA,PML,,1
GILENYA,PML,,1
GILENYA,PML,,1
GILENYA,PML,,1
GILENYA,PML,,1
GILENYA,progressive weakness on one side of the body,,1
GILENYA,progressive weakness on one side of the body,,0
GILENYA,progressive weakness on one side of the body,,1
GILENYA,progressive weakness on one side of the body,,0
GILENYA,progressive weakness on one side of the body,,0
GILENYA,clumsiness of limbs,,1
GILENYA,clumsiness of limbs,,1
GILENYA,clumsiness of limbs,,0
GILENYA,clumsiness of limbs,,1
GILENYA,clumsiness of limbs,,0
GILENYA,clumsiness of limbs,,0
GILENYA,clumsiness of limbs,,1
GILENYA,clumsiness of limbs,,1
GILENYA,clumsiness of limbs,,1
GILENYA,clumsiness of limbs,,0
GILENYA,disturbance of vision,,0
GILENYA,disturbance of vision,,1
GILENYA,disturbance of vision,,0
GILENYA,disturbance of vision,,0
GILENYA,changes in thinking,,1
GILENYA,changes in thinking,,1
GILENYA,changes in thinking,,1
GILENYA,changes in thinking,,1
GILENYA,changes in thinking,,0
GILENYA,changes in thinking,,0
GILENYA,changes in thinking,,1
GILENYA,changes in thinking,,1
GILENYA,changes in thinking,,1
GILENYA,changes in thinking,,0
GILENYA,confusion,,0
GILENYA,confusion,,1
GILENYA,confusion,,1
GILENYA,confusion,,0
GILENYA,confusion,,1
GILENYA,confusion,,0
GILENYA,macular edema,,1
GILENYA,macular edema,,0
GILENYA,macular edema,,1
GILENYA,macular edema,,1
GILENYA,macular edema,,0
GILENYA,macular edema,,1
GILENYA,macular edema,,1
GILENYA,macular edema,,0
GILENYA,macular edema,,0
GILENYA,macular edema,,0
GILENYA,macular edema,,1
GILENYA,macular edema,,0
GILENYA,macular edema,,1
GILENYA,macular edema,,0
GILENYA,macular edema,,1
GILENYA,macular edema,,0
GILENYA,macular edema,,1
GILENYA,macular edema,,1
GILENYA,visual symptoms,,0
GILENYA,visual symptoms,,1
GILENYA,visual symptoms,,1
GILENYA,visual symptoms,,0
GILENYA,visual symptoms,,1
GILENYA,Macular edema,,1
GILENYA,Macular edema,,0
GILENYA,Macular edema,,1
GILENYA,Macular edema,,0
GILENYA,Macular edema,,0
GILENYA,Macular edema,,1
GILENYA,Macular edema,,0
GILENYA,Macular edema,,0
GILENYA,macular edema,,1
GILENYA,macular edema,,0
GILENYA,macular edema,,1
GILENYA,macular edema,,0
GILENYA,macular edema,,0
GILENYA,macular edema,,0
GILENYA,macular edema,,1
GILENYA,macular edema,,1
GILENYA,macular edema,,1
GILENYA,macular edema,,1
GILENYA,blurred vision,,0
GILENYA,blurred vision,,0
GILENYA,blurred vision,,0
GILENYA,decreased visual acuity,,0
GILENYA,decreased visual acuity,,0
GILENYA,decreased visual acuity,,0
GILENYA,macular edema,,0
GILENYA,macular edema,,1
GILENYA,macular edema,,0
GILENYA,macular edema,,1
GILENYA,macular edema,,1
GILENYA,visual symptoms,,0
GILENYA,visual symptoms,,1
GILENYA,visual symptoms,,0
GILENYA,visual symptoms,,0
GILENYA,Macular edema,,1
GILENYA,Macular edema,,1
GILENYA,Macular edema,,1
GILENYA,Macular edema,,1
GILENYA,Macular edema,,0
GILENYA,Macular edema,,1
GILENYA,Macular edema,,1
GILENYA,Macular edema,,0
GILENYA,Macular edema,,1
GILENYA,Macular edema,,0
GILENYA,visual acuity loss,,0
GILENYA,visual acuity loss,,1
GILENYA,visual acuity loss,,1
GILENYA,visual acuity loss,,0
GILENYA,visual acuity loss,,0
GILENYA,visual acuity loss,,0
GILENYA,visual acuity loss,,1
GILENYA,macular edema,,0
GILENYA,macular edema,,1
GILENYA,macular edema,,0
GILENYA,macular edema,,0
GILENYA,macular edema,,1
GILENYA,macular edema,,0
GILENYA,macular edema,,0
GILENYA,macular edema,,0
GILENYA,macular edema,,1
GILENYA,macular edema,,0
GILENYA,Macular edema,,1
GILENYA,Macular edema,,0
GILENYA,Macular edema,,0
GILENYA,Macular edema,,1
GILENYA,Macular edema,,1
GILENYA,Macular edema,,0
GILENYA,Macular edema,,0
GILENYA,Macular edema,,0
GILENYA,Macular edema,,1
GILENYA,Macular edema,,1
GILENYA,macular edema,,1
GILENYA,macular edema,,0
GILENYA,macular edema,,0
GILENYA,macular edema,,1
GILENYA,macular edema,,1
GILENYA,macular edema,,0
GILENYA,macular edema,,1
GILENYA,macular edema,,1
GILENYA,macular edema,,1
GILENYA,macular edema,,0
GILENYA,macular edema,,0
GILENYA,macular edema,,1
GILENYA,macular edema,,0
GILENYA,macular edema,,1
GILENYA,macular edema,,0
GILENYA,macular edema,,1
GILENYA,macular edema,,1
GILENYA,macular edema,,1
GILENYA,macular edema,,1
GILENYA,macular edema,,0
GILENYA,macular edema,,1
GILENYA,macular edema,,1
GILENYA,macular edema,,0
GILENYA,macular edema,,0
GILENYA,macular edema,,1
GILENYA,macular edema,,0
GILENYA,macular edema,,1
GILENYA,macular edema,,1
GILENYA,macular edema,,0
GILENYA,macular edema,,0
GILENYA,macular edema,,0
GILENYA,posterior reversible encephalopathy syndrome,,1
GILENYA,posterior reversible encephalopathy syndrome,,1
GILENYA,posterior reversible encephalopathy syndrome,,0
GILENYA,posterior reversible encephalopathy syndrome,,0
GILENYA,posterior reversible encephalopathy syndrome,,0
GILENYA,posterior reversible encephalopathy syndrome,,1
GILENYA,posterior reversible encephalopathy syndrome,,0
GILENYA,posterior reversible encephalopathy syndrome,,1
GILENYA,posterior reversible encephalopathy syndrome,,0
GILENYA,PRES,,0
GILENYA,PRES,,1
GILENYA,PRES,,1
GILENYA,PRES,,0
GILENYA,PRES,,1
GILENYA,PRES,,0
GILENYA,PRES,,0
GILENYA,headache,,0
GILENYA,headache,,1
GILENYA,headache,,1
GILENYA,headache,,1
GILENYA,visual disturbances,,1
GILENYA,visual disturbances,,0
GILENYA,visual disturbances,,1
GILENYA,seizure,,0
GILENYA,seizure,,1
GILENYA,seizure,,0
GILENYA,seizure,,0
GILENYA,seizure,,1
GILENYA,PRES,,0
GILENYA,PRES,,1
GILENYA,PRES,,0
GILENYA,PRES,,1
GILENYA,PRES,,1
GILENYA,PRES,,1
GILENYA,PRES,,0
GILENYA,PRES,,1
GILENYA,PRES,,1
GILENYA,PRES,,1
GILENYA,ischemic stroke,,0
GILENYA,ischemic stroke,,1
GILENYA,ischemic stroke,,1
GILENYA,ischemic stroke,,0
GILENYA,ischemic stroke,,1
GILENYA,ischemic stroke,,1
GILENYA,ischemic stroke,,0
GILENYA,cerebral hemorrhage,,0
GILENYA,cerebral hemorrhage,,1
GILENYA,changes in FEV1,,1
GILENYA,changes in FEV1,,0
GILENYA,changes in FEV1,,0
GILENYA,changes in FEV1,,1
GILENYA,changes in FEV1,,1
GILENYA,changes in FEV1,,1
GILENYA,changes in FEV1,,0
GILENYA,changes in FEV1,,1
GILENYA,dyspnea,,0
GILENYA,dyspnea,,1
GILENYA,dyspnea,,0
GILENYA,dyspnea,,1
GILENYA,dyspnea,,1
GILENYA,dyspnea,,1
GILENYA,dyspnea,,0
GILENYA,dyspnea,,0
GILENYA,dyspnea,,0
GILENYA,dyspnea,,0
GILENYA,dyspnea,,1
GILENYA,dyspnea,,0
GILENYA,dyspnea,,1
GILENYA,dyspnea,,1
GILENYA,dyspnea,,0
GILENYA,dyspnea,,0
GILENYA,dyspnea,,0
GILENYA,Elevations of liver enzymes,,0
GILENYA,Elevations of liver enzymes,,0
GILENYA,Elevations of liver enzymes,,0
GILENYA,Elevations of liver enzymes,,0
GILENYA,Elevations of liver enzymes,,0
GILENYA,Elevations of liver enzymes,,1
GILENYA,Elevations of liver enzymes,,0
GILENYA,elevation of liver transaminases,,0
GILENYA,elevation of liver transaminases,,1
GILENYA,elevation of liver transaminases,,1
GILENYA,elevation of liver transaminases,,0
GILENYA,elevation of liver transaminases,,1
GILENYA,elevation of liver transaminases,,0
GILENYA,liver transaminase elevations,,0
GILENYA,liver transaminase elevations,,1
GILENYA,elevated liver enzymes,,0
GILENYA,elevated liver enzymes,,0
GILENYA,elevated liver enzymes,,0
GILENYA,elevated liver enzymes,,0
GILENYA,elevated liver enzymes,,1
GILENYA,elevated liver enzymes,,0
GILENYA,elevated liver enzymes,,1
GILENYA,elevated liver enzymes,,0
GILENYA,elevated liver enzymes,,0
GILENYA,elevated liver enzymes,,1
GILENYA,fetal harm,,1
GILENYA,decreased lymphocyte counts,,1
GILENYA,decreased lymphocyte counts,,1
GILENYA,decreased lymphocyte counts,,0
GILENYA,decreased lymphocyte counts,,1
GILENYA,decreased lymphocyte counts,,1
GILENYA,decreased lymphocyte counts,,0
GILENYA,decreased lymphocyte counts,,1
GILENYA,decreased lymphocyte counts,,0
GILENYA,decreased lymphocyte counts,,0
GILENYA,immunosuppressant effects,,1
GILENYA,immunosuppressant effects,,0
GILENYA,immunosuppressant effects,,0
GILENYA,immunosuppressant effects,,1
BENLYSTA,Mortality,Mortality,1
BENLYSTA,Mortality,Mortality,1
BENLYSTA,Infections,,0
BENLYSTA,Infections,Infections,1
BENLYSTA,Infections,and Precautions,0
BENLYSTA,Infections,see Warnings,0
BENLYSTA,Infections,Infections,1
BENLYSTA,Infections,Infections,1
BENLYSTA,Infections,and Precautions Serious,0
BENLYSTA,Infections,Serious,0
BENLYSTA,Infections,Mortality see Warnings and Precautions,0
BENLYSTA,Malignancy,Precautions,0
BENLYSTA,Malignancy,Anaphylax,0
BENLYSTA,Malignancy,Malignancy,1
BENLYSTA,Malignancy,,0
BENLYSTA,Malignancy,Infections see,0
BENLYSTA,Malignancy,see Warnings and,0
BENLYSTA,Malignancy,Infections see Warnings and Malignancy,1
BENLYSTA,Hypersensitivity Reactions,Reactions,1
BENLYSTA,Hypersensitivity Reactions,Hypersensitivity,1
BENLYSTA,Anaphylaxis,Anaphylaxis,1
BENLYSTA,Anaphylaxis,Anaphylaxis,1
BENLYSTA,Anaphylaxis,and Precautions Hypersensitivity Reactions Anaphylaxis,1
BENLYSTA,Anaphylaxis,Anaphylaxis,1
BENLYSTA,Anaphylaxis,,0
BENLYSTA,Anaphylaxis,Anaphylaxis,1
BENLYSTA,Infusion Reactions,Reactions,1
BENLYSTA,Infusion Reactions,Warnings and Precautions Depression see Warnings,0
BENLYSTA,Infusion Reactions,and Infusion Reactions,1
BENLYSTA,Infusion Reactions,Reactions,1
BENLYSTA,Infusion Reactions,Infusion,1
BENLYSTA,Infusion Reactions,Infusion Reactions,1
BENLYSTA,Depression,adverse reactions in cl,0
BENLYSTA,Depression,Depression,1
BENLYSTA,Depression,Depression,1
BENLYSTA,Depression,,0
BENLYSTA,Depression,Infusion Reactions see,0
BENLYSTA,Depression,,0
BENLYSTA,Depression,Infusion Reactions see,0
BENLYSTA,Depression,Depression,1
BENLYSTA,Depression,,0
BENLYSTA,Depression,Depression,1
BENLYSTA,nausea,nausea,1
BENLYSTA,nausea,nausea,1
BENLYSTA,nausea,EXCERPT Common adverse reactions in,0
BENLYSTA,nausea,nausea,1
BENLYSTA,diarrhea,were diarrhea,1
BENLYSTA,diarrhea,diarrhea,1
BENLYSTA,diarrhea,diarrhea,1
BENLYSTA,diarrhea,diarrhea,1
BENLYSTA,diarrhea,Common,0
BENLYSTA,pyrexia,,0
BENLYSTA,pyrexia,clinical trials were nausea pyrexia,1
BENLYSTA,pyrexia,pyrexia,1
BENLYSTA,pyrexia,clinical trials were,0
BENLYSTA,pyrexia,in clinical,0
BENLYSTA,pyrexia,nausea pyrexia,1
BENLYSTA,pyrexia,,0
BENLYSTA,pyrexia,pyrexia,1
BENLYSTA,pyrexia,pyrexia,1
BENLYSTA,pyrexia,clinical,0
BENLYSTA,nasopharyngitis,,0
BENLYSTA,bronchitis,,0
BENLYSTA,bronchitis,bronchitis,1
BENLYSTA,bronchitis,in extremity depression,0
BENLYSTA,bronchitis,bronchitis,1
BENLYSTA,bronchitis,bronchitis,1
BENLYSTA,bronchitis,bronchitis,1
BENLYSTA,bronchitis,bronchitis,1
BENLYSTA,bronchitis,clinical trials were,0
BENLYSTA,bronchitis,To report,0
BENLYSTA,bronchitis,pharyngitis To report,0
BENLYSTA,depression,,0
BENLYSTA,depression,depression,1
BENLYSTA,depression,nasopharyngitis bronchitis insomnia,0
BENLYSTA,depression,,0
BENLYSTA,depression,migraine and pharyngitis,0
BENLYSTA,depression,depression,1
BENLYSTA,migraine,pain in extremity migraine,1
BENLYSTA,migraine,extremity migraine,1
BENLYSTA,migraine,bronchitis,0
BENLYSTA,migraine,migraine,1
BENLYSTA,migraine,extremity depression,0
BENLYSTA,migraine,To report SUSPECTED ADVERSE REACTIONS contact GlaxoSmithKline at,0
BENLYSTA,migraine,To report SUSPECTED ADVERSE REACTIONS,0
BENLYSTA,migraine,bronchitis insomnia pain,0
BENLYSTA,migraine,migraine,1
BENLYSTA,migraine,migraine,1
BENLYSTA,pharyngitis,pharyngitis,1
BENLYSTA,pharyngitis,nasopharyngitis bronchitis insomnia pain in extremity depression,0
BENLYSTA,pharyngitis,pharyngitis,1
BENLYSTA,pharyngitis,pharyngitis,1
BENLYSTA,pharyngitis,pyrexia nasopharyngitis bronchitis insomnia,0
BENLYSTA,pharyngitis,,0
BENLYSTA,infections,infections,1
BENLYSTA,infections,treated with placebo The most,0
BENLYSTA,infections,infections,1
BENLYSTA,infections,,0
BENLYSTA,infections,groups,0
BENLYSTA,infections,infections,1
BENLYSTA,infections,infections,1
BENLYSTA,infections,reactions were infections,1
BENLYSTA,nausea,,0
BENLYSTA,diarrhea,patients in clinical trials,0
BENLYSTA,diarrhea,diarrhea,1
BENLYSTA,diarrhea,in of,0
BENLYSTA,pyrexia,depression,0
BENLYSTA,pyrexia,pyrexia,1
BENLYSTA,pyrexia,,0
BENLYSTA,pyrexia,and pharyngitis,0
BENLYSTA,pyrexia,trials were nausea pyrexia,1
BENLYSTA,pyrexia,were nausea,0
BENLYSTA,pyrexia,,0
BENLYSTA,nasopharyngitis,depression,0
BENLYSTA,nasopharyngitis,,0
BENLYSTA,bronchitis,and pharyngitis The proportion of,0
BENLYSTA,bronchitis,bronchitis,1
BENLYSTA,bronchitis,,0
BENLYSTA,bronchitis,,0
BENLYSTA,bronchitis,bronchitis,1
BENLYSTA,bronchitis,bronchitis,1
BENLYSTA,bronchitis,The proportion of patients,0
BENLYSTA,bronchitis,patients in clinical trials were nausea diarrhea pyrexia,0
BENLYSTA,insomnia,proportion of patients who disco,0
BENLYSTA,insomnia,diarrhea pyrexia nasopharyngitis,0
BENLYSTA,insomnia,of patients who,0
BENLYSTA,insomnia,,0
BENLYSTA,insomnia,insomnia,1
BENLYSTA,insomnia,,0
BENLYSTA,insomnia,insomnia,1
BENLYSTA,insomnia,diarrhea pyrexia nasopharyngitis,0
BENLYSTA,insomnia,trials,0
BENLYSTA,insomnia,depression,0
BENLYSTA,pain in extremity,,0
BENLYSTA,pain in extremity,pain in extremity,1
BENLYSTA,pain in extremity,pain in extremity,1
BENLYSTA,pain in extremity,,0
BENLYSTA,depression,proportion of patients who,0
BENLYSTA,depression,ad,0
BENLYSTA,depression,and pharyngitis The proportion of patients who discontinued treatment due to any ad,0
BENLYSTA,depression,depression,1
BENLYSTA,depression,depression,1
BENLYSTA,depression,migraine and pharyngitis The proportion of patients who discontinued,0
BENLYSTA,migraine,extremity migraine,1
BENLYSTA,migraine,migraine,1
BENLYSTA,migraine,reac,0
BENLYSTA,migraine,migraine,1
BENLYSTA,migraine,migraine,1
BENLYSTA,migraine,migraine,1
BENLYSTA,pharyngitis,proportion of patients,0
BENLYSTA,pharyngitis,,0
BENLYSTA,pharyngitis,pharyngitis,1
BENLYSTA,pharyngitis,pharyngitis,1
BENLYSTA,pharyngitis,extremity depression migraine and,0
BENLYSTA,pharyngitis,migraine,0
BENLYSTA,infusion reactions,discontinuation of,0
BENLYSTA,infusion reactions,infusion reactions,1
BENLYSTA,lupus nephritis,lupus nephritis,1
BENLYSTA,lupus nephritis,nephritis,1
BENLYSTA,Diarrhea,Diarrhea,1
BENLYSTA,Pyrexia,Pyrexia,1
BENLYSTA,Pyrexia,,0
BENLYSTA,Pyrexia,,0
BENLYSTA,Pyrexia,,0
BENLYSTA,Pyrexia,,0
BENLYSTA,Pyrexia,,0
BENLYSTA,Pyrexia,Pyrexia,1
BENLYSTA,Bronchitis,Bronchitis,1
BENLYSTA,Bronchitis,,0
BENLYSTA,Bronchitis,gitis,0
BENLYSTA,Bronchitis,,0
BENLYSTA,Bronchitis,Bronchitis,1
BENLYSTA,Bronchitis,gitis,0
BENLYSTA,Bronchitis,Bronchitis,1
BENLYSTA,Bronchitis,Bronchitis,1
BENLYSTA,Bronchitis,gitis,0
BENLYSTA,Bronchitis,,0
BENLYSTA,Insomnia,Insomnia,1
BENLYSTA,Pain in extremity,,0
BENLYSTA,Pain in extremity,Pain,1
BENLYSTA,Pain in extremity,Pain,1
BENLYSTA,Pain in extremity,Pain,1
BENLYSTA,Pain in extremity,,0
BENLYSTA,Pain in extremity,Pain in extremity Depress,1
BENLYSTA,Pain in extremity,Pain in extremity Depress,1
BENLYSTA,Pain in extremity,Pain,1
BENLYSTA,Pain in extremity,Pain in extremity Depress,1
BENLYSTA,Depression,Depression,1
BENLYSTA,Depression,tremity Depression,1
BENLYSTA,Depression,tremity,0
BENLYSTA,Depression,tremity Depression,1
BENLYSTA,Migraine,Migraine,1
BENLYSTA,Migraine,,0
BENLYSTA,Migraine,,0
BENLYSTA,Migraine,,0
BENLYSTA,Migraine,,0
BENLYSTA,Migraine,,0
BENLYSTA,Pharyngitis,Pharyngitis C,1
BENLYSTA,Pharyngitis,Pharyngitis C,1
BENLYSTA,Leukopenia,Leukopenia,1
BENLYSTA,Leukopenia,Leukopenia,1
BENLYSTA,Leukopenia,,0
BENLYSTA,Leukopenia,,0
BENLYSTA,Leukopenia,,0
BENLYSTA,Leukopenia,Leukopenia,1
BENLYSTA,Leukopenia,,0
BENLYSTA,Leukopenia,,0
BENLYSTA,Gastroenteritis viral,,0
BENLYSTA,Gastroenteritis viral,,0
BENLYSTA,Gastroenteritis viral,,0
BENLYSTA,Gastroenteritis viral,Gastroenteritis,1
BENLYSTA,Gastroenteritis viral,,0
BENLYSTA,Gastroenteritis viral,Gastroenteritis,1
BENLYSTA,nausea,mgkg Three patients with antibelimumab antibodies experienced,0
BENLYSTA,nausea,mgkg Three patients with,0
BENLYSTA,nausea,nausea,1
BENLYSTA,nausea,nausea,1
BENLYSTA,nausea,antibelimumab antibodies experienced mild infusion reactions,0
BENLYSTA,nausea,nausea,1
BENLYSTA,nausea,and dyspnea none,0
BENLYSTA,erythematous rash,of erythematous rash,1
BENLYSTA,erythematous rash,infusion reactions of erythematous rash,1
BENLYSTA,erythematous rash,,0
BENLYSTA,erythematous rash,eyelid edema headache and dyspnea none of,0
BENLYSTA,erythematous rash,,0
BENLYSTA,erythematous rash,experienced mild infusion reactions of nausea,0
BENLYSTA,erythematous rash,mild infusion reactions of erythematous,1
BENLYSTA,erythematous rash,erythematous rash,1
BENLYSTA,erythematous rash,of nausea,0
BENLYSTA,eyelid edema,,0
BENLYSTA,eyelid edema,and dyspnea none of the reactions,0
BENLYSTA,eyelid edema,eyelid edema,1
BENLYSTA,eyelid edema,erythematous rash eyelid,1
BENLYSTA,headache,nausea erythematous rash,0
BENLYSTA,headache,nausea erythematous rash,0
BENLYSTA,headache,reactions was lifethreatening,0
BENLYSTA,headache,,0
BENLYSTA,headache,lifethreatening The,0
BENLYSTA,headache,headache,1
BENLYSTA,headache,headache,1
BENLYSTA,headache,rash pruritus eyelid edema,0
BENLYSTA,headache,experienced mild infusion reactions of nausea erythematous rash pruritus,0
BENLYSTA,dyspnea,headache dyspnea,1
BENLYSTA,Fatal,establish a causal relationship to drug,0
BENLYSTA,anaphylaxis,drug exposure anaphylaxis,1
BENLYSTA,anaphylaxis,relationship to drug exposure anaphylaxis,1
BENLYSTA,anaphylaxis,a causal relationship to,0
BENLYSTA,anaphylaxis,exposure Fatal,0
BENLYSTA,anaphylaxis,anaphylaxis,1
BENLYSTA,anaphylaxis,anaphylaxis,1
BENLYSTA,Mortality, conducte,1
BENLYSTA,deaths,ying c onditions adverse reaction rates observed,1
BENLYSTA,deaths,onditions adverse,0
BENLYSTA,deaths,ying c onditions adverse,1
BENLYSTA,deaths,ying c,1
BENLYSTA,deaths,directly,0
BENLYSTA,deaths,ying c onditions adverse reaction,1
BENLYSTA,deaths,ying,1
BENLYSTA,deaths,,0
BENLYSTA,deaths,,0
BENLYSTA,deaths,c onditions adverse reaction,1
BENLYSTA,Infections,with rates n the clin ical trials of,1
BENLYSTA,Infections,with rates n the clin ical trials of,1
BENLYSTA,Infections,rates n the clin ical trials of,1
BENLYSTA,Infections,the clin ical trials of,1
BENLYSTA,fatal,been,0
BENLYSTA,fatal,trials of another rug,1
BENLYSTA,fatal,a nd may not,1
BENLYSTA,fatal,following have been observed with BENLYST,0
BENLYSTA,fatal,of another d,0
BENLYSTA,infections,been observed with BENLYSTA and are d,0
BENLYSTA,infections,of another drug d may not  reflect the rates,1
BENLYSTA,infections,drug cannot be directly compared with rates in the clinical trials of another drug,0
BENLYSTA,infections,drug d may not  reflect the rates,1
BENLYSTA,infections,not reflect the rates,1
BENLYSTA,infections,trials of another drug d,1
BENLYSTA,infections,are,0
BENLYSTA,infections,clinical trials,0
BENLYSTA,Progressive Multifocal Leukoencephalopathy,Precautions (5.2) ] * Malignancy see Warnings and,1
BENLYSTA,Progressive Multifocal Leukoencephalopathy,Infections,0
BENLYSTA,Progressive Multifocal Leukoencephalopathy,Warnings and Precautions Hypersensitivity,0
BENLYSTA,Progressive Multifocal Leukoencephalopathy,Serious Infections,0
BENLYSTA,Progressive Multifocal Leukoencephalopathy,and Precautions,0
BENLYSTA,Progressive Multifocal Leukoencephalopathy,,0
BENLYSTA,PML,[ s ee Warnings and,1
BENLYSTA,PML,Malignancy,0
BENLYSTA,Hypersensitivity Reactions,"Depression see Warnings and autions (5.6)  ]  
      E XCERPT Common adverse",1
BENLYSTA,Hypersensitivity Reactions,see Warnings and Precautions Depression see,0
BENLYSTA,Hypersensitivity Reactions,adverse reactions,0
BENLYSTA,Hypersensitivity Reactions,"Warnings and autions (5.6)  ]  
      E XCERPT Common adverse",1
BENLYSTA,Hypersensitivity Reactions,autions,1
BENLYSTA,Hypersensitivity Reactions,,0
BENLYSTA,Hypersensitivity Reactions,and autions (5.6) ],1
BENLYSTA,Hypersensitivity Reactions,see Warnings and autions (5.6) ],1
BENLYSTA,Hypersensitivity Reactions,Depression see Warnings and autions (5.6),1
BENLYSTA,Anaphylaxis,Warnings and Precautions EXCERPT,0
BENLYSTA,Anaphylaxis,advers e reactions in,1
BENLYSTA,Anaphylaxis,EXCERPT mmon advers e reactions in,1
BENLYSTA,Anaphylaxis,mmon advers e reactions in,1
BENLYSTA,Anaphylaxis,Warnings and,0
BENLYSTA,Anaphylaxis,mmon,1
BENLYSTA,Anaphylaxis,Precautions EXCERPT mmon,1
BENLYSTA,Anaphylaxis,,0
BENLYSTA,Anaphylaxis,clinical trials were nausea diarrhea pyrexia nasopharyngitis bronchitis,0
BENLYSTA,Anaphylaxis,mmon advers e reactions in,1
BENLYSTA,fatal,,0
BENLYSTA,fatal,=5%)  in clinical trials,1
BENLYSTA,fatal,=5%)  in clinical trials,1
BENLYSTA,fatal,EXCERPT Common adverse,0
BENLYSTA,fatal,Precautions EXCERPT Common adverse =5%)  in clinical trials,1
BENLYSTA,fatal,Common adverse,0
BENLYSTA,fatal,,0
BENLYSTA,fatal,Precautions EXCERPT Common adverse =5%)  in clinical trials,1
BENLYSTA,fatal,=5%)  in clinical trials,1
BENLYSTA,fatal,=5%)  in clinical trials,1
BENLYSTA,Depression,ADVERSE REACTIONS contact GlaxoSmithKline -6597,1
BENLYSTA,Depression,,0
BENLYSTA,Depression,-6597 or F DA at FDA,1
BENLYSTA,Depression,report SUSPECTED ADVERSE REACTIONS contact,0
BENLYSTA,Depression,contact GlaxoSmithKline -6597 or F DA at FDA,1
BENLYSTA,Depression,ADVERSE,0
BENLYSTA,Depression,-6597 or,1
BENLYSTA,Depression,F DA at FDA,1
BENLYSTA,Depression,at or at,1
BENLYSTA,Depression,or  at 1-800- FDA or wwwfdagovmedwatch,1
BENLYSTA,Depression,or,0
BENLYSTA,Depression,,0
BENLYSTA,Depression,,0
BENLYSTA,suicidality,FDA at 088 or www. fdagovmedwatch Clinical Trials,1
BENLYSTA,suicidality,reflect expos,0
BENLYSTA,suicidality,described below reflect expos,0
BENLYSTA,suicidality,at or FDA at 088 or www. fdagovmedwatch Clinical Trials,1
BENLYSTA,suicidality,fdagovmedwatch Clinical Trials Experience The,0
BENLYSTA,suicidality,at or FDA at 088 or,1
BENLYSTA,suicidality,contact GlaxoSmithKline at or FDA at FDA,0
BENLYSTA,suicidality,088 or,1
BENLYSTA,deaths,and then every,0
BENLYSTA,deaths,mgkg N or placebo =,1
BENLYSTA,deaths,= 675) intravenously over a,1
BENLYSTA,deaths,N Trial,0
BENLYSTA,deaths,the trials Trial and,0
BENLYSTA,deaths,whil e in the,1
BENLYSTA,deaths,,0
BENLYSTA,deaths,Clinical Studies,0
BENLYSTA,deaths,"for , whil e in the",1
BENLYSTA,death,displays the results for the,0
BENLYSTA,death,the results,0
BENLYSTA,death,for e 3 d oses pooled unless,1
BENLYSTA,death,,0
BENLYSTA,death,below are presented for e 3,1
BENLYSTA,death,safety data summarized,0
BENLYSTA,death,,0
BENLYSTA,death,e 3 d oses pooled unless,1
BENLYSTA,death,displays the results,0
BENLYSTA,infection,ated; the adverse reaction table,1
BENLYSTA,infection,summarized below are presented,0
BENLYSTA,infection,otherwise ated;,1
BENLYSTA,infection,dose of mgkg,0
BENLYSTA,cardiovascular disease,the doses pooled unless otherwise indicated,0
BENLYSTA,cardiovascular disease,,0
BENLYSTA,cardiovascular disease,indicated the dverse reaction table  displays the results,1
BENLYSTA,cardiovascular disease,the dverse reaction table  displays the results,1
BENLYSTA,cardiovascular disease,,0
BENLYSTA,cardiovascular disease,dverse reaction table displays the results,1
BENLYSTA,cardiovascular disease,dverse reaction table  displays the results,1
BENLYSTA,suicide,ys the  results for the,1
BENLYSTA,suicide,reaction table ys,1
BENLYSTA,suicide,adverse reaction table ys the  results for the,1
BENLYSTA,suicide,the adverse reaction table ys,1
BENLYSTA,suicide,the,0
BENLYSTA,suicide,reaction table ys,1
BENLYSTA,suicide,table ys the  results for the,1
BENLYSTA,suicide,adverse reaction table ys,1
BENLYSTA,infections,mean age of range,0
BENLYSTA,infections,table displays the results for the recommended dose of mgkg,0
BENLYSTA,infections,The population had a,1
BENLYSTA,infections,"diarrhea,  pyrexia nasopharyngitis bronchitis",1
BENLYSTA,infections,"in clinical trials were diarrhea,  pyrexia nasopharyngitis bronchitis",1
BENLYSTA,infections,"diarrhea,  pyrexia nasopharyngitis bronchitis",1
BENLYSTA,infections,"trials were diarrhea,  pyrexia nasopharyngitis bronchitis",1
BENLYSTA,infections,bronchitis insomnia pain in extremity depression migraine,0
BENLYSTA,infections,the controlled,0
BENLYSTA,infections,and pharyngitis  proportio n of patients,1
BENLYSTA,infections,,0
BENLYSTA,infections,bronchitis,0
BENLYSTA,infections,n of patients who discontinued treatment due to any adverse,0
BENLYSTA,infections,pain in,0
BENLYSTA,upper respiratory tract infection,proportion of patients who discontinued treatment,0
BENLYSTA,upper respiratory tract infection,BENLYSTA and for,0
BENLYSTA,upper respiratory tract infection,receiving BENLYSTA and,0
BENLYSTA,upper respiratory tract infection,discontinued treatment,0
BENLYSTA,upper respiratory tract infection,patients who discontinued treatment e to any adverse reaction during  the controlled clinical,1
BENLYSTA,urinary tract infection,during e controlled,1
BENLYSTA,urinary tract infection,of patients who discontinued treatment due,0
BENLYSTA,urinary tract infection,controlled clinical t rials was for,1
BENLYSTA,urinary tract infection,patients receiving BENLYSTA and for patients receiving,0
BENLYSTA,urinary tract infection,clinical t rials was for,1
BENLYSTA,urinary tract infection,BENLYSTA and for patients,0
BENLYSTA,urinary tract infection,was for patients receiving BENLYSTA and,0
BENLYSTA,urinary tract infection,patients receiving BENLYSTA and for patients receiving placebo The,0
BENLYSTA,nasopharyngitis,controlled clinical als was 6.2%,1
BENLYSTA,nasopharyngitis,during the controlled clinical als was 6.2% fo r patients receiving,1
BENLYSTA,nasopharyngitis,the controlled clinical als was 6.2%,1
BENLYSTA,nasopharyngitis,during the controlled clinical als,1
BENLYSTA,nasopharyngitis,controlled clinical als was 6.2% fo r patients receiving,1
BENLYSTA,nasopharyngitis,adverse reaction during the,0
BENLYSTA,nasopharyngitis,the controlled clinical als was 6.2% fo r patients receiving,1
BENLYSTA,nasopharyngitis,adverse reaction during the controlled clinical,0
BENLYSTA,nasopharyngitis,als was 6.2% fo r patients receiving,1
BENLYSTA,sinusitis,patients  receiving BENLYSTA and,1
BENLYSTA,sinusitis,patients  receiving BENLYSTA and,1
BENLYSTA,sinusitis,for patients receiving placebo The,0
BENLYSTA,sinusitis,clinical trials,0
BENLYSTA,sinusitis,patients  receiving BENLYSTA and,1
BENLYSTA,sinusitis,patients  receiving BENLYSTA and,1
BENLYSTA,sinusitis,for,0
BENLYSTA,sinusitis,patients  receiving BENLYSTA and,1
BENLYSTA,sinusitis,patients  receiving BENLYSTA and,1
BENLYSTA,sinusitis,BENLYSTA and for,0
BENLYSTA,bronchitis,the controlled clinical trials was for patients,0
BENLYSTA,bronchitis,was for patients ceiving BE NLYSTA and for,1
BENLYSTA,infections,pa,0
BENLYSTA,infections,resulting in discontinuation of treatment of pa,0
BENLYSTA,infections,BENLYSTA and for nts,1
BENLYSTA,infections,receiving BENLYSTA and for nts receiv ing placebo The,1
BENLYSTA,infections,BENLYSTA and for nts,1
BENLYSTA,infections,,0
BENLYSTA,infections,receiving A,1
BENLYSTA,infections,or place bo were infusion,1
BENLYSTA,pneumonia,or placebo were nfusion,1
BENLYSTA,pneumonia,BENLYSTA or placebo were nfusion,1
BENLYSTA,pneumonia,r eactions BENLYSTA and,1
BENLYSTA,pneumonia,inf,0
BENLYSTA,pneumonia,or placebo were nfusion,1
BENLYSTA,pneumonia,BENLYSTA or placebo were nfusion r eactions BENLYSTA and,1
BENLYSTA,pneumonia,or placebo were,0
BENLYSTA,pneumonia,placebo were nfusion,1
BENLYSTA,pneumonia,r eactions BENLYSTA and,1
BENLYSTA,urinary tract infection,or placebo were infusion rea,0
BENLYSTA,urinary tract infection,ctions (1.6% BENLYSTA,1
BENLYSTA,urinary tract infection,ctions (1.6% BENLYSTA a nd placebo lupus,1
BENLYSTA,urinary tract infection,ctions (1.6% BENLYSTA a nd placebo lupus,1
BENLYSTA,urinary tract infection,in discontinuation of treatment of,0
BENLYSTA,urinary tract infection,placebo were infusion ctions (1.6% BENLYSTA a nd placebo lupus,1
BENLYSTA,urinary tract infection,ctions,1
BENLYSTA,cellulitis,and infections BENLYSTA,0
BENLYSTA,cellulitis,0.9%,1
BENLYSTA,cellulitis,were infusion reactions BENLYSTA  0.9% plac ebo lupus nephritis,1
BENLYSTA,cellulitis,,0
BENLYSTA,cellulitis,were infusion reactions BENLYSTA  0.9% plac ebo lupus nephritis,1
BENLYSTA,bronchitis,,0
BENLYSTA,bronchitis,patients receiving BENLYSTA,0
BENLYSTA,bronchitis,Table,0
BENLYSTA,bronchitis,lupus neph ritis BENLYSTA and,1
BENLYSTA,bronchitis,BENLYSTA and placebo Table,0
BENLYSTA,bronchitis,and lupus,1
BENLYSTA,bronchitis,placebo were,0
BENLYSTA,bronchitis,lupus neph ritis BENLYSTA and,1
BENLYSTA,bronchitis,,0
BENLYSTA,Infections,,0
BENLYSTA,Infections,BENLYSTA and placebo lupus,0
BENLYSTA,Infections,lupus tis (0.7%  BENLYSTA and placebo,1
BENLYSTA,Infections,tis (0.7% BENLYSTA and placebo,1
BENLYSTA,Infections,,0
BENLYSTA,Infections,tis (0.7%  BENLYSTA and placebo,1
BENLYSTA,death,adverse,0
BENLYSTA,death,,0
BENLYSTA,death,SLE who received BENLYSTA,0
BENLYSTA,JC virus,ce of Ad verse Reactions occurring,1
BENLYSTA,JC virus,Treated with BENLYSTA mgkg plus,0
BENLYSTA,PML,of Patients Treated with,0
BENLYSTA,PML,ons occurring in at,1
BENLYSTA,PML,Table Incidence of Adverse ons occurring in at,1
BENLYSTA,PML,Patients Treated with BENLYSTA mgkg plus Standard of Care and at Le,0
BENLYSTA,PML,in at Least,0
BENLYSTA,PML,ons occurring in at,1
BENLYSTA,neurological deficits,of Patien ts Treated with,1
BENLYSTA,neurological deficits,of Adverse Reactions occurring at,1
BENLYSTA,neurological deficits,Adverse Reactions occurring at Least 3% of Patien ts Treated with,1
BENLYSTA,neurological deficits,of Adverse Reactions occurring at Least 3% of Patien ts Treated with,1
BENLYSTA,neurological deficits,and at Least More Frequently than in Pati,0
BENLYSTA,neurological deficits,with BENLYSTA mgkg plus Standard of Care and at Least More Frequently than in Pati,0
BENLYSTA,neurological deficits,studies,0
BENLYSTA,fatal,Table Incidence of,0
BENLYSTA,fatal,Adverse Reactions occurring in at Least of,0
BENLYSTA,fatal,,0
BENLYSTA,fatal,B ENLYSTA mgkg plus,1
BENLYSTA,fatal,at Least,0
BENLYSTA,fatal,Least of Patients Treated ith B ENLYSTA mgkg plus,1
BENLYSTA,fatal,at Least More Frequently than in,0
BENLYSTA,fatal,than,0
BENLYSTA,malignancies,9            Bronchitis,1
BENLYSTA,malignancies,,0
BENLYSTA,malignancies,,0
BENLYSTA,malignancies,9            Bronchitis,1
BENLYSTA,malignancies,9            Bronchitis,1
BENLYSTA,malignancies,Nasopharyngitis,0
BENLYSTA,malignancies,Bronchitis,0
BENLYSTA,malignancies,Nasopharyngitis,0
BENLYSTA,malignancies,Nasopharyngitis,0
BENLYSTA,non-melanoma skin cancers,           7              Bronchitis,1
BENLYSTA,non-melanoma skin cancers,           7              Bronchitis,1
BENLYSTA,non-melanoma skin cancers,           7              Bronchitis,1
BENLYSTA,non-melanoma skin cancers,Nasopharyngitis,0
BENLYSTA,non-melanoma skin cancers,Nasopharyngitis,0
BENLYSTA,non-melanoma skin cancers,           7              Bronchitis,1
BENLYSTA,non-melanoma skin cancers,Nasopharyngitis,0
BENLYSTA,malignancies,,0
BENLYSTA,malignancies,itis,0
BENLYSTA,malignancies,Depression,0
BENLYSTA,malignancies,Depression,0
BENLYSTA,malignancies,             Migraine,1
BENLYSTA,Acute hypersensitivity reactions,"Depression           
  Migraine            Pharyngit",1
BENLYSTA,Acute hypersensitivity reactions,,0
BENLYSTA,Acute hypersensitivity reactions,"          
  Migraine            Pharyngit",1
BENLYSTA,Acute hypersensitivity reactions,"Depression           
  Migraine            Pharyngit",1
BENLYSTA,Acute hypersensitivity reactions,"          
  Migraine            Pharyngit",1
BENLYSTA,Acute hypersensitivity reactions,Pharyngit,0
BENLYSTA,Acute hypersensitivity reactions,"          
  Migraine            Pharyngit",1
BENLYSTA,Acute hypersensitivity reactions,"Depression           
  Migraine            Pharyngit",1
BENLYSTA,Acute hypersensitivity reactions,"Depression           
  Migraine            Pharyngit",1
BENLYSTA,Acute hypersensitivity reactions,"          
  Migraine            Pharyngit",1
BENLYSTA,anaphylaxis,Migraine       5     Pharyngitis,1
BENLYSTA,anaphylaxis,      5     Pharyngitis,1
BENLYSTA,death,,0
BENLYSTA,death,      Pharyngitis,1
BENLYSTA,hypersensitivity reactions,Pharyngitis,0
BENLYSTA,hypersensitivity reactions,Pharyngitis,0
BENLYSTA,hypersensitivity reactions,"Pharyngitis            
  Cystitis     Le",1
BENLYSTA,hypersensitivity reactions,Le,0
BENLYSTA,hypersensitivity reactions,"Pharyngitis            
  Cystitis     Le",1
BENLYSTA,hypersensitivity reactions,,0
BENLYSTA,rash,Leukopenia,0
BENLYSTA,rash,,0
BENLYSTA,rash,Cystitis,0
BENLYSTA,rash,     Leukopenia,1
BENLYSTA,nausea,,0
BENLYSTA,nausea,Cystitis,0
BENLYSTA,nausea,Leukopenia,0
BENLYSTA,nausea,Cystitis        Leukopenia,1
BENLYSTA,nausea,,0
BENLYSTA,nausea,Cystitis,0
BENLYSTA,nausea,       Leukopenia,1
BENLYSTA,fatigue,4       Leukopenia,1
BENLYSTA,fatigue,4       Leukopenia,1
BENLYSTA,fatigue,Cystitis,0
BENLYSTA,fatigue,4       Leukopenia,1
BENLYSTA,fatigue,,0
BENLYSTA,fatigue,Cystitis 4       Leukopenia,1
BENLYSTA,fatigue,4       Leukopenia,1
BENLYSTA,fatigue,Cystitis,0
BENLYSTA,fatigue,Cystitis 4       Leukopenia,1
BENLYSTA,myalgia,Cystitis         Leukopenia,1
BENLYSTA,myalgia,Cystitis,0
BENLYSTA,myalgia,Cystitis         Leukopenia,1
BENLYSTA,myalgia,        Leukopenia,1
BENLYSTA,myalgia,Leukopenia,0
BENLYSTA,myalgia,,0
BENLYSTA,myalgia,Cystitis         Leukopenia,1
BENLYSTA,headache,         Leukopenia,1
BENLYSTA,headache,         Leukopenia,1
BENLYSTA,headache,,0
BENLYSTA,headache,         Leukopenia,1
BENLYSTA,headache,Cystitis,0
BENLYSTA,headache,Cystitis          Leukopenia,1
BENLYSTA,facial edema,Cystitis,0
BENLYSTA,facial edema,Cystitis,0
BENLYSTA,Hypersensitivity,        2       ,1
BENLYSTA,Hypersensitivity,        2       ,1
BENLYSTA,Hypersensitivity,        2        Gastroenteritis viral,1
BENLYSTA,Hypersensitivity,Leukopenia,0
BENLYSTA,Hypersensitivity,        2        Gastroenteritis,1
BENLYSTA,Hypersensitivity,Leukopenia,0
BENLYSTA,Hypersensitivity,,0
BENLYSTA,Hypersensitivity,        2       ,1
BENLYSTA,Hypersensitivity,,0
BENLYSTA,Hypersensitivity,Leukopenia         2       ,1
BENLYSTA,Hypersensitivity,Gastroenteritis viral,0
BENLYSTA,hypersensitivity reactions,in of patients receiving  mg/kg and in 27 of 559 (4 patients receiving,1
BENLYSTA,hypersensitivity reactions,559 (4 patients receiving,1
BENLYSTA,hypersensitivity reactions,antibelimumab,0
BENLYSTA,hypersensitivity reactions,and antibelimumab antibodies were detected in of patients,0
BENLYSTA,hypersensitivity reactions,patients receiving BENLYSTA mgkg The reported frequency for the group receiving mgkg ma,0
BENLYSTA,hypersensitivity reactions,(4 patients receiving,1
BENLYSTA,hypersensitivity reactions,in of patients receiving mg/kg,1
BENLYSTA,Anaphylaxis,due to lower ay sensitiv ity in,1
BENLYSTA,hypotension,receiving BENLYSTA mgkg Three,0
BENLYSTA,hypotension,erythematous rash,0
BENLYSTA,hypotension,were detected in patients receiving,0
BENLYSTA,hypotension,mgkg Three,0
BENLYSTA,hypotension,detected,0
BENLYSTA,hypotension,detected in patients receiving BENLYSTA mgkg,0
BENLYSTA,hypotension,,0
BENLYSTA,angioedema, anti-beli mumab antibodies,1
BENLYSTA,angioedema,,0
BENLYSTA,angioedema, anti-beli mumab antibodies,1
BENLYSTA,angioedema,detected in patients receiving BENLYSTA,0
BENLYSTA,angioedema,BENLYSTA mgkg Three patients with,0
BENLYSTA,angioedema,BENLYSTA mgkg Three patients  anti-beli mumab antibodies,1
BENLYSTA,angioedema,patients with,0
BENLYSTA,angioedema,reactions,0
BENLYSTA,urticaria,patients with mab,1
BENLYSTA,urticaria,mab antib odies experienced,1
BENLYSTA,urticaria,head,0
BENLYSTA,urticaria,detected in,0
BENLYSTA,urticaria,mgkg Three patients with mab antib odies experienced,1
BENLYSTA,urticaria,mild infusion reactions of,0
BENLYSTA,urticaria,rash pruritus eyelid,0
BENLYSTA,rash,rien ced mild,1
BENLYSTA,pruritus,patients with,0
BENLYSTA,pruritus,with antibelimumab antibodies d mild i nfusion reactions,1
BENLYSTA,pruritus,pruritus eyelid edema headache,0
BENLYSTA,pruritus,antibodies,0
BENLYSTA,pruritus,antibodies,0
BENLYSTA,pruritus,pruritus,0
BENLYSTA,pruritus,in patients receiving BENLYSTA mgkg,0
BENLYSTA,dyspnea,mild n,1
BENLYSTA,dyspnea,erythematous rash pruritus eyelid edema headache and dyspnea none of the,0
BENLYSTA,dyspnea,experienced mild n react ions of,1
BENLYSTA,dyspnea,experienced,0
BENLYSTA,dyspnea,n react ions of,1
BENLYSTA,dyspnea,n react ions of,1
BENLYSTA,hypersensitivity reactions,of the reactions was l ifethreatening The,1
BENLYSTA,hypersensitivity reactions,one of the,1
BENLYSTA,hypersensitivity reactions,dyspnea n,0
BENLYSTA,hypersensitivity reactions,of nausea,0
BENLYSTA,hypersensitivity reactions,edema headache and dyspnea n,0
BENLYSTA,hypersensitivity reactions,of the,0
BENLYSTA,hypersensitivity reactions,erythematous rash pruritus eyelid edema headache and,0
BENLYSTA,hypersensitivity reactions,is not,0
BENLYSTA,infusion reactions,The data reflect,0
BENLYSTA,infusion reactions,cl inical relevance,1
BENLYSTA,infusion reactions,reflect,0
BENLYSTA,infusion reactions,hreatening.,1
BENLYSTA,infusion reactions,,0
BENLYSTA,infusion reactions,of antibelimumab antibodies is not known,0
BENLYSTA,adverse events associated with the infusion,estimate their frequency,0
BENLYSTA,adverse events associated with the infusion,a causal relationship to drug exp osure Fatal,1
BENLYSTA,adverse events associated with the infusion,to drug exp osure Fatal,1
BENLYSTA,adverse events associated with the infusion,drug exp osure Fatal,1
BENLYSTA,adverse events associated with the infusion,and Precautions,0
BENLYSTA,adverse events associated with the infusion,frequency establish a causal,1
BENLYSTA,adverse events associated with the infusion,,0
BENLYSTA,adverse events associated with the infusion,establish a causal relationship to drug exp osure Fatal,1
BENLYSTA,infusion reactions,,1
BENLYSTA,infusion reactions,,1
BENLYSTA,infusion reactions,,0
BENLYSTA,infusion reactions,,1
BENLYSTA,infusion reactions,,1
BENLYSTA,infusion reactions,,1
BENLYSTA,infusion reactions,,1
BENLYSTA,infusion reactions,,0
BENLYSTA,infusion reactions,,0
BENLYSTA,hypersensitivity reactions,,0
BENLYSTA,bradycardia,,1
BENLYSTA,bradycardia,,1
BENLYSTA,myalgia,,1
BENLYSTA,myalgia,,1
BENLYSTA,myalgia,,0
BENLYSTA,myalgia,,1
BENLYSTA,myalgia,,0
BENLYSTA,headache,,0
BENLYSTA,headache,,0
BENLYSTA,headache,,0
BENLYSTA,headache,,0
BENLYSTA,headache,,1
BENLYSTA,headache,,1
BENLYSTA,headache,,0
BENLYSTA,headache,,0
BENLYSTA,rash,,1
BENLYSTA,rash,,0
BENLYSTA,rash,,1
BENLYSTA,rash,,0
BENLYSTA,rash,,1
BENLYSTA,rash,,0
BENLYSTA,rash,,0
BENLYSTA,rash,,1
BENLYSTA,urticaria,,1
BENLYSTA,urticaria,,0
BENLYSTA,urticaria,,0
BENLYSTA,urticaria,,0
BENLYSTA,urticaria,,1
BENLYSTA,hypotension,,0
BENLYSTA,hypotension,,0
BENLYSTA,hypotension,,0
BENLYSTA,infusion reactions,,1
BENLYSTA,infusion reactions,,1
BENLYSTA,headache,,0
BENLYSTA,headache,,0
BENLYSTA,headache,,0
BENLYSTA,headache,,1
BENLYSTA,headache,,0
BENLYSTA,headache,,0
BENLYSTA,nausea,,0
BENLYSTA,nausea,,0
BENLYSTA,nausea,,0
BENLYSTA,nausea,,1
BENLYSTA,nausea,,0
BENLYSTA,nausea,,0
BENLYSTA,nausea,,1
BENLYSTA,nausea,,0
BENLYSTA,skin reactions,,0
BENLYSTA,skin reactions,,1
BENLYSTA,skin reactions,,0
BENLYSTA,skin reactions,,0
BENLYSTA,skin reactions,,1
BENLYSTA,skin reactions,,0
BENLYSTA,skin reactions,,1
BENLYSTA,skin reactions,,1
BENLYSTA,skin reactions,,1
BENLYSTA,skin reactions,,1
BENLYSTA,hypersensitivity reactions,,1
BENLYSTA,hypersensitivity reactions,,1
BENLYSTA,hypersensitivity reactions,,0
BENLYSTA,hypersensitivity reactions,,1
BENLYSTA,hypersensitivity reactions,,1
BENLYSTA,hypersensitivity reactions,,1
BENLYSTA,hypersensitivity reactions,,1
BENLYSTA,hypersensitivity reactions,,1
BENLYSTA,hypersensitivity reactions,,1
BENLYSTA,hypersensitivity reactions,,0
BENLYSTA,infusion reactions,,0
BENLYSTA,infusion reactions,,1
BENLYSTA,infusion reactions,,0
BENLYSTA,infusion reactions,,1
BENLYSTA,infusion reactions,,0
BENLYSTA,psychiatric events,,0
BENLYSTA,depression,,0
BENLYSTA,depression,,1
BENLYSTA,depression,,0
BENLYSTA,depression,,1
BENLYSTA,depression,,1
BENLYSTA,depression,,1
BENLYSTA,depression,,0
BENLYSTA,depression,,0
BENLYSTA,insomnia,,0
BENLYSTA,insomnia,,0
BENLYSTA,insomnia,,0
BENLYSTA,insomnia,,0
BENLYSTA,insomnia,,0
BENLYSTA,insomnia,,0
BENLYSTA,insomnia,,1
BENLYSTA,insomnia,,1
BENLYSTA,insomnia,,1
BENLYSTA,insomnia,,0
BENLYSTA,anxiety,,1
BENLYSTA,anxiety,,0
BENLYSTA,anxiety,,1
BENLYSTA,anxiety,,1
BENLYSTA,anxiety,,1
BENLYSTA,anxiety,,1
BENLYSTA,anxiety,,0
BENLYSTA,psychiatric events,,0
BENLYSTA,psychiatric events,,1
BENLYSTA,depression,,0
BENLYSTA,depression,,1
BENLYSTA,depression,,1
BENLYSTA,depression,,1
BENLYSTA,depression,,1
BENLYSTA,suicides,,1
BENLYSTA,suicides,,0
BENLYSTA,suicides,,0
BENLYSTA,suicides,,1
BENLYSTA,depression,,1
BENLYSTA,depression,,1
BENLYSTA,depression,,0
BENLYSTA,depression,,1
BENLYSTA,depression,,1
BENLYSTA,depression,,1
BENLYSTA,suicidal behavior,,0
BENLYSTA,suicidal behavior,,1
BENLYSTA,suicidal behavior,,1
BENLYSTA,suicidal behavior,,0
BENLYSTA,suicidal behavior,,1
BENLYSTA,suicidal behavior,,0
BENLYSTA,suicidal behavior,,0
BENLYSTA,suicidal behavior,,1
XALKORI,Hepatotoxicity,,0
XALKORI,Hepatotoxicity,Hepatotoxicity,1
XALKORI,Hepatotoxicity,,0
XALKORI,Hepatotoxicity,in other,0
XALKORI,Hepatotoxicity,Hepatotoxicity,1
XALKORI,Hepatotoxicity,other sections of the Hepatotoxicity,1
XALKORI,Hepatotoxicity,Hepatotoxicity,1
XALKORI,Hepatotoxicity,the Hepatotoxicity,1
XALKORI,Hepatotoxicity,sections of the Hepatotoxicity,1
XALKORI,Hepatotoxicity,Hepatotoxicity,1
XALKORI,Interstitial Lung Disease,Hepatotoxicity see Warnings and Interstitial,1
XALKORI,Pneumonitis,Pneumonitis,1
XALKORI,Pneumonitis,Precautions Interstitial Lung,0
XALKORI,Pneumonitis,Interstitial,0
XALKORI,Pneumonitis,Pneumonitis,1
XALKORI,QT Interval Prolongation,see,0
XALKORI,QT Interval Prolongation,QT Interval Prolongation,1
XALKORI,QT Interval Prolongation,,0
XALKORI,QT Interval Prolongation,Lung DiseasePneumonitis see Warnings and Precautions,0
XALKORI,QT Interval Prolongation,see Warnings and QT Interval Prolongation,1
XALKORI,QT Interval Prolongation,Prolongation,1
XALKORI,QT Interval Prolongation,,0
XALKORI,QT Interval Prolongation,and QT,1
XALKORI,Bradycardia,and Precautions Severe Visual Loss,0
XALKORI,Bradycardia,Bradycardia,1
XALKORI,Bradycardia,Interval Prolongation see Warnings and Precautions,0
XALKORI,Bradycardia,Bradycardia,1
XALKORI,Bradycardia,Precautions Severe Visual Loss,0
XALKORI,Bradycardia,Warnings,0
XALKORI,Bradycardia,Bradycardia,1
XALKORI,Bradycardia,,0
XALKORI,Bradycardia,Precautions Severe,0
XALKORI,Bradycardia,Bradycardia,1
XALKORI,Visual Loss,Visual Loss,1
XALKORI,Visual Loss,and Precautions EXCERPT The most common,0
XALKORI,Visual Loss,see Warnings,0
XALKORI,Visual Loss,EXCERPT The,0
XALKORI,Visual Loss,Visual Loss,1
XALKORI,Visual Loss,Warnings,0
XALKORI,Visual Loss,and Precautions Bradycardia see Warnings and Precautions Severe,0
XALKORI,Visual Loss,and Precautions,0
XALKORI,Visual Loss,reactions,0
XALKORI,vision disorders,reactions vision disorders,1
XALKORI,vision disorders,disorders,1
XALKORI,vision disorders,reactions vision disorders,1
XALKORI,vision disorders,,0
XALKORI,vision disorders,nausea vomiting constipation edema elevated transaminases upper respiratory infecti,0
XALKORI,vision disorders,,0
XALKORI,vision disorders,common,0
XALKORI,vision disorders,,0
XALKORI,diarrhea,diarrhea,1
XALKORI,diarrhea,most common adverse reactions are vision,0
XALKORI,diarrhea,transaminases upper respiratory infection,0
XALKORI,nausea,common adverse reactions are vision disorders diarrhea,0
XALKORI,nausea,vision disorders nausea,1
XALKORI,nausea,nausea,1
XALKORI,nausea,,0
XALKORI,nausea,common,0
XALKORI,nausea,common adverse reactions are vision,0
XALKORI,nausea,are vision disorders nausea,1
XALKORI,nausea,most common,0
XALKORI,nausea,vision disorders nausea,1
XALKORI,vomiting,vomiting,1
XALKORI,vomiting,and,0
XALKORI,vomiting,,0
XALKORI,vomiting,vomiting,1
XALKORI,vomiting,vomiting,1
XALKORI,vomiting,vomiting,1
XALKORI,vomiting,vision disorders diarrhea,0
XALKORI,vomiting,most common adverse reactions,0
XALKORI,vomiting,The most common adverse reactions are vision disorders,0
XALKORI,vomiting,diarrhea vomiting,1
XALKORI,edema,,0
XALKORI,edema,infection decreased appetite and,0
XALKORI,edema,diarrhea nausea vomiting,0
XALKORI,edema,edema,1
XALKORI,edema,vomiting,0
XALKORI,edema,edema,1
XALKORI,edema,constipation,0
XALKORI,edema,and,0
XALKORI,elevated transaminases,,0
XALKORI,elevated transaminases,respiratory infection decreased,0
XALKORI,elevated transaminases,,0
XALKORI,elevated transaminases,elevated,1
XALKORI,elevated transaminases,constipation elevated,1
XALKORI,elevated transaminases,nausea vomiting constipation elevated transaminases,1
XALKORI,elevated transaminases,vision disorders diarrhea nausea vomiting constipation edema,0
XALKORI,elevated transaminases,vomiting constipation,0
XALKORI,elevated transaminases,transaminases,1
XALKORI,upper respiratory infection,decreased appetite and dysgeusia To report,0
XALKORI,upper respiratory infection,To report SUSPECTED ADVERSE REACTIONS,0
XALKORI,upper respiratory infection,constipation edema elevated upper respiratory infection,1
XALKORI,upper respiratory infection,elevated,0
XALKORI,upper respiratory infection,nausea vomiting constipation edema elevated transaminases,0
XALKORI,upper respiratory infection,vomiting constipation edema elevated upper respiratory infection,1
XALKORI,upper respiratory infection,contact,0
XALKORI,upper respiratory infection,upper respiratory infection,1
XALKORI,decreased appetite,appetite,1
XALKORI,decreased appetite,appetite,1
XALKORI,decreased appetite,contact Pfizer,0
XALKORI,decreased appetite,nausea vomiting constipation edema elevated,0
XALKORI,decreased appetite,SUSPECTED ADVERSE REACTIONS contact Pfizer Inc at,0
XALKORI,decreased appetite,,0
XALKORI,decreased appetite,,0
XALKORI,decreased appetite,contact Pfizer,0
XALKORI,decreased appetite,transaminases,0
XALKORI,decreased appetite,,0
XALKORI,dysgeusia,infection decreased,0
XALKORI,dysgeusia,dysgeusia,1
XALKORI,dysgeusia,respiratory infection decreased appetite and,0
XALKORI,dysgeusia,decreased appetite and,0
XALKORI,dysgeusia,dysgeusia,1
XALKORI,dysgeusia,dysgeusia,1
XALKORI,dysgeusia,and,0
XALKORI,dysgeusia,transaminases upper respiratory,0
XALKORI,vision disorders,in Studies and vision,1
XALKORI,vision disorders,Studies and vision,1
XALKORI,diarrhea,diarrhea,1
XALKORI,diarrhea,are vision disorders,0
XALKORI,diarrhea,diarrhea,1
XALKORI,nausea,,0
XALKORI,nausea,nausea,1
XALKORI,vomiting,vomiting,1
XALKORI,vomiting,of XALKORI in Studies and are vision disorders diarrhea nausea,0
XALKORI,constipation,infection decreased appetite,0
XALKORI,constipation,constipation,1
XALKORI,constipation,of,0
XALKORI,constipation,diarrhea nausea constipation,1
XALKORI,constipation,constipation,1
XALKORI,constipation,constipation,1
XALKORI,constipation,,0
XALKORI,constipation,are vision disorders diarrhea,0
XALKORI,constipation,nausea,0
XALKORI,constipation,and are,0
XALKORI,edema,in Studies and are vision disorders diarrhea nausea,0
XALKORI,edema,Studies and are vision disorders,0
XALKORI,edema,are vision disorders diarrhea nausea,0
XALKORI,edema,,0
XALKORI,edema,elevated transaminases upper respiratory infection decreased appetite and dysgeusia Pr,0
XALKORI,edema,respiratory infection decreased appetite and dysgeusia Pr,0
XALKORI,elevated transaminases,transaminases,1
XALKORI,upper respiratory infection,edema elevated upper respiratory,1
XALKORI,upper respiratory infection,infection,1
XALKORI,decreased appetite,respiratory decreased,1
XALKORI,dysgeusia,edema elevated transaminases upper respiratory infection decreased,0
XALKORI,dyspnea,adverse events reported in patients treated with XALKORI were,0
XALKORI,dyspnea,,0
XALKORI,dyspnea,dyspnea,1
XALKORI,dyspnea,dyspnea,1
XALKORI,dyspnea,with XALKORI dyspnea,1
XALKORI,dyspnea,dyspnea,1
XALKORI,dyspnea,XALKORI dyspnea,1
XALKORI,dyspnea,Fatal adverse events in XALKORItreated patients occurred,0
XALKORI,dyspnea,XALKORI The most frequent serious adverse events reported in patients treated with,0
XALKORI,dyspnea,dyspnea,1
XALKORI,pulmonary embolism,XALKORItreated patients occurred in patients consisting,0
XALKORI,septic shock,in patients consisting septic shock,1
XALKORI,septic shock,occurred in patients consisting septic shock,1
XALKORI,acute respiratory failure,of septic acute respiratory,1
XALKORI,acute respiratory failure,patients consisting of septic,0
XALKORI,acute respiratory failure,occurred in patients,0
XALKORI,acute respiratory failure,acute respiratory failure,1
XALKORI,acute respiratory failure,diabetic,0
XALKORI,acute respiratory failure,to,0
XALKORI,diabetic ketoacidosis,required,0
XALKORI,diabetic ketoacidosis,,0
XALKORI,diabetic ketoacidosis,acute respiratory failure diabetic,1
XALKORI,diabetic ketoacidosis,and,0
XALKORI,nausea,nausea,1
XALKORI,nausea,transaminases Permanent discontinuation of XALKORI treatment for,0
XALKORI,elevated transaminases,transaminases,1
XALKORI,elevated transaminases,were nausea elevated,1
XALKORI,elevated transaminases,patients were nausea elevated transaminases,1
XALKORI,elevated transaminases,to,0
XALKORI,elevated transaminases,nausea elevated transaminases,1
XALKORI,elevated transaminases,for adverse,0
XALKORI,elevated transaminases,transaminases,1
XALKORI,elevated transaminases,elevated transaminases,1
XALKORI,elevated transaminases,led,0
XALKORI,elevated transaminases,adverse reactions that led to permanent discontinuation in XALKORItreated,0
XALKORI,elevated transaminases,patients elevated,1
XALKORI,elevated transaminases,elevated transaminases,1
XALKORI,elevated transaminases,,0
XALKORI,elevated transaminases,,0
XALKORI,elevated transaminases,transaminases,1
XALKORI,elevated transaminases,XALKORItreated patients elevated transaminases,1
XALKORI,elevated transaminases,elevated,1
XALKORI,hepatotoxicity,hepatotoxicity,1
XALKORI,hepatotoxicity,hepatotoxicity,1
XALKORI,hepatotoxicity,discontinuation in XALKORItreated patients were elevated,0
XALKORI,ILD,in XALKORItreated patients,0
XALKORI,ILD,ILD,1
XALKORI,ILD,,0
XALKORI,ILD,ILD,1
XALKORI,Electrocardiogram QT prolonged,Bradycardia,0
XALKORI,Electrocardiogram QT prolonged,,0
XALKORI,Electrocardiogram QT prolonged,prolonged Bradycardia,1
XALKORI,Bradycardia,Bradycardia,1
XALKORI,Bradycardia,,0
XALKORI,Bradycardia,Bradycardia,1
XALKORI,Vision disorder,Vision disorder Ga,1
XALKORI,Vision disorder,Vision,1
XALKORI,Vision disorder,,0
XALKORI,Vision disorder,Vision disorder Ga,1
XALKORI,Vision disorder,,0
XALKORI,Vision disorder,disorder Ga,1
XALKORI,Vision disorder,Vision,1
XALKORI,Vomiting,nal Vomiting,1
XALKORI,Vomiting,Vomiting,1
XALKORI,Vomiting,,0
XALKORI,Vomiting,,0
XALKORI,Vomiting,Vomiting,1
XALKORI,Vomiting,,0
XALKORI,Diarrhea,,0
XALKORI,Diarrhea,Diarrhea,1
XALKORI,Diarrhea,,0
XALKORI,Diarrhea,,0
XALKORI,Diarrhea,Diarrhea,1
XALKORI,Diarrhea,Diarrhea,1
XALKORI,Constipation,Constipation,1
XALKORI,Constipation,Constipation,1
XALKORI,Constipation,,0
XALKORI,Dyspepsia,Dyspepsia,1
XALKORI,Dyspepsia,Dyspepsia,1
XALKORI,Dyspepsia,Dyspepsia,1
XALKORI,Dyspepsia,,0
XALKORI,Dysphagia,Dysphagia,1
XALKORI,Dysphagia,,0
XALKORI,Dysphagia,Dysphagia,1
XALKORI,Dysphagia,,0
XALKORI,Dysphagia,,0
XALKORI,Dysphagia,Dysphagia,1
XALKORI,Dysphagia,Dysphagia,1
XALKORI,Dysphagia,Dysphagia,1
XALKORI,Dysphagia,,0
XALKORI,Abdominal pain,Abdominal,1
XALKORI,Abdominal pain,,0
XALKORI,Abdominal pain,Abdominal,1
XALKORI,Abdominal pain,,0
XALKORI,Edema,tration Site Edema,1
XALKORI,Pyrexia,Pyrexia,1
XALKORI,Pyrexia,Pyrexia,1
XALKORI,Pyrexia,Pyrexia,1
XALKORI,Pyrexia,Pyrexia,1
XALKORI,Upper respiratory infection,d Upper respiratory infection Investigations,1
XALKORI,Upper respiratory infection,Upper respiratory infection Investigations,1
XALKORI,Upper respiratory infection,d Upper respiratory,1
XALKORI,Upper respiratory infection,d Upper respiratory infection Investigations,1
XALKORI,Upper respiratory infection,,0
XALKORI,Upper respiratory infection,,0
XALKORI,Upper respiratory infection,Upper respiratory infection Investigations,1
XALKORI,Upper respiratory infection,Investigations,0
XALKORI,Weight increased,,0
XALKORI,Weight increased,increased Mus,1
XALKORI,Weight increased,s Weight,1
XALKORI,Weight increased,s Weight increased Mus,1
XALKORI,Weight increased,s,0
XALKORI,Weight increased,s Weight,1
XALKORI,Weight increased,s Weight,1
XALKORI,Weight increased,Mus,0
XALKORI,Pain in extremity,,0
XALKORI,Pain in extremity,extremity Musc,1
XALKORI,Pain in extremity,Disorders,0
XALKORI,Pain in extremity,Tissue,0
XALKORI,Pain in extremity,,0
XALKORI,Pain in extremity,extremity Musc,1
XALKORI,Pain in extremity,in extremity Musc,1
XALKORI,Pain in extremity,Tissue,0
XALKORI,Pain in extremity,ective Tissue Pain in extremity Musc,1
XALKORI,Pain in extremity,extremity Musc,1
XALKORI,Muscle spasm,,0
XALKORI,Muscle spasm,mity Muscle,1
XALKORI,Muscle spasm,,0
XALKORI,Muscle spasm,mity Muscle spasm,1
XALKORI,Muscle spasm,,0
XALKORI,Muscle spasm,mity Muscle spasm,1
XALKORI,Muscle spasm,mity,0
XALKORI,Dizziness,Dizziness,1
XALKORI,Dysgeusia,Dysgeusia,1
XALKORI,Dysgeusia,,0
XALKORI,Dysgeusia,Dysgeusia,1
XALKORI,Dysgeusia,Dysgeusia,1
XALKORI,Dysgeusia,Dysgeusia,1
XALKORI,Dysgeusia,,0
XALKORI,Dysgeusia,Dysgeusia,1
XALKORI,Headache,,0
XALKORI,Headache,,0
XALKORI,nausea,included gait,0
XALKORI,nausea,at an overall incidence between and in patients treated with XALKORI included,0
XALKORI,nausea,,0
XALKORI,nausea,overall incidence between and,0
XALKORI,decreased appetite,muscular,0
XALKORI,neuropathy,neuropathy,1
XALKORI,neuropathy,included nausea decreased,0
XALKORI,neuropathy,neuropathy,1
XALKORI,gait disturbance,appetite,0
XALKORI,gait disturbance,included nausea,0
XALKORI,gait disturbance,appetite fatigue neuropathy which gait,1
XALKORI,gait disturbance,,0
XALKORI,gait disturbance,peripheral paraesthesia,0
XALKORI,gait disturbance,,0
XALKORI,gait disturbance,which gait disturbance,1
XALKORI,hypoaesthesia,hypoaesthesia,1
XALKORI,hypoaesthesia,hypoaesthesia,1
XALKORI,hypoaesthesia,hypoaesthesia,1
XALKORI,hypoaesthesia,muscular weakness neuralgia neuropathy,0
XALKORI,hypoaesthesia,sensory neuropathy,0
XALKORI,hypoaesthesia,hypoaesthesia,1
XALKORI,hypoaesthesia,neuropathy,0
XALKORI,muscular weakness,included gait,0
XALKORI,neuralgia,gait disturbance hypoaesthesia muscular neuralgia,1
XALKORI,neuralgia,muscular,0
XALKORI,neuralgia,hypoaesthesia muscular neuralgia,1
XALKORI,neuralgia,disturbance,0
XALKORI,neuropathy peripheral,neuropathy peripheral,1
XALKORI,neuropathy peripheral,peripheral,1
XALKORI,neuropathy peripheral,muscular weakness neuropathy,1
XALKORI,neuropathy peripheral,polyneuropathy sensory,0
XALKORI,neuropathy peripheral,neuropathy peripheral,1
XALKORI,paraesthesia,weakness neuralgia neuropathy peripheral,0
XALKORI,paraesthesia,weakness neuralgia neuropathy paraesthesia,1
XALKORI,paraesthesia,paraesthesia,1
XALKORI,paraesthesia,paraesthesia,1
XALKORI,paraesthesia,peripheral,0
XALKORI,paraesthesia,paraesthesia,1
XALKORI,paraesthesia,paraesthesia,1
XALKORI,paraesthesia,polyneuropathy sensory disturbance rash renal cyst,0
XALKORI,paraesthesia,neuropathy,0
XALKORI,paraesthesia,neuralgia neuropathy paraesthesia,1
XALKORI,peripheral sensory neuropathy,neuropathy,1
XALKORI,peripheral sensory neuropathy,neuralgia neuropathy peripheral peripheral sensory neuropathy,1
XALKORI,peripheral sensory neuropathy,renal cyst ILD ILD pneumonitis and,0
XALKORI,peripheral sensory neuropathy,sensory neuropathy,1
XALKORI,peripheral sensory neuropathy,,0
XALKORI,peripheral sensory neuropathy,,0
XALKORI,peripheral sensory neuropathy,weakness,0
XALKORI,peripheral sensory neuropathy,and,0
XALKORI,peripheral sensory neuropathy,rash renal cyst,0
XALKORI,polyneuropathy,ILD pneumonitis,0
XALKORI,polyneuropathy,polyneuropathy,1
XALKORI,polyneuropathy,,0
XALKORI,polyneuropathy,polyneuropathy,1
XALKORI,polyneuropathy,polyneuropathy,1
XALKORI,polyneuropathy,peripheral sensory polyneuropathy,1
XALKORI,polyneuropathy,weakness neuralgia neuropathy peripheral,0
XALKORI,polyneuropathy,polyneuropathy,1
XALKORI,polyneuropathy,polyneuropathy,1
XALKORI,polyneuropathy,polyneuropathy,1
XALKORI,sensory disturbance,ILD pneumonitis and syncope Table Summary o,0
XALKORI,sensory disturbance,paraesthesia peripheral sensory neuropathy sensory disturbance,1
XALKORI,sensory disturbance,neuropathy peripheral paraesthesia peripheral sensory,0
XALKORI,sensory disturbance,sensory neuropathy sensory disturbance,1
XALKORI,sensory disturbance,,0
XALKORI,sensory disturbance,paraesthesia peripheral sensory neuropathy sensory disturbance,1
XALKORI,sensory disturbance,paraesthesia peripheral sensory neuropathy sensory disturbance,1
XALKORI,rash,,0
XALKORI,rash,,0
XALKORI,rash,rash,1
XALKORI,rash,cyst ILD ILD pneumonitis and,0
XALKORI,rash,and,0
XALKORI,rash,ILD pneumonitis and,0
XALKORI,renal cyst,TreatmentEmergent,0
XALKORI,renal cyst,renal,1
XALKORI,renal cyst,,0
XALKORI,renal cyst,sensory disturbance rash,0
XALKORI,renal cyst,disturbance renal,1
XALKORI,renal cyst,renal cyst,1
XALKORI,renal cyst,renal cyst,1
XALKORI,renal cyst,cyst,1
XALKORI,renal cyst,polyneuropathy sensory disturbance rash,0
XALKORI,renal cyst,Summary of,0
XALKORI,ILD,disturbance rash renal ILD,1
XALKORI,ILD,and,0
XALKORI,ILD,ILD,1
XALKORI,ILD,ILD,1
XALKORI,ILD,ILD,1
XALKORI,ILD,rash renal,0
XALKORI,ILD,pneumonitis and syncope,0
XALKORI,ILD,renal,0
XALKORI,ILD,of,0
XALKORI,ILD,rash renal cyst ILD,1
XALKORI,pneumonitis,pneumonitis,1
XALKORI,pneumonitis,pneumonitis,1
XALKORI,pneumonitis,pneumonitis,1
XALKORI,syncope,syncope,1
XALKORI,syncope,TreatmentEmergent Laboratory Abnormalities with Grade or Inciden,0
XALKORI,syncope,,0
XALKORI,syncope,of,0
XALKORI,syncope,syncope,1
XALKORI,syncope,of,0
XALKORI,syncope,,0
XALKORI,syncope,ILD ILD pneumonitis and,0
XALKORI,syncope,of TreatmentEmergent Laboratory Abnormalities,0
XALKORI,syncope,Abnormalities with,0
XALKORI,Neutropenia,Neutropenia,1
XALKORI,Neutropenia,Neutropenia,1
XALKORI,ALT elevation,elevation,1
XALKORI,ALT elevation,ALT elevation,1
XALKORI,AST elevation,AST elevation,1
XALKORI,AST elevation,AST elevation,1
XALKORI,Hypophosphatemia,,0
XALKORI,Hypophosphatemia,Hypophosphatemia,1
XALKORI,Hypophosphatemia,Hypophosphatemia,1
XALKORI,Hypophosphatemia,Hypophosphatemia,1
XALKORI,Hypophosphatemia,Hypophosphatemia,1
XALKORI,Hypophosphatemia,Hypophosphatemia,1
XALKORI,Hypophosphatemia,Hypophosphatemia,1
XALKORI,pneumonia,with XALKORI pneumonia,1
XALKORI,pneumonia,pneumonia,1
XALKORI,pneumonia,reported in patients treated,0
XALKORI,pulmonary embolism,with XALKORI were pulmonary,1
XALKORI,pulmonary embolism,pulmonary embolism,1
XALKORI,pulmonary embolism,,0
XALKORI,pulmonary embolism,with XALKORI were pulmonary embolism,1
XALKORI,pulmonary embolism,dyspnea and ILD Fatal adverse reactions in XALKORItreated patients in Stud,0
XALKORI,dyspnea,dyspnea,1
XALKORI,dyspnea,patients,0
XALKORI,dyspnea,XALKORI were pneumonia pulmonary dyspnea,1
XALKORI,dyspnea,dyspnea,1
XALKORI,dyspnea,and ILD Fatal adverse reactions in XALKORItreated patients in Study occurred in,0
XALKORI,dyspnea,dyspnea,1
XALKORI,ILD,with XALKORI,0
XALKORI,ILD,dyspnea,0
XALKORI,ILD,ILD,1
XALKORI,ILD,pulmonary embolism dyspnea ILD,1
XALKORI,ILD,reactions,0
XALKORI,ILD,ILD,1
XALKORI,Fatal,ILD,0
XALKORI,Fatal,Fatal,1
XALKORI,Fatal,Fatal,1
XALKORI,Fatal,XALKORItreated patients,0
XALKORI,Fatal,dyspnea and Fatal,1
XALKORI,Fatal,Fatal,1
XALKORI,Fatal,ILD,0
XALKORI,Fatal,consisting of,0
XALKORI,Fatal,pulmonary embolism dyspnea and Fatal,1
XALKORI,Fatal,Fatal,1
XALKORI,acute respiratory distress syndrome,in XALKORItreated patients in Study occurred in,0
XALKORI,acute respiratory distress syndrome,,0
XALKORI,acute respiratory distress syndrome,consisting acute,1
XALKORI,arrhythmia,respiratory failure and,0
XALKORI,arrhythmia,arrhythmia,1
XALKORI,arrhythmia,,0
XALKORI,arrhythmia,and sepsis Dose,0
XALKORI,arrhythmia,acute respiratory distress arrhythmia,1
XALKORI,arrhythmia,pneumonia,0
XALKORI,arrhythmia,failure,0
XALKORI,arrhythmia,arrhythmia,1
XALKORI,arrhythmia,arrhythmia,1
XALKORI,dyspnea,ILD respiratory failure and sepsis Dose,0
XALKORI,dyspnea,,0
XALKORI,dyspnea,,0
XALKORI,pneumonia,pneumonitis pulmonary embolism ILD respiratory failure and sepsis Dose reductions due,0
XALKORI,pneumonitis,reacti,0
XALKORI,pneumonitis,,0
XALKORI,pneumonitis,pneumonitis,1
XALKORI,pneumonitis,pneumonitis,1
XALKORI,pneumonitis,respiratory distress syndrome arrhythmia,0
XALKORI,pulmonary embolism,dyspnea pneumonia pulmonary,1
XALKORI,pulmonary embolism,syndrome arrhythmia,0
XALKORI,pulmonary embolism,pulmonary embolism,1
XALKORI,pulmonary embolism,ILD,0
XALKORI,pulmonary embolism,pulmonary embolism,1
XALKORI,pulmonary embolism,reductions due to adverse reactions were required,0
XALKORI,pulmonary embolism,respiratory distress syndrome arrhythmia dyspnea pneumonia pneumonitis,0
XALKORI,pulmonary embolism,,0
XALKORI,pulmonary embolism,pulmonary embolism,1
XALKORI,ILD,and sepsis Dose,0
XALKORI,ILD,ILD,1
XALKORI,ILD,syndrome arrhythmia dyspnea pneumonia pneumonitis pulmonary,0
XALKORI,sepsis,,0
XALKORI,sepsis,sepsis,1
XALKORI,sepsis,sepsis,1
XALKORI,sepsis,reactions were required in of XALKORItreated,0
XALKORI,sepsis,XALKORItreated patients The,0
XALKORI,sepsis,sepsis,1
XALKORI,sepsis,ILD respiratory failure sepsis,1
XALKORI,sepsis,sepsis,1
XALKORI,sepsis,sepsis,1
XALKORI,QTc prolongation,prolongation,1
XALKORI,QTc prolongation,AST QTc prolongation,1
XALKORI,QTc prolongation,concurrent aspartate aminotransferase AST QTc,1
XALKORI,QTc prolongation,discontinued for adverse reactions in of,0
XALKORI,QTc prolongation,aminotransferase AST QTc prolongation,1
XALKORI,QTc prolongation,with concurrent aspartate aminotransferase AST elevation,0
XALKORI,QTc prolongation,aspartate aminotransferase AST QTc prolongation,1
XALKORI,QTc prolongation,AST QTc prolongation,1
XALKORI,QTc prolongation,some patients,0
XALKORI,neutropenia,neutropenia,1
XALKORI,ILD,ILD,1
XALKORI,ILD,patients The most frequent adverse reactions that led to discontinuation of XALKORI,0
XALKORI,ILD,ILD,1
XALKORI,ILD,of,0
XALKORI,ILD,adverse reactions that led to discontinuation,0
XALKORI,AST elevation,common,0
XALKORI,AST elevation,XALKORI were ILD ALT AST elevation,1
XALKORI,AST elevation,,0
XALKORI,AST elevation,elevation,1
XALKORI,AST elevation,AST elevation,1
XALKORI,AST elevation,AST,1
XALKORI,AST elevation,XALKORI were ILD ALT AST elevation,1
XALKORI,AST elevation,ILD ALT AST elevation,1
XALKORI,AST elevation,Tables and,0
XALKORI,AST elevation,were ILD ALT AST,1
XALKORI,dyspnea,dyspnea,1
XALKORI,dyspnea,summarize common adverse reactions and,0
XALKORI,dyspnea,dyspnea,1
XALKORI,pulmonary embolism,AST elevation dyspnea and,0
XALKORI,Dizziness,Dizziness,1
XALKORI,Dizziness,Dizziness,1
XALKORI,Dizziness,Disorder,0
XALKORI,Dizziness,,0
XALKORI,Dizziness,m Dizziness,1
XALKORI,Dizziness,Disorder,0
XALKORI,Dizziness,Dizziness,1
XALKORI,Dysgeusia,,0
XALKORI,Dysgeusia,Dysgeusia,1
XALKORI,Syncope,Syncope,1
XALKORI,Vision disorder,,0
XALKORI,Vision disorder,,0
XALKORI,Vision disorder,,0
XALKORI,Vision disorder,Vision,1
XALKORI,Vision disorder,Vision disorder Ca,1
XALKORI,Vision disorder,Vision disorder Ca,1
XALKORI,Vision disorder,Vision disorder Ca,1
XALKORI,Electrocardiogram QT prolonged,ders,0
XALKORI,Electrocardiogram QT prolonged,ders Electrocardiogram QT prolonged Bradycardia,1
XALKORI,Electrocardiogram QT prolonged,ders Electrocardiogram QT,1
XALKORI,Electrocardiogram QT prolonged,QT prolonged Bradycardia,1
XALKORI,Electrocardiogram QT prolonged,ders Electrocardiogram QT prolonged Bradycardia,1
XALKORI,Electrocardiogram QT prolonged,ders Electrocardiogram QT,1
XALKORI,Electrocardiogram QT prolonged,ders Electrocardiogram QT prolonged Bradycardia,1
XALKORI,Electrocardiogram QT prolonged,QT prolonged Bradycardia,1
XALKORI,Bradycardia,Bradycardia,1
XALKORI,Weight decreased,s,0
XALKORI,Weight decreased,decreased Gas,1
XALKORI,Weight decreased,s,0
XALKORI,Vomiting,,0
XALKORI,Vomiting,Vomiting,1
XALKORI,Vomiting,Vomiting,1
XALKORI,Vomiting,Vomiting,1
XALKORI,Vomiting,Disorders,0
XALKORI,Nausea,Nausea,1
XALKORI,Diarrhea,Diarrhea,1
XALKORI,Constipation,,0
XALKORI,Constipation,Constipation,1
XALKORI,Constipation,,0
XALKORI,Constipation,Constipation,1
XALKORI,Constipation,Constipation,1
XALKORI,Dyspepsia,Dyspepsia,1
XALKORI,Dyspepsia,,0
XALKORI,Dyspepsia,Dyspepsia,1
XALKORI,Dyspepsia,Dyspepsia,1
XALKORI,Dyspepsia,,0
XALKORI,Dyspepsia,Dyspepsia,1
XALKORI,Dyspepsia,Dyspepsia,1
XALKORI,Dyspepsia,Dyspepsia,1
XALKORI,Dyspepsia,,0
XALKORI,Upper respiratory infection,Infestations,0
XALKORI,Upper respiratory infection,d Upper respiratory infection,1
XALKORI,Upper respiratory infection,d Upper respiratory infection,1
XALKORI,Upper respiratory infection,Upper,1
XALKORI,Upper respiratory infection,,0
XALKORI,Upper respiratory infection,,0
XALKORI,Upper respiratory infection,Upper respiratory infection,1
XALKORI,Upper respiratory infection,Upper respiratory infection,1
XALKORI,Upper respiratory infection,d Upper respiratory,1
XALKORI,Upper respiratory infection,,0
XALKORI,Pulmonary embolism,Mediastinal Pulmonary embolism Gener,1
XALKORI,Pulmonary embolism,,0
XALKORI,Pulmonary embolism,Pulmonary,1
XALKORI,Pulmonary embolism,,0
XALKORI,Pulmonary embolism,embolism Gener,1
XALKORI,Pulmonary embolism,embolism Gener,1
XALKORI,Pulmonary embolism,Mediastinal,0
XALKORI,Pulmonary embolism,Mediastinal Pulmonary embolism Gener,1
XALKORI,Pulmonary embolism,,0
XALKORI,Edema,,0
XALKORI,Edema,tration Site Edema,1
XALKORI,Edema,,0
XALKORI,Edema,,0
XALKORI,Edema,Edema,1
XALKORI,Edema,,0
XALKORI,Edema,Edema,1
XALKORI,Edema,Edema,1
XALKORI,fatigue,neuralgia,0
XALKORI,fatigue,XALKORI fatigue,1
XALKORI,fatigue,fatigue,1
XALKORI,fatigue,fatigue,1
XALKORI,fatigue,fatigue,1
XALKORI,fatigue,fatigue,1
XALKORI,fatigue,fatigue,1
XALKORI,fatigue,treated with XALKORI fatigue,1
XALKORI,fatigue,,0
XALKORI,fatigue,,0
XALKORI,gait disturbance,fatigue neuropathy gait disturbance,1
XALKORI,gait disturbance,,0
XALKORI,gait disturbance,,0
XALKORI,gait disturbance,gait,1
XALKORI,gait disturbance,,0
XALKORI,gait disturbance,sensory,0
XALKORI,gait disturbance,,0
XALKORI,gait disturbance,disturbance,1
XALKORI,gait disturbance,peripheral neuropathy parasthesia peripheral sensory,0
XALKORI,hypoesthesia,dysesthesia gait hypoesthesia,1
XALKORI,muscular weakness,sensory neuropathy polyneuropathy,0
XALKORI,muscular weakness,,0
XALKORI,muscular weakness,,0
XALKORI,muscular weakness,hypoesthesia,0
XALKORI,muscular weakness,muscular weakness,1
XALKORI,neuralgia,neuralgia,1
XALKORI,neuralgia,neuralgia,1
XALKORI,neuralgia,polyneuropathy burning,0
XALKORI,neuralgia,weakness,0
XALKORI,neuralgia,neuralgia,1
XALKORI,neuralgia,neuralgia,1
XALKORI,peripheral neuropathy,neuropathy polyneuropathy,0
XALKORI,peripheral neuropathy,dysesthesia gait disturbance,0
XALKORI,parasthesia,neuralgia peripheral parasthesia,1
XALKORI,parasthesia,rash,0
XALKORI,parasthesia,neuropathy,0
XALKORI,parasthesia,parasthesia,1
XALKORI,parasthesia,,0
XALKORI,parasthesia,,0
XALKORI,parasthesia,,0
XALKORI,parasthesia,neuralgia peripheral parasthesia,1
XALKORI,peripheral sensory neuropathy,neuropathy,1
XALKORI,peripheral sensory neuropathy,peripheral sensory neuropathy,1
XALKORI,peripheral sensory neuropathy,,0
XALKORI,peripheral sensory neuropathy,neuralgia peripheral neuropathy peripheral sensory neuropathy,1
XALKORI,peripheral sensory neuropathy,,0
XALKORI,peripheral sensory neuropathy,sensory neuropathy,1
XALKORI,peripheral sensory neuropathy,,0
XALKORI,peripheral sensory neuropathy,,0
XALKORI,polyneuropathy,neuropathy parasthesia peripheral sensory polyneuropathy,1
XALKORI,polyneuropathy,neuropathy,0
XALKORI,burning sensation in skin,neuropathy,0
XALKORI,burning sensation in skin,sensory neuropathy burning sensation in,1
XALKORI,rash,,0
XALKORI,rash,,0
XALKORI,rash,sensation,0
XALKORI,rash,burning sensation in skin,0
XALKORI,rash,sensation in rash,1
XALKORI,acute respiratory distress syndrome,,0
XALKORI,acute respiratory distress syndrome,sensation,0
XALKORI,acute respiratory distress syndrome,in skin rash acute,1
XALKORI,acute respiratory distress syndrome,sensory,0
XALKORI,acute respiratory distress syndrome,in skin rash acute,1
XALKORI,acute respiratory distress syndrome,,0
XALKORI,acute respiratory distress syndrome,,0
XALKORI,acute respiratory distress syndrome,,0
XALKORI,acute respiratory distress syndrome,skin rash acute respiratory,1
XALKORI,ILD,ILD,1
XALKORI,ILD,cyst,0
XALKORI,ILD,ILD,1
XALKORI,ILD,ILD acute respiratory distress ILD,1
XALKORI,ILD,skin rash ILD acute,0
XALKORI,ILD,ILD,1
XALKORI,ILD,skin rash ILD acute respiratory distress,0
XALKORI,ILD,ILD,1
XALKORI,pneumonitis,renal cyst and hepatic failure,0
XALKORI,pneumonitis,pneumonitis,1
XALKORI,pneumonitis,pneumonitis,1
XALKORI,pneumonitis,TreatmentEmergent Laboratory,0
XALKORI,pneumonitis,pneumonitis,1
XALKORI,pneumonitis,pneumonitis,1
XALKORI,pneumonitis,pneumonitis,1
XALKORI,pneumonitis,burning sensation in skin rash ILD acute respiratory,0
XALKORI,pneumonitis,syndrome pneumonitis,1
XALKORI,renal cyst,respiratory distress syndrome ILD renal cyst,1
XALKORI,renal cyst,syndrome ILD pneumonitis,0
XALKORI,renal cyst,,0
XALKORI,renal cyst,distress syndrome ILD renal cyst,1
XALKORI,hepatic failure,hepatic failure,1
XALKORI,Neutropenia,,0
XALKORI,Neutropenia,,0
XALKORI,Neutropenia,Neutropenia,1
XALKORI,ALT elevation,ALT elevation,1
XALKORI,ALT elevation,ALT elevation,1
XALKORI,ALT elevation,,0
XALKORI,ALT elevation,ALT,1
XALKORI,Hypokalemia,Hypokalemia,1
XALKORI,Hypokalemia,Hypokalemia,1
XALKORI,Hypokalemia,Hypokalemia,1
XALKORI,Hypokalemia,Hypokalemia,1
XALKORI,Hypokalemia,Hypokalemia,1
XALKORI,Hypokalemia,Hypokalemia,1
XALKORI,Hypokalemia,Hypokalemia,1
XALKORI,Hypokalemia,,0
XALKORI,Hypokalemia,,0
XALKORI,Hypokalemia,Hypokalemia,1
XALKORI,Hypophosphatemia,,0
XALKORI,Hypophosphatemia,,0
XALKORI,Hypophosphatemia,,0
XALKORI,Hypophosphatemia,,0
XALKORI,Vision disorders,,0
XALKORI,Vision disorders,occurred in,0
XALKORI,Vision disorders,or vitreous floaters occurred,0
XALKORI,Vision disorders,photopsia blurred vision or vitreous,0
XALKORI,Vision disorders,Vision,1
XALKORI,Vision disorders,vitreous floaters occurred in,0
XALKORI,Vision disorders,,0
XALKORI,Vision disorders,disorders,1
XALKORI,Vision disorders,visual,0
XALKORI,Vision disorders,,0
XALKORI,visual impairment,Vision,0
XALKORI,visual impairment,Vision disorders most visual,1
XALKORI,visual impairment,impairment,1
XALKORI,photopsia,or vitreous floaters occurred in of patients,0
XALKORI,photopsia,visual impairment,0
XALKORI,photopsia,,0
XALKORI,photopsia,photopsia,1
XALKORI,photopsia,visual photopsia,1
XALKORI,photopsia,,0
XALKORI,photopsia,blurred vision or vitreous floaters occurred in,0
XALKORI,photopsia,photopsia,1
XALKORI,photopsia,vision or vitreous floaters occurred in of,0
XALKORI,photopsia,,0
XALKORI,blurred vision,impairment blurred,1
XALKORI,blurred vision,blurred vision,1
XALKORI,vitreous floaters,vitreous floaters,1
XALKORI,vitreous floaters,vitreous,1
XALKORI,vitreous floaters,floaters,1
XALKORI,vitreous floaters,blurred vision vitreous floaters,1
XALKORI,vitreous floaters,floaters,1
XALKORI,visual adverse reactions,patients with Grade and patients with Grade,0
XALKORI,visual adverse reactions,There were patients with Grade and patients with Grade visual impairment,0
XALKORI,visual adverse reactions,patients,0
XALKORI,visual impairment,on the Visual Symptom Assessment,0
XALKORI,visual impairment,Grade and patients with visual impairment,1
XALKORI,visual impairment,visual impairment,1
XALKORI,visual impairment,on the Visual Symptom Assessment Questionnaire,0
XALKORI,visual impairment,and patients with visual impairment,1
XALKORI,visual impairment,,0
XALKORI,visual impairment,with Grade and patients with Grade,0
XALKORI,visual impairment,impairment,1
XALKORI,visual impairment,visual,1
XALKORI,visual impairment,with visual impairment,1
XALKORI,visual impairment,visual impairment,1
XALKORI,visual impairment,visual,1
XALKORI,visual impairment,visual,1
XALKORI,visual impairment,VSAQALK,0
XALKORI,visual impairment,Questionnaire VSAQALK patients treated with XALKORI,0
XALKORI,visual impairment,VSAQALK patients treated with XALKORI,0
XALKORI,visual impairment,VSAQALK patients treated with XALKORI,0
XALKORI,vision disorder,patients,0
XALKORI,visual disturbances,arms in Studies and visual disturbances,1
XALKORI,Renal cysts,Renal Renal,1
XALKORI,Renal cysts,Renal cysts,1
XALKORI,Renal cysts,,0
XALKORI,Renal cysts,patient,0
XALKORI,renal cysts,,0
XALKORI,renal cysts,renal cysts,1
XALKORI,renal cysts,renal cysts,1
XALKORI,renal cysts,cysts,1
XALKORI,renal cysts,renal cysts,1
XALKORI,renal cysts,,0
XALKORI,renal cysts,,0
XALKORI,Local cystic invasion beyond the kidney,of abscess formation,0
XALKORI,Local cystic invasion beyond the kidney,patients were Local cystic invasion beyond the kidney,1
XALKORI,Local cystic invasion beyond the kidney,,0
XALKORI,Local cystic invasion beyond the kidney,beyond the kidney,1
XALKORI,Local cystic invasion beyond the kidney,beyond the kidney,1
XALKORI,Local cystic invasion beyond the kidney,in XALKORItreated patients were Local cystic invasion beyond the,1
XALKORI,Local cystic invasion beyond the kidney,acro,0
XALKORI,Local cystic invasion beyond the kidney,Local cystic invasion beyond the kidney,1
XALKORI,Local cystic invasion beyond the kidney,invasion beyond the kidney,1
XALKORI,Local cystic invasion beyond the kidney,kidney,1
XALKORI,abscess,abscess,1
XALKORI,renal abscesses,clinical trials renal,1
XALKORI,renal abscesses,abscesses,1
XALKORI,renal abscesses,,0
XALKORI,Hepatotoxicity,,0
XALKORI,Hepatotoxicity,Warnings,0
XALKORI,Hepatotoxicity,ctions are dis cussed in greater detail,1
XALKORI,Hepatotoxicity,ctions,1
XALKORI,Hepatotoxicity,ctions are dis cussed,1
XALKORI,Hepatotoxicity,see Warnings,0
XALKORI,Hepatotoxicity,ctions are dis cussed in greater,1
XALKORI,Hepatotoxicity,,0
XALKORI,Fatal,,0
XALKORI,Fatal,,0
XALKORI,Fatal,other sections of the labeling Hepatotoxicity see Warnings and Precau,0
XALKORI,Fatal,other sections of the labeling Hepatotoxicity see,0
XALKORI,Fatal,ssed  in greater detail in other,1
XALKORI,hepatotoxicity,n greater deta il in other sections of,1
XALKORI,hepatotoxicity,n greater,1
XALKORI,hepatotoxicity,n greater deta,1
XALKORI,hepatotoxicity,n,1
XALKORI,hepatotoxicity,n greater deta,1
XALKORI,Interstitial Lung Disease,,0
XALKORI,Interstitial Lung Disease,nings and,1
XALKORI,Interstitial Lung Disease,(5.,1
XALKORI,ILD,Warnings and Precautions Bradycardia see Warn,0
XALKORI,ILD,see Warnings and   ],1
XALKORI,ILD,  ],1
XALKORI,ILD,,0
XALKORI,ILD,  ],1
XALKORI,Pneumonitis,QT Int,1
XALKORI,Pneumonitis,"
 *  QT Int",1
XALKORI,Pneumonitis,Int,1
XALKORI,Pneumonitis,erval Prolongation see Warnings and Precautions Bradycardia see Warnings and Prec,0
XALKORI,Pneumonitis,see Warnings and * QT,1
XALKORI,Pneumonitis,* QT Int,1
XALKORI,QT Interval Prolongation,see Warnings and Precautio,0
XALKORI,QT Interval Prolongation,see Warnings and ns (5.4) ] *,1
XALKORI,QT Interval Prolongation,Visual Loss see Warnings,0
XALKORI,QT Interval Prolongation,"and ns (5.4)  ]  
 *  Severe",1
XALKORI,QT Interval Prolongation,"ns (5.4)  ]  
 *  Severe",1
XALKORI,QT Interval Prolongation,Warnings,0
XALKORI,QT Interval Prolongation,* Severe,1
XALKORI,QT Interval Prolongation,,0
XALKORI,QT Interval Prolongation,Loss see Warnings and Precautions EXCERPT The most common adverse reac,0
XALKORI,QT Interval Prolongation,] * Severe,1
XALKORI,Bradycardia,Pfizer Inc,0
XALKORI,Bradycardia,,0
XALKORI,Bradycardia,,0
XALKORI,Bradycardia,Pfizer Inc at or FDA at FDA or,0
XALKORI,Bradycardia,infection decreased appetite and To report,1
XALKORI,Bradycardia,infection,0
XALKORI,bradycardia,at FDA or,0
XALKORI,bradycardia,con,1
XALKORI,bradycardia,"report SUSPECTED ADVERSE CTIONS,",1
XALKORI,bradycardia,tact Pfizer,0
XALKORI,Visual Loss,Because nical trial,1
XALKORI,Visual Loss,nical trial,1
XALKORI,Visual Loss,Clinical Trials Experience Because nical,1
XALKORI,Visual Loss,Because nical trial,1
XALKORI,Visual Loss,Trials,0
XALKORI,Visual Loss,s are conducted under widely varying conditions adverse reaction rates observed,0
XALKORI,Visual Loss,Clinical Trials Experience Because nical trial,1
XALKORI,Visual Loss,wwwfdagovmedwatch,0
XALKORI,Embryofetal Toxicity,the clinic,1
XALKORI,Embryofetal Toxicity,the clinic,1
XALKORI,Embryofetal Toxicity,compared rates,1
XALKORI,Embryofetal Toxicity,adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to,0
XALKORI,Embryofetal Toxicity,,0
XALKORI,Embryofetal Toxicity,clinic,1
XALKORI,Embryofetal Toxicity,be directly compared  rates in the clinic,1
XALKORI,Embryofetal Toxicity,be directly compared  rates in the clinic,1
XALKORI,Embryofetal Toxicity,cannot be directly compared  rates in the clinic,1
XALKORI,Embryofetal Toxicity,rates in,1
XALKORI,fetal harm,XALKORI,0
XALKORI,fetal harm,in the clinical trials of a drug cannot be directly compared to,0
XALKORI,elevations in ALT,nausea vomiting constipation,0
XALKORI,elevations in ALT,"nausea vomiting constipation a, elevated trans",1
XALKORI,elevations in ALT,,0
XALKORI,elevations in ALT,"diarrhea nausea vomiting constipation a,",1
XALKORI,elevations in ALT,"vomiting constipation a, elevated trans",1
XALKORI,elevations in ALT,"a, elevated trans",1
XALKORI,elevations in ALT,"diarrhea nausea vomiting constipation a, elevated",1
XALKORI,elevations in ALT,"diarrhea nausea vomiting constipation a,",1
XALKORI,elevations in ALT,and,0
XALKORI,elevations in ALT,"a,",1
XALKORI,elevated transaminases,patients with ALKpositive metastatic NSCLC who had not,0
XALKORI,elevated transaminases,data in  are derived from 340 ,1
XALKORI,elevated transaminases,340,1
XALKORI,elevated transaminases,Untreated ALKPositive Metastatic,0
XALKORI,elevated transaminases,treatment for,0
XALKORI,elevated transaminases,,0
XALKORI,elevated transaminases,,0
XALKORI,elevated transaminases,Study The data in are derived,1
XALKORI,elevated transaminases,The data in are,1
XALKORI,Transaminase elevations,disease,0
XALKORI,Transaminase elevations,with ALK-positiv,1
XALKORI,fatal,area under the,0
XALKORI,interstitial lung disease, 5 or 6 mg?min/mL (n=78).,1
XALKORI,interstitial lung disease,curve AUC  5 or 6 mg?min/mL (n=78).,1
XALKORI,interstitial lung disease,mg?min/mL (n=78).,1
XALKORI,interstitial lung disease,given by intravenous infusion every weeks for up to cycles,0
XALKORI,interstitial lung disease,the,0
XALKORI,interstitial lung disease, 5 or 6 mg?min/mL (n=78).,1
XALKORI,interstitial lung disease,concentrationtime curve AUC  5 or 6 mg?min/mL (n=78).,1
XALKORI,interstitial lung disease,curve AUC 5 or 6,1
XALKORI,interstitial lung disease,mg?min/mL (n=78).,1
XALKORI,interstitial lung disease,cycles in,0
XALKORI,interstitial lung disease,the concentrationtime curve AUC 5,1
XALKORI,interstitial lung disease,weeks for up to cycles in the absence,0
XALKORI,interstitial lung disease,5,1
XALKORI,interstitial lung disease,6 mg?min/mL (n=78).,1
XALKORI,interstitial lung disease,the,0
XALKORI,interstitial lung disease,,0
XALKORI,ILD,to produce an area under the concentrationtime curve AUC of or mgminmL n C,0
XALKORI,ILD,n hem,1
XALKORI,ILD,hem,1
XALKORI,ILD,up to cycles in the absence of,0
XALKORI,ILD,,0
XALKORI,ILD,hem,1
XALKORI,ILD,by intravenous infusion every weeks for up,0
XALKORI,ILD,the absence,0
XALKORI,ILD,area under the concentrationtime curve AUC of or mgminmL n,0
XALKORI,ILD,hem,1
XALKORI,ILD,,0
XALKORI,ILD,produce,0
XALKORI,ILD,of or mgminmL n hem,1
XALKORI,pneumonitis,n Chemot,0
XALKORI,pneumonitis,was,1
XALKORI,pneumonitis,to produce an area,0
XALKORI,pneumonitis,was,1
XALKORI,ILD,tox,1
XALKORI,ILD,and tum,0
XALKORI,ILD,to cycles,0
XALKORI,ILD,tox,1
XALKORI,ILD,absence of,0
XALKORI,ILD,infusion every weeks for up to,0
XALKORI,ILD,of doselimiting tox,1
XALKORI,ILD,on study,0
XALKORI,ILD,on  wi,1
XALKORI,ILD,,0
XALKORI,ILD, wi,1
XALKORI,ILD, wi,1
XALKORI,ILD,on  wi,1
XALKORI,ILD,,0
XALKORI,ILD,documented disease prog,0
XALKORI,fatal,no additional anticancer,0
XALKORI,fatal,,0
XALKORI,fatal,with no additional treat,1
XALKORI,fatal,treat,1
XALKORI,fatal,duration,0
XALKORI,ILD,ent,1
XALKORI,ILD,additional anticancer ent,1
XALKORI,ILD,,0
XALKORI,ILD,ent,1
XALKORI,ILD,After cycles patients remained on,0
XALKORI,ILD,on study with no additional anticancer treatm,0
XALKORI,ILD,ent,1
XALKORI,ILD,ent,1
XALKORI,QTc prolongation,median age was of patients were,1
XALKORI,QTc prolongation,who were treated,0
XALKORI,QTc prolongation,was of patients,1
XALKORI,QTc prolongation,the median age was of,1
XALKORI,QTc prolongation,of patients were,1
XALKORI,QTc prolongation,years A total of of patients were female,0
XALKORI,QTc prolongation,of patients,1
XALKORI,QTc prolongation,of patients were,1
XALKORI,QTc prolongation,patients were,1
XALKORI,Symptomatic bradycardia,,0
XALKORI,Symptomatic bradycardia,for Grades with KORI than Chemotherapy ,1
XALKORI,Symptomatic bradycardia,Higher for Grades with,0
XALKORI,bradycardia,71)   Chemo,1
XALKORI,heart rate less than 50 beats per minute,Grade,1
XALKORI,visual field defect,,0
XALKORI,visual field defect,Dyspepsia           2         Dysphagia,1
XALKORI,visual field defect,          2         Dysphagia,1
XALKORI,visual field defect,          2         Dysphagia,1
XALKORI,visual field defect,Dyspepsia,0
XALKORI,visual field defect,          2         Dysphagia,1
XALKORI,visual field defect,Dyspepsia           2         Dysphagia,1
XALKORI,visual field defect,          2         Dysphagia,1
XALKORI,visual field defect,          2         Dysphagia,1
XALKORI,visual field defect,Dyspepsia,0
XALKORI,vision loss,Dyspepsia,0
XALKORI,Optic atrophy,Dysphagia               Abdominal pain,1
XALKORI,Optic atrophy,,0
XALKORI,Optic atrophy,Dysphagia               Abdominal,1
XALKORI,Optic atrophy,Dysphagia,0
XALKORI,optic nerve disorder,              10     Abdominal pain,1
XALKORI,optic nerve disorder,              10     Abdominal pain,1
XALKORI,vision loss,Dysphagia    1        Abdominal,1
XALKORI,vision loss,   1        Abdominal,1
XALKORI,vision loss,Dysphagia,0
XALKORI,fetal harm,12         Investigations,1
XALKORI,fetal harm,,0
XALKORI,fetal harm,12         Investigations,1
XALKORI,fetal harm,12         Investigations,1
XALKORI,fetal harm,12         Investigations,1
XALKORI,fetal harm,Investigations,0
XALKORI,fetal harm,Investigations,0
XALKORI,fetal harm,infection,0
XALKORI,fetal harm,12         Investigations,1
XALKORI,embryotoxicity,Tissue Disorders,0
XALKORI,embryotoxicity,,0
XALKORI,embryotoxicity,"          
    Musculoskeletal",1
CLEVIPREX,Hypotension,Tachycardia see Warnings,0
CLEVIPREX,Hypotension,,0
CLEVIPREX,Hypotension,Warnings and Precautions EXCERPT,0
CLEVIPREX,Hypotension,,0
CLEVIPREX,Hypotension,EXCERPT,0
CLEVIPREX,Hypotension,Hypotension and Reflex Tachycardia see Warnings,1
CLEVIPREX,Hypotension,Reflex Tachycardia see Warnings,0
CLEVIPREX,Reflex Tachycardia,Hypotension Reflex Tachycardia see Warnings,1
CLEVIPREX,Reflex Tachycardia,Hypotension Reflex,1
CLEVIPREX,Reflex Tachycardia,Reflex Tachycardia see Warnings,1
CLEVIPREX,Reflex Tachycardia,labeling,0
CLEVIPREX,Reflex Tachycardia,Tachycardia see Warnings,1
CLEVIPREX,Reflex Tachycardia,in the labeling,0
CLEVIPREX,Reflex Tachycardia,in the labeling Hypotension Reflex Tachycardia see Warnings,1
CLEVIPREX,Reflex Tachycardia,Tachycardia see Warnings,1
CLEVIPREX,headache,SUSPECTED,0
CLEVIPREX,headache,headache nausea and,1
CLEVIPREX,headache,Most common,0
CLEVIPREX,headache,are,0
CLEVIPREX,headache,and vomiting To report SUSPECTED ADVERSE REACTIONS contact The,0
CLEVIPREX,headache,headache nausea and,1
CLEVIPREX,headache,,0
CLEVIPREX,nausea,nausea and vomiting,1
CLEVIPREX,nausea,Most common,0
CLEVIPREX,nausea,nausea and vomiting,1
CLEVIPREX,nausea,nausea and vomiting,1
CLEVIPREX,nausea,report SUSPECTED,0
CLEVIPREX,vomiting,vomiting To report,1
CLEVIPREX,vomiting,reactions are headache nausea and,0
CLEVIPREX,vomiting,are headache nausea and,0
CLEVIPREX,vomiting,ADVERSE REACTIONS contact The Medicines Company at,0
CLEVIPREX,vomiting,Medicines Company,0
CLEVIPREX,vomiting,Most common adverse reactions are headache nausea and,0
CLEVIPREX,vomiting,vomiting To report,1
CLEVIPREX,vomiting,vomiting To report,1
CLEVIPREX,vomiting,M,0
CLEVIPREX,vomiting,vomiting To report,1
CLEVIPREX,Acute renal failure,,0
CLEVIPREX,Acute renal failure,,0
CLEVIPREX,Acute renal failure,Acute renal failure,1
CLEVIPREX,Acute renal failure,,0
CLEVIPREX,Acute renal failure,,0
CLEVIPREX,Acute renal failure,Acute renal,1
CLEVIPREX,Acute renal failure,,0
CLEVIPREX,Acute renal failure,,0
CLEVIPREX,Atrial fibrillation,Atrial fibrillation,1
CLEVIPREX,Atrial fibrillation,Atrial,1
CLEVIPREX,Atrial fibrillation,,0
CLEVIPREX,Atrial fibrillation,,0
CLEVIPREX,Atrial fibrillation,Atrial,1
CLEVIPREX,Atrial fibrillation,,0
CLEVIPREX,headache,headache,1
CLEVIPREX,headache,headache,1
CLEVIPREX,headache,headache,1
CLEVIPREX,headache,,0
CLEVIPREX,headache,nausea and vomiting The incidence of adverse events leading to study drug,0
CLEVIPREX,headache,nausea and vomiting The incidence of adverse events leading to study,0
CLEVIPREX,nausea,for Cleviprex in severe hypertension included,0
CLEVIPREX,nausea,for Cleviprex in,0
CLEVIPREX,nausea,nausea,1
CLEVIPREX,nausea,vomiting The incidence of,0
CLEVIPREX,nausea,,0
CLEVIPREX,nausea,of adverse,0
CLEVIPREX,nausea,headache,0
CLEVIPREX,vomiting,to study drug,0
CLEVIPREX,vomiting,vomiting,1
CLEVIPREX,vomiting,Cleviprex,0
CLEVIPREX,vomiting,,0
CLEVIPREX,vomiting,headache nausea vomiting,1
CLEVIPREX,vomiting,nausea vomiting,1
CLEVIPREX,myocardial infarction,,0
CLEVIPREX,myocardial infarction,essential hypertension myocardial,1
CLEVIPREX,myocardial infarction,severe or essential hypertension,0
CLEVIPREX,myocardial infarction,essential hypertension myocardial,1
CLEVIPREX,myocardial infarction,infarction,1
CLEVIPREX,myocardial infarction,essential hypertension includedCardiac,0
CLEVIPREX,myocardial infarction,and Other,0
CLEVIPREX,cardiac arrest,infarction,0
CLEVIPREX,cardiac arrest,,0
CLEVIPREX,cardiac arrest,cardiac arrest,1
CLEVIPREX,cardiac arrest,arrest,1
CLEVIPREX,cardiac arrest,cardiac arrest,1
CLEVIPREX,increased blood triglycerides,during,0
CLEVIPREX,increased blood triglycerides,use of increased blood triglycerides,1
CLEVIPREX,ileus,hypersensitivity hypotension nausea decreased oxygen,0
CLEVIPREX,ileus,ileus,1
CLEVIPREX,ileus,postapproval use of Cleviprex increased,0
CLEVIPREX,ileus,,0
CLEVIPREX,hypotension,use,0
CLEVIPREX,hypotension,triglycerides ileus hypotension,1
CLEVIPREX,hypotension,possible pulmonary shunting and reflex tachycardia,0
CLEVIPREX,hypotension,increased blood triglycerides ileus,0
CLEVIPREX,hypotension,hypotension,1
CLEVIPREX,hypotension,ileus hypotension,1
CLEVIPREX,hypotension,hypotension,1
CLEVIPREX,hypotension,hypotension,1
CLEVIPREX,hypotension,during postapproval,0
CLEVIPREX,hypotension,hypotension,1
CLEVIPREX,nausea,nausea,1
CLEVIPREX,nausea,of,0
CLEVIPREX,nausea,,0
CLEVIPREX,nausea,nausea,1
CLEVIPREX,nausea,nausea,1
CLEVIPREX,nausea,hypersensitivity,0
CLEVIPREX,nausea,nausea,1
CLEVIPREX,pulmonary shunting,and,0
CLEVIPREX,pulmonary shunting,,0
CLEVIPREX,pulmonary shunting,pulmonary shunting,1
CLEVIPREX,reflex tachycardia,"Warnings and     
      EXCERPT",1
CLEVIPREX,reflex tachycardia,"    
      EXCERPT",1
CLEVIPREX,reflex tachycardia,"    
      EXCERPT",1
CLEVIPREX,reflex tachycardia,Warnings and Precautions,0
CLEVIPREX,reflex tachycardia,see Warnings and,0
CLEVIPREX,reflex tachycardia,Hypotension and Reflex Tachycardia see Warnings and Precautions,0
CLEVIPREX,reflex tachycardia,nausea and vomiting,0
CLEVIPREX,reflex tachycardia,"    
      EXCERPT",1
CLEVIPREX,reflex tachycardia,Precautions,0
CLEVIPREX,negative inotropic effects,or,0
CLEVIPREX,negative inotropic effects,conta,0
CLEVIPREX,negative inotropic effects,ADVERSE,0
CLEVIPREX,negative inotropic effects,ADVERSE REACTIONS conta,0
CLEVIPREX,exacerbate heart failure,or FD,1
CLEVIPREX,systemic hypotension,,0
CLEVIPREX,systemic hypotension,as a continuous infusion in,0
CLEVIPREX,systemic hypotension,patien,1
CLEVIPREX,systemic hypotension,,0
CLEVIPREX,systemic hypotension,was infused as a continuous,0
CLEVIPREX,systemic hypotension,a continuous infusion in additional 93,1
CLEVIPREX,systemic hypotension,infused as a continuous infusion,0
CLEVIPREX,systemic hypotension,,0
CLEVIPREX,systemic hypotension,infusion in an,0
CLEVIPREX,systemic hypotension,infusion in an,0
CLEVIPREX,negative inotropic effects,in placebo-controll,1
CLEVIPREX,exacerbate heart failure,,0
CLEVIPREX,exacerbate heart failure,"in placebocontrolled rioperative studies. 
  ",1
CLEVIPREX,exacerbate heart failure,reactions in placebocontrolled,0
CLEVIPREX,exacerbate heart failure,"reactions in placebocontrolled rioperative studies. 
  ",1
LUMIZYME,hypersensitivity reactions,EXCERPT The most frequently reported adverse reactions in clinical trials,0
LUMIZYME,hypersensitivity reactions,and included anaphylaxis rash pyrexia flushingfeeling hot urticaria headache hyperhidrosis,0
LUMIZYME,hypersensitivity reactions,,0
LUMIZYME,hypersensitivity reactions,,0
LUMIZYME,hypersensitivity reactions,clinical trials hypersensitivity reactions,1
LUMIZYME,hypersensitivity reactions,,0
LUMIZYME,anaphylaxis,anaphylaxis,1
LUMIZYME,anaphylaxis,,0
LUMIZYME,anaphylaxis,clinical trials were hypersensitivity reactions,0
LUMIZYME,rash,reactions and included rash,1
LUMIZYME,rash,in clinical trials were hypersensitivity,0
LUMIZYME,flushing,flushing,1
LUMIZYME,flushing,decreased oxygen saturation,0
LUMIZYME,flushing,clinical trials were hypersensitivity reactions and included anaphylaxis rash pyrexia,0
LUMIZYME,flushing,flushing,1
LUMIZYME,flushing,included anaphylaxis rash flushing,1
LUMIZYME,flushing,and included anaphylaxis rash flushing,1
LUMIZYME,flushing,flushing,1
LUMIZYME,flushing,included anaphylaxis rash flushing,1
LUMIZYME,flushing,flushing,1
LUMIZYME,feeling hot,rash pyrexia feeling,1
LUMIZYME,feeling hot,,0
LUMIZYME,feeling hot,feeling hot,1
LUMIZYME,feeling hot,and included anaphylaxis,0
LUMIZYME,urticaria,were hypersensitivity reactions and included anaphylaxis rash pyrexia flushingfeeling hot,0
LUMIZYME,urticaria,urticaria,1
LUMIZYME,urticaria,urticaria,1
LUMIZYME,urticaria,chest,0
LUMIZYME,urticaria,tachypnea,0
LUMIZYME,headache,headache,1
LUMIZYME,headache,hot urticaria,0
LUMIZYME,headache,rash pyrexia flushingfeeling hot headache,1
LUMIZYME,headache,flushingfeeling hot,0
LUMIZYME,headache,headache,1
LUMIZYME,headache,oxygen saturation tachycardia tachypnea chest,0
LUMIZYME,headache,headache,1
LUMIZYME,headache,headache,1
LUMIZYME,headache,headache,1
LUMIZYME,nausea,,0
LUMIZYME,nausea,rash pyrexia flushingfeeling,0
LUMIZYME,nausea,urticaria headache hyperhidrosis,0
LUMIZYME,decreased oxygen saturation,decreased oxygen,1
LUMIZYME,decreased oxygen saturation,oxygen saturation,1
LUMIZYME,decreased oxygen saturation,nausea decreased oxygen saturation,1
LUMIZYME,decreased oxygen saturation,agitation cyanosis,0
LUMIZYME,decreased oxygen saturation,,0
LUMIZYME,tachycardia,,0
LUMIZYME,tachycardia,tachycardia,1
LUMIZYME,tachycardia,tachycardia,1
LUMIZYME,tachycardia,,0
LUMIZYME,tachycardia,tachycardia,1
LUMIZYME,tachycardia,twitching agitation cyanosis,0
LUMIZYME,tachycardia,chest discomfort dizziness muscle,0
LUMIZYME,tachycardia,agitation cyanosis erythema hypertens,0
LUMIZYME,chest discomfort,decreased oxygen saturation tachycardia chest discomfort,1
LUMIZYME,chest discomfort,tachycardia tachypnea,0
LUMIZYME,chest discomfort,hyperhidrosis nausea cough decreased oxygen saturation tachycardia,0
LUMIZYME,dizziness,ri,0
LUMIZYME,dizziness,decreased oxygen saturation tachycardia,0
LUMIZYME,dizziness,dizziness,1
LUMIZYME,dizziness,erythema hypertensionincreased blood pressure pallor,0
LUMIZYME,dizziness,pallor ri,0
LUMIZYME,dizziness,tachypnea chest discomfort,0
LUMIZYME,dizziness,,0
LUMIZYME,muscle twitching,,0
LUMIZYME,muscle twitching,hypertensionincreased blood pressure pallor rigors tremor vomi,0
LUMIZYME,muscle twitching,hypertensionincreased blood pressure,0
LUMIZYME,muscle twitching,rigors tremor vomi,0
LUMIZYME,muscle twitching,discomfort muscle,1
LUMIZYME,muscle twitching,muscle twitching,1
LUMIZYME,agitation,tremor,0
LUMIZYME,agitation,twitching,0
LUMIZYME,agitation,,0
LUMIZYME,agitation,agitation,1
LUMIZYME,agitation,tachycardia,0
LUMIZYME,agitation,vomiting fatig,0
LUMIZYME,agitation,hypertensionincreased blood,0
LUMIZYME,agitation,agitation,1
LUMIZYME,agitation,agitation,1
LUMIZYME,agitation,agitation,1
LUMIZYME,hypertension,hypertension,1
LUMIZYME,hypertension,hypertension,1
LUMIZYME,hypertension,increased blood pressure pallor,0
LUMIZYME,hypertension,hypertension,1
LUMIZYME,increased blood pressure,,0
LUMIZYME,increased blood pressure,rigors tremor vomiting fatigue,0
LUMIZYME,increased blood pressure,increased,1
LUMIZYME,increased blood pressure,ADVERSE R,0
LUMIZYME,increased blood pressure,report SUSPECTED,0
LUMIZYME,increased blood pressure,twitching agitation cyanosis erythema increased blood pressure,1
LUMIZYME,increased blood pressure,discomfort dizziness muscle twitching,0
LUMIZYME,increased blood pressure,agitation cyanosis erythema hypertension,0
LUMIZYME,pallor,pallor,1
LUMIZYME,pallor,pallor,1
LUMIZYME,rigors,rigors,1
LUMIZYME,rigors,,0
LUMIZYME,vomiting,REACTIONS contact Genzyme at,0
LUMIZYME,vomiting,,0
LUMIZYME,vomiting,vomiting,1
LUMIZYME,fatigue,fatigue,1
LUMIZYME,fatigue,tremor,0
LUMIZYME,myalgia,,0
LUMIZYME,myalgia,pallor rigors tremor vomiting,0
LUMIZYME,myalgia,vomiting fatigue myalgia,1
LUMIZYME,myalgia,myalgia,1
LUMIZYME,myalgia,erythema hypertensionincreased blood pressure,0
LUMIZYME,myalgia,rigors tremor vomiting fatigue myalgia,1
LUMIZYME,myalgia,or,0
LUMIZYME,myalgia,pressure pallor,0
LUMIZYME,hypersensitivity reactions,treatment hypersensitivity reactions,1
LUMIZYME,hypersensitivity reactions,following alglucosidase alfa treatment hypersensitivity,1
LUMIZYME,hypersensitivity reactions,hypersensitivity,1
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions,1
LUMIZYME,hypersensitivity reactions,pyrexia flushingfeeling hot urticaria headache,0
LUMIZYME,hypersensitivity reactions,,0
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions,1
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions,1
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions,1
LUMIZYME,hypersensitivity reactions,trials the,0
LUMIZYME,anaphylaxis,hot,0
LUMIZYME,anaphylaxis,hypersensitivity reactions and included,0
LUMIZYME,anaphylaxis,flushingfeeling hot,0
LUMIZYME,anaphylaxis,anaphylaxis,1
LUMIZYME,anaphylaxis,anaphylaxis,1
LUMIZYME,anaphylaxis,alfa treatment were hypersensitivity,0
LUMIZYME,anaphylaxis,were hypersensitivity,0
LUMIZYME,anaphylaxis,,0
LUMIZYME,anaphylaxis,anaphylaxis,1
LUMIZYME,anaphylaxis,flushingfeeling hot urticaria headache,0
LUMIZYME,rash,rash,1
LUMIZYME,rash,reactions and included rash,1
LUMIZYME,rash,reactions and included rash,1
LUMIZYME,rash,headache hyperhidrosis nausea cough,0
LUMIZYME,rash,rash,1
LUMIZYME,rash,treatment were hypersensitivity reactions and,0
LUMIZYME,pyrexia,reactions and included anaphylaxis pyrexia,1
LUMIZYME,pyrexia,,0
LUMIZYME,pyrexia,hypersensitivity reactions and included anaphylaxis,0
LUMIZYME,pyrexia,anaphylaxis pyrexia,1
LUMIZYME,pyrexia,alglucosidase alfa treatment were hypersensitivity,0
LUMIZYME,pyrexia,hypersensitivity reactions and,0
LUMIZYME,pyrexia,pyrexia,1
LUMIZYME,pyrexia,were hypersensitivity reactions and,0
LUMIZYME,pyrexia,rash,0
LUMIZYME,pyrexia,pyrexia,1
LUMIZYME,flushing,,0
LUMIZYME,flushing,and included anaphylaxis rash flushing,1
LUMIZYME,flushing,flushing,1
LUMIZYME,flushing,flushing,1
LUMIZYME,feeling hot,,0
LUMIZYME,feeling hot,anaphylaxis rash pyrexia feeling hot,1
LUMIZYME,feeling hot,feeling hot,1
LUMIZYME,feeling hot,hot,1
LUMIZYME,feeling hot,included,0
LUMIZYME,feeling hot,,0
LUMIZYME,feeling hot,nausea cough decreased oxygen saturation tachycardia,0
LUMIZYME,feeling hot,rash pyrexia feeling,1
LUMIZYME,urticaria,pyrexia flushingfeeling urticaria,1
LUMIZYME,urticaria,hyperhidrosis nausea,0
LUMIZYME,urticaria,hypersensitivity reactions and included anaphylaxis rash pyrexia flushingfeeling hot,0
LUMIZYME,urticaria,anaphylaxis rash pyrexia flushingfeeling urticaria,1
LUMIZYME,urticaria,headache hyperhidrosis nausea cough,0
LUMIZYME,headache,headache,1
LUMIZYME,headache,flushingfeeling hot,0
LUMIZYME,headache,hot headache,1
LUMIZYME,headache,pyrexia,0
LUMIZYME,headache,decreased,0
LUMIZYME,headache,cough decreased oxygen saturation tachycardia tachypnea chest discomfor,0
LUMIZYME,headache,saturation tachycardia,0
LUMIZYME,hyperhidrosis,hyperhidrosis,1
LUMIZYME,hyperhidrosis,reactions and included anaphylaxis rash pyrexia,0
LUMIZYME,hyperhidrosis,,0
LUMIZYME,hyperhidrosis,flushingfeeling hot urticaria headache,0
LUMIZYME,hyperhidrosis,hyperhidrosis,1
LUMIZYME,hyperhidrosis,hyperhidrosis,1
LUMIZYME,hyperhidrosis,hyperhidrosis,1
LUMIZYME,hyperhidrosis,oxygen saturation tachycardia tachypnea chest discomfort,0
LUMIZYME,hyperhidrosis,hot urticaria hyperhidrosis,1
LUMIZYME,nausea,included,0
LUMIZYME,nausea,headache nausea,1
LUMIZYME,nausea,nausea,1
LUMIZYME,nausea,nausea,1
LUMIZYME,nausea,nausea,1
LUMIZYME,nausea,nausea,1
LUMIZYME,nausea,muscle tw,0
LUMIZYME,decreased oxygen saturation,,0
LUMIZYME,decreased oxygen saturation,headache hyperhidrosis nausea decreased oxygen saturation,1
LUMIZYME,decreased oxygen saturation,saturation,1
LUMIZYME,decreased oxygen saturation,oxygen saturation,1
LUMIZYME,tachycardia,tachycardia,1
LUMIZYME,tachypnea,muscle twitching agitation cyanosis,0
LUMIZYME,tachypnea,discomfort,0
LUMIZYME,tachypnea,tachypnea,1
LUMIZYME,tachypnea,saturation,0
LUMIZYME,tachypnea,urticaria headache hyperhidrosis nausea cough decreased oxygen,0
LUMIZYME,tachypnea,tachypnea,1
LUMIZYME,tachypnea,tachypnea,1
LUMIZYME,tachypnea,tachypnea,1
LUMIZYME,tachypnea,tachypnea,1
LUMIZYME,chest discomfort,saturation tachycardia chest discomfort,1
LUMIZYME,chest discomfort,discomfort,1
LUMIZYME,chest discomfort,blood pressure,0
LUMIZYME,chest discomfort,saturation tachycardia,0
LUMIZYME,dizziness,dizziness,1
LUMIZYME,dizziness,dizziness,1
LUMIZYME,muscle twitching,discomfort dizziness,0
LUMIZYME,muscle twitching,,0
LUMIZYME,muscle twitching,,0
LUMIZYME,muscle twitching,saturation tachycardia,0
LUMIZYME,muscle twitching,tachycardia tachypnea chest discomfort muscle,1
LUMIZYME,muscle twitching,tachypnea chest discomfort muscle twitching,1
LUMIZYME,agitation,tachycardia tachypnea chest,0
LUMIZYME,agitation,,0
LUMIZYME,agitation,erythema hypertensionincreased,0
LUMIZYME,agitation,chest discomfort dizziness muscle agitation,1
LUMIZYME,agitation,rigors,0
LUMIZYME,agitation,agitation,1
LUMIZYME,agitation,oxygen saturation tachycardia tachypnea chest discomfort dizziness,0
LUMIZYME,agitation,blood pressure pallor,0
LUMIZYME,agitation,tachypnea chest discomfort,0
LUMIZYME,cyanosis,cyanosis,1
LUMIZYME,erythema,and,0
LUMIZYME,erythema,tachypnea chest discomfort,0
LUMIZYME,erythema,erythema,1
LUMIZYME,erythema,and myalgia,0
LUMIZYME,erythema,,0
LUMIZYME,erythema,,0
LUMIZYME,hypertension,,0
LUMIZYME,hypertension,hypertension,1
LUMIZYME,hypertension,fatigue and myalgia,0
LUMIZYME,hypertension,hypertension,1
LUMIZYME,increased blood pressure,,0
LUMIZYME,increased blood pressure,erythema increased blood pressure,1
LUMIZYME,increased blood pressure,pressure,1
LUMIZYME,increased blood pressure,cyanosis erythema increased,1
LUMIZYME,pallor,muscle twitching agitation cyanosis,0
LUMIZYME,pallor,pallor,1
LUMIZYME,pallor,hypertensionincreased blood,0
LUMIZYME,pallor,pallor,1
LUMIZYME,pallor,,0
LUMIZYME,pallor,pallor,1
LUMIZYME,rigors,pressure,0
LUMIZYME,rigors,rigors,1
LUMIZYME,rigors,rigors,1
LUMIZYME,rigors,agitation cyanosis,0
LUMIZYME,rigors,cyanosis erythema hypertensionincreased blood,0
LUMIZYME,rigors,rigors,1
LUMIZYME,rigors,rigors,1
LUMIZYME,tremor,tremor,1
LUMIZYME,tremor,tremor,1
LUMIZYME,tremor,and,0
LUMIZYME,tremor,tremor,1
LUMIZYME,tremor,tremor,1
LUMIZYME,vomiting,agitation cyanosis erythema,0
LUMIZYME,fatigue,fatigue,1
LUMIZYME,fatigue,rigors tremor,0
LUMIZYME,fatigue,fatigue,1
LUMIZYME,fatigue,pressure pallor rigors tremor vomiting,0
LUMIZYME,anaphylaxis,serious adverse,0
LUMIZYME,anaphylaxis,The most serious,0
LUMIZYME,anaphylaxis,alglucosidase alfa treatment anaphylaxis,1
LUMIZYME,anaphylaxis,and acute cardiorespiratory failure The most common adverse reactions requiring intervention i,0
LUMIZYME,anaphylaxis,The most common adverse reactions requiring intervention,0
LUMIZYME,anaphylaxis,anaphylaxis,1
LUMIZYME,anaphylaxis,anaphylaxis,1
LUMIZYME,acute cardiorespiratory failure,most common adverse reactions requiring,0
LUMIZYME,acute cardiorespiratory failure,treatment included anaphylaxis acute cardiorespiratory,1
LUMIZYME,acute cardiorespiratory failure,treatment included anaphylaxis,0
LUMIZYME,acute cardiorespiratory failure,reactions reported with alglucosidase,0
LUMIZYME,acute cardiorespiratory failure,acute cardiorespiratory failure,1
LUMIZYME,acute cardiorespiratory failure,reactions requiring intervention in clinical trials,0
LUMIZYME,hypersensitivity reactions,rash,0
LUMIZYME,hypersensitivity reactions,,0
LUMIZYME,hypersensitivity reactions,clinical trials hypersensitivity reactions,1
LUMIZYME,hypersensitivity reactions,pyrexia,0
LUMIZYME,rash,rash,1
LUMIZYME,rash,rash,1
LUMIZYME,rash,rash,1
LUMIZYME,rash,rash,1
LUMIZYME,rash,rash,1
LUMIZYME,rash,,0
LUMIZYME,rash,oxygen,0
LUMIZYME,pyrexia,alglucosidase,0
LUMIZYME,pyrexia,and included pyrexia,1
LUMIZYME,pyrexia,pyrexia,1
LUMIZYME,pyrexia,pyrexia,1
LUMIZYME,pyrexia,alfa and included pyrexia,1
LUMIZYME,pyrexia,,0
LUMIZYME,pyrexia,rash,0
LUMIZYME,pyrexia,pyrexia,1
LUMIZYME,urticaria,in of patients treated with,0
LUMIZYME,urticaria,and included,0
LUMIZYME,flushing,flushing,1
LUMIZYME,decreased oxygen saturation,decreased,1
LUMIZYME,decreased oxygen saturation,decreased,1
LUMIZYME,decreased oxygen saturation,included rash pyrexia urticaria decreased oxygen saturation,1
LUMIZYME,decreased oxygen saturation,rash pyrexia urticaria decreased oxygen saturation,1
LUMIZYME,decreased oxygen saturation,alfa and included rash pyrexia,0
LUMIZYME,decreased oxygen saturation,decreased oxygen saturation,1
LUMIZYME,decreased oxygen saturation,,0
LUMIZYME,decreased oxygen saturation,oxygen saturation,1
LUMIZYME,decreased oxygen saturation,decreased oxygen saturation,1
LUMIZYME,decreased oxygen saturation,included rash pyrexia urticaria decreased oxygen saturation,1
LUMIZYME,cough,cough,1
LUMIZYME,tachypnea,urticaria flushing,0
LUMIZYME,tachypnea,tachypnea,1
LUMIZYME,tachypnea,tachycardia hypertensionincreased blood pressure,0
LUMIZYME,tachypnea,flushing decreased oxygen saturation,0
LUMIZYME,tachypnea,tachypnea,1
LUMIZYME,tachypnea,oxygen saturation cough,0
LUMIZYME,hypertension,cough tachypnea,0
LUMIZYME,hypertension,hypertension,1
LUMIZYME,hypertension,blood pressure pallor rigors vomiting cyanosis agitation and tremor These reaction,0
LUMIZYME,hypertension,rash pyrexia urticaria flushing decreased oxygen saturation cough tachypnea tachycardia,0
LUMIZYME,hypertension,reaction,0
LUMIZYME,hypertension,hypertension,1
LUMIZYME,increased blood pressure,oxygen saturation cough,0
LUMIZYME,increased blood pressure,flushing decreased oxygen saturation cough tachypnea,0
LUMIZYME,increased blood pressure,,0
LUMIZYME,increased blood pressure,cough tachypnea tachycardia increased,1
LUMIZYME,increased blood pressure,tachypnea tachycardia increased blood pressure,1
LUMIZYME,increased blood pressure,tachycardia increased blood,1
LUMIZYME,pallor,oxygen saturation cough tachypnea tachycardia,0
LUMIZYME,pallor,pallor,1
LUMIZYME,pallor,and tremor These reactions,0
LUMIZYME,pallor,pallor,1
LUMIZYME,pallor,hypertensionincreased blood pallor,1
LUMIZYME,pallor,These,0
LUMIZYME,pallor,tachycardia hypertensionincreased blood pallor,1
LUMIZYME,rigors,higher i,0
LUMIZYME,rigors,rigors,1
LUMIZYME,rigors,tremor These reactions were more likely,0
LUMIZYME,rigors,blood pressure,0
LUMIZYME,rigors,,0
LUMIZYME,rigors,blood pressure rigors,1
LUMIZYME,rigors,rigors,1
LUMIZYME,rigors,tachypnea tachycardia hypertensionincreased blood,0
LUMIZYME,rigors,i,0
LUMIZYME,rigors,rigors,1
LUMIZYME,vomiting,pallor vomiting,1
LUMIZYME,cyanosis,agitation and tremor These reactions were more likely to occur with,0
LUMIZYME,cyanosis,tremor These reactions were more likely to occur with higher infusion,0
LUMIZYME,cyanosis,cyanosis,1
LUMIZYME,cyanosis,cyanosis,1
LUMIZYME,cyanosis,cyanosis,1
LUMIZYME,cyanosis,cyanosis,1
LUMIZYME,cyanosis,pressure pallor rigors cyanosis,1
LUMIZYME,agitation,agitation,1
LUMIZYME,agitation,agitation,1
LUMIZYME,agitation,agitation,1
LUMIZYME,agitation,agitation,1
LUMIZYME,agitation,reactions were more,0
LUMIZYME,tremor,tremor,1
LUMIZYME,tremor,cyanosis agitation tremor,1
LUMIZYME,hypersensitivity reactions,corticosteroids still hypersensitivity reactions,1
LUMIZYME,hypersensitivity reactions,in of patients or more patients,0
LUMIZYME,hypersensitivity reactions,were pretreated with antihistamines antipyretics andor corticosteroids still experienced,0
LUMIZYME,hypersensitivity reactions,were pretreated with antihistamines antipyretics andor corticosteroids,0
LUMIZYME,hypersensitivity reactions,reactions,1
LUMIZYME,hypersensitivity reactions,,0
LUMIZYME,hypersensitivity reactions,pretreated with antihistamines,0
LUMIZYME,hypersensitivity reactions,corticosteroids still hypersensitivity,1
LUMIZYME,Rash,macular and,0
LUMIZYME,Rash,rash erythematous rash macular and,0
LUMIZYME,Rash,,0
LUMIZYME,Rash,tion,0
LUMIZYME,Rash,Rash including rash erythematous rash,1
LUMIZYME,Rash,erythematous rash macular and,0
LUMIZYME,rash erythematous,rash erythematous,1
LUMIZYME,rash erythematous,,0
LUMIZYME,rash erythematous,rash macular and maculopapular Pyrexia,0
LUMIZYME,rash erythematous,Rash rash,1
LUMIZYME,rash erythematous,Rash rash,1
LUMIZYME,rash erythematous,Rash rash,1
LUMIZYME,rash erythematous,Rash rash erythematous,1
LUMIZYME,rash erythematous,Rash rash,1
LUMIZYME,rash erythematous,Rash rash erythematous,1
LUMIZYME,rash erythematous,rash erythematous,1
LUMIZYME,rash macular,,0
LUMIZYME,rash macular,,0
LUMIZYME,Pyrexia,Pyrexia,1
LUMIZYME,Pyrexia,,0
LUMIZYME,Pyrexia,Pyrexia,1
LUMIZYME,Pyrexia,,0
LUMIZYME,Pyrexia,Pyrexia,1
LUMIZYME,Pyrexia,,0
LUMIZYME,Pyrexia,,0
LUMIZYME,Pyrexia,,0
LUMIZYME,Pyrexia,,0
LUMIZYME,Pyrexia,erythematous rash macular and Pyrexia,1
LUMIZYME,Urticaria,Urticaria Fl,1
LUMIZYME,Urticaria,Urticaria Fl,1
LUMIZYME,Urticaria,,0
LUMIZYME,Flushing,Flushing H,1
LUMIZYME,Flushing,Flushing H,1
LUMIZYME,Flushing,,0
LUMIZYME,Flushing,ia,0
LUMIZYME,Flushing,Flushing H,1
LUMIZYME,Flushing,ia Flushing H,1
LUMIZYME,Flushing,,0
LUMIZYME,Flushing,ia,0
LUMIZYME,Flushing,ia Flushing H,1
LUMIZYME,Flushing,ia,0
LUMIZYME,Hypertension,Hypertension,1
LUMIZYME,Hypertension,Hypertension Increased Blood Pressure Decre,1
LUMIZYME,Increased Blood Pressure,Hypertension Increased Blood Pressure,1
LUMIZYME,Increased Blood Pressure,Hypertension,0
LUMIZYME,Decreased Oxygen Saturation,,0
LUMIZYME,Cough,,0
LUMIZYME,Cough,,0
LUMIZYME,Cough,Oxygen Cough,1
LUMIZYME,Cough,Cough,1
LUMIZYME,Cough,,0
LUMIZYME,Cough,Cough,1
LUMIZYME,Cough,Cough,1
LUMIZYME,Cough,Cough,1
LUMIZYME,Tachypnea,Tachypnea Ta,1
LUMIZYME,Tachypnea,Tachypnea Ta,1
LUMIZYME,Tachypnea,,0
LUMIZYME,Tachypnea,Tachypnea Ta,1
LUMIZYME,Tachypnea,Tachypnea Ta,1
LUMIZYME,Tachypnea,,0
LUMIZYME,Tachycardia,Tachycardia Eryt,1
LUMIZYME,Tachycardia,ea,0
LUMIZYME,Tachycardia,ea,0
LUMIZYME,Tachycardia,Tachycardia Eryt,1
LUMIZYME,Erythema,Erythema V,1
LUMIZYME,Erythema,Erythema V,1
LUMIZYME,Erythema,,0
LUMIZYME,Erythema,,0
LUMIZYME,Erythema,rdia Erythema V,1
LUMIZYME,Erythema,,0
LUMIZYME,Erythema,Erythema V,1
LUMIZYME,Vomiting,Vomiting R,1
LUMIZYME,Vomiting,Vomiting R,1
LUMIZYME,Vomiting,Vomiting R,1
LUMIZYME,Vomiting,R,0
LUMIZYME,Vomiting,Vomiting R,1
LUMIZYME,Vomiting,Vomiting R,1
LUMIZYME,Vomiting,a,0
LUMIZYME,Vomiting,Vomiting R,1
LUMIZYME,Vomiting,Vomiting R,1
LUMIZYME,Rigors,,0
LUMIZYME,Rigors,,0
LUMIZYME,Rigors,Rigors,1
LUMIZYME,Rigors,Rigors,1
LUMIZYME,Rigors,g Rigors,1
LUMIZYME,Rigors,,0
LUMIZYME,Rigors,Rigors,1
LUMIZYME,Rigors,Rigors,1
LUMIZYME,Pallor,,0
LUMIZYME,Pallor,Pallor,1
LUMIZYME,Pallor,Pallor,1
LUMIZYME,Pallor,,0
LUMIZYME,Pallor,Pallor,1
LUMIZYME,Pallor,Pallor,1
LUMIZYME,Agitation,Agitation Tr,1
LUMIZYME,Agitation,Agitation Tr,1
LUMIZYME,Agitation,Agitation Tr,1
LUMIZYME,Agitation,Agitation Tr,1
LUMIZYME,Agitation,Agitation Tr,1
LUMIZYME,Agitation,s,0
LUMIZYME,Agitation,s,0
LUMIZYME,Agitation,Agitation Tr,1
LUMIZYME,hypersensitivity reactions,clinical trials hypersensitivity,1
LUMIZYME,hypersensitivity reactions,trials hypersensitivity reactions observed,1
LUMIZYME,hypersensitivity reactions,disease patients who,0
LUMIZYME,hypersensitivity reactions,in other clinical trials hypersensitivity reactions observed,1
LUMIZYME,hypersensitivity reactions,who received alglucosidase alfa in other clinical,0
LUMIZYME,hypersensitivity reactions,reactions observed,1
LUMIZYME,hypersensitivity reactions,clinical trials hypersensitivity reactions observed,1
LUMIZYME,hypersensitivity reactions,Additional,0
LUMIZYME,retching,retching increased,1
LUMIZYME,retching,,0
LUMIZYME,retching,reticularis retching increased,1
LUMIZYME,retching,expanded access,0
LUMIZYME,increased lacrimation,and cold sweat,0
LUMIZYME,ventricular extrasystoles,alglucosidase alfa,0
LUMIZYME,ventricular extrasystoles,,0
LUMIZYME,nodal rhythm,rhythm rales,1
LUMIZYME,nodal rhythm,,0
LUMIZYME,nodal rhythm,retching increased lacrimation ventricular,0
LUMIZYME,nodal rhythm,retching increased lacrimation ventricular nodal rhythm rales,1
LUMIZYME,rales,,0
LUMIZYME,rales,rales respiratory,1
LUMIZYME,rales,rales respiratory,1
LUMIZYME,rales,and cold sweat Safety was also,0
LUMIZYME,rales,rales respiratory,1
LUMIZYME,rales,rales respiratory,1
LUMIZYME,respiratory tract irritation,extrasystoles nodal rhythm respiratory,1
LUMIZYME,respiratory tract irritation,rhythm rales,0
LUMIZYME,respiratory tract irritation,in patients male,0
LUMIZYME,cold sweat,extrasystoles,0
LUMIZYME,cold sweat,male females with Pompe disease in,0
LUMIZYME,cold sweat,extrasystoles nodal rhythm rales respiratory tract irritation and,0
LUMIZYME,cold sweat,,0
LUMIZYME,cold sweat,disease in an ongoin,0
LUMIZYME,cold sweat,with Pompe disease in an ongoin,0
LUMIZYME,cold sweat,sweat Safety,1
LUMIZYME,cold sweat,an ongoin,0
LUMIZYME,cold sweat,rales respiratory tract irritation cold sweat Safety,1
LUMIZYME,cold sweat,respiratory tract irritation cold,1
LUMIZYME,anaphylactic reactions,in the placebo group Two patients receiving alglucosidase alfa discontinued the trial due to,0
LUMIZYME,anaphylactic reactions,anaphylactic reactions Serious,1
LUMIZYME,anaphylactic reactions,discontinued the trial due anaphylactic,1
LUMIZYME,anaphylactic reactions,discontinued the,0
LUMIZYME,anaphylactic reactions,anaphylactic reactions Serious,1
LUMIZYME,anaphylactic reactions,anaphylactic reactions Serious,1
LUMIZYME,anaphylactic reactions,which present,0
LUMIZYME,anaphylactic reactions,the trial due anaphylactic,1
LUMIZYME,anaphylactic reactions,anaphylactic reactions Serious,1
LUMIZYME,anaphylactic reactions,the trial due anaphylactic,1
LUMIZYME,anaphylaxis,anaphylaxis which,1
LUMIZYME,anaphylaxis,anaphylactic reactions Serious adverse reactions reported,0
LUMIZYME,anaphylaxis,,0
LUMIZYME,anaphylaxis,alglucosidase alfa anaphylaxis which,1
LUMIZYME,anaphylaxis,anaphylaxis which,1
LUMIZYME,anaphylaxis,alfa included,0
LUMIZYME,anaphylaxis,angioedema throat tightness and,0
LUMIZYME,anaphylaxis,reactions reported with alglucosidase alfa,0
LUMIZYME,anaphylaxis,anaphylaxis which,1
LUMIZYME,angioedema,presented angioedema throat,1
LUMIZYME,angioedema,angioedema throat,1
LUMIZYME,angioedema,a history of,0
LUMIZYME,angioedema,angioedema throat,1
LUMIZYME,angioedema,patient with,0
LUMIZYME,angioedema,patient with,0
LUMIZYME,throat tightness,which presented as throat,1
LUMIZYME,throat tightness,throat tightness and,1
LUMIZYME,chest pain,chest pain discomfort,1
LUMIZYME,chest pain,with a history of WolffParkinsonWhite syndrome experienced a,0
LUMIZYME,chest pain,as angioedema throat tightness chest pain discomfort,1
LUMIZYME,chest pain,,0
LUMIZYME,chest pain,angioedema throat tightness chest pain discomfort,1
LUMIZYME,hypersensitivity reactions,in alglucosidase alfatreated patients hypersensitivity reactions and,1
LUMIZYME,hypersensitivity reactions,alglucosidase alfatreated patients,0
LUMIZYME,anaphylaxis,hypersensitivity reactions and anaphylaxis headache,1
LUMIZYME,anaphylaxis,anaphylaxis headache,1
LUMIZYME,anaphylaxis,,0
LUMIZYME,anaphylaxis,alglucosidase alfatreated patients were hypersensitivity,0
LUMIZYME,anaphylaxis,flushingfeelin,0
LUMIZYME,anaphylaxis,were hypersensitivity reactions and anaphylaxis headache,1
LUMIZYME,anaphylaxis,,0
LUMIZYME,headache,discomfort vomiting hyperhidrosis,0
LUMIZYME,headache,,0
LUMIZYME,headache,headache nausea,1
LUMIZYME,headache,headache nausea,1
LUMIZYME,headache,anaphylaxis,0
LUMIZYME,headache,headache nausea,1
LUMIZYME,nausea,chest discomfort vomiting hyperhidrosis flushingfeeling hot increased b,0
LUMIZYME,nausea,and included anaphylaxis,0
LUMIZYME,nausea,nausea urticaria,1
LUMIZYME,nausea,nausea urticaria,1
LUMIZYME,nausea,alfatreated patients,0
LUMIZYME,nausea,hyperhidrosis flushingfeeling hot increased b,0
LUMIZYME,nausea,and included anaphylaxis nausea urticaria,1
LUMIZYME,urticaria,urticaria dizziness,1
LUMIZYME,urticaria,increased,0
LUMIZYME,urticaria,hyperhidrosis flushingfeeling hot increased,0
LUMIZYME,urticaria,dizziness chest,0
LUMIZYME,urticaria,flushingfeeling hot increased,0
LUMIZYME,urticaria,urticaria dizziness,1
LUMIZYME,dizziness,vomiting,0
LUMIZYME,dizziness,vomiting,0
LUMIZYME,dizziness,chest discomfort vomiting hyperhidrosis flushingfeeling hot,0
LUMIZYME,chest discomfort,urticaria chest discomfort vomiting,1
LUMIZYME,chest discomfort,anaphylaxis headache nausea urticaria,0
LUMIZYME,chest discomfort,,0
LUMIZYME,chest discomfort,dizziness,0
LUMIZYME,chest discomfort,anaphylaxis headache nausea urticaria chest,1
LUMIZYME,chest discomfort,headache nausea urticaria chest discomfort vomiting,1
LUMIZYME,vomiting,,0
LUMIZYME,vomiting,urticaria dizziness chest vomiting hyperhidrosis,1
LUMIZYME,vomiting,dizziness chest vomiting hyperhidrosis,1
LUMIZYME,vomiting,paresthesia pyrexia local,0
LUMIZYME,vomiting,vomiting hyperhidrosis,1
LUMIZYME,vomiting,headache nausea urticaria dizziness chest,0
LUMIZYME,vomiting,included anaphylaxis headache nausea urticaria dizziness chest,0
LUMIZYME,vomiting,vomiting hyperhidrosis,1
LUMIZYME,vomiting,hot increased blood pressure paresthesia pyrexia local,0
LUMIZYME,hyperhidrosis,hyperhidrosis flushingfeeling,1
LUMIZYME,hyperhidrosis,hyperhidrosis flushingfeeling,1
LUMIZYME,hyperhidrosis,hyperhidrosis flushingfeeling,1
LUMIZYME,flushing,vomiting hyperhidrosis,0
LUMIZYME,flushing,flushing feeling,1
LUMIZYME,flushing,flushing feeling,1
LUMIZYME,flushing,headache nausea urticaria dizziness chest discomfort vomiting hyperhidrosis,0
LUMIZYME,flushing,swelling diarrhea pruritus ra,0
LUMIZYME,flushing,vomiting flushing feeling,1
LUMIZYME,flushing,flushing feeling,1
LUMIZYME,flushing,,0
LUMIZYME,feeling hot,vomiting hyperhidrosis feeling hot increased,1
LUMIZYME,feeling hot,vomiting hyperhidrosis feeling,1
LUMIZYME,feeling hot,hot increased,1
LUMIZYME,feeling hot,nausea urticaria dizziness chest discomfort vomiting,0
LUMIZYME,feeling hot,,0
LUMIZYME,feeling hot,discomfort vomiting hyperhidrosis feeling hot increased,1
LUMIZYME,increased blood pressure,pressure paresthesia,1
LUMIZYME,increased blood pressure,hyperhidrosis flushingfeeling increased blood,1
LUMIZYME,increased blood pressure,hyperhidrosis flushingfeeling increased blood,1
LUMIZYME,increased blood pressure,flushingfeeling increased blood,1
LUMIZYME,paresthesia,hyperhidrosis flushingfeeling hot increased,0
LUMIZYME,paresthesia,diarrhea pruritus,0
LUMIZYME,paresthesia,diarrhea pruritus rash and throat tightness,0
LUMIZYME,paresthesia,paresthesia pyrexia,1
LUMIZYME,paresthesia,throat tightness Delayedonset,0
LUMIZYME,paresthesia,hot increased blood pressure,0
LUMIZYME,paresthesia,chest discomfort vomiting hyperhidrosis flushingfeeling hot increased blood pressure,0
LUMIZYME,paresthesia,local swelling diarrhea pruritus rash and throat tightness Delayedonset reactio,0
LUMIZYME,paresthesia,paresthesia pyrexia,1
LUMIZYME,pyrexia,pyrexia local,1
LUMIZYME,pyrexia,,0
LUMIZYME,pyrexia,pyrexia local,1
LUMIZYME,pyrexia,hot increased blood,0
LUMIZYME,pyrexia,and throat tightness,0
LUMIZYME,pyrexia,defin,0
LUMIZYME,pyrexia,pressure pyrexia local,1
LUMIZYME,local swelling,local swelling diarrhea,1
LUMIZYME,local swelling,local swelling diarrhea,1
LUMIZYME,diarrhea,diarrhea pruritus,1
LUMIZYME,diarrhea,paresthesia pyrexia local,0
LUMIZYME,diarrhea,diarrhea pruritus,1
LUMIZYME,diarrhea,Delayedonset reactions defined,0
LUMIZYME,diarrhea,local swelling,0
LUMIZYME,diarrhea,diarrhea pruritus,1
LUMIZYME,pruritus,occurring,0
LUMIZYME,pruritus,,0
LUMIZYME,pruritus,blood pressure paresthesia,0
LUMIZYME,pruritus,pruritus rash,1
LUMIZYME,pruritus,pruritus rash,1
LUMIZYME,pruritus,pruritus rash,1
LUMIZYME,pruritus,pruritus rash,1
LUMIZYME,pruritus,local swelling pruritus rash,1
LUMIZYME,pruritus,pruritus rash,1
LUMIZYME,rash,blood,0
LUMIZYME,rash,,0
LUMIZYME,rash,rash and,1
LUMIZYME,rash,throat tightness Delayedonset reactions defined as adverse reactions occurring h,0
LUMIZYME,rash,rash and,1
LUMIZYME,rash,diarrhea rash and,1
LUMIZYME,throat tightness,completion,0
LUMIZYME,throat tightness,pruritus rash throat,1
LUMIZYME,throat tightness,rash throat,1
LUMIZYME,fatigue,in alglucosidase alfatreated patients fatigue myalgia,1
LUMIZYME,fatigue,of,0
LUMIZYME,myalgia,reactions occurring,0
LUMIZYME,myalgia,alglucosidase alfatreated patients included fatigue,0
LUMIZYME,myalgia,myalgia and,1
LUMIZYME,myalgia,delayedonset reactions occurring in alglucosidase alfatreated,0
LUMIZYME,myalgia,included fatigue,0
LUMIZYME,myalgia,alglucosidase alfatreated patients included fatigue,0
LUMIZYME,myalgia,myalgia and,1
LUMIZYME,nausea,nausea Patients,1
LUMIZYME,nausea,counseled,0
LUMIZYME,nausea,nausea Patients,1
LUMIZYME,nausea,occurring in alglucosidase alfatreated patients included fatigue,0
LUMIZYME,nausea,nausea Patients,1
LUMIZYME,Hyperhidrosis,Hyperhidrosis Urti,1
LUMIZYME,Hyperhidrosis,Alglucosidase AlfanN Hyperhidrosis Urti,1
LUMIZYME,Hyperhidrosis,Alglucosidase,0
LUMIZYME,Hyperhidrosis,,0
LUMIZYME,Hyperhidrosis,,0
LUMIZYME,Hyperhidrosis,Urti,0
LUMIZYME,Hyperhidrosis,Hyperhidrosis Urti,1
LUMIZYME,Anaphylaxis,,0
LUMIZYME,Anaphylaxis,,0
LUMIZYME,Anaphylaxis,Anaphylaxis Ch,1
LUMIZYME,Chest Discomfort,is,0
LUMIZYME,Chest Discomfort,is Chest Discomfort Muscle,1
LUMIZYME,Chest Discomfort,is,0
LUMIZYME,Chest Discomfort,is,0
LUMIZYME,Chest Discomfort,,0
LUMIZYME,Chest Discomfort,is,0
LUMIZYME,Chest Discomfort,is,0
LUMIZYME,Muscle Twitching,comfort,0
LUMIZYME,Myalgia,Myalgia,1
LUMIZYME,Myalgia,itching Myalgia,1
LUMIZYME,Myalgia,Myalgia,1
LUMIZYME,Myalgia,itching,0
LUMIZYME,Flushing,,0
LUMIZYME,Feeling Hot,Feeling Hot Increased B,1
LUMIZYME,Feeling Hot,Flushing Feeling,1
LUMIZYME,Feeling Hot,,0
LUMIZYME,Feeling Hot,,0
LUMIZYME,Feeling Hot,Flushing Feeling,1
LUMIZYME,Feeling Hot,Flushing,0
LUMIZYME,Feeling Hot,,0
LUMIZYME,Feeling Hot,Flushing Feeling,1
LUMIZYME,Feeling Hot,Flushing Feeling,1
LUMIZYME,Increased Blood Pressure,Increased Blood Pressure Vomiting,1
LUMIZYME,Increased Blood Pressure,Increased,1
LUMIZYME,Increased Blood Pressure,,0
LUMIZYME,Increased Blood Pressure,Blood Pressure Vomiting,1
LUMIZYME,Increased Blood Pressure,Increased,1
LUMIZYME,Increased Blood Pressure,Increased,1
LUMIZYME,Vomiting,Vomiting,1
LUMIZYME,Vomiting,Vomiting,1
LUMIZYME,Vomiting,Vomiting,1
LUMIZYME,Vomiting,Blood Vomiting,1
LUMIZYME,Vomiting,,0
LUMIZYME,Vomiting,,0
LUMIZYME,Vomiting,Pressure,0
LUMIZYME,Vomiting,,0
LUMIZYME,Vomiting,Vomiting,1
LUMIZYME,Vomiting,,0
LUMIZYME,"Edema, Peripheral",,0
LUMIZYME,"Edema, Peripheral","Edema, Peripheral Pruritus",1
LUMIZYME,"Edema, Peripheral","Edema, Peripheral Pruritus",1
LUMIZYME,"Edema, Peripheral","Edema,",1
LUMIZYME,"Edema, Peripheral",,0
LUMIZYME,"Edema, Peripheral","Edema, Peripheral Pruritus",1
LUMIZYME,"Edema, Peripheral","Edema, Peripheral Pruritus",1
LUMIZYME,"Edema, Peripheral","Edema, Peripheral Pruritus",1
LUMIZYME,"Edema, Peripheral",,0
LUMIZYME,"Edema, Peripheral",,0
LUMIZYME,Pruritus,Pruritus,1
LUMIZYME,Pruritus,Pruritus,1
LUMIZYME,Pruritus,,0
LUMIZYME,Pruritus,,0
LUMIZYME,Pruritus,ripheral,0
LUMIZYME,Pruritus,Pruritus,1
LUMIZYME,Pruritus,Pruritus,1
LUMIZYME,Pruritus,,0
LUMIZYME,Rash Papular,Rash Papular Thr,1
LUMIZYME,Rash Papular,Papular Thr,1
LUMIZYME,Rash Papular,,0
LUMIZYME,Rash Papular,Rash,1
LUMIZYME,Rash Papular,Rash Papular Thr,1
LUMIZYME,Rash Papular,Rash Papular Thr,1
LUMIZYME,Rash Papular,Papular Thr,1
LUMIZYME,Rash Papular,Rash,1
LUMIZYME,Throat Tightness,lar,0
LUMIZYME,Throat Tightness,lar,0
LUMIZYME,Throat Tightness,lar,0
LUMIZYME,Throat Tightness,lar Throat Tightness,1
LUMIZYME,Throat Tightness,lar Throat,1
LUMIZYME,Throat Tightness,lar,0
LUMIZYME,anaphylaxis,with infusion interruption decreased infusion,0
LUMIZYME,anaphylaxis,,0
LUMIZYME,anaphylaxis,clinical anaphylaxis,1
LUMIZYME,anaphylaxis,and hypersensitivity reactions were managed with,0
LUMIZYME,anaphylactic reactions,some cases of,0
LUMIZYME,anaphylactic reactions,anaphylactic reactions,1
LUMIZYME,anaphylactic reactions,anaphylaxis or,0
LUMIZYME,anaphylactic reactions,some cases,0
LUMIZYME,anaphylactic reactions,epinephrine was administered Patients who have experienced anaphylaxis or hypersensitivity,0
LUMIZYME,IgG antibody titers with inhibitory activity,activity,1
LUMIZYME,IgG antibody titers with inhibitory activity,the presence of high IgG antibody titers with inhibitory,1
LUMIZYME,IgG antibody titers with inhibitory activity,in motor,0
LUMIZYME,IgG antibody titers with inhibitory activity,the presence of high IgG antibody titers with inhibitory activity,1
LUMIZYME,IgG antibody titers with inhibitory activity,decrease in,0
LUMIZYME,IgG antibody titers with inhibitory activity,reduced clinical effect in,0
LUMIZYME,IgG antibody titers with inhibitory activity,sustained,0
LUMIZYME,IgG antibody titers with inhibitory activity,the presence of high IgG antibody titers with inhibitory activity,1
LUMIZYME,recurrent hypersensitivity reactions,hypersensitivity reactions,1
LUMIZYME,recurrent hypersensitivity reactions,in patients who experienced moderate to,0
LUMIZYME,recurrent hypersensitivity reactions,hypersensitivity reactions,1
LUMIZYME,recurrent hypersensitivity reactions,to severe recurrent,1
LUMIZYME,recurrent hypersensitivity reactions,experienced moderate to,0
LUMIZYME,recurrent hypersensitivity reactions,experienced moderate to severe recurrent,1
LUMIZYME,recurrent hypersensitivity reactions,tested positive for algluco,0
LUMIZYME,recurrent hypersensitivity reactions,IgE antibodies Testing was performed in patients,0
LUMIZYME,hypersensitivity reactions,which mastcell activation was suspected Some of the patients who,0
LUMIZYME,hypersensitivity reactions,the,0
LUMIZYME,hypersensitivity reactions,,0
LUMIZYME,hypersensitivity reactions,reactions,1
LUMIZYME,anaphylactic reactions,alfaspecific IgE antibodies anaphylactic reactions,1
LUMIZYME,anaphylactic reactions,,0
LUMIZYME,anaphylactic reactions,antibodies anaphylactic,1
LUMIZYME,anaphylactic reactions,a,0
LUMIZYME,anaphylactic reactions,anaphylactic reactions,1
LUMIZYME,anaphylactic reactions,reactions,1
LUMIZYME,anaphylactic reactions,anaphylactic reactions,1
LUMIZYME,anaphylaxis,anaphylaxis,1
LUMIZYME,anaphylaxis,reactions have been reported anaphylaxis,1
LUMIZYME,anaphylaxis,anaphylaxis,1
LUMIZYME,anaphylaxis,been reported anaphylaxis,1
LUMIZYME,anaphylaxis,been reported including,0
LUMIZYME,anaphylaxis,reported,0
LUMIZYME,Acute cardiorespiratory failure,with,0
LUMIZYME,Acute cardiorespiratory failure,Acute cardiorespiratory failure,1
LUMIZYME,Acute cardiorespiratory failure,in infantileonset,0
LUMIZYME,Acute cardiorespiratory failure,and Precautions,0
LUMIZYME,Acute cardiorespiratory failure,disease patien,0
LUMIZYME,Acute cardiorespiratory failure,Acute cardiorespiratory failure,1
LUMIZYME,Acute cardiorespiratory failure,with fluid overload has been reported in infantileonset Pompe disease patien,0
LUMIZYME,fluid overload,with preexisting hypertrophic,0
LUMIZYME,fluid overload,associated fluid overload,1
LUMIZYME,fluid overload,overload,1
LUMIZYME,fluid overload,possibly associated fluid,1
LUMIZYME,fluid overload,and Precautions Acute cardiorespiratory failure possibly,0
LUMIZYME,fluid overload,overload,1
LUMIZYME,fluid overload,failure possibly associated fluid,1
LUMIZYME,fluid overload,possibly associated,0
LUMIZYME,fluid overload,fluid,1
LUMIZYME,flu-like illness,Precautions Recurrent reactions consisting flu-like illness,1
LUMIZYME,pyrexia,combination of events such pyrexia,1
LUMIZYME,pyrexia,,0
LUMIZYME,pyrexia,pyrexia,1
LUMIZYME,pyrexia,pyrexia,1
LUMIZYME,chills,occurring after completion of infusions,0
LUMIZYME,chills,or,0
LUMIZYME,chills,chills,1
LUMIZYME,chills,combination of events such,0
LUMIZYME,chills,chills,1
LUMIZYME,chills,myalgia arthralgia,0
LUMIZYME,chills,chills,1
LUMIZYME,chills,pain or fatigue occurring after completion of infusions and lasting usually,0
LUMIZYME,myalgia,such as pyrexia,0
LUMIZYME,arthralgia,of flulike illness or a combination,0
LUMIZYME,arthralgia,a combination of events such,0
LUMIZYME,arthralgia,arthralgia,1
LUMIZYME,arthralgia,arthralgia,1
LUMIZYME,arthralgia,a combination of events such as pyrexia chills,0
LUMIZYME,arthralgia,arthralgia,1
LUMIZYME,arthralgia,occurring after completion of infusions and,0
LUMIZYME,arthralgia,for days have b,0
LUMIZYME,arthralgia,a combination of events such as pyrexia,0
LUMIZYME,pain,a combination of events such as pyrexia chills myalgia,0
LUMIZYME,pain,pain,1
LUMIZYME,pain,such as pyrexia,0
LUMIZYME,pain,occurring after completion,0
LUMIZYME,pain,pain,1
LUMIZYME,pain,pain,1
LUMIZYME,pain,pain,1
LUMIZYME,pain,combination of events such as pyrexia,0
LUMIZYME,pain,pain,1
LUMIZYME,pain,usually for days have been ob,0
LUMIZYME,fatigue,fatigue,1
LUMIZYME,fatigue,for days have been observed in,0
LUMIZYME,fatigue,myalgia arthralgia pain fatigue,1
LUMIZYME,fatigue,,0
LUMIZYME,fatigue,fatigue,1
LUMIZYME,fatigue,fatigue,1
LUMIZYME,fatigue,fatigue,1
LUMIZYME,fatigue,fatigue,1
LUMIZYME,fatigue,arthralgia pain,0
LUMIZYME,fatigue,myalgia arthralgia pain fatigue,1
LUMIZYME,hypersensitivity reactions,hypersensitivity,1
LUMIZYME,hypersensitivity reactions,reactions,1
LUMIZYME,hypersensitivity reactions,hypersensitivity,1
LUMIZYME,anaphylactic shock,shock,1
LUMIZYME,anaphylactic shock,patients and,0
LUMIZYME,anaphylactic shock,anaphylactic shock,1
LUMIZYME,anaphylactic shock,least patients and anaphylactic shock,1
LUMIZYME,respiratory failure,been reported in at least patients,0
LUMIZYME,respiratory failure,and included anaphylactic respiratory failure,1
LUMIZYME,respiratory failure,arrest cardiac arrest hypoxia dyspnea wheezing convulsions peripheral,0
LUMIZYME,respiratory failure,included anaphylactic respiratory,1
LUMIZYME,respiratory failure,wheezing convulsions peripheral coldness,0
LUMIZYME,respiratory failure,anaphylactic respiratory,1
LUMIZYME,respiratory failure,dyspnea wheezing,0
LUMIZYME,respiratory failure,respiratory arrest cardiac arrest hypoxia,0
LUMIZYME,respiratory failure,patients and included anaphylactic respiratory,1
LUMIZYME,respiratory arrest,respiratory,1
LUMIZYME,respiratory arrest,respiratory arrest,1
LUMIZYME,respiratory arrest,arrest,1
LUMIZYME,respiratory arrest,least patients,0
LUMIZYME,respiratory arrest,,0
LUMIZYME,cardiac arrest,included anaphylactic shock,0
LUMIZYME,hypoxia,peripheral coldness restlessness nervousness back pain,0
LUMIZYME,hypoxia,hypoxia,1
LUMIZYME,hypoxia,,0
LUMIZYME,hypoxia,arrest cardiac hypoxia,1
LUMIZYME,dyspnea,arrest cardiac arrest dyspnea,1
LUMIZYME,dyspnea,back pain stridor,0
LUMIZYME,dyspnea,dyspnea,1
LUMIZYME,dyspnea,dyspnea,1
LUMIZYME,dyspnea,arrest cardiac arrest dyspnea,1
LUMIZYME,dyspnea,stridor,0
LUMIZYME,dyspnea,dyspnea,1
LUMIZYME,wheezing,wheezing,1
LUMIZYME,wheezing,wheezing,1
LUMIZYME,wheezing,wheezing,1
LUMIZYME,wheezing,wheezing,1
LUMIZYME,wheezing,anaphylactic shock respiratory failure respiratory arrest cardiac arrest hypoxia,0
LUMIZYME,wheezing,arrest cardiac arrest hypoxia wheezing,1
LUMIZYME,wheezing,wheezing,1
LUMIZYME,wheezing,wheezing,1
LUMIZYME,wheezing,wheezing,1
LUMIZYME,wheezing,cardiac arrest hypoxia wheezing,1
LUMIZYME,restlessness,,0
LUMIZYME,restlessness,restlessness,1
LUMIZYME,restlessness,convulsions peripheral restlessness,1
LUMIZYME,restlessness,dyspnea wheezing convulsions peripheral restlessness,1
LUMIZYME,restlessness,cardiac arrest hypoxia dyspnea wheezing convulsions peripheral coldness,0
LUMIZYME,restlessness,restlessness,1
LUMIZYME,restlessness,restlessness,1
LUMIZYME,nervousness,,0
LUMIZYME,nervousness,nervousness,1
LUMIZYME,nervousness,nervousness,1
LUMIZYME,nervousness,nervousness,1
LUMIZYME,nervousness,muscle spasm,0
LUMIZYME,back pain,abdominal pain apnea muscle spasm and conjunctivitis,0
LUMIZYME,back pain,peripheral coldness restlessness back pain,1
LUMIZYME,back pain,restlessness back pain,1
LUMIZYME,back pain,convulsions peripheral coldness restlessness back pain,1
LUMIZYME,back pain,peripheral coldness restlessness back,1
LUMIZYME,back pain,back pain,1
LUMIZYME,back pain,,0
LUMIZYME,back pain,restlessness nervousness,0
LUMIZYME,stridor,stridor,1
LUMIZYME,stridor,abdominal pain apnea muscle,0
LUMIZYME,stridor,stridor,1
LUMIZYME,stridor,stridor,1
LUMIZYME,pharyngeal edema,pharyngeal edema,1
LUMIZYME,pharyngeal edema,pharyngeal edema,1
LUMIZYME,pharyngeal edema,nervousness back pain pharyngeal,1
LUMIZYME,pharyngeal edema,of hyperparathyroid,0
LUMIZYME,pharyngeal edema,back pain pharyngeal edema,1
LUMIZYME,pharyngeal edema,restlessness nervousness back pain pharyngeal,1
LUMIZYME,pharyngeal edema,edema,1
LUMIZYME,pharyngeal edema,hyperparathyroid,0
LUMIZYME,abdominal pain,,0
LUMIZYME,abdominal pain,abdominal pain,1
LUMIZYME,abdominal pain,pain stridor pharyngeal,0
LUMIZYME,abdominal pain,,0
LUMIZYME,abdominal pain,muscle spasm and conjunctivitis In addition one case of hyperparathyroidism,0
LUMIZYME,abdominal pain,abdominal pain,1
LUMIZYME,apnea,apnea,1
LUMIZYME,apnea,apnea,1
LUMIZYME,apnea,edema abdominal apnea,1
LUMIZYME,apnea,edema abdominal,0
LUMIZYME,apnea,apnea,1
LUMIZYME,apnea,coldness restlessness nervousness back pain stridor pharyngeal edema abdominal,0
LUMIZYME,muscle spasm,spasm,1
LUMIZYME,muscle spasm,muscle spasm,1
LUMIZYME,muscle spasm,abdominal pain muscle,1
LUMIZYME,hyperparathyroidism,,0
LUMIZYME,hyperparathyroidism,hyperparathyroidism,1
LUMIZYME,hyperparathyroidism,hyperparathyroidism,1
LUMIZYME,hyperparathyroidism,proteinuria and,0
LUMIZYME,hyperparathyroidism,hyperparathyroidism,1
LUMIZYME,hyperparathyroidism,In addition one case hyperparathyroidism,1
LUMIZYME,hyperparathyroidism,hyperparathyroidism,1
LUMIZYME,hyperparathyroidism,,0
LUMIZYME,cutaneous immune-mediated reactions,reported Systemic cutaneous immune-mediated,1
LUMIZYME,cutaneous immune-mediated reactions,reactions,1
LUMIZYME,cutaneous immune-mediated reactions,,0
LUMIZYME,cutaneous immune-mediated reactions,hyperparathyroidism has been,0
LUMIZYME,cutaneous immune-mediated reactions,secondary to membranous glomerulonephritis,0
LUMIZYME,cutaneous immune-mediated reactions,Systemic cutaneous immune-mediated reactions,1
LUMIZYME,cutaneous immune-mediated reactions,has been reported,0
LUMIZYME,cutaneous immune-mediated reactions,reported Systemic cutaneous immune-mediated reactions,1
LUMIZYME,cutaneous immune-mediated reactions,reported Systemic cutaneous immune-mediated reactions,1
LUMIZYME,cutaneous immune-mediated reactions,and,0
LUMIZYME,proteinuria,membranous,0
LUMIZYME,proteinuria,membranous glomerulonephritis and necrotizing,0
LUMIZYME,nephrotic syndrome,including proteinuria nephrotic,1
LUMIZYME,nephrotic syndrome,syndrome,1
LUMIZYME,membranous glomerulonephritis,reactions including proteinuria,0
LUMIZYME,membranous glomerulonephritis,,0
LUMIZYME,membranous glomerulonephritis,secondary membranous glomerulonephritis,1
LUMIZYME,ANAPHYLAXIS,trials,0
LUMIZYME,ANAPHYLAXIS,,0
LUMIZYME,ANAPHYLAXIS,clinical trials,0
LUMIZYME,ANAPHYLAXIS,reactions in clinical trials were hypersensitivity reactions,0
LUMIZYME,ANAPHYLAXIS,The mos t,1
LUMIZYME,HYPERSENSITIVITY,clinical trials,0
LUMIZYME,HYPERSENSITIVITY,and included anaph,0
LUMIZYME,HYPERSENSITIVITY,reactions,0
LUMIZYME,HYPERSENSITIVITY,frequently repor ted adverse reactions,1
LUMIZYME,IMMUNE-MEDIATED REACTIONS,were hypersensitivity reactions and included anaphylaxis rash pyrexia,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,in clinical trials were hypersensitivity reactions and included anaphylaxis,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,clinical,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,dverse,1
LUMIZYME,IMMUNE-MEDIATED REACTIONS,,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,dverse,1
LUMIZYME,CARDIORESPIRATORY FAILURE,EXCERPT The most frequently reported adverse reactions in clinical tr,0
LUMIZYME,CARDIORESPIRATORY FAILURE,ials,1
LUMIZYME,CARDIORESPIRATORY FAILURE,clinical ials were,1
LUMIZYME,CARDIORESPIRATORY FAILURE,ials were hypersensitivit y,1
LUMIZYME,ANAPHYLAXIS,were hypersensitivity reactions,0
LUMIZYME,ANAPHYLAXIS,hyperhidrosis nausea cough,0
LUMIZYME,ANAPHYLAXIS,anaphylax is,1
LUMIZYME,ANAPHYLAXIS,were hypersensitivity reactions and,0
LUMIZYME,ANAPHYLAXIS,hyperhidrosis nausea cough decrease,0
LUMIZYME,ANAPHYLAXIS,and : anaphylax is,1
LUMIZYME,ANAPHYLAXIS,urticaria headache,0
LUMIZYME,ANAPHYLAXIS,reported adverse reactions in clinical trials were hypersensitivity,0
LUMIZYME,ANAPHYLAXIS,hot urticaria,0
LUMIZYME,HYPERSENSITIVITY,,0
LUMIZYME,HYPERSENSITIVITY,"rash, pyrexia, flushingfeeling",1
LUMIZYME,HYPERSENSITIVITY,"included , rash, pyrexia, flushingfeeling",1
LUMIZYME,HYPERSENSITIVITY,reactions and,0
LUMIZYME,HYPERSENSITIVITY,"pyrexia, flushingfeeling",1
LUMIZYME,HYPERSENSITIVITY,"included , rash, pyrexia, flushingfeeling",1
LUMIZYME,HYPERSENSITIVITY,hypersensitivity reactions and included anaphylaxis,0
LUMIZYME,HYPERSENSITIVITY,"reactions and included ,",1
LUMIZYME,HYPERSENSITIVITY,,0
LUMIZYME,HYPERSENSITIVITY,oxygen saturatio,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,"hing/feeling hot, urticar ia",1
LUMIZYME,IMMUNE-MEDIATED REACTIONS,saturation tachycardia,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,hing/feeling,1
LUMIZYME,IMMUNE-MEDIATED REACTIONS,hyperhidrosis,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,reactions,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,tachycardia,0
LUMIZYME,CARDIORESPIRATORY FAILURE,headache,0
LUMIZYME,CARDIORESPIRATORY FAILURE,reactions and included anaphylaxis rash pyrexia flushingfeeling hot urticaria,0
LUMIZYME,CARDIORESPIRATORY FAILURE,"urticaria hyperhidrosis, nausea, co ugh",1
LUMIZYME,CARDIORESPIRATORY FAILURE,dizziness muscle,0
LUMIZYME,CARDIORESPIRATORY FAILURE,reactions and included anaphylaxis rash pyrexia flushingfeeling hot,0
LUMIZYME,CARDIORESPIRATORY FAILURE,urticaria headache,0
LUMIZYME,CARDIORESPIRATORY FAILURE,"urticaria hyperhidrosis, nausea,",1
LUMIZYME,CARDIORESPIRATORY FAILURE,"hot urticaria hyperhidrosis, nausea, co ugh",1
LUMIZYME,hypersensitivity reactions,"discomfort, dizziness, muscle",1
LUMIZYME,hypersensitivity reactions,"tachypnea st discomfort,",1
LUMIZYME,hypersensitivity reactions,"tachypnea st discomfort,",1
LUMIZYME,hypersensitivity reactions,"tachypnea st discomfort, dizziness,  muscle",1
LUMIZYME,respiratory distress,fatigue,0
LUMIZYME,respiratory distress,tremor vomiting fatigue and m,0
LUMIZYME,respiratory distress,s erythema hypertensionincreased blood pressure pallor rigors,0
LUMIZYME,respiratory distress,"muscle ,",1
LUMIZYME,respiratory distress,",",1
LUMIZYME,respiratory distress,,0
LUMIZYME,respiratory distress,"chest discomfort dizziness muscle , agitation, cyanosi s",1
LUMIZYME,respiratory distress,cyanosi s,1
LUMIZYME,respiratory distress,"agitation, cyanosi s",1
LUMIZYME,respiratory distress,cyanosi s,1
LUMIZYME,apnea,and,0
LUMIZYME,apnea,myalgia,0
LUMIZYME,apnea,"muscle twitching agitation cyanosis , hyp ertensionincreased",1
LUMIZYME,apnea,blood pressure pallor rigors tremor vomiting fatigue and,0
LUMIZYME,apnea,"agitation cyanosis , hyp ertensionincreased",1
LUMIZYME,dyspnea,agitation cyanosis erythema tension increased,1
LUMIZYME,dyspnea,twitching agitation cyanosis erythema tension increased,1
LUMIZYME,dyspnea,tachypnea chest discomfort dizziness muscle twitching agitation cyanosis erythema hyper,0
LUMIZYME,bradycardia,ncreased bl ood,1
LUMIZYME,bradycardia,agitation cyanosis erythema ncreased,1
LUMIZYME,bradycardia,bl ood,1
LUMIZYME,bradycardia,,0
LUMIZYME,bradycardia,ood,0
LUMIZYME,bradycardia,discomfort dizziness muscle,0
LUMIZYME,bradycardia,cyanosis erythema ncreased bl ood,1
LUMIZYME,bradycardia,erythema,0
LUMIZYME,bradycardia,twitching agitation cyanosis erythema ncreased,1
LUMIZYME,bradycardia,erythema ncreased,1
LUMIZYME,tachycardia,"d pressure, pallor",1
LUMIZYME,tachycardia,"hypertensionincreased d pressure, pallor",1
LUMIZYME,tachycardia,"d pressure, pallor",1
LUMIZYME,tachycardia,"d pressure, pallor",1
LUMIZYME,tachycardia,"d pressure, pallor",1
LUMIZYME,throat tightness,blood pressure,0
LUMIZYME,hypotension,contact Genzyme,0
LUMIZYME,hypotension,"rigors tremor fatigue,",1
LUMIZYME,hypotension,erythema hypertensionincreased blood pressure pallor rigors tremor,0
LUMIZYME,hypotension,"pallor rigors tremor fatigue,",1
LUMIZYME,hypotension,myalgia To report SUSPECTED ADVERSE REACTIONS contact,0
LUMIZYME,hypotension,a nd,1
LUMIZYME,hypotension,To report SUSPECTED ADVERSE REACTIONS contact Genzyme,0
LUMIZYME,hypotension,"rigors tremor  fatigue, a nd",1
LUMIZYME,hypotension,cyanosis erythema hypertensionincreased blood pressure pallor rigors,0
LUMIZYME,hypotension,a nd,1
LUMIZYME,angioedema,,0
LUMIZYME,angioedema,hypertensionincreased blood pressure,0
LUMIZYME,angioedema,at or,0
LUMIZYME,angioedema,at or FDA at,0
LUMIZYME,angioedema,and,0
LUMIZYME,angioedema,To report SUSPECTED ADVERSE REACTIONS contact Genzyme at,0
LUMIZYME,lip swelling,A DVERSE,1
LUMIZYME,lip swelling,To SUSPECTED,1
LUMIZYME,periorbital edema,"ERSE REACTIONS, c ontact",1
LUMIZYME,periorbital edema,pallor rigors tremor vomiting fatigue and myalgia,0
LUMIZYME,periorbital edema,and myalgia To report SUSPECTED ADV,0
LUMIZYME,periorbital edema,ontact Genzyme at or FDA at FDA or,0
LUMIZYME,face edema,REACTIONS Genzyme,1
LUMIZYME,face edema,FDA or wwwfdagovmedwatch Clinical Trials,0
LUMIZYME,face edema,,0
LUMIZYME,face edema,Genzyme,1
LUMIZYME,face edema,ADVERSE REACTIONS  Genzyme a t,1
LUMIZYME,face edema,wwwfdagovmedwatch Clinical,0
LUMIZYME,face edema,Genzyme,1
LUMIZYME,face edema,Genzyme,1
LUMIZYME,face edema,SUSPECTED ADVERSE REACTIONS,0
LUMIZYME,urticaria,contact Genzyme,0
LUMIZYME,urticaria,Experience Becaus,0
LUMIZYME,urticaria,contact Genzyme -745-4447 or,1
LUMIZYME,urticaria,REACTIONS contact Genzyme -745-4447 or,1
LUMIZYME,urticaria,-745-4447 or,1
LUMIZYME,urticaria,-745-4447 or,1
LUMIZYME,urticaria,-745-4447 or,1
LUMIZYME,urticaria,FDA or wwwfdagovmedwatch Clinical Trials Experience Becaus,0
LUMIZYME,Immune-mediated reactions,"wwwfdagovmedwatch Clinical Trials xperience

  Because clin ical",1
LUMIZYME,Immune-mediated reactions,Clinical Trials xperience Because,1
LUMIZYME,Immune-mediated reactions,or,0
LUMIZYME,Immune-mediated reactions,,0
LUMIZYME,Immune-mediated reactions,,0
LUMIZYME,Immune-mediated reactions,Trials xperience,1
LUMIZYME,Immune-mediated reactions,cl,0
LUMIZYME,Immune-mediated reactions,or,0
LUMIZYME,proteinuria,Trials Experience Because clinical trials are,0
LUMIZYME,proteinuria, conducted  under,1
LUMIZYME,nephrotic syndrome,der widely varying conditions,1
LUMIZYME,necrotizing skin lesions,"varying tions, adverse",1
LUMIZYME,necrotizing skin lesions,"tions,",1
LUMIZYME,necrotizing skin lesions,"tions, adverse",1
LUMIZYME,fluid overload,nausea,0
LUMIZYME,fluid overload,ta chypnea,1
LUMIZYME,fluid overload,headache hyperhidrosis nausea cough decreased oxygen saturation t,0
LUMIZYME,fluid overload,twitching,0
LUMIZYME,fluid overload,,0
LUMIZYME,fluid overload,,0
LUMIZYME,ANAPHYLAXIS,erythema sed blood p ressure,1
LUMIZYME,ANAPHYLAXIS,cyanosis erythema sed blood,1
LUMIZYME,ANAPHYLAXIS,Trials in,0
LUMIZYME,ANAPHYLAXIS,twitching agitation cyanosis erythema sed,1
LUMIZYME,ANAPHYLAXIS,twitching agitation cyanosis erythema sed blood p ressure,1
LUMIZYME,ANAPHYLAXIS,hypertensionincrea,0
LUMIZYME,ANAPHYLAXIS,sed blood,1
LUMIZYME,ANAPHYLAXIS,erythema sed blood p ressure,1
LUMIZYME,ANAPHYLAXIS,blood p ressure,1
LUMIZYME,ANAPHYLAXIS,agitation cyanosis erythema sed,1
LUMIZYME,HYPERSENSITIVITY,erythema hypertensionincreased blood pre,0
LUMIZYME,HYPERSENSITIVITY,igors tremor,0
LUMIZYME,HYPERSENSITIVITY,and,0
LUMIZYME,HYPERSENSITIVITY,pre,0
LUMIZYME,HYPERSENSITIVITY,"ssure, pallor, r igors",1
LUMIZYME,HYPERSENSITIVITY,,0
LUMIZYME,HYPERSENSITIVITY,"ssure, pallor, r igors",1
LUMIZYME,HYPERSENSITIVITY,"cyanosis erythema hypertensionincreased blood ssure, pallor, r igors",1
LUMIZYME,IMMUNE-MEDIATED REACTIONS,fatig ue,1
LUMIZYME,IMMUNE-MEDIATED REACTIONS,"blood pressure pallor , tremor, vomiting,",1
LUMIZYME,IMMUNE-MEDIATED REACTIONS,pressure pallor rigors,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,and JuvenileOnset Pompe Disease,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,Clinical,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,hypertensionincreased blood,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,"hypertensionincreased blood pressure pallor ,",1
LUMIZYME,IMMUNE-MEDIATED REACTIONS,"hypertensionincreased blood pressure pallor , tremor,",1
LUMIZYME,IMMUNE-MEDIATED REACTIONS,"pallor , tremor, vomiting, fatig ue",1
LUMIZYME,CARDIORESPIRATORY FAILURE,in InfantileOnset and JuvenileOnset Pompe Disease Two multicenter openlabel clinical,0
LUMIZYME,CARDIORESPIRATORY FAILURE,hypertensionincreased blood pressure pallor rigors tremor vomiting,0
LUMIZYME,CARDIORESPIRATORY FAILURE,"and a.
 

     Clinical Trial s",1
LUMIZYME,CARDIORESPIRATORY FAILURE,and a.,1
LUMIZYME,anaphylactic reactions,,0
LUMIZYME,anaphylactic reactions,Two multicenter openlabel al trials were conduct ed,1
LUMIZYME,hypersensitivity reactions,ages month to years old Approximately half of,0
LUMIZYME,Immune-mediated reactions,alglucosidase alfa or mgkg every other week for periods ranging from to,0
LUMIZYME,Immune-mediated reactions,Pompe disease patients ages month to years old Approximately half of,0
LUMIZYME,Immune-mediated reactions,the 4%) were,1
LUMIZYME,Immune-mediated reactions,Approximately half of the 4%) were male. Patients,1
LUMIZYME,Immune-mediated reactions,4%) were male. Patients w ere,1
LUMIZYME,Immune-mediated reactions,Approximately half of the 4%) were male. Patients w ere,1
LUMIZYME,Immune-mediated reactions,,0
LUMIZYME,proteinuria,mgkg,0
LUMIZYME,proteinuria,Patients were treated h,1
LUMIZYME,proteinuria,were treated h,1
LUMIZYME,proteinuria,h alglucosi dase,1
LUMIZYME,proteinuria,male Patients were treated h alglucosi dase,1
LUMIZYME,proteinuria,week for periods ranging from to,0
LUMIZYME,proteinuria,to weeks,0
LUMIZYME,proteinuria,Patients were treated h,1
LUMIZYME,proteinuria,years,0
LUMIZYME,nephrotic syndrome,m gkg,1
LUMIZYME,nephrotic syndrome,or 40 m gkg,1
LUMIZYME,nephrotic syndrome,of,0
LUMIZYME,nephrotic syndrome,Patients were treated with se alfa 20 or 40 m gkg,1
LUMIZYME,nephrotic syndrome,male Patients,0
LUMIZYME,nephrotic syndrome,serious,0
LUMIZYME,necrotizing skin lesions,very,1
LUMIZYME,necrotizing skin lesions,from to weeks mean weeks The most serious adverse,0
LUMIZYME,necrotizing skin lesions,very other week for peri ods,1
LUMIZYME,necrotizing skin lesions,wi,0
LUMIZYME,fluid overload,kely to occur with,1
LUMIZYME,fluid overload,were more kely to occur  with,1
LUMIZYME,fluid overload,more kely to,1
LUMIZYME,fluid overload,These reactions were more kely to,1
LUMIZYME,Anaphylaxis, frequently reported adverse reactions,1
LUMIZYME,Anaphylaxis,,0
LUMIZYME,Anaphylaxis, frequently reported adverse reactions in,1
LUMIZYME,Anaphylaxis,hypersensitivity,0
LUMIZYME,Anaphylaxis,trials were hypersensitivity reactions,0
LUMIZYME,Anaphylaxis, frequently reported,1
LUMIZYME,Anaphylaxis, frequently reported,1
LUMIZYME,Anaphylaxis,,0
LUMIZYME,Anaphylaxis,,0
LUMIZYME,Anaphylaxis, frequently reported adverse reactions in clinical,1
LUMIZYME,Hypersensitivity Reactions,,0
LUMIZYME,Hypersensitivity Reactions,in clinical trials,0
LUMIZYME,anaphylaxis,adverse reactions in clinical ials were h ypersensitivity reactions and included,1
LUMIZYME,anaphylaxis,reactions in clinical ials,1
LUMIZYME,anaphylaxis,,0
LUMIZYME,anaphylaxis,reactions in clinical ials were h ypersensitivity reactions and included,1
LUMIZYME,anaphylaxis,rash pyrexia flushingfeeling hot urticaria,0
LUMIZYME,anaphylaxis,anaphylaxis,0
LUMIZYME,anaphylaxis,ypersensitivity reactions and included,0
LUMIZYME,anaphylaxis,were h ypersensitivity reactions and included,1
LUMIZYME,anaphylaxis,anaphylaxis rash pyrexia flushingfeeling,0
LUMIZYME,hypersensitivity reactions,i ncluded anaphylaxis rash pyrexia,1
LUMIZYME,hypersensitivity reactions,ensitivity reactions and i ncluded anaphylaxis rash pyrexia,1
LUMIZYME,hypersensitivity reactions,and i ncluded anaphylaxis rash pyrexia,1
LUMIZYME,hypersensitivity reactions,were hypers,0
LUMIZYME,hypersensitivity reactions,i ncluded anaphylaxis rash pyrexia,1
LUMIZYME,hypersensitivity reactions,trials were ensitivity reactions and,1
LUMIZYME,Immune-Mediated Reactions,blood pressure pallor,0
LUMIZYME,Immune-Mediated Reactions,To report SPECTED ADVERSE,1
LUMIZYME,Immune-Mediated Reactions,report SPECTED ADVERSE REACTIONS contact Genzyme at or,1
LUMIZYME,Immune-Mediated Reactions,SPECTED ADVERSE REACTIONS contact Genzyme at or,1
LUMIZYME,Immune-Mediated Reactions,myalgia To report SPECTED,1
LUMIZYME,Immune-Mediated Reactions,and myalgia To report SPECTED ADVERSE REACTIONS contact Genzyme at or,1
LUMIZYME,Immune-Mediated Reactions,REACTIONS contact Genzyme at or,1
LUMIZYME,Immune-Mediated Reactions,To report SPECTED,1
LUMIZYME,Immune-Mediated Reactions,rigors tremor vomiting fatigue and myalgia To report SU,0
LUMIZYME,Immune-Mediated Reactions,REACTIONS contact Genzyme at or,1
LUMIZYME,Acute Cardiorespiratory Failure,wwwfdagovmedwatch Clinical Trials Experience ecause clinical trials are cond ucted under widely varying,1
LUMIZYME,Acute Cardiorespiratory Failure,wwwfdagovmedwatch Clinical Trials Experience ecause clinical,1
LUMIZYME,Acute Cardiorespiratory Failure,wwwfdagovmedwatch Clinical Trials Experience ecause clinical trials are cond ucted under widely varying,1
LUMIZYME,Acute Cardiorespiratory Failure,ecause clinical trials are,1
LUMIZYME,Acute Cardiorespiratory Failure,clinical trials are cond ucted under widely varying,1
LUMIZYME,Acute Cardiorespiratory Failure,a d,0
LUMIZYME,Acute Cardiorespiratory Failure,Clinical Trials Experience ecause clinical trials are cond ucted under widely varying,1
LUMIZYME,acute cardiorespiratory failure,rates observed,0
LUMIZYME,acute cardiorespiratory failure,the,0
LUMIZYME,acute cardiorespiratory failure,,0
LUMIZYME,acute cardiorespiratory failure,observed in clinical trials of a drug canno t be directly compared,1
LUMIZYME,acute cardiorespiratory failure,trials of a drug canno t be directly compared,1
LUMIZYME,acute cardiorespiratory failure,the,0
LUMIZYME,acute cardiorespiratory failure,adverse reaction,0
LUMIZYME,acute cardiorespiratory failure,observed in clinical,1
LUMIZYME,acute cardiorespiratory failure,drug canno t be directly compared,1
LUMIZYME,acute cardiorespiratory failure,directly compared to rates,0
LUMIZYME,Cardiac Arrhythmia,Anaphylaxis and hypersensitivity reactions seeWarnings,1
LUMIZYME,Cardiac Arrhythmia,reactions are described below and,0
LUMIZYME,Cardiac Arrhythmia,and elsewhere in the *,1
LUMIZYME,Cardiac Arrhythmia,reactions seeWarnings and Precautions,0
LUMIZYME,Cardiac Arrhythmia,in,0
LUMIZYME,Cardiac Arrhythmia,"


 *  Anaphylaxis and hypersensitivity reactions seeWarnings",1
LUMIZYME,Cardiac Arrhythmia,,0
LUMIZYME,Cardiac Arrhythmia,and,0
LUMIZYME,Cardiac Arrhythmia,"the 


 *  Anaphylaxis and hypersensitivity reactions seeWarnings",1
LUMIZYME,Cardiac Arrhythmia,the,0
LUMIZYME,Sudden Cardiac Death,the labeling Anaphylaxis hypersensitivity,1
LUMIZYME,Sudden Cardiac Death,Anaphylaxis hypersensitivity rea ctions seeWarnings and Precautions,1
LUMIZYME,Sudden Cardiac Death,and,0
LUMIZYME,Sudden Cardiac Death,Anaphylaxis hypersensitivity,1
LUMIZYME,Sudden Cardiac Death,Anaphylaxis hypersensitivity,1
LUMIZYME,Sudden Cardiac Death,labeling Anaphylaxis hypersensitivity rea ctions seeWarnings and Precautions,1
LUMIZYME,Sudden Cardiac Death,the labeling Anaphylaxis hypersensitivity,1
LUMIZYME,Anaphylaxis,muscle,0
LUMIZYME,Anaphylaxis,,0
LUMIZYME,Anaphylaxis,,0
LUMIZYME,Anaphylaxis,"nausea, cou gh decreased oxygen saturation",1
LUMIZYME,Anaphylaxis,"nausea, cou gh decreased oxygen saturation",1
LUMIZYME,Anaphylaxis,"headache nausea, cou gh decreased oxygen saturation",1
LUMIZYME,Anaphylaxis,,0
LUMIZYME,hypersensitivity reactions,rash pyrexia flushingfeeling hot urticaria headache,0
LUMIZYME,hypersensitivity reactions,ecreased oxygen saturation tachycardia tachypnea chest discomfort,1
LUMIZYME,hypersensitivity reactions,cough ecreased oxygen saturation tachycardia tachypnea chest discomfort,1
LUMIZYME,hypersensitivity reactions,pyrexia flushingfeeling hot urticaria,0
LUMIZYME,hypersensitivity reactions,ecreased oxygen saturation tachycardia tachypnea chest discomfort,1
LUMIZYME,anaphylactic shock,Pompe,0
LUMIZYME,anaphylactic shock,"pressure ,",1
LUMIZYME,anaphylactic shock,agitation cyanosis erythema hypertensionincreased,0
LUMIZYME,anaphylactic shock,,0
LUMIZYME,anaphylactic shock,vomiting fatigue and myalgia,0
LUMIZYME,anaphylactic shock,"erythema hypertensionincreased blood pressure , rigors,",1
LUMIZYME,anaphylactic shock,vomiting fatigue,0
LUMIZYME,anaphylactic shock,"rigors, tremor, vomiting fatigue and myalgia",1
LUMIZYME,anaphylactic shock,"tremor, vomiting fatigue and myalgia",1
LUMIZYME,anaphylactic shock,"pressure , rigors,",1
LUMIZYME,anaphylactic shock,erythema hypertensionincreased blood,0
LUMIZYME,cardiac arrest,"miting, fatigu e and myalgia Clinical",1
LUMIZYME,cardiac arrest,"pressure pallor rigors tremor miting,",1
LUMIZYME,cardiac arrest,"miting, fatigu e and myalgia Clinical",1
LUMIZYME,cardiac arrest,"rigors tremor miting,",1
LUMIZYME,cardiac arrest,"pallor rigors tremor miting, fatigu e and myalgia Clinical",1
LUMIZYME,cardiac arrest,"pressure pallor rigors tremor miting,",1
LUMIZYME,cardiac arrest,"rigors tremor miting, fatigu e and myalgia Clinical",1
LUMIZYME,cardiac arrest,vo,0
LUMIZYME,cardiac arrest,in InfantileOnset and JuvenileOnset Pompe Disease,0
LUMIZYME,cardiac arrest,"rigors tremor miting, fatigu e and myalgia Clinical",1
LUMIZYME,cardiac arrest,"rigors tremor miting, fatigu e and myalgia Clinical",1
LUMIZYME,cardiac arrest,in InfantileOnset and JuvenileOnset,0
LUMIZYME,respiratory arrest,and,1
LUMIZYME,respiratory arrest,myalgia. Clinical Trials in InfantileOnset,1
LUMIZYME,respiratory arrest,tremor vomiting and,1
LUMIZYME,respiratory arrest," and myalgia.
 

  Clinical Trials in InfantileOnset",1
LUMIZYME,respiratory arrest,Clinical Trials in InfantileOnset and JuvenileOnset Pompe Disease Two,0
LUMIZYME,respiratory arrest,fatigue,0
LUMIZYME,respiratory arrest,myalgia. Clinical Trials in InfantileOnset,1
LUMIZYME,respiratory arrest,multicenter open,0
LUMIZYME,respiratory arrest,,0
LUMIZYME,respiratory arrest,pallor rigors tremor,0
LUMIZYME,respiratory arrest,,0
LUMIZYME,respiratory arrest,Pompe,0
LUMIZYME,respiratory arrest," and myalgia.
 

  Clinical Trials in InfantileOnset",1
LUMIZYME,respiratory arrest,and myalgia. Clinical Trials in InfantileOnset,1
LUMIZYME,respiratory arrest,"tremor vomiting  and myalgia.
 

  Clinical Trials in InfantileOnset",1
LUMIZYME,respiratory arrest,vomiting and,1
LUMIZYME,respiratory distress,tremor,0
LUMIZYME,respiratory distress,,0
LUMIZYME,respiratory distress,tremor vomiting fatigue and   Clinical Trials in InfantileOnset and JuvenileOnset Pompe,1
LUMIZYME,respiratory distress,vomiting fatigue and   Clinical Trials in InfantileOnset and JuvenileOnset Pompe,1
LUMIZYME,respiratory distress,Disease Two,0
LUMIZYME,respiratory distress,fatigue and   Clinical Trials in InfantileOnset and JuvenileOnset Pompe,1
LUMIZYME,respiratory distress,Trials in InfantileOnset and JuvenileOnset Pompe,1
LUMIZYME,respiratory distress,vomiting fatigue and   Clinical Trials in InfantileOnset and JuvenileOnset Pompe,1
LUMIZYME,respiratory distress,pressure pallor rigors tremor vomiting,0
LUMIZYME,respiratory distress,tremor vomiting fatigue and   Clinical Trials in InfantileOnset and JuvenileOnset Pompe,1
LUMIZYME,respiratory distress,fatigue and   Clinical Trials in InfantileOnset and JuvenileOnset Pompe,1
LUMIZYME,hypoxia,and JuvenileOnset Pompe Disease Two multicenter openlabel clinical trials were,0
LUMIZYME,hypoxia,nfantil eOnset and JuvenileOnset Pompe,1
LUMIZYME,hypoxia,nfantil eOnset and JuvenileOnset Pompe,1
LUMIZYME,hypoxia,were,0
LUMIZYME,hypoxia,nfantil eOnset and JuvenileOnset Pompe,1
LUMIZYME,hypoxia,nfantil eOnset and JuvenileOnset Pompe,1
LUMIZYME,hypoxia,openlabel clinical trials were cond,0
LUMIZYME,hypoxia,nfantil eOnset and JuvenileOnset Pompe,1
LUMIZYME,hypoxia,nfantil eOnset and JuvenileOnset Pompe,1
LUMIZYME,hypoxia,,0
LUMIZYME,hypoxia,nfantil eOnset and JuvenileOnset Pompe,1
LUMIZYME,hypoxia,nfantil eOnset and JuvenileOnset Pompe,1
LUMIZYME,hypoxia,openlabel clinical trials,0
LUMIZYME,apnea,pallor rigors tremor vomiting,0
LUMIZYME,apnea,Onset and JuvenileOnset Pompe Disease,1
LUMIZYME,apnea,rigors tremor vomiting fatigue and myalgia Clinical Trials in Infantile,0
LUMIZYME,apnea,Infantile,0
LUMIZYME,apnea,multicenter openlabel clinical trials were,0
LUMIZYME,apnea,fatigue and,0
LUMIZYME,apnea,i,0
LUMIZYME,dyspnea,nileOnset Pompe,0
LUMIZYME,dyspnea,a,0
LUMIZYME,dyspnea,in infa,0
LUMIZYME,dyspnea,in InfantileOnset nd Juve nileOnset Pompe Disease Two,1
LUMIZYME,dyspnea,in InfantileOnset nd,1
LUMIZYME,dyspnea,Juve nileOnset Pompe Disease Two,1
LUMIZYME,dyspnea,nd Juve nileOnset Pompe Disease Two,1
LUMIZYME,dyspnea,InfantileOnset nd Juve nileOnset Pompe Disease Two,1
LUMIZYME,dyspnea,nd Juve nileOnset Pompe Disease Two,1
LUMIZYME,dyspnea,Pompe,0
LUMIZYME,bradycardia,Po mpe Disease Two multicenter,1
LUMIZYME,bradycardia,le-Onset Po mpe Disease Two multicenter,1
LUMIZYME,bradycardia,and le-Onset,1
LUMIZYME,bradycardia,trials were conducted in infantileonset,0
LUMIZYME,bradycardia,infantileonset P,0
LUMIZYME,bradycardia,fatigue and myalgia Clinical Trials,0
LUMIZYME,bradycardia,and le-Onset Po mpe Disease Two multicenter,1
LUMIZYME,bradycardia,InfantileOnset and le-Onset Po mpe Disease Two multicenter,1
LUMIZYME,bradycardia,and le-Onset,1
LUMIZYME,bradycardia,and le-Onset Po mpe Disease Two multicenter,1
LUMIZYME,bradycardia,in InfantileOnset and,0
LUMIZYME,bradycardia,Po mpe Disease Two multicenter,1
LUMIZYME,bradycardia,P,0
LUMIZYME,tachycardia,were conducted in infantileonset,0
LUMIZYME,tachycardia,and JuvenileOnset Pomp,0
LUMIZYME,tachycardia,Clinical Trials in InfantileOnset and JuvenileOnset,0
LUMIZYME,tachycardia,InfantileOnset and JuvenileOnset e,1
LUMIZYME,bronchospasm,Trials,0
LUMIZYME,bronchospasm,multi center openlabel clinical trials,1
LUMIZYME,bronchospasm,Pompe,0
LUMIZYME,bronchospasm,Two multi center openlabel clinical trials,1
LUMIZYME,bronchospasm,and JuvenileOnset Pompe Two,1
LUMIZYME,bronchospasm,"Pompe 

 Two multi center openlabel clinical trials",1
LUMIZYME,bronchospasm,,0
LUMIZYME,bronchospasm,InfantileOnset and JuvenileOnset Pompe Two,1
LUMIZYME,bronchospasm,"and JuvenileOnset Pompe 

 Two multi center openlabel clinical trials",1
LUMIZYME,bronchospasm,Clinical Trials,0
LUMIZYME,bronchospasm,,0
LUMIZYME,bronchospasm,openlabel clinical trials were conducted in infantileonset Pompe disease patients ages,0
LUMIZYME,bronchospasm,InfantileOnset and JuvenileOnset Pompe Two,1
LUMIZYME,throat tightness,,0
LUMIZYME,throat tightness,Disease Two multice,0
LUMIZYME,throat tightness,"Disease Two nter,",1
LUMIZYME,throat tightness,,0
LUMIZYME,throat tightness,"nter, open-label clinical trials were conducted",1
LUMIZYME,throat tightness,Trials in InfantileOnset and JuvenileOnset,0
LUMIZYME,throat tightness,"nter,",1
LUMIZYME,throat tightness,"Two nter,",1
LUMIZYME,throat tightness,"JuvenileOnset Pompe Disease Two nter, open-label clinical trials were conducted",1
LUMIZYME,throat tightness,InfantileOnset,0
LUMIZYME,throat tightness,"Pompe Disease Two nter,",1
LUMIZYME,throat tightness,open-label clinical trials were conducted,1
LUMIZYME,throat tightness,"Pompe Disease Two nter, open-label clinical trials were conducted",1
LUMIZYME,throat tightness,"nter, open-label clinical trials were conducted",1
LUMIZYME,throat tightness,open-label clinical trials were conducted,1
LUMIZYME,throat tightness,open-label clinical trials were conducted,1
LUMIZYME,throat tightness,clinical trials were conducted in infantileonset Pompe disease patients ages month to ye,0
LUMIZYME,throat tightness,InfantileOnset and JuvenileOnset Pompe Disease Two multice,0
LUMIZYME,throat tightness,,0
LUMIZYME,throat tightness,disease patients ages month to,0
LUMIZYME,hypotension,,0
LUMIZYME,hypotension,Two multicenter openlabel linical tri als were conducted in,1
LUMIZYME,hypotension,multicenter openlabel linical,1
LUMIZYME,hypotension,,0
LUMIZYME,hypotension,tri als were conducted in,1
LUMIZYME,hypotension,,0
LUMIZYME,hypotension,Two multicenter openlabel linical tri als were conducted in,1
LUMIZYME,hypotension,linical tri als were conducted in,1
LUMIZYME,hypotension,,0
LUMIZYME,hypotension,openlabel linical tri als were conducted in,1
LUMIZYME,hypotension,InfantileOnset and JuvenileOnset Pompe,0
LUMIZYME,hypotension,linical tri als were conducted in,1
LUMIZYME,hypotension,and JuvenileOnset Pompe,0
LUMIZYME,angioedema,in,0
LUMIZYME,angioedema,,0
LUMIZYME,angioedema,con ducted in infantileonset Pompe,1
LUMIZYME,angioedema,trial,0
LUMIZYME,angioedema,Pompe disease patients ages month to years old,0
LUMIZYME,lip swelling,conducted in -onset Pompe disease patients ages month,1
LUMIZYME,lip swelling,in -onset Pompe disease patients ages month,1
LUMIZYME,lip swelling,in -onset Pompe disease patients ages month,1
LUMIZYME,lip swelling,trials were conducted in -onset,1
LUMIZYME,lip swelling,were male,0
LUMIZYME,lip swelling,openlabel clinical trials were conducted,0
LUMIZYME,lip swelling,conducted in -onset,1
LUMIZYME,lip swelling,Pompe Disease Two multicenter openlabel clinical trials,0
LUMIZYME,lip swelling,Pompe disease patients ages month,1
LUMIZYME,lip swelling,,0
LUMIZYME,lip swelling,,0
LUMIZYME,lip swelling,Two,0
LUMIZYME,lip swelling,conducted in -onset Pompe disease patients ages month,1
LUMIZYME,lip swelling,in -onset Pompe disease patients ages month,1
LUMIZYME,lip swelling,conducted in -onset Pompe disease patients ages month,1
LUMIZYME,lip swelling,patients were male,0
LUMIZYME,periorbital edema,to years old Approximately half of the patients were,0
LUMIZYME,periorbital edema,,0
LUMIZYME,periorbital edema,infantileonset Pompe isease,1
LUMIZYME,periorbital edema,were tre,0
LUMIZYME,periorbital edema,"in infantileonset Pompe isease patients,  ages month to years",1
LUMIZYME,periorbital edema,d,0
LUMIZYME,periorbital edema,,0
LUMIZYME,periorbital edema,old Approximately half of the patients were male,0
LUMIZYME,periorbital edema,"patients, ages month to years",1
LUMIZYME,periorbital edema,"isease patients, ages month to years",1
LUMIZYME,periorbital edema,male Patients were tre,0
LUMIZYME,periorbital edema,to years old Approximately half of the patients were male,0
LUMIZYME,periorbital edema,in infantileonset Pompe isease,1
LUMIZYME,periorbital edema,"in infantileonset Pompe isease patients,  ages month to years",1
LUMIZYME,periorbital edema,in infantileonset Pompe isease,1
LUMIZYME,periorbital edema,multicenter openlabel clinical trials,0
LUMIZYME,periorbital edema,in infantileonset Pompe isease,1
LUMIZYME,periorbital edema,Approximately,0
LUMIZYME,periorbital edema,the patients were male Patients were,0
LUMIZYME,periorbital edema,"isease patients, ages month to years",1
LUMIZYME,face edema,clinical trials were conducted in infantileonset Pompe disease,0
LUMIZYME,face edema,Pompe disease patients  month to  years old Approximately half,1
LUMIZYME,face edema,to years old Approximately half,1
LUMIZYME,face edema,were treated with algluc,0
LUMIZYME,face edema,to years old Approximately half,1
LUMIZYME,face edema, month to  years old Approximately half,1
LUMIZYME,face edema,patients ages,0
LUMIZYME,face edema,Pompe disease patients  month to  years old Approximately half,1
LUMIZYME,face edema,ages,0
LUMIZYME,face edema,the,0
LUMIZYME,face edema,infantileonset Pompe disease patients month,1
LUMIZYME,face edema,male Patients were treated with algluc,0
LUMIZYME,face edema,month to years old Approximately half,1
LUMIZYME,face edema,openlabel clinical trials were conducted in infantileonset Pompe disease,0
LUMIZYME,face edema,to years old Approximately half,1
LUMIZYME,face edema,infantileonset Pompe disease patients month,1
LUMIZYME,face edema,to years old Approximately half,1
LUMIZYME,face edema,were conducted in,0
LUMIZYME,face edema,disease patients  month to  years old Approximately half,1
LUMIZYME,urticaria,in infantileonset Pompe,0
LUMIZYME,urticaria,,0
LUMIZYME,urticaria,,0
LUMIZYME,urticaria,,0
LUMIZYME,urticaria,A pproximately half of the,1
LUMIZYME,urticaria,old. A pproximately half of the,1
LUMIZYME,urticaria,pproximately half of the patients were male Patients,0
LUMIZYME,urticaria,conducted in infantileonset Pompe disease patients ages month,0
LUMIZYME,urticaria,rs old. A pproximately half of the,1
LUMIZYME,urticaria,infantileonset Pompe disease patients ages,0
LUMIZYME,chest discomfort,,0
LUMIZYME,chest discomfort,,0
LUMIZYME,chest discomfort,Approximately half of the were male. Patie nts were treated with,1
LUMIZYME,chest discomfort,Approximately half of the were,1
LUMIZYME,chest discomfort,,0
LUMIZYME,wheezing,to years old Approximately half of the,0
LUMIZYME,wheezing,Patients,0
LUMIZYME,wheezing,were male Patients e,1
LUMIZYME,wheezing,,0
LUMIZYME,wheezing,e treate d with alglucosidase alfa,1
LUMIZYME,wheezing,alfa or mgkg every other week for periods ranging,0
LUMIZYME,wheezing,Patients,0
LUMIZYME,tachypnea,patients,0
LUMIZYME,tachypnea,with algl ucosidase alfa or mgkg,1
LUMIZYME,tachypnea,were with,1
LUMIZYME,tachypnea,were male Patients were with algl ucosidase alfa or mgkg,1
LUMIZYME,tachypnea,from to,0
LUMIZYME,tachypnea,algl ucosidase alfa or mgkg,1
LUMIZYME,tachypnea,algl ucosidase alfa or mgkg,1
LUMIZYME,tachypnea,were male Patients were with,1
LUMIZYME,tachypnea,ranging from to weeks mean wee,0
LUMIZYME,cyanosis,osidase  alfa or mgkg every,1
LUMIZYME,cyanosis,treated with osidase  alfa or mgkg every,1
LUMIZYME,cyanosis,,0
LUMIZYME,cyanosis,osidase  alfa or mgkg every,1
LUMIZYME,cyanosis,osidase  alfa or mgkg every,1
LUMIZYME,cyanosis,were treated with osidase  alfa or mgkg every,1
LUMIZYME,cyanosis,,0
LUMIZYME,cyanosis,Patients were treated with osidase  alfa or mgkg every,1
LUMIZYME,cyanosis,osidase  alfa or mgkg every,1
LUMIZYME,cyanosis,osidase  alfa or mgkg every,1
LUMIZYME,decreased oxygen saturation,fa 20 or 40 mg/kg every oth er week for periods,1
LUMIZYME,decreased oxygen saturation,fa 20 or 40 mg/kg every oth er week for periods,1
LUMIZYME,decreased oxygen saturation,half of the patients were male,0
LUMIZYME,decreased oxygen saturation,most serious adverse react,0
LUMIZYME,decreased oxygen saturation,treated with alglucosidase fa 20 or 40 mg/kg every oth er week for periods,1
LUMIZYME,decreased oxygen saturation,,0
LUMIZYME,decreased oxygen saturation,40 mg/kg every oth er week for periods,1
LUMIZYME,decreased oxygen saturation,er week,0
LUMIZYME,convulsions,adverse,0
LUMIZYME,convulsions,eriods ranging from to weeks mean weeks The most serious adverse reactions reported,0
LUMIZYME,convulsions,mean weeks The most,0
LUMIZYME,convulsions,were male Patients were treated with alglucosidase alfa or,0
LUMIZYME,convulsions,The most serious adverse reactions,0
LUMIZYME,convulsions,every week,1
LUMIZYME,convulsions,every,0
LUMIZYME,convulsions,mgkg every  week for p eriods ranging from to,1
LUMIZYME,convulsions,week for,1
LUMIZYME,convulsions,Patients were treated with alglucosidase alfa or mgkg every,0
LUMIZYME,rash,other week for,0
LUMIZYME,rash,alfa or mgkg every other,0
LUMIZYME,rash,mean weeks The most,0
LUMIZYME,rash,periods ng,1
LUMIZYME,rash,for periods ng,1
LUMIZYME,rash,,0
LUMIZYME,rash,mgkg,0
LUMIZYME,rash,for periods ng,1
LUMIZYME,hyperhidrosis,treatm,0
LUMIZYME,hyperhidrosis,alglucosidase alfa,0
LUMIZYME,hyperhidrosis,adverse reactions reported with alglucosidase alfa treatm,0
LUMIZYME,hyperhidrosis,to 106 we eks mean weeks The,1
LUMIZYME,hyperhidrosis,mgkg every other week for,0
LUMIZYME,hyperhidrosis,alglucosidase,0
LUMIZYME,hyperhidrosis,weeks The most serious,0
LUMIZYME,nausea,(mea n weeks The most,1
LUMIZYME,dizziness,serious adverse reactions reported with alglucosidase alfa treatment included anaphy,0
LUMIZYME,dizziness,from to weeks 61,1
LUMIZYME,dizziness,alglucosidase alfa or mgkg every other week for periods ranging from to,0
LUMIZYME,hypertension,to weeks mean The,1
LUMIZYME,hypertension,"weeks mean 



 The mos t serious adverse reactions",1
LUMIZYME,hypertension,"



 The mos t serious adverse reactions",1
LUMIZYME,hypertension,every,0
LUMIZYME,hypertension,to weeks mean The,1
LUMIZYME,hypertension,"weeks mean 



 The mos t serious adverse reactions",1
LUMIZYME,increased blood pressure,serious adverse reactio ns reported with alglucosidase,1
LUMIZYME,increased blood pressure,and acute cardiorespiratory,0
LUMIZYME,flushing,alfa treatment included anaphylaxis and,0
LUMIZYME,flushing,most serious adverse  reporte d with alglucosidase alfa,1
LUMIZYME,flushing,from to weeks mean weeks,0
LUMIZYME,flushing,anaphylaxis and acute cardiorespiratory failure,0
LUMIZYME,flushing,for periods ranging from to weeks mean weeks The most,0
LUMIZYME,flushing,serious adverse  reporte d with alglucosidase alfa,1
LUMIZYME,feeling hot,adverse reactions with,1
LUMIZYME,feeling hot,reactions  with alglu cosidase alfa treatment included,1
LUMIZYME,feeling hot,The most,0
LUMIZYME,erythema,acute cardiorespiratory failure The most common adverse,0
LUMIZYME,erythema,sidase a lfa treatment included anaphylaxis,1
LUMIZYME,erythema,sidase a lfa treatment included anaphylaxis,1
LUMIZYME,erythema,sidase,1
LUMIZYME,erythema,adverse reactions reported with sidase,1
LUMIZYME,erythema,a lfa treatment included anaphylaxis,1
LUMIZYME,erythema,cardiorespiratory failure The,0
LUMIZYME,erythema,most,0
LUMIZYME,erythema,sidase,1
LUMIZYME,pyrexia,treat ment included anaphylaxis and,1
LUMIZYME,pyrexia,serious adverse reactions reported with alglucosidase,0
LUMIZYME,pyrexia,failure The most common,0
LUMIZYME,pyrexia,adverse reactions reported,0
LUMIZYME,pyrexia,a treat ment included anaphylaxis and,1
LUMIZYME,pyrexia,reactions reported with alglucosidase a treat ment included anaphylaxis and,1
LUMIZYME,pyrexia,a treat ment included anaphylaxis and,1
LUMIZYME,pyrexia,treat ment included anaphylaxis and,1
LUMIZYME,pyrexia,a treat ment included anaphylaxis and,1
LUMIZYME,pallor,acute cardiorespiratory,0
LUMIZYME,pallor,reactions,0
LUMIZYME,pallor,nt inc luded anaphylaxis and acute,1
LUMIZYME,pallor,nt inc luded anaphylaxis and acute,1
LUMIZYME,pallor,weeks The most serious adverse reactions reported with,0
LUMIZYME,pallor,nt inc luded anaphylaxis and acute,1
LUMIZYME,pallor,,0
LUMIZYME,pallor,with alglucosidase alfa nt inc luded anaphylaxis and acute,1
LUMIZYME,peripheral coldness,anaphylaxis and acute cardiorespiratory failure The,1
LUMIZYME,nervousness,,0
LUMIZYME,nervousness,common adverse,0
LUMIZYME,nervousness,piratory fa ilure The most common,1
LUMIZYME,nervousness,piratory fa ilure The most common,1
LUMIZYME,headache,"ure.



 The most common adverse",1
LUMIZYME,headache,most common adverse reactions requiring,0
LUMIZYME,back pain,and acute cardiorespiratory failure he most c ommon adverse reactions requiring,1
LUMIZYME,back pain,c ommon adverse reactions requiring,1
LUMIZYME,back pain,c ommon adverse reactions requiring,1
LUMIZYME,paresthesia,most adverse rea ctions requiring intervention in,1
LUMIZYME,paresthesia,failure The most adverse rea ctions requiring intervention in,1
LUMIZYME,paresthesia,intervention in clinical trials were hypersensitivity reactions occurring in of,0
LUMIZYME,paresthesia,included anaphylaxis and acute cardiorespiratory failure The most,0
LUMIZYME,paresthesia,trials were,0
LUMIZYME,paresthesia,included anaphylaxis and acute cardiorespiratory,0
LUMIZYME,Immune-mediated cutaneous reactions,Pyrexia,0
LUMIZYME,Immune-mediated cutaneous reactions,"     
  
   Rash (including rash er ythematous rash macular and",1
LUMIZYME,Immune-mediated cutaneous reactions,,0
LUMIZYME,Immune-mediated cutaneous reactions,,0
LUMIZYME,Immune-mediated cutaneous reactions,ythematous,0
LUMIZYME,Immune-mediated cutaneous reactions,Rash (including rash er ythematous rash macular and,1
LUMIZYME,Immune-mediated cutaneous reactions,ythematous rash,0
LUMIZYME,Immune-mediated cutaneous reactions,and,0
LUMIZYME,Immune-mediated cutaneous reactions,"Adverse      
  
   Rash (including rash er ythematous rash macular and",1
LUMIZYME,necrotizing skin lesions,erythematous rash macular,0
LUMIZYME,necrotizing skin lesions,rash macular and       7 (18)             Pyrexia,1
LUMIZYME,Systemic immune-mediated reactions,                                   Urticaria,1
LUMIZYME,Systemic immune-mediated reactions,macular and,0
LUMIZYME,Systemic immune-mediated reactions,                                   Urticaria,1
LUMIZYME,Systemic immune-mediated reactions,                                   Urticaria,1
LUMIZYME,Systemic immune-mediated reactions,,0
LUMIZYME,Systemic immune-mediated reactions,                                   Urticaria,1
LUMIZYME,Systemic immune-mediated reactions,,0
LUMIZYME,Systemic immune-mediated reactions,                                   Urticaria,1
LUMIZYME,Systemic immune-mediated reactions,                                   Urticaria,1
LUMIZYME,Systemic immune-mediated reactions,and maculopapular                                    Urticaria,1
LUMIZYME,type III immune-mediated reactions,Pyrexia,0
LUMIZYME,type III immune-mediated reactions,,0
LUMIZYME,type III immune-mediated reactions,ria,0
LUMIZYME,type III immune-mediated reactions,Pyrexia,0
LUMIZYME,deposition of anti-rhGAA antibodies,) Hypertension Increased Blood,1
LUMIZYME,deposition of anti-rhGAA antibodies,Flushing,0
LUMIZYME,deposition of anti-rhGAA antibodies,,0
LUMIZYME,inflammatory arthropathy,Oxygen,0
LUMIZYME,inflammatory arthropathy,Decreased Oxygen,0
LUMIZYME,pyrexia,,0
LUMIZYME,pyrexia, Decrea sed Oxygen Saturation,1
LUMIZYME,pyrexia, Decrea sed Oxygen Saturation,1
LUMIZYME,pyrexia, Decrea sed Oxygen Saturation,1
LUMIZYME,pyrexia,Oxygen Saturation,0
LUMIZYME,pyrexia,Blood,0
LUMIZYME,pyrexia,ensionIncreased Blood  Decrea sed Oxygen Saturation,1
LUMIZYME,pyrexia, Decrea sed Oxygen Saturation,1
LUMIZYME,membranous glomerulonephritis,Saturation,0
LUMIZYME,membranous glomerulonephritis,"Decreased Oxygen )                  
   Cough ",1
LUMIZYME,membranous glomerulonephritis,Decreased Oxygen ),1
LUMIZYME,membranous glomerulonephritis,),1
LUMIZYME,membranous glomerulonephritis,Saturation,0
LUMIZYME,positive anti-rhGAA IgG antibody titers,   Tachypnea                            Tachycardia,1
LUMIZYME,positive anti-rhGAA IgG antibody titers,   Tachypnea                            Tachycardia,1
LUMIZYME,positive anti-rhGAA IgG antibody titers,   Tachypnea                            Tachycardia,1
LUMIZYME,positive anti-rhGAA IgG antibody titers,   Tachypnea                            Tachycardia,1
LUMIZYME,positive anti-rhGAA IgG antibody titers,,0
LUMIZYME,immune complex deposition,Tachypnea,0
LUMIZYME,immune complex deposition,Tachypnea,0
LUMIZYME,immune complex deposition,Tachypnea,0
LUMIZYME,immune complex deposition,Tachypnea,0
LUMIZYME,immune complex deposition,"Tachypnea              
   Tachycar",1
LUMIZYME,immune complex deposition,E,0
LUMIZYME,immune complex deposition,"             
   Tachycar dia E",1
LUMIZYME,immune complex deposition,"             
   Tachycar",1
LUMIZYME,immune complex deposition,"             
   Tachycar dia E",1
LUMIZYME,immune complex deposition,"             
   Tachycar dia",1
LUMIZYME,Ventricular arrhythmias, 1 to 18 years with a m edian,1
LUMIZYME,Ventricular arrhythmias,Patients were 1,1
LUMIZYME,Ventricular arrhythmias,Patients were  1 to 18 years with a m edian,1
LUMIZYME,Ventricular arrhythmias,alglucosidase alfa Patients were aged,0
LUMIZYME,Ventricular arrhythmias,were 1 to 18 years with,1
LUMIZYME,Ventricular arrhythmias,alglucosidase alfa Patients were 1 to 18 years with,1
LUMIZYME,Ventricular arrhythmias,duration of treatment of days range to days No new safety findings were observed,0
LUMIZYME,Ventricular arrhythmias,alglucosidase,0
LUMIZYME,Ventricular arrhythmias,to 18 years with a m edian,1
LUMIZYME,Ventricular arrhythmias,years with a m edian,1
LUMIZYME,cardiac arrest,437,1
LUMIZYME,cardiac arrest,,0
LUMIZYME,cardiac arrest,437 days (rang e,1
LUMIZYME,cardiac arrest,437,1
LUMIZYME,cardiac arrest,treatment 437 days (rang e,1
LUMIZYME,death,of days  to 4 days,1
LUMIZYME,death,4 days,1
LUMIZYME,death,to 4 days,1
LUMIZYME,death,of days to,1
LUMIZYME,death,alfa,0
LUMIZYME,death,,0
LUMIZYME,death,alglucosidase,0
LUMIZYME,death,of treatment of days to,1
LUMIZYME,reduced clinical efficacy,ve,1
LUMIZYME,reduced clinical efficacy,enzyme replacement therapy,1
LUMIZYME,reduced clinical efficacy,patients were,0
LUMIZYME,reduced clinical efficacy,to enzyme replacement therapy,1
LUMIZYME,death,females n i,0
LUMIZYME,death,,0
LUMIZYME,death,therapy Patients were randomized in,0
CERDELGA,fatigue,fatigue headache nausea diarrhea back,1
CERDELGA,fatigue,in extremities and upper abdominal,0
CERDELGA,fatigue,,0
CERDELGA,fatigue,,0
CERDELGA,fatigue,fatigue,1
CERDELGA,fatigue,,0
CERDELGA,fatigue,fatigue headache,1
CERDELGA,nausea,upper abdominal,0
CERDELGA,nausea,fatigue headache,0
CERDELGA,nausea,reactions are fatigue nausea diarrhea,1
CERDELGA,nausea,nausea diarrhea,1
CERDELGA,nausea,EXCERPT The,0
CERDELGA,nausea,adverse,0
CERDELGA,nausea,nausea diarrhea,1
CERDELGA,nausea,extremities,0
CERDELGA,nausea,,0
CERDELGA,diarrhea,nausea,0
CERDELGA,diarrhea,diarrhea back,1
CERDELGA,diarrhea,EXCERPT The most common adverse reactions are fatigue,0
CERDELGA,diarrhea,diarrhea back,1
CERDELGA,diarrhea,,0
CERDELGA,diarrhea,To,0
CERDELGA,diarrhea,are fatigue headache diarrhea back,1
CERDELGA,diarrhea,most common adverse reactions are,0
CERDELGA,back pain,fatigue headache nausea diarrhea,0
CERDELGA,back pain,,0
CERDELGA,back pain,,0
CERDELGA,pain in extremities,pain in,1
CERDELGA,pain in extremities,pain in extremities and,1
CERDELGA,pain in extremities,back pain in extremities and,1
CERDELGA,pain in extremities,ADVERSE REACTIONS contact Genzyme,0
CERDELGA,pain in extremities,pain in extremities and,1
CERDELGA,pain in extremities,To report SUSPECTED ADVERSE REACTIONS contact Genzyme Corpora,0
CERDELGA,pain in extremities,in extremities and,1
CERDELGA,pain in extremities,diarrhea back pain in,1
CERDELGA,pain in extremities,,0
CERDELGA,upper abdominal pain,upper abdominal pain To,1
CERDELGA,fatigue,fatigue headache,1
CERDELGA,headache,were headache nausea,1
CERDELGA,nausea,,0
CERDELGA,nausea,nausea diarrhea,1
CERDELGA,nausea,nausea diarrhea,1
CERDELGA,nausea,,0
CERDELGA,nausea,extremities,0
CERDELGA,nausea,,0
CERDELGA,nausea,,0
CERDELGA,nausea,nausea diarrhea,1
CERDELGA,nausea,nausea diarrhea,1
CERDELGA,nausea,Trials and were,0
CERDELGA,diarrhea,diarrhea back,1
CERDELGA,diarrhea,patients treated with CERDELGA across Trials and were fatigue headache,0
CERDELGA,diarrhea,diarrhea back,1
CERDELGA,diarrhea,treated with CERDELGA,0
CERDELGA,diarrhea,diarrhea back,1
CERDELGA,diarrhea,diarrhea back,1
CERDELGA,diarrhea,diarrhea back,1
CERDELGA,diarrhea,with CERDELGA across Trials and were fatigue,0
CERDELGA,diarrhea,,0
CERDELGA,back pain,with CERDELGA across Trials and were fatigue headache nausea,0
CERDELGA,back pain,headache nausea back pain pain,1
CERDELGA,back pain,treated with CERDELGA across Trials,0
CERDELGA,back pain,back pain pain,1
CERDELGA,pain in extremities,back pain in,1
CERDELGA,pain in extremities,pain in extremities and,1
CERDELGA,pain in extremities,and were fatigue,0
CERDELGA,pain in extremities,CERDELGA is,0
CERDELGA,pain in extremities,upper abdominal pain The adverse reaction profile of CERDELGA is based,0
CERDELGA,pain in extremities,back pain in extremities and,1
CERDELGA,pain in extremities,,0
CERDELGA,pain in extremities,back pain,1
CERDELGA,pain in extremities,with CERDELGA across Trials,0
CERDELGA,upper abdominal pain,abdominal pain The,1
CERDELGA,upper abdominal pain,pain pain in extremities and,0
CERDELGA,upper abdominal pain,profile of CERDELGA is based on two controlled studies Trials and,0
CERDELGA,upper abdominal pain,back pain pain in extremities and,0
CERDELGA,Arthralgia,Arthralgia H,1
CERDELGA,Arthralgia,Arthralgia H,1
CERDELGA,Arthralgia,Patientsn Arthralgia H,1
CERDELGA,Arthralgia,Patientsn,0
CERDELGA,Arthralgia,on Patientsn Arthralgia H,1
CERDELGA,Arthralgia,,0
CERDELGA,Arthralgia,Arthralgia H,1
CERDELGA,Arthralgia,Arthralgia H,1
CERDELGA,Headache,Headache,1
CERDELGA,Headache,a,0
CERDELGA,Headache,Headache,1
CERDELGA,Migraine,Migraine,1
CERDELGA,Migraine,Migraine,1
CERDELGA,Migraine,,0
CERDELGA,Flatulence,,0
CERDELGA,Flatulence,Flatulence N,1
CERDELGA,Flatulence,Flatulence N,1
CERDELGA,Flatulence,,0
CERDELGA,Flatulence,Flatulence N,1
CERDELGA,Nausea,,0
CERDELGA,Nausea,Nausea,1
CERDELGA,Oropharyngeal pain,Oropharyngeal pain Tab,1
CERDELGA,Oropharyngeal pain,,0
CERDELGA,Oropharyngeal pain,,0
CERDELGA,Oropharyngeal pain,,0
CERDELGA,Oropharyngeal pain,,0
CERDELGA,Oropharyngeal pain,Oropharyngeal,1
CERDELGA,Oropharyngeal pain,,0
CERDELGA,Oropharyngeal pain,Oropharyngeal,1
CERDELGA,Oropharyngeal pain,Oropharyngeal pain Tab,1
CERDELGA,Oropharyngeal pain,Oropharyngeal pain Tab,1
CERDELGA,Fatigue,Fatigue,1
CERDELGA,Fatigue,Patientsn Patientsn,0
CERDELGA,Nausea,,0
CERDELGA,Diarrhea,,0
CERDELGA,Diarrhea,,0
CERDELGA,Diarrhea,Diarrhea,1
CERDELGA,Diarrhea,Diarrhea,1
CERDELGA,Diarrhea,Diarrhea,1
CERDELGA,Diarrhea,Diarrhea,1
CERDELGA,Diarrhea,,0
CERDELGA,Diarrhea,Diarrhea,1
CERDELGA,Diarrhea,,0
CERDELGA,Diarrhea,,0
CERDELGA,Back pain,,0
CERDELGA,Back pain,,0
CERDELGA,Back pain,,0
CERDELGA,Back pain,,0
CERDELGA,Upper abdominal pain,Upper abdominal pain Dizziness,1
CERDELGA,Upper abdominal pain,xtremity Upper abdominal pain Dizziness,1
CERDELGA,Upper abdominal pain,xtremity Upper,1
CERDELGA,Upper abdominal pain,Dizziness,0
CERDELGA,Upper abdominal pain,,0
CERDELGA,Upper abdominal pain,xtremity Upper abdominal,1
CERDELGA,Dyspepsia,Dyspepsia,1
CERDELGA,Dyspepsia,,0
CERDELGA,Gastroesophageal reflux disease,,0
CERDELGA,Gastroesophageal reflux disease,Constipation,0
CERDELGA,Gastroesophageal reflux disease,,0
CERDELGA,Gastroesophageal reflux disease,Gastroesophageal reflux,1
CERDELGA,Gastroesophageal reflux disease,Constipation,0
CERDELGA,Constipation,,0
CERDELGA,Constipation,Constipation Pal,1
CERDELGA,Constipation,,0
CERDELGA,Constipation,phageal reflux Constipation Pal,1
CERDELGA,Constipation,disease,0
CERDELGA,Constipation,,0
CERDELGA,Constipation,Constipation Pal,1
CERDELGA,Constipation,,0
CERDELGA,Constipation,Pal,0
CERDELGA,Constipation,,0
CERDELGA,Palpitations,ion,0
CERDELGA,Palpitations,ion Palpitations Ras,1
CERDELGA,Palpitations,ion,0
CERDELGA,Palpitations,,0
CERDELGA,Palpitations,,0
CERDELGA,Rash,ons Rash,1
CERDELGA,Rash,,0
CERDELGA,Rash,Rash,1
CERDELGA,Rash,Rash,1
CERDELGA,Rash,Rash,1
CERDELGA,Rash,ons Rash,1
CERDELGA,Rash,ons,0
CERDELGA,Rash,Rash,1
CERDELGA,Rash,ons,0
CERDELGA,ECG Changes,adverse r eactions are fatigue headache nausea,1
CERDELGA,ECG Changes,n adverse r eactions are fatigue,1
CERDELGA,ECG Changes,n,1
CERDELGA,ECG Changes,n adverse r,1
CERDELGA,ECG Changes,eactions,0
CERDELGA,ECG Changes,n adverse r,1
CERDELGA,ECG Changes,n adverse r eactions are fatigue headache nausea,1
CERDELGA,Cardiac Arrhythmias,To report S,0
CERDELGA,Cardiac Arrhythmias,headach e nausea diarrhea back,1
CERDELGA,cardiac arrhythmias,,0
CERDELGA,cardiac arrhythmias,a drug cannot be directly,0
CERDELGA,cardiac arrhythmias,trials of a,0
CERDELGA,cardiac arrhythmias,clinical trials of another drug and may,1
CERDELGA,cardiac arrhythmias,rates in clinical trials,1
CERDELGA,cardiac arrhythmias,clinical trials,1
CERDELGA,cardiac arrhythmias,clinical,0
CERDELGA,cardiac arrhythmias,compared to rates,0
CERDELGA,cardiac arrhythmias, clinical trials of another drug and may,1
CERDELGA,cardiac arrhythmias,to rates in  clinical trials of another drug and may,1
NEURACEQ,injection site reaction,injection site reaction consisting of,1
NEURACEQ,injection site reactions,receiving Neuraceq injection site,1
NEURACEQ,injection site reactions,Neuraceq injection site,1
NEURACEQ,injection site reactions,,0
NEURACEQ,injection site reactions,All adverse reactions,0
NEURACEQ,injection site reactions,were mild to moderate in,0
NEURACEQ,injection site reactions,reactions consisting of,1
NEURACEQ,injection site reactions,,0
NEURACEQ,injection site reactions,drug reactions,0
NEURACEQ,application site erythema,,0
NEURACEQ,application site erythema,application,1
NEURACEQ,application site erythema,reaction n application,1
NEURACEQ,application site erythema,,0
NEURACEQ,application site erythema,,0
NEURACEQ,Injection site irritation,application site Injection site,1
NEURACEQ,Injection site irritation,,0
NEURACEQ,Injection site irritation,Injection application site Injection site irritation Injection site,1
NEURACEQ,Injection site irritation,,0
NEURACEQ,Injection site irritation,Injection site,1
NEURACEQ,Injection site irritation,site erythema,0
NEURACEQ,Injection site irritation,Injection site,1
NEURACEQ,Injection site irritation,site,0
NEURACEQ,Injection site pain,,0
NEURACEQ,Injection site pain,Injection site,0
NEURACEQ,Injection site pain,irritation,0
NEURACEQ,Injection site pain,Injection site,1
NEURACEQ,Injection site pain,,0
NEURACEQ,long-term cumulative radiation exposure,"REACTIONS, contact Piramal at or FDA",1
NEURACEQ,long-term cumulative radiation exposure,,0
NEURACEQ,long-term cumulative radiation exposure,e drug,1
NEURACEQ,long-term cumulative radiation exposure,Subjects e drug reaction      n (%)              Injection application,1
NEURACEQ,long-term cumulative radiation exposure,Reported in Clinical Trials n Administrations in,0
NEURACEQ,Long-term cumulative radiation exposure,Injection / application site er ythema Injection,1
NEURACEQ,Long-term cumulative radiation exposure,/ application site er ythema Injection,1
NEURACEQ,Long-term cumulative radiation exposure,site er ythema Injection,1
NEURACEQ,Long-term cumulative radiation exposure,site er ythema Injection,1
NEURACEQ,Long-term cumulative radiation exposure,drug,0
NEURACEQ,Long-term cumulative radiation exposure,"drug reaction       
 Injection / application site er ythema Injection",1
NEURACEQ,cancer,,0
PROLIA,Hypocalcemia,the Hypocalcemia see Warnings,1
PROLIA,Hypocalcemia,labeling,0
PROLIA,Hypocalcemia,Warnings,0
PROLIA,Hypocalcemia,,0
PROLIA,Hypocalcemia,Hypocalcemia see Warnings,1
PROLIA,Hypocalcemia,Hypocalcemia see Warnings,1
PROLIA,Hypocalcemia,Hypocalcemia see Warnings,1
PROLIA,Infections,Infections see Warnings,1
PROLIA,Dermatologic Adverse Reactions,see Warnings and Dermatologic Adverse Reactions see Warnings,1
PROLIA,Dermatologic Adverse Reactions,Precautions,0
PROLIA,Dermatologic Adverse Reactions,Warnings and Dermatologic Adverse,1
PROLIA,Dermatologic Adverse Reactions,Serious Infections see Warnings and Precautions,0
PROLIA,Dermatologic Adverse Reactions,Warnings and,0
PROLIA,Dermatologic Adverse Reactions,Reactions see Warnings,1
PROLIA,Dermatologic Adverse Reactions,Infections see Warnings and Dermatologic,1
PROLIA,Dermatologic Adverse Reactions,Warnings and Dermatologic Adverse,1
PROLIA,Dermatologic Adverse Reactions,Adverse Reactions see Warnings,1
PROLIA,Osteonecrosis of the Jaw,Warnings and Osteonecrosis of the Jaw see Warnings,1
PROLIA,back pain,musculoskeletal pain hypercholesterolemia and cystitis The,0
PROLIA,pain in extremity,are back pain,0
PROLIA,pain in extremity,,0
PROLIA,pain in extremity,pain in extremity musculoskeletal pain,1
PROLIA,pain in extremity,back pain in extremity musculoskeletal pain,1
PROLIA,pain in extremity,pain in,1
PROLIA,musculoskeletal pain,patients with postmenopausal osteoporosis are back pain,0
PROLIA,musculoskeletal pain,pain pain in musculoskeletal,1
PROLIA,musculoskeletal pain,postmenopausal osteoporosis are back pain pain in extremity,0
PROLIA,hypercholesterolemia,with,0
PROLIA,hypercholesterolemia,hypercholesterolemia and cystitis,1
PROLIA,hypercholesterolemia,reported with Prolia in men with,0
PROLIA,hypercholesterolemia,hypercholesterolemia and cystitis,1
PROLIA,hypercholesterolemia,in extremity musculoskeletal hypercholesterolemia and cystitis,1
PROLIA,hypercholesterolemia,hypercholesterolemia and cystitis,1
PROLIA,hypercholesterolemia,hypercholesterolemia and cystitis,1
PROLIA,hypercholesterolemia,extremity musculoskeletal hypercholesterolemia and cystitis,1
PROLIA,hypercholesterolemia,hypercholesterolemia and cystitis,1
PROLIA,hypercholesterolemia,hypercholesterolemia and cystitis,1
PROLIA,cystitis,cystitis The most,1
PROLIA,cystitis,pain in extremity musculoskeletal pain,0
PROLIA,back pain,nasopharyngitis The most common per patient incidence adverse reacti,0
PROLIA,back pain,back pain arthralgia and,1
PROLIA,back pain,,0
PROLIA,back pain,in men with osteoporosis are,0
PROLIA,back pain,The most common per patient incidence adverse,0
PROLIA,back pain,men with osteoporosis back,1
PROLIA,back pain,men with osteoporosis back,1
PROLIA,back pain,adverse,0
PROLIA,arthralgia,arthralgia and nasopharyngitis,1
PROLIA,nasopharyngitis,are back pain arthralgia nasopharyngitis The most,1
PROLIA,nasopharyngitis,nasopharyngitis The most,1
PROLIA,nasopharyngitis,patie,0
PROLIA,nasopharyngitis,with Prolia in men with osteoporosis are,0
PROLIA,nasopharyngitis,arthralgia,0
PROLIA,nasopharyngitis,most common per patient incidence,0
PROLIA,nasopharyngitis,pain arthralgia nasopharyngitis The most,1
PROLIA,nasopharyngitis,back pain arthralgia nasopharyngitis The most,1
PROLIA,nasopharyngitis,men with osteoporosis are back pain,0
PROLIA,arthralgia,are,0
PROLIA,arthralgia,pain Pain in extremity and musculoskeletal pain have also been reported in clinical,0
PROLIA,arthralgia,arthralgia and back,1
PROLIA,arthralgia,or adjuvant aromatase,0
PROLIA,arthralgia,therapy for breast cancer arthralgia and back,1
PROLIA,arthralgia,for breast cancer arthralgia and back,1
PROLIA,arthralgia,pain Pain in,0
PROLIA,back pain,,0
PROLIA,back pain,,0
PROLIA,back pain,been reported in clinical trials,0
PROLIA,Pain in extremity,,0
PROLIA,Pain in extremity,arthralgia and back Pain,1
PROLIA,Pain in extremity,The,0
PROLIA,Pain in extremity,,0
PROLIA,Pain in extremity,The most common,0
PROLIA,Pain in extremity,have,0
PROLIA,Pain in extremity,r,0
PROLIA,Pain in extremity,arthralgia and back Pain in extremity and musculoskeletal,1
PROLIA,Pain in extremity,and back Pain in extremity and musculoskeletal,1
PROLIA,musculoskeletal pain,pain Pain in extremity musculoskeletal pain have also,1
PROLIA,musculoskeletal pain,in extremity and,0
PROLIA,musculoskeletal pain,trials,0
PROLIA,musculoskeletal pain,musculoskeletal,1
PROLIA,musculoskeletal pain,musculoskeletal pain have also,1
PROLIA,musculoskeletal pain,in extremity musculoskeletal,1
PROLIA,back pain,pain and constipation,1
PROLIA,constipation,constipation The Prolia,1
PROLIA,constipation,to discontinuation of Prolia in patients with postmenopausal osteoporosis are,0
PROLIA,back pain,,0
PROLIA,back pain,placebo were,0
PROLIA,back pain,has been,0
PROLIA,back pain,common than placebo back,1
PROLIA,back pain,common than placebo back,1
PROLIA,back pain,osteoporosis Most common,0
PROLIA,pain in extremity,clinic,0
PROLIA,hypercholesterolemia,common than placebo,0
PROLIA,hypercholesterolemia,hypercholesterolemia musculoskeletal pain,1
PROLIA,hypercholesterolemia,more common than placebo were back pain pain in,0
PROLIA,hypercholesterolemia,pain in hypercholesterolemia musculoskeletal pain,1
PROLIA,cystitis,cystitis Pancreatitis has,1
PROLIA,cystitis,cystitis Pancreatitis has,1
PROLIA,cystitis,cystitis Pancreatitis has,1
PROLIA,cystitis,pain pain in extremity hypercholesterolemia,0
PROLIA,Pancreatitis,Male Osteoporosis Most common adverse,0
PROLIA,Pancreatitis,,0
PROLIA,Pancreatitis,musculoskeletal pain and cystitis,0
PROLIA,Pancreatitis,adverse,0
PROLIA,Pancreatitis,common adverse reaction,0
PROLIA,Pancreatitis,hypercholesterolemia musculoskeletal pain and Pancreatitis has been,1
PROLIA,arthralgia,due to hormone ablation for cancer Most common,0
PROLIA,arthralgia,arthralgia and nasopharyngitis,1
PROLIA,arthralgia,back pain,0
PROLIA,arthralgia,reactions and more common than,0
PROLIA,arthralgia,arthralgia and nasopharyngitis,1
PROLIA,arthralgia,arthralgia and nasopharyngitis,1
PROLIA,arthralgia,arthralgia and nasopharyngitis,1
PROLIA,nasopharyngitis,,0
PROLIA,nasopharyngitis,adverse reactions and more common,0
PROLIA,nasopharyngitis,and more common than placebo were back pain arthralgia and,0
PROLIA,nasopharyngitis,nasopharyngitis Bone loss,1
PROLIA,nasopharyngitis,nasopharyngitis Bone loss,1
PROLIA,nasopharyngitis,nasopharyngitis Bone loss,1
PROLIA,arthralgia,common than placebo arthralgia and back,1
PROLIA,arthralgia,cancer Most common adverse reactions and,0
PROLIA,arthralgia,arthralgia and back,1
PROLIA,arthralgia,arthralgia and back,1
PROLIA,back pain,,0
PROLIA,Pain in extremity,in extremity and musculoskeletal,1
PROLIA,Pain in extremity,back Pain,1
PROLIA,Pain in extremity,arthralgia and back Pain in,1
PROLIA,Pain in extremity,common adverse reactions and,0
PROLIA,Pain in extremity,arthralgia and,0
PROLIA,Pain in extremity,pain have also been reported in clinical,0
PROLIA,Pain in extremity,reactions and more common than placebo were,0
PROLIA,musculoskeletal pain,pain have also,1
PROLIA,musculoskeletal pain,musculoskeletal pain have also,1
PROLIA,musculoskeletal pain,extremity musculoskeletal,1
PROLIA,musculoskeletal pain,extremity musculoskeletal pain have also,1
PROLIA,musculoskeletal pain,pain have also,1
PROLIA,musculoskeletal pain,musculoskeletal,1
PROLIA,musculoskeletal pain,Pain in,0
PROLIA,musculoskeletal pain,in extremity musculoskeletal pain have also,1
PROLIA,musculoskeletal pain,Pain in extremity musculoskeletal pain have also,1
PROLIA,musculoskeletal pain,extremity musculoskeletal pain have also,1
PROLIA,mortality,The incidence of mortality was n,1
PROLIA,mortality,vitamin D supplementation per day The incidence of,0
PROLIA,mortality,mortality was n,1
PROLIA,Anemia,Anemia CARDIAC DISORDERS,1
PROLIA,Anemia,Anemia CARDIAC DISORDERS,1
PROLIA,Anemia,Anemia CARDIAC DISORDERS,1
PROLIA,Vertigo,AND,0
PROLIA,Vertigo,DISORDERS,0
PROLIA,Abdominal pain upper,,0
PROLIA,Abdominal pain upper,GASTROINTESTINAL,0
PROLIA,Abdominal pain upper,,0
PROLIA,Flatulence,Flatulence Gastroesophageal reflux,1
PROLIA,Gastroesophageal reflux disease,,0
PROLIA,Gastroesophageal reflux disease,reflux disease GENERAL DISORDERS,1
PROLIA,Gastroesophageal reflux disease,Gastroesophageal reflux disease GENERAL DISORDERS,1
PROLIA,Edema peripheral,GENERAL DISORDERS,0
PROLIA,Edema peripheral,Edema peripheral Asthenia INFECTIONS,1
PROLIA,Edema peripheral,,0
PROLIA,Edema peripheral,DISORDERS AND ADMINISTRATION SITE Edema,1
PROLIA,Edema peripheral,GENERAL DISORDERS,0
PROLIA,Asthenia,SITE CONDITIONS Edema Asthenia INFECTIONS AND,1
PROLIA,Asthenia,AND INFESTATIONS Cystitis,0
PROLIA,Asthenia,CONDITIONS,0
PROLIA,Asthenia,Asthenia INFECTIONS AND,1
PROLIA,Asthenia,AND INFESTATIONS,0
PROLIA,Asthenia,Asthenia INFECTIONS AND,1
PROLIA,Asthenia,Asthenia INFECTIONS AND,1
PROLIA,Asthenia,INFESTATIONS,0
PROLIA,Asthenia,Asthenia INFECTIONS AND,1
PROLIA,Asthenia,Asthenia INFECTIONS AND,1
PROLIA,Cystitis,INFECTIONS AND Cystitis Upper respiratory,1
PROLIA,Cystitis,Cystitis Upper respiratory,1
PROLIA,Cystitis,INFECTIONS AND Cystitis Upper respiratory,1
PROLIA,Cystitis,P,0
PROLIA,Cystitis,Cystitis Upper respiratory,1
PROLIA,Cystitis,Cystitis Upper respiratory,1
PROLIA,Cystitis,Cystitis Upper respiratory,1
PROLIA,Cystitis,Cystitis Upper respiratory,1
PROLIA,Cystitis,Cystitis Upper respiratory,1
PROLIA,Upper respiratory tract infection,Cystitis,0
PROLIA,Upper respiratory tract infection,,0
PROLIA,Upper respiratory tract infection,,0
PROLIA,Upper respiratory tract infection,INFECTIONS AND INFESTATIONS Upper respiratory tract infection Pneumonia Pharyngitis,1
PROLIA,Upper respiratory tract infection,infection Pneumonia Pharyngitis,1
PROLIA,Pneumonia,,0
PROLIA,Pharyngitis,Pharyngitis Herpes zoster,1
PROLIA,Pharyngitis,Pneumonia,0
PROLIA,Pharyngitis,AND NUTRITION D,0
PROLIA,Pharyngitis,infection,0
PROLIA,Pharyngitis,tract infection Pharyngitis Herpes zoster,1
PROLIA,Herpes zoster,DISORDERS,0
PROLIA,Herpes zoster,Pharyngitis,0
PROLIA,Herpes zoster,DISORDERS Hypercholesterolemia,0
PROLIA,Herpes zoster,Pneumonia Herpes,1
PROLIA,Herpes zoster,Pharyngitis,0
PROLIA,Herpes zoster,Pneumonia Herpes,1
PROLIA,Herpes zoster,Pharyngitis,0
PROLIA,Herpes zoster,METABOLISM AND,0
PROLIA,Herpes zoster,METABOLISM AND,0
PROLIA,Herpes zoster,Pharyngitis,0
PROLIA,Hypercholesterolemia,,0
PROLIA,Hypercholesterolemia,,0
PROLIA,Hypercholesterolemia,Hypercholesterolemia MUSCULOSKELETAL AND,1
PROLIA,Hypercholesterolemia,Hypercholesterolemia MUSCULOSKELETAL AND,1
PROLIA,Hypercholesterolemia,,0
PROLIA,Hypercholesterolemia,Hypercholesterolemia MUSCULOSKELETAL AND,1
PROLIA,Pain in extremity,Back,0
PROLIA,Pain in extremity,DISORDERS Back Pain in extremity Musculoskeletal pain,1
PROLIA,Pain in extremity,TISSUE,0
PROLIA,Pain in extremity,AND CONNECTIVE TISSUE DISORDERS Back,0
PROLIA,Pain in extremity,CONNECTIVE TISSUE DISORDERS Back Pain,1
PROLIA,Pain in extremity,DISORDERS Back,0
PROLIA,Musculoskeletal pain,Myalgia,0
PROLIA,Musculoskeletal pain,Pain in Musculoskeletal pain Bone pain,1
PROLIA,Musculoskeletal pain,pain Myalgia,0
PROLIA,Musculoskeletal pain,in Musculoskeletal pain Bone pain,1
PROLIA,Musculoskeletal pain,Musculoskeletal pain Bone pain,1
PROLIA,Musculoskeletal pain,pain Pain in extremity,0
PROLIA,Musculoskeletal pain,,0
PROLIA,Bone pain,,0
PROLIA,Bone pain,,0
PROLIA,Bone pain,,0
PROLIA,Bone pain,Bone,1
PROLIA,Bone pain,Bone pain Myalgia Spinal,1
PROLIA,Bone pain,,0
PROLIA,Bone pain,pain,0
PROLIA,Bone pain,Spinal,0
PROLIA,Bone pain,Bone pain Myalgia Spinal,1
PROLIA,Bone pain,extremity Musculoskeletal Bone,1
PROLIA,Myalgia,Bone,0
PROLIA,Myalgia,Spinal osteoarthritis,0
PROLIA,Myalgia,pain,0
PROLIA,Spinal osteoarthritis,Spinal osteoarthritis NERVOUS SYSTEM,1
PROLIA,Spinal osteoarthritis,Spinal osteoarthritis NERVOUS SYSTEM,1
PROLIA,Spinal osteoarthritis,,0
PROLIA,Spinal osteoarthritis,pain Spinal,1
PROLIA,Spinal osteoarthritis,pain Spinal,1
PROLIA,Sciatica,,0
PROLIA,Sciatica,NERVOUS SYSTEM Sciatica PSYCHIATRIC DISORDERS,1
PROLIA,Sciatica,Sciatica PSYCHIATRIC DISORDERS,1
PROLIA,Sciatica,Sciatica PSYCHIATRIC DISORDERS,1
PROLIA,Sciatica,PSYCHIATRIC DISORDERS Insomnia,0
PROLIA,Sciatica,Insomnia,0
PROLIA,Sciatica,Sciatica PSYCHIATRIC DISORDERS,1
PROLIA,Sciatica,PSYCHIATRIC DISORDERS Insomnia,0
PROLIA,Insomnia,PSYCHIATRIC,0
PROLIA,Insomnia,Insomnia SKIN AND,1
PROLIA,Insomnia,Insomnia SKIN AND,1
PROLIA,Insomnia,,0
PROLIA,Insomnia,Sciatica PSYCHIATRIC,0
PROLIA,Insomnia,Insomnia SKIN AND,1
PROLIA,Insomnia,DISORDERS Sciatica PSYCHIATRIC DISORDERS,0
PROLIA,Insomnia,PSYCHIATRIC DISORDERS,0
PROLIA,Insomnia,PSYCHIATRIC Insomnia SKIN AND,1
PROLIA,Rash,Rash Pruritus Hypocalcemia,1
PROLIA,Rash,TISSUE,0
PROLIA,Rash,SKIN AND SUBCUTANEOUS TISSUE,0
PROLIA,Rash,Rash Pruritus Hypocalcemia,1
PROLIA,Rash,TISSUE,0
PROLIA,Rash,Rash Pruritus Hypocalcemia,1
PROLIA,Rash,Rash Pruritus Hypocalcemia,1
PROLIA,Pruritus,SUBCUTANEOUS TISSUE DISORDERS Pruritus Hypocalcemia Decreases,1
PROLIA,Pruritus,TISSUE DISORDERS Pruritus Hypocalcemia Decreases,1
PROLIA,Pruritus,DISORDERS Pruritus Hypocalcemia Decreases,1
PROLIA,Pruritus,Rash,0
PROLIA,Pruritus,,0
PROLIA,Pruritus,Pruritus Hypocalcemia Decreases,1
PROLIA,Pruritus,,0
PROLIA,Decreases in serum calcium levels,Decreases in,1
PROLIA,Decreases in serum calcium levels,in the placebo,0
PROLIA,Decreases in serum calcium levels,Decreases in,1
PROLIA,Decreases in serum calcium levels,Pruritus Decreases in serum calcium levels to less,1
PROLIA,Decreases in serum calcium levels,Decreases in serum calcium levels to less,1
PROLIA,Decreases in serum calcium levels,than mgdL at any visit were reported in women in the,0
PROLIA,Decreases in serum calcium levels,Hypocalcemia,0
PROLIA,Decreases in serum calcium levels,less than mgdL at any visit were reported in women in the placebo group,0
PROLIA,Decreases in serum calcium levels,Pruritus Decreases in serum calcium levels to less,1
PROLIA,Decreases in serum calcium levels,visit were reported in women in the placebo group,0
PROLIA,symptomatic hypocalcemia,of subjects,0
PROLIA,symptomatic hypocalcemia,of renal function serum calcium,0
PROLIA,symptomatic hypocalcemia,hypocalcemia were observed,1
PROLIA,symptomatic hypocalcemia,hypocalcemia were observed,1
PROLIA,symptomatic hypocalcemia,levels mgdL symptomatic,1
PROLIA,symptomatic hypocalcemia,subjects with varying degrees of renal function,0
PROLIA,symptomatic hypocalcemia,varying degrees of renal function serum,0
PROLIA,infection,infection In the,1
PROLIA,infection,clinical study of postmenopausal women with osteoporosis,0
PROLIA,infection,study of postmenopausal women with osteoporosis the incidence of,0
PROLIA,infection,infection In the,1
PROLIA,infection,infec,0
PROLIA,infection,infection In the,1
PROLIA,infection,,0
PROLIA,infection,may increase the risk infection In the,1
PROLIA,infections,infections resulting in,1
PROLIA,death,death was in,1
PROLIA,infections in the abdomen,the Prolia groups Hospitalizations due to,0
PROLIA,infections in the abdomen,due to infections in the abdomen placebo vs,1
PROLIA,infections in the abdomen,vs Prolia and ear,0
PROLIA,infections in the abdomen,tract placebo vs Prolia and ear,0
PROLIA,infections in the abdomen,and in the Prolia groups Hospitalizations due to,0
PROLIA,infections in the abdomen,vs Prolia urinary tract placebo vs Prolia and ear placebo,0
PROLIA,infections in the abdomen,due to infections in the abdomen placebo vs,1
PROLIA,infections in the abdomen,the Prolia groups Hospitalizations due to,0
PROLIA,infections in the abdomen,,0
PROLIA,Endocarditis,infections,0
PROLIA,Endocarditis,Endocarditis was reported,1
PROLIA,Endocarditis,Endocarditis was reported,1
PROLIA,Endocarditis,ear placebo vs,0
PROLIA,Skin infections,Endocarditis was,0
PROLIA,Skin infections,Skin infections including erysipelas,1
PROLIA,Skin infections,patients receiving,0
PROLIA,Skin infections,erysipelas and cellulitis leading to hospitalization,0
PROLIA,Skin infections,no,0
PROLIA,Skin infections,and patients receiving Skin,1
PROLIA,Skin infections,and patients receiving Skin infections including erysipelas,1
PROLIA,Skin infections,more,0
PROLIA,Skin infections,were reported more,0
PROLIA,Skin infections,reported Endocarditis was reported in no,0
PROLIA,cellulitis,and,0
PROLIA,cellulitis,patients receiving Prolia Skin infections,0
PROLIA,opportunistic infections,opportunistic infections was similar,1
PROLIA,opportunistic infections,infections was similar,1
PROLIA,opportunistic infections,incidence opportunistic,1
PROLIA,opportunistic infections,infections was similar,1
PROLIA,opportunistic infections,patients treated with Prolia placebo vs Prolia The incidence,0
PROLIA,opportunistic infections,significantly higher,0
PROLIA,opportunistic infections,similar to that reported with placebo Dermatologic Reactions,0
PROLIA,opportunistic infections,,0
PROLIA,dermal adverse events,Prolia developed epidermal and,0
PROLIA,dermal adverse events,placebo,0
PROLIA,dermal adverse events,A significantly higher number of patients treated with Prolia developed epidermal,0
PROLIA,dermal adverse events,developed epidermal dermal adverse events such as,1
PROLIA,dermal adverse events,number of patients treated with,0
PROLIA,dermal adverse events,,0
PROLIA,dermal adverse events,with Prolia developed epidermal dermal adverse events such as,1
PROLIA,dermal adverse events,dermal adverse,1
PROLIA,dermal adverse events,with Prolia developed epidermal dermal,1
PROLIA,dermatitis,dermatitis eczema and,1
PROLIA,dermatitis,the placebo,0
PROLIA,dermatitis,of,0
PROLIA,dermatitis,Prolia developed epidermal and dermal adverse events such,0
PROLIA,dermatitis,dermatitis eczema and,1
PROLIA,dermatitis,dermatitis eczema and,1
PROLIA,eczema,eczema and rashes,1
PROLIA,eczema,as eczema and rashes,1
PROLIA,eczema,with Prolia developed epidermal and dermal adverse,0
PROLIA,eczema,,0
PROLIA,eczema,as eczema and rashes,1
PROLIA,eczema,patients treated with Prolia developed epidermal,0
PROLIA,eczema,eczema and rashes,1
PROLIA,eczema,eczema and rashes,1
PROLIA,rashes,rashes with these,1
PROLIA,ONJ,,0
PROLIA,atypical femoral fractures,and Diaphyseal Fractures In the osteoporosis clinical trial program,0
PROLIA,atypical femoral fractures,fractures were reported,1
PROLIA,atypical femoral fractures,fractures were reported,1
PROLIA,atypical femoral fractures,patients treated with Prolia The duration of Prolia exposure to time,0
PROLIA,atypical femoral fracture,Prolia exposure to time atypical,1
PROLIA,atypical femoral fracture,,0
PROLIA,atypical femoral fracture,atypical femoral fracture diagnosis was,1
PROLIA,atypical femoral fracture,to time atypical femoral fracture diagnosis was,1
PROLIA,atypical femoral fracture,of Prolia exposure to,0
PROLIA,atypical femoral fracture,of,0
PROLIA,atypical femoral fracture,atypical femoral fracture diagnosis was,1
PROLIA,atypical femoral fracture,femoral fracture diagnosis was,1
PROLIA,Pancreatitis,the placebo and patients in the Prolia groups Of,0
PROLIA,Pancreatitis,Of the,0
PROLIA,Pancreatitis,was as,0
PROLIA,Pancreatitis,patients,0
PROLIA,Pancreatitis,was as early,0
PROLIA,Pancreatitis,Pancreatitis was reported,1
PROLIA,death,group Several patients had,0
PROLIA,death,ad,0
PROLIA,death,death in the,1
PROLIA,death,patients had a prior history of pancreatitis The time,0
PROLIA,death,pancreatitis The time from product ad,0
PROLIA,death,including death in the,1
PROLIA,death,including death in the,1
PROLIA,death,death in the,1
PROLIA,death,death in the,1
PROLIA,malignancies,incidence of malignancies was in,1
PROLIA,malignancies,malignancies was in,1
PROLIA,malignancies,placebo and in the Prolia groups,0
PROLIA,malignancies,Malignancies The,0
PROLIA,malignancies,malignancies was in,1
PROLIA,mortality,mortality was n,1
PROLIA,mortality,day,0
PROLIA,mortality,,0
PROLIA,mortality,The incidence of nonfat,0
PROLIA,mortality,mortality was n,1
PROLIA,mortality,mortality was n,1
PROLIA,mortality,mortality was n,1
PROLIA,mortality,mortality was n,1
PROLIA,mortality,mortality was n,1
PROLIA,mortality,day The,0
PROLIA,back pain,arthralgia placebo,0
PROLIA,back pain,and more frequently with,0
PROLIA,back pain,patients back,1
PROLIA,back pain,and,0
PROLIA,back pain,pain placebo vs,1
PROLIA,back pain,placebo vs Prolia arthralgia placebo,0
PROLIA,back pain,than,0
PROLIA,back pain,back,1
PROLIA,back pain,osteoporosis and more frequently with Prolia than,0
PROLIA,back pain,Prolia than,0
PROLIA,nasopharyngitis,,0
PROLIA,nasopharyngitis,,0
PROLIA,nasopharyngitis,,0
PROLIA,nasopharyngitis,,0
PROLIA,nasopharyngitis,vs Prolia nasopharyngitis placebo vs,1
PROLIA,infection,vs Prolia Serious Infections,0
PROLIA,infection,infection was reported,1
PROLIA,infection,in patient in the placebo group and,0
PROLIA,infection,infection was reported,1
PROLIA,dermal adverse events,,0
PROLIA,dermal adverse events,Reactions Epidermal,0
PROLIA,dermal adverse events,events such as,1
PROLIA,dermal adverse events,events such as,1
PROLIA,dermal adverse events,and,0
PROLIA,dermal adverse events,Reactions Epidermal dermal,1
PROLIA,dermal adverse events,Reactions Epidermal,0
PROLIA,dermatitis,in the placebo,0
PROLIA,dermatitis,,0
PROLIA,eczema,Dermatologic Reactions Epidermal and dermal adverse events such as,0
PROLIA,eczema,eczema and rashes,1
PROLIA,eczema,placebo group,0
PROLIA,eczema,eczema and rashes,1
PROLIA,eczema,,0
PROLIA,eczema,group Dermatologic Reactions Epidermal and dermal adverse,0
PROLIA,eczema,adverse,0
PROLIA,eczema,adverse events,0
PROLIA,eczema,eczema and rashes,1
PROLIA,eczema,adverse events,0
PROLIA,rashes,dermal,0
PROLIA,rashes,Prolia group,0
PROLIA,rashes,Prolia group,0
PROLIA,rashes,adverse events such as dermatitis eczema,0
PROLIA,rashes,were reported in patients in the placebo group and patients in the Prolia,0
PROLIA,rashes,rashes were reported,1
PROLIA,rashes,eczema,0
PROLIA,rashes,dermatitis eczema and,0
PROLIA,rashes,Prolia group,0
PROLIA,ONJ,in the Prolia group Osteonecrosis of the Jaw No,0
PROLIA,ONJ,the Jaw No cases ONJ were reported,1
PROLIA,ONJ,the Jaw No cases ONJ were reported,1
PROLIA,ONJ,in,0
PROLIA,ONJ,,0
PROLIA,ONJ,Jaw No cases ONJ were reported,1
PROLIA,ONJ,ONJ were reported,1
PROLIA,ONJ,were reported Pancreatitis,0
PROLIA,Pancreatitis,Osteonecrosis,0
PROLIA,Pancreatitis,of ONJ were reported Pancreatitis was reported,1
PROLIA,Pancreatitis,Pancreatitis was reported,1
PROLIA,Pancreatitis,Pancreatitis was reported,1
PROLIA,Pancreatitis,group,0
PROLIA,Pancreatitis,Pancreatitis was reported,1
PROLIA,malignancies,malignancies were reported,1
PROLIA,malignancies,cancers,0
PROLIA,malignancies,malignancies were reported,1
PROLIA,malignancies,group New Malignancies malignancies were reported,1
PROLIA,malignancies,no,0
PROLIA,malignancies,,0
PROLIA,malignancies,malignancies were reported,1
PROLIA,malignancies,malignancies were reported,1
PROLIA,prostate cancers,placebo group and prostate cancers basal cell,1
PROLIA,prostate cancers,,0
PROLIA,prostate cancers,group Treatment of Bone Loss,0
PROLIA,prostate cancers,prostate,1
PROLIA,prostate cancers,prostate cancers basal cell,1
PROLIA,prostate cancers,prostate cancers basal cell,1
PROLIA,prostate cancers,group and prostate,1
PROLIA,arthralgia,arthralgia placebo vs,1
PROLIA,arthralgia,vs,0
PROLIA,arthralgia,vs Prolia and back pain,0
PROLIA,arthralgia,Prolia,0
PROLIA,arthralgia,,0
PROLIA,arthralgia,AI therapy for breast cancer,0
PROLIA,arthralgia,arthralgia placebo vs,1
PROLIA,arthralgia,arthralgia placebo vs,1
PROLIA,arthralgia,arthralgia placebo vs,1
PROLIA,arthralgia,arthralgia placebo vs,1
PROLIA,back pain,vs Prolia and musculoskele,0
PROLIA,back pain,and musculoskele,0
PROLIA,back pain,Prolia Pain in extremity,0
PROLIA,back pain,than in the placebotreated,0
PROLIA,back pain,placebo vs Prolia back pain placebo vs,1
PROLIA,back pain,,0
PROLIA,back pain,vs Prolia back pain placebo vs,1
PROLIA,back pain,,0
PROLIA,back pain,placebo vs Prolia back pain placebo vs,1
PROLIA,Pain in extremity,Pain in extremity placebo vs,1
PROLIA,Pain in extremity,,0
PROLIA,Pain in extremity,extremity placebo vs,1
PROLIA,Pain in extremity,Pain in,1
PROLIA,musculoskeletal pain,,0
PROLIA,musculoskeletal pain,placebo vs Prolia musculoskeletal pain placebo vs,1
PROLIA,musculoskeletal pain,Prolia Pain in extremity placebo vs Prolia,0
PROLIA,musculoskeletal pain,vs Prolia musculoskeletal pain placebo vs,1
PROLIA,musculoskeletal pain,placebo vs Prolia have also,0
PROLIA,cataracts,cataracts was observed,1
PROLIA,cataracts,mgdL,0
PROLIA,cataracts,,0
PROLIA,cataracts,cataracts was observed,1
PROLIA,cataracts,a greater incidence cataracts was observed,1
PROLIA,cataracts,of,0
PROLIA,cataracts,cataracts was observed,1
PROLIA,cataracts,,0
PROLIA,cataracts,cataracts was observed,1
PROLIA,cataracts,Proliatreated men with nonmetastatic prostate cancer receiving,0
PROLIA,Hypocalcemia,Proliatreated,0
PROLIA,Hypocalcemia,of cataracts was observed placebo,0
PROLIA,Hypocalcemia,incidence of,0
PROLIA,Hypocalcemia,Hypocalcemia serum calcium,1
PROLIA,Hypocalcemia,placebo vs,0
PROLIA,Hypocalcemia,a greater incidence,0
PROLIA,hypersensitivity reactions,and erythema,0
PROLIA,hypersensitivity reactions,,0
PROLIA,hypersensitivity reactions,,0
PROLIA,hypersensitivity reactions,urticaria facial swelling and erythema,0
PROLIA,hypersensitivity reactions,swelling and erythema Hypocalcemia,0
PROLIA,hypersensitivity reactions,,0
PROLIA,hypersensitivity reactions,during post approval,0
PROLIA,anaphylaxis,,0
PROLIA,anaphylaxis,anaphylaxis rash urticaria,1
PROLIA,anaphylaxis,erythema Hypocalcemia severe symptomatic hypocalcemi,0
PROLIA,anaphylaxis,Hypocalcemia severe,0
PROLIA,anaphylaxis,,0
PROLIA,anaphylaxis,Drugrelated hypersensitivity anaphylaxis rash urticaria,1
PROLIA,anaphylaxis,rash urticaria facial swelling and erythema Hypocalcemia severe symptomatic,0
PROLIA,anaphylaxis,anaphylaxis rash urticaria,1
PROLIA,anaphylaxis,anaphylaxis rash urticaria,1
PROLIA,anaphylaxis,and erythema,0
PROLIA,rash,hypersensitivity reactions rash urticaria facial,1
PROLIA,facial swelling,Musculoskeletal pain,0
PROLIA,facial swelling,facial swelling and erythema,1
PROLIA,facial swelling,facial swelling and erythema,1
PROLIA,facial swelling,use of Prolia Drugrelated hypersensitivity reactions anaphylaxis rash urticaria,0
PROLIA,facial swelling,hypocalcemia Musculoskeletal pain,0
PROLIA,facial swelling,,0
PROLIA,facial swelling,facial swelling and erythema,1
PROLIA,facial swelling,anaphylaxis rash facial,1
PROLIA,erythema,erythema Hypocalcemia severe,1
PROLIA,erythema,erythema Hypocalcemia severe,1
PROLIA,erythema,erythema Hypocalcemia severe,1
PROLIA,erythema,erythema Hypocalcemia severe,1
PROLIA,erythema,erythema Hypocalcemia severe,1
PROLIA,erythema,erythema Hypocalcemia severe,1
PROLIA,erythema,urticaria facial swelling erythema Hypocalcemia severe,1
PROLIA,erythema,erythema Hypocalcemia severe,1
PROLIA,erythema,facial swelling,0
PROLIA,erythema,erythema Hypocalcemia severe,1
PROLIA,Hypocalcemia,swelling and,0
PROLIA,Hypocalcemia,Hypocalcemia severe symptomatic,1
PROLIA,Hypocalcemia,swelling and Hypocalcemia severe symptomatic,1
PROLIA,Hypocalcemia,symptomatic hypocalcemia Musculoskeletal pain including severe cases Parathyroid,0
PROLIA,Hypocalcemia,Hypocalcemia severe symptomatic,1
PROLIA,Hypocalcemia,severe cases,0
PROLIA,Hypocalcemia,urticaria facial swelling and erythema,0
PROLIA,symptomatic hypocalcemia,,0
PROLIA,symptomatic hypocalcemia,symptomatic hypocalcemia Musculoskeletal pain,1
PROLIA,hypocalcemia,pain including severe cases Parathyroid,0
PROLIA,hypocalcemia,,0
PROLIA,hypocalcemia,and erythema Hypocalcemia severe hypocalcemia Musculoskeletal pain,1
PROLIA,hypocalcemia,,0
PROLIA,hypocalcemia,hypocalcemia Musculoskeletal pain,1
PROLIA,hypocalcemia,,0
PROLIA,Musculoskeletal pain,Musculoskeletal pain including severe,1
PROLIA,Musculoskeletal pain,symptomatic Musculoskeletal pain including severe,1
PROLIA,Musculoskeletal pain,Musculoskeletal pain including severe,1
PROLIA,Musculoskeletal pain,pain including severe,1
PROLIA,toxicity,clinical response was associated with,0
PROLIA,toxicity,of altered pharmacokinetic toxicity profile or,1
PROLIA,toxicity,toxicity profile or,1
PROLIA,toxicity,toxicity profile or,1
PROLIA,toxicity,clinical response was associated with binding antibody development The incidence o,0
PROLIA,Hypersensitivity,Warnings,1
PROLIA,Hypersensitivity,Hypocalcemia Warnings,1
PROLIA,Hypersensitivity,the labeling Hypocalcemia see,0
PROLIA,anaphylactic reactions,Serious Infections see,1
PROLIA,anaphylactic reactions,"see Warnings and  5.3  )]  
 *  Serious Infections see",1
PROLIA,anaphylactic reactions,Infections see Warnings and Precautions Dermatologic Adverse Reactions see Warni,0
PROLIA,anaphylactic reactions,* Serious Infections see,1
PROLIA,anaphylactic reactions,elsewhere in the,0
PROLIA,anaphylactic reactions,and Precautions,0
PROLIA,anaphylactic reactions," 5.3  )]  
 *  Serious Infections see",1
PROLIA,anaphylactic reactions,5.3 )] * Serious Infections see,1
PROLIA,anaphylactic reactions,the,0
PROLIA,Hypocalcemia,Warnings,1
PROLIA,Hypocalcemia,Precautions Dermatologic Adverse Reactions Warnings,1
PROLIA,Hypocalcemia,Precautions Dermatologic Adverse Reactions Warnings and Precautions Osteonecrosis,1
PROLIA,Hypocalcemia,Precautions Osteonecrosis of the Jaw see,0
PROLIA,Hypocalcemia,Dermatologic Adverse Reactions Warnings and Precautions Osteonecrosis,1
PROLIA,Hypocalcemia,Warnings,1
PROLIA,Hypocalcemia,Adverse Reactions Warnings and Precautions Osteonecrosis,1
PROLIA,Hypocalcemia,Dermatologic Adverse Reactions Warnings and Precautions Osteonecrosis,1
PROLIA,Hypocalcemia,,0
PROLIA,Osteonecrosis of the jaw,with,0
PROLIA,Osteonecrosis of the jaw,Femoral Fractures see Warnings and,0
PROLIA,Osteonecrosis of the jaw,)] The most,1
PROLIA,Osteonecrosis of the jaw,Warnings and,0
PROLIA,Osteonecrosis of the jaw,,0
PROLIA,Atypical femoral fractures,postmenopausal os teoporosis are,1
PROLIA,Atypical femoral fractures,,0
PROLIA,Atypical femoral fractures,Prolia,0
PROLIA,Atypical femoral fractures,and cystiti,0
PROLIA,Atypical femoral fractures,nts with postmenopausal os teoporosis are,1
PROLIA,Atypical femoral fractures,in nts with postmenopausal os teoporosis are,1
PROLIA,Atypical femoral fractures,Prolia in nts with postmenopausal os teoporosis are,1
PROLIA,Atypical femoral fractures,,0
PROLIA,infections,and cystitis The most mon advers e reactions,1
PROLIA,infections,and cystitis The most mon advers e reactions,1
PROLIA,infections,,0
PROLIA,infections,The most mon advers e reactions,1
PROLIA,infections,cystitis The most mon advers e reactions,1
PROLIA,skin infections,reported,1
PROLIA,skin infections,,0
PROLIA,skin infections, reported with  Prolia in,1
PROLIA,skin infections,arthralgia and nasopharyngitis The most common,0
PROLIA,skin infections,Prolia in men with osteoporosis are back,0
PROLIA,skin infections,back pain arthralgia and nasopharyngitis,0
PROLIA,skin infections,reported,1
PROLIA,skin infections,most common adverse  reported with  Prolia in,1
PROLIA,skin infections,most common adverse  reported with  Prolia in,1
PROLIA,Dermatitis,therapy for prostate,0
PROLIA,rashes,n ther apy for,1
PROLIA,eczema,deprivation therapy r pros tate cancer,1
PROLIA,eczema,,0
PROLIA,eczema,are arthralgia and,0
PROLIA,eczema,aromatase inhibitor therapy,0
PROLIA,eczema,pros tate cancer,1
PROLIA,eczema,r pros tate cancer,1
PROLIA,eczema,r pros tate cancer,1
PROLIA,eczema,Prolia in,0
PROLIA,eczema,aromatase inhibitor,0
PROLIA,Muscle Pain,in emity,1
PROLIA,Muscle Pain,pain Pain in,0
PROLIA,Muscle Pain,emity and m usculoskeletal pain,1
PROLIA,Muscle Pain,,0
PROLIA,Muscle Pain,emity,1
PROLIA,Suppression of bone turnover,in extremity and musculoskeletal pain have also been reported in clinical,0
PROLIA,Suppression of bone turnover,are back pain,0
PROLIA,Suppression of bone turnover,Pain in extremity and musculoskeletal pain have,0
PROLIA,Suppression of bone turnover,most common adverse react ions leading,1
PROLIA,Suppression of bone turnover,clinical trials he,1
PROLIA,Suppression of bone turnover,,0
PROLIA,Suppression of bone turnover,reported in clinical trials he most common,1
PROLIA,Suppression of bone turnover,clinical trials he most common adverse react ions leading,1
PROLIA,Suppression of bone turnover,,0
PROLIA,hypersensitivity,reactions and more,0
PROLIA,hypersensitivity,common adverse reactions and more common t,0
PROLIA,anaphylaxis,osteoporosis Most common,0
PROLIA,anaphylaxis,information about this program *,1
PROLIA,anaphylaxis,* Post menopausal osteoporosis,1
PROLIA,anaphylaxis,this program     *  Post menopausal osteoporosis,1
PROLIA,anaphylaxis,about this program *,1
PROLIA,anaphylaxis,common adverse reactions and more common than,0
PROLIA,anaphylaxis,reactions and more,0
PROLIA,anaphylaxis,,0
PROLIA,hypotension,were back pain pain in extremity hypercholesterolemia,0
PROLIA,hypotension,m ore common,1
PROLIA,hypotension,back pain pain in extremity hypercholesterolemia musculoskeletal,0
PROLIA,hypotension,adverse (> 5% and,1
PROLIA,hypotension,adverse (>,1
PROLIA,hypotension,(> 5% and,1
PROLIA,hypotension,5% and m ore common,1
PROLIA,hypotension,adverse (>,1
PROLIA,hypotension,pain pain in extremity hypercholesterolemia musculoskeletal,0
PROLIA,dyspnea,common adverse reactions and e,1
PROLIA,dyspnea,e,1
PROLIA,dyspnea,EXCERPT Postmenopausal osteoporosis Most common adverse,0
PROLIA,dyspnea,adverse reactions and e commo n than,1
PROLIA,dyspnea,common adverse reactions and e commo n than,1
PROLIA,upper airway edema,,0
PROLIA,upper airway edema,extremit y hypercholesterolemia,1
PROLIA,upper airway edema,", pain in extremit y hypercholesterolemia",1
PROLIA,upper airway edema,"were back , pain in",1
PROLIA,upper airway edema,,0
PROLIA,pruritus, hyperch olesterolemia musculoskeletal,1
PROLIA,pruritus,more common than placebo were back pain pain in extremity,0
PROLIA,pruritus, hyperch olesterolemia musculoskeletal,1
PROLIA,pruritus,trials,0
PROLIA,pruritus, hyperch olesterolemia musculoskeletal,1
PROLIA,Hypocalcemia,Treatment of Postmenopausal Women ith Osteopor osis The,1
PROLIA,Hypocalcemia,ith Osteopor osis The,1
PROLIA,Hypocalcemia,osteoporosis was assessed in a,0
PROLIA,Hypocalcemia,Postmenopausal Women ith Osteopor osis The,1
PROLIA,Hypocalcemia,Osteopor osis The,1
PROLIA,Hypocalcemia,Women ith Osteopor osis The,1
PROLIA,Hypocalcemia,Treatment of Postmenopausal Women ith,1
PROLIA,Hypocalcemia,postmenopausal osteoporosis was,0
PROLIA,elevations of serum parathyroid hormone,91 years. A total of women were,1
PROLIA,elevations of serum parathyroid hormone,of,0
PROLIA,elevations of serum parathyroid hormone,study of,0
PROLIA,ONJ,the,0
PROLIA,ONJ,,0
PROLIA,ONJ,,0
PROLIA,Atypical femoral fractures,Decreases in serum calcium levels to less,0
PROLIA,thigh pain,approximately day after,0
PROLIA,thigh pain,women in Prolia,1
PROLIA,thigh pain,in  Prolia gr oup The,1
PROLIA,thigh pain,at,0
PROLIA,thigh pain,day,0
PROLIA,infections,serum,0
PROLIA,infections,"rosis, the mean change",1
PROLIA,infections,study of postmenopausal,0
PROLIA,infections,study of postmenopausal women,0
PROLIA,infections,"women with rosis,",1
PROLIA,infections,the mean change,1
PROLIA,infections,"rosis, the mean change",1
PROLIA,infections,"with rosis,",1
PROLIA,infections,"rosis,",1
PROLIA,skin infections,with creatinine clearance mLmin vs,0
PROLIA,skin infections,mLmin vs n subjects with creatinine clearance,1
PROLIA,infections of the abdomen,with creatinine learance,1
PROLIA,infections of the abdomen,vs in subjects with creatinine c,0
PROLIA,infections of the abdomen,>= 30 mL/min. Serious Infections,1
PROLIA,infections of the abdomen,30 mL/min. Serious Infections,1
PROLIA,infections of the abdomen,"subjects with creatinine learance >= 30 mL/min. 

 Serious Infections",1
PROLIA,infections of the abdomen,expressed,0
PROLIA,infections of the abdomen,clearance mLmin vs in subjects with creatinine c,0
PROLIA,infections of the abdomen,,0
PROLIA,infections of the abdomen,,0
PROLIA,infections of the abdomen,learance >=,1
PROLIA,opportunistic infections,inhibitor such as Prolia may increase,1
PROLIA,opportunistic infections,Therefore a inhibitor,1
PROLIA,opportunistic infections,Prolia may increase,1
PROLIA,opportunistic infections,,0
PROLIA,opportunistic infections,of infection In the clinical study of postmenopausal women with,0
PROLIA,opportunistic infections,activated T and,0
PROLIA,opportunistic infections,in lymph nodes Therefore a RANKL,0
PROLIA,opportunistic infections,,0
PROLIA,opportunistic infections,inhibitor such as Prolia may increase,1
PROLIA,opportunistic infections,and B lymphocytes and in lymph,0
PROLIA,infections,menopausal women with,1
PROLIA,infections,death was in,0
PROLIA,infections,as Prolia may increase the risk of infection,0
PROLIA,infections,menopausal women with,1
PROLIA,infections,menopausal women with,1
PROLIA,infections,menopausal women with,1
PROLIA,infections,(0.7% pl acebo vs,1
PROLIA,infections,ear,0
PROLIA,infections,,0
PROLIA,infections,the n (0.7% pl acebo vs,1
PROLIA,infections,Prolia urinary tract placebo,0
PROLIA,infections,the n (0.7% pl acebo vs,1
PROLIA,dermal adverse events,in patients treated with rolia (<,1
PROLIA,dermal adverse events,reported more frequently in patients treated with P,0
PROLIA,dermal adverse events,in patients treated with rolia (<,1
PROLIA,dermal adverse events,in patients treated with rolia (<,1
PROLIA,dermatitis,"Prolia placebo  Prolia).
 The incidence",1
PROLIA,dermatitis,was similar,0
PROLIA,dermatitis,vs,0
PROLIA,dermatitis,patients treated with Prolia,0
PROLIA,eczema,"
 The  incidence of",1
PROLIA,eczema,"
 The  incidence of",1
PROLIA,eczema,Prolia,0
PROLIA,eczema,"
 The  incidence of",1
PROLIA,rashes,,0
PROLIA,rashes,of opportunistic infections,1
PROLIA,rashes,Dermatologic Reactions,0
PROLIA,muscle pain,p Most of these events were,0
PROLIA,muscle pain,,0
PROLIA,muscle pain,Most of these events were not s,0
PROLIA,muscle pain,,0
PROLIA,muscle pain,events were not,0
PROLIA,muscle pain,were,0
PROLIA,muscle pain,to the injection,1
PROLIA,suppression of bone remodeling,The duration of ia exposure to,1
PROLIA,suppression of bone remodeling,time of atypica l femoral,1
PROLIA,suppression of bone remodeling,years see Warnings and Precautions,0
PROLIA,suppression of bone remodeling,as years see,0
PROLIA,suppression of bone remodeling,fractures were reported in patients treated with,0
PROLIA,suppression of bone remodeling,of atypica l femoral,1
PROLIA,suppression of bone remodeling,of ia exposure to time of atypica l femoral,1
PROLIA,suppression of bone remodeling,duration of ia exposure to time of atypica l femoral,1
PROLIA,suppression of bone remodeling,duration of ia exposure to time of atypica l femoral,1
PROLIA,suppression of bone remodeling,patients,0
PROLIA,suppression of bone remodeling,the placebo group and 8 patients in the Prolia group had serious,1
PROLIA,suppression of bone remodeling,these reports patient in the placebo group and,0
PROLIA,suppression of bone remodeling,8 patients in the Prolia group had serious,1
PROLIA,osteonecrosis of the jaw,including one death in the,0
PROLIA,osteonecrosis of the jaw,Prolia group Sev,0
PROLIA,osteonecrosis of the jaw,of pancreatitis The time from product administration to event occurrence,0
PROLIA,osteonecrosis of the jaw,prio r history,1
PROLIA,osteonecrosis of the jaw,a prio r history,1
PROLIA,osteonecrosis of the jaw,eral patients had a prio r history,1
PROLIA,osteonecrosis of the jaw,group had serious events including one death in,0
PROLIA,atypical fractures,history of pancrea titis The,1
PROLIA,atypical fractures,variable New,0
PROLIA,atypical fractures,Several patients had a history,1
PROLIA,atypical fractures,,0
PROLIA,atypical fractures,group,0
PROLIA,atypical fractures,Malignancies,0
PROLIA,atypical fractures,pancrea titis The,1
PROLIA,atypical fractures,Several patients had a history of pancrea titis The,1
PROLIA,atypical fractures,group had serious events including,0
PROLIA,delayed fracture healing,of new,0
PROLIA,delayed fracture healing,a prior history of The time from product,1
PROLIA,delayed fracture healing,prior history of The time from,1
PROLIA,delayed fracture healing,event occurrence was variable New Malignancies The overall incidence,0
FANAPT,dizziness,nasal congestion orthostatic hypotension somnolence,0
FANAPT,dizziness,adverse reactions incidence and fold greater than placebo,0
FANAPT,dizziness,dizziness dry mouth,1
FANAPT,dry mouth,were dry mouth fatigue nasal,1
FANAPT,dry mouth,than placebo were dizziness,0
FANAPT,dry mouth,mouth fatigue nasal,1
FANAPT,dry mouth,dry,1
FANAPT,dry mouth,dry,1
FANAPT,dry mouth,than placebo were dry mouth fatigue nasal,1
FANAPT,fatigue,,0
FANAPT,fatigue,fatigue nasal congestion,1
FANAPT,fatigue,dizziness dry,0
FANAPT,fatigue,adverse reactions incidence and fold greater than placebo,0
FANAPT,fatigue,,0
FANAPT,fatigue,fatigue nasal congestion,1
FANAPT,fatigue,fatigue nasal congestion,1
FANAPT,fatigue,fatigue nasal congestion,1
FANAPT,fatigue,dizziness,0
FANAPT,nasal congestion,were dizziness dry mouth nasal congestion orthostatic hypotension,1
FANAPT,nasal congestion,tachycardia and weight increased,0
FANAPT,nasal congestion,dry mouth nasal congestion orthostatic hypotension,1
FANAPT,nasal congestion,hypotension somnolence tachycardia,0
FANAPT,nasal congestion,,0
FANAPT,nasal congestion,,0
FANAPT,nasal congestion,dry mouth nasal congestion orthostatic hypotension,1
FANAPT,nasal congestion,,0
FANAPT,nasal congestion,nasal,1
FANAPT,orthostatic hypotension,placebo were dizziness dry,0
FANAPT,orthostatic hypotension,nasal,0
FANAPT,somnolence,congestion orthostatic somnolence tachycardia and,1
FANAPT,somnolence,increased To report SUSPECTED ADVERSE REACTIONS contact,0
FANAPT,somnolence,somnolence tachycardia and,1
FANAPT,somnolence,orthostatic somnolence tachycardia and,1
FANAPT,somnolence,somnolence tachycardia and,1
FANAPT,somnolence,,0
FANAPT,somnolence,nasal congestion orthostatic,0
FANAPT,somnolence,nasal,0
FANAPT,tachycardia,mouth fatigue nasal congestion orthostatic,0
FANAPT,tachycardia,tachycardia and weight,1
FANAPT,tachycardia,contact Novartis Phar,0
FANAPT,tachycardia,weight increased,0
FANAPT,tachycardia,tachycardia and weight,1
FANAPT,tachycardia,and weight increased To report SUSPECTED ADVERSE REACTIONS contact Novartis Phar,0
FANAPT,tachycardia,fatigue nasal congestion orthostatic hypotension somnolence,0
FANAPT,tachycardia,mouth,0
FANAPT,tachycardia,were dizziness dry mouth fatigue nasal,0
FANAPT,Arthralgia,Arthralgia Fatigue,1
FANAPT,Arthralgia,Arthralgia Fatigue,1
FANAPT,Arthralgia,,0
FANAPT,Arthralgia,,0
FANAPT,Arthralgia,Arthralgia Fatigue,1
FANAPT,Arthralgia,,0
FANAPT,Arthralgia,a Arthralgia Fatigue,1
FANAPT,Fatigue,,0
FANAPT,Fatigue,Musculoskeletal,0
FANAPT,Fatigue,Arthralgia Fatigue Musculoskeletal,1
FANAPT,Fatigue,Arthralgia,0
FANAPT,Fatigue,Arthralgia,0
FANAPT,Fatigue,Arthralgia,0
FANAPT,Fatigue,,0
FANAPT,Musculoskeletal Stiffness,Fatigue Musculoskeletal Stiffness Weight Increased,1
FANAPT,Musculoskeletal Stiffness,Fatigue Musculoskeletal Stiffness Weight Increased,1
FANAPT,Musculoskeletal Stiffness,Fatigue Musculoskeletal Stiffness Weight,1
FANAPT,Musculoskeletal Stiffness,Increased,0
FANAPT,Weight Increased,,0
FANAPT,Tachycardia,Cardiac Tachycardia Eye Disorders,1
FANAPT,Tachycardia,,0
FANAPT,Tachycardia,Tachycardia Eye Disorders,1
FANAPT,Tachycardia,Tachycardia Eye Disorders,1
FANAPT,Tachycardia,Tachycardia Eye Disorders,1
FANAPT,Tachycardia,Tachycardia Eye Disorders,1
FANAPT,Tachycardia,Tachycardia Eye Disorders,1
FANAPT,Tachycardia,Tachycardia Eye Disorders,1
FANAPT,Tachycardia,,0
FANAPT,Tachycardia,Disorders,0
FANAPT,Vision Blurred,Blurred Gastrointestinal Disorders,1
FANAPT,Vision Blurred,Gastrointestinal Disorders,0
FANAPT,Vision Blurred,Blurred Gastrointestinal Disorders,1
FANAPT,Vision Blurred,Blurred Gastrointestinal Disorders,1
FANAPT,Vision Blurred,Vision Blurred Gastrointestinal Disorders,1
FANAPT,Vision Blurred,Gastrointestinal Disorders,0
FANAPT,Vision Blurred,,0
FANAPT,Vision Blurred,Eye Vision,1
FANAPT,Vision Blurred,Vision Blurred Gastrointestinal Disorders,1
FANAPT,Vision Blurred,Disorders,0
FANAPT,Nausea,Nausea Dry Mouth,1
FANAPT,Dry Mouth,Nausea Dry,1
FANAPT,Dry Mouth,Mouth Diarrhea,1
FANAPT,Dry Mouth,Nausea Dry,1
FANAPT,Dry Mouth,,0
FANAPT,Dry Mouth,Nausea Dry Mouth Diarrhea,1
FANAPT,Diarrhea,Diarrhea Abdominal,1
FANAPT,Diarrhea,Mouth,0
FANAPT,Diarrhea,,0
FANAPT,Diarrhea,Diarrhea Abdominal,1
FANAPT,Diarrhea,Discomfort,0
FANAPT,Diarrhea,Mouth,0
FANAPT,Diarrhea,Abdominal Discomfort,0
FANAPT,Diarrhea,,0
FANAPT,Diarrhea,,0
FANAPT,Diarrhea,Diarrhea Abdominal,1
FANAPT,Nasopharyngitis,,0
FANAPT,Nasopharyngitis,Nasopharyngitis Upper Respiratory Tract,1
FANAPT,Nasopharyngitis,Infections,0
FANAPT,Nasopharyngitis,Infections Nasopharyngitis Upper,1
FANAPT,Nasopharyngitis,Infections Nasopharyngitis Upper Respiratory Tract Infection,1
FANAPT,Upper Respiratory Tract Infection,Nervous,0
FANAPT,Upper Respiratory Tract Infection,Infection Nervous System Disorders,1
FANAPT,Upper Respiratory Tract Infection,Nasopharyngitis,0
FANAPT,Upper Respiratory Tract Infection,Upper Respiratory Tract Infection,1
FANAPT,Upper Respiratory Tract Infection,Nasopharyngitis,0
FANAPT,Dizziness,Disorders,0
FANAPT,Dizziness,Dizziness Somnolence,1
FANAPT,Dizziness,Dizziness Somnolence,1
FANAPT,Dizziness,Dizziness Somnolence,1
FANAPT,Dizziness,System Dizziness Somnolence,1
FANAPT,Somnolence,Dizziness,0
FANAPT,Extrapyramidal Disorder,Somnolence Extrapyramidal Disorder Tremor,1
FANAPT,Extrapyramidal Disorder,Somnolence,0
FANAPT,Extrapyramidal Disorder,Somnolence Extrapyramidal Disorder Tremor,1
FANAPT,Extrapyramidal Disorder,Somnolence Extrapyramidal,1
FANAPT,Extrapyramidal Disorder,Somnolence Extrapyramidal Disorder Tremor,1
FANAPT,Extrapyramidal Disorder,Somnolence Extrapyramidal,1
FANAPT,Extrapyramidal Disorder,Somnolence Extrapyramidal Disorder Tremor,1
FANAPT,Tremor,Tremor Lethargy,1
FANAPT,Tremor,,0
FANAPT,Tremor,Tremor Lethargy,1
FANAPT,Ejaculation Failure,Reproductive Ejaculation,1
FANAPT,Ejaculation Failure,Ejaculation Failure Respiratory,1
FANAPT,Ejaculation Failure,Failure Respiratory,1
FANAPT,Ejaculation Failure,Reproductive Ejaculation,1
FANAPT,Ejaculation Failure,,0
FANAPT,Ejaculation Failure,Reproductive Ejaculation Failure Respiratory,1
FANAPT,Ejaculation Failure,Reproductive Ejaculation,1
FANAPT,Ejaculation Failure,Ejaculation,1
FANAPT,Nasal Congestion,Nasal Congestion Dyspnea,1
FANAPT,Nasal Congestion,,0
FANAPT,Nasal Congestion,,0
FANAPT,Nasal Congestion,Respiratory Nasal,1
FANAPT,Nasal Congestion,Congestion Dyspnea,1
FANAPT,Nasal Congestion,Respiratory,0
FANAPT,Nasal Congestion,Respiratory Nasal Congestion Dyspnea,1
FANAPT,Nasal Congestion,Respiratory,0
FANAPT,Dyspnea,Dyspnea Skin,1
FANAPT,Dyspnea,Congestion,0
FANAPT,Dyspnea,,0
FANAPT,Dyspnea,Congestion,0
FANAPT,Dyspnea,,0
FANAPT,Dyspnea,Dyspnea Skin,1
FANAPT,Rash,,0
FANAPT,Rash,Skin,0
FANAPT,Rash,,0
FANAPT,Rash,Skin,0
FANAPT,Rash,Rash Vascular Disorders,1
FANAPT,Hypotension,Hypotension Table includes,1
FANAPT,Hypotension,adverse reactions,0
FANAPT,Hypotension,Hypotension Table includes,1
FANAPT,Hypotension,Orthostatic Hypotension Table includes,1
FANAPT,Hypotension,Hypotension Table includes,1
FANAPT,Hypotension,,0
FANAPT,Hypotension,Hypotension,0
FANAPT,Hypotension,adverse reactions,0
FANAPT,Hypotension,Hypotension,0
FANAPT,Hypotension,Hypotension,0
FANAPT,abdominal discomfort,,0
FANAPT,abdominal discomfort,FANAPT to mgday,0
FANAPT,dizziness,dizziness hypotension musculoskeletal,1
FANAPT,dizziness,hypotension musculoskeletal stiffness tachycardia and weight,0
FANAPT,dizziness,dizziness hypotension musculoskeletal,1
FANAPT,dizziness,musculoskeletal stiffness tachycardia and weight increased Common and Drug,0
FANAPT,dizziness,dizziness hypotension musculoskeletal,1
FANAPT,dizziness,dizziness hypotension musculoskeletal,1
FANAPT,dizziness,with FANAPT to mgday were abdominal,0
FANAPT,hypotension,hypotension musculoskeletal stiffness,1
FANAPT,hypotension,hypotension musculoskeletal stiffness,1
FANAPT,hypotension,were abdominal discomfort,0
FANAPT,hypotension,were abdominal discomfort hypotension musculoskeletal stiffness,1
FANAPT,hypotension,hypotension musculoskeletal stiffness,1
FANAPT,hypotension,hypotension musculoskeletal stiffness,1
FANAPT,hypotension,hypotension musculoskeletal stiffness,1
FANAPT,hypotension,stiffness,0
FANAPT,hypotension,and weight increased Common and DrugRelated Adver,0
FANAPT,hypotension,and,0
FANAPT,musculoskeletal stiffness,tachycardia and weight increased Common and DrugRelated Adverse,0
FANAPT,musculoskeletal stiffness,musculoskeletal stiffness tachycardia and,1
FANAPT,musculoskeletal stiffness,stiffness tachycardia and,1
FANAPT,musculoskeletal stiffness,tachycardia and weight increased,0
FANAPT,musculoskeletal stiffness,dizziness musculoskeletal stiffness tachycardia and,1
FANAPT,musculoskeletal stiffness,dizziness musculoskeletal stiffness tachycardia and,1
FANAPT,musculoskeletal stiffness,musculoskeletal stiffness tachycardia and,1
FANAPT,musculoskeletal stiffness,dizziness musculoskeletal stiffness tachycardia and,1
FANAPT,musculoskeletal stiffness,were abdominal discomfort dizziness musculoskeletal,1
FANAPT,musculoskeletal stiffness,stiffness tachycardia and,1
FANAPT,tachycardia,tachycardia and weight,1
FANAPT,weight increased,,0
FANAPT,weight increased,hypotension musculoskeletal stiffness tachycardia weight,1
FANAPT,dizziness,,0
FANAPT,dizziness,,0
FANAPT,dizziness,dizziness dry mouth,1
FANAPT,dizziness,dizziness dry mouth,1
FANAPT,dizziness,dizziness dry mouth,1
FANAPT,dizziness,dizziness dry mouth,1
FANAPT,dizziness,dizziness dry mouth,1
FANAPT,dizziness,least dizziness dry mouth,1
FANAPT,dizziness,dry,0
FANAPT,dry mouth,treated with FANAPT and at least twice the placebo,0
FANAPT,fatigue,congestion somnolence tachycardia orthostatic hypotension and weight,0
FANAPT,nasal congestion,nasal congestion somnolence tachycardia,1
FANAPT,nasal congestion,congestion somnolence tachycardia,1
FANAPT,nasal congestion,dizziness dry mouth nasal,1
FANAPT,nasal congestion,hypotension and weight,0
FANAPT,nasal congestion,congestion somnolence tachycardia,1
FANAPT,somnolence,and,0
FANAPT,somnolence,,0
FANAPT,somnolence,placebo rate for at least,0
FANAPT,somnolence,,0
FANAPT,tachycardia,rate for at least dose dizziness dry mouth fatigue,0
FANAPT,tachycardia,tachycardia orthostatic hypotension,1
FANAPT,tachycardia,tachycardia orthostatic hypotension,1
FANAPT,tachycardia,rate for at least,0
FANAPT,tachycardia,tachycardia orthostatic hypotension,1
FANAPT,tachycardia,dizziness dry,0
FANAPT,tachycardia,tachycardia orthostatic hypotension,1
FANAPT,tachycardia,somnolence,0
FANAPT,tachycardia,nasal congestion tachycardia orthostatic hypotension,1
FANAPT,orthostatic hypotension,as,0
FANAPT,orthostatic hypotension,congestion somnolence,0
FANAPT,orthostatic hypotension,somnolence orthostatic,1
FANAPT,orthostatic hypotension,least twice as common,0
FANAPT,orthostatic hypotension,least twice as common o,0
FANAPT,orthostatic hypotension,mouth fatigue nasal congestion somnolence,0
FANAPT,orthostatic hypotension,hypotension and weight,1
FANAPT,orthostatic hypotension,twice as,0
FANAPT,weight increased,,0
FANAPT,weight increased,,0
FANAPT,weight increased,tachycardia orthostatic hypotension weight increased Dizziness tachycardia,1
FANAPT,weight increased,common,0
FANAPT,weight increased,at least twice as common on to mgday,0
FANAPT,weight increased,weight increased Dizziness tachycardia,1
FANAPT,weight increased,orthostatic hypotension weight increased Dizziness tachycardia,1
FANAPT,weight increased,increased Dizziness tachycardia,1
FANAPT,Dizziness,were at least twice as common on,0
FANAPT,Dizziness,mgday as on to,0
FANAPT,Dizziness,orthostatic hypotension and weight increased,0
FANAPT,Dizziness,orthostatic hypotension,0
FANAPT,Dizziness,congestion somnolence tachycardia orthostatic hypotension and weight,0
FANAPT,Dizziness,Dizziness tachycardia and,1
FANAPT,Dizziness,hypotension,0
FANAPT,Dizziness,,0
FANAPT,tachycardia,and,0
FANAPT,weight increased,weight increased Dizziness tachycardia and,0
FANAPT,weight increased,increased were at,1
FANAPT,weight increased,weight increased Dizziness tachycardia weight,1
FANAPT,weight increased,,0
FANAPT,weight increased,increased were at,1
FANAPT,weight increased,to mgday Extrapyramidal Sympto,0
FANAPT,weight increased,Dizziness tachycardia and,0
FANAPT,weight increased,weight,1
FANAPT,weight increased,twice as common on to mgday,0
FANAPT,EPS,the following rates of EPSrelated,0
FANAPT,EPS,,0
FANAPT,EPS,week fixed or flexibledose studies provided,0
FANAPT,EPS-related adverse events,EPS-related adverse events as shown,1
FANAPT,EPS-related adverse events,EPS-related adverse events as shown,1
FANAPT,EPS-related adverse events,showed the following rates EPS-related adverse,1
FANAPT,EPS-related adverse events,of,0
FANAPT,EPS-related adverse events,trials,0
FANAPT,EPS-related adverse events,rates EPS-related adverse,1
FANAPT,EPS-related adverse events,rates EPS-related,1
FANAPT,EPS-related adverse events,the following rates,0
FANAPT,EPS-related adverse events,,0
FANAPT,EPS,EPS Compared to,1
FANAPT,EPS,,0
FANAPT,EPS,Table Table Percentage EPS Compared to,1
FANAPT,EPS,,0
FANAPT,EPS,to,0
FANAPT,Akathisia,Akathisia Bradykinesia,1
FANAPT,Akathisia,,0
FANAPT,Akathisia,,0
FANAPT,Dyskinesia,,0
FANAPT,Dystonia,,0
FANAPT,Dystonia,Dyskinesia,0
FANAPT,Dystonia,Dystonia Parkinsonism,1
FANAPT,Dystonia,Dyskinesia,0
FANAPT,Dystonia,Dyskinesia,0
FANAPT,Parkinsonism,Parkinsonism Tremor,1
FANAPT,Parkinsonism,Parkinsonism Tremor,1
FANAPT,Parkinsonism,Dystonia,0
FANAPT,Parkinsonism,,0
FANAPT,Parkinsonism,Parkinsonism Tremor,1
FANAPT,Tremor,Reactions Associ,0
FANAPT,Tremor,Parkinsonism,0
FANAPT,Tremor,Parkinsonism Tremor,1
FANAPT,Tremor,Tremor Adverse,1
FANAPT,Tremor,Parkinsonism,0
FANAPT,anemia,anemia iron deficiency,1
FANAPT,anemia,Disorders Infrequent,0
FANAPT,anemia,anemia iron deficiency,1
FANAPT,anemia,Rare leukopenia Cardiac Disorders Frequent palpitations,0
FANAPT,iron deficiency anemia,Blood and,0
FANAPT,iron deficiency anemia,Infrequent iron deficiency anemia Rare leukopenia,1
FANAPT,iron deficiency anemia,deficiency anemia Rare leukopenia,1
FANAPT,iron deficiency anemia,iron deficiency anemia Rare leukopenia,1
FANAPT,iron deficiency anemia,fewer than,0
FANAPT,iron deficiency anemia,deficiency anemia Rare leukopenia,1
FANAPT,iron deficiency anemia,iron,1
FANAPT,iron deficiency anemia,Frequent palpitations Rare,0
FANAPT,iron deficiency anemia,,0
FANAPT,leukopenia,leukopenia Cardiac Disorders,1
FANAPT,leukopenia,leukopenia Cardiac Disorders,1
FANAPT,leukopenia,,0
FANAPT,leukopenia,leukopenia Cardiac Disorders,1
FANAPT,leukopenia,Cardiac Disorders Frequent palpitations Rare arrhythmia,0
FANAPT,leukopenia,deficiency anemia Rare,0
FANAPT,leukopenia,leukopenia Cardiac Disorders,1
FANAPT,leukopenia,,0
FANAPT,palpitations,anemia iron deficiency anemia Rare leukopenia Cardiac,0
FANAPT,palpitations,palpitations Rare arrhythmia,1
FANAPT,palpitations,palpitations Rare arrhythmia,1
FANAPT,palpitations,Disorders,0
FANAPT,palpitations,leukopenia Cardiac Disorders,0
FANAPT,palpitations,Disorders palpitations Rare arrhythmia,1
FANAPT,palpitations,Cardiac Disorders Frequent,0
FANAPT,palpitations,leukopenia,0
FANAPT,palpitations,palpitations Rare arrhythmia,1
FANAPT,arrhythmia,,0
FANAPT,arrhythmia,arrhythmia atrioventricular block,1
FANAPT,arrhythmia,arrhythmia atrioventricular block,1
FANAPT,arrhythmia,atrioventricular block first degree cardiac failure including congestive,0
FANAPT,arrhythmia,Frequent palpitations arrhythmia atrioventricular block,1
FANAPT,arrhythmia,arrhythmia atrioventricular block,1
FANAPT,arrhythmia,arrhythmia atrioventricular block,1
FANAPT,cardiac failure,block first cardiac failure including congestive,1
FANAPT,cardiac failure,block first degree,0
FANAPT,cardiac failure,,0
FANAPT,cardiac failure,cardiac,1
FANAPT,cardiac failure,palpitations Rare arrhythmia atrioventricular block,0
FANAPT,cardiac failure,Disorders Frequent palpitations Rare arrhythmia,0
FANAPT,cardiac failure,block first cardiac,1
FANAPT,vertigo,,0
FANAPT,vertigo,vertigo tinnitus Endocrine,1
FANAPT,vertigo,,0
FANAPT,vertigo,Endocrine Disorders Infrequent,0
FANAPT,vertigo,vertigo tinnitus Endocrine,1
FANAPT,vertigo,,0
FANAPT,tinnitus,tinnitus Endocrine Disorders,1
FANAPT,tinnitus,tinnitus Endocrine Disorders,1
FANAPT,tinnitus,tinnitus Endocrine Disorders,1
FANAPT,tinnitus,Ear and Labyrinth Disorders Infrequent vertigo,0
FANAPT,tinnitus,Eye Disorders Frequent conjunctiv,0
FANAPT,hypothyroidism,Disorders hypothyroidism Eye Disorders,1
FANAPT,hypothyroidism,Endocrine,0
FANAPT,hypothyroidism,,0
FANAPT,hypothyroidism,tinnitus,0
FANAPT,conjunctivitis,Eye Disorders,0
FANAPT,dry eye,Frequent conjunctivitis including allergic dry eye blepharitis eyelid,1
FANAPT,dry eye,cataract hyperemia including,0
FANAPT,dry eye,eye swelling lenticular opacities cataract hyperemia including conj,0
FANAPT,dry eye,including allergic dry eye blepharitis eyelid,1
FANAPT,dry eye,Frequent conjunctivitis including allergic dry eye blepharitis eyelid,1
FANAPT,dry eye,including allergic dry,1
FANAPT,dry eye,Eye Disorders Frequent,0
FANAPT,dry eye,including allergic dry eye blepharitis eyelid,1
FANAPT,dry eye,swelling lenticular opacities cataract hyperemia including conj,0
FANAPT,blepharitis,blepharitis eyelid edema,1
FANAPT,eyelid edema,dry,0
FANAPT,eyelid edema,eye eyelid edema eye swelling,1
FANAPT,lenticular opacities,opacities cataract hyperemia,1
FANAPT,lenticular opacities,edema eye lenticular,1
FANAPT,lenticular opacities,including conjunctival,0
FANAPT,lenticular opacities,blepharitis eyelid edema eye lenticular opacities cataract hyperemia,1
FANAPT,lenticular opacities,eye lenticular opacities cataract hyperemia,1
FANAPT,lenticular opacities,,0
FANAPT,lenticular opacities,blepharitis eyelid edema eye lenticular,1
FANAPT,lenticular opacities,lenticular opacities cataract hyperemia,1
FANAPT,cataract,opacities,0
FANAPT,cataract,eyelid edema eye swelling lenticular,0
FANAPT,cataract,,0
FANAPT,cataract,eye,0
FANAPT,cataract,cataract hyperemia including,1
FANAPT,cataract,Gastrointestinal Disorders Infrequent gastritis sali,0
FANAPT,cataract,dry eye,0
FANAPT,cataract,lenticular cataract hyperemia including,1
FANAPT,cataract,swelling lenticular opacities,0
FANAPT,hyperemia,salivary hypers,0
FANAPT,hyperemia,opacities hyperemia including conjunctival,1
FANAPT,hyperemia,,0
FANAPT,gastritis,Disorders gastritis salivary hypersecretion,1
FANAPT,gastritis,Gastrointestinal Disorders gastritis salivary hypersecretion,1
FANAPT,gastritis,conjunctival Gastrointestinal Disorders gastritis salivary hypersecretion,1
FANAPT,gastritis,including conjunctival Gastrointestinal Disorders gastritis salivary hypersecretion,1
FANAPT,gastritis,cataract hyperemia including conjunctival Gastrointestinal Disorders Infrequent,0
FANAPT,salivary hypersecretion,stomatitis duodenal ulcer hiatus,0
FANAPT,salivary hypersecretion,Infrequent salivary hypersecretion fecal incontinence,1
FANAPT,salivary hypersecretion,hyperemia including conjunctival Gastrointestinal,0
FANAPT,salivary hypersecretion,salivary,1
FANAPT,salivary hypersecretion,,0
FANAPT,salivary hypersecretion,hypersecretion fecal incontinence,1
FANAPT,salivary hypersecretion,,0
FANAPT,salivary hypersecretion,hypersecretion fecal incontinence,1
FANAPT,salivary hypersecretion,,0
FANAPT,fecal incontinence,incontinence mouth ulceration,1
FANAPT,fecal incontinence,gastritis salivary fecal,1
FANAPT,mouth ulceration,mouth ulceration Rare aphthous,1
FANAPT,mouth ulceration,,0
FANAPT,mouth ulceration,ulceration Rare aphthous,1
FANAPT,mouth ulceration,mouth ulceration Rare aphthous,1
FANAPT,aphthous stomatitis,salivary hypersecretion fecal incontinence,0
FANAPT,aphthous stomatitis,hernia hyperchlorhydria lip ulceration reflux esophagitis stomatitis,0
FANAPT,aphthous stomatitis,ulceration aphthous stomatitis duodenal ulcer,1
FANAPT,aphthous stomatitis,hernia hyperchlorhydria lip ulceration,0
FANAPT,aphthous stomatitis,stomatitis duodenal ulcer,1
FANAPT,aphthous stomatitis,incontinence mouth ulceration,0
FANAPT,aphthous stomatitis,mouth ulceration aphthous,1
FANAPT,aphthous stomatitis,mouth ulceration aphthous,1
FANAPT,aphthous stomatitis,aphthous stomatitis duodenal ulcer,1
FANAPT,aphthous stomatitis,fecal,0
FANAPT,hiatus hernia,hernia hyperchlorhydria lip,1
FANAPT,hiatus hernia,hiatus hernia hyperchlorhydria lip,1
FANAPT,hyperchlorhydria,hyperchlorhydria lip ulceration,1
FANAPT,lip ulceration,ulcer hiatus hernia lip ulceration reflux esophagitis,1
FANAPT,stomatitis,,0
FANAPT,stomatitis,stomatitis duodenal ulcer hiatus hernia,0
FANAPT,stomatitis,Conditions Infrequent,0
FANAPT,stomatitis,stomatitis General Disorders,1
FANAPT,stomatitis,hernia hyperchlorhydria lip ulceration reflux,0
FANAPT,edema,General Disorders and Administrative Site Conditions Infrequent,0
FANAPT,edema,edema general pitting,1
FANAPT,edema,Site,0
FANAPT,edema,edema general pitting,1
FANAPT,edema,Administrative Site Conditions,0
FANAPT,edema,to cardiac disease difficulty in walking thirst Rare,0
FANAPT,edema,Conditions,0
FANAPT,edema,,0
FANAPT,edema,edema general pitting,1
FANAPT,edema,,0
FANAPT,difficulty in walking,,0
FANAPT,difficulty in walking,Site Conditions Infrequent,0
FANAPT,thirst,thirst Rare hyperthermia,1
FANAPT,thirst,hyperthermia Hepatobiliary Disorders Infrequent cholelithiasis Investigat,0
FANAPT,thirst,Hepatobiliary Disorders Infrequent cholelithiasis Investigat,0
FANAPT,thirst,walking,0
FANAPT,thirst,Infrequent cholelithiasis,0
FANAPT,thirst,difficulty in thirst Rare hyperthermia,1
FANAPT,thirst,Rare hyperthermia Hepatobiliary Disorders Infrequent cholelithiasis Investigat,0
FANAPT,thirst,thirst Rare hyperthermia,1
FANAPT,hyperthermia,cholelithiasis Investigations,0
FANAPT,hyperthermia,hyperthermia Hepatobiliary Disorders,1
FANAPT,hyperthermia,Investigations,0
FANAPT,hyperthermia,hyperthermia Hepatobiliary Disorders,1
FANAPT,hyperthermia,difficulty in walking thirst hyperthermia Hepatobiliary Disorders,1
FANAPT,hyperthermia,hyperthermia Hepatobiliary Disorders,1
FANAPT,hyperthermia,,0
FANAPT,hyperthermia,hyperthermia Hepatobiliary Disorders,1
FANAPT,hyperthermia,to,0
FANAPT,hyperthermia,Investigations Frequent,0
FANAPT,cholelithiasis,,0
FANAPT,cholelithiasis,,0
FANAPT,cholelithiasis,cholelithiasis Investigations Frequent,1
FANAPT,cholelithiasis,Investigations Frequent weight,0
FANAPT,cholelithiasis,Frequent weight decreased Infrequent,0
FANAPT,cholelithiasis,decreased Infrequent hemoglobin decreased neutrophil,0
FANAPT,weight decreased,weight decreased Infrequent hemoglobin,1
FANAPT,weight decreased,Infrequent hemoglobin decreased neutrophil,0
FANAPT,weight decreased,,0
FANAPT,weight decreased,decreased Infrequent hemoglobin,1
FANAPT,weight decreased,Disorders Infrequent cholelithiasis Investigations Frequent,0
FANAPT,weight decreased,,0
FANAPT,weight decreased,Investigations weight decreased Infrequent hemoglobin,1
FANAPT,weight decreased,,0
FANAPT,hemoglobin decreased,decreased hemoglobin,1
FANAPT,hemoglobin decreased,cholelithiasis Investigations Frequent weight decreased,0
FANAPT,hemoglobin decreased,Investigations Frequent weight decreased Infrequent,0
FANAPT,hemoglobin decreased,Investigations Frequent weight decreased hemoglobin,1
FANAPT,neutrophil count increased,hemoglobin neutrophil count,1
FANAPT,neutrophil count increased,hemoglobin neutrophil,1
FANAPT,neutrophil count increased,decreased Metabolism and Nutrition Disorders Infrequent,0
FANAPT,neutrophil count increased,Infrequent hemoglobin neutrophil count,1
FANAPT,neutrophil count increased,Disorders Infrequent increased appetit,0
FANAPT,hematocrit decreased,Infrequent increased appetite,0
FANAPT,hematocrit decreased,hypoka,0
FANAPT,hematocrit decreased,count,0
FANAPT,dehydration,,0
FANAPT,dehydration,retention Musculoskeletal and Connective Tissue Disorders Frequent my,0
FANAPT,dehydration,dehydration hypokalemia fluid,1
FANAPT,dehydration,Infrequent increased,0
FANAPT,dehydration,dehydration hypokalemia fluid,1
FANAPT,dehydration,,0
FANAPT,dehydration,Tissue Disorders,0
FANAPT,hypokalemia,,0
FANAPT,hypokalemia,Connective Tissue Disorders,0
FANAPT,hypokalemia,Disorders Frequent myalgia muscle,0
FANAPT,hypokalemia,hypokalemia fluid retention,1
FANAPT,fluid retention,Nutrition Disorders Infrequent increased appetite dehydration hypokalemia,0
FANAPT,myalgia,torticollis,0
FANAPT,myalgia,myalgia muscle spasms,1
FANAPT,myalgia,,0
FANAPT,myalgia,myalgia muscle spasms,1
FANAPT,muscle spasms,,0
FANAPT,muscle spasms,retention Musculoskeletal and Connective,0
FANAPT,muscle spasms,Tissue Disorders Frequent muscle,1
FANAPT,muscle spasms,Connective Tissue Disorders Frequent muscle,1
FANAPT,muscle spasms,muscle spasms Rare torticollis,1
FANAPT,muscle spasms,Disorders Frequent muscle spasms Rare torticollis,1
FANAPT,muscle spasms,spasms Rare torticollis,1
FANAPT,torticollis,torticollis Nervous System,1
FANAPT,torticollis,torticollis Nervous System,1
FANAPT,torticollis,torticollis Nervous System,1
FANAPT,torticollis,Nervous System Disorders Infrequent paresthesia psychomotor,0
FANAPT,paresthesia,System Disorders Infrequent,0
FANAPT,paresthesia,,0
FANAPT,paresthesia,Rare restless legs syndrome,0
FANAPT,paresthesia,paresthesia psychomotor hyperactivity,1
FANAPT,paresthesia,legs,0
FANAPT,paresthesia,paresthesia psychomotor hyperactivity,1
FANAPT,paresthesia,hyperactivity restlessness amnesia,0
FANAPT,paresthesia,psychomotor hyperactivity,0
FANAPT,paresthesia,syndrome,0
FANAPT,paresthesia,paresthesia psychomotor hyperactivity,1
FANAPT,psychomotor hyperactivity,torticollis,0
FANAPT,psychomotor hyperactivity,Disorders Infrequent psychomotor,1
FANAPT,psychomotor hyperactivity,Rare torticollis Nervous,0
FANAPT,psychomotor hyperactivity,Disorders Infrequent psychomotor hyperactivity restlessness amnesia,1
FANAPT,psychomotor hyperactivity,psychomotor hyperactivity restlessness amnesia,1
FANAPT,psychomotor hyperactivity,hyperactivity restlessness amnesia,1
FANAPT,psychomotor hyperactivity,Psychiatric Disorders,0
FANAPT,psychomotor hyperactivity,System Disorders Infrequent psychomotor,1
FANAPT,psychomotor hyperactivity,System Disorders Infrequent psychomotor,1
FANAPT,psychomotor hyperactivity,muscle spasms Rare torticollis Nervous,0
FANAPT,restlessness,restl,0
FANAPT,restlessness,restlessness amnesia nystagmus,1
FANAPT,restlessness,paresthesia psychomotor hyperactivity,0
FANAPT,restlessness,legs syndrome Psychiatric Disorders Frequent restl,0
FANAPT,restlessness,Rare restless legs syndrome,0
FANAPT,restlessness,restlessness amnesia nystagmus,1
FANAPT,amnesia,Disorders Frequent,0
FANAPT,amnesia,Disorders Infrequent paresthesia,0
FANAPT,amnesia,amnesia nystagmus Rare,1
FANAPT,amnesia,,0
FANAPT,amnesia,amnesia nystagmus Rare,1
FANAPT,amnesia,Infrequent paresthesia psychomotor hyperactivity amnesia nystagmus Rare,1
FANAPT,amnesia,,0
FANAPT,nystagmus,Frequent restlessness aggression,0
FANAPT,nystagmus,nystagmus Rare restless,1
FANAPT,nystagmus,nystagmus Rare restless,1
FANAPT,nystagmus,nystagmus Rare restless,1
FANAPT,nystagmus,nystagmus Rare restless,1
FANAPT,restless legs syndrome,nystagmus restless legs,1
FANAPT,restless legs syndrome,restless legs syndrome Psychiatric Disorders,1
FANAPT,restless legs syndrome,restlessness amnesia nystagmus restless legs syndrome Psychiatric Disorders,1
FANAPT,restless legs syndrome,,0
FANAPT,restlessness,,0
FANAPT,restlessness,restlessness aggression delusion,1
FANAPT,restlessness,restlessness aggression delusion,1
FANAPT,restlessness,,0
FANAPT,restlessness,restlessness aggression delusion,1
FANAPT,restlessness,legs syndrome Psychiatric Disorders restlessness aggression delusion,1
FANAPT,restlessness,legs syndrome Psychiatric Disorders Frequent,0
FANAPT,aggression,paranoia anorgasmia,0
FANAPT,aggression,aggression delusion Infrequent,1
FANAPT,aggression,,0
FANAPT,aggression,Frequent aggression delusion Infrequent,1
FANAPT,aggression,aggression delusion Infrequent,1
FANAPT,aggression,Disorders Frequent aggression delusion Infrequent,1
FANAPT,aggression,syndrome Psychiatric Disorders Frequent aggression delusion Infrequent,1
FANAPT,aggression,,0
FANAPT,delusion,delusion Infrequent hostility,1
FANAPT,delusion,delusion Infrequent hostility,1
FANAPT,delusion,delusion Infrequent hostility,1
FANAPT,hostility,,0
FANAPT,hostility,state mania catatonia mood swings,0
FANAPT,hostility,,0
FANAPT,hostility,hostility libido decreased,1
FANAPT,hostility,hostility libido decreased,1
FANAPT,hostility,,0
FANAPT,hostility,state mania,0
FANAPT,hostility,hostility libido decreased,1
FANAPT,hostility,Frequent restlessness aggression delusion,0
FANAPT,hostility,confusional state mania,0
FANAPT,paranoia,libido paranoia anorgasmia confusional,1
FANAPT,paranoia,panic,0
FANAPT,paranoia,state mania catatonia mood swings panic,0
FANAPT,paranoia,paranoia anorgasmia confusional,1
FANAPT,paranoia,catatonia mood swings panic attack obsessivecompulsive d,0
FANAPT,anorgasmia,anorgasmia confusional state,1
FANAPT,confusional state,hostility libido decreased paranoia confusional state mania catatonia,1
FANAPT,confusional state,swings,0
FANAPT,confusional state,confusional state mania catatonia,1
FANAPT,confusional state,mania catatonia mood swings panic attack obsessivecompulsive,0
FANAPT,confusional state,catatonia mood swings panic,0
FANAPT,confusional state,libido decreased paranoia confusional state mania catatonia,1
FANAPT,mania,mania catatonia mood,1
FANAPT,mania,decreased paranoia anorgasmia confusional mania catatonia mood,1
FANAPT,mania,decreased paranoia anorgasmia,0
FANAPT,mania,mania catatonia mood,1
FANAPT,mania,anorgasmia confusional mania catatonia mood,1
FANAPT,mania,,0
FANAPT,mania,mania catatonia mood,1
FANAPT,mania,,0
FANAPT,mania,catatonia mood swings panic attack obsessivecompulsive disorder bulimia nervosa delirium,0
FANAPT,catatonia,catatonia mood swings,1
FANAPT,catatonia,libido decreased paranoia anorgasmia,0
FANAPT,catatonia,delirium,0
FANAPT,catatonia,,0
FANAPT,catatonia,anorgasmia confusional state mania,0
FANAPT,catatonia,catatonia mood swings,1
FANAPT,catatonia,ps,0
FANAPT,catatonia,paranoia anorgasmia,0
FANAPT,catatonia,obsessivecompulsive disorder bulimia nervosa,0
FANAPT,catatonia,catatonia mood swings,1
FANAPT,panic attack,obsessivecompulsive disorder bulimia,0
FANAPT,panic attack,state mania catatonia mood panic,1
FANAPT,obsessive-compulsive disorder,obsessive-compulsive disorder bulimia nervosa,1
FANAPT,bulimia nervosa,attack,0
FANAPT,bulimia nervosa,obsessivecompulsive bulimia nervosa delirium polydipsia,1
FANAPT,bulimia nervosa,swings panic attack obsessivecompulsive bulimia nervosa delirium polydipsia,1
FANAPT,bulimia nervosa,obsessivecompulsive bulimia,1
FANAPT,bulimia nervosa,bulimia nervosa delirium polydipsia,1
FANAPT,bulimia nervosa,major depression Renal and Urina,0
FANAPT,bulimia nervosa,disorder,0
FANAPT,bulimia nervosa,,0
FANAPT,bulimia nervosa,bulimia nervosa delirium polydipsia,1
FANAPT,bulimia nervosa,catatonia mood swings panic attack obsessivecompulsive disorder,0
FANAPT,delirium,attack obsessivecompulsive,0
FANAPT,delirium,and Urinary Disorde,0
FANAPT,delirium,disorder major,0
FANAPT,polydipsia psychogenic,nervosa polydipsia psychogenic impulsecontrol disorder,1
FANAPT,polydipsia psychogenic,swings panic attack obsessivecompulsive disorder bulimia nervosa delirium,0
FANAPT,polydipsia psychogenic,psychogenic impulsecontrol disorder,1
FANAPT,polydipsia psychogenic,attack obsessivecompulsive,0
FANAPT,polydipsia psychogenic,,0
FANAPT,polydipsia psychogenic,polydipsia psychogenic impulsecontrol disorder,1
FANAPT,polydipsia psychogenic,Renal and Urinary Disorders Frequent,0
FANAPT,impulse-control disorder,nervosa delirium polydipsia impulse-control disorder major depression,1
FANAPT,impulse-control disorder,polydipsia impulse-control disorder major depression,1
FANAPT,impulse-control disorder,obsessivecompulsive disorder bulimia nervosa delirium polydipsia,0
FANAPT,impulse-control disorder,bulimia nervosa,0
FANAPT,impulse-control disorder,bulimia nervosa delirium polydipsia impulse-control,1
FANAPT,impulse-control disorder,,0
FANAPT,impulse-control disorder,major depression Renal and Urinary Disorders Frequent urinary,0
FANAPT,impulse-control disorder,impulse-control disorder major depression,1
FANAPT,major depression,impulsecontrol major depression Renal and,1
FANAPT,major depression,Urinary Disorders Frequent urinary,0
FANAPT,major depression,major depression Renal and,1
FANAPT,major depression,depression Renal and,1
FANAPT,major depression,major depression Renal and,1
FANAPT,major depression,major depression Renal and,1
FANAPT,major depression,impulsecontrol disorder,0
FANAPT,major depression,delirium polydipsia psychogenic impulsecontrol major,1
FANAPT,dysuria,dysuria pollakiuria enuresis,1
FANAPT,dysuria,and Urinary Disorders Frequent,0
FANAPT,dysuria,,0
FANAPT,dysuria,dysuria pollakiuria enuresis,1
FANAPT,pollakiuria,pollakiuria enuresis nephrolithiasis,1
FANAPT,pollakiuria,Frequent urinary incontinence Infrequent,0
FANAPT,pollakiuria,pollakiuria enuresis nephrolithiasis,1
FANAPT,pollakiuria,retention renal,0
FANAPT,enuresis,Infrequent dysuria enuresis nephrolithiasis Rare,1
FANAPT,enuresis,incontinence Infrequent,0
FANAPT,enuresis,Infrequent dysuria pollakiuria,0
FANAPT,enuresis,incontinence Infrequent dysuria pollakiuria,0
FANAPT,enuresis,urinary incontinence Infrequent dysuria enuresis nephrolithiasis Rare,1
FANAPT,enuresis,System and,0
FANAPT,nephrolithiasis,dysuria pollakiuria nephrolithiasis Rare urinary,1
FANAPT,nephrolithiasis,dysuria pollakiuria nephrolithiasis Rare urinary,1
FANAPT,nephrolithiasis,nephrolithiasis Rare urinary,1
FANAPT,nephrolithiasis,nephrolithiasis Rare urinary,1
FANAPT,nephrolithiasis,renal,0
FANAPT,nephrolithiasis,urinary incontinence Infrequent,0
FANAPT,nephrolithiasis,pollakiuria nephrolithiasis Rare urinary,1
FANAPT,nephrolithiasis,nephrolithiasis Rare urinary,1
FANAPT,nephrolithiasis,nephrolithiasis Rare urinary,1
FANAPT,urinary retention,retention renal failure,1
FANAPT,urinary retention,retention renal failure,1
FANAPT,urinary retention,,0
FANAPT,urinary retention,dysuria pollakiuria enuresis nephrolithiasis urinary retention renal failure,1
FANAPT,urinary retention,urinary retention renal failure,1
FANAPT,renal failure acute,retention,0
FANAPT,renal failure acute,renal failure acute Reproductive System,1
FANAPT,renal failure acute,and Breast Disorders Frequent erectile dysfunction,0
FANAPT,erectile dysfunction,erectile dysfunction Infrequent testicular,1
FANAPT,erectile dysfunction,testicular pain amenorrhea breast pain,0
FANAPT,erectile dysfunction,,0
FANAPT,erectile dysfunction,,0
FANAPT,erectile dysfunction,breast,0
FANAPT,erectile dysfunction,pain,0
FANAPT,erectile dysfunction,testicular pain amenorrhea breast pain Rare menstruation,0
FANAPT,erectile dysfunction,retention renal failure acute Reproductive System and,0
FANAPT,erectile dysfunction,erectile dysfunction Infrequent testicular,1
FANAPT,testicular pain,testicular pain amenorrhea breast,1
FANAPT,testicular pain,erectile dysfunction,0
FANAPT,testicular pain,testicular pain amenorrhea breast,1
FANAPT,amenorrhea,testicular amenorrhea breast pain,1
FANAPT,breast pain,pain Rare menstruation,1
FANAPT,breast pain,menstruation irregular gynecomastia,0
FANAPT,breast pain,,0
FANAPT,breast pain,breast,1
FANAPT,breast pain,dysfunction Infrequent testicular pain breast pain Rare menstruation,1
FANAPT,menstruation irregular,pain menstruation,1
FANAPT,menstruation irregular,,0
FANAPT,gynecomastia,gynecomastia menorrhagia metrorrhagia,1
FANAPT,gynecomastia,pain Rare menstruation gynecomastia menorrhagia metrorrhagia,1
FANAPT,gynecomastia,gynecomastia menorrhagia metrorrhagia,1
FANAPT,gynecomastia,pain amenorrhea breast pain Rare,0
FANAPT,gynecomastia,Rare menstruation gynecomastia menorrhagia metrorrhagia,1
FANAPT,gynecomastia,gynecomastia menorrhagia metrorrhagia,1
FANAPT,menorrhagia,Rare menstruation irregular gynecomastia,0
FANAPT,menorrhagia,,0
FANAPT,menorrhagia,menorrhagia metrorrhagia postmenopausal,1
FANAPT,menorrhagia,Rare menstruation irregular menorrhagia metrorrhagia postmenopausal,1
FANAPT,menorrhagia,metrorrhagia postmenopausal hemorrhage prostatitis,0
FANAPT,metrorrhagia,,0
FANAPT,metrorrhagia,postmenopausal hemorrhage prostatitis Respiratory Thoracic,0
FANAPT,metrorrhagia,metrorrhagia postmenopausal hemorrhage,1
FANAPT,metrorrhagia,metrorrhagia postmenopausal hemorrhage,1
FANAPT,metrorrhagia,metrorrhagia postmenopausal hemorrhage,1
FANAPT,metrorrhagia,metrorrhagia postmenopausal hemorrhage,1
FANAPT,metrorrhagia,hemorrhage prostatitis,0
FANAPT,metrorrhagia,irregular gynecomastia metrorrhagia postmenopausal hemorrhage,1
FANAPT,metrorrhagia,,0
FANAPT,metrorrhagia,menstruation irregular gynecomastia metrorrhagia postmenopausal hemorrhage,1
FANAPT,postmenopausal hemorrhage,,0
FANAPT,postmenopausal hemorrhage,menstruation irregular gynecomastia menorrhagia postmenopausal,1
FANAPT,postmenopausal hemorrhage,,0
FANAPT,postmenopausal hemorrhage,menstruation irregular gynecomastia menorrhagia metrorrhagia,0
FANAPT,prostatitis,menorrhagia metrorrhagia postmenopausal prostatitis Respiratory Thoracic,1
FANAPT,prostatitis,Mediastinal Disorders Infrequent epistaxis asthma rhinorrhea,0
FANAPT,prostatitis,,0
FANAPT,prostatitis,gynecomastia menorrhagia metrorrhagia postmenopausal hemorrhage,0
FANAPT,prostatitis,metrorrhagia postmenopausal,0
FANAPT,prostatitis,postmenopausal hemorrhage,0
FANAPT,epistaxis,,0
FANAPT,epistaxis,Infrequent,0
FANAPT,epistaxis,Rare dry,0
FANAPT,epistaxis,nasal dryness Rare dry throat sleep apnea syndrome dy,0
FANAPT,asthma,asthma rhinorrhea sinus,1
FANAPT,asthma,asthma rhinorrhea sinus,1
FANAPT,asthma,Disorders Infrequent asthma rhinorrhea sinus,1
FANAPT,asthma,asthma rhinorrhea sinus,1
FANAPT,asthma,asthma rhinorrhea sinus,1
FANAPT,asthma,asthma rhinorrhea sinus,1
FANAPT,asthma,asthma rhinorrhea sinus,1
FANAPT,asthma,asthma rhinorrhea sinus,1
FANAPT,asthma,Infrequent epistaxis,0
FANAPT,rhinorrhea,,0
FANAPT,rhinorrhea,rhinorrhea sinus congestion,1
FANAPT,rhinorrhea,epistaxis,0
FANAPT,sinus congestion,Disorders Infrequent epistaxis asthma,0
FANAPT,sinus congestion,throat,0
FANAPT,sinus congestion,sleep apnea syndrome dyspnea,0
FANAPT,sinus congestion,Infrequent epistaxis asthma sinus congestion nasal dryness,1
FANAPT,sinus congestion,Disorders Infrequent epistaxis asthma sinus congestion nasal dryness,1
FANAPT,sinus congestion,asthma sinus,1
FANAPT,sinus congestion,sinus congestion nasal dryness,1
FANAPT,sinus congestion,congestion nasal dryness,1
FANAPT,nasal dryness,epistaxis asthma rhinorrhea sinus nasal dryness Rare dry,1
FANAPT,nasal dryness,rhinorrhea sinus nasal dryness Rare dry,1
FANAPT,nasal dryness,Postmarketing,0
FANAPT,nasal dryness,dryness Rare dry,1
FANAPT,dry throat,dry throat sleep apnea,1
FANAPT,sleep apnea syndrome,Rare dry sleep apnea syndrome dyspnea exertional,1
FANAPT,sleep apnea syndrome,asthma rhinorrhea sinus congestion nasal,0
FANAPT,sleep apnea syndrome,syndrome dyspnea exertional,1
FANAPT,sleep apnea syndrome,dryness Rare dry sleep apnea syndrome dyspnea exertional,1
FANAPT,sleep apnea syndrome,apnea syndrome dyspnea exertional,1
FANAPT,sleep apnea syndrome,rhinorrhea,0
FANAPT,sleep apnea syndrome,dry sleep apnea syndrome dyspnea exertional,1
FANAPT,sleep apnea syndrome,reactions,0
FANAPT,sleep apnea syndrome,sleep,1
FANAPT,dyspnea exertional,rhinorrhea sinus congestion nasal dryness Rare dry,0
FANAPT,dyspnea exertional,apnea dyspnea exertional Postmarketing Experience,1
FANAPT,dyspnea exertional,duri,0
FANAPT,dyspnea exertional,dyspnea exertional Postmarketing Experience,1
FANAPT,dyspnea exertional,exertional Postmarketing Experience,1
FANAPT,dyspnea exertional,have,0
FANAPT,dyspnea exertional,dyspnea,1
FANAPT,MORTALITY,,0
FANAPT,death,"To report SUSPECTED ADVERSE NS,",1
FANAPT,death,,0
FANAPT,death,"NS, c ontact Novartis Pharmaceuticals Corporation",1
FANAPT,death,"report SUSPECTED ADVERSE NS, c ontact Novartis Pharmaceuticals Corporation",1
FANAPT,death,Pharmaceuticals,0
FANAPT,death,"report SUSPECTED ADVERSE NS, c ontact Novartis Pharmaceuticals Corporation",1
FANAPT,death,"ADVERSE NS, c ontact Novartis Pharmaceuticals Corporation",1
FANAPT,death,FDA at FDA or,0
FANAPT,death,"SUSPECTED ADVERSE NS, c ontact Novartis Pharmaceuticals Corporation",1
FANAPT,death,"SUSPECTED ADVERSE NS,",1
FANAPT,death,FDA at FDA or wwwfdagovmedwatch Clinical Studies Exp,0
FANAPT,death,erien ce Because clinical trials,1
FANAPT,death,widely varying conditions,0
FANAPT,death,directly compared rates in the clinical trials,1
FANAPT,death,rates in the clinical trials,1
FANAPT,death,rates in the clinical trials,1
FANAPT,death,trials of another drug and may not reflect the,0
FANAPT,death,rates in the clinical trials,1
FANAPT,death,of a drug cannot,0
FANAPT,death,rates in the clinical trials,1
FANAPT,death,clinical practice,0
FANAPT,death,The information,0
FANAPT,death,is derived from a clinical,1
FANAPT,death,ow is derived from a clinical,1
FANAPT,death,of another,0
FANAPT,death,not reflect the rates observed in clinical,0
FANAPT,death,observed in clinical practice The,0
FANAPT,death,for FANAPT consisting of patients exposed,0
FANAPT,death,,0
FANAPT,deaths,a clinical rial,1
FANAPT,deaths,is derived,0
FANAPT,deaths,d atabase for FANAPT consisting,1
FANAPT,deaths,below is derived from a clinical,0
FANAPT,deaths,from a clinical rial d atabase for FANAPT consisting,1
FANAPT,deaths,a clinical t,0
FANAPT,deaths,,0
FANAPT,sudden death,at dose s of mgday or,1
FANAPT,sudden death,at dose s of mgday or,1
FANAPT,sudden death,database for FANAPT consisting of,0
FANAPT,sudden death,from a clinical trial database for FANAPT consisting of patients exposed,0
FANAPT,sudden death,NAPT,1
FANAPT,sudden death,dose s of mgday or,1
FANAPT,pneumonia,"or er,",1
FANAPT,pneumonia,FANAPT at doses of mgday or great,0
FANAPT,pneumonia,"or er, for",1
FANAPT,pneumonia,"er, for t he treatment of schizophrenia",1
FANAPT,pneumonia,exposed to FANAPT at,0
FANAPT,pneumonia,,0
FANAPT,pneumonia,mgday,0
FANAPT,pneumonia,"mgday or er, for",1
FANAPT,MORTALITY,during exposu,0
FANAPT,MORTALITY,investigators,0
FANAPT,MORTALITY,inquiry and recorded by clinical investigators using their,0
FANAPT,MORTALITY,recorded by clinical investigators using their own,0
FANAPT,death,adverse reactions represent,0
FANAPT,death,,0
FANAPT,death, cate gories using MedDRA terminology,1
FANAPT,death,gories using MedDRA terminology The stated frequencies of adverse reactions represent the,0
FANAPT,death,thost atic hypotension somnolence tachycardia,1
FANAPT,death,hypotension somnolence tachycardia and weight increased To report SUSPECTED,0
FANAPT,death,mouth fatigue,0
FANAPT,cerebrovascular-related adverse events,"tachycardia, and weight increased To",1
FANAPT,cerebrovascular-related adverse events,"mouth fatigue nasal congestion hypotension, somnolence, tachycardia,  and weight increased To",1
FANAPT,cerebrovascular-related adverse events,"congestion hypotension, somnolence, tachycardia,  and weight increased To",1
FANAPT,cerebrovascular-related adverse events,dizziness dry mouth fatigue nasal congestion,0
FANAPT,cerebrovascular-related adverse events,REACTIONS,0
FANAPT,cerebrovascular-related adverse events,increased To report SUSPECTED ADVERSE REACTIONS contact Novartis Pharma,0
FANAPT,stroke,ncreas ed To report SUSPECTED,1
FANAPT,stroke,To report,0
FANAPT,stroke,and weight ncreas ed To report SUSPECTED,1
FANAPT,QT prolongation,increased,0
FANAPT,QT prolongation,,0
FANAPT,QT prolongation,SUS PECTED ADVERSE REACTIONS contact,1
FANAPT,QT prolongation,,0
FANAPT,QT prolongation,SUS PECTED ADVERSE REACTIONS contact,1
FANAPT,Prolongs QT interval,weight increased To report CTED ADVERSE,1
FANAPT,Prolongs QT interval,To report CTED,1
FANAPT,arrhythmia,euticals C orporation at or FDA,1
FANAPT,sudden death,1-8 or FDA at FDA,1
FANAPT,sudden death,at,0
FANAPT,sudden death,,0
FANAPT,sudden death,,0
FANAPT,sudden death,at 1-8 or FDA at FDA,1
FANAPT,sudden death,FDA at FDA or wwwfdagovmedwatch,0
FANAPT,sudden death,REACTIONS contact Novartis Pharmaceuticals ation at,1
FANAPT,sudden death,Pharmaceuticals ation,1
FANAPT,sudden death,ation at 1-8 or FDA at FDA,1
FANAPT,sudden death,contact Novartis Pharmaceuticals ation,1
FANAPT,Neuroleptic Malignant Syndrome,of patients exposed to FANAPT,0
FANAPT,Neuroleptic Malignant Syndrome,consisting of patients exposed to FANAPT,0
FANAPT,Tardive dyskinesia,below is derived,0
FANAPT,Tardive dyskinesia,FANAPT consisting of patients ed to FANAPT at do ses of mgday or,1
FANAPT,Tardive dyskinesia,to FANAPT at do ses of mgday or,1
FANAPT,Tardive dyskinesia,ses of mgday or greater for the treatment of schizophrenia Of these received FANAPT for,0
FANAPT,Tardive dyskinesia,of schizophrenia Of these received FANAPT for a,0
FANAPT,Tardive dyskinesia,for FANAPT,0
FANAPT,Hyperglycemia,these received FANAPT for at,1
FANAPT,Hyperglycemia,of nia. Of these received FANAPT for at,1
FANAPT,Hyperglycemia,treatment of nia. Of these received FANAPT for at,1
FANAPT,Hyperglycemia,of nia. Of these received FANAPT for at,1
FANAPT,Hyperglycemia,received FANAPT,0
FANAPT,Hyperglycemia,at least months with exposed to FANAPT for,0
FANAPT,Hyperglycemia,these received FANAPT for at,1
FANAPT,Hyperglycemia,,0
FANAPT,Hyperglycemia,for the treatment of nia. Of,1
FANAPT,Hyperglycemia,of mgday or greater,0
FANAPT,diabetes mellitus,FANAPT for at least months,1
FANAPT,diabetes mellitus, received FANAPT  for at least months,1
FANAPT,diabetes mellitus,treatment of schizophrenia Of  received FANAPT  for at least months,1
FANAPT,diabetes mellitus,received FANAPT for at least months,1
FANAPT,diabetes mellitus,FANAPT for at least months,1
FANAPT,diabetes mellitus,schizophrenia Of received,1
FANAPT,Dyslipidemia,clinical trials The conditions,0
FANAPT,Weight Gain,phases of studies inpatients and outpatients,1
FANAPT,Metabolic Changes,"and e studies, and sh ortterm and longerterm exposure",1
FANAPT,Metabolic Changes,"e studies, and sh ortterm and longerterm exposure",1
FANAPT,Metabolic Changes,"studies, and sh ortterm and longerterm exposure",1
FANAPT,Metabolic Changes,,0
FANAPT,Metabolic Changes,sh ortterm and longerterm exposure,1
FANAPT,Metabolic Changes,"fixeddose and e studies, and sh ortterm and longerterm exposure",1
FANAPT,Metabolic Changes,"fixeddose and e studies, and sh ortterm and longerterm exposure",1
FANAPT,hyperglycemia,own erminology. C onsequently to provide a,1
FANAPT,hyperglycemia,,0
FANAPT,hyperglycemia,investigators using their own erminology. C onsequently to provide a,1
FANAPT,hyperglycemia,investigators using their own erminology.,1
FANAPT,hyperglycemia,to provide a meaningful estimate of the proportion of individuals experiencing,0
FANAPT,hyperglycemia,own erminology. C onsequently to provide a,1
FANAPT,hyperglycemia,,0
FANAPT,hyperglycemia,the proportion of individuals experiencing adverse,0
FANAPT,hyperglycemia,,0
FANAPT,hyperglycemia,clinical,0
FANAPT,dyslipidemia,"their own terminology sequently,",1
FANAPT,dyslipidemia,"terminology sequently, t o provide a meaningful",1
FANAPT,dyslipidemia,of the,0
FANAPT,dyslipidemia,clinical investigators using their own,0
FANAPT,dyslipidemia,t o provide a meaningful,1
FANAPT,dyslipidemia,"sequently,",1
FANAPT,dyslipidemia,general,0
FANAPT,dyslipidemia,inquiry and recorded by clinical investigators,0
FANAPT,dyslipidemia,by,0
FANAPT,Orthostatic hypotension,the proportions of individuals who experienced a treatme,0
FANAPT,Orthostatic hypotension,"MedDRA inology.



 The stated frequencies of adverse reactions",1
FANAPT,Orthostatic hypotension,categories using MedDRA inology.,1
FANAPT,Orthostatic hypotension,stated frequencies of adverse reactions,1
FANAPT,Orthostatic hypotension,,0
FANAPT,Orthostatic hypotension,"inology.



 The stated frequencies of adverse reactions",1
FANAPT,Orthostatic hypotension,were grouped in standardized categories,0
FANAPT,Orthostatic hypotension,standardized,0
FANAPT,Orthostatic hypotension,represent,0
FANAPT,Orthostatic hypotension,"standardized categories using MedDRA inology.



 The stated frequencies of adverse reactions",1
FANAPT,Dizziness,individuals,0
FANAPT,tachycardia,MedDRA terminology The stated of adverse  reactions represent the proportions,1
FANAPT,tachycardia,stated of adverse  reactions represent the proportions,1
FANAPT,syncope,standardized categories using MedDRA terminology The stated frequencies of,0
FANAPT,syncope,reaction of,0
FANAPT,syncope,The stated frequencies,0
FANAPT,syncope,frequencies of adverse ons,1
FANAPT,syncope,frequencies of adverse,0
FANAPT,syncope,ons rep resent the proportions of,1
FANAPT,Neutropenia,a,1
FANAPT,Neutropenia,the proportions of individuals,0
FANAPT,Neutropenia,a treatment emergent adverse reaction of,1
FANAPT,Agranulocytosis,adverse rea ction of the type,1
FANAPT,Agranulocytosis,ent adverse rea ction of the type,1
FANAPT,Agranulocytosis,first,0
FANAPT,Suicide,week fixed or flexibledose studies in patients who received FANAPT at daily,0
FANAPT,Suicide,n a ran ge of to mg,1
FANAPT,Suicide,n a ran ge of to mg,1
FANAPT,Suicide,an Incidence,0
FANAPT,Suicide,at daily doses n a ran ge of to mg,1
FANAPT,Suicide,n a ran ge of to mg,1
FANAPT,Suicide,daily doses n a ran ge of to mg,1
FANAPT,Suicide,n a ran ge of to mg,1
FANAPT,Suicide,at daily,0
FANAPT,Suicide,doses,0
FANAPT,Priapism,an Incidence of or More,1
FANAPT,motor impairment,Frequent than Placebo able 7 enumerate s the pooled incidences,1
FANAPT,motor impairment,More Frequent than Placebo able 7 enumerate s the pooled incidences,1
FANAPT,motor impairment,More Frequent than Placebo able 7 enumerate s the pooled incidences,1
FANAPT,motor impairment,Placebo able 7 enumerate s the pooled incidences,1
FANAPT,motor impairment,able 7,1
FANAPT,motor impairment,Patients,0
FANAPT,death,dose group was greater n the incidence in patients treated,1
FANAPT,death,n the incidence in patients treated,1
FANAPT,death,n the incidence in patients treated,1
FANAPT,death,dose group was greater tha,0
FANAPT,death,the incidence in patients treated,1
FANAPT,death,of TreatmentEmergent Adverse,0
FANAPT,death,for which the incidence in FANAPTtreated patients in any dose group was,0
FANAPT,death,was greater n the incidence in patients treated,1
FANAPT,death,was greater n,1
FANAPT,death,n the incidence in patients treated,1
FANAPT,cerebrovascular adverse events,,0
FANAPT,cerebrovascular adverse events,,0
FANAPT,cerebrovascular adverse events,Whole,0
FANAPT,cerebrovascular accidents,"    
   Body as a Whole   Arthralgia",1
FANAPT,cerebrovascular accidents,Dictionaryderived Term,0
FANAPT,cerebrovascular accidents,Dictionaryderived Term N N Body as,1
FANAPT,cerebrovascular accidents,,0
FANAPT,cerebrovascular accidents,,0
FANAPT,cerebrovascular accidents,Dictionaryderived Term N N Body,1
FANAPT,cerebrovascular accidents,,0
FANAPT,cerebrovascular accidents,,0
FANAPT,transient ischemic attacks,                           Arthralgia,1
FANAPT,transient ischemic attacks,                           Arthralgia,1
FANAPT,transient ischemic attacks,,0
FANAPT,transient ischemic attacks,N Body as a Whole,0
FANAPT,transient ischemic attacks,N Body as a,0
FANAPT,fatalities,Whole,0
FANAPT,fatalities,,0
FANAPT,fatalities,,0
FANAPT,fatalities,as a Whole,0
FANAPT,fatalities,as a Whole,0
FANAPT,fatalities,           Arthralgia Fatigue,1
FANAPT,fatalities,a Whole,0
FANAPT,fatalities,a            Arthralgia Fatigue,1
FANAPT,QTc prolongation,,0
FANAPT,torsade de pointes,,0
FANAPT,torsade de pointes,"Nausea            
      ",1
FANAPT,torsade de pointes,Nausea,0
FANAPT,torsade de pointes,"           
      ",1
FANAPT,cardiac arrhythmias,            8       Diarrhea,1
FANAPT,cardiac arrhythmias,            8       Diarrhea,1
FANAPT,cardiac arrhythmias,            8       Diarrhea,1
FANAPT,Neuroleptic Malignant Syndrome,,0
FANAPT,Neuroleptic Malignant Syndrome,stiffness tachycardia and,0
FANAPT,Neuroleptic Malignant Syndrome,patients reated with FANAPT 10 to 16 mg,1
FANAPT,Neuroleptic Malignant Syndrome,musculoskeletal stiffness tachycardia and,0
FANAPT,Neuroleptic Malignant Syndrome,incidence in patients reated with FANAPT 10 to 16,1
FANAPT,Neuroleptic Malignant Syndrome,mg,1
FANAPT,Neuroleptic Malignant Syndrome,patients reated with FANAPT 10 to 16 mg,1
FANAPT,Neuroleptic Malignant Syndrome,,0
FANAPT,Neuroleptic Malignant Syndrome,10 to 16 mg,1
FANAPT,NMS,ay ,1
FANAPT,NMS,FANAPT to ay ,1
FANAPT,NMS,FANAPT to ay ,1
FANAPT,NMS,hypotension musculoskeletal stiffness tachycardia and weig,0
FANAPT,NMS,ay ,1
FANAPT,NMS,musculoskeletal stiffness tachycardia,0
FANAPT,hyperpyrexia,and weight increased Common nd Drug-Rela,1
FANAPT,hyperpyrexia,,0
FANAPT,hyperpyrexia,nd Drug-Rela,1
FANAPT,hyperpyrexia,in Clinical Trials Based,0
FANAPT,hyperpyrexia,Clinical Trials Based on,0
FANAPT,hyperpyrexia,nd Drug-Rela,1
FANAPT,muscle rigidity,,0
FANAPT,muscle rigidity,increased Common and d Adverse React,1
FANAPT,muscle rigidity,Adverse React,1
FANAPT,muscle rigidity,Adverse React,1
FANAPT,altered mental status,pooled data from placebocontrolled or week fixed or flexibledose,0
FANAPT,altered mental status,and DrugRelated Adverse ns in Clinical Trials,1
FANAPT,altered mental status,and DrugRelated Adverse ns in Clinical Trials,1
FANAPT,altered mental status,,0
FANAPT,altered mental status,Common and DrugRelated Adverse ns in Clinical,1
FANAPT,altered mental status,,0
FANAPT,altered mental status,in Clinical Trials,1
FANAPT,altered mental status,Common and DrugRelated,0
FANAPT,altered mental status,and DrugRelated Adverse ns in Clinical Trials,1
FANAPT,catatonic signs,from placebocontrolled or week fixed or flexibledose studies the following adverse,0
FANAPT,catatonic signs, on the pooled ,1
FANAPT,catatonic signs,placebocontrolled or week fixed or flexibledose,0
FANAPT,catatonic signs,Clinical Trials on,1
FANAPT,irregular pulse,the pooled data from placebocontrolled,0
FANAPT,irregular pulse,fixed- or,1
FANAPT,irregular pulse,from placebocontrolled or w,0
FANAPT,irregular pulse,following adverse reactions occurred,0
FANAPT,irregular pulse,"from placebocontrolled or eek, fixed- or ",1
FANAPT,irregular pulse,tr,0
FANAPT,irregular pulse,"eek, fixed- or ",1
FANAPT,tachycardia,patients treated with FANAPT and,0
FANAPT,tachycardia,from placebocontrolled or week fixed or flexibledose,0
FANAPT,diaphoresis,adverse,1
FANAPT,diaphoresis,or flexibledose studies the ing,1
FANAPT,diaphoresis,or flexibledose studies the ing adverse,1
FANAPT,diaphoresis,or flexibledose studies the ing adverse,1
FANAPT,diaphoresis,pooled data from placebocontrolled or week fixed or,0
FANAPT,diaphoresis,ing adverse,1
FANAPT,diaphoresis,ing adverse,1
FANAPT,diaphoresis,,0
FANAPT,cardiac dysrhythmia,occurred in >=,1
FANAPT,cardiac dysrhythmia,studies the following adverse ions occurred,1
FANAPT,cardiac dysrhythmia,incidence in,0
FANAPT,cardiac dysrhythmia,following adverse ions occurred in,1
FANAPT,cardiac dysrhythmia,studies the following adverse ions occurred in >=,1
FANAPT,cardiac dysrhythmia,or flexibledose studies the following,0
FANAPT,cardiac dysrhythmia,adverse ions occurred,1
FANAPT,cardiac dysrhythmia,or week fixed or,0
FANAPT,myoglobinuria,,0
FANAPT,myoglobinuria,dose,0
FANAPT,myoglobinuria,at least ce the placeb,1
FANAPT,rhabdomyolysis,twice,0
FANAPT,rhabdomyolysis,le,1
FANAPT,rhabdomyolysis,congestion somnolence tachycardia,0
FANAPT,rhabdomyolysis,least twice the rate for at le,1
FANAPT,acute renal failure,"for at least ose: dizziness,",1
FANAPT,acute renal failure,"least ose: dizziness, dry",1
FANAPT,acute renal failure,mouth fatigue nasal congestion somnolence,0
FANAPT,acute renal failure,the patients treated with FANAPT and at least twice the placebo rate for,0
FANAPT,acute renal failure,"least ose: dizziness, dry",1
FANAPT,acute renal failure,the placebo rate for at least d,0
FANAPT,acute renal failure,with FANAPT and at least twice the placebo rate for at,0
FANAPT,Tardive dyskinesia,Tremor,0
FANAPT,Tardive dyskinesia,,0
FANAPT,Tardive dyskinesia,     1.9          ,1
FANAPT,Tardive dyskinesia,Associated with,0
FANAPT,Tardive dyskinesia,,0
FANAPT,Tardive dyskinesia,     1.9          ,1
FANAPT,Tardive dyskinesia,     1.9          ,1
FANAPT,Tardive dyskinesia,Parkinsonism      1.9          ,1
FANAPT,Tardive dyskinesia,Tremor,0
FANAPT,"involuntary, dyskinetic movements",Tremor erse Reactions Associated with Di,1
FANAPT,"involuntary, dyskinetic movements",,0
FANAPT,"involuntary, dyskinetic movements",with Di,1
FANAPT,"involuntary, dyskinetic movements",erse Reactions Associated with Di,1
FANAPT,"involuntary, dyskinetic movements",,0
FANAPT,"involuntary, dyskinetic movements",erse Reactions Associated with Di,1
FANAPT,"involuntary, dyskinetic movements",erse Reactions,1
FANAPT,"involuntary, dyskinetic movements",Tremor erse Reactions Associated with Di,1
FANAPT,"involuntary, dyskinetic movements",in Clinical Trials,0
FANAPT,"involuntary, dyskinetic movements",Based on the pooled data from,0
FANAPT,hyperglycemia,it. R,1
FANAPT,hyperglycemia,"not necessarily  by it.



 R",1
FANAPT,hyperglycemia,"were not necessarily  by it.



 R",1
FANAPT,hyperglycemia,by MedDRA system organ class,0
FANAPT,hyperglycemia,by it.,1
FANAPT,hyperglycemia," by it.



 R",1
FANAPT,hyperglycemia,it. R,1
FANAPT,hyperglycemia,freq,0
FANAPT,hyperglycemia,by it. R,1
FANAPT,dyslipidemia,ctions are,1
FANAPT,dyslipidemia,system organ class and listed in,0
FANAPT,dyslipidemia,urther categorized by MedDRA system organ class and listed in,0
FANAPT,dyslipidemia,necessarily caused by it ctions are,1
FANAPT,dyslipidemia,are f,1
FANAPT,dyslipidemia,ctions are,1
FANAPT,dyslipidemia,were not necessarily caused by it Rea,0
FANAPT,dyslipidemia,ctions are f,1
FANAPT,dyslipidemia,ctions are f,1
FANAPT,dyslipidemia,ctions are f,1
FANAPT,body weight gain,,0
FANAPT,body weight gain,categorized by,1
FANAPT,body weight gain,by it Reactions are categorized,1
FANAPT,body weight gain,during treatment with FANAPT they were not necessarily caused by,0
FANAPT,body weight gain,Reactions are categorized,1
FANAPT,body weight gain,organ class and listed in order of,0
FANAPT,body weight gain,categorized,1
FANAPT,Hyperglycemia,,0
FANAPT,Hyperglycemia,,0
FANAPT,Hyperglycemia,listing requent,1
FANAPT,Hyperglycemia,in,0
FANAPT,Hyperglycemia,appear in this listing requent,1
FANAPT,Hyperglycemia,in this listing requent adver,1
FANAPT,Hyperglycemia,patients rare,0
FANAPT,Hyperglycemia,occurring in to patients rare events are,0
FANAPT,Hyperglycemia,appear in this,0
FANAPT,Hyperglycemia,this listing requent adver,1
FANAPT,Hyperglycemia,listing requent,1
FANAPT,Hyperglycemia,this listing requent,1
FANAPT,Hyperglycemia,those not listed in Table appear in,0
FANAPT,Hyperglycemia,this listing requent,1
FANAPT,Hyperglycemia,this listing requent adver,1
FANAPT,Hyperglycemia,,0
FANAPT,Hyperglycemia,those occurring in,0
FANAPT,ketoacidosis,in  1/1000 pati,1
FANAPT,ketoacidosis,in to,0
FANAPT,ketoacidosis,are those occurring in 1/1000,1
FANAPT,ketoacidosis,Disor,0
FANAPT,ketoacidosis,pati,1
FANAPT,ketoacidosis,Table appear in this listing infrequent,0
FANAPT,ketoacidosis,in this listing infrequent adverse reactions are those,0
FANAPT,ketoacidosis,pati,1
FANAPT,ketoacidosis,those occurring in 1/1000,1
FANAPT,hyperosmolar coma,adverse reactions are,0
FANAPT,hyperosmolar coma,Disorders Infrequent a,0
FANAPT,hyperosmolar coma,,0
FANAPT,hyperosmolar coma,; rare events,1
FANAPT,hyperosmolar coma,those occurring in fewer than,0
FANAPT,hyperosmolar coma,in fewer than patients Blood,0
FANAPT,hyperosmolar coma,in to ; rare events are,1
FANAPT,hyperosmolar coma,in to ; rare events are,1
FANAPT,death,are tho,0
FANAPT,death,,0
FANAPT,death,Lymphatic,0
FANAPT,death,,0
FANAPT,death,oc,1
FANAPT,death,se,1
FANAPT,hyperglycemia-related adverse events,conjunctival) Gastroi,1
FANAPT,hyperglycemia-related adverse events,lenticular opacities cataract,0
FANAPT,Undesirable alterations in lipids,of uncertain size it is not possible to reliably estimate their frequency,0
FANAPT,Undesirable alterations in lipids,their frequency or  a causal relationship to drug ex posure,1
FANAPT,Undesirable alterations in lipids,to drug ex posure,1
FANAPT,Undesirable alterations in lipids,to drug ex posure,1
FANAPT,Undesirable alterations in lipids,drug ex posure,1
FANAPT,Undesirable alterations in lipids,ex posure,1
FANAPT,Undesirable alterations in lipids,a causal relationship to drug ex posure,1
FANAPT,Undesirable alterations in lipids,ex posure,1
FANAPT,Undesirable alterations in lipids,causal relationship to drug ex posure,1
FANAPT,Weight gain,,1
FANAPT,Weight gain,,0
FANAPT,Weight gain,,1
FANAPT,Weight gain,,1
FANAPT,Weight gain,,1
FANAPT,Weight gain,,0
FANAPT,Weight gain,,1
FANAPT,Weight gain,,0
FANAPT,Weight gain,,1
FANAPT,Weight gain,,0
FANAPT,gain in body weight,,0
FANAPT,gain in body weight,,1
FANAPT,gain in body weight,,1
FANAPT,gain in body weight,,1
FANAPT,gain in body weight,,0
FANAPT,seizures,,1
FANAPT,seizures,,1
FANAPT,seizures,,0
FANAPT,seizures,,0
FANAPT,seizures,,0
FANAPT,seizures,,0
FANAPT,seizures,,1
FANAPT,seizures,,0
FANAPT,seizures,,0
FANAPT,orthostatic hypotension,,0
FANAPT,orthostatic hypotension,,1
FANAPT,orthostatic hypotension,,1
FANAPT,orthostatic hypotension,,0
FANAPT,dizziness,,0
FANAPT,dizziness,,1
FANAPT,tachycardia,,1
FANAPT,tachycardia,,1
FANAPT,tachycardia,,1
FANAPT,syncope,,1
FANAPT,syncope,,1
FANAPT,syncope,,0
FANAPT,syncope,,0
FANAPT,syncope,,0
FANAPT,syncope,,0
FANAPT,Orthostatic hypotension,,1
FANAPT,Orthostatic hypotension,,1
FANAPT,Orthostatic hypotension,,0
FANAPT,Orthostatic hypotension,,1
FANAPT,leukopenia,,1
FANAPT,leukopenia,,1
FANAPT,leukopenia,,0
FANAPT,leukopenia,,1
FANAPT,leukopenia,,1
FANAPT,neutropenia,,1
FANAPT,neutropenia,,0
FANAPT,neutropenia,,0
FANAPT,neutropenia,,1
FANAPT,neutropenia,,1
FANAPT,neutropenia,,0
FANAPT,neutropenia,,0
FANAPT,neutropenia,,0
FANAPT,neutropenia,,0
FANAPT,neutropenia,,0
FANAPT,Agranulocytosis,,1
FANAPT,fatal,,1
FANAPT,fatal,,1
FANAPT,fatal,,1
FANAPT,fatal,,0
FANAPT,fatal,,0
FANAPT,fatal,,0
FANAPT,fatal,,0
FANAPT,leukopenia,,0
FANAPT,leukopenia,,0
FANAPT,leukopenia,,0
FANAPT,leukopenia,,0
FANAPT,leukopenia,,0
FANAPT,leukopenia,,1
FANAPT,leukopenia,,0
FANAPT,leukopenia,,1
FANAPT,neutropenia,,1
FANAPT,neutropenia,,0
FANAPT,neutropenia,,1
FANAPT,neutropenia,,0
FANAPT,neutropenia,,1
FANAPT,neutropenia,,0
FANAPT,elevates prolactin levels,,1
FANAPT,elevates prolactin levels,,1
FANAPT,elevates prolactin levels,,1
FANAPT,elevates prolactin levels,,0
FANAPT,elevates prolactin levels,,1
FANAPT,elevates prolactin levels,,0
FANAPT,elevates prolactin levels,,1
FANAPT,Hyperprolactinemia,,0
FANAPT,Hyperprolactinemia,,1
FANAPT,Hyperprolactinemia,,1
FANAPT,Hyperprolactinemia,,0
FANAPT,Hyperprolactinemia,,1
FANAPT,Hyperprolactinemia,,1
FANAPT,suppress hypothalamic GnRH,,1
FANAPT,suppress hypothalamic GnRH,,0
FANAPT,suppress hypothalamic GnRH,,1
FANAPT,suppress hypothalamic GnRH,,0
FANAPT,reduced pituitary gonadotropin secretion,,1
FANAPT,reduced pituitary gonadotropin secretion,,1
FANAPT,inhibit reproductive function,,0
FANAPT,inhibit reproductive function,,1
FANAPT,inhibit reproductive function,,0
FANAPT,inhibit reproductive function,,0
FANAPT,inhibit reproductive function,,1
FANAPT,inhibit reproductive function,,0
FANAPT,inhibit reproductive function,,1
FANAPT,impairing gonadalsteroidogenesis,,0
FANAPT,impairing gonadalsteroidogenesis,,0
FANAPT,impairing gonadalsteroidogenesis,,0
FANAPT,impairing gonadalsteroidogenesis,,0
FANAPT,impairing gonadalsteroidogenesis,,1
FANAPT,impairing gonadalsteroidogenesis,,0
FANAPT,impairing gonadalsteroidogenesis,,0
FANAPT,impairing gonadalsteroidogenesis,,1
FANAPT,impairing gonadalsteroidogenesis,,1
FANAPT,Galactorrhea,,1
FANAPT,Galactorrhea,,0
FANAPT,Galactorrhea,,0
FANAPT,Galactorrhea,,0
FANAPT,Galactorrhea,,0
FANAPT,Galactorrhea,,1
FANAPT,Galactorrhea,,0
FANAPT,Galactorrhea,,0
FANAPT,Galactorrhea,,0
FANAPT,Galactorrhea,,1
FANAPT,amenorrhea,,1
FANAPT,amenorrhea,,0
FANAPT,amenorrhea,,0
FANAPT,amenorrhea,,0
FANAPT,amenorrhea,,1
FANAPT,amenorrhea,,1
FANAPT,amenorrhea,,0
FANAPT,amenorrhea,,0
FANAPT,gynecomastia,,1
FANAPT,gynecomastia,,0
FANAPT,gynecomastia,,1
FANAPT,gynecomastia,,0
FANAPT,gynecomastia,,0
FANAPT,gynecomastia,,1
FANAPT,gynecomastia,,1
FANAPT,gynecomastia,,1
FANAPT,gynecomastia,,0
FANAPT,impotence,,0
FANAPT,impotence,,0
FANAPT,impotence,,1
FANAPT,hypogonadism,,1
FANAPT,hypogonadism,,1
FANAPT,hypogonadism,,0
FANAPT,hypogonadism,,1
FANAPT,hypogonadism,,0
FANAPT,hypogonadism,,1
FANAPT,hypogonadism,,1
FANAPT,hypogonadism,,0
FANAPT,hypogonadism,,1
FANAPT,hypogonadism,,1
FANAPT,decreased bone density,,0
FANAPT,decreased bone density,,0
FANAPT,decreased bone density,,1
FANAPT,decreased bone density,,0
FANAPT,decreased bone density,,0
FANAPT,Mammary gland proliferative changes,,0
FANAPT,Mammary gland proliferative changes,,0
FANAPT,Mammary gland proliferative changes,,1
FANAPT,Mammary gland proliferative changes,,1
FANAPT,increases in serum prolactin,,1
FANAPT,increases in serum prolactin,,0
FANAPT,elevated plasma prolactin levels,,1
FANAPT,elevated plasma prolactin levels,,0
FANAPT,elevated plasma prolactin levels,,1
FANAPT,elevated plasma prolactin levels,,1
FANAPT,elevated plasma prolactin levels,,0
FANAPT,elevated plasma prolactin levels,,0
FANAPT,prolactin elevation,,1
FANAPT,prolactin elevations,,1
FANAPT,prolactin elevations,,0
FANAPT,prolactin elevations,,1
FANAPT,prolactin elevations,,1
FANAPT,prolactin elevations,,1
FANAPT,prolactin elevations,,1
FANAPT,prolactin elevations,,1
FANAPT,prolactin elevations,,1
FANAPT,prolactin elevations,,0
FANAPT,prolactin elevations,,0
FANAPT,gynecomastia,,1
FANAPT,gynecomastia,,0
FANAPT,galactorrhea,,1
FANAPT,galactorrhea,,0
FANAPT,galactorrhea,,1
FANAPT,Disruption of the body's ability to reduce core body temperature,,1
FANAPT,Disruption of the body's ability to reduce core body temperature,,1
FANAPT,Disruption of the body's ability to reduce core body temperature,,0
FANAPT,Disruption of the body's ability to reduce core body temperature,,1
FANAPT,Disruption of the body's ability to reduce core body temperature,,0
FANAPT,Disruption of the body's ability to reduce core body temperature,,1
FANAPT,Disruption of the body's ability to reduce core body temperature,,1
FANAPT,Esophageal dysmotility,,0
FANAPT,Esophageal dysmotility,,1
FANAPT,Esophageal dysmotility,,0
FANAPT,Esophageal dysmotility,,0
FANAPT,Esophageal dysmotility,,1
FANAPT,Esophageal dysmotility,,0
FANAPT,aspiration,,1
FANAPT,aspiration,,0
FANAPT,aspiration,,1
FANAPT,aspiration,,0
FANAPT,priapism,,1
FANAPT,priapism,,0
FANAPT,priapism,,1
FANAPT,priapism,,1
FANAPT,priapism,,1
FANAPT,priapism,,0
FANAPT,priapism,,1
FANAPT,impair judgment,,1
FANAPT,impair judgment,,0
FANAPT,impair judgment,,1
FANAPT,impair judgment,,1
FANAPT,impair judgment,,1
FANAPT,impair judgment,,1
FANAPT,impair judgment,,1
FANAPT,somnolence,,1
FANAPT,somnolence,,0
FANAPT,somnolence,,0
FANAPT,somnolence,,1
FANAPT,somnolence,,0
FANAPT,somnolence,,1
FANAPT,somnolence,,0
FANAPT,sedation,,1
FANAPT,sedation,,0
FANAPT,sedation,,1
FANAPT,sedation,,0
FANAPT,sedation,,0
FANAPT,sedation,,0
FANAPT,sedation,,1
FANAPT,sedation,,1
FULYZAQ,Upper respiratory tract infection,Reaction Crofelemer mg BIDN n,0
FULYZAQ,Upper respiratory tract infection,BIDN n PlaceboN,0
FULYZAQ,Upper respiratory tract infection,respiratory tract infection,1
FULYZAQ,Upper respiratory tract infection,mg,0
FULYZAQ,Upper respiratory tract infection,Bronchitis,0
FULYZAQ,Upper respiratory tract infection,,0
FULYZAQ,Upper respiratory tract infection,infection,1
FULYZAQ,Upper respiratory tract infection,infection,1
FULYZAQ,Upper respiratory tract infection,mg BIDN,0
FULYZAQ,Bronchitis,tract Bronchitis,1
FULYZAQ,Bronchitis,,0
FULYZAQ,Bronchitis,Upper respiratory tract Bronchitis,1
FULYZAQ,Bronchitis,Bronchitis,1
FULYZAQ,Bronchitis,Bronchitis,1
FULYZAQ,Bronchitis,,0
FULYZAQ,Bronchitis,tract,0
FULYZAQ,Bronchitis,Bronchitis,1
FULYZAQ,Bronchitis,Bronchitis,1
FULYZAQ,Bronchitis,Bronchitis,1
FULYZAQ,Flatulence,Flatulence,1
FULYZAQ,Flatulence,,0
FULYZAQ,Flatulence,,0
FULYZAQ,Flatulence,Increased bilirubin,0
FULYZAQ,Flatulence,,0
FULYZAQ,Increased bilirubin,Nausea,0
FULYZAQ,Increased bilirubin,,0
FULYZAQ,Increased bilirubin,bilirubin,1
FULYZAQ,Increased bilirubin,Flatulence Increased,1
FULYZAQ,Increased bilirubin,Flatulence,0
FULYZAQ,Increased bilirubin,Back,0
FULYZAQ,Increased bilirubin,,0
FULYZAQ,Nausea,Back,0
FULYZAQ,Nausea,Nausea Back pain,1
FULYZAQ,Nausea,,0
FULYZAQ,Nausea,bilirubin,0
FULYZAQ,Nausea,Back,0
FULYZAQ,Back pain,Back pain Arthralgia U,1
FULYZAQ,Arthralgia,,0
FULYZAQ,Arthralgia,pain,0
FULYZAQ,Arthralgia,,0
FULYZAQ,Arthralgia,tract,0
FULYZAQ,Arthralgia,Arthralgia Urinary tract,1
FULYZAQ,Arthralgia,tract,0
FULYZAQ,Arthralgia,,0
FULYZAQ,Arthralgia,pain,0
FULYZAQ,Arthralgia,,0
FULYZAQ,Urinary tract infection,Arthralgia,0
FULYZAQ,Urinary tract infection,infection Nasopharyngitis Mus,1
FULYZAQ,Urinary tract infection,Urinary,1
FULYZAQ,Urinary tract infection,,0
FULYZAQ,Nasopharyngitis,,0
FULYZAQ,Nasopharyngitis,Musculoskeletal pain,0
FULYZAQ,Nasopharyngitis,Urinary tract Nasopharyngitis Musculoskeletal pain,1
FULYZAQ,Nasopharyngitis,pain,0
FULYZAQ,Nasopharyngitis,Urinary tract Nasopharyngitis Musculoskeletal pain,1
FULYZAQ,Nasopharyngitis,,0
FULYZAQ,Musculoskeletal pain,,0
FULYZAQ,Musculoskeletal pain,Nasopharyngitis,0
FULYZAQ,Musculoskeletal pain,ion Musculoskeletal,1
FULYZAQ,Musculoskeletal pain,Musculoskeletal pain Hemorrhoids Giard,1
FULYZAQ,Musculoskeletal pain,,0
FULYZAQ,Musculoskeletal pain,Giard,0
FULYZAQ,Musculoskeletal pain,Musculoskeletal,1
FULYZAQ,Hemorrhoids,,0
FULYZAQ,Hemorrhoids,pain,0
FULYZAQ,Giardiasis,,0
FULYZAQ,Giardiasis,,0
FULYZAQ,Giardiasis,,0
FULYZAQ,Giardiasis,,0
FULYZAQ,Giardiasis,,0
FULYZAQ,Giardiasis,,0
FULYZAQ,Giardiasis,,0
FULYZAQ,Giardiasis,pain Giardiasis Anxiety In,1
FULYZAQ,Giardiasis,Giardiasis Anxiety In,1
FULYZAQ,Anxiety,Anxiety Increased alanine,1
FULYZAQ,Anxiety,,0
FULYZAQ,Anxiety,Anxiety Increased alanine,1
FULYZAQ,Anxiety,,0
FULYZAQ,Anxiety,Anxiety Increased alanine,1
FULYZAQ,Anxiety,aminotransferase,0
FULYZAQ,Increased alanine aminotransferase,Anxiety,0
FULYZAQ,Increased alanine aminotransferase,,0
FULYZAQ,Increased alanine aminotransferase,Anxiety,0
FULYZAQ,Increased alanine aminotransferase,Anxiety,0
FULYZAQ,Abdominal distension,Abdominal distension Twice daily,1
FULYZAQ,Abdominal distension,,0
FULYZAQ,Abdominal distension,Increased alanine Abdominal distension Twice daily,1
FULYZAQ,abdominal pain,a mg daily dose of FULYZAQ,0
FULYZAQ,abdominal pain,aspartate aminotransferase,0
FULYZAQ,acne,acne increased aspartate,1
FULYZAQ,acne,acne increased aspartate,1
FULYZAQ,acne,mg daily dose of FULYZAQ,0
FULYZAQ,acne,,0
FULYZAQ,increased aspartate aminotransferase,between and of patients,0
FULYZAQ,increased aspartate aminotransferase,conjugated bilirubin increased,0
FULYZAQ,increased aspartate aminotransferase,,0
FULYZAQ,increased aspartate aminotransferase,FULYZAQ were abdominal pain increased aspartate aminotransferase increased conjugated,1
FULYZAQ,increased aspartate aminotransferase,mg daily dose of FULYZAQ were abdominal,0
FULYZAQ,increased aspartate aminotransferase,constipation depression,0
FULYZAQ,increased aspartate aminotransferase,blood bilirubin constipation depression,0
FULYZAQ,increased aspartate aminotransferase,,0
FULYZAQ,increased conjugated bilirubin,increased aspartate increased conjugated bilirubin increased unconjugated,1
FULYZAQ,increased conjugated bilirubin,aspartate increased conjugated bilirubin increased unconjugated,1
FULYZAQ,increased conjugated bilirubin,aspartate increased,1
FULYZAQ,increased conjugated bilirubin,conjugated bilirubin increased unconjugated,1
FULYZAQ,increased conjugated bilirubin,increased aspartate increased,1
FULYZAQ,increased conjugated bilirubin,increased conjugated bilirubin increased unconjugated,1
FULYZAQ,increased conjugated bilirubin,acne increased aspartate increased,1
FULYZAQ,increased conjugated bilirubin,constipation depression,0
FULYZAQ,constipation,nephrolit,0
FULYZAQ,constipation,,0
FULYZAQ,constipation,increased unconjugated blood constipation depression dermatitis,1
FULYZAQ,depression,depression dermatitis dizziness,1
FULYZAQ,dermatitis,unconjugated blood,0
FULYZAQ,dermatitis,blood bilirubin constipation dermatitis dizziness dry,1
FULYZAQ,dizziness,gastroenteritis,0
FULYZAQ,dizziness,blood bilirubin constipation depression dizziness dry mouth,1
FULYZAQ,dizziness,,0
FULYZAQ,dizziness,dizziness dry mouth,1
FULYZAQ,dizziness,depression dizziness dry mouth,1
FULYZAQ,dizziness,blood bilirubin constipation depression dizziness dry mouth,1
FULYZAQ,dyspepsia,,0
FULYZAQ,gastroenteritis,,0
FULYZAQ,gastroenteritis,,0
FULYZAQ,gastroenteritis,dizziness dry mouth gastroenteritis herpes zoster,1
FULYZAQ,gastroenteritis,,0
FULYZAQ,gastroenteritis,,0
FULYZAQ,gastroenteritis,bilirubin constipation depression dermatitis dizziness dry mouth dyspepsia,0
FULYZAQ,gastroenteritis,pain in,0
FULYZAQ,gastroenteritis,gastroenteritis herpes zoster,1
FULYZAQ,gastroenteritis,nephrolithiasis pain in extremity pollakiuria procedural pain,0
FULYZAQ,herpes zoster,dermatitis,0
FULYZAQ,herpes zoster,zoster nephrolithiasis pain,1
FULYZAQ,herpes zoster,herpes zoster nephrolithiasis pain,1
FULYZAQ,herpes zoster,,0
FULYZAQ,herpes zoster,herpes zoster nephrolithiasis pain,1
FULYZAQ,herpes zoster,herpes zoster nephrolithiasis pain,1
FULYZAQ,herpes zoster,herpes zoster nephrolithiasis pain,1
FULYZAQ,herpes zoster,pain seasonal allergy sinusitis,0
FULYZAQ,nephrolithiasis,nephrolithiasis pain in,1
FULYZAQ,nephrolithiasis,in extremity pollakiuria procedural pain seasonal allergy sinusitis and decreased white,0
FULYZAQ,nephrolithiasis,,0
FULYZAQ,nephrolithiasis,dry mouth dyspepsia gastroenteritis herpes zoster,0
FULYZAQ,nephrolithiasis,nephrolithiasis pain in,1
FULYZAQ,nephrolithiasis,nephrolithiasis pain in,1
FULYZAQ,nephrolithiasis,pollakiuria procedural pain seasonal allergy sinusitis,0
FULYZAQ,nephrolithiasis,dyspepsia gastroenteritis herpes nephrolithiasis pain in,1
FULYZAQ,pain in extremity,dyspepsia gastroenteritis herpes zoster,0
FULYZAQ,pain in extremity,,0
FULYZAQ,pain in extremity,nephrolithiasis,0
FULYZAQ,pollakiuria,pollakiuria procedural pain,1
FULYZAQ,procedural pain,seasonal allergy,0
FULYZAQ,procedural pain,extremity procedural pain seasonal allergy,1
FULYZAQ,procedural pain,extremity,0
FULYZAQ,seasonal allergy,were,0
FULYZAQ,seasonal allergy,seasonal,1
FULYZAQ,seasonal allergy,pain in,0
FULYZAQ,sinusitis,nephrolithiasis pain in extremity,0
FULYZAQ,decreased white blood cell count,count Adverse reactions,1
FULYZAQ,decreased white blood cell count,pain seasonal allergy sinusitis decreased white blood,1
FULYZAQ,decreased white blood cell count,seasonal allergy sinusitis decreased white blood cell count Adverse reactions,1
FULYZAQ,decreased white blood cell count,extremity pollakiuria procedural pain,0
FULYZAQ,upper respiratory tract infection,incidence upper respiratory tract,1
FULYZAQ,upper respiratory tract infection,tract infection bronchitis cough,1
FULYZAQ,upper respiratory tract infection,adverse reactions incidence are,0
FULYZAQ,upper respiratory tract infection,reactions incidence upper respiratory tract infection bronchitis cough,1
FULYZAQ,upper respiratory tract infection,Most,0
FULYZAQ,upper respiratory tract infection,adverse reactions incidence upper respiratory,1
FULYZAQ,bronchitis,bilirubin To report SUSPECTED ADVERSE,0
FULYZAQ,bronchitis,,0
FULYZAQ,bronchitis,report SUSPECTED ADVERSE,0
FULYZAQ,bronchitis,bronchitis cough flatulence,1
FULYZAQ,bronchitis,and increased,0
FULYZAQ,bronchitis,upper respiratory tract bronchitis cough flatulence,1
FULYZAQ,bronchitis,infection,0
FULYZAQ,bronchitis,incidence are upper respiratory tract infection,0
FULYZAQ,cough,respiratory tract infection bronchitis,0
FULYZAQ,cough,reactions incidence,0
FULYZAQ,cough,cough flatulence and,1
FULYZAQ,cough,cough flatulence and,1
FULYZAQ,cough,,0
FULYZAQ,cough,,0
FULYZAQ,cough,cough flatulence and,1
FULYZAQ,cough,adverse,0
FULYZAQ,flatulence,increased bilirubin To,0
FULYZAQ,increased bilirubin,cough flatulence increased,1
FULYZAQ,increased bilirubin,bilirubin To report,1
FULYZAQ,increased bilirubin,flatulence increased bilirubin To report,1
FULYZAQ,increased bilirubin,infection,0
FULYZAQ,increased bilirubin,Salix,0
FULYZAQ,increased bilirubin,increased bilirubin To report,1
FULYZAQ,increased bilirubin,infection bronchitis,0
FULYZAQ,increased bilirubin,increased bilirubin To report,1
FULYZAQ,increased bilirubin,increased bilirubin To report,1
EOVIST,Nephrogenic systemic fibrosis,elsewhere in the labeling,0
EOVIST,NSF,labeling Nephrogenic systemic NSF see Boxed,1
EOVIST,NSF,Warning and Warnings and Precautions,0
EOVIST,NSF,NSF see Boxed,1
EOVIST,NSF,NSF see Boxed,1
EOVIST,NSF,reactions,0
EOVIST,NSF,elsewhere in,0
EOVIST,Hypersensitivity reactions,Hypersensitivity reactions see Contraindications,1
EOVIST,nausea,nausea headache feeling,1
EOVIST,headache,,0
EOVIST,headache,incidence are headache feeling hot,1
EOVIST,headache,To report SUSPECTED ADVERSE REACTIONS,0
EOVIST,headache,headache feeling hot,1
EOVIST,headache,common adverse reactions incidence are nausea,0
EOVIST,headache,hot dizziness and back pain To,0
EOVIST,headache,dizziness and back pain To report,0
EOVIST,headache,headache feeling hot,1
EOVIST,headache,reactions incidence are headache feeling hot,1
EOVIST,feeling hot,feeling hot dizziness and,1
EOVIST,feeling hot,feeling,1
EOVIST,feeling hot,,0
EOVIST,feeling hot,hot dizziness and,1
EOVIST,dizziness,,0
EOVIST,dizziness,contact Bayer HealthCare Pharmace,0
EOVIST,dizziness,,0
EOVIST,dizziness,dizziness and back,1
EOVIST,dizziness,are nausea headache,0
EOVIST,back pain,dizziness back pain To report,1
EOVIST,back pain,feeling hot dizziness back pain To report,1
EOVIST,back pain,back pain To report,1
EOVIST,back pain,headache feeling hot dizziness,0
EOVIST,back pain,hot,0
EOVIST,back pain,common adverse reactions incidence are nausea headache,0
EOVIST,back pain,pain To report,1
EOVIST,back pain,common adverse reactions,0
EOVIST,back pain,headache feeling hot dizziness back pain To report,1
EOVIST,nausea,Adverse reactions were predominantly of,0
EOVIST,nausea,reactions associated with the use,0
EOVIST,nausea,nausea headache feeling,1
EOVIST,nausea,frequent adverse reactions associated with the use,0
EOVIST,nausea,headache,0
EOVIST,nausea,nausea headache feeling,1
EOVIST,nausea,frequent adverse reactions associated,0
EOVIST,headache,use of,0
EOVIST,headache,headache feeling hot,1
EOVIST,headache,hot dizziness and back pain Adverse reactions were,0
EOVIST,headache,headache feeling hot,1
EOVIST,headache,headache feeling hot,1
EOVIST,headache,of EOVIST,0
EOVIST,headache,back pain Adverse,0
EOVIST,headache,headache feeling hot,1
EOVIST,feeling hot,nausea feeling,1
EOVIST,feeling hot,EOVIST were nausea feeling,1
EOVIST,feeling hot,were nausea feeling hot dizziness and,1
EOVIST,feeling hot,predominantly of mild to moderate severity,0
EOVIST,feeling hot,feeling,1
EOVIST,feeling hot,,0
EOVIST,feeling hot,,0
EOVIST,feeling hot,nausea feeling hot dizziness and,1
EOVIST,feeling hot,feeling hot dizziness and,1
EOVIST,feeling hot,feeling,1
EOVIST,back pain,reactions associated with the use of EOVIST were,0
EOVIST,back pain,lists,0
EOVIST,back pain,hot dizziness back pain Adverse reactions,1
EOVIST,back pain,back,1
EOVIST,back pain,feeling hot dizziness back,1
EOVIST,back pain,back pain Adverse reactions,1
EOVIST,back pain,adverse,0
EOVIST,back pain,feeling hot dizziness back pain Adverse reactions,1
EOVIST,Nausea,Nausea Headache,1
EOVIST,Nausea,,0
EOVIST,Nausea,,0
EOVIST,Nausea,Nausea Headache,1
EOVIST,Nausea,,0
EOVIST,Nausea,,0
EOVIST,Nausea,,0
EOVIST,Nausea,n,0
EOVIST,Nausea,Reactions Reaction Rate Nausea Headache,1
EOVIST,Nausea,Reactions Reaction Rate Nausea Headache,1
EOVIST,Headache,Headache Feeling hot,1
EOVIST,Headache,Headache Feeling hot,1
EOVIST,Headache,Headache Feeling hot,1
EOVIST,Headache,Feeling,0
EOVIST,Headache,,0
EOVIST,Headache,Headache Feeling hot,1
EOVIST,Headache,Nausea,0
EOVIST,Headache,n,0
EOVIST,Feeling hot,Headache Feeling,1
EOVIST,Feeling hot,hot Dizziness,1
EOVIST,Feeling hot,Headache Feeling,1
EOVIST,Feeling hot,,0
EOVIST,Feeling hot,Headache,0
EOVIST,Feeling hot,Headache,0
EOVIST,Feeling hot,Headache,0
EOVIST,Feeling hot,Headache,0
EOVIST,Dizziness,hot,0
EOVIST,Dizziness,hot,0
EOVIST,Dizziness,Dizziness Back,1
EOVIST,Dizziness,,0
EOVIST,Dizziness,,0
EOVIST,Dizziness,,0
EOVIST,Back pain,Back pain Vomiting,1
EOVIST,Back pain,Dizziness Back,1
EOVIST,Back pain,Dizziness,0
EOVIST,Back pain,Dizziness,0
EOVIST,Back pain,Dizziness Back pain Vomiting,1
EOVIST,Back pain,Vomiting,0
EOVIST,Back pain,Vomiting,0
EOVIST,Vomiting,Vomiting Blood,1
EOVIST,Vomiting,Vomiting Blood,1
EOVIST,Vomiting,Blood pressure increased,0
EOVIST,Vomiting,Back Vomiting Blood,1
EOVIST,Blood pressure increased,Vomiting Blood pressure,1
EOVIST,Blood pressure increased,Vomiting Blood pressure,1
EOVIST,Blood pressure increased,,0
EOVIST,Blood pressure increased,Vomiting,0
EOVIST,Injection site reactions,,0
EOVIST,Injection site reactions,pressure,0
EOVIST,Injection site reactions,site reactions pain burning coldness extravasation,1
EOVIST,Injection site reactions,,0
EOVIST,Injection site reactions,irritation Dysgeusia,0
EOVIST,Injection site reactions,pressure increased,0
EOVIST,Injection site reactions,Injection site reactions pain burning coldness extravasation,1
EOVIST,Injection site reactions,site reactions pain burning coldness extravasation,1
EOVIST,Dysgeusia,,0
EOVIST,Dysgeusia,,0
EOVIST,Dysgeusia,coldness extravasation,0
EOVIST,Dysgeusia,,0
EOVIST,Dysgeusia,coldness extravasation,0
EOVIST,Dysgeusia,reactions,0
EOVIST,Dysgeusia,,0
EOVIST,Paresthesia,Paresthesia Flushing,1
EOVIST,Paresthesia,,0
EOVIST,Paresthesia,Paresthesia Flushing,1
EOVIST,Paresthesia,,0
EOVIST,Paresthesia,,0
EOVIST,Flushing,Flushing Parosmia,1
EOVIST,Flushing,Paresthesia,0
EOVIST,Flushing,,0
EOVIST,Flushing,Paresthesia,0
EOVIST,Flushing,Flushing Parosmia,1
EOVIST,Flushing,Parosmia,0
EOVIST,Flushing,Flushing Parosmia,1
EOVIST,Flushing,Flushing Parosmia,1
EOVIST,Flushing,Paresthesia,0
EOVIST,Flushing,Flushing Parosmia,1
EOVIST,Rash,Rash Respiratory,1
EOVIST,Respiratory disorders,Rash,0
EOVIST,Respiratory disorders,,0
EOVIST,Respiratory disorders,Rash,0
EOVIST,Respiratory disorders,distress,0
EOVIST,dyspnea,Respiratory dyspnea respiratory distress Fatigue,1
EOVIST,respiratory distress,respiratory distress Fatigue Chest pain,1
EOVIST,Fatigue,disorders dyspnea respiratory distress,0
EOVIST,Fatigue,dyspnea respiratory,0
EOVIST,Fatigue,Fatigue Chest pain,1
EOVIST,Fatigue,Fatigue Chest pain,1
EOVIST,Chest pain,Vertigo,0
EOVIST,Chest pain,Chest pain Vertigo,1
EOVIST,Chest pain,distress Chest,1
EOVIST,Chest pain,,0
EOVIST,Chest pain,distress Chest,1
EOVIST,Chest pain,pain Vertigo,1
EOVIST,Chest pain,,0
EOVIST,Chest pain,,0
EOVIST,Chest pain,Chest pain Vertigo,1
EOVIST,Vertigo,Vertigo Dry mouth,1
EOVIST,Vertigo,Vertigo Dry mouth,1
EOVIST,Vertigo,mouth,0
EOVIST,Dry mouth,Vertigo Dry mouth Chills,1
EOVIST,Chills,Chills Feeling,1
EOVIST,Chills,Chills Feeling,1
EOVIST,Feeling abnormal,Chills Feeling abnormal Adverse,1
EOVIST,Feeling abnormal,Chills Feeling abnormal Adverse,1
EOVIST,Feeling abnormal,Chills Feeling,1
EOVIST,Feeling abnormal,Chills Feeling,1
EOVIST,tremor,tremor akathisia bundle branch block palpitation,1
EOVIST,tremor,,0
EOVIST,tremor,tremor akathisia bundle branch block palpitation,1
EOVIST,tremor,received EOVIST,0
EOVIST,tremor,,0
EOVIST,tremor,tremor akathisia bundle branch block palpitation,1
EOVIST,akathisia,hypersecretion maculopapular,0
EOVIST,akathisia,that occurred,0
EOVIST,bundle branch block,tremor bundle branch block palpitation oral discomfort salivary hypersecretion,1
EOVIST,bundle branch block,EOVIST include tremor bundle branch block palpitation oral discomfort salivary hypersecretion,1
EOVIST,oral discomfort,,0
EOVIST,oral discomfort,branch,0
EOVIST,oral discomfort,bundle branch block oral discomfort salivary hypersecretion maculopapular rash hyperhidrosis,1
EOVIST,oral discomfort,discomfort salivary hypersecretion maculopapular rash hyperhidrosis,1
EOVIST,oral discomfort,,0
EOVIST,salivary hypersecretion,and,0
EOVIST,salivary hypersecretion,of serum iron values and,0
EOVIST,salivary hypersecretion,tremor akathisia bundle branch block,0
EOVIST,salivary hypersecretion,oral salivary hypersecretion maculopapular rash hyperhidrosis discomfort and,1
EOVIST,salivary hypersecretion,hypersecretion maculopapular rash hyperhidrosis discomfort and,1
EOVIST,maculopapular rash,,0
EOVIST,maculopapular rash,bundle,0
EOVIST,maculopapular rash,salivary maculopapular,1
EOVIST,maculopapular rash,tremor akathisia,0
EOVIST,discomfort,rash discomfort and malaise Elevation of serum,1
EOVIST,malaise,discomfort salivary hypersecretion maculopapular rash hyperhidrosis discomfort and,0
EOVIST,malaise,were,0
EOVIST,malaise,laboratory values,0
EOVIST,malaise,malaise Elevation of serum iron values,1
EOVIST,malaise,salivary,0
EOVIST,malaise,malaise Elevation of serum iron values,1
EOVIST,malaise,hyperhidrosis discomfort malaise Elevation of serum iron values,1
EOVIST,malaise,hyperhidrosis discomfort malaise Elevation of serum iron values,1
EOVIST,Elevation of serum iron,serum iron values and serum bilirubin laboratory,1
EOVIST,Elevation of serum iron,and Elevation of serum,1
EOVIST,Elevation of serum iron,,0
EOVIST,Hypersensitivity reactions,reactions anaphylacticshock hypotension pharyngolaryngeal edema urticaria,1
EOVIST,anaphylacticshock,,0
EOVIST,anaphylacticshock,anaphylacticshock hypotension pharyngolaryngeal edema urticaria face,1
EOVIST,anaphylacticshock,,0
EOVIST,hypotension,a causal relationship to drug,0
EOVIST,hypotension,hypotension pharyngolaryngeal edema urticaria face edema,1
EOVIST,hypotension,hypotension pharyngolaryngeal edema urticaria face edema,1
EOVIST,hypotension,,0
EOVIST,hypotension,reactions hypotension pharyngolaryngeal edema urticaria face edema,1
EOVIST,hypotension,hypotension pharyngolaryngeal edema urticaria face edema,1
EOVIST,hypotension,abdominal,0
EOVIST,hypotension,anaphylacticshock,0
EOVIST,hypotension,exposure Hypersensitivity reactions anaphylacticshock,0
EOVIST,urticaria,,0
EOVIST,urticaria,urticaria face edema rhinitis conjunctivitis abdominal,1
EOVIST,urticaria,conjunctivitis abdominal,0
EOVIST,urticaria,urticaria face edema rhinitis conjunctivitis abdominal,1
EOVIST,urticaria,urticaria face edema rhinitis conjunctivitis abdominal,1
EOVIST,urticaria,rhinitis conjunctivitis,0
EOVIST,urticaria,urticaria face edema rhinitis conjunctivitis abdominal,1
EOVIST,urticaria,Hypersensitivity reactions anaphylacticshock hypotension pharyngolaryngeal,0
EOVIST,face edema,face edema rhinitis conjunctivitis abdominal pain hypoesthesia,1
EOVIST,face edema,pharyngolaryngeal edema face edema rhinitis conjunctivitis abdominal pain hypoesthesia,1
EOVIST,face edema,,0
EOVIST,face edema,face edema rhinitis conjunctivitis abdominal pain hypoesthesia,1
EOVIST,face edema,face edema rhinitis conjunctivitis abdominal pain hypoesthesia,1
EOVIST,face edema,abdominal,0
EOVIST,face edema,anaphylacticshock,0
EOVIST,face edema,,0
EOVIST,face edema,,0
EOVIST,face edema,hypotension pharyngolaryngeal edema face edema rhinitis conjunctivitis abdominal pain hypoesthesia,1
EOVIST,rhinitis,face rhinitis conjunctivitis abdominal pain hypoesthesia sneezing,1
EOVIST,rhinitis,,0
EOVIST,rhinitis,face,0
EOVIST,rhinitis,rhinitis conjunctivitis abdominal pain hypoesthesia sneezing,1
EOVIST,rhinitis,rhinitis conjunctivitis abdominal pain hypoesthesia sneezing,1
EOVIST,rhinitis,urticaria face edema,0
EOVIST,rhinitis,rhinitis conjunctivitis abdominal pain hypoesthesia sneezing,1
EOVIST,rhinitis,rhinitis conjunctivitis abdominal pain hypoesthesia sneezing,1
EOVIST,conjunctivitis,,0
EOVIST,conjunctivitis,conjunctivitis abdominal pain hypoesthesia sneezing cough,1
EOVIST,conjunctivitis,anaphylacticshock hypotension pharyngolaryngeal edema urticaria face,0
EOVIST,conjunctivitis,and pallor see Warnings and,0
EOVIST,conjunctivitis,rhinitis,0
EOVIST,conjunctivitis,edema,0
EOVIST,conjunctivitis,Precautions,0
EOVIST,abdominal pain,pain hypoesthesia sneezing cough and pallor,1
EOVIST,abdominal pain,urticaria face edema rhinitis abdominal pain hypoesthesia sneezing cough and pallor,1
EOVIST,abdominal pain,pallor,0
EOVIST,abdominal pain,,0
EOVIST,abdominal pain,,0
EOVIST,abdominal pain,urticaria face edema rhinitis abdominal pain hypoesthesia sneezing cough and pallor,1
EOVIST,hypoesthesia,hypoesthesia sneezing cough and pallor see,1
EOVIST,hypoesthesia,hypoesthesia sneezing cough and pallor see,1
EOVIST,hypoesthesia,face,0
EOVIST,hypoesthesia,hypoesthesia sneezing cough and pallor see,1
EOVIST,sneezing,sneezing cough and pallor see Warnings,1
EOVIST,sneezing,,0
EOVIST,sneezing,edema rhinitis conjunctivitis abdominal pain,0
EOVIST,sneezing,rhinitis conjunctivitis abdominal pain sneezing cough and pallor see Warnings,1
EOVIST,sneezing,edema rhinitis conjunctivitis,0
EOVIST,sneezing,,0
EOVIST,sneezing,rhinitis conjunctivitis abdominal,0
EOVIST,sneezing,edema rhinitis conjunctivitis,0
EOVIST,sneezing,conjunctivitis abdominal pain sneezing cough and pallor see Warnings,1
EOVIST,sneezing,,0
EOVIST,cough,cough and pallor see Warnings and,1
EOVIST,cough,cough and pallor see Warnings and,1
EOVIST,cough,face edema rhinitis conjunctivitis abdominal pain hypoesthesia sneezing,0
EOVIST,cough,hypoesthesia cough and pallor see Warnings and,1
EOVIST,cough,cough and pallor see Warnings and,1
EOVIST,cough,cough and pallor see Warnings and,1
EOVIST,cough,conjunctivitis abdominal pain hypoesthesia cough and pallor see Warnings and,1
EOVIST,cough,abdominal pain hypoesthesia cough and pallor see Warnings and,1
EOVIST,cough,cough and pallor see Warnings and,1
EOVIST,cough,Precautions Tachycardia Restlessness,0
EOVIST,pallor,hypoesthesia sneezing cough and,0
EOVIST,pallor,Tachycardia Restlessness,0
EOVIST,Tachycardia,Tachycardia Restlessness,1
EOVIST,Tachycardia,Warnings and Tachycardia Restlessness,1
EOVIST,Restlessness,cough and pallor see Warnings and Precautions,0
EOVIST,Restlessness,Restlessness,1
EOVIST,Restlessness,Restlessness,1
EOVIST,Restlessness,,0
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,,0
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,,0
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,,0
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,re actionsare discussed elsewhere in,1
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,re actionsare discussed elsewhere in,1
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,following serious adverse,1
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,adverse re actionsare discussed elsewhere in,1
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,,0
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,Bo,0
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS, following serious adverse re actionsare,1
EOVIST,NSF,tio nsare discussed elsewhere in,1
EOVIST,NSF,,0
EOVIST,NSF,see Boxed,0
EOVIST,NSF,labeling Nephrogenic,0
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,"d elsewhere in the labeling:
 Nephrogenic systemic",1
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,"d elsewhere in the labeling:
",1
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,,0
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,,0
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,,0
EOVIST,NSF,labeling,0
EOVIST,NSF,"
 * Nephrogenic systemic fibrosis",1
EOVIST,NSF,Hypersensitivity reactions see Contraindications,0
EOVIST,NSF,a nd Precautions Hypersensitivity,1
EOVIST,NSF,see Boxed Warning and s a nd Precautions Hypersensitivity,1
EOVIST,NSF,Nephrogenic,0
EOVIST,NSF,NSF see Boxed Warning and Warning,0
EOVIST,NSF,e,1
EOVIST,NSF,common adverse reactions incidence e,1
EOVIST,NSF,common adverse reactions incidence e,1
EOVIST,NSF,reactions,0
EOVIST,NSF,reactions incidence e,1
EOVIST,fatal,fee ling hot dizziness,1
EOVIST,fatal,Most common adverse reactions incidence are,0
EOVIST,fatal,"are nausea ,",1
EOVIST,fatal,"are nausea ,",1
EOVIST,fatal,headache,0
EOVIST,fatal,fee ling hot dizziness,1
EOVIST,fatal,reactions incidence,0
EOVIST,fatal,"are nausea ,",1
EOVIST,fibrosis,"headache feeling hot ss, and  back pain To",1
EOVIST,fibrosis,"hot ss, and  back pain To",1
EOVIST,NSF,yer HealthCare Pharmaceuticals Inc,1
EOVIST,NSF,,0
EOVIST,NSF,pain To report SUSPECTED,0
EOVIST,NSF,at BAYER or FDA,0
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,,0
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,other ethnic,0
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,groups The average age was years age,0
EOVIST,NSF,ack and of subjects,1
EOVIST,NSF,,0
EOVIST,NSF,Hispanic ack and of subjects,1
EOVIST,NSF,ack and of subjects,1
EOVIST,NSF,ack and of subjects,1
EOVIST,NSF,distribution,0
EOVIST,NSF,ack and of subjects,1
EOVIST,NSF,ack and of subjects,1
EOVIST,NSF,,0
EOVIST,NSF,to years Overall of bje cts reported one,1
EOVIST,NSF,bje cts reported one,1
EOVIST,NSF,were predominantly of mild to moderate severity Table lists adverse reactions that occ,0
EOVIST,NSF,rea ctions were predominantly,1
EOVIST,NSF,rea ctions were predominantly,1
EOVIST,hypersensitivity reactions,common adverse reactions,0
EOVIST,hypersensitivity reactions,EXCERPT Most common,0
EOVIST,hypersensitivity reactions,Hypersensitivity,0
EOVIST,hypersensitivity reactions,utions EXCERPT Most common adverse reactions incidence are nausea h,0
EOVIST,hypersensitivity reactions,reactions see   ) and Warnings and Preca utions EXCERPT Most,1
EOVIST,hypersensitivity reactions,see Contraindications,0
EOVIST,hypersensitivity reactions,Precautions Hypersensitivity reactions see   ) and Warnings and Preca utions EXCERPT Most,1
EOVIST,hypersensitivity reactions,and Warnings and Preca utions EXCERPT Most,1
EOVIST,hypersensitivity reactions,Precautions Hypersensitivity reactions see   ) and Warnings and Preca utions EXCERPT Most,1
EOVIST,cutaneous manifestations,Warnings and Precautions EXCERPT ost,1
EOVIST,cutaneous manifestations,ost common adverse react ions incidence are,1
EOVIST,cutaneous manifestations,react ions incidence are,1
EOVIST,cutaneous manifestations,Precautions EXCERPT ost common adverse react ions incidence are,1
EOVIST,cutaneous manifestations,common adverse react ions incidence are,1
EOVIST,cutaneous manifestations,feeling hot dizziness and back,0
EOVIST,shock,are nausea headache,0
EOVIST,shock,,0
EOVIST,shock,reactions incidence,0
EOVIST,shock,ling  hot dizziness and,1
EOVIST,shock,are nausea headache ling  hot dizziness and,1
EOVIST,shock,ling  hot dizziness and,1
EOVIST,shock,ling  hot dizziness and,1
EOVIST,shock,pain To report SUSPECTED,0
EOVIST,shock,and,0
EOVIST,shock,ling  hot dizziness and,1
EOVIST,nephrogenic systemic fibrosis,at FDA,0
EOVIST,nephrogenic systemic fibrosis,FDA or 6.1 Clinical,1
EOVIST,nephrogenic systemic fibrosis,Clinical Trials E xperience Because clinical,1
EOVIST,nephrogenic systemic fibrosis,Clinical Trials E xperience Because clinical,1
EOVIST,nephrogenic systemic fibrosis,Inc,0
EOVIST,nephrogenic systemic fibrosis,Inc at BAYER or FDA at,0
EOVIST,nephrogenic systemic fibrosis,"


 

  6.1 Clinical Trials E xperience Because clinical",1
EOVIST,nephrogenic systemic fibrosis,"or 


 

  6.1 Clinical Trials E xperience Because clinical",1
EOVIST,NSF,fle ct the rates,1
EOVIST,NSF,rates observed in clinical,0
EOVIST,NSF,fle ct the rates,1
EOVIST,NSF,another drug and may not,0
EOVIST,NSF,ct the rates observed in clinical practice The,0
EOVIST,NSF, of other ethnic groups,1
EOVIST,fatal,Hispanic Black and of subjects consisted of other ethnic,0
EOVIST,fatal,of,0
EOVIST,fatal,roups The average age,1
EOVIST,fatal,roups The average age,1
EOVIST,fatal,roups The average age,1
EOVIST,fatal,other ethnic roups The average age,1
EOVIST,fatal,from to years Overall of subjects,0
EOVIST,fibrosis,years Overall of subjects reported,0
EOVIST,fibrosis,and of subjects consisted of other ethnic groups The average age,0
EOVIST,fibrosis,,0
EOVIST,fibrosis,,0
EOVIST,NSF,,0
EOVIST,NSF," 
  Vomiting Blood pressure",1
EOVIST,NSF," 
  Vomiting Blood pressure",1
EOVIST,NSF,"Back  
  Vomiting Blood pressure",1
EOVIST,NSF,Vomiting Blood pressure increased,0
EOVIST,NSF," 
  Vomiting Blood pressure",1
EOVIST,NSF,"Back  
  Vomiting Blood pressure",1
EOVIST,NSF," 
  Vomiting Blood pressure",1
EOVIST,NSF,pain,0
EOVIST,NSF,"Back  
  Vomiting Blood pressure",1
EOVIST,hypersensitivity reactions,Vertigo,0
EOVIST,hypersensitivity reactions,s Fatigue Chest n                          Vertigo Dry mou,1
EOVIST,hypersensitivity reactions,n                          Vertigo Dry mou,1
EOVIST,hypersensitivity reactions,Chest n                          Vertigo Dry mou,1
EOVIST,hypersensitivity reactions,,0
EOVIST,cutaneous manifestations,Vertigo,0
EOVIST,cutaneous manifestations,                         Dry mouth Chill,1
EOVIST,cutaneous manifestations,,0
EOVIST,cutaneous manifestations,Dry,0
EOVIST,cutaneous manifestations,                         Dry mouth Chill,1
EOVIST,cutaneous manifestations,                         Dry mouth Chill,1
EOVIST,cutaneous manifestations,                         Dry mouth Chill,1
EOVIST,cutaneous manifestations,                         Dry mouth Chill,1
EOVIST,cutaneous manifestations,,0
EOVIST,cutaneous manifestations,,0
EOVIST,shock,Dry       Chills,1
EOVIST,shock,mouth,0
EOVIST,shock,Dry       Chills,1
EOVIST,shock,      Chills,1
EOVIST,shock,,0
EOVIST,acute kidney injury,voluntarily from a n of uncertain size it is not,1
EOVIST,acute kidney injury,n of uncertain size it is not,1
EOVIST,acute kidney injury,from a n of uncertain size it is not,1
EOVIST,acute kidney injury,,0
EOVIST,acute kidney injury,not possible to reliably estimate their frequency or establish a causal,0
EOVIST,acute kidney injury,uncertain size it is not,1
EOVIST,acute kidney injury,n,1
EOVIST,acute kidney injury,voluntarily from a n of uncertain size it is not,1
EOVIST,acute kidney injury,,0
EOVIST,acute kidney injury,a causal ship to drug,1
EOVIST,acute kidney injury,hypotension,0
EOVIST,acute kidney injury,their frequency or establish a,0
EOVIST,acute kidney injury,causal ship to drug,1
ONFI,Somnolence,Somnolence or Sedation see,1
ONFI,Somnolence,include the Somnolence or Sedation see,1
ONFI,Sedation,Sedation see Warnings and,1
ONFI,Sedation,Sedation from,0
ONFI,Sedation,,0
ONFI,Sedation,Sedation see Warnings and,1
ONFI,Sedation,Somnolence Sedation see Warnings and,1
ONFI,Sedation,Warnings and Precautions Potentiation,0
ONFI,Sedation,following Somnolence Sedation see Warnings and,1
ONFI,Potentiation of Sedation,and Potentiation of Sedation from Concomitant Use,1
ONFI,Potentiation of Sedation,following Somnolence or Sedation see Warnings and,0
ONFI,Potentiation of Sedation,Somnolence or Sedation see Warnings,0
ONFI,Potentiation of Sedation,Potentiation of Sedation from Concomitant Use,1
ONFI,Potentiation of Sedation,and Potentiation of Sedation from Concomitant Use,1
ONFI,Dermatological Reactions,see Warnings and Precautions Dermatological Reactions see Contraindications Warnings,1
ONFI,Dermatological Reactions,Precautions Physical and Psycholo,0
ONFI,Dermatological Reactions,Contraindications Warnings and,0
ONFI,Dermatological Reactions,,0
ONFI,Dermatological Reactions,and Precautions Dermatological,1
ONFI,Dermatological Reactions,Warnings and Precautions Dermatological,1
ONFI,Dermatological Reactions,Withdrawal Symptoms see Warnings and,0
ONFI,Dermatological Reactions,,0
ONFI,Dermatological Reactions,Serious,0
ONFI,Psychological Dependence,Behavior and Ideation see Warnings,0
ONFI,Psychological Dependence,see Contraindications,0
ONFI,Psychological Dependence,,0
ONFI,Psychological Dependence,Physical,0
ONFI,Psychological Dependence,Physical,0
ONFI,Psychological Dependence,Warnings and,0
ONFI,Psychological Dependence,Dependence see Warnings and,1
ONFI,Psychological Dependence,see Warnings,0
ONFI,Psychological Dependence,Physical Psychological Dependence see Warnings and,1
ONFI,Suicidal Behavior,Warnings and Suicidal,1
ONFI,Suicidal Behavior,,0
ONFI,Suicidal Behavior,see Warnings and Suicidal Behavior and Ideation see,1
ONFI,Suicidal Behavior,Behavior and Ideation see,1
ONFI,constipation,ONFI dose constipation somnolence or sedation,1
ONFI,constipation,constipation somnolence or sedation,1
ONFI,constipation,constipation somnolence or sedation,1
ONFI,constipation,,0
ONFI,constipation,dose constipation somnolence or sedation,1
ONFI,somnolence,any ONFI dose included somnolence or sedation pyrexia,1
ONFI,somnolence,somnolence or sedation pyrexia,1
ONFI,somnolence,somnolence or sedation pyrexia,1
ONFI,sedation,included constipation somnolence sedation pyrexia lethargy and,1
ONFI,sedation,sedation pyrexia lethargy and,1
ONFI,sedation,,0
ONFI,sedation,at least more frequently than placebo in any,0
ONFI,sedation,sedation pyrexia lethargy and,1
ONFI,pyrexia,lethargy,0
ONFI,pyrexia,sedation,0
ONFI,pyrexia,pyrexia lethargy and drooling,1
ONFI,lethargy,lethargy and drooling To,1
ONFI,lethargy,lethargy and drooling To,1
ONFI,lethargy,or sedation pyrexia,0
ONFI,lethargy,lethargy and drooling To,1
ONFI,lethargy,To,0
ONFI,lethargy,sedation lethargy and drooling To,1
ONFI,drooling,contact Lundbeck,0
ONFI,drooling,pyrexia lethargy drooling To report SUSPECTED,1
ONFI,drooling,dose,0
ONFI,drooling,dose included constipation somnolence or,0
ONFI,drooling,drooling To report SUSPECTED,1
ONFI,drooling,contact Lundbeck at or,0
ONFI,drooling,pyrexia lethargy drooling To report SUSPECTED,1
ONFI,drooling,REACTIONS contact Lundbeck,0
ONFI,lethargy,lethargy somnolence ataxia aggression,1
ONFI,lethargy,order of frequency lethargy somnolence ataxia aggression,1
ONFI,lethargy,lethargy somnolence ataxia aggression,1
ONFI,lethargy,lethargy somnolence ataxia aggression,1
ONFI,lethargy,treatment discontinuation in of patients in decreasing order,0
ONFI,lethargy,,0
ONFI,lethargy,of patients in decreasing order of frequency included,0
ONFI,lethargy,of,0
ONFI,lethargy,decreasing order of frequency,0
ONFI,somnolence,somnolence ataxia aggression fatigue,1
ONFI,somnolence,,0
ONFI,somnolence,order of frequency included somnolence ataxia aggression fatigue,1
ONFI,somnolence,in of patients in decreasing order of frequency included lethargy,0
ONFI,somnolence,,0
ONFI,somnolence,somnolence ataxia aggression fatigue,1
ONFI,somnolence,of frequency included somnolence ataxia aggression fatigue,1
ONFI,somnolence,fatigue,0
ONFI,somnolence,frequency included somnolence ataxia aggression fatigue,1
ONFI,somnolence,,0
ONFI,ataxia,ataxia aggression fatigue and,1
ONFI,ataxia,lethargy ataxia aggression fatigue and,1
ONFI,ataxia,in an LGS,0
ONFI,ataxia,frequency included lethargy ataxia aggression fatigue and,1
ONFI,ataxia,frequency included lethargy ataxia aggression fatigue and,1
ONFI,ataxia,ataxia aggression fatigue and,1
ONFI,aggression,frequency included lethargy somnolence aggression fatigue and insomnia,1
ONFI,aggression,aggression fatigue and insomnia,1
ONFI,insomnia,somnolence ataxia aggression fatigue insomnia Most Common Adverse,1
ONFI,insomnia,decreasing order,0
ONFI,insomnia,,0
ONFI,insomnia,aggression fatigue insomnia Most Common Adverse,1
ONFI,Vomiting,Con,0
ONFI,Vomiting,c N Gastrointestinal,0
ONFI,Vomiting,Vomiting Con,1
ONFI,Vomiting,Vomiting Con,1
ONFI,Constipation,Constipation Dysp,1
ONFI,Dysphagia,tion Dysphagia General,1
ONFI,Dysphagia,,0
ONFI,Dysphagia,tion,0
ONFI,Pyrexia,and,0
ONFI,Pyrexia,Site Conditions,0
ONFI,Pyrexia,and Administration Site Conditions,0
ONFI,Pyrexia,Pyrexia Ir,1
ONFI,Pyrexia,Pyrexia Ir,1
ONFI,Irritability,Irritability Fati,1
ONFI,Fatigue,lity Fatigue Infec,1
ONFI,Urinary tract infection,onia Urinary tract,1
ONFI,Bronchitis,Metabol,0
ONFI,Bronchitis,tion Bronchitis Metabol,1
ONFI,Increased appetite,appetite Nervous,1
ONFI,Increased appetite,tite,0
ONFI,Somnolence,Somnolence or,1
ONFI,Somnolence,Somnolence or,1
ONFI,Somnolence,,0
ONFI,Sedation,Sedation,1
ONFI,Sedation,,0
ONFI,Sedation,Sedation,1
ONFI,Sedation,Sedation,1
ONFI,Sedation,System,0
ONFI,Somnolence,,0
ONFI,Somnolence,,0
ONFI,Somnolence,Somnolence,1
ONFI,Somnolence,,0
ONFI,Somnolence,,0
ONFI,Somnolence,,0
ONFI,Somnolence,Somnolence,1
ONFI,Somnolence,Somnolence,1
ONFI,Somnolence,Somnolence,1
ONFI,Sedation,,0
ONFI,Sedation,Sedation Leth,1
ONFI,Sedation,Sedation Leth,1
ONFI,Drooling,rgy Drooling Ata,1
ONFI,Drooling,rgy,0
ONFI,Drooling,rgy Drooling Ata,1
ONFI,Drooling,,0
ONFI,Drooling,,0
ONFI,Drooling,Drooling Ata,1
ONFI,Drooling,rgy Drooling Ata,1
ONFI,Ataxia,ing,0
ONFI,Ataxia,ing,0
ONFI,Ataxia,Ataxia P,1
ONFI,Ataxia,Ataxia P,1
ONFI,Ataxia,ing Ataxia P,1
ONFI,Ataxia,,0
ONFI,Ataxia,ing Ataxia P,1
ONFI,Ataxia,ing,0
ONFI,Ataxia,,0
ONFI,Ataxia,Ataxia P,1
ONFI,Dysarthria,vity,0
ONFI,Aggression,Aggression Inso,1
ONFI,Aggression,,0
ONFI,Aggression,Aggression Inso,1
ONFI,Aggression,Aggression Inso,1
ONFI,Aggression,Disorders,0
ONFI,Aggression,Disorders,0
ONFI,Insomnia,Insomnia Respir,1
ONFI,Insomnia,Insomnia Respir,1
ONFI,Insomnia,Insomnia Respir,1
ONFI,Insomnia,,0
ONFI,Insomnia,sion,0
ONFI,Insomnia,Insomnia Respir,1
ONFI,Insomnia,,0
ONFI,Insomnia,sion,0
ONFI,Insomnia,Insomnia Respir,1
ONFI,Insomnia,Insomnia Respir,1
ONFI,Cough,Cough,1
ONFI,Cough,Cough,1
ONFI,Anemia,,0
ONFI,Anemia,categorized by system organ class,0
ONFI,Anemia,Anemia,1
ONFI,Anemia,,0
ONFI,Anemia,Anemia,1
ONFI,Anemia,Anemia,1
ONFI,Anemia,system organ class Blood Anemia,1
ONFI,Anemia,organ class,0
ONFI,Anemia,Adverse reactions are,0
ONFI,eosinophilia,Disorders Anemia,0
ONFI,eosinophilia,leukopenia thrombocytopenia Eye Disorders Diplopia vision blurred,0
ONFI,eosinophilia,Disorders eosinophilia,1
ONFI,eosinophilia,eosinophilia,1
ONFI,eosinophilia,,0
ONFI,eosinophilia,organ class Blood Disorders eosinophilia,1
ONFI,eosinophilia,eosinophilia,1
ONFI,eosinophilia,Gastrointestinal,0
ONFI,leukopenia,,0
ONFI,leukopenia,leukopenia,1
ONFI,leukopenia,leukopenia,1
ONFI,leukopenia,thrombocytopenia Eye Disorders Diplopia vision blurred,0
ONFI,leukopenia,leukopenia,1
ONFI,leukopenia,leukopenia,1
ONFI,leukopenia,leukopenia,1
ONFI,leukopenia,Disorders Anemia eosinophilia,0
ONFI,leukopenia,thrombocytopenia Eye Disorders Diplopia vision blurred Gastrointestinal Disorders,0
ONFI,thrombocytopenia,thrombocytopenia,1
ONFI,thrombocytopenia,,0
ONFI,thrombocytopenia,Blood Disorders Anemia eosinophilia,0
ONFI,thrombocytopenia,thrombocytopenia,1
ONFI,thrombocytopenia,organ class,0
ONFI,thrombocytopenia,thrombocytopenia,1
ONFI,thrombocytopenia,Gastrointestinal Disorders,0
ONFI,Diplopia,eosinophilia leukopenia,0
ONFI,Diplopia,thrombocytopenia Eye Diplopia,1
ONFI,Diplopia,,0
ONFI,Diplopia,Diplopia,1
ONFI,Diplopia,distention General,0
ONFI,Diplopia,Diplopia,1
ONFI,vision blurred,and Administration Site,0
ONFI,vision blurred,thrombocytopenia,0
ONFI,Abdominal distention,distention,1
ONFI,Abdominal distention,Disorders Diplopia vision blurred Gastrointestinal Disorders,0
ONFI,Abdominal distention,vision blurred Gastrointestinal Abdominal,1
ONFI,Abdominal distention,Conditions Hypothermia,0
ONFI,Abdominal distention,Abdominal,1
ONFI,Abdominal distention,blurred Gastrointestinal Abdominal distention,1
ONFI,Abdominal distention,Conditions Hypothermia Investigations,0
ONFI,Abdominal distention,Abdominal distention,1
ONFI,Abdominal distention,General Disorders and Administration Site Conditions Hypothermia Investigations,0
ONFI,Abdominal distention,blurred Gastrointestinal Abdominal distention,1
ONFI,Hepatic enzyme increased,Hepatic enzyme increased,1
ONFI,Muscle spasms,Investigations Hepatic enzyme increased Muscle spasms,1
ONFI,Agitation,depression delirium delusion,0
ONFI,Agitation,Disorders,0
ONFI,Agitation,Psychiatric Agitation,1
ONFI,Agitation,Musculoskeletal Muscle spasms Psychiatric Agitation,1
ONFI,Agitation,anxiety apathy,0
ONFI,Agitation,state depression delirium delusion,0
ONFI,Agitation,hallucination Renal and Uri,0
ONFI,Agitation,Muscle spasms,0
ONFI,anxiety,spasms Psychiatric Disorders anxiety,1
ONFI,apathy,delirium delusion hallucination Renal,0
ONFI,apathy,Musculoskeletal Muscle spasms Psychiatric Disorders Agitation,0
ONFI,apathy,,0
ONFI,apathy,apathy,1
ONFI,apathy,,0
ONFI,apathy,,0
ONFI,confusional state,,0
ONFI,confusional state,spasms Psychiatric,0
ONFI,depression,Disorders Urinary retention,0
ONFI,depression,anxiety apathy confusional depression,1
ONFI,depression,anxiety,0
ONFI,depression,apathy confusional depression,1
ONFI,depression,state,0
ONFI,depression,apathy confusional depression,1
ONFI,depression,depression,1
ONFI,delirium,delirium,1
ONFI,delirium,Respiratory Disord,0
ONFI,delirium,anxiety apathy confusional state delirium,1
ONFI,delirium,Respiratory,0
ONFI,delirium,delirium,1
ONFI,delirium,Agitation anxiety apathy confusional state,0
ONFI,delirium,delirium,1
ONFI,delirium,Disorders Agitation anxiety apathy,0
ONFI,delirium,Disorders Agitation anxiety apathy confusional state depression,0
ONFI,delirium,confusional state delirium,1
ONFI,hallucination,hallucination,1
ONFI,hallucination,state depression,0
ONFI,hallucination,delusion,0
ONFI,hallucination,,0
ONFI,hallucination,hallucination,1
ONFI,Urinary retention,Urinary Urinary,1
ONFI,Urinary retention,depression Skin and Subcutaneous,0
ONFI,Urinary retention,retention,1
ONFI,Urinary retention,Disorders,0
ONFI,Urinary retention,Disorders Aspiration respiratory depression Skin and Subcutaneous,0
ONFI,Urinary retention,Renal and Urinary Disorders,0
ONFI,Urinary retention,Urinary Urinary retention,1
ONFI,Urinary retention,Disorders Aspiration,0
ONFI,Urinary retention,Renal and Urinary Urinary retention,1
ONFI,Urinary retention,Respiratory Disorders Aspiration respiratory depression Skin and,0
ONFI,respiratory depression,,0
ONFI,respiratory depression,angioedema and facial and,0
ONFI,respiratory depression,Disorders,0
ONFI,respiratory depression,retention Respiratory Disorders respiratory,1
ONFI,respiratory depression,depression,1
ONFI,respiratory depression,respiratory depression,1
ONFI,respiratory depression,Urinary Disorders Urinary retention Respiratory Disorders Aspiration,0
ONFI,respiratory depression,respiratory depression,1
ONFI,Rash,urticaria angioedema and facial and,0
ONFI,Rash,and facial and,0
ONFI,Rash,Rash,1
ONFI,Rash,Rash,1
ONFI,Rash,Skin and Subcutaneous Tissue Rash,1
ONFI,Rash,Rash,1
ONFI,urticaria,urticaria,1
ONFI,urticaria,Disorders urticaria,1
ONFI,urticaria,urticaria,1
ONFI,urticaria,urticaria,1
ONFI,angioedema,Rash angioedema,1
ONFI,angioedema,angioedema,1
ONFI,lip edema,angioedema and facial lip edema,1
ONFI,lip edema,Subcutaneous Tissue,0
ONFI,lip edema,,0
ONFI,lip edema,and Subcutaneous Tissue Disorders Rash urticaria angioedema and facial,0
ONFI,lip edema,,0
ONFI,Somnolence,,0
ONFI,Somnolence,,0
ONFI,Somnolence,,0
ONFI,Somnolence,dverse rea ctions,1
ONFI,Somnolence,dverse rea ctions that appear,1
ONFI,Somnolence,following Somnolence or,0
ONFI,Somnolence,dverse rea ctions,1
ONFI,Sedation,see,0
ONFI,Sedation,ns that  appear in,1
ONFI,Sedation,ns that appear in,1
ONFI,Sedation,in other sections of the labeling include the following,0
ONFI,Sedation,,0
ONFI,Sedation,ns that ,1
ONFI,Sedation,,0
ONFI,Sedation,,0
ONFI,Sedation,,0
ONFI,Sedation,ns,1
ONFI,Dermatological Reactions,Warnings and Precautions ithdrawal,1
ONFI,Dermatological Reactions,Warnings and Precautions Serious Dermatological,0
ONFI,Dermatological Reactions,Precautions ithdrawal,1
ONFI,Dermatological Reactions,[see,1
ONFI,Dermatological Reactions,Central Nervous System Depressants,0
ONFI,Dermatological Reactions,[see,1
ONFI,Dermatological Reactions,and Precautions ithdrawal,1
ONFI,Stevens-Johnson syndrome,( 5.3,1
ONFI,Stevens-Johnson syndrome,Warnings d Precautions (    5.3  ,1
ONFI,Stevens-Johnson syndrome,,0
ONFI,Stevens-Johnson syndrome,Depressants see Warnings and Precautions Withdrawal Symptoms see Warnings an,0
ONFI,Stevens-Johnson syndrome,Reactions see,0
ONFI,toxic epidermal necrolysis,and Precautions,0
ONFI,toxic epidermal necrolysis,Precautions,0
ONFI,toxic epidermal necrolysis,Contraindications Warnings,0
ONFI,Psychological Dependence,,0
ONFI,Psychological Dependence,and cal Dependence [see Warn,1
ONFI,Psychological Dependence,,0
ONFI,Psychological Dependence,[see Warn,1
ONFI,Psychological Dependence,and Precautions Physical and cal Dependence [see Warn,1
ONFI,Psychological Dependence,[see Warn,1
ONFI,Psychological Dependence,,0
ONFI,Psychological Dependence,and cal Dependence [see,1
ONFI,Suicidal Behavior,and,0
ONFI,Suicidal Behavior,dose,0
ONFI,Suicidal Behavior,Ad,1
ONFI,Suicidal Behavior,EXCERPT:,1
ONFI,Suicidal Behavior,Ad,1
ONFI,Suicidal Behavior,and Ideation,0
ONFI,somnolence,yrexia lethargy and drooling To report SUSPECTED ADVERSE REACTIONS,0
ONFI,somnolence,"constipation somnolence or edation,",1
ONFI,somnolence,"or edation, p",1
ONFI,sedation,REACTIONS,0
ONFI,sedation,"a,",1
ONFI,sedation,frequently than,0
ONFI,sedation,any ONFI dose,0
ONFI,sedation,"a, letha",1
ONFI,sedation,"constipation somnolence or sedation a,",1
ONFI,sedation,ONFI dose included constipation somnolence,0
ONFI,sedation,,0
ONFI,sedation,than placebo,0
ONFI,somnolence,contact Lundbeck at,0
ONFI,somnolence,ADVERSE REACTIONS contact Lundbeck at,0
ONFI,somnolence,or,0
ONFI,somnolence,"sedation pyrexia lethargy and .1  )   
 ",1
ONFI,somnolence,),1
ONFI,somnolence,ONFI,0
ONFI,somnolence,"and .1  )   
 ",1
ONFI,somnolence,report SUSPECTED ADVERSE REACTIONS contact Lundbeck at,0
ONFI,sedation,To repo,1
ONFI,sedation, To repo,1
ONFI,sedation,and drooling,0
ONFI,sedation,lethargy and To,1
ONFI,sedation,sedation pyrexia lethargy and  To repo,1
ONFI,sedation,contact Lundbeck at or FDA at,0
ONFI,somnolence,,0
ONFI,somnolence,FDA t,1
ONFI,somnolence,SUSPECTED ADVERSE REACTIONS contact Lundbeck at or,0
ONFI,sedation,wwwfdagovmedwatch Clinical,0
ONFI,sedation,clinical trials are,0
ONFI,sedation,8 or,1
ONFI,sedation,or FDA at FDA,0
ONFI,skin reactions,g body weight;,1
ONFI,skin reactions,kg body,0
ONFI,skin reactions,,0
ONFI,skin reactions,weight;,1
ONFI,skin reactions,weight mg for kg body weight c Maximum daily dose of mg for,0
ONFI,skin reactions,body weight c Maximum daily dose of,0
ONFI,skin reactions,g body weight;,1
ONFI,skin reactions,mg for g body weight;,1
ONFI,skin reactions,body weight;,1
ONFI,skin reactions,body weight;,1
ONFI,Stevens-Johnson syndrome,mg for kg body weight c Maximum daily dose,0
ONFI,Stevens-Johnson syndrome,"body weight mg 30 kg body weight   
  
",1
ONFI,Stevens-Johnson syndrome,Placebo N ONFI,0
ONFI,Stevens-Johnson syndrome,30 kg body weight,1
ONFI,Stevens-Johnson syndrome,,0
ONFI,Stevens-Johnson syndrome,ONFI Dose Level All,0
ONFI,Stevens-Johnson syndrome,"body weight mg 30 kg body weight   
  
",1
ONFI,Stevens-Johnson syndrome,body weight mg 30,1
ONFI,SJS,,0
ONFI,SJS,for kg body    ,1
ONFI,SJS,   ,1
ONFI,SJS,for kg body    ,1
ONFI,SJS,mg for kg body    ,1
ONFI,SJS,mg for kg body,0
ONFI,SJS,Low a,0
ONFI,SJS,weight,0
ONFI,SJS,,0
ONFI,SJS,   ,1
ONFI,toxic epidermal necrolysis,All ONFI N Low a N Medium,0
ONFI,TEN,   ,1
ONFI,TEN,,0
ONFI,TEN,   ,1
ONFI,TEN,   ,1
ONFI,TEN,   ,1
ONFI,TEN,   ,1
ONFI,suicidal thoughts,    10            Pneumonia,1
ONFI,suicidal thoughts,Infestations Upper,0
ONFI,suicidal thoughts,    10            Pneumonia,1
ONFI,suicidal thoughts,Pneumonia,0
ONFI,suicidal thinking,appetite,0
ONFI,suicidal thinking,appetite,0
ONFI,suicidal thinking,               3 ,1
ONFI,suicidal thinking,               3 ,1
ONFI,suicidal thinking,               3 ,1
ONFI,suicidal thinking,               3 ,1
ONFI,suicidal thinking,,0
ONFI,suicidal thinking,appetite,0
ONFI,suicidal thinking,               3 ,1
ONFI,suicidal behavior,,0
ONFI,suicidal behavior,System Disorders,0
ONFI,suicidal thinking,,0
ONFI,suicidal thinking,              25  Sedation,1
ONFI,suicidal thinking,              25  Sedation,1
ONFI,suicidal thinking,Somnolence,0
ONFI,suicidal thinking,              25  Sedation,1
ONFI,suicidal thinking,Somnolence,0
ONFI,suicides,,0
ONFI,suicides,,0
ONFI,suicides,Sedation          Lethargy,1
ONFI,suicidal thoughts,,0
ONFI,suicidal thoughts,Droo,0
ONFI,suicidal thoughts,,0
ONFI,suicidal thoughts,Ataxia,0
ONFI,suicidal thoughts,,0
ONFI,suicidal thoughts,Droo,0
ONFI,suicidal thoughts,Droo,0
ONFI,suicidal thoughts,Droo ling     3        Ataxia,1
ONFI,suicidal thoughts,Dysarthria,0
ONFI,suicidal thoughts,                2 Psychiatric Disorders,1
ONFI,suicidal thoughts,Dysarthria,0
ONFI,suicidal thoughts,                2 Psychiatric Disorders,1
ONFI,suicidal thoughts,Dysarthria                 2 Psychiatric,1
ONFI,suicidal thoughts,Dysarthria                 2,1
ONFI,suicidal thoughts,Dysarthria,0
ONFI,suicidal thoughts,                2,1
ONFI,suicidal thoughts,                2 Psychiatric Disorders,1
ONFI,suicidal thoughts,Dysarthria,0
ONFI,suicidal thoughts,llucination,1
ONFI,suicidal thoughts,Disorders Agitation anxiety apathy confusional,0
ONFI,suicidal thoughts,delirium delusion llucination,1
ONFI,suicidal thoughts,confusional state depression delirium delusion ha,0
COMETRIQ,Perforations,elsewhere in the Perforations,1
COMETRIQ,Perforations,Warning Warnings and Precautions,0
COMETRIQ,Perforations,in the Perforations,1
COMETRIQ,Perforations,reactions are discussed elsewhere in,0
COMETRIQ,Perforations,Perforations,1
COMETRIQ,Perforations,,0
COMETRIQ,Perforations,Warning Warnings and Precautions Hemorrhage see,0
COMETRIQ,Perforations,Perforations,1
COMETRIQ,Perforations,,0
COMETRIQ,Fistula,Fistula,1
COMETRIQ,Fistula,Fistula,1
COMETRIQ,Fistula,are discussed elsewhere in the,0
COMETRIQ,Hemorrhage,and Hemorrhage,1
COMETRIQ,Hemorrhage,Hemorrhage,1
COMETRIQ,Hemorrhage,see Wa,0
COMETRIQ,Hemorrhage,Hemorrhage,1
COMETRIQ,Hemorrhage,and Fistula see Boxed,0
COMETRIQ,Hemorrhage,Hemorrhage,1
COMETRIQ,Thromboembolic Events,,0
COMETRIQ,Thromboembolic Events,Warnings and,0
COMETRIQ,Thromboembolic Events,Hemorrhage see Boxed Warning,0
COMETRIQ,Thromboembolic Events,,0
COMETRIQ,Thromboembolic Events,Thromboembolic Events,1
COMETRIQ,Hypertension,,0
COMETRIQ,Hypertension,,0
COMETRIQ,Hypertension,Hypertension,1
COMETRIQ,Hypertension,see,0
COMETRIQ,Hypertension,Hypertension,1
COMETRIQ,Hypertension,Complications see,0
COMETRIQ,Hypertension,Hypertension,1
COMETRIQ,Hypertension,,0
COMETRIQ,Osteonecrosis of the Jaw,see Warnings and Precautions,0
COMETRIQ,Osteonecrosis of the Jaw,,0
COMETRIQ,Osteonecrosis of the Jaw,Osteonecrosis of,1
COMETRIQ,Osteonecrosis of the Jaw,see Warnings and Osteonecrosis,1
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,see Warnings and Palmar-plantar erythrodysesthesia syndrome,1
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,Warnings and Precautions,0
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,syndrome,1
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,Palmar-plantar erythrodysesthesia syndrome,1
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,Warnings and Palmar-plantar erythrodysesthesia,1
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,Warnings and Precautions Proteinuria see,0
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,see Warnings and Palmar-plantar erythrodysesthesia syndrome,1
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,see Warnings and Palmar-plantar,1
COMETRIQ,Proteinuria,and Precautions,0
COMETRIQ,Proteinuria,,0
COMETRIQ,Proteinuria,Proteinuria,1
COMETRIQ,Proteinuria,,0
COMETRIQ,Proteinuria,Proteinuria,1
COMETRIQ,Proteinuria,and Precautions,0
COMETRIQ,Reversible Posterior Leukoencephalopathy Syndrome,Proteinuria see Warnings and Reversible Posterior Leukoencephalopathy Syndrome,1
COMETRIQ,Reversible Posterior Leukoencephalopathy Syndrome,reported,0
COMETRIQ,Reversible Posterior Leukoencephalopathy Syndrome,Proteinuria see Warnings and Reversible Posterior Leukoencephalopathy Syndrome,1
COMETRIQ,diarrhea,diarrhea,1
COMETRIQ,diarrhea,diarrhea,1
COMETRIQ,diarrhea,diarrhea,1
COMETRIQ,diarrhea,decreased weight,0
COMETRIQ,diarrhea,diarrhea,1
COMETRIQ,diarrhea,most commonly reported adverse drug,0
COMETRIQ,diarrhea,PPES decreased weight decreased appetit,0
COMETRIQ,diarrhea,are,0
COMETRIQ,stomatitis,appetite,0
COMETRIQ,stomatitis,appetite nausea f,0
COMETRIQ,stomatitis,are,0
COMETRIQ,stomatitis,stomatitis,1
COMETRIQ,stomatitis,stomatitis,1
COMETRIQ,stomatitis,stomatitis,1
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,drug reactions are diarrhea palmar-plantar,1
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,,0
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,palmar-plantar erythrodysesthesia syndrome,1
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,fatigue oral pain hair color changes dysge,0
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,palmar-plantar erythrodysesthesia syndrome,1
COMETRIQ,PPES,,0
COMETRIQ,PPES,PPES,1
COMETRIQ,PPES,PPES,1
COMETRIQ,PPES,stomatitis palmarplantar erythrodysesthesia PPES,1
COMETRIQ,PPES,palmarplantar erythrodysesthesia syndrome,0
COMETRIQ,PPES,,0
COMETRIQ,PPES,erythrodysesthesia,0
COMETRIQ,PPES,PPES,1
COMETRIQ,PPES,PPES,1
COMETRIQ,PPES,,0
COMETRIQ,decreased weight,dysgeusia,0
COMETRIQ,decreased weight,weight,1
COMETRIQ,decreased weight,palmarplantar erythrodysesthesia syndrome decreased,1
COMETRIQ,decreased weight,nausea fatigue,0
COMETRIQ,decreased weight,syndrome decreased weight,1
COMETRIQ,decreased weight,color,0
COMETRIQ,decreased weight,decreased weight,1
COMETRIQ,decreased weight,fatigue oral pain hair color changes,0
COMETRIQ,decreased weight,decreased,0
COMETRIQ,decreased weight,stomatitis palmarplantar erythrodysesthesia syndrome,0
COMETRIQ,decreased appetite,decreased decreased,1
COMETRIQ,decreased appetite,syndrome PPES decreased weight,0
COMETRIQ,decreased appetite,hypertension,0
COMETRIQ,decreased appetite,decreased appetite,1
COMETRIQ,decreased appetite,weight,0
COMETRIQ,decreased appetite,PPES decreased decreased,1
COMETRIQ,decreased appetite,PPES decreased decreased,1
COMETRIQ,decreased appetite,syndrome PPES decreased decreased,1
COMETRIQ,decreased appetite,,0
COMETRIQ,nausea,pain and,0
COMETRIQ,nausea,decreased appetite,0
COMETRIQ,nausea,nausea,1
COMETRIQ,nausea,fatigue oral pain hair color changes dysgeusia hypertension abdominal pain and,0
COMETRIQ,fatigue,erythrodysesthesia syndrome PPES decreased weight decreased appetite,0
COMETRIQ,oral pain,oral pain,1
COMETRIQ,oral pain,decreased appetite nausea oral pain,1
COMETRIQ,hair color changes,fatigue oral hair,1
COMETRIQ,hair color changes,pain and,0
COMETRIQ,hair color changes,changes,1
COMETRIQ,dysgeusia,,0
COMETRIQ,dysgeusia,,0
COMETRIQ,dysgeusia,and constipation The most common laboratory,0
COMETRIQ,dysgeusia,dysgeusia,1
COMETRIQ,dysgeusia,hair color dysgeusia,1
COMETRIQ,dysgeusia,color dysgeusia,1
COMETRIQ,dysgeusia,dysgeusia,1
COMETRIQ,dysgeusia,fatigue oral pain,0
COMETRIQ,hypertension,hypertension,1
COMETRIQ,hypertension,decreased appetite nausea fatigue,0
COMETRIQ,hypertension,hypertension,1
COMETRIQ,hypertension,hypertension,1
COMETRIQ,hypertension,increased,0
COMETRIQ,hypertension,hypertension,1
COMETRIQ,hypertension,color changes hypertension,1
COMETRIQ,hypertension,nausea fatigue oral pain hair,0
COMETRIQ,abdominal pain,color changes dysgeusia abdominal pain,1
COMETRIQ,abdominal pain,pain,1
COMETRIQ,abdominal pain,hair color changes dysgeusia abdominal,1
COMETRIQ,abdominal pain,pain hair color changes,0
COMETRIQ,abdominal pain,pain,1
COMETRIQ,abdominal pain,pain,1
COMETRIQ,abdominal pain,dysgeusia abdominal pain,1
COMETRIQ,abdominal pain,abdominal pain,1
COMETRIQ,abdominal pain,color changes dysgeusia abdominal pain,1
COMETRIQ,abdominal pain,,0
COMETRIQ,constipation,,0
COMETRIQ,constipation,oral pain hair color changes dysgeusia hypertension abdominal,0
COMETRIQ,constipation,,0
COMETRIQ,constipation,constipation,1
COMETRIQ,increased AST,laboratory abnormalities increased AST,1
COMETRIQ,increased AST,lymphopenia increased alkaline phosphatase hypocalcemia neutropenia,0
COMETRIQ,increased AST,increased AST,1
COMETRIQ,increased AST,and constipation The most common laboratory abnormalities,0
COMETRIQ,increased AST,AST,1
COMETRIQ,increased AST,increased AST,1
COMETRIQ,increased AST,pain and constipation The most common,0
COMETRIQ,increased AST,and,0
COMETRIQ,increased ALT,are increased increased,1
COMETRIQ,increased ALT,are increased increased ALT,1
COMETRIQ,increased ALT,increased increased ALT,1
COMETRIQ,increased ALT,are increased increased ALT,1
COMETRIQ,increased ALT,increased alkaline phosphatase hypocalcemia neutropenia,0
COMETRIQ,increased ALT,,0
COMETRIQ,lymphopenia,lymphopenia,1
COMETRIQ,lymphopenia,increased lymphopenia,1
COMETRIQ,lymphopenia,AST increased lymphopenia,1
COMETRIQ,lymphopenia,,0
COMETRIQ,lymphopenia,,0
COMETRIQ,lymphopenia,lymphopenia,1
COMETRIQ,lymphopenia,most common laboratory abnormalities are increased,0
COMETRIQ,lymphopenia,The most common laboratory abnormalities,0
COMETRIQ,increased alkaline phosphatase,alkaline phosphatase,1
COMETRIQ,increased alkaline phosphatase,AST increased ALT,0
COMETRIQ,hypocalcemia,,0
COMETRIQ,hypocalcemia,,0
COMETRIQ,hypocalcemia,increased alkaline phosphatase,0
COMETRIQ,neutropenia,increased,0
COMETRIQ,neutropenia,neutropenia,1
COMETRIQ,neutropenia,neutropenia,1
COMETRIQ,thrombocytopenia,increased alkaline phosphatase hypocalcemia thrombocytopenia,1
COMETRIQ,thrombocytopenia,thrombocytopenia,1
COMETRIQ,thrombocytopenia,alkaline phosphatase hypocalcemia,0
COMETRIQ,thrombocytopenia,increased alkaline phosphatase hypocalcemia thrombocytopenia,1
COMETRIQ,thrombocytopenia,thrombocytopenia,1
COMETRIQ,thrombocytopenia,hypocalcemia thrombocytopenia,1
COMETRIQ,thrombocytopenia,thrombocytopenia,1
COMETRIQ,thrombocytopenia,,0
COMETRIQ,thrombocytopenia,To report SUSPECTED ADVERSE REACTIONS,0
COMETRIQ,hypophosphatemia,hypophosphatemia,1
COMETRIQ,hypophosphatemia,hypophosphatemia,1
COMETRIQ,hyperbilirubinemia,hyperbilirubinemia,1
COMETRIQ,hyperbilirubinemia,hyperbilirubinemia,1
COMETRIQ,hyperbilirubinemia,hyperbilirubinemia,1
COMETRIQ,hyperbilirubinemia,SUSPECTED,0
COMETRIQ,hyperbilirubinemia,ADVERSE REACTIONS contact Exelixis Inc at or,0
COMETRIQ,hyperbilirubinemia,hyperbilirubinemia,1
COMETRIQ,hyperbilirubinemia,hyperbilirubinemia,1
COMETRIQ,hyperbilirubinemia,,0
COMETRIQ,diarrhea,arm with a betweenarm difference of included in,0
COMETRIQ,diarrhea,weight decreased,0
COMETRIQ,diarrhea,diarrhea,1
COMETRIQ,diarrhea,of,0
COMETRIQ,diarrhea,,0
COMETRIQ,diarrhea,of decreasing diarrhea,1
COMETRIQ,diarrhea,palmarplantar erythrodysesthesia syndrome PPES decreased,0
COMETRIQ,diarrhea,difference of included in order of decreasing frequency,0
COMETRIQ,stomatitis,order of decreasing frequency stomatitis,1
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,included in order of decreasing frequency diarrhea,0
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,decreasing frequency diarrhea palmar-plantar erythrodysesthesia syndrome,1
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,frequency diarrhea palmar-plantar erythrodysesthesia syndrome,1
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,pain hair color,0
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,,0
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,color changes,0
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,nausea fatigue oral pain hair color changes,0
COMETRIQ,PPES,diarrhea stomatitis palmarplantar erythrodysesthesia PPES,1
COMETRIQ,PPES,palmarplantar erythrodysesthesia PPES,1
COMETRIQ,decreased weight,decreased weight,1
COMETRIQ,decreased weight,,0
COMETRIQ,decreased weight,,0
COMETRIQ,decreased weight,stomatitis palmarplantar erythrodysesthesia syndrome PPES,0
COMETRIQ,decreased weight,syndrome decreased,1
COMETRIQ,decreased weight,,0
COMETRIQ,decreased weight,fatigue oral,0
COMETRIQ,decreased weight,hypertension abdom,0
COMETRIQ,decreased weight,weight,1
COMETRIQ,decreased weight,oral,0
COMETRIQ,decreased appetite,PPES decreased decreased appetite,1
COMETRIQ,decreased appetite,PPES decreased decreased appetite,1
COMETRIQ,decreased appetite,abdominal pain and,0
COMETRIQ,decreased appetite,erythrodysesthesia syndrome,0
COMETRIQ,decreased appetite,appetite,1
COMETRIQ,decreased appetite,pain and,0
COMETRIQ,decreased appetite,changes dysgeusia hypertension abdominal pain and,0
COMETRIQ,decreased appetite,syndrome PPES decreased decreased appetite,1
COMETRIQ,decreased appetite,abdominal,0
COMETRIQ,nausea,erythrodysesthesia,0
COMETRIQ,fatigue,fatigue,1
COMETRIQ,fatigue,weight decreased appetite fatigue,1
COMETRIQ,oral pain,oral pain,1
COMETRIQ,oral pain,oral,1
COMETRIQ,oral pain,constipation The,0
COMETRIQ,oral pain,nausea oral,1
COMETRIQ,oral pain,oral pain,1
COMETRIQ,oral pain,decreased appetite nausea oral,1
COMETRIQ,oral pain,weight decreased appetite nausea oral pain,1
COMETRIQ,oral pain,,0
COMETRIQ,oral pain,appetite nausea oral pain,1
COMETRIQ,oral pain,oral pain,1
COMETRIQ,hair color changes,changes,1
COMETRIQ,hair color changes,color changes,1
COMETRIQ,hair color changes,nausea fatigue oral pain,0
COMETRIQ,hair color changes,fatigue oral hair color,1
COMETRIQ,hair color changes,,0
COMETRIQ,hair color changes,nausea fatigue oral,0
COMETRIQ,hair color changes,decreased,0
COMETRIQ,hair color changes,color changes,1
COMETRIQ,dysgeusia,decreased,0
COMETRIQ,dysgeusia,dysgeusia,1
COMETRIQ,dysgeusia,appetite nausea fatigue oral pain hair color changes,0
COMETRIQ,dysgeusia,dysgeusia,1
COMETRIQ,hypertension,constipation The most common,0
COMETRIQ,hypertension,dysgeusia,0
COMETRIQ,hypertension,color changes hypertension,1
COMETRIQ,hypertension,hypertension,1
COMETRIQ,hypertension,hypertension,1
COMETRIQ,hypertension,changes hypertension,1
COMETRIQ,hypertension,color changes hypertension,1
COMETRIQ,hypertension,pain hair,0
COMETRIQ,hypertension,and constipation The most common,0
COMETRIQ,constipation,constipation,1
COMETRIQ,constipation,hypertension abdominal pain constipation,1
COMETRIQ,increased ALT,The most common,0
COMETRIQ,increased ALT,abnormalities were,0
COMETRIQ,increased ALT,,0
COMETRIQ,increased ALT,increased,1
COMETRIQ,increased ALT,most common laboratory,0
COMETRIQ,lymphopenia,laboratory abnormalities were increased AST,0
COMETRIQ,lymphopenia,hypophosphatemia,0
COMETRIQ,lymphopenia,were increased,0
COMETRIQ,lymphopenia,increased AST increased lymphopenia,1
COMETRIQ,increased ALP,increased,0
COMETRIQ,increased ALP,increased ALT lymphopenia,0
COMETRIQ,increased ALP,common laboratory abnormalities were increased,0
COMETRIQ,increased ALP,The most common laboratory abnormalities,0
COMETRIQ,increased ALP,AST increased ALT increased ALP,1
COMETRIQ,increased ALP,AST increased ALT increased,1
COMETRIQ,increased ALP,ALT increased,1
COMETRIQ,hypocalcemia,,0
COMETRIQ,hypocalcemia,,0
COMETRIQ,hypocalcemia,hypocalcemia,1
COMETRIQ,hypocalcemia,hypocalcemia,1
COMETRIQ,hypocalcemia,,0
COMETRIQ,hypocalcemia,hypocalcemia,1
COMETRIQ,hypocalcemia,,0
COMETRIQ,hypocalcemia,,0
COMETRIQ,hypocalcemia,hyperbilirubinemia Grade,0
COMETRIQ,neutropenia,increased AST increased,0
COMETRIQ,neutropenia,and hyperbilirubinemia Grade adverse reactions,0
COMETRIQ,neutropenia,neutropenia,1
COMETRIQ,neutropenia,,0
COMETRIQ,neutropenia,abnormalities were,0
COMETRIQ,neutropenia,were,0
COMETRIQ,neutropenia,adverse,0
COMETRIQ,neutropenia,increased,0
COMETRIQ,thrombocytopenia,increased ALP hypocalcemia thrombocytopenia,1
COMETRIQ,hypophosphatemia,increased ALP hypocalcemia neutropenia hypophosphatemia,1
COMETRIQ,hypophosphatemia,hypophosphatemia,1
COMETRIQ,hypophosphatemia,hypophosphatemia,1
COMETRIQ,hypophosphatemia,hypophosphatemia,1
COMETRIQ,hypophosphatemia,neutropenia,0
COMETRIQ,hypophosphatemia,hypophosphatemia,1
COMETRIQ,hypophosphatemia,,0
COMETRIQ,hyperbilirubinemia,reactions and laboratory abnormalities which,0
COMETRIQ,diarrhea,diarrhea,1
COMETRIQ,diarrhea,diarrhea,1
COMETRIQ,PPES,fatigue hypertension,0
COMETRIQ,PPES,order of,0
COMETRIQ,PPES,PPES,1
COMETRIQ,PPES,PPES,1
COMETRIQ,PPES,increased ALT,0
COMETRIQ,hypocalcemia,hypocalcemia,1
COMETRIQ,hypocalcemia,,0
COMETRIQ,hypocalcemia,frequency diarrhea PPES hypocalcemia,1
COMETRIQ,hypocalcemia,appeti,0
COMETRIQ,hypocalcemia,hypocalcemia,1
COMETRIQ,hypocalcemia,fatigue hypertension asthenia increased ALT decreased weight stomatitis and,0
COMETRIQ,fatigue,fatigue,1
COMETRIQ,fatigue,hypertension asthenia increased ALT decreased weight,0
COMETRIQ,fatigue,decreased appetite,0
COMETRIQ,fatigue,fatigue,1
COMETRIQ,fatigue,diarrhea PPES lymphopenia fatigue,1
COMETRIQ,fatigue,of decreasing frequency,0
COMETRIQ,fatigue,,0
COMETRIQ,fatigue,fatigue,1
COMETRIQ,fatigue,decreased,0
COMETRIQ,hypertension,,0
COMETRIQ,hypertension,hypertension,1
COMETRIQ,hypertension,hypertension,1
COMETRIQ,increased ALT,,0
COMETRIQ,increased ALT,increased ALT,1
COMETRIQ,increased ALT,see Table Table,0
COMETRIQ,increased ALT,hypertension increased,1
COMETRIQ,increased ALT,,0
COMETRIQ,decreased weight,hypertension asthenia increased decreased weight,1
COMETRIQ,decreased weight,Table Fatal adverse,0
COMETRIQ,decreased weight,decreased weight,1
COMETRIQ,decreased weight,asthenia increased decreased,1
COMETRIQ,stomatitis,stomatitis,1
COMETRIQ,stomatitis,and decreased appetite see,0
COMETRIQ,stomatitis,fatigue hypertension,0
COMETRIQ,stomatitis,stomatitis,1
COMETRIQ,decreased appetite,decreased,1
COMETRIQ,decreased appetite,decreased appetite,1
COMETRIQ,decreased appetite,hypertension asthenia increased,0
COMETRIQ,decreased appetite,weight stomatitis decreased appetite,1
COMETRIQ,decreased appetite,stomatitis and,0
COMETRIQ,decreased appetite,decreased weight stomatitis decreased appetite,1
COMETRIQ,decreased appetite,see Table Table Fatal adverse reactions occurred in of patients receiving,0
COMETRIQ,Fatal,Table Fatal,1
COMETRIQ,Fatal,receiving COMETRIQ and resulted,0
COMETRIQ,Fatal,see,0
COMETRIQ,Fatal,appetite see Table Fatal,1
COMETRIQ,Fatal,Fatal,1
COMETRIQ,Fatal,Fatal,1
COMETRIQ,Fatal,,0
COMETRIQ,hemorrhage,receiving COMETRIQ and resulted hemorrhage,1
COMETRIQ,hemorrhage,resulted hemorrhage,1
COMETRIQ,hemorrhage,in of,0
COMETRIQ,hemorrhage,hemorrhage,1
COMETRIQ,hemorrhage,hemorrhage,1
COMETRIQ,pneumonia,pneumonia,1
COMETRIQ,pneumonia,pneumonia,1
COMETRIQ,pneumonia,adverse,0
COMETRIQ,pneumonia,occurred in of,0
COMETRIQ,pneumonia,cardiac arrest respiratory,0
COMETRIQ,pneumonia,pneumonia,1
COMETRIQ,septicemia,septicemia,1
COMETRIQ,septicemia,septicemia,1
COMETRIQ,septicemia,septicemia,1
COMETRIQ,septicemia,occurred in of patients receiving,0
COMETRIQ,septicemia,reactions occurred in,0
COMETRIQ,fistulas,hemorrhage pneumonia fistulas,1
COMETRIQ,cardiac arrest,cardiac arrest,1
COMETRIQ,cardiac arrest,fistulas,0
COMETRIQ,cardiac arrest,resulted,0
COMETRIQ,respiratory failure,arrest,0
COMETRIQ,respiratory failure,receiving placebo,0
COMETRIQ,respiratory failure,COMETRIQ and resulted from hemorrhage pneumonia,0
COMETRIQ,respiratory failure,cardiac respiratory,1
COMETRIQ,respiratory failure,respiratory failure,1
COMETRIQ,respiratory failure,,0
COMETRIQ,death,death,1
COMETRIQ,death,death,1
COMETRIQ,death,and,0
COMETRIQ,death,death,1
COMETRIQ,death,of,0
COMETRIQ,death,from septicemia,0
COMETRIQ,death,death,1
COMETRIQ,death,Fatal,0
COMETRIQ,death,,0
COMETRIQ,death,death,1
COMETRIQ,Fatal,,0
COMETRIQ,Fatal,Fatal,1
COMETRIQ,septicemia,reactions occurred in of patients,0
COMETRIQ,pneumonia,pneumonia,1
COMETRIQ,pneumonia,and resulted from pneumonia,1
COMETRIQ,pneumonia,pneumonia,1
COMETRIQ,pneumonia,pneumonia,1
COMETRIQ,pneumonia,reactions occurred in of patients receiving placebo and resulted,0
COMETRIQ,hypocalcemia,fo,0
COMETRIQ,hypocalcemia,hypocalcemia,1
COMETRIQ,increased lipase,treated with COMETRIQ were increased lipase,1
COMETRIQ,increased lipase,,0
COMETRIQ,increased lipase,pancreatitis tracheal fistula formation and,0
COMETRIQ,increased lipase,treated with COMETRIQ were increased,1
COMETRIQ,increased lipase,lipase,1
COMETRIQ,PPES,PPES,1
COMETRIQ,PPES,pancreatitis tracheal fistula,0
COMETRIQ,PPES,formation,0
COMETRIQ,PPES,PPES,1
COMETRIQ,PPES,treated with COMETRIQ,0
COMETRIQ,PPES,nausea pancreatitis tracheal fistula formation and vomiting,0
COMETRIQ,PPES,were hypocalcemia increased PPES,1
COMETRIQ,PPES,,0
COMETRIQ,PPES,hypocalcemia increased PPES,1
COMETRIQ,PPES,PPES,1
COMETRIQ,diarrhea,PPES,0
COMETRIQ,diarrhea,hypertension nausea pancreatitis tracheal fistula formation and,0
COMETRIQ,diarrhea,diarrhea,1
COMETRIQ,diarrhea,diarrhea,1
COMETRIQ,fatigue,in patients treated with COMETRIQ were,0
COMETRIQ,fatigue,fatigue,1
COMETRIQ,fatigue,fatigue,1
COMETRIQ,fatigue,fatigue,1
COMETRIQ,fatigue,fatigue,1
COMETRIQ,fatigue,hypocalcemia increased lipase PPES fatigue,1
COMETRIQ,hypertension,hypertension,1
COMETRIQ,nausea,increased,0
COMETRIQ,nausea,nausea,1
COMETRIQ,nausea,nausea,1
COMETRIQ,nausea,nausea,1
COMETRIQ,nausea,,0
COMETRIQ,nausea,nausea,1
COMETRIQ,nausea,PPES diarrhea fatigue nausea,1
COMETRIQ,pancreatitis,of thyroid,0
COMETRIQ,pancreatitis,were hypocalcemia,0
COMETRIQ,pancreatitis,of,0
COMETRIQ,pancreatitis,vomiting Increased,0
COMETRIQ,pancreatitis,pancreatitis,1
COMETRIQ,pancreatitis,pancreatitis,1
COMETRIQ,pancreatitis,,0
COMETRIQ,pancreatitis,formation and vomiting Increased,0
COMETRIQ,tracheal fistula formation,fatigue hypertension nausea tracheal,1
COMETRIQ,tracheal fistula formation,hypertension nausea tracheal fistula formation,1
COMETRIQ,tracheal fistula formation,of pat,0
COMETRIQ,tracheal fistula formation,stimulating hormone,0
COMETRIQ,tracheal fistula formation,fatigue hypertension nausea tracheal fistula formation,1
COMETRIQ,tracheal fistula formation,fatigue hypertension nausea,0
COMETRIQ,tracheal fistula formation,,0
COMETRIQ,tracheal fistula formation,fatigue hypertension nausea tracheal,1
COMETRIQ,tracheal fistula formation,diarrhea fatigue hypertension nausea pancreatitis,0
COMETRIQ,Increased levels of thyroid stimulating hormone,fistula formation and Increased levels of,1
COMETRIQ,Increased levels of thyroid stimulating hormone,stimulating hormone,1
COMETRIQ,Increased levels of thyroid stimulating hormone,tracheal fistula formation and Increased levels,1
COMETRIQ,Increased levels of thyroid stimulating hormone,fistula formation and Increased levels of thyroid stimulating hormone,1
COMETRIQ,Diarrhea,,0
COMETRIQ,Diarrhea,,0
COMETRIQ,Diarrhea,Diarrhea,1
COMETRIQ,Diarrhea,,0
COMETRIQ,Diarrhea,,0
COMETRIQ,Diarrhea,,0
COMETRIQ,Diarrhea,Diarrhea,1
COMETRIQ,Diarrhea,,0
COMETRIQ,Diarrhea,,0
COMETRIQ,Stomatitis,,0
COMETRIQ,Stomatitis,,0
COMETRIQ,Stomatitis,,0
COMETRIQ,Stomatitis,,0
COMETRIQ,Stomatitis,Stomatitis,1
COMETRIQ,Stomatitis,,0
COMETRIQ,Stomatitis,,0
COMETRIQ,Stomatitis,,0
COMETRIQ,Stomatitis,,0
COMETRIQ,Stomatitis,,0
COMETRIQ,Nausea,,0
COMETRIQ,Nausea,Nausea,1
COMETRIQ,Nausea,,0
COMETRIQ,Nausea,Nausea,1
COMETRIQ,Oral pain,Oral,1
COMETRIQ,Oral pain,,0
COMETRIQ,Oral pain,Oral pain,1
COMETRIQ,Oral pain,Oral pain,1
COMETRIQ,Oral pain,,0
COMETRIQ,Oral pain,,0
COMETRIQ,Oral pain,,0
COMETRIQ,Oral pain,,0
COMETRIQ,Constipation,Constipation A,1
COMETRIQ,Constipation,,0
COMETRIQ,Constipation,,0
COMETRIQ,Constipation,,0
COMETRIQ,Constipation,Constipation A,1
COMETRIQ,Abdominal pain,n Abdominal,1
COMETRIQ,Abdominal pain,n Abdominal pain Vom,1
COMETRIQ,Abdominal pain,n Abdominal pain Vom,1
COMETRIQ,Abdominal pain,n,0
COMETRIQ,Abdominal pain,n Abdominal pain Vom,1
COMETRIQ,Abdominal pain,Vom,0
COMETRIQ,Abdominal pain,Vom,0
COMETRIQ,Abdominal pain,pain Vom,1
COMETRIQ,Abdominal pain,n Abdominal,1
COMETRIQ,Abdominal pain,n,0
COMETRIQ,Vomiting,,0
COMETRIQ,Vomiting,ain Vomiting,1
COMETRIQ,Vomiting,,0
COMETRIQ,Vomiting,,0
COMETRIQ,Vomiting,ain,0
COMETRIQ,Vomiting,Vomiting,1
COMETRIQ,Vomiting,ain Vomiting,1
COMETRIQ,Vomiting,Vomiting,1
COMETRIQ,Vomiting,ain,0
COMETRIQ,Vomiting,Vomiting,1
COMETRIQ,Dysphagia,,0
COMETRIQ,Dysphagia,Dysphagia,1
COMETRIQ,Dyspepsia,,0
COMETRIQ,Dyspepsia,Dyspepsia,1
COMETRIQ,Dyspepsia,Dyspepsia,1
COMETRIQ,Dyspepsia,Dyspepsia,1
COMETRIQ,Dyspepsia,Dyspepsia,1
COMETRIQ,Dyspepsia,Dyspepsia,1
COMETRIQ,Dyspepsia,Dyspepsia,1
COMETRIQ,Hemorrhoids,Hemorrhoids GENER,1
COMETRIQ,Hemorrhoids,,0
COMETRIQ,Hemorrhoids,GENER,0
COMETRIQ,Hemorrhoids,,0
COMETRIQ,Fatigue,Fatigue,1
COMETRIQ,Fatigue,,0
COMETRIQ,Fatigue,CONDITIONS,0
COMETRIQ,Fatigue,SITE Fatigue,1
COMETRIQ,Fatigue,SITE Fatigue,1
COMETRIQ,Fatigue,Fatigue,1
COMETRIQ,Fatigue,DISORDERS AND ADMINISTRATION SITE Fatigue,1
COMETRIQ,Fatigue,Fatigue,1
COMETRIQ,Decreased weight,,0
COMETRIQ,Decreased weight,INVESTIGATIONS,0
COMETRIQ,Decreased weight,,0
COMETRIQ,Decreased weight,INVESTIGATIONS Decreased,1
COMETRIQ,Decreased weight,INVESTIGATIONS,0
COMETRIQ,Decreased weight,INVESTIGATIONS Decreased,1
COMETRIQ,Decreased weight,METABOLISM,0
COMETRIQ,Decreased weight,INVESTIGATIONS Decreased weight METABOLISM,1
COMETRIQ,Decreased appetite,,0
COMETRIQ,Decreased appetite,METABOLISM AND NUTRITION Decreased appetite Dehydra,1
COMETRIQ,Decreased appetite,,0
COMETRIQ,Decreased appetite,,0
COMETRIQ,Decreased appetite,NUTRITION Decreased appetite Dehydra,1
COMETRIQ,Decreased appetite,,0
COMETRIQ,Decreased appetite,Decreased appetite Dehydra,1
COMETRIQ,Decreased appetite,Decreased appetite Dehydra,1
COMETRIQ,Arthralgia,TISSUE Arthralgia,1
COMETRIQ,Arthralgia,AND CONNECTIVE TISSUE Arthralgia,1
COMETRIQ,Muscle spasms,Muscle,1
COMETRIQ,Muscle spasms,Muscle spasms Mu,1
COMETRIQ,Muscle spasms,Muscle,1
COMETRIQ,Musculoskeletal chest pain,ms Musculoskeletal,1
COMETRIQ,Musculoskeletal chest pain,,0
COMETRIQ,Musculoskeletal chest pain,ms Musculoskeletal chest pain,1
COMETRIQ,Dysgeusia,NERVOUS SYSTEM Dysgeusia,1
COMETRIQ,Dysgeusia,SYSTEM Dysgeusia,1
COMETRIQ,Dysgeusia,,0
COMETRIQ,Dysgeusia,Dysgeusia,1
COMETRIQ,Dysgeusia,,0
COMETRIQ,Dysgeusia,Dysgeusia,1
COMETRIQ,Dysgeusia,DISORDERS,0
COMETRIQ,Dysgeusia,SYSTEM Dysgeusia,1
COMETRIQ,Dysgeusia,Dysgeusia,1
COMETRIQ,Dysgeusia,DISORDERS,0
COMETRIQ,Headache,,0
COMETRIQ,Headache,Headache,1
COMETRIQ,Headache,,0
COMETRIQ,Headache,,0
COMETRIQ,Headache,,0
COMETRIQ,Headache,Headache,1
COMETRIQ,Headache,,0
COMETRIQ,Headache,,0
COMETRIQ,Headache,Headache,1
COMETRIQ,Dizziness,,0
COMETRIQ,Dizziness,,0
COMETRIQ,Dizziness,,0
COMETRIQ,Paresthesia,,0
COMETRIQ,Peripheral sensory neuropathy,sensory neuropathy Peripheral,1
COMETRIQ,Peripheral sensory neuropathy,,0
COMETRIQ,Peripheral sensory neuropathy,neuropathy Peripheral neuropa,1
COMETRIQ,Peripheral sensory neuropathy,,0
COMETRIQ,Peripheral sensory neuropathy,Peripheral sensory neuropathy Peripheral,1
COMETRIQ,Peripheral sensory neuropathy,Peripheral sensory,1
COMETRIQ,Peripheral sensory neuropathy,,0
COMETRIQ,Peripheral sensory neuropathy,Peripheral sensory neuropathy Peripheral neuropa,1
COMETRIQ,Peripheral sensory neuropathy,Peripheral,1
COMETRIQ,Peripheral sensory neuropathy,,0
COMETRIQ,Anxiety,DISORDERS,0
COMETRIQ,Anxiety,,0
COMETRIQ,Anxiety,Anxiety R,1
COMETRIQ,Anxiety,,0
COMETRIQ,Anxiety,,0
COMETRIQ,Anxiety,Anxiety R,1
COMETRIQ,Dysphonia,THORACIC AND MEDIASTINAL Dysphonia SKI,1
COMETRIQ,Dysphonia,,0
COMETRIQ,Dysphonia,MEDIASTINAL,0
COMETRIQ,Dysphonia,THORACIC AND MEDIASTINAL Dysphonia SKI,1
COMETRIQ,Dysphonia,,0
COMETRIQ,Dysphonia,AND,0
COMETRIQ,PPES,PPES,1
COMETRIQ,PPES,SUBCUTANEOUS,0
COMETRIQ,PPES,TISSUE PPES,1
COMETRIQ,Hair color changes,depigmentation graying,0
COMETRIQ,Hair color changes,changes depigmentation graying,1
COMETRIQ,Hair color changes,,0
COMETRIQ,Hair color changes,Hair color,1
COMETRIQ,Hair color changes,Hair color changes depigmentation graying,1
COMETRIQ,Hair color changes,Hair color changes depigmentation,1
COMETRIQ,Hair color changes,Hair color changes,1
COMETRIQ,Hair color changes,,0
COMETRIQ,Hair color changes,depigmentation,0
COMETRIQ,Rash,,0
COMETRIQ,Rash,depigmentation Rash,1
COMETRIQ,Dry skin,,0
COMETRIQ,Dry skin,,0
COMETRIQ,Dry skin,Dry,1
COMETRIQ,Dry skin,,0
COMETRIQ,Dry skin,Dry,1
COMETRIQ,Dry skin,,0
COMETRIQ,Dry skin,,0
COMETRIQ,Dry skin,,0
COMETRIQ,Dry skin,Dry,1
COMETRIQ,Dry skin,Dry skin,1
COMETRIQ,Alopecia,Alopecia,1
COMETRIQ,Alopecia,,0
COMETRIQ,Alopecia,Alopecia,1
COMETRIQ,Alopecia,Alopecia,1
COMETRIQ,Alopecia,Alopecia,1
COMETRIQ,Alopecia,Alopecia,1
COMETRIQ,Alopecia,Alopecia,1
COMETRIQ,Alopecia,,0
COMETRIQ,Erythema,,0
COMETRIQ,Erythema,,0
COMETRIQ,Hypertension,Hypertension H,1
COMETRIQ,Hypertension,Hypertension H,1
COMETRIQ,Hypotension,Hypotension,1
COMETRIQ,Hypotension,n,0
COMETRIQ,Hypotension,,0
COMETRIQ,Hypotension,n,0
COMETRIQ,Hypotension,Hypotension,1
COMETRIQ,Hypotension,n Hypotension,1
COMETRIQ,Increased AST,Increased AST In,1
COMETRIQ,Increased AST,,0
COMETRIQ,Increased AST,AST In,1
COMETRIQ,Increased AST,,0
COMETRIQ,Increased AST,,0
COMETRIQ,Increased AST,Increased,1
COMETRIQ,Increased AST,,0
COMETRIQ,Increased ALT,ST Increased ALT In,1
COMETRIQ,Increased ALT,ST Increased,1
COMETRIQ,Increased ALT,ST,0
COMETRIQ,Increased ALT,ST Increased ALT In,1
COMETRIQ,Increased ALT,ST Increased,1
COMETRIQ,Increased ALT,,0
COMETRIQ,Increased ALT,In,0
COMETRIQ,Increased ALT,ST,0
COMETRIQ,Increased ALT,ST,0
COMETRIQ,Increased ALT,ST,0
COMETRIQ,Increased ALP,LT Increased ALP Hy,1
COMETRIQ,Increased ALP,LT Increased ALP Hy,1
COMETRIQ,Increased ALP,,0
COMETRIQ,Increased ALP,,0
COMETRIQ,Increased ALP,LT Increased ALP Hy,1
COMETRIQ,Increased ALP,,0
COMETRIQ,Increased ALP,,0
COMETRIQ,Increased ALP,ALP Hy,1
COMETRIQ,Hypocalcemia,,0
COMETRIQ,Hypocalcemia,LP,0
COMETRIQ,Hypocalcemia,LP,0
COMETRIQ,Hypocalcemia,Hypocalcemia H,1
COMETRIQ,Hyperbilirubinemia,,0
COMETRIQ,Hyperbilirubinemia,Hyperbilirubinemia Hypomag,1
COMETRIQ,Hyperbilirubinemia,temia,0
COMETRIQ,Hyperbilirubinemia,Hyperbilirubinemia Hypomag,1
COMETRIQ,Hyperbilirubinemia,Hypomag,0
COMETRIQ,Hyperbilirubinemia,Hyperbilirubinemia Hypomag,1
COMETRIQ,Hyperbilirubinemia,temia,0
COMETRIQ,Hypomagnesemia,binemia Hypomagnesemia Hyp,1
COMETRIQ,Hypokalemia,mia,0
COMETRIQ,Hypokalemia,,0
COMETRIQ,Hypokalemia,,0
COMETRIQ,Hypokalemia,mia Hypokalemia,1
COMETRIQ,Hypokalemia,,0
COMETRIQ,Hypokalemia,mia Hypokalemia,1
COMETRIQ,Hypokalemia,,0
COMETRIQ,Hypokalemia,mia Hypokalemia,1
COMETRIQ,Hypokalemia,Hypokalemia,1
COMETRIQ,Hypokalemia,,0
COMETRIQ,Hyponatremia,Hyponatremia Hemato,1
COMETRIQ,Hyponatremia,Hyponatremia Hemato,1
COMETRIQ,Hyponatremia,Hyponatremia Hemato,1
COMETRIQ,Hyponatremia,,0
COMETRIQ,Hyponatremia,Hyponatremia Hemato,1
COMETRIQ,Hyponatremia,,0
COMETRIQ,Hyponatremia,Hyponatremia Hemato,1
COMETRIQ,Hyponatremia,,0
COMETRIQ,Lymphopenia,,0
COMETRIQ,Lymphopenia,,0
COMETRIQ,Lymphopenia,Lymphopenia,1
COMETRIQ,Lymphopenia,,0
COMETRIQ,Neutropenia,,0
COMETRIQ,Neutropenia,Neutropenia,1
COMETRIQ,Thrombocytopenia,,0
COMETRIQ,Thrombocytopenia,Thrombocytopenia,1
COMETRIQ,Thrombocytopenia,Thrombocytopenia,1
COMETRIQ,Thrombocytopenia,Thrombocytopenia,1
COMETRIQ,Thrombocytopenia,,0
COMETRIQ,Thrombocytopenia,Thrombocytopenia,1
COMETRIQ,hypertension,of hypertension,1
COMETRIQ,malignant hypertension,malignant hypertension,1
COMETRIQ,malignant hypertension,No patients developed,0
COMETRIQ,malignant hypertension,Hypertension JNCStag,0
COMETRIQ,malignant hypertension,XL,0
COMETRIQ,malignant hypertension,patients malignant hypertension,1
COMETRIQ,malignant hypertension,hypertension,1
COMETRIQ,Hypertension,Hypertension,1
COMETRIQ,Hypertension,hypertension Table PerPatient,0
COMETRIQ,Hypertension,Protocol XL,0
COMETRIQ,Hypertension,in Protocol Hypertension,1
COMETRIQ,Hypertension,Hypertension,1
COMETRIQ,Pre-hypertension,or,0
COMETRIQ,Pre-hypertension,Pre-hypertension,1
COMETRIQ,Pre-hypertension,Diastolic Pre-hypertension,1
COMETRIQ,Pre-hypertension,Systolic mmHg or,0
COMETRIQ,PERFORATIONS,elsewhere in the label,0
COMETRIQ,FISTULAS,s advers e reactions are discussed elsewhere,1
COMETRIQ,FISTULAS,s advers e reactions are discussed,1
COMETRIQ,HEMORRHAGE,tions,1
COMETRIQ,PERFORATIONS,,0
COMETRIQ,PERFORATIONS,,0
COMETRIQ,PERFORATIONS,ewhere in th,1
COMETRIQ,FISTULAS,the lab,0
COMETRIQ,FISTULAS,"el:



 ",1
COMETRIQ,HEMORRHAGE,elsewhere in the label forations ,1
COMETRIQ,HEMORRHAGE,the,0
COMETRIQ,HEMORRHAGE,Precautions Hemorrhage see,0
COMETRIQ,HEMORRHAGE,forations ,1
COMETRIQ,HEMORRHAGE,Per,0
COMETRIQ,Perforations,,0
COMETRIQ,Perforations,,0
COMETRIQ,Perforations,,0
COMETRIQ,Perforations,see,1
COMETRIQ,fistulas,,0
COMETRIQ,fistulas,are discussed elsewhere,0
COMETRIQ,fistulas,and Pr,0
COMETRIQ,fistulas,Fistula see,0
COMETRIQ,fistulas,d Warnin,1
COMETRIQ,fistulas,elsewhere in the label Perforations,0
COMETRIQ,fistulas,d Warnin,1
COMETRIQ,fistulas,Hemorrhage see Boxed,0
COMETRIQ,Gastrointestinal perforations,and Fistula see Boxed Warning,0
COMETRIQ,Gastrointestinal perforations,Warning,0
COMETRIQ,Gastrointestinal perforations,"Fistula see Boxed  ,  Warnings and Precautions ",1
COMETRIQ,Gastrointestinal perforations,discussed elsewhere in the,0
COMETRIQ,Gastrointestinal perforations,,0
COMETRIQ,Gastrointestinal perforations,,0
COMETRIQ,fistula formation,[ see B,1
COMETRIQ,fistula formation,Events see Warnings an,0
COMETRIQ,fistula formation,Thromboembolic Events see Warnings an,0
COMETRIQ,fistula formation,and Precautions morrhage [,1
COMETRIQ,fistula formation,Precautions morrhage [ see  B,1
COMETRIQ,fistula formation,see Warnings,0
COMETRIQ,fistula formation,[ see B,1
COMETRIQ,Hemorrhage,Warnings and,0
COMETRIQ,Hemorrhage,Warn,0
COMETRIQ,Hemorrhage,Wound Complications see ings and P,1
COMETRIQ,Hemorrhage,Precautions Wound Complications see ings and P,1
COMETRIQ,Hemorrhage,and Precautions Wound Complications see Warn,0
COMETRIQ,Hemorrhage,Wound,0
COMETRIQ,Hemorrhage,Wound Complications see Warn,0
COMETRIQ,fatal,) ],1
COMETRIQ,fatal,Jaw see,0
COMETRIQ,fatal,"and ) ] 
",1
COMETRIQ,fatal,"Warnings and ) ] 
",1
COMETRIQ,fatal,Jaw see,0
COMETRIQ,fatal,Complications see Warnings and ),1
COMETRIQ,fatal,,0
COMETRIQ,fatal,see,0
COMETRIQ,hemorrhage,  Hyperten,1
COMETRIQ,hemorrhage,see Warnings and,0
COMETRIQ,hemorrhage,  Hyperten,1
COMETRIQ,hemorrhage,  Hyperten,1
COMETRIQ,hemorrhage,  Hyperten,1
COMETRIQ,hemorrhage,Complications see Warnings and   Hyperten,1
COMETRIQ,hemorrhage,  Hyperten,1
COMETRIQ,hemorrhage,Precautions Osteonecrosis,0
COMETRIQ,hemorrhage,see Warnings and Precautions Osteonecrosis of the,0
COMETRIQ,hemorrhage,  Hyperten,1
COMETRIQ,hemorrhage,,0
COMETRIQ,hemoptysis,and Precautions Osteonecrosis of,0
COMETRIQ,hemoptysis,and Precautions Hypertension  Warnings ,1
COMETRIQ,hemoptysis,see Warnings and,0
COMETRIQ,hemoptysis, Warnings ,1
COMETRIQ,gastrointestinal hemorrhage,"Hypertension see Warnings and recautions  (  5.5  ) ] 
 *",1
COMETRIQ,gastrointestinal hemorrhage,Warnings and Precautions Hypertension see Warnings and P,0
COMETRIQ,gastrointestinal hemorrhage,Precautions,0
COMETRIQ,gastrointestinal hemorrhage,recautions ( 5.5 ),1
COMETRIQ,gastrointestinal hemorrhage,see Warnings and Precautions Hypertension see Warnings and,0
COMETRIQ,gastrointestinal hemorrhage,] *,1
COMETRIQ,gastrointestinal hemorrhage,Hypertension see Warnings and recautions ( 5.5 ) ],1
COMETRIQ,gastrointestinal hemorrhage,Hypertension,0
COMETRIQ,PERFORATIONS,sterior Leuk,1
COMETRIQ,PERFORATIONS,Precautions Reversible sterior Leuk,1
COMETRIQ,PERFORATIONS,Reversible sterior Leuk,1
COMETRIQ,FISTULAS,Syndrome,0
COMETRIQ,FISTULAS,Warnings and Precautions,0
COMETRIQ,FISTULAS,phalopat,1
COMETRIQ,FISTULAS,Precautions EXCERPT The most commonly reporte,0
COMETRIQ,FISTULAS,Reversible Posterior phalopat,1
COMETRIQ,FISTULAS,Warnings,0
COMETRIQ,FISTULAS,EXCERPT The,0
COMETRIQ,Perforations,commonly eported,1
COMETRIQ,Perforations,eported adve,1
COMETRIQ,Perforations,,0
COMETRIQ,Perforations,adve,1
COMETRIQ,Fistulas,reac,1
COMETRIQ,Fistulas,stomatitis palmarplantar,0
COMETRIQ,Gastrointestinal perforations,"drug ons (>=25%) are diarrhea, sto",1
COMETRIQ,Gastrointestinal perforations,"ons (>=25%) are diarrhea, sto",1
COMETRIQ,Gastrointestinal perforations,"adverse drug ons (>=25%) are diarrhea, sto",1
COMETRIQ,fistula formation,tar erythrodysest,1
COMETRIQ,fistula formation,tar erythrodysest,1
COMETRIQ,fistula formation,erythrodysest,1
COMETRIQ,fistula formation,reactions are diarrhea stomatitis tar erythrodysest,1
COMETRIQ,fistula formation,commonly reported adverse drug reactions are,0
COMETRIQ,fistula formation,stomatitis tar erythrodysest,1
COMETRIQ,Hemorrhage,nausea fatigue oral pain hair color changes,0
COMETRIQ,Hemorrhage,"ysgeusia, ",1
COMETRIQ,Hemorrhage,"ysgeusia, ",1
COMETRIQ,Hemorrhage,"changes ysgeusia, ",1
COMETRIQ,Hemorrhage,"hair color changes ysgeusia, ",1
COMETRIQ,Hemorrhage,"ysgeusia, ",1
COMETRIQ,Hemorrhage,,0
COMETRIQ,Hemorrhage,The,0
COMETRIQ,Hemorrhage,"ysgeusia, ",1
COMETRIQ,fatal,,0
COMETRIQ,fatal,nal p,1
COMETRIQ,fatal,p,1
COMETRIQ,fatal,nal p,1
COMETRIQ,fatal,changes dysgeusia hypertension nal,1
COMETRIQ,fatal,,0
COMETRIQ,fatal,oral,0
COMETRIQ,fatal,dysgeusia hypertension nal,1
COMETRIQ,hemorrhage,most common laboratory abnormalities are,0
COMETRIQ,hemorrhage,are increased AST increased ALT,0
COMETRIQ,hemorrhage,"changes dysgeusia hypertension abdominal n, and con",1
COMETRIQ,hemoptysis,alka,0
COMETRIQ,hemoptysis,The most c,1
COMETRIQ,hemoptysis,The most c,1
COMETRIQ,hemoptysis,The most c,1
COMETRIQ,gastrointestinal hemorrhage,abnormalities (,1
COMETRIQ,gastrointestinal hemorrhage,,0
COMETRIQ,gastrointestinal hemorrhage,(,1
COMETRIQ,gastrointestinal hemorrhage,and constipation The most laboratory,1
COMETRIQ,gastrointestinal hemorrhage,(,1
COMETRIQ,gastrointestinal hemorrhage,laboratory abnormalities (,1
COMETRIQ,Thrombotic Events,erse reactions,1
COMETRIQ,Thrombotic Events,reactions ar e discussed elsewhere in,1
COMETRIQ,Thrombotic Events,erse,1
COMETRIQ,Thrombotic Events,,0
COMETRIQ,Thrombotic Events,erse reactions ar e discussed elsewhere in,1
COMETRIQ,Thrombotic Events,,0
COMETRIQ,Thrombotic Events,,0
COMETRIQ,Thrombotic Events,erse,1
COMETRIQ,Thrombotic Events,erse reactions ar e discussed elsewhere in the,1
COMETRIQ,Wound Complications,Warning Warnings and  Hemorrhage [ see   Boxed Warning Warnings and Precautions,1
COMETRIQ,Wound Complications, Hemorrhage [ see   Boxed Warning Warnings and Precautions,1
COMETRIQ,Wound Complications,Hemorrhage [ see Boxed Warning Warnings and Precautions,1
COMETRIQ,Wound Complications,Warning Warnings,0
COMETRIQ,Osteonecrosis of the jaw,Precautions,0
COMETRIQ,Osteonecrosis of the jaw,Precautions tension [ see  Warnings  and Precautions Osteonecrosis of the,1
COMETRIQ,Osteonecrosis of the jaw,the Jaw see Warnings and,0
COMETRIQ,Osteonecrosis of the jaw,Osteonecrosis,0
COMETRIQ,Osteonecrosis of the jaw,,0
COMETRIQ,Palmar-plantar Erythrodysesthesia syndrome,syndrome,0
COMETRIQ,Palmar-plantar Erythrodysesthesia syndrome,and,0
COMETRIQ,Palmar-plantar Erythrodysesthesia syndrome,erythrodysesthesia,0
COMETRIQ,Palmar-plantar Erythrodysesthesia syndrome,,0
COMETRIQ,Palmar-plantar Erythrodysesthesia syndrome,ecrosis of the Jaw [ see,1
COMETRIQ,Palmar-plantar Erythrodysesthesia syndrome,and Precautions ecrosis of the Jaw [ see  Warnings and Pre cautions Palmarplantar erythrodysesthesia syndrome see,1
COMETRIQ,Palmar-plantar Erythrodysesthesia syndrome,Warnings and Precautions ecrosis of,1
COMETRIQ,Palmar-plantar Erythrodysesthesia syndrome,and,0
COMETRIQ,Palmar-plantar Erythrodysesthesia syndrome,Precautions ecrosis of,1
COMETRIQ,Palmar-plantar Erythrodysesthesia syndrome,Palmarplantar,0
COMETRIQ,PPES,,0
COMETRIQ,Proteinuria,,0
COMETRIQ,Proteinuria,a syndrome see Warnings and Precautions Proteinuria,1
COMETRIQ,Proteinuria,and Precautions Palmarplantar a syndrome  see Warnings and Precautions Proteinuria,1
COMETRIQ,Proteinuria,Proteinuria see Warnings and Precautions,0
COMETRIQ,Proteinuria,a syndrome see Warnings and Precautions Proteinuria,1
COMETRIQ,Proteinuria,Precautions Palmarplantar a syndrome  see Warnings and Precautions Proteinuria,1
COMETRIQ,Proteinuria,Warnings and Precautions Proteinuria see,0
COMETRIQ,Proteinuria,syndrome see Warnings and Precautions Proteinuria,1
COMETRIQ,Proteinuria,a syndrome see Warnings and Precautions Proteinuria,1
COMETRIQ,Reversible posterior leukoencephalopathy syndrome,Leukoencephalopathy Syndrome see Warnings and Precautions EXCERPT,0
COMETRIQ,Reversible posterior leukoencephalopathy syndrome,* Reversible Po sterior Leukoencephalopathy Syndrome see Warnings,1
COMETRIQ,Reversible posterior leukoencephalopathy syndrome,see Warnings and,0
COMETRIQ,Reversible posterior leukoencephalopathy syndrome,Syndrome see Warnings and Precautions EXCERPT,0
COMETRIQ,RPLS,see Warnings,0
COMETRIQ,Embryofetal toxicity,,0
COMETRIQ,Embryofetal toxicity,rnings and Precautio ns EXCERPT The most commonly,1
COMETRIQ,Embryofetal toxicity,ns EXCERPT The most commonly reported,0
COMETRIQ,fetal harm,see Warnings and ),1
COMETRIQ,fetal harm,Leukoencephalopathy Syndrome see,0
COMETRIQ,fetal harm,drug,0
COMETRIQ,fetal harm,") ] 
      EXCERPT The most commonly reported",1
COMETRIQ,fetal harm,"Warnings and ) ] 
      EXCERPT The most commonly reported",1
COMETRIQ,GI fistula,"n, abdomin al pain and constipation The",1
COMETRIQ,GI fistula,,0
COMETRIQ,GI fistula,fatigue oral pain hair color changes dysgeusia,0
COMETRIQ,GI fistula,fatigue oral,0
COMETRIQ,GI fistula,"changes dysgeusia n, abdomin al pain and constipation The",1
COMETRIQ,GI fistula,"n, abdomin al pain and constipation The",1
COMETRIQ,GI fistula,hypertensio,0
COMETRIQ,GI fistula,"color changes dysgeusia n, abdomin al pain and constipation The",1
COMETRIQ,GI fistula,oral pain hair,0
COMETRIQ,GI fistula,,0
COMETRIQ,Non-GI fistulas,color changes dysgeusia,0
COMETRIQ,Non-GI fistulas,abdominal pain and pation. The mos t common laboratory abnormalities are,1
COMETRIQ,Non-GI fistulas,pain hair color changes dysgeusia,0
COMETRIQ,Non-GI fistulas,and pation. The mos t common laboratory abnormalities are,1
COMETRIQ,Non-GI fistulas,increased AST increased ALT lymphopenia,0
COMETRIQ,Non-GI fistulas,and pation. The,1
COMETRIQ,Non-GI fistulas,pain and pation. The mos t common laboratory abnormalities are,1
COMETRIQ,fatal,increased AST increased ALT lymphopenia increased,0
COMETRIQ,fatal,lymphopenia increased ine,1
COMETRIQ,fatal,ine p hosphatase hypocalcemia neutropenia thrombocytopenia hypophosphatemia,1
COMETRIQ,fatal,hypophosphatemia,0
COMETRIQ,fatal,increased ine p hosphatase hypocalcemia neutropenia thrombocytopenia hypophosphatemia,1
COMETRIQ,fatal,hypocalcemia neutropenia thrombocytopenia,0
COMETRIQ,fatal,at,0
COMETRIQ,fatal,REACTIONS contact Exelixis Inc 935,1
COMETRIQ,fatal,To report SUSPECTED ADVERSE REACTIONS contact,0
COMETRIQ,fatal,,0
COMETRIQ,fatal,Trial,0
COMETRIQ,hemorrhage,Inc at or,0
COMETRIQ,hemorrhage,wwwfdagovmedwatch Clinical Trial,0
COMETRIQ,hemorrhage,,0
COMETRIQ,hemorrhage,Inc at FDA,1
COMETRIQ,hemorrhage,Experience,0
COMETRIQ,hemorrhage,Inc at FDA,1
COMETRIQ,hemorrhage,report SUSPECTED ADVERSE REACTIONS contact Exelixis Inc at,0
COMETRIQ,hemorrhage,Trial Experience Because clin,0
COMETRIQ,hemorrhage,Trial Experience Because,0
COMETRIQ,hemorrhage,Trial,0
COMETRIQ,hemorrhage,Because clin,0
COMETRIQ,hemorrhage,Inc at  FDA at 1- FDA or wwwfdagovmedwatch Clinical Trial,1
COMETRIQ,hemorrhage,Inc at FDA,1
COMETRIQ,hemorrhage,,0
COMETRIQ,hemorrhage,Clinical Trial,0
COMETRIQ,hemorrhage,Exelixis Inc at FDA,1
COMETRIQ,hemorrhage,Inc at  FDA at 1- FDA or wwwfdagovmedwatch Clinical Trial,1
COMETRIQ,hemorrhagic events,under widely varying,0
COMETRIQ,hemorrhagic events,"at FDA or 
  6.1 Clinical Tr ial Experience Because clinical trials",1
COMETRIQ,hemorrhagic events,"
  6.1 Clinical Tr ial Experience Because clinical trials",1
COMETRIQ,hemorrhagic events,rea,0
COMETRIQ,hemorrhagic events,at FDA or wwwfdagovmedwatch,0
COMETRIQ,hemorrhagic events,"or 
  6.1 Clinical Tr ial Experience Because clinical trials",1
COMETRIQ,hemorrhagic events,Tr ial Experience Because clinical trials,1
COMETRIQ,thrombotic events,reflect the observed,1
COMETRIQ,thrombotic events,may not reflect the observed in,1
COMETRIQ,thrombotic events,in pract ice The safety of COMETRIQ,1
COMETRIQ,thrombotic events,reflect the observed in pract ice The safety of COMETRIQ,1
COMETRIQ,thrombotic events,observed in pract ice The safety of COMETRIQ,1
COMETRIQ,thrombotic events,not reflect the observed in,1
COMETRIQ,thrombotic events,to rates in the,0
COMETRIQ,thrombotic events,ice The safety of,0
COMETRIQ,thrombotic events,in pract ice The safety of COMETRIQ,1
COMETRIQ,venous thromboembolism,The safety of C OMETRIQ was evaluated in patients,1
COMETRIQ,arterial thromboembolism,randomized to receive mg,0
COMETRIQ,arterial thromboembolism,in 330 patients wi th progressive metastatic medullary thyroid,1
COMETRIQ,arterial thromboembolism,the rates,0
COMETRIQ,Wound complications,in a randomized doubleblind controlled trial,0
COMETRIQ,Wound complications,,0
COMETRIQ,Wound complications,below reflect a median exposure to COMETRIQ,0
COMETRIQ,Wound complications,controlled,0
COMETRIQ,Wound complications,below reflect a median exposure to COMETRIQ for days The,0
COMETRIQ,hypertension,PPES decreased weight decreased appetite nausea fatigue oral pain hair color,0
COMETRIQ,hypertension,,0
COMETRIQ,hypertension,,0
COMETRIQ,hypertension,frequency diarrhea,0
COMETRIQ,hypertension,palmarplantar,0
COMETRIQ,hypertension,erythrodyse,0
COMETRIQ,hypertension,palmarplantar sthesia,1
COMETRIQ,hypertension,stomatitis palmarplantar sthesia synd rome PPES decreased weight decreased,1
COMETRIQ,hypertension,synd rome PPES decreased weight decreased,1
COMETRIQ,hypertension,nausea fatigue oral pain hair,0
COMETRIQ,Osteonecrosis of the jaw,ncreased ALT decreased weight stomatitis and decreased appetite,0
COMETRIQ,Osteonecrosis of the jaw,of decreasing frequency,0
COMETRIQ,Osteonecrosis of the jaw,decreasing frequency,0
COMETRIQ,Osteonecrosis of the jaw,,0
COMETRIQ,Osteonecrosis of the jaw,decreased weight stomatitis and decreased appetite,0
COMETRIQ,jaw pain,,0
COMETRIQ,jaw pain,1 Table Fatal adverse reactions occurred,1
COMETRIQ,jaw pain,weight,0
COMETRIQ,osteomyelitis,and resulted from,0
COMETRIQ,osteomyelitis,"decreased appetite see ,",1
COMETRIQ,osteomyelitis,stomatitis and decreased appetite see,0
COMETRIQ,osteomyelitis,"and decreased appetite see ,  Table 2  ) Fatal adverse reactions occurred in",1
COMETRIQ,osteomyelitis,Table 2 ) Fatal adverse reactions occurred in,1
COMETRIQ,osteitis,of patients receiving COMETRIQ and resulted from,0
COMETRIQ,osteitis,ALT decreased weight stomatitis and decreased appetite see Table,0
COMETRIQ,osteitis,of patients receiving COMETRIQ and resulted from,0
COMETRIQ,osteitis,"


 Fata l adverse reactions occurred in",1
COMETRIQ,osteitis,l adverse reactions occurred in of patients receiving COMETRIQ and resulted from,0
COMETRIQ,osteitis,decreased weight stomatitis and decreased appetite,0
COMETRIQ,osteitis,"


 Fata l adverse reactions occurred in",1
COMETRIQ,osteitis,"Table 


 Fata l adverse reactions occurred in",1
COMETRIQ,bone erosion,Table Table adverse,1
COMETRIQ,bone erosion,hemorrhage,0
COMETRIQ,bone erosion,occurred in of,0
COMETRIQ,bone erosion,see,0
COMETRIQ,periodontal infection,red in,1
COMETRIQ,periodontal infection,decreased appetite see Table Table Fatal,0
COMETRIQ,periodontal infection,COMETRIQ and resulted from,0
COMETRIQ,periodontal infection,Table Table Fatal,0
COMETRIQ,periodontal infection,Fatal adverse reactions,0
COMETRIQ,toothache,of patients eceiving  COMETRIQ and resulted from hemorrhage,1
COMETRIQ,toothache,eceiving  COMETRIQ and resulted from hemorrhage,1
COMETRIQ,toothache,eceiving  COMETRIQ and resulted from hemorrhage,1
COMETRIQ,toothache,in,0
COMETRIQ,toothache,eceiving  COMETRIQ and resulted from hemorrhage,1
COMETRIQ,toothache,resulted from hemorrhage pneumonia septicemia fistulas cardiac arrest,0
COMETRIQ,toothache,eceiving  COMETRIQ and resulted from hemorrhage,1
COMETRIQ,toothache,r,0
COMETRIQ,toothache,Table Table Fatal adverse reactions occurred,0
COMETRIQ,gingival ulceration,receiving,0
COMETRIQ,gingival ulceration,resulted from hemorrhage pneumonia septicemia fistulas,1
COMETRIQ,gingival ulceration,of patients receiving METRIQ and resulted from hemorrhage pneumonia septicemia fistulas,1
COMETRIQ,gingival ulceration,resulted from hemorrhage pneumonia septicemia fistulas,1
COMETRIQ,gingival ulceration,,0
COMETRIQ,gingival ulceration,patients receiving METRIQ and resulted from hemorrhage pneumonia septicemia fistulas,1
COMETRIQ,gingival ulceration,patients receiving METRIQ,1
COMETRIQ,persistent jaw pain,"resulted from age,",1
COMETRIQ,persistent jaw pain,sep ticemia fistulas cardiac arrest respiratory,1
COMETRIQ,persistent jaw pain,in of patients receiving COMETRIQ and resulted,0
COMETRIQ,persistent jaw pain,ticemia fistulas cardiac,0
COMETRIQ,persistent jaw pain,reactio,0
COMETRIQ,persistent jaw pain,"age, pneumonia, sep ticemia fistulas cardiac arrest respiratory",1
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,,0
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,in patients receiving Q compared to,1
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,treatment discontinuation in of patients,0
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,lacebo Adverse reactions led to study treatment,0
COMETRIQ,PPES,reactions led to study treatment discontinuation in of patients,0
COMETRIQ,PPES,in patients receiving cebo Adverse reactions led to study,1
COMETRIQ,PPES,,0
COMETRIQ,PPES,in,0
COMETRIQ,PPES,patients receiving COMETRIQ,0
COMETRIQ,PPES,one in patients receiving COMETRIQ compared to none in patients receiving pla,0
COMETRIQ,Proteinuria,"PPES, diarrhea fatigue hypertension nausea pancreatitis",1
COMETRIQ,RPLS,a prior thyroidectomy d,1
COMETRIQ,RPLS,prior thyroidectomy,0
COMETRIQ,subcortical vasogenic edema,of Selected Adverse Reactions,0
COMETRIQ,subcortical vasogenic edema,taking roid hormone replacement pr ior to the first dose,1
COMETRIQ,subcortical vasogenic edema,taking roid,1
COMETRIQ,subcortical vasogenic edema,PerPatient Incidence of Selected Adverse Reactions in Protocol X,0
COMETRIQ,subcortical vasogenic edema,pr ior to the first dose,1
COMETRIQ,subcortical vasogenic edema,taking roid hormone,1
COMETRIQ,fetal harm,           Nausea,1
COMETRIQ,fetal harm,Stomatitis,0
COMETRIQ,fetal harm,           Nausea,1
COMETRIQ,fetal harm,,0
COMETRIQ,embryolethal,       Nause a,1
COMETRIQ,embryolethal,       Nause a,1
COMETRIQ,skeletal variations," 0         
       ",1
COMETRIQ,skeletal variations,Nausea,0
COMETRIQ,skeletal variations," 0         
        Oral",1
COMETRIQ,skeletal variations," 0         
       ",1
COMETRIQ,skeletal variations,"Nausea  0         
       ",1
COMETRIQ,visceral variations,                    Constipation,1
COMETRIQ,visceral variations,pain,0
COMETRIQ,visceral variations,,0
COMETRIQ,visceral variations,                    Constipation,1
COMETRIQ,visceral variations,                    Constipation,1
COMETRIQ,visceral variations,                    Constipation,1
COMETRIQ,visceral variations,,0
COMETRIQ,visceral variations,,0
COMETRIQ,visceral variations,Oral                     Constipation,1
COMETRIQ,visceral variations,,0
NULOJIX,PTLD,,0
NULOJIX,PTLD,PTLD predominantly CNS PTLD,1
NULOJIX,CNS PTLD,are PTLD CNS,1
NULOJIX,CNS PTLD,CNS,1
NULOJIX,CNS PTLD,serious adverse reactions reported with NULOJIX are PTLD,0
NULOJIX,CNS PTLD,CNS,1
NULOJIX,CNS PTLD,reported with,0
NULOJIX,CNS PTLD,and Warnings,0
NULOJIX,malignancies,malignancies see Boxed Warning,1
NULOJIX,malignancies,other,0
NULOJIX,malignancies,malignancies see Boxed Warning,1
NULOJIX,malignancies,and Precautions Serious,0
NULOJIX,malignancies,malignancies see Boxed Warning,1
NULOJIX,malignancies,malignancies see Boxed Warning,1
NULOJIX,infections,Boxed Warning and Warnings and Precautions Serious,0
NULOJIX,infections,infections including JC virusassociated,1
NULOJIX,infections,Precautions infections including JC virusassociated,1
NULOJIX,infections,see Boxed Warning and Warnings and Precautions Serious,0
NULOJIX,PML,PML and polyoma virus,1
NULOJIX,PML,Precautions,0
NULOJIX,PML,infections including JC PML and polyoma virus,1
NULOJIX,PML,PML and polyoma virus,1
NULOJIX,polyoma virus nephropathy,polyoma virus nephropathy see Warnings and,1
NULOJIX,polyoma virus nephropathy,JC virusassociated PML polyoma virus,1
NULOJIX,polyoma virus nephropathy,,0
NULOJIX,polyoma virus nephropathy,common adverse rea,0
NULOJIX,polyoma virus nephropathy,and Precautions EXCERPT Most,0
NULOJIX,polyoma virus nephropathy,virus nephropathy see Warnings and,1
NULOJIX,anemia,tract infection peripheral edema constipation hypertension pyrexia graft,0
NULOJIX,anemia,anemia diarrhea urinary tract,1
NULOJIX,diarrhea,diarrhea urinary tract infection,1
NULOJIX,diarrhea,common adverse,0
NULOJIX,diarrhea,diarrhea urinary tract infection,1
NULOJIX,diarrhea,diarrhea urinary tract infection,1
NULOJIX,urinary tract infection,anemia urinary tract infection peripheral edema constipation,1
NULOJIX,urinary tract infection,edema constipation hypertension pyrexia graft dysfunction cough nausea,0
NULOJIX,urinary tract infection,NULOJIX treatment are anemia urinary,1
NULOJIX,urinary tract infection,hypertension pyrexia,0
NULOJIX,urinary tract infection,hypertension pyrexia graft dysfunction cough,0
NULOJIX,peripheral edema,,0
NULOJIX,peripheral edema,infection,0
NULOJIX,constipation,constipation hypertension pyrexia graft,1
NULOJIX,constipation,headache,0
NULOJIX,hypertension,peripheral edema hypertension pyrexia graft dysfunction,1
NULOJIX,hypertension,hypertension pyrexia graft dysfunction,1
NULOJIX,hypertension,and leuk,0
NULOJIX,hypertension,nausea vomiting headache hypokalemia,0
NULOJIX,hypertension,peripheral edema hypertension pyrexia graft dysfunction,1
NULOJIX,hypertension,,0
NULOJIX,hypertension,edema hypertension pyrexia graft dysfunction,1
NULOJIX,pyrexia,pyrexia graft dysfunction cough,1
NULOJIX,pyrexia,edema constipation pyrexia graft dysfunction cough,1
NULOJIX,pyrexia,pyrexia graft dysfunction cough,1
NULOJIX,pyrexia,hypokalemia hyperkalemia and,0
NULOJIX,pyrexia,graft dysfunction,0
NULOJIX,pyrexia,pyrexia graft dysfunction cough,1
NULOJIX,pyrexia,,0
NULOJIX,graft dysfunction,graft dysfunction cough nausea vomiting,1
NULOJIX,graft dysfunction,pyrexia,0
NULOJIX,graft dysfunction,dysfunction cough nausea vomiting,1
NULOJIX,graft dysfunction,graft dysfunction cough nausea vomiting,1
NULOJIX,graft dysfunction,graft dysfunction cough nausea vomiting,1
NULOJIX,graft dysfunction,graft dysfunction cough nausea vomiting,1
NULOJIX,graft dysfunction,nausea vomiting,0
NULOJIX,graft dysfunction,graft dysfunction cough nausea vomiting,1
NULOJIX,graft dysfunction,vomiting headache hypokalemia,0
NULOJIX,cough,peripheral edema constipation hypertension,0
NULOJIX,cough,dysfunction,0
NULOJIX,cough,pyrexia graft dysfunction,0
NULOJIX,cough,cough nausea vomiting headache,1
NULOJIX,cough,headache,0
NULOJIX,cough,cough nausea vomiting headache,1
NULOJIX,cough,pyrexia graft dysfunction,0
NULOJIX,cough,and,0
NULOJIX,nausea,and leukopenia To,0
NULOJIX,nausea,nausea vomiting headache hypokalemia,1
NULOJIX,nausea,,0
NULOJIX,nausea,infection peripheral edema constipation hypertension,0
NULOJIX,vomiting,vomiting headache hypokalemia hyperkalemia,1
NULOJIX,vomiting,vomiting headache hypokalemia hyperkalemia,1
NULOJIX,vomiting,SUSPECTED ADVERSE,0
NULOJIX,vomiting,,0
NULOJIX,vomiting,pyrexia graft dysfunction cough vomiting headache hypokalemia hyperkalemia,1
NULOJIX,vomiting,nausea,0
NULOJIX,vomiting,vomiting headache hypokalemia hyperkalemia,1
NULOJIX,headache,report SUSPECTED,0
NULOJIX,hypokalemia,hypokalemia hyperkalemia and leukopenia,1
NULOJIX,hypokalemia,pyrexia graft dysfunction cough nausea vomiting headache,0
NULOJIX,hyperkalemia,headache hyperkalemia and leukopenia To,1
NULOJIX,leukopenia,headache hypokalemia hyperkalemia leukopenia To report SUSPECTED,1
NULOJIX,leukopenia,vomiting headache hypokalemia hyperkalemia,0
NULOJIX,leukopenia,Squibb at,0
NULOJIX,leukopenia,,0
NULOJIX,CNS PTLD,infections were more frequently observed in association with a,0
NULOJIX,CNS PTLD,CNS PTLD PML and other,1
NULOJIX,CNS PTLD,years,0
NULOJIX,CNS PTLD,followed,0
NULOJIX,PML,PML and other CNS,1
NULOJIX,PML,PML and other CNS,1
NULOJIX,PML,PML and other CNS,1
NULOJIX,PML,PML and other CNS,1
NULOJIX,PML,PML and other CNS,1
NULOJIX,PML,PML and other CNS,1
NULOJIX,PML,CNS PML and other CNS,1
NULOJIX,PML,mofetil and corticosteroids,0
NULOJIX,PML,,0
NULOJIX,CNS infections,higher cumulative dose and m,0
NULOJIX,CNS infections,association with,0
NULOJIX,diarrhea,diarrhea urinary tract infection,1
NULOJIX,diarrhea,diarrhea urinary tract infection,1
NULOJIX,diarrhea,diarrhea urinary tract infection,1
NULOJIX,diarrhea,anemia,0
NULOJIX,diarrhea,diarrhea urinary tract infection,1
NULOJIX,diarrhea,hypertension pyrexia graft,0
NULOJIX,diarrhea,diarrhea urinary tract infection,1
NULOJIX,diarrhea,diarrhea urinary tract infection,1
NULOJIX,urinary tract infection,of NULOJIX were anemia urinary tract,1
NULOJIX,peripheral edema,vomiting headache,0
NULOJIX,peripheral edema,diarrhea urinary tract peripheral edema constipation hypertension pyrexia,1
NULOJIX,constipation,urinary tract infection peripheral,0
NULOJIX,constipation,NULOJIX were anemia diarrhea urinary tract,0
NULOJIX,constipation,infection peripheral edema,0
NULOJIX,constipation,vomiting headache hypokalemia hyperkal,0
NULOJIX,constipation,constipation hypertension pyrexia graft,1
NULOJIX,constipation,dysfunction cough nausea vomiting,0
NULOJIX,constipation,and frequency of NULOJIX were anemia diarrhea urinary tract infection peripheral,0
NULOJIX,constipation,constipation hypertension pyrexia graft,1
NULOJIX,constipation,constipation hypertension pyrexia graft,1
NULOJIX,hypertension,,0
NULOJIX,hypertension,cough,0
NULOJIX,hypertension,infection peripheral,0
NULOJIX,hypertension,,0
NULOJIX,hypertension,NULOJIX were anemia diarrhea urinary tract infection peripheral edema,0
NULOJIX,hypertension,infection peripheral edema hypertension pyrexia graft dysfunction,1
NULOJIX,hypertension,NULOJIX were anemia diarrhea,0
NULOJIX,hypertension,hypertension pyrexia graft dysfunction,1
NULOJIX,hypertension,hypertension pyrexia graft dysfunction,1
NULOJIX,hypertension,headache hypokalemia hyperkalemia,0
NULOJIX,pyrexia,urinary tract infection peripheral edema constipation,0
NULOJIX,pyrexia,,0
NULOJIX,pyrexia,pyrexia graft dysfunction cough,1
NULOJIX,graft dysfunction,edema constipation hypertension,0
NULOJIX,graft dysfunction,graft,1
NULOJIX,graft dysfunction,,0
NULOJIX,graft dysfunction,dysfunction cough nausea vomiting,1
NULOJIX,graft dysfunction,urinary tract infection peripheral,0
NULOJIX,graft dysfunction,peripheral edema constipation hypertension graft,1
NULOJIX,graft dysfunction,constipation hypertension graft,1
NULOJIX,cough,hypertension pyrexia graft cough nausea vomiting headache,1
NULOJIX,cough,cough nausea vomiting headache,1
NULOJIX,cough,graft cough nausea vomiting headache,1
NULOJIX,cough,cough nausea vomiting headache,1
NULOJIX,cough,dysfunction,0
NULOJIX,cough,cough nausea vomiting headache,1
NULOJIX,cough,pyrexia graft cough nausea vomiting headache,1
NULOJIX,nausea,hyperkalemia and leukopenia The proportion of,0
NULOJIX,nausea,,0
NULOJIX,nausea,graft dysfunction nausea vomiting headache hypokalemia,1
NULOJIX,nausea,nausea vomiting headache hypokalemia,1
NULOJIX,nausea,nausea vomiting headache hypokalemia,1
NULOJIX,nausea,nausea vomiting headache hypokalemia,1
NULOJIX,nausea,edema constipation hypertension,0
NULOJIX,nausea,nausea vomiting headache hypokalemia,1
NULOJIX,vomiting,vomiting headache hypokalemia hyperkalemia,1
NULOJIX,vomiting,peripheral edema constipation hypertension pyrexia graft dysfunction cough,0
NULOJIX,vomiting,headache hypokalemia hyperkalemia and,0
NULOJIX,vomiting,edema constipation hypertension,0
NULOJIX,vomiting,vomiting headache hypokalemia hyperkalemia,1
NULOJIX,vomiting,vomiting headache hypokalemia hyperkalemia,1
NULOJIX,headache,headache hypokalemia hyperkalemia and,1
NULOJIX,hyperkalemia,hyperkalemia and leukopenia The,1
NULOJIX,hyperkalemia,hyperkalemia and leukopenia The,1
NULOJIX,hyperkalemia,hyperkalemia and leukopenia The,1
NULOJIX,hyperkalemia,hyperkalemia and leukopenia The,1
NULOJIX,hyperkalemia,pyrexia graft dysfunction cough nausea vomiting headache hypokalemia,0
NULOJIX,leukopenia,leukopenia The proportion of,1
NULOJIX,cytomegalovirus infection,infection and complications of,1
NULOJIX,cytomegalovirus infection,infection and complications of,1
NULOJIX,cytomegalovirus infection,reactions leading to,0
NULOJIX,cytomegalovirus infection,cytomegalovirus infection and complications of,1
NULOJIX,complications of transplanted kidney,during clinical,0
NULOJIX,complications of transplanted kidney,complications of transplanted kidney Information on selected,1
NULOJIX,PTLD,Disorder Reported,0
NULOJIX,PTLD,PTLD up to months,1
NULOJIX,PTLD,PTLD up to months,1
NULOJIX,PTLD,NULOJIX by pooling both dosage regimens,0
NULOJIX,PTLD,by pooling both dosage regimens of NULOJ,0
NULOJIX,PTLD,posttransplant,0
NULOJIX,PTLD,Reported cases of posttransplant,0
NULOJIX,PTLD,both dosage regimens,0
NULOJIX,PTLD,Lymphoproliferative Disorder Reported cases,0
NULOJIX,PTLD,PTLD up to months,1
NULOJIX,PTLD,PTLD in EBV seropositive,1
NULOJIX,PTLD,of,0
NULOJIX,PTLD,,0
NULOJIX,PTLD,in EBV seronegative patients Two of the cases presented wi,0
NULOJIX,PTLD,NULOJIX regimen there were,0
NULOJIX,PTLD,and in,0
NULOJIX,PTLD,with cyclosporine,0
NULOJIX,PTLD,treated with cyclosporine PTLD without CNS involvement,1
NULOJIX,PTLD,,0
NULOJIX,PTLD,PTLD without CNS involvement,1
NULOJIX,PTLD,PTLD without CNS involvement,1
NULOJIX,PTLD,cyclosporine developed PTLD without CNS involvement All cases,0
NULOJIX,PTLD,without CNS involvement All cases of,0
NULOJIX,PTLD,NULOJIX or cyclosporinetreated patients presented,0
NULOJIX,PTLD,PTLD Reported in Studies,1
NULOJIX,PTLD,,0
NULOJIX,PTLD,Boxed Warning and Contraindications,0
NULOJIX,PTLD,of,0
NULOJIX,CNS PTLD,different in Study CNS,1
NULOJIX,CNS PTLD,CNS PTLD,1
NULOJIX,CNS PTLD,CNS PTLD,1
NULOJIX,CNS PTLD,,0
NULOJIX,CNS PTLD,,0
NULOJIX,CNS PTLD,CNS PTLD,1
NULOJIX,CNS PTLD,Study CNS PTLD,1
NULOJIX,Non-CNSPTLD,,0
NULOJIX,Non-CNSPTLD,Non-CNSPTLD,1
NULOJIX,CNS PTLD,CNS PTLD,1
NULOJIX,CNS PTLD,,0
NULOJIX,Non-CNSPTLD,,0
NULOJIX,Non-CNSPTLD,,0
NULOJIX,Non-CNSPTLD,Non-CNSPTLD,1
NULOJIX,Non-CNSPTLD,Non-CNSPTLD,1
NULOJIX,Non-CNSPTLD,Non-CNSPTLD,1
NULOJIX,Non-CNSPTLD,Non-CNSPTLD,1
NULOJIX,Non-CNSPTLD,,0
NULOJIX,Non-CNSPTLD,Non-CNSPTLD,1
NULOJIX,PTLD,,0
NULOJIX,PTLD,PTLD,1
NULOJIX,PTLD,PTLD,1
NULOJIX,PTLD,The clinical significance of CMV serology,0
NULOJIX,PTLD,PTLD,1
NULOJIX,PTLD,however,0
NULOJIX,PTLD,PTLD,1
NULOJIX,PTLD,as a risk,0
NULOJIX,PTLD,CMV,0
NULOJIX,Malignancies,and Study in,0
NULOJIX,Malignancies,nonmelanoma skin cancer and PTLD were reported in,0
NULOJIX,non-melanoma skin cancer,non-melanoma skin cancer,1
NULOJIX,non-melanoma skin cancer,Precautions Other Malignancies Malignancies non-melanoma skin cancer,1
NULOJIX,non-melanoma skin cancer,Precautions Other Malignancies Malignancies non-melanoma skin cancer,1
NULOJIX,non-melanoma skin cancer,Malignancies,0
NULOJIX,non-melanoma skin cancer,Study in of patients treated,0
NULOJIX,non-melanoma skin cancer,Study and Study in of patients,0
NULOJIX,non-melanoma skin cancer,were reported in Study,0
NULOJIX,PTLD,cancer and,0
NULOJIX,Non-melanoma skin cancer,Non-melanoma skin cancer,1
NULOJIX,Non-melanoma skin cancer,the cyclosporine control Non-melanoma skin cancer,1
NULOJIX,Non-melanoma skin cancer,skin cancer,1
NULOJIX,Non-melanoma skin cancer,control Non-melanoma skin cancer,1
NULOJIX,Non-melanoma skin cancer,recommended NULOJIX regimen and in,0
NULOJIX,Non-melanoma skin cancer,skin cancer,1
NULOJIX,Non-melanoma skin cancer,regimen and,0
NULOJIX,Non-melanoma skin cancer,cancer,1
NULOJIX,Non-melanoma skin cancer,and,0
NULOJIX,Non-melanoma skin cancer,cyclosporine control Non-melanoma skin cancer,1
NULOJIX,fatal,fatal,1
NULOJIX,fatal,and Precautions,0
NULOJIX,fatal,fatal,1
NULOJIX,fatal,Warnings and Precautions,0
NULOJIX,fatal,,0
NULOJIX,fatal,Multifocal,0
NULOJIX,fatal,Progressive,0
NULOJIX,fatal,reported among patients,0
NULOJIX,fatal,fatal,1
NULOJIX,progressive multifocal leukoencephalopathy,Two fatal cases progressive multifocal leukoencephalopathy,1
NULOJIX,progressive multifocal leukoencephalopathy,fatal cases progressive multifocal leukoencephalopathy,1
NULOJIX,PML,PML,1
NULOJIX,PML,,0
NULOJIX,PML,cases of progressive multifocal PML,1
NULOJIX,PML,,0
NULOJIX,PML,PML,1
NULOJIX,PML,cases PML,1
NULOJIX,PML,,0
NULOJIX,PML,,0
NULOJIX,PML,PML,1
NULOJIX,PML,NULOJIX regimen or the control regimen in th,0
NULOJIX,PML,of patients No cases PML,1
NULOJIX,PML,one patient in a trial of liver transplant trial of patients,0
NULOJIX,infectious etiology,reported,0
NULOJIX,infections,infections,1
NULOJIX,infections,infections,1
NULOJIX,infections,the physician The overall,0
NULOJIX,infections,infections,1
NULOJIX,infections,infections,1
NULOJIX,infections,number infections,1
NULOJIX,infections,The overall number of,0
NULOJIX,infections,infections,1
NULOJIX,infections,reported in,0
NULOJIX,infections,infections,1
NULOJIX,infections,infections,1
NULOJIX,infections,infections,1
NULOJIX,infections,infections,1
NULOJIX,infections,infections,1
NULOJIX,infections,number of infections,0
NULOJIX,infections,the,0
NULOJIX,Fungal infections,and are shown in,0
NULOJIX,Fungal infections,are shown in Table,0
NULOJIX,Fungal infections,are shown in Fungal,1
NULOJIX,Fungal infections,are shown in Fungal infections,1
NULOJIX,Fungal infections,recommended regimen or the cyclosporine control in Studies and are shown,0
NULOJIX,Fungal infections,are shown in Fungal,1
NULOJIX,Fungal infections,shown in Fungal,1
NULOJIX,Fungal infections,in Fungal infections,1
NULOJIX,mucocutaneous fungal infections,skin mucocutaneous,1
NULOJIX,mucocutaneous fungal infections,tha,0
NULOJIX,mucocutaneous fungal infections,skin mucocutaneous fungal infections,1
NULOJIX,mucocutaneous fungal infections,infections,1
NULOJIX,Tuberculosis,and,0
NULOJIX,herpes infections,,0
NULOJIX,herpes infections,mucocutaneous,0
NULOJIX,herpes infections,cyclosporine primarily due to skin,0
NULOJIX,herpes infections,infections Tuberculosis herpes infections,1
NULOJIX,herpes infections,Tuberculosis herpes,1
NULOJIX,tuberculosis,tuberculosis,1
NULOJIX,tuberculosis,more frequently in patients receiving,0
NULOJIX,tuberculosis,tuberculosis,1
NULOJIX,tuberculosis,prevalence,0
NULOJIX,tuberculosis,tuberculosis,1
NULOJIX,tuberculosis,tuberculosis,1
NULOJIX,tuberculosis,the patients who tuberculosis,1
NULOJIX,Infections,Overall,0
NULOJIX,Infections,Infections,1
NULOJIX,Infections,Infections,1
NULOJIX,Infections,Infections,1
NULOJIX,Infections,Infections,1
NULOJIX,Infections,Group following,0
NULOJIX,Infections,Select,0
NULOJIX,Infections,,0
NULOJIX,Infections,,0
NULOJIX,Infections,Overall Infections and Infections,1
NULOJIX,Infections,Etiology by Treatment Group following One and Three Years of Treatment,0
NULOJIX,Infections,by Treatment Group following One and Three Years,0
NULOJIX,infections,infectious adverse reactions,0
NULOJIX,infections,and,0
NULOJIX,infections,fungal and other organisms For infectious adverse reactions,0
NULOJIX,infections,causat,0
NULOJIX,infections,infections,1
NULOJIX,infectious adverse reactions,and other organisms infectious adverse reactions,1
NULOJIX,infectious adverse reactions,organisms infectious adverse reactions,1
NULOJIX,death,death,1
NULOJIX,Infections,existing Infections,1
NULOJIX,Infections,considered nonserious BK virusassociated,0
NULOJIX,Infections,,0
NULOJIX,Infections,virusassociated nephropathy was re,0
NULOJIX,Infections,prolongation of existing Infections,1
NULOJIX,BK virus-associated nephropathy,nephropathy,1
NULOJIX,herpes infections,herpes,1
NULOJIX,herpes infections,loss by Year herpes infections,1
NULOJIX,herpes infections,herpes,1
NULOJIX,herpes infections,nonserious and led,0
NULOJIX,herpes infections,graft loss by Year herpes,1
NULOJIX,herpes infections,herpes infections,1
NULOJIX,herpes infections,graft loss by Year herpes,1
NULOJIX,herpes infections,cyclosporine patients none of which resulted in graft loss by Year Most,0
NULOJIX,herpes infections,patients none of which resulted in graft loss by Year Most,0
NULOJIX,infections,infections,1
NULOJIX,infections,treatment discontinuation All,0
NULOJIX,infections,infections,1
NULOJIX,infections,,0
NULOJIX,infections,,0
NULOJIX,infections,were nonserious and led to,0
NULOJIX,infections,were nonserious and led to treatment discontinuation All,0
NULOJIX,infections,,0
NULOJIX,infections,infections,1
NULOJIX,infections,infections S CMV,1
NULOJIX,infections,Serious,0
NULOJIX,infections,Serious,0
NULOJIX,infections,Serious infections S,1
NULOJIX,infections,Serious infections S,1
NULOJIX,infections,Serious infections S CMV,1
NULOJIX,infections,infections,1
NULOJIX,infections,,0
NULOJIX,infections,Serious,0
NULOJIX,infections,infections S,1
NULOJIX,Tuberculosis,,0
NULOJIX,Tuberculosis,,0
NULOJIX,cryptococcal meningitis,of treatment in Studies cryptococcal,1
NULOJIX,cryptococcal meningitis,Studies cryptococcal meningitis,1
NULOJIX,cryptococcal meningitis,,0
NULOJIX,cryptococcal meningitis,in Studies cryptococcal meningitis,1
NULOJIX,CNS infections,CNS infections,1
NULOJIX,CNS infections,were reported to have CNS,1
NULOJIX,CNS infections,CNS infections,1
NULOJIX,CNS infections,than recommended in Studies and were reported to have,0
NULOJIX,CNS infections,infections,1
NULOJIX,CNS infections,CNS,1
NULOJIX,CNS infections,infections,1
NULOJIX,CNS infections,were reported to have CNS,1
NULOJIX,CNS infections,CNS infections,1
NULOJIX,CNS infections,recommended in Studies,0
NULOJIX,Chagas encephalitis,cases of cryptococcal meningitis one case,0
NULOJIX,Chagas encephalitis,,0
NULOJIX,Chagas encephalitis,cases of cryptococcal,0
NULOJIX,Chagas encephalitis,,0
NULOJIX,Chagas encephalitis,Chagas,1
NULOJIX,Chagas encephalitis,Chagas encephalitis,1
NULOJIX,Chagas encephalitis,,0
NULOJIX,cryptococcal meningitis,Chagas encephalitis,0
NULOJIX,cryptococcal meningitis,of cryptococcal meningitis one case of Chagas encephalitis,0
NULOJIX,cryptococcal meningitis,Chagas encephalitis,0
NULOJIX,cryptococcal meningitis,case of West Nile encephalitis and one case of,0
NULOJIX,cryptococcal meningitis,case of Chagas encephalitis cryptococcal,1
NULOJIX,cryptococcal meningitis,Chagas encephalitis cryptococcal,1
NULOJIX,cryptococcal meningitis,case of Chagas encephalitis cryptococcal meningitis,1
NULOJIX,cryptococcal meningitis,with,0
NULOJIX,cryptococcal meningitis,,0
NULOJIX,cerebral aspergillosis,cerebral aspergillosis,1
NULOJIX,cerebral aspergillosis,meningitis one,0
NULOJIX,cerebral aspergillosis,aspergillosis,1
NULOJIX,West Nile encephalitis,one case West Nile encephalitis,1
NULOJIX,West Nile encephalitis,,0
NULOJIX,West Nile encephalitis,West Nile encephalitis,1
NULOJIX,West Nile encephalitis,cryptococcal meningitis one case of cerebral aspergillosis one,0
NULOJIX,West Nile encephalitis,with cryptococcal meningitis one case of cerebral aspergillosis one case,0
NULOJIX,West Nile encephalitis,aspergillosis one case West Nile,1
NULOJIX,West Nile encephalitis,case West Nile,1
NULOJIX,West Nile encephalitis,cerebral aspergillosis one case West Nile,1
NULOJIX,West Nile encephalitis,,0
NULOJIX,West Nile encephalitis,There were no reports of anaphy,0
NULOJIX,PML,one,0
NULOJIX,PML,and one case PML,1
NULOJIX,PML,PML,1
NULOJIX,PML,Infusion Reactions,0
NULOJIX,anaphylaxis,reports anaphylaxis,1
NULOJIX,anaphylaxis,hypersensitivity in patients treated with NULOJIX in,0
NULOJIX,anaphylaxis,anaphylaxis,1
NULOJIX,anaphylaxis,anaphylaxis,1
NULOJIX,anaphylaxis,anaphylaxis,1
NULOJIX,anaphylaxis,anaphylaxis,1
NULOJIX,drug hypersensitivity,,0
NULOJIX,drug hypersensitivity,no reports of anaphylaxis drug,1
NULOJIX,drug hypersensitivity,drug hypersensitivity,1
NULOJIX,drug hypersensitivity,reports of anaphylaxis drug hypersensitivity,1
NULOJIX,Infusion-related reactions,Infusion-related,1
NULOJIX,Infusion-related reactions,Infusion-related reactions,1
NULOJIX,Infusion-related reactions,,0
NULOJIX,Infusion-related reactions,three Infusion-related,1
NULOJIX,Infusion-related reactions,patients treated with NULOJIX in Studies,0
NULOJIX,Infusion-related reactions,and through three Infusion-related reactions,1
NULOJIX,Infusion-related reactions,Studies and through three Infusion-related,1
NULOJIX,Infusion-related reactions,one hour of infusion were reported,0
NULOJIX,Infusion-related reactions,in patients treated with NULOJIX,0
NULOJIX,proteinuria,regimen was,0
NULOJIX,proteinuria,proteinuria,1
NULOJIX,proteinuria,proteinuria,1
NULOJIX,proteinuria,,0
NULOJIX,proteinuria,and,0
NULOJIX,proteinuria,treated with,0
NULOJIX,proteinuria,,0
NULOJIX,proteinuria,proteinuria,1
NULOJIX,proteinuria,proteinuria,1
NULOJIX,proteinuria,regimen The frequency proteinuria,1
NULOJIX,proteinuria,proteinuria,1
NULOJIX,proteinuria,,0
NULOJIX,proteinuria,of,0
NULOJIX,proteinuria,after,0
NULOJIX,proteinuria,proteinuria,1
NULOJIX,proteinuria,The frequency proteinuria,1
NULOJIX,proteinuria,of,0
NULOJIX,proteinuria,proteinuria,1
NULOJIX,proteinuria,proteinuria in both studies at any time point and no,0
NULOJIX,proteinuria,in early proteinuria,0
NULOJIX,proteinuria,,0
NULOJIX,proteinuria,point and no,0
NULOJIX,proteinuria,significance of this increase in early,0
NULOJIX,proteinuria,proteinuria,1
NULOJIX,proteinuria,,0
NULOJIX,proteinuria,proteinuria,1
NULOJIX,proteinuria,proteinuria,1
NULOJIX,proteinuria,time point,0
NULOJIX,early proteinuria,,0
NULOJIX,early proteinuria,Immunogenicity Antibodies directed against the belatacept molecule were assess,0
NULOJIX,early proteinuria,,0
NULOJIX,early proteinuria,point and no patients,0
NULOJIX,early proteinuria,of this increase early,1
NULOJIX,early proteinuria,experienced proteinuria The clinical significance of this,0
NULOJIX,early proteinuria,early proteinuria,1
NULOJIX,early proteinuria,of this increase early proteinuria,1
NULOJIX,early proteinuria,this increase early,1
NULOJIX,new-onset diabetes after transplantation,may be misleading NewOnset Diabetes After,0
NULOJIX,new-onset diabetes after transplantation,use of an antidiabetic agent for days or,0
NULOJIX,new-onset diabetes after transplantation,an antidiabetic,0
NULOJIX,new-onset diabetes after transplantation,incidence of,0
NULOJIX,new-onset diabetes after transplantation,The,0
NULOJIX,new-onset diabetes after transplantation,After Transplantation The incidence new-onset diabetes after transplantation,1
NULOJIX,new-onset diabetes after transplantation,diabetes after transplantation,1
NULOJIX,NODAT,diabetes after NODAT,1
NULOJIX,NODAT,incidence,0
NULOJIX,NODAT,the NULOJIX recommended regimen NODAT,1
NULOJIX,NODAT,NODAT,1
NULOJIX,NODAT,NODAT,1
NULOJIX,NODAT,recommended regimen,0
NULOJIX,NODAT,regimen NODAT,1
NULOJIX,NODAT,regimen NODAT,1
NULOJIX,NODAT,compared to of patients,0
NULOJIX,NODAT,NODAT,1
NULOJIX,NODAT,treated with the NULOJIX recommended regimen,0
NULOJIX,Hypertension,of NULOJIXtreated patients and of,0
NULOJIX,Hypertension,Hypertension,1
NULOJIX,Hypertension,Hypertension,1
NULOJIX,Hypertension,cyclosporinetreated,0
NULOJIX,Urinary tract infection,Infestations,0
NULOJIX,Urinary tract infection,,0
NULOJIX,Urinary tract infection,Urinary tract,1
NULOJIX,Upper respiratory infection,Upper respiratory infection Nasopharyngitis,1
NULOJIX,Upper respiratory infection,,0
NULOJIX,Upper respiratory infection,Nasopharyngitis,0
NULOJIX,Upper respiratory infection,,0
NULOJIX,Upper respiratory infection,,0
NULOJIX,Upper respiratory infection,ract Upper,1
NULOJIX,Upper respiratory infection,,0
NULOJIX,Upper respiratory infection,Upper respiratory infection Nasopharyngitis,1
NULOJIX,Nasopharyngitis,Cytome,0
NULOJIX,Nasopharyngitis,,0
NULOJIX,Nasopharyngitis,,0
NULOJIX,Nasopharyngitis,,0
NULOJIX,Nasopharyngitis,,0
NULOJIX,Cytomegalovirus infection,Cytomegalovirus infection Influenza,1
NULOJIX,Cytomegalovirus infection,ngitis Cytomegalovirus,1
NULOJIX,Influenza,Influenza,1
NULOJIX,Influenza,,0
NULOJIX,Influenza,,0
NULOJIX,Bronchitis,Gastr,0
NULOJIX,Bronchitis,,0
NULOJIX,Bronchitis,,0
NULOJIX,Bronchitis,Bronchitis Gastr,1
NULOJIX,Bronchitis,,0
NULOJIX,Bronchitis,Bronchitis Gastr,1
NULOJIX,Bronchitis,Bronchitis Gastr,1
NULOJIX,Diarrhea,Diarrhea,1
NULOJIX,Diarrhea,,0
NULOJIX,Diarrhea,,0
NULOJIX,Constipation,,0
NULOJIX,Constipation,,0
NULOJIX,Constipation,,0
NULOJIX,Constipation,Constipation Nau,1
NULOJIX,Constipation,,0
NULOJIX,Constipation,Constipation Nau,1
NULOJIX,Constipation,,0
NULOJIX,Nausea,,0
NULOJIX,Nausea,Nausea,1
NULOJIX,Nausea,Nausea,1
NULOJIX,Nausea,Nausea,1
NULOJIX,Vomiting,Vomiting,1
NULOJIX,Vomiting,Vomiting,1
NULOJIX,Vomiting,,0
NULOJIX,Vomiting,,0
NULOJIX,Vomiting,Vomiting,1
NULOJIX,Vomiting,,0
NULOJIX,Abdominal pain,Abdominal pain Abdom,1
NULOJIX,Abdominal pain,Abdom,0
NULOJIX,Abdominal pain,,0
NULOJIX,Abdominal pain,,0
NULOJIX,Abdominal pain,Abdominal,1
NULOJIX,Abdominal pain,,0
NULOJIX,Abdominal pain,,0
NULOJIX,Abdominal pain,Abdominal,1
NULOJIX,Abdominal pain,,0
NULOJIX,Abdominal pain upper,pain,0
NULOJIX,Abdominal pain upper,pain,0
NULOJIX,Abdominal pain upper,pain Abdominal,1
NULOJIX,Abdominal pain upper,pain Abdominal pain upper Metabolism and,1
NULOJIX,Abdominal pain upper,Metabolism,0
NULOJIX,Abdominal pain upper,pain,0
NULOJIX,Abdominal pain upper,pain Abdominal pain upper,1
NULOJIX,Hyperkalemia,d Nutrition Hyperkalemia Hyp,1
NULOJIX,Hypokalemia,Hypokalemia Hy,1
NULOJIX,Hypokalemia,mia,0
NULOJIX,Hypokalemia,,0
NULOJIX,Hypokalemia,Hypokalemia Hy,1
NULOJIX,Hypokalemia,Hypokalemia Hy,1
NULOJIX,Hypokalemia,mia,0
NULOJIX,Hypophosphatemia,Hypophosphatemia Dyslipi,1
NULOJIX,Hyperglycemia,mia,0
NULOJIX,Hypocalcemia,,0
NULOJIX,Hypocalcemia,emia,0
NULOJIX,Hypocalcemia,,0
NULOJIX,Hypocalcemia,emia,0
NULOJIX,Hypocalcemia,emia Hypocalcemia Hyp,1
NULOJIX,Hypercholesterolemia,Hypercholesterolemia Hypomagnese,1
NULOJIX,Hypercholesterolemia,,0
NULOJIX,Hypercholesterolemia,mia Hypercholesterolemia Hypomagnese,1
NULOJIX,Hypercholesterolemia,,0
NULOJIX,Hypomagnesemia,esterolemia,0
NULOJIX,Hypomagnesemia,,0
NULOJIX,Hypomagnesemia,esterolemia Hypomagnesemia Hyper,1
NULOJIX,Hypomagnesemia,Hypomagnesemia Hyper,1
NULOJIX,Hypomagnesemia,esterolemia Hypomagnesemia Hyper,1
NULOJIX,Hypomagnesemia,esterolemia,0
NULOJIX,Hypomagnesemia,esterolemia,0
NULOJIX,Hyperuricemia,Procedur,0
NULOJIX,Hyperuricemia,semia Hyperuricemia Procedur,1
NULOJIX,Hyperuricemia,Hyperuricemia Procedur,1
NULOJIX,Graft dysfunction,mplications Graft dysfunction General Diso,1
NULOJIX,Graft dysfunction,General,0
NULOJIX,Peripheral edema,Pyrexia,0
NULOJIX,Peripheral edema,ders,0
NULOJIX,Pyrexia,Bl,0
NULOJIX,Pyrexia,Bl,0
NULOJIX,Pyrexia,l Pyrexia Bl,1
NULOJIX,Pyrexia,Pyrexia Bl,1
NULOJIX,Pyrexia,Pyrexia Bl,1
NULOJIX,Pyrexia,Pyrexia Bl,1
NULOJIX,Pyrexia,edema,0
NULOJIX,Pyrexia,Pyrexia Bl,1
NULOJIX,Pyrexia,,0
NULOJIX,Proteinuria,Proteinuria Dy,1
NULOJIX,Proteinuria,,0
NULOJIX,Proteinuria,,0
NULOJIX,Proteinuria,Proteinuria Dy,1
NULOJIX,Proteinuria,Proteinuria Dy,1
NULOJIX,Dysuria,,0
NULOJIX,Dysuria,ia Dysuria,1
NULOJIX,Dysuria,ia,0
NULOJIX,Renal tubular necrosis,Renal tubular necrosis Vascular Disorder,1
NULOJIX,Renal tubular necrosis,,0
NULOJIX,Renal tubular necrosis,Renal tubular necrosis Vascular,1
NULOJIX,Renal tubular necrosis,,0
NULOJIX,Renal tubular necrosis,Renal,1
NULOJIX,Renal tubular necrosis,,0
NULOJIX,Renal tubular necrosis,Renal tubular,1
NULOJIX,Renal tubular necrosis,,0
NULOJIX,Renal tubular necrosis,Renal tubular necrosis,1
NULOJIX,Hypertension,Hypertension Hyp,1
NULOJIX,Hypertension,,0
NULOJIX,Hypertension,Hypertension Hyp,1
NULOJIX,Hypertension,Hypertension Hyp,1
NULOJIX,Hypertension,Hypertension Hyp,1
NULOJIX,Hypertension,rders,0
NULOJIX,Hypertension,Hypertension Hyp,1
NULOJIX,Hypotension,ion Hypotension Respir,1
NULOJIX,Hypotension,Respir,0
NULOJIX,Hypotension,ion,0
NULOJIX,Hypotension,ion Hypotension Respir,1
NULOJIX,Hypotension,Hypotension Respir,1
NULOJIX,Hypotension,ion Hypotension Respir,1
NULOJIX,Hypotension,ion,0
NULOJIX,Hypotension,,0
NULOJIX,Cough,Cough,1
NULOJIX,Cough,Cough,1
NULOJIX,Cough,Cough,1
NULOJIX,Cough,Cough,1
NULOJIX,Cough,Cough,1
NULOJIX,Cough,,0
NULOJIX,Dyspnea,Dyspnea In,1
NULOJIX,Dyspnea,Dyspnea In,1
NULOJIX,Dyspnea,Dyspnea In,1
NULOJIX,Dyspnea,Dyspnea In,1
NULOJIX,Dyspnea,,0
NULOJIX,Dyspnea,Dyspnea In,1
NULOJIX,Dyspnea,,0
NULOJIX,Dyspnea,,0
NULOJIX,Blood creatinine increased,s Blood creatinine increased,1
NULOJIX,Blood creatinine increased,Musculoskeletal and C,0
NULOJIX,Blood creatinine increased,s,0
NULOJIX,Blood creatinine increased,creatinine increased,1
NULOJIX,Arthralgia,,0
NULOJIX,Arthralgia,Arthralgia B,1
NULOJIX,Arthralgia,,0
NULOJIX,Back pain,a,0
NULOJIX,Back pain,,0
NULOJIX,Back pain,a,0
NULOJIX,Back pain,a Back,1
NULOJIX,Back pain,a,0
NULOJIX,Back pain,a,0
NULOJIX,Headache,,0
NULOJIX,Headache,Disorders,0
NULOJIX,Headache,,0
NULOJIX,Headache,Headache,1
NULOJIX,Headache,,0
NULOJIX,Headache,Disorders,0
NULOJIX,Headache,,0
NULOJIX,Dizziness,,0
NULOJIX,Tremor,,0
NULOJIX,Tremor,Tremor S,1
NULOJIX,Tremor,Tremor S,1
NULOJIX,Tremor,,0
NULOJIX,Acne,,0
NULOJIX,Acne,Acne,1
NULOJIX,Acne,,0
NULOJIX,Acne,Tissue,0
NULOJIX,Acne,Tissue,0
NULOJIX,Insomnia,isorders,0
NULOJIX,Insomnia,isorders,0
NULOJIX,Insomnia,isorders,0
NULOJIX,Insomnia,Insomnia,1
NULOJIX,Insomnia,isorders Insomnia,1
NULOJIX,Insomnia,isorders Insomnia,1
NULOJIX,Insomnia,Insomnia,1
NULOJIX,Insomnia,,0
NULOJIX,Insomnia,,0
NULOJIX,Guillain-Barre syndrome,Guillain-Barre syndrome,1
NULOJIX,Guillain-Barre syndrome,Immune System Guillain-Barre syndrome,1
NULOJIX,Guillain-Barre syndrome,Guillain-Barre syndrome,1
NULOJIX,Guillain-Barre syndrome,,0
NULOJIX,stomatitis,stomatitis,1
NULOJIX,stomatitis,Infections and Infestations see,0
NULOJIX,stomatitis,stomatitis,1
NULOJIX,stomatitis,Gastrointestinal Disorders,0
NULOJIX,aphthous stomatitis,,0
NULOJIX,aphthous stomatitis,Table Gastrointestinal Disorders stomatitis aphthous stomatitis,1
NULOJIX,aphthous stomatitis,stomatitis,1
NULOJIX,aphthous stomatitis,Gastrointestinal Disorders stomatitis aphthous,1
NULOJIX,aphthous stomatitis,,0
NULOJIX,aphthous stomatitis,aphthous stomatitis,1
NULOJIX,chronic allograft nephropathy,,0
NULOJIX,chronic allograft nephropathy,,0
NULOJIX,chronic allograft nephropathy,Procedural chronic allograft nephropathy,1
NULOJIX,chronic allograft nephropathy,Complications,0
NULOJIX,chronic allograft nephropathy,,0
NULOJIX,chronic allograft nephropathy,arteriovenous fistula thrombosis,0
NULOJIX,complications of transplanted kidney,chronic allograft complications of,1
NULOJIX,complications of transplanted kidney,Procedural Complications chronic allograft complications of,1
NULOJIX,complications of transplanted kidney,nephropathy,0
NULOJIX,complications of transplanted kidney,chronic allograft complications of transplanted,1
NULOJIX,complications of transplanted kidney,Complications chronic allograft complications of transplanted,1
NULOJIX,complications of transplanted kidney,,0
NULOJIX,complications of transplanted kidney,Procedural Complications chronic allograft nephropathy,0
NULOJIX,complications of transplanted kidney,allograft complications of,1
NULOJIX,complications of transplanted kidney,Poisoning and Procedural Complications chronic allograft,0
NULOJIX,complications of transplanted kidney,,0
NULOJIX,wound dehiscence,including,0
NULOJIX,wound dehiscence,Disorders neutropenia,0
NULOJIX,wound dehiscence,Disorders,0
NULOJIX,wound dehiscence,wound,1
NULOJIX,wound dehiscence,,0
NULOJIX,wound dehiscence,complications of transplanted kidney wound,1
NULOJIX,wound dehiscence,,0
NULOJIX,arteriovenous fistula thrombosis,,0
NULOJIX,arteriovenous fistula thrombosis,arteriovenous fistula thrombosis,1
NULOJIX,arteriovenous fistula thrombosis,thrombosis,1
NULOJIX,arteriovenous fistula thrombosis,transplanted kidney including wound arteriovenous fistula thrombosis,1
NULOJIX,arteriovenous fistula thrombosis,including wound,0
NULOJIX,arteriovenous fistula thrombosis,including wound dehiscence,0
NULOJIX,arteriovenous fistula thrombosis,transplanted kidney including wound arteriovenous fistula,1
NULOJIX,arteriovenous fistula thrombosis,Blood and Lymphatic System Disorders neutropenia,0
NULOJIX,neutropenia,Blood and Lymphatic System Disorders,0
NULOJIX,neutropenia,Disorders renal impairment including acute renal failure renal,0
NULOJIX,neutropenia,thrombosis Blood and Lymphatic System Disorders,0
NULOJIX,neutropenia,neutropenia,1
NULOJIX,neutropenia,neutropenia,1
NULOJIX,neutropenia,neutropenia,1
NULOJIX,renal impairment,renal,1
NULOJIX,acute renal failure,Disorders renal impairment acute renal failure,1
NULOJIX,acute renal failure,impairment acute renal failure,1
NULOJIX,acute renal failure,urinary incontinence hydronephrosis Vascular,0
NULOJIX,acute renal failure,Disorders renal impairment acute renal failure,1
NULOJIX,acute renal failure,impairment acute renal failure,1
NULOJIX,acute renal failure,Urinary Disorders renal impairment acute renal failure,1
NULOJIX,acute renal failure,impairment acute renal failure,1
NULOJIX,acute renal failure,renal impairment acute renal,1
NULOJIX,renal artery stenosis,renal artery stenosis,1
NULOJIX,renal artery stenosis,urinary incontinence hydronephrosis Vascular,0
NULOJIX,renal artery stenosis,Vascular,0
NULOJIX,renal artery stenosis,acute renal failure,0
NULOJIX,renal artery stenosis,Disorders hematoma,0
NULOJIX,renal artery stenosis,,0
NULOJIX,renal artery stenosis,renal,0
NULOJIX,renal artery stenosis,hematoma,0
NULOJIX,renal artery stenosis,including acute renal renal,1
NULOJIX,urinary incontinence,failure renal artery urinary incontinence,1
NULOJIX,urinary incontinence,urinary incontinence,1
NULOJIX,urinary incontinence,failure renal artery urinary,1
NULOJIX,urinary incontinence,renal failure renal artery urinary incontinence,1
NULOJIX,urinary incontinence,lymphocele Musculoskeletal and,0
NULOJIX,hydronephrosis,,0
NULOJIX,hydronephrosis,hydronephrosis,1
NULOJIX,hydronephrosis,,0
NULOJIX,hydronephrosis,hydronephrosis,1
NULOJIX,hydronephrosis,,0
NULOJIX,hematoma,Musculoskeletal and Connective,0
NULOJIX,hematoma,artery stenosis urinary incontinence,0
NULOJIX,hematoma,failure renal artery stenosis urinary,0
NULOJIX,hematoma,,0
NULOJIX,hematoma,Tissue,0
NULOJIX,hematoma,hematoma,1
NULOJIX,hematoma,hematoma,1
NULOJIX,lymphocele,lymphocele,1
NULOJIX,lymphocele,lymphocele,1
NULOJIX,lymphocele,lymphocele,1
NULOJIX,lymphocele,lymphocele,1
NULOJIX,lymphocele,lymphocele,1
NULOJIX,lymphocele,lymphocele,1
NULOJIX,lymphocele,,0
NULOJIX,lymphocele,Disorders lymphocele,1
NULOJIX,lymphocele,lymphocele,1
NULOJIX,lymphocele,hematoma,0
NULOJIX,musculoskeletal pain,Disorders alopecia hyperhidrosis Cardiac Disorders,0
NULOJIX,musculoskeletal pain,Tissue musculoskeletal pain,1
NULOJIX,musculoskeletal pain,Musculoskeletal and Connective Tissue musculoskeletal,1
NULOJIX,musculoskeletal pain,,0
NULOJIX,musculoskeletal pain,Connective Tissue musculoskeletal pain,1
NULOJIX,musculoskeletal pain,and Connective Tissue musculoskeletal pain,1
NULOJIX,musculoskeletal pain,musculoskeletal pain,1
NULOJIX,musculoskeletal pain,Connective Tissue musculoskeletal,1
NULOJIX,musculoskeletal pain,Musculoskeletal and Connective Tissue musculoskeletal,1
NULOJIX,alopecia,alopecia,1
NULOJIX,hyperhidrosis,,0
NULOJIX,hyperhidrosis,hyperhidrosis,1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,,0
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,wit h NULOJIX,1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,reactions reported wit h NULOJIX are PTLD predominantly,1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,serious adverse reactions reported wit h NULOJIX,1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,malignancies see Boxed,0
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,most serious adverse reactions reported,1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, most serious adverse reactions reported wit h NULOJIX are PTLD,1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, most serious adverse reactions reported wit h,1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, most serious adverse reactions reported wit h NULOJIX are,1
NULOJIX,MALIGNANCIES,,0
NULOJIX,MALIGNANCIES,"X are:



 * PTLD predominantly CNS PTLD and",1
NULOJIX,MALIGNANCIES,"X are:



 * PTLD predominantly CNS PTLD and",1
NULOJIX,MALIGNANCIES,and Warnings,0
NULOJIX,MALIGNANCIES,"X are:



 * PTLD",1
NULOJIX,MALIGNANCIES,"X are:



 * PTLD predominantly",1
NULOJIX,MALIGNANCIES,,0
NULOJIX,MALIGNANCIES,PTLD and other malignancies see Boxed Warning and Warnings and,0
NULOJIX,INFECTIONS,reported,0
NULOJIX,INFECTIONS,and other malignancies see Boxed Warning and,0
NULOJIX,INFECTIONS,ominantly  CNS PTLD and other malignancies,1
NULOJIX,INFECTIONS,ominantly  CNS PTLD and other malignancies,1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,,0
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,reactions,0
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,PTLD,0
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,nd Warnings and Precautions,0
NULOJIX,MALIGNANCIES,and nings and,1
NULOJIX,MALIGNANCIES,nings,1
NULOJIX,MALIGNANCIES,Pr ecautions Serious infections including JC,1
NULOJIX,MALIGNANCIES,Boxed Warning and War,0
NULOJIX,MALIGNANCIES,and nings and,1
NULOJIX,MALIGNANCIES,Warning and nings and,1
NULOJIX,MALIGNANCIES,including JC virusassociated PML and,0
NULOJIX,MALIGNANCIES,predominantly CNS PTLD,0
NULOJIX,MALIGNANCIES,Warning and,0
NULOJIX,MALIGNANCIES,and nings,1
NULOJIX,INFECTIONS,Serious infections including JC virusassociated PML and,0
NULOJIX,INFECTIONS,", 5.3) Serious infections including JC virusassociated",1
NULOJIX,INFECTIONS,and polyoma virus nephropathy,0
NULOJIX,INFECTIONS,Serious infections including JC,0
NULOJIX,INFECTIONS,JC virusassociated,0
NULOJIX,INFECTIONS,and Warnings and Precautions,0
NULOJIX,post-transplant lymphoproliferative disorder,,0
NULOJIX,post-transplant lymphoproliferative disorder,infections,0
NULOJIX,post-transplant lymphoproliferative disorder,see Warnings and Precautions,0
NULOJIX,post-transplant lymphoproliferative disorder,and Precautions Serious infections ding JC virus-associated PML and polyoma vir us nephropathy see Warnings and,1
NULOJIX,post-transplant lymphoproliferative disorder,Serious infections ding JC,1
NULOJIX,post-transplant lymphoproliferative disorder,Warnings,0
NULOJIX,post-transplant lymphoproliferative disorder,EXCERPT,0
NULOJIX,post-transplant lymphoproliferative disorder,ding JC,1
NULOJIX,post-transplant lymphoproliferative disorder,and,0
NULOJIX,post-transplant lymphoproliferative disorder,see Warnings and,0
NULOJIX,Increased susceptibility to infection,a total of patients t,0
NULOJIX,Increased susceptibility to infection,see Dosage and Administration in a total,0
NULOJIX,Increased susceptibility to infection,,0
NULOJIX,Increased susceptibility to infection,total  patients compared to a cyclosporine  control regimen in a total,1
NULOJIX,Increased susceptibility to infection,total  patients compared to a cyclosporine  control regimen in a total,1
NULOJIX,malignancies,a cyclosporine,0
NULOJIX,malignancies,,0
NULOJIX,malignancies, patients. T hese two trials also included,1
NULOJIX,malignancies,T hese two trials also included,1
NULOJIX,malignancies,regimen in a total patients.,1
NULOJIX,malignancies,trials also included a total of patients treated with a NULOJIX regimen of,0
NULOJIX,malignancies,in a total  patients. T hese two trials also included,1
NULOJIX,malignancies,patients. T hese two trials also included,1
NULOJIX,malignancies,in a total  patients. T hese two trials also included,1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,mofetil and corticosteroids ts were treated,1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,"mycophenolate mofetil and corticosteroids ts were treated and followed for 3 years.


 CNS PTLD PML and other",1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,CNS infections were more frequently observed in,0
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,induction mycophenolate mofetil,0
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,"mofetil and corticosteroids ts were treated and followed for 3 years.


 CNS PTLD PML and other",1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,also received basiliximab induction mycophenolate,0
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,mofetil and corticosteroids ts were treated and,1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,a NULOJI,0
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,induction mycophenolate mofetil and corticosteroids Patien,0
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,PML and,0
NULOJIX,MALIGNANCIES,and followed for,0
NULOJIX,MALIGNANCIES,"followed for years CNS LD, PML, and other CNS infections were more",1
NULOJIX,MALIGNANCIES,PT,0
NULOJIX,MALIGNANCIES,"PML, and other CNS infections were more",1
NULOJIX,INFECTIONS,we re more frequently observed in,1
NULOJIX,INFECTIONS,CNS PTLD PML and,0
NULOJIX,INFECTIONS,and other CNS ections,1
NULOJIX,INFECTIONS,years,0
NULOJIX,INFECTIONS,for,0
NULOJIX,INFECTIONS,we re more frequently observed in,1
NULOJIX,INFECTIONS,ections we re more frequently observed in,1
NULOJIX,INFECTIONS,cumulative,0
NULOJIX,INFECTIONS,and other CNS ections,1
NULOJIX,INFECTIONS,and other CNS ections,1
NULOJIX,post-transplant lymphoproliferative disorder,than the,0
NULOJIX,post-transplant lymphoproliferative disorder,and more frequent osing compared to the recommended regimen; t herefore administration of higher than,1
NULOJIX,post-transplant lymphoproliferative disorder,to the recommended regimen; t herefore administration of higher than,1
NULOJIX,post-transplant lymphoproliferative disorder,,0
NULOJIX,post-transplant lymphoproliferative disorder,and more frequent osing compared to,1
NULOJIX,post-transplant lymphoproliferative disorder,dose and more frequent osing compared to,1
NULOJIX,post-transplant lymphoproliferative disorder,osing,1
NULOJIX,post-transplant lymphoproliferative disorder,more frequent osing compared to the recommended regimen; t herefore administration of higher than,1
NULOJIX,post-transplant lymphoproliferative disorder,observed in association with a NULOJIX regimen of higher cumulative dose and more frequent d,0
NULOJIX,post-transplant lymphoproliferative disorder,compared to the recommended regimen; t herefore administration of higher than,1
NULOJIX,Increased susceptibility to infection,States and 75% from other countries Because clinical trials are conducted,1
NULOJIX,Increased susceptibility to infection,were from the d States and 75%,1
NULOJIX,malignancies,other countries Because clinical,0
NULOJIX,Post-Transplant Lymphoproliferative Disorder,ctions,1
NULOJIX,Post-Transplant Lymphoproliferative Disorder,ctions reported,1
NULOJIX,Post-Transplant Lymphoproliferative Disorder,P TLD,1
NULOJIX,Post-Transplant Lymphoproliferative Disorder,are: * P,1
NULOJIX,Post-Transplant Lymphoproliferative Disorder,,0
NULOJIX,Post-Transplant Lymphoproliferative Disorder,PTLD and other malignancies see Boxed,0
NULOJIX,Post-Transplant Lymphoproliferative Disorder,"ctions reported with NULOJIX are:



 *    P TLD predominantly CNS PTLD and",1
NULOJIX,Post-Transplant Lymphoproliferative Disorder,"ctions reported with NULOJIX are:



 *    P TLD predominantly CNS",1
NULOJIX,Post-Transplant Lymphoproliferative Disorder,predominantly CNS PTLD and other malignancies see Boxed Warning and Warnings and Precau,0
NULOJIX,Post-Transplant Lymphoproliferative Disorder,ctions reported with NULOJIX,1
NULOJIX,PTLD,malignancies see Boxed,0
NULOJIX,PTLD,"NULOJIX are D,",1
NULOJIX,PTLD,"D, p redominantly CNS PTLD",1
NULOJIX,PTLD,most serious adverse reactions reported with NULOJIX are,0
NULOJIX,PTLD,are,0
NULOJIX,malignancies,JC virusassociated PML and,0
NULOJIX,malignancies,Warnings and Precautions EXCERPT Most common adverse rea,0
NULOJIX,malignancies,virusassociated PML and polyoma  nephropathy see Warnings and,1
NULOJIX,malignancies, nephropathy see Warnings and,1
NULOJIX,malignancies, nephropathy see Warnings and,1
NULOJIX,malignancies,polyoma,0
NULOJIX,Progressive Multifocal Leukoencephalopathy,dysfunction cough nausea,0
NULOJIX,Progressive Multifocal Leukoencephalopathy,headache hypokalemia hy,0
NULOJIX,Progressive Multifocal Leukoencephalopathy,"edema, consti pation hypertension pyrexia",1
NULOJIX,Progressive Multifocal Leukoencephalopathy,"edema, consti pation hypertension pyrexia",1
NULOJIX,Progressive Multifocal Leukoencephalopathy,"anemia diarrhea  tract infection, peripheral edema, consti pation hypertension pyrexia",1
NULOJIX,Progressive Multifocal Leukoencephalopathy,"treatment are anemia diarrhea  tract infection, peripheral edema, consti pation hypertension pyrexia",1
NULOJIX,Progressive Multifocal Leukoencephalopathy,"treatment are anemia diarrhea tract infection,",1
NULOJIX,Progressive Multifocal Leukoencephalopathy,"treatment are anemia diarrhea  tract infection, peripheral edema, consti pation hypertension pyrexia",1
NULOJIX,PML,are anemia diarrhea urinary,0
NULOJIX,PML,treatment are anemia diarrhea urinary tract infection,0
NULOJIX,PML,tio n hypertension pyrexia,1
NULOJIX,PML,nausea vomiting headache hypokalemia,0
NULOJIX,PML,pyrexia graft dysfunction,0
NULOJIX,PML,tio n hypertension pyrexia,1
NULOJIX,PML,treatment are anemia diarrhea urinary tract infection peripheral edema constipa,0
NULOJIX,PML,,0
NULOJIX,PML,tio n hypertension pyrexia,1
NULOJIX,infections,ADVERSE REACTIONS contact,0
NULOJIX,infections,-FDA-1088  or wwwfdagovmedwatch Clinical,1
NULOJIX,protozoal infections,wwwfdagovmedwatch cal Studies,1
NULOJIX,protozoal infections,cal Studies Experien ce The data,1
NULOJIX,protozoal infections,cal,1
NULOJIX,protozoal infections,wwwfdagovmedwatch cal Studies,1
NULOJIX,protozoal infections,Experien ce The data,1
NULOJIX,protozoal infections,randomized activecontrolled threeyear tr,0
NULOJIX,protozoal infections,ce The,0
NULOJIX,opportunistic infections,Experience The ta described,1
NULOJIX,opportunistic infections,,0
NULOJIX,tuberculosis,transplant,0
NULOJIX,tuberculosis,novo kidney transplant patien,0
NULOJIX,tuberculosis,,0
NULOJIX,infections,"domized,",1
NULOJIX,infections,data,0
NULOJIX,infections,ran,0
NULOJIX,infections,,0
NULOJIX,infections,"domized,",1
NULOJIX,infections,"two domized,",1
NULOJIX,infections,,0
NULOJIX,infections,a ctivecontrolled threeyear trials,1
NULOJIX,infections,"primarily derive from two domized,",1
NULOJIX,infections,"primarily derive from two domized, a ctivecontrolled threeyear trials",1
NULOJIX,fatal,contr olled threeyear trials,1
NULOJIX,fatal,threeyear trials of NULOJIX in de novo kidney,0
NULOJIX,fatal,contr olled threeyear trials,1
NULOJIX,fatal,contr olled threeyear trials,1
NULOJIX,fatal,contr olled threeyear trials,1
NULOJIX,fatal,,0
NULOJIX,fatal,below primarily derive from two,0
NULOJIX,fatal,contr olled threeyear trials,1
NULOJIX,Polyoma virus-associated nephropathy,of NULOJIX in de novo kidney,1
NULOJIX,Polyoma virus-associated nephropathy,was studied at,0
NULOJIX,Polyoma virus-associated nephropathy,two randomized led three-year trials,1
NULOJIX,Polyoma virus-associated nephropathy,led,1
NULOJIX,Polyoma virus-associated nephropathy,patients In Study and,0
NULOJIX,Polyoma virus-associated nephropathy,two randomized led three-year trials of NULOJIX in  de novo kidney,1
NULOJIX,kidney graft loss,,0
NULOJIX,kidney graft loss,the,0
NULOJIX,kidney graft loss,in de novo ney transplant pa tients In Study,1
NULOJIX,kidney graft loss,ney transplant pa tients In Study,1
NULOJIX,kidney graft loss,dose and frequency,0
NULOJIX,kidney graft loss,,0
NULOJIX,kidney graft loss,pa tients In Study,1
NULOJIX,kidney graft loss,was studied at the recommended dose and frequency see Do,0
NULOJIX,post-transplant lymphoproliferative disorder,a NULOJIX regimen,0
NULOJIX,post-transplant lymphoproliferative disorder,more frequent dosing compared to the r ecommended regimen therefore,1
NULOJIX,post-transplant lymphoproliferative disorder,NULOJIX regimen of,0
NULOJIX,post-transplant lymphoproliferative disorder,administration of higher than the recommended doses andor,0
NULOJIX,post-transplant lymphoproliferative disorder,and more frequent dosing compared to the r ecommended regimen therefore,1
NULOJIX,post-transplant lymphoproliferative disorder,than the,0
NULOJIX,post-transplant lymphoproliferative disorder,of higher cumulative e and more frequent,1
NULOJIX,post-transplant lymphoproliferative disorder,were,0
NULOJIX,post-transplant lymphoproliferative disorder,more frequently observed in association with a NULOJIX regimen of,0
NULOJIX,PTLD,omme nded regimen therefore,1
NULOJIX,PTLD,dosing compared to the omme nded regimen therefore,1
NULOJIX,PTLD,NULOJIX,0
NULOJIX,PTLD,dosing compared to the omme nded regimen therefore,1
NULOJIX,PTLD,a NULOJIX regimen of higher cumulative dose and more frequent dosing compared to,0
NULOJIX,PTLD,reaction rates ed,1
NULOJIX,PTLD,trials and may not reflect the rates observed,0
NULOJIX,malignancies,,0
NULOJIX,PTLD,ativ e dose and,1
NULOJIX,PTLD,and more frequent dosing than recommended there were,0
NULOJIX,PTLD,and treated with the NULOJIX,0
NULOJIX,protozoal infections,,0
NULOJIX,protozoal infections,,0
NULOJIX,opportunistic infections,NonCNSPTLD,0
NULOJIX,opportunistic infections,                         NonCNSPTLD,1
NULOJIX,infections,,0
NULOJIX,infections,           NonCNSPTLD,1
NULOJIX,infections,NonCNSPTLD,0
NULOJIX,infections,           NonCNSPTLD,1
NULOJIX,infections,,0
NULOJIX,infections,           NonCNSPTLD,1
NULOJIX,JC virus,,0
NULOJIX,JC virus,Tot al,1
NULOJIX,JC virus,al (%),1
NULOJIX,polyoma virus-associated nephropathy,Total,0
NULOJIX,polyoma virus-associated nephropathy,Total 0 1,1
NULOJIX,polyoma virus-associated nephropathy,Total         0           1 (1.8)    0     EBV Seropositive Subpopulation Among,1
NULOJIX,polyoma virus-associated nephropathy,Seropositive Subpopulation Among the EBV seropositive,0
NULOJIX,polyoma virus-associated nephropathy,(1.8) 0 EBV Seropositive Subpopulation Among the,1
NULOJIX,polyoma virus-associated nephropathy,Total         0           1 (1.8)    0     EBV Seropositive Subpopulation,1
NULOJIX,polyoma virus-associated nephropathy,EBV seropositive,0
NULOJIX,PVAN,,0
NULOJIX,BK virus infection,Seropositiv e,1
NULOJIX,PVAN,EBV Seropositive Subpopulation ng t he,1
NULOJIX,PVAN,patients with,0
NULOJIX,PVAN,Seropositive Subpopulation,0
NULOJIX,PVAN,ng t he,1
NULOJIX,PVAN,Subpopulation ng,1
NULOJIX,PVAN,Seropositive,0
NULOJIX,PVAN,,0
NULOJIX,PVAN,Subpopulation ng t he,1
NULOJIX,deteriorating renal function,,0
NULOJIX,deteriorating renal function,with known CMV,0
NULOJIX,deteriorating renal function,with known CMV,0
NULOJIX,deteriorating renal function,with eith er,1
NULOJIX,deteriorating renal function,er NULOJIX regimen,0
NULOJIX,kidney graft loss,percent of,0
NULOJIX,kidney graft loss,with either LOJIX,1
NULOJIX,kidney graft loss,percent of CMV seronegative patients developed PTLD compared to,0
NULOJIX,kidney graft loss,with known CMV serostatus treated,0
NULOJIX,kidney graft loss,,0
NULOJIX,kidney graft loss,percent,0
NULOJIX,kidney graft loss,LOJIX regimen in Studies,1
NULOJIX,kidney graft loss,regimen in Studies,1
NULOJIX,kidney graft loss,serostatus treated with either LOJIX regimen in  Studies,1
NULOJIX,graft loss,reported in  1 and Stu dy,1
NULOJIX,graft loss,reported in 1,1
NULOJIX,graft loss,Stu dy,1
NULOJIX,graft loss,1 and Stu dy,1
NULOJIX,graft loss,were reported in 1 and,1
NULOJIX,graft loss,dy in,0
NULOJIX,graft loss,reported in,0
NULOJIX,graft loss,PTLD were reported in 1 and,1
NULOJIX,graft loss,and Stu dy,1
NULOJIX,graft loss,Stu dy,1
NULOJIX,death,and of patients,0
NULOJIX,death,t,0
NULOJIX,death,3. of,1
NULOJIX,death,in Study and in,1
NULOJIX,death,cancer and PTLD,0
NULOJIX,death,3. of,1
NULOJIX,PTLD,skin,0
NULOJIX,PTLD,recommended NULOJIX,0
NULOJIX,PTLD,,0
NULOJIX,PTLD, and of,1
NULOJIX,PTLD, and of,1
NULOJIX,PTLD,with the cyclosporine control regimen Nonmelanoma skin,0
NULOJIX,PTLD,,0
NULOJIX,fatal,regimen Nonmelanoma skin cancer was reported,0
NULOJIX,fatal,patients treated ith t he,1
NULOJIX,fatal,patients,0
NULOJIX,fatal,w,0
NULOJIX,fatal,ith t he,1
NULOJIX,fatal,and of patients treated ith t he,1
NULOJIX,fatal,was reported in,0
NULOJIX,fatal,orine control,1
NULOJIX,PML,patients treated,0
NULOJIX,PML,of patients treated with the cyclosporine control,0
NULOJIX,PML,,0
NULOJIX,PML,reg imen,1
NULOJIX,PML,reg imen,1
NULOJIX,PML,reg imen,1
NULOJIX,fatal,patients treated,0
NULOJIX,fatal, trea ted,1
NULOJIX,fatal, trea ted,1
NULOJIX,fatal,with the recommended NULOJIX regimen,0
NULOJIX,fatal,recommended NULOJIX,0
NULOJIX,fatal,Leuk,0
NULOJIX,fatal, trea ted,1
NULOJIX,fatal,recommended NULOJIX regimen and in,0
NULOJIX,fatal,,0
NULOJIX,PML,in of patients treated cyc losporine,1
NULOJIX,PML,treated with the recommended NULOJIX regimen and in,0
NULOJIX,PML,cyc losporine,1
NULOJIX,PML,treated with the,0
NULOJIX,PML,of patients treated cyc losporine,1
NULOJIX,Graft loss,dosing than reco,0
GILOTRIF,Diarrhea,other sections of the Diarrhea see,1
GILOTRIF,Diarrhea,see Warnings,0
GILOTRIF,Diarrhea,Diarrhea see,1
GILOTRIF,Diarrhea,discussed in greater detail in other sections of,0
GILOTRIF,Diarrhea,and,0
GILOTRIF,Diarrhea,are discussed,0
GILOTRIF,Diarrhea,other sections of the labeling,0
GILOTRIF,Diarrhea,,0
GILOTRIF,Exfoliative Skin Disorders,Exfoliative Skin,1
GILOTRIF,Exfoliative Skin Disorders,Warnings and,0
GILOTRIF,Exfoliative Skin Disorders,,0
GILOTRIF,Exfoliative Skin Disorders,Exfoliative Skin Disorders see,1
GILOTRIF,Exfoliative Skin Disorders,Warnings and,0
GILOTRIF,Exfoliative Skin Disorders,Exfoliative Skin Disorders see,1
GILOTRIF,Exfoliative Skin Disorders,,0
GILOTRIF,Exfoliative Skin Disorders,,0
GILOTRIF,Exfoliative Skin Disorders,,0
GILOTRIF,Keratitis,Keratitis see,1
GILOTRIF,Keratitis,and Keratitis see,1
GILOTRIF,diarrhea,diarrhea rashdermatitis,1
GILOTRIF,diarrhea,stomatitis paronychia,0
GILOTRIF,diarrhea,adverse reactions diarrhea rashdermatitis,1
GILOTRIF,diarrhea,reactions diarrhea rashdermatitis,1
GILOTRIF,diarrhea,diarrhea rashdermatitis,1
GILOTRIF,diarrhea,diarrhea rashdermatitis,1
GILOTRIF,diarrhea,adverse reactions diarrhea rashdermatitis,1
GILOTRIF,diarrhea,adverse,0
GILOTRIF,diarrhea,Warnings and Precautions EXCERPT,0
GILOTRIF,diarrhea,Most common adverse reactions diarrhea rashdermatitis,1
GILOTRIF,rash,rash dermatitis,1
GILOTRIF,rash,,0
GILOTRIF,rash,rash dermatitis,1
GILOTRIF,rash,Most common adverse reactions are,0
GILOTRIF,dermatitis acneiform,dry skin decreased,0
GILOTRIF,stomatitis,stomatitis paronychia,1
GILOTRIF,stomatitis,stomatitis paronychia,1
GILOTRIF,stomatitis,stomatitis paronychia,1
GILOTRIF,stomatitis,stomatitis paronychia,1
GILOTRIF,stomatitis,stomatitis paronychia,1
GILOTRIF,stomatitis,,0
GILOTRIF,stomatitis,stomatitis paronychia,1
GILOTRIF,stomatitis,,0
GILOTRIF,paronychia,paronychia dry,1
GILOTRIF,paronychia,,0
GILOTRIF,paronychia,paronychia dry,1
GILOTRIF,paronychia,decreased appetite nausea vomiting pruritus To,0
GILOTRIF,paronychia,skin decreased appetite nausea vomiting,0
GILOTRIF,paronychia,diarrhea rashdermatitis acneiform paronychia dry,1
GILOTRIF,paronychia,vomiting,0
GILOTRIF,dry skin,adverse,0
GILOTRIF,dry skin,skin decreased,1
GILOTRIF,dry skin,dry skin decreased,1
GILOTRIF,dry skin,adverse reactions are,0
GILOTRIF,dry skin,adverse reactions are diarrhea rashdermatitis acneiform,0
GILOTRIF,dry skin,dry skin decreased,1
GILOTRIF,dry skin,pruritus To report SUSPECTED ADVERSE REACTIONS,0
GILOTRIF,decreased appetite,paronychia dry decreased appetite nausea,1
GILOTRIF,decreased appetite,decreased appetite nausea,1
GILOTRIF,decreased appetite,contact,0
GILOTRIF,decreased appetite,stomatitis paronychia dry decreased,1
GILOTRIF,nausea,,0
GILOTRIF,nausea,dry skin decreased,0
GILOTRIF,nausea,,0
GILOTRIF,nausea,nausea vomiting,1
GILOTRIF,vomiting,vomiting pruritus,1
GILOTRIF,vomiting,vomiting pruritus,1
GILOTRIF,vomiting,,0
GILOTRIF,pruritus,pruritus To,1
GILOTRIF,pruritus,,0
GILOTRIF,pruritus,ADVERSE,0
GILOTRIF,pruritus,stomatitis,0
GILOTRIF,vomiting,fatigue and hypokalemia each Fatal,0
GILOTRIF,vomiting,with GILOTRIF were vomiting and,1
GILOTRIF,vomiting,with GILOTRIF were,0
GILOTRIF,vomiting,vomiting and,1
GILOTRIF,dyspnea,patients treated with GILOTRIF were,0
GILOTRIF,dyspnea,reported in patients treated with GILOTRIF were,0
GILOTRIF,dyspnea,dyspnea fatigue,1
GILOTRIF,dyspnea,dyspnea fatigue,1
GILOTRIF,dyspnea,dyspnea fatigue,1
GILOTRIF,dyspnea,dyspnea fatigue,1
GILOTRIF,dyspnea,hypokalemia each Fatal adverse reactions in GILOTRIFtreated patients in Stud,0
GILOTRIF,dyspnea,GILOTRIF were diarrhea vomiting dyspnea fatigue,1
GILOTRIF,dyspnea,dyspnea fatigue,1
GILOTRIF,dyspnea,patients treated with GILOTRIF were diarrhea,0
GILOTRIF,fatigue,hypokalemia each Fatal adverse reactions in GILOTRIFtreated patients in,0
GILOTRIF,hypokalemia,patients in Study included,0
GILOTRIF,hypokalemia,treated with,0
GILOTRIF,Fatal,Fatal adverse,1
GILOTRIF,Fatal,GILOTRIFtreated patients in Study,0
GILOTRIF,Fatal,Fatal adverse,1
GILOTRIF,Fatal,diarrhea vomiting,0
GILOTRIF,Fatal,pulmonary,0
GILOTRIF,Fatal,,0
GILOTRIF,Fatal,in GILOTRIFtreated patients in Study,0
GILOTRIF,Fatal,were diarrhea vomiting and dyspnea fatigue,0
GILOTRIF,Fatal,and dyspnea fatigue,0
GILOTRIF,pulmonary toxicity,,0
GILOTRIF,pulmonary toxicity,each Fatal,0
GILOTRIF,pulmonary toxicity,pulmonary toxicity ILDlike,1
GILOTRIF,pulmonary toxicity,pulmonary toxicity ILDlike,1
GILOTRIF,pulmonary toxicity,GILOTRIFtreated patients in Study pulmonary,1
GILOTRIF,pulmonary toxicity,in Study included,0
GILOTRIF,pulmonary toxicity,,0
GILOTRIF,pulmonary toxicity,GILOTRIFtreated patients in Study pulmonary,1
GILOTRIF,pulmonary toxicity,toxicity ILDlike,1
GILOTRIF,pulmonary toxicity,,0
GILOTRIF,ILD-like adverse reactions,adverse reactions sepsis,1
GILOTRIF,ILD-like adverse reactions,,0
GILOTRIF,ILD-like adverse reactions,in Study included pulmonary ILD-like adverse reactions sepsis,1
GILOTRIF,ILD-like adverse reactions,Study included pulmonary ILD-like adverse reactions sepsis,1
GILOTRIF,ILD-like adverse reactions,reactions in GILOTRIFtreated patients in Study included pulmonary,0
GILOTRIF,ILD-like adverse reactions,,0
GILOTRIF,ILD-like adverse reactions,ILD-like adverse reactions sepsis,1
GILOTRIF,ILD-like adverse reactions,toxicity,0
GILOTRIF,ILD-like adverse reactions,,0
GILOTRIF,ILD-like adverse reactions,Dose reductions due to adverse reactions were,0
GILOTRIF,sepsis,due to adverse reactions were required,0
GILOTRIF,sepsis,Dose reductions due to adverse,0
GILOTRIF,sepsis,Study included pulmonary,0
GILOTRIF,pneumonia,Study,0
GILOTRIF,pneumonia,,0
GILOTRIF,pneumonia,pneumonia Dose,1
GILOTRIF,pneumonia,to adverse reactions were,0
GILOTRIF,pneumonia,pulmonary toxicityILDlike adverse,0
GILOTRIF,pneumonia,,0
GILOTRIF,pneumonia,pneumonia Dose,1
GILOTRIF,diarrhea,diarrhea rashacne,1
GILOTRIF,diarrhea,diarrhea rashacne,1
GILOTRIF,diarrhea,,0
GILOTRIF,diarrhea,treated with GILOTRIF diarrhea rashacne,1
GILOTRIF,rash,with GILOTRIF were rash acne,1
GILOTRIF,rash,rash acne,1
GILOTRIF,rash,of therapy,0
GILOTRIF,rash,treated with GILOTRIF were rash acne,1
GILOTRIF,rash,treated with GILOTRIF were,0
GILOTRIF,rash,,0
GILOTRIF,rash,rash acne,1
GILOTRIF,rash,rash acne,1
GILOTRIF,rash,led to dose reduction in the patients treated with GILOTRIF were,0
GILOTRIF,acne,that led to dose reduction,0
GILOTRIF,paronychia,paronychia and,1
GILOTRIF,paronychia,in the patients treated with GILOTRIF were diarrhea,0
GILOTRIF,diarrhea,diarrhea ILD,1
GILOTRIF,diarrhea,of GILOTRIF excluded,0
GILOTRIF,diarrhea,,0
GILOTRIF,diarrhea,diarrhea ILD,1
GILOTRIF,diarrhea,,0
GILOTRIF,diarrhea,diarrhea ILD,1
GILOTRIF,diarrhea,Clinical trials of GILOTRIF excluded patients with a,0
GILOTRIF,diarrhea,discontinuation in GILOTRIFtreated patients diarrhea ILD,1
GILOTRIF,diarrhea,patients diarrhea ILD,1
GILOTRIF,diarrhea,diarrhea ILD,1
GILOTRIF,ILD,were,0
GILOTRIF,ILD,ILD and,1
GILOTRIF,ILD,ILD and,1
GILOTRIF,ILD,ILD and,1
GILOTRIF,ILD,discontinuation in GILOTRIFtreated patients were diarrhea,0
GILOTRIF,paronychia,paronychia Clinical,1
GILOTRIF,paronychia,,0
GILOTRIF,paronychia,paronychia Clinical,1
GILOTRIF,ventricular dysfunction,patients,0
GILOTRIF,ventricular dysfunction,group More GILOTRIFtreated patients n experienced,0
GILOTRIF,ventricular dysfunction,n ventricular,1
GILOTRIF,ventricular dysfunction,dysfunction defined,1
GILOTRIF,diastolic dysfunction,,0
GILOTRIF,diastolic dysfunction,dysfunction or ventricular dilation,0
GILOTRIF,diastolic dysfunction,dysfunction left,1
GILOTRIF,diastolic dysfunction,experienced ventricular dysfunction,0
GILOTRIF,diastolic dysfunction,diastolic dysfunction left,1
GILOTRIF,diastolic dysfunction,all,0
GILOTRIF,diastolic dysfunction,ventricular dysfunction defined diastolic dysfunction left,1
GILOTRIF,diastolic dysfunction,,0
GILOTRIF,diastolic dysfunction,ventricular dysfunction defined diastolic,1
GILOTRIF,diastolic dysfunction,dysfunction defined diastolic dysfunction left,1
GILOTRIF,left ventricular dysfunction,Grade,0
GILOTRIF,left ventricular dysfunction,,0
GILOTRIF,left ventricular dysfunction,left ventricular dysfunction or,1
GILOTRIF,ventricular dilation,to,0
GILOTRIF,ventricular dilation,dysfunction ventricular dilation all,1
GILOTRIF,ventricular dilation,ventricular,1
GILOTRIF,ventricular dilation,ventricular dilation all,1
GILOTRIF,ventricular dilation,dysfunction left ventricular dysfunction ventricular,1
GILOTRIF,stomatitis,in Study,0
GILOTRIF,stomatitis,table stomatitis one,1
GILOTRIF,stomatitis,stomatitis one,1
GILOTRIF,stomatitis,stomatitis one,1
GILOTRIF,stomatitis,stomatitis one,1
GILOTRIF,stomatitis,,0
GILOTRIF,stomatitis,ulceration oral mucosa erosion,0
GILOTRIF,stomatitis,stomatitis aphthous,1
GILOTRIF,stomatitis,stomatitis aphthous,1
GILOTRIF,stomatitis,Grade in severity stomatitis aphthous,1
GILOTRIF,stomatitis,stomatitis aphthous,1
GILOTRIF,stomatitis,mucosal,0
GILOTRIF,stomatitis,in severity stomatitis aphthous,1
GILOTRIF,stomatitis,,0
GILOTRIF,stomatitis,oral mucosa erosion,0
GILOTRIF,stomatitis,inflammation mouth ulceration oral mucosa erosion mucosal erosion,0
GILOTRIF,aphthous stomatitis,in severity Includes aphthous,1
GILOTRIF,aphthous stomatitis,Grade in severity Includes aphthous stomatitis mucosal,1
GILOTRIF,aphthous stomatitis,stomatitis mucosal,1
GILOTRIF,aphthous stomatitis,,0
GILOTRIF,mucosal inflammation,of r,0
GILOTRIF,mucosal inflammation,severity Includes stomatitis aphthous mucosal inflammation mouth,1
GILOTRIF,mucosal inflammation,severity Includes stomatitis aphthous,0
GILOTRIF,mucosal inflammation,,0
GILOTRIF,mouth ulceration,in severity,0
GILOTRIF,mouth ulceration,Includes stomatitis aphthous stomatitis mucosal,0
GILOTRIF,mouth ulceration,stomatitis aphthous stomatitis mucosal mouth,1
GILOTRIF,mouth ulceration,stomatitis aphthous stomatitis,0
GILOTRIF,mouth ulceration,ulceration oral,1
GILOTRIF,mouth ulceration,aphthous stomatitis mucosal mouth,1
GILOTRIF,mouth ulceration,stomatitis mucosal mouth ulceration oral,1
GILOTRIF,mucosal erosion,preferred terms acne,0
GILOTRIF,mucosal erosion,mucosal erosion mucosal,1
GILOTRIF,mucosal erosion,group,0
GILOTRIF,mucosal erosion,acne acne,0
GILOTRIF,mucosal ulceration,erosion mucosal mucosal,1
GILOTRIF,mucosal ulceration,Includes group of rash preferred terms acne acne pustular dermatitis,0
GILOTRIF,mucosal ulceration,inflammation mouth ulceration oral mucosa,0
GILOTRIF,mucosal ulceration,acne acne pustular,0
GILOTRIF,mucosal ulceration,erosion,0
GILOTRIF,mucosal ulceration,mucosal ulceration Includes,1
GILOTRIF,mucosal ulceration,ulceration Includes,1
GILOTRIF,mucosal ulceration,erosion,0
GILOTRIF,rash,rash preferred,1
GILOTRIF,rash,rash preferred,1
GILOTRIF,rash,infection,0
GILOTRIF,rash,rash preferred,1
GILOTRIF,rash,acne acne pustular dermatitis acneiform Includes paronychia nail,0
GILOTRIF,rash,rash preferred,1
GILOTRIF,rash,nail infection,0
GILOTRIF,rash,group rash preferred,1
GILOTRIF,acne,infection,0
GILOTRIF,acne,,0
GILOTRIF,acne,pustular dermatitis acneiform Includes paronychia,0
GILOTRIF,acne,,0
GILOTRIF,acne,acne acne,1
GILOTRIF,acne,acne acne,1
GILOTRIF,acne,rash preferred acne acne,1
GILOTRIF,acne,rash preferred acne acne,1
GILOTRIF,acne,,0
GILOTRIF,acne,acne acne,1
GILOTRIF,acne pustular,pustular dermatitis,1
GILOTRIF,acne pustular,erosion mucosal erosion mucosal ulceration Includes group of,0
GILOTRIF,acne pustular,acne pustular dermatitis,1
GILOTRIF,acne pustular,terms acne pustular dermatitis,1
GILOTRIF,acne pustular,terms acne,0
GILOTRIF,acne pustular,preferred terms acne pustular dermatitis,1
GILOTRIF,acne pustular,infection,0
GILOTRIF,acne pustular,acneiform Includes paronychia nail infection nail,0
GILOTRIF,acne pustular,,0
GILOTRIF,acne pustular,acne,1
GILOTRIF,dermatitis acneiform,acne dermatitis,1
GILOTRIF,dermatitis acneiform,,0
GILOTRIF,dermatitis acneiform,terms acne acne dermatitis acneiform Includes,1
GILOTRIF,dermatitis acneiform,dermatitis acneiform Includes,1
GILOTRIF,dermatitis acneiform,dermatitis acneiform Includes,1
GILOTRIF,dermatitis acneiform,Includes group of rash,0
GILOTRIF,dermatitis acneiform,paronychia nail infection nail bed,0
GILOTRIF,paronychia,paronychia nail,1
GILOTRIF,paronychia,paronychia nail,1
GILOTRIF,paronychia,acne acne pustular,0
GILOTRIF,paronychia,rash preferred terms acne,0
GILOTRIF,nail infection,Includes nail,1
GILOTRIF,nail infection,pustular dermatitis acneiform Includes nail infection nail,1
GILOTRIF,nail infection,nail bed infection GILOTRIFn,0
GILOTRIF,nail infection,nail infection nail,1
GILOTRIF,nail bed infection,nail nail bed infection GILOTRIFn,1
GILOTRIF,nail bed infection,paronychia nail nail bed infection GILOTRIFn,1
GILOTRIF,nail bed infection,paronychia nail nail bed,1
GILOTRIF,nail bed infection,acne acne pustular dermatitis acneiform Includes paronychia nail infection,0
GILOTRIF,nail bed infection,nail bed infection GILOTRIFn,1
GILOTRIF,nail bed infection,Includes paronychia nail nail bed infection GILOTRIFn,1
GILOTRIF,Diarrhea,,0
GILOTRIF,Diarrhea,,0
GILOTRIF,Stomatitis,Diarrhea Stomatitis Nausea,1
GILOTRIF,Stomatitis,,0
GILOTRIF,Stomatitis,Diarrhea,0
GILOTRIF,Stomatitis,Diarrhea Stomatitis Nausea,1
GILOTRIF,Stomatitis,Diarrhea,0
GILOTRIF,Stomatitis,Nausea,0
GILOTRIF,Stomatitis,Diarrhea Stomatitis Nausea,1
GILOTRIF,Stomatitis,Stomatitis Nausea,1
GILOTRIF,Stomatitis,,0
GILOTRIF,Stomatitis,,0
GILOTRIF,Nausea,,0
GILOTRIF,Nausea,,0
GILOTRIF,Nausea,Nausea Vomiting,1
GILOTRIF,Vomiting,Nausea,0
GILOTRIF,Vomiting,,0
GILOTRIF,Vomiting,Vomiting Cheilitis,1
GILOTRIF,Vomiting,Nausea Vomiting Cheilitis,1
GILOTRIF,Vomiting,Nausea Vomiting Cheilitis,1
GILOTRIF,Vomiting,Nausea,0
GILOTRIF,Vomiting,Nausea Vomiting Cheilitis,1
GILOTRIF,Vomiting,Vomiting Cheilitis,1
GILOTRIF,Cheilitis,Vomiting,0
GILOTRIF,Cheilitis,Vomiting Cheilitis Skin and subcutaneous,1
GILOTRIF,Cheilitis,Vomiting Cheilitis Skin and subcutaneous tis,1
GILOTRIF,Cheilitis,,0
GILOTRIF,Cheilitis,Cheilitis Skin,1
GILOTRIF,Cheilitis,Vomiting,0
GILOTRIF,Cheilitis,Vomiting,0
GILOTRIF,Rash,and subcutaneous tissue Rash Dermatitis acneiform,1
GILOTRIF,Rash,Rash Dermatitis acneiform,1
GILOTRIF,Rash,and subcutaneous tissue disorders,0
GILOTRIF,Rash,,0
GILOTRIF,Rash,,0
GILOTRIF,Rash,,0
GILOTRIF,Rash,Rash Dermatitis acneiform,1
GILOTRIF,Rash,Rash Dermatitis acneiform,1
GILOTRIF,Rash,tissue Rash Dermatitis acneiform,1
GILOTRIF,Rash,tissue Rash Dermatitis acneiform,1
GILOTRIF,Dermatitis acneiform,,0
GILOTRIF,Pruritus,Pruritus Dry skin,1
GILOTRIF,Pruritus,atitis Pruritus Dry skin,1
GILOTRIF,Pruritus,skin,0
GILOTRIF,Pruritus,acneiform,0
GILOTRIF,Pruritus,acneiform,0
GILOTRIF,Dry skin,,0
GILOTRIF,Dry skin,Dry skin,1
GILOTRIF,Dry skin,Pruritus Dry,1
GILOTRIF,Dry skin,Infections,0
GILOTRIF,Dry skin,infestati,0
GILOTRIF,Dry skin,Pruritus Dry,1
GILOTRIF,Dry skin,Pruritus Dry skin Infections and,1
GILOTRIF,Dry skin,Pruritus Dry skin Infections and,1
GILOTRIF,Dry skin,Pruritus,0
GILOTRIF,Dry skin,,0
GILOTRIF,Paronychia,Infections and Paronychia Cystitis,1
GILOTRIF,Paronychia,,0
GILOTRIF,Paronychia,Paronychia Cystitis,1
GILOTRIF,Paronychia,Paronychia Cystitis,1
GILOTRIF,Paronychia,,0
GILOTRIF,Paronychia,Paronychia Cystitis,1
GILOTRIF,Paronychia,Paronychia Cystitis,1
GILOTRIF,Paronychia,Paronychia Cystitis,1
GILOTRIF,Decreased appetite,disorders,0
GILOTRIF,Decreased appetite,Decreased appetite Respiratory thoracic and,1
GILOTRIF,Decreased appetite,Decreased appetite Respiratory thoracic and,1
GILOTRIF,Decreased appetite,appetite Respiratory thoracic and,1
GILOTRIF,Decreased appetite,Decreased appetite Respiratory thoracic and,1
GILOTRIF,Decreased appetite,appetite Respiratory thoracic and,1
GILOTRIF,Epistaxis,Epistaxis Rhinorrhea,1
GILOTRIF,Epistaxis,Rhinorrhea,0
GILOTRIF,Epistaxis,,0
GILOTRIF,Epistaxis,Epistaxis Rhinorrhea,1
GILOTRIF,Epistaxis,,0
GILOTRIF,Epistaxis,thoracic and mediastinal Epistaxis Rhinorrhea,1
GILOTRIF,Epistaxis,Epistaxis Rhinorrhea,1
GILOTRIF,Epistaxis,mediastinal disorders,0
GILOTRIF,Epistaxis,Epistaxis Rhinorrhea,1
GILOTRIF,Epistaxis,Rhinorrhea,0
GILOTRIF,Rhinorrhea,Epistaxis,0
GILOTRIF,Rhinorrhea,Rhinorrhea Investigations,1
GILOTRIF,Rhinorrhea,Epistaxis,0
GILOTRIF,Rhinorrhea,,0
GILOTRIF,Rhinorrhea,Epistaxis Rhinorrhea Investigations,1
GILOTRIF,Rhinorrhea,Rhinorrhea Investigations,1
GILOTRIF,Weight Decreased,Investigations,0
GILOTRIF,Weight Decreased,Investigations Weight Decreased,1
GILOTRIF,Weight Decreased,Investigations,0
GILOTRIF,Weight Decreased,Investigations Weight,1
GILOTRIF,Weight Decreased,Investigations Weight,1
GILOTRIF,Weight Decreased,Investigations Weight Decreased General,1
GILOTRIF,Weight Decreased,Investigations Weight Decreased General disorders and,1
GILOTRIF,Weight Decreased,Investigations Weight,1
GILOTRIF,Weight Decreased,Investigations,0
GILOTRIF,Pyrexia,Pyrexia,1
GILOTRIF,Pyrexia,Pyrexia,1
GILOTRIF,Pyrexia,Pyrexia,1
GILOTRIF,Pyrexia,Pyrexia,1
GILOTRIF,Pyrexia,,0
GILOTRIF,Pyrexia,Pyrexia,1
GILOTRIF,Pyrexia,Pyrexia,1
GILOTRIF,Pyrexia,and administration,0
GILOTRIF,Conjunctivitis,Table Adverse,0
GILOTRIF,Conjunctivitis,Adverse Reactio,0
GILOTRIF,Conjunctivitis,,0
GILOTRIF,Conjunctivitis,Conjunctivitis,1
GILOTRIF,Conjunctivitis,disorders,0
GILOTRIF,Conjunctivitis,Table Adverse Reactio,0
GILOTRIF,hypokalemia,GILOTRIFTreated Patients in Study hypokalemia,1
GILOTRIF,hypokalemia,,0
GILOTRIF,hypokalemia,potassium decreasedSOCsystem organ class GILOTRIFn Pemet,0
GILOTRIF,blood potassium decreased,GILOTRIFn PemetrexedCisplatinn,0
GILOTRIF,blood potassium decreased,Study Includes blood potassium decreased,1
GILOTRIF,blood potassium decreased,Study Includes blood potassium,1
GILOTRIF,blood potassium decreased,SOCsystem organ class,0
GILOTRIF,blood potassium decreased,Reported in of GILOTRIFTreated Patients in Study,0
GILOTRIF,blood potassium decreased,class,0
GILOTRIF,Alanine aminotransferase increased,,0
GILOTRIF,Alanine aminotransferase increased,Alanine aminotransferase increased Hypokalemia,1
GILOTRIF,Alanine aminotransferase increased,aminotransferase increased Hypokalemia,1
GILOTRIF,Alanine aminotransferase increased,,0
GILOTRIF,Alanine aminotransferase increased,Grades All Grades Alanine aminotransferase,1
GILOTRIF,Alanine aminotransferase increased,All Grades Alanine aminotransferase increased Hypokalemia,1
GILOTRIF,Alanine aminotransferase increased,Grades Alanine aminotransferase increased Hypokalemia,1
GILOTRIF,Hypokalemia,,0
GILOTRIF,Hypokalemia,increased,0
GILOTRIF,Hypokalemia,increased,0
GILOTRIF,Aspartate aminotransferase increased,,0
GILOTRIF,Aspartate aminotransferase increased,Hypokalemia,0
GILOTRIF,Aspartate aminotransferase increased,Aspartate aminotransferase increased Postmarketing,1
GILOTRIF,Aspartate aminotransferase increased,Hypokalemia,0
GILOTRIF,Aspartate aminotransferase increased,Postmarketing Ex,0
GILOTRIF,Aspartate aminotransferase increased,Hypokalemia,0
GILOTRIF,Aspartate aminotransferase increased,Hypokalemia Aspartate aminotransferase increased Postmarketing,1
GILOTRIF,Aspartate aminotransferase increased,Hypokalemia,0
GILOTRIF,Aspartate aminotransferase increased,aminotransferase increased Postmarketing Ex,1
GILOTRIF,Aspartate aminotransferase increased,Hypokalemia,0
GILOTRIF,Pancreatitis,Pancreatitis,1
GILOTRIF,Pancreatitis,reliably estimate their,0
GILOTRIF,Pancreatitis,to drug Pancreatitis,1
GILOTRIF,Pancreatitis,,0
GILOTRIF,dehydration,,0
GILOTRIF,dehydration, detail in  other sections of the labeling,1
GILOTRIF,dehydration,other sections of the labeling Diarrhea see Warnings and Precautions,0
GILOTRIF,dehydration,,0
GILOTRIF,renal failure,in greater detail in sections,1
GILOTRIF,renal failure,greater detail in sections,1
GILOTRIF,renal failure,Bullous and,0
GILOTRIF,renal failure,greater detail in sections,1
GILOTRIF,renal failure,sections of the,1
GILOTRIF,renal failure,The following adverse reactions are discussed in greater detail in,0
GILOTRIF,renal failure,Diarrhea see Warnings and Precautions Bullous,0
GILOTRIF,Interstitial lung disease,Precautions EXCERPT Most common rse reactions (>=20%),1
GILOTRIF,Interstitial lung disease,EXCERPT Most common rse reactions (>=20%),1
GILOTRIF,Interstitial lung disease,diarrhea,0
GILOTRIF,ILD,decreased appetite nausea vomit,0
GILOTRIF,ILD,stomatitis paronychia dry skin decreased appetite,0
GILOTRIF,ILD,dry skin decreased appetite nausea vomit,0
GILOTRIF,ILD,Most common adverse reactions are d,0
GILOTRIF,Hepatic toxicity,Pharmaceuticals Inc at or TTY or FDA,0
GILOTRIF,Hepatic toxicity,contact B oehringer,1
GILOTRIF,Hepatic toxicity,"report SUSPECTED ADVERSE TIONS, contact B oehringer",1
GILOTRIF,Fatal,ADVERSE REACTIONS contact,0
GILOTRIF,Fatal,,0
GILOTRIF,hepatic impairment,ceuticals Inc at,0
GILOTRIF,hepatic impairment,,0
GILOTRIF,Keratitis,,0
GILOTRIF,Keratitis,under,0
GILOTRIF,Keratitis,ause clin ical,1
GILOTRIF,Embryofetal toxicity,es in the,1
GILOTRIF,Embryofetal toxicity,a drug cannot,0
GILOTRIF,Embryofetal toxicity,t rials,1
GILOTRIF,fetal harm,clinical trials of ther drug  and,1
GILOTRIF,fetal harm,of ther drug  and,1
GILOTRIF,Diarrhea,00 patie nts,1
GILOTRIF,Diarrhea,00 patie nts,1
GILOTRIF,Diarrhea,The safety evaluation of GILOTRIF is based on the,0
GILOTRIF,dehydration,than patients 35,1
GILOTRIF,dehydration,NSCLC pa tients,1
GILOTRIF,dehydration,from more than patients 35 NSCLC pa tients,1
GILOTRIF,renal impairment,patients including NSCLC patients GILOTRIF,1
GILOTRIF,renal impairment,than patients,0
GILOTRIF,renal impairment,patients including NSCLC patients GILOTRIF monothe rapy,1
GILOTRIF,renal impairment,patients GILOTRIF monothe rapy,1
GILOTRIF,renal impairment,GILOTRIF monothe rapy,1
GILOTRIF,renal impairment,patients GILOTRIF monothe rapy,1
GILOTRIF,renal impairment,patients including NSCLC patients GILOTRIF,1
GILOTRIF,renal impairment,including NSCLC patients GILOTRIF,1
GILOTRIF,renal impairment,or above the recommended dose Controlled Study The data in Tables and below,0
GILOTRIF,fatal,nai,0
GILOTRIF,fatal,ended dose,1
GILOTRIF,fatal,NSCLC patients receiving GILOTRIF monotherapy at or above the recomm,0
GILOTRIF,diarrhea,Tables and below reflect exposure,0
GILOTRIF,diarrhea,The data in Tables and below reflect exposure,0
GILOTRIF,diarrhea,data in Tables and,0
GILOTRIF,diarrhea,ontrolle d,1
GILOTRIF,diarrhea,,0
GILOTRIF,diarrhea,the recommended dose ontrolle d,1
GILOTRIF,diarrhea,ontrolle d,1
GILOTRIF,diarrhea,ontrolle d,1
GILOTRIF,diarrhea,NSCLC patients receiving GILOTRIF monotherapy at or,0
GILOTRIF,diarrhea,recommended dose ontrolle d,1
GILOTRIF,diarrhea,ontrolle d,1
GILOTRIF,diarrhea,,0
GILOTRIF,Renal impairment,EGFR mutationpositive metastatic nonsquamous enrolled in a ra ndomized,1
GILOTRIF,Renal impairment,ra ndomized,1
GILOTRIF,Renal impairment,ra ndomized,1
GILOTRIF,Renal impairment,EGFR mutationpositive metastatic nonsquamous enrolled in a ra ndomized,1
GILOTRIF,Renal impairment,metastatic nonsquamous enrolled,1
GILOTRIF,Renal impairment,metastatic nonsquamous enrolled in a ra ndomized,1
GILOTRIF,Renal impairment,trial Study Patients received GILOTRIF,0
GILOTRIF,Renal impairment,,0
GILOTRIF,Renal impairment,mutationpositive metastatic nonsquamous enrolled in a,1
GILOTRIF,Renal impairment,enrolled in a,1
GILOTRIF,Renal impairment,enrolled in,1
GILOTRIF,Renal impairment,metastatic,0
GILOTRIF,Renal impairment,mutationpositive metastatic nonsquamous enrolled in a ra ndomized,1
GILOTRIF,Renal impairment,mutationpositive metastatic nonsquamous enrolled,1
GILOTRIF,diarrhea,"enrolled in a randomized ,",1
GILOTRIF,diarrhea,", open-l abel",1
GILOTRIF,diarrhea,nonsquamous,0
GILOTRIF,diarrhea,"a randomized , open-l abel",1
GILOTRIF,diarrhea,metastatic nonsquamous NSCLC enrolled in a randomized,0
GILOTRIF,diarrhea,", open-l abel",1
GILOTRIF,diarrhea,", open-l abel",1
GILOTRIF,diarrhea,"randomized ,",1
GILOTRIF,cutaneous reactions,total of of,1
GILOTRIF,cutaneous reactions,arm were younger years. A,1
GILOTRIF,cutaneous reactions,the pemetrexedcisplatin arm were younger than,0
GILOTRIF,cutaneous reactions,years. A total of of,1
GILOTRIF,cutaneous reactions,years. A total of of,1
GILOTRIF,cutaneous reactions,More,0
GILOTRIF,cutaneous reactions,years.,1
GILOTRIF,cutaneous reactions,patients on GILOTRIF and of pemetrexedcisplatin patients were,0
GILOTRIF,exfoliating lesions,pa tients,1
GILOTRIF,exfoliating lesions,younger than years A total of of patients on GILOTRIF and of peme,0
GILOTRIF,exfoliating lesions,trexed/cisplatin pa tients,1
GILOTRIF,exfoliating lesions,pa tients,1
GILOTRIF,cutaneous reactions,were,0
GILOTRIF,cutaneous reactions,,0
GILOTRIF,cutaneous reactions,% of patients treat ed,1
GILOTRIF,rash,adverse reactions were reported in of patients treated with GILOTRI,0
GILOTRIF,rash,with GILOTRI,0
GILOTRIF,rash,adverse reactions reported in patients treated with GILOTRIF,0
GILOTRIF,rash,,0
GILOTRIF,rash,F. T he,1
GILOTRIF,rash,with F. T he,1
GILOTRIF,rash,patients treated with F. T he,1
GILOTRIF,rash,with F.,1
GILOTRIF,rash,adverse,0
GILOTRIF,rash,,0
GILOTRIF,erythema,GILOTRIF most,1
GILOTRIF,erythema,equent serious adverse reactions,0
GILOTRIF,erythema,GILOTRIF  most fr equent,1
GILOTRIF,erythema,treated with,0
GILOTRIF,erythema,GILOTRIF The,0
GILOTRIF,acneiform rash,diarrhea vomiting and,0
GILOTRIF,acneiform rash,in patients treated with GILOTRIF were,0
GILOTRIF,acneiform rash,were diarrhea vomiting and d,0
GILOTRIF,acneiform rash,reported in of patients treated with GILOTRIF,0
GILOTRIF,acneiform rash,diarrhea vomiting and,0
GILOTRIF,acneiform rash,adver se,1
GILOTRIF,acneiform rash,,0
GILOTRIF,acneiform rash,,0
GILOTRIF,cutaneous reactions,ed with GILOTRIF we re,1
GILOTRIF,cutaneous reactions,most frequent serious adverse reactions,0
GILOTRIF,palmar-plantar erythrodysesthesia syndrome,"vomiting and fatigue, and hypokalemia (1.7% each). Fata l",1
GILOTRIF,palmar-plantar erythrodysesthesia syndrome,"fatigue, and hypokalemia",1
GILOTRIF,palmar-plantar erythrodysesthesia syndrome,l adverse reactions in GILOTRIFtreated,0
GILOTRIF,palmar-plantar erythrodysesthesia syndrome,reported in,0
GILOTRIF,palmar-plantar erythrodysesthesia syndrome,"diarrhea vomiting and fatigue, and",1
GILOTRIF,palmar-plantar erythrodysesthesia syndrome,Fata l,1
GILOTRIF,palmar-plantar erythrodysesthesia syndrome,"fatigue, and hypokalemia (1.7% each). Fata l",1
GILOTRIF,palmar-plantar erythrodysesthesia syndrome,,0
GILOTRIF,ILD,was The,1
GILOTRIF,ILD,was The,1
GILOTRIF,ILD-like adverse reactions,,0
GILOTRIF,ILD-like adverse reactions,diarrhea,0
GILOTRIF,ILD-like adverse reactions,adverse reactions 0%. The most frequent adve rse,1
GILOTRIF,pneumonitis,led to iscontinuat ion,1
GILOTRIF,pneumonitis,that led to iscontinuat ion,1
GILOTRIF,pneumonitis,iscontinuat ion,1
GILOTRIF,alveolitis allergic,"were rhea (1.3%), ILD",1
GILOTRIF,fatal,icula r,1
GILOTRIF,fatal,an,0
GILOTRIF,fatal,icula r,1
GILOTRIF,fatal,icula r,1
GILOTRIF,fatal,GILOTRIF excluded,0
GILOTRIF,fatal,icula r,1
GILOTRIF,ILD, (L VEF,1
GILOTRIF,ILD,abnormal left ventricular ejection  (L VEF,1
GILOTRIF,ILD,trials of GILOTRIF excluded patients with,0
GILOTRIF,ILD,f,0
GILOTRIF,ILD, (L VEF,1
GILOTRIF,ILD,institutional lower limit of normal In Study all,0
GILOTRIF,ILD,needed in the pemetrexedcisplatin,0
GILOTRIF,ILD,normal In Study all patients were evaluated,0
GILOTRIF,ILD,eek s,1
GILOTRIF,ILD,at screening and every eek s,1
GILOTRIF,ILD,every,0
GILOTRIF,ILD,evaluated for LVEF at,0
GILOTRIF,ILD,eek s,1
GILOTRIF,ILD,at screening and every eek s,1
GILOTRIF,ILD,eek s,1
GILOTRIF,death,screening and every weeks thereafter in the,0
GILOTRIF,death,More GILOTRIFtreated,0
GILOTRIF,liver test abnormalities,patients n 1 Adverse Reactions Repo rted,1
GILOTRIF,liver test abnormalities,rted in of GILOTRIFTreated,0
GILOTRIF,liver test abnormalities,dilation all Grade compared,0
GILOTRIF,liver test abnormalities,reactions in this tabl,0
GILOTRIF,liver test abnormalities,chemotherapytreated patients n 1 Adverse Reactions,1
GILOTRIF,fatal,Treat ed,1
GILOTRIF,fatal,None of the adverse,0
GILOTRIF,fatal,Reported,0
GILOTRIF,fatal,Treat ed,1
GILOTRIF,fatal,n Table Adverse Reactions Reported in of,0
GILOTRIF,fatal,the adverse reactions in this table except stomatitis one patien,0
GILOTRIF,fatal,Treat ed,1
GILOTRIF,fatal,adverse reactions in this table except stomatitis one patien,0
GILOTRIF,fatal,patien,0
GILOTRIF,fatal,n Table Adverse Reactions Reported in of GILOTRIF,0
GILOTRIF,liver test abnormalities,GILOTRIF were Grade in,0
GILOTRIF,liver test abnormalities,Table Adverse Reactions Reported in of GILOTRIFTreated Patients in,0
GILOTRIF,worsening eye inflammation,,0
GILOTRIF,worsening eye inflammation,TRIFn=229 Pemetrexed/ Cisplatinn,1
GILOTRIF,worsening eye inflammation,Grades Grade,0
GILOTRIF,worsening eye inflammation,TRIFn=229 Pemetrexed/ Cisplatinn,1
GILOTRIF,worsening eye inflammation,All,0
GILOTRIF,worsening eye inflammation,nail bed infection TRIFn=229,1
GILOTRIF,worsening eye inflammation,Grades,0
GILOTRIF,lacrimation,,0
GILOTRIF,lacrimation,,0
GILOTRIF,lacrimation,infection,0
GILOTRIF,lacrimation,splatinn=11 Adverse,1
GILOTRIF,lacrimation,,0
GILOTRIF,lacrimation,splatinn=11 Adverse,1
GILOTRIF,light sensitivity,,0
GILOTRIF,light sensitivity,All,0
GILOTRIF,light sensitivity,,0
GILOTRIF,light sensitivity,Adverse R eaction,1
GILOTRIF,light sensitivity,All Grades Grade,0
GILOTRIF,light sensitivity,"infection GILOTRIFn     
   Adverse R eaction",1
GILOTRIF,light sensitivity,infection GILOTRIFn Adverse,1
GILOTRIF,blurred vision,Rea,0
GILOTRIF,blurred vision,ction,1
GILOTRIF,blurred vision,ction      All Grades,1
GILOTRIF,eye pain,rades(%) Grade,1
GILOTRIF,eye pain,,0
GILOTRIF,eye pain,Adverse Reaction All,0
GILOTRIF,eye pain,rades(%) Grade,1
GILOTRIF,eye pain,,0
GILOTRIF,eye pain,Reaction All rades(%) Grade,1
GILOTRIF,eye pain,Adverse Reaction All G,0
GILOTRIF,red eye,Adverse Reaction All,0
GILOTRIF,red eye,de 3*(% All,1
GILOTRIF,red eye,3*(% All,1
GILOTRIF,red eye,All Grades de 3*(% All,1
GILOTRIF,red eye,3*(% All,1
GILOTRIF,red eye,,0
GILOTRIF,red eye,Grades de 3*(% All,1
GILOTRIF,red eye,All Grades de,1
GILOTRIF,red eye,de 3*(% All,1
GILOTRIF,red eye,Adverse Reaction All Grades de,1
GILOTRIF,Keratitis,,0
GILOTRIF,Keratitis,96        Stomatitis,1
GILOTRIF,Keratitis,disorders Diarrhea,0
GILOTRIF,Keratitis,96        Stomatitis,1
GILOTRIF,Keratitis,96        Stomatitis,1
GILOTRIF,Keratitis,,0
GILOTRIF,fetal harm,skin,0
GILOTRIF,fetal harm,           Infections,1
GILOTRIF,fetal harm,           Infections,1
GILOTRIF,embryotoxic,"   
        Paronychia",1
GILOTRIF,embryotoxic,"Infections and    
        Paronychia",1
GILOTRIF,embryotoxic,"   
        Paronychia",1
GILOTRIF,embryotoxic,,0
GILOTRIF,embryotoxic,"   
        Paronychia",1
GILOTRIF,embryotoxic,,0
GILOTRIF,abortions at late gestational stages,0,1
GILOTRIF,abortions at late gestational stages,infestations 0,1
GILOTRIF,abortions at late gestational stages,0 Cystitis,1
GILOTRIF,abortions at late gestational stages,infestations,0
GILOTRIF,abortions at late gestational stages,and infestations    0                0                Cystitis,1
DATSCAN,injection site reactions,trials,0
DATSCAN,headache,report SU,0
DATSCAN,headache,adverse,0
DATSCAN,headache,headache nausea vertigo dry mouth,1
DATSCAN,headache,most common adverse headache nausea vertigo dry mouth,1
DATSCAN,headache,adverse reactions,0
DATSCAN,headache,headache nausea vertigo dry mouth,1
DATSCAN,nausea,nausea vertigo dry mouth or,1
DATSCAN,nausea,nausea vertigo dry mouth or,1
DATSCAN,nausea,,0
DATSCAN,vertigo,vertigo dry mouth or dizziness,1
DATSCAN,vertigo,vertigo dry mouth or dizziness,1
DATSCAN,dry mouth,headache nausea dry,1
DATSCAN,dry mouth,SUSPECTED,0
DATSCAN,dry mouth,reactions headache nausea dry,1
DATSCAN,dry mouth,or dizziness,0
DATSCAN,dry mouth,adverse reactions headache nausea dry,1
DATSCAN,dry mouth,nausea dry,1
DATSCAN,dry mouth,nausea dry,1
DATSCAN,dry mouth,in of subjects To report SUSPECTED ADVERSE,0
DATSCAN,dry mouth,nausea dry mouth or dizziness occurred in,1
DATSCAN,dizziness,dizziness occurred in of subjects,1
DATSCAN,dizziness,,0
DATSCAN,dizziness,dizziness occurred in of subjects,1
DATSCAN,dizziness,dizziness occurred in of subjects,1
DATSCAN,headache,reactions occurred at a rate of or less and,0
DATSCAN,headache,headache nausea vertigo dry mouth,1
DATSCAN,headache,the reported events consisted headache nausea vertigo dry mouth,1
DATSCAN,nausea,nausea vertigo dry mouth or,1
DATSCAN,nausea,nausea vertigo dry mouth or,1
DATSCAN,nausea,nausea vertigo dry mouth or,1
DATSCAN,vertigo,vertigo dry mouth or dizziness,1
DATSCAN,vertigo,,0
DATSCAN,vertigo,vertigo dry mouth or dizziness,1
DATSCAN,dry mouth,were of mild to moderate,0
DATSCAN,dry mouth,moderate,0
DATSCAN,dry mouth,of,0
DATSCAN,dry mouth,consisted of headache nausea dry,1
DATSCAN,dry mouth,mouth or dizziness These reactions,1
DATSCAN,dizziness,dizziness These reactions were of,1
DATSCAN,dizziness,of mild to moderate severity Postmarketing Experience Because,0
DATSCAN,dizziness,vertigo,0
DATSCAN,dizziness,dizziness These reactions were of,1
DATSCAN,dizziness,vertigo dry mouth dizziness These reactions were of,1
DATSCAN,hypersensitivity reactions,the postmarketing hypersensitivity,1
DATSCAN,hypersensitivity reactions,the postmarketing hypersensitivity,1
DATSCAN,hypersensitivity reactions,exposure In the postmarketing hypersensitivity reactions have been reported The,1
DATSCAN,hypersensitivity reactions,hypersensitivity reactions have been reported The,1
DATSCAN,hypersensitivity reactions,to drug exposure In the postmarketing,0
DATSCAN,hypersensitivity reactions,frequency or establish a,0
DATSCAN,hypersensitivity reactions,exposure In the postmarketing hypersensitivity,1
DATSCAN,hypersensitivity reactions,reactions have been reported The,1
DATSCAN,rash,related rash and pruritis within minutes,1
DATSCAN,rash,rash and pruritis within minutes,1
DATSCAN,rash,rash and pruritis within minutes,1
DATSCAN,pruritis,pruritis within minutes of DaTscan,1
DATSCAN,pruritis,pruritis within minutes of DaTscan,1
DATSCAN,pruritis,pruritis within minutes of DaTscan,1
DATSCAN,pruritis,pruritis within minutes of DaTscan,1
DATSCAN,pruritis,pruritis within minutes of DaTscan,1
DATSCAN,pruritis,,0
DATSCAN,Injection site pain,been,0
DATSCAN,Injection site pain,corticosteroids and Injection site,1
DATSCAN,Injection site pain,,0
DATSCAN,Injection site pain,pain has also been reported,1
DATSCAN,Hypersensitivity reactions,,0
DATSCAN,Hypersensitivity reactions,report SUSPECTED ADVERSE,0
DATSCAN,Hypersensitivity reactions,REACTIONS contact GE Healthcare at,0
DATSCAN,Hypersensitivity reactions,contact GE Healthcare 118 or FDA,1
DATSCAN,Hypersensitivity reactions,contact GE Healthcare 118 or FDA at 1-800-FDA-10 or wwwfdagovmedwatch Clinical Study,1
DATSCAN,Hypersensitivity reactions,Experience The data from clinical,0
DATSCAN,Hypersensitivity reactions,118 or FDA at 1-800-FDA-10 or wwwfdagovmedwatch Clinical Study,1
DATSCAN,Hypersensitivity reactions,or FDA at 1-800-FDA-10 or wwwfdagovmedwatch Clinical Study,1
DATSCAN,Hypersensitivity reactions,or FDA at 1-800-FDA-10 or wwwfdagovmedwatch Clinical Study,1
DATSCAN,Hypersensitivity reactions,contact GE Healthcare 118 or FDA,1
DATSCAN,Hypersensitivity reactions,GE,0
DATSCAN,skin erythema,942 subjects with a mean age,1
DATSCAN,skin erythema,,0
DATSCAN,skin erythema,reflect exposure to DaTscan  942 subjects with a mean age,1
KALBITOR,Hypersensitivity,Hypersensitivity,1
KALBITOR,Hypersensitivity,treated with KALBITOR,0
KALBITOR,Hypersensitivity,,0
KALBITOR,Hypersensitivity,,0
KALBITOR,Hypersensitivity,,0
KALBITOR,Hypersensitivity,,0
KALBITOR,anaphylaxis,anaphylaxis have occurred,1
KALBITOR,anaphylaxis,anaphylaxis have occurred in patients treated,1
KALBITOR,anaphylaxis,anaphylaxis have,1
KALBITOR,anaphylaxis,treated with KALBITOR see,0
KALBITOR,anaphylaxis,anaphylaxis have,1
KALBITOR,anaphylaxis,with KALBITOR see,0
KALBITOR,anaphylaxis,anaphylaxis have occurred in,1
KALBITOR,headache,greater than placebo headache nausea diarrhea pyrexia,1
KALBITOR,headache,headache nausea diarrhea pyrexia,1
KALBITOR,headache,injection site reactions and,0
KALBITOR,nausea,nausea diarrhea pyrexia injection,1
KALBITOR,diarrhea,are headache diarrhea pyrexia injection site,1
KALBITOR,diarrhea,ADVERSE,0
KALBITOR,diarrhea,placebo are headache diarrhea pyrexia injection site,1
KALBITOR,diarrhea,placebo are headache,0
KALBITOR,diarrhea,diarrhea pyrexia injection site,1
KALBITOR,pyrexia,are headache nausea diarrhea,0
KALBITOR,pyrexia,KALBITORtreated patients and greater than placebo are,0
KALBITOR,injection site reactions,,0
KALBITOR,injection site reactions,nausea diarrhea pyrexia,0
KALBITOR,injection site reactions,injection site reactions and nasopharyngitis To,1
KALBITOR,nasopharyngitis,Dyax Corp at or FDA,0
KALBITOR,nasopharyngitis,ADVERSE,0
KALBITOR,headache,patients with HAE headache nausea fatigue diarrhea,1
KALBITOR,headache,patients with HAE were,0
KALBITOR,headache,headache nausea fatigue diarrhea,1
KALBITOR,headache,headache nausea fatigue diarrhea,1
KALBITOR,headache,nausea fatigue,0
KALBITOR,headache,headache nausea fatigue diarrhea,1
KALBITOR,headache,HAE headache nausea fatigue diarrhea,1
KALBITOR,headache,headache nausea fatigue diarrhea,1
KALBITOR,nausea,nausea fatigue diarrhea upper,1
KALBITOR,nausea,injection site reacti,0
KALBITOR,nausea,tract infection injection site,0
KALBITOR,nausea,fatigue diarrhea upper respiratory,0
KALBITOR,fatigue,fatigue diarrhea upper respiratory,1
KALBITOR,fatigue,injection site reactions,0
KALBITOR,fatigue,reactions in patients with HAE were headache nausea,0
KALBITOR,diarrhea,diarrhea upper respiratory tract,1
KALBITOR,diarrhea,site,0
KALBITOR,diarrhea,patients with HAE,0
KALBITOR,upper respiratory tract infection,nausea fatigue upper respiratory tract infection injection site reactions,1
KALBITOR,injection site reactions,,0
KALBITOR,injection site reactions,,0
KALBITOR,injection site reactions,respiratory tract injection site,1
KALBITOR,injection site reactions,site reactions nasopharyngitis vomiting pruritus,1
KALBITOR,nasopharyngitis,nasopharyngitis vomiting pruritus upper,1
KALBITOR,nasopharyngitis,pruritus upper abdominal,0
KALBITOR,nasopharyngitis,respiratory tract infection injection,0
KALBITOR,nasopharyngitis,pruritus,0
KALBITOR,nasopharyngitis,infection injection site reactions,0
KALBITOR,nasopharyngitis,nasopharyngitis vomiting pruritus upper,1
KALBITOR,nasopharyngitis,pyrexia,0
KALBITOR,nasopharyngitis,respiratory tract infection injection site,0
KALBITOR,nasopharyngitis,and pyrexia Anaphylaxis wa,0
KALBITOR,nasopharyngitis,nasopharyngitis vomiting pruritus upper,1
KALBITOR,vomiting,vomiting pruritus upper abdominal,1
KALBITOR,vomiting,Anaphylaxis was reported in,0
KALBITOR,vomiting,infection injection site reactions vomiting pruritus upper abdominal,1
KALBITOR,vomiting,respiratory tract infection injection site,0
KALBITOR,vomiting,reactions vomiting pruritus upper abdominal,1
KALBITOR,vomiting,vomiting pruritus upper abdominal,1
KALBITOR,pruritus,,0
KALBITOR,upper abdominal pain,,0
KALBITOR,upper abdominal pain,,0
KALBITOR,upper abdominal pain,reactions nasopharyngitis vomiting upper abdominal,1
KALBITOR,upper abdominal pain,injection,0
KALBITOR,upper abdominal pain,with HAE Injection,0
KALBITOR,upper abdominal pain,vomiting pruritus,0
KALBITOR,pyrexia,and,0
KALBITOR,pyrexia,in of patients with,0
KALBITOR,pyrexia,site,0
KALBITOR,pyrexia,pyrexia Anaphylaxis was reported,1
KALBITOR,Anaphylaxis,upper abdominal pain and Anaphylaxis was reported in,1
KALBITOR,Anaphylaxis,pruritus,0
KALBITOR,Anaphylaxis,reactions were characterized by,0
KALBITOR,Anaphylaxis,Injection site reactions,0
KALBITOR,Anaphylaxis,upper abdominal pain and Anaphylaxis was reported in,1
KALBITOR,Anaphylaxis,by local,0
KALBITOR,Anaphylaxis,pyrexia,0
KALBITOR,Injection site reactions,with,0
KALBITOR,Injection site reactions,andor bruising,0
KALBITOR,Injection site reactions,reactions were characterized by,1
KALBITOR,Injection site reactions,,0
KALBITOR,Injection site reactions,Injection site,1
KALBITOR,Injection site reactions,was,0
KALBITOR,Injection site reactions,Injection site reactions were characterized by,1
KALBITOR,Headache,,0
KALBITOR,Headache,Headache Nausea,1
KALBITOR,Headache,Headache Nausea,1
KALBITOR,Headache,Headache Nausea,1
KALBITOR,Headache,,0
KALBITOR,Nausea,,0
KALBITOR,Nausea,Nausea Diarrhea,1
KALBITOR,Nausea,Headache,0
KALBITOR,Diarrhea,Pyrexia,0
KALBITOR,Diarrhea,Nausea,0
KALBITOR,Pyrexia,,0
KALBITOR,Pyrexia,Pyrexia Injection site reaction,1
KALBITOR,Pyrexia,Injection site reaction,0
KALBITOR,Pyrexia,,0
KALBITOR,Injection site reactions,,0
KALBITOR,Injection site reactions,Pyrexia,0
KALBITOR,Injection site reactions,Nasopharyngitis,0
KALBITOR,Nasopharyngitis,Nasopharyngitis Some,1
KALBITOR,Nasopharyngitis,site,0
KALBITOR,Nasopharyngitis,Nasopharyngitis Some,1
KALBITOR,Nasopharyngitis,site reactions,0
KALBITOR,Nasopharyngitis,,0
KALBITOR,Nasopharyngitis,Nasopharyngitis Some,1
KALBITOR,Nasopharyngitis,Injection site Nasopharyngitis Some,1
KALBITOR,Nasopharyngitis,site Nasopharyngitis Some,1
KALBITOR,ANAPHYLAXIS,persensitiv ity reactions including,1
KALBITOR,ANAPHYLAXIS,persensitiv ity reactions including anaphylaxis have,1
KALBITOR,ANAPHYLAXIS,persensitiv ity reactions including anaphylaxis,1
KALBITOR,ANAPHYLAXIS,persensitiv ity,1
KALBITOR,ANAPHYLAXIS,patients,0
KALBITOR,ANAPHYLAXIS,persensitiv ity reactions,1
KALBITOR,ANAPHYLAXIS,",",1
KALBITOR,ANAPHYLAXIS,,0
KALBITOR,ANAPHYLAXIS,",",1
KALBITOR,ANAPHYLAXIS,patients treated with KALBITOR see,0
KALBITOR,ANAPHYLAXIS,,0
KALBITOR,ANAPHYLAXIS,patients treated with KALBITOR see Contraindications and,0
KALBITOR,ANAPHYLAXIS,", including anaphylaxis have occurred",1
KALBITOR,ANAPHYLAXIS,",",1
KALBITOR,ANAPHYLAXIS,KALBITOR see Contraindications and,0
KALBITOR,ANAPHYLAXIS,,0
KALBITOR,Anaphylaxis,hav e occurred in patients,1
KALBITOR,Anaphylaxis,e occurred in patients treated with KALBITOR see Contraindications and,0
KALBITOR,Anaphylaxis,"ylaxis, hav e occurred in patients",1
KALBITOR,Anaphylaxis,,0
KALBITOR,Anaphylaxis,,0
KALBITOR,Anaphylaxis,KALBITOR see,0
KALBITOR,Anaphylaxis,"ylaxis,",1
KALBITOR,ANAPHYLAXIS,KALBITOR in patie,0
KALBITOR,ANAPHYLAXIS,t the rates observed in practice The safety,1
KALBITOR,ANAPHYLAXIS,t the rates observed in practice The safety,1
KALBITOR,ANAPHYLAXIS,may not t the,1
KALBITOR,Anaphylaxis,wit h HAE treated with either,1
KALBITOR,Anaphylaxis,,0
KALBITOR,Anaphylaxis,The safety data described below reflect exposure to KALBITOR in,0
KALBITOR,Anaphylaxis,to KALBITOR in atients wit h HAE treated with either,1
KALBITOR,Anaphylaxis,below reflect exposure to KALBITOR in p,0
KALBITOR,Anaphylaxis,KALBITOR,0
KALBITOR,Hypersensitivity Reactions,"s, including",1
KALBITOR,Hypersensitivity Reactions,"s, including anaphylaxis,  have occurred in patients treated",1
KALBITOR,Hypersensitivity Reactions,"s, including anaphylaxis,  have occurred in patients",1
KALBITOR,Hypersensitivity Reactions,have occurred in,0
KALBITOR,Hypersensitivity Reactions,"s,",1
KALBITOR,Hypersensitivity Reactions,"s, including anaphylaxis,  have occurred in patients",1
KALBITOR,Hypersensitivity Reactions,"s, including",1
KALBITOR,Anaphylaxis,ed,1
KALBITOR,Anaphylaxis,,0
KALBITOR,Anaphylaxis,,0
KALBITOR,Anaphylaxis,,0
KALBITOR,Anaphylaxis,ed in patie nts treated with KALBITOR see,1
KALBITOR,Anaphylaxis,,0
KALBITOR,Anaphylaxis,,0
KALBITOR,Anaphylaxis,w ith,1
KALBITOR,Anaphylaxis,,0
KALBITOR,Anaphylaxis,s treated,1
KALBITOR,Anaphylaxis,have occurred in s treated w ith,1
KALBITOR,Anaphylaxis,,0
KALBITOR,Anaphylaxis,EXC,0
KALBITOR,Anaphylaxis,have occurred in s,1
KALBITOR,Anaphylaxis,in s treated,1
KALBITOR,hypersensitivity,SUSPECTED ADVERSE REACTIONS tact Dyax Corp.  at,1
KALBITOR,hypersensitivity,ADVERSE REACTIONS tact Dyax Corp.  at,1
KALBITOR,hypersensitivity,tact,1
KALBITOR,hypersensitivity,FDA at FDA or wwwfdagovmedwatch Clinical Trials,0
KALBITOR,hypersensitivity,REACTIONS tact Dyax Corp.  at,1
KALBITOR,hypersensitivity,SUSPECTED ADVERSE REACTIONS tact Dyax Corp.  at,1
KALBITOR,hypersensitivity,REACTIONS tact Dyax,1
KALBITOR,hypersensitivity,To report,0
KALBITOR,anaphylaxis,clinical trials of a drug cannot be directly compared to rates in,0
KALBITOR,anaphylaxis,under widely varying,0
KALBITOR,anaphylaxis,Because,0
KALBITOR,anaphylaxis,adverse reaction,0
KALBITOR,anaphylaxis,Because clinical trials are conducted under widely varying conditions adverse reaction rat,0
KALBITOR,anaphylaxis,Because clinical trials are,0
KALBITOR,anaphylaxis,trials are conducted under widely varying conditions adverse,0
KALBITOR,anaphylaxis,clinical trials of other,1
KALBITOR,anaphylaxis,,0
KALBITOR,anaphylaxis,trials of other drug  and,1
KALBITOR,anaphylaxis,clinical trials,0
KALBITOR,anaphylaxis,the clinical trials of other drug  and,1
KALBITOR,anaphylaxis,clinical,0
KALBITOR,chest discomfort,rates observed in practice he safety data d escribed,1
KALBITOR,chest discomfort,he safety data d escribed,1
KALBITOR,chest discomfort,rates observed in practice T,0
KALBITOR,flushing,KALBITOR in patients with,0
KALBITOR,pharyngeal edema,the rates observed in practice The,0
KALBITOR,pruritus,in patients with HAE treated with either intravenous or,0
KALBITOR,pruritus,data,0
KALBITOR,pruritus,intravenous or,0
KALBITOR,pruritus,to KAL BITOR,1
KALBITOR,rhinorrhea,,0
KALBITOR,rhinorrhea,to,0
KALBITOR,rhinorrhea,below reflect exposure to KALBI,0
KALBITOR,sneezing,KALBITOR Of,0
KALBITOR,sneezing,treated,0
KALBITOR,sneezing,described below reflect exposure to,0
KALBITOR,sneezing,to KALBITOR in,0
KALBITOR,sneezing,practice The safety data described below reflect exposure,0
KALBITOR,sneezing,atients  with,1
KALBITOR,sneezing,exposure to KALBITOR in atients  with,1
KALBITOR,sneezing,exposure to KALBITOR in atients  with,1
KALBITOR,sneezing,described below reflect exposure to KALBITOR in p,0
KALBITOR,sneezing,in atients  with,1
KALBITOR,nasal congestion,w ith,1
KALBITOR,nasal congestion,to KALBITOR in patients th,1
KALBITOR,nasal congestion,th HAE treated w ith,1
KALBITOR,throat irritation,patients with HAE treated h either intraven ous,1
KALBITOR,throat irritation,HAE treated wit,0
KALBITOR,throat irritation,Of the patients of patients were female and,0
KALBITOR,throat irritation,intraven ous,1
KALBITOR,throat irritation,,0
KALBITOR,throat irritation,in patients with HAE treated wit,0
KALBITOR,throat irritation,with HAE treated h either intraven ous,1
KALBITOR,throat irritation,with HAE treated h either intraven ous,1
KALBITOR,throat irritation,to,0
KALBITOR,throat irritation,safety data described below reflect exposure to KALBITOR in patients,0
KALBITOR,urticaria,HAE treated with either s or subc utaneous,1
KALBITOR,urticaria,to KALBITOR in patients with HAE treated,0
KALBITOR,wheezing,K ALBITOR,1
KALBITOR,wheezing,HAE treated with either intravenous or,0
KALBITOR,wheezing,with either,0
KALBITOR,wheezing,exposure to KALBITOR in patients with HAE treated with either intravenous,0
KALBITOR,hypotension,or subcutaneous R. Of the,1
KALBITOR,hypotension,intravenous or subcutaneous,0
KALBITOR,hypotension,were female and were,0
KALBITOR,hypotension,HAE treated with either intravenous,0
KALBITOR,hypotension,either intravenous or subcutaneous R. Of the 2 patients,1
KALBITOR,hypotension,subcutaneous R. Of,1
KALBITOR,hypersensitivity,een the ages of and,1
KALBITOR,pruritus,years Overall the ost comm on,1
KALBITOR,pruritus,ost comm on,1
KALBITOR,pruritus,years Overall the ost,1
KALBITOR,pruritus,ost comm on,1
KALBITOR,pruritus,the ages of and years Overall the,0
KALBITOR,pruritus,,0
KALBITOR,pruritus,in patients with HAE were headache,0
KALBITOR,rash,rse  reactions,1
KALBITOR,rash,rse  reactions,1
KALBITOR,urticaria,adverse reactions n 255 pat ients,1
KALBITOR,urticaria,common adverse,0
KALBITOR,urticaria,diarrhea upper,0
KALBITOR,urticaria,were between the ages of and years Overall the,0
KALBITOR,urticaria,the ages of and years,0
KALBITOR,urticaria,n 255 pat ients,1
APTIOM,Suicidal Behavior,Behavior and,1
APTIOM,Suicidal Behavior,Ideation see Warnings and Precautions Serious Dermatologic,0
APTIOM,Suicidal Behavior,Behavior and,1
APTIOM,Suicidal Behavior,Suicidal Behavior and,1
APTIOM,Suicidal Behavior,section of the Suicidal Behavior and,1
APTIOM,Dermatologic Reactions,Dermatologic Reactions see,1
APTIOM,Dermatologic Reactions,Reaction with Eosinophilia and Systemic,0
APTIOM,Dermatologic Reactions,Warnings and,0
APTIOM,Dermatologic Reactions,and,0
APTIOM,Dermatologic Reactions,Serious,0
APTIOM,Dermatologic Reactions,,0
APTIOM,Dermatologic Reactions,Behavior and Ideation see Warnings and,0
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,Warnings and Drug Reaction,1
APTIOM,DRESS,,0
APTIOM,DRESS,Anaphylactic Reactions,0
APTIOM,DRESS,DRESS Multiorgan,1
APTIOM,DRESS,Precautions Drug Reaction with Eosinophilia,0
APTIOM,DRESS,Warnings and Precautions,0
APTIOM,DRESS,DRESS Multiorgan,1
APTIOM,Multiorgan Hypersensitivity,Reaction with Eosinophilia,0
APTIOM,Multiorgan Hypersensitivity,DRESS,0
APTIOM,Multiorgan Hypersensitivity,Eosinophilia and Systemic Symptoms Multiorgan,1
APTIOM,Multiorgan Hypersensitivity,and Systemic Symptoms Multiorgan,1
APTIOM,Multiorgan Hypersensitivity,Symptoms DRESS,0
APTIOM,Multiorgan Hypersensitivity,and,0
APTIOM,Multiorgan Hypersensitivity,Angioedema see,0
APTIOM,Multiorgan Hypersensitivity,Reaction with Eosinophilia and Systemic,0
APTIOM,Multiorgan Hypersensitivity,Symptoms Multiorgan,1
APTIOM,Anaphylactic Reactions,Anaphylactic Reactions and,1
APTIOM,Anaphylactic Reactions,Hypersensitivity see Warnings and Anaphylactic Reactions and,1
APTIOM,Anaphylactic Reactions,and Anaphylactic Reactions and,1
APTIOM,Anaphylactic Reactions,Anaphylactic Reactions and,1
APTIOM,Anaphylactic Reactions,Anaphylactic Reactions and,1
APTIOM,Anaphylactic Reactions,DRESSMultiorgan,0
APTIOM,Anaphylactic Reactions,and Precautions,0
APTIOM,Anaphylactic Reactions,Reactions and,1
APTIOM,Angioedema,Anaphylactic Reactions Angioedema see,1
APTIOM,Angioedema,and Precautions Anaphylactic Reactions Angioedema see,1
APTIOM,Angioedema,,0
APTIOM,Hyponatremia,Hyponatremia see,1
APTIOM,Hyponatremia,and,0
APTIOM,Hyponatremia,and Precautions Neurological Adverse,0
APTIOM,Hyponatremia,Hyponatremia see,1
APTIOM,Hyponatremia,,0
APTIOM,Neurological Adverse Reactions,Neurological,1
APTIOM,Drug Induced Liver Injury,Drug Induced Liver,1
APTIOM,Drug Induced Liver Injury,Liver Injury see,1
APTIOM,dizziness,APTIOM and greater than dizziness somnolence,1
APTIOM,dizziness,greater than placebo,0
APTIOM,somnolence,dizziness,0
APTIOM,somnolence,somnolence nausea,1
APTIOM,somnolence,somnolence nausea,1
APTIOM,somnolence,somnolence nausea,1
APTIOM,somnolence,somnolence nausea,1
APTIOM,somnolence,reactions in patients receiving APTIOM and greater than,0
APTIOM,somnolence,than placebo somnolence nausea,1
APTIOM,somnolence,somnolence nausea,1
APTIOM,somnolence,and greater than placebo,0
APTIOM,nausea,nausea headache,1
APTIOM,nausea,than placebo dizziness nausea headache,1
APTIOM,nausea,placebo dizziness nausea headache,1
APTIOM,nausea,,0
APTIOM,nausea,than placebo dizziness,0
APTIOM,nausea,nausea headache,1
APTIOM,nausea,,0
APTIOM,nausea,nausea headache,1
APTIOM,nausea,nausea headache,1
APTIOM,headache,headache diplopia,1
APTIOM,headache,ataxia blurred vision and tremor,0
APTIOM,headache,than placebo dizziness somnolence headache diplopia,1
APTIOM,headache,,0
APTIOM,diplopia,and tremor To report SUSPECTE,0
APTIOM,diplopia,somnolence nausea diplopia vomiting,1
APTIOM,diplopia,diplopia vomiting,1
APTIOM,diplopia,diplopia vomiting,1
APTIOM,diplopia,diplopia vomiting,1
APTIOM,diplopia,diplopia vomiting,1
APTIOM,diplopia,diplopia vomiting,1
APTIOM,diplopia,,0
APTIOM,diplopia,placebo dizziness somnolence nausea diplopia vomiting,1
APTIOM,diplopia,nausea diplopia vomiting,1
APTIOM,vomiting,headache diplopia,0
APTIOM,fatigue,,0
APTIOM,fatigue,placebo dizziness somnolence nausea,0
APTIOM,fatigue,blurred vision and tremor To report SUSPECTED ADVERSE,0
APTIOM,fatigue,fatigue vertigo,1
APTIOM,fatigue,To report,0
APTIOM,fatigue,,0
APTIOM,fatigue,fatigue vertigo,1
APTIOM,fatigue,nausea headache diplopia fatigue vertigo,1
APTIOM,fatigue,ataxia blurred vision and tremor To,0
APTIOM,vertigo,nausea headache diplopia vomiting,0
APTIOM,vertigo,contact,0
APTIOM,vertigo,greater,0
APTIOM,vertigo,,0
APTIOM,vertigo,,0
APTIOM,vertigo,diplopia vomiting vertigo ataxia,1
APTIOM,ataxia,vomiting fatigue vertigo,0
APTIOM,ataxia,ataxia blurred,1
APTIOM,ataxia,ataxia blurred,1
APTIOM,ataxia,,0
APTIOM,ataxia,ataxia blurred,1
APTIOM,ataxia,,0
APTIOM,ataxia,,0
APTIOM,ataxia,ataxia blurred,1
APTIOM,ataxia,than placebo dizziness somnolence,0
APTIOM,ataxia,ataxia blurred,1
APTIOM,blurred vision,fatigue vertigo blurred vision and,1
APTIOM,blurred vision,somnolence nausea headache diplopia vomiting fatigue vertigo,0
APTIOM,blurred vision,,0
APTIOM,tremor,tremor To,1
APTIOM,tremor,vomiting,0
APTIOM,tremor,or FDA a,0
APTIOM,tremor,vomiting fatigue vertigo ataxia,0
APTIOM,tremor,report SUSPECTED ADVERSE REACTIONS contact Sunovion,0
APTIOM,tremor,tremor To,1
APTIOM,hyponatremia,these studies were generally similar to those observed,0
APTIOM,hyponatremia,hyponatremia Adverse,1
APTIOM,hyponatremia,hyponatremia Adverse,1
APTIOM,hyponatremia,hyponatremia Adverse,1
APTIOM,hyponatremia,these studies were generally similar to those observed and attri,0
APTIOM,hyponatremia,similar to,0
APTIOM,hyponatremia,discontinuation was,0
APTIOM,hyponatremia,hyponatremia Adverse,1
APTIOM,hyponatremia,APTIOM leading to discontinuation hyponatremia Adverse,1
APTIOM,Dizziness,not include a,0
APTIOM,Dizziness,causality could not be Dizziness nausea,1
APTIOM,nausea,did not include a placebo control group causality could,0
APTIOM,nausea,be established,0
APTIOM,nausea,not include a,0
APTIOM,nausea,incidences during the AED Withdrawal Phase,0
APTIOM,nausea,nausea somnolence,1
APTIOM,nausea,nausea somnolence,1
APTIOM,nausea,,0
APTIOM,somnolence,AED Withdrawal Phase and,0
APTIOM,somnolence,and fatigue were all reported at lower,0
APTIOM,somnolence,all reported at lower incidences during the AED,0
APTIOM,somnolence,control group causality could not,0
APTIOM,somnolence,somnolence and,1
APTIOM,somnolence,somnolence and,1
APTIOM,somnolence,established Dizziness somnolence and,1
APTIOM,somnolence,somnolence and,1
APTIOM,somnolence,somnolence and,1
APTIOM,fatigue,somnolence fatigue were,1
APTIOM,fatigue,compare,0
APTIOM,fatigue,Dizziness nausea somnolence fatigue were,1
APTIOM,fatigue,,0
APTIOM,dizziness,dizziness nausea,1
APTIOM,dizziness,frequency,0
APTIOM,dizziness,dizziness nausea,1
APTIOM,nausea,blurred,0
APTIOM,nausea,order of frequency were nausea vomiting,1
APTIOM,ataxia,frequency were dizziness nausea ataxia diplopia,1
APTIOM,ataxia,,0
APTIOM,ataxia,vertigo,0
APTIOM,ataxia,vertigo asthenia,0
APTIOM,ataxia,were dizziness nausea ataxia diplopia,1
APTIOM,ataxia,ataxia diplopia,1
APTIOM,ataxia,,0
APTIOM,ataxia,dizziness nausea vomiting,0
APTIOM,ataxia,ataxia diplopia,1
APTIOM,diplopia,diplopia somnolence,1
APTIOM,diplopia,diplopia somnolence,1
APTIOM,diplopia,descending,0
APTIOM,somnolence,diplopia,0
APTIOM,somnolence,somnolence headache,1
APTIOM,somnolence,nausea vomiting ataxia somnolence headache,1
APTIOM,somnolence,somnolence headache,1
APTIOM,somnolence,most f,0
APTIOM,somnolence,somnolence headache,1
APTIOM,headache,,0
APTIOM,headache,headache blurred,1
APTIOM,headache,The,0
APTIOM,headache,headache blurred,1
APTIOM,headache,nausea vomiting ataxia diplopia headache blurred,1
APTIOM,headache,The most frequently,0
APTIOM,headache,ataxia diplopia headache blurred,1
APTIOM,headache,headache blurred,1
APTIOM,headache,rash dysarthria and tremor,0
APTIOM,blurred vision,somnolence blurred,1
APTIOM,blurred vision,blurred vision vertigo,1
APTIOM,blurred vision,of frequency were dizziness nausea vomiting ataxia,0
APTIOM,vertigo,ataxia diplopia,0
APTIOM,vertigo,frequently reported,0
APTIOM,vertigo,vertigo asthenia,1
APTIOM,vertigo,somnolence headache,0
APTIOM,vertigo,vertigo asthenia,1
APTIOM,vertigo,vertigo asthenia,1
APTIOM,vertigo,vomiting ataxia diplopia somnolence headache,0
APTIOM,vertigo,,0
APTIOM,vertigo,blurred vertigo asthenia,1
APTIOM,asthenia,asthenia fatigue,1
APTIOM,asthenia,dizziness nausea vomiting ataxia diplopia somnolence headache,0
APTIOM,asthenia,headache blurred vision asthenia fatigue,1
APTIOM,asthenia,asthenia fatigue,1
APTIOM,asthenia,,0
APTIOM,asthenia,asthenia fatigue,1
APTIOM,asthenia,somnolence headache blurred vision vertigo,0
APTIOM,fatigue,fatigue rash,1
APTIOM,fatigue,fatigue rash,1
APTIOM,fatigue,patients recei,0
APTIOM,fatigue,vomiting ataxia diplopia somnolence,0
APTIOM,fatigue,fatigue rash,1
APTIOM,fatigue,fatigue rash,1
APTIOM,fatigue,fatigue rash,1
APTIOM,fatigue,rash dysarthria and tremor The most frequently reported adverse reactions in patients recei,0
APTIOM,fatigue,ataxia diplopia,0
APTIOM,fatigue,reported adverse reactions,0
APTIOM,rash,rash dysarthria,1
APTIOM,rash,diplopia somnolence,0
APTIOM,rash,tremor The most frequently reported adverse reactions in,0
APTIOM,rash,rash dysarthria,1
APTIOM,rash,,0
APTIOM,rash,,0
APTIOM,rash,and tremor The,0
APTIOM,rash,vision vertigo asthenia fatigue,0
APTIOM,dysarthria,ataxia diplopia somnolence headache,0
APTIOM,dysarthria,dos,0
APTIOM,dysarthria,headache blurred vision,0
APTIOM,dysarthria,dysarthria and,1
APTIOM,dysarthria,dysarthria and,1
APTIOM,tremor,,0
APTIOM,tremor,tremor The,1
APTIOM,tremor,tremor The,1
APTIOM,tremor,tremor The,1
APTIOM,somnolence,tremor,0
APTIOM,somnolence,vertigo,0
APTIOM,somnolence,,0
APTIOM,somnolence,mg and greater than placebo were,0
APTIOM,somnolence,,0
APTIOM,somnolence,diplopia vomiting fatigue vertigo ataxia blurred vision,0
APTIOM,somnolence,diplopia vomiting,0
APTIOM,somnolence,somnolence nausea,1
APTIOM,nausea,nausea headache,1
APTIOM,nausea,nausea headache,1
APTIOM,nausea,nausea headache,1
APTIOM,nausea,dizziness nausea headache,1
APTIOM,nausea,and greater than placebo were dizziness somnolence,0
APTIOM,nausea,headache diplopia vomiting fatigue,0
APTIOM,nausea,were dizziness nausea headache,1
APTIOM,nausea,nausea headache,1
APTIOM,nausea,nausea headache,1
APTIOM,nausea,ataxia blurred vision,0
APTIOM,headache,placebo were dizziness somnolence headache diplopia,1
APTIOM,headache,somnolence headache diplopia,1
APTIOM,headache,headache diplopia,1
APTIOM,headache,were dizziness somnolence headache diplopia,1
APTIOM,headache,headache diplopia,1
APTIOM,headache,headache diplopia,1
APTIOM,diplopia,diplopia vomiting,1
APTIOM,diplopia,diplopia vomiting,1
APTIOM,vomiting,vomiting fatigue,1
APTIOM,vomiting,and greater than placebo were dizziness somnolence nausea headache diplopia,0
APTIOM,vomiting,somnolence nausea headache diplopia,0
APTIOM,vomiting,vomiting fatigue,1
APTIOM,vomiting,vision and tremor Table gives the incidence,0
APTIOM,fatigue,fatigue vertigo,1
APTIOM,fatigue,fatigue vertigo,1
APTIOM,vertigo,the,0
APTIOM,vertigo,diplopia vomiting vertigo ataxia,1
APTIOM,vertigo,were dizziness somnolence nausea,0
APTIOM,vertigo,vomiting vertigo ataxia,1
APTIOM,vertigo,vertigo ataxia,1
APTIOM,vertigo,vertigo ataxia,1
APTIOM,vertigo,vertigo ataxia,1
APTIOM,vertigo,tremor Table gives the,0
APTIOM,ataxia,placebo were dizziness somnolence nausea headache,0
APTIOM,ataxia,fatigue vertigo,0
APTIOM,ataxia,occurred,0
APTIOM,ataxia,headache diplopia vomiting fatigue vertigo,0
APTIOM,ataxia,ataxia blurred,1
APTIOM,blurred vision,vomiting fatigue vertigo blurred vision and,1
APTIOM,tremor,and,0
APTIOM,tremor,the incidence of adverse,0
APTIOM,tremor,,0
APTIOM,tremor,tremor Table,1
APTIOM,tremor,tremor Table,1
APTIOM,Vertigo,,0
APTIOM,Vertigo,,0
APTIOM,Vertigo,,0
APTIOM,Vertigo,disorders,0
APTIOM,Vertigo,Ear and labyrinth,0
APTIOM,Diplopia,Diplopia Blurred,1
APTIOM,Diplopia,Diplopia Blurred,1
APTIOM,Diplopia,Diplopia Blurred,1
APTIOM,Blurred vision,vision Visual,1
APTIOM,Blurred vision,disorders Blurred,1
APTIOM,Blurred vision,Blurred vision Visual,1
APTIOM,Nausea,,0
APTIOM,Nausea,,0
APTIOM,Nausea,Constipation Abdominal pain,0
APTIOM,Nausea,Nausea Vomiting,1
APTIOM,Nausea,al Nausea Vomiting,1
APTIOM,Nausea,Nausea Vomiting,1
APTIOM,Nausea,,0
APTIOM,Nausea,Diarrhea Constipation Abdominal pain,0
APTIOM,Nausea,Abdominal,0
APTIOM,Vomiting,Vomiting Diarrhea,1
APTIOM,Vomiting,,0
APTIOM,Vomiting,Nausea,0
APTIOM,Vomiting,Vomiting Diarrhea,1
APTIOM,Vomiting,Vomiting Diarrhea,1
APTIOM,Vomiting,Vomiting Diarrhea,1
APTIOM,Diarrhea,Diarrhea Constipation,1
APTIOM,Diarrhea,,0
APTIOM,Diarrhea,Nausea Diarrhea Constipation,1
APTIOM,Diarrhea,Diarrhea Constipation,1
APTIOM,Diarrhea,Diarrhea Constipation,1
APTIOM,Constipation,,0
APTIOM,Constipation,Gastritis,0
APTIOM,Constipation,Constipation Abdominal,1
APTIOM,Constipation,pain,0
APTIOM,Constipation,Constipation Abdominal,1
APTIOM,Constipation,Vomiting,0
APTIOM,Constipation,Constipation Abdominal,1
APTIOM,Abdominal pain,Gastritis General disorders,0
APTIOM,Abdominal pain,Nausea Vomiting Diarrhea Abdominal pain Gastritis,1
APTIOM,Abdominal pain,Nausea Vomiting Diarrhea Abdominal pain Gastritis,1
APTIOM,Abdominal pain,Nausea Vomiting Diarrhea Abdominal,1
APTIOM,Fatigue,Fatigue Asthenia,1
APTIOM,Fatigue,,0
APTIOM,Fatigue,Fatigue Asthenia,1
APTIOM,Asthenia,Asthenia Gait,1
APTIOM,Asthenia,disturbance,0
APTIOM,Asthenia,conditions Asthenia Gait,1
APTIOM,Gait disturbance,Gait disturbance Peripheral,1
APTIOM,Gait disturbance,,0
APTIOM,Gait disturbance,Peripheral edema Infections,0
APTIOM,Gait disturbance,Asthenia,0
APTIOM,Gait disturbance,Gait disturbance Peripheral,1
APTIOM,Peripheral edema,,0
APTIOM,Peripheral edema,Fatigue Asthenia Gait Peripheral edema Infections,1
APTIOM,Peripheral edema,Peripheral edema Infections,1
APTIOM,Peripheral edema,Gait Peripheral edema Infections,1
APTIOM,Peripheral edema,,0
APTIOM,Peripheral edema,Gait disturbance,0
APTIOM,Peripheral edema,disturbance,0
APTIOM,Peripheral edema,and Infestations,0
APTIOM,Peripheral edema,Gait Peripheral edema Infections,1
APTIOM,Peripheral edema,Gait Peripheral edema Infections,1
APTIOM,Urinary tract infections,poisoning and,0
APTIOM,Urinary tract infections,Urinary tract,1
APTIOM,Fall,procedural Fall,1
APTIOM,Fall,,0
APTIOM,Fall,Fall,1
APTIOM,Fall,Fall,1
APTIOM,Fall,Fall,1
APTIOM,Fall,,0
APTIOM,Fall,,0
APTIOM,Fall,,0
APTIOM,Fall,,0
APTIOM,Hyponatremia,,0
APTIOM,Hyponatremia,Nervous,0
APTIOM,Hyponatremia,Hyponatremia Nervous,1
APTIOM,Hyponatremia,,0
APTIOM,Hyponatremia,nutrition Hyponatremia Nervous,1
APTIOM,Hyponatremia,Hyponatremia Nervous,1
APTIOM,Hyponatremia,Hyponatremia Nervous,1
APTIOM,Hyponatremia,Hyponatremia Nervous,1
APTIOM,Hyponatremia,Hyponatremia Nervous,1
APTIOM,Hyponatremia,,0
APTIOM,Dizziness,Ataxia Balance disorder Tremor Dysarthria Memory im,0
APTIOM,Dizziness,Dizziness Somnolence,1
APTIOM,Dizziness,disorder Tremor Dysarthria,0
APTIOM,Dizziness,Dizziness Somnolence,1
APTIOM,Dizziness,Dizziness Somnolence,1
APTIOM,Dizziness,disorders,0
APTIOM,Dizziness,Dizziness Somnolence,1
APTIOM,Dizziness,Dizziness Somnolence,1
APTIOM,Dizziness,Nervous system Dizziness Somnolence,1
APTIOM,Somnolence,Somnolence Headache,1
APTIOM,Somnolence,Somnolence Headache,1
APTIOM,Somnolence,Memory,0
APTIOM,Somnolence,Nervous system disorders Somnolence Headache,1
APTIOM,Somnolence,disorders,0
APTIOM,Somnolence,,0
APTIOM,Somnolence,,0
APTIOM,Somnolence,,0
APTIOM,Somnolence,disorders,0
APTIOM,Somnolence,Ny,0
APTIOM,Headache,Dysarthria Memory impairment Nystagmus,0
APTIOM,Headache,Nervous system disorders Dizziness Headache Ataxia,1
APTIOM,Headache,Nervous system disorders Dizziness Headache Ataxia,1
APTIOM,Headache,Somnolence,0
APTIOM,Headache,system disorders Dizziness Headache Ataxia,1
APTIOM,Headache,Headache Ataxia,1
APTIOM,Ataxia,Ataxia Balance,1
APTIOM,Ataxia,Somnolence,0
APTIOM,Ataxia,Memory impairment,0
APTIOM,Ataxia,Ataxia Balance,1
APTIOM,Ataxia,,0
APTIOM,Ataxia,impairment Nystagmus,0
APTIOM,Ataxia,Ataxia Balance,1
APTIOM,Ataxia,Ataxia Balance,1
APTIOM,Balance disorder,disorders Dizziness Somnolence,0
APTIOM,Balance disorder,Balance disorder Tremor,1
APTIOM,Balance disorder,Tremor,0
APTIOM,Balance disorder,disorder Tremor,1
APTIOM,Balance disorder,Dizziness Somnolence Headache Balance,1
APTIOM,Balance disorder,Balance disorder Tremor,1
APTIOM,Balance disorder,disorders Dizziness,0
APTIOM,Balance disorder,disorder Tremor,1
APTIOM,Balance disorder,disorder Tremor,1
APTIOM,Tremor,Somnolence Headache Ataxia Balance Tremor Dysarthria,1
APTIOM,Tremor,Headache Ataxia Balance Tremor Dysarthria,1
APTIOM,Tremor,,0
APTIOM,Tremor,Tremor Dysarthria,1
APTIOM,Tremor,Tremor Dysarthria,1
APTIOM,Tremor,Tremor Dysarthria,1
APTIOM,Tremor,Tremor Dysarthria,1
APTIOM,Tremor,Ataxia,0
APTIOM,Dysarthria,Ataxia Balance disorder Dysarthria Memory,1
APTIOM,Dysarthria,disorder Dysarthria Memory,1
APTIOM,Dysarthria,Dysarthria Memory,1
APTIOM,Dysarthria,Dysarthria Memory,1
APTIOM,Dysarthria,Memory,0
APTIOM,Dysarthria,Dysarthria Memory,1
APTIOM,Dysarthria,Ataxia Balance disorder Dysarthria Memory,1
APTIOM,Dysarthria,Dysarthria Memory,1
APTIOM,Dysarthria,Headache Ataxia Balance,0
APTIOM,Memory impairment,disorder Tremor Memory,1
APTIOM,Memory impairment,impairment Nystagmus,1
APTIOM,Memory impairment,,0
APTIOM,Memory impairment,Nystagmus Psychiatric,0
APTIOM,Memory impairment,Tremor Memory impairment Nystagmus,1
APTIOM,Memory impairment,Somnolence,0
APTIOM,Memory impairment,Memory,1
APTIOM,Memory impairment,,0
APTIOM,Memory impairment,Headache Ataxia Balance disorder Tremor,0
APTIOM,Nystagmus,Nystagmus Psychiatric,1
APTIOM,Nystagmus,Tremor Dysarthria Memory impairment,0
APTIOM,Nystagmus,,0
APTIOM,Depression,Depression Insomnia,1
APTIOM,Insomnia,,0
APTIOM,Insomnia,disorders Insomnia Respiratory,1
APTIOM,Insomnia,Depression,0
APTIOM,Insomnia,Insomnia Respiratory,1
APTIOM,Insomnia,Insomnia Respiratory,1
APTIOM,Cough,,0
APTIOM,Cough,Cough S,1
APTIOM,Cough,,0
APTIOM,Rash,Rash Vascular,1
APTIOM,Rash,Hyperten,0
APTIOM,Rash,,0
APTIOM,Rash,Rash Vascular,1
APTIOM,Rash,disorders Hyperten,0
APTIOM,Rash,disorders,0
APTIOM,Hypertension,Rash Vascular Hypertension Other,1
APTIOM,Hypertension,Hypertension Other,1
APTIOM,Hypertension,Other Adverse,0
APTIOM,Hypertension,Hypertension Other,1
APTIOM,Suicidal Behavior,ctions are descri bed,1
APTIOM,Suicidal Behavior,ctions,1
APTIOM,Suicidal Behavior,,0
APTIOM,Suicidal Behavior,ctions are,1
APTIOM,Suicidal Behavior,,0
APTIOM,Suicidal Behavior,,0
APTIOM,Suicidal Behavior,,0
APTIOM,Suicidal Behavior,ctions are,1
APTIOM,Suicidal Behavior,in the,0
APTIOM,Suicidal Behavior,ctions are,1
APTIOM,Dermatologic Reactions,Suicidal Behavior,1
APTIOM,Dermatologic Reactions,section of the Suicidal Behavior,1
APTIOM,Dermatologic Reactions,and Ideation see Warnings,1
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,"and deation [see Warnings and Precautions (  5.1  )]  
 * Serious Dermatologic Reactions",1
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,Behavior,0
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,Behavior,0
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,Warnings and Precautions Drug Reaction with E,0
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,and deation [see Warnings and Precautions (,1
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,in the Warnings and,0
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,Warnings and Precautions section of,0
APTIOM,DRESS,Serio us Dermatologic Reactions,1
APTIOM,Anaphylactic Reactions,see Warnings and Precautions Dermatologic,1
APTIOM,Anaphylactic Reactions,and Precautions Dermatologic,1
APTIOM,Anaphylactic Reactions,Precautions Dermatologic,1
APTIOM,Anaphylactic Reactions,Precautions Drug,0
APTIOM,Anaphylactic Reactions,Reactions see Warnings and,1
APTIOM,Anaphylactic Reactions,Ideation see Warnings and Precautions Serious,0
APTIOM,Anaphylactic Reactions,Dermatologic Reactions see Warnings and,1
APTIOM,Anaphylactic Reactions,see Warnings and Precautions Dermatologic Reactions see Warnings and,1
APTIOM,Anaphylactic Reactions,,0
APTIOM,Angioedema,Serious Dermatologic,0
APTIOM,Angioedema,Eosinophilia and Systemic Symptoms DRESSMulti,0
APTIOM,Angioedema,DRESSMulti,0
APTIOM,Angioedema,and Precautions Serious,0
APTIOM,Angioedema,and Precautions Drug,0
APTIOM,Angioedema, Warnings  and Precautions Drug,1
APTIOM,Angioedema,,0
APTIOM,Angioedema, Warnings  and Precautions Drug,1
APTIOM,Angioedema,and Precautions Drug Reaction with Eosinophilia and Systemic Symptoms,0
APTIOM,Angioedema, Warnings  and Precautions Drug,1
APTIOM,Hyponatremia,Systemic Symptoms ltiorgan Hyp ersensitivity see Warnings,1
APTIOM,Hyponatremia,Symptoms ltiorgan Hyp ersensitivity see Warnings,1
APTIOM,Hyponatremia,and,0
APTIOM,Hyponatremia,ltiorgan Hyp ersensitivity see Warnings,1
APTIOM,Hyponatremia,Eosinophilia and Systemic Symptoms ltiorgan,1
APTIOM,Hyponatremia,Reaction with Eosinophilia and Systemic Symptoms,0
APTIOM,Hyponatremia,ltiorgan Hyp ersensitivity see Warnings,1
APTIOM,Neurological Adverse Reactions,,0
APTIOM,Neurological Adverse Reactions,and Angioedema see nings and Precautions (  5.4   Hyponatremia see Warnings,1
APTIOM,Neurological Adverse Reactions,nings and Precautions ( 5.4 Hyponatremia see Warnings,1
APTIOM,Drug Induced Liver Injury,ons in patients receiving APTIOM and greater,1
APTIOM,Drug Induced Liver Injury,,0
APTIOM,Drug Induced Liver Injury,EXCERPT Most common adverse ons in patients receiving APTIOM and greater,1
APTIOM,Drug Induced Liver Injury,in patients receiving APTIOM and greater,1
APTIOM,suicidal thoughts,tremor To report SUSPECTED,0
APTIOM,suicidal thoughts,REACTIONS ontact Sunovion,1
APTIOM,suicidal thoughts,SUSPECTED ADVERSE REACTIONS ontact,1
APTIOM,suicidal thoughts,Clinical Trials,0
APTIOM,suicidal thoughts,To report SUSPECTED ADVERSE REACTIONS c,0
APTIOM,suicidal thinking,"IOM, of whom 225  were treated for",1
APTIOM,suicidal thinking,for longer than months Of the patients in those t,0
APTIOM,suicidal thinking,"Studies patients received IOM, of whom 225  were treated for",1
APTIOM,suicidal thinking,"Clinical Studies patients received IOM, of whom 225  were treated for",1
APTIOM,suicidal thinking,seizures Study and Study see,0
APTIOM,suicidal thinking,"Clinical Studies patients received IOM,",1
APTIOM,suicidal thinking,than,0
APTIOM,suicidal thinking,"Clinical Studies patients received IOM, of",1
APTIOM,suicidal thinking,of whom 225 were treated for,1
APTIOM,suicidal behavior,and 84% w ere Caucasian Across,1
APTIOM,suicidal behavior,patients,0
APTIOM,suicidal behavior,"e male, and 84% w ere Caucasian Across",1
APTIOM,suicidal behavior,"e male, and 84% w ere Caucasian Across",1
APTIOM,suicidal behavior,"e male, and 84% w ere Caucasian Across",1
APTIOM,suicidal thinking,adjunctive,0
APTIOM,suicidal thinking,were treated for longer than months,1
APTIOM,suicidal thinking,for partialonset seizures,0
APTIOM,suicidal thinking,,0
APTIOM,suicidal thinking,longer,0
APTIOM,suicidal thinking,placebo controlled adjunctive,0
APTIOM,suicidal thinking,,0
APTIOM,suicidal thinking,were treated,1
APTIOM,suicides,patients with partialonset,0
APTIOM,suicides,than months In e placeb o controlled adjunctive,1
APTIOM,suicides,,0
APTIOM,suicides,In e placeb o controlled adjunctive,1
APTIOM,suicides,e,1
APTIOM,suicides,and,0
APTIOM,suicides,APTIOM of whom were treated for,0
APTIOM,suicide,those t rials approximately were,1
APTIOM,suicide,were male,0
APTIOM,suicide,rials approximately were between,0
APTIOM,suicide,Of the patients those,1
APTIOM,suicide,and approxim,0
APTIOM,suicide,were between and years old approximately,0
APTIOM,suicide,seizures Study Study and Study patients received APTIOM Of the patients in,0
APTIOM,suicide,Of the patients those t rials approximately were,1
APTIOM,suicide,Of the patients those t rials approximately were,1
APTIOM,suicide,,0
APTIOM,suicidal thoughts,e between 18 and years old approximately,1
APTIOM,suicidal thoughts,approximately e between,1
APTIOM,suicidal thoughts,those trials approximately e,1
APTIOM,suicidal thoughts,18 and years old approximately,1
APTIOM,suicidal thoughts,trials approximately e between 18 and  years old approximately,1
APTIOM,suicidal thoughts,years old approximately were male and approximately were Caucasian,0
APTIOM,suicidal thoughts,received APTIOM Of the patients,0
APTIOM,suicidal thoughts,approximately e,1
APTIOM,suicidal thoughts,,0
APTIOM,suicidal thoughts,at,1
APTIOM,suicidal thoughts,recommend ed doses of,1
APTIOM,suicidal thoughts,to receive at the,1
APTIOM,suicidal thoughts,at the,1
APTIOM,suicidal thoughts,patients randomized to receive  at the recommend ed doses of,1
APTIOM,suicidal thoughts,the recommend ed doses of,1
APTIOM,suicidal thoughts,the recommend ed doses of,1
APTIOM,suicidal thoughts,epilepsy trials Study and,0
APTIOM,suicidal thoughts,the recommend ed doses of,1
APTIOM,suicidal thoughts,discontinued from the als,1
APTIOM,suicidal thoughts,,0
APTIOM,Suicidal Thoughts,established Dizziness nausea somnolence and fatigue were,0
APTIOM,Suicidal Thoughts,,0
APTIOM,Suicidal Thoughts,reported at incidences,1
APTIOM,Suicidal Thoughts,durin g the AED,1
APTIOM,Suicidal Thoughts,at  incidences durin g the AED,1
APTIOM,Suicidal Thoughts,durin g the AED,1
APTIOM,Suicidal Thoughts,were all reported at incidences,1
APTIOM,Suicidal Thoughts,incidences durin g the AED,1
APTIOM,Suicidal Thoughts,at lower,0
APTIOM,Suicidal Thoughts,AED Withdrawal Phase and Monotherapy Phase compared with the Titration Phase Adjuncti,0
APTIOM,suicidal thoughts,,0
APTIOM,suicidal thoughts,were dizzine ss somnolence nausea,1
APTIOM,suicidal thoughts,and greater than ebo) were,1
APTIOM,suicidal thoughts,than ebo),1
APTIOM,suicidal thoughts,vomiting,0
APTIOM,morbidity,at an l,1
APTIOM,morbidity,began therapy at an l dose of mg for week,1
APTIOM,morbidity,l dose of mg for week,1
APTIOM,morbidity,,0
APTIOM,mortality,dose mg for,1
APTIOM,mortality,initial dose mg for 1  week and then,1
APTIOM,mortality,patients who initiated therapy,0
APTIOM,mortality,and then,0
APTIOM,mortality,patients who,0
APTIOM,mortality,1 week and then,1
APTIOM,mortality,initial dose mg for 1  week and then,1
APTIOM,mortality,dose mg for,1
APTIOM,suicidal thoughts,and then increased,0
APTIOM,dermatologic reactions,      1151             Gastrointestinal disorders,1
APTIOM,dermatologic reactions,vision Visual       1151             Gastrointestinal disorders,1
APTIOM,dermatologic reactions,,0
APTIOM,dermatologic reactions,vision Visual impairment,0
APTIOM,dermatologic reactions,      1151             Gastrointestinal disorders,1
APTIOM,dermatologic reactions,,0
APTIOM,dermatologic reactions,Blurred vision Visual       1151             Gastrointestinal disorders,1
APTIOM,dermatologic reactions,      1151             Gastrointestinal disorders,1
APTIOM,Stevens-Johnson Syndrome,vision Visual Gastrointestinal,1
APTIOM,Stevens-Johnson Syndrome,Gastrointestinal disor ders Nausea,1
APTIOM,Stevens-Johnson Syndrome,vision Visual impairment,0
APTIOM,Stevens-Johnson Syndrome,,0
APTIOM,Stevens-Johnson Syndrome,"Visual 
 Gastrointestinal disor ders Nausea",1
APTIOM,Stevens-Johnson Syndrome,rred vision Visual Gastrointestinal,1
APTIOM,Stevens-Johnson Syndrome,impairment,0
APTIOM,Stevens-Johnson Syndrome,Gastrointestinal disor ders Nausea,1
APTIOM,Stevens-Johnson Syndrome,,0
APTIOM,SJS,rs  Nausea Vo,1
APTIOM,SJS,Gastrointestinal,0
APTIOM,SJS,Nausea Vo,0
APTIOM,SJS,airment Gastrointestinal rs  Nausea Vo,1
APTIOM,SJS,,0
APTIOM,SJS,,0
APTIOM,fatal,disorders,0
APTIOM,fatal,,0
APTIOM,fatal,      Nausea Vomiting Diarrhea,1
APTIOM,dermatologic reactions,      Nausea     Vomit ing Diarrhea Constipation,1
APTIOM,dermatologic reactions,Constipation,0
APTIOM,dermatologic reactions,      Nausea     Vomit ing Diarrhea Constipation,1
APTIOM,dermatologic reactions,Diarrhea Constipation Abdominal pain,0
APTIOM,dermatologic reactions,      Nausea     Vomit ing Diarrhea Constipation,1
APTIOM,toxic epidermal necrolysis,Abdominal pain Gastritis,0
APTIOM,toxic epidermal necrolysis,pain,0
APTIOM,toxic epidermal necrolysis,Constipation Abdominal pain Gastritis,1
APTIOM,toxic epidermal necrolysis,Nausea Vomiting rhea,1
APTIOM,toxic epidermal necrolysis,Constipation Abdominal pain Gastritis,1
APTIOM,toxic epidermal necrolysis,Vomiting rhea,1
APTIOM,toxic epidermal necrolysis,Vomiting,0
APTIOM,TEN,dom inal pain Gastritis,1
APTIOM,TEN,,0
APTIOM,TEN,,0
APTIOM,TEN,Vomiting Diarrhea Constipation dom inal pain Gastritis,1
APTIOM,TEN,dom inal pain Gastritis,1
APTIOM,TEN,dom inal pain Gastritis,1
APTIOM,TEN,Diarrhea Constipation dom inal pain Gastritis,1
APTIOM,TEN,dom inal pain Gastritis,1
APTIOM,TEN,dom inal pain Gastritis,1
APTIOM,TEN,Diarrhea Constipation Ab,0
APTIOM,SJS,ain Gastritis General disorders,1
APTIOM,SJS,,0
APTIOM,SJS,,0
APTIOM,SJS,ain Gastritis General disorders,1
APTIOM,SJS,ain Gastritis General disorders,1
APTIOM,SJS,Gastritis General,0
APTIOM,dermatologic reactions,,0
APTIOM,dermatologic reactions,Peripheral,0
APTIOM,dermatologic reactions,Urinary tract,0
APTIOM,dermatologic reactions,           7321        Infections and Infestations,1
APTIOM,dermatologic reactions,           7321        Infections and Infestations,1
APTIOM,dermatologic reactions,,0
APTIOM,dermatologic reactions,and Infestations Urinary,0
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,Nervous sy,0
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,nutrition disorders,0
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,Nervous,0
APTIOM,DRESS,Hyponatremia,0
APTIOM,DRESS,,0
APTIOM,DRESS,      Nervous system di,1
APTIOM,DRESS,Hyponatremia,0
APTIOM,DRESS,Nervous syste m disorders Dizziness Somnolence Headache,1
APTIOM,DRESS,syste m,1
APTIOM,DRESS,,0
APTIOM,DRESS,syste m disorders,1
APTIOM,DRESS,syste,1
APTIOM,DRESS,Nervous syste m disorders Dizziness,1
APTIOM,DRESS,Nervous,0
APTIOM,DRESS,Nervous,0
APTIOM,DRESS,,0
APTIOM,DRESS,Nervous syste m,1
APTIOM,DRESS,Nervous,0
APTIOM,DRESS,Balance,0
APTIOM,DRESS,Nervous syste,1
APTIOM,DRESS,Balance disorder,0
APTIOM,DRESS,syste m disorders Dizziness Somnolence Headache,1
APTIOM,DRESS,Nervous,0
APTIOM,fatal,ers   Dizziness Somnolence,1
APTIOM,fatal,Ataxia Balance disorder Tremor Dysarthria,0
APTIOM,fatal,,0
APTIOM,fatal,Dizziness Somnolence Headache Ataxia Balance disorder Tremor Dysarthria,0
APTIOM,fatal,ers   Dizziness Somnolence,1
APTIOM,DRESS,Dizziness,0
APTIOM,DRESS,Memory impairment,0
APTIOM,DRESS,lence Headache Ataxia,1
APTIOM,DRESS,Somno,0
APTIOM,DRESS,Headache Ataxia Balance disorder Tremor Dysarthria Memory impairment Ny,0
APTIOM,DRESS,lence Headache Ataxia,1
APTIOM,DRESS,Nervous system disorders Dizziness lence Headache Ataxia,1
APTIOM,DRESS,,0
APTIOM,fever,emor  Dysarthria Memory,1
APTIOM,rash,Ataxia Balance disorder Tremor,0
APTIOM,rash,sarthria Memory impairment,0
APTIOM,lymphadenopathy,Balance disorder Tremor     Memory impa irment Nystagmus,1
APTIOM,hepatitis,,0
APTIOM,hepatitis,Insomnia,0
APTIOM,hepatitis,disorders Depression,0
APTIOM,hepatitis,181563422 Psychiatric disorders,1
APTIOM,hepatitis,Insomnia,0
APTIOM,hepatitis,181563422 Psychiatric disorders,1
APTIOM,hepatitis,Memory impairment,0
APTIOM,hepatitis,impairment 181563422 Psychiatric disorders,1
APTIOM,hepatitis,,0
APTIOM,nephritis,impairment,0
APTIOM,nephritis,,0
APTIOM,hematological abnormalities,impairment Nystagmus,0
APTIOM,myocarditis,  Depressio n Insomnia,1
APTIOM,myocarditis,Insomnia Respiratory thor,0
APTIOM,myocarditis,Psychiatric   Depressio n Insomnia,1
APTIOM,myocarditis,,0
APTIOM,myocarditis,n Insomnia Respiratory,0
APTIOM,myositis,,0
APTIOM,Eosinophilia,Psychiatric disorders Depression              Respiratory thoracic,1
APTIOM,hypersensitivity,Cough        2         Skin and,1
APTIOM,fever,   1  Skin,1
APTIOM,fever,Cough    1  Skin and subcutaneous tissue,1
APTIOM,fever,,0
APTIOM,fever,Cough,0
APTIOM,fever,Cough,0
APTIOM,lymphadenopathy,Cough,0
APTIOM,lymphadenopathy,                Skin and subcutaneous,1
APTIOM,lymphadenopathy,Cough,0
APTIOM,lymphadenopathy,,0
APTIOM,lymphadenopathy,Cough,0
APTIOM,lymphadenopathy,Cough,0
APTIOM,lymphadenopathy,                Skin and,1
APTIOM,lymphadenopathy,Cough                 Skin and subcutaneous,1
APTIOM,lymphadenopathy,Cough,0
APTIOM,anaphylaxis,triglycerides,0
APTIOM,anaphylaxis,", and",1
APTIOM,anaphylaxis,creatine phosphokinase Adverse Reactions Based on Gender,0
APTIOM,angioedema,and in creatin,1
APTIOM,angioedema,Gender and Race No significant gender diff,0
APTIOM,angioedema,creatin,1
APTIOM,angioedema,creatin,1
APTIOM,angioedema,Adverse Reactions Based on Gender and Race No significant,0
APTIOM,angioedema,creatin,1
APTIOM,Anaphylaxis,,0
APTIOM,angioedema,"Race  



",1
APTIOM,angioedema,gender differences were noted,0
APTIOM,angioedema,in the incidence of adverse,0
APTIOM,angioedema,"Race  



",1
APTIOM,angioedema,increases in creatine phosphokinase Adverse Reactions Based on,0
APTIOM,laryngeal edema,ender differenc,1
APTIOM,laryngeal edema,,0
APTIOM,hyponatremia,,0
APTIOM,hyponatremia,,1
APTIOM,hyponatremia,,0
APTIOM,hyponatremia,,0
APTIOM,hyponatremia,,1
APTIOM,hyponatremia,,1
APTIOM,decreases in sodium values,,0
APTIOM,decreases in sodium values,,1
APTIOM,decreases in sodium values,,0
APTIOM,hyponatremia,,0
APTIOM,hyponatremia,,0
APTIOM,hyponatremia,,1
APTIOM,hyponatremia,,0
APTIOM,seizures,,0
APTIOM,seizures,,1
APTIOM,seizures,,0
APTIOM,seizures,,1
APTIOM,seizures,,0
APTIOM,seizures,,0
APTIOM,seizures,,1
APTIOM,nausea,,0
APTIOM,nausea,,0
APTIOM,nausea,,1
APTIOM,nausea,,0
APTIOM,vomiting,,1
APTIOM,vomiting,,1
APTIOM,vomiting,,0
APTIOM,vomiting,,0
APTIOM,vomiting,,0
APTIOM,vomiting,,1
APTIOM,gait instability,,1
APTIOM,gait instability,,0
APTIOM,gait instability,,0
APTIOM,gait instability,,1
APTIOM,gait instability,,1
APTIOM,gait instability,,0
APTIOM,gait instability,,0
APTIOM,injury,,0
APTIOM,injury,,0
APTIOM,injury,,1
APTIOM,injury,,1
APTIOM,injury,,1
APTIOM,injury,,1
APTIOM,injury,,0
APTIOM,hypochloremia,,0
APTIOM,hypochloremia,,1
APTIOM,hypochloremia,,1
APTIOM,hypochloremia,,1
APTIOM,Hyponatremia,,0
APTIOM,Hyponatremia,,0
APTIOM,Hyponatremia,,0
APTIOM,Hyponatremia,,0
APTIOM,Hyponatremia,,0
APTIOM,dizziness,,1
APTIOM,dizziness,,1
APTIOM,dizziness,,1
APTIOM,dizziness,,1
APTIOM,dizziness,,0
APTIOM,dizziness,,0
APTIOM,dizziness,,0
APTIOM,dizziness,,1
APTIOM,dizziness,,1
APTIOM,dizziness,,0
APTIOM,dizziness,,0
APTIOM,dizziness,,1
APTIOM,dizziness,,1
APTIOM,dizziness,,1
APTIOM,vertigo,,1
APTIOM,balance disorder,,1
APTIOM,balance disorder,,0
APTIOM,balance disorder,,1
APTIOM,balance disorder,,0
APTIOM,gait disturbance,,0
APTIOM,gait disturbance,,1
APTIOM,gait disturbance,,0
APTIOM,nystagmus,,0
APTIOM,nystagmus,,0
APTIOM,nystagmus,,0
APTIOM,nystagmus,,0
APTIOM,nystagmus,,0
APTIOM,nystagmus,,0
APTIOM,nystagmus,,0
APTIOM,nystagmus,,0
APTIOM,nystagmus,,1
APTIOM,nystagmus,,1
APTIOM,abnormal coordination,,1
APTIOM,abnormal coordination,,1
APTIOM,dizziness,,1
APTIOM,dizziness,,1
APTIOM,dizziness,,1
APTIOM,dizziness,,0
APTIOM,disturbance in gait,,0
APTIOM,disturbance in gait,,1
APTIOM,disturbance in gait,,0
APTIOM,disturbance in gait,,0
APTIOM,disturbance in gait,,0
APTIOM,disturbance in gait,,0
APTIOM,disturbance in gait,,1
APTIOM,disturbance in gait,,1
APTIOM,Nausea,,0
APTIOM,Nausea,,0
APTIOM,Nausea,,1
APTIOM,Nausea,,0
APTIOM,Nausea,,1
APTIOM,Nausea,,1
APTIOM,Nausea,,0
APTIOM,Nausea,,0
APTIOM,Nausea,,0
APTIOM,vomiting,,0
APTIOM,vomiting,,1
APTIOM,vomiting,,1
APTIOM,vomiting,,1
APTIOM,vomiting,,0
APTIOM,vomiting,,1
APTIOM,Dizziness,,0
APTIOM,Dizziness,,0
APTIOM,Dizziness,,0
APTIOM,Dizziness,,0
APTIOM,Dizziness,,1
APTIOM,Dizziness,,0
APTIOM,dizziness,,0
APTIOM,dizziness,,0
APTIOM,dizziness,,0
APTIOM,dizziness,,0
APTIOM,dizziness,,1
APTIOM,dizziness,,1
APTIOM,dizziness,,1
APTIOM,dizziness,,0
APTIOM,somnolence,,0
APTIOM,somnolence,,0
APTIOM,somnolence,,1
APTIOM,somnolence,,1
APTIOM,somnolence,,1
APTIOM,fatigue,,1
APTIOM,fatigue,,0
APTIOM,fatigue,,1
APTIOM,fatigue,,0
APTIOM,fatigue,,0
APTIOM,fatigue,,1
APTIOM,fatigue,,1
APTIOM,fatigue,,0
APTIOM,fatigue,,1
APTIOM,fatigue,,1
APTIOM,malaise,,1
APTIOM,malaise,,1
APTIOM,malaise,,0
APTIOM,malaise,,1
APTIOM,malaise,,0
APTIOM,malaise,,0
APTIOM,hypersomnia,,0
APTIOM,hypersomnia,,0
APTIOM,hypersomnia,,1
APTIOM,hypersomnia,,0
APTIOM,hypersomnia,,0
APTIOM,hypersomnia,,1
APTIOM,sedation,,0
APTIOM,sedation,,0
APTIOM,sedation,,1
APTIOM,sedation,,0
APTIOM,sedation,,1
APTIOM,sedation,,0
APTIOM,sedation,,0
APTIOM,sedation,,1
APTIOM,sedation,,1
APTIOM,lethargy,,0
APTIOM,lethargy,,0
APTIOM,Somnolence,,0
APTIOM,Somnolence,,0
APTIOM,Somnolence,,1
APTIOM,Somnolence,,1
APTIOM,Somnolence,,1
APTIOM,Somnolence,,0
APTIOM,Somnolence,,0
APTIOM,Somnolence,,1
APTIOM,Somnolence,,0
APTIOM,Somnolence,,0
APTIOM,Somnolence,,0
APTIOM,Somnolence,,1
APTIOM,Somnolence,,1
APTIOM,Somnolence,,1
APTIOM,Somnolence,,1
APTIOM,Somnolence,,0
APTIOM,fatigue,,0
APTIOM,fatigue,,1
APTIOM,fatigue,,1
APTIOM,fatigue,,1
APTIOM,fatigue,,0
APTIOM,fatigue,,0
APTIOM,fatigue,,0
APTIOM,cognitive dysfunction,,1
APTIOM,memory impairment,,0
APTIOM,memory impairment,,0
APTIOM,memory impairment,,0
APTIOM,memory impairment,,0
APTIOM,memory impairment,,1
APTIOM,memory impairment,,0
APTIOM,memory impairment,,0
APTIOM,memory impairment,,0
APTIOM,memory impairment,,1
APTIOM,memory impairment,,0
APTIOM,disturbance in attention,,0
APTIOM,disturbance in attention,,0
APTIOM,disturbance in attention,,1
APTIOM,amnesia,,1
APTIOM,amnesia,,0
APTIOM,amnesia,,0
APTIOM,confusional state,,1
APTIOM,confusional state,,0
APTIOM,confusional state,,1
APTIOM,confusional state,,1
APTIOM,confusional state,,0
APTIOM,confusional state,,1
APTIOM,confusional state,,1
APTIOM,aphasia,,1
APTIOM,aphasia,,0
APTIOM,aphasia,,0
APTIOM,aphasia,,1
APTIOM,aphasia,,1
APTIOM,aphasia,,1
APTIOM,aphasia,,0
APTIOM,slowness of thought,,1
APTIOM,slowness of thought,,0
APTIOM,psychomotor retardation,,0
APTIOM,psychomotor retardation,,1
APTIOM,psychomotor retardation,,1
APTIOM,psychomotor retardation,,1
APTIOM,psychomotor retardation,,1
APTIOM,psychomotor retardation,,0
APTIOM,Cognitive dysfunction,,0
APTIOM,Cognitive dysfunction,,1
APTIOM,Cognitive dysfunction,,0
APTIOM,Cognitive dysfunction,,0
APTIOM,Cognitive dysfunction,,0
APTIOM,Cognitive dysfunction,,1
APTIOM,Cognitive dysfunction,,1
APTIOM,Cognitive dysfunction,,0
APTIOM,Cognitive dysfunction,,1
APTIOM,Cognitive dysfunction,,0
APTIOM,Cognitive dysfunction,,0
APTIOM,Cognitive dysfunction,,0
APTIOM,Cognitive dysfunction,,1
APTIOM,Cognitive dysfunction,,1
APTIOM,Cognitive dysfunction,,0
APTIOM,Cognitive dysfunction,,0
APTIOM,Cognitive dysfunction,,1
APTIOM,Cognitive dysfunction,,1
APTIOM,Cognitive dysfunction,,0
APTIOM,Cognitive dysfunction,,0
APTIOM,diplopia,,1
APTIOM,diplopia,,1
APTIOM,diplopia,,0
APTIOM,diplopia,,1
APTIOM,diplopia,,0
APTIOM,impaired vision,,0
APTIOM,impaired vision,,1
APTIOM,impaired vision,,0
APTIOM,impaired vision,,0
APTIOM,Eye events,,0
APTIOM,Eye events,,0
APTIOM,Eye events,,1
APTIOM,Eye events,,1
APTIOM,Eye events,,1
APTIOM,Eye events,,0
APTIOM,Eye events,,1
APTIOM,Eye events,,0
APTIOM,Eye events,,0
APTIOM,Eye events,,1
APTIOM,diplopia,,0
APTIOM,diplopia,,0
APTIOM,diplopia,,0
APTIOM,diplopia,,0
APTIOM,diplopia,,0
APTIOM,diplopia,,0
APTIOM,visual changes,,1
APTIOM,visual changes,,0
APTIOM,elevations in transaminases,,1
APTIOM,elevations in transaminases,,1
APTIOM,elevations in transaminases,,1
APTIOM,elevations in transaminases,,0
APTIOM,elevations in transaminases,,1
APTIOM,elevations in transaminases,,0
APTIOM,elevations in transaminases,,1
APTIOM,elevations in transaminases,,0
APTIOM,elevations in transaminases,,0
APTIOM,elevations of total bilirubin,,1
APTIOM,transaminase elevations,,0
APTIOM,transaminase elevations,,1
APTIOM,transaminase elevations,,1
APTIOM,transaminase elevations,,1
APTIOM,transaminase elevations,,1
APTIOM,transaminase elevations,,1
APTIOM,transaminase elevations,,1
APTIOM,elevated bilirubin,,1
APTIOM,liver injury,,1
APTIOM,liver injury,,0
APTIOM,liver injury,,1
APTIOM,liver injury,,1
APTIOM,liver injury,,0
APTIOM,liver injury,,1
APTIOM,liver injury,,1
APTIOM,liver injury,,0
APTIOM,abnormal thyroid function,,1
APTIOM,abnormal thyroid function,,0
APTIOM,abnormal thyroid function,,1
APTIOM,hypothyroidism,,0
APTIOM,hypothyroidism,,0
APTIOM,hypothyroidism,,1
APTIOM,hypothyroidism,,1
APTIOM,hypothyroidism,,1
APTIOM,hypothyroidism,,0
APTIOM,hypothyroidism,,0
APTIOM,hypothyroidism,,0
APTIOM,hypothyroidism,,1
DUAVEE,Cardiovascular Disorders,of the Cardiovascular,1
DUAVEE,Cardiovascular Disorders,of the,0
DUAVEE,Cardiovascular Disorders,sections of the Cardiovascular,1
DUAVEE,Cardiovascular Disorders,Disorders,1
DUAVEE,Malignant Neoplasms,and Precautions Gallbladder Disease see Warnings,0
DUAVEE,Gallbladder Disease,and Precautions Malignant Neoplasms see Warnings and,0
DUAVEE,Gallbladder Disease,Disease,1
DUAVEE,Gallbladder Disease,see Warnings and Gallbladder,1
DUAVEE,Gallbladder Disease,Precautions Malignant Neoplasms see Warnings,0
DUAVEE,Hypertriglyceridemia,Hypertriglyceridemia,1
DUAVEE,Hypertriglyceridemia,see Warnings and,0
DUAVEE,Hypertriglyceridemia,In four,0
DUAVEE,Hypertriglyceridemia,Hypertriglyceridemia,1
DUAVEE,Hypertriglyceridemia,Hypertriglyceridemia,1
DUAVEE,Hypertriglyceridemia,Hypertriglyceridemia,1
DUAVEE,Hypertriglyceridemia,,0
DUAVEE,Hypertriglyceridemia,Hypertriglyceridemia,1
DUAVEE,Hypertriglyceridemia,,0
DUAVEE,muscle spasms,diarrhea dyspepsia,0
DUAVEE,muscle spasms,muscle spasms,1
DUAVEE,muscle spasms,spasms,1
DUAVEE,muscle spasms,muscle spasms,1
DUAVEE,muscle spasms,randomized placebocontrolled trials the common adverse reactions incidence were,0
DUAVEE,nausea,nausea,1
DUAVEE,diarrhea,,0
DUAVEE,diarrhea,,0
DUAVEE,diarrhea,diarrhea,1
DUAVEE,diarrhea,the common adverse reactions incidence were muscle,0
DUAVEE,diarrhea,diarrhea,1
DUAVEE,diarrhea,diarrhea,1
DUAVEE,dyspepsia,reactions incidence were,0
DUAVEE,dyspepsia,neck pain To report SUSPE,0
DUAVEE,dyspepsia,common adverse reactions,0
DUAVEE,dyspepsia,trials,0
DUAVEE,dyspepsia,reactions,0
DUAVEE,abdominal pain upper,,0
DUAVEE,abdominal pain upper,abdominal,1
DUAVEE,abdominal pain upper,the,0
DUAVEE,abdominal pain upper,To report SUSPECTED ADVERSE,0
DUAVEE,abdominal pain upper,muscle spasms nausea diarrhea abdominal pain,1
DUAVEE,abdominal pain upper,pain upper,1
DUAVEE,abdominal pain upper,abdominal pain upper,1
DUAVEE,abdominal pain upper,reactions incidence were muscle spasms nausea,0
DUAVEE,abdominal pain upper,abdominal pain upper,1
DUAVEE,abdominal pain upper,were muscle spasms nausea diarrhea,0
DUAVEE,oropharyngeal pain,dyspepsia abdominal pain upper,0
DUAVEE,oropharyngeal pain,,0
DUAVEE,oropharyngeal pain,oropharyngeal pain,1
DUAVEE,oropharyngeal pain,oropharyngeal,1
DUAVEE,oropharyngeal pain,REACTIONS,0
DUAVEE,oropharyngeal pain,ADVERSE REACTIONS,0
DUAVEE,oropharyngeal pain,dyspepsia abdominal pain oropharyngeal,1
DUAVEE,oropharyngeal pain,diarrhea dyspepsia abdominal pain oropharyngeal pain,1
DUAVEE,dizziness,dyspepsia abdominal pain,0
DUAVEE,dizziness,report,0
DUAVEE,dizziness,muscle spasms nausea diarrhea dyspepsia abdominal pain upper,0
DUAVEE,dizziness,dizziness,1
DUAVEE,dizziness,abdominal pain upper,0
DUAVEE,dizziness,dizziness,1
DUAVEE,dizziness,abdominal pain upper oropharyngeal dizziness,1
DUAVEE,dizziness,oropharyngeal dizziness,1
DUAVEE,neck pain,upper oropharyngeal pain dizziness neck,1
DUAVEE,neck pain,upper oropharyngeal pain dizziness neck pain,1
DUAVEE,neck pain,neck pain,1
DUAVEE,neck pain,,0
DUAVEE,neck pain,oropharyngeal,0
DUAVEE,neck pain,oropharyngeal pain dizziness,0
DUAVEE,neck pain,pain,1
DUAVEE,neck pain,REACTIONS contact Pfizer Inc,0
DUAVEE,mortality,no calcium and vitamin D supplementation as part of the,0
DUAVEE,mortality,mortality,1
DUAVEE,mortality,mortality,1
DUAVEE,mortality,protocol The incidence of mortality,1
DUAVEE,mortality,the protocol,0
DUAVEE,mortality,as part of the protocol The incidence of allcause,0
DUAVEE,mortality,the protocol The incidence,0
DUAVEE,abdominal pain upper,hot abdominal pain upper,1
DUAVEE,abdominal pain upper,pain upper,1
DUAVEE,abdominal pain upper,abdominal pain upper,1
DUAVEE,abdominal pain upper,to discontinuation were hot abdominal,1
DUAVEE,abdominal pain upper,,0
DUAVEE,abdominal pain upper,adverse reactions,0
DUAVEE,abdominal pain upper,,0
DUAVEE,nausea,to discontinuation were hot flush abdominal,0
DUAVEE,Nausea,Nausea,1
DUAVEE,Nausea,,0
DUAVEE,Nausea,Nausea,1
DUAVEE,Nausea,,0
DUAVEE,Nausea,Nausea,1
DUAVEE,Nausea,Nausea,1
DUAVEE,Nausea,,0
DUAVEE,Nausea,Placebo Nn Gastrointestinal disorders,0
DUAVEE,Nausea,Nn Gastrointestinal,0
DUAVEE,Nausea,Nausea,1
DUAVEE,Diarrhea,,0
DUAVEE,Diarrhea,Diarrhea,1
DUAVEE,Diarrhea,,0
DUAVEE,Diarrhea,Diarrhea,1
DUAVEE,Diarrhea,Diarrhea,1
DUAVEE,Diarrhea,,0
DUAVEE,Diarrhea,,0
DUAVEE,Diarrhea,Diarrhea,1
DUAVEE,Diarrhea,Diarrhea,1
DUAVEE,Diarrhea,Diarrhea,1
DUAVEE,Dyspepsia,Dyspepsia,1
DUAVEE,Dyspepsia,Dyspepsia,1
DUAVEE,Dyspepsia,,0
DUAVEE,Dyspepsia,,0
DUAVEE,Dyspepsia,Dyspepsia,1
DUAVEE,Dyspepsia,Dyspepsia,1
DUAVEE,Dyspepsia,Dyspepsia,1
DUAVEE,Abdominal pain upper,,0
DUAVEE,Abdominal pain upper,Abdominal pain,1
DUAVEE,Abdominal pain upper,Abdominal pain upper Musculosk,1
DUAVEE,Abdominal pain upper,Abdominal,1
DUAVEE,Muscle spasms,connective tissue Muscle spasms Neck,1
DUAVEE,Muscle spasms,,0
DUAVEE,Muscle spasms,and connective tissue Muscle,1
DUAVEE,Muscle spasms,and connective tissue Muscle spasms Neck,1
DUAVEE,Muscle spasms,,0
DUAVEE,Muscle spasms,,0
DUAVEE,Muscle spasms,,0
DUAVEE,Muscle spasms,Muscle spasms Neck,1
DUAVEE,Muscle spasms,,0
DUAVEE,Neck pain,Neck pain,1
DUAVEE,Neck pain,Neck pain,1
DUAVEE,Neck pain,asms,0
DUAVEE,Neck pain,asms,0
DUAVEE,Neck pain,,0
DUAVEE,Neck pain,asms Neck pain,1
DUAVEE,Neck pain,asms Neck pain,1
DUAVEE,Neck pain,,0
DUAVEE,Dizziness,,0
DUAVEE,Dizziness,disorders,0
DUAVEE,Oropharyngeal pain,mediastinal disorders,0
DUAVEE,Oropharyngeal pain,,0
DUAVEE,Oropharyngeal pain,mediastinal Oropharyngeal,1
DUAVEE,Oropharyngeal pain,Oropharyngeal,1
DUAVEE,Oropharyngeal pain,,0
DUAVEE,Oropharyngeal pain,Oropharyngeal,1
DUAVEE,Oropharyngeal pain,,0
DUAVEE,venous thromboembolism,with DUAVEE,0
DUAVEE,venous thromboembolism,thrombosis,0
DUAVEE,venous thromboembolism,DUAVEE the reporting rates venous,1
DUAVEE,venous thromboembolism,venous thromboembolism,1
DUAVEE,venous thromboembolism,rates venous thromboembolism,1
DUAVEE,venous thromboembolism,venous thromboembolism,1
DUAVEE,venous thromboembolism,the reporting rates venous thromboembolism,1
DUAVEE,venous thromboembolism,,0
DUAVEE,venous thromboembolism,the reporting rates venous,1
DUAVEE,deep venous thrombosis,rates for venous deep venous thrombosis,1
DUAVEE,deep venous thrombosis,with,0
DUAVEE,deep venous thrombosis,thrombosis,1
DUAVEE,deep venous thrombosis,for venous deep,1
DUAVEE,deep venous thrombosis,venous thrombosis,1
DUAVEE,deep venous thrombosis,,0
DUAVEE,deep venous thrombosis,deep venous thrombosis,1
DUAVEE,deep venous thrombosis,the reporting,0
DUAVEE,pulmonary embolism,rates for venous thromboembolism,0
DUAVEE,pulmonary embolism,pulmonary embolism,1
DUAVEE,pulmonary embolism,venous pulmonary embolism,1
DUAVEE,pulmonary embolism,deep venous pulmonary,1
DUAVEE,pulmonary embolism,embolism,1
DUAVEE,retinal vein thrombosis,rates for venous thromboembolism deep venous thrombosis pulmonary embolism and,0
DUAVEE,retinal vein thrombosis,for venous thromboembolism deep venous thrombosis pulmonary,0
DUAVEE,retinal vein thrombosis,embolism retinal vein thrombosis,1
DUAVEE,retinal vein thrombosis,pulmonary embolism retinal vein,1
DUAVEE,retinal vein thrombosis,,0
DUAVEE,retinal vein thrombosis,embolism retinal vein,1
DUAVEE,retinal vein thrombosis,for venous thromboembolism deep venous thrombosis,0
DUAVEE,retinal vein thrombosis,retinal,1
DUAVEE,retinal vein thrombosis,embolism retinal,1
DUAVEE,retinal vein thrombosis,rates for,0
DUAVEE,venous thromboembolism,thromboembolism,1
DUAVEE,venous thromboembolism,Adverse reactions,0
DUAVEE,venous thromboembolism,groups Adverse reactions,0
DUAVEE,venous thromboembolism,thromboembolism,1
DUAVEE,venous thromboembolism,were reported in of patients treated with DUAVEE and of,0
DUAVEE,venous thromboembolism,low in all treatment,0
DUAVEE,venous thromboembolism,thromboembolism,1
DUAVEE,venous thromboembolism,retinal vein thrombosis were low in all treatment groups Adverse reactions,0
DUAVEE,venous thromboembolism,venous thromboembolism,1
DUAVEE,venous thromboembolism,,0
DUAVEE,venous thromboembolism,both groups it,0
DUAVEE,venous thromboembolism,the risk venous,1
DUAVEE,venous thromboembolism,venous,1
DUAVEE,ENDOMETRIAL CANCER,following,1
DUAVEE,ENDOMETRIAL CANCER,following,1
DUAVEE,ENDOMETRIAL CANCER,other sections of the label,0
DUAVEE,ENDOMETRIAL CANCER,following,1
DUAVEE,ENDOMETRIAL CANCER,following,1
DUAVEE,CARDIOVASCULAR DISORDERS,,0
DUAVEE,DEMENTIA,see Warnings and,0
DUAVEE,DEMENTIA,label Cardiovascular Disorders see Warnings and,0
DUAVEE,DEMENTIA,,0
DUAVEE,DEMENTIA,in oth er sections of the label,1
DUAVEE,DEMENTIA,l,1
DUAVEE,DEMENTIA,sections of the label Cardiovascular,0
DUAVEE,ENDOMETRIAL CANCER,in other sections of he label:,1
DUAVEE,ENDOMETRIAL CANCER,C ardiovascular Disorders see,1
DUAVEE,ENDOMETRIAL CANCER,he label: *,1
DUAVEE,ENDOMETRIAL CANCER,he,1
DUAVEE,ENDOMETRIAL CANCER,Malignant Neoplasms,0
DUAVEE,ENDOMETRIAL CANCER,,0
DUAVEE,CARDIOVASCULAR DISORDERS,the label diovascular,1
DUAVEE,CARDIOVASCULAR DISORDERS,[s ee Warnings and,1
DUAVEE,CARDIOVASCULAR DISORDERS,sections of the label diovascular Disorders [s ee Warnings and,1
DUAVEE,CARDIOVASCULAR DISORDERS,the label diovascular Disorders [s ee Warnings and,1
DUAVEE,CARDIOVASCULAR DISORDERS,Disorders [s ee Warnings and,1
DUAVEE,CARDIOVASCULAR DISORDERS,[s ee Warnings and,1
DUAVEE,DEMENTIA,Warnings d,1
DUAVEE,endometrial hyperplasia,and Precautions EXCERPT In four prospective,0
DUAVEE,endometrial hyperplasia,"mized,",1
DUAVEE,endometrial hyperplasia,,0
DUAVEE,endometrial hyperplasia,four,0
DUAVEE,endometrial hyperplasia,trials,0
DUAVEE,endometrial hyperplasia,"mized, placebo-controll ed trials the",1
DUAVEE,endometrial hyperplasia,"prospective mized,",1
DUAVEE,endometrial hyperplasia,,0
DUAVEE,endometrial hyperplasia,"prospective mized, placebo-controll ed trials the",1
DUAVEE,endometrial hyperplasia,"mized, placebo-controll ed trials the",1
DUAVEE,stroke,observed in the clinical trials of a,0
DUAVEE,stroke,clinical practice The,0
DUAVEE,stroke,clinical ials,1
DUAVEE,stroke,conjug,0
DUAVEE,stroke,in clinical practice The safety of,0
DUAVEE,deep vein thrombosis,ther drug and may no t reflect the,1
DUAVEE,deep vein thrombosis,and may no t reflect the,1
DUAVEE,deep vein thrombosis,of ther drug,1
DUAVEE,deep vein thrombosis,of ther,1
DUAVEE,deep vein thrombosis,of ther drug and may,1
DUAVEE,dementia,patients were,0
DUAVEE,dementia,,0
DUAVEE,dementia,treated  with DUAVEE and,1
DUAVEE,dementia,,0
DUAVEE,dementia,enrolled in Studies,0
DUAVEE,dementia,women age to years mean age years A total,0
DUAVEE,dementia,treated  with DUAVEE and,1
DUAVEE,dementia,total of patients treated  with DUAVEE and,1
DUAVEE,ENDOMETRIAL CANCER,eactions leading,1
DUAVEE,ENDOMETRIAL CANCER,eactions leading t o discontinuation were,1
DUAVEE,ENDOMETRIAL CANCER,the placebo group The most,0
DUAVEE,ENDOMETRIAL CANCER,The most common adverse eactions,1
DUAVEE,CARDIOVASCULAR DISORDERS,discontinuation were hot flush abdominal pain,1
DUAVEE,CARDIOVASCULAR DISORDERS,reactions leading discontinuation were,1
DUAVEE,CARDIOVASCULAR DISORDERS,and,0
DUAVEE,CARDIOVASCULAR DISORDERS,discontinuation,1
DUAVEE,CARDIOVASCULAR DISORDERS,hot flush abdominal pain,1
DUAVEE,CARDIOVASCULAR DISORDERS,common adverse reactions leading,0
DUAVEE,CARDIOVASCULAR DISORDERS,discontinuation were hot flush abdominal pain,1
DUAVEE,DEMENTIA,incidence,0
DUAVEE,DEMENTIA,al,1
DUAVEE,DEMENTIA,discontinuation were hot flush al pain  upper and nausea,1
DUAVEE,DEMENTIA,hot flush al pain  upper and nausea,1
DUAVEE,DEMENTIA,al pain upper and nausea,1
DUAVEE,DEMENTIA,pain upper and nausea,1
DUAVEE,endometrial cancer,Table 1: Adv erse Reactions Incidence,1
DUAVEE,stroke,,0
DUAVEE,DVT,,0
DUAVEE,DVT,    Diarrhea,1
DUAVEE,DVT,    Diarrhea,1
DUAVEE,DVT,Diarrhea,0
DUAVEE,DVT,    Diarrhea,1
DUAVEE,DVT,    Diarrhea,1
DUAVEE,DVT,Diarrhea,0
DUAVEE,DVT,disorders,0
DUAVEE,DVT,,0
DUAVEE,dementia,,0
DUAVEE,dementia,         Dyspepsia,1
DUAVEE,dementia,         Dyspepsia,1
DUAVEE,dementia,         Dyspepsia,1
DUAVEE,dementia,Dyspepsia,0
DUAVEE,dementia,,0
DUAVEE,dementia,         Dyspepsia,1
DUAVEE,Cardiovascular disorders,see Warnings and,0
DUAVEE,pulmonary embolism,(5.3),1
DUAVEE,pulmonary embolism,Warnings  Precautions (5.3),1
DUAVEE,pulmonary embolism, Precautions (5.3),1
DUAVEE,stroke,see,0
DUAVEE,stroke,and Precautions Hypertriglyceridemia see,0
DUAVEE,stroke,Warnings and ],1
DUAVEE,stroke,Warnings,0
DUAVEE,retinal vascular thrombosis,and Precautions bladder Disease,1
DUAVEE,retinal vascular thrombosis,Warnings and Precautions bladder Disease [see  Warni,1
DUAVEE,retinal vascular thrombosis,see Warnings and Precautions bladder Disease [see  Warni,1
DUAVEE,Malignant neoplasms,Precautions,0
DUAVEE,Malignant neoplasms,and Precautions Gallbladder Disease,0
DUAVEE,Malignant neoplasms,"Disease see Warnings and )  ]  
 *  Hypertri",1
DUAVEE,Malignant neoplasms,glyceridemia see Warnings and Precautions,0
DUAVEE,endometrial cancer,Warnings an,1
DUAVEE,endometrial cancer,see Warnings and Precautions  [see  Warnings an,1
DUAVEE,endometrial cancer,Warnings an,1
DUAVEE,endometrial cancer,Warnings an,1
DUAVEE,endometrial cancer,see Warnings and Precautions  [see  Warnings an,1
DUAVEE,endometrial cancer,,0
DUAVEE,breast cancer,,0
DUAVEE,breast cancer,Precautions Hypertriglyceridemia see Warnings Precautions (,1
DUAVEE,ovarian cancer,Warnings and ],1
DUAVEE,ovarian cancer,randomized placebocontrolled trials the common adverse,0
DUAVEE,gallbladder disease,-controlled trials,1
DUAVEE,gallbladder disease,In four prospective randomized -controlled,1
DUAVEE,gallbladder disease,-controlled trials,1
DUAVEE,VTE, 3 ,1
DUAVEE,VTE, 3 ,1
DUAVEE,VTE, 3 ,1
DUAVEE,VTE,was evaluated in,0
DUAVEE,VTE, 3 ,1
DUAVEE,VTE,,0
DUAVEE,stroke,in duration,0
DUAVEE,stroke,clinical trials ranging m,1
DUAVEE,stroke,in four Phase,0
DUAVEE,stroke,in four,0
DUAVEE,DVT,to ,1
DUAVEE,DVT,ranging from to ,1
DUAVEE,DVT,to ,1
DUAVEE,DVT,estrogensbazedoxifene was evaluated in four,0
DUAVEE,DVT,trials ranging from,0
DUAVEE,DVT,women age to,0
DUAVEE,DVT,duration and enrolling postmenopausal women age to years mean,0
DUAVEE,DVT,trials ranging from,0
DUAVEE,DVT,age,0
DUAVEE,stroke,advers,1
DUAVEE,stroke,in the DUAVEE group,0
DUAVEE,stroke,advers,1
DUAVEE,stroke,,0
DUAVEE,stroke,advers,1
DUAVEE,stroke,commonly observed,0
DUAVEE,coronary heart disease,Nausea,0
DUAVEE,CHD,Nn Gastrointestinal disorders,0
DUAVEE,myocardial infarction,Nn Gastrointestinal disorders 100,1
DUAVEE,myocardial infarction,(8) Diarrhea,1
DUAVEE,myocardial infarction,Nn Gastrointestinal disorders 100,1
DUAVEE,myocardial infarction,disorders              100 (8)  Diarrhea,1
DUAVEE,myocardial infarction,,0
DUAVEE,myocardial infarction,,0
DUAVEE,silent myocardial infarction,                          58 Diarrhea,1
DUAVEE,CHD death,          Diarrhea,1
DUAVEE,CHD death,Nausea           Diarrhea,1
DUAVEE,CHD death,,0
DUAVEE,CHD death,Nausea,0
DUAVEE,CHD,Dyspepsia     Abdominal,1
DUAVEE,VTE,connective tissue disorders Muscle spasms,0
DUAVEE,VTE,connective tissue disorders Muscle 10  Neck,1
DUAVEE,VTE,10  Neck,1
DUAVEE,VTE,10  Neck,1
DUAVEE,VTE,disorders Muscle 10  Neck,1
DUAVEE,VTE,and,0
DUAVEE,VTE,connective tissue disorders Muscle 10  Neck,1
DUAVEE,VTE,and connective tissue disorders Muscle,0
DUAVEE,DVT,Muscle )   Neck,1
DUAVEE,DVT,Neck,0
DUAVEE,DVT,,0
DUAVEE,DVT,tissue disorders Muscle )   Neck,1
DUAVEE,DVT,Neck,0
DUAVEE,pulmonary embolism,                   Neck,1
DUAVEE,pulmonary embolism,,0
DUAVEE,pulmonary embolism,,0
DUAVEE,pulmonary embolism,,0
DUAVEE,pulmonary embolism,                   Neck,1
DUAVEE,pulmonary embolism,tissue disorders Muscle                    Neck,1
DUAVEE,pulmonary embolism,tissue disorders Muscle                    Neck,1
DUAVEE,pulmonary embolism,                   Neck,1
DUAVEE,PE,,0
DUAVEE,PE,,0
DUAVEE,DVT,ine ss,1
DUAVEE,DVT,system disorders ine ss,1
DUAVEE,DVT,ine ss,1
DUAVEE,DVT,ine ss,1
DUAVEE,DVT,disorders Dizz,0
DUAVEE,DVT,ine ss,1
DUAVEE,DVT,ine ss,1
DUAVEE,DVT,ine ss,1
DUAVEE,DVT,,0
DUAVEE,DVT,ine ss,1
DUAVEE,VTE,Dizziness     Respiratory thoracic and,1
DUAVEE,VTE,    Respiratory,1
DUAVEE,VTE,    Respiratory thoracic and mediastinal,1
DUAVEE,VTE,Dizziness,0
DUAVEE,VTE,Dizziness     Respiratory thoracic,1
DUAVEE,VTE,Dizziness,0
DUAVEE,endometrial cancer,Warnings and ,1
DUAVEE,endometrial cancer,and ,1
DUAVEE,endometrial cancer,,1
DUAVEE,endometrial cancer,,0
DUAVEE,endometrial cancer,,0
DUAVEE,endometrial cancer,,1
DUAVEE,invasive breast cancer,,1
DUAVEE,invasive breast cancer,,1
DUAVEE,invasive breast cancer,,1
DUAVEE,invasive breast cancer,,1
DUAVEE,invasive breast cancer,,0
DUAVEE,invasive breast cancer,,0
DUAVEE,invasive breast cancer,,0
DUAVEE,invasive breast cancer,,0
DUAVEE,invasive breast cancer,,1
DUAVEE,invasive breast cancer,,0
DUAVEE,ovarian cancer,,0
DUAVEE,ovarian cancer,,0
DUAVEE,ovarian cancer,,1
DUAVEE,ovarian cancer,,1
DUAVEE,ovarian cancer,,0
DUAVEE,ovarian cancer,,1
DUAVEE,ovarian cancer,,0
DUAVEE,dementia,,0
DUAVEE,dementia,,1
DUAVEE,dementia,,0
DUAVEE,dementia,,0
DUAVEE,dementia,,0
DUAVEE,dementia,,0
DUAVEE,dementia,,0
DUAVEE,dementia,,0
DUAVEE,gallbladder disease,,1
DUAVEE,gallbladder disease,,1
DUAVEE,Retinal vascular thrombosis,,1
DUAVEE,Retinal vascular thrombosis,,0
DUAVEE,increases in blood pressure,,0
DUAVEE,increases in blood pressure,,0
DUAVEE,pancreatitis,,1
DUAVEE,pancreatitis,,1
DUAVEE,pancreatitis,,1
DUAVEE,pancreatitis,,0
DUAVEE,pancreatitis,,0
DUAVEE,increased TBG,,0
DUAVEE,increased TBG,,0
DUAVEE,increased TBG,,0
DUAVEE,fluid retention,,1
DUAVEE,fluid retention,,0
DUAVEE,fluid retention,,0
DUAVEE,fluid retention,,0
DUAVEE,fluid retention,,1
DUAVEE,fluid retention,,1
DUAVEE,fluid retention,,0
DUAVEE,fluid retention,,1
DUAVEE,fluid retention,,0
DUAVEE,Accelerated prothrombin time,,0
DUAVEE,Accelerated prothrombin time,,0
DUAVEE,Accelerated prothrombin time,,1
DUAVEE,Accelerated prothrombin time,,1
DUAVEE,Accelerated prothrombin time,,0
DUAVEE,increased platelet count,,1
DUAVEE,increased factors II,,0
DUAVEE,increased factors II,,0
DUAVEE,increased factors II,,1
DUAVEE,increased factors II,,1
DUAVEE,increased factors II,,0
DUAVEE,increased factors II,,1
DUAVEE,increased factors II,,0
DUAVEE,increased factors II,,1
DUAVEE,increased factors II,,0
DUAVEE,decreased levels of antifactor Xa,,1
DUAVEE,decreased levels of antifactor Xa,,0
DUAVEE,decreased antithrombin III activity,,1
DUAVEE,increased levels of fibrinogen,,0
DUAVEE,increased levels of fibrinogen,,1
DUAVEE,increased levels of fibrinogen,,1
DUAVEE,increased levels of fibrinogen,,1
DUAVEE,increased levels of fibrinogen,,0
DUAVEE,increased plasminogen antigen,,0
DUAVEE,increased plasminogen antigen,,1
DUAVEE,Increased thyroid-binding globulin,,1
DUAVEE,Increased thyroid-binding globulin,,1
DUAVEE,increased circulating total thyroid hormone,,1
DUAVEE,increased circulating total thyroid hormone,,1
DUAVEE,increased circulating total thyroid hormone,,1
DUAVEE,increased circulating total thyroid hormone,,0
DUAVEE,increased circulating total thyroid hormone,,0
DUAVEE,increased circulating total thyroid hormone,,1
DUAVEE,increased circulating total thyroid hormone,,0
DUAVEE,increased circulating total thyroid hormone,,1
DUAVEE,increased circulating total thyroid hormone,,1
DUAVEE,elevated TBG,,0
DUAVEE,elevated TBG,,1
DUAVEE,elevated TBG,,0
DUAVEE,elevated TBG,,1
DUAVEE,elevated TBG,,0
DUAVEE,elevated TBG,,0
DUAVEE,elevated TBG,,0
DUAVEE,elevated TBG,,0
DUAVEE,increased total circulating corticosteroids,,1
DUAVEE,increased total circulating corticosteroids,,1
DUAVEE,increased total circulating corticosteroids,,1
DUAVEE,Increased plasma high-density lipoprotein,,1
DUAVEE,Increased plasma high-density lipoprotein,,0
DUAVEE,Increased plasma high-density lipoprotein,,0
DUAVEE,Increased plasma high-density lipoprotein,,0
DUAVEE,Increased plasma high-density lipoprotein,,0
DUAVEE,Increased plasma high-density lipoprotein,,0
DUAVEE,increased triglyceride levels,,1
DUAVEE,Impaired glucose tolerance,,0
DUAVEE,Impaired glucose tolerance,,0
DUAVEE,Impaired glucose tolerance,,0
DUAVEE,Impaired glucose tolerance,,0
DUAVEE,Impaired glucose tolerance,,1
DUAVEE,Impaired glucose tolerance,,1
DUAVEE,Impaired glucose tolerance,,1
DUAVEE,Impaired glucose tolerance,,1
DUAVEE,Impaired glucose tolerance,,1
DUAVEE,Impaired glucose tolerance,,0
KALYDECO,Transaminase Elevations,EXCERPT,0
KALYDECO,Transaminase Elevations,in other sections of the label,0
KALYDECO,Transaminase Elevations,sections of the Transaminase,1
KALYDECO,Transaminase Elevations,reaction is discussed in greater detail in,0
KALYDECO,Transaminase Elevations,Warnings and,0
KALYDECO,Transaminase Elevations,other sections of the Transaminase,1
KALYDECO,Transaminase Elevations,adverse,0
KALYDECO,Transaminase Elevations,Transaminase Elevations,1
KALYDECO,Transaminase Elevations,,0
KALYDECO,Transaminase Elevations,adverse drug,0
KALYDECO,headache,pain upper respiratory tract,0
KALYDECO,headache,headache,1
KALYDECO,headache,have,0
KALYDECO,oropharyngeal pain,in of patients with CF who have a GD mutation in,0
KALYDECO,oropharyngeal pain,the CFTR gene were oropharyngeal pain,1
KALYDECO,oropharyngeal pain,the CFTR gene were,0
KALYDECO,oropharyngeal pain,oropharyngeal pain,1
KALYDECO,oropharyngeal pain,,0
KALYDECO,upper respiratory tract infection,infection,1
KALYDECO,upper respiratory tract infection,headache oropharyngeal upper,1
KALYDECO,upper respiratory tract infection,CF who have a GD mutation in the CFTR gene,0
KALYDECO,upper respiratory tract infection,were headache oropharyngeal upper respiratory tract infection,1
KALYDECO,upper respiratory tract infection,rash nausea,0
KALYDECO,upper respiratory tract infection,and,0
KALYDECO,upper respiratory tract infection,oropharyngeal pain,0
KALYDECO,upper respiratory tract infection,in the CFTR gene were headache oropharyngeal pain,0
KALYDECO,upper respiratory tract infection,tract infection,1
KALYDECO,nasal congestion,dizziness To,0
KALYDECO,nasal congestion,tract nasal,1
KALYDECO,nasal congestion,pain upper respiratory,0
KALYDECO,nasal congestion,upper respiratory tract nasal,1
KALYDECO,nasal congestion,CFTR gene were headache,0
KALYDECO,nasal congestion,upper respiratory tract nasal congestion,1
KALYDECO,nasal congestion,diarrhea rash nausea and dizziness To report,0
KALYDECO,nasal congestion,headache oropharyngeal pain upper respiratory tract,0
KALYDECO,nasal congestion,nasal congestion,1
KALYDECO,nasal congestion,,0
KALYDECO,abdominal pain,abdominal pain,1
KALYDECO,abdominal pain,tract infection nasal abdominal pain,1
KALYDECO,abdominal pain,abdominal pain,1
KALYDECO,abdominal pain,upper,0
KALYDECO,abdominal pain,nasal,0
KALYDECO,abdominal pain,,0
KALYDECO,nasopharyngitis,nasopharyngitis,1
KALYDECO,nasopharyngitis,,0
KALYDECO,nasopharyngitis,and dizziness To report SUSPECTED ADVERSE REACTIONS cont,0
KALYDECO,nasopharyngitis,ADVERSE REACTIONS,0
KALYDECO,nasopharyngitis,infection nasal congestion abdominal nasopharyngitis,1
KALYDECO,nasopharyngitis,nasopharyngitis,1
KALYDECO,nasopharyngitis,upper,0
KALYDECO,diarrhea,diarrhea,1
KALYDECO,diarrhea,,0
KALYDECO,nausea,nausea,1
KALYDECO,dizziness,,0
KALYDECO,dizziness,Incorporated,0
KALYDECO,dizziness,nausea and,0
KALYDECO,dizziness,To report SUSPECTED ADVERSE REACTIONS,0
KALYDECO,dizziness,pain nasopharyngitis diarrhea,0
KALYDECO,dizziness,dizziness,1
KALYDECO,dizziness,dizziness,1
KALYDECO,abdominal pain,hypoglycemia The most common adverse reactions,0
KALYDECO,abdominal pain,patients abdominal,1
KALYDECO,abdominal pain,abdominal pain,1
KALYDECO,abdominal pain,,0
KALYDECO,abdominal pain,KALYDECOtreated patients,0
KALYDECO,headache,,0
KALYDECO,upper respiratory tract infection,upper respiratory tract infection,1
KALYDECO,upper respiratory tract infection,,0
KALYDECO,upper respiratory tract infection,infection,1
KALYDECO,upper respiratory tract infection,with KALYDECO were upper respiratory tract infection,1
KALYDECO,upper respiratory tract infection,treated with KALYDECO were upper,1
KALYDECO,upper respiratory tract infection,upper respiratory tract infection,1
KALYDECO,upper respiratory tract infection,KALYDECO were upper respiratory tract infection,1
KALYDECO,upper respiratory tract infection,rhinitis dizziness,0
KALYDECO,nasal congestion,tract nasal,1
KALYDECO,nasal congestion,sp,0
KALYDECO,nasal congestion,nausea rash rhinitis dizziness arthralgia and bacteria in sp,0
KALYDECO,nasal congestion,congestion,1
KALYDECO,nasal congestion,infection,0
KALYDECO,nasal congestion,,0
KALYDECO,nasal congestion,nasal congestion,1
KALYDECO,nasal congestion,nasal congestion,1
KALYDECO,nasal congestion,respiratory tract infection,0
KALYDECO,nasal congestion,nasal congestion,1
KALYDECO,nausea,bacteria in sputum,0
KALYDECO,nausea,nausea,1
KALYDECO,nausea,in,0
KALYDECO,nausea,nausea,1
KALYDECO,nausea,nausea,1
KALYDECO,rash,rash,1
KALYDECO,rash,rash,1
KALYDECO,rash,,0
KALYDECO,rash,,0
KALYDECO,rash,headache upper respiratory,0
KALYDECO,rhinitis,,0
KALYDECO,rhinitis,rhinitis,1
KALYDECO,dizziness,sputum The incidence of adverse reactions,0
KALYDECO,dizziness,dizziness,1
KALYDECO,dizziness,congestion,0
KALYDECO,dizziness,dizziness,1
KALYDECO,dizziness,dizziness,1
KALYDECO,dizziness,rash dizziness,1
KALYDECO,arthralgia,arthralgia,1
KALYDECO,arthralgia,rash rhinitis dizziness,0
KALYDECO,arthralgia,infection,0
KALYDECO,bacteria in sputum,congestion nausea rash rhinitis dizziness,0
KALYDECO,bacteria in sputum,sputum,1
KALYDECO,bacteria in sputum,rhinitis dizziness arthralgia,0
KALYDECO,bacteria in sputum,rash rhinitis dizziness arthralgia bacteria in sputum,1
KALYDECO,bacteria in sputum,is,0
KALYDECO,bacteria in sputum,rash rhinitis dizziness arthralgia bacteria in sputum,1
KALYDECO,bacteria in sputum,rhinitis dizziness arthralgia bacteria in sputum,1
KALYDECO,Headache,Headache,1
KALYDECO,Headache,Headache,1
KALYDECO,Headache,Headache,1
KALYDECO,Headache,Headache,1
KALYDECO,Headache,Headache,1
KALYDECO,Headache,Headache,1
KALYDECO,Headache,,0
KALYDECO,Oropharyngeal pain,,0
KALYDECO,Oropharyngeal pain,Oropharyngeal pain,1
KALYDECO,Oropharyngeal pain,Oropharyngeal,1
KALYDECO,Oropharyngeal pain,pain,1
KALYDECO,Oropharyngeal pain,Oropharyngeal pain,1
KALYDECO,Oropharyngeal pain,Oropharyngeal pain,1
KALYDECO,Oropharyngeal pain,Oropharyngeal pain,1
KALYDECO,Oropharyngeal pain,Oropharyngeal pain Upper res,1
KALYDECO,Oropharyngeal pain,Oropharyngeal,1
KALYDECO,Oropharyngeal pain,Oropharyngeal pain,1
KALYDECO,Upper respiratory tract infection,,0
KALYDECO,Upper respiratory tract infection,congestion,0
KALYDECO,Nasal congestion,piratory tract Nasal congestion Abdomin,1
KALYDECO,Nasal congestion,,0
KALYDECO,Nasal congestion,Nasal congestion Abdomin,1
KALYDECO,Nasal congestion,Nasal congestion Abdomin,1
KALYDECO,Nasal congestion,congestion Abdomin,1
KALYDECO,Nasal congestion,Abdomin,0
KALYDECO,Nasal congestion,congestion Abdomin,1
KALYDECO,Nasal congestion,Abdomin,0
KALYDECO,Abdominal pain,gestion Abdominal,1
KALYDECO,Abdominal pain,,0
KALYDECO,Abdominal pain,pain Nasop,1
KALYDECO,Abdominal pain,Abdominal pain Nasop,1
KALYDECO,Abdominal pain,gestion Abdominal,1
KALYDECO,Nasopharyngitis,Nasopharyngitis Diarrh,1
KALYDECO,Nasopharyngitis,,0
KALYDECO,Nasopharyngitis,Nasopharyngitis Diarrh,1
KALYDECO,Nasopharyngitis,Nasopharyngitis Diarrh,1
KALYDECO,Nasopharyngitis,Nasopharyngitis Diarrh,1
KALYDECO,Nasopharyngitis,Nasopharyngitis Diarrh,1
KALYDECO,Nasopharyngitis,pain Nasopharyngitis Diarrh,1
KALYDECO,Nasopharyngitis,pain Nasopharyngitis Diarrh,1
KALYDECO,Nasopharyngitis,Nasopharyngitis Diarrh,1
KALYDECO,Nasopharyngitis,pain,0
KALYDECO,Rash,Rash,1
KALYDECO,Rash,Rash,1
KALYDECO,Rash,Rash,1
KALYDECO,Rash,Rash,1
KALYDECO,Rash,,0
KALYDECO,Rash,Rash,1
KALYDECO,Rash,,0
KALYDECO,Nausea,Nausea,1
KALYDECO,Nausea,,0
KALYDECO,Nausea,Nausea,1
KALYDECO,Nausea,Nausea,1
KALYDECO,Nausea,Nausea,1
KALYDECO,Nausea,,0
KALYDECO,Nausea,Nausea,1
KALYDECO,Nausea,,0
KALYDECO,Nausea,,0
KALYDECO,Nausea,,0
KALYDECO,Dizziness,,0
KALYDECO,bacteria in sputum,rhinitis Investigations aspartate aminotransferase bacteria in,1
KALYDECO,bacteria in sputum,connective,0
KALYDECO,bacteria in sputum,rhinitis Investigations aspartate aminotransferase bacteria in sputum,1
KALYDECO,bacteria in sputum,sputum,1
KALYDECO,bacteria in sputum,,0
KALYDECO,bacteria in sputum,and,0
KALYDECO,bacteria in sputum,bacteria in sputum,1
KALYDECO,bacteria in sputum,,0
KALYDECO,blood glucose increased,blood glucose,1
KALYDECO,blood glucose increased,aminotransferase increased,0
KALYDECO,blood glucose increased,disorders arthralgia,0
KALYDECO,blood glucose increased,increased Musculoskeletal and connective tissue disorders arthralgia,0
KALYDECO,blood glucose increased,increased bacteria in blood glucose increased,1
KALYDECO,blood glucose increased,enzyme increased,0
KALYDECO,blood glucose increased,bacteria in blood,1
KALYDECO,blood glucose increased,aminotransferase increased bacteria,0
KALYDECO,blood glucose increased,disorders,0
KALYDECO,blood glucose increased,aminotransferase increased bacteria in blood glucose,1
KALYDECO,hepatic enzyme increased,,0
KALYDECO,arthralgia,hepatic enzyme increased Musculoskeletal and connective,0
KALYDECO,arthralgia,and connective tissue disorders,0
KALYDECO,arthralgia,disorders,0
KALYDECO,arthralgia,increased Musculoskeletal and,0
KALYDECO,arthralgia,,0
KALYDECO,musculoskeletal chest pain,disorders musculoskeletal chest,1
KALYDECO,sinus headache,,0
KALYDECO,sinus headache,,0
KALYDECO,sinus headache,Nervous system sinus,1
KALYDECO,sinus headache,pain myalgia Nervous system sinus,1
KALYDECO,sinus headache,,0
KALYDECO,sinus headache,Respiratory thoracic and mediastinal disorders pharyngeal erythema pleuritic,0
KALYDECO,sinus headache,system,0
KALYDECO,sinus headache,sinus headache,1
KALYDECO,sinus headache,sinus headache,1
KALYDECO,wheezing,,0
KALYDECO,wheezing,wheezing,1
KALYDECO,wheezing,wheezing,1
KALYDECO,wheezing,wheezing,1
KALYDECO,wheezing,patients e,0
KALYDECO,wheezing,wheezing,1
KALYDECO,wheezing,wheezing,1
KALYDECO,wheezing,,0
KALYDECO,wheezing,,0
KALYDECO,acne,other clinical trials,0
KALYDECO,acne,,0
KALYDECO,acne,acne,1
KALYDECO,acne,safety profile for the CF patients enrolled in the other clinical trials,0
KALYDECO,acne,and subcutaneous tissue,0
KALYDECO,elevated transaminases,KALYDECO permanently discontinued treatment elevated transaminases,1
KALYDECO,elevated transaminases,serious adverse reactions,0
KALYDECO,elevated transaminases,transaminases,1
KALYDECO,elevated transaminases,transaminases,1
KALYDECO,transaminase elevations,transaminase elevations,1
KALYDECO,transaminase elevations,incidence of patients transaminase elevations,1
KALYDECO,transaminase elevations,transaminase elevations,1
KALYDECO,transaminase elevations,was All patients had maximum ALT or,0
KALYDECO,transaminase elevations,the incidence of patients transaminase elevations,1
KALYDECO,transaminase elevations,transaminase elevations,1
KALYDECO,transaminase elevations,transaminase,1
KALYDECO,transaminase elevations,elevations,1
KALYDECO,AST levels >8 * ULN,maximum ALT AST levels >8 *,1
KALYDECO,AST levels >8 * ULN,maximum ALT AST levels,1
KALYDECO,AST levels >8 * ULN,AST levels,1
KALYDECO,AST levels >8 * ULN,AST levels >8,1
KALYDECO,AST levels >8 * ULN,ALT AST levels >8 * ULN,1
KALYDECO,AST levels >8 * ULN,ALT or AST ULN was All patients,0
KALYDECO,AST levels >8 * ULN,patients had maximum ALT AST levels >8 * ULN,1
KALYDECO,Elevated transaminases,ction is discussed in ,1
KALYDECO,Cataracts,practice.,1
KALYDECO,Cataracts,practice.,1
KALYDECO,Elevated transaminases,Fdel n (Trial 3). In additi,1
KALYDECO,Elevated transaminases,the,0
KALYDECO,Elevated transaminases,been conducted see Clinical,0
KALYDECO,Elevated transaminases,or were homozygous for,0
KALYDECO,Elevated transaminases,(Trial 3). In additi,1
KALYDECO,Elevated transaminases,Clinical Pharmacology and,0
KALYDECO,Elevated transaminases,the Fdel n (Trial 3). In additi,1
KALYDECO,Elevated transaminases,were,0
KALYDECO,Elevated transaminases,,0
KALYDECO,Elevated transaminases,n (Trial 3). In additi,1
AMYVID,headache,,0
AMYVID,headache,,0
AMYVID,headache,headache occurring in of patients,1
AMYVID,headache,headache occurring in of patients,1
AMYVID,headache,headache occurring in,1
AMYVID,headache,of patients followed by musculoskeletal pain blood pressure increased,0
AMYVID,headache,headache,1
AMYVID,headache,headache,1
AMYVID,blood pressure increased,increased,1
AMYVID,blood pressure increased,in of,0
AMYVID,blood pressure increased,patients followed by musculoskeletal blood,1
AMYVID,blood pressure increased,pressure increased,1
AMYVID,blood pressure increased,blood pressure increased,1
AMYVID,blood pressure increased,blood pressure increased,1
AMYVID,blood pressure increased,adverse reaction was headache occurring in of patients followed,0
AMYVID,blood pressure increased,musculoskeletal blood,1
AMYVID,blood pressure increased,followed by musculoskeletal blood pressure,1
AMYVID,fatigue,fatigue,1
AMYVID,fatigue,occurring in of,0
AMYVID,fatigue,by musculoskeletal pain,0
AMYVID,fatigue,fatigue,1
AMYVID,fatigue,fatigue,1
AMYVID,nausea,and injection site reaction all,0
AMYVID,nausea,and injection site reaction all occurring in of patients,0
AMYVID,nausea,nausea,1
AMYVID,nausea,reaction all occurring,0
AMYVID,injection site reaction,,0
AMYVID,injection site reaction,site reaction,1
AMYVID,injection site reaction,all occurring in of patients To,0
AMYVID,injection site reaction,site reaction,1
AMYVID,injection site reaction,musculoskeletal,0
AMYVID,injection site reaction,fatigue nausea injection site reaction,1
AMYVID,blood pressure increased,patients a Includes the terms,0
AMYVID,hypertension,increased hypertension,1
AMYVID,hypertension,increased hypertension,1
AMYVID,hypertension,hypertension,1
AMYVID,hypertension,hypertension,1
AMYVID,hypertension,hypertension,1
AMYVID,injection site haemorrhage,increased and hypertension b Includes the,0
AMYVID,injection site haemorrhage,Includes the terms,0
AMYVID,injection site haemorrhage,Includes the injection site haemorrhage,1
AMYVID,injection site haemorrhage,,0
AMYVID,injection site irritation,Adverse,0
AMYVID,injection site irritation,terms,0
AMYVID,injection site irritation,blood pressure increased and hypertension b,0
AMYVID,injection site pain,pain,1
AMYVID,injection site pain,site pain,1
AMYVID,injection site pain,chills Adverse,0
AMYVID,injection site pain,,0
AMYVID,feeling cold,of,0
AMYVID,feeling cold,injection site,0
AMYVID,feeling cold,and chills Adverse,0
AMYVID,feeling cold,cold,1
AMYVID,feeling cold,feeling cold,1
AMYVID,feeling cold,site pain c Includes the terms,0
AMYVID,feeling cold,,0
AMYVID,feeling cold,cold,1
AMYVID,feeling cold,,0
AMYVID,chills,Reactions N Percent,0
AMYVID,chills,chills,1
AMYVID,chills,,0
AMYVID,Headache,,0
AMYVID,Headache,Headache Mu,1
AMYVID,Headache,N Percent of Headache Mu,1
AMYVID,Headache,Percent,0
AMYVID,Headache,Headache Mu,1
AMYVID,Headache,patients,0
AMYVID,Headache,Reactions N,0
AMYVID,Headache,,0
AMYVID,Headache,N Percent of patients,0
AMYVID,Headache,Headache Mu,1
AMYVID,Musculoskeletal pain,,0
AMYVID,Musculoskeletal pain,Blood pressure,0
AMYVID,Musculoskeletal pain,he,0
AMYVID,Musculoskeletal pain,,0
AMYVID,Musculoskeletal pain,he Musculoskeletal,1
AMYVID,Musculoskeletal pain,he Musculoskeletal,1
AMYVID,Musculoskeletal pain,he,0
AMYVID,Blood pressure increased,,0
AMYVID,Blood pressure increased,a,0
AMYVID,Nausea,Nausea,1
AMYVID,Fatigue,Fatigue I,1
AMYVID,Fatigue,,0
AMYVID,Fatigue,,0
AMYVID,Fatigue,Fatigue I,1
AMYVID,Fatigue,,0
AMYVID,Fatigue,,0
AMYVID,Fatigue,Fatigue I,1
AMYVID,Fatigue,Fatigue I,1
AMYVID,Fatigue,Fatigue I,1
AMYVID,Injection site reaction,,0
AMYVID,Injection site reaction,e,0
AMYVID,Injection site reaction,e Injection site reaction b Anxiety,1
AMYVID,Injection site reaction,e Injection site reaction,1
AMYVID,Injection site reaction,e Injection site,1
AMYVID,Injection site reaction,e Injection site reaction b Anxiety,1
AMYVID,Injection site reaction,e Injection site reaction b Anxiety,1
AMYVID,Injection site reaction,e Injection site reaction b,1
AMYVID,Injection site reaction,e,0
AMYVID,Anxiety,,0
AMYVID,Anxiety,,0
AMYVID,Anxiety,b,0
AMYVID,Anxiety,Anxiety B,1
AMYVID,Anxiety,B,0
AMYVID,Anxiety,,0
AMYVID,Anxiety,,0
AMYVID,Anxiety,B,0
AMYVID,Back pain,Back pain Cla,1
AMYVID,Back pain,y,0
AMYVID,Back pain,Cla,0
AMYVID,Back pain,y Back pain Cla,1
AMYVID,Back pain,,0
AMYVID,Back pain,pain Cla,1
AMYVID,Back pain,y Back pain Cla,1
AMYVID,Back pain,y,0
AMYVID,Back pain,y Back,1
AMYVID,Back pain,pain Cla,1
AMYVID,Claustrophobia,,0
AMYVID,Claustrophobia,Claustrophobia Dizzines,1
AMYVID,Claustrophobia,,0
AMYVID,Claustrophobia,,0
AMYVID,Claustrophobia,ain Claustrophobia Dizzines,1
AMYVID,Claustrophobia,ain Claustrophobia Dizzines,1
AMYVID,Claustrophobia,Claustrophobia Dizzines,1
AMYVID,Claustrophobia,ain Claustrophobia Dizzines,1
AMYVID,Claustrophobia,Claustrophobia Dizzines,1
AMYVID,Dizziness,Dizziness Fee,1
AMYVID,Dizziness,rophobia Dizziness Fee,1
AMYVID,Dizziness,rophobia,0
AMYVID,Dizziness,rophobia Dizziness Fee,1
AMYVID,Feeling cold,,0
AMYVID,Feeling cold,Insomn,0
AMYVID,infusion site rash,rash dysgeusia pruritis,1
AMYVID,infusion site rash,infusion site,1
AMYVID,infusion site rash,and infusion site,1
AMYVID,infusion site rash,frequencies and infusion site,1
AMYVID,infusion site rash,urticaria and flushing,0
AMYVID,infusion site rash,at lower frequencies and infusion site rash dysgeusia pruritis,1
AMYVID,infusion site rash,,0
AMYVID,dysgeusia,dysgeusia pruritis urticaria,1
AMYVID,dysgeusia,,0
AMYVID,dysgeusia,urticaria and,0
AMYVID,dysgeusia,dysgeusia pruritis urticaria,1
AMYVID,dysgeusia,,0
AMYVID,dysgeusia,at lower frequencies and included,0
AMYVID,dysgeusia,dysgeusia pruritis urticaria,1
AMYVID,dysgeusia,dysgeusia pruritis urticaria,1
AMYVID,dysgeusia,dysgeusia pruritis urticaria,1
AMYVID,pruritis,pruritis urticaria and,1
AMYVID,pruritis,pruritis urticaria and,1
AMYVID,pruritis,,0
AMYVID,pruritis,,0
AMYVID,urticaria,urticaria and flushing,1
AMYVID,urticaria,urticaria and flushing,1
AMYVID,urticaria,,0
AMYVID,urticaria,and flushing,0
AMYVID,flushing,,0
AMYVID,flushing,flushing,1
AMYVID,flushing,dysgeusia pruritis urticaria flushing,1
AMYVID,flushing,,0
AMYVID,flushing,rash dysgeusia pruritis urticaria flushing,1
AMYVID,flushing,flushing,1
AMYVID,Radiation risk,of patients followed by eletal,1
AMYVID,Radiation risk,patients followed by eletal,1
AMYVID,Radiation risk,"pain, b lood pressure",1
AMYVID,Radiation risk,in of patie,0
AMYVID,Radiation risk,lood,0
AMYVID,Radiation risk,"eletal pain, b lood pressure",1
AMYVID,Radiation risk,"pain, b lood pressure",1
AMYVID,long-term cumulative radiation exposure,patients ( 6 ). To report,1
AMYVID,long-term cumulative radiation exposure,increased fatigue nausea and injection,0
AMYVID,long-term cumulative radiation exposure,( 6 ). To report,1
AMYVID,long-term cumulative radiation exposure,pressure increased fatigue nausea and injection site reaction all,0
AMYVID,long-term cumulative radiation exposure,pain c Includes the,0
AMYVID,long-term cumulative radiation exposure,haemorrhage injection site irritation and injection site pain c,0
AMYVID,long-term cumulative radiation exposure,c Includes the terms ing cold and,1
AMYVID,long-term cumulative radiation exposure,Reactions N,0
AMYVID,long-term cumulative radiation exposure,,0
AMYVID,Long-term cumulative radiation exposure,Reactions                               N Percent,1
AMYVID,cancer,,0
AMYVID,cancer,Reactions N,0
AMYVID,cancer,Percent of,0
AMYVID,cancer,,0
TIVICAY,Hypersensitivity,Hypersensitivity reactions see,1
TIVICAY,Hypersensitivity,other,0
TIVICAY,Fat Redistribution,see Warnings and Fat Redistribution see Warnings,1
TIVICAY,Fat Redistribution,Fat Redistribution see Warnings,1
TIVICAY,Fat Redistribution,coinfection see Warnings and Fat Redistribution see Warnings,1
TIVICAY,Fat Redistribution,coinfection see Warnings and Precautions,0
TIVICAY,Fat Redistribution,Fat Redistribution see Warnings,1
TIVICAY,Fat Redistribution,Fat Redistribution see Warnings,1
TIVICAY,Immune Reconstitution Syndrome,Redistribution see Warnings and Immune Reconstitution,1
TIVICAY,Immune Reconstitution Syndrome,and Immune Reconstitution,1
TIVICAY,Immune Reconstitution Syndrome,see Warnings and Immune Reconstitution,1
TIVICAY,Immune Reconstitution Syndrome,Fat Redistribution see Warnings and,0
TIVICAY,Immune Reconstitution Syndrome,and Immune Reconstitution,1
TIVICAY,Immune Reconstitution Syndrome,and Precautions Because clinical trials are conducted under widely,0
TIVICAY,insomnia,insomnia fatigue and,1
TIVICAY,insomnia,insomnia fatigue and,1
TIVICAY,insomnia,any one adult trial insomnia fatigue and,1
TIVICAY,fatigue,SUSPECTED ADVERSE REACTIONS contact ViiV,0
TIVICAY,fatigue,fatigue and headache,1
TIVICAY,headache,headache To report,1
TIVICAY,headache,headache To report,1
TIVICAY,headache,,0
TIVICAY,headache,report SUSPECTED ADVERSE REACTIONS,0
TIVICAY,headache,headache To report,1
TIVICAY,headache,fatigue headache To report,1
TIVICAY,headache,REACTIONS contact ViiV Healthcare at,0
TIVICAY,Insomnia,Insomnia,1
TIVICAY,Insomnia,Insomnia,1
TIVICAY,Insomnia,Insomnia,1
TIVICAY,Insomnia,,0
TIVICAY,Insomnia,,0
TIVICAY,Insomnia,Insomnia,1
TIVICAY,Insomnia,Insomnia,1
TIVICAY,Abnormal dreams,dreams Ne,1
TIVICAY,Abnormal dreams,Abnormal dreams Ne,1
TIVICAY,Dizziness,,0
TIVICAY,Dizziness,Dizziness,1
TIVICAY,Dizziness,m,0
TIVICAY,Dizziness,m Dizziness,1
TIVICAY,Headache,Headache,1
TIVICAY,Headache,,0
TIVICAY,Headache,Headache,1
TIVICAY,Nausea,Nausea,1
TIVICAY,Nausea,Nausea,1
TIVICAY,Nausea,Nausea,1
TIVICAY,Nausea,Nausea,1
TIVICAY,Nausea,,0
TIVICAY,Nausea,Nausea,1
TIVICAY,Diarrhea,Diarrhea,1
TIVICAY,Diarrhea,Diarrhea,1
TIVICAY,Diarrhea,Diarrhea,1
TIVICAY,Rash,a,0
TIVICAY,Rash,a,0
TIVICAY,Rash,a,0
TIVICAY,Rash,,0
TIVICAY,Fatigue,,0
TIVICAY,Fatigue,,0
TIVICAY,Fatigue,Fatigue,1
TIVICAY,Fatigue,Fatigue,1
TIVICAY,Fatigue,ders Fatigue,1
TIVICAY,Fatigue,Fatigue,1
TIVICAY,Fatigue,ders,0
TIVICAY,Vertigo,inth,0
TIVICAY,Vertigo,inth Vertigo,1
TIVICAY,Vertigo,inth,0
TIVICAY,Vertigo,Vertigo,1
TIVICAY,Vertigo,Vertigo,1
TIVICAY,rash,rash generalized,0
TIVICAY,rash,,0
TIVICAY,rash,and drug eruption In,0
TIVICAY,rash,rash,1
TIVICAY,rash,rash,1
TIVICAY,rash,rash,1
TIVICAY,rash,,0
TIVICAY,rash,rash,1
TIVICAY,rash,terms,0
TIVICAY,rash generalized,rash generalized,1
TIVICAY,rash generalized,macular rash maculopapular rash pruritic and drug,0
TIVICAY,rash generalized,eruption In,0
TIVICAY,rash generalized,In addition Grade,0
TIVICAY,rash generalized,rash,0
TIVICAY,rash generalized,,0
TIVICAY,rash generalized,generalized,1
TIVICAY,rash generalized,Includes pooled terms rash,1
TIVICAY,rash generalized,,0
TIVICAY,rash maculo-papular,generalized rash rash maculo-papular,1
TIVICAY,rash maculo-papular,pooled terms rash rash generalized,0
TIVICAY,rash maculo-papular,and drug eruption In addition Grade insomnia,0
TIVICAY,drug eruption,terms rash rash generalized rash macular rash maculopapular,0
TIVICAY,drug eruption,rash maculopapular rash pruritic drug eruption,1
TIVICAY,drug eruption,maculopapular,0
TIVICAY,drug eruption,terms rash rash generalized rash macular rash maculopapular rash pruritic and,0
TIVICAY,drug eruption,rash maculopapular rash pruritic drug,1
TIVICAY,drug eruption,pruritic drug eruption,1
TIVICAY,drug eruption,rash maculopapular rash pruritic drug eruption,1
TIVICAY,drug eruption,rash maculopapular rash pruritic drug,1
TIVICAY,drug eruption,rash macular rash,0
TIVICAY,insomnia,insomnia,1
TIVICAY,insomnia,maculopapular rash pruritic and drug,0
TIVICAY,insomnia,,0
TIVICAY,insomnia,In addition insomnia,1
TIVICAY,insomnia,macular,0
TIVICAY,diarrhea,treatment group diarrhea,1
TIVICAY,diarrhea,either treatment group diarrhea,1
TIVICAY,diarrhea,least frequency in,0
TIVICAY,diarrhea,either treatment group diarrhea,1
TIVICAY,diarrhea,,0
TIVICAY,diarrhea,treatment group diarrhea,1
TIVICAY,diarrhea,diarrhea,1
TIVICAY,diarrhea,diarrhea,1
TIVICAY,Abdominal pain,Gastrointestinal Abdominal,1
TIVICAY,Abdominal pain,pain,0
TIVICAY,flatulence,pain vomiting Hepatobiliary Disorders Hepatitis Musculoskeletal D,0
TIVICAY,flatulence,Musculoskeletal D,0
TIVICAY,flatulence,causal relationship Gastrointestinal Disorders Abdominal pain abdominal discomfort,0
TIVICAY,upper abdominal pain,pain abdominal discomfort upper abdominal pain,1
TIVICAY,upper abdominal pain,pain,0
TIVICAY,vomiting,pain,0
TIVICAY,vomiting,vomiting,1
TIVICAY,vomiting,vomiting,1
TIVICAY,vomiting,Disorders,0
TIVICAY,vomiting,Hepatobiliary Disorders Hepatitis Musculoskeletal,0
TIVICAY,vomiting,,0
TIVICAY,vomiting,vomiting,1
TIVICAY,vomiting,,0
TIVICAY,Hepatitis,abdominal pain vomiting Hepatobiliary Hepatitis,1
TIVICAY,Hepatitis,Disorders Myositis Psychiatric Disorders Suicidal,0
TIVICAY,Hepatitis,Hepatitis,1
TIVICAY,Hepatitis,Hepatitis,1
TIVICAY,Myositis,,0
TIVICAY,Myositis,Myositis,1
TIVICAY,Suicidal ideation,Musculoskeletal Disorders Myositis Psychiatric Suicidal ideation,1
TIVICAY,Suicidal ideation,Disorders Myositis Psychiatric Disorders,0
TIVICAY,Suicidal ideation,Hepatitis Musculoskeletal Disorders Myositis Psychiatric,0
TIVICAY,Renal impairment,Renal,1
TIVICAY,Renal impairment,and Urinary Renal impairment,1
TIVICAY,Renal impairment,and Urinary Renal,1
TIVICAY,Renal impairment,impairment,1
TIVICAY,Renal impairment,Renal and Urinary Renal impairment,1
TIVICAY,Renal impairment,Skin and Subcutaneous Tissue Disorders,0
TIVICAY,Renal impairment,Disorders,0
TIVICAY,Renal impairment,and Urinary Renal impairment,1
TIVICAY,Renal impairment,illness Renal and Urinary Disorders,0
TIVICAY,Pruritus,and Subcutaneous Tissue Pruritus,1
TIVICAY,Pruritus,Pruritus,1
TIVICAY,Pruritus,Pruritus,1
TIVICAY,Pruritus,,0
TIVICAY,Hyperglycemia,Hyperglycemia,1
TIVICAY,Hyperglycemia,,0
TIVICAY,Hyperglycemia,Hyperglycemia,1
TIVICAY,Hyperglycemia,Hyperglycemia,1
TIVICAY,Hyperglycemia,,0
TIVICAY,Hyperglycemia,Hyperglycemia,1
TIVICAY,Hyperglycemia,Hyperglycemia,1
TIVICAY,elevated ALT,elevated ALT,1
TIVICAY,elevated ALT,elevated ALT,1
TIVICAY,elevated ALT,Week elevated,1
TIVICAY,elevated ALT,to combined observed in VIKING at,0
TIVICAY,elevated ALT,at Week elevated ALT,1
TIVICAY,elevated ALT,AST cholesterol creatine kinase hyperglycemia and,0
TIVICAY,hyperglycemia,hyperglycemia,1
TIVICAY,hyperglycemia,to treatmentemergent,0
TIVICAY,hyperglycemia,elevated ALT AST cholesterol,0
TIVICAY,hyperglycemia,creatine hyperglycemia,1
TIVICAY,hyperglycemia,hyperglycemia,1
TIVICAY,hyperglycemia,,0
TIVICAY,hyperglycemia,hyperglycemia,1
TIVICAY,hyperglycemia,cholesterol,0
TIVICAY,hyperglycemia,hyperglycemia,1
TIVICAY,hyperglycemia,of subjects had a Grade to,0
TIVICAY,neutropenia,hematology laboratory abnormality neutropenia,1
TIVICAY,neutropenia,neutropenia,1
TIVICAY,neutropenia,,0
TIVICAY,neutropenia,neutropenia,1
TIVICAY,neutropenia,neutropenia,1
TIVICAY,neutropenia,frequently reported Hepatitis B andor Hepatitis,0
TIVICAY,neutropenia,neutropenia,1
TIVICAY,ALT abnormalities,ALT abnormalities,1
TIVICAY,ALT abnormalities,all treatment groups Grades ALT abnormalities,1
TIVICAY,ALT abnormalities,were,0
TIVICAY,ALT abnormalities,groups Grades ALT,1
TIVICAY,ALT abnormalities,with hepatitis B andor C virus coinfection for all treatment groups,0
TIVICAY,ALT abnormalities,all treatment groups Grades ALT abnormalities,1
TIVICAY,ALT abnormalities,hepatitis B andor C virus coinfection for all treatment groups,0
TIVICAY,ALT abnormalities,Grades ALT,1
TIVICAY,ALT abnormalities,all treatment groups Grades ALT abnormalities,1
TIVICAY,ALT abnormalities,all treatment,0
TIVICAY,ALT abnormalities,monoinfected subjects,0
TIVICAY,Liver chemistry elevations,mg oncedaily dose and vs,0
TIVICAY,Liver chemistry elevations,were observed,0
TIVICAY,Liver chemistry elevations,,0
TIVICAY,Liver chemistry elevations,,0
TIVICAY,Liver chemistry elevations,dose,0
TIVICAY,immune reconstitution syndrome,consistent immune reconstitution,1
TIVICAY,immune reconstitution syndrome,immune reconstitution syndrome,1
TIVICAY,immune reconstitution syndrome,chemistry elevations consistent immune reconstitution syndrome,1
TIVICAY,immune reconstitution syndrome,Liver chemistry elevations consistent immune,1
TIVICAY,immune reconstitution syndrome,reconstitution syndrome,1
TIVICAY,immune reconstitution syndrome,vs with the mg twicedaily dose Liver chemistry,0
TIVICAY,immune reconstitution syndrome,,0
TIVICAY,immune reconstitution syndrome,in some subjects with hepatitis B andor C at the start of therapy with,0
TIVICAY,immune reconstitution syndrome,immune reconstitution syndrome,1
TIVICAY,immune reconstitution syndrome,in some subjects with,0
TIVICAY,increase serum creatinine,Serum Creatinine Dolutegravir has been shown to,0
TIVICAY,increase serum creatinine,increase serum,1
TIVICAY,Increases in serum creatinine,weeks In treat,0
TIVICAY,Increases in serum creatinine,function see Clinical,0
TIVICAY,Increases in serum creatinine,,0
TIVICAY,Increases in serum creatinine,renal glomerular function,0
TIVICAY,Increases in serum creatinine,serum creatinine,1
TIVICAY,Increases in serum creatinine,Clinical Increases in serum creatinine,1
TIVICAY,Increases in serum creatinine,,0
TIVICAY,Increases in serum creatinine,glomerular function see Clinical Increases in,1
TIVICAY,Increases in serum creatinine,Increases in serum creatinine,1
TIVICAY,Creatinine increases,treatmentexperienced,0
TIVICAY,Creatinine increases,,0
TIVICAY,Creatinine increases,were,0
TIVICAY,Creatinine increases,observed after weeks of Creatinine,1
TIVICAY,Creatinine increases,increases,1
TIVICAY,Creatinine increases,of Creatinine increases,1
TIVICAY,rash,rash,1
TIVICAY,rash,reported The,0
TIVICAY,rash,,0
TIVICAY,abdominal pain,least subject were rash abdominal pain,1
TIVICAY,abdominal pain,,0
TIVICAY,abdominal pain,abdominal pain,1
TIVICAY,abdominal pain,,0
TIVICAY,abdominal pain,rash abdominal pain,1
TIVICAY,abdominal pain,Grade or ADRs were,0
TIVICAY,abdominal pain,abdominal pain,1
TIVICAY,abdominal pain,or ADRs,0
TIVICAY,abdominal pain,pain,1
TIVICAY,abdominal pain,were rash abdominal pain,1
TIVICAY,diarrhea,Grade,0
TIVICAY,diarrhea,,0
TIVICAY,diarrhea,were,0
TIVICAY,diarrhea,least,0
TIVICAY,diarrhea,No Grade or ADRs were,0
TIVICAY,elevated total bilirubin,ADRs were reported The Grade laboratory abnormalities were,0
TIVICAY,elevated total bilirubin,laboratory abnormalities elevated total bilirubin,1
TIVICAY,elevated total bilirubin,abnormalities elevated total,1
TIVICAY,elevated total bilirubin,lipase reported in subject each No Grade laboratory abnormalities were reported,0
TIVICAY,elevated total bilirubin,Grade laboratory abnormalities elevated total,1
TIVICAY,elevated total bilirubin,n No,0
TIVICAY,Hypersensitivity reactions,reactions,1
TIVICAY,Hypersensitivity reactions,,0
TIVICAY,Hypersensitivity reactions,events,1
TIVICAY,Hypersensitivity reactions,reactions (adverse events assessed as causally related,1
TIVICAY,Hypersensitivity reactions,reactions (adverse events  assessed as,1
TIVICAY,Hypersensitivity reactions,(adverse events assessed,1
TIVICAY,Hypersensitivity reactions,investigator or ADRs,0
TIVICAY,Hypersensitivity reactions,,0
TIVICAY,Hypersensitivity reactions,events assessed as,1
TIVICAY,Hypersensitivity reactions,reactions (adverse,1
TIVICAY,rash,labeling Hypers,0
TIVICAY,rash,r elated by the investigator or,1
TIVICAY,organ dysfunction,other sections of the labeling Hypersensitivity,1
TIVICAY,organ dysfunction,other sections of the labeling Hypersensitivity,1
TIVICAY,organ dysfunction,labeling Hypersensitivity reactions see Warnings and,0
TIVICAY,organ dysfunction,reactions adverse events assessed as causally related by the investigator,0
TIVICAY,organ dysfunction,are iscussed in other sections of the labeling Hypersensitivity,1
TIVICAY,organ dysfunction,reactions adverse events assessed as causally related,0
TIVICAY,liver injury,other sections  the labelin g Hypersensitivity reactions see Warnings,1
TIVICAY,liver injury,the labelin g Hypersensitivity reactions see Warnings,1
TIVICAY,liver injury, the labelin g Hypersensitivity reactions see Warnings,1
TIVICAY,liver injury,Precautions Effects on,0
TIVICAY,liver injury,the labelin g Hypersensitivity reactions see Warnings,1
TIVICAY,liver injury,the labelin g Hypersensitivity reactions see Warnings,1
TIVICAY,liver injury,discussed in other sections the,1
TIVICAY,transaminase elevations,Syndrome see,0
TIVICAY,transaminase elevations,varying,0
TIVICAY,transaminase elevations,Syndrome see Warnings and recautions,1
TIVICAY,transaminase elevations,reaction rates obse,0
TIVICAY,accumulation of body fat,"in actice.
 

   EXCERPT:   The most common adverse reactions",1
TIVICAY,accumulation of body fat,tho,0
TIVICAY,accumulation of body fat,EXCERPT: The most common adverse reactions,1
TIVICAY,accumulation of body fat,and may not,0
TIVICAY,accumulation of body fat,,0
TIVICAY,accumulation of body fat,in pr,0
TIVICAY,accumulation of body fat,severe intensity and incidence at least in tho,0
TIVICAY,accumulation of body fat,EXCERPT: The most common adverse reactions,1
TIVICAY,accumulation of body fat,rates observed in actice.,1
TIVICAY,accumulation of body fat,the rates,0
TIVICAY,immune reconstitution syndrome,observed in practice EXCERPT most common,1
TIVICAY,immune reconstitution syndrome,may not reflect the rates observed in practice,0
TIVICAY,immune reconstitution syndrome,EXCERPT most common,1
TIVICAY,immune reconstitution syndrome,EXCERPT most common adverse reactions  of moderate to severe intensity,1
TIVICAY,immune reconstitution syndrome,adverse reactions of moderate to severe intensity,1
TIVICAY,Hypersensitivity,( 6.1 ) To report SUSPECTED ADVERSE REACTIONS,1
TIVICAY,Hypersensitivity,receiving TIVICAY in any one adult trial are insomnia fatigue,0
TIVICAY,Hypersensitivity,TIVICAY in any,0
TIVICAY,Hypersensitivity,,0
TIVICAY,Hypersensitivity,and headache,0
TIVICAY,Hypersensitivity,To report SUSPECTED ADVERSE REACTIONS contact ViiV Healthcare at,0
TIVICAY,Hypersensitivity,) To report SUSPECTED ADVERSE REACTIONS,1
TIVICAY,Hypersensitivity,,0
TIVICAY,Hypersensitivity,"(  6.1  )



    To report SUSPECTED ADVERSE REACTIONS",1
TIVICAY,rash,thca re at or FDA at,1
TIVICAY,rash,thca re at or FDA at,1
TIVICAY,rash,thca re at or FDA at,1
TIVICAY,rash,and headache To report SUSPECTED ADVERSE REACTIONS contact,0
TIVICAY,rash,REACTIONS contact ViiV thca re at or FDA at,1
TIVICAY,organ dysfunction,,0
TIVICAY,organ dysfunction,SUSPECTED ADVERSE REACTIONS contact,0
TIVICAY,organ dysfunction,,0
TIVICAY,organ dysfunction,at or FDA at 1088 or,1
TIVICAY,liver injury,or FDA at FDA or wwwfdagovmedwatch,0
TIVICAY,liver injury,Adult Subjects,0
TIVICAY,liver injury,Adverse Drug Reactions,0
TIVICAY,liver injury,"or     



 

  Clinical Trials Experience in Adult",1
TIVICAY,liver injury,"    



 

  Clinical Trials Experience in Adult",1
TIVICAY,liver injury,,0
TIVICAY,liver injury,"    



 

  Clinical Trials Experience in Adult",1
TIVICAY,liver injury,,0
TIVICAY,liver injury,"    



 

  Clinical Trials Experience in Adult",1
TIVICAY,transaminase elevations,at least dose of ther TIVICAY,1
TIVICAY,transaminase elevations,,0
TIVICAY,transaminase elevations,ther TIVICAY 50 mg with fixeddose abacavir sulfate and lamivudine,1
TIVICAY,immune reconstitution syndrome,efavirenzemtricitabinetenofovir,0
TIVICAY,immune reconstitution syndrome,fixeddose efavirenzemtricitabinetenofovir   (r)  ) once daily. Through 9 weeks the rates of adverse,1
TIVICAY,immune reconstitution syndrome,subjects receiving,0
TIVICAY,immune reconstitution syndrome,) once daily. Through 9 weeks the rates of adverse,1
TIVICAY,immune reconstitution syndrome,,0
TIVICAY,immune reconstitution syndrome,,0
TIVICAY,hepatitis B reactivation,,0
TIVICAY,hepatitis B reactivation,daily,0
TIVICAY,hepatitis B reactivation,daily or fixeddose efavirenzemtricitabinetenofovir ATRIPLA r,0
TIVICAY,hepatitis B reactivation,daily or fixeddose efavirenzemtricitabinetenofovir,0
TIVICAY,hepatitis B reactivation,daily or fixeddose efavirenzemtricitabinetenofovir ATRIPLA r once daily Through,0
TIVICAY,hepatitis B reactivation,"daily Through eks,",1
TIVICAY,accumulation of body fat,tabulation is t o simplify presentation direct comparisons,1
TIVICAY,accumulation of body fat,are provided in Table -by-side tabulation is t o simplify presentation direct comparisons,1
TIVICAY,accumulation of body fat,in Table -by-side tabulation is t o simplify presentation direct comparisons,1
TIVICAY,accumulation of body fat,are provided in Table -by-side tabulation is t o simplify presentation direct comparisons,1
TIVICAY,accumulation of body fat,Table -by-side tabulation is t o simplify presentation direct comparisons,1
TIVICAY,accumulation of body fat,comparisons across trials should not be,0
TIVICAY,central obesity,should not be made due,0
TIVICAY,central obesity,resentation; di rect comparisons across trials should,1
TIVICAY,central obesity,tabulation is to simplify resentation; di rect comparisons across trials should,1
TIVICAY,central obesity,,0
TIVICAY,central obesity,are provided,0
TIVICAY,central obesity,tabulation is to simplify resentation; di rect comparisons across trials should,1
TIVICAY,central obesity,di rect comparisons across trials should,1
TIVICAY,buffalo hump,comparisons across trials,0
TIVICAY,facial wasting,"to differing rial designs.
 Table Treatmentemergent Adverse Drug Reactions",1
TIVICAY,facial wasting,designs. Table Treatmentemergent Adverse Drug Reactions,1
TIVICAY,facial wasting,designs. Table Treatmentemergent Adverse Drug Reactions,1
TIVICAY,facial wasting,"to differing rial designs.
 Table Treatmentemergent Adverse Drug Reactions",1
TIVICAY,facial wasting,across trials,0
TIVICAY,facial wasting,rial designs. Table Treatmentemergent Adverse Drug Reactions,1
TIVICAY,breast enlargement,"due to differing trial 
 Table 2. Treatme ntemergent Adverse Drug Reactions of",1
TIVICAY,breast enlargement,,0
TIVICAY,breast enlargement,Drug Reactions of at Least,0
TIVICAY,breast enlargement,,0
TIVICAY,breast enlargement,to differing trial Table 2.,1
TIVICAY,breast enlargement,direct comparisons across trials should,0
TIVICAY,breast enlargement,2. Treatme ntemergent Adverse Drug Reactions of,1
TIVICAY,breast enlargement,Drug Reactions of at Least,0
TIVICAY,breast enlargement,due to differing,0
TIVICAY,breast enlargement,differing trial Table,1
TIVICAY,cushingoid appearance,Adverse Drug Rea ctions of at Least Moderate,1
TIVICAY,cushingoid appearance,,0
TIVICAY,Immune reconstitution syndrome,TIVICAY mg EPZICOM,0
TIVICAY,Immune reconstitution syndrome,Class Preferred Term SPRING TIVICAY 50,1
TIVICAY,Immune reconstitution syndrome,Daily + 2 NRTIs n Raltegravir mg Twice,1
TIVICAY,Immune reconstitution syndrome,Class Preferred Term SPRING,0
TIVICAY,Immune reconstitution syndrome,Analysis System Organ Class Preferred,0
TIVICAY,Immune reconstitution syndrome,50 mg Once Daily + 2 NRTIs n Raltegravir mg Twice,1
TIVICAY,Immune reconstitution syndrome,TIVICAY 50 mg Once Daily +,1
TIVICAY,Immune reconstitution syndrome,Preferred Term SPRING   TIVICAY 50 mg Once Daily + 2 NRTIs n Raltegravir mg Twice,1
TIVICAY,Immune reconstitution syndrome,,0
TIVICAY,inflammatory response,                      Insomnia,1
TIVICAY,inflammatory response,                      Insomnia,1
TIVICAY,inflammatory response,Dailyn,0
TIVICAY,inflammatory response,                      Insomnia,1
TIVICAY,Mycobacterium avium infection,Insomnia                   <1%          Depression,1
TIVICAY,Mycobacterium avium infection,,0
TIVICAY,Mycobacterium avium infection,,0
TIVICAY,Mycobacterium avium infection,                  <1%          Depression,1
TIVICAY,Pneumocystis jirovecii pneumonia,"              2%               
  Depression",1
TIVICAY,Pneumocystis jirovecii pneumonia,"Insomnia               2%               
  Depression",1
TIVICAY,Pneumocystis jirovecii pneumonia,"Insomnia               2%               
  Depression",1
TIVICAY,Pneumocystis jirovecii pneumonia,"              2%               
  Depression",1
TIVICAY,PCP,,0
TIVICAY,PCP,epr ession,1
TIVICAY,PCP,epr ession,1
TIVICAY,PCP,D,0
TIVICAY,PCP,D,0
TIVICAY,tuberculosis,Depression,0
TIVICAY,tuberculosis,             Abnormal,1
TIVICAY,tuberculosis,             Abnormal,1
TIVICAY,tuberculosis,             Abnormal,1
TIVICAY,tuberculosis,,0
TIVICAY,tuberculosis,Depression              Abnormal,1
TIVICAY,tuberculosis,Depression,0
TIVICAY,tuberculosis,,0
TIVICAY,Autoimmune disorders,Depression         2%          ,1
TIVICAY,Autoimmune disorders,        2%           Abnormal dreams,1
TIVICAY,Autoimmune disorders,,0
TIVICAY,Autoimmune disorders,,0
TIVICAY,Autoimmune disorders,        2%          ,1
TIVICAY,Graves' disease,Ab normal dreams   Nerv,1
TIVICAY,Graves' disease,Ab,0
TIVICAY,polymyositis,      <1%    Nervous,1
TIVICAY,polymyositis,      <1%    Nervous,1
TIVICAY,polymyositis,System,0
TIVICAY,polymyositis,dreams,0
TIVICAY,polymyositis,      <1%    Nervous,1
TIVICAY,polymyositis,,0
TIVICAY,polymyositis,Abnormal       <1%    Nervous,1
TIVICAY,polymyositis,dreams,0
TIVICAY,Guillain-Barre syndrome,           <1%          Nervous,1
TIVICAY,Guillain-Barre syndrome,Abnormal            <1%          Nervous,1
TIVICAY,Guillain-Barre syndrome,           <1%          Nervous,1
TIVICAY,Guillain-Barre syndrome,,0
TIVICAY,Guillain-Barre syndrome,           <1%          Nervous,1
TIVICAY,Guillain-Barre syndrome,dreams,0
TIVICAY,Guillain-Barre syndrome,System,0
TIVICAY,Guillain-Barre syndrome,System,0
ULESFIA,ocular irritation,,0
ULESFIA,ocular irritation,EXCERPT Most common adverse,0
ULESFIA,ocular irritation,with ocular irritation application,1
ULESFIA,application site irritation,with placebo,0
ULESFIA,application site irritation,and application site anesthesia and,0
ULESFIA,application site irritation,and hypoesthesia To report SUSPECTED ADVERSE REACTI,0
ULESFIA,application site irritation,application site,1
ULESFIA,application site irritation,application site irritation and,1
ULESFIA,application site irritation,Most common adverse reactions and more common,0
ULESFIA,application site irritation,with placebo ocular application site,1
ULESFIA,application site irritation,with placebo ocular application site irritation and,1
ULESFIA,Application site Irritation,Symptoms Event ULESFIA,0
ULESFIA,Application site Irritation,Application site Irritation Application,1
ULESFIA,Application site Irritation,r Lotion Vehicle,0
ULESFIA,Application site Irritation,site,0
ULESFIA,Application site Irritation,Lotion Application site Irritation Application,1
ULESFIA,Application site Irritation,Irritation Application,1
ULESFIA,Application site anesthesia,site Application site,1
ULESFIA,Application site anesthesia,hypoesthesia,0
ULESFIA,Application site anesthesia,Vehicle Application,0
ULESFIA,Application site anesthesia,Lotion Vehicle Application site Application,1
ULESFIA,Application site anesthesia,Pain,0
ULESFIA,Application site anesthesia,site anesthesia hypoesthesia,1
ULESFIA,Application site anesthesia,anesthesia hypoesthesia,1
ULESFIA,Pain,anesthesia Pain The,1
ULESFIA,Pain,Pain The,1
ULESFIA,Pain,site,0
ULESFIA,Pruritus,Monitored Adverse Pruritus Erythema,1
ULESFIA,Pruritus,Irritation with Onset After Treatment SignsSymptoms,0
ULESFIA,Pruritus,Onset After Treatment SignsSymptoms ULESFIA,0
ULESFIA,Pruritus,results are presented in Table Table Monitored Adverse,0
ULESFIA,Pruritus,Pruritus Erythema,1
ULESFIA,Pruritus,Pruritus Erythema,1
ULESFIA,Pruritus,Pruritus Erythema,1
ULESFIA,Pruritus,Pruritus Erythema,1
ULESFIA,Pruritus,Pruritus Erythema,1
ULESFIA,Erythema,Reactions Erythema Pyoderma,1
ULESFIA,Erythema,Erythema Pyoderma,1
ULESFIA,Erythema,Erythema Pyoderma,1
ULESFIA,Erythema,,0
ULESFIA,Erythema,Monitored Adverse Reactions,0
ULESFIA,Erythema,Table Monitored Adverse,0
ULESFIA,Erythema,Erythema Pyoderma,1
ULESFIA,Pyoderma,Pyoderma and,1
ULESFIA,Pyoderma,Table Table,0
ULESFIA,Pyoderma,Reactions Pruritus Pyoderma and,1
ULESFIA,Pyoderma,Pruritus Pyoderma and,1
ULESFIA,Pyoderma,Pyoderma and,1
ULESFIA,Pyoderma,Ocular Irritation with Onset After,0
ULESFIA,Pyoderma,Erythema,0
ULESFIA,Pyoderma,,0
ULESFIA,Ocular Irritation,Table Table Monitored Adverse Reactions Pruritus Erythema Pyoderma,0
ULESFIA,Ocular Irritation,Lotion Vehicle,0
ULESFIA,Ocular Irritation,Treatment SignsSymptoms,0
ULESFIA,Ocular Irritation,Reactions Pruritus Erythema Pyoderma Ocular,1
ULESFIA,Ocular Irritation,ULESFIA r Lotion Vehicle Pruritu,0
ULESFIA,Ocular Irritation,Ocular Irritation with,1
ULESFIA,Ocular Irritation,Pruritus Erythema Pyoderma Ocular,1
ULESFIA,Ocular Irritation,,0
ULESFIA,Pruritus,,0
ULESFIA,Pruritus,,0
ULESFIA,Pruritus,Pruritus Erythema,1
ULESFIA,Pruritus,,0
ULESFIA,Pyoderma,Erythema Pyoderma Ocular,1
ULESFIA,Pyoderma,Pyoderma,1
ULESFIA,Pyoderma,Erythema,0
ULESFIA,Pyoderma,Pyoderma Ocular,1
ULESFIA,Pyoderma,Pyoderma Ocular irritation,1
ULESFIA,Ocular irritation,Pyoderma Ocular irritation Other less common reactions less,1
ULESFIA,Ocular irritation,but m,0
ULESFIA,application site dryness,common reactions less,0
ULESFIA,application site excoriation,but more than were in decreasing order,0
ULESFIA,application site excoriation,application,1
ULESFIA,application site excoriation,in,0
ULESFIA,application site excoriation,than were in decreasing order,0
ULESFIA,application site excoriation,application site excoriation paraesthesia application site dermatitis excoriation,1
ULESFIA,paraesthesia,of,0
ULESFIA,paraesthesia,paraesthesia application site dermatitis excoriation thermal,1
ULESFIA,paraesthesia,paraesthesia application site dermatitis excoriation thermal,1
ULESFIA,paraesthesia,paraesthesia application site dermatitis excoriation thermal,1
ULESFIA,application site dermatitis,burn dandruff erythema rash and skin,0
ULESFIA,excoriation,,0
ULESFIA,excoriation,excoriation thermal burn dandruff erythema rash,1
ULESFIA,thermal burn,site dermatitis,0
ULESFIA,thermal burn,paraesthesia application site dermatitis thermal,1
ULESFIA,thermal burn,,0
ULESFIA,thermal burn,,0
ULESFIA,thermal burn,application site excoriation,0
ULESFIA,thermal burn,excoriation paraesthesia application site,0
ULESFIA,thermal burn,paraesthesia application site dermatitis thermal,1
ULESFIA,dandruff,dandruff erythema rash and skin exfoliation,1
ULESFIA,dandruff,dandruff erythema rash and skin exfoliation,1
ULESFIA,erythema,thermal burn erythema rash and skin exfoliation,1
ULESFIA,erythema,erythema rash and skin exfoliation,1
ULESFIA,erythema,excoriation thermal burn erythema rash and skin exfoliation,1
ULESFIA,rash,thermal burn dandruff erythema,0
ULESFIA,rash,site dermatitis excoriation,0
ULESFIA,rash,rash and skin exfoliation,1
ULESFIA,rash,,0
ULESFIA,rash,site dermatitis excoriation thermal burn,0
ULESFIA,rash,rash and skin exfoliation,1
ULESFIA,skin exfoliation,dandruff erythema rash skin,1
ULESFIA,skin exfoliation,erythema rash skin,1
ULESFIA,skin exfoliation,,0
ULESFIA,Neonatal toxicity,reaction s and more common,1
ULESFIA,Neonatal toxicity,s and more common than,0
ULESFIA,gasping syndrome,d more common th an with,1
ULESFIA,gasping syndrome,d more common th an with,1
ULESFIA,gasping syndrome,,0
ULESFIA,Eye irritation,more common than with placebo ocular irritation,0
ULESFIA,Eye irritation,"application site rritation,",1
ULESFIA,Eye irritation,"application site rritation, and",1
ULESFIA,Eye irritation,irritation,0
ULESFIA,Eye irritation,application,0
ULESFIA,Eye irritation,"site rritation,",1
ULESFIA,Eye irritation,common than with placebo,0
ULESFIA,Eye irritation,ocular irritation application site i,0
ULESFIA,Eye irritation,"irritation application site rritation, and",1
ULESFIA,Eye irritation,and,1
ULESFIA,neonatal gasping syndrome,reflect e rates observed in clini,1
ULESFIA,neonatal gasping syndrome,of another drug and may not reflect th,0
ULESFIA,neonatal gasping syndrome,may not,0
ULESFIA,neonatal gasping syndrome,reflect e rates observed in clini,1
ULESFIA,neonatal gasping syndrome,clini,1
ULESFIA,metabolic acidosis,of adv,1
ULESFIA,metabolic acidosis,erse reactions below were derived from two randomized multicenter vehiclecontrolled clinical tri,0
ULESFIA,metabolic acidosis,observed in clinical The rates,1
ULESFIA,metabolic acidosis,observed in clinical The rates of,1
ULESFIA,metabolic acidosis,in clinical   The rates of adv,1
ULESFIA,metabolic acidosis,  The rates of adv,1
ULESFIA,metabolic acidosis,  The rates of adv,1
ULESFIA,gasping respirations,The rates of se reactions below w,1
ULESFIA,gasping respirations,reactions below w,1
ULESFIA,gasping respirations,The rates of se reactions below w,1
ULESFIA,gasping respirations,The rates of se reactions,1
ULESFIA,gasping respirations,se reactions below w,1
ULESFIA,gasping respirations,one openlabel,0
ULESFIA,gasping respirations,rates of se reactions below w,1
ULESFIA,gasping respirations,se reactions below w,1
ULESFIA,gasping respirations,rates of se reactions,1
ULESFIA,progressive hypotension,below e derived from two rand,1
ULESFIA,progressive hypotension,reactions below e derived from two rand,1
ULESFIA,progressive hypotension,e derived from two rand,1
ULESFIA,progressive hypotension,,0
ULESFIA,progressive hypotension,practice The rates,0
ULESFIA,progressive hypotension,h,0
ULESFIA,progressive hypotension,below e derived from two rand,1
ULESFIA,progressive hypotension,reactions below e derived from two rand,1
ULESFIA,progressive hypotension,e derived,1
ULESFIA,progressive hypotension,observed in clinical,0
ULESFIA,seizures,,0
ULESFIA,seizures,"two ized, mu",1
ULESFIA,seizures,"ized, mu",1
ULESFIA,seizures,"ized, mu",1
ULESFIA,central nervous system depression,vehicle-controlled clin,1
ULESFIA,central nervous system depression,"i-center, vehicle-controlled",1
ULESFIA,intraventricular hemorrhage,derived from two randomized multicenter vehiclecontrolled,0
ULESFIA,intraventricular hemorrhage,open-labe,1
ULESFIA,intraventricular hemorrhage,open-labe,1
ULESFIA,intraventricular hemorrhage,,0
ULESFIA,intraventricular hemorrhage,multicenter vehiclecontrolled al trials,1
ULESFIA,intraventricular hemorrhage,open-labe,1
ULESFIA,intraventricular hemorrhage,from two randomized multicenter vehiclecontrolled,0
ULESFIA,death,two randomized multicenter vehiclecontrolled,0
ULESFIA,death,and one openlabel y in ,1
ULESFIA,death,in,1
ULESFIA,death,one openlabel y in ,1
ULESFIA,gasping syndrome,,0
ULESFIA,gasping syndrome,,0
ULESFIA,gasping syndrome,symp,1
ULESFIA,gasping syndrome,about the presence of n and scalp symp,1
ULESFIA,gasping syndrome,scalp symp,1
ULESFIA,eye irritation,,0
ULESFIA,eye irritation,site /478),1
ULESFIA,eye irritation,/478) 1%,1
ULESFIA,eye irritation,/478),1
ULESFIA,eye irritation,Application site /478)      1% ,1
ULESFIA,eye irritation,anesthesia,0
ULESFIA,irritant dermatitis,"and lp, or ocular",1
ULESFIA,irritant dermatitis,for these signs and symptoms after treatment,0
ULESFIA,irritant dermatitis,subjects who did not have pruritus erythema edema or pyoderma of,0
ULESFIA,irritant dermatitis,ocular irrit,1
ULESFIA,irritant dermatitis,to treatment were assessed for these signs and symptoms after,0
ULESFIA,irritant dermatitis,pyoderma of skin and sca,0
ULESFIA,irritant dermatitis,did,0
ULESFIA,irritant dermatitis,"skin and lp,",1
JUBLIA,ingrown toenails,,0
JUBLIA,ingrown toenails,ingrown,1
JUBLIA,ingrown toenails,,0
JUBLIA,application site dermatitis,ingrown application site dermatitis application site vesicles and application,1
JUBLIA,application site dermatitis,The most common adverse,0
JUBLIA,application site dermatitis,REACTIONS EXCERPT The most,0
JUBLIA,application site dermatitis,application site dermatitis application site vesicles and application,1
JUBLIA,application site vesicles,toenails application site application,1
JUBLIA,application site vesicles,vesicles and application site pain To,1
JUBLIA,application site vesicles,application site application site,1
JUBLIA,application site vesicles,site application site vesicles and application site pain To,1
JUBLIA,application site vesicles,vesicles and application site pain To,1
JUBLIA,application site vesicles,site application site vesicles and application site pain To,1
JUBLIA,application site pain,vesicles application site pain To report SUSPECTED ADVERSE REACTIONS,1
JUBLIA,application site pain,ADVERSE REACTIONS contact Valeant Pharmaceuticals North,0
JUBLIA,application site pain,site vesicles application site pain To report SUSPECTED ADVERSE REACTIONS,1
JUBLIA,application site pain,contact Valeant Pharmaceuticals North Americ,0
JUBLIA,Ingrown toenail,site dermatitis,0
JUBLIA,Ingrown toenail,Application site,0
JUBLIA,Ingrown toenail,toenail Application site dermatitis,1
JUBLIA,Ingrown toenail,JUBLIAN,0
JUBLIA,Application site dermatitis,eN Ingrown Application site,1
JUBLIA,Application site dermatitis,Application site,0
JUBLIA,Application site dermatitis,eN Ingrown Application site dermatitis Application site vesicles,1
JUBLIA,Application site dermatitis,toenail,0
JUBLIA,Application site dermatitis,eN Ingrown Application site dermatitis Application site vesicles,1
JUBLIA,Application site dermatitis,site dermatitis Application site vesicles,1
JUBLIA,Application site dermatitis,Application site,1
JUBLIA,Application site dermatitis,toenail,0
JUBLIA,Application site vesicles,site vesicles Application site pain,1
JUBLIA,Application site vesicles,Application site vesicles Application site pain,1
JUBLIA,Application site vesicles,vesicles Application site pain,1
JUBLIA,Application site pain,site,0
JUBLIA,Application site pain,site Application site pain,1
JUBLIA,Application site pain,,0
TRULICITY,Thyroid C-cell Tumors,Thyroid,1
TRULICITY,Thyroid C-cell Tumors,,0
TRULICITY,Thyroid C-cell Tumors,below or elsewhere in the prescribing information,0
TRULICITY,Thyroid C-cell Tumors,Risk Thyroid C-cell Tumors see Warnings and Precautions Pancreatitis,1
TRULICITY,Thyroid C-cell Tumors,prescribing information,0
TRULICITY,Thyroid C-cell Tumors,Tumors see Warnings and Precautions Pancreatitis,1
TRULICITY,Thyroid C-cell Tumors,C-cell Tumors see Warnings and Precautions Pancreatitis,1
TRULICITY,Pancreatitis,Pancreatitis see Warnings and Precautions Hypoglycemia,1
TRULICITY,Pancreatitis,,0
TRULICITY,Pancreatitis,Pancreatitis see Warnings and Precautions Hypoglycemia,1
TRULICITY,Pancreatitis,see Warnings and Precautions,0
TRULICITY,Hypoglycemia,Hypoglycemia with Concomitant Use of Insulin,1
TRULICITY,Hypoglycemia,Hypoglycemia with Concomitant Use of Insulin,1
TRULICITY,Hypoglycemia,Pancreatitis see,0
TRULICITY,Hypoglycemia,see,0
TRULICITY,Hypoglycemia,Hypoglycemia with Concomitant Use of Insulin,1
TRULICITY,Hypoglycemia,Pancreatitis see Warnings and Hypoglycemia with Concomitant Use of Insulin,1
TRULICITY,Hypoglycemia,Concomitant Use of Insulin,0
TRULICITY,Hypoglycemia,,0
TRULICITY,Hypoglycemia,Hypoglycemia with Concomitant Use of Insulin,1
TRULICITY,Hypersensitivity,,0
TRULICITY,Hypersensitivity,,0
TRULICITY,Hypersensitivity,Hypersensitivity reactions see Warnings and Precautions,1
TRULICITY,Renal impairment,Severe Gastrointestinal,0
TRULICITY,Renal impairment,see Warnings and Renal impairment see Warnings and Precautions Severe,1
TRULICITY,Renal impairment,impairment see Warnings and Precautions Severe,1
TRULICITY,Renal impairment,Warnings and Renal,1
TRULICITY,Renal impairment,reactions see Warnings and Renal,1
TRULICITY,Renal impairment,Renal impairment see Warnings and Precautions Severe,1
TRULICITY,Renal impairment,Renal,1
TRULICITY,Renal impairment,impairment see Warnings and Precautions Severe,1
TRULICITY,Renal impairment,and Precautions Severe Gastrointestinal Disease,0
TRULICITY,Renal impairment,Severe Gastrointestinal Disease see Warnings and Pr,0
TRULICITY,Gastrointestinal Disease,,0
TRULICITY,diarrhea,of patients treated with TRULICITY,0
TRULICITY,vomiting,vomiting abdominal pain and decreased appetite,1
TRULICITY,vomiting,vomiting abdominal pain and decreased appetite,1
TRULICITY,vomiting,vomiting abdominal pain and decreased appetite,1
TRULICITY,vomiting,,0
TRULICITY,abdominal pain,,0
TRULICITY,abdominal pain,nausea diarrhea abdominal pain and decreased appetite To report,1
TRULICITY,abdominal pain,are nausea diarrhea abdominal pain and decreased appetite To report,1
TRULICITY,abdominal pain,,0
TRULICITY,abdominal pain,vomiting,0
TRULICITY,decreased appetite,decreased appetite To report SUSPECTED ADVERSE REACTIONS,1
TRULICITY,decreased appetite,abdominal pain decreased,1
TRULICITY,hypoglycemia,,0
TRULICITY,hypoglycemia,hypoglycemia associated with the use of,1
TRULICITY,hypoglycemia,hypoglycemia associated with the use of,1
TRULICITY,fecal volume increased,fecal volume increased frequent bowel movements b Includes,1
TRULICITY,fecal volume increased,volume increased frequent bowel movements b Includes,1
TRULICITY,fecal volume increased,Includes fecal,1
TRULICITY,fecal volume increased,in of TRULICITYTreated Patients a Includes diarrhea,0
TRULICITY,fecal volume increased,fecal volume increased frequent bowel movements b Includes,1
TRULICITY,fecal volume increased,Includes retching vomiting,0
TRULICITY,fecal volume increased,Includes retching vomiting vomiting projectile c Includ,0
TRULICITY,fecal volume increased,Includes retching,0
TRULICITY,fecal volume increased,Reported in of TRULICITYTreated,0
TRULICITY,fecal volume increased,volume increased frequent bowel movements b Includes,1
TRULICITY,frequent bowel movements,diarrhea fecal volume frequent,1
TRULICITY,frequent bowel movements,frequent bowel movements b Includes retching vomiting vomiting,1
TRULICITY,frequent bowel movements,TRULICITYTreated Patients,0
TRULICITY,frequent bowel movements,frequent,1
TRULICITY,frequent bowel movements,volume,0
TRULICITY,frequent bowel movements,discomfort a,0
TRULICITY,frequent bowel movements,in of TRULICITYTreated Patients a Includes diarrhea fecal,0
TRULICITY,frequent bowel movements,movements b Includes retching vomiting vomiting,1
TRULICITY,retching,retching vomiting vomiting projectile c Includes,1
TRULICITY,retching,retching vomiting vomiting projectile c Includes,1
TRULICITY,retching,pa,0
TRULICITY,retching,movements b retching vomiting vomiting projectile c Includes,1
TRULICITY,retching,abdominal pain,0
TRULICITY,retching,Includes abdominal discomfort abdominal,0
TRULICITY,retching,discomfort abdominal pain abdominal,0
TRULICITY,retching,abdominal,0
TRULICITY,retching,a Includes diarrhea fecal volume,0
TRULICITY,retching,,0
TRULICITY,vomiting,vomiting vomiting projectile c Includes abdominal,1
TRULICITY,vomiting,,0
TRULICITY,vomiting,,0
TRULICITY,vomiting,volume increased frequent,0
TRULICITY,vomiting,pain lower,0
TRULICITY,vomiting projectile,Includes retching vomiting,1
TRULICITY,vomiting projectile,pain,0
TRULICITY,vomiting projectile,projectile c Includes abdominal discomfort abdominal,1
TRULICITY,vomiting projectile,Includes retching vomiting projectile c Includes abdominal discomfort abdominal,1
TRULICITY,abdominal discomfort,,0
TRULICITY,abdominal discomfort,movements b,0
TRULICITY,abdominal discomfort,,0
TRULICITY,abdominal discomfort,pain abdominal pain lower abdominal,0
TRULICITY,abdominal discomfort,retching vomiting vomiting,0
TRULICITY,abdominal discomfort,discomfort abdominal pain abdominal pain lower,1
TRULICITY,abdominal discomfort,projectile c abdominal,1
TRULICITY,abdominal discomfort,vomiting vomiting projectile c Includes,0
TRULICITY,abdominal discomfort,discomfort abdominal pain abdominal pain lower,1
TRULICITY,abdominal discomfort,c Includes,0
TRULICITY,abdominal pain,abdominal abdominal pain abdominal pain lower abdominal pain,1
TRULICITY,abdominal pain,,0
TRULICITY,abdominal pain,vomiting projectile c,0
TRULICITY,abdominal pain lower,,0
TRULICITY,abdominal pain lower,abdominal pain upper abdominal tenderness gastrointestinal pain d Includes fatigue asthe,0
TRULICITY,abdominal pain lower,abdominal pain lower abdominal pain upper abdominal tenderness,1
TRULICITY,abdominal pain lower,lower abdominal pain upper abdominal tenderness,1
TRULICITY,abdominal pain lower,gastrointestinal pain d Includes fatigue,0
TRULICITY,abdominal pain lower,,0
TRULICITY,abdominal pain lower,pain lower abdominal pain upper abdominal tenderness,1
TRULICITY,abdominal pain lower,tenderness gastrointestinal pain d Includes,0
TRULICITY,abdominal pain lower,c Includes abdominal discomfort abdominal pain,0
TRULICITY,abdominal pain upper,abdominal pain abdominal pain abdominal pain upper abdominal tenderness gastrointestinal pain d,1
TRULICITY,abdominal tenderness,pain lower abdominal pain abdominal,1
TRULICITY,abdominal tenderness,lower abdominal pain abdominal,1
TRULICITY,gastrointestinal pain,malaise Note,0
TRULICITY,gastrointestinal pain,gastrointestinal,1
TRULICITY,gastrointestinal pain,gastrointestinal pain d Includes fatigue asthenia malaise,1
TRULICITY,gastrointestinal pain,gastrointestinal,1
TRULICITY,gastrointestinal pain,upper abdominal gastrointestinal,1
TRULICITY,gastrointestinal pain,,0
TRULICITY,gastrointestinal pain,abdominal pain upper abdominal gastrointestinal pain d Includes fatigue asthenia malaise,1
TRULICITY,asthenia,asthenia malaise Note Percentages reflect the,1
TRULICITY,asthenia,asthenia malaise Note Percentages reflect the,1
TRULICITY,asthenia,,0
TRULICITY,asthenia,asthenia malaise Note Percentages reflect the,1
TRULICITY,asthenia,asthenia malaise Note Percentages reflect the,1
TRULICITY,malaise,malaise Note Percentages reflect the number,1
TRULICITY,Nausea,Trulicity mg N Trulicity mg N,0
TRULICITY,Nausea,Nausea,1
TRULICITY,Diarrhea,Diarrhea a,1
TRULICITY,Diarrhea,,0
TRULICITY,Diarrhea,,0
TRULICITY,Vomiting,,0
TRULICITY,Vomiting,a,0
TRULICITY,Vomiting,,0
TRULICITY,Vomiting,Vomiting b,1
TRULICITY,Vomiting,a Vomiting b,1
TRULICITY,Vomiting,Vomiting b,1
TRULICITY,Vomiting,a Vomiting b,1
TRULICITY,Abdominal Pain,b,0
TRULICITY,Abdominal Pain,b Abdominal,1
TRULICITY,Abdominal Pain,Pain,1
TRULICITY,Abdominal Pain,b Abdominal,1
TRULICITY,Abdominal Pain,b Abdominal Pain c Decre,1
TRULICITY,Abdominal Pain,b Abdominal Pain c Decre,1
TRULICITY,Abdominal Pain,b Abdominal Pain,1
TRULICITY,Abdominal Pain,,0
TRULICITY,Abdominal Pain,b Abdominal,1
TRULICITY,Abdominal Pain,b,0
TRULICITY,Decreased Appetite,Dyspepsia,0
TRULICITY,Decreased Appetite,Appetite Dyspepsia,1
TRULICITY,Decreased Appetite,,0
TRULICITY,Decreased Appetite,Decreased Appetite Dyspepsia,1
TRULICITY,Decreased Appetite,Pain Decreased,1
TRULICITY,Fatigue,,0
TRULICITY,gastrointestinal adverse reactions,gastrointestinal adverse reactions occurred,1
TRULICITY,gastrointestinal adverse reactions,trials,0
TRULICITY,gastrointestinal adverse reactions,gastrointestinal adverse reactions occurred,1
TRULICITY,gastrointestinal adverse reactions,than placebo placebo,0
TRULICITY,gastrointestinal adverse reactions,adverse reactions occurred,1
TRULICITY,gastrointestinal adverse reactions,placebo placebo,0
TRULICITY,gastrointestinal adverse reactions,placebo mg,0
TRULICITY,gastrointestinal adverse reactions,of placebocontrolled gastrointestinal adverse reactions occurred,1
TRULICITY,gastrointestinal adverse reactions,pool of placebocontrolled,0
TRULICITY,gastrointestinal adverse reactions,patients receiving placebo Investigators graded the severity of,0
TRULICITY,gastrointestinal adverse reactions,respectively,0
TRULICITY,gastrointestinal adverse reactions,gastrointestinal adverse reactions occurring,1
TRULICITY,gastrointestinal adverse reactions,the severity gastrointestinal adverse,1
TRULICITY,gastrointestinal adverse reactions,severity gastrointestinal adverse reactions occurring,1
TRULICITY,gastrointestinal adverse reactions,and mg of,0
TRULICITY,gastrointestinal adverse reactions,the severity gastrointestinal adverse reactions occurring,1
TRULICITY,gastrointestinal adverse reactions,graded the severity gastrointestinal adverse,1
TRULICITY,gastrointestinal adverse reactions,adverse reactions than patients receiving placebo Investigators graded the severity,0
TRULICITY,gastrointestinal adverse reactions,mg and mg of TRULICITY as mild,0
TRULICITY,constipation,as placebo mg constipation flatulence,1
TRULICITY,constipation,listed,0
TRULICITY,constipation,distension gastroe,0
TRULICITY,flatulence,mg mg flatulence abdominal,1
TRULICITY,flatulence,flatulence abdominal,1
TRULICITY,flatulence,placebo,0
TRULICITY,flatulence,abdominal distension gastroesophageal,0
TRULICITY,flatulence,flatulence abdominal,1
TRULICITY,flatulence,flatulence abdominal,1
TRULICITY,flatulence,flatulence abdominal,1
TRULICITY,flatulence,flatulence abdominal,1
TRULICITY,abdominal distension,placebo mg mg constipation abdominal distension gastroesophageal,1
TRULICITY,abdominal distension,,0
TRULICITY,abdominal distension,,0
TRULICITY,abdominal distension,placebo mg,0
TRULICITY,abdominal distension,as placebo mg,0
TRULICITY,abdominal distension,,0
TRULICITY,abdominal distension,,0
TRULICITY,abdominal distension,eructation,0
TRULICITY,abdominal distension,gastroesophageal reflux,0
TRULICITY,gastroesophageal reflux disease,reflux disease and,1
TRULICITY,gastroesophageal reflux disease,ipation flatulence abdominal gastroesophageal reflux disease and,1
TRULICITY,gastroesophageal reflux disease,flatulence abdominal gastroesophageal reflux disease and,1
TRULICITY,gastroesophageal reflux disease,distension,0
TRULICITY,gastroesophageal reflux disease,gastroesophageal,1
TRULICITY,gastroesophageal reflux disease,abdominal gastroesophageal reflux disease and,1
TRULICITY,gastroesophageal reflux disease,of Placebo and ActiveControll,0
TRULICITY,gastroesophageal reflux disease,ipation flatulence abdominal gastroesophageal reflux disease and,1
TRULICITY,gastroesophageal reflux disease,flatulence,0
TRULICITY,eructation,eructation Pool,1
TRULICITY,eructation,reflux disease eructation Pool,1
TRULICITY,eructation,disease,0
TRULICITY,eructation,occurrence of,0
TRULICITY,eructation,gastroesophageal reflux disease eructation Pool,1
TRULICITY,eructation,The occurrence of,0
TRULICITY,hypoglycemia,adverse reactions hypoglycemia were,1
TRULICITY,hypoglycemia,adverse reactions hypoglycemia were,1
TRULICITY,hypoglycemia,hypoglycemia were,1
TRULICITY,hypoglycemia,common,0
TRULICITY,hypoglycemia,,0
TRULICITY,hypoglycemia,common adverse reactions hypoglycemia were,1
TRULICITY,hypoglycemia,hypoglycemia were,1
TRULICITY,hypoglycemia,hypoglycemia were,1
TRULICITY,hypoglycemia,hypoglycemia were,1
TRULICITY,hypoglycemia,incidence of documented symptomatic mgdL glucose threshold and,0
TRULICITY,hypoglycemia,Symptomatic,0
TRULICITY,hypoglycemia,hypoglycemia in,1
TRULICITY,hypoglycemia,hypoglycemia in,1
TRULICITY,hypoglycemia,glucose threshold and hypoglycemia in,1
TRULICITY,Hypoglycemia,Documented Symptomatic and Hypoglycemia Adverse,1
TRULICITY,Hypoglycemia,of,0
TRULICITY,Hypoglycemia,Placebo,0
TRULICITY,Hypoglycemia,Hypoglycemia Adverse,1
TRULICITY,Hypoglycemia,and,0
TRULICITY,Hypoglycemia,Trials Placebo,0
TRULICITY,Hypoglycemia,Reactions,0
TRULICITY,Hypoglycemia,Hypoglycemia was more frequent when,1
TRULICITY,Hypoglycemia,Hypoglycemia was more,1
TRULICITY,Hypoglycemia,Hypoglycemia was more frequent,1
TRULICITY,Hypoglycemia,Hypoglycemia was more frequent when,1
TRULICITY,Hypoglycemia,Hypoglycemia was,1
TRULICITY,Hypoglycemia,,0
TRULICITY,Hypoglycemia,Hypoglycemia was more frequent when,1
TRULICITY,Hypoglycemia,Hypoglycemia was,1
TRULICITY,Hypoglycemia,,0
TRULICITY,Hypoglycemia,Hypoglycemia was more,1
TRULICITY,symptomatic hypoglycemia,hypoglycemia occurred in,1
TRULICITY,symptomatic hypoglycemia,of patients when TRULICITY mg and mg respectively was,0
TRULICITY,symptomatic hypoglycemia,and Precautions symptomatic,1
TRULICITY,symptomatic hypoglycemia,see Warnings and Precautions,0
TRULICITY,symptomatic hypoglycemia,symptomatic hypoglycemia occurred in,1
TRULICITY,symptomatic hypoglycemia,Precautions symptomatic hypoglycemia occurred in,1
TRULICITY,hypoglycemia,mg respectively was coadministered with,0
TRULICITY,hypoglycemia,hypoglycemia occurred in,1
TRULICITY,hypoglycemia,and mg respectively was coadminis,0
TRULICITY,hypoglycemia,occurred,0
TRULICITY,symptomatic hypoglycemia,coadministered with a sulfonylurea symptomatic hypoglycemia occurred in,1
TRULICITY,symptomatic hypoglycemia,a sulfonylurea symptomatic hypoglycemia occurred in,1
TRULICITY,symptomatic hypoglycemia,and of patients when TRULICITY mg and mg,0
TRULICITY,symptomatic hypoglycemia,,0
TRULICITY,symptomatic hypoglycemia,occurred in and of patients,0
TRULICITY,symptomatic hypoglycemia,symptomatic hypoglycemia occurred in,1
TRULICITY,symptomatic hypoglycemia,mg and mg respectively was coadministered with,0
TRULICITY,hypoglycemia,coadministered with prandial insulin hypoglycemia occurred in,1
TRULICITY,hypoglycemia,,0
TRULICITY,hypoglycemia,hypoglycemia occurred in,1
TRULICITY,hypoglycemia,insulin hypoglycemia occurred in,1
TRULICITY,hypoglycemia,and of patients when TRULICITY mg,0
TRULICITY,hypoglycemia,,0
TRULICITY,hypoglycemia,prandial insulin hypoglycemia occurred in,1
TRULICITY,hypoglycemia,hypoglycemia occurred in,1
TRULICITY,hypoglycemia,occurred in and of patients when TRULICITY mg and,0
TRULICITY,hypoglycemia,and of patients when TRULICITY,0
TRULICITY,increase in HR,of beats per,0
TRULICITY,increase in HR,The longterm clinical effects,0
TRULICITY,increase in HR,effects of the,0
TRULICITY,increase in HR,in heart rate HR of beats per minute bpm The longterm,0
TRULICITY,increase in HR,longterm clinical effects of increase in HR have not,1
TRULICITY,increase in HR,effects of increase,1
TRULICITY,sinus tachycardia,,0
TRULICITY,sinus tachycardia,reported in,0
TRULICITY,Sinus tachycardia,to Sinus tachycardia was reported,1
TRULICITY,Sinus tachycardia,were reported more frequently in patients exposed,0
TRULICITY,Sinus tachycardia,,0
TRULICITY,Sinus tachycardia,to Sinus tachycardia was reported,1
TRULICITY,Sinus tachycardia,exposed to Sinus tachycardia was reported,1
TRULICITY,Sinus tachycardia,to TRULICITY,0
TRULICITY,Sinus tachycardia,Sinus tachycardia was reported,1
TRULICITY,Sinus tachycardia,placebo TRULICITY mg and TRULICI,0
TRULICITY,Sinus tachycardia,Sinus tachycardia was reported,1
TRULICITY,Sinus tachycardia,Sinus tachycardia was reported,1
TRULICITY,Persistence of sinus tachycardia,TRULICITY mg and TRULICITY mg,0
TRULICITY,Persistence of sinus tachycardia,reported at more than visits was reported,0
TRULICITY,Persistence of sinus tachycardia,Persistence,1
TRULICITY,Persistence of sinus tachycardia,was reported in and of patients treated with,0
TRULICITY,Persistence of sinus tachycardia,,0
TRULICITY,Persistence of sinus tachycardia,mg Persistence,1
TRULICITY,Persistence of sinus tachycardia,placebo TRULICITY mg and TRULICITY mg respectively,0
TRULICITY,Persistence of sinus tachycardia,treated,0
TRULICITY,sinus tachycardia,were,0
TRULICITY,sinus tachycardia,associated with a concomitant increase from baseline in heart rate of beats per,0
TRULICITY,sinus tachycardia,mg respectively Episodes sinus tachycardia associated with,1
TRULICITY,sinus tachycardia,mg and TRULICITY mg respectively Episodes,0
TRULICITY,sinus tachycardia,with,0
TRULICITY,sinus tachycardia,beats per,0
TRULICITY,sinus tachycardia,TRULICITY mg respectively Episodes sinus tachycardia associated with,1
TRULICITY,sinus tachycardia,respectively Episodes sinus,1
TRULICITY,sinus tachycardia,with,0
TRULICITY,sinus tachycardia,respectively Episodes of,0
TRULICITY,Systemic hypersensitivity,Systemic hypersensitivity adverse reactions,1
TRULICITY,Systemic hypersensitivity,other,0
TRULICITY,Systemic hypersensitivity,other products Systemic hypersensitivity adverse reactions,1
TRULICITY,Systemic hypersensitivity,hypersensitivity adverse reactions,1
TRULICITY,Systemic hypersensitivity,swelli,0
TRULICITY,Systemic hypersensitivity,products Systemic hypersensitivity adverse reactions,1
TRULICITY,Systemic hypersensitivity,adverse reactions sometimes severe eg,0
TRULICITY,Systemic hypersensitivity,compared,0
TRULICITY,Systemic hypersensitivity,other products Systemic,1
TRULICITY,Systemic hypersensitivity,of other products Systemic,1
TRULICITY,Systemic hypersensitivity,hypersensitivity adverse reactions,1
TRULICITY,urticaria,urticaria systemic rash,1
TRULICITY,urticaria,eg urticaria systemic rash,1
TRULICITY,urticaria,urticaria systemic rash,1
TRULICITY,urticaria,urticaria systemic rash,1
TRULICITY,urticaria,patients on TRULICITY in the,0
TRULICITY,urticaria,urticaria systemic rash,1
TRULICITY,urticaria,urticaria systemic rash,1
TRULICITY,urticaria,urticaria systemic rash,1
TRULICITY,systemic rash,eg severe urticaria,0
TRULICITY,systemic rash,,0
TRULICITY,systemic rash,,0
TRULICITY,systemic rash,rash facial edema,1
TRULICITY,systemic rash,lip swelling occurred in of patients,0
TRULICITY,systemic rash,Phase,0
TRULICITY,systemic rash,systemic rash facial edema,1
TRULICITY,facial edema,lip swelling occurred in of patients on TRULICITY in the four Phase and five Phase,0
TRULICITY,facial edema,reactions sometimes severe eg severe urticaria,0
TRULICITY,facial edema,in the four Phase,0
TRULICITY,facial edema,reactions sometimes severe eg severe urticaria systemic rash,0
TRULICITY,lip swelling,,0
TRULICITY,lip swelling,eg severe urticaria systemic rash,0
TRULICITY,lip swelling,Phase and five Phase,0
TRULICITY,lip swelling,,0
TRULICITY,lip swelling,Phase studies In,0
TRULICITY,injection-site reactions,Injectionsite Reactions In the placebocontrolled studies,0
TRULICITY,injection-site reactions,In the placebocontrolled injection-site,1
TRULICITY,injection-site reactions,the placebocontrolled injection-site reactions eg injectionsite,1
TRULICITY,injection-site reactions,placebocontrolled injection-site,1
TRULICITY,injection-site reactions,injection-site reactions eg injectionsite,1
TRULICITY,injection-site reactions,,0
TRULICITY,injection-site reactions,reactions eg injectionsite,1
TRULICITY,injection-site reactions,injection-site reactions eg injectionsite,1
TRULICITY,injection-site reactions,injection-site reactions eg injectionsite,1
TRULICITY,injection-site reactions,injection-site reactions eg injectionsite,1
TRULICITY,injection-site rash,injectionsite reactions injection-site rash erythema were,1
TRULICITY,injection-site rash,the placebocontrolled,0
TRULICITY,injection-site rash,placebocontrolled studies injectionsite reactions injection-site rash erythema were,1
TRULICITY,injection-site rash,studies injectionsite reactions eg,0
TRULICITY,injection-site rash,,0
TRULICITY,first degree AV block,The adverse reaction first degree AV block occurred more,1
TRULICITY,first degree AV block,first degree AV block occurred more,1
TRULICITY,first degree AV block,first degree AV block occurred more,1
TRULICITY,first degree AV block,TRULICITY than placebo and,0
TRULICITY,first degree AV block,adverse reaction first degree AV block occurred more,1
TRULICITY,first degree AV block,,0
TRULICITY,first degree AV block,first degree AV block occurred more,1
TRULICITY,first degree AV block,degree AV block occurred more,1
TRULICITY,first degree AV block,placebotreated patients The adverse reaction,0
TRULICITY,first degree AV block,adverse reaction first,1
TRULICITY,PR interval increase,electrocardiograms PR interval,1
TRULICITY,PR interval increase,increase to at,1
TRULICITY,PR interval increase,respectively On electrocardiograms PR interval increase to at,1
TRULICITY,PR interval increase,observed in,0
TRULICITY,PR interval increase,interval increase to at,1
TRULICITY,PR interval increase,to at least milliseconds was observed,0
TRULICITY,PR interval increase,placebo TRULICITY mg and TRULICITY mg respectively,0
TRULICITY,PR interval increase,and TRULICITY mg respectively On,0
TRULICITY,PR interval increase,for placebo TRULICITY mg and TRULICITY mg respectively On electrocardiograms a,0
TRULICITY,THYROID C-CELL TUMORS,ng serious reactions  are described below or elsewhere,1
TRULICITY,THYROID C-CELL TUMORS,,0
TRULICITY,THYROID C-CELL TUMORS,serious reactions are described below,1
TRULICITY,THYROID C-CELL TUMORS,ng serious reactions  are described below,1
TRULICITY,THYROID C-CELL TUMORS,prescribing information Risk of Thyroid,0
TRULICITY,THYROID C-CELL TUMORS,,0
TRULICITY,THYROID C-CELL TUMORS,elsewhere in the pres cribing information,1
TRULICITY,THYROID C-CELL TUMORS,elsewhere in,1
TRULICITY,THYROID C-CELL TUMORS,elsewhere,1
TRULICITY,THYROID C-CELL TUMORS,,0
TRULICITY,THYROID C-CELL TUMORS,elsewhere in the pres cribing information Risk,1
TRULICITY,THYROID C-CELL TUMORS,pres cribing information Risk,1
TRULICITY,thyroid C-cell tumors,and Precautions Pancreatitis see and Precautions (,1
TRULICITY,thyroid C-cell tumors,,0
TRULICITY,thyroid C-cell tumors,and,1
TRULICITY,thyroid C-cell tumors,see Warnings,0
TRULICITY,thyroid C-cell tumors,5. Hypoglycemia with Concomitant,1
TRULICITY,thyroid C-cell tumors,Tumors see,0
TRULICITY,thyroid C-cell tumors,,0
TRULICITY,thyroid C-cell tumors,,0
TRULICITY,thyroid C-cell tumors,see ings,1
TRULICITY,MTC,ns  see Warnings and,1
TRULICITY,thyroid C-cell tumors,Precautions Renal t [see Warnings and P recautions Severe Gastrointestinal,1
TRULICITY,thyroid C-cell tumors,Warnings and P recautions Severe Gastrointestinal,1
TRULICITY,thyroid C-cell tumors,Precautions Renal t [see Warnings,1
TRULICITY,thyroid C-cell tumors,Warnings and P recautions Severe Gastrointestinal,1
TRULICITY,thyroid C-cell tumors,Precautions Renal t [see Warnings,1
TRULICITY,thyroid C-cell tumors,and P recautions Severe Gastrointestinal,1
TRULICITY,thyroid C-cell tumors,P recautions Severe Gastrointestinal,1
TRULICITY,thyroid C-cell tumors,,0
TRULICITY,thyroid C-cell tumors,,0
TRULICITY,thyroid C-cell tumors,are derived f rom the placebocontrolled,1
TRULICITY,thyroid C-cell tumors,Studies These,0
TRULICITY,thyroid C-cell tumors,practice Pool of Placebocontrolled,0
TRULICITY,thyroid C-cell tumors,data in able 1 are derived,1
TRULICITY,thyroid C-cell tumors,able 1 are derived,1
TRULICITY,thyroid C-cell tumors,The data in,0
TRULICITY,thyroid C-cell tumors,f rom the placebocontrolled,1
TRULICITY,thyroid C-cell tumors,The data in able 1  are derived f rom the placebocontrolled,1
TRULICITY,thyroid C-cell tumors,1 are derived f rom the placebocontrolled,1
TRULICITY,thyroid C-cell tumors,practice Pool of Placebocontrolled Trials The data in T,0
TRULICITY,thyroid C-cell tumors,from the,0
TRULICITY,thyroid C-cell tumors,see Studies (,1
TRULICITY,thyroid C-cell tumors,Table,0
TRULICITY,thyroid C-cell tumors,"Studies (  14  )]  .
 These data reflect",1
TRULICITY,thyroid C-cell tumors,data reflect exposure of patients to,0
TRULICITY,thyroid C-cell tumors,see Studies (,1
TRULICITY,thyroid C-cell tumors,Table are derived from the placebocontrolled trials,0
TRULICITY,thyroid C-cell tumors,a mean duration of exposure,0
TRULICITY,thyroid C-cell tumors,TRU,0
TRULICITY,medullary thyroid carcinoma,,0
TRULICITY,medullary thyroid carcinoma,reflect exposure of 1670 patients to TRULICITY,1
TRULICITY,medullary thyroid carcinoma,and a mean duration of exposure to TRULICITY of weeks Across the,0
TRULICITY,MTC,ati ents to TRULICITY,1
TRULICITY,MTC,These,0
TRULICITY,MTC,of ati ents to TRULICITY,1
TRULICITY,MTC,ati ents to TRULICITY,1
TRULICITY,MTC,duration of exposure to TRULICITY of weeks,0
TRULICITY,thyroid C-cell tumors,23.8 weeks.,1
TRULICITY,thyroid C-cell tumors,to TRULICITY of,0
TRULICITY,thyroid C-cell tumors,to TRULICITY 23.8 weeks. Across th e treatment arms,1
TRULICITY,thyroid C-cell tumors,were male,0
TRULICITY,thyroid C-cell tumors,to TRULICITY 23.8 weeks.,1
TRULICITY,thyroid C-cell tumors,,0
TRULICITY,thyroid C-cell tumors,TRULICITY 23.8,1
TRULICITY,thyroid C-cell tumors,or,0
TRULICITY,thyroid C-cell tumors,arms,0
TRULICITY,Thyroid C-cell Tumors,tions are described b elow or,1
TRULICITY,Thyroid C-cell Tumors,or elsewhere in the prescribing information Risk,0
TRULICITY,Thyroid C-cell Tumors,tions,1
TRULICITY,Thyroid C-cell Tumors,tions,1
TRULICITY,Pancreatitis,information: Risk,1
TRULICITY,Pancreatitis,information: Risk,1
TRULICITY,Pancreatitis,,0
TRULICITY,Pancreatitis,information: Risk,1
TRULICITY,Pancreatitis,or elsewhere in,0
TRULICITY,Pancreatitis,following serious reactions are described below or,0
TRULICITY,Hypoglycemia,,0
TRULICITY,Hypersensitivity,and Precautio ns,1
TRULICITY,Hypersensitivity,Disease see gs,1
TRULICITY,Hypersensitivity,The most common adverse reactions reported,0
TRULICITY,Hypersensitivity,Disease,0
TRULICITY,Hypersensitivity,common adverse reactions reported in of,0
TRULICITY,thyroid C-cell tumors,ect the rates observe d,1
TRULICITY,thyroid C-cell tumors,observe d,1
TRULICITY,thyroid C-cell tumors,not ect the,1
TRULICITY,thyroid C-cell tumors,,0
TRULICITY,thyroid C-cell tumors,,0
TRULICITY,thyroid C-cell tumors,not ect the rates observe d,1
TRULICITY,thyroid C-cell tumors,ect the,1
TRULICITY,thyroid C-cell tumors,drug cannot be directly compared to rates in the clinical studies,0
TRULICITY,thyroid C-cell adenomas,( 14 )] . These data,1
TRULICITY,thyroid C-cell adenomas,. These data,1
TRULICITY,thyroid C-cell adenomas,,0
TRULICITY,thyroid C-cell adenomas,a mean duration of exposure,0
TRULICITY,thyroid C-cell adenomas,in Table are derived from the placebocontrolled,0
TRULICITY,thyroid C-cell adenomas,see Clinical ( 14,1
TRULICITY,thyroid C-cell adenomas,"trials see Clinical (  14  )]  .



 These  data",1
TRULICITY,thyroid C-cell adenomas,in,0
TRULICITY,thyroid C-cell adenomas,Clinical ( 14,1
TRULICITY,thyroid C-cell tumors,TRULICITY of . Across,1
TRULICITY,thyroid C-cell tumors,Across the treatmen t,1
TRULICITY,medullary thyroid carcinoma,treatment arms mean age of,1
TRULICITY,MTC,ear s,1
TRULICITY,MTC,of patients was ear s,1
TRULICITY,MTC,age of patients was ear s,1
TRULICITY,MTC,age of patients was,0
TRULICITY,MTC,years or older and were male The population,0
TRULICITY,MTC,the mean age,0
TRULICITY,MTC,n;  were,1
TRULICITY,MTC,for an average of,0
TRULICITY,MTC,n;  were,1
TRULICITY,MTC,he  population,1
TRULICITY,MTC,renal function was normal or,0
TRULICITY,MTC,he  population,1
TRULICITY,MTC,he  population,1
TRULICITY,MTC,At baseline of he  population,1
TRULICITY,MTC,and had a mean HbAc of At baseline,0
TRULICITY,MTC,lud ing,1
TRULICITY,MTC,study,0
TRULICITY,pancreatitis,Diarrhea              Vomiting,1
TRULICITY,hypoglycemia,receiving TRULICITY mg and ULICITY,1
TRULICITY,hypoglycemia,TRULICITY mg and ULICITY 1.5  mg,1
TRULICITY,hypoglycemia,ULICITY 1.5  mg,1
TRULICITY,hypoglycemia,TRULICITY mg,0
TRULICITY,hypoglycemia,receiving TRULICITY mg and ULICITY,1
TRULICITY,hypoglycemia,1.5 mg,1
TRULICITY,hypoglycemia,1.5 mg,1
TRULICITY,hypoglycemia,receiving TRULICITY mg and ULICITY 1.5  mg,1
TRULICITY,hypoglycemia,and ULICITY 1.5  mg,1
TRULICITY,Systemic hypersensitivity,"% of cases, respectively, or",1
TRULICITY,Systemic hypersensitivity,and,0
TRULICITY,Systemic hypersensitivity,cases respectively moderate in,0
TRULICITY,Systemic hypersensitivity,"cases, respectively, or",1
TRULICITY,Systemic hypersensitivity,severe in and of cases,0
TRULICITY,Systemic hypersensitivity,mg of TRULICITY as mild in and of cases respectively moderate in and,0
TRULICITY,Systemic hypersensitivity,or severe in and of cases respectively In,0
TRULICITY,acute renal failure,"(0.7%, 2.9%, 2 gastroesophageal",1
TRULICITY,acute renal failure,,0
TRULICITY,acute renal failure,"sion (0.7%, 2.9%, 2 gastroesophageal",1
TRULICITY,acute renal failure,flatulence,0
TRULICITY,acute renal failure,constipation flatulence,0
TRULICITY,acute renal failure,reflux disease and,0
TRULICITY,acute renal failure,"(0.7%, 2.9%, 2 gastroesophageal",1
TRULICITY,acute renal failure,"2.9%, 2 gastroesophageal",1
TRULICITY,acute renal failure,,0
TRULICITY,chronic renal failure,geal reflux disease ( and,1
TRULICITY,chronic renal failure,abdominal distension geal reflux disease,1
TRULICITY,chronic renal failure,,0
TRULICITY,nausea,patients,0
TRULICITY,nausea, type  diabetes,1
TRULICITY,nausea,larger pool of patients  type  diabetes,1
TRULICITY,nausea,reactions was also evaluated in a,0
TRULICITY,nausea,,0
TRULICITY,nausea, type  diabetes,1
TRULICITY,nausea,,0
TRULICITY,nausea, type  diabetes,1
TRULICITY,nausea, type  diabetes,1
TRULICITY,nausea, type  diabetes,1
TRULICITY,vomiting,also,0
TRULICITY,vomiting,patients with diabetes participating,1
TRULICITY,vomiting,diabetes participating,1
TRULICITY,vomiting,diabetes participating,1
TRULICITY,vomiting,,0
TRULICITY,vomiting,adverse reactions was also evaluated in a larger pool of patients,0
TRULICITY,vomiting,pool of patients with diabetes participating,1
TRULICITY,vomiting,activecontrolled trials evaluating the use of TRULICITY as monothe,0
TRULICITY,vomiting,trials,0
TRULICITY,vomiting,was also evaluated in,0
TRULICITY,diarrhea,articipa ting,1
TRULICITY,diarrhea,articipa ting,1
TRULICITY,diarrhea,articipa ting,1
TRULICITY,diarrhea,articipa ting,1
TRULICITY,diarrhea,evaluated in a larger,0
TRULICITY,diarrhea,articipa ting,1
TRULICITY,diarrhea,articipa ting,1
TRULICITY,diarrhea,ting in placebo and activecontrolled trials evaluating the use of TRULICITY as monotherapy and a,0
TRULICITY,dehydration,also evaluated in a larger pool of patients with,0
TRULICITY,dehydration,pool of patients with type,0
TRULICITY,dehydration,also evaluated in,0
TRULICITY,dehydration,type diabetes participating,0
TRULICITY,gastrointestinal adverse reactions,an average of,0
TRULICITY,gastrointestinal adverse reactions,"African American, 11% Asian; 32% w ere",1
TRULICITY,gastrointestinal adverse reactions,population had diabetes for an,0
TRULICITY,gastrointestinal adverse reactions,"studies was White Black African American, 11% Asian; 32%",1
TRULICITY,gastrointestinal adverse reactions,32% w ere,1
TRULICITY,gastrointestinal adverse reactions,or Latino ethnicity At baseline the population had diabetes for an,0
TRULICITY,gastrointestinal adverse reactions,,0
TRULICITY,gastrointestinal adverse reactions,,0
TRULICITY,gastrointestinal adverse reactions,had,0
TRULICITY,gastrointestinal adverse reactions,"African American, 11% Asian;",1
TRULICITY,gastrointestinal adverse reactions,baseline,0
TEFLARO,Hypersensitivity Reactions,difficile Associated diarrhea,0
TEFLARO,Hypersensitivity Reactions,Warnings and Precautions Hypersensitivity,1
TEFLARO,Hypersensitivity Reactions,Hypersensitivity Reactions see,1
TEFLARO,Hypersensitivity Reactions,Reactions see,1
TEFLARO,Hypersensitivity Reactions,Hypersensitivity Reactions see,1
TEFLARO,Hypersensitivity Reactions,and Precautions Clostridium difficile Associated diarrhea see,0
TEFLARO,Clostridium difficile -Associated diarrhea,and,0
TEFLARO,Clostridium difficile -Associated diarrhea,see Warnings,0
TEFLARO,Clostridium difficile -Associated diarrhea,,0
TEFLARO,Direct Coombs' Test Seroconversion,,0
TEFLARO,diarrhea,diarrhea nausea,1
TEFLARO,diarrhea,diarrhea nausea,1
TEFLARO,diarrhea,ADVERSE REACTIONS contact,0
TEFLARO,diarrhea,diarrhea nausea,1
TEFLARO,diarrhea,Laboratori,0
TEFLARO,diarrhea,diarrhea nausea,1
TEFLARO,diarrhea,,0
TEFLARO,nausea,Forest,0
TEFLARO,nausea,nausea and,1
TEFLARO,nausea,and rash To report SUSPECTED ADVERSE REACTIONS,0
TEFLARO,nausea,in of patients are diarrhea,0
TEFLARO,rash,rash To,1
TEFLARO,rash,are diarrhea nausea rash To,1
TEFLARO,rash,patients,0
TEFLARO,rash,patients are diarrhea nausea rash To,1
TEFLARO,rash,rash To,1
TEFLARO,hypersensitivity,hypersensitivity for,1
TEFLARO,hypersensitivity,treatment groups at a rate of in the,0
TEFLARO,hypersensitivity,hypersensitivity for,1
TEFLARO,hypersensitivity,Teflaro group and in,0
TEFLARO,hypersensitivity,discontinuation hypersensitivity for,1
TEFLARO,diarrhea,phase clinical trials diarrhea nausea,1
TEFLARO,diarrhea,and rash Table lists adverse reactions occurring in,0
TEFLARO,diarrhea,diarrhea nausea,1
TEFLARO,diarrhea,rash Table lists adverse reactions occurring,0
TEFLARO,diarrhea,,0
TEFLARO,diarrhea,lists adverse reactions occurring in of patients,0
TEFLARO,diarrhea,diarrhea nausea,1
TEFLARO,diarrhea,phase clinical trials were,0
TEFLARO,diarrhea,,0
TEFLARO,diarrhea,diarrhea nausea,1
TEFLARO,nausea,lists adverse reactions occurring,0
TEFLARO,nausea,,0
TEFLARO,nausea,clinical,0
TEFLARO,rash,rash Table,1
TEFLARO,rash,,0
TEFLARO,rash,rash Table,1
TEFLARO,rash,receiving Teflaro in,0
TEFLARO,rash,nausea rash Table,1
TEFLARO,rash,rash Table,1
TEFLARO,rash,in the pooled phase clinical trials were,0
TEFLARO,Diarrhea,,0
TEFLARO,Diarrhea,Diarrhea N,1
TEFLARO,Diarrhea,N Gastrointestinal Diarrhea N,1
TEFLARO,Diarrhea,Diarrhea N,1
TEFLARO,Diarrhea,,0
TEFLARO,Diarrhea,Diarrhea N,1
TEFLARO,Diarrhea,Diarrhea N,1
TEFLARO,Diarrhea,Diarrhea N,1
TEFLARO,Nausea,Nausea,1
TEFLARO,Nausea,,0
TEFLARO,Nausea,Nausea,1
TEFLARO,Nausea,,0
TEFLARO,Nausea,a,0
TEFLARO,Nausea,Nausea,1
TEFLARO,Constipation,,0
TEFLARO,Constipation,,0
TEFLARO,Constipation,,0
TEFLARO,Constipation,,0
TEFLARO,Constipation,,0
TEFLARO,Constipation,,0
TEFLARO,Constipation,Constipation Vomit,1
TEFLARO,Constipation,,0
TEFLARO,Constipation,Constipation Vomit,1
TEFLARO,Constipation,Constipation Vomit,1
TEFLARO,Vomiting,Vomiting,1
TEFLARO,Vomiting,,0
TEFLARO,Vomiting,Vomiting,1
TEFLARO,Vomiting,Vomiting,1
TEFLARO,Vomiting,ation Vomiting,1
TEFLARO,Vomiting,ation,0
TEFLARO,Vomiting,,0
TEFLARO,Vomiting,ation,0
TEFLARO,Vomiting,Vomiting,1
TEFLARO,Increased transaminases,Investigations,0
TEFLARO,Increased transaminases,transaminases,1
TEFLARO,Increased transaminases,Metabolism,0
TEFLARO,Increased transaminases,,0
TEFLARO,Increased transaminases,Metabolism,0
TEFLARO,Increased transaminases,Laboratory Increased transaminases,1
TEFLARO,Hypokalemia,,0
TEFLARO,Hypokalemia,,0
TEFLARO,Hypokalemia,Hypokalemia Sk,1
TEFLARO,Rash,Rash,1
TEFLARO,Rash,and Subcutaneous Tissue Disorders,0
TEFLARO,Phlebitis,Phlebitis,1
TEFLARO,Phlebitis,,0
TEFLARO,Phlebitis,Phlebitis,1
TEFLARO,Phlebitis,,0
TEFLARO,Phlebitis,Phlebitis,1
TEFLARO,Phlebitis,,0
TEFLARO,Phlebitis,Phlebitis,1
TEFLARO,Phlebitis,Phlebitis,1
TEFLARO,Eosinophilia,,0
TEFLARO,Neutropenia,system disorders,0
TEFLARO,Thrombocytopenia,less than Blood and lymphatic system,0
TEFLARO,Thrombocytopenia,,0
TEFLARO,Thrombocytopenia,Gastrointestinal disorders Abdominal,0
TEFLARO,Bradycardia,Bradycardia,1
TEFLARO,Bradycardia,pain General,0
TEFLARO,Bradycardia,Bradycardia,1
TEFLARO,Bradycardia,General disorders and admini,0
TEFLARO,Bradycardia,Bradycardia,1
TEFLARO,Bradycardia,Bradycardia,1
TEFLARO,Palpitations,disorders Abdominal pain,0
TEFLARO,Palpitations,Palpitations,1
TEFLARO,Abdominal pain,Cardiac disorders Bradycardia Palpitations Gastrointestinal,0
TEFLARO,Abdominal pain,disorders Bradycardia Palpitations Gastrointestinal Abdominal pain,1
TEFLARO,Abdominal pain,disorders,0
TEFLARO,Abdominal pain,Abdominal pain,1
TEFLARO,Pyrexia,Pyrexia,1
TEFLARO,Pyrexia,and administration site Pyrexia,1
TEFLARO,Pyrexia,disorders and administration site Pyrexia,1
TEFLARO,Pyrexia,,0
TEFLARO,Pyrexia,Pyrexia,1
TEFLARO,Pyrexia,disorders Hypersensitivity,0
TEFLARO,Pyrexia,site Pyrexia,1
TEFLARO,Pyrexia,Hepatitis Immune,0
TEFLARO,Hepatitis,conditions Pyrexia Hepatobiliary,0
TEFLARO,Hepatitis,Anaphylaxis Infections and infestations,0
TEFLARO,Hepatitis,,0
TEFLARO,Hepatitis,and administration,0
TEFLARO,Hepatitis,conditions Pyrexia Hepatobiliary Hepatitis,1
TEFLARO,Hepatitis,and administration site conditions Pyrexia Hepatobiliary disorders,0
TEFLARO,Hypersensitivity,Pyrexia Hepatobiliary disorders Hepatitis Immune system disorders,0
TEFLARO,Hypersensitivity,Hypersensitivity,1
TEFLARO,Hypersensitivity,system Hypersensitivity,1
TEFLARO,Hypersensitivity,Hypersensitivity,1
TEFLARO,Hypersensitivity,,0
TEFLARO,Hypersensitivity,,0
TEFLARO,Hypersensitivity,colitis Metabolism,0
TEFLARO,Hypersensitivity,Anaphylaxis Infections and infestations,0
TEFLARO,Hypersensitivity,Pyrexia Hepatobiliary,0
TEFLARO,Anaphylaxis,,0
TEFLARO,Anaphylaxis,Anaphylaxis,1
TEFLARO,Anaphylaxis,system disorders Anaphylaxis,1
TEFLARO,Anaphylaxis,Infections and infestations Clostridium difficile colitis Metabolism and,0
TEFLARO,Anaphylaxis,Clostridium difficile colitis Metabolism and,0
TEFLARO,Anaphylaxis,Hepatobiliary disorders Hepatitis Immune system,0
TEFLARO,Anaphylaxis,Hepatitis Immune system disorders,0
TEFLARO,Anaphylaxis,Infections and infestations Clostridium difficile colitis,0
TEFLARO,Clostridium difficile colitis,system disorders Hypersensitivity Anaphylaxis Infections,0
TEFLARO,Clostridium difficile colitis,disord,0
TEFLARO,Clostridium difficile colitis,Hypersensitivity Anaphylaxis,0
TEFLARO,Clostridium difficile colitis,,0
TEFLARO,Clostridium difficile colitis,colitis,1
TEFLARO,Clostridium difficile colitis,Hypersensitivity Anaphylaxis Infections and,0
TEFLARO,Hyperglycemia,Hyperglycemia,1
TEFLARO,Hyperkalemia,Renal,0
TEFLARO,Hyperkalemia,Metabolism and nutrition disorders,0
TEFLARO,Hyperkalemia,Hyperkalemia,1
TEFLARO,Hyperkalemia,Hyperkalemia,1
TEFLARO,Hyperkalemia,disorders Hyperkalemia,1
TEFLARO,Hyperkalemia,Clostridium difficile colitis Metabolism,0
TEFLARO,Hyperkalemia,Hyperkalemia,1
TEFLARO,Hyperkalemia,difficile colitis Metabolism,0
TEFLARO,Dizziness,Dizziness,1
TEFLARO,Dizziness,Hyperkalemia Nervous system Dizziness,1
TEFLARO,Dizziness,Dizziness,1
TEFLARO,Dizziness,Dizziness,1
TEFLARO,Convulsion,disorders Convulsion,1
TEFLARO,Convulsion,Nervous system,0
TEFLARO,Convulsion,Convulsion,1
TEFLARO,Convulsion,,0
TEFLARO,Convulsion,Convulsion,1
TEFLARO,Convulsion,system disorders Convulsion,1
TEFLARO,Convulsion,Convulsion,1
TEFLARO,Convulsion,Convulsion,1
TEFLARO,Renal failure,disorders,0
TEFLARO,Renal failure,and subcutaneous tissue disorders Urticaria Postmarketing,0
TEFLARO,Renal failure,,0
TEFLARO,Renal failure,Renal and urinary Renal failure,1
TEFLARO,Renal failure,and urinary Renal failure,1
TEFLARO,Renal failure,disorders Urticaria Postmarketing,0
TEFLARO,Renal failure,and urinary Renal failure,1
TEFLARO,Renal failure,,0
TEFLARO,Renal failure,Convulsion Renal and urinary Renal failure,1
TEFLARO,Renal failure,and urinary Renal,1
TEFLARO,Urticaria,Urticaria,1
TEFLARO,Urticaria,Urticaria,1
TEFLARO,Urticaria,disorders,0
TEFLARO,Urticaria,Urticaria,1
TEFLARO,Agranulocytosis,,0
TEFLARO,Agranulocytosis,lymphatic system,0
TEFLARO,Agranulocytosis,Agranulocytosis,1
TEFLARO,Clostridium difficile -associated diarrhea,,0
TEFLARO,Clostridium difficile -associated diarrhea,diarrhea [see Warnings and Precautions,1
TEFLARO,Clostridium difficile -associated diarrhea,and Precautions Clostridium difficile diarrhea [see Warnings and Precautions,1
TEFLARO,CDAD,.2  ,1
TEFLARO,CDAD,see Warnings and .2  ,1
TEFLARO,CDAD,.2  ,1
TEFLARO,CDAD,Direct Coombs Test Seroconversion see Warnings and,0
TEFLARO,CDAD,Clostridium difficile Associated diarrhea see Warnings,0
TEFLARO,CDAD,Warnings,0
TEFLARO,Direct Coombs' test seroconversion,actions occurring in >2,1
TEFLARO,Direct Coombs' test seroconversion,adverse actions occurring in >2 % of patie,1
TEFLARO,Direct Coombs' test seroconversion,The most common adverse actions occurring in >2 % of patie,1
TEFLARO,Direct Coombs' test seroconversion,patie,1
TEFLARO,Direct Coombs' test seroconversion,most common adverse actions occurring in >2 % of,1
TEFLARO,Direct Coombs' test seroconversion,,0
TEFLARO,Direct Coombs' test seroconversion,,0
TEFLARO,Direct Coombs' test seroconversion,of patie,1
TEFLARO,fatal,idely,1
TEFLARO,fatal,clinical trials,0
TEFLARO,fatal,idely,1
TEFLARO,fatal,idely,1
TEFLARO,fatal,idely,1
TEFLARO,fatal,under w,0
TEFLARO,fatal,clinical,0
TEFLARO,fatal,trials of a,0
TEFLARO,skin reactions,clinical tria,1
TEFLARO,skin reactions,reaction rates observed  clinical tria,1
TEFLARO,skin reactions,in,0
TEFLARO,skin reactions,rates observed  clinical tria,1
TEFLARO,skin reactions,rates from clinical,0
TEFLARO,skin reactions,rates observed clinical,1
TEFLARO,Clostridium difficile -associated diarrhea,"predominantly male and asian (82%).



     Serious Adverse Reacti",1
TEFLARO,Clostridium difficile -associated diarrhea,were predominantly male and asian,1
TEFLARO,CDAD,Adverse s an,1
TEFLARO,CDAD,,0
TEFLARO,diarrhea,and,0
TEFLARO,diarrhea,,0
TEFLARO,diarrhea,receiving Teflaro and of patients receiving,0
TEFLARO,diarrhea,adverse s,1
TEFLARO,diarrhea,trials serious adverse s,1
TEFLARO,diarrhea,adverse s (SARs),1
TEFLARO,diarrhea,s (SARs),1
TEFLARO,diarrhea,s (SARs),1
TEFLARO,diarrhea,(SARs),1
TEFLARO,colitis,in 98/1,1
TEFLARO,colitis,adverse reactions SARs in,1
TEFLARO,colitis,in 98/1,1
TEFLARO,colitis,serious adverse reactions SARs in,1
TEFLARO,colitis,serious adverse reactions SARs in,1
TEFLARO,colitis,adverse reactions SARs occurred,0
TEFLARO,colitis,adverse reactions SARs in 98/1,1
TEFLARO,colitis,SARs in,1
TEFLARO,colitis,of patients receiving Teflaro,0
TEFLARO,Seroconversion from a negative to a positive direct Coombs' test result,IV very,1
TEFLARO,Seroconversion from a negative to a positive direct Coombs' test result,vancomycin gram IV very 12h plus aztreonam 1 gram IV every 12h in the Phase 3 ABSSSI trial,1
TEFLARO,Seroconversion from a negative to a positive direct Coombs' test result,vancomycin gram IV very 12h plus aztreonam 1 gram IV every 12h in the,1
TEFLARO,Seroconversion from a negative to a positive direct Coombs' test result,aztreonam 1 gram IV every 12h in the Phase 3 ABSSSI trial,1
TEFLARO,Seroconversion from a negative to a positive direct Coombs' test result,vancomycin gram IV,0
TEFLARO,Seroconversion from a negative to a positive direct Coombs' test result,ceftriaxone gram IV every h in the Phase CABP trials Adverse,0
TEFLARO,seroconverted from a negative to a positive direct Coombs' test result,,0
TEFLARO,seroconverted from a negative to a positive direct Coombs' test result,,0
TEFLARO,seroconverted from a negative to a positive direct Coombs' test result,,0
TEFLARO,seroconverted from a negative to a positive direct Coombs' test result,Diarrhea Nausea,1
TEFLARO,seroconverted from a negative to a positive direct Coombs' test result,Teflaro N,0
TEFLARO,seroconverted from a negative to a positive direct Coombs' test result,a Gastrointestinal Disorders,1
TEFLARO,seroconverted from a negative to a positive direct Coombs' test result,,0
TEFLARO,hemolytic anemia,                 Nausea,1
JARDIANCE,Impairment in Renal Function,in Renal Function,1
JARDIANCE,Impairment in Renal Function,and,0
JARDIANCE,Impairment in Renal Function,in Renal Function,1
JARDIANCE,Impairment in Renal Function,Warnings and Impairment in Renal Function,1
JARDIANCE,Impairment in Renal Function,Impairment,1
JARDIANCE,Impairment in Renal Function,and,0
JARDIANCE,Impairment in Renal Function,,0
JARDIANCE,Impairment in Renal Function,Concomitant Use,0
JARDIANCE,Impairment in Renal Function,,0
JARDIANCE,Hypoglycemia,and Insulin Secretagogues see,0
JARDIANCE,Hypoglycemia,Precautions,0
JARDIANCE,Hypoglycemia,Hypoglycemia,1
JARDIANCE,Hypoglycemia,in Renal Function see,0
JARDIANCE,Hypoglycemia,Secretagogues see,0
JARDIANCE,Hypoglycemia,see Warnings,0
JARDIANCE,Hypoglycemia,Secretagogues see Warnings,0
JARDIANCE,Urinary Tract Infections,and Urinary Tract,1
JARDIANCE,Urinary Tract Infections,Urinary,1
JARDIANCE,Urinary Tract Infections,and Precautions Increased,0
JARDIANCE,Urinary Tract Infections,Precautions,0
JARDIANCE,Urinary Tract Infections,Infections,1
JARDIANCE,Urinary Tract Infections,Infections,1
JARDIANCE,Urinary Tract Infections,Precautions,0
JARDIANCE,Urinary Tract Infections,,0
JARDIANCE,Urinary Tract Infections,and Urinary,1
JARDIANCE,Urinary Tract Infections,see Warnings and Urinary Tract Infections,1
JARDIANCE,Increased Low-Density Lipoprotein Cholesterol,Infections see Warnings and Increased Low-Density Lipoprotein,1
JARDIANCE,Increased Low-Density Lipoprotein Cholesterol,Cholesterol,1
JARDIANCE,Increased Low-Density Lipoprotein Cholesterol,and Increased,1
JARDIANCE,Increased Low-Density Lipoprotein Cholesterol,Increased Low-Density Lipoprotein Cholesterol,1
JARDIANCE,Increased Low-Density Lipoprotein Cholesterol,Lipoprotein Cholesterol,1
JARDIANCE,Increased Low-Density Lipoprotein Cholesterol,and,0
JARDIANCE,Increased Low-Density Lipoprotein Cholesterol,Urinary Tract Infections see Warnings and Precautions,0
JARDIANCE,Increased Low-Density Lipoprotein Cholesterol,Precautions The most,0
JARDIANCE,urinary tract infections,and female genital mycotic infections EXCERPT,0
JARDIANCE,urinary tract infections,urinary tract infections,1
JARDIANCE,urinary tract infections,adverse reactions associated with JARDIANCE or greater,0
JARDIANCE,genital mycotic infections,urinary tract infections and genital mycotic infections,1
JARDIANCE,genital mycotic infections,infections and genital,1
JARDIANCE,genital mycotic infections,and,0
JARDIANCE,genital mycotic infections,genital mycotic infections,1
JARDIANCE,hypoglycemia,hypoglycemia,1
JARDIANCE,hypoglycemia,hypoglycemia,1
JARDIANCE,hypoglycemia,hypoglycemia,1
JARDIANCE,hypoglycemia,Table shows common,0
JARDIANCE,hypoglycemia,JARDIANCE,0
JARDIANCE,hypoglycemia,of JARDIANCE The adverse reactions were,0
JARDIANCE,hypoglycemia,eGFR mLmin m,0
JARDIANCE,hypoglycemia,common adverse reactions hypoglycemia,1
JARDIANCE,hypoglycemia,reactions hypoglycemia,1
JARDIANCE,hypoglycemia,common adverse reactions hypoglycemia,1
JARDIANCE,urinary tract infection,,0
JARDIANCE,urinary tract infection,Female genital mycotic infections include,0
JARDIANCE,urinary tract infection,but not limited urinary,1
JARDIANCE,urinary tract infection,grouping including but not limited,0
JARDIANCE,asymptomatic bacteriuria,but not limited to urinary tract infection,0
JARDIANCE,asymptomatic bacteriuria,asymptomatic,1
JARDIANCE,cystitis,cystitis,1
JARDIANCE,cystitis,infection asymptomatic cystitis,1
JARDIANCE,cystitis,urinary tract infection asymptomatic cystitis,1
JARDIANCE,cystitis,mycotic infections include the following adverse reactions,0
JARDIANCE,Female genital mycotic infections,tract infection asymptomatic,0
JARDIANCE,Female genital mycotic infections,infection asymptomatic bacteriuria cystitis Female genital,1
JARDIANCE,Female genital mycotic infections,infections,1
JARDIANCE,Female genital mycotic infections,mycotic infections,1
JARDIANCE,Female genital mycotic infections,asymptomatic bacteriuria,0
JARDIANCE,Female genital mycotic infections,b,0
JARDIANCE,Female genital mycotic infections,genital mycotic infections,1
JARDIANCE,Female genital mycotic infections,infection asymptomatic bacteriuria cystitis Female genital mycotic infections,1
JARDIANCE,Female genital mycotic infections,to,0
JARDIANCE,Female genital mycotic infections,vulvovaginal mycotic infection,0
JARDIANCE,vulvovaginal mycotic infection,include the following adverse vulvovaginal mycotic infection,1
JARDIANCE,vulvovaginal mycotic infection,,0
JARDIANCE,vaginal infection,infection,0
JARDIANCE,vaginal infection,reactions vulvovaginal,0
JARDIANCE,vaginal infection,vaginal infection,1
JARDIANCE,vaginal infection,following adverse,0
JARDIANCE,vaginal infection,adverse reactions vulvovaginal,0
JARDIANCE,vaginal infection,vaginal,1
JARDIANCE,vaginal infection,vulvovaginal mycotic vaginal,1
JARDIANCE,vaginal infection,,0
JARDIANCE,vaginal infection,candidiasis genital,0
JARDIANCE,vulvitis,vulvitis,1
JARDIANCE,vulvitis,,0
JARDIANCE,vulvitis,vulvovaginal mycotic infection vaginal vulvitis,1
JARDIANCE,vulvitis,vulvitis,1
JARDIANCE,vulvitis,vulvitis,1
JARDIANCE,vulvovaginal candidiasis,vulvovaginal candidiasis,1
JARDIANCE,vulvovaginal candidiasis,mycotic infection vaginal,0
JARDIANCE,vulvovaginal candidiasis,candidiasis,1
JARDIANCE,vulvovaginal candidiasis,adverse,0
JARDIANCE,vulvovaginal candidiasis,genital candidiasis genital infection fungal genitourinary,0
JARDIANCE,vulvovaginal candidiasis,mycotic infection vaginal infection vulvovaginal candidiasis,1
JARDIANCE,vulvovaginal candidiasis,,0
JARDIANCE,vulvovaginal candidiasis,infection vaginal infection vulvovaginal,1
JARDIANCE,vulvovaginal candidiasis,candidiasis,1
JARDIANCE,vulvovaginal candidiasis,genital,0
JARDIANCE,genital infection,vaginal infection vulvitis vulvovaginal genital,1
JARDIANCE,genital infection,,0
JARDIANCE,genital infection,vulvovaginitis cerv,0
JARDIANCE,genital infection,genitourinary tract infection,0
JARDIANCE,genital infection,infection,1
JARDIANCE,genital infection,infection,1
JARDIANCE,genital infection,genitourinary tract,0
JARDIANCE,genital infection,infection,0
JARDIANCE,genital infection,vulvovaginal mycotic infection vaginal,0
JARDIANCE,genital candidiasis,,0
JARDIANCE,genital candidiasis,,0
JARDIANCE,genital candidiasis,candidiasis,1
JARDIANCE,genital candidiasis,mycotic infection vaginal infection vulvitis vulvovaginal candidiasis genital,0
JARDIANCE,genital candidiasis,genital candidiasis,1
JARDIANCE,genital candidiasis,candidiasis,1
JARDIANCE,genital infection fungal,urogenital infection fungal vaginitis,0
JARDIANCE,genital infection fungal,infection fungal,1
JARDIANCE,genital infection fungal,genital genital infection fungal,1
JARDIANCE,genital infection fungal,,0
JARDIANCE,genital infection fungal,fungal,1
JARDIANCE,genital infection fungal,genital infection genital genital infection,1
JARDIANCE,vulvovaginitis,vaginitis bacterial Percentages calculated,0
JARDIANCE,vulvovaginitis,fungal genitourinary tract infection,0
JARDIANCE,vulvovaginitis,genital candidiasis genital infection,0
JARDIANCE,vulvovaginitis,vulvovaginitis,1
JARDIANCE,vulvovaginitis,vulvovaginitis,1
JARDIANCE,vulvovaginitis,the numb,0
JARDIANCE,vulvovaginitis,vulvovaginitis,1
JARDIANCE,vulvovaginitis,infection fungal genitourinary tract vulvovaginitis,1
JARDIANCE,vulvovaginitis,genital candidiasis genital infection fungal genitourinary tract infection,0
JARDIANCE,cervicitis,with the number of female,0
JARDIANCE,cervicitis,cervicitis,1
JARDIANCE,cervicitis,candidiasis genital infection fungal genitourinary,0
JARDIANCE,urogenital infection fungal,tract infection vulvovaginitis urogenital infection fungal,1
JARDIANCE,urogenital infection fungal,,0
JARDIANCE,urogenital infection fungal,candidiasis genital infection,0
JARDIANCE,urogenital infection fungal,calculated with,0
JARDIANCE,vaginitis bacterial,cervicitis urogenital infection vaginitis,1
JARDIANCE,vaginitis bacterial,vaginitis,1
JARDIANCE,vaginitis bacterial,cervicitis urogenital infection fungal,0
JARDIANCE,vaginitis bacterial,vaginitis bacterial,1
JARDIANCE,vaginitis bacterial,,0
JARDIANCE,vaginitis bacterial,vulvovaginitis cervicitis urogenital infection vaginitis bacterial,1
JARDIANCE,vaginitis bacterial,bacterial,1
JARDIANCE,vaginitis bacterial,tract,0
JARDIANCE,vaginitis bacterial,urogenital infection fungal,0
JARDIANCE,vaginitis bacterial,infection,0
JARDIANCE,polyuria,infections include the following adverse r,0
JARDIANCE,pollakiuria,pollakiuria,1
JARDIANCE,pollakiuria,c Predefined,0
JARDIANCE,pollakiuria,pollakiuria,1
JARDIANCE,pollakiuria,mycotic infections include the following,0
JARDIANCE,pollakiuria,not limited to pollakiuria,1
JARDIANCE,pollakiuria,d Male genital mycotic infections include the following adverse,0
JARDIANCE,pollakiuria,reactions,0
JARDIANCE,pollakiuria,but not limited to pollakiuria,1
JARDIANCE,pollakiuria,following adverse reactions bal,0
JARDIANCE,nocturia,pollakiuria nocturia,1
JARDIANCE,nocturia,polyuria pollakiuria nocturia,1
JARDIANCE,nocturia,grouping including but not limited to polyuria pollakiuria and,0
JARDIANCE,nocturia,pollakiuria nocturia,1
JARDIANCE,nocturia,event grouping including but not limited,0
JARDIANCE,nocturia,nocturia,1
JARDIANCE,nocturia,,0
JARDIANCE,balanoposthitis,the following adverse reactions,0
JARDIANCE,balanoposthitis,the following adverse balanoposthitis,1
JARDIANCE,balanoposthitis,balanoposthitis,1
JARDIANCE,balanoposthitis,balanoposthitis,1
JARDIANCE,balanoposthitis,balanoposthitis,1
JARDIANCE,balanoposthitis,the following adverse balanoposthitis,1
JARDIANCE,balanitis,balanitis,1
JARDIANCE,balanitis,reactions balanitis,1
JARDIANCE,balanitis,scrotal abscess peni,0
JARDIANCE,balanitis,balanitis,1
JARDIANCE,balanitis,balanitis,1
JARDIANCE,balanitis,balanitis,1
JARDIANCE,balanitis,,0
JARDIANCE,balanitis,,0
JARDIANCE,balanitis,balanitis,1
JARDIANCE,genitourinary tract infection,calculated with the number of,0
JARDIANCE,balanitis candida,infection,0
JARDIANCE,balanitis candida,reactions balanoposthitis balanitis genital infections fungal genitourinary,0
JARDIANCE,scrotal abscess,genitourinary tract infection balanitis scrotal,1
JARDIANCE,penile infection,,0
JARDIANCE,penile infection,infection,1
JARDIANCE,penile infection,group as denominator,0
JARDIANCE,penile infection,infection,1
JARDIANCE,penile infection,infection,1
JARDIANCE,penile infection,genital infections fungal genitourinary tract infection balanitis candida scrotal,0
JARDIANCE,penile infection,candida scrotal abscess,0
JARDIANCE,Urinary tract infection,,0
JARDIANCE,Urinary tract infection,mgN JARDIANCE mgN,0
JARDIANCE,Urinary tract infection,,0
JARDIANCE,Female genital mycotic infections,ct infection Female genital mycotic,1
JARDIANCE,Female genital mycotic infections,Female genital mycotic infections,1
JARDIANCE,Female genital mycotic infections,ct infection Female genital mycotic infections,1
JARDIANCE,Female genital mycotic infections,Upper,0
JARDIANCE,Female genital mycotic infections,Female genital mycotic infections,1
JARDIANCE,Female genital mycotic infections,ct infection Female genital mycotic infections,1
JARDIANCE,Upper respiratory tract infection,Upper respiratory,1
JARDIANCE,Upper respiratory tract infection,Upper respiratory tract infection,1
JARDIANCE,Dyslipidemia,,0
JARDIANCE,Dyslipidemia,A,0
JARDIANCE,Dyslipidemia,,0
JARDIANCE,Dyslipidemia,Dyslipidemia A,1
JARDIANCE,Dyslipidemia,A,0
JARDIANCE,Dyslipidemia,A,0
JARDIANCE,Dyslipidemia,Dyslipidemia A,1
JARDIANCE,Dyslipidemia,,0
JARDIANCE,Dyslipidemia,c,0
JARDIANCE,Arthralgia,a,0
JARDIANCE,Arthralgia,Arthralgia,1
JARDIANCE,Arthralgia,Arthralgia,1
JARDIANCE,Arthralgia,a Arthralgia,1
JARDIANCE,Arthralgia,Arthralgia,1
JARDIANCE,Arthralgia,a,0
JARDIANCE,Male genital mycotic infections,,0
JARDIANCE,Male genital mycotic infections,genital mycotic infections,1
JARDIANCE,Male genital mycotic infections,,0
JARDIANCE,Male genital mycotic infections,,0
JARDIANCE,Nausea,,0
JARDIANCE,Nausea,Nausea,1
JARDIANCE,Nausea,Nausea,1
JARDIANCE,Nausea,infections,0
JARDIANCE,Nausea,Nausea,1
JARDIANCE,Nausea,,0
JARDIANCE,Nausea,Nausea,1
JARDIANCE,Nausea,,0
JARDIANCE,polydipsia,polydipsia,1
JARDIANCE,polydipsia,mg and JARDIANCE mg,0
JARDIANCE,polydipsia,including,0
JARDIANCE,polydipsia,polydipsia,1
JARDIANCE,polydipsia,and JARDIANCE mg,0
JARDIANCE,polydipsia,including,0
JARDIANCE,polydipsia,polydipsia,1
JARDIANCE,polydipsia,,0
JARDIANCE,osmotic diuresis,volume,0
JARDIANCE,intravascular volume contraction,intravascular,1
JARDIANCE,intravascular volume contraction,diuresis which may lead,0
JARDIANCE,intravascular volume contraction,may lead to,0
JARDIANCE,intravascular volume contraction,which may lead intravascular volume,1
JARDIANCE,intravascular volume contraction,which may lead intravascular,1
JARDIANCE,intravascular volume contraction,which may lead intravascular volume contraction,1
JARDIANCE,intravascular volume contraction,volume contraction,1
JARDIANCE,intravascular volume contraction,depletion In the pool of,0
JARDIANCE,intravascular volume contraction,intravascular volume contraction,1
JARDIANCE,intravascular volume contraction,,0
JARDIANCE,volume depletion,related to volume deplet,0
JARDIANCE,volume depletion,related volume depletion,1
JARDIANCE,volume depletion,volume contraction,0
JARDIANCE,volume depletion,contraction and adverse,0
JARDIANCE,volume depletion,depletion,1
JARDIANCE,volume depletion,placebocontrolled clinical trials,0
JARDIANCE,volume depletion,and adverse reactions related volume depletion,1
JARDIANCE,volume depletion,,0
JARDIANCE,volume depletion,to,0
JARDIANCE,volume depletion,reactions related volume depletion,1
JARDIANCE,volume depletion,five placebocontrolled,0
JARDIANCE,volume depletion,trials adverse reactions related volume depletion,1
JARDIANCE,volume depletion,trials adverse reactions related volume,1
JARDIANCE,blood pressure systolic decreased,pressure ambulatory blood pressure systolic decreased,1
JARDIANCE,blood pressure systolic decreased,blood pressure ambulatory blood pressure systolic decreased,1
JARDIANCE,blood pressure systolic decreased,blood pressure ambulatory,0
JARDIANCE,blood pressure systolic decreased,blood pressure ambulatory blood,1
JARDIANCE,blood pressure systolic decreased,blood pressure ambulatory blood pressure,1
JARDIANCE,blood pressure systolic decreased,ambulatory blood pressure systolic decreased,1
JARDIANCE,blood pressure systolic decreased,pressure ambulatory decreased,0
JARDIANCE,blood pressure systolic decreased,pressure systolic decreased,1
JARDIANCE,blood pressure systolic decreased,hypotension and,0
JARDIANCE,blood pressure systolic decreased,orthostatic hypotension and syncope,0
JARDIANCE,hypovolemia,decreased dehydration hypotension,0
JARDIANCE,orthostatic hypotension,,0
JARDIANCE,orthostatic hypotension,,0
JARDIANCE,orthostatic hypotension,and syncope were reported,0
JARDIANCE,orthostatic hypotension,decreased,0
JARDIANCE,orthostatic hypotension,orthostatic hypotension,1
JARDIANCE,orthostatic hypotension,reported by and of patients treated with,0
JARDIANCE,syncope,syncope,1
JARDIANCE,syncope,syncope,1
JARDIANCE,syncope,syncope,1
JARDIANCE,syncope,with placebo,0
JARDIANCE,hypotension,increase,0
JARDIANCE,hypotension,Precautions and Use in Spec,0
JARDIANCE,hypotension,risk of,0
JARDIANCE,hypotension,hypotension,1
JARDIANCE,hypotension,risk,0
JARDIANCE,Increased Urination,of increased urination,0
JARDIANCE,Increased Urination,Urination,1
JARDIANCE,Increased Urination,Specific Populations,0
JARDIANCE,increased urination,increased urination,1
JARDIANCE,increased urination,pool of five placebocontrolled clinical,0
JARDIANCE,increased urination,,0
JARDIANCE,polyuria,polyuria,1
JARDIANCE,polyuria,polyuria,1
JARDIANCE,polyuria,polyuria,1
JARDIANCE,polyuria,polyuria,1
JARDIANCE,polyuria,on,0
JARDIANCE,polyuria,polyuria,1
JARDIANCE,polyuria,polyuria,1
JARDIANCE,polyuria,adverse reactions of increased urination eg,0
JARDIANCE,nocturia,polyuria pollakiuria nocturia,1
JARDIANCE,nocturia,polyuria pollakiuria nocturia,1
JARDIANCE,nocturia,nocturia,1
JARDIANCE,nocturia,,0
JARDIANCE,nocturia,Table Specifically nocturia was,0
JARDIANCE,nocturia,polyuria pollakiuria nocturia,1
JARDIANCE,nocturia,nocturia,1
JARDIANCE,nocturia,on placebo see,0
JARDIANCE,nocturia,and,0
JARDIANCE,nocturia,frequently on JARDIANCE than on placebo see Table Specifically,0
JARDIANCE,nocturia,nocturia,1
JARDIANCE,nocturia,placebo JARDIANCE,0
JARDIANCE,nocturia,nocturia,1
JARDIANCE,nocturia,nocturia,1
JARDIANCE,nocturia,nocturia,1
JARDIANCE,nocturia,nocturia,1
JARDIANCE,Impairment in Renal Function,see Tabl,0
JARDIANCE,Impairment in Renal Function,JARDIANCE mg Impairment in Renal,1
JARDIANCE,Impairment in Renal Function,and JARDIANCE,0
JARDIANCE,Impairment in Renal Function,mg Impairment in Renal Function,1
JARDIANCE,Impairment in Renal Function,increases in,0
JARDIANCE,increases in serum creatinine,increases in serum creatinine,1
JARDIANCE,increases in serum creatinine,was associated increases in serum creatinine,1
JARDIANCE,increases in serum creatinine,,0
JARDIANCE,increases in serum creatinine,JARDIANCE was associated increases in serum creatinine,1
JARDIANCE,increases in serum creatinine,with,0
JARDIANCE,increases in serum creatinine,of JARDIANCE was associated increases in serum creatinine,1
JARDIANCE,increases in serum creatinine,creatinine,1
JARDIANCE,increases in serum creatinine,see Table Patients with moderate renal impairment at baseline had,0
JARDIANCE,increases in serum creatinine,see Table Patients,0
JARDIANCE,decreases in eGFR,decreases in eGFR,1
JARDIANCE,decreases in eGFR,,0
JARDIANCE,decreases in eGFR,moderate renal impairment at,0
JARDIANCE,decreases in eGFR,increases in serum creatinine decreases in eGFR,1
JARDIANCE,decreases in eGFR,increases in serum creatinine decreases in eGFR,1
JARDIANCE,decreases in eGFR,increases in serum creatinine decreases,1
JARDIANCE,decreases in eGFR,,0
JARDIANCE,eGFR 30 to less than 60 mL/min/1.73 m 2,of Week PlaceboControlled Studies,0
JARDIANCE,eGFR 30 to less than 60 mL/min/1.73 m 2,from renal impairment study eGFR 30 to less than 60,1
JARDIANCE,Hypoglycemia,study is shown in Table The incidence of hypoglycemia increase,0
JARDIANCE,Hypoglycemia,shown in Table The incidence of hypoglycemia,0
JARDIANCE,Hypoglycemia,shown in,0
JARDIANCE,Hypoglycemia,Table The incidence of hypoglycemia,0
JARDIANCE,Hypoglycemia,mLmin Hypoglycemia,1
JARDIANCE,Hypoglycemia,m,0
JARDIANCE,Hypoglycemia,,0
JARDIANCE,Hypoglycemia,Hypoglycemia,1
JARDIANCE,Hypoglycemia,Hypoglycemia,1
JARDIANCE,Hypoglycemia,Hypoglycemia,1
JARDIANCE,hypoglycemia,hypoglycemia,1
JARDIANCE,hypoglycemia,hypoglycemia,1
JARDIANCE,hypoglycemia,hypoglycemia by study is shown,0
JARDIANCE,hypoglycemia,,0
JARDIANCE,hypoglycemia,hypoglycemia,1
JARDIANCE,Hypoglycemic Events,of Overalla and Hypoglycemic Events,1
JARDIANCE,Hypoglycemic Events,Hypoglycemic Events,1
JARDIANCE,Hypoglycemic Events,Events,1
JARDIANCE,Hypoglycemic Events,,0
JARDIANCE,Hypoglycemic Events,of,0
JARDIANCE,Hypoglycemic Events,Studies a Overall hypoglycemic events plasma or,0
JARDIANCE,Hypoglycemic Events,Hypoglycemic Events,1
JARDIANCE,Hypoglycemic Events,and Hypoglycemic Events,1
JARDIANCE,Hypoglycemic Events,Studies a Overall hypoglycemic events plasma or,0
JARDIANCE,Hypoglycemic Events,Precautions Table Incidence of Overalla,0
JARDIANCE,Hypoglycemic Events,Precautions Table Incidence,0
JARDIANCE,hypoglycemic events,events,1
JARDIANCE,hypoglycemic events,Clinical Studies a hypoglycemic events,1
JARDIANCE,hypoglycemic events,PlaceboControlled Clinical Studies a hypoglycemic,1
JARDIANCE,hypoglycemic events,Severeb Hypoglycemic Events,0
JARDIANCE,hypoglycemic events,PlaceboControlled Clinical Studies a hypoglycemic events,1
JARDIANCE,hypoglycemic events,plasma or capillary glucose of less than or equal,0
JARDIANCE,hypoglycemic events,hypoglycemic,1
JARDIANCE,hypoglycemic events,b hypoglycemic,1
JARDIANCE,hypoglycemic events,or equal to mgdL b Severe,0
JARDIANCE,hypoglycemic events,,0
JARDIANCE,Genital Mycotic Infections,,0
JARDIANCE,Genital Mycotic Infections,five placebocontrolled clinical trials,0
JARDIANCE,Genital Mycotic Infections,Mycotic Infections In the pool,1
JARDIANCE,Genital Mycotic Infections,Genital,1
JARDIANCE,Genital Mycotic Infections,Genital Mycotic Infections In the,1
JARDIANCE,Genital Mycotic Infections,Genital Mycotic,1
JARDIANCE,Genital Mycotic Infections,,0
JARDIANCE,genital mycotic infections,eg vaginal mycotic infection,0
JARDIANCE,genital mycotic infections,,0
JARDIANCE,genital mycotic infections,vulvovaginal candidi,0
JARDIANCE,genital mycotic infections,genital mycotic infections eg vaginal mycotic,1
JARDIANCE,genital mycotic infections,incidence genital mycotic,1
JARDIANCE,genital mycotic infections,of five placebocontrolled clinical trials the incidence of,0
JARDIANCE,genital mycotic infections,clinical trials the incidence of,0
JARDIANCE,vaginal mycotic infection,vulvovaginal candidiasis and vulvitis,0
JARDIANCE,vaginal mycotic infection,vaginal mycotic infection vaginal infection genital,1
JARDIANCE,vaginal mycotic infection,genital infection fungal vulvovaginal candidiasis and,0
JARDIANCE,vaginal mycotic infection,vaginal mycotic infection vaginal infection genital,1
JARDIANCE,vaginal mycotic infection,mycotic infection vaginal infection genital,1
JARDIANCE,genital infection fungal,vaginal mycotic infection vaginal genital,1
JARDIANCE,genital infection fungal,fungal vulvovaginal candidiasis and,1
JARDIANCE,genital infection fungal,,0
JARDIANCE,genital infection fungal,vaginal mycotic infection vaginal genital,1
JARDIANCE,genital infection fungal,vaginal genital infection fungal vulvovaginal candidiasis and,1
JARDIANCE,vulvovaginal candidiasis,genital infection vulvovaginal candidiasis and vulvitis was,1
JARDIANCE,vulvovaginal candidiasis,placebo occurring in,0
JARDIANCE,vulvovaginal candidiasis,candidiasis and vulvitis was,1
JARDIANCE,vulvitis,was increased in patients treated with JARDIANCE compared to placebo occurring in and,0
JARDIANCE,vulvitis,fungal vulvovaginal candidiasis and,0
JARDIANCE,vulvitis,vulvitis was increased in,1
JARDIANCE,vulvitis,placebo occurring in and,0
JARDIANCE,vulvitis,and,0
JARDIANCE,vulvitis,vulvitis was increased in,1
JARDIANCE,vulvitis,with JARDIANCE compared,0
JARDIANCE,vulvitis,vulvovaginal candidiasis and,0
JARDIANCE,vulvitis,vulvitis was increased in,1
JARDIANCE,vulvitis,increased in patients,0
JARDIANCE,genital infection,from study due genital infection occurred in of,1
JARDIANCE,genital infection,placebotreated patients and of,0
JARDIANCE,genital infection,infection occurred in of,1
JARDIANCE,genital infection,infection occurred in of,1
JARDIANCE,genital infection,and of patients treated with either,0
JARDIANCE,genital infection,Discontinuation from study due genital infection occurred in of,1
JARDIANCE,genital infection,from study due genital infection occurred in of,1
JARDIANCE,genital infection,infection occurred in of,1
JARDIANCE,genital infection,to,0
JARDIANCE,genital infection,due genital infection occurred in of,1
JARDIANCE,Genital mycotic infections,Genital mycotic infections occurred more frequently,1
JARDIANCE,Genital mycotic infections,,0
JARDIANCE,Genital mycotic infections,mycotic infections occurred more frequently,1
JARDIANCE,Genital mycotic infections,Genital mycotic infections occurred more frequently,1
JARDIANCE,Genital mycotic infections,and of patients treated with,0
JARDIANCE,Phimosis,JARDIANCE mg less than and JARDIAN,0
JARDIANCE,Phimosis,Phimosis occurred more frequently,1
JARDIANCE,Phimosis,Table,0
JARDIANCE,Phimosis,JARDIAN,0
JARDIANCE,Phimosis,Phimosis occurred more frequently,1
JARDIANCE,Phimosis,treated with JARDIANCE mg less than and,0
JARDIANCE,Phimosis,than male patients see Phimosis occurred more frequently,1
JARDIANCE,Phimosis,Phimosis occurred more frequently,1
JARDIANCE,Phimosis,than male patients see Phimosis occurred more frequently,1
JARDIANCE,Phimosis,,0
JARDIANCE,Urinary Tract Infections,Urinary Tract Infections In the pool,1
JARDIANCE,Urinary Tract Infections,mg less than and,0
JARDIANCE,urinary tract infections,tract infections eg urinary tract,1
JARDIANCE,urinary tract infections,clinical trials the incidence urinary tract,1
JARDIANCE,urinary tract infections,trials the incidence urinary tract infections eg urinary tract,1
JARDIANCE,urinary tract infections,infections eg urinary tract,1
JARDIANCE,cystitis,and,0
JARDIANCE,cystitis,cystitis was increased in,1
JARDIANCE,cystitis,infection,0
JARDIANCE,cystitis,cystitis was increased in,1
JARDIANCE,cystitis,cystitis was increased in,1
JARDIANCE,cystitis,cystitis was increased in,1
JARDIANCE,cystitis,tract infections eg urinary tract infection asymptomatic bacteriuria and,0
JARDIANCE,cystitis,cystitis was increased in,1
JARDIANCE,urinary tract infection,to experience urinary tract infection The rate of,1
JARDIANCE,urinary tract infection,infections were more likely,0
JARDIANCE,urinary tract infection,infection The rate of,1
JARDIANCE,urinary tract infection,urinary,1
JARDIANCE,urinary tract infection,urinary tract infections were more likely,0
JARDIANCE,urinary tract infections,of,0
JARDIANCE,Urinary tract infections,urinary,0
JARDIANCE,Urinary tract infections,Urinary tract infections occurred more frequently,1
JARDIANCE,Urinary tract infections,and JARDIANCE mg Urinary tract infections occurred more frequently,1
JARDIANCE,urinary tract infections,patients randomized to,0
JARDIANCE,urinary tract infections,infections in female patients,1
JARDIANCE,urinary tract infections,in female patients randomized to placebo JARDIANCE mg and JARDIANCE mg was an,0
JARDIANCE,urinary tract infections,patients The incidence urinary,1
JARDIANCE,urinary tract infections,incidence urinary tract infections in female patients,1
JARDIANCE,urinary tract infections,was an,0
JARDIANCE,urinary tract infections,infections occurred,0
JARDIANCE,urinary tract infections,incidence urinary tract infections in female patients,1
JARDIANCE,Increase in Low-Density Lipoprotein Cholesterol,Laboratory Increase in,1
JARDIANCE,increases in low-density lipoprotein cholesterol,in low-density lipoprotein cholesterol LDLC were observed,1
JARDIANCE,increases in low-density lipoprotein cholesterol,and i,0
JARDIANCE,increases in low-density lipoprotein cholesterol,increases in low-density lipoprotein cholesterol LDLC were observed,1
JARDIANCE,LDL-C increased,LDL-C increased by and in,1
JARDIANCE,LDL-C increased,patients treated with LDL-C,1
JARDIANCE,LDL-C increased,in,0
JARDIANCE,LDL-C increased,with LDL-C increased by and in,1
JARDIANCE,LDL-C increased,,0
JARDIANCE,LDL-C increased,placebo JARDIANCE mg and,0
JARDIANCE,LDL-C increased,increased by and in,1
JARDIANCE,LDL-C increased,treated with LDL-C increased by and in,1
JARDIANCE,Increase in Hematocrit,was to mgdL across treatment,0
JARDIANCE,Increase in Hematocrit,Hematocrit In a pool,1
JARDIANCE,Increase in Hematocrit,treatment Increase,1
JARDIANCE,Increase in Hematocrit,a pool of four placebocontrolled studies median hematocrit decreased by in placebo and i,0
JARDIANCE,hematocrit decreased,four placebocontrolled studies hematocrit,1
JARDIANCE,hematocrit decreased,hematocrit decreased by in placebo,1
JARDIANCE,hematocrit decreased,hematocrit decreased by in placebo,1
JARDIANCE,Hypotension,,0
JARDIANCE,Hypotension,,0
JARDIANCE,Hypotension,verse,1
JARDIANCE,Hypotension,in the labeling Hypotension see,0
JARDIANCE,Hypotension,verse,1
JARDIANCE,Impairment in renal function,nsulin Secretagogues [see Wa rnings,1
JARDIANCE,Impairment in renal function,Insulin and nsulin Secretagogues,1
JARDIANCE,Impairment in renal function,Genital Mycotic Infections see,0
JARDIANCE,Impairment in renal function,with Insulin and nsulin Secretagogues,1
JARDIANCE,Impairment in renal function,Mycotic Infections see Warnings and Precautions,0
JARDIANCE,Impairment in renal function,and,0
JARDIANCE,Hypoglycemia,Tract Infections see rnings,1
JARDIANCE,Hypoglycemia,Warnings and,0
JARDIANCE,Hypoglycemia,Infections see rnings and P recautions,1
JARDIANCE,Hypoglycemia,Infections see rnings and,1
JARDIANCE,Hypoglycemia,see,0
JARDIANCE,Hypoglycemia,and P recautions,1
JARDIANCE,Hypoglycemia,LowDensity Lipoprotein Cholesterol LDLC see,0
JARDIANCE,Hypoglycemia,Urinary Tract Infections see rnings and,1
JARDIANCE,Hypoglycemia,,0
JARDIANCE,Hypoglycemia,Wa,0
JARDIANCE,Genital mycotic infections,LDLC see Warnings and Precautions The most,0
JARDIANCE,Genital mycotic infections,and Precautions The,0
JARDIANCE,Urinary tract infections,w,0
JARDIANCE,Urinary tract infections,JARDIANCE or greater incidence ere urinary tract,1
JARDIANCE,Urinary tract infections,and female genital mycotic infections EXCERPT To,0
JARDIANCE,Urinary tract infections,with,0
JARDIANCE,Urinary tract infections,,0
JARDIANCE,Urinary tract infections,ions,0
JARDIANCE,Urinary tract infections,or greater incidence ere urinary tract,1
JARDIANCE,Urinary tract infections,,0
JARDIANCE,Increased LDL-C,Ingelheim Pharmaceuticals Inc,0
JARDIANCE,Increased LDL-C,EXCERP T,1
JARDIANCE,Increased LDL-C,mycotic,0
JARDIANCE,Increased LDL-C,,0
JARDIANCE,Increased LDL-C,were urinary tract infections,0
JARDIANCE,Increased LDL-C,report SUSPECTED ADVERSE REACTIONS contact Boehringer Ingelheim,0
JARDIANCE,Increased LDL-C,ADVERSE REACTIONS contact Boehringer Ingelheim Pharmaceuticals Inc at,0
JARDIANCE,Increased LDL-C,contact,0
JARDIANCE,Increased LDL-C,and female genital mycotic ),1
JARDIANCE,intravascular volume contraction,Clinical,0
JARDIANCE,Symptomatic hypotension,conducted under widely va,0
JARDIANCE,Symptomatic hypotension,"conducted under widely rying conditions, adver se",1
JARDIANCE,Symptomatic hypotension,"are conducted under widely rying conditions, adver se",1
JARDIANCE,Symptomatic hypotension,conducted under widely,0
JARDIANCE,Symptomatic hypotension,adver se,1
JARDIANCE,Symptomatic hypotension,"rying conditions, adver se",1
JARDIANCE,increases serum creatinine,trials,0
JARDIANCE,increases serum creatinine,patients to JARDIANC E,1
JARDIANCE,increases serum creatinine,to JARDIANC E,1
JARDIANCE,decreases eGFR,,0
JARDIANCE,decreases eGFR,to JARDIANCE h a mean expos ure,1
JARDIANCE,impaired renal function,approximately weeks Patients eceived placebo (N=995) JARDIANCE,1
JARDIANCE,impaired renal function,approximately weeks Patients eceived placebo (N=995) JARDIANCE,1
JARDIANCE,impaired renal function,the population was,0
JARDIANCE,impaired renal function,Patients eceived,1
JARDIANCE,impaired renal function,eceived placebo (N=995) JARDIANCE,1
JARDIANCE,impaired renal function,eceived,1
JARDIANCE,impaired renal function,eceived placebo (N=995) JARDIANCE,1
JARDIANCE,impaired renal function,eceived placebo,1
JARDIANCE,impaired renal function,of patients to JARDIANCE with a mean exposure duration,0
JARDIANCE,impaired renal function,Patients eceived,1
JARDIANCE,hypoglycemia,of,0
JARDIANCE,hypoglycemia,"pathy (8%), or",1
JARDIANCE,hypoglycemia,"diabetic nephropathy pathy (8%),  or",1
JARDIANCE,hypoglycemia,baseline included diabetic nephropathy pathy,1
JARDIANCE,hypoglycemia,at baseline included diabetic nephropathy retino,0
JARDIANCE,hypoglycemia,,0
JARDIANCE,hypoglycemia,neuropathy Baseline renal function was normal or,0
JARDIANCE,hypoglycemia,was normal or mildly impaired in of patients and,0
JARDIANCE,hypoglycemia,diabetic nephropathy pathy,1
JARDIANCE,hypoglycemia,"pathy (8%), or",1
JARDIANCE,genital mycotic infections,JARDIANCE than on ebo and,1
JARDIANCE,genital mycotic infections,JARDIANCE than on ebo and occurred in greate r,1
JARDIANCE,genital mycotic infections,on JARDIANCE than on ebo and occurred,1
JARDIANCE,genital mycotic infections,on JARDIANCE than on plac,0
JARDIANCE,genital mycotic infections,ebo and occurred in greate r,1
JARDIANCE,genital mycotic infections,than on ebo and occurred in greate r,1
JARDIANCE,genital mycotic infections,on ebo and occurred in greate r,1
JARDIANCE,genital mycotic infections,JARDIANCE than on ebo and,1
JARDIANCE,genital mycotic infections,,0
JARDIANCE,genital mycotic infections,greate r,1
JARDIANCE,mycotic genital infections,Reported in of  Treated with JARDIANCE an d,1
JARDIANCE,mycotic genital infections, Treated with JARDIANCE an d,1
JARDIANCE,mycotic genital infections,Reactions Reported in of  Treated with JARDIANCE an d,1
JARDIANCE,mycotic genital infections,Pooled PlaceboControlled Clinical Studies of JARDIANCE Monotherapy or Com,0
JARDIANCE,mycotic genital infections,Reported in of Treated,1
JARDIANCE,mycotic genital infections,in of  Treated with JARDIANCE an d,1
JARDIANCE,mycotic genital infections,Adverse Reactions Reported in of,0
JARDIANCE,mycotic genital infections,Reported in of Treated with,1
JARDIANCE,urinary tract infections,,0
JARDIANCE,urinary tract infections,PlaceboControlled Clinical,0
JARDIANCE,urinary tract infections,to urinary tract infection,0
JARDIANCE,urinary tract infections,JARDIANCE Monotherapy or,0
JARDIANCE,urinary tract infections,"Monotherapy or Combination herapy 
   a  Predefined adverse",1
JARDIANCE,urinary tract infections,JARDIANCE Monotherapy or Combination herapy,1
JARDIANCE,urinary tract infections,"Monotherapy or Combination herapy 
   a  Predefined adverse",1
JARDIANCE,urinary tract infections,herapy a Predefined adverse,1
JARDIANCE,Increases in LDL-C,cystitis b Female genital cotic infections i nclude,1
JARDIANCE,Increases in LDL-C,i nclude,1
JARDIANCE,Increases in LDL-C,genital cotic infections i nclude,1
ULORIC,liver function abnormalities,ADVERSE REACTIONS,0
ULORIC,liver function abnormalities,abnormalities nausea,1
ULORIC,liver function abnormalities,patients and at least greater than placebo,0
ULORIC,liver function abnormalities,liver,1
ULORIC,nausea,placebo are liver function nausea arthralgia,1
ULORIC,nausea,function nausea arthralgia,1
ULORIC,nausea,,0
ULORIC,nausea,function nausea arthralgia,1
ULORIC,nausea,arthralgia and rash To report,0
ULORIC,nausea,function nausea arthralgia,1
ULORIC,nausea,nausea arthralgia,1
ULORIC,nausea,are liver function abnormalities,0
ULORIC,arthralgia,are liver function abnormalities arthralgia and,1
ULORIC,arthralgia,liver function abnormalities arthralgia and,1
ULORIC,rash,function abnormalities nausea arthralgia rash To,1
ULORIC,rash,report SUSPECTED ADVERSE REACTIONS contact,0
ULORIC,rash,ADVERSE REACTIONS contact Takeda Pharmaceuticals at,0
ULORIC,rash,rash To,1
ULORIC,Liver Function Abnormalities,Liver Function Abnormalities Nausea,1
ULORIC,Liver Function Abnormalities,Liver Function Abnormalities Nausea,1
ULORIC,Liver Function Abnormalities,Nausea,0
ULORIC,Liver Function Abnormalities,dailyN,0
ULORIC,Liver Function Abnormalities,Function Abnormalities Nausea,1
ULORIC,Nausea,Nausea,1
ULORIC,Nausea,Nausea,1
ULORIC,Nausea,Nausea,1
ULORIC,Nausea,Abnormalities,0
ULORIC,Arthralgia,Arthralgia,1
ULORIC,Arthralgia,Arthralgia,1
ULORIC,Arthralgia,,0
ULORIC,Rash,Rash,1
ULORIC,Rash,Rash,1
ULORIC,Rash,,0
ULORIC,Rash,Rash,1
ULORIC,Rash,,0
ULORIC,Rash,Rash,1
ULORIC,Rash,,0
ULORIC,Rash,,0
ULORIC,liver function abnormalities,was,0
ULORIC,liver function abnormalities,reaction leading to discontinuation from therapy was,0
ULORIC,liver function abnormalities,from therapy liver,1
ULORIC,liver function abnormalities,liver function abnormalities,1
ULORIC,liver function abnormalities,from therapy was,0
ULORIC,liver function abnormalities,leading,0
ULORIC,liver function abnormalities,,0
ULORIC,liver function abnormalities,therapy liver,1
ULORIC,dizziness,adverse,0
ULORIC,dizziness,dizziness,1
ULORIC,dizziness,dizziness,1
ULORIC,dizziness,than of ULORICtreated subjects although,0
ULORIC,anemia,thrombocytopenic purpura leukocytosisleukopenia neutropenia pancytopenia splenomeg,0
ULORIC,anemia,Blood and,0
ULORIC,idiopathic thrombocytopenic purpura,Disorders anemia,0
ULORIC,leukocytosis,anemia idiopathic thrombocytopenic leukocytosis,1
ULORIC,leukocytosis,Disorders anemia idiopathic thrombocytopenic purpura,0
ULORIC,leukocytosis,Disorders a,0
ULORIC,leukocytosis,pancytopenia splenomegaly thrombocytopenia,0
ULORIC,leukocytosis,thrombocytopenia Cardiac,0
ULORIC,leukocytosis,,0
ULORIC,leukocytosis,,0
ULORIC,leukopenia,leukopenia,1
ULORIC,leukopenia,idiopathic thrombocytopenic purpura leukopenia,1
ULORIC,leukopenia,angina,0
ULORIC,leukopenia,leukopenia,1
ULORIC,leukopenia,leukopenia,1
ULORIC,leukopenia,leukopenia,1
ULORIC,leukopenia,purpura leukopenia,1
ULORIC,pancytopenia,purpura leukocytosisleukopenia pancytopenia,1
ULORIC,pancytopenia,pancytopenia,1
ULORIC,pancytopenia,pancytopenia,1
ULORIC,pancytopenia,angina pectoris,0
ULORIC,pancytopenia,leukocytosisleukopenia pancytopenia,1
ULORIC,pancytopenia,,0
ULORIC,pancytopenia,pancytopenia,1
ULORIC,pancytopenia,pancytopenia,1
ULORIC,splenomegaly,splenomegaly,1
ULORIC,splenomegaly,splenomegaly,1
ULORIC,splenomegaly,,0
ULORIC,splenomegaly,splenomegaly,1
ULORIC,splenomegaly,angina pectoris atrial fibrillationflutter,0
ULORIC,thrombocytopenia,,0
ULORIC,thrombocytopenia,thrombocytopenia,1
ULORIC,thrombocytopenia,thrombocytopenia,1
ULORIC,angina pectoris,atrial fibrillationflutter cardiac murmur ECG abnormal,0
ULORIC,angina pectoris,splenomegaly thrombocytopenia Cardiac Disorders,0
ULORIC,angina pectoris,pectoris,1
ULORIC,angina pectoris,angina pectoris,1
ULORIC,angina pectoris,thrombocytopenia Cardiac angina pectoris,1
ULORIC,angina pectoris,pancytopenia splenomegaly thrombocytopenia Cardiac angina,1
ULORIC,atrial fibrillation,,0
ULORIC,atrial fibrillation,angina atrial,1
ULORIC,atrial fibrillation,Cardiac Disorders angina pectoris,0
ULORIC,atrial fibrillation,fibrillation,1
ULORIC,atrial fibrillation,angina atrial fibrillation,1
ULORIC,atrial fibrillation,angina atrial fibrillation,1
ULORIC,atrial fibrillation,Cardiac Disorders angina atrial,1
ULORIC,atrial fibrillation,atrial fibrillation,1
ULORIC,atrial fibrillation,,0
ULORIC,cardiac murmur,pectoris atrial cardiac,1
ULORIC,cardiac murmur,,0
ULORIC,cardiac murmur,sinus bradycardia tachycardia Ear and,0
ULORIC,cardiac murmur,angina,0
ULORIC,cardiac murmur,pectoris,0
ULORIC,ECG abnormal,cardiac ECG abnormal,1
ULORIC,ECG abnormal,tachycardia Ear and Labyrinth,0
ULORIC,palpitations,palpitations,1
ULORIC,palpitations,tinnitus vertigo,0
ULORIC,palpitations,palpitations,1
ULORIC,palpitations,palpitations,1
ULORIC,palpitations,palpitations,1
ULORIC,palpitations,fibrillationflutter,0
ULORIC,palpitations,abnormal,0
ULORIC,palpitations,angina pectoris atrial fibrillationflutter cardiac,0
ULORIC,sinus bradycardia,sinus bradycardia,1
ULORIC,sinus bradycardia,Disorders,0
ULORIC,sinus bradycardia,,0
ULORIC,sinus bradycardia,murmur ECG abnormal sinus bradycardia,1
ULORIC,sinus bradycardia,murmur ECG abnormal sinus,1
ULORIC,sinus bradycardia,murmur ECG abnormal sinus bradycardia,1
ULORIC,sinus bradycardia,murmur ECG abnormal sinus,1
ULORIC,sinus bradycardia,abnormal sinus bradycardia,1
ULORIC,sinus bradycardia,atrial fibrillationflutter cardiac,0
ULORIC,tachycardia,tachycardia,1
ULORIC,tachycardia,tachycardia,1
ULORIC,tachycardia,sinus bradycardia,0
ULORIC,tachycardia,tachycardia,1
ULORIC,tachycardia,,0
ULORIC,deafness,blurred,0
ULORIC,tinnitus,Labyrinth Disorders,0
ULORIC,tinnitus,tinnitus,1
ULORIC,tinnitus,Ear and Labyrinth Disorders tinnitus,1
ULORIC,tinnitus,Labyrinth Disorders tinnitus,1
ULORIC,tinnitus,Disorders tinnitus,1
ULORIC,tinnitus,tinnitus,1
ULORIC,tinnitus,Ear and Labyrinth,0
ULORIC,vertigo,tinnitus,0
ULORIC,vertigo,Disorders deafness vertigo,1
ULORIC,vertigo,vertigo,1
ULORIC,vision blurred,vision blurred,1
ULORIC,vision blurred,vision,1
ULORIC,vision blurred,Eye vision blurred,1
ULORIC,vision blurred,Eye vision blurred,1
ULORIC,vision blurred,blurred,1
ULORIC,vision blurred,,0
ULORIC,vision blurred,deafness tinnitus vertigo Eye vision,1
ULORIC,vision blurred,vision blurred,1
ULORIC,vision blurred,tinnitus vertigo,0
ULORIC,vision blurred,tinnitus vertigo Eye vision,1
ULORIC,abdominal distention,vision blurred Gastrointestinal,0
ULORIC,abdominal distention,stools gastritis,0
ULORIC,abdominal pain,pain,1
ULORIC,abdominal pain,,0
ULORIC,abdominal pain,Disorders,0
ULORIC,abdominal pain,,0
ULORIC,abdominal pain,Disorders abdominal abdominal,1
ULORIC,constipation,constipation,1
ULORIC,constipation,reflux disease gas,0
ULORIC,constipation,constipation,1
ULORIC,dry mouth,dry mouth,1
ULORIC,dry mouth,blurred Gastrointestinal,0
ULORIC,dry mouth,,0
ULORIC,dry mouth,abdominal distention,0
ULORIC,dyspepsia,dyspepsia,1
ULORIC,dyspepsia,reflux disease,0
ULORIC,dyspepsia,abdominal,0
ULORIC,frequent stools,abdominal distention,0
ULORIC,gastritis,gingival,0
ULORIC,gastritis,gastritis,1
ULORIC,gastritis,gastritis,1
ULORIC,gastritis,mouth dyspepsia flatulence frequent,0
ULORIC,gastritis,frequent stools,0
ULORIC,gastroesophageal reflux disease,stools gastroesophageal reflux disease,1
ULORIC,gastroesophageal reflux disease,stools,0
ULORIC,gastroesophageal reflux disease,constipation dry,0
ULORIC,gastroesophageal reflux disease,reflux disease,1
ULORIC,gastroesophageal reflux disease,flatulence frequent stools gastritis,0
ULORIC,gastroesophageal reflux disease,dry mouth dyspepsia flatulence frequent stools gastritis,0
ULORIC,gastroesophageal reflux disease,frequent stools gastroesophageal,1
ULORIC,gastroesophageal reflux disease,reflux disease,1
ULORIC,gastrointestinal discomfort,reflux gastrointestinal discomfort,1
ULORIC,gastrointestinal discomfort,gastroesophageal reflux gastrointestinal,1
ULORIC,gastrointestinal discomfort,,0
ULORIC,gingival pain,gingival pain,1
ULORIC,gingival pain,reflux disease gastrointestinal gingival,1
ULORIC,gingival pain,reflux disease gastrointestinal gingival,1
ULORIC,gingival pain,gastrointestinal,0
ULORIC,gingival pain,disease gastrointestinal gingival,1
ULORIC,gingival pain,gingival pain,1
ULORIC,haematemesis,haematemesis,1
ULORIC,haematemesis,haematemesis,1
ULORIC,haematemesis,hematochezia mouth,0
ULORIC,haematemesis,pancreatitis peptic ulcer vomiting,0
ULORIC,haematemesis,mouth ulceration pancreatitis peptic ulcer vomiting,0
ULORIC,haematemesis,haematemesis,1
ULORIC,hyperchlorhydria,hyperchlorhydria,1
ULORIC,hyperchlorhydria,hyperchlorhydria,1
ULORIC,hyperchlorhydria,hyperchlorhydria,1
ULORIC,hyperchlorhydria,gastrointestinal discomfort gingival pain hyperchlorhydria,1
ULORIC,hyperchlorhydria,hyperchlorhydria,1
ULORIC,hyperchlorhydria,ulcer vomiting,0
ULORIC,hyperchlorhydria,pancreatitis peptic,0
ULORIC,hyperchlorhydria,hyperchlorhydria,1
ULORIC,hematochezia,hematochezia,1
ULORIC,hematochezia,gingival pain,0
ULORIC,mouth ulceration,discomfort gingival pain haematemesis,0
ULORIC,mouth ulceration,pain haematemesis hyperchlorhydria,0
ULORIC,mouth ulceration,mouth ulceration,1
ULORIC,mouth ulceration,gastrointestinal discomfort gingival pain haematemesis hyperchlorhydria hematochezia,0
ULORIC,mouth ulceration,mouth,1
ULORIC,mouth ulceration,mouth ulceration,1
ULORIC,mouth ulceration,gingival pain haematemesis hyperchlorhydria mouth,1
ULORIC,mouth ulceration,,0
ULORIC,mouth ulceration,pain haematemesis hyperchlorhydria mouth,1
ULORIC,pancreatitis,pancreatitis,1
ULORIC,pancreatitis,pancreatitis,1
ULORIC,pancreatitis,pancreatitis,1
ULORIC,pancreatitis,hematochezia mouth ulceration,0
ULORIC,pancreatitis,Site Conditions,0
ULORIC,pancreatitis,,0
ULORIC,pancreatitis,pancreatitis,1
ULORIC,pancreatitis,ulcer vomiting General Disorders and Administration Site,0
ULORIC,peptic ulcer,hematochezia mouth ulceration peptic ulcer,1
ULORIC,peptic ulcer,ulcer,1
ULORIC,peptic ulcer,pain haematemesis,0
ULORIC,peptic ulcer,hematochezia mouth ulceration peptic,1
ULORIC,peptic ulcer,hyperchlorhydria hematochezia,0
ULORIC,vomiting,vomiting,1
ULORIC,vomiting,Site Conditions asthenia chest paindiscomfort,0
ULORIC,vomiting,chest,0
ULORIC,vomiting,vomiting,1
ULORIC,vomiting,chest paindiscomfort ede,0
ULORIC,vomiting,pancreatitis peptic vomiting,1
ULORIC,vomiting,hyperchlorhydria hematochezia mouth ulceration pancreatitis peptic,0
ULORIC,vomiting,pancreatitis peptic vomiting,1
ULORIC,asthenia,asthenia,1
ULORIC,asthenia,and Administration Site asthenia,1
ULORIC,asthenia,,0
ULORIC,asthenia,asthenia,1
ULORIC,asthenia,Disorders and Administration Site asthenia,1
ULORIC,chest pain,vomiting General Disorders,0
ULORIC,chest pain,and Administration Site Conditions chest pain,1
ULORIC,chest pain,chest,1
ULORIC,chest pain,chest pain,1
ULORIC,chest pain,Conditions chest pain,1
ULORIC,chest pain,Administration Site Conditions chest,1
ULORIC,edema,,0
ULORIC,edema,Site Conditions,0
ULORIC,edema,asthenia chest paindiscomfort,0
ULORIC,edema,Disorders and Administration Site Conditions asthenia chest,0
ULORIC,edema,feeling abnormal gait disturbance,0
ULORIC,edema,General Disorders and Administration,0
ULORIC,edema,fatigue feeling abnormal,0
ULORIC,edema,edema,1
ULORIC,edema,edema,1
ULORIC,edema,chest edema,1
ULORIC,fatigue,paindiscomfort fatigue,1
ULORIC,fatigue,chest paindiscomfort fatigue,1
ULORIC,fatigue,disturbance influenzalike symptoms,0
ULORIC,gait disturbance,gait disturbance,1
ULORIC,gait disturbance,gait disturbance,1
ULORIC,influenza-like symptoms,cholelithiasischolecystitis hepatic steatos,0
ULORIC,pain,pain,1
ULORIC,cholelithiasis,cholelithiasis,1
ULORIC,cholelithiasis,hepatitis hepatomegaly Immune System Disorder,0
ULORIC,cholelithiasis,Hepatobiliary cholelithiasis,1
ULORIC,cholecystitis,cholecystitis,1
ULORIC,cholecystitis,cholecystitis,1
ULORIC,cholecystitis,,0
ULORIC,cholecystitis,cholecystitis,1
ULORIC,cholecystitis,Disorders cholecystitis,1
ULORIC,cholecystitis,symptoms mass pain thirst Hepatobiliary,0
ULORIC,hepatic steatosis,Hepatobiliary,0
ULORIC,hepatic steatosis,pain thirst,0
ULORIC,hepatic steatosis,symptoms mass,0
ULORIC,hepatic steatosis,,0
ULORIC,hepatitis,hepatic hepatitis,1
ULORIC,hepatomegaly,Disorders,0
ULORIC,hepatomegaly,zost,0
ULORIC,hepatomegaly,hepatomegaly,1
ULORIC,hepatomegaly,hepatomegaly,1
ULORIC,hepatomegaly,Infections and Infestations,0
ULORIC,hepatomegaly,hepatitis,0
ULORIC,hepatomegaly,hepatomegaly,1
ULORIC,hepatomegaly,cholelithiasischolecystitis,0
ULORIC,hepatomegaly,hepatomegaly,1
ULORIC,hypersensitivity,hypersensitivity,1
ULORIC,hypersensitivity,System Disorder,0
ULORIC,hypersensitivity,hypersensitivity,1
ULORIC,herpes zoster,hypersensitivity Infections and herpes,1
ULORIC,herpes zoster,Infections and herpes,1
ULORIC,contusion,and Nutrition Disorders anorexia appetite decreasedincreased,0
ULORIC,contusion,contusion,1
ULORIC,contusion,contusion,1
ULORIC,contusion,herpes zoster Procedural contusion,1
ULORIC,anorexia,contusion Metabolism,0
ULORIC,anorexia,anorexia,1
ULORIC,anorexia,Complications contusion Metabolism and Nutrition Disorders,0
ULORIC,anorexia,hyperglycemia,0
ULORIC,anorexia,anorexia,1
ULORIC,anorexia,anorexia,1
ULORIC,anorexia,mellitus hypercholesterolemia,0
ULORIC,anorexia,anorexia,1
ULORIC,anorexia,anorexia,1
ULORIC,dehydration,Nutrition Disorders anorexia,0
ULORIC,dehydration,,0
ULORIC,dehydration,decreasedincreased,0
ULORIC,dehydration,mellitus,0
ULORIC,diabetes mellitus,,0
ULORIC,diabetes mellitus,appetite decreasedincreased diabetes mellitus,1
ULORIC,diabetes mellitus,hypertriglyceridemia,0
ULORIC,diabetes mellitus,Metabolism and Nutrition Disorders,0
ULORIC,diabetes mellitus,hyperglycemia hyperlipidemia hypertriglyceridemia hypokalemia weight dec,0
ULORIC,diabetes mellitus,Disorders anorexia,0
ULORIC,diabetes mellitus,Metabolism,0
ULORIC,diabetes mellitus,decreasedincreased diabetes,1
ULORIC,hypercholesterolemia,hypercholesterolemia,1
ULORIC,hypercholesterolemia,Disorders anorexia appetite decreasedincreased dehydration diabetes mellitus,0
ULORIC,hypercholesterolemia,hypercholesterolemia,1
ULORIC,hypercholesterolemia,,0
ULORIC,hyperlipidemia,hypokalemia weight decreasedincreased Musculoskeletal,0
ULORIC,hyperlipidemia,,0
ULORIC,hyperlipidemia,,0
ULORIC,hyperlipidemia,hyperlipidemia,1
ULORIC,hyperlipidemia,hyperlipidemia,1
ULORIC,hyperlipidemia,hypercholesterolemia hyperglycemia,0
ULORIC,hypertriglyceridemia,hypertriglyceridemia,1
ULORIC,hypertriglyceridemia,hypertriglyceridemia,1
ULORIC,hypertriglyceridemia,hypercholesterolemia hyperglycemia hypertriglyceridemia,1
ULORIC,hypertriglyceridemia,hypercholesterolemia,0
ULORIC,hypertriglyceridemia,hypertriglyceridemia,1
ULORIC,hypertriglyceridemia,hypertriglyceridemia,1
ULORIC,hypertriglyceridemia,diabetes mellitus hypercholesterolemia hyperglycemia hyperlipidemia,0
ULORIC,hypertriglyceridemia,hypertriglyceridemia,1
ULORIC,hypokalemia,Tissue Disorders arthritis jo,0
ULORIC,hypokalemia,decreasedincreased Musculoskeletal and Connective Tissue Disorders,0
ULORIC,hypokalemia,,0
ULORIC,hypokalemia,hypokalemia,1
ULORIC,hypokalemia,hypokalemia,1
ULORIC,weight decreased,hyperlipidemia hypertriglyceridemia weight decreased,1
ULORIC,weight decreased,hyperglycemia hyperlipidemia hypertriglyceridemia weight decreased,1
ULORIC,weight decreased,weight decreased,1
ULORIC,weight decreased,,0
ULORIC,weight decreased,joi,0
ULORIC,weight decreased,hypercholesterolemia hyperglycemia hyperlipidemia,0
ULORIC,weight decreased,decreased,1
ULORIC,weight decreased,hyperlipidemia hypertriglyceridemia weight,1
ULORIC,weight decreased,hypertriglyceridemia weight decreased,1
ULORIC,weight decreased,,0
ULORIC,arthritis,arthritis,1
ULORIC,arthritis,arthritis,1
ULORIC,arthritis,arthritis,1
ULORIC,arthritis,decreasedincreased Musculoskeletal,0
ULORIC,arthritis,Musculoskeletal and Connective Tissue arthritis,1
ULORIC,arthritis,arthritis,1
ULORIC,arthritis,stiffness,0
ULORIC,arthritis,Connective Tissue Disorders,0
ULORIC,arthritis,pain,0
ULORIC,arthritis,,0
ULORIC,joint stiffness,Tissue Disorders joint,1
ULORIC,joint stiffness,spasmstwitchingtightnessweakness,0
ULORIC,joint stiffness,and Connective Tissue Disorders joint stiffness,1
ULORIC,joint swelling,,0
ULORIC,joint swelling,arthritis joint joint,1
ULORIC,joint swelling,joint swelling,1
ULORIC,joint swelling,joint swelling,1
ULORIC,joint swelling,joint swelling,1
ULORIC,joint swelling,,0
ULORIC,joint swelling,arthritis joint stiffness,0
ULORIC,joint swelling,joint joint,1
ULORIC,joint swelling,swelling,1
ULORIC,muscle spasms,stiffness joint muscle,1
ULORIC,muscle spasms,muscle spasms,1
ULORIC,muscle spasms,stiffness joint muscle,1
ULORIC,muscle spasms,muscle spasms,1
ULORIC,muscle spasms,muscle spasms,1
ULORIC,muscle spasms,spasms,1
ULORIC,muscle spasms,joint stiffness joint muscle,1
ULORIC,muscle spasms,muscle spasms,1
ULORIC,muscle spasms,spasms,1
ULORIC,musculoskeletal pain,muscle musculoskeletal pain,1
ULORIC,myalgia,myalgia,1
ULORIC,myalgia,myalgia,1
ULORIC,myalgia,myalgia,1
ULORIC,myalgia,disorder cerebrovascular accident,0
ULORIC,altered taste,altered taste,1
ULORIC,altered taste,Disorders,0
ULORIC,altered taste,myalgia Nervous,0
ULORIC,altered taste,Nervous System,0
ULORIC,balance disorder,balance disorder,1
ULORIC,balance disorder,balance disorder,1
ULORIC,balance disorder,altered taste,0
ULORIC,balance disorder,Disorders altered balance disorder,1
ULORIC,cerebrovascular accident,altered taste balance cerebrovascular accident,1
ULORIC,cerebrovascular accident,GuillainBarre syndrome headache hemiparesis hypoesthesia hyposmia lacunar infarction,0
ULORIC,cerebrovascular accident,balance cerebrovascular,1
ULORIC,cerebrovascular accident,cerebrovascular accident,1
ULORIC,cerebrovascular accident,altered taste balance cerebrovascular,1
ULORIC,Guillain-Barre syndrome,Guillain-Barre syndrome,1
ULORIC,Guillain-Barre syndrome,,0
ULORIC,Guillain-Barre syndrome,Guillain-Barre syndrome,1
ULORIC,Guillain-Barre syndrome,disorder cerebrovascular Guillain-Barre,1
ULORIC,Guillain-Barre syndrome,Guillain-Barre syndrome,1
ULORIC,Guillain-Barre syndrome,lacunar infarction lethargy mental impairment mi,0
ULORIC,headache,impairment migraine,0
ULORIC,headache,headache,1
ULORIC,headache,pa,0
ULORIC,headache,disorder cerebrovascular accident,0
ULORIC,headache,taste balance disorder cerebrovascular accident,0
ULORIC,hemiparesis,disorder cerebrovascular accident GuillainBarre syndrome,0
ULORIC,hemiparesis,hemiparesis,1
ULORIC,hemiparesis,hemiparesis,1
ULORIC,hemiparesis,hemiparesis,1
ULORIC,hemiparesis,hemiparesis,1
ULORIC,hemiparesis,,0
ULORIC,hemiparesis,cerebrovascular accident GuillainBarre syndrome hemiparesis,1
ULORIC,hypoesthesia,hypoesthesia,1
ULORIC,hypoesthesia,hypoesthesia,1
ULORIC,hypoesthesia,accident GuillainBarre syndrome headache hypoesthesia,1
ULORIC,hypoesthesia,paresthesia somnolence,0
ULORIC,hypoesthesia,lethargy mental impairment migraine,0
ULORIC,hypoesthesia,syndrome headache hypoesthesia,1
ULORIC,hypoesthesia,hypoesthesia,1
ULORIC,hypoesthesia,,0
ULORIC,hypoesthesia,hypoesthesia,1
ULORIC,hyposmia,lacunar infarction lethargy mental impairment migraine,0
ULORIC,hyposmia,GuillainBarre syndrome headache hemiparesis hyposmia,1
ULORIC,hyposmia,syndrome headache hemiparesis hypoesthesia,0
ULORIC,hyposmia,migraine paresthesia somnolence transient,0
ULORIC,hyposmia,hemiparesis hypoesthesia,0
ULORIC,hyposmia,hyposmia,1
ULORIC,hyposmia,paresthesia,0
ULORIC,hyposmia,syndrome headache hemiparesis hyposmia,1
ULORIC,hyposmia,hyposmia,1
ULORIC,hyposmia,migraine paresthesia somnolence,0
ULORIC,lacunar infarction,syndrome headache hemiparesis hypoesthesia,0
ULORIC,lacunar infarction,headache hemiparesis hypoesthesia lacunar infarction,1
ULORIC,lacunar infarction,infarction,1
ULORIC,lacunar infarction,hypoesthesia lacunar,1
ULORIC,lethargy,lethargy,1
ULORIC,lethargy,hypoesthesia hyposmia lacunar infarction,0
ULORIC,mental impairment,hyposmia lacunar infarction mental impairment,1
ULORIC,mental impairment,infarction lethargy,0
ULORIC,mental impairment,lacunar infarction,0
ULORIC,mental impairment,lacunar infarction,0
ULORIC,mental impairment,impairment,1
ULORIC,mental impairment,lethargy,0
ULORIC,mental impairment,impairment,1
ULORIC,mental impairment,lacunar infarction mental,1
ULORIC,migraine,paresthesia somnolence transient ischemic attack tremor Psychiatric Disorders agitati,0
ULORIC,migraine,migraine,1
ULORIC,migraine,,0
ULORIC,migraine,migraine,1
ULORIC,migraine,migraine,1
ULORIC,paresthesia,Psychiatric,0
ULORIC,paresthesia,ischemic attack,0
ULORIC,paresthesia,impairment paresthesia,1
ULORIC,paresthesia,somnolence transient ischemic attack tremor Psychiatric,0
ULORIC,paresthesia,somnolence,0
ULORIC,paresthesia,ischemic attack tremor Psychiatric Disorders agitation anxiety,0
ULORIC,somnolence,migraine somnolence,1
ULORIC,somnolence,anxiety,0
ULORIC,somnolence,mental impairment,0
ULORIC,somnolence,hyposmia lacunar infarction,0
ULORIC,somnolence,somnolence,1
ULORIC,transient ischemic attack,ischemic attack,1
ULORIC,transient ischemic attack,migraine paresthesia transient,1
ULORIC,tremor,agitation anxiety depression insomnia irritability,0
ULORIC,tremor,depression insomnia irritability libido,0
ULORIC,tremor,tremor,1
ULORIC,tremor,tremor,1
ULORIC,tremor,tremor,1
ULORIC,agitation,depression insomnia irritability libido,0
ULORIC,anxiety,panic attack,0
ULORIC,anxiety,Disorders agitation,0
ULORIC,anxiety,anxiety,1
ULORIC,anxiety,anxiety,1
ULORIC,anxiety,anxiety,1
ULORIC,depression,attack tremor Psychiatric Disorders agitation anxiety,0
ULORIC,depression,depression,1
ULORIC,depression,Psychiatric Disorders agitation,0
ULORIC,depression,change,0
ULORIC,depression,depression,1
ULORIC,depression,,0
ULORIC,insomnia,agitation anxiety insomnia,1
ULORIC,insomnia,decreased nervousness panic attack personality change,0
ULORIC,insomnia,irritability libido decreased nervousness panic attack personality change,0
ULORIC,irritability,irritability,1
ULORIC,libido decreased,anxiety depression insomnia libido decreased,1
ULORIC,libido decreased,agitation anxiety depression insomnia libido decreased,1
ULORIC,libido decreased,,0
ULORIC,libido decreased,anxiety depression insomnia,0
ULORIC,libido decreased,Renal,0
ULORIC,libido decreased,agitation anxiety depression insomnia libido decreased,1
ULORIC,nervousness,irritability libido decreased,0
ULORIC,nervousness,attack personality change,0
ULORIC,nervousness,depression insomnia irritability libido nervousness,1
ULORIC,panic attack,irritability libido decreased,0
ULORIC,panic attack,attack,1
ULORIC,panic attack,panic attack,1
ULORIC,panic attack,insomnia irritability libido decreased panic,1
ULORIC,panic attack,panic attack,1
ULORIC,panic attack,and,0
ULORIC,panic attack,panic attack,1
ULORIC,panic attack,panic attack,1
ULORIC,panic attack,,0
ULORIC,panic attack,attack,1
ULORIC,personality change,libido decreased nervousness panic personality,1
ULORIC,personality change,panic personality change,1
ULORIC,personality change,personality change,1
ULORIC,personality change,nervousness panic personality,1
ULORIC,personality change,decreased nervousness panic personality change,1
ULORIC,personality change,panic attack,0
ULORIC,personality change,,0
ULORIC,personality change,depression insomnia irritability libido decreased nervousness,0
ULORIC,nephrolithiasis,Renal and Urinary Disorders nephrolithiasis,1
ULORIC,nephrolithiasis,nephrolithiasis,1
ULORIC,nephrolithiasis,Disorders nephrolithiasis,1
ULORIC,nephrolithiasis,incontinence Reprodu,0
ULORIC,nephrolithiasis,nephrolithiasis,1
ULORIC,nephrolithiasis,nephrolithiasis,1
ULORIC,nephrolithiasis,personality change Renal and Urinary Disorders hematuria,0
ULORIC,nephrolithiasis,and Urinary,0
ULORIC,pollakiuria,,0
ULORIC,pollakiuria,,0
ULORIC,pollakiuria,pollakiuria,1
ULORIC,pollakiuria,urgency incontinence Reproductive,0
ULORIC,pollakiuria,,0
ULORIC,pollakiuria,change Renal and Urinary Disorders hematuria,0
ULORIC,pollakiuria,pollakiuria,1
ULORIC,pollakiuria,pollakiuria,1
ULORIC,proteinuria,,0
ULORIC,proteinuria,Disorders hematuria nephrolithiasis pollakiuria,0
ULORIC,proteinuria,proteinuria,1
ULORIC,proteinuria,proteinuria,1
ULORIC,proteinuria,nephrolithiasis proteinuria,1
ULORIC,proteinuria,and Urinary Disorders hematuria nephrolithiasis,0
ULORIC,proteinuria,proteinuria,1
ULORIC,proteinuria,,0
ULORIC,renal failure,Disorders hematuria nephrolithiasis pollakiuria renal,1
ULORIC,renal failure,renal,1
ULORIC,renal failure,nephrolithiasis pollakiuria renal,1
ULORIC,renal failure,pollakiuria,0
ULORIC,renal failure,hematuria nephrolithiasis pollakiuria renal failure,1
ULORIC,renal failure,renal insufficiency urgency incontinence Reproductive System and,0
ULORIC,renal failure,breast,0
ULORIC,renal failure,,0
ULORIC,renal failure,hematuria nephrolithiasis pollakiuria renal,1
ULORIC,renal insufficiency,renal insufficiency,1
ULORIC,renal insufficiency,insufficiency,1
ULORIC,renal insufficiency,,0
ULORIC,erectile dysfunction,and,0
ULORIC,erectile dysfunction,erectile dysfunction,1
ULORIC,erectile dysfunction,erectile dysfunction,1
ULORIC,erectile dysfunction,incontinence Reproductive System and,0
ULORIC,gynecomastia,Changes breast pain erectile gynecomastia,1
ULORIC,gynecomastia,pain erectile dysfunction,0
ULORIC,bronchitis,and Mediastinal bronchitis,1
ULORIC,cough,cough,1
ULORIC,cough,and Mediastinal Disorders bronchitis,0
ULORIC,cough,cough,1
ULORIC,cough,Disorders cough,1
ULORIC,cough,cough,1
ULORIC,cough,cough,1
ULORIC,cough,nasal dryness paranasal sinus hypersecretion pharyngeal,0
ULORIC,cough,cough,1
ULORIC,cough,hypersecretion pharyngeal edema respiratory t,0
ULORIC,cough,Respiratory,0
ULORIC,dyspnea,and Mediastinal Disorders bronchitis dyspnea,1
ULORIC,epistaxis,Thoracic and Mediastinal Disorders bronchitis,0
ULORIC,epistaxis,Mediastinal Disorders,0
ULORIC,epistaxis,,0
ULORIC,epistaxis,Disorders bronchitis cough dyspnea,0
ULORIC,epistaxis,Mediastinal,0
ULORIC,nasal dryness,dyspnea nasal,1
ULORIC,nasal dryness,Respiratory Thoracic and Mediastinal Disorders,0
ULORIC,nasal dryness,Thoracic and Mediastinal,0
ULORIC,nasal dryness,cough dyspnea,0
ULORIC,nasal dryness,dyspnea nasal dryness,1
ULORIC,nasal dryness,dyspnea nasal dryness,1
ULORIC,nasal dryness,throat i,0
ULORIC,nasal dryness,nasal dryness,1
ULORIC,nasal dryness,,0
ULORIC,nasal dryness,sinus hypersecretion pharyngeal edema respiratory tract congestion sneezing,0
ULORIC,paranasal sinus hypersecretion,cough dyspnea epistaxis nasal paranasal sinus hypersecretion,1
ULORIC,paranasal sinus hypersecretion,dyspnea epistaxis nasal paranasal sinus,1
ULORIC,paranasal sinus hypersecretion,bronchitis cough dyspnea epistaxis,0
ULORIC,pharyngeal edema,,0
ULORIC,pharyngeal edema,sinus pharyngeal edema,1
ULORIC,respiratory tract congestion,hypersecretion pharyngeal respiratory tract congestion,1
ULORIC,sneezing,upper respiratory tract infection,0
ULORIC,sneezing,tract,0
ULORIC,sneezing,sneezing,1
ULORIC,sneezing,sneezing,1
ULORIC,sneezing,,0
ULORIC,sneezing,irritation upper respiratory tract infection Skin and,0
ULORIC,sneezing,tract sneezing,1
ULORIC,sneezing,respiratory tract sneezing,1
ULORIC,sneezing,pharyngeal edema respiratory tract congestion,0
ULORIC,throat irritation,throat,1
ULORIC,throat irritation,edema,0
ULORIC,throat irritation,,0
ULORIC,throat irritation,,0
ULORIC,throat irritation,respiratory tract infection Skin and Subcutaneous Tissue Disorders,0
ULORIC,throat irritation,hypersecretion pharyngeal edema respiratory tract,0
ULORIC,throat irritation,Skin,0
ULORIC,throat irritation,edema respiratory tract congestion throat,1
ULORIC,upper respiratory tract infection,upper respiratory tract infection,1
ULORIC,upper respiratory tract infection,respiratory tract infection,1
ULORIC,upper respiratory tract infection,sneezing throat upper respiratory,1
ULORIC,upper respiratory tract infection,Skin and Subcutaneous,0
ULORIC,upper respiratory tract infection,respiratory tract congestion sneezing throat,0
ULORIC,upper respiratory tract infection,tract congestion sneezing throat upper respiratory,1
ULORIC,upper respiratory tract infection,,0
ULORIC,alopecia,alopecia,1
ULORIC,alopecia,Skin and,0
ULORIC,alopecia,alopecia,1
ULORIC,alopecia,alopecia,1
ULORIC,alopecia,,0
ULORIC,alopecia,alopecia,1
ULORIC,angio-edema,ecchymosis eczema hair color changes hair,0
ULORIC,angio-edema,angio-edema,1
ULORIC,angio-edema,angio-edema,1
ULORIC,angio-edema,and Subcutaneous Tissue Disorders,0
ULORIC,angio-edema,Tissue Disorders angio-edema,1
ULORIC,angio-edema,color changes hair growth,0
ULORIC,angio-edema,growth,0
ULORIC,angio-edema,ecchymosis,0
ULORIC,angio-edema,angio-edema,1
ULORIC,angio-edema,upper respiratory tract infection Skin and,0
ULORIC,dermatitis,abnormal hyperhidrosis pee,0
ULORIC,ecchymosis,peeling skin petechiae,0
ULORIC,ecchymosis,peeling skin petechiae,0
ULORIC,ecchymosis,ecchymosis,1
ULORIC,ecchymosis,ecchymosis,1
ULORIC,ecchymosis,ecchymosis,1
ULORIC,ecchymosis,ecchymosis,1
ULORIC,ecchymosis,eczema hair color changes,0
ULORIC,ecchymosis,color changes hair growth abnormal,0
ULORIC,ecchymosis,dermatitis ecchymosis,1
ULORIC,ecchymosis,dermatitis ecchymosis,1
ULORIC,eczema,dermatitis dermographism eczema,1
ULORIC,eczema,eczema,1
ULORIC,eczema,hair growth,0
ULORIC,eczema,dermographism,0
ULORIC,hair color changes,hair color changes,1
ULORIC,hair color changes,hyperhidrosis peeling skin petechiae photosensitivity,0
ULORIC,hair color changes,hair color changes,1
ULORIC,hair color changes,,0
ULORIC,hair color changes,eczema,0
ULORIC,hair color changes,peeling skin petechiae,0
ULORIC,hair color changes,dermographism ecchymosis hair,1
ULORIC,hyperhidrosis,,0
ULORIC,hyperhidrosis,hyperhidrosis,1
ULORIC,hyperhidrosis,,0
ULORIC,hyperhidrosis,hyperhidrosis,1
ULORIC,hyperhidrosis,changes hair growth,0
ULORIC,hyperhidrosis,changes,0
ULORIC,hyperhidrosis,hyperhidrosis,1
ULORIC,hyperhidrosis,hyperhidrosis,1
ULORIC,peeling skin,purpura skin,0
ULORIC,peeling skin,hair color changes hair growth,0
ULORIC,peeling skin,peeling skin,1
ULORIC,photosensitivity,hyperhidrosis peeling,0
ULORIC,photosensitivity,,0
ULORIC,photosensitivity,petechiae,0
ULORIC,photosensitivity,photosensitivity,1
ULORIC,photosensitivity,color changes,0
ULORIC,pruritus,petechiae photosensitivity,0
ULORIC,pruritus,,0
ULORIC,pruritus,abnormal hyperhidrosis peeling skin petechiae,0
ULORIC,pruritus,,0
ULORIC,pruritus,hair growth abnormal hyperhidrosis peeling skin petechiae,0
ULORIC,purpura,peeling skin petechiae,0
ULORIC,purpura,skin petechiae photosensitivity purpura,1
ULORIC,purpura,skin discolorationaltered pigmentation skin lesion skin,0
ULORIC,purpura,,0
ULORIC,skin discoloration,hyperhidrosis,0
ULORIC,skin discoloration,skin petechiae photosensitivity pruritus purpura,0
ULORIC,skin discoloration,skin,1
ULORIC,skin discoloration,skin petechiae photosensitivity pruritus skin,1
ULORIC,skin discoloration,Vascular Disorders,0
ULORIC,skin discoloration,flush,0
ULORIC,skin discoloration,skin petechiae photosensitivity pruritus skin,1
ULORIC,skin discoloration,hyperhidrosis peeling,0
ULORIC,skin lesion,skin odor abnormal urticaria Vascular,0
ULORIC,skin lesion,skin petechiae photosensitivity,0
ULORIC,skin lesion,,0
ULORIC,skin lesion,urticaria,0
ULORIC,skin lesion,pruritus purpura skin discolorationaltered skin,1
ULORIC,skin lesion,pruritus,0
ULORIC,skin lesion,lesion,1
ULORIC,skin lesion,odor,0
ULORIC,skin odor abnormal,,0
ULORIC,skin odor abnormal,skin odor abnormal,1
ULORIC,skin odor abnormal,,0
ULORIC,skin odor abnormal,Vascular Disorders flushing hot flush,0
ULORIC,skin odor abnormal,hypertension hypotension Labor,0
ULORIC,skin odor abnormal,,0
ULORIC,skin odor abnormal,,0
ULORIC,skin odor abnormal,discolorationaltered pigmentation skin skin,1
ULORIC,urticaria,purpura skin,0
ULORIC,flushing,flushing,1
ULORIC,flushing,flushing,1
ULORIC,flushing,partial thromboplast,0
ULORIC,flushing,flushing,1
ULORIC,flushing,flushing,1
ULORIC,hot flush,hot flush,1
ULORIC,hot flush,Disorders hot flush,1
ULORIC,hot flush,hot flush,1
ULORIC,hot flush,abnormal urticaria Vascular Disorders hot,1
ULORIC,hot flush,thromboplastin,0
ULORIC,hot flush,,0
ULORIC,hot flush,thromboplastin time pro,0
ULORIC,hot flush,Disorders hot flush,1
ULORIC,hypertension,hypotension Laboratory Parameters activated,0
ULORIC,hypertension,hypertension,1
ULORIC,hypertension,abnormal urticaria,0
ULORIC,hypertension,skin odor abnormal urticaria Vascular,0
ULORIC,hypertension,hot hypertension,1
ULORIC,hypertension,Disorders flushing,0
ULORIC,hypertension,hypertension,1
ULORIC,hypertension,hypertension,1
ULORIC,hypotension,hypotension,1
ULORIC,hypotension,,0
ULORIC,hypotension,flushing hot,0
ULORIC,hypotension,hypotension,1
ULORIC,hypotension,creatine,0
ULORIC,hypotension,hypotension,1
ULORIC,hypotension,Vascular Disorders flushing hot flush,0
ULORIC,activated partial thromboplastin time prolonged,flush hypertension hypotension Laboratory activated partial thromboplastin time prolonged,1
ULORIC,activated partial thromboplastin time prolonged,creatine,0
ULORIC,activated partial thromboplastin time prolonged,prolonged,1
ULORIC,creatine increased,activated partial thromboplastin time creatine,1
ULORIC,creatine increased,creatine,1
ULORIC,creatine increased,,0
ULORIC,creatine increased,creatine increased,1
ULORIC,creatine increased,partial thromboplastin time creatine,1
ULORIC,creatine increased,,0
ULORIC,creatine increased,sodium increased EEG abnormal glucose increased cholesterol,0
ULORIC,creatine increased,thromboplastin time creatine,1
ULORIC,creatine increased,increased,1
ULORIC,sodium increased,creatine increased bicarbonate sodium increased,1
ULORIC,sodium increased,prolonged creatine increased bicarbonate sodium increased,1
ULORIC,sodium increased,,0
ULORIC,EEG abnormal,prolonged,0
ULORIC,glucose increased,triglycerides increased amylase increased potassium increased TSH,0
ULORIC,glucose increased,increased,1
ULORIC,glucose increased,triglycerides increased amylase increased potassium increased,0
ULORIC,glucose increased,sodium increased EEG,0
ULORIC,glucose increased,EEG abnormal,0
ULORIC,cholesterol increased,glucose cholesterol increased,1
ULORIC,cholesterol increased,increased bicarbonate decreased sodium increased EEG abnormal,0
ULORIC,cholesterol increased,creatine increased bicarbonate decreased sodium increased EEG abnormal glucose increased,0
ULORIC,amylase increased,,0
ULORIC,potassium increased,increased amylase increased,0
ULORIC,potassium increased,count,0
ULORIC,potassium increased,increased,1
ULORIC,TSH increased,,0
ULORIC,TSH increased,TSH increased,1
ULORIC,TSH increased,TSH increased,1
ULORIC,TSH increased,increased,1
ULORIC,TSH increased,decreased,0
ULORIC,TSH increased,amylase increased potassium TSH,1
ULORIC,TSH increased,hematocrit decreased,0
ULORIC,TSH increased,hematocrit decreased hemoglobin decreased,0
ULORIC,platelet count decreased,increased triglycerides increased amylase increased potassium increased,0
ULORIC,platelet count decreased,increased,0
ULORIC,platelet count decreased,platelet count,1
ULORIC,platelet count decreased,MCV,0
ULORIC,platelet count decreased,decreased,1
ULORIC,platelet count decreased,count decreased,1
ULORIC,platelet count decreased,increased TSH platelet,1
ULORIC,hemoglobin decreased,hematocrit,0
ULORIC,hemoglobin decreased,creatinine increased blood urea increased BUNcreatinine ratio inc,0
ULORIC,MCV increased,decreased hematocrit decreased hemoglobin MCV,1
ULORIC,MCV increased,increased,1
ULORIC,MCV increased,,0
ULORIC,creatinine increased,increased,1
ULORIC,blood urea increased,decreased creatinine blood,1
ULORIC,blood urea increased,decreased hemoglobin decreased MCV increased RBC decreased creatinine,0
ULORIC,blood urea increased,blood urea increased,1
ULORIC,blood urea increased,BUNcreatinine ratio increased creatine,0
ULORIC,blood urea increased,,0
ULORIC,blood urea increased,creatinine blood urea increased,1
ULORIC,blood urea increased,blood urea increased,1
ULORIC,BUN/creatinine ratio increased,decreased MCV increased RBC decreased creatinine,0
ULORIC,BUN/creatinine ratio increased,,0
ULORIC,alkaline phosphatase increased,count,0
ULORIC,alkaline phosphatase increased,LDH increased PSA increased urine output increaseddecreased lymphocyte count,0
ULORIC,alkaline phosphatase increased,phosphokinase CPK alkaline phosphatase increased,1
ULORIC,alkaline phosphatase increased,,0
ULORIC,alkaline phosphatase increased,creatine phosphokinase CPK alkaline phosphatase,1
ULORIC,alkaline phosphatase increased,increased urine output increaseddecreased lymphocyte count decreased neutro,0
ULORIC,LDH increased,CPK increased alkaline phosphatase LDH increased,1
ULORIC,LDH increased,phosphatase LDH increased,1
ULORIC,LDH increased,LDH increased,1
ULORIC,LDH increased,LDH increased,1
ULORIC,LDH increased,LDH increased,1
ULORIC,LDH increased,phosphatase LDH,1
ULORIC,LDH increased,,0
ULORIC,LDH increased,alkaline phosphatase increased,0
ULORIC,LDH increased,increased creatine phosphokinase CPK increased,0
ULORIC,PSA increased,,0
ULORIC,PSA increased,PSA,1
ULORIC,PSA increased,output increaseddecreased lymphocyte count decreased,0
ULORIC,PSA increased,urine output,0
ULORIC,PSA increased,increased,0
ULORIC,PSA increased,increased LDH PSA increased,1
ULORIC,urine output increased,urine output increased,1
ULORIC,urine output increased,output increased,1
ULORIC,urine output increased,increased LDH increased PSA urine output increased,1
ULORIC,urine output increased,urine output increased,1
ULORIC,urine output increased,increased LDH increased PSA urine output,1
ULORIC,urine output increased,,0
ULORIC,urine output increased,urine output increased,1
ULORIC,urine output increased,output increased,1
ULORIC,urine output increased,,0
ULORIC,neutrophil count decreased,increased,0
ULORIC,WBC increased,increaseddecreased lymphocyte count decreased neutrophil count decreased,0
ULORIC,WBC increased,count,0
ULORIC,coagulation test abnormal,abnormal,1
ULORIC,coagulation test abnormal,prolonged urinary casts,0
ULORIC,coagulation test abnormal,decreased WBC coagulation test abnormal,1
ULORIC,coagulation test abnormal,abnormal,1
ULORIC,coagulation test abnormal,,0
ULORIC,coagulation test abnormal,coagulation test abnormal,1
ULORIC,coagulation test abnormal,coagulation,1
ULORIC,coagulation test abnormal,count decreased WBC coagulation test abnormal,1
ULORIC,coagulation test abnormal,count decreased WBC coagulation test abnormal,1
ULORIC,urinary casts,Cardiovascular Safety,0
ULORIC,urinary casts,urinary,1
ULORIC,urinary casts,and,0
ULORIC,urinary casts,white blood cells and protein Cardiovascular Safety,0
ULORIC,urinary casts,urinary casts,1
ULORIC,urine positive for white blood cells,prothrombin time prolonged urinary urine positive for,1
ULORIC,urine positive for white blood cells,urine positive for,1
ULORIC,urine positive for white blood cells,lipoprotein LDL,0
ULORIC,urine positive for white blood cells,protein Cardiovascular Safety Cardiovascular events and deaths were,0
ULORIC,urine positive for white blood cells,urine positive,1
ULORIC,urine positive for white blood cells,,0
ULORIC,Cardiovascular events,and,0
ULORIC,Cardiovascular events,cells and protein Cardiovascular Cardiovascular events,1
ULORIC,Cardiovascular events,,0
ULORIC,Cardiovascular events,Cardiovascular events,1
ULORIC,Cardiovascular events,for white blood cells,0
ULORIC,Cardiovascular events,protein Cardiovascular Cardiovascular,1
ULORIC,deaths,white blood cells,0
ULORIC,deaths,were,0
ULORIC,deaths,for white blood cells,0
ULORIC,deaths,one of the,0
ULORIC,deaths,one of the predefined endpoints from the AntiPlatelet Trialists,0
ULORIC,deaths,deaths,1
ULORIC,deaths,events deaths,1
ULORIC,deaths,,0
ULORIC,cardiovascular death,,0
ULORIC,cardiovascular death,the AntiPlatelet Trialists Collaborations cardiovascular death,1
ULORIC,cardiovascular death,AntiPlatelet Trialists Collaborations cardiovascular,1
ULORIC,myocardial infarction,longterm,0
ULORIC,myocardial infarction,from the AntiPlatelet Trialists,0
ULORIC,myocardial infarction,the AntiPlatelet Trialists Collaborations APTC,0
ULORIC,myocardial infarction,APTC cardiovascular death myocardial infarction,1
ULORIC,myocardial infarction,Collaborations APTC cardiovascular death myocardial,1
ULORIC,stroke,In the Phase randomized,0
ULORIC,stroke,myocardial infarction and stroke,1
ULORIC,stroke,in the randomized controlled and,0
ULORIC,stroke,and stroke,1
ULORIC,stroke,,0
ULORIC,stroke,randomized controlled,0
ULORIC,stroke,APTC cardiovascular,0
ULORIC,stroke,and stroke,1
ULORIC,hepatic failure,a causal relationship Hepatobiliary hepatic,1
ULORIC,hepatic failure,relationship Hepatobiliary hepatic failure,1
ULORIC,hepatic failure,failure,1
ULORIC,hepatic failure,hepatic,1
ULORIC,hepatic failure,hepatic failure,1
ULORIC,hepatic failure,a causal relationship Hepatobiliary hepatic failure,1
ULORIC,hepatic failure,serious cases of abnormal liver,0
ULORIC,fatal,function test results liver disorder Immune Sys,0
ULORIC,fatal,liver disorder Immune,0
ULORIC,abnormal liver function,jaundice serious cases abnormal liver function,1
ULORIC,abnormal liver function,results liver disorder Immune System Disorders anaphylaxis,0
ULORIC,abnormal liver function,function,1
ULORIC,liver disorder,disorder,1
ULORIC,anaphylaxis,anaphylaxis,1
ULORIC,anaphylactic reaction,,0
ULORIC,anaphylactic reaction,test results liver disorder Immune System Disorders anaphylaxis,0
ULORIC,anaphylactic reaction,anaphylactic reaction,1
ULORIC,anaphylactic reaction,,0
ULORIC,anaphylactic reaction,Tissue Disorders rhabdomyolysis,0
ULORIC,anaphylactic reaction,System Disorders,0
ULORIC,anaphylactic reaction,reaction,1
ULORIC,rhabdomyolysis,Psychiatric Disorders psychotic,0
ULORIC,psychotic behavior,Disorders rhabdomyolysis Psychiatric psychotic,1
ULORIC,psychotic behavior,Disorders tubulointerstitial,0
ULORIC,psychotic behavior,Tissue Disorders rhabdomyolysis Psychiatric Disorders,0
ULORIC,psychotic behavior,Disorders tubulointerstitial nephritis,0
ULORIC,psychotic behavior,Renal and Urinary Disorders tubulointerstitial,0
ULORIC,psychotic behavior,psychotic behavior,1
ULORIC,psychotic behavior,Disorders rhabdomyolysis Psychiatric psychotic behavior,1
ULORIC,psychotic behavior,Disorders rhabdomyolysis Psychiatric psychotic,1
ULORIC,psychotic behavior,,0
ULORIC,aggressive thoughts,,0
ULORIC,aggressive thoughts,nephritis Skin and Subcutaneous,0
ULORIC,aggressive thoughts,Disorders psychotic,0
ULORIC,aggressive thoughts,nephritis,0
ULORIC,aggressive thoughts,Disorders psychotic behavior including,0
ULORIC,aggressive thoughts,and Urinary Disorders tubulointerstitial,0
ULORIC,aggressive thoughts,aggressive thoughts,1
ULORIC,aggressive thoughts,behavior including,0
ULORIC,tubulointerstitial nephritis,Johnson,0
ULORIC,tubulointerstitial nephritis,Disorders,0
ULORIC,tubulointerstitial nephritis,tubulointerstitial nephritis,1
ULORIC,tubulointerstitial nephritis,and Subcutaneous Tissue Disorders generalized,0
ULORIC,tubulointerstitial nephritis,Urinary tubulointerstitial,1
ULORIC,tubulointerstitial nephritis,rash Stevens Johnson Syndrome,0
ULORIC,tubulointerstitial nephritis,Tissue Disorders generalized rash Stevens Johnson,0
ULORIC,tubulointerstitial nephritis,,0
ULORIC,generalized rash,and Subcutaneous Tissue generalized rash,1
ULORIC,generalized rash,Stevens Johnson Syndrome hypersensitivity,0
ULORIC,generalized rash,and Subcutaneous Tissue generalized,1
ULORIC,generalized rash,Syndrome,0
ULORIC,Stevens Johnson Syndrome,Subcutaneous Tissue Disorders generalized Stevens Johnson Syndrome,1
ULORIC,Stevens Johnson Syndrome,reactions,0
ULORIC,Stevens Johnson Syndrome,Subcutaneous Tissue Disorders,0
ULORIC,Stevens Johnson Syndrome,hypersensitivity,0
ULORIC,hypersensitivity skin reactions,hypersensitivity skin reactions,1
ULORIC,hypersensitivity skin reactions,hypersensitivity,1
ULORIC,hypersensitivity skin reactions,generalized rash Stevens Johnson hypersensitivity skin,1
ULORIC,hypersensitivity skin reactions,Johnson hypersensitivity skin reactions,1
ULORIC,hypersensitivity skin reactions,,0
ULORIC,hypersensitivity skin reactions,Syndrome,0
ULORIC,hypersensitivity skin reactions,,0
ULORIC,gout flares,patients and at least greater than placebo are liver function abnormalities,0
ULORIC,gout flares, ULORIC-tre ated patients and at,1
ULORIC,gout flares, ULORIC-tre ated patients,1
ULORIC,gout flares,,0
ULORIC,gout flares, ULORIC-tre ated patients and,1
ULORIC,gout flares, ULORIC-tre ated,1
ULORIC,gout flares, ULORIC-tre ated patients and at least,1
ULORIC,gout flares,,0
ULORIC,gout flares, ULORIC-tre ated,1
ULORIC,Cardiovascular Events,conducted under,0
ULORIC,Cardiovascular Events,Clinical Trials,0
ULORIC,Cardiovascular Events,clinical trials are,1
ULORIC,Cardiovascular Events,Clinical Trials Experience ause clinical trials  are,1
ULORIC,Cardiovascular Events,varying conditions adverse reaction rates,0
ULORIC,Cardiovascular Events,wwwfdagovmedwatch Clinical Trials Experience ause clinical trials  are,1
ULORIC,Cardiovascular Events,wwwfdagovmedwatch,0
ULORIC,Cardiovascular Events,rates observed in the,0
ULORIC,Cardiovascular Events,varying conditions adverse,0
ULORIC,Cardiovascular Events,,0
ULORIC,cardiovascular thromboembolic events,"widely varying conditions, adverse r eaction",1
ULORIC,cardiovascular thromboembolic events,cannot,0
ULORIC,Hepatic Effects,t the rates obs erved,1
ULORIC,Hepatic Effects,obs erved,1
ULORIC,Hepatic Effects,ULORIC,0
ULORIC,Hepatic Effects,,0
ULORIC,Hepatic Effects,to rates in the clinical trials of,0
ULORIC,Hepatic Effects,obs erved,1
ULORIC,hepatic failure,,0
ULORIC,hepatic failure,sub jects,1
ULORIC,hepatic failure,,0
ULORIC,hepatic failure,,0
ULORIC,hepatic failure,2757 sub jects,1
ULORIC,hepatic failure,with ULORIC mg or,0
ULORIC,fatal,yperu ricemia,1
ULORIC,fatal,yperu ricemia,1
ULORIC,fatal,yperu ricemia,1
ULORIC,fatal,yperu ricemia,1
ULORIC,fatal,yperu ricemia,1
ULORIC,fatal,subjects with yperu ricemia,1
ULORIC,fatal,yperu ricemia,1
ULORIC,fatal,with yperu ricemia,1
ULORIC,gout flares,years Most Common Adverse Reactions,0
ULORIC,gout flares,randomized controlled linical,1
ULORIC,gout flares,randomized controlled linical stu dies,1
ULORIC,gout flares,,0
ULORIC,gout flares,linical stu dies,1
ULORIC,gout flares,In three randomized controlled linical,1
ULORIC,gout flares,controlled linical,1
ULORIC,gout flares,Adverse Reactions In three randomized,0
ULORIC,gout flares,three randomized controlled linical,1
ULORIC,gout flares,Reactions In three randomized,0
ULORIC,cardiovascular thromboembolic events,than Seen in Receiving Placebo in Controlled Stud ies,1
ULORIC,cardiovascular thromboembolic events,Greater than Seen in Receiving Placebo in Controlled Stud ies,1
ULORIC,cardiovascular thromboembolic events,of ULORICTreated Patients and at Least Greater,0
ULORIC,cardiovascular thromboembolic events,Placebo in Controlled Stud ies,1
ULORIC,cardiovascular thromboembolic events,Stud ies,1
ULORIC,cardiovascular deaths,"Receiving Placebo in Controlled s    
  Adverse React ions",1
ULORIC,cardiovascular deaths,"in Controlled s    
  Adverse React ions",1
ULORIC,cardiovascular deaths,Least Greater than Seen,0
ULORIC,cardiovascular deaths,Least Greater than,0
ULORIC,cardiovascular deaths,than Seen in Patients Receiving Placebo in Controlled Studie,0
ULORIC,cardiovascular deaths,"in Controlled s    
  Adverse React ions",1
ULORIC,cardiovascular deaths,who rece,0
ULORIC,cardiovascular deaths,"Controlled s    
  Adverse React ions",1
ULORIC,cardiovascular deaths,,0
ULORIC,cardiovascular deaths,Controlled s Adverse,1
ULORIC,fatal,,0
ULORIC,fatal,sea  ,1
ULORIC,hepatic failure,Nausea,0
ULORIC,hepatic failure,Nausea         0.7%    Arthralgia,1
ULORIC,hepatic failure,Nausea,0
ULORIC,hepatic failure,Nausea,0
ULORIC,hepatic failure,Nausea,0
ULORIC,hepatic failure,Nausea,0
ULORIC,hepatic failure,        0.7%    Arthralgia,1
ULORIC,hepatic failure,        0.7%    Arthralgia,1
ULORIC,transaminase elevations,Arthralgia,0
ULORIC,transaminase elevations,       0.7%             Rash,1
ULORIC,transaminase elevations,Arthralgia,0
ULORIC,transaminase elevations,Arthralgia        0.7%             Rash,1
KYPROLIS,Acute Renal Failure,of the labeling Cardiac Toxicities see Warnings,0
KYPROLIS,Acute Renal Failure,Renal Failure,1
KYPROLIS,Acute Renal Failure,of the labeling Cardiac,0
KYPROLIS,Acute Renal Failure,and Acute Renal,1
KYPROLIS,Acute Renal Failure,,0
KYPROLIS,Acute Renal Failure,see Warnings and Acute,1
KYPROLIS,Tumor Lysis Syndrome,Failure see Warnings and Tumor,1
KYPROLIS,Tumor Lysis Syndrome,,0
KYPROLIS,Tumor Lysis Syndrome,Tumor Lysis Syndrome,1
KYPROLIS,Tumor Lysis Syndrome,see Warnings and Precautions,0
KYPROLIS,Tumor Lysis Syndrome,and,0
KYPROLIS,Tumor Lysis Syndrome,Precautions,0
KYPROLIS,Tumor Lysis Syndrome,Failure see Warnings and Tumor Lysis Syndrome,1
KYPROLIS,Tumor Lysis Syndrome,Pulmonary Toxicity,0
KYPROLIS,Tumor Lysis Syndrome,Tumor Lysis Syndrome,1
KYPROLIS,Tumor Lysis Syndrome,Tumor Lysis Syndrome,1
KYPROLIS,Pulmonary Toxicity,Toxicity,1
KYPROLIS,Pulmonary Toxicity,Lysis Syndrome see,0
KYPROLIS,Pulmonary Toxicity,Hypertension see,0
KYPROLIS,Pulmonary Hypertension,Hypertension,1
KYPROLIS,Pulmonary Hypertension,see Warnings and Pulmonary,1
KYPROLIS,Pulmonary Hypertension,Hypertension,1
KYPROLIS,Pulmonary Hypertension,Warnings and Pulmonary,1
KYPROLIS,Pulmonary Hypertension,Toxicity see Warnings and Pulmonary,1
KYPROLIS,Pulmonary Hypertension,Pulmonary,0
KYPROLIS,Pulmonary Hypertension,Warnings and,0
KYPROLIS,Pulmonary Hypertension,see Warnings and Pulmonary Hypertension,1
KYPROLIS,Dyspnea,Warnings and Dyspnea,1
KYPROLIS,Dyspnea,Warnings and Precautions Hypertension see Warnings and,0
KYPROLIS,Dyspnea,,0
KYPROLIS,Dyspnea,Pulmonary,0
KYPROLIS,Dyspnea,,0
KYPROLIS,Hypertension,Hypertension,1
KYPROLIS,Venous Thrombosis,see,0
KYPROLIS,Venous Thrombosis,Venous Thrombosis,1
KYPROLIS,Venous Thrombosis,Hypertension see Warnings and Venous Thrombosis,1
KYPROLIS,Infusion Reactions,Reactions,1
KYPROLIS,Infusion Reactions,Thrombosis see Warnings and Infusion,1
KYPROLIS,Infusion Reactions,Thrombosis see Warnings and Infusion Reactions,1
KYPROLIS,Infusion Reactions,see Warnings,0
KYPROLIS,Infusion Reactions,,0
KYPROLIS,Infusion Reactions,and Precautions Thrombocytopenia see Warnings,0
KYPROLIS,Infusion Reactions,,0
KYPROLIS,Infusion Reactions,,0
KYPROLIS,Infusion Reactions,and,0
KYPROLIS,Infusion Reactions,Warnings,0
KYPROLIS,Thrombocytopenia,,0
KYPROLIS,Hepatic Toxicity,Hepatic Failure see Warnings and Precautions,0
KYPROLIS,Hepatic Toxicity,Hepatic,1
KYPROLIS,Hepatic Toxicity,Thrombocytopenia see Warnings and Hepatic Toxicity,1
KYPROLIS,Hepatic Toxicity,and,0
KYPROLIS,Hepatic Toxicity,,0
KYPROLIS,Hepatic Toxicity,Thrombocytopenia see,0
KYPROLIS,Hepatic Toxicity,Warnings and Hepatic,1
KYPROLIS,Hepatic Toxicity,,0
KYPROLIS,Hepatic Failure,Failure,1
KYPROLIS,Hepatic Failure,Warnings and Precautions Hepatic Toxicity and,0
KYPROLIS,Hepatic Failure,Hepatic Failure,1
KYPROLIS,Hepatic Failure,Failure,1
KYPROLIS,Hepatic Failure,Precautions Thrombotic Thrombocytopenic PurpuraHemolyt,0
KYPROLIS,Thrombotic Thrombocytopenic Purpura,Thrombocytopenic Purpura,1
KYPROLIS,Thrombotic Thrombocytopenic Purpura,Thrombotic Thrombocytopenic Purpura,1
KYPROLIS,Hemolytic Uremic Syndrome,Thrombocytopenic Hemolytic Uremic Syndrome,1
KYPROLIS,Hemolytic Uremic Syndrome,Thrombotic Thrombocytopenic Hemolytic Uremic,1
KYPROLIS,Hemolytic Uremic Syndrome,Thrombotic Thrombocytopenic Hemolytic Uremic,1
KYPROLIS,Hemolytic Uremic Syndrome,Precautions Posterior,0
KYPROLIS,Hemolytic Uremic Syndrome,and Precautions Thrombotic Thrombocytopenic Hemolytic Uremic Syndrome,1
KYPROLIS,Hemolytic Uremic Syndrome,Precautions,0
KYPROLIS,Hemolytic Uremic Syndrome,Thrombotic Thrombocytopenic Hemolytic,1
KYPROLIS,Posterior Reversible Encephalopathy Syndrome,,0
KYPROLIS,PRES,PRES,1
KYPROLIS,PRES,PRES,1
KYPROLIS,PRES,Precautions Posterior,0
KYPROLIS,PRES,Reversible Encephalopathy PRES,1
KYPROLIS,PRES,Posterior Reversible Encephalopathy PRES,1
KYPROLIS,PRES,see,0
KYPROLIS,PRES,Syndrome,0
KYPROLIS,PRES,PRES,1
KYPROLIS,anemia,Kyprolis in monotherapy anemia,1
KYPROLIS,anemia,adverse events occurring in at least of patients treated with Kyprolis in,0
KYPROLIS,anemia,monotherapy anemia,1
KYPROLIS,fatigue,fatigue,1
KYPROLIS,fatigue,Kyprolis in monotherapy trials anemia,0
KYPROLIS,fatigue,fatigue,1
KYPROLIS,fatigue,fatigue,1
KYPROLIS,fatigue,diarrhea decreased lymphocyte h,0
KYPROLIS,fatigue,fatigue,1
KYPROLIS,thrombocytopenia,with,0
KYPROLIS,thrombocytopenia,thrombocytopenia,1
KYPROLIS,thrombocytopenia,dyspnea diarrhea decreased lymphocyte,0
KYPROLIS,thrombocytopenia,,0
KYPROLIS,thrombocytopenia,,0
KYPROLIS,thrombocytopenia,thrombocytopenia,1
KYPROLIS,thrombocytopenia,thrombocytopenia,1
KYPROLIS,nausea,fatigue nausea,1
KYPROLIS,nausea,,0
KYPROLIS,nausea,,0
KYPROLIS,nausea,monotherapy trials anemia fatigue nausea,1
KYPROLIS,nausea,nausea,1
KYPROLIS,nausea,,0
KYPROLIS,pyrexia,pyrexia,1
KYPROLIS,pyrexia,fatigue thrombocytopenia nausea,0
KYPROLIS,pyrexia,fatigue thrombocytopenia pyrexia,1
KYPROLIS,pyrexia,pyrexia,1
KYPROLIS,dyspnea,dyspnea,1
KYPROLIS,dyspnea,pyrexia decreased dyspnea,1
KYPROLIS,dyspnea,peripheral,0
KYPROLIS,diarrhea,diarrhea,1
KYPROLIS,diarrhea,decreased lymphocyte headache decreased,0
KYPROLIS,diarrhea,decreased hemoglobin cough edema,0
KYPROLIS,diarrhea,nausea pyrexia decreased platelets diarrhea,1
KYPROLIS,diarrhea,diarrhea,1
KYPROLIS,diarrhea,diarrhea,1
KYPROLIS,diarrhea,decreased lymphocyte headache decreased hemoglobin cough edema peripheral The,0
KYPROLIS,diarrhea,,0
KYPROLIS,decreased lymphocyte,lymphocyte,1
KYPROLIS,decreased lymphocyte,headache decreased hemoglobin cough edema peripheral The most,0
KYPROLIS,decreased lymphocyte,lymphocyte,1
KYPROLIS,decreased lymphocyte,platelets dyspnea decreased,1
KYPROLIS,decreased lymphocyte,decreased platelets dyspnea,0
KYPROLIS,decreased lymphocyte,,0
KYPROLIS,headache,headache,1
KYPROLIS,headache,headache,1
KYPROLIS,headache,headache,1
KYPROLIS,headache,headache,1
KYPROLIS,headache,diarrhea decreased lymphocyte,0
KYPROLIS,headache,platelets dyspnea diarrhea decreased headache,1
KYPROLIS,headache,headache,1
KYPROLIS,headache,headache,1
KYPROLIS,decreased hemoglobin,decreased hemoglobin,1
KYPROLIS,decreased hemoglobin,diarrhea decreased lymphocyte decreased,1
KYPROLIS,decreased hemoglobin,,0
KYPROLIS,decreased hemoglobin,,0
KYPROLIS,decreased hemoglobin,,0
KYPROLIS,decreased hemoglobin,headache,0
KYPROLIS,decreased hemoglobin,decreased,1
KYPROLIS,decreased hemoglobin,,0
KYPROLIS,decreased hemoglobin,decreased hemoglobin,1
KYPROLIS,cough,cough,1
KYPROLIS,cough,cough,1
KYPROLIS,edema peripheral,hemoglobin edema,1
KYPROLIS,edema peripheral,headache decreased hemoglobin edema peripheral,1
KYPROLIS,edema peripheral,decreased,0
KYPROLIS,edema peripheral,hemoglobin edema,1
KYPROLIS,edema peripheral,lymphocyte headache decreased,0
KYPROLIS,edema peripheral,edema peripheral,1
KYPROLIS,edema peripheral,The most common adverse events occurring in at least of patients treated with Kyp,0
KYPROLIS,edema peripheral,headache decreased hemoglobin edema,1
KYPROLIS,edema peripheral,in at least of patients treated with Kyp,0
KYPROLIS,edema peripheral,decreased hemoglobin edema,1
KYPROLIS,decreased lymphocytes,of patients treated with Kyprolis in the combination therapy trial,0
KYPROLIS,decreased lymphocytes,the combination therapy decreased lymphocytes,1
KYPROLIS,decreased lymphocytes,therapy trial,0
KYPROLIS,decreased lymphocytes,in the combination therapy decreased,1
KYPROLIS,decreased lymphocytes,combination,0
KYPROLIS,decreased lymphocytes,decreased phosphorus anemia neutropenia decreased total wh,0
KYPROLIS,decreased lymphocytes,lymphocytes,1
KYPROLIS,decreased lymphocytes,in the combination therapy decreased,1
KYPROLIS,decreased lymphocytes,Kyprolis,0
KYPROLIS,decreased lymphocytes,Kyprolis,0
KYPROLIS,decreased absolute neutrophil count,absolute neutrophil count,1
KYPROLIS,decreased absolute neutrophil count,anemia neutropenia decreased total white blood cell count decreased,0
KYPROLIS,decreased absolute neutrophil count,phosphorus anemia neutropenia decreased total white blood cell count decreased,0
KYPROLIS,decreased absolute neutrophil count,decreased absolute neutrophil count,1
KYPROLIS,decreased absolute neutrophil count,decreased decreased absolute neutrophil count,1
KYPROLIS,decreased absolute neutrophil count,,0
KYPROLIS,decreased absolute neutrophil count,of patients treated with Kyprolis in,0
KYPROLIS,decreased phosphorus,lymphocytes decreased absolute neutrophil decreased,1
KYPROLIS,anemia,count decreased,0
KYPROLIS,anemia,anemia,1
KYPROLIS,anemia,anemia,1
KYPROLIS,anemia,anemia,1
KYPROLIS,anemia,decreased absolute neutrophil count,0
KYPROLIS,anemia,neutropenia,0
KYPROLIS,anemia,decreased anemia,1
KYPROLIS,neutropenia,neutropenia,1
KYPROLIS,neutropenia,neutropenia,1
KYPROLIS,neutropenia,neutropenia,1
KYPROLIS,neutropenia,neutropenia,1
KYPROLIS,neutropenia,cell count decreased,0
KYPROLIS,neutropenia,decreased absolute,0
KYPROLIS,neutropenia,neutrophil count decreased phosphorus neutropenia,1
KYPROLIS,neutropenia,lymphocytes decreased absolute,0
KYPROLIS,decreased total white blood cell count,absolute neutrophil count decreased phosphorus anemia,0
KYPROLIS,decreased total white blood cell count,lymphocytes decreased absolute neutrophil count,0
KYPROLIS,diarrhea,phosphorus anemia neutropenia decreased total white blood cell count decreased,0
KYPROLIS,diarrhea,neutropenia decreased total white blood cell,0
KYPROLIS,fatigue,muscle spasm cough upper respiratory tract infection decreased,0
KYPROLIS,fatigue,decreased platelets fatigue,1
KYPROLIS,fatigue,fatigue,1
KYPROLIS,fatigue,muscle spasm cough upper respiratory tract infection,0
KYPROLIS,fatigue,infection decreased,0
KYPROLIS,fatigue,fatigue,1
KYPROLIS,fatigue,platelets fatigue,1
KYPROLIS,thrombocytopenia,hypokalemia,0
KYPROLIS,thrombocytopenia,thrombocytopenia,1
KYPROLIS,thrombocytopenia,decreased total white blood cell count,0
KYPROLIS,thrombocytopenia,decreased platelets diarrhea thrombocytopenia,1
KYPROLIS,thrombocytopenia,thrombocytopenia,1
KYPROLIS,pyrexia,pyrexia,1
KYPROLIS,pyrexia,platelets diarrhea fatigue pyrexia,1
KYPROLIS,pyrexia,pyrexia,1
KYPROLIS,pyrexia,fatigue pyrexia,1
KYPROLIS,pyrexia,blood cell count decreased platelets,0
KYPROLIS,muscle spasm,,0
KYPROLIS,muscle spasm,tract infection decreased hemoglobin hypokalemia To,0
KYPROLIS,muscle spasm,decreased platelets diarrhea fatigue thrombocytopenia,0
KYPROLIS,muscle spasm,spasm,1
KYPROLIS,muscle spasm,fatigue thrombocytopenia muscle,1
KYPROLIS,muscle spasm,muscle,1
KYPROLIS,muscle spasm,upper respiratory tract infection decreased hemoglobin hypokalemia To,0
KYPROLIS,cough,decreased hemoglobin hypokalemia,0
KYPROLIS,cough,pyrexia muscle cough,1
KYPROLIS,cough,cough,1
KYPROLIS,cough,thrombocytopenia pyrexia muscle cough,1
KYPROLIS,cough,cough,1
KYPROLIS,cough,muscle cough,1
KYPROLIS,cough,cough,1
KYPROLIS,cough,tract infection decreased hemoglobin hypokalemia To,0
KYPROLIS,cough,pyrexia muscle cough,1
KYPROLIS,upper respiratory tract infection,upper respiratory tract infection,1
KYPROLIS,upper respiratory tract infection,muscle spasm upper respiratory tract infection,1
KYPROLIS,upper respiratory tract infection,upper respiratory tract,1
KYPROLIS,upper respiratory tract infection,diarrhea fatigue thrombocytopenia pyrexia muscle,0
KYPROLIS,upper respiratory tract infection,pyrexia muscle spasm upper respiratory tract,1
KYPROLIS,upper respiratory tract infection,tract infection,1
KYPROLIS,upper respiratory tract infection,infection,1
KYPROLIS,decreased hemoglobin,spasm cough upper,0
KYPROLIS,decreased hemoglobin,decreased hemoglobin,1
KYPROLIS,decreased hemoglobin,Medical Informatio,0
KYPROLIS,decreased hemoglobin,hemoglobin,1
KYPROLIS,hypokalemia,hypokalemia,1
KYPROLIS,hypokalemia,To report SUSPECTED ADVERSE REACTIONS contact Amgen Medical Information,0
KYPROLIS,hypokalemia,infection decreased hemoglobin,0
KYPROLIS,hypokalemia,hypokalemia,1
KYPROLIS,hypokalemia,cough upper respiratory tract infection decreased,0
KYPROLIS,hypokalemia,hypokalemia,1
KYPROLIS,Deaths,was cycles for,0
KYPROLIS,Deaths,for the Rd Deaths,1
KYPROLIS,Deaths,Deaths,1
KYPROLIS,Deaths,of the last dose of any,0
KYPROLIS,Deaths,for the Rd Deaths,1
KYPROLIS,Deaths,number of,0
KYPROLIS,Deaths,Rd arm,0
KYPROLIS,Deaths,arm occurred in,0
KYPROLIS,Deaths,Deaths,1
KYPROLIS,Deaths,the last dose of any therapy in the KRd arm,0
KYPROLIS,died,therapy in the KRd,0
KYPROLIS,died,any Rd therapy The most common cause,0
KYPROLIS,died,compared with patients died,1
KYPROLIS,died,,0
KYPROLIS,died,died,1
KYPROLIS,died,patients compared with patients,0
KYPROLIS,died,,0
KYPROLIS,died,compared with patients died,1
KYPROLIS,deaths,cause deaths,1
KYPROLIS,deaths,common cause of,0
KYPROLIS,deaths,,0
KYPROLIS,deaths,,0
KYPROLIS,deaths,deaths,1
KYPROLIS,deaths,The most common cause of,0
KYPROLIS,deaths,deaths,1
KYPROLIS,deaths,deaths,1
KYPROLIS,pneumonia,pneumonia,1
KYPROLIS,pneumonia,and,0
KYPROLIS,pneumonia,pneumonia,1
KYPROLIS,pneumonia,were,0
KYPROLIS,pneumonia,the Rd arm,0
KYPROLIS,pneumonia,respiratory,0
KYPROLIS,respiratory tract infection,Rd arm were pneumonia,0
KYPROLIS,pyrexia,,0
KYPROLIS,pyrexia,,0
KYPROLIS,pyrexia,respiratory tract infection pyrexia,1
KYPROLIS,pyrexia,versus Discontinuation due to any adverse,0
KYPROLIS,pyrexia,pyrexia,1
KYPROLIS,pyrexia,pyrexia,1
KYPROLIS,pyrexia,infection,0
KYPROLIS,pyrexia,pyrexia,1
KYPROLIS,pulmonary embolism,versus pulmonary embolism,1
KYPROLIS,pulmonary embolism,,0
KYPROLIS,pulmonary embolism,,0
KYPROLIS,pulmonary embolism,versus respiratory tract infection versus pyrexia versus and,0
KYPROLIS,pneumonia,pneumonia,1
KYPROLIS,pneumonia,pneumonia,1
KYPROLIS,pneumonia,pneumonia,1
KYPROLIS,pneumonia,the most common events pneumonia,1
KYPROLIS,pneumonia,,0
KYPROLIS,pneumonia,upper respiratory,0
KYPROLIS,pneumonia,the most common events pneumonia,1
KYPROLIS,myocardial infarction,infarction,1
KYPROLIS,myocardial infarction,Kyprolis occurred in of patients and,0
KYPROLIS,upper respiratory tract infection,included pneumonia myocardial infarction upper respiratory tract infection,1
KYPROLIS,upper respiratory tract infection,included pneumonia myocardial infarction upper respiratory tract infection,1
KYPROLIS,upper respiratory tract infection,in the first cycles,0
KYPROLIS,Pneumonia,Pneumonia,1
KYPROLIS,Pneumonia,and lowdose,0
KYPROLIS,Pneumonia,bronchopneumonia b Peripheral neuropathies,0
KYPROLIS,Pneumonia,terms of pneumonia bronchopneumonia b Peripheral neuropathies NEC,0
KYPROLIS,Pneumonia,Pneumonia,1
KYPROLIS,Pneumonia,neuropathies,0
KYPROLIS,Pneumonia,Pneumonia,1
KYPROLIS,pneumonia,preferred terms under HLT,0
KYPROLIS,pneumonia,terms of,0
KYPROLIS,bronchopneumonia,bronchopneumonia,1
KYPROLIS,bronchopneumonia,NEC c,0
KYPROLIS,bronchopneumonia,Pneumonia includes preferred terms of,0
KYPROLIS,bronchopneumonia,bronchopneumonia,1
KYPROLIS,bronchopneumonia,bronchopneumonia,1
KYPROLIS,Peripheral neuropathies NEC,Peripheral neuropathies NEC,1
KYPROLIS,Peripheral neuropathies NEC,bronchopneumonia Peripheral,1
KYPROLIS,Peripheral neuropathies NEC,,0
KYPROLIS,Peripheral neuropathies NEC,pneumonia bronchopneumonia,0
KYPROLIS,Peripheral neuropathies NEC,of pneumonia bronchopneumonia Peripheral neuropathies,1
KYPROLIS,Peripheral neuropathies NEC,neuropathies NEC,1
KYPROLIS,peripheral neuropathies NEC,Dyspnea includes preferred terms of dyspnea dyspnea exertional d Embolic,0
KYPROLIS,Dyspnea,Dyspnea,1
KYPROLIS,Dyspnea,peripheral neuropathies NEC,0
KYPROLIS,Dyspnea,terms under HLT peripheral neuropathies NEC c,0
KYPROLIS,Dyspnea,Dyspnea,1
KYPROLIS,Dyspnea,NEC includes preferred terms under HLT,0
KYPROLIS,Dyspnea,,0
KYPROLIS,dyspnea,preferred terms dyspnea,1
KYPROLIS,dyspnea,preferred terms dyspnea,1
KYPROLIS,dyspnea,,0
KYPROLIS,dyspnea,,0
KYPROLIS,dyspnea,c,0
KYPROLIS,dyspnea,c Dyspnea includes,0
KYPROLIS,dyspnea exertional,includes preferred terms of dyspnea exertional,1
KYPROLIS,dyspnea exertional,d,0
KYPROLIS,dyspnea exertional,includes,0
KYPROLIS,dyspnea exertional,Embolic and thrombotic events venous include preferred terms in MedDRA SMQ narrow scope sear,0
KYPROLIS,dyspnea exertional,,0
KYPROLIS,dyspnea exertional,,0
KYPROLIS,dyspnea exertional,MedDRA SMQ narrow scope sear,0
KYPROLIS,dyspnea exertional,and thrombotic,0
KYPROLIS,dyspnea exertional,SMQ narrow scope,0
KYPROLIS,"Embolic and thrombotic events, venous","thrombotic events, venous",1
KYPROLIS,"Embolic and thrombotic events, venous","Embolic and thrombotic events, venous",1
KYPROLIS,"Embolic and thrombotic events, venous",dyspnea dyspnea exertional,0
KYPROLIS,"Embolic and thrombotic events, venous",neuropathies NEC c,0
KYPROLIS,"Embolic and thrombotic events, venous",thrombotic,0
KYPROLIS,"Embolic and thrombotic events, venous",NEC c Dyspnea includes preferred,0
KYPROLIS,"Embolic and thrombotic events, venous","and thrombotic events, venous",1
KYPROLIS,"Embolic and thrombotic events, venous","and thrombotic events, venous",1
KYPROLIS,"embolic and thrombotic events, venous",include preferred terms in MedDRA SMQ,0
KYPROLIS,"embolic and thrombotic events, venous",narrow scope search embolic and thrombotic,1
KYPROLIS,"embolic and thrombotic events, venous",,0
KYPROLIS,"embolic and thrombotic events, venous","events, venous",1
KYPROLIS,"embolic and thrombotic events, venous",preferred terms of,0
KYPROLIS,"embolic and thrombotic events, venous",terms of hypertension hypertensive crisis hypertensive eme,0
KYPROLIS,"embolic and thrombotic events, venous","events, venous",1
KYPROLIS,Hypertension,hypertensive,0
KYPROLIS,Hypertension,venous e,0
KYPROLIS,Hypertension,Hypertension,1
KYPROLIS,Hypertension,preferred terms in MedDRA SMQ narrow scope search of,0
KYPROLIS,Hypertension,SMQ narrow scope search of embolic and thrombotic events,0
KYPROLIS,Hypertension,MedDRA SMQ narrow scope search of embolic and thrombotic events venous e,0
KYPROLIS,Hypertension,Hypertension,1
KYPROLIS,Hypertension,Hypertension,1
KYPROLIS,hypertension,e Hypertension includes preferred,0
KYPROLIS,hypertension,hypertension,1
KYPROLIS,hypertension,System,0
KYPROLIS,hypertension,Hypertension includes preferred terms hypertension,1
KYPROLIS,hypertension,hypertension,1
KYPROLIS,hypertension,hypertension,1
KYPROLIS,hypertensive crisis,hypertensive crisis,1
KYPROLIS,hypertensive crisis,,0
KYPROLIS,hypertensive emergency,terms of hypertension hypertensive crisis,0
KYPROLIS,hypertensive emergency,Hypertension includes preferred terms,0
KYPROLIS,hypertensive emergency,hypertensive emergency,1
KYPROLIS,hypertensive emergency,hypertension hypertensive hypertensive emergency,1
KYPROLIS,hypertensive emergency,hypertensive hypertensive,1
KYPROLIS,hypertensive emergency,hypertensive hypertensive,1
KYPROLIS,hypertensive emergency,hypertensive emergency,1
KYPROLIS,hypertensive emergency,,0
KYPROLIS,hypertensive emergency,events venous e Hypertension,0
KYPROLIS,hypertensive emergency,of hypertension hypertensive hypertensive,1
KYPROLIS,Anemia,Anemia,1
KYPROLIS,Anemia,Anemia,1
KYPROLIS,Anemia,Anemia,1
KYPROLIS,Anemia,Disorders,0
KYPROLIS,Anemia,,0
KYPROLIS,Thrombocytopenia,Thrombocytopenia Gastr,1
KYPROLIS,Thrombocytopenia,Thrombocytopenia Gastr,1
KYPROLIS,Thrombocytopenia,Thrombocytopenia Gastr,1
KYPROLIS,Thrombocytopenia,Thrombocytopenia Gastr,1
KYPROLIS,Thrombocytopenia,,0
KYPROLIS,Thrombocytopenia,,0
KYPROLIS,Thrombocytopenia,,0
KYPROLIS,Diarrhea,Disorders,0
KYPROLIS,Diarrhea,Diarrhea,1
KYPROLIS,Diarrhea,Diarrhea,1
KYPROLIS,Diarrhea,Disorders,0
KYPROLIS,Diarrhea,Diarrhea,1
KYPROLIS,Diarrhea,Disorders Diarrhea,1
KYPROLIS,Diarrhea,Disorders,0
KYPROLIS,Diarrhea,Disorders Diarrhea,1
KYPROLIS,Nausea,,0
KYPROLIS,Nausea,Nausea,1
KYPROLIS,Nausea,Nausea,1
KYPROLIS,Nausea,Nausea,1
KYPROLIS,Nausea,Nausea,1
KYPROLIS,Fatigue,Fatigue,1
KYPROLIS,Fatigue,Site Fatigue,1
KYPROLIS,Fatigue,,0
KYPROLIS,Fatigue,Fatigue,1
KYPROLIS,Fatigue,,0
KYPROLIS,Fatigue,Site Conditions,0
KYPROLIS,Fatigue,Fatigue,1
KYPROLIS,Fatigue,,0
KYPROLIS,Fatigue,Fatigue,1
KYPROLIS,Pyrexia,,0
KYPROLIS,Pyrexia,,0
KYPROLIS,Pyrexia,Pyrexia,1
KYPROLIS,Pyrexia,Pyrexia,1
KYPROLIS,Pyrexia,,0
KYPROLIS,Pyrexia,,0
KYPROLIS,Pyrexia,Pyrexia,1
KYPROLIS,Pyrexia,,0
KYPROLIS,Edema Peripheral,Edema Peripheral As,1
KYPROLIS,Edema Peripheral,As,0
KYPROLIS,Edema Peripheral,Edema,1
KYPROLIS,Edema Peripheral,Edema Peripheral As,1
KYPROLIS,Edema Peripheral,,0
KYPROLIS,Edema Peripheral,,0
KYPROLIS,Edema Peripheral,,0
KYPROLIS,Edema Peripheral,,0
KYPROLIS,Edema Peripheral,Edema Peripheral As,1
KYPROLIS,Asthenia,Asthenia,1
KYPROLIS,Asthenia,Asthenia,1
KYPROLIS,Asthenia,Asthenia,1
KYPROLIS,Asthenia,,0
KYPROLIS,Asthenia,al,0
KYPROLIS,Asthenia,al,0
KYPROLIS,Asthenia,al,0
KYPROLIS,Asthenia,Asthenia,1
KYPROLIS,Upper Respiratory Tract Infection,,0
KYPROLIS,Upper Respiratory Tract Infection,festations,0
KYPROLIS,Upper Respiratory Tract Infection,festations Upper Respiratory Tract Infection Nasopharyngitis,1
KYPROLIS,Upper Respiratory Tract Infection,festations Upper Respiratory Tract Infection Nasopharyngitis,1
KYPROLIS,Upper Respiratory Tract Infection,Tract Infection Nasopharyngitis,1
KYPROLIS,Upper Respiratory Tract Infection,,0
KYPROLIS,Upper Respiratory Tract Infection,festations Upper Respiratory,1
KYPROLIS,Upper Respiratory Tract Infection,festations Upper Respiratory Tract,1
KYPROLIS,Upper Respiratory Tract Infection,festations,0
KYPROLIS,Upper Respiratory Tract Infection,Upper Respiratory Tract Infection Nasopharyngitis,1
KYPROLIS,Nasopharyngitis,Nasopharyngitis B,1
KYPROLIS,Nasopharyngitis,Tract Infection,0
KYPROLIS,Nasopharyngitis,,0
KYPROLIS,Nasopharyngitis,ory Tract Nasopharyngitis B,1
KYPROLIS,Nasopharyngitis,Tract,0
KYPROLIS,Nasopharyngitis,B,0
KYPROLIS,Nasopharyngitis,Nasopharyngitis B,1
KYPROLIS,Nasopharyngitis,B,0
KYPROLIS,Nasopharyngitis,,0
KYPROLIS,Nasopharyngitis,Infection,0
KYPROLIS,Bronchitis,,0
KYPROLIS,Pneumonia,Pneumonia a,1
KYPROLIS,Pneumonia,Pneumonia a,1
KYPROLIS,Pneumonia,Pneumonia a,1
KYPROLIS,Pneumonia,Pneumonia a,1
KYPROLIS,Pneumonia,Pneumonia a,1
KYPROLIS,Hypokalemia,,0
KYPROLIS,Hypokalemia,,0
KYPROLIS,Hypokalemia,Hypokalemia,1
KYPROLIS,Hypocalcemia,Hypocalcemia,1
KYPROLIS,Hypocalcemia,,0
KYPROLIS,Hypocalcemia,Hypocalcemia,1
KYPROLIS,Hypocalcemia,,0
KYPROLIS,Hypocalcemia,,0
KYPROLIS,Hypocalcemia,,0
KYPROLIS,Hypocalcemia,Hypocalcemia,1
KYPROLIS,Hypocalcemia,Hypocalcemia,1
KYPROLIS,Hypocalcemia,,0
KYPROLIS,Hypocalcemia,,0
KYPROLIS,Muscle Spasms,,0
KYPROLIS,Muscle Spasms,,0
KYPROLIS,Muscle Spasms,,0
KYPROLIS,Muscle Spasms,Muscle Spasms Ne,1
KYPROLIS,Muscle Spasms,Spasms Ne,1
KYPROLIS,Muscle Spasms,Tissue Muscle Spasms Ne,1
KYPROLIS,Muscle Spasms,Spasms Ne,1
KYPROLIS,Peripheral Neuropathies NEC,,0
KYPROLIS,Peripheral Neuropathies NEC,,0
KYPROLIS,Peripheral Neuropathies NEC,sorders Peripheral,1
KYPROLIS,Peripheral Neuropathies NEC,sorders Peripheral Neuropathies,1
KYPROLIS,Peripheral Neuropathies NEC,sorders Peripheral Neuropathies NEC b Psychiatric,1
KYPROLIS,Peripheral Neuropathies NEC,,0
KYPROLIS,Peripheral Neuropathies NEC,NEC b Psychiatric,1
KYPROLIS,Insomnia,Insomnia,1
KYPROLIS,Insomnia,ders Insomnia,1
KYPROLIS,Insomnia,Insomnia,1
KYPROLIS,Insomnia,ders Insomnia,1
KYPROLIS,Insomnia,ders,0
KYPROLIS,Insomnia,,0
KYPROLIS,Insomnia,Insomnia,1
KYPROLIS,Insomnia,ders,0
KYPROLIS,Insomnia,Insomnia,1
KYPROLIS,Insomnia,ders Insomnia,1
KYPROLIS,Cough,,0
KYPROLIS,Cough,,0
KYPROLIS,Cough,Cough,1
KYPROLIS,Cough,,0
KYPROLIS,Cough,Disorders,0
KYPROLIS,Cough,and Mediastinal Cough,1
KYPROLIS,Cough,Cough,1
KYPROLIS,Dyspnea,Dyspnea c,1
KYPROLIS,Dyspnea,,0
KYPROLIS,Dyspnea,,0
KYPROLIS,Dyspnea,c,0
KYPROLIS,Dyspnea,,0
KYPROLIS,Rash,,0
KYPROLIS,Rash,eous Tissue Rash,1
KYPROLIS,Rash,,0
KYPROLIS,Rash,,0
KYPROLIS,Rash,Rash,1
KYPROLIS,Rash,eous Tissue Rash,1
KYPROLIS,Rash,Tissue Rash,1
KYPROLIS,Rash,,0
KYPROLIS,Rash,Rash,1
KYPROLIS,Rash,,0
KYPROLIS,"Embolic and Thrombotic Events, Venous",d,0
KYPROLIS,"Embolic and Thrombotic Events, Venous",,0
KYPROLIS,"Embolic and Thrombotic Events, Venous",s Embolic and,1
KYPROLIS,"Embolic and Thrombotic Events, Venous","and Thrombotic Events, Venous d Hypertensione",1
KYPROLIS,"Embolic and Thrombotic Events, Venous",s Embolic and,1
KYPROLIS,Hypertension,Venousd,0
KYPROLIS,Hypertension,Hypertension e,1
KYPROLIS,Hypertension,Events Hypertension e,1
KYPROLIS,Hypertension,Hypertension e,1
KYPROLIS,Hypertension,,0
KYPROLIS,Hypertension,Events Hypertension e,1
KYPROLIS,Hypertension,Events Venousd,0
KYPROLIS,Hypertension,,0
KYPROLIS,Hypertension,Hypertension e,1
KYPROLIS,febrile neutropenia,,0
KYPROLIS,febrile neutropenia,febrile neutropenia lymphopenia Cardiac,1
KYPROLIS,febrile neutropenia,lymphatic system febrile,1
KYPROLIS,febrile neutropenia,cardiac failure,0
KYPROLIS,febrile neutropenia,a Frequency of Blood and lymphatic system,0
KYPROLIS,lymphopenia,lymphopenia Cardiac disorders,1
KYPROLIS,lymphopenia,disorders febrile lymphopenia Cardiac disorders,1
KYPROLIS,lymphopenia,febrile lymphopenia Cardiac disorders,1
KYPROLIS,lymphopenia,lymphopenia Cardiac disorders,1
KYPROLIS,lymphopenia,disorders febrile lymphopenia Cardiac disorders,1
KYPROLIS,cardiac arrest,cardiac,1
KYPROLIS,cardiac arrest,,0
KYPROLIS,cardiac arrest,myocardial infarction myocardial,0
KYPROLIS,cardiac arrest,congestive myocardial infarction,0
KYPROLIS,cardiac arrest,,0
KYPROLIS,cardiac failure congestive,arrest cardiac cardiac failure congestive myocardial infarction,1
KYPROLIS,cardiac failure congestive,,0
KYPROLIS,cardiac failure congestive,disorders cataract vision,0
KYPROLIS,cardiac failure congestive,congestive myocardial infarction,1
KYPROLIS,cardiac failure congestive,cardiac failure congestive myocardial infarction,1
KYPROLIS,cardiac failure congestive,infarction myocardial ischemia Eye disorders cataract,0
KYPROLIS,cardiac failure congestive,cardiac arrest cardiac cardiac failure congestive myocardial infarction,1
KYPROLIS,cardiac failure congestive,myocardial ischemia Eye disorders cataract vision blurred,0
KYPROLIS,myocardial ischemia,,0
KYPROLIS,myocardial ischemia,myocardial myocardial,1
KYPROLIS,myocardial ischemia,cardiac,0
KYPROLIS,myocardial ischemia,cardiac failure cardiac failure congestive,0
KYPROLIS,myocardial ischemia,failure,0
KYPROLIS,myocardial ischemia,arrest,0
KYPROLIS,myocardial ischemia,myocardial myocardial,1
KYPROLIS,cataract,Gastrointestinal,0
KYPROLIS,cataract,cataract vision blurred,1
KYPROLIS,cataract,cataract vision blurred,1
KYPROLIS,cataract,cataract vision blurred,1
KYPROLIS,vision blurred,disorders vision,1
KYPROLIS,vision blurred,pain,0
KYPROLIS,abdominal pain,Gastrointestinal abdominal,1
KYPROLIS,abdominal pain upper,,0
KYPROLIS,abdominal pain upper,,0
KYPROLIS,abdominal pain upper,disorders abdominal abdominal pain upper dyspepsia toothache,1
KYPROLIS,abdominal pain upper,blurred Gastrointestinal disorders abdominal abdominal pain,1
KYPROLIS,abdominal pain upper,Gastrointestinal disorders abdominal abdominal,1
KYPROLIS,abdominal pain upper,abdominal abdominal,1
KYPROLIS,abdominal pain upper,abdominal abdominal,1
KYPROLIS,abdominal pain upper,disorders abdominal pain,0
KYPROLIS,toothache,,0
KYPROLIS,toothache,toothache General disorders,1
KYPROLIS,toothache,disorders and administration site conditions chills infusion site reaction,0
KYPROLIS,toothache,Gastrointestinal disorders abdominal,0
KYPROLIS,chills,infusion site reaction multiorgan failure,0
KYPROLIS,chills,infusion,0
KYPROLIS,chills,,0
KYPROLIS,chills,administration site chills infusion site,1
KYPROLIS,chills,chills infusion site,1
KYPROLIS,chills,dyspepsia toothache General disorders and administration,0
KYPROLIS,chills,chills infusion site,1
KYPROLIS,chills,chills infusion site,1
KYPROLIS,chills,chills infusion site,1
KYPROLIS,chills,,0
KYPROLIS,infusion site reaction,toothache General disorders and administration site,0
KYPROLIS,infusion site reaction,pain Infections and infestations influenza,0
KYPROLIS,infusion site reaction,infusion site reaction multiorgan failure,1
KYPROLIS,multi-organ failure,infestations,0
KYPROLIS,multi-organ failure,failure pain Infections,1
KYPROLIS,multi-organ failure,and administration,0
KYPROLIS,multi-organ failure,Infections and,0
KYPROLIS,multi-organ failure,multi-organ failure pain Infections,1
KYPROLIS,pain,pain Infections and,1
KYPROLIS,pain,pain Infections and,1
KYPROLIS,pain,and infestations influenza sepsis,0
KYPROLIS,pain,sepsis urinary tract,0
KYPROLIS,pain,site conditions chills infusion site reaction multiorgan failure,0
KYPROLIS,pain,site reaction multiorgan failure,0
KYPROLIS,pain,pain Infections and,1
KYPROLIS,influenza,,0
KYPROLIS,influenza,failure pain Infections and influenza sepsis urinary,1
KYPROLIS,influenza,Infections and influenza sepsis urinary,1
KYPROLIS,influenza,tract,0
KYPROLIS,influenza,Infections and influenza sepsis urinary,1
KYPROLIS,influenza,sepsis urinary tract infection viral infection Metabolism and,0
KYPROLIS,influenza,Metabolism and nutrition disorders,0
KYPROLIS,sepsis,sepsis urinary tract,1
KYPROLIS,sepsis,infection viral infection,0
KYPROLIS,urinary tract infection,reaction multiorgan failure pain Infections and infestations,0
KYPROLIS,urinary tract infection,infection Metabolism,0
KYPROLIS,viral infection,viral infection Metabolism and,1
KYPROLIS,dehydration,tumor lysis,0
KYPROLIS,dehydration,tumor lysis syndrome Musculosk,0
KYPROLIS,dehydration,hyponatremia tumor lysis syndrome,0
KYPROLIS,dehydration,dehydration hyperkalemia hyperuricemia,1
KYPROLIS,dehydration,,0
KYPROLIS,hyperkalemia,hyperkalemia hyperuricemia hypoalbuminemia,1
KYPROLIS,hyperkalemia,tract infection viral infection Metabolism and nutrition disorders,0
KYPROLIS,hyperkalemia,infection Metabolism and nutrition,0
KYPROLIS,hyperkalemia,disorders hyperkalemia hyperuricemia hypoalbuminemia,1
KYPROLIS,hyperkalemia,nutrition disorders dehydration,0
KYPROLIS,hyperkalemia,hyperkalemia hyperuricemia hypoalbuminemia,1
KYPROLIS,hyperkalemia,hyponatremia tumor,0
KYPROLIS,hyperkalemia,disorders hyperkalemia hyperuricemia hypoalbuminemia,1
KYPROLIS,hyperkalemia,hyperkalemia hyperuricemia hypoalbuminemia,1
KYPROLIS,hyperkalemia,hypoalbuminemia hyponatremia tumor lysis syndrome Musculoskeletal and con,0
KYPROLIS,hyperuricemia,Metabolism and,0
KYPROLIS,hyperuricemia,disorders dehydration hyperuricemia hypoalbuminemia hyponatremia,1
KYPROLIS,hypoalbuminemia,hypoalbuminemia hyponatremia tumor,1
KYPROLIS,hypoalbuminemia,hypoalbuminemia hyponatremia tumor,1
KYPROLIS,hypoalbuminemia,disorders,0
KYPROLIS,hypoalbuminemia,hypoalbuminemia hyponatremia tumor,1
KYPROLIS,hypoalbuminemia,and nutrition disorders dehydration hyperkalemia hyperuricemia,0
KYPROLIS,hypoalbuminemia,hypoalbuminemia hyponatremia tumor,1
KYPROLIS,hypoalbuminemia,hypoalbuminemia hyponatremia tumor,1
KYPROLIS,hypoalbuminemia,hyperkalemia hyperuricemia,0
KYPROLIS,hyponatremia,dehydration hyperkalemia hyperuricemia hyponatremia tumor lysis,1
KYPROLIS,hyponatremia,hyponatremia tumor lysis,1
KYPROLIS,hyponatremia,hyponatremia tumor lysis,1
KYPROLIS,hyponatremia,tissue disorders,0
KYPROLIS,hyponatremia,,0
KYPROLIS,hyponatremia,muscular weakness,0
KYPROLIS,hyponatremia,hyponatremia tumor lysis,1
KYPROLIS,hyponatremia,disorders dehydration hyperkalemia hyperuricemia hyponatremia tumor lysis,1
KYPROLIS,hyponatremia,,0
KYPROLIS,hyponatremia,,0
KYPROLIS,muscular weakness,Musculoskeletal and connective tissue muscular,1
KYPROLIS,muscular weakness,muscular weakness myalgia Nervous,1
KYPROLIS,muscular weakness,disorders,0
KYPROLIS,muscular weakness,paresthesia deafness Psychiatric,0
KYPROLIS,muscular weakness,tissue disorders,0
KYPROLIS,myalgia,hypoesthesia paresthesia deafness Psychiatric disorders,0
KYPROLIS,hypoesthesia,hypoesthesia paresthesia deafness,1
KYPROLIS,hypoesthesia,Renal and urinary,0
KYPROLIS,hypoesthesia,hypoesthesia paresthesia deafness,1
KYPROLIS,hypoesthesia,d,0
KYPROLIS,paresthesia,muscular,0
KYPROLIS,paresthesia,system disorders paresthesia deafness Psychiatric,1
KYPROLIS,paresthesia,disorders paresthesia deafness Psychiatric,1
KYPROLIS,paresthesia,disorders,0
KYPROLIS,deafness,Nervous system disorders hypoesthesia deafness Psychiatric disorders,1
KYPROLIS,deafness,disorders renal,0
KYPROLIS,deafness,deafness Psychiatric disorders,1
KYPROLIS,deafness,system disorders hypoesthesia deafness Psychiatric disorders,1
KYPROLIS,deafness,delirium Renal and urinary disorders renal,0
KYPROLIS,deafness,deafness Psychiatric disorders,1
KYPROLIS,deafness,muscular weakness myalgia Nervous system disorders hypoesthesia paresthesia,0
KYPROLIS,deafness,system disorders hypoesthesia,0
KYPROLIS,deafness,deafness Psychiatric disorders,1
KYPROLIS,anxiety,anxiety delirium Renal,1
KYPROLIS,delirium,delirium Renal and,1
KYPROLIS,delirium,delirium Renal and,1
KYPROLIS,delirium,Renal and urinary disorders renal failure renal failure acute,0
KYPROLIS,delirium,,0
KYPROLIS,delirium,failure acute,0
KYPROLIS,delirium,paresthesia deafness Psychiatric disorders,0
KYPROLIS,delirium,disorders anxiety,0
KYPROLIS,renal failure,deafness Psychiatric,0
KYPROLIS,renal failure,renal,0
KYPROLIS,renal failure acute,,0
KYPROLIS,renal failure acute,acute renal impairment,1
KYPROLIS,renal failure acute,renal renal,1
KYPROLIS,renal failure acute,,0
KYPROLIS,renal impairment,renal failure renal,1
KYPROLIS,renal impairment,renal failure renal impairment Respiratory thoracic,1
KYPROLIS,renal impairment,thoracic and mediastinal disorders dysphonia epistaxis,0
KYPROLIS,renal impairment,renal failure renal failure renal impairment Respiratory thoracic,1
KYPROLIS,renal impairment,impairment Respiratory thoracic,1
KYPROLIS,renal impairment,Respiratory thoracic,0
KYPROLIS,renal impairment,renal impairment Respiratory thoracic,1
KYPROLIS,renal impairment,and urinary disorders renal failure,0
KYPROLIS,dysphonia,dysphonia epistaxis oropharyngeal,1
KYPROLIS,dysphonia,thoracic and mediastinal dysphonia epistaxis oropharyngeal,1
KYPROLIS,epistaxis,,0
KYPROLIS,epistaxis,and mediastinal disorders epistaxis oropharyngeal pain,1
KYPROLIS,epistaxis,tissue,0
KYPROLIS,epistaxis,mediastinal disorders dysphonia,0
KYPROLIS,oropharyngeal pain,,0
KYPROLIS,oropharyngeal pain,oropharyngeal,1
KYPROLIS,oropharyngeal pain,,0
KYPROLIS,oropharyngeal pain,pulmonary edema Skin,0
KYPROLIS,oropharyngeal pain,and mediastinal disorders dysphonia epistaxis,0
KYPROLIS,oropharyngeal pain,oropharyngeal pain pulmonary embolism,1
KYPROLIS,oropharyngeal pain,pain pulmonary embolism,1
KYPROLIS,oropharyngeal pain,pain pulmonary embolism,1
KYPROLIS,oropharyngeal pain,and mediastinal disorders dysphonia oropharyngeal,1
KYPROLIS,oropharyngeal pain,mediastinal disorders dysphonia oropharyngeal pain pulmonary embolism,1
KYPROLIS,pulmonary embolism,,0
KYPROLIS,pulmonary embolism,dysphonia epistaxis oropharyngeal pulmonary embolism pulmonary edema,1
KYPROLIS,pulmonary embolism,oropharyngeal pulmonary embolism pulmonary edema,1
KYPROLIS,pulmonary embolism,dysphonia epistaxis oropharyngeal pulmonary embolism pulmonary edema,1
KYPROLIS,pulmonary embolism,embolism pulmonary edema,1
KYPROLIS,pulmonary embolism,oropharyngeal,0
KYPROLIS,pulmonary embolism,subcutaneous tissue,0
KYPROLIS,pulmonary embolism,,0
KYPROLIS,pulmonary embolism,dysphonia epistaxis oropharyngeal pulmonary embolism pulmonary edema,1
KYPROLIS,pulmonary embolism,mediastinal disorders dysphonia,0
KYPROLIS,erythema,Skin,0
KYPROLIS,erythema,pulmonary edema,0
KYPROLIS,erythema,,0
KYPROLIS,erythema,vein thrombosis hypotension,0
KYPROLIS,erythema,vein thrombosis,0
KYPROLIS,erythema,disorders deep vein thrombosis hypotension Grade,0
KYPROLIS,erythema,pulmonary embolism pulmonary edema Skin and subcutaneous tissue disorders,0
KYPROLIS,erythema,pulmonary edema Skin and subcutaneous tissue disorders,0
KYPROLIS,hyperhidrosis,pulmonary edema Skin and subcutaneous,0
KYPROLIS,hyperhidrosis,subcutaneous tissue disorders hyperhidrosis pruritus Vascular,1
KYPROLIS,hyperhidrosis,disorders,0
KYPROLIS,hyperhidrosis,subcutaneous tissue disorders hyperhidrosis pruritus Vascular,1
KYPROLIS,hyperhidrosis,hyperhidrosis pruritus Vascular,1
KYPROLIS,pruritus,pruritus Vascular disorders,1
KYPROLIS,deep vein thrombosis,thrombosis hypotension Grade,1
KYPROLIS,hypotension,disorders erythema hyperhidrosis pruritus Vascular disorders deep,0
KYPROLIS,hypotension,higher adverse reactions that,0
KYPROLIS,hypotension,hypotension Grade and,1
KYPROLIS,hypotension,hypotension Grade and,1
KYPROLIS,neutropenia,neutropenia thrombocytopenia hypokalemia,1
KYPROLIS,neutropenia,neutropenia thrombocytopenia hypokalemia,1
KYPROLIS,neutropenia,with a substantial difference between,0
KYPROLIS,neutropenia,arms neutropenia thrombocytopenia hypokalemia,1
KYPROLIS,neutropenia,neutropenia thrombocytopenia hypokalemia,1
KYPROLIS,neutropenia,neutropenia thrombocytopenia hypokalemia,1
KYPROLIS,neutropenia,neutropenia thrombocytopenia hypokalemia,1
KYPROLIS,neutropenia,,0
KYPROLIS,neutropenia,,0
KYPROLIS,thrombocytopenia,thrombocytopenia hypokalemia and,1
KYPROLIS,thrombocytopenia,thrombocytopenia hypokalemia and,1
KYPROLIS,thrombocytopenia,the two arms were thrombocytopenia hypokalemia and,1
KYPROLIS,thrombocytopenia,hypophosphatemia Laboratory Abnormalities,0
KYPROLIS,thrombocytopenia,,0
KYPROLIS,thrombocytopenia,Table describes,0
KYPROLIS,thrombocytopenia,a substantial difference between the,0
KYPROLIS,thrombocytopenia,neutropenia,0
KYPROLIS,thrombocytopenia,thrombocytopenia hypokalemia and,1
KYPROLIS,thrombocytopenia,were thrombocytopenia hypokalemia and,1
KYPROLIS,hypokalemia,Abnormalities Table describes Grade labo,0
KYPROLIS,hypokalemia,hypokalemia and hypophosphatemia,1
KYPROLIS,hypokalemia,thrombocytopenia,0
KYPROLIS,hypokalemia,arms were neutropenia hypokalemia and hypophosphatemia,1
KYPROLIS,hypokalemia,hypokalemia and hypophosphatemia,1
KYPROLIS,hypokalemia,two arms were neutropenia hypokalemia and hypophosphatemia,1
KYPROLIS,hypophosphatemia,,0
KYPROLIS,Decreased Lymphocytes,Lymphocytes Decreased Ab,1
KYPROLIS,Decreased Lymphocytes,Lymphocytes Decreased Ab,1
KYPROLIS,Decreased Lymphocytes,Lymphocytes Decreased Ab,1
KYPROLIS,Decreased Lymphocytes,Decreased,1
KYPROLIS,Decreased Lymphocytes,,0
KYPROLIS,Decreased Lymphocytes,y Abnormality KRd N Decreased,1
KYPROLIS,Decreased Lymphocytes,,0
KYPROLIS,Decreased Lymphocytes,,0
KYPROLIS,Decreased Lymphocytes,,0
KYPROLIS,Decreased Absolute Neutrophil Count,Decreased Phosphorus,0
KYPROLIS,Decreased Absolute Neutrophil Count,Phosphorus,0
KYPROLIS,Decreased Absolute Neutrophil Count,Lymphocytes Decreased Absolute,1
KYPROLIS,Decreased Absolute Neutrophil Count,Lymphocytes Decreased Absolute Neutrophil,1
KYPROLIS,Decreased Platelets,Decreased,0
KYPROLIS,Decreased Platelets,Phosphorus Decreased Platelets Decreased,1
KYPROLIS,Decreased Platelets,Phosphorus Decreased Platelets Decreased,1
KYPROLIS,Decreased Platelets,Phosphorus,0
KYPROLIS,Decreased Platelets,,0
KYPROLIS,Decreased Platelets,,0
KYPROLIS,Decreased Platelets,Phosphorus Decreased Platelets Decreased,1
KYPROLIS,Decreased Platelets,Platelets Decreased,1
KYPROLIS,Decreased Platelets,Platelets Decreased,1
KYPROLIS,Decreased Total White Blood Cell Count,Platelets,0
KYPROLIS,Decreased Total White Blood Cell Count,Platelets Decreased Total White Blood Cell Count,1
KYPROLIS,Decreased Total White Blood Cell Count,Platelets,0
KYPROLIS,Decreased Total White Blood Cell Count,Total White Blood Cell Count Decreased,1
KYPROLIS,Decreased Total White Blood Cell Count,Platelets Decreased Total White Blood Cell,1
KYPROLIS,Decreased Total White Blood Cell Count,Platelets Decreased Total White Blood,1
KYPROLIS,Decreased Total White Blood Cell Count,Platelets Decreased Total White Blood Cell Count Decreased Hemoglobin,1
KYPROLIS,Decreased Total White Blood Cell Count,Platelets Decreased Total White Blood Cell Count Decreased,1
KYPROLIS,Decreased Hemoglobin,White Blood Cell Decreased,1
KYPROLIS,Decreased Hemoglobin,Decreased,0
KYPROLIS,Decreased Hemoglobin,White Blood Cell Decreased Hemoglobin Decreased,1
KYPROLIS,Decreased Hemoglobin,Count,0
KYPROLIS,Decreased Hemoglobin,White Blood,0
KYPROLIS,Decreased Hemoglobin,Hemoglobin Decreased,1
KYPROLIS,Decreased Hemoglobin,Blood Cell Decreased,1
KYPROLIS,Decreased Hemoglobin,White Blood Cell Decreased Hemoglobin Decreased,1
KYPROLIS,Decreased Potassium,,0
KYPROLIS,Decreased Potassium,Hemoglobin Decreased,1
KYPROLIS,Decreased Potassium,,0
KYPROLIS,Decreased Potassium,,0
KYPROLIS,Decreased Potassium,,0
KYPROLIS,Decreased Potassium,,0
KYPROLIS,pneumonia,pneumonia,1
KYPROLIS,pneumonia,acute renal,0
KYPROLIS,acute renal failure,monotherapy studies n The most common serious adverse events were pneumonia,0
KYPROLIS,acute renal failure,were acute renal failure,1
KYPROLIS,acute renal failure,pyrexia hypercalcemia congestive heart failure,0
KYPROLIS,acute renal failure,progression pyrexia hypercalcemia congestive heart failure,0
KYPROLIS,acute renal failure,failure,1
KYPROLIS,disease progression,multiple,0
KYPROLIS,pyrexia,pyrexia,1
KYPROLIS,pyrexia,congestive heart failure multiple myeloma anemia and,0
KYPROLIS,pyrexia,pyrexia,1
KYPROLIS,pyrexia,progression,0
KYPROLIS,pyrexia,pyrexia,1
KYPROLIS,pyrexia,disease progression,0
KYPROLIS,pyrexia,,0
KYPROLIS,pyrexia,pyrexia,1
KYPROLIS,hypercalcemia,hypercalcemia,1
KYPROLIS,hypercalcemia,renal failure disease progression pyrexia,0
KYPROLIS,hypercalcemia,events were pneumonia acute renal failure,0
KYPROLIS,hypercalcemia,,0
KYPROLIS,hypercalcemia,acute renal failure disease progression,0
KYPROLIS,hypercalcemia,hypercalcemia,1
KYPROLIS,hypercalcemia,,0
KYPROLIS,hypercalcemia,multiple myeloma anemia and dyspnea,0
KYPROLIS,congestive heart failure,failure disease progression pyrexia congestive heart failure,1
KYPROLIS,congestive heart failure,pyrexia congestive,1
KYPROLIS,congestive heart failure,congestive heart failure,1
KYPROLIS,congestive heart failure,heart failure,1
KYPROLIS,congestive heart failure,pyrexia congestive heart failure,1
KYPROLIS,congestive heart failure,progression pyrexia,0
KYPROLIS,congestive heart failure,anemia and dyspnea In patients treated,0
KYPROLIS,congestive heart failure,disease progression pyrexia congestive heart failure,1
KYPROLIS,congestive heart failure,congestive heart failure,1
KYPROLIS,anemia,,0
KYPROLIS,anemia,,0
KYPROLIS,dyspnea,hypercalcemia congestive heart failure multiple,0
KYPROLIS,dyspnea,dyspnea,1
KYPROLIS,dyspnea,dyspnea,1
KYPROLIS,dyspnea,dyspnea,1
KYPROLIS,dyspnea,dyspnea,1
KYPROLIS,Deaths,Deaths,1
KYPROLIS,Deaths,Deaths,1
KYPROLIS,Deaths,occurred in patients,0
KYPROLIS,Deaths,Deaths,1
KYPROLIS,Deaths,those years old see,0
KYPROLIS,Deaths,Deaths,1
KYPROLIS,Deaths,Deaths,1
KYPROLIS,Deaths,Use,0
KYPROLIS,cardiac disorders,patients and,0
KYPROLIS,infections,,0
KYPROLIS,infections,Kyprolis monotherapy These adverse events were related to cardiac disorders in patients,0
KYPROLIS,infections,infections,1
KYPROLIS,infections,cardiac disorders in,0
KYPROLIS,infections,related to cardiac disorders,0
KYPROLIS,infections,infections,1
KYPROLIS,infections,disorders in patients,0
KYPROLIS,infections,disorders in infections,1
KYPROLIS,infections,in infections,1
KYPROLIS,infections,adverse events were related to,0
KYPROLIS,renal disorders,in renal,1
KYPROLIS,renal disorders,renal disorders,1
KYPROLIS,renal disorders,disorders,1
KYPROLIS,renal disorders,related to cardiac,0
KYPROLIS,renal disorders,related to cardiac disorders in patients infections,0
KYPROLIS,renal disorders,infections in renal,1
KYPROLIS,mortality,and refractory multiple mortality,1
KYPROLIS,mortality,patients treated with Kyprolis in comparison to the control,0
KYPROLIS,mortality,subgroup o,0
KYPROLIS,mortality,mortality,1
KYPROLIS,mortality,relapsed and refractory multiple myeloma,0
KYPROLIS,acute renal failure,failure,1
KYPROLIS,acute renal failure,acute renal failure,1
KYPROLIS,acute renal failure,acute renal failure,1
KYPROLIS,Pneumonia,Pneumonia,1
KYPROLIS,Pneumonia,Events with Kyprolis Monotherapy Pneumonia,1
KYPROLIS,Pneumonia,Commonly Reported Adverse Events with,0
KYPROLIS,Pneumonia,Events with Kyprolis Monotherapy Pneumonia,1
KYPROLIS,Pneumonia,Pneumonia,1
KYPROLIS,Pneumonia,neuropathies,0
KYPROLIS,Pneumonia,Pneumonia,1
KYPROLIS,Pneumonia,pneumonia bronchopneumonia b Peripheral neuropathies NEC incl,0
KYPROLIS,Pneumonia,with Kyprolis Monotherapy a,0
KYPROLIS,Pneumonia,,0
KYPROLIS,pneumonia,includes the preferred terms pneumonia,1
KYPROLIS,pneumonia,,0
KYPROLIS,pneumonia,pneumonia,1
KYPROLIS,pneumonia,includes the preferred terms pneumonia,1
KYPROLIS,pneumonia,b Peripheral neuropathies NEC includes the preferred terms under HLT periphe,0
KYPROLIS,pneumonia,a Pneumonia,0
KYPROLIS,pneumonia,terms pneumonia,1
KYPROLIS,pneumonia,pneumonia,1
KYPROLIS,pneumonia,preferred terms under HLT periphe,0
KYPROLIS,pneumonia,pneumonia,1
KYPROLIS,bronchopneumonia,preferred terms,0
KYPROLIS,bronchopneumonia,the preferred terms,0
KYPROLIS,Peripheral neuropathies NEC,,0
KYPROLIS,Peripheral neuropathies NEC,pneumonia bronchopneumonia Peripheral neuropathies,1
KYPROLIS,Peripheral neuropathies NEC,terms of pneumonia bronchopneumonia Peripheral neuropathies NEC,1
KYPROLIS,Peripheral neuropathies NEC,,0
KYPROLIS,Peripheral neuropathies NEC,,0
KYPROLIS,Peripheral neuropathies NEC,under HLT peripheral neuropathies NEC c Dyspnea includes the,0
KYPROLIS,peripheral neuropathies NEC,Peripheral neuropathies NEC,0
KYPROLIS,peripheral neuropathies NEC,preferred,0
KYPROLIS,peripheral neuropathies NEC,terms under peripheral neuropathies NEC,1
KYPROLIS,peripheral neuropathies NEC,b Peripheral neuropathies NEC includes the,0
KYPROLIS,peripheral neuropathies NEC,,0
KYPROLIS,peripheral neuropathies NEC,terms under peripheral neuropathies NEC,1
KYPROLIS,Dyspnea,neuropathies NEC Dyspnea,1
KYPROLIS,Dyspnea,includes the prefer,0
KYPROLIS,Dyspnea,Dyspnea,1
KYPROLIS,Dyspnea,Dyspnea,1
KYPROLIS,Dyspnea,terms of dyspnea dyspnea exertional d Hypertension,0
KYPROLIS,dyspnea,dyspnea,1
KYPROLIS,Hypertension,dyspnea exertional Hypertension,1
KYPROLIS,hypertension,,0
KYPROLIS,hypertension,the preferred terms hypertension,1
KYPROLIS,hypertension,terms hypertension,1
KYPROLIS,hypertension,the preferred,0
KYPROLIS,hypertension,hypertension,1
KYPROLIS,hypertension,,0
KYPROLIS,hypertensive crisis,hypertensive emergency,0
KYPROLIS,Anemia,Anemia,1
KYPROLIS,Anemia,Anemia,1
KYPROLIS,Anemia,,0
KYPROLIS,Thrombocytopenia,,0
KYPROLIS,Thrombocytopenia,,0
KYPROLIS,Leukopenia,Leukopenia Gast,1
KYPROLIS,Leukopenia,,0
KYPROLIS,Leukopenia,ia,0
KYPROLIS,Leukopenia,Leukopenia Gast,1
KYPROLIS,Leukopenia,ia,0
KYPROLIS,Vomiting,Vomiting,1
KYPROLIS,Vomiting,,0
KYPROLIS,Vomiting,Vomiting,1
KYPROLIS,Vomiting,Vomiting,1
KYPROLIS,Vomiting,,0
KYPROLIS,Vomiting,Vomiting,1
KYPROLIS,Vomiting,Vomiting,1
KYPROLIS,Constipation,Constipation Genera,1
KYPROLIS,Fatigue,,0
KYPROLIS,Fatigue,,0
KYPROLIS,Fatigue,and Administration Site,0
KYPROLIS,Fatigue,,0
KYPROLIS,Pyrexia,Pyrexia,1
KYPROLIS,Pyrexia,Pyrexia,1
KYPROLIS,Pyrexia,,0
KYPROLIS,Pyrexia,Pyrexia,1
KYPROLIS,Pyrexia,Pyrexia,1
KYPROLIS,Pyrexia,,0
KYPROLIS,Pyrexia,,0
KYPROLIS,Edema Peripheral,,0
KYPROLIS,Edema Peripheral,Edema,1
KYPROLIS,Edema Peripheral,,0
KYPROLIS,Edema Peripheral,Peripheral Chills,1
KYPROLIS,Edema Peripheral,,0
KYPROLIS,Edema Peripheral,,0
KYPROLIS,Edema Peripheral,,0
KYPROLIS,Edema Peripheral,,0
KYPROLIS,Edema Peripheral,,0
KYPROLIS,Edema Peripheral,,0
KYPROLIS,Chills,ipheral,0
KYPROLIS,Chills,ipheral Chills,1
KYPROLIS,Chills,ipheral Chills,1
KYPROLIS,Chills,,0
KYPROLIS,Chills,,0
KYPROLIS,Chills,ipheral Chills,1
KYPROLIS,Asthenia,Asthenia In,1
KYPROLIS,Asthenia,,0
KYPROLIS,Asthenia,In,0
KYPROLIS,Asthenia,,0
KYPROLIS,Asthenia,,0
KYPROLIS,Asthenia,Asthenia In,1
KYPROLIS,Asthenia,,0
KYPROLIS,Upper Respiratory Tract Infection,Infestations,0
KYPROLIS,Upper Respiratory Tract Infection,Upper Respiratory Tract Infection Pneumoniaa,1
KYPROLIS,Upper Respiratory Tract Infection,nd Upper,1
KYPROLIS,Upper Respiratory Tract Infection,nd Upper Respiratory Tract Infection Pneumoniaa,1
KYPROLIS,Upper Respiratory Tract Infection,nd Upper Respiratory,1
KYPROLIS,Upper Respiratory Tract Infection,,0
KYPROLIS,Upper Respiratory Tract Infection,Pneumoniaa,0
KYPROLIS,Upper Respiratory Tract Infection,nd Upper Respiratory Tract Infection Pneumoniaa,1
KYPROLIS,Pneumonia,,0
KYPROLIS,Pneumonia,Met,0
KYPROLIS,Pneumonia,Tract Pneumonia a,1
KYPROLIS,Pneumonia,,0
KYPROLIS,Pneumonia,,0
KYPROLIS,Decreased Appetite,Nutrition Disorders,0
KYPROLIS,Hypercalcemia,Appetite Hypercalcemia Hypo,1
KYPROLIS,Hypercalcemia,,0
KYPROLIS,Hypercalcemia,,0
KYPROLIS,Hypercalcemia,Appetite,0
KYPROLIS,Hypercalcemia,Appetite,0
KYPROLIS,Hypercalcemia,Hypercalcemia Hypo,1
KYPROLIS,Hypercalcemia,Appetite,0
KYPROLIS,Hypercalcemia,Hypercalcemia Hypo,1
KYPROLIS,Hypercalcemia,Appetite,0
KYPROLIS,Hypercalcemia,Hypercalcemia Hypo,1
KYPROLIS,Hypokalemia,Hypokalemia Muscu,1
KYPROLIS,Hypokalemia,Hypokalemia Muscu,1
KYPROLIS,Back Pain,and Connective Tissue,0
KYPROLIS,Back Pain,and Connective Tissue Back Pain,1
KYPROLIS,Back Pain,Disorders,0
KYPROLIS,Back Pain,Connective Tissue,0
KYPROLIS,Back Pain,Back Pain,1
KYPROLIS,Back Pain,Tissue Back,1
KYPROLIS,Back Pain,,0
KYPROLIS,Arthralgia,Arthralgia P,1
KYPROLIS,Pain in Extremity,a Pain,1
KYPROLIS,Pain in Extremity,Pain in Extremity,1
KYPROLIS,Pain in Extremity,a Pain,1
KYPROLIS,Muscle Spasms,,0
KYPROLIS,Muscle Spasms,,0
KYPROLIS,Muscle Spasms,xtremity,0
KYPROLIS,Musculoskeletal Pain,asms Musculoskeletal Pain,1
KYPROLIS,Musculoskeletal Pain,asms,0
KYPROLIS,Musculoskeletal Pain,Musculoskeletal Pain,1
KYPROLIS,Headache,Headache,1
KYPROLIS,Headache,Headache,1
KYPROLIS,Dizziness,Dizziness,1
KYPROLIS,Peripheral Neuropathies NEC,Peripheral,1
KYPROLIS,Peripheral Neuropathies NEC,Peripheral Neuropathies NEC,1
KYPROLIS,Insomnia,Insomnia Re,1
KYPROLIS,Insomnia,Disorders Insomnia Re,1
KYPROLIS,Insomnia,Disorders,0
KYPROLIS,Insomnia,Disorders,0
KYPROLIS,Insomnia,Insomnia Re,1
KYPROLIS,Insomnia,Disorders,0
KYPROLIS,Dyspnea,Mediastinal,0
KYPROLIS,Dyspnea,,0
KYPROLIS,Dyspnea,Dyspnea c,1
KYPROLIS,Cough,,0
KYPROLIS,Cough,Cough,1
KYPROLIS,Epistaxis,Epistaxis Ren,1
KYPROLIS,Epistaxis,Epistaxis Ren,1
KYPROLIS,Epistaxis,,0
KYPROLIS,Renal Failure,ers,0
KYPROLIS,Renal Failure,,0
KYPROLIS,Renal Failure,,0
KYPROLIS,Renal Failure,ers,0
KYPROLIS,Renal Failure,Vascula,0
KYPROLIS,Renal Failure,Renal Failure Vascula,1
KYPROLIS,Renal Failure,ers,0
KYPROLIS,Hypertension,orders,0
KYPROLIS,Hypertension,orders,0
KYPROLIS,febrile neutropenia,infarction myoca,0
KYPROLIS,febrile neutropenia,,0
KYPROLIS,febrile neutropenia,system febrile,1
KYPROLIS,febrile neutropenia,Cardiac disorders cardiac arrest cardiac,0
KYPROLIS,febrile neutropenia,cardiac arrest cardiac failure,0
KYPROLIS,febrile neutropenia,arrest cardiac failure,0
KYPROLIS,febrile neutropenia,neutropenia Cardiac,1
KYPROLIS,febrile neutropenia,febrile neutropenia Cardiac,1
KYPROLIS,febrile neutropenia,infarction,0
KYPROLIS,febrile neutropenia,at a Frequency of Blood and lymphatic system disorders,0
KYPROLIS,cardiac arrest,cata,0
KYPROLIS,cardiac arrest,febrile neutropenia Cardiac cardiac,1
KYPROLIS,cardiac arrest,,0
KYPROLIS,cardiac arrest,arrest cardiac,1
KYPROLIS,cardiac arrest,,0
KYPROLIS,cardiac arrest,cardiac arrest cardiac,1
KYPROLIS,cardiac arrest,neutropenia Cardiac cardiac arrest cardiac,1
KYPROLIS,cardiac failure congestive,neutropenia Cardiac disorders cardiac cardiac failure,1
KYPROLIS,cardiac failure congestive,,0
KYPROLIS,cardiac failure congestive,febrile,0
KYPROLIS,myocardial infarction,neutropenia Cardiac disorders cardiac,0
KYPROLIS,myocardial infarction,Cardiac disorders cardiac arrest,0
KYPROLIS,myocardial infarction,,0
KYPROLIS,myocardial infarction,infarction myocardial,1
KYPROLIS,myocardial infarction,,0
KYPROLIS,myocardial infarction,cataract blurred vision Gastrointestinal,0
KYPROLIS,myocardial infarction,infarction myocardial,1
KYPROLIS,myocardial ischemia,,0
KYPROLIS,myocardial ischemia,ischemia Eye,1
KYPROLIS,myocardial ischemia,failure congestive myocardial infarction,0
KYPROLIS,myocardial ischemia,vision Gastrointestinal disorders,0
KYPROLIS,myocardial ischemia,cardiac failure congestive myocardial myocardial ischemia Eye,1
KYPROLIS,myocardial ischemia,congestive myocardial myocardial ischemia Eye,1
KYPROLIS,myocardial ischemia,,0
KYPROLIS,myocardial ischemia,pain,0
KYPROLIS,myocardial ischemia,abdominal pain,0
KYPROLIS,myocardial ischemia,congestive myocardial myocardial ischemia Eye,1
KYPROLIS,cataract,,0
KYPROLIS,blurred vision,infarction,0
KYPROLIS,blurred vision,,0
KYPROLIS,blurred vision,blurred vision Gastrointestinal,1
KYPROLIS,blurred vision,myocardial ischemia Eye disorders blurred,1
KYPROLIS,blurred vision,Eye disorders blurred,1
KYPROLIS,blurred vision,,0
KYPROLIS,blurred vision,abdominal pain abdominal pain upper,0
KYPROLIS,abdominal pain,pain abdominal,1
KYPROLIS,abdominal pain,disorders and administration,0
KYPROLIS,abdominal pain,Gastrointestinal abdominal pain abdominal,1
KYPROLIS,abdominal pain,cataract blurred vision Gastrointestinal abdominal,1
KYPROLIS,abdominal pain,pain abdominal,1
KYPROLIS,abdominal pain upper,disorders abdominal abdominal pain,1
KYPROLIS,dyspepsia,abdominal pain abdominal pain dyspepsia toothache,1
KYPROLIS,dyspepsia,dyspepsia toothache,1
KYPROLIS,dyspepsia,Gastrointestinal,0
KYPROLIS,dyspepsia,dyspepsia toothache,1
KYPROLIS,dyspepsia,disorders and administration site conditions,0
KYPROLIS,dyspepsia,mu,0
KYPROLIS,dyspepsia,dyspepsia toothache,1
KYPROLIS,dyspepsia,,0
KYPROLIS,dyspepsia,dyspepsia toothache,1
KYPROLIS,toothache,pain upper toothache General,1
KYPROLIS,toothache,,0
KYPROLIS,toothache,upper toothache General,1
KYPROLIS,toothache,toothache General,1
KYPROLIS,infusion site reaction,pain Hepatobiliary disorders hepatic failure Infections and,0
KYPROLIS,infusion site reaction,,0
KYPROLIS,infusion site reaction,infusion site reaction multiorgan,1
KYPROLIS,infusion site reaction,Hepatobiliary disorders hepatic failure Infections and,0
KYPROLIS,infusion site reaction,and administration site infusion,1
KYPROLIS,infusion site reaction,and administration,0
KYPROLIS,infusion site reaction,upper dyspepsia,0
KYPROLIS,infusion site reaction,hepatic failure Infections,0
KYPROLIS,infusion site reaction,,0
KYPROLIS,multi-organ failure,failure pain,1
KYPROLIS,multi-organ failure,Hepatobiliary disorders hepatic failure,0
KYPROLIS,multi-organ failure,site multi-organ failure pain,1
KYPROLIS,multi-organ failure,conditions,0
KYPROLIS,multi-organ failure,bronchi,0
KYPROLIS,pain,infusion site reaction multiorgan pain Hepatobiliary,1
KYPROLIS,pain,,0
KYPROLIS,pain,conditions infusion site reaction multiorgan failure,0
KYPROLIS,pain,multiorgan failure,0
KYPROLIS,pain,and infestations,0
KYPROLIS,pain,pain Hepatobiliary,1
KYPROLIS,pain,pain Hepatobiliary,1
KYPROLIS,hepatic failure,disorders,0
KYPROLIS,hepatic failure,,0
KYPROLIS,hepatic failure,conditions infusion site reaction multiorgan failure pain Hepatobiliary disorders,0
KYPROLIS,bronchitis,disorders hepatic failure Infections and infestations,0
KYPROLIS,bronchitis,pain Hepatobiliary disorders hepatic failure Infections,0
KYPROLIS,bronchitis,,0
KYPROLIS,bronchitis,and infestations,0
KYPROLIS,bronchitis,bronchitis influenza,1
KYPROLIS,bronchitis,bronchitis influenza,1
KYPROLIS,bronchitis,nasopharyngitis respiratory tract infection sepsis urinary,0
KYPROLIS,influenza,infection Metabolism,0
KYPROLIS,nasopharyngitis,Infections and infestations bronchitis nasopharyngitis respiratory,1
KYPROLIS,nasopharyngitis,nasopharyngitis respiratory,1
KYPROLIS,nasopharyngitis,failure Infections and infestations bronchitis influenza,0
KYPROLIS,nasopharyngitis,nasopharyngitis respiratory,1
KYPROLIS,nasopharyngitis,nasopharyngitis respiratory,1
KYPROLIS,nasopharyngitis,,0
KYPROLIS,respiratory tract infection,infection sepsis,1
KYPROLIS,sepsis,Metabolism and nutrition disorders,0
KYPROLIS,sepsis,tract,0
KYPROLIS,sepsis,infection Metabolism and,0
KYPROLIS,sepsis,tract sepsis urinary,1
KYPROLIS,sepsis,urinary tract infection Metabolism and nutrition disorders hyperglycemia hyperkalemia,0
KYPROLIS,sepsis,respiratory tract sepsis urinary,1
KYPROLIS,sepsis,sepsis urinary,1
KYPROLIS,sepsis,disorders,0
KYPROLIS,urinary tract infection,urinary tract infection Metabolism,1
KYPROLIS,urinary tract infection,urinary tract infection Metabolism,1
KYPROLIS,urinary tract infection,infestations bronchitis,0
KYPROLIS,urinary tract infection,hyperglycemia,0
KYPROLIS,urinary tract infection,Metabolism and nutrition,0
KYPROLIS,urinary tract infection,hyperuricemia,0
KYPROLIS,urinary tract infection,urinary tract infection Metabolism,1
KYPROLIS,urinary tract infection,nasopharyngitis respiratory tract infection urinary tract,1
KYPROLIS,urinary tract infection,respiratory tract infection urinary,1
KYPROLIS,urinary tract infection,urinary tract,1
KYPROLIS,hyperglycemia,nutrition hyperglycemia hyperkalemia,1
KYPROLIS,hyperkalemia,hypocalcemia hypomagnesemia hyponatremia hypophosphatemia tumo,0
KYPROLIS,hyperkalemia,,0
KYPROLIS,hyperkalemia,hyperglycemia,0
KYPROLIS,hyperkalemia,nutrition disorders hyperkalemia hyperuricemia,1
KYPROLIS,hyperkalemia,and nutrition,0
KYPROLIS,hyperkalemia,hyperkalemia hyperuricemia,1
KYPROLIS,hyperkalemia,,0
KYPROLIS,hyperkalemia,hyperkalemia hyperuricemia,1
KYPROLIS,hyperkalemia,hypophosphatemia tumo,0
KYPROLIS,hyperkalemia,,0
KYPROLIS,hyperuricemia,and,0
KYPROLIS,hyperuricemia,,0
KYPROLIS,hyperuricemia,hyperuricemia hypoalbuminemia,1
KYPROLIS,hyperuricemia,disorders,0
KYPROLIS,hyperuricemia,hyperuricemia hypoalbuminemia,1
KYPROLIS,hyperuricemia,hyperkalemia,0
KYPROLIS,hyperuricemia,hyperglycemia hyperuricemia hypoalbuminemia,1
KYPROLIS,hypoalbuminemia,,0
KYPROLIS,hypoalbuminemia,syndrome,0
KYPROLIS,hypoalbuminemia,hypoalbuminemia hypocalcemia,1
KYPROLIS,hypoalbuminemia,tumor lysis,0
KYPROLIS,hypoalbuminemia,,0
KYPROLIS,hypoalbuminemia,disorders,0
KYPROLIS,hypoalbuminemia,infection Metabolism and nutrition,0
KYPROLIS,hypoalbuminemia,,0
KYPROLIS,hypocalcemia,hypocalcemia hypomagnesemia,1
KYPROLIS,hypocalcemia,hypocalcemia hypomagnesemia,1
KYPROLIS,hypocalcemia,hypocalcemia hypomagnesemia,1
KYPROLIS,hypocalcemia,hypoalbuminemia,0
KYPROLIS,hyponatremia,,0
KYPROLIS,hypophosphatemia,connective tissue disorders musculoskeletal,0
KYPROLIS,hypophosphatemia,,0
KYPROLIS,hypophosphatemia,hypophosphatemia tumor,1
KYPROLIS,hypophosphatemia,hypoalbuminemia hypocalcemia hypomagnesemia hypophosphatemia tumor,1
KYPROLIS,hypophosphatemia,hypophosphatemia tumor,1
KYPROLIS,hypophosphatemia,hypoalbuminemia hypocalcemia hypomagnesemia hypophosphatemia tumor,1
KYPROLIS,tumor lysis syndrome,musculoskeletal chest,0
KYPROLIS,tumor lysis syndrome,hyponatremia tumor lysis syndrome Musculoskeletal,1
KYPROLIS,tumor lysis syndrome,Musculoskeletal and connective tissue disorders musculoskeletal chest,0
KYPROLIS,tumor lysis syndrome,syndrome Musculoskeletal,1
KYPROLIS,tumor lysis syndrome,hypoalbuminemia hypocalcemia,0
KYPROLIS,musculoskeletal chest pain,disorders,0
KYPROLIS,musculoskeletal chest pain,Psychiatric,0
KYPROLIS,musculoskeletal chest pain,tissue musculoskeletal chest,1
KYPROLIS,myalgia,myalgia Nervous,1
KYPROLIS,myalgia,tissue disorders musculoskeletal chest myalgia Nervous,1
KYPROLIS,myalgia,,0
KYPROLIS,myalgia,,0
KYPROLIS,myalgia,and connective tissue disorders musculoskeletal,0
KYPROLIS,myalgia,system disorders,0
KYPROLIS,myalgia,myalgia Nervous,1
KYPROLIS,myalgia,myalgia Nervous,1
KYPROLIS,myalgia,Nervous system disorders hypoesthesia paresthesia Psychiatric disorders anxiety,0
KYPROLIS,hypoesthesia,chest pain myalgia,0
KYPROLIS,hypoesthesia,,0
KYPROLIS,hypoesthesia,,0
KYPROLIS,hypoesthesia,myalgia Nervous,0
KYPROLIS,hypoesthesia,hypoesthesia paresthesia,1
KYPROLIS,hypoesthesia,,0
KYPROLIS,paresthesia,hypoesthesia,0
KYPROLIS,paresthesia,paresthesia Psychiatric,1
KYPROLIS,renal impairment,urinary renal impairment Respiratory,1
KYPROLIS,renal impairment,urinary renal impairment Respiratory,1
KYPROLIS,renal impairment,impairment Respiratory,1
KYPROLIS,renal impairment,Renal and urinary renal,1
KYPROLIS,renal impairment,Renal and urinary renal,1
KYPROLIS,renal impairment,renal impairment Respiratory,1
KYPROLIS,renal impairment,thoracic and mediastinal disorders dysphonia,0
KYPROLIS,renal impairment,thoracic and mediastinal disorders dysphonia,0
KYPROLIS,dysphonia,pulmonary edema Skin and subcutaneous tissue disorders erythema,0
KYPROLIS,dysphonia,and mediastinal dysphonia oropharyngeal,1
KYPROLIS,dysphonia,dysphonia oropharyngeal,1
KYPROLIS,dysphonia,dysphonia oropharyngeal,1
KYPROLIS,dysphonia,,0
KYPROLIS,dysphonia,and urinary disorders renal impairment Respiratory thoracic and,0
KYPROLIS,dysphonia,impairment Respiratory thoracic,0
KYPROLIS,dysphonia,Respiratory thoracic and mediastinal dysphonia oropharyngeal,1
KYPROLIS,oropharyngeal pain,,0
KYPROLIS,oropharyngeal pain,hyperhidrosis,0
KYPROLIS,oropharyngeal pain,disorders oropharyngeal pain pulmonary,1
KYPROLIS,oropharyngeal pain,,0
KYPROLIS,oropharyngeal pain,pain pulmonary,1
KYPROLIS,oropharyngeal pain,thoracic and mediastinal disorders oropharyngeal,1
KYPROLIS,oropharyngeal pain,mediastinal disorders oropharyngeal pain pulmonary,1
KYPROLIS,oropharyngeal pain,,0
KYPROLIS,oropharyngeal pain,impairment Respiratory thoracic and mediastinal disorders,0
KYPROLIS,pulmonary edema,dysphonia oropharyngeal pulmonary,1
KYPROLIS,erythema,erythema hyperhidrosis,1
KYPROLIS,hyperhidrosis,Skin and subcutaneous tissue disorders,0
KYPROLIS,hyperhidrosis,tissue disorders hyperhidrosis pruritus,1
KYPROLIS,hyperhidrosis,hyperhidrosis pruritus,1
KYPROLIS,hyperhidrosis,,0
KYPROLIS,hyperhidrosis,including,0
KYPROLIS,hyperhidrosis,Skin and subcutaneous tissue disorders,0
KYPROLIS,hyperhidrosis,subcutaneous tissue disorders hyperhidrosis pruritus,1
KYPROLIS,hyperhidrosis,hyperhidrosis pruritus,1
KYPROLIS,pruritus,events,0
KYPROLIS,pruritus,and subcutaneous tissue disorders erythema,0
KYPROLIS,pruritus,vein thromb,0
KYPROLIS,pruritus,erythema pruritus rash,1
KYPROLIS,pruritus,,0
KYPROLIS,pruritus,,0
KYPROLIS,pruritus,,0
KYPROLIS,pruritus,pruritus rash,1
KYPROLIS,rash,rash Vascular,1
KYPROLIS,rash,a,0
KYPROLIS,"embolic and thrombotic events, venous",,0
KYPROLIS,"embolic and thrombotic events, venous",,0
KYPROLIS,"embolic and thrombotic events, venous","events, venous including",1
KYPROLIS,"embolic and thrombotic events, venous",Vascular,0
KYPROLIS,"embolic and thrombotic events, venous",,0
KYPROLIS,"embolic and thrombotic events, venous",,0
KYPROLIS,"embolic and thrombotic events, venous","rash Vascular embolic and thrombotic events, venous including",1
KYPROLIS,"embolic and thrombotic events, venous","hyperhidrosis pruritus rash Vascular embolic and thrombotic events, venous including",1
KYPROLIS,"embolic and thrombotic events, venous","hyperhidrosis pruritus rash Vascular embolic and thrombotic events,",1
KYPROLIS,deep vein thrombosis,and thrombotic events venous including,0
KYPROLIS,deep vein thrombosis,events venous including,0
KYPROLIS,deep vein thrombosis,events venous deep,1
KYPROLIS,pulmonary embolism,thrombosis pulmonary embolism hypotension,1
KYPROLIS,febrile neutropenia,congestive pain sepsis urinary tract,0
KYPROLIS,febrile neutropenia,neutropenia cardiac,1
KYPROLIS,febrile neutropenia,neutropenia cardiac,1
KYPROLIS,febrile neutropenia,an incidence of febrile,1
KYPROLIS,febrile neutropenia,tract infection hyperglycemia,0
KYPROLIS,febrile neutropenia,neutropenia cardiac,1
KYPROLIS,febrile neutropenia,febrile neutropenia cardiac,1
KYPROLIS,cardiac arrest,cardiac arrest cardiac,1
KYPROLIS,cardiac arrest,,0
KYPROLIS,cardiac arrest,,0
KYPROLIS,cardiac arrest,arrest cardiac,1
KYPROLIS,cardiac arrest,include febrile cardiac arrest cardiac,1
KYPROLIS,cardiac failure congestive,of include,0
KYPROLIS,cardiac failure congestive,include febrile neutropenia cardiac cardiac failure congestive pain,1
KYPROLIS,cardiac failure congestive,include febrile neutropenia cardiac cardiac failure congestive pain,1
KYPROLIS,cardiac failure congestive,urinary tract infection,0
KYPROLIS,cardiac failure congestive,congestive pain,1
KYPROLIS,cardiac failure congestive,infection hyperglycemia hyperkalemia hyperuricemia,0
KYPROLIS,cardiac failure congestive,cardiac failure congestive pain,1
KYPROLIS,cardiac failure congestive,failure congestive pain,1
KYPROLIS,cardiac failure congestive,febrile neutropenia cardiac cardiac,1
KYPROLIS,pain,pain sepsis,1
KYPROLIS,pain,incidence of include febrile neutropenia cardiac arrest cardiac failure,0
KYPROLIS,pain,cardiac arrest cardiac failure pain sepsis,1
KYPROLIS,pain,hyperkalemia hyperuricemia,0
KYPROLIS,sepsis,cardiac failure congestive pain,0
KYPROLIS,sepsis,,0
KYPROLIS,sepsis,arrest cardiac failure,0
KYPROLIS,urinary tract infection,infection hyperglycemia,1
KYPROLIS,urinary tract infection,cardiac failure congestive pain urinary tract infection hyperglycemia,1
KYPROLIS,hyperglycemia,hyperglycemia hyperkalemia,1
KYPROLIS,hyperglycemia,,0
KYPROLIS,hyperglycemia,tract hyperglycemia hyperkalemia,1
KYPROLIS,hyperglycemia,hyperglycemia hyperkalemia,1
KYPROLIS,hyperglycemia,hyperglycemia hyperkalemia,1
KYPROLIS,hyperglycemia,hyperglycemia hyperkalemia,1
KYPROLIS,hyperglycemia,hyperglycemia hyperkalemia,1
KYPROLIS,hyperglycemia,hyperglycemia hyperkalemia,1
KYPROLIS,hyperglycemia,hyperglycemia hyperkalemia,1
KYPROLIS,hyperkalemia,hyperkalemia hyperuricemia,1
KYPROLIS,hyperkalemia,sepsis urinary tract infection hyperkalemia hyperuricemia,1
KYPROLIS,hyperkalemia,sepsis urinary,0
KYPROLIS,hyperuricemia,hyperuricemia hypoalbuminemia,1
KYPROLIS,hypoalbuminemia,hypoalbuminemia hypocalcemia,1
KYPROLIS,hypoalbuminemia,renal failure renal failure acute,0
KYPROLIS,hypoalbuminemia,infection hyperglycemia hyperkalemia hypoalbuminemia hypocalcemia,1
KYPROLIS,hypoalbuminemia,hypoalbuminemia hypocalcemia,1
KYPROLIS,hypoalbuminemia,hyponatremia,0
KYPROLIS,hypoalbuminemia,hypoalbuminemia hypocalcemia,1
KYPROLIS,hypoalbuminemia,hyperkalemia hypoalbuminemia hypocalcemia,1
KYPROLIS,hypoalbuminemia,renal failure,0
KYPROLIS,hypoalbuminemia,urinary tract infection,0
KYPROLIS,hypocalcemia,hypocalcemia hyponatremia,1
KYPROLIS,hyponatremia,,0
KYPROLIS,hyponatremia,,0
KYPROLIS,hyponatremia,hyperglycemia hyperkalemia hyperuricemia hypoalbuminemia hyponatremia hypophosphatemia,1
KYPROLIS,hyponatremia,hyponatremia hypophosphatemia,1
KYPROLIS,hyponatremia,renal failure acute renal impairment pulmonary edema,0
KYPROLIS,hyponatremia,hyponatremia hypophosphatemia,1
KYPROLIS,hyponatremia,hyperuricemia hypoalbuminemia hyponatremia hypophosphatemia,1
KYPROLIS,hyponatremia,hyponatremia hypophosphatemia,1
KYPROLIS,hypophosphatemia,,0
KYPROLIS,hypophosphatemia,hypophosphatemia renal,1
KYPROLIS,renal failure,renal failure renal,1
KYPROLIS,renal failure,and hypotension Laboratory Abnorm,0
KYPROLIS,renal failure,hypoalbuminemia hypocalcemia hyponatremia hypophosphatemia,0
KYPROLIS,renal failure,renal,1
KYPROLIS,renal failure,hypoalbuminemia hypocalcemia hyponatremia,0
KYPROLIS,renal failure,failure renal,1
KYPROLIS,renal failure,hypoalbuminemia hypocalcemia hyponatremia renal,1
KYPROLIS,renal failure acute,renal failure,1
KYPROLIS,renal failure acute,hypocalcemia,0
KYPROLIS,renal failure acute,renal failure acute renal,1
KYPROLIS,renal failure acute,,0
KYPROLIS,renal failure acute,renal impairment pulmonary,0
KYPROLIS,renal impairment,edema and,0
KYPROLIS,renal impairment,failure renal impairment pulmonary,1
KYPROLIS,renal impairment,failure renal,0
KYPROLIS,renal impairment,Abnormalities Table describes Gr,0
KYPROLIS,renal impairment,failure renal failure renal impairment pulmonary,1
KYPROLIS,renal impairment,renal failure renal failure renal impairment pulmonary,1
KYPROLIS,renal impairment,renal,1
KYPROLIS,renal impairment,hyponatremia hypophosphatemia renal failure renal,0
KYPROLIS,renal impairment,failure renal failure renal,1
KYPROLIS,renal impairment,,0
KYPROLIS,pulmonary edema,,0
KYPROLIS,pulmonary edema,,0
KYPROLIS,pulmonary edema,renal pulmonary,1
KYPROLIS,pulmonary edema,and hypotension Laboratory Abnormalities Table,0
KYPROLIS,pulmonary edema,Abnormalities Table describes,0
KYPROLIS,pulmonary edema,describes,0
KYPROLIS,pulmonary edema,Grade laborator,0
KYPROLIS,pulmonary edema,renal failure acute renal pulmonary,1
KYPROLIS,pulmonary edema,renal failure acute renal pulmonary,1
KYPROLIS,hypotension,failure acute renal impairment,0
KYPROLIS,hypotension,Laboratory,0
KYPROLIS,hypotension,describes Grade laboratory abnormalities,0
KYPROLIS,hypotension,hypotension Laboratory,1
KYPROLIS,hypotension,hypotension Laboratory,1
KYPROLIS,hypotension,laboratory abnormalities r,0
KYPROLIS,hypotension,hypotension Laboratory,1
KYPROLIS,hypotension,describes Grade laboratory,0
KYPROLIS,Decreased Platelets,,0
KYPROLIS,Decreased Platelets,Reaction Decreased,1
KYPROLIS,Decreased Platelets,Decreased,1
KYPROLIS,Decreased Platelets,,0
KYPROLIS,Decreased Platelets,,0
KYPROLIS,Decreased Lymphocytes,Decreased Lymphocytes Decreased,1
KYPROLIS,Decreased Lymphocytes,,0
KYPROLIS,Decreased Lymphocytes,Decreased,1
KYPROLIS,Decreased Lymphocytes,,0
KYPROLIS,Decreased Lymphocytes,Hemoglobin,0
KYPROLIS,Decreased Hemoglobin,Decreased Total White Bloo,0
KYPROLIS,Decreased Hemoglobin,White Bloo,0
KYPROLIS,Decreased Hemoglobin,Decreased Decreased,1
KYPROLIS,Decreased Hemoglobin,Decreased Decreased,1
KYPROLIS,Decreased Hemoglobin,Hemoglobin Decreased,1
KYPROLIS,Decreased Hemoglobin,Hemoglobin Decreased,1
KYPROLIS,Decreased Hemoglobin,Hemoglobin Decreased,1
KYPROLIS,Decreased Hemoglobin,Decreased,1
KYPROLIS,Decreased Hemoglobin,Decreased Decreased Hemoglobin Decreased,1
KYPROLIS,Decreased Total White Blood Cell Count,Decreased,0
KYPROLIS,Decreased Total White Blood Cell Count,Hemoglobin,0
KYPROLIS,Decreased Total White Blood Cell Count,,0
KYPROLIS,Decreased Sodium,Cell,0
KYPROLIS,Decreased Sodium,Decreased Sodium Decreased,1
KYPROLIS,Decreased Sodium,Decreased,1
KYPROLIS,Decreased Sodium,Total White,0
KYPROLIS,Decreased Sodium,Absolute Neu,0
KYPROLIS,Decreased Absolute Neutrophil Count,Decreased Absolute Neutrophil Count Postmarketing,1
KYPROLIS,Decreased Absolute Neutrophil Count,,0
KYPROLIS,Decreased Absolute Neutrophil Count,,0
KYPROLIS,Decreased Absolute Neutrophil Count,Postmarketing Experience,0
KYPROLIS,Decreased Absolute Neutrophil Count,,0
KYPROLIS,Decreased Absolute Neutrophil Count,,0
KYPROLIS,Decreased Absolute Neutrophil Count,Absolute Neutrophil Count Postmarketing,1
KYPROLIS,Decreased Absolute Neutrophil Count,,0
KYPROLIS,Decreased Absolute Neutrophil Count,Neutrophil Count Postmarketing,1
KYPROLIS,Decreased Absolute Neutrophil Count,Sodium,0
KYPROLIS,dehydration,estimate their frequency or establish a causal relationship to drug exposure,0
KYPROLIS,dehydration,relationship to drug,0
KYPROLIS,dehydration,,0
KYPROLIS,thrombotic thrombocytopenic purpura,purpura hemolytic,1
KYPROLIS,thrombotic thrombocytopenic purpura,drug exposure thrombotic thrombocytopenic,1
KYPROLIS,thrombotic thrombocytopenic purpura,uremic syndrome TTPHUS tumor lysis syndrome including fatal outcomes,0
KYPROLIS,thrombotic thrombocytopenic purpura,,0
KYPROLIS,thrombotic thrombocytopenic purpura,thrombotic thrombocytopenic purpura hemolytic,1
KYPROLIS,thrombotic thrombocytopenic purpura,thrombotic thrombocytopenic purpura hemolytic,1
KYPROLIS,thrombotic thrombocytopenic purpura,uremic syndrome TTPHUS tumor lysis syndrome,0
KYPROLIS,thrombotic thrombocytopenic purpura,fatal,0
KYPROLIS,hemolytic uremic syndrome,thrombotic thrombocytopenic purpura,0
KYPROLIS,hemolytic uremic syndrome,hemolytic uremic syndrome TTPHUS,1
KYPROLIS,hemolytic uremic syndrome,causal relationship to,0
KYPROLIS,hemolytic uremic syndrome,thrombotic thrombocytopenic hemolytic uremic syndrome TTPHUS,1
KYPROLIS,hemolytic uremic syndrome,outcomes and posterior reversible encephalopathy,0
KYPROLIS,hemolytic uremic syndrome,hemolytic,1
KYPROLIS,hemolytic uremic syndrome,syndrome TTPHUS,1
KYPROLIS,hemolytic uremic syndrome,tumor lysis syndrome,0
KYPROLIS,TTP,uremic TTP HUS,1
KYPROLIS,HUS,HUS tumor,1
KYPROLIS,HUS,HUS tumor,1
KYPROLIS,HUS,outcomes and posterior reversible encephalopathy syndrome,0
KYPROLIS,HUS,thrombotic thrombocytopenic purpurahemolytic uremic syndrome,0
KYPROLIS,tumor lysis syndrome,purpurahemolytic uremic syndrome TTPHUS,0
KYPROLIS,tumor lysis syndrome,uremic,0
KYPROLIS,tumor lysis syndrome,uremic syndrome tumor lysis syndrome including,1
KYPROLIS,fatal,lysis syndrome fatal outcomes,1
KYPROLIS,fatal,outcomes and posterior,0
KYPROLIS,fatal,tumor lysis syndrome fatal outcomes,1
KYPROLIS,fatal,syndrome TTPHUS tumor lysis syndrome including,0
KYPROLIS,fatal,thrombocytopenic purpurahemolytic uremic syndrome TTPHUS,0
KYPROLIS,fatal,PRES,0
KYPROLIS,fatal,,0
KYPROLIS,posterior reversible encephalopathy syndrome,syndrome,0
KYPROLIS,posterior reversible encephalopathy syndrome,lysis,0
KYPROLIS,posterior reversible encephalopathy syndrome,fatal outcomes posterior reversible encephalopathy,1
KYPROLIS,posterior reversible encephalopathy syndrome,reversible encephalopathy syndrome PRES,1
KYPROLIS,posterior reversible encephalopathy syndrome,encephalopathy syndrome PRES,1
KYPROLIS,posterior reversible encephalopathy syndrome,syndrome including fatal outcomes,0
KYPROLIS,posterior reversible encephalopathy syndrome,,0
KYPROLIS,posterior reversible encephalopathy syndrome,,0
KYPROLIS,posterior reversible encephalopathy syndrome,including fatal outcomes posterior reversible,1
KYPROLIS,PRES,lysis syndrome,0
KYPROLIS,PRES,PRES,1
KYPROLIS,Cardiac toxicities,ions are discussed in greater detail in other,1
KYPROLIS,Cardiac toxicities,in other sections of the,0
KYPROLIS,Cardiac toxicities,ions are discussed in greater detail in,1
KYPROLIS,Cardiac toxicities,ions are discussed,1
KYPROLIS,cardiac failure,er detail in,1
KYPROLIS,cardiac failure,,0
KYPROLIS,cardiac failure,,0
KYPROLIS,cardiac failure,er detail in ot her sections of,1
KYPROLIS,cardiac failure,er detail in ot,1
KYPROLIS,myocardial infarction,Failur,0
KYPROLIS,myocardial infarction,other ections of,1
KYPROLIS,fatal,see Warnings and Precautions Acute,0
KYPROLIS,fatal,,0
KYPROLIS,fatal,in greater detail,0
KYPROLIS,myocardial ischemia,discussed in greater detail in other,0
KYPROLIS,myocardial ischemia,Warnin,1
KYPROLIS,myocardial ischemia,Failure,0
KYPROLIS,myocardial ischemia,Precautions,0
KYPROLIS,Tumor Lysis Syndrome,and,0
KYPROLIS,Tumor Lysis Syndrome,e,1
KYPROLIS,TLS,and Precautions Tumor,0
KYPROLIS,TLS,Warnings,0
KYPROLIS,TLS,see Warnings and,0
KYPROLIS,TLS,Pulmonary,0
KYPROLIS,TLS,,0
KYPROLIS,TLS,and ion,1
KYPROLIS,TLS,Lysis,0
KYPROLIS,TLS,,0
KYPROLIS,TLS,ion,1
KYPROLIS,Pulmonary Toxicity,Hypertension see Warnings d Precautions (,1
KYPROLIS,Pulmonary Toxicity,Dyspnea see Warnings and Precautions Hypertension see Warnings,0
KYPROLIS,Pulmonary Toxicity,d Precautions,1
KYPROLIS,Pulmonary Toxicity,Precautions Hypertension,0
KYPROLIS,Pulmonary Toxicity,Precautions ( 5,1
KYPROLIS,Pulmonary Toxicity,Warnings d Precautions (,1
KYPROLIS,Pulmonary Toxicity,see Warnings an,0
KYPROLIS,Pulmonary Toxicity,Warnings,0
KYPROLIS,Acute Respiratory Distress Syndrome,see Warnings and Precautions Venous,0
KYPROLIS,Acute Respiratory Distress Syndrome,Pulmonary Hypertension see Warnings and,0
KYPROLIS,Acute Respiratory Distress Syndrome,and Preca,1
KYPROLIS,Acute Respiratory Distress Syndrome,Warnings and Dyspnea [ see Warnings and,1
KYPROLIS,acute respiratory failure,and Precaut,0
KYPROLIS,acute respiratory failure,and Precautions Dyspnea see Warnings and Precaut,0
KYPROLIS,acute respiratory failure,Dyspnea see Warnings and ions ( 5.6 ) ],1
KYPROLIS,acute respiratory failure,Dyspnea see Warnings and ions ( 5.6,1
KYPROLIS,acute respiratory failure,,0
KYPROLIS,acute respiratory failure,see,0
KYPROLIS,acute diffuse infiltrative pulmonary disease,Reactions,0
KYPROLIS,acute diffuse infiltrative pulmonary disease,Reactions,0
KYPROLIS,acute diffuse infiltrative pulmonary disease,Warnings,0
KYPROLIS,acute diffuse infiltrative pulmonary disease,Precautions nsion [ see Warnings and Precautions,1
KYPROLIS,acute diffuse infiltrative pulmonary disease,Hyperte,0
KYPROLIS,acute diffuse infiltrative pulmonary disease,Precautions,0
KYPROLIS,acute diffuse infiltrative pulmonary disease,and Precautions nsion [ see Warnings and Precautions (,1
KYPROLIS,acute diffuse infiltrative pulmonary disease,5.7,1
KYPROLIS,Pulmonary Hypertension,s (,1
KYPROLIS,Pulmonary Hypertension,Warnings and s,1
KYPROLIS,Pulmonary Hypertension,see Warnings and s ( 5.8,1
KYPROLIS,Pulmonary Hypertension,Warnings and Precautions Thrombocytopenia see Warni,0
KYPROLIS,Pulmonary Hypertension,Warni,0
KYPROLIS,Pulmonary Hypertension,Venous Thrombosis see,0
KYPROLIS,Pulmonary Hypertension,"Thrombosis see Warnings and s (  5.8  ) ] 
 *    I",1
KYPROLIS,Pulmonary Hypertension,] * I,1
KYPROLIS,Pulmonary Hypertension,see Warnings and Precaution,0
KYPROLIS,Dyspnea,    5.9,1
KYPROLIS,Dyspnea,see Warnings and     5.9,1
KYPROLIS,hypertensive crisis,ilure,1
KYPROLIS,hypertensive crisis,Thrombotic Thrombocytopenic PurpuraHemolytic Uremic Synd,0
KYPROLIS,hypertensive crisis,,0
KYPROLIS,hypertensive crisis,,0
KYPROLIS,hypertensive crisis,Fa,0
KYPROLIS,hypertensive crisis,Toxicity and,0
KYPROLIS,hypertensive crisis,gs and Precautions Thrombotic Thrombocytopenic PurpuraHemolytic Uremic Synd,0
KYPROLIS,hypertensive crisis,Hepatic,0
KYPROLIS,Venous Thrombosis,and Precautions,0
KYPROLIS,Venous Thrombosis,Uremic,0
KYPROLIS,Venous Thrombosis,Precautions Reversible,1
KYPROLIS,Venous Thrombosis,com,0
KYPROLIS,Infusion Reactions,PRES see Warnings and s (,1
KYPROLIS,Infusion Reactions,s,1
KYPROLIS,Infusion Reactions,adverse events occurring in at least of patients treated with Ky,0
KYPROLIS,Infusion Reactions,,0
KYPROLIS,Infusion Reactions,5.13 )],1
KYPROLIS,Infusion Reactions,"see Warnings and s (   5.13   )] 
 ",1
KYPROLIS,Infusion Reactions,"PRES see Warnings and s (   5.13   )] 
 ",1
KYPROLIS,Infusion Reactions,"Warnings and s (   5.13   )] 
 ",1
KYPROLIS,Thrombocytopenia,occurring at,1
KYPROLIS,Thrombocytopenia,events,0
KYPROLIS,Thrombocytopenia,occurring at least,1
KYPROLIS,Thrombocytopenia,adverse events occurring at least,1
KYPROLIS,Thrombocytopenia,thrombocytopenia,0
KYPROLIS,Thrombocytopenia,occurring at least,1
KYPROLIS,Thrombocytopenia,at least 20% of,1
KYPROLIS,Thrombocytopenia,at least 20% of ,1
KYPROLIS,Thrombocytopenia,events occurring at least 20% of ,1
KYPROLIS,Hepatic Toxicity,,0
KYPROLIS,Hepatic Toxicity,peripheral,0
KYPROLIS,Hepatic Toxicity,"d platelets, dys",1
KYPROLIS,Hepatic Toxicity,thrombocytopenia nausea pyrexia d,1
KYPROLIS,Hepatic Toxicity,lymphocyte headache,0
KYPROLIS,Hepatic Toxicity,"thrombocytopenia nausea pyrexia d platelets, dys",1
KYPROLIS,Hepatic Toxicity,"nausea pyrexia d platelets, dys",1
KYPROLIS,Hepatic Failure,"diarrhea, decr",1
KYPROLIS,Hepatic Failure,decr,1
KYPROLIS,Hepatic Failure,decreased hemoglobin cough,0
KYPROLIS,Hepatic Failure," diarrhea, decr",1
KYPROLIS,Hepatic Failure,"decreased platelets  diarrhea, decr",1
KYPROLIS,Hepatic Failure,"diarrhea, decr",1
KYPROLIS,Hepatic Failure," diarrhea, decr",1
KYPROLIS,Hepatic Failure,"diarrhea,",1
KYPROLIS,Hepatic Failure,"pyrexia decreased platelets  diarrhea, decr",1
KYPROLIS,hemolytic uremic syndrome,,0
KYPROLIS,hemolytic uremic syndrome,l,1
KYPROLIS,hemolytic uremic syndrome,most common  events occurring in at l,1
KYPROLIS,hemolytic uremic syndrome,edema peripheral,0
KYPROLIS,hemolytic uremic syndrome,,0
KYPROLIS,hemolytic uremic syndrome,common events occurring in,1
KYPROLIS,hemolytic uremic syndrome,most common adverse,0
KYPROLIS,hemolytic uremic syndrome,peripheral The most common,0
KYPROLIS,hemolytic uremic syndrome,in the,0
KYPROLIS,hemolytic uremic syndrome, events occurring in at l,1
KYPROLIS,TTP,,0
KYPROLIS,TTP,lea,0
KYPROLIS,TTP,,0
KYPROLIS,TTP,common adverse events occurring in at,0
KYPROLIS,TTP,lymphocytes,0
KYPROLIS,TTP,events,0
KYPROLIS,TTP,,0
KYPROLIS,HUS,0% ,1
KYPROLIS,Posterior reversible encephalopathy syndrome,,0
KYPROLIS,Posterior reversible encephalopathy syndrome,"therapy trial decreased lymphocytes d absolute neutrophil count, decreased phosp",1
KYPROLIS,Posterior reversible encephalopathy syndrome,platelets diarrhea f,0
KYPROLIS,Embryo-fetal Toxicity,"thrombocytopenia pyrexia muscle spasm ough,",1
KYPROLIS,Embryo-fetal Toxicity,decreased platelets diarrhea fatigue thrombocytopenia pyrexia muscle,0
KYPROLIS,Embryo-fetal Toxicity,hypokalemia,0
KYPROLIS,Embryo-fetal Toxicity,muscle spasm c,0
KYPROLIS,Embryo-fetal Toxicity,diarrhea,0
KYPROLIS,Embryo-fetal Toxicity,,0
KYPROLIS,worsening of pre-existing cardiac failure,clinical trials are,0
KYPROLIS,worsening of pre-existing cardiac failure,Amgen,0
KYPROLIS,worsening of pre-existing cardiac failure,conducted under,0
KYPROLIS,worsening of pre-existing cardiac failure,"at A-1088 or    www.fda.gov/medwatch    .  
",1
KYPROLIS,congestive heart failure,,0
KYPROLIS,congestive heart failure,at FDA or,0
KYPROLIS,congestive heart failure,Clinical Trials Expe,1
KYPROLIS,congestive heart failure,or wwwfdagovmedwatch,0
KYPROLIS,congestive heart failure,Expe,1
KYPROLIS,pulmonary edema,"Clinical Trials ence

  Because",1
KYPROLIS,pulmonary edema,"ence

  Because",1
KYPROLIS,pulmonary edema,"Clinical Trials ence

  Because",1
KYPROLIS,decreased ejection fraction,linical trials are conducte,1
KYPROLIS,decreased ejection fraction,Clinical Trials Experience Because linical trials are conducte,1
KYPROLIS,decreased ejection fraction,,0
KYPROLIS,decreased ejection fraction,Experience Because linical trials are conducte,1
KYPROLIS,decreased ejection fraction,are conducte,1
KYPROLIS,decreased ejection fraction,Clinical Trials Experience Because linical trials,1
KYPROLIS,decreased ejection fraction,linical trials are conducte,1
KYPROLIS,restrictive cardiomyopathy,clinical trials are conducted u,0
KYPROLIS,restrictive cardiomyopathy,nder widely varying condit,1
KYPROLIS,restrictive cardiomyopathy,conducted nder widely varying condit,1
KYPROLIS,restrictive cardiomyopathy,Clinical Trials Experience Because clinical trials are,0
KYPROLIS,myocardial ischemia,"varying ns,",1
KYPROLIS,myocardial ischemia,trials are,0
KYPROLIS,myocardial ischemia,are,0
KYPROLIS,myocardial ischemia,are conducted under widely,0
KYPROLIS,myocardial ischemia,"widely varying ns, adverse reactio",1
KYPROLIS,myocardial infarction,trials of a drug cannot be directly compared with rates in the clinical trials of another,0
KYPROLIS,myocardial infarction,the,0
KYPROLIS,myocardial infarction,observed in the cli,1
KYPROLIS,myocardial infarction,,0
KYPROLIS,myocardial infarction,reaction rate,0
KYPROLIS,myocardial infarction,varying conditions adverse reaction s observed,1
KYPROLIS,myocardial infarction,observed in the cli,1
KYPROLIS,myocardial infarction,conditions adverse reaction s observed in the,1
KYPROLIS,myocardial infarction,a drug cannot be directly compared with rates in the clinical trials of another,0
KYPROLIS,myocardial infarction,adverse reaction s observed in the cli,1
KYPROLIS,fatalities,the clinical s of a dru,1
KYPROLIS,fatalities,in the clinical trials of,0
KYPROLIS,fatalities,s of a dru,1
KYPROLIS,fatalities,of a dru,1
KYPROLIS,fatalities,clinical s of,1
KYPROLIS,fatalities,,0
KYPROLIS,fatalities,the clinical s of a dru,1
KYPROLIS,fatalities,s,1
KYPROLIS,Death,Safety Experience ith,1
KYPROLIS,Death,Combination with,0
KYPROLIS,cardiac arrest,Combination,1
KYPROLIS,cardiac arrest,Experience with in,1
KYPROLIS,Renal insufficiency adverse events,to any,0
KYPROLIS,renal impairment,"tract infection versus pyrexia s 2%), and",1
KYPROLIS,renal impairment,"tract infection versus pyrexia s 2%), and pulmo",1
KYPROLIS,renal impairment,"tract infection versus pyrexia s 2%), and pulmo",1
KYPROLIS,renal failure,tract,0
KYPROLIS,Acute renal failure,KRd arm versus in,0
KYPROLIS,Acute renal failure,and the most common events includ,0
KYPROLIS,Acute renal failure,in the Rd rm.,1
KYPROLIS,Acute renal failure,any adverse event occurred in in the KRd arm,0
KYPROLIS,Acute renal failure,of Kyprolis occurred in of patients and the,0
KYPROLIS,Acute renal failure,most common events,0
KYPROLIS,tumor lysis syndrome,"e,and",1
KYPROLIS,tumor lysis syndrome,Occurring in Cycles Combination Therapy KRd Kyprolis lenalidomid,0
KYPROLIS,tumor lysis syndrome,p,0
KYPROLIS,tumor lysis syndrome,Kyprolis lenalidomid,0
KYPROLIS,tumor lysis syndrome,Occurring in Cycles Combination Therapy KRd Kyprolis lenalidomid,0
KYPROLIS,tumor lysis syndrome,a Pneumonia,0
KYPROLIS,tumor lysis syndrome,dexam,1
KYPROLIS,TLS,has,1
KYPROLIS,TLS,KRd Kyprolis lenalidomideand lowdose,0
KYPROLIS,TLS,lowdose dexamethasone a,0
KYPROLIS,TLS,,0
KYPROLIS,TLS,terms of,0
KYPROLIS,TLS,KRd Kyprolis,0
KYPROLIS,TLS,has,1
KYPROLIS,fatal,lowdose dexamethasone Rd alido,1
KYPROLIS,fatal,lenalidomideand lowdose dexamethasone Rd alido,1
KYPROLIS,fatal,and lowdose dexamethasone a Pneumonia includes preferred,0
KYPROLIS,fatal,alido,1
KYPROLIS,fatal,Rd,0
KYPROLIS,fatal,alido,1
KYPROLIS,fatal,dexamethasone,0
KYPROLIS,fatal,Kyprolis lenalidomideand,0
KYPROLIS,fatal,Rd alido,1
KYPROLIS,fatal,alido,1
KYPROLIS,Acute Respiratory Distress Syndrome,"389)    
  Preferred Term          ",1
KYPROLIS,Acute Respiratory Distress Syndrome,389) Preferred,1
KYPROLIS,Acute Respiratory Distress Syndrome,ArmN Rd ArmN,0
KYPROLIS,Acute Respiratory Distress Syndrome,Class KRd,0
KYPROLIS,Acute Respiratory Distress Syndrome,,0
KYPROLIS,Acute Respiratory Distress Syndrome,,0
KYPROLIS,Acute Respiratory Distress Syndrome,"389)    
  Preferred Term          ",1
KYPROLIS,Acute Respiratory Distress Syndrome,emergency System Organ,0
KYPROLIS,Acute Respiratory Distress Syndrome,Class KRd ArmN Rd ArmN,0
KYPROLIS,ARDS,,0
KYPROLIS,ARDS,,0
KYPROLIS,ARDS,,0
KYPROLIS,ARDS,    ,1
KYPROLIS,ARDS,    ,1
KYPROLIS,ARDS,Grade,0
KYPROLIS,ARDS,Rd ArmN Preferred     ,1
KYPROLIS,ARDS,    ,1
KYPROLIS,acute respiratory failure,,0
KYPROLIS,acute respiratory failure,ArmN Preferred                  Any Grad,1
KYPROLIS,acute respiratory failure,Grad,1
KYPROLIS,acute respiratory failure,,0
KYPROLIS,acute diffuse infiltrative pulmonary disease,ArmN Preferred,0
KYPROLIS,acute diffuse infiltrative pulmonary disease,and Lymphatic,0
KYPROLIS,acute diffuse infiltrative pulmonary disease,ArmN Preferred Term Any >= Grade 3,1
KYPROLIS,acute diffuse infiltrative pulmonary disease,Preferred Term Any      >= Grade 3       Any Grade          >= ,1
KYPROLIS,acute diffuse infiltrative pulmonary disease,Lymphatic,0
KYPROLIS,acute diffuse infiltrative pulmonary disease,>=,1
KYPROLIS,pneumonitis,"Grade Any Grade      
  Blo",1
KYPROLIS,pneumonitis,od,0
KYPROLIS,pneumonitis,Grade Any Grade,0
KYPROLIS,pneumonitis,,0
KYPROLIS,pneumonitis,Disorders,0
KYPROLIS,pneumonitis,Grade,0
KYPROLIS,pneumonitis,"     
  Blo",1
KYPROLIS,pneumonitis,"     
  Blo",1
KYPROLIS,pneumonitis,Grade Grade Any Grade Grade,0
KYPROLIS,interstitial lung disease,Grade Blood d,1
KYPROLIS,interstitial lung disease,Grade,0
KYPROLIS,interstitial lung disease,d Lymphatic,1
KYPROLIS,fatal,nemia,1
KYPROLIS,fatal,,0
KYPROLIS,fatal,,0
KYPROLIS,fatal,,0
KYPROLIS,fatal,nemia,1
KYPROLIS,fatal,nemia,1
KYPROLIS,fatal,System Disorders nemia,1
KYPROLIS,fatal,nemia,1
KYPROLIS,fatal,System Disorders nemia,1
KYPROLIS,Pulmonary arterial hypertension,Neutropenia        104 (27%)       115 (30% Thrombocytopenia,1
KYPROLIS,Pulmonary arterial hypertension,Neutropenia,0
KYPROLIS,Pulmonary arterial hypertension,115 (30% Thrombocytopenia,1
KYPROLIS,Pulmonary arterial hypertension,Neutropenia 104 (27%) 115,1
KYPROLIS,Pulmonary arterial hypertension,,0
KYPROLIS,Pulmonary arterial hypertension,,0
KYPROLIS,Pulmonary arterial hypertension,104 (27%) 115 (30% Thrombocytopenia,1
KYPROLIS,Pulmonary arterial hypertension,Neutropenia 104 (27%),1
KYPROLIS,Pulmonary arterial hypertension,Thrombocytopenia,0
KYPROLIS,Pulmonary arterial hypertension,(27%) 115 (30% Thrombocytopenia,1
KYPROLIS,PAH,    Thrombocytopenia,1
KYPROLIS,PAH,Neutropenia     Thrombocytopenia,1
KYPROLIS,PAH,Neutropenia,0
KYPROLIS,PAH,Thrombocytopenia,0
KYPROLIS,PAH,Neutropenia,0
KYPROLIS,PAH,Neutropenia,0
KYPROLIS,PAH,Neutropenia     Thrombocytopenia,1
KYPROLIS,PAH,    Thrombocytopenia,1
KYPROLIS,Dyspnea,Constipation,0
KYPROLIS,Dyspnea,Constipation      0  Nausea,1
KYPROLIS,Dyspnea,     0  Nausea,1
KYPROLIS,Dyspnea,Constipation,0
KYPROLIS,Dyspnea,,0
KYPROLIS,Dyspnea,,0
KYPROLIS,Dyspnea,Constipation,0
KYPROLIS,Dyspnea,Constipation,0
KYPROLIS,Dyspnea,Constipation,0
KYPROLIS,hypertensive crisis,,0
KYPROLIS,hypertensive crisis,,0
KYPROLIS,hypertensive crisis,57 (15%) Asthenia,1
KYPROLIS,hypertensive crisis,,0
KYPROLIS,hypertensive crisis,57 (15%) Asthenia,1
KYPROLIS,hypertensive crisis,Peripheral,0
KYPROLIS,hypertensive emergency,,0
KYPROLIS,hypertensive emergency,(1%) As thenia,1
KYPROLIS,hypertensive emergency,Edema (1%),1
KYPROLIS,hypertensive emergency,,0
KYPROLIS,hypertensive emergency,,0
KYPROLIS,hypertensive emergency,Edema (1%),1
KYPROLIS,fatal,Asthenia,0
KYPROLIS,fatal,Asthenia,0
KYPROLIS,fatal,      Infections and,1
KYPROLIS,fatal,Asthenia,0
KYPROLIS,fatal,      Infections,1
KYPROLIS,fatal,Asthenia      ,1
KYPROLIS,fatal,Asthenia,0
KYPROLIS,fatal,Infections,0
KYPROLIS,fatal,and Infestations,0
KYPROLIS,Venous thromboembolic events,Nasopharyngitis                         63 ( Bronchitis,1
KYPROLIS,deep venous thrombosis,,0
KYPROLIS,deep venous thrombosis,Nasopharyngitis 0               43 (11 Bronchitis,1
KYPROLIS,deep venous thrombosis,43 (11 Bronchitis,1
KYPROLIS,deep venous thrombosis,,0
KYPROLIS,deep venous thrombosis,Nasopharyngitis 0 43,1
KYPROLIS,deep venous thrombosis,(11 Bronchitis,1
KYPROLIS,deep venous thrombosis,Nasopharyngitis 0 43,1
KYPROLIS,pulmonary embolism,Nasopharyngitis,0
KYPROLIS,pulmonary embolism,     0             Bronchitis,1
KYPROLIS,pulmonary embolism,     0             Bronchitis,1
KYPROLIS,venous thromboembolic events,Bronchitis       39 (10%)        2 (1%) Pneumoniaa,1
KYPROLIS,venous thromboembolic events,Bronchitis,0
KYPROLIS,venous thromboembolic events,(1%) Pneumoniaa,1
KYPROLIS,venous thromboembolic events,(10%) 2 (1%) Pneumoniaa,1
KYPROLIS,venous thromboembolic events,39 (10%) 2 (1%) Pneumoniaa,1
KYPROLIS,venous thromboembolic events,Bronchitis,0
KYPROLIS,venous thromboembolic events,Bronchitis 39 (10%) 2,1
KYPROLIS,venous thromboembolic events,Hypokalemia,0
KYPROLIS,venous thromboembolic events,,0
KYPROLIS,Infusion reactions,,0
KYPROLIS,Infusion reactions,,0
KYPROLIS,fever,Hyperglycem,0
KYPROLIS,fever,,0
KYPROLIS,fever,ia    Muscu,1
KYPROLIS,fever,Hyperglycem,0
KYPROLIS,fever,ia    Muscu,1
KYPROLIS,fever,ia    Muscu,1
KYPROLIS,fever,,0
KYPROLIS,fever,Hyperglycem ia    Muscu,1
KYPROLIS,fever,ia    Muscu,1
KYPROLIS,fever,Hyperglycem,0
KYPROLIS,chills,       Musculoskelet,1
KYPROLIS,chills,,0
KYPROLIS,chills,Musculoskelet,0
KYPROLIS,arthralgia,Hyperglycemia,0
KYPROLIS,arthralgia,           Musculoskeletal,1
KYPROLIS,arthralgia,Hyperglycemia           ,1
KYPROLIS,arthralgia,           Musculoskeletal,1
KYPROLIS,arthralgia,           Musculoskeletal,1
KYPROLIS,arthralgia,Hyperglycemia,0
KYPROLIS,arthralgia,and,0
KYPROLIS,arthralgia,           Musculoskeletal and Conne,1
KYPROLIS,arthralgia,Hyperglycemia,0
KYPROLIS,arthralgia,           Musculoskeletal and Conne,1
KYPROLIS,myalgia,,0
KYPROLIS,myalgia,Hyperglycemia,0
KYPROLIS,myalgia,Hyperglycemia,0
KYPROLIS,myalgia,      4,1
KYPROLIS,myalgia,Musculoskeletal,0
KYPROLIS,myalgia,      4,1
KYPROLIS,myalgia,      4 Musculoskeletal,1
KYPROLIS,myalgia,Hyperglycemia       4 Musculoskeletal and,1
KYPROLIS,myalgia,      4 Musculoskeletal and Connective Tis,1
KYPROLIS,myalgia,      4 Musculoskeletal and Connective,1
KYPROLIS,facial flushing,Hyperglycemia (11%),1
KYPROLIS,facial flushing,Disorders,0
KYPROLIS,facial edema,Hyperglycemia 5%)          Musculoskeletal and Connective,1
KYPROLIS,facial edema,5%)          Musculoskeletal and Connective,1
KYPROLIS,facial edema,5%)          Musculoskeletal,1
KYPROLIS,facial edema,5%)          Musculoskeletal and,1
KYPROLIS,facial edema,Tissue Disorders,0
KYPROLIS,facial edema,Connective Tissue Disorders,0
KYPROLIS,facial edema,5%)         ,1
KYPROLIS,facial edema,Disorders,0
KYPROLIS,vomiting,Hyperglycemia  (9%)   ,1
KYPROLIS,vomiting,Hyperglycemia,0
KYPROLIS,vomiting,Connective Tissue Disorders,0
KYPROLIS,vomiting,Disorders,0
KYPROLIS,vomiting,Hyperglycemia  (9%)    Musculoskeletal and Connective Tissue Disorders,1
KYPROLIS,vomiting,Connective,0
KYPROLIS,vomiting, (9%)   ,1
KYPROLIS,vomiting, (9%)    Musculoskeletal and Connective Tissue,1
KYPROLIS,vomiting,Hyperglycemia  (9%)    Musculoskeletal and Connective Tissue Disorders,1
KYPROLIS,weakness,,0
KYPROLIS,weakness,Connective Tissue,0
KYPROLIS,weakness,Hyperglycemia 15,1
KYPROLIS,weakness,Hyperglycemia 15,1
KYPROLIS,weakness,Hyperglycemia 15,1
KYPROLIS,weakness,,0
KYPROLIS,weakness,Hyperglycemia 15,1
KYPROLIS,weakness,Hyperglycemia,0
KYPROLIS,weakness,,0
KYPROLIS,shortness of breath,Hyperglycemia,0
KYPROLIS,hypotension,Musculos,0
KYPROLIS,hypotension,Musculos keletal,1
KYPROLIS,hypotension,Tissue Disorders,0
KYPROLIS,hypotension,Musculos,0
KYPROLIS,hypotension,keletal and Connective,1
KYPROLIS,hypotension,Musculos,0
KYPROLIS,hypotension,Musculos,0
KYPROLIS,hypotension,Musculos,0
KYPROLIS,syncope,Tissue Disorders,0
KYPROLIS,syncope,,0
KYPROLIS,syncope,Disorders,0
KYPROLIS,syncope,and C,0
KYPROLIS,syncope,Musculoskeletal and onnecti ve Tissue,1
KYPROLIS,syncope,onnecti ve Tissue,1
KYPROLIS,syncope,onnecti ve Tissue,1
KYPROLIS,syncope,and onnecti ve Tissue,1
KYPROLIS,chest tightness,,0
KYPROLIS,chest tightness,Disorde rs Muscle,1
KYPROLIS,chest tightness,and Connective,0
KYPROLIS,platelet nadirs,Disorders,0
KYPROLIS,platelet nadirs,Disorders,0
KYPROLIS,platelet nadirs,"              
 Insomnia",1
KYPROLIS,platelet nadirs,,0
KYPROLIS,hepatic failure,Subcutaneous sue Disorders   Rash,1
KYPROLIS,hepatic failure,,0
KYPROLIS,hepatic failure,Rash,0
KYPROLIS,hepatic failure,sue Disorders   Rash,1
KYPROLIS,hepatic failure,,0
KYPROLIS,hepatic failure,Subcutaneous sue,1
KYPROLIS,hepatic failure,and,0
KYPROLIS,increased serum transaminases,45 (12%) Vascular,1
KYPROLIS,increased serum transaminases,Vascular,0
KYPROLIS,increased serum transaminases,Rash,0
KYPROLIS,increased serum transaminases,45 (12%) Vascular,1
KYPROLIS,increased serum transaminases,Rash,0
KYPROLIS,increased serum transaminases,Rash 45,1
KYPROLIS,increased serum transaminases,Rash 45,1
KYPROLIS,increased serum transaminases,Rash,0
KYPROLIS,thrombotic thrombocytopenic purpura,,0
KYPROLIS,thrombotic thrombocytopenic purpura,,0
KYPROLIS,thrombotic thrombocytopenic purpura,Thrombotic Events         22 (6%)         9 (2%)      Hypertensione,1
KYPROLIS,thrombotic thrombocytopenic purpura,,0
KYPROLIS,thrombotic thrombocytopenic purpura,,0
KYPROLIS,thrombotic thrombocytopenic purpura,Events,0
KYPROLIS,thrombotic thrombocytopenic purpura,and,0
KYPROLIS,thrombotic thrombocytopenic purpura,Thrombotic Events Venousd,0
KYPROLIS,thrombotic thrombocytopenic purpura,Hypertensione,0
KYPROLIS,TTP,   ,1
KYPROLIS,TTP,,0
KYPROLIS,TTP,,0
KYPROLIS,TTP,Hypertensione,0
KYPROLIS,TTP,Hypertensione,0
KYPROLIS,HUS,    Ther,1
KYPROLIS,HUS,    Ther,1
KYPROLIS,HUS,Ther,0
KYPROLIS,HUS,Hypertensione,0
KYPROLIS,HUS,Ther,0
KYPROLIS,fatal,Hypertensione,0
KYPROLIS,fatal,,0
KYPROLIS,fatal,      There,1
KYPROLIS,fatal,Hypertensione,0
KYPROLIS,fatal,,0
KYPROLIS,fatal,,0
KYPROLIS,fatal,Hypertensione,0
KYPROLIS,PRES,c ardiac arrest,1
KYPROLIS,PRES,s: c ardiac arrest,1
KYPROLIS,PRES,infarction myocardial ischem,0
KYPROLIS,PRES,febrile neutropenia lymphopenia Cardiac s: c ardiac arrest,1
KYPROLIS,PRES,lymphopenia Cardiac s:,1
KYPROLIS,PRES,ardiac,0
KYPROLIS,fetal harm,,0
KYPROLIS,fetal harm,hyponatremia tumor,0
YERVOY,Immune-mediated enterocolitis,Immunemediated hepatitis see Warnings and Prec,0
YERVOY,Immune-mediated enterocolitis,of the Immune-mediated,1
YERVOY,Immune-mediated enterocolitis,sections of the Immune-mediated enterocolitis see Warnings,1
YERVOY,Immune-mediated enterocolitis,sections of the Immune-mediated,1
YERVOY,Immune-mediated enterocolitis,in greater detail in other,0
YERVOY,Immune-mediated enterocolitis,the Immune-mediated,1
YERVOY,Immune-mediated enterocolitis,the Immune-mediated,1
YERVOY,Immune-mediated enterocolitis,,0
YERVOY,Immune-mediated hepatitis,,0
YERVOY,Immune-mediated hepatitis,see Warnings and Immune-mediated,1
YERVOY,Immune-mediated dermatitis,Immune-mediated dermatitis see Warnings,1
YERVOY,Immune-mediated dermatitis,Immunemediated,0
YERVOY,Immune-mediated dermatitis,and Precautions Immunemediated neuropathies see Warnings,0
YERVOY,Immune-mediated dermatitis,hepatitis see Warnings and Immune-mediated dermatitis see Warnings,1
YERVOY,Immune-mediated dermatitis,and Immune-mediated dermatitis see Warnings,1
YERVOY,Immune-mediated neuropathies,and Precautions Immunemediated endocrinopathies see,0
YERVOY,Immune-mediated neuropathies,Warnings,0
YERVOY,Immune-mediated neuropathies,dermatitis see Warnings and Immune-mediated,1
YERVOY,Immune-mediated neuropathies,,0
YERVOY,Immune-mediated neuropathies,dermatitis see Warnings and Immune-mediated,1
YERVOY,Immune-mediated neuropathies,and Immune-mediated,1
YERVOY,Immune-mediated neuropathies,Warnings and Immune-mediated neuropathies see Warnings,1
YERVOY,Immune-mediated neuropathies,Warnings and Immune-mediated neuropathies see Warnings,1
YERVOY,Immune-mediated endocrinopathies,,0
YERVOY,Immune-mediated endocrinopathies,Warnings and Immune-mediated,1
YERVOY,Immune-mediated endocrinopathies,,0
YERVOY,Immune-mediated endocrinopathies,,0
YERVOY,Immune-mediated endocrinopathies,see Warnings,0
YERVOY,Immune-mediated endocrinopathies,Warnings and Immune-mediated,1
YERVOY,immune-mediated adverse reactions,immune-mediated adverse reactions including ocular,1
YERVOY,immune-mediated adverse reactions,Other,0
YERVOY,immune-mediated adverse reactions,see Warnings and Precautions immune-mediated adverse reactions including ocular,1
YERVOY,immune-mediated adverse reactions,adverse reactions including ocular,1
YERVOY,immune-mediated adverse reactions,Warnings and,0
YERVOY,immune-mediated adverse reactions,Precautions EXCERPT Most,0
YERVOY,ocular manifestations,adverse reactions ocular,1
YERVOY,ocular manifestations,Warnings and Precautions Other,0
YERVOY,ocular manifestations,ocular manifestations see Warnings,1
YERVOY,ocular manifestations,manifestations see Warnings,1
YERVOY,ocular manifestations,adverse,0
YERVOY,ocular manifestations,immunemediated adverse reactions ocular manifestations see Warnings,1
YERVOY,ocular manifestations,Precautions EXCERPT Most common,0
YERVOY,ocular manifestations,manifestations see Warnings,1
YERVOY,fatigue,fatigue diarrhea pruritus,1
YERVOY,fatigue,Most common adverse reactions fatigue diarrhea pruritus,1
YERVOY,fatigue,,0
YERVOY,fatigue,rash,0
YERVOY,fatigue,adverse reactions are,0
YERVOY,fatigue,common adverse reactions are,0
YERVOY,fatigue,fatigue diarrhea pruritus,1
YERVOY,fatigue,common adverse,0
YERVOY,diarrhea,diarrhea pruritus rash,1
YERVOY,diarrhea,diarrhea pruritus rash,1
YERVOY,diarrhea,diarrhea pruritus rash,1
YERVOY,diarrhea,diarrhea pruritus rash,1
YERVOY,diarrhea,,0
YERVOY,diarrhea,fatigue,0
YERVOY,diarrhea,pruritus rash and,0
YERVOY,diarrhea,diarrhea pruritus rash,1
YERVOY,diarrhea,diarrhea pruritus rash,1
YERVOY,diarrhea,diarrhea pruritus rash,1
YERVOY,pruritus,reactions are,0
YERVOY,pruritus,pruritus rash and,1
YERVOY,rash,are fatigue diarrhea rash and colitis,1
YERVOY,rash,rash and colitis,1
YERVOY,rash,diarrhea,0
YERVOY,rash,adverse reactions are fatigue,0
YERVOY,colitis,,0
YERVOY,colitis,colitis To report,1
YERVOY,colitis,,0
YERVOY,colitis,colitis To report,1
YERVOY,colitis,diarrhea pruritus,0
YERVOY,colitis,Most common adverse reactions are fatigue diarrhea,0
YERVOY,colitis,rash and,0
YERVOY,colitis,fatigue diarrhea pruritus rash colitis To report,1
YERVOY,colitis,reactions,0
YERVOY,fatigue,fatigue diarrhea pruritus,1
YERVOY,fatigue,received YERVOY at mgkg fatigue diarrhea pruritus,1
YERVOY,fatigue,fatigue diarrhea pruritus,1
YERVOY,fatigue,presents,0
YERVOY,fatigue,fatigue diarrhea pruritus,1
YERVOY,fatigue,selected,0
YERVOY,fatigue,in patients,0
YERVOY,fatigue,adverse reactions from,0
YERVOY,fatigue,received YERVOY at,0
YERVOY,fatigue,in patients,0
YERVOY,diarrhea,mgkg were diarrhea pruritus rash,1
YERVOY,diarrhea,adverse reactions in patients,0
YERVOY,diarrhea,,0
YERVOY,pruritus,were fatigue pruritus rash and,1
YERVOY,pruritus,pruritus rash and,1
YERVOY,pruritus,pruritus rash and,1
YERVOY,pruritus,adverse reactions from,0
YERVOY,pruritus,pruritus rash and,1
YERVOY,pruritus,pruritus rash and,1
YERVOY,rash,rash and colitis,1
YERVOY,rash,and colitis Table presents,0
YERVOY,rash,rash and colitis,1
YERVOY,rash,rash and colitis,1
YERVOY,Diarrhea,AnyGrade Grade Gastrointestinal Diarrhea,1
YERVOY,Diarrhea,,0
YERVOY,Diarrhea,Gastrointestinal Diarrhea,1
YERVOY,Diarrhea,Diarrhea,1
YERVOY,Diarrhea,Diarrhea,1
YERVOY,Diarrhea,,0
YERVOY,Diarrhea,,0
YERVOY,Diarrhea,Diarrhea,1
YERVOY,Diarrhea,Diarrhea,1
YERVOY,Diarrhea,Grade,0
YERVOY,Colitis,Colitis,1
YERVOY,Colitis,,0
YERVOY,Colitis,Colitis,1
YERVOY,Colitis,Colitis,1
YERVOY,Colitis,,0
YERVOY,Colitis,,0
YERVOY,Colitis,Colitis,1
YERVOY,Pruritus,Skin and Subcutaneous Tissue Pruritus,1
YERVOY,Pruritus,Pruritus,1
YERVOY,Pruritus,,0
YERVOY,Pruritus,Pruritus,1
YERVOY,Pruritus,and Subcutaneous Tissue Pruritus,1
YERVOY,Rash,,0
YERVOY,Rash,Rash,1
YERVOY,Rash,Rash,1
YERVOY,Rash,Rash,1
YERVOY,Rash,Rash,1
YERVOY,Rash,,0
YERVOY,Fatigue,Fatigue,1
YERVOY,Fatigue,Conditions,0
YERVOY,Fatigue,Fatigue,1
YERVOY,Fatigue,Site Fatigue,1
YERVOY,Fatigue,and Administration,0
YERVOY,Fatigue,,0
YERVOY,Fatigue,Fatigue,1
YERVOY,Fatigue,and Administration Site Fatigue,1
YERVOY,Fatigue,,0
YERVOY,Fatigue,Fatigue,1
YERVOY,fatal,fatal,1
YERVOY,immune-mediated adverse reactions,perpatient incidence of severe lifethreatening or,0
YERVOY,immune-mediated adverse reactions,Table Severe,0
YERVOY,immune-mediated adverse reactions,lifethreatening or fatal,0
YERVOY,Fatal,Study Table Severe Fatal,1
YERVOY,Immune-mediated Adverse Reactions,Table Severe to Immune-mediated,1
YERVOY,Immune-mediated Adverse Reactions,Severe,0
YERVOY,Immune-mediated Adverse Reactions,or fatal immunemediated adverse reactions from Study Table,0
YERVOY,Immune-mediated Adverse Reactions,Severe,0
YERVOY,Immune-mediated Adverse Reactions,Study Table Severe to,0
YERVOY,Immune-mediated Adverse Reactions,b Including intestinal perforation c Under,0
YERVOY,fatal,Reactions,0
YERVOY,fatal,fatal,1
YERVOY,fatal,a fatal,1
YERVOY,fatal,fatal,1
YERVOY,intestinal perforation,Including fatal,0
YERVOY,intestinal perforation,Including,0
YERVOY,intestinal perforation,outcome b Including,0
YERVOY,intestinal perforation,Immunemediated Adverse Reactions in Study a,0
YERVOY,intestinal perforation,in Study,0
YERVOY,intestinal perforation,outcome b intestinal,1
YERVOY,intestinal perforation,intestinal perforation,1
YERVOY,intestinal perforation,Including fatal outcome b intestinal,1
YERVOY,Enterocolitis,Enterocolitis,1
YERVOY,Enterocolitis,,0
YERVOY,Enterocolitis,Enterocolitis,1
YERVOY,Enterocolitis,,0
YERVOY,Enterocolitis,Adverse Enterocolitis,1
YERVOY,Enterocolitis,,0
YERVOY,Dermatitis,Dermatitis a N,1
YERVOY,Dermatitis,Dermatitis a,1
YERVOY,Dermatitis,icitya,0
YERVOY,Dermatitis,,0
YERVOY,Dermatitis,Dermatitis a N,1
YERVOY,Dermatitis,icitya Dermatitis a N,1
YERVOY,Dermatitis,icitya Dermatitis a,1
YERVOY,Dermatitis,,0
YERVOY,Dermatitis,,0
YERVOY,Neuropathy,sa Neuropathy a,1
YERVOY,Neuropathy,sa Neuropathy a E,1
YERVOY,Neuropathy,sa,0
YERVOY,Neuropathy,sa,0
YERVOY,Neuropathy,sa Neuropathy,1
YERVOY,Neuropathy,Neuropathy,1
YERVOY,Neuropathy,Neuropathy a E,1
YERVOY,Endocrinopathy,Endocrinopathy H,1
YERVOY,Endocrinopathy,,0
YERVOY,Endocrinopathy,Endocrinopathy H,1
YERVOY,Endocrinopathy,,0
YERVOY,Hypopituitarism,y,0
YERVOY,Hypopituitarism,,0
YERVOY,Hypopituitarism,y,0
YERVOY,Hypopituitarism,y,0
YERVOY,Hypopituitarism,y Hypopituitarism Adrena,1
YERVOY,Hypopituitarism,y,0
YERVOY,Hypopituitarism,Hypopituitarism Adrena,1
YERVOY,Hypopituitarism,y,0
YERVOY,Hypopituitarism,Hypopituitarism Adrena,1
YERVOY,Hypopituitarism,y Hypopituitarism Adrena,1
YERVOY,Adrenal insufficiency,tarism Adrenal,1
YERVOY,Adrenal insufficiency,,0
YERVOY,Adrenal insufficiency,tarism Adrenal insufficiency Other,1
YERVOY,Adrenal insufficiency,tarism,0
YERVOY,Adrenal insufficiency,tarism Adrenal insufficiency Other,1
YERVOY,Adrenal insufficiency,insufficiency Other,1
YERVOY,Adrenal insufficiency,tarism,0
YERVOY,Adrenal insufficiency,tarism Adrenal,1
YERVOY,Adrenal insufficiency,tarism Adrenal,1
YERVOY,Adrenal insufficiency,tarism Adrenal insufficiency Other,1
YERVOY,Pneumonitis,,0
YERVOY,Pneumonitis,Pneumonitis Me,1
YERVOY,Pneumonitis,Pneumonitis Me,1
YERVOY,Pneumonitis,Pneumonitis Me,1
YERVOY,Pneumonitis,Pneumonitis Me,1
YERVOY,Meningitis,,0
YERVOY,Meningitis,is,0
YERVOY,Meningitis,Meningitis N,1
YERVOY,Meningitis,is,0
YERVOY,Meningitis,is,0
YERVOY,Meningitis,,0
YERVOY,Meningitis,,0
YERVOY,Meningitis,is,0
YERVOY,Meningitis,N,0
YERVOY,Meningitis,is,0
YERVOY,Nephritis,,0
YERVOY,Nephritis,,0
YERVOY,Nephritis,,0
YERVOY,Nephritis,Nephritis,1
YERVOY,Nephritis,Nephritis,1
YERVOY,Nephritis,s,0
YERVOY,Eosinophilia,Eosinophilia c Per,1
YERVOY,Eosinophilia,Eosinophilia c,1
YERVOY,Eosinophilia,,0
YERVOY,Eosinophilia,Eosinophilia c,1
YERVOY,Eosinophilia,,0
YERVOY,Eosinophilia,Eosinophilia,1
YERVOY,Eosinophilia,Eosinophilia,1
YERVOY,Pericarditis,Pericarditis ac,1
YERVOY,Pericarditis,Pericarditis ac,1
YERVOY,Pericarditis,liac Pericarditis ac,1
YERVOY,Pericarditis,Pericarditis ac,1
YERVOY,Pericarditis,Pericarditis ac,1
YERVOY,Pericarditis,Pericarditis ac,1
YERVOY,Pericarditis,liac Pericarditis ac,1
YERVOY,Pericarditis,,0
YERVOY,Pericarditis,liac Pericarditis ac,1
YERVOY,Pericarditis,,0
YERVOY,urticaria,urticaria,1
YERVOY,urticaria,urticaria,1
YERVOY,urticaria,urticaria,1
YERVOY,urticaria,otherwise urticaria,1
YERVOY,urticaria,urticaria,1
YERVOY,urticaria,urticaria,1
YERVOY,urticaria,adverse reactions were also,0
YERVOY,urticaria,unless,0
YERVOY,large intestinal ulcer,reactions were also reported incidence less than unless,0
YERVOY,esophagitis,renal failure,0
YERVOY,acute respiratory distress syndrome,renal failure,0
YERVOY,acute respiratory distress syndrome,esophagitis,0
YERVOY,renal failure,failure,1
YERVOY,renal failure,large intestinal ulcer esophagitis acute,0
YERVOY,renal failure,renal failure,1
YERVOY,renal failure,,0
YERVOY,infusion reaction,intestinal ulcer,0
YERVOY,infusion reaction,reaction,1
YERVOY,infusion reaction,syndrome renal,0
YERVOY,infusion reaction,renal failure infusion,1
YERVOY,enterocolitis,Postmarketing Experience The,0
YERVOY,enterocolitis,severity,0
YERVOY,enterocolitis,and severity enterocolitis,1
YERVOY,hepatitis,hepatitis,1
YERVOY,Drug reaction with eosinophilia and systemic symptoms,,0
YERVOY,Drug reaction with eosinophilia and systemic symptoms,exposure Skin and,0
YERVOY,Drug reaction with eosinophilia and systemic symptoms,Immunogenicity In clinical studies of evaluable,0
YERVOY,Drug reaction with eosinophilia and systemic symptoms,Tissue Drug reaction with eosinophilia and systemic symptoms,1
YERVOY,Drug reaction with eosinophilia and systemic symptoms,of,0
YERVOY,DRESS syndrome,eosinophilia and systemic DRESS,1
YERVOY,DRESS syndrome,Tissue Disorders Drug reaction with eosinophilia and systemic,0
YERVOY,DRESS syndrome,clinical studies of evaluable patients,0
YERVOY,DRESS syndrome,tested positive,0
YERVOY,peri-infusional reactions,,0
YERVOY,peri-infusional reactions,ipilimumab Infusionrelated peri-infusional reactions,1
YERVOY,peri-infusional reactions,ipilimumab Infusionrelated peri-infusional reactions,1
YERVOY,peri-infusional reactions,peri-infusional reactions,1
YERVOY,peri-infusional reactions,Infusionrelated,0
YERVOY,peri-infusional reactions,reactions,1
YERVOY,peri-infusional reactions,patients nor were neu,0
YERVOY,hypersensitivity,hypersensitivity,1
YERVOY,hypersensitivity,ipil,0
YERVOY,hypersensitivity,the,0
YERVOY,hypersensitivity,antibodies against ipil,0
YERVOY,hypersensitivity,neutralizing antibodies against,0
YERVOY,hypersensitivity,were not reported in these,0
YERVOY,hypersensitivity,reactions,0
YERVOY,anaphylaxis,with hypersensitivity anaphylaxis,1
YERVOY,anaphylaxis,these patients,0
YERVOY,anaphylaxis,reactions consistent with hypersensitivity anaphylaxis,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,The following adverse reactions a re,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,The following adverse reactions a re discussed,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,re discussed in,0
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,,0
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,,0
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,greater detail in other sectio ns of the labeling Immunemediated,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,,0
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,other sectio ns of the,1
YERVOY,fatal,,0
YERVOY,fatal,,0
YERVOY,fatal,ediat ed enterocolitis see,1
YERVOY,fatal,ediat ed enterocolitis see,1
YERVOY,fatal,other sections of,0
YERVOY,fatal,detail in,0
YERVOY,immune-mediated adverse reactions,[see Warnings an d Precautions Immunemediated,1
YERVOY,immune-mediated adverse reactions,of the labeling d enterocolitis [see Warnings,1
YERVOY,immune-mediated adverse reactions,the labeling d enterocolitis [see  Warnings an d Precautions Immunemediated,1
YERVOY,immune-mediated adverse reactions,Precautions,0
YERVOY,immune-mediated adverse reactions,sections of the,0
YERVOY,immune-mediated adverse reactions,labeling d,1
YERVOY,immune-mediated adverse reactions,enterocolitis [see Warnings an d Precautions Immunemediated,1
YERVOY,immune-mediated reactions,,0
YERVOY,immune-mediated reactions,,0
YERVOY,immune-mediated reactions,Immunemediated patitis,1
YERVOY,immune-mediated reactions,Precautions Immunemediated patitis [see  Warnings an d Precautions Immunemediated,1
YERVOY,immune-mediated reactions,see Warnings and Precautions Immunemediated,0
YERVOY,immune-mediated reactions,patitis [see  Warnings an d Precautions Immunemediated,1
YERVOY,immune-mediated adverse reactions,Immunemediated neuropathies,0
YERVOY,immune-mediated adverse reactions,Immune,0
YERVOY,immune-mediated adverse reactions,e  Warnings and Precautions (5.3) Immunemediated neuropathies see,1
YERVOY,enterocolitis,Immunemediated endocrino,0
YERVOY,enterocolitis,neuropathies see Warnings and Precautions,0
YERVOY,enterocolitis,Precautions Immunemediated endocrino,0
YERVOY,enterocolitis,endocrino,0
YERVOY,enterocolitis,Precautions Immunemediated endocrino,0
YERVOY,enterocolitis,endocrino,0
YERVOY,enterocolitis,Warnings and Precautions Immunemediated,0
YERVOY,enterocolitis,Warnings and,0
YERVOY,hepatitis,,0
YERVOY,hepatitis,dermatitis,0
YERVOY,hepatitis,,0
YERVOY,hepatitis,-mediated neuropathies see Warnings,1
YERVOY,dermatitis,europathie s see Warnings,1
YERVOY,toxic epidermal necrolysis,,0
YERVOY,toxic epidermal necrolysis,and Precautions Immunemediated,0
YERVOY,toxic epidermal necrolysis,neuropathies see ings,1
YERVOY,toxic epidermal necrolysis,see ings and Precautions (5.4) Immunemediated endocrinopathies see,1
YERVOY,toxic epidermal necrolysis,Precautions (5.4) Immunemediated endocrinopathies see,1
YERVOY,toxic epidermal necrolysis,and Precautions (5.4) Immunemediated endocrinopathies see,1
YERVOY,toxic epidermal necrolysis,see Warnings and Precautions,0
YERVOY,toxic epidermal necrolysis,neuropathies see Warn,0
YERVOY,toxic epidermal necrolysis,Immunemediated,0
YERVOY,neuropathy,Immunemediated endocrinopathies see Warnings and Precautions,0
YERVOY,neuropathy,,0
YERVOY,neuropathy,Immunemediated,0
YERVOY,neuropathy,neuropathies see Warnings,0
YERVOY,neuropathy,Precautions,0
YERVOY,neuropathy,? Immunemediated endocrinopathies see,1
YERVOY,neuropathy,Immunemediated endocrinopathies see Warnings and Precautions Other immunemed,0
YERVOY,neuropathy,neuropathies see Warnings and . *,1
YERVOY,endocrinopathy,e-mediated end ocrinopathies see Warnings,1
YERVOY,endocrinopathy,,0
YERVOY,endocrinopathy,,0
YERVOY,endocrinopathy,see Warnings and Precautions e-mediated end ocrinopathies see Warnings,1
YERVOY,endocrinopathy,e-mediated end ocrinopathies see Warnings,1
YERVOY,endocrinopathy,e-mediated end ocrinopathies see Warnings,1
YERVOY,endocrinopathy,adverse,0
YERVOY,endocrinopathy,e-mediated,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,experience with therapeutics n the same class and may not refl ect the rates,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,experience with therapeutics n the same class and may not refl ect the rates,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,,0
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,i,0
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,or experience with therapeutics n the same class and may not refl ect the rates,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,be directly compared with rates in other clinical,0
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,observed in clinical practice The clinical development program excluded,0
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,n the same class and may not,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,n the same class and may not refl ect the rates,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,experience with therapeutics n the same class and may not refl ect the rates,1
YERVOY,fatal,,0
YERVOY,fatal,patients with ive,1
YERVOY,fatal,ive a utoimmune disease or,1
YERVOY,fatal,ive a utoimmune disease or,1
YERVOY,fatal,or those receiving systemic immunosuppression for organ transplantation,0
YERVOY,fatal,development program,0
YERVOY,fatal,in clinical practice The,0
YERVOY,fatal,ive a utoimmune disease or,1
YERVOY,immune-mediated adverse reactions,patients with,0
YERVOY,immune-mediated adverse reactions,for doses,0
YERVOY,immune-mediated adverse reactions,active toimmune disease or those receivi ng systemic immunosuppression,1
YERVOY,immune-mediated adverse reactions,in treated,1
YERVOY,immune-mediated adverse reactions,infusion in  treated patients with unresectab le or metastatic,1
YERVOY,immune-mediated adverse reactions,study,0
YERVOY,immune-mediated adverse reactions,doubleblind,0
YERVOY,immune-mediated adverse reactions, treated patients with unresectab le or metastatic,1
YERVOY,immune-mediated adverse reactions,to,0
YERVOY,immune-mediated adverse reactions,in previously,0
YERVOY,immune-mediated adverse reactions,,0
YERVOY,immune-mediated adverse reactions,,0
YERVOY,immune-mediated adverse reactions,infusion in previously,0
YERVOY,enterocolitis,doses,0
YERVOY,enterocolitis,,0
YERVOY,enterocolitis,unresectable metastatic,1
YERVOY,enterocolitis,m elanoma was assessed,1
YERVOY,enterocolitis,with unresectable metastatic,1
YERVOY,enterocolitis,with unresectable  metastatic m elanoma was assessed,1
YERVOY,hepatitis,in previously treated patients with unresectable,0
YERVOY,hepatitis,was assessed in a,1
YERVOY,hepatitis,given by intravenous infusion in previously,0
YERVOY,hepatitis,in previously treated patients with unresectable or metastatic mel,0
YERVOY,hepatitis,was assessed in a,1
YERVOY,hepatitis,given by intravenous infusion,0
YERVOY,dermatitis,One,0
YERVOY,dermatitis,unresectable or metastatic melanoma,0
YERVOY,toxic epidermal necrolysis,was assessed in,0
YERVOY,toxic epidermal necrolysis,metastatic melanoma was assessed in a randomize,0
YERVOY,neuropathy,assessed in a randomized,0
YERVOY,neuropathy,1 See Clinical Studies,1
YERVOY,neuropathy,1 See Clinical Studies,1
YERVOY,neuropathy,,0
YERVOY,neuropathy,1 See Clinical Studies,1
YERVOY,endocrinopathy,ee  Clinical S tudies One hundred,1
YERVOY,endocrinopathy,ee Clinical S tudies One hundred,1
YERVOY,endocrinopathy,S tudies One hundred,1
YERVOY,endocrinopathy,S tudies One hundred,1
YERVOY,fatal,,0
YERVOY,fatal,of the,0
YERVOY,fatal,ssed  in greater detail in,1
YERVOY,fatal,,0
YERVOY,immune-mediated reactions,see Warnings and Precautions,0
YERVOY,immune-mediated reactions,of the labeling Immunemediated enterocolitis see Warnings and Precautions,0
YERVOY,immune-mediated reactions,detail in other sections of the labeling,1
YERVOY,immune-mediated reactions,and Precautions,0
YERVOY,Immune-mediated adverse reactions,"and ecautions (5.1)  ] . 
 *  ?  Immu nemediated hepatitis see Warnings and",1
YERVOY,Immune-mediated adverse reactions,,0
YERVOY,Immune-mediated adverse reactions,ecautions (5.1) ] . * ?,1
YERVOY,Immune-mediated adverse reactions,enterocolitis see Warnings,0
YERVOY,Immune-mediated adverse reactions,"enterocolitis see Warnings and ecautions (5.1)  ] . 
 *  ?  Immu nemediated hepatitis see Warnings and",1
YERVOY,Immune-mediated adverse reactions,Warnings and ecautions (5.1) ],1
YERVOY,Immune-mediated adverse reactions,"Warnings and ecautions (5.1)  ] . 
 *  ?  Immu nemediated hepatitis see Warnings and",1
YERVOY,Immune-mediated hepatitis,"Warnings and 
      EXCERPT:   Most co mmon adverse reactions are fatigue",1
YERVOY,Immune-mediated hepatitis,"see Warnings and 
      EXCERPT:   Most co mmon adverse reactions are fatigue",1
YERVOY,Immune-mediated hepatitis,"Warnings and 
      EXCERPT:   Most co mmon adverse reactions are fatigue",1
YERVOY,Immune-mediated hepatitis,and,0
YERVOY,Immune-mediated hepatitis,Most co mmon adverse reactions are fatigue,1
YERVOY,Immune-mediated hepatitis,EXCERPT: Most co mmon adverse reactions are fatigue,1
YERVOY,Immune-mediated endocrinopathies,diarrhea pruritus rash and coli,0
YERVOY,Immune-mediated endocrinopathies,rash,0
YERVOY,fatal,conditions,0
YERVOY,fatal,trials,0
YERVOY,fatal,be tly c ompared with rates in other,1
YERVOY,fatal,trials or,0
YERVOY,diarrhea,and,0
YERVOY,diarrhea,cannot be directly pared wi th rates in other clinical,1
YERVOY,diarrhea,th rates in other clinical trials or experience with therapeutics in the same class,0
YERVOY,diarrhea,directly com,0
YERVOY,diarrhea,adverse reaction rates observed cannot be,0
YERVOY,fever,exper ience with therapeutics in the,1
YERVOY,fever,other clinical trials exper ience with therapeutics in the,1
YERVOY,fever,trials exper ience with therapeutics in the,1
YERVOY,fever,exper ience with therapeutics in the,1
YERVOY,fever,exper ience with therapeutics in the,1
YERVOY,ileus,,0
YERVOY,ileus,nce w ith therapeutics in the same,1
YERVOY,ileus,may not reflect,0
YERVOY,ileus,nce w ith therapeutics in the same,1
YERVOY,peritoneal signs,be directly compared with rates in,0
YERVOY,peritoneal signs,experience h therapeutics,1
YERVOY,immune-mediated enterocolitis,ass and may not reflect the r ates observed in clinical practice,1
YERVOY,immune-mediated enterocolitis,,0
YERVOY,diarrhea,practice The clinical ment pro gram excluded patients with active,1
YERVOY,diarrhea,,0
YERVOY,diarrhea,clinical practice The,0
YERVOY,diarrhea,,0
YERVOY,diarrhea,the rates observed,0
YERVOY,diarrhea,systemic,0
YERVOY,diarrhea,The clinical,0
YERVOY,diarrhea,practice The clinical ment,1
YERVOY,diarrhea,ment pro gram excluded patients with active,1
YERVOY,diarrhea,develop,0
YERVOY,abdominal pain,disea se or those receiving systemic,1
YERVOY,abdominal pain,excluded patients with active toimmune disea se or those receiving systemic,1
YERVOY,abdominal pain,,0
YERVOY,abdominal pain,,0
YERVOY,abdominal pain,disea se or those receiving systemic,1
YERVOY,abdominal pain,se or those receiving,0
YERVOY,abdominal pain,excluded patients,0
YERVOY,abdominal pain,YERVOY,0
YERVOY,abdominal pain,in clinical practice The clinical development program excluded patients,0
YERVOY,abdominal pain,receiving systemic immunosuppression for organ,0
YERVOY,blood in stool,receiving,1
YERVOY,blood in stool,Exposure to YERVOY mgkg for doses given by,0
YERVOY,blood in stool,receiving sys temic immunosuppression for organ transplantation,1
YERVOY,blood in stool,disease or receiving,1
YERVOY,enterocolitis,osuppression  for organ transplantation Exposure to,1
YERVOY,enterocolitis,osuppression  for organ transplantation Exposure to,1
YERVOY,enterocolitis,or those receiving systemic osuppression  for organ transplantation Exposure to,1
YERVOY,enterocolitis,osuppression  for organ transplantation Exposure to,1
YERVOY,enterocolitis,osuppression  for organ transplantation Exposure to,1
YERVOY,intestinal perforation,d patients with unrese ctable or metastatic melanoma was,1
YERVOY,intestinal perforation,in previously d patients with unrese ctable or metastatic melanoma was,1
YERVOY,intestinal perforation,,0
YERVOY,intestinal perforation,by intravenous infusion in previously,0
YERVOY,died,doubleblind,0
YERVOY,died,,0
YERVOY,died,,0
YERVOY,died,or metastatic,0
YERVOY,enterocolitis,doubleblind clinical study Study Clinical,1
YERVOY,enterocolitis,,0
YERVOY,enterocolitis,vaccine gp and patients median age,0
YERVOY,enterocolitis,age years ale),1
YERVOY,enterocolitis,as a,0
YERVOY,enterocolitis,patients median age years,0
YERVOY,enterocolitis,vestigational gp peptide vaccine gp and,1
YERVOY,enterocolitis,peptide vaccine gp and patients median age years male received gp pept,0
YERVOY,enterocolitis,median age,0
YERVOY,enterocolitis,vestigational gp peptide vaccine gp and,1
YERVOY,enterocolitis,vestigational gp peptide vaccine gp and,1
YERVOY,enterocolitis,YERVOY with an in,0
YERVOY,enterocolitis,with an vestigational gp peptide vaccine gp and,1
YERVOY,enterocolitis,male received gp,0
YERVOY,enterocolitis,"and patients median 7 years,",1
YERVOY,enterocolitis,,0
YERVOY,enterocolitis,received a median of doses,0
YERVOY,enterocolitis,gp peptide,0
YERVOY,enterocolitis,,0
YERVOY,enterocolitis,7,1
YERVOY,enterocolitis,,0
YERVOY,enterocolitis,"7 years, 54% male received gp peptide vaccine",1
YERVOY,enterocolitis,peptide vaccine gp and patients,0
YERVOY,enterocolitis,,0
YERVOY,enterocolitis,reactions in patients who,0
YERVOY,enterocolitis,pruritus rash and colitis Table presents,1
YERVOY,enterocolitis,reactions in patients who received YERVOY at mgkg,0
YERVOY,enterocolitis,which,0
YERVOY,enterocolitis,,0
YERVOY,enterocolitis,from Study which occurred in,0
YERVOY,enterocolitis,and colitis Table presents,0
YERVOY,enterocolitis,at mgkg were fatigue,0
YERVOY,immune-mediated enterocolitis,a Incidences presen ted in this table are,1
YERVOY,enterocolitis,Percentage,0
YERVOY,enterocolitis,,0
YERVOY,enterocolitis,,0
YERVOY,enterocolitis,,0
YERVOY,enterocolitis,AnyGrade,0
YERVOY,enterocolitis,"00n=132    
  System Organ ClassPreferred Term AnyGrade",1
YERVOY,enterocolitis,"00n=132    
  System Organ ClassPreferred Term AnyGrade",1
YERVOY,enterocolitis,"00n=132    
  System Organ ClassPreferred Term AnyGrade",1
YERVOY,enterocolitis,"00n=132    
  System Organ ClassPreferred Term AnyGrade",1
YERVOY,enterocolitis,"mgkgn YERVOY mgkggpn 00n=132    
  System Organ ClassPreferred Term AnyGrade",1
YERVOY,enterocolitis,,0
YERVOY,fatal,intestinal orati on c Underlying etiology not,1
YERVOY,fatal,Adverse Reactions in Study a Including fatal outcome b Including intestinal perf,0
YERVOY,fatal,not established Pe,0
YERVOY,fatal,c Underlying etiology not established Pe,0
YERVOY,fatal,on c Underlying etiology not,0
YERVOY,hepatotoxicity,c Unde rlying etiology not established Percentage,1
YERVOY,hepatotoxicity,c Unde rlying etiology not established Percentage,1
YERVOY,hepatotoxicity,n. c,1
YERVOY,hepatotoxicity,outcome b Including intestinal n. c,1
YERVOY,hepatotoxicity,intestinal n.  c     Unde rlying etiology not established Percentage,1
YERVOY,hepatotoxicity,intestinal n. c,1
YERVOY,hepatotoxicity,b Including intestinal n.,1
YERVOY,hepatotoxicity,Unde rlying etiology not established Percentage,1
YERVOY,hepatotoxicity,n.,1
YERVOY,hepatotoxicity,,0
YERVOY,ALT elevations,c Underlying iology not,1
YERVOY,ALT elevations,,0
YERVOY,ALT elevations,iology not est ablished Percentage of Patients,1
YERVOY,ALT elevations,Percentage of,0
YERVOY,ALT elevations,ablished,0
YERVOY,ALT elevations,perforation c Underlying iology not,1
YERVOY,total bilirubin elevations,perforation c Underlying,0
YERVOY,total bilirubin elevations,(%) of Patients YERVOY mgkgn YERVOY,1
YERVOY,total bilirubin elevations,Underlying etiology not          Percentage (%) of Patients YERVOY mgkgn YERVOY,1
YERVOY,fatal,nts YERVOY mgkgn YERVOY gp100 n Any Immunemediated Adverse Reaction,1
YERVOY,fatal,mgkgn YERVOY mgkg,0
YERVOY,fatal,YERVOY gp100 n Any Immunemediated Adverse Reaction,1
YERVOY,fatal,gp100 n Any Immunemediated Adverse Reaction,1
YERVOY,fatal,gp100 n Any Immunemediated Adverse Reaction,1
YERVOY,fatal,YERVOY,0
YERVOY,fatal,n Any Immunemediated Adverse Reaction,0
YERVOY,fatal,gp100 n Any Immunemediated Adverse Reaction,1
YERVOY,fatal,gp100 n Any Immunemediated Adverse Reaction,1
YERVOY,fatal,mgkgn YERVOY gp100 n Any Immunemediated Adverse Reaction,1
YERVOY,hepatotoxicity,"Reaction tisa,b         Hepatotoxicitya",1
YERVOY,liver function test abnormalities,   7                              Hepatotoxicitya,1
YERVOY,liver function test abnormalities,Enterocolitisab,0
YERVOY,liver function test abnormalities,   7                              Hepatotoxicitya,1
YERVOY,liver function test abnormalities,   7                              Hepatotoxicitya,1
YERVOY,liver function test abnormalities,   7                              Hepatotoxicitya,1
YERVOY,liver function test abnormalities,   7                              Hepatotoxicitya,1
YERVOY,liver function test abnormalities,,0
YERVOY,liver function test abnormalities,   7                              Hepatotoxicitya,1
YERVOY,liver function test abnormalities,Enterocolitisab,0
YERVOY,ALT elevations,Hepatotoxicitya,0
YERVOY,total bilirubin elevation,         2                Dermatitisa,1
YERVOY,total bilirubin elevation,Hepatotoxicitya          2                Dermatitisa,1
YERVOY,total bilirubin elevation,Dermatitisa,0
YERVOY,total bilirubin elevation,         2                Dermatitisa,1
YERVOY,total bilirubin elevation,,0
YERVOY,immune-mediated hepatitis,,0
YERVOY,immune-mediated hepatitis,                       <1 Endocrinopathy,1
YERVOY,increases in transaminases,,0
YERVOY,increases in transaminases,following adverse s were also reported,1
YERVOY,increases in total bilirubin,incidence less than unless erwise noted): urticaria,1
YERVOY,increases in total bilirubin,than unless erwise noted): urticaria (2% large,1
YERVOY,increases in total bilirubin,incidence less,0
YERVOY,immune-mediated dermatitis,Experience The following,0
YERVOY,immune-mediated dermatitis,program for melanoma the incidence,0
YERVOY,immune-mediated dermatitis,a nd,1
YERVOY,immune-mediated dermatitis,incidence and everity of enterocolitis a nd,1
YERVOY,immune-mediated dermatitis,melanoma the incidence and everity of enterocolitis a nd,1
YERVOY,immune-mediated dermatitis,,0
YERVOY,immune-mediated dermatitis,the,0
YERVOY,immune-mediated dermatitis,everity of enterocolitis a nd,1
YERVOY,immune-mediated dermatitis,incidence and everity of enterocolitis a nd,1
YERVOY,Stevens-Johnson syndrome,in the entire clinical program for melanoma the incidence and severity of enterocolitis and hep,0
YERVOY,toxic epidermal necrolysis,ependent. 6.2 Post marketing,1
YERVOY,toxic epidermal necrolysis,dose,0
YERVOY,rash,during,0
YERVOY,rash,severity of enterocolitis and hepatitis appear to be dose dependent Postmarke,0
YERVOY,rash,ting Experience,1
YERVOY,rash,dependent ting Experience,1
YERVOY,rash,,0
YERVOY,dermal ulceration,following verse reactions,1
YERVOY,died,of in s ize,1
YERVOY,died,s ize,1
YERVOY,died,population of in,1
YERVOY,died,,0
YERVOY,died,voluntarily from a population of,0
YERVOY,died,population of in,1
YERVOY,died,population of in s ize,1
YERVOY,died,reported,0
YERVOY,died,estimate their,0
YERVOY,died,,0
YERVOY,dermatitis,causal relationship drug,1
YERVOY,dermatitis,Disorders g,1
YERVOY,dermatitis,,0
YERVOY,dermatitis,,0
YERVOY,immune-mediated dermatitis,clinica l,1
YERVOY,immune-mediated dermatitis,"syndrome munogenicity

  In clinica l",1
YERVOY,immune-mediated dermatitis,studies,0
YERVOY,immune-mediated dermatitis,Disorders Drug reaction with eosinophilia and systemic symptoms DRESS,0
YERVOY,dermatitis,antibodies,0
YERVOY,dermatitis,cent (ECL) based,1
YERVOY,dermatitis,patients tested positive for binding antibodies against ipilimumab,0
YERVOY,dermatitis,an cent (ECL) based,1
YERVOY,dermatitis,binding antibodies against ipilimumab in an electrochemilumines,0
YERVOY,dermatitis,This assay has substantial limitations in,0
YERVOY,dermatitis,This assay has substantial,0
YERVOY,dermatitis,,0
YERVOY,dermatitis,tralizing  antibodies,1
YERVOY,dermatitis,levels of,0
YERVOY,dermatitis,tralizing  antibodies,1
YERVOY,dermatitis,,0
YERVOY,dermatitis,hypersensitivity or anaphylaxis were not reported in these patients nor were,0
YERVOY,dermatitis,antibodies against ipilimumab Immunogenicity assay results are,0
YERVOY,dermatitis,treated with mgkg dose  positive  for,1
YERVOY,dermatitis, positive  for,1
YERVOY,dermatitis,assay results are,0
YERVOY,dermatitis, positive  for,1
YERVOY,fatal,,1
YERVOY,fatal,,0
YERVOY,fatal,,1
YERVOY,fatal,,0
YERVOY,fatal,,0
YERVOY,fatal,,1
YERVOY,fatal,,1
YERVOY,fatal,,0
YERVOY,fatal,,1
YERVOY,fatal,,1
YERVOY,Guillain-Barre syndrome,,0
YERVOY,Guillain-Barre syndrome,,1
YERVOY,peripheral motor neuropathy,,0
YERVOY,peripheral motor neuropathy,,1
YERVOY,peripheral motor neuropathy,,0
YERVOY,peripheral motor neuropathy,,1
YERVOY,peripheral motor neuropathy,,0
YERVOY,peripheral motor neuropathy,,0
YERVOY,peripheral motor neuropathy,,0
YERVOY,peripheral motor neuropathy,,1
YERVOY,myasthenia gravis,,1
YERVOY,myasthenia gravis,,1
YERVOY,myasthenia gravis,,0
YERVOY,myasthenia gravis,,1
YERVOY,myasthenia gravis,,0
YERVOY,immune-mediated endocrinopathies,,0
YERVOY,immune-mediated endocrinopathies,,0
YERVOY,immune-mediated endocrinopathies,,0
YERVOY,immune-mediated endocrinopathies,,0
YERVOY,immune-mediated endocrinopathies,,1
YERVOY,immune-mediated endocrinopathies,,0
YERVOY,hypopituitarism,,0
YERVOY,endocrinopathies,,1
YERVOY,adrenal insufficiency,,1
YERVOY,adrenal insufficiency,,0
YERVOY,adrenal insufficiency,,0
YERVOY,adrenal insufficiency,,0
YERVOY,adrenal insufficiency,,0
YERVOY,adrenal insufficiency,,0
YERVOY,adrenal insufficiency,,1
YERVOY,adrenal insufficiency,,0
YERVOY,adrenal insufficiency,,1
YERVOY,hypogonadism,,1
YERVOY,hypogonadism,,1
YERVOY,hypogonadism,,1
YERVOY,hypogonadism,,1
YERVOY,hypogonadism,,1
YERVOY,hypogonadism,,1
YERVOY,hypogonadism,,0
YERVOY,hypogonadism,,1
YERVOY,hypogonadism,,0
YERVOY,hypogonadism,,1
YERVOY,hypothyroidism,,0
YERVOY,hypothyroidism,,0
YERVOY,hypothyroidism,,0
YERVOY,hypothyroidism,,1
YERVOY,hypothyroidism,,1
YERVOY,hypothyroidism,,1
YERVOY,hypothyroidism,,1
YERVOY,hypothyroidism,,1
YERVOY,hypothyroidism,,1
YERVOY,hypothyroidism,,1
YERVOY,endocrinopathies,,0
YERVOY,endocrinopathies,,0
YERVOY,endocrinopathies,,0
YERVOY,endocrinopathy,,0
YERVOY,endocrinopathy,,1
YERVOY,endocrinopathy,,0
YERVOY,endocrinopathy,,1
YERVOY,endocrinopathy,,0
YERVOY,endocrinopathy,,0
YERVOY,hypothyroidism,,1
YERVOY,hypothyroidism,,0
YERVOY,hypothyroidism,,0
YERVOY,hypothyroidism,,0
YERVOY,hypothyroidism,,1
YERVOY,hypothyroidism,,1
YERVOY,hypothyroidism,,0
YERVOY,hypothyroidism,,1
YERVOY,adrenal insufficiency,,1
YERVOY,adrenal insufficiency,,1
YERVOY,adrenal insufficiency,,0
YERVOY,adrenal insufficiency,,1
YERVOY,adrenal insufficiency,,1
YERVOY,adrenal insufficiency,,1
YERVOY,adrenal insufficiency,,1
YERVOY,hypopituitarism,,1
YERVOY,hypopituitarism,,1
YERVOY,hypopituitarism,,1
YERVOY,hypopituitarism,,1
YERVOY,hypopituitarism,,1
YERVOY,hypopituitarism,,1
YERVOY,hypopituitarism,,1
YERVOY,hyperthyroidism,,0
YERVOY,hyperthyroidism,,0
YERVOY,hyperthyroidism,,0
YERVOY,hyperthyroidism,,1
YERVOY,hyperthyroidism,,1
YERVOY,hyperthyroidism,,1
YERVOY,Cushing's syndrome,,0
YERVOY,Cushing's syndrome,,1
YERVOY,Cushing's syndrome,,0
YERVOY,Cushing's syndrome,,1
YERVOY,Cushing's syndrome,,0
YERVOY,Cushing's syndrome,,1
YERVOY,Cushing's syndrome,,1
YERVOY,Cushing's syndrome,,0
YERVOY,Cushing's syndrome,,1
YERVOY,Cushing's syndrome,,0
YERVOY,immune-mediated endocrinopathy,,1
YERVOY,immune-mediated endocrinopathy,,1
YERVOY,immune-mediated endocrinopathy,,0
YERVOY,immune-mediated endocrinopathy,,1
YERVOY,endocrinopathy,,1
YERVOY,endocrinopathy,,0
YERVOY,endocrinopathy,,1
YERVOY,hypophysitis,,0
YERVOY,hypophysitis,,0
YERVOY,hypophysitis,,1
YERVOY,immune-mediated adverse reactions,,1
YERVOY,immune-mediated adverse reactions,,1
YERVOY,immune-mediated adverse reactions,,1
YERVOY,immune-mediated adverse reactions,,0
YERVOY,immune-mediated adverse reactions,,0
YERVOY,immune-mediated adverse reactions,,0
YERVOY,nephritis,,0
YERVOY,nephritis,,0
YERVOY,nephritis,,1
YERVOY,nephritis,,1
YERVOY,nephritis,,1
YERVOY,nephritis,,1
YERVOY,nephritis,,1
YERVOY,nephritis,,0
YERVOY,nephritis,,1
YERVOY,nephritis,,1
YERVOY,pneumonitis,,1
YERVOY,pneumonitis,,1
YERVOY,pneumonitis,,0
YERVOY,pneumonitis,,0
YERVOY,pneumonitis,,1
YERVOY,pneumonitis,,1
YERVOY,pneumonitis,,0
YERVOY,pneumonitis,,0
YERVOY,pneumonitis,,1
YERVOY,pneumonitis,,0
YERVOY,meningitis,,1
YERVOY,meningitis,,1
YERVOY,meningitis,,1
YERVOY,meningitis,,0
YERVOY,meningitis,,0
YERVOY,meningitis,,0
YERVOY,pericarditis,,0
YERVOY,uveitis,,0
YERVOY,uveitis,,0
YERVOY,iritis,,1
YERVOY,iritis,,1
YERVOY,iritis,,0
YERVOY,hemolytic anemia,,0
YERVOY,hemolytic anemia,,1
YERVOY,hemolytic anemia,,1
YERVOY,hemolytic anemia,,0
YERVOY,hemolytic anemia,,1
YERVOY,immune-mediated adverse reactions,,1
YERVOY,immune-mediated adverse reactions,,1
YERVOY,immune-mediated adverse reactions,,1
YERVOY,myocarditis,,1
YERVOY,myocarditis,,0
YERVOY,myocarditis,,0
YERVOY,myocarditis,,0
YERVOY,myocarditis,,1
YERVOY,myocarditis,,0
YERVOY,angiopathy,,0
YERVOY,angiopathy,,1
YERVOY,angiopathy,,0
YERVOY,angiopathy,,0
YERVOY,angiopathy,,1
YERVOY,angiopathy,,1
YERVOY,angiopathy,,1
YERVOY,angiopathy,,1
YERVOY,angiopathy,,0
YERVOY,angiopathy,,1
YERVOY,temporal arteritis,,1
YERVOY,temporal arteritis,,0
YERVOY,temporal arteritis,,1
YERVOY,temporal arteritis,,0
YERVOY,temporal arteritis,,1
YERVOY,temporal arteritis,,0
YERVOY,temporal arteritis,,1
YERVOY,vasculitis,,1
YERVOY,vasculitis,,0
YERVOY,vasculitis,,0
YERVOY,vasculitis,,1
YERVOY,vasculitis,,1
YERVOY,vasculitis,,1
YERVOY,vasculitis,,1
YERVOY,vasculitis,,0
YERVOY,vasculitis,,1
YERVOY,polymyalgia rheumatica,,1
YERVOY,polymyalgia rheumatica,,0
YERVOY,polymyalgia rheumatica,,1
YERVOY,polymyalgia rheumatica,,1
YERVOY,polymyalgia rheumatica,,0
YERVOY,polymyalgia rheumatica,,1
YERVOY,conjunctivitis,,1
YERVOY,conjunctivitis,,1
YERVOY,conjunctivitis,,0
YERVOY,blepharitis,,1
YERVOY,blepharitis,,1
YERVOY,blepharitis,,1
YERVOY,blepharitis,,1
YERVOY,blepharitis,,1
YERVOY,blepharitis,,0
YERVOY,blepharitis,,0
YERVOY,blepharitis,,1
YERVOY,episcleritis,,0
YERVOY,episcleritis,,1
YERVOY,episcleritis,,1
YERVOY,episcleritis,,0
YERVOY,episcleritis,,0
YERVOY,episcleritis,,0
YERVOY,episcleritis,,1
YERVOY,episcleritis,,1
YERVOY,scleritis,,1
YERVOY,scleritis,,1
YERVOY,scleritis,,0
YERVOY,scleritis,,1
YERVOY,scleritis,,1
YERVOY,scleritis,,1
YERVOY,scleritis,,0
YERVOY,leukocytoclastic vasculitis,,1
YERVOY,leukocytoclastic vasculitis,,0
YERVOY,leukocytoclastic vasculitis,,1
YERVOY,leukocytoclastic vasculitis,,1
YERVOY,leukocytoclastic vasculitis,,1
YERVOY,leukocytoclastic vasculitis,,0
YERVOY,leukocytoclastic vasculitis,,0
YERVOY,leukocytoclastic vasculitis,,1
YERVOY,leukocytoclastic vasculitis,,1
YERVOY,erythema multiforme,,1
YERVOY,erythema multiforme,,0
YERVOY,erythema multiforme,,0
YERVOY,erythema multiforme,,1
YERVOY,erythema multiforme,,1
YERVOY,erythema multiforme,,0
YERVOY,erythema multiforme,,0
YERVOY,erythema multiforme,,0
YERVOY,erythema multiforme,,1
YERVOY,pancreatitis,,1
YERVOY,pancreatitis,,1
YERVOY,pancreatitis,,0
YERVOY,pancreatitis,,0
YERVOY,arthritis,,0
YERVOY,arthritis,,1
YERVOY,arthritis,,1
YERVOY,arthritis,,1
YERVOY,autoimmune thyroiditis,,0
YERVOY,autoimmune thyroiditis,,1
YERVOY,autoimmune thyroiditis,,0
YERVOY,autoimmune thyroiditis,,0
YERVOY,autoimmune thyroiditis,,1
YERVOY,autoimmune thyroiditis,,1
YERVOY,autoimmune thyroiditis,,0
YERVOY,neurosensory hypoacusis,,1
YERVOY,neurosensory hypoacusis,,1
YERVOY,neurosensory hypoacusis,,0
YERVOY,neurosensory hypoacusis,,1
YERVOY,autoimmune central neuropathy,,0
YERVOY,autoimmune central neuropathy,,0
YERVOY,autoimmune central neuropathy,,0
YERVOY,autoimmune central neuropathy,,0
YERVOY,autoimmune central neuropathy,,0
YERVOY,autoimmune central neuropathy,,1
YERVOY,autoimmune central neuropathy,,1
YERVOY,autoimmune central neuropathy,,1
YERVOY,autoimmune central neuropathy,,1
YERVOY,encephalitis,,1
YERVOY,encephalitis,,1
YERVOY,encephalitis,,1
YERVOY,encephalitis,,0
YERVOY,myositis,,1
YERVOY,polymyositis,,1
YERVOY,polymyositis,,0
YERVOY,polymyositis,,0
YERVOY,polymyositis,,0
YERVOY,polymyositis,,1
YERVOY,polymyositis,,1
YERVOY,polymyositis,,1
YERVOY,ocular myositis,,0
YERVOY,ocular myositis,,1
YERVOY,ocular myositis,,1
YERVOY,ocular myositis,,0
YERVOY,ocular myositis,,1
YERVOY,ocular myositis,,1
GADAVIST,Nephrogenic Systemic Fibrosis,elsewhere in,0
GADAVIST,Nephrogenic Systemic Fibrosis,Boxed Warning and Warnings and Precautions,0
GADAVIST,Nephrogenic Systemic Fibrosis,serious adverse reactions are discussed elsewhere in,0
GADAVIST,Nephrogenic Systemic Fibrosis,adverse reactions are discussed elsewhere,0
GADAVIST,Nephrogenic Systemic Fibrosis,discussed elsewhere in,0
GADAVIST,Nephrogenic Systemic Fibrosis,discussed elsewhere in Nephrogenic Systemic,1
GADAVIST,Nephrogenic Systemic Fibrosis,are discussed,0
GADAVIST,NSF,,0
GADAVIST,NSF,NSF,1
GADAVIST,NSF,reactions are discussed elsewhere in labeling Nephrogenic Systemic Fibrosis,0
GADAVIST,NSF,NSF,1
GADAVIST,NSF,Precautions Hypersensitivity reactions see,0
GADAVIST,NSF,NSF,1
GADAVIST,NSF,NSF,1
GADAVIST,Hypersensitivity reactions,Most,0
GADAVIST,headache,headache,1
GADAVIST,headache,EXCERPT Most common adverse reactions incidence,0
GADAVIST,headache,,0
GADAVIST,headache,headache,1
GADAVIST,headache,headache,1
GADAVIST,headache,headache,1
GADAVIST,headache,incidence headache,1
GADAVIST,headache,headache,1
GADAVIST,nausea,SUSPECTED ADVERSE REACTIONS,0
GADAVIST,nausea,nausea,1
GADAVIST,nausea,,0
GADAVIST,nausea,nausea,1
GADAVIST,nausea,nausea,1
GADAVIST,nausea,reactions incidence are,0
GADAVIST,dizziness,common adverse reactions incidence are,0
GADAVIST,dizziness,are headache nausea dizziness,1
GADAVIST,dizziness,dizziness,1
GADAVIST,dizziness,incidence are headache nausea dizziness,1
GADAVIST,dizziness,reactions incidence,0
GADAVIST,dizziness,dizziness,1
GADAVIST,dizziness,report SUSPECTED ADVERSE,0
GADAVIST,dizziness,REACTIONS contact Bayer HealthCare Pharmaceuticals In,0
GADAVIST,Headache,,0
GADAVIST,Dizziness,usea,0
GADAVIST,Dizziness,Dizziness Dysgeus,1
GADAVIST,Dysgeusia,,0
GADAVIST,Dysgeusia,,0
GADAVIST,Feeling Hot,sgeusia,0
GADAVIST,Feeling Hot,Feeling Hot Injection,1
GADAVIST,Feeling Hot,sgeusia,0
GADAVIST,Feeling Hot,Hot Injection,1
GADAVIST,Feeling Hot,sgeusia Feeling,1
GADAVIST,Feeling Hot,Hot Injection,1
GADAVIST,Feeling Hot,sgeusia,0
GADAVIST,Feeling Hot,sgeusia,0
GADAVIST,Injection site reactions,Hot,0
GADAVIST,Vomiting,,0
GADAVIST,Vomiting,Rash,0
GADAVIST,Vomiting,,0
GADAVIST,Vomiting,jection site Vomiting Rash,1
GADAVIST,Vomiting,,0
GADAVIST,Vomiting,,0
GADAVIST,Vomiting,,0
GADAVIST,Vomiting,reactions,0
GADAVIST,Vomiting,jection site Vomiting Rash,1
GADAVIST,Vomiting,site reactions,0
GADAVIST,Rash,miting,0
GADAVIST,Rash,miting,0
GADAVIST,Rash,macular papular,0
GADAVIST,Rash,Rash includes generalized,1
GADAVIST,Rash,miting,0
GADAVIST,Rash,miting,0
GADAVIST,Rash,miting Rash includes generalized macular papular pruritic,1
GADAVIST,Rash,miting,0
GADAVIST,Rash,Rash includes generalized macular papular pruritic,1
GADAVIST,Pruritus,,0
GADAVIST,Pruritus,macular papular Pruritus includes generalized Erythe,1
GADAVIST,Hypersensitivity,,0
GADAVIST,Hypersensitivity,,0
GADAVIST,Hypersensitivity,ythema Hypersensitivity Anaphylactoid Dyspnea,1
GADAVIST,Hypersensitivity,Hypersensitivity,1
GADAVIST,Hypersensitivity,ythema,0
GADAVIST,Hypersensitivity,ythema,0
GADAVIST,Hypersensitivity,,0
GADAVIST,Anaphylactoid,Anaphylactoid Dyspnea,1
GADAVIST,Anaphylactoid,Hypersensitivity,0
GADAVIST,Anaphylactoid,Hypersensitivity Anaphylactoid Dyspnea,1
GADAVIST,Anaphylactoid,Hypersensitivity Anaphylactoid Dyspnea,1
GADAVIST,Anaphylactoid,Hypersensitivity Anaphylactoid Dyspnea,1
GADAVIST,Anaphylactoid,Anaphylactoid Dyspnea,1
GADAVIST,Anaphylactoid,Hypersensitivity Anaphylactoid Dyspnea,1
GADAVIST,Anaphylactoid,Anaphylactoid Dyspnea,1
GADAVIST,Anaphylactoid,Anaphylactoid Dyspnea,1
GADAVIST,Dyspnea,Dyspnea Pares,1
GADAVIST,Dyspnea,Dyspnea Pares,1
GADAVIST,Dyspnea,Dyspnea Pares,1
GADAVIST,Dyspnea,Pares,0
GADAVIST,Dyspnea,Dyspnea Pares,1
GADAVIST,Dyspnea,,0
GADAVIST,Dyspnea,Dyspnea Pares,1
GADAVIST,Dyspnea,Dyspnea Pares,1
GADAVIST,Dyspnea,Pares,0
GADAVIST,Paresthesia,Paresthesia Hy,1
GADAVIST,Paresthesia,spnea,0
GADAVIST,Paresthesia,,0
GADAVIST,Paresthesia,spnea Paresthesia Hy,1
GADAVIST,anaphylactoid reaction,may occur with,0
GADAVIST,anaphylactoid reaction,Hypersensitivity,0
GADAVIST,anaphylactoid reaction,,0
GADAVIST,anaphylactoid reaction,Hypersensitivity,0
GADAVIST,anaphylactoid reaction,Hypersensitivity anaphylactoid reaction may occur with,1
GADAVIST,anaphylactoid reaction,of the following adverse,0
GADAVIST,anaphylactoid reaction,Hypersensitivity anaphylactoid reaction may occur with one or,1
GADAVIST,anaphylactoid reaction,for example hypotension urticaria,0
GADAVIST,hypotension,hypotension urticaria face,1
GADAVIST,hypotension,more of the following,0
GADAVIST,hypotension,hypotension urticaria face,1
GADAVIST,hypotension,hypotension urticaria face,1
GADAVIST,hypotension,hypotension urticaria face,1
GADAVIST,urticaria,for example urticaria face edema,1
GADAVIST,urticaria,one,0
GADAVIST,urticaria,that occurred with a,0
GADAVIST,urticaria,urticaria face edema,1
GADAVIST,urticaria,urticaria face edema,1
GADAVIST,urticaria,urticaria face edema,1
GADAVIST,face edema,edema eyelid edema,1
GADAVIST,face edema,reactions for example hypotension face,1
GADAVIST,face edema,eyelid edema flushing Adverse reactions that occurred,0
GADAVIST,face edema,following,0
GADAVIST,face edema,hypotension face,1
GADAVIST,eyelid edema,one or more of the following adverse reactions for example hypotension urticaria face,0
GADAVIST,eyelid edema,more of the following adverse reactions for example hypotension urticaria face,0
GADAVIST,flushing,in,0
GADAVIST,flushing,face edema eyelid flushing Adverse reactions,1
GADAVIST,flushing,face edema eyelid flushing Adverse reactions,1
GADAVIST,flushing,,0
GADAVIST,loss of consciousness,parosmia tachycardia palpitation dry,0
GADAVIST,loss of consciousness,received Gadavist loss of consciousness convulsion parosmia,1
GADAVIST,parosmia,consciousness parosmia tachycardia palpitation,1
GADAVIST,parosmia,consciousness parosmia tachycardia palpitation,1
GADAVIST,parosmia,convulsion,0
GADAVIST,parosmia,frequency of in subjects who,0
GADAVIST,parosmia,of in subjects,0
GADAVIST,parosmia,consciousness convulsion,0
GADAVIST,parosmia,include loss of consciousness convulsion,0
GADAVIST,parosmia,include loss of consciousness parosmia tachycardia palpitation,1
GADAVIST,parosmia,,0
GADAVIST,parosmia,parosmia tachycardia palpitation,1
GADAVIST,tachycardia,Gadavist include loss,0
GADAVIST,tachycardia,,0
GADAVIST,tachycardia,,0
GADAVIST,tachycardia,tachycardia palpitation dry,1
GADAVIST,tachycardia,of consciousness convulsion tachycardia palpitation dry,1
GADAVIST,palpitation,of consciousness convulsion parosmia palpitation dry mouth,1
GADAVIST,dry mouth,convulsion parosmia tachycardia dry mouth malaise and,1
GADAVIST,dry mouth,dry mouth malaise and,1
GADAVIST,malaise,malaise and feeling,1
GADAVIST,malaise,,0
GADAVIST,malaise,parosmia tachycardia,0
GADAVIST,malaise,,0
GADAVIST,feeling cold,palpitation dry mouth malaise feeling,1
GADAVIST,feeling cold,reactions have,0
GADAVIST,feeling cold,feeling cold Postmarketing Experience,1
GADAVIST,feeling cold,and,0
GADAVIST,Cardiac arrest,Cardiac arrest Nephrogenic Systemic,1
GADAVIST,Cardiac arrest,Systemic Fibrosis NSF Hypersensitivity reactions anaphylactic shock c,0
GADAVIST,Cardiac arrest,arrest Nephrogenic Systemic,1
GADAVIST,Cardiac arrest,causal relationship to drug Cardiac,1
GADAVIST,Cardiac arrest,,0
GADAVIST,Nephrogenic Systemic Fibrosis,exposure Cardiac Nephrogenic Systemic Fibrosis NSF Hypersensitivity,1
GADAVIST,Nephrogenic Systemic Fibrosis,Cardiac arrest,0
GADAVIST,Nephrogenic Systemic Fibrosis,Nephrogenic Systemic Fibrosis NSF Hypersensitivity,1
GADAVIST,NSF,NSF Hypersensitivity reactions,1
GADAVIST,NSF,NSF Hypersensitivity reactions,1
GADAVIST,NSF,arrest Nephrogenic Systemic,0
GADAVIST,NSF,NSF Hypersensitivity reactions,1
GADAVIST,Hypersensitivity reactions,Nephrogenic Systemic Fibrosis Hypersensitivity reactions anaphylactic shock,1
GADAVIST,Hypersensitivity reactions,Systemic Fibrosis,0
GADAVIST,Hypersensitivity reactions,edema bronchospasm,0
GADAVIST,anaphylactic shock,NSF,0
GADAVIST,anaphylactic shock,anaphylactic shock circulatory collapse,1
GADAVIST,anaphylactic shock,shock circulatory collapse,1
GADAVIST,anaphylactic shock,anaphylactic,1
GADAVIST,anaphylactic shock,cyanosis oropharyngeal,0
GADAVIST,anaphylactic shock,arrest Nephrogenic Systemic Fibrosis NSF Hypersensitivity,0
GADAVIST,circulatory collapse,reactions anaphylactic,0
GADAVIST,circulatory collapse,reactions anaphylactic circulatory collapse respiratory arrest,1
GADAVIST,circulatory collapse,shock,0
GADAVIST,circulatory collapse,Nephrogenic Systemic Fibrosis NSF,0
GADAVIST,respiratory arrest,edema blood,0
GADAVIST,respiratory arrest,,0
GADAVIST,respiratory arrest,reactions,0
GADAVIST,respiratory arrest,circulatory respiratory,1
GADAVIST,respiratory arrest,respiratory arrest pulmonary edema,1
GADAVIST,respiratory arrest,respiratory arrest pulmonary edema,1
GADAVIST,respiratory arrest,Fibrosis NSF Hypersensitivity reactions,0
GADAVIST,respiratory arrest,,0
GADAVIST,pulmonary edema,pulmonary edema bronchospasm cyanosis,1
GADAVIST,pulmonary edema,pulmonary edema bronchospasm cyanosis,1
GADAVIST,pulmonary edema,pulmonary edema bronchospasm cyanosis,1
GADAVIST,pulmonary edema,respiratory pulmonary,1
GADAVIST,pulmonary edema,laryngeal edema blood pressure increased,0
GADAVIST,bronchospasm,bronchospasm cyanosis oropharyngeal,1
GADAVIST,bronchospasm,arrest pulmonary,0
GADAVIST,bronchospasm,bronchospasm cyanosis oropharyngeal,1
GADAVIST,bronchospasm,anaphylactic shock circulatory collapse respiratory,0
GADAVIST,oropharyngeal swelling,oropharyngeal swelling laryngeal edema,1
GADAVIST,oropharyngeal swelling,pulmonary edema bronchospasm oropharyngeal,1
GADAVIST,oropharyngeal swelling,collapse,0
GADAVIST,laryngeal edema,cyanosis oropharyngeal laryngeal edema blood pressure,1
GADAVIST,blood pressure increased,conjunctivitis hyperhidrosis cough sneezing,0
GADAVIST,blood pressure increased,laryngeal blood pressure,1
GADAVIST,blood pressure increased,swelling laryngeal blood,1
GADAVIST,blood pressure increased,swelling laryngeal blood pressure increased chest pain,1
GADAVIST,blood pressure increased,laryngeal blood pressure increased chest pain,1
GADAVIST,blood pressure increased,pulmonary edema bronchospasm cyanosis oropharyngeal swelling,0
GADAVIST,blood pressure increased,laryngeal blood pressure increased chest pain,1
GADAVIST,chest pain,bronchospasm cyanosis oropharyngeal swelling laryngeal,0
GADAVIST,chest pain,edema blood pressure chest,1
GADAVIST,chest pain,sensation and pallor,0
GADAVIST,chest pain,sensation and,0
GADAVIST,chest pain,edema blood pressure increased,0
GADAVIST,chest pain,chest,1
GADAVIST,angioedema,angioedema conjunctivitis hyperhidrosis,1
GADAVIST,angioedema,pressure increased chest angioedema conjunctivitis hyperhidrosis,1
GADAVIST,angioedema,P,0
GADAVIST,angioedema,P,0
GADAVIST,angioedema,blood pressure increased chest angioedema conjunctivitis hyperhidrosis,1
GADAVIST,angioedema,increased chest pain,0
GADAVIST,conjunctivitis,conjunctivitis hyperhidrosis cough,1
GADAVIST,conjunctivitis,blood pressure increased,0
GADAVIST,conjunctivitis,laryngeal edema blood pressure increased,0
GADAVIST,hyperhidrosis,and pallor see Warnings and Precautions,0
GADAVIST,hyperhidrosis,angioedema hyperhidrosis cough sneezing,1
GADAVIST,hyperhidrosis,angioedema hyperhidrosis cough sneezing,1
GADAVIST,hyperhidrosis,increased chest pain angioedema hyperhidrosis cough sneezing,1
GADAVIST,cough,,0
GADAVIST,cough,cough sneezing burning,1
GADAVIST,cough,chest pain angioedema conjunctivitis cough sneezing burning,1
GADAVIST,cough,cough sneezing burning,1
GADAVIST,cough,cough sneezing burning,1
GADAVIST,cough,pain angioedema,0
GADAVIST,sneezing,sneezing burning sensation,1
GADAVIST,sneezing,sneezing burning sensation,1
GADAVIST,sneezing,sneezing burning sensation,1
GADAVIST,sneezing,and,0
GADAVIST,sneezing,hyperhidrosis,0
GADAVIST,sneezing,sneezing burning sensation,1
GADAVIST,burning sensation,,0
GADAVIST,burning sensation,and pallor see Warnings and,0
GADAVIST,burning sensation,pain angioedema conjunctivitis,0
GADAVIST,burning sensation,pain angioedema,0
GADAVIST,burning sensation,pallor see,0
GADAVIST,burning sensation,burning sensation and pallor,1
GADAVIST,pallor,pallor see Warnings,1
GADAVIST,pallor,sneezing burning sensation pallor see Warnings,1
GADAVIST,pallor,sneezing burning sensation pallor see Warnings,1
GADAVIST,pallor,pallor see Warnings,1
GADAVIST,pallor,pallor see Warnings,1
GADAVIST,pallor,and Precautions,0
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,following serious adv erse,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,The following serious adv erse reactions are,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,,0
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,,0
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,in,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,,0
GADAVIST,NSF,Warnings and Precautions Hypersensitivity reactions see Contraindications,0
GADAVIST,NSF,reactions see,0
GADAVIST,NSF,are discussed elsewhere in labeling Nephrogenic Systemic Fibrosis,0
GADAVIST,NSF,see Contraindications,0
GADAVIST,NSF,Nephrogenic,0
GADAVIST,NSF,nin g and,1
GADAVIST,NSF,To report SUSPECTED,0
GADAVIST,NSF,Warnings and Precautions EXCERPT Most,0
GADAVIST,NSF,nci dence are,1
GADAVIST,NSF,nci dence are,1
GADAVIST,NSF,nci dence are,1
GADAVIST,NSF,common adverse reactions nci dence are,1
GADAVIST,NSF,nci dence are,1
GADAVIST,NSF,adverse reactions i,0
GADAVIST,NSF,nci dence are,1
GADAVIST,NSF,report SUSPECTED,0
GADAVIST,fatal,common,0
GADAVIST,fatal,h eadache nausea,1
GADAVIST,fatal,are h eadache nausea,1
GADAVIST,fatal,Most common adverse reactions,0
GADAVIST,fibrosis,report,0
GADAVIST,fibrosis,,0
GADAVIST,fibrosis,common,0
GADAVIST,fibrosis,reactions incidence are headache nausea,0
GADAVIST,fibrosis,reactions incidence are headache and dizz iness To,1
GADAVIST,fibrosis,reactions incidence are headache,0
GADAVIST,fibrosis,reactions incidence are,0
GADAVIST,fibrosis,adverse,0
GADAVIST,NSF,,0
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,male a,0
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,nd the ethnic,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,s Caucasian,0
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,nd the ethnic distribution wa s Caucasian,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,a,0
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,s Caucasian Asian Hispanic Black and patients,0
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,the subjects were male nd the ethnic distribution,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,were male nd the ethnic distribution wa s Caucasian,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,,0
GADAVIST,NSF,and the ethnic distribution 60% Caucasian Asian,1
GADAVIST,NSF,60% Caucasian Asian,1
GADAVIST,NSF,the ethnic distribution was,0
GADAVIST,NSF,yea rs Overall,1
GADAVIST,NSF,Overall approximately of,0
GADAVIST,NSF,yea rs Overall,1
GADAVIST,NSF,yea rs Overall,1
GADAVIST,NSF,yea rs Overall,1
GADAVIST,NSF,,0
GADAVIST,NSF,yea rs Overall,1
GADAVIST,NSF,yea rs Overall,1
GADAVIST,NSF,,0
GADAVIST,NSF,,0
GADAVIST,NSF,of  Gadavist were,1
GADAVIST,NSF,in nature Table lists advers,0
GADAVIST,NSF,reactions associated with the of  Gadavist were,1
GADAVIST,NSF,administration Adverse reactions associated with the,0
GADAVIST,NSF,of  Gadavist were,1
GADAVIST,NSF,Table,0
GADAVIST,Nephrogenic Systemic Fibrosis,discu ssed elsewhere in labeling,1
GADAVIST,Nephrogenic Systemic Fibrosis,s adverse reactions are,1
GADAVIST,Nephrogenic Systemic Fibrosis,,0
GADAVIST,Nephrogenic Systemic Fibrosis,,0
GADAVIST,Nephrogenic Systemic Fibrosis,s adverse,1
GADAVIST,hypersensitivity reactions,,0
GADAVIST,hypersensitivity reactions,an d Precautions EXCERPT Most common,1
GADAVIST,hypersensitivity reactions,,0
GADAVIST,hypersensitivity reactions,ations (4),1
GADAVIST,hypersensitivity reactions,,0
GADAVIST,hypersensitivity reactions,reactions see ations (4) and Warnings,1
GADAVIST,hypersensitivity reactions,Contraindic,0
GADAVIST,hypersensitivity reactions,,0
GADAVIST,hypersensitivity reactions,EXCERPT Most common adverse reactions incidence,0
GADAVIST,cutaneous manifestations,and Precautions CERPT:    *    Most comm on adverse reactions incidence are,1
GADAVIST,cutaneous manifestations,,0
GADAVIST,cutaneous manifestations,,0
GADAVIST,cutaneous manifestations,reactions,0
GADAVIST,cutaneous manifestations,,0
GADAVIST,death,,0
GADAVIST,death,adverse reactions are h eadache nausea and dizziness To,1
GADAVIST,death,reactions,0
GADAVIST,death,,0
GADAVIST,nephrogenic systemic fibrosis,at,0
GADAVIST,nephrogenic systemic fibrosis,FDA at,0
GADAVIST,nephrogenic systemic fibrosis,FDA at FDA,0
GADAVIST,nephrogenic systemic fibrosis,wwwfdagovmedwatch,0
GADAVIST,NSF,"ce
 Because clinical trials are conducted",1
GADAVIST,NSF,FDA at FDA or wwwfdagovmedwatch Clinical,0
GADAVIST,NSF,conducted under widely varying conditions,0
GADAVIST,NSF,at,0
GADAVIST,NSF,,0
GADAVIST,NSF,"ce
 Because clinical trials are conducted",1
GADAVIST,NSF,at FDA or wwwfdagovmedwatch Clinical,0
GADAVIST,NSF,FDA,0
GADAVIST,NSF,clinical trials are conducted under,0
GADAVIST,NSF,Experien,0
GADAVIST,NSF,and may t,1
GADAVIST,NSF,w,0
GADAVIST,NSF,His panic Black and patients of,1
GADAVIST,fatal,"Caucasian Asian Hispanic , and patients of other ethnic groups",1
GADAVIST,fatal,Black,0
GADAVIST,fatal,of other ethnic groups The average age was years range from week,0
GADAVIST,fatal,"Caucasian Asian Hispanic , and patients of other ethnic groups",1
GADAVIST,fatal,Black,0
GADAVIST,fatal,to years,0
GADAVIST,fatal,age was years range from week to years,0
GADAVIST,fatal,",",1
GADAVIST,fatal,range from week to,0
GADAVIST,fibrosis,years range,0
GADAVIST,fibrosis,nic groups The average age was,0
GADAVIST,fibrosis,the ethnic distribution was,0
GADAVIST,fibrosis,eth nic groups The average age,1
GADAVIST,fibrosis,and patients,0
GADAVIST,fibrosis,eth nic groups The average age,1
GADAVIST,hypersensitivity reactions,                           Dyspnea,1
GADAVIST,death,Paresthesia,0
GADAVIST,death,      Paresthesia,1
GADAVIST,death,Paresthesia,0
GADAVIST,death,,0
GADAVIST,death,,0
GADAVIST,death,      Paresthesia,1
GADAVIST,acute kidney injury,genic Systemic Fibr,1
OTEZLA,diarrhea,most common adverse reactions diarrhea,1
OTEZLA,diarrhea,common adverse reactions are,0
OTEZLA,diarrhea,common adverse,0
OTEZLA,nausea,diarrhea,0
OTEZLA,nausea,nausea,1
OTEZLA,nausea,are nausea,1
OTEZLA,nausea,most common adverse reactions,0
OTEZLA,nausea,common adverse,0
OTEZLA,nausea,most common,0
OTEZLA,nausea,EXCERPT Psoriatic Arthritis,0
OTEZLA,nausea,reactions are nausea,1
OTEZLA,nausea,common adverse reactions are diarrhea nausea,0
OTEZLA,nausea,nausea,1
OTEZLA,headache,nausea headache,1
OTEZLA,headache,headache,1
OTEZLA,headache,reactions are diarrhea nausea upper respir,0
OTEZLA,headache,headache,1
OTEZLA,diarrhea,adverse reactions diarrhea,1
OTEZLA,diarrhea,headache To,0
OTEZLA,diarrhea,tract infection and headache including,0
OTEZLA,diarrhea,reactions diarrhea,1
OTEZLA,diarrhea,nausea upper,0
OTEZLA,nausea,diarrhea,0
OTEZLA,nausea,Psoriasis The most common adverse reactions,0
OTEZLA,nausea,headache To report,0
OTEZLA,nausea,nausea,1
OTEZLA,nausea,adverse reactions are nausea,1
OTEZLA,nausea,S,0
OTEZLA,nausea,,0
OTEZLA,nausea,nausea,1
OTEZLA,nausea,most,0
OTEZLA,nausea,headache To report,0
OTEZLA,upper respiratory tract infection,upper respiratory,1
OTEZLA,headache,headache,1
OTEZLA,headache,headache,1
OTEZLA,headache,headache,1
OTEZLA,headache,headache,1
OTEZLA,headache,reactions,0
OTEZLA,headache,Corpo,0
OTEZLA,tension headache,respiratory,0
OTEZLA,tension headache,,0
OTEZLA,tension headache,,0
OTEZLA,tension headache,tension headache,1
OTEZLA,tension headache,infection and headache tension headache,1
OTEZLA,tension headache,are diarrhea nausea,0
OTEZLA,tension headache,Celgene Corporation at or,0
OTEZLA,Diarrhea,time with continued Diarrhea,1
OTEZLA,Diarrhea,time,0
OTEZLA,Diarrhea,time with continued Diarrhea,1
OTEZLA,Diarrhea,weeks,0
OTEZLA,Diarrhea,time with continued Diarrhea,1
OTEZLA,Diarrhea,Diarrhea,1
OTEZLA,Diarrhea,re,0
OTEZLA,Diarrhea,continued Diarrhea,1
OTEZLA,Diarrhea,Diarrhea,1
OTEZLA,headache,time with continued dosing headache,1
OTEZLA,nausea,resolve over,0
OTEZLA,nausea,nausea,1
OTEZLA,nausea,to,0
OTEZLA,nausea,nausea,1
OTEZLA,nausea,to,0
OTEZLA,nausea,nausea,1
OTEZLA,nausea,nausea,1
OTEZLA,nausea,for patients taking OTEZLA nausea,1
OTEZLA,nausea,taking OTEZLA nausea,1
OTEZLA,diarrhea,were diarrhea,1
OTEZLA,diarrhea,diarrhea,1
OTEZLA,diarrhea,diarrhea,1
OTEZLA,diarrhea,nausea,0
OTEZLA,diarrhea,headache The proportion of patients with psoriatic,0
OTEZLA,diarrhea,leading to discontinuation for patients,0
OTEZLA,diarrhea,taking OTEZLA were diarrhea,1
OTEZLA,diarrhea,diarrhea,1
OTEZLA,diarrhea,adverse reactions leading to discontinuation for patients taking OTEZLA were,0
OTEZLA,diarrhea,diarrhea,1
OTEZLA,gastrointestinal adverse reactions,adverse reactions,1
OTEZLA,gastrointestinal adverse reactions,mg twice dail,0
OTEZLA,gastrointestinal adverse reactions,,0
OTEZLA,gastrointestinal adverse reactions,the gastrointestinal adverse reactions,1
OTEZLA,gastrointestinal adverse reactions,Observed in Patients on Placebo for up to Day Week,0
OTEZLA,gastrointestinal adverse reactions,reactions,1
OTEZLA,gastrointestinal adverse reactions,Week,0
OTEZLA,gastrointestinal adverse reactions,adverse reactions,1
OTEZLA,nausea,daily subject treated with OTEZLA,0
OTEZLA,vomiting,OTEZLA mg,0
OTEZLA,vomiting,subject experienced a serious adverse reaction,0
OTEZLA,vomiting,vomiting,1
OTEZLA,vomiting,serious,0
OTEZLA,vomiting,vomiting,1
OTEZLA,vomiting,reaction of nausea vomiting,1
OTEZLA,vomiting,subject treated with OTEZLA,0
OTEZLA,vomiting,mg twice daily,0
OTEZLA,vomiting,and,0
OTEZLA,diarrhea,a serious adverse reaction diarrhea,1
OTEZLA,diarrhea,treated with OTEZLA mg twice daily experienced a,0
OTEZLA,diarrhea,diarrhea,1
OTEZLA,diarrhea,a serious adverse reaction diarrhea,1
OTEZLA,diarrhea,diarrhea,1
OTEZLA,diarrhea,twice daily experienced a serious adverse,0
OTEZLA,diarrhea,daily experienced a serious adverse reaction,0
OTEZLA,diarrhea,mg twice daily experienced a serious adverse reaction of,0
OTEZLA,diarrhea,,0
OTEZLA,headache,reaction headache,1
OTEZLA,headache,headache,1
OTEZLA,Diarrhea,a,0
OTEZLA,Diarrhea,Day,0
OTEZLA,Diarrhea,,0
OTEZLA,Diarrhea,Diarrhea a,1
OTEZLA,Diarrhea,to Day Nn Day to Nn Day to Day Nn,0
OTEZLA,Nausea,Nausea a,1
OTEZLA,Nausea,Nausea a,1
OTEZLA,Nausea,,0
OTEZLA,Nausea,,0
OTEZLA,Nausea,Nausea a,1
OTEZLA,Nausea,Nausea a,1
OTEZLA,Nausea,Nausea a,1
OTEZLA,Nausea,Nausea a,1
OTEZLA,Headache,Headache a,1
OTEZLA,Headache,Headache a,1
OTEZLA,Upper respiratory tractinfection,,0
OTEZLA,Upper respiratory tractinfection,Upper,1
OTEZLA,Upper respiratory tractinfection,Upper respiratory tractinfection b,1
OTEZLA,Nasopharyngitis,b,0
OTEZLA,Nasopharyngitis,,0
OTEZLA,Nasopharyngitis,,0
OTEZLA,Nasopharyngitis,,0
OTEZLA,Nasopharyngitis,,0
OTEZLA,Nasopharyngitis,Nasopharyngitis b,1
OTEZLA,Nasopharyngitis,Nasopharyngitis b,1
OTEZLA,Abdominal pain upper,Abdominal pain upper b,1
OTEZLA,Abdominal pain upper,,0
OTEZLA,Abdominal pain upper,,0
OTEZLA,Abdominal pain upper,,0
OTEZLA,Hypersensitivity,extension studies Immune system Hypersensitivity,1
OTEZLA,Hypersensitivity,system Hypersensitivity,1
OTEZLA,Hypersensitivity,clinical studies,0
OTEZLA,Hypersensitivity,patients on OTEZLA in clinical studies including extension studies Immune system,0
OTEZLA,Hypersensitivity,gastroesop,0
OTEZLA,Hypersensitivity,Hypersensitivity,1
OTEZLA,Hypersensitivity,decrease Gastrointestinal,0
OTEZLA,Hypersensitivity,,0
OTEZLA,Hypersensitivity,,0
OTEZLA,Hypersensitivity,Hypersensitivity,1
OTEZLA,Weight decrease,decrease,1
OTEZLA,Weight decrease,decrease,1
OTEZLA,Weight decrease,system disorders Hypersensitivity Weight,1
OTEZLA,Weight decrease,Hypersensitivity Weight decrease,1
OTEZLA,Weight decrease,Hypersensitivity,0
OTEZLA,Weight decrease,Weight decrease,1
OTEZLA,Weight decrease,system disorders Hypersensitivity Weight decrease,1
OTEZLA,Weight decrease,Disorders Frequent bowel movement gastroesophageal reflux disease dyspepsia,0
OTEZLA,Weight decrease,Immune system disorders Hypersensitivity Weight,1
OTEZLA,Frequent bowel movement,Metabolism and Nutrition Disorders,0
OTEZLA,Frequent bowel movement,Investigations Weight decrease Gastrointestinal Disorders,0
OTEZLA,Frequent bowel movement,Frequent bowel movement,1
OTEZLA,Frequent bowel movement,Nutrition,0
OTEZLA,Frequent bowel movement,Metabolism and Nutrition Disorders,0
OTEZLA,Frequent bowel movement,decrease,0
OTEZLA,Frequent bowel movement,,0
OTEZLA,Frequent bowel movement,Weight decrease Gastrointestinal Frequent bowel movement,1
OTEZLA,gastroesophageal reflux disease,bowel gastroesophageal reflux disease,1
OTEZLA,gastroesophageal reflux disease,Frequent bowel gastroesophageal reflux disease,1
OTEZLA,dyspepsia,System Disorders,0
OTEZLA,dyspepsia,dyspepsia,1
OTEZLA,dyspepsia,Disorders Migraine Res,0
OTEZLA,dyspepsia,dyspepsia,1
OTEZLA,dyspepsia,dyspepsia,1
OTEZLA,dyspepsia,Gastrointestinal Disorders Frequent bowel movement gastroesophageal,0
OTEZLA,Decreased appetite,gastroesophageal reflux disease dyspepsia Metabolism and Nutrition Disorders,0
OTEZLA,Migraine,Migraine,1
OTEZLA,Migraine,Metabolism and Nutrition Disorders Decreased appetite,0
OTEZLA,Migraine,Metabolism and Nutrition Disorders Decreased appetite,0
OTEZLA,Migraine,Disorders Cough Skin and Subcutaneous Tissue,0
OTEZLA,Migraine,Migraine,1
OTEZLA,Cough,Cough,1
OTEZLA,Cough,Cough,1
OTEZLA,Cough,Cough,1
OTEZLA,Cough,Tissue Disorders,0
OTEZLA,Cough,Disorders Rash patient treated with OTEZLA mg twice daily,0
OTEZLA,Cough,Cough,1
OTEZLA,Diarrhea,of Diarrhea,1
OTEZLA,Diarrhea,Diarrhea,1
OTEZLA,Diarrhea,of Diarrhea,1
OTEZLA,Diarrhea,Diarrhea,1
OTEZLA,Diarrhea,,0
OTEZLA,Diarrhea,,0
OTEZLA,nausea,were the most commonly reported adverse reactions The most,0
OTEZLA,nausea,nausea,1
OTEZLA,nausea,in age,0
OTEZLA,nausea,,0
OTEZLA,nausea,most commonly reported adverse,0
OTEZLA,nausea,nausea,1
OTEZLA,nausea,reported,0
OTEZLA,nausea,,0
OTEZLA,nausea,,0
OTEZLA,nausea,respiratory tract infection were the most commonly reported,0
OTEZLA,upper respiratory tract infection,upper respiratory tract infection,1
OTEZLA,upper respiratory tract infection,respiratory tract infection,1
OTEZLA,upper respiratory tract infection,overall median age of years Diarrhea nausea and,0
OTEZLA,upper respiratory tract infection,upper respiratory tract infection,1
OTEZLA,upper respiratory tract infection,years Diarrhea nausea upper respiratory tract infection,1
OTEZLA,upper respiratory tract infection,nausea upper respiratory tract infection,1
OTEZLA,upper respiratory tract infection,upper respiratory tract infection,1
OTEZLA,upper respiratory tract infection,The most common adverse reactions leading to,0
OTEZLA,upper respiratory tract infection,upper respiratory tract infection,1
OTEZLA,nausea,nausea,1
OTEZLA,nausea,nausea,1
OTEZLA,nausea,with psoriasis,0
OTEZLA,nausea,The,0
OTEZLA,nausea,for subjects taking,0
OTEZLA,diarrhea,discontinued treatment d,0
OTEZLA,diarrhea,diarrhea,1
OTEZLA,diarrhea,headache The proportion of subjects with psoriasis who,0
OTEZLA,diarrhea,diarrhea,1
OTEZLA,diarrhea,,0
OTEZLA,diarrhea,diarrhea,1
OTEZLA,headache,headache,1
OTEZLA,headache,due to any adverse,0
OTEZLA,abdominal pain,adverse reaction abdominal,1
OTEZLA,abdominal pain,reaction,0
OTEZLA,abdominal pain,,0
OTEZLA,abdominal pain,Day Week,0
OTEZLA,abdominal pain,serious adverse reaction abdominal,1
OTEZLA,abdominal pain,reaction abdominal pain,1
OTEZLA,abdominal pain,Day Week Two subjects treated with,0
OTEZLA,Diarrhea,Nausea,0
OTEZLA,Nausea,BID Nn Nausea,1
OTEZLA,Nausea,Nausea,1
OTEZLA,Nausea,tract,0
OTEZLA,Upper respiratory tract infection,tract infection,1
OTEZLA,Upper respiratory tract infection,Nausea,0
OTEZLA,Upper respiratory tract infection,headache,0
OTEZLA,Upper respiratory tract infection,Nausea Upper respiratory tract infection,1
OTEZLA,Upper respiratory tract infection,Nausea Upper respiratory tract,1
OTEZLA,Upper respiratory tract infection,infection Tension headache,1
OTEZLA,Upper respiratory tract infection,Nausea,0
OTEZLA,Upper respiratory tract infection,,0
OTEZLA,Upper respiratory tract infection,Nausea Upper respiratory,1
OTEZLA,Tension headache,infection,0
OTEZLA,Tension headache,Upper respiratory tract Tension headache Headache,1
OTEZLA,Tension headache,Tension headache Headache,1
OTEZLA,Tension headache,,0
OTEZLA,Tension headache,,0
OTEZLA,Tension headache,tract,0
OTEZLA,Tension headache,respiratory tract infection,0
OTEZLA,Tension headache,Tension,1
OTEZLA,Tension headache,tract Tension headache Headache,1
OTEZLA,Tension headache,tract,0
OTEZLA,Headache,headache,0
OTEZLA,Abdominal pain,Headache,0
OTEZLA,Abdominal pain,Headache,0
OTEZLA,Abdominal pain,Headache Abdominal,1
OTEZLA,Abdominal pain,Headache Abdominal pain Vomiting,1
OTEZLA,Abdominal pain,Vomiting,0
OTEZLA,Abdominal pain,Headache Abdominal,1
OTEZLA,Abdominal pain,pain Vomiting,1
OTEZLA,Abdominal pain,Abdominal pain Vomiting,1
OTEZLA,Vomiting,Vomiting Fatigue,1
OTEZLA,Vomiting,Vomiting Fatigue,1
OTEZLA,Vomiting,,0
OTEZLA,Vomiting,,0
OTEZLA,Vomiting,,0
OTEZLA,Vomiting,,0
OTEZLA,Vomiting,,0
OTEZLA,Vomiting,,0
OTEZLA,Vomiting,,0
OTEZLA,Fatigue,Vomiting Fatigue Dyspepsia,1
OTEZLA,Fatigue,Vomiting Fatigue Dyspepsia,1
OTEZLA,Fatigue,Fatigue Dyspepsia,1
OTEZLA,Fatigue,Fatigue Dyspepsia,1
OTEZLA,Dyspepsia,,0
OTEZLA,Dyspepsia,Dyspepsia Decrease,1
OTEZLA,Dyspepsia,Decrease appetite,0
OTEZLA,Dyspepsia,Fatigue,0
OTEZLA,Dyspepsia,Fatigue Dyspepsia Decrease,1
OTEZLA,Dyspepsia,Fatigue,0
OTEZLA,Dyspepsia,Dyspepsia Decrease,1
OTEZLA,Dyspepsia,,0
OTEZLA,Dyspepsia,Dyspepsia,1
OTEZLA,Decrease appetite,Dyspepsia,0
OTEZLA,Decrease appetite,Decrease appetite Insomnia,1
OTEZLA,Decrease appetite,,0
OTEZLA,Decrease appetite,Dyspepsia,0
OTEZLA,Decrease appetite,appetite Insomnia,1
OTEZLA,Insomnia,Insomnia,1
OTEZLA,Insomnia,Decrease Insomnia,1
OTEZLA,Insomnia,Decrease Insomnia,1
OTEZLA,Back pain,,0
OTEZLA,Back pain,Insomnia Back pain Migraine,1
OTEZLA,Back pain,Back pain Migraine,1
OTEZLA,Back pain,Insomnia Back pain Migraine,1
OTEZLA,Migraine,pain,0
OTEZLA,Migraine,,0
OTEZLA,Migraine,Migraine Frequent,1
OTEZLA,Migraine,Migraine Frequent,1
OTEZLA,Migraine,pain,0
OTEZLA,Migraine,,0
OTEZLA,Frequent bowel movements,Frequent bowel movements Depression,1
OTEZLA,Frequent bowel movements,Migraine,0
OTEZLA,Frequent bowel movements,movements Depression,1
OTEZLA,Frequent bowel movements,Migraine Frequent,1
OTEZLA,Frequent bowel movements,,0
OTEZLA,Frequent bowel movements,Migraine,0
OTEZLA,Depression,Depression Bronchitis,1
OTEZLA,Depression,,0
OTEZLA,Depression,bowel movements,0
OTEZLA,Depression,Bronchitis,0
OTEZLA,Depression,bowel movements,0
OTEZLA,Depression,,0
OTEZLA,Depression,Frequent bowel Depression Bronchitis,1
OTEZLA,Bronchitis,Depression,0
OTEZLA,Bronchitis,Bronchitis Tooth abscess,1
OTEZLA,Bronchitis,Tooth abscess,0
OTEZLA,Bronchitis,Depression Bronchitis Tooth,1
OTEZLA,Bronchitis,Depression,0
OTEZLA,Bronchitis,Depression,0
OTEZLA,Bronchitis,Depression,0
OTEZLA,Tooth abscess,Bronchitis Tooth,1
OTEZLA,Tooth abscess,Tooth abscess Folliculitis,1
OTEZLA,Tooth abscess,Bronchitis Tooth,1
OTEZLA,Tooth abscess,Bronchitis Tooth,1
OTEZLA,Tooth abscess,Tooth abscess Folliculitis,1
OTEZLA,Folliculitis,,0
OTEZLA,Folliculitis,,0
OTEZLA,Folliculitis,Tooth Folliculitis,1
OTEZLA,Folliculitis,Tooth Folliculitis,1
OTEZLA,Folliculitis,,0
OTEZLA,Folliculitis,Tooth Folliculitis,1
OTEZLA,Sinus headache,Folliculitis,0
OTEZLA,Sinus headache,Folliculitis,0
OTEZLA,Sinus headache,Folliculitis Sinus headache Severe worsening of,1
OTEZLA,depression,and PsA of similar design,0
OTEZLA,depression,[Studies P sA PsA and,1
OTEZLA,depression,placebocontrolled [Studies,1
OTEZLA,depression,,0
OTEZLA,depression,randomized doubleblind,0
OTEZLA,depression,doubleblind placebocontrolled,0
OTEZLA,depression,majority of,0
OTEZLA,depression,of treatment and tended,0
OTEZLA,depressed mood,reactions esented inTabl e occurred within,1
OTEZLA,depressed mood,esented inTabl e occurred within,1
OTEZLA,depression,with continued dosing Diarrhea,0
OTEZLA,depression,mmonly rep orted adverse reactions,1
OTEZLA,depression,were the most mmonly,1
OTEZLA,depression,,0
OTEZLA,depression,leading to discontinuation,0
OTEZLA,depression,were the most mmonly rep orted adverse reactions,1
OTEZLA,depression,leading to discontinuation for,0
OTEZLA,depression,and,0
OTEZLA,depression,mmonly rep orted adverse reactions,1
OTEZLA,depression,tended to,0
OTEZLA,depressed mood,were the most commonly reporte,0
OTEZLA,depressed mood,over time with continued dosing Diarrhea headache and nausea,0
OTEZLA,depressed mood,common adverse reactions leading to,0
OTEZLA,depressed mood,d adverse reac tions The most,1
OTEZLA,depressed mood,continued dosing Diarrhea headache and nausea were the most,0
OTEZLA,depressed mood,most,0
OTEZLA,depressed mood,adverse reac tions The most,1
OTEZLA,depressed mood,,0
OTEZLA,depressed mood,to discontinuation for patients,0
OTEZLA,Depression,most commonly reported adverse reactions The most common adverse,0
OTEZLA,Depression,The proportion,0
OTEZLA,Depression,to disco,0
OTEZLA,Depression,headache,0
OTEZLA,Depression,ntinuation for patients taking,1
OTEZLA,Depression,ntinuation for patients taking,1
OTEZLA,Depression,were nausea diarrhea and headache,0
OTEZLA,suicidal ideation,any adverse reaction,0
OTEZLA,suicidal ideation,proportion of patients with,0
OTEZLA,suicidal ideation,discontinued tr eatment due to,1
OTEZLA,suicidal ideation,with psoriatic arthritis o discontinued tr eatment due to,1
OTEZLA,suicidal ideation,to any adverse reaction was for patients taking OTEZLA,0
OTEZLA,suicidal ideation,o discontinued tr eatment due to,1
OTEZLA,suicidal ideation,o discontinued tr eatment due to,1
OTEZLA,suicide,OTEZLA mg,0
OTEZLA,suicide,T,0
OTEZLA,suicide,Adverse,0
OTEZLA,suicide,wice Da ily and Than,1
OTEZLA,depression,of nausea and miting in  OTEZLA mg twice,1
OTEZLA,depression,nausea and miting,1
OTEZLA,depression,and,0
OTEZLA,depression,and vo,0
OTEZLA,depression,twice daily subject treated with OTEZLA mg,0
OTEZLA,depression,serious adve,0
OTEZLA,depression,experienced a serious adverse reaction of,0
OTEZLA,depression,of diarrhea patient treated,0
OTEZLA,depression,,0
OTEZLA,Depression,Of the reported adverse drug reactions none were serious c n indicates,0
OTEZLA,suicidal behavior,to,0
OTEZLA,suicidal behavior,serious c n,0
OTEZLA,suicidal behavior,patients and                 P lacebo OTEZLA mg,1
OTEZLA,suicidal behavior,                P lacebo OTEZLA mg,1
OTEZLA,suicidal behavior,BID Preferred Term Day to N,0
OTEZLA,suicidal behavior,                P lacebo OTEZLA mg,1
OTEZLA,suicidal behavior,                P lacebo OTEZLA mg,1
OTEZLA,suicidal behavior,,0
OTEZLA,attempted suicide,Day to Day Nn Day to Nn Day,0
OTEZLA,attempted suicide,to 12(N=493)n,1
OTEZLA,attempted suicide,to 12(N=493)n,1
OTEZLA,attempted suicide,(%) Diarrhea a,1
OTEZLA,attempted suicide,to Nn Day to 12(N=493)n (%)    Diarrhea a,1
OTEZLA,attempted suicide,,0
OTEZLA,suicide,Day to Day Nn Diarrhea a,0
OTEZLA,suicide,Day Nn Diarrhea,0
OTEZLA,suicide,        Nausea a,1
OTEZLA,suicide,Nn Diarrhea,0
OTEZLA,suicide,        Nausea a,1
OTEZLA,suicide,to Day,0
OTEZLA,suicide,a,0
OTEZLA,weight decrease,             7 ,1
OTEZLA,weight decrease,,0
OTEZLA,weight decrease,a,0
OTEZLA,weight decrease,             7 ,1
OTEZLA,weight decrease,,0
OTEZLA,weight decrease,,0
OTEZLA,weight decrease,             7 ,1
OTEZLA,Weight decrease,Vomitin,0
OTEZLA,Weight decrease,Vomitin,0
DYSPORT,Spread of Effects from Toxin,between Botulinum,0
DYSPORT,Spread of Effects from Toxin,from Toxin,1
DYSPORT,Spread of Effects from Toxin,Products seeWarnings and Spread of Effects from Toxin,1
DYSPORT,Spread of Effects from Toxin,Toxin,1
DYSPORT,Spread of Effects from Toxin,of Effects from Toxin,1
DYSPORT,Spread of Effects from Toxin,,0
DYSPORT,Spread of Effects from Toxin,seeWarnings and Precautions Dysphagia and Breathing Difficulties seeWarnings and Pr,0
DYSPORT,Spread of Effects from Toxin,and Precautions,0
DYSPORT,Dysphagia,Dysphagia,1
DYSPORT,Dysphagia,Dysphagia,1
DYSPORT,Dysphagia,Spread of Effects from Toxin seeWarnings,0
DYSPORT,Dysphagia,from Toxin seeWarnings and Dysphagia,1
DYSPORT,Dysphagia,Anatomy in the Treatmen,0
DYSPORT,Breathing Difficulties,seeWarnings and Precautions Dysphagia Breathing,1
DYSPORT,Breathing Difficulties,,0
DYSPORT,Breathing Difficulties,and Precautions Dysphagia Breathing,1
DYSPORT,Breathing Difficulties,Difficulties,1
DYSPORT,Intradermal Immune Reaction,commonly obs,0
DYSPORT,Intradermal Immune Reaction,Intradermal Immune Reaction,1
DYSPORT,Intradermal Immune Reaction,Cervical Dystonia Most commonly,0
DYSPORT,muscular weakness,of patients muscular,1
DYSPORT,muscular weakness,patients muscular,1
DYSPORT,muscular weakness,mouth injection site discomfort fatigue headache neck pain musculoskeletal,0
DYSPORT,muscular weakness,Cervical,0
DYSPORT,muscular weakness,commonly observed adverse reactions of,0
DYSPORT,muscular weakness,,0
DYSPORT,muscular weakness,commonly observed adverse reactions of patients,0
DYSPORT,muscular weakness,discomfort fatigue headache neck pain musculoskeletal,0
DYSPORT,muscular weakness,muscular weakness,1
DYSPORT,dysphagia,,0
DYSPORT,dysphagia,dysphagia,1
DYSPORT,dysphagia,patients are muscular dysphagia,1
DYSPORT,dysphagia,headache neck,0
DYSPORT,dysphagia,are muscular dysphagia,1
DYSPORT,dry mouth,mouth,1
DYSPORT,dry mouth,weakness dry mouth,1
DYSPORT,dry mouth,mouth,1
DYSPORT,dry mouth,are muscular weakness dry mouth,1
DYSPORT,dry mouth,mouth,1
DYSPORT,dry mouth,are muscular weakness dry mouth,1
DYSPORT,dry mouth,weakness dry mouth,1
DYSPORT,dry mouth,commonly observed adverse reactions of patients are muscular weakness,0
DYSPORT,injection site discomfort,dysphagia dry injection site discomfort,1
DYSPORT,injection site discomfort,muscular weakness dysphagia dry injection site discomfort,1
DYSPORT,injection site discomfort,,0
DYSPORT,injection site discomfort,dysphagia dry injection site,1
DYSPORT,injection site discomfort,pain,0
DYSPORT,injection site discomfort,dysphagia,0
DYSPORT,injection site discomfort,,0
DYSPORT,injection site discomfort,dry mouth,0
DYSPORT,injection site discomfort,,0
DYSPORT,injection site discomfort,pain,0
DYSPORT,fatigue,pain,0
DYSPORT,fatigue,,0
DYSPORT,fatigue,fatigue,1
DYSPORT,fatigue,site fatigue,1
DYSPORT,headache,are muscular,0
DYSPORT,headache,mouth injection site discomfort headache,1
DYSPORT,headache,pain dysphonia injection site pain and,0
DYSPORT,headache,and eye,0
DYSPORT,neck pain,discomfort,0
DYSPORT,neck pain,injection site discomfort fatigue neck,1
DYSPORT,neck pain,site discomfort fatigue neck,1
DYSPORT,neck pain,muscular weakness dysphagia dry,0
DYSPORT,neck pain,neck pain,1
DYSPORT,neck pain,,0
DYSPORT,neck pain,muscular weakness dysphagia,0
DYSPORT,musculoskeletal pain,pain and eye disorders Glabellar Lines The most,0
DYSPORT,musculoskeletal pain,discomfort fatigue headache neck musculoskeletal,1
DYSPORT,musculoskeletal pain,pain,1
DYSPORT,musculoskeletal pain,,0
DYSPORT,musculoskeletal pain,,0
DYSPORT,musculoskeletal pain,discomfort fatigue headache neck musculoskeletal pain,1
DYSPORT,musculoskeletal pain,pain,1
DYSPORT,dysphonia,site discomfort fatigue headache neck,0
DYSPORT,dysphonia,disorders Glabellar Lines,0
DYSPORT,dysphonia,site,0
DYSPORT,dysphonia,pain,0
DYSPORT,dysphonia,disorders Glabellar Lines The,0
DYSPORT,dysphonia,eye disorders Glabellar,0
DYSPORT,dysphonia,,0
DYSPORT,dysphonia,dry mouth injection site discomfort fatigue,0
DYSPORT,dysphonia,eye disorders Glabellar,0
DYSPORT,dysphonia,pain musculoskeletal,0
DYSPORT,injection site pain,reaction,0
DYSPORT,injection site pain,disorders Glabellar,0
DYSPORT,injection site pain,injection site,1
DYSPORT,injection site pain,pain musculoskeletal pain,0
DYSPORT,injection site pain,,0
DYSPORT,injection site pain,Glabellar Lines The most frequently reported adverse,0
DYSPORT,eye disorders,,0
DYSPORT,eye disorders,,0
DYSPORT,nasopharyngitis,nasopharyngitis,1
DYSPORT,nasopharyngitis,frequently reported adverse reactions nasopharyngitis,1
DYSPORT,headache,headache,1
DYSPORT,headache,,0
DYSPORT,headache,are headache,1
DYSPORT,headache,Lines The,0
DYSPORT,injection site pain,are nasopharyngitis injection site,1
DYSPORT,injection site pain,frequently reported adverse reactions are nasopharyngitis headache,0
DYSPORT,injection site pain,reactions are nasopharyngitis injection site,1
DYSPORT,injection site pain,adverse reactions are nasopharyngitis injection site pain,1
DYSPORT,injection site pain,injection site pain,1
DYSPORT,injection site pain,sinusitis,0
DYSPORT,injection site pain,nasopharyngitis,0
DYSPORT,injection site pain,site pain,1
DYSPORT,injection site reaction,reaction,1
DYSPORT,injection site reaction,tract infection eyelid edema eyelid ptosis sinusitis and nausea,0
DYSPORT,injection site reaction,respiratory tract infection eyelid edema eyelid ptosis sinusitis,0
DYSPORT,upper respiratory tract infection,respiratory tract infection,1
DYSPORT,upper respiratory tract infection,edema eyelid ptosis sinusitis and nausea,0
DYSPORT,upper respiratory tract infection,The mo,0
DYSPORT,upper respiratory tract infection,injection site upper respiratory,1
DYSPORT,upper respiratory tract infection,upper respiratory tract infection,1
DYSPORT,upper respiratory tract infection,upper respiratory tract,1
DYSPORT,upper respiratory tract infection,site upper,1
DYSPORT,upper respiratory tract infection,tract infection,1
DYSPORT,upper respiratory tract infection,upper respiratory tract,1
DYSPORT,upper respiratory tract infection,eyelid edema eyelid ptosis sinusitis and,0
DYSPORT,eyelid edema,upper respiratory tract eyelid edema,1
DYSPORT,eyelid edema,Spasticity,0
DYSPORT,eyelid edema,respiratory tract infection,0
DYSPORT,eyelid edema,upper respiratory tract eyelid edema,1
DYSPORT,eyelid edema,Limb Spasticity,0
DYSPORT,eyelid ptosis,eyelid eyelid ptosis,1
DYSPORT,sinusitis,sinusitis,1
DYSPORT,sinusitis,The most frequently,0
DYSPORT,sinusitis,sinusitis,1
DYSPORT,nausea,nausea,1
DYSPORT,nausea,nausea,1
DYSPORT,nausea,edema eyelid ptosis,0
DYSPORT,nausea,,0
DYSPORT,urinary tract infection,infection,1
DYSPORT,urinary tract infection,The most frequently,0
DYSPORT,urinary tract infection,Limb Spasticity The most frequently reported adverse,0
DYSPORT,urinary tract infection,reported adverse reactions urinary tract,1
DYSPORT,urinary tract infection,,0
DYSPORT,urinary tract infection,are,0
DYSPORT,nasopharyngitis,pain dizziness fall and depression To report SUSP,0
DYSPORT,nasopharyngitis,nasopharyngitis,1
DYSPORT,nasopharyngitis,,0
DYSPORT,nasopharyngitis,nasopharyngitis,1
DYSPORT,nasopharyngitis,urinary tract nasopharyngitis,1
DYSPORT,muscular weakness,muscular weakness,1
DYSPORT,muscular weakness,SUSPECTED,0
DYSPORT,muscular weakness,infection nasopharyngitis,0
DYSPORT,musculoskeletal pain,muscular musculoskeletal pain,1
DYSPORT,musculoskeletal pain,musculoskeletal,1
DYSPORT,musculoskeletal pain,musculoskeletal pain,1
DYSPORT,dizziness,muscular weakness,0
DYSPORT,dizziness,dizziness,1
DYSPORT,dizziness,muscular weakness musculoskeletal dizziness,1
DYSPORT,dizziness,muscular weakness,0
DYSPORT,dizziness,,0
DYSPORT,dizziness,tract infection nasopharyngitis,0
DYSPORT,dizziness,dizziness,1
DYSPORT,fall,and depression To report SUSPECTED,0
DYSPORT,fall,fall,1
DYSPORT,depression,depression,1
DYSPORT,depression,,0
DYSPORT,depression,depression,1
DYSPORT,depression,musculoskeletal pain dizziness fall depression,1
DYSPORT,muscular weakness,r in the placebo controlled,0
DYSPORT,muscular weakness,fatigue headache,0
DYSPORT,muscular weakness,trials in,0
DYSPORT,muscular weakness,headache neck,0
DYSPORT,muscular weakness,,0
DYSPORT,dry mouth,pain musculoskeletal pain,0
DYSPORT,dry mouth,trials in cervical dystonia patients were muscular,0
DYSPORT,dry mouth,site discomfort fatigue headache neck,0
DYSPORT,dry mouth,mouth,1
DYSPORT,dry mouth,,0
DYSPORT,dry mouth,clinical trials,0
DYSPORT,dry mouth,weakness dry mouth,1
DYSPORT,dry mouth,discomfort fatigue headache neck pain,0
DYSPORT,dry mouth,were muscular weakness dry,1
DYSPORT,injection site discomfort,clinical trials in cervical dystonia patients were muscular weakness dysphagia dry,0
DYSPORT,injection site discomfort,discomfort,1
DYSPORT,injection site discomfort,dysphagia dry injection site,1
DYSPORT,fatigue,dystonia,0
DYSPORT,fatigue,mouth injection site fatigue,1
DYSPORT,fatigue,site fatigue,1
DYSPORT,fatigue,injection site fatigue,1
DYSPORT,fatigue,dysphagia dry,0
DYSPORT,fatigue,eye disorders cons,0
DYSPORT,headache,headache,1
DYSPORT,headache,headache,1
DYSPORT,headache,headache,1
DYSPORT,headache,fatigue,0
DYSPORT,headache,headache,1
DYSPORT,headache,site discomfort headache,1
DYSPORT,neck pain,pain,1
DYSPORT,neck pain,site discomfort fatigue neck pain,1
DYSPORT,neck pain,site discomfort fatigue neck pain,1
DYSPORT,neck pain,discomfort fatigue,0
DYSPORT,neck pain,pain,1
DYSPORT,neck pain,discomfort fatigue neck,1
DYSPORT,neck pain,pain and eye disorders consisting of blurred vis,0
DYSPORT,neck pain,dysphonia injection,0
DYSPORT,neck pain,injection site discomfort fatigue neck,1
DYSPORT,neck pain,,0
DYSPORT,musculoskeletal pain,neck musculoskeletal,1
DYSPORT,musculoskeletal pain,headache neck musculoskeletal,1
DYSPORT,musculoskeletal pain,,0
DYSPORT,musculoskeletal pain,dry mouth injection site discomfort fatigue headache neck pain,0
DYSPORT,musculoskeletal pain,fatigue headache neck musculoskeletal,1
DYSPORT,musculoskeletal pain,,0
DYSPORT,musculoskeletal pain,discomfort fatigue headache neck musculoskeletal pain,1
DYSPORT,musculoskeletal pain,neck musculoskeletal,1
DYSPORT,dysphonia,fatigue headache,0
DYSPORT,dysphonia,and reduced visual,0
DYSPORT,dysphonia,eye disorders consisting of blurred vision diplopia,0
DYSPORT,dysphonia,dysphonia,1
DYSPORT,dysphonia,dysphonia,1
DYSPORT,dysphonia,disorders consisting of blurred vision diplopia and,0
DYSPORT,dysphonia,,0
DYSPORT,dysphonia,dysphonia,1
DYSPORT,injection site pain,site pain,1
DYSPORT,injection site pain,pain,1
DYSPORT,injection site pain,discomfort fatigue headache neck pain musculoskeletal,0
DYSPORT,injection site pain,neck pain musculoskeletal pain injection site,1
DYSPORT,injection site pain,pain,1
DYSPORT,injection site pain,site pain,1
DYSPORT,blurred vision,injection site,0
DYSPORT,blurred vision,eye disorders consisting blurred vision,1
DYSPORT,blurred vision,consisting blurred vision,1
DYSPORT,blurred vision,eye disorders consisting blurred,1
DYSPORT,blurred vision,visual acuity and accommodation,0
DYSPORT,blurred vision,and eye disorders consisting blurred,1
DYSPORT,blurred vision,eye,0
DYSPORT,blurred vision,,0
DYSPORT,blurred vision,dysphonia injection site pain,0
DYSPORT,diplopia,disorders consisting of blurred diplopia,1
DYSPORT,diplopia,accommodation Other than injection,0
DYSPORT,diplopia,acuity and accommodation Other than injection site,0
DYSPORT,diplopia,dysphonia injection site pain and eye disorders consisting of blurred vision,0
DYSPORT,diplopia,diplopia,1
DYSPORT,diplopia,diplopia,1
DYSPORT,diplopia,,0
DYSPORT,reduced visual acuity,accommodation Other than injection site reactions most,0
DYSPORT,reduced visual acuity,,0
DYSPORT,reduced visual acuity,Other than,0
DYSPORT,reduced visual acuity,,0
DYSPORT,reduced visual acuity,accommodation Other than injection,0
DYSPORT,injection site reactions,injection site reactions,1
DYSPORT,injection site reactions,reactions,1
DYSPORT,injection site reactions,site reactions,1
DYSPORT,injection site reactions,about one week after treatment and lasted several weeks,0
DYSPORT,injection site reactions,injection site reactions,1
DYSPORT,disturbance in attention,patient disturbance in,1
DYSPORT,disturbance in attention,disturbance in attention,1
DYSPORT,disturbance in attention,in attention,1
DYSPORT,disturbance in attention,patient experienced dysphagia Table,0
DYSPORT,disturbance in attention,reactions leading to withdrawal One patient,0
DYSPORT,disturbance in attention,one patient,0
DYSPORT,disturbance in attention,One patient disturbance in attention,1
DYSPORT,disturbance in attention,disturbance in,1
DYSPORT,eyelid disorder,disorder,1
DYSPORT,eyelid disorder,Table compares the inc,0
DYSPORT,eyelid disorder,,0
DYSPORT,eyelid disorder,,0
DYSPORT,eyelid disorder,disorder,1
DYSPORT,feeling abnormal,feeling abnormal,1
DYSPORT,feeling abnormal,in attention eyelid feeling,1
DYSPORT,feeling abnormal,,0
DYSPORT,feeling abnormal,disorder,0
DYSPORT,feeling abnormal,attention eyelid feeling abnormal,1
DYSPORT,headache,,0
DYSPORT,headache,headache,1
DYSPORT,headache,headache,1
DYSPORT,headache,Table compares the incidence of the,0
DYSPORT,headache,eyelid disorder feeling abnormal and,0
DYSPORT,headache,headache,1
DYSPORT,headache,,0
DYSPORT,headache,and one patient experienced dysphagia Table compares the,0
DYSPORT,dysphagia,dysphagia,1
DYSPORT,dysphagia,dysphagia,1
DYSPORT,dysphagia,attention eyelid disorder feeling abnormal and headache and,0
DYSPORT,dysphagia,feeling abnormal and headache,0
DYSPORT,dysphagia,the most,0
DYSPORT,dysphagia,patient dysphagia,1
DYSPORT,Injection site discomfort,,0
DYSPORT,Injection site discomfort,,0
DYSPORT,Fatigue,discomfort,0
DYSPORT,Fatigue,Fatigue,1
DYSPORT,Fatigue,discomfort,0
DYSPORT,Fatigue,,0
DYSPORT,Fatigue,,0
DYSPORT,Fatigue,,0
DYSPORT,Fatigue,,0
DYSPORT,Fatigue,,0
DYSPORT,Fatigue,Fatigue,1
DYSPORT,Fatigue,,0
DYSPORT,Injection site pain,Musculoske,0
DYSPORT,Injection site pain,Injection site pain Musculoske,1
DYSPORT,Injection site pain,Injection,1
DYSPORT,Injection site pain,,0
DYSPORT,Muscular weakness,tissue,0
DYSPORT,Musculoskeletal pain,weakness,0
DYSPORT,Musculoskeletal pain,weakness,0
DYSPORT,Musculoskeletal pain,,0
DYSPORT,Dysphagia,Dysphagia,1
DYSPORT,Dysphagia,Dysphagia,1
DYSPORT,Dry mouth,,0
DYSPORT,Dry mouth,Dry mouth,1
DYSPORT,Dry mouth,Dry,1
DYSPORT,Dry mouth,Dry mouth,1
DYSPORT,Headache,Headache,1
DYSPORT,Headache,Headache,1
DYSPORT,Headache,,0
DYSPORT,Dysphonia,,0
DYSPORT,Dysphonia,Dysphonia,1
DYSPORT,Dysphonia,thoracic and mediastinal Dysphonia,1
DYSPORT,Dysphonia,Dysphonia,1
DYSPORT,Dysphonia,mediastinal disorders,0
DYSPORT,Dysphagia,Dysphagia,1
DYSPORT,Dysphagia,,0
DYSPORT,Dysphagia,,0
DYSPORT,Dry Mouth,,0
DYSPORT,Dry Mouth,,0
DYSPORT,Dry Mouth,,0
DYSPORT,Dry Mouth,,0
DYSPORT,Dry Mouth,Dry Mouth,1
DYSPORT,Dry Mouth,Dry,1
DYSPORT,Dry Mouth,,0
DYSPORT,Muscular Weakness,Weakness Inje,1
DYSPORT,Muscular Weakness,,0
DYSPORT,Muscular Weakness,Muscular,1
DYSPORT,Muscular Weakness,,0
DYSPORT,Muscular Weakness,Weakness Inje,1
DYSPORT,Muscular Weakness,,0
DYSPORT,Muscular Weakness,,0
DYSPORT,Muscular Weakness,Muscular,1
DYSPORT,Dysphonia,,0
DYSPORT,Dysphonia,Dysphonia,1
DYSPORT,Facial Paresis,,0
DYSPORT,Facial Paresis,,0
DYSPORT,Facial Paresis,,0
DYSPORT,Facial Paresis,,0
DYSPORT,Facial Paresis,Paresis E,1
DYSPORT,Facial Paresis,Facial Paresis E,1
DYSPORT,Facial Paresis,Facial Paresis E,1
DYSPORT,Facial Paresis,E,0
DYSPORT,Facial Paresis,Facial Paresis E,1
DYSPORT,Injection site discomfort,and,0
DYSPORT,Injection site discomfort,Site Injection,1
DYSPORT,Injection site discomfort,Site,0
DYSPORT,Injection site discomfort,Injection Site Injection,1
DYSPORT,Injection site discomfort,site discomfort and,1
DYSPORT,Injection site discomfort,,0
DYSPORT,injection site pain,Injection site discomfort injection site,1
DYSPORT,injection site pain,DYSPORT r administration Less,0
DYSPORT,injection site pain,injection site pain were,1
DYSPORT,injection site pain,Reactions Injection site discomfort injection,1
DYSPORT,injection site pain,injection site pain were,1
DYSPORT,injection site pain,,0
DYSPORT,injection site pain,DYSPORT,0
DYSPORT,injection site pain,adverse reactions following DYSPORT r administration Less,0
DYSPORT,Breathing difficulties,Breathing Breathing,1
DYSPORT,dyspnea,The,0
DYSPORT,dyspnea,doubleblind phase These consisted mainly of,0
DYSPORT,dyspnea,,0
DYSPORT,dyspnea,,0
DYSPORT,dyspnea,in,0
DYSPORT,dyspnea,dyspnea The,1
DYSPORT,dyspnea,in clinical trials during the doubleblind phase,0
DYSPORT,dyspnea,was approximately one week and,0
DYSPORT,dyspnea,dyspnea The,1
DYSPORT,dizziness,in the doubleblind phase,0
DYSPORT,dizziness,the,0
DYSPORT,dizziness,dizziness in,1
DYSPORT,dizziness,treated patients and of,0
DYSPORT,dizziness,of DYSPORT r treated patients and of placebotreated patients and muscle,0
DYSPORT,dizziness,of DYSPORT r treated patients and,0
DYSPORT,dizziness,,0
DYSPORT,dizziness,,0
DYSPORT,muscle atrophy,L,0
DYSPORT,muscle atrophy,treated patients and of placebotreated patients and,0
DYSPORT,muscle atrophy,atrophy in,1
DYSPORT,muscle atrophy,and of placebotreated patients muscle atrophy in,1
DYSPORT,muscle atrophy,atrophy in,1
DYSPORT,muscle atrophy,of DYSPORT r treated patients and of placebotreated,0
DYSPORT,muscle atrophy,of placebotreated patients muscle atrophy in,1
DYSPORT,muscle atrophy,muscle atrophy in,1
DYSPORT,reduction in heart rate,in heart rate compared,1
DYSPORT,reduction in heart rate,or active control This study showed a statistically,0
DYSPORT,reduction in heart rate,,0
DYSPORT,reduction in heart rate,study showed a statistically,0
DYSPORT,reduction in heart rate,This study,0
DYSPORT,nasopharyngitis,nasopharyngitis headache,1
DYSPORT,nasopharyngitis,of DYSPORT r nasopharyngitis headache,1
DYSPORT,nasopharyngitis,injection site pain injection site reaction upper respiratory,0
DYSPORT,nasopharyngitis,nasopharyngitis headache,1
DYSPORT,nasopharyngitis,r were,0
DYSPORT,headache,common adverse reactions following injection of DYSPORT,0
DYSPORT,headache,headache injection,1
DYSPORT,injection site pain,tract infection,0
DYSPORT,injection site pain,respiratory tract infection eyelid edema eyelid,0
DYSPORT,injection site pain,,0
DYSPORT,injection site pain,DYSPORT r were nasopharyngitis injection site,1
DYSPORT,injection site pain,r were nasopharyngitis injection,1
DYSPORT,injection site pain,injection site pain injection,1
DYSPORT,injection site pain,,0
DYSPORT,injection site reaction,eyelid ptosis sinusitis,0
DYSPORT,injection site reaction,eyelid ptosis sinusitis and nausea,0
DYSPORT,injection site reaction,upper respiratory,0
DYSPORT,injection site reaction,injection site injection site reaction upper,1
DYSPORT,upper respiratory tract infection,nausea Table reflects exposure to,0
DYSPORT,upper respiratory tract infection,site,0
DYSPORT,upper respiratory tract infection,injection site pain injection site,0
DYSPORT,eyelid edema,to DYSPORT,0
DYSPORT,eyelid edema,respiratory tract infection,0
DYSPORT,eyelid edema,site pain,0
DYSPORT,eyelid edema,reaction upper respiratory tract eyelid,1
DYSPORT,eyelid ptosis,nausea,0
DYSPORT,eyelid ptosis,reaction upper respiratory tract infection,0
DYSPORT,eyelid ptosis,site,0
DYSPORT,eyelid ptosis,respiratory tract infection eyelid eyelid,1
DYSPORT,eyelid ptosis,eyelid eyelid ptosis sinusitis,1
DYSPORT,eyelid ptosis,eyelid ptosis sinusitis,1
DYSPORT,eyelid ptosis,and nausea Table reflects exposure to DYSPORT r in patients,0
DYSPORT,eyelid ptosis,upper,0
DYSPORT,eyelid ptosis,eyelid eyelid ptosis sinusitis,1
DYSPORT,eyelid ptosis,sinusitis and nausea Table reflects exposure to DYSPORT,0
DYSPORT,sinusitis,sinusitis and,1
DYSPORT,sinusitis,eyelid,0
DYSPORT,sinusitis,sinusitis and,1
DYSPORT,nausea,sinusitis nausea Table,1
DYSPORT,nausea,reaction upper respiratory tract infection eyelid edema,0
DYSPORT,nausea,nausea Table,1
DYSPORT,nausea,nausea Table,1
DYSPORT,nausea,age who,0
DYSPORT,nausea,eyelid ptosis sinusitis nausea Table,1
DYSPORT,nausea,edema eyelid ptosis,0
DYSPORT,nausea,nausea Table,1
DYSPORT,Eyelid Ptosis,ema Eyelid Ptosis Gast,1
DYSPORT,Eyelid Ptosis,Ptosis Gast,1
DYSPORT,Eyelid Ptosis,ema Eyelid Ptosis Gast,1
DYSPORT,Eyelid Ptosis,ema Eyelid,1
DYSPORT,Eyelid Ptosis,Eyelid Ptosis Gast,1
DYSPORT,Eyelid Ptosis,Eyelid Ptosis Gast,1
DYSPORT,Eyelid Ptosis,ema,0
DYSPORT,Nausea,Nausea,1
DYSPORT,Nausea,,0
DYSPORT,Injection Site Reaction,Injection Site Reaction,1
DYSPORT,Injection Site Reaction,Site Injection Site Reaction,1
DYSPORT,Injection Site Reaction,,0
DYSPORT,Injection Site Reaction,Pain,0
DYSPORT,Injection Site Reaction,Reaction,1
DYSPORT,Injection Site Reaction,Reaction,1
DYSPORT,Injection Site Reaction,Injection Site Reaction,1
DYSPORT,Injection Site Reaction,Injection,1
DYSPORT,Nasopharyngitis,,0
DYSPORT,Nasopharyngitis,Nasopharyngitis Upper,1
DYSPORT,Nasopharyngitis,s and Nasopharyngitis Upper,1
DYSPORT,Sinusitis,,0
DYSPORT,Blood Present in Urine,tions Blood Present in Urine Nervous,1
DYSPORT,Blood Present in Urine,tions Blood Present in,1
DYSPORT,Blood Present in Urine,Nervous,0
DYSPORT,Headache,,0
DYSPORT,headache,these adverse reactions headache nasopharyngitis injection,1
DYSPORT,headache,and injection site,0
DYSPORT,headache,,0
DYSPORT,headache,headache nasopharyngitis injection,1
DYSPORT,headache,The most frequently reported of these adverse,0
DYSPORT,headache,headache nasopharyngitis injection,1
DYSPORT,injection site pain,adverse reactions were headache injection site,1
DYSPORT,injection site pain,site reaction numbness,0
DYSPORT,injection site pain,sinusitis URI injection,0
DYSPORT,sinusitis,sinusitis URI injection,1
DYSPORT,sinusitis,headache nasopharyngitis injection site pain,0
DYSPORT,sinusitis,sinusitis URI injection,1
DYSPORT,sinusitis,headache nasopharyngitis injection site sinusitis URI injection,1
DYSPORT,URI,,0
DYSPORT,URI,pain URI injection site,1
DYSPORT,URI,URI injection site,1
DYSPORT,URI,URI injection site,1
DYSPORT,URI,these,0
DYSPORT,URI,pain URI injection site,1
DYSPORT,URI,URI injection site,1
DYSPORT,URI,,0
DYSPORT,URI,URI injection site,1
DYSPORT,URI,URI injection site,1
DYSPORT,injection site bruising,these adverse reactions were headache,0
DYSPORT,injection site bruising,injection site,1
DYSPORT,injection site bruising,tingling itching stingi,0
DYSPORT,injection site bruising,pain sinusitis injection site bruising and injection,1
DYSPORT,injection site reaction,itching,0
DYSPORT,injection site reaction,URI injection site bruising,0
DYSPORT,injection site reaction,URI injection site bruising injection site reaction numbness discomfort,1
DYSPORT,injection site reaction,URI injection site bruising injection site,1
DYSPORT,bronchitis,in of the population bronchitis influenza pharyngolaryngeal,1
DYSPORT,bronchitis,bronchitis influenza pharyngolaryngeal,1
DYSPORT,bronchitis,repeated,0
DYSPORT,influenza,,0
DYSPORT,influenza,population,0
DYSPORT,influenza,influenza pharyngolaryngeal pain,1
DYSPORT,influenza,of the population included bronchitis,0
DYSPORT,influenza,the population,0
DYSPORT,influenza,included influenza pharyngolaryngeal pain,1
DYSPORT,influenza,site dis,0
DYSPORT,influenza,dermatitis injection site swelling and,0
DYSPORT,influenza,,0
DYSPORT,pharyngolaryngeal pain,pain cough contact,1
DYSPORT,cough,cough contact dermatitis,1
DYSPORT,contact dermatitis,cough,0
DYSPORT,contact dermatitis,pain contact dermatitis injection site,1
DYSPORT,contact dermatitis,of the population included bronchitis influenza pharyngolaryngeal,0
DYSPORT,contact dermatitis,contact dermatitis injection site,1
DYSPORT,injection site swelling,injection site swelling and injection,1
DYSPORT,injection site swelling,site swelling and injection,1
DYSPORT,injection site swelling,not increase in the longter,0
DYSPORT,injection site swelling,site swelling and injection,1
DYSPORT,injection site swelling,bronchitis influenza pharyngolaryngeal pain cough,0
DYSPORT,injection site swelling,pain cough contact injection site swelling and injection,1
DYSPORT,injection site swelling,,0
DYSPORT,injection site swelling,,0
DYSPORT,injection site swelling,influenza pharyngolaryngeal pain,0
DYSPORT,injection site discomfort,injection site discomfort The incidence,1
DYSPORT,injection site discomfort,swelling injection site discomfort The incidence,1
DYSPORT,injection site discomfort,dermatitis injection site swelling injection site discomfort The incidence,1
DYSPORT,injection site discomfort,with,0
DYSPORT,eyelid ptosis,eyelid ptosis did not,1
DYSPORT,eyelid ptosis,discomfort The incidence eyelid,1
DYSPORT,eyelid ptosis,The incidence eyelid,1
DYSPORT,eyelid ptosis,site discomfort,0
DYSPORT,eyelid ptosis,discomfort The incidence eyelid,1
DYSPORT,eyelid ptosis,dermatitis injection site swelling and injection site discomfort,0
DYSPORT,eyelid ptosis,ptosis did not,1
DYSPORT,eyelid ptosis,The incidence of,0
DYSPORT,eyelid ptosis,not increase in the longterm safety studies with multiple retreatments at,0
DYSPORT,eyelid ptosis,,0
DYSPORT,eyelid ptosis,the reports eyelid,1
DYSPORT,eyelid ptosis,three months The majority of,0
DYSPORT,eyelid ptosis,ptosis were mild,1
DYSPORT,eyelid ptosis,at intervals three months The majority of,0
DYSPORT,eyelid ptosis,reports eyelid ptosis were mild,1
DYSPORT,eyelid ptosis,,0
DYSPORT,eyelid ptosis,majority of the reports eyelid ptosis were mild,1
DYSPORT,eyelid ptosis,eyelid ptosis were mild,1
DYSPORT,eyelid ptosis,ptosis were mild,1
DYSPORT,Nasopharyngitis,,0
DYSPORT,Nasopharyngitis,Nasopharyngitis Urin,1
DYSPORT,Nasopharyngitis,Nasopharyngitis Urin,1
DYSPORT,Nasopharyngitis,infestations,0
DYSPORT,Nasopharyngitis,,0
DYSPORT,Nasopharyngitis,,0
DYSPORT,Urinary tract infection,tract infection Influenza,1
DYSPORT,Urinary tract infection,itis Urinary,1
DYSPORT,Urinary tract infection,itis Urinary tract,1
DYSPORT,Urinary tract infection,Urinary tract infection Influenza,1
DYSPORT,Urinary tract infection,itis,0
DYSPORT,Urinary tract infection,itis Urinary tract,1
DYSPORT,Urinary tract infection,itis Urinary tract,1
DYSPORT,Urinary tract infection,,0
DYSPORT,Urinary tract infection,itis,0
DYSPORT,Urinary tract infection,itis Urinary tract infection Influenza,1
DYSPORT,Influenza,,0
DYSPORT,Influenza,,0
DYSPORT,Influenza,Influenza,1
DYSPORT,Influenza,,0
DYSPORT,Influenza,ct Influenza,1
DYSPORT,Influenza,Influenza,1
DYSPORT,Infection,,0
DYSPORT,Infection,Infection,1
DYSPORT,Infection,,0
DYSPORT,Infection,Infection,1
DYSPORT,Infection,Infection,1
DYSPORT,Infection,,0
DYSPORT,Muscular weakness,,0
DYSPORT,Muscular weakness,,0
DYSPORT,Muscular weakness,,0
DYSPORT,Muscular weakness,weakness,1
DYSPORT,Muscular weakness,Muscular weakness,1
DYSPORT,Muscular weakness,,0
DYSPORT,Pain in extremity,,0
DYSPORT,Pain in extremity,akness Pain in extremity Muscul,1
DYSPORT,Pain in extremity,akness Pain in extremity Muscul,1
DYSPORT,Pain in extremity,akness,0
DYSPORT,Pain in extremity,,0
DYSPORT,Back pain,Back pain,1
DYSPORT,Back pain,Back pain,1
DYSPORT,Back pain,,0
DYSPORT,Back pain,etal Back pain,1
DYSPORT,Headache,,0
DYSPORT,Headache,disorders,0
DYSPORT,Headache,Headache,1
DYSPORT,Headache,Headache,1
DYSPORT,Headache,Headache,1
DYSPORT,Headache,disorders,0
DYSPORT,Headache,tem Headache,1
DYSPORT,Headache,Headache,1
DYSPORT,Headache,,0
DYSPORT,Dizziness,Dizziness,1
DYSPORT,Convulsion,,0
DYSPORT,Convulsion,,0
DYSPORT,Convulsion,Convulsion,1
DYSPORT,Convulsion,,0
DYSPORT,Convulsion,Convulsion,1
DYSPORT,Convulsion,Convulsion,1
DYSPORT,Convulsion,Convulsion,1
DYSPORT,Convulsion,,0
DYSPORT,Convulsion,Convulsion,1
DYSPORT,Convulsion,,0
DYSPORT,Syncope,,0
DYSPORT,Syncope,,0
DYSPORT,Syncope,Syncope,1
DYSPORT,Syncope,,0
DYSPORT,Syncope,,0
DYSPORT,Syncope,,0
DYSPORT,Syncope,Syncope,1
DYSPORT,Syncope,,0
DYSPORT,Syncope,,0
DYSPORT,Syncope,,0
DYSPORT,Hypoaesthesia,Hypoaesthesia Pa,1
DYSPORT,Hypoaesthesia,Pa,0
DYSPORT,Hypoaesthesia,Hypoaesthesia Pa,1
DYSPORT,Hypoaesthesia,Hypoaesthesia Pa,1
DYSPORT,Partial seizures,Gener,0
DYSPORT,Fatigue,,0
DYSPORT,Fatigue,Fatigue,1
DYSPORT,Fatigue,Fatigue,1
DYSPORT,Fatigue,,0
DYSPORT,Fatigue,Fatigue,1
DYSPORT,Fatigue,rders and administration site Fatigue,1
DYSPORT,Fatigue,and administration site,0
DYSPORT,Fatigue,,0
DYSPORT,Fatigue,conditions,0
DYSPORT,Fatigue,Fatigue,1
DYSPORT,Asthenia,,0
DYSPORT,Fall,Fall,1
DYSPORT,Fall,,0
DYSPORT,Fall,,0
DYSPORT,Fall,procedural,0
DYSPORT,Fall,,0
DYSPORT,Fall,,0
DYSPORT,Fall,Fall,1
DYSPORT,Fall,,0
DYSPORT,Fall,Fall,1
DYSPORT,Injury,Injury,1
DYSPORT,Injury,,0
DYSPORT,Injury,,0
DYSPORT,Injury,Injury,1
DYSPORT,Contusion,Contusion,1
DYSPORT,Contusion,,0
DYSPORT,Contusion,Contusion,1
DYSPORT,Contusion,Contusion,1
DYSPORT,Contusion,Contusion,1
DYSPORT,Contusion,Contusion,1
DYSPORT,Contusion,,0
DYSPORT,Nausea,Nausea,1
DYSPORT,Nausea,Nausea,1
DYSPORT,Nausea,,0
DYSPORT,Nausea,,0
DYSPORT,Constipation,,0
DYSPORT,Constipation,Constipation I,1
DYSPORT,Constipation,,0
DYSPORT,Constipation,,0
DYSPORT,Constipation,Constipation I,1
DYSPORT,Constipation,Constipation I,1
DYSPORT,Constipation,Constipation I,1
DYSPORT,Blood triglycerides increased,on Blood triglycerides,1
DYSPORT,Blood triglycerides increased,on Blood,1
DYSPORT,Blood triglycerides increased,triglycerides increased Respiratory,1
DYSPORT,Blood triglycerides increased,on Blood triglycerides increased Respiratory tho,1
DYSPORT,Blood triglycerides increased,on Blood triglycerides,1
DYSPORT,Blood triglycerides increased,,0
DYSPORT,Blood triglycerides increased,on Blood triglycerides increased,1
DYSPORT,Cough,,0
DYSPORT,Hypertension,Hypertension P,1
DYSPORT,Hypertension,P,0
DYSPORT,Depression,,0
DYSPORT,Injection site reactions,Injection Site Injection site,1
DYSPORT,Injection site reactions,occurred,0
DYSPORT,injection site erythema,Less,0
DYSPORT,injection site erythema,erythema,1
DYSPORT,injection site erythema,reactions eg pain bruising injection site erythema,1
DYSPORT,injection site erythema,Site,0
DYSPORT,injection site erythema,reactions eg pain bruising haemorrhage,0
DYSPORT,injection site erythema,Less,0
DYSPORT,injection site erythema,pain bruising injection site,1
DYSPORT,injection site erythema,eg pain bruising injection site,1
DYSPORT,injection site erythema,pain bruising injection site,1
DYSPORT,injection site erythema,injection site erythema,1
DYSPORT,dysphagia,,0
DYSPORT,dysphagia,dysphagia,1
DYSPORT,dysphagia,sensation of heaviness,0
DYSPORT,dysphagia,dysphagia,1
DYSPORT,gait disturbance,Becau,0
DYSPORT,hypertonia,gait,0
DYSPORT,hypertonia,treatment groups included,0
DYSPORT,hypertonia,,0
DYSPORT,hypertonia,hypertonia,1
DYSPORT,hypertonia,included dysphagia gait hypertonia,1
DYSPORT,hypertonia,heaviness Postmarketing Experience Because adverse,0
DYSPORT,sensation of heaviness,,0
DYSPORT,sensation of heaviness,Experience Because adverse reactions,0
DYSPORT,sensation of heaviness,hypertonia sensation of,1
DYSPORT,sensation of heaviness,Because adverse,0
DYSPORT,vertigo,vertigo,1
DYSPORT,vertigo,burning sensation,0
DYSPORT,vertigo,illness,0
DYSPORT,photophobia,photophobia,1
DYSPORT,photophobia,,0
DYSPORT,influenza-like illness,,0
DYSPORT,influenza-like illness,hypoesthesia erythema and excessive granulation t,0
DYSPORT,influenza-like illness,burning sensation,0
DYSPORT,influenza-like illness,r vertigo photophobia,0
DYSPORT,influenza-like illness,,0
DYSPORT,influenza-like illness,influenza-like illness,1
DYSPORT,influenza-like illness,and,0
DYSPORT,influenza-like illness,,0
DYSPORT,influenza-like illness,influenza-like,1
DYSPORT,amyotrophy,illness,0
DYSPORT,amyotrophy,amyotrophy,1
DYSPORT,amyotrophy,erythema and,0
DYSPORT,amyotrophy,amyotrophy,1
DYSPORT,amyotrophy,of DYSPORT r vertigo photophobia influenzalike illness,0
DYSPORT,amyotrophy,postapproval use of DYSPORT,0
DYSPORT,amyotrophy,,0
DYSPORT,burning sensation,photophobia influenzalike illness burning,1
DYSPORT,burning sensation,,0
DYSPORT,burning sensation,sensation,1
DYSPORT,burning sensation,burning sensation,1
DYSPORT,burning sensation,influenzalike illness burning,1
DYSPORT,burning sensation,illness burning sensation,1
DYSPORT,burning sensation,r vertigo,0
DYSPORT,facial paresis,facial paresis,1
DYSPORT,hypoesthesia,vertigo photophobia influenzalike illness amyotrophy,0
DYSPORT,hypoesthesia,hypoesthesia,1
DYSPORT,hypoesthesia,hypoesthesia,1
DYSPORT,hypoesthesia,amyotrophy burning,0
DYSPORT,hypoesthesia,,0
DYSPORT,hypoesthesia,hypoesthesia,1
DYSPORT,erythema,erythema,1
DYSPORT,excessive granulation tissue,,0
DYSPORT,excessive granulation tissue,illness amyotrophy burning sensation facial paresis hypoesthesia,0
DYSPORT,excessive granulation tissue,a,0
DYSPORT,excessive granulation tissue,granulation tissue,1
DYSPORT,DISTANT SPREAD OF TOXIN EFFECT,following serious adverse rea ctions are discussed,1
DYSPORT,DISTANT SPREAD OF TOXIN EFFECT,,0
DYSPORT,DISTANT SPREAD OF TOXIN EFFECT,,0
DYSPORT,DISTANT SPREAD OF TOXIN EFFECT,scussed below and elsewhere,1
DYSPORT,DISTANT SPREAD OF TOXIN EFFECT,in labeling Distant,1
DYSPORT,asthenia,from Toxin and,1
DYSPORT,asthenia,Pre cautions Dysphagia,1
DYSPORT,asthenia,of Effects from Toxin  and Pre cautions Dysphagia,1
DYSPORT,asthenia,of Effects from Toxin  and Pre cautions Dysphagia,1
DYSPORT,asthenia,,0
DYSPORT,asthenia,and Pre cautions Dysphagia,1
DYSPORT,asthenia,and,0
DYSPORT,diplopia,and Precautions  and Bre athing Difficulties,1
DYSPORT,diplopia,Bre athing Difficulties,1
DYSPORT,diplopia,Effects from Toxin seeWarnings and Precautions,0
DYSPORT,diplopia,,0
DYSPORT,diplopia,Bre athing Difficulties,1
DYSPORT,blurred vision,ies seeWarnings and Precautions Facial Anatomy in the Treatment of Glabellar Lines se,0
DYSPORT,blurred vision,Precautions Dysphagia and hing Difficult ies seeWarnings,1
DYSPORT,blurred vision,Precautions Facial Anatomy in the Treatment of Glabellar Lines se,0
DYSPORT,blurred vision,and Precautions Dysphagia and Breat,0
DYSPORT,blurred vision,Facial Anatomy in the Treatment of Glabellar Lines,0
DYSPORT,blurred vision,Dysphagia and hing,1
DYSPORT,blurred vision,Precautions Dysphagia and hing,1
DYSPORT,ptosis,and Precautions Dysphagia and Breathing,0
DYSPORT,ptosis,and Breathing s,1
DYSPORT,ptosis,Precautions,0
DYSPORT,ptosis,Precautions Dysphagia and Breathing s [see Warnings and,1
DYSPORT,ptosis,[see Warnings and,1
DYSPORT,ptosis,s,1
DYSPORT,dysphagia,Difficulties rnings,1
DYSPORT,dysphagia,Dysphagia and Breathing Difficulties rnings an d Precautions,1
DYSPORT,dysphagia,Dysphagia and,0
DYSPORT,dysphagia,seeWarnings and Precautions,0
DYSPORT,dysphagia,from Toxin seeWarnings and Precautions,0
DYSPORT,dysphagia,from Toxin seeWarnings and Precautions Dysphagia and,0
DYSPORT,dysphagia,of Glabellar Lines seeWarnings and,0
DYSPORT,dysphagia,rnings,1
DYSPORT,dysphagia,Difficulties rnings an d Precautions,1
DYSPORT,dysphagia,Precautions,0
DYSPORT,dysphonia,Precautio ns Facial,1
DYSPORT,dysphonia,and Breathing Difficulties seeWarnings Precautio ns Facial,1
DYSPORT,dysphonia,Precautio ns Facial,1
DYSPORT,dysphonia,Precautio ns Facial,1
DYSPORT,dysphonia,Precautio ns Facial,1
DYSPORT,dysphonia,Precautio ns Facial,1
DYSPORT,dysphonia,Precautio ns Facial,1
DYSPORT,dysphonia,,0
DYSPORT,dysphonia,Treatment of Glabellar Lines seeWarnings and Precautions,0
DYSPORT,dysarthria," (5.3)]  
 Facial Anatomy",1
DYSPORT,dysarthria,Treatment of Glabellar Lines seeWarnings and,0
DYSPORT,dysarthria,"seeWarnings and  (5.3)]  
 Facial Anatomy",1
DYSPORT,dysarthria," (5.3)]  
 Facial Anatomy",1
DYSPORT,dysarthria," (5.3)]  
 Facial Anatomy",1
DYSPORT,dysarthria," (5.3)]  
 Facial Anatomy",1
DYSPORT,dysarthria,Anatomy in the Treatment of Glabellar Lines seeWarnings and Precautions,0
DYSPORT,dysarthria,"Difficulties seeWarnings and  (5.3)]  
 Facial Anatomy",1
DYSPORT,dysarthria,,0
DYSPORT,urinary incontinence,Difficulties seeWarnings and Facial,1
DYSPORT,breathing difficulties,and Precautions Preexisting Neuromuscular Disorders seeWarnings,0
DYSPORT,breathing difficulties,Neuromuscular Disorders,0
DYSPORT,breathing difficulties,of Glabellar Lines seeWarnings,1
DYSPORT,breathing difficulties,Neuromuscular Disorders,0
DYSPORT,breathing difficulties,the reatment,1
DYSPORT,breathing difficulties,the T,0
DYSPORT,breathing difficulties,Precautions Facial Anatomy,0
DYSPORT,breathing difficulties,seeWarnings and Precautions Facial Anatomy in,0
DYSPORT,breathing difficulties,Preexisting Neuromuscular,0
DYSPORT,breathing difficulties,s [seeWarnings and Pre cautions Human,1
DYSPORT,breathing difficulties,cautions Human Albumin seeWarnings and,0
DYSPORT,breathing difficulties,of,0
DYSPORT,breathing difficulties,Neuromuscular Disorder,0
DYSPORT,breathing difficulties,[seeWarnings and Pre cautions Human,1
DYSPORT,breathing difficulties,Precautions Preexisting Neuromuscular s,1
DYSPORT,breathing difficulties,s,1
DYSPORT,breathing difficulties,s,1
DYSPORT,breathing difficulties,Neuromuscular,0
DYSPORT,breathing difficulties,,0
DYSPORT,death,cauti ons Intradermal,1
DYSPORT,DISTANT SPREAD OF TOXIN EFFECT,site,0
DYSPORT,DISTANT SPREAD OF TOXIN EFFECT,infect ion eyelid,1
DYSPORT,DISTANT SPREAD OF TOXIN EFFECT,pain injection,0
DYSPORT,breathing difficulties,,0
DYSPORT,breathing difficulties,and depression To,0
DYSPORT,breathing difficulties,Ipsen Bi opharmaceuticals Inc,1
DYSPORT,breathing difficulties,Bi opharmaceuticals Inc,1
DYSPORT,breathing difficulties,SUSPECTED ADVERSE REACT,0
DYSPORT,breathing difficulties,,0
DYSPORT,breathing difficulties,report SUSPECTED,0
DYSPORT,breathing difficulties,,0
DYSPORT,breathing difficulties,To report SUSPECTED,0
DYSPORT,death,at or FDA at DA-10 or wwwfdagovmedwatch,1
DYSPORT,death,DA-10 or wwwfdagovmedwatch,1
DYSPORT,death,,0
DYSPORT,swallowing difficulties,the Treatment of Glabellar [seeWarnings,1
DYSPORT,swallowing difficulties,Treatment of Glabellar [seeWarnings,1
DYSPORT,swallowing difficulties,and Precau tions Preexisting,1
DYSPORT,swallowing difficulties,[seeWarnings and Precau tions Preexisting,1
DYSPORT,swallowing difficulties,Precautions,0
DYSPORT,CJD,observed,0
DYSPORT,CJD,ion s EXCERPT,1
DYSPORT,viral diseases,,0
DYSPORT,viral diseases,observed adverse reactions,0
DYSPORT,viral diseases," Dystonia  
 
 Most commonly",1
DYSPORT,viral diseases,dry,0
DYSPORT,viral diseases,"EXCERPT  Dystonia  
 
 Most commonly",1
DYSPORT,viral diseases,"Precautions EXCERPT  Dystonia  
 
 Most commonly",1
DYSPORT,viral diseases,Immune Reaction seeWarnings and Precautions,0
DYSPORT,CJD,observed adverse reactions of patients are muscular weakness,0
DYSPORT,CJD,,0
DYSPORT,CJD,seeWarnings,0
DYSPORT,asthenia,or .fda.gov medwatch Clinical,1
DYSPORT,asthenia,.fda.gov medwatch Clinical,1
DYSPORT,asthenia,Clinical Trials Experience Because clinical trials are,0
DYSPORT,asthenia,.fda.gov medwatch Clinical,1
DYSPORT,asthenia,Biopharmaceuticals Inc at or,0
DYSPORT,asthenia,at FDA or www,0
DYSPORT,asthenia,.fda.gov medwatch Clinical,1
DYSPORT,asthenia,,0
DYSPORT,asthenia,Ipsen Biopharmaceuticals Inc at or FDA at FDA or www,0
DYSPORT,generalized muscle weakness,under,0
DYSPORT,generalized muscle weakness,Because clinical trials are,0
DYSPORT,generalized muscle weakness,Trials,0
DYSPORT,generalized muscle weakness,Inc at or FDA at FDA or wwwfdagovm,0
DYSPORT,generalized muscle weakness,"edwatch  



 

  6.1 Clini cal Trials",1
DYSPORT,generalized muscle weakness,at FDA or edwatch,1
DYSPORT,generalized muscle weakness,FDA at FDA or edwatch,1
DYSPORT,generalized muscle weakness,Because clinical trials are conducted under widely varying,0
DYSPORT,generalized muscle weakness,"FDA or edwatch  



 

  6.1 Clini cal Trials",1
DYSPORT,diplopia,at FDA or wwwfdagovmedwatch,0
DYSPORT,diplopia,are conducted under,0
DYSPORT,blurred vision,B ecause clinical,1
DYSPORT,blurred vision,rates,0
DYSPORT,blurred vision,or wwwfdagovmedwatch Clinical,0
DYSPORT,blurred vision,"Clinical Trials xperience

  B ecause clinical",1
DYSPORT,blurred vision,xperience,1
DYSPORT,blurred vision,Trials xperience,1
DYSPORT,blurred vision,Trials xperience,1
DYSPORT,ptosis,Trials Experience ause c linical trials,1
DYSPORT,ptosis,c linical trials,1
DYSPORT,ptosis,,0
DYSPORT,ptosis,wwwfdagovmedwatch Clinical Trials Experience ause c linical trials,1
DYSPORT,ptosis,at FDA or wwwfdagovmedwatch Clinical,0
DYSPORT,dysphagia,widely varying conditions adverse reaction,0
DYSPORT,dysphagia,,0
DYSPORT,dysphonia,clinical trials of a,0
DYSPORT,dysphonia,widely varying conditions adverse,0
DYSPORT,dysarthria,trials are cted,1
DYSPORT,dysarthria,,0
DYSPORT,dysarthria,cted under widely varying,1
DYSPORT,breathing difficulties,adverse reaction rate s observed,1
DYSPORT,breathing difficulties,the clinical,0
DYSPORT,breathing difficulties,Trials Experience Because clinical trials are conducted under widely varying conditions,0
DYSPORT,breathing difficulties,under widely varying  adverse reaction rate s observed,1
DYSPORT,breathing difficulties,Trials Experience Because clinical trials are conducted under,0
DYSPORT,breathing difficulties,varying  adverse reaction rate s observed,1
DYSPORT,breathing difficulties,conducted under widely varying  adverse reaction rate s observed,1
DYSPORT,death, prac tice Cervical,1
DYSPORT,death, prac tice Cervical,1
DYSPORT,death, prac tice Cervical,1
DYSPORT,death,r,0
DYSPORT,death, prac tice Cervical,1
DYSPORT,spread of toxin effect,cycles was allowed The ion was almost entirel y Caucasian,1
DYSPORT,spread of toxin effect,was allowed The ion,1
DYSPORT,spread of toxin effect,years range years Most patients,0
DYSPORT,breathing difficulties,of patients who received,1
DYSPORT,Deaths,commod ation Other,1
DYSPORT,Deaths,visual acuity and commod ation Other,1
DYSPORT,dysphagia,treatment,0
DYSPORT,dysphagia,we,0
DYSPORT,Dysphagia,afte r treatment,1
DYSPORT,Dysphagia,adverse reactions were,0
DYSPORT,Dysphagia,reactions most adverse reactions became noticeable about one,0
DYSPORT,Dysphagia,week afte r treatment,1
DYSPORT,Aspiration,trials During the clinical,0
DYSPORT,Aspiration,in the combined,0
DYSPORT,Aspiration,,0
DYSPORT,Aspiration,and,1
DYSPORT,Aspiration,combined and,1
DYSPORT,Aspiration,trials,0
DYSPORT,Aspiration,and open-l abel experience,1
DYSPORT,Aspiration,in the combined and open-l abel experience,1
DYSPORT,Aspiration,in the combined and open-l abel experience,1
DYSPORT,Aspiration,and open-l abel experience,1
DYSPORT,dysphagia,experience than the place bocontrolled trials,1
DYSPORT,dysphagia,than the place bocontrolled trials,1
DYSPORT,dysphagia,of adverse reactions were higher in the combined controlled and openlabel experience than,0
DYSPORT,dysphagia,experienced adverse,0
DYSPORT,dysphagia,place bocontrolled trials,1
DYSPORT,dysphagia,,0
DYSPORT,dysphagia,and openlabel experience than the,1
DYSPORT,weaken neck muscles,eyel,0
DYSPORT,weaken neck muscles,,0
DYSPORT,weaken neck muscles,adverse reactions leading to withdrawal One patient experienced disturbance in,0
DYSPORT,weaken neck muscles,"disorder, feelin g abnormal",1
DYSPORT,weaken neck muscles,reactions leading to withdrawal One patient experienced disturbance,0
DYSPORT,weaken neck muscles,in attention id,1
DYSPORT,weaken neck muscles,"experienced disturbance in attention id disorder,",1
DYSPORT,loss of breathing capacity,from a single,0
DYSPORT,loss of breathing capacity,the incidence of the most frequent,1
DYSPORT,loss of breathing capacity,from a single treatment,0
DYSPORT,loss of breathing capacity,pares the incidence of the most frequent,1
DYSPORT,loss of breathing capacity,the most frequent,1
DYSPORT,loss of breathing capacity,cycle of Units of DYSPORT r,0
DYSPORT,loss of breathing capacity,reactions from a single treatment cycle of Units of DYSPORT,0
DYSPORT,loss of breathing capacity,,0
DYSPORT,loss of breathing capacity,patient experienced dysphagia Table pares the incidence,1
DYSPORT,loss of breathing capacity,Table com,0
DYSPORT,breathing difficulties,Reactions and Greater than Placebo in the,0
DYSPORT,breathing difficulties,Phase,0
DYSPORT,breathing difficulties,and Greater than Placebo in the Pooled Doubleblind Phase of,0
DYSPORT,breathing difficulties,Most Com mon Adverse,1
DYSPORT,breathing difficulties,Greater than Placebo in the Pooled Doubleblind Phase of,0
DYSPORT,breathing difficulties,"compared to placebo seeClinical 



 Table 3: Most Com mon Adverse",1
DYSPORT,respiratory failure,,0
DYSPORT,respiratory failure,the,0
DYSPORT,respiratory failure,Most Common Reactions (>5%) and Greater than,1
DYSPORT,respiratory failure,Table Most Common Reactions,1
DYSPORT,respiratory failure,r compared to placebo seeClinical Studies,0
DYSPORT,respiratory failure,Common Reactions (>5%) and Greater than,1
DYSPORT,respiratory failure,Most Common Reactions,1
DYSPORT,respiratory failure,seeClinical,0
DYSPORT,respiratory failure,Patients,0
DYSPORT,respiratory failure,than Placebo in the Pooled Doubleblind Phase of Clinical Trials in,0
DYSPORT,eyelid ptosis,"        
   M usculoskeletal pain",1
DYSPORT,eyelid ptosis,"        
   M usculoskeletal pain",1
DYSPORT,eyelid ptosis,,0
DYSPORT,eyelid ptosis,,0
DYSPORT,eyelid ptosis,usculoskeletal pain,0
DYSPORT,eyelid ptosis,"        
   M usculoskeletal pain",1
DYSPORT,eyelid ptosis,,0
DYSPORT,eyelid ptosis,,0
DYSPORT,eyelid ptosis,,0
DYSPORT,dysphagia,Nervous system disorders,0
DYSPORT,dysphagia,      7   Nervous system,1
DYSPORT,dysphagia,      7   Nervous system,1
DYSPORT,dysphagia,      7   Nervous system,1
DYSPORT,dysphagia,      7   Nervous system,1
DYSPORT,respiratory compromise,Nervous sy stem disorders,1
DYSPORT,respiratory compromise,Dry Nervous,1
DYSPORT,respiratory compromise,stem disorders,0
DYSPORT,respiratory compromise,"Dry         
   Nervous sy stem disorders",1
DYSPORT,respiratory compromise,"        
   Nervous sy stem disorders",1
DYSPORT,respiratory compromise,Dry Nervous,1
DYSPORT,viral diseases,and infestations,0
DYSPORT,viral diseases,Respiratory thoracic and,0
DYSPORT,viral diseases,thoracic,0
DYSPORT,viral diseases,,0
DYSPORT,viral diseases,       9       Respiratory thoracic,1
DYSPORT,Creutzfeldt-Jakob disease,and diastinal disorders       Dysphonia,1
DYSPORT,Creutzfeldt-Jakob disease,,0
DYSPORT,Creutzfeldt-Jakob disease,Dysphonia,0
DYSPORT,Creutzfeldt-Jakob disease,diastinal disorders       Dysphonia,1
DYSPORT,Creutzfeldt-Jakob disease,,0
DYSPORT,Creutzfeldt-Jakob disease,diastinal disorders       Dysphonia,1
DYSPORT,Creutzfeldt-Jakob disease,diastinal disorders Dysphonia,1
DYSPORT,Creutzfeldt-Jakob disease,,0
DYSPORT,Creutzfeldt-Jakob disease,diastinal disorders       Dysphonia,1
DYSPORT,CJD,mediastinal disorders,0
DYSPORT,CJD,    Dysphonia,1
DYSPORT,CJD,    Dysphonia,1
DYSPORT,CJD,mediastinal     Dysphonia,1
DYSPORT,CJD,    Dysphonia,1
DYSPORT,CJD,and mediastinal     Dysphonia,1
DYSPORT,CJD,    Dysphonia,1
DYSPORT,CJD,    Dysphonia,1
DYSPORT,CJD,,0
DYSPORT,CJD,Dysphonia,0
DYSPORT,viral diseases,,0
DYSPORT,viral diseases,disorders Dysphonia,0
DYSPORT,viral diseases,               Eye Disorders,1
DYSPORT,viral diseases,               Eye Disorders,1
DYSPORT,viral diseases,               Eye Disorders,1
DYSPORT,viral diseases,mediastinal disorders                Eye Disorders,1
DYSPORT,viral diseases,,0
DYSPORT,viral diseases,               Eye Disorders,1
DYSPORT,CJD,    Eye Disorders,1
DYSPORT,CJD,    Eye Disorders,1
DYSPORT,CJD,    Eye Disorders,1
DYSPORT,CJD,    Eye Disorders,1
DYSPORT,CJD,Dysphonia,0
DYSPORT,CJD,,0
DYSPORT,CJD,Dysphonia,0
DYSPORT,CJD,Dysphonia,0
FIRAZYR,pyrexia,than of patients pyrexia transaminase increase,1
FIRAZYR,pyrexia,pyrexia transaminase increase,1
FIRAZYR,pyrexia,report SUSPECTED ADVERSE,0
FIRAZYR,pyrexia,clinical trials Other common adverse,0
FIRAZYR,pyrexia,patients pyrexia transaminase increase,1
FIRAZYR,pyrexia,Other common adverse reactions occurring in greater than of patients included,0
FIRAZYR,pyrexia,pyrexia transaminase increase,1
FIRAZYR,pyrexia,report SUSPECTED ADVERSE,0
FIRAZYR,pyrexia,greater than of patients pyrexia transaminase increase,1
FIRAZYR,pyrexia,greater than of patients pyrexia transaminase increase,1
FIRAZYR,transaminase increase,,0
FIRAZYR,transaminase increase,occurring,0
FIRAZYR,transaminase increase,increase dizziness and,1
FIRAZYR,transaminase increase,than of patients,0
FIRAZYR,transaminase increase,increase dizziness and,1
FIRAZYR,transaminase increase,than of patients included transaminase,1
FIRAZYR,transaminase increase,greater than,0
FIRAZYR,transaminase increase,increase dizziness and,1
FIRAZYR,transaminase increase,than of patients included transaminase increase dizziness and,1
FIRAZYR,dizziness,,0
FIRAZYR,dizziness,transaminase dizziness and rash,1
FIRAZYR,dizziness,dizziness and rash,1
FIRAZYR,dizziness,dizziness and rash,1
FIRAZYR,dizziness,occurring in greater than of patients included pyrexia transaminase,0
FIRAZYR,rash,dizziness and,0
FIRAZYR,rash,rash To report,1
FIRAZYR,rash,report SUSPECTED ADVERSE,0
FIRAZYR,rash,rash To report,1
FIRAZYR,rash,rash To report,1
FIRAZYR,rash,occurring in greater than of patients included pyrexia transaminase increase dizziness,0
FIRAZYR,rash,,0
FIRAZYR,rash,rash To report,1
FIRAZYR,Injection site reaction,site reaction Pyrexia,1
FIRAZYR,Pyrexia,Pyrexia,1
FIRAZYR,Pyrexia,reaction,0
FIRAZYR,Pyrexia,Pyrexia,1
FIRAZYR,Transaminase increased,Investigations,0
FIRAZYR,Transaminase increased,,0
FIRAZYR,Transaminase increased,increased Nervous sys,1
FIRAZYR,Transaminase increased,Transaminase increased Nervous,1
FIRAZYR,Transaminase increased,,0
FIRAZYR,Dizziness,Dizziness,1
FIRAZYR,Dizziness,Dizziness,1
FIRAZYR,Dizziness,,0
FIRAZYR,Dizziness,Dizziness,1
FIRAZYR,Dizziness,Dizziness,1
FIRAZYR,Dizziness,system,0
FIRAZYR,Dizziness,,0
FIRAZYR,rash,adverse reactions reported rash nausea and,1
FIRAZYR,rash,reactions reported rash nausea and,1
FIRAZYR,rash,patients exposed to FIRAZYR,0
FIRAZYR,rash,reported,0
FIRAZYR,nausea,nausea and headache,1
FIRAZYR,nausea,,0
FIRAZYR,nausea,reactions reported included rash,0
FIRAZYR,nausea,nausea and headache,1
FIRAZYR,nausea,nausea and headache,1
FIRAZYR,nausea,to FIRAZYR The safety of,0
FIRAZYR,nausea,nausea and headache,1
FIRAZYR,nausea,reactions reported included nausea and headache,1
FIRAZYR,nausea,,0
FIRAZYR,nausea,nausea and headache,1
FIRAZYR,headache,headache in patients,1
FIRAZYR,headache,headache in patients,1
FIRAZYR,headache,trials Other adverse reactions reported included,0
FIRAZYR,headache,,0
FIRAZYR,headache,nausea and,0
FIRAZYR,headache,included rash nausea headache in patients,1
FIRAZYR,headache,headache in patients,1
FIRAZYR,headache,headache in patients,1
FIRAZYR,headache,in a,0
FIRAZYR,hypersensitivity,were negative hypersensitivity or anaphylactic,1
FIRAZYR,hypersensitivity,negative No,0
FIRAZYR,hypersensitivity,hypersensitivity or anaphylactic,1
FIRAZYR,hypersensitivity,hypersensitivity or anaphylactic,1
FIRAZYR,hypersensitivity,,0
FIRAZYR,anaphylactic reactions,reactions were reported,1
INVOKANA,Hypotension,and Precautions Impairment,0
INVOKANA,Hypotension,,0
INVOKANA,Hypotension,Hypotension see Warnings,1
INVOKANA,Hypotension,below and elsewhere in the,0
INVOKANA,Hypotension,the Hypotension see Warnings,1
INVOKANA,Hypotension,Hypotension see Warnings,1
INVOKANA,Hypotension,,0
INVOKANA,Hypotension,adverse reactions are described below and elsewhere in the labeling,0
INVOKANA,Hypotension,Hypotension see Warnings,1
INVOKANA,Hypotension,Hypotension see Warnings,1
INVOKANA,Impairment in Renal Function,see Warnings and,0
INVOKANA,Impairment in Renal Function,in Renal Function see Warnings,1
INVOKANA,Hyperkalemia,and Precautions Hypoglycemia with Concomitant Use with,0
INVOKANA,Hyperkalemia,and Precautions Hypoglycemia with Concomitant Use with Insulin,0
INVOKANA,Hyperkalemia,,0
INVOKANA,Hypoglycemia,Hypoglycemia with Concomitant,1
INVOKANA,Hypoglycemia,Insulin Secretagogues see,0
INVOKANA,Genital Mycotic Infections,and,0
INVOKANA,Genital Mycotic Infections,see Warnings and Precautions Hypersensitivity Reactions see Warnings,0
INVOKANA,Genital Mycotic Infections,see,0
INVOKANA,Bone Fracture,Bone,1
INVOKANA,Bone Fracture,Warnings and Bone,1
INVOKANA,Bone Fracture,see Warnings and Bone Fracture see Warnings,1
INVOKANA,Increases in Low-Density Lipoprotein,,0
INVOKANA,Increases in Low-Density Lipoprotein,Fracture see Warnings and Increases,1
INVOKANA,Increases in Low-Density Lipoprotein,wi,0
INVOKANA,Increases in Low-Density Lipoprotein,see,0
INVOKANA,Increases in Low-Density Lipoprotein,,0
INVOKANA,female genital mycotic infections,female genital mycotic infections urinary tract,1
INVOKANA,female genital mycotic infections,tract infection and increased urination EXCERPT To report,0
INVOKANA,female genital mycotic infections,or greater female genital mycotic infections urinary tract,1
INVOKANA,urinary tract infection,,0
INVOKANA,urinary tract infection,reactions associated with INVOKANA or greater incidence female,0
INVOKANA,urinary tract infection,female genital mycotic urinary tract infection and increased,1
INVOKANA,urinary tract infection,increased,0
INVOKANA,Urinary tract infections,Increased uri,0
INVOKANA,Increased urination,Male gen,0
INVOKANA,Male genital mycotic infections,rination,0
INVOKANA,Male genital mycotic infections,rination,0
INVOKANA,Male genital mycotic infections,rination,0
INVOKANA,Vulvovaginal pruritus,mycotic Vulvovaginal,1
INVOKANA,Vulvovaginal pruritus,Vulvovaginal,1
INVOKANA,Vulvovaginal pruritus,infections,0
INVOKANA,Vulvovaginal pruritus,Vulvovaginal pruritus Thirst,1
INVOKANA,Thirst,pruritus,0
INVOKANA,Thirst,Thirst,1
INVOKANA,Thirst,,0
INVOKANA,Thirst,Thirst,1
INVOKANA,Thirst,pruritus,0
INVOKANA,Thirst,Thirst,1
INVOKANA,Thirst,Thirst,1
INVOKANA,Constipation,Constipation N,1
INVOKANA,Constipation,,0
INVOKANA,Constipation,,0
INVOKANA,Constipation,Constipation N,1
INVOKANA,Nausea,Nausea,1
INVOKANA,Nausea,,0
INVOKANA,Nausea,Nausea,1
INVOKANA,Nausea,Nausea,1
INVOKANA,Nausea,Nausea,1
INVOKANA,Nausea,n,0
INVOKANA,Nausea,,0
INVOKANA,Nausea,,0
INVOKANA,fatigue,fatigue,1
INVOKANA,fatigue,,0
INVOKANA,fatigue,and loss of streng,0
INVOKANA,fatigue,fatigue,1
INVOKANA,fatigue,with the adverse reactions fatigue,1
INVOKANA,fatigue,fatigue,1
INVOKANA,fatigue,fatigue,1
INVOKANA,fatigue,fatigue,1
INVOKANA,fatigue,fatigue,1
INVOKANA,fatigue,fatigue,1
INVOKANA,loss of strength,of strength,1
INVOKANA,loss of strength,mg,0
INVOKANA,loss of strength,mg and with,0
INVOKANA,loss of strength,and with INVOKANA mg and,0
INVOKANA,loss of strength,loss of,1
INVOKANA,loss of strength,comparator with INVOKANA mg and with INVOKANA mg and,0
INVOKANA,loss of strength,loss of strength,1
INVOKANA,loss of strength,,0
INVOKANA,hypersensitivity-related adverse reactions,mg respectively,0
INVOKANA,erythema,,0
INVOKANA,erythema,erythema,1
INVOKANA,erythema,hypersensitivityrelated adverse reactions erythema,1
INVOKANA,erythema,the pool of eight,0
INVOKANA,erythema,erythema,1
INVOKANA,erythema,erythema,1
INVOKANA,erythema,hypersensitivityrelated adverse reactions erythema,1
INVOKANA,erythema,adverse reactions erythema,1
INVOKANA,erythema,the pool of eight clinical trials hypersensitivityrelated adverse reactions,0
INVOKANA,urticaria,,0
INVOKANA,angioedema,of patients receiving comparator INVOKANA mg and INVOKANA,0
INVOKANA,angioedema,erythema rash pruritus urticaria angioedema,1
INVOKANA,angioedema,urticaria,0
INVOKANA,angioedema,angioedema,1
INVOKANA,hypersensitivity,of,0
INVOKANA,hypersensitivity,serious adverse reactions hypersensitivity,1
INVOKANA,hypersensitivity,hypersensitivity,1
INVOKANA,hypersensitivity,which included patients with urticaria and patient with a diffuse rash,0
INVOKANA,hypersensitivity,serious,0
INVOKANA,hypersensitivity,with a,0
INVOKANA,hypersensitivity,hypersensitivity,1
INVOKANA,hypersensitivity,hypersensitivity,1
INVOKANA,hypersensitivity,diffuse rash,0
INVOKANA,urticaria,of exposure to,0
INVOKANA,urticaria,urticaria,1
INVOKANA,urticaria,included,0
INVOKANA,diffuse rash,and patient with diffuse,1
INVOKANA,diffuse rash,,0
INVOKANA,urticaria,urticaria,1
INVOKANA,urticaria,occurring,0
INVOKANA,urticaria,urticaria,1
INVOKANA,urticaria,urticaria,1
INVOKANA,urticaria,a diffuse,0
INVOKANA,urticaria,urticaria and,0
INVOKANA,urticaria,a diffuse rash urticaria,1
INVOKANA,urticaria,urticaria,1
INVOKANA,urticaria,rash,0
INVOKANA,urticaria,and patient with a diffuse rash and,0
INVOKANA,urticaria,One patient urticaria,1
INVOKANA,urticaria,urticaria,1
INVOKANA,urticaria,urticaria,1
INVOKANA,urticaria,urticaria,1
INVOKANA,urticaria,urticaria,1
INVOKANA,urticaria,INVOKANA Among these patients,0
INVOKANA,urticaria,INVOKANA One patient,0
INVOKANA,urticaria,discontinued INVOKANA One patient,0
INVOKANA,urticaria,patient,0
INVOKANA,Photosensitivity-related adverse reactions,when INVOKANA was Photosensitivity-related adverse,1
INVOKANA,Photosensitivity-related adverse reactions,adverse reactions,1
INVOKANA,Photosensitivity-related adverse reactions,,0
INVOKANA,Photosensitivity-related adverse reactions,patient,0
INVOKANA,Photosensitivity-related adverse reactions,recurrence when INVOKANA was Photosensitivity-related adverse,1
INVOKANA,Photosensitivity-related adverse reactions,,0
INVOKANA,Photosensitivity-related adverse reactions,occurred,0
INVOKANA,photosensitivity reaction,reinitiated Photosensitivityrelated adverse reactions photosensitivity,1
INVOKANA,photosensitivity reaction,adverse reactions photosensitivity,1
INVOKANA,photosensitivity reaction,reactions photosensitivity,1
INVOKANA,photosensitivity reaction,photosensitivity reaction,1
INVOKANA,photosensitivity reaction,,0
INVOKANA,photosensitivity reaction,light eruption and,0
INVOKANA,photosensitivity reaction,and sunburn occurred in and,0
INVOKANA,photosensitivity reaction,including,0
INVOKANA,photosensitivity reaction,photosensitivity reaction,1
INVOKANA,polymorphic light eruption,sunburn occurred in and of patients receiving comparator INVOKANA,0
INVOKANA,polymorphic light eruption,Photosensitivityrelated adverse reactions including photosensitivity,0
INVOKANA,polymorphic light eruption,polymorphic light eruption,1
INVOKANA,polymorphic light eruption,polymorphic light,1
INVOKANA,polymorphic light eruption,including photosensitivity reaction,0
INVOKANA,polymorphic light eruption,light eruption,1
INVOKANA,polymorphic light eruption,polymorphic,1
INVOKANA,polymorphic light eruption,adverse reactions,0
INVOKANA,osmotic diuresis,Reactions,0
INVOKANA,osmotic diuresis,osmotic,1
INVOKANA,osmotic diuresis,diuresis,1
INVOKANA,osmotic diuresis,Reactions INVOKANA results in osmotic,1
INVOKANA,osmotic diuresis,,0
INVOKANA,osmotic diuresis,osmotic diuresis,1
INVOKANA,osmotic diuresis,Reactions INVOKANA results in osmotic diuresis,1
INVOKANA,reductions in intravascular volume,an osmotic diuresis which may,0
INVOKANA,reductions in intravascular volume,osmotic diuresis which may lead,0
INVOKANA,reductions in intravascular volume,reductions,1
INVOKANA,reductions in intravascular volume,in the,0
INVOKANA,reductions in intravascular volume,dosedependent,0
INVOKANA,reductions in intravascular volume,which may lead reductions in intravascular volume,1
INVOKANA,reductions in intravascular volume,may lead reductions,1
INVOKANA,reductions in intravascular volume,diuresis which may lead reductions in intravascular volume,1
INVOKANA,reductions in intravascular volume,In clinical studies treatment with INVOKANA was associated,0
INVOKANA,volume depletion-related adverse reactions,depletion-related adverse reactions,1
INVOKANA,volume depletion-related adverse reactions,increase in the incidence,0
INVOKANA,hypotension,hypotension,1
INVOKANA,hypotension,hypotension,1
INVOKANA,postural dizziness,reactions eg postural,1
INVOKANA,postural dizziness,reactions eg postural dizziness,1
INVOKANA,postural dizziness,incidence was observed in,0
INVOKANA,postural dizziness,syncope and dehydration,0
INVOKANA,postural dizziness,,0
INVOKANA,postural dizziness,reactions,0
INVOKANA,postural dizziness,,0
INVOKANA,postural dizziness,postural dizziness,1
INVOKANA,orthostatic hypotension,hypotension,1
INVOKANA,orthostatic hypotension,eg hypotension postural orthostatic hypotension,1
INVOKANA,orthostatic hypotension,orthostatic,1
INVOKANA,orthostatic hypotension,orthostatic,1
INVOKANA,orthostatic hypotension,postural orthostatic,1
INVOKANA,orthostatic hypotension,eg hypotension postural orthostatic,1
INVOKANA,orthostatic hypotension,syncope and dehydration An increased incidence was observed in patients on the mg dose,0
INVOKANA,syncope,syncope,1
INVOKANA,syncope,syncope,1
INVOKANA,syncope,orthostatic,0
INVOKANA,syncope,reactions eg hypotension postural dizziness orthostatic,0
INVOKANA,syncope,syncope,1
INVOKANA,syncope,postural dizziness orthostatic syncope,1
INVOKANA,syncope,hypotension postural dizziness orthostatic syncope,1
INVOKANA,syncope,was,0
INVOKANA,syncope,syncope,1
INVOKANA,syncope,syncope,1
INVOKANA,dehydration,dehydration,1
INVOKANA,dehydration,dehydration,1
INVOKANA,dehydration,dehydration,1
INVOKANA,dehydration,orthostatic hypotension syncope,0
INVOKANA,dehydration,dehydration,1
INVOKANA,dehydration,dehydration,1
INVOKANA,dehydration,associated,0
INVOKANA,dehydration,dehydration,1
INVOKANA,dehydration,three factors,0
INVOKANA,dehydration,orthostatic hypotension syncope dehydration,1
INVOKANA,volume depletion-related adverse reactions,increase volume depletion-related adverse reactions,1
INVOKANA,volume depletion-related adverse reactions,with the largest increase volume depletion-related adverse,1
INVOKANA,volume depletion-related adverse reactions,with the largest increase volume depletion-related adverse reactions,1
INVOKANA,volume depletion-related adverse reactions,with the largest increase in,0
INVOKANA,Volume Depletion-Related Adverse Reaction,Patients With at Least Volume Depletion-Related Adverse Reaction,1
INVOKANA,Volume Depletion-Related Adverse Reaction,from,0
INVOKANA,Volume Depletion-Related Adverse Reaction,Pooled Results from Clinical Trials,0
INVOKANA,Volume Depletion-Related Adverse Reaction,Volume Depletion-Related,1
INVOKANA,Volume Depletion-Related Adverse Reaction,,0
INVOKANA,Volume Depletion-Related Adverse Reaction,Baseline Characteristic,0
INVOKANA,eGFR less than 60 mL/min/1.73 m 2,and eGFR less,1
INVOKANA,eGFR less than 60 mL/min/1.73 m 2,,0
INVOKANA,eGFR less than 60 mL/min/1.73 m 2,,0
INVOKANA,eGFR less than 60 mL/min/1.73 m 2,,0
INVOKANA,eGFR less than 60 mL/min/1.73 m 2,,0
INVOKANA,eGFR less than 60 mL/min/1.73 m 2,60 mL/min/1.73 m 2,1
INVOKANA,falls,with,0
INVOKANA,falls,to INVOKANA,0
INVOKANA,falls,falls,1
INVOKANA,falls,the proportion of,0
INVOKANA,falls,with comparator INVOKANA mg and INVOKANA mg respectively The h,0
INVOKANA,falls,proportion of,0
INVOKANA,falls,,0
INVOKANA,increase in serum creatinine,creatinine,1
INVOKANA,increase in serum creatinine,is associated with a increase in serum creatinine,1
INVOKANA,increase in serum creatinine,,0
INVOKANA,increase in serum creatinine,at basel,0
INVOKANA,increase in serum creatinine,is associated with a increase in serum creatinine,1
INVOKANA,increase in serum creatinine,Function INVOKANA is associated with a,0
INVOKANA,Changes in Serum Creatinine,had larger mean changes Changes in Serum Creatinine,1
INVOKANA,Changes in Serum Creatinine,had larger mean,0
INVOKANA,Changes in Serum Creatinine,of Four PlaceboControlled Trials and Moderate,0
INVOKANA,Changes in Serum Creatinine,,0
INVOKANA,Changes in Serum Creatinine,had larger mean changes Changes in Serum,1
INVOKANA,Changes in Serum Creatinine,,0
INVOKANA,Changes in Serum Creatinine,INVOKANA,0
INVOKANA,eGFR below 80 mL/min/1.73 m 2,one event of significant renal function decline,0
INVOKANA,eGFR below 80 mL/min/1.73 m 2,function decline defined as eGFR below 80 mL/min/1.73 m  2,1
INVOKANA,eGFR below 80 mL/min/1.73 m 2,as eGFR below 80 mL/min/1.73,1
INVOKANA,eGFR below 80 mL/min/1.73 m 2,patients who experienced at least,0
INVOKANA,eGFR below 80 mL/min/1.73 m 2,defined as eGFR below 80 mL/min/1.73 m  2,1
INVOKANA,eGFR below 80 mL/min/1.73 m 2,significant renal function decline defined,0
INVOKANA,renal function decline,INVOKANA mg had a renal function,1
INVOKANA,renal function decline,,0
INVOKANA,renal function decline,mg had a,0
INVOKANA,renal function decline,least,0
INVOKANA,renal function decline,renal,1
INVOKANA,eGFR 30% lower than baseline,at least one event of significant renal function decline defined as an,0
INVOKANA,eGFR 30% lower than baseline,placebo with,0
INVOKANA,eGFR 30% lower than baseline,at least one,0
INVOKANA,eGFR 30% lower than baseline,function,0
INVOKANA,eGFR 30% lower than baseline,as,0
INVOKANA,eGFR 30% lower than baseline,as an,0
INVOKANA,eGFR 30% lower than baseline,with placebo with INVOKANA mg and with INVOKANA mg At the,0
INVOKANA,renal function decline,INVOKANA mg had a renal function decline,1
INVOKANA,renal function decline,,0
INVOKANA,renal function decline,has been associated with an increased,0
INVOKANA,renal-related adverse reactions,increased incidence renal-related,1
INVOKANA,renal-related adverse reactions,incidence of,0
INVOKANA,renal-related adverse reactions,incidence renal-related,1
INVOKANA,renal-related adverse reactions,renal-related adverse reactions,1
INVOKANA,renal-related adverse reactions,blood,0
INVOKANA,renal-related adverse reactions,has been associated with an increased,0
INVOKANA,increased blood creatinine,reactions increased blood creatinine,1
INVOKANA,increased blood creatinine,and acute,0
INVOKANA,increased blood creatinine,renalrelated adverse reactions increased,1
INVOKANA,increased blood creatinine,renalrelated adverse reactions increased blood creatinine,1
INVOKANA,increased blood creatinine,of renalrelated,0
INVOKANA,increased blood creatinine,with an increased incidence of renalrelated,0
INVOKANA,increased blood creatinine,,0
INVOKANA,increased blood creatinine,creatinine,1
INVOKANA,increased blood creatinine,has been associated with an increased incidence of renalrelated adverse reactions eg,0
INVOKANA,increased blood creatinine,blood creatinine,1
INVOKANA,decreased glomerular filtration rate,reactions eg increased,0
INVOKANA,decreased glomerular filtration rate,glomerular filtration rate,1
INVOKANA,renal impairment,increased blood creatinine decreased glomerular filtration,0
INVOKANA,renal impairment,creatinine decreased glomerular filtration renal impairment,1
INVOKANA,acute renal failure,impairment acute renal failure,1
INVOKANA,renal-related adverse reactions,adverse reactions,1
INVOKANA,renal-related adverse reactions,renal-related adverse reactions,1
INVOKANA,renal-related adverse reactions,with INVOKANA mg Discontinuations,0
INVOKANA,renal-related adverse reactions,of,0
INVOKANA,renal-related adverse reactions,adverse reactions,1
INVOKANA,renal-related adverse reactions,INVOKANA,0
INVOKANA,renal-related adverse reactions,reactions,1
INVOKANA,renal-related adverse reactions,,0
INVOKANA,renal-related adverse events,adverse events,1
INVOKANA,renal-related adverse events,placebo with INVOKANA,0
INVOKANA,female genital mycotic infections,four placebocontrolled clinical female,1
INVOKANA,female genital mycotic infections,,0
INVOKANA,female genital mycotic infections,the pool of four placebocontrolled,0
INVOKANA,female genital mycotic infections,of four placebocontrolled clinical female genital mycotic infections,1
INVOKANA,female genital mycotic infections,four,0
INVOKANA,female genital mycotic infections,clinical female genital,1
INVOKANA,female genital mycotic infections,placebocontrolled clinical female genital mycotic infections,1
INVOKANA,female genital mycotic infections,trials,0
INVOKANA,vulvovaginal mycotic infection,vulvovaginal candidiasis,0
INVOKANA,vulvovaginitis,vulvovaginitis,1
INVOKANA,vulvovaginitis,vulvovaginitis,1
INVOKANA,vulvovaginitis,mycotic infection vulvovaginal candidiasis,0
INVOKANA,genital mycotic infections,genital mycotic infections,1
INVOKANA,genital mycotic infections,genital mycotic infections,1
INVOKANA,genital mycotic infections,genital mycotic,1
INVOKANA,genital mycotic infections,mycotic infections,1
INVOKANA,male genital mycotic infections,genital mycotic infections,1
INVOKANA,candidal balanitis,candidal balanitis,1
INVOKANA,candidal balanitis,treated with placebo INVOKANA mg,0
INVOKANA,candidal balanitis,candidal,1
INVOKANA,candidal balanitis,INVOKANA,0
INVOKANA,candidal balanitis,placebo INVOKANA,0
INVOKANA,candidal balanitis,infections candidal,1
INVOKANA,candidal balanitis,pool of four placebocontrolled clinical trials male genital mycotic infections eg,0
INVOKANA,candidal balanitis,,0
INVOKANA,candidal balanitis,genital mycotic infections candidal,1
INVOKANA,balanoposthitis,candidal,0
INVOKANA,balanoposthitis,,0
INVOKANA,balanoposthitis,with,0
INVOKANA,balanoposthitis,balanoposthitis,1
INVOKANA,balanoposthitis,clinical trials male genital mycotic infections eg candidal,0
INVOKANA,balanoposthitis,eg candidal balanoposthitis,1
INVOKANA,Male genital mycotic infections,in uncircumcised,0
INVOKANA,Male genital mycotic infections,more commonly in uncircumcised males and in males with,0
INVOKANA,Male genital mycotic infections,mg Male genital mycotic infections,1
INVOKANA,Male genital mycotic infections,treated with placebo INVOKANA mg and INVOKANA mg respectively,0
INVOKANA,Male genital mycotic infections,commonly in uncircumcised males and in males,0
INVOKANA,Male genital mycotic infections,mg Male genital mycotic infections,1
INVOKANA,Male genital mycotic infections,prior history of balanitis,0
INVOKANA,Male genital mycotic infections,INVOKANA mg Male,1
INVOKANA,Male genital mycotic infections,occurred more commonly in uncircumcised males and in males with a prior history of,0
INVOKANA,Male genital mycotic infections,genital mycotic infections,1
INVOKANA,phimosis,phimosis,1
INVOKANA,phimosis,the pooled analysis,0
INVOKANA,phimosis,patients treated with,0
INVOKANA,phimosis,and INVOKANA respectively In the pooled analysis of,0
INVOKANA,phimosis,,0
INVOKANA,phimosis,in of uncircumcised male patients treated with INVOKANA and,0
INVOKANA,phimosis,In the pooled analysis of controlled trials,0
INVOKANA,phimosis,phimosis,1
INVOKANA,phimosis,phimosis,1
INVOKANA,phimosis,circumc,0
INVOKANA,phimosis,to treat the,0
INVOKANA,phimosis,phimosis,1
INVOKANA,phimosis,,0
INVOKANA,phimosis,phimosis,1
INVOKANA,phimosis,treat phimosis,1
INVOKANA,phimosis,to treat phimosis,1
INVOKANA,phimosis,phimosis,1
INVOKANA,phimosis,phimosis,1
INVOKANA,phimosis,phimosis,1
INVOKANA,hypoglycemia,INVOKANA,0
INVOKANA,hypoglycemia,trials see Clinical Studies episodes,0
INVOKANA,hypoglycemia,hypoglycemia,1
INVOKANA,hypoglycemia,hypoglycemia,1
INVOKANA,Hypoglycemia,Hypoglycemia,1
INVOKANA,Hypoglycemia,Hypoglycemia,1
INVOKANA,Hypoglycemia,Hypoglycemia,1
INVOKANA,Hypoglycemia,Precautions Table Incidence,0
INVOKANA,Hypoglycemia,Hypoglycemia,1
INVOKANA,Hypoglycemia,Hypoglycemia,1
INVOKANA,Hypoglycemia,Hypoglycemia,1
INVOKANA,hypoglycemia,,0
INVOKANA,hypoglycemia,hypoglycemia,1
INVOKANA,hypoglycemia,hypoglycemia,1
INVOKANA,hypoglycemia,at least one event hypoglycemia,1
INVOKANA,hypoglycemia,hypoglycemia,1
INVOKANA,hypoglycemia,,0
INVOKANA,hypoglycemia,one event hypoglycemia,1
INVOKANA,hypoglycemia,hypoglycemia,1
INVOKANA,hypoglycemic events,hypoglycemic,1
INVOKANA,hypoglycemic events,episodes or,0
INVOKANA,hypoglycemic events,,0
INVOKANA,bone fractures,was evaluated in a pool of nine clinical trials,0
INVOKANA,bone fractures,trials with a mean duration of,0
INVOKANA,bone fractures,nine clinical trials with a mean duration of,0
INVOKANA,bone fractures,Fracture The occurrence bone fractures,1
INVOKANA,bone fractures,Bone Fracture The occurrence bone fractures,1
INVOKANA,bone fractures,The occurrence bone,1
INVOKANA,bone fractures,,0
INVOKANA,bone fractures,,0
INVOKANA,bone fractures,fractures,1
INVOKANA,bone fractures,comparator INVOKANA mg and,0
INVOKANA,bone fractures,The incidence rates of bone fractures,1
INVOKANA,bone fractures,mean duration,0
INVOKANA,bone fractures,rates of bone fractures,1
INVOKANA,bone fractures,of exposure in the comparator INVOKANA,0
INVOKANA,bone fractures,mg and,0
INVOKANA,bone fractures,bone fractures,1
INVOKANA,Fractures,,0
INVOKANA,Fractures,,0
INVOKANA,Fractures,after treatment initiation and were more likely to,0
INVOKANA,Fractures,Fractures,1
INVOKANA,Fractures,and INVOKANA mg groups Fractures,1
INVOKANA,Fractures,respectively,0
INVOKANA,Fractures,in the comparator INVOKANA,0
INVOKANA,Fractures,INVOKANA mg groups Fractures,1
INVOKANA,Fractures,and were,0
INVOKANA,Fractures,respectively,0
INVOKANA,Fractures,were more likely to be low trauma,0
INVOKANA,Fractures,mg groups Fractures,1
INVOKANA,increases in serum potassium,patients N with moderate renal impairment eGFR,0
INVOKANA,increases in serum potassium,m,0
INVOKANA,increases in serum potassium,with moderate renal impairment eGFR,0
INVOKANA,increases in serum potassium,patients N with moderate renal impairment eGFR to less than,0
INVOKANA,increases in serum potassium,of,0
INVOKANA,increases in serum potassium,and of,0
INVOKANA,increases in potassium,In these increases,1
INVOKANA,increases in potassium,In these increases in potassium,1
INVOKANA,increases in potassium,mg In,0
INVOKANA,increases in potassium,those with elevated potassium at,0
INVOKANA,increases in potassium,INVOKANA mg In these increases,1
INVOKANA,increases in potassium,increases,1
INVOKANA,increases in potassium,with INVOKANA mg and of patients treated with INVOKANA mg In,0
INVOKANA,increases in potassium,INVOKANA mg and of patients treated with INVOKANA mg In these,0
INVOKANA,increases in potassium,mg In these increases,1
INVOKANA,increases in serum magnesium,increases,1
INVOKANA,increases in serum magnesium,increases in serum magnesium,1
INVOKANA,increases in serum magnesium,Use in Specific Populations Increases in Serum Magnesium Doserelated,0
INVOKANA,increases in serum magnesium,,0
INVOKANA,increases in serum magnesium,early after initiation,0
INVOKANA,increases in serum magnesium,increases in serum magnesium,1
INVOKANA,increases in serum magnesium,and remained elevated throughout,0
INVOKANA,increases in serum magnesium,elevated throughout,0
INVOKANA,increases in serum magnesium,in,0
INVOKANA,increases in serum magnesium,,0
INVOKANA,serum magnesium levels increased,impairment see Clinical serum,1
INVOKANA,serum magnesium levels increased,levels increased,1
INVOKANA,serum magnesium levels increased,renal impairment see Clinical serum magnesium levels,1
INVOKANA,serum magnesium levels increased,renal impairment see Clinical serum magnesium levels increased,1
INVOKANA,serum magnesium levels increased,Studies,0
INVOKANA,serum magnesium levels increased,by and with placebo INVOKANA mg and INVOKANA mg respectively,0
INVOKANA,serum magnesium levels increased,renal,0
INVOKANA,serum magnesium levels increased,with,0
INVOKANA,increases in serum phosphate,increases in serum phosphate,1
INVOKANA,increases in serum phosphate,Serum Phosphate increases in serum,1
INVOKANA,increases in serum phosphate,serum phosphate,1
INVOKANA,change in serum phosphate levels,respectively compared to with pl,0
INVOKANA,change in serum phosphate levels,the mean change in serum phosphate,1
INVOKANA,change in serum phosphate levels,change in serum phosphate levels,1
INVOKANA,change in serum phosphate levels,,0
INVOKANA,change in serum phosphate levels,the mean change in serum phosphate levels,1
INVOKANA,change in serum phosphate levels,controlled trials the mean percent,0
INVOKANA,serum phosphate levels increased,Studies the serum phosphate levels increased,1
INVOKANA,serum phosphate levels increased,Studies the serum phosphate levels increased,1
INVOKANA,serum phosphate levels increased,,0
INVOKANA,serum phosphate levels increased,mg,0
INVOKANA,serum phosphate levels increased,see Clinical Studies the serum phosphate levels increased,1
INVOKANA,serum phosphate levels increased,and with placebo INVOKANA mg and INVOKANA mg respectively,0
INVOKANA,serum phosphate levels increased,Clinical Studies the mean,0
INVOKANA,serum phosphate levels increased,phosphate levels increased,1
INVOKANA,serum phosphate levels increased,mg respectively I,0
INVOKANA,increases in LDL-C,in LDL-C,1
INVOKANA,increases in LDL-C,LDL-C,1
INVOKANA,increases in LDL-C,percent changes from baseline in,0
INVOKANA,increases in LDL-C,trials increases in LDL-C,1
INVOKANA,increases in LDL-C,with INVOKANA,0
INVOKANA,increases in LDL-C,placebocontrolled trials increases in,1
INVOKANA,increases in LDL-C,to,0
INVOKANA,increases in LDL-C,changes from baseline in LDLC,0
INVOKANA,increases in LDL-C,increases in LDL-C,1
INVOKANA,increases in LDL-C,of four placebocontrolled trials increases,1
INVOKANA,increases in non-HDL-C,increases in,1
INVOKANA,increases in non-HDL-C,see Warnings and Precautions increases in,1
INVOKANA,increases in non-HDL-C,and Precautions increases in non-HDL-C,1
INVOKANA,increases in non-HDL-C,were observed Mean changes,0
INVOKANA,increases in non-HDL-C,non-HDL-C,1
INVOKANA,increases in non-HDL-C,increases in,1
INVOKANA,increases in non-HDL-C,Warnings and Precautions Doserelated,0
INVOKANA,declines in BMD at the total hip,spine,0
INVOKANA,declines in BMD at the total hip,and respectively and at the,0
INVOKANA,declines in BMD at the total hip,mg,0
INVOKANA,declines in BMD at the total hip,at the,0
INVOKANA,declines in BMD at the total hip,INVOKANA mg and INVOKANA,0
INVOKANA,declines in BMD at the total hip,,0
INVOKANA,Hypotension,,0
INVOKANA,Hypotension,,0
INVOKANA,Hypotension,dverse,1
INVOKANA,Hypotension,,0
INVOKANA,Hypotension,dverse,1
INVOKANA,Hypotension,dverse reac tions are,1
INVOKANA,Impairment in Renal Function,Precautions Hypoglyc,0
INVOKANA,Impairment in Renal Function,and Precautions emia with Concomitant Use wi th Insulin,1
INVOKANA,Impairment in Renal Function,and Precautions Genital Mycotic,0
INVOKANA,Impairment in Renal Function,,0
INVOKANA,Impairment in Renal Function,emia with Concomitant Use wi th Insulin,1
INVOKANA,Impairment in Renal Function,emia with Concomitant Use wi th Insulin,1
INVOKANA,Impairment in Renal Function,Precautions emia with Concomitant Use,1
INVOKANA,Impairment in Renal Function,see Warnings and Precautions emia with Concomitant Use wi th Insulin,1
INVOKANA,Impairment in Renal Function,Precautions emia with Concomitant Use wi th Insulin,1
INVOKANA,Hyperkalemia,")  ]  
 *  H ypersensitivity Reactions",1
INVOKANA,Hyperkalemia,Precautions,0
INVOKANA,Hyperkalemia,,0
INVOKANA,Hypoglycemia,in nsity,1
INVOKANA,Hypoglycemia,Precautions Most common adverse reactions,0
INVOKANA,Genital mycotic infections,enital mycotic,1
INVOKANA,Genital mycotic infections,INVOKANA or greater incidence female g,0
INVOKANA,Genital mycotic infections,"incidence female enital mycotic infections, urinary tract",1
INVOKANA,Genital mycotic infections,INVOKANA or,0
INVOKANA,Hypersensitivity reactions,tract,0
INVOKANA,Hypersensitivity reactions,contact Janssen Pharmaceuticals Inc at,0
INVOKANA,Hypersensitivity reactions,n ( 6.1,1
INVOKANA,Hypersensitivity reactions,n ( 6.1 ) EXCERPT To report,1
INVOKANA,Hypersensitivity reactions,SUSPECTED ADVERSE REACTIONS contact Janssen Pharmaceuticals Inc at,0
INVOKANA,Hypersensitivity reactions,EXCERPT To report,1
INVOKANA,Hypersensitivity reactions,"infection and increased n (  6.1  ) 
      EXCERPT To report",1
INVOKANA,Hypersensitivity reactions,,0
INVOKANA,Hypersensitivity reactions,"and increased n (  6.1  ) 
      EXCERPT To report",1
INVOKANA,Hypersensitivity reactions,,0
INVOKANA,Bone fracture,Janssen Pharmaceuticals,0
INVOKANA,Increased LDL-C,"wwwfdagovmedwatch Clinical Studies ience

  Becaus e clinical",1
INVOKANA,Increased LDL-C,Becaus e clinical,1
INVOKANA,Increased LDL-C,"wwwfdagovmedwatch Clinical Studies ience

  Becaus e clinical",1
INVOKANA,Increased LDL-C,at FDA,0
INVOKANA,Increased LDL-C,Clinical Studies ience,1
INVOKANA,intravascular volume contraction,,0
INVOKANA,intravascular volume contraction,rates observed the clinical trials of a,1
INVOKANA,decreases eGFR,,0
INVOKANA,decreases eGFR,Fifty percent of the pulation was m ale and,1
INVOKANA,decreases eGFR,of the pulation was m ale and,1
INVOKANA,decreases eGFR,Fifty percent of the pulation was m ale and,1
INVOKANA,decreases eGFR,percent of the pulation was,1
INVOKANA,Renal function abnormalities,and were Black or Afric,0
INVOKANA,hyperkalemia,adverse reactions associated with the use of INVOKANA These adverse reactions were,0
INVOKANA,hyperkalemia,mLmin Table,1
INVOKANA,hyperkalemia,Table 1 shows common,1
INVOKANA,hyperkalemia,renal function was normal or mildly impaired mean eGFR mLmin m,0
INVOKANA,hyperkalemia,Four Week PlaceboControlled Studies Reported,0
INVOKANA,hyperkalemia,"INVOKANA mg or  300 mg.



 Table Adverse",1
INVOKANA,hyperkalemia,300,1
INVOKANA,hyperkalemia,"either INVOKANA mg or  300 mg.



 Table Adverse",1
INVOKANA,hyperkalemia,300 mg. Table Adverse,1
INVOKANA,hyperkalemia,treated with either INVOKANA,0
INVOKANA,hyperkalemia,mg. Table Adverse,1
INVOKANA,hyperkalemia,either INVOKANA mg or 300,1
INVOKANA,hyperkalemia,Studies Reported in o,0
INVOKANA,hyperkalemia,either INVOKANA mg or 300,1
INVOKANA,hypoglycemia,Urinary tract,0
INVOKANA,genital mycotic infections,0.6% 4. Vulvovaginal pruritus,1
INVOKANA,genital mycotic infections,,0
INVOKANA,genital mycotic infections,Male genital mycotic   0.6%                  4. Vulvovaginal pruritus,1
INVOKANA,genital mycotic infections,,0
INVOKANA,genital mycotic infections,genital mycotic,0
INVOKANA,genital mycotic infections,genital mycotic 0.6%,1
INVOKANA,genital mycotic infections,pruritus,0
INVOKANA,genital mycotic infections,Vulvovaginal 1.6%,1
INVOKANA,genital mycotic infections,,0
INVOKANA,Hypersensitivity reactions,"          
 Constipation   Nau",1
INVOKANA,Hypersensitivity reactions,"          
 Constipation   Nau",1
INVOKANA,Hypersensitivity reactions,"          
 Constipation   Nau",1
INVOKANA,Hypersensitivity reactions,Thirst,0
INVOKANA,Hypersensitivity reactions,Thirst,0
INVOKANA,Hypersensitivity reactions,"Thirst           
 Constipation   Nau",1
INVOKANA,Hypersensitivity reactions,Thirst,0
INVOKANA,Hypersensitivity reactions,"          
 Constipation   Nau",1
INVOKANA,generalized urticaria,Constipation                       Nausea,1
INVOKANA,generalized urticaria,Constipation,0
INVOKANA,generalized urticaria,Nausea,0
INVOKANA,generalized urticaria,Constipation,0
INVOKANA,generalized urticaria,                      Nausea,1
INVOKANA,generalized urticaria,                      Nausea,1
INVOKANA,bone fracture,occurrence,0
INVOKANA,bone fracture,Pool,0
INVOKANA,bone fracture,Placebo and ActiveCont,0
INVOKANA,bone fracture,and rolled Trials The,1
INVOKANA,bone fracture,and rolled Trials The,1
INVOKANA,increases in LDL-C,duration of ex posure,1
INVOKANA,increases in LDL-C,The ean duration,1
XTANDI,Seizure,Seizure see,1
XTANDI,Seizure,Seizure see,1
XTANDI,Seizure,the Seizure see,1
XTANDI,Seizure,Seizure see,1
XTANDI,Seizure,Seizure see,1
XTANDI,Seizure,The most common adverse,0
XTANDI,asthenia,,0
XTANDI,asthenia,,0
XTANDI,asthenia,asthenia fatigue,1
XTANDI,asthenia,constipation arthralgia diarrhea hot flush upper,0
XTANDI,asthenia,reactions,0
XTANDI,asthenia,most common adverse,0
XTANDI,asthenia,The most common adverse,0
XTANDI,asthenia,flush upper respir,0
XTANDI,asthenia,,0
XTANDI,back pain,back,1
XTANDI,decreased appetite,back decreased appetite constipation,1
XTANDI,decreased appetite,adverse,0
XTANDI,decreased appetite,are astheniafatigue back decreased,1
XTANDI,decreased appetite,,0
XTANDI,decreased appetite,hot flush,0
XTANDI,decreased appetite,back,0
XTANDI,decreased appetite,edema,0
XTANDI,constipation,constipation arthralgia,1
XTANDI,constipation,pain decreased constipation arthralgia,1
XTANDI,constipation,constipation arthralgia,1
XTANDI,constipation,constipation arthralgia,1
XTANDI,constipation,back pain decreased constipation arthralgia,1
XTANDI,constipation,constipation arthralgia,1
XTANDI,arthralgia,decreased appetite,0
XTANDI,arthralgia,arthralgia diarrhea,1
XTANDI,arthralgia,decreased appetite arthralgia diarrhea,1
XTANDI,arthralgia,respiratory tract infection peripheral edema dyspnea,0
XTANDI,arthralgia,arthralgia diarrhea,1
XTANDI,arthralgia,diarrhea hot flush upper respiratory tract,0
XTANDI,diarrhea,back pain decreased appetite constipation arthralgia,0
XTANDI,diarrhea,,0
XTANDI,diarrhea,diarrhea hot,1
XTANDI,diarrhea,,0
XTANDI,diarrhea,diarrhea hot,1
XTANDI,diarrhea,,0
XTANDI,diarrhea,edema dyspnea musculoskeletal pain wei,0
XTANDI,diarrhea,hot flush upper respiratory tract infection,0
XTANDI,hot flush,hot flush upper,1
XTANDI,hot flush,hot,1
XTANDI,hot flush,arthralgia hot flush upper,1
XTANDI,hot flush,constipation arthralgia hot flush upper,1
XTANDI,hot flush,constipation arthralgia hot flush upper,1
XTANDI,upper respiratory tract infection,tract infection peripheral,1
XTANDI,upper respiratory tract infection,pain decreased,0
XTANDI,upper respiratory tract infection,,0
XTANDI,upper respiratory tract infection,diarrhea hot,0
XTANDI,upper respiratory tract infection,hot upper respiratory,1
XTANDI,upper respiratory tract infection,hot,0
XTANDI,upper respiratory tract infection,upper respiratory tract,1
XTANDI,upper respiratory tract infection,pain decreased appetite constipation arthralgia diarrhea hot flush,0
XTANDI,upper respiratory tract infection,diarrhea hot upper respiratory tract,1
XTANDI,peripheral edema,respiratory tract peripheral edema dyspnea,1
XTANDI,dyspnea,dyspnea musculoskeletal,1
XTANDI,dyspnea,musculoskeletal pain weight decreased,0
XTANDI,dyspnea,peripheral dyspnea musculoskeletal,1
XTANDI,dyspnea,tract infection peripheral dyspnea musculoskeletal,1
XTANDI,dyspnea,dizzinessvertigo,0
XTANDI,dyspnea,dyspnea musculoskeletal,1
XTANDI,dyspnea,dizzinessvertigo,0
XTANDI,dyspnea,,0
XTANDI,weight decreased,decreased headache,1
XTANDI,weight decreased,,0
XTANDI,weight decreased,edema,0
XTANDI,weight decreased,dizzinessvertigo To report SUSPECTED,0
XTANDI,weight decreased,infection peripheral edema dyspnea,0
XTANDI,weight decreased,edema dyspnea musculoskeletal weight decreased headache,1
XTANDI,weight decreased,dyspnea musculoskeletal weight,1
XTANDI,weight decreased,and dizzinessvertigo To report SUSPECTED,0
XTANDI,weight decreased,peripheral edema dyspnea musculoskeletal,0
XTANDI,weight decreased,dyspnea musculoskeletal weight,1
XTANDI,headache,dyspnea musculoskeletal,0
XTANDI,headache,dyspnea,0
XTANDI,headache,ADVERSE REACTIONS,0
XTANDI,headache,,0
XTANDI,headache,pain weight headache hypertension,1
XTANDI,headache,musculoskeletal pain weight headache hypertension,1
XTANDI,headache,and dizzinessvertigo,0
XTANDI,headache,REACTIONS,0
XTANDI,hypertension,pain weight decreased,0
XTANDI,hypertension,hypertension and,1
XTANDI,hypertension,,0
XTANDI,hypertension,,0
XTANDI,dizziness,hypertension dizziness vertigo,1
XTANDI,dizziness,hypertension dizziness vertigo,1
XTANDI,dizziness,dyspnea musculoskeletal pain weight decreased headache hypertension,0
XTANDI,dizziness,hypertension dizziness vertigo,1
XTANDI,dizziness,decreased headache hypertension dizziness vertigo,1
XTANDI,dizziness,dizziness vertigo,1
XTANDI,dizziness,report SUSPECTED ADVERSE REACTIONS contact Astellas Pharma US Inc,0
XTANDI,dizziness,dyspnea,0
XTANDI,dizziness,dizziness vertigo,1
XTANDI,dizziness,dizziness vertigo,1
XTANDI,vertigo,at,0
XTANDI,vertigo,vertigo To,1
XTANDI,vertigo,dyspnea musculoskeletal pain weight decreased,0
XTANDI,vertigo,and vertigo To,1
XTANDI,vertigo,vertigo To,1
XTANDI,vertigo,hypertension and vertigo To,1
XTANDI,vertigo,,0
XTANDI,asthenia,two randomized clinical trials asthenia fatigue,1
XTANDI,fatigue,fatigue back,1
XTANDI,fatigue,fatigue back,1
XTANDI,fatigue,fatigue back,1
XTANDI,fatigue,fatigue back,1
XTANDI,decreased appetite,arthralgia diarrhea,0
XTANDI,decreased appetite,astheniafatigue back decreased appetite constipation,1
XTANDI,constipation,tract infection peripheral edema dyspnea,0
XTANDI,constipation,,0
XTANDI,constipation,constipation arthralgia,1
XTANDI,constipation,infection peripheral edema,0
XTANDI,constipation,flush,0
XTANDI,constipation,decreased appetite,0
XTANDI,arthralgia,,0
XTANDI,arthralgia,infection,0
XTANDI,arthralgia,arthralgia diarrhea,1
XTANDI,arthralgia,arthralgia diarrhea,1
XTANDI,diarrhea,upper respiratory,0
XTANDI,diarrhea,were,0
XTANDI,diarrhea,diarrhea hot,1
XTANDI,diarrhea,trials,0
XTANDI,diarrhea,diarrhea hot,1
XTANDI,diarrhea,diarrhea hot,1
XTANDI,diarrhea,diarrhea hot,1
XTANDI,hot flush,,0
XTANDI,hot flush,hot flush upper,1
XTANDI,hot flush,hot,1
XTANDI,hot flush,weight,0
XTANDI,hot flush,trials were,0
XTANDI,hot flush,arthralgia,0
XTANDI,hot flush,,0
XTANDI,hot flush,edema dyspnea musculoskeletal pain,0
XTANDI,hot flush,back,0
XTANDI,peripheral edema,appetite constipation,0
XTANDI,peripheral edema,peripheral,1
XTANDI,peripheral edema,,0
XTANDI,peripheral edema,appetite constipation arthralgia diarrhea hot flush,0
XTANDI,peripheral edema,musculoskeletal pain,0
XTANDI,peripheral edema,constipation arthralgia diarrhea hot,0
XTANDI,dyspnea,peripheral dyspnea musculoskeletal,1
XTANDI,dyspnea,hypertension and dizzinessvertigo,0
XTANDI,dyspnea,dyspnea musculoskeletal,1
XTANDI,dyspnea,tract infection peripheral dyspnea musculoskeletal,1
XTANDI,dyspnea,dyspnea musculoskeletal,1
XTANDI,musculoskeletal pain,pain weight,1
XTANDI,musculoskeletal pain,weight decreased headache hypertension and,0
XTANDI,musculoskeletal pain,tract infection peripheral edema musculoskeletal pain weight,1
XTANDI,weight decreased,pain,0
XTANDI,weight decreased,tract infection peripheral,0
XTANDI,weight decreased,respiratory tract infection peripheral edema dyspnea,0
XTANDI,weight decreased,hypertension and dizzinessvertigo Study,0
XTANDI,hypertension,Cancer,0
XTANDI,hypertension,,0
XTANDI,hypertension,weight decreased headache,0
XTANDI,hypertension,musculoskeletal pain,0
XTANDI,hypertension,Metastatic CastrationResistant Prostate,0
XTANDI,hypertension,Study Metastatic CastrationResistant Prostate Cancer Following Ch,0
XTANDI,hypertension,hypertension and,1
XTANDI,hypertension,pain,0
XTANDI,hypertension,hypertension and,1
XTANDI,dizziness,,0
XTANDI,dizziness,weight decreased headache,0
XTANDI,dizziness,headache hypertension dizziness vertigo,1
XTANDI,dizziness,weight decreased headache hypertension dizziness vertigo,1
XTANDI,dizziness,dizziness vertigo,1
XTANDI,dizziness,,0
XTANDI,vertigo,Metastatic CastrationResistant,0
XTANDI,vertigo,vertigo Study,1
XTANDI,vertigo,Study,0
XTANDI,vertigo,Study,0
XTANDI,vertigo,weight decreased headache hypertension and,0
XTANDI,vertigo,vertigo Study,1
XTANDI,vertigo,Chemotherapy Study,0
XTANDI,vertigo,enr,0
XTANDI,seizure,seizure which,1
XTANDI,seizure,which occurred in of the XTANDItreated patients compared to,0
XTANDI,Asthenic Conditions,Asthenic Conditions b,1
XTANDI,Asthenic Conditions,Grade Grade General Asthenic,1
XTANDI,Asthenic Conditions,Asthenic Conditions b,1
XTANDI,Asthenic Conditions,General Disorders,0
XTANDI,Asthenic Conditions,,0
XTANDI,Asthenic Conditions,,0
XTANDI,Asthenic Conditions,Grade General Asthenic Conditions b,1
XTANDI,Peripheral Edema,Edema Musculosk,1
XTANDI,Peripheral Edema,nditionsb Peripheral,1
XTANDI,Peripheral Edema,,0
XTANDI,Peripheral Edema,nditionsb Peripheral Edema Musculosk,1
XTANDI,Peripheral Edema,nditionsb,0
XTANDI,Peripheral Edema,Musculosk,0
XTANDI,Peripheral Edema,,0
XTANDI,Peripheral Edema,nditionsb Peripheral Edema Musculosk,1
XTANDI,Back Pain,,0
XTANDI,Back Pain,,0
XTANDI,Back Pain,,0
XTANDI,Back Pain,,0
XTANDI,Back Pain,Musculoskeletal And Connective Tissue Back,1
XTANDI,Arthralgia,,0
XTANDI,Arthralgia,,0
XTANDI,Arthralgia,,0
XTANDI,Arthralgia,,0
XTANDI,Arthralgia,,0
XTANDI,Arthralgia,,0
XTANDI,Musculoskeletal Pain,Musculoskeletal Pain Muscular,1
XTANDI,Musculoskeletal Pain,,0
XTANDI,Musculoskeletal Pain,Musculoskeletal Pain Muscular,1
XTANDI,Musculoskeletal Pain,Muscular,0
XTANDI,Musculoskeletal Pain,Pain Muscular,1
XTANDI,Musculoskeletal Pain,,0
XTANDI,Musculoskeletal Pain,,0
XTANDI,Musculoskeletal Pain,Musculoskeletal Pain Muscular,1
XTANDI,Musculoskeletal Pain,Musculoskeletal Pain Muscular,1
XTANDI,Muscular Weakness,,0
XTANDI,Muscular Weakness,Pain,0
XTANDI,Muscular Weakness,,0
XTANDI,Muscular Weakness,Muscular Weakness Muscul,1
XTANDI,Musculoskeletal Stiffness,akness Musculoskeletal Stiffness Gastrointestinal,1
XTANDI,Musculoskeletal Stiffness,,0
XTANDI,Musculoskeletal Stiffness,akness Musculoskeletal,1
XTANDI,Musculoskeletal Stiffness,,0
XTANDI,Musculoskeletal Stiffness,akness,0
XTANDI,Musculoskeletal Stiffness,akness Musculoskeletal Stiffness Gastrointestinal,1
XTANDI,Musculoskeletal Stiffness,akness Musculoskeletal Stiffness Gastrointestinal,1
XTANDI,Musculoskeletal Stiffness,,0
XTANDI,Musculoskeletal Stiffness,akness Musculoskeletal Stiffness Gastrointestinal,1
XTANDI,Hot Flush,,0
XTANDI,Hot Flush,Hot Flush,1
XTANDI,Hot Flush,,0
XTANDI,Hot Flush,Hot,1
XTANDI,Hot Flush,,0
XTANDI,Hot Flush,,0
XTANDI,Hot Flush,,0
XTANDI,Hot Flush,Vascular Hot Flush,1
XTANDI,Hot Flush,,0
XTANDI,Hypertension,Hypertension Nervo,1
XTANDI,Hypertension,,0
XTANDI,Hypertension,Nervo,0
XTANDI,Hypertension,,0
XTANDI,Hypertension,,0
XTANDI,Headache,,0
XTANDI,Headache,Nervous System Headache,1
XTANDI,Headache,,0
XTANDI,Headache,Nervous System Headache,1
XTANDI,Headache,,0
XTANDI,Headache,Headache,1
XTANDI,Headache,System Headache,1
XTANDI,Headache,Headache,1
XTANDI,Headache,Headache,1
XTANDI,Dizziness,,0
XTANDI,Dizziness,Dizziness c,1
XTANDI,Dizziness,Dizziness c,1
XTANDI,Dizziness,Dizziness c,1
XTANDI,Dizziness,,0
XTANDI,Dizziness,,0
XTANDI,Dizziness,,0
XTANDI,Dizziness,,0
XTANDI,Spinal Cord Compression,Spinal,1
XTANDI,Spinal Cord Compression,Syndrome,0
XTANDI,Cauda Equina Syndrome,,0
XTANDI,Cauda Equina Syndrome,,0
XTANDI,Cauda Equina Syndrome,Cord,0
XTANDI,Cauda Equina Syndrome,Spinal Cord Compression Cauda Equina,1
XTANDI,Cauda Equina Syndrome,Syndrome Paresthesia,1
XTANDI,Cauda Equina Syndrome,Cord Compression Cauda Equina Syndrome Paresthesia,1
XTANDI,Cauda Equina Syndrome,,0
XTANDI,Mental Impairment Disorders,Mental,1
XTANDI,Mental Impairment Disorders,,0
XTANDI,Mental Impairment Disorders,Mental,1
XTANDI,Mental Impairment Disorders,,0
XTANDI,Hypoesthesia,Disordersd,0
XTANDI,Hypoesthesia,,0
XTANDI,Hypoesthesia,Hypoesthesia Infec,1
XTANDI,Hypoesthesia,Disordersd,0
XTANDI,Hypoesthesia,Hypoesthesia Infec,1
XTANDI,Hypoesthesia,,0
XTANDI,Hypoesthesia,Hypoesthesia Infec,1
XTANDI,Upper Respiratory Tract Infection,,0
XTANDI,Upper Respiratory Tract Infection,And Infestations,0
XTANDI,Upper Respiratory Tract Infection,Infections And Upper Respiratory Tract     Infection e Lower,1
XTANDI,Upper Respiratory Tract Infection,And Upper Respiratory Tract     Infection e Lower,1
XTANDI,Upper Respiratory Tract Infection,,0
XTANDI,Lung Infection,Lower Respiratory Tract Lung Infection f Psychiatric,1
XTANDI,Lung Infection,,0
XTANDI,Lung Infection,Tract Lung Infection f Psychiatric,1
XTANDI,Lung Infection,Lung,1
XTANDI,Lung Infection,Lung Infection f Psychiatric,1
XTANDI,Lung Infection,,0
XTANDI,Lung Infection,Respiratory Tract Lung Infection f Psychiatric,1
XTANDI,Lung Infection,,0
XTANDI,Insomnia,Insomnia,1
XTANDI,Insomnia,Insomnia,1
XTANDI,Insomnia,Disorders,0
XTANDI,Insomnia,Insomnia,1
XTANDI,Insomnia,Insomnia,1
XTANDI,Insomnia,,0
XTANDI,Insomnia,Disorders,0
XTANDI,Insomnia,Insomnia,1
XTANDI,Insomnia,Insomnia,1
XTANDI,Anxiety,,0
XTANDI,Anxiety,Anxiety,1
XTANDI,Anxiety,,0
XTANDI,Anxiety,Anxiety,1
XTANDI,Anxiety,Anxiety,1
XTANDI,Anxiety,,0
XTANDI,Anxiety,Anxiety,1
XTANDI,Anxiety,Anxiety,1
XTANDI,Hematuria,,0
XTANDI,Pollakiuria,Pollakiuria Inju,1
XTANDI,Pollakiuria,Inju,0
XTANDI,Pollakiuria,Pollakiuria Inju,1
XTANDI,Pollakiuria,Pollakiuria Inju,1
XTANDI,Pollakiuria,Pollakiuria Inju,1
XTANDI,Pollakiuria,Pollakiuria Inju,1
XTANDI,Pollakiuria,,0
XTANDI,Pollakiuria,Pollakiuria Inju,1
XTANDI,Fall,,0
XTANDI,Fall,Fall,1
XTANDI,Fall,Fall,1
XTANDI,Fall,Fall,1
XTANDI,Fall,And,0
XTANDI,Fall,And,0
XTANDI,Fall,Complications,0
XTANDI,Fall,And Procedural Fall,1
XTANDI,Fall,And Procedural,0
XTANDI,Non-pathologic Fractures,Non-pathologic Fractures,1
XTANDI,Pruritus,Tissue Pruritus,1
XTANDI,Pruritus,Pruritus,1
XTANDI,Dry Skin,Dry Skin R,1
XTANDI,Dry Skin,Dry Skin R,1
XTANDI,Dry Skin,Skin R,1
XTANDI,Dry Skin,,0
XTANDI,Dry Skin,Dry Skin R,1
XTANDI,Dry Skin,,0
XTANDI,Epistaxis,a,0
XTANDI,Epistaxis,Epistaxis a,1
XTANDI,Epistaxis,Epistaxis a,1
XTANDI,Epistaxis,Epistaxis a,1
XTANDI,Epistaxis,Epistaxis a,1
XTANDI,asthenia,asthenia,1
XTANDI,asthenia,asthenia,1
XTANDI,fatigue,and vertigod Includes amnesia memory impairment cognitive disorder a,0
XTANDI,fatigue,fatigue,1
XTANDI,fatigue,fatigue,1
XTANDI,fatigue,Includes asthenia and,0
XTANDI,vertigo,impairment cognitive disorder and disturbance,0
XTANDI,vertigo,vertigo,1
XTANDI,vertigo,dizziness,0
XTANDI,vertigo,,0
XTANDI,amnesia,amnesia,1
XTANDI,amnesia,amnesia,1
XTANDI,amnesia,amnesia,1
XTANDI,amnesia,amnesia,1
XTANDI,amnesia,amnesia,1
XTANDI,amnesia,disturbance in attentione,0
XTANDI,amnesia,and disturbance in attentione Includes,0
XTANDI,cognitive disorder,vertigod Includes amnesia memory cognitive,1
XTANDI,cognitive disorder,and disturbance in,0
XTANDI,cognitive disorder,dizziness and,0
XTANDI,cognitive disorder,memory cognitive disorder,1
XTANDI,cognitive disorder,,0
XTANDI,disturbance in attention,impairment cognitive disorder disturbance,1
XTANDI,disturbance in attention,,0
XTANDI,disturbance in attention,disorder disturbance in attention,1
XTANDI,disturbance in attention,disturbance in attention,1
XTANDI,nasopharyngitis,,0
XTANDI,nasopharyngitis,nasopharyngitis,1
XTANDI,nasopharyngitis,respiratory tract infection sinusitis rhinitis pharyngitis and laryngitisf Includes,0
XTANDI,nasopharyngitis,,0
XTANDI,upper respiratory tract infection,disturbance in attentione Includes upper respiratory,1
XTANDI,upper respiratory tract infection,in attentione Includes upper respiratory tract infection,1
XTANDI,upper respiratory tract infection,Includes nasopharyngitis,0
XTANDI,upper respiratory tract infection,tract infection,1
XTANDI,sinusitis,upper,0
XTANDI,sinusitis,tract sinusitis,1
XTANDI,sinusitis,tract,0
XTANDI,sinusitis,lower respiratory tract,0
XTANDI,sinusitis,Includes,0
XTANDI,sinusitis,respiratory,0
XTANDI,sinusitis,sinusitis,1
XTANDI,sinusitis,nasopharyngitis upper respiratory tract sinusitis,1
XTANDI,sinusitis,and laryngitisf Includes pneumonia,0
XTANDI,rhinitis,rhinitis,1
XTANDI,rhinitis,attentione Includes nasopharyngitis upper respiratory tract,0
XTANDI,rhinitis,,0
XTANDI,pharyngitis,tract infection sinusitis,0
XTANDI,pharyngitis,nasopharyngitis upper,0
XTANDI,laryngitis,laryngitis,1
XTANDI,laryngitis,tract infection sinusitis rhinitis pharyngitis,0
XTANDI,laryngitis,laryngitis,1
XTANDI,laryngitis,laryngitis,1
XTANDI,laryngitis,respiratory tract infection sinusitis rhinitis pharyngitis,0
XTANDI,laryngitis,respiratory tract infection bronchitis and lung infection,0
XTANDI,laryngitis,laryngitis,1
XTANDI,laryngitis,respiratory tract infection sinusitis rhinitis pharyngitis,0
XTANDI,laryngitis,,0
XTANDI,pneumonia,infection Study Chemo,0
XTANDI,pneumonia,pneumonia,1
XTANDI,pneumonia,pneumonia,1
XTANDI,pneumonia,pharyngitis and laryngitisf,0
XTANDI,pneumonia,pneumonia,1
XTANDI,pneumonia,Includes,0
XTANDI,pneumonia,and laryngitisf pneumonia,1
XTANDI,pneumonia,respiratory tract infection sinusitis,0
XTANDI,lower respiratory tract infection,Includes lower respiratory tract infection,1
XTANDI,lower respiratory tract infection,Includes,0
XTANDI,lower respiratory tract infection,and laryngitisf Includes pneumonia,0
XTANDI,lower respiratory tract infection,Includes lower respiratory tract,1
XTANDI,bronchitis,lung infection Study,0
XTANDI,lung infection,infection,1
XTANDI,fatigue,reaction leading to treatment discontinuation,0
XTANDI,asthenia,most common adverse reaction leading,0
XTANDI,asthenia,most common adverse reaction,0
XTANDI,asthenia,to,0
XTANDI,asthenia,asthenia,1
XTANDI,asthenia,asthenia,1
XTANDI,asthenia,asthenia,1
XTANDI,asthenia,asthenia,1
XTANDI,Asthenic Conditions,General Disorders,0
XTANDI,Asthenic Conditions,Periphe,0
XTANDI,Asthenic Conditions,Conditions,1
XTANDI,Asthenic Conditions,,0
XTANDI,Asthenic Conditions,Grade Grade General Asthenic,1
XTANDI,Asthenic Conditions,Grade Grade General Asthenic Conditions,1
XTANDI,Asthenic Conditions,Periphe,0
XTANDI,Asthenic Conditions,Grade General,0
XTANDI,Asthenic Conditions,Asthenic Conditions,1
XTANDI,Asthenic Conditions,Grade General Asthenic Conditions,1
XTANDI,Peripheral Edema,ditionsb Peripheral,1
XTANDI,Back Pain,Connective Tissue Back Pain,1
XTANDI,Back Pain,Musculoskeletal And Connective Tissue Back,1
XTANDI,Back Pain,Connective Tissue Back,1
XTANDI,Back Pain,And Connective Tissue Back,1
XTANDI,Back Pain,Connective,0
XTANDI,Back Pain,,0
XTANDI,Back Pain,And Connective Tissue Back Pain,1
XTANDI,Back Pain,Musculoskeletal And Connective Tissue Back Pain,1
XTANDI,Arthralgia,,0
XTANDI,Arthralgia,,0
XTANDI,Arthralgia,,0
XTANDI,Arthralgia,Arthralgia Ga,1
XTANDI,Arthralgia,,0
XTANDI,Arthralgia,,0
XTANDI,Constipation,,0
XTANDI,Constipation,Disorders,0
XTANDI,Constipation,Constipation,1
XTANDI,Constipation,,0
XTANDI,Constipation,,0
XTANDI,Constipation,Gastrointestinal Constipation,1
XTANDI,Constipation,Constipation,1
XTANDI,Constipation,Constipation,1
XTANDI,Constipation,,0
XTANDI,Diarrhea,Diarrhea,1
XTANDI,Diarrhea,Diarrhea,1
XTANDI,Diarrhea,,0
XTANDI,Diarrhea,,0
XTANDI,Hypertension,,0
XTANDI,Dizziness,Dizziness c,1
XTANDI,Dizziness,Dizziness c,1
XTANDI,Dizziness,,0
XTANDI,Dizziness,Dizziness c,1
XTANDI,Dizziness,Disorders,0
XTANDI,Headache,,0
XTANDI,Headache,,0
XTANDI,Headache,Headache,1
XTANDI,Headache,Headache,1
XTANDI,Headache,Headache,1
XTANDI,Headache,,0
XTANDI,Headache,,0
XTANDI,Headache,,0
XTANDI,Headache,,0
XTANDI,Headache,Headache,1
XTANDI,Dysgeusia,,0
XTANDI,Dysgeusia,,0
XTANDI,Dysgeusia,Dysgeusia,1
XTANDI,Dysgeusia,,0
XTANDI,Dysgeusia,,0
XTANDI,Mental Impairment Disorders,Mental Impairment Disorders,1
XTANDI,Mental Impairment Disorders,Mental Impairment,1
XTANDI,Mental Impairment Disorders,d,0
XTANDI,Mental Impairment Disorders,Mental Impairment Disorders d Restless,1
XTANDI,Mental Impairment Disorders,Restless Leg,0
XTANDI,Mental Impairment Disorders,Mental Impairment Disorders,1
XTANDI,Mental Impairment Disorders,Leg,0
XTANDI,Mental Impairment Disorders,Disorders d,1
XTANDI,Mental Impairment Disorders,Restless Leg,0
XTANDI,Mental Impairment Disorders,Mental Impairment,1
XTANDI,Restless Legs Syndrome,,0
XTANDI,Restless Legs Syndrome,Respiratory,0
XTANDI,Restless Legs Syndrome,Legs Syndrome Respiratory Di,1
XTANDI,Restless Legs Syndrome,Restless Legs,1
XTANDI,Dyspneae,,0
XTANDI,Upper Respiratory Tract Infection,Respiratory Tract Infection f Lower,1
XTANDI,Upper Respiratory Tract Infection,And,0
XTANDI,Upper Respiratory Tract Infection,Infections And Upper Respiratory Tract     Infection f Lower,1
XTANDI,Lung Infection,,0
XTANDI,Lung Infection,Respiratory Tract Lung Infection g Psychiatric,1
XTANDI,Lung Infection,Lower Respiratory Tract Lung Infection g Psychiatric,1
XTANDI,Lung Infection,And,0
XTANDI,Lung Infection,g,0
XTANDI,Lung Infection,,0
XTANDI,Lung Infection,Lung Infection g Psychiatric,1
XTANDI,Lung Infection,,0
XTANDI,Lung Infection,,0
XTANDI,Insomnia,Insomnia,1
XTANDI,Insomnia,,0
XTANDI,Insomnia,,0
XTANDI,Insomnia,,0
XTANDI,Hematuria,,0
XTANDI,Hematuria,Urinary Disorders,0
XTANDI,Hematuria,And Urinary Hematuria I,1
XTANDI,Hematuria,I,0
XTANDI,Hematuria,,0
XTANDI,Hematuria,Urinary,0
XTANDI,Hematuria,Hematuria I,1
XTANDI,Fall,Fall,1
XTANDI,Fall,,0
XTANDI,Fall,Poisoning And Procedural Complications,0
XTANDI,Fall,Procedural Fall,1
XTANDI,Fall,Fall,1
XTANDI,Fall,Fall,1
XTANDI,Fall,Procedural Fall,1
XTANDI,Fall,And Procedural Fall,1
XTANDI,Fall,,0
XTANDI,Fall,Injury Poisoning And Procedural Fall,1
XTANDI,Non-Pathological Fracture,Non-Pathological Fracture Metabolism and Nu,1
XTANDI,Non-Pathological Fracture,,0
XTANDI,Non-Pathological Fracture,,0
XTANDI,Non-Pathological Fracture,,0
XTANDI,Non-Pathological Fracture,,0
XTANDI,Non-Pathological Fracture,Metabolism and Nu,0
XTANDI,Non-Pathological Fracture,Non-Pathological Fracture,1
XTANDI,Non-Pathological Fracture,Fracture,1
XTANDI,Non-Pathological Fracture,Fracture,1
XTANDI,Decreased Appetite,Disorders,0
XTANDI,Decreased Appetite,,0
XTANDI,Decreased Appetite,Nutrition Decreased,1
XTANDI,Decreased Appetite,and Nutrition,0
XTANDI,Decreased Appetite,Appetite Investigat,1
XTANDI,Decreased Appetite,,0
XTANDI,Decreased Appetite,Appetite Investigat,1
XTANDI,Decreased Appetite,,0
XTANDI,Decreased Appetite,Nutrition,0
XTANDI,Weight Decreased,Investigations Weight Decreased Reproduc,1
XTANDI,Weight Decreased,,0
XTANDI,Weight Decreased,,0
XTANDI,Weight Decreased,Investigations Weight,1
XTANDI,Gynecomastia,disorders,0
XTANDI,Gynecomastia,Gynecomastia a,1
XTANDI,Gynecomastia,Gynecomastia a,1
XTANDI,Gynecomastia,Gynecomastia a,1
XTANDI,Gynecomastia,Gynecomastia a,1
XTANDI,Gynecomastia,Gynecomastia a,1
XTANDI,Gynecomastia,Breast disorders,0
XTANDI,Gynecomastia,Gynecomastia a,1
XTANDI,Gynecomastia,,0
XTANDI,asthenia,CTCAE vb asthenia and,1
XTANDI,asthenia,asthenia and,1
XTANDI,asthenia,asthenia and,1
XTANDI,fatigue,,0
XTANDI,fatigue,fatigue c,1
XTANDI,fatigue,Includes asthenia and,0
XTANDI,fatigue,fatigue c,1
XTANDI,fatigue,CTCAE vb Includes asthenia fatigue c,1
XTANDI,fatigue,Includes dizziness and vertigod,0
XTANDI,fatigue,fatigue c,1
XTANDI,fatigue,fatigue c,1
XTANDI,fatigue,Includes asthenia,0
XTANDI,dizziness,Includes asthenia and fatiguec dizziness and,1
XTANDI,vertigo,and,0
XTANDI,vertigo,and disturbance in,0
XTANDI,amnesia,Includes dyspnea,0
XTANDI,amnesia,impairment cognitive,0
XTANDI,amnesia,amnesia memory,1
XTANDI,amnesia,amnesia memory,1
XTANDI,memory impairment,and vertigod Includes amnesia,0
XTANDI,cognitive disorder,,0
XTANDI,cognitive disorder,and disturbance in attentione Includes dyspnea exertional,0
XTANDI,cognitive disorder,fatiguec Includes dizziness and vertigod Includes amnesia,0
XTANDI,disturbance in attention,at restf Includes,0
XTANDI,dyspnea,in attentione dyspnea exertional,1
XTANDI,dyspnea,nasopharyngitis,0
XTANDI,dyspnea,dyspnea exertional,1
XTANDI,dyspnea,and dyspnea at restf Includes nasopharyngitis upper,0
XTANDI,dyspnea,Includes,0
XTANDI,dyspnea at rest,dyspnea,0
XTANDI,dyspnea at rest,dyspnea dyspnea at,1
XTANDI,dyspnea at rest,at rest f,1
XTANDI,dyspnea at rest,,0
XTANDI,dyspnea at rest,dyspnea at,1
XTANDI,nasopharyngitis,tract infection sinusitis,0
XTANDI,nasopharyngitis,nasopharyngitis upper,1
XTANDI,sinusitis,pneumonia lower,0
XTANDI,sinusitis,,0
XTANDI,sinusitis,restf Includes nasopharyngitis upper respiratory tract,0
XTANDI,sinusitis,lower respiratory,0
XTANDI,sinusitis,at restf,0
XTANDI,rhinitis,rhinitis pharyngitis,1
XTANDI,rhinitis,rhinitis pharyngitis,1
XTANDI,rhinitis,rhinitis pharyngitis,1
XTANDI,rhinitis,tract infection,0
XTANDI,rhinitis,sinusitis,0
XTANDI,rhinitis,restf Includes nasopharyngitis upper respiratory tract infection sinusitis,0
XTANDI,rhinitis,laryngitisg Includes pneumonia lower respiratory tract infection,0
XTANDI,rhinitis,sinusitis,0
XTANDI,rhinitis,,0
XTANDI,rhinitis,rhinitis pharyngitis,1
XTANDI,pharyngitis,,0
XTANDI,pharyngitis,sinusitis pharyngitis and,1
XTANDI,pharyngitis,sinusitis,0
XTANDI,pharyngitis,pharyngitis and,1
XTANDI,laryngitis,lung,0
XTANDI,laryngitis,tract infection bronchitis and lung,0
XTANDI,pneumonia,pneumonia lower,1
XTANDI,pneumonia,rhinitis pharyngitis and laryngitisg Includes,0
XTANDI,pneumonia,,0
XTANDI,pneumonia,pneumonia lower,1
XTANDI,pneumonia,tract,0
XTANDI,pneumonia,pneumonia lower,1
XTANDI,lower respiratory tract infection,lower respiratory tract infection bronchitis,1
XTANDI,lower respiratory tract infection,tract infection sinusitis rhinitis pharyngitis and,0
XTANDI,lower respiratory tract infection,,0
XTANDI,lower respiratory tract infection,,0
XTANDI,lower respiratory tract infection,lower,1
XTANDI,bronchitis,and,0
XTANDI,bronchitis,,0
XTANDI,bronchitis,,0
XTANDI,bronchitis,bronchitis and,1
XTANDI,bronchitis,Includes pneumonia lower respiratory tract,0
XTANDI,bronchitis,bronchitis and,1
XTANDI,bronchitis,pharyngitis and laryngitisg Includes pneumonia,0
XTANDI,lung infection,In the two,0
XTANDI,lung infection,and laryngitisg Includes,0
XTANDI,lung infection,randomized clinical trials,0
XTANDI,lung infection,tract infection bronchitis lung infection Laboratory,1
XTANDI,lung infection,respiratory tract infection bronchitis lung infection Laboratory,1
XTANDI,lung infection,lung infection Laboratory,1
XTANDI,lung infection,lung infection Laboratory,1
XTANDI,neutropenia,,0
XTANDI,neutropenia,neutropenia occurred,1
XTANDI,neutropenia,trials neutropenia occurred,1
XTANDI,neutropenia,and in of patients treated,0
XTANDI,neutropenia,neutropenia occurred,1
XTANDI,neutropenia,neutropenia occurred,1
XTANDI,neutropenia,treated,0
XTANDI,neutropenia,randomized clinical trials neutropenia occurred,1
XTANDI,neutropenia,in of,0
XTANDI,neutropenia,of patients,0
XTANDI,neutropenia,XTANDI Grade and in of patients treated with,0
XTANDI,neutropenia,neutropenia occurred,1
XTANDI,thrombocytopenia,thrombocytopenia was,1
XTANDI,thrombocytopenia,,0
XTANDI,thrombocytopenia,of patients treated,0
XTANDI,thrombocytopenia,,0
XTANDI,thrombocytopenia,,0
XTANDI,thrombocytopenia,thrombocytopenia was,1
XTANDI,thrombocytopenia,treated with XTANDI,0
XTANDI,thrombocytopenia,thrombocytopenia was,1
XTANDI,thrombocytopenia,thrombocytopenia was,1
XTANDI,thrombocytopenia,placebo,0
XTANDI,thrombocytopenia,thrombocytopenia was,1
XTANDI,thrombocytopenia,thrombocytopenia was,1
XTANDI,thrombocytopenia,thrombocytopenia was,1
XTANDI,thrombocytopenia,of,0
XTANDI,thrombocytopenia,placebo Grade The,0
XTANDI,thrombocytopenia,incidence of thrombocytopenia was,1
XTANDI,thrombocytopenia,Grade The incidence of thrombocytopenia was,1
XTANDI,thrombocytopenia,thrombocytopenia was,1
XTANDI,elevations in ALT,ALT occurred,1
XTANDI,elevations in ALT,elevations in ALT occurred,1
XTANDI,elevations in ALT,treated,0
XTANDI,elevations in ALT,with XTANDI Grade and of,0
XTANDI,elevations in ALT,with placebo Grade elevations in,1
XTANDI,elevations in ALT,treated with placebo Grade elevations in ALT occurred,1
XTANDI,elevations in ALT,with p,0
XTANDI,elevations in ALT,patients treated with XTANDI Grade and of,0
XTANDI,elevations in ALT,with XTANDI Grade and of,0
XTANDI,elevations in ALT,treated with placebo,0
XTANDI,elevations in ALT,elevations in ALT occurred,1
XTANDI,elevations in ALT,,0
XTANDI,elevations in ALT,treated with placebo Grade elevations in ALT occurred,1
XTANDI,elevations in ALT,elevations in ALT occurred,1
XTANDI,elevations in ALT,placebo,0
XTANDI,elevations in ALT,in ALT occurred,1
XTANDI,elevations in bilirubin,,0
XTANDI,elevations in bilirubin,patients treated with placebo,0
XTANDI,elevations in bilirubin,with placebo Grade elevations in,1
XTANDI,elevations in bilirubin,of patients treated with,0
XTANDI,elevations in bilirubin,,0
XTANDI,elevations in bilirubin,treated with placebo,0
XTANDI,elevations in bilirubin,in of patients,0
XTANDI,elevations in bilirubin,Grade,0
XTANDI,elevations in bilirubin,Grade and,0
XTANDI,elevations in bilirubin,bilirubin occurred,1
XTANDI,died,patients treated with,0
XTANDI,died,treated with XTANDI,0
XTANDI,infections,infections or,1
XTANDI,infections,infections or,1
XTANDI,sepsis,sepsis In,1
XTANDI,sepsis,,0
XTANDI,sepsis,sepsis In,1
XTANDI,sepsis,in each treatment,0
XTANDI,sepsis,sepsis In,1
XTANDI,sepsis,placebo died from infections sepsis In,1
XTANDI,infection,infection resulting,1
XTANDI,infection,infection resulting,1
XTANDI,infection,each treatment group had infection resulting,1
XTANDI,infection,from infections or sepsis In Study patient in each treatment,0
XTANDI,infection,from infections or sepsis In Study patient in each treatment group had,0
XTANDI,infection,,0
XTANDI,infection,treatment group,0
XTANDI,infection,,0
XTANDI,infection,and Fallrelated Injuries In the two,0
XTANDI,death,,0
XTANDI,death,sepsis In Study patient in each treatment group had an infection resulting,0
XTANDI,death,death Falls,1
XTANDI,death,death Falls,1
XTANDI,death,each,0
XTANDI,death,fall,0
XTANDI,falls,falls including,1
XTANDI,Falls,,0
XTANDI,Falls,with loss of consciousness or seizure Fallrelated injuries,0
XTANDI,Falls,Falls were,1
XTANDI,seizure,severe in patients treated,0
XTANDI,seizure,severe in,0
XTANDI,seizure,treated with placebo Falls were not,0
XTANDI,seizure,seizure Fallrelated,1
XTANDI,seizure,consciousness,0
XTANDI,Fall-related injuries,injuries were,1
XTANDI,Fall-related injuries,joint injur,0
XTANDI,Fall-related injuries,were more severe in patients treated with XTANDI and included nonpathologic fractures joint,0
XTANDI,non-pathologic fractures,treated with XTANDI and non-pathologic,1
XTANDI,non-pathologic fractures,hypertension was,0
XTANDI,non-pathologic fractures,non-pathologic,1
XTANDI,non-pathologic fractures,,0
XTANDI,non-pathologic fractures,and hematomas Hypertension In,0
XTANDI,non-pathologic fractures,patients treated with,0
XTANDI,non-pathologic fractures,and included,0
XTANDI,joint injuries,severe in patients,0
XTANDI,joint injuries,XTANDI and included nonpathologic joint,1
XTANDI,joint injuries,the two randomized trials hypertension was,0
XTANDI,joint injuries,patients,0
XTANDI,hematomas,hematomas Hypertension,1
XTANDI,hematomas,hematomas Hypertension,1
XTANDI,hematomas,nonpathologic,0
XTANDI,Hypertension,randomized trials hypertension was reported in,0
XTANDI,Hypertension,Hypertension In,1
XTANDI,Hypertension,included nonpathologic fractures joint,0
XTANDI,Hypertension,reported in of,0
XTANDI,Hypertension,,0
XTANDI,Hypertension,injuries and Hypertension In,1
XTANDI,Hypertension,,0
XTANDI,Hypertension,included nonpathologic fractures,0
XTANDI,Hypertension,fractures joint injuries and Hypertension In,1
XTANDI,Hypertension,hypertension was reported in of patients receiving,0
XTANDI,hypertension,randomized trials,0
XTANDI,hypertension,hypertension was,1
XTANDI,hypertension,joint injuries and hematomas Hypertension In the two randomized,0
XTANDI,hypertension,the two randomized hypertension was,1
XTANDI,hypertensive crisis,receiving placebo No patients hypertensive,1
XTANDI,hypertensive crisis,placebo No patients hypertensive,1
XTANDI,hypertensive crisis,patients hypertensive crisis Medical,1
XTANDI,Hypertension,in of patients in,0
XTANDI,Hypertension,patients in each,0
XTANDI,Hypertension,Hypertension led,1
XTANDI,Seizure,cussed  in more,1
XTANDI,seizure,"SUSPECTED ADVERSE NS,",1
XTANDI,seizure,"To report SUSPECTED ADVERSE NS, con tact Astellas",1
XTANDI,seizure,"NS, con tact Astellas",1
XTANDI,seizure,,0
XTANDI,seizure,,0
XTANDI,seizure,at,0
XTANDI,seizure,wwwfdagovmedwatch Clinical Trial Experience Because cli,0
XTANDI,seizure,Astellas Pharma US Inc at or F,0
XTANDI,seizure,1 FDA or,1
XTANDI,seizure,REACTIONS contact Astellas Pharma US Inc,0
XTANDI,seizure,DA at 1 FDA or,1
XTANDI,seizure,DA at,1
XTANDI,seizure,Because cli,0
XTANDI,seizure,F,0
XTANDI,seizure, trials of a,1
XTANDI,seizure,ectly c ompared to,1
XTANDI,seizure,ectly c ompared to,1
XTANDI,seizure,the clinical trials of a drug cannot,0
XTANDI,seizure,c ompared to,1
XTANDI,seizure,may not,0
XTANDI,seizure,,0
XTANDI,seizure,reflect the,0
XTANDI,seizure,of another drug and may not,0
XTANDI,seizure,ectly c ompared to,1
XTANDI,seizure,rates observed in the clinical trials,0
AFINITOR,Non-infectious pneumonitis,another section of,0
AFINITOR,Non-infectious pneumonitis,Non-infectious,1
AFINITOR,Non-infectious pneumonitis,Non-infectious pneumonitis see Warnings,1
AFINITOR,Non-infectious pneumonitis,greater detail,0
AFINITOR,Non-infectious pneumonitis,see Warnings,0
AFINITOR,Infections,Infections see Warnings,1
AFINITOR,Infections,Infections see Warnings,1
AFINITOR,Infections,see Warnings and Precautions Angioedema with concomitant,0
AFINITOR,Oral ulceration,ulceration see Warnings,1
AFINITOR,Oral ulceration,Oral ulceration see Warnings,1
AFINITOR,Oral ulceration,and Oral ulceration see Warnings,1
AFINITOR,Oral ulceration,Oral ulceration see Warnings,1
AFINITOR,Oral ulceration,and Oral,1
AFINITOR,Oral ulceration,,0
AFINITOR,Oral ulceration,and Precautions Renal failure see Warnings,0
AFINITOR,Oral ulceration,and Oral ulceration see Warnings,1
AFINITOR,Oral ulceration,inhibitors see Warnings and Oral ulceration see Warnings,1
AFINITOR,Renal failure,ulceration see Warnings and Renal,1
AFINITOR,Renal failure,,0
AFINITOR,Renal failure,see Warnings and Renal failure see Warnings,1
AFINITOR,Renal failure,failure see Warnings,1
AFINITOR,Renal failure,and Precautions Impaired wound healing,0
AFINITOR,Renal failure,Precautions Impaired wound healing see,0
AFINITOR,Renal failure,failure see Warnings,1
AFINITOR,Renal failure,and Precautions Oral ulceration,0
AFINITOR,Renal failure,Precautions,0
AFINITOR,Renal failure,Precautions Oral ulceration,0
AFINITOR,Impaired wound healing,,0
AFINITOR,Impaired wound healing,healing see Warnings,1
AFINITOR,Impaired wound healing,see Warnings and Impaired wound,1
AFINITOR,Impaired wound healing,Impaired wound healing see Warnings,1
AFINITOR,Impaired wound healing,,0
AFINITOR,Impaired wound healing,clinical,0
AFINITOR,Impaired wound healing,Warnings and Impaired,1
AFINITOR,Impaired wound healing,Impaired wound,1
AFINITOR,Impaired wound healing,failure see,0
AFINITOR,Impaired wound healing,see,0
AFINITOR,stomatitis,infections rash fatigue diarrhea edema abdominal pain nausea fever asthenia cough headac,0
AFINITOR,stomatitis,stomatitis infections rash,1
AFINITOR,stomatitis,infections rash fatigue,0
AFINITOR,stomatitis,fatigue diarrhea edema abdominal pain nausea fever asthenia,0
AFINITOR,stomatitis,adverse reactions incidence stomatitis infections rash,1
AFINITOR,stomatitis,HR BC advanced PNET advanced RCC Most common adverse reactions,0
AFINITOR,stomatitis,stomatitis infections rash,1
AFINITOR,stomatitis,stomatitis infections rash,1
AFINITOR,stomatitis,Most common adverse reactions incidence,0
AFINITOR,stomatitis,advanced RCC Most common adverse reactions,0
AFINITOR,infections,infections rash fatigue,1
AFINITOR,infections,incidence include infections rash fatigue,1
AFINITOR,infections,diarrhea edema abdominal pain,0
AFINITOR,infections,include stomatitis,0
AFINITOR,infections,infections rash fatigue,1
AFINITOR,infections,common adverse reactions incidence include,0
AFINITOR,rash,incidence include,0
AFINITOR,rash,RCC Most common,0
AFINITOR,rash,rash fatigue diarrhea,1
AFINITOR,rash,adverse reactions,0
AFINITOR,rash,advanced RCC Most common adverse reactions incidence include stomatitis,0
AFINITOR,rash,rash fatigue diarrhea,1
AFINITOR,rash,reactions incidence include,0
AFINITOR,rash,rash fatigue diarrhea,1
AFINITOR,rash,reactions incidence include stomatitis rash fatigue diarrhea,1
AFINITOR,fatigue,,0
AFINITOR,fatigue,infections fatigue diarrhea edema,1
AFINITOR,fatigue,common adverse reactions incidence,0
AFINITOR,fatigue,incidence include stomatitis infections fatigue diarrhea edema,1
AFINITOR,fatigue,common adverse reactions,0
AFINITOR,fatigue,stomatitis infections,0
AFINITOR,fatigue,fever,0
AFINITOR,fatigue,fatigue diarrhea edema,1
AFINITOR,edema,edema abdominal pain,1
AFINITOR,edema,,0
AFINITOR,edema,appetite,0
AFINITOR,edema,rash fatigue edema abdominal pain,1
AFINITOR,edema,stomatitis infections rash fatigue diarrhea,0
AFINITOR,edema,,0
AFINITOR,edema,asthenia cough headache and decreased appetite,0
AFINITOR,edema,edema abdominal pain,1
AFINITOR,edema,fatigue diarrhea,0
AFINITOR,edema,rash fatigue edema abdominal pain,1
AFINITOR,nausea,angio,0
AFINITOR,nausea,nausea fever asthenia,1
AFINITOR,nausea,appetite Renal angio,0
AFINITOR,nausea,abdominal pain,0
AFINITOR,nausea,nausea fever asthenia,1
AFINITOR,nausea,abdominal nausea fever asthenia,1
AFINITOR,nausea,nausea fever asthenia,1
AFINITOR,nausea,fatigue diarrhea edema abdominal nausea fever asthenia,1
AFINITOR,nausea,fever asthenia cough,0
AFINITOR,fever,pain fever asthenia cough,1
AFINITOR,fever,nausea,0
AFINITOR,fever,and decreased,0
AFINITOR,fever,fever asthenia cough,1
AFINITOR,fever,diarrhea edema abdominal pain fever asthenia cough,1
AFINITOR,fever,fever asthenia cough,1
AFINITOR,fever,fatigue diarrhea edema,0
AFINITOR,asthenia,,0
AFINITOR,asthenia,,0
AFINITOR,asthenia,TS,0
AFINITOR,asthenia,appetite Renal angiomyolipoma with TS,0
AFINITOR,asthenia,abdominal pain nausea asthenia cough headache,1
AFINITOR,asthenia,abdominal pain,0
AFINITOR,asthenia,asthenia cough headache,1
AFINITOR,asthenia,asthenia cough headache,1
AFINITOR,cough,cough headache and,1
AFINITOR,cough,fever cough headache and,1
AFINITOR,cough,cough headache and,1
AFINITOR,cough,cough headache and,1
AFINITOR,cough,cough headache and,1
AFINITOR,cough,with,0
AFINITOR,cough,nausea fever cough headache and,1
AFINITOR,cough,pain nausea fever cough headache and,1
AFINITOR,cough,cough headache and,1
AFINITOR,headache,with,0
AFINITOR,headache,headache and decreased,1
AFINITOR,headache,diarrhea edema abdominal,0
AFINITOR,headache,nausea,0
AFINITOR,headache,fatigue diarrhea edema abdominal pain nausea fever asthenia cough,0
AFINITOR,headache,headache and decreased,1
AFINITOR,headache,,0
AFINITOR,headache,headache and decreased,1
AFINITOR,headache,,0
AFINITOR,stomatitis,stomatitis SEGA with,1
AFINITOR,stomatitis,stomatitis SEGA with,1
AFINITOR,stomatitis,and,0
AFINITOR,stomatitis,common adverse reaction incidence stomatitis SEGA with,1
AFINITOR,stomatitis,stomatitis and respiratory,1
AFINITOR,stomatitis,stomatitis and respiratory,1
AFINITOR,stomatitis,,0
AFINITOR,stomatitis,stomatitis and respiratory,1
AFINITOR,stomatitis,SUSPECTED ADVERSE,0
AFINITOR,stomatitis,stomatitis and respiratory,1
AFINITOR,stomatitis,stomatitis and respiratory,1
AFINITOR,respiratory tract infection,respiratory,1
AFINITOR,respiratory tract infection,ADVERSE,0
AFINITOR,respiratory tract infection,stomatitis,0
AFINITOR,respiratory tract infection,stomatitis respiratory tract,1
AFINITOR,stomatitis,of approximately,0
AFINITOR,stomatitis,were,0
AFINITOR,stomatitis,stomatitis infections rash,1
AFINITOR,stomatitis,most common adverse reactions incidence were,0
AFINITOR,stomatitis,diarrhea and decreased appetite The,0
AFINITOR,stomatitis,stomatitis infections rash,1
AFINITOR,stomatitis,approximately months,0
AFINITOR,stomatitis,diarrhea and decreased appetite The most common Grade adverse,0
AFINITOR,infections,most common adverse reactions incidence were stomatitis,0
AFINITOR,infections,incidence were infections rash fatigue,1
AFINITOR,infections,Grade adverse reactions,0
AFINITOR,infections,infections rash fatigue,1
AFINITOR,infections,infections rash fatigue,1
AFINITOR,infections,infections rash fatigue,1
AFINITOR,infections,Grade adverse,0
AFINITOR,infections,decreased,0
AFINITOR,infections,adverse reactions,0
AFINITOR,rash,rash fatigue diarrhea,1
AFINITOR,rash,rash fatigue diarrhea,1
AFINITOR,rash,rash fatigue diarrhea,1
AFINITOR,rash,rash fatigue diarrhea,1
AFINITOR,rash,The most common adverse,0
AFINITOR,fatigue,incidence,0
AFINITOR,fatigue,were stomatitis infections rash,0
AFINITOR,fatigue,most common adverse reactions incidence were,0
AFINITOR,fatigue,fatigue diarrhea and,1
AFINITOR,fatigue,incidence we,0
AFINITOR,fatigue,infections rash,0
AFINITOR,fatigue,fatigue diarrhea and,1
AFINITOR,fatigue,diarrhea and decreased appetite,0
AFINITOR,fatigue,fatigue diarrhea and,1
AFINITOR,diarrhea,diarrhea and decreased,1
AFINITOR,diarrhea,were stomatitis infections rash diarrhea and decreased,1
AFINITOR,diarrhea,were stomati,0
AFINITOR,decreased appetite,adverse reactions incidence,0
AFINITOR,decreased appetite,Grade adverse reactions incidence were,0
AFINITOR,stomatitis,stomatitis infections hyperglycemia,1
AFINITOR,stomatitis,hyperglycemia fatigue dyspnea pneumonitis and diarrhea The,0
AFINITOR,stomatitis,incidence were,0
AFINITOR,infections,Grade,0
AFINITOR,infections,infections hyperglycemia fatigue,1
AFINITOR,infections,,0
AFINITOR,infections,were infections hyperglycemia fatigue,1
AFINITOR,infections,adverse reactions incidence were infections hyperglycemia fatigue,1
AFINITOR,infections,reactions incidence were infections hyperglycemia fatigue,1
AFINITOR,infections,adverse reactions incidence were infections hyperglycemia fatigue,1
AFINITOR,infections,reactions incidence were infections hyperglycemia fatigue,1
AFINITOR,infections,common laboratory,0
AFINITOR,infections,incidence were infections hyperglycemia fatigue,1
AFINITOR,hyperglycemia,,0
AFINITOR,hyperglycemia,were stomatitis hyperglycemia fatigue dyspnea,1
AFINITOR,hyperglycemia,reactions incidence were stomatitis hyperglycemia fatigue dyspnea,1
AFINITOR,hyperglycemia,reactions incidence were,0
AFINITOR,hyperglycemia,pneumonitis and diarrhea The,0
AFINITOR,dyspnea,were stomatitis infections hyperglycemia dyspnea pneumonitis and,1
AFINITOR,dyspnea,diarrhea The,0
AFINITOR,dyspnea,dyspnea pneumonitis and,1
AFINITOR,dyspnea,were stomatitis infections hyperglycemia dyspnea pneumonitis and,1
AFINITOR,dyspnea,dyspnea pneumonitis and,1
AFINITOR,dyspnea,adverse reactions incidence were,0
AFINITOR,dyspnea,dyspnea pneumonitis and,1
AFINITOR,dyspnea,dyspnea pneumonitis and,1
AFINITOR,pneumonitis,were,0
AFINITOR,hypercholesterolemia,hypercholesterolemia hyperglycemia increased,1
AFINITOR,hyperglycemia,hyperglycemia increased aspartate,1
AFINITOR,hyperglycemia,laboratory abnormalities incidence,0
AFINITOR,hyperglycemia,were hypercholesterolemia,0
AFINITOR,hyperglycemia,,0
AFINITOR,hyperglycemia,,0
AFINITOR,hyperglycemia,common laboratory abnormalities incidence were,0
AFINITOR,increased aspartate transaminase,increased aspartate transaminase AST anemia,1
AFINITOR,increased aspartate transaminase,increased aspartate transaminase AST anemia,1
AFINITOR,increased aspartate transaminase,,0
AFINITOR,anemia,anemia leukopenia thrombocytopenia,1
AFINITOR,anemia,anemia leukopenia thrombocytopenia,1
AFINITOR,anemia,anemia leukopenia thrombocytopenia,1
AFINITOR,anemia,anemia leukopenia thrombocytopenia,1
AFINITOR,anemia,,0
AFINITOR,anemia,,0
AFINITOR,anemia,transaminase anemia leukopenia thrombocytopenia,1
AFINITOR,thrombocytopenia,transaminase AST anemia thrombocytopenia lymphopenia increased,1
AFINITOR,thrombocytopenia,thrombocytopenia lymphopenia increased,1
AFINITOR,lymphopenia,increased,0
AFINITOR,lymphopenia,transaminase ALT and hypertriglyceridemia The most common,0
AFINITOR,lymphopenia,lymphopenia increased alanine,1
AFINITOR,lymphopenia,lymphopenia increased alanine,1
AFINITOR,lymphopenia,hyperglycemia increased aspartate transaminase AST,0
AFINITOR,lymphopenia,anemia leukopenia,0
AFINITOR,increased alanine transaminase,increased alanine transaminase ALT and,1
AFINITOR,increased alanine transaminase,AST anemia leukopenia thrombocytopenia increased alanine,1
AFINITOR,increased alanine transaminase,alanine transaminase ALT and,1
AFINITOR,hypertriglyceridemia,hypertriglyceridemia The most,1
AFINITOR,hypertriglyceridemia,ALT hypertriglyceridemia The most,1
AFINITOR,hypertriglyceridemia,transaminase,0
AFINITOR,hypertriglyceridemia,hypertriglyceridemia The most,1
AFINITOR,hypertriglyceridemia,most common Grade laboratory,0
AFINITOR,hypertriglyceridemia,increased alanine transaminase ALT hypertriglyceridemia The most,1
AFINITOR,hypertriglyceridemia,hypertriglyceridemia The most,1
AFINITOR,hypertriglyceridemia,ALT and,0
AFINITOR,lymphopenia,incidence lymphopenia hyperglycemia anemia,1
AFINITOR,lymphopenia,Grade laboratory abnormalities incidence lymphopenia hyperglycemia anemia,1
AFINITOR,lymphopenia,hyperglycemia,0
AFINITOR,lymphopenia,lymphopenia hyperglycemia anemia,1
AFINITOR,lymphopenia,,0
AFINITOR,lymphopenia,,0
AFINITOR,lymphopenia,lymphopenia hyperglycemia anemia,1
AFINITOR,lymphopenia,lymphopenia hyperglycemia anemia,1
AFINITOR,lymphopenia,lymphopenia hyperglycemia anemia,1
AFINITOR,lymphopenia,lymphopenia hyperglycemia anemia,1
AFINITOR,hyperglycemia,hyperglycemia anemia decreased,1
AFINITOR,hyperglycemia,and thrombocytopenia Fatal adverse,0
AFINITOR,hyperglycemia,,0
AFINITOR,hyperglycemia,and thrombocytopenia Fatal,0
AFINITOR,hyperglycemia,,0
AFINITOR,hyperglycemia,anemia,0
AFINITOR,hyperglycemia,hyperglycemia anemia decreased,1
AFINITOR,hyperglycemia,laboratory abnormalities incidence were hyperglycemia anemia decreased,1
AFINITOR,hyperglycemia,,0
AFINITOR,hyperglycemia,adverse,0
AFINITOR,anemia,anemia decreased potassium,1
AFINITOR,anemia,ALT and thrombocytopenia Fatal adverse reactio,0
AFINITOR,anemia,,0
AFINITOR,anemia,anemia decreased potassium,1
AFINITOR,anemia,,0
AFINITOR,anemia,most common,0
AFINITOR,anemia,,0
AFINITOR,decreased potassium,were lymphopenia hyperglycemia decreased,1
AFINITOR,decreased potassium,incidence were lymphopenia hyperglycemia decreased potassium increased AST,1
AFINITOR,decreased potassium,,0
AFINITOR,decreased potassium,more,0
AFINITOR,decreased potassium,,0
AFINITOR,decreased potassium,decreased potassium increased AST,1
AFINITOR,decreased potassium,incidence were lymphopenia hyperglycemia decreased,1
AFINITOR,decreased potassium,lymphopenia hyperglycemia decreased,1
AFINITOR,decreased potassium,more freq,0
AFINITOR,increased AST,adverse reactions occurred more frequently in,0
AFINITOR,increased AST,hyperglycemia anemia decreased increased AST increased ALT,1
AFINITOR,increased ALT,increased,1
AFINITOR,increased ALT,,0
AFINITOR,increased ALT,patients,0
AFINITOR,thrombocytopenia,,0
AFINITOR,thrombocytopenia,thrombocytopenia Fatal adverse,1
AFINITOR,thrombocytopenia,AST increased ALT thrombocytopenia Fatal adverse,1
AFINITOR,thrombocytopenia,thrombocytopenia Fatal adverse,1
AFINITOR,Fatal,Fatal adverse reactions,1
AFINITOR,Fatal,Fatal adverse reactions,1
AFINITOR,Fatal,Fatal adverse reactions,1
AFINITOR,Fatal,potassium increased AST increased,0
AFINITOR,Fatal,received AFINITOR plus exemestane,0
AFINITOR,Fatal,,0
AFINITOR,Fatal,plus exemestane,0
AFINITOR,Fatal,in patients who received AFINITOR plus exemestane,0
AFINITOR,Fatal,in,0
AFINITOR,stomatitis,stomatitis mouth ulceration,1
AFINITOR,stomatitis,a Exemestane mgday b stomatitis mouth ulceration,1
AFINITOR,stomatitis,a Exemestane mgday b stomatitis mouth ulceration,1
AFINITOR,stomatitis,,0
AFINITOR,stomatitis,stomatitis mouth ulceration,1
AFINITOR,stomatitis,a Exemestane mgday b stomatitis mouth ulceration,1
AFINITOR,stomatitis,stomatitis mouth ulceration,1
AFINITOR,stomatitis,stomatitis mouth ulceration,1
AFINITOR,stomatitis,glossitis and lip ulceration c,0
AFINITOR,stomatitis,stomatitis mouth ulceration,1
AFINITOR,mouth ulceration,Exemestane,0
AFINITOR,mouth ulceration,,0
AFINITOR,mouth ulceration,Exemestane mgday b Includes mouth,1
AFINITOR,mouth ulceration,all pre,0
AFINITOR,mouth ulceration,mgday b Includes mouth ulceration aphthous stomatitis,1
AFINITOR,mouth ulceration,ulceration aphthous stomatitis,1
AFINITOR,mouth ulceration,glossodynia gingival pain glossitis and lip,0
AFINITOR,aphthous stomatitis,aphthous stomatitis glossodynia gingival,1
AFINITOR,aphthous stomatitis,b Includes stomatitis mouth aphthous,1
AFINITOR,glossodynia,gingival pain glossitis and,0
AFINITOR,glossodynia,glossodynia gingival pain,1
AFINITOR,glossodynia,glossodynia gingival pain,1
AFINITOR,glossodynia,ulceration aphthous,0
AFINITOR,glossodynia,glossodynia gingival pain,1
AFINITOR,glossodynia,glossodynia gingival pain,1
AFINITOR,glossodynia,,0
AFINITOR,glossodynia,,0
AFINITOR,glossodynia,glossodynia gingival pain,1
AFINITOR,gingival pain,gingival pain glossitis and,1
AFINITOR,glossitis,mouth ulceration aphthous stomatitis glossodynia gingival,0
AFINITOR,glossitis,stomatitis glossodynia gingival glossitis and lip,1
AFINITOR,glossitis,,0
AFINITOR,glossitis,stomatitis glossodynia gingival,0
AFINITOR,glossitis,glossitis and lip,1
AFINITOR,glossitis,b Includes stomatitis mouth ulceration aphthous stomatitis glossodynia,0
AFINITOR,lip ulceration,,0
AFINITOR,lip ulceration,stomatitis glossodynia gingival pain,0
AFINITOR,nasopharyngitis,nasopharyngitis urinary tract,1
AFINITOR,nasopharyngitis,the most common being,0
AFINITOR,nasopharyngitis,infections and infestations system organ class the,0
AFINITOR,nasopharyngitis,system organ class the most,0
AFINITOR,nasopharyngitis,nasopharyngitis urinary tract,1
AFINITOR,nasopharyngitis,class the most common nasopharyngitis urinary tract,1
AFINITOR,nasopharyngitis,tract infection pneumonia,0
AFINITOR,urinary tract infection,infection upper respiratory,1
AFINITOR,urinary tract infection,,0
AFINITOR,upper respiratory tract infection,,0
AFINITOR,bronchitis,upper respiratory tract infection bronchitis cystitis sinusitis,1
AFINITOR,cystitis,cystitis sinusitis and,1
AFINITOR,cystitis,cystitis sinusitis and,1
AFINITOR,cystitis,pneumonia cystitis sinusitis and,1
AFINITOR,cystitis,C,0
AFINITOR,cystitis,pneumonia,0
AFINITOR,cystitis,and also including,0
AFINITOR,sinusitis,sinusitis and also,1
AFINITOR,sinusitis,infection pneumonia bronchitis sinusitis and also,1
AFINITOR,sinusitis,sinusitis and also,1
AFINITOR,candidiasis,candidiasis and sepsis,1
AFINITOR,candidiasis,cystitis sinusitis and also,0
AFINITOR,candidiasis,candidiasis and sepsis,1
AFINITOR,candidiasis,sinusitis and also candidiasis and sepsis,1
AFINITOR,candidiasis,and sepsis and hepatitis C d Includes,0
AFINITOR,candidiasis,candidiasis and sepsis,1
AFINITOR,candidiasis,and also including,0
AFINITOR,candidiasis,candidiasis and sepsis,1
AFINITOR,sepsis,sepsis and hepatitis,1
AFINITOR,sepsis,and also,0
AFINITOR,sepsis,including candidiasis and,0
AFINITOR,sepsis,sepsis and hepatitis,1
AFINITOR,sepsis,sepsis and hepatitis,1
AFINITOR,sepsis,sepsis and hepatitis,1
AFINITOR,sepsis,hepatitis C d Includes pneumonitis interstitial lung disease lung infiltratio,0
AFINITOR,sepsis,including candidiasis sepsis and hepatitis,1
AFINITOR,sepsis,,0
AFINITOR,hepatitis C,including candidiasis and,0
AFINITOR,hepatitis C,including candidiasis and sepsis hepatitis,1
AFINITOR,hepatitis C,hepatitis C d Includes,1
AFINITOR,hepatitis C,hepatitis,1
AFINITOR,hepatitis C,C d Includes,1
AFINITOR,hepatitis C,lung infiltration and pulmonary fibros,0
AFINITOR,hepatitis C,and sepsis and,0
AFINITOR,hepatitis C,and sepsis hepatitis C d Includes,1
AFINITOR,pneumonitis,AFINITOR or,0
AFINITOR,pneumonitis,pneumonitis interstitial lung,1
AFINITOR,pneumonitis,pneumonitis interstitial lung,1
AFINITOR,pneumonitis,candidiasis and sepsis and hepatitis C d Includes,0
AFINITOR,pneumonitis,and also including candidiasis and sepsis,0
AFINITOR,pneumonitis,and,0
AFINITOR,pneumonitis,including candidiasis and sepsis and hepatitis C d,0
AFINITOR,pneumonitis,hepatitis C d pneumonitis interstitial lung,1
AFINITOR,pneumonitis,pneumonitis interstitial lung,1
AFINITOR,interstitial lung disease,,0
AFINITOR,interstitial lung disease,candidiasis and sepsis and hepatitis C d,0
AFINITOR,interstitial lung disease,candidiasis and sepsis and hepatitis C d,0
AFINITOR,interstitial lung disease,including candidiasis and,0
AFINITOR,interstitial lung disease,d Includes,0
AFINITOR,interstitial lung disease,,0
AFINITOR,interstitial lung disease,d Includes interstitial lung disease lung infiltration,1
AFINITOR,interstitial lung disease,lung disease lung infiltration,1
AFINITOR,interstitial lung disease,C d Includes interstitial lung,1
AFINITOR,interstitial lung disease,interstitial lung,1
AFINITOR,lung infiltration,infiltration and pulmonary,1
AFINITOR,lung infiltration,lung lung infiltration and pulmonary,1
AFINITOR,lung infiltration,d Includes pneumonitis,0
AFINITOR,lung infiltration,,0
AFINITOR,lung infiltration,C d Includes pneumonitis interstitial,0
AFINITOR,lung infiltration,to AFINITOR or placebo AFINITOR,0
AFINITOR,lung infiltration,lung lung infiltration and pulmonary,1
AFINITOR,lung infiltration,,0
AFINITOR,pulmonary fibrosis,C d Includes,0
AFINITOR,pulmonary fibrosis,e Exposure to AFINITOR,0
AFINITOR,pulmonary fibrosis,lung infiltration pulmonary fibrosis e Exposure,1
AFINITOR,pulmonary fibrosis,or placebo AFINITOR mgday exemestane,0
AFINITOR,pulmonary fibrosis,placebo AFINITOR,0
AFINITOR,Diarrhea,,0
AFINITOR,Diarrhea,Diarrhea,1
AFINITOR,Diarrhea,Diarrhea,1
AFINITOR,Diarrhea,,0
AFINITOR,Diarrhea,,0
AFINITOR,Diarrhea,,0
AFINITOR,Diarrhea,Diarrhea,1
AFINITOR,Diarrhea,,0
AFINITOR,Diarrhea,Diarrhea,1
AFINITOR,Nausea,,0
AFINITOR,Nausea,,0
AFINITOR,Nausea,Nausea,1
AFINITOR,Nausea,Nausea,1
AFINITOR,Nausea,,0
AFINITOR,Nausea,,0
AFINITOR,Nausea,,0
AFINITOR,Nausea,Nausea,1
AFINITOR,Nausea,Nausea,1
AFINITOR,Constipation,Constipation,1
AFINITOR,Constipation,Constipation,1
AFINITOR,Constipation,,0
AFINITOR,Dry mouth,Dry mouth,1
AFINITOR,Dry mouth,Dry,1
AFINITOR,Dry mouth,Dry,1
AFINITOR,Fatigue,,0
AFINITOR,Fatigue,Fatigue,1
AFINITOR,Fatigue,,0
AFINITOR,Fatigue,Fatigue,1
AFINITOR,Fatigue,site conditions,0
AFINITOR,Fatigue,and administration site Fatigue,1
AFINITOR,Fatigue,,0
AFINITOR,Fatigue,Fatigue,1
AFINITOR,Edema peripheral,,0
AFINITOR,Edema peripheral,peripheral,1
AFINITOR,Edema peripheral,peripheral,1
AFINITOR,Edema peripheral,,0
AFINITOR,Edema peripheral,,0
AFINITOR,Edema peripheral,,0
AFINITOR,Edema peripheral,Edema peripheral,1
AFINITOR,Edema peripheral,,0
AFINITOR,Pyrexia,,0
AFINITOR,Pyrexia,,0
AFINITOR,Pyrexia,Pyrexia,1
AFINITOR,Pyrexia,,0
AFINITOR,Pyrexia,Pyrexia,1
AFINITOR,Pyrexia,Pyrexia,1
AFINITOR,Pyrexia,Pyrexia,1
AFINITOR,Pyrexia,Pyrexia,1
AFINITOR,Pyrexia,,0
AFINITOR,Asthenia,Asthenia,1
AFINITOR,Asthenia,,0
AFINITOR,Asthenia,,0
AFINITOR,Infections,,0
AFINITOR,Weight decreased,Weight decreased,1
AFINITOR,Weight decreased,Investigations Weight decreased,1
AFINITOR,Weight decreased,,0
AFINITOR,Weight decreased,Investigations Weight decreased,1
AFINITOR,Weight decreased,,0
AFINITOR,Weight decreased,,0
AFINITOR,Weight decreased,Investigations Weight decreased,1
AFINITOR,Weight decreased,Investigations,0
AFINITOR,Decreased appetite,,0
AFINITOR,Decreased appetite,Decreased appetite,1
AFINITOR,Decreased appetite,Decreased appetite,1
AFINITOR,Decreased appetite,Decreased appetite,1
AFINITOR,Decreased appetite,,0
AFINITOR,Hyperglycemia,Hyperglycemia,1
AFINITOR,Hyperglycemia,Hyperglycemia,1
AFINITOR,Hyperglycemia,,0
AFINITOR,Hyperglycemia,,0
AFINITOR,Hyperglycemia,Hyperglycemia,1
AFINITOR,Arthralgia,Arthralgia,1
AFINITOR,Arthralgia,Arthralgia,1
AFINITOR,Arthralgia,and,0
AFINITOR,Arthralgia,,0
AFINITOR,Arthralgia,connective tissue,0
AFINITOR,Arthralgia,,0
AFINITOR,Arthralgia,Arthralgia,1
AFINITOR,Arthralgia,Arthralgia,1
AFINITOR,Arthralgia,and connective tissue Arthralgia,1
AFINITOR,Arthralgia,,0
AFINITOR,Back pain,,0
AFINITOR,Back pain,Back,1
AFINITOR,Back pain,pain,1
AFINITOR,Back pain,,0
AFINITOR,Back pain,Back,1
AFINITOR,Pain in extremity,Pain,1
AFINITOR,Pain in extremity,,0
AFINITOR,Pain in extremity,Pain in extremity,1
AFINITOR,Pain in extremity,,0
AFINITOR,Pain in extremity,,0
AFINITOR,Pain in extremity,Pain in extremity,1
AFINITOR,Pain in extremity,,0
AFINITOR,Pain in extremity,,0
AFINITOR,Pain in extremity,,0
AFINITOR,Dysgeusia,Dysgeusia,1
AFINITOR,Dysgeusia,system,0
AFINITOR,Dysgeusia,,0
AFINITOR,Dysgeusia,,0
AFINITOR,Dysgeusia,system disorders,0
AFINITOR,Dysgeusia,,0
AFINITOR,Headache,Headache,1
AFINITOR,Headache,,0
AFINITOR,Headache,,0
AFINITOR,Headache,,0
AFINITOR,Headache,,0
AFINITOR,Insomnia,Insomnia,1
AFINITOR,Insomnia,,0
AFINITOR,Insomnia,,0
AFINITOR,Insomnia,Insomnia,1
AFINITOR,Insomnia,,0
AFINITOR,Dyspnea,,0
AFINITOR,Epistaxis,Epistaxis,1
AFINITOR,Epistaxis,Epistaxis,1
AFINITOR,Epistaxis,,0
AFINITOR,Epistaxis,,0
AFINITOR,Epistaxis,,0
AFINITOR,Epistaxis,,0
AFINITOR,Epistaxis,Epistaxis,1
AFINITOR,Epistaxis,Epistaxis,1
AFINITOR,Epistaxis,,0
AFINITOR,Rash,subcutaneous tissue,0
AFINITOR,Rash,,0
AFINITOR,Rash,Rash,1
AFINITOR,Rash,tissue Rash,1
AFINITOR,Rash,,0
AFINITOR,Rash,disorders,0
AFINITOR,Rash,Rash,1
AFINITOR,Pruritus,,0
AFINITOR,Pruritus,Pruritus,1
AFINITOR,Pruritus,Pruritus,1
AFINITOR,Hot flush,,0
AFINITOR,Hot flush,Hot flush,1
AFINITOR,anemia,reports of,0
AFINITOR,anemia,reports anemia,1
AFINITOR,leukopenia,reaction reports of leukopenia,1
AFINITOR,leukopenia,leukopenia,1
AFINITOR,leukopenia,at l,0
AFINITOR,lymphopenia,reports of anemia lymphopenia,1
AFINITOR,neutropenia,neutropenia,1
AFINITOR,neutropenia,neutropenia,1
AFINITOR,neutropenia,corresponding adverse drug reaction reports of anemia leukopenia lymphopenia,0
AFINITOR,neutropenia,collectively,0
AFINITOR,neutropenia,neutropenia,1
AFINITOR,neutropenia,neutropenia,1
AFINITOR,thrombocytopenia,drug reaction,0
AFINITOR,thrombocytopenia,anemia leukopenia lymphopenia neutropenia thrombocytopenia,1
AFINITOR,thrombocytopenia,,0
AFINITOR,thrombocytopenia,reaction reports of anemia leukopenia,0
AFINITOR,thrombocytopenia,of anemia leukopenia lymphopenia neutropenia and,0
AFINITOR,thrombocytopenia,reaction reports of anemia leukopenia,0
AFINITOR,pancytopenia,pancytopenia,1
AFINITOR,pancytopenia,anemia leukopenia lymphopenia neutropenia,0
AFINITOR,pancytopenia,pancytopenia,1
AFINITOR,pancytopenia,e,0
AFINITOR,pancytopenia,collectively pancytopenia,1
AFINITOR,pancytopenia,anemia leukopenia lymphopenia neutropenia,0
AFINITOR,Hemoglobin decreased,,0
AFINITOR,Hemoglobin decreased,b,0
AFINITOR,Hemoglobin decreased,,0
AFINITOR,Hemoglobin decreased,Hematology Hemoglobin decreased,1
AFINITOR,Hemoglobin decreased,,0
AFINITOR,Hemoglobin decreased,b,0
AFINITOR,Hemoglobin decreased,Hemoglobin decreased,1
AFINITOR,Hemoglobin decreased,,0
AFINITOR,Hemoglobin decreased,Hematology Hemoglobin,1
AFINITOR,WBC decreased,,0
AFINITOR,WBC decreased,WBC decreased,1
AFINITOR,WBC decreased,,0
AFINITOR,WBC decreased,WBC decreased,1
AFINITOR,WBC decreased,WBC decreased,1
AFINITOR,WBC decreased,,0
AFINITOR,WBC decreased,WBC decreased,1
AFINITOR,WBC decreased,,0
AFINITOR,Platelets decreased,,0
AFINITOR,Platelets decreased,Platelets,1
AFINITOR,Platelets decreased,decreased,1
AFINITOR,Platelets decreased,,0
AFINITOR,Platelets decreased,,0
AFINITOR,Lymphocytes decreased,Lymphocytes decreased,1
AFINITOR,Lymphocytes decreased,,0
AFINITOR,Lymphocytes decreased,,0
AFINITOR,Lymphocytes decreased,Lymphocytes,1
AFINITOR,Lymphocytes decreased,decreased,1
AFINITOR,Lymphocytes decreased,,0
AFINITOR,Lymphocytes decreased,,0
AFINITOR,Lymphocytes decreased,,0
AFINITOR,Lymphocytes decreased,,0
AFINITOR,Neutrophils decreased,Neutrophils,1
AFINITOR,Neutrophils decreased,,0
AFINITOR,Glucose increased,Glucose increased,1
AFINITOR,Glucose increased,,0
AFINITOR,Glucose increased,,0
AFINITOR,Glucose increased,Glucose increased,1
AFINITOR,Glucose increased,increased,1
AFINITOR,Glucose increased,chemistry,0
AFINITOR,Cholesterol increased,Cholesterol,1
AFINITOR,Triglycerides increased,,0
AFINITOR,Albumin decreased,Albumin decreased,1
AFINITOR,Albumin decreased,Albumin,1
AFINITOR,Albumin decreased,Albumin decreased,1
AFINITOR,Albumin decreased,,0
AFINITOR,Albumin decreased,Albumin decreased,1
AFINITOR,Potassium decreased,,0
AFINITOR,Potassium decreased,decreased,1
AFINITOR,Potassium decreased,,0
AFINITOR,Potassium decreased,Potassium,1
AFINITOR,Potassium decreased,Potassium,1
AFINITOR,Potassium decreased,,0
AFINITOR,Creatinine increased,,0
AFINITOR,Creatinine increased,,0
AFINITOR,Creatinine increased,Creatinine increased,1
AFINITOR,Creatinine increased,Creatinine increased,1
AFINITOR,Creatinine increased,,0
AFINITOR,Creatinine increased,,0
AFINITOR,stomatitis,adverse reactions incidence stomatitis,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,edema abdominal pain nausea fever and headache The most common Grade,0
AFINITOR,rash,,0
AFINITOR,rash,The most common Grade a,0
AFINITOR,rash,rash,1
AFINITOR,rash,rash,1
AFINITOR,rash,rash,1
AFINITOR,rash,reactions incidence were rash,1
AFINITOR,fatigue,most common Grade adverse reactions i,0
AFINITOR,fatigue,fatigue,1
AFINITOR,fatigue,fatigue,1
AFINITOR,fatigue,fatigue,1
AFINITOR,fatigue,fever and headache The,0
AFINITOR,fatigue,common Grade,0
AFINITOR,fatigue,Grade,0
AFINITOR,edema,most common Grade adverse,0
AFINITOR,edema,abdominal,0
AFINITOR,abdominal pain,most common adverse reactions incidence were stomatitis rash diarrhea fatigue edema,0
AFINITOR,abdominal pain,abdominal,1
AFINITOR,abdominal pain,reactions incidence were stomatitis,0
AFINITOR,nausea,incidence were stomatitis,0
AFINITOR,nausea,edema abdominal pain,0
AFINITOR,nausea,The,0
AFINITOR,nausea,and,0
AFINITOR,nausea,stomatitis,0
AFINITOR,nausea,diarrhea fatigue,0
AFINITOR,nausea,Grade adverse reactions,0
AFINITOR,nausea,nausea,1
AFINITOR,nausea,fatigue edema abdominal nausea,1
AFINITOR,headache,headache,1
AFINITOR,headache,,0
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,and diarrhea The most common,0
AFINITOR,stomatitis,headache,0
AFINITOR,stomatitis,incidence stomatitis,1
AFINITOR,stomatitis,common laboratory abnormalities incidence,0
AFINITOR,stomatitis,,0
AFINITOR,stomatitis,decreased,0
AFINITOR,diarrhea,common Grade adverse,0
AFINITOR,diarrhea,hemoglobin hyperglycem,0
AFINITOR,diarrhea,diarrhea,1
AFINITOR,diarrhea,adverse,0
AFINITOR,diarrhea,were decreased hemoglobin,0
AFINITOR,diarrhea,hyperglycem,0
AFINITOR,diarrhea,common Grade adverse reactions incidence were stomatitis,0
AFINITOR,diarrhea,diarrhea,1
AFINITOR,diarrhea,were stomatitis diarrhea,1
AFINITOR,decreased hemoglobin,most common laboratory abnormalities,0
AFINITOR,decreased hemoglobin,common laboratory abnormalities incidence decreased hemoglobin,1
AFINITOR,decreased hemoglobin,abnormalities incidence decreased,1
AFINITOR,alkaline phosphatase increased,decreased hemoglobin alkaline,1
AFINITOR,alkaline phosphatase increased,laboratory abnormalities incidence were decreased hemoglobin,0
AFINITOR,hypercholesterolemia,hypercholesterolemia,1
AFINITOR,hypercholesterolemia,alkaline phosphatase hypercholesterolemia,1
AFINITOR,hypercholesterolemia,phosphatase hypercholesterolemia,1
AFINITOR,hypercholesterolemia,increased aspartate,0
AFINITOR,hypercholesterolemia,hemoglobin hyperglycemia alkaline phosphatase hypercholesterolemia,1
AFINITOR,hypercholesterolemia,hypercholesterolemia,1
AFINITOR,bicarbonate decreased,,0
AFINITOR,bicarbonate decreased,alkaline phosphatase increased,0
AFINITOR,hyperglycemia,most common Grade,0
AFINITOR,lymphopenia,laboratory abnormalities incidence were lymphopenia,1
AFINITOR,lymphopenia,lymphopenia,1
AFINITOR,lymphopenia,were hyperglycemia,0
AFINITOR,lymphopenia,AST The most common,0
AFINITOR,lymphopenia,incidence were lymphopenia,1
AFINITOR,lymphopenia,The most common,0
AFINITOR,lymphopenia,most,0
AFINITOR,lymphopenia,lymphopenia,1
AFINITOR,lymphopenia,common Grade laboratory abnormalities incidence,0
AFINITOR,decreased hemoglobin,were hyperglycemia,0
AFINITOR,decreased hemoglobin,increased,0
AFINITOR,decreased hemoglobin,neutropenia,0
AFINITOR,decreased hemoglobin,hyperglycemia decreased hemoglobin,1
AFINITOR,decreased hemoglobin,lymphopenia,0
AFINITOR,decreased hemoglobin,hyperglycemia decreased hemoglobin,1
AFINITOR,decreased hemoglobin,Grade laboratory,0
AFINITOR,decreased hemoglobin,incidence were hyperglycemia decreased,1
AFINITOR,decreased hemoglobin,neutropenia,0
AFINITOR,decreased hemoglobin,,0
AFINITOR,hypophosphatemia,lymphopenia decreased hemoglobin,0
AFINITOR,hypophosphatemia,lymphopenia decreased hypophosphatemia,1
AFINITOR,hypophosphatemia,aspartate transaminase AST,0
AFINITOR,hypophosphatemia,incidence were hyperglycemia lymphopenia,0
AFINITOR,increased alkaline phosphatase,increased,1
AFINITOR,increased alkaline phosphatase,increased alkaline phosphatase,1
AFINITOR,increased alkaline phosphatase,lymphopenia,0
AFINITOR,increased alkaline phosphatase,thrombocytopenia,0
AFINITOR,neutropenia,lymphopenia decreased hemoglobin hypophosphatemia increased alkaline phosphatase,0
AFINITOR,neutropenia,neutropenia,1
AFINITOR,neutropenia,decreased hemoglobin hypophosphatemia increased alkaline phosphatase,0
AFINITOR,neutropenia,neutropenia,1
AFINITOR,neutropenia,increased alkaline phosphatase,0
AFINITOR,neutropenia,neutropenia,1
AFINITOR,neutropenia,increased alkaline neutropenia,1
AFINITOR,neutropenia,aspartate transaminase AST potassium decreased and thrombocytopenia Deaths,0
AFINITOR,increased aspartate transaminase,alkaline phosphatase increased,1
AFINITOR,increased aspartate transaminase,aspartate transaminase,1
AFINITOR,increased aspartate transaminase,where an ad,0
AFINITOR,potassium decreased,neutropenia increased aspartate,0
AFINITOR,potassium decreased,transaminase potassium,1
AFINITOR,potassium decreased,aspartate transaminase potassium decreased,1
AFINITOR,potassium decreased,increased aspartate transaminase potassium decreased,1
AFINITOR,potassium decreased,decreased,1
AFINITOR,potassium decreased,aspartate,0
AFINITOR,potassium decreased,potassium,1
AFINITOR,potassium decreased,increased aspartate transaminase potassium decreased,1
AFINITOR,potassium decreased,increased aspartate transaminase potassium decreased,1
AFINITOR,potassium decreased,event was the primary,0
AFINITOR,thrombocytopenia,thrombocytopenia,1
AFINITOR,thrombocytopenia,transaminase AST potassium decreased thrombocytopenia,1
AFINITOR,thrombocytopenia,thrombocytopenia,1
AFINITOR,thrombocytopenia,decreased,0
AFINITOR,thrombocytopenia,,0
AFINITOR,Deaths,during doubleblind treatment where,0
AFINITOR,Deaths,treatment where an adverse,0
AFINITOR,Deaths,in seven,0
AFINITOR,Deaths,seven patien,0
AFINITOR,Deaths,Deaths,1
AFINITOR,Deaths,Deaths,1
AFINITOR,Deaths,Deaths,1
AFINITOR,Deaths,,0
AFINITOR,Deaths,increased aspartate,0
AFINITOR,Deaths,and thrombocytopenia,0
AFINITOR,acute renal failure,the acute renal failure,1
AFINITOR,acute renal failure,of the acute renal,1
AFINITOR,acute renal failure,,0
AFINITOR,acute renal failure,of,0
AFINITOR,acute renal failure,on,0
AFINITOR,acute respiratory distress,the,0
AFINITOR,acute respiratory distress,the following,0
AFINITOR,acute respiratory distress,acute,1
AFINITOR,acute respiratory distress,cause unknown hepatic failure pneumonia and sepsis There,0
AFINITOR,acute respiratory distress,the AFINITOR arm included one case,0
AFINITOR,acute respiratory distress,,0
AFINITOR,cardiac arrest,one case of each of the following acute renal failure acute respiratory,0
AFINITOR,cardiac arrest,cardiac arrest,1
AFINITOR,cardiac arrest,,0
AFINITOR,cardiac arrest,was one death due,0
AFINITOR,cardiac arrest,cardiac arrest,1
AFINITOR,cardiac arrest,cardiac arrest,1
AFINITOR,death,death,1
AFINITOR,death,death,1
AFINITOR,death,each of the following,0
AFINITOR,pneumonia,acute respiratory distress cardiac arrest death cause,0
AFINITOR,pneumonia,pneumonia,1
AFINITOR,pneumonia,cardiac arrest death cause unknown hepatic failure,0
AFINITOR,pneumonia,cause,0
AFINITOR,pneumonia,failure acute respiratory distress,0
AFINITOR,pneumonia,pneumonia,1
AFINITOR,pneumonia,pneumonia,1
AFINITOR,pneumonia,arrest,0
AFINITOR,pneumonia,pneumonia,1
AFINITOR,sepsis,sepsis,1
AFINITOR,sepsis,death cause,0
AFINITOR,sepsis,sepsis,1
AFINITOR,sepsis,failure pneumonia sepsis,1
AFINITOR,sepsis,sepsis,1
AFINITOR,sepsis,,0
AFINITOR,sepsis,sepsis,1
AFINITOR,sepsis,sepsis,1
AFINITOR,death,the placebo arm After crossover to,0
AFINITOR,death,,0
AFINITOR,death,hepatic,0
AFINITOR,death,There was death,1
AFINITOR,death,death,1
AFINITOR,pulmonary embolism,was one death due pulmonary embolism,1
AFINITOR,pulmonary embolism,pulmonary embolism,1
AFINITOR,pulmonary embolism,death due,0
AFINITOR,pulmonary embolism,,0
AFINITOR,pulmonary embolism,sepsis There was one death,0
AFINITOR,pulmonary embolism,,0
AFINITOR,pulmonary embolism,one death due pulmonary,1
AFINITOR,pulmonary embolism,,0
AFINITOR,deaths,there were three deaths,1
AFINITOR,deaths,deaths,1
AFINITOR,deaths,in a,0
AFINITOR,deaths,with,0
AFINITOR,deaths,one due to hypoglycemia and cardiac,0
AFINITOR,deaths,,0
AFINITOR,deaths,AFINITOR there were three deaths,1
AFINITOR,deaths,one due to hypoglycemia and cardiac arrest in a patient with insulinoma one due,0
AFINITOR,deaths,deaths,1
AFINITOR,hypoglycemia,,0
AFINITOR,hypoglycemia,hypoglycemia,1
AFINITOR,hypoglycemia,hypoglycemia,1
AFINITOR,hypoglycemia,AFINITOR there were,0
AFINITOR,hypoglycemia,congestive h,0
AFINITOR,hypoglycemia,hypoglycemia,1
AFINITOR,hypoglycemia,a patient with insulinoma one due to myocardial infarction,0
AFINITOR,hypoglycemia,,0
AFINITOR,hypoglycemia,were,0
AFINITOR,cardiac arrest,three additional deaths one due to hypoglycemia and,0
AFINITOR,cardiac arrest,myocardial infarction with,0
AFINITOR,cardiac arrest,arrest,1
AFINITOR,cardiac arrest,infarction with congestive heart,0
AFINITOR,cardiac arrest,due to hypoglycemia cardiac arrest,1
AFINITOR,cardiac arrest,one due to hypoglycemia cardiac arrest,1
AFINITOR,cardiac arrest,cardiac arrest,1
AFINITOR,congestive heart failure,to sudden death The rates of,0
AFINITOR,congestive heart failure,heart failure,1
AFINITOR,congestive heart failure,myocardial infarction congestive heart failure,1
AFINITOR,congestive heart failure,myocardial infarction congestive heart failure,1
AFINITOR,congestive heart failure,,0
AFINITOR,congestive heart failure,failure,1
AFINITOR,congestive heart failure,congestive heart failure,1
AFINITOR,congestive heart failure,myocardial infarction congestive heart failure,1
AFINITOR,congestive heart failure,cardiac arrest in a patient with insulinoma,0
AFINITOR,congestive heart failure,heart failure,1
AFINITOR,sudden death,the other due sudden,1
AFINITOR,sudden death,the other due to,0
AFINITOR,sudden death,sudden death,1
AFINITOR,renal failure,renal failure,1
AFINITOR,renal failure,patients and of placebo patients Grade,0
AFINITOR,renal failure,in of everolimus patients and of,0
AFINITOR,renal failure,patients renal failure,1
AFINITOR,renal failure,of placebo patients renal failure,1
AFINITOR,renal failure,and of placebo patients renal,1
AFINITOR,renal failure,of placebo patients renal,1
AFINITOR,renal failure,and of placebo patients renal failure,1
AFINITOR,renal failure,arm and three patients in,0
AFINITOR,Thrombotic events,everolimus arm and three patients in,0
AFINITOR,Thrombotic events,,0
AFINITOR,Thrombotic events,the placebo arm,0
AFINITOR,Thrombotic events,patients in the placebo Thrombotic,1
AFINITOR,Thrombotic events,arm,0
AFINITOR,Thrombotic events,occurred in six patients in the everolimus arm and three patients in the,0
AFINITOR,pulmonary embolus,arm and,0
AFINITOR,pulmonary embolus,pulmonary embolus,1
AFINITOR,pulmonary embolus,events included five patients with,0
AFINITOR,pulmonary embolus,events included five patients pulmonary,1
AFINITOR,pulmonary embolus,,0
AFINITOR,pulmonary embolus,pulmonary embolus,1
AFINITOR,pulmonary embolus,,0
AFINITOR,pulmonary embolus,patients pulmonary embolus,1
AFINITOR,pulmonary embolus,,0
AFINITOR,thrombosis,thrombosis,1
AFINITOR,thrombosis,thrombosis,1
AFINITOR,thrombosis,,0
AFINITOR,thrombosis,thrombosis,1
AFINITOR,thrombosis,of,0
AFINITOR,thrombosis,incidence,0
AFINITOR,thrombosis,two in the placebo arm Table compares the incidence,0
AFINITOR,stomatitis,a Includes,0
AFINITOR,stomatitis,of Patients with Advanced PNET Grading according to CTCAE Version a Includes,0
AFINITOR,stomatitis,stomatitis,1
AFINITOR,aphthous stomatitis,stomatitis,1
AFINITOR,aphthous stomatitis,Includes aphthous,1
AFINITOR,aphthous stomatitis,CTCAE Version a Includes aphthous stomatitis,1
AFINITOR,aphthous stomatitis,Includes aphthous stomatitis,1
AFINITOR,aphthous stomatitis,glossodynia lip,0
AFINITOR,aphthous stomatitis,aphthous stomatitis,1
AFINITOR,aphthous stomatitis,CTCAE Version a Includes aphthous stomatitis,1
AFINITOR,aphthous stomatitis,CTCAE Version a Includes aphthous stomatitis,1
AFINITOR,aphthous stomatitis,CTCAE Version a Includes aphthous,1
AFINITOR,gingival pain,aphthous gingival,1
AFINITOR,gingival pain,aphthous gingival,1
AFINITOR,gingival pain,ulceration tongue,0
AFINITOR,gingival pain,PNET Grading according to CTCAE,0
AFINITOR,gingival pain,CTCAE Version a Includes stomatitis,0
AFINITOR,gingival pain,a Includes stomatitis aphthous gingival pain,1
AFINITOR,glossitis,b I,0
AFINITOR,glossitis,gingival,0
AFINITOR,glossitis,,0
AFINITOR,glossitis,and,0
AFINITOR,glossitis,b,0
AFINITOR,glossitis,gingival glossitis,1
AFINITOR,glossitis,glossitis,1
AFINITOR,glossodynia,mouth ulceration tongue ulceration and mucosal inflammation b Includes diarr,0
AFINITOR,glossodynia,a Includes stomatitis aphthous stomatitis gingival painswellingulceration glossitis,0
AFINITOR,lip ulceration,lip ulceration,1
AFINITOR,lip ulceration,glossitis lip ulceration,1
AFINITOR,lip ulceration,ulceration,1
AFINITOR,lip ulceration,lip ulceration,1
AFINITOR,lip ulceration,mucosal inflammation b,0
AFINITOR,mouth ulceration,inflammation b Includes diarrhea enteritis enterocolitis,0
AFINITOR,mouth ulceration,ulceration,1
AFINITOR,mouth ulceration,mucosal inflammation b Includes diarrhea enteritis enterocolitis,0
AFINITOR,mouth ulceration,stomatitis gingival painswellingulceration glossitis,0
AFINITOR,mouth ulceration,,0
AFINITOR,mouth ulceration,glossitis glossodynia lip mouth ulceration,1
AFINITOR,mouth ulceration,col,0
AFINITOR,tongue ulceration,ulceration,1
AFINITOR,tongue ulceration,ulceration mouth ulceration,0
AFINITOR,tongue ulceration,b Includes diarrhea enteritis enterocolitis colitis defecation ur,0
AFINITOR,tongue ulceration,ulceration,1
AFINITOR,mucosal inflammation,ulceration tongue ulceration mucosal inflammation,1
AFINITOR,diarrhea,ulceration tongue ulceration and mucosal inflammation b Includes,0
AFINITOR,diarrhea,urgency and steatorrhea c,0
AFINITOR,diarrhea,defecation urgency and steatorrhea c Includes pneumonitis,0
AFINITOR,diarrhea,inflammation b diarrhea,1
AFINITOR,enteritis,Includes diarrhea,0
AFINITOR,enteritis,,0
AFINITOR,enteritis,urgency and steatorrhea c Includes pneumonitis interstitia,0
AFINITOR,enteritis,enteritis,1
AFINITOR,enterocolitis,enterocolitis,1
AFINITOR,enterocolitis,enterocolitis,1
AFINITOR,enterocolitis,lung disease,0
AFINITOR,enterocolitis,defecation urgency and steatorrhea c Includes pneumonitis interstitial lung disease,0
AFINITOR,colitis,b Includes diarrhea enteritis colitis,1
AFINITOR,colitis,and mucosal inflammation b Includes diarrhea,0
AFINITOR,colitis,colitis,1
AFINITOR,colitis,colitis,1
AFINITOR,colitis,diarrhea,0
AFINITOR,defecation urgency,pneumonitis,0
AFINITOR,defecation urgency,enteritis enterocolitis defecation urgency,1
AFINITOR,defecation urgency,urgency,1
AFINITOR,steatorrhea,and restrictive pulmonary,0
AFINITOR,steatorrhea,disease,0
AFINITOR,steatorrhea,steatorrhea,1
AFINITOR,steatorrhea,lung disease pulmonary fibrosis and,0
AFINITOR,steatorrhea,steatorrhea,1
AFINITOR,steatorrhea,steatorrhea,1
AFINITOR,steatorrhea,urgency steatorrhea,1
AFINITOR,pneumonitis,pneumonitis,1
AFINITOR,pneumonitis,diarrhea enteritis enterocolitis colitis defecation urgency,0
AFINITOR,pneumonitis,c,0
AFINITOR,pneumonitis,,0
AFINITOR,pneumonitis,pneumonitis,1
AFINITOR,pneumonitis,pneumonitis,1
AFINITOR,pneumonitis,defecation urgency and steatorrhea c Includes,0
AFINITOR,pneumonitis,pneumonitis,1
AFINITOR,pneumonitis,colitis defecation,0
AFINITOR,pneumonitis,,0
AFINITOR,interstitial lung disease,,0
AFINITOR,interstitial lung disease,disease,1
AFINITOR,interstitial lung disease,,0
AFINITOR,pulmonary fibrosis,pulmonary fibrosis,1
AFINITOR,pulmonary fibrosis,,0
AFINITOR,pulmonary fibrosis,pneumonitis interstitial lung,0
AFINITOR,pulmonary fibrosis,,0
AFINITOR,pulmonary fibrosis,lung pulmonary fibrosis,1
AFINITOR,pulmonary fibrosis,pulmonary disease AFINITOR N Placebo N,0
AFINITOR,pulmonary fibrosis,restrictive pulmonary disease,0
AFINITOR,pulmonary fibrosis,pulmonary fibrosis,1
AFINITOR,pulmonary fibrosis,Includes pneumonitis interstitial lung,0
AFINITOR,pulmonary fibrosis,lung disease,0
AFINITOR,restrictive pulmonary disease,N,0
AFINITOR,restrictive pulmonary disease,All,0
AFINITOR,restrictive pulmonary disease,fibrosis restrictive pulmonary,1
AFINITOR,restrictive pulmonary disease,N Placebo,0
AFINITOR,restrictive pulmonary disease,pulmonary fibrosis restrictive,1
AFINITOR,Stomatitis,Stomatitis a,1
AFINITOR,Stomatitis,Stomatitis a,1
AFINITOR,Stomatitis,Stomatitis a,1
AFINITOR,Stomatitis,disorders,0
AFINITOR,Stomatitis,Stomatitis a,1
AFINITOR,Diarrhea,Diarrhea b,1
AFINITOR,Diarrhea,,0
AFINITOR,Diarrhea,Diarrhea b,1
AFINITOR,Diarrhea,Diarrhea b,1
AFINITOR,Diarrhea,,0
AFINITOR,Abdominal pain,,0
AFINITOR,Abdominal pain,Abdominal pain,1
AFINITOR,Abdominal pain,Abdominal,1
AFINITOR,Abdominal pain,,0
AFINITOR,Abdominal pain,Abdominal pain,1
AFINITOR,Abdominal pain,,0
AFINITOR,Abdominal pain,,0
AFINITOR,Abdominal pain,,0
AFINITOR,Abdominal pain,Abdominal,1
AFINITOR,Abdominal pain,Abdominal,1
AFINITOR,Nausea,Nausea,1
AFINITOR,Nausea,Nausea,1
AFINITOR,Nausea,Nausea,1
AFINITOR,Nausea,,0
AFINITOR,Nausea,,0
AFINITOR,Nausea,Nausea,1
AFINITOR,Nausea,,0
AFINITOR,Vomiting,,0
AFINITOR,Vomiting,,0
AFINITOR,Vomiting,Vomiting,1
AFINITOR,Vomiting,Vomiting,1
AFINITOR,Constipation,Constipation,1
AFINITOR,Constipation,Constipation,1
AFINITOR,Constipation,,0
AFINITOR,Constipation,,0
AFINITOR,Constipation,,0
AFINITOR,Constipation,,0
AFINITOR,Constipation,Constipation,1
AFINITOR,Constipation,Constipation,1
AFINITOR,Constipation,,0
AFINITOR,Dry mouth,,0
AFINITOR,Fatigue,Fatigue malaise,1
AFINITOR,Fatigue,malaise,0
AFINITOR,Fatigue,malaise,0
AFINITOR,Fatigue,and administration site conditions,0
AFINITOR,Fatigue,Fatigue malaise,1
AFINITOR,Fatigue,,0
AFINITOR,malaise,malaise,1
AFINITOR,malaise,,0
AFINITOR,Fever,,0
AFINITOR,Fever,Fever,1
AFINITOR,Fever,Fever,1
AFINITOR,Fever,Fever,1
AFINITOR,Fever,Fever,1
AFINITOR,Fever,,0
AFINITOR,Nasopharyngitis,,0
AFINITOR,Nasopharyngitis,Nasopharyngitis rhinitisURI,1
AFINITOR,Nasopharyngitis,and infestations,0
AFINITOR,Nasopharyngitis,infestations,0
AFINITOR,Nasopharyngitis,and Nasopharyngitis rhinitisURI,1
AFINITOR,Nasopharyngitis,rhinitisURI,0
AFINITOR,Nasopharyngitis,Nasopharyngitis rhinitisURI,1
AFINITOR,Nasopharyngitis,,0
AFINITOR,rhinitis,rhinitis URI,1
AFINITOR,rhinitis,URI,0
AFINITOR,URI,,0
AFINITOR,Urinary tract infection,tract infection,1
AFINITOR,Urinary tract infection,,0
AFINITOR,Urinary tract infection,,0
AFINITOR,Urinary tract infection,,0
AFINITOR,Urinary tract infection,,0
AFINITOR,Urinary tract infection,,0
AFINITOR,Urinary tract infection,Urinary tract,1
AFINITOR,Urinary tract infection,tract infection,1
AFINITOR,Urinary tract infection,Urinary tract infection,1
AFINITOR,Urinary tract infection,,0
AFINITOR,Weight decreased,Investigations Weight decreased,1
AFINITOR,Weight decreased,,0
AFINITOR,Weight decreased,,0
AFINITOR,Weight decreased,decreased,1
AFINITOR,Weight decreased,Investigations Weight,1
AFINITOR,Decreased appetite,,0
AFINITOR,Decreased appetite,Decreased appetite,1
AFINITOR,Decreased appetite,Decreased appetite,1
AFINITOR,Decreased appetite,Metabolism and nutrition Decreased appetite,1
AFINITOR,Decreased appetite,Decreased,1
AFINITOR,Decreased appetite,nutrition,0
AFINITOR,Decreased appetite,and nutrition Decreased,1
AFINITOR,Diabetes mellitus,,0
AFINITOR,Diabetes mellitus,mellitus,1
AFINITOR,Diabetes mellitus,Diabetes mellitus,1
AFINITOR,Diabetes mellitus,mellitus,1
AFINITOR,Diabetes mellitus,,0
AFINITOR,Diabetes mellitus,Diabetes,1
AFINITOR,Diabetes mellitus,,0
AFINITOR,Diabetes mellitus,mellitus,1
AFINITOR,Diabetes mellitus,Diabetes mellitus,1
AFINITOR,Diabetes mellitus,,0
AFINITOR,Arthralgia,tissue Arthralgia,1
AFINITOR,Arthralgia,,0
AFINITOR,Arthralgia,,0
AFINITOR,Arthralgia,,0
AFINITOR,Arthralgia,,0
AFINITOR,Arthralgia,Arthralgia,1
AFINITOR,Back pain,,0
AFINITOR,Back pain,Back pain,1
AFINITOR,Back pain,Back,1
AFINITOR,Back pain,,0
AFINITOR,Back pain,Back,1
AFINITOR,Back pain,Back,1
AFINITOR,Back pain,Back pain,1
AFINITOR,Pain in extremity,,0
AFINITOR,Pain in extremity,,0
AFINITOR,Pain in extremity,in extremity,1
AFINITOR,Pain in extremity,,0
AFINITOR,Pain in extremity,Pain in,1
AFINITOR,Pain in extremity,,0
AFINITOR,Pain in extremity,,0
AFINITOR,migraine,migraine,1
AFINITOR,Dysgeusia,Dysgeusia,1
AFINITOR,Dysgeusia,,0
AFINITOR,Dysgeusia,Dysgeusia,1
AFINITOR,Dysgeusia,,0
AFINITOR,Dysgeusia,Dysgeusia,1
AFINITOR,Dysgeusia,,0
AFINITOR,Dysgeusia,Dysgeusia,1
AFINITOR,Dysgeusia,,0
AFINITOR,Dysgeusia,Dysgeusia,1
AFINITOR,Dizziness,,0
AFINITOR,Dizziness,,0
AFINITOR,Dizziness,Dizziness,1
AFINITOR,Dizziness,,0
AFINITOR,Insomnia,Insomnia,1
AFINITOR,Insomnia,,0
AFINITOR,Insomnia,,0
AFINITOR,Insomnia,,0
AFINITOR,Insomnia,,0
AFINITOR,Insomnia,Insomnia,1
AFINITOR,Insomnia,Insomnia,1
AFINITOR,Insomnia,Insomnia,1
AFINITOR,Cough,Cough,1
AFINITOR,Cough,and mediastinal Cough,1
AFINITOR,Cough,thoracic and mediastinal,0
AFINITOR,Cough,Cough,1
AFINITOR,Cough,Cough,1
AFINITOR,Cough,disorders,0
AFINITOR,Cough,,0
AFINITOR,Cough,mediastinal,0
AFINITOR,Cough,Cough,1
AFINITOR,productive cough,productive cough,1
AFINITOR,productive cough,,0
AFINITOR,productive cough,productive,1
AFINITOR,productive cough,productive cough,1
AFINITOR,productive cough,mediastinal disorders productive cough,1
AFINITOR,productive cough,and mediastinal disorders productive cough,1
AFINITOR,productive cough,productive,1
AFINITOR,productive cough,and mediastinal disorders Cough,0
AFINITOR,productive cough,productive cough,1
AFINITOR,Epistaxis,Epistaxis,1
AFINITOR,Epistaxis,Epistaxis,1
AFINITOR,Epistaxis,,0
AFINITOR,Epistaxis,Epistaxis,1
AFINITOR,Epistaxis,,0
AFINITOR,Dyspnea,Dyspnea,1
AFINITOR,Dyspnea,Dyspnea dyspnea exertional,1
AFINITOR,Dyspnea,,0
AFINITOR,Dyspnea,Dyspnea dyspnea exertional,1
AFINITOR,Dyspnea,,0
AFINITOR,dyspnea exertional,Dyspnea,0
AFINITOR,dyspnea exertional,Dyspnea dyspnea,1
AFINITOR,dyspnea exertional,exertional,1
AFINITOR,dyspnea exertional,dyspnea exertional,1
AFINITOR,Pneumonitis,,0
AFINITOR,Pneumonitis,Pneumonitis c,1
AFINITOR,Pneumonitis,Pneumonitis c,1
AFINITOR,Pneumonitis,,0
AFINITOR,Pneumonitis,,0
AFINITOR,Pneumonitis,Pneumonitis c,1
AFINITOR,Pneumonitis,Pneumonitis c,1
AFINITOR,Oropharyngeal pain,pain,1
AFINITOR,Oropharyngeal pain,,0
AFINITOR,Oropharyngeal pain,,0
AFINITOR,Oropharyngeal pain,,0
AFINITOR,Oropharyngeal pain,,0
AFINITOR,Oropharyngeal pain,,0
AFINITOR,Rash,,0
AFINITOR,Rash,,0
AFINITOR,Rash,,0
AFINITOR,Rash,Rash,1
AFINITOR,Rash,Rash,1
AFINITOR,Rash,and,0
AFINITOR,Rash,,0
AFINITOR,Rash,and subcutaneous Rash,1
AFINITOR,Rash,Rash,1
AFINITOR,Rash,disorders,0
AFINITOR,Nail disorders,,0
AFINITOR,Nail disorders,,0
AFINITOR,Nail disorders,disorders,1
AFINITOR,Nail disorders,,0
AFINITOR,Nail disorders,Nail disorders,1
AFINITOR,Pruritus,,0
AFINITOR,Pruritus,,0
AFINITOR,Pruritus,,0
AFINITOR,Pruritus,,0
AFINITOR,Pruritus,Pruritus,1
AFINITOR,Pruritus,Pruritus pruritus,1
AFINITOR,Pruritus,,0
AFINITOR,Pruritus,,0
AFINITOR,Pruritus,pruritus,0
AFINITOR,Pruritus,Pruritus,1
AFINITOR,pruritus generalized,Pruritus pruritus generalized,1
AFINITOR,pruritus generalized,,0
AFINITOR,pruritus generalized,pruritus generalized,1
AFINITOR,Dry skin,skin xeroderma,1
AFINITOR,Dry skin,xeroderma,0
AFINITOR,Dry skin,Dry,1
AFINITOR,Dry skin,Dry skin xeroderma,1
AFINITOR,Dry skin,,0
AFINITOR,Dry skin,,0
AFINITOR,Dry skin,,0
AFINITOR,xeroderma,xeroderma,1
AFINITOR,xeroderma,,0
AFINITOR,xeroderma,xeroderma,1
AFINITOR,xeroderma,xeroderma,1
AFINITOR,Hypertension,Vascular Hypertension,1
AFINITOR,Hypertension,disorders,0
AFINITOR,Hypertension,Hypertension,1
AFINITOR,irregular menstruation,In female patients aged,0
AFINITOR,irregular menstruation,female patients aged to,0
AFINITOR,irregular menstruation,to years,0
AFINITOR,Hemoglobin decreased,Hematology Hemoglobin decreased Lymphocytes decreased,1
AFINITOR,Hemoglobin decreased,,0
AFINITOR,Hemoglobin decreased,Hematology Hemoglobin,1
AFINITOR,Hemoglobin decreased,,0
AFINITOR,Lymphocytes decreased,decreased,0
AFINITOR,Lymphocytes decreased,decreased,0
AFINITOR,Lymphocytes decreased,decreased Platelets decreased,1
AFINITOR,Platelets decreased,,0
AFINITOR,WBC decreased,decreased,0
AFINITOR,Alkaline phosphatase increased,nical Alkaline,1
AFINITOR,Alkaline phosphatase increased,Alkaline phosphatase increased Glucose fasting,1
AFINITOR,Alkaline phosphatase increased,phosphatase increased Glucose fasting,1
AFINITOR,Glucose (fasting) increased,increased,0
AFINITOR,Glucose (fasting) increased,,0
AFINITOR,Glucose (fasting) increased,Glucose (fasting) increased Cholesterol increased,1
AFINITOR,Glucose (fasting) increased,increased Cholesterol increased,1
AFINITOR,Glucose (fasting) increased,increased Cholesterol increased,1
AFINITOR,Glucose (fasting) increased,,0
AFINITOR,Cholesterol increased,,0
AFINITOR,Cholesterol increased,,0
AFINITOR,Bicarbonate decreased,,0
AFINITOR,Bicarbonate decreased,,0
AFINITOR,Bicarbonate decreased,Bicarbonate,1
AFINITOR,Bicarbonate decreased,,0
AFINITOR,Bicarbonate decreased,,0
AFINITOR,Bicarbonate decreased,decreased Aspartate transaminas,1
AFINITOR,Phosphate decreased,decreased Triglycerides increas,1
AFINITOR,Phosphate decreased,inase ALT Phosphate decreased Triglycerides increas,1
AFINITOR,Phosphate decreased,Phosphate decreased Triglycerides increas,1
AFINITOR,Phosphate decreased,inase ALT Phosphate,1
AFINITOR,Calcium decreased,Calcium decreased Potassium decreased,1
AFINITOR,Calcium decreased,,0
AFINITOR,Calcium decreased,Calcium,1
AFINITOR,Calcium decreased,Calcium decreased Potassium decreased,1
AFINITOR,Calcium decreased,increased,0
AFINITOR,Calcium decreased,iglycerides Calcium,1
AFINITOR,Calcium decreased,Potassium,0
AFINITOR,Calcium decreased,Calcium decreased Potassium decreased,1
AFINITOR,Calcium decreased,iglycerides Calcium,1
AFINITOR,Potassium decreased,decreased Creatinine increased,1
AFINITOR,Potassium decreased,decreased Creatinine increased,1
AFINITOR,Potassium decreased,increased,0
AFINITOR,Potassium decreased,,0
AFINITOR,Creatinine increased,Creatinine,1
AFINITOR,Creatinine increased,,0
AFINITOR,Creatinine increased,,0
AFINITOR,Sodium decreased,Sodium decreased Albumin decreased,1
AFINITOR,Albumin decreased,decreased,0
AFINITOR,Albumin decreased,,0
AFINITOR,Albumin decreased,Albumin decreased Bilirubin increased,1
AFINITOR,Albumin decreased,decreased,0
AFINITOR,Albumin decreased,Albumin,1
AFINITOR,Albumin decreased,,0
AFINITOR,Bilirubin increased,Potassium increased,0
AFINITOR,Bilirubin increased,,0
AFINITOR,Bilirubin increased,Bilirubin increased Potassium increased,1
AFINITOR,Bilirubin increased,increased Potassium increased,1
AFINITOR,Bilirubin increased,Bilirubin,1
AFINITOR,Bilirubin increased,Albumin Bilirubin increased Potassium increased,1
AFINITOR,Bilirubin increased,Bilirubin increased Potassium increased,1
AFINITOR,Bilirubin increased,,0
AFINITOR,Bilirubin increased,decreased,0
AFINITOR,Potassium increased,Potassium,1
AFINITOR,Potassium increased,Potassium increased Clinica,1
AFINITOR,Potassium increased,Bilirubin Potassium increased Clinica,1
AFINITOR,Potassium increased,Clinica,0
AFINITOR,Potassium increased,increased,0
AFINITOR,stomatitis,stomatitis infections asthenia,1
AFINITOR,stomatitis,reactions,0
AFINITOR,stomatitis,adverse reactions incidence stomatitis infections asthenia,1
AFINITOR,stomatitis,common adverse,0
AFINITOR,stomatitis,The most common adverse reactions incidence were,0
AFINITOR,stomatitis,stomatitis infections asthenia,1
AFINITOR,stomatitis,stomatitis infections asthenia,1
AFINITOR,stomatitis,stomatitis infections asthenia,1
AFINITOR,infections,incidence were,0
AFINITOR,infections,The,0
AFINITOR,infections,infections asthenia fatigue,1
AFINITOR,infections,infections asthenia fatigue,1
AFINITOR,infections,,0
AFINITOR,infections,receiving placebo The most,0
AFINITOR,asthenia,i,0
AFINITOR,asthenia,asthenia fatigue cough,1
AFINITOR,asthenia,,0
AFINITOR,asthenia,incidence were stomatitis asthenia fatigue cough,1
AFINITOR,asthenia,were stomatitis infections,0
AFINITOR,asthenia,asthenia fatigue cough,1
AFINITOR,fatigue,incidence,0
AFINITOR,fatigue,,0
AFINITOR,fatigue,fatigue cough and,1
AFINITOR,fatigue,fatigue cough and,1
AFINITOR,fatigue,fatigue cough and,1
AFINITOR,fatigue,fatigue cough and,1
AFINITOR,fatigue,infections fatigue cough and,1
AFINITOR,fatigue,Grade adverse reactions incidence were,0
AFINITOR,cough,infections asthenia cough and diarrhea,1
AFINITOR,cough,and diarrhea The most common Grade,0
AFINITOR,cough,cough and diarrhea,1
AFINITOR,cough,were infections,0
AFINITOR,cough,cough and diarrhea,1
AFINITOR,cough,,0
AFINITOR,cough,infections asthenia cough and diarrhea,1
AFINITOR,cough,cough and diarrhea,1
AFINITOR,cough,infections asthenia,0
AFINITOR,cough,cough and diarrhea,1
AFINITOR,diarrhea,diarrhea The most,1
AFINITOR,diarrhea,diarrhea The most,1
AFINITOR,diarrhea,infections asthenia fatigue cough diarrhea The most,1
AFINITOR,diarrhea,stomatitis infections asthenia fatigue cough,0
AFINITOR,diarrhea,diarrhea The most,1
AFINITOR,diarrhea,reactions incidence were infections,0
AFINITOR,diarrhea,diarrhea The most,1
AFINITOR,diarrhea,diarrhea The most,1
AFINITOR,infections,The most,0
AFINITOR,dyspnea,,0
AFINITOR,dyspnea,stomatitis dehydration pneumonitis abdominal pain and asthenia The,0
AFINITOR,fatigue,were infections fatigue stomatitis dehydration,1
AFINITOR,fatigue,most common Grade,0
AFINITOR,fatigue,incidence were infections dyspnea,0
AFINITOR,fatigue,asthenia The most common,0
AFINITOR,fatigue,,0
AFINITOR,fatigue,,0
AFINITOR,fatigue,The most common laboratory abn,0
AFINITOR,stomatitis,stomatitis dehydration pneumonitis,1
AFINITOR,stomatitis,stomatitis dehydration pneumonitis,1
AFINITOR,stomatitis,dyspnea fatigue,0
AFINITOR,stomatitis,,0
AFINITOR,dehydration,were infections dyspnea fatigue stomatitis,0
AFINITOR,dehydration,infections dyspnea fatigue stomatitis,0
AFINITOR,pneumonitis,incidence were infections dyspnea,0
AFINITOR,pneumonitis,pneumonitis abdominal pain,1
AFINITOR,pneumonitis,pneumonitis abdominal pain,1
AFINITOR,pneumonitis,most,0
AFINITOR,pneumonitis,most common,0
AFINITOR,pneumonitis,incidence were,0
AFINITOR,asthenia,abdominal pain and,0
AFINITOR,asthenia,and,0
AFINITOR,anemia,,0
AFINITOR,anemia,anemia hypercholesterolemia hypertriglyceridemia,1
AFINITOR,anemia,anemia hypercholesterolemia hypertriglyceridemia,1
AFINITOR,anemia,incidence were,0
AFINITOR,anemia,incidence anemia hypercholesterolemia hypertriglyceridemia,1
AFINITOR,anemia,abdominal pain and asthenia The most,0
AFINITOR,anemia,,0
AFINITOR,anemia,common laboratory abnormalities incidence were,0
AFINITOR,anemia,laboratory abnormalities incidence were,0
AFINITOR,hyperglycemia,,0
AFINITOR,hyperglycemia,anemia hypercholesterolemia,0
AFINITOR,hyperglycemia,,0
AFINITOR,hyperglycemia,inciden,0
AFINITOR,hyperglycemia,hyperglycemia lymphopenia and,1
AFINITOR,hyperglycemia,,0
AFINITOR,hyperglycemia,anemia hypercholesterolemia hyperglycemia lymphopenia and,1
AFINITOR,hyperglycemia,anemia hypercholesterolemia hypertriglyceridemia,0
AFINITOR,hyperglycemia,hyperglycemia lymphopenia and,1
AFINITOR,hyperglycemia,hyperglycemia lymphopenia and,1
AFINITOR,lymphopenia,lymphopenia and increased,1
AFINITOR,lymphopenia,hypercholesterolemia hypertriglyceridemia lymphopenia and increased,1
AFINITOR,increased creatinine,most common Grade laboratory abnormalities incidence,0
AFINITOR,increased creatinine,lymphopenia and,0
AFINITOR,increased creatinine,increased creatinine The most,1
AFINITOR,increased creatinine,hyperglycemia lymphopenia increased creatinine The most,1
AFINITOR,increased creatinine,hypertriglyceridemia hyperglycemia lymphopenia increased,1
AFINITOR,increased creatinine,,0
AFINITOR,lymphopenia,lymphopenia hyperglycemia anemia,1
AFINITOR,hyperglycemia,hypophosphatemia and hypercholesterolemia Deaths due,0
AFINITOR,anemia,anemia hypophosphatemia and,1
AFINITOR,anemia,anemia hypophosphatemia and,1
AFINITOR,anemia,,0
AFINITOR,anemia,hyperglycemia,0
AFINITOR,anemia,anemia hypophosphatemia and,1
AFINITOR,anemia,incidence were lymphopenia,0
AFINITOR,anemia,common Grade laboratory abnormalities,0
AFINITOR,anemia,anemia hypophosphatemia and,1
AFINITOR,anemia,Grade,0
AFINITOR,hypophosphatemia,hypophosphatemia and hypercholesterolemia,1
AFINITOR,hypophosphatemia,hypophosphatemia and hypercholesterolemia,1
AFINITOR,hypophosphatemia,hyperglycemia hypophosphatemia and hypercholesterolemia,1
AFINITOR,hypophosphatemia,hyperglycemia anemia,0
AFINITOR,hypophosphatemia,hypophosphatemia and hypercholesterolemia,1
AFINITOR,hypophosphatemia,abnormalities,0
AFINITOR,hypophosphatemia,hypophosphatemia and hypercholesterolemia,1
AFINITOR,hypophosphatemia,,0
AFINITOR,hypercholesterolemia,acute renal failure w,0
AFINITOR,hypercholesterolemia,,0
AFINITOR,hypercholesterolemia,anemia hypophosphatemia hypercholesterolemia Deaths due,1
AFINITOR,hypercholesterolemia,hypercholesterolemia Deaths due,1
AFINITOR,hypercholesterolemia,lymphopenia hyperglycemia anemia hypophosphatemia hypercholesterolemia Deaths due,1
AFINITOR,Deaths,,0
AFINITOR,Deaths,hypophosphatemia and,0
AFINITOR,Deaths,Deaths due to,1
AFINITOR,Deaths,Deaths due to,1
AFINITOR,Deaths,,0
AFINITOR,Deaths,Deaths due to,1
AFINITOR,Deaths,failure,0
AFINITOR,Deaths,to acute respiratory failure infection,0
AFINITOR,acute respiratory failure,failure infection and,1
AFINITOR,acute respiratory failure,,0
AFINITOR,acute respiratory failure,on the,0
AFINITOR,acute respiratory failure,acute,1
AFINITOR,infection,acute respiratory,0
AFINITOR,infection,hypercholesterolemia Deaths,0
AFINITOR,infection,to,0
AFINITOR,infection,infection and acute,1
AFINITOR,infection,acute respiratory infection and acute,1
AFINITOR,infection,infection and acute,1
AFINITOR,infection,,0
AFINITOR,infection,to acute respiratory infection and acute,1
AFINITOR,infection,infection and acute,1
AFINITOR,infection,placebo ar,0
AFINITOR,acute renal failure,observed,0
AFINITOR,acute renal failure,infection and,0
AFINITOR,pneumonitis,causality leading to treatment discontinuation,0
AFINITOR,pneumonitis,leading to,0
AFINITOR,pneumonitis,pneumonitis and dyspnea,1
AFINITOR,pneumonitis,treatment,0
AFINITOR,pneumonitis,treatment discontinuation pneumonitis and dyspnea,1
AFINITOR,pneumonitis,pneumonitis and dyspnea,1
AFINITOR,pneumonitis,discontinuation pneumonitis and dyspnea,1
AFINITOR,pneumonitis,of causality leading to treatment discontinuation were,0
AFINITOR,pneumonitis,leading to,0
AFINITOR,dyspnea,of causality leading,0
AFINITOR,dyspnea,dyspnea Infections stomatitis,1
AFINITOR,dyspnea,leading,0
AFINITOR,dyspnea,,0
AFINITOR,dyspnea,dyspnea Infections stomatitis,1
AFINITOR,dyspnea,dyspnea Infections stomatitis,1
AFINITOR,dyspnea,treatment discontinuation were pneumonitis dyspnea Infections stomatitis,1
AFINITOR,dyspnea,,0
AFINITOR,Infections,and Infections stomatitis and,1
AFINITOR,Infections,or dose reduction Th,0
AFINITOR,Infections,the most common reasons for treatment delay or dose reduction Th,0
AFINITOR,Infections,,0
AFINITOR,Infections,Infections stomatitis and,1
AFINITOR,Infections,most common,0
AFINITOR,pneumonitis,and dyspnea Infections stomatitis pneumonitis were the,1
AFINITOR,pneumonitis,pneumonitis were the,1
AFINITOR,pneumonitis,,0
AFINITOR,pneumonitis,pneumonitis were the,1
AFINITOR,pneumonitis,pneumonitis were the,1
AFINITOR,pneumonitis,reasons for treatment delay or dose reduction The most common,0
AFINITOR,pneumonitis,pneumonitis were the,1
AFINITOR,pneumonitis,the most common reasons for treatment delay or dose reduction The most,0
AFINITOR,infections,infections anemia and,1
AFINITOR,infections,reduction The most,0
AFINITOR,infections,AFINITOR treatment were infections anemia and,1
AFINITOR,infections,medical,0
AFINITOR,infections,anemia and stomatitis Table compares the incidence of treatmentemergent adverse,0
AFINITOR,infections,during AFINITOR treatment were infections anemia and,1
AFINITOR,infections,infections anemia and,1
AFINITOR,anemia,of treatmentemergent adverse,0
AFINITOR,anemia,AFINITOR treatment were for anemia and stomatitis,1
AFINITOR,anemia,for,0
AFINITOR,anemia,anemia and stomatitis,1
AFINITOR,anemia,and stomatitis Table compares the incidence,0
AFINITOR,anemia,required during AFINITOR treatment were for infections,0
AFINITOR,anemia,anemia and stomatitis,1
AFINITOR,stomatitis,stomatitis Table compares,1
AFINITOR,stomatitis,,0
AFINITOR,Stomatitis,according to CTCAE Version Stomatitis including aphthous,1
AFINITOR,Stomatitis,to CTCAE Version Stomatitis including aphthous,1
AFINITOR,aphthous stomatitis,within the infections and,0
AFINITOR,aphthous stomatitis,in,0
AFINITOR,nasopharyngitis,class the most common nasopharyngitis pneumonia urinary,1
AFINITOR,nasopharyngitis,nasopharyngitis pneumonia urinary,1
AFINITOR,nasopharyngitis,,0
AFINITOR,nasopharyngitis,nasopharyngitis pneumonia urinary,1
AFINITOR,urinary tract infection,most common being nasopharyngitis urinary tract,1
AFINITOR,urinary tract infection,nasopharyngitis urinary tract,1
AFINITOR,urinary tract infection,infestations system organ,0
AFINITOR,urinary tract infection,urinary tract infection bronchitis and,1
AFINITOR,urinary tract infection,urinary tract infection bronchitis and,1
AFINITOR,urinary tract infection,and also,0
AFINITOR,urinary tract infection,urinary tract infection bronchitis and,1
AFINITOR,urinary tract infection,candidiasis,0
AFINITOR,urinary tract infection,,0
AFINITOR,urinary tract infection,infection bronchitis and,1
AFINITOR,bronchitis,and sepsis,0
AFINITOR,bronchitis,bronchitis and sinusitis,1
AFINITOR,bronchitis,nasopharyngitis pneumonia urinary tract bronchitis and sinusitis,1
AFINITOR,bronchitis,being nasopharyngitis pneumonia urinary,0
AFINITOR,bronchitis,pneumonia urinary tract bronchitis and sinusitis,1
AFINITOR,bronchitis,bronchitis and sinusitis,1
AFINITOR,bronchitis,aspergillosis candidiasis and sepsis,0
AFINITOR,bronchitis,bronchitis and sinusitis,1
AFINITOR,bronchitis,bronchitis and sinusitis,1
AFINITOR,bronchitis,also including aspergillosis candidiasis,0
AFINITOR,sinusitis,sinusitis and also,1
AFINITOR,sinusitis,and sepsis,0
AFINITOR,sinusitis,candidiasis,0
AFINITOR,sinusitis,sinusitis and also,1
AFINITOR,sinusitis,sepsis,0
AFINITOR,sinusitis,sinusitis and also,1
AFINITOR,sinusitis,nasopharyngitis pneumonia urinary tract,0
AFINITOR,sinusitis,,0
AFINITOR,sinusitis,and,0
AFINITOR,sinusitis,infection bronchitis sinusitis and also,1
AFINITOR,sepsis,pulmonary,0
AFINITOR,sepsis,,0
AFINITOR,sepsis,also including aspergillosis candidiasis sepsis c Includes,1
AFINITOR,pneumonitis,alveolar,0
AFINITOR,pneumonitis,candidiasis and sepsis,0
AFINITOR,pneumonitis,hemorrhage pulmonary toxicity a,0
AFINITOR,pneumonitis,pneumonitis interstitial lung,1
AFINITOR,pneumonitis,pneumonitis interstitial lung,1
AFINITOR,pneumonitis,,0
AFINITOR,interstitial lung disease,and sepsis c Includes interstitial,1
AFINITOR,interstitial lung disease,,0
AFINITOR,interstitial lung disease,c Includes interstitial,1
AFINITOR,interstitial lung disease,interstitial lung disease lung infiltration,1
AFINITOR,pulmonary alveolar hemorrhage,pulmonary alveolar hemorrhage pulmonary toxicity,1
AFINITOR,pulmonary alveolar hemorrhage,interstitial lung disease lung pulmonary alveolar hemorrhage pulmonary toxicity,1
AFINITOR,pulmonary alveolar hemorrhage,alveolar hemorrhage pulmonary toxicity,1
AFINITOR,pulmonary alveolar hemorrhage,AFINITOR mgday,0
AFINITOR,pulmonary toxicity,hemorrhage,0
AFINITOR,pulmonary toxicity,,0
AFINITOR,pulmonary toxicity,lung infiltration pulmonary alveolar pulmonary,1
AFINITOR,pulmonary toxicity,pulmonary alveolar pulmonary,1
AFINITOR,alveolitis,AFINITOR,0
AFINITOR,alveolitis,alveolitis AFINITOR mgday,1
AFINITOR,Stomatitis,Stomatitis a,1
AFINITOR,Stomatitis,,0
AFINITOR,Stomatitis,,0
AFINITOR,Stomatitis,,0
AFINITOR,Stomatitis,,0
AFINITOR,Diarrhea,,0
AFINITOR,Diarrhea,,0
AFINITOR,Diarrhea,,0
AFINITOR,Diarrhea,Diarrhea,1
AFINITOR,Diarrhea,,0
AFINITOR,Diarrhea,,0
AFINITOR,Diarrhea,,0
AFINITOR,Diarrhea,,0
AFINITOR,Diarrhea,Diarrhea,1
AFINITOR,Nausea,,0
AFINITOR,Nausea,Nausea,1
AFINITOR,Nausea,Nausea,1
AFINITOR,Nausea,Nausea,1
AFINITOR,Nausea,Nausea,1
AFINITOR,Nausea,,0
AFINITOR,Fatigue,,0
AFINITOR,Fatigue,,0
AFINITOR,Fatigue,,0
AFINITOR,Fatigue,Fatigue,1
AFINITOR,Fatigue,Fatigue,1
AFINITOR,Fatigue,Fatigue,1
AFINITOR,Edema peripheral,Edema peripheral,1
AFINITOR,Edema peripheral,Edema peripheral,1
AFINITOR,Edema peripheral,Edema peripheral,1
AFINITOR,Edema peripheral,peripheral,1
AFINITOR,Pyrexia,,0
AFINITOR,Pyrexia,Pyrexia,1
AFINITOR,Pyrexia,Pyrexia,1
AFINITOR,Mucosal inflammation,,0
AFINITOR,Mucosal inflammation,Mucosal,1
AFINITOR,Mucosal inflammation,Mucosal inflammation,1
AFINITOR,Mucosal inflammation,,0
AFINITOR,Mucosal inflammation,Mucosal,1
AFINITOR,Mucosal inflammation,,0
AFINITOR,Mucosal inflammation,Mucosal inflammation,1
AFINITOR,Cough,,0
AFINITOR,Cough,,0
AFINITOR,Cough,ediastinal d Cough,1
AFINITOR,Cough,Cough,1
AFINITOR,Cough,Cough,1
AFINITOR,Cough,Cough,1
AFINITOR,Dyspnea,Dyspnea,1
AFINITOR,Epistaxis,Epistaxis,1
AFINITOR,Epistaxis,,0
AFINITOR,Epistaxis,Epistaxis,1
AFINITOR,Epistaxis,Epistaxis,1
AFINITOR,Epistaxis,Epistaxis,1
AFINITOR,Pneumonitis,,0
AFINITOR,Pneumonitis,,0
AFINITOR,Pneumonitis,Pneumonitis c,1
AFINITOR,Pneumonitis,,0
AFINITOR,Pneumonitis,c,0
AFINITOR,Rash,ubcutaneous t issue d Rash,1
AFINITOR,Rash,s ubcutaneous t issue d isorders,0
AFINITOR,Rash,Rash,1
AFINITOR,Rash,issue,0
AFINITOR,Pruritus,,0
AFINITOR,Pruritus,,0
AFINITOR,Pruritus,Pruritus,1
AFINITOR,Pruritus,,0
AFINITOR,Pruritus,,0
AFINITOR,Pruritus,,0
AFINITOR,Pruritus,Pruritus,1
AFINITOR,Pruritus,Pruritus,1
AFINITOR,Pruritus,,0
AFINITOR,Pruritus,Pruritus,1
AFINITOR,Anorexia,,0
AFINITOR,Anorexia,,0
AFINITOR,Anorexia,Anorexia,1
AFINITOR,Anorexia,,0
AFINITOR,Anorexia,d isorders,0
AFINITOR,Anorexia,Anorexia,1
AFINITOR,Headache,d Headache,1
AFINITOR,Headache,Headache,1
AFINITOR,Headache,Headache,1
AFINITOR,Headache,Headache,1
AFINITOR,Headache,Headache,1
AFINITOR,Headache,,0
AFINITOR,Headache,Nervous s ystem d Headache,1
AFINITOR,Headache,d,0
AFINITOR,Headache,Headache,1
AFINITOR,Dysgeusia,,0
AFINITOR,Dysgeusia,Dysgeusia,1
AFINITOR,Dysgeusia,,0
AFINITOR,Abdominal pain,include Gastrointestinal Abdominal,1
AFINITOR,Abdominal pain,,0
AFINITOR,Abdominal pain,pain,1
AFINITOR,Abdominal pain,Abdominal pain,1
AFINITOR,Abdominal pain,,0
AFINITOR,Abdominal pain,pain,1
AFINITOR,Abdominal pain,of include Gastrointestinal disorders,0
AFINITOR,Abdominal pain,Abdominal,1
AFINITOR,Abdominal pain,an incidence of,0
AFINITOR,Abdominal pain,with an incidence of include Gastrointestinal,0
AFINITOR,dry mouth,dry mouth,1
AFINITOR,hemorrhoids,,0
AFINITOR,hemorrhoids,hemorrhoids,1
AFINITOR,hemorrhoids,hemorrhoids,1
AFINITOR,dysphagia,dysphagia,1
AFINITOR,dysphagia,dysphagia,1
AFINITOR,dysphagia,,0
AFINITOR,dysphagia,General disorders and administration site conditions Weight decreased chest,0
AFINITOR,dysphagia,dysphagia,1
AFINITOR,dysphagia,,0
AFINITOR,dysphagia,dysphagia,1
AFINITOR,dysphagia,mouth dysphagia,1
AFINITOR,dysphagia,,0
AFINITOR,dysphagia,dysphagia,1
AFINITOR,Weight decreased,disorders and administration site Weight,1
AFINITOR,Weight decreased,Weight decreased,1
AFINITOR,chest pain,administration site conditions Weight chest,1
AFINITOR,chills,conditions Weight decreased chest chills,1
AFINITOR,chills,chills,1
AFINITOR,impaired wound healing,impaired wound healing,1
AFINITOR,impaired wound healing,,0
AFINITOR,impaired wound healing,conditions Weight decreased chest pain,0
AFINITOR,impaired wound healing,wound healing,1
AFINITOR,Pleural effusion,effusion,1
AFINITOR,pharyngolaryngeal pain,disorders,0
AFINITOR,pharyngolaryngeal pain,pharyngolaryngeal pain,1
AFINITOR,pharyngolaryngeal pain,healing Respiratory thoracic and mediastinal disorders,0
AFINITOR,pharyngolaryngeal pain,syndrome,0
AFINITOR,pharyngolaryngeal pain,pharyngolaryngeal,1
AFINITOR,rhinorrhea,effusion pharyngolaryngeal rhinorrhea,1
AFINITOR,rhinorrhea,tissue disorders,0
AFINITOR,rhinorrhea,and,0
AFINITOR,rhinorrhea,rhinorrhea,1
AFINITOR,Hand-foot syndrome,Skin and subcutaneous tissue Hand-foot syndrome,1
AFINITOR,Hand-foot syndrome,and subcutaneous tissue Hand-foot,1
AFINITOR,Hand-foot syndrome,disorder erythema,0
AFINITOR,Hand-foot syndrome,,0
AFINITOR,palmar-plantar erythrodysesthesia syndrome,nail disorder erythema onychoclasis skin,0
AFINITOR,palmar-plantar erythrodysesthesia syndrome,palmar-plantar,1
AFINITOR,palmar-plantar erythrodysesthesia syndrome,as,0
AFINITOR,palmar-plantar erythrodysesthesia syndrome,syndrome,1
AFINITOR,palmar-plantar erythrodysesthesia syndrome,syndrome,0
AFINITOR,palmar-plantar erythrodysesthesia syndrome,onychoclasis skin lesion acneiform dermatitis,0
AFINITOR,palmar-plantar erythrodysesthesia syndrome,palmar-plantar erythrodysesthesia syndrome,1
AFINITOR,palmar-plantar erythrodysesthesia syndrome,,0
AFINITOR,palmar-plantar erythrodysesthesia syndrome,reported palmar-plantar erythrodysesthesia,1
AFINITOR,palmar-plantar erythrodysesthesia syndrome,erythrodysesthesia syndrome,1
AFINITOR,nail disorder,as palmarplantar erythrodysesthesia nail disorder,1
AFINITOR,nail disorder,as palmarplantar,0
AFINITOR,nail disorder,nail disorder,1
AFINITOR,nail disorder,skin,0
AFINITOR,nail disorder,,0
AFINITOR,erythema,erythema,1
AFINITOR,erythema,nail erythema,1
AFINITOR,erythema,disorder,0
AFINITOR,erythema,palmarplantar erythrodysesthesia syndrome nail erythema,1
AFINITOR,erythema,erythema,1
AFINITOR,erythema,nail erythema,1
AFINITOR,erythema,palmarplantar erythrodysesthesia syndrome,0
AFINITOR,erythema,lesion acneiform dermatitis,0
AFINITOR,erythema,erythema,1
AFINITOR,erythema,palmarplantar erythrodysesthesia syndrome nail erythema,1
AFINITOR,skin lesion,disorder erythema skin lesion,1
AFINITOR,skin lesion,syndrome nail disorder erythema skin,1
AFINITOR,skin lesion,and nutrition,0
AFINITOR,skin lesion,and,0
AFINITOR,skin lesion,,0
AFINITOR,skin lesion,skin,1
AFINITOR,skin lesion,,0
AFINITOR,skin lesion,skin lesion,1
AFINITOR,acneiform dermatitis,disorder erythema onychoclasis skin acneiform dermatitis,1
AFINITOR,acneiform dermatitis,erythema onychoclasis skin acneiform,1
AFINITOR,angioedema,angioedema,1
AFINITOR,angioedema,Exacerbation of preexisting diabetes,0
AFINITOR,angioedema,angioedema,1
AFINITOR,new onset of diabetes mellitus,of diabetes mellitus,1
AFINITOR,new onset of diabetes mellitus,new onset of diabetes mellitus,1
AFINITOR,new onset of diabetes mellitus,new onset of diabetes mellitus,1
AFINITOR,new onset of diabetes mellitus,mellitus,1
AFINITOR,new onset of diabetes mellitus,disorders Exacerbation of,0
AFINITOR,new onset of diabetes mellitus,of preexisting diabetes new onset of diabetes mellitus,1
AFINITOR,Insomnia,diabetes mellitus Psychiatric Insomnia,1
AFINITOR,Dizziness,,0
AFINITOR,Dizziness,,0
AFINITOR,paresthesia,paresthesia,1
AFINITOR,paresthesia,disorders Insomnia Nervous system disorders Dizziness,0
AFINITOR,paresthesia,disorders Insomnia Nervous system disorders,0
AFINITOR,paresthesia,paresthesia,1
AFINITOR,paresthesia,disorders,0
AFINITOR,paresthesia,,0
AFINITOR,paresthesia,Insomnia Nervous system disorders,0
AFINITOR,paresthesia,system,0
AFINITOR,paresthesia,,0
AFINITOR,Eyelid edema,disorders Dizziness paresthesia Eye Eyelid edema,1
AFINITOR,Eyelid edema,paresthesia,0
AFINITOR,Eyelid edema,paresthesia Eye Eyelid,1
AFINITOR,Eyelid edema,paresthesia Eye Eyelid edema,1
AFINITOR,Eyelid edema,thrombosis,0
AFINITOR,Eyelid edema,,0
AFINITOR,Eyelid edema,Dizziness paresthesia Eye Eyelid,1
AFINITOR,conjunctivitis,,0
AFINITOR,conjunctivitis,Eye disorders Eyelid conjunctivitis,1
AFINITOR,conjunctivitis,Dizziness paresthesia,0
AFINITOR,conjunctivitis,conjunctivitis,1
AFINITOR,conjunctivitis,conjunctivitis,1
AFINITOR,conjunctivitis,Eyelid conjunctivitis,1
AFINITOR,conjunctivitis,conjunctivitis,1
AFINITOR,conjunctivitis,disorders Hypertension deep vein,0
AFINITOR,conjunctivitis,,0
AFINITOR,Hypertension,Renal and,0
AFINITOR,Hypertension,Hypertension,1
AFINITOR,Hypertension,,0
AFINITOR,deep vein thrombosis,vein thrombosis,1
AFINITOR,deep vein thrombosis,deep vein thrombosis,1
AFINITOR,deep vein thrombosis,Vascular disorders,0
AFINITOR,deep vein thrombosis,deep vein,1
AFINITOR,deep vein thrombosis,deep vein thrombosis,1
AFINITOR,deep vein thrombosis,Hypertension,0
AFINITOR,deep vein thrombosis,deep vein thrombosis,1
AFINITOR,deep vein thrombosis,edema conjunctivitis Vascular disorders deep vein thrombosis,1
AFINITOR,deep vein thrombosis,Hypertension,0
AFINITOR,deep vein thrombosis,,0
AFINITOR,Renal failure,,0
AFINITOR,Tachycardia,Cardiac,0
AFINITOR,Tachycardia,Renal failure Cardiac,0
AFINITOR,Tachycardia,,0
AFINITOR,Tachycardia,Cardiac Tachycardia,1
AFINITOR,Tachycardia,Tachycardia,1
AFINITOR,Tachycardia,connective tissue disorders Ja,0
AFINITOR,Tachycardia,Tachycardia,1
AFINITOR,congestive cardiac failure,Musculoskeletal and connective tissue disorders Jaw pain Hematologic,0
AFINITOR,congestive cardiac failure,pain Hematologic,0
AFINITOR,congestive cardiac failure,Cardiac disorders congestive cardiac,1
AFINITOR,Jaw pain,are,0
AFINITOR,Jaw pain,and connective tissue Jaw pain,1
AFINITOR,Jaw pain,failure,0
AFINITOR,Jaw pain,Jaw pain,1
AFINITOR,Jaw pain,and connective tissue Jaw,1
AFINITOR,Jaw pain,Jaw pain,1
AFINITOR,Jaw pain,connective tissue Jaw pain,1
AFINITOR,Jaw pain,,0
AFINITOR,Hemorrhage,Hemorrhage,1
AFINITOR,Hemorrhage,tissue disorders Jaw pain Hematologic disorders,0
AFINITOR,Hemorrhage,Hemorrhage,1
AFINITOR,Hemorrhage,Table Table Key,0
AFINITOR,anemia,anemia,1
AFINITOR,anemia,reaction reports anemia,1
AFINITOR,anemia,anemia,1
AFINITOR,leukopenia,reaction reports of,0
AFINITOR,leukopenia,Reflects corresponding adverse drug reaction reports,0
AFINITOR,leukopenia,leukopenia,1
AFINITOR,leukopenia,a Reflects corresponding adverse,0
AFINITOR,leukopenia,leukopenia,1
AFINITOR,leukopenia,leukopenia,1
AFINITOR,leukopenia,leukopenia,1
AFINITOR,leukopenia,reaction reports of,0
AFINITOR,leukopenia,,0
AFINITOR,leukopenia,leukopenia,1
AFINITOR,lymphopenia,neutropenia and,0
AFINITOR,lymphopenia,lymphopenia,1
AFINITOR,lymphopenia,reports of anemia lymphopenia,1
AFINITOR,lymphopenia,lymphopenia,1
AFINITOR,lymphopenia,adverse,0
AFINITOR,lymphopenia,lymphopenia,1
AFINITOR,lymphopenia,anemia lymphopenia,1
AFINITOR,lymphopenia,Reflects corresponding adverse drug reaction reports of,0
AFINITOR,lymphopenia,,0
AFINITOR,lymphopenia,which occurred at,0
AFINITOR,neutropenia,reaction reports of anemia leukopenia lymphopenia,0
AFINITOR,neutropenia,collectively pancytopenia which,0
AFINITOR,neutropenia,adverse drug reaction reports,0
AFINITOR,neutropenia,neutropenia,1
AFINITOR,neutropenia,neutropenia,1
AFINITOR,neutropenia,reports of anemia leukopenia neutropenia,1
AFINITOR,neutropenia,of anemia,0
AFINITOR,neutropenia,neutropenia,1
AFINITOR,neutropenia,,0
AFINITOR,thrombocytopenia,aramete,0
AFINITOR,thrombocytopenia,p,0
AFINITOR,thrombocytopenia,neutropenia thrombocytopenia,1
AFINITOR,pancytopenia,lower frequency,0
AFINITOR,pancytopenia,pancytopenia,1
AFINITOR,pancytopenia,thrombocytopenia collectively,0
AFINITOR,pancytopenia,mgda,0
AFINITOR,pancytopenia,pancytopenia,1
AFINITOR,pancytopenia,,0
AFINITOR,pancytopenia,lymphopenia neutropenia and thrombocytopenia pancytopenia,1
AFINITOR,Hemoglobin decreased,,0
AFINITOR,Hemoglobin decreased,Hemoglobin decreased,1
AFINITOR,Hemoglobin decreased,,0
AFINITOR,Hemoglobin decreased,Hemoglobin decreased,1
AFINITOR,Hemoglobin decreased,Hemoglobin decreased,1
AFINITOR,Hemoglobin decreased,Hemoglobin,1
AFINITOR,Hemoglobin decreased,,0
AFINITOR,Hemoglobin decreased,,0
AFINITOR,Lymphocytes decreased,Lymphocytes decreased,1
AFINITOR,Lymphocytes decreased,Lymphocytes decreased,1
AFINITOR,Lymphocytes decreased,,0
AFINITOR,Lymphocytes decreased,,0
AFINITOR,Lymphocytes decreased,Lymphocytes decreased,1
AFINITOR,Lymphocytes decreased,,0
AFINITOR,Lymphocytes decreased,Lymphocytes,1
AFINITOR,Lymphocytes decreased,,0
AFINITOR,Neutrophils decreased,Neutrophils decreased,1
AFINITOR,Neutrophils decreased,,0
AFINITOR,Neutrophils decreased,,0
AFINITOR,Neutrophils decreased,,0
AFINITOR,Neutrophils decreased,Neutrophils decreased,1
AFINITOR,Neutrophils decreased,,0
AFINITOR,Neutrophils decreased,Neutrophils,1
AFINITOR,Neutrophils decreased,,0
AFINITOR,Cholesterol increased,Cholesterol increased,1
AFINITOR,Triglycerides increased,,0
AFINITOR,Triglycerides increased,Triglycerides increased,1
AFINITOR,Triglycerides increased,,0
AFINITOR,Glucose increased,,0
AFINITOR,Glucose increased,,0
AFINITOR,Glucose increased,,0
AFINITOR,Glucose increased,,0
AFINITOR,Glucose increased,Glucose increased,1
AFINITOR,Glucose increased,increased,1
AFINITOR,Glucose increased,Glucose,1
AFINITOR,Glucose increased,increased,1
AFINITOR,Creatinine increased,,0
AFINITOR,Creatinine increased,Creatinine,1
AFINITOR,Creatinine increased,Creatinine increased,1
AFINITOR,Creatinine increased,,0
AFINITOR,Creatinine increased,,0
AFINITOR,Creatinine increased,,0
AFINITOR,Creatinine increased,increased,1
AFINITOR,Creatinine increased,Creatinine increased,1
AFINITOR,Phosphate decreased,Phosphate decreased,1
AFINITOR,Phosphate decreased,,0
AFINITOR,Phosphate decreased,Phosphate decreased,1
AFINITOR,Phosphate decreased,Phosphate decreased,1
AFINITOR,Phosphate decreased,Phosphate decreased,1
AFINITOR,Phosphate decreased,Phosphate decreased,1
AFINITOR,Bilirubin increased,Bilirubin,1
AFINITOR,Bilirubin increased,increased,1
AFINITOR,Bilirubin increased,,0
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,for AFINITOR incidence stomatitis,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,,0
AFINITOR,stomatitis,incidence stomatitis,1
AFINITOR,stomatitis,,0
AFINITOR,stomatitis,incidence were,0
AFINITOR,amenorrhea,amenorrhea,1
AFINITOR,amenorrhea,hypercholesterolemia hypertrigly,0
AFINITOR,amenorrhea,stomatitis amenorrhea,1
AFINITOR,amenorrhea,hypercholesterolemia,0
AFINITOR,hypercholesterolemia,common laboratory abnormalities incidence hypercholesterolemia,1
AFINITOR,hypercholesterolemia,,0
AFINITOR,hypercholesterolemia,abnormalities incidence were,0
AFINITOR,hypertriglyceridemia,laboratory abnormalities incidence were hypertriglyceridemia,1
AFINITOR,hypertriglyceridemia,,0
AFINITOR,hypertriglyceridemia,common laboratory abnormalities incidence were hypercholesterolemia,0
AFINITOR,hypertriglyceridemia,abnormality,0
AFINITOR,hypertriglyceridemia,hypertriglyceridemia,1
AFINITOR,hypertriglyceridemia,hypertriglyceridemia,1
AFINITOR,hypertriglyceridemia,common,0
AFINITOR,hypertriglyceridemia,anemia The most common Grade,0
AFINITOR,hypertriglyceridemia,The most,0
AFINITOR,anemia,laboratory abnormalities incidence,0
AFINITOR,anemia,was hypophosphatemia,0
AFINITOR,anemia,was hypophosphatemia,0
AFINITOR,anemia,anemia,1
AFINITOR,anemia,,0
AFINITOR,anemia,incidence was hypophosphatemia The,0
AFINITOR,hypophosphatemia,Grade laboratory abnormality,0
AFINITOR,hypophosphatemia,hypophosphatemia,1
AFINITOR,hypophosphatemia,hypophosphatemia,1
AFINITOR,hypophosphatemia,AFINITOR,0
AFINITOR,hypersensitivity,hypersensitivity,1
AFINITOR,hypersensitivity,arm hypersensitivity,1
AFINITOR,hypersensitivity,hypersensitivity,1
AFINITOR,hypersensitivity,hypersensitivity,1
AFINITOR,angioedema,angioedema,1
AFINITOR,bronchospasm,convulsion and hypophosphatemia Dose adjustments interruptions or reductions,0
AFINITOR,bronchospasm,,0
AFINITOR,bronchospasm,to,0
AFINITOR,bronchospasm,the AFINITOR arm were bronchospasm,1
AFINITOR,bronchospasm,due,0
AFINITOR,bronchospasm,discontinuation in the AFINITOR arm,0
AFINITOR,bronchospasm,were bronchospasm,1
AFINITOR,bronchospasm,bronchospasm,1
AFINITOR,bronchospasm,bronchospasm,1
AFINITOR,bronchospasm,AFINITOR arm were hypersensitivityangioedema,0
AFINITOR,convulsion,convulsion,1
AFINITOR,convulsion,the,0
AFINITOR,convulsion,,0
AFINITOR,convulsion,reactions,0
AFINITOR,hypophosphatemia,in the AFINITOR arm were hypersensitivityangioedemabronchospasm convulsion,0
AFINITOR,hypophosphatemia,,0
AFINITOR,hypophosphatemia,in the AFINITOR arm were hypersensitivityangioedemabronchospasm convulsion and,0
AFINITOR,hypophosphatemia,,0
AFINITOR,hypophosphatemia,hypophosphatemia,1
AFINITOR,hypophosphatemia,hypophosphatemia,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,,0
AFINITOR,stomatitis,common,0
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,AFINITOR dose adjustment stomatitis,1
AFINITOR,stomatitis,of adverse,0
AFINITOR,stomatitis,AFINITOR dose adjustment stomatitis,1
AFINITOR,stomatitis,incidence of for p,0
AFINITOR,stomatitis,Angiomyolipoma,0
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,according to CTCAE Version,0
AFINITOR,stomatitis,CTCAE Version a stomatitis,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,CTCAE Version a stomatitis,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,aphthous stomatitis,,0
AFINITOR,aphthous stomatitis,Includes aphthous,1
AFINITOR,aphthous stomatitis,aphthous,1
AFINITOR,aphthous stomatitis,glossodynia AFINITOR,0
AFINITOR,aphthous stomatitis,aphthous stomatitis,1
AFINITOR,aphthous stomatitis,Version a Includes aphthous stomatitis,1
AFINITOR,aphthous stomatitis,,0
AFINITOR,mouth ulceration,Version a Includes stomatitis aphthous stomatitis,0
AFINITOR,mouth ulceration,,0
AFINITOR,mouth ulceration,stomatitis aphthous stomatitis,0
AFINITOR,mouth ulceration,mouth ulceration,1
AFINITOR,mouth ulceration,Includes stomatitis aphthous,0
AFINITOR,mouth ulceration,stomatitis aphthous mouth,1
AFINITOR,mouth ulceration,ulceration,1
AFINITOR,mouth ulceration,mouth ulceration,1
AFINITOR,mouth ulceration,mouth ulceration,1
AFINITOR,mouth ulceration,aphthous mouth ulceration,1
AFINITOR,gingival pain,Includes,0
AFINITOR,gingival pain,pain,1
AFINITOR,glossodynia,ulceration,0
AFINITOR,glossodynia,a Includes stomatitis,0
AFINITOR,glossodynia,glossodynia,1
AFINITOR,glossodynia,pain glossitis glossodynia,1
AFINITOR,glossodynia,glossodynia,1
AFINITOR,glossodynia,glossitis glossodynia,1
AFINITOR,glossodynia,glossodynia,1
AFINITOR,glossodynia,glossodynia,1
AFINITOR,glossodynia,pain glossitis glossodynia,1
AFINITOR,glossodynia,glossodynia,1
AFINITOR,Stomatitis,Stomatitis a,1
AFINITOR,Stomatitis,Stomatitis a,1
AFINITOR,Stomatitis,Stomatitis a,1
AFINITOR,Stomatitis,,0
AFINITOR,Stomatitis,Stomatitis a,1
AFINITOR,Stomatitis,a,0
AFINITOR,Stomatitis,Stomatitis a,1
AFINITOR,Stomatitis,Stomatitis a,1
AFINITOR,Stomatitis,Stomatitis a,1
AFINITOR,Stomatitis,,0
AFINITOR,Vomiting,Vomiting,1
AFINITOR,Vomiting,,0
AFINITOR,Vomiting,Vomiting,1
AFINITOR,Vomiting,,0
AFINITOR,Vomiting,,0
AFINITOR,Diarrhea,Diarrhea,1
AFINITOR,Diarrhea,,0
AFINITOR,Diarrhea,,0
AFINITOR,Peripheral edema,Peripheral edema,1
AFINITOR,Peripheral edema,Peripheral edema,1
AFINITOR,Peripheral edema,,0
AFINITOR,Peripheral edema,Peripheral,1
AFINITOR,Peripheral edema,Peripheral,1
AFINITOR,Peripheral edema,,0
AFINITOR,Upper respiratory tract infection,,0
AFINITOR,Upper respiratory tract infection,,0
AFINITOR,Upper respiratory tract infection,,0
AFINITOR,Upper respiratory tract infection,,0
AFINITOR,Upper respiratory tract infection,,0
AFINITOR,Upper respiratory tract infection,,0
AFINITOR,Upper respiratory tract infection,Upper respiratory tract infection,1
AFINITOR,Upper respiratory tract infection,Upper respiratory tract,1
AFINITOR,Arthralgia,Arthralgia,1
AFINITOR,Arthralgia,Arthralgia,1
AFINITOR,Arthralgia,,0
AFINITOR,Arthralgia,,0
AFINITOR,Acne,Acne,1
AFINITOR,Acne,,0
AFINITOR,Acne,,0
AFINITOR,Acne,Acne,1
AFINITOR,Acne,,0
AFINITOR,Acne,,0
AFINITOR,Acne,,0
AFINITOR,Amenorrhea,Amenorrhea occurred in of AFINITORtreated females,1
AFINITOR,Amenorrhea,,0
AFINITOR,Amenorrhea,AFINITORtreated females of and of of females,0
AFINITOR,Amenorrhea,,0
AFINITOR,Amenorrhea,Amenorrhea occurred in,1
AFINITOR,Amenorrhea,Amenorrhea occurred in of,1
AFINITOR,Amenorrhea,Amenorrhea occurred,1
AFINITOR,Amenorrhea,,0
AFINITOR,menorrhagia,female reproductive system menorrhagia menstrual irregularities and,1
AFINITOR,vaginal hemorrhage,hemorrhage The following additional,1
AFINITOR,vaginal hemorrhage,vaginal hemorrhage The following additional,1
AFINITOR,vaginal hemorrhage,hemorrhage The following additional,1
AFINITOR,vaginal hemorrhage,system were menorrhagia menstrual irregularities and,0
AFINITOR,vaginal hemorrhage,vaginal,1
AFINITOR,vaginal hemorrhage,were menorrhagia menstrual irregularities vaginal,1
AFINITOR,vaginal hemorrhage,were menorrhagia menstrual irregularities vaginal hemorrhage The following additional,1
AFINITOR,vaginal hemorrhage,The following additional adverse,0
AFINITOR,vaginal hemorrhage,vaginal hemorrhage The following additional,1
AFINITOR,vaginal hemorrhage,vaginal hemorrhage The following additional,1
AFINITOR,epistaxis,,0
AFINITOR,epistaxis,in less than,0
AFINITOR,epistaxis,epistaxis decreased appetite otitis,1
AFINITOR,epistaxis,treated,0
AFINITOR,epistaxis,depression abnormal taste increased b,0
AFINITOR,epistaxis,epistaxis decreased appetite otitis,1
AFINITOR,epistaxis,of AFINITOR treated epistaxis decreased appetite otitis,1
AFINITOR,decreased appetite,decreased appetite otitis media depression,1
AFINITOR,decreased appetite,patients decreased appetite otitis media depression,1
AFINITOR,decreased appetite,decreased appetite otitis media depression,1
AFINITOR,otitis media,otitis,1
AFINITOR,otitis media,media depression abnormal taste,1
AFINITOR,otitis media,decreased otitis,1
AFINITOR,otitis media,of AFINITOR treated patients epistaxis decreased appetite,0
AFINITOR,depression,otitis depression abnormal taste increased,1
AFINITOR,depression,epistaxis,0
AFINITOR,depression,blood fo,0
AFINITOR,depression,blood luteinizing hormone LH levels increased blood,0
AFINITOR,abnormal taste,patients epistaxis decreased appetite otitis media,0
AFINITOR,abnormal taste,otitis,0
AFINITOR,abnormal taste,otitis media abnormal taste increased blood luteinizing,1
AFINITOR,abnormal taste,decreased appetite otitis media abnormal taste increased blood luteinizing,1
AFINITOR,abnormal taste,abnormal taste increased blood luteinizing,1
AFINITOR,abnormal taste,,0
AFINITOR,abnormal taste,hormone,0
AFINITOR,abnormal taste,,0
AFINITOR,abnormal taste,decreased appetite otitis media abnormal taste increased blood luteinizing,1
AFINITOR,abnormal taste,decreased appetite otitis media,0
AFINITOR,hypersensitivity,hypersensitivity ovarian cyst pneumonitis,1
AFINITOR,hypersensitivity,hypersensitivity ovarian cyst pneumonitis,1
AFINITOR,hypersensitivity,stimulating,0
AFINITOR,hypersensitivity,FSH hypersensitivity ovarian cyst pneumonitis,1
AFINITOR,hypersensitivity,blood follicle stimulating hormone FSH levels,0
AFINITOR,hypersensitivity,Abnorma,0
AFINITOR,hypersensitivity,hormone LH levels increased blood follicle stimulating,0
AFINITOR,hypersensitivity,cyst pneumonitis and angioedema Table Key,0
AFINITOR,hypersensitivity,hormone,0
AFINITOR,ovarian cyst,FSH levels ovarian,1
AFINITOR,ovarian cyst,,0
AFINITOR,ovarian cyst,FSH levels,0
AFINITOR,ovarian cyst,cyst pneumonitis and angioedema,1
AFINITOR,pneumonitis,follicle stimulating hormone,0
AFINITOR,pneumonitis,angioedema Table Key,0
AFINITOR,pneumonitis,hypersensitivity ovarian pneumonitis and angioedema Table,1
AFINITOR,pneumonitis,pneumonitis and angioedema Table,1
AFINITOR,angioedema,pneumonitis angioedema Table Key Laboratory,1
AFINITOR,angioedema,angioedema Table Key Laboratory,1
AFINITOR,angioedema,hypersensitivity ovarian cyst pneumonitis angioedema Table Key Laboratory,1
AFINITOR,angioedema,,0
AFINITOR,angioedema,angioedema Table Key Laboratory,1
AFINITOR,angioedema,angioedema Table Key Laboratory,1
AFINITOR,angioedema,pneumonitis,0
AFINITOR,angioedema,angioedema Table Key Laboratory,1
AFINITOR,angioedema,angioedema Table Key Laboratory,1
AFINITOR,Leucopenia,,0
AFINITOR,Leucopenia,Leucopenia,1
AFINITOR,Leucopenia,,0
AFINITOR,Neutropenia,Neutropenia,1
AFINITOR,Neutropenia,,0
AFINITOR,Neutropenia,,0
AFINITOR,Neutropenia,Neutropenia,1
AFINITOR,Neutropenia,,0
AFINITOR,Neutropenia,Neutropenia,1
AFINITOR,Neutropenia,,0
AFINITOR,Neutropenia,Neutropenia,1
AFINITOR,Neutropenia,Neutropenia,1
AFINITOR,Neutropenia,Neutropenia,1
AFINITOR,Lymphopenia,,0
AFINITOR,Lymphopenia,Lymphopenia,1
AFINITOR,Lymphopenia,,0
AFINITOR,Lymphopenia,,0
AFINITOR,Lymphopenia,,0
AFINITOR,Lymphopenia,,0
AFINITOR,Thrombocytopenia,Thrombocytopenia,1
AFINITOR,Thrombocytopenia,,0
AFINITOR,Thrombocytopenia,Thrombocytopenia,1
AFINITOR,Hypertriglyceridemia,,0
AFINITOR,Hypertriglyceridemia,,0
AFINITOR,Hypertriglyceridemia,,0
AFINITOR,Hypertriglyceridemia,Hypertriglyceridemia,1
AFINITOR,Hypertriglyceridemia,,0
AFINITOR,Hypertriglyceridemia,,0
AFINITOR,Hypertriglyceridemia,,0
AFINITOR,Hypertriglyceridemia,,0
AFINITOR,Hypertriglyceridemia,Hypertriglyceridemia,1
AFINITOR,Hypophosphatemia,,0
AFINITOR,Hypophosphatemia,Hypophosphatemia,1
AFINITOR,Hypophosphatemia,,0
AFINITOR,Alkaline phosphatase increased,,0
AFINITOR,Alkaline phosphatase increased,Alkaline,1
AFINITOR,Alkaline phosphatase increased,Alkaline,1
AFINITOR,Alkaline phosphatase increased,Alkaline phosphatase,1
AFINITOR,Alkaline phosphatase increased,,0
AFINITOR,Alkaline phosphatase increased,,0
AFINITOR,Alkaline phosphatase increased,,0
AFINITOR,Elevated aspartate transaminase,,0
AFINITOR,Elevated aspartate transaminase,Elevated aspartate transaminase AST,1
AFINITOR,Elevated aspartate transaminase,,0
AFINITOR,Elevated aspartate transaminase,transaminase AST,1
AFINITOR,Elevated aspartate transaminase,,0
AFINITOR,Elevated aspartate transaminase,Elevated aspartate transaminase AST,1
AFINITOR,Elevated aspartate transaminase,,0
AFINITOR,Elevated aspartate transaminase,,0
AFINITOR,Fasting hyperglycemia,,0
AFINITOR,Fasting hyperglycemia,,0
AFINITOR,Fasting hyperglycemia,,0
AFINITOR,Fasting hyperglycemia,,0
AFINITOR,Fasting hyperglycemia,,0
AFINITOR,Fasting hyperglycemia,,0
AFINITOR,Fasting hyperglycemia,Fasting,1
AFINITOR,Fasting hyperglycemia,Fasting,1
AFINITOR,stomatitis,most common Grade adverse reactions incidence were,0
AFINITOR,respiratory tract infection,,0
AFINITOR,respiratory tract infection,for,0
AFINITOR,respiratory tract infection,reactions reported,0
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,aggression agitation and amenorrhea The,0
AFINITOR,stomatitis,,0
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,most common,0
AFINITOR,stomatitis,stomatitis,1
AFINITOR,pyrexia,adverse reactions incidence were stomatitis,0
AFINITOR,pyrexia,laboratory,0
AFINITOR,pyrexia,laboratory,0
AFINITOR,pyrexia,reactions incidence were,0
AFINITOR,pyrexia,,0
AFINITOR,pyrexia,adverse reactions incidence were pyrexia,1
AFINITOR,pyrexia,pyrexia,1
AFINITOR,pyrexia,,0
AFINITOR,pyrexia,The most,0
AFINITOR,pneumonia,pyrexia,0
AFINITOR,pneumonia,pneumonia,1
AFINITOR,gastroenteritis,gastroenteritis,1
AFINITOR,gastroenteritis,pneumonia,0
AFINITOR,gastroenteritis,gastroenteritis,1
AFINITOR,gastroenteritis,pyrexia gastroenteritis,1
AFINITOR,gastroenteritis,were stomatitis pyrexia gastroenteritis,1
AFINITOR,gastroenteritis,common Grade adverse reactions incidence were stomatitis,0
AFINITOR,gastroenteritis,stomatitis,0
AFINITOR,gastroenteritis,,0
AFINITOR,gastroenteritis,gastroenteritis,1
AFINITOR,aggression,common key laboratory abnormalities incidence,0
AFINITOR,aggression,aggression,1
AFINITOR,aggression,were stomatitis pyrexia pneumonia gastroenteritis,0
AFINITOR,aggression,reactions incidence were stomatitis pyrexia pneumonia gastroenteritis,0
AFINITOR,aggression,adverse reactions incidence were stomatitis,0
AFINITOR,aggression,pyrexia pneumonia,0
AFINITOR,aggression,aggression,1
AFINITOR,aggression,aggression,1
AFINITOR,agitation,pneumonia gastroenteritis agitation,1
AFINITOR,agitation,agitation,1
AFINITOR,agitation,agitation,1
AFINITOR,amenorrhea,pyrexia pneumonia gastroenteritis aggression agitation,0
AFINITOR,amenorrhea,pneumonia gastroenteritis aggression agitation amenorrhea,1
AFINITOR,amenorrhea,,0
AFINITOR,amenorrhea,amenorrhea,1
AFINITOR,hypercholesterolemia,partial thromboplastin time The most,0
AFINITOR,hypercholesterolemia,elevated partial thromboplastin,0
AFINITOR,elevated partial thromboplastin time,abnormality incidence was neutropenia There were,0
AFINITOR,elevated partial thromboplastin time,,0
AFINITOR,elevated partial thromboplastin time,hypercholesterolemia and,0
AFINITOR,elevated partial thromboplastin time,incidence were hypercholesterolemia elevated,1
AFINITOR,elevated partial thromboplastin time,incidence were hypercholesterolemia elevated partial thromboplastin time,1
AFINITOR,elevated partial thromboplastin time,The most common key laboratory abnormalities incidence were hypercholesterolemia and,0
AFINITOR,elevated partial thromboplastin time,thromboplastin time,1
AFINITOR,elevated partial thromboplastin time,abnormalities incidence were hypercholesterolemia elevated partial,1
AFINITOR,elevated partial thromboplastin time,,0
AFINITOR,stomatitis,adjustment stomatitis,1
AFINITOR,stomatitis,incidence of adverse reactions reported with an incidence,0
AFINITOR,stomatitis,to AFINITOR dose adjustment stomatitis,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,The most,0
AFINITOR,stomatitis,AFINITOR dose adjustment stomatitis,1
AFINITOR,stomatitis,for,0
AFINITOR,stomatitis,,0
AFINITOR,stomatitis,incidence of adverse reactions reported,0
AFINITOR,stomatitis,stomatitis,1
AFINITOR,mouth ulceration,b Includes respiratory tract infection upper respiratory,0
AFINITOR,mouth ulceration,ulceration,1
AFINITOR,mouth ulceration,i,0
AFINITOR,mouth ulceration,a mouth,1
AFINITOR,stomatitis,SEGA in Study Grading according to CTCAE Version a Includes,0
AFINITOR,lip ulceration,stomatitis lip,1
AFINITOR,respiratory tract infection,respiratory tract,1
AFINITOR,respiratory tract infection,lip,0
AFINITOR,respiratory tract infection,respiratory tract infection and respiratory,0
AFINITOR,respiratory tract infection,ulceration b respiratory,1
AFINITOR,respiratory tract infection,Includes,0
AFINITOR,upper respiratory tract infection,tract upper respiratory tract infection,1
AFINITOR,upper respiratory tract infection,tract infection,1
AFINITOR,upper respiratory tract infection,Includes gastroenteritis gastroenteritis viral and gas,0
AFINITOR,upper respiratory tract infection,,0
AFINITOR,upper respiratory tract infection,tract infection,0
AFINITOR,upper respiratory tract infection,and respiratory tract infection viral c Includes gastroenteritis gastroenteritis,0
AFINITOR,upper respiratory tract infection,Includes respiratory tract infection,0
AFINITOR,upper respiratory tract infection,respiratory tract upper respiratory tract infection,1
AFINITOR,upper respiratory tract infection,Includes respiratory tract,0
AFINITOR,upper respiratory tract infection,,0
AFINITOR,respiratory tract infection viral,upper respiratory tract infection respiratory tract,1
AFINITOR,respiratory tract infection viral,,0
AFINITOR,respiratory tract infection viral,tract infection respiratory tract infection viral,1
AFINITOR,respiratory tract infection viral,infection viral,1
AFINITOR,respiratory tract infection viral,b,0
AFINITOR,respiratory tract infection viral,viral,1
AFINITOR,gastroenteritis viral,Includes gastroenteritis viral,1
AFINITOR,gastroenteritis viral,gastroenteritis viral,1
AFINITOR,gastroenteritis viral,infection viral c Includes gastroenteritis viral,1
AFINITOR,gastroenteritis viral,viral,1
AFINITOR,gastroenteritis viral,viral,1
AFINITOR,gastroenteritis viral,tract infection viral,0
AFINITOR,gastrointestinal infection,,0
AFINITOR,gastrointestinal infection,infection viral c Includes,0
AFINITOR,gastrointestinal infection,gastrointestinal,1
AFINITOR,gastrointestinal infection,c Includes,0
AFINITOR,gastrointestinal infection,viral gastrointestinal,1
AFINITOR,gastrointestinal infection,,0
AFINITOR,gastrointestinal infection,abnormal,0
AFINITOR,agitation,and,0
AFINITOR,anxiety,gastroenteritis viral and gastrointestinal infection,0
AFINITOR,anxiety,,0
AFINITOR,anxiety,Includes anxiety,1
AFINITOR,anxiety,anxiety,1
AFINITOR,anxiety,,0
AFINITOR,aggression,anxiety panic aggression,1
AFINITOR,abnormal behavior,generalized,0
AFINITOR,abnormal behavior,,0
AFINITOR,abnormal behavior,panic attack abnormal behavior,1
AFINITOR,abnormal behavior,abnormal behavior,1
AFINITOR,abnormal behavior,,0
AFINITOR,abnormal behavior,attack abnormal,1
AFINITOR,abnormal behavior,abnormal behavior,1
AFINITOR,abnormal behavior,Includes agitation,0
AFINITOR,abnormal behavior,abnormal behavior,1
AFINITOR,abnormal behavior,d Includes agitation anxiety panic,0
AFINITOR,obsessive compulsive disorder,Includes rash rash generalized rash,0
AFINITOR,rash,rash,0
AFINITOR,rash,allergic and urtica,0
AFINITOR,rash generalized,disorder e Includes rash,1
AFINITOR,rash generalized,urticaria,0
AFINITOR,rash generalized,allergic and,0
AFINITOR,rash macular,rash,1
AFINITOR,rash macular,rash rash macular,1
AFINITOR,rash macular,maculopapular,0
AFINITOR,rash macular,Includes rash rash rash,1
AFINITOR,rash macular,rash rash macular,1
AFINITOR,rash macular,and obsessive compulsive disorder e Includes rash,0
AFINITOR,rash macular,abnormal behavior and obsessive compulsive disorder e Includes rash,0
AFINITOR,rash macular,Includes rash rash rash,1
AFINITOR,rash maculo-papular,rash maculo-papular,1
AFINITOR,rash papular,generalized rash macular rash rash papular,1
AFINITOR,rash papular,rash papular,1
AFINITOR,rash papular,generalized rash macular rash rash papular,1
AFINITOR,rash papular,rash,1
AFINITOR,rash papular,rash papular,1
AFINITOR,rash papular,allergic and urticaria AFINITOR N Placebo,0
AFINITOR,rash papular,,0
AFINITOR,rash papular,Placebo N,0
AFINITOR,rash papular,,0
AFINITOR,rash papular,rash papular,1
AFINITOR,dermatitis allergic,allergic,1
AFINITOR,dermatitis allergic,allergic,1
AFINITOR,dermatitis allergic,dermatitis allergic,1
AFINITOR,dermatitis allergic,,0
AFINITOR,dermatitis allergic,allergic,1
AFINITOR,dermatitis allergic,macular rash maculopapular rash dermatitis allergic,1
AFINITOR,dermatitis allergic,Includes rash rash generalized rash,0
AFINITOR,dermatitis allergic,papular,0
AFINITOR,dermatitis allergic,rash dermatitis allergic,1
AFINITOR,urticaria,urticaria,1
AFINITOR,urticaria,All,0
AFINITOR,urticaria,urticaria,1
AFINITOR,urticaria,rash rash generalized,0
AFINITOR,urticaria,,0
AFINITOR,urticaria,maculopapular rash papular dermatitis allergic and,0
AFINITOR,urticaria,grades,0
AFINITOR,Stomatitis,,0
AFINITOR,Stomatitis,,0
AFINITOR,Stomatitis,Stomatitis a,1
AFINITOR,Stomatitis,,0
AFINITOR,Stomatitis,Stomatitis a,1
AFINITOR,Stomatitis,,0
AFINITOR,Stomatitis,,0
AFINITOR,Stomatitis,Stomatitis a,1
AFINITOR,Stomatitis,Stomatitis a,1
AFINITOR,Vomiting,Vomiting,1
AFINITOR,Vomiting,,0
AFINITOR,Vomiting,Vomiting,1
AFINITOR,Vomiting,Vomiting,1
AFINITOR,Vomiting,Vomiting,1
AFINITOR,Vomiting,,0
AFINITOR,Vomiting,Vomiting,1
AFINITOR,Diarrhea,Diarrhea,1
AFINITOR,Constipation,,0
AFINITOR,Constipation,Constipation,1
AFINITOR,Constipation,Constipation,1
AFINITOR,Constipation,Constipation,1
AFINITOR,Respiratory tract infection,,0
AFINITOR,Respiratory tract infection,,0
AFINITOR,Respiratory tract infection,Respiratory tract infection b,1
AFINITOR,Respiratory tract infection,,0
AFINITOR,Respiratory tract infection,,0
AFINITOR,Respiratory tract infection,,0
AFINITOR,Respiratory tract infection,Respiratory,1
AFINITOR,Gastroenteritis,,0
AFINITOR,Gastroenteritis,Gastroenteritis c,1
AFINITOR,Gastroenteritis,,0
AFINITOR,Pyrexia,,0
AFINITOR,Pyrexia,Pyrexia,1
AFINITOR,Pyrexia,,0
AFINITOR,Pyrexia,,0
AFINITOR,Pyrexia,,0
AFINITOR,Pyrexia,,0
AFINITOR,Pyrexia,Pyrexia,1
AFINITOR,Pyrexia,Pyrexia,1
AFINITOR,Pyrexia,Pyrexia,1
AFINITOR,Pyrexia,Pyrexia,1
AFINITOR,Fatigue,Fatigue,1
AFINITOR,Fatigue,,0
AFINITOR,Fatigue,,0
AFINITOR,Fatigue,Fatigue,1
AFINITOR,Fatigue,Fatigue,1
AFINITOR,Fatigue,Fatigue,1
AFINITOR,Fatigue,Fatigue,1
AFINITOR,Fatigue,,0
AFINITOR,Anxiety,Anxiety aggression or other behavioral disturbance,1
AFINITOR,Anxiety,Anxiety aggression,1
AFINITOR,Anxiety,Anxiety aggression or other behavioral disturbance,1
AFINITOR,Anxiety,,0
AFINITOR,Anxiety,Anxiety aggression or other behavioral,1
AFINITOR,aggression,or other behavioral disturbance,0
AFINITOR,aggression,aggression or other behavioral,1
AFINITOR,aggression,Anxiety,0
AFINITOR,aggression,aggression,1
AFINITOR,aggression,Anxiety aggression or other,1
AFINITOR,aggression,aggression or other behavioral,1
AFINITOR,aggression,aggression,1
AFINITOR,aggression,Anxiety aggression or other,1
AFINITOR,behavioral disturbance,,0
AFINITOR,behavioral disturbance,Anxiety aggression or behavioral,1
AFINITOR,behavioral disturbance,or behavioral disturbance d,1
AFINITOR,Rash,Rash e,1
AFINITOR,Rash,,0
AFINITOR,Acne,,0
AFINITOR,Acne,,0
AFINITOR,Acne,,0
AFINITOR,Amenorrhea,,0
AFINITOR,Amenorrhea,,0
AFINITOR,Amenorrhea,Amenorrhea occurred in of AFINITORtreated females,1
AFINITOR,Amenorrhea,Amenorrhea occurred in of AFINITORtreated,1
AFINITOR,Amenorrhea,Amenorrhea occurred in of,1
AFINITOR,menstrual abnormalities,of AFINITORtreated females the menstrual abnormalities were reported dysmenorrhea,1
AFINITOR,menstrual abnormalities,females in the placebo group For this same group of,0
AFINITOR,menstrual abnormalities,metrorrhagia and,0
AFINITOR,dysmenorrhea,following menstrual abnormalities were dysmenorrhea menorrhagia metrorrhagia and,1
AFINITOR,dysmenorrhea,dysmenorrhea menorrhagia metrorrhagia and,1
AFINITOR,dysmenorrhea,,0
AFINITOR,dysmenorrhea,,0
AFINITOR,dysmenorrhea,,0
AFINITOR,dysmenorrhea,and unspecified,0
AFINITOR,dysmenorrhea,,0
AFINITOR,menorrhagia,menstrual abnormalities,0
AFINITOR,menorrhagia,menstrual abnormalities were reported menorrhagia metrorrhagia and unspecified,1
AFINITOR,menorrhagia,menorrhagia metrorrhagia and unspecified,1
AFINITOR,menorrhagia,,0
AFINITOR,menorrhagia,and unspecified menstrual irregularity The following additional,0
AFINITOR,metrorrhagia,menorrhagia,0
AFINITOR,metrorrhagia,and unspecified menstrual irregularity The following additional adverse reactions o,0
AFINITOR,metrorrhagia,unspecified menstrual irregularity The following,0
AFINITOR,metrorrhagia,,0
AFINITOR,metrorrhagia,metrorrhagia and unspecified menstrual,1
AFINITOR,metrorrhagia,metrorrhagia and unspecified menstrual,1
AFINITOR,unspecified menstrual irregularity,metrorrhagia,0
AFINITOR,unspecified menstrual irregularity,reported dysmenorrhea menorrhagia metrorrhagia unspecified menstrual,1
AFINITOR,unspecified menstrual irregularity,adverse,0
AFINITOR,nausea,nausea pain in extremity,1
AFINITOR,nausea,nausea pain in extremity,1
AFINITOR,nausea,than of AFINITORtreated nausea pain in extremity,1
AFINITOR,nausea,adverse,0
AFINITOR,nausea,less than of AFINITORtreated,0
AFINITOR,nausea,less than of,0
AFINITOR,pain in extremity,pain in,1
AFINITOR,pain in extremity,extremity insomnia pneumonia epistaxis,1
AFINITOR,pain in extremity,patients pain,1
AFINITOR,pain in extremity,insomnia,0
AFINITOR,pain in extremity,of AFINITORtreated patients pain in extremity insomnia pneumonia epistaxis,1
AFINITOR,pain in extremity,extremity insomnia pneumonia epistaxis,1
AFINITOR,pain in extremity,than of AFINITORtreated patients pain in extremity insomnia pneumonia epistaxis,1
AFINITOR,pain in extremity,patients pain in extremity insomnia pneumonia epistaxis,1
AFINITOR,pain in extremity,insomnia pneumonia epistaxis hypersensitivity increased blood,0
AFINITOR,pain in extremity,blood luteini,0
AFINITOR,insomnia,,0
AFINITOR,insomnia,than,0
AFINITOR,insomnia,insomnia pneumonia epistaxis hypersensitivity,1
AFINITOR,insomnia,,0
AFINITOR,insomnia,AFINITORtreated patients nausea,0
AFINITOR,pneumonia,pneumonia epistaxis hypersensitivity increased,1
AFINITOR,pneumonia,pneumonia epistaxis hypersensitivity increased,1
AFINITOR,pneumonia,LH,0
AFINITOR,pneumonia,hypersensitivity,0
AFINITOR,pneumonia,pneumonia epistaxis hypersensitivity increased,1
AFINITOR,pneumonia,pneumonia epistaxis hypersensitivity increased,1
AFINITOR,pneumonia,pneumonia epistaxis hypersensitivity increased,1
AFINITOR,pneumonia,,0
AFINITOR,pneumonia,of AFINITORtreated patients nausea pain in,0
AFINITOR,epistaxis,nausea,0
AFINITOR,epistaxis,blood,0
AFINITOR,epistaxis,extremity insomnia,0
AFINITOR,epistaxis,hormone LH levels,0
AFINITOR,epistaxis,LH levels,0
AFINITOR,epistaxis,in extremity insomnia epistaxis hypersensitivity increased blood,1
AFINITOR,hypersensitivity,extremity insomnia pneumonia,0
AFINITOR,hypersensitivity,,0
AFINITOR,hypersensitivity,hypersensitivity increased blood luteinizing,1
AFINITOR,hypersensitivity,patients,0
AFINITOR,hypersensitivity,hypersensitivity increased blood luteinizing,1
AFINITOR,pneumonitis,Table Key Laboratory Abnormalities Reported in AFINITORtreated Patients with,0
AFINITOR,pneumonitis,levels,0
AFINITOR,pneumonitis,pneumonitis Table Key Laboratory,1
AFINITOR,pneumonitis,pneumonitis Table Key Laboratory,1
AFINITOR,Elevated partial thromboplastin time,Elevated partial thromboplastin time,1
AFINITOR,Elevated partial thromboplastin time,,0
AFINITOR,Elevated partial thromboplastin time,Elevated partial thromboplastin time,1
AFINITOR,Neutropenia,,0
AFINITOR,Neutropenia,,0
AFINITOR,Neutropenia,Neutropenia,1
AFINITOR,Neutropenia,Neutropenia,1
AFINITOR,Neutropenia,,0
AFINITOR,Neutropenia,Neutropenia,1
AFINITOR,Neutropenia,Neutropenia,1
AFINITOR,Anemia,Anemia,1
AFINITOR,Anemia,Anemia,1
AFINITOR,Anemia,Anemia,1
AFINITOR,Anemia,Anemia,1
AFINITOR,Anemia,,0
AFINITOR,Anemia,Anemia,1
AFINITOR,Anemia,Anemia,1
AFINITOR,Hypercholesterolemia,,0
AFINITOR,Elevated aspartate transaminase,,0
AFINITOR,Elevated aspartate transaminase,Elevated aspartate transaminase AST,1
AFINITOR,Elevated aspartate transaminase,Elevated aspartate transaminase AST,1
AFINITOR,Hypertriglyceridemia,Hypertriglyceridemia,1
AFINITOR,Hypertriglyceridemia,Hypertriglyceridemia,1
AFINITOR,Hypertriglyceridemia,Hypertriglyceridemia,1
AFINITOR,Hypertriglyceridemia,,0
AFINITOR,Hypertriglyceridemia,Hypertriglyceridemia,1
AFINITOR,Elevated alanine transaminase,Elevated,1
AFINITOR,Elevated alanine transaminase,,0
AFINITOR,Elevated alanine transaminase,,0
AFINITOR,Elevated alanine transaminase,Elevated alanine transaminase ALT,1
AFINITOR,cellulitis,cellulitis,1
AFINITOR,cellulitis,reactions and key laboratory cellulitis,1
AFINITOR,cellulitis,cellulitis,1
AFINITOR,cellulitis,the following additional notable adverse reactions and key,0
AFINITOR,cellulitis,and key laboratory cellulitis,1
AFINITOR,cellulitis,,0
AFINITOR,cellulitis,and elevated creatinine Postmarketing Experience,0
AFINITOR,hyperglycemia,and elevated creatinine Postmarketing Experience The following,0
AFINITOR,hyperglycemia,and key laboratory abnormalities hyperglycemia,1
AFINITOR,hyperglycemia,abnormalities hyperglycemia,1
AFINITOR,elevated creatinine,elevated creatinine,1
AFINITOR,elevated creatinine,cellulitis hyperglycemia and,0
AFINITOR,elevated creatinine,elevated creatinine,1
AFINITOR,elevated creatinine,,0
AFINITOR,acute pancreatitis,cholelithiasis arterial thrombotic events and reflex sympathetic,0
AFINITOR,acute pancreatitis,causal relationship to drug acute,1
AFINITOR,acute pancreatitis,,0
AFINITOR,acute pancreatitis,reliably,0
AFINITOR,acute pancreatitis,drug acute,1
AFINITOR,acute pancreatitis,causal relationship to drug acute,1
AFINITOR,cholecystitis,cholecystitis,1
AFINITOR,cholelithiasis,reflex sympathetic,0
AFINITOR,cholelithiasis,cholelithiasis,1
AFINITOR,cholelithiasis,pancreatitis cholelithiasis,1
AFINITOR,cholelithiasis,sympathetic,0
AFINITOR,cholelithiasis,drug exposure acute pancreatitis cholelithiasis,1
AFINITOR,cholelithiasis,,0
AFINITOR,cholelithiasis,cholelithiasis,1
AFINITOR,cholelithiasis,cholecystitis,0
AFINITOR,cholelithiasis,cholelithiasis,1
AFINITOR,cholelithiasis,,0
AFINITOR,arterial thrombotic events,cholelithiasis,0
AFINITOR,arterial thrombotic events,,0
AFINITOR,arterial thrombotic events,pancreatitis,0
AFINITOR,arterial thrombotic events,pancreatitis cholecystitis arterial thrombotic events,1
AFINITOR,arterial thrombotic events,,0
AFINITOR,arterial thrombotic events,,0
AFINITOR,arterial thrombotic events,,0
AFINITOR,arterial thrombotic events,,0
AFINITOR,arterial thrombotic events,cholecystitis arterial thrombotic,1
AFINITOR,reflex sympathetic dystrophy,,0
AFINITOR,reflex sympathetic dystrophy,reflex sympathetic dystrophy,1
AFINITOR,reflex sympathetic dystrophy,cholecystitis cholelithiasis,0
AFINITOR,reflex sympathetic dystrophy,events reflex,1
AFINITOR,reflex sympathetic dystrophy,events reflex sympathetic dystrophy,1
AFINITOR,reflex sympathetic dystrophy,sympathetic dystrophy,1
AFINITOR,reflex sympathetic dystrophy,arterial thrombotic events reflex sympathetic,1
AFINITOR,reflex sympathetic dystrophy,cholelithiasis arterial thrombotic events reflex,1
AFINITOR,reflex sympathetic dystrophy,,0
AFINITOR,Non-infectious pneumonitis,see Warnings and Precautions,0
AFINITOR,Non-infectious pneumonitis,,0
AFINITOR,Non-infectious pneumonitis,,0
AFINITOR,Non-infectious pneumonitis,,0
AFINITOR,Non-infectious pneumonitis,another section of the label,0
AFINITOR,fatal,,0
AFINITOR,fatal,e War nings and Precautions Noninfectious pneumonitis,1
AFINITOR,fatal,of the label e,1
AFINITOR,fatal,label se,0
AFINITOR,fatal,and Precautions,0
AFINITOR,fatal,War nings and Precautions Noninfectious pneumonitis,1
AFINITOR,fatal,of the label e War nings and Precautions Noninfectious pneumonitis,1
AFINITOR,fatal,label e War nings and Precautions Noninfectious pneumonitis,1
AFINITOR,fatal,pneumonitis,0
AFINITOR,Infections,Infections see Warnings and Preca,0
AFINITOR,Infections,use of ACE,0
AFINITOR,Infections,utions,1
AFINITOR,Infections,,0
AFINITOR,Infections,,0
AFINITOR,infections,Precautions a with con comitant use of ACE inhibitors,1
AFINITOR,infections,Infections see Warnings and Precautions Angioedem,0
AFINITOR,infections,and Precautions a with con comitant use of ACE inhibitors,1
AFINITOR,infections,a with con comitant use of ACE inhibitors,1
AFINITOR,infections,Infections,0
AFINITOR,infections,comitant use of ACE inhibitors see Warnings,0
AFINITOR,infections,,0
AFINITOR,fatal,of ACE inhibitors see,0
AFINITOR,fatal,Warnings,0
AFINITOR,fatal,t use of ACE inhibitors see Warnings,1
AFINITOR,fatal,and Precautions Angioedema with t use of ACE inhibitors see Warnings,1
AFINITOR,fatal,t use of ACE inhibitors see Warnings,1
AFINITOR,fatal,Precautions Angioedema with t,1
AFINITOR,Angioedema,Warnings and,0
AFINITOR,Angioedema,lceration  see Warnings and Precautions Renal,1
AFINITOR,Angioedema,lceration  see Warnings and Precautions Renal,1
AFINITOR,Oral ulceration,healin g see Warnings and Precautions,1
AFINITOR,Mouth ulcers,Warning s and Precautions Because clinical,1
AFINITOR,Mouth ulcers,,0
AFINITOR,Mouth ulcers,Warnings and Precautions,0
AFINITOR,Mouth ulcers,Warning s and Precautions Because clinical,1
AFINITOR,Mouth ulcers,[see Warning s and Precautions Because clinical,1
AFINITOR,Mouth ulcers,Warnings and,0
AFINITOR,Mouth ulcers,[see Warning s and Precautions Because clinical,1
AFINITOR,Mouth ulcers,s and,0
AFINITOR,Mouth ulcers,and Precautions Impaired wound [see Warning s and Precautions Because clinical,1
AFINITOR,Mouth ulcers,Precautions Because clinical trials are conducted under,0
AFINITOR,stomatitis,Impaired wound healing see and Precau tions Because clinical trials are,1
AFINITOR,stomatitis,see and Precau tions Because clinical trials are,1
AFINITOR,stomatitis,and,1
AFINITOR,oral mucositis,"and (5.6)] . 
     Because clinical trials are conducted",1
AFINITOR,oral mucositis,Impaired wound,0
AFINITOR,oral mucositis,(5.6)],1
AFINITOR,oral mucositis,the adverse,0
AFINITOR,Renal failure,,0
AFINITOR,Renal failure,trials,0
AFINITOR,renal failure,conditions the adverse reaction rates observed c,0
AFINITOR,renal failure,dire ctly compared to rates in,1
AFINITOR,renal failure,observed annot,1
AFINITOR,renal failure,and may not,0
AFINITOR,renal failure,be dire ctly compared to rates in,1
AFINITOR,renal failure,annot be dire ctly compared to rates in,1
AFINITOR,renal failure,reaction rates,0
AFINITOR,renal failure,annot be dire ctly compared to rates in,1
AFINITOR,acute renal failure,d to rates in other trials and may not reflect,1
AFINITOR,acute renal failure,d to rates in other trials and may not reflect,1
AFINITOR,acute renal failure,,0
AFINITOR,acute renal failure,clinical practice EXCERPT,0
AFINITOR,acute renal failure,cannot be directly d to rates in other trials and may not reflect,1
AFINITOR,acute renal failure,clinical practice EXCERPT Advanced HR B,0
AFINITOR,acute renal failure,reflect the rates observed in clinical practice EXCERPT,0
AFINITOR,acute renal failure,d to,1
AFINITOR,fatal, not  reflect the rates observed in,1
AFINITOR,fatal, not  reflect the rates observed in,1
AFINITOR,fatal, not  reflect the rates observed in,1
AFINITOR,fatal, not  reflect the rates observed in,1
AFINITOR,fatal, not  reflect the rates observed in,1
AFINITOR,fatal,other trials and  not  reflect the rates observed in,1
AFINITOR,fatal,directly compared,0
AFINITOR,fatal,BC advanced PNET ad,0
AFINITOR,fatal,in other trials and may,0
AFINITOR,fatal,EXCERPT,0
AFINITOR,Impaired wound healing,"observed in clinical ce.
 

   EXCERPT:   A dvanced HR BC advanced PNET",1
AFINITOR,Impaired wound healing,,0
AFINITOR,Impaired wound healing,advanced RCC,0
AFINITOR,Impaired wound healing,rates observed in clinical ce.,1
AFINITOR,Impaired wound healing,rates in other trials and may not reflect the rates observed in clinical practi,0
AFINITOR,Impaired wound healing,in clinical ce.,1
AFINITOR,Impaired wound healing,"in clinical ce.
 

   EXCERPT:   A dvanced HR BC advanced PNET",1
AFINITOR,Impaired wound healing,"observed in clinical ce.
 

   EXCERPT:   A dvanced HR BC advanced PNET",1
AFINITOR,Impaired wound healing,in other trials and may not reflect the,0
AFINITOR,Elevations of serum creatinine,"nausea, fever, asthenia, cough headache and decreased appetite",1
AFINITOR,Elevations of serum creatinine,angiomyolipoma with TSC,0
AFINITOR,Elevations of serum creatinine,"pain, nausea, fever, asthenia, cough headache and decreased appetite",1
AFINITOR,Elevations of serum creatinine,"pain, nausea,",1
AFINITOR,Elevations of serum creatinine,incidence include stomatitis infections rash fatigue diarrhea edema,0
AFINITOR,Elevations of serum creatinine,diarrhea edema abdominal,0
AFINITOR,Elevations of serum creatinine,"diarrhea edema pain, nausea, fever, asthenia, cough headache and decreased appetite",1
AFINITOR,Elevations of serum creatinine,stomatitis,0
AFINITOR,Decreases in hemoglobin,,0
AFINITOR,Decreases in hemoglobin,pain nausea fever asthenia cough headache and,0
AFINITOR,Decreases in hemoglobin,"decreased  ,  6.3  )



 Renal an giomyolipoma with TSC Most common",1
AFINITOR,Decreases in hemoglobin," ,  6.3  )



 Renal an giomyolipoma with TSC Most common",1
AFINITOR,Decreases in hemoglobin,"decreased  ,  6.3  )



 Renal an giomyolipoma with TSC Most common",1
AFINITOR,Decreases in hemoglobin,"headache and decreased , 6.3 )",1
AFINITOR,Decreases in hemoglobin,,0
AFINITOR,Decreases in hemoglobin,"cough headache and decreased , 6.3",1
AFINITOR,Decreases in hemoglobin,,0
AFINITOR,Decreases in hemoglobin,TSC Most common,0
AFINITOR,Non-infectious pneumonitis,ReceptorPositive HERNegative Breast Cancer,0
AFINITOR,Non-infectious pneumonitis,HERNegative Breast The efficacy and safety of AFINITOR mgday plus exemestane mgday,1
AFINITOR,Non-infectious pneumonitis,ReceptorPositive HERNegative Breast The efficacy,1
AFINITOR,Non-infectious pneumonitis,HERNegative Breast The efficacy,1
AFINITOR,Non-infectious pneumonitis,in Advanced Hormone ReceptorPositive,0
AFINITOR,Non-infectious pneumonitis,AFINITOR mgday plus exemestane mgday,0
AFINITOR,Non-infectious pneumonitis,exemestane (2 mgday n was evaluated in,1
AFINITOR,Non-infectious pneumonitis,plus exemestane (2 mgday n was evaluated in,1
AFINITOR,non-infectious pneumonitis,median age of patients was years,1
AFINITOR,non-infectious pneumonitis, breast cancer. The median age of patients was years,1
AFINITOR,non-infectious pneumonitis,hormone receptorpositive  breast cancer. The median age of patients was years,1
AFINITOR,non-infectious pneumonitis,with advanced or metastatic hormone receptorpositive,0
AFINITOR,non-infectious pneumonitis,,0
AFINITOR,non-infectious pneumonitis,hormone receptorpositive breast cancer. The,1
AFINITOR,non-infectious pneumonitis,,0
AFINITOR,non-infectious pneumonitis,median age of patients was years,1
AFINITOR,non-infectious pneumonitis,hormone,0
AFINITOR,non-infectious pneumonitis,hormone receptorpositive  breast cancer. The median age of patients was years,1
AFINITOR,non-infectious pneumonitis,patients with advanced or metastatic hormone receptorpositive,0
AFINITOR,non-infectious pneumonitis,,0
AFINITOR,non-infectious pneumonitis,hormone receptorpositive breast cancer.,1
AFINITOR,non-infectious pneumonitis,receptorpositive breast cancer.,1
AFINITOR,non-infectious pneumonitis,cancer. The median age of patients was years,1
AFINITOR,non-infectious pneumonitis,median age of patients was years,1
AFINITOR,non-infectious pneumonitis,in patients with advanced or metastatic hormone receptorpositive,0
AFINITOR,Fatal,and were Caucasian,0
AFINITOR,Fatal,on a median followup of approximately months,1
AFINITOR,Fatal,age of patients was years range years and were Caucasian Safety results,0
AFINITOR,Fatal,results are  on a median followup of approximately months,1
AFINITOR,Fatal,approximately months The most common,0
AFINITOR,Fatal,of approximately months The,0
AFINITOR,Fatal,reactions incidence,0
AFINITOR,pneumonitis,pain glossitis and,0
AFINITOR,pneumonitis, stomatitis mouth ulceration aphthous stomatitis glossodynia,1
AFINITOR,pneumonitis,lip ulceration,0
AFINITOR,pneumonitis, stomatitis mouth ulceration aphthous stomatitis glossodynia,1
AFINITOR,pneumonitis,,0
AFINITOR,pneumonitis,exposed to AFINITOR therapy for a period,0
AFINITOR,pneumonitis,Exemestane mgday b  stomatitis mouth ulceration aphthous stomatitis glossodynia,1
AFINITOR,protozoal infections,"class, the most common being nasopharyngitis urinary",1
AFINITOR,infections with opportunistic pathogens,being nasopharyngitis,1
AFINITOR,infections with opportunistic pathogens,"organ class the most being nasopharyngitis (10%), urinary",1
AFINITOR,infections with opportunistic pathogens,"the most being nasopharyngitis (10%), urinary tr act infection upper respiratory tract",1
AFINITOR,infections with opportunistic pathogens,preferred terms within,0
AFINITOR,pneumonia,"tract infection pneumonia bronchitis tis (3%), sinusitis and also including candidiasis",1
AFINITOR,pneumonia,"tract infection pneumonia bronchitis tis (3%), sinusitis and also including candidiasis",1
AFINITOR,pneumonia,"tis (3%), sinusitis and also including candidiasis",1
AFINITOR,pneumonia,"bronchitis tis (3%), sinusitis and also including candidiasis",1
AFINITOR,mycobacterial infections,"inusitis (3%), and also  including candidiasis and sepsis and",1
AFINITOR,mycobacterial infections,"pneumonia bronchitis cystitis inusitis (3%), and also  including candidiasis and sepsis and",1
AFINITOR,mycobacterial infections,and sepsis and,0
AFINITOR,bacterial infections,infection pneumonia bronchitis cystitis sinusitis and,0
AFINITOR,bacterial infections,sinusitis and also g candidiasis,1
AFINITOR,bacterial infections,pneumonia bronchitis cystitis sinusitis,0
AFINITOR,bacterial infections,"candidiasis (<1%), and sepsis and hepatitis C",1
AFINITOR,invasive fungal infections,candidiasis nd sepsis,1
AFINITOR,invasive fungal infections,C d Includes pneumonitis interstitial lung disease lung infiltration and pulmonary,0
AFINITOR,invasive fungal infections,also,0
AFINITOR,invasive fungal infections,C,0
AFINITOR,invasive fungal infections,hepat itis C d Includes pneumonitis,1
AFINITOR,aspergillosis,and sepsis and hepatitis %). d,1
AFINITOR,aspergillosis,and hepatitis %).  d  Inclu des pneumonitis interstitial lung disease,1
AFINITOR,aspergillosis,%). d,1
AFINITOR,aspergillosis,hepatitis %).  d  Inclu des pneumonitis interstitial lung disease,1
AFINITOR,aspergillosis,%). d Inclu des pneumonitis interstitial lung disease,1
AFINITOR,aspergillosis,,0
AFINITOR,aspergillosis,lung infiltration and,0
AFINITOR,aspergillosis,sepsis,0
AFINITOR,aspergillosis,,0
AFINITOR,candidiasis,hepatitis C d s,1
AFINITOR,candidiasis,s pneumonit is interstitial lung disease lung,1
AFINITOR,candidiasis,also including candidiasis and sepsis and hepatitis C d Include,0
AFINITOR,candidiasis,d s pneumonit is interstitial lung disease lung,1
AFINITOR,candidiasis,and sepsis and,0
AFINITOR,PJP,fil tration and pulmonary fibrosis e,1
AFINITOR,PJP,C d Includes pneumonitis interstitial lung,0
AFINITOR,PJP,lung disease lung fil tration and pulmonary fibrosis e,1
AFINITOR,PJP,fil tration and pulmonary fibrosis e,1
AFINITOR,PJP,interstitial lung disease lung fil tration and pulmonary fibrosis e,1
AFINITOR,PJP,fil tration and pulmonary fibrosis e,1
AFINITOR,PJP,interstitial lung,0
AFINITOR,PJP,fil tration and pulmonary fibrosis e,1
AFINITOR,PJP,fil tration and pulmonary fibrosis e,1
AFINITOR,viral infections,interstitial lung disease,0
AFINITOR,viral infections,"n, and pulmonary fibrosis e Exposure to AFINITOR",1
AFINITOR,viral infections,"lung disease lung n,",1
AFINITOR,viral infections,,0
AFINITOR,viral infections,,0
AFINITOR,viral infections,"disease lung n, and",1
AFINITOR,viral infections,C d Includes pneumonitis interstitial lung disease lung,0
AFINITOR,reactivation of hepatitis B virus,and pulmonary e Exposure to AFINITOR or,1
AFINITOR,reactivation of hepatitis B virus,infiltration and pulmonary fibrosis,0
AFINITOR,reactivation of hepatitis B virus,e Exposure to AFINITOR or placeb o AFINITOR mgday exemestane a,1
AFINITOR,reactivation of hepatitis B virus,mgday exemestane a,0
AFINITOR,reactivation of hepatitis B virus,e Exposure to AFINITOR or placeb o AFINITOR mgday exemestane a,1
AFINITOR,reactivation of hepatitis B virus,and pulmonary e Exposure to AFINITOR,1
AFINITOR,reactivation of hepatitis B virus,e  Exposure to AFINITOR or placeb o AFINITOR mgday exemestane a,1
AFINITOR,reactivation of hepatitis B virus,N,0
AFINITOR,reactivation of hepatitis B virus,Includes pneumonitis interstitial lung disease,0
AFINITOR,infections,mgday estane,1
AFINITOR,infections,AFINITOR mgday estane,1
AFINITOR,infections,grades Grad,0
AFINITOR,infections,,0
AFINITOR,infections,estane a N Placebo exemestane a N,1
AFINITOR,infections,estane a N Placebo exemestane a N,1
AFINITOR,infections,to,0
AFINITOR,infections,,0
AFINITOR,hepatic failure,N Placebo exemestane a                 All grades Grade Grade All,1
AFINITOR,hepatic failure,a N Placebo exemestane a N,0
AFINITOR,hepatic failure,                All grades Grade Grade All,1
AFINITOR,hepatic failure,exemestane a N Placebo,0
AFINITOR,hepatic failure,                All grades Grade Grade All,1
AFINITOR,hepatic failure,                All grades Grade Grade All,1
AFINITOR,hepatic failure,                All grades Grade Grade All,1
AFINITOR,hepatic failure,,0
AFINITOR,fatal,Placebo exemestane a All g rades Grade Grade All grades,1
AFINITOR,fatal,Placebo,0
AFINITOR,Pneumocystis jiroveci pneumonia,2 0.2 Nausea,1
AFINITOR,Pneumocystis jiroveci pneumonia,Diarrhea,0
AFINITOR,Pneumocystis jiroveci pneumonia,2 0.2 Nausea,1
AFINITOR,Pneumocystis jiroveci pneumonia,,0
AFINITOR,Pneumocystis jiroveci pneumonia,0.2 Nausea,1
AFINITOR,Pneumocystis jiroveci pneumonia,0.2 Nausea,1
AFINITOR,Pneumocystis jiroveci pneumonia,Diarrhea,0
AFINITOR,fatal,      Nausea,1
AFINITOR,fatal,Diarrhea       Nausea,1
AFINITOR,fatal,Diarrhea,0
AFINITOR,fatal,Diarrhea,0
AFINITOR,fatal,,0
AFINITOR,fatal,Diarrhea,0
AFINITOR,fatal,,0
AFINITOR,fatal,      Nausea,1
AFINITOR,fatal,Nausea,0
AFINITOR,angioedema,,0
AFINITOR,angioedema,       7  ,1
AFINITOR,angioedema,       7  ,1
AFINITOR,swelling of the airways,      0                ,1
AFINITOR,swelling of the airways,General disorders and administration site conditions,0
AFINITOR,swelling of the airways,      0                ,1
AFINITOR,swelling of the airways,      0                ,1
AFINITOR,swelling of the airways,      0                ,1
AFINITOR,swelling of the airways,      0                ,1
AFINITOR,swelling of the airways,      0                ,1
AFINITOR,swelling of the airways,      0                ,1
AFINITOR,swelling of the airways,      0                ,1
AFINITOR,swelling of the airways,      0                ,1
AFINITOR,respiratory impairment,,0
AFINITOR,angioedema,site,0
AFINITOR,angioedema,     27    Edema peripheral,1
AFINITOR,angioedema,,0
AFINITOR,angioedema,conditions      27    Edema peripheral,1
AFINITOR,angioedema,,0
AFINITOR,angioedema,     27    Edema peripheral,1
AFINITOR,angioedema,     27    Edema peripheral,1
AFINITOR,angioedema,site conditions Fatigue,0
AFINITOR,angioedema,,0
AFINITOR,Mouth ulcers,,0
AFINITOR,Mouth ulcers,             Pyrexia,1
AFINITOR,Mouth ulcers,             Pyrexia,1
AFINITOR,Mouth ulcers,Pyrexia,0
AFINITOR,Mouth ulcers,,0
AFINITOR,Mouth ulcers,a              Pyrexia,1
AFINITOR,stomatitis,,0
AFINITOR,oral mucositis,Pyrex,0
AFINITOR,oral mucositis,ia 15,1
AFINITOR,oral mucositis,Pyrex,0
AFINITOR,oral mucositis,Pyrex ia,1
AFINITOR,oral mucositis,Pyrex ia    15      ,1
AFINITOR,oral mucositis,,0
AFINITOR,renal failure,"  
       Dec",1
AFINITOR,renal failure,"  
       Dec",1
AFINITOR,renal failure,nutrition,0
AFINITOR,acute renal failure,,0
AFINITOR,acute renal failure,,0
AFINITOR,acute renal failure,,0
AFINITOR,acute renal failure,disorders Decreased,0
AFINITOR,acute renal failure,Hyp,0
AFINITOR,acute renal failure,,0
AFINITOR,acute renal failure,,0
AFINITOR,acute renal failure,disorders Decreased appet,0
AFINITOR,fatal,      Hyperglycemia,1
AFINITOR,fatal,      Hyperglycemia,1
AFINITOR,fatal,nutrition disorders Decreased       Hyperglycemia,1
AFINITOR,fatal,disorders,0
AFINITOR,fatal,      Hyperglycemia,1
AFINITOR,wound dehiscence,,0
AFINITOR,wound dehiscence,"tissue  
       Arthral gia",1
AFINITOR,wound dehiscence,"connective tissue  
       Arthral gia",1
AFINITOR,wound dehiscence," 
       Arthral gia",1
AFINITOR,wound dehiscence," 
       Arthral gia",1
AFINITOR,wound dehiscence,,0
AFINITOR,wound dehiscence,"Musculoskeletal and connective tissue  
       Arthral gia",1
AFINITOR,wound dehiscence," 
       Arthral gia",1
AFINITOR,wound dehiscence," 
       Arthral gia",1
AFINITOR,wound infection,connective tissue disorders a,1
AFINITOR,wound infection,and,0
AFINITOR,wound infection,20 B,1
AFINITOR,incisional hernia,connective tissue disorders Arthralgia,0
AFINITOR,incisional hernia,   0.8           ,1
AFINITOR,incisional hernia,   0.8           ,1
AFINITOR,incisional hernia,   0.8           ,1
AFINITOR,incisional hernia,and connective,0
AFINITOR,lymphocele,,0
AFINITOR,lymphocele,Arthralgia,0
AFINITOR,lymphocele, 0        ,1
AFINITOR,lymphocele,tissue disorders  0        ,1
AFINITOR,lymphocele,Back pain,0
AFINITOR,lymphocele,tissue disorders Arthralgia,0
AFINITOR,seroma,Arthralgia,0
AFINITOR,seroma,pain,0
AFINITOR,seroma,  17  ,1
AFINITOR,seroma,onnective tissue disorders   17  ,1
AFINITOR,seroma,,0
AFINITOR,seroma,onnective tissue disorders   17  ,1
AFINITOR,seroma,,0
AFINITOR,Elevations of serum creatinine,disorders 0,1
AFINITOR,Elevations of serum creatinine,disorders 0,1
AFINITOR,Elevations of serum creatinine,Dyspnea,0
AFINITOR,Elevations of serum creatinine,disorders Cough,0
AFINITOR,Elevations of serum creatinine,and mediastinal disorders Cough,0
AFINITOR,proteinuria,  0         Dyspnea,1
AFINITOR,proteinuria,Dyspnea,0
AFINITOR,proteinuria,  0         Dyspnea,1
AFINITOR,proteinuria,  0         Dyspnea,1
AFINITOR,proteinuria,Dyspnea,0
AFINITOR,proteinuria,,0
AFINITOR,proteinuria,Cough,0
AFINITOR,proteinuria,  0         Dyspnea,1
AFINITOR,proteinuria,disorders   0         Dyspnea,1
AFINITOR,Hyperglycemia,,0
AFINITOR,Hyperglycemia,              Pruritus,1
AFINITOR,Hyperglycemia,              Pruritus,1
AFINITOR,Hyperglycemia,              Pruritus,1
AFINITOR,Hyperglycemia,,0
AFINITOR,Hyperglycemia,              Pruritus,1
AFINITOR,Hyperglycemia,              Pruritus,1
AFINITOR,Hyperglycemia,subcutaneous,0
AFINITOR,hyperlipidemia,,0
AFINITOR,hyperlipidemia,,0
AFINITOR,hypertriglyceridemia,              0      Pruritus,1
AFINITOR,hypertriglyceridemia,              0      Pruritus,1
AFINITOR,hypertriglyceridemia,              0      Pruritus,1
AFINITOR,hypertriglyceridemia,disorders,0
AFINITOR,hypertriglyceridemia,              0      Pruritus,1
AFINITOR,hypertriglyceridemia,,0
AFINITOR,hypertriglyceridemia,              0      Pruritus,1
AFINITOR,hypertriglyceridemia,              0      Pruritus,1
AFINITOR,hypertriglyceridemia,,0
AFINITOR,hypertriglyceridemia,              0      Pruritus,1
AFINITOR,Decreased hemoglobin,observed laboratory abnormalities are resented in Table 3.,1
AFINITOR,Decreased hemoglobin,are resented,1
AFINITOR,Decreased hemoglobin,,0
AFINITOR,Decreased hemoglobin,are resented in,1
AFINITOR,Decreased hemoglobin,observed laboratory abnormalities are p,0
AFINITOR,Decreased hemoglobin,resented in Table 3.,1
AFINITOR,Decreased hemoglobin,p,0
AFINITOR,Decreased hemoglobin,abnormalities are resented in Table,1
AFINITOR,hepatic impairment,,0
AFINITOR,hepatic impairment,,0
AFINITOR,hepatic impairment,WBC           5       ,1
AFINITOR,hepatic impairment,,0
AFINITOR,hepatic impairment,,0
AFINITOR,hepatic impairment,"    
 Lymphocytes  decreased",1
AFINITOR,hepatic impairment,,0
AFINITOR,hepatic impairment,"    
 Lymphocytes  decreased",1
AFINITOR,hepatic impairment,"    
 Lymphocytes  decreased",1
AFINITOR,hepatic impairment,,0
AFINITOR,fetal harm,patients with advanced PNET the,0
AFINITOR,fetal harm,Pancreatic,0
AFINITOR,fetal harm,random,1
AFINITOR,embryo-fetal toxicities,AFINITOR (n=204),1
AFINITOR,embryo-fetal toxicities,Tumors In a randomized controlled tri,0
AFINITOR,embryo-fetal toxicities,al,1
AFINITOR,embryo-fetal toxicities,randomized controlled al,1
AFINITOR,embryo-fetal toxicities,PNET the median age,0
AFINITOR,embryo-fetal toxicities,controlled al,1
ENTEREG,dyspepsia,incidence occurring with a higher frequency,0
ENTEREG,dyspepsia,than placebo dyspepsia,1
ENTEREG,dyspepsia,higher frequency,0
ENTEREG,dyspepsia,placebo was,0
ENTEREG,MYOCARDIAL INFARCTION,ommon adverse reactio,1
ENTEREG,MYOCARDIAL INFARCTION,higher,0
ENTEREG,MYOCARDIAL INFARCTION,ommon adverse reactio n incidence occurring with,1
ENTEREG,MYOCARDIAL INFARCTION,,0
ENTEREG,MYOCARDIAL INFARCTION,ommon adverse reactio n incidence occurring with,1
ENTEREG,MYOCARDIAL INFARCTION,a higher frequency than placebo among ENTEREGtreated,0
ENTEREG,MYOCARDIAL INFARCTION,n incidence occurring with a higher frequency than placebo among ENTEREGtreated,0
ENTEREG,MYOCARDIAL INFARCTION,ted patients undergoi ng surgeries that included a,1
ENTEREG,myocardial infarction,are conducted der widely varying co nditions adverse reaction rates observed,1
ENTEREG,myocardial infarction,are conducted der widely varying co nditions adverse reaction rates observed,1
ENTEREG,myocardial infarction,undergoing a ery that included bow el resection The first dose,1
ENTEREG,myocardial infarction,hours before the,0
ENTEREG,myocardial infarction,,0
ENTEREG,myocardial infarction,,0
ENTEREG,myocardial infarctions,,0
ENTEREG,myocardial infarctions,with a higher frequency than placebo,0
ENTEREG,myocardial infarctions,,0
ENTEREG,myocardial infarctions,n (incidence >=1.5%) o ccurring with a,1
ENTEREG,myocardial infarctions,,0
ENTEREG,abdominal pain,tria ls are conducted under,1
ENTEREG,abdominal pain,Experience clinical,1
ENTEREG,abdominal pain,clinical tria ls are conducted under,1
ENTEREG,nausea,Because clinical  are c onducted under widely varying,1
ENTEREG,nausea,Experience Because,0
ENTEREG,nausea,trials of,0
ENTEREG,nausea,clinical,0
ENTEREG,nausea,are c onducted under widely varying,1
ENTEREG,nausea,are c onducted under widely varying,1
ENTEREG,nausea,,0
ENTEREG,nausea,,0
ENTEREG,nausea,clinical are,1
ENTEREG,vomiting,ted unde r widely varying conditions,1
ENTEREG,diarrhea,ly varyi ng conditions adverse reaction,1
ENTEREG,diarrhea,under wide,0
ENTEREG,diarrhea,varyi ng conditions adverse reaction,1
ENTEREG,diarrhea,reaction rates observed in the clinical trials of a drug cannot be,0
ENTEREG,myocardial infarctions,ENTEREG mg patients in 10,1
ENTEREG,myocardial infarctions,placebo controlled studies The population,1
ENTEREG,myocardial infarctions,patients,1
ENTEREG,myocardial infarctions,,0
ENTEREG,myocardial infarctions,reflect exposure to,0
ENTEREG,myocardial infarctions,,0
ENTEREG,myocardial infarctions,studies The population was to years old were female and were Caucasian,0
ENTEREG,myocardial infarctions,postoperative treatment Amo,0
ENTEREG,myocardial infarctions,hours before the scheduled of surgery and,1
ENTEREG,myocardial infarctions,hours before the scheduled of surgery and,1
ENTEREG,abdominal pain,,1
ENTEREG,abdominal pain,,1
ENTEREG,abdominal pain,,1
ENTEREG,abdominal pain,,1
ENTEREG,nausea,,0
ENTEREG,nausea,,1
ENTEREG,nausea,,0
ENTEREG,nausea,,0
ENTEREG,nausea,,1
ENTEREG,nausea,,0
ENTEREG,vomiting,,1
ENTEREG,vomiting,,1
ENTEREG,vomiting,,0
ENTEREG,diarrhea,,0
ENTEREG,diarrhea,,1
ENTEREG,diarrhea,,1
ENTEREG,diarrhea,,0
ENTEREG,diarrhea,,1
ENTEREG,diarrhea,,0
COARTEM,headache,adults headache,1
COARTEM,anorexia,dizziness asthenia arthralgia and myalgia The most common,0
COARTEM,anorexia,are anorexia,1
COARTEM,anorexia,adults are anorexia,1
COARTEM,anorexia,reactions in adults are anorexia,1
COARTEM,anorexia,common adverse reactions in adults are,0
COARTEM,dizziness,in children are pyrexia,0
COARTEM,dizziness,EXCERPT The most common adverse,0
COARTEM,asthenia,,0
COARTEM,asthenia,adults are headache anorexia asthenia,1
COARTEM,myalgia,asthenia arthralgia myalgia,1
COARTEM,pyrexia,adverse reactions in children pyrexia,1
COARTEM,pyrexia,SUSPECTED ADVERSE REACTIONS contac,0
COARTEM,pyrexia,pyrexia,1
COARTEM,pyrexia,asthenia arthralgia and myalgia,0
COARTEM,pyrexia,and myalgia The,0
COARTEM,pyrexia,asthenia arthralgia and myalgia,0
COARTEM,pyrexia,pyrexia,1
COARTEM,pyrexia,reactions in children pyrexia,1
COARTEM,pyrexia,pyrexia,1
COARTEM,cough,are cough,1
COARTEM,cough,headache To report SUSPECTED ADVERSE REACTIONS contact Novar,0
COARTEM,cough,,0
COARTEM,anorexia,adverse reactions in children are,0
COARTEM,anorexia,report SUSPECTED ADVERSE REACTIONS,0
COARTEM,anorexia,common adverse reactions in children are,0
COARTEM,anorexia,anorexia,1
COARTEM,anorexia,children are pyrexia cough anorexia,1
COARTEM,headache,headache,1
COARTEM,Hypersensitivity Reactions,in other sections of Hypersensitivity,1
COARTEM,Hypersensitivity Reactions,Adverse Reactions,0
COARTEM,Hypersensitivity Reactions,Hypersensitivity,1
COARTEM,Hypersensitivity Reactions,Contraindications,0
COARTEM,Hypersensitivity Reactions,sections,0
COARTEM,Hypersensitivity Reactions,Hypersensitivity Reactions,1
COARTEM,Hypersensitivity Reactions,Hypersensitivity Reactions,1
COARTEM,Hypersensitivity Reactions,in other sections of Hypersensitivity,1
COARTEM,headache,anorexia dizziness and asthenia In children the adverse,0
COARTEM,headache,adverse reactions,0
COARTEM,headache,vomitin,0
COARTEM,headache,headache,1
COARTEM,headache,reactions headache,1
COARTEM,anorexia,adults the,0
COARTEM,anorexia,anorexia,1
COARTEM,anorexia,anorexia,1
COARTEM,anorexia,asthenia In children the adverse reactions,0
COARTEM,anorexia,the adverse reactions were,0
COARTEM,anorexia,anorexia,1
COARTEM,anorexia,the most frequently reported adverse reactions were headache,0
COARTEM,dizziness,reactions were pyrexia cough vomiting anorexia and,0
COARTEM,dizziness,dizziness,1
COARTEM,dizziness,adverse reactions were headache anorexia,0
COARTEM,asthenia,asthenia,1
COARTEM,asthenia,adverse reactions were headache anorexia dizziness and,0
COARTEM,asthenia,asthenia,1
COARTEM,asthenia,vomiting anorexia and headache,0
COARTEM,asthenia,reported adverse,0
COARTEM,asthenia,asthenia,1
COARTEM,asthenia,pyrexia,0
COARTEM,asthenia,anorexia dizziness asthenia,1
COARTEM,pyrexia,adverse,0
COARTEM,pyrexia,pyrexia,1
COARTEM,pyrexia,Most adverse reactions were mild,0
COARTEM,cough,did not lead to discontinuatio,0
COARTEM,cough,anorexia dizziness and asthenia,0
COARTEM,cough,reactions were cough,1
COARTEM,vomiting,vomiting,1
COARTEM,vomiting,of,0
COARTEM,vomiting,vomiting,1
COARTEM,vomiting,vomiting,1
COARTEM,vomiting,dizziness and asthenia In,0
COARTEM,vomiting,discontinuation of,0
COARTEM,vomiting,pyrexia vomiting,1
COARTEM,vomiting,were pyrexia vomiting,1
COARTEM,vomiting,vomiting,1
COARTEM,anorexia,did not lead,0
COARTEM,anorexia,pyrexia cough anorexia,1
COARTEM,anorexia,lead to,0
COARTEM,anorexia,the adverse reactions were pyrexia,0
COARTEM,anorexia,,0
COARTEM,anorexia,were mild did not lead to,0
COARTEM,anorexia,anorexia,1
COARTEM,anorexia,and asthenia In children,0
COARTEM,headache,children the adverse reactions were pyrexia cough vomiting anorexia and,0
COARTEM,headache,headache,1
COARTEM,headache,cough vomiting anorexia headache,1
COARTEM,Headache,,0
COARTEM,Headache,,0
COARTEM,Headache,Headache,1
COARTEM,Headache,N Nervous system Headache,1
COARTEM,Headache,Dizziness Metabolism,0
COARTEM,Headache,,0
COARTEM,Dizziness,Anorexia,0
COARTEM,Dizziness,Dizziness,1
COARTEM,Dizziness,,0
COARTEM,Dizziness,,0
COARTEM,Dizziness,Dizziness,1
COARTEM,Dizziness,,0
COARTEM,Anorexia,General,0
COARTEM,Anorexia,Anorexia,1
COARTEM,Anorexia,nutrition Anorexia,1
COARTEM,Anorexia,Metabolism and nutrition disorders,0
COARTEM,Anorexia,Metabolism and nutrition Anorexia,1
COARTEM,Anorexia,Anorexia,1
COARTEM,Anorexia,nutrition Anorexia,1
COARTEM,Anorexia,Anorexia,1
COARTEM,Anorexia,Metabolism,0
COARTEM,Anorexia,and nutrition Anorexia,1
COARTEM,Asthenia,Asthenia Pyrexia,1
COARTEM,Pyrexia,,0
COARTEM,Pyrexia,conditions,0
COARTEM,Pyrexia,,0
COARTEM,Pyrexia,Pyrexia Chills,1
COARTEM,Pyrexia,Pyrexia Chills,1
COARTEM,Pyrexia,Pyrexia Chills,1
COARTEM,Chills,Pyrexia Chills Fatigue,1
COARTEM,Chills,Chills Fatigue,1
COARTEM,Chills,,0
COARTEM,Fatigue,Fatigue,1
COARTEM,Fatigue,Chills Fatigue Malaise Musculoskeletal,1
COARTEM,Fatigue,Chills Fatigue,1
COARTEM,Fatigue,Fatigue Malaise,1
COARTEM,Fatigue,Chills,0
COARTEM,Fatigue,Malaise,0
COARTEM,Malaise,Malaise Musculoskeletal and,1
COARTEM,Malaise,connective,0
COARTEM,Malaise,Malaise Musculoskeletal and connective tissue disorders,1
COARTEM,Malaise,Fatigue Malaise,1
COARTEM,Arthralgia,tissue Arthralgia,1
COARTEM,Arthralgia,Arthralgia,1
COARTEM,Arthralgia,Arthralgia,1
COARTEM,Arthralgia,Arthralgia,1
COARTEM,Myalgia,and,0
COARTEM,Myalgia,Myalgia,1
COARTEM,Myalgia,Myalgia,1
COARTEM,Myalgia,tissue disorders Myalgia,1
COARTEM,Myalgia,Myalgia,1
COARTEM,Myalgia,and,0
COARTEM,Myalgia,disorders Myalgia,1
COARTEM,Myalgia,Gastrointestinal,0
COARTEM,Myalgia,Myalgia,1
COARTEM,Nausea,,0
COARTEM,Nausea,Gastrointestinal,0
COARTEM,Nausea,Gastrointestinal,0
COARTEM,Nausea,Myalgia Gastrointestinal Nausea Vomiting,1
COARTEM,Nausea,,0
COARTEM,Nausea,Gastrointestinal,0
COARTEM,Vomiting,,0
COARTEM,Vomiting,disorders Vomiting,1
COARTEM,Vomiting,Nausea,0
COARTEM,Vomiting,Nausea,0
COARTEM,Vomiting,pain,0
COARTEM,Vomiting,Vomiting,1
COARTEM,Abdominal pain,Vomiting Abdominal,1
COARTEM,Diarrhea,Diarrhea Psychiatric,1
COARTEM,Diarrhea,disorder,0
COARTEM,Diarrhea,Diarrhea Psychiatric,1
COARTEM,Diarrhea,Abdominal Diarrhea Psychiatric,1
COARTEM,Diarrhea,Diarrhea Psychiatric,1
COARTEM,Insomnia,Psychiatric disorders Sleep Insomnia Cardiac,1
COARTEM,Insomnia,Palpitations Hepatobiliary,0
COARTEM,Insomnia,,0
COARTEM,Insomnia,Sleep disorder,0
COARTEM,Palpitations,Palpitations Hepatobiliary,1
COARTEM,Palpitations,rder Insomnia Cardiac Palpitations Hepatobiliary,1
COARTEM,Palpitations,Palpitations Hepatobiliary,1
COARTEM,Palpitations,lym,0
COARTEM,Palpitations,Palpitations Hepatobiliary,1
COARTEM,Palpitations,,0
COARTEM,Palpitations,Palpitations Hepatobiliary,1
COARTEM,Palpitations,Palpitations Hepatobiliary,1
COARTEM,Palpitations,Palpitations Hepatobiliary,1
COARTEM,Hepatomegaly,,0
COARTEM,Hepatomegaly,Hepatomegaly Blood,1
COARTEM,Hepatomegaly,and,0
COARTEM,Splenomegaly,Splenomegaly Anemia,1
COARTEM,Splenomegaly,Splenomegaly Anemia,1
COARTEM,Splenomegaly,,0
COARTEM,Splenomegaly,Hepatomegaly Blood,0
COARTEM,Splenomegaly,,0
COARTEM,Splenomegaly,Anemia,0
COARTEM,Anemia,Anemia Respiratory,1
COARTEM,Anemia,Anemia Respiratory,1
COARTEM,Anemia,Anemia Respiratory,1
COARTEM,Anemia,Anemia Respiratory,1
COARTEM,Anemia,Anemia Respiratory,1
COARTEM,Anemia,disorders Splenomegaly,0
COARTEM,Anemia,Anemia Respiratory,1
COARTEM,Anemia,and lymphatic system,0
COARTEM,Cough,mediastinal,0
COARTEM,Cough,,0
COARTEM,Cough,Cough Skin,1
COARTEM,Cough,mediastinal,0
COARTEM,Cough,Respiratory thoracic and mediastinal Cough Skin,1
COARTEM,Pruritus,Pruritus Rash,1
COARTEM,Pruritus,tissue Pruritus Rash,1
COARTEM,Pruritus,subcutaneous tissue Pruritus Rash,1
COARTEM,Pruritus,Pruritus Rash,1
COARTEM,Pruritus,Rash Ear and labyrinth,0
COARTEM,Pruritus,disorders Cough Skin and,0
COARTEM,Pruritus,,0
COARTEM,Pruritus,Cough Skin and subcutaneous,0
COARTEM,Pruritus,Pruritus Rash,1
COARTEM,Pruritus,Ear,0
COARTEM,Rash,Rash Ear,1
COARTEM,Rash,,0
COARTEM,Rash,Rash Ear,1
COARTEM,Rash,and subcutaneous tissue,0
COARTEM,Rash,tissue disorders Rash Ear,1
COARTEM,Rash,Pruritus,0
COARTEM,Vertigo,Vertigo Infections,1
COARTEM,Vertigo,,0
COARTEM,Vertigo,Vertigo Infections,1
COARTEM,Vertigo,Rash Ear and labyrinth Vertigo Infections,1
COARTEM,Vertigo,Vertigo Infections,1
COARTEM,Vertigo,Vertigo Infections,1
COARTEM,Malaria,infestations,0
COARTEM,Malaria,,0
COARTEM,Malaria,,0
COARTEM,Malaria,Malaria Nasopharyngitis,1
COARTEM,Nasopharyngitis,as years of age Table Adverse Reac,0
COARTEM,Nasopharyngitis,Reac,0
COARTEM,Pyrexia,Pyrexia Chills,1
COARTEM,Pyrexia,,0
COARTEM,Chills,,0
COARTEM,Chills,administration site conditions Chills Asthenia,1
COARTEM,Chills,Chills Asthenia,1
COARTEM,Chills,Chills Asthenia,1
COARTEM,Chills,Asthenia,0
COARTEM,Fatigue,,0
COARTEM,Fatigue,Asthenia,0
COARTEM,Fatigue,Fatigue Respiratory thoracic and,1
COARTEM,Fatigue,Fatigue Respiratory thoracic and mediastinal,1
COARTEM,Fatigue,Asthenia,0
COARTEM,Fatigue,Fatigue,1
COARTEM,Fatigue,Asthenia,0
COARTEM,Fatigue,Fatigue,1
COARTEM,Cough,mediastinal Cough,1
COARTEM,Cough,Cough,1
COARTEM,Cough,Cough,1
COARTEM,Vomiting,disorders Cough Gastrointestinal Vomiting,1
COARTEM,Vomiting,Vomiting,1
COARTEM,Vomiting,Vomiting,1
COARTEM,Vomiting,disorders Cough Gastrointestinal Vomiting,1
COARTEM,Vomiting,Abdominal pain,0
COARTEM,Vomiting,mediastinal disorders Cough Gastrointestinal,0
COARTEM,Vomiting,Gastrointestinal,0
COARTEM,Vomiting,Vomiting,1
COARTEM,Abdominal pain,disorders Abdominal pain,1
COARTEM,Abdominal pain,,0
COARTEM,Abdominal pain,Gastrointestinal disorders Abdominal pain,1
COARTEM,Abdominal pain,,0
COARTEM,Abdominal pain,disorders Abdominal,1
COARTEM,Abdominal pain,,0
COARTEM,Diarrhea,Abdominal Diarrhea,1
COARTEM,Diarrhea,Infections and in,0
COARTEM,Diarrhea,Diarrhea,1
COARTEM,Diarrhea,,0
COARTEM,Diarrhea,and in,0
COARTEM,Diarrhea,,0
COARTEM,Diarrhea,,0
COARTEM,Diarrhea,Diarrhea,1
COARTEM,Diarrhea,Abdominal Diarrhea,1
COARTEM,Nausea,Nausea,1
COARTEM,Plasmodium falciparum infection,falciparum infection,1
COARTEM,Plasmodium falciparum infection,,0
COARTEM,Plasmodium falciparum infection,Rhinitis Metabolism and,0
COARTEM,Plasmodium falciparum infection,infestations,0
COARTEM,Plasmodium falciparum infection,Infections,0
COARTEM,Rhinitis,,0
COARTEM,Anorexia,,0
COARTEM,Anorexia,Anorexia,1
COARTEM,Anorexia,Metabolism and,0
COARTEM,Anorexia,nutrition,0
COARTEM,Headache,,0
COARTEM,Headache,,0
COARTEM,Dizziness,Headache,0
COARTEM,Dizziness,,0
COARTEM,Dizziness,Dizziness,1
COARTEM,Dizziness,Dizziness,1
COARTEM,Dizziness,Dizziness,1
COARTEM,Splenomegaly,Hepatobiliary disorde,0
COARTEM,Splenomegaly,disorders,0
COARTEM,Splenomegaly,Splenomegaly,1
COARTEM,Splenomegaly,lymphatic system Splenomegaly,1
COARTEM,Splenomegaly,Splenomegaly,1
COARTEM,Splenomegaly,Splenomegaly,1
COARTEM,Splenomegaly,lymphatic system Splenomegaly,1
COARTEM,Splenomegaly,Blood and lymphatic system Splenomegaly,1
COARTEM,Splenomegaly,,0
COARTEM,Splenomegaly,Splenomegaly,1
COARTEM,Anemia,Anemia,1
COARTEM,Anemia,lymphatic system disorders Anemia,1
COARTEM,Anemia,Anemia,1
COARTEM,Anemia,Anemia,1
COARTEM,Hepatomegaly,Hepatobiliary,0
COARTEM,Hepatomegaly,Hepatobiliary disorders,0
COARTEM,Hepatomegaly,,0
COARTEM,Hepatomegaly,disorders,0
COARTEM,Hepatomegaly,Anemia Hepatobiliary Hepatomegaly,1
COARTEM,Hepatomegaly,,0
COARTEM,Hepatomegaly,Anemia Hepatobiliary Hepatomegaly,1
COARTEM,Hepatomegaly,,0
COARTEM,Hepatomegaly,Hepatobiliary Hepatomegaly,1
COARTEM,Aspartate aminotransferase increased,Hepatomegaly Aspartate aminotransferase,1
COARTEM,Aspartate aminotransferase increased,Aspartate aminotransferase increased,1
COARTEM,Aspartate aminotransferase increased,Hepatomegaly Investigations,0
COARTEM,Arthralgia,aminotransferase increased Musculoskeletal and connective tissue,0
COARTEM,Arthralgia,Arthralgia,1
COARTEM,Arthralgia,and connective tissue disorders,0
COARTEM,Myalgia,Myalgia,1
COARTEM,Myalgia,Myalgia,1
COARTEM,Myalgia,disorders,0
COARTEM,Myalgia,Myalgia,1
COARTEM,eosinophilia,disorders conjunctivitis G,0
COARTEM,eosinophilia,eosinophilia,1
COARTEM,eosinophilia,listed,0
COARTEM,eosinophilia,Blood and lymphatic system eosinophilia,1
COARTEM,eosinophilia,,0
COARTEM,eosinophilia,system eosinophilia,1
COARTEM,eosinophilia,eosinophilia,1
COARTEM,eosinophilia,and lymphatic system eosinophilia,1
COARTEM,eosinophilia,lymphatic system eosinophilia,1
COARTEM,tinnitus,eosinophilia,0
COARTEM,tinnitus,tinnitus,1
COARTEM,tinnitus,tinnitus,1
COARTEM,tinnitus,conjunctivitis,0
COARTEM,conjunctivitis,Ge,0
COARTEM,conjunctivitis,Ear and labyrinth disorders tinnitus Eye disorders,0
COARTEM,conjunctivitis,conjunctivitis,1
COARTEM,conjunctivitis,conjunctivitis,1
COARTEM,conjunctivitis,,0
COARTEM,conjunctivitis,conjunctivitis,1
COARTEM,conjunctivitis,conjunctivitis,1
COARTEM,conjunctivitis,conjunctivitis,1
COARTEM,dyspepsia,disorders gait disturbance Infections and inf,0
COARTEM,dyspepsia,dyspepsia,1
COARTEM,dyspepsia,dyspepsia,1
COARTEM,dyspepsia,disorders conjunctivitis,0
COARTEM,dyspepsia,dyspepsia,1
COARTEM,dyspepsia,conjunctivitis Gastrointestinal disorders dyspepsia,1
COARTEM,dyspepsia,conjunctivitis Gastrointestinal disorders dyspepsia,1
COARTEM,dyspepsia,disturbance Infections and,0
COARTEM,dysphagia,,0
COARTEM,peptic ulcer,and,0
COARTEM,peptic ulcer,dysphagia,0
COARTEM,peptic ulcer,constipation dyspepsia peptic ulcer,1
COARTEM,peptic ulcer,ulcer,1
COARTEM,peptic ulcer,disorders constipation dyspepsia peptic,1
COARTEM,peptic ulcer,ulcer,1
COARTEM,gait disturbance,disorders,0
COARTEM,gait disturbance,General gait disturbance,1
COARTEM,gait disturbance,disorders,0
COARTEM,abscess,abscess,1
COARTEM,abscess,disorders gait,0
COARTEM,abscess,infestations,0
COARTEM,bronchitis,infection gastroenteritis helminthic infection hookworm infection impetigo influenza,0
COARTEM,bronchitis,infection gastroenteritis helminthic infection,0
COARTEM,bronchitis,bronchitis,1
COARTEM,bronchitis,bronchitis,1
COARTEM,bronchitis,,0
COARTEM,bronchitis,,0
COARTEM,bronchitis,Infections and infestations abscess bronchitis,1
COARTEM,gastroenteritis,and infestations abscess acrodermatitis,0
COARTEM,gastroenteritis,gastroenteritis,1
COARTEM,helminthic infection,abscess,0
COARTEM,helminthic infection,ear infection helminthic      infection,1
COARTEM,hookworm infection,infection,1
COARTEM,hookworm infection,infection gastroenteritis,0
COARTEM,impetigo,impetigo,1
COARTEM,impetigo,impetigo,1
COARTEM,impetigo,infection hookworm impetigo,1
COARTEM,impetigo,malaria,0
COARTEM,influenza,gastroenteritis helminthic,0
COARTEM,influenza,infection,0
COARTEM,influenza,influenza,1
COARTEM,influenza,infection influenza,1
COARTEM,influenza,influenza,1
COARTEM,influenza,,0
COARTEM,influenza,infection gastroenteritis helminthic infection hookworm infection impetigo,0
COARTEM,influenza,,0
COARTEM,influenza,hookworm infection,0
COARTEM,lower respiratory tract infection,infection,0
COARTEM,lower respiratory tract infection,,0
COARTEM,nasopharyngitis,tract infection subcutaneous abscess,0
COARTEM,nasopharyngitis,herpes pneumonia respiratory tract infection,0
COARTEM,nasopharyngitis,nasopharyngitis,1
COARTEM,nasopharyngitis,respiratory tract infection nasopharyngitis,1
COARTEM,nasopharyngitis,pneumonia,0
COARTEM,nasopharyngitis,tract infection subcutaneous,0
COARTEM,nasopharyngitis,tract infection malaria,0
COARTEM,nasopharyngitis,lower respiratory tract infection nasopharyngitis,1
COARTEM,nasopharyngitis,nasopharyngitis,1
COARTEM,pneumonia,upper respiratory tract,0
COARTEM,pneumonia,pneumonia,1
COARTEM,pneumonia,oral,0
COARTEM,pneumonia,upper respiratory tract,0
COARTEM,pneumonia,nasopharyngitis,0
COARTEM,pneumonia,infection urinary,0
COARTEM,pneumonia,respiratory tract infection,0
COARTEM,pneumonia,malaria nasopharyngitis oral pneumonia,1
COARTEM,pneumonia,,0
COARTEM,pneumonia,pneumonia,1
COARTEM,respiratory tract infection,malaria nasopharyngitis oral herpes respiratory tract,1
COARTEM,respiratory tract infection,oral herpes respiratory tract infection,1
COARTEM,respiratory tract infection,respiratory tract infection malaria nasopharyngitis,0
COARTEM,respiratory tract infection,nasopharyngitis oral herpes respiratory tract,1
COARTEM,respiratory tract infection,herpes respiratory,1
COARTEM,respiratory tract infection,tract infection,1
COARTEM,respiratory tract infection,,0
COARTEM,subcutaneous abscess,abscess,1
COARTEM,upper respiratory tract infection,infection subcutaneous upper      respiratory tract infection,1
COARTEM,upper respiratory tract infection,,0
COARTEM,upper respiratory tract infection,upper respiratory tract infection,1
COARTEM,upper respiratory tract infection,herpes pneumonia,0
COARTEM,urinary tract infection,tract urinary,1
COARTEM,urinary tract infection,increased,0
COARTEM,urinary tract infection,,0
COARTEM,urinary tract infection,urinary tract infection,1
COARTEM,urinary tract infection,alanine aminotransferase increased aspartate,0
COARTEM,urinary tract infection,,0
COARTEM,urinary tract infection,upper respiratory tract urinary tract infection,1
COARTEM,urinary tract infection,tract infection,1
COARTEM,urinary tract infection,,0
COARTEM,alanine aminotransferase increased,infection urinary,0
COARTEM,alanine aminotransferase increased,hematocrit decreased,0
COARTEM,alanine aminotransferase increased,tract infection Investigations,0
COARTEM,alanine aminotransferase increased,infection Investigations,0
COARTEM,alanine aminotransferase increased,tract,0
COARTEM,alanine aminotransferase increased,infection alanine aminotransferase increased,1
COARTEM,alanine aminotransferase increased,,0
COARTEM,alanine aminotransferase increased,respiratory tract infection,0
COARTEM,aspartate aminotransferase increased,increased,1
COARTEM,aspartate aminotransferase increased,,0
COARTEM,aspartate aminotransferase increased,Investigations alanine aminotransferase aspartate aminotransferase increased,1
COARTEM,aspartate aminotransferase increased,aminotransferase aspartate aminotransferase,1
COARTEM,hematocrit decreased,platelet count decreased platelet count increased white,0
COARTEM,lymphocyte morphology abnormal,increased,0
COARTEM,lymphocyte morphology abnormal,aminotransferase increased aspartate aminotransferase increased hematocrit,0
COARTEM,platelet count decreased,platelet count decreased,1
COARTEM,platelet count decreased,decreased lymphocyte morphology abnormal,0
COARTEM,platelet count decreased,platelet count decreased,1
COARTEM,platelet count decreased,decreased white,0
COARTEM,platelet count decreased,decreased,1
COARTEM,platelet count decreased,morphology platelet,1
COARTEM,platelet count decreased,hematocrit decreased,0
COARTEM,platelet count decreased,,0
COARTEM,platelet count decreased,aminotransferase increased hematocrit decreased,0
COARTEM,platelet count increased,platelet count increased,1
COARTEM,platelet count increased,white blood cell count increased,0
COARTEM,platelet count increased,,0
COARTEM,platelet count increased,morphology abnormal platelet count platelet count increased,1
COARTEM,platelet count increased,morphology abnormal platelet count platelet count,1
COARTEM,white blood cell count decreased,white blood cell count decreased,1
COARTEM,white blood cell count decreased,count increased Metabolism and nutrition disorders,0
COARTEM,white blood cell count decreased,white blood cell count decreased,1
COARTEM,white blood cell count decreased,count decreased,1
COARTEM,white blood cell count decreased,count decreased,0
COARTEM,white blood cell count decreased,and nutrition,0
COARTEM,white blood cell count decreased,,0
COARTEM,white blood cell count decreased,,0
COARTEM,white blood cell count increased,Musculoskeletal,0
COARTEM,white blood cell count increased,white blood,1
COARTEM,white blood cell count increased,decreased,0
COARTEM,white blood cell count increased,white blood cell count white blood cell count,1
COARTEM,hypokalemia,hypokalemia,1
COARTEM,hypokalemia,,0
COARTEM,hypokalemia,and connective,0
COARTEM,hypokalemia,hypokalemia,1
COARTEM,hypokalemia,hypokalemia,1
COARTEM,back pain,clonus fine motor delay hyperreflexia,0
COARTEM,back pain,back pain,1
COARTEM,back pain,and connective,0
COARTEM,back pain,,0
COARTEM,back pain,back pain,1
COARTEM,back pain,connective tissue back,1
COARTEM,ataxia,back pain Nervous system ataxia,1
COARTEM,ataxia,ataxia,1
COARTEM,ataxia,and connective tissue disorders,0
COARTEM,ataxia,ataxia,1
COARTEM,ataxia,clonus fine motor,0
COARTEM,clonus,,0
COARTEM,clonus,clonus,1
COARTEM,clonus,hypoesthesia nystagmus tremor Psychiatric,0
COARTEM,clonus,,0
COARTEM,clonus,connective tissue disorders back,0
COARTEM,clonus,clonus,1
COARTEM,clonus,,0
COARTEM,fine motor delay,fine motor,1
COARTEM,fine motor delay,,0
COARTEM,fine motor delay,motor delay,1
COARTEM,fine motor delay,,0
COARTEM,fine motor delay,motor delay,1
COARTEM,fine motor delay,delay,1
COARTEM,fine motor delay,Psychiatric disorders agitation mo,0
COARTEM,fine motor delay,pain Nervous system disorders ataxia,0
COARTEM,hyperreflexia,hyperreflexia,1
COARTEM,hyperreflexia,disorders ataxia clonus fine motor,0
COARTEM,hyperreflexia,hyperreflexia,1
COARTEM,hyperreflexia,tremor Psychiatric,0
COARTEM,hyperreflexia,hyperreflexia,1
COARTEM,hyperreflexia,fine motor hyperreflexia,1
COARTEM,hyperreflexia,tissue disorders back pain Nervous system disorders,0
COARTEM,nystagmus,,0
COARTEM,nystagmus,,0
COARTEM,nystagmus,di,0
COARTEM,nystagmus,nystagmus,1
COARTEM,nystagmus,disorders,0
COARTEM,tremor,tremor,1
COARTEM,tremor,tremor,1
COARTEM,agitation,Psychiatric agitation,1
COARTEM,agitation,t,0
COARTEM,agitation,t,0
COARTEM,agitation,nystagmus,0
COARTEM,agitation,agitation,1
COARTEM,agitation,,0
COARTEM,agitation,disorders hematuria,0
COARTEM,agitation,nystagmus tremor Psychiatric disorders,0
COARTEM,agitation,agitation,1
COARTEM,agitation,motor delay hyperreflexia hypoesthesia,0
COARTEM,mood swings,,0
COARTEM,mood swings,nystagmus tremor Psychiatric disorders mood swings,1
COARTEM,hematuria,hematuria,1
COARTEM,hematuria,disorders agitation mood swings Renal and,0
COARTEM,hematuria,Renal and urinary disorders,0
COARTEM,hematuria,hematuria,1
COARTEM,proteinuria,pain,0
COARTEM,proteinuria,disorders agitation mood swings,0
COARTEM,pharyngo-laryngeal pain,pharyngo-laryngeal pain,1
COARTEM,pharyngo-laryngeal pain,and subcutaneous tissue disorders urticaria Postmarketing Experience,0
COARTEM,pharyngo-laryngeal pain,disorders pharyngo-laryngeal,1
COARTEM,pharyngo-laryngeal pain,Respiratory thoracic and,0
COARTEM,urticaria,urticaria,1
COARTEM,urticaria,disorders asthma pharyngolaryngeal pain Skin and subcutaneous tissue,0
COARTEM,urticaria,duri,0
COARTEM,urticaria,urticaria,1
COARTEM,urticaria,Skin and subcutaneous tissue urticaria,1
COARTEM,urticaria,urticaria,1
COARTEM,anaphylaxis,serious,0
COARTEM,anaphylaxis,causal relationship to drug,0
COARTEM,anaphylaxis,establish a causal relationship to drug exposure Hypersensitivity reactions,0
COARTEM,urticaria,urticaria,1
COARTEM,urticaria,bullous,0
COARTEM,urticaria,urticaria,1
COARTEM,angioedema,angioedema,1
COARTEM,angioedema,reported,0
COARTEM,angioedema,reported,0
COARTEM,angioedema,,0
COARTEM,skin reactions,anaphylaxis urticaria angioedema and skin reactions,1
COARTEM,skin reactions,anaphylaxis urticaria angioedema and skin reactions,1
COARTEM,skin reactions,urticaria angioedema and skin,1
COARTEM,skin reactions,,0
COARTEM,bullous eruption,,0
COARTEM,bullous eruption,serious skin bullous eruption,1
COARTEM,bullous eruption,serious skin bullous,1
COARTEM,bullous eruption,serious skin bullous eruption,1
COARTEM,bullous eruption,urticaria angioedema and serious skin,0
COARTEM,bullous eruption,bullous,1
COARTEM,bullous eruption,,0
COARTEM,bullous eruption,serious skin bullous,1
COARTEM,bullous eruption,and serious skin bullous eruption,1
COARTEM,prolongation of the QT interval,sure to a 6-dose,1
COARTEM,QT prolongation,rs Palpitations Hepatobiliary disorders Blood,1
COARTEM,QT prolongation,Blood and,1
COARTEM,QT prolongation,Palpitations Hepatobiliary disorders Blood,1
COARTEM,QT prolongation,,0
COARTEM,QT prolongation,Blood and ly,1
DALVANCE,nausea,The most common adverse reactions,0
DALVANCE,nausea,nausea,1
DALVANCE,nausea,nausea,1
DALVANCE,nausea,nausea,1
DALVANCE,nausea,patients treated with DALVANCE nausea,1
DALVANCE,nausea,adverse reactions in patients,0
DALVANCE,nausea,were,0
DALVANCE,nausea,nausea,1
DALVANCE,nausea,with DALVANCE,0
DALVANCE,headache,headache,1
DALVANCE,headache,diarrhea To report,0
DALVANCE,headache,contact Durata Thera,0
DALVANCE,headache,headache,1
DALVANCE,headache,Durata Thera,0
DALVANCE,headache,Durata Thera,0
DALVANCE,headache,headache,1
DALVANCE,diarrhea,diarrhea,1
DALVANCE,diarrhea,diarrhea,1
DALVANCE,diarrhea,,0
DALVANCE,diarrhea,diarrhea,1
DALVANCE,diarrhea,nausea headache and,0
DALVANCE,diarrhea,diarrhea,1
DALVANCE,nausea,patients treated with DALVANCE nausea,1
DALVANCE,headache,headache,1
DALVANCE,headache,with DALVANCE were headache,1
DALVANCE,headache,median duration of adverse reactions was,0
DALVANCE,headache,treatmen,0
DALVANCE,headache,headache,1
DALVANCE,headache,headache,1
DALVANCE,headache,headache,1
DALVANCE,headache,headache,1
DALVANCE,headache,headache,1
DALVANCE,headache,headache,1
DALVANCE,diarrhea,,0
DALVANCE,diarrhea,diarrhea,1
DALVANCE,diarrhea,were nausea headache diarrhea,1
DALVANCE,diarrhea,diarrhea,1
DALVANCE,diarrhea,diarrhea,1
DALVANCE,Nausea,,0
DALVANCE,Nausea,,0
DALVANCE,Nausea,Nausea Vomiting,1
DALVANCE,Nausea,Nausea Vomiting,1
DALVANCE,Nausea,Dalbavancin Comparator N Nausea Vomiting,1
DALVANCE,Nausea,Nausea Vomiting,1
DALVANCE,Nausea,Dalbavancin Comparator N Nausea Vomiting,1
DALVANCE,Vomiting,Vomiting Diarrhea,1
DALVANCE,Vomiting,Vomiting Diarrhea,1
DALVANCE,Diarrhea,,0
DALVANCE,Diarrhea,Diarrhea Headache,1
DALVANCE,Diarrhea,Headache,0
DALVANCE,Diarrhea,Vomiting,0
DALVANCE,Diarrhea,Vomiting,0
DALVANCE,Diarrhea,,0
DALVANCE,Headache,Headache Rash,1
DALVANCE,Headache,Diarrhea,0
DALVANCE,Headache,Diarrhea,0
DALVANCE,Headache,,0
DALVANCE,Headache,Headache Rash,1
DALVANCE,Headache,,0
DALVANCE,Rash,Rash Pruritus,1
DALVANCE,Rash,,0
DALVANCE,anemia,anemia,1
DALVANCE,anemia,neutropenia thrombocytopenia petechiae,0
DALVANCE,anemia,,0
DALVANCE,anemia,anemia,1
DALVANCE,anemia,lymphatic,0
DALVANCE,anemia,and lymphatic system,0
DALVANCE,anemia,a rate of less than,0
DALVANCE,hemorrhagic anemia,and lymphatic system disorders hemorrhagic,1
DALVANCE,hemorrhagic anemia,,0
DALVANCE,hemorrhagic anemia,lymphatic system disorders hemorrhagic anemia,1
DALVANCE,hemorrhagic anemia,thrombocytopenia petechiae eosinophilia,0
DALVANCE,leucopenia,leucopenia,1
DALVANCE,leucopenia,leucopenia,1
DALVANCE,leucopenia,hemorrhagic leucopenia,1
DALVANCE,leucopenia,leucopenia,1
DALVANCE,leucopenia,anemia hemorrhagic leucopenia,1
DALVANCE,leucopenia,diso,0
DALVANCE,petechiae,petechiae,1
DALVANCE,petechiae,anemia leucopenia neutropenia petechiae,1
DALVANCE,petechiae,petechiae,1
DALVANCE,petechiae,anemia leucopenia neutropenia petechiae,1
DALVANCE,petechiae,,0
DALVANCE,petechiae,anemia leucopenia,0
DALVANCE,petechiae,hemorrhagic anemia leucopenia neutropenia petechiae,1
DALVANCE,petechiae,,0
DALVANCE,petechiae,,0
DALVANCE,petechiae,Gastrointestinal disorders,0
DALVANCE,eosinophilia,eosinophilia,1
DALVANCE,eosinophilia,eosinophilia,1
DALVANCE,eosinophilia,,0
DALVANCE,thrombocytosis,Gastrointestinal disorders gastrointestinal hemorrhage melena hematochezia abdominal pa,0
DALVANCE,thrombocytosis,hemorrhagic anemia,0
DALVANCE,thrombocytosis,melena,0
DALVANCE,thrombocytosis,thrombocytosis,1
DALVANCE,thrombocytosis,thrombocytosis,1
DALVANCE,thrombocytosis,thrombocytosis,1
DALVANCE,gastrointestinal hemorrhage,gastrointestinal hemorrhage,1
DALVANCE,gastrointestinal hemorrhage,,0
DALVANCE,hematochezia,hematochezia,1
DALVANCE,hematochezia,hematochezia,1
DALVANCE,hematochezia,hemorrhage hematochezia,1
DALVANCE,hematochezia,conditions,0
DALVANCE,hematochezia,hemorrhage hematochezia,1
DALVANCE,infusion-related reactions,infusion-related reactions,1
DALVANCE,infusion-related reactions,,0
DALVANCE,hepatotoxicity,reactions Hepatobiliary,0
DALVANCE,hepatotoxicity,administration site conditions infusionrelated,0
DALVANCE,hepatotoxicity,hepatotoxicity,1
DALVANCE,hepatotoxicity,hepatotoxicity,1
DALVANCE,hepatotoxicity,,0
DALVANCE,hepatotoxicity,,0
DALVANCE,hepatotoxicity,,0
DALVANCE,hepatotoxicity,hepatotoxicity,1
DALVANCE,hepatotoxicity,hepatotoxicity,1
DALVANCE,anaphylactoid reaction,,0
DALVANCE,Clostridium difficile colitis,Clostridium difficile colitis,1
DALVANCE,Clostridium difficile colitis,Clostridium difficile  colitis,1
DALVANCE,Clostridium difficile colitis,,0
DALVANCE,Clostridium difficile colitis,anaphylactoid reaction,0
DALVANCE,Clostridium difficile colitis,Clostridium difficile  colitis,1
DALVANCE,oral candidiasis,anaphylactoid reaction,0
DALVANCE,oral candidiasis,difficile oral,1
DALVANCE,oral candidiasis,oral candidiasis,1
DALVANCE,oral candidiasis,difficile oral candidiasis,1
DALVANCE,oral candidiasis,oral candidiasis,1
DALVANCE,oral candidiasis,and infestations Clostridium difficile oral,1
DALVANCE,oral candidiasis,vulvovaginal mycotic infection Investigations hepatic transaminases increased,0
DALVANCE,oral candidiasis,anaphylactoid reaction Infections and,0
DALVANCE,vulvovaginal mycotic infection,infection,1
DALVANCE,vulvovaginal mycotic infection,oral vulvovaginal mycotic infection,1
DALVANCE,vulvovaginal mycotic infection,oral vulvovaginal mycotic infection,1
DALVANCE,vulvovaginal mycotic infection,oral vulvovaginal mycotic,1
DALVANCE,hepatic transaminases increased,mycotic infection hepatic transaminases increased,1
DALVANCE,hepatic transaminases increased,infection hepatic transaminases,1
DALVANCE,hepatic transaminases increased,difficile,0
DALVANCE,hepatic transaminases increased,transaminases increased,1
DALVANCE,hepatic transaminases increased,mycotic infection hepatic,1
DALVANCE,hepatic transaminases increased,,0
DALVANCE,hepatic transaminases increased,hepatic transaminases increased,1
DALVANCE,hepatic transaminases increased,difficile colitis oral candidiasis vulvovaginal,0
DALVANCE,hepatic transaminases increased,transaminases increased,1
DALVANCE,hepatic transaminases increased,vulvovaginal mycotic infection hepatic transaminases,1
DALVANCE,international normalized ratio increased,phosphatase,0
DALVANCE,international normalized ratio increased,phosphatase international normalized ratio increased,1
DALVANCE,international normalized ratio increased,hepatic,0
DALVANCE,international normalized ratio increased,Metabolism and nutrition,0
DALVANCE,international normalized ratio increased,blood alkaline,0
DALVANCE,international normalized ratio increased,hypoglycemia Nervous System,0
DALVANCE,international normalized ratio increased,nutrition disorders,0
DALVANCE,hypoglycemia,hypoglycemia,1
DALVANCE,hypoglycemia,hypoglycemia,1
DALVANCE,hypoglycemia,dizziness,0
DALVANCE,hypoglycemia,nutrition hypoglycemia,1
DALVANCE,hypoglycemia,nutrition hypoglycemia,1
DALVANCE,hypoglycemia,increased Metabolism and nutrition hypoglycemia,1
DALVANCE,dizziness,bronchospasm Skin and,0
DALVANCE,dizziness,,0
DALVANCE,dizziness,dizziness,1
DALVANCE,dizziness,,0
DALVANCE,dizziness,thoracic and mediastinal disorders bronchospasm Skin and Subcutaneous T,0
DALVANCE,dizziness,Respiratory thoracic and mediastinal,0
DALVANCE,dizziness,Skin and,0
DALVANCE,dizziness,System disorders,0
DALVANCE,dizziness,dizziness,1
DALVANCE,dizziness,dizziness,1
DALVANCE,urticaria,Subcutaneous Tissue urticaria,1
DALVANCE,urticaria,and mediastinal disorders bronchospasm Skin and Subcutaneous Tissue disorders,0
DALVANCE,urticaria,disorders bronchospasm Skin and,0
DALVANCE,urticaria,Subcutaneous Tissue urticaria,1
DALVANCE,urticaria,urticaria,1
DALVANCE,urticaria,,0
DALVANCE,urticaria,urticaria,1
DALVANCE,urticaria,Skin and Subcutaneous Tissue urticaria,1
DALVANCE,urticaria,,0
DALVANCE,flushing,flushing,1
DALVANCE,flushing,flushing,1
DALVANCE,flushing,Tissue disorders urticaria Vascular flushing,1
DALVANCE,flushing,hemorrhage,0
DALVANCE,flushing,flushing,1
DALVANCE,wound hemorrhage,and Subcutaneous Tissue disorders urticaria Vascular disorders flushing,0
DALVANCE,wound hemorrhage,,0
DALVANCE,wound hemorrhage,and Subcutaneous Tissue disorders urticaria,0
DALVANCE,wound hemorrhage,Among patients,0
DALVANCE,spontaneous hematoma,with normal,0
DALVANCE,spontaneous hematoma,phlebitis wound spontaneous hematoma,1
DALVANCE,spontaneous hematoma,Aminotransferase ALT Elevations Among patients with,0
DALVANCE,spontaneous hematoma,spontaneous,1
DALVANCE,spontaneous hematoma,,0
DALVANCE,spontaneous hematoma,disorders flushing phlebitis wound spontaneous,1
DALVANCE,ALT elevations,ALT elevations,1
DALVANCE,ALT elevations,levels more DALVANCE than comparatortreated patients,0
DALVANCE,ALT elevations,ALT elevations,1
DALVANCE,ALT elevations,levels more,0
DALVANCE,ALT elevations,upper,0
DALVANCE,ALT elevations,greater than times the upper limit of normal ULN vs respectively,0
DALVANCE,ALT elevations,postbaseline,0
DALVANCE,ALT elevations,normal ULN vs respectively,0
DALVANCE,ALT elevations,more DALVANCE than comparatortreated patients had,0
DALVANCE,ALT values greater than 10 times ULN,ULN,1
DALVANCE,ALT values greater than 10 times ULN,subjects with ALT values greater than 10 times,1
DALVANCE,ALT values greater than 10 times ULN,including three subjects with ALT values greater than 10 times ULN,1
DALVANCE,ALT values greater than 10 times ULN,including three subjects with ALT,1
DALVANCE,ALT elevations,of alcohol abuse In addition one DALVANCEtreated subject in a Phase trial,0
DALVANCE,ALT elevations,had ALT elevations,1
DALVANCE,ALT elevations,elevations,1
DALVANCE,ALT elevations,ALT elevations,1
DALVANCE,ALT elevations,had ALT,1
DALVANCE,ALT elevations,elevations greater than times ALT elevations,1
DALVANCE,ALT elevations,,0
DALVANCE,ALT elevations,ALT elevations,1
DALVANCE,ALT elevations,than,0
DALVANCE,ALT elevations,elevations,1
DALVANCE,ALT elevations,than times ALT elevations,1
DALVANCE,ALT elevation,normal baseline transaminases had ALT elevation,1
DALVANCE,ALT elevation,ALT elevation,1
DALVANCE,skin reactions,trials of DALVANCE cannot be directly compared to rates,0
DALVANCE,skin reactions,,0
DALVANCE,skin reactions,,0
DALVANCE,ALT elevations,,0
DALVANCE,ALT elevations,"DALVANCE were a (5.5%), head ache and diarrhea",1
DALVANCE,ALT elevations,To report,0
DALVANCE,Clostridium difficile -associated diarrhea,"report SUSPECTED ADVERSE ACTIONS, contact Durata Therapeutics, Inc. at or FDA",1
DALVANCE,Clostridium difficile -associated diarrhea,or,0
DALVANCE,Clostridium difficile -associated diarrhea,"ACTIONS,",1
DALVANCE,Clostridium difficile -associated diarrhea,"contact Durata Therapeutics, Inc. at or FDA",1
DALVANCE,Clostridium difficile -associated diarrhea,"contact Durata Therapeutics, Inc. at or FDA",1
DALVANCE,Clostridium difficile -associated diarrhea,"Therapeutics, Inc. at or FDA",1
DALVANCE,Clostridium difficile -associated diarrhea,nausea headache and diarrhea To report,0
DALVANCE,Clostridium difficile -associated diarrhea,"report SUSPECTED ADVERSE ACTIONS, contact",1
DALVANCE,Clostridium difficile -associated diarrhea,"contact Durata Therapeutics, Inc. at or FDA",1
DALVANCE,Clostridium difficile -associated diarrhea,report SUSPECTED,0
DALVANCE,CDAD,,0
DALVANCE,skin reactions,betwe,0
DALVANCE,Red-Man Syndrome,comparator,1
DALVANCE,Red-Man Syndrome,and the,0
DALVANCE,Red-Man Syndrome,,0
DALVANCE,Red-Man Syndrome,reaction in patients and comparator,1
DALVANCE,Red-Man Syndrome,and,0
DALVANCE,Red-Man Syndrome,in patients and comparator,1
DALVANCE,Red-Man Syndrome,comparator was discontinued due to,1
DALVANCE,Red-Man Syndrome,Common Adverse,0
DALVANCE,flushing of the upper body,Common Adverse Reactions The most common adverse,0
DALVANCE,flushing of the upper body,and the comparator was due to an,1
DALVANCE,flushing of the upper body,was due to an,1
DALVANCE,flushing of the upper body,an adverse reaction in patients Most,1
DALVANCE,flushing of the upper body,the comparator was due to an adverse,1
DALVANCE,flushing of the upper body,due to,1
DALVANCE,flushing of the upper body,due,1
DALVANCE,flushing of the upper body,to an adverse reaction in patients Most,1
DALVANCE,urticaria,reaction n,1
DALVANCE,urticaria,n 35/1224 patients Most Common,1
DALVANCE,pruritus,pa tients Most Common,1
DALVANCE,pruritus,and,0
DALVANCE,pruritus,,0
DALVANCE,pruritus,2.8%),1
DALVANCE,pruritus,an adverse reaction 2.8%) pa tients Most Common,1
DALVANCE,pruritus,reactions in,0
DALVANCE,pruritus,Most Common Adverse Reactions The most common adverse reactions in,0
DALVANCE,pruritus,an adverse reaction 2.8%),1
DALVANCE,Clostridium difficile -associated diarrhea,Dalbavancin Comparator N N a           98 (5.5)         78 (6.4)       Vomiting Diarrhea,1
DALVANCE,Clostridium difficile -associated diarrhea,(5.5) 78 (6.4) Vomiting Diarrhea,1
DALVANCE,CDAD,Vomiting Diarrhea,0
DALVANCE,CDAD," 
   Vomiting Diarrhea",1
DALVANCE,diarrhea,Diarrhea 83,1
DALVANCE,diarrhea,,0
DALVANCE,diarrhea,,0
DALVANCE,diarrhea,Diarrhea 83 (4.7) Rash Pruritus,1
DALVANCE,diarrhea,,0
DALVANCE,fatal,      Rash Pruritus,1
DALVANCE,fatal,      Rash Pruritus,1
DALVANCE,fatal,,0
DALVANCE,fatal,      Rash Pruritus,1
DALVANCE,fatal,      Rash Pruritus,1
DALVANCE,fatal,      Rash Pruritus,1
DALVANCE,colitis,Diarrhea 9 (4.8) Rash Pruritus,1
DALVANCE,colitis,9 (4.8) Rash Pruritus,1
DALVANCE,colitis,9,1
DALVANCE,colitis,Headache,0
DALVANCE,colitis,,0
DALVANCE,colitis,Diarrhea 9,1
FERRIPROX,chromaturia,chromaturia nausea vomiting and,1
FERRIPROX,chromaturia,chromaturia nausea vomiting and,1
FERRIPROX,chromaturia,abdominal,0
FERRIPROX,chromaturia,alanine aminotransferase increased,0
FERRIPROX,chromaturia,chromaturia nausea vomiting and,1
FERRIPROX,nausea,nausea vomiting and abdominal,1
FERRIPROX,nausea,are incidence nausea vomiting and abdominal,1
FERRIPROX,nausea,arthralgia and neutropenia,0
FERRIPROX,nausea,increased arthralgia and,0
FERRIPROX,vomiting,vomiting and abdominal pain,1
FERRIPROX,vomiting,most common adverse reactions are,0
FERRIPROX,vomiting,vomiting and abdominal pain,1
FERRIPROX,vomiting,,0
FERRIPROX,vomiting,,0
FERRIPROX,vomiting,chromaturia,0
FERRIPROX,vomiting,vomiting and abdominal pain,1
FERRIPROX,vomiting,The most common,0
FERRIPROX,vomiting,vomiting and abdominal pain,1
FERRIPROX,alanine aminotransferase increased,and abdominal alanine aminotransferase increased arthralgia and neutropenia,1
FERRIPROX,alanine aminotransferase increased,neutropenia To report SUSPECTED ADVERSE REACTIONS cont,0
FERRIPROX,alanine aminotransferase increased,alanine aminotransferase increased arthralgia and neutropenia,1
FERRIPROX,alanine aminotransferase increased,increased arthralgia and neutropenia,1
FERRIPROX,alanine aminotransferase increased,alanine aminotransferase increased arthralgia and neutropenia,1
FERRIPROX,alanine aminotransferase increased,adverse reactions are incidence,0
FERRIPROX,arthralgia,To,0
FERRIPROX,arthralgia,arthralgia and neutropenia To,1
FERRIPROX,arthralgia,arthralgia and neutropenia To,1
FERRIPROX,arthralgia,SUSPECTED,0
FERRIPROX,arthralgia,,0
FERRIPROX,arthralgia,arthralgia and neutropenia To,1
FERRIPROX,neutropenia,pain alanine,0
FERRIPROX,neutropenia,neutropenia To report SUSPECTED,1
FERRIPROX,neutropenia,neutropenia To report SUSPECTED,1
FERRIPROX,Agranulocytosis,other,0
FERRIPROX,Agranulocytosis,adverse,0
FERRIPROX,Agranulocytosis,are also,0
FERRIPROX,Agranulocytosis,Agranulocytosis Neutropenia see Warnings,1
FERRIPROX,Agranulocytosis,Agranulocytosis Neutropenia see Warnings,1
FERRIPROX,Agranulocytosis,Neutropenia see Warnings and Precautions,0
FERRIPROX,Agranulocytosis,Agranulocytosis Neutropenia see Warnings,1
FERRIPROX,Agranulocytosis,Agranulocytosis Neutropenia see Warnings,1
FERRIPROX,Agranulocytosis,,0
FERRIPROX,Agranulocytosis,Precautions Elevated ALT Decreased plasma zin,0
FERRIPROX,Neutropenia,Neutropenia see Warnings and,1
FERRIPROX,Neutropenia,Neutropenia see Warnings and,1
FERRIPROX,Neutropenia,are also discussed,0
FERRIPROX,Neutropenia,,0
FERRIPROX,Neutropenia,zinc concentrat,0
FERRIPROX,Elevated ALT,,0
FERRIPROX,Elevated ALT,of the labeling AgranulocytosisNeutropenia see,0
FERRIPROX,Elevated ALT,and Elevated ALT Decreased plasma zinc,1
FERRIPROX,Elevated ALT,plasma zinc concentrations Because clinical trials,0
FERRIPROX,Elevated ALT,Elevated,1
FERRIPROX,Elevated ALT,conducted,0
FERRIPROX,Decreased plasma zinc concentrations,Decreased plasma,1
FERRIPROX,chromaturia,chromaturia nausea vomiting abdominal,1
FERRIPROX,chromaturia,chromaturia nausea vomiting abdominal,1
FERRIPROX,chromaturia,and neutropenia,0
FERRIPROX,chromaturia,pain alanine aminotransferase increased,0
FERRIPROX,chromaturia,during clinical trials,0
FERRIPROX,chromaturia,nausea vomiting abdominal pain alanine aminotransferase increased arthralgia and,0
FERRIPROX,chromaturia,abdominal pain alanine,0
FERRIPROX,chromaturia,reported during clinical trials chromaturia nausea vomiting abdominal,1
FERRIPROX,chromaturia,,0
FERRIPROX,chromaturia,most common adverse reactions reported,0
FERRIPROX,vomiting,neutropenia The table belo,0
FERRIPROX,vomiting,vomiting abdominal pain alanine,1
FERRIPROX,vomiting,aminotransferase increased arthralgia and,0
FERRIPROX,vomiting,vomiting abdominal pain alanine,1
FERRIPROX,vomiting,clinical trials were chromaturia vomiting abdominal pain alanine,1
FERRIPROX,vomiting,,0
FERRIPROX,vomiting,abdominal,0
FERRIPROX,vomiting,nausea,0
FERRIPROX,abdominal pain,trials,0
FERRIPROX,abdominal pain,were chromaturia nausea abdominal pain alanine aminotransferase increased,1
FERRIPROX,abdominal pain,nausea vomiting,0
FERRIPROX,abdominal pain,abdominal pain alanine aminotransferase increased,1
FERRIPROX,abdominal pain,trials were chromaturia nausea abdominal,1
FERRIPROX,abdominal pain,reported during clinical trials were,0
FERRIPROX,abdominal pain,pain alanine aminotransferase increased,1
FERRIPROX,abdominal pain,chromaturia nausea,0
FERRIPROX,alanine aminotransferase increased,chromaturia nausea vomiting abdominal alanine aminotransferase increased arthralgia and neutropenia,1
FERRIPROX,alanine aminotransferase increased,and neutropenia The table below lists,0
FERRIPROX,alanine aminotransferase increased,lists the adverse drug reactions,0
FERRIPROX,alanine aminotransferase increased,chromaturia nausea vomiting abdominal alanine aminotransferase,1
FERRIPROX,alanine aminotransferase increased,,0
FERRIPROX,alanine aminotransferase increased,chromaturia nausea vomiting abdominal alanine aminotransferase increased arthralgia and neutropenia,1
FERRIPROX,alanine aminotransferase increased,The table below lists the adverse drug reactions,0
FERRIPROX,alanine aminotransferase increased,,0
FERRIPROX,alanine aminotransferase increased,,0
FERRIPROX,alanine aminotransferase increased,clinical trials were chromaturia nausea vomiting abdominal pain,0
FERRIPROX,arthralgia,trials were chromaturia nausea vomiting abdominal pain alanine,0
FERRIPROX,arthralgia,table below,0
FERRIPROX,arthralgia,chromaturia nausea vomiting abdominal pain alanine aminotransferase increased,0
FERRIPROX,arthralgia,arthralgia and neutropenia The,1
FERRIPROX,arthralgia,neutropenia The table below lists the adverse,0
FERRIPROX,arthralgia,trials were chromaturia nausea vomiting abdominal pain alanine,0
FERRIPROX,arthralgia,aminotransferase increased,0
FERRIPROX,arthralgia,The table below,0
FERRIPROX,neutropenia,neutropenia The table below,1
FERRIPROX,neutropenia,neutropenia The table below,1
FERRIPROX,neutropenia,aminotransferase increased arthralgia,0
FERRIPROX,neutropenia,table below lists the adverse drug,0
FERRIPROX,neutropenia,pain alanine aminotransferase increased arthralgia and,0
FERRIPROX,neutropenia,neutropenia The table below,1
FERRIPROX,Neutropenia,Neutropenia Agranulocytosis,1
FERRIPROX,Neutropenia,AND LYMPHATIC SYSTEM DISORDERS,0
FERRIPROX,Neutropenia,Neutropenia Agranulocytosis,1
FERRIPROX,Neutropenia,AND LYMPHATIC SYSTEM,0
FERRIPROX,Agranulocytosis,Neutropenia,0
FERRIPROX,Agranulocytosis,,0
FERRIPROX,Agranulocytosis,Agranulocytosis GASTROINTESTINAL,1
FERRIPROX,Agranulocytosis,Agranulocytosis GASTROINTESTINAL,1
FERRIPROX,Agranulocytosis,Neutropenia,0
FERRIPROX,Agranulocytosis,Neutropenia,0
FERRIPROX,Agranulocytosis,,0
FERRIPROX,Agranulocytosis,Neutropenia Agranulocytosis,1
FERRIPROX,Agranulocytosis,Neutropenia,0
FERRIPROX,Agranulocytosis,Neutropenia,0
FERRIPROX,Nausea,DISORDERS,0
FERRIPROX,Nausea,,0
FERRIPROX,Nausea,,0
FERRIPROX,Nausea,Nausea Abdominal,1
FERRIPROX,Nausea,DISORDERS,0
FERRIPROX,Abdominal pain,Nausea,0
FERRIPROX,Abdominal pain,,0
FERRIPROX,Abdominal pain,Nausea,0
FERRIPROX,Vomiting,paindiscomfort,0
FERRIPROX,Vomiting,,0
FERRIPROX,Vomiting,,0
FERRIPROX,Vomiting,Vomiting Diarrhea,1
FERRIPROX,Vomiting,Diarrhea,0
FERRIPROX,Vomiting,Vomiting Diarrhea,1
FERRIPROX,Vomiting,,0
FERRIPROX,Diarrhea,Vomiting,0
FERRIPROX,Diarrhea,Vomiting Diarrhea Dyspepsia,1
FERRIPROX,Diarrhea,,0
FERRIPROX,Diarrhea,Diarrhea Dyspepsia,1
FERRIPROX,Diarrhea,Diarrhea Dyspepsia,1
FERRIPROX,Diarrhea,Vomiting Diarrhea Dyspepsia,1
FERRIPROX,Diarrhea,Vomiting,0
FERRIPROX,Diarrhea,,0
FERRIPROX,Diarrhea,Diarrhea Dyspepsia,1
FERRIPROX,Dyspepsia,Dyspepsia INVESTIGATIONS,1
FERRIPROX,Dyspepsia,Diarrhea,0
FERRIPROX,Alanine Aminotransferase increased,,0
FERRIPROX,Neutrophil count decreased,,0
FERRIPROX,Neutrophil count decreased,,0
FERRIPROX,Neutrophil count decreased,decreased,1
FERRIPROX,Neutrophil count decreased,Neutrophil count decreased,1
FERRIPROX,Neutrophil count decreased,Weight,0
FERRIPROX,Neutrophil count decreased,Aminotransferase increased,0
FERRIPROX,Neutrophil count decreased,Alanine Aminotransferase Neutrophil,1
FERRIPROX,Weight increased,Weight,1
FERRIPROX,Weight increased,Weight increased,1
FERRIPROX,Weight increased,,0
FERRIPROX,Aspartate Aminotransferase increased,,0
FERRIPROX,Aspartate Aminotransferase increased,,0
FERRIPROX,Aspartate Aminotransferase increased,Aspartate,1
FERRIPROX,Aspartate Aminotransferase increased,,0
FERRIPROX,Aspartate Aminotransferase increased,,0
FERRIPROX,Aspartate Aminotransferase increased,Aspartate Aminotransferase increased,1
FERRIPROX,Aspartate Aminotransferase increased,Weight Aspartate Aminotransferase,1
FERRIPROX,Aspartate Aminotransferase increased,Weight Aspartate Aminotransferase,1
FERRIPROX,Increased appetite,NUTRITION Increased,1
FERRIPROX,Increased appetite,METABOLISM AND NUTRITION Increased,1
FERRIPROX,Increased appetite,,0
FERRIPROX,Increased appetite,Increased appetite,1
FERRIPROX,Increased appetite,DISORDERS,0
FERRIPROX,Increased appetite,NUTRITION Increased appetite,1
FERRIPROX,Decreased appetite,,0
FERRIPROX,Decreased appetite,Decreased,1
FERRIPROX,Arthralgia,Arthralgia,1
FERRIPROX,Arthralgia,Arthralgia,1
FERRIPROX,Arthralgia,AND,0
FERRIPROX,Arthralgia,Arthralgia,1
FERRIPROX,Arthralgia,CONNECTIVE TISSUE DISORDERS,0
FERRIPROX,Arthralgia,pain,0
FERRIPROX,Arthralgia,Arthralgia,1
FERRIPROX,Back pain,,0
FERRIPROX,Back pain,Arthralgia Back pain Pain in,1
FERRIPROX,Back pain,Arthralgia,0
FERRIPROX,Back pain,Arthralgia,0
FERRIPROX,Back pain,Arthralgia Back pain Pain,1
FERRIPROX,Back pain,Arthralgia Back pain Pain,1
FERRIPROX,Back pain,Arthralgia Back,1
FERRIPROX,Back pain,,0
FERRIPROX,Arthropathy,Arthropathy NERVOUS,1
FERRIPROX,Arthropathy,,0
FERRIPROX,Arthropathy,in extremity,0
FERRIPROX,Arthropathy,Arthropathy NERVOUS,1
FERRIPROX,Arthropathy,extremity,0
FERRIPROX,Headache,SYSTEM Headache URINARY,1
FERRIPROX,Headache,,0
FERRIPROX,Headache,Headache URINARY,1
FERRIPROX,Headache,Headache URINARY,1
FERRIPROX,Headache,Headache URINARY,1
FERRIPROX,Headache,,0
FERRIPROX,Headache,Headache URINARY,1
FERRIPROX,Headache,DISORDERS,0
FERRIPROX,Headache,,0
FERRIPROX,Chromaturia,Chromaturia Gastrointestinal,1
FERRIPROX,Chromaturia,Chromaturia Gastrointestinal,1
FERRIPROX,Chromaturia,,0
FERRIPROX,nausea,Gastrointestinal symptoms,0
FERRIPROX,nausea,the most frequent adverse,0
FERRIPROX,vomiting,vomiting and,1
FERRIPROX,vomiting,as nausea,0
FERRIPROX,vomiting,pain were the most frequent adverse reactions,0
FERRIPROX,vomiting,symptoms such,0
FERRIPROX,vomiting,,0
FERRIPROX,vomiting,vomiting and,1
FERRIPROX,vomiting,as,0
FERRIPROX,vomiting,such as nausea,0
FERRIPROX,vomiting,Gastrointestinal symptoms,0
FERRIPROX,vomiting,,0
FERRIPROX,abdominal pain,,0
FERRIPROX,abdominal pain,clinical trials and,0
FERRIPROX,abdominal pain,vomiting abdominal,1
FERRIPROX,abdominal pain,as nausea vomiting abdominal,1
FERRIPROX,abdominal pain,the most frequent adverse reactions reported by patients participating in clinical trials and,0
FERRIPROX,Chromaturia,Chromaturia reddishbrown,1
FERRIPROX,Chromaturia,Ferriprox therapy in of Chromaturia reddishbrown,1
FERRIPROX,Chromaturia,Chromaturia reddishbrown,1
FERRIPROX,Chromaturia,led to the discontinuation of,0
FERRIPROX,Chromaturia,discoloration of the urine is a result,0
FERRIPROX,thrombocytosis,Blood and lymphatic system thrombocytosis pancytopenia,1
FERRIPROX,pancytopenia,pancytopenia Cardiac,1
FERRIPROX,atrial fibrillation,disorders hypospadias Eye di,0
FERRIPROX,atrial fibrillation,thrombocytosis pancytopenia Cardiac,0
FERRIPROX,atrial fibrillation,pancytopenia Cardiac atrial fibrillation cardiac,1
FERRIPROX,atrial fibrillation,disorders thrombocytosis pancytopenia Cardiac atrial,1
FERRIPROX,atrial fibrillation,disorders thrombocytosis pancytopenia Cardiac atrial fibrillation cardiac,1
FERRIPROX,atrial fibrillation,and genetic disorders hypospadias,0
FERRIPROX,atrial fibrillation,Cardiac atrial,1
FERRIPROX,atrial fibrillation,system disorders,0
FERRIPROX,atrial fibrillation,pancytopenia Cardiac atrial fibrillation cardiac,1
FERRIPROX,atrial fibrillation,pancytopenia Cardiac atrial,1
FERRIPROX,cardiac failure,genetic disorders,0
FERRIPROX,cardiac failure,Cardiac disorders atrial cardiac failure Congenital,1
FERRIPROX,cardiac failure,disorders atrial cardiac failure Congenital,1
FERRIPROX,cardiac failure,Cardiac disorders atrial cardiac,1
FERRIPROX,cardiac failure,disorders atrial cardiac,1
FERRIPROX,cardiac failure,familial and genetic disorders hypospadias Eye,0
FERRIPROX,cardiac failure,cardiac,1
FERRIPROX,cardiac failure,cardiac failure Congenital,1
FERRIPROX,hypospadias,hypospadias Eye,1
FERRIPROX,hypospadias,hypospadias Eye,1
FERRIPROX,hypospadias,hypospadias Eye,1
FERRIPROX,hypospadias,hypospadias Eye,1
FERRIPROX,hypospadias,hypospadias Eye,1
FERRIPROX,hypospadias,hypospadias Eye,1
FERRIPROX,hypospadias,,0
FERRIPROX,hypospadias,,0
FERRIPROX,hypospadias,hypospadias Eye,1
FERRIPROX,hypospadias,hypospadias Eye,1
FERRIPROX,diplopia,familial,0
FERRIPROX,diplopia,diplopia papilledema,1
FERRIPROX,papilledema,familial and,0
FERRIPROX,papilledema,enterocolitis rectal hemorrhage,0
FERRIPROX,papilledema,Eye disorders papilledema retinal,1
FERRIPROX,papilledema,papilledema retinal,1
FERRIPROX,papilledema,Eye disorders,0
FERRIPROX,retinal toxicity,,0
FERRIPROX,retinal toxicity,familial,0
FERRIPROX,retinal toxicity,,0
FERRIPROX,retinal toxicity,Eye disorders diplopia retinal,1
FERRIPROX,retinal toxicity,toxicity Gastrointestinal,1
FERRIPROX,enterocolitis,enterocolitis rectal,1
FERRIPROX,enterocolitis,retinal toxicity Gastrointestinal enterocolitis rectal,1
FERRIPROX,enterocolitis,gland enlargement General,0
FERRIPROX,enterocolitis,enterocolitis rectal,1
FERRIPROX,rectal hemorrhage,toxicity Gastrointestinal disorders rectal,1
FERRIPROX,rectal hemorrhage,diplopia papilledema retinal toxicity Gastrointestinal disorders enterocolitis,0
FERRIPROX,gastric ulcer,rectal gastric ulcer pancreatitis,1
FERRIPROX,gastric ulcer,ulcer pancreatitis,1
FERRIPROX,gastric ulcer,hemorrhage,0
FERRIPROX,gastric ulcer,ulcer pancreatitis,1
FERRIPROX,pancreatitis,,0
FERRIPROX,pancreatitis,hemorrhage gastric pancreatitis parotid,1
FERRIPROX,pancreatitis,pancreatitis parotid,1
FERRIPROX,pancreatitis,toxicity Gastrointestinal disorders enterocolitis rectal,0
FERRIPROX,pancreatitis,disorders and administration site conditions chills p,0
FERRIPROX,pancreatitis,and administration site conditions chills p,0
FERRIPROX,pancreatitis,pancreatitis parotid,1
FERRIPROX,pancreatitis,toxicity,0
FERRIPROX,pancreatitis,pancreatitis parotid,1
FERRIPROX,pancreatitis,pancreatitis parotid,1
FERRIPROX,parotid gland enlargement,disorders enterocolitis rectal hemorrhage gastric,0
FERRIPROX,parotid gland enlargement,disorders enterocolitis rectal,0
FERRIPROX,parotid gland enlargement,pyrexia edema,0
FERRIPROX,parotid gland enlargement,pancreatitis,0
FERRIPROX,parotid gland enlargement,site,0
FERRIPROX,parotid gland enlargement,parotid gland,1
FERRIPROX,parotid gland enlargement,enlargement General,1
FERRIPROX,parotid gland enlargement,rectal hemorrhage gastric ulcer parotid gland,1
FERRIPROX,parotid gland enlargement,hemorrhage gastric ulcer pancreatitis,0
FERRIPROX,chills,and administration site chills pyrexia,1
FERRIPROX,chills,chills pyrexia,1
FERRIPROX,chills,chills pyrexia,1
FERRIPROX,pyrexia,,0
FERRIPROX,pyrexia,pyrexia edema,1
FERRIPROX,pyrexia,peripheral multiorgan failure Hepatobiliary disorders jaundice,0
FERRIPROX,edema peripheral,General disorders and,0
FERRIPROX,edema peripheral,edema peripheral multiorgan,1
FERRIPROX,edema peripheral,jaundice,0
FERRIPROX,edema peripheral,chills edema peripheral multiorgan,1
FERRIPROX,edema peripheral,enlargement General disorders and administration,0
FERRIPROX,edema peripheral,,0
FERRIPROX,edema peripheral,administration site conditions chills,0
FERRIPROX,edema peripheral,edema,1
FERRIPROX,edema peripheral,,0
FERRIPROX,jaundice,,0
FERRIPROX,jaundice,jaundice hepatomegaly,1
FERRIPROX,jaundice,,0
FERRIPROX,hepatomegaly,jaundice,0
FERRIPROX,hepatomegaly,system disorders anaphylactic shock hypersensitivity I nfections and inf,0
FERRIPROX,hepatomegaly,multiorgan failure Hepatobiliary disorders hepatomegaly Immune,1
FERRIPROX,hepatomegaly,hepatomegaly Immune,1
FERRIPROX,hepatomegaly,Immune,0
FERRIPROX,hepatomegaly,Immune,0
FERRIPROX,hepatomegaly,hepatomegaly Immune,1
FERRIPROX,hepatomegaly,hepatomegaly Immune,1
FERRIPROX,hypersensitivity,shock,0
FERRIPROX,hypersensitivity,jaundice hepatomegaly Immune,0
FERRIPROX,hypersensitivity,hypersensitivity I,1
FERRIPROX,hypersensitivity,hypersensitivity I,1
FERRIPROX,hypersensitivity,hypersensitivity I,1
FERRIPROX,hypersensitivity,hypersensitivity I,1
FERRIPROX,hypersensitivity,system disorders anaphylactic,0
FERRIPROX,cryptococcal cutaneous infection,and cryptococcal cutaneous,1
FERRIPROX,cryptococcal cutaneous infection,and cryptococcal cutaneous infection enteroviral,1
FERRIPROX,cryptococcal cutaneous infection,nfections and cryptococcal cutaneous infection enteroviral,1
FERRIPROX,cryptococcal cutaneous infection,infection enteroviral,1
FERRIPROX,cryptococcal cutaneous infection,infection enteroviral,1
FERRIPROX,cryptococcal cutaneous infection,I nfections and cryptococcal,1
FERRIPROX,cryptococcal cutaneous infection,nfections and cryptococcal cutaneous,1
FERRIPROX,cryptococcal cutaneous infection,rash,0
FERRIPROX,enteroviral encephalitis,cutaneous enteroviral encephalitis pharyngitis,1
FERRIPROX,pharyngitis,pharyngitis pneumonia,1
FERRIPROX,pharyngitis,,0
FERRIPROX,pharyngitis,pharyngitis pneumonia,1
FERRIPROX,pneumonia,,0
FERRIPROX,pneumonia,infection,0
FERRIPROX,sepsis,pharyngitis pneumonia,0
FERRIPROX,sepsis,hepatitis rash,0
FERRIPROX,sepsis,sepsis furuncle,1
FERRIPROX,furuncle,furuncle infectious,1
FERRIPROX,furuncle,,0
FERRIPROX,furuncle,encephalitis pharyngitis pneumonia furuncle infectious,1
FERRIPROX,furuncle,infection enteroviral,0
FERRIPROX,furuncle,furuncle infectious,1
FERRIPROX,furuncle,furuncle infectious,1
FERRIPROX,furuncle,furuncle infectious,1
FERRIPROX,infectious hepatitis,encephalitis pharyngitis pneumonia sepsis infectious,1
FERRIPROX,infectious hepatitis,,0
FERRIPROX,infectious hepatitis,enteroviral encephalitis pharyngitis,0
FERRIPROX,infectious hepatitis,encephalitis pharyngitis pneumonia sepsis infectious hepatitis rash,1
FERRIPROX,infectious hepatitis,infectious hepatitis rash,1
FERRIPROX,infectious hepatitis,infectious hepatitis rash,1
FERRIPROX,infectious hepatitis,abscess Investigations blood bilirubin increased blood,0
FERRIPROX,infectious hepatitis,encephalitis pharyngitis pneumonia sepsis infectious,1
FERRIPROX,infectious hepatitis,pharyngitis pneumonia sepsis infectious hepatitis rash,1
FERRIPROX,infectious hepatitis,encephalitis pharyngitis pneumonia sepsis infectious,1
FERRIPROX,subcutaneous abscess,subcutaneous,1
FERRIPROX,subcutaneous abscess,subcutaneous abscess Investigations,1
FERRIPROX,subcutaneous abscess,abscess Investigations,1
FERRIPROX,subcutaneous abscess,infectious hepatitis rash subcutaneous,1
FERRIPROX,blood bilirubin increased,rash pustular subcutaneous abscess blood bilirubin,1
FERRIPROX,blood bilirubin increased,,0
FERRIPROX,blood creatinine phosphokinase increased,acidosis,0
FERRIPROX,blood creatinine phosphokinase increased,pustular subcutaneous abscess Investigations blood bilirubin increased,0
FERRIPROX,blood creatinine phosphokinase increased,Investigations blood bilirubin blood creatinine phosphokinase increased Metabolism,1
FERRIPROX,blood creatinine phosphokinase increased,abscess Investigations,0
FERRIPROX,blood creatinine phosphokinase increased,metabolic acidosis,0
FERRIPROX,blood creatinine phosphokinase increased,abscess Investigations blood,0
FERRIPROX,blood creatinine phosphokinase increased,bilirubin blood creatinine,1
FERRIPROX,dehydration,disorders metabolic dehydration Musculoskeletal,1
FERRIPROX,dehydration,metabolic dehydration Musculoskeletal,1
FERRIPROX,dehydration,dehydration Musculoskeletal,1
FERRIPROX,dehydration,dehydration Musculoskeletal,1
FERRIPROX,dehydration,dehydration Musculoskeletal,1
FERRIPROX,dehydration,dehydration Musculoskeletal,1
FERRIPROX,dehydration,connective tissue disorders myositis,0
FERRIPROX,dehydration,Metabolism and nutrition disorders metabolic,0
FERRIPROX,dehydration,dehydration Musculoskeletal,1
FERRIPROX,myositis,acidosis,0
FERRIPROX,myositis,myositis chondropathy,1
FERRIPROX,myositis,,0
FERRIPROX,myositis,,0
FERRIPROX,myositis,and,0
FERRIPROX,myositis,myositis chondropathy,1
FERRIPROX,chondropathy,connective tissue,0
FERRIPROX,chondropathy,Musculoskeletal,0
FERRIPROX,trismus,system disorders cerebellar syndrome cerebral hemorrhage convulsion gait distu,0
FERRIPROX,trismus,trismus Nervous,1
FERRIPROX,trismus,and connective tissue,0
FERRIPROX,trismus,trismus Nervous,1
FERRIPROX,trismus,trismus Nervous,1
FERRIPROX,trismus,,0
FERRIPROX,trismus,hemorrhage,0
FERRIPROX,trismus,tissue disorders myositis trismus Nervous,1
FERRIPROX,cerebellar syndrome,disorders myositis chondropathy trismus Nervous,0
FERRIPROX,cerebral hemorrhage,cerebellar cerebral hemorrhage convulsion,1
FERRIPROX,cerebral hemorrhage,convulsion gait disturbance intracranial pressure increased psychomotor,0
FERRIPROX,cerebral hemorrhage,disorders cerebellar cerebral hemorrhage convulsion,1
FERRIPROX,cerebral hemorrhage,,0
FERRIPROX,cerebral hemorrhage,hemorrhage convulsion,1
FERRIPROX,cerebral hemorrhage,convulsion gait disturbance,0
FERRIPROX,cerebral hemorrhage,system disorders cerebellar cerebral,1
FERRIPROX,cerebral hemorrhage,gait disturbance intracranial pressure increased psychomotor skills impaired,0
FERRIPROX,cerebral hemorrhage,trismus Nervous system disorders,0
FERRIPROX,convulsion,Nervous system disorders cerebellar syndrome cerebral,0
FERRIPROX,convulsion,syndrome,0
FERRIPROX,convulsion,cerebral,0
FERRIPROX,convulsion,skills,0
FERRIPROX,gait disturbance,syndrome cerebral hemorrhage convulsion,0
FERRIPROX,gait disturbance,cerebellar syndrome cerebral hemorrhage gait disturbance intracranial,1
FERRIPROX,gait disturbance,hemorrhage gait,1
FERRIPROX,intracranial pressure increased,,0
FERRIPROX,intracranial pressure increased,intracranial pressure,1
FERRIPROX,intracranial pressure increased,,0
FERRIPROX,intracranial pressure increased,gait intracranial,1
FERRIPROX,intracranial pressure increased,intracranial pressure increased psychomotor,1
FERRIPROX,intracranial pressure increased,cerebral hemorrhage convulsion gait intracranial pressure increased psychomotor,1
FERRIPROX,intracranial pressure increased,pressure increased psychomotor,1
FERRIPROX,intracranial pressure increased,,0
FERRIPROX,intracranial pressure increased,,0
FERRIPROX,intracranial pressure increased,gait intracranial pressure increased psychomotor,1
FERRIPROX,psychomotor skills impaired,Psychiatric disorders,0
FERRIPROX,psychomotor skills impaired,disorders bruxism depression,0
FERRIPROX,psychomotor skills impaired,gait disturbance intracranial pressure psychomotor skills impaired pyramidal,1
FERRIPROX,pyramidal tract syndrome,skills pyramidal tract syndrome somnolence,1
FERRIPROX,pyramidal tract syndrome,skills pyramidal tract,1
FERRIPROX,pyramidal tract syndrome,psychomotor skills pyramidal,1
FERRIPROX,pyramidal tract syndrome,,0
FERRIPROX,pyramidal tract syndrome,pressure increased psychomotor skills pyramidal,1
FERRIPROX,pyramidal tract syndrome,tract syndrome somnolence,1
FERRIPROX,pyramidal tract syndrome,pyramidal tract syndrome somnolence,1
FERRIPROX,pyramidal tract syndrome,tract syndrome somnolence,1
FERRIPROX,pyramidal tract syndrome,,0
FERRIPROX,somnolence,,0
FERRIPROX,somnolence,somnolence Psychiatric,1
FERRIPROX,somnolence,somnolence Psychiatric,1
FERRIPROX,bruxism,bruxism depression,1
FERRIPROX,bruxism,psychomotor skills impaired pyramidal tract syndrome somnolence Psychiatric disorders,0
FERRIPROX,bruxism,Psychiatric disorders,0
FERRIPROX,bruxism,impaired pyramidal,0
FERRIPROX,bruxism,Psychiatric,0
FERRIPROX,bruxism,bruxism depression,1
FERRIPROX,bruxism,Renal disorders,0
FERRIPROX,bruxism,disorder Renal disorders glycosuria,0
FERRIPROX,bruxism,,0
FERRIPROX,bruxism,pyramidal tract syndrome somnolence Psychiatric,0
FERRIPROX,depression,depression obsessivecompulsive,1
FERRIPROX,depression,tract syndrome somnolence Psychiatric,0
FERRIPROX,obsessive-compulsive disorder,obsessive-compulsive disorder Renal,1
FERRIPROX,obsessive-compulsive disorder,,0
FERRIPROX,obsessive-compulsive disorder,bruxism obsessive-compulsive,1
FERRIPROX,obsessive-compulsive disorder,disorder Renal,1
FERRIPROX,obsessive-compulsive disorder,somnolence Psychiatric disorders bruxism depression,0
FERRIPROX,obsessive-compulsive disorder,pyramidal tract syndrome somnolence Psychiatric,0
FERRIPROX,obsessive-compulsive disorder,glycosuria hemoglobinuria Respiratory thoracic,0
FERRIPROX,obsessive-compulsive disorder,somnolence Psychiatric disorders bruxism obsessive-compulsive disorder Renal,1
FERRIPROX,obsessive-compulsive disorder,bruxism obsessive-compulsive disorder Renal,1
FERRIPROX,obsessive-compulsive disorder,somnolence Psychiatric disorders bruxism obsessive-compulsive,1
FERRIPROX,glycosuria,obsessivecompulsive,0
FERRIPROX,glycosuria,glycosuria hemoglobinuria,1
FERRIPROX,glycosuria,obsessivecompulsive disorder Renal glycosuria hemoglobinuria,1
FERRIPROX,glycosuria,glycosuria hemoglobinuria,1
FERRIPROX,hemoglobinuria,disorder Renal disorders hemoglobinuria Respiratory,1
FERRIPROX,acute respiratory distress syndrome,epistaxis hemoptysis pulmonary embolism,0
FERRIPROX,acute respiratory distress syndrome,disorders hyperhidros,0
FERRIPROX,acute respiratory distress syndrome,thoracic and mediastinal acute respiratory distress,1
FERRIPROX,acute respiratory distress syndrome,and mediastinal acute respiratory distress,1
FERRIPROX,acute respiratory distress syndrome,and mediastinal acute respiratory distress syndrome epistaxis,1
FERRIPROX,acute respiratory distress syndrome,Skin subcutaneous tissue disorders,0
FERRIPROX,acute respiratory distress syndrome,,0
FERRIPROX,acute respiratory distress syndrome,mediastinal disorders,0
FERRIPROX,acute respiratory distress syndrome,syndrome epistaxis,1
FERRIPROX,epistaxis,epistaxis hemoptysis,1
FERRIPROX,epistaxis,,0
FERRIPROX,epistaxis,syndrome,0
FERRIPROX,epistaxis,epistaxis hemoptysis,1
FERRIPROX,epistaxis,Respiratory thoracic and mediastinal disorders acute respiratory,0
FERRIPROX,epistaxis,epistaxis hemoptysis,1
FERRIPROX,epistaxis,subcutaneous tissue disorders,0
FERRIPROX,epistaxis,acute respiratory,0
FERRIPROX,epistaxis,respiratory,0
FERRIPROX,epistaxis,epistaxis hemoptysis,1
FERRIPROX,hemoptysis,hemoptysis pulmonary,1
FERRIPROX,hemoptysis,acute respiratory,0
FERRIPROX,hemoptysis,hemoptysis pulmonary,1
FERRIPROX,hemoptysis,subcutaneous,0
FERRIPROX,hemoptysis,respiratory distress syndrome hemoptysis pulmonary,1
FERRIPROX,hemoptysis,,0
FERRIPROX,hemoptysis,mediastinal disorders acute respiratory distress syndrome,0
FERRIPROX,hemoptysis,hemoptysis pulmonary,1
FERRIPROX,hemoptysis,hemoptysis pulmonary,1
FERRIPROX,hemoptysis,tissue,0
FERRIPROX,pulmonary embolism,subcutaneous tissue disorders hyperhidrosis periorbital edema photosensitivity,0
FERRIPROX,pulmonary embolism,pulmonary embolism Skin,1
FERRIPROX,pulmonary embolism,pulmonary embolism Skin,1
FERRIPROX,pulmonary embolism,,0
FERRIPROX,pulmonary embolism,pulmonary embolism Skin,1
FERRIPROX,pulmonary embolism,and mediastinal disorders acute,0
FERRIPROX,pulmonary embolism,tissue disorders hyperhidrosis,0
FERRIPROX,pulmonary embolism,photosensitivity rea,0
FERRIPROX,hyperhidrosis,urticaria,0
FERRIPROX,hyperhidrosis,hyperhidrosis periorbital,1
FERRIPROX,hyperhidrosis,,0
FERRIPROX,hyperhidrosis,hyperhidrosis periorbital,1
FERRIPROX,hyperhidrosis,Skin subcutaneous tissue,0
FERRIPROX,hyperhidrosis,hyperhidrosis periorbital,1
FERRIPROX,hyperhidrosis,,0
FERRIPROX,hyperhidrosis,,0
FERRIPROX,hyperhidrosis,tissue hyperhidrosis periorbital,1
FERRIPROX,hyperhidrosis,,0
FERRIPROX,periorbital edema,tissue disorders periorbital edema photosensitivity,1
FERRIPROX,periorbital edema,subcutaneous tissue disorders periorbital,1
FERRIPROX,periorbital edema,tissue,0
FERRIPROX,periorbital edema,tissue disorders periorbital,1
FERRIPROX,photosensitivity reaction,tissue disorders hyperhidrosis periorbital photosensitivity reaction pruritis,1
FERRIPROX,photosensitivity reaction,disorders hyperhidrosis periorbital edema,0
FERRIPROX,photosensitivity reaction,HenochSchonlein purpura Vascular,0
FERRIPROX,photosensitivity reaction,subcutaneous,0
FERRIPROX,photosensitivity reaction,periorbital photosensitivity,1
FERRIPROX,photosensitivity reaction,periorbital photosensitivity reaction pruritis,1
FERRIPROX,photosensitivity reaction,tissue disorders hyperhidrosis periorbital photosensitivity,1
FERRIPROX,photosensitivity reaction,periorbital photosensitivity reaction pruritis,1
FERRIPROX,photosensitivity reaction,periorbital,0
FERRIPROX,photosensitivity reaction,photosensitivity reaction pruritis,1
FERRIPROX,pruritis,pruritis urticaria,1
FERRIPROX,pruritis,hypotension,0
FERRIPROX,pruritis,hyperhidrosis periorbital edema photosensitivity pruritis urticaria,1
FERRIPROX,pruritis,pruritis urticaria,1
FERRIPROX,urticaria,periorbital edema photosensitivity reaction urticaria rash,1
FERRIPROX,urticaria,periorbital edema photosensitivity reaction urticaria rash,1
FERRIPROX,urticaria,photosensitivity reaction urticaria rash,1
FERRIPROX,urticaria,reaction urticaria rash,1
FERRIPROX,urticaria,,0
FERRIPROX,urticaria,rash HenochSchonlein purpura Vascular disorders hypotension hypertension,0
FERRIPROX,rash,edema photosensitivity reaction pruritis rash HenochSchonlein,1
FERRIPROX,rash,purpura Vascular disorders,0
FERRIPROX,rash,,0
FERRIPROX,rash,pruritis rash HenochSchonlein,1
FERRIPROX,rash,hyperhidrosis periorbital edema photosensitivity reaction pruritis urticaria,0
FERRIPROX,rash,reaction pruritis rash HenochSchonlein,1
FERRIPROX,rash,rash HenochSchonlein,1
FERRIPROX,rash,,0
FERRIPROX,Henoch-Schonlein purpura,Vascular,0
FERRIPROX,Henoch-Schonlein purpura,Henoch-Schonlein purpura Vascular,1
FERRIPROX,Henoch-Schonlein purpura,,0
FERRIPROX,Henoch-Schonlein purpura,reaction pruritis urticaria Henoch-Schonlein,1
FERRIPROX,Henoch-Schonlein purpura,hyperhidrosis periorbital edema photosensitivity,0
FERRIPROX,Henoch-Schonlein purpura,purpura Vascular,1
FERRIPROX,Henoch-Schonlein purpura,Henoch-Schonlein purpura Vascular,1
FERRIPROX,Henoch-Schonlein purpura,purpura Vascular,1
FERRIPROX,hypotension,,0
FERRIPROX,hypotension,hypotension hypertension,1
FERRIPROX,hypotension,,0
FERRIPROX,hypotension,,0
FERRIPROX,hypotension,pruritis urticaria rash HenochSchonlein,0
FERRIPROX,hypotension,disorders,0
FERRIPROX,hypotension,purpura,0
FERRIPROX,hypotension,pruritis urticaria rash,0
FERRIPROX,hypotension,,0
FERRIPROX,hypotension,,0
FERRIPROX,hypertension,,0
FERRIPROX,hypertension,,0
FERRIPROX,hypertension,hypertension,1
FERRIPROX,hypertension,hypertension,1
FERRIPROX,hypertension,hypertension,1
FERRIPROX,AGRANULOCYTOSIS,EXCERPT:,1
FERRIPROX,AGRANULOCYTOSIS,EXCERPT:    *   The most common adverse,1
FERRIPROX,AGRANULOCYTOSIS,EXCERPT:    *   The,1
FERRIPROX,AGRANULOCYTOSIS,,0
FERRIPROX,AGRANULOCYTOSIS,chromaturia nausea vomiting and,0
FERRIPROX,AGRANULOCYTOSIS,nausea vomiting,0
FERRIPROX,AGRANULOCYTOSIS,EXCERPT: * The most common adverse,1
FERRIPROX,AGRANULOCYTOSIS,,0
FERRIPROX,AGRANULOCYTOSIS,,0
FERRIPROX,NEUTROPENIA,he,1
FERRIPROX,NEUTROPENIA,he most com mon adverse,1
FERRIPROX,NEUTROPENIA,he,1
FERRIPROX,NEUTROPENIA,he,1
FERRIPROX,NEUTROPENIA,he most,1
FERRIPROX,NEUTROPENIA,reactions are incidence chromaturia nausea,0
FERRIPROX,NEUTROPENIA,,0
FERRIPROX,AGRANULOCYTOSIS,abdominal pain alanine aminotransferase increased,0
FERRIPROX,AGRANULOCYTOSIS,,0
FERRIPROX,AGRANULOCYTOSIS,eactions are (i ncidence chromaturia nausea vomiting and,1
FERRIPROX,AGRANULOCYTOSIS,are (i ncidence chromaturia,1
FERRIPROX,AGRANULOCYTOSIS,eactions,1
FERRIPROX,AGRANULOCYTOSIS,ncidence chromaturia nausea,0
FERRIPROX,AGRANULOCYTOSIS,pain alanine aminotransferase,0
FERRIPROX,AGRANULOCYTOSIS,,0
FERRIPROX,NEUTROPENIA,,0
FERRIPROX,NEUTROPENIA,>= chromaturia nausea vomiting,1
FERRIPROX,NEUTROPENIA,,0
FERRIPROX,NEUTROPENIA,abdominal pain alanine,0
FERRIPROX,NEUTROPENIA,,0
FERRIPROX,agranulocytosis,are incidence chromaturia nausea ting and abdomi nal pain alanine aminotransferase,1
FERRIPROX,agranulocytosis,pain alanine aminotransferase increased arthralgia,0
FERRIPROX,agranulocytosis,abdomi nal pain alanine aminotransferase,1
FERRIPROX,agranulocytosis,vomi,0
FERRIPROX,agranulocytosis,nausea ting and abdomi nal pain alanine aminotransferase,1
FERRIPROX,agranulocytosis,chromaturia nausea ting and abdomi nal pain alanine aminotransferase,1
FERRIPROX,agranulocytosis,ting and abdomi nal pain alanine aminotransferase,1
FERRIPROX,agranulocytosis,aminotransferase increased arthralgia and,0
FERRIPROX,infections,nsferase i ncreased arthralgia and neutropenia,1
FERRIPROX,infections,pain alanine nsferase i ncreased arthralgia and neutropenia,1
FERRIPROX,death,arthralgia and neutropenia To report SUSPECTED ADVERSE REACTIONS contac,0
FERRIPROX,death,,0
FERRIPROX,agranulocytosis,neutropenia,0
FERRIPROX,agranulocytosis,contact ApoPharma,0
FERRIPROX,agranulocytosis,"increased arthralgia and  
    

  To re port SUSPECTED ADVERSE REACTIONS",1
FERRIPROX,agranulocytosis,aminotransferase increased arthralgia,0
FERRIPROX,agranulocytosis,alanine aminotransferase,0
FERRIPROX,agranulocytosis,Inc at Telephone,0
FERRIPROX,agranulocytosis,increased arthralgia and To,1
FERRIPROX,agranulocytosis,"aminotransferase increased arthralgia and  
    

  To re port SUSPECTED ADVERSE REACTIONS",1
FERRIPROX,agranulocytosis,,0
FERRIPROX,AGRANULOCYTOSIS,cannot be directly compared,0
FERRIPROX,AGRANULOCYTOSIS,varying conditions e reaction,1
FERRIPROX,NEUTROPENIA,reaction rates erved,1
FERRIPROX,NEUTROPENIA,reaction rates erved in th e clinical trials of,1
FERRIPROX,NEUTROPENIA,are conducted under widely varying conditions,0
FERRIPROX,NEUTROPENIA,under widely varying conditions adverse,0
FERRIPROX,NEUTROPENIA,the clinical trials of another d,0
FERRIPROX,agranulocytosis,Adverse reaction,0
FERRIPROX,agranulocytosis,trials of another rug and may not reflect the rates observed,1
FERRIPROX,agranulocytosis,reaction,0
FERRIPROX,agranulocytosis,rug and may not reflect the rates observed,1
FERRIPROX,agranulocytosis,clinical trials of a,0
FERRIPROX,agranulocytosis,clinical trials of another rug and,1
FERRIPROX,infections,reflect the rates d in,1
FERRIPROX,infections,represents the pooled,0
FERRIPROX,infections,pract ice Adverse reaction information,1
FERRIPROX,infections,to rates in the clinical trials of another drug,0
FERRIPROX,infections,may not reflect,0
FERRIPROX,infections,the rates observe,0
FERRIPROX,infections,rates in,0
FERRIPROX,infections,pract ice Adverse reaction information,1
FERRIPROX,death,another drug and may not reflect the rates,0
FERRIPROX,death,"


 A dverse reaction information for",1
FERRIPROX,Neutropenia,reflect the rates observed,0
FERRIPROX,Neutropenia,collected from patients who participated,0
FERRIPROX,Neutropenia,rates observed in practice erse,1
FERRIPROX,Neutropenia,in practice erse,1
FERRIPROX,Neutropenia,erse reacti on information for Ferriprox,1
FERRIPROX,agranulocytosis,poo led data collected from,1
FERRIPROX,fetal harm,aminotransferase,0
FERRIPROX,fetal harm,A,0
FERRIPROX,Fatal,medic alsafetyapopharmacom or FDA at,1
FERRIPROX,Fatal,Inc at Telephone medic alsafetyapopharmacom or FDA at,1
FERRIPROX,Fatal,at Telephone medic alsafetyapopharmacom or FDA at,1
FERRIPROX,Fatal,,0
FERRIPROX,agranulocytosis,lsafety@apophar macom or FDA at,1
FERRIPROX,agranulocytosis,at Telephone Email lsafety@apophar macom or FDA at,1
FERRIPROX,agranulocytosis,medica,0
FERRIPROX,agranulocytosis,lsafety@apophar macom or FDA at,1
FERRIPROX,agranulocytosis,or FDA at FDA or wwwfdagovmedwatch Clinical Trial,0
FERRIPROX,agranulocytosis,or wwwfdagovmedwatch Clinical Trial,0
FERRIPROX,agranulocytosis,Telephone Email medica,0
FERRIPROX,neutropenia,FDA,0
FERRIPROX,neutropenia,discussed,0
FERRIPROX,neutropenia,,0
FERRIPROX,neutropenia,/medwatch   Clinical Trial Experience The,1
FERRIPROX,neutropenia,,0
FERRIPROX,agranulocytosis,in,1
FERRIPROX,agranulocytosis,information for Ferriprox represents the pooled data,0
FERRIPROX,agranulocytosis,practice. Adverse reaction information for,1
FERRIPROX,agranulocytosis,in practice. Adverse reaction information for,1
FERRIPROX,agranulocytosis,practice. Adverse reaction information for,1
FERRIPROX,agranulocytosis,the,0
FERRIPROX,agranulocytosis,col lected from patients who,1
FERRIPROX,agranulocytosis,pooled data col lected from patients who,1
FERRIPROX,agranulocytosis,,0
FERRIPROX,neutropenia,icipated in single arm or activecontrolled,1
FERRIPROX,neutropenia,collected from patients who,0
FERRIPROX,neutropenia,or activecontrolled clinical studies The most serious adverse,0
FERRIPROX,neutropenia,single arm or activecontrolled clinical studies The,0
FERRIPROX,neutropenia,patients who icipated in single arm or activecontrolled,1
FERRIPROX,neutropenia,icipated in single arm or activecontrolled,1
FERRIPROX,neutropenia,single arm or activecontrolled clinical studies The most serious adverse reaction reported in,0
FERRIPROX,neutropenia,patients who icipated,1
FERRIPROX,agranulocytosis,see Warnings,0
FERRIPROX,agranulocytosis,Ferriprox was agranulocytosis,0
FERRIPROX,agranulocytosis,single,0
FERRIPROX,agranulocytosis,arm or,0
FERRIPROX,agranulocytosis,trials with,0
FERRIPROX,agranulocytosis,,0
FERRIPROX,agranulocytosis,Warnings and,0
FERRIPROX,agranulocytosis,ction,1
FERRIPROX,agranulocytosis,single,0
FERRIPROX,death,studies The most serious,0
FERRIPROX,death,trial s with Ferriprox was,1
FERRIPROX,death,trial s with Ferriprox was,1
FERRIPROX,death,reaction reported in trial s with Ferriprox was,1
FERRIPROX,death,adverse reaction reported in trial s with Ferriprox was,1
FERRIPROX,death,Warnings and Precautions,0
FERRIPROX,death,clinical,0
FERRIPROX,genotoxicity,             Vomiting,1
FERRIPROX,genotoxicity,             Vomiting,1
FERRIPROX,genotoxicity,,0
FERRIPROX,genotoxicity,             Vomiting,1
FERRIPROX,genotoxicity,             Vomiting,1
FERRIPROX,genotoxicity,             Vomiting,1
FERRIPROX,genotoxicity,,0
FERRIPROX,genotoxicity,,0
FERRIPROX,genotoxicity,             Vomiting,1
FERRIPROX,fetal harm,,0
FERRIPROX,fetal harm,           Diarrhea,1
FERRIPROX,fetal harm,,0
FERRIPROX,fetal harm,Vomiting,0
FERRIPROX,fetal harm,           Diarrhea,1
FERRIPROX,fetal harm,iscomfort            Diarrhea,1
FERRIPROX,fetal harm,,0
FERRIPROX,fetal harm,iscomfort            Diarrhea,1
FERRIPROX,embryofetal death,                  INVESTIGATIONS Alanine Amino,1
FERRIPROX,increased ALT values,ppetite MUSCULOSKELETAL AND CONNECTIVE,0
FERRIPROX,increased ALT values,Decreased,1
FERRIPROX,increased serum ALT,NECTIVE TISSUE DISO RDERS Arthralgia,1
FERRIPROX,increased serum ALT,appetite,0
FERRIPROX,increased serum ALT,DISO RDERS Arthralgia,1
FERRIPROX,increased serum ALT,appetite MUSCULOSKELETAL AND NECTIVE TISSUE DISO RDERS Arthralgia,1
FERRIPROX,increased serum ALT,,0
FERRIPROX,increased serum ALT,,0
FERRIPROX,increased serum ALT,TISSUE DISO RDERS Arthralgia,1
FERRIPROX,increased serum ALT,MUSCULOSKELETAL,0
FERRIPROX,increased serum ALT,appetite MUSCULOSKELETAL AND NECTIVE TISSUE DISO RDERS Arthralgia,1
FERRIPROX,increased serum ALT,MUSCULOSKELETAL AND,0
FERRIPROX,Decreased plasma zinc concentrations,,0
FERRIPROX,Decreased plasma zinc concentrations,NERVOUS SYSTEM DISORDERS Hea,0
FERRIPROX,Decreased plasma zinc concentrations,                Arthropathy          NERVOUS SYSTEM DISORDERS Hea,1
FERRIPROX,Decreased plasma zinc concentrations,,0
FERRIPROX,Decreased plasma zinc concentrations,Pain in                 Arthropathy          NERVOUS SYSTEM DISORDERS Hea,1
FERRIPROX,Decreased plasma zinc concentrations,,0
PRADAXA,bleeding,bleeding see Warnings and Precautions,1
PRADAXA,bleeding,bleeding see Warnings and Precautions,1
PRADAXA,gastritis,gastritis like symptoms and bleeding,1
PRADAXA,gastritis,To report SUSPECTED ADVERSE REACTIONS,0
PRADAXA,gastritis,like symptoms and,0
PRADAXA,gastritis,gastritis like symptoms and bleeding,1
PRADAXA,bleeding,are gastritislike symptoms bleeding To report SUSPECTED ADVERSE,1
PRADAXA,bleeding,gastritislike symptoms bleeding To report SUSPECTED ADVERSE,1
PRADAXA,bleeding,are gastritislike symptoms and,0
PRADAXA,bleeding,bleeding To report SUSPECTED ADVERSE,1
PRADAXA,bleeding,bleeding and gastrointestinal events ie,1
PRADAXA,gastrointestinal events,most frequent adverse reactions leading to discontinuation of PRADAXA were,0
PRADAXA,gastrointestinal events,of PRADAXA were bleeding,0
PRADAXA,gastrointestinal events,gastrointestinal,1
PRADAXA,gastrointestinal events,of PRADAXA were bleeding gastrointestinal events ie dyspepsia nausea upper,1
PRADAXA,dyspepsia,dyspepsia nausea upper abdominal pain,1
PRADAXA,nausea,nausea upper abdominal pain gastrointestinal,1
PRADAXA,nausea,nausea upper abdominal pain gastrointestinal,1
PRADAXA,upper abdominal pain,,0
PRADAXA,upper abdominal pain,gastrointestinal events,0
PRADAXA,upper abdominal pain,abdominal pain gastrointestinal hemorrhage and diarrhea,1
PRADAXA,upper abdominal pain,of PRADAXA were bleeding and gastrointestinal events ie dyspepsia nausea,0
PRADAXA,gastrointestinal hemorrhage,Precautions T,0
PRADAXA,gastrointestinal hemorrhage,hemorrhage and diarrhea Bleeding see,1
PRADAXA,gastrointestinal hemorrhage,upper abdominal gastrointestinal hemorrhage and diarrhea Bleeding see,1
PRADAXA,gastrointestinal hemorrhage,dyspepsia nausea upper abdominal gastrointestinal,1
PRADAXA,gastrointestinal hemorrhage,gastrointestinal hemorrhage and diarrhea Bleeding see,1
PRADAXA,diarrhea,gastrointestinal hemorrhage diarrhea Bleeding see Warnings and,1
PRADAXA,diarrhea,abdominal pain gastrointestinal hemorrhage diarrhea Bleeding see Warnings and,1
PRADAXA,diarrhea,diarrhea Bleeding see Warnings and,1
PRADAXA,diarrhea,diarrhea Bleeding see Warnings and,1
PRADAXA,diarrhea,diarrhea Bleeding see Warnings and,1
PRADAXA,diarrhea,diarrhea Bleeding see Warnings and,1
PRADAXA,diarrhea,diarrhea Bleeding see Warnings and,1
PRADAXA,diarrhea,Bleeding see Warnings,0
PRADAXA,diarrhea,diarrhea Bleeding see Warnings and,1
PRADAXA,diarrhea,Table,0
PRADAXA,bleeding,Warnings and Precautions Table shows the number,0
PRADAXA,bleeding,study with the bleeding,0
PRADAXA,bleeding,RELY study with,0
PRADAXA,bleeding,bleeding events during the treatment,1
PRADAXA,bleeding,the bleeding rate,0
PRADAXA,bleeding,subjectyears,0
PRADAXA,bleeding,per subjectyears,0
PRADAXA,bleeding,bleeding rate per subjectyears Major,1
PRADAXA,bleeding,bleeding rate per subjectyears Major,1
PRADAXA,bleeding,bleeding rate per subjectyears Major,1
PRADAXA,bleeding,period in the RELY study,0
PRADAXA,bleeding,bleeding rate per subjectyears Major,1
PRADAXA,bleeding,major bleeding events during the treatment,0
PRADAXA,bleeding,per subjectyears,0
PRADAXA,bleeding,,0
PRADAXA,bleeding,one or more,0
PRADAXA,bleeding,bleeding rate per,0
PRADAXA,bleeding,with the bleeding,0
PRADAXA,bleeding,,0
PRADAXA,bleeding,with the bleeding rate,0
PRADAXA,bleeding,subjectyears Major,0
PRADAXA,bleeding,bleeding is defined bleeding accompanied by one or,1
PRADAXA,bleeding,gdL,0
PRADAXA,bleeding,bleeding is defined bleeding accompanied by one or,1
PRADAXA,bleeding,study with the bleeding rate per subjectyears Major bleeding is defined as,0
PRADAXA,bleeding,defined as,0
PRADAXA,bleeding,bleeding accompanied by one or,1
PRADAXA,bleeding,a transfusion,0
PRADAXA,decrease in hemoglobin,of the following decrease,1
PRADAXA,decrease in hemoglobin,of packed red blood cells,0
PRADAXA,bleeding at a critical site,a critical site or with a fatal,1
PRADAXA,bleeding at a critical site,intracerebral hemorrhagic stroke,0
PRADAXA,bleeding at a critical site,at a critical site or with a fatal,1
PRADAXA,bleeding at a critical site,blood bleeding at a critical site or with a fatal,1
PRADAXA,bleeding at a critical site,of packed red blood bleeding at a critical site or with a fatal,1
PRADAXA,bleeding at a critical site,bleeding at a critical site or with a fatal,1
PRADAXA,fatal,fatal outcome Intracranial hemorrhage included,1
PRADAXA,fatal,fatal outcome Intracranial hemorrhage included,1
PRADAXA,fatal,outcome Intracranial hemorrhage included intracerebral hemorrhagic stroke,0
PRADAXA,fatal,fatal outcome Intracranial hemorrhage included,1
PRADAXA,Intracranial hemorrhage,,0
PRADAXA,hemorrhagic stroke,included hemorrhagic stroke subarachnoid and subdural bleeds,1
PRADAXA,hemorrhagic stroke,intracerebral,0
PRADAXA,hemorrhagic stroke,hemorrhage included intracerebral,0
PRADAXA,hemorrhagic stroke,a critical site or with a fatal outcome Intracranial hemorrhage included intracerebral,0
PRADAXA,hemorrhagic stroke,stroke subarachnoid and subdural bleeds,1
PRADAXA,hemorrhagic stroke,,0
PRADAXA,hemorrhagic stroke,included intracerebral,0
PRADAXA,subdural bleeds,,0
PRADAXA,subdural bleeds,hemorrhage included intracerebral hemorrhagic stroke subarachnoid,0
PRADAXA,Bleeding,treatment or within days of,0
PRADAXA,Bleeding,subdural bleeds Table Adjudicated Bleeding Events in Treated Patientsa,1
PRADAXA,Bleeding,Table Adjudicated Bleeding Events in Treated Patientsa,1
PRADAXA,Bleeding,hemorrhagic,0
PRADAXA,Bleeding,subdural bleeds Table Adjudicated Bleeding Events in Treated Patientsa,1
PRADAXA,Bleeding,Bleeding Events in Treated Patientsa,1
PRADAXA,bleeding,bleeding events within each subcategory,1
PRADAXA,bleeding,,0
PRADAXA,bleeding,bleeding events within each subcategory,1
PRADAXA,bleeding,bleeding events within each subcategory,1
PRADAXA,bleeding,considered cDefined as,0
PRADAXA,bleeding,in hemoglobin of gdL,0
PRADAXA,bleeding,more of the following a decrease in hemoglobin of gdL a transfusion of,0
PRADAXA,bleeding,bleeding accompanied by one or,1
PRADAXA,bleeding,was considered cDefined bleeding accompanied by one or,1
PRADAXA,decrease in hemoglobin,,0
PRADAXA,bleeding at a critical site,of packed red blood bleeding at a critical site or with fatal outcome,1
PRADAXA,bleeding at a critical site,bleed included intracerebral hemorrhagic,0
PRADAXA,bleeding at a critical site,bleeding,1
PRADAXA,bleeding at a critical site,of or more,0
PRADAXA,bleeding at a critical site,subarachno,0
PRADAXA,bleeding at a critical site,red blood bleeding at a critical site or with fatal outcome,1
PRADAXA,bleeding at a critical site,bleeding at a,1
PRADAXA,fatal,fatal outcome dIntracranial bleed included,1
PRADAXA,fatal,site or fatal outcome dIntracranial bleed included,1
PRADAXA,Intracranial bleed,bleeds,0
PRADAXA,Intracranial bleed,or with fatal outcome Intracranial bleed included intracerebral hemorrhagic stroke,1
PRADAXA,hemorrhagic stroke,,0
PRADAXA,subdural bleeds,intracerebral hemorrhagic stroke subarachnoid subdural bleeds eOntreatment analysis based on,1
PRADAXA,Fatal,and,0
PRADAXA,Fatal,defined above with investigator,0
PRADAXA,Fatal,in Section,0
PRADAXA,Fatal,Fatal bleed Adjudicated major bleed,1
PRADAXA,Fatal,fatal,0
PRADAXA,Fatal,in Section Clinical Studies Fatal bleed Adjudicated major bleed,1
PRADAXA,Fatal,in Section Clinical Studies Fatal bleed Adjudicated major bleed,1
PRADAXA,Fatal,the safety population compared to ITT analysis presented in Section Clinical,0
PRADAXA,Fatal,Section Clinical,0
PRADAXA,bleed,,0
PRADAXA,bleed,analysis presented in Section Clinical Studies fFatal bleed,0
PRADAXA,fatal,,0
PRADAXA,fatal,,0
PRADAXA,fatal,as defined above with investigator,0
PRADAXA,fatal,fatal outcome and adjudicated death,1
PRADAXA,death,reported fatal outcome and death with primary cause from,1
PRADAXA,death,and adjudicated,0
PRADAXA,death,death with primary cause from,1
PRADAXA,death,death with primary cause from,1
PRADAXA,bleeding,from,0
PRADAXA,bleeding,bleeding gNonintracranial fatal bleed Adjudicated,1
PRADAXA,bleeding,defined above and adjudicated,0
PRADAXA,bleeding,investigator,0
PRADAXA,bleeding,primary cause,0
PRADAXA,bleeding,fatal bleed,0
PRADAXA,bleeding,,0
PRADAXA,bleeding,cause bleeding gNonintracranial fatal bleed Adjudicated,1
PRADAXA,bleeding,cause bleeding gNonintracranial fatal bleed Adjudicated,1
PRADAXA,bleeding,cause bleeding gNonintracranial fatal bleed Adjudicated,1
PRADAXA,fatal,from,0
PRADAXA,fatal,adjudicated death with primary cause from bleeding gNonintracranial,0
PRADAXA,fatal,fatal bleed Adjudicated major bleed,1
PRADAXA,fatal,cause from bleeding fatal bleed Adjudicated major bleed,1
PRADAXA,fatal,death with primary,0
PRADAXA,bleed,,0
PRADAXA,bleed,bleed as defined above and,1
PRADAXA,bleed,fatal bleed Adjudicated bleed as defined above and,1
PRADAXA,bleed,Adjudicated major,0
PRADAXA,bleed,death with primary cause from bleeding but without,0
PRADAXA,bleed,fatal bleed,0
PRADAXA,bleed,bleed as defined above and,1
PRADAXA,bleed,bleed as defined above and,1
PRADAXA,bleed,bleed as defined above and,1
PRADAXA,bleed,bleeding but without symptomatic,0
PRADAXA,death,intracranial bleed based,0
PRADAXA,death,,0
PRADAXA,death,fatal bleed Adjudicated major,0
PRADAXA,death,fatal bleed Adjudicated major bleed as,0
PRADAXA,bleeding,primary cause bleeding but without symptomatic intracranial,1
PRADAXA,symptomatic intracranial bleed,intracranial bleed based on investigators clinical,1
PRADAXA,symptomatic intracranial bleed,bleed based on investigators clinical,1
PRADAXA,symptomatic intracranial bleed,Event PRADAXA mgN,0
PRADAXA,symptomatic intracranial bleed,intracranial bleed based on investigators clinical,1
PRADAXA,symptomatic intracranial bleed,symptomatic intracranial bleed based on investigators clinical,1
PRADAXA,symptomatic intracranial bleed,,0
PRADAXA,symptomatic intracranial bleed,intracranial bleed based on investigators clinical,1
PRADAXA,symptomatic intracranial bleed,cause from bleeding but symptomatic intracranial bleed based on investigators clinical,1
PRADAXA,symptomatic intracranial bleed,intracranial bleed based on investigators clinical,1
PRADAXA,symptomatic intracranial bleed,on investigators clinical assessment Event PRADAXA,0
PRADAXA,Bleeding,,0
PRADAXA,Bleeding,Bleeding c,1
PRADAXA,Bleeding,Bleeding c,1
PRADAXA,Bleeding,Bleeding c,1
PRADAXA,Bleeding,Bleeding c,1
PRADAXA,Bleeding,Bleeding c,1
PRADAXA,Bleeding,Bleeding c,1
PRADAXA,Bleeding,Bleeding c,1
PRADAXA,Intracranial Hemorrhage,d,0
PRADAXA,Intracranial Hemorrhage,Hemorrhage,1
PRADAXA,Intracranial Hemorrhage,c,0
PRADAXA,Intracranial Hemorrhage,c,0
PRADAXA,Intracranial Hemorrhage,,0
PRADAXA,Intracranial Hemorrhage,,0
PRADAXA,Intracranial Hemorrhage,Hemorrhage,1
PRADAXA,Intracranial Hemorrhage,c Intracranial,1
PRADAXA,ICH,,0
PRADAXA,ICH,ICH,1
PRADAXA,ICH,,0
PRADAXA,ICH,ICH G,1
PRADAXA,ICH,Other,0
PRADAXA,ICH,,0
PRADAXA,ICH,Other,0
PRADAXA,ICH,Other ICH G,1
PRADAXA,ICH,Other,0
PRADAXA,ICH,ICH G,1
PRADAXA,ICH,,0
PRADAXA,ICH,ICH G,1
PRADAXA,Fatal,tinal Fatal,1
PRADAXA,Fatal,Fatal,1
PRADAXA,Fatal,tinal Fatal Bleeding f,1
PRADAXA,Fatal,Fatal Bleeding,1
PRADAXA,Fatal,,0
PRADAXA,ICH,ICH,1
PRADAXA,ICH,f ICH,1
PRADAXA,ICH,ICH,1
PRADAXA,ICH,f,0
PRADAXA,ICH,,0
PRADAXA,ICH,f,0
PRADAXA,ICH,,0
PRADAXA,ICH,f ICH,1
PRADAXA,ICH,,0
PRADAXA,gastrointestinal bleeds,higher rate of gastrointestinal bleeds,1
PRADAXA,gastrointestinal bleeds,was a,0
PRADAXA,gastrointestinal bleeds,higher,0
PRADAXA,gastrointestinal bleeds,rate of gastrointestinal,1
PRADAXA,gastrointestinal bleeds,receiving,0
PRADAXA,bleeds,defined by baseline,0
PRADAXA,bleeds,warfarin,0
PRADAXA,bleeds,bleeds,1
PRADAXA,bleeds,bleeds,1
PRADAXA,bleeds,bleeds,1
PRADAXA,bleeds,risk of major,0
PRADAXA,bleeds,of bleeds,1
PRADAXA,bleeds,major subgroups defined by baseline characteris,0
PRADAXA,bleeding,of age Figure,0
PRADAXA,bleeding,trend towards a,0
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,higher incidence of bleeding,1
PRADAXA,Bleeding,for patients years of age Figure Adjudicated Major,0
PRADAXA,Bleeding,patients years of age Figure Adjudicated,0
PRADAXA,Bleeding,Bleeding,1
PRADAXA,Bleeding,Bleeding,1
PRADAXA,Bleeding,Characteristics Including Hemorrhagic Stroke Treated Patients Note,0
PRADAXA,Bleeding,Bleeding,1
PRADAXA,Bleeding,Bleeding,1
PRADAXA,Bleeding,Major,0
PRADAXA,Bleeding,Bleeding,1
PRADAXA,Bleeding,,0
PRADAXA,gastrointestinal adverse reactions,had an increased incidence of,0
PRADAXA,gastrointestinal adverse reactions,an,0
PRADAXA,gastrointestinal adverse reactions,incidence gastrointestinal,1
PRADAXA,dyspepsia,on warfarin These were commonly,0
PRADAXA,dyspepsia,incidence of gastrointestinal adverse reactions vs on warfarin These were commonly,0
PRADAXA,dyspepsia,These were dyspepsia,1
PRADAXA,dyspepsia,vs on,0
PRADAXA,dyspepsia,on warfarin These were,0
PRADAXA,dyspepsia,warfarin These were dyspepsia,1
PRADAXA,dyspepsia,commonly,0
PRADAXA,dyspepsia,dyspepsia,1
PRADAXA,abdominal pain upper,and epigastric discomfort and,0
PRADAXA,abdominal pain upper,These were commonly dyspepsia abdominal pain,1
PRADAXA,abdominal pain upper,These were commonly dyspepsia abdominal pain upper,1
PRADAXA,abdominal pain upper,and,0
PRADAXA,abdominal pain upper,upper,1
PRADAXA,abdominal pain upper,abdominal pain upper,1
PRADAXA,abdominal pain upper,abdominal pain abdominal discomfort and,0
PRADAXA,abdominal pain upper,and epigastric discomfort,0
PRADAXA,abdominal pain upper,symptoms,0
PRADAXA,abdominal pain upper,commonly,0
PRADAXA,abdominal discomfort,pain upper abdominal abdominal discomfort,1
PRADAXA,abdominal discomfort,,0
PRADAXA,epigastric discomfort,and gastritislike,0
PRADAXA,epigastric discomfort,,0
PRADAXA,gastritis,discomfort,0
PRADAXA,gastritis,gastritis,1
PRADAXA,gastritis,gast,0
PRADAXA,gastritis,including GERD,0
PRADAXA,gastritis,gastritis,1
PRADAXA,gastritis,symptoms,0
PRADAXA,gastritis,gastritis,1
PRADAXA,gastritis,gastritis,1
PRADAXA,GERD,GERD,1
PRADAXA,GERD,and epigastric discomfort and gastritislike,0
PRADAXA,GERD,GERD,1
PRADAXA,GERD,GERD,1
PRADAXA,GERD,symptoms GERD,1
PRADAXA,esophagitis,and epigastric discomfort and gastritislike,0
PRADAXA,esophagitis,,0
PRADAXA,esophagitis,esophagitis,1
PRADAXA,esophagitis,esophagitis,1
PRADAXA,esophagitis,including esophagitis,1
PRADAXA,erosive gastritis,gastritis,1
PRADAXA,erosive gastritis,gastritis,1
PRADAXA,erosive gastritis,erosive,1
PRADAXA,erosive gastritis,erosive,1
PRADAXA,hemorrhagic gastritis,,0
PRADAXA,hemorrhagic gastritis,gastritis gastric hemorrhage,0
PRADAXA,hemorrhagic gastritis,erosive gastritis and gastrointestinal ulcer,0
PRADAXA,hemorrhagic gastritis,hemorrhagic gastritis,1
PRADAXA,hemorrhagic gastritis,erosive gastritis gastric hemorrhagic gastritis,1
PRADAXA,hemorrhagic gastritis,esophagitis erosive gastritis gastric hemorrhagic gastritis,1
PRADAXA,hemorrhagic gastritis,,0
PRADAXA,gastrointestinal ulcer,hemorrhagic erosive gastritis gastrointestinal,1
PRADAXA,hypersensitivity,hypersensitivity,1
PRADAXA,hypersensitivity,allergic edema anaphylactic,0
PRADAXA,hypersensitivity,hypersensitivity,1
PRADAXA,hypersensitivity,,0
PRADAXA,hypersensitivity,hypersensitivity,1
PRADAXA,hypersensitivity,and anaphylactic,0
PRADAXA,hypersensitivity,pruritus allergic,0
PRADAXA,hypersensitivity,drug,0
PRADAXA,hypersensitivity,hypersensitivity,1
PRADAXA,urticaria,hypersensitivity,0
PRADAXA,urticaria,hypersensitivity urticaria,1
PRADAXA,urticaria,urticaria,1
PRADAXA,rash,rash,1
PRADAXA,rash,drug hypersensitivity,0
PRADAXA,rash,study,0
PRADAXA,rash,rash,1
PRADAXA,rash,rash,1
PRADAXA,rash,RELY study,0
PRADAXA,rash,,0
PRADAXA,rash,rash,1
PRADAXA,rash,shock were,0
PRADAXA,rash,rash,1
PRADAXA,pruritus,pruritus,1
PRADAXA,pruritus,pruritus,1
PRADAXA,pruritus,including urticaria rash pruritus,1
PRADAXA,pruritus,hypersensitivity including urticaria rash pruritus,1
PRADAXA,pruritus,were,0
PRADAXA,anaphylactic reaction,rash and pruritus allergic anaphylactic,1
PRADAXA,anaphylactic reaction,,0
PRADAXA,anaphylactic reaction,rash and pruritus allergic anaphylactic,1
PRADAXA,anaphylactic reaction,rash and pruritus allergic anaphylactic,1
PRADAXA,anaphylactic reaction,,0
PRADAXA,anaphylactic reaction,,0
PRADAXA,anaphylactic reaction,reported in of patients receiving PRADAXA,0
PRADAXA,anaphylactic reaction,drug hypersensitivity including urticaria rash and,0
PRADAXA,Bleeding,events if,0
PRADAXA,Bleeding,a mean CrCl of Bleeding,1
PRADAXA,Bleeding,at least one of the,0
PRADAXA,Bleeding,Bleeding,1
PRADAXA,Bleeding,if at least,0
PRADAXA,Bleeding,Bleeding,1
PRADAXA,Bleeding,were,0
PRADAXA,Bleeding,of mLmin,0
PRADAXA,Bleeding,mean CrCl of mLmin,0
PRADAXA,Bleeding,Bleeding,1
PRADAXA,bleeding,studies were classified as bleeding,1
PRADAXA,bleeding,as bleeding,1
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,major,0
PRADAXA,bleeding,classified as bleeding,1
PRADAXA,bleeding,if at least one,0
PRADAXA,bleeding,,0
PRADAXA,bleeding,criteria applied fatal,0
PRADAXA,bleeding,fatal bleeding symptomatic bleeding in a,0
PRADAXA,bleeding,,0
PRADAXA,fatal,fatal,1
PRADAXA,fatal,intracranial,0
PRADAXA,bleeding,a critical area or organ intraocular intracranial intraspinal or,0
PRADAXA,bleeding,as major bleeding events if at least one of,0
PRADAXA,bleeding,least one of,0
PRADAXA,bleeding,bleeding,0
PRADAXA,bleeding,bleeding,1
PRADAXA,symptomatic bleeding in a critical area,intramuscular with compartment syndrome,0
PRADAXA,symptomatic bleeding in a critical area,a critical area,1
PRADAXA,symptomatic bleeding in a critical area,,0
PRADAXA,symptomatic bleeding in a critical area,symptomatic bleeding,1
PRADAXA,compartment syndrome,bleeding bleeding causing a f,0
PRADAXA,compartment syndrome,retroperitoneal bleeding intraarticular bleeding or pericardial,0
PRADAXA,compartment syndrome,compartment syndrome,1
PRADAXA,compartment syndrome,intraspinal or intramuscular compartment syndrome,1
PRADAXA,compartment syndrome,in a critical area or organ intraocular intracranial intraspinal or intramuscular with,0
PRADAXA,compartment syndrome,or organ intraocular intracranial,0
PRADAXA,compartment syndrome,intraarticular bleeding or pericardial bleeding bleeding causing,0
PRADAXA,compartment syndrome,compartment syndrome,1
PRADAXA,compartment syndrome,bleeding or pericardial bleeding bleeding causing,0
PRADAXA,compartment syndrome,compartment syndrome,1
PRADAXA,retroperitoneal bleeding,or intramuscular with compartment retroperitoneal bleeding,1
PRADAXA,retroperitoneal bleeding,retroperitoneal bleeding,1
PRADAXA,retroperitoneal bleeding,bleeding causing a fall in hemoglobin level,0
PRADAXA,retroperitoneal bleeding,compartment retroperitoneal bleeding,1
PRADAXA,retroperitoneal bleeding,intracranial intraspinal or intramuscular,0
PRADAXA,intra-articular bleeding,bleeding,1
PRADAXA,intra-articular bleeding,intra-articular bleeding,1
PRADAXA,pericardial bleeding,intraarticular bleeding pericardial bleeding,1
PRADAXA,pericardial bleeding,retroperitoneal bleeding,0
PRADAXA,pericardial bleeding,bleeding,1
PRADAXA,pericardial bleeding,pericardial,1
PRADAXA,pericardial bleeding,pericardial bleeding,1
PRADAXA,pericardial bleeding,intraarticular,0
PRADAXA,bleeding,retroperitoneal bleeding intraarticular,0
PRADAXA,fall in hemoglobin level,retroperitoneal bleeding intraarticular bleeding,0
PRADAXA,fall in hemoglobin level,intraarticular bleeding,0
PRADAXA,fall in hemoglobin level,bleeding bleeding causing fall in hemoglobin level,1
PRADAXA,fall in hemoglobin level,hemoglobin level,1
PRADAXA,fall in hemoglobin level,pericardial bleeding bleeding causing fall in hemoglobin level,1
PRADAXA,fall in hemoglobin level,gdL mmolL or more or leading to transfusion of or more units of whole blood or re,0
PRADAXA,fall in hemoglobin level,in hemoglobin level,1
PRADAXA,bleeding,patients bleeding,1
PRADAXA,bleeding,with parenteral therapy Table shows the number of patients experiencing,0
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,,0
PRADAXA,bleeding,of patients bleeding,1
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,RECOVER and RECOVER II studies during the full treatment includi,0
PRADAXA,bleeding,,0
PRADAXA,bleeding,bleeding,1
PRADAXA,Bleeding,treatment,0
PRADAXA,Bleeding,Bleeding,1
PRADAXA,Bleeding,Bleeding,1
PRADAXA,Bleeding,parenteral and oral,0
PRADAXA,Bleeding,Bleeding,1
PRADAXA,Bleeding,Bleeding,1
PRADAXA,Bleeding,randomization Bleeding,1
PRADAXA,Bleeding,randomization Table,0
PRADAXA,Bleeding,Patients Note MBE can belong to more,0
PRADAXA,Bleeding,randomization Bleeding,1
PRADAXA,MBE,b Bleeding site based on investigator assessment Patients,0
PRADAXA,MBE,can belong to more than one criterion a Patients with at least one,0
PRADAXA,MBE,MBE,1
PRADAXA,Bleeding,Bleeding,1
PRADAXA,Bleeding,Bleeding,1
PRADAXA,Bleeding,one,0
PRADAXA,Bleeding,more than,0
PRADAXA,Bleeding,Bleeding,1
PRADAXA,bleeding,investigator,0
PRADAXA,bleeding,Confidence interval Patients,0
PRADAXA,bleeding,site bleeding,1
PRADAXA,bleeding,,0
PRADAXA,Bleeding,event,0
PRADAXA,Bleeding,sites,0
PRADAXA,Bleeding,sites for MBE b,0
PRADAXA,Bleeding,,0
PRADAXA,Bleeding,Bleeding,1
PRADAXA,Bleeding,for MBE b,0
PRADAXA,Bleeding,for MBE,0
PRADAXA,Bleeding,,0
PRADAXA,MBE,MBE b,1
PRADAXA,MBE,,0
PRADAXA,MBE,,0
PRADAXA,MBE,a Bleeding,0
PRADAXA,MBE,event a,0
PRADAXA,MBE,MBE b,1
PRADAXA,MBE,,0
PRADAXA,MBE,,0
PRADAXA,MBE,MBE b,1
PRADAXA,MBE,b,0
PRADAXA,bleeding,,0
PRADAXA,bleeding,,0
PRADAXA,bleeding,bleeds,0
PRADAXA,bleeding,bleeds in patients,0
PRADAXA,bleeding,Clinically relevant bleeding,1
PRADAXA,bleeding,bleeding,1
PRADAXA,gastrointestinal bleeds,bleeds,1
PRADAXA,gastrointestinal bleeds,Any,0
PRADAXA,gastrointestinal bleeds,of gastrointestinal,1
PRADAXA,gastrointestinal bleeds,gastrointestinal bleeds,1
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,the number of patients bleeding,1
PRADAXA,bleeding,Patients,0
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,the number of patients bleeding,1
PRADAXA,bleeding,bleeding,1
PRADAXA,Bleeding,Bleeding,1
PRADAXA,Bleeding,MBE,0
PRADAXA,Bleeding,of patients experiencing bleeding events in,0
PRADAXA,Bleeding,Bleeding,1
PRADAXA,Bleeding,the study Bleeding,1
PRADAXA,Bleeding,Bleeding,1
PRADAXA,MBE,the study Table,0
PRADAXA,MBE,in REMEDY Treated Patients MBE,1
PRADAXA,MBE,MBE,1
PRADAXA,MBE,belong to,0
PRADAXA,MBE,MBE,1
PRADAXA,MBE,MBE,1
PRADAXA,bleeding,one site bleeding,1
PRADAXA,bleeding,,0
PRADAXA,bleeding,than one site bleeding,1
PRADAXA,bleeding,,0
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,,0
PRADAXA,bleeding,more,0
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,of bleeding c Confidence interval Patients Major,0
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,bleeding,1
PRADAXA,Bleeding,,0
PRADAXA,Bleeding,,0
PRADAXA,Bleeding,,0
PRADAXA,Bleeding,b,0
PRADAXA,Bleeding,,0
PRADAXA,MBE,MBE b,1
PRADAXA,MBE,for,0
PRADAXA,MBE,sites MBE b,1
PRADAXA,MBE,for,0
PRADAXA,MBE,MBE b,1
PRADAXA,MBE,,0
PRADAXA,MBE,Bleeding sites,0
PRADAXA,MBE,MBE b,1
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,Clinically relevant nonmajor bleeding bleeding,1
PRADAXA,bleeding,REMEDY study the rate of,0
PRADAXA,gastrointestinal bleeds,rate of gastrointestinal,1
PRADAXA,gastrointestinal bleeds,gastrointestinal bleeds,1
PRADAXA,gastrointestinal bleeds,study the rate of gastrointestinal bleeds,1
PRADAXA,Bleeding,in the,0
PRADAXA,Bleeding,to more,0
PRADAXA,Bleeding,the study Table,0
PRADAXA,MBE,MBE,1
PRADAXA,MBE,belong to more than one criterion a Patients with at,0
PRADAXA,MBE,MBE,1
PRADAXA,MBE,MBE,1
PRADAXA,MBE,MBE,1
PRADAXA,MBE,MBE,1
PRADAXA,MBE,MBE,1
PRADAXA,MBE,the study Table Bleeding Events in,0
PRADAXA,MBE,MBE,1
PRADAXA,MBE,MBE,1
PRADAXA,Bleeding,Bleeding,1
PRADAXA,Bleeding,Bleeding,1
PRADAXA,Bleeding,with at,0
PRADAXA,Bleeding,b,0
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,,0
PRADAXA,bleeding,event a Clinically relevant bleeding,1
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,,0
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,,0
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,any gastrointestinal bleeds in patients receiving PR,0
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,,0
PRADAXA,gastrointestinal bleeds,the rate of gastrointestinal,1
PRADAXA,gastrointestinal bleeds,bleeding In the RESONATE study the,0
PRADAXA,gastrointestinal bleeds,bleeds,1
PRADAXA,gastrointestinal bleeds,study the rate of gastrointestinal bleeds,1
PRADAXA,myocardial infarction,of myocardial,1
PRADAXA,myocardial infarction,a higher rate of myocardial infarction,1
PRADAXA,myocardial infarction,,0
PRADAXA,myocardial infarction,,0
PRADAXA,myocardial infarction,a higher rate of myocardial infarction,1
PRADAXA,myocardial infarction,myocardial,1
PRADAXA,myocardial infarction,Myocardial Infarction Events In the activecontrolled VTE studies a higher rate of,0
PRADAXA,myocardial infarction,rate of myocardial,1
PRADAXA,myocardial infarction,rate of myocardial,1
PRADAXA,myocardial infarction,myocardial infarction,1
PRADAXA,fatal,fatal,1
PRADAXA,fatal,clinical myocardial infarction was reported in patients who received PRADAXA per patie,0
PRADAXA,fatal,fatal,1
PRADAXA,fatal,and,0
PRADAXA,fatal,In the placebocontrolled study a similar rate of nonfatal,0
PRADAXA,fatal,fatal,1
PRADAXA,fatal,nonfatal fatal,1
PRADAXA,myocardial infarction,a similar rate of nonfatal and,0
PRADAXA,myocardial infarction,a,0
PRADAXA,gastrointestinal adverse reactions,had a similar incidence gastrointestinal adverse reactions,1
PRADAXA,gastrointestinal adverse reactions,mg had,0
PRADAXA,Dyspepsia,vs,0
PRADAXA,Dyspepsia,Dyspepsia,1
PRADAXA,Dyspepsia,,0
PRADAXA,abdominal pain upper,discomfort occurred in,0
PRADAXA,abdominal pain upper,warfarin Dyspepsia abdominal pain,1
PRADAXA,abdominal pain upper,warfarin Dyspepsia abdominal,1
PRADAXA,abdominal pain upper,and epigastric discomfort,0
PRADAXA,abdominal pain upper,,0
PRADAXA,abdominal pain,warfarin,0
PRADAXA,abdominal pain,abdominal pain abdominal,1
PRADAXA,abdominal pain,Dyspepsia including abdominal pain abdominal pain,1
PRADAXA,abdominal pain,abdominal pain abdominal pain,1
PRADAXA,abdominal pain,abdominal pain,1
PRADAXA,abdominal pain,pain,1
PRADAXA,abdominal pain,pain abdominal,1
PRADAXA,abdominal pain,warfarin Dyspepsia including,0
PRADAXA,abdominal pain,abdominal,0
PRADAXA,abdominal pain,warfarin,0
PRADAXA,abdominal discomfort,patients on PRADAXA in vs on warfarin and,0
PRADAXA,abdominal discomfort,occurred in patients,0
PRADAXA,abdominal discomfort,abdominal discomfort,1
PRADAXA,abdominal discomfort,upper abdominal abdominal,1
PRADAXA,abdominal discomfort,abdominal pain upper abdominal abdominal discomfort,1
PRADAXA,abdominal discomfort,pain upper abdominal abdominal discomfort,1
PRADAXA,abdominal discomfort,abdominal abdominal discomfort,1
PRADAXA,epigastric discomfort,abdominal discomfort epigastric discomfort,1
PRADAXA,epigastric discomfort,abdominal pain abdominal discomfort epigastric discomfort,1
PRADAXA,epigastric discomfort,discomfort epigastric,1
PRADAXA,epigastric discomfort,upper abdominal pain abdominal,0
PRADAXA,epigastric discomfort,warfarin Dyspepsia including abdominal,0
PRADAXA,epigastric discomfort,abdominal pain abdominal discomfort epigastric discomfort,1
PRADAXA,epigastric discomfort,discomfort,1
PRADAXA,epigastric discomfort,discomfort,1
PRADAXA,epigastric discomfort,epigastric discomfort,1
PRADAXA,gastritis,and epigastric discomfort occurred in patients on PRADAXA in vs on warfarin and,0
PRADAXA,gastritis,gastritis GERD esophagitis erosive,0
PRADAXA,gastritis,gastritis GERD esophagitis,0
PRADAXA,gastritis,gastritis,1
PRADAXA,gastritis,gastritis,1
PRADAXA,gastritis,and gastritislike symptoms gastritis,1
PRADAXA,gastritis,patients on PRADAXA in vs,0
PRADAXA,gastritis,gastritis,1
PRADAXA,gastritis,gastritis,1
PRADAXA,gastritis,gastritis,1
PRADAXA,gastritis,occurred,0
PRADAXA,gastritis,,0
PRADAXA,gastritis,gastritis,1
PRADAXA,gastritis,gastritis,1
PRADAXA,GERD,gastritislike symptoms including GERD,1
PRADAXA,GERD,and gastritislike symptoms,0
PRADAXA,GERD,erosive,0
PRADAXA,GERD,erosive gastritis and,0
PRADAXA,GERD,,0
PRADAXA,GERD,on PRADAXA in vs on warfarin and gastritislike,0
PRADAXA,GERD,GERD,1
PRADAXA,esophagitis,gastritislike symptoms including gastritis GERD,0
PRADAXA,esophagitis,including gastritis esophagitis,1
PRADAXA,esophagitis,symptoms,0
PRADAXA,esophagitis,esophagitis,1
PRADAXA,esophagitis,PRADAXA in vs on warfarin and gastritislike symptoms including,0
PRADAXA,esophagitis,esophagitis,1
PRADAXA,esophagitis,gastritis esophagitis,1
PRADAXA,esophagitis,vs on warfarin and gastritislike symptoms,0
PRADAXA,esophagitis,symptoms including gastritis esophagitis,1
PRADAXA,erosive gastritis,erosive gastritis,1
PRADAXA,erosive gastritis,gastritis,1
PRADAXA,erosive gastritis,gastritis,1
PRADAXA,erosive gastritis,,0
PRADAXA,erosive gastritis,on warfarin and gastritislike,0
PRADAXA,erosive gastritis,,0
PRADAXA,erosive gastritis,symptoms including gastritis GERD erosive gastritis,1
PRADAXA,erosive gastritis,,0
PRADAXA,erosive gastritis,and gastric hemorrhage occurred,0
PRADAXA,erosive gastritis,gastritis GERD erosive,1
PRADAXA,gastric hemorrhage,esophagitis erosive gastritis gastric,1
PRADAXA,hypersensitivity,,0
PRADAXA,hypersensitivity,rash and pruritus allergic edema,0
PRADAXA,hypersensitivity,hypersensitivity,1
PRADAXA,hypersensitivity,In the pivotal studies hypersensitivity,1
PRADAXA,hypersensitivity,respectively Hypersensitivity Reactions In,0
PRADAXA,urticaria,edema anaphylactic reaction and anaphylactic,0
PRADAXA,urticaria,In the pivotal studies drug,0
PRADAXA,urticaria,urticaria,1
PRADAXA,rash,pivotal studies drug,0
PRADAXA,rash,shock were reported in,0
PRADAXA,rash,rash,1
PRADAXA,rash,rash,1
PRADAXA,rash,,0
PRADAXA,rash,pruritus allergic edema anaphylactic reaction and anaphylactic shock,0
PRADAXA,rash,rash,1
PRADAXA,pruritus,reaction and anaphylactic shock were reported in of patients r,0
PRADAXA,pruritus,,0
PRADAXA,pruritus,including,0
PRADAXA,allergic edema,edema,1
PRADAXA,allergic edema,and allergic edema,1
PRADAXA,allergic edema,allergic edema,1
PRADAXA,allergic edema,urticaria rash and pruritus,0
PRADAXA,allergic edema,the pivotal studies drug hypersensitivity including urticaria rash and pruritus,0
PRADAXA,allergic edema,anaphylactic reaction and anaphylactic shock were reported,0
PRADAXA,allergic edema,including urticaria rash and allergic edema,1
PRADAXA,anaphylactic reaction,and pruritus allergic anaphylactic reaction,1
PRADAXA,anaphylactic shock,were reported in of patients receiving PRADAXA Postmarketing Experience,0
PRADAXA,anaphylactic shock,allergic edema anaphylactic,0
PRADAXA,anaphylactic shock,anaphylactic shock,1
PRADAXA,anaphylactic shock,allergic edema anaphylactic,0
PRADAXA,anaphylactic shock,anaphylactic reaction,0
PRADAXA,anaphylactic shock,edema anaphylactic,0
PRADAXA,anaphylactic shock,anaphylactic reaction anaphylactic,1
PRADAXA,angioedema,,0
PRADAXA,angioedema,,0
PRADAXA,angioedema,reactions have been,0
PRADAXA,thrombocytopenia,have been identified during post approval use,0
PRADAXA,thrombocytopenia,have been identified during post approval,0
PRADAXA,thrombocytopenia,thrombocytopenia,1
PRADAXA,thrombocytopenia,during post approval use of PRADAXA,0
PRADAXA,thrombocytopenia,esophageal ulcer,0
PRADAXA,esophageal ulcer,,0
PRADAXA,esophageal ulcer,of PRADAXA,0
PRADAXA,esophageal ulcer,esophageal ulcer,1
PRADAXA,EPIDURAL HEMATOMA,to bleeding,0
PRADAXA,EPIDURAL HEMATOMA,Precautions,1
PRADAXA,EPIDURAL HEMATOMA,adverse reactions,0
PRADAXA,EPIDURAL HEMATOMA,symptoms and,0
PRADAXA,spinal hematomas,in practice Reduction of Risk of S,0
PRADAXA,spinal hematomas,of Risk of troke and System,1
PRADAXA,spinal hematomas,of Risk of troke and System,1
PRADAXA,spinal hematomas,Evaluation of,0
PRADAXA,spinal hematomas,may not reflect,0
PRADAXA,spinal hematomas,in Nonvalvular Atrial Fibrillation The RELY,0
PRADAXA,spinal hematomas,Nonvalvular,0
PRADAXA,spinal hematomas,Risk of troke,1
PRADAXA,spinal hematomas,practice Reduction of Risk of,0
PRADAXA,spinal hematomas,of Longter,0
PRADAXA,hematomas,,0
PRADAXA,hematomas,Anticoagulant y),1
PRADAXA,hematomas,and warfarin see Clinical Studies,0
PRADAXA,permanent paralysis,Therapy study provided safety on the use of two do,1
PRADAXA,permanent paralysis,Anticoagulant,0
PRADAXA,EPIDURAL HEMATOMA,were for XA 150 mg and,1
PRADAXA,EPIDURAL HEMATOMA,for XA,1
PRADAXA,spinal hematomas,or of the following,1
PRADAXA,spinal hematomas,Major bleeding,0
PRADAXA,spinal hematomas,by one or of the following,1
PRADAXA,spinal hematomas,the following,1
PRADAXA,spinal hematomas,the following,1
PRADAXA,spinal hematomas,cells,0
PRADAXA,spinal hematomas,one or of the following,1
PRADAXA,permanent paralysis,hemorrhage,1
PRADAXA,permanent paralysis,cells bleeding at a critical site,0
PRADAXA,permanent paralysis,outcome hemorrhage,1
PRADAXA,permanent paralysis,subdural bleeds Table Adjudicated,0
PRADAXA,permanent paralysis,critical site or,0
PRADAXA,permanent paralysis,included,1
PRADAXA,permanent paralysis,,0
PRADAXA,permanent paralysis,hemorrhage included,1
PRADAXA,permanent paralysis,hemorrhage included,1
PRADAXA,Bleeding,reaction s reported with,1
PRADAXA,Bleeding,reaction s reported with,1
PRADAXA,Bleeding,,0
PRADAXA,Bleeding,reaction s,1
PRADAXA,Bleeding,,0
PRADAXA,Bleeding,reaction,1
PRADAXA,Bleeding,reaction s reported with PRADAXA were,1
PRADAXA,Bleeding,reaction s reported with PRADAXA,1
PRADAXA,Bleeding,reaction s reported,1
PRADAXA,fatal,common adverse,0
PRADAXA,fatal,,0
PRADAXA,fatal,ated  to bleeding see Warnings and,1
PRADAXA,bleeding,,0
PRADAXA,bleeding,,0
PRADAXA,bleeding,,0
PRADAXA,bleeding,,0
PRADAXA,bleeding,o,1
PRADAXA,bleeding,,0
PRADAXA,bleeding,o,1
PRADAXA,bleeding,o bleedi ng see,1
PRADAXA,bleeding,,0
PRADAXA,bleeding,,0
PRADAXA,bleeding,and,0
PRADAXA,bleeding,,0
PRADAXA,bleeding,o bleedi ng,1
PRADAXA,bleeding,o,1
PRADAXA,bleeding, reflect the rates observed,1
PRADAXA,bleeding, reflect the rates observed,1
PRADAXA,bleeding, reflect the rates observed,1
PRADAXA,bleeding, reflect the rates observed,1
PRADAXA,fatal,the clinical trials of another drug and may not reflect the rates observed in,0
PRADAXA,fatal,ducti on of Risk,1
PRADAXA,bleeding,,0
PRADAXA,bleeding,,0
PRADAXA,bleeding,Ris k of Stroke,1
PRADAXA,spinal hematoma,,0
PRADAXA,spinal hematoma,,0
PRADAXA,spinal hematoma,PRADAXA were bleeding and gastrointestinal events,0
PRADAXA,spinal hematoma,,0
PRADAXA,spinal hematoma,,0
PRADAXA,spinal hematoma,nausea upper,0
PRADAXA,spinal hematoma, gastrointestin al hemorrhage and,1
PRADAXA,permanent paralysis,"  

        Bleedin g see Warnings",1
PRADAXA,permanent paralysis,ie dyspepsia nausea upper,0
PRADAXA,permanent paralysis,"  

        Bleedin g see Warnings",1
PRADAXA,permanent paralysis,the number,0
PRADAXA,permanent paralysis,"  

        Bleedin g see Warnings",1
PRADAXA,paralysis,  Bleedin g see Warnings,1
PRADAXA,paralysis,  Bleedin g see Warnings,1
PRADAXA,paralysis,Table shows the number of adjudicated m,0
PRADAXA,paralysis,number of adjudicated,0
PRADAXA,paralysis,adjudicated m,0
PRADAXA,paralysis,adjudicated m,0
PRADAXA,paralysis,  Bleedin g see Warnings,1
PRADAXA,paralysis,  Bleedin g see Warnings,1
PRADAXA,transient ischemic attack,adjudicated death ith primary cause from bl eeding gNonintracranial fatal,1
PRADAXA,transient ischemic attack,defined above with investigator reported fatal outcome and adjudicated death,0
PRADAXA,transient ischemic attack,outcome and adjudicated death w,0
PRADAXA,transient ischemic attack,reported fatal outcome and adjudicated death w,0
PRADAXA,transient ischemic attack,adjudicated death ith,1
PRADAXA,transient ischemic attack,,0
PRADAXA,transient ischemic attack,death ith primary cause from bl eeding gNonintracranial fatal,1
PRADAXA,transient ischemic attack,,0
PRADAXA,transient ischemic attack,outcome and adjudicated death,0
PRADAXA,myocardial infarction,gNon-intracranial fatal bleed Adjudicated,1
PRADAXA,myocardial infarction,and adjudicated death with primary cause from,0
PRADAXA,myocardial infarction,adjudicated,0
PRADAXA,myocardial infarction,fatal bleed Adjudicated major bleed as defined above,0
PRADAXA,myocardial infarction,from .  gNon-intracranial  fatal bleed Adjudicated,1
PRADAXA,bleeding,primary cause from,0
PRADAXA,bleeding,major,1
PRADAXA,bleeding,as defined above and adjudicated death with primary cause,0
PRADAXA,bleeding,as defined,0
PRADAXA,bleeding,major,1
PRADAXA,bleeding,death with primary cause from bleeding,0
PRADAXA,bleeding,with primary cause from bleeding,0
PRADAXA,bleeding,and adjudicated death with primary cause from,0
PRADAXA,pericardial effusions,defined above and cated death with,1
PRADAXA,pericardial effusions,,0
PRADAXA,pericardial effusions,from bleeding but without,0
PRADAXA,bleeding,         PRADAXA mgN n,1
PRADAXA,bleeding,investigators clinical assessment          PRADAXA mgN n,1
PRADAXA,bleeding,b,0
PRADAXA,bleeding,         PRADAXA mgN n,1
PRADAXA,bleeding,investigators clinical assessment Event,0
PRADAXA,bleeding,,0
PRADAXA,bleeding,         PRADAXA mgN n,1
PRADAXA,bleeding,year,0
PRADAXA,bleeding,         PRADAXA mgN n,1
PRADAXA,bleeding,         PRADAXA mgN n,1
PRADAXA,thromboembolic events,PRADAXA,1
VORAXAZE,allergic reactions,,0
VORAXAZE,allergic reactions,,0
VORAXAZE,allergic reactions,,0
VORAXAZE,allergic reactions,,0
VORAXAZE,allergic reactions,allergic,1
VORAXAZE,allergic reactions,reactions including,1
VORAXAZE,allergic reactions,,0
VORAXAZE,allergic reactions,,0
VORAXAZE,allergic reactions,,0
VORAXAZE,allergic reactions,reactions including,1
VORAXAZE,anaphylactic reactions,anaphylactic,1
VORAXAZE,anaphylactic reactions,anaphylactic reactions,1
VORAXAZE,anaphylactic reactions,incidence with VORAXAZE,0
VORAXAZE,anaphylactic reactions,anaphylactic,1
VORAXAZE,paraesthesias,paraesthesias flushing nausea andor,1
VORAXAZE,paraesthesias,paraesthesias flushing nausea andor,1
VORAXAZE,paraesthesias,The most common adverse reactions incidence with,0
VORAXAZE,paraesthesias,paraesthesias flushing nausea andor,1
VORAXAZE,paraesthesias,paraesthesias flushing nausea andor,1
VORAXAZE,paraesthesias,paraesthesias flushing nausea andor,1
VORAXAZE,paraesthesias,with VORAXAZE,0
VORAXAZE,paraesthesias,,0
VORAXAZE,nausea,andor vomiting hypotension and headache EXCERPT In clinical trials the most common,0
VORAXAZE,nausea,VORAXAZE are paraesthesias nausea andor vomiting hypotension,1
VORAXAZE,nausea,nausea andor vomiting hypotension,1
VORAXAZE,nausea,are paraesthesias nausea andor vomiting hypotension,1
VORAXAZE,nausea,paraesthesias flushing,0
VORAXAZE,vomiting,vomiting hypotension and headache,1
VORAXAZE,vomiting,vomiting hypotension and headache,1
VORAXAZE,vomiting,,0
VORAXAZE,hypotension,occurri,0
VORAXAZE,hypotension,hypotension and headache EXCERPT,1
VORAXAZE,hypotension,,0
VORAXAZE,hypotension,In clinical trials the most common related,0
VORAXAZE,hypotension,flushing,0
VORAXAZE,headache,andor vomiting hypotension headache EXCERPT In clinical,1
VORAXAZE,headache,headache EXCERPT In clinical,1
VORAXAZE,headache,In clinical trials the most common related adverse events,0
VORAXAZE,headache,headache EXCERPT In clinical,1
VORAXAZE,headache,adverse,0
VORAXAZE,headache,vomiting hypotension headache EXCERPT In clinical,1
VORAXAZE,headache,headache EXCERPT In clinical,1
VORAXAZE,headache,paraesthesias flushing nausea,0
VORAXAZE,headache,hypotension headache EXCERPT In clinical,1
VORAXAZE,paraesthesia,SUSPECTED,0
VORAXAZE,flushing,headache To,0
VORAXAZE,flushing,flushing nausea andor vomiting,1
VORAXAZE,flushing,flushing nausea andor vomiting,1
VORAXAZE,flushing,common related adverse events occurring in of patients,0
VORAXAZE,flushing,,0
VORAXAZE,flushing,most common,0
VORAXAZE,flushing,of patients were paraesthesia,0
VORAXAZE,flushing,To,0
VORAXAZE,flushing,,0
VORAXAZE,flushing,,0
VORAXAZE,nausea,patients were paraesthesia nausea andor vomiting hypotension,1
VORAXAZE,nausea,related,0
VORAXAZE,nausea,,0
VORAXAZE,nausea,,0
VORAXAZE,nausea,nausea andor vomiting hypotension,1
VORAXAZE,nausea,occurring in,0
VORAXAZE,hypotension,flushing nausea andor hypotension and headache To,1
VORAXAZE,hypotension,andor hypotension and headache To,1
VORAXAZE,hypotension,andor hypotension and headache To,1
VORAXAZE,hypotension,hypotension and headache To,1
VORAXAZE,hypotension,hypotension and headache To,1
VORAXAZE,hypotension,patients were paraesthesia flushing,0
VORAXAZE,hypotension,call or contac,0
VORAXAZE,headache,headache To report SUSPECTED,1
VORAXAZE,headache,headache To report SUSPECTED,1
VORAXAZE,headache,FDA at,0
VORAXAZE,flushing,related flushing The most common,1
VORAXAZE,flushing,,0
VORAXAZE,flushing,flushing The most common,1
VORAXAZE,paresthesia,flushing and nausea andor vomiting which each occurred in of,0
VORAXAZE,paresthesia,each occurred in of patients Table Table,0
VORAXAZE,paresthesia,paresthesia flushing and nausea,1
VORAXAZE,paresthesia,paresthesia flushing and nausea,1
VORAXAZE,paresthesia,which each occurred in of,0
VORAXAZE,flushing,,0
VORAXAZE,flushing,paresthesia,0
VORAXAZE,flushing,vomiting which each occurred,0
VORAXAZE,flushing,flushing and nausea andor,1
VORAXAZE,flushing,renal events were flushing and nausea andor,1
VORAXAZE,flushing,that were,0
VORAXAZE,flushing,flushing and nausea andor,1
VORAXAZE,vomiting,andor,0
VORAXAZE,vomiting,vomiting which each occurred,1
VORAXAZE,vomiting,paresthesia flushing and nausea vomiting which each occurred,1
VORAXAZE,vomiting,each occurred in of patients,0
VORAXAZE,vomiting,Patient,0
VORAXAZE,vomiting,vomiting which each occurred,1
VORAXAZE,vomiting,of,0
VORAXAZE,flushing,flushing feeling hot burning,1
VORAXAZE,flushing,,0
VORAXAZE,flushing,One of these reactions was classified as Grade in severity,0
VORAXAZE,feeling hot,,0
VORAXAZE,feeling hot,hot burning sensation One,1
VORAXAZE,burning sensation,One of these reactions was classified as Grade in severity Adverse Reaction,0
VORAXAZE,Paresthesias,Paresthesias Flushing,1
VORAXAZE,Paresthesias,Adverse Reaction,0
VORAXAZE,Paresthesias,in severity Adverse Reaction,0
VORAXAZE,Flushing,Flushing NauseaVomiting,1
VORAXAZE,Flushing,,0
VORAXAZE,Flushing,,0
VORAXAZE,Flushing,,0
VORAXAZE,Flushing,N n Flushing NauseaVomiting,1
VORAXAZE,Nausea,Nausea,1
VORAXAZE,Nausea,Nausea Vomiting,1
VORAXAZE,Nausea,,0
VORAXAZE,Nausea,Flushing,0
VORAXAZE,Nausea,Flushing Nausea Vomiting,1
VORAXAZE,Nausea,Nausea Vomiting Headache,1
VORAXAZE,Vomiting,Vomiting Headache H,1
VORAXAZE,Vomiting,,0
VORAXAZE,Vomiting,Flushing Vomiting Headache H,1
VORAXAZE,Vomiting,Vomiting Headache H,1
VORAXAZE,Vomiting,Nausea,0
VORAXAZE,Vomiting,Vomiting Headache H,1
VORAXAZE,Headache,NauseaVomiting Headache Hypotension,1
VORAXAZE,Headache,NauseaVomiting,0
VORAXAZE,Headache,NauseaVomiting,0
VORAXAZE,Hypotension,Hypotension Blurred,1
VORAXAZE,Hypotension,Hypotension Blurred,1
VORAXAZE,Hypotension,Hypotension Blurred,1
VORAXAZE,Hypotension,,0
VORAXAZE,Hypotension,Headache,0
VORAXAZE,Hypotension,Hypotension Blurred,1
VORAXAZE,Hypotension,Headache,0
VORAXAZE,Blurred Vision,Diarrhea,0
VORAXAZE,Blurred Vision,Hypotension,0
VORAXAZE,Blurred Vision,Hypotension Blurred Vision Diarrhea,1
VORAXAZE,Blurred Vision,,0
VORAXAZE,Blurred Vision,Hypotension Blurred,1
VORAXAZE,Blurred Vision,Hypotension,0
VORAXAZE,Blurred Vision,Hypotension,0
VORAXAZE,Diarrhea,,0
VORAXAZE,Diarrhea,,0
VORAXAZE,Diarrhea,Diarrhea Hypersensitivity,1
VORAXAZE,Diarrhea,Diarrhea Hypersensitivity,1
VORAXAZE,Diarrhea,Vision,0
VORAXAZE,Diarrhea,Blurred Diarrhea Hypersensitivity,1
VORAXAZE,Hypersensitivity,Hypersensitivity Hypertension,1
VORAXAZE,Hypersensitivity,Hypersensitivity Hypertension Ra,1
VORAXAZE,Hypersensitivity,Hypersensitivity Hypertension,1
VORAXAZE,Hypersensitivity,Hypersensitivity,1
VORAXAZE,Hypersensitivity,Hypersensitivity Hypertension Ra,1
VORAXAZE,Hypersensitivity,Diarrhea Hypersensitivity Hypertension,1
VORAXAZE,Hypersensitivity,Diarrhea Hypersensitivity,1
VORAXAZE,Hypertension,,0
VORAXAZE,Hypertension,Hypersensitivity,0
VORAXAZE,Hypertension,Hypersensitivity,0
VORAXAZE,Hypertension,Hypersensitivity,0
VORAXAZE,Hypertension,Hypersensitivity,0
VORAXAZE,Hypertension,Rash,0
VORAXAZE,Rash,ty Rash,1
VORAXAZE,Rash,ty Rash,1
VORAXAZE,Rash,Rash,1
VORAXAZE,Rash,,0
VORAXAZE,Rash,,0
VORAXAZE,Throat irritation,Throat tightness,0
VORAXAZE,Throat irritation,Rash,0
VORAXAZE,Throat irritation,Rash Throat,1
VORAXAZE,Throat irritation,Rash Throat,1
VORAXAZE,Throat irritation,Rash,0
VORAXAZE,Throat tightness,Throat,0
VORAXAZE,Throat tightness,irritation,0
VORAXAZE,Throat tightness,Rash Throat Throat,1
VORAXAZE,Throat tightness,Throat tightness Tremor,1
VORAXAZE,Throat tightness,,0
VORAXAZE,Throat tightness,irritation,0
VORAXAZE,Throat tightness,,0
VORAXAZE,Throat tightness,tightness Tremor,1
VORAXAZE,Throat tightness,Rash Throat Throat tightness Tremor,1
VORAXAZE,Throat tightness,,0
VORAXAZE,Tremor,Tremor Immunogenicity,1
VORAXAZE,Tremor,with all th,0
VORAXAZE,Tremor,,0
VORAXAZE,Tremor,Tremor Immunogenicity,1
VORAXAZE,Tremor,As with,0
VORAXAZE,Tremor,tightness,0
VORAXAZE,allergic reactions,,0
VORAXAZE,allergic reactions,ing,1
VORAXAZE,allergic reactions,,0
VORAXAZE,allergic reactions,ing anaphylactic r,1
VORAXAZE,allergic reactions,,0
VORAXAZE,allergic reactions,r,1
VORAXAZE,allergic reactions,,0
VORAXAZE,allergic reactions,,0
VORAXAZE,allergic reactions,anaphylactic r,1
VORAXAZE,anaphylactic reactions,y occur. The most comm,1
VORAXAZE,anaphylactic reactions,y occur. The most comm on adverse reactions incidence with,1
VORAXAZE,anaphylactic reactions,,0
VORAXAZE,anaphylactic reactions,y occur. The most comm on adverse reactions incidence,1
VORAXAZE,anaphylactic reactions,with VORAXAZE are paraesthesias,0
VORAXAZE,anaphylactic reactions,,0
VORAXAZE,anaphylactic reactions,y occur. The,1
VORAXAZE,anaphylactic reactions,y occur. The most comm on adverse reactions,1
VORAXAZE,allergic reactions,trials of other drugs nd may not reflect the rates observed,1
HORIZANT,Somnolence,of the,0
HORIZANT,Somnolence,in more detail in the Warnings and,0
HORIZANT,Somnolence,Somnolence sedation and dizziness,1
HORIZANT,Somnolence,common,0
HORIZANT,Somnolence,Somnolence sedation and dizziness,1
HORIZANT,Somnolence,Somnolence sedation and dizziness,1
HORIZANT,Somnolence,,0
HORIZANT,Somnolence,Somnolence sedation and dizziness,1
HORIZANT,Somnolence,Somnolence sedation and dizziness,1
HORIZANT,sedation,more detail in the Warnings and Precautions section of the label,0
HORIZANT,sedation,sedation and dizziness see,1
HORIZANT,sedation,sedation and dizziness see,1
HORIZANT,sedation,and Precautions section of the,0
HORIZANT,sedation,sedation and dizziness see,1
HORIZANT,sedation,sedation and dizziness see,1
HORIZANT,sedation,sedation and dizziness see,1
HORIZANT,sedation,sedation and dizziness see,1
HORIZANT,dizziness,Warnings and Precautions RLS Most common adverse reactions and,0
HORIZANT,dizziness,,0
HORIZANT,dizziness,dizziness see Warnings and,1
HORIZANT,dizziness,dizziness see Warnings and,1
HORIZANT,dizziness,dizziness see Warnings and,1
HORIZANT,dizziness,Precautions section of,0
HORIZANT,somnolence,somnolence sedation and dizziness,1
HORIZANT,somnolence,somnolence sedation and dizziness,1
HORIZANT,somnolence,somnolence sedation and dizziness,1
HORIZANT,somnolence,somnolence sedation and dizziness,1
HORIZANT,somnolence,of placebo were,0
HORIZANT,somnolence,greater than,0
HORIZANT,dizziness,and greater than,0
HORIZANT,dizziness,were somnolencesedation dizziness PHN Most common,1
HORIZANT,dizziness,reactions and at least times,0
HORIZANT,dizziness,dizziness PHN Most common,1
HORIZANT,dizziness,of placebo were somnolencesedation dizziness PHN Most common,1
HORIZANT,dizziness,reactions and greater than,0
HORIZANT,dizziness,PHN Most common adverse reactions and,0
HORIZANT,dizziness,dizziness PHN Most common,1
HORIZANT,dizziness,dizziness somnolence and headache,1
HORIZANT,dizziness,dizziness somnolence and headache,1
HORIZANT,dizziness,dizziness somnolence and headache,1
HORIZANT,dizziness,ADVERSE,0
HORIZANT,dizziness,dizziness somnolence and headache,1
HORIZANT,dizziness,were,0
HORIZANT,dizziness,dizziness somnolence and headache,1
HORIZANT,dizziness,PHN Most common adverse reactions and,0
HORIZANT,dizziness,adverse reactions,0
HORIZANT,somnolence,reactions and greater,0
HORIZANT,somnolence,common adverse reactions and greater,0
HORIZANT,somnolence,REACTIONS contact,0
HORIZANT,somnolence,somnolence and headache EXCERPT,1
HORIZANT,somnolence,,0
HORIZANT,somnolence,,0
HORIZANT,somnolence,To report SUSPECTED ADVERSE REACTIONS,0
HORIZANT,headache,X,0
HORIZANT,headache,reactions and greater than placebo were dizziness,0
HORIZANT,headache,headache EXCERPT To report,1
HORIZANT,headache,adverse reactions and greater than placebo were dizziness,0
HORIZANT,headache,,0
HORIZANT,headache,somnolence headache EXCERPT To report,1
HORIZANT,headache,headache EXCERPT To report,1
HORIZANT,headache,headache EXCERPT To report,1
HORIZANT,headache,than placebo were dizziness,0
HORIZANT,somnolence,somnolence sedation and dizziness,1
HORIZANT,somnolence,and dizziness see Table Table lists treatmentemergent adverse,0
HORIZANT,somnolence,somnolence sedation and dizziness,1
HORIZANT,somnolence,sedation and dizziness see Table Table lists treatmentemergent adverse,0
HORIZANT,somnolence,for the mg dose of,0
HORIZANT,somnolence,in these trials for the mg dose of HORIZANT were,0
HORIZANT,somnolence,of HORIZANT somnolence sedation and dizziness,1
HORIZANT,somnolence,HORIZANT somnolence sedation and dizziness,1
HORIZANT,somnolence,somnolence sedation and dizziness,1
HORIZANT,somnolence,placebo in these trials for,0
HORIZANT,sedation,of placebo in these trials for the mg dose,0
HORIZANT,sedation,adverse reactions,0
HORIZANT,sedation,that occurred,0
HORIZANT,sedation,sedation and dizziness see,1
HORIZANT,dizziness,dizziness see Table Table,1
HORIZANT,Somnolence,disorders,0
HORIZANT,Somnolence,Somnolence sedation,1
HORIZANT,Somnolence,Somnolence sedation,1
HORIZANT,Somnolence,Somnolence sedation,1
HORIZANT,Somnolence,,0
HORIZANT,Somnolence,disorders,0
HORIZANT,Somnolence,Somnolence sedation,1
HORIZANT,Somnolence,Somnolence sedation,1
HORIZANT,sedation,Somnolence,0
HORIZANT,Dizziness,,0
HORIZANT,Dizziness,sedation Dizziness,1
HORIZANT,Dizziness,,0
HORIZANT,Dizziness,sedation,0
HORIZANT,Dizziness,sedation,0
HORIZANT,Headache,,0
HORIZANT,Headache,,0
HORIZANT,Headache,Headache G,1
HORIZANT,Headache,,0
HORIZANT,Headache,,0
HORIZANT,Dry mouth,,0
HORIZANT,Dry mouth,Dry mouth,1
HORIZANT,Dry mouth,Dry mouth,1
HORIZANT,Dry mouth,Dry mouth,1
HORIZANT,Flatulence,Flatulence Gen,1
HORIZANT,Flatulence,,0
HORIZANT,Flatulence,Flatulence Gen,1
HORIZANT,Fatigue,conditions,0
HORIZANT,Fatigue,,0
HORIZANT,Irritability,Irritability F,1
HORIZANT,Irritability,,0
HORIZANT,Irritability,Irritability F,1
HORIZANT,Irritability,Irritability F,1
HORIZANT,Irritability,,0
HORIZANT,Irritability,Irritability F,1
HORIZANT,Irritability,,0
HORIZANT,Feeling abnormal,,0
HORIZANT,Feeling abnormal,nk Feeling abnormal Perip,1
HORIZANT,Peripheral edema,Peripheral edema Metabolis,1
HORIZANT,Peripheral edema,ormal Peripheral,1
HORIZANT,Peripheral edema,edema Metabolis,1
HORIZANT,Peripheral edema,,0
HORIZANT,Peripheral edema,,0
HORIZANT,Peripheral edema,,0
HORIZANT,Peripheral edema,,0
HORIZANT,Weight increased,,0
HORIZANT,Increased appetite,Increased appetite Ear and,1
HORIZANT,Increased appetite,eased,0
HORIZANT,Increased appetite,eased,0
HORIZANT,Increased appetite,appetite Ear,1
HORIZANT,Increased appetite,appetite,1
HORIZANT,Increased appetite,Increased appetite Ear,1
HORIZANT,Increased appetite,eased,0
HORIZANT,Increased appetite,eased Increased appetite Ear,1
HORIZANT,Vertigo,,0
HORIZANT,Vertigo,disorders,0
HORIZANT,Vertigo,disorders,0
HORIZANT,Vertigo,disorders,0
HORIZANT,Vertigo,,0
HORIZANT,Vertigo,disorders Vertigo,1
HORIZANT,Vertigo,Vertigo,1
HORIZANT,Vertigo,Vertigo,1
HORIZANT,Vertigo,disorders Vertigo,1
HORIZANT,Vertigo,Vertigo,1
HORIZANT,Depression,orders Depression,1
HORIZANT,Depression,Depression,1
HORIZANT,Depression,orders,0
HORIZANT,Depression,Depression,1
HORIZANT,Depression,Depression,1
HORIZANT,Depression,Depression,1
HORIZANT,Depression,Depression,1
HORIZANT,Depression,Depression,1
HORIZANT,Depression,,0
HORIZANT,Libido decreased,,0
HORIZANT,Libido decreased,decreased a,1
HORIZANT,Libido decreased,a,0
HORIZANT,Libido decreased,,0
HORIZANT,Libido decreased,Libido decreased a,1
HORIZANT,Libido decreased,Libido decreased a,1
HORIZANT,Libido decreased,Libido,1
HORIZANT,balance disorder,balance disorder blurred,1
HORIZANT,balance disorder,balance disorder blurred,1
HORIZANT,balance disorder,placebo balance disorder blurred,1
HORIZANT,balance disorder,balance disorder blurred,1
HORIZANT,balance disorder,placebo balance,1
HORIZANT,balance disorder,and,0
HORIZANT,balance disorder,,0
HORIZANT,balance disorder,treated with mg of HORIZANT and numerically greater than placebo,0
HORIZANT,balance disorder,balance disorder blurred,1
HORIZANT,disorientation,disorder blurred disorientation feeling,1
HORIZANT,disorientation,balance disorder blurred,0
HORIZANT,disorientation,balance disorder blurred,0
HORIZANT,disorientation,disorientation feeling,1
HORIZANT,disorientation,greater than placebo were,0
HORIZANT,disorientation,disorientation feeling,1
HORIZANT,feeling drunk,placebo were balance disorder,0
HORIZANT,feeling drunk,vision disorientation,0
HORIZANT,feeling drunk,,0
HORIZANT,feeling drunk,drunk lethargy,1
HORIZANT,feeling drunk,somnolencesedation,0
HORIZANT,feeling drunk,vertigo The following,0
HORIZANT,feeling drunk,vertigo,0
HORIZANT,lethargy,blurred vision disorientation feeling lethargy and,1
HORIZANT,lethargy,lethargy and,1
HORIZANT,lethargy,balance disorder blurred vision disorientation feeling drunk,0
HORIZANT,lethargy,lethargy and,1
HORIZANT,lethargy,lethargy and,1
HORIZANT,lethargy,lethargy and,1
HORIZANT,lethargy,lethargy and,1
HORIZANT,lethargy,disorientation feeling lethargy and,1
HORIZANT,lethargy,,0
HORIZANT,vertigo,feeling drunk lethargy vertigo The,1
HORIZANT,vertigo,vertigo The,1
HORIZANT,vertigo,feeling dru,0
HORIZANT,vertigo,vertigo The,1
HORIZANT,sedation,adverse reactions were doserelated sedation dizziness,1
HORIZANT,sedation,vertigo,0
HORIZANT,sedation,following adverse reactions were doserelated,0
HORIZANT,sedation,peripheral edema and,0
HORIZANT,dizziness,dizziness feeling,1
HORIZANT,dizziness,and vertigo,0
HORIZANT,dizziness,,0
HORIZANT,dizziness,dizziness feeling,1
HORIZANT,dizziness,dizziness feeling,1
HORIZANT,dizziness,and vertigo The following adverse reactions,0
HORIZANT,dizziness,peripheral edema and vertigo Posthe,0
HORIZANT,dizziness,dizziness feeling,1
HORIZANT,dizziness,and vertigo The following,0
HORIZANT,libido decreased,decreased depression,1
HORIZANT,depression,depression headache,1
HORIZANT,depression,feeling drunk libido depression headache,1
HORIZANT,depression,depression headache,1
HORIZANT,depression,depression headache,1
HORIZANT,depression,depression headache,1
HORIZANT,depression,,0
HORIZANT,depression,,0
HORIZANT,depression,feeling drunk libido depression headache,1
HORIZANT,depression,,0
HORIZANT,depression,depression headache,1
HORIZANT,headache,headache peripheral,1
HORIZANT,headache,somnolencesedation dizziness,0
HORIZANT,headache,headache peripheral,1
HORIZANT,headache,headache peripheral,1
HORIZANT,headache,in,0
HORIZANT,headache,decreased,0
HORIZANT,peripheral edema,depression peripheral edema and,1
HORIZANT,vertigo,drunk libido decreased depression headache peripheral edema,0
HORIZANT,vertigo,headache peripheral edema vertigo Postherpetic,1
HORIZANT,vertigo,,0
HORIZANT,dizziness,dizziness somnolence,1
HORIZANT,dizziness,dizziness somnolence,1
HORIZANT,dizziness,placebo in,0
HORIZANT,dizziness,dizziness somnolence,1
HORIZANT,dizziness,than placebo in this trial for the mg dose of,0
HORIZANT,dizziness,dizziness somnolence,1
HORIZANT,dizziness,dizziness somnolence,1
HORIZANT,dizziness,reactions and greater than placebo in this trial,0
HORIZANT,dizziness,Table Table lists treatmentemergent adverse,0
HORIZANT,somnolence,somnolence and,1
HORIZANT,headache,see Table Table lists treatmentemergent adverse reactions that,0
HORIZANT,headache,lists treatmentemergent adverse reactions that occurred,0
HORIZANT,headache,headache see,1
HORIZANT,headache,headache see,1
HORIZANT,headache,headache see,1
HORIZANT,headache,were dizziness,0
HORIZANT,Dizziness,,0
HORIZANT,Dizziness,,0
HORIZANT,Dizziness,Dizziness,1
HORIZANT,Dizziness,Dizziness,1
HORIZANT,Dizziness,,0
HORIZANT,Dizziness,,0
HORIZANT,Dizziness,Dizziness,1
HORIZANT,Dizziness,Dizziness,1
HORIZANT,Dizziness,,0
HORIZANT,Somnolence,,0
HORIZANT,Somnolence,,0
HORIZANT,Somnolence,,0
HORIZANT,Headache,Headache,1
HORIZANT,Headache,,0
HORIZANT,Headache,Headache,1
HORIZANT,Headache,,0
HORIZANT,Headache,,0
HORIZANT,Headache,,0
HORIZANT,Fatigue,Fatigue Asthenia,1
HORIZANT,Fatigue,Fatigue Asthenia,1
HORIZANT,Fatigue,Fatigue Asthenia,1
HORIZANT,Fatigue,,0
HORIZANT,Asthenia,Fatigue,0
HORIZANT,Asthenia,Fatigue Asthenia,1
HORIZANT,Asthenia,Asthenia,1
HORIZANT,Asthenia,Asthenia,1
HORIZANT,Asthenia,Fatigue,0
HORIZANT,Asthenia,Fatigue,0
HORIZANT,Asthenia,Asthenia,1
HORIZANT,Asthenia,Fatigue,0
HORIZANT,Peripheral edema,Peripheral,1
HORIZANT,Peripheral edema,,0
HORIZANT,Peripheral edema,edema,1
HORIZANT,Peripheral edema,,0
HORIZANT,Peripheral edema,Peripheral,1
HORIZANT,Peripheral edema,,0
HORIZANT,Insomnia,Insomnia,1
HORIZANT,Insomnia,Insomnia,1
HORIZANT,Insomnia,Insomnia,1
HORIZANT,Weight increased,,0
HORIZANT,Weight increased,,0
HORIZANT,Weight increased,Weight,1
HORIZANT,Weight increased,,0
HORIZANT,Weight increased,Weight increased,1
HORIZANT,Blurred vision,Blurred vision,1
HORIZANT,Blurred vision,,0
HORIZANT,Blurred vision,,0
HORIZANT,Blurred vision,,0
HORIZANT,Blurred vision,Blurred,1
HORIZANT,Blurred vision,Blurred vision,1
HORIZANT,Blurred vision,,0
HORIZANT,Blurred vision,Blurred vision,1
HORIZANT,Blurred vision,Blurred vision,1
HORIZANT,balance disorder,were at balance disorder,1
HORIZANT,balance disorder,balance,1
HORIZANT,balance disorder,appetite irritability and vertig,0
HORIZANT,balance disorder,state depression,0
HORIZANT,depression,appetite irritability and,0
HORIZANT,depression,balance disorder confusional depression,1
HORIZANT,depression,Dizziness,0
HORIZANT,depression,,0
HORIZANT,depression,mouth flatulence increased appetite irritability and vertigo Dizziness somnolence fatig,0
HORIZANT,dry mouth,confusional state dry mouth,1
HORIZANT,dry mouth,disorder confusional state dry mouth,1
HORIZANT,irritability,irritability,1
HORIZANT,irritability,show,0
HORIZANT,irritability,flatulence increased irritability,1
HORIZANT,irritability,irritability,1
HORIZANT,irritability,irritability,1
HORIZANT,irritability,flatulence increased,0
HORIZANT,irritability,irritability,1
HORIZANT,irritability,irritability,1
HORIZANT,irritability,dry mouth,0
HORIZANT,irritability,irritability,1
HORIZANT,vertigo,vertigo,1
HORIZANT,vertigo,appetite irritability vertigo,1
HORIZANT,vertigo,vertigo,1
HORIZANT,vertigo,vertigo,1
HORIZANT,vertigo,vertigo,1
HORIZANT,vertigo,vertigo,1
HORIZANT,vertigo,flatulence,0
HORIZANT,vertigo,vertigo,1
HORIZANT,vertigo,irritability vertigo,1
HORIZANT,vertigo,vertigo,1
HORIZANT,Dizziness,increased appetite irritability and Dizziness,1
HORIZANT,Dizziness,,0
HORIZANT,Dizziness,irritability and,0
HORIZANT,Dizziness,state depression dry mouth flatulence increased appetite irritability and,0
HORIZANT,Dizziness,state depression dry mouth flatulence increased appetite irritability and,0
HORIZANT,Dizziness,,0
HORIZANT,somnolence,somnolence,1
HORIZANT,somnolence,depression,0
HORIZANT,somnolence,irritability and vertigo somnolence,1
HORIZANT,somnolence,vertigo somnolence,1
HORIZANT,somnolence,somnolence,1
HORIZANT,fatigue,vertigo Dizziness fatigue,1
HORIZANT,fatigue,irritability and vertigo Dizziness fatigue,1
HORIZANT,fatigue,and,0
HORIZANT,fatigue,irritability and vertigo,0
HORIZANT,fatigue,fatigue,1
HORIZANT,fatigue,Dizziness somnolence,0
HORIZANT,fatigue,fatigue,1
HORIZANT,fatigue,appeared to show a dose relationship,0
HORIZANT,insomnia,Gabapentin The,0
HORIZANT,insomnia,insomnia,1
HORIZANT,insomnia,,0
HORIZANT,insomnia,show a dose relationship Adverse Events Associated With Gabapentin The fo,0
HORIZANT,insomnia,insomnia,1
HORIZANT,insomnia,irritability and vertigo Dizziness,0
HORIZANT,insomnia,,0
HORIZANT,insomnia,Gabapentin The fo,0
HORIZANT,insomnia,insomnia,1
HORIZANT,insomnia,insomnia,1
HORIZANT,breast enlargement,in patients receiving gabapentin either,0
HORIZANT,breast enlargement,trials or,0
HORIZANT,gynecomastia,gynecomastia,1
HORIZANT,elevated creatine kinase,enlargement gynecomastia elevated creatine kinase,1
HORIZANT,elevated creatine kinase,elevated creatine kinase,1
HORIZANT,elevated creatine kinase,,0
HORIZANT,elevated creatine kinase,breast enlargement,0
HORIZANT,elevated creatine kinase,postmarketing breast enlargement gynecomastia elevated creatine,1
HORIZANT,elevated creatine kinase,,0
HORIZANT,Driving impairment,,0
HORIZANT,Driving impairment,ons are described  in,1
HORIZANT,Somnolence,,0
HORIZANT,Somnolence,see Warnings and RLS:,1
HORIZANT,Somnolence,Warnings and RLS:,1
HORIZANT,Somnolence,and at least times the rate,0
HORIZANT,Somnolence,see Warnings and,0
HORIZANT,Somnolence,dizziness see,0
HORIZANT,Somnolence,,0
HORIZANT,Somnolence,dizziness see Warnings and RLS:,1
HORIZANT,sedation, common  adverse,1
HORIZANT,sedation, common  adverse,1
HORIZANT,sedation,RLS  common  adverse,1
HORIZANT,sedation,,0
HORIZANT,sedation, common  adverse,1
HORIZANT,sedation,,0
HORIZANT,sedation, common  adverse,1
HORIZANT,sedation,placebo were somnolencesedation and dizz,0
HORIZANT,sedation,RLS  common  adverse,1
HORIZANT,sedation,Precautions,0
HORIZANT,dizziness,and,0
HORIZANT,dizziness,Precautions RLS Most common se reacti ons,1
HORIZANT,dizziness,Precautions RLS Most common adver,0
HORIZANT,Suicidal thoughts,and dizziness PHN Most common adverse reactions and greater,0
HORIZANT,Suicidal thoughts,dizziness,0
HORIZANT,Suicidal thoughts,reactions and  than placebo) we re,1
HORIZANT,Suicidal thoughts, than placebo) we re,1
HORIZANT,Suicidal thoughts,reactions and greater,0
HORIZANT,suicidal thoughts,"NS, contact",1
HORIZANT,suicidal thoughts,,0
HORIZANT,suicidal thoughts,"SUSPECTED ADVERSE NS, contact",1
HORIZANT,suicidal thoughts,FDA,0
HORIZANT,suicidal thoughts,FDA,0
HORIZANT,driving impairment,Clinical Trials Experience Because ical trials,1
HORIZANT,driving impairment,Trials Experience Because ical trials are co nducted,1
HORIZANT,driving impairment,Experience Because ical trials,1
HORIZANT,driving impairment,Clinical Trials Experience Because ical,1
HORIZANT,driving impairment,Clinical Trials Experience Because ical trials are,1
HORIZANT,driving impairment,Experience Because ical trials are co nducted,1
HORIZANT,driving impairment,under widely,0
HORIZANT,driving impairment,are co nducted,1
HORIZANT,driving impairment,varying conditions adverse reaction,0
HORIZANT,driving impairment,clinical trials of a drug cannot be directly compared with rates in the clinical trials,0
HORIZANT,driving impairment,ion rates observed in,1
HORIZANT,driving impairment,ion rates observed in,1
HORIZANT,driving impairment,adverse ion rates observed in,1
HORIZANT,driving impairment,,0
HORIZANT,driving impairment,ion,1
HORIZANT,driving impairment,varying,0
HORIZANT,driving impairment,clinical,0
HORIZANT,driving impairment,varying conditions adverse ion rates observed in,1
HORIZANT,driving impairment,widely varying conditions adverse ion rates observed in,1
HORIZANT,somnolence,Syndrome The exposure to HORIZANT in patients with RLS,0
HORIZANT,somnolence,at,0
HORIZANT,somnolence,osed for a t,1
HORIZANT,somnolence,in placebocontrolled trials n nd in long term,1
HORIZANT,sedation,trials n and in term,1
HORIZANT,sedation,term fol lowup,1
HORIZANT,sedation,trials n and in term fol lowup,1
HORIZANT,sedation,fol lowup,1
HORIZANT,sedation,n and in term,1
HORIZANT,dizziness,to years of age with being female and being Cau,0
HORIZANT,dizziness,n and in longterm p,1
HORIZANT,dizziness,longterm p studies The,1
HORIZANT,dizziness,and in longterm p studies The,1
HORIZANT,somnolence,mg se was stu died,1
HORIZANT,somnolence,died in of the studies Eleven out of patients treated with,0
HORIZANT,somnolence,The mg se,1
HORIZANT,somnolence,RLS in double blind placebocontrolled week clinical,0
HORIZANT,somnolence,of the studies Eleven out,0
HORIZANT,sedation,,0
HORIZANT,somnolence,p,0
HORIZANT,somnolence,,0
HORIZANT,somnolence,treatment due to,0
HORIZANT,somnolence,the patients w,0
HORIZANT,somnolence,of p,0
HORIZANT,somnolence,the patients ho,1
HORIZANT,somnolence,with of the patients ho,1
HORIZANT,somnolence,at,0
HORIZANT,somnolence,T he,1
HORIZANT,somnolence,patients who received plac,0
HORIZANT,somnolence,,0
HORIZANT,somnolence,the rate of,0
HORIZANT,somnolence,who received plac,0
HORIZANT,somnolence,most commonly observed adverse reactions and at least times the rate of placebo,0
HORIZANT,somnolence,reactions and at least times the,0
HORIZANT,somnolence,"received ebo.



 T he",1
HORIZANT,Dizziness,at least times the rate of placebo in,0
HORIZANT,Dizziness,these for the 6 mg,1
HORIZANT,Dizziness,these for the 6 mg,1
HORIZANT,Dizziness,,0
HORIZANT,Dizziness,,0
HORIZANT,Dizziness,the 6 mg,1
HORIZANT,Dizziness,,0
HORIZANT,dizziness,LS treate d,1
HORIZANT,dizziness,LS treate d,1
HORIZANT,dizziness,and numerically greater than placebo Table Incidence of,0
HORIZANT,dizziness,in of patients with LS,1
HORIZANT,dizziness,LS,1
HORIZANT,dizziness,patients with LS,1
HORIZANT,dizziness,lists treatmentemergent adverse reactions that occurred in of patients,0
HORIZANT,dizziness,adverse reactions that occurred,0
HORIZANT,Somnolence,of patients with RLS treated with HORIZANT and numerically greater,0
HORIZANT,Somnolence,than placebo,0
HORIZANT,Somnolence,"numerically greater than .



 Tabl e",1
HORIZANT,sedation,4. Inci dence,1
HORIZANT,sedation,with RLS treated with HORIZANT and numerically greater than placebo,0
HORIZANT,sedation,of,0
HORIZANT,sedation,,0
HORIZANT,sedation,numerically greater than placebo  4. Inci dence,1
HORIZANT,sedation,dence of Adverse Reactions in Week RLS,0
HORIZANT,sedation,numerically greater than placebo 4.,1
HORIZANT,sedation,,0
HORIZANT,Dizziness,SystemAdverse,0
HORIZANT,Dizziness,in,0
HORIZANT,Dizziness,nts Treat ed,1
HORIZANT,Dizziness,nts Treat ed,1
HORIZANT,Dizziness,With,0
HORIZANT,Dizziness,Studies Reported in of nts Treat ed,1
HORIZANT,somnolence,c N Nervous system disorders,0
HORIZANT,somnolence,           Somnolencesedation,1
HORIZANT,somnolence,Somnolencesedation,0
HORIZANT,somnolence,           Somnolencesedation,1
HORIZANT,somnolence,           Somnolencesedation,1
HORIZANT,somnolence,Nervous system            Somnolencesedation,1
HORIZANT,somnolence,Nervous system            Somnolencesedation,1
HORIZANT,somnolence,           Somnolencesedation,1
HORIZANT,Fatigue,Somnolencesedation,0
HORIZANT,Fatigue,    20  Dizziness,1
HORIZANT,Fatigue,Somnolencesedation     20  Dizziness,1
HORIZANT,Fatigue,Somnolencesedation,0
HORIZANT,Fatigue,Somnolencesedation,0
HORIZANT,Fatigue,Somnolencesedation,0
HORIZANT,Fatigue,Somnolencesedation,0
HORIZANT,asthenia,Somnolencesedation,0
HORIZANT,asthenia,,0
HORIZANT,asthenia,         Dizziness,1
HORIZANT,asthenia,Dizziness,0
HORIZANT,asthenia,Somnolencesedation,0
HORIZANT,asthenia,Somnolencesedation,0
HORIZANT,asthenia,Somnolencesedation,0
HORIZANT,asthenia,Somnolencesedation          Dizziness,1
HORIZANT,asthenia,         Dizziness,1
HORIZANT,somnolence,Headache,0
HORIZANT,somnolence,Headache           ,1
HORIZANT,somnolence,Headache           ,1
HORIZANT,somnolence,disorders,0
HORIZANT,Dizziness,          Nausea,1
HORIZANT,Dizziness,          Nausea,1
HORIZANT,Dizziness,disorders,0
HORIZANT,dizziness,      3   Flatulence,1
HORIZANT,dizziness,mouth,0
HORIZANT,dizziness,mouth,0
HORIZANT,dizziness,mouth,0
HORIZANT,dizziness,      3   Flatulence,1
HORIZANT,dizziness,      3   Flatulence,1
HORIZANT,Somnolence,mouth,0
HORIZANT,Somnolence,,0
HORIZANT,Dizziness, administ,1
HORIZANT,Dizziness,and,0
HORIZANT,Dizziness, administ,1
HORIZANT,Dizziness,site,0
HORIZANT,Dizziness, administ,1
HORIZANT,Dizziness, administ,1
HORIZANT,suicidal thoughts,,0
HORIZANT,suicidal thinking,    Depression    Li,1
HORIZANT,suicidal thinking,,0
HORIZANT,suicidal thinking,disorders     Depression    Li,1
HORIZANT,suicidal thinking,    Depression    Li,1
HORIZANT,suicidal behavior,a Placebo was a treatment arm in each of the,0
HORIZANT,suicidal behavior,Libido                 2,1
HORIZANT,suicidal behavior,Placebo was a treatment arm in each of the doubleblind,0
HORIZANT,suicidal behavior,                2,1
HORIZANT,suicidal behavior,Libido                 2,1
HORIZANT,suicidal behavior,,0
HORIZANT,suicidal behavior,                2,1
HORIZANT,suicidal behavior,                2,1
HORIZANT,suicidal behavior,                2,1
HORIZANT,suicidal thinking,arm in of the doubleblind placebocontrolled week clinical trials,0
HORIZANT,suicidal thinking,week clinical trials,0
HORIZANT,suicide,"


 Adv",1
HORIZANT,suicidal thoughts,reported in,0
HORIZANT,suicidal thoughts,in hese three 12,1
HORIZANT,suicidal thoughts,with mg of HORIZANT and numerically greater than,0
HORIZANT,suicidal thoughts,hese three 12 wee,1
HORIZANT,suicidal thoughts,hese three 12 wee,1
HORIZANT,suicidal thoughts,periphe,1
HORIZANT,suicidal thoughts,With mgday of,0
HORIZANT,suicidal thoughts,Reactions in At Least of Patients Treated With mgday of HORIZANT and Numerically,0
HORIZANT,suicidal thoughts,and Numerically r Than the Placeb,1
HORIZANT,suicidal thoughts,HORIZANT and Numerically r Than the Placeb,1
HORIZANT,Drug Reaction with Eosinophilia and Systemic Symptoms,4 10,1
HORIZANT,Drug Reaction with Eosinophilia and Systemic Symptoms,10 Peripheral,1
HORIZANT,Drug Reaction with Eosinophilia and Systemic Symptoms,FatigueAsthenia                   4                          10      ,1
HORIZANT,Drug Reaction with Eosinophilia and Systemic Symptoms,,0
HORIZANT,Drug Reaction with Eosinophilia and Systemic Symptoms,FatigueAsthenia 4,1
HORIZANT,Drug Reaction with Eosinophilia and Systemic Symptoms,FatigueAsthenia,0
HORIZANT,Drug Reaction with Eosinophilia and Systemic Symptoms,FatigueAsthenia 4,1
HORIZANT,multiorgan hypersensitivity,Peripheral edema 0,1
HORIZANT,multiorgan hypersensitivity,0,1
HORIZANT,multiorgan hypersensitivity,   Peripheral edema      0 ,1
HORIZANT,multiorgan hypersensitivity,,0
HORIZANT,multiorgan hypersensitivity,,0
HORIZANT,multiorgan hypersensitivity,,0
HORIZANT,multiorgan hypersensitivity,Peripheral edema 0,1
HORIZANT,multiorgan hypersensitivity,,0
HORIZANT,multiorgan hypersensitivity,   Peripheral edema      0 ,1
HORIZANT,multiorgan hypersensitivity,,0
HORIZANT,fatal,Ins,0
HORIZANT,fatal,      Ins,1
HORIZANT,fatal,      Ins,1
HORIZANT,fatal,Ins,0
HORIZANT,fatal,,0
HORIZANT,DRESS,,0
HORIZANT,DRESS,,0
HORIZANT,DRESS,disorders,0
HORIZANT,DRESS,      Insomnia,1
HORIZANT,DRESS,      Insomnia,1
HORIZANT,fever,      Insomnia,1
HORIZANT,fever,      Insomnia,1
HORIZANT,fever,      Insomnia,1
HORIZANT,fever,      Insomnia,1
HORIZANT,rash,,0
HORIZANT,rash,     Insomnia,1
HORIZANT,rash,     Insomnia,1
HORIZANT,lymphadenopathy,In somnia         ,1
HORIZANT,lymphadenopathy,somnia         ,1
HORIZANT,hepatitis,Insomnia,0
HORIZANT,hepatitis,          Metabolism and,1
HORIZANT,nephritis,and nutritional,0
HORIZANT,nephritis,Insomnia,0
HORIZANT,nephritis,Insomnia,0
HORIZANT,nephritis,,0
HORIZANT,nephritis,,0
HORIZANT,hematological abnormalities,  7                         Metabolism and nutritional,1
HORIZANT,myocarditis," 
  Metabol ism and nutritional disorders",1
HORIZANT,myocarditis," 
  Metabol ism",1
HORIZANT,myocarditis,,0
HORIZANT,myocarditis," 
  Metabol",1
HORIZANT,myocarditis,,0
HORIZANT,myocarditis," 
  Metabol ism and nutritional disorders",1
HORIZANT,myocarditis,,0
HORIZANT,myocarditis," 
  Metabol ism",1
HORIZANT,myocarditis,,0
HORIZANT,myositis,Metabolism nd nutri tional,1
HORIZANT,myositis,,0
HORIZANT,myositis,Metabolism nd,1
HORIZANT,myositis,,0
HORIZANT,myositis,nd nutri tional,1
HORIZANT,myositis,Metabolism nd nutri tional,1
HORIZANT,myositis,nd nutri tional,1
HORIZANT,myositis,,0
HORIZANT,myositis,a,0
HORIZANT,myositis,disorders,0
HORIZANT,Eosinophilia,nutritional              Weight,1
HORIZANT,Eosinophilia,nutritional disorders,0
HORIZANT,Eosinophilia,             Weight,1
HORIZANT,Eosinophilia,,0
HORIZANT,Eosinophilia,             Weight,1
HORIZANT,Eosinophilia,             Weight,1
HORIZANT,Eosinophilia,Weight,0
HORIZANT,Eosinophilia,Weight,0
HORIZANT,Eosinophilia,,0
HORIZANT,hypersensitivity,,0
HORIZANT,hypersensitivity,increased,0
HORIZANT,hypersensitivity,,0
HORIZANT,hypersensitivity,increased                  Eye,1
HORIZANT,hypersensitivity,increased,0
HORIZANT,hypersensitivity,,0
HORIZANT,hypersensitivity,                ,1
HORIZANT,hypersensitivity,                 Eye disorders,1
HORIZANT,hypersensitivity,increased,0
HORIZANT,hypersensitivity,,0
HORIZANT,fever,,0
HORIZANT,fever, Eye  disorders,1
HORIZANT,fever, Eye  disorders,1
HORIZANT,fever, Eye  disorders,1
HORIZANT,fever, Eye  disorders,1
HORIZANT,lymphadenopathy,rders          ,1
HORIZANT,lymphadenopathy,rders          ,1
HORIZANT,lymphadenopathy,rders          ,1
HORIZANT,lymphadenopathy,rders          ,1
HORIZANT,rash,Blurred,0
HORIZANT,rash,,0
HORIZANT,rash,    ,1
HORIZANT,rash,    ,1
HORIZANT,rash,,0
HORIZANT,rash,,0
HORIZANT,rash,    ,1
HORIZANT,rash,,0
HORIZANT,pancreatic acinar cell adenoma,,0
HORIZANT,pancreatic acinar cell adenoma,ted creatine ,1
HORIZANT,pancreatic acinar cell adenoma,,1
HORIZANT,pancreatic acinar cell adenoma,,0
HORIZANT,pancreatic acinar cell adenoma,,1
HORIZANT,pancreatic acinar cell adenoma,kinase,0
HORIZANT,pancreatic acinar cell adenoma,,1
HORIZANT,pancreatic acinar cell adenoma,creatine,0
HORIZANT,tumors,,1
HORIZANT,tumors,,1
HORIZANT,tumors,,1
HORIZANT,tumors,,1
HORIZANT,tumors,,1
HORIZANT,tumors,,1
HORIZANT,non-Hodgkin's lymphoma,,1
HORIZANT,non-Hodgkin's lymphoma,,0
HORIZANT,non-Hodgkin's lymphoma,,1
HORIZANT,non-Hodgkin's lymphoma,,1
HORIZANT,non-Hodgkin's lymphoma,,0
HORIZANT,non-Hodgkin's lymphoma,,1
HORIZANT,non-Hodgkin's lymphoma,,0
HORIZANT,endometrial carcinoma in situ,,0
STENDRA,headache,headache,1
STENDRA,headache,nasopharyngitis and back pain To report,0
STENDRA,headache,nasal congestion nasopharyngitis and back pain To report SUSPECTED,0
STENDRA,headache,to headache,1
STENDRA,flushing,to include flushing,1
STENDRA,nasal congestion,congestion,1
STENDRA,nasal congestion,pain To report SUSPECTED ADVERSE,0
STENDRA,nasal congestion,include headache nasal congestion,1
STENDRA,nasopharyngitis,nasopharyngitis,1
STENDRA,nasopharyngitis,headache flushing nasal nasopharyngitis,1
STENDRA,nasopharyngitis,flushing nasal congestion,0
STENDRA,nasopharyngitis,nasopharyngitis,1
STENDRA,nasopharyngitis,nasopharyngitis,1
STENDRA,nasopharyngitis,nasopharyngitis,1
STENDRA,nasopharyngitis,SUSPECTED ADVERSE REACTIONS contact or FDA at,0
STENDRA,back pain,report SUSPECTED ADVERSE REACTIONS,0
STENDRA,back pain,flushing nasal congestion nasopharyngitis back,1
STENDRA,back pain,pain,1
STENDRA,Headache,mgN STENDRA,0
STENDRA,Headache,mgN STENDRA mgN STENDRA Headache,1
STENDRA,Headache,Headache,1
STENDRA,Headache,,0
STENDRA,Headache,STENDRA mgN STENDRA Headache,1
STENDRA,Flushing,,0
STENDRA,Flushing,,0
STENDRA,Flushing,Flushing,1
STENDRA,Flushing,Flushing,1
STENDRA,Flushing,Flushing,1
STENDRA,Flushing,Flushing,1
STENDRA,Flushing,Flushing,1
STENDRA,Flushing,,0
STENDRA,Flushing,Flushing,1
STENDRA,Nasal congestion,Nasal congestion Nas,1
STENDRA,Nasal congestion,Nasal,1
STENDRA,Nasal congestion,,0
STENDRA,Nasal congestion,congestion Nas,1
STENDRA,Nasal congestion,,0
STENDRA,Nasopharyngitis,ion,0
STENDRA,Nasopharyngitis,Nasopharyngitis Ba,1
STENDRA,Nasopharyngitis,Nasopharyngitis Ba,1
STENDRA,Nasopharyngitis,Nasopharyngitis Ba,1
STENDRA,Nasopharyngitis,ion,0
STENDRA,Nasopharyngitis,Nasopharyngitis Ba,1
STENDRA,Nasopharyngitis,ion,0
STENDRA,Nasopharyngitis,ion,0
STENDRA,Back pain,,0
STENDRA,Back pain,is Back pain,1
STENDRA,Back pain,is Back pain,1
STENDRA,Back pain,is Back pain,1
STENDRA,Back pain,is Back,1
STENDRA,Back pain,is Back pain,1
STENDRA,URI,placebo included upper respiratory URI,1
STENDRA,URI,URI,1
STENDRA,URI,STENDRA dose group,0
STENDRA,URI,STENDRA dose group and greater than placebo included,0
STENDRA,URI,,0
STENDRA,URI,included upper respiratory URI,1
STENDRA,URI,respiratory URI,1
STENDRA,URI,,0
STENDRA,URI,URI,1
STENDRA,bronchitis,bronchitis,1
STENDRA,bronchitis,constipation and rash,0
STENDRA,bronchitis,,0
STENDRA,bronchitis,,0
STENDRA,bronchitis,,0
STENDRA,bronchitis,,0
STENDRA,influenza,greater than,0
STENDRA,influenza,influenza,1
STENDRA,sinusitis,constipation and,0
STENDRA,sinusitis,,0
STENDRA,sinusitis,sinusitis,1
STENDRA,sinusitis,,0
STENDRA,sinusitis,sinusitis,1
STENDRA,sinusitis,respiratory infection URI bronchitis sinusitis,1
STENDRA,sinusitis,sinusitis,1
STENDRA,sinusitis,hypertension dyspepsia nausea constipation and rash In an openlabel l,0
STENDRA,sinus congestion,than placebo included,0
STENDRA,sinus congestion,rash In an openlabel longterm,0
STENDRA,sinus congestion,congestion,1
STENDRA,sinus congestion,and rash In an openlabel longterm extension,0
STENDRA,hypertension,and rash In an openlabel longterm extension study of,0
STENDRA,hypertension,hypertension,1
STENDRA,hypertension,URI,0
STENDRA,hypertension,upper respiratory infection URI bronchitis influenza,0
STENDRA,dyspepsia,sinusitis sinus congestion dyspepsia,1
STENDRA,nausea,sinusitis sinus congestion hypertension nausea,1
STENDRA,nausea,,0
STENDRA,nausea,URI bronchitis influenza sinusitis,0
STENDRA,nausea,congestion hypertension nausea,1
STENDRA,nausea,URI bronchitis influenza,0
STENDRA,nausea,study of two of,0
STENDRA,nausea,sinus congestion hypertension nausea,1
STENDRA,nausea,nausea,1
STENDRA,nausea,two of,0
STENDRA,nausea,nausea,1
STENDRA,constipation,rash In an openlabel longterm extension study of two of these randomized doubleblind,0
STENDRA,constipation,constipation,1
STENDRA,constipation,doubleblind,0
STENDRA,constipation,,0
STENDRA,constipation,constipation,1
STENDRA,Headache,,0
STENDRA,Headache,,0
STENDRA,Headache,,0
STENDRA,Headache,Headache F,1
STENDRA,Flushing,Flushing N,1
STENDRA,Nasopharyngitis,g Nasopharyngitis,1
STENDRA,Nasopharyngitis,g,0
STENDRA,Nasopharyngitis,Nasopharyngitis Nasal,1
STENDRA,Nasopharyngitis,Nasopharyngitis Nasal,1
STENDRA,Nasopharyngitis,,0
STENDRA,Nasopharyngitis,g Nasopharyngitis Nasal,1
STENDRA,Nasopharyngitis,g Nasopharyngitis Nasal co,1
STENDRA,Nasopharyngitis,Nasal,0
STENDRA,Nasopharyngitis,g Nasopharyngitis Nasal co,1
STENDRA,Nasal congestion,congestion Ad,1
STENDRA,Nasal congestion,ryngitis,0
STENDRA,Nasal congestion,ryngitis,0
STENDRA,Nasal congestion,Ad,0
STENDRA,Nasal congestion,ryngitis,0
STENDRA,upper respiratory infection,openlabel extension study upper respiratory,1
STENDRA,upper respiratory infection,of patients in,0
STENDRA,upper respiratory infection,upper,1
STENDRA,upper respiratory infection,upper respiratory,1
STENDRA,upper respiratory infection,to,0
STENDRA,upper respiratory infection,but less than of patients in the openlabel extension,0
STENDRA,upper respiratory infection,,0
STENDRA,upper respiratory infection,,0
STENDRA,URI,URI influenza,1
STENDRA,sinusitis,sinusitis bronchitis,1
STENDRA,sinusitis,sinusitis bronchitis,1
STENDRA,bronchitis,back pain arthralgia hypertension and diarrhea The following,0
STENDRA,bronchitis,events occurred,0
STENDRA,back pain,sinusitis bronchitis back,1
STENDRA,back pain,study included upper,0
STENDRA,arthralgia,arthralgia hypertension,1
STENDRA,arthralgia,events occurred in,0
STENDRA,arthralgia,sinusitis bronchitis dizziness back arthralgia hypertension,1
STENDRA,arthralgia,arthralgia hypertension,1
STENDRA,arthralgia,arthralgia hypertension,1
STENDRA,arthralgia,bronchitis dizziness back arthralgia hypertension,1
STENDRA,arthralgia,in less than,0
STENDRA,arthralgia,back arthralgia hypertension,1
STENDRA,hypertension,URI influenza sinusitis bronchitis dizziness back pain arthralgia,0
STENDRA,hypertension,,0
STENDRA,hypertension,back pain,0
STENDRA,hypertension,diarrhea The following events occurred in less than of,0
STENDRA,hypertension,hypertension and,1
STENDRA,diarrhea,back pain arthralgia hypertension diarrhea The,1
STENDRA,diarrhea,diarrhea The,1
STENDRA,diarrhea,hypertension,0
STENDRA,diarrhea,in less than of patients,0
STENDRA,diarrhea,diarrhea The,1
STENDRA,edema peripheral,Body as a edema,1
STENDRA,edema peripheral,edema,1
STENDRA,edema peripheral,Cardiovascular,0
STENDRA,edema peripheral,Cardiovascular angina unstable angina deep vein thrombosis palpitations,0
STENDRA,edema peripheral,,0
STENDRA,edema peripheral,vein thrombosis palpitations,0
STENDRA,edema peripheral,meaningful Body as a edema peripheral fatigue,1
STENDRA,angina,Cardiovascular,0
STENDRA,angina,edema peripheral fatigue angina unstable,1
STENDRA,angina,angina unstable,1
STENDRA,angina,peripheral fatigue angina unstable,1
STENDRA,angina,a whole edema peripheral,0
STENDRA,angina,angina unstable,1
STENDRA,angina,,0
STENDRA,angina,,0
STENDRA,deep vein thrombosis,Cardiovascular angina unstable deep vein thrombosis palpitations,1
STENDRA,deep vein thrombosis,angina unstable,0
STENDRA,deep vein thrombosis,Cardiovascular angina unstable deep,1
STENDRA,deep vein thrombosis,unstable deep vein thrombosis palpitations,1
STENDRA,deep vein thrombosis,whole edema peripheral fatigue,0
STENDRA,deep vein thrombosis,fatigue Cardiovascular angina unstable angina,0
STENDRA,deep vein thrombosis,,0
STENDRA,deep vein thrombosis,Digestive gastritis gastroesophageal,0
STENDRA,palpitations,palpitations Digestive,1
STENDRA,palpitations,palpitations Digestive,1
STENDRA,palpitations,disease,0
STENDRA,palpitations,Digestive gastritis,0
STENDRA,gastritis,gastritis gastroesophageal,1
STENDRA,gastritis,angina unstable angina deep,0
STENDRA,gastritis,disease hypoglycemia blood glucose,0
STENDRA,gastritis,gastritis gastroesophageal,1
STENDRA,gastritis,gastritis gastroesophageal,1
STENDRA,gastritis,gastritis gastroesophageal,1
STENDRA,gastroesophageal reflux disease,pain sto,0
STENDRA,hypoglycemia,vein thrombosis palpitations Digestive gastritis gastroesophageal reflux,0
STENDRA,hypoglycemia,,0
STENDRA,hypoglycemia,glucose increased alanine aminotransferase increased oropharyngeal pain,0
STENDRA,blood glucose increased,glucose increased alanine,1
STENDRA,blood glucose increased,blood glucose increased alanine,1
STENDRA,blood glucose increased,glucose increased alanine,1
STENDRA,blood glucose increased,,0
STENDRA,blood glucose increased,reflux,0
STENDRA,blood glucose increased,,0
STENDRA,blood glucose increased,gastritis gastroesophageal reflux disease blood,1
STENDRA,blood glucose increased,discomfort vomiting,0
STENDRA,blood glucose increased,,0
STENDRA,alanine aminotransferase increased,hypoglycemia blood glucose,0
STENDRA,alanine aminotransferase increased,,0
STENDRA,oropharyngeal pain,oropharyngeal pain stomach,1
STENDRA,oropharyngeal pain,aminotransferase,0
STENDRA,oropharyngeal pain,reflux disease hypoglycemia blood glucose increased alanine,0
STENDRA,oropharyngeal pain,blood glucose,0
STENDRA,oropharyngeal pain,discomfort vomiting Musculoskeletal muscle,0
STENDRA,stomach discomfort,stomach,1
STENDRA,stomach discomfort,,0
STENDRA,stomach discomfort,stomach discomfort vomiting,1
STENDRA,stomach discomfort,oropharyngeal stomach,1
STENDRA,stomach discomfort,muscle spasms musculoskeletal pain myalgia pain in extremity,0
STENDRA,stomach discomfort,,0
STENDRA,vomiting,glucose increased,0
STENDRA,vomiting,vomiting Musculoskeletal,1
STENDRA,vomiting,oropharyngeal,0
STENDRA,vomiting,vomiting Musculoskeletal,1
STENDRA,vomiting,vomiting Musculoskeletal,1
STENDRA,vomiting,vomiting Musculoskeletal,1
STENDRA,vomiting,discomfort,0
STENDRA,muscle spasms,vomiting muscle,1
STENDRA,muscle spasms,oropharyngeal pain stomach discomfort vomiting,0
STENDRA,muscle spasms,spasms musculoskeletal,1
STENDRA,myalgia,,0
STENDRA,myalgia,myalgia pain,1
STENDRA,myalgia,spasms musculoskeletal pain,0
STENDRA,pain in extremity,muscle spasms musculoskeletal pain pain,1
STENDRA,pain in extremity,vertigo Respiratory cough dyspnea,0
STENDRA,pain in extremity,somnolence vertigo Respiratory,0
STENDRA,pain in extremity,Nervous depression insomnia somnolence,0
STENDRA,pain in extremity,musculoskeletal pain pain in,1
STENDRA,pain in extremity,extremity Nervous,1
STENDRA,depression,epistaxis wheezing,0
STENDRA,depression,spasms musculoskeletal pain myalgia pain in,0
STENDRA,depression,myalgia pain in extremity depression insomnia,1
STENDRA,depression,depression insomnia,1
STENDRA,depression,,0
STENDRA,depression,depression insomnia,1
STENDRA,depression,Respiratory cough,0
STENDRA,depression,Nervous,0
STENDRA,insomnia,somnolence vertigo,0
STENDRA,insomnia,exertional,0
STENDRA,insomnia,,0
STENDRA,somnolence,somnolence vertigo,1
STENDRA,somnolence,somnolence vertigo,1
STENDRA,somnolence,extremity Nervous depression somnolence vertigo,1
STENDRA,somnolence,somnolence vertigo,1
STENDRA,somnolence,,0
STENDRA,somnolence,,0
STENDRA,somnolence,myalgia pain,0
STENDRA,somnolence,myalgia,0
STENDRA,somnolence,pain in,0
STENDRA,somnolence,somnolence vertigo,1
STENDRA,vertigo,vertigo Respiratory,1
STENDRA,vertigo,vertigo Respiratory,1
STENDRA,vertigo,vertigo Respiratory,1
STENDRA,vertigo,vertigo Respiratory,1
STENDRA,vertigo,vertigo Respiratory,1
STENDRA,vertigo,,0
STENDRA,dyspnea exertional,balanitis erection,0
STENDRA,dyspnea exertional,insomnia somnolence,0
STENDRA,wheezing,,0
STENDRA,wheezing,wheezing Skin,1
STENDRA,wheezing,,0
STENDRA,wheezing,somnolence vertigo Respiratory,0
STENDRA,wheezing,wheezing Skin,1
STENDRA,wheezing,wheezing Skin,1
STENDRA,wheezing,Respiratory cough dyspnea exertional wheezing Skin,1
STENDRA,wheezing,wheezing Skin,1
STENDRA,pruritus,pruritus Urogenital,1
STENDRA,pruritus,balanitis erection increased hematuria,0
STENDRA,pruritus,pruritus Urogenital,1
STENDRA,pruritus,pruritus Urogenital,1
STENDRA,pruritus,wheezing Skin and pruritus Urogenital,1
STENDRA,pruritus,pruritus Urogenital,1
STENDRA,pruritus,Skin and,0
STENDRA,pruritus,epistaxis wheezing Skin and pruritus Urogenital,1
STENDRA,balanitis,balanitis erection,1
STENDRA,erection increased,,0
STENDRA,erection increased,pruritus Urogenital erection increased hematuria,1
STENDRA,hematuria,hematuria nephrolithiasis,1
STENDRA,nephrolithiasis,an additional randomized doubleblind placebocontro,0
STENDRA,nephrolithiasis,Urogenital balanitis erection increased nephrolithiasis pollakiuria,1
STENDRA,pollakiuria,tract infection In an additional,0
STENDRA,pollakiuria,increased hematuria pollakiuria urinary,1
STENDRA,pollakiuria,pollakiuria urinary,1
STENDRA,urinary tract infection,tract infection In,1
STENDRA,urinary tract infection,,0
STENDRA,urinary tract infection,tract infection In,1
STENDRA,urinary tract infection,nephrolithiasis urinary tract infection In,1
STENDRA,urinary tract infection,placebocontrolled study lasting up to,0
STENDRA,urinary tract infection,infection In,1
STENDRA,urinary tract infection,randomized doubleblind placebocontrolled study lasting up to,0
STENDRA,urinary tract infection,,0
STENDRA,urinary tract infection,tract infection In,1
STENDRA,urinary tract infection,infection In,1
STENDRA,Headache,Headache,1
STENDRA,Headache,,0
STENDRA,Headache,,0
STENDRA,Headache,Headache,1
STENDRA,Headache,STENDRA mgN,0
STENDRA,Headache,STENDRA mgN,0
STENDRA,Headache,Headache,1
STENDRA,Flushing,Flushing,1
STENDRA,Flushing,,0
STENDRA,Flushing,,0
STENDRA,Flushing,Flushing,1
STENDRA,Flushing,Flushing,1
STENDRA,Flushing,,0
STENDRA,Nasopharyngitis,Nasopharyngitis Uppe,1
STENDRA,Nasopharyngitis,Nasopharyngitis Uppe,1
STENDRA,Upper respiratory infection,Nasal,0
STENDRA,Upper respiratory infection,itis,0
STENDRA,Upper respiratory infection,itis,0
STENDRA,Upper respiratory infection,Nasal,0
STENDRA,Nasal congestion,,0
STENDRA,Nasal congestion,,0
STENDRA,Nasal congestion,congestion Back,1
STENDRA,Nasal congestion,,0
STENDRA,Nasal congestion,Nasal congestion Back,1
STENDRA,Nasal congestion,Nasal congestion Back,1
STENDRA,Nasal congestion,Nasal congestion Back,1
STENDRA,Nasal congestion,Nasal congestion Back,1
STENDRA,Nasal congestion,infection,0
STENDRA,Nasal congestion,,0
STENDRA,Back pain,Back pain,1
STENDRA,Back pain,stion Back,1
STENDRA,Back pain,stion,0
STENDRA,Back pain,,0
STENDRA,Back pain,,0
STENDRA,Electrocardiogram abnormal,,0
STENDRA,Electrocardiogram abnormal,,0
STENDRA,Electrocardiogram abnormal,abnormal Dizziness,1
STENDRA,Electrocardiogram abnormal,,0
STENDRA,Electrocardiogram abnormal,,0
STENDRA,Electrocardiogram abnormal,Electrocardiogram abnormal Dizziness,1
STENDRA,Electrocardiogram abnormal,,0
STENDRA,Electrocardiogram abnormal,Electrocardiogram abnormal Dizziness,1
STENDRA,Dizziness,Dizziness,1
STENDRA,Dizziness,,0
STENDRA,Dizziness,,0
STENDRA,Dizziness,Dizziness,1
STENDRA,Dizziness,,0
STENDRA,Dizziness,Dizziness,1
STENDRA,Dizziness,abnormal,0
STENDRA,Dizziness,Dizziness,1
STENDRA,Dizziness,Dizziness,1
STENDRA,Headache,Headache,1
STENDRA,Headache,Headache,1
STENDRA,Headache,Headache,1
STENDRA,Headache,Headache,1
STENDRA,Headache,Headache,1
STENDRA,Gastroenteritis viral,stion Gastroenteritis,1
STENDRA,Gastroenteritis viral,stion,0
STENDRA,Gastroenteritis viral,stion Gastroenteritis viral A,1
STENDRA,Gastroenteritis viral,stion,0
STENDRA,Gastroenteritis viral,stion Gastroenteritis viral A,1
STENDRA,Gastroenteritis viral,Gastroenteritis viral A,1
STENDRA,change in color vision,,0
STENDRA,change in color vision,change in,1
STENDRA,change in color vision,in color vision,1
STENDRA,change in color vision,vision,1
STENDRA,Non-arteritic anterior ischemic optic neuropathy,Experience Non-arteritic anterior ischemic optic,1
STENDRA,Non-arteritic anterior ischemic optic neuropathy,vision Postmarketing Experience Non-arteritic anterior ischemic optic,1
STENDRA,Non-arteritic anterior ischemic optic neuropathy,of vision has been reported,0
STENDRA,Non-arteritic anterior ischemic optic neuropathy,vision Postmarketing Experience Non-arteritic anterior ischemic optic neuropathy,1
STENDRA,Non-arteritic anterior ischemic optic neuropathy,vision Postmarketing Experience Non-arteritic anterior ischemic optic neuropathy,1
STENDRA,Non-arteritic anterior ischemic optic neuropathy,color vision Postmarketing Experience Non-arteritic anterior ischemic optic neuropathy,1
STENDRA,Non-arteritic anterior ischemic optic neuropathy,Experience Non-arteritic anterior ischemic optic neuropathy,1
STENDRA,Non-arteritic anterior ischemic optic neuropathy,decreased vision including permanent,0
STENDRA,Non-arteritic anterior ischemic optic neuropathy,color vision Postmarketing Experience Non-arteritic anterior ischemic optic neuropathy,1
STENDRA,NAION,,0
STENDRA,decreased vision,NAION a cause of,0
STENDRA,decreased vision,vision,1
STENDRA,decreased vision,vision,1
STENDRA,decreased vision,a cause,0
STENDRA,decreased vision,been,0
STENDRA,decreased vision,decreased vision,1
STENDRA,decreased vision,cause decreased,1
STENDRA,decreased vision,decreased vision,1
STENDRA,decreased vision,rarely postmarketing in,0
STENDRA,decreased vision,vision,1
STENDRA,permanent loss of vision,permanent,1
STENDRA,permanent loss of vision,vision,1
STENDRA,hypotension,be,0
STENDRA,hypotension,clinical trials f another d,1
STENDRA,hypotension,in the clinical trials f another d,1
STENDRA,hypotension,f another,1
STENDRA,hypotension,trials f another d,1
STENDRA,hypotension,not reflect the rates observed in practice STENDRA was administered to men dur,0
STENDRA,hypotension,STENDRA was administered,0
STENDRA,hypotension,in practice,0
STENDRA,hypotension,d,1
STENDRA,hypotension,to rates in,0
STENDRA,cardiac risk,The discontinuation rate due to adverse reactions,0
STENDRA,cardiac risk,"50 mg, 10",1
STENDRA,cardiac risk,to for placebotreated,0
STENDRA,cardiac risk,and respectively compared,0
STENDRA,cardiac risk,and,0
STENDRA,cardiac risk,was and respectively compared to,0
STENDRA,cardiac risk,reactions for patients treated with,0
STENDRA,cardiac risk,10,1
STENDRA,cardiac risk,"treated with RA 50 mg, 10",1
STENDRA,transient decreases in sitting blood pressure,"URI bronchitis influenza sinusitis s congestion,",1
STENDRA,transient decreases in sitting blood pressure,"sinusitis s congestion, hypertension, dyspepsia, nausea",1
STENDRA,transient decreases in sitting blood pressure,included upper respiratory infection URI bronchitis influenza sinusitis,0
STENDRA,transient decreases in sitting blood pressure,than placebo included upper respiratory infection URI bronchitis influenza sinusitis sinu,0
STENDRA,transient decreases in sitting blood pressure,URI,0
STENDRA,transient decreases in sitting blood pressure,and rash In an openlabel longterm extension study of,0
STENDRA,transient decreases in sitting blood pressure,"hypertension, dyspepsia, nausea",1
STENDRA,transient decreases in sitting blood pressure,"URI bronchitis influenza sinusitis s congestion, hypertension, dyspepsia, nausea",1
STENDRA,transient decreases in sitting blood pressure,,0
STENDRA,Prolonged erection,STENDRAN                    Flushing,1
STENDRA,Prolonged erection,,0
STENDRA,Prolonged erection,                   Flushing,1
STENDRA,Prolonged erection,,0
STENDRA,Prolonged erection,,0
STENDRA,Prolonged erection,Headache,0
STENDRA,Prolonged erection,Flushing,0
STENDRA,Prolonged erection,,0
STENDRA,Prolonged erection,,0
STENDRA,priapism,Headache,0
STENDRA,priapism,,0
STENDRA,painful erections,Headache,0
STENDRA,painful erections,           5.6%   Flushing,1
STENDRA,painful erections,,0
STENDRA,painful erections,Flushing,0
STENDRA,painful erections,Flushing,0
STENDRA,painful erections,           5.6%   Flushing,1
STENDRA,painful erections,           5.6%   Flushing,1
STENDRA,painful erections,           5.6%   Flushing,1
STENDRA,non-arteritic anterior ischemic optic neuropathy,,0
STENDRA,non-arteritic anterior ischemic optic neuropathy,lasting months A causal p to STENDRA is,1
STENDRA,non-arteritic anterior ischemic optic neuropathy,relation to,0
STENDRA,non-arteritic anterior ischemic optic neuropathy,A causal,0
STENDRA,non-arteritic anterior ischemic optic neuropathy,,0
STENDRA,non-arteritic anterior ischemic optic neuropathy,longterm extension study lasting months,0
STENDRA,non-arteritic anterior ischemic optic neuropathy,STENDRA is uncertain. Excluded from this li,1
STENDRA,non-arteritic anterior ischemic optic neuropathy,p to STENDRA,1
STENDRA,non-arteritic anterior ischemic optic neuropathy,is uncertain. Excluded from this li,1
STENDRA,NAION,this  are ,1
STENDRA,decreased vision,no plausib,1
STENDRA,decreased vision,events that were minor with,1
STENDRA,permanent loss of vision,edema peripheral,0
STENDRA,permanent loss of vision,fatigue,0
STENDRA,NAION,muscle,0
STENDRA,NAION,stomach,0
STENDRA,NAION,muscle spasms musculoskeletal pain myalgia pain in,0
STENDRA,NAION,,0
STENDRA,NAION,oropharyngeal pain,0
STENDRA,NAION,"rt,",1
STENDRA,NAION,"musculoskeletal , mya",1
STENDRA,NAION,"spasms musculoskeletal , mya",1
STENDRA,NAION,", mya",1
STENDRA,NAION,"musculoskeletal , mya",1
STENDRA,NAION,Respiratory,0
STENDRA,NAION,muscle spasms musculoskeletal pain,0
STENDRA,NAION,"musculoskeletal ,",1
STENDRA,NAION,Musculoskeletal muscle spasms musculoskeletal pain,0
STENDRA,NAION,"Musculoskeletal muscle spasms musculoskeletal ,",1
STENDRA,NAION,"spasms musculoskeletal , mya",1
STENDRA,tinnitus,STENDRA mgN,0
STENDRA,tinnitus,,0
STENDRA,dizziness,   8.1%   Flushing,1
STENDRA,dizziness,mgN,0
STENDRA,dizziness,,0
STENDRA,dizziness,STENDRA mgN    8.1%   Flushing,1
STENDRA,dizziness,   8.1%   Flushing,1
STENDRA,symptomatic hypotension,"to onset of of STENDRA,",1
STENDRA,symptomatic hypotension,"to onset of of STENDRA,",1
STENDRA,symptomatic hypotension,time,0
STENDRA,dizziness,to,0
STENDRA,dizziness,Table presents the adverse,0
STENDRA,lightheadedness,STENDRA defined,0
STENDRA,lightheadedness,time to the rst,1
STENDRA,lightheadedness,i,0
STENDRA,lightheadedness,to the rst,1
STENDRA,symptomatic hypotension,o Determine,1
STENDRA,symptomatic hypotension,,0
STENDRA,potentiates the anti-aggregatory effect of sodium nitroprusside,,0
STENDRA,potentiates the anti-aggregatory effect of sodium nitroprusside,,1
ADCETRIS,Peripheral Neuropathy,sections of the prescribing Peripheral,1
ADCETRIS,Peripheral Neuropathy,sections of the prescribing Peripheral Neuropathy,1
ADCETRIS,Peripheral Neuropathy,,0
ADCETRIS,Peripheral Neuropathy,Peripheral Neuropathy,1
ADCETRIS,Peripheral Neuropathy,Neuropathy,1
ADCETRIS,Peripheral Neuropathy,of the prescribing Peripheral Neuropathy,1
ADCETRIS,Peripheral Neuropathy,Peripheral Neuropathy,1
ADCETRIS,Peripheral Neuropathy,,0
ADCETRIS,Anaphylaxis,Reactions see Warnings and Precautions Hematologic,0
ADCETRIS,Infusion Reactions,Anaphylaxis Infusion Reactions,1
ADCETRIS,Infusion Reactions,Anaphylaxis,0
ADCETRIS,Infusion Reactions,Infusion Reactions,1
ADCETRIS,Infusion Reactions,Warnings,0
ADCETRIS,Infusion Reactions,Infusion Reactions,1
ADCETRIS,Infusion Reactions,Precautions Anaphylaxis and,0
ADCETRIS,Infusion Reactions,Precautions Anaphylaxis and,0
ADCETRIS,Infusion Reactions,Infusion Reactions,1
ADCETRIS,Opportunistic Infections,Opportunistic,1
ADCETRIS,Opportunistic Infections,Infections Opportunistic Infections,1
ADCETRIS,Opportunistic Infections,,0
ADCETRIS,Opportunistic Infections,,0
ADCETRIS,Opportunistic Infections,,0
ADCETRIS,Opportunistic Infections,Opportunistic Infections,1
ADCETRIS,Opportunistic Infections,Toxicities see Warnings and Precautions Serious Infections and,0
ADCETRIS,Opportunistic Infections,Warnings,0
ADCETRIS,Tumor Lysis Syndrome,and Precautions,0
ADCETRIS,Tumor Lysis Syndrome,Tumor Lysis Syndrome,1
ADCETRIS,Tumor Lysis Syndrome,Infections,0
ADCETRIS,Tumor Lysis Syndrome,,0
ADCETRIS,Tumor Lysis Syndrome,Infections see Warnings and Tumor,1
ADCETRIS,Tumor Lysis Syndrome,,0
ADCETRIS,Increased Toxicity,Increased Toxicity,1
ADCETRIS,Increased Toxicity,and Increased,1
ADCETRIS,Increased Toxicity,Increased Toxicity,1
ADCETRIS,Increased Toxicity,Toxicity,1
ADCETRIS,Increased Toxicity,see Warnings and Precautions,0
ADCETRIS,Increased Toxicity,Syndrome see,0
ADCETRIS,Increased Toxicity,Increased Toxicity,1
ADCETRIS,Increased Toxicity,Warnings and,0
ADCETRIS,Increased Toxicity,Syndrome see Warnings and Increased Toxicity,1
ADCETRIS,Increased Toxicity,,0
ADCETRIS,Increased Toxicity,Warnings,0
ADCETRIS,Increased Toxicity,Increased,1
ADCETRIS,Increased Toxicity,Increased Toxicity,1
ADCETRIS,Increased Toxicity,and Precautions,0
ADCETRIS,Increased Toxicity,see Warnings and Increased,1
ADCETRIS,Increased Toxicity,in the Presence of Moderate or Severe Hepatic Impairment see Warnings,0
ADCETRIS,Increased Toxicity,Warnings and Increased Toxicity,1
ADCETRIS,Increased Toxicity,,0
ADCETRIS,Increased Toxicity,Presence of,0
ADCETRIS,Hepatotoxicity,Hepatotoxicity,1
ADCETRIS,Hepatotoxicity,Hepatotoxicity,1
ADCETRIS,Hepatotoxicity,Impairment see Warnings and Hepatotoxicity,1
ADCETRIS,Hepatotoxicity,see Warnings and Hepatotoxicity,1
ADCETRIS,Hepatotoxicity,and,0
ADCETRIS,Hepatotoxicity,see Warnings and Precautions,0
ADCETRIS,Hepatotoxicity,Moderate or Severe Hepatic,0
ADCETRIS,Hepatotoxicity,see Warnings,0
ADCETRIS,Hepatotoxicity,Hepatotoxicity,1
ADCETRIS,Hepatotoxicity,and Precautions Progressive Multifocal,0
ADCETRIS,Pulmonary Toxicity,see Warnings and Precautions,0
ADCETRIS,Pulmonary Toxicity,Toxicity,1
ADCETRIS,Pulmonary Toxicity,Leukoencephalopathy see Warnings and Pulmonary Toxicity,1
ADCETRIS,Pulmonary Toxicity,Multifocal Leukoencephalopathy see Warnings and,0
ADCETRIS,Pulmonary Toxicity,Pulmonary Toxicity,1
ADCETRIS,neutropenia,HL and relapsed,0
ADCETRIS,neutropenia,upper respiratory tract,0
ADCETRIS,neutropenia,diarrhe,0
ADCETRIS,neutropenia,anemia upper respiratory tract,0
ADCETRIS,neutropenia,neutropenia,1
ADCETRIS,neutropenia,,0
ADCETRIS,neutropenia,,0
ADCETRIS,neutropenia,neutropenia,1
ADCETRIS,neutropenia,,0
ADCETRIS,peripheral sensory neuropathy,tract infection,0
ADCETRIS,peripheral sensory neuropathy,,0
ADCETRIS,peripheral sensory neuropathy,were Relapsed,0
ADCETRIS,peripheral sensory neuropathy,fatigue nausea anemia upper,0
ADCETRIS,fatigue,fatigue,1
ADCETRIS,fatigue,fatigue,1
ADCETRIS,fatigue,sensory neuropathy,0
ADCETRIS,fatigue,,0
ADCETRIS,fatigue,fatigue,1
ADCETRIS,fatigue,,0
ADCETRIS,anemia,anemia,1
ADCETRIS,anemia,anemia,1
ADCETRIS,anemia,sensory neuropathy,0
ADCETRIS,anemia,neutropenia peripheral,0
ADCETRIS,anemia,,0
ADCETRIS,anemia,,0
ADCETRIS,anemia,,0
ADCETRIS,anemia,anemia,1
ADCETRIS,anemia,cough and,0
ADCETRIS,upper respiratory tract infection,pyrexia rash thrombocytopenia cough and,0
ADCETRIS,upper respiratory tract infection,fatigue nausea upper respiratory tract,1
ADCETRIS,upper respiratory tract infection,,0
ADCETRIS,upper respiratory tract infection,sensory neuropathy fatigue nausea upper respiratory,1
ADCETRIS,upper respiratory tract infection,fatigue nausea upper respiratory tract infection,1
ADCETRIS,upper respiratory tract infection,respiratory tract infection,1
ADCETRIS,upper respiratory tract infection,rash thrombocytopenia cough and vomiting Classical HL postau,0
ADCETRIS,upper respiratory tract infection,sensory neuropathy fatigue nausea upper respiratory tract,1
ADCETRIS,upper respiratory tract infection,neuropathy fatigue nausea upper respiratory tract infection,1
ADCETRIS,diarrhea,diarrhea,1
ADCETRIS,diarrhea,tract,0
ADCETRIS,diarrhea,diarrhea,1
ADCETRIS,pyrexia,fatigue nausea,0
ADCETRIS,pyrexia,pyrexia,1
ADCETRIS,pyrexia,postautoHSCT,0
ADCETRIS,pyrexia,anemia upper respiratory tract infection,0
ADCETRIS,pyrexia,,0
ADCETRIS,pyrexia,,0
ADCETRIS,pyrexia,neuropathy fatigue nausea anemia upper respiratory tract infection diarrhea,0
ADCETRIS,pyrexia,pyrexia,1
ADCETRIS,rash,respiratory tract infection diarrhea rash,1
ADCETRIS,rash,,0
ADCETRIS,rash,tract infection diarrhea rash,1
ADCETRIS,rash,rash,1
ADCETRIS,rash,rash,1
ADCETRIS,rash,rash,1
ADCETRIS,rash,infection diarrhea rash,1
ADCETRIS,thrombocytopenia,vomiting Classical,0
ADCETRIS,thrombocytopenia,thrombocytopenia,1
ADCETRIS,thrombocytopenia,,0
ADCETRIS,thrombocytopenia,anemia upper respiratory tract,0
ADCETRIS,cough,sen,0
ADCETRIS,cough,cough,1
ADCETRIS,cough,,0
ADCETRIS,cough,diarrhea pyrexia rash thrombocytopenia,0
ADCETRIS,cough,upper respiratory tract infection diarrhea pyrexia rash,0
ADCETRIS,cough,cough,1
ADCETRIS,cough,diarrhea pyrexia rash cough,1
ADCETRIS,cough,,0
ADCETRIS,vomiting,pyrexia rash thrombocytopenia cough vomiting,1
ADCETRIS,vomiting,neutropenia,0
ADCETRIS,vomiting,thrombocytopenia cough vomiting,1
ADCETRIS,vomiting,vomiting,1
ADCETRIS,vomiting,tract infection,0
ADCETRIS,vomiting,,0
ADCETRIS,vomiting,neutropenia peripheral,0
ADCETRIS,vomiting,Classical HL postautoHSCT consolidation neutropenia,0
ADCETRIS,vomiting,tract infection diarrhea pyrexia rash thrombocytopenia cough,0
ADCETRIS,vomiting,anemia upper respiratory tract infection diarrhea pyrexia rash thrombocytopenia,0
ADCETRIS,neutropenia,neutropenia,1
ADCETRIS,neutropenia,Classical HL postautoHSCT neutropenia,1
ADCETRIS,neutropenia,postautoHSCT neutropenia,1
ADCETRIS,neutropenia,upper respiratory tract,0
ADCETRIS,neutropenia,neutropenia,1
ADCETRIS,neutropenia,neutropenia,1
ADCETRIS,neutropenia,postautoHSCT neutropenia,1
ADCETRIS,neutropenia,neutropenia,1
ADCETRIS,neutropenia,neutropenia,1
ADCETRIS,neutropenia,Classical HL postautoHSCT,0
ADCETRIS,peripheral sensory neuropathy,neuropathy,1
ADCETRIS,peripheral sensory neuropathy,peripheral,1
ADCETRIS,peripheral sensory neuropathy,consolidation peripheral sensory neuropathy,1
ADCETRIS,peripheral sensory neuropathy,sensory neuropathy,1
ADCETRIS,peripheral sensory neuropathy,upper respiratory tract infection fatigue peripheral motor neuropathy,0
ADCETRIS,thrombocytopenia,sensory,0
ADCETRIS,thrombocytopenia,thrombocytopenia,1
ADCETRIS,thrombocytopenia,,0
ADCETRIS,thrombocytopenia,neutropenia peripheral sensory thrombocytopenia,1
ADCETRIS,anemia,consolidation,0
ADCETRIS,anemia,neuropathy anemia,1
ADCETRIS,anemia,neuropathy thrombocytopenia,0
ADCETRIS,anemia,peripheral motor neuropathy nausea cough,0
ADCETRIS,anemia,anemia,1
ADCETRIS,anemia,peripheral sensory neuropathy anemia,1
ADCETRIS,anemia,peripheral sensory neuropathy thrombocytopenia,0
ADCETRIS,anemia,tract infection fatigue peripheral motor,0
ADCETRIS,anemia,anemia,1
ADCETRIS,upper respiratory tract infection,upper respiratory tract infection,1
ADCETRIS,upper respiratory tract infection,infection,1
ADCETRIS,fatigue,fatigue,1
ADCETRIS,fatigue,,0
ADCETRIS,peripheral motor neuropathy,Seattl,0
ADCETRIS,peripheral motor neuropathy,cough and diarrhea To report SUSPECTED ADVERSE REACTIONS,0
ADCETRIS,peripheral motor neuropathy,tract infection peripheral,1
ADCETRIS,peripheral motor neuropathy,,0
ADCETRIS,peripheral motor neuropathy,infection peripheral motor neuropathy,1
ADCETRIS,peripheral motor neuropathy,tract infection peripheral,1
ADCETRIS,peripheral motor neuropathy,upper respiratory tract infection peripheral motor,1
ADCETRIS,peripheral motor neuropathy,,0
ADCETRIS,peripheral motor neuropathy,tract,0
ADCETRIS,nausea,fatigue peripheral motor nausea,1
ADCETRIS,nausea,nausea,1
ADCETRIS,nausea,respiratory tract infection fatigue,0
ADCETRIS,nausea,fatigue peripheral motor nausea,1
ADCETRIS,cough,contact Seattle Genetics Inc,0
ADCETRIS,diarrhea,,0
ADCETRIS,diarrhea,peripheral motor neuropathy nausea cough,0
ADCETRIS,diarrhea,diarrhea,1
ADCETRIS,diarrhea,diarrhea,1
ADCETRIS,diarrhea,Inc,0
ADCETRIS,diarrhea,neuropathy nausea cough diarrhea,1
ADCETRIS,diarrhea,respiratory tract infection fatigue peripheral motor neuropathy nausea cough and,0
ADCETRIS,diarrhea,cough and,0
ADCETRIS,diarrhea,neuropathy nausea cough diarrhea,1
ADCETRIS,diarrhea,contact Seattle Genetics Inc,0
ADCETRIS,peripheral sensory neuropathy,,0
ADCETRIS,peripheral sensory neuropathy,neuropathy,1
ADCETRIS,peripheral sensory neuropathy,peripheral sensory neuropathy,1
ADCETRIS,peripheral sensory neuropathy,neuropathy,1
ADCETRIS,fatigue,pyrexia rash thrombocytopenia coug,0
ADCETRIS,fatigue,fatigue,1
ADCETRIS,fatigue,peripheral sensory neuropathy,0
ADCETRIS,fatigue,peripheral sensory fatigue,1
ADCETRIS,fatigue,fatigue,1
ADCETRIS,fatigue,thrombocytopenia coug,0
ADCETRIS,fatigue,fatigue,1
ADCETRIS,anemia,peripheral sensory neuropathy,0
ADCETRIS,anemia,neuropathy fatigue,0
ADCETRIS,anemia,anemia,1
ADCETRIS,anemia,infection,0
ADCETRIS,anemia,anemia,1
ADCETRIS,anemia,anemia,1
ADCETRIS,anemia,pyrexia rash thrombocytopenia,0
ADCETRIS,anemia,neuropathy,0
ADCETRIS,anemia,causality were,0
ADCETRIS,upper respiratory tract infection,diarrhea pyrexia rash thrombocytopenia,0
ADCETRIS,upper respiratory tract infection,sensory,0
ADCETRIS,upper respiratory tract infection,tract infection,1
ADCETRIS,pyrexia,infection,0
ADCETRIS,pyrexia,pyrexia,1
ADCETRIS,pyrexia,pyrexia,1
ADCETRIS,pyrexia,pyrexia,1
ADCETRIS,pyrexia,infection pyrexia,1
ADCETRIS,pyrexia,pyrexia,1
ADCETRIS,pyrexia,pyrexia,1
ADCETRIS,pyrexia,pyrexia,1
ADCETRIS,rash,The most common adverse reactions occurring in at least,0
ADCETRIS,rash,,0
ADCETRIS,rash,,0
ADCETRIS,rash,rash,1
ADCETRIS,rash,respiratory tract infection diarrhea pyrexia,0
ADCETRIS,rash,rash,1
ADCETRIS,rash,rash,1
ADCETRIS,thrombocytopenia,The most common adverse reactions occurring in at least of patients in ei,0
ADCETRIS,thrombocytopenia,diarrhea pyrexia thrombocytopenia,1
ADCETRIS,cough,in at least of patients in either St,0
ADCETRIS,cough,,0
ADCETRIS,cough,either St,0
ADCETRIS,cough,anemia upper respiratory tract,0
ADCETRIS,cough,diarrhea pyrexia,0
ADCETRIS,vomiting,adverse reactions occurring,0
ADCETRIS,vomiting,,0
ADCETRIS,vomiting,tract infection diarrhea pyrexia rash thrombocytopenia cough,0
ADCETRIS,neutropenia,causality were,0
ADCETRIS,neutropenia,causality,0
ADCETRIS,neutropenia,neutropenia,1
ADCETRIS,neutropenia,the ADCETRIStreatment arm regardless,0
ADCETRIS,neutropenia,thrombocytopenia anemia,0
ADCETRIS,neutropenia,,0
ADCETRIS,neutropenia,neuropathy,0
ADCETRIS,neutropenia,adverse reactions in the ADCETRIStreatment,0
ADCETRIS,thrombocytopenia,peripheral sensory neuropathy,0
ADCETRIS,thrombocytopenia,peripheral sensory thrombocytopenia,1
ADCETRIS,thrombocytopenia,upper respiratory tract,0
ADCETRIS,thrombocytopenia,respiratory tract infection,0
ADCETRIS,thrombocytopenia,tract infection fatigue peripheral motor neuropathy nausea cough,0
ADCETRIS,anemia,tract infection fatigue peripheral motor neuropathy nausea cough and diarrh,0
ADCETRIS,anemia,,0
ADCETRIS,anemia,diarrh,0
ADCETRIS,anemia,neuropathy anemia,1
ADCETRIS,anemia,anemia,1
ADCETRIS,anemia,and,0
ADCETRIS,anemia,were neutropenia peripheral sensory,0
ADCETRIS,anemia,neuropathy,0
ADCETRIS,anemia,peripheral sensory neuropathy anemia,1
ADCETRIS,upper respiratory tract infection,diarrhea,0
ADCETRIS,upper respiratory tract infection,,0
ADCETRIS,upper respiratory tract infection,tract infection,1
ADCETRIS,upper respiratory tract infection,diarrhea The most,0
ADCETRIS,upper respiratory tract infection,thrombocytopenia upper,1
ADCETRIS,upper respiratory tract infection,,0
ADCETRIS,fatigue,fatigue,1
ADCETRIS,peripheral motor neuropathy,upper respiratory tract infection peripheral motor neuropathy,1
ADCETRIS,peripheral motor neuropathy,upper respiratory tract infection peripheral motor,1
ADCETRIS,peripheral motor neuropathy,thrombocytopenia anemia upper,0
ADCETRIS,peripheral motor neuropathy,respiratory tract infection peripheral,1
ADCETRIS,peripheral motor neuropathy,respiratory tract infection peripheral,1
ADCETRIS,peripheral motor neuropathy,peripheral motor,1
ADCETRIS,peripheral motor neuropathy,infection peripheral,1
ADCETRIS,peripheral motor neuropathy,,0
ADCETRIS,nausea,nausea,1
ADCETRIS,nausea,infection fatigue peripheral,0
ADCETRIS,nausea,infection fatigue peripheral motor nausea,1
ADCETRIS,nausea,anemia upper respiratory tract,0
ADCETRIS,nausea,in at least of patients usin,0
ADCETRIS,nausea,,0
ADCETRIS,nausea,peripheral motor nausea,1
ADCETRIS,cough,cough,1
ADCETRIS,cough,respiratory tract infection fatigue peripheral,0
ADCETRIS,cough,The most common adverse reactions occurring in at least of patients,0
ADCETRIS,diarrhea,diarrhea,1
ADCETRIS,diarrhea,motor neuropathy nausea cough diarrhea,1
ADCETRIS,diarrhea,,0
ADCETRIS,diarrhea,NCI CTC Version,0
ADCETRIS,diarrhea,diarrhea,1
ADCETRIS,diarrhea,diarrhea,1
ADCETRIS,neutropenia,neutropenia,1
ADCETRIS,neutropenia,nausea diarrhea anemi,0
ADCETRIS,fatigue,were neutropenia peripheral,0
ADCETRIS,fatigue,of causality were neutropenia,0
ADCETRIS,nausea,respiratory,0
ADCETRIS,nausea,nausea,1
ADCETRIS,nausea,,0
ADCETRIS,nausea,neutropenia peripheral sensory neuropathy fatigue upper respiratory,0
ADCETRIS,nausea,respiratory tract nausea,1
ADCETRIS,nausea,fatigue upper respiratory tract nausea,1
ADCETRIS,diarrhea,diarrhea,1
ADCETRIS,diarrhea,respiratory,0
ADCETRIS,diarrhea,of,0
ADCETRIS,diarrhea,diarrhea,1
ADCETRIS,anemia,thrombocytopenia rash abdominal pain cough and vomiting Summary,0
ADCETRIS,anemia,anemia,1
ADCETRIS,anemia,respiratory tract infection nausea diarrhea,0
ADCETRIS,anemia,nausea diarrhea,0
ADCETRIS,anemia,tract,0
ADCETRIS,anemia,anemia,1
ADCETRIS,anemia,tract infection nausea anemia,1
ADCETRIS,pyrexia,pyrexia,1
ADCETRIS,pyrexia,Clinical,0
ADCETRIS,thrombocytopenia,and vomiting Summary of Clinical Trial Experience in,0
ADCETRIS,thrombocytopenia,thrombocytopenia,1
ADCETRIS,rash,anemia pyrexia rash,1
ADCETRIS,rash,tract infection nausea diarrhea anemia pyrexia thrombocytopenia,0
ADCETRIS,rash,infection nausea diarrhea anemia,0
ADCETRIS,rash,pyrexia rash,1
ADCETRIS,rash,rash,1
ADCETRIS,rash,pyrexia thrombocytopenia,0
ADCETRIS,rash,fatigue upper respiratory,0
ADCETRIS,rash,rash,1
ADCETRIS,abdominal pain,pain,1
ADCETRIS,abdominal pain,pain,1
ADCETRIS,abdominal pain,tract infection nausea diarrhea anemia,0
ADCETRIS,abdominal pain,in Classical HL PostautoHSCT,0
ADCETRIS,abdominal pain,upper respiratory tract infection nausea diarrhea anemia pyrexia,0
ADCETRIS,abdominal pain,abdominal pain,1
ADCETRIS,abdominal pain,,0
ADCETRIS,abdominal pain,,0
ADCETRIS,abdominal pain,upper respiratory tract infection,0
ADCETRIS,cough,cough,1
ADCETRIS,cough,Experience in Classical HL,0
ADCETRIS,cough,rash abdominal cough,1
ADCETRIS,cough,pyrexia thrombocytopenia rash,0
ADCETRIS,cough,and vomiting Summary of Clinical Trial Experience in Classical HL,0
ADCETRIS,cough,,0
ADCETRIS,cough,Consolid,0
ADCETRIS,cough,pyrexia thrombocytopenia rash abdominal cough,1
ADCETRIS,cough,cough,1
ADCETRIS,vomiting,,0
ADCETRIS,vomiting,thrombocytopenia rash abdominal pain,0
ADCETRIS,vomiting,,0
ADCETRIS,vomiting,vomiting,1
ADCETRIS,vomiting,cough,0
ADCETRIS,neutropenia,,0
ADCETRIS,neutropenia,neutropenia,1
ADCETRIS,neutropenia,neutropenia,1
ADCETRIS,neutropenia,neutropenia,1
ADCETRIS,anemia,of causality were,0
ADCETRIS,anemia,anemia,1
ADCETRIS,anemia,anemia,1
ADCETRIS,anemia,anemia,1
ADCETRIS,anemia,anemia,1
ADCETRIS,anemia,causality were anemia,1
ADCETRIS,anemia,of causality,0
ADCETRIS,anemia,anemia,1
ADCETRIS,peripheral sensory neuropathy,regardless of causality were,0
ADCETRIS,peripheral sensory neuropathy,causality were neutropenia peripheral sensory neuropathy,1
ADCETRIS,peripheral sensory neuropathy,causality were neutropenia peripheral sensory,1
ADCETRIS,peripheral sensory neuropathy,Reported,0
ADCETRIS,peripheral sensory neuropathy,,0
ADCETRIS,peripheral sensory neuropathy,common adverse reactions regardless,0
ADCETRIS,peripheral sensory neuropathy,peripheral sensory,1
ADCETRIS,peripheral sensory neuropathy,neutropenia peripheral sensory neuropathy,1
ADCETRIS,fatigue,peripheral sensory fatigue,1
ADCETRIS,fatigue,fatigue,1
ADCETRIS,fatigue,,0
ADCETRIS,fatigue,neutropenia anemia peripheral sensory fatigue,1
ADCETRIS,fatigue,were neutropenia anemia,0
ADCETRIS,fatigue,neutropenia anemia peripheral sensory fatigue,1
ADCETRIS,nausea,nausea,1
ADCETRIS,nausea,Table Most Commonly Reported Adverse Reactions i,0
ADCETRIS,nausea,anemia peripheral sensory neuropathy nausea,1
ADCETRIS,nausea,nausea,1
ADCETRIS,nausea,nausea,1
ADCETRIS,nausea,,0
ADCETRIS,nausea,nausea,1
ADCETRIS,nausea,nausea,1
ADCETRIS,nausea,nausea,1
ADCETRIS,nausea,neuropathy nausea,1
ADCETRIS,rash,sensory neuropathy fatigue nausea,0
ADCETRIS,rash,fatigue nausea rash,1
ADCETRIS,rash,rash,1
ADCETRIS,rash,neuropathy fatigue nausea rash,1
ADCETRIS,rash,pain Table Most Commonly Reported,0
ADCETRIS,rash,rash,1
ADCETRIS,rash,rash,1
ADCETRIS,rash,rash,1
ADCETRIS,diarrhea,diarrhea,1
ADCETRIS,pain,peripheral,0
ADCETRIS,pain,pain,1
ADCETRIS,pain,Reported Adverse,0
ADCETRIS,pain,fatigue nausea pyrexia,0
ADCETRIS,pain,and,0
ADCETRIS,pain,,0
ADCETRIS,pain,pain,1
ADCETRIS,Neutropenia,Neutropenia,1
ADCETRIS,Neutropenia,Neutropenia,1
ADCETRIS,Neutropenia,disorders,0
ADCETRIS,Neutropenia,,0
ADCETRIS,Neutropenia,,0
ADCETRIS,Neutropenia,disorders,0
ADCETRIS,Anemia,Anemia,1
ADCETRIS,Thrombocytopenia,Thrombocytopenia,1
ADCETRIS,Thrombocytopenia,,0
ADCETRIS,Thrombocytopenia,Thrombocytopenia,1
ADCETRIS,Thrombocytopenia,Thrombocytopenia,1
ADCETRIS,Thrombocytopenia,Thrombocytopenia,1
ADCETRIS,Thrombocytopenia,,0
ADCETRIS,Thrombocytopenia,Thrombocytopenia,1
ADCETRIS,Lymphadenopathy,Lymphadenopathy,1
ADCETRIS,Lymphadenopathy,Lymphadenopathy,1
ADCETRIS,Lymphadenopathy,,0
ADCETRIS,Lymphadenopathy,Lymphadenopathy,1
ADCETRIS,Lymphadenopathy,,0
ADCETRIS,Lymphadenopathy,,0
ADCETRIS,Peripheral sensory neuropathy,sensory neuropathy Peripheral m,1
ADCETRIS,Peripheral sensory neuropathy,rders,0
ADCETRIS,Peripheral sensory neuropathy,rders,0
ADCETRIS,Peripheral sensory neuropathy,neuropathy,1
ADCETRIS,Peripheral motor neuropathy,y Peripheral motor neuropathy Headache,1
ADCETRIS,Peripheral motor neuropathy,,0
ADCETRIS,Peripheral motor neuropathy,Peripheral motor neuropathy Headache,1
ADCETRIS,Peripheral motor neuropathy,neuropathy,0
ADCETRIS,Peripheral motor neuropathy,Peripheral,1
ADCETRIS,Peripheral motor neuropathy,Peripheral motor neuropathy Headache,1
ADCETRIS,Peripheral motor neuropathy,neuropathy,0
ADCETRIS,Headache,neuropathy,0
ADCETRIS,Headache,,0
ADCETRIS,Headache,neuropathy Headache,1
ADCETRIS,Dizziness,Dizziness,1
ADCETRIS,Fatigue,,0
ADCETRIS,Fatigue,conditions,0
ADCETRIS,Fatigue,Fatigue,1
ADCETRIS,Fatigue,Fatigue,1
ADCETRIS,Fatigue,,0
ADCETRIS,Fatigue,site conditions,0
ADCETRIS,Fatigue,Fatigue,1
ADCETRIS,Chills,,0
ADCETRIS,Chills,,0
ADCETRIS,Chills,Chills,1
ADCETRIS,Chills,,0
ADCETRIS,Chills,,0
ADCETRIS,Pain,Pain,1
ADCETRIS,Pain,,0
ADCETRIS,Pain,,0
ADCETRIS,Edema peripheral,Edema,1
ADCETRIS,Edema peripheral,,0
ADCETRIS,Edema peripheral,Edema,1
ADCETRIS,Edema peripheral,,0
ADCETRIS,Edema peripheral,,0
ADCETRIS,Edema peripheral,,0
ADCETRIS,Edema peripheral,,0
ADCETRIS,Upper respiratory tract infection,,0
ADCETRIS,Upper respiratory tract infection,stations,0
ADCETRIS,Upper respiratory tract infection,Gastrointestinal d,0
ADCETRIS,Upper respiratory tract infection,stations Upper respiratory,1
ADCETRIS,Upper respiratory tract infection,stations Upper respiratory tract infection Gastrointestinal,1
ADCETRIS,Upper respiratory tract infection,,0
ADCETRIS,Nausea,Nausea,1
ADCETRIS,Nausea,sorders Nausea,1
ADCETRIS,Nausea,Nausea,1
ADCETRIS,Nausea,Nausea,1
ADCETRIS,Nausea,Nausea,1
ADCETRIS,Nausea,,0
ADCETRIS,Nausea,sorders,0
ADCETRIS,Nausea,,0
ADCETRIS,Nausea,Nausea,1
ADCETRIS,Nausea,sorders,0
ADCETRIS,Diarrhea,,0
ADCETRIS,Diarrhea,Diarrhea,1
ADCETRIS,Diarrhea,Diarrhea,1
ADCETRIS,Diarrhea,,0
ADCETRIS,Diarrhea,,0
ADCETRIS,Diarrhea,Diarrhea,1
ADCETRIS,Diarrhea,Diarrhea,1
ADCETRIS,Diarrhea,,0
ADCETRIS,Abdominal pain,pain,1
ADCETRIS,Abdominal pain,,0
ADCETRIS,Abdominal pain,Abdominal pain,1
ADCETRIS,Abdominal pain,,0
ADCETRIS,Abdominal pain,Abdominal pain,1
ADCETRIS,Vomiting,Vomiting,1
ADCETRIS,Vomiting,,0
ADCETRIS,Constipation,,0
ADCETRIS,Constipation,Constipation,1
ADCETRIS,Constipation,Constipation,1
ADCETRIS,Constipation,Constipation,1
ADCETRIS,Constipation,,0
ADCETRIS,Constipation,Constipation,1
ADCETRIS,Constipation,,0
ADCETRIS,Constipation,Constipation,1
ADCETRIS,Constipation,Constipation,1
ADCETRIS,Rash,,0
ADCETRIS,Rash,Rash,1
ADCETRIS,Rash,tissue Rash,1
ADCETRIS,Rash,Rash,1
ADCETRIS,Rash,us tissue Rash,1
ADCETRIS,Rash,Rash,1
ADCETRIS,Rash,,0
ADCETRIS,Rash,us tissue Rash,1
ADCETRIS,Rash,,0
ADCETRIS,Rash,Rash,1
ADCETRIS,Pruritus,Pruritus,1
ADCETRIS,Pruritus,,0
ADCETRIS,Pruritus,,0
ADCETRIS,Pruritus,Pruritus,1
ADCETRIS,Pruritus,,0
ADCETRIS,Pruritus,Pruritus,1
ADCETRIS,Pruritus,Pruritus,1
ADCETRIS,Pruritus,,0
ADCETRIS,Pruritus,Pruritus,1
ADCETRIS,Pruritus,,0
ADCETRIS,Alopecia,Alopecia,1
ADCETRIS,Alopecia,,0
ADCETRIS,Alopecia,Alopecia,1
ADCETRIS,Alopecia,Alopecia,1
ADCETRIS,Alopecia,,0
ADCETRIS,Alopecia,Alopecia,1
ADCETRIS,Alopecia,Alopecia,1
ADCETRIS,Alopecia,Alopecia,1
ADCETRIS,Alopecia,,0
ADCETRIS,Alopecia,,0
ADCETRIS,Night sweats,Night sweats,1
ADCETRIS,Night sweats,Night,1
ADCETRIS,Night sweats,,0
ADCETRIS,Night sweats,,0
ADCETRIS,Night sweats,Night,1
ADCETRIS,Night sweats,,0
ADCETRIS,Night sweats,,0
ADCETRIS,Night sweats,,0
ADCETRIS,Dry skin,,0
ADCETRIS,Dry skin,Dry skin,1
ADCETRIS,Dry skin,skin,1
ADCETRIS,Cough,Cough,1
ADCETRIS,Cough,,0
ADCETRIS,Cough,Cough,1
ADCETRIS,Cough,,0
ADCETRIS,Cough,,0
ADCETRIS,Cough,disorders,0
ADCETRIS,Cough,Cough,1
ADCETRIS,Cough,mediastinal Cough,1
ADCETRIS,Cough,Cough,1
ADCETRIS,Oropharyngeal pain,Oropharyngeal pain Mus,1
ADCETRIS,Oropharyngeal pain,,0
ADCETRIS,Oropharyngeal pain,Oropharyngeal pain Mus,1
ADCETRIS,Oropharyngeal pain,Oropharyngeal,1
ADCETRIS,Arthralgia,,0
ADCETRIS,Arthralgia,disorders,0
ADCETRIS,Arthralgia,Arthralgia,1
ADCETRIS,Arthralgia,,0
ADCETRIS,Arthralgia,Arthralgia,1
ADCETRIS,Arthralgia,Arthralgia,1
ADCETRIS,Arthralgia,Arthralgia,1
ADCETRIS,Arthralgia,,0
ADCETRIS,Arthralgia,Arthralgia,1
ADCETRIS,Arthralgia,Arthralgia,1
ADCETRIS,Myalgia,,0
ADCETRIS,Myalgia,,0
ADCETRIS,Myalgia,,0
ADCETRIS,Myalgia,Myalgia,1
ADCETRIS,Myalgia,Myalgia,1
ADCETRIS,Myalgia,,0
ADCETRIS,Myalgia,,0
ADCETRIS,Myalgia,,0
ADCETRIS,Pain in extremity,,0
ADCETRIS,Pain in extremity,,0
ADCETRIS,Pain in extremity,,0
ADCETRIS,Pain in extremity,,0
ADCETRIS,Pain in extremity,Pain,1
ADCETRIS,Pain in extremity,,0
ADCETRIS,Muscle spasms,,0
ADCETRIS,Insomnia,,0
ADCETRIS,Insomnia,rs Insomnia,1
ADCETRIS,Insomnia,rs,0
ADCETRIS,Insomnia,,0
ADCETRIS,Insomnia,,0
ADCETRIS,Insomnia,rs,0
ADCETRIS,Insomnia,rs Insomnia,1
ADCETRIS,Insomnia,rs Insomnia,1
ADCETRIS,Insomnia,,0
ADCETRIS,Insomnia,,0
ADCETRIS,Anxiety,,0
ADCETRIS,Anxiety,,0
ADCETRIS,Decreased appetite,ition Decreased,1
ADCETRIS,Decreased appetite,appetite Inv,1
ADCETRIS,Decreased appetite,Decreased appetite Inv,1
ADCETRIS,Decreased appetite,ition Decreased,1
ADCETRIS,Decreased appetite,,0
ADCETRIS,Decreased appetite,,0
ADCETRIS,Decreased appetite,,0
ADCETRIS,Decreased appetite,,0
ADCETRIS,Decreased appetite,ition Decreased appetite Inv,1
ADCETRIS,Weight decreased,Weight decreased,1
ADCETRIS,Weight decreased,,0
ADCETRIS,Weight decreased,Weight decreased,1
ADCETRIS,Weight decreased,Weight decreased,1
ADCETRIS,Weight decreased,,0
ADCETRIS,Weight decreased,,0
ADCETRIS,Weight decreased,Weight decreased,1
ADCETRIS,Neutropenia,Neutropenia,1
ADCETRIS,Neutropenia,,0
ADCETRIS,Neutropenia,Neutropenia,1
ADCETRIS,Thrombocytopenia,,0
ADCETRIS,Thrombocytopenia,,0
ADCETRIS,Thrombocytopenia,,0
ADCETRIS,Thrombocytopenia,Thrombocytopenia,1
ADCETRIS,Thrombocytopenia,Thrombocytopenia,1
ADCETRIS,Thrombocytopenia,Thrombocytopenia,1
ADCETRIS,Thrombocytopenia,Thrombocytopenia,1
ADCETRIS,Thrombocytopenia,,0
ADCETRIS,Thrombocytopenia,Thrombocytopenia,1
ADCETRIS,Thrombocytopenia,Thrombocytopenia,1
ADCETRIS,Anemia,,0
ADCETRIS,Anemia,Anemia,1
ADCETRIS,Anemia,Anemia,1
ADCETRIS,Anemia,Anemia,1
ADCETRIS,Anemia,Anemia,1
ADCETRIS,Anemia,,0
ADCETRIS,Anemia,,0
ADCETRIS,Peripheral sensory neuropathy,rders,0
ADCETRIS,Peripheral sensory neuropathy,rders,0
ADCETRIS,Peripheral sensory neuropathy,rders Peripheral sensory neuropathy Peripheral,1
ADCETRIS,Peripheral sensory neuropathy,,0
ADCETRIS,Peripheral sensory neuropathy,rders,0
ADCETRIS,Peripheral sensory neuropathy,rders Peripheral sensory,1
ADCETRIS,Peripheral sensory neuropathy,sensory neuropathy Peripheral m,1
ADCETRIS,Peripheral sensory neuropathy,neuropathy Peripheral,1
ADCETRIS,Peripheral sensory neuropathy,Peripheral m,0
ADCETRIS,Peripheral sensory neuropathy,rders,0
ADCETRIS,Peripheral motor neuropathy,neuropathy Headache,1
ADCETRIS,Headache,neuropathy,0
ADCETRIS,Headache,Headache,1
ADCETRIS,Headache,Headache,1
ADCETRIS,Headache,Headache,1
ADCETRIS,Headache,Headache,1
ADCETRIS,Headache,,0
ADCETRIS,Headache,Headache,1
ADCETRIS,Headache,neuropathy,0
ADCETRIS,Headache,Headache,1
ADCETRIS,Upper respiratory tract infection,stations Upper respiratory tract infection General disorders,1
ADCETRIS,Upper respiratory tract infection,stations Upper,1
ADCETRIS,Upper respiratory tract infection,,0
ADCETRIS,Upper respiratory tract infection,stations,0
ADCETRIS,Upper respiratory tract infection,,0
ADCETRIS,Upper respiratory tract infection,stations Upper respiratory tract infection General disorders,1
ADCETRIS,Upper respiratory tract infection,stations,0
ADCETRIS,Fatigue,Fatigue,1
ADCETRIS,Fatigue,Fatigue,1
ADCETRIS,Fatigue,site,0
ADCETRIS,Pyrexia,,0
ADCETRIS,Pyrexia,Pyrexia,1
ADCETRIS,Pyrexia,,0
ADCETRIS,Pyrexia,,0
ADCETRIS,Pyrexia,Pyrexia,1
ADCETRIS,Pyrexia,Pyrexia,1
ADCETRIS,Pyrexia,,0
ADCETRIS,Pyrexia,Pyrexia,1
ADCETRIS,Pyrexia,,0
ADCETRIS,Pyrexia,Pyrexia,1
ADCETRIS,Chills,Chills,1
ADCETRIS,Chills,Chills,1
ADCETRIS,Nausea,,0
ADCETRIS,Diarrhea,,0
ADCETRIS,Diarrhea,Diarrhea,1
ADCETRIS,Diarrhea,,0
ADCETRIS,Diarrhea,Diarrhea,1
ADCETRIS,Diarrhea,Diarrhea,1
ADCETRIS,Diarrhea,,0
ADCETRIS,Diarrhea,,0
ADCETRIS,Diarrhea,Diarrhea,1
ADCETRIS,Diarrhea,Diarrhea,1
ADCETRIS,Diarrhea,Diarrhea,1
ADCETRIS,Vomiting,Vomiting,1
ADCETRIS,Vomiting,,0
ADCETRIS,Vomiting,Vomiting,1
ADCETRIS,Abdominal pain,,0
ADCETRIS,Abdominal pain,pain,1
ADCETRIS,Abdominal pain,,0
ADCETRIS,Abdominal pain,,0
ADCETRIS,Abdominal pain,Abdominal pain,1
ADCETRIS,Abdominal pain,,0
ADCETRIS,Abdominal pain,Abdominal pain,1
ADCETRIS,Constipation,Constipation,1
ADCETRIS,Weight decreased,,0
ADCETRIS,Weight decreased,,0
ADCETRIS,Weight decreased,,0
ADCETRIS,Weight decreased,M,0
ADCETRIS,Weight decreased,Weight decreased M,1
ADCETRIS,Arthralgia,tissue Arthralgia,1
ADCETRIS,Arthralgia,tissue disorders,0
ADCETRIS,Arthralgia,Arthralgia,1
ADCETRIS,Muscle spasms,spasms,1
ADCETRIS,Myalgia,,0
ADCETRIS,Myalgia,,0
ADCETRIS,Myalgia,Myalgia,1
ADCETRIS,Myalgia,,0
ADCETRIS,Myalgia,Myalgia,1
ADCETRIS,Myalgia,Myalgia,1
ADCETRIS,Myalgia,,0
ADCETRIS,Myalgia,Myalgia,1
ADCETRIS,Myalgia,Myalgia,1
ADCETRIS,Pruritus,Pruritus,1
ADCETRIS,Pruritus,Pruritus,1
ADCETRIS,Pruritus,,0
ADCETRIS,Pruritus,Pruritus,1
ADCETRIS,Pruritus,tissue Pruritus,1
ADCETRIS,Pruritus,,0
ADCETRIS,Pruritus,tissue Pruritus,1
ADCETRIS,Decreased appetite,ition Decreased appetite,1
ADCETRIS,Decreased appetite,,0
ADCETRIS,Decreased appetite,Decreased,1
ADCETRIS,Decreased appetite,,0
ADCETRIS,Decreased appetite,,0
ADCETRIS,Decreased appetite,disorders,0
ADCETRIS,Decreased appetite,appetite,1
ADCETRIS,Decreased appetite,,0
ADCETRIS,Decreased appetite,,0
ADCETRIS,Decreased appetite,disorders,0
ADCETRIS,neuropathy,of,0
ADCETRIS,neuropathy,complete resolution had partial improvement,0
ADCETRIS,neuropathy,neuropathy,1
ADCETRIS,neuropathy,any grade neuropathy,1
ADCETRIS,neuropathy,any grade neuropathy,1
ADCETRIS,neuropathy,neuropathy,1
ADCETRIS,neuropathy,had complete resolution had,0
ADCETRIS,neuropathy,neuropathy,1
ADCETRIS,neuropathy,neuropathy,1
ADCETRIS,residual neuropathy,who reported neuropathy residual,1
ADCETRIS,residual neuropathy,last evaluation In Study,0
ADCETRIS,residual neuropathy,who reported neuropathy residual,1
ADCETRIS,residual neuropathy,residual neuropathy,1
ADCETRIS,residual neuropathy,neuropathy residual,1
ADCETRIS,residual neuropathy,no,0
ADCETRIS,residual neuropathy,neuropathy,1
ADCETRIS,residual neuropathy,who reported neuropathy residual neuropathy,1
ADCETRIS,neuropathy,last evaluation In Study of patients treated with ADCETRIS experienced any,0
ADCETRIS,neuropathy,neuropathy,1
ADCETRIS,neuropathy,neuropathy,1
ADCETRIS,neuropathy,who neuropathy,1
ADCETRIS,neuropathy,,0
ADCETRIS,neuropathy,who,0
ADCETRIS,neuropathy,complete resolution and had residual neuropathy partial,0
ADCETRIS,neuropathy,patients,0
ADCETRIS,neuropathy,neuropathy,1
ADCETRIS,residual neuropathy,the,0
ADCETRIS,residual neuropathy,time of their last,0
ADCETRIS,residual neuropathy,residual neuropathy,1
ADCETRIS,residual neuropathy,improvement at the time of,0
ADCETRIS,residual neuropathy,complete resolution and residual,1
ADCETRIS,residual neuropathy,resolution and residual,1
ADCETRIS,residual neuropathy,reported neuropathy had complete resolution and,0
ADCETRIS,residual neuropathy,no improvement at the time,0
ADCETRIS,residual neuropathy,,0
ADCETRIS,anaphylaxis,,0
ADCETRIS,infusion-related reactions,infusion-related reactions,1
ADCETRIS,infusion-related reactions,infusion-related reactions,1
ADCETRIS,infusion-related reactions,of anaphylaxis,0
ADCETRIS,infusion-related reactions,infusion-related reactions,1
ADCETRIS,infusion-related reactions,infusion-related reactions,1
ADCETRIS,infusion-related reactions,infusion-related reactions,1
ADCETRIS,infusion-related reactions,infusion-related reactions,1
ADCETRIS,infusion-related reactions,There were no Grade infusion-related,1
ADCETRIS,infusion-related reactions,the dosefinding trials There were no Grade,0
ADCETRIS,infusion-related reactions,common adverse reactions associated infusion-related,1
ADCETRIS,infusion-related reactions,adverse reactions associated infusion-related reactions,1
ADCETRIS,infusion-related reactions,In Studies and the,0
ADCETRIS,infusion-related reactions,reactions,1
ADCETRIS,infusion-related reactions,pyrexia,0
ADCETRIS,chills,chills,1
ADCETRIS,chills,chills,1
ADCETRIS,chills,and cough In Study infus,0
ADCETRIS,nausea,infusionrelated,0
ADCETRIS,nausea,cough In Study infusionrelated r,0
ADCETRIS,nausea,cough In,0
ADCETRIS,dyspnea,infusionrelated reactions were chills nausea,0
ADCETRIS,dyspnea,reactions,0
ADCETRIS,dyspnea,dyspnea,1
ADCETRIS,dyspnea,were chills nausea,0
ADCETRIS,dyspnea,were chills nausea,0
ADCETRIS,dyspnea,with infusionrelated reactions were chills nausea,0
ADCETRIS,dyspnea,pruritus pyrexia and cough,0
ADCETRIS,pruritus,nausea pruritus,1
ADCETRIS,pruritus,associated with infusionrelated reactions were chills nausea dyspnea,0
ADCETRIS,pruritus,pruritus,1
ADCETRIS,pruritus,pruritus,1
ADCETRIS,pyrexia,,0
ADCETRIS,cough,cough,1
ADCETRIS,cough,cough,1
ADCETRIS,cough,reactions were reported in patients,0
ADCETRIS,cough,infusionrelated reactions were,0
ADCETRIS,cough,cough,1
ADCETRIS,cough,cough,1
ADCETRIS,infusion-related reactions,infusion-related reactions,1
ADCETRIS,infusion-related reactions,arm and patients in the placebo a,0
ADCETRIS,infusion-related reactions,and cough In infusion-related reactions,1
ADCETRIS,infusion-related reactions,,0
ADCETRIS,infusion-related reactions,arm and patients,0
ADCETRIS,infusion-related reactions,patients in the placebo,0
ADCETRIS,infusion-related reactions,dyspnea pruritus,0
ADCETRIS,infusion-related reactions,infusion-related reactions,1
ADCETRIS,infusion-related reactions,reactions,1
ADCETRIS,infusion-related reactions,treated with ADCETRIS who infusion-related,1
ADCETRIS,infusion-related reactions,,0
ADCETRIS,infusion-related reactions,ADCETRIS who infusion-related,1
ADCETRIS,infusion-related reactions,ADCETRIS,0
ADCETRIS,infusion-related reactions,reactions No infusion-related reactions,1
ADCETRIS,infusion-related reactions,patients treated with ADCETRIS who,0
ADCETRIS,infusion-related reactions,with infusionrelated,0
ADCETRIS,infusion-related reactions,Grade,0
ADCETRIS,infusion-related reactions,reactions,1
ADCETRIS,infusion-related reactions,reactions No infusion-related reactions,1
ADCETRIS,infusion-related reactions,infusionrelated reactions No infusion-related reactions,1
ADCETRIS,infusion-related reactions,infusionrelated reactions No infusion-related,1
ADCETRIS,infusion-related reactions,adverse reactions associated infusion-related,1
ADCETRIS,infusion-related reactions,reported The most common adverse reactions,0
ADCETRIS,infusion-related reactions,were reported The most common adverse reactions associated with,0
ADCETRIS,infusion-related reactions,infusion-related,1
ADCETRIS,infusion-related reactions,infusion-related reactions,1
ADCETRIS,nausea,associated with,0
ADCETRIS,nausea,nausea,1
ADCETRIS,nausea,,0
ADCETRIS,nausea,nausea,1
ADCETRIS,nausea,rash back pain and,0
ADCETRIS,nausea,reactions associated with,0
ADCETRIS,nausea,nausea,1
ADCETRIS,nausea,nausea,1
ADCETRIS,nausea,nausea,1
ADCETRIS,chills,with infusionrelated reactions were chills,1
ADCETRIS,chills,chills,1
ADCETRIS,chills,pain and vomiting,0
ADCETRIS,chills,infusionrelated,0
ADCETRIS,chills,reactions were nausea,0
ADCETRIS,chills,chills,1
ADCETRIS,chills,chills,1
ADCETRIS,dyspnea,,0
ADCETRIS,dyspnea,Pulmonary,0
ADCETRIS,dyspnea,nausea dyspnea,1
ADCETRIS,dyspnea,dyspnea,1
ADCETRIS,dyspnea,headache,0
ADCETRIS,dyspnea,dyspnea,1
ADCETRIS,dyspnea,dyspnea,1
ADCETRIS,dyspnea,infusionrelated,0
ADCETRIS,dyspnea,dyspnea,1
ADCETRIS,headache,pain and vomiting Pulmonary,0
ADCETRIS,headache,associated with infusionrelated reactions,0
ADCETRIS,headache,headache,1
ADCETRIS,headache,headache,1
ADCETRIS,headache,,0
ADCETRIS,headache,reactions were nausea chills headache,1
ADCETRIS,headache,nausea chills,0
ADCETRIS,headache,with,0
ADCETRIS,pruritus,rash back pain,0
ADCETRIS,pruritus,nausea chills dyspnea headache,0
ADCETRIS,pruritus,and,0
ADCETRIS,pruritus,were nausea chills dyspnea headache,0
ADCETRIS,pruritus,Toxicity,0
ADCETRIS,pruritus,dyspnea pruritus,1
ADCETRIS,rash,back pain and vomiting Pulmonary Toxicity,0
ADCETRIS,rash,back pain and vomiting Pulmonary,0
ADCETRIS,rash,were nausea chills,0
ADCETRIS,rash,rash,1
ADCETRIS,rash,,0
ADCETRIS,rash,reactions,0
ADCETRIS,rash,rash,1
ADCETRIS,rash,were nausea chills dyspnea,0
ADCETRIS,back pain,nausea chills dyspnea headache,0
ADCETRIS,back pain,reactions were nausea chills dyspnea headache pruritus,0
ADCETRIS,back pain,reactions were nausea chills dyspnea headache pruritus,0
ADCETRIS,back pain,chills dyspnea headache pruritus back pain,1
ADCETRIS,back pain,dyspnea headache pruritus back pain,1
ADCETRIS,vomiting,vomiting,1
ADCETRIS,vomiting,vomiting,1
ADCETRIS,vomiting,vomiting,1
ADCETRIS,vomiting,rash back pain vomiting,1
ADCETRIS,vomiting,rash back pain vomiting,1
ADCETRIS,vomiting,,0
ADCETRIS,non-infectious pulmonary toxicity,with ABVD adriamycin,0
ADCETRIS,non-infectious pulmonary toxicity,regimen the rate non-infectious,1
ADCETRIS,non-infectious pulmonary toxicity,non-infectious pulmonary toxicity,1
ADCETRIS,non-infectious pulmonary toxicity,pulmonary toxicity,1
ADCETRIS,non-infectious pulmonary toxicity,classical HL that studied ADCETRIS with,0
ADCETRIS,non-infectious pulmonary toxicity,regimen the rate non-infectious pulmonary toxicity,1
ADCETRIS,non-infectious pulmonary toxicity,,0
ADCETRIS,non-infectious pulmonary toxicity,pulmonary toxicity,1
ADCETRIS,cough,vinblastine dacarbazine Patients typically cough,1
ADCETRIS,cough,adriamycin bleomycin vinblastine,0
ADCETRIS,cough,Patients typically cough,1
ADCETRIS,cough,vinblastine dacarbazine Patients typically cough,1
ADCETRIS,dyspnea,radiographs,0
ADCETRIS,dyspnea,dyspnea,1
ADCETRIS,pulmonary toxicity,Contraindications Cases pulmonary,1
ADCETRIS,pulmonary toxicity,,0
ADCETRIS,pulmonary toxicity,bleomycin is,0
ADCETRIS,pulmonary toxicity,in patients receiving ADCETRIS In,0
ADCETRIS,pulmonary toxicity,see Contraindications Cases,0
ADCETRIS,peripheral motor neuropathy,pneumonitis pneumothorax pyelonephr,0
ADCETRIS,peripheral motor neuropathy,motor neuropathy,1
ADCETRIS,peripheral motor neuropathy,HL peripheral,1
ADCETRIS,abdominal pain,,0
ADCETRIS,pulmonary embolism,,0
ADCETRIS,pulmonary embolism,,0
ADCETRIS,pulmonary embolism,motor neuropathy abdominal pulmonary,1
ADCETRIS,pulmonary embolism,neuropathy abdominal pulmonary,1
ADCETRIS,pulmonary embolism,by patients with classical HL include peripheral motor neuropathy,0
ADCETRIS,pulmonary embolism,abdominal pulmonary,1
ADCETRIS,pneumonitis,pneumonitis,1
ADCETRIS,pneumonitis,pneumonitis,1
ADCETRIS,pneumonitis,pneumonitis,1
ADCETRIS,pneumonitis,and pyrexia,0
ADCETRIS,pyelonephritis,embolism pneumonitis,0
ADCETRIS,pyelonephritis,pyelonephritis,1
ADCETRIS,pyelonephritis,pyelonephritis,1
ADCETRIS,pyelonephritis,pulmonary embolism pneumonitis pyelonephritis,1
ADCETRIS,pyelonephritis,sALC,0
ADCETRIS,pyelonephritis,pyelonephritis,1
ADCETRIS,pyelonephritis,The most common serious adverse reactions experienced by,0
ADCETRIS,pyrexia,pneumonitis,0
ADCETRIS,septic shock,shock,1
ADCETRIS,septic shock,O,0
ADCETRIS,septic shock,common serious adverse,0
ADCETRIS,septic shock,septic,1
ADCETRIS,septic shock,pain in extremity and urinary,0
ADCETRIS,supraventricular arrhythmia,septic supraventricular,1
ADCETRIS,pain in extremity,shock supraventricular pain in extremity,1
ADCETRIS,pain in extremity,supraventricular pain in extremity,1
ADCETRIS,pain in extremity,by patients with sALCL were septic,0
ADCETRIS,pain in extremity,by patients with,0
ADCETRIS,pain in extremity,pain in extremity,1
ADCETRIS,pain in extremity,shock supraventricular pain in,1
ADCETRIS,pain in extremity,were septic shock supraventricular pain in extremity,1
ADCETRIS,pain in extremity,,0
ADCETRIS,urinary tract infection,urinary tract infection,1
ADCETRIS,urinary tract infection,adverse reactions reported include PML StevensJohnson,0
ADCETRIS,urinary tract infection,urinary tract infection,1
ADCETRIS,urinary tract infection,syndrome,0
ADCETRIS,urinary tract infection,infection,1
ADCETRIS,urinary tract infection,pain in,0
ADCETRIS,urinary tract infection,,0
ADCETRIS,urinary tract infection,tract infection,1
ADCETRIS,PML,tract,0
ADCETRIS,PML,Other important serious,0
ADCETRIS,PML,PML,1
ADCETRIS,PML,PML,1
ADCETRIS,PML,PML,1
ADCETRIS,PML,PML,1
ADCETRIS,PML,adverse reactions reported,0
ADCETRIS,PML,PML,1
ADCETRIS,PML,PML,1
ADCETRIS,PML,PML,1
ADCETRIS,Stevens-Johnson syndrome,reactions regardless of causality were,0
ADCETRIS,Stevens-Johnson syndrome,reported include Stevens-Johnson syndrome,1
ADCETRIS,Stevens-Johnson syndrome,reported include Stevens-Johnson syndrome,1
ADCETRIS,Stevens-Johnson syndrome,syndrome,1
ADCETRIS,Stevens-Johnson syndrome,syndrome,1
ADCETRIS,Stevens-Johnson syndrome,,0
ADCETRIS,tumor lysis syndrome,PML StevensJohnson syndrome tumor,1
ADCETRIS,tumor lysis syndrome,include PML StevensJohnson syndrome tumor lysis syndrome,1
ADCETRIS,tumor lysis syndrome,important,0
ADCETRIS,tumor lysis syndrome,include PML StevensJohnson syndrome tumor lysis syndrome,1
ADCETRIS,tumor lysis syndrome,important serious adverse reactions reported include PML StevensJohnson syndrome,0
ADCETRIS,pneumonia,pneumonia,1
ADCETRIS,pneumonia,nausea hepatotoxicity and,0
ADCETRIS,pneumonia,vomiting,0
ADCETRIS,pneumonia,,0
ADCETRIS,pneumonia,adverse reactions pneumonia,1
ADCETRIS,pneumonia,pneumonia,1
ADCETRIS,pneumonia,pneumonia,1
ADCETRIS,vomiting,vomiting,1
ADCETRIS,vomiting,adverse reactions were pneumonia vomiting,1
ADCETRIS,vomiting,,0
ADCETRIS,nausea,reactions were pneumonia pyrexia vomiting,0
ADCETRIS,nausea,,0
ADCETRIS,nausea,,0
ADCETRIS,nausea,were pneumonia pyrexia nausea,1
ADCETRIS,nausea,sensory neuropathy,0
ADCETRIS,nausea,nausea,1
ADCETRIS,nausea,nausea,1
ADCETRIS,hepatotoxicity,neuropathy Dose modifications,0
ADCETRIS,hepatotoxicity,,0
ADCETRIS,hepatotoxicity,,0
ADCETRIS,hepatotoxicity,neuropathy,0
ADCETRIS,hepatotoxicity,vomiting hepatotoxicity,1
ADCETRIS,hepatotoxicity,hepatotoxicity,1
ADCETRIS,hepatotoxicity,,0
ADCETRIS,hepatotoxicity,adverse reactions were pneumonia pyrexia vomiting nausea,0
ADCETRIS,hepatotoxicity,hepatotoxicity,1
ADCETRIS,peripheral sensory neuropathy,vomiting,0
ADCETRIS,peripheral sensory neuropathy,sensory neuropathy,1
ADCETRIS,peripheral sensory neuropathy,vomiting nausea hepatotoxicity peripheral sensory,1
ADCETRIS,peripheral sensory neuropathy,delays in more than of,0
ADCETRIS,peripheral sensory neuropathy,vomiting nausea,0
ADCETRIS,peripheral sensory neuropathy,reactions that led to dose,0
ADCETRIS,peripheral sensory neuropathy,in more,0
ADCETRIS,peripheral sensory neuropathy,sensory neuropathy,1
ADCETRIS,peripheral sensory neuropathy,,0
ADCETRIS,peripheral sensory neuropathy,sensory neuropathy,1
ADCETRIS,peripheral sensory neuropathy,peripheral sensory,1
ADCETRIS,peripheral sensory neuropathy,neuropathy,1
ADCETRIS,peripheral sensory neuropathy,sensory neuropathy,1
ADCETRIS,peripheral sensory neuropathy,that led to dose delays in more than of patients in Studies and,0
ADCETRIS,neutropenia,,0
ADCETRIS,neutropenia,neutropenia,1
ADCETRIS,neutropenia,neutropenia,1
ADCETRIS,neutropenia,neuropathy upper respiratory tract infection and,0
ADCETRIS,neutropenia,neuropathy,0
ADCETRIS,neutropenia,neutropenia,1
ADCETRIS,peripheral sensory neuropathy,of ADCETRIStreated patients in,0
ADCETRIS,peripheral sensory neuropathy,in Study were peripheral sensory neuropathy,1
ADCETRIS,peripheral sensory neuropathy,peripheral,1
ADCETRIS,peripheral sensory neuropathy,Study were neutropenia,0
ADCETRIS,peripheral sensory neuropathy,,0
ADCETRIS,peripheral sensory neuropathy,neuropathy,1
ADCETRIS,peripheral sensory neuropathy,dose delays in,0
ADCETRIS,peripheral sensory neuropathy,patients in Study were peripheral,1
ADCETRIS,upper respiratory tract infection,,0
ADCETRIS,upper respiratory tract infection,,0
ADCETRIS,upper respiratory tract infection,infection,1
ADCETRIS,upper respiratory tract infection,neuropathy,0
ADCETRIS,upper respiratory tract infection,,0
ADCETRIS,peripheral motor neuropathy,respiratory tract infection peripheral,1
ADCETRIS,peripheral motor neuropathy,respiratory tract infection peripheral motor neuropathy,1
ADCETRIS,peripheral motor neuropathy,upper respiratory tract infection peripheral motor neuropathy,1
ADCETRIS,peripheral motor neuropathy,peripheral motor,1
ADCETRIS,peripheral motor neuropathy,respiratory tract infection peripheral,1
ADCETRIS,peripheral motor neuropathy,and,0
ADCETRIS,peripheral motor neuropathy,tract infection peripheral motor neuropathy,1
ADCETRIS,peripheral sensory neuropathy,sALCL peripheral sensory neuropathy,1
ADCETRIS,peripheral sensory neuropathy,classical HL or sALCL peripheral sensory neuropathy,1
ADCETRIS,peripheral sensory neuropathy,more patients with classical HL or,0
ADCETRIS,peripheral sensory neuropathy,neuropathy,1
ADCETRIS,peripheral sensory neuropathy,reactions that led to treatment discontinuation,0
ADCETRIS,peripheral sensory neuropathy,more patients peripheral sensory,1
ADCETRIS,peripheral sensory neuropathy,syndrome paraesthesia,0
ADCETRIS,peripheral sensory neuropathy,paraesthesia,0
ADCETRIS,peripheral sensory neuropathy,patients peripheral,1
ADCETRIS,peripheral sensory neuropathy,that led to treatment discontinuation in or more patients,0
ADCETRIS,peripheral sensory neuropathy,peripheral motor,0
ADCETRIS,peripheral sensory neuropathy,,0
ADCETRIS,peripheral sensory neuropathy,peripheral sensory neuropathy,1
ADCETRIS,peripheral motor neuropathy,neuropathy,1
ADCETRIS,peripheral motor neuropathy,were peripheral sensory peripheral motor neuropathy,1
ADCETRIS,peripheral motor neuropathy,and vomiting,0
ADCETRIS,peripheral motor neuropathy,motor neuropathy,1
ADCETRIS,peripheral motor neuropathy,sensory peripheral motor neuropathy,1
ADCETRIS,acute respiratory distress syndrome,Experience,0
ADCETRIS,acute respiratory distress syndrome,peripheral sensory neuropathy peripheral motor,0
ADCETRIS,acute respiratory distress syndrome,acute respiratory,1
ADCETRIS,acute respiratory distress syndrome,,0
ADCETRIS,acute respiratory distress syndrome,peripheral motor acute respiratory distress syndrome,1
ADCETRIS,acute respiratory distress syndrome,more patients were peripheral sensory,0
ADCETRIS,acute respiratory distress syndrome,peripheral motor,0
ADCETRIS,paraesthesia,respiratory distress paraesthesia,1
ADCETRIS,vomiting,identified d,0
ADCETRIS,febrile neutropenia,Blood and lymphatic system febrile,1
ADCETRIS,febrile neutropenia,system febrile,1
ADCETRIS,febrile neutropenia,febrile neutropenia,1
ADCETRIS,febrile neutropenia,see Warnings and,0
ADCETRIS,febrile neutropenia,see,0
ADCETRIS,febrile neutropenia,neutropenia,1
ADCETRIS,febrile neutropenia,febrile,1
ADCETRIS,febrile neutropenia,Precautions,0
ADCETRIS,febrile neutropenia,a causal relationship to drug exposure,0
ADCETRIS,febrile neutropenia,and lymphatic system febrile neutropenia,1
ADCETRIS,hepatotoxicity,see Warnings and Precautions Hepatobiliary disorders,0
ADCETRIS,hepatotoxicity,Boxed,0
ADCETRIS,hepatotoxicity,see Warnings and Precautions Hepatobiliary,0
ADCETRIS,PML,Boxed Warning Warnings and Precautions,0
ADCETRIS,PML,Infections,0
ADCETRIS,PML,PML,1
ADCETRIS,PML,and Precautions PML,1
ADCETRIS,PML,serious,0
ADCETRIS,PML,hepatotoxicity see Warnings,0
ADCETRIS,PML,PML,1
ADCETRIS,PML,,0
ADCETRIS,PML,and Precautions PML,1
ADCETRIS,PML,PML,1
ADCETRIS,infections,infections,1
ADCETRIS,opportunistic infections,PML see Boxed Warning Warnings and Precautions serious,0
ADCETRIS,opportunistic infections,infections opportunistic infections,1
ADCETRIS,opportunistic infections,infections,1
ADCETRIS,opportunistic infections,Warnings and,0
ADCETRIS,opportunistic infections,Precautions serious infections opportunistic,1
ADCETRIS,opportunistic infections,infections opportunistic,1
ADCETRIS,hyperglycemia,Pancreatitis,0
ADCETRIS,hyperglycemia,diagnos,0
ADCETRIS,hyperglycemia,fatal outcomes Consider the,0
ADCETRIS,hyperglycemia,hyperglycemia,1
ADCETRIS,hyperglycemia,and nutrition hyperglycemia,1
ADCETRIS,hyperglycemia,,0
ADCETRIS,hyperglycemia,Precautions Metabolism,0
ADCETRIS,fatal,diagnosis of pancreatitis for,0
ADCETRIS,fatal,of pancreatitis for patients,0
ADCETRIS,fatal,patients,0
ADCETRIS,fatal,fatal,1
ADCETRIS,fatal,fatal,1
ADCETRIS,noninfectious pulmonary toxicity,,0
ADCETRIS,noninfectious pulmonary toxicity,pneumonitis interstitial lung disease and ARDS some with fatal outcomes see Warnin,0
ADCETRIS,noninfectious pulmonary toxicity,thoracic and mediastinal noninfectious pulmonary toxicity,1
ADCETRIS,pneumonitis,noninfectious,0
ADCETRIS,pneumonitis,disorders noninfectious pulmonary toxicity including,0
ADCETRIS,pneumonitis,,0
ADCETRIS,pneumonitis,pneumonitis,1
ADCETRIS,pneumonitis,pneumonitis,1
ADCETRIS,pneumonitis,thoracic and mediastinal disorders noninfectious,0
ADCETRIS,pneumonitis,pneumonitis,1
ADCETRIS,pneumonitis,,0
ADCETRIS,pneumonitis,see Warnings,0
ADCETRIS,pneumonitis,disease and,0
ADCETRIS,interstitial lung disease,pulmonary toxicity including interstitial lung,1
ADCETRIS,interstitial lung disease,ARDS some with fatal outcomes see Warnings and,0
ADCETRIS,interstitial lung disease,and,0
ADCETRIS,interstitial lung disease,interstitial lung disease,1
ADCETRIS,interstitial lung disease,interstitial,1
ADCETRIS,interstitial lung disease,including interstitial lung disease,1
ADCETRIS,interstitial lung disease,mediastinal,0
ADCETRIS,interstitial lung disease,see Warnings and Precautions and Adverse,0
ADCETRIS,interstitial lung disease,and mediastinal disorders,0
ADCETRIS,interstitial lung disease,disorders noninfectious pulmonary toxicity,0
ADCETRIS,ARDS,ARDS,1
ADCETRIS,ARDS,pneumonitis interstitial lung,0
ADCETRIS,ARDS,with fatal outcomes see Warnings and Precautions and Adverse Reactions,0
ADCETRIS,ARDS,interstitial lung disease ARDS,1
ADCETRIS,ARDS,and,0
ADCETRIS,fatal,,0
ADCETRIS,fatal,some fatal,1
ADCETRIS,fatal,toxicity including,0
ADCETRIS,fatal,fatal,1
ADCETRIS,fatal,and Adverse,0
ADCETRIS,Toxic epidermal necrolysis,subcutaneous tissue Toxic epidermal necrolysis,1
ADCETRIS,Toxic epidermal necrolysis,tissue Toxic epidermal necrolysis,1
ADCETRIS,Toxic epidermal necrolysis,and subcutaneous tissue disorders,0
ADCETRIS,Toxic epidermal necrolysis,tissue Toxic epidermal necrolysis,1
ADCETRIS,Toxic epidermal necrolysis,subcutaneous tissue Toxic epidermal,1
ADCETRIS,Toxic epidermal necrolysis,tissue disorders,0
ADCETRIS,Toxic epidermal necrolysis,,0
ADCETRIS,Toxic epidermal necrolysis,subcutaneous tissue disorders,0
ADCETRIS,Toxic epidermal necrolysis,Adverse Reactions Skin,0
ADCETRIS,Toxic epidermal necrolysis,tissue,0
ADCETRIS,fatal,Toxic epidermal necrolysis fatal,1
ADCETRIS,fatal,epidermal necrolysis fatal,1
ADCETRIS,fatal,necrolysis,0
ADCETRIS,fatal,,0
ADCETRIS,infusion reactions,infusion reactions,1
ADCETRIS,infusion reactions,led to discontinuation of,0
ADCETRIS,infusion reactions,of infusion related reactions,0
ADCETRIS,infusion reactions,adverse reactions,0
ADCETRIS,infusion reactions,to discontinuation of treatment Overall a,0
ADCETRIS,infusion reactions,,0
ADCETRIS,infusion reactions,experienced,0
ADCETRIS,infusion reactions,of treatment Overall a higher incidence of infusion related,0
ADCETRIS,infusion reactions,experienced adverse reactions consistent,0
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,serious adverse reactions are d iscussed in greater,1
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,are d iscussed,1
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,,0
ADCETRIS,PML,,0
ADCETRIS,PML,cus sed in greater detail,1
ADCETRIS,PML,cus,1
ADCETRIS,PML,cus sed,1
ADCETRIS,PML,,0
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,other sections of the prescribing information,1
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,,0
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,etail in other,1
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,,0
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,,0
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,other sections of the prescribing information Peripheral Neuropathy see,1
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,,0
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,etail in other sections of the prescribing information Peripheral Neuropathy,1
ADCETRIS,PML,and Precautions,0
ADCETRIS,PML,rmation Peripheral Neuropathy,0
ADCETRIS,PML,,0
ADCETRIS,PML,nfo rmation Peripheral Neuropathy,1
ADCETRIS,PML,Precautions,0
ADCETRIS,JC virus infection,,0
ADCETRIS,JC virus infection,"


 *  Peripheral  Neuropathy see Warnings",1
ADCETRIS,JC virus infection,and Precautions Anaphylaxis and,0
ADCETRIS,JC virus infection,Reacti,0
ADCETRIS,JC virus infection,Anaphylaxis and,0
ADCETRIS,JC virus infection,in greater detail in other sections,0
ADCETRIS,JC virus infection,see Warnings and Precautions Anaphylaxis and Infusion Reacti,0
ADCETRIS,JC virus infection,"the prescribing 


 *  Peripheral  Neuropathy see Warnings",1
ADCETRIS,JC virus infection,Reacti,0
ADCETRIS,PML,Infusion,0
ADCETRIS,PML,Neuropathy e   Warnings and Precautions,1
ADCETRIS,PML,Peripheral Neuropathy se,0
ADCETRIS,PML,Reactions,0
ADCETRIS,PML,the,0
ADCETRIS,PML,e   Warnings and Precautions,1
ADCETRIS,PML,see,0
ADCETRIS,death,information Peripheral,0
ADCETRIS,death,see,0
ADCETRIS,death,Neuropathy see ngs,1
ADCETRIS,death,see ngs,1
ADCETRIS,death,,0
ADCETRIS,death,a nd Precautions Anaphylaxis,1
ADCETRIS,PML,and Precautions rio us Infections and,1
ADCETRIS,PML,and Opportunistic Infections see Warnings,0
ADCETRIS,PML,rio us Infections and,1
ADCETRIS,PML,Infections and Opportunistic Infections,0
ADCETRIS,PML,rio us Infections and,1
ADCETRIS,PML,,0
ADCETRIS,PML,and Precautions Tumor Lysis ndr ome see Warnings,1
ADCETRIS,PML,ndr ome see Warnings,1
ADCETRIS,PML,,0
ADCETRIS,PML,ndr ome see Warnings,1
ADCETRIS,PML,Warnings and Precautions,0
ADCETRIS,PML,ndr ome see Warnings,1
ADCETRIS,death,see   Warnings and Precautions,1
ADCETRIS,death,see   Warnings and Precautions,1
ADCETRIS,death,Tumor Lysis see   Warnings and Precautions,1
ADCETRIS,death,Precautions Tumor Lysis see   Warnings and Precautions,1
ADCETRIS,death,see   Warnings and Precautions,1
ADCETRIS,death,and Precautions Tumor Lysis,0
ADCETRIS,Peripheral neuropathy,,0
ADCETRIS,Peripheral neuropathy,e reactions are discu ssed in greater detail,1
ADCETRIS,Peripheral neuropathy,e reactions are discu ssed in greater,1
ADCETRIS,Peripheral neuropathy,,0
ADCETRIS,Peripheral neuropathy,e reactions are discu ssed in greater detail,1
ADCETRIS,Peripheral neuropathy,,0
ADCETRIS,Peripheral neuropathy,e reactions are discu ssed in greater,1
ADCETRIS,Peripheral neuropathy,detail in,0
ADCETRIS,Peripheral neuropathy,discu ssed,1
ADCETRIS,Peripheral neuropathy,,0
ADCETRIS,infusion reactions,Precautio,1
ADCETRIS,infusion reactions,Peripheral Neuropathy see Warn,0
ADCETRIS,infusion reactions,Neuropathy see Warn,0
ADCETRIS,infusion reactions,ings and,1
ADCETRIS,infusion reactions,Neuropathy see ings,1
ADCETRIS,infusion reactions,Anaphylaxis and Infusion Reactions,0
ADCETRIS,infusion reactions,the prescribing information Peripheral Neuropathy see Warn,0
ADCETRIS,infusion reactions,Precautio,1
ADCETRIS,Hematologic toxicities,Hematologic T,0
ADCETRIS,Hematologic toxicities,Hematologic oxicities,1
ADCETRIS,Hematologic toxicities,Precautions,0
ADCETRIS,Hematologic toxicities,Warnin,1
ADCETRIS,infections,see,0
ADCETRIS,infections,,0
ADCETRIS,infections,Syndrome see Warnings,0
ADCETRIS,infections,,0
ADCETRIS,infections,in,0
ADCETRIS,infections,Toxicity in the esence of ,1
ADCETRIS,infections,and Precautions,0
ADCETRIS,infections,esence,1
ADCETRIS,infections,Warnings and Precautions Increased Toxicity,0
ADCETRIS,opportunistic infections,e Renal Impairment [see ,1
ADCETRIS,opportunistic infections,and Precautions Increased Toxicity in,0
ADCETRIS,opportunistic infections,Toxicity in the Presence of,0
ADCETRIS,opportunistic infections,the Presence of e Renal Impairment [see ,1
ADCETRIS,opportunistic infections,Increased Toxicity in the Presence,0
ADCETRIS,opportunistic infections,,0
ADCETRIS,opportunistic infections,Moderate,0
ADCETRIS,opportunistic infections,Presence,0
ADCETRIS,Tumor lysis syndrome,Severe Hepatic,1
ADCETRIS,Tumor lysis syndrome,Severe Hepatic Impai,1
ADCETRIS,Tumor lysis syndrome,of Moderate Severe Hepatic Impai,1
ADCETRIS,Tumor lysis syndrome,of Moderate Severe,1
ADCETRIS,Tumor lysis syndrome,Moderate Severe Hepatic Impai,1
ADCETRIS,Tumor lysis syndrome,of Moderate or,0
ADCETRIS,Tumor lysis syndrome,of Moderate Severe Hepatic Impai,1
ADCETRIS,Tumor lysis syndrome,rment see Warnings and Precautions Hepatotoxicity see Warnings,0
ADCETRIS,Tumor lysis syndrome,the Presence of,0
ADCETRIS,Hepatotoxicity,Warnings and,0
ADCETRIS,Hepatotoxicity,,0
ADCETRIS,Hepatotoxicity,Precautions Hepatotoxicity see,0
ADCETRIS,Hepatotoxicity,see Warnings Precautions ( ,1
ADCETRIS,Hepatotoxicity,and Precautions,0
ADCETRIS,Hepatotoxicity,and,0
ADCETRIS,Hepatotoxicity,Leukoencephalopathy see Warnings,0
ADCETRIS,Hepatotoxicity,Precautions Hepatotoxicity see Warnings Precautions ( ,1
ADCETRIS,Hepatotoxicity,Precautions (,1
ADCETRIS,Hepatotoxicity,Warnings Precautions ( ,1
ADCETRIS,Pulmonary Toxicity,Precautions,0
ADCETRIS,Pulmonary Toxicity,Progressive Multifocal cephalopathy,1
ADCETRIS,Pulmonary Toxicity,Precautions Progressive,0
ADCETRIS,Pulmonary Toxicity,and Precautions Progressive Multifocal cephalopathy,1
ADCETRIS,Pulmonary Toxicity,cephalopathy [see,1
ADCETRIS,Pulmonary Toxicity,,0
ADCETRIS,dermatologic reactions,Precautions Pulmonary Toxicity se,0
ADCETRIS,dermatologic reactions,and Precau,1
ADCETRIS,dermatologic reactions,e Warnings and Precau,1
ADCETRIS,dermatologic reactions,se,0
ADCETRIS,dermatologic reactions,se,0
ADCETRIS,dermatologic reactions,e  Warnings and Precau,1
ADCETRIS,dermatologic reactions,Serious Dermatologic Reactions,0
ADCETRIS,dermatologic reactions,,0
ADCETRIS,Embryo-fetal toxicity,neutr,0
ADCETRIS,Embryo-fetal toxicity,e most common adverse reactions were Relapsed classical HL and,0
ADCETRIS,Embryo-fetal toxicity,"and  
      EXCERPT:   Th",1
ADCETRIS,Fetal harm,,0
ADCETRIS,peripheral neuropathy,and relapsed sALCL neutropenia,0
ADCETRIS,peripheral motor neuropathy,"bocytopenia, cough, and",1
ADCETRIS,peripheral motor neuropathy,"bocytopenia, cough, and vom",1
ADCETRIS,peripheral motor neuropathy,nausea anemia upper respiratory tract,0
ADCETRIS,peripheral motor neuropathy,consolidation neutropenia,0
ADCETRIS,peripheral motor neuropathy,"pyrexia rash bocytopenia, cough, and",1
ADCETRIS,peripheral motor neuropathy,consolidation neutropenia,0
ADCETRIS,peripheral motor neuropathy,postautoHSCT consolidation neutropenia peripheral sensory,0
ADCETRIS,peripheral motor neuropathy,"infection diarrhea pyrexia rash bocytopenia,",1
ADCETRIS,peripheral neuropathy,peripheral sensory neuropathy thrombocytopenia anemia upper,0
ADCETRIS,neuropathy, periphera,1
ADCETRIS,neuropathy,fatigue,0
ADCETRIS,neuropathy,infection fatigue,0
ADCETRIS,neuropathy,,0
ADCETRIS,residual neuropathy,FDA at 1-800-FDA-10,1
ADCETRIS,residual neuropathy,at 1-800-FDA-10,1
ADCETRIS,residual neuropathy,Inc at FDA at 1-800-FDA-10,1
ADCETRIS,residual neuropathy,,0
ADCETRIS,residual neuropathy,at 1-800-FDA-10,1
ADCETRIS,residual neuropathy,Genetics Inc at FDA at,1
ADCETRIS,Infusion-related reactions,,0
ADCETRIS,Infusion-related reactions,large cell lymphoma (,1
ADCETRIS,Infusion-related reactions,,0
ADCETRIS,Infusion-related reactions,sALCL including patients in two uncontrolled singlearm trials Studies and and patie,0
ADCETRIS,Infusion-related reactions,,0
ADCETRIS,Infusion-related reactions,patients in two uncontrolled,0
ADCETRIS,Infusion-related reactions,HL and systemic stic large cell lymphoma,1
ADCETRIS,Infusion-related reactions,,0
ADCETRIS,anaphylaxis,,0
ADCETRIS,anaphylaxis,trials Studies and and,0
ADCETRIS,anaphylaxis,incl,0
ADCETRIS,anaphylaxis,large cell lymphoma sALCL uding 160 p,1
ADCETRIS,anaphylaxis,large cell lymphoma sALCL uding,1
ADCETRIS,thrombocytopenia,"shown in Table In 3, the",1
ADCETRIS,anemia,advers,1
ADCETRIS,Febrile neutropenia, ADCETRIS-treatment,1
ADCETRIS,Febrile neutropenia, ADCETRIS-treatment,1
ADCETRIS,Febrile neutropenia,most common adverse reactions in the,0
ADCETRIS,Febrile neutropenia, ADCETRIS-treatment,1
ADCETRIS,Febrile neutropenia, ADCETRIS-treatment,1
ADCETRIS,Febrile neutropenia,,0
ADCETRIS,Febrile neutropenia,shown in Table In Study the most common adverse reactions,0
ADCETRIS,infections,patients with lassical,1
ADCETRIS,opportunistic infections,Study ADCETRIS was studied,0
ADCETRIS,opportunistic infections,studied in,0
ADCETRIS,opportunistic infections,single arm clinical tr,1
ADCETRIS,pneumonia,starting dose,0
ADCETRIS,pneumonia,in,0
ADCETRIS,pneumonia,arm clinical trial in ich the r,1
ADCETRIS,pneumonia,ich the r,1
ADCETRIS,pneumonia,,0
ADCETRIS,pneumonia,was mgkg intravenously every,0
ADCETRIS,bacteremia,in patients with classical,0
ADCETRIS,bacteremia,single arm clinical,0
ADCETRIS,bacteremia,s,1
ADCETRIS,bacteremia,in patients with classical HL in a single arm clinical trial in which the,0
ADCETRIS,bacteremia,ommended s,1
ADCETRIS,bacteremia,which the ommended s,1
ADCETRIS,bacteremia,classical HL in a single arm clinical trial in,0
ADCETRIS,bacteremia,in which the ommended s,1
ADCETRIS,bacteremia,studied in patients,0
ADCETRIS,sepsis,clinical trial,0
ADCETRIS,sepsis,recommended g,1
ADCETRIS,sepsis,dose,1
ADCETRIS,sepsis,recommended g dose,1
ADCETRIS,septic shock,the recommended starting dose  schedule wa,1
ADCETRIS,septic shock,mgkg intravenously every weeks Median duration of,0
ADCETRIS,septic shock,clinical trial in,0
ADCETRIS,septic shock,the recommended starting dose  schedule wa,1
ADCETRIS,septic shock,wa,1
ADCETRIS,septic shock, schedule wa,1
ADCETRIS,fatal,intra,1
ADCETRIS,fatal,every weeks Median duration of treatment was cycles range,0
ADCETRIS,fatal,intra,1
ADCETRIS,tumor lysis syndrome,and vomiting Summary,0
ADCETRIS,tumor lysis syndrome,diarrhea,0
ADCETRIS,tumor lysis syndrome,"emia, pyrexia, throm",1
ADCETRIS,tumor lysis syndrome,peripheral sensory neuropathy fatigue upper respiratory tract infection nausea,0
ADCETRIS,tumor lysis syndrome,Clinical Trial,0
ADCETRIS,tumor lysis syndrome,"emia,",1
ADCETRIS,tumor lysis syndrome,"diarrhea emia, pyrexia,",1
ADCETRIS,deaths,the ADCETRIStreatment arm received cycles,0
ADCETRIS,deaths,in the ADCETRIStreatment,0
ADCETRIS,deaths,  [see,1
ADCETRIS,deaths,  [see,1
ADCETRIS,deaths,  [see,1
ADCETRIS,hepatotoxicity,"(range, 0-20",1
ADCETRIS,hepatotoxicity,"s (range, 0-20",1
ADCETRIS,hepatotoxicity,"a median duration of s (range,",1
ADCETRIS,fatal,months range and tient,1
ADCETRIS,fatal,tient,1
ADCETRIS,fatal,tient,1
ADCETRIS,fatal,tient,1
ADCETRIS,fatal,VZV prophylaxis with,0
ADCETRIS,fatal,and,0
ADCETRIS,fatal,pa,0
ADCETRIS,fatal,received PCP,0
ADCETRIS,fatal,tient,1
ADCETRIS,hepatocellular injury,in,1
ADCETRIS,hepatocellular injury,Large Cell Lymphoma Summary of Clinical,0
ADCETRIS,hepatocellular injury,"



   Experience in ",1
ADCETRIS,hepatocellular injury,duration of months Experience,1
ADCETRIS,hepatocellular injury,received PCP prophylaxis with a median,0
ADCETRIS,hepatocellular injury,median duration of months,0
ADCETRIS,hepatocellular injury,a median duration of months range,0
ADCETRIS,hepatocellular injury,Experience in,1
ADCETRIS,hepatocellular injury,Trial Experience in,0
ADCETRIS,elevations of transaminases,in Systemic plastic Large Cell Lymphoma,1
ADCETRIS,elevations of transaminases,plastic Large,1
ADCETRIS,elevations of transaminases,Systemic plastic Large,1
ADCETRIS,elevations of transaminases,Lymphoma,1
ADCETRIS,elevations of transaminases,Experience in Relapsed sALCL Study ADCETRIS was stu,0
ADCETRIS,elevations of transaminases,prophylaxis with a,0
ADCETRIS,elevations of transaminases,of,0
ADCETRIS,elevations of transaminases,Large Cell Lymphoma,1
ADCETRIS,elevations of transaminases,Study ADCETRIS was stu,0
ADCETRIS,JC virus infection,Commonl,0
ADCETRIS,JC virus infection,"anemia, peripher",1
ADCETRIS,PML,Most Commonly,0
ADCETRIS,PML,neutropenia anemia peripheral sensory rop,1
ADCETRIS,PML,rop,1
ADCETRIS,PML,,0
ADCETRIS,PML,pain Table Most Commonly Reported,0
ADCETRIS,PML,rop,1
ADCETRIS,PML,neutropenia anemia peripheral sensory rop,1
ADCETRIS,PML,,0
ADCETRIS,death,anemia peripheral sensory  fati,1
ADCETRIS,death,anemia peripheral sensory  fati,1
ADCETRIS,death,neuropathy,0
ADCETRIS,death,,0
ADCETRIS,death, fati,1
ADCETRIS,noninfectious pulmonary toxicity,"           
     Anemia         ",1
ADCETRIS,noninfectious pulmonary toxicity,Neutropenia,0
ADCETRIS,noninfectious pulmonary toxicity,"Neutropenia            
     Anemia         ",1
ADCETRIS,noninfectious pulmonary toxicity,"Neutropenia            
     Anemia         ",1
ADCETRIS,noninfectious pulmonary toxicity,,0
ADCETRIS,noninfectious pulmonary toxicity,,0
ADCETRIS,noninfectious pulmonary toxicity,,0
ADCETRIS,noninfectious pulmonary toxicity,"           
     Anemia         ",1
ADCETRIS,noninfectious pulmonary toxicity,"           
     Anemia         ",1
ADCETRIS,noninfectious pulmonary toxicity,"           
     Anemia         ",1
ADCETRIS,pneumonitis,            Thrombocytopenia,1
ADCETRIS,pneumonitis,            Thrombocytopenia,1
ADCETRIS,pneumonitis,Thrombocytopenia,0
ADCETRIS,pneumonitis,Thrombocytopenia,0
ADCETRIS,interstitial lung disease,8 Thrombocytopenia,1
ADCETRIS,interstitial lung disease,Anemia,0
ADCETRIS,interstitial lung disease,Anemia 33,1
ADCETRIS,interstitial lung disease,,0
ADCETRIS,interstitial lung disease,Anemia,0
ADCETRIS,interstitial lung disease,Anemia      33         8         Thrombocytopenia,1
ADCETRIS,interstitial lung disease,Anemia 33,1
ADCETRIS,acute respiratory distress syndrome,,0
ADCETRIS,ARDS,     Thrombocytopenia,1
ADCETRIS,fatal,Thrombo,0
ADCETRIS,fatal,Thrombo,0
ADCETRIS,fatal,cytop enia,1
ADCETRIS,fatal,enia,0
ADCETRIS,fatal,,0
ADCETRIS,fatal,cytop enia,1
ADCETRIS,fatal,enia,0
ADCETRIS,fatal,Thrombo,0
ADCETRIS,Stevens-Johnson syndrome,                        ,1
ADCETRIS,Stevens-Johnson syndrome,                        ,1
ADCETRIS,Stevens-Johnson syndrome,                        ,1
ADCETRIS,Stevens-Johnson syndrome,                        ,1
ADCETRIS,Stevens-Johnson syndrome,neuropathy,0
ADCETRIS,Stevens-Johnson syndrome,                        ,1
ADCETRIS,Stevens-Johnson syndrome,neuropathy,0
ADCETRIS,Stevens-Johnson syndrome,                        ,1
ADCETRIS,Stevens-Johnson syndrome,                        ,1
ADCETRIS,Stevens-Johnson syndrome,                        ,1
ADCETRIS,SJS,   ,1
ADCETRIS,SJS,,0
ADCETRIS,SJS,,0
ADCETRIS,SJS,Peripheral sensory,0
ADCETRIS,toxic epidermal necrolysis,rders Peripheral sensory neuropa,1
ADCETRIS,toxic epidermal necrolysis,neuropa thy Periphera,1
ADCETRIS,toxic epidermal necrolysis,rders,0
ADCETRIS,toxic epidermal necrolysis,Peripheral sensory neuropa thy,1
ADCETRIS,toxic epidermal necrolysis,neuropa thy,1
ADCETRIS,toxic epidermal necrolysis,rders Peripheral sensory,1
ADCETRIS,toxic epidermal necrolysis,rders Peripheral sensory neuropa thy,1
ADCETRIS,TEN,y   Peripheral,1
ADCETRIS,TEN,y   Peripheral,1
ADCETRIS,TEN,sensory neuropath,0
ADCETRIS,TEN,Peripheral mot,0
ADCETRIS,TEN,y   Peripheral,1
ADCETRIS,TEN,,0
ADCETRIS,TEN,y   Peripheral,1
ADCETRIS,TEN,y   Peripheral,1
ADCETRIS,fatal,Peripheral,0
ADCETRIS,fetal harm,Dizziness,0
ADCETRIS,fetal harm,      11   General disorders and,1
ADCETRIS,fetal harm,Dizziness       11   General,1
ADCETRIS,fetal harm,Dizziness,0
ADCETRIS,fetal harm,,0
ADCETRIS,fetal harm,Dizziness       11   General disorders,1
ADCETRIS,fetal harm,Dizziness       11   General disorders and administrat,1
ADCETRIS,fetal harm,Dizziness,0
ADCETRIS,fetal harm,,0
ADCETRIS,embryo-fetal toxicities,,0
ADCETRIS,embryo-fetal toxicities,General,1
ADCETRIS,embryo-fetal toxicities,General disorders and a dministration site,1
ADCETRIS,embryo-fetal toxicities,,0
ADCETRIS,embryo-fetal toxicities,General,1
ADCETRIS,embryo-fetal toxicities,,0
ADCETRIS,decreased embryo viability,ons                        Fatigue,1
ADCETRIS,decreased embryo viability,,0
ADCETRIS,decreased embryo viability,Fatigue,0
ADCETRIS,decreased embryo viability,ons                        Fatigue,1
ADCETRIS,decreased embryo viability,,0
ADCETRIS,fetal malformations,,0
ZERBAXA,Hypersensitivity reactions,and Precautions Hypersensitivity,1
ZERBAXA,Hypersensitivity reactions,Hypersensitivity reactions,1
ZERBAXA,Hypersensitivity reactions,reactions,1
ZERBAXA,Hypersensitivity reactions,Hypersensitivity,1
ZERBAXA,Hypersensitivity reactions,,0
ZERBAXA,Hypersensitivity reactions,the Warnings and Precautions Hypersensitivity reactions,1
ZERBAXA,Clostridium difficile -associated diarrhea,Warnings and Clostridium difficile -associated diarrhea,1
ZERBAXA,Clostridium difficile -associated diarrhea,Clostridium difficile -associated diarrhea,1
ZERBAXA,Clostridium difficile -associated diarrhea,see Warnings and Clostridium difficile -associated diarrhea,1
ZERBAXA,Clostridium difficile -associated diarrhea,EXCERPT The most common adverse,0
ZERBAXA,Clostridium difficile -associated diarrhea,common,0
ZERBAXA,nausea,ADVERSE REACTIONS contact,0
ZERBAXA,nausea,nausea,1
ZERBAXA,nausea,either indication nausea,1
ZERBAXA,diarrhea,diarrhea,1
ZERBAXA,diarrhea,diarrhea,1
ZERBAXA,diarrhea,diarrhea,1
ZERBAXA,diarrhea,,0
ZERBAXA,diarrhea,indication are nausea,0
ZERBAXA,diarrhea,contact Merck Sharp,0
ZERBAXA,diarrhea,SUSPECTED ADVERSE,0
ZERBAXA,diarrhea,indication,0
ZERBAXA,headache,The most common adverse reactions in either indication are nausea,0
ZERBAXA,headache,,0
ZERBAXA,headache,headache,1
ZERBAXA,headache,headache,1
ZERBAXA,headache,,0
ZERBAXA,headache,most common adverse reactions in,0
ZERBAXA,headache,report SUSPECTED,0
ZERBAXA,headache,headache,1
ZERBAXA,headache,headache,1
ZERBAXA,pyrexia,Sharp Dohme Corp a,0
ZERBAXA,nausea,nausea,1
ZERBAXA,nausea,nausea,1
ZERBAXA,nausea,nausea,1
ZERBAXA,nausea,nausea,1
ZERBAXA,nausea,receiving ZERBAXA nausea,1
ZERBAXA,diarrhea,diarrhea,1
ZERBAXA,diarrhea,diarrhea,1
ZERBAXA,diarrhea,in patients receiving ZERBAXA were nausea,0
ZERBAXA,diarrhea,diarrhea,1
ZERBAXA,diarrhea,,0
ZERBAXA,diarrhea,,0
ZERBAXA,diarrhea,patients receiving ZERBAXA were diarrhea,1
ZERBAXA,diarrhea,ZERBAXA were nausea,0
ZERBAXA,diarrhea,reactions occurring,0
ZERBAXA,headache,headache,1
ZERBAXA,headache,occurring,0
ZERBAXA,headache,ZERBAXA were nausea headache,1
ZERBAXA,headache,headache,1
ZERBAXA,headache,headache,1
ZERBAXA,headache,ZERBAXA were nausea headache,1
ZERBAXA,pyrexia,pyrexia,1
ZERBAXA,pyrexia,pyrexia,1
ZERBAXA,pyrexia,were nausea diarrhea,0
ZERBAXA,pyrexia,ZERBAXA were,0
ZERBAXA,pyrexia,,0
ZERBAXA,pyrexia,headache pyrexia,1
ZERBAXA,Nausea,,0
ZERBAXA,Nausea,MeropenemN ZERBAXAN Nausea,1
ZERBAXA,Nausea,Nausea,1
ZERBAXA,Nausea,ZERBAXAN MeropenemN ZERBAXAN,0
ZERBAXA,Nausea,Nausea,1
ZERBAXA,Nausea,ZERBAXAN MeropenemN ZERBAXAN LevofloxacinN,0
ZERBAXA,Nausea,,0
ZERBAXA,Headache,,0
ZERBAXA,Headache,,0
ZERBAXA,Pyrexia,Pyrexia,1
ZERBAXA,Pyrexia,,0
ZERBAXA,Pyrexia,,0
ZERBAXA,Pyrexia,Pyrexia,1
ZERBAXA,Pyrexia,,0
ZERBAXA,Constipation,,0
ZERBAXA,Constipation,,0
ZERBAXA,Constipation,Constipation,1
ZERBAXA,Constipation,Constipation,1
ZERBAXA,Constipation,Constipation,1
ZERBAXA,Constipation,Constipation,1
ZERBAXA,Insomnia,,0
ZERBAXA,Insomnia,,0
ZERBAXA,Insomnia,Insomnia,1
ZERBAXA,Insomnia,Insomnia,1
ZERBAXA,Insomnia,Insomnia,1
ZERBAXA,Insomnia,Insomnia,1
ZERBAXA,Insomnia,Insomnia,1
ZERBAXA,Insomnia,Insomnia,1
ZERBAXA,Vomiting,,0
ZERBAXA,Hypokalemia,Hypokalemia,1
ZERBAXA,Hypokalemia,Hypokalemia,1
ZERBAXA,Hypokalemia,Hypokalemia,1
ZERBAXA,Hypokalemia,,0
ZERBAXA,Anemia,Anemia,1
ZERBAXA,Anemia,Anemia,1
ZERBAXA,Anemia,,0
ZERBAXA,Anemia,Anemia,1
ZERBAXA,Thrombocytosis,,0
ZERBAXA,Thrombocytosis,,0
ZERBAXA,Thrombocytosis,Thrombocytosis A,1
ZERBAXA,Thrombocytosis,,0
ZERBAXA,Thrombocytosis,Thrombocytosis A,1
ZERBAXA,Thrombocytosis,Thrombocytosis A,1
ZERBAXA,Thrombocytosis,Thrombocytosis A,1
ZERBAXA,Abdominal pain,s,0
ZERBAXA,Abdominal pain,,0
ZERBAXA,Anxiety,,0
ZERBAXA,Hypotension,Hypotension,1
ZERBAXA,Hypotension,Hypotension,1
ZERBAXA,Hypotension,Hypotension,1
ZERBAXA,Hypotension,,0
ZERBAXA,Hypotension,Hypotension,1
ZERBAXA,Hypotension,,0
ZERBAXA,Atrial fibrillation,,0
ZERBAXA,Atrial fibrillation,,0
ZERBAXA,Atrial fibrillation,,0
ZERBAXA,Rash,lation,0
ZERBAXA,Rash,Rash,1
ZERBAXA,Rash,lation,0
ZERBAXA,Rash,,0
ZERBAXA,Rash,,0
ZERBAXA,Rash,Rash,1
ZERBAXA,Rash,Rash,1
ZERBAXA,Rash,Rash,1
ZERBAXA,renal impairment,impairment including the renal impairment,1
ZERBAXA,renal failure,,0
ZERBAXA,renal failure,including the terms,0
ZERBAXA,renal failure,of,0
ZERBAXA,renal failure,terms renal impairment,0
ZERBAXA,renal failure,impairment including the terms renal,0
ZERBAXA,renal failure,to discontinuation of treatment in,0
ZERBAXA,renal failure,renal,1
ZERBAXA,renal failure acute,renal failure renal failure acute,1
ZERBAXA,death,ZERBAXA and in,0
ZERBAXA,death,in,0
ZERBAXA,death,death,1
ZERBAXA,death,,0
ZERBAXA,death,,0
ZERBAXA,death,and in of patients receiving m,0
ZERBAXA,death,The causes death,1
ZERBAXA,complications of infection,Common,0
ZERBAXA,complications of infection,complications of infection,1
ZERBAXA,complications of infection,,0
ZERBAXA,complications of infection,,0
ZERBAXA,tachycardia,than Cardiac tachycardia,1
ZERBAXA,tachycardia,subjects at a rate of less,0
ZERBAXA,tachycardia,ZERBAXAtreated subjects at a,0
ZERBAXA,tachycardia,at a,0
ZERBAXA,tachycardia,tachycardia,1
ZERBAXA,tachycardia,pectoris Gastrointestinal disorders ileus gastritis abdominal,0
ZERBAXA,tachycardia,tachycardia,1
ZERBAXA,angina pectoris,than Cardiac disorders angina pectoris,1
ZERBAXA,angina pectoris,subjects at a rate of less than Cardiac,0
ZERBAXA,angina pectoris,disorders ileus gastritis abdominal,0
ZERBAXA,angina pectoris,less than Cardiac disorders angina,1
ZERBAXA,angina pectoris,distension dyspepsia,0
ZERBAXA,angina pectoris,angina pectoris,1
ZERBAXA,angina pectoris,Gastrointestinal disorders,0
ZERBAXA,angina pectoris,,0
ZERBAXA,ileus,tachycardia angina pectoris Gastrointestinal disorders,0
ZERBAXA,gastritis,dyspepsia flatulence ileus paralytic,0
ZERBAXA,gastritis,abdominal distension dyspepsia flatulence ileus paralytic General disorders and admini,0
ZERBAXA,gastritis,,0
ZERBAXA,gastritis,ileus paralytic General disorders and admini,0
ZERBAXA,dyspepsia,,0
ZERBAXA,dyspepsia,dyspepsia,1
ZERBAXA,dyspepsia,administration site conditions,0
ZERBAXA,dyspepsia,dyspepsia,1
ZERBAXA,dyspepsia,ileus gastritis abdominal,0
ZERBAXA,flatulence,flatulence,1
ZERBAXA,flatulence,gastritis,0
ZERBAXA,flatulence,gastritis abdominal distension flatulence,1
ZERBAXA,flatulence,flatulence,1
ZERBAXA,flatulence,abdominal,0
ZERBAXA,flatulence,General disorders and administration,0
ZERBAXA,flatulence,distension,0
ZERBAXA,flatulence,flatulence,1
ZERBAXA,ileus paralytic,gastritis abdominal distension dyspepsia ileus paralytic,1
ZERBAXA,infusion site reactions,site infusion site reactions,1
ZERBAXA,infusion site reactions,administration site infusion,1
ZERBAXA,infusion site reactions,ileus paralytic General disorders and administration,0
ZERBAXA,infusion site reactions,conditions,0
ZERBAXA,infusion site reactions,,0
ZERBAXA,infusion site reactions,and administration site infusion site reactions,1
ZERBAXA,infusion site reactions,fungal urinary tract infection,0
ZERBAXA,candidiasis,urinary,0
ZERBAXA,candidiasis,candidiasis,1
ZERBAXA,fungal urinary tract infection,serum gammaglutamyl transpeptidase GGT increased,0
ZERBAXA,fungal urinary tract infection,infection,1
ZERBAXA,increased serum gamma-glutamyl transpeptidase,fungal urinary tract infection increased serum gamma-glutamyl transpeptidase,1
ZERBAXA,increased serum gamma-glutamyl transpeptidase,fungal urinary tract infection increased serum gamma-glutamyl transpeptidase,1
ZERBAXA,increased serum alkaline phosphatase,increased serum gammaglutamyl transpeptidase increased serum,1
ZERBAXA,increased serum alkaline phosphatase,serum gammaglutamyl transpeptidase,0
ZERBAXA,increased serum alkaline phosphatase,gammaglutamyl,0
ZERBAXA,increased serum alkaline phosphatase,phosphatase,1
ZERBAXA,increased serum alkaline phosphatase,gammaglutamyl,0
ZERBAXA,increased serum alkaline phosphatase,gammaglutamyl transpeptidase increased serum,1
ZERBAXA,increased serum alkaline phosphatase,,0
ZERBAXA,increased serum alkaline phosphatase,Investigations increased serum gammaglutamyl transpeptidase GGT,0
ZERBAXA,positive Coombs test,GGT increased serum alkaline,0
ZERBAXA,positive Coombs test,test,1
ZERBAXA,positive Coombs test,hypomagnesemia hypophosphatemia,0
ZERBAXA,positive Coombs test,alkaline positive Coombs test,1
ZERBAXA,positive Coombs test,gammaglutamyl,0
ZERBAXA,positive Coombs test,GGT increased serum alkaline positive Coombs test,1
ZERBAXA,positive Coombs test,positive Coombs test,1
ZERBAXA,positive Coombs test,alkaline positive Coombs,1
ZERBAXA,positive Coombs test,,0
ZERBAXA,hyperglycemia,disorders ischemic stroke Renal,0
ZERBAXA,hyperglycemia,nutrition hyperglycemia,1
ZERBAXA,hyperglycemia,hyperglycemia,1
ZERBAXA,hypomagnesemia,hyperglycemia,0
ZERBAXA,hypomagnesemia,system disorders ischemic stroke,0
ZERBAXA,hypomagnesemia,hypomagnesemia,1
ZERBAXA,hypomagnesemia,hypomagnesemia,1
ZERBAXA,hypomagnesemia,disorders hypomagnesemia,1
ZERBAXA,hypomagnesemia,disorders hypomagnesemia,1
ZERBAXA,hypomagnesemia,disorders hyperglycemia,0
ZERBAXA,hypophosphatemia,,0
ZERBAXA,hypophosphatemia,hypophosphatemia,1
ZERBAXA,hypophosphatemia,hypophosphatemia,1
ZERBAXA,hypophosphatemia,and,0
ZERBAXA,hypophosphatemia,test Metabolism and nutrition disorders hyperglycemia,0
ZERBAXA,hypophosphatemia,hypophosphatemia,1
ZERBAXA,ischemic stroke,ischemic,1
ZERBAXA,ischemic stroke,renal failure,0
ZERBAXA,ischemic stroke,,0
ZERBAXA,ischemic stroke,stroke,1
ZERBAXA,ischemic stroke,and urinary system renal impairment renal failure,0
ZERBAXA,ischemic stroke,Nervous,0
ZERBAXA,renal impairment,impairment,1
ZERBAXA,renal impairment,urinary renal,1
ZERBAXA,renal failure,system renal renal failure,1
ZERBAXA,renal failure,urinary system renal renal,1
ZERBAXA,renal failure,renal renal,1
ZERBAXA,renal failure,Respiratory,0
ZERBAXA,renal failure,renal renal,1
ZERBAXA,renal failure,renal failure,1
ZERBAXA,renal failure,renal failure,1
ZERBAXA,renal failure,,0
ZERBAXA,renal failure,and urinary system renal renal failure,1
ZERBAXA,dyspnea,dyspnea,1
ZERBAXA,dyspnea,system renal impairment renal failure Respiratory thoracic and,0
ZERBAXA,dyspnea,renal impairment renal failure,0
ZERBAXA,dyspnea,dyspnea,1
ZERBAXA,urticaria,disorders,0
ZERBAXA,urticaria,urticaria,1
ZERBAXA,urticaria,tissue urticaria,1
ZERBAXA,urticaria,,0
ZERBAXA,urticaria,mediastinal,0
ZERBAXA,urticaria,tissue urticaria,1
ZERBAXA,urticaria,disorders dyspnea,0
ZERBAXA,urticaria,and subcutaneous tissue urticaria,1
ZERBAXA,venous thrombosis,Vascular venous thrombosis,1
ZERBAXA,venous thrombosis,thrombosis,1
ZERBAXA,venous thrombosis,venous thrombosis,1
ZERBAXA,venous thrombosis,tissue disorders urticaria Vascular venous thrombosis,1
ZERBAXA,venous thrombosis,subcutaneous tissue disorders urticaria,0
ZERBAXA,venous thrombosis,,0
ZERBAXA,venous thrombosis,thrombosis,1
ZERBAXA,venous thrombosis,urticaria Vascular venous thrombosis,1
ZERBAXA,venous thrombosis,,0
ZERBAXA,venous thrombosis,thrombosis,1
ZERBAXA,Clostridium difficile -associated diarrhea,"Corp., a su",1
ZERBAXA,Clostridium difficile -associated diarrhea,"SUSPECTED ADVERSE S, contact Merck Sharp & Dohme Corp., a su",1
ZERBAXA,Clostridium difficile -associated diarrhea,Co Inc at or FDA at FDA or wwwfdagovmedwatch,0
ZERBAXA,Clostridium difficile -associated diarrhea,ADVERSE REACTION,0
ZERBAXA,Clostridium difficile -associated diarrhea,"SUSPECTED ADVERSE S, contact Merck Sharp & Dohme Corp., a",1
ZERBAXA,Clostridium difficile -associated diarrhea,at,0
ZERBAXA,CDAD,idia,1
ZERBAXA,CDAD,Corp a idia,1
ZERBAXA,CDAD,idia,1
ZERBAXA,fatal,ZERBAXA in Phase clinical trials Table Adverse,0
ZERBAXA,fatal,were nausea diarrhea headache,0
ZERBAXA,fatal,adverse reactions g in ,1
ZERBAXA,Clostridium difficile -associated diarrhea,,0
ZERBAXA,Clostridium difficile -associated diarrhea,Headache,0
ZERBAXA,Clostridium difficile -associated diarrhea,Diarrhea Pyrexia,1
ZERBAXA,Clostridium difficile -associated diarrhea,"Headache (4.9)         
 Diarrhea                    Pyrexia",1
ZERBAXA,Clostridium difficile -associated diarrhea,"Headache (4.9)         
 Diarrhea                    Pyrexia",1
ZERBAXA,Clostridium difficile -associated diarrhea,Headache (4.9),1
ZERBAXA,Clostridium difficile -associated diarrhea,Headache,0
ZERBAXA,CDAD,Diarrhea 0 (6 Pyrexia,1
ZERBAXA,CDAD,,0
ZERBAXA,CDAD,Diarrhea,0
ZERBAXA,CDAD,Diarrhea,0
ZERBAXA,CDAD,Diarrhea,0
ZERBAXA,CDAD,,0
ZERBAXA,CDAD,Diarrhea,0
ZERBAXA,CDAD,Diarrhea 0,1
ZERBAXA,CDAD,Pyrexia,0
ZERBAXA,CDAD,Diarrhea 0,1
ZERBAXA,diarrhea,Pyrexia,0
ZERBAXA,diarrhea,Pyrexia,0
ZERBAXA,fatal,Pyrexia,0
ZERBAXA,fatal,,0
ZERBAXA,fatal, (4)  Constipation,1
ZERBAXA,colitis,Pyrexia,0
ZERBAXA,colitis,        Constipation,1
ZERBAXA,colitis,        Constipation,1
ZERBAXA,colitis,        Constipation,1
ZERBAXA,colitis,Pyrexia         Constipation,1
ZERBAXA,colitis,,0
ZERBAXA,colitis,        Constipation,1
ZERBAXA,colitis,        Constipation,1
ZERBAXA,colitis,Pyrexia         Constipation,1
ZERBAXA,colitis,        Constipation,1
ZYDELIG,Hepatotoxicity,,0
ZYDELIG,Diarrhea,Warnings and Precautions,0
ZYDELIG,Diarrhea,Precautions Diarrhea or,1
ZYDELIG,Diarrhea,or Colitis see,0
ZYDELIG,Diarrhea,Diarrhea or,1
ZYDELIG,Colitis,Precautions Severe Diarrhea or,0
ZYDELIG,Colitis,Colitis see,1
ZYDELIG,Colitis,and Precautions Severe Diarrhea Colitis see,1
ZYDELIG,Colitis,and Precautions Severe Diarrhea Colitis see,1
ZYDELIG,Colitis,Diarrhea Colitis see,1
ZYDELIG,Colitis,Severe Diarrhea Colitis see,1
ZYDELIG,Pneumonitis,see Warnings and Pneumonitis see,1
ZYDELIG,Intestinal Perforation,Warnings and Intestinal,1
ZYDELIG,Intestinal Perforation,Warnings and Intestinal Perforation see,1
ZYDELIG,Intestinal Perforation,,0
ZYDELIG,Intestinal Perforation,and Precautions Pneumonitis see Warnings,0
ZYDELIG,Intestinal Perforation,Intestinal Perforation see,1
ZYDELIG,Intestinal Perforation,Perforation see,1
ZYDELIG,Cutaneous Reactions,Warnings and Precautions Cutaneous,1
ZYDELIG,Cutaneous Reactions,and Precautions,0
ZYDELIG,Cutaneous Reactions,see Warnings and Precautions Cutaneous Reactions see,1
ZYDELIG,Cutaneous Reactions,Perforation see Warnings,0
ZYDELIG,Cutaneous Reactions,Cutaneous Reactions see,1
ZYDELIG,Neutropenia,Neutropenia see,1
ZYDELIG,Neutropenia,Neutropenia see,1
ZYDELIG,Neutropenia,Neutropenia see,1
ZYDELIG,Neutropenia,and Precautions Anaphylaxis see Warnings and,0
ZYDELIG,Neutropenia,Neutropenia see,1
ZYDELIG,Neutropenia,Neutropenia see,1
ZYDELIG,Neutropenia,see Warnings and Precautions EXCERPT The most,0
ZYDELIG,Neutropenia,see Warnings and Precautions EXCERPT The most common adverse reactions,0
ZYDELIG,Neutropenia,see Warnings and Neutropenia see,1
ZYDELIG,diarrhea,diarrhea pyrexia,1
ZYDELIG,diarrhea,,0
ZYDELIG,diarrhea,The most common adverse reactions incidence are,0
ZYDELIG,pyrexia,common,0
ZYDELIG,pyrexia,,0
ZYDELIG,pyrexia,incidence are pyrexia fatigue,1
ZYDELIG,pyrexia,pneumonia abdominal pain chills and rash The,0
ZYDELIG,pyrexia,pneumonia abdominal pain chills,0
ZYDELIG,pyrexia,pyrexia fatigue,1
ZYDELIG,pyrexia,and rash The most,0
ZYDELIG,fatigue,reactions incidence are diarrhea fatigue nausea,1
ZYDELIG,fatigue,fatigue nausea,1
ZYDELIG,fatigue,fatigue nausea,1
ZYDELIG,fatigue,fatigue nausea,1
ZYDELIG,fatigue,fatigue nausea,1
ZYDELIG,fatigue,fatigue nausea,1
ZYDELIG,fatigue,fatigue nausea,1
ZYDELIG,fatigue,nausea cough pneumonia abdominal pain chills,0
ZYDELIG,fatigue,fatigue nausea,1
ZYDELIG,fatigue,common adverse reactions incidence are,0
ZYDELIG,nausea,incidence are diarrhea pyrexia nausea cough,1
ZYDELIG,nausea,abdominal,0
ZYDELIG,nausea,pyrexia nausea cough,1
ZYDELIG,nausea,nausea cough,1
ZYDELIG,nausea,nausea cough,1
ZYDELIG,nausea,,0
ZYDELIG,nausea,pyrexia nausea cough,1
ZYDELIG,cough,diarrhea pyrexia fatigue,0
ZYDELIG,cough,The most common laboratory abnormalitie,0
ZYDELIG,cough,The most common,0
ZYDELIG,cough,cough pneumonia,1
ZYDELIG,pneumonia,,0
ZYDELIG,pneumonia,incidenc,0
ZYDELIG,pneumonia,pneumonia abdominal,1
ZYDELIG,pneumonia,diarrhea pyrexia fatigue nausea pneumonia abdominal,1
ZYDELIG,pneumonia,pneumonia abdominal,1
ZYDELIG,pneumonia,pneumonia abdominal,1
ZYDELIG,pneumonia,pyrexia fatigue nausea pneumonia abdominal,1
ZYDELIG,pneumonia,nausea pneumonia abdominal,1
ZYDELIG,pneumonia,pneumonia abdominal,1
ZYDELIG,abdominal pain,abdominal pain chills,1
ZYDELIG,rash,pneumonia abdominal pain chills rash The,1
ZYDELIG,rash,diarrhea pyrexia fatigue nausea cough pneumonia abdominal pain chills,0
ZYDELIG,rash,pain chills rash The,1
ZYDELIG,rash,rash The,1
ZYDELIG,rash,abdominal pain chills rash The,1
ZYDELIG,neutropenia,and AST elevations To,0
ZYDELIG,neutropenia,neutropenia hypertriglyceridemia,1
ZYDELIG,neutropenia,neutropenia hypertriglyceridemia,1
ZYDELIG,neutropenia,hypertriglyceridemia hyperglycemia ALT elevations,0
ZYDELIG,neutropenia,common laboratory abnormalities incidence neutropenia hypertriglyceridemia,1
ZYDELIG,hypertriglyceridemia,and AST elevations To report SUSPECTED,0
ZYDELIG,hypertriglyceridemia,are,0
ZYDELIG,hypertriglyceridemia,common,0
ZYDELIG,hyperglycemia,incidence are neutropenia hyperglycemia ALT,1
ZYDELIG,hyperglycemia,,0
ZYDELIG,hyperglycemia,elevations and AST elevations To report SUSPECTED ADVERSE,0
ZYDELIG,hyperglycemia,hyperglycemia ALT,1
ZYDELIG,hyperglycemia,most common laboratory abnormalities,0
ZYDELIG,hyperglycemia,are neutropenia hyperglycemia ALT,1
ZYDELIG,ALT elevations,,0
ZYDELIG,ALT elevations,elevations and,1
ZYDELIG,ALT elevations,hypertriglyceridemia ALT,1
ZYDELIG,ALT elevations,elevations and,1
ZYDELIG,ALT elevations,hypertriglyceridemia ALT elevations and,1
ZYDELIG,AST elevations,hypertriglyceridemia hyperglycemia ALT elevations AST,1
ZYDELIG,AST elevations,and,0
ZYDELIG,AST elevations,hypertriglyceridemia hyperglycemia ALT elevations and,0
ZYDELIG,AST elevations,AST elevations To,1
ZYDELIG,AST elevations,elevations To,1
ZYDELIG,AST elevations,REACTIONS contact Gilead Sciences,0
ZYDELIG,pneumonia,,0
ZYDELIG,pneumonia,diarrhea Adverse reactions tha,0
ZYDELIG,pneumonia,pneumonia pyrexia,1
ZYDELIG,pneumonia,,0
ZYDELIG,pyrexia,pyrexia sepsis,1
ZYDELIG,pyrexia,Adverse reactions that led to,0
ZYDELIG,pyrexia,Adverse,0
ZYDELIG,pyrexia,reactions reported for subjects treated with Zydelig,0
ZYDELIG,pyrexia,pyrexia sepsis,1
ZYDELIG,sepsis,,0
ZYDELIG,sepsis,,0
ZYDELIG,sepsis,Zydelig were pneumonia sepsis febrile,1
ZYDELIG,sepsis,diarrhea Adverse reactions that led to,0
ZYDELIG,sepsis,diarrhea Adverse reactions that led,0
ZYDELIG,sepsis,sepsis febrile,1
ZYDELIG,sepsis,reactions,0
ZYDELIG,febrile neutropenia,with Zydelig were pneumonia pyrexia sepsis,0
ZYDELIG,diarrhea,Zydelig were pneumonia pyrexia sepsis febrile,0
ZYDELIG,hepatotoxicity,hepatotoxicity and,1
ZYDELIG,hepatotoxicity,sixteen subjects,0
ZYDELIG,hepatotoxicity,to treatment discontinuations hepatotoxicity and,1
ZYDELIG,hepatotoxicity,hepatotoxicity and,1
ZYDELIG,hepatotoxicity,treatment discontinuations hepatotoxicity and,1
ZYDELIG,diarrhea,diarrhea colitis,1
ZYDELIG,diarrhea,that led to treatment,0
ZYDELIG,diarrhea,The most common,0
ZYDELIG,diarrhea,diarrhea colitis,1
ZYDELIG,diarrhea,discontinuations were hepatotoxicity and,0
ZYDELIG,diarrhea,were hepatotoxicity diarrhea colitis,1
ZYDELIG,diarrhea,diarrhea colitis,1
ZYDELIG,diarrhea,discontinuations,0
ZYDELIG,diarrhea,diarrhea colitis,1
ZYDELIG,diarrhea,diarrhea colitis,1
ZYDELIG,elevated transaminases,for dose reductions elevated transaminases diarrhea,1
ZYDELIG,elevated transaminases,reductions elevated transaminases diarrhea,1
ZYDELIG,elevated transaminases,reductions elevated,1
ZYDELIG,elevated transaminases,common adverse reactions and labo,0
ZYDELIG,elevated transaminases,adverse reactions or laboratory,0
ZYDELIG,elevated transaminases,,0
ZYDELIG,elevated transaminases,and,0
ZYDELIG,elevated transaminases,most common reasons for dose reductions,0
ZYDELIG,diarrhea,elevated diarrhea or,1
ZYDELIG,diarrhea,diarrhea or,1
ZYDELIG,diarrhea,reductions,0
ZYDELIG,diarrhea,transaminases,0
ZYDELIG,diarrhea,were,0
ZYDELIG,diarrhea,abn,0
ZYDELIG,colitis,,0
ZYDELIG,colitis,most common reasons for dose reductions were elevated transaminases,0
ZYDELIG,colitis,elevated transaminases diarrhea colitis and,1
ZYDELIG,nausea,,0
ZYDELIG,nausea,nausea,1
ZYDELIG,nausea,rituximab,0
ZYDELIG,vomiting,,0
ZYDELIG,vomiting,vomiting,1
ZYDELIG,vomiting,vomiting,1
ZYDELIG,vomiting,vomiting,1
ZYDELIG,vomiting,,0
ZYDELIG,vomiting,,0
ZYDELIG,diarrhea,,0
ZYDELIG,diarrhea,diarrhea,1
ZYDELIG,gastroesophageal reflux disease,,0
ZYDELIG,gastroesophageal reflux disease,gastroesophageal reflux disease stomatitis,1
ZYDELIG,gastroesophageal reflux disease,,0
ZYDELIG,gastroesophageal reflux disease,gastroesophageal reflux disease stomatitis,1
ZYDELIG,stomatitis,stomatitis,1
ZYDELIG,stomatitis,,0
ZYDELIG,headache,system disorders,0
ZYDELIG,headache,headache,1
ZYDELIG,headache,system headache,1
ZYDELIG,pyrexia,,0
ZYDELIG,pyrexia,,0
ZYDELIG,pyrexia,conditions,0
ZYDELIG,chills,chills,1
ZYDELIG,chills,chills,1
ZYDELIG,chills,chills,1
ZYDELIG,chills,chills,1
ZYDELIG,chills,chills,1
ZYDELIG,chills,chills,1
ZYDELIG,pain,,0
ZYDELIG,pain,pain,1
ZYDELIG,rash,and subcutaneous tissue,0
ZYDELIG,pneumonia,,0
ZYDELIG,pneumonia,pneumonia,1
ZYDELIG,pneumonia,,0
ZYDELIG,pneumonia,,0
ZYDELIG,pneumonia,pneumonia,1
ZYDELIG,nasal congestion,,0
ZYDELIG,nasal congestion,nasal congestion Infec,1
ZYDELIG,nasal congestion,nasal congestion Infec,1
ZYDELIG,sepsis,sepsis,1
ZYDELIG,sepsis,,0
ZYDELIG,sepsis,Infections and sepsis,1
ZYDELIG,bronchitis,,0
ZYDELIG,bronchitis,,0
ZYDELIG,bronchitis,,0
ZYDELIG,bronchitis,bronchitis,1
ZYDELIG,bronchitis,bronchitis,1
ZYDELIG,bronchitis,bronchitis,1
ZYDELIG,bronchitis,bronchitis,1
ZYDELIG,bronchitis,bronchitis,1
ZYDELIG,bronchitis,bronchitis,1
ZYDELIG,bronchitis,,0
ZYDELIG,sinusitis,sinusitis,1
ZYDELIG,sinusitis,,0
ZYDELIG,sinusitis,sinusitis,1
ZYDELIG,sinusitis,,0
ZYDELIG,sinusitis,sinusitis,1
ZYDELIG,sinusitis,,0
ZYDELIG,sinusitis,sinusitis,1
ZYDELIG,sinusitis,sinusitis,1
ZYDELIG,sinusitis,sinusitis,1
ZYDELIG,urinary tract infection,,0
ZYDELIG,urinary tract infection,,0
ZYDELIG,urinary tract infection,urinary tract infection Musculoskele,1
ZYDELIG,urinary tract infection,urinary tract infection Musculoskele,1
ZYDELIG,arthralgia,arthralgia,1
ZYDELIG,arthralgia,arthralgia,1
ZYDELIG,arthralgia,connective tissue arthralgia,1
ZYDELIG,arthralgia,,0
ZYDELIG,arthralgia,arthralgia,1
ZYDELIG,arthralgia,and,0
ZYDELIG,arthralgia,and connective tissue,0
ZYDELIG,neutrophil count decreased,neutrophil count decreased lymphocyte,1
ZYDELIG,neutrophil count decreased,,0
ZYDELIG,neutrophil count decreased,neutrophil count decreased lymphocyte,1
ZYDELIG,neutrophil count decreased,R rituximab Hematology neutrophil count decreased lymphocyte,1
ZYDELIG,neutrophil count decreased,,0
ZYDELIG,neutrophil count decreased,count decreased lymphocyte,1
ZYDELIG,lymphocyte count decreased,unt lymphocyte count decreased lymphocyte,1
ZYDELIG,lymphocyte count decreased,lymphocyte count decreased lymphocyte,1
ZYDELIG,lymphocyte count decreased,co,0
ZYDELIG,lymphocyte count decreased,lymphocyte count decreased lymphocyte,1
ZYDELIG,lymphocyte count decreased,decreased lymphocyte,1
ZYDELIG,lymphocyte count decreased,,0
ZYDELIG,lymphocyte count decreased,lymphocyte,1
ZYDELIG,lymphocyte count decreased,decreased lymphocyte,1
ZYDELIG,lymphocyte count decreased,unt lymphocyte,1
ZYDELIG,lymphocyte count decreased,,0
ZYDELIG,lymphocyte count increased,,0
ZYDELIG,AST increased,AST increased,1
ZYDELIG,AST increased,AST increased,1
ZYDELIG,AST increased,,0
ZYDELIG,AST increased,,0
ZYDELIG,AST increased,,0
ZYDELIG,AST increased,,0
ZYDELIG,GGT increased,GGT increased,1
ZYDELIG,GGT increased,,0
ZYDELIG,GGT increased,GGT increased,1
ZYDELIG,GGT increased,GGT increased,1
ZYDELIG,GGT increased,GGT,1
ZYDELIG,GGT increased,,0
ZYDELIG,GGT increased,,0
ZYDELIG,GGT increased,,0
ZYDELIG,hypertriglyceridemia,,0
ZYDELIG,hypertriglyceridemia,hypertriglyceridemia hyperglycemia,1
ZYDELIG,hypertriglyceridemia,triglycerides,0
ZYDELIG,hypertriglyceridemia,hypertriglyceridemia hyperglycemia,1
ZYDELIG,hypertriglyceridemia,triglycerides,0
ZYDELIG,hypertriglyceridemia,triglycerides,0
ZYDELIG,hypertriglyceridemia,hyperglycemia,0
ZYDELIG,hypertriglyceridemia,,0
ZYDELIG,hypertriglyceridemia,triglycerides,0
ZYDELIG,hyperglycemia,,0
ZYDELIG,hyperglycemia,hypertriglyceridemia hyperglycemia,1
ZYDELIG,hyperglycemia,hyperglycemia,1
ZYDELIG,hypoglycemia,hypoglycemia,1
ZYDELIG,hypoglycemia,,0
ZYDELIG,hypoglycemia,,0
ZYDELIG,hyponatremia,hyponatremia,1
ZYDELIG,hyponatremia,,0
ZYDELIG,hyponatremia,,0
ZYDELIG,hyponatremia,hyponatremia,1
ZYDELIG,hyponatremia,hyponatremia,1
ZYDELIG,pneumonia,,0
ZYDELIG,pneumonia,serious adverse reactions that,0
ZYDELIG,pneumonia,pneumonia,1
ZYDELIG,pneumonia,reactions that occurred were,0
ZYDELIG,pneumonia,pneumonia,1
ZYDELIG,pneumonia,,0
ZYDELIG,pneumonia,pneumonia,1
ZYDELIG,pneumonia,pneumonia,1
ZYDELIG,diarrhea,were diarrhea,1
ZYDELIG,diarrhea,,0
ZYDELIG,diarrhea,,0
ZYDELIG,diarrhea,Adverse reactions,0
ZYDELIG,diarrhea,were,0
ZYDELIG,diarrhea,interruption,0
ZYDELIG,diarrhea,reactions resulted in interruption or discontinuation,0
ZYDELIG,diarrhea,diarrhea,1
ZYDELIG,pyrexia,occurred were pneumonia diarrhea pyrexia,1
ZYDELIG,pyrexia,or discontinuation,0
ZYDELIG,pyrexia,pyrexia,1
ZYDELIG,pyrexia,,0
ZYDELIG,pyrexia,pyrexia,1
ZYDELIG,pyrexia,reactions resulted in interruption,0
ZYDELIG,pyrexia,pyrexia,1
ZYDELIG,pyrexia,pneumonia diarrhea pyrexia,1
ZYDELIG,pyrexia,interruption or discontinuation for subjects,0
ZYDELIG,pyrexia,or discontinuation for subjects,0
ZYDELIG,diarrhea,diarrhea,1
ZYDELIG,diarrhea,diarrhea,1
ZYDELIG,diarrhea,diarrhea,1
ZYDELIG,diarrhea,,0
ZYDELIG,diarrhea,or discontinuations diarrhea,1
ZYDELIG,diarrhea,diarrhea,1
ZYDELIG,diarrhea,transaminases Table provides the adverse,0
ZYDELIG,diarrhea,reasons for interruption,0
ZYDELIG,elevated transaminases,were diarrhea pneumonia elevated transaminases,1
ZYDELIG,elevated transaminases,,0
ZYDELIG,elevated transaminases,diarrhea pneumonia elevated,1
ZYDELIG,elevated transaminases,,0
ZYDELIG,elevated transaminases,diarrhea pneumonia elevated,1
ZYDELIG,nausea,,0
ZYDELIG,nausea,,0
ZYDELIG,nausea,,0
ZYDELIG,nausea,,0
ZYDELIG,nausea,,0
ZYDELIG,nausea,nausea,1
ZYDELIG,nausea,nausea,1
ZYDELIG,nausea,,0
ZYDELIG,nausea,,0
ZYDELIG,nausea,nausea,1
ZYDELIG,abdominal pain,,0
ZYDELIG,abdominal pain,,0
ZYDELIG,abdominal pain,abdominal,1
ZYDELIG,abdominal pain,abdominal,1
ZYDELIG,abdominal pain,,0
ZYDELIG,abdominal pain,abdominal,1
ZYDELIG,abdominal pain,vomit,0
ZYDELIG,vomiting,vomiting G,1
ZYDELIG,fatigue,conditions,0
ZYDELIG,fatigue,site conditions,0
ZYDELIG,fatigue,fatigue,1
ZYDELIG,fatigue,conditions,0
ZYDELIG,fatigue,,0
ZYDELIG,fatigue,fatigue,1
ZYDELIG,fatigue,fatigue,1
ZYDELIG,fatigue,fatigue,1
ZYDELIG,fatigue,fatigue,1
ZYDELIG,pyrexia,,0
ZYDELIG,pyrexia,,0
ZYDELIG,pyrexia,pyrexia,1
ZYDELIG,pyrexia,,0
ZYDELIG,pyrexia,pyrexia,1
ZYDELIG,pyrexia,,0
ZYDELIG,pyrexia,pyrexia,1
ZYDELIG,pyrexia,,0
ZYDELIG,asthenia,asthenia,1
ZYDELIG,asthenia,,0
ZYDELIG,peripheral edema,,0
ZYDELIG,peripheral edema,,0
ZYDELIG,peripheral edema,,0
ZYDELIG,peripheral edema,Infection,0
ZYDELIG,peripheral edema,peripheral edema Infection,1
ZYDELIG,peripheral edema,Infection,0
ZYDELIG,peripheral edema,,0
ZYDELIG,peripheral edema,peripheral edema Infection,1
ZYDELIG,upper respiratory tract infection,,0
ZYDELIG,upper respiratory tract infection,Infections and upper respiratory,1
ZYDELIG,upper respiratory tract infection,and,0
ZYDELIG,pneumonia,pneumonia,1
ZYDELIG,pneumonia,pneumonia,1
ZYDELIG,pneumonia,pneumonia,1
ZYDELIG,pneumonia,,0
ZYDELIG,pneumonia,pneumonia,1
ZYDELIG,pneumonia,pneumonia,1
ZYDELIG,dyspnea,dyspnea,1
ZYDELIG,dyspnea,,0
ZYDELIG,dyspnea,dyspnea,1
ZYDELIG,dyspnea,,0
ZYDELIG,dyspnea,dyspnea,1
ZYDELIG,dyspnea,,0
ZYDELIG,dyspnea,dyspnea,1
ZYDELIG,dyspnea,,0
ZYDELIG,dyspnea,,0
ZYDELIG,rash,,0
ZYDELIG,rash,rash,1
ZYDELIG,rash,,0
ZYDELIG,decreased appetite,disorders,0
ZYDELIG,decreased appetite,,0
ZYDELIG,decreased appetite,nutrition decreased,1
ZYDELIG,decreased appetite,appetite Psychiatric,1
ZYDELIG,decreased appetite,,0
ZYDELIG,decreased appetite,,0
ZYDELIG,ALT increased,ALT increased AS,1
ZYDELIG,ALT increased,AS,0
ZYDELIG,ALT increased,increased AS,1
ZYDELIG,ALT increased,abnormalities,0
ZYDELIG,neutrophils decreased,neutrophils,1
ZYDELIG,neutrophils decreased,decreased hemoglobin,1
ZYDELIG,neutrophils decreased,Hematology neutrophils,1
ZYDELIG,hemoglobin decreased,decreased hemoglobin,1
ZYDELIG,hemoglobin decreased,decreased hemoglobin decreased platelets,1
ZYDELIG,hemoglobin decreased,decreased hemoglobin,1
ZYDELIG,hemoglobin decreased,decreased hemoglobin,1
ZYDELIG,platelets decreased,decreased platelets,1
ZYDELIG,platelets decreased,decreased,1
ZYDELIG,platelets decreased,decreased platelets decreased,1
ZYDELIG,platelets decreased,decreased platelets decreased,1
ZYDELIG,platelets decreased,decreased platelets decreased,1
ZYDELIG,platelets decreased,decreased,0
ZYDELIG,platelets decreased,,0
ZYDELIG,platelets decreased,decreased platelets,1
ZYDELIG,platelets decreased,decreased platelets decreased,1
ZYDELIG,FATAL,,0
ZYDELIG,FATAL,,0
ZYDELIG,FATAL,,0
ZYDELIG,FATAL,,0
ZYDELIG,FATAL,owing serious adverse,0
ZYDELIG,FATAL,serious,0
ZYDELIG,TOXICITIES,r eactions have been associated,1
ZYDELIG,TOXICITIES,,0
ZYDELIG,TOXICITIES,in clinical trials and are discussed in greater detail in,0
ZYDELIG,TOXICITIES, adverse r eactions have been,1
ZYDELIG,TOXICITIES, adverse r eactions have been associated with,1
ZYDELIG,TOXICITIES,,0
ZYDELIG,TOXICITIES,,0
ZYDELIG,TOXICITIES, adverse r eactions have,1
ZYDELIG,TOXICITIES,adverse,1
ZYDELIG,DIARRHEA,discussed in greater detail in other,0
ZYDELIG,DIARRHEA,,0
ZYDELIG,DIARRHEA, associa ted with Zydelig,1
ZYDELIG,DIARRHEA,,0
ZYDELIG,DIARRHEA, associa ted with Zydelig in clinical,1
ZYDELIG,DIARRHEA,in clinical,0
ZYDELIG,DIARRHEA, associa,1
ZYDELIG,DIARRHEA, associa ted with Zydelig in clinical,1
ZYDELIG,DIARRHEA,discussed in greater detail in other sections of,0
ZYDELIG,DIARRHEA, associa ted with Zydelig in,1
ZYDELIG,COLITIS,with Zydelig,1
ZYDELIG,COLITIS,,0
ZYDELIG,COLITIS,,0
ZYDELIG,COLITIS,,0
ZYDELIG,COLITIS,clinical trials and are discussed in greater detail in other sections of the,0
ZYDELIG,COLITIS,d,1
ZYDELIG,COLITIS,d,1
ZYDELIG,PNEUMONITIS,,0
ZYDELIG,INTESTINAL PERFORATION,with Zydelig in,0
ZYDELIG,INTESTINAL PERFORATION,discuss ed in greater detail in,1
ZYDELIG,INTESTINAL PERFORATION,trials and,1
ZYDELIG,INTESTINAL PERFORATION,discuss ed in greater detail in,1
ZYDELIG,INTESTINAL PERFORATION,in greater detail in other sections of,0
ZYDELIG,INTESTINAL PERFORATION,greater,0
ZYDELIG,FATAL, deta il in other sections of,1
ZYDELIG,TOXICITIES,ections of the prescribing information Hepatotoxicity see,1
ZYDELIG,TOXICITIES,discussed in greater,0
ZYDELIG,TOXICITIES,ections of the prescribing information Hepatotoxicity see,1
ZYDELIG,TOXICITIES,of the prescribing information Hepatotoxicity see,1
ZYDELIG,TOXICITIES,with Zydelig in,0
ZYDELIG,TOXICITIES,prescribing information Hepatotoxicity see,0
ZYDELIG,TOXICITIES,greater detail in,0
ZYDELIG,DIARRHEA,the prescribing nformati on Hepatotoxicity see Warnings and,1
ZYDELIG,DIARRHEA,are discussed in,0
ZYDELIG,DIARRHEA,prescribing nformati on Hepatotoxicity see Warnings and,1
ZYDELIG,DIARRHEA,nformati on Hepatotoxicity see Warnings and,1
ZYDELIG,DIARRHEA,nformati on Hepatotoxicity see Warnings and,1
ZYDELIG,DIARRHEA,nformati on Hepatotoxicity see Warnings and,1
ZYDELIG,DIARRHEA,on Hepatotoxicity see Warnings and Precautions Severe Diarrhea,0
ZYDELIG,DIARRHEA,,0
ZYDELIG,DIARRHEA,Diarrhea or,0
ZYDELIG,DIARRHEA,nformati on Hepatotoxicity see Warnings and,1
ZYDELIG,COLITIS,"sections of the prescribing .



 * Hepatotoxicity see Warnings and Precautions",1
ZYDELIG,COLITIS,detail in other,0
ZYDELIG,COLITIS,,0
ZYDELIG,PNEUMONITIS,of the prescribing information,0
ZYDELIG,PNEUMONITIS,Hepatotoxic ity see Warnings and Precautions,1
ZYDELIG,PNEUMONITIS,sections,0
ZYDELIG,PNEUMONITIS,Hepatotoxic ity see Warnings and Precautions,1
ZYDELIG,PNEUMONITIS,sections of the prescribing Hepatotoxic ity see Warnings and Precautions,1
ZYDELIG,PNEUMONITIS,Hepatotoxic ity see Warnings and Precautions,1
ZYDELIG,INTESTINAL PERFORATION,Hepatotoxicity e  Warnings and Precau tions Severe Diarrhea or Colitis,1
ZYDELIG,Fatal,,0
ZYDELIG,Fatal,1) ] Severe Diarrhea or Colitis see,1
ZYDELIG,Fatal,1) ] Severe Diarrhea or Colitis see,1
ZYDELIG,hepatotoxicity,or Coli tis see Warnings and Precautions,1
ZYDELIG,Fatal,"Warnings and ]  
  Anaphylaxis see Warnings and Precautions",1
ZYDELIG,diarrhea,and Precautions Anaphylaxis see Warnin,0
ZYDELIG,colitis,utions  Neutropenia see Warnings and Precautions,1
ZYDELIG,colitis,utions  Neutropenia see Warnings and Precautions,1
ZYDELIG,colitis,Anaphylaxis see Warnings and utions  Neutropenia see Warnings and Precautions,1
ZYDELIG,Fatal,pain chills and rash he mo st common laboratory abnormalities incidence,1
ZYDELIG,Fatal,,0
ZYDELIG,Fatal,pain chills and rash he,1
ZYDELIG,Fatal,abdominal,0
ZYDELIG,Fatal,he mo st common laboratory abnormalities incidence,1
ZYDELIG,Fatal,cough pneumonia abdominal pain,0
ZYDELIG,Fatal,neutropenia hypertriglyceridemia hypergly,0
ZYDELIG,pneumonitis,most common oratory,1
ZYDELIG,Fatal,at GILEAD or FDA,0
ZYDELIG,Fatal,00-FD A or wwwfdagovmedwatch Clinical Trial,1
ZYDELIG,Fatal,Sciences Inc at GILEAD or FDA,0
ZYDELIG,Fatal,ar,0
ZYDELIG,Fatal,contact Gilead,0
ZYDELIG,Fatal,,0
ZYDELIG,Fatal,00-FD A or wwwfdagovmedwatch Clinical Trial,1
ZYDELIG,Fatal,A or wwwfdagovmedwatch,0
ZYDELIG,Fatal,00-FD A or wwwfdagovmedwatch Clinical Trial,1
ZYDELIG,Fatal,00-FD A or wwwfdagovmedwatch Clinical Trial,1
ZYDELIG,FATAL,,0
ZYDELIG,FATAL,of a canno t be directly compared to,1
ZYDELIG,FATAL,a,0
ZYDELIG,FATAL,canno t be directly compared to,1
ZYDELIG,FATAL,canno t be directly compared to,1
ZYDELIG,FATAL,canno t be directly compared to,1
ZYDELIG,FATAL,,0
ZYDELIG,FATAL,canno t be directly compared to,1
ZYDELIG,TOXICITIES,trials,0
ZYDELIG,TOXICITIES, compared  to rates in the clinical,1
ZYDELIG,TOXICITIES,,0
ZYDELIG,DIARRHEA,,0
ZYDELIG,COLITIS,rates in the clinical als of  another drug and may not,1
ZYDELIG,COLITIS,compared to rates in the clinical,0
ZYDELIG,COLITIS,the clinical trials of a drug,0
ZYDELIG,COLITIS,Summary of Clinical Trial,0
ZYDELIG,COLITIS,rates in the clinical,0
ZYDELIG,COLITIS,drug,0
ZYDELIG,PNEUMONITIS,the clinical trials of other drug  and may not reflect the,1
ZYDELIG,PNEUMONITIS,a drug cannot be directly compared to rates in the,0
ZYDELIG,PNEUMONITIS,and may,0
ZYDELIG,PNEUMONITIS,the clinical trials of a drug,0
ZYDELIG,PNEUMONITIS,clinical trials of other,1
ZYDELIG,PNEUMONITIS,trials of other,1
ZYDELIG,PNEUMONITIS,observed,0
ZYDELIG,PNEUMONITIS,of other,1
ZYDELIG,INTESTINAL PERFORATION,ma,0
ZYDELIG,INTESTINAL PERFORATION,of another drug and y not reflect,1
ZYDELIG,Fatal,Clinical,0
ZYDELIG,Fatal,reflect the rates observed in practice Summary of Clinical Trials in,0
ZYDELIG,Fatal,ic Le ukemia The safety data reflect,1
ZYDELIG,Fatal,The safety data reflect subject exposure,0
ZYDELIG,Fatal,Le ukemia The safety data reflect,1
ZYDELIG,Fatal,Zydelig from Study in,0
ZYDELIG,Fatal,in Chronic ic Le ukemia The safety data reflect,1
ZYDELIG,Fatal,Trials in Chronic ic,1
ZYDELIG,hepatotoxicity,Chronic Lymphocytic Leukemia he,1
ZYDELIG,hepatotoxicity,Clinical Trials,0
ZYDELIG,hepatotoxicity,safety data reflect subject exposure to Zydelig,1
ZYDELIG,hepatotoxicity,data reflect subject exposure to Zydelig,1
ZYDELIG,hepatotoxicity,safety data reflect subject exposure to Zydelig,1
ZYDELIG,hepatotoxicity,received,0
ZYDELIG,hepatotoxicity,Leukemia he safety data reflect subject exposure to Zydelig,1
ZYDELIG,hepatotoxicity,Leukemia he,1
ZYDELIG,hepatotoxicity,Leukemia he,1
ZYDELIG,hepatotoxicity,,0
ZYDELIG,Fatal,without Zydelig mg daily The median duration of exposure,1
ZYDELIG,diarrhea,doses of rituximab with or without,0
ZYDELIG,diarrhea,adverse reactions were reported in,0
ZYDELIG,diarrhea,Zydelig mg twice daily,0
ZYDELIG,diarrhea,duration of posure t o Zydelig was months Serious,1
ZYDELIG,diarrhea,months Serious,0
ZYDELIG,diarrhea,The median duration of posure t o Zydelig was months Serious,1
ZYDELIG,diarrhea,of posure,1
ZYDELIG,diarrhea,o,0
ZYDELIG,diarrhea,median duration of posure,1
ZYDELIG,diarrhea,of posure,1
ZYDELIG,colitis,duration of exposure to delig w as months Serious adverse reactions,1
ZYDELIG,colitis,w as months Serious adverse reactions,1
ZYDELIG,colitis,exposure to,0
ZYDELIG,colitis,to delig w as months Serious adverse reactions,1
ZYDELIG,colitis,w as months Serious adverse reactions,1
ZYDELIG,colitis,w as months Serious adverse reactions,1
ZYDELIG,colitis,w as months Serious adverse reactions,1
ZYDELIG,Fatal,rted  for subjects treated with Zydelig,1
ZYDELIG,Fatal,repo,0
ZYDELIG,Fatal,,0
ZYDELIG,Fatal,,0
ZYDELIG,pneumonitis,and,0
ZYDELIG,pneumonitis,Zydelig were pneumonia pyrexia sepsis febrile,0
ZYDELIG,pneumonitis,reported for treated,1
ZYDELIG,pneumonitis,adverse reactions reported for treated wit h Zydelig were pneumonia pyrexia,1
ZYDELIG,pneumonitis,treated,1
ZYDELIG,pneumonitis,treated wit h Zydelig were pneumonia pyrexia,1
ZYDELIG,Fatal,discontinuation of ig,1
ZYDELIG,Fatal,led to discontinuation of ig oc curred in subjects The most,1
ZYDELIG,Fatal,subjects The most common adverse reactions that led to treatment,0
ZYDELIG,Fatal,of,0
ZYDELIG,Fatal,ig oc curred in subjects The most,1
ZYDELIG,Fatal,ig,1
ZYDELIG,Fatal,oc curred in subjects The most,1
ZYDELIG,Fatal,The most common adverse reactions that led,0
ZYDELIG,intestinal perforation,(10%) subjects. The,1
ZYDELIG,intestinal perforation,,0
ZYDELIG,intestinal perforation,st common adverse reactions that led,0
ZYDELIG,intestinal perforation,discontinuation of Zydelig occurred (10%) subjects. The,1
ZYDELIG,intestinal perforation,treatment discontinuations were hepatotoxicity and,0
ZYDELIG,intestinal perforation,(10%) subjects. The mo st common adverse reactions that,1
ZYDELIG,intestinal perforation,The mo st common adverse reactions that,1
ZYDELIG,Neutropenia,see Warnings and Severe,1
ZYDELIG,Neutropenia,and  Severe Dia rrhea or Colitis see Warnings,1
ZYDELIG,Embryo-fetal toxicity,Warnings a,0
ZYDELIG,Embryo-fetal toxicity,] Pneumonitis see Warnings and Precautions,1
ZYDELIG,Embryo-fetal toxicity,cautions,1
ZYDELIG,Embryo-fetal toxicity,Warnings,0
ZYDELIG,Embryo-fetal toxicity,Diarrhea or,0
ZYDELIG,Embryo-fetal toxicity,Warnings and Pre,0
ZYDELIG,fetal harm,Diarrhea or Colitis see,0
ZYDELIG,fetal harm,Perforation see,0
ZYDELIG,fetal harm,Precautions is [see  W arnings and Precautions Intestinal Perforation,1
ZYDELIG,fetal harm,Warnings and Precautions is [see  W arnings and Precautions Intestinal Perforation,1
ZYDELIG,fetal harm,,0
ZYDELIG,fetal harm,Precautions is [see  W arnings and Precautions Intestinal Perforation,1
ZYDELIG,fetal harm,or Colitis see Warnings and Precautions,0
ZYDELIG,fetal harm,Precautions is,1
ZYDELIG,Fatal,Severe,0
ZYDELIG,Fatal,[see  Warnings and Precautions Anaphylaxis see,1
ZYDELIG,Fatal,Reactions,0
ZYDELIG,Elevations in ALT,* Neutropenia see Warnings and Precautions,1
ZYDELIG,Elevations in ALT,Reactions see Warnings and Precautions Anaphylaxis see Warnings and,0
ZYDELIG,Elevations in ALT,,0
ZYDELIG,Elevations in ALT,,0
ZYDELIG,Elevations in ALT,Warnings and Precautions,0
ZYDELIG,Elevations in ALT,* Neutropenia see Warnings and Precautions,1
ZYDELIG,diarrhea,with relapsed LL,1
ZYDELIG,colitis,up to 8 doses of rituximab with or,1
ZYDELIG,colitis,up to 8 doses of rituximab with or,1
ZYDELIG,Diarrhea,,0
ZYDELIG,Diarrhea,exposure to,0
ZYDELIG,Diarrhea,of exposure to Zydelig was months,0
ZYDELIG,Diarrhea,"
 Seriou s adverse reactions were reported",1
ZYDELIG,Diarrhea,"
 Seriou s adverse reactions were reported",1
ZYDELIG,Diarrhea,"
 Seriou s adverse reactions were reported",1
ZYDELIG,Diarrhea,"
 Seriou s adverse reactions were reported",1
ZYDELIG,Diarrhea,was,0
ZYDELIG,Diarrhea,of exposure to,0
ZYDELIG,Diarrhea,"was 
 Seriou s adverse reactions were reported",1
ZYDELIG,Diarrhea,treated with Zydelig were pneumonia,0
ZYDELIG,Fatal,adverse tions that led to treatment discontinuations,1
ZYDELIG,Fatal,common adverse tions that led to treatment discontinuations,1
ZYDELIG,Fatal,tions that led to treatment discontinuations,1
ZYDELIG,Fatal,tions that led to treatment discontinuations,1
ZYDELIG,Fatal,,0
ZYDELIG,Fatal,,0
ZYDELIG,pneumonitis,treatment d iscontinuations were hepatotoxicity and diarrheacolitis,1
ZYDELIG,pneumonitis,led treatment,1
ZYDELIG,pneumonitis,d iscontinuations were hepatotoxicity and diarrheacolitis,1
ZYDELIG,pneumonitis,led treatment d iscontinuations were hepatotoxicity and diarrheacolitis,1
ZYDELIG,pneumonitis,that led treatment d iscontinuations were hepatotoxicity and diarrheacolitis,1
ZYDELIG,pneumonitis,common,0
ZYDELIG,pneumonitis,had,0
ZYDELIG,pneumonitis,that led to,0
ZYDELIG,pneumonitis,d iscontinuations were hepatotoxicity and diarrheacolitis,1
ZYDELIG,pneumonitis,adverse reactions that led treatment,1
ZYDELIG,Fatal,Higher Incidence n Sub jects Receiving Zydelig Zydelig RN,1
ZYDELIG,Fatal,Incidence,0
ZYDELIG,Fatal,Sub jects Receiving Zydelig Zydelig RN,1
ZYDELIG,Fatal,n Sub jects Receiving Zydelig Zydelig RN,1
ZYDELIG,diarrhea,         Any Grade Grade Any Grade,1
ZYDELIG,diarrhea,Adverse,0
ZYDELIG,toxic epidermal necrolysis,disorders 23 (21),1
ZYDELIG,toxic epidermal necrolysis,disorders      23 (21)          0    vomiting,1
ZYDELIG,toxic epidermal necrolysis,,0
ZYDELIG,toxic epidermal necrolysis,nausea,0
ZYDELIG,toxic epidermal necrolysis,0 vomiting,1
ZYDELIG,TEN,nausea,0
ZYDELIG,TEN,,0
ZYDELIG,TEN,    vomiting,1
ZYDELIG,TEN,    vomiting,1
ZYDELIG,TEN,nausea,0
ZYDELIG,TEN,,0
ZYDELIG,TEN,    vomiting,1
ZYDELIG,TEN,    vomiting,1
ZYDELIG,TEN,    vomiting,1
ZYDELIG,TEN,nausea,0
ZYDELIG,cutaneous reactions,diarrhea            gastro,1
ZYDELIG,cutaneous reactions,diarrhea            gastro,1
ZYDELIG,cutaneous reactions,diarrhea            gastro,1
ZYDELIG,cutaneous reactions,diarrhea            gastro,1
ZYDELIG,cutaneous reactions,diarrhea            gastro,1
ZYDELIG,cutaneous reactions,diarrhea            gastro,1
ZYDELIG,cutaneous reactions,,0
ZYDELIG,cutaneous reactions,gastro,0
ZYDELIG,cutaneous reactions,,0
ZYDELIG,cutaneous reactions,diarrhea            gastro,1
ZYDELIG,dermatitis exfoliative,,0
ZYDELIG,dermatitis exfoliative,23 (21) gastroesophageal reflux disease,1
ZYDELIG,dermatitis exfoliative,diarrhea,0
ZYDELIG,dermatitis exfoliative,diarrhea          23 (21)       gastroesophageal reflux,1
ZYDELIG,dermatitis exfoliative,,0
ZYDELIG,dermatitis exfoliative,diarrhea,0
ZYDELIG,rash,  6  gastroesophageal,1
ZYDELIG,rash,diarrhea,0
ZYDELIG,rash,diarrhea,0
ZYDELIG,rash,reflux disease,0
ZYDELIG,rash,  6  gastroesophageal reflux,1
ZYDELIG,rash,,0
ZYDELIG,rash,diarrhea,0
ZYDELIG,rash erythematous,diarrhea,0
ZYDELIG,rash erythematous,reflux,0
ZYDELIG,rash erythematous,diarrhea,0
ZYDELIG,rash erythematous,diarrhea ) 17,1
ZYDELIG,rash erythematous,diarrhea ),1
ZYDELIG,rash generalized,diarrhea )          0     gastroesophageal,1
ZYDELIG,rash generalized,diarrhea )          0     gastroesophageal reflux,1
ZYDELIG,rash generalized,diarrhea,0
ZYDELIG,rash generalized,,0
ZYDELIG,rash macular,diarrhea,0
ZYDELIG,rash maculo-papular,,0
ZYDELIG,rash maculo-papular,,0
ZYDELIG,rash maculo-papular, gastroesophageal r eflux disease stoma,1
ZYDELIG,rash maculo-papular,stoma,0
ZYDELIG,rash maculo-papular,,0
ZYDELIG,rash maculo-papular, gastroesophageal r eflux,1
ZYDELIG,rash maculo-papular, gastroesophageal r eflux disease,1
ZYDELIG,rash maculo-papular,gastroesophageal,1
ZYDELIG,rash papular,lux,1
ZYDELIG,rash papular,ref,0
ZYDELIG,rash papular,,0
ZYDELIG,skin disorder,,0
ZYDELIG,skin disorder,,0
ZYDELIG,skin disorder,,0
ZYDELIG,skin disorder,,0
ZYDELIG,allergic reactions,"Nervous system      
   headache ",1
ZYDELIG,allergic reactions,,0
ZYDELIG,allergic reactions,,0
ZYDELIG,allergic reactions,"     
   headache ",1
ZYDELIG,allergic reactions,"     
   headache ",1
ZYDELIG,allergic reactions,system disorders,0
ZYDELIG,anaphylaxis,Nervous system disorders            ,1
ZYDELIG,anaphylaxis,disorders            ,1
ZYDELIG,anaphylaxis,disorders            ,1
ZYDELIG,anaphylaxis,system disorders            ,1
ZYDELIG,anaphylaxis,           ,1
ZYDELIG,anaphylaxis,,0
ZYDELIG,anaphylaxis,,0
ZYDELIG,anaphylaxis,headache,0
ZYDELIG,neutropenia,pyrexia             chills,1
ZYDELIG,neutropenia,pyrexia,0
ZYDELIG,neutropenia,,0
ZYDELIG,neutropenia,pyrexia             chills,1
ZYDELIG,fetal harm,Respira,0
ZYDELIG,fetal harm,"tory, thor acic and",1
ZYDELIG,fetal harm,"Respira tory,",1
ZYDELIG,fetal harm,Respira,0
ZYDELIG,fetal harm,"Respira tory, thor acic and",1
ZYDELIG,fetal harm,Respira,0
ZYDELIG,fetal harm,mediastinal disorders,0
ZYDELIG,fetal harm,Respira,0
ZYDELIG,fetal harm,Respira,0
SIMPONI,Infections,,0
SIMPONI,Malignancies,reactions incidence,0
SIMPONI,Malignancies,Infections see Warnings and Malignancies see Warnings and Precautions EXCERPT,1
SIMPONI,upper respiratory tract infection,SUSPECTED,0
SIMPONI,upper respiratory tract infection,bronchitis,0
SIMPONI,upper respiratory tract infection,tract infection viral infection bronchitis hypertension and,1
SIMPONI,upper respiratory tract infection,hypertension and rash To report SUSPECTED,0
SIMPONI,upper respiratory tract infection,respiratory tract infection viral infection bronchitis hypertension and,1
SIMPONI,upper respiratory tract infection,incidence upper respiratory tract infection viral infection bronchitis hypertension and,1
SIMPONI,upper respiratory tract infection,bronchitis hypertension and rash To report,0
SIMPONI,upper respiratory tract infection,common adverse reactions incidence upper respiratory,1
SIMPONI,viral infection,respiratory tract viral,1
SIMPONI,viral infection,adverse reactions incidence,0
SIMPONI,viral infection,infection bronchitis hypertension and rash To,1
SIMPONI,viral infection,infection bronchitis hypertension and rash To,1
SIMPONI,bronchitis,bronchitis hypertension and rash To report,1
SIMPONI,bronchitis,report SUSPECTED ADVERSE REACTIONS contactJanssen,0
SIMPONI,bronchitis,ADVERSE REACTIONS contactJanssen,0
SIMPONI,bronchitis,bronchitis hypertension and rash To report,1
SIMPONI,bronchitis,report SUSPECTED ADVERSE REACTIONS contactJanssen Biot,0
SIMPONI,hypertension,respiratory tract infection viral infection bronchitis,0
SIMPONI,hypertension,hypertension and rash To report SUSPECTED,1
SIMPONI,hypertension,hypertension and rash To report SUSPECTED,1
SIMPONI,hypertension,respiratory tract infection viral,0
SIMPONI,hypertension,tract infection viral infection,0
SIMPONI,hypertension,report SUSPECTED ADVERSE,0
SIMPONI,hypertension,are upper,0
SIMPONI,hypertension,reactions incidence are upper respiratory tract infection viral infection,0
SIMPONI,hypertension,infection hypertension and rash To report SUSPECTED,1
SIMPONI,Upper respiratory tract infection,adverse reaction reported in the trial through Week,0
SIMPONI,Upper respiratory tract infection,trial,0
SIMPONI,Upper respiratory tract infection,tract infection was the most common adverse,1
SIMPONI,Upper respiratory tract infection,respiratory tract infection was the most common adverse,1
SIMPONI,Upper respiratory tract infection,patients,0
SIMPONI,Upper respiratory tract infection,Upper respiratory tract infection was the most common adverse,1
SIMPONI,Upper respiratory tract infection,,0
SIMPONI,Upper respiratory tract infection,Upper respiratory tract infection was the most common adverse,1
SIMPONI,Upper respiratory tract infection,,0
SIMPONI,Upper respiratory tract infection,reported in the trial through Week occurring,0
SIMPONI,infections,Infections,0
SIMPONI,sepsis,Infections Serious infections observed in SIMPONI ARIAtreated patients,0
SIMPONI,sepsis,sepsis pneumonia cellulitis abscess opportunistic infections,1
SIMPONI,pneumonia,included sepsis,0
SIMPONI,pneumonia,included,0
SIMPONI,pneumonia,pneumonia cellulitis abscess opportunistic infections tuberculosis,1
SIMPONI,pneumonia,included pneumonia cellulitis abscess opportunistic infections tuberculosis,1
SIMPONI,cellulitis,included sepsis cellulitis abscess opportunistic infections tuberculosis TB,1
SIMPONI,cellulitis,cellulitis abscess opportunistic infections tuberculosis TB,1
SIMPONI,cellulitis,cellulitis abscess opportunistic infections tuberculosis TB,1
SIMPONI,cellulitis,sepsis cellulitis abscess opportunistic infections tuberculosis TB,1
SIMPONI,cellulitis,,0
SIMPONI,cellulitis,,0
SIMPONI,cellulitis,,0
SIMPONI,cellulitis,TB and invasive fungal infections Cases,0
SIMPONI,cellulitis,cellulitis abscess opportunistic infections tuberculosis TB,1
SIMPONI,abscess,ARIAtreated patients included sepsis,0
SIMPONI,abscess,SIMPONI,0
SIMPONI,abscess,,0
SIMPONI,abscess,abscess opportunistic infections tuberculosis TB and,1
SIMPONI,opportunistic infections,included sepsis pneumonia cellulitis opportunistic infections tuberculosis TB and invasive fungal,1
SIMPONI,opportunistic infections,in SIMPONI ARIAtreated patients included sepsis,0
SIMPONI,opportunistic infections,sepsis pneumonia cellulitis opportunistic,1
SIMPONI,opportunistic infections,sepsis pneumonia cellulitis opportunistic,1
SIMPONI,opportunistic infections,abscess,0
SIMPONI,opportunistic infections,infections tuberculosis TB and invasive fungal,1
SIMPONI,opportunistic infections,extrapulmona,0
SIMPONI,opportunistic infections,,0
SIMPONI,tuberculosis,abscess opportunistic infections,0
SIMPONI,tuberculosis,tuberculosis TB and invasive fungal infections,1
SIMPONI,invasive fungal infections,,0
SIMPONI,invasive fungal infections,tuberculosis TB invasive fungal infections Cases of TB included pulmonary,1
SIMPONI,invasive fungal infections,TB included pulmonary and extrapulmonary TB The majority of the,0
SIMPONI,invasive fungal infections,TB invasive fungal,1
SIMPONI,invasive fungal infections,invasive fungal infections Cases of TB included pulmonary,1
SIMPONI,invasive fungal infections,infections Cases of TB included pulmonary,1
SIMPONI,invasive fungal infections,The majority of the TB cases occurred in cou,0
SIMPONI,invasive fungal infections,,0
SIMPONI,invasive fungal infections,the,0
SIMPONI,invasive fungal infections,fungal infections Cases of TB included pulmonary,1
SIMPONI,TB,,0
SIMPONI,extrapulmonary TB,extrapulmonary TB The majority of the TB,1
SIMPONI,extrapulmonary TB,cases occurred in countries with,0
SIMPONI,TB,TB cases occurred in countries with,1
SIMPONI,infections,Trial through infections were observed in of SIMPONI,1
SIMPONI,infections,Trial through infections were observed in of SIMPONI,1
SIMPONI,infections,infections were observed in of SIMPONI,1
SIMPONI,infections,the controlled phase,0
SIMPONI,infections,Trial through infections were observed in of SIMPONI,1
SIMPONI,infections,infections were observed in of SIMPONI,1
SIMPONI,infections,and,0
SIMPONI,infections,with of controltreated patients,0
SIMPONI,infections,infections were observed in of SIMPONI,1
SIMPONI,infections,infections were observed in of SIMPONI,1
SIMPONI,infections,patients,0
SIMPONI,infections,incidence of infections per patientyears of followup was,1
SIMPONI,infections,,0
SIMPONI,infections,infections per patientyears of followup was,1
SIMPONI,infections,,0
SIMPONI,infections,the incidence of infections per patientyears of followup was,1
SIMPONI,infections,infections per patientyears of followup was,1
SIMPONI,infections,of all,0
SIMPONI,infections,see Warnings and Precautions,0
SIMPONI,infections,in patients receiving SIMPONI ARIA see Warnings and Precautions,0
SIMPONI,infections,infections was CI in patients receiving,1
SIMPONI,infections,approximately weeks the incidence per patientyears of,0
SIMPONI,infections,all infections was CI in patients receiving,1
SIMPONI,infections,infections was CI in patients receiving,1
SIMPONI,infections,infections was CI in patients receiving,1
SIMPONI,infections,receiving SIMPONI ARIA see Warnings and Precautions,0
SIMPONI,active TB,patientyears was CI and,0
SIMPONI,active TB,CI and the incidence of other opportunistic infect,0
SIMPONI,active TB,treated patients the,0
SIMPONI,opportunistic infections,and the incidence of opportunistic infections per patientyears was CI Malignancies,1
SIMPONI,opportunistic infections,infections per patientyears was CI Malignancies,1
SIMPONI,opportunistic infections,incidence of opportunistic infections per patientyears was CI Malignancies,1
SIMPONI,opportunistic infections,infections per patientyears was CI Malignancies,1
SIMPONI,opportunistic infections,and,0
SIMPONI,opportunistic infections,infections per patientyears was CI Malignancies,1
SIMPONI,opportunistic infections,of opportunistic infections per patientyears was CI Malignancies,1
SIMPONI,opportunistic infections,,0
SIMPONI,malignancy,CI Malignancies One,0
SIMPONI,lymphoma,lymphoma and NMSC with SIMPONI ARIA,1
SIMPONI,NMSC,NMSC with SIMPONI ARIA was reported,1
SIMPONI,NMSC,other than lymphoma and,0
SIMPONI,NMSC,was reported through Week during,0
SIMPONI,NMSC,the,0
SIMPONI,NMSC,Malignancies One case of malignancy other than lymphoma and,0
SIMPONI,NMSC,than lymphoma NMSC with SIMPONI ARIA was reported,1
SIMPONI,NMSC,through Week during the controlled phase of Trial,0
SIMPONI,malignancies,malignancies per patientyears other than lymphoma,1
SIMPONI,malignancies,,0
SIMPONI,malignancies,malignancies per patientyears other than lymphoma,1
SIMPONI,malignancies,,0
SIMPONI,malignancies,was,0
SIMPONI,malignancies,the incidence malignancies per patientyears other than lymphoma,1
SIMPONI,lymphoma,lymphoma and NMSC in SIMPONI ARIAtreated,1
SIMPONI,lymphoma,patientyears other lymphoma and NMSC in SIMPONI ARIAtreated,1
SIMPONI,lymphoma,lymphoma and NMSC in SIMPONI ARIAtreated,1
SIMPONI,NMSC,patientyears other than lymphoma NMSC in SIMPONI ARIAtreated patients was,1
SIMPONI,NMSC,NMSC in SIMPONI ARIAtreated patients was,1
SIMPONI,NMSC,NMSC in SIMPONI ARIAtreated patients was,1
SIMPONI,NMSC,patientyears other than lymphoma NMSC in SIMPONI ARIAtreated patients was,1
SIMPONI,NMSC,patientyears other than lymphoma NMSC in SIMPONI ARIAtreated patients was,1
SIMPONI,NMSC,SIMPONI ARIAtreated patients was CI and the incidence of NMSC,0
SIMPONI,NMSC,incidence NMSC was CI Liver Enzyme Elevations,1
SIMPONI,NMSC,NMSC was CI Liver Enzyme Elevations,1
SIMPONI,NMSC,of seve,0
SIMPONI,NMSC,been reports of seve,0
SIMPONI,NMSC,Liver Enzyme Elevations There have,0
SIMPONI,NMSC,Liver Enzyme Elevations There have been,0
SIMPONI,NMSC,incidence NMSC was CI Liver Enzyme Elevations,1
SIMPONI,hepatic reactions,been reports of hepatic,1
SIMPONI,hepatic reactions,reports of severe,0
SIMPONI,hepatic reactions,hepatic,1
SIMPONI,hepatic reactions,have been reports of hepatic reactions including acute liver failure in,1
SIMPONI,acute liver failure,acute,1
SIMPONI,ALT elevations,through ALT elevations ULN occurred in of SIMPONI,1
SIMPONI,ALT elevations,through ALT elevations ULN occurred in of SIMPONI,1
SIMPONI,ALT elevations,ARIAtreated patients,0
SIMPONI,ALT elevations,,0
SIMPONI,ALT elevations,ALT,1
SIMPONI,ALT elevations,ALT elevations ULN occurred in of SIMPONI,1
SIMPONI,formation of autoantibodies,associated with formation of autoantibodies and rarely with the development,1
SIMPONI,formation of autoantibodies,with the development of a lupuslike syndrome At,0
SIMPONI,formation of autoantibodies,is a member,0
SIMPONI,formation of autoantibodies,associated,0
SIMPONI,formation of autoantibodies,with formation,1
SIMPONI,formation of autoantibodies,of autoantibodies and rarely with the development,1
SIMPONI,formation of autoantibodies,the,0
SIMPONI,formation of autoantibodies,autoantibodies and rarely with the development,1
SIMPONI,lupus-like syndrome,lupus-like syndrome At Week in Trial of,1
SIMPONI,lupus-like syndrome,with the,0
SIMPONI,lupus-like syndrome,syndrome At Week in Trial of,1
SIMPONI,newly ANA-positive,and,0
SIMPONI,newly ANA-positive,one SIMPONI ARIAtreated patient and no,0
SIMPONI,newly ANA-positive,patients,0
SIMPONI,newly ANA-positive,patients newly ANA-positive at titers of or greater,1
SIMPONI,newly ANA-positive,patients and of,0
SIMPONI,newly ANA-positive,were,0
SIMPONI,newly ANA-positive,,0
SIMPONI,newly ANA-positive,of control patients,0
SIMPONI,newly ANA-positive,SIMPONI ARIAtreated,0
SIMPONI,newly positive anti-dsDNA antibodies,controlled phase,0
SIMPONI,infusion reaction,infusion reaction compared with of infusions in,1
SIMPONI,infusion reaction,associated with infusion reaction compared with of infusions in,1
SIMPONI,infusion reaction,infusion reaction compared with of infusions in,1
SIMPONI,infusion reaction,infusions were associated with infusion reaction compared with of infusions in,1
SIMPONI,infusion reaction,phase of Trial through Week of SIMPONI ARIA infusions were associated,0
SIMPONI,infusion reaction,were associated with infusion,1
SIMPONI,infusion reaction,,0
SIMPONI,infusion reaction,infusions were associated with infusion reaction compared with of infusions in,1
SIMPONI,rash,most common infusion reaction in SIMPONI ARIA,0
SIMPONI,rash,rash No serious infusion reactions were,1
SIMPONI,rash,rash No serious infusion reactions were,1
SIMPONI,rash,,0
SIMPONI,rash,control group The most common infusion reaction in,0
SIMPONI,rash,rash No serious infusion reactions were,1
SIMPONI,rash,in SIMPONI ARIA treated patients,0
SIMPONI,Upper respiratory tract infection,and Upper respiratory tract infection such as upper respiratory tract,1
SIMPONI,upper respiratory tract infection,infection such,0
SIMPONI,upper respiratory tract infection,,0
SIMPONI,nasopharyngitis,nasopharyngitis pharyngitis laryngitis and rhinitis,1
SIMPONI,nasopharyngitis,as,0
SIMPONI,nasopharyngitis,nasopharyngitis pharyngitis laryngitis and rhinitis,1
SIMPONI,nasopharyngitis,,0
SIMPONI,nasopharyngitis,rhinitis,0
SIMPONI,nasopharyngitis,,0
SIMPONI,pharyngitis,,0
SIMPONI,pharyngitis,respiratory tract infection pharyngitis laryngitis and rhinitis Viral infec,1
SIMPONI,laryngitis,laryngitis and rhinitis Viral infections such,1
SIMPONI,laryngitis,laryngitis and rhinitis Viral infections such,1
SIMPONI,laryngitis,laryngitis and rhinitis Viral infections such,1
SIMPONI,laryngitis,and,0
SIMPONI,laryngitis,laryngitis and rhinitis Viral infections such,1
SIMPONI,laryngitis,such as upper,0
SIMPONI,laryngitis,rhinitis Viral,0
SIMPONI,laryngitis,laryngitis and rhinitis Viral infections such,1
SIMPONI,laryngitis,laryngitis and rhinitis Viral infections such,1
SIMPONI,rhinitis,such as influenza,0
SIMPONI,rhinitis,laryngitis rhinitis Viral infections such as influenza,1
SIMPONI,Viral infections,laryngitis and Viral infections such as influenza and herpes,1
SIMPONI,influenza,,0
SIMPONI,influenza,influenza and herpes Bacterial infections,1
SIMPONI,influenza,Viral infections,0
SIMPONI,influenza,infections such,0
SIMPONI,influenza,,0
SIMPONI,influenza,rhinitis Viral infections,0
SIMPONI,Bacterial infections,Bacterial infections Bronchitis,1
SIMPONI,Bacterial infections,infections Bronchitis,1
SIMPONI,Bacterial infections,Bacterial infections Bronchitis,1
SIMPONI,Bacterial infections,Bacterial,1
SIMPONI,Bacterial infections,Bacterial infections Bronchitis,1
SIMPONI,Bacterial infections,as influenza and Bacterial infections Bronchitis,1
SIMPONI,Bacterial infections,Bacterial infections Bronchitis,1
SIMPONI,Bacterial infections,as influenza and Bacterial infections Bronchitis,1
SIMPONI,Bronchitis,,0
SIMPONI,Bronchitis,infections Bronchitis Va,1
SIMPONI,Bronchitis,infections,0
SIMPONI,Bronchitis,infections,0
SIMPONI,Bronchitis,Bronchitis Va,1
SIMPONI,Vascular disorders,is Vascular disorders Hyperten,1
SIMPONI,Vascular disorders,,0
SIMPONI,Vascular disorders,is,0
SIMPONI,Vascular disorders,Vascular disorders Hyperten,1
SIMPONI,Vascular disorders,is Vascular,1
SIMPONI,Vascular disorders,,0
SIMPONI,Vascular disorders,is Vascular disorders Hyperten,1
SIMPONI,Vascular disorders,,0
SIMPONI,Hypertension,,0
SIMPONI,Hypertension,,0
SIMPONI,Hypertension,Hypertension Skin,1
SIMPONI,Hypertension,isorders Hypertension Skin,1
SIMPONI,Hypertension,isorders,0
SIMPONI,Hypertension,Hypertension Skin,1
SIMPONI,Hypertension,,0
SIMPONI,Hypertension,Skin,0
SIMPONI,Hypertension,Hypertension Skin,1
SIMPONI,Rash,Rash,1
SIMPONI,Rash,ubcutaneous Rash,1
SIMPONI,Rash,Rash,1
SIMPONI,Pyrexia,,0
SIMPONI,lymphatic disorders,Blood lymphatic disorders Leukopenia,1
SIMPONI,lymphatic disorders,,0
SIMPONI,lymphatic disorders,Leukopenia,0
SIMPONI,lymphatic disorders,Leukopenia,0
SIMPONI,lymphatic disorders,lymphatic disorders Leukopenia,1
SIMPONI,lymphatic disorders,lymphatic disorders Leukopenia,1
SIMPONI,lymphatic disorders,,0
SIMPONI,lymphatic disorders,disorders Leukopenia,1
SIMPONI,lymphatic disorders,,0
SIMPONI,lymphatic disorders,Blood lymphatic disorders Leukopenia,1
SIMPONI,Leukopenia,Leukopenia,1
SIMPONI,Leukopenia,,0
SIMPONI,Leukopenia,Leukopenia,1
SIMPONI,Leukopenia,,0
SIMPONI,Leukopenia,Leukopenia,1
SIMPONI,Leukopenia,Leukopenia,1
SIMPONI,Leukopenia,Leukopenia,1
SIMPONI,Leukopenia,Leukopenia,1
SIMPONI,Leukopenia,Leukopenia,1
SIMPONI,Leukopenia,Leukopenia,1
SIMPONI,Superficial fungal infection,sinusitis abscess lower respiratory,0
SIMPONI,Superficial fungal infection,infection sinusitis,1
SIMPONI,Superficial fungal infection,Superficial fungal,1
SIMPONI,Superficial fungal infection,and,0
SIMPONI,Superficial fungal infection,Infestations,0
SIMPONI,Superficial fungal infection,,0
SIMPONI,Superficial fungal infection,Superficial fungal infection sinusitis,1
SIMPONI,Superficial fungal infection,respiratory tract,0
SIMPONI,Superficial fungal infection,infection pneumonia,0
SIMPONI,sinusitis,sinusitis abscess,1
SIMPONI,sinusitis,sinusitis abscess,1
SIMPONI,sinusitis,listed by system organ class Infections and Infestations,0
SIMPONI,sinusitis,sinusitis abscess,1
SIMPONI,abscess,,0
SIMPONI,abscess,lower respiratory tract infection pneumonia,0
SIMPONI,lower respiratory tract infection,sinusitis lower respiratory,1
SIMPONI,lower respiratory tract infection,infection,0
SIMPONI,lower respiratory tract infection,sinusitis lower respiratory tract infection pneumonia,1
SIMPONI,lower respiratory tract infection,lower,1
SIMPONI,lower respiratory tract infection,pyelonephritis Investigations Alanine aminotransferase,0
SIMPONI,lower respiratory tract infection,infection sinusitis lower respiratory tract infection pneumonia,1
SIMPONI,lower respiratory tract infection,Superficial fungal infection sinusitis lower respiratory tract,1
SIMPONI,lower respiratory tract infection,respiratory tract infection pneumonia,1
SIMPONI,lower respiratory tract infection,lower respiratory tract,1
SIMPONI,lower respiratory tract infection,and,0
SIMPONI,pneumonia,abscess lower respiratory tract pneumonia pyelonephritis,1
SIMPONI,pneumonia,lower respiratory tract pneumonia pyelonephritis,1
SIMPONI,pneumonia,increased aspartate,0
SIMPONI,pneumonia,respiratory tract pneumonia pyelonephritis,1
SIMPONI,pyelonephritis,pyelonephritis Investigations,1
SIMPONI,pyelonephritis,increased,0
SIMPONI,pyelonephritis,lower respiratory tract infection pyelonephritis Investigations,1
SIMPONI,pyelonephritis,pyelonephritis Investigations,1
SIMPONI,Alanine aminotransferase increased,pneumonia pyelonephritis,0
SIMPONI,Alanine aminotransferase increased,tract infection pneumonia pyelonephritis Alanine aminotransferase increased aspartate,1
SIMPONI,aspartate aminotransferase increased,,0
SIMPONI,aspartate aminotransferase increased,,0
SIMPONI,aspartate aminotransferase increased,Investigations,0
SIMPONI,aspartate aminotransferase increased,Alanine aminotransferase aspartate aminotransferase increased neutrophil,1
SIMPONI,aspartate aminotransferase increased,Alanine aminotransferase aspartate aminotransferase increased neutrophil,1
SIMPONI,aspartate aminotransferase increased,system disorders,0
SIMPONI,aspartate aminotransferase increased,Alanine aminotransferase aspartate aminotransferase increased neutrophil,1
SIMPONI,aspartate aminotransferase increased,,0
SIMPONI,aspartate aminotransferase increased,Alanine,0
SIMPONI,aspartate aminotransferase increased,,0
SIMPONI,neutrophil count decreased,aminotransferase,0
SIMPONI,neutrophil count decreased,aminotransferase neutrophil count decreased Nervous,1
SIMPONI,neutrophil count decreased,disorders Dizziness paresthesia Gastrointestinal,0
SIMPONI,neutrophil count decreased,aminotransferase neutrophil,1
SIMPONI,neutrophil count decreased,aspartate aminotransferase neutrophil count,1
SIMPONI,neutrophil count decreased,aminotransferase,0
SIMPONI,neutrophil count decreased,aspartate aminotransferase,0
SIMPONI,Dizziness,Dizziness paresthesia,1
SIMPONI,Dizziness,,0
SIMPONI,paresthesia,count decreased Nervous system disorders Dizziness,0
SIMPONI,paresthesia,paresthesia Gastrointestinal,1
SIMPONI,paresthesia,no,0
SIMPONI,paresthesia,no,0
SIMPONI,Constipation,Constipation Postmarketing,1
SIMPONI,Constipation,Gastrointestinal disorders,0
SIMPONI,Constipation,available for SIMPONI,0
SIMPONI,Melanoma,Precautions Immune System Disorders Serious systemic,0
SIMPONI,Melanoma,Neoplasm Benign,0
SIMPONI,Melanoma,Neoplasm Benign and Melanoma see,1
SIMPONI,Melanoma,,0
SIMPONI,Melanoma,exposure Neoplasm Benign and Malignant,0
SIMPONI,Melanoma,Melanoma see,1
SIMPONI,Melanoma,exposure,0
SIMPONI,Melanoma,causal,0
SIMPONI,systemic hypersensitivity reactions,,0
SIMPONI,systemic hypersensitivity reactions,see,0
SIMPONI,systemic hypersensitivity reactions,System Disorders systemic,1
SIMPONI,systemic hypersensitivity reactions,sarcoidosis,0
SIMPONI,systemic hypersensitivity reactions,System Disorders systemic hypersensitivity reactions including,1
SIMPONI,systemic hypersensitivity reactions,Warnings and Precautions,0
SIMPONI,systemic hypersensitivity reactions,hypersensitivity reactions including,1
SIMPONI,systemic hypersensitivity reactions,Precautions Immune System,0
SIMPONI,systemic hypersensitivity reactions,Precautions Immune,0
SIMPONI,systemic hypersensitivity reactions,Precautions sarcoidosis Re,0
SIMPONI,anaphylactic reaction,reaction see,1
SIMPONI,sarcoidosis,sarcoidosis Respiratory,1
SIMPONI,sarcoidosis,Warnings and,0
SIMPONI,sarcoidosis,and,0
SIMPONI,sarcoidosis,see Warnings and sarcoidosis Respiratory,1
SIMPONI,sarcoidosis,sarcoidosis Respiratory,1
SIMPONI,sarcoidosis,,0
SIMPONI,sarcoidosis,sarcoidosis Respiratory,1
SIMPONI,sarcoidosis,reactions including anaphylactic reaction see Warnings and,0
SIMPONI,sarcoidosis,sarcoidosis Respiratory,1
SIMPONI,sarcoidosis,,0
SIMPONI,Interstitial lung disease,,0
SIMPONI,Interstitial lung disease,,0
SIMPONI,Interstitial lung disease,tissue disorders Skin exfoliation bullous skin,0
SIMPONI,Skin exfoliation,,0
SIMPONI,Skin exfoliation,tissue,0
SIMPONI,Skin exfoliation,exfoliation bullous,1
SIMPONI,Skin exfoliation,,0
SIMPONI,Skin exfoliation,Skin exfoliation bullous,1
SIMPONI,Skin exfoliation,Skin and subcutaneous tissue Skin exfoliation bullous,1
SIMPONI,Skin exfoliation,bullous skin,0
SIMPONI,Skin exfoliation,Interstitial,0
SIMPONI,Skin exfoliation,,0
SIMPONI,Skin exfoliation,,0
SIMPONI,bullous skin reactions,,0
SIMPONI,INFECTIONS,adve rse reactions,1
SIMPONI,INFECTIONS,,0
SIMPONI,INFECTIONS,Malignan,0
SIMPONI,INFECTIONS,,0
SIMPONI,INFECTIONS,Serious Infections see Warnings and,0
SIMPONI,INFECTIONS,,0
SIMPONI,INFECTIONS,,0
SIMPONI,MALIGNANCY,eactions w ere Serious Infections,1
SIMPONI,MALIGNANCY,,0
SIMPONI,MALIGNANCY,eactions w ere Serious Infections see Warnings,1
SIMPONI,MALIGNANCY,eactions,1
SIMPONI,MALIGNANCY,,0
SIMPONI,MALIGNANCY,see Warnings and Precautions Malignancies see,0
SIMPONI,MALIGNANCY,eactions w ere,1
SIMPONI,MALIGNANCY,eactions,1
SIMPONI,MALIGNANCY,eactions,1
SIMPONI,INFECTIONS,Warnings,0
SIMPONI,INFECTIONS,,0
SIMPONI,INFECTIONS,,0
SIMPONI,INFECTIONS,,0
SIMPONI,INFECTIONS,ections,1
SIMPONI,INFECTIONS,,0
SIMPONI,INFECTIONS,,0
SIMPONI,INFECTIONS,ections,1
SIMPONI,MALIGNANCY,,0
SIMPONI,MALIGNANCY,see arnings,1
SIMPONI,MALIGNANCY,,0
SIMPONI,MALIGNANCY,see rnings and Precautions EXCERPT,1
SIMPONI,MALIGNANCY,Warnings and Precautions,0
SIMPONI,MALIGNANCY,Infections,0
SIMPONI,MALIGNANCY,,0
SIMPONI,infections,tract,0
SIMPONI,infections,,0
SIMPONI,death,"upper respiratory tract ,",1
SIMPONI,death,"tract ,",1
SIMPONI,tuberculosis,"respiratory tract infection viral n, bronchiti s hypertension",1
SIMPONI,tuberculosis,s hypertension and rash To report,0
SIMPONI,tuberculosis,"respiratory tract infection viral n,",1
SIMPONI,tuberculosis,upper respiratory tract infection viral infectio,0
SIMPONI,tuberculosis,contactJanssen Bio,0
SIMPONI,tuberculosis,"n, bronchiti s hypertension",1
SIMPONI,tuberculosis,respiratory tract infection viral infectio,0
SIMPONI,TB,infection viral infection  h ypertension and,1
SIMPONI,histoplasmosis,hypertension and rash To,0
SIMPONI,histoplasmosis,and rash To rt SUSPECTED,1
SIMPONI,histoplasmosis,rt SUSPECTED A DVERSE REACTIONS,1
SIMPONI,histoplasmosis,A DVERSE REACTIONS,1
SIMPONI,histoplasmosis,or,0
SIMPONI,histoplasmosis,,0
SIMPONI,histoplasmosis,To rt SUSPECTED,1
SIMPONI,histoplasmosis,rt SUSPECTED A DVERSE REACTIONS,1
SIMPONI,histoplasmosis,repo,0
SIMPONI,opportunistic infections,ech Inc at JANSSEN or FDA,0
SIMPONI,Lymphoma,eflect t he rates,1
SIMPONI,Lymphoma,,0
SIMPONI,Lymphoma,compared to rates in the clinical trials of another,0
SIMPONI,Lymphoma,drug and may not eflect t he rates,1
SIMPONI,Lymphoma,eflect t he rates,1
SIMPONI,malignancies,reflect the rates served in cl inical practice,1
SIMPONI,malignancies,not,0
SIMPONI,malignancies,reflect the rates served,1
SIMPONI,malignancies,served in cl inical practice,1
SIMPONI,malignancies,rates served in cl inical practice,1
SIMPONI,infections,SIMPONI ARIA at Week or Week either by,0
SIMPONI,infections,with SIMPONI ARIA at Week or Week either by patient response,0
SIMPONI,infections,rec eive treatment,1
SIMPONI,death,provisions for patients taking placebo to receive treatment with SIMPONI,0
SIMPONI,death,with SIMPONI ARIA at,0
SIMPONI,death,activity,0
SIMPONI,death,,0
SIMPONI,death,eek 1 or Week,1
SIMPONI,death,ARIA at eek 1 or Week,1
SIMPONI,death,treatment with,0
SIMPONI,death,patient response based on uncontrolled,0
SIMPONI,death,,0
SIMPONI,infections,by desig n so,1
SIMPONI,infections,that adverse events cannot always be,0
SIMPONI,infections,,0
SIMPONI,infections,activity,0
SIMPONI,infections,r by desig n so,1
SIMPONI,Active tuberculosis,of exposure Trial,0
SIMPONI,Active tuberculosis,ARIA at Week The proportion,0
SIMPONI,Active tuberculosis,,0
SIMPONI,Active tuberculosis,of patients,0
SIMPONI,tuberculosis,controlled,0
SIMPONI,tuberculosis,ARIA at eek 16).,1
SIMPONI,tuberculosis,at eek 16). The proportion of,1
SIMPONI,Invasive fungal infections,ARIAtreated patients and for placebotreated patients Upper respiratory tr,0
SIMPONI,Invasive fungal infections,placebotreated patients Upper respiratory act infection was the most common adverse,1
SIMPONI,Invasive fungal infections,infection was the most common adverse,1
SIMPONI,Invasive fungal infections,adverse reaction reported in the trial through Week,0
SIMPONI,Invasive fungal infections,reaction reported in the trial through Week occurring in of,0
SIMPONI,Invasive fungal infections,the most common adverse,1
SIMPONI,Invasive fungal infections,reported in the trial through Week,0
SIMPONI,Invasive fungal infections,act,1
SIMPONI,histoplasmosis,the most common,0
SIMPONI,coccidioidomycosis,compared with of,0
SIMPONI,coccidioidomycosis,orted in the,1
SIMPONI,coccidioidomycosis,most common adverse reaction orted,1
SIMPONI,coccidioidomycosis,trial through Week,1
SIMPONI,coccidioidomycosis,patients Upper respiratory tract infection was the most common,0
SIMPONI,coccidioidomycosis,adverse reaction orted in the trial through Week,1
SIMPONI,candidiasis,trial hrough Week occurring in,1
SIMPONI,candidiasis,Week occurring in,1
SIMPONI,candidiasis,compared with of controltreated pati,0
SIMPONI,candidiasis,was the most common,0
SIMPONI,candidiasis,in,0
SIMPONI,candidiasis,,0
SIMPONI,aspergillosis,4 occurring i n of,1
SIMPONI,aspergillosis,,0
SIMPONI,aspergillosis,through 4,1
SIMPONI,aspergillosis,common,0
SIMPONI,aspergillosis,trial through Week,0
SIMPONI,blastomycosis,Week occurring 6.5%,1
SIMPONI,blastomycosis,6.5% of SIMPO NI ARIAtreated,1
SIMPONI,blastomycosis,Week occurring 6.5%,1
SIMPONI,blastomycosis,6.5% of,1
SIMPONI,blastomycosis,was the most common adverse reaction reported in the,0
SIMPONI,blastomycosis,trial through Week occurring 6.5% of,1
SIMPONI,blastomycosis,Week occurring 6.5%,1
SIMPONI,pneumocystosis,reported in the trial through Week occurring in of SIMPONI AR,0
SIMPONI,pneumocystosis,of SIMPONI IA-treated,1
SIMPONI,pneumocystosis,SIMPONI IA-treated pat ients as,1
SIMPONI,pneumocystosis,as compared with of controltreated patients,0
SIMPONI,pneumocystosis,controltreated patients respectively Infections Seri,0
SIMPONI,pneumocystosis,IA-treated pat ients as,1
SIMPONI,pneumocystosis,in of SIMPONI IA-treated,1
SIMPONI,pneumocystosis,SIMPONI IA-treated,1
SIMPONI,infections due to opportunistic pathogens,the TB,0
SIMPONI,infections due to opportunistic pathogens,,0
SIMPONI,infections due to opportunistic pathogens, a high incidence rate of TB  [see  Warni ngs and,1
SIMPONI,infections due to opportunistic pathogens,Warni ngs and,1
SIMPONI,infections due to opportunistic pathogens,occurred in countries  a high incidence rate of TB  [see  Warni ngs and,1
SIMPONI,infections due to opportunistic pathogens,,0
SIMPONI,infections due to opportunistic pathogens,The majority of the TB cases occurred in countries with,0
SIMPONI,infections due to opportunistic pathogens,occurred in,0
SIMPONI,infections due to opportunistic pathogens,The majority of the TB,0
SIMPONI,Lymphoma,and uncontrolled ortions  of Trial,1
SIMPONI,Lymphoma,,0
SIMPONI,Lymphoma,of Trial total patientyears of followup,0
SIMPONI,Lymphoma,uncontrolled ortions  of Trial,1
SIMPONI,malignancies,p atientyears of,1
SIMPONI,malignancies,958 total p atientyears of,1
SIMPONI,malignancies,portions of  958 total p atientyears of,1
SIMPONI,malignancies,total p atientyears of,1
SIMPONI,malignancies,,0
SIMPONI,malignancies,p atientyears of,1
SIMPONI,fatal,followup of,0
SIMPONI,fatal,years of followup,1
SIMPONI,fatal,,0
SIMPONI,fatal,Trial total years of followup,1
SIMPONI,fatal,years of followup,1
SIMPONI,fatal,the incidence per,0
SIMPONI,fatal,total patient,0
SIMPONI,infections,,0
SIMPONI,infections,,0
SIMPONI,Invasive fungal infections,u pper respiratory tract infection,1
SIMPONI,Invasive fungal infections,adverse ns (incidence >=3%) are: u pper respiratory tract infection,1
SIMPONI,Invasive fungal infections,,0
SIMPONI,Invasive fungal infections,EXCERPT,0
SIMPONI,Invasive fungal infections,,0
SIMPONI,Invasive fungal infections,tract infection viral infection,0
SIMPONI,Invasive fungal infections,ns (incidence >=3%) are: u pper respiratory tract infection,1
SIMPONI,Invasive fungal infections,(incidence >=3%) are: u pper respiratory tract infection,1
SIMPONI,Hepatitis B reactivation,Biotech Inc at  (1-800-526-7736) or FDA at FDA or wwwfdagovmedwatch,1
SIMPONI,Hepatitis B reactivation,or wwwfdagovmedwatch Clinical,0
SIMPONI,Hepatitis B reactivation,Inc at,0
SIMPONI,Hepatitis B reactivation,Inc at  (1-800-526-7736) or FDA at FDA or wwwfdagovmedwatch,1
SIMPONI,Hepatitis B reactivation,SUSPECTED ADVERSE REACTIONS,0
SIMPONI,Hepatitis B reactivation,at FDA,0
SIMPONI,Hepatitis B reactivation,Biotech Inc,0
SIMPONI,Hepatitis B reactivation,REACTIONS,0
SIMPONI,Malignancies,"under widely varying nditions, ad verse reaction rates observed",1
SIMPONI,lymphoma,to rates,0
SIMPONI,lymphoma,tes,1
SIMPONI,lymphoma,are conducted under widely varying conditions,0
SIMPONI,lymphoma,reaction tes obse rved in the clinical,1
SIMPONI,lymphoma,conditions adverse reaction tes obse rved in the clinical,1
SIMPONI,lymphoma,rved in the clinical trials of a drug cannot be directly compared,0
SIMPONI,lymphoma,tes obse rved in the clinical,1
SIMPONI,lymphoma,obse rved in the clinical,1
SIMPONI,lymphoma,conducted under widely varying conditions adverse reaction ra,0
SIMPONI,lymphoma,clinical trials,0
SIMPONI,Heart failure,bas ed on one randomized,1
SIMPONI,Heart failure,The safety data below are bas ed on one randomized,1
SIMPONI,Heart failure,,0
SIMPONI,Demyelinating disease,infusion Trial The protocol included,1
SIMPONI,Demyelinating disease,RA receiving SIMPONI ARIA intravenous infusion  Trial The protocol included,1
SIMPONI,Demyelinating disease,ARIA intravenous infusion  Trial The protocol included,1
SIMPONI,Hypersensitivity reactions,for s taking placebo to receiv e treatment with SIMPONI,1
SIMPONI,Hypersensitivity reactions,provisions for s taking placebo to receiv e treatment with SIMPONI,1
SIMPONI,Hypersensitivity reactions,protocol included provisions for s taking placebo to receiv e treatment with SIMPONI,1
SIMPONI,Hypersensitivity reactions,s,1
SIMPONI,Hypersensitivity reactions,at Week or Week,0
SIMPONI,Hypersensitivity reactions,at Week or,0
SIMPONI,Hypersensitivity reactions,protocol included provisions for s taking placebo to receiv e treatment with SIMPONI,1
SIMPONI,Hypersensitivity reactions,infusion,0
SIMPONI,Hypersensitivity reactions,for s taking placebo to,1
SIMPONI,systemic hypersensitivity reactions,on uncontrolled disease,0
SIMPONI,systemic hypersensitivity reactions,uncontrolled disease activity,0
SIMPONI,systemic hypersensitivity reactions,provisions for patients taking,0
SIMPONI,systemic hypersensitivity reactions,or by design,0
SIMPONI,systemic hypersensitivity reactions,taking placebo to receive t with SIMPONI ARIA at Week 16 or W eek either by patient,1
SIMPONI,anaphylaxis,treatment with SIMPONI ARIA at Week or Week eith,0
SIMPONI,anaphylaxis,so that adverse events cannot,0
SIMPONI,anaphylaxis,patients taking placebo,0
SIMPONI,anaphylaxis,to receive treatment,0
SIMPONI,anaphylaxis,Week or Week er by patie nt response based on,1
SIMPONI,anaphylaxis,at Week or Week er by,1
SIMPONI,anaphylaxis,,0
SIMPONI,anaphylaxis,patie nt response based on,1
SIMPONI,anaphylaxis,to receive treatment with SIMPONI ARIA at Week or,0
SIMPONI,anaphylaxis,patie nt response based on,1
SIMPONI,infections,so that adverse events cannot always be unambiguously attributed,0
SIMPONI,infections,treatment. Comparisons between placebo and,1
SIMPONI,infections,treatment. Comparisons between placebo and,1
SIMPONI,infections,attributed to a treatment. Comparisons between placebo and,1
SIMPONI,death,of ex posure Trial included controltreated,1
SIMPONI,death,on,0
SIMPONI,death,were based on the,0
SIMPONI,death,ex posure Trial included controltreated,1
SIMPONI,Opportunistic infections,"first weeks of .



 Trial 1 included 1 controltreated patients and SIMPONI",1
SIMPONI,Opportunistic infections,"first weeks of .



 Trial 1 included 1 controltreated patients and SIMPONI",1
SIMPONI,Opportunistic infections,.,1
SIMPONI,Opportunistic infections,the first weeks,0
SIMPONI,Opportunistic infections,,0
SIMPONI,Opportunistic infections,,0
SIMPONI,Opportunistic infections,based on the first weeks of exposure,0
SIMPONI,aspergillosis,reated patien ts who switched to,1
SIMPONI,aspergillosis,patien ts who switched to,1
SIMPONI,aspergillosis,controltreated patients and,0
SIMPONI,aspergillosis,controltreated patients and SIMPONI ARIAtreated patients which,0
SIMPONI,aspergillosis,patien ts who switched to,1
SIMPONI,blastomycosis, who switched to SIMPONI ARIA at,1
SIMPONI,blastomycosis,includes controltreated who,1
SIMPONI,candidiasis,due to,0
SIMPONI,candidiasis,treatment due to,0
SIMPONI,candidiasis,who switched,0
SIMPONI,candidiasis,who switched o SIMPONI A RIA at Week The,1
SIMPONI,candidiasis,discontinued treatment due to adverse reactions in t,0
SIMPONI,coccidioidomycosis,Week 16). The proportion of patients who,1
SIMPONI,coccidioidomycosis,who discontinued treatment due to adverse reactions in,0
SIMPONI,coccidioidomycosis,controlled,0
SIMPONI,coccidioidomycosis,treatment due to adverse reactions in the controlled phase,0
SIMPONI,histoplasmosis,roportion of p atients who discontinued treatment,1
SIMPONI,histoplasmosis,ARIA at Week The roportion,1
SIMPONI,legionellosis,ients who dis continued treatment due to,1
SIMPONI,legionellosis,includes controltreated patients who switched to SIMPONI ARIA at Week The proportion of,0
SIMPONI,legionellosis,dis continued treatment due to,1
SIMPONI,legionellosis,to SIMPONI,0
SIMPONI,legionellosis,was,0
SIMPONI,legionellosis,in the controlled,0
SIMPONI,legionellosis,who dis continued treatment due to,1
SIMPONI,legionellosis,who dis continued treatment due to,1
SIMPONI,legionellosis,patients who switched,0
SIMPONI,legionellosis,The proportion of ients who dis continued treatment due to,1
SIMPONI,listeriosis,proportion of patients who ntinued tre atment due to adverse,1
SIMPONI,pneumocystosis,,0
SIMPONI,pneumocystosis,patients who discontinued ment,1
SIMPONI,pneumocystosis,switched to SIMPONI ARIA at Week The proportion of patients who discontinued,0
SIMPONI,pneumocystosis,discontinued treat,0
SIMPONI,pneumocystosis,patients who discontinued ment,1
SIMPONI,pneumocystosis,,0
SIMPONI,pneumocystosis,patients who discontinued ment due to,1
SIMPONI,tuberculosis,treatment due to reactions in the controlled phase of,1
SIMPONI,tuberculosis,,0
SIMPONI,tuberculosis,reactions in the controlled phase of,1
SIMPONI,tuberculosis,to reactions in the controlled phase of,1
SIMPONI,tuberculosis,through Week,0
SIMPONI,tuberculosis,to reactions,1
SIMPONI,tuberculosis,SIMPONI ARIA at Week The proportion of patients who discontinued treatment,0
SIMPONI,tuberculosis,due to reactions,1
SIMPONI,tuberculosis,to reactions,1
SIMPONI,tuberculosis,and,0
SIMPONI,reactivation of tuberculosis,Malignancies One case,0
SIMPONI,reactivation of tuberculosis,infections patient-years was,1
SIMPONI,reactivation of tuberculosis,of other opportunistic infections patient-years,1
SIMPONI,reactivation of tuberculosis,of other opportunistic infections patient-years was 0.42 (95%  CI Malignancies One case,1
SIMPONI,reactivation of tuberculosis,incidence of other opportunistic infections per,0
SIMPONI,reactivation of tuberculosis,0.42 (95% CI Malignancies One case,1
SIMPONI,new tuberculosis infections,,0
SIMPONI,new tuberculosis infections,malignancy other than lymphoma and NMSC with,0
SIMPONI,new tuberculosis infections,,0
SIMPONI,new tuberculosis infections,SIMPONI,0
SIMPONI,new tuberculosis infections,1.07). Malign ancies One case of,1
SIMPONI,new tuberculosis infections,,0
SIMPONI,new tuberculosis infections,"0.11, 1.07).",1
SIMPONI,new tuberculosis infections,Malign ancies One case of,1
SIMPONI,reactivation of hepatitis B virus,and are in addition highly dependent on,0
SIMPONI,reactivation of hepatitis B virus,and thus results are an underestimate of t he rate of product,1
SIMPONI,reactivation of hepatitis B virus,thus results are an underestimate of t he rate of product,1
SIMPONI,reactivation of hepatitis B virus,results are,1
SIMPONI,reactivation of hepatitis B virus,and thus results are an underestimate of,1
SIMPONI,reactivation of hepatitis B virus,ELISA assay The ELISA assay is subject to interference by copresent golimumab and thus the,0
SIMPONI,reactivation of hepatitis B virus,t he rate of product,1
SIMPONI,HBV reactivation,Addit ionally the observed incidence,1
SIMPONI,HBV reactivation,assay. Addit ionally the observed incidence,1
SIMPONI,HBV reactivation,and specificity the assay. Addit ionally the observed incidence,1
SIMPONI,HBV reactivation,may be influenced by,0
SIMPONI,HBV reactivation,influenced by several,0
SIMPONI,HBV reactivation,specificity the assay. Addit ionally the observed incidence,1
SIMPONI,HBV reactivation,antibody positivity in an assay may be influenced by,0
SIMPONI,Malignancies,influenza,0
SIMPONI,Malignancies,             Bacterial infections,1
SIMPONI,Malignancies,such as,0
SIMPONI,Malignancies,infections,0
SIMPONI,Malignancies,such as influenza and              Bacterial infections,1
SIMPONI,Malignancies,such as influenza and              Bacterial infections,1
SIMPONI,Malignancies,,0
SIMPONI,Malignancies,             Bacterial infections,1
SIMPONI,fatal,and       Bacterial infections,1
SIMPONI,fatal,,0
SIMPONI,fatal,      Bacterial infections,1
SIMPONI,fatal,      Bacterial infections,1
SIMPONI,fatal,influenza and       Bacterial infections,1
SIMPONI,fatal,such as influenza and       Bacterial infections,1
SIMPONI,fatal,herpes,0
SIMPONI,fatal,,0
SIMPONI,lymphomas,,0
SIMPONI,lymphomas,s ascular d isorders,1
SIMPONI,lymphomas,isorders,0
SIMPONI,lymphomas,isorders,0
SIMPONI,lymphomas,isorders,0
SIMPONI,lymphomas,ascular d isorders,1
SIMPONI,lymphomas,,0
SIMPONI,lymphomas,d isorders,1
SIMPONI,non-Hodgkin's lymphoma,Vascular                        Hypertension,1
SIMPONI,non-Hodgkin's lymphoma,disorders,0
SIMPONI,non-Hodgkin's lymphoma,                       Hypertension,1
SIMPONI,non-Hodgkin's lymphoma,,0
SIMPONI,non-Hodgkin's lymphoma,                       Hypertension,1
SIMPONI,non-Hodgkin's lymphoma,                       Hypertension,1
SIMPONI,non-Hodgkin's lymphoma,                       Hypertension,1
SIMPONI,non-Hodgkin's lymphoma,,0
SIMPONI,malignancies,"ascular     
    Hyp ertension",1
SIMPONI,malignancies,,0
SIMPONI,malignancies,,0
SIMPONI,malignancies,,0
SIMPONI,malignancies,,0
SIMPONI,malignancies,"    
    Hyp ertension",1
SIMPONI,rare malignancies,                  Skin,1
SIMPONI,rare malignancies,and subcutaneous,0
SIMPONI,rare malignancies,                  Skin and subcutaneous di,1
SIMPONI,rare malignancies,subcutaneous,0
SIMPONI,immunosuppression,                  Skin and,1
SIMPONI,immunosuppression,                  Skin and subcutaneous,1
SIMPONI,immunosuppression,                  Skin and subcutaneous disorders,1
SIMPONI,immunosuppression,Hypertension                   Skin and subcutaneous,1
SIMPONI,immunosuppression,                  Skin,1
SIMPONI,immunosuppression,Hypertension,0
SIMPONI,immunosuppression,Hypertension                   Skin and subcutaneous disorders,1
SIMPONI,immunosuppression,                  Skin and subcutaneous,1
SIMPONI,immunosuppression,Hypertension,0
SIMPONI,immunosuppression,                 ,1
SIMPONI,lymphoma,Precautions section included the lowing,1
SIMPONI,lymphoma,e,1
SIMPONI,lymphoma,lowing,1
SIMPONI,lymphoma,e,1
SIMPONI,lymphoma,lowing e,1
SIMPONI,lymphoma,"


   Ga",1
SIMPONI,lymphoma,"system disorders Dizziness 


   Ga",1
SIMPONI,lymphoma,"


   Ga",1
SIMPONI,lymphoma,neutrophil count decreased Nervous,0
SIMPONI,lymphoma,"system disorders Dizziness 


   Ga",1
SIMPONI,lymphoma,"disorders Dizziness 


   Ga",1
SIMPONI,lymphoma,"


   Ga",1
SIMPONI,chronic leukemia,The following adverse reactions,0
SIMPONI,chronic leukemia,Experience,1
SIMPONI,chronic leukemia,available for SIMPONI ARIA The following adverse reactions,0
SIMPONI,chronic leukemia,ere is,0
SIMPONI,chronic leukemia,Gastrointestinal disorders Constipation Postmarketing,0
SIMPONI,chronic leukemia,,0
SIMPONI,chronic leukemia,Gastrointestinal,0
SIMPONI,chronic leukemia,Th,1
SIMPONI,chronic leukemia,disorders Constipation Postmarketing,0
SIMPONI,chronic leukemia,The following adverse reactions,0
SIMPONI,hepatosplenic T-cell lymphoma,to reliably estimate ir frequency or establish a c,1
SIMPONI,hepatosplenic T-cell lymphoma,see,0
SIMPONI,hepatosplenic T-cell lymphoma,or establish a c,1
SIMPONI,hepatosplenic T-cell lymphoma,to,0
SIMPONI,hepatosplenic T-cell lymphoma,ir frequency or establish a,1
SIMPONI,hepatosplenic T-cell lymphoma,a c,1
SIMPONI,hepatosplenic T-cell lymphoma,estimate ir frequency or establish a c,1
SIMPONI,hepatosplenic T-cell lymphoma,reliably estimate ir frequency,1
SIMPONI,hepatosplenic T-cell lymphoma,size it is not always possible,0
SIMPONI,HSTCL,is not always possible,0
SIMPONI,HSTCL,establish a sal r,1
SIMPONI,HSTCL,or establish a sal r,1
SIMPONI,HSTCL,or establish a sal r,1
SIMPONI,HSTCL,not always,0
SIMPONI,HSTCL,or establish a sal r,1
SIMPONI,HSTCL,r,1
SIMPONI,rare type of T-cell lymphoma,Benign and : Melanoma,1
SIMPONI,fatal,and Precautions Immune System rs,1
SIMPONI,fatal,,0
SIMPONI,fatal,Precautions Immune System rs  :,1
SIMPONI,fatal,System rs  :,1
SIMPONI,fatal,,0
SIMPONI,fatal,rs :,1
SIMPONI,fatal,System rs  :,1
SIMPONI,fatal,System rs,1
SIMPONI,fatal,reactions including anaphylactic reaction see Warnings,0
SIMPONI,fatal,anaphylactic reaction,0
SIMPONI,Melanoma,,0
SIMPONI,Melanoma,,0
SIMPONI,Melanoma,,0
SIMPONI,Merkel cell carcinoma,,1
SIMPONI,Merkel cell carcinoma,,1
SIMPONI,Merkel cell carcinoma,,1
SIMPONI,Merkel cell carcinoma,,1
SIMPONI,malignancies,,0
SIMPONI,malignancies,,1
SIMPONI,malignancies,,1
SIMPONI,malignancies,,0
SIMPONI,malignancies,,1
SIMPONI,malignancies,,0
SIMPONI,malignancies,,0
SIMPONI,malignancies,,1
SIMPONI,malignancies,,1
SIMPONI,malignancies,,1
SIMPONI,malignancies,,1
SIMPONI,malignancies,,0
SIMPONI,malignancies,,0
SIMPONI,malignancies,,0
SIMPONI,malignancies,,1
SIMPONI,malignancies,,1
SIMPONI,malignancies,,0
SIMPONI,malignancies,,0
SIMPONI,worsening congestive heart failure,,1
SIMPONI,worsening congestive heart failure,,0
SIMPONI,worsening congestive heart failure,,1
SIMPONI,worsening congestive heart failure,,1
SIMPONI,CHF exacerbations,,1
SIMPONI,CHF exacerbations,,1
SIMPONI,increased mortality,,0
SIMPONI,MS,,0
SIMPONI,MS,,1
SIMPONI,MS,,0
SIMPONI,peripheral demyelinating disorders,,1
SIMPONI,peripheral demyelinating disorders,,1
SIMPONI,peripheral demyelinating disorders,,0
SIMPONI,peripheral demyelinating disorders,,0
SIMPONI,Guillain-Barre syndrome,,0
SIMPONI,Guillain-Barre syndrome,,0
SIMPONI,Guillain-Barre syndrome,,1
SIMPONI,Guillain-Barre syndrome,,1
SIMPONI,Guillain-Barre syndrome,,1
SIMPONI,Guillain-Barre syndrome,,0
SIMPONI,central demyelination,,0
SIMPONI,central demyelination,,0
SIMPONI,central demyelination,,1
SIMPONI,MS,,1
SIMPONI,MS,,0
SIMPONI,MS,,0
SIMPONI,MS,,0
SIMPONI,MS,,0
SIMPONI,MS,,1
SIMPONI,MS,,1
SIMPONI,MS,,0
SIMPONI,MS,,0
SIMPONI,MS,,1
SIMPONI,optic neuritis,,1
SIMPONI,peripheral demyelinating polyneuropathy,,0
SIMPONI,peripheral demyelinating polyneuropathy,,1
SIMPONI,peripheral demyelinating polyneuropathy,,0
SIMPONI,pancytopenia,,0
SIMPONI,pancytopenia,,1
SIMPONI,pancytopenia,,0
SIMPONI,pancytopenia,,1
SIMPONI,leukopenia,,1
SIMPONI,leukopenia,,0
SIMPONI,leukopenia,,0
SIMPONI,leukopenia,,0
SIMPONI,leukopenia,,1
SIMPONI,neutropenia,,0
SIMPONI,neutropenia,,0
SIMPONI,neutropenia,,0
SIMPONI,aplastic anemia,,0
SIMPONI,aplastic anemia,,0
SIMPONI,thrombocytopenia,,0
SIMPONI,thrombocytopenia,,1
SIMPONI,thrombocytopenia,,1
SIMPONI,thrombocytopenia,,1
SIMPONI,thrombocytopenia,,1
SIMPONI,thrombocytopenia,,1
SIMPONI,thrombocytopenia,,1
SIMPONI,thrombocytopenia,,0
SIMPONI,pancytopenia,,0
SIMPONI,pancytopenia,,1
SIMPONI,pancytopenia,,0
SIMPONI,pancytopenia,,1
SIMPONI,pancytopenia,,1
SIMPONI,pancytopenia,,0
SIMPONI,pancytopenia,,0
SIMPONI,leukopenia,,1
SIMPONI,leukopenia,,1
SIMPONI,leukopenia,,1
SIMPONI,leukopenia,,0
SIMPONI,leukopenia,,0
SIMPONI,leukopenia,,0
SIMPONI,leukopenia,,0
SIMPONI,leukopenia,,0
SIMPONI,neutropenia,,1
SIMPONI,neutropenia,,0
SIMPONI,neutropenia,,0
SIMPONI,neutropenia,,1
SIMPONI,neutropenia,,0
SIMPONI,neutropenia,,0
SIMPONI,neutropenia,,0
SIMPONI,neutropenia,,1
SIMPONI,thrombocytopenia,,1
SIMPONI,thrombocytopenia,,0
SIMPONI,thrombocytopenia,,1
SIMPONI,thrombocytopenia,,0
SIMPONI,thrombocytopenia,,1
SIMPONI,thrombocytopenia,,1
SIMPONI,thrombocytopenia,,1
SIMPONI,thrombocytopenia,,1
SIMPONI,hypersensitivity reactions,,0
SIMPONI,hypersensitivity reactions,,0
SIMPONI,anaphylactic reaction,,1
SIMPONI,anaphylactic reaction,,1
SIMPONI,anaphylactic reaction,,1
SIMPONI,anaphylactic reaction,,1
SIMPONI,anaphylactic reaction,,1
SIMPONI,anaphylactic reaction,,0
SIMPONI,anaphylactic reaction,,0
SIMPONI,anaphylactic reaction,,1
SIMPONI,anaphylactic reaction,,0
SIMPONI,anaphylactic reaction,,1
BLINCYTO,Cytokine Release Syndrome,see Warnings and,0
BLINCYTO,Neurological Toxicities,,0
BLINCYTO,Neurological Toxicities,Neurological Toxicities,1
BLINCYTO,Neurological Toxicities,Syndrome see Warnings and Neurological,1
BLINCYTO,Neurological Toxicities,Toxicities,1
BLINCYTO,Neurological Toxicities,,0
BLINCYTO,Neurological Toxicities,Neurological Toxicities,1
BLINCYTO,Neurological Toxicities,Neurological Toxicities,1
BLINCYTO,Infections,Infections,1
BLINCYTO,Infections,,0
BLINCYTO,Infections,Infections,1
BLINCYTO,Infections,Infections,1
BLINCYTO,Infections,Infections,1
BLINCYTO,Infections,and,0
BLINCYTO,Infections,Precautions,0
BLINCYTO,Infections,,0
BLINCYTO,Infections,Infections,1
BLINCYTO,Infections,,0
BLINCYTO,Tumor Lysis Syndrome,Infections see,0
BLINCYTO,Tumor Lysis Syndrome,Tumor Lysis Syndrome,1
BLINCYTO,Tumor Lysis Syndrome,and Precautions,0
BLINCYTO,Neutropenia,Effects on Ability,0
BLINCYTO,Febrile Neutropenia,see,0
BLINCYTO,Febrile Neutropenia,and Precautions Neutropenia Febrile,1
BLINCYTO,Febrile Neutropenia,Febrile Neutropenia,1
BLINCYTO,Febrile Neutropenia,see,0
BLINCYTO,Febrile Neutropenia,Syndrome see Warnings,0
BLINCYTO,Febrile Neutropenia,and Precautions Neutropenia Febrile Neutropenia,1
BLINCYTO,Effects on Ability to Drive,Neutropenia see Warnings and Effects on Ability,1
BLINCYTO,Effects on Ability to Drive,Warnings and Effects on Ability to Drive,1
BLINCYTO,Effects on Ability to Drive,Warnings and Effects on Ability to,1
BLINCYTO,Effects on Ability to Drive,see Warnings and Effects on Ability to Drive,1
BLINCYTO,Effects on Ability to Drive,Effects on Ability to Drive,1
BLINCYTO,Effects on Ability to Drive,Neutropenia see Warnings and,0
BLINCYTO,Elevated Liver Enzymes,to Drive and Use Machines see Warnings and,0
BLINCYTO,Elevated Liver Enzymes,and Precautions Leukoencephalopathy see Warnings and Precautions,0
BLINCYTO,Elevated Liver Enzymes,to Drive,0
BLINCYTO,Elevated Liver Enzymes,Precautions,0
BLINCYTO,Elevated Liver Enzymes,and Elevated Liver Enzymes,1
BLINCYTO,Elevated Liver Enzymes,,0
BLINCYTO,Elevated Liver Enzymes,Enzymes,1
BLINCYTO,Elevated Liver Enzymes,Leukoencephalopathy see Warnings,0
BLINCYTO,Leukoencephalopathy,Leukoencephalopathy,1
BLINCYTO,Leukoencephalopathy,see Warnings and Leukoencephalopathy,1
BLINCYTO,Leukoencephalopathy,and Leukoencephalopathy,1
BLINCYTO,Leukoencephalopathy,,0
BLINCYTO,Leukoencephalopathy,Warnings and,0
BLINCYTO,Leukoencephalopathy,Enzymes see Warnings and Leukoencephalopathy,1
BLINCYTO,Leukoencephalopathy,Warnings and Leukoencephalopathy,1
BLINCYTO,Leukoencephalopathy,see Warnings and Leukoencephalopathy,1
BLINCYTO,Leukoencephalopathy,Elevated Liver Enzymes,0
BLINCYTO,pyrexia,pyrexia,1
BLINCYTO,pyrexia,pyrexia,1
BLINCYTO,pyrexia,reactions pyrexia,1
BLINCYTO,pyrexia,,0
BLINCYTO,pyrexia,,0
BLINCYTO,pyrexia,pyrexia,1
BLINCYTO,pyrexia,peripheral edema febrile neutropenia nausea hypokalemia,0
BLINCYTO,headache,tremor rash and constipation,0
BLINCYTO,headache,headache,1
BLINCYTO,peripheral edema,adverse reactions were pyrexia peripheral,1
BLINCYTO,peripheral edema,edema,1
BLINCYTO,peripheral edema,peripheral,1
BLINCYTO,peripheral edema,,0
BLINCYTO,febrile neutropenia,headache,0
BLINCYTO,febrile neutropenia,reactions were pyrexia headache,0
BLINCYTO,febrile neutropenia,febrile neutropenia,1
BLINCYTO,febrile neutropenia,peripheral febrile neutropenia,1
BLINCYTO,febrile neutropenia,tremor rash and,0
BLINCYTO,febrile neutropenia,pyrexia headache peripheral febrile,1
BLINCYTO,nausea,nausea,1
BLINCYTO,nausea,hypokalemia tremor rash and constipation EXCERPT To report SU,0
BLINCYTO,nausea,nausea,1
BLINCYTO,nausea,constipation,0
BLINCYTO,nausea,nausea,1
BLINCYTO,nausea,To report,0
BLINCYTO,hypokalemia,hypokalemia,1
BLINCYTO,hypokalemia,hypokalemia,1
BLINCYTO,hypokalemia,hypokalemia,1
BLINCYTO,hypokalemia,EXCERPT,0
BLINCYTO,hypokalemia,hypokalemia,1
BLINCYTO,hypokalemia,,0
BLINCYTO,hypokalemia,,0
BLINCYTO,hypokalemia,febrile neutropenia hypokalemia,1
BLINCYTO,tremor,tremor,1
BLINCYTO,rash,hypokalemia,0
BLINCYTO,rash,headache peripheral edema febrile neutropenia nausea,0
BLINCYTO,rash,,0
BLINCYTO,rash,ADVERSE REACTIONS,0
BLINCYTO,rash,peripheral edema febrile neutropenia nausea hypokalemia tremor,0
BLINCYTO,rash,,0
BLINCYTO,rash,report SUSPECTED,0
BLINCYTO,rash,report SUSPECTED ADVERSE REACTIONS,0
BLINCYTO,rash,,0
BLINCYTO,constipation,SUSPECTED ADVERSE,0
BLINCYTO,pyrexia,febrile neutropenia nausea,0
BLINCYTO,pyrexia,adverse reactions,0
BLINCYTO,pyrexia,Black or African American,0
BLINCYTO,pyrexia,pyrexia,1
BLINCYTO,headache,headache,1
BLINCYTO,headache,and,0
BLINCYTO,peripheral edema,edema,1
BLINCYTO,peripheral edema,most common adverse,0
BLINCYTO,peripheral edema,peripheral edema,1
BLINCYTO,peripheral edema,pyrexia,0
BLINCYTO,peripheral edema,,0
BLINCYTO,peripheral edema,edema,1
BLINCYTO,peripheral edema,nausea hypokalemia and constipation,0
BLINCYTO,febrile neutropenia,reactions were pyrexia headache peripheral,0
BLINCYTO,febrile neutropenia,hypokalemia and constipation Serious,0
BLINCYTO,nausea,nausea,1
BLINCYTO,nausea,pyrexia headache peripheral edema,0
BLINCYTO,nausea,nausea,1
BLINCYTO,nausea,were reported,0
BLINCYTO,nausea,nausea,1
BLINCYTO,nausea,edema febrile nausea,1
BLINCYTO,nausea,nausea,1
BLINCYTO,nausea,edema febrile nausea,1
BLINCYTO,hypokalemia,hypokalemia,1
BLINCYTO,hypokalemia,in of patients,0
BLINCYTO,hypokalemia,hypokalemia,1
BLINCYTO,hypokalemia,neutropenia nausea,0
BLINCYTO,hypokalemia,headache peripheral,0
BLINCYTO,hypokalemia,edema febrile neutropenia hypokalemia,1
BLINCYTO,hypokalemia,pyrexia headache,0
BLINCYTO,constipation,constipation,1
BLINCYTO,constipation,Serious adverse reactions were reported in of,0
BLINCYTO,febrile neutropenia,,0
BLINCYTO,febrile neutropenia,febrile neutropenia,1
BLINCYTO,febrile neutropenia,The most,0
BLINCYTO,pyrexia,pyrexia,1
BLINCYTO,pyrexia,,0
BLINCYTO,pyrexia,patients The most,0
BLINCYTO,pyrexia,pyrexia,1
BLINCYTO,pyrexia,pyrexia,1
BLINCYTO,pneumonia,pneumonia,1
BLINCYTO,pneumonia,pyrexia,0
BLINCYTO,pneumonia,pneumonia,1
BLINCYTO,pneumonia,,0
BLINCYTO,pneumonia,most common serious adverse reactions included febrile neutropenia pyrexia,0
BLINCYTO,pneumonia,pneumonia,1
BLINCYTO,pneumonia,pneumonia,1
BLINCYTO,pneumonia,serious adverse reactions included febrile neutropenia,0
BLINCYTO,sepsis,confusion St,0
BLINCYTO,neutropenia,neutropenia,1
BLINCYTO,device-related infection,infection,1
BLINCYTO,device-related infection,infection,1
BLINCYTO,device-related infection,adverse reactions,0
BLINCYTO,device-related infection,infection,0
BLINCYTO,device-related infection,reactions included febrile,0
BLINCYTO,device-related infection,neutropenia pyrexia pneumonia sepsis device-related,1
BLINCYTO,device-related infection,device-related,1
BLINCYTO,device-related infection,infection,1
BLINCYTO,device-related infection,neutropenia pyrexia pneumonia sepsis device-related infection,1
BLINCYTO,device-related infection,device-related,1
BLINCYTO,tremor,,0
BLINCYTO,tremor,tremor,1
BLINCYTO,tremor,pyrexia,0
BLINCYTO,tremor,tremor,1
BLINCYTO,tremor,headache Adv,0
BLINCYTO,tremor,tremor,1
BLINCYTO,tremor,tremor,1
BLINCYTO,tremor,neutropenia devicerelated,0
BLINCYTO,tremor,pneumonia sepsis neutropenia devicerelated tremor,1
BLINCYTO,infection,confusion Staphylococcal bacteremia,0
BLINCYTO,infection,infection,1
BLINCYTO,overdose,overdose,1
BLINCYTO,overdose,headache Adverse reactions of Grade or,0
BLINCYTO,overdose,neutropenia devicerelated,0
BLINCYTO,overdose,overdose,1
BLINCYTO,overdose,and headache,0
BLINCYTO,overdose,overdose,1
BLINCYTO,overdose,tremor encephalopathy overdose,1
BLINCYTO,overdose,devicerelated infection tremor encephalopathy overdose,1
BLINCYTO,overdose,devicerelated infection tremor encephalopathy overdose,1
BLINCYTO,Staphylococcal bacteremia,Grade or higher were reported in of patients,0
BLINCYTO,Staphylococcal bacteremia,bacteremia,1
BLINCYTO,Staphylococcal bacteremia,neutropenia devicerelated infection,0
BLINCYTO,Staphylococcal bacteremia,patients Discont,0
BLINCYTO,Staphylococcal bacteremia,devicerelated infection tremor encephalopathy infection,0
BLINCYTO,Staphylococcal bacteremia,or higher were reported in,0
BLINCYTO,Staphylococcal bacteremia,Discont,0
BLINCYTO,headache,headache,1
BLINCYTO,headache,tremor encephalopathy infection,0
BLINCYTO,headache,headache,1
BLINCYTO,headache,headache,1
BLINCYTO,headache,,0
BLINCYTO,encephalopathy,adverse events occurred in of,0
BLINCYTO,encephalopathy,discontinuation of treatment included,0
BLINCYTO,encephalopathy,,0
BLINCYTO,sepsis,of patients The majority of these events were,0
BLINCYTO,sepsis,encephalopathy and,0
BLINCYTO,sepsis,sepsis,1
BLINCYTO,sepsis,these,0
BLINCYTO,sepsis,sepsis,1
BLINCYTO,sepsis,sepsis,1
BLINCYTO,sepsis,sepsis,1
BLINCYTO,sepsis,No,0
BLINCYTO,sepsis,patients The,0
BLINCYTO,Fatal,No fatal,0
BLINCYTO,Fatal,included encephalopathy and Fatal,1
BLINCYTO,Fatal,Fatal,1
BLINCYTO,Fatal,Fatal,1
BLINCYTO,Fatal,the reason,0
BLINCYTO,Fatal,of patients The majority of these,0
BLINCYTO,Fatal,and Fatal,1
BLINCYTO,Fatal,Fatal,1
BLINCYTO,infections,infections,1
BLINCYTO,infections,infections,1
BLINCYTO,infections,events infections,1
BLINCYTO,fatal,events,0
BLINCYTO,fatal,adverse reactions with,0
BLINCYTO,fatal,fatal,1
BLINCYTO,fatal,in of patients The majority of these,0
BLINCYTO,Neutropenia,Neutropenia,1
BLINCYTO,Neutropenia,Gastrointestinal d,0
BLINCYTO,Neutropenia,neutropenia Neutropenia,1
BLINCYTO,Neutropenia,Thrombocytopenia,0
BLINCYTO,Neutropenia,,0
BLINCYTO,Neutropenia,Thrombocytopenia Leukopenia,0
BLINCYTO,Neutropenia,Neutropenia,1
BLINCYTO,Neutropenia,Leukopenia,0
BLINCYTO,Neutropenia,Neutropenia,1
BLINCYTO,Neutropenia,,0
BLINCYTO,Thrombocytopenia,,0
BLINCYTO,Thrombocytopenia,Febrile neutropenia Anemia Thrombocytopenia,1
BLINCYTO,Thrombocytopenia,Thrombocytopenia,1
BLINCYTO,Thrombocytopenia,Anemia Thrombocytopenia,1
BLINCYTO,Thrombocytopenia,Thrombocytopenia,1
BLINCYTO,Thrombocytopenia,,0
BLINCYTO,Thrombocytopenia,Leukopenia Gastrointestinal disorders,0
BLINCYTO,Thrombocytopenia,Febrile neutropenia Anemia Thrombocytopenia,1
BLINCYTO,Leukopenia,Leukopenia,1
BLINCYTO,Leukopenia,Leukopenia,1
BLINCYTO,Leukopenia,,0
BLINCYTO,Leukopenia,neutropenia Anemia Neutropenia Leukopenia,1
BLINCYTO,Leukopenia,,0
BLINCYTO,Leukopenia,system disorders Febrile neutropenia,0
BLINCYTO,Nausea,Leukopenia Gastrointestinal Nausea,1
BLINCYTO,Nausea,Gastrointestinal Nausea,1
BLINCYTO,Nausea,disorders,0
BLINCYTO,Nausea,Nausea,1
BLINCYTO,Nausea,Gastrointestinal,0
BLINCYTO,Constipation,Constipation,1
BLINCYTO,Constipation,Constipation,1
BLINCYTO,Constipation,Constipation,1
BLINCYTO,Constipation,,0
BLINCYTO,Constipation,Constipation,1
BLINCYTO,Constipation,Constipation,1
BLINCYTO,Constipation,Leukopenia Gastrointestinal disorders Constipation,1
BLINCYTO,Constipation,Constipation,1
BLINCYTO,Constipation,Constipation,1
BLINCYTO,Diarrhea,terms colitis diarrhea enteritis and neutropenic colitis,0
BLINCYTO,Diarrhea,Diarrhea,1
BLINCYTO,Diarrhea,,0
BLINCYTO,Diarrhea,Diarrhea,1
BLINCYTO,Diarrhea,Diarrhea,1
BLINCYTO,Diarrhea,Diarrhea,1
BLINCYTO,Diarrhea,Diarrhea,1
BLINCYTO,Diarrhea,,0
BLINCYTO,Diarrhea,Nausea Constipation Diarrhea,1
BLINCYTO,Diarrhea,,0
BLINCYTO,Diarrhea,enteritis,0
BLINCYTO,Diarrhea,Constipation,0
BLINCYTO,Diarrhea,,0
BLINCYTO,Diarrhea,Nausea,0
BLINCYTO,Diarrhea,,0
BLINCYTO,Diarrhea,disorders Nausea Constipation Diarrhea,1
BLINCYTO,colitis,,0
BLINCYTO,colitis,colitis,1
BLINCYTO,colitis,Nausea Constipation DiarrheaDiarrhea includes the following terms,0
BLINCYTO,colitis,disorders Nausea Constipation DiarrheaDiarrhea includes the following terms,0
BLINCYTO,colitis,neutropenic colitis Abdominal,0
BLINCYTO,diarrhea,includes the following terms,0
BLINCYTO,diarrhea,pain Vomiting,0
BLINCYTO,diarrhea,,0
BLINCYTO,enteritis,the following terms colitis enteritis,1
BLINCYTO,enteritis,enteritis,1
BLINCYTO,enteritis,,0
BLINCYTO,enteritis,following terms colitis enteritis,1
BLINCYTO,enteritis,DiarrheaDiarrhea,0
BLINCYTO,enteritis,enteritis,1
BLINCYTO,enteritis,following terms colitis enteritis,1
BLINCYTO,neutropenic colitis,diarrhea enteritis neutropenic colitis,1
BLINCYTO,neutropenic colitis,terms colitis diarrhea enteritis and,0
BLINCYTO,neutropenic colitis,terms colitis diarrhea enteritis,0
BLINCYTO,neutropenic colitis,enteritis neutropenic colitis,1
BLINCYTO,neutropenic colitis,and,0
BLINCYTO,neutropenic colitis,diarrhea enteritis neutropenic,1
BLINCYTO,neutropenic colitis,following,0
BLINCYTO,neutropenic colitis,DiarrheaDiarrhea includes the following terms colitis diarrhea,0
BLINCYTO,Abdominal pain,,0
BLINCYTO,Vomiting,neutropenic colitis Abdominal Vomiting,1
BLINCYTO,Vomiting,site,0
BLINCYTO,Vomiting,following terms colitis diarrhea enteritis and,0
BLINCYTO,Vomiting,and neutropenic colitis,0
BLINCYTO,Vomiting,Vomiting,1
BLINCYTO,Vomiting,administration site,0
BLINCYTO,Vomiting,Vomiting,1
BLINCYTO,Vomiting,Vomiting,1
BLINCYTO,Pyrexia,conditions,0
BLINCYTO,Pyrexia,conditions,0
BLINCYTO,Pyrexia,Pyrexia,1
BLINCYTO,Pyrexia,pain,0
BLINCYTO,Pyrexia,conditions,0
BLINCYTO,Peripheral edema,administration site conditions,0
BLINCYTO,Peripheral edema,site conditions Pyrexia,0
BLINCYTO,Peripheral edema,Peripheral edema,1
BLINCYTO,Peripheral edema,and administration site,0
BLINCYTO,Peripheral edema,pain,0
BLINCYTO,Peripheral edema,pain Immune,0
BLINCYTO,Peripheral edema,Peripheral,1
BLINCYTO,Fatigue,,0
BLINCYTO,Fatigue,Fatigue,1
BLINCYTO,Chills,,0
BLINCYTO,Chills,Chills,1
BLINCYTO,Chills,Chest pain,0
BLINCYTO,Chills,and administration site conditions Pyrexia Peripheral,0
BLINCYTO,Chills,Chills,1
BLINCYTO,Chills,Chest pain Immune system disorders Cytokine,0
BLINCYTO,Chills,Chills,1
BLINCYTO,Chills,pain Immune system disorders,0
BLINCYTO,Chest pain,and administration,0
BLINCYTO,Chest pain,Fatigue Chest pain,1
BLINCYTO,Chest pain,Chest,1
BLINCYTO,Cytokine release syndrome,pain Immune system,0
BLINCYTO,Cytokine release syndrome,,0
BLINCYTO,Cytokine release syndrome,Immune system Cytokine release syndrome,1
BLINCYTO,Bacterial infections,Other pathogen Bacterial,1
BLINCYTO,Bacterial infections,infections,1
BLINCYTO,Bacterial infections,infections,0
BLINCYTO,Bacterial infections,Bacterial infections,1
BLINCYTO,Bacterial infections,and,0
BLINCYTO,Bacterial infections,Bacterial infections,1
BLINCYTO,Bacterial infections,Other pathogen Bacterial infections,1
BLINCYTO,Bacterial infections,and,0
BLINCYTO,Bacterial infections,Other pathogen,0
BLINCYTO,Fungal infections,pathogen infections Bacterial Fungal infections,1
BLINCYTO,Fungal infections,infections,1
BLINCYTO,Fungal infections,infections,1
BLINCYTO,Fungal infections,infections Bacterial Fungal,1
BLINCYTO,Fungal infections,Fungal infections,1
BLINCYTO,Fungal infections,,0
BLINCYTO,Fungal infections,Investigation,0
BLINCYTO,Fungal infections,,0
BLINCYTO,Fungal infections,infections Bacterial Fungal infections,1
BLINCYTO,Fungal infections,Investigation,0
BLINCYTO,Viral infections,Viral infections,1
BLINCYTO,Viral infections,Fungal Viral infections,1
BLINCYTO,Viral infections,Increased,0
BLINCYTO,Viral infections,Pneumonia Sepsis,0
BLINCYTO,Viral infections,infections Fungal infections,0
BLINCYTO,Viral infections,Fungal Viral infections,1
BLINCYTO,Viral infections,,0
BLINCYTO,Viral infections,infections Bacterial,0
BLINCYTO,Sepsis,Viral infections Sepsis,1
BLINCYTO,Sepsis,Sepsis,1
BLINCYTO,Sepsis,Sepsis,1
BLINCYTO,Sepsis,Fungal infections Viral,0
BLINCYTO,Increased alanine aminotransferase,alanine aminotransferase,1
BLINCYTO,Increased alanine aminotransferase,Pneumonia Sepsis Increased alanine aminotransferase,1
BLINCYTO,Increased alanine aminotransferase,Increased,1
BLINCYTO,Increased aspartate aminotransferase,Investigations Increased alanine,0
BLINCYTO,Increased aspartate aminotransferase,Investigations Increased alanine Increased aspartate aminotransferase,1
BLINCYTO,Increased aspartate aminotransferase,Increased alanine Increased aspartate,1
BLINCYTO,Increased aspartate aminotransferase,Increased aspartate aminotransferase,1
BLINCYTO,Increased aspartate aminotransferase,Investigations Increased alanine aminotransferase,0
BLINCYTO,Increased aspartate aminotransferase,aminotransferase,1
BLINCYTO,Increased aspartate aminotransferase,Increased alanine aminotransferase,0
BLINCYTO,Increased aspartate aminotransferase,Increased alanine aminotransferase,0
BLINCYTO,Increased aspartate aminotransferase,Investigations Increased,0
BLINCYTO,Increased aspartate aminotransferase,s Investigations Increased alanine Increased,1
BLINCYTO,Increased weight,,0
BLINCYTO,Increased weight,Increased aspartate,0
BLINCYTO,Increased weight,Increased aspartate Increased weight,1
BLINCYTO,Increased weight,aminotransferase Increased aspartate aminotransferase,0
BLINCYTO,Increased weight,aspartate Increased,1
BLINCYTO,Increased weight,,0
BLINCYTO,Hypokalemia,and nutrition Hypokalemia,1
BLINCYTO,Hypokalemia,,0
BLINCYTO,Hypokalemia,,0
BLINCYTO,Hypokalemia,Hypokalemia,1
BLINCYTO,Hypokalemia,,0
BLINCYTO,Hypokalemia,Hypokalemia,1
BLINCYTO,Hypokalemia,nutrition Hypokalemia,1
BLINCYTO,Hypomagnesemia,Hyperglycemia Decreased,0
BLINCYTO,Hypomagnesemia,appetite Hypophosphatemia,0
BLINCYTO,Hyperglycemia,,0
BLINCYTO,Hyperglycemia,Hyperglycemia,1
BLINCYTO,Hyperglycemia,Hyperglycemia,1
BLINCYTO,Hyperglycemia,Hyperglycemia,1
BLINCYTO,Hyperglycemia,Hyperglycemia,1
BLINCYTO,Hyperglycemia,,0
BLINCYTO,Decreased appetite,,0
BLINCYTO,Hypophosphatemia,,0
BLINCYTO,Hypophosphatemia,appetite,0
BLINCYTO,Hypophosphatemia,Hypophosphatemia,1
BLINCYTO,Hypophosphatemia,appetite,0
BLINCYTO,Hypophosphatemia,disorders Hypokalemia Hypomagnesemia Hyperglycemia,0
BLINCYTO,Hypophosphatemia,Hypokalemia Hypomagnesemia Hyperglycemia Decreased Hypophosphatemia,1
BLINCYTO,Back pain,and connective tissue Back,1
BLINCYTO,Back pain,Musculoskeletal and connective tissue Back pain,1
BLINCYTO,Back pain,connective,0
BLINCYTO,Back pain,Musculoskeletal and connective tissue Back pain,1
BLINCYTO,Back pain,extremity Bone,0
BLINCYTO,Back pain,connective tissue,0
BLINCYTO,Pain in extremity,in extremity,1
BLINCYTO,Pain in extremity,,0
BLINCYTO,Pain in extremity,Pain in extremity,1
BLINCYTO,Pain in extremity,and connective tissue disorders Back pain,0
BLINCYTO,Pain in extremity,disorders Back,0
BLINCYTO,Bone pain,Bone pain,1
BLINCYTO,Bone pain,,0
BLINCYTO,Bone pain,pain Pain in Bone pain,1
BLINCYTO,Arthralgia,Nervous system disorders,0
BLINCYTO,Headache,system Headache,1
BLINCYTO,Headache,TremorTremor includes the following terms resting,0
BLINCYTO,Tremor,Tremor,1
BLINCYTO,Tremor,Tremor,1
BLINCYTO,Tremor,Nervous system disorders Headache,0
BLINCYTO,Tremor,Tremor,0
BLINCYTO,Tremor,,0
BLINCYTO,Tremor,Tremor,1
BLINCYTO,Tremor,Tremor,1
BLINCYTO,Tremor,Nervous system disorders Headache Tremor,1
BLINCYTO,Tremor,Nervous system disorders Headache Tremor,1
BLINCYTO,Tremor,Tremor,0
BLINCYTO,Tremor,Tremor,1
BLINCYTO,resting tremor,TremorTremor includes the following resting,1
BLINCYTO,resting tremor,following resting,1
BLINCYTO,resting tremor,disorders Headache TremorTremor includes the following,0
BLINCYTO,resting tremor,the following resting,1
BLINCYTO,resting tremor,Insomnia,0
BLINCYTO,resting tremor,includes the following resting,1
BLINCYTO,tremor,terms resting tremor tremor,1
BLINCYTO,tremor,includes the following terms resting tremor,0
BLINCYTO,tremor,Insomnia,0
BLINCYTO,tremor,,0
BLINCYTO,tremor,tremor,1
BLINCYTO,tremor,tremor,1
BLINCYTO,tremor,tremor,1
BLINCYTO,Dizziness,includes the following,0
BLINCYTO,Dizziness,terms resting tremor and tremor,0
BLINCYTO,Dizziness,resting tremor and,0
BLINCYTO,Dizziness,Insomnia,0
BLINCYTO,Dizziness,Dizziness,1
BLINCYTO,Insomnia,Insomnia,1
BLINCYTO,Insomnia,Psychiatric disorders,0
BLINCYTO,Insomnia,and tremor Dizziness Psychiatric Insomnia,1
BLINCYTO,Insomnia,tremor Dizziness Psychiatric Insomnia,1
BLINCYTO,Insomnia,,0
BLINCYTO,Insomnia,Insomnia,1
BLINCYTO,Insomnia,Insomnia,1
BLINCYTO,Insomnia,Psychiatric Insomnia,1
BLINCYTO,Insomnia,tremor and tremor Dizziness Psychiatric,0
BLINCYTO,Insomnia,disorders Cough Dyspn,0
BLINCYTO,Cough,Cough,1
BLINCYTO,Cough,thoracic and mediastinal,0
BLINCYTO,Cough,mediastinal,0
BLINCYTO,Cough,Respiratory thoracic and mediastinal Cough,1
BLINCYTO,Cough,hyperactivity,0
BLINCYTO,Cough,Cough,1
BLINCYTO,Cough,Cough,1
BLINCYTO,Dyspnea,Dyspnea,1
BLINCYTO,Dyspnea,Dyspnea,1
BLINCYTO,Dyspnea,mediastinal disorders Dyspnea,1
BLINCYTO,Dyspnea,Dyspnea,1
BLINCYTO,Dyspnea,,0
BLINCYTO,acute respiratory failure,respiratory failure,1
BLINCYTO,acute respiratory failure,respiratory failure,1
BLINCYTO,bronchial hyperactivity,exertional respiratory distress respiratory failure,0
BLINCYTO,bronchial hyperactivity,bronchial hyperactivity,1
BLINCYTO,bronchial hyperactivity,hyperactivity,1
BLINCYTO,bronchospasm,bronchospasm,1
BLINCYTO,bronchospasm,bronchospasm,1
BLINCYTO,dyspnea,failure bronchial hyperactivity dyspnea,1
BLINCYTO,dyspnea,,0
BLINCYTO,dyspnea,respiratory,0
BLINCYTO,dyspnea,the following,0
BLINCYTO,dyspnea,acute,0
BLINCYTO,dyspnea,wheezing,0
BLINCYTO,dyspnea exertional,wheezing,0
BLINCYTO,dyspnea exertional,,0
BLINCYTO,dyspnea exertional,an,0
BLINCYTO,dyspnea exertional,hyperactivity bronchospasm dyspnea,1
BLINCYTO,dyspnea exertional,,0
BLINCYTO,respiratory distress,,0
BLINCYTO,respiratory distress,dyspnea respiratory,1
BLINCYTO,respiratory distress,respiratory distress,1
BLINCYTO,respiratory distress,hyperactivity bronchospasm dyspnea dyspnea respiratory distress,1
BLINCYTO,respiratory distress,and wheezing Skin and subcutaneous,0
BLINCYTO,respiratory distress,distress,1
BLINCYTO,respiratory distress,respiratory failure and wheezing Skin and,0
BLINCYTO,respiratory distress,respiratory distress,1
BLINCYTO,respiratory failure,bronchospasm dyspnea,0
BLINCYTO,respiratory failure,and subcutaneous,0
BLINCYTO,respiratory failure,exertional respiratory respiratory,1
BLINCYTO,respiratory failure,exertional respiratory respiratory,1
BLINCYTO,respiratory failure,,0
BLINCYTO,respiratory failure,dyspnea dyspnea exertional respiratory respiratory,1
BLINCYTO,respiratory failure,bronchial hyperactivity bronchospasm dyspnea dyspnea exertional respiratory,0
BLINCYTO,respiratory failure,dyspnea exertional respiratory respiratory,1
BLINCYTO,respiratory failure,and wheezing Skin,0
BLINCYTO,respiratory failure,respiratory failure,1
BLINCYTO,Rash,subcutaneous tissue Rash,1
BLINCYTO,Rash,,0
BLINCYTO,Rash,erythema rash erythematous rash generalized rash macular rash,0
BLINCYTO,Rash,generalized rash,0
BLINCYTO,Rash,subcutaneous,0
BLINCYTO,Rash,macular,0
BLINCYTO,Rash,Rash,1
BLINCYTO,Rash,Rash,1
BLINCYTO,Rash,and subcutaneous tissue,0
BLINCYTO,Rash,Rash,1
BLINCYTO,erythema,,0
BLINCYTO,erythema,RashRash,0
BLINCYTO,erythema,erythema,1
BLINCYTO,erythema,and subcutaneous tissue disorders RashRash includes,0
BLINCYTO,rash,rash,1
BLINCYTO,rash,following terms rash,1
BLINCYTO,rash,rash,1
BLINCYTO,rash,macular rash maculopapular rash,0
BLINCYTO,rash,rash,1
BLINCYTO,erythematous rash,maculopapular rash papular rash and vesicular rash,0
BLINCYTO,erythematous rash,the following terms,0
BLINCYTO,erythematous rash,the following,0
BLINCYTO,erythematous rash,erythema erythematous,1
BLINCYTO,erythematous rash,,0
BLINCYTO,generalized rash,rash erythematous generalized,1
BLINCYTO,generalized rash,rash erythematous generalized,1
BLINCYTO,generalized rash,generalized rash,1
BLINCYTO,generalized rash,generalized rash,1
BLINCYTO,generalized rash,erythema rash erythematous generalized rash,1
BLINCYTO,generalized rash,rash erythematous generalized rash,1
BLINCYTO,generalized rash,disorders RashRash includes the following terms erythema rash erythematous rash,0
BLINCYTO,generalized rash,rash Vascu,0
BLINCYTO,generalized rash,terms erythema rash erythematous generalized,1
BLINCYTO,macular rash,macular rash,1
BLINCYTO,macular rash,disorders,0
BLINCYTO,macular rash,Vascular disorders,0
BLINCYTO,macular rash,macular rash,1
BLINCYTO,macular rash,macular rash,1
BLINCYTO,macular rash,Vascular disorders,0
BLINCYTO,macular rash,rash generalized,0
BLINCYTO,macular rash,generalized macular rash,1
BLINCYTO,macular rash,rash,0
BLINCYTO,maculo-papular rash,maculo-papular,1
BLINCYTO,maculo-papular rash,generalized,0
BLINCYTO,maculo-papular rash,macular rash,0
BLINCYTO,maculo-papular rash,Vascular,0
BLINCYTO,maculo-papular rash,rash and vesicular rash Vascular disorders,0
BLINCYTO,papular rash,papular rash,1
BLINCYTO,papular rash,papular,1
BLINCYTO,papular rash,rash macular rash maculopapular papular,1
BLINCYTO,papular rash,macular rash maculopapular papular,1
BLINCYTO,papular rash,Hypertension,0
BLINCYTO,papular rash,and vesicular rash Vascular disorders Hypotension,0
BLINCYTO,papular rash,rash,1
BLINCYTO,papular rash,rash generalized,0
BLINCYTO,papular rash,terms erythema,0
BLINCYTO,papular rash,rash,1
BLINCYTO,vesicular rash,rash papular rash vesicular rash,1
BLINCYTO,Hypotension,reactions that di,0
BLINCYTO,Hypotension,vesicular rash Vascular Hypotension,1
BLINCYTO,Hypotension,Hypotension,1
BLINCYTO,Hypertension,,0
BLINCYTO,Hypertension,reactions that did not meet the,0
BLINCYTO,Hypertension,disorders Hypertension,1
BLINCYTO,Hypertension,,0
BLINCYTO,Hypertension,vesicular rash Vascular disorders Hypertension,1
BLINCYTO,Hypertension,vesicular,0
BLINCYTO,Hypertension,Vascular disorders Hypertension,1
BLINCYTO,Hypertension,Hypertension,1
BLINCYTO,leukocytosis,leukocytosis,1
BLINCYTO,leukocytosis,leukocytosis,1
BLINCYTO,leukocytosis,,0
BLINCYTO,leukocytosis,leukocytosis,1
BLINCYTO,lymphopenia,Table were Blood and lymphatic,0
BLINCYTO,lymphopenia,,0
BLINCYTO,lymphopenia,inclusion,0
BLINCYTO,lymphopenia,disorders lymphopenia,1
BLINCYTO,lymphopenia,lymphopenia,1
BLINCYTO,lymphopenia,in Table were Blood,0
BLINCYTO,lymphopenia,lymphopenia,1
BLINCYTO,lymphopenia,and lymphatic system disorders lymphopenia,1
BLINCYTO,tachycardia,tachycardia,1
BLINCYTO,tachycardia,disorders and,0
BLINCYTO,tachycardia,lymphatic system disorders leukocytosis lymphopenia,0
BLINCYTO,edema,,0
BLINCYTO,cytokine storm,bilirubin increas,0
BLINCYTO,cytokine storm,disorders,0
BLINCYTO,cytokine storm,disorders and administration site conditions edema Immune system,0
BLINCYTO,cytokine storm,edema Immune system cytokine,1
BLINCYTO,cytokine storm,,0
BLINCYTO,cytokine storm,cytokine storm,1
BLINCYTO,cytokine storm,and administration site conditions edema Immune system disorders,0
BLINCYTO,increased blood bilirubin,liver enzymes,0
BLINCYTO,increased blood bilirubin,cytokine storm Investigations,0
BLINCYTO,increased blood bilirubin,Investigations decreased increased blood bilirubin,1
BLINCYTO,increased blood bilirubin,Investigations decreased increased blood bilirubin,1
BLINCYTO,increased blood bilirubin,disorders cytokine storm Investigations decreased immunoglobulins,0
BLINCYTO,increased blood bilirubin,increased blood bilirubin,1
BLINCYTO,increased blood bilirubin,,0
BLINCYTO,increased blood bilirubin,,0
BLINCYTO,increased blood bilirubin,storm Investigations decreased immunoglobulins,0
BLINCYTO,increased blood bilirubin,cytokine storm Investigations decreased,0
BLINCYTO,increased gamma-glutamyl-transferase,increased blood increased,1
BLINCYTO,increased gamma-glutamyl-transferase,increased gamma-glutamyl-transferase,1
BLINCYTO,increased gamma-glutamyl-transferase,increased liver enzymes Metabolism and,0
BLINCYTO,increased gamma-glutamyl-transferase,storm Investigations decreased immunoglobulins increased blood,0
BLINCYTO,increased gamma-glutamyl-transferase,increased liver,0
BLINCYTO,increased gamma-glutamyl-transferase,decreased immunoglobulins increased,0
BLINCYTO,increased gamma-glutamyl-transferase,increased gamma-glutamyl-transferase,1
BLINCYTO,increased gamma-glutamyl-transferase,immunoglobulins increased blood increased gamma-glutamyl-transferase,1
BLINCYTO,increased gamma-glutamyl-transferase,increased gamma-glutamyl-transferase,1
BLINCYTO,increased gamma-glutamyl-transferase,disorders tumor,0
BLINCYTO,increased liver enzymes,increased liver enzymes,1
BLINCYTO,tumor lysis syndrome,,0
BLINCYTO,hypoalbuminemia,,0
BLINCYTO,hypoalbuminemia,hypoalbuminemia,1
BLINCYTO,hypoalbuminemia,hypoalbuminemia,1
BLINCYTO,encephalopathy,encephalopathy,1
BLINCYTO,encephalopathy,Nervous system encephalopathy,1
BLINCYTO,encephalopathy,encephalopathy,1
BLINCYTO,encephalopathy,impairment cognitive,0
BLINCYTO,encephalopathy,Nervous system encephalopathy,1
BLINCYTO,encephalopathy,encephalopathy,1
BLINCYTO,encephalopathy,hypoalbuminemia Nervous system encephalopathy,1
BLINCYTO,encephalopathy,hypoalbuminemia Nervous system encephalopathy,1
BLINCYTO,encephalopathy,,0
BLINCYTO,encephalopathy,system encephalopathy,1
BLINCYTO,paresthesia,disorders,0
BLINCYTO,paresthesia,Nervous system disorders paresthesia,1
BLINCYTO,paresthesia,system,0
BLINCYTO,paresthesia,system,0
BLINCYTO,paresthesia,paresthesia,1
BLINCYTO,paresthesia,Nervous system disorders,0
BLINCYTO,paresthesia,paresthesia,1
BLINCYTO,paresthesia,system disorders encephalopathy,0
BLINCYTO,aphasia,encephalopathy paresthesia,0
BLINCYTO,aphasia,aphasia,1
BLINCYTO,aphasia,,0
BLINCYTO,aphasia,aphasia,1
BLINCYTO,aphasia,aphasia,1
BLINCYTO,aphasia,disorders encephalopathy,0
BLINCYTO,aphasia,aphasia,1
BLINCYTO,convulsion,paresthesia convulsion,1
BLINCYTO,cognitive disorder,convulsion memory cognitive disorder,1
BLINCYTO,cognitive disorder,confusion,0
BLINCYTO,cognitive disorder,convulsion memory cognitive,1
BLINCYTO,cognitive disorder,paresthesia aphasia convulsion,0
BLINCYTO,cognitive disorder,aphasia convulsion,0
BLINCYTO,cognitive disorder,,0
BLINCYTO,cognitive disorder,memory impairment,0
BLINCYTO,speech disorder,disorder,1
BLINCYTO,speech disorder,disorders,0
BLINCYTO,speech disorder,Psychiatric disorders confusion disorientation,0
BLINCYTO,speech disorder,impairment cognitive speech,1
BLINCYTO,speech disorder,memory impairment cognitive speech disorder,1
BLINCYTO,confusion,disorientation Vascular disorders,0
BLINCYTO,confusion,disorders capillary leak syndrome,0
BLINCYTO,confusion,,0
BLINCYTO,confusion,speech disorder,0
BLINCYTO,confusion,,0
BLINCYTO,confusion,Psychiatric confusion,1
BLINCYTO,confusion,,0
BLINCYTO,disorientation,disorientation,1
BLINCYTO,disorientation,disorientation,1
BLINCYTO,disorientation,,0
BLINCYTO,capillary leak syndrome,hypersensitivity,0
BLINCYTO,capillary leak syndrome,,0
BLINCYTO,capillary leak syndrome,and,0
BLINCYTO,capillary leak syndrome,,0
BLINCYTO,capillary leak syndrome,leak syndrome,1
BLINCYTO,capillary leak syndrome,disorders confusion disorientation Vascular capillary,1
BLINCYTO,capillary leak syndrome,Vascular capillary leak,1
BLINCYTO,Hypersensitivity reactions,,0
BLINCYTO,Hypersensitivity reactions,to BLINCYTO treatment were hypersensitivity and bronchospasm Imm,0
BLINCYTO,Hypersensitivity reactions,hypersensitivity and bronchospasm,0
BLINCYTO,hypersensitivity,hypersensitivity,1
BLINCYTO,hypersensitivity,hypersensitivity,1
BLINCYTO,hypersensitivity,,0
BLINCYTO,hypersensitivity,hypersensitivity,1
BLINCYTO,hypersensitivity,treatment hypersensitivity,1
BLINCYTO,hypersensitivity,hypersensitivity,1
BLINCYTO,bronchospasm,reactions related to BLINCYTO treatment were,0
BLINCYTO,bronchospasm,bronchospasm,1
BLINCYTO,bronchospasm,BLINCYTO treatment were hypersensitivity bronchospasm,1
BLINCYTO,bronchospasm,,0
BLINCYTO,CYTOKINE RELEASE SYNDROME,e following adverse,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,Warnings and Precautions,0
BLINCYTO,CYTOKINE RELEASE SYNDROME,the label: Cytokine Release,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,,0
BLINCYTO,CYTOKINE RELEASE SYNDROME,r sections of the label:  Cytokine Release Syndrome see Warnings,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,r sections of the label:  Cytokine Release Syndrome see Warnings,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,r sections of,1
BLINCYTO,Cytokine Release Syndrome,Warnings and Precautions,0
BLINCYTO,Cytokine Release Syndrome,Syndrome e,1
BLINCYTO,Cytokine Release Syndrome,greater detail in other sections of the label,0
BLINCYTO,Cytokine Release Syndrome,other sections of the label Cytokine,0
BLINCYTO,Cytokine Release Syndrome,Cytokine Release Syndrome e Warnings and Precaution s Neurological Toxicities see Warnings,1
BLINCYTO,Cytokine Release Syndrome,Cytokine Release Syndrome e Warnings and Precaution s Neurological Toxicities see Warnings,1
BLINCYTO,Cytokine Release Syndrome,Syndrome e Warnings,1
BLINCYTO,Cytokine Release Syndrome,the label Cytokine Release,0
BLINCYTO,Cytokine Release Syndrome,other sections of the label Cytokine Release,0
BLINCYTO,Cytokine Release Syndrome,Warnings and,0
BLINCYTO,CRS,(   Neurological Toxicities see Warnings and,1
BLINCYTO,CRS,see Warnings and (   Neurological Toxicities see Warnings and,1
BLINCYTO,CRS,(   Neurological Toxicities see Warnings and,1
BLINCYTO,CRS,,0
BLINCYTO,CRS,(   Neurological Toxicities see Warnings and,1
BLINCYTO,CRS,Warnings and Precautions,0
BLINCYTO,CRS,Precautions Infections,0
BLINCYTO,CRS,,0
BLINCYTO,CRS,label,0
BLINCYTO,CRS,(   Neurological Toxicities see Warnings and,1
BLINCYTO,fatal,Precautions Neurological s,1
BLINCYTO,fatal,Warnings and Precautions Neurological s [se e Warnings and Precautions Infections,1
BLINCYTO,fatal,Infections see Warnings and,0
BLINCYTO,fatal,Infections see,0
BLINCYTO,fatal,,0
BLINCYTO,fatal,Neurological s [se e Warnings and Precautions Infections,1
BLINCYTO,fatal,[se e Warnings and Precautions Infections,1
BLINCYTO,fatal,s [se e Warnings and Precautions Infections,1
BLINCYTO,fatal,s [se e Warnings and Precautions Infections,1
BLINCYTO,Neurological toxicities,tropenia and Febrile,1
BLINCYTO,Neurological toxicities,tropenia and Febrile Ne utropenia see Warnings and Precautions,1
BLINCYTO,Neurological toxicities,Use,0
BLINCYTO,fatal,,0
BLINCYTO,fatal,see Warnings and .5  ) Effects on Ability to Drive,1
BLINCYTO,fatal,see Warnings and .5,1
BLINCYTO,fatal,,0
BLINCYTO,fatal,) Effects on Ability to Drive,1
BLINCYTO,fatal,,0
BLINCYTO,fatal,.5,1
BLINCYTO,fatal,Warnings and .5,1
BLINCYTO,fatal,.5  ) Effects on Ability to Drive,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,e,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,and Precautions Leukoencephalopathy e Warnings and Precaution s Preparation and Administration Errors,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,Precautions Leukoencephalopathy e Warnings and Precaution s Preparation and Administration Errors,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,Warnings and Precautions Leukoencephalopathy e Warnings and,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,Warnings and Precaution s Preparation and Administration Errors,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,,0
BLINCYTO,CYTOKINE RELEASE SYNDROME,Warnings and Precautions Leukoencephalopathy e,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,Warnings and Precautions Leukoencephalopathy e Warnings and Precaution s Preparation and Administration Errors,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,and Administration Errors,0
BLINCYTO,NEUROLOGICAL TOXICITIES,Leukoencephalopathy see Warnings and 5.8 )],1
BLINCYTO,NEUROLOGICAL TOXICITIES,"see Warnings and 5.8  )]  
 *  Preparati on and Administration Errors see",1
BLINCYTO,NEUROLOGICAL TOXICITIES,see Warnings and 5.8,1
BLINCYTO,NEUROLOGICAL TOXICITIES,Preparati on and Administration Errors see,1
BLINCYTO,NEUROLOGICAL TOXICITIES,* Preparati on and Administration Errors see,1
BLINCYTO,NEUROLOGICAL TOXICITIES,"Leukoencephalopathy see Warnings and 5.8  )]  
 *  Preparati on and Administration Errors see",1
BLINCYTO,Cytokine Release Syndrome,Errors see Warnings and The most common,1
BLINCYTO,Cytokine Release Syndrome,Errors,0
BLINCYTO,Cytokine Release Syndrome,and The,1
BLINCYTO,Cytokine Release Syndrome,see,0
BLINCYTO,Cytokine Release Syndrome,Errors see Warnings,0
BLINCYTO,Cytokine Release Syndrome, The most common adverse  reactions were pyrexia headache peripheral,1
BLINCYTO,Cytokine Release Syndrome,common adverse reactions were pyrexia headache peripheral,1
BLINCYTO,Cytokine Release Syndrome,and  The most common adverse  reactions were pyrexia headache peripheral,1
BLINCYTO,Cytokine Release Syndrome,Errors see Warnings and The most common,1
BLINCYTO,Cytokine Release Syndrome,Errors see,0
BLINCYTO,CRS,,0
BLINCYTO,CRS,act ions were pyrexia headache peripheral,1
BLINCYTO,CRS,see Warnings and Precautions The,0
BLINCYTO,CRS,act ions were pyrexia headache peripheral,1
BLINCYTO,CRS,nausea hypokalemia,0
BLINCYTO,CRS,act ions were pyrexia headache peripheral,1
BLINCYTO,CRS,act ions were pyrexia headache peripheral,1
BLINCYTO,CRS,act ions were pyrexia headache peripheral,1
BLINCYTO,CRS,act ions were pyrexia headache peripheral,1
BLINCYTO,CRS,tr,0
BLINCYTO,CRS,re,0
BLINCYTO,CRS,act ions were pyrexia headache peripheral,1
BLINCYTO,CRS,,0
BLINCYTO,CRS,,0
BLINCYTO,fatal,were,0
BLINCYTO,fatal,were pyrexia headache,0
BLINCYTO,fatal,rash,0
BLINCYTO,fatal,The most common adverse,0
BLINCYTO,Neurological toxicities,To r eport SUSPECTED ADVERSE REACTIONS contact,1
BLINCYTO,Neurological toxicities,constipation RPT: }} To,1
BLINCYTO,Neurological toxicities,RPT: }} To r eport SUSPECTED ADVERSE REACTIONS contact,1
BLINCYTO,Neurological toxicities,tremor rash and constipation,0
BLINCYTO,Neurological toxicities,at AMGEN or FDA,0
BLINCYTO,Neurological toxicities,"tremor rash and constipation RPT:   

}}        To r eport SUSPECTED ADVERSE REACTIONS contact",1
BLINCYTO,Neurological toxicities,contact Amgen Inc at AMGEN,0
BLINCYTO,fatal,mgen  Inc at AMGEN or FDA,1
BLINCYTO,fatal,SUSPECTED ADVERSE REACTIONS contact mgen  Inc at AMGEN or FDA,1
BLINCYTO,Infections,ctions,1
BLINCYTO,Infections,ctions are discussed in greater detail,1
BLINCYTO,Infections,ctions,1
BLINCYTO,Infections,ctions,1
BLINCYTO,Infections,ctions,1
BLINCYTO,Infections,ctions are,1
BLINCYTO,Infections,are discussed in greater detail in,1
BLINCYTO,Effects on Ability to Drive,sections of the label Release Syndrome,1
BLINCYTO,Effects on Ability to Drive,,0
BLINCYTO,Effects on Ability to Drive,in greater detail in,0
BLINCYTO,Effects on Ability to Drive,Release Syndrome [see Warni ngs and Precautions Neurological Toxicities,1
BLINCYTO,Cytokine Release Syndrome,and Elevated Liver Enzymes,1
BLINCYTO,Cytokine Release Syndrome,see Warnings and Elevated Liver Enzymes [s ee Warnings and Precautions Leukoencephalopathy,1
BLINCYTO,Cytokine Release Syndrome,Enzymes [s ee Warnings and Precautions Leukoencephalopathy,1
BLINCYTO,Cytokine Release Syndrome,and Precautions Leukoencephalopathy see Warnings and Precautions,0
BLINCYTO,Cytokine Release Syndrome,Machines see Warnings and Elevated Liver Enzymes,1
BLINCYTO,Cytokine Release Syndrome,Enzymes [s ee Warnings and Precautions Leukoencephalopathy,1
BLINCYTO,Cytokine Release Syndrome,,0
BLINCYTO,Cytokine Release Syndrome,Machines see Warnings and Elevated Liver Enzymes [s ee Warnings and Precautions Leukoencephalopathy,1
BLINCYTO,Cytokine Release Syndrome,[s ee Warnings and Precautions Leukoencephalopathy,1
BLINCYTO,Cytokine Release Syndrome,Warnings and Precautions,0
BLINCYTO,CRS, Wa rnings and Precautions Leukoencephalopathy see,1
BLINCYTO,CRS, Wa rnings and Precautions Leukoencephalopathy see,1
BLINCYTO,CRS,and Precautions,0
BLINCYTO,CRS, Wa rnings and Precautions Leukoencephalopathy see,1
BLINCYTO,CRS,Precautions Elevated Liver Enzymes  Wa rnings and Precautions Leukoencephalopathy see,1
BLINCYTO,CRS,Drive and Use Machines see Warnings and Precautions Elevated Liver,0
BLINCYTO,CRS,Machines,0
BLINCYTO,CRS,Precautions,0
BLINCYTO,CRS,Drive and Use Machines see Warnings and Precautions,0
BLINCYTO,CRS, Wa rnings and Precautions Leukoencephalopathy see,1
BLINCYTO,fatal,,0
BLINCYTO,fatal,and *,1
BLINCYTO,fatal,and Precautions Preparation,0
BLINCYTO,fatal,*,1
BLINCYTO,fatal,Precautions Elevated Liver,0
BLINCYTO,fatal,L eukoencephalopathy see Warnings and Precautions,1
BLINCYTO,fatal,Precautions Elevated Liver Enzymes,0
BLINCYTO,fatal,Warnings and  *  L eukoencephalopathy see Warnings and Precautions,1
BLINCYTO,fatal,Enzymes see,0
BLINCYTO,fatal,eukoencephalopathy see Warnings,0
BLINCYTO,Infusion reactions,( 5.8 )] * Preparation and Administration Errors see,1
BLINCYTO,Infusion reactions,Leukoencephalopathy see Warnings and ( 5.8,1
BLINCYTO,CRS,constipation,0
BLINCYTO,CRS,"ma, febrile neutropenia nausea hypokalemia tremor",1
BLINCYTO,CRS,"ma, febrile neutropenia nausea hypokalemia tremor",1
BLINCYTO,CRS,"headache peripheral ma, febrile neutropenia nausea hypokalemia tremor",1
BLINCYTO,CRS,"ma, febrile neutropenia nausea hypokalemia tremor",1
BLINCYTO,CRS,and constipation EXCERPT,0
BLINCYTO,CRS,peripheral,0
BLINCYTO,pyrexia,peripheral edema,0
BLINCYTO,pyrexia,,0
BLINCYTO,pyrexia,hypokalemia,0
BLINCYTO,pyrexia,headache,0
BLINCYTO,pyrexia,eutrope nia nausea hypokalemia tremor rash,1
BLINCYTO,pyrexia,eutrope nia nausea hypokalemia tremor rash,1
BLINCYTO,pyrexia,eutrope nia nausea hypokalemia tremor rash,1
BLINCYTO,pyrexia,peripheral edema febrile eutrope nia nausea hypokalemia tremor rash,1
BLINCYTO,headache,"febrile a,",1
BLINCYTO,headache,were pyrexia,0
BLINCYTO,headache,reactions were pyrexia headache peripheral edema,0
BLINCYTO,headache,a hypokalemia tremor rash and constipation EXCERPT To report S,0
BLINCYTO,headache,"a, nause a hypokalemia tremor rash and",1
BLINCYTO,headache,"peripheral edema febrile a,",1
BLINCYTO,headache,rash and constipation EXCERPT,0
BLINCYTO,headache,hypokalemia tremor rash and constipation EXCERPT To report,0
BLINCYTO,nausea,febrile neutropenia  hypok alemia tremor rash and constipation,1
BLINCYTO,nausea,constipation EXCERPT To report,0
BLINCYTO,nausea,To report SUSPECTED,0
BLINCYTO,asthenia,To report SUSPECTED ADVERSE R,0
BLINCYTO,asthenia,hypokal,0
BLINCYTO,asthenia,"emia, tr emor rash and constipation EXCERPT",1
BLINCYTO,asthenia,"emia, tr emor rash and constipation EXCERPT",1
BLINCYTO,asthenia,pyrexia,0
BLINCYTO,asthenia,were pyrexia headache peripheral,0
BLINCYTO,asthenia,"febrile neutropenia nausea emia,",1
BLINCYTO,asthenia,and,0
BLINCYTO,asthenia,"emia, tr emor rash and constipation EXCERPT",1
BLINCYTO,hypotension,edema febrile neutropenia nausea,0
BLINCYTO,hypotension,REACTIONS con,0
BLINCYTO,hypotension,pyrexia headache peripheral edema febrile neutropenia nausea hypokalemia,0
BLINCYTO,increased alanine aminotransferase,( 6.1 ) E XCERPT To report SUSPECTED ADVERSE,1
BLINCYTO,increased alanine aminotransferase,"hypokalemia tremor rash  constipation. (  6.1  )
 
      E XCERPT To report SUSPECTED ADVERSE",1
BLINCYTO,increased aspartate aminotransferase,To report SUSPEC TED ADVERSE REACTIONS contact Amgen,1
BLINCYTO,fatal,Because clinical trials,0
BLINCYTO,fatal,.gov/ medwatch Clinical Trials Experience Because,1
BLINCYTO,fatal,.gov/ medwatch Clinical Trials Experience Because,1
BLINCYTO,fatal,Clinical Trials Experience Because clinical trials are,0
BLINCYTO,fatal,.gov/ medwatch Clinical Trials Experience Because,1
BLINCYTO,fatal,.gov/ medwatch Clinical Trials Experience Because,1
BLINCYTO,CRS,edw atch Clinical Trials Experience Because,1
BLINCYTO,CRS,edw atch Clinical Trials Experience Because,1
BLINCYTO,CRS,Trials Experience Because clinical,0
BLINCYTO,CRS,edw atch Clinical Trials Experience Because,1
BLINCYTO,CRS,FDA at FDA or edw atch Clinical Trials Experience Because,1
BLINCYTO,DIC,widely var,0
BLINCYTO,DIC,co,0
BLINCYTO,capillary leak syndrome,,0
BLINCYTO,capillary leak syndrome,adverse reac tion rates observed in the,1
BLINCYTO,capillary leak syndrome,clinical trials are conducted under widely varying c,0
BLINCYTO,capillary leak syndrome,reac tion rates observed in the,1
BLINCYTO,capillary leak syndrome,"conducted under widely varying onditions, adverse",1
BLINCYTO,capillary leak syndrome,directly compared to rates in the cli,0
BLINCYTO,capillary leak syndrome,"under widely varying onditions,",1
BLINCYTO,CLS,on  rates observed in the clinical,1
BLINCYTO,CLS,on  rates observed in the clinical,1
BLINCYTO,hemophagocytic lymphohistiocytosis,trials,0
BLINCYTO,hemophagocytic lymphohistiocytosis,rates bserved in the,1
BLINCYTO,macrophage activation syndrome,,0
BLINCYTO,macrophage activation syndrome,clinical trials of  drug cannot be directly compa red to rates in the,1
BLINCYTO,macrophage activation syndrome,adverse reaction rates,0
BLINCYTO,macrophage activation syndrome,of a,0
BLINCYTO,macrophage activation syndrome,,0
BLINCYTO,macrophage activation syndrome,clinical trials of another drug and may not reflect the,0
BLINCYTO,macrophage activation syndrome,drug cannot be directly compa red to rates in the,1
BLINCYTO,HLH,drug cannot be,0
BLINCYTO,HLH,d t o rates in the clinical,1
BLINCYTO,HLH,the clinical trials of a drug cannot be,0
BLINCYTO,HLH,d t o rates in the clinical,1
BLINCYTO,MAS,be directly compared  ra tes in the clinical trials,1
BLINCYTO,MAS,,0
BLINCYTO,MAS,cannot be directly compared  ra tes in the clinical trials,1
BLINCYTO,CRS,trials of a drug cannot be directly compared to rates in the clinical trials of another,0
BLINCYTO,CRS,rug and may not reflect the,1
BLINCYTO,CRS,section r,0
BLINCYTO,CRS,in the clinical trials of,0
BLINCYTO,CRS,rug and may not reflect the,1
BLINCYTO,neurological toxicities,37 years (range: 18,1
BLINCYTO,neurological toxicities,years (range: 18 to years were male were White,1
BLINCYTO,neurological toxicities,37 years (range: 18 to years were male were White,1
BLINCYTO,neurological toxicities,to years were male were White,1
BLINCYTO,fatal,Black or,0
BLINCYTO,fatal,African American The most common,0
BLINCYTO,fatal,hypokalemia and,0
BLINCYTO,neurological toxicities,were pyrexia che,1
BLINCYTO,neurological toxicities,,0
BLINCYTO,neurological toxicities,,0
BLINCYTO,neurological toxicities,"adverse reactions were pyrexia che (36%), peripheral e dema febrile neutropenia nausea hypokalemia",1
BLINCYTO,neurological toxicities,"were pyrexia che (36%), peripheral e dema febrile neutropenia nausea hypokalemia",1
BLINCYTO,neurological toxicities,nausea hypokalemia,0
BLINCYTO,neurological toxicities,were pyrexia che,1
BLINCYTO,neurological toxicities,"reactions were pyrexia che (36%), peripheral e dema febrile neutropenia nausea hypokalemia",1
BLINCYTO,neurological toxicities,reactions were pyrexia che,1
BLINCYTO,encephalopathy,adverse re actions were reported in of,1
BLINCYTO,encephalopathy,ous adverse re actions were reported in of,1
BLINCYTO,encephalopathy,nausea hypokalemia and constipation ous adverse,1
BLINCYTO,encephalopathy,constipation,0
BLINCYTO,encephalopathy,nausea hypokalemia and constipation ous adverse re actions were reported in of,1
BLINCYTO,encephalopathy,of patients The most common serious adverse reactions included,0
BLINCYTO,encephalopathy,and constipation Seri,0
BLINCYTO,encephalopathy,Seri,0
BLINCYTO,encephalopathy,in of patients The most common,0
BLINCYTO,encephalopathy,adverse re actions were reported in of,1
BLINCYTO,convulsions,nausea hypokalemia and,0
BLINCYTO,convulsions,Serious adverse tions were  reported in of patients The,1
BLINCYTO,convulsions,constipation Serious adverse tions were  reported in of patients The,1
BLINCYTO,convulsions,and constipation Serious adverse tions,1
BLINCYTO,convulsions,adverse tions were  reported in of patients The,1
BLINCYTO,convulsions,Serious adverse,0
BLINCYTO,speech disorders,in 65% of patients The most common serious,1
BLINCYTO,speech disorders,ported in 65%,1
BLINCYTO,speech disorders,neutropenia,0
BLINCYTO,speech disorders,were ported in 65% of patients The most common serious,1
BLINCYTO,speech disorders,in 65% of patients The most common serious,1
BLINCYTO,speech disorders,,0
BLINCYTO,speech disorders,Serious adverse reactions were ported in,1
BLINCYTO,disturbances in consciousness,seri ous adverse reactions included febrile,1
BLINCYTO,disturbances in consciousness,of atients. The most common seri ous adverse reactions included febrile,1
BLINCYTO,disturbances in consciousness,and constipation Serious,0
BLINCYTO,disturbances in consciousness,common seri ous adverse reactions included febrile,1
BLINCYTO,disturbances in consciousness,seri ous adverse reactions included febrile,1
BLINCYTO,disturbances in consciousness,of atients. The most,1
BLINCYTO,disturbances in consciousness,,0
BLINCYTO,confusion,The most common s,1
BLINCYTO,confusion,common s,1
BLINCYTO,confusion,reactions included febrile neutropenia pyrexia pneumonia,0
BLINCYTO,confusion,were reported in of patients The most common seriou,0
BLINCYTO,confusion,adverse reactions were reported in,0
BLINCYTO,confusion,reactions included febrile neutropenia pyrexia pneumonia sepsis,0
BLINCYTO,confusion,,0
BLINCYTO,confusion,s adverse reactions included febrile neutropenia pyrexia,1
BLINCYTO,confusion,s adverse reactions included febrile neutropenia pyrexia,1
BLINCYTO,confusion,s,1
BLINCYTO,disorientation,,0
BLINCYTO,disorientation,adverse reactions were reported in,0
BLINCYTO,disorientation,pneumonia sepsis neutropenia,0
BLINCYTO,disorientation,patients The most common serious,0
BLINCYTO,disorientation,tions (>= 2%) included febrile neutropenia pyrexia pneumonia,1
BLINCYTO,disorientation,adverse reactions were reported in of patients The most common serious,0
BLINCYTO,balance disorders,infection overdose,0
BLINCYTO,balance disorders,"adverse reactions included febrile penia,",1
BLINCYTO,balance disorders,"included febrile penia,",1
BLINCYTO,balance disorders,p neumonia sepsis neutropenia devicerelated infection,1
BLINCYTO,balance disorders,"included febrile penia,",1
BLINCYTO,balance disorders,of patients The most common,0
BLINCYTO,balance disorders,adverse reactions included,0
BLINCYTO,balance disorders,"adverse reactions included febrile penia, pyrexia, p neumonia sepsis neutropenia devicerelated infection",1
BLINCYTO,infections,discontinu ation of treatment included encephalopathy,1
BLINCYTO,infections,most frequently,0
BLINCYTO,infections,of patie,0
BLINCYTO,infections,discontinu ation of treatment included encephalopathy,1
BLINCYTO,infections,The adverse reactions reported most frequently as the reason for,0
BLINCYTO,infections,discontinu ation of treatment included encephalopathy,1
BLINCYTO,infections,as the reason discontinu ation of treatment included encephalopathy,1
BLINCYTO,infections,reactions reported,0
BLINCYTO,infections,patients treated with BLINCYTO The adverse reactions reported most frequently as the,0
BLINCYTO,sepsis,and sepsis Fatal adverse,0
BLINCYTO,sepsis,reason for discontinuation treatm ent included encephalopathy and sepsis,1
BLINCYTO,sepsis,treatm ent included encephalopathy and sepsis,1
BLINCYTO,sepsis,and sepsis,0
BLINCYTO,sepsis,treatm ent included encephalopathy and sepsis,1
BLINCYTO,pneumonia,,0
BLINCYTO,pneumonia,majority of,0
BLINCYTO,pneumonia,frequently as the,0
BLINCYTO,pneumonia,The majority,0
BLINCYTO,pneumonia,most frequently as,0
BLINCYTO,pneumonia,,0
BLINCYTO,bacteremia,reason for discontinuation of treatment included,0
BLINCYTO,bacteremia,,0
BLINCYTO,bacteremia,as the reason,0
BLINCYTO,bacteremia,of these events,0
BLINCYTO,bacteremia,encephalop athy and sepsis Fatal adverse,1
BLINCYTO,opportunistic infections,included hy and sepsis. Fatal adv erse events occurred in of,1
BLINCYTO,opportunistic infections,patients The majority of,0
BLINCYTO,opportunistic infections,adv erse events occurred in of,1
BLINCYTO,opportunistic infections,discontinuation of treatment included hy and sepsis. Fatal adv erse events occurred in of,1
BLINCYTO,opportunistic infections,and sepsis. Fatal adv erse events occurred in of,1
BLINCYTO,opportunistic infections,,0
BLINCYTO,catheter-site infections,,0
BLINCYTO,catheter-site infections,vents occurred in 15% of patients The majority of these,1
BLINCYTO,catheter-site infections,of treatment included encephalopathy and,0
BLINCYTO,catheter-site infections,adverse vents occurred in 15% of patients The majority of these,1
BLINCYTO,catheter-site infections,15% of patients The majority of these,1
BLINCYTO,catheter-site infections,Fatal adverse vents occurred in 15% of patients The majority of these,1
BLINCYTO,catheter-site infections,events were infections No fatal adverse events occurred on,0
BLINCYTO,catheter-site infections,majority of these events were infections No fatal,0
BLINCYTO,catheter-site infections,adverse vents occurred in 15% of patients The majority of these,1
BLINCYTO,catheter-site infections,vents occurred in 15% of patients The majority of these,1
BLINCYTO,fatal,The majority of these,0
BLINCYTO,fatal,d,1
BLINCYTO,fatal,d on treatment among patients in remission,1
BLINCYTO,fatal,No fatal adverse events d,1
BLINCYTO,fatal,on treatment among patients in remission,1
BLINCYTO,fatal,events d,1
BLINCYTO,fatal,these,0
BLINCYTO,Tumor lysis syndrome,Incidence for Grade or Higher N Adverse,1
BLINCYTO,Tumor lysis syndrome,Incidence for Any Grade >=,1
BLINCYTO,Tumor lysis syndrome,Incidence for Any Grade  >= 5% Incidence for Grade or Higher N Adverse,1
BLINCYTO,Tumor lysis syndrome,Common Terminology,0
BLINCYTO,TLS,rad e or Higher N Adverse,1
BLINCYTO,TLS,,0
BLINCYTO,TLS,rad e or Higher N Adverse,1
BLINCYTO,TLS,rad e or Higher N Adverse,1
BLINCYTO,TLS,or Incidence for rad e or Higher N Adverse,1
BLINCYTO,TLS,,0
BLINCYTO,TLS,Incidence for rad e or Higher N Adverse,1
BLINCYTO,TLS,for rad e or Higher N Adverse,1
BLINCYTO,TLS,Adverse,0
BLINCYTO,TLS,Table Adverse,0
BLINCYTO,TLS,rad e or Higher N Adverse,1
BLINCYTO,TLS,Common Terminology,0
BLINCYTO,TLS,With Incidence for Any Grade or Incidence for G,0
BLINCYTO,TLS,,0
BLINCYTO,TLS,Adverse,0
BLINCYTO,fatal,eacti on Any GradeGrading based on,1
BLINCYTO,fatal,eacti on Any GradeGrading based on,1
BLINCYTO,Neutropenia,,0
BLINCYTO,Neutropenia,neutropenic tis.     Ab dominal pain Vomiting General disorders,1
BLINCYTO,Neutropenia,,0
BLINCYTO,Neutropenia,tis.,1
BLINCYTO,Neutropenia,terms colitis diarrhea enteritis and neutropenic coli,0
BLINCYTO,Neutropenia,enteritis and neutropenic tis.     Ab dominal pain Vomiting General disorders,1
BLINCYTO,Neutropenia,tis.,1
BLINCYTO,Neutropenia,Ab dominal pain Vomiting General disorders,1
BLINCYTO,Neutropenia,and,0
BLINCYTO,febrile neutropenia,pain Vomitin g General disorders and administration,1
BLINCYTO,febrile neutropenia,neutropenic colitis al pain     Vomitin g General disorders and administration,1
BLINCYTO,febrile neutropenia,,0
BLINCYTO,febrile neutropenia,al pain Vomitin g General disorders and administration,1
BLINCYTO,febrile neutropenia,colitis al pain     Vomitin g General disorders and administration,1
BLINCYTO,febrile neutropenia,Vomitin g General disorders and administration,1
BLINCYTO,neurologic events,,0
BLINCYTO,neurologic events,,0
BLINCYTO,neurologic events,rial infections Fungal infections Viral infections Pneumonia,1
BLINCYTO,neurologic events,Other pathogen infections rial,1
BLINCYTO,neurologic events,,0
BLINCYTO,neurologic events,infections rial infections   Fungal infections Viral infections Pneumonia,1
BLINCYTO,neurologic events,,0
BLINCYTO,neurologic events,,0
BLINCYTO,neurologic events,infestations Other pathogen infections rial,1
BLINCYTO,seizures,infections Bacterial infections,0
BLINCYTO,seizures,,0
BLINCYTO,seizures,fections Viral infections Pneumonia Sepsis Investigation,1
BLINCYTO,seizures,fections Viral infections Pneumonia Sepsis Investigation,1
BLINCYTO,seizures,fections Viral infections Pneumonia Sepsis Investigation,1
BLINCYTO,loss of consciousness,aspartate,0
BLINCYTO,loss of consciousness,Sepsis,0
BLINCYTO,loss of consciousness,        4419151397    Investigations Increased alanine aminotransferase Increased,1
BLINCYTO,loss of consciousness,,0
BLINCYTO,loss of consciousness,aminotransferase Increased aspartate am,0
BLINCYTO,loss of consciousness,infections,0
BLINCYTO,elevations in liver enzymes,al and connective tissue disorders Back pain Pain in extremity Bone pain,0
BLINCYTO,elevations in liver enzymes,connective,0
BLINCYTO,elevations in liver enzymes,,0
BLINCYTO,elevations in liver enzymes,al and,0
BLINCYTO,elevations in liver enzymes,"  60735    
  Musculoskelet al and connective tissue disorders",1
BLINCYTO,CRS,,0
BLINCYTO,CRS,    Bone pain Arthralgia Nervous system,1
BLINCYTO,CRS,    Bone pain Arthralgia Nervous system,1
BLINCYTO,CRS,Back pain Pain in     Bone pain Arthralgia Nervous system,1
BLINCYTO,CRS,connective tissue disorders Back,0
BLINCYTO,CRS,Back pain Pain,0
BLINCYTO,CRS,    Bone pain Arthralgia Nervous system,1
BLINCYTO,CRS,,0
BLINCYTO,CRS,disorders Hea,0
BLINCYTO,CRS,pain Pain in     Bone pain Arthralgia Nervous system,1
BLINCYTO,elevations in liver enzymes,remor.,1
BLINCYTO,elevations in liver enzymes,tremor and remor.,1
BLINCYTO,elevations in liver enzymes,,0
BLINCYTO,elevations in liver enzymes,disorders Insomnia,0
BLINCYTO,elevations in liver enzymes,and remor.,1
BLINCYTO,elevations in liver enzymes,,0
BLINCYTO,elevations in liver enzymes,and remor.,1
BLINCYTO,elevations in liver enzymes,tremor and remor.,1
BLINCYTO,elevations in liver enzymes,Resp,0
BLINCYTO,CRS,Dizziness,0
BLINCYTO,CRS,Insomni,0
BLINCYTO,CRS,Insomni,0
BLINCYTO,CRS,,0
BLINCYTO,CRS,and,0
BLINCYTO,CRS,tremor Dizziness Psychiatric disorders a   Respiratory thoracic and mediastinal disorders,1
BLINCYTO,CRS,a   Respiratory thoracic and mediastinal disorders,1
BLINCYTO,CRS,a   Respiratory thoracic and mediastinal disorders,1
BLINCYTO,CRS,a   Respiratory thoracic and mediastinal disorders,1
BLINCYTO,CRS,thoracic and,0
BLINCYTO,leukoencephalopathy,papular rash and vesicular,0
BLINCYTO,leukoencephalopathy,papular rash and vesicular .        21       2 Vascular disorders Hypotension Hypertension Add,1
BLINCYTO,leukoencephalopathy,.,1
BLINCYTO,leukoencephalopathy,vesicular .        21       2 Vascular disorders Hypotension Hypertension Add,1
BLINCYTO,leukoencephalopathy,. 21 2 Vascular disorders Hypotension Hypertension Add,1
NATAZIA,cardiovascular events,in,0
NATAZIA,cardiovascular events,and,0
NATAZIA,cardiovascular events,the labeling cardiovascular events and stroke see Boxed Warning,1
NATAZIA,cardiovascular events,stroke see Boxed Warning and Warnings and,0
NATAZIA,cardiovascular events,cardiovascular events and stroke see Boxed Warning,1
NATAZIA,cardiovascular events,stroke see Boxed Warning and,0
NATAZIA,stroke,stroke see Boxed Warning and Warnings,1
NATAZIA,stroke,in,0
NATAZIA,stroke,cardiovascular,0
NATAZIA,stroke,Serious,0
NATAZIA,stroke,Vascular events,0
NATAZIA,stroke,,0
NATAZIA,stroke,,0
NATAZIA,stroke,events stroke see Boxed Warning and Warnings,1
NATAZIA,Vascular events,disease see Warnings and,0
NATAZIA,Vascular events,events see Warnings and Precautions Liver,1
NATAZIA,Vascular events,Boxed,0
NATAZIA,Vascular events,Warnings and Precautions,0
NATAZIA,Vascular events,and Vascular events see Warnings and Precautions Liver,1
NATAZIA,Vascular events,Warnings and Vascular events see Warnings and Precautions Liver,1
NATAZIA,Vascular events,see Boxed Warning and Warnings and,0
NATAZIA,Vascular events,Warning and Warnings,0
NATAZIA,Liver disease,Precautions,0
NATAZIA,Liver disease,see Warnings and Liver,1
NATAZIA,Liver disease,events see Warnings and,0
NATAZIA,Liver disease,,0
NATAZIA,Liver disease,see Warnings and Liver disease see Warnings and Precautions Adverse,1
NATAZIA,Liver disease,see Warnings and Liver disease see Warnings and Precautions Adverse,1
NATAZIA,Liver disease,see Warnings and Precautions Adverse reactions,0
NATAZIA,Liver disease,events see Warnings,0
NATAZIA,Liver disease,Warnings and,0
NATAZIA,Irregular uterine bleeding,EXCERPT The,0
NATAZIA,Irregular uterine bleeding,Irregular uterine bleeding Nausea Breast tenderness Headache EXCERPT,1
NATAZIA,Irregular uterine bleeding,Precautions Adverse reactions commonly reported by,0
NATAZIA,Irregular uterine bleeding,EXCERPT,0
NATAZIA,Irregular uterine bleeding,Irregular uterine bleeding Nausea Breast tenderness Headache EXCERPT,1
NATAZIA,Irregular uterine bleeding,by COC users,0
NATAZIA,Irregular uterine bleeding,most common,0
NATAZIA,Irregular uterine bleeding,by COC users Irregular,1
NATAZIA,Nausea,Nausea Breast tenderness Headache EXCERPT The,1
NATAZIA,Breast tenderness,Breast tenderness Headache EXCERPT The most common,1
NATAZIA,Breast tenderness,,0
NATAZIA,Breast tenderness,Irregular uterine bleeding Breast tenderness Headache EXCERPT The most common,1
NATAZIA,Breast tenderness,clinical trials,0
NATAZIA,Breast tenderness,by,0
NATAZIA,Breast tenderness,,0
NATAZIA,Headache,Nausea Breast,0
NATAZIA,Headache,,0
NATAZIA,Headache,uterine bleeding Nausea Breast Headache EXCERPT The most common adverse,1
NATAZIA,Headache,,0
NATAZIA,Headache,Headache EXCERPT The most common adverse,1
NATAZIA,Headache,,0
NATAZIA,Headache,EXCERPT The most common,0
NATAZIA,headaches,The most common adverse reactions,0
NATAZIA,headaches,uterine,0
NATAZIA,headaches,headaches irregular uterine bleedingheadache including migraines,1
NATAZIA,headaches,trials for Natazia headaches irregular uterine bleedingheadache including migraines,1
NATAZIA,headaches,most common adverse,0
NATAZIA,headaches,for Natazia headaches irregular uterine bleedingheadache including migraines,1
NATAZIA,headaches,,0
NATAZIA,irregular uterine bleeding,are irregular uterine bleeding headache including migraines breast tendernesspain,1
NATAZIA,irregular uterine bleeding,bleeding headache including migraines breast tendernesspain,1
NATAZIA,irregular uterine bleeding,for Natazia are irregular uterine bleeding headache including migraines breast tendernesspain,1
NATAZIA,irregular uterine bleeding,uterine bleeding headache including migraines breast tendernesspain,1
NATAZIA,irregular uterine bleeding,irregular uterine bleeding headache including migraines breast tendernesspain,1
NATAZIA,irregular uterine bleeding,disorders nausea,0
NATAZIA,irregular uterine bleeding,,0
NATAZIA,irregular uterine bleeding,,0
NATAZIA,irregular uterine bleeding,for Natazia are irregular,1
NATAZIA,headache,headaches irregular uterine headache including migraines breast tendernesspain menstrual,1
NATAZIA,headache,vomiting,0
NATAZIA,headache,,0
NATAZIA,headache,headache including migraines breast tendernesspain menstrual,1
NATAZIA,headache,headache including migraines breast tendernesspain menstrual,1
NATAZIA,headache,menstrual disorders nausea or,0
NATAZIA,headache,tendernesspain menstrual,0
NATAZIA,migraines,breast tendernesspain,0
NATAZIA,migraines,mood,0
NATAZIA,migraines,bleedingheadache migraines breast tendernesspain menstrual disorders nausea,1
NATAZIA,migraines,migraines breast tendernesspain menstrual disorders nausea,1
NATAZIA,migraines,breast tendernesspain menstrual disorders nausea,0
NATAZIA,breast tenderness,menstrual disorders nausea,0
NATAZIA,breast tenderness,,0
NATAZIA,breast tenderness,breast tenderness pain menstrual disorders nausea or,1
NATAZIA,breast tenderness,vomiting acne mood changes and increased,0
NATAZIA,breast tenderness,,0
NATAZIA,breast tenderness,,0
NATAZIA,breast tenderness,Natazia are headaches irregular,0
NATAZIA,breast tenderness,uterine bleedingheadache including breast tenderness pain menstrual disorders nausea or,1
NATAZIA,breast tenderness,,0
NATAZIA,breast tenderness,irregular uterine bleedingheadache including breast tenderness pain menstrual disorders nausea or,1
NATAZIA,menstrual disorders,migraines breast tendernesspain,0
NATAZIA,menstrual disorders,nausea or vomiting acne mood changes and,0
NATAZIA,menstrual disorders,breast menstrual,1
NATAZIA,menstrual disorders,,0
NATAZIA,menstrual disorders,irregular uterine bleedingheadache,0
NATAZIA,menstrual disorders,menstrual disorders nausea or vomiting acne mood,1
NATAZIA,menstrual disorders,menstrual disorders nausea or vomiting acne mood,1
NATAZIA,menstrual disorders,including migraines breast menstrual disorders nausea or vomiting acne mood,1
NATAZIA,nausea,,0
NATAZIA,nausea,,0
NATAZIA,vomiting,or,0
NATAZIA,acne,,0
NATAZIA,mood changes,,0
NATAZIA,mood changes,disorders,0
NATAZIA,mood changes,changes and increased weight To report,1
NATAZIA,mood changes,ADVERSE,0
NATAZIA,mood changes,nausea or vomiting acne,0
NATAZIA,mood changes,mood changes and increased weight To report,1
NATAZIA,mood changes,menstrual disorders nausea or vomiting,0
NATAZIA,mood changes,contact,0
NATAZIA,mood changes,mood changes and increased weight To report,1
NATAZIA,increased weight,REACTIONS contact Bayer,0
NATAZIA,increased weight,increased weight To report SUSPECTED ADVERSE REACTIONS,1
NATAZIA,increased weight,,0
NATAZIA,increased weight,report SUSPECTED ADVERSE REACTIONS contact,0
NATAZIA,increased weight,increased,1
NATAZIA,menstrual disorder,discontinuation menstrual,1
NATAZIA,menstrual disorder,reactions leading to discontinuation menstrual disorder metrorrhagia menorrhagia menstruation irregular genital,1
NATAZIA,menstrual disorder,reactions leading to discontinuation menstrual,1
NATAZIA,menstrual disorder,disorder metrorrhagia menorrhagia menstruation irregular genital,1
NATAZIA,menstrual disorder,hemorrhage vaginal,0
NATAZIA,menstrual disorder,menstruation irregular genital hemorrhage vaginal hemorrhage,0
NATAZIA,menstrual disorder,disorder metrorrhagia menorrhagia menstruation irregular genital,1
NATAZIA,menstrual disorder,adverse reactions leading to,0
NATAZIA,metrorrhagia,,0
NATAZIA,metrorrhagia,metrorrhagia menorrhagia menstruation irregular genital hemorrhage,1
NATAZIA,metrorrhagia,metrorrhagia menorrhagia menstruation irregular genital hemorrhage,1
NATAZIA,metrorrhagia,were menstrual metrorrhagia menorrhagia menstruation irregular genital hemorrhage,1
NATAZIA,metrorrhagia,metrorrhagia menorrhagia menstruation irregular genital hemorrhage,1
NATAZIA,metrorrhagia,hemorrhage,0
NATAZIA,metrorrhagia,vaginal,0
NATAZIA,menorrhagia,most,0
NATAZIA,menorrhagia,menorrhagia menstruation irregular genital hemorrhage vaginal,1
NATAZIA,menorrhagia,menorrhagia menstruation irregular genital hemorrhage vaginal,1
NATAZIA,menorrhagia,bleeding,0
NATAZIA,menorrhagia,menorrhagia menstruation irregular genital hemorrhage vaginal,1
NATAZIA,menorrhagia,most frequent,0
NATAZIA,menorrhagia,menorrhagia menstruation irregular genital hemorrhage vaginal,1
NATAZIA,menorrhagia,menorrhagia menstruation irregular genital hemorrhage vaginal,1
NATAZIA,menstruation irregular,metrorrhagia menstruation irregular genital hemorrhage vaginal hemorrhage dysfunctional,1
NATAZIA,menstruation irregular,metrorrhagia menstruation,1
NATAZIA,menstruation irregular,,0
NATAZIA,menstruation irregular,menstrual disorder metrorrhagia menstruation irregular genital hemorrhage vaginal hemorrhage dysfunctional,1
NATAZIA,menstruation irregular,were menstrual disorder,0
NATAZIA,menstruation irregular,were menstrual disorder metrorrhagia menstruation irregular genital hemorrhage vaginal hemorrhage dysfunctional,1
NATAZIA,menstruation irregular,menstrual disorder metrorrhagia menstruation irregular genital hemorrhage vaginal hemorrhage dysfunctional,1
NATAZIA,menstruation irregular,disorder metrorrhagia menstruation,1
NATAZIA,menstruation irregular,irregular genital hemorrhage vaginal hemorrhage dysfunctional,1
NATAZIA,menstruation irregular,disorder metrorrhagia menstruation,1
NATAZIA,genital hemorrhage,discontinuation were,0
NATAZIA,genital hemorrhage,genital hemorrhage vaginal hemorrhage dysfunctional uterine bleeding,1
NATAZIA,genital hemorrhage,genital,1
NATAZIA,genital hemorrhage,metrorrhagia menorrhagia menstruation genital,1
NATAZIA,genital hemorrhage,to discontinuation were menstrual disorder metrorrhagia menorrhagia menstruation irregular,0
NATAZIA,genital hemorrhage,,0
NATAZIA,vaginal hemorrhage,depression mood swings mood,0
NATAZIA,vaginal hemorrhage,menorrhagia menstruation irregular genital vaginal,1
NATAZIA,vaginal hemorrhage,mood changes depression mood swings mood altered,0
NATAZIA,vaginal hemorrhage,genital,0
NATAZIA,vaginal hemorrhage,menstrual disorder metrorrhagia menorrhagia,0
NATAZIA,dysfunctional uterine bleeding,,0
NATAZIA,dysfunctional uterine bleeding,irregular genital hemorrhage vaginal hemorrhage,0
NATAZIA,dysfunctional uterine bleeding,hemorrhage vaginal dysfunctional uterine bleeding mood changes depression mood swings,1
NATAZIA,dysfunctional uterine bleeding,genital hemorrhage vaginal dysfunctional uterine bleeding mood changes depression mood swings,1
NATAZIA,mood changes,mood changes depression mood swings mood altered,1
NATAZIA,mood changes,mood changes depression mood swings mood altered,1
NATAZIA,mood changes,mood altered depressed,0
NATAZIA,mood changes,,0
NATAZIA,mood changes,hemorrhage vaginal hemorrhage dysfunctional uterine bleeding,0
NATAZIA,mood changes,uterine mood changes depression mood swings mood altered,1
NATAZIA,mood changes,dysthymic disorder crying,0
NATAZIA,mood changes,hemorrhage,0
NATAZIA,depression,depression mood swings mood altered depressed,1
NATAZIA,mood swings,mood altered depressed mood dysthymic disorder crying acne,0
NATAZIA,mood swings,uterine bleeding mood changes mood,1
NATAZIA,mood swings,acne headache,0
NATAZIA,mood swings,uterine bleeding mood changes mood swings mood altered depressed mood dysthymic,1
NATAZIA,mood swings,mood changes mood,1
NATAZIA,mood swings,,0
NATAZIA,mood swings,hemorrhage dysfunctional uterine bleeding mood changes depression,0
NATAZIA,mood swings,crying acne headache,0
NATAZIA,mood swings,swings mood altered depressed mood dysthymic,1
NATAZIA,mood swings,mood changes mood,1
NATAZIA,mood altered,mood changes depression mood swings,0
NATAZIA,mood altered,acne headache including,0
NATAZIA,mood altered,mood mood altered depressed mood dysthymic disorder crying,1
NATAZIA,depressed mood,depression mood,0
NATAZIA,depressed mood,,0
NATAZIA,depressed mood,mood dysthymic disorder crying acne headache,1
NATAZIA,depressed mood,depression mood swings mood depressed mood dysthymic disorder crying acne headache,1
NATAZIA,depressed mood,mood changes depression mood swings mood,0
NATAZIA,depressed mood,depressed mood dysthymic disorder crying acne headache,1
NATAZIA,depressed mood,crying acne,0
NATAZIA,depressed mood,,0
NATAZIA,depressed mood,mood swings mood depressed,1
NATAZIA,depressed mood,depressed,1
NATAZIA,dysthymic disorder,swings mood altered depressed dysthymic,1
NATAZIA,dysthymic disorder,disorder crying acne headache including migraines,1
NATAZIA,dysthymic disorder,,0
NATAZIA,dysthymic disorder,bleeding mood changes depression,0
NATAZIA,dysthymic disorder,mood altered depressed dysthymic disorder crying acne headache including migraines,1
NATAZIA,dysthymic disorder,swings mood altered depressed dysthymic disorder crying acne headache including migraines,1
NATAZIA,crying,,0
NATAZIA,crying,including,0
NATAZIA,crying,migraines,0
NATAZIA,crying,swings mood altered,0
NATAZIA,crying,crying acne headache including migraines and,1
NATAZIA,acne,acne headache including migraines and weight,1
NATAZIA,acne,disorder acne headache including migraines and weight,1
NATAZIA,acne,mood dysthymic disorder crying,0
NATAZIA,acne,acne headache including migraines and weight,1
NATAZIA,headache,headache including migraines and weight increased,1
NATAZIA,headache,Common Adverse Reactions,0
NATAZIA,headache,headache including migraines and weight increased,1
NATAZIA,headache,headache including migraines and weight increased,1
NATAZIA,headache,headache including migraines and weight increased,1
NATAZIA,headache,headache including migraines and weight increased,1
NATAZIA,headache,swings mood altered depressed mood dysthymic disorder,0
NATAZIA,headache,Adverse,0
NATAZIA,headache,altered depressed,0
NATAZIA,migraines,and weight increased Common Adverse,0
NATAZIA,migraines,crying acne headache including,0
NATAZIA,migraines,disorder crying,0
NATAZIA,migraines,altered depressed,0
NATAZIA,migraines,Adverse Reactions headache including,0
NATAZIA,migraines,migraines and weight increased Common Adverse,1
NATAZIA,migraines,headache migraines and weight increased Common Adverse,1
NATAZIA,migraines,headache including,0
NATAZIA,weight increased,including migraines weight increased Common Adverse Reactions headache including,1
NATAZIA,weight increased,weight increased Common Adverse Reactions headache including,1
NATAZIA,weight increased,Reactions,0
NATAZIA,headache,headache including migraines breast pain discomfort,1
NATAZIA,headache,,0
NATAZIA,headache,headache including migraines breast pain discomfort,1
NATAZIA,headache,headache including migraines breast pain discomfort,1
NATAZIA,headache,headache including migraines breast pain discomfort,1
NATAZIA,headache,disorders m,0
NATAZIA,headache,,0
NATAZIA,headache,migraines breast pain discomfort or tenderness,0
NATAZIA,headache,Common,0
NATAZIA,migraines,migraines breast pain discomfort or tenderness,1
NATAZIA,migraines,migraines breast pain discomfort or tenderness,1
NATAZIA,breast pain,breast pain discomfort or tenderness menstrual disorders,1
NATAZIA,breast pain,including breast pain discomfort or tenderness menstrual disorders,1
NATAZIA,breast pain,including,0
NATAZIA,breast pain,Adverse Reactions headache including breast pain discomfort or tenderness menstrual disorders,1
NATAZIA,menstrual disorders,or menstrual disorders metrorrhagia menstruation irregular menorrhagia vaginal,1
NATAZIA,menstrual disorders,breast pain discomfort or menstrual disorders metrorrhagia menstruation irregular menorrhagia vaginal,1
NATAZIA,menstrual disorders,breast pain discomfort or menstrual disorders metrorrhagia menstruation irregular menorrhagia vaginal,1
NATAZIA,menstrual disorders,pain discomfort or menstrual,1
NATAZIA,menstrual disorders,disorders metrorrhagia menstruation irregular menorrhagia vaginal,1
NATAZIA,menstrual disorders,menstrual disorders metrorrhagia menstruation irregular menorrhagia vaginal,1
NATAZIA,menstrual disorders,menstruation irregular menorrhagia,0
NATAZIA,metrorrhagia,breast pain discomfort or tenderness,0
NATAZIA,metrorrhagia,irregular,0
NATAZIA,metrorrhagia,bleeding genital,0
NATAZIA,metrorrhagia,metrorrhagia menstruation irregular menorrhagia vaginal hemorrhage,1
NATAZIA,metrorrhagia,menstrual,0
NATAZIA,metrorrhagia,metrorrhagia menstruation irregular menorrhagia vaginal hemorrhage,1
NATAZIA,metrorrhagia,or tenderness menstrual metrorrhagia menstruation irregular menorrhagia vaginal hemorrhage,1
NATAZIA,metrorrhagia,metrorrhagia menstruation irregular menorrhagia vaginal hemorrhage,1
NATAZIA,metrorrhagia,metrorrhagia menstruation irregular menorrhagia vaginal hemorrhage,1
NATAZIA,menstruation irregular,irregular menorrhagia vaginal hemorrhage dysfunctional uterine,1
NATAZIA,menstruation irregular,menstrual disorders menstruation,1
NATAZIA,menstruation irregular,menstrual disorders menstruation irregular menorrhagia vaginal hemorrhage dysfunctional uterine,1
NATAZIA,menorrhagia,,0
NATAZIA,menorrhagia,dysfunctional uterine bleeding genital hemorrhage,0
NATAZIA,menorrhagia,bleeding genital hemorrhage abnormal withdrawal,0
NATAZIA,menorrhagia,menorrhagia vaginal hemorrhage dysfunctional uterine bleeding,1
NATAZIA,menorrhagia,,0
NATAZIA,menorrhagia,menorrhagia vaginal hemorrhage dysfunctional uterine bleeding,1
NATAZIA,menorrhagia,menorrhagia vaginal hemorrhage dysfunctional uterine bleeding,1
NATAZIA,menorrhagia,,0
NATAZIA,vaginal hemorrhage,disorders metrorrhagia menstruation irregular vaginal hemorrhage dysfunctional uterine bleeding genital hemorrhage,1
NATAZIA,vaginal hemorrhage,metrorrhagia menstruation irregular vaginal hemorrhage dysfunctional uterine bleeding genital hemorrhage,1
NATAZIA,vaginal hemorrhage,metrorrhagia menstruation irregular vaginal,1
NATAZIA,vaginal hemorrhage,genital hemorrhage abnormal withdrawal bleeding uterine hemorrha,0
NATAZIA,vaginal hemorrhage,menstruation irregular vaginal hemorrhage dysfunctional uterine bleeding genital hemorrhage,1
NATAZIA,vaginal hemorrhage,withdrawal bleeding uterine,0
NATAZIA,vaginal hemorrhage,,0
NATAZIA,dysfunctional uterine bleeding,abnormal withdrawal bleeding uterine hemorrhage nausea or vomiting,0
NATAZIA,dysfunctional uterine bleeding,uterine hemorrhage nausea or vomiting,0
NATAZIA,dysfunctional uterine bleeding,uterine bleeding genital hemorrhage abnormal withdrawal bleeding,1
NATAZIA,dysfunctional uterine bleeding,vomiting,0
NATAZIA,dysfunctional uterine bleeding,menorrhagia vaginal hemorrhage,0
NATAZIA,dysfunctional uterine bleeding,menorrhagia,0
NATAZIA,dysfunctional uterine bleeding,uterine bleeding genital hemorrhage abnormal withdrawal bleeding,1
NATAZIA,dysfunctional uterine bleeding,dysfunctional uterine bleeding genital hemorrhage abnormal withdrawal bleeding,1
NATAZIA,dysfunctional uterine bleeding,dysfunctional uterine bleeding genital hemorrhage abnormal withdrawal bleeding,1
NATAZIA,genital hemorrhage,dysfunctional uterine genital hemorrhage abnormal withdrawal bleeding uterine hemorrhage,1
NATAZIA,genital hemorrhage,genital,1
NATAZIA,genital hemorrhage,hemorrhage,0
NATAZIA,genital hemorrhage,genital hemorrhage abnormal withdrawal bleeding uterine hemorrhage,1
NATAZIA,genital hemorrhage,hemorrhage dysfunctional uterine genital,1
NATAZIA,abnormal withdrawal bleeding,abnormal withdrawal bleeding uterine hemorrhage nausea or vomiting,1
NATAZIA,abnormal withdrawal bleeding,bleeding genital abnormal withdrawal bleeding uterine hemorrhage nausea or vomiting,1
NATAZIA,abnormal withdrawal bleeding,,0
NATAZIA,abnormal withdrawal bleeding,bleeding uterine hemorrhage nausea or vomiting,1
NATAZIA,uterine hemorrhage,hemorrhage,0
NATAZIA,uterine hemorrhage,hemorrhage nausea or vomiting acne mood,1
NATAZIA,nausea,swings depressed mood mood altere,0
NATAZIA,nausea,nausea or vomiting acne mood changes,1
NATAZIA,nausea,genital hemorrhage,0
NATAZIA,nausea,nausea or vomiting acne mood changes,1
NATAZIA,nausea,abnormal withdrawal,0
NATAZIA,nausea,nausea or vomiting acne mood changes,1
NATAZIA,nausea,abnormal withdrawal,0
NATAZIA,nausea,withdrawal bleeding uterine nausea or vomiting acne mood changes,1
NATAZIA,nausea,nausea or vomiting acne mood changes,1
NATAZIA,nausea,nausea or vomiting acne mood changes,1
NATAZIA,acne,acne mood changes depression mood swings,1
NATAZIA,acne,hemorrhage nausea,0
NATAZIA,acne,uterine hemorrhage nausea or acne mood changes depression mood swings,1
NATAZIA,mood changes,mood,1
NATAZIA,mood changes,mood changes depression mood swings depressed mood,1
NATAZIA,mood changes,nausea or vomiting mood changes depression mood swings depressed mood,1
NATAZIA,mood changes,mood swings depressed mood mood altered affect lability dysthymic,0
NATAZIA,mood changes,uterine hemorrhage nausea or vomiting,0
NATAZIA,mood changes,or vomiting mood,1
NATAZIA,mood changes,nausea or vomiting mood,1
NATAZIA,depression,lability dysthymic disorder crying and,0
NATAZIA,depression,depressed mood mood altered,0
NATAZIA,depression,,0
NATAZIA,depression,,0
NATAZIA,depression,depression mood swings depressed mood mood,1
NATAZIA,depression,lability dysthymic disorder crying,0
NATAZIA,depression,depression mood swings depressed mood mood,1
NATAZIA,depression,,0
NATAZIA,mood swings,swings depressed mood mood altered affect,1
NATAZIA,mood swings,hemorrhage nausea or vomiting acne mood changes,0
NATAZIA,mood swings,swings depressed mood mood altered affect,1
NATAZIA,mood swings,mood swings depressed mood mood altered affect,1
NATAZIA,depressed mood,depressed mood mood altered affect lability dysthymic,1
NATAZIA,depressed mood,mood mood altered affect lability dysthymic,1
NATAZIA,depressed mood,depressed mood mood altered affect lability dysthymic,1
NATAZIA,depressed mood,mood depressed,1
NATAZIA,depressed mood,depression mood,0
NATAZIA,mood altered,mood swings depressed mood,1
NATAZIA,affect lability,depressed mood mood affect,1
NATAZIA,affect lability,affect,1
NATAZIA,affect lability,mood changes depression,0
NATAZIA,affect lability,depressed mood mood,0
NATAZIA,affect lability,depression mood swings depressed,0
NATAZIA,dysthymic disorder,altered affect dysthymic,1
NATAZIA,crying,dysthymic crying and increased weight Serious Adverse,1
NATAZIA,crying,disorder,0
NATAZIA,crying,crying and increased weight Serious Adverse,1
NATAZIA,crying,,0
NATAZIA,crying,crying and increased weight Serious Adverse,1
NATAZIA,increased weight,disorder crying increased weight Serious Adverse Reactions myocardial infarction,1
NATAZIA,increased weight,weight Serious Adverse Reactions myocardial infarction,1
NATAZIA,myocardial infarction,myocardial infarction cases ruptured ovarian cyst cases,1
NATAZIA,ruptured ovarian cyst,myocardial infarction ruptured ovarian cyst cases deep vein thrombosis focal,1
NATAZIA,ruptured ovarian cyst,vein thrombosis focal nodular hyperplasia of the liver,0
NATAZIA,ruptured ovarian cyst,ovarian cyst cases deep vein thrombosis focal,1
NATAZIA,ruptured ovarian cyst,Reactions,0
NATAZIA,deep vein thrombosis,vein thrombosis focal nodular hyperplasia of the,1
NATAZIA,deep vein thrombosis,,0
NATAZIA,deep vein thrombosis,,0
NATAZIA,deep vein thrombosis,deep vein thrombosis focal nodular hyperplasia of the,1
NATAZIA,deep vein thrombosis,thrombosis focal nodular hyperplasia of the,1
NATAZIA,deep vein thrombosis,deep vein thrombosis focal nodular hyperplasia of the,1
NATAZIA,deep vein thrombosis,ovarian cyst deep vein,1
NATAZIA,deep vein thrombosis,cholecystitis,0
NATAZIA,deep vein thrombosis,cases ruptured ovarian cyst,0
NATAZIA,focal nodular hyperplasia of the liver,,0
NATAZIA,uterine leiomyoma,Postmarketing,0
NATAZIA,uterine leiomyoma,uterine leiomyoma acute cholecystitis and chronic acalculous,1
NATAZIA,uterine leiomyoma,nodular hyperplasia of the uterine leiomyoma acute cholecystitis and chronic acalculous,1
NATAZIA,uterine leiomyoma,uterine leiomyoma acute cholecystitis and chronic acalculous,1
NATAZIA,uterine leiomyoma,leiomyoma acute cholecystitis and chronic acalculous,1
NATAZIA,uterine leiomyoma,acute cholecystitis and,0
NATAZIA,uterine leiomyoma,,0
NATAZIA,chronic acalculous cholecystitis,cholecystitis Postmarketing Experience The following adverse,1
NATAZIA,chronic acalculous cholecystitis,uterine leiomyoma acute cholecystitis chronic acalculous cholecystitis Postmarketing Experience The following adverse,1
NATAZIA,chronic acalculous cholecystitis,cholecystitis Postmarketing Experience The following adverse,1
NATAZIA,chronic acalculous cholecystitis,been identified,0
NATAZIA,chronic acalculous cholecystitis,chronic acalculous,1
NATAZIA,chronic acalculous cholecystitis,thrombosis focal nodular hyperplasia of the,0
NATAZIA,chronic acalculous cholecystitis,chronic acalculous cholecystitis Postmarketing Experience The following adverse,1
NATAZIA,arterial thromboembolic events,emboli deep vein thrombosis cerebral thrombosis myocardial infarction,0
NATAZIA,pulmonary emboli,arterial thromboembolic events pulmonary emboli deep vein thrombosis cerebral thrombosis,1
NATAZIA,deep vein thrombosis,including pulmonary deep vein thrombosis cerebral thrombosis myocardial infarction and,1
NATAZIA,deep vein thrombosis,thrombosis cerebral thrombosis myocardial infarction and,1
NATAZIA,deep vein thrombosis,and,0
NATAZIA,deep vein thrombosis,events including pulmonary emboli,0
NATAZIA,deep vein thrombosis,thrombosis,0
NATAZIA,deep vein thrombosis,pulmonary deep,1
NATAZIA,deep vein thrombosis,thrombosis cerebral thrombosis myocardial infarction and,1
NATAZIA,deep vein thrombosis,deep vein thrombosis cerebral thrombosis myocardial infarction and,1
NATAZIA,deep vein thrombosis,disorders Venous and arterial thromboembolic events including pulmonary,0
NATAZIA,deep vein thrombosis,thrombosis myocardial infarction and stroke hypertension,0
NATAZIA,cerebral thrombosis,cerebral,1
NATAZIA,cerebral thrombosis,stroke hypertension Hepatobiliary disorders,0
NATAZIA,myocardial infarction,myocardial infarction and stroke hypertension Hepatobiliary disorders,1
NATAZIA,myocardial infarction,cerebral myocardial,1
NATAZIA,stroke,stroke hypertension Hepatobiliary disorders Gallbladder disease,1
NATAZIA,stroke,Hepatobiliary disorders Gallbladder,0
NATAZIA,stroke,thrombosis cerebral thrombosis myocardial infarction and,0
NATAZIA,stroke,stroke hypertension Hepatobiliary disorders Gallbladder disease,1
NATAZIA,stroke,stroke hypertension Hepatobiliary disorders Gallbladder disease,1
NATAZIA,hypertension,thrombosis,0
NATAZIA,hypertension,thrombosis cerebral,0
NATAZIA,Gallbladder disease,Immune system disorders Hypersensitivity Metabolism and,0
NATAZIA,Gallbladder disease,Hepatobiliary Gallbladder disease hepatitis Immune system disorders Hypersensitivity,1
NATAZIA,Gallbladder disease,and stroke hypertension Hepatobiliary Gallbladder disease hepatitis Immune system disorders Hypersensitivity,1
NATAZIA,Gallbladder disease,Hypersensitivity Metabolism and,0
NATAZIA,Gallbladder disease,,0
NATAZIA,hepatitis,hepatitis Immune system disorders Hypersensitivity Metabolism,1
NATAZIA,hepatitis,hypertension Hepatobiliary disorders Gallbladder hepatitis Immune system disorders Hypersensitivity Metabolism,1
NATAZIA,hepatitis,Hypersensitivity Metabolism and nutrition,0
NATAZIA,hepatitis,infarction and stroke hypertension Hepatobiliary disorders Gallbladder,0
NATAZIA,hepatitis,Hypersensitivity Metabolism and nutrition disorders Fluid retenti,0
NATAZIA,hepatitis,disease,0
NATAZIA,hepatitis,disorders,0
NATAZIA,hepatitis,hepatitis Immune system disorders Hypersensitivity Metabolism,1
NATAZIA,hepatitis,and nutrition disorders Fluid,0
NATAZIA,Hypersensitivity,Hypersensitivity Metabolism and nutrition disorders Fluid,1
NATAZIA,Hypersensitivity,,0
NATAZIA,Hypersensitivity,Hypersensitivity Metabolism and nutrition disorders Fluid,1
NATAZIA,Hypersensitivity,Hypersensitivity Metabolism and nutrition disorders Fluid,1
NATAZIA,Hypersensitivity,hepatitis Immune system,0
NATAZIA,Hypersensitivity,system Hypersensitivity Metabolism and nutrition disorders Fluid,1
NATAZIA,Hypersensitivity,di,0
NATAZIA,Fluid retention,,0
NATAZIA,Fluid retention,and,0
NATAZIA,Fluid retention,Hypersensitivity Metabolism and nutrition Fluid,1
NATAZIA,Dizziness,disorders,0
NATAZIA,Dizziness,retention hypertriglyceridemia Nervous system Dizziness Skin and subcutaneous tissue disorders,1
NATAZIA,Dizziness,retention hypertriglyceridemia Nervous system Dizziness Skin and subcutaneous tissue disorders,1
NATAZIA,Dizziness,disorders,0
NATAZIA,Dizziness,nutrition,0
NATAZIA,Chloasma,Chloasma angioedema erythema nodosum erythema multiforme,1
NATAZIA,Chloasma,Skin and subcutaneous tissue Chloasma angioedema erythema nodosum erythema multiforme,1
NATAZIA,Chloasma,Gastrointestinal disorders Gastrointestinal,0
NATAZIA,Chloasma,erythema multiforme,0
NATAZIA,Chloasma,,0
NATAZIA,Chloasma,and subcutaneous tissue Chloasma angioedema erythema nodosum erythema multiforme,1
NATAZIA,Chloasma,Skin and subcutaneous tissue Chloasma angioedema erythema nodosum erythema multiforme,1
NATAZIA,Chloasma,Chloasma angioedema erythema nodosum erythema multiforme,1
NATAZIA,Chloasma,Chloasma angioedema erythema nodosum erythema multiforme,1
NATAZIA,Chloasma,Skin and subcutaneous tissue Chloasma angioedema erythema nodosum erythema multiforme,1
NATAZIA,erythema nodosum,angioedema,0
NATAZIA,erythema nodosum,disorders Chloasma erythema nodosum erythema multiforme Gastrointestinal disorders Gastrointestinal,1
NATAZIA,erythema nodosum,nodosum erythema multiforme Gastrointestinal disorders Gastrointestinal,1
NATAZIA,erythema nodosum,Dizziness Skin and subcutaneous tissue disorders Chloasma angioedema,0
NATAZIA,erythema nodosum,erythema nodosum erythema multiforme Gastrointestinal disorders Gastrointestinal,1
NATAZIA,erythema nodosum,Dizziness Skin and subcutaneous,0
NATAZIA,erythema nodosum,disorders Gastrointestinal symptoms for example abdomi,0
NATAZIA,erythema nodosum,,0
NATAZIA,erythema nodosum,angioedema,0
NATAZIA,erythema nodosum,subcutaneous tissue disorders Chloasma erythema nodosum erythema multiforme Gastrointestinal disorders Gastrointestinal,1
NATAZIA,erythema multiforme,Skin and subcutaneous,0
NATAZIA,erythema multiforme,disorders Chloasma angioedema erythema erythema,1
NATAZIA,erythema multiforme,Chloasma angioedema erythema erythema multiforme Gastrointestinal disorders Gastrointestinal symptoms for,1
NATAZIA,erythema multiforme,,0
NATAZIA,erythema multiforme,disorders Chloasma angioedema erythema erythema multiforme Gastrointestinal disorders Gastrointestinal symptoms for,1
NATAZIA,erythema multiforme,erythema erythema multiforme Gastrointestinal disorders Gastrointestinal symptoms for,1
NATAZIA,Gastrointestinal symptoms,Chloasma angioedema erythema nodosum erythema multiforme Gastrointestinal,0
NATAZIA,Gastrointestinal symptoms,angioedema erythema nodosum,0
NATAZIA,Gastrointestinal symptoms,example abdominal pain Infections and infestations Vulvovaginal candidiasis,0
NATAZIA,Gastrointestinal symptoms,Gastrointestinal,1
NATAZIA,Gastrointestinal symptoms,multiforme Gastrointestinal Gastrointestinal symptoms for example abdominal pain Infections,1
NATAZIA,Gastrointestinal symptoms,Vulvovaginal,0
NATAZIA,Gastrointestinal symptoms,,0
NATAZIA,abdominal pain,,0
NATAZIA,abdominal pain,,0
NATAZIA,abdominal pain,,0
NATAZIA,abdominal pain,disorders Gastrointestinal symptoms for abdominal,1
NATAZIA,abdominal pain,pain Infections and infestations Vulvovaginal candidiasis,1
NATAZIA,abdominal pain,erythema multiforme Gastrointestinal,0
NATAZIA,abdominal pain,abdominal pain Infections and infestations Vulvovaginal candidiasis,1
NATAZIA,Vulvovaginal candidiasis,,0
NATAZIA,Vulvovaginal candidiasis,,0
NATAZIA,Vulvovaginal candidiasis,Infections and infestations,0
NATAZIA,CARDIOVASCULAR EVENTS,o f,1
NATAZIA,CARDIOVASCULAR EVENTS,ctions with the use o f COCs,1
NATAZIA,CARDIOVASCULAR EVENTS,ctions,1
NATAZIA,CARDIOVASCULAR EVENTS,,0
NATAZIA,CARDIOVASCULAR EVENTS,the use o f,1
NATAZIA,CARDIOVASCULAR EVENTS,ctions with the,1
NATAZIA,CARDIOVASCULAR EVENTS,,0
NATAZIA,CARDIOVASCULAR EVENTS,,0
NATAZIA,CARDIOVASCULAR EVENTS,ctions with the,1
NATAZIA,CARDIOVASCULAR EVENTS,ing:,1
NATAZIA,CARDIOVASCULAR EVENTS,ing: *,1
NATAZIA,CARDIOVASCULAR EVENTS,Serious cardiovascular events and stroke,1
NATAZIA,CARDIOVASCULAR EVENTS,Serious cardiovascular events and stroke,1
NATAZIA,cardiovascular events,Warnings and Preca utions Vascular events see,1
NATAZIA,cardiovascular events,see Boxed Warning nd Warnings and Preca utions Vascular events see,1
NATAZIA,cardiovascular events,Warnings and Preca utions Vascular events see,1
NATAZIA,cardiovascular events,cardiovascular events and stroke see Boxed,0
NATAZIA,cardiovascular events,Serious cardiovascular events and stroke see,0
NATAZIA,cardiovascular events,and Preca utions Vascular events see,1
NATAZIA,cardiovascular events,see Boxed Warning nd Warnings and Preca utions Vascular events see,1
NATAZIA,CARDIOVASCULAR EVENTS,for Natazia are headaches irregular uterine bleedingheadache including migraines bre,0
NATAZIA,CARDIOVASCULAR EVENTS,Headache EXCERPT The,0
NATAZIA,CARDIOVASCULAR EVENTS,most common,0
NATAZIA,CARDIOVASCULAR EVENTS,,0
NATAZIA,cardiovascular events,tendernesspain menstrual disorders nausea or,0
NATAZIA,cardiovascular events,es (3%) and increased weight To report SUSPECTED,1
NATAZIA,Liver disease,"see Warnings and ]  
 *    Liv er disease see Warnings",1
NATAZIA,High blood pressure,reactions comm only reported by COC,1
NATAZIA,High blood pressure,reactions comm only reported by COC,1
NATAZIA,High blood pressure,and,0
NATAZIA,High blood pressure,only reported by COC users are Irregular uterine bleeding Nausea Breast tend,0
NATAZIA,High blood pressure,Liver disease see Warnings,0
NATAZIA,High blood pressure,see Warnings and Precautions erse reactions comm only reported by COC,1
NATAZIA,lipid metabolic effects,clinical,0
NATAZIA,lipid metabolic effects,Breast tenderness Headache The most common adverse reactions in clinical trials,1
NATAZIA,lipid metabolic effects,Breast tenderness Headache The most common adverse reactions in clinical trials,1
NATAZIA,lipid metabolic effects,Nausea Breast tenderness Headache The most,1
NATAZIA,lipid metabolic effects,Natazia are,0
NATAZIA,lipid metabolic effects,common adverse reactions in clinical trials,1
NATAZIA,lipid metabolic effects,clinical trials for Natazia are headaches irregular,0
NATAZIA,Uterine bleeding,HealthCare Pharmaceuticals Inc at or,0
NATAZIA,Uterine bleeding,To report SU SPECTED ADVERSE REACTIONS contact,1
NATAZIA,Uterine bleeding,,0
NATAZIA,Uterine bleeding,changes and increased weight,0
NATAZIA,venous thromboembolism,years of age who took at least one,0
NATAZIA,VTE,Natazia as,0
NATAZIA,VTE,studies with a treatment  up to cycles with Natazia,1
NATAZIA,VTE,total of subjects,0
NATAZIA,VTE,oral contraceptive and subjects in the two phase clinical,0
NATAZIA,VTE,,0
NATAZIA,VTE,an oral contraceptive and subjects in the two,0
NATAZIA,VTE, up to cycles with Natazia,1
NATAZIA,VTE, up to cycles with Natazia,1
NATAZIA,VTE, up to cycles with Natazia,1
NATAZIA,VTE,studies with a treatment  up to cycles with Natazia,1
NATAZIA,VTE,women without organic pathology,0
NATAZIA,VTE,Adverse,0
NATAZIA,VTE,in women without organic pathology,0
NATAZIA,VTE,  1 Adverse Reactions Leading to,1
NATAZIA,VTE,women,0
NATAZIA,arterial thromboses,,0
NATAZIA,arterial thromboses,trials due to,0
NATAZIA,arterial thromboses,adverse reaction the,0
NATAZIA,strokes,menstruation irregular,0
NATAZIA,strokes,clinical trials due to an adverse reaction the most frequent,0
NATAZIA,myocardial infarctions,leading to nuation were,1
NATAZIA,myocardial infarctions,to nuation,1
NATAZIA,myocardial infarctions,,0
NATAZIA,myocardial infarctions,reactions leading to,0
NATAZIA,myocardial infarctions,adverse reactions leading to nuation were menstrual disorder metrorrhagia menorrhagia menstruation,1
NATAZIA,myocardial infarctions,were menstrual disorder metrorrhagia menorrhagia menstruation,1
NATAZIA,myocardial infarctions,nuation were menstrual disorder metrorrhagia menorrhagia menstruation,1
NATAZIA,myocardial infarctions,leading to nuation were,1
NATAZIA,thromboembolic disease,mood changes depression mood swings,0
NATAZIA,thromboembolic disease,"irregular genital ,",1
NATAZIA,thromboembolic disease,",",1
NATAZIA,cerebrovascular events,"hemorrhage nausea or (6.0%),",1
NATAZIA,cerebrovascular events,"(6.0%), acne (3.9%), mood changes depression mood",1
NATAZIA,cerebrovascular events,,0
NATAZIA,cerebrovascular events,"(6.0%), acne (3.9%), mood changes depression mood",1
NATAZIA,cerebrovascular events,"uterine hemorrhage nausea or (6.0%),",1
NATAZIA,cerebrovascular events,,0
NATAZIA,cerebrovascular events,"(3.9%), mood changes depression mood",1
NATAZIA,cerebrovascular events,"nausea or (6.0%),",1
NATAZIA,cerebrovascular events,or,0
NATAZIA,hemorrhagic strokes,affect lability dysthymic disorder crying and increased,0
NATAZIA,hemorrhagic strokes,vomiting,0
NATAZIA,hemorrhagic strokes,"mood changes ression, mood",1
NATAZIA,hemorrhagic strokes,"ression, mood swing s depressed mood mood",1
NATAZIA,hemorrhagic strokes,crying and increased,0
NATAZIA,stroke,: myo cardial infarction cases ruptured,1
NATAZIA,stroke,myo cardial infarction cases ruptured,1
NATAZIA,stroke,vein thrombosis focal nodular,0
NATAZIA,stroke,cardial infarction cases ruptured ovarian cyst cases deep vein,0
NATAZIA,stroke,increased weight Serious Adverse :,1
NATAZIA,stroke,Serious Adverse :  myo cardial infarction cases ruptured,1
NATAZIA,breast cancer,vein t hrombosis cerebral thrombosis myocardial,1
NATAZIA,breast cancer,deep vein t hrombosis cerebral thrombosis myocardial,1
NATAZIA,breast cancer,isorders,0
NATAZIA,breast cancer,Gallbladder disease hepatitis,0
NATAZIA,cervical cancer,"and nutrition disorders Fluid tion,",1
NATAZIA,cervical cancer,system disorders Dizziness Skin and,0
NATAZIA,cervical cancer,disorders Hypersensitivity Metabolism and nutrition disorders,0
NATAZIA,cervical cancer,and nutrition disorders Fluid,0
NATAZIA,cervical cancer,,0
NATAZIA,cervical cancer,,0
NATAZIA,cervical cancer,disorders,0
NATAZIA,cervical cancer,Dizziness Skin and,0
NATAZIA,cervical cancer,disorders,0
NATAZIA,cervical cancer,"tion, hypertrig lyceridemia Nervous system disorders",1
NATAZIA,Hepatic adenomas,,0
NATAZIA,Hepatic adenomas,,0
NATAZIA,Hepatic adenomas,,1
NATAZIA,Hepatic adenomas,,0
NATAZIA,Hepatic adenomas,,1
NATAZIA,Hepatic adenomas,,1
NATAZIA,Hepatic adenomas,,1
NATAZIA,Hepatic adenomas,,0
NATAZIA,Rupture of hepatic adenomas,,0
NATAZIA,Rupture of hepatic adenomas,,0
NATAZIA,Rupture of hepatic adenomas,,0
NATAZIA,Rupture of hepatic adenomas,,1
NATAZIA,Rupture of hepatic adenomas,,0
NATAZIA,Rupture of hepatic adenomas,,0
NATAZIA,Rupture of hepatic adenomas,,1
NATAZIA,Rupture of hepatic adenomas,,1
NATAZIA,death,,1
NATAZIA,death,,1
NATAZIA,death,,0
NATAZIA,death,,1
NATAZIA,death,,0
NATAZIA,death,,0
NATAZIA,death,,0
NATAZIA,intra-abdominal hemorrhage,,0
NATAZIA,intra-abdominal hemorrhage,,0
NATAZIA,intra-abdominal hemorrhage,,0
NATAZIA,intra-abdominal hemorrhage,,1
NATAZIA,intra-abdominal hemorrhage,,0
NATAZIA,intra-abdominal hemorrhage,,1
NATAZIA,hepatocellular carcinoma,,1
NATAZIA,hepatocellular carcinoma,,1
NATAZIA,hepatocellular carcinoma,,1
NATAZIA,hepatocellular carcinoma,,1
NATAZIA,hepatocellular carcinoma,,1
NATAZIA,hepatocellular carcinoma,,1
NATAZIA,hepatocellular carcinoma,,1
NATAZIA,hepatocellular carcinoma,,0
NATAZIA,hepatocellular carcinoma,,1
NATAZIA,hepatocellular carcinoma,,0
NATAZIA,liver cancers,,1
NATAZIA,liver cancers,,0
NATAZIA,cholestasis,,0
NATAZIA,cholestasis,,1
NATAZIA,cholestasis,,0
NATAZIA,cholestasis,,0
NATAZIA,cholestasis,,1
NATAZIA,hypertension,,1
NATAZIA,hypertension,,1
NATAZIA,hypertension,,0
NATAZIA,hypertension,,0
NATAZIA,hypertension,,1
NATAZIA,hypertension,,0
NATAZIA,hypertension,,0
NATAZIA,gallbladder disease,,0
NATAZIA,adverse lipid changes,,1
NATAZIA,pancreatitis,,1
NATAZIA,pancreatitis,,0
NATAZIA,cerebrovascular event,,0
NATAZIA,cerebrovascular event,,0
NATAZIA,cerebrovascular event,,1
NATAZIA,cerebrovascular event,,0
NATAZIA,cerebrovascular event,,1
NATAZIA,cerebrovascular event,,0
NATAZIA,cerebrovascular event,,1
NATAZIA,cerebrovascular event,,1
NATAZIA,cerebrovascular event,,0
NATAZIA,Breakthrough bleeding,,1
NATAZIA,Breakthrough bleeding,,1
NATAZIA,Breakthrough bleeding,,0
NATAZIA,Breakthrough bleeding,,0
NATAZIA,spotting,,0
NATAZIA,spotting,,0
NATAZIA,spotting,,0
NATAZIA,spotting,,1
NATAZIA,spotting,,1
NATAZIA,spotting,,1
NATAZIA,spotting,,0
NATAZIA,spotting,,0
NATAZIA,spotting,,0
NATAZIA,spotting,,0
NATAZIA,amenorrhea,,1
NATAZIA,amenorrhea,,0
NATAZIA,amenorrhea,,1
NATAZIA,amenorrhea,,1
NATAZIA,amenorrhea,,0
NATAZIA,amenorrhea,,1
NATAZIA,amenorrhea,,1
NATAZIA,amenorrhea,,0
NATAZIA,amenorrhea,,0
NATAZIA,amenorrhea,,1
NATAZIA,amenorrhea,,0
NATAZIA,amenorrhea,,0
NATAZIA,amenorrhea,,1
NATAZIA,amenorrhea,,0
NATAZIA,amenorrhea,,1
NATAZIA,amenorrhea,,1
NATAZIA,oligomenorrhea,,0
NATAZIA,oligomenorrhea,,0
NATAZIA,oligomenorrhea,,0
NATAZIA,oligomenorrhea,,1
NATAZIA,oligomenorrhea,,1
NATAZIA,oligomenorrhea,,0
NATAZIA,oligomenorrhea,,0
NATAZIA,oligomenorrhea,,0
NATAZIA,oligomenorrhea,,1
NATAZIA,intracyclic bleeding,,0
NATAZIA,intracyclic bleeding,,1
NATAZIA,intracyclic bleeding,,1
NATAZIA,intracyclic bleeding,,0
NATAZIA,intracyclic bleeding,,0
NATAZIA,birth defects,,1
NATAZIA,birth defects,,0
NATAZIA,birth defects,,0
NATAZIA,cardiac anomalies,,0
NATAZIA,cardiac anomalies,,0
NATAZIA,cardiac anomalies,,1
NATAZIA,limb-reduction defects,,1
NATAZIA,limb-reduction defects,,0
NATAZIA,limb-reduction defects,,1
NATAZIA,limb-reduction defects,,1
NATAZIA,thyroid-binding globulin increase,,1
NATAZIA,thyroid-binding globulin increase,,1
NATAZIA,thyroid-binding globulin increase,,0
NATAZIA,thyroid-binding globulin increase,,0
NATAZIA,thyroid-binding globulin increase,,0
NATAZIA,thyroid-binding globulin increase,,1
NATAZIA,Chloasma,,0
NATAZIA,Chloasma,,1
DIFICID,nausea,,0
DIFICID,nausea,,0
DIFICID,nausea,gastrointestinal,0
DIFICID,abdominal pain,common adverse reactions are,0
DIFICID,abdominal pain,adverse reactions are nausea abdominal,1
DIFICID,abdominal pain,nausea abdominal pain gastrointestinal hemorrhage anemia and neutropenia,1
DIFICID,gastrointestinal hemorrhage,are nausea vomiting abdominal gastrointestinal hemorrhage anemia and neutropenia To report,1
DIFICID,gastrointestinal hemorrhage,are nausea vomiting,0
DIFICID,neutropenia,Pharmaceuticals at,0
DIFICID,neutropenia,abdominal pain gastrointestinal,0
DIFICID,neutropenia,neutropenia To report SUSPECTED ADVERSE REACTIONS,1
DIFICID,Vomiting,Vomiting was the primary adverse reaction,1
DIFICID,Vomiting,Vomiting was the primary adverse reaction,1
DIFICID,Anemia,System,0
DIFICID,Anemia,and Lymphatic System,0
DIFICID,Anemia,Blood and Lymphatic System Anemia,1
DIFICID,Anemia,Anemia,1
DIFICID,Anemia,Anemia,1
DIFICID,Anemia,Anemia,1
DIFICID,Anemia,Anemia,1
DIFICID,Anemia,System Anemia,1
DIFICID,Nausea,,0
DIFICID,Nausea,Nausea,1
DIFICID,Nausea,Disorders,0
DIFICID,Nausea,,0
DIFICID,Vomiting,,0
DIFICID,Vomiting,Vomiting,1
DIFICID,Vomiting,,0
DIFICID,Vomiting,Vomiting,1
DIFICID,Vomiting,,0
DIFICID,Vomiting,,0
DIFICID,Vomiting,,0
DIFICID,Vomiting,Vomiting,1
DIFICID,Abdominal Pain,Abdominal Pain Gastr,1
DIFICID,Gastrointestinal Hemorrhage,Pain Gastrointestinal Hemorrhage The,1
DIFICID,Gastrointestinal Hemorrhage,Pain Gastrointestinal Hemorrhage The,1
DIFICID,Gastrointestinal Hemorrhage,Pain Gastrointestinal,1
DIFICID,Gastrointestinal Hemorrhage,Hemorrhage,1
DIFICID,Gastrointestinal Hemorrhage,,0
DIFICID,Gastrointestinal Hemorrhage,Pain,0
DIFICID,Gastrointestinal Hemorrhage,The following,0
DIFICID,Gastrointestinal Hemorrhage,Pain Gastrointestinal,1
DIFICID,Gastrointestinal Hemorrhage,Pain,0
DIFICID,Gastrointestinal Hemorrhage,The following,0
DIFICID,abdominal distension,,0
DIFICID,abdominal distension,Gastrointestinal abdominal distension abdominal,1
DIFICID,abdominal distension,trials Gastrointestinal abdominal,1
DIFICID,abdominal distension,controlled trials Gastrointestinal abdominal distension abdominal,1
DIFICID,abdominal distension,distension abdominal,1
DIFICID,abdominal distension,in controlled trials Gastrointestinal abdominal distension abdominal,1
DIFICID,abdominal distension,controlled trials Gastrointestinal abdominal,1
DIFICID,abdominal distension,trials Gastrointestinal abdominal distension abdominal,1
DIFICID,abdominal distension,dysphagia flatulence intestinal obstruction,0
DIFICID,abdominal distension,,0
DIFICID,abdominal tenderness,abdominal tenderness dyspepsia,1
DIFICID,abdominal tenderness,dyspepsia dysphagia,0
DIFICID,abdominal tenderness,abdominal abdominal,1
DIFICID,abdominal tenderness,flatulence intestinal,0
DIFICID,abdominal tenderness,tablets in,0
DIFICID,abdominal tenderness,Disorders abdominal abdominal,1
DIFICID,abdominal tenderness,,0
DIFICID,abdominal tenderness,abdominal abdominal,1
DIFICID,abdominal tenderness,,0
DIFICID,dyspepsia,distension,0
DIFICID,dysphagia,dysphagia flatulence,1
DIFICID,dysphagia,intestinal obstruction megacolon,0
DIFICID,dysphagia,abdominal distension abdominal tenderness dyspepsia,0
DIFICID,dysphagia,,0
DIFICID,dysphagia,distension abdominal tenderness dysphagia flatulence,1
DIFICID,dysphagia,dysphagia flatulence,1
DIFICID,dysphagia,dysphagia flatulence,1
DIFICID,dysphagia,tenderness dysphagia flatulence,1
DIFICID,flatulence,flatulence intestinal,1
DIFICID,intestinal obstruction,intestinal obstruction megacolon,1
DIFICID,intestinal obstruction,abdominal tenderness dyspepsia dysphagia intestinal,1
DIFICID,intestinal obstruction,obstruction megacolon,1
DIFICID,intestinal obstruction,dysphagia intestinal,1
DIFICID,intestinal obstruction,abdominal distension abdominal,0
DIFICID,intestinal obstruction,blood,0
DIFICID,intestinal obstruction,intestinal,1
DIFICID,intestinal obstruction,intestinal obstruction megacolon,1
DIFICID,intestinal obstruction,intestinal obstruction megacolon,1
DIFICID,megacolon,abdominal tenderness dyspepsia dysphagia flatulence intestinal,0
DIFICID,megacolon,megacolon Investigations,1
DIFICID,megacolon,,0
DIFICID,megacolon,intestinal,0
DIFICID,decreased blood bicarbonate,alkaline decreased blood bicarbonate increased,1
DIFICID,decreased blood bicarbonate,Investigations increased blood alkaline decreased blood bicarbonate increased,1
DIFICID,decreased blood bicarbonate,alkaline decreased,1
DIFICID,decreased blood bicarbonate,count Metabolism and,0
DIFICID,increased hepatic enzymes,hepatic enzymes decreased,1
DIFICID,increased hepatic enzymes,hepatic enzymes decreased,1
DIFICID,increased hepatic enzymes,enzymes decreased,1
DIFICID,increased hepatic enzymes,,0
DIFICID,increased hepatic enzymes,blood increased hepatic enzymes decreased,1
DIFICID,increased hepatic enzymes,decreased,0
DIFICID,increased hepatic enzymes,increased hepatic enzymes decreased,1
DIFICID,increased hepatic enzymes,,0
DIFICID,increased hepatic enzymes,,0
DIFICID,increased hepatic enzymes,increased hepatic enzymes decreased,1
DIFICID,decreased platelet count,blood bicarbonate increased hepatic decreased,1
DIFICID,decreased platelet count,blood bicarbonate increased hepatic decreased platelet,1
DIFICID,decreased platelet count,hepatic decreased platelet count Metabolism,1
DIFICID,decreased platelet count,count Metabolism,1
DIFICID,decreased platelet count,Nutrition Disorders hyperglycemia metabolic acidosis Skin and,0
DIFICID,decreased platelet count,decreased platelet,1
DIFICID,decreased platelet count,count Metabolism,1
DIFICID,hyperglycemia,Tissue Disorders,0
DIFICID,metabolic acidosis,acidosis Skin,1
DIFICID,metabolic acidosis,and Nutrition Disorders metabolic acidosis Skin,1
DIFICID,metabolic acidosis,Nutrition Disorders metabolic,1
DIFICID,metabolic acidosis,acidosis Skin,1
DIFICID,metabolic acidosis,,0
DIFICID,metabolic acidosis,,0
DIFICID,metabolic acidosis,Subcutaneous Tissue Disorders drug eruption pruritus rash Post Marke,0
DIFICID,metabolic acidosis,acidosis Skin,1
DIFICID,drug eruption,Tissue drug eruption pruritus,1
DIFICID,drug eruption,eruption pruritus,1
DIFICID,drug eruption,Experience Adverse reactions,0
DIFICID,drug eruption,reported,0
DIFICID,drug eruption,,0
DIFICID,pruritus,Disorders drug eruption,0
DIFICID,pruritus,Disorders drug pruritus rash,1
DIFICID,pruritus,pruritus rash,1
DIFICID,pruritus,pruritus rash,1
DIFICID,pruritus,Adverse reactions reported in the post marketing,0
DIFICID,pruritus,pruritus rash,1
DIFICID,pruritus,,0
DIFICID,pruritus,Experience,0
DIFICID,rash,rash Post,1
DIFICID,rash,drug eruption rash Post,1
DIFICID,rash,drug eruption pruritus,0
DIFICID,rash,drug eruption rash Post,1
DIFICID,rash,rash Post,1
DIFICID,rash,rash Post,1
DIFICID,Hypersensitivity reactions,to drug exposure is not always,0
DIFICID,Hypersensitivity reactions,Hypersensitivity reactions dyspnea,1
DIFICID,dyspnea,exposure is,0
DIFICID,dyspnea,dyspnea angioedema,1
DIFICID,dyspnea,relationship,0
DIFICID,angioedema,always possible,0
DIFICID,angioedema,pruritus have been reported,0
DIFICID,angioedema,angioedema rash,1
DIFICID,angioedema,possible Hypersensitivity reactions angioedema rash,1
DIFICID,rash,,0
DIFICID,rash,rash and,1
DIFICID,rash,rash and,1
DIFICID,rash,Hypersensitivity reactions dyspnea rash and,1
DIFICID,rash,rash and,1
DIFICID,rash,Hypersensitivity reactions dyspnea rash and,1
DIFICID,rash,rash and,1
DIFICID,rash,rash and,1
DIFICID,rash,rash and,1
DIFICID,pruritus,angioedema rash pruritus have,1
DIFICID,Acute hypersensitivity reactions,"(6%), gastrointestinal",1
DIFICID,Acute hypersensitivity reactions,reactions are nausea vomiting abdominal,0
DIFICID,Acute hypersensitivity reactions,"nausea vomiting abdominal  (6%), gastrointestinal hemorrha ge",1
DIFICID,Acute hypersensitivity reactions,"are nausea vomiting abdominal (6%),",1
DIFICID,Acute hypersensitivity reactions,"abdominal  (6%), gastrointestinal hemorrha ge",1
DIFICID,angioedema," (4%), ane mia",1
DIFICID,angioedema,"pain gastrointestinal (4%),",1
DIFICID,angioedema," (4%), ane mia",1
DIFICID,angioedema,"(4%), ane mia",1
DIFICID,angioedema,"abdominal pain gastrointestinal (4%),",1
DIFICID,angioedema,reactions are,0
DIFICID,angioedema,ane mia,1
DIFICID,angioedema,report SUSPECTED ADVERSE REACTIONS contact Cubist,0
DIFICID,angioedema,,0
DIFICID,dyspnea,contact Cubist,0
DIFICID,dyspnea,"(2%), and",1
DIFICID,dyspnea,are nausea,0
DIFICID,dyspnea,"(2%), and",1
DIFICID,pruritus,,0
DIFICID,pruritus,nd neutr openia,1
DIFICID,pruritus,neutr openia,1
DIFICID,pruritus,nd neutr openia,1
DIFICID,pruritus,REACTIONS,0
DIFICID,pruritus,,0
DIFICID,Acute hypersensitivity reactions,rates observed in practi ce,1
DIFICID,Acute hypersensitivity reactions,twice a day for days was evaluated,0
DIFICID,Acute hypersensitivity reactions,and may not ect the rates observed in,1
DIFICID,Acute hypersensitivity reactions,may,0
DIFICID,dyspnea,t,0
DIFICID,dyspnea,,0
DIFICID,dyspnea,safety  of,1
DIFICID,dyspnea,rates observed in practice safety  of,1
DIFICID,dyspnea,safety  of,1
DIFICID,dyspnea,trials of any other drug and may not reflect the rates observed,0
DIFICID,dyspnea,safety  of,1
DIFICID,dyspnea,safety  of,1
DIFICID,dyspnea,practice safety  of,1
DIFICID,dyspnea,safety  of,1
DIFICID,rash, DIF ICID,1
DIFICID,rash,of any other drug and may not reflect,0
DIFICID,rash, DIF ICID,1
DIFICID,rash, DIF ICID,1
DIFICID,rash, DIF ICID,1
DIFICID,rash,rates observed in practice,0
DIFICID,rash,not reflect the rates observed in practice The safety of,0
DIFICID,rash, DIF ICID,1
DIFICID,rash,in,0
DIFICID,rash, DIF ICID,1
DIFICID,angioedema of the mouth,of DIFICID mg lets taken twice a day  for,1
DIFICID,hypersensitivity reactions,in withdrawal from the study varied consi,0
DIFICID,hypersensitivity reactions,,0
DIFICID,hypersensitivity reactions,ithdrew from trials as a r esult,1
DIFICID,hypersensitivity reactions,Thirtythree,0
DIFICID,hypersensitivity reactions,study varied consi,0
DIFICID,hypersensitivity reactions,DIFICID ithdrew from trials,1
DIFICID,hypersensitivity reactions,resulting in withdrawal from,0
EDARBI,diarrhea,diarrhea To report,1
EDARBI,diarrhea,To report SUSPECTED,0
EDARBI,diarrhea,,0
EDARBI,diarrhea,contact Arbor Pharmaceuticals,0
EDARBI,diarrhea,diarrhea To,1
EDARBI,hypotension,patients randomized,0
EDARBI,hypotension,hypotension orthostatic,1
EDARBI,hypotension,adverse event leading to hypotension orthostatic,1
EDARBI,diarrhea,age,0
EDARBI,diarrhea,in patients treated with Edarbi mg daily compared,0
EDARBI,diarrhea,age gender,0
EDARBI,asthenia,asthenia fatigue,1
EDARBI,asthenia,General Disorders and Administration Site Conditions,0
EDARBI,asthenia,Disorders and Administration,0
EDARBI,asthenia,asthenia fatigue,1
EDARBI,asthenia,asthenia fatigue,1
EDARBI,asthenia,asthenia fatigue,1
EDARBI,asthenia,asthenia fatigue,1
EDARBI,asthenia,asthenia fatigue,1
EDARBI,fatigue,Disorders nausea General Disorders,0
EDARBI,fatigue,and Connective Tissue Disorders muscle spasm Nervous System Disorders,0
EDARBI,fatigue,and Administration Site,0
EDARBI,muscle spasm,Musculoskeletal and Connective Tissue muscle,1
EDARBI,muscle spasm,postural Respiratory Thoracic,0
EDARBI,muscle spasm,Site Conditions asthenia,0
EDARBI,muscle spasm,dizziness postural Respiratory,0
EDARBI,muscle spasm,Connective Tissue muscle,1
EDARBI,muscle spasm,,0
EDARBI,muscle spasm,Tissue,0
EDARBI,muscle spasm,dizziness,0
EDARBI,dizziness,,0
EDARBI,dizziness,,0
EDARBI,dizziness,,0
EDARBI,dizziness,postural Respiratory,0
EDARBI,dizziness,Disorders,0
EDARBI,dizziness,spasm Nervous System dizziness dizziness,1
EDARBI,dizziness postural,,0
EDARBI,dizziness postural,Disorders dizziness,0
EDARBI,dizziness postural,,0
EDARBI,dizziness postural,postural Respiratory,1
EDARBI,dizziness postural,Disorders dizziness postural Respiratory,1
EDARBI,dizziness postural,and Connective Tissue Disorders muscle,0
EDARBI,dizziness postural,spasm Nervous System Disorders dizziness postural Respiratory,1
EDARBI,cough,cough Clinical,1
EDARBI,cough,Disorders,0
EDARBI,cough,cough Clinical,1
EDARBI,cough,cough Clinical,1
EDARBI,cough,cough Clinical,1
EDARBI,cough,Respiratory Thoracic and Mediastinal cough Clinical,1
EDARBI,cough,cough Clinical,1
EDARBI,increases in serum creatinine,Serum creatinine Small increases in serum creatinine are,1
EDARBI,increases in serum creatinine,creatinine Small increases in serum creatinine are,1
EDARBI,increases in serum creatinine,,0
EDARBI,increases in serum creatinine,patients,0
EDARBI,serum creatinine increases,serum creatinine increases HemoglobinHematocrit,1
EDARBI,serum creatinine increases,were more likely to serum creatinine increases HemoglobinHematocrit,1
EDARBI,serum creatinine increases,to serum creatinine increases HemoglobinHematocrit,1
EDARBI,serum creatinine increases,,0
EDARBI,serum creatinine increases,,0
EDARBI,serum creatinine increases,to serum creatinine,1
EDARBI,serum creatinine increases,serum creatinine increases HemoglobinHematocrit,1
EDARBI,serum creatinine increases,were more likely to serum creatinine,1
EDARBI,Low hemoglobin,report serum creatinine increases Low,1
EDARBI,Low hemoglobin,serum,0
EDARBI,Low hemoglobin,serum creatinine increases Low hemoglobin hematocrit,1
EDARBI,Low hemoglobin,creatinine increases HemoglobinHematocrit,0
EDARBI,Nausea,Nausea Muscle,1
EDARBI,Nausea,,0
EDARBI,Nausea,Nausea Muscle,1
EDARBI,Muscle spasms,,0
EDARBI,Muscle spasms,or establish a causal relationship,0
EDARBI,Muscle spasms,to drug,0
EDARBI,Muscle spasms,exposure Muscle,1
EDARBI,Muscle spasms,,0
EDARBI,Rash,relationship to drug exposure Nausea Muscle,0
EDARBI,Rash,causal relationship to drug exposure Nausea Muscle spasms,0
EDARBI,Rash,,0
EDARBI,Rash,Nausea Muscle Rash Pruritus,1
EDARBI,Rash,Rash Pruritus,1
EDARBI,Rash,,0
EDARBI,Rash,,0
EDARBI,Pruritus,relationship to drug,0
EDARBI,Pruritus,Pruritus Angioedema,1
EDARBI,Pruritus,to drug exposure Nausea Muscle spasms,0
EDARBI,Angioedema,Angioedema,1
EDARBI,Angioedema,,0
EDARBI,Angioedema,Rash Angioedema,1
EDARBI,Angioedema,Angioedema,1
EDARBI,Angioedema,,0
EDARBI,Angioedema,,0
EDARBI,Angioedema,,0
EDARBI,Angioedema,,0
EDARBI,FETAL TOXICITY,ERPT: The,1
EDARBI,FETAL TOXICITY,ERPT:   The mo st common adverse reaction in,1
EDARBI,FETAL TOXICITY,,0
EDARBI,FETAL TOXICITY,was diarrhea,0
EDARBI,FETAL TOXICITY,ERPT:   The mo st,1
EDARBI,FETAL TOXICITY,,0
EDARBI,FETAL TOXICITY,ERPT: The,1
EDARBI,FETAL TOXICITY,ERPT:,1
EDARBI,FETAL TOXICITY,SUSPECTED,0
EDARBI,FETAL TOXICITY,reaction in,1
EDARBI,FETAL TOXICITY,se reaction in adults was diarrhea To report,1
EDARBI,FETAL TOXICITY,in adults,1
EDARBI,FETAL TOXICITY,,0
EDARBI,FETAL TOXICITY,adults was diarrhea To report SUSPECTED ADVERSE REACTIONS contact,0
EDARBI,FETAL TOXICITY,report SUSPECTED ADVERSE REACTIONS contact Arbor Pharmace,0
EDARBI,FETAL TOXICITY,,0
EDARBI,death to the developing fetus,Experience Be cause,1
EDARBI,death to the developing fetus,reaction rates,0
EDARBI,death to the developing fetus,cause clinical trials are conducted under widely varying conditions,0
EDARBI,death to the developing fetus,rates,0
EDARBI,FETAL TOXICITY,"are conducted under widely conditions, ad verse",1
EDARBI,FETAL TOXICITY,"conditions, ad verse",1
EDARBI,FETAL TOXICITY,rates observed in the clinical trials of,0
EDARBI,FETAL TOXICITY,"conditions,",1
EDARBI,FETAL TOXICITY,Experience Because clinical trials are conducted under widely varying,0
EDARBI,death to the developing fetus,in clinical trials,0
EDARBI,reduces fetal renal function,"trials are conducted under dely varying conditions, adv erse",1
EDARBI,reduces fetal renal function,adv erse,1
EDARBI,reduces fetal renal function,trials of a drug cannot be directly compared,0
EDARBI,reduces fetal renal function,rates,0
EDARBI,reduces fetal renal function,under wi,0
EDARBI,reduces fetal renal function,observed in the clinical trials of a drug cannot,0
EDARBI,reduces fetal renal function,"trials are conducted under dely varying conditions,",1
EDARBI,reduces fetal renal function,under dely,1
EDARBI,reduces fetal renal function,"conducted under dely varying conditions, adv erse",1
EDARBI,neonatal morbidity,,0
EDARBI,neonatal morbidity,clinica l,1
EDARBI,neonatal morbidity,clinica l,1
EDARBI,neonatal morbidity,adverse reaction rates ved,1
EDARBI,oligohydramnios,,0
EDARBI,oligohydramnios,clinical trials of another drug and may not reflect the rates,0
EDARBI,oligohydramnios,of another drug and may not reflect the rates observed,0
EDARBI,oligohydramnios,,0
EDARBI,oligohydramnios,varying conditions adverse,0
EDARBI,oligohydramnios,of a drug not,1
EDARBI,oligohydramnios,rates observed,0
EDARBI,oligohydramnios,not be directly compared,1
EDARBI,oligohydramnios,directly compared,1
EDARBI,oligohydramnios,directly compared,1
EDARBI,fetal lung hypoplasia,in th,0
EDARBI,fetal lung hypoplasia,directly compared,0
EDARBI,neonatal adverse effects,reflect the ates observed in,1
EDARBI,neonatal adverse effects,the,0
EDARBI,neonatal adverse effects,may not reflect the ates observed in practic e,1
EDARBI,neonatal adverse effects,not,0
EDARBI,neonatal adverse effects,of,0
EDARBI,neonatal adverse effects,may not reflect the ates,1
EDARBI,neonatal adverse effects,practic e,1
EDARBI,neonatal adverse effects,,0
EDARBI,symptomatic hypotension,to adverse events in acebo-controlled,1
EDARBI,changes in renal function,placebocontrolled monotherapy,0
EDARBI,changes in renal function,patients treated th Edarbi 80 mg,1
EDARBI,changes in renal function,,0
EDARBI,changes in renal function,daily com pared,1
EDARBI,changes in renal function,Other adverse reactions with a,0
EDARBI,changes in renal function,treated th Edarbi 80 mg,1
EDARBI,changes in renal function,th Edarbi 80 mg daily com pared,1
EDARBI,oliguria,Disorders and Administration,0
EDARBI,oliguria,General Disorders and Administration Site,0
EDARBI,oliguria,Disorders and Administration Site :  asthe nia,1
EDARBI,oliguria,and,0
EDARBI,oliguria,spasm,0
EDARBI,oliguria,Musculoskeletal,0
EDARBI,oliguria,: asthe nia,1
EDARBI,oliguria,,0
EDARBI,oliguria,,0
EDARBI,progressive azotemia,fatigue Muscu loskeletal,1
EDARBI,acute renal failure,Musculoskeletal,0
EDARBI,death,Disorders,0
EDARBI,death,Musculoskeletal and Connective,0
EDARBI,death,s: m uscle,1
EDARBI,death,Musculoskeletal and Connective Tissue s:,1
EDARBI,death,Connective Tissue s:  m uscle,1
EDARBI,death,Thorac,0
EDARBI,death,and Connective Tissue s:,1
EDARBI,increases in serum creatinine,with a dministration,1
EDARBI,increases in serum creatinine,uncommon with a dministration,1
IMBRUVICA,Hemorrhage,more detail in other sections,0
IMBRUVICA,Infections,Infections see,1
IMBRUVICA,Infections,other sections,0
IMBRUVICA,Infections,Infections see,1
IMBRUVICA,Infections,Infections see,1
IMBRUVICA,Infections,Infections see,1
IMBRUVICA,Infections,Infections see,1
IMBRUVICA,Infections,Infections see,1
IMBRUVICA,Infections,Hemorrhage see Warnings,0
IMBRUVICA,Cytopenias,and Precautions,0
IMBRUVICA,Atrial Fibrillation,Atrial Fibrillation see,1
IMBRUVICA,Atrial Fibrillation,and Precautions Second Primary Malignancies,0
IMBRUVICA,Atrial Fibrillation,Warnings,0
IMBRUVICA,Atrial Fibrillation,Warnings and Atrial,1
IMBRUVICA,Atrial Fibrillation,Warnings and Precau,0
IMBRUVICA,Atrial Fibrillation,Fibrillation see,1
IMBRUVICA,Second Primary Malignancies,Second Primary,1
IMBRUVICA,Second Primary Malignancies,Malignancies see,1
IMBRUVICA,Second Primary Malignancies,Warnings and Second,1
IMBRUVICA,Second Primary Malignancies,,0
IMBRUVICA,Second Primary Malignancies,Second Primary Malignancies see,1
IMBRUVICA,Second Primary Malignancies,and Second Primary Malignancies see,1
IMBRUVICA,Second Primary Malignancies,Second Primary Malignancies see,1
IMBRUVICA,Second Primary Malignancies,Precautions Atrial Fibrillation see Warnings and Precautions,0
IMBRUVICA,Second Primary Malignancies,Warnings and,0
IMBRUVICA,Tumor Lysis Syndrome,Tumor Lysis,1
IMBRUVICA,Tumor Lysis Syndrome,,0
IMBRUVICA,Tumor Lysis Syndrome,Syndrome see,1
IMBRUVICA,Tumor Lysis Syndrome,see Warnings and Tumor Lysis Syndrome see,1
IMBRUVICA,Tumor Lysis Syndrome,and Tumor,1
IMBRUVICA,Tumor Lysis Syndrome,under widely va,0
IMBRUVICA,thrombocytopenia,thrombocytopenia neutropenia,1
IMBRUVICA,thrombocytopenia,diarrhea anemia fatigue musculoskeletal pain bruising nausea upper,0
IMBRUVICA,thrombocytopenia,fatigue musculoskeletal pain bruising nausea upper,0
IMBRUVICA,thrombocytopenia,fatigue musculoskeletal,0
IMBRUVICA,thrombocytopenia,malignancies MCL CLL,0
IMBRUVICA,thrombocytopenia,respiratory,0
IMBRUVICA,thrombocytopenia,MCL CLL WM thrombocytopenia neutropenia,1
IMBRUVICA,neutropenia,fatigue musculoskeletal pain bruising nausea,0
IMBRUVICA,neutropenia,pain bruising nausea upper respiratory tract infecti,0
IMBRUVICA,neutropenia,anemia fatigue musculoskeletal pain bruising nausea,0
IMBRUVICA,diarrhea,,0
IMBRUVICA,anemia,nausea upper respiratory tract,0
IMBRUVICA,anemia,anemia fatigue,1
IMBRUVICA,anemia,thrombocytopenia neutropenia anemia fatigue,1
IMBRUVICA,fatigue,fatigue musculoskeletal,1
IMBRUVICA,fatigue,thrombocytopenia neutropenia,0
IMBRUVICA,musculoskeletal pain,neutropenia diarrhea anemia,0
IMBRUVICA,musculoskeletal pain,,0
IMBRUVICA,musculoskeletal pain,malignancies MCL CLL WM were thrombocytopenia,0
IMBRUVICA,musculoskeletal pain,pain bruising,1
IMBRUVICA,musculoskeletal pain,upper respiratory,0
IMBRUVICA,musculoskeletal pain,WM were thrombocytopenia neutropenia diarrhea anemia,0
IMBRUVICA,musculoskeletal pain,anemia musculoskeletal,1
IMBRUVICA,musculoskeletal pain,diarrhea anemia musculoskeletal,1
IMBRUVICA,bruising,bruising nausea,1
IMBRUVICA,bruising,bruising nausea,1
IMBRUVICA,bruising,bruising nausea,1
IMBRUVICA,bruising,bruising nausea,1
IMBRUVICA,bruising,musculoskeletal pain,0
IMBRUVICA,nausea,,0
IMBRUVICA,nausea,tract infection and rash To report,0
IMBRUVICA,nausea,nausea upper,1
IMBRUVICA,nausea,upper respiratory tract infection and rash To report SUSPECTED ADVERSE REACTIONS,0
IMBRUVICA,upper respiratory tract infection,bruising upper respiratory tract infection and,1
IMBRUVICA,upper respiratory tract infection,nausea,0
IMBRUVICA,upper respiratory tract infection,upper,1
IMBRUVICA,upper respiratory tract infection,To report SUSPECTED,0
IMBRUVICA,upper respiratory tract infection,fatigue musculoskeletal pain bruising upper respiratory tract infection and,1
IMBRUVICA,rash,,0
IMBRUVICA,rash,rash To,1
IMBRUVICA,rash,rash To,1
IMBRUVICA,rash,,0
IMBRUVICA,rash,infection and,0
IMBRUVICA,rash,nausea,0
IMBRUVICA,rash,rash To,1
IMBRUVICA,rash,infection rash To,1
IMBRUVICA,rash,respiratory tract,0
IMBRUVICA,thrombocytopenia,thrombocytopenia diarrhea,1
IMBRUVICA,diarrhea,diarrhea neutropenia,1
IMBRUVICA,diarrhea,fatigue,0
IMBRUVICA,diarrhea,diarrhea neutropenia,1
IMBRUVICA,diarrhea,diarrhea neutropenia,1
IMBRUVICA,diarrhea,diarrhea neutropenia,1
IMBRUVICA,neutropenia,respiratory tract infection nausea,0
IMBRUVICA,neutropenia,neutropenia anemia,1
IMBRUVICA,neutropenia,musculoskeletal,0
IMBRUVICA,anemia,reactions,0
IMBRUVICA,fatigue,fatigue musculoskeletal,1
IMBRUVICA,musculoskeletal pain,reactions,0
IMBRUVICA,musculoskeletal pain,were thrombocytopenia,0
IMBRUVICA,musculoskeletal pain,,0
IMBRUVICA,musculoskeletal pain,anemia musculoskeletal pain peripheral,1
IMBRUVICA,musculoskeletal pain,thrombocytopenia diarrhea neutropenia anemia,0
IMBRUVICA,musculoskeletal pain,,0
IMBRUVICA,musculoskeletal pain,anemia,0
IMBRUVICA,musculoskeletal pain,upper respiratory tract infection nausea,0
IMBRUVICA,musculoskeletal pain,pain peripheral,1
IMBRUVICA,peripheral edema,fatigue musculoskeletal peripheral,1
IMBRUVICA,peripheral edema,peripheral edema upper,1
IMBRUVICA,peripheral edema,upper respiratory,0
IMBRUVICA,peripheral edema,edema upper,1
IMBRUVICA,peripheral edema,rash abdominal,0
IMBRUVICA,peripheral edema,musculoskeletal peripheral,1
IMBRUVICA,peripheral edema,peripheral edema upper,1
IMBRUVICA,peripheral edema,nausea,0
IMBRUVICA,peripheral edema,musculoskeletal,0
IMBRUVICA,upper respiratory tract infection,tract infection nausea,1
IMBRUVICA,upper respiratory tract infection,tract infection nausea,1
IMBRUVICA,upper respiratory tract infection,pain peripheral upper,1
IMBRUVICA,upper respiratory tract infection,infection nausea,1
IMBRUVICA,upper respiratory tract infection,se,0
IMBRUVICA,upper respiratory tract infection,neutropenia anemia fatigue musculoskeletal pain,0
IMBRUVICA,upper respiratory tract infection,pain,0
IMBRUVICA,nausea,musculoskeletal pain peripheral edema upper respiratory,0
IMBRUVICA,nausea,nausea bruising,1
IMBRUVICA,nausea,nausea bruising,1
IMBRUVICA,nausea,appetite,0
IMBRUVICA,nausea,tract nausea bruising,1
IMBRUVICA,nausea,tract nausea bruising,1
IMBRUVICA,bruising,pain peripheral edema,0
IMBRUVICA,bruising,rash abdominal,0
IMBRUVICA,dyspnea,dyspnea constipation,1
IMBRUVICA,dyspnea,tract infection nausea dyspnea constipation,1
IMBRUVICA,dyspnea,vomiting and decreased appetite see,0
IMBRUVICA,dyspnea,dyspnea constipation,1
IMBRUVICA,dyspnea,dyspnea constipation,1
IMBRUVICA,dyspnea,abdominal,0
IMBRUVICA,dyspnea,dyspnea constipation,1
IMBRUVICA,constipation,peripheral edema upper respiratory tract infection nausea,0
IMBRUVICA,constipation,constipation rash,1
IMBRUVICA,constipation,rash abdominal,0
IMBRUVICA,constipation,and,0
IMBRUVICA,rash,rash abdominal,1
IMBRUVICA,abdominal pain,pain vomiting,1
IMBRUVICA,abdominal pain,vomiting and decreased appetite see Tables and The most common,0
IMBRUVICA,abdominal pain,dyspnea constipation abdominal,1
IMBRUVICA,abdominal pain,rash,0
IMBRUVICA,abdominal pain,dyspnea constipation abdominal pain vomiting,1
IMBRUVICA,vomiting,vomiting and,1
IMBRUVICA,vomiting,constipation rash abdominal vomiting and,1
IMBRUVICA,vomiting,vomiting and,1
IMBRUVICA,decreased appetite,rash abdominal pain vomiting decreased appetite see,1
IMBRUVICA,decreased appetite,tract infection nausea bruising dyspnea constipation rash,0
IMBRUVICA,decreased appetite,decreased appetite see,1
IMBRUVICA,pneumonia,and The most common Grade or nonhematological adverse reactions were,0
IMBRUVICA,pneumonia,The most common Grade,0
IMBRUVICA,pneumonia,,0
IMBRUVICA,pneumonia,adverse reactions were,0
IMBRUVICA,pneumonia,or nonhematological adverse,0
IMBRUVICA,pneumonia,nonhematological adverse reactions pneumonia abdominal,1
IMBRUVICA,pneumonia,pneumonia abdominal,1
IMBRUVICA,pneumonia,nonhematological adverse reactions pneumonia abdominal,1
IMBRUVICA,pneumonia,were,0
IMBRUVICA,abdominal pain,abdominal pain atrial,1
IMBRUVICA,abdominal pain,abdominal pain atrial,1
IMBRUVICA,abdominal pain,,0
IMBRUVICA,abdominal pain,diarrhea fatigue,0
IMBRUVICA,abdominal pain,and skin infections Fatal and serious,0
IMBRUVICA,abdominal pain,common,0
IMBRUVICA,abdominal pain,Grade or,0
IMBRUVICA,abdominal pain,adverse reactions were abdominal,1
IMBRUVICA,atrial fibrillation,abdominal,0
IMBRUVICA,diarrhea,pain atrial diarrhea fatigue,1
IMBRUVICA,diarrhea,atrial,0
IMBRUVICA,skin infections,,0
IMBRUVICA,skin infections,have occurred with IMBRUVICA therapy,0
IMBRUVICA,renal failure,serious cases renal failure have,1
IMBRUVICA,renal failure,therapy,0
IMBRUVICA,renal failure,serious,0
IMBRUVICA,renal failure,failure have,1
IMBRUVICA,renal failure,,0
IMBRUVICA,renal failure,and serious cases renal,1
IMBRUVICA,renal failure,and serious cases renal,1
IMBRUVICA,renal failure,atrial fibrillation,0
IMBRUVICA,Increases in creatinine,patients Adverse reactions,0
IMBRUVICA,Diarrhea,Diarrhea Nausea,1
IMBRUVICA,Diarrhea,Grade or Gastrointestinal Diarrhea Nausea,1
IMBRUVICA,Diarrhea,Diarrhea Nausea,1
IMBRUVICA,Constipation,Constipation Abdominal pain,1
IMBRUVICA,Constipation,Nausea,0
IMBRUVICA,Constipation,Nausea,0
IMBRUVICA,Abdominal pain,Constipation Abdominal pain Vomiting,1
IMBRUVICA,Abdominal pain,Constipation,0
IMBRUVICA,Vomiting,,0
IMBRUVICA,Vomiting,,0
IMBRUVICA,Vomiting,pain,0
IMBRUVICA,Vomiting,pain,0
IMBRUVICA,Vomiting,Vomiting Stomatitis,1
IMBRUVICA,Vomiting,,0
IMBRUVICA,Vomiting,,0
IMBRUVICA,Vomiting,Vomiting Stomatitis,1
IMBRUVICA,Vomiting,Abdominal Vomiting Stomatitis,1
IMBRUVICA,Stomatitis,Vomiting,0
IMBRUVICA,Stomatitis,Vomiting,0
IMBRUVICA,Stomatitis,Vomiting,0
IMBRUVICA,Stomatitis,Vomiting,0
IMBRUVICA,Dyspepsia,Stomatitis Dyspepsia Infections,1
IMBRUVICA,Dyspepsia,Stomatitis Dyspepsia Infections and infestat,1
IMBRUVICA,Dyspepsia,Stomatitis,0
IMBRUVICA,Upper respiratory tract infection,tract,0
IMBRUVICA,Upper respiratory tract infection,and infestations,0
IMBRUVICA,Upper respiratory tract infection,respiratory tract infection Urinary tract,1
IMBRUVICA,Upper respiratory tract infection,and Upper respiratory tract infection Urinary tract,1
IMBRUVICA,Upper respiratory tract infection,respiratory tract infection Urinary tract,1
IMBRUVICA,Upper respiratory tract infection,infection,0
IMBRUVICA,Urinary tract infection,Upper respiratory tract Urinary tract infection Pneumonia,1
IMBRUVICA,Urinary tract infection,,0
IMBRUVICA,Urinary tract infection,infection Pneumonia,1
IMBRUVICA,Pneumonia,Pneumonia Skin infections,1
IMBRUVICA,Pneumonia,,0
IMBRUVICA,Pneumonia,Pneumonia Skin infections,1
IMBRUVICA,Pneumonia,Pneumonia Skin infections,1
IMBRUVICA,Pneumonia,Pneumonia Skin infections,1
IMBRUVICA,Pneumonia,Pneumonia Skin infections,1
IMBRUVICA,Pneumonia,tract infection,0
IMBRUVICA,Skin infections,Pneumonia,0
IMBRUVICA,Skin infections,Pneumonia,0
IMBRUVICA,Skin infections,Pneumonia,0
IMBRUVICA,Skin infections,,0
IMBRUVICA,Skin infections,Skin infections Sinusitis,1
IMBRUVICA,Skin infections,,0
IMBRUVICA,Skin infections,Pneumonia,0
IMBRUVICA,Skin infections,Pneumonia Skin,1
IMBRUVICA,Skin infections,Pneumonia Skin infections Sinusitis,1
IMBRUVICA,Sinusitis,a,0
IMBRUVICA,Sinusitis,General disorders,0
IMBRUVICA,Sinusitis,Sinusitis General,1
IMBRUVICA,Sinusitis,,0
IMBRUVICA,Fatigue,administrative site conditions,0
IMBRUVICA,Fatigue,,0
IMBRUVICA,Fatigue,Fatigue Peripheral,1
IMBRUVICA,Fatigue,administrative site Fatigue Peripheral,1
IMBRUVICA,Fatigue,administrative site,0
IMBRUVICA,Fatigue,edema,0
IMBRUVICA,Fatigue,site conditions,0
IMBRUVICA,Fatigue,Fatigue Peripheral,1
IMBRUVICA,Peripheral edema,Pyrexia,0
IMBRUVICA,Peripheral edema,Pyrexia,0
IMBRUVICA,Peripheral edema,conditions Peripheral,1
IMBRUVICA,Peripheral edema,,0
IMBRUVICA,Pyrexia,Pyrexia Asthenia,1
IMBRUVICA,Pyrexia,,0
IMBRUVICA,Pyrexia,Pyrexia Asthenia,1
IMBRUVICA,Pyrexia,,0
IMBRUVICA,Pyrexia,Pyrexia Asthenia,1
IMBRUVICA,Pyrexia,Pyrexia Asthenia,1
IMBRUVICA,Pyrexia,edema,0
IMBRUVICA,Pyrexia,Pyrexia Asthenia,1
IMBRUVICA,Pyrexia,,0
IMBRUVICA,Pyrexia,Pyrexia Asthenia,1
IMBRUVICA,Asthenia,Pyrexia,0
IMBRUVICA,Asthenia,Asthenia Skin and,1
IMBRUVICA,Asthenia,Asthenia Skin and subcutaneous,1
IMBRUVICA,Asthenia,Pyrexia Asthenia Skin,1
IMBRUVICA,Asthenia,and subcutaneous,0
IMBRUVICA,Asthenia,,0
IMBRUVICA,Bruising,Rash,0
IMBRUVICA,Bruising,and subcutaneous tissue Bruising Rash,1
IMBRUVICA,Bruising,Bruising Rash,1
IMBRUVICA,Bruising,tissue Bruising Rash,1
IMBRUVICA,Bruising,Bruising Rash,1
IMBRUVICA,Rash,,0
IMBRUVICA,Rash,Rash Petechiae,1
IMBRUVICA,Rash,Bruising,0
IMBRUVICA,Petechiae,Petechiae,1
IMBRUVICA,Musculoskeletal pain,,0
IMBRUVICA,Musculoskeletal pain,Musculoskeletal pain,1
IMBRUVICA,Musculoskeletal pain,connective tissue,0
IMBRUVICA,Musculoskeletal pain,,0
IMBRUVICA,Musculoskeletal pain,Musculoskeletal pain,1
IMBRUVICA,Musculoskeletal pain,pain,1
IMBRUVICA,Musculoskeletal pain,Musculoskeletal,1
IMBRUVICA,Musculoskeletal pain,,0
IMBRUVICA,Muscle spasms,Muscle spasms Arthralgia,1
IMBRUVICA,Muscle spasms,,0
IMBRUVICA,Muscle spasms,pain,0
IMBRUVICA,Muscle spasms,Musculoskeletal Muscle,1
IMBRUVICA,Muscle spasms,,0
IMBRUVICA,Muscle spasms,,0
IMBRUVICA,Muscle spasms,Musculoskeletal Muscle,1
IMBRUVICA,Arthralgia,Arthralgia,1
IMBRUVICA,Cough,,0
IMBRUVICA,Cough,disorders Cough Epistaxis,1
IMBRUVICA,Cough,Cough Epistaxis,1
IMBRUVICA,Cough,,0
IMBRUVICA,Cough,disorders Cough Epistaxis,1
IMBRUVICA,Cough,Cough Epistaxis,1
IMBRUVICA,Cough,disorders,0
IMBRUVICA,Cough,,0
IMBRUVICA,Epistaxis,Cough Epistaxis Metabolism and nutritio,1
IMBRUVICA,Epistaxis,Epistaxis Metabolism,1
IMBRUVICA,Epistaxis,,0
IMBRUVICA,Epistaxis,Metabolism and,0
IMBRUVICA,Epistaxis,,0
IMBRUVICA,Epistaxis,Cough Epistaxis Metabolism and,1
IMBRUVICA,Epistaxis,Epistaxis Metabolism and,1
IMBRUVICA,Epistaxis,Epistaxis,1
IMBRUVICA,Epistaxis,Cough,0
IMBRUVICA,Epistaxis,Epistaxis Metabolism and,1
IMBRUVICA,Decreased appetite,Decreased,1
IMBRUVICA,Dehydration,Dehydration Nervous system,1
IMBRUVICA,Dehydration,Nervous system,0
IMBRUVICA,Dehydration,,0
IMBRUVICA,Dehydration,Decreased Dehydration Nervous system,1
IMBRUVICA,Dehydration,,0
IMBRUVICA,Dehydration,disorders,0
IMBRUVICA,Dehydration,disorders,0
IMBRUVICA,Dehydration,,0
IMBRUVICA,Dizziness,,0
IMBRUVICA,Dizziness,Dizziness Headache,1
IMBRUVICA,Headache,Treatme,0
IMBRUVICA,Decrease of Hemoglobin,Patients with MCL N,0
IMBRUVICA,Decrease of Hemoglobin,,0
IMBRUVICA,Decrease of Hemoglobin,Decrease of Hemoglobin Platelets or,1
IMBRUVICA,Decrease of Hemoglobin,or,0
IMBRUVICA,Decrease of Hemoglobin,,0
IMBRUVICA,Decrease of Hemoglobin,adverse,0
IMBRUVICA,Decrease of Hemoglobin,,0
IMBRUVICA,Decrease of Hemoglobin,adverse Decrease,1
IMBRUVICA,Decrease of Hemoglobin,,0
IMBRUVICA,Neutrophils Decreased,Decreased,0
IMBRUVICA,Hemoglobin Decreased,,0
IMBRUVICA,Hemoglobin Decreased,Hemoglobin Decreased Ten,1
IMBRUVICA,Hemoglobin Decreased,ls Hemoglobin,1
IMBRUVICA,Hemoglobin Decreased,Decreased Ten,1
IMBRUVICA,Hemoglobin Decreased,Hemoglobin Decreased Ten,1
IMBRUVICA,subdural hematoma,to,0
IMBRUVICA,subdural hematoma,frequent adverse,0
IMBRUVICA,subdural hematoma,hematoma,1
IMBRUVICA,subdural hematoma,N The most frequent adverse reaction leading to treatment discontinuation,0
IMBRUVICA,subdural hematoma,discontinuation subdural hematoma,1
IMBRUVICA,subdural hematoma,subdural hematoma,1
IMBRUVICA,subdural hematoma,discontinuation subdural hematoma,1
IMBRUVICA,elevated uric acid levels,elevated uric acid levels,1
IMBRUVICA,elevated uric acid levels,Forty percent of patients elevated uric acid,1
IMBRUVICA,elevated uric acid levels,percent of patients elevated uric acid levels,1
IMBRUVICA,elevated uric acid levels,cases were in,0
IMBRUVICA,elevated uric acid levels,progression Forty percent,0
IMBRUVICA,elevated uric acid levels,f,0
IMBRUVICA,elevated uric acid levels,uric acid levels,1
IMBRUVICA,elevated uric acid levels,levels,1
IMBRUVICA,elevated uric acid levels,elevated uric acid levels,1
IMBRUVICA,hyperuricemia,reaction hyperuricemia,1
IMBRUVICA,hyperuricemia,was,0
IMBRUVICA,hyperuricemia,hyperuricemia,1
IMBRUVICA,thrombocytopenia,anemia,0
IMBRUVICA,neutropenia,infection rash nausea,0
IMBRUVICA,neutropenia,neutropenia,1
IMBRUVICA,neutropenia,fatigue musculoskeletal,0
IMBRUVICA,neutropenia,adverse reactions in Study,0
IMBRUVICA,diarrhea,diarrhea,1
IMBRUVICA,fatigue,tract infection rash nausea and,0
IMBRUVICA,fatigue,fatigue,1
IMBRUVICA,fatigue,pyrexia Approximat,0
IMBRUVICA,fatigue,fatigue,1
IMBRUVICA,fatigue,and pyrexia,0
IMBRUVICA,musculoskeletal pain,upper respiratory tract infection rash nausea and pyrexia,0
IMBRUVICA,musculoskeletal pain,pain,1
IMBRUVICA,musculoskeletal pain,percent of,0
IMBRUVICA,musculoskeletal pain,pyrexia Approximately five percent of,0
IMBRUVICA,musculoskeletal pain,neutropenia diarrhea anemia musculoskeletal pain,1
IMBRUVICA,upper respiratory tract infection,pyrexia Approximately five percent,0
IMBRUVICA,upper respiratory tract infection,,0
IMBRUVICA,upper respiratory tract infection,patients,0
IMBRUVICA,rash,infection,0
IMBRUVICA,nausea,anemia fatigue musculoskeletal pain upper respiratory,0
IMBRUVICA,nausea,and,0
IMBRUVICA,nausea,receiving IMBRUVICA in Study,0
IMBRUVICA,nausea,nausea,1
IMBRUVICA,pyrexia,pyrexia,1
IMBRUVICA,pyrexia,pyrexia,1
IMBRUVICA,infections,leading to dose reduction occurred in approximatel,0
IMBRUVICA,infections,,0
IMBRUVICA,infections,infections,1
IMBRUVICA,infections,infections,1
IMBRUVICA,infections,These infections,1
IMBRUVICA,infections,IMBRUVICA in Study and Study discontinued,0
IMBRUVICA,subdural hematomas,subdural hematomas,1
IMBRUVICA,subdural hematomas,,0
IMBRUVICA,subdural hematomas,reduction occurred,0
IMBRUVICA,subdural hematomas,hematomas,1
IMBRUVICA,subdural hematomas,and Study discontinued treatment,0
IMBRUVICA,subdural hematomas,of patients,0
IMBRUVICA,subdural hematomas,leading to dose,0
IMBRUVICA,diarrhea,events,0
IMBRUVICA,diarrhea,diarrhea,1
IMBRUVICA,diarrhea,diarrhea,1
IMBRUVICA,diarrhea,subdural hematomas diarrhea,1
IMBRUVICA,diarrhea,,0
IMBRUVICA,diarrhea,in approximately of,0
IMBRUVICA,diarrhea,events These included infections subdural,0
IMBRUVICA,diarrhea,treatment due to adverse events These included infections,0
IMBRUVICA,Diarrhea,,0
IMBRUVICA,Diarrhea,,0
IMBRUVICA,Diarrhea,Diarrhea Constipation,1
IMBRUVICA,Diarrhea,Diarrhea Constipation,1
IMBRUVICA,Diarrhea,,0
IMBRUVICA,Diarrhea,Gastrointestinal,0
IMBRUVICA,Constipation,Constipation Nausea,1
IMBRUVICA,Constipation,Constipation Nausea,1
IMBRUVICA,Constipation,Constipation Nausea,1
IMBRUVICA,Constipation,Constipation Nausea,1
IMBRUVICA,Constipation,Nausea,0
IMBRUVICA,Constipation,Constipation Nausea,1
IMBRUVICA,Constipation,Constipation Nausea,1
IMBRUVICA,Constipation,,0
IMBRUVICA,Stomatitis,Stomatitis Vomiting,1
IMBRUVICA,Vomiting,Vomiting Abdominal,1
IMBRUVICA,Vomiting,Vomiting Abdominal,1
IMBRUVICA,Vomiting,Abdominal pain,0
IMBRUVICA,Vomiting,Vomiting Abdominal pain,1
IMBRUVICA,Vomiting,Vomiting Abdominal pain,1
IMBRUVICA,Vomiting,Vomiting Abdominal,1
IMBRUVICA,Vomiting,Vomiting Abdominal pain,1
IMBRUVICA,Vomiting,Vomiting,1
IMBRUVICA,Abdominal pain,Vomiting Abdominal,1
IMBRUVICA,Abdominal pain,Abdominal pain Dyspepsia,1
IMBRUVICA,Dyspepsia,,0
IMBRUVICA,Dyspepsia,pain,0
IMBRUVICA,Dyspepsia,,0
IMBRUVICA,Upper respiratory tract infection,,0
IMBRUVICA,Upper respiratory tract infection,infestations,0
IMBRUVICA,Upper respiratory tract infection,,0
IMBRUVICA,Upper respiratory tract infection,Upper respiratory tract infection Sinusitis,1
IMBRUVICA,Upper respiratory tract infection,Upper respiratory tract infection Sinusitis,1
IMBRUVICA,Sinusitis,,0
IMBRUVICA,Sinusitis,tract Sinusitis,1
IMBRUVICA,Sinusitis,Sinusitis,1
IMBRUVICA,Skin infection,,0
IMBRUVICA,Skin infection,Sinusitis Skin,1
IMBRUVICA,Skin infection,Sinusitis Skin,1
IMBRUVICA,Skin infection,Sinusitis Skin infection Pneumonia,1
IMBRUVICA,Skin infection,Sinusitis,0
IMBRUVICA,Urinary tract infection,Pneumonia,0
IMBRUVICA,Urinary tract infection,Pneumonia Urinary,1
IMBRUVICA,Urinary tract infection,Pneumonia,0
IMBRUVICA,Urinary tract infection,Pneumonia Urinary,1
IMBRUVICA,Urinary tract infection,,0
IMBRUVICA,Urinary tract infection,Pneumonia,0
IMBRUVICA,Urinary tract infection,and,0
IMBRUVICA,Urinary tract infection,Pneumonia Urinary,1
IMBRUVICA,Fatigue,administrative site conditions,0
IMBRUVICA,Pyrexia,Peripheral edema,0
IMBRUVICA,Pyrexia,e site conditions Pyrexia Peripheral edema,1
IMBRUVICA,Pyrexia,,0
IMBRUVICA,Pyrexia,Pyrexia Peripheral edema,1
IMBRUVICA,Peripheral edema,Pyrexia,0
IMBRUVICA,Chills,Asthenia,0
IMBRUVICA,Chills,Asthenia,0
IMBRUVICA,Chills,Asthenia,0
IMBRUVICA,Chills,Chills Skin and,1
IMBRUVICA,Bruising,subcutaneous tissue disorders,0
IMBRUVICA,Rash,,0
IMBRUVICA,Rash,Rash Petechiae,1
IMBRUVICA,Rash,Bruising,0
IMBRUVICA,Rash,Bruising,0
IMBRUVICA,Rash,,0
IMBRUVICA,Rash,,0
IMBRUVICA,Rash,,0
IMBRUVICA,Rash,Rash Petechiae,1
IMBRUVICA,Rash,,0
IMBRUVICA,Petechiae,Petechiae,1
IMBRUVICA,Cough,Cough,1
IMBRUVICA,Cough,,0
IMBRUVICA,Cough,thoracic and,0
IMBRUVICA,Cough,,0
IMBRUVICA,Musculoskeletal pain,connective tissue Musculoskeletal,1
IMBRUVICA,Musculoskeletal pain,connective,0
IMBRUVICA,Musculoskeletal pain,tissue,0
IMBRUVICA,Musculoskeletal pain,and connective tissue Musculoskeletal pain Arthralgia,1
IMBRUVICA,Musculoskeletal pain,,0
IMBRUVICA,Musculoskeletal pain,,0
IMBRUVICA,Arthralgia,Arthralgia,1
IMBRUVICA,Arthralgia,,0
IMBRUVICA,Arthralgia,pain,0
IMBRUVICA,Muscle spasms,Arthralgia,0
IMBRUVICA,Muscle spasms,spasms,1
IMBRUVICA,Muscle spasms,system disorde,0
IMBRUVICA,Dizziness,system disorders,0
IMBRUVICA,Dizziness,Dizziness Headache,1
IMBRUVICA,Dizziness,Dizziness Headache,1
IMBRUVICA,Dizziness,Dizziness Headache,1
IMBRUVICA,Dizziness,Headache,0
IMBRUVICA,Dizziness,,0
IMBRUVICA,Dizziness,,0
IMBRUVICA,Dizziness,Headache,0
IMBRUVICA,Dizziness,Dizziness Headache,1
IMBRUVICA,Headache,Headache Peripheral neuropat,1
IMBRUVICA,Headache,,0
IMBRUVICA,Headache,Headache Peripheral neuropat,1
IMBRUVICA,Headache,disorders Dizziness,0
IMBRUVICA,Headache,,0
IMBRUVICA,Headache,disorders Headache Peripheral neuropat,1
IMBRUVICA,Headache,,0
IMBRUVICA,Headache,disorders Dizziness,0
IMBRUVICA,Headache,disorders,0
IMBRUVICA,Headache,Headache Peripheral neuropat,1
IMBRUVICA,Peripheral neuropathy,Peripheral neuropathy,1
IMBRUVICA,Decreased appetite,Metabolism and nutrition Decreased,1
IMBRUVICA,Decreased appetite,Decreased appetite,1
IMBRUVICA,Decreased appetite,appetite,1
IMBRUVICA,Decreased appetite,Neoplasms benign malignant,0
IMBRUVICA,Decreased appetite,and nutrition,0
IMBRUVICA,Second malignancies,Second malignancies,1
IMBRUVICA,Second malignancies,Neoplasms benign malignant Second malignancies,1
IMBRUVICA,Second malignancies,,0
IMBRUVICA,Second malignancies,Second,1
IMBRUVICA,Second malignancies,malignant Second malignancies,1
IMBRUVICA,Second malignancies,,0
IMBRUVICA,Laceration,Laceration,1
IMBRUVICA,Laceration,,0
IMBRUVICA,Laceration,Psychiatric,0
IMBRUVICA,Laceration,Laceration,1
IMBRUVICA,Laceration,,0
IMBRUVICA,Laceration,,0
IMBRUVICA,Laceration,Laceration,1
IMBRUVICA,Laceration,poisoning and procedural complications,0
IMBRUVICA,Laceration,poisoning and procedural Laceration,1
IMBRUVICA,Laceration,Laceration,1
IMBRUVICA,Anxiety,Psychiatric Anxiety Insomnia,1
IMBRUVICA,Anxiety,Psychiatric Anxiety Insomnia,1
IMBRUVICA,Anxiety,Anxiety Insomnia,1
IMBRUVICA,Anxiety,,0
IMBRUVICA,Insomnia,Insomnia,1
IMBRUVICA,Hypertension,Hypertension,1
IMBRUVICA,Hypertension,,0
IMBRUVICA,Hypertension,Vascular Hypertension,1
IMBRUVICA,Hypertension,Hypertension,1
IMBRUVICA,Hypertension,disorders,0
IMBRUVICA,Hypertension,disorders,0
IMBRUVICA,Hypertension,,0
IMBRUVICA,Hypertension,,0
IMBRUVICA,Hypertension,Hypertension,1
IMBRUVICA,Hypertension,,0
IMBRUVICA,Decrease of Hemoglobin,Decrease,1
IMBRUVICA,Decrease of Hemoglobin,per,0
IMBRUVICA,Decrease of Hemoglobin,criteria and adverse Decrease,1
IMBRUVICA,Decrease of Hemoglobin,laboratory measurements per,0
IMBRUVICA,Decrease of Hemoglobin,Decrease of Hemoglobin,1
IMBRUVICA,Decrease of Hemoglobin,Neutrophils in Patients with CLL N in Study,0
IMBRUVICA,Platelets Decreased,Grade Platelets Decreased Neutrophil,1
IMBRUVICA,Neutrophils Decreased,Decreased Neutrophils Decreased Hemoglobin D,1
IMBRUVICA,Neutrophils Decreased,,0
IMBRUVICA,Neutrophils Decreased,Decreased Neutrophils Decreased Hemoglobin,1
IMBRUVICA,Neutrophils Decreased,Decreased Neutrophils Decreased Hemoglobin,1
IMBRUVICA,Neutrophils Decreased,Decreased Neutrophils Decreased Hemoglobin,1
IMBRUVICA,Hemoglobin Decreased,,0
IMBRUVICA,Hemoglobin Decreased,Decreased,1
IMBRUVICA,Hemoglobin Decreased,ls Hemoglobin Decreased,1
IMBRUVICA,Hemoglobin Decreased,Hemoglobin Decreased,1
IMBRUVICA,Hemoglobin Decreased,Hemoglobin Decreased,1
IMBRUVICA,Hemoglobin Decreased,Hemoglobin Decreased,1
IMBRUVICA,Hemoglobin Decreased,,0
IMBRUVICA,Hemoglobin Decreased,,0
IMBRUVICA,Hemoglobin Decreased,,0
IMBRUVICA,Hemoglobin Decreased,Hemoglobin,1
IMBRUVICA,Diarrhea,,0
IMBRUVICA,Nausea,,0
IMBRUVICA,Stomatitis,,0
IMBRUVICA,Stomatitis,,0
IMBRUVICA,Stomatitis,,0
IMBRUVICA,Stomatitis,,0
IMBRUVICA,Constipation,,0
IMBRUVICA,Constipation,Constipation,1
IMBRUVICA,Constipation,Constipation,1
IMBRUVICA,Constipation,Constipation,1
IMBRUVICA,Constipation,Constipation,1
IMBRUVICA,Vomiting,,0
IMBRUVICA,Vomiting,,0
IMBRUVICA,Vomiting,Vomiting,1
IMBRUVICA,Vomiting,,0
IMBRUVICA,Fatigue,conditions,0
IMBRUVICA,Fatigue,Fatigue,1
IMBRUVICA,Pyrexia,Pyrexia,1
IMBRUVICA,Pyrexia,Pyrexia,1
IMBRUVICA,Pyrexia,,0
IMBRUVICA,Pyrexia,,0
IMBRUVICA,Pyrexia,Pyrexia,1
IMBRUVICA,Upper respiratory tract infection,,0
IMBRUVICA,Upper respiratory tract infection,d Upper respiratory tract infection Pneumonia,1
IMBRUVICA,Upper respiratory tract infection,,0
IMBRUVICA,Upper respiratory tract infection,,0
IMBRUVICA,Upper respiratory tract infection,Upper respiratory tract,1
IMBRUVICA,Pneumonia,,0
IMBRUVICA,Pneumonia,,0
IMBRUVICA,Pneumonia,,0
IMBRUVICA,Sinusitis,,0
IMBRUVICA,Sinusitis,Sinusitis,1
IMBRUVICA,Sinusitis,Sinusitis,1
IMBRUVICA,Sinusitis,,0
IMBRUVICA,Sinusitis,Sinusitis,1
IMBRUVICA,Sinusitis,,0
IMBRUVICA,Sinusitis,Sinusitis,1
IMBRUVICA,Sinusitis,,0
IMBRUVICA,Sinusitis,,0
IMBRUVICA,Urinary tract infection,,0
IMBRUVICA,Rash,,0
IMBRUVICA,Rash,disorders,0
IMBRUVICA,Rash,Rash,1
IMBRUVICA,Rash,issue Rash,1
IMBRUVICA,Rash,,0
IMBRUVICA,Petechiae,,0
IMBRUVICA,Petechiae,Petechiae,1
IMBRUVICA,Petechiae,Petechiae,1
IMBRUVICA,Petechiae,,0
IMBRUVICA,Bruising,,0
IMBRUVICA,Bruising,Bruising,1
IMBRUVICA,Bruising,Bruising,1
IMBRUVICA,Bruising,Bruising,1
IMBRUVICA,Musculoskeletal Pain,Musculoskeletal,1
IMBRUVICA,Musculoskeletal Pain,Musculoskeletal Pain Arthral,1
IMBRUVICA,Musculoskeletal Pain,Musculoskeletal,1
IMBRUVICA,Arthralgia,,0
IMBRUVICA,Arthralgia,Arthralgia,1
IMBRUVICA,Arthralgia,,0
IMBRUVICA,Arthralgia,Pain,0
IMBRUVICA,Arthralgia,,0
IMBRUVICA,Arthralgia,Arthralgia,1
IMBRUVICA,Headache,Headache,1
IMBRUVICA,Headache,m Headache,1
IMBRUVICA,Headache,Headache,1
IMBRUVICA,Headache,,0
IMBRUVICA,Headache,m Headache,1
IMBRUVICA,Headache,disorders,0
IMBRUVICA,Headache,Headache,1
IMBRUVICA,Headache,,0
IMBRUVICA,Headache,,0
IMBRUVICA,Headache,disorders,0
IMBRUVICA,Dizziness,Dizziness,1
IMBRUVICA,Dizziness,Dizziness,1
IMBRUVICA,Dizziness,Dizziness,1
IMBRUVICA,Dizziness,,0
IMBRUVICA,Dizziness,,0
IMBRUVICA,Dizziness,Dizziness,1
IMBRUVICA,Dizziness,,0
IMBRUVICA,Dizziness,,0
IMBRUVICA,Contusion,,0
IMBRUVICA,Contusion,Contusion,1
IMBRUVICA,Contusion,Contusion,1
IMBRUVICA,Contusion,Contusion,1
IMBRUVICA,Contusion,,0
IMBRUVICA,Contusion,,0
IMBRUVICA,Contusion,Contusion,1
IMBRUVICA,Contusion,Contusion,1
IMBRUVICA,Contusion,complications,0
IMBRUVICA,Vision blurred,Vision,1
IMBRUVICA,Vision blurred,,0
IMBRUVICA,Vision blurred,,0
IMBRUVICA,Vision blurred,Vision blurred,1
IMBRUVICA,Vision blurred,,0
IMBRUVICA,Vision blurred,,0
IMBRUVICA,Vision blurred,Vision,1
IMBRUVICA,Decrease of Hemoglobin,on laboratory measurements,0
IMBRUVICA,Decrease of Hemoglobin,in,0
IMBRUVICA,Decrease of Hemoglobin,on laboratory measurements per IWCLL criteria,0
IMBRUVICA,Decrease of Hemoglobin,,0
IMBRUVICA,Decrease of Hemoglobin,,0
IMBRUVICA,Decrease of Hemoglobin,Decrease of Hemoglobin,1
IMBRUVICA,Decrease of Hemoglobin,of Hemoglobin,1
IMBRUVICA,Decrease of Hemoglobin,per IWCLL Decrease of Hemoglobin,1
IMBRUVICA,Neutrophils Decreased,,0
IMBRUVICA,Neutrophils Decreased,or All Grades Grade Neutrophils,1
IMBRUVICA,Neutrophils Decreased,Decreased Platelet,1
IMBRUVICA,Neutrophils Decreased,Grades Grade Neutrophils Decreased Platelet,1
IMBRUVICA,Neutrophils Decreased,Grades Grade Neutrophils Decreased Platelet,1
IMBRUVICA,Neutrophils Decreased,,0
IMBRUVICA,Platelets Decreased,Decreased Hemogl,1
IMBRUVICA,Platelets Decreased,Platelets Decreased Hemogl,1
IMBRUVICA,Platelets Decreased,Decreased Hemogl,1
IMBRUVICA,Platelets Decreased,Hemogl,0
IMBRUVICA,Platelets Decreased,ecreased Platelets,1
IMBRUVICA,Platelets Decreased,ecreased,0
IMBRUVICA,Platelets Decreased,,0
IMBRUVICA,Hemoglobin Decreased,reased Hemoglobin,1
IMBRUVICA,Hemoglobin Decreased,,0
IMBRUVICA,Hemoglobin Decreased,Decreased,1
IMBRUVICA,neutropenia,WM trial neutropenia,1
IMBRUVICA,diarrhea,spasms and fatigue Six percent of,0
IMBRUVICA,diarrhea,diarrhea,1
IMBRUVICA,diarrhea,rash nausea muscle,0
IMBRUVICA,diarrhea,neutropenia diarrhea,1
IMBRUVICA,diarrhea,patients receiving IMBRUVICA,0
IMBRUVICA,diarrhea,,0
IMBRUVICA,diarrhea,fatigue Six percent of patients receiving,0
IMBRUVICA,diarrhea,diarrhea,1
IMBRUVICA,rash,thrombocytopenia rash,1
IMBRUVICA,rash,,0
IMBRUVICA,rash,in the WM trial were neutropenia,0
IMBRUVICA,rash,were neutropenia thrombocytopenia rash,1
IMBRUVICA,rash,WM trial were neutropenia,0
IMBRUVICA,nausea,spasms and fatigue Six percent of patients receiving IMBRUVICA,0
IMBRUVICA,nausea,in the WM trial were neutropenia,0
IMBRUVICA,nausea,,0
IMBRUVICA,nausea,nausea,1
IMBRUVICA,nausea,nausea,1
IMBRUVICA,nausea,,0
IMBRUVICA,nausea,were neutropenia thrombocytopenia diarrhea nausea,1
IMBRUVICA,nausea,nausea,1
IMBRUVICA,muscle spasms,trial,0
IMBRUVICA,muscle spasms,,0
IMBRUVICA,muscle spasms,,0
IMBRUVICA,muscle spasms,spasms,1
IMBRUVICA,muscle spasms,the,0
IMBRUVICA,muscle spasms,diarrhea rash muscle,1
IMBRUVICA,fatigue,fatigue,1
IMBRUVICA,fatigue,WM trial discontinued treatment due,0
IMBRUVICA,fatigue,thrombocytopenia diarrhea,0
IMBRUVICA,fatigue,fatigue,1
IMBRUVICA,fatigue,spasms fatigue,1
IMBRUVICA,fatigue,fatigue,1
IMBRUVICA,Diarrhea,Diarrhea,1
IMBRUVICA,Diarrhea,,0
IMBRUVICA,Diarrhea,Diarrhea,1
IMBRUVICA,Diarrhea,frequency,0
IMBRUVICA,Diarrhea,Diarrhea,1
IMBRUVICA,Diarrhea,Diarrhea,1
IMBRUVICA,Diarrhea,Diarrhea,1
IMBRUVICA,Diarrhea,,0
IMBRUVICA,Nausea,Nausea,1
IMBRUVICA,Nausea,,0
IMBRUVICA,Nausea,,0
IMBRUVICA,Nausea,,0
IMBRUVICA,Nausea,,0
IMBRUVICA,Nausea,Nausea,1
IMBRUVICA,Nausea,,0
IMBRUVICA,Nausea,Nausea,1
IMBRUVICA,Stomatitis,,0
IMBRUVICA,Stomatitis,,0
IMBRUVICA,Stomatitis,Stomatitis,1
IMBRUVICA,Stomatitis,,0
IMBRUVICA,Stomatitis,,0
IMBRUVICA,Stomatitis,Stomatitis,1
IMBRUVICA,Stomatitis,,0
IMBRUVICA,Stomatitis,Stomatitis,1
IMBRUVICA,Stomatitis,Stomatitis,1
IMBRUVICA,Rash,Skin and subcutaneous tissue Rash Bruising,1
IMBRUVICA,Bruising,Bruising Pruritus,1
IMBRUVICA,Pruritus,Bruising Pruritus General disorders a,1
IMBRUVICA,Fatigue,,0
IMBRUVICA,Fatigue,Fatigue Musculoskeletal and connecti,1
IMBRUVICA,Fatigue,Fatigue Musculoskeletal and connecti,1
IMBRUVICA,Fatigue,Fatigue Musculoskeletal and connecti,1
IMBRUVICA,Fatigue,,0
IMBRUVICA,Fatigue,Fatigue Musculoskeletal and connecti,1
IMBRUVICA,Muscle spasms,tissue Muscle,1
IMBRUVICA,Muscle spasms,,0
IMBRUVICA,Arthropathy,Infections and,0
IMBRUVICA,Arthropathy,and,0
IMBRUVICA,Arthropathy,and infesta,0
IMBRUVICA,Arthropathy,Arthropathy Infections and infesta,1
IMBRUVICA,Arthropathy,Arthropathy Infections and infesta,1
IMBRUVICA,Upper respiratory tract infection,,0
IMBRUVICA,Upper respiratory tract infection,Infections and Upper respiratory tract,1
IMBRUVICA,Upper respiratory tract infection,Upper respiratory tract infection Sinusitis,1
IMBRUVICA,Upper respiratory tract infection,Infections and Upper respiratory tract infection Sinusitis,1
IMBRUVICA,Sinusitis,Sinusitis Pneumonia,1
IMBRUVICA,Pneumonia,Pneumonia,1
IMBRUVICA,Skin infection,Pneumonia Skin infection Respiratory,1
IMBRUVICA,Skin infection,Pneumonia,0
IMBRUVICA,Skin infection,,0
IMBRUVICA,Skin infection,Pneumonia,0
IMBRUVICA,Skin infection,Pneumonia Skin infection Respiratory thoracic,1
IMBRUVICA,Skin infection,Pneumonia,0
IMBRUVICA,Skin infection,infection Respiratory thoracic and,1
IMBRUVICA,Skin infection,Skin infection Respiratory,1
IMBRUVICA,Skin infection,Pneumonia Skin infection Respiratory thoracic and,1
IMBRUVICA,Skin infection,infection Respiratory,1
IMBRUVICA,Epistaxis,Epistaxis Cough,1
IMBRUVICA,Epistaxis,,0
IMBRUVICA,Epistaxis,,0
IMBRUVICA,Epistaxis,,0
IMBRUVICA,Epistaxis,disorders,0
IMBRUVICA,Cough,Cough Nervous,1
IMBRUVICA,Cough,Cough Nervous,1
IMBRUVICA,Cough,Cough Nervous,1
IMBRUVICA,Cough,diastinal disorders Cough Nervous,1
IMBRUVICA,Cough,Cough Nervous,1
IMBRUVICA,Cough,disorders Cough Nervous,1
IMBRUVICA,Cough,Cough Nervous,1
IMBRUVICA,Cough,Cough Nervous,1
IMBRUVICA,Cough,Cough Nervous,1
IMBRUVICA,Dizziness,,0
IMBRUVICA,Dizziness,system disorders,0
IMBRUVICA,Dizziness,,0
IMBRUVICA,Dizziness,system Dizziness,1
IMBRUVICA,Headache,Headache Neoplasms benign,1
IMBRUVICA,Headache,Headache,1
IMBRUVICA,Headache,malignant,0
IMBRUVICA,Headache,Headache,1
IMBRUVICA,Headache,,0
IMBRUVICA,Headache,,0
IMBRUVICA,Skin cancer,Skin cancer Table,1
IMBRUVICA,Skin cancer,cysts and Skin cancer Table,1
IMBRUVICA,Skin cancer,and Skin,1
IMBRUVICA,Skin cancer,and Skin cancer Table,1
IMBRUVICA,Skin cancer,unspecified,0
IMBRUVICA,Skin cancer,Table TreatmentEmerg,0
IMBRUVICA,Skin cancer,,0
IMBRUVICA,Decrease of Hemoglobin,on laboratory,0
IMBRUVICA,Decrease of Hemoglobin,on,0
IMBRUVICA,Decrease of Hemoglobin,Decrease of Hemoglobin Platelets,1
IMBRUVICA,Platelets Decreased,Decreased Neutrophil,1
IMBRUVICA,Platelets Decreased,All Grades Grade or,0
IMBRUVICA,Platelets Decreased,N All Grades,0
IMBRUVICA,Neutrophils Decreased,Decreased Neutrophils,1
IMBRUVICA,Neutrophils Decreased,Decreased Neutrophils,1
IMBRUVICA,Neutrophils Decreased,D,0
IMBRUVICA,Hemoglobin Decreased,Hemoglobin Decreased,1
IMBRUVICA,Hemoglobin Decreased,,0
IMBRUVICA,Hemoglobin Decreased,Decreased,0
IMBRUVICA,Hemoglobin Decreased,,0
IMBRUVICA,Hemoglobin Decreased,,0
IMBRUVICA,Hemoglobin Decreased,,0
IMBRUVICA,Hemoglobin Decreased,Decreased,0
IMBRUVICA,Hemoglobin Decreased,Hemoglobin Decreased,1
IMBRUVICA,Hemoglobin Decreased,,0
IMBRUVICA,Hemoglobin Decreased,Decreased,0
IMBRUVICA,Hypersensitivity reactions,frequency or establish a causal relationship to,0
IMBRUVICA,Hypersensitivity reactions,a causal relationship to drug exposure,0
IMBRUVICA,Hypersensitivity reactions,,0
IMBRUVICA,Hypersensitivity reactions,to drug Hypersensitivity reactions,1
IMBRUVICA,Hypersensitivity reactions,Hypersensitivity reactions,1
IMBRUVICA,Hypersensitivity reactions,reliably estimate their frequency or establish,0
IMBRUVICA,anaphylactic shock,,0
IMBRUVICA,anaphylactic shock,Hypersensitivity reactions anaphylactic,1
IMBRUVICA,anaphylactic shock,exposure,0
IMBRUVICA,anaphylactic shock,and angioedema have been reported,0
IMBRUVICA,anaphylactic shock,exposure Hypersensitivity reactions anaphylactic shock,1
IMBRUVICA,fatal,fatal,1
IMBRUVICA,fatal,fatal,1
IMBRUVICA,fatal,angioedema have been,0
IMBRUVICA,fatal,,0
IMBRUVICA,fatal,,0
IMBRUVICA,urticaria,,0
IMBRUVICA,urticaria,urticaria,1
IMBRUVICA,urticaria,urticaria,1
IMBRUVICA,urticaria,urticaria,1
IMBRUVICA,angioedema,,0
IMBRUVICA,angioedema,shock fatal urticaria angioedema,1
IMBRUVICA,Infections,th,1
IMBRUVICA,Infections,detail in other ions of th,1
IMBRUVICA,Infections,are discussed,0
IMBRUVICA,Infections,reactions are discussed in more,0
IMBRUVICA,Infections,other ions,1
IMBRUVICA,Cytopenias,and Precautions Cytopenias see,0
IMBRUVICA,Cytopenias,,0
IMBRUVICA,Cytopenias,sections of the labeling Hemorrhage see,0
IMBRUVICA,Cytopenias,see Warnings and Precautions ions,1
IMBRUVICA,Cytopenias,[see,1
IMBRUVICA,Cytopenias,,0
IMBRUVICA,Cytopenias,ions [see,1
IMBRUVICA,Cytopenias,ions [see ,1
IMBRUVICA,Cytopenias,and Precautions Infect,0
IMBRUVICA,Cytopenias,sections of the labeling Hemorrhage see Warnings and Precautions Infect,0
IMBRUVICA,Atrial Fibrillation,Cytopenias ee,1
IMBRUVICA,Atrial Fibrillation,see Warnings and Precautions Second,0
IMBRUVICA,Atrial Fibrillation,,0
IMBRUVICA,Atrial Fibrillation,Warnings and Precautions Cytopenias ee  Warnings and Pr,1
IMBRUVICA,Atrial Fibrillation,and Precautions Cytopenias ee  Warnings and Pr,1
IMBRUVICA,Atrial Fibrillation,and Precautions,0
IMBRUVICA,Atrial Fibrillation,Warnings and Precautions Cytopenias ee Warnings,1
IMBRUVICA,Second Primary Malignancies,and Precautions,1
IMBRUVICA,Second Primary Malignancies,Second,0
IMBRUVICA,Second Primary Malignancies,],1
IMBRUVICA,Second Primary Malignancies,and Precautions (5.4) ],1
IMBRUVICA,Second Primary Malignancies,,0
IMBRUVICA,Second Primary Malignancies,,0
IMBRUVICA,Second Primary Malignancies,and Precautions (5.4) ],1
IMBRUVICA,Second Primary Malignancies,see  and Precautions (5.4)  ]  ,1
IMBRUVICA,Second Primary Malignancies, and Precautions (5.4)  ]  ,1
IMBRUVICA,malignancies,Precautions Atrial Fibrillation see Warnings,0
IMBRUVICA,malignancies,Atrial Fibrillation see Warnings,0
IMBRUVICA,malignancies,Warnings,0
IMBRUVICA,malignancies,Precautions ond,1
IMBRUVICA,malignancies,Precautions Tumor,0
IMBRUVICA,malignancies,Precautions,0
IMBRUVICA,malignancies,see Warnings and Precautions Tumor Lysis,0
IMBRUVICA,malignancies,see,0
IMBRUVICA,skin cancers,tions (5.5),1
IMBRUVICA,skin cancers,(5.5),1
IMBRUVICA,skin cancers,Second Primary Malignancies see Warnings and Precau,0
IMBRUVICA,skin cancers,Warnings,0
IMBRUVICA,skin cancers,Warnings and tions,1
IMBRUVICA,skin cancers,see Warnings and tions,1
IMBRUVICA,skin cancers,clinical trials,0
IMBRUVICA,skin cancers,see Warnings and,0
IMBRUVICA,skin cancers,Lysis,0
IMBRUVICA,carcinomas,see,0
IMBRUVICA,carcinomas,Warnings and Precautions or,1
IMBRUVICA,carcinomas,S,1
IMBRUVICA,carcinomas,and Precautions or Lysis S,1
IMBRUVICA,carcinomas,Warnings,0
IMBRUVICA,Tumor Lysis Syndrome,,0
IMBRUVICA,Tumor Lysis Syndrome,Malignancies see,0
IMBRUVICA,Tumor Lysis Syndrome,Lysis Syndrome see nings,1
IMBRUVICA,Tumor Lysis Syndrome,,0
IMBRUVICA,Tumor Lysis Syndrome,,0
IMBRUVICA,Tumor Lysis Syndrome,s Because,0
IMBRUVICA,Tumor Lysis Syndrome,conducted under widely variable conditions,0
IMBRUVICA,Tumor Lysis Syndrome,see nings,1
IMBRUVICA,Tumor Lysis Syndrome,nings and Precaution,1
IMBRUVICA,Tumor Lysis Syndrome,Because clinical trials are conducted under widely variable conditions,0
IMBRUVICA,TLS,under widely variable conditions adverse event,0
IMBRUVICA,TLS,Syndrome see Warnings and (5.,1
IMBRUVICA,TLS,(5.,1
IMBRUVICA,TLS,,0
IMBRUVICA,Embryo-Fetal Toxicity,"tions,",1
IMBRUVICA,Embryo-Fetal Toxicity,"conducted under widely variable tions, adverse",1
IMBRUVICA,Embryo-Fetal Toxicity,with rates of clinical,0
IMBRUVICA,Embryo-Fetal Toxicity,"tions, adverse event",1
IMBRUVICA,Embryo-Fetal Toxicity,"widely variable tions,",1
IMBRUVICA,Embryo-Fetal Toxicity,be directly compared with rates of clinical,0
IMBRUVICA,fetal harm,conducted under,0
IMBRUVICA,fetal harm,,0
IMBRUVICA,fetal harm,and,0
IMBRUVICA,fetal harm,clinical trials of another drug and,0
IMBRUVICA,fetal harm,clinical trials are conducted under widely variable conditions adverse event rates observ,0
IMBRUVICA,fetal harm,ical trials of a drug cannot be directly compared with rates of clinical trials of,0
IMBRUVICA,Fatal,and,0
IMBRUVICA,Fatal,,0
IMBRUVICA,bleeding events,in,0
IMBRUVICA,bleeding events,most common adverse reactions in patients with Bcell malignancies MCL CLL WM,0
IMBRUVICA,bleeding events,in,0
IMBRUVICA,bleeding events,ice.,1
IMBRUVICA,bleeding events,EXCE,1
IMBRUVICA,bleeding events,"in ice.
 

   EXCE",1
IMBRUVICA,bleeding events,"ice.
 

   EXCE",1
IMBRUVICA,bleeding events,"rates observed in ice.
 

   EXCE",1
IMBRUVICA,bleeding events,another drug and may not reflect the rates observed,0
IMBRUVICA,bleeding events,with Bcell malignancies MCL CLL WM,0
IMBRUVICA,bleeding events,with ell,1
IMBRUVICA,bleeding events,musculoskeletal,0
IMBRUVICA,bleeding events,in patients with,0
IMBRUVICA,bleeding events,malignancie,1
IMBRUVICA,bleeding events,anemia fatigue musculoskeletal,0
IMBRUVICA,bleeding events,with ell malignancie,1
IMBRUVICA,subdural hematoma,"in patients with Bcell (MCL, CLL, WM) we",1
IMBRUVICA,subdural hematoma,,0
IMBRUVICA,subdural hematoma,common,0
IMBRUVICA,subdural hematoma,pain bruising nausea,0
IMBRUVICA,gastrointestinal bleeding,,0
IMBRUVICA,gastrointestinal bleeding,,0
IMBRUVICA,hematuria,nausea upper respiratory,0
IMBRUVICA,hematuria,in patients with Bcell malignancies MCL CLL,0
IMBRUVICA,hematuria,patients with Bcell,0
IMBRUVICA,hematuria,"were thrombocytopenia nia, diar",1
IMBRUVICA,hematuria,,0
IMBRUVICA,hematuria,patients with Bcell malignancies MCL CLL,0
IMBRUVICA,post procedural hemorrhage,,0
IMBRUVICA,post procedural hemorrhage,"anemia, fatigue, musculos",1
IMBRUVICA,post procedural hemorrhage,"WM were thrombocytopenia neutropenia anemia, fatigue,",1
IMBRUVICA,post procedural hemorrhage,"were thrombocytopenia neutropenia anemia,",1
IMBRUVICA,post procedural hemorrhage,,0
IMBRUVICA,post procedural hemorrhage,,0
IMBRUVICA,post procedural hemorrhage,bruising nausea upper respiratory tract infection and rash To report,0
IMBRUVICA,bruising,tract infection and To,1
IMBRUVICA,bruising,ADVERSE REACTIONS contact Pharmacyclics at or FDA at FDA or,0
IMBRUVICA,bruising,To rep,1
IMBRUVICA,bruising,SUSPECTED ADVERSE REACTIONS contact,0
IMBRUVICA,bruising,,0
IMBRUVICA,bruising,respiratory tract infection and,0
IMBRUVICA,bruising,respiratory tract infection and   To rep,1
IMBRUVICA,bruising,,0
IMBRUVICA,bruising,rep,1
IMBRUVICA,bruising,infection and rash,0
IMBRUVICA,petechiae,or,0
IMBRUVICA,petechiae,USPECTED ,1
IMBRUVICA,petechiae,infection and,0
IMBRUVICA,petechiae,tract infection and rash To,0
IMBRUVICA,petechiae,To report S,0
IMBRUVICA,petechiae,and rash To report USPECTED ,1
IMBRUVICA,petechiae,rash To report USPECTED ,1
IMBRUVICA,petechiae,upper respiratory tract infection and rash To,0
IMBRUVICA,hemorrhage,ma,1
IMBRUVICA,hemorrhage,,0
IMBRUVICA,hemorrhage,,0
IMBRUVICA,hemorrhage,exposure to,0
IMBRUVICA,hemorrhage,ma T,1
IMBRUVICA,hemorrhage,Trials Experience Mantle,0
IMBRUVICA,hemorrhage,,0
IMBRUVICA,Fatal,pain peripheral edema upper respiratory tract,0
IMBRUVICA,Fatal,iarrh,1
IMBRUVICA,Fatal,reactions were thrombocytopenia iarrh,1
IMBRUVICA,Fatal,,0
IMBRUVICA,Fatal,were thrombocytopenia d,0
IMBRUVICA,Fatal,iarrh,1
IMBRUVICA,Fatal,,0
IMBRUVICA,Fatal,iarrh,1
IMBRUVICA,infections,"diarrhea ,",1
IMBRUVICA,infections,thrombocytopenia diarrhea neutropenia,0
IMBRUVICA,infections,"diarrhea , anemia, ",1
IMBRUVICA,infections,upper respiratory tract,0
IMBRUVICA,infections,",",1
IMBRUVICA,infections,"thrombocytopenia diarrhea , anemia, ",1
IMBRUVICA,infections,reactions,0
IMBRUVICA,infections,"reactions were thrombocytopenia diarrhea , anemia, ",1
IMBRUVICA,infections,commonly occurring adverse,0
IMBRUVICA,infections,,0
IMBRUVICA,infections,neutropenia anemia fatigue musculoskeletal pain peripheral,0
IMBRUVICA,infections,abdominal pain vomiting,0
IMBRUVICA,progressive multifocal leukoencephalopathy,bruising dyspnea constipation rash,0
IMBRUVICA,progressive multifocal leukoencephalopathy,iting and decreased appetite (see Tables,1
IMBRUVICA,progressive multifocal leukoencephalopathy,rash abdominal pain,0
IMBRUVICA,progressive multifocal leukoencephalopathy,infection nausea bruising dyspnea constipation rash abdominal pain vom,0
IMBRUVICA,progressive multifocal leukoencephalopathy,common Grade or,0
IMBRUVICA,progressive multifocal leukoencephalopathy,,0
IMBRUVICA,progressive multifocal leukoencephalopathy,constipation rash abdominal pain iting,1
IMBRUVICA,progressive multifocal leukoencephalopathy,iting and decreased appetite (see,1
IMBRUVICA,progressive multifocal leukoencephalopathy,dyspnea,0
IMBRUVICA,cytopenias,"diarrhea fatigue and skin s.



 Fat",1
IMBRUVICA,cytopenias,have occurred with,0
IMBRUVICA,cytopenias,Increases in,0
IMBRUVICA,cytopenias,,0
IMBRUVICA,neutropenia,and ous cases o,1
IMBRUVICA,neutropenia,Fatal and ous,1
IMBRUVICA,neutropenia,,0
IMBRUVICA,neutropenia,diarrhea fatigue and skin infections,0
IMBRUVICA,neutropenia,ous cases o,1
IMBRUVICA,neutropenia,failure have occurred,0
IMBRUVICA,neutropenia,ous cases o,1
IMBRUVICA,neutropenia,Fatal and ous cases,1
IMBRUVICA,thrombocytopenia,fatigue and skin infections Fatal,0
IMBRUVICA,thrombocytopenia,cases of renal failure occurred,1
IMBRUVICA,thrombocytopenia,cases of renal failure occurred with IM,1
IMBRUVICA,thrombocytopenia,of renal failure occurred with,1
IMBRUVICA,thrombocytopenia,occurred in of,0
IMBRUVICA,thrombocytopenia,cases of,0
IMBRUVICA,thrombocytopenia,renal failure occurred,1
IMBRUVICA,thrombocytopenia,failure occurred with,1
IMBRUVICA,thrombocytopenia,occurred with,1
IMBRUVICA,thrombocytopenia,failure occurred with,1
IMBRUVICA,Atrial fibrillation,560,1
IMBRUVICA,Atrial fibrillation,agent,1
IMBRUVICA,Atrial fibrillation,using agent IMBRUVICA 560,1
IMBRUVICA,Atrial fibrillation,,0
IMBRUVICA,Atrial fibrillation,mg daily,0
IMBRUVICA,Atrial fibrillation,daily occurring at a rate of,0
IMBRUVICA,Atrial fibrillation,of patients,0
IMBRUVICA,Atrial fibrillation,using agent IMBRUVICA,1
IMBRUVICA,Atrial fibrillation,560,1
IMBRUVICA,Atrial fibrillation,N using agent IMBRUVICA 560,1
IMBRUVICA,atrial flutter,in Table Table,0
IMBRUVICA,atrial flutter,agent IMBRUVICA,0
IMBRUVICA,atrial flutter,IMBRUVICA mg aily occurring,1
IMBRUVICA,atrial flutter,Adverse,0
IMBRUVICA,atrial flutter,mg d,0
IMBRUVICA,atrial flutter,at a rate of are presented,0
IMBRUVICA,atrial flutter,,0
IMBRUVICA,atrial flutter,agent IMBRUVICA mg aily,1
IMBRUVICA,atrial flutter,occurring,1
IMBRUVICA,malignancies,,0
IMBRUVICA,malignancies,,0
IMBRUVICA,non-skin carcinomas,,0
IMBRUVICA,non-skin carcinomas,Stomatitis,0
IMBRUVICA,non-skin carcinomas,                  2 Stomatitis,1
IMBRUVICA,non-skin carcinomas,                  2 Stomatitis,1
IMBRUVICA,non-skin carcinomas,,0
IMBRUVICA,second primary malignancy,                          Dyspepsia,1
IMBRUVICA,second primary malignancy,Stomatitis,0
IMBRUVICA,second primary malignancy,                          Dyspepsia,1
IMBRUVICA,second primary malignancy,                          Dyspepsia,1
IMBRUVICA,second primary malignancy,Stomatitis                           Dyspepsia,1
IMBRUVICA,second primary malignancy,                          Dyspepsia,1
IMBRUVICA,second primary malignancy,Stomatitis,0
IMBRUVICA,second primary malignancy,                          Dyspepsia,1
IMBRUVICA,second primary malignancy,Stomatitis,0
IMBRUVICA,non-melanoma skin cancer,"Stomatitis       1               
  Dyspepsia",1
IMBRUVICA,non-melanoma skin cancer,,0
IMBRUVICA,non-melanoma skin cancer,Infections,0
IMBRUVICA,non-melanoma skin cancer,"Stomatitis       1               
  Dyspepsia Infections",1
IMBRUVICA,non-melanoma skin cancer,and,0
IMBRUVICA,non-melanoma skin cancer,Infections and,0
IMBRUVICA,Tumor lysis syndrome,,0
IMBRUVICA,Tumor lysis syndrome,and infestations Upper respiratory tract,0
IMBRUVICA,Tumor lysis syndrome,       0             Infections and infestations Upper respiratory,1
IMBRUVICA,Tumor lysis syndrome,       0             Infections,1
IMBRUVICA,Tumor lysis syndrome,Upper respiratory,0
IMBRUVICA,fetal harm,Pneumonia,0
IMBRUVICA,fetal harm,Skin,0
IMBRUVICA,fetal harm,          ,1
IMBRUVICA,fetal harm,Pneumonia            Skin,1
IMBRUVICA,malformations,,0
IMBRUVICA,malformations,,0
IMBRUVICA,malformations,,0
IMBRUVICA,malformations,              Sinusitis,1
IMBRUVICA,malformations,              Sinusitis,1
IMBRUVICA,malformations,Skin               Sinusitis,1
IMBRUVICA,malformations,              Sinusitis,1
IMBRUVICA,Reduced fetal weights,Peripheral,0
DUREZOL,elevated intraocular pressure,,0
DUREZOL,elevated intraocular pressure,elevated intraocular pressure which,1
DUREZOL,elevated intraocular pressure,intraocular pressure which may be associated with,1
DUREZOL,elevated intraocular pressure,posterior,0
DUREZOL,elevated intraocular pressure,which may be associated with optic nerve damage,0
DUREZOL,optic nerve damage,may be associated optic nerve damage visual,1
DUREZOL,optic nerve damage,,0
DUREZOL,posterior subcapsular cataract formation,ocular infection from,0
DUREZOL,posterior subcapsular cataract formation,acuity and field posterior subcapsular cataract formation secondary,1
DUREZOL,posterior subcapsular cataract formation,field posterior subcapsular cataract formation secondary,1
DUREZOL,posterior subcapsular cataract formation,,0
DUREZOL,secondary ocular infection,optic nerve damage visual,0
DUREZOL,secondary ocular infection,globe where there,0
DUREZOL,secondary ocular infection,field defects posterior subcapsular,0
DUREZOL,secondary ocular infection,simplex,0
DUREZOL,secondary ocular infection,posterior,0
DUREZOL,secondary ocular infection,defects posterior subcapsular cataract secondary ocular,1
DUREZOL,secondary ocular infection,damage visual,0
DUREZOL,secondary ocular infection,field defects posterior subcapsular,0
DUREZOL,secondary ocular infection,defects posterior subcapsular cataract formation,0
DUREZOL,secondary ocular infection,posterior subcapsular cataract secondary ocular infection from,1
DUREZOL,perforation of the globe,herpes simplex perforation,1
DUREZOL,perforation of the globe,cornea or sclera Ocular Surgery Ocular adverse,0
DUREZOL,perforation of the globe,perforation of the globe where,1
DUREZOL,perforation of the globe,adverse reactio,0
DUREZOL,perforation of the globe,pathogens including herpes,0
DUREZOL,perforation of the globe,cataract formation secondary ocular infection from pathogens including herpes,0
DUREZOL,perforation of the globe,perforation of the globe where,1
DUREZOL,perforation of the globe,herpes simplex perforation,1
DUREZOL,perforation of the globe,,0
DUREZOL,corneal edema,in clinical studies with DUREZOL,0
DUREZOL,corneal edema,opacification,0
DUREZOL,conjunctival hyperemia,corneal edema ciliary conjunctival,1
DUREZOL,conjunctival hyperemia,pain photophobia,0
DUREZOL,conjunctival hyperemia,,0
DUREZOL,conjunctival hyperemia,conjunctival hyperemia eye,1
DUREZOL,conjunctival hyperemia,included corneal edema ciliary conjunctival hyperemia eye,1
DUREZOL,conjunctival hyperemia,DUREZOL,0
DUREZOL,conjunctival hyperemia,included corneal edema ciliary conjunctival hyperemia eye,1
DUREZOL,conjunctival hyperemia,chamber,0
DUREZOL,conjunctival hyperemia,edema ciliary conjunctival hyperemia eye,1
DUREZOL,conjunctival hyperemia,ciliary conjunctival hyperemia eye,1
DUREZOL,eye pain,opacification anterior chamber cells,0
DUREZOL,eye pain,anterior chamber cells anterior,0
DUREZOL,eye pain,cells anterior,0
DUREZOL,eye pain,and conjunctival eye pain photophobia,1
DUREZOL,photophobia,photophobia posterior,1
DUREZOL,photophobia,DUREZOL included corneal edema ciliary,0
DUREZOL,photophobia,chamber cells anterior chamber flare conjunctival,0
DUREZOL,photophobia,opacification anterior chamber cells anterior chamber flare conjunctival edem,0
DUREZOL,photophobia,photophobia posterior,1
DUREZOL,photophobia,edema,0
DUREZOL,photophobia,photophobia posterior,1
DUREZOL,photophobia,photophobia posterior,1
DUREZOL,posterior capsule opacification,,0
DUREZOL,posterior capsule opacification,,0
DUREZOL,posterior capsule opacification,,0
DUREZOL,anterior chamber cells,cells anterior,1
DUREZOL,anterior chamber cells,posterior,0
DUREZOL,conjunctival edema,anterior chamber conjunctival edema and,1
DUREZOL,conjunctival edema,conjunctival edema and,1
DUREZOL,reduced visual acuity,acuity punctate,1
DUREZOL,reduced visual acuity,occurring in of subjects reduced visual,1
DUREZOL,punctate keratitis,ocular adverse reactions occurring in of subjects included reduced visual acuity,0
DUREZOL,punctate keratitis,subjects included reduced visual punctate keratitis eye,1
DUREZOL,punctate keratitis,Other ocular adverse reactions,0
DUREZOL,punctate keratitis,included reduced visual punctate keratitis eye,1
DUREZOL,punctate keratitis,visual punctate keratitis eye,1
DUREZOL,punctate keratitis,adverse reactions occurring,0
DUREZOL,punctate keratitis,in of subjects included,0
DUREZOL,punctate keratitis,subjects included,0
DUREZOL,punctate keratitis,visual punctate,1
DUREZOL,eye inflammation,eye inflammation and,1
DUREZOL,eye inflammation,acuity punctate eye inflammation and,1
DUREZOL,eye inflammation,visual,0
DUREZOL,iritis,iritis Ocular,1
DUREZOL,iritis,iritis Ocular,1
DUREZOL,iritis,inflammation iritis Ocular,1
DUREZOL,application site discomfort,subjects application site,1
DUREZOL,application site discomfort,application,1
DUREZOL,corneal pigmentation,site discomfort or corneal pigmentation and,1
DUREZOL,corneal pigmentation,site discomfort or corneal,1
DUREZOL,corneal pigmentation,eyelid irritation,0
DUREZOL,corneal pigmentation,reactions occurring in of subjects included application site discomfort,0
DUREZOL,episcleritis,site discomfort or irritation corneal pigmentation,0
DUREZOL,episcleritis,lacrimation,0
DUREZOL,episcleritis,pigmentation and episcleritis eye,1
DUREZOL,episcleritis,episcleritis eye,1
DUREZOL,episcleritis,foreign body sensation increased lacrimation,0
DUREZOL,episcleritis,episcleritis eye,1
DUREZOL,eye pruritis,lacrimation macular,0
DUREZOL,eye pruritis,and striae eye pruritis eyelid,1
DUREZOL,eye pruritis,crusting foreign body sensation increased,0
DUREZOL,eye pruritis,eye,1
DUREZOL,eye pruritis,pigmentation and striae eye pruritis eyelid,1
DUREZOL,eye pruritis,eyelid irritation,0
DUREZOL,eye pruritis,corneal pigmentation and striae eye pruritis eyelid,1
DUREZOL,eye pruritis,eye pruritis eyelid,1
DUREZOL,eye pruritis,foreign body sensation increased lacrimation macular,0
DUREZOL,eye pruritis,,0
DUREZOL,eyelid irritation,irritation and,1
DUREZOL,eyelid irritation,site discomfort,0
DUREZOL,eyelid irritation,striae episcleritis eye eyelid irritation and,1
DUREZOL,eyelid irritation,,0
DUREZOL,eyelid irritation,eyelid,1
DUREZOL,eyelid irritation,edema sclera hyperemia,0
DUREZOL,increased lacrimation,foreign body increased,1
DUREZOL,increased lacrimation,increased lacrimation macular,1
DUREZOL,increased lacrimation,foreign,0
DUREZOL,increased lacrimation,and crusting foreign body increased lacrimation macular,1
DUREZOL,increased lacrimation,increased lacrimation macular,1
DUREZOL,increased lacrimation,and crusting foreign body increased,1
DUREZOL,increased lacrimation,crusting foreign body,0
DUREZOL,increased lacrimation,increased lacrimation macular,1
DUREZOL,increased lacrimation,macular edema sclera hyperemia and uveitis Most of these reactions may have,0
DUREZOL,increased lacrimation,increased lacrimation macular,1
DUREZOL,macular edema,increased macular edema sclera,1
DUREZOL,macular edema,foreign body sensation increased macular,1
DUREZOL,macular edema,body sensation increased macular,1
DUREZOL,macular edema,macular,1
DUREZOL,macular edema,,0
DUREZOL,macular edema,and uveitis Most of these reactions may have been,0
DUREZOL,macular edema,eyelid irritation and,0
DUREZOL,macular edema,macular edema sclera,1
DUREZOL,sclera hyperemia,macular sclera,1
DUREZOL,sclera hyperemia,have been the,0
DUREZOL,sclera hyperemia,and crusting,0
DUREZOL,sclera hyperemia,may have been the consequence of the surgical procedure,0
DUREZOL,sclera hyperemia,uveitis Most of these reactions may have been the consequence,0
DUREZOL,sclera hyperemia,sclera hyperemia and,1
DUREZOL,sclera hyperemia,macular edema,0
DUREZOL,sclera hyperemia,sclera hyperemia and,1
DUREZOL,sclera hyperemia,hyperemia and,1
DUREZOL,uveitis,macular edema sclera hyperemia uveitis Most,1
DUREZOL,uveitis,uveitis Most,1
DUREZOL,blurred vision,occurring in of subjects blurred,1
DUREZOL,blurred vision,blurred,1
DUREZOL,blurred vision,vision eye,1
DUREZOL,blurred vision,increased,0
DUREZOL,blurred vision,common adverse reactions of those exposed to DUREZOL occurring in of subjects included,0
DUREZOL,blurred vision,vision eye,1
DUREZOL,blurred vision,irritation eye,0
DUREZOL,eye irritation,subjects included blurred eye,1
DUREZOL,eye pain,pain headache,1
DUREZOL,eye pain,vision eye eye pain headache,1
DUREZOL,eye pain,eye eye pain headache,1
DUREZOL,eye pain,blurred vision eye eye pain headache,1
DUREZOL,eye pain,and,0
DUREZOL,eye pain,those,0
DUREZOL,eye pain,pain headache,1
DUREZOL,eye pain,,0
DUREZOL,headache,,0
DUREZOL,headache,headache increased,1
DUREZOL,headache,and conjunctival,0
DUREZOL,headache,headache increased,1
DUREZOL,headache,blurred vision eye irritation,0
DUREZOL,increased IOP,occ,0
DUREZOL,increased IOP,increased IOP iritis,1
DUREZOL,increased IOP,in of subjects included blurred vision,0
DUREZOL,increased IOP,irritation eye pain increased IOP iritis,1
DUREZOL,iritis,iritis limbal,1
DUREZOL,iritis,iritis limbal,1
DUREZOL,iritis,headache increased iritis limbal,1
DUREZOL,iritis,,0
DUREZOL,iritis,iritis limbal,1
DUREZOL,iritis,and,0
DUREZOL,iritis,iritis limbal,1
DUREZOL,iritis,iritis limbal,1
DUREZOL,iritis,,0
DUREZOL,conjunctival hyperemia,irritation eye pain headache increased IOP,0
DUREZOL,conjunctival hyperemia,conjunctival,1
DUREZOL,conjunctival hyperemia,pain,0
DUREZOL,conjunctival hyperemia,vision eye irritation eye pain headache increased IOP iritis limbal and,0
DUREZOL,conjunctival hyperemia,Adverse reactions occurring in,0
DUREZOL,conjunctival hyperemia,eye irritation eye pain headache increased IOP iritis limbal and,0
DUREZOL,conjunctival hyperemia,hyperemia punctate,1
DUREZOL,conjunctival hyperemia,increased IOP iritis limbal conjunctival,1
DUREZOL,conjunctival hyperemia,increased IOP iritis limbal and,0
DUREZOL,conjunctival hyperemia,Adverse reactions,0
DUREZOL,punctate keratitis,limbal and conjunctival punctate keratitis and,1
DUREZOL,punctate keratitis,,0
DUREZOL,uveitis,uveitis Adverse,1
DUREZOL,uveitis,uveitis Adverse,1
DUREZOL,uveitis,,0
DUREZOL,uveitis,,0
DUREZOL,uveitis,edema,0
DUREZOL,uveitis,,0
DUREZOL,uveitis,,0
DUREZOL,anterior chamber flare,included,0
DUREZOL,anterior chamber flare,chamber flare corneal,1
DUREZOL,anterior chamber flare,anterior chamber flare corneal,1
DUREZOL,anterior chamber flare,flare corneal,1
DUREZOL,anterior chamber flare,occurring in of subjects anterior,1
DUREZOL,anterior chamber flare,and uveitis Adverse reactions,0
DUREZOL,anterior chamber flare,anterior,1
DUREZOL,corneal edema,in of subjects included anterior chamber flare,0
DUREZOL,corneal edema,subjects included anterior chamber corneal,1
DUREZOL,corneal edema,reduced,0
DUREZOL,corneal edema,corneal edema dry,1
DUREZOL,corneal edema,edema dry,1
DUREZOL,corneal edema,anterior chamber corneal edema dry,1
DUREZOL,corneal edema,,0
DUREZOL,dry eye,included anterior chamber flare corneal,0
DUREZOL,dry eye,corneal dry eye iridocyclitis,1
DUREZOL,dry eye,Adverse reactions occurring in of subjects included anterior chamber flare corneal edema,0
DUREZOL,dry eye,flare corneal edema,0
DUREZOL,dry eye,dry eye iridocyclitis,1
DUREZOL,iridocyclitis,iridocyclitis photophobia,1
DUREZOL,iridocyclitis,subjects included anterior,0
DUREZOL,iridocyclitis,dry,0
DUREZOL,photophobia,photophobia and,1
DUREZOL,reduced visual acuity,eye iridocyclitis photophobia reduced,1
DUREZOL,reduced visual acuity,photophobia reduced visual acuity,1
DUREZOL,glaucoma,pressure which may be ciated,1
DUREZOL,glaucoma,may be ciated w ith,1
DUREZOL,glaucoma,w ith,1
DUREZOL,glaucoma,w ith,1
DUREZOL,glaucoma,with ophthalmic steroids include elevated intraocular pressure which may,0
DUREZOL,glaucoma,ciated w ith,1
DUREZOL,defects in visual acuity,"damage visual uity and field defects,  posterior",1
DUREZOL,defects in visual acuity,visual uity,1
DUREZOL,defects in visual acuity,"field defects, posterior",1
DUREZOL,defects in visual acuity,"field defects, posterior",1
DUREZOL,defects in visual acuity,"defects, posterior",1
DUREZOL,defects in visual acuity,"field defects, posterior",1
DUREZOL,defects in visual acuity,damage,0
DUREZOL,defects in visual acuity,from pathogens including,0
DUREZOL,defects in visual acuity,"uity and field defects, posterior",1
DUREZOL,posterior subcapsular cataract,"of  cornea or sclera.



   6.1 O cular",1
DUREZOL,posterior subcapsular cataract,or sclera. 6.1 O cular,1
DUREZOL,posterior subcapsular cataract," cornea or sclera.



   6.1 O cular",1
DUREZOL,posterior subcapsular cataract,the,0
DUREZOL,posterior subcapsular cataract,reactions,0
DUREZOL,posterior subcapsular cataract,studies with,0
DUREZOL,posterior subcapsular cataract,"is thinning of  cornea or sclera.



   6.1 O cular",1
DUREZOL,delay healing,studies h DUREZOL inc luded,1
DUREZOL,delay healing,studies h DUREZOL inc luded,1
DUREZOL,delay healing,studies h DUREZOL inc luded,1
DUREZOL,delay healing,studies h DUREZOL inc luded,1
DUREZOL,perforations,"tion, anteri or",1
DUREZOL,perforations,"tion, anteri or",1
DUREZOL,suppress the host response,body sensation increased lacrimation,0
DUREZOL,suppress the host response,and striae episcleritis eye  eyelid irritation and cru sting,1
DUREZOL,suppress the host response,,0
DUREZOL,secondary ocular infections,"creased lacrimation, macula r",1
DUREZOL,secondary ocular infections,sensation in,0
DUREZOL,Fungal infections of the cornea,conjunctival hyperemia punctate  and uveitis.  Adverse reaction s,1
DUREZOL,Fungal infections of the cornea,and conjunctival hyperemia punctate and,1
DUREZOL,Fungal infections of the cornea,hyperemia punctate  and uveitis.  Adverse reaction s,1
DUREZOL,Fungal infections of the cornea,pain headache increased,0
DUREZOL,Fungal infections of the cornea,and uveitis. Adverse reaction s,1
DUREZOL,Fungal infections of the cornea,IOP iritis limbal and conjunctival hyperemia,0
DUREZOL,Fungal infections of the cornea,hyperemia punctate  and uveitis.  Adverse reaction s,1
DUREZOL,Fungal infections of the cornea,,0
DUREZOL,Fungal infections of the cornea,and uveitis. Adverse reaction s,1
DUREZOL,Fungal infections of the cornea,hyperemia punctate  and uveitis.  Adverse reaction s,1
DUREZOL,glaucoma,,1
DUREZOL,glaucoma,,0
DUREZOL,glaucoma,,1
DUREZOL,glaucoma,,0
DUREZOL,glaucoma,,0
DUREZOL,glaucoma,,0
DUREZOL,glaucoma,,0
DUREZOL,glaucoma,,1
DUREZOL,glaucoma,,0
DUREZOL,glaucoma,,1
DUREZOL,damage to the optic nerve,,0
DUREZOL,damage to the optic nerve,,0
DUREZOL,damage to the optic nerve,,1
DUREZOL,damage to the optic nerve,,0
DUREZOL,damage to the optic nerve,,0
DUREZOL,damage to the optic nerve,,0
DUREZOL,damage to the optic nerve,,1
DUREZOL,posterior subcapsular cataract,,0
DUREZOL,posterior subcapsular cataract,,1
DUREZOL,delay healing,,0
DUREZOL,delay healing,,0
DUREZOL,delay healing,,1
DUREZOL,delay healing,,0
DUREZOL,delay healing,,1
DUREZOL,delay healing,,1
DUREZOL,delay healing,,0
DUREZOL,delay healing,,1
DUREZOL,delay healing,,1
DUREZOL,delay healing,,0
DUREZOL,perforations,,1
DUREZOL,perforations,,1
DUREZOL,perforations,,1
DUREZOL,perforations,,0
DUREZOL,perforations,,0
DUREZOL,perforations,,1
DUREZOL,suppress the host response,,1
DUREZOL,suppress the host response,,1
DUREZOL,suppress the host response,,0
DUREZOL,suppress the host response,,1
DUREZOL,suppress the host response,,0
DUREZOL,suppress the host response,,0
DUREZOL,suppress the host response,,0
DUREZOL,suppress the host response,,0
DUREZOL,suppress the host response,,0
DUREZOL,secondary ocular infections,,0
DUREZOL,secondary ocular infections,,1
DUREZOL,secondary ocular infections,,1
DUREZOL,secondary ocular infections,,1
DUREZOL,secondary ocular infections,,0
DUREZOL,Fungal infections of the cornea,,0
DUREZOL,Fungal infections of the cornea,,1
DUREZOL,Fungal infections of the cornea,,1
DUREZOL,Fungal infections of the cornea,,0
DUREZOL,Fungal infections of the cornea,,1
DUREZOL,Fungal infections of the cornea,,1
DUREZOL,Fungal infections of the cornea,,0
DUREZOL,Fungal infections of the cornea,,1
DUREZOL,Fungal infections of the cornea,,0
ZYKADIA,Gastrointestinal Toxicity,in greater detail in other sections of the labeling Severe,0
ZYKADIA,Gastrointestinal Toxicity,,0
ZYKADIA,Gastrointestinal Toxicity,Severe or Gastrointestinal,1
ZYKADIA,Gastrointestinal Toxicity,are discussed in greater detail in other sections of,0
ZYKADIA,Hepatotoxicity,Hepatotoxicity,1
ZYKADIA,Hepatotoxicity,Warnings,0
ZYKADIA,Hepatotoxicity,Hepatotoxicity,1
ZYKADIA,Hepatotoxicity,Hepatotoxicity,1
ZYKADIA,Hepatotoxicity,Hepatotoxicity,1
ZYKADIA,Hepatotoxicity,,0
ZYKADIA,Hepatotoxicity,,0
ZYKADIA,Hepatotoxicity,Hepatotoxicity,1
ZYKADIA,Hepatotoxicity,and,0
ZYKADIA,Pneumonitis,Pneumonitis,1
ZYKADIA,Pneumonitis,and Precautions Interstitial Lung Pneumonitis,1
ZYKADIA,Pneumonitis,Hepatotoxicity see Warnings and Precautions Interstitial Lung,0
ZYKADIA,Pneumonitis,Pneumonitis,1
ZYKADIA,Pneumonitis,,0
ZYKADIA,QT Interval Prolongation,Warnings and QT,1
ZYKADIA,QT Interval Prolongation,Interval Prolongation,1
ZYKADIA,QT Interval Prolongation,Warnings and QT Interval,1
ZYKADIA,QT Interval Prolongation,and,0
ZYKADIA,QT Interval Prolongation,and QT,1
ZYKADIA,QT Interval Prolongation,QT Interval Prolongation,1
ZYKADIA,Hyperglycemia,Hyperglycemia,1
ZYKADIA,Hyperglycemia,Warnings and Precautions and Clin,0
ZYKADIA,Hyperglycemia,see Warnings and Precautions Bradycardia see,0
ZYKADIA,Hyperglycemia,Precautions Bradycardia see Warnings,0
ZYKADIA,Hyperglycemia,Hyperglycemia,1
ZYKADIA,Bradycardia,see Warnings,0
ZYKADIA,Bradycardia,and Bradycardia,1
ZYKADIA,Bradycardia,and Clinical Pharmacology Pancreatitis see,0
ZYKADIA,Bradycardia,Pharmacology Pancreatitis see,0
ZYKADIA,Bradycardia,Bradycardia,1
ZYKADIA,Pancreatitis,,0
ZYKADIA,Pancreatitis,Pancreatitis,1
ZYKADIA,diarrhea,incidence of at least diarrhea,1
ZYKADIA,diarrhea,diarrhea,1
ZYKADIA,diarrhea,pain fatigue,0
ZYKADIA,diarrhea,diarrhea,1
ZYKADIA,diarrhea,diarrhea,1
ZYKADIA,diarrhea,EXCERPT,0
ZYKADIA,diarrhea,adverse,0
ZYKADIA,nausea,nausea,1
ZYKADIA,nausea,common adverse reactions incidence of at least,0
ZYKADIA,nausea,nausea,1
ZYKADIA,nausea,,0
ZYKADIA,nausea,of at least are nausea,1
ZYKADIA,nausea,,0
ZYKADIA,nausea,of at least are diarrhea,0
ZYKADIA,nausea,most common adverse reactions incidence of at least are,0
ZYKADIA,nausea,common adverse reactions,0
ZYKADIA,nausea,abdominal pain fatigue decreased,0
ZYKADIA,elevated transaminases,least are diarrhea elevated transaminases,1
ZYKADIA,elevated transaminases,report S,0
ZYKADIA,elevated transaminases,vomiting abdominal pain fatigue decreased appetite and constipation,0
ZYKADIA,elevated transaminases,are diarrhea,0
ZYKADIA,elevated transaminases,,0
ZYKADIA,elevated transaminases,transaminases,1
ZYKADIA,elevated transaminases,transaminases,1
ZYKADIA,vomiting,appetite and constipation To report SUSPECTED,0
ZYKADIA,vomiting,fatigue decreased appetite and constipation To report SUSPECTED,0
ZYKADIA,vomiting,vomiting,1
ZYKADIA,vomiting,vomiting,1
ZYKADIA,vomiting,vomiting,1
ZYKADIA,vomiting,vomiting,1
ZYKADIA,vomiting,SUSPECTED,0
ZYKADIA,vomiting,and constipation To report,0
ZYKADIA,abdominal pain,abdominal,1
ZYKADIA,abdominal pain,transaminases abdominal pain,1
ZYKADIA,abdominal pain,report,0
ZYKADIA,abdominal pain,report SUSPECTED,0
ZYKADIA,abdominal pain,REACTIONS,0
ZYKADIA,abdominal pain,nausea elevated transaminases abdominal,1
ZYKADIA,abdominal pain,transaminases abdominal,1
ZYKADIA,abdominal pain,are,0
ZYKADIA,abdominal pain,transaminases abdominal pain,1
ZYKADIA,fatigue,fatigue,1
ZYKADIA,decreased appetite,decreased appetite,1
ZYKADIA,decreased appetite,,0
ZYKADIA,decreased appetite,elevated transaminases vomiting,0
ZYKADIA,constipation,To report SUSPECTED ADVERSE REACTIONS contact Novartis,0
ZYKADIA,constipation,Pharmaceuticals,0
ZYKADIA,constipation,constipation,1
ZYKADIA,constipation,,0
ZYKADIA,constipation,constipation,1
ZYKADIA,constipation,constipation,1
ZYKADIA,constipation,abdominal pain fatigue decreased appetite and,0
ZYKADIA,constipation,decreased appetite constipation,1
ZYKADIA,constipation,Novartis Pharmaceuticals,0
ZYKADIA,constipation,constipation,1
ZYKADIA,increased ALT,reductions or interruptions increased ALT,1
ZYKADIA,increased ALT,dose reductions or interruptions increased ALT,1
ZYKADIA,increased ALT,,0
ZYKADIA,increased ALT,Serious adverse,0
ZYKADIA,increased ALT,,0
ZYKADIA,increased ALT,patients that led to dose,0
ZYKADIA,nausea,were increased nausea,1
ZYKADIA,nausea,led to dose reductions or interruptions,0
ZYKADIA,nausea,least of patients that led to dose reductions or,0
ZYKADIA,nausea,least of patients that,0
ZYKADIA,nausea,nausea,1
ZYKADIA,nausea,nausea,1
ZYKADIA,nausea,nausea,1
ZYKADIA,increased AST,Serious adverse drug reactions reported in or,0
ZYKADIA,increased AST,interruptions were increased ALT increased AST,1
ZYKADIA,increased AST,ALT increased,1
ZYKADIA,increased AST,patients that led to dose reductions or interruptions were increased ALT,0
ZYKADIA,increased AST,to dose,0
ZYKADIA,increased AST,or more of,0
ZYKADIA,increased AST,AST,1
ZYKADIA,increased AST,increased ALT increased,1
ZYKADIA,diarrhea,diarrhea,1
ZYKADIA,diarrhea,to dose reductions or interruptions were increased ALT nausea,0
ZYKADIA,diarrhea,diarrhea,1
ZYKADIA,diarrhea,nausea,0
ZYKADIA,diarrhea,reductions or interruptions were increased ALT nausea increased,0
ZYKADIA,diarrhea,diarrhea,1
ZYKADIA,diarrhea,diarrhea,1
ZYKADIA,diarrhea,nausea,0
ZYKADIA,vomiting,AST diarrhea vomiting,1
ZYKADIA,vomiting,vomiting,1
ZYKADIA,vomiting,nausea increased,0
ZYKADIA,vomiting,,0
ZYKADIA,vomiting,,0
ZYKADIA,vomiting,vomiting,1
ZYKADIA,convulsion,drug reactions reported in or more of patients,0
ZYKADIA,convulsion,adverse drug reactions reported in or more of patients in,0
ZYKADIA,convulsion,convulsion,1
ZYKADIA,convulsion,patients,0
ZYKADIA,convulsion,in Study convulsion,1
ZYKADIA,convulsion,patients in Study convulsion,1
ZYKADIA,convulsion,convulsion,1
ZYKADIA,convulsion,,0
ZYKADIA,pneumonia,Study were pneumonia,1
ZYKADIA,pneumonia,Study were pneumonia,1
ZYKADIA,pneumonia,nausea Fatal adverse reactions in patie,0
ZYKADIA,pneumonia,pneumonia,1
ZYKADIA,pneumonia,pneumonia,1
ZYKADIA,pneumonia,dyspnea,0
ZYKADIA,pneumonia,were pneumonia,1
ZYKADIA,pneumonia,pneumonia,1
ZYKADIA,ILD,were convulsion pneumonia,0
ZYKADIA,ILD,,0
ZYKADIA,ILD,convulsion ILD,1
ZYKADIA,ILD,Study were convulsion ILD,1
ZYKADIA,ILD,Study were convulsion ILD,1
ZYKADIA,ILD,were convulsion ILD,1
ZYKADIA,ILD,reported in,0
ZYKADIA,ILD,Study were convulsion,0
ZYKADIA,ILD,ILD,1
ZYKADIA,ILD,,0
ZYKADIA,pneumonitis,pneumonia,0
ZYKADIA,pneumonitis,with,0
ZYKADIA,pneumonitis,reactions in,0
ZYKADIA,pneumonitis,pneumonia pneumonitis,1
ZYKADIA,pneumonitis,in patients treated,0
ZYKADIA,pneumonitis,in Study were convulsion,0
ZYKADIA,pneumonitis,dyspnea dehydration hyperglycemia and nausea Fatal adverse reactions in patients,0
ZYKADIA,pneumonitis,nausea,0
ZYKADIA,pneumonitis,pneumonitis,1
ZYKADIA,pneumonitis,pneumonitis,1
ZYKADIA,dyspnea,convulsion pneumonia,0
ZYKADIA,dyspnea,patients in Study were,0
ZYKADIA,dyspnea,,0
ZYKADIA,dyspnea,with ZYKADIA o,0
ZYKADIA,dyspnea,dyspnea,1
ZYKADIA,dyspnea,patients in Study were convulsion,0
ZYKADIA,dyspnea,adverse reactions in patients,0
ZYKADIA,dyspnea,convulsion pneumonia dyspnea,1
ZYKADIA,dyspnea,convulsion pneumonia dyspnea,1
ZYKADIA,dyspnea,convulsion pneumonia dyspnea,1
ZYKADIA,dehydration,convulsion pneumonia ILDpneumonitis dehydration,1
ZYKADIA,dehydration,dehydration,1
ZYKADIA,dehydration,pneumonia ILDpneumonitis dehydration,1
ZYKADIA,dehydration,pneumonia ILDpneumonitis dehydration,1
ZYKADIA,dehydration,dehydration,1
ZYKADIA,dehydration,nausea Fatal adverse reactions in,0
ZYKADIA,hyperglycemia,,0
ZYKADIA,hyperglycemia,with ZYKADIA occurred,0
ZYKADIA,hyperglycemia,hyperglycemia,1
ZYKADIA,hyperglycemia,hyperglycemia,1
ZYKADIA,hyperglycemia,more of patients in Study were convulsion pneumonia,0
ZYKADIA,hyperglycemia,hyperglycemia,1
ZYKADIA,hyperglycemia,hyperglycemia,1
ZYKADIA,hyperglycemia,were convulsion pneumonia ILDpneumonitis dyspnea dehydration,0
ZYKADIA,nausea,nausea,1
ZYKADIA,nausea,nausea,1
ZYKADIA,nausea,,0
ZYKADIA,nausea,,0
ZYKADIA,nausea,,0
ZYKADIA,nausea,,0
ZYKADIA,Fatal,Fatal,1
ZYKADIA,Fatal,were convulsion pneumonia ILDpneumonitis dyspnea dehydration hyperglycemia and nausea,0
ZYKADIA,pneumonia,of patients,0
ZYKADIA,pneumonia,patients treated with ZYKADIA occurred in of,0
ZYKADIA,pneumonia,reactions in patients treated,0
ZYKADIA,pneumonia,,0
ZYKADIA,pneumonia,treated with ZYKADIA occurred in of patients consisting of,0
ZYKADIA,respiratory failure,,0
ZYKADIA,respiratory failure,respiratory failure,1
ZYKADIA,respiratory failure,respiratory failure,1
ZYKADIA,respiratory failure,pneumonia patients,0
ZYKADIA,respiratory failure,deterioration,0
ZYKADIA,respiratory failure,,0
ZYKADIA,respiratory failure,patients treated with ZYKADIA occurred in,0
ZYKADIA,respiratory failure,physical health deterioration,0
ZYKADIA,respiratory failure,hemorrhage general physical,0
ZYKADIA,ILD,ILD,1
ZYKADIA,ILD,ILD,1
ZYKADIA,ILD,occurred in of patients consisting of pneumonia patients respiratory failure,0
ZYKADIA,ILD,pneumonia patients respiratory ILD,1
ZYKADIA,ILD,,0
ZYKADIA,ILD,physical,0
ZYKADIA,ILD,patients,0
ZYKADIA,pneumonitis,respiratory failure pneumonitis,1
ZYKADIA,pneumonitis,patients respiratory failure pneumonitis,1
ZYKADIA,pneumonitis,,0
ZYKADIA,pneumonitis,tuberculosis,0
ZYKADIA,pneumonitis,consisting of pneumonia,0
ZYKADIA,pneumonitis,pneumonitis,1
ZYKADIA,pneumonitis,respiratory,0
ZYKADIA,gastric hemorrhage,respiratory failure ILDpneumonitis gastric hemorrhage,1
ZYKADIA,gastric hemorrhage,gastric,1
ZYKADIA,general physical health deterioration,,0
ZYKADIA,general physical health deterioration,patients respiratory failure ILDpneumonitis pneumothorax,0
ZYKADIA,pulmonary tuberculosis,health pulmonary,1
ZYKADIA,pulmonary tuberculosis,general,0
ZYKADIA,pulmonary tuberculosis,general physical health,0
ZYKADIA,pulmonary tuberculosis,pulmonary tuberculosis,1
ZYKADIA,pulmonary tuberculosis,of therapy due,0
ZYKADIA,pulmonary tuberculosis,general physical health pulmonary,1
ZYKADIA,pulmonary tuberculosis,physical health pulmonary,1
ZYKADIA,pulmonary tuberculosis,health pulmonary tuberculosis,1
ZYKADIA,pulmonary tuberculosis,physical health pulmonary tuberculosis,1
ZYKADIA,pulmonary tuberculosis,pulmonary tuberculosis,1
ZYKADIA,cardiac tamponade,,0
ZYKADIA,cardiac tamponade,hemorrhage general physical health,0
ZYKADIA,cardiac tamponade,to adverse reactions occurred in o,0
ZYKADIA,cardiac tamponade,therapy due,0
ZYKADIA,sepsis,sepsis,1
ZYKADIA,sepsis,due to adverse reactions occurred in of patients t,0
ZYKADIA,sepsis,pulmonary tuberculosis cardiac tamponade and,0
ZYKADIA,sepsis,sepsis,1
ZYKADIA,sepsis,sepsis,1
ZYKADIA,sepsis,sepsis,1
ZYKADIA,pneumonia,pneumonia,1
ZYKADIA,pneumonia,or more of patients in Study,0
ZYKADIA,pneumonia,pneumonia,1
ZYKADIA,pneumonia,,0
ZYKADIA,pneumonia,to discontinuation in,0
ZYKADIA,pneumonia,of patients in Study,0
ZYKADIA,pneumonia,pneumonia,1
ZYKADIA,pneumonia,,0
ZYKADIA,pneumonia,in or more of patients in Study were,0
ZYKADIA,ILD,Tables and summarize,0
ZYKADIA,Abdominal pain,Abdominal pain,1
ZYKADIA,Abdominal pain,discomfort b,0
ZYKADIA,Abdominal pain,pain upper abdominal,0
ZYKADIA,upper abdominal pain,upper abdominal pain,1
ZYKADIA,upper abdominal pain,,0
ZYKADIA,abdominal discomfort,,0
ZYKADIA,abdominal discomfort,abdominal abdominal discomfort,1
ZYKADIA,epigastric discomfort,epigastric discomfort,1
ZYKADIA,Esophageal disorder,,0
ZYKADIA,dyspepsia,discomfort b Esophageal dyspepsia,1
ZYKADIA,dyspepsia,abdominal discomfort epigastric,0
ZYKADIA,dyspepsia,dyspepsia,1
ZYKADIA,dyspepsia,b Esophageal disorder,0
ZYKADIA,dyspepsia,,0
ZYKADIA,gastroesophageal reflux disease,,0
ZYKADIA,gastroesophageal reflux disease,reflux disease,1
ZYKADIA,gastroesophageal reflux disease,b Esophageal disorder dyspepsia,0
ZYKADIA,gastroesophageal reflux disease,discomfort b Esophageal disorder gastroesophageal reflux disease,1
ZYKADIA,gastroesophageal reflux disease,d Rash rash maculopapular rash acneiform,0
ZYKADIA,gastroesophageal reflux disease,gastroesophageal,1
ZYKADIA,gastroesophageal reflux disease,discomfort b Esophageal,0
ZYKADIA,gastroesophageal reflux disease,pain abdominal discomfort epigastric discomfort b Esophageal,0
ZYKADIA,dysphagia,c Fatigue fatigue asthenia d Rash rash,0
ZYKADIA,dysphagia,dysphagia,1
ZYKADIA,dysphagia,dyspepsia gastroesophageal reflux dysphagia,1
ZYKADIA,dysphagia,,0
ZYKADIA,dysphagia,dysphagia,1
ZYKADIA,Fatigue,,0
ZYKADIA,Fatigue,disease dysphagia Fatigue,1
ZYKADIA,asthenia,asthenia,1
ZYKADIA,asthenia,c Fatigue asthenia,1
ZYKADIA,asthenia,disorder dyspepsia gastroesophageal reflux,0
ZYKADIA,asthenia,,0
ZYKADIA,asthenia,asthenia,1
ZYKADIA,asthenia,Fatigue asthenia,1
ZYKADIA,asthenia,Fatigue asthenia,1
ZYKADIA,asthenia,fatigue,0
ZYKADIA,asthenia,asthenia,1
ZYKADIA,asthenia,dyspepsia gastroesophageal reflux disease dysphagia c Fatigue fatigue,0
ZYKADIA,Rash,c Fatigue fatigue asthenia d,0
ZYKADIA,Rash,rash maculopapular rash acneiform dermatitis ZYKADIAN,0
ZYKADIA,rash,rash,1
ZYKADIA,rash,rash,1
ZYKADIA,rash,ZYKADIAN,0
ZYKADIA,rash,rash,1
ZYKADIA,rash,rash,1
ZYKADIA,rash,fatigue asthenia d Rash,0
ZYKADIA,rash,rash,1
ZYKADIA,rash,rash,1
ZYKADIA,rash,fatigue asthenia,0
ZYKADIA,rash,rash,1
ZYKADIA,acneiform dermatitis,,0
ZYKADIA,acneiform dermatitis,acneiform dermatitis,1
ZYKADIA,Diarrhea,Diarrhea Nausea,1
ZYKADIA,Diarrhea,Diarrhea Nausea,1
ZYKADIA,Diarrhea,Diarrhea Nausea,1
ZYKADIA,Diarrhea,disorders,0
ZYKADIA,Diarrhea,Gastrointestinal Diarrhea Nausea,1
ZYKADIA,Diarrhea,Diarrhea Nausea,1
ZYKADIA,Nausea,Nausea Vomiting,1
ZYKADIA,Nausea,Nausea Vomiting,1
ZYKADIA,Nausea,Diarrhea,0
ZYKADIA,Nausea,,0
ZYKADIA,Nausea,Nausea Vomiting,1
ZYKADIA,Nausea,Vomiting,0
ZYKADIA,Nausea,Diarrhea,0
ZYKADIA,Nausea,Nausea Vomiting,1
ZYKADIA,Vomiting,Nausea,0
ZYKADIA,Abdominal pain,a,0
ZYKADIA,Abdominal pain,pain a Constipation,1
ZYKADIA,Abdominal pain,Vomiting Abdominal pain a,1
ZYKADIA,Abdominal pain,Vomiting Abdominal,1
ZYKADIA,Abdominal pain,Vomiting,0
ZYKADIA,Abdominal pain,Vomiting,0
ZYKADIA,Abdominal pain,Vomiting,0
ZYKADIA,Abdominal pain,Abdominal pain a,1
ZYKADIA,Abdominal pain,Vomiting,0
ZYKADIA,Abdominal pain,Vomiting Abdominal pain,1
ZYKADIA,Constipation,,0
ZYKADIA,Constipation,Constipation,1
ZYKADIA,Constipation,Constipation,1
ZYKADIA,Constipation,Abdominal pain Constipation,1
ZYKADIA,Constipation,Constipation,1
ZYKADIA,Constipation,Constipation,1
ZYKADIA,Constipation,Constipation,1
ZYKADIA,Esophageal disorder,Esophageal disorder b General disorders and,1
ZYKADIA,Esophageal disorder,Constipation,0
ZYKADIA,Esophageal disorder,disorder b General disorders and administration,1
ZYKADIA,Esophageal disorder,Constipation Esophageal disorder b,1
ZYKADIA,Esophageal disorder,disorder b General disorders and,1
ZYKADIA,Esophageal disorder,Constipation,0
ZYKADIA,Esophageal disorder,Constipation Esophageal disorder b General disorders,1
ZYKADIA,Esophageal disorder,Esophageal disorder b,1
ZYKADIA,Esophageal disorder,disorder b,1
ZYKADIA,Esophageal disorder,Constipation Esophageal disorder b,1
ZYKADIA,Fatigue,Fatigue c,1
ZYKADIA,Fatigue,Fatigue c,1
ZYKADIA,Fatigue,,0
ZYKADIA,Fatigue,disorders and administration,0
ZYKADIA,Fatigue,administration site Fatigue c,1
ZYKADIA,Fatigue,Fatigue c,1
ZYKADIA,Fatigue,disorders,0
ZYKADIA,Decreased appetite,Decreased appetite Skin,1
ZYKADIA,Decreased appetite,nutrition Decreased appetite Skin,1
ZYKADIA,Decreased appetite,Metabolism and nutrition Decreased appetite Skin,1
ZYKADIA,Decreased appetite,nutrition Decreased appetite Skin,1
ZYKADIA,Decreased appetite,Decreased appetite Skin,1
ZYKADIA,Rash,tissue Rash d,1
ZYKADIA,Rash,,0
ZYKADIA,Rash,Rash d,1
ZYKADIA,Rash,Rash d,1
ZYKADIA,Rash,d Respiratory,0
ZYKADIA,Rash,,0
ZYKADIA,Rash,Rash d,1
ZYKADIA,Rash,Rash d,1
ZYKADIA,Rash,,0
ZYKADIA,Interstitial lung disease,and mediastinal Interstitial lung disease pneumonitis,1
ZYKADIA,Interstitial lung disease,clinically significant adverse,0
ZYKADIA,Interstitial lung disease,mediastinal Interstitial lung disease pneumonitis,1
ZYKADIA,Interstitial lung disease,Interstitial lung,1
ZYKADIA,Interstitial lung disease,Interstitial lung disease pneumonitis,1
ZYKADIA,Interstitial lung disease,Interstitial lung disease pneumonitis,1
ZYKADIA,Interstitial lung disease,Respiratory thoracic and mediastinal Interstitial,1
ZYKADIA,pneumonitis,Interstitial lung disease,0
ZYKADIA,pneumonitis,and,0
ZYKADIA,pneumonitis,,0
ZYKADIA,neuropathy,neuropathy comprised,1
ZYKADIA,paresthesia,comprised paresthesia muscular,1
ZYKADIA,muscular weakness,paresthesia,0
ZYKADIA,muscular weakness,included neuropathy comprised of muscular,1
ZYKADIA,muscular weakness,of patients treated with ZYKADIA included neuropathy comprised of,0
ZYKADIA,muscular weakness,muscular weakness gait,1
ZYKADIA,muscular weakness,sensory neuropathy,0
ZYKADIA,muscular weakness,muscular weakness gait,1
ZYKADIA,muscular weakness,patients treated with ZYKADIA included neuropathy comprised,0
ZYKADIA,muscular weakness,,0
ZYKADIA,muscular weakness,of muscular weakness gait,1
ZYKADIA,gait disturbance,neuropathy hypoesthesia peripheral sensory,0
ZYKADIA,gait disturbance,muscular,0
ZYKADIA,gait disturbance,gait disturbance peripheral,1
ZYKADIA,gait disturbance,included neuropathy comprised of paresthesia,0
ZYKADIA,gait disturbance,comprised of paresthesia muscular gait,1
ZYKADIA,gait disturbance,comprised of paresthesia muscular gait disturbance peripheral,1
ZYKADIA,gait disturbance,paresthesia muscular gait,1
ZYKADIA,peripheral neuropathy,sensory neuropathy,0
ZYKADIA,peripheral neuropathy,gait peripheral neuropathy hypoesthesia,1
ZYKADIA,peripheral neuropathy,included neuropathy comprised of paresthesia muscular weakness gait,0
ZYKADIA,peripheral neuropathy,hypoesthesia peripheral sensory,0
ZYKADIA,peripheral neuropathy,peripheral neuropathy hypoesthesia,1
ZYKADIA,peripheral neuropathy,neuropathy,0
ZYKADIA,hypoesthesia,,0
ZYKADIA,hypoesthesia,hypoesthesia peripheral,1
ZYKADIA,hypoesthesia,hypoesthesia peripheral,1
ZYKADIA,hypoesthesia,neuropathy dysesthesia neuralgia,0
ZYKADIA,hypoesthesia,hypoesthesia peripheral,1
ZYKADIA,hypoesthesia,comprised,0
ZYKADIA,hypoesthesia,,0
ZYKADIA,hypoesthesia,weakness gait,0
ZYKADIA,hypoesthesia,of paresthesia,0
ZYKADIA,hypoesthesia,muscular,0
ZYKADIA,peripheral sensory neuropathy,,0
ZYKADIA,peripheral sensory neuropathy,neuropathy dysesthesia,1
ZYKADIA,peripheral sensory neuropathy,peripheral sensory neuropathy dysesthesia,1
ZYKADIA,peripheral sensory neuropathy,,0
ZYKADIA,dysesthesia,dysesthesia neuralgia,1
ZYKADIA,dysesthesia,disturbance peripheral neuropathy hypoesthesia peripheral sensory neuropathy,0
ZYKADIA,dysesthesia,sensory,0
ZYKADIA,dysesthesia,gait disturbance peripheral neuropathy hypoesthesia peripheral sensory neuropathy,0
ZYKADIA,dysesthesia,dysesthesia neuralgia,1
ZYKADIA,dysesthesia,,0
ZYKADIA,dysesthesia,neuropathy hypoesthesia peripheral sensory dysesthesia neuralgia,1
ZYKADIA,peripheral motor neuropathy,peripheral motor neuropathy hypotonia,1
ZYKADIA,peripheral motor neuropathy,peripheral sensory neuropathy dysesthesia peripheral motor neuropathy hypotonia,1
ZYKADIA,peripheral motor neuropathy,neuropathy dysesthesia neuralgia,0
ZYKADIA,peripheral motor neuropathy,neuralgia,0
ZYKADIA,peripheral motor neuropathy,peripheral,1
ZYKADIA,peripheral motor neuropathy,neuropathy dysesthesia peripheral motor,1
ZYKADIA,hypotonia,polyneuropathy vision disorder comprised of vision,0
ZYKADIA,hypotonia,,0
ZYKADIA,hypotonia,vision impairment blurred vision photopsia,0
ZYKADIA,hypotonia,vision impairment blurred vision photopsia,0
ZYKADIA,hypotonia,motor,0
ZYKADIA,hypotonia,hypotonia or,1
ZYKADIA,polyneuropathy,,0
ZYKADIA,polyneuropathy,neuropathy hypotonia polyneuropathy vision,1
ZYKADIA,polyneuropathy,motor neuropathy hypotonia polyneuropathy vision,1
ZYKADIA,polyneuropathy,,0
ZYKADIA,polyneuropathy,neuropathy,0
ZYKADIA,polyneuropathy,neuropathy hypotonia polyneuropathy vision,1
ZYKADIA,polyneuropathy,neuropathy dysesthesia neuralgia peripheral,0
ZYKADIA,polyneuropathy,polyneuropathy vision,1
ZYKADIA,vision disorder,motor neuropathy hypotonia or,0
ZYKADIA,vision impairment,hypotonia or,0
ZYKADIA,vision impairment,vision disorder comprised vision impairment blurred,1
ZYKADIA,vision impairment,,0
ZYKADIA,vision impairment,visual acuity,0
ZYKADIA,vision impairment,vision disorder comprised vision,1
ZYKADIA,vision impairment,,0
ZYKADIA,blurred vision,acuity,0
ZYKADIA,blurred vision,,0
ZYKADIA,blurred vision,of vision blurred,1
ZYKADIA,blurred vision,blurred,1
ZYKADIA,blurred vision,comprised of vision blurred vision photopsia,1
ZYKADIA,blurred vision,blurred vision photopsia,1
ZYKADIA,blurred vision,comprised of vision blurred,1
ZYKADIA,photopsia,photopsia accommodation,1
ZYKADIA,photopsia,prolonged,0
ZYKADIA,photopsia,,0
ZYKADIA,photopsia,photopsia accommodation,1
ZYKADIA,photopsia,photopsia accommodation,1
ZYKADIA,photopsia,photopsia accommodation,1
ZYKADIA,photopsia,vision,0
ZYKADIA,photopsia,,0
ZYKADIA,accommodation disorder,impairment,0
ZYKADIA,accommodation disorder,visual acuity prolonged QT interval,0
ZYKADIA,reduced visual acuity,visual acuity prolonged,1
ZYKADIA,reduced visual acuity,visual acuity prolonged,1
ZYKADIA,prolonged QT interval,prolonged QT,1
ZYKADIA,prolonged QT interval,QT interval and,1
ZYKADIA,prolonged QT interval,interval and,1
ZYKADIA,prolonged QT interval,reduced visual acuity,0
ZYKADIA,prolonged QT interval,,0
ZYKADIA,prolonged QT interval,interval and,1
ZYKADIA,prolonged QT interval,reduced visual prolonged,1
ZYKADIA,bradycardia,bradycardia Table,1
ZYKADIA,bradycardia,prolonged QT,0
ZYKADIA,bradycardia,Laboratory Abnormalities Occurring in All NCI CTCAE Grades,0
ZYKADIA,bradycardia,accommodation disorder presbyopia or reduced visual acuity,0
ZYKADIA,bradycardia,bradycardia Table,1
ZYKADIA,bradycardia,QT interval,0
ZYKADIA,bradycardia,presbyopia or reduced visual acuity,0
ZYKADIA,bradycardia,interval bradycardia Table,1
ZYKADIA,bradycardia,Key Laboratory,0
ZYKADIA,Hemoglobin decreased,All Grades Hemoglobin,1
ZYKADIA,Creatinine increased,transaminase AST,0
ZYKADIA,Glucose increased,,0
ZYKADIA,Glucose increased,decreased,0
ZYKADIA,Glucose increased,Glucose increased Phosphate,1
ZYKADIA,Phosphate decreased,,0
ZYKADIA,Lipase increased,Lipase increased Bilirubin,1
ZYKADIA,Lipase increased,Phosphate Lipase increased Bilirubin,1
ZYKADIA,Lipase increased,decreased,0
ZYKADIA,Lipase increased,,0
ZYKADIA,Lipase increased,Phosphate Lipase increased Bilirubin,1
ZYKADIA,Lipase increased,,0
ZYKADIA,Lipase increased,Lipase,1
ZYKADIA,Lipase increased,increased Bilirubin,1
ZYKADIA,Lipase increased,Phosphate Lipase increased Bilirubin,1
ZYKADIA,diarrhea,other sections of the g:,1
ZYKADIA,diarrhea,Hepatoto,0
ZYKADIA,diarrhea,labelin,0
ZYKADIA,diarrhea,of the g:,1
ZYKADIA,diarrhea,g: * Severe,1
ZYKADIA,nausea,Hepatotoxicity,0
ZYKADIA,nausea,,0
ZYKADIA,nausea,the,0
ZYKADIA,nausea,Severe or,1
ZYKADIA,nausea,discussed in greater,0
ZYKADIA,nausea,Severe or,1
ZYKADIA,nausea,,0
ZYKADIA,nausea,,0
ZYKADIA,nausea,see Warnings,0
ZYKADIA,vomiting,,0
ZYKADIA,vomiting,see Warnings and Precautions Hepatotoxicity see,0
ZYKADIA,abdominal pain, Gastrointesti nal,1
ZYKADIA,abdominal pain,Severe or,0
ZYKADIA,abdominal pain,or Persistent,0
ZYKADIA,abdominal pain,Precautions,0
ZYKADIA,abdominal pain,discussed in,0
ZYKADIA,abdominal pain, Gastrointesti nal,1
ZYKADIA,abdominal pain, Gastrointesti nal,1
ZYKADIA,abdominal pain, Gastrointesti nal,1
ZYKADIA,Hepatotoxicity,,0
ZYKADIA,Hepatotoxicity,Interstitial Lung umonitis [see  Warnings,1
ZYKADIA,Hepatotoxicity,Lung umonitis [see  Warnings,1
ZYKADIA,Hepatotoxicity,Precautions,0
ZYKADIA,Hepatotoxicity,umonitis [see Warnings,1
ZYKADIA,Hepatotoxicity,umonitis [see Warnings,1
ZYKADIA,hepatotoxicity,(5.3)] QT,1
ZYKADIA,Interstitial Lung Disease,,0
ZYKADIA,ILD,yca rdia,1
ZYKADIA,ILD,and Precautions yca rdia,1
ZYKADIA,ILD,Warnings and Precautions yca rdia,1
ZYKADIA,Pneumonitis,,0
ZYKADIA,Pneumonitis,,0
ZYKADIA,Pneumonitis,and Precautions ia [see War nings,1
ZYKADIA,QT Interval Prolongation,The most mon adverse reactions,1
ZYKADIA,QTc interval prolongation,nausea elevated,1
ZYKADIA,QTc interval prolongation,Precautions EXCERPT The most,0
ZYKADIA,QTc interval prolongation,most common adverse,0
ZYKADIA,QTc interval prolongation,nausea elevated,1
ZYKADIA,QTc interval prolongation,reactions incidence of at 25%),1
ZYKADIA,Hyperglycemia,obse,0
ZYKADIA,Hyperglycemia," Experience

 Because",1
ZYKADIA,Bradycardia,of Z YKADIA,1
ZYKADIA,Bradycardia,The safety,0
ZYKADIA,Bradycardia,Z YKADIA,1
ZYKADIA,bradycardia,in Study patients with NSCLC,0
ZYKADIA,bradycardia,5 ALK-posit ive,1
ZYKADIA,bradycardia,and patients with,0
ZYKADIA,bradycardia,in,0
ZYKADIA,Pancreatitis,daily The,0
ZYKADIA,Pancreatitis,,0
ZYKADIA,Pancreatitis,daily The dian duratio n,1
ZYKADIA,Pancreatitis,The dian,1
ZYKADIA,Pancreatitis,mg daily The dian duratio n,1
ZYKADIA,Elevations of lipase,to ZYKADI A,1
ZYKADIA,Elevations of lipase,,0
ZYKADIA,Elevations of lipase,exposure to ZYKADI A,1
ZYKADIA,Elevations of lipase,age years age,0
ZYKADIA,Elevations of lipase,who received ZYKADIA at,0
ZYKADIA,Elevations of lipase,months The study population characteristics were median,0
ZYKADIA,pancreatitis,months The,0
ZYKADIA,pancreatitis,months study,1
ZYKADIA,Embryofetal Toxicity,number of prior,0
ZYKADIA,Embryofetal Toxicity,,0
ZYKADIA,Embryofetal Toxicity,"female Caucasian Asian NSCLC a histology (90%), n ever",1
ZYKADIA,Embryofetal Toxicity,"Asian NSCLC a histology (90%), n ever",1
ZYKADIA,Embryofetal Toxicity,PS or brain metastasis and,0
ZYKADIA,Diarrhea,in at least of patients that led to dose reduc,0
ZYKADIA,Diarrhea,of patients treated h,1
ZYKADIA,Diarrhea,patients treated wit,0
ZYKADIA,Diarrhea,reported in at,0
ZYKADIA,Diarrhea,to,0
ZYKADIA,Diarrhea,in at least of patients that led to dose reduc,0
ZYKADIA,Diarrhea,reactions reported in at least of patients that led to dose,0
ZYKADIA,Diarrhea,h ZYKADI A,1
ZYKADIA,Diarrhea,patients treated,0
ZYKADIA,nausea,with The,1
ZYKADIA,nausea,ZYKADIA,0
ZYKADIA,nausea,patients that led to dose,0
ZYKADIA,nausea,with ZYKADIA,0
ZYKADIA,nausea,The m ost,1
ZYKADIA,nausea,The m ost,1
ZYKADIA,nausea,The m ost,1
ZYKADIA,nausea,,0
ZYKADIA,nausea,treated with,0
ZYKADIA,nausea,reductions,0
ZYKADIA,nausea,of,0
ZYKADIA,nausea,of patients treated with The,1
ZYKADIA,vomiting,with,0
ZYKADIA,vomiting,least of patients that led to,0
ZYKADIA,vomiting,to adverse reactions occurred in of patients,0
ZYKADIA,vomiting,of patients treated with ZYKADIA The,0
ZYKADIA,vomiting,patients that,0
ZYKADIA,vomiting,,0
ZYKADIA,vomiting,of,0
ZYKADIA,vomiting,nt adverse reactions reported,0
ZYKADIA,abdominal pain,verse reaction s,1
ZYKADIA,abdominal pain,of patients treated with ZYKADIA The most frequent ad,0
ZYKADIA,abdominal pain,in at least of patients that led to dose reductions or interruptions were increase,0
ZYKADIA,abdominal pain,ZYKADIA The most frequent verse reaction s,1
ZYKADIA,abdominal pain,,0
ZYKADIA,abdominal pain,dose,0
ZYKADIA,abdominal pain,reductions or interruptions were,0
ZYKADIA,abdominal pain,most frequent verse,1
ZYKADIA,abdominal pain,reaction s,1
ZYKADIA,abdominal pain,verse reaction s,1
ZYKADIA,abdominal pain,The most frequent verse,1
ZYKADIA,abdominal pain,in of,0
ZYKADIA,diarrhea,,0
ZYKADIA,diarrhea,vomiting Serious adverse drug reactions reported in or more of,0
ZYKADIA,diarrhea,nausea sed,1
ZYKADIA,diarrhea,were increased ALT nausea sed AST  diarrhea,1
ZYKADIA,nausea,"increased 6%),",1
ZYKADIA,nausea,"increased 6%), d iarrhea",1
ZYKADIA,nausea,or more of patients,0
ZYKADIA,nausea,"ALT nausea increased 6%),",1
ZYKADIA,nausea,patients,0
ZYKADIA,nausea,nausea increased,0
ZYKADIA,nausea,drug reactions,0
ZYKADIA,vomiting,rrhea (1 and,1
ZYKADIA,vomiting,(1 and,1
ZYKADIA,vomiting,rrhea (1 and,1
ZYKADIA,vomiting,nausea increased AST,0
ZYKADIA,abdominal pain,AST and vomiting,1
ZYKADIA,abdominal pain,ALT nausea increased AST and vomiting ( Serious,1
ZYKADIA,abdominal pain,vomiting ( Serious,1
ZYKADIA,abdominal pain,in or more of patients in Study were,0
ZYKADIA,abdominal pain,,0
ZYKADIA,abdominal pain,increased AST and,1
ZYKADIA,abdominal pain,,0
ZYKADIA,abdominal pain,,0
ZYKADIA,hepatotoxicity,,0
ZYKADIA,hepatotoxicity,,0
ZYKADIA,hepatotoxicity,"hemorrhage general physical health ion, pulmonary tuberculosis",1
ZYKADIA,hepatotoxicity,to adv,0
ZYKADIA,hepatotoxicity,"health ion,",1
ZYKADIA,hepatotoxicity,general,0
ZYKADIA,hepatotoxicity,"ion, pulmonary tuberculosis",1
ZYKADIA,hepatotoxicity,,0
ZYKADIA,Elevations in alanine aminotransferase,each). Discontinuation of therapy,1
ZYKADIA,Elevations in alanine aminotransferase, (1 patient each). Discontinuation of  therapy,1
ZYKADIA,jaundice, pneumon ia,1
ZYKADIA,jaundice,drug reactions that led to discontinuation in or more of,0
ZYKADIA,jaundice, pneumon ia,1
ZYKADIA,jaundice,in or,0
ZYKADIA,jaundice,and summarize,0
ZYKADIA,elevations in ALT,,0
ZYKADIA,elevations in ALT,,0
ZYKADIA,elevations in ALT,"pneumonia onitis,",1
ZYKADIA,elevations in ALT,,0
ZYKADIA,elevations in ALT,"onitis, and decre ased",1
ZYKADIA,elevations in ALT,"in Study were pneumonia onitis, and",1
ZYKADIA,elevations in ALT,and decre ased,1
ZYKADIA,elevations in ALT,"in Study were pneumonia onitis, and decre ased",1
ZYKADIA,fatal,      Grade,1
ZYKADIA,fatal,dermatitis ZYKADIAN,0
ZYKADIA,fatal,dermatitis ZYKADIAN All       Grade,1
ZYKADIA,fatal,Grades,0
ZYKADIA,fatal,All Grades,0
ZYKADIA,fatal,      Grade,1
ZYKADIA,fatal,ZYKADIAN,0
ZYKADIA,fatal,All       Grade,1
ZYKADIA,fatal,All       Grade,1
ZYKADIA,ILD,,0
ZYKADIA,ILD,,0
ZYKADIA,ILD,rad e,1
ZYKADIA,ILD,,0
ZYKADIA,ILD,All Grades rad e,1
ZYKADIA,ILD,rad e,1
ZYKADIA,ILD,rad e,1
ZYKADIA,ILD,Grades,0
ZYKADIA,ILD,Grades,0
ZYKADIA,ILD,All Grades rad e,1
ZYKADIA,ILD,e Gastrointestinal,0
ZYKADIA,ILD,rad e,1
ZYKADIA,ILD,,0
ZYKADIA,pneumonitis, 3-4        Gastrointestinal,1
ZYKADIA,pneumonitis,dermatitis ZYKADIAN All Grades,0
ZYKADIA,pneumonitis, 3-4        Gastrointestinal,1
ZYKADIA,pneumonitis, 3-4        Gastrointestinal,1
ZYKADIA,pneumonitis,dermatitis ZYKADIAN All,0
ZYKADIA,pneumonitis, 3-4        Gastrointestinal,1
ZYKADIA,pneumonitis,,0
ZYKADIA,pneumonitis,Gastrointestinal,0
ZYKADIA,pneumonitis, 3-4        Gastrointestinal,1
ZYKADIA,pneumonitis,Grades  3-4        Gastrointestinal,1
ZYKADIA,pneumonitis, Gastrointe stinal,1
ZYKADIA,pneumonitis, Gastrointe stinal,1
ZYKADIA,pneumonitis,,0
ZYKADIA,pneumonitis,Grades,0
ZYKADIA,ILD,,0
ZYKADIA,pneumonitis,Diarrhea,0
ZYKADIA,pneumonitis,          6 Nausea,1
ZYKADIA,pneumonitis,          6 Nausea,1
ZYKADIA,pneumonitis,,0
ZYKADIA,pneumonitis,disorders Diarrhea,0
ZYKADIA,pneumonitis,          6 Nausea,1
ZYKADIA,pneumonitis,disorders           6 Nausea,1
ZYKADIA,pneumonitis,          6 Nausea,1
ZYKADIA,pneumonitis,          6 Nausea,1
ZYKADIA,pneumonitis,          6 Nausea,1
ZYKADIA,fatal,0     Vomiting,1
ZYKADIA,ILD,    Vomiting,1
ZYKADIA,ILD,    Vomiting,1
ZYKADIA,ILD,,0
ZYKADIA,ILD,,0
ZYKADIA,ILD,,0
ZYKADIA,pneumonitis,,0
ZYKADIA,pneumonitis,,0
ZYKADIA,pneumonitis,,0
ZYKADIA,pneumonitis,      4     Vomiting,1
ZYKADIA,pneumonitis,      4     Vomiting,1
ZYKADIA,pneumonitis,      4     Vomiting,1
ZYKADIA,pneumonitis,      4     Vomiting,1
ZYKADIA,pneumonitis,      4     Vomiting,1
ZYKADIA,pneumonitis,Diarrhea       4     Vomiting,1
ZYKADIA,pneumonitis,Nausea,0
ZYKADIA,ILD,,0
ZYKADIA,ILD,Abdominal pain a,0
ZYKADIA,ILD,    Constipation,1
ZYKADIA,ILD,,0
ZYKADIA,ILD,Constipation Esophageal disorder b,0
ZYKADIA,ILD,    Constipation,1
ZYKADIA,ILD,pain     Constipation,1
ZYKADIA,ILD,Abdominal pain     Constipation,1
ZYKADIA,ILD,,0
ZYKADIA,pneumonitis,            Constipation,1
ZYKADIA,pneumonitis,,0
ZYKADIA,QTc interval prolongation,"           
     Decrease d",1
ZYKADIA,QTc interval prolongation,disorders,0
ZYKADIA,QTc interval prolongation,and nutrition,0
ZYKADIA,ventricular tachyarrhythmias,,0
ZYKADIA,ventricular tachyarrhythmias,and subcutaneo us,1
ZYKADIA,ventricular tachyarrhythmias,,0
ZYKADIA,ventricular tachyarrhythmias,d,0
ZYKADIA,ventricular tachyarrhythmias,subcutaneo us,1
ZYKADIA,Torsade de pointes,Respirator,0
ZYKADIA,Torsade de pointes,tissu,0
ZYKADIA,QTc interval increase,sorders               Interstitial,1
ZYKADIA,QTc interval increase,,0
ZYKADIA,increase from baseline QTc,"neuropathy omprised of paresthesia, m uscular",1
ZYKADIA,increase from baseline QTc,"of paresthesia, m uscular",1
ZYKADIA,increase from baseline QTc,"omprised of paresthesia,",1
ZYKADIA,increase from baseline QTc,m uscular,1
ZYKADIA,increase from baseline QTc,"included neuropathy omprised of paresthesia, m uscular",1
ZYKADIA,increase from baseline QTc,with ZYKADIA,0
ZYKADIA,increase from baseline QTc,,0
ZYKADIA,increases in the QTc interval,neuropathy,0
ZYKADIA,increases in the QTc interval,vision impa,0
ZYKADIA,increases in the QTc interval,"dysesthesia, neuralgia, perip heral",1
ZYKADIA,increases in the QTc interval,perip heral,1
ZYKADIA,increases in the QTc interval,disorder comprised of,0
ZYKADIA,increases in the QTc interval,,0
ZYKADIA,Hyperglycemia,"Phosphate     
     Lip ase",1
ZYKADIA,Hyperglycemia,"eased Phosphate     
     Lip ase",1
ZYKADIA,hyperglycemia,al) increased,1
ZYKADIA,hyperglycemia,,0
ZYKADIA,hyperglycemia,,0
ZYKADIA,hyperglycemia,,0
ZYKADIA,hyperglycemia,,0
ZYKADIA,hyperglycemia,,1
ZYKADIA,hyperglycemia,,1
ZYKADIA,hyperglycemia,,1
ZYKADIA,hyperglycemia,,0
ZYKADIA,hyperglycemia,,0
ZYKADIA,Bradycardia,,1
ZYKADIA,Bradycardia,,1
ZYKADIA,Bradycardia,,1
ZYKADIA,Bradycardia,,1
ZYKADIA,Bradycardia,,0
ZYKADIA,Bradycardia,,1
ZYKADIA,Bradycardia,,0
ZYKADIA,sinus bradycardia,,1
ZYKADIA,sinus bradycardia,,1
ZYKADIA,sinus bradycardia,,1
ZYKADIA,sinus bradycardia,,0
ZYKADIA,sinus bradycardia,,1
ZYKADIA,sinus bradycardia,,0
ZYKADIA,heart rate of less than 50 beats per minute,,1
ZYKADIA,heart rate of less than 50 beats per minute,,1
ZYKADIA,heart rate of less than 50 beats per minute,,1
ZYKADIA,heart rate of less than 50 beats per minute,,0
ZYKADIA,heart rate of less than 50 beats per minute,,1
ZYKADIA,heart rate of less than 50 beats per minute,,0
ZYKADIA,heart rate of less than 50 beats per minute,,1
ZYKADIA,heart rate of less than 50 beats per minute,,0
ZYKADIA,heart rate of less than 50 beats per minute,,0
ZYKADIA,Bradycardia,,1
ZYKADIA,Bradycardia,,1
ZYKADIA,Bradycardia,,1
ZYKADIA,Bradycardia,,1
ZYKADIA,Bradycardia,,0
ZYKADIA,Bradycardia,,0
ZYKADIA,Bradycardia,,0
ZYKADIA,Bradycardia,,1
ZYKADIA,Bradycardia,,0
ZYKADIA,Pancreatitis,,0
ZYKADIA,Pancreatitis,,1
ZYKADIA,Pancreatitis,,0
ZYKADIA,Pancreatitis,,1
ZYKADIA,Pancreatitis,,0
ZYKADIA,Pancreatitis,,0
ZYKADIA,Pancreatitis,,0
ZYKADIA,Pancreatitis,,0
ZYKADIA,Pancreatitis,,1
ZYKADIA,fatality,,1
ZYKADIA,fatality,,0
ZYKADIA,fatality,,0
ZYKADIA,fatality,,1
ZYKADIA,fatality,,1
ZYKADIA,elevations of lipase,,0
ZYKADIA,elevations of lipase,,0
ZYKADIA,elevations of lipase,,0
ZYKADIA,elevations of lipase,,1
ZYKADIA,elevations of lipase,,1
ZYKADIA,elevations of lipase,,1
ZYKADIA,elevations of lipase,,0
ZYKADIA,elevations of lipase,,1
ZYKADIA,elevations of lipase,,0
ZYKADIA,elevations of lipase,,0
ZYKADIA,increases in skeletal anomalies,,1
ZYKADIA,increases in skeletal anomalies,,1
ZYKADIA,increases in skeletal anomalies,,1
ZYKADIA,increases in skeletal anomalies,,1
ZYKADIA,increases in skeletal anomalies,,0
ZYKADIA,increases in skeletal anomalies,,1
ZYKADIA,increases in skeletal anomalies,,0
ZYKADIA,increases in skeletal anomalies,,0
ZYKADIA,increases in skeletal anomalies,,0
ZYKADIA,increases in skeletal anomalies,,0
CHOLINE,injection site reaction,,0
CHOLINE,injection site reaction,reaction,1
CHOLINE,injection site reaction,,0
CHOLINE,injection site reaction,injection site reaction,1
CHOLINE,injection site reaction,have,0
CHOLINE,injection site reaction,injection site reaction,1
CHOLINE,injection site reaction,site reaction,1
CHOLINE,injection site reaction,injection site reaction,1
CHOLINE,injection site reaction,,0
CHOLINE,injection site reaction,adverse reactions have been reported To report,0
CHOLINE,Allergic reactions,other adverse reactions have,0
CHOLINE,Allergic reactions,reported To report,0
CHOLINE,Radiation risk,ERSE REACTIONS contact Division of Nuclear Medicine,0
CHOLINE,Radiation risk,,0
CHOLINE,Radiation risk,site reaction no other adverse,0
CHOLINE,allergic reactions,,1
CHOLINE,allergic reactions,,0
CHOLINE,allergic reactions,,1
CHOLINE,allergic reactions,,1
CHOLINE,allergic reactions,,0
CHOLINE,allergic reactions,,0
CHOLINE,allergic reactions,,1
CHOLINE,allergic reactions,,1
CHOLINE,allergic reactions,,1
CHOLINE,anaphylaxis,,1
CHOLINE,anaphylaxis,,0
CHOLINE,anaphylaxis,,1
CHOLINE,cancer,,1
CHOLINE,cancer,,1
CHOLINE,cancer,,1
CHOLINE,cancer,,1
CHOLINE,cancer,,0
CHOLINE,cancer,,0
CHOLINE,cancer,,1
CHOLINE,cancer,,1
ERWINAZE,Hypersensitivity reactions,the Hypersensitivity reactions,1
ERWINAZE,Hypersensitivity reactions,,0
ERWINAZE,Hypersensitivity reactions,of,0
ERWINAZE,Hypersensitivity reactions,Precautions Pancreatitis see,0
ERWINAZE,Hypersensitivity reactions,other sections of the Hypersensitivity reactions,1
ERWINAZE,Hypersensitivity reactions,Hypersensitivity reactions,1
ERWINAZE,Hypersensitivity reactions,Hypersensitivity reactions,1
ERWINAZE,Pancreatitis,Pancreatitis,1
ERWINAZE,Pancreatitis,Pancreatitis,1
ERWINAZE,Pancreatitis,Pancreatitis,1
ERWINAZE,Pancreatitis,Pancreatitis,1
ERWINAZE,Pancreatitis,see Warnings and Pancreatitis,1
ERWINAZE,Pancreatitis,Pancreatitis,1
ERWINAZE,Glucose intolerance,see Warnings and Glucose intolerance,1
ERWINAZE,Glucose intolerance,Glucose intolerance,1
ERWINAZE,Glucose intolerance,Pancreatitis see,0
ERWINAZE,Glucose intolerance,and Glucose,1
ERWINAZE,Glucose intolerance,,0
ERWINAZE,Thrombosis,and Thrombosis,1
ERWINAZE,Thrombosis,Thrombosis,1
ERWINAZE,Thrombosis,intolerance see Warnings and Thrombosis,1
ERWINAZE,Thrombosis,Thrombosis,1
ERWINAZE,Thrombosis,and Precautions Glucose intolerance see Warnings and,0
ERWINAZE,Thrombosis,Thrombosis,1
ERWINAZE,Thrombosis,and Precautions The most common adverse reactions incid,0
ERWINAZE,Thrombosis,,0
ERWINAZE,Thrombosis,Thrombosis,1
ERWINAZE,hemorrhage,,0
ERWINAZE,hemorrhage,The most common,0
ERWINAZE,systemic hypersensitivity,with ERWINAZE treatment systemic,1
ERWINAZE,systemic hypersensitivity,systemic hypersensitivity,1
ERWINAZE,systemic hypersensitivity,pancreatitis local reactions vomiting nausea thr,0
ERWINAZE,hyperglycemia,hyperglycemia,1
ERWINAZE,hyperglycemia,are systemic hypersensitivity,0
ERWINAZE,hyperglycemia,hyperglycemia,1
ERWINAZE,transaminases abnormal,nausea,0
ERWINAZE,transaminases abnormal,thrombosis hyperbilirubinemia,0
ERWINAZE,transaminases abnormal,fever,0
ERWINAZE,transaminases abnormal,thrombosis hyperbilirubinemia abdominal,0
ERWINAZE,transaminases abnormal,hypersensitivity transaminases abnormal,1
ERWINAZE,transaminases abnormal,are systemic hypersensitivity hyperglycemia,0
ERWINAZE,transaminases abnormal,systemic hypersensitivity transaminases,1
ERWINAZE,transaminases abnormal,systemic hypersensitivity transaminases,1
ERWINAZE,transaminases abnormal,are systemic hypersensitivity transaminases,1
ERWINAZE,transaminases abnormal,treatment are systemic hypersensitivity transaminases,1
ERWINAZE,fever,treatment are systemic hypersensitivity hyperglycemia,0
ERWINAZE,fever,fever,1
ERWINAZE,fever,fever,1
ERWINAZE,fever,fever,1
ERWINAZE,fever,,0
ERWINAZE,fever,fever,1
ERWINAZE,fever,fever,1
ERWINAZE,fever,reactions vomiting nausea,0
ERWINAZE,fever,hypersensitivity hyperglycemia transaminases fever,1
ERWINAZE,pancreatitis,pancreatitis,1
ERWINAZE,pancreatitis,hypersensitivity hyperglycemia transaminases,0
ERWINAZE,pancreatitis,transaminases abnormal pancreatitis,1
ERWINAZE,pancreatitis,pancreatitis,1
ERWINAZE,pancreatitis,,0
ERWINAZE,pancreatitis,hyperglycemia transaminases abnormal,0
ERWINAZE,pancreatitis,pancreatitis,1
ERWINAZE,pancreatitis,abdominal paindiscomfort,0
ERWINAZE,pancreatitis,pancreatitis,1
ERWINAZE,pancreatitis,,0
ERWINAZE,local reactions,thrombosis hyperbilirubinemia abdominal paindiscomfort and diarrhea,0
ERWINAZE,local reactions,vomiting nausea thrombosis,0
ERWINAZE,local reactions,transaminases abnormal fever local reactions,1
ERWINAZE,local reactions,local reactions,1
ERWINAZE,local reactions,reactions,1
ERWINAZE,local reactions,reactions,1
ERWINAZE,local reactions,abnormal,0
ERWINAZE,vomiting,abnormal fever pancreatitis local vomiting,1
ERWINAZE,vomiting,abdominal paindiscomfort and diarrhea,0
ERWINAZE,vomiting,vomiting,1
ERWINAZE,vomiting,pancreatitis local,0
ERWINAZE,vomiting,local vomiting,1
ERWINAZE,vomiting,,0
ERWINAZE,vomiting,vomiting,1
ERWINAZE,nausea,abdominal paindiscomfort,0
ERWINAZE,nausea,abnormal fever pancreatitis local reactions vomiting,0
ERWINAZE,nausea,abdominal paindiscomfort and,0
ERWINAZE,nausea,nausea,1
ERWINAZE,nausea,nausea,1
ERWINAZE,nausea,and diarrhea,0
ERWINAZE,nausea,,0
ERWINAZE,thrombosis,vomiting,0
ERWINAZE,thrombosis,common adverse,0
ERWINAZE,thrombosis,thrombosis,1
ERWINAZE,thrombosis,thrombosis,1
ERWINAZE,hyperbilirubinemia,reactions,0
ERWINAZE,hyperbilirubinemia,local reactions,0
ERWINAZE,hyperbilirubinemia,abnormal fever,0
ERWINAZE,hyperbilirubinemia,hyperbilirubinemia,1
ERWINAZE,hyperbilirubinemia,pancreatitis,0
ERWINAZE,hyperbilirubinemia,fever pancreatitis local reactions,0
ERWINAZE,hyperbilirubinemia,hyperbilirubinemia,1
ERWINAZE,hyperbilirubinemia,hyperbilirubinemia,1
ERWINAZE,hyperbilirubinemia,abdominal paindiscomfort and diarrhea,0
ERWINAZE,hyperbilirubinemia,hyperbilirubinemia,1
ERWINAZE,abdominal pain,,0
ERWINAZE,abdominal pain,and diarrhea EXCERPT Most,0
ERWINAZE,abdominal pain,hyperbilirubinemia,0
ERWINAZE,abdominal pain,,0
ERWINAZE,abdominal pain,thrombosis abdominal,1
ERWINAZE,abdominal pain,pancreatitis local reactions,0
ERWINAZE,abdominal pain,vomiting nausea thrombosis abdominal,1
ERWINAZE,abdominal pain,abdominal pain,1
ERWINAZE,diarrhea,common adverse reactions incidence,0
ERWINAZE,diarrhea,common adverse reactions incidence or greater are systemic,0
ERWINAZE,diarrhea,paindiscomfort and,0
ERWINAZE,diarrhea,diarrhea,1
ERWINAZE,diarrhea,abdominal paindiscomfort diarrhea,1
ERWINAZE,diarrhea,hyperbilirubinemia abdominal paindiscomfort diarrhea,1
ERWINAZE,diarrhea,thrombosis hyperbilirubinemia abdominal paindiscomfort diarrhea,1
ERWINAZE,systemic hypersensitivity,or greater systemic,1
ERWINAZE,systemic hypersensitivity,reactions incidence or greater systemic hypersensitivity,1
ERWINAZE,systemic hypersensitivity,,0
ERWINAZE,systemic hypersensitivity,or greater systemic,1
ERWINAZE,systemic hypersensitivity,hypersensitivity,1
ERWINAZE,systemic hypersensitivity,abnormal fever pancreatitis local reactions,0
ERWINAZE,systemic hypersensitivity,,0
ERWINAZE,systemic hypersensitivity,vomiting nausea,0
ERWINAZE,systemic hypersensitivity,greater systemic hypersensitivity,1
ERWINAZE,hyperglycemia,,0
ERWINAZE,hyperglycemia,,0
ERWINAZE,hyperglycemia,,0
ERWINAZE,hyperglycemia,reactions incidence or greater,0
ERWINAZE,hyperglycemia,,0
ERWINAZE,hyperglycemia,hyperglycemia,1
ERWINAZE,hyperglycemia,,0
ERWINAZE,transaminases abnormal,are systemic hypersensitivity transaminases,1
ERWINAZE,transaminases abnormal,greater are systemic hypersensitivity transaminases abnormal,1
ERWINAZE,transaminases abnormal,transaminases,1
ERWINAZE,transaminases abnormal,,0
ERWINAZE,transaminases abnormal,hyperglycemia,0
ERWINAZE,transaminases abnormal,systemic hypersensitivity transaminases,1
ERWINAZE,transaminases abnormal,greater are systemic hypersensitivity transaminases abnormal,1
ERWINAZE,transaminases abnormal,,0
ERWINAZE,transaminases abnormal,reactions incidence or greater are systemic,0
ERWINAZE,transaminases abnormal,abnormal,1
ERWINAZE,fever,or greater are,0
ERWINAZE,fever,or greater,0
ERWINAZE,fever,fever,1
ERWINAZE,fever,transaminases,0
ERWINAZE,fever,fever,1
ERWINAZE,fever,transaminases fever,1
ERWINAZE,fever,fever,1
ERWINAZE,fever,hyperglycemia transaminases fever,1
ERWINAZE,fever,greater,0
ERWINAZE,pancreatitis,or greater are systemic hypersensitivity,0
ERWINAZE,pancreatitis,,0
ERWINAZE,pancreatitis,,0
ERWINAZE,pancreatitis,pancreatitis,1
ERWINAZE,pancreatitis,systemic hypersensitivity hyperglycemia transaminases abnormal fever,0
ERWINAZE,local reactions,local reactions,1
ERWINAZE,local reactions,are systemic,0
ERWINAZE,local reactions,pancreatitis,0
ERWINAZE,nausea,,0
ERWINAZE,nausea,fever pancreatitis local reactions nausea,1
ERWINAZE,nausea,reactions nausea,1
ERWINAZE,nausea,hyperbilirubinemia abdominal paindiscomfort and diarrhea To,0
ERWINAZE,nausea,nausea,1
ERWINAZE,nausea,,0
ERWINAZE,thrombosis,thrombosis,1
ERWINAZE,thrombosis,thrombosis,1
ERWINAZE,thrombosis,diarrhea To,0
ERWINAZE,hyperbilirubinemia,hyperbilirubinemia,1
ERWINAZE,hyperbilirubinemia,abnormal fever pancreatitis local reactions,0
ERWINAZE,hyperbilirubinemia,thrombosis,0
ERWINAZE,hyperbilirubinemia,transaminases abnormal fever pancreatitis local reactions vomiting,0
ERWINAZE,hyperbilirubinemia,and diarrhea To report SUSPECTED ADVERSE REACTIONS contact,0
ERWINAZE,hyperbilirubinemia,To report,0
ERWINAZE,hyperbilirubinemia,hyperbilirubinemia,1
ERWINAZE,hyperbilirubinemia,hyperbilirubinemia,1
ERWINAZE,hyperbilirubinemia,hyperbilirubinemia,1
ERWINAZE,abdominal pain,SUSPECTED ADVERSE REACTIONS,0
ERWINAZE,abdominal pain,SUSPECTED ADVERSE REACTIONS contact Jazz Pharmaceuticals Inc,0
ERWINAZE,abdominal pain,pain,1
ERWINAZE,abdominal pain,reactions vomiting nausea,0
ERWINAZE,abdominal pain,pain,1
ERWINAZE,allergic reactions,patients stopped therapy prior to completion seven due to,0
ERWINAZE,allergic reactions,completion seven due allergic reactions,1
ERWINAZE,allergic reactions,,0
ERWINAZE,allergy,allergy,1
ERWINAZE,allergy,allergy,1
ERWINAZE,allergy,adverse events were reported for the following adverse events,0
ERWINAZE,allergy,events of special allergy,1
ERWINAZE,allergy,the,0
ERWINAZE,pancreatitis,,0
ERWINAZE,pancreatitis,were reported for the following adverse events of special,0
ERWINAZE,pancreatitis,the following adverse events of,0
ERWINAZE,pancreatitis,thrombosis or infarct hyperbilirubinemia,0
ERWINAZE,pancreatitis,,0
ERWINAZE,pancreatitis,were reported for the following adverse events of special interest,0
ERWINAZE,coagulopathy,coagulopathy,1
ERWINAZE,coagulopathy,,0
ERWINAZE,coagulopathy,coagulopathy,1
ERWINAZE,coagulopathy,coagulopathy,1
ERWINAZE,coagulopathy,,0
ERWINAZE,hemorrhage,hemorrhage,1
ERWINAZE,hemorrhage,allergy pancreatitis,0
ERWINAZE,hemorrhage,hemorrhage,1
ERWINAZE,hemorrhage,or infarct hyperbilirubinemia hyperglycemia,0
ERWINAZE,hemorrhage,,0
ERWINAZE,thrombosis,thrombosis,1
ERWINAZE,thrombosis,coagulopathy thrombosis,1
ERWINAZE,thrombosis,thrombosis,1
ERWINAZE,thrombosis,hyperbilirubinemia hyperglycemia,0
ERWINAZE,thrombosis,pancreatitis coagulopathy thrombosis,1
ERWINAZE,thrombosis,thrombosis,1
ERWINAZE,thrombosis,thrombosis,1
ERWINAZE,thrombosis,,0
ERWINAZE,thrombosis,coagulopathy,0
ERWINAZE,thrombosis,adverse events of special interest allergy pancreatitis coagulopathy hemorrhage,0
ERWINAZE,infarct,of,0
ERWINAZE,hyperbilirubinemia,hyperbilirubinemia,1
ERWINAZE,hyperbilirubinemia,,0
ERWINAZE,hyperbilirubinemia,events hemorrhage thrombosis or,0
ERWINAZE,hyperbilirubinemia,pancreatitis coagulopathy hemorrhage,0
ERWINAZE,hyperbilirubinemia,,0
ERWINAZE,hyperbilirubinemia,or infarction,0
ERWINAZE,hyperbilirubinemia,hemorrhage thrombosis or hyperbilirubinemia,1
ERWINAZE,hyperbilirubinemia,hyperglycemia,0
ERWINAZE,hyperbilirubinemia,hyperbilirubinemia,1
ERWINAZE,hyperbilirubinemia,or hyperbilirubinemia,1
ERWINAZE,hyperglycemia,hyperbilirubinemia,0
ERWINAZE,hyperglycemia,infarct hyperglycemia,1
ERWINAZE,hyperglycemia,,0
ERWINAZE,hyperglycemia,infarct,0
ERWINAZE,hyperglycemia,,0
ERWINAZE,hyperglycemia,hyperglycemia,1
ERWINAZE,hyperglycemia,hemorrhage thrombosis or,0
ERWINAZE,hyperglycemia,hyperglycemia,1
ERWINAZE,hyperglycemia,pancreatitis coagulopathy hemorrhage thrombosis or infarct hyperbilirubinemia,0
ERWINAZE,hyperglycemia,hyperglycemia,1
ERWINAZE,hyperlipidemia,hyperbilirubinemia hyperglycemia,0
ERWINAZE,hyperlipidemia,thrombosis or infarct hyperbilirubinemia hyperlipidemia,1
ERWINAZE,hyperlipidemia,hemorrhage thrombosis,0
ERWINAZE,hyperlipidemia,or infarct hyperbilirubinemia hyperlipidemia,1
ERWINAZE,ketoacidosis,or infarct hyperbilirubinemia hyperglycemia ketoacidosis,1
ERWINAZE,ketoacidosis,ketoacidosis,1
ERWINAZE,ketoacidosis,or infarction and cerebral venous thrombosis and only,0
ERWINAZE,ketoacidosis,ketoacidosis,1
ERWINAZE,ketoacidosis,hyperbilirubinemia hyperglycemia hyperlipidemia,0
ERWINAZE,ketoacidosis,ketoacidosis,1
ERWINAZE,ketoacidosis,hyperglycemia ketoacidosis,1
ERWINAZE,ketoacidosis,,0
ERWINAZE,ketoacidosis,infarction and cerebral venous thrombosis and only,0
ERWINAZE,CNS events,thrombosis or infarct hyperbilirubinemia,0
ERWINAZE,CNS events,,0
ERWINAZE,CNS events,hyperbilirubinemia hyperglycemia hyperlipidemia ketoacidosis CNS,1
ERWINAZE,CNS events,,0
ERWINAZE,CNS events,hyperlipidemia ketoacidosis CNS,1
ERWINAZE,CNS events,CNS events,1
ERWINAZE,CNS events,ketoacidosis,0
ERWINAZE,CNS events,,0
ERWINAZE,cerebral venous thrombosis,or infarction and,0
ERWINAZE,cerebral venous thrombosis,cerebral venous thrombosis,1
ERWINAZE,cerebral venous thrombosis,hemorrhage thrombosis or infarction cerebral venous thrombosis,1
ERWINAZE,cerebral venous thrombosis,adverse events In Study all,0
ERWINAZE,cerebral venous thrombosis,thrombosis,1
ERWINAZE,cerebral venous thrombosis,infarction cerebral venous thrombosis,1
ERWINAZE,cerebral venous thrombosis,hemorrhage thrombosis or infarction cerebral venous thrombosis,1
ERWINAZE,allergic reactions,information on,0
ERWINAZE,allergic reactions,,0
ERWINAZE,allergic reactions,requested information on occurrence allergic,1
ERWINAZE,allergic reactions,occurrence allergic reactions,1
ERWINAZE,allergic reactions,requested information on,0
ERWINAZE,thrombotic events,requested information on,0
ERWINAZE,thrombotic events,The forms specifically requested information on occurrence of allergic reactions,0
ERWINAZE,thrombotic events,of,0
ERWINAZE,thrombotic events,reactions,0
ERWINAZE,thrombotic events,,0
ERWINAZE,thrombotic events,thrombotic events,1
ERWINAZE,thrombotic events,thrombotic events,1
ERWINAZE,thrombotic events,events hepatobiliary disorders pancreatic disorders and hyperglycemia,0
ERWINAZE,thrombotic events,thrombotic events,1
ERWINAZE,thrombotic events,,0
ERWINAZE,hemorrhagic events,reactions thrombotic hemorrhagic events,1
ERWINAZE,hemorrhagic events,allergic reactions thrombotic hemorrhagic,1
ERWINAZE,hemorrhagic events,allergic reactions thrombotic hemorrhagic events,1
ERWINAZE,hemorrhagic events,hemorrhagic events,1
ERWINAZE,hemorrhagic events,occurrence of,0
ERWINAZE,hemorrhagic events,events,1
ERWINAZE,hemorrhagic events,hemorrhagic events,1
ERWINAZE,hepatobiliary disorders,,0
ERWINAZE,hepatobiliary disorders,disorders,1
ERWINAZE,hepatobiliary disorders,disorders,1
ERWINAZE,hepatobiliary disorders,hemorrhagic hepatobiliary,1
ERWINAZE,hepatobiliary disorders,disorders,1
ERWINAZE,hepatobiliary disorders,disorders,1
ERWINAZE,hepatobiliary disorders,on occurrence of allergic reactions thrombotic,0
ERWINAZE,hepatobiliary disorders,noninfectious adv,0
ERWINAZE,hepatobiliary disorders,hepatobiliary,1
ERWINAZE,hepatobiliary disorders,disorders,1
ERWINAZE,hyperglycemia,,0
ERWINAZE,hyperglycemia,hyperglycemia,1
ERWINAZE,hyperglycemia,nonhematologic noninfectious adverse events all Grades in,0
ERWINAZE,hyperglycemia,hyperglycemia,1
ERWINAZE,hyperglycemia,hyperglycemia,1
ERWINAZE,hypersensitivity reaction,Of these ADA positive patients one,0
ERWINAZE,hypersensitivity reactions,patients,0
ERWINAZE,hypersensitivity reactions,hypersensitivity reactions,1
ERWINAZE,hypersensitivity reactions,who received ERWINAZE through intravenous infusion compared to intramuscular administra,0
ERWINAZE,hypersensitivity reactions,reactions,1
ERWINAZE,hypersensitivity reactions,hypersensitivity reactions,1
ERWINAZE,hypersensitivity reactions,risk hypersensitivity,1
ERWINAZE,hypersensitivity reactions,infusion compared to intramuscular,0
ERWINAZE,hypersensitivity reactions,,0
ERWINAZE,hypersensitivity reactions,hypersensitivity reactions,1
ERWINAZE,hypersensitivity reactions,with a higher risk hypersensitivity reactions,1
ERWINAZE,hypersensitivity reactions,reactions,1
ERWINAZE,hypersensitivity reactions,see Warnings and,0
ERWINAZE,hypersensitivity reactions,,0
ERWINAZE,hemorrhagic pancreatitis,Hypersensitivity reactions ee Warnings,1
ERWINAZE,hemorrhagic pancreatitis,,0
ERWINAZE,hemorrhagic pancreatitis,reactions ee Warnings,1
ERWINAZE,hemorrhagic pancreatitis,Pancreatitis see Warnings and Precautions Glucose,0
ERWINAZE,hemorrhagic pancreatitis,the label Hypersensitivity reactions ee Warnings and Precauti,1
ERWINAZE,hemorrhagic pancreatitis,Glucose,0
ERWINAZE,hemorrhagic pancreatitis,Precauti,1
ERWINAZE,hemorrhagic pancreatitis,Warnings and Precauti,1
ERWINAZE,hemorrhagic pancreatitis,Warnings,0
ERWINAZE,hemorrhagic pancreatitis,,0
ERWINAZE,pancreatitis,Glucose intolerance,0
ERWINAZE,pancreatitis,reactions see and Precauti,1
ERWINAZE,pancreatitis,the label,0
ERWINAZE,pancreatitis,Pancreatitis see Warnings,0
ERWINAZE,pancreatitis,label Hypersensitivity reactions see and,1
ERWINAZE,pancreatitis,see,0
ERWINAZE,pancreatitis,sections of the,0
ERWINAZE,Glucose intolerance,Warnings and * Pancreatitis,1
ERWINAZE,Glucose intolerance,and Precautions,0
ERWINAZE,Glucose intolerance,and *    Pancreatitis [,1
ERWINAZE,Glucose intolerance,[,1
ERWINAZE,Glucose intolerance,label Hypersensitivity reactions see Warnings and,0
ERWINAZE,Thrombosis,P,1
ERWINAZE,Thrombosis,hemorrhage see ings and P,1
ERWINAZE,Thrombosis,see ings,1
ERWINAZE,Thrombosis,common adverse reactions incidence,0
ERWINAZE,Thrombosis,,0
ERWINAZE,hemorrhage,,0
ERWINAZE,hemorrhage,,0
ERWINAZE,hypersensitivity reactions,vomiting nausea,0
ERWINAZE,hypersensitivity reactions,,0
ERWINAZE,hypersensitivity reactions,hy,1
ERWINAZE,hypersensitivity reactions,reactions incidence or greater with,0
ERWINAZE,hypersensitivity reactions,"hypersensitivity, hy",1
ERWINAZE,hypersensitivity reactions,transaminases abnormal fever pancreatitis local reactions,0
ERWINAZE,hypersensitivity reactions,"treatment are temic hypersensitivity, hy",1
ERWINAZE,Pancreatitis,paindiscomfort and diarrhea To report SUSPECTED,0
ERWINAZE,Pancreatitis,"vomiting ,",1
ERWINAZE,Pancreatitis,abnormal fever pancreatitis local,0
ERWINAZE,Pancreatitis,", thrombosis",1
ERWINAZE,Pancreatitis,vomiting nausea,0
ERWINAZE,glucose intolerance,oth intramuscular,0
ERWINAZE,glucose intolerance,Treatment Protocol EMTP an d access program,1
ERWINAZE,glucose intolerance,administration the ERWINAZE Master Treatment,0
ERWINAZE,glucose intolerance,an d access program (b,1
ERWINAZE,glucose intolerance,Protocol EMTP an d access program (b,1
ERWINAZE,glucose intolerance,d access program (b,1
ERWINAZE,glucose intolerance,,0
ERWINAZE,glucose intolerance,an d access program,1
ERWINAZE,glucose intolerance,the ERWINAZE Master Treatment Protocol EMTP an,0
ERWINAZE,glucose intolerance,or unknown administration,0
ERWINAZE,thrombotic events,treated on Na,1
ERWINAZE,thrombotic events,PK study trial,0
ERWINAZE,thrombotic events,unable to,0
ERWINAZE,thrombotic events,administration of ERWINAZEStudy enrolled nts treated on Na,1
ERWINAZE,thrombotic events,nts,1
ERWINAZE,thrombotic events,were unable,0
ERWINAZE,thrombotic events,Na,1
ERWINAZE,thrombotic events,were unable to,0
ERWINAZE,sagittal sinus thrombosis,intravenous administration of ERWINAZEStudy enrolled patients treated on National,0
ERWINAZE,sagittal sinus thrombosis,treated on National r Institute (NCI)-sponsor,1
ERWINAZE,sagittal sinus thrombosis,who were unable to,0
ERWINAZE,sagittal sinus thrombosis,were unable to continue to,0
ERWINAZE,sagittal sinus thrombosis,on National r Institute (NCI)-sponsor,1
ERWINAZE,sagittal sinus thrombosis,ERWINAZEStudy enrolled patients treated on National Cance,0
ERWINAZE,sagittal sinus thrombosis,continue to receive,0
ERWINAZE,sagittal sinus thrombosis,Institute (NCI)-sponsor,1
ERWINAZE,sagittal sinus thrombosis,treated on National r,1
ERWINAZE,sagittal sinus thrombosis,r Institute (NCI)-sponsor,1
ERWINAZE,pulmonary embolism,of ERWINAZEStudy enrolled patients,0
ERWINAZE,pulmonary embolism,reactions,0
SAPHRIS,Neuroleptic Malignant Syndrome,Neuroleptic,1
SAPHRIS,Neuroleptic Malignant Syndrome,with DementiaRelated Psychosis seeBoxed Warningand Warnings and Precautions,0
SAPHRIS,Neuroleptic Malignant Syndrome,Precautions Neuroleptic,1
SAPHRIS,Neuroleptic Malignant Syndrome,Warningand Warnings and Precautions Neuroleptic Malignant Syndrome,1
SAPHRIS,Neuroleptic Malignant Syndrome,Tardive Dyskinesia see Warnings and,0
SAPHRIS,Tardive Dyskinesia,Warnings and Precautions,0
SAPHRIS,Tardive Dyskinesia,Dyskinesia,1
SAPHRIS,Metabolic Changes,,0
SAPHRIS,Metabolic Changes,Hypersensitivity Reactions,0
SAPHRIS,Metabolic Changes,Metabolic Changes,1
SAPHRIS,Metabolic Changes,Dyskinesia see Warnings and Metabolic Changes,1
SAPHRIS,Metabolic Changes,Contraindications,0
SAPHRIS,Hypersensitivity Reactions,Reactions,1
SAPHRIS,Hypersensitivity Reactions,Hypersensitivity Reactions,1
SAPHRIS,Hypersensitivity Reactions,Hypersensitivity Reactions,1
SAPHRIS,Hypersensitivity Reactions,and Hypersensitivity Reactions,1
SAPHRIS,Hypersensitivity Reactions,,0
SAPHRIS,Hypersensitivity Reactions,Precautions Metabolic Changes see Warnings and,0
SAPHRIS,Application site reactions,and Patient Counseling Application site reactions,1
SAPHRIS,Application site reactions,Warnings and Precautions and Patient Counseling,0
SAPHRIS,Orthostatic Hypotension,inflammation see Adverse Orthostatic Hypotension,1
SAPHRIS,Orthostatic Hypotension,Orthostatic Hypotension,1
SAPHRIS,Orthostatic Hypotension,and,0
SAPHRIS,Orthostatic Hypotension,,0
SAPHRIS,Syncope,Syncope,1
SAPHRIS,Syncope,Syncope,1
SAPHRIS,Syncope,and Precautions Leukopenia,0
SAPHRIS,Syncope,Leukopenia Neutropenia,0
SAPHRIS,Hemodynamic Effects,Hemodynamic Effects,1
SAPHRIS,Hemodynamic Effects,Leukopenia Neutropenia and Agranulocytosis see,0
SAPHRIS,Hemodynamic Effects,Syncope and Hemodynamic Effects,1
SAPHRIS,Hemodynamic Effects,and inflammation see Adverse,0
SAPHRIS,Hemodynamic Effects,,0
SAPHRIS,Hemodynamic Effects,Hemodynamic Effects,1
SAPHRIS,Hemodynamic Effects,see Adverse Reactions Orthostatic Hypotension,0
SAPHRIS,Hemodynamic Effects,and,0
SAPHRIS,Leukopenia,Leukopenia,1
SAPHRIS,Neutropenia,Agranulocytosis,0
SAPHRIS,Neutropenia,Neutropenia,1
SAPHRIS,Agranulocytosis,Agranulocytosis,1
SAPHRIS,Agranulocytosis,and Precautions QT Interval,0
SAPHRIS,Agranulocytosis,Agranulocytosis,1
SAPHRIS,Agranulocytosis,Agranulocytosis,1
SAPHRIS,Agranulocytosis,other Hemodynamic Effects see,0
SAPHRIS,Agranulocytosis,Precautions Leukopenia Neutropenia,0
SAPHRIS,Agranulocytosis,Agranulocytosis,1
SAPHRIS,Agranulocytosis,Agranulocytosis,1
SAPHRIS,QT Interval Prolongation,,0
SAPHRIS,QT Interval Prolongation,see Warnings and Precautions Hyperprolactinemia see Warnings and Precautions,0
SAPHRIS,QT Interval Prolongation,Warnings and,0
SAPHRIS,QT Interval Prolongation,Interval Prolongation,1
SAPHRIS,QT Interval Prolongation,Precautions,0
SAPHRIS,QT Interval Prolongation,,0
SAPHRIS,QT Interval Prolongation,Agranulocytosis see Warnings and,0
SAPHRIS,Seizures,,0
SAPHRIS,Seizures,,0
SAPHRIS,Seizures,see Warnings and,0
SAPHRIS,Seizures,and Motor,0
SAPHRIS,Seizures,Seizures,1
SAPHRIS,Motor Impairment,Cognitive Motor,1
SAPHRIS,Motor Impairment,Warnings and,0
SAPHRIS,Motor Impairment,Precautions Body Temperature Regulation see Warnings and,0
SAPHRIS,Motor Impairment,Precautions Potential for Cognitive Motor Impairment,1
SAPHRIS,Motor Impairment,see Warnings and Precautio,0
SAPHRIS,Motor Impairment,Motor Impairment,1
SAPHRIS,Motor Impairment,Precautions Potential for Cognitive Motor,1
SAPHRIS,Suicide,Suicide,1
SAPHRIS,Suicide,Warnings and,0
SAPHRIS,Suicide,see Warnings and Suicide,1
SAPHRIS,Suicide,Regulation see Warnings and,0
SAPHRIS,Suicide,Suicide,1
SAPHRIS,Suicide,and,0
SAPHRIS,Suicide,Body,0
SAPHRIS,Dysphagia,,0
SAPHRIS,akathisia,akathisia,1
SAPHRIS,akathisia,twice the,0
SAPHRIS,akathisia,akathisia,1
SAPHRIS,akathisia,schizophrenia akathisia,1
SAPHRIS,akathisia,akathisia,1
SAPHRIS,akathisia,adults with schizophrenia were,0
SAPHRIS,akathisia,and somnolence The safety profile of SAPHRIS in the maintenance treatment,0
SAPHRIS,oral hypoesthesia,schizophrenia,0
SAPHRIS,oral hypoesthesia,SAPHRIS in the maintenance treatment of schizophrenia in,0
SAPHRIS,somnolence,schizophrenia,0
SAPHRIS,somnolence,somnolence,1
SAPHRIS,somnolence,somnolence,1
SAPHRIS,somnolence,akathisia oral hypoesthesia and,0
SAPHRIS,somnolence,somnolence,1
SAPHRIS,somnolence,somnolence,1
SAPHRIS,somnolence,,0
SAPHRIS,dizziness,dizziness,1
SAPHRIS,dizziness,manic or,0
SAPHRIS,dizziness,increased weight and during the adjunctive,0
SAPHRIS,extrapyramidal symptoms,symptoms,1
SAPHRIS,akathisia,akathisia,1
SAPHRIS,akathisia,,0
SAPHRIS,akathisia,extrapyramidal symptoms other akathisia,1
SAPHRIS,akathisia,extrapyramidal symptoms,0
SAPHRIS,increased weight,therapy trial in bipolar I disorder in adults were somnolence and oral hy,0
SAPHRIS,increased weight,increased weight,1
SAPHRIS,increased weight,increased weight,1
SAPHRIS,increased weight,,0
SAPHRIS,increased weight,than akathisia,0
SAPHRIS,increased weight,other than akathisia increased,1
SAPHRIS,increased weight,other than akathisia increased,1
SAPHRIS,somnolence,oral hypoesthesia The adult information below is derived from a clinical,0
SAPHRIS,somnolence,somnolence,1
SAPHRIS,somnolence,,0
SAPHRIS,somnolence,is derived from a clinical trial database,0
SAPHRIS,somnolence,,0
SAPHRIS,somnolence,somnolence,1
SAPHRIS,oral hypoesthesia,bipolar I,0
SAPHRIS,oral hypoesthesia,somnolence oral,1
SAPHRIS,oral hypoesthesia,were somnolence,0
SAPHRIS,oral hypoesthesia,information below is derived from a clinical trial database for SAPHRIS,0
SAPHRIS,somnolence,with SAPHRIS somnolence,1
SAPHRIS,somnolence,dizziness dysgeusia oral paresthesia nausea increased appetite fatigue and,0
SAPHRIS,somnolence,,0
SAPHRIS,somnolence,,0
SAPHRIS,somnolence,I disorder treated with SAPHRIS,0
SAPHRIS,somnolence,somnolence,1
SAPHRIS,somnolence,with SAPHRIS somnolence,1
SAPHRIS,somnolence,appetite,0
SAPHRIS,somnolence,somnolence,1
SAPHRIS,dizziness,were dizziness,1
SAPHRIS,dizziness,SAPHRIS were,0
SAPHRIS,dizziness,treated with SAPHRIS were dizziness,1
SAPHRIS,dizziness,dizziness,1
SAPHRIS,dizziness,,0
SAPHRIS,dizziness,dizziness,1
SAPHRIS,dizziness,dizziness,1
SAPHRIS,dysgeusia,were somnolence dizziness,0
SAPHRIS,dysgeusia,dysgeusia,1
SAPHRIS,dysgeusia,dysgeusia,1
SAPHRIS,dysgeusia,dysgeusia,1
SAPHRIS,dysgeusia,pediatric patients with bipolar I disorder treated with SAPHRIS were,0
SAPHRIS,dysgeusia,dysgeusia,1
SAPHRIS,dysgeusia,SAPHRIS were somnolence dysgeusia,1
SAPHRIS,dysgeusia,SAPHRIS were somnolence dysgeusia,1
SAPHRIS,oral paresthesia,were somnolence dizziness oral paresthesia,1
SAPHRIS,oral paresthesia,oral paresthesia,1
SAPHRIS,oral paresthesia,oral paresthesia,1
SAPHRIS,oral paresthesia,weight No new major,0
SAPHRIS,oral paresthesia,oral paresthesia,1
SAPHRIS,oral paresthesia,dysgeusia,0
SAPHRIS,nausea,dysgeusia oral nausea,1
SAPHRIS,nausea,SAPHRIS were somnolence dizziness dysgeusia oral paresthesia,0
SAPHRIS,nausea,somnolence dizziness dysgeusia oral nausea,1
SAPHRIS,increased appetite,increased appetite,1
SAPHRIS,increased appetite,paresthesia,0
SAPHRIS,increased appetite,dizziness dysgeusia oral paresthesia increased,1
SAPHRIS,increased appetite,with SAPHRIS were somnolence,0
SAPHRIS,increased appetite,paresthesia increased,1
SAPHRIS,increased appetite,dysgeusia oral paresthesia increased appetite,1
SAPHRIS,fatigue,fatigue,1
SAPHRIS,fatigue,fatigue,1
SAPHRIS,fatigue,were somnolence dizziness dysgeusia oral paresthesia nausea,0
SAPHRIS,fatigue,fatigue,1
SAPHRIS,increased weight,openlabel,0
SAPHRIS,increased weight,dizziness dysgeusia oral paresthesia,0
SAPHRIS,increased weight,increased,1
SAPHRIS,increased weight,safety findings were reported from,0
SAPHRIS,increased weight,nausea increased appetite fatigue increased weight,1
SAPHRIS,increased weight,nausea increased appetite fatigue,0
SAPHRIS,increased weight,fatigue increased,1
SAPHRIS,increased weight,a week openlabel uncontrolled safety,0
SAPHRIS,akathisia,for placebo,0
SAPHRIS,akathisia,for placebo were Schizophrenia Adults,0
SAPHRIS,somnolence,Adults Monotherapy somnolence dizziness extrapyramidal,0
SAPHRIS,somnolence,akathisia oral somnolence,1
SAPHRIS,somnolence,,0
SAPHRIS,somnolence,somnolence,1
SAPHRIS,somnolence,somnolence,1
SAPHRIS,somnolence,symptoms other,0
SAPHRIS,somnolence,were Schizophrenia Adults akathisia,0
SAPHRIS,somnolence,symptoms other than akathisia increased weight Bipolar Disorder,0
SAPHRIS,somnolence,hypoesthesia somnolence Bipolar Disorder,0
SAPHRIS,somnolence,somnolence,1
SAPHRIS,somnolence,weight Bipolar Disorder,0
SAPHRIS,somnolence,akathisia increased,0
SAPHRIS,somnolence,oral hypoesthesia somnolence Bipolar,0
SAPHRIS,dizziness,dizziness,1
SAPHRIS,dizziness,dizziness,1
SAPHRIS,dizziness,dizziness,1
SAPHRIS,dizziness,dizziness,1
SAPHRIS,dizziness,dizziness,1
SAPHRIS,akathisia,dizziness,0
SAPHRIS,akathisia,akathisia,1
SAPHRIS,akathisia,akathisia,1
SAPHRIS,akathisia,,0
SAPHRIS,akathisia,extrapyramidal symptoms other,0
SAPHRIS,akathisia,,0
SAPHRIS,akathisia,dizziness,0
SAPHRIS,akathisia,akathisia,1
SAPHRIS,increased weight,somnolence,0
SAPHRIS,dizziness,dysgeusia oral paresthesia nausea increased appetite fatigue increased,0
SAPHRIS,dizziness,dizziness,1
SAPHRIS,dizziness,increased weight Bipolar Disorder Pediatric Patients Monotherapy somnolence,0
SAPHRIS,dizziness,Disorder Pediatric Patients,0
SAPHRIS,dizziness,Pediatric Patients Monotherapy dizziness,1
SAPHRIS,dizziness,dizziness,1
SAPHRIS,dizziness,dizziness,1
SAPHRIS,dysgeusia,Pediatric Patients Monotherapy somnolence dysgeusia,1
SAPHRIS,dysgeusia,Pediatric Patients Monotherapy somnolence dysgeusia,1
SAPHRIS,oral paresthesia,somnolence dizziness oral paresthesia,1
SAPHRIS,oral paresthesia,increased appetite fatigue,0
SAPHRIS,oral paresthesia,Bipolar Disorder Pediatric Patients,0
SAPHRIS,oral paresthesia,oral,1
SAPHRIS,oral paresthesia,somnolence dizziness oral,1
SAPHRIS,oral paresthesia,somnolence dizziness oral,1
SAPHRIS,oral paresthesia,somnolence dizziness oral paresthesia,1
SAPHRIS,oral paresthesia,,0
SAPHRIS,oral paresthesia,Pediatric Patients Monotherapy somnolence dizziness dysgeusia,0
SAPHRIS,nausea,nausea,1
SAPHRIS,nausea,somnole,0
SAPHRIS,nausea,dysgeusia,0
SAPHRIS,nausea,nausea,1
SAPHRIS,nausea,nausea,1
SAPHRIS,nausea,increased appetite,0
SAPHRIS,nausea,,0
SAPHRIS,nausea,nausea,1
SAPHRIS,nausea,somnolence dizziness dysgeusia oral nausea,1
SAPHRIS,nausea,nausea,1
SAPHRIS,increased appetite,increased weight Bipolar Disorder Adults,0
SAPHRIS,increased appetite,dysgeusia oral paresthesia increased appetite,1
SAPHRIS,increased appetite,oral paresthesia,0
SAPHRIS,increased appetite,Adults Adjunctive,0
SAPHRIS,increased appetite,Pediatric,0
SAPHRIS,increased appetite,dizziness dysgeusia oral paresthesia increased appetite,1
SAPHRIS,increased appetite,,0
SAPHRIS,fatigue,fatigue,1
SAPHRIS,fatigue,,0
SAPHRIS,fatigue,Disorder Adults Adjunctive somnolence oral,0
SAPHRIS,fatigue,Disorder Adults Adjunctive somnolence,0
SAPHRIS,fatigue,fatigue,1
SAPHRIS,fatigue,Adults Adjunctive,0
SAPHRIS,fatigue,oral hypoesthesia,0
SAPHRIS,fatigue,somnolence dizziness dysgeusia oral paresthesia nausea increased,0
SAPHRIS,increased weight,,0
SAPHRIS,increased weight,,0
SAPHRIS,increased weight,,0
SAPHRIS,oral hypoesthesia,,0
SAPHRIS,oral hypoesthesia,oral hypoesthesia,1
SAPHRIS,oral hypoesthesia,oral,1
SAPHRIS,oral hypoesthesia,hypoesthesia,1
SAPHRIS,oral hypoesthesia,appetite fatigue increased weight Bipolar,0
SAPHRIS,oral hypoesthesia,oral hypoesthesia,1
SAPHRIS,oral hypoesthesia,,0
SAPHRIS,oral hypoesthesia,Disorder Adults Adjunctive oral hypoesthesia,1
SAPHRIS,Akathisia,symptoms,0
SAPHRIS,Akathisia,Group in Week Schizophrenia Akathisia,1
SAPHRIS,Akathisia,Akathisia,1
SAPHRIS,Akathisia,Akathisia,1
SAPHRIS,Akathisia,includes akathisia and hyperkinesia,0
SAPHRIS,akathisia,akathisia,1
SAPHRIS,akathisia,Trials Akathisia akathisia,1
SAPHRIS,akathisia,in Week Schizophrenia Trials Akathisia includes,0
SAPHRIS,akathisia,symptoms included dystonia oculogyration,0
SAPHRIS,akathisia,akathisia,1
SAPHRIS,akathisia,Group in,0
SAPHRIS,akathisia,Akathisia akathisia,1
SAPHRIS,akathisia,Schizophrenia Trials Akathisia akathisia,1
SAPHRIS,akathisia,tard,0
SAPHRIS,akathisia,and hyperkinesia Extrapyramidal symptoms included dystonia oculogyration,0
SAPHRIS,hyperkinesia,hyperkinesia,1
SAPHRIS,hyperkinesia,hyperkinesia,1
SAPHRIS,hyperkinesia,hyperkinesia,1
SAPHRIS,hyperkinesia,oculogyration dyskinesia tardive dyskinesia,0
SAPHRIS,hyperkinesia,hyperkinesia,1
SAPHRIS,hyperkinesia,dyskinesia tardive dyskinesia,0
SAPHRIS,hyperkinesia,dystonia oculogyration,0
SAPHRIS,hyperkinesia,Extrapyramidal,0
SAPHRIS,Extrapyramidal symptoms,symptoms,1
SAPHRIS,Extrapyramidal symptoms,Week Schizophrenia Trials,0
SAPHRIS,Extrapyramidal symptoms,tardive,0
SAPHRIS,dystonia,dystonia,1
SAPHRIS,dystonia,dyskinesia muscle rigidity parkinsonism tremor and extrapyr,0
SAPHRIS,dystonia,dyskinesia tardive dyskinesia muscle rigidity,0
SAPHRIS,dystonia,akathisia and hyperkinesia Extrapyramidal,0
SAPHRIS,dystonia,muscle rigidity parkinsonism tremor and extrapyr,0
SAPHRIS,dystonia,dystonia,1
SAPHRIS,dystonia,dyskinesia tardive dyskinesia,0
SAPHRIS,dystonia,dystonia,1
SAPHRIS,dystonia,dystonia,1
SAPHRIS,dystonia,and hyperkinesia Extrapyramidal symptoms dystonia,1
SAPHRIS,oculogyration,muscle rigidity parkinsonism tremor,0
SAPHRIS,oculogyration,includes akathisia and hyperkinesia Extrapyramidal symptoms included,0
SAPHRIS,oculogyration,hyperkinesia Extrapyramidal symptoms included oculogyration,1
SAPHRIS,oculogyration,akathisia and,0
SAPHRIS,oculogyration,,0
SAPHRIS,dyskinesia,dyskinesia,1
SAPHRIS,dyskinesia,dyskinesia,1
SAPHRIS,dyskinesia,dyskinesia,1
SAPHRIS,dyskinesia,Extrapyramidal symptoms included dystonia dyskinesia,1
SAPHRIS,dyskinesia,,0
SAPHRIS,dyskinesia,dyskinesia,1
SAPHRIS,tardive dyskinesia,and extrapyramidal disorder excluding,0
SAPHRIS,tardive dyskinesia,and extrapyramidal,0
SAPHRIS,tardive dyskinesia,tardive dyskinesia,1
SAPHRIS,tardive dyskinesia,tardive,1
SAPHRIS,tardive dyskinesia,,0
SAPHRIS,tardive dyskinesia,tardive dyskinesia,1
SAPHRIS,muscle rigidity,included dystonia oculogyration dyskinesia,0
SAPHRIS,muscle rigidity,muscle,1
SAPHRIS,muscle rigidity,rigidity,1
SAPHRIS,muscle rigidity,extrapyramidal disorder excluding akathisia,0
SAPHRIS,muscle rigidity,oculogyration dyskinesia tardive muscle,1
SAPHRIS,muscle rigidity,muscle rigidity,1
SAPHRIS,muscle rigidity,rigidity,1
SAPHRIS,muscle rigidity,Somnolence includ,0
SAPHRIS,muscle rigidity,excluding,0
SAPHRIS,parkinsonism,,0
SAPHRIS,parkinsonism,parkinsonism,1
SAPHRIS,parkinsonism,muscle rigidity,0
SAPHRIS,parkinsonism,,0
SAPHRIS,tremor,Somnolence includes,0
SAPHRIS,tremor,oculogyration dyskinesia tardive dyskinesia muscle,0
SAPHRIS,extrapyramidal disorder,parkinsonism tremor,0
SAPHRIS,extrapyramidal disorder,tremor and,0
SAPHRIS,extrapyramidal disorder,extrapyramidal,1
SAPHRIS,extrapyramidal disorder,dyskinesia muscle rigidity parkinsonism tremor and,0
SAPHRIS,akathisia,rigidity parkinsonism tremor,0
SAPHRIS,akathisia,akathisia,1
SAPHRIS,akathisia,akathisia,1
SAPHRIS,Somnolence,Somnolence,1
SAPHRIS,Somnolence,,0
SAPHRIS,Somnolence,excluding Somnolence,1
SAPHRIS,Somnolence,Somnolence,1
SAPHRIS,Somnolence,and extrapyramidal disorder excluding,0
SAPHRIS,Somnolence,tremor and extrapyramidal disorder,0
SAPHRIS,Somnolence,Somnolence,1
SAPHRIS,Somnolence,Somnolence,1
SAPHRIS,Somnolence,Somnolence,1
SAPHRIS,somnolence,,0
SAPHRIS,somnolence,somnolence,1
SAPHRIS,somnolence,,0
SAPHRIS,somnolence,S,0
SAPHRIS,somnolence,includes the following somnolence,1
SAPHRIS,somnolence,somnolence,1
SAPHRIS,somnolence,somnolence,1
SAPHRIS,somnolence,Somnolence includes the following somnolence,1
SAPHRIS,somnolence,somnolence,1
SAPHRIS,hypersomnia,events somnolence sedation and,0
SAPHRIS,hypersomnia,Preferred Term,0
SAPHRIS,hypersomnia,following events somnolence sedation hypersomnia,1
SAPHRIS,hypersomnia,events,0
SAPHRIS,hypersomnia,events somnolence sedation hypersomnia,1
SAPHRIS,Constipation,disorders,0
SAPHRIS,Dry mouth,,0
SAPHRIS,Dry mouth,n Dry mouth,1
SAPHRIS,Dry mouth,,0
SAPHRIS,Dry mouth,n Dry mouth,1
SAPHRIS,Dry mouth,,0
SAPHRIS,Dry mouth,n,0
SAPHRIS,Dry mouth,,0
SAPHRIS,Dry mouth,,0
SAPHRIS,Oral hypoesthesia,,0
SAPHRIS,Oral hypoesthesia,Oral hypoesthesia Saliva,1
SAPHRIS,Oral hypoesthesia,Saliva,0
SAPHRIS,Oral hypoesthesia,,0
SAPHRIS,Oral hypoesthesia,Saliva,0
SAPHRIS,Oral hypoesthesia,Oral hypoesthesia Saliva,1
SAPHRIS,Oral hypoesthesia,Oral hypoesthesia Saliva,1
SAPHRIS,Oral hypoesthesia,Oral hypoesthesia Saliva,1
SAPHRIS,Oral hypoesthesia,Oral,1
SAPHRIS,Oral hypoesthesia,,0
SAPHRIS,Salivary hypersecretion,,0
SAPHRIS,Salivary hypersecretion,,0
SAPHRIS,Salivary hypersecretion,thesia,0
SAPHRIS,Salivary hypersecretion,,0
SAPHRIS,Salivary hypersecretion,Salivary hypersecretion Stomach,1
SAPHRIS,Salivary hypersecretion,thesia Salivary hypersecretion Stomach,1
SAPHRIS,Salivary hypersecretion,thesia Salivary,1
SAPHRIS,Stomach discomfort,persecretion Stomach discomfort Vomitin,1
SAPHRIS,Stomach discomfort,,0
SAPHRIS,Stomach discomfort,,0
SAPHRIS,Stomach discomfort,persecretion,0
SAPHRIS,Stomach discomfort,persecretion,0
SAPHRIS,Vomiting,,0
SAPHRIS,Vomiting,Vomiting,1
SAPHRIS,Fatigue,Fatigue,1
SAPHRIS,Fatigue,,0
SAPHRIS,Fatigue,ers,0
SAPHRIS,Fatigue,ers,0
SAPHRIS,Fatigue,Fatigue,1
SAPHRIS,Fatigue,Fatigue,1
SAPHRIS,Fatigue,Fatigue,1
SAPHRIS,Fatigue,ers,0
SAPHRIS,Fatigue,Fatigue,1
SAPHRIS,Fatigue,Fatigue,1
SAPHRIS,Irritability,Irritability Inve,1
SAPHRIS,Irritability,Irritability Inve,1
SAPHRIS,Irritability,Irritability Inve,1
SAPHRIS,Irritability,,0
SAPHRIS,Irritability,Inve,0
SAPHRIS,Increased weight,,0
SAPHRIS,Increased weight,Increased weight Metaboli,1
SAPHRIS,Increased weight,weight Metaboli,1
SAPHRIS,Increased weight,,0
SAPHRIS,Increased weight,weight Metaboli,1
SAPHRIS,Increased weight,weight Metaboli,1
SAPHRIS,Increased weight,Increased weight Metaboli,1
SAPHRIS,Increased appetite,sy,0
SAPHRIS,Increased appetite,appetite,1
SAPHRIS,Increased appetite,orders Increased appetite Nervous sy,1
SAPHRIS,Increased appetite,sy,0
SAPHRIS,Increased appetite,sy,0
SAPHRIS,Increased appetite,,0
SAPHRIS,Increased appetite,orders,0
SAPHRIS,Increased appetite,,0
SAPHRIS,Akathisia,disorders,0
SAPHRIS,Akathisia,disorders,0
SAPHRIS,Akathisia,Akathisia,1
SAPHRIS,Akathisia,disorders,0
SAPHRIS,Akathisia,,0
SAPHRIS,Akathisia,Akathisia,1
SAPHRIS,Akathisia,Akathisia,1
SAPHRIS,Akathisia,disorders Akathisia,1
SAPHRIS,Akathisia,disorders Akathisia,1
SAPHRIS,Akathisia,disorders Akathisia,1
SAPHRIS,Dizziness,Dizziness,1
SAPHRIS,Dizziness,,0
SAPHRIS,Dizziness,Dizziness,1
SAPHRIS,Dizziness,Dizziness,1
SAPHRIS,Dizziness,Dizziness,1
SAPHRIS,Dizziness,Dizziness,1
SAPHRIS,Dizziness,Dizziness,1
SAPHRIS,Dizziness,Dizziness,1
SAPHRIS,akathisia,,0
SAPHRIS,akathisia,symptoms excluding,0
SAPHRIS,akathisia,,0
SAPHRIS,akathisia,excluding,0
SAPHRIS,akathisia,akathisia Somnolence,1
SAPHRIS,akathisia,symptoms,0
SAPHRIS,akathisia,Extrapyramidal symptoms akathisia Somnolence,1
SAPHRIS,Somnolence,akathisia,0
SAPHRIS,Somnolence,,0
SAPHRIS,Somnolence,Somnolence Ps,1
SAPHRIS,Somnolence,cluding Somnolence Ps,1
SAPHRIS,Somnolence,,0
SAPHRIS,Somnolence,Somnolence Ps,1
SAPHRIS,Insomnia,sorders Insomnia,1
SAPHRIS,Insomnia,,0
SAPHRIS,Insomnia,Insomnia,1
SAPHRIS,Insomnia,,0
SAPHRIS,Insomnia,,0
SAPHRIS,Insomnia,Insomnia,1
SAPHRIS,Insomnia,sorders Insomnia,1
SAPHRIS,Insomnia,,0
SAPHRIS,Insomnia,Insomnia,1
SAPHRIS,Hypertension,,0
SAPHRIS,Hypertension,Hypertension,1
SAPHRIS,Hypertension,Hypertension,1
SAPHRIS,Hypertension,Hypertension,1
SAPHRIS,Hypertension,ders,0
SAPHRIS,Hypertension,Hypertension,1
SAPHRIS,Hypertension,,0
SAPHRIS,akathisia,short term schizophrenia,0
SAPHRIS,akathisia,akathisia,1
SAPHRIS,akathisia,akathisia,1
SAPHRIS,akathisia,akathisia,1
SAPHRIS,anxiety,anxiety,1
SAPHRIS,anxiety,rate anxiety,1
SAPHRIS,anxiety,twice the placebo rate anxiety,1
SAPHRIS,anxiety,and at least twice the placebo rate were,0
SAPHRIS,oral hypoesthesia,placebo rate were anxiety oral,1
SAPHRIS,oral hypoesthesia,least twice,0
SAPHRIS,oral hypoesthesia,oral hypoesthesia,1
SAPHRIS,oral hypoesthesia,Occurring at an Incidence,0
SAPHRIS,oral hypoesthesia,were anxiety oral,1
SAPHRIS,oral hypoesthesia,and at least twice the placebo,0
SAPHRIS,oral hypoesthesia,,0
SAPHRIS,oral hypoesthesia,at least twice the placebo rate were anxiety,0
SAPHRIS,Extrapyramidal symptoms,flexible,0
SAPHRIS,Extrapyramidal symptoms,daily with flexible Extrapyramidal symptoms,1
SAPHRIS,Extrapyramidal symptoms,,0
SAPHRIS,Extrapyramidal symptoms,,0
SAPHRIS,Extrapyramidal symptoms,Extrapyramidal symptoms,1
SAPHRIS,Extrapyramidal symptoms,Mania,0
SAPHRIS,Extrapyramidal symptoms,flexible Extrapyramidal symptoms,1
SAPHRIS,dystonia,dystonia,1
SAPHRIS,blepharospasm,blepharospasm,1
SAPHRIS,blepharospasm,dyskinesia,0
SAPHRIS,blepharospasm,flexible,0
SAPHRIS,torticollis,torticollis,1
SAPHRIS,torticollis,torticollis,1
SAPHRIS,torticollis,torticollis,1
SAPHRIS,torticollis,torticollis,1
SAPHRIS,torticollis,dyskinesia,0
SAPHRIS,torticollis,blepharospasm,0
SAPHRIS,torticollis,torticollis,1
SAPHRIS,dyskinesia,symptoms included dystonia blepharospasm dyskinesia,1
SAPHRIS,dyskinesia,dosing,0
SAPHRIS,dyskinesia,,0
SAPHRIS,tardive dyskinesia,dystonia blepharospasm torticollis,0
SAPHRIS,tardive dyskinesia,dystonia blepharospasm torticollis tardive dyskinesia,1
SAPHRIS,tardive dyskinesia,Extrapyramidal symptoms included dystonia blepharospasm torticollis dyskinesia,0
SAPHRIS,tardive dyskinesia,tardive,1
SAPHRIS,tardive dyskinesia,symptoms included dystonia blepharospasm torticollis dyskinesia,0
SAPHRIS,muscle rigidity,muscle rigidity,1
SAPHRIS,muscle rigidity,tardive muscle rigidity,1
SAPHRIS,muscle rigidity,blepharospasm torticollis dyskinesia tardive muscle rigidity,1
SAPHRIS,muscle rigidity,tardive muscle rigidity,1
SAPHRIS,muscle rigidity,included dystonia blepharospasm torticollis dyskinesia,0
SAPHRIS,muscle rigidity,,0
SAPHRIS,muscle rigidity,dyskinesia tardive muscle rigidity,1
SAPHRIS,parkinsonism,dystonia blepharospasm torticollis dyskinesia tardive dyskinesia muscle,0
SAPHRIS,parkinsonism,parkinsonism,1
SAPHRIS,parkinsonism,parkinsonism,1
SAPHRIS,parkinsonism,includes the,0
SAPHRIS,parkinsonism,masked facies and,0
SAPHRIS,parkinsonism,tardive,0
SAPHRIS,masked facies,masked facies,1
SAPHRIS,masked facies,events somnolence se,0
SAPHRIS,masked facies,somnolence,0
SAPHRIS,masked facies,dyskinesia,0
SAPHRIS,masked facies,masked facies,1
SAPHRIS,tremor,facies,0
SAPHRIS,tremor,events,0
SAPHRIS,tremor,,0
SAPHRIS,tremor,disturbance,0
SAPHRIS,tremor,includes the following events somnolence,0
SAPHRIS,akathisia,akathisia,1
SAPHRIS,akathisia,muscle rigidity parkinsonism gait,0
SAPHRIS,akathisia,disturbance masked facies,0
SAPHRIS,somnolence,tremor excluding akathisia Somnolence includes the,0
SAPHRIS,sedation,sedation,1
SAPHRIS,sedation,includes the following events sedation,1
SAPHRIS,sedation,and hypersomnia System,0
SAPHRIS,sedation,hypersomnia System Organ ClassPreferred Term Placebo N,0
SAPHRIS,sedation,events sedation,1
SAPHRIS,hypersomnia,following events somnolence sedation hypersomnia,1
SAPHRIS,hypersomnia,hypersomnia,1
SAPHRIS,hypersomnia,hypersomnia,1
SAPHRIS,hypersomnia,System Organ ClassPreferred Term,0
SAPHRIS,hypersomnia,hypersomnia,1
SAPHRIS,hypersomnia,hypersomnia,1
SAPHRIS,hypersomnia,N,0
SAPHRIS,hypersomnia,and,0
SAPHRIS,hypersomnia,hypersomnia,1
SAPHRIS,hypersomnia,events somnolence sedation hypersomnia,1
SAPHRIS,Dry mouth,,0
SAPHRIS,Dry mouth,Dy,0
SAPHRIS,Dry mouth,mg twice daily N,0
SAPHRIS,Dyspepsia,th Dyspepsia Or,1
SAPHRIS,Dyspepsia,Dyspepsia Or,1
SAPHRIS,Dyspepsia,th,0
SAPHRIS,Dyspepsia,,0
SAPHRIS,Dyspepsia,th,0
SAPHRIS,Dyspepsia,Dyspepsia Or,1
SAPHRIS,Dyspepsia,Dyspepsia Or,1
SAPHRIS,Oral hypoesthesia,ia Oral hypoesthesia Toothache,1
SAPHRIS,Oral hypoesthesia,,0
SAPHRIS,Oral hypoesthesia,ia Oral,1
SAPHRIS,Oral hypoesthesia,ia Oral,1
SAPHRIS,Oral hypoesthesia,ia,0
SAPHRIS,Oral hypoesthesia,ia Oral hypoesthesia Toothache,1
SAPHRIS,Oral hypoesthesia,hypoesthesia Toothache,1
SAPHRIS,Toothache,poesthesia,0
SAPHRIS,Toothache,Toothache Gener,1
SAPHRIS,Toothache,poesthesia,0
SAPHRIS,Toothache,,0
SAPHRIS,Toothache,Toothache Gener,1
SAPHRIS,Toothache,Gener,0
SAPHRIS,Toothache,poesthesia,0
SAPHRIS,Toothache,Toothache Gener,1
SAPHRIS,Toothache,Toothache Gener,1
SAPHRIS,Fatigue,,0
SAPHRIS,Fatigue,disorders,0
SAPHRIS,Increased weight,Investigations,0
SAPHRIS,Increased weight,Investigations Increased weight Metabolism d,1
SAPHRIS,Increased appetite,,0
SAPHRIS,Increased appetite,,0
SAPHRIS,Increased appetite,,0
SAPHRIS,Increased appetite,disorders,0
SAPHRIS,Increased appetite,,0
SAPHRIS,Increased appetite,Increased,1
SAPHRIS,Increased appetite,appetite Musculoskeleta,1
SAPHRIS,Increased appetite,Increased appetite Musculoskeleta,1
SAPHRIS,Increased appetite,,0
SAPHRIS,Arthralgia,Arthralgia Pai,1
SAPHRIS,Arthralgia,Arthralgia Pai,1
SAPHRIS,Arthralgia,,0
SAPHRIS,Arthralgia,and connective tissue,0
SAPHRIS,Arthralgia,,0
SAPHRIS,Arthralgia,Arthralgia Pai,1
SAPHRIS,Pain in extremity,extremity,1
SAPHRIS,Pain in extremity,gia,0
SAPHRIS,Pain in extremity,Pain in extremity,1
SAPHRIS,Pain in extremity,gia Pain in extremity Nervous,1
SAPHRIS,Pain in extremity,gia,0
SAPHRIS,Pain in extremity,,0
SAPHRIS,Pain in extremity,gia Pain,1
SAPHRIS,Pain in extremity,gia,0
SAPHRIS,Pain in extremity,,0
SAPHRIS,Pain in extremity,gia,0
SAPHRIS,Akathisia,Akathisia Di,1
SAPHRIS,Akathisia,system disorders,0
SAPHRIS,Akathisia,,0
SAPHRIS,Akathisia,system Akathisia Di,1
SAPHRIS,Akathisia,system Akathisia Di,1
SAPHRIS,Akathisia,disorders,0
SAPHRIS,Akathisia,,0
SAPHRIS,Dizziness,,0
SAPHRIS,Dizziness,Dizziness Dy,1
SAPHRIS,Dizziness,ia,0
SAPHRIS,Dizziness,ia,0
SAPHRIS,Dizziness,Dy,0
SAPHRIS,Dizziness,,0
SAPHRIS,Dizziness,Dizziness Dy,1
SAPHRIS,Dizziness,ia Dizziness Dy,1
SAPHRIS,Dizziness,Dy,0
SAPHRIS,Dizziness,Dy,0
SAPHRIS,Dysgeusia,Dysgeusia He,1
SAPHRIS,Dysgeusia,Dysgeusia He,1
SAPHRIS,Dysgeusia,Dysgeusia He,1
SAPHRIS,Dysgeusia,Dysgeusia He,1
SAPHRIS,Dysgeusia,ss,0
SAPHRIS,Dysgeusia,Dysgeusia He,1
SAPHRIS,extrapyramidal symptoms,Other,0
SAPHRIS,extrapyramidal symptoms,extrapyramidal symptoms excluding,1
SAPHRIS,extrapyramidal symptoms,,0
SAPHRIS,extrapyramidal symptoms,Other,0
SAPHRIS,extrapyramidal symptoms,Other,0
SAPHRIS,extrapyramidal symptoms,Other extrapyramidal symptoms excluding akathisia,1
SAPHRIS,extrapyramidal symptoms,excluding akathisia Somnolenc,0
SAPHRIS,akathisia,extrapyramidal symptoms,0
SAPHRIS,akathisia,akathisia Somnolence,1
SAPHRIS,akathisia,akathisia Somnolence,1
SAPHRIS,akathisia,akathisia Somnolence,1
SAPHRIS,akathisia,akathisia Somnolence,1
SAPHRIS,Somnolence,,0
SAPHRIS,Somnolence,,0
SAPHRIS,Somnolence,,0
SAPHRIS,Somnolence,Somnolence Psychi,1
SAPHRIS,Somnolence,Somnolence Psychi,1
SAPHRIS,Somnolence,Somnolence Psychi,1
SAPHRIS,Somnolence,akathisia,0
SAPHRIS,Somnolence,Somnolence Psychi,1
SAPHRIS,Somnolence,excluding akathisia,0
SAPHRIS,Somnolence,Somnolence Psychi,1
SAPHRIS,Anxiety,,0
SAPHRIS,Anxiety,disorders,0
SAPHRIS,Anxiety,,0
SAPHRIS,Anxiety,disorders,0
SAPHRIS,Anxiety,Anxiety,1
SAPHRIS,Anxiety,Psychiatric Anxiety,1
SAPHRIS,Anxiety,disorders,0
SAPHRIS,Anxiety,disorders,0
SAPHRIS,Anxiety,,0
SAPHRIS,Anxiety,disorders,0
SAPHRIS,Depression,Depression Ins,1
SAPHRIS,Depression,Depression Ins,1
SAPHRIS,Depression,,0
SAPHRIS,Depression,Depression Ins,1
SAPHRIS,Insomnia,ion,0
SAPHRIS,Insomnia,ion Insomnia,1
SAPHRIS,Insomnia,Insomnia,1
SAPHRIS,Insomnia,ion Insomnia,1
SAPHRIS,Insomnia,Insomnia,1
SAPHRIS,Insomnia,ion Insomnia,1
SAPHRIS,Insomnia,Insomnia,1
SAPHRIS,Insomnia,ion,0
SAPHRIS,somnolence,somnolence,1
SAPHRIS,somnolence,at least,0
SAPHRIS,somnolence,somnolence,1
SAPHRIS,somnolence,the,0
SAPHRIS,somnolence,somnolence,1
SAPHRIS,somnolence,somnolence,1
SAPHRIS,somnolence,somnolence,1
SAPHRIS,somnolence,somnolence,1
SAPHRIS,somnolence,arm and at least twice the placebo,0
SAPHRIS,abdominal pain,abdominal pain,1
SAPHRIS,abdominal pain,daily abdominal pain,1
SAPHRIS,abdominal pain,abdominal,1
SAPHRIS,abdominal pain,twice daily abdominal pain,1
SAPHRIS,abdominal pain,mg twice daily,0
SAPHRIS,abdominal pain,abdominal pain,1
SAPHRIS,abdominal pain,pain,1
SAPHRIS,abdominal pain,pain,1
SAPHRIS,abdominal pain,in the mg twice daily group and in the mg twice daily group,0
SAPHRIS,nausea,,0
SAPHRIS,nausea,group nausea,1
SAPHRIS,nausea,nausea,1
SAPHRIS,nausea,nausea,1
SAPHRIS,nausea,dropped out,0
SAPHRIS,nausea,nausea,1
SAPHRIS,nausea,the mg twice daily group abdominal pain in the mg twice daily group and,0
SAPHRIS,tachycardia,tachycardia,1
SAPHRIS,tachycardia,Trial Includes the preferred tachycardia,1
SAPHRIS,tachycardia,Trial Includes the preferred tachycardia,1
SAPHRIS,tachycardia,the,0
SAPHRIS,tachycardia,increased Includes the preferred,0
SAPHRIS,tachycardia,the preferred tachycardia,1
SAPHRIS,heart rate increased,preferred terms tachycardia heart rate,1
SAPHRIS,oral hypoesthesia,oral hypoesthesia,1
SAPHRIS,oral paresthesia,pain abdominal,0
SAPHRIS,oral paresthesia,oral dysesthesia Includes,0
SAPHRIS,oral paresthesia,preferred terms oral oral paresthesia,1
SAPHRIS,oral paresthesia,oral,0
SAPHRIS,oral dysesthesia,pain lower,0
SAPHRIS,abdominal pain,abdominal pain lower and abdominal discomfort Includes the preferre,0
SAPHRIS,abdominal pain,oral dysesthesia Includes,0
SAPHRIS,abdominal pain,the preferred abdominal pain,1
SAPHRIS,abdominal pain,,0
SAPHRIS,abdominal pain lower,Includes,0
SAPHRIS,abdominal pain lower,pain lower,1
SAPHRIS,abdominal discomfort,abdominal discomfort,1
SAPHRIS,abdominal discomfort,abdominal discomfort,1
SAPHRIS,lethargy,lethargy,1
SAPHRIS,lethargy,pain lower,0
SAPHRIS,lethargy,and,0
SAPHRIS,lethargy,lethargy,1
SAPHRIS,hyperinsulinemia,hyperinsulinemia,1
SAPHRIS,hyperinsulinemia,preferred hyperinsulinemia,1
SAPHRIS,hyperinsulinemia,hyperinsulinemia,1
SAPHRIS,hyperinsulinemia,the preferred,0
SAPHRIS,hyperinsulinemia,Includes,0
SAPHRIS,hyperinsulinemia,the preferred terms,0
SAPHRIS,hyperinsulinemia,,0
SAPHRIS,somnolence,the,0
SAPHRIS,somnolence,,0
SAPHRIS,somnolence,the preferred somnolence,1
SAPHRIS,somnolence,somnolence,1
SAPHRIS,somnolence,hypersomnia System Organ,0
SAPHRIS,somnolence,hyperinsulinemia and blood insulin increased Includes the,0
SAPHRIS,somnolence,Includes the preferred somnolence,1
SAPHRIS,somnolence,somnolence,1
SAPHRIS,somnolence,somnolence,1
SAPHRIS,sedation,Class AE Preferred Term Placebo,0
SAPHRIS,sedation,Term,0
SAPHRIS,sedation,sedation,1
SAPHRIS,sedation,preferred terms sedation,1
SAPHRIS,hypersomnia,Placebo N,0
SAPHRIS,hypersomnia,Class AE Preferred Term Placebo,0
SAPHRIS,hypersomnia,hypersomnia,1
SAPHRIS,hypersomnia,somnolence sedation hypersomnia,1
SAPHRIS,hypersomnia,,0
SAPHRIS,hypersomnia,hypersomnia,1
SAPHRIS,hypersomnia,terms somnolence sedation hypersomnia,1
SAPHRIS,hypersomnia,and,0
SAPHRIS,hypersomnia,hypersomnia,1
SAPHRIS,hypersomnia,Placebo SAPHRIS,0
SAPHRIS,Tachycardia,,0
SAPHRIS,Tachycardia,,0
SAPHRIS,Tachycardia,Tachycardia,1
SAPHRIS,Tachycardia,Tachycardia,1
SAPHRIS,Nausea,esia,0
SAPHRIS,Nausea,,0
SAPHRIS,Nausea,esia,0
SAPHRIS,Vomiting,Vomiting,1
SAPHRIS,Vomiting,Vomiting,1
SAPHRIS,Vomiting,,0
SAPHRIS,Vomiting,,0
SAPHRIS,Vomiting,Vomiting,1
SAPHRIS,Abdominal pain,,0
SAPHRIS,Abdominal pain,Abdominal,1
SAPHRIS,Abdominal pain,pain G,1
SAPHRIS,Abdominal pain,G,0
SAPHRIS,Abdominal pain,,0
SAPHRIS,Abdominal pain,Abdominal pain G,1
SAPHRIS,Abdominal pain,Abdominal,1
SAPHRIS,Abdominal pain,,0
SAPHRIS,Abdominal pain,,0
SAPHRIS,Glossodynia,n,0
SAPHRIS,Glossodynia,Glossodynia,1
SAPHRIS,Glossodynia,Glossodynia,1
SAPHRIS,Glossodynia,n,0
SAPHRIS,Glossodynia,Glossodynia,1
SAPHRIS,Glossodynia,Glossodynia,1
SAPHRIS,Glossodynia,n Glossodynia,1
SAPHRIS,Fatigue,and Administrative Site,0
SAPHRIS,Fatigue,Fatigue,1
SAPHRIS,Fatigue,and Administrative Site Disorders,0
SAPHRIS,Fatigue,Site Fatigue,1
SAPHRIS,Fatigue,,0
SAPHRIS,Irritability,Irritability,1
SAPHRIS,Irritability,,0
SAPHRIS,Irritability,,0
SAPHRIS,Irritability,Irritability,1
SAPHRIS,Irritability,,0
SAPHRIS,Irritability,Irritability,1
SAPHRIS,Muscle strain,and Procedural,0
SAPHRIS,Muscle strain,I,0
SAPHRIS,Muscle strain,Procedural Complications,0
SAPHRIS,Increased weight,Increased weight Hyp,1
SAPHRIS,Increased weight,Increased,1
SAPHRIS,Increased weight,Increased weight Hyp,1
SAPHRIS,Increased weight,,0
SAPHRIS,Hyperinsulinemia,,0
SAPHRIS,Hyperinsulinemia,Hyperinsulinemia ALT,1
SAPHRIS,Hyperinsulinemia,ght,0
SAPHRIS,Hyperinsulinemia,ght Hyperinsulinemia ALT,1
SAPHRIS,Hyperinsulinemia,ALT,0
SAPHRIS,Hyperinsulinemia,,0
SAPHRIS,Hyperinsulinemia,ght Hyperinsulinemia ALT,1
SAPHRIS,ALT increased,ALT increased,1
SAPHRIS,ALT increased,,0
SAPHRIS,AST increased,,0
SAPHRIS,AST increased,AST,1
SAPHRIS,AST increased,AST increased M,1
SAPHRIS,AST increased,,0
SAPHRIS,AST increased,,0
SAPHRIS,Increased appetite,,0
SAPHRIS,Dehydration,Dehydration,1
SAPHRIS,Dehydration,Dehydration,1
SAPHRIS,Dehydration,Dehydration,1
SAPHRIS,Dehydration,etite,0
SAPHRIS,Myalgia,Connective Tissue Myalgia,1
SAPHRIS,Myalgia,Tissue Myalgia,1
SAPHRIS,Myalgia,Myalgia,1
SAPHRIS,Myalgia,Myalgia,1
SAPHRIS,Somnolence,Somnolence,1
SAPHRIS,Somnolence,Disorders,0
SAPHRIS,Somnolence,System,0
SAPHRIS,Somnolence,System Somnolence,1
SAPHRIS,Headache,,0
SAPHRIS,Headache,Headache,1
SAPHRIS,Headache,Headache,1
SAPHRIS,Headache,Headache,1
SAPHRIS,Headache,,0
SAPHRIS,Headache,,0
SAPHRIS,Headache,Headache,1
SAPHRIS,Dizziness,,0
SAPHRIS,Dizziness,,0
SAPHRIS,Dizziness,,0
SAPHRIS,Dizziness,,0
SAPHRIS,Dizziness,,0
SAPHRIS,Dizziness,Dizziness,1
SAPHRIS,Dizziness,,0
SAPHRIS,Parkinsonism,Parkinsonism,1
SAPHRIS,Parkinsonism,Parkinsonism,1
SAPHRIS,Parkinsonism,,0
SAPHRIS,Parkinsonism,,0
SAPHRIS,Parkinsonism,,0
SAPHRIS,Insomnia,,0
SAPHRIS,Suicidal ideation,,0
SAPHRIS,Anger,Anger,1
SAPHRIS,Anger,,0
SAPHRIS,Anger,tion Anger,1
SAPHRIS,Anger,,0
SAPHRIS,Anger,,0
SAPHRIS,Anger,tion Anger,1
SAPHRIS,Anger,tion Anger,1
SAPHRIS,Anger,Anger,1
SAPHRIS,Dysmenorrhea,Dysmenorrhea,1
SAPHRIS,Oropharyngeal pain,Disorders,0
SAPHRIS,Oropharyngeal pain,Oropharyngeal,1
SAPHRIS,Oropharyngeal pain,Nasal,0
SAPHRIS,Oropharyngeal pain,Nasal,0
SAPHRIS,Oropharyngeal pain,Nasal,0
SAPHRIS,Nasal congestion,Nasal congestion Dys,1
SAPHRIS,Nasal congestion,Nasal congestion Dys,1
SAPHRIS,Nasal congestion,,0
SAPHRIS,Nasal congestion,pain,0
SAPHRIS,Nasal congestion,pain,0
SAPHRIS,Nasal congestion,pain,0
SAPHRIS,Nasal congestion,pain,0
SAPHRIS,Nasal congestion,pain,0
SAPHRIS,Nasal congestion,Nasal congestion Dys,1
SAPHRIS,Nasal congestion,Dys,0
SAPHRIS,Dyspnea,Dyspnea,1
SAPHRIS,Dyspnea,ion,0
SAPHRIS,Dyspnea,,0
SAPHRIS,Rash,Rash,1
SAPHRIS,fatigue,incidence of,0
SAPHRIS,fatigue,,0
SAPHRIS,fatigue,,0
SAPHRIS,fatigue,fatigue,1
SAPHRIS,fatigue,In the short,0
SAPHRIS,fatigue,the short term pediatric bipolar trials the,0
SAPHRIS,fatigue,the,0
SAPHRIS,fatigue,trials the incidence fatigue,1
SAPHRIS,fatigue,fatigue,1
SAPHRIS,fatigue,fatigue,1
SAPHRIS,depression,,0
SAPHRIS,depression,rate depression,1
SAPHRIS,depression,depression,1
SAPHRIS,depression,depressive,0
SAPHRIS,suicidal ideation,Adverse,0
SAPHRIS,suicidal ideation,bipolar I disorder insomnia and depressive symptoms Adverse,0
SAPHRIS,suicidal ideation,,0
SAPHRIS,suicidal ideation,ideation,1
SAPHRIS,suicidal ideation,the placebo rate were suicidal,1
SAPHRIS,suicidal ideation,suicidal ideation,1
SAPHRIS,bipolar I disorder,were depression suicidal bipolar I disorder,1
SAPHRIS,bipolar I disorder,symptoms,0
SAPHRIS,bipolar I disorder,,0
SAPHRIS,bipolar I disorder,placebo rate were depression suicidal,0
SAPHRIS,bipolar I disorder,were depression suicidal bipolar I disorder,1
SAPHRIS,insomnia,ideation bipolar I insomnia,1
SAPHRIS,insomnia,Occurring at an,0
SAPHRIS,insomnia,insomnia,1
SAPHRIS,insomnia,insomnia,1
SAPHRIS,insomnia,depressive symptoms Adverse,0
SAPHRIS,depressive symptoms,depressive symptoms,1
SAPHRIS,Extrapyramidal symptoms,symptoms,1
SAPHRIS,Extrapyramidal symptoms,,0
SAPHRIS,Extrapyramidal symptoms,,0
SAPHRIS,Extrapyramidal symptoms,Extrapyramidal symptoms,1
SAPHRIS,Extrapyramidal symptoms,Somnolen,0
SAPHRIS,dystonia,to mg,0
SAPHRIS,dystonia,symptoms dystonia,1
SAPHRIS,dystonia,,0
SAPHRIS,dystonia,,0
SAPHRIS,dystonia,dystonia,1
SAPHRIS,dystonia,,0
SAPHRIS,dystonia,excluding akathisia Somnolence includes the,0
SAPHRIS,dystonia,dystonia,1
SAPHRIS,dystonia,dystonia,1
SAPHRIS,dystonia,dystonia,1
SAPHRIS,parkinsonism,parkinsonism,1
SAPHRIS,parkinsonism,twice,0
SAPHRIS,parkinsonism,parkinsonism,1
SAPHRIS,parkinsonism,flexible dosing,0
SAPHRIS,parkinsonism,parkinsonism,1
SAPHRIS,parkinsonism,Extrapyramidal symptoms included parkinsonism,1
SAPHRIS,parkinsonism,parkinsonism,1
SAPHRIS,parkinsonism,flexible,0
SAPHRIS,parkinsonism,parkinsonism,1
SAPHRIS,tremor,tremor,1
SAPHRIS,tremor,dystonia parkinsonism oculogyration tremor,1
SAPHRIS,tremor,tremor,1
SAPHRIS,tremor,tremor,1
SAPHRIS,tremor,,0
SAPHRIS,tremor,tremor,1
SAPHRIS,tremor,tremor,1
SAPHRIS,akathisia,akathisia,1
SAPHRIS,akathisia,symptoms included dystonia parkinsonism oculogyration,0
SAPHRIS,akathisia,akathisia,1
SAPHRIS,akathisia,symptoms included dystonia parkinsonism oculogyration and tremor,0
SAPHRIS,akathisia,akathisia,1
SAPHRIS,Somnolence,and tremor excluding Somnolence,1
SAPHRIS,Somnolence,tremor excluding Somnolence,1
SAPHRIS,somnolence,and tremor excluding akathisia Somnolence includes the following,0
SAPHRIS,somnolence,somnolence,1
SAPHRIS,somnolence,,0
SAPHRIS,somnolence,Somnolence includes the following somnolence,1
SAPHRIS,somnolence,Placebo,0
SAPHRIS,somnolence,somnolence,1
SAPHRIS,somnolence,the following somnolence,1
SAPHRIS,somnolence,somnolence,1
SAPHRIS,sedation,akathisia Somnolence includes the,0
SAPHRIS,sedation,sedation,1
SAPHRIS,sedation,tremor,0
SAPHRIS,sedation,sedation,1
SAPHRIS,sedation,sedation,1
SAPHRIS,sedation,following events somnolence and,0
SAPHRIS,sedation,sedation,1
SAPHRIS,sedation,SAPHRIS,0
SAPHRIS,sedation,ClassPreferred Term Placebo N,0
SAPHRIS,sedation,sedation,1
SAPHRIS,Dyspepsia,N Gastrointestinal disorders,0
SAPHRIS,Dyspepsia,or mg twice daily N Gastrointestinal disorders,0
SAPHRIS,Dyspepsia,Dyspepsia O,1
SAPHRIS,Dyspepsia,daily N Gastrointestinal,0
SAPHRIS,Dyspepsia,disorders,0
SAPHRIS,Dyspepsia,,0
SAPHRIS,Dyspepsia,Gastrointestinal disorders,0
SAPHRIS,Dyspepsia,Dyspepsia O,1
SAPHRIS,Oral hypoesthesia,,0
SAPHRIS,Oral hypoesthesia,,0
SAPHRIS,Oral hypoesthesia,a Oral hypoesthesia,1
SAPHRIS,Oral hypoesthesia,a,0
SAPHRIS,Fatigue,,0
SAPHRIS,Fatigue,Fatigue,1
SAPHRIS,Edema peripheral,,0
SAPHRIS,Edema peripheral,Edema,1
SAPHRIS,Edema peripheral,,0
SAPHRIS,Edema peripheral,Edema,1
SAPHRIS,Increased weight,,0
SAPHRIS,Increased weight,Investigations Increased,1
SAPHRIS,Increased weight,Investigations,0
SAPHRIS,Increased weight,Nervous s,0
SAPHRIS,Increased weight,Investigations,0
SAPHRIS,Dizziness,Dizziness O,1
SAPHRIS,Dizziness,,0
SAPHRIS,extrapyramidal symptoms,Other,0
SAPHRIS,extrapyramidal symptoms,,0
SAPHRIS,extrapyramidal symptoms,Other extrapyramidal,1
SAPHRIS,extrapyramidal symptoms,Other extrapyramidal symptoms excluding akathisia,1
SAPHRIS,extrapyramidal symptoms,,0
SAPHRIS,extrapyramidal symptoms,Other,0
SAPHRIS,extrapyramidal symptoms,akathisia,0
SAPHRIS,extrapyramidal symptoms,Other extrapyramidal,1
SAPHRIS,extrapyramidal symptoms,symptoms excluding akathisia Somnolence,1
SAPHRIS,akathisia,akathisia Somnolence,1
SAPHRIS,akathisia,Other extrapyramidal symptoms akathisia Somnolence,1
SAPHRIS,akathisia,,0
SAPHRIS,akathisia,akathisia Somnolence,1
SAPHRIS,akathisia,,0
SAPHRIS,akathisia,symptoms,0
SAPHRIS,akathisia,Other extrapyramidal symptoms akathisia Somnolence,1
SAPHRIS,akathisia,akathisia Somnolence,1
SAPHRIS,akathisia,akathisia Somnolence,1
SAPHRIS,akathisia,akathisia Somnolence,1
SAPHRIS,Somnolence,excluding akathisia,0
SAPHRIS,Somnolence,Somnolence Psy,1
SAPHRIS,Somnolence,,0
SAPHRIS,Somnolence,,0
SAPHRIS,Somnolence,Somnolence Psy,1
SAPHRIS,Somnolence,symptoms excluding,0
SAPHRIS,Somnolence,excluding,0
SAPHRIS,Somnolence,,0
SAPHRIS,Insomnia,,0
SAPHRIS,Insomnia,Insomnia V,1
SAPHRIS,Insomnia,,0
SAPHRIS,Hypertension,Hypertension,1
SAPHRIS,Hypertension,,0
SAPHRIS,dystonia,dystonia prolonged abnormal contractions,1
SAPHRIS,dystonia,the,0
SAPHRIS,dystonia,dystonia prolonged abnormal contractions,1
SAPHRIS,dystonia,individuals during,0
SAPHRIS,dystonia,,0
SAPHRIS,prolonged abnormal contractions of muscle groups,Symptoms of dystonia,0
SAPHRIS,prolonged abnormal contractions of muscle groups,,0
SAPHRIS,prolonged abnormal contractions of muscle groups,,0
SAPHRIS,prolonged abnormal contractions of muscle groups,of dystonia,0
SAPHRIS,prolonged abnormal contractions of muscle groups,prolonged abnormal contractions of muscle groups may occur in,1
SAPHRIS,Dystonic symptoms,during,0
SAPHRIS,Dystonic symptoms,symptoms include spasm of,1
SAPHRIS,Dystonic symptoms,of Dystonic,1
SAPHRIS,Dystonic symptoms,Dystonic,1
SAPHRIS,Dystonic symptoms,swallowing di,0
SAPHRIS,Dystonic symptoms,Dystonic symptoms include spasm of,1
SAPHRIS,Dystonic symptoms,first few days of Dystonic symptoms include spasm of,1
SAPHRIS,Dystonic symptoms,neck muscles sometimes progressing,0
SAPHRIS,spasm of the neck muscles,symptoms spasm of the neck,1
SAPHRIS,spasm of the neck muscles,breathing,0
SAPHRIS,spasm of the neck muscles,progressing to tightness of,0
SAPHRIS,tightness of the throat,throat swallowing difficulty difficulty,1
SAPHRIS,tightness of the throat,neck muscles sometimes progressing tightness of the throat swallowing difficulty difficulty,1
SAPHRIS,swallowing difficulty,progressing to tightness of the,0
SAPHRIS,swallowing difficulty,of the swallowing,1
SAPHRIS,swallowing difficulty,tightness of the swallowing,1
SAPHRIS,swallowing difficulty,andor protrusion of the tongue While these symptoms can occur,0
SAPHRIS,swallowing difficulty,the swallowing,1
SAPHRIS,swallowing difficulty,of the tongue While these symptoms can,0
SAPHRIS,swallowing difficulty,,0
SAPHRIS,swallowing difficulty,occur at low doses,0
SAPHRIS,swallowing difficulty,symptoms include spasm of the neck,0
SAPHRIS,protrusion of the tongue,difficulty breathing protrusion of the tongue While these symptoms,1
SAPHRIS,protrusion of the tongue,swallowing difficulty difficulty,0
SAPHRIS,protrusion of the tongue,the,0
SAPHRIS,acute dystonia,drugs An elevated,0
SAPHRIS,acute dystonia,dystonia is observed in,1
SAPHRIS,acute dystonia,,0
SAPHRIS,acute dystonia,An elevated risk acute dystonia is observed in,1
SAPHRIS,acute dystonia,acute dystonia is observed in,1
SAPHRIS,acute dystonia,,0
SAPHRIS,acute dystonia,dystonia is observed in,1
SAPHRIS,extrapyramidal symptoms,Angus Rating Scale extrapyramidal,1
SAPHRIS,extrapyramidal symptoms,Rating,0
SAPHRIS,EPS,EPS the Barnes Akathisia,1
SAPHRIS,EPS,fo,0
SAPHRIS,EPS,EPS the Barnes Akathisia,1
SAPHRIS,EPS,EPS the Barnes Akathisia,1
SAPHRIS,EPS,Akathisia Scale for,0
SAPHRIS,EPS,EPS the Barnes Akathisia,1
SAPHRIS,EPS,collected on the Simpson Angus Rating,0
SAPHRIS,akathisia,akathisia and the Assessments,1
SAPHRIS,akathisia,akathisia and the Assessments,1
SAPHRIS,akathisia,akathisia and the Assessments,1
SAPHRIS,akathisia,akathisia and the Assessments,1
SAPHRIS,akathisia,of Involuntary Movement Scales for dyskinesias The mean change from,0
SAPHRIS,akathisia,and the Assessments of Involuntary Movement,0
SAPHRIS,akathisia,the,0
SAPHRIS,dyskinesias,dyskinesias The mean change,1
SAPHRIS,dyskinesias,Assessments,0
SAPHRIS,dyskinesias,,0
SAPHRIS,dyskinesias,akathisia and the Assessments of Involuntary,0
SAPHRIS,dyskinesias,dyskinesias The mean change,1
SAPHRIS,dyskinesias,dyskinesias The mean change,1
SAPHRIS,dyskinesias,allSAPHRIS mg or mg twice,0
SAPHRIS,dyskinesias,was com,0
SAPHRIS,EPS-related events,,0
SAPHRIS,akathisia,akathisia for SAPHRIStreated patients,1
SAPHRIS,akathisia,events related,0
SAPHRIS,akathisia,akathisia for SAPHRIStreated patients,1
SAPHRIS,akathisia,akathisia for SAPHRIStreated patients,1
SAPHRIS,akathisia,related akathisia for SAPHRIStreated patients,1
SAPHRIS,akathisia,akathisia for SAPHRIStreated patients,1
SAPHRIS,akathisia,patients was versus for placebo and the incidence of,0
SAPHRIS,akathisia,adult trials the incidence of reported EPSrelated events excluding events,0
SAPHRIS,akathisia,excluding events related akathisia for SAPHRIStreated patients,1
SAPHRIS,akathisia,for,0
SAPHRIS,akathisia,for placebo In shortterm,0
SAPHRIS,akathisia,events for SAPHRIStreated patients was versus for,0
SAPHRIS,akathisia,akathisia related events for,1
SAPHRIS,akathisia,akathisia related events for,1
SAPHRIS,akathisia,placebocon,0
SAPHRIS,akathisia,akathisia related events for,1
SAPHRIS,akathisia,akathisia related events for,1
SAPHRIS,akathisia,to akathisia for SAPHRIStreated patients was versus,0
SAPHRIS,akathisia,akathisia related events for,1
SAPHRIS,EPS-related events,EPS-related events excluding events related,1
SAPHRIS,EPS-related events,incidence EPS-related events excluding events related,1
SAPHRIS,EPS-related events,trials the incidence EPS-related,1
SAPHRIS,EPS-related events,trials the incidence EPS-related,1
SAPHRIS,EPS-related events,shortterm placebocontrolled bipolar mania adult trials the incidence of,0
SAPHRIS,EPS-related events,EPS-related,1
SAPHRIS,EPS-related events,incidence EPS-related,1
SAPHRIS,EPS-related events,the incidence of,0
SAPHRIS,EPS-related events,versus for,0
SAPHRIS,EPS-related events,events,0
SAPHRIS,akathisia,,0
SAPHRIS,akathisia,and the incidence akathisia related events for,1
SAPHRIS,EPS-related events,disorder the,0
SAPHRIS,EPS-related events,I disorder the incidences EPS-related events excluding events related,1
SAPHRIS,EPS-related events,placebocontrolled pediatric trial with bipolar,0
SAPHRIS,EPS-related events,the incidences of,0
SAPHRIS,EPS-related events,disorder the incidences EPS-related,1
SAPHRIS,EPS-related events,akathisia were and for patients treated,0
SAPHRIS,EPS-related events,EPS-related events excluding events related,1
SAPHRIS,EPS-related events,events excluding events related,1
SAPHRIS,akathisia,akathisia were and for,1
SAPHRIS,akathisia,akathisia were and for,1
SAPHRIS,akathisia,akathisia were and for,1
SAPHRIS,akathisia,to,0
SAPHRIS,akathisia,,0
SAPHRIS,akathisia,akathisia were and for,1
SAPHRIS,akathisia,were and for patients treated with SAPHRIS mg mg and mg,0
SAPHRIS,akathisia,akathisia were and for,1
SAPHRIS,EPS-related events,,0
SAPHRIS,bradykinesia,events bradykinesia dyskinesia dystonia oromandibular,1
SAPHRIS,bradykinesia,bradykinesia dyskinesia dystonia oromandibular,1
SAPHRIS,bradykinesia,bradykinesia dyskinesia dystonia oromandibular,1
SAPHRIS,bradykinesia,bradykinesia dyskinesia dystonia oromandibular,1
SAPHRIS,dyskinesia,dyskinesia dystonia oromandibular dystonia,1
SAPHRIS,dyskinesia,dyskinesia dystonia oromandibular dystonia,1
SAPHRIS,dyskinesia,dyskinesia dystonia oromandibular dystonia,1
SAPHRIS,dyskinesia,,0
SAPHRIS,dyskinesia,dyskinesia dystonia oromandibular dystonia,1
SAPHRIS,dyskinesia,dyskinesia dystonia oromandibular dystonia,1
SAPHRIS,dyskinesia,for placebotreated patients EPSrelated events include bradykinesia,0
SAPHRIS,dyskinesia,patients EPSrelated events include bradykinesia,0
SAPHRIS,dyskinesia,dystonia muscle contractions,0
SAPHRIS,dystonia,dystonia oromandibular dystonia muscle,1
SAPHRIS,dystonia,dyskinesia,0
SAPHRIS,dystonia,dyskinesia,0
SAPHRIS,dystonia,,0
SAPHRIS,dystonia,dystonia muscle contractions involuntary muscle,0
SAPHRIS,dystonia,events include bradykinesia dystonia oromandibular dystonia muscle,1
SAPHRIS,dystonia,,0
SAPHRIS,dystonia,dystonia oromandibular dystonia muscle,1
SAPHRIS,oromandibular dystonia,dyskinesia oromandibular,1
SAPHRIS,oromandibular dystonia,dyskinesia dystonia,0
SAPHRIS,oromandibular dystonia,oromandibular dystonia muscle contractions involuntary,1
SAPHRIS,oromandibular dystonia,oromandibular dystonia muscle contractions involuntary,1
SAPHRIS,oromandibular dystonia,patients EPSrelated events include,0
SAPHRIS,oromandibular dystonia,dystonia muscle contractions involuntary,1
SAPHRIS,oromandibular dystonia,include bradykinesia dyskinesia oromandibular dystonia muscle contractions involuntary,1
SAPHRIS,oromandibular dystonia,muscle contractions involuntary,0
SAPHRIS,muscle twitching,,0
SAPHRIS,musculoskeletal stiffness,For events,0
SAPHRIS,parkinsonism,parkinsonism protrusion tongue resting,1
SAPHRIS,parkinsonism,parkinsonism protrusion tongue resting,1
SAPHRIS,parkinsonism,,0
SAPHRIS,protrusion tongue,,0
SAPHRIS,protrusion tongue,muscle twitching musculoskeletal stiffness protrusion,1
SAPHRIS,protrusion tongue,protrusion,1
SAPHRIS,protrusion tongue,stiffness protrusion tongue resting tremor and,1
SAPHRIS,protrusion tongue,muscle twitching musculoskeletal stiffness protrusion,1
SAPHRIS,protrusion tongue,muscle twitching musculoskeletal stiffness protrusion tongue resting tremor and,1
SAPHRIS,protrusion tongue,and,0
SAPHRIS,resting tremor,akathisia incidences were and,0
SAPHRIS,resting tremor,resting tremor and tremor For,1
SAPHRIS,resting tremor,,0
SAPHRIS,tremor,tremor For events of,1
SAPHRIS,tremor,tremor For events of,1
SAPHRIS,tremor,tremor For events of,1
SAPHRIS,tremor,stiffness,0
SAPHRIS,tremor,tremor For events of,1
SAPHRIS,tremor,patients treated with,0
SAPHRIS,tremor,events of akathisia,0
SAPHRIS,tremor,tongue,0
SAPHRIS,tremor,tremor For events of,1
SAPHRIS,akathisia,events akathisia incidences were and,1
SAPHRIS,akathisia,akathisia incidences were and,1
SAPHRIS,Oral hypoesthesia,,0
SAPHRIS,Oral hypoesthesia,Other Oral hypoesthesia andor oral paresthesia,1
SAPHRIS,oral paresthesia,,0
SAPHRIS,oral paresthesia,resolves,0
SAPHRIS,oral paresthesia,,0
SAPHRIS,oral paresthesia,placebotreated patients Other Findings,0
SAPHRIS,oral paresthesia,oral paresthesia may occur directly,1
SAPHRIS,oral paresthesia,SAPHRIS and usually resolves within hour Labo,0
SAPHRIS,oral paresthesia,Findings Oral hypoesthesia oral paresthesia may occur directly,1
SAPHRIS,oral paresthesia,placebotreated patients Other Findings Oral hypoesthesia andor,0
SAPHRIS,elevations in serum transaminases,Transient,0
SAPHRIS,elevations in serum transaminases,Transaminases elevations in,1
SAPHRIS,elevations in serum transaminases,elevations in serum,1
SAPHRIS,increase in transaminase levels,decrease of unitsL for placebotrea,0
SAPHRIS,increase in transaminase levels,transaminase levels for SAPHRIStreated patients,1
SAPHRIS,increase in transaminase levels,adult trials the increase in,1
SAPHRIS,increase in transaminase levels,adult trials the increase in transaminase levels for SAPHRIStreated patients,1
SAPHRIS,increase in transaminase levels,levels for SAPHRIStreated patients,1
SAPHRIS,increase in transaminase levels,for SAPHRIStreated patients was unitsL compared to,0
SAPHRIS,increase in transaminase levels,unitsL,0
SAPHRIS,increase in transaminase levels,trials the,0
SAPHRIS,transaminase elevations,The proportion of patients transaminase elevations times ULN at,1
SAPHRIS,transaminase elevations,transaminase,1
SAPHRIS,transaminase elevations,patients transaminase,1
SAPHRIS,transaminase elevations,,0
SAPHRIS,transaminase elevations,proportion of patients transaminase,1
SAPHRIS,transaminase elevations,,0
SAPHRIS,transaminase elevations,for,0
SAPHRIS,transaminase elevations,,0
SAPHRIS,transaminase elevations,to a decrease,0
SAPHRIS,transaminase elevations,for SAPHRIStreated patients versus for placebotreated,0
SAPHRIS,increase in transaminase levels,trials the increase in transaminase levels for SAPHRIStreated patients,1
SAPHRIS,increase in transaminase levels,bipolar,0
SAPHRIS,increase in transaminase levels,the increase,1
SAPHRIS,increase in transaminase levels,adult mania trials the increase in transaminase,1
SAPHRIS,increase in transaminase levels,,0
SAPHRIS,increase in transaminase levels,increase in transaminase levels for SAPHRIStreated patients,1
SAPHRIS,increase in transaminase levels,SAPHRIStreated patients was unitsL compared to a decrease,0
SAPHRIS,ALT elevations,treated patients,0
SAPHRIS,ALT elevations,treated with SAPHRIS mg twice,0
SAPHRIS,ALT elevations,pediatric patients ALT,1
SAPHRIS,ALT elevations,of pediatric,0
SAPHRIS,ALT elevations,ALT elevations times upper limit,1
SAPHRIS,ALT elevations,proportion of pediatric patients ALT,1
SAPHRIS,ALT elevations,of normal ULN was for patients treated with,0
SAPHRIS,ALT elevations,times upper limit of normal ULN was for patients treated with SAPHRIS mg twice daily,0
SAPHRIS,decreases in prolactin levels,the decreases in prolactin levels were ngmL for,1
SAPHRIS,prolactin elevations,The proportion of patients prolactin elevations times ULN at,1
SAPHRIS,prolactin elevations,versus,0
SAPHRIS,prolactin elevations,proportion,0
SAPHRIS,prolactin elevations,with,0
SAPHRIS,prolactin elevations,patients prolactin elevations times ULN at,1
SAPHRIS,prolactin elevations,,0
SAPHRIS,increase in prolactin levels,bipolar mania adult,0
SAPHRIS,prolactin elevations,prolactin elevations times ULN at,1
SAPHRIS,prolactin elevations,prolactin,1
SAPHRIS,prolactin elevations,,0
SAPHRIS,prolactin elevations,The proportion of patients prolactin,1
SAPHRIS,prolactin elevations,The proportion of patients prolactin,1
SAPHRIS,decrease in prolactin,prolactin from baseline for,1
SAPHRIS,decrease in prolactin,adult trial that included primarily patients with schizophrenia the mean,0
SAPHRIS,decrease in prolactin,,0
SAPHRIS,decrease in prolactin,in prolactin from baseline for,1
SAPHRIS,decrease in prolactin,schizophrenia the decrease in prolactin from baseline for,1
SAPHRIS,decrease in prolactin,schizophrenia the decrease in prolactin from baseline for,1
SAPHRIS,decrease in prolactin,decrease in prolactin from baseline for,1
SAPHRIS,prolactin elevations,of ngmL for placebotreated patients There were no,0
SAPHRIS,prolactin elevations,There were no reports,0
SAPHRIS,prolactin elevations,Galactorrhea or,0
SAPHRIS,prolactin elevations,reports prolactin,1
SAPHRIS,prolactin elevations,reports prolactin,1
SAPHRIS,prolactin elevations,prolactin elevations times ULN at,1
SAPHRIS,prolactin elevations,reports prolactin,1
SAPHRIS,prolactin elevations,ngmL for placebotreated,0
SAPHRIS,prolactin elevations,were no reports of,0
SAPHRIS,prolactin elevations,,0
SAPHRIS,Galactorrhea,treated with SAPHRIS or Galactorrhea or dysmenorrhea were,1
SAPHRIS,dysmenorrhea,placebo Galactorrhea dysmenorrhea were reported in,1
SAPHRIS,dysmenorrhea,Galactorrhea,0
SAPHRIS,dysmenorrhea,placebo Galactorrhea,0
SAPHRIS,gynecomastia,gynecomastia in this trial,1
SAPHRIS,gynecomastia,patients with CK elevations,0
SAPHRIS,gynecomastia,gynecomastia in this trial,1
SAPHRIS,gynecomastia,gynecomastia in this trial,1
SAPHRIS,gynecomastia,were no reports,0
SAPHRIS,gynecomastia,,0
SAPHRIS,CK elevations,this trial,0
SAPHRIS,CK elevations,elevations times ULN at,1
SAPHRIS,CK elevations,patients,0
SAPHRIS,CK elevations,patients CK,1
SAPHRIS,CK elevations,of adult patients CK,1
SAPHRIS,CK elevations,Kinase CK The,0
SAPHRIS,CK elevations,time were and for patients treated with SAPHRIS mg twice daily and,0
SAPHRIS,CK elevations,CK elevations times ULN at,1
SAPHRIS,CK elevations,CK elevations times ULN during,1
SAPHRIS,CK elevations,time were and,0
SAPHRIS,CK elevations,a week trial in pediatric bipolar I disorder at any,0
SAPHRIS,CK elevations,proportion of patients CK,1
SAPHRIS,CK elevations,The proportion of,0
SAPHRIS,thrombocytopenia,disorders inf,0
SAPHRIS,thrombocytopenia,infrequent anemia thrombocytopenia Cardiac disorders infrequent,1
SAPHRIS,thrombocytopenia,disorders infrequent temporary bundle branch block Eye disorders inf,0
SAPHRIS,thrombocytopenia,,0
SAPHRIS,temporary bundle branch block,anemia,0
SAPHRIS,temporary bundle branch block,disorders temporary bundle branch block Eye disorders infrequent,1
SAPHRIS,temporary bundle branch block,thrombocytopenia Cardiac disorders temporary bundle branch block Eye disorders infrequent,1
SAPHRIS,temporary bundle branch block,,0
SAPHRIS,temporary bundle branch block,Gastrointestinal,0
SAPHRIS,temporary bundle branch block,,0
SAPHRIS,temporary bundle branch block,,0
SAPHRIS,temporary bundle branch block,temporary,1
SAPHRIS,temporary bundle branch block,Cardiac disorders temporary bundle branch block Eye disorders infrequent,1
SAPHRIS,temporary bundle branch block,rare thrombocytopenia,0
SAPHRIS,accommodation disorder,disorders accommodation disorder Gastrointestinal disorders infrequent,1
SAPHRIS,accommodation disorder,Gastrointestinal disorders infrequent swollen tongue,0
SAPHRIS,accommodation disorder,Gastrointestinal disorders infrequent swollen,0
SAPHRIS,accommodation disorder,block Eye disorders accommodation disorder Gastrointestinal disorders infrequent,1
SAPHRIS,accommodation disorder,infrequent,0
SAPHRIS,swollen tongue,,0
SAPHRIS,swollen tongue,disorder Gastrointestinal,0
SAPHRIS,swollen tongue,drug,0
SAPHRIS,idiosyncratic drug reaction,disorders,0
SAPHRIS,idiosyncratic drug reaction,disorders infrequent swollen tongue,0
SAPHRIS,idiosyncratic drug reaction,idiosyncratic,1
SAPHRIS,hyponatremia,MedDRA terms,0
SAPHRIS,hyponatremia,reaction Investigations,0
SAPHRIS,hyponatremia,,0
SAPHRIS,hyponatremia,hyponatremia Nervous system disorders,1
SAPHRIS,hyponatremia,disorders rare,0
SAPHRIS,hyponatremia,hyponatremia Nervous system disorders,1
SAPHRIS,hyponatremia,hyponatremia Nervous system disorders,1
SAPHRIS,hyponatremia,Investigations hyponatremia Nervous system disorders,1
SAPHRIS,hyponatremia,hyponatremia Nervous system disorders,1
SAPHRIS,hyponatremia,hyponatremia Nervous system disorders,1
SAPHRIS,dysarthria,infrequent hyponatremia,0
SAPHRIS,dysarthria,adults or,0
SAPHRIS,diplopia,diplopia vision blurred Gastrointestinal,1
SAPHRIS,vision blurred,Gastrointestinal disorders infrequent gastroesophageal,0
SAPHRIS,vision blurred,trial within the database of pediatric patients Eye disorders,0
SAPHRIS,vision blurred,vision blurred Gastrointestinal disorders infrequent,1
SAPHRIS,vision blurred,,0
SAPHRIS,vision blurred,,0
SAPHRIS,vision blurred,vision,1
SAPHRIS,vision blurred,Eye disorders infrequent vision blurred Gastrointestinal disorders infrequent,1
SAPHRIS,vision blurred,infrequent vision,1
SAPHRIS,vision blurred,blurred Gastrointestinal disorders infrequent,1
SAPHRIS,gastroesophageal reflux disease,Gastrointestinal disorders gastroesophageal reflux disease Injury Poisoning and,1
SAPHRIS,gastroesophageal reflux disease,disorders gastroesophageal,1
SAPHRIS,gastroesophageal reflux disease,vision blurred Gastrointestinal disorders gastroesophageal reflux disease Injury Poisoning and,1
SAPHRIS,gastroesophageal reflux disease,blurred Gastrointestinal disorders gastroesophageal reflux,1
SAPHRIS,gastroesophageal reflux disease,infrequent,0
SAPHRIS,gastroesophageal reflux disease,,0
SAPHRIS,gastroesophageal reflux disease,Complications infrequent fall,0
SAPHRIS,gastroesophageal reflux disease,infrequent fall Skin and,0
SAPHRIS,fall,Complications,0
SAPHRIS,fall,Injury Poisoning and Procedural Complications infrequent,0
SAPHRIS,fall,fall Skin and subcutaneous,1
SAPHRIS,fall,,0
SAPHRIS,fall,Poisoning and Procedural Complications fall Skin and subcutaneous,1
SAPHRIS,fall,fall Skin and subcutaneous,1
SAPHRIS,photosensitivity reaction,reaction Renal and urinary,1
SAPHRIS,photosensitivity reaction,reaction Renal and urinary,1
SAPHRIS,enuresis,enuresis Postmarketing Experience The,1
SAPHRIS,enuresis,disorders,0
SAPHRIS,enuresis,disorders,0
SAPHRIS,enuresis,been identified during,0
SAPHRIS,enuresis,photosensitivity reaction Renal,0
SAPHRIS,enuresis,reactions,0
SAPHRIS,enuresis,enuresis Postmarketing Experience The,1
SAPHRIS,enuresis,enuresis Postmarketing Experience The,1
SAPHRIS,Application site reactions,led to discontinuation of Application site,1
SAPHRIS,Application site reactions,of,0
SAPHRIS,Application site reactions,site reactions primarily in the,1
SAPHRIS,Application site reactions,therapy,0
SAPHRIS,Application site reactions,,0
SAPHRIS,application site reactions,and inflammation Choking has been reported,0
SAPHRIS,application site reactions,been reported application site,1
SAPHRIS,application site reactions,,0
SAPHRIS,application site reactions,reported application site reactions included oral ulcers,1
SAPHRIS,application site reactions,site reactions primarily in the sublingual area have been,0
SAPHRIS,Choking,ulcers blisters peelingsloughing and,0
SAPHRIS,Choking,been reported by patients some of whom,0
SAPHRIS,Choking,Choking has been reported,1
SAPHRIS,Choking,Choking has been reported,1
SAPHRIS,Choking,patients some,0
SAPHRIS,Choking,some of whom may have also experienced,0
SAPHRIS,Choking,,0
SAPHRIS,oropharyngeal muscular dysfunction,also oropharyngeal muscular,1
SAPHRIS,oropharyngeal muscular dysfunction,patients some of whom may have also,0
SAPHRIS,INCREASED MORTALITY,Use i n Elderly Patients,1
SAPHRIS,INCREASED MORTALITY,following adverse,0
SAPHRIS,INCREASED MORTALITY,n Elderly Patients with DementiaRelated,0
SAPHRIS,INCREASED MORTALITY,eling:,1
SAPHRIS,INCREASED MORTALITY,sections of the eling:,1
SAPHRIS,INCREASED MORTALITY,seeBoxed Warningand,0
SAPHRIS,INCREASED MORTALITY,other sections of the eling:,1
SAPHRIS,death,ution s Tardive Dyskinesia,1
SAPHRIS,death,,0
SAPHRIS,death,Hem odynamic Effects see,1
SAPHRIS,death,Hem odynamic Effects see,1
SAPHRIS,death,,0
SAPHRIS,death,Hypotension Syncope and r Hem odynamic Effects see,1
SAPHRIS,death,r,1
SAPHRIS,Cerebrovascular Adverse Events,ons are discussed in more deta,1
SAPHRIS,Cerebrovascular Adverse Events,labeling Use in,0
SAPHRIS,Cerebrovascular Adverse Events,,0
SAPHRIS,Cerebrovascular Adverse Events,sections of the labeling Use in Elderly Patients with,0
SAPHRIS,Cerebrovascular Adverse Events,ons are,1
SAPHRIS,Cerebrovascular Adverse Events,are discussed in more deta il in,1
SAPHRIS,Cerebrovascular Adverse Events,in Elderly,0
SAPHRIS,Cerebrovascular Adverse Events,ons,1
SAPHRIS,cerebrovascular adverse events,Elderl y,1
SAPHRIS,cerebrovascular adverse events,,0
SAPHRIS,cerebrovascular adverse events,discussed in more detail,0
SAPHRIS,cerebrovascular adverse events,more detail in other,0
SAPHRIS,cerebrovascular adverse events,labeling: *,1
SAPHRIS,cerebrovascular adverse events,"sections of labeling:



 *  Use in Elderl y",1
SAPHRIS,cerebrovascular adverse events,* Use in Elderl y,1
SAPHRIS,cerebrovascular adverse events,of labeling:,1
SAPHRIS,cerebrovascular adverse events,"sections of labeling:



 *  Use in Elderl y",1
SAPHRIS,stroke,sections of the labeling Use,0
SAPHRIS,stroke,Use in Elderly ts wit h,1
SAPHRIS,transient ischemic attack,Dementia-Related Psychosi s,1
SAPHRIS,transient ischemic attack,Dementia-Related Psychosi s,1
SAPHRIS,transient ischemic attack,,0
SAPHRIS,transient ischemic attack,s seeBoxed Warningand Warnings,0
SAPHRIS,Metabolic Changes,and inflammation see Adverse Reactions,0
SAPHRIS,Metabolic Changes,,0
SAPHRIS,Metabolic Changes,,0
SAPHRIS,metabolic changes,other Hemodynamic Effects,0
SAPHRIS,metabolic changes,blisters peelingsloughing and inflammation,0
SAPHRIS,metabolic changes,see Adverse *,1
SAPHRIS,metabolic changes,"Adverse   
 *  Orthostati c",1
SAPHRIS,cerebrovascular risk,and Hemodynamic,1
SAPHRIS,cerebrovascular risk,,0
SAPHRIS,metabolic changes,,0
SAPHRIS,metabolic changes,other Hemodynamic Effects see nings and,1
SAPHRIS,metabolic changes,,0
SAPHRIS,metabolic changes,,0
SAPHRIS,metabolic changes,see nings and,1
SAPHRIS,metabolic changes,War,0
SAPHRIS,metabolic changes,nings and Precaut ions,1
SAPHRIS,metabolic changes,see War,0
SAPHRIS,hyperglycemia,,0
SAPHRIS,dyslipidemia,,0
SAPHRIS,dyslipidemia,"and Precautions enia,",1
SAPHRIS,dyslipidemia,Neutro penia,1
SAPHRIS,dyslipidemia,"see Warnings and Precautions enia,",1
SAPHRIS,dyslipidemia,see Warnings,0
SAPHRIS,weight gain,Warnings and Precautions Leukopenia  and Agranu locytosis,1
SAPHRIS,weight gain,other Hemodynamic Effects see Warnings and Precautions Leukopenia,0
SAPHRIS,weight gain,and Precautions QT Interval Prolongation see Warnings and Prec,0
SAPHRIS,weight gain,Effects see Warnings and Precautions,0
SAPHRIS,weight gain,and other Hemodynamic Effects see Warnings and Precautions,0
SAPHRIS,Hypersensitivity Reactions,Agranulocytosis Warnings and,1
SAPHRIS,Hypersensitivity Reactions,Interval Prolongation see Warnings and,0
SAPHRIS,Hypersensitivity Reactions, Warnings and Precautions  QT,1
SAPHRIS,Hypersensitivity Reactions, Warnings and Precautions  QT,1
SAPHRIS,Hypersensitivity Reactions,,0
SAPHRIS,Hypersensitivity Reactions,,0
SAPHRIS,Hypersensitivity Reactions,and Agranulocytosis  Warnings and Precautions  QT,1
SAPHRIS,Hypersensitivity Reactions,and Precautions Leukopenia Neutropenia and,0
SAPHRIS,anaphylaxis,ee,1
SAPHRIS,angioedema,Precaution s,1
SAPHRIS,angioedema,,0
SAPHRIS,angioedema,and Precautions QT Interval Prolongation,0
SAPHRIS,angioedema,Precaution s,1
SAPHRIS,angioedema,Warnings Precaution s,1
SAPHRIS,angioedema,Interval Prolongation see Warnings Precaution s,1
SAPHRIS,angioedema,see,0
SAPHRIS,angioedema,Interval,0
SAPHRIS,Orthostatic Hypotension,see,0
SAPHRIS,Orthostatic Hypotension,Warnings and Preca utions,1
SAPHRIS,Orthostatic Hypotension,Prolongation see Warnings,0
SAPHRIS,Orthostatic Hypotension,Interval Prolongation see Warnings,0
SAPHRIS,Orthostatic Hypotension,and Preca utions,1
SAPHRIS,Orthostatic Hypotension,[see Warnings and Preca utions,1
SAPHRIS,Orthostatic Hypotension,,0
SAPHRIS,Orthostatic Hypotension,,0
SAPHRIS,Orthostatic Hypotension,Warnings and Precautions Potential for Cognitive,0
SAPHRIS,Orthostatic Hypotension,,0
SAPHRIS,Hemodynamic Effects,,0
SAPHRIS,Hemodynamic Effects,,0
SAPHRIS,Hemodynamic Effects,see Warnings and,0
SAPHRIS,Dizziness,Seizures see s and Pre cautions,1
SAPHRIS,Dizziness,Precautions Seizures see s and Pre cautions,1
SAPHRIS,tachycardia,Potential for Cognitive and Motor Impairment see Warnings and,0
SAPHRIS,tachycardia,utions (5.1 Potential,1
SAPHRIS,syncope,and Precautions Potential,0
SAPHRIS,syncope,see Warnings and,0
SAPHRIS,syncope,and Precautions Potential or,1
SAPHRIS,syncope,or Cogn itive,1
SAPHRIS,Leukopenia,and tions (5.1 Dysphagia,1
SAPHRIS,Leukopenia,,0
SAPHRIS,Leukopenia,see Warnings and tions,1
SAPHRIS,Leukopenia,Use in Patients with Concomitant Ill,0
SAPHRIS,Leukopenia,Suicide see Warnings and Precau,0
SAPHRIS,Leukopenia,and Precautions Suicide,0
SAPHRIS,Leukopenia,,0
SAPHRIS,Leukopenia,see Warnings and tions,1
SAPHRIS,Leukopenia,(5.1 Dysphagia,1
SAPHRIS,Leukopenia,and tions (5.1 Dysphagia,1
SAPHRIS,Agranulocytosis,Precautions  [see Warnings  and,1
SAPHRIS,Agranulocytosis,,0
SAPHRIS,Agranulocytosis,Warnings and Precautions  [see Warnings  and,1
SAPHRIS,QT Prolongation,the maintenance treatment of renia in adults was,1
SAPHRIS,QT Prolongation,adults was,1
SAPHRIS,QT Prolongation,renia in adults was,1
SAPHRIS,QT Prolongation,of renia,1
SAPHRIS,QT Prolongation,the maintenance treatment of renia in adults was,1
SAPHRIS,QT Prolongation,that seen with acute treatment The most common adverse,0
SAPHRIS,Increases in QT interval,that seen with,1
SAPHRIS,Increases in QT interval,reactions and at least twice the rate of,0
SAPHRIS,Increases in QT interval,of SAPHRIS in the maintenance treatment of schizophrenia in,0
SAPHRIS,Increases in QT interval,and at least,0
SAPHRIS,Increases in QT interval,in adults,0
SAPHRIS,Increases in QT interval,,0
SAPHRIS,Increases in QT interval,schizophrenia in adults as similar,1
SAPHRIS,Increases in QT interval,,0
SAPHRIS,Increases in QT interval,as similar to that seen  with,1
SAPHRIS,Seizures,with acute herapy t reatment,1
SAPHRIS,Seizures,herapy t reatment,1
SAPHRIS,Seizures,acute herapy t reatment,1
SAPHRIS,Motor Impairment,"sia, and increas ed",1
SAPHRIS,Suicide,adults were somnolence and oral hypoesthesia The adult information below,0
SAPHRIS,Suicide,bipolar I,1
SAPHRIS,Suicide,and oral hypoesthesia The adult information below,0
SAPHRIS,Suicide,bipolar I,1
SAPHRIS,Suicide,adults were somnolence and oral hypoesthesia The adult information,0
SAPHRIS,Suicide,bipolar I,1
SAPHRIS,Suicide,bipolar I,1
SAPHRIS,Suicide,bipolar I,1
SAPHRIS,death,,0
SAPHRIS,death,at least weeks and APHRI Streated,1
SAPHRIS,death,bipolar I disorder treated,0
SAPHRIS,death,,0
SAPHRIS,death,"sia,  nausea",1
SAPHRIS,death,"oral sia,  nausea",1
SAPHRIS,death,weight No new,0
SAPHRIS,death,"oral sia,  nausea",1
SAPHRIS,death,with bipolar I disorder treated with SAPHRIS were somnolence,0
SAPHRIS,death,en-la bel,1
SAPHRIS,death,major safety findings,0
SAPHRIS,death,en-la bel,1
SAPHRIS,deaths,,0
SAPHRIS,deaths,,0
SAPHRIS,deaths,"rial.
 A",1
SAPHRIS,deaths,"safety rial.
 A",1
SAPHRIS,deaths,of pediatric patients were treated with,0
SAPHRIS,deaths,"rial.
 A",1
SAPHRIS,deaths,"safety rial.
 A",1
SAPHRIS,deaths,"rial.
 A",1
SAPHRIS,deaths,SAPHRIS Of these,0
SAPHRIS,heart failure,these patients pediatric patients were treated with SAPHRIS for,0
SAPHRIS,heart failure,with SA PHRIS,1
SAPHRIS,heart failure,of pediatric patients were eated with SA PHRIS,1
SAPHRIS,heart failure,,0
SAPHRIS,heart failure,Of these patients pediatric patients,0
SAPHRIS,sudden death,RIS. Of thes e,1
SAPHRIS,sudden death,with RIS. Of thes e,1
SAPHRIS,sudden death,trial A total of pediatric patients,0
SAPHRIS,sudden death,patients were treated with RIS. Of thes e,1
SAPHRIS,sudden death,thes e,1
SAPHRIS,sudden death,patients were treated with RIS. Of thes e,1
SAPHRIS,sudden death,treated with,0
SAPHRIS,sudden death,at least days and,0
SAPHRIS,sudden death,were treated with RIS. Of thes e,1
SAPHRIS,pneumonia,,0
SAPHRIS,increased mortality,pediatric patients bipolar I,1
SAPHRIS,increased mortality,a,0
SAPHRIS,increased mortality,of whom,0
SAPHRIS,increased mortality,,0
SAPHRIS,increased mortality,bipolar I disorder  who,1
SAPHRIS,increased mortality,evaluated in pediatric patients bipolar,1
SAPHRIS,increased mortality,evaluated in pediatric patients bipolar,1
SAPHRIS,cerebrovascular adverse reactions,Bipolar,0
SAPHRIS,cerebrovascular adverse reactions,e Schizophrenia Adults,0
SAPHRIS,cerebrovascular adverse reactions,incidence and least twice that,1
SAPHRIS,cerebrovascular adverse reactions,placebo) wer e,1
SAPHRIS,cerebrovascular adverse reactions,evaluation EXCERPT Commonly observed,0
SAPHRIS,cerebrovascular adverse reactions,Adults,0
SAPHRIS,cerebrovascular adverse reactions,reactions incidence and least twice that for placebo) wer e,1
SAPHRIS,transient ischemic attacks,"were Schizophrenia dults: akathisia, oral hyp oesthesia",1
SAPHRIS,transient ischemic attacks,dizziness extrapyra,0
SAPHRIS,fatalities,that,0
SAPHRIS,fatal,fatigue increased,0
SAPHRIS,fatal,nausea rease d,1
SAPHRIS,fatal,Bipolar Disorder,0
SAPHRIS,fatal,rease d,1
SAPHRIS,Neuroleptic Malignant Syndrome,   Bipolar Disorder Adults (Ad junctive,1
SAPHRIS,Neuroleptic Malignant Syndrome,oral,0
SAPHRIS,Neuroleptic Malignant Syndrome,dysgeusia oral paresthesia nausea increased appetite fatigue increased,0
SAPHRIS,Neuroleptic Malignant Syndrome,increased Bipolar,1
SAPHRIS,hyperpyrexia,contact Forest Laboratories LLC 5 or FDA at  FDA,1
SAPHRIS,hyperpyrexia,FDA at FDA,1
SAPHRIS,hyperpyrexia,To report SUSPECTED,0
SAPHRIS,hyperpyrexia,,0
SAPHRIS,hyperpyrexia,FDA or wwwfdagovmedwatch,0
SAPHRIS,hyperpyrexia,REACTIONS contact Forest,0
SAPHRIS,muscle rigidity,,0
SAPHRIS,muscle rigidity,,0
SAPHRIS,muscle rigidity,at or FDA 800-FDA-1088 or wwwfdagovmedwatch,1
SAPHRIS,altered mental status,ww.fda.gov/medwatch.  Clinical,1
SAPHRIS,altered mental status,at or FDA at,0
SAPHRIS,altered mental status,ww.fda.gov/medwatch.  Clinical,1
SAPHRIS,altered mental status,ww.fda.gov/medwatch.  Clinical,1
SAPHRIS,autonomic instability,,0
SAPHRIS,autonomic instability,ical Trials Experienc e,1
SAPHRIS,irregular pulse,,0
SAPHRIS,irregular pulse,Trials Because,1
SAPHRIS,irregular pulse,or wwwfdagovmedwatch,0
SAPHRIS,irregular pulse,Because clin ical,1
SAPHRIS,irregular pulse,Because clin ical,1
SAPHRIS,irregular pulse,,0
SAPHRIS,tachycardia,Because clinical trials are ucted,1
SAPHRIS,tachycardia,ucted under widely,1
SAPHRIS,tachycardia,,0
SAPHRIS,tachycardia,under widely,1
SAPHRIS,tachycardia,trials are ucted under widely,1
SAPHRIS,tachycardia,cond,0
SAPHRIS,tachycardia,clinical trials are ucted under widely,1
SAPHRIS,tachycardia,clinical trials are ucted,1
SAPHRIS,diaphoresis,under idely,1
SAPHRIS,diaphoresis,varyi ng,1
SAPHRIS,diaphoresis,trials are conducted under idely varyi ng,1
SAPHRIS,diaphoresis,idely,1
SAPHRIS,diaphoresis,clinical trials,0
SAPHRIS,diaphoresis,Clinical Trials Experience Because,0
SAPHRIS,diaphoresis,idely varyi ng,1
SAPHRIS,diaphoresis,conducted under w,0
SAPHRIS,cardiac dysrhythmia,cannot be,0
SAPHRIS,cardiac dysrhythmia,Trials Experience Because clinical trials are conducted,0
SAPHRIS,cardiac dysrhythmia,under widely,0
SAPHRIS,cardiac dysrhythmia,be,0
SAPHRIS,cardiac dysrhythmia,re action,1
SAPHRIS,cardiac dysrhythmia,trials are conducted,0
SAPHRIS,cardiac dysrhythmia,re action,1
SAPHRIS,cardiac dysrhythmia,"conducted under widely varying ditions, adverse re action",1
SAPHRIS,elevated creatine phosphokinase,nical trials of a drug,1
SAPHRIS,elevated creatine phosphokinase,in,0
SAPHRIS,elevated creatine phosphokinase,the nical trials of a drug cannot b e,1
SAPHRIS,elevated creatine phosphokinase,the nical trials of a drug cannot b e,1
SAPHRIS,elevated creatine phosphokinase,observed in the nical trials of a,1
SAPHRIS,elevated creatine phosphokinase,in the nical trials of a drug cannot b e,1
SAPHRIS,elevated creatine phosphokinase,are conducted under widely varying,0
SAPHRIS,elevated creatine phosphokinase,trials are,0
SAPHRIS,myoglobinuria,reflect the rates observed,0
SAPHRIS,myoglobinuria,a drug cannot directly,1
SAPHRIS,myoglobinuria,cannot directly comp ared,1
SAPHRIS,myoglobinuria,,0
SAPHRIS,myoglobinuria,directly comp ared,1
SAPHRIS,rhabdomyolysis,be directly compar,0
SAPHRIS,rhabdomyolysis,be directly compar,0
SAPHRIS,rhabdomyolysis,drug cannot be directly ed to rates in the,1
SAPHRIS,rhabdomyolysis,be directly,0
SAPHRIS,rhabdomyolysis,another drug and may not reflect the rates observed,0
SAPHRIS,rhabdomyolysis,,0
SAPHRIS,rhabdomyolysis,ed to,1
SAPHRIS,acute renal failure,directly compared to rates in the,0
SAPHRIS,acute renal failure,the inical trials,1
SAPHRIS,acute renal failure,inical trials of an other,1
SAPHRIS,acute renal failure,the inical trials of an other,1
SAPHRIS,acute renal failure,other drug and may,0
SAPHRIS,"involuntary, dyskinetic movements",Any PHRIS,1
SAPHRIS,"involuntary, dyskinetic movements",Adult Patients in Any PHRIS Dose Group and Which Occurr ed,1
SAPHRIS,"involuntary, dyskinetic movements",and Which Occurr ed,1
SAPHRIS,"involuntary, dyskinetic movements",Group and Which Occurr ed,1
SAPHRIS,Tardive Dyskinesia,,0
SAPHRIS,Tardive Dyskinesia,excluding akathisia Somnolence includes the following events somnolence sedation and,0
SAPHRIS,Tardive Dyskinesia,Also includes the Flexibledose trial N System Organ Class Preferred Term,0
SAPHRIS,TD,S  Also,1
SAPHRIS,TD,S  Also,1
SAPHRIS,TD,sedation,0
SAPHRIS,TD,S  Also,1
SAPHRIS,TD,following events somnolence sedation and hypersomnia,0
SAPHRIS,TD,includes,0
SAPHRIS,TD,,0
SAPHRIS,TD,the Flexibledose trial N System Organ,0
SAPHRIS,TD,Class Preferred Term Placebo,0
SAPHRIS,TD,,0
SAPHRIS,TD,Term Placebo N SAPHRIS mg twice daily,0
SAPHRIS,TD,includes the Flexibledose trial    System,1
SAPHRIS,TD,   System,1
SAPHRIS,TD,the Flexibledose trial    System,1
SAPHRIS,TD,,0
SAPHRIS,TD,Term Placebo N SAPHRIS,0
SAPHRIS,metabolic changes,e                 Nervous,1
SAPHRIS,metabolic changes,appetit,0
SAPHRIS,metabolic changes,Nervous system disorders,0
SAPHRIS,metabolic changes,,0
SAPHRIS,metabolic changes,,0
SAPHRIS,metabolic changes,"        
   Nervo us",1
SAPHRIS,metabolic changes,"        
   Nervo us",1
SAPHRIS,metabolic changes,"        
   Nervo us",1
SAPHRIS,metabolic changes,us system,0
SAPHRIS,metabolic changes,,0
SAPHRIS,metabolic changes,appetite,0
SAPHRIS,metabolic changes,"        
   Nervo us",1
SAPHRIS,metabolic changes,system,0
SAPHRIS,dyslipidemia,             Akathisia,1
SAPHRIS,dyslipidemia,,0
SAPHRIS,dyslipidemia,             Akathisia,1
SAPHRIS,dyslipidemia,,0
SAPHRIS,dyslipidemia,system,0
SAPHRIS,dyslipidemia,system              Akathisia,1
SAPHRIS,dyslipidemia,system disorders,0
SAPHRIS,dyslipidemia,disorders,0
SAPHRIS,dyslipidemia,,0
SAPHRIS,body weight gain,                 Akathisia,1
SAPHRIS,body weight gain,,0
SAPHRIS,body weight gain,,0
SAPHRIS,metabolic changes,                3 Dizziness,1
SAPHRIS,metabolic changes,Akathisia,0
SAPHRIS,metabolic changes,Akathisia                 3 Dizziness,1
SAPHRIS,metabolic changes,                3 Dizziness,1
SAPHRIS,metabolic changes,Akathisia                 3 Dizziness,1
SAPHRIS,metabolic changes,Akathisia,0
SAPHRIS,metabolic changes,Akathisia                 3 Dizziness,1
SAPHRIS,metabolic changes,Akathisia,0
SAPHRIS,metabolic changes,                3 Dizziness,1
SAPHRIS,Hyperglycemia,Dizziness,0
SAPHRIS,Hyperglycemia,     4       ,1
SAPHRIS,Hyperglycemia,     4        Extrapyramidal symptoms,1
SAPHRIS,Hyperglycemia,     4        Extrapyramidal,1
SAPHRIS,Hyperglycemia,Dizziness,0
SAPHRIS,Hyperglycemia,Dizziness,0
SAPHRIS,Hyperglycemia,     4       ,1
SAPHRIS,Hyperglycemia,symptoms,0
SAPHRIS,Hyperglycemia,Dizziness,0
SAPHRIS,Hyperglycemia,     4        Extrapyramidal symptoms excludi,1
SAPHRIS,Hyperglycemia,Dizziness      4       ,1
SAPHRIS,hyperosmolar coma,ziness,0
SAPHRIS,hyperosmolar coma,ziness,0
SAPHRIS,hyperosmolar coma,ziness,0
SAPHRIS,hyperosmolar coma,midal symptoms excluding,0
SAPHRIS,death,l sym ptoms,1
SAPHRIS,death,Extrapyramida l sym ptoms excluding,1
SAPHRIS,death,Extrapyramida,0
SAPHRIS,death,l sym ptoms,1
SAPHRIS,death,Extrapyramida l sym ptoms,1
SAPHRIS,death,Extrapyramida l sym,1
SAPHRIS,death,sym ptoms excluding akathisia,1
SAPHRIS,death,excluding,0
SAPHRIS,hyperglycemia,Vascular dis orders,1
SAPHRIS,hyperglycemia,a Vascular,1
SAPHRIS,hyperglycemia,a,0
SAPHRIS,hyperglycemia,a Vascular,1
SAPHRIS,hyperglycemia,a,0
SAPHRIS,hyperglycemia,              DoseRelated,1
SAPHRIS,hyperglycemia,             ,1
SAPHRIS,hyperglycemia,             ,1
SAPHRIS,hyperglycemia,              DoseRelated Adverse Reaction,1
SAPHRIS,hyperglycemia,Hypertension               DoseRelated Adverse,1
SAPHRIS,hyperglycemia,Hypertension,0
SAPHRIS,hyperglycemia,              DoseRelated,1
SAPHRIS,hyperglycemia,              DoseRelated Adverse Reaction,1
SAPHRIS,hyperglycemia,DoseRelated,0
SAPHRIS,hyperglycemia,Hypertension,0
SAPHRIS,hyperglycemia,term schizophr,0
SAPHRIS,hyperglycemia,,0
SAPHRIS,Dyslipidemia,excluding akathisia,0
SAPHRIS,Dyslipidemia,,0
SAPHRIS,Dyslipidemia,symptoms excluding              Somnolence,1
SAPHRIS,Dyslipidemia,akathisia,0
SAPHRIS,Dyslipidemia,Somnolence,0
SAPHRIS,Undesirable alterations in lipids,,0
SAPHRIS,Undesirable alterations in lipids,excluding akathisia,0
SAPHRIS,Undesirable alterations in lipids,Somnolence,1
SAPHRIS,Undesirable alterations in lipids,Somnolence ? Psychiatric disor,1
SAPHRIS,Undesirable alterations in lipids,Psychiatric disor,0
SAPHRIS,Undesirable alterations in lipids,,0
SAPHRIS,Undesirable alterations in lipids,trapyramidal symptoms excluding Somnolence,1
SAPHRIS,Undesirable alterations in lipids,"excluding      
      Somnolence  ?         Psychiatric disor",1
SAPHRIS,Undesirable alterations in lipids,,0
SAPHRIS,total cholesterol elevations,,0
SAPHRIS,elevations in triglycerides,the preferred,0
SAPHRIS,elevations in triglycerides,"ms oral hypoesthesia,",1
SAPHRIS,elevations in triglycerides,,0
SAPHRIS,elevations in triglycerides,paresthesia and oral dysesthesia Includes the preferred terms abdominal pain,0
SAPHRIS,elevations in triglycerides,increased Includes the preferred ms,1
SAPHRIS,elevations in triglycerides,Includes the preferred ms oral,1
SAPHRIS,elevations in triglycerides,"preferred ms oral hypoesthesia,",1
SAPHRIS,elevations in triglycerides,"hypoesthesia, oral paresthesia and oral",1
SAPHRIS,elevations in triglycerides,pai,0
SAPHRIS,total cholesterol elevations,preferred,0
SAPHRIS,total cholesterol elevations,5Inc ludes the preferred,1
SAPHRIS,total cholesterol elevations,Includes the preferred terms gue and,1
SAPHRIS,total cholesterol elevations,preferred terms,0
SAPHRIS,total cholesterol elevations,and,0
SAPHRIS,total cholesterol elevations,preferred terms gue and,1
SAPHRIS,total cholesterol elevations,Includes the preferred terms gue,1
SAPHRIS,total cholesterol elevations,"preferred terms gue and lethargy.    
  5Inc ludes the preferred",1
SAPHRIS,elevations in triglycerides,"and somnia.    
  
   System Or gan Class AE",1
SAPHRIS,elevations in triglycerides,"sedation and somnia.    
  
   System Or gan Class AE",1
SAPHRIS,elevations in triglycerides,"terms somnolence sedation and somnia.    
  
   System Or gan Class AE",1
SAPHRIS,elevations in triglycerides,,0
SAPHRIS,elevations in triglycerides,"sedation and somnia.    
  
   System Or gan Class AE",1
SAPHRIS,elevations in triglycerides,somnia. System Or gan Class AE,1
SAPHRIS,elevations in triglycerides,Or gan Class AE,1
SAPHRIS,elevations in triglycerides,blood insulin increased Includes the preferred terms somnolence,0
SAPHRIS,elevations in triglycerides,Includes the preferred terms somnolence,0
SAPHRIS,weight gain, 0          Metabolism and Nutrition,1
SAPHRIS,weight gain,,0
SAPHRIS,weight gain,Metabolism,0
SAPHRIS,weight gain, 0          Metabolism and Nutrition,1
SAPHRIS,weight gain, 0          Metabolism and Nutrition,1
SAPHRIS,weight gain,and,0
SAPHRIS,weight gain, 0          Metabolism and Nutrition,1
SAPHRIS,Increase in Body Weight,    Headache            Dizzin,1
SAPHRIS,Increase in Body Weight,,0
SAPHRIS,Increase in Body Weight,    Headache            Dizzin,1
SAPHRIS,Increase in Body Weight,    Headache            Dizzin,1
SAPHRIS,Increase in Body Weight,    Headache            Dizzin,1
SAPHRIS,Increase in Body Weight,e,0
SAPHRIS,Increase in Body Weight,e,0
SAPHRIS,increase in body weight,,0
SAPHRIS,increase in body weight,1 Dizziness,1
SAPHRIS,increase in body weight,1 Dizziness,1
SAPHRIS,increase in body weight,,0
SAPHRIS,increase in body weight,Headache         8             1 Dizziness,1
SAPHRIS,increase in body weight,Headache,0
SAPHRIS,increase in body weight,8 1 Dizziness,1
SAPHRIS,increase in body weight,Headache,0
SAPHRIS,weight gain,Dysgeusia             Akathisia,1
SAPHRIS,weight gain,            Akathisia,1
SAPHRIS,weight gain,Dysgeusia,0
SAPHRIS,weight gain,Dysgeusia,0
SAPHRIS,weight gain,Dysgeusia,0
SAPHRIS,weight gain,Dysgeusia,0
SAPHRIS,weight gain,Dysgeusia             Akathisia,1
SAPHRIS,weight gain,            Akathisia,1
SAPHRIS,increase in body weight,,0
SAPHRIS,weight change,Di,0
SAPHRIS,weight change,             ,1
SAPHRIS,weight change,             ,1
SAPHRIS,weight change,Parkinsonism              ,1
SAPHRIS,weight change,              Psychiatric Di,1
SAPHRIS,weight change,              Psychiatric,1
SAPHRIS,weight gain,      1     Psychiatric,1
SAPHRIS,weight gain,,0
SAPHRIS,increase in body weight,Repr,0
SAPHRIS,increase in body weight,,0
SAPHRIS,increase in body weight,Repr oductive System and Bre ast Disorders,1
SAPHRIS,increase in body weight,Repr,0
SAPHRIS,changes in body weight,Dysmenorrhea,0
SAPHRIS,changes in body weight,Dysmenorrhea,0
SAPHRIS,weight gain,,0
SAPHRIS,weight gain,a,0
SAPHRIS,weight gain,Respiratory Thoracic nd,1
SAPHRIS,weight gain,,0
SAPHRIS,weight gain,,0
SAPHRIS,weight gain,Thoracic a,0
SAPHRIS,weight gain,,0
SAPHRIS,weight gain,nd Mediasti nal Disorders Oro,1
SAPHRIS,weight gain,Respiratory Thoracic nd Mediasti nal Disorders Oro,1
SAPHRIS,increase in body weight,11% (18/ on placebo The most common,1
SAPHRIS,Hypersensitivity reactions,with SAPHRIS,0
SAPHRIS,Hypersensitivity reactions,placebo rate) we re depression suicidal ideation bipolar,1
SAPHRIS,Hypersensitivity reactions,,0
SAPHRIS,Hypersensitivity reactions,discontinuation in subjects treated with SAPHRIS rates at,0
SAPHRIS,hypersensitivity reactions,insomnia and depressive Adverse,1
SAPHRIS,anaphylaxis,an,1
SAPHRIS,anaphylaxis,an Incidenc e of or More Among,1
SAPHRIS,anaphylaxis,,0
SAPHRIS,anaphylaxis,,0
SAPHRIS,anaphylaxis,an Incidenc e of or More Among,1
SAPHRIS,anaphylaxis,,0
SAPHRIS,anaphylaxis,Occurring an Incidenc e of or More Among,1
SAPHRIS,anaphylaxis,,0
SAPHRIS,anaphylaxis,symptoms Adverse Reactions Occurring an Incidenc e of or More Among,1
SAPHRIS,angioedema,Adverse Reactions Occurring at an Incidence,0
SAPHRIS,angioedema,,0
SAPHRIS,angioedema,an of 2% or M ore Among SAPHRISTreated Adjunctive Bipolar,1
SAPHRIS,angioedema,Occurring,0
SAPHRIS,hypotension,associated,0
SAPHRIS,hypotension,,0
SAPHRIS,hypotension,Incidence of or e Among SAP HRISTreated Adjunctive Bipolar Patients Adverse,1
SAPHRIS,swollen tongue,use of SAPHRIS incidence,0
SAPHRIS,swollen tongue,djunctive) Bip olar Patients Adverse reactions associated,1
SAPHRIS,swollen tongue,SAPHRISTreated djunctive) Bip olar Patients Adverse reactions associated,1
SAPHRIS,dyspnea,of or More Among SAPHRISTreated,0
SAPHRIS,dyspnea,use,0
SAPHRIS,dyspnea,Adverse reactions associated with the use of SAPHRIS,0
SAPHRIS,dyspnea,ar Pati ents Adverse reactions associated with,1
SAPHRIS,dyspnea,,0
SAPHRIS,dyspnea,of or More Among,0
SAPHRIS,dyspnea,SAPHRISTreated Adjunctive ar Pati ents Adverse reactions associated with,1
SAPHRIS,dyspnea,incidence of or greater rounded,0
SAPHRIS,dyspnea,Pati ents Adverse reactions associated with,1
SAPHRIS,wheezing,SAPHRISTreated Adjunctive Bipolar ts:,1
SAPHRIS,wheezing,the use of SAPHRIS incidence of or greater rounded to,0
SAPHRIS,wheezing,Adv erse reactions associated with the,1
SAPHRIS,wheezing,with the use of SAPHRIS incidence,0
SAPHRIS,wheezing,SAPHRISTreated Adjunctive Bipolar ts:  Adv erse reactions associated with the,1
SAPHRIS,wheezing,use of SAPHRIS incidence of or greater rounded to the neares,0
SAPHRIS,wheezing,use of SAPHRIS incidence of or greater rounded to the,0
SAPHRIS,wheezing,with the use,0
SAPHRIS,wheezing,Adv erse reactions associated with the,1
SAPHRIS,rash,use of SAPHRIS incidence of or greater rounded to,0
SAPHRIS,rash,reac tions associated with the use,1
SAPHRIS,rash,at an Incidence of,0
SAPHRIS,rash,Bipolar Patients reac tions associated with the use,1
SAPHRIS,rash,Among SAPHRISTreated Adjunctive Bipolar,0
SAPHRIS,orthostatic hypotension,that occurred during acute adjunctive therapy at weeks a time when,0
SAPHRIS,orthostatic hypotension,time,0
SAPHRIS,orthostatic hypotension,,0
SAPHRIS,orthostatic hypotension,the nearest percent SAPHRIS,1
SAPHRIS,orthostatic hypotension,to the nearest percent SAPHRIS incidence,1
SAPHRIS,orthostatic hypotension,with the use of,0
SAPHRIS,syncope,during acute adjunctive therapy at weeks a,0
SAPHRIS,syncope,an plac ebo that occurred during acute,1
SAPHRIS,syncope,an plac ebo that occurred during acute,1
SAPHRIS,syncope,plac ebo that occurred during acute,1
SAPHRIS,syncope,,0
SAPHRIS,syncope,incidence greater an plac ebo that occurred during acute,1
SAPHRIS,syncope,occurred during acute adjunctive therapy at weeks a time,0
SAPHRIS,syncope,,0
SAPHRIS,syncope,SAPHRIS mg to mg twice daily,0
SAPHRIS,syncope,Incidence Than in the Placebo,0
SAPHRIS,syncope,or,0
SAPHRIS,syncope,somnolence and sedation System Organ ClassPreferre,0
SAPHRIS,syncope,N SAPHRIS mg or mg twice daily N,0
SAPHRIS,syncope,,0
SAPHRIS,syncope,Dyspepsia,0
SAPHRIS,syncope,testina l disorders Dyspepsia,1
SAPHRIS,syncope,testina l disorders Dyspepsia,1
SAPHRIS,leukopenia,Dystonia :,1
SAPHRIS,leukopenia,Dystonia,0
SAPHRIS,leukopenia,Dystonia,0
SAPHRIS,leukopenia,Dystonia,0
SAPHRIS,leukopenia,Dystonia :,1
SAPHRIS,neutropenia,Symptoms of,0
SAPHRIS,neutropenia,of,0
SAPHRIS,neutropenia,Symptoms,0
SAPHRIS,neutropenia,rolonged abnormal contractions of muscle groups may occur in susceptible individuals during the,0
SAPHRIS,neutropenia,"Symptoms dystonia,",1
SAPHRIS,neutropenia,groups may occur in,0
SAPHRIS,neutropenia,of,0
SAPHRIS,neutropenia,p rolonged abnormal contractions of muscle,1
SAPHRIS,neutropenia,"Dystonia Symptoms dystonia, p rolonged abnormal contractions of muscle",1
SAPHRIS,fatal,s,1
SAPHRIS,fatal,few s of  treatment Dystonic symptoms include spasm,1
SAPHRIS,increases in QTc interval,akathisiarelated events for d patients was 6% versus  for placebo In shortterm placebocontrolled,1
SAPHRIS,increases in QTc interval,of akathisiarelated events for d patients was 6% versus  for placebo In shortterm placebocontrolled,1
SAPHRIS,increases in QTc interval,mania adult trials the incidence of EPSre,0
SAPHRIS,QTc increases,f EPS-related events excluding events related to,1
SAPHRIS,QTc increases,was versus for pl,0
SAPHRIS,QTc increases,f,1
SAPHRIS,QTc increases,akathisia for SAPHRIStreated patients was versus,0
SAPHRIS,QTc increases,was,0
SAPHRIS,QTc increases,incidence f EPS-related events excluding events related to,1
SAPHRIS,QTc increases,EPS-related events excluding events related to,1
SAPHRIS,QTc increases,f EPS-related events excluding events related to,1
SAPHRIS,QTc increases,the incidence f,1
SAPHRIS,QT prolongations,excluding,0
SAPHRIS,Torsade de Pointes,patients treated w,0
SAPHRIS,delayed ventricular repolarization,,0
SAPHRIS,delayed ventricular repolarization,events include bradykinesia dyskinesia,0
SAPHRIS,delayed ventricular repolarization,compared to 3% for placebo-treated patients EPSrelated events include bradykinesia,1
SAPHRIS,delayed ventricular repolarization,for placebo-treated patients EPSrelated events include bradykinesia,1
SAPHRIS,delayed ventricular repolarization,twice,0
SAPHRIS,delayed ventricular repolarization,patients treated with SAPHRIS mg mg and mg twice,0
SAPHRIS,elevate prolactin levels,treated patients In shortterm trolled schizophrenia,1
SAPHRIS,elevate prolactin levels,In shortterm trolled schizophrenia ad ult trials the mean increase,1
SAPHRIS,elevate prolactin levels,common in treated patients,0
SAPHRIS,elevate prolactin levels,the mean,0
SAPHRIS,Hyperprolactinemia,to,0
SAPHRIS,Hyperprolactinemia,The proportion,0
SAPHRIS,Hyperprolactinemia,patients was unitsL compared to a,1
SAPHRIS,Hyperprolactinemia,,0
SAPHRIS,Hyperprolactinemia,in transaminase levels for S-treated patients was unitsL compared to a,1
SAPHRIS,Hyperprolactinemia,trials the,0
SAPHRIS,Hyperprolactinemia,S-treated patients was unitsL compared to a,1
SAPHRIS,suppress hypothalamic GnRH,units/L compared to a decrease of unitsL for placebotreated,1
SAPHRIS,suppress hypothalamic GnRH,levels for SAPHRIStreated,0
SAPHRIS,suppress hypothalamic GnRH,to a decrease of unitsL for placebotreated,1
SAPHRIS,suppress hypothalamic GnRH,adult trials,0
SAPHRIS,suppress hypothalamic GnRH,The proportion of patients with transaminase e,0
SAPHRIS,suppress hypothalamic GnRH,,0
SAPHRIS,suppress hypothalamic GnRH,a decrease of unitsL for placebotreated,1
SAPHRIS,suppress hypothalamic GnRH,with transaminase e,0
SAPHRIS,reduced pituitary gonadotropin secretion,in transaminase levels,0
SAPHRIS,reduced pituitary gonadotropin secretion,to a decrease  units/L for placebo-treated patients. T he proportion of patients with,1
SAPHRIS,reduced pituitary gonadotropin secretion,of patients with transaminase elevations times ULN at Endpoint,0
SAPHRIS,inhibit reproductive function,,0
SAPHRIS,inhibit reproductive function,patients,0
SAPHRIS,inhibit reproductive function,ents with transaminase elevat ions times ULN at Endpoint,1
SAPHRIS,inhibit reproductive function,The proportion of ents with transaminase,1
SAPHRIS,inhibit reproductive function,with transaminase elevat ions times ULN at Endpoint,1
SAPHRIS,inhibit reproductive function,to a decrease of unitsL for placebotreated patients The proportion of,0
SAPHRIS,inhibit reproductive function,with transaminase elevat ions times ULN at Endpoint,1
SAPHRIS,inhibit reproductive function,,0
SAPHRIS,impairing gonadal steroidogenesis,>=3 times ULN (at Endpoint),1
SAPHRIS,impairing gonadal steroidogenesis,unitsL for placebotreated patients The proportion of patients with transaminase,0
SAPHRIS,impairing gonadal steroidogenesis,patients The,0
SAPHRIS,impairing gonadal steroidogenesis,,0
SAPHRIS,impairing gonadal steroidogenesis,,0
SAPHRIS,Galactorrhea,ersus 1.3% f or placebotreated patients In shortterm,1
SAPHRIS,Galactorrhea,Endpoint was for,0
SAPHRIS,impotence,adult mania trials the mean increase in transaminase levels for,0
SAPHRIS,impotence,patients short-ter m placebocontrolled bipolar adult mania,1
SAPHRIS,hyperprolactinemia,for SAPHRIS-tr eated patients was unitsL compared,1
SAPHRIS,hyperprolactinemia,mean increase in transaminase els,1
SAPHRIS,hyperprolactinemia,trials the mean,0
SAPHRIS,hyperprolactinemia,els for SAPHRIS-tr eated patients was unitsL compared,1
SAPHRIS,hyperprolactinemia,bipolar adult,0
SAPHRIS,hypogonadism,com pared to a decrease of,1
SAPHRIS,hypogonadism,of patients with,0
SAPHRIS,hypogonadism,levels for SAPHRIStreated patients  units/L com pared to a decrease of,1
SAPHRIS,hypogonadism,SAPHRIStreated patients  units/L com pared to a decrease of,1
SAPHRIS,hypogonadism,patients  units/L com pared to a decrease of,1
SAPHRIS,decreased bone density,crease of 4.9 units/L in placebotreated patients The proportion,1
SAPHRIS,decreased bone density,,0
SAPHRIS,tumorigenesis,were ngmL for patients,1
SAPHRIS,tumorigenesis,for patients,1
SAPHRIS,tumorigenesis,comp ared to ngmL for placebotreated,1
SAPHRIS,tumorigenesis,mean decreases in prolactin levels,0
SAPHRIS,tumorigenesis,patients,1
SAPHRIS,seizures,at oint) we re for SAPHRIStreated patients versus,1
SAPHRIS,seizures,patients The proportion of patients with prolactin elevations,0
SAPHRIS,seizures,a,0
SAPHRIS,seizures,oint) we re for SAPHRIStreated patients versus,1
SAPHRIS,seizures,oint) we re for SAPHRIStreated patients versus,1
SAPHRIS,seizures,The proportion of,0
SAPHRIS,seizures,included primarily,0
SAPHRIS,seizures,( week doubleblind comparatorcontrolled adult trial,1
SAPHRIS,seizures,versus for placebotreated,0
SAPHRIS,seizures,In a g-term ( week doubleblind comparatorcontrolled adult trial,1
SAPHRIS,seizures,patients In a g-term ( week doubleblind comparatorcontrolled adult trial,1
SAPHRIS,seizures,patients In a g-term,1
SAPHRIS,seizures,patients versus for placebotreated,0
SAPHRIS,seizures,placebotreated patients In a g-term ( week doubleblind comparatorcontrolled adult trial,1
SAPHRIS,Somnolence,patients with,1
SAPHRIS,somnolence,Endpoint)  for patients treated with SAPHRIS,1
SAPHRIS,somnolence,CK The,0
SAPHRIS,somnolence,SAPHRIS mg twice daily,0
SAPHRIS,somnolence,to of cebo-treat ed patients There were no,1
SAPHRIS,somnolence,CK elevations times ULN at,0
SAPHRIS,somnolence,mg twice,0
SAPHRIS,somnolence,daily respectively,0
SAPHRIS,somnolence,for placebotreated,0
SAPHRIS,somnolence,d with,1
SAPHRIS,somnolence,were and for patients d with SAP HRIS mg twice daily and,1
SAPHRIS,somnolence,for patients d with SAP HRIS mg twice daily and,1
SAPHRIS,somnolence,daily respectively as compared to,0
SAPHRIS,Somnolence,mg twice daily and,0
SAPHRIS,Somnolence,in,0
SAPHRIS,Somnolence,,0
SAPHRIS,sedation,times ULN,0
SAPHRIS,sedation,ULN,0
SAPHRIS,sedation,trial in pediatric bipolar I disorder at,0
SAPHRIS,sedation, 3-week  trial in pediatric bipolar I,1
SAPHRIS,sedation,bipolar I disorder at,0
SAPHRIS,sedation, 3-week  trial in pediatric bipolar I,1
SAPHRIS,hypersomnia,ic bipolar I disorder,0
SAPHRIS,Somnolence,respectively versus for -treated p atients Other Adverse Reactions Observed,1
SAPHRIS,Somnolence,the Premarketing Evaluation,0
SAPHRIS,Somnolence,twice daily respectively versus for,0
SAPHRIS,Disruption of the body's ability to reduce core body temperature,other parts of Adverse Reactions or those considered in Contraindicati,0
SAPHRIS,Disruption of the body's ability to reduce core body temperature,patients in other parts of Adverse Reactions or those considered in Contraindicati,0
SAPHRIS,Disruption of the body's ability to reduce core body temperature,adults or p ediatric patients in other parts,1
SAPHRIS,Disruption of the body's ability to reduce core body temperature,pharmacologic r other grounds. Reactions already listed for either,1
SAPHRIS,Disruption of the body's ability to reduce core body temperature,already listed for either adults or p ediatric patients in other parts,1
SAPHRIS,Disruption of the body's ability to reduce core body temperature,parts of Adverse Reactions,0
SAPHRIS,Disruption of the body's ability to reduce core body temperature,r other grounds. Reactions already listed for either adults or p ediatric patients in other parts,1
SAPHRIS,Disruption of the body's ability to reduce core body temperature,o,0
SAPHRIS,Disruption of the body's ability to reduce core body temperature,importance as well as reactions that are plausibly drugrelated on,0
SAPHRIS,body temperature increases,not included Reactions e further categorized by M edDRA system organ class and,1
SAPHRIS,body temperature increases,not,0
SAPHRIS,body temperature increases,those not already d in the tabulated results from placebocontrolled trials appear in,1
SAPHRIS,body temperature increases,appear in this,0
SAPHRIS,body temperature increases,already d in,1
SAPHRIS,body temperature increases,in the tabulated results from placebocontrolled trials appear in,1
SAPHRIS,body temperature increases,d in the tabulated results from placebocontrolled trials appear in,1
SAPHRIS,pyrexia,tabulated results rom,1
SAPHRIS,pyrexia,cebocontrolled trials appear in this listing those occurring in,0
SAPHRIS,feeling hot,results,0
SAPHRIS,feeling hot,controlled  trials appear in this listing,1
SAPHRIS,feeling hot,in this listing those occurring in to patients infrequent,0
SAPHRIS,feeling hot,from controlled  trials appear in this listing,1
SAPHRIS,feeling hot,controlled  trials appear in this listing,1
SAPHRIS,feeling hot,placebo,0
SAPHRIS,feeling hot,,0
SAPHRIS,feeling hot,in to,0
SAPHRIS,feeling hot,results from controlled  trials appear in this listing,1
SAPHRIS,feeling hot,patients frequent only those not,0
SAPHRIS,Esophageal dysmotility,other parts of rse Reactions,1
SAPHRIS,Esophageal dysmotility,of MedDRA,0
SAPHRIS,Esophageal dysmotility,"Reactions (6) , o r those considered in Contraindications",1
SAPHRIS,Esophageal dysmotility,"of rse Reactions (6) ,",1
SAPHRIS,Esophageal dysmotility,"rse Reactions (6) , o r those considered in Contraindications",1
SAPHRIS,aspiration,se conside red in Contraindications Warnings and,1
SAPHRIS,aspiration,Warnings and Precautions or,0
SAPHRIS,aspiration,Precautions or Overdosage that reflect,0
SAPHRIS,aspiration,se conside red in Contraindications Warnings and,1
SAPHRIS,aspiration,,0
SAPHRIS,aspiration,of Adverse Reactions,0
SAPHRIS,Dysphagia,(5) or Overdosage that reflect adverse,1
SAPHRIS,dysphagia,diplopia vision blurred Gastrointestinal disorders infrequent,0
CARBAGLU,Infections,,0
CARBAGLU,Infections,Infections vomiting abdominal pain pyrexia tonsilitis,1
CARBAGLU,Infections,pain,0
CARBAGLU,Infections,diarrhea nasopharyngitis a,0
CARBAGLU,Infections,,0
CARBAGLU,Infections,pain pyrexia tonsilitis anemia,0
CARBAGLU,vomiting,vomiting abdominal pain,1
CARBAGLU,vomiting,anemia ear,0
CARBAGLU,vomiting,vomiting,1
CARBAGLU,vomiting,vomiting abdominal pain,1
CARBAGLU,vomiting,vomiting abdominal pain pyrexia,1
CARBAGLU,vomiting,vomiting abdominal,1
CARBAGLU,vomiting,,0
CARBAGLU,abdominal pain,tonsilitis anemia ear infection,0
CARBAGLU,abdominal pain,abdominal,1
CARBAGLU,abdominal pain,abdominal,1
CARBAGLU,abdominal pain,,0
CARBAGLU,abdominal pain,abdominal,1
CARBAGLU,abdominal pain,,0
CARBAGLU,abdominal pain,abdominal,1
CARBAGLU,abdominal pain,,0
CARBAGLU,abdominal pain,abdominal pain pyrexia tonsilitis,1
CARBAGLU,abdominal pain,,0
CARBAGLU,pyrexia,pyrexia tonsilitis anemia ear infection,1
CARBAGLU,pyrexia,To rep,0
CARBAGLU,pyrexia,,0
CARBAGLU,pyrexia,are Infections vomiting abdominal pyrexia tonsilitis anemia ear infection,1
CARBAGLU,pyrexia,Infections vomiting abdominal pyrexia tonsilitis anemia ear infection,1
CARBAGLU,pyrexia,pyrexia tonsilitis anemia ear infection,1
CARBAGLU,pyrexia,diarrhea,0
CARBAGLU,pyrexia,,0
CARBAGLU,pyrexia,pyrexia tonsilitis anemia ear infection,1
CARBAGLU,tonsilitis,tonsilitis anemia ear infection diarrhea,1
CARBAGLU,tonsilitis,abdominal pain tonsilitis anemia ear infection diarrhea,1
CARBAGLU,tonsilitis,are,0
CARBAGLU,tonsilitis,tonsilitis anemia ear infection diarrhea,1
CARBAGLU,tonsilitis,tonsilitis anemia ear infection diarrhea,1
CARBAGLU,tonsilitis,tonsilitis anemia ear infection diarrhea,1
CARBAGLU,ear infection,abdominal pain pyrexia tonsilitis ear infection diarrhea nasopharyngitis and headache,1
CARBAGLU,diarrhea,To report SUSPECTED ADVERSE REACTIONS contact Accr,0
CARBAGLU,diarrhea,,0
CARBAGLU,diarrhea,,0
CARBAGLU,diarrhea,diarrhea nasopharyngitis and headache To,1
CARBAGLU,diarrhea,Infections vomiting abdominal pain pyrexia tonsilitis,0
CARBAGLU,diarrhea,anemia ear,0
CARBAGLU,diarrhea,diarrhea nasopharyngitis and headache To,1
CARBAGLU,nasopharyngitis,tonsilitis anemia ear infection nasopharyngitis and headache To report,1
CARBAGLU,nasopharyngitis,pyrexia tonsilitis,0
CARBAGLU,nasopharyngitis,,0
CARBAGLU,nasopharyngitis,,0
CARBAGLU,nasopharyngitis,infection,0
CARBAGLU,headache,,0
CARBAGLU,headache,,0
CARBAGLU,headache,Group Inc,0
CARBAGLU,headache,nasopharyngitis,0
CARBAGLU,headache,ADVERSE REACTIONS contact Accredo Health Group Inc,0
CARBAGLU,headache,headache To report SUSPECTED ADVERSE,1
CARBAGLU,headache,report SUSPECTED,0
CARBAGLU,headache,headache To report SUSPECTED ADVERSE,1
CARBAGLU,headache,headache To report SUSPECTED ADVERSE,1
CARBAGLU,Infections,Infections vomiting abdominal pain pyrexia,1
CARBAGLU,Infections,Infections vomiting abdominal pain pyrexia,1
CARBAGLU,Infections,Infections vomiting abdominal pain pyrexia,1
CARBAGLU,Infections,Infections vomiting abdominal pain pyrexia,1
CARBAGLU,Infections,regardless of causality Infections vomiting abdominal pain pyrexia,1
CARBAGLU,Infections,a,0
CARBAGLU,Infections,patients regardless of causality are,0
CARBAGLU,Infections,,0
CARBAGLU,Infections,causality Infections vomiting abdominal pain pyrexia,1
CARBAGLU,vomiting,causality are vomiting abdominal pain pyrexia tonsilitis,1
CARBAGLU,vomiting,vomiting abdominal pain pyrexia tonsilitis,1
CARBAGLU,vomiting,pyrexia tonsilitis anemia ear,0
CARBAGLU,vomiting,occurring in of patients regardless of,0
CARBAGLU,vomiting,of causality are vomiting abdominal pain pyrexia tonsilitis,1
CARBAGLU,vomiting,,0
CARBAGLU,vomiting,vomiting abdominal pain pyrexia tonsilitis,1
CARBAGLU,vomiting,vomiting abdominal pain pyrexia tonsilitis,1
CARBAGLU,vomiting,headach,0
CARBAGLU,abdominal pain,occurring in of patients regardless of causality are,0
CARBAGLU,abdominal pain,abdominal pain pyrexia tonsilitis anemia ear,1
CARBAGLU,abdominal pain,vomiting,0
CARBAGLU,abdominal pain,are Infections vomiting,0
CARBAGLU,abdominal pain,diarrhea,0
CARBAGLU,abdominal pain,anemia ear infection diarrhea nasopharyngitis,0
CARBAGLU,abdominal pain,causality are Infections abdominal pain pyrexia tonsilitis anemia ear,1
CARBAGLU,abdominal pain,are Infections abdominal pain pyrexia tonsilitis anemia ear,1
CARBAGLU,pyrexia,pyrexia tonsilitis anemia ear infection,1
CARBAGLU,pyrexia,pyrexia tonsilitis anemia ear infection,1
CARBAGLU,tonsilitis,pain tonsilitis anemia ear infection diarrhea,1
CARBAGLU,tonsilitis,tonsilitis anemia ear infection diarrhea,1
CARBAGLU,tonsilitis,infection diarrhea nasopharyngitis and headache Table summarizes adverse react,0
CARBAGLU,tonsilitis,tonsilitis anemia ear infection diarrhea,1
CARBAGLU,tonsilitis,of causality are Infections vomiting abdominal pain,0
CARBAGLU,tonsilitis,tonsilitis anemia ear infection diarrhea,1
CARBAGLU,anemia,regardless of causality are,0
CARBAGLU,ear infection,,0
CARBAGLU,ear infection,,0
CARBAGLU,ear infection,,0
CARBAGLU,ear infection,pyrexia tonsilitis ear,1
CARBAGLU,ear infection,abdominal pain pyrexia tonsilitis ear infection diarrhea nasopharyngitis and headache,1
CARBAGLU,ear infection,adverse,0
CARBAGLU,ear infection,,0
CARBAGLU,ear infection,ear infection diarrhea nasopharyngitis and headache,1
CARBAGLU,nasopharyngitis,tonsilitis anemia ear infection nasopharyngitis and headache Table summarizes,1
CARBAGLU,nasopharyngitis,nasopharyngitis and headache Table summarizes,1
CARBAGLU,nasopharyngitis,headache Table summarizes adverse reactions occurring in or more patients,0
CARBAGLU,nasopharyngitis,nasopharyngitis and headache Table summarizes,1
CARBAGLU,nasopharyngitis,anemia ear infection nasopharyngitis and headache Table summarizes,1
CARBAGLU,nasopharyngitis,nasopharyngitis and headache Table summarizes,1
CARBAGLU,nasopharyngitis,nasopharyngitis and headache Table summarizes,1
CARBAGLU,nasopharyngitis,nasopharyngitis and headache Table summarizes,1
CARBAGLU,nasopharyngitis,nasopharyngitis and headache Table summarizes,1
CARBAGLU,headache,diarrhea nasopharyngitis headache Table summarizes adverse reactions,1
CARBAGLU,headache,headache Table summarizes adverse reactions,1
CARBAGLU,headache,,0
CARBAGLU,Ear infection,,0
CARBAGLU,Ear infection,Ear,1
CARBAGLU,Ear infection,,0
CARBAGLU,Ear infection,Ear,1
CARBAGLU,Ear infection,disorders,0
CARBAGLU,Ear infection,infection Gastro,1
CARBAGLU,Abdominal pain,Abdominal pain Diarrhe,1
CARBAGLU,Diarrhea,Diarrhea V,1
CARBAGLU,Diarrhea,pain,0
CARBAGLU,Diarrhea,Diarrhea V,1
CARBAGLU,Diarrhea,Diarrhea V,1
CARBAGLU,Diarrhea,Diarrhea V,1
CARBAGLU,Diarrhea,Diarrhea V,1
CARBAGLU,Diarrhea,Diarrhea V,1
CARBAGLU,Vomiting,a Vomiting D,1
CARBAGLU,Dysgeusia,Dysgeusia Ge,1
CARBAGLU,Dysgeusia,g Dysgeusia Ge,1
CARBAGLU,Dysgeusia,g,0
CARBAGLU,Dysgeusia,g Dysgeusia Ge,1
CARBAGLU,Dysgeusia,g,0
CARBAGLU,Dysgeusia,g,0
CARBAGLU,Dysgeusia,g Dysgeusia Ge,1
CARBAGLU,Dysgeusia,g,0
CARBAGLU,Asthenia,and administration site,0
CARBAGLU,Asthenia,Asthenia H,1
CARBAGLU,Asthenia,site Asthenia H,1
CARBAGLU,Asthenia,Asthenia H,1
CARBAGLU,Asthenia,,0
CARBAGLU,Asthenia,,0
CARBAGLU,Asthenia,Asthenia H,1
CARBAGLU,Asthenia,disorders and administration site Asthenia H,1
CARBAGLU,Asthenia,site Asthenia H,1
CARBAGLU,Asthenia,site conditions,0
CARBAGLU,Hyperhidrosis,Hyperhidrosis Pyrexi,1
CARBAGLU,Hyperhidrosis,a Hyperhidrosis Pyrexi,1
CARBAGLU,Hyperhidrosis,a,0
CARBAGLU,Hyperhidrosis,,0
CARBAGLU,Hyperhidrosis,,0
CARBAGLU,Hyperhidrosis,Hyperhidrosis Pyrexi,1
CARBAGLU,Hyperhidrosis,,0
CARBAGLU,Hyperhidrosis,,0
CARBAGLU,Hyperhidrosis,a Hyperhidrosis Pyrexi,1
CARBAGLU,Pyrexia,drosis Pyrexia,1
CARBAGLU,Pyrexia,Pyrexia,1
CARBAGLU,Pyrexia,Pyrexia,1
CARBAGLU,Pyrexia,Pyrexia,1
CARBAGLU,Pyrexia,Pyrexia,1
CARBAGLU,Pyrexia,drosis,0
CARBAGLU,Influenza,Influenza Na,1
CARBAGLU,Influenza,on,0
CARBAGLU,Influenza,Influenza Na,1
CARBAGLU,Influenza,on Influenza Na,1
CARBAGLU,Influenza,Influenza Na,1
CARBAGLU,Influenza,on Influenza Na,1
CARBAGLU,Influenza,Influenza Na,1
CARBAGLU,Influenza,Influenza Na,1
CARBAGLU,Nasopharyngitis,za,0
CARBAGLU,Nasopharyngitis,za,0
CARBAGLU,Pneumonia,ryngitis,0
CARBAGLU,Pneumonia,Pneumonia To,1
CARBAGLU,Pneumonia,ryngitis Pneumonia To,1
CARBAGLU,Pneumonia,,0
CARBAGLU,Pneumonia,To,0
CARBAGLU,Pneumonia,Pneumonia To,1
CARBAGLU,Pneumonia,ryngitis Pneumonia To,1
CARBAGLU,Pneumonia,,0
CARBAGLU,Pneumonia,,0
CARBAGLU,Tonsillitis,Tonsillitis Inve,1
CARBAGLU,Tonsillitis,,0
CARBAGLU,Tonsillitis,Inve,0
CARBAGLU,Tonsillitis,,0
CARBAGLU,Hemoglobin decreased,Hemoglobin decreased Weight,1
CARBAGLU,Hemoglobin decreased,gations,0
CARBAGLU,Hemoglobin decreased,,0
CARBAGLU,Hemoglobin decreased,decrea,0
CARBAGLU,Hemoglobin decreased,decreased Weight decrea,1
CARBAGLU,Hemoglobin decreased,Hemoglobin decreased Weight decrea,1
CARBAGLU,Hemoglobin decreased,,0
CARBAGLU,Weight decreased,,0
CARBAGLU,Anorexia,ism and nutrition Anorexia N,1
CARBAGLU,Anorexia,,0
CARBAGLU,Headache,Headache S,1
CARBAGLU,Somnolence,Somnolence Ski,1
CARBAGLU,Somnolence,Ski,0
CARBAGLU,Somnolence,e,0
CARBAGLU,Somnolence,e Somnolence Ski,1
CARBAGLU,Somnolence,,0
CARBAGLU,Rash,,0
CARBAGLU,Rash,Rash,1
CARBAGLU,Rash,,0
CARBAGLU,Rash,tissue Rash,1
CARBAGLU,Rash,,0
CARBAGLU,Rash,tissue disorders,0
CARBAGLU,Hyperammonemia,The most commo n adverse,1
CARBAGLU,Hyperammonemia,of patients are Infections vomiting,0
CARBAGLU,Hyperammonemia,The most commo n adverse,1
PROMACTA,Hepatic Decompensation,Decompensation in Patients,1
PROMACTA,Hepatic Decompensation,Hepatic Decompensation in Patients,1
PROMACTA,Hepatic Decompensation,are described in other Hepatic,1
PROMACTA,Hepatic Decompensation,in other Hepatic,1
PROMACTA,Hepatic Decompensation,with Chronic Hepatitis,0
PROMACTA,Hepatic Decompensation,associated with PROMACTA,0
PROMACTA,Hepatotoxicity,ThromboticThromboembolic,0
PROMACTA,Hepatotoxicity,Warnings,0
PROMACTA,Hepatotoxicity,Hepatotoxicity see Warnings,1
PROMACTA,Thromboembolic Complications,Thrombotic,0
PROMACTA,Thromboembolic Complications,Precautions Thromboembolic,1
PROMACTA,Thromboembolic Complications,Warnings and Precautions Thromboembolic Complications see Warnings,1
PROMACTA,Thromboembolic Complications,see Warnings and Precautions Cataracts see Warnings,0
PROMACTA,Thromboembolic Complications,Warnings and Precautions,0
PROMACTA,Cataracts,Cataracts see Warnings,1
PROMACTA,Cataracts,,0
PROMACTA,Cataracts,see Warnings and Precautions In,0
PROMACTA,Cataracts,,0
PROMACTA,Cataracts,Warnings and Cataracts see Warnings,1
PROMACTA,Cataracts,Complications see Warnings and Cataracts see Warnings,1
PROMACTA,Cataracts,Complications see Warnings and,0
PROMACTA,Cataracts,Cataracts see Warnings,1
PROMACTA,nausea,nausea diarrhea upper,1
PROMACTA,nausea,myalgia and urinary,0
PROMACTA,diarrhea,diarrhea upper respiratory,1
PROMACTA,diarrhea,than,0
PROMACTA,diarrhea,diarrhea upper respiratory,1
PROMACTA,diarrhea,diarrhea upper respiratory,1
PROMACTA,diarrhea,diarrhea upper respiratory,1
PROMACTA,diarrhea,diarrhea upper respiratory,1
PROMACTA,diarrhea,infection,0
PROMACTA,upper respiratory tract infection,respiratory tract infection vomiting increased,1
PROMACTA,upper respiratory tract infection,upper respiratory tract infection vomiting increased,1
PROMACTA,upper respiratory tract infection,upper respiratory tract infection vomiting increased,1
PROMACTA,upper respiratory tract infection,adverse reactions greater than or equal to and greater,0
PROMACTA,upper respiratory tract infection,placebo were nausea upper respiratory tract infection vomiting increased,1
PROMACTA,upper respiratory tract infection,ALT myalgia,0
PROMACTA,upper respiratory tract infection,upper respiratory tract infection vomiting increased,1
PROMACTA,vomiting,vomiting increased ALT,1
PROMACTA,vomiting,vomiting increased ALT,1
PROMACTA,vomiting,infection,0
PROMACTA,vomiting,placebo were,0
PROMACTA,vomiting,vomiting increased ALT,1
PROMACTA,vomiting,myalgia and,0
PROMACTA,vomiting,diarrhea upper respiratory tract vomiting increased ALT,1
PROMACTA,vomiting,pediatric patients age,0
PROMACTA,increased ALT,ALT myalgia and,1
PROMACTA,increased ALT,upper,0
PROMACTA,urinary tract infection,common,0
PROMACTA,urinary tract infection,tract infection In pediatric,1
PROMACTA,urinary tract infection,with ITP the,0
PROMACTA,urinary tract infection,myalgia urinary tract infection In pediatric,1
PROMACTA,urinary tract infection,myalgia urinary tract infection In pediatric,1
PROMACTA,upper respiratory tract infection,placebo were,0
PROMACTA,upper respiratory tract infection,upper respiratory,1
PROMACTA,upper respiratory tract infection,than placebo upper respiratory tract,1
PROMACTA,upper respiratory tract infection,patients with chronic hepatitis,0
PROMACTA,nasopharyngitis,patients with,0
PROMACTA,nasopharyngitis,were upper respiratory tract nasopharyngitis and rhinitis,1
PROMACTA,nasopharyngitis,tract nasopharyngitis and rhinitis,1
PROMACTA,nasopharyngitis,nasopharyngitis and rhinitis,1
PROMACTA,nasopharyngitis,upper respiratory,0
PROMACTA,rhinitis,rhinitis In patients,1
PROMACTA,rhinitis,,0
PROMACTA,rhinitis,,0
PROMACTA,rhinitis,rhinitis In patients,1
PROMACTA,rhinitis,hepatitis Cassociated thrombocytopenia the,0
PROMACTA,rhinitis,hepatitis Cassociated thrombocytopenia the,0
PROMACTA,rhinitis,and,0
PROMACTA,anemia,anemia pyrexia fatigue,1
PROMACTA,anemia,anemia pyrexia fatigue,1
PROMACTA,anemia,placebo anemia pyrexia fatigue,1
PROMACTA,anemia,,0
PROMACTA,anemia,anemia pyrexia fatigue,1
PROMACTA,anemia,fatigue headache nausea diarrhea decreased,0
PROMACTA,anemia,greater than placebo anemia pyrexia fatigue,1
PROMACTA,anemia,anemia pyrexia fatigue,1
PROMACTA,pyrexia,pyrexia fatigue headache,1
PROMACTA,pyrexia,pyrexia fatigue headache,1
PROMACTA,pyrexia,pyrexia fatigue headache,1
PROMACTA,pyrexia,illness asthenia insomni,0
PROMACTA,pyrexia,common adverse reactions greater than or equal to and greater than placebo,0
PROMACTA,pyrexia,,0
PROMACTA,fatigue,fatigue headache nausea,1
PROMACTA,fatigue,were anemia fatigue headache nausea,1
PROMACTA,fatigue,anemia fatigue headache nausea,1
PROMACTA,headache,greater than placebo,0
PROMACTA,headache,placebo,0
PROMACTA,headache,were anemia pyrexia headache nausea diarrhea,1
PROMACTA,headache,headache nausea diarrhea,1
PROMACTA,headache,headache nausea diarrhea,1
PROMACTA,headache,equal to and,0
PROMACTA,headache,reactions greater,0
PROMACTA,nausea,greater than placebo were,0
PROMACTA,nausea,nausea diarrhea decreased,1
PROMACTA,nausea,,0
PROMACTA,nausea,nausea diarrhea decreased,1
PROMACTA,nausea,fatigue nausea diarrhea decreased,1
PROMACTA,nausea,nausea diarrhea decreased,1
PROMACTA,diarrhea,fatigue headache diarrhea decreased appetite,1
PROMACTA,diarrhea,decreased appetite influenzalike illness asthenia insomnia cough pruritus chills myalgia,0
PROMACTA,diarrhea,headache diarrhea decreased appetite,1
PROMACTA,diarrhea,greater than,0
PROMACTA,diarrhea,to and greater than placebo were anemia pyrexia fatigue headache nausea,0
PROMACTA,diarrhea,,0
PROMACTA,diarrhea,diarrhea decreased appetite,1
PROMACTA,diarrhea,than placebo were anemia pyrexia fatigue headache,0
PROMACTA,decreased appetite,appetite influenzalike illness,1
PROMACTA,decreased appetite,headache nausea decreased appetite influenzalike illness,1
PROMACTA,decreased appetite,myalgia alopecia,0
PROMACTA,decreased appetite,,0
PROMACTA,influenza-like illness,nausea,0
PROMACTA,influenza-like illness,diarrhea decreased,0
PROMACTA,influenza-like illness,influenza-like illness asthenia insomnia,1
PROMACTA,influenza-like illness,appetite,0
PROMACTA,influenza-like illness,,0
PROMACTA,influenza-like illness,diarrhea decreased,0
PROMACTA,influenza-like illness,diarrhea decreased influenza-like,1
PROMACTA,asthenia,and,0
PROMACTA,asthenia,asthenia insomnia cough,1
PROMACTA,asthenia,myalgia alopecia and,0
PROMACTA,asthenia,asthenia insomnia cough,1
PROMACTA,asthenia,peripheral edema In,0
PROMACTA,cough,peripheral edema In patients with sever,0
PROMACTA,cough,peripheral,0
PROMACTA,cough,,0
PROMACTA,chills,,0
PROMACTA,chills,edema In patients with severe,0
PROMACTA,chills,aplastic anemia,0
PROMACTA,myalgia,cough pruritus myalgia alopecia and,1
PROMACTA,myalgia,,0
PROMACTA,alopecia,insomnia,0
PROMACTA,peripheral edema,edema In patients,1
PROMACTA,peripheral edema,anemia the,0
PROMACTA,peripheral edema,peripheral edema In patients,1
PROMACTA,peripheral edema,anemia the most common adverse reactions,0
PROMACTA,peripheral edema,myalgia alopecia peripheral edema In patients,1
PROMACTA,peripheral edema,chills,0
PROMACTA,peripheral edema,illness asthenia insomnia cough pruritus chills myalgia alopecia and,0
PROMACTA,peripheral edema,alopecia peripheral edema In patients,1
PROMACTA,peripheral edema,alopecia peripheral edema In patients,1
PROMACTA,peripheral edema,,0
PROMACTA,nausea,nausea fatigue cough,1
PROMACTA,nausea,the most,0
PROMACTA,nausea,nausea fatigue cough,1
PROMACTA,nausea,nausea fatigue cough,1
PROMACTA,nausea,EXCERPT To report,0
PROMACTA,nausea,to nausea fatigue cough,1
PROMACTA,nausea,To report SUSPECTED ADVERSE,0
PROMACTA,nausea,severe aplastic anemia the most common adverse reactions greater than or equal to were,0
PROMACTA,nausea,nausea fatigue cough,1
PROMACTA,fatigue,fatigue cough diarrhea,1
PROMACTA,fatigue,ADVERSE REACTIONS,0
PROMACTA,fatigue,fatigue cough diarrhea,1
PROMACTA,fatigue,fatigue cough diarrhea,1
PROMACTA,fatigue,cough diarrhea and headache EXCERPT To report SUSPECTED,0
PROMACTA,fatigue,greater,0
PROMACTA,fatigue,to were fatigue cough diarrhea,1
PROMACTA,fatigue,fatigue cough diarrhea,1
PROMACTA,fatigue,fatigue cough diarrhea,1
PROMACTA,fatigue,,0
PROMACTA,cough,to,0
PROMACTA,cough,cough diarrhea and,1
PROMACTA,cough,cough diarrhea and,1
PROMACTA,cough,cough diarrhea and,1
PROMACTA,cough,SUSPECTED ADVERSE,0
PROMACTA,cough,REACTIONS conta,0
PROMACTA,cough,SUSPECTED ADVERSE REACTIONS,0
PROMACTA,cough,were nausea cough diarrhea and,1
PROMACTA,diarrhea,fatigue diarrhea and headache,1
PROMACTA,diarrhea,equal to were nausea fatigue,0
PROMACTA,diarrhea,adverse reactions greater than or equal to were nausea,0
PROMACTA,diarrhea,diarrhea and headache,1
PROMACTA,diarrhea,reactions,0
PROMACTA,diarrhea,diarrhea and headache,1
PROMACTA,diarrhea,were nausea fatigue cough,0
PROMACTA,diarrhea,were nausea fatigue diarrhea and headache,1
PROMACTA,headache,,0
PROMACTA,headache,cough diarrhea headache EXCERPT To,1
PROMACTA,headache,fatigue cough diarrhea,0
PROMACTA,headache,headache EXCERPT To,1
PROMACTA,headache,at,0
PROMACTA,headache,greater than or equal to,0
PROMACTA,headache,cough diarrhea headache EXCERPT To,1
PROMACTA,headache,and,0
PROMACTA,headache,headache EXCERPT To,1
PROMACTA,headache,fatigue cough diarrhea headache EXCERPT To,1
PROMACTA,hemorrhage,hemorrhage was the,1
PROMACTA,hemorrhage,hemorrhage was the,1
PROMACTA,hemorrhage,reactions followed discontinuatio,0
PROMACTA,hemorrhage,clinical hemorrhage was the,1
PROMACTA,hemorrhage,hemorrhage was the,1
PROMACTA,hemorrhage,hemorrhage was the,1
PROMACTA,hemorrhage,,0
PROMACTA,hemorrhage,hemorrhage was the,1
PROMACTA,hemorrhage,Chronic Immune Idiopathic Thrombocytopenia,0
PROMACTA,hemorrhage,clinical hemorrhage was the,1
PROMACTA,hemorrhagic reactions,Other serious adverse reactions,0
PROMACTA,hemorrhagic reactions,included thromboticthromboem,0
PROMACTA,hemorrhagic reactions,serious adverse reaction and hemorrhagic,1
PROMACTA,hemorrhagic reactions,reactions followed discontinuation,1
PROMACTA,hemorrhagic reactions,and hemorrhagic,1
PROMACTA,hemorrhagic reactions,hemorrhagic,1
PROMACTA,hemorrhagic reactions,,0
PROMACTA,hemorrhagic reactions,the most common serious,0
PROMACTA,hemorrhagic reactions,,0
PROMACTA,hemorrhagic reactions,serious adverse reactions included thromboticthromboem,0
PROMACTA,Nausea,mg n Placebo Nausea,1
PROMACTA,Nausea,mg n Placebo,0
PROMACTA,Nausea,Nausea,1
PROMACTA,Nausea,,0
PROMACTA,Nausea,Nausea,1
PROMACTA,Nausea,,0
PROMACTA,Nausea,,0
PROMACTA,Diarrhea,Diarrhea,1
PROMACTA,Upper respiratory tract infection,Upper respiratory tract infection Vomiting,1
PROMACTA,Upper respiratory tract infection,Upper respiratory tract,1
PROMACTA,Upper respiratory tract infection,,0
PROMACTA,Upper respiratory tract infection,Upper respiratory tract infection Vomiting,1
PROMACTA,Upper respiratory tract infection,Upper,1
PROMACTA,Vomiting,,0
PROMACTA,Vomiting,infection,0
PROMACTA,Vomiting,Vomiting,1
PROMACTA,Vomiting,,0
PROMACTA,Vomiting,,0
PROMACTA,Vomiting,piratory tract Vomiting,1
PROMACTA,Vomiting,tract,0
PROMACTA,Vomiting,tract Vomiting,1
PROMACTA,Vomiting,,0
PROMACTA,Vomiting,Vomiting,1
PROMACTA,Increased ALT,Increased ALT Myal,1
PROMACTA,Increased ALT,,0
PROMACTA,Increased ALT,,0
PROMACTA,Increased ALT,Increased ALT Myal,1
PROMACTA,Increased ALT,Increased ALT Myal,1
PROMACTA,Increased ALT,Increased ALT Myal,1
PROMACTA,Myalgia,Myalgia,1
PROMACTA,Myalgia,Myalgia,1
PROMACTA,Myalgia,,0
PROMACTA,Myalgia,ALT,0
PROMACTA,Myalgia,ALT,0
PROMACTA,Myalgia,,0
PROMACTA,Myalgia,Myalgia,1
PROMACTA,Myalgia,,0
PROMACTA,Myalgia,,0
PROMACTA,Urinary tract infection,Oropharyngeal,0
PROMACTA,Urinary tract infection,Urinary,1
PROMACTA,Urinary tract infection,,0
PROMACTA,Urinary tract infection,Urinary tract infection Oropharyngeal,1
PROMACTA,Oropharyngeal pain,Oropharyngeal pain Increased,1
PROMACTA,Oropharyngeal pain,,0
PROMACTA,Oropharyngeal pain,ract Oropharyngeal pain Increased,1
PROMACTA,Oropharyngeal pain,ract Oropharyngeal,1
PROMACTA,Oropharyngeal pain,infection,0
PROMACTA,Oropharyngeal pain,Increased,0
PROMACTA,Oropharyngeal pain,,0
PROMACTA,Oropharyngeal pain,infection,0
PROMACTA,Oropharyngeal pain,,0
PROMACTA,Increased AST,Increased,1
PROMACTA,Increased AST,Increased,1
PROMACTA,Increased AST,geal Increased,1
PROMACTA,Increased AST,,0
PROMACTA,Increased AST,Increased,1
PROMACTA,Pharyngitis,Ba,0
PROMACTA,Pharyngitis,AST Pharyngitis Ba,1
PROMACTA,Pharyngitis,AST,0
PROMACTA,Pharyngitis,Pharyngitis Ba,1
PROMACTA,Pharyngitis,AST Pharyngitis Ba,1
PROMACTA,Pharyngitis,,0
PROMACTA,Pharyngitis,AST,0
PROMACTA,Pharyngitis,,0
PROMACTA,Pharyngitis,AST Pharyngitis Ba,1
PROMACTA,Back pain,pain,1
PROMACTA,Influenza,Influenza,1
PROMACTA,Influenza,Influenza,1
PROMACTA,Influenza,Influenza,1
PROMACTA,Influenza,,0
PROMACTA,Influenza,,0
PROMACTA,Influenza,Influenza,1
PROMACTA,Influenza,,0
PROMACTA,Influenza,,0
PROMACTA,Influenza,,0
PROMACTA,Influenza,,0
PROMACTA,Paresthesia,Paresthesia Ra,1
PROMACTA,Paresthesia,Paresthesia Ra,1
PROMACTA,Rash,ia Rash,1
PROMACTA,Rash,ia,0
PROMACTA,alopecia,alopecia,1
PROMACTA,alopecia,alopecia,1
PROMACTA,alopecia,mouth were the,0
PROMACTA,musculoskeletal pain,chronic ITP trials musculoskeletal,1
PROMACTA,musculoskeletal pain,increased and dry mouth were the adverse reactions reported in,0
PROMACTA,musculoskeletal pain,ITP trials musculoskeletal pain,1
PROMACTA,musculoskeletal pain,trials,0
PROMACTA,musculoskeletal pain,of p,0
PROMACTA,musculoskeletal pain,trials musculoskeletal pain,1
PROMACTA,blood alkaline phosphatase increased,blood alkaline phosphatase,1
PROMACTA,dry mouth,dry mouth,1
PROMACTA,Headache,PROMACTA,0
PROMACTA,Headache,Headache H,1
PROMACTA,Headache,n,0
PROMACTA,Headache,Headache H,1
PROMACTA,Headache,mg Headache H,1
PROMACTA,Headache,mg Headache H,1
PROMACTA,Headache,PROMACTA mg n,0
PROMACTA,Headache,Headache H,1
PROMACTA,Hyperbilirubinemia,e Hyperbilirubinemia,1
PROMACTA,Hyperbilirubinemia,e,0
PROMACTA,Hyperbilirubinemia,Hyperbilirubinemia ALT increas,1
PROMACTA,Hyperbilirubinemia,Hyperbilirubinemia ALT increas,1
PROMACTA,ALT increased,Catara,0
PROMACTA,ALT increased,lirubinemia ALT increased Catara,1
PROMACTA,ALT increased,increased Catara,1
PROMACTA,ALT increased,increased Catara,1
PROMACTA,Cataract,reased,0
PROMACTA,Cataract,Cataract A,1
PROMACTA,Cataract,reased Cataract A,1
PROMACTA,Cataract,,0
PROMACTA,Cataract,Cataract A,1
PROMACTA,Cataract,Cataract A,1
PROMACTA,Cataract,Cataract A,1
PROMACTA,Cataract,,0
PROMACTA,AST increased,t AST,1
PROMACTA,AST increased,,0
PROMACTA,AST increased,,0
PROMACTA,AST increased,,0
PROMACTA,AST increased,AST increased Fatigu,1
PROMACTA,AST increased,t,0
PROMACTA,AST increased,,0
PROMACTA,AST increased,,0
PROMACTA,Fatigue,reased Fatigue,1
PROMACTA,Fatigue,reased Fatigue,1
PROMACTA,Fatigue,,0
PROMACTA,Nausea,Nausea,1
PROMACTA,Nausea,Nausea,1
PROMACTA,Nausea,,0
PROMACTA,Nausea,,0
PROMACTA,Nausea,Nausea,1
PROMACTA,Nausea,,0
PROMACTA,serum liver test abnormalities,chronic ITP serum liver test abnormalities,1
PROMACTA,serum liver test abnormalities,chronic ITP serum liver,1
PROMACTA,serum liver test abnormalities,chronic,0
PROMACTA,serum liver test abnormalities,ITP serum,1
PROMACTA,serum liver test abnormalities,less in severity were,0
PROMACTA,serum liver test abnormalities,ITP serum liver test abnormalities,1
PROMACTA,serum liver test abnormalities,trials,0
PROMACTA,serum liver test abnormalities,ITP serum liver test abnormalities,1
PROMACTA,serum liver test abnormalities,chronic ITP,0
PROMACTA,serum liver test abnormalities,test abnormalities,1
PROMACTA,serum liver test abnormalities,three controlled chronic ITP serum liver test,1
PROMACTA,serum liver test abnormalities,liver test abnormalities,1
PROMACTA,serum liver test abnormalities,,0
PROMACTA,hepatobiliary laboratory abnormalities,in the placebo,0
PROMACTA,hepatobiliary laboratory abnormalities,abnormalities,1
PROMACTA,hepatobiliary laboratory abnormalities,due hepatobiliary laboratory abnormalities,1
PROMACTA,hepatobiliary laboratory abnormalities,,0
PROMACTA,hepatobiliary laboratory abnormalities,treated with PROMACTA in the controlled trials with hepatobiliary,0
PROMACTA,hepatobiliary laboratory abnormalities,,0
PROMACTA,hepatobiliary laboratory abnormalities,group discontinued treatment due hepatobiliary laboratory abnormalities,1
PROMACTA,hepatobiliary laboratory abnormalities,,0
PROMACTA,hepatobiliary laboratory abnormalities,laboratory abnormalities,1
PROMACTA,hepatobiliary laboratory abnormalities,,0
PROMACTA,hepatobiliary laboratory abnormalities,in the controlled trials hepatobiliary laboratory abnormalities,1
PROMACTA,hepatobiliary laboratory abnormalities,the controlled trials hepatobiliary laboratory abnormalities,1
PROMACTA,hepatobiliary laboratory abnormalities,the controlled trials hepatobiliary,1
PROMACTA,hepatobiliary laboratory abnormalities,laboratory abnormalities,1
PROMACTA,hepatobiliary laboratory abnormalities,the controlled trials hepatobiliary,1
PROMACTA,hepatobiliary laboratory abnormalities,controlled trials hepatobiliary,1
PROMACTA,liver test abnormalities,these patients,0
PROMACTA,liver test abnormalities,the extension trial Six of these patients again,0
PROMACTA,liver test abnormalities,again liver test abnormalities,1
PROMACTA,liver test abnormalities,again liver test abnormalities,1
PROMACTA,liver test abnormalities,patients again,0
PROMACTA,liver test abnormalities,patients again,0
PROMACTA,liver test abnormalities,liver test abnormalities,1
PROMACTA,liver test abnormalities,chronic ITP trial one additional patient had PROMACTA discontinued due to,0
PROMACTA,liver test abnormalities,liver test abnormalities,1
PROMACTA,portal vein thromboses,,0
PROMACTA,portal vein thromboses,related to ITP six,0
PROMACTA,portal vein thromboses,and one patient in the,0
PROMACTA,portal vein thromboses,see,0
PROMACTA,portal vein thromboses,related to ITP six patients treated with PROMACTA and one,0
PROMACTA,Upper respiratory tract infection,action Upper,1
PROMACTA,Nasopharyngitis,Nasopharyngitis Rhini,1
PROMACTA,Nasopharyngitis,Nasopharyngitis Rhini,1
PROMACTA,Nasopharyngitis,Nasopharyngitis Rhini,1
PROMACTA,Nasopharyngitis,infection,0
PROMACTA,Nasopharyngitis,Nasopharyngitis Rhini,1
PROMACTA,Nasopharyngitis,Nasopharyngitis Rhini,1
PROMACTA,Nasopharyngitis,Rhini,0
PROMACTA,Nasopharyngitis,iratory tract Nasopharyngitis Rhini,1
PROMACTA,Nasopharyngitis,,0
PROMACTA,Nasopharyngitis,infection,0
PROMACTA,Rhinitis,gitis,0
PROMACTA,Rhinitis,Rhinitis,1
PROMACTA,Rhinitis,Rhinitis,1
PROMACTA,Rhinitis,Rhinitis,1
PROMACTA,Rhinitis,Rhinitis,1
PROMACTA,Rhinitis,,0
PROMACTA,Rhinitis,Rhinitis,1
PROMACTA,Rhinitis,,0
PROMACTA,Rhinitis,gitis,0
PROMACTA,Rhinitis,,0
PROMACTA,Abdominal pain,Abdominal pain Coug,1
PROMACTA,Abdominal pain,,0
PROMACTA,Abdominal pain,Coug,0
PROMACTA,Abdominal pain,Abdominal pain Coug,1
PROMACTA,Abdominal pain,Abdominal,1
PROMACTA,Abdominal pain,,0
PROMACTA,Abdominal pain,Abdominal pain Coug,1
PROMACTA,Abdominal pain,Abdominal pain Coug,1
PROMACTA,Abdominal pain,pain Coug,1
PROMACTA,Cough,pain Cough,1
PROMACTA,Cough,pain Cough,1
PROMACTA,Cough,,0
PROMACTA,Cough,pain Cough,1
PROMACTA,Cough,pain,0
PROMACTA,Cough,Cough,1
PROMACTA,Cough,Cough,1
PROMACTA,Cough,Cough,1
PROMACTA,Cough,,0
PROMACTA,Oropharyngeal pain,,0
PROMACTA,Oropharyngeal pain,Oropharyngeal,1
PROMACTA,Oropharyngeal pain,,0
PROMACTA,Oropharyngeal pain,,0
PROMACTA,Toothache,pain,0
PROMACTA,Toothache,Toothache,1
PROMACTA,Toothache,eal Toothache,1
PROMACTA,Diarrhea,Diarrhea,1
PROMACTA,Diarrhea,sed,0
PROMACTA,Diarrhea,Diarrhea,1
PROMACTA,Rash,Rash,1
PROMACTA,Rash,,0
PROMACTA,Rash,,0
PROMACTA,Rash,,0
PROMACTA,Rash,,0
PROMACTA,Rash,Rash,1
PROMACTA,ALT increased,ALT,1
PROMACTA,ALT increased,ALT increased a,1
PROMACTA,Vitamin D deficiency,D deficiency,1
PROMACTA,Anemia,PeginterferonRibavirin n Placebo PeginterferonRibavirin Anemia,1
PROMACTA,Anemia,Placebo PeginterferonRibavirin,0
PROMACTA,Pyrexia,Pyrexia,1
PROMACTA,Pyrexia,,0
PROMACTA,Pyrexia,Pyrexia,1
PROMACTA,Pyrexia,,0
PROMACTA,Pyrexia,Pyrexia,1
PROMACTA,Fatigue,Fatigue,1
PROMACTA,Fatigue,Fatigue,1
PROMACTA,Fatigue,,0
PROMACTA,Fatigue,,0
PROMACTA,Fatigue,,0
PROMACTA,Headache,Headache,1
PROMACTA,Headache,,0
PROMACTA,Headache,,0
PROMACTA,Nausea,Nausea,1
PROMACTA,Nausea,Nausea,1
PROMACTA,Nausea,Nausea,1
PROMACTA,Nausea,Nausea,1
PROMACTA,Nausea,Nausea,1
PROMACTA,Nausea,Nausea,1
PROMACTA,Nausea,,0
PROMACTA,Nausea,,0
PROMACTA,Diarrhea,,0
PROMACTA,Diarrhea,,0
PROMACTA,Diarrhea,,0
PROMACTA,Diarrhea,Diarrhea,1
PROMACTA,Influenza-like illness,appetite,0
PROMACTA,Influenza-like illness,appetite,0
PROMACTA,Influenza-like illness,appetite Influenza-like illness Asthenia,1
PROMACTA,Influenza-like illness,,0
PROMACTA,Influenza-like illness,appetite,0
PROMACTA,Influenza-like illness,appetite,0
PROMACTA,Influenza-like illness,illness Asthenia,1
PROMACTA,Influenza-like illness,,0
PROMACTA,Influenza-like illness,illness Asthenia,1
PROMACTA,Influenza-like illness,appetite,0
PROMACTA,Asthenia,like Asthenia,1
PROMACTA,Asthenia,like Asthenia,1
PROMACTA,Asthenia,,0
PROMACTA,Asthenia,,0
PROMACTA,Asthenia,Asthenia,1
PROMACTA,Asthenia,Asthenia,1
PROMACTA,Insomnia,,0
PROMACTA,Insomnia,Insomnia,1
PROMACTA,Insomnia,,0
PROMACTA,Insomnia,Insomnia,1
PROMACTA,Insomnia,,0
PROMACTA,Insomnia,,0
PROMACTA,Insomnia,Insomnia,1
PROMACTA,Insomnia,Insomnia,1
PROMACTA,Cough,Cough,1
PROMACTA,Cough,,0
PROMACTA,Cough,,0
PROMACTA,Pruritus,,0
PROMACTA,Pruritus,,0
PROMACTA,Pruritus,,0
PROMACTA,Pruritus,,0
PROMACTA,Pruritus,,0
PROMACTA,Pruritus,,0
PROMACTA,Pruritus,,0
PROMACTA,Pruritus,,0
PROMACTA,Pruritus,Pruritus,1
PROMACTA,Chills,Chills,1
PROMACTA,Chills,Chills,1
PROMACTA,Chills,Chills,1
PROMACTA,Chills,Chills,1
PROMACTA,Chills,,0
PROMACTA,Chills,,0
PROMACTA,Alopecia,,0
PROMACTA,Alopecia,,0
PROMACTA,Alopecia,,0
PROMACTA,Alopecia,Alopecia,1
PROMACTA,Alopecia,,0
PROMACTA,Peripheral edema,,0
PROMACTA,Peripheral edema,edema,1
PROMACTA,Peripheral edema,Peripheral,1
PROMACTA,Peripheral edema,,0
PROMACTA,Peripheral edema,,0
PROMACTA,Peripheral edema,edema,1
PROMACTA,Peripheral edema,edema,1
PROMACTA,hyperbilirubinemia,patients with chronic hepatitis,0
PROMACTA,hyperbilirubinemia,with,0
PROMACTA,hyperbilirubinemia,hyperbilirubinemia,1
PROMACTA,hyperbilirubinemia,chronic,0
PROMACTA,hyperbilirubinemia,the two controlled,0
PROMACTA,hyperbilirubinemia,clinical trials in patients with chronic hepatitis,0
PROMACTA,hyperbilirubinemia,hyperbilirubinemia,1
PROMACTA,hyperbilirubinemia,hyperbilirubinemia,1
PROMACTA,Total bilirubin greater than or equal to 1.5 x ULN,for Total bilirubin greater than or equal to 1.5 x ULN,1
PROMACTA,AST greater than or equal to 3 x ULN,patients receiving PROMACTA,0
PROMACTA,AST greater than or equal to 3 x ULN,patients,0
PROMACTA,AST greater than or equal to 3 x ULN,,0
PROMACTA,AST greater than or equal to 3 x ULN,ALT AST greater than or equal to 3 x ULN,1
PROMACTA,AST greater than or equal to 3 x ULN,respectively ALT AST greater than or equal to 3 x ULN,1
PROMACTA,nausea,nausea,1
PROMACTA,nausea,Table,0
PROMACTA,nausea,or equal to nausea,1
PROMACTA,nausea,nausea,1
PROMACTA,nausea,equal to nausea,1
PROMACTA,nausea,greater than or equal,0
PROMACTA,nausea,nausea,1
PROMACTA,nausea,nausea,1
PROMACTA,nausea,nausea,1
PROMACTA,nausea,fatigue cough diarrhea and headache Table,0
PROMACTA,fatigue,to were fatigue,1
PROMACTA,fatigue,,0
PROMACTA,fatigue,fatigue,1
PROMACTA,fatigue,,0
PROMACTA,fatigue,Adverse Reactions from One Openlabel Trial,0
PROMACTA,fatigue,adverse reactions greater than or equal to,0
PROMACTA,fatigue,diarrhea and headache,0
PROMACTA,cough,One Openlabel Trial,0
PROMACTA,cough,cough,1
PROMACTA,cough,common adverse reactions greater than,0
PROMACTA,cough,to were nausea cough,1
PROMACTA,cough,from One Openlabel Trial,0
PROMACTA,cough,cough,1
PROMACTA,cough,cough,1
PROMACTA,cough,,0
PROMACTA,diarrhea,,0
PROMACTA,headache,headache,1
PROMACTA,headache,to were nausea fatigue cough diarrhea,0
PROMACTA,headache,Openlabel,0
PROMACTA,headache,headache,1
PROMACTA,headache,fatigue cough diarrhea headache,1
PROMACTA,headache,headache,1
PROMACTA,headache,nausea fatigue cough diarrhea headache,1
PROMACTA,Fatigue,,0
PROMACTA,Fatigue,Fatigue,1
PROMACTA,Cough,,0
PROMACTA,Cough,Cough,1
PROMACTA,Cough,Cough,1
PROMACTA,Diarrhea,,0
PROMACTA,Diarrhea,H,0
PROMACTA,Diarrhea,Diarrhea H,1
PROMACTA,Diarrhea,Diarrhea H,1
PROMACTA,Diarrhea,H,0
PROMACTA,Diarrhea,,0
PROMACTA,Headache,,0
PROMACTA,Headache,a,0
PROMACTA,Headache,a Headache P,1
PROMACTA,Headache,a,0
PROMACTA,Headache,P,0
PROMACTA,Headache,a Headache P,1
PROMACTA,Headache,P,0
PROMACTA,Headache,Headache P,1
PROMACTA,Headache,,0
PROMACTA,Headache,a,0
PROMACTA,Pain in extremity,Pain in extremity Dyspnea,1
PROMACTA,Pain in extremity,,0
PROMACTA,Pain in extremity,,0
PROMACTA,Pain in extremity,e Pain in extremity Dyspnea,1
PROMACTA,Pain in extremity,extremity Dyspnea,1
PROMACTA,Dyspnea,extremity,0
PROMACTA,Dyspnea,Dyspnea,1
PROMACTA,Pyrexia,,0
PROMACTA,Dizziness,Dizziness Or,1
PROMACTA,Dizziness,,0
PROMACTA,Dizziness,Or,0
PROMACTA,Dizziness,Dizziness Or,1
PROMACTA,Dizziness,,0
PROMACTA,Dizziness,Dizziness Or,1
PROMACTA,Dizziness,Dizziness Or,1
PROMACTA,Dizziness,Or,0
PROMACTA,Dizziness,,0
PROMACTA,Oropharyngeal pain,Oropharyngeal pain,1
PROMACTA,Febrile neutropenia,yngeal Febrile,1
PROMACTA,Febrile neutropenia,Febrile,1
PROMACTA,Febrile neutropenia,yngeal Febrile,1
PROMACTA,Febrile neutropenia,pa,0
PROMACTA,Febrile neutropenia,,0
PROMACTA,Febrile neutropenia,Febrile,1
PROMACTA,Febrile neutropenia,yngeal Febrile neutropenia,1
PROMACTA,Febrile neutropenia,pain,0
PROMACTA,Abdominal pain,Abdominal pain Ecchymo,1
PROMACTA,Abdominal pain,neutropenia,0
PROMACTA,Abdominal pain,,0
PROMACTA,Abdominal pain,neutropenia Abdominal pain Ecchymo,1
PROMACTA,Abdominal pain,Abdominal pain Ecchymo,1
PROMACTA,Abdominal pain,neutropenia Abdominal,1
PROMACTA,Abdominal pain,neutropenia Abdominal pain Ecchymo,1
PROMACTA,Abdominal pain,Abdominal pain Ecchymo,1
PROMACTA,Abdominal pain,neutropenia,0
PROMACTA,Ecchymosis,,0
PROMACTA,Ecchymosis,pain,0
PROMACTA,Ecchymosis,,0
PROMACTA,Ecchymosis,pain,0
PROMACTA,Ecchymosis,,0
PROMACTA,Ecchymosis,Ecchymosis Mus,1
PROMACTA,Ecchymosis,pain,0
PROMACTA,Ecchymosis,al Ecchymosis Mus,1
PROMACTA,Transaminases increased,spasms Transaminases,1
PROMACTA,Transaminases increased,spasms,0
PROMACTA,Arthralgia,,0
PROMACTA,Arthralgia,,0
PROMACTA,Arthralgia,increased,0
PROMACTA,Arthralgia,Arthralgia Rhi,1
PROMACTA,Arthralgia,,0
PROMACTA,Arthralgia,,0
PROMACTA,Rhinorrhea,gia,0
PROMACTA,Rhinorrhea,gia,0
PROMACTA,Rhinorrhea,gia Rhinorrhea,1
PROMACTA,Rhinorrhea,,0
PROMACTA,Rhinorrhea,Rhinorrhea,1
PROMACTA,Rhinorrhea,gia Rhinorrhea,1
PROMACTA,Rhinorrhea,,0
PROMACTA,cytogenetic abnormality,abnormalities Eight patients had a new,0
PROMACTA,cytogenetic abnormality,a cytogenetic abnormality,1
PROMACTA,cytogenetic abnormality,reported on therapy including patients who had complex changes in chromosome Postma,0
PROMACTA,cytogenetic abnormality,patients had a new,0
PROMACTA,cytogenetic abnormality,marrow aspirates evaluated for cytogenetic abnormalities Eight patients had a,0
PROMACTA,cytogenetic abnormality,patients had a,0
PROMACTA,cytogenetic abnormality,abnormality,1
PROMACTA,cytogenetic abnormality,had a cytogenetic abnormality,1
PROMACTA,Thrombotic microangiopathy,renal,0
PROMACTA,Thrombotic microangiopathy,,0
PROMACTA,Thrombotic microangiopathy,with,0
PROMACTA,Thrombotic microangiopathy,with acute,0
PROMACTA,Thrombotic microangiopathy,Vascular Thrombotic,1
PROMACTA,Thrombotic microangiopathy,microangiopathy,1
PROMACTA,Thrombotic microangiopathy,renal failure,0
PROMACTA,Thrombotic microangiopathy,with acute renal failure,0
PROMACTA,Thrombotic microangiopathy,establish,0
PROMACTA,acute renal failure,acute,1
PROMACTA,acute renal failure,drug exposure Vascular Disorders Thrombotic,0
PROMACTA,acute renal failure,Thrombotic microangiopathy acute,1
PROMACTA,acute renal failure,Vascular Disorders Thrombotic microangiopathy acute renal,1
PROMACTA,acute renal failure,Vascular Disorders Thrombotic microangiopathy with,0
PROMACTA,acute renal failure,acute renal failure,1
PROMACTA,acute renal failure,,0
PROMACTA,HEPATIC DECOMPENSATION,,0
PROMACTA,HEPATIC DECOMPENSATION,g serious adverse reac tions associated with,1
PROMACTA,HEPATIC DECOMPENSATION,,0
PROMACTA,HEPATIC DECOMPENSATION,g serious adverse reac tions associated with,1
PROMACTA,HEPATIC DECOMPENSATION,g,1
PROMACTA,HEPATIC DECOMPENSATION,,0
PROMACTA,HEPATIC DECOMPENSATION,sections Hepatic Decompensation in,0
PROMACTA,HEPATIC DECOMPENSATION,g serious adverse reac tions,1
PROMACTA,HEPATIC DECOMPENSATION,adverse reac tions associated with,1
PROMACTA,HEPATIC DECOMPENSATION,described,0
PROMACTA,hepatic decompensation,Precautions /Thromboembolic Compli cations see Warnings,1
PROMACTA,hepatic decompensation,and,0
PROMACTA,hepatic decompensation,Precautions /Thromboembolic,1
PROMACTA,hepatic decompensation,see,0
PROMACTA,hepatic decompensation,/Thromboembolic Compli cations see Warnings,1
PROMACTA,hepatic decompensation,see Warnings and,0
PROMACTA,hepatic decompensation,and Precautions Cataracts,0
PROMACTA,hepatic decompensation,see Warnings and Precautions /Thromboembolic Compli cations see Warnings,1
PROMACTA,hepatic decompensation,Warnings and Precautions /Thromboembolic Compli cations see Warnings,1
PROMACTA,HEPATIC DECOMPENSATION,see Warnings and Precautions,0
PROMACTA,HEPATIC DECOMPENSATION,greater than or equal,0
PROMACTA,HEPATIC DECOMPENSATION,Cataracts see Warnings Precautions,1
PROMACTA,HEPATIC DECOMPENSATION,(5.4)] In adult patients,1
PROMACTA,HEPATIC DECOMPENSATION,,0
PROMACTA,HEPATIC DECOMPENSATION,Complications see Warnings and Precautions Cataracts,0
PROMACTA,HEPATIC DECOMPENSATION,ITP the most common adverse reactions greater than or equal to,0
PROMACTA,Hepatotoxicity,a ssociated with,1
PROMACTA,Hepatotoxicity,se reactions a ssociated with PROMACTA,1
PROMACTA,Hepatotoxicity,se reactions a ssociated,1
PROMACTA,Hepatotoxicity,se reactions a,1
PROMACTA,Hepatotoxicity,,0
PROMACTA,Hepatotoxicity,se reactions,1
PROMACTA,Hepatotoxicity,sections Hepatic,0
PROMACTA,Thromboembolic Complications,with Ch,1
PROMACTA,Thromboembolic Complications,see Warnings and Prec,0
PROMACTA,Portal vein thrombosis,and Precautions T,0
PROMACTA,Portal vein thrombosis,,0
PROMACTA,Portal vein thrombosis,in other sections,0
PROMACTA,Portal vein thrombosis,Patients with nic Hepatitis C,1
PROMACTA,Portal vein thrombosis,,0
PROMACTA,Portal vein thrombosis,nic Hepatitis C [see W,1
PROMACTA,hepatic decompensation,were nausea diarrhea upper respiratory,0
PROMACTA,hepatic decompensation,nausea diarrhea upper respiratory tract,0
PROMACTA,hepatic decompensation,to 5% and greater,1
PROMACTA,hepatic decompensation,,0
PROMACTA,hepatic decompensation,reactions greater than or qual to,1
PROMACTA,hepatic decompensation,,0
PROMACTA,hepatic decompensation,qual to,1
PROMACTA,hepatic decompensation,the most common,0
PROMACTA,hepatic decompensation,common adverse reactions greater than or e,0
PROMACTA,hepatic decompensation,diarrhea,0
PROMACTA,ascites,"infection vomiting increased LT, mya",1
PROMACTA,ascites,pediatric,0
PROMACTA,ascites,vomiting increased,0
PROMACTA,ascites,infection vomiting increased,0
PROMACTA,ascites,lgia and urinary tract infection In pediatric patients age years and older with,0
PROMACTA,ascites,,0
PROMACTA,ascites,,0
PROMACTA,ascites,were nausea diarrhea upper respiratory tract infection vomiting,0
PROMACTA,ascites,pediatric patients age years and,0
PROMACTA,encephalopathy,ALT  and urinary t,1
PROMACTA,encephalopathy,infection vomiting increased ALT  and urinary t,1
PROMACTA,encephalopathy,diarrhea upper respiratory tract infection,0
PROMACTA,encephalopathy,ract infection In,0
PROMACTA,encephalopathy,increased ALT and,1
PROMACTA,hepatic decompensation,with chronic hepatitis associated,1
PROMACTA,hepatic decompensation,with chronic hepatitis associated,1
PROMACTA,hepatic decompensation,hepatitis,0
PROMACTA,hepatic decompensation,hepatitis C,0
PROMACTA,liver enzyme elevations,ill,1
PROMACTA,liver enzyme elevations,appet,0
PROMACTA,liver enzyme elevations,placebo were anemia pyrexia fatigue headache nausea diarrhea decreased appet,0
PROMACTA,liver enzyme elevations,insomnia cough pruritus,0
PROMACTA,liver enzyme elevations,decreased,0
PROMACTA,liver enzyme elevations,ness asthenia insomnia cough pruritus chills myalgia alopecia,0
PROMACTA,liver enzyme elevations,chills myalgia alopecia and peripheral,0
PROMACTA,liver enzyme elevations,,0
PROMACTA,liver enzyme elevations,decreased,0
PROMACTA,liver enzyme elevations,,0
PROMACTA,indirect hyperbilirubinemia,"To report SUSPECTED ADVERSE NS,",1
PROMACTA,indirect hyperbilirubinemia,,0
PROMACTA,indirect hyperbilirubinemia,contact GlaxoSmithKline,1
PROMACTA,indirect hyperbilirubinemia,GlaxoSmithKline,1
PROMACTA,indirect hyperbilirubinemia,"SUSPECTED ADVERSE NS, contact GlaxoSmithKline",1
PROMACTA,indirect hyperbilirubinemia,,0
PROMACTA,indirect hyperbilirubinemia,headache EXCERPT To report SUSPECTED ADVERSE REACTIO,0
PROMACTA,indirect hyperbilirubinemia,"report SUSPECTED ADVERSE NS, contact GlaxoSmithKline",1
PROMACTA,indirect hyperbilirubinemia,contact GlaxoSmithKline,1
PROMACTA,indirect hyperbilirubinemia,"SUSPECTED ADVERSE NS, contact",1
PROMACTA,Hepatotoxicity,for,0
PROMACTA,Hepatotoxicity, administered ,1
PROMACTA,Hepatotoxicity,placebocontrolled trials PROMACTA  administered ,1
PROMACTA,Hepatotoxicity,three placebocontrolled trials PROMACTA  administered ,1
PROMACTA,Hepatotoxicity, administered ,1
PROMACTA,thrombotic event,,0
PROMACTA,thrombotic event,placebo Table Adverse tions,1
PROMACTA,thrombotic event,Chronic Immune,0
PROMACTA,thrombotic event,Adverse Reac,0
PROMACTA,thrombotic event,,0
PROMACTA,thrombotic event,Adverse tions (>=3%) fro,1
PROMACTA,thromboembolic complications,n,0
PROMACTA,increases in platelet counts,                             Diarrhea,1
PROMACTA,thromboembolic complications,             3               Diarrhea,1
PROMACTA,thromboembolic complications,             3               Diarrhea,1
PROMACTA,thromboembolic complications,             3               Diarrhea,1
PROMACTA,thrombotic events, AST              Pharyngitis,1
PROMACTA,thrombotic events, AST              Pharyngitis,1
PROMACTA,thrombotic events, AST              Pharyngitis,1
PROMACTA,thrombotic events,Increased,0
PROMACTA,thrombotic events,Increased,0
PROMACTA,thrombotic events,Increased  AST              Pharyngitis,1
PROMACTA,thrombotic events,Increased,0
PROMACTA,thrombotic events,Increased,0
PROMACTA,thrombotic events,Pharyngitis,0
PROMACTA,thrombotic events, AST              Pharyngitis,1
PROMACTA,thrombotic complications,"    
  Pharyngitis      ",1
PROMACTA,thrombotic complications,pai,0
PROMACTA,thrombotic complications,AST,0
PROMACTA,thrombotic complications,Back pai,0
PROMACTA,thrombotic complications,"    
  Pharyngitis      ",1
PROMACTA,thrombotic complications,"    
  Pharyngitis      ",1
PROMACTA,thrombotic complications,pai,0
PROMACTA,thrombotic complications,"    
  Pharyngitis      ",1
PROMACTA,thrombotic complications,,0
PROMACTA,thrombotic complications,Back                   2      Influenza,1
PROMACTA,thrombotic complications,                  2      Influenza,1
PROMACTA,thrombotic complications,Back                   2      Influenza,1
PROMACTA,portal vein thrombosis,Influenza                3       Paresthesia,1
PROMACTA,portal vein thrombosis,Influenza,0
PROMACTA,portal vein thrombosis,               3       Paresthesia,1
PROMACTA,portal vein thrombosis,Influenza,0
PROMACTA,portal vein thrombosis,,0
PROMACTA,portal vein thrombosis,               3       Paresthesia,1
PROMACTA,portal vein thrombosis,Influenza,0
PROMACTA,portal vein thrombosis,Influenza                3       Paresthesia,1
PROMACTA,PVT,Influenza,0
PROMACTA,PVT,    Paresthesia,1
PROMACTA,PVT,Influenza,0
PROMACTA,PVT,Influenza     Paresthesia,1
PROMACTA,PVT,Influenza     Paresthesia,1
PROMACTA,PVT,Influenza     Paresthesia,1
PROMACTA,PVT,Influenza,0
PROMACTA,PVT,,0
PROMACTA,PVT,Influenza     Paresthesia,1
PROMACTA,PVT,Influenza     Paresthesia,1
PROMACTA,PVT,Influenza     Paresthesia,1
PROMACTA,PVT,Paresthesia,0
PROMACTA,PVT,    Paresthesia,1
PROMACTA,PVT,    Paresthesia,1
PROMACTA,PVT,,0
PROMACTA,PVT,    Paresthesia,1
PROMACTA,abdominal pain,Influenza,0
PROMACTA,abdominal pain,Influenza                Paresthesia,1
PROMACTA,abdominal pain,Influenza,0
PROMACTA,nausea, Pares thesia,1
PROMACTA,nausea,,0
PROMACTA,nausea,a,0
PROMACTA,nausea,,0
PROMACTA,nausea,a  Pares thesia,1
PROMACTA,nausea, Pares thesia,1
PROMACTA,nausea,,0
PROMACTA,vomiting,Rash,0
PROMACTA,vomiting,Paresth,0
PROMACTA,vomiting,esia     Rash,1
PROMACTA,vomiting,Rash,0
PROMACTA,vomiting,esia     Rash,1
PROMACTA,vomiting,esia     Rash,1
PROMACTA,diarrhea,,0
PROMACTA,diarrhea,,0
PROMACTA,diarrhea,Paresthesia,0
PROMACTA,diarrhea,Paresthesia          Rash,1
PROMACTA,diarrhea,         Rash,1
PROMACTA,diarrhea,Paresthesia          Rash,1
PROMACTA,diarrhea,Paresthesia          Rash,1
PROMACTA,diarrhea,Paresthesia,0
PROMACTA,diarrhea,         Rash,1
PROMACTA,thrombotic complication,"
  Rash                 In",1
PROMACTA,thrombotic complication,"hesia 
  Rash                 In t",1
PROMACTA,thrombotic complication,hesia,0
PROMACTA,portal venous thrombosis,,0
PROMACTA,portal venous thrombosis,the three rolled clinical chronic  ITP,1
PROMACTA,cataracts,trial the adverse reactions occurred in a pattern similar to,0
PROMACTA,cataracts,chronic ITP,0
PROMACTA,cataracts,PR OMACTA,1
PROMACTA,cataracts,who ceived PR OMACTA,1
PROMACTA,cataracts,ITP who ceived PR OMACTA,1
PROMACTA,cataracts,ITP,0
PROMACTA,cataracts,extension trial the adverse reactions occurred in a pattern similar to,0
PROMACTA,cataracts,ITP who ceived,1
PROMACTA,cataracts,reactions occurred in a pattern similar to that seen in the,0
PROMACTA,cataracts,placebocontrolled trials,0
PROMACTA,cataracts,in,0
PROMACTA,cataracts,than,0
PROMACTA,cataracts,the adverse reactions occurred in a pattern similar to that seen in the placebocontrolled,0
PROMACTA,cataracts,. Table 5 presents,1
PROMACTA,cataracts,Reactions from,1
PROMACTA,cataracts,Treatmentrelated Reactions from,1
PROMACTA,cataracts,PROMACTA from the,0
PROMACTA,cataracts,Reactions from,1
PROMACTA,cataracts,Reactions from,1
PROMACTA,cataracts,Table,0
PROMACTA,cataracts,Reactions from,1
PROMACTA,cataracts,Reactions from,1
PROMACTA,cataracts,Reactions from,1
PROMACTA,cataracts,Reactions from,1
BESIVANCE,ocular adverse reaction,reaction was,1
BESIVANCE,ocular adverse reaction,with clinical,0
BESIVANCE,conjunctival redness,,0
BESIVANCE,conjunctival redness,,0
BESIVANCE,conjunctival redness,ocular adverse reaction,0
BESIVANCE,conjunctival redness,patients,0
BESIVANCE,conjunctival redness,reaction conjunctival,1
BESIVANCE,conjunctival redness,,0
BESIVANCE,conjunctival redness,,0
BESIVANCE,conjunctival redness,patients receivi,0
BESIVANCE,blurred vision,eye irritation eye pruritus and headache,0
BESIVANCE,blurred vision,receiving,0
BESIVANCE,blurred vision,vision eye,1
BESIVANCE,blurred vision,vision eye,1
BESIVANCE,blurred vision,eye,0
BESIVANCE,blurred vision,of patients blurred,1
BESIVANCE,blurred vision,blurred vision eye,1
BESIVANCE,blurred vision,occurring in approximately,0
BESIVANCE,eye pain,and headache EXCERPT The,0
BESIVANCE,eye pain,Besivance,0
BESIVANCE,eye irritation,eye pruritus and headache EXCERPT The most common,0
BESIVANCE,eye irritation,headache EXCERPT The most,0
BESIVANCE,eye irritation,included blurred vision eye eye,1
BESIVANCE,eye irritation,vision eye eye,1
BESIVANCE,eye pruritus,common adverse reaction reported in of patients,0
BESIVANCE,eye pruritus,,0
BESIVANCE,eye pruritus,most common adverse reaction reported in of patients treated,0
BESIVANCE,eye pruritus,vision eye pain eye,0
BESIVANCE,eye pruritus,,0
BESIVANCE,eye pruritus,irritation,0
BESIVANCE,headache,headache EXCERPT,1
BESIVANCE,headache,headache EXCERPT,1
BESIVANCE,headache,pain eye irritation eye pruritus,0
BESIVANCE,headache,headache EXCERPT,1
BESIVANCE,headache,pruritus headache EXCERPT,1
BESIVANCE,headache,headache EXCERPT,1
BESIVANCE,headache,headache EXCERPT,1
BESIVANCE,headache,pain eye irritation eye,0
BESIVANCE,headache,headache EXCERPT,1
BESIVANCE,headache,,0
BESIVANCE,conjunctival redness,,0
BESIVANCE,conjunctival redness,treated with Besivance conjunctival,1
BESIVANCE,conjunctival redness,To report SUSPECTED,0
BESIVANCE,conjunctival redness,To report SUSPECTED ADVERSE REACTIONS contact Bausch Lomb,0
BESIVANCE,conjunctival redness,Lomb,0
BESIVANCE,overgrowth of non-susceptible organisms,headache. EXCERPT,1
INLYTA,hypertension,,0
INLYTA,hypertension,detail,0
INLYTA,hypertension,,0
INLYTA,hypertension,label seeWarnings and hypertension arterial,1
INLYTA,hypertension,detail in other sections of the,0
INLYTA,hypertension,hypertension arterial,1
INLYTA,hypertension,failure gastroi,0
INLYTA,hypertension,,0
INLYTA,hypertension,hypertension arterial,1
INLYTA,arterial thromboembolic events,events venous,1
INLYTA,venous thromboembolic events,hypertension arterial thromboembolic venous thromboembolic events hemorrhage,1
INLYTA,venous thromboembolic events,venous,1
INLYTA,venous thromboembolic events,hypertension arterial,0
INLYTA,venous thromboembolic events,venous thromboembolic,1
INLYTA,hemorrhage,thromboembolic events,0
INLYTA,hemorrhage,hemorrhage cardiac,1
INLYTA,hemorrhage,hemorrhage cardiac,1
INLYTA,hemorrhage,events venous thromboembolic,0
INLYTA,hemorrhage,cardiac failure gastrointestinal perforation and fistula formation thyroid dysfunction wound,0
INLYTA,gastrointestinal perforation,,0
INLYTA,gastrointestinal perforation,events venous,0
INLYTA,gastrointestinal perforation,events hemorrhage cardiac gastrointestinal,1
INLYTA,gastrointestinal perforation,events hemorrhage,0
INLYTA,fistula formation,formation thyroid,1
INLYTA,fistula formation,,0
INLYTA,fistula formation,wound healing,0
INLYTA,fistula formation,h,0
INLYTA,fistula formation,hemorrhage cardiac failure,0
INLYTA,fistula formation,failure gastrointestinal perforation and,0
INLYTA,fistula formation,fistula formation thyroid,1
INLYTA,fistula formation,of liver,0
INLYTA,thyroid dysfunction,perforation and fistula thyroid,1
INLYTA,thyroid dysfunction,perforation and fistula thyroid dysfunction wound,1
INLYTA,thyroid dysfunction,fistula thyroid dysfunction wound,1
INLYTA,thyroid dysfunction,gastrointestinal perforation and fistula thyroid,1
INLYTA,thyroid dysfunction,dysfunction wound,1
INLYTA,thyroid dysfunction,dysfunction wound,1
INLYTA,thyroid dysfunction,and fistula thyroid,1
INLYTA,thyroid dysfunction,gastrointestinal perforation and fistula thyroid dysfunction wound,1
INLYTA,wound healing complications,fetal,0
INLYTA,wound healing complications,wound,1
INLYTA,wound healing complications,wound healing complications RPLS,1
INLYTA,wound healing complications,enzymes hepatic impairment and fetal development,0
INLYTA,wound healing complications,cardiac failure gastrointestinal perforation and fistula,0
INLYTA,wound healing complications,fetal development,0
INLYTA,wound healing complications,fistula formation thyroid wound healing complications RPLS,1
INLYTA,wound healing complications,and fistula formation thyroid wound healing complications RPLS,1
INLYTA,RPLS,RPLS proteinuria,1
INLYTA,RPLS,RPLS proteinuria,1
INLYTA,RPLS,hepatic impairment and fetal,0
INLYTA,RPLS,RPLS proteinuria,1
INLYTA,RPLS,thyroid dysfunction wound healing,0
INLYTA,RPLS,complications,0
INLYTA,RPLS,and fetal,0
INLYTA,RPLS,RPLS proteinuria,1
INLYTA,RPLS,RPLS proteinuria,1
INLYTA,RPLS,RPLS proteinuria,1
INLYTA,proteinuria,proteinuria elevation,1
INLYTA,proteinuria,proteinuria elevation,1
INLYTA,proteinuria,proteinuria elevation,1
INLYTA,proteinuria,healing complications proteinuria elevation,1
INLYTA,elevation of liver enzymes,complications RPLS elevation of liver enzymes hepatic,1
INLYTA,elevation of liver enzymes,,0
INLYTA,elevation of liver enzymes,wound healing complications,0
INLYTA,elevation of liver enzymes,,0
INLYTA,hepatic impairment,,0
INLYTA,hepatic impairment,proteinuria elevation of liver hepatic,1
INLYTA,diarrhea,common adverse reactions,0
INLYTA,diarrhea,and fetal development,0
INLYTA,diarrhea,diarrhea hypertension,1
INLYTA,hypertension,and fetal,0
INLYTA,hypertension,hypertension fatigue,1
INLYTA,hypertension,hypertension fatigue,1
INLYTA,hypertension,hypertension fatigue,1
INLYTA,hypertension,adverse reactions are hypertension fatigue,1
INLYTA,fatigue,diarrhea hypertension,0
INLYTA,fatigue,,0
INLYTA,fatigue,fatigue decreased,1
INLYTA,decreased appetite,hypertension decreased appetite nausea,1
INLYTA,decreased appetite,syndrome,0
INLYTA,decreased appetite,decreased appetite nausea,1
INLYTA,decreased appetite,The most common adverse reactions are,0
INLYTA,decreased appetite,,0
INLYTA,decreased appetite,decreased,1
INLYTA,decreased appetite,decreased,0
INLYTA,decreased appetite,decreased appetite nausea,1
INLYTA,decreased appetite,,0
INLYTA,nausea,erythrodysesthesia handfoot syndrome weight,0
INLYTA,nausea,hypertension fatigue decreased appetite,0
INLYTA,nausea,nausea dysphonia,1
INLYTA,nausea,dysphonia palmarplantar erythrodysesthesia handfoot syndrome weight decreased,0
INLYTA,nausea,common,0
INLYTA,dysphonia,dysphonia palmarplantar,1
INLYTA,dysphonia,dysphonia palmarplantar,1
INLYTA,vomiting,vomiting asthenia,1
INLYTA,vomiting,syndrome weight,0
INLYTA,vomiting,and constipation To report SUSPECTED,0
INLYTA,vomiting,vomiting asthenia,1
INLYTA,vomiting,vomiting asthenia,1
INLYTA,vomiting,vomiting asthenia,1
INLYTA,constipation,constipation To,1
INLYTA,constipation,Pfizer Inc at or,0
INLYTA,diarrhea,decreased appetite nausea,0
INLYTA,diarrhea,with,0
INLYTA,diarrhea,following treatment with INLYTA diarrhea hypertension,1
INLYTA,diarrhea,,0
INLYTA,diarrhea,diarrhea hypertension,1
INLYTA,diarrhea,diarrhea hypertension,1
INLYTA,hypertension,hypertension fatigue,1
INLYTA,hypertension,INLYTA were hypertension fatigue,1
INLYTA,fatigue,fatigue decreased,1
INLYTA,fatigue,INLYTA were diarrhea fatigue decreased,1
INLYTA,fatigue,fatigue decreased,1
INLYTA,fatigue,fatigue decreased,1
INLYTA,fatigue,hypertension,0
INLYTA,fatigue,fatigue decreased,1
INLYTA,fatigue,fatigue decreased,1
INLYTA,fatigue,erythrodysesthesia handfoot,0
INLYTA,fatigue,were diarrhea fatigue decreased,1
INLYTA,fatigue,fatigue decreased,1
INLYTA,decreased appetite,were diarrhea hypertension fatigue,0
INLYTA,decreased appetite,hypertension,0
INLYTA,decreased appetite,INLYTA were diarrhea,0
INLYTA,nausea,INLYTA were,0
INLYTA,nausea,nausea dysphonia,1
INLYTA,nausea,were diarrhea hypertension fatigue decreased,0
INLYTA,dysphonia,fatigue decreased appetite dysphonia palmarplantar,1
INLYTA,dysphonia,,0
INLYTA,dysphonia,dysphonia palmarplantar,1
INLYTA,dysphonia,dysphonia palmarplantar,1
INLYTA,dysphonia,syndrome weight decreased vomiting,0
INLYTA,weight decreased,asthenia,0
INLYTA,weight decreased,,0
INLYTA,weight decreased,and constipation Table presents adverse reactions,0
INLYTA,weight decreased,erythrodysesthesia handfoot weight,1
INLYTA,weight decreased,weight decreased vomiting,1
INLYTA,weight decreased,palmarplantar erythrodysesthesia handfoot weight,1
INLYTA,vomiting,vomiting asthenia,1
INLYTA,asthenia,asthenia and,1
INLYTA,asthenia,adverse reactions reported in patients who,0
INLYTA,asthenia,who received INLYT,0
INLYTA,constipation,received INLYTA or,0
INLYTA,constipation,and,0
INLYTA,Diarrhea,,0
INLYTA,Diarrhea,,0
INLYTA,Diarrhea,Diarrhea,1
INLYTA,Hypertension,,0
INLYTA,Hypertension,,0
INLYTA,Hypertension,,0
INLYTA,Hypertension,Hypertension,1
INLYTA,Fatigue,Fatigue,1
INLYTA,Fatigue,Fatigue,1
INLYTA,Fatigue,,0
INLYTA,Fatigue,Fatigue,1
INLYTA,Fatigue,,0
INLYTA,Fatigue,Fatigue,1
INLYTA,Fatigue,,0
INLYTA,Fatigue,Fatigue,1
INLYTA,Fatigue,,0
INLYTA,Nausea,etite Nausea,1
INLYTA,Nausea,Nausea,1
INLYTA,Dysphonia,,0
INLYTA,Dysphonia,Dysphonia,1
INLYTA,Palmar-plantar erythrodysesthesia syndrome,Palmar-plantar erythrodysesthesia syndrome Weight,1
INLYTA,Palmar-plantar erythrodysesthesia syndrome,Palmar-plantar erythrodysesthesia,1
INLYTA,Palmar-plantar erythrodysesthesia syndrome,,0
INLYTA,Palmar-plantar erythrodysesthesia syndrome,decreased,0
INLYTA,Palmar-plantar erythrodysesthesia syndrome,,0
INLYTA,Palmar-plantar erythrodysesthesia syndrome,syndrome,1
INLYTA,Palmar-plantar erythrodysesthesia syndrome,,0
INLYTA,Palmar-plantar erythrodysesthesia syndrome,Weight decreased,0
INLYTA,Palmar-plantar erythrodysesthesia syndrome,,0
INLYTA,Weight decreased,decreased Vom,1
INLYTA,Vomiting,sed,0
INLYTA,Vomiting,Vomiting,1
INLYTA,Vomiting,sed,0
INLYTA,Vomiting,Vomiting,1
INLYTA,Vomiting,sed,0
INLYTA,Vomiting,,0
INLYTA,Vomiting,,0
INLYTA,Asthenia,,0
INLYTA,Asthenia,,0
INLYTA,Asthenia,Asthenia,1
INLYTA,Asthenia,Asthenia,1
INLYTA,Asthenia,Asthenia,1
INLYTA,Asthenia,Asthenia,1
INLYTA,Constipation,Constipation,1
INLYTA,Constipation,,0
INLYTA,Constipation,,0
INLYTA,Constipation,Constipation,1
INLYTA,Constipation,Constipation,1
INLYTA,Constipation,,0
INLYTA,Constipation,Constipation,1
INLYTA,Hypothyroidism,Hypothyroidism C,1
INLYTA,Hypothyroidism,C,0
INLYTA,Hypothyroidism,,0
INLYTA,Hypothyroidism,C,0
INLYTA,Hypothyroidism,Hypothyroidism C,1
INLYTA,Cough,m Cough,1
INLYTA,Cough,m Cough,1
INLYTA,Cough,m Cough,1
INLYTA,Cough,Cough,1
INLYTA,Cough,Cough,1
INLYTA,Cough,m,0
INLYTA,Cough,,0
INLYTA,Cough,Cough,1
INLYTA,Mucosal inflammation,,0
INLYTA,Mucosal inflammation,Mucosal,1
INLYTA,Mucosal inflammation,Mucosal inflammation Arthral,1
INLYTA,Mucosal inflammation,,0
INLYTA,Arthralgia,,0
INLYTA,Arthralgia,,0
INLYTA,Arthralgia,Arthralgia,1
INLYTA,Arthralgia,,0
INLYTA,Stomatitis,Stomatitis,1
INLYTA,Stomatitis,,0
INLYTA,Dyspnea,Dyspnea,1
INLYTA,Dyspnea,Dyspnea,1
INLYTA,Dyspnea,,0
INLYTA,Abdominal pain,,0
INLYTA,Abdominal pain,Abdominal pain H,1
INLYTA,Abdominal pain,Abdominal pain H,1
INLYTA,Abdominal pain,Abdominal pain H,1
INLYTA,Abdominal pain,Abdominal pain H,1
INLYTA,Abdominal pain,Abdominal pain H,1
INLYTA,Abdominal pain,,0
INLYTA,Headache,,0
INLYTA,Headache,,0
INLYTA,Pain in extremity,,0
INLYTA,Pain in extremity,,0
INLYTA,Pain in extremity,Pain in,1
INLYTA,Pain in extremity,,0
INLYTA,Pain in extremity,extremity Rash,1
INLYTA,Pain in extremity,Rash,0
INLYTA,Pain in extremity,,0
INLYTA,Pain in extremity,,0
INLYTA,Proteinuria,Proteinuria,1
INLYTA,Proteinuria,Proteinuria,1
INLYTA,Dysgeusia,Dysgeusia,1
INLYTA,Dyspepsia,,0
INLYTA,Pruritus,,0
INLYTA,Pruritus,,0
INLYTA,Alopecia,,0
INLYTA,Alopecia,Alopecia,1
INLYTA,Erythema,,0
INLYTA,Erythema,,0
INLYTA,Erythema,,0
INLYTA,Erythema,,0
INLYTA,Erythema,,0
INLYTA,Erythema,Erythema,1
INLYTA,Erythema,,0
INLYTA,Erythema,Erythema,1
INLYTA,Erythema,,0
INLYTA,Erythema,Erythema,1
INLYTA,myalgia,abdominal myalgia,1
INLYTA,myalgia,upper abdominal myalgia,1
INLYTA,myalgia,myalgia,1
INLYTA,myalgia,upper abdominal myalgia,1
INLYTA,myalgia,upper,0
INLYTA,myalgia,dehydration epistaxis anemia hemorrhoids,0
INLYTA,myalgia,,0
INLYTA,dehydration,pain dehydration,1
INLYTA,dehydration,abdominal pain dehydration,1
INLYTA,dehydration,dehydration,1
INLYTA,dehydration,treated with INLYTA included dizziness upper abdominal pain,0
INLYTA,dehydration,treated with INLYTA included dizziness upper abdominal pain,0
INLYTA,anemia,,0
INLYTA,anemia,anemia,1
INLYTA,anemia,dehydration anemia,1
INLYTA,anemia,upper,0
INLYTA,hemorrhoids,hemorrhoids,1
INLYTA,hemorrhoids,lipase increased glossodynia pulmonary,0
INLYTA,hemorrhoids,lipase increased glossodynia,0
INLYTA,hemorrhoids,,0
INLYTA,hemorrhoids,hemorrhoids,1
INLYTA,hemorrhoids,tinnitus,0
INLYTA,hemorrhoids,epistaxis hemorrhoids,1
INLYTA,hemorrhoids,epistaxis hemorrhoids,1
INLYTA,hemorrhoids,hemorrhoids,1
INLYTA,hemorrhoids,hemorrhoids,1
INLYTA,hematuria,epistaxis,0
INLYTA,hematuria,hematuria,1
INLYTA,hematuria,pain myalgia dehydration epistaxis,0
INLYTA,hematuria,hematuria,1
INLYTA,hematuria,hematuria,1
INLYTA,hematuria,glossodynia pulmonary,0
INLYTA,hematuria,hematuria,1
INLYTA,tinnitus,tinnitus,1
INLYTA,tinnitus,tinnitus,1
INLYTA,tinnitus,tinnitus,1
INLYTA,tinnitus,,0
INLYTA,tinnitus,hematuria,0
INLYTA,tinnitus,tinnitus,1
INLYTA,tinnitus,glossodynia pulmonary embolism rectal hemorrhage,0
INLYTA,lipase increased,lipase increased,1
INLYTA,lipase increased,anemia hemorrhoids hematuria lipase increased,1
INLYTA,lipase increased,hematuria lipase,1
INLYTA,lipase increased,hemoptysis,0
INLYTA,lipase increased,lipase increased,1
INLYTA,lipase increased,anemia hemorrhoids hematuria tinnitus,0
INLYTA,lipase increased,anemia hemorrhoids hematuria lipase increased,1
INLYTA,glossodynia,hematuria tinnitus lipase glossodynia,1
INLYTA,glossodynia,tinnitus lipase glossodynia,1
INLYTA,glossodynia,tinnitus lipase glossodynia,1
INLYTA,glossodynia,glossodynia,1
INLYTA,glossodynia,lipase glossodynia,1
INLYTA,glossodynia,tinnitus,0
INLYTA,glossodynia,hematuria tinnitus lipase glossodynia,1
INLYTA,glossodynia,,0
INLYTA,glossodynia,glossodynia,1
INLYTA,glossodynia,lipase increased,0
INLYTA,pulmonary embolism,embolism,1
INLYTA,pulmonary embolism,tinnitus lipase increased pulmonary embolism,1
INLYTA,pulmonary embolism,glossodynia,0
INLYTA,pulmonary embolism,increased pulmonary embolism,1
INLYTA,pulmonary embolism,lipase increased,0
INLYTA,rectal hemorrhage,lipase increased glossodynia pulmonary rectal,1
INLYTA,rectal hemorrhage,occlusionthrombosis,0
INLYTA,rectal hemorrhage,lipase increased glossodynia pulmonary rectal hemorrhage,1
INLYTA,rectal hemorrhage,rectal hemorrhage,1
INLYTA,rectal hemorrhage,polycythe,0
INLYTA,hemoptysis,hemoptysis,1
INLYTA,hemoptysis,polycythemia,0
INLYTA,hemoptysis,hemoptysis,1
INLYTA,hemoptysis,embolism rectal hemoptysis,1
INLYTA,hemoptysis,hemoptysis,1
INLYTA,hemoptysis,hemoptysis,1
INLYTA,hemoptysis,hemoptysis,1
INLYTA,hemoptysis,hemoptysis,1
INLYTA,deep vein thrombosis,embolism rectal hemorrhage deep,1
INLYTA,deep vein thrombosis,hemorrhage deep vein thrombosis,1
INLYTA,polycythemia,polycythemia,1
INLYTA,polycythemia,retinalvein polycythemia,1
INLYTA,polycythemia,deep vein thrombosis retinalvein occlusionthrombosis,0
INLYTA,polycythemia,deep vein thrombosis retinalvein polycythemia,1
INLYTA,polycythemia,occlusionthrombosis,0
INLYTA,transient ischemic attack,,0
INLYTA,Hemoglobin decreased,,0
INLYTA,Hemoglobin decreased,,0
INLYTA,Hemoglobin decreased,,0
INLYTA,Hemoglobin decreased,Lym,0
INLYTA,Hemoglobin decreased,,0
INLYTA,Hemoglobin decreased,Hemoglobin decreased Lym,1
INLYTA,Hemoglobin decreased,Hemoglobin,1
INLYTA,Lymphocytes (absolute) decreased,sed Lymphocytes (absolute),1
INLYTA,Lymphocytes (absolute) decreased,sed Lymphocytes (absolute) decreased Platelets,1
INLYTA,Lymphocytes (absolute) decreased,,0
INLYTA,Lymphocytes (absolute) decreased,sed,0
INLYTA,Lymphocytes (absolute) decreased,,0
INLYTA,Lymphocytes (absolute) decreased,,0
INLYTA,Platelets decreased,Platelets decreased Wh,1
INLYTA,Platelets decreased,Platelets decreased Wh,1
INLYTA,Platelets decreased,,0
INLYTA,Platelets decreased,Platelets decreased Wh,1
INLYTA,Platelets decreased,Platelets decreased Wh,1
INLYTA,Creatinine increased,increased Bic,1
INLYTA,Creatinine increased,,0
INLYTA,Creatinine increased,,0
INLYTA,Creatinine increased,Creatinine,1
INLYTA,Creatinine increased,Creatinine increased Bic,1
INLYTA,Bicarbonate decreased,sed,0
INLYTA,Hypocalcemia,Hypocalcemia,1
INLYTA,Hypocalcemia,ased Hypocalcemia,1
INLYTA,Hypocalcemia,,0
INLYTA,Hypocalcemia,,0
INLYTA,Hypocalcemia,ased Hypocalcemia,1
INLYTA,Hypocalcemia,ased,0
INLYTA,Hypocalcemia,Hypocalcemia,1
INLYTA,ALP increased,,0
INLYTA,ALP increased,ALP,1
INLYTA,ALP increased,,0
INLYTA,ALP increased,ALP increased,1
INLYTA,ALP increased,,0
INLYTA,ALP increased,,0
INLYTA,ALP increased,,0
INLYTA,ALP increased,ALP increased,1
INLYTA,Hyperglycemia,,0
INLYTA,Hyperglycemia,,0
INLYTA,Lipase increased,Lipase increased,1
INLYTA,Lipase increased,Lipase increased,1
INLYTA,Lipase increased,Lipase increased,1
INLYTA,Lipase increased,increased,1
INLYTA,Lipase increased,Lipase,1
INLYTA,Lipase increased,,0
INLYTA,Lipase increased,,0
INLYTA,Lipase increased,Lipase increased,1
INLYTA,Amylase increased,,0
INLYTA,Amylase increased,,0
INLYTA,Amylase increased,Amylase increased,1
INLYTA,Amylase increased,,0
INLYTA,ALT increased,ALT,1
INLYTA,AST increased,,0
INLYTA,AST increased,,0
INLYTA,AST increased,,0
INLYTA,AST increased,,0
INLYTA,AST increased,AST,1
INLYTA,AST increased,AST,1
INLYTA,Hypernatremia,,0
INLYTA,Hypernatremia,Hypernatremia,1
INLYTA,Hypernatremia,,0
INLYTA,Hypernatremia,,0
INLYTA,Hypernatremia,Hypernatremia,1
INLYTA,Hypernatremia,Hypernatremia,1
INLYTA,Hypoalbuminemia,,0
INLYTA,Hypoalbuminemia,Hypoalbuminemia,1
INLYTA,Hypoalbuminemia,Hypoalbuminemia,1
INLYTA,Hypoalbuminemia,Hypoalbuminemia,1
INLYTA,Hypoalbuminemia,Hypoalbuminemia,1
INLYTA,Hypoalbuminemia,,0
INLYTA,Hypoalbuminemia,,0
INLYTA,Hypoalbuminemia,Hypoalbuminemia,1
INLYTA,Hypoalbuminemia,,0
INLYTA,Hypoalbuminemia,,0
INLYTA,Hyperkalemia,,0
INLYTA,Hyperkalemia,Hyperkalemia,1
INLYTA,Hyperkalemia,,0
INLYTA,Hyperkalemia,Hyperkalemia,1
INLYTA,Hyperkalemia,Hyperkalemia,1
INLYTA,Hyperkalemia,,0
INLYTA,Hyperkalemia,,0
INLYTA,Hyperkalemia,,0
INLYTA,Hyperkalemia,Hyperkalemia,1
INLYTA,Hyperkalemia,Hyperkalemia,1
INLYTA,Hypoglycemia,,0
INLYTA,Hyponatremia,Hyponatremia,1
INLYTA,Hyponatremia,,0
INLYTA,Hyponatremia,Hyponatremia,1
INLYTA,Hyponatremia,,0
INLYTA,Hyponatremia,,0
INLYTA,Hyponatremia,Hyponatremia,1
INLYTA,Hyponatremia,,0
INLYTA,Hypophosphatemia,Hypophosphatemia,1
INLYTA,Hypophosphatemia,Hypophosphatemia,1
INLYTA,Hypophosphatemia,Hypophosphatemia,1
INLYTA,Hypophosphatemia,Hypophosphatemia,1
INLYTA,Hypophosphatemia,,0
INLYTA,Hypophosphatemia,,0
INLYTA,Hypophosphatemia,,0
INLYTA,hemoglobin increased,increased,1
INLYTA,hemoglobin increased,limit of normal for INLYTA versus for,0
INLYTA,hemoglobin increased,sorafenib and hypercalcemia for,0
INLYTA,hemoglobin increased,treated with INLYTA hemoglobin increased,1
INLYTA,hemoglobin increased,INLYTA hemoglobin,1
INLYTA,hypercalcemia,,0
INLYTA,hypercalcemia,,0
INLYTA,hypercalcemia,limit of,0
INLYTA,hypercalcemia,hypercalcemia,1
INLYTA,hypercalcemia,sorafenib hypercalcemia,1
INLYTA,hypercalcemia,sorafenib,0
INLYTA,hypercalcemia,,0
INLYTA,hypercalcemia,sorafenib hypercalcemia,1
INLYTA,hypertensive crisis,,0
INLYTA,hypertensive crisis,,0
INLYTA,hypertensive crisis,dely varying condit ions adverse reaction rates observed,1
INLYTA,hypertensive crisis,dely varying,1
INLYTA,hypertensive crisis,,0
INLYTA,hypertensive crisis,,0
INLYTA,hypertensive crisis,dely varying condit ions,1
INLYTA,hypertensive crisis,,0
INLYTA,hypertensive crisis,dely varying,1
INLYTA,hypertensive crisis,,0
INLYTA,venous thrombotic events,Reactions,0
INLYTA,venous thrombotic events,been evaluated 5 patients,1
INLYTA,venous thrombotic events,clinical practice The,0
INLYTA,venous thrombotic events,has been evaluated 5 patients,1
INLYTA,fatal,included atien ts with advanced,1
INLYTA,fatal,evaluated in patients,0
INLYTA,Hemorrhagic events,Reactions reflect exposure o INLYTA in 359 pa tients with advanced,1
INLYTA,Hemorrhagic events,exposure o INLYTA in 359 pa tients with advanced,1
INLYTA,fatal,advan ced RCC who,1
INLYTA,fatal,INLYTA in patients,0
INLYTA,fatal,patients advan ced RCC who,1
INLYTA,fatal,versus,0
INLYTA,fatal,exposure,0
INLYTA,fatal,advan ced RCC who,1
INLYTA,fatal,reflect exposure to,0
INLYTA,fatal,advan ced RCC who,1
INLYTA,fatal,,0
INLYTA,fatal,RCC who participated in,0
INLYTA,Cardiac failure,detail in er,1
INLYTA,Cardiac failure,,0
INLYTA,fatal,detail in other sections of,0
INLYTA,fatal,ecaut ions hypertension arterial,1
INLYTA,fatal,taken are discussed in greater detail in other sections of the label,0
INLYTA,fatal,ions hypertension arterial thromboembolic events venous,0
INLYTA,fatal,and,0
INLYTA,Gastrointestinal perforation,"cardiac failure, gastrointestinal perforation and",1
INLYTA,Gastrointestinal perforation,"hemorrhage, cardiac failure, gastrointestinal perforation and",1
INLYTA,Gastrointestinal perforation,"venous thromboembolic hemorrhage,",1
INLYTA,Gastrointestinal perforation,hypertension arterial thromboembolic events venous,0
INLYTA,Gastrointestinal perforation,"venous thromboembolic hemorrhage, cardiac",1
INLYTA,Gastrointestinal perforation,"venous thromboembolic hemorrhage, cardiac",1
INLYTA,Gastrointestinal perforation,dysfunction wound healing complication,0
INLYTA,Gastrointestinal perforation,"thromboembolic events venous thromboembolic hemorrhage, cardiac",1
INLYTA,death,,0
INLYTA,Hypothyroidism,and fetal development EXCERPT,0
INLYTA,Hypothyroidism,"r enzymes, hep atic impairment and",1
INLYTA,Hypothyroidism,"r enzymes, hep atic impairment and",1
INLYTA,Hypothyroidism,,0
INLYTA,RPLS,To report SUSPECTED ADVERSE REACTIONS contact,0
INLYTA,RPLS,ADVERSE REACTIONS contact Pfizer Inc at or FDA,0
INLYTA,RPLS,"asthenia and .1)
 To report SUSPECTED",1
INLYTA,RPLS,,0
INLYTA,RPLS,constipation,0
INLYTA,RPLS,syndrome weight decreased vomiting asthenia and,0
INLYTA,Liver enzyme elevation,to for patients who,0
INLYTA,Liver enzyme elevation,months range 20.1) for patients who received sorafenib Dose,1
INLYTA,fetal harm,receiving sorafenib The most 0%) advers e reactions observed,1
INLYTA,fetal harm,0%) advers e reactions observed,1
INLYTA,fetal harm,receiving sorafenib The most,0
INLYTA,fetal harm,advers e reactions observed,1
INLYTA,hypertension,ctions Occur ring in of,1
INLYTA,hypertension,,0
INLYTA,hypertension,received INLYTA or,0
INLYTA,hypertension,or sorafenib Table Adverse ctions,1
INLYTA,hypertension,ctions,1
INLYTA,hypertension,Reaction,0
INLYTA,hypertension,or,0
INLYTA,hypertension,Sorafenib Adverse,0
INLYTA,hypertension,or Sorafenib Adverse Reaction         Sora fenib N N,1
INLYTA,hypertension,        Sora fenib N N,1
INLYTA,hypertension,Who Received,0
INLYTA,hypertension,,0
INLYTA,hypertension,        Sora fenib N N,1
INLYTA,hypertension,        Sora fenib N N,1
INLYTA,Hypertensive crisis,                 Gr ade All Grades,1
INLYTA,Hypertensive crisis,,0
INLYTA,Hypertensive crisis,Grades,0
INLYTA,Hypertensive crisis,Grades Grade,0
INLYTA,hypertension,Grade      %       Diarrhea,1
INLYTA,hypertension,     %       Diarrhea,1
INLYTA,hypertension,,0
INLYTA,hypertension,     %       Diarrhea,1
INLYTA,systolic blood pressure >150 mmHg,Hypertension,0
INLYTA,systolic blood pressure >150 mmHg,,0
INLYTA,systolic blood pressure >150 mmHg,"  
  
 Diarrhea                   Hypertension",1
INLYTA,systolic blood pressure >150 mmHg,"  
  
 Diarrhea                   Hypertension",1
INLYTA,systolic blood pressure >150 mmHg,"  
  
 Diarrhea                   Hypertension",1
INLYTA,systolic blood pressure >150 mmHg,"  
  
 Diarrhea                   Hypertension",1
INLYTA,systolic blood pressure >150 mmHg,Hypertension,0
INLYTA,systolic blood pressure >150 mmHg,,0
INLYTA,systolic blood pressure >150 mmHg,"  
  
 Diarrhea                   Hypertension",1
INLYTA,diastolic blood pressure >100 mmHg,,0
INLYTA,diastolic blood pressure >100 mmHg,                  55               Hypertension,1
INLYTA,diastolic blood pressure >100 mmHg,Diarrhea                   55               Hypertension,1
INLYTA,diastolic blood pressure >100 mmHg,                  55               Hypertension,1
INLYTA,diastolic blood pressure >100 mmHg,Hypertension,0
INLYTA,blood pressure increases,                         Fatigue,1
INLYTA,blood pressure increases,Hypertension,0
INLYTA,blood pressure increases,Hypertension                          Fatigue,1
INLYTA,blood pressure increases,Hypertension                          Fatigue,1
INLYTA,blood pressure increases,                         Fatigue,1
INLYTA,blood pressure increases,,0
INLYTA,blood pressure increases,,0
INLYTA,blood pressure increases,Hypertension,0
INLYTA,blood pressure increases,                         Fatigue,1
INLYTA,hypertension,Fatigue   5          Decreased appetite,1
INLYTA,hypertension,,0
INLYTA,arterial thromboembolic events,Constipation 0,1
INLYTA,arterial thromboembolic events,Constipation,0
INLYTA,arterial thromboembolic events,0 1 Hypothyroidism,1
INLYTA,arterial thromboembolic events,Hypothyroidism,0
INLYTA,arterial thromboembolic events,Constipation,0
INLYTA,arterial thromboembolic events,,0
INLYTA,arterial thromboembolic events,1 Hypothyroidism,1
INLYTA,arterial thromboembolic events,,0
INLYTA,arterial thromboembolic events,"Hypothyroidism   0          
 Cough           Mu",1
INLYTA,Fatal,Mu,0
INLYTA,Fatal,,0
INLYTA,arterial thromboembolic events,Arthralgia,0
INLYTA,arterial thromboembolic events,Arthralgia,0
INLYTA,arterial thromboembolic events,Arthralgia 1,1
INLYTA,transient ischemic attack,Stomatitis                           Dyspnea,1
INLYTA,transient ischemic attack,                          Dyspnea,1
INLYTA,transient ischemic attack,Dyspnea,0
INLYTA,transient ischemic attack,                          Dyspnea,1
INLYTA,transient ischemic attack,,0
INLYTA,transient ischemic attack,,0
INLYTA,transient ischemic attack,Stomatitis                           Dyspnea,1
INLYTA,transient ischemic attack,,0
INLYTA,cerebrovascular accident,Stomatitis     15                1  Dyspnea,1
INLYTA,cerebrovascular accident,Stomatitis,0
INLYTA,cerebrovascular accident,15 1 Dyspnea,1
INLYTA,cerebrovascular accident,,0
INLYTA,cerebrovascular accident,Stomatitis     15                1  Dyspnea,1
INLYTA,cerebrovascular accident,,0
INLYTA,cerebrovascular accident,Dyspnea,0
INLYTA,cerebrovascular accident,,0
INLYTA,cerebrovascular accident,1 Dyspnea,1
INLYTA,retinal artery occlusion,Stomatitis <1,1
INLYTA,retinal artery occlusion,Stomatitis <1,1
INLYTA,retinal artery occlusion,Stomatitis,0
INLYTA,retinal artery occlusion,Dyspnea,1
INLYTA,retinal artery occlusion,Stomatitis <1,1
INLYTA,deaths,       Abdominal,1
INLYTA,deaths,Dyspnea,0
INLYTA,deaths,,0
INLYTA,deaths,Abdominal,0
INLYTA,deaths,       Abdominal,1
INLYTA,deaths,       Abdominal,1
INLYTA,deaths,Dyspnea,0
INLYTA,deaths,,0
INLYTA,deaths,Dyspnea       ,1
INLYTA,deaths,pain,0
INLYTA,cerebrovascular accident,Dyspnea 12,1
INLYTA,cerebrovascular accident,pain,0
INLYTA,cerebrovascular accident,Dyspnea     12                3  Abdominal,1
INLYTA,cerebrovascular accident,Abdominal pain,0
INLYTA,venous thromboembolic events,32 4 Proteinuria,1
INLYTA,venous thromboembolic events,Rash 32,1
INLYTA,venous thromboembolic events,,0
INLYTA,venous thromboembolic events,Proteinuria,0
INLYTA,venous thromboembolic events,Rash,0
INLYTA,venous thromboembolic events,teinuria,0
INLYTA,venous thromboembolic events,s,0
INLYTA,venous thromboembolic events,,0
INLYTA,venous thromboembolic events,"teinuria         
 Dysgeusia          Dry s",1
INLYTA,venous thromboembolic events,,0
INLYTA,venous thromboembolic events,teinuria,0
INLYTA,venous thromboembolic events,Dry,0
INLYTA,venous thromboembolic events,s,0
INLYTA,venous thromboembolic events,Dry s,0
INLYTA,venous thromboembolic events,teinuria,0
INLYTA,pulmonary embolism,                0 ,1
INLYTA,pulmonary embolism,Dysgeusia,0
INLYTA,pulmonary embolism,Dysgeusia,0
INLYTA,pulmonary embolism,                0 ,1
INLYTA,pulmonary embolism,                0 ,1
INLYTA,pulmonary embolism,                0  Dry,1
INLYTA,pulmonary embolism,                0  Dry skin,1
INLYTA,pulmonary embolism,skin,0
INLYTA,deep vein thrombosis,eusia Dry,1
INLYTA,retinal vein occlusion,,0
INLYTA,retinal vein occlusion,Dry                        Dyspepsia,1
INLYTA,retinal vein occlusion,                       Dyspepsia,1
INLYTA,retinal vein thrombosis,,0
INLYTA,retinal vein thrombosis,Dry         10              Dyspepsia,1
INLYTA,Fatal,,0
INLYTA,Fatal,,0
INLYTA,Fatal,,0
INLYTA,Fatal,,0
INLYTA,Fatal," 
 Dy spepsia",1
INLYTA,Fatal," 
 Dy spepsia",1
INLYTA,Fatal," 
 Dy spepsia",1
INLYTA,Fatal,spepsia,0
INLYTA,Fatal," 
 Dy spepsia",1
INLYTA,Fatal,,0
INLYTA,pulmonary embolism,Dys pepsia             Pruritus,1
INLYTA,pulmonary embolism,Dys,0
INLYTA,pulmonary embolism,Dys,0
INLYTA,pulmonary embolism,Dys pepsia             Pruritus,1
INLYTA,venous thromboembolic events,Pruritus         7                0   Alopecia,1
INLYTA,venous thromboembolic events,Pruritus         7                0   Alopecia,1
INLYTA,venous thromboembolic events,,0
INLYTA,venous thromboembolic events,,0
INLYTA,venous thromboembolic events,Pruritus 7,1
INLYTA,venous thromboembolic events,Pruritus,0
INLYTA,venous thromboembolic events,,0
INLYTA,venous thromboembolic events,Pruritus,0
INLYTA,venous thromboembolic events,Alopecia,0
INLYTA,deaths,,0
INLYTA,deaths,Alope cia   ,1
INLYTA,deaths,cia   ,1
INLYTA,deaths,Alope cia   ,1
INLYTA,deaths,,0
INLYTA,deaths,cia   ,1
INLYTA,pulmonary embolism,Alopecia                    Erythema,1
INLYTA,pulmonary embolism,Alopecia,0
INLYTA,pulmonary embolism,Alopecia                    Erythema,1
INLYTA,pulmonary embolism,                   Erythema,1
INLYTA,pulmonary embolism,Alopecia,0
INLYTA,pulmonary embolism,Alopecia,0
INLYTA,pulmonary embolism,Alopecia,0
INLYTA,pulmonary embolism,,0
INLYTA,pulmonary embolism,                   Erythema,1
INLYTA,pulmonary embolism,Erythema,0
INLYTA,hemorrhagic events,"anemia hemorrhoids hematuria %),",1
INLYTA,cerebral hemorrhage,,0
INLYTA,hematuria,"rectal hemorrhage (2%),",1
INLYTA,hematuria,pulmonary embolism rectal hemorrhage hemoptysis,0
INLYTA,hematuria,"embolism rectal hemorrhage (2%),",1
INLYTA,hematuria,,0
INLYTA,hematuria,"rectal hemorrhage (2%), dee",1
INLYTA,hematuria,hemorrhage hemoptysis,0
INLYTA,hematuria,"embolism rectal hemorrhage (2%),",1
INLYTA,hematuria,increased glossodynia pulmonary embolism rectal hemorrhage,0
INLYTA,hematuria,,0
INLYTA,hemoptysis,throm,1
INLYTA,hemoptysis,throm,1
INLYTA,hemoptysis,occlusionthrombosis polycythemia and,0
INLYTA,hemoptysis,bosis retinalvein,0
INLYTA,hemoptysis,retinalvein occlusionthrombosis,0
INLYTA,hemoptysis,transient ischemic attack,0
INLYTA,lower gastrointestinal hemorrhage,occlusion/,1
INLYTA,lower gastrointestinal hemorrhage,rectal hemorrhage,0
INLYTA,melena,osis (,1
INLYTA,melena,osis (,1
INLYTA,melena,,0
INLYTA,melena,osis (,1
INLYTA,melena,osis (,1
INLYTA,melena,retinalvein occlusionthromb,0
INLYTA,melena,,0
INLYTA,melena,polycythemia,0
INLYTA,melena,vein thrombosis retinalvein,0
INLYTA,Fatal,ttack,1
INLYTA,Fatal,patients,0
INLYTA,Fatal,ischemic ttack,1
INLYTA,Fatal,ttack,1
INLYTA,Fatal,ttack,1
INLYTA,Fatal,transient ischemic ttack,1
INLYTA,Fatal,ttack,1
INLYTA,hemorrhage,"(1%).
 

 ",1
INLYTA,hemorrhage,"(1%).
 

 ",1
INLYTA,gastric hemorrhage,Laboratory,0
INLYTA,gastric hemorrhage,who received INLYTA or sorafenib Table,0
INLYTA,gastric hemorrhage,,0
INLYTA,gastric hemorrhage,laboratory abnormalitie,0
INLYTA,gastric hemorrhage,laboratory s reported in >=10,1
INLYTA,cardiac failure,,0
INLYTA,cardiac failure,alkaline pho,0
INLYTA,cardiac failure,ALT:,1
INLYTA,cardiac failure,ALT:,1
INLYTA,cardiac failure,pho,0
INLYTA,cardiac failure,,0
INLYTA,cardiac failure,,0
INLYTA,cardiac failure,alkaline sphatase;,1
INLYTA,cardiac failure,alkaline sphatase; ALT: ,1
INLYTA,cardiac failure,aspartate aminotransferase                ,1
INLYTA,cardiac failure,               ,1
INLYTA,cardiac failure,Lymphocytes,0
INLYTA,cardiac failure,,0
INLYTA,cardiac failure,          35   ,1
INLYTA,gastrointestinal perforation,increa,0
INLYTA,gastrointestinal perforation,istry                       ,1
INLYTA,gastrointestinal perforation,istry                       ,1
INLYTA,gastrointestinal perforation,istry                       ,1
INLYTA,gastrointestinal perforation,istry                       ,1
INLYTA,death,Bicarbonate ecrea,1
INLYTA,death,ecrea,1
INLYTA,death,ecrea,1
INLYTA,death,,0
INLYTA,death,ecrea,1
INLYTA,death,,0
INLYTA,death,,0
INLYTA,gastrointestinal perforation,<1 Hypocalcemia,1
INLYTA,gastrointestinal perforation,,0
INLYTA,gastrointestinal perforation,,0
INLYTA,gastrointestinal perforation,<1 Hypocalcemia,1
INLYTA,gastrointestinal perforation,Hypocalcemia,0
INLYTA,gastrointestinal perforation,Bicarbonate  314          44          <1 Hypocalcemia,1
INLYTA,gastrointestinal perforation,44 <1 Hypocalcemia,1
INLYTA,gastrointestinal perforation,314 44 <1 Hypocalcemia,1
INLYTA,gastrointestinal perforation,,0
INLYTA,gastrointestinal perforation,Bicarbonate 314 44,1
INLYTA,hypothyroidism,yperglycemia  ,1
INLYTA,hypothyroidism,H,0
INLYTA,hypothyroidism,,0
INLYTA,hypothyroidism,H,0
INLYTA,hypothyroidism,,0
INLYTA,hypothyroidism,H,0
INLYTA,Hyperthyroidism,d,0
INLYTA,Hyperthyroidism,,0
INLYTA,Hyperthyroidism,Lipase,1
INLYTA,Hyperthyroidism,increase d,1
INLYTA,Hyperthyroidism,,0
INLYTA,reversible posterior leukoencephalopathy syndrome,Hyponatremia,0
INLYTA,reversible posterior leukoencephalopathy syndrome,2 Hypophosphatemia,1
INLYTA,reversible posterior leukoencephalopathy syndrome,Hyponatremia,0
INLYTA,reversible posterior leukoencephalopathy syndrome,,0
INLYTA,reversible posterior leukoencephalopathy syndrome,Hyponatremia,0
INLYTA,reversible posterior leukoencephalopathy syndrome,,0
INLYTA,reversible posterior leukoencephalopathy syndrome,Hyponatremia,0
INLYTA,RPLS,,0
INLYTA,RPLS,     Sele,1
INLYTA,RPLS,     Sele,1
INLYTA,RPLS,     Sele,1
INLYTA,RPLS,Hypophosphatemia,0
INLYTA,RPLS,Hypophosphatemia,0
INLYTA,RPLS,Sele,0
INLYTA,RPLS,treated with INLYTA included hemoglobin increased above the upper limit,0
INLYTA,RPLS,f pa tients,1
INLYTA,RPLS,were,0
INLYTA,RPLS,grades that were,0
INLYTA,RPLS,bin  increased,1
INLYTA,RPLS,INLYTA versus for sorafenib and,0
INLYTA,RPLS,,0
INLYTA,RPLS,bin  increased,1
INLYTA,RPLS,bin  increased,1
INLYTA,RPLS,limit of normal for,0
INLYTA,RPLS,,0
INLYTA,headache,limit of normal for,0
INLYTA,headache,limit of normal  INLYTA  versus,1
INLYTA,headache, INLYTA  versus,1
INLYTA,headache, INLYTA  versus,1
INLYTA,seizure,sorafenib,0
INLYTA,seizure,1% for,1
INLYTA,seizure,hypercalcemia,0
INLYTA,lethargy,INLYTA included,0
INLYTA,lethargy,for,0
INLYTA,lethargy,of normal for INLYTA versus,0
INLYTA,lethargy,soraf enib,1
INLYTA,lethargy,INLYTA versus or soraf enib,1
INLYTA,lethargy,normal for INLYTA versus or,1
INLYTA,lethargy,or,1
INLYTA,lethargy,normal for,0
INLYTA,confusion,versus for ib) and,1
INLYTA,confusion,,0
INLYTA,confusion,and h ypercalcemia,1
INLYTA,confusion,ib) and h ypercalcemia,1
INLYTA,confusion,h ypercalcemia,1
INLYTA,confusion,versus for ib) and h ypercalcemia,1
INLYTA,confusion,for ib),1
INLYTA,confusion,for INLYTA versus for ib),1
INLYTA,confusion,for INLYTA versus for ib),1
INLYTA,blindness,limit of normal for,0
INLYTA,blindness,ercalcemi a,1
INLYTA,blindness,versus,0
INLYTA,blindness,normal for INLYTA versus for sorafenib and hyp,0
INLYTA,neurologic disturbances,"s 2% for sorafenib).
",1
INLYTA,neurologic disturbances,s,1
INLYTA,neurologic disturbances,,0
INLYTA,neurologic disturbances,s 2% for sorafenib).,1
INLYTA,neurologic disturbances,and hypercalcemia for INLYTA s 2% for,1
INLYTA,neurologic disturbances,for INLYTA,0
INLYTA,hypertension,,1
INLYTA,hypertension,,0
INLYTA,hypertension,,0
INLYTA,proteinuria,,0
INLYTA,proteinuria,,0
INLYTA,proteinuria,,1
INLYTA,proteinuria,,1
INLYTA,proteinuria,,0
INLYTA,proteinuria,,0
INLYTA,proteinuria,,1
INLYTA,proteinuria,,1
INLYTA,proteinuria,,0
INLYTA,proteinuria,,1
INLYTA,proteinuria,,1
INLYTA,proteinuria,,1
INLYTA,proteinuria,,1
INLYTA,proteinuria,,1
INLYTA,fetal harm,,1
INLYTA,fetal harm,,0
INLYTA,fetal harm,,1
INLYTA,fetal harm,,1
INLYTA,fetal harm,,0
INLYTA,fetal harm,,0
INLYTA,fetal harm,,1
INLYTA,fetal harm,,1
INLYTA,teratogenic,,1
INLYTA,teratogenic,,1
INLYTA,teratogenic,,0
INLYTA,teratogenic,,1
INLYTA,teratogenic,,1
INLYTA,teratogenic,,1
INLYTA,teratogenic,,1
INLYTA,teratogenic,,1
INLYTA,teratogenic,,0
INLYTA,teratogenic,,0
INLYTA,embryotoxic,,1
INLYTA,embryotoxic,,1
INLYTA,embryotoxic,,0
INLYTA,embryotoxic,,1
INLYTA,fetotoxic,,0
INLYTA,fetotoxic,,1
INLYTA,fetotoxic,,0
NORTHERA,Supine Hypertension,Hypertension,1
NORTHERA,Supine Hypertension,Supine,1
NORTHERA,Supine Hypertension,Hypertension,1
NORTHERA,Supine Hypertension,Precautions section of the Supine,1
NORTHERA,Supine Hypertension,the Supine Hypertension,1
NORTHERA,Supine Hypertension,Supine Hypertension,1
NORTHERA,Supine Hypertension,in the,0
NORTHERA,Supine Hypertension,detail in the Warnings and Precautions section,0
NORTHERA,Hyperpyrexia,Hyperpyrexia,1
NORTHERA,Hyperpyrexia,Warnings,0
NORTHERA,Hyperpyrexia,Hyperpyrexia,1
NORTHERA,Headache,congestive heart,0
NORTHERA,Headache,To report SUSPECTED,0
NORTHERA,Headache,Warnings and Precautions Headache,1
NORTHERA,Headache,,0
NORTHERA,Headache,Headache,1
NORTHERA,Headache,To report,0
NORTHERA,Headache,To report SUSPECTED,0
NORTHERA,dizziness,failure see Warnings and,0
NORTHERA,dizziness,EXCERPT,0
NORTHERA,nausea,,0
NORTHERA,nausea,EXCERPT,0
NORTHERA,nausea,heart failure see,0
NORTHERA,nausea,and Precautions EXCERPT Headache nausea,1
NORTHERA,nausea,heart failure see Warnings and,0
NORTHERA,nausea,nausea,1
NORTHERA,nausea,nausea,1
NORTHERA,nausea,nausea,1
NORTHERA,nausea,nausea,1
NORTHERA,nausea,,0
NORTHERA,fatigue,fatigue,1
NORTHERA,fatigue,and Precautions EXCERPT Headache dizziness,0
NORTHERA,fatigue,Headache dizziness nausea hypertension fatigue,1
NORTHERA,fatigue,fatigue,1
NORTHERA,fatigue,than To report SUSPECTED ADVERSE,0
NORTHERA,fatigue,nausea hypertension fatigue,1
NORTHERA,fatigue,Lundbeck at,0
NORTHERA,fatigue,,0
NORTHERA,fatigue,fatigue,1
NORTHERA,headache,placebocontrolled,0
NORTHERA,headache,headache,1
NORTHERA,headache,headache,1
NORTHERA,headache,placebocontrolled trials headache,1
NORTHERA,headache,headache,1
NORTHERA,headache,nausea hypertension The,0
NORTHERA,headache,hypertension The most common adverse,0
NORTHERA,headache,placebo group in NORTHERAtreated patients during the three placebocontrolled trials were,0
NORTHERA,headache,to discontinuation fro,0
NORTHERA,dizziness,dizziness,1
NORTHERA,dizziness,in NORTHERAtreated,0
NORTHERA,dizziness,NORTHERAtreated patients during the three placebocontrolled trials,0
NORTHERA,dizziness,the three placebocontrolled trials were headache,0
NORTHERA,dizziness,the three placebocontrolled,0
NORTHERA,dizziness,were headache,0
NORTHERA,dizziness,placebocontrolled,0
NORTHERA,dizziness,,0
NORTHERA,dizziness,patients during the,0
NORTHERA,dizziness,dizziness,1
NORTHERA,nausea,reactions leading to discontinuation from,0
NORTHERA,nausea,from,0
NORTHERA,nausea,nausea,1
NORTHERA,nausea,,0
NORTHERA,nausea,headache dizziness,0
NORTHERA,hypertension,hypertension,1
NORTHERA,hypertension,,0
NORTHERA,hypertension,were hypertension or,0
NORTHERA,hypertension,hypertension,1
NORTHERA,hypertension,were headache dizziness hypertension,1
NORTHERA,hypertension,hypertension,1
NORTHERA,hypertension,from NORTHERA were,0
NORTHERA,hypertension,hypertension,1
NORTHERA,hypertension,hypertension,1
NORTHERA,hypertension,F,0
NORTHERA,hypertension,Common,0
NORTHERA,hypertension,,0
NORTHERA,hypertension,NORTHERA hypertension,1
NORTHERA,hypertension,hypertension,1
NORTHERA,hypertension,from NORTHERA hypertension,1
NORTHERA,hypertension,hypertension,1
NORTHERA,hypertension,hypertension,1
NORTHERA,hypertension,hypertension,1
NORTHERA,increased blood pressure,Frequently in the NORTHERA Gr,0
NORTHERA,increased blood pressure,hypertension,0
NORTHERA,increased blood pressure,Frequently in,0
NORTHERA,nausea,nausea,1
NORTHERA,nausea,in the,0
NORTHERA,nausea,,0
NORTHERA,nausea,nausea,1
NORTHERA,nausea,nausea,1
NORTHERA,nausea,,0
NORTHERA,nausea,nausea,1
NORTHERA,Headache,,0
NORTHERA,Headache,NORTHERA N Headache Dizziness,1
NORTHERA,Headache,Headache Dizziness,1
NORTHERA,Headache,Headache Dizziness,1
NORTHERA,Headache,,0
NORTHERA,Headache,NORTHERA N n,0
NORTHERA,Headache,,0
NORTHERA,Headache,Headache Dizziness,1
NORTHERA,Headache,,0
NORTHERA,Dizziness,Headache,0
NORTHERA,Dizziness,Headache Dizziness Nausea,1
NORTHERA,Dizziness,Headache Dizziness Nausea,1
NORTHERA,Dizziness,Headache,0
NORTHERA,Dizziness,Dizziness Nausea,1
NORTHERA,Dizziness,Dizziness Nausea,1
NORTHERA,Dizziness,,0
NORTHERA,Nausea,Dizziness Nausea Hypertension,1
NORTHERA,Nausea,Dizziness,0
NORTHERA,Nausea,Dizziness Nausea Hypertension,1
NORTHERA,Nausea,Nausea Hypertension,1
NORTHERA,Hypertension,Nausea Hypertension Note,1
NORTHERA,Hypertension,Nausea,0
NORTHERA,Hypertension,Hypertension,1
NORTHERA,Hypertension,,0
NORTHERA,Hypertension,nnumber,0
NORTHERA,Hypertension,Nausea Hypertension Note nnumber,1
NORTHERA,Hypertension,Nausea,0
NORTHERA,Hypertension,Nausea,0
NORTHERA,falls,commonly reported adverse events falls urinary tract infections,1
NORTHERA,urinary tract infections,,0
NORTHERA,urinary tract infections,reported,0
NORTHERA,urinary tract infections,,0
NORTHERA,urinary tract infections,approximately one year The commonly reported adverse,0
NORTHERA,urinary tract infections,syncope and,0
NORTHERA,urinary tract infections,tract infections headache syncope and,1
NORTHERA,urinary tract infections,infections headache syncope and,1
NORTHERA,headache,falls urinary tract headache syncope and dizziness,1
NORTHERA,headache,The commonly reported adverse events,0
NORTHERA,syncope,,0
NORTHERA,syncope,syncope and dizziness,1
NORTHERA,syncope,and,0
NORTHERA,dizziness,dizziness,1
NORTHERA,SUPINE HYPERTENSION,NORTHERA are included in more detail in,0
NORTHERA,SUPINE HYPERTENSION, following adverse  reactions with NORTHERA,1
NORTHERA,SUPINE HYPERTENSION,l,0
NORTHERA,SUPINE HYPERTENSION,following adverse reactions,1
NORTHERA,SUPINE HYPERTENSION, following adverse  reactions with NORTHERA are included,1
NORTHERA,SUPINE HYPERTENSION,NORTHERA,1
NORTHERA,SUPINE HYPERTENSION,NORTHERA are includ,1
NORTHERA,SUPINE HYPERTENSION,,0
NORTHERA,SUPINE HYPERTENSION,NORTHERA,1
NORTHERA,SUPINE HYPERTENSION,,0
NORTHERA,SUPINE HYPERTENSION,contact Lundbeck at or FDA at,0
NORTHERA,SUPINE HYPERTENSION,6.1 To report SUSPECTED ADVERSE,1
NORTHERA,SUPINE HYPERTENSION,and fatigue er than 5%) (  6.1  To report SUSPECTED ADVERSE,1
NORTHERA,SUPINE HYPERTENSION,ADVERSE REACTIONS,0
NORTHERA,SUPINE HYPERTENSION,at F,0
NORTHERA,supine hypertension,Supine Hypertension see War,0
NORTHERA,supine hypertension,,0
NORTHERA,supine hypertension,and Precautions section of the,0
NORTHERA,supine hypertension,A are included in m ore detail in,1
NORTHERA,supine hypertension,A are included in,1
NORTHERA,supine hypertension,,0
NORTHERA,supine hypertension,A are included in m ore detail,1
NORTHERA,supine hypertension,Hypertension,0
NORTHERA,supine hypertension,included in m ore detail in the,1
NORTHERA,cardiovascular risk,and Precau tions section of the,1
NORTHERA,cardiovascular risk,REACTIONS The following adverse reactions with NORTHERA are included in more detail,0
NORTHERA,cardiovascular risk,Warnings and Precau tions section of the,1
NORTHERA,supine hypertension,and s,1
NORTHERA,Hyperpyrexia,Warnings and Precautions Hyperpyrexia and Confusion,1
NORTHERA,Hyperpyrexia,,0
NORTHERA,Hyperpyrexia,,0
NORTHERA,Hyperpyrexia,of,0
NORTHERA,Hyperpyrexia,detail in the Warnings and Precautions section,0
NORTHERA,confusion,autions ( Hyperpyrexia and Confusion see,1
NORTHERA,Allergic reactions,May exacerbate existing ischemic heart disease,0
NORTHERA,Allergic reactions,,0
NORTHERA,Allergic reactions,"ischemic heart disease as, and congestive heart failure see Warnings",1
NORTHERA,Allergic reactions,May exacerbate existing,0
NORTHERA,Allergic reactions,exacerbate existing ischemic,0
NORTHERA,Allergic reactions,congestive heart failure see Warnings,1
NORTHERA,neuroleptic malignant syndrome,rates in the clinical trials of another drug and may not reflect,0
NORTHERA,neuroleptic malignant syndrome,in,1
NORTHERA,neuroleptic malignant syndrome,"rates in clinical practice.



 The  safety evaluation of NORTHERA",1
NORTHERA,neuroleptic malignant syndrome,may,0
NORTHERA,neuroleptic malignant syndrome,The safety evaluation of NORTHERA,1
NORTHERA,neuroleptic malignant syndrome,reflect the rates in clinical,1
NORTHERA,neuroleptic malignant syndrome,"in clinical practice.



 The  safety evaluation of NORTHERA",1
NORTHERA,NMS,fet y evaluation of NORTHERA,1
NORTHERA,NMS,fet y evaluation of NORTHERA,1
NORTHERA,NMS,tot al of patients with,1
NORTHERA,NMS,In the placebocontrolled studies,0
NORTHERA,NMS,patients with Parkinsons disease multiple,0
NORTHERA,NMS,the placebocontrolled studies tot al of patients with,1
NORTHERA,NMS,studies tot al of patients with,1
NORTHERA,NMS,tot al of patients with,1
NORTHERA,NMS,the,0
NORTHERA,NMS,Parkinsons,0
NORTHERA,NMS,placebocontrolled studies a,0
NORTHERA,fever,disease multiple system rophy pure autonomic failure dopamine,1
NORTHERA,fever,betahydroxylase deficiency or nondiabetic autonomic,0
NORTHERA,fever,disease,0
NORTHERA,fever,betahydroxylase deficiency or nondiabetic,0
NORTHERA,fever,dopamine betahydroxylase deficiency or,0
NORTHERA,fever,rophy pure autonomic failure dopamine,1
NORTHERA,fever,,0
NORTHERA,fever,rophy pure autonomic failure dopamine,1
NORTHERA,hyperthermia,atrophy re autonomic failure dopamine betahydroxylase deficiency,1
NORTHERA,hyperthermia,autonomic failure dopamine betahydroxylase deficiency,1
NORTHERA,muscle rigidity,"ailure,",1
NORTHERA,muscle rigidity,,0
NORTHERA,muscle rigidity,"atrophy pure autonomic ailure, dopamin e betahydroxylase deficiency or",1
NORTHERA,muscle rigidity,e betahydroxylase deficiency or nondiabetic autonomic neuropathy,0
NORTHERA,muscle rigidity,"ailure, dopamin e betahydroxylase deficiency or",1
NORTHERA,muscle rigidity,neuropathy were randomized,0
NORTHERA,muscle rigidity,multiple system atrophy,0
NORTHERA,muscle rigidity,"ailure,",1
NORTHERA,muscle rigidity,"atrophy pure autonomic ailure, dopamin e betahydroxylase deficiency or",1
NORTHERA,muscle rigidity,"atrophy pure autonomic ailure, dopamin e betahydroxylase deficiency or",1
NORTHERA,involuntary movements,or nondiabetic autonomic neuropathy were randomized and treated,0
NORTHERA,involuntary movements,beta-hydroxylase defi ciency or nondiabetic autonomic,1
NORTHERA,involuntary movements,with NORTHERA,0
NORTHERA,involuntary movements,pure autonomic failure beta-hydroxylase,1
NORTHERA,altered consciousness,dopamine betahydroxylase,0
NORTHERA,altered consciousness,"ency, or non-diabetic autonomic neuropathy were randomized",1
NORTHERA,altered consciousness,,0
NORTHERA,altered consciousness,atrophy pure autonomic,0
NORTHERA,altered consciousness,atrophy pure autonomic failure dopamine betahydroxylase,0
NORTHERA,altered consciousness,"failure dopamine betahydroxylase ency, or non-diabetic autonomic neuropathy were randomized",1
NORTHERA,altered consciousness,"failure dopamine betahydroxylase ency,",1
NORTHERA,altered consciousness,multiple system atrophy pure autonomic failure dopamine betahydroxylase defici,0
NORTHERA,altered consciousness,or non-diabetic autonomic neuropathy were randomized,1
NORTHERA,altered consciousness,multiple system atrophy pure,0
NORTHERA,mental status changes,betahydroxylase deficiency,0
NORTHERA,mental status changes,see,0
NORTHERA,mental status changes,atrophy pure autonomic failure,0
NORTHERA,mental status changes,neuropathy were randomized and treated with,1
NORTHERA,mental status changes,dopamine betahydroxylase,0
NORTHERA,mental status changes,neuropathy were randomized and treated with,1
NORTHERA,mental status changes,,0
NORTHERA,bronchial asthma,reactions leading to discontinuation NORTHERA,1
NORTHERA,bronchial asthma,leading to discontinuation NORTHERA were hy pertension or increased blood,1
NORTHERA,bronchial asthma,discontinuation NORTHERA were hy pertension or increased blood,1
NORTHERA,bronchial asthma,were hy pertension or increased blood,1
